-DOCSTART- -18711222- O O

Association NNP N
of IN N
chronic JJ i
kidney NN i
disease NN i
with IN p
outcomes NNS p
in IN p
chronic JJ o
heart NN o
failure NN o
: : o
a DT N
propensity-matched JJ N
study NN N
. . N

BACKGROUND NNP N
Chronic NNP i
kidney NN i
disease NN i
( ( i
CKD NNP i
) ) i
is VBZ N
associated VBN N
with IN N
increased JJ N
mortality NN o
in IN N
patients NNS p
with IN p
heart NN i
failure NN i
( ( i
HF NNP i
) ) i
. . i

However RB N
, , N
its PRP$ N
association NN N
with IN N
hospitalization NN N
in IN N
HF NNP p
patients NNS p
has VBZ N
not RB N
been VBN N
well RB N
studied VBN N
. . N

METHODS NNP N
Of IN p
7788 CD p
patients NNS p
in IN p
the DT p
Digitalis NNP p
Investigation NNP p
Group NNP p
trial NN p
, , p
3527 CD p
had VBD p
CKD NNP p
, , p
defined VBN p
by IN p
an DT p
estimated VBN p
glomerular JJ p
filtration NN p
rate NN p
( ( p
GFR NNP p
) ) p
< VBD p
60 CD p
ml/min/1.73 NNS p
m NN p
( ( p
2 CD p
) ) p
body NN p
surface JJ p
area NN p
( ( p
BSA NNP p
) ) p
. . p

Propensity NN N
scores NNS N
for IN N
CKD NNP i
were VBD N
calculated VBN N
using VBG N
a DT N
multivariable JJ i
logistic JJ i
regression NN i
model NN i
and CC N
used VBN N
to TO N
match VB N
2399 CD N
pairs NNS N
of IN N
patients NNS i
with IN i
and CC i
without IN i
CKD NNP i
. . i

Matched NNP i
Cox NNP i
regression NN i
analyses NNS i
were VBD N
used VBN N
to TO N
estimate VB N
association NN N
of IN N
CKD NNP i
with IN N
outcomes NNS N
. . N

RESULTS NNP N
All-cause NNP o
hospitalization NN o
occurred VBD N
in IN N
1636 CD N
( ( N
rate NN N
, , N
4233/10,000 CD N
person-years NNS N
) ) N
and CC N
1587 CD N
( ( N
rate NN N
, , N
3733/10,000 CD N
person-years NNS N
) ) N
patients NNS N
respectively RB N
, , N
with IN i
and CC i
without IN i
CKD NNP i
( ( N
matched VBN N
hazard RB N
ratio JJ N
[ NNP N
HR NNP N
] NNP N
for IN N
CKD NNP N
, , N
1.18 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
1.08-1.29 JJ N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

Matched VBN o
HR NNP o
for IN o
cardiovascular JJ o
and CC o
HF NNP o
hospitalization NN o
were VBD N
respectively RB N
1.17 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
1.06-1.28 JJ N
, , N
P NNP N
= NNP N
0.002 CD N
) ) N
and CC N
1.28 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
1.13-1.45 JJ N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

Compared VBN N
to TO N
GFR NNP N
> NNP N
or=60 MD N
ml/min/1.73 VB N
m NN N
( ( N
2 CD N
) ) N
BSA NNP N
, , N
HR NNP o
for IN o
all-cause JJ o
hospitalization NN o
for IN o
GFR NNP o
45-59 CD N
and CC N
< $ N
45 CD N
ml/min/1.73 NN N
m NN N
( ( N
2 CD N
) ) N
BSA NNP N
were VBD N
respectively RB N
1.04 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.94-1.16 NNP N
; : N
P NNP N
= NNP N
0.422 CD N
) ) N
and CC N
1.58 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
1.34-1.87 JJ N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

Similarly RB N
, , N
HR NNP o
for IN o
all-cause JJ o
death NN o
for IN o
GFR NNP o
45-59 CD o
and CC o
< $ o
45 CD o
ml/min/1.73 NN o
m NN o
( ( o
2 CD o
) ) o
BSA NNP o
were VBD N
respectively RB N
1.03 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.90-1.18 NNP N
; : N
P NNP N
= NNP N
0.651 CD N
) ) N
and CC N
1.70 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
1.40-2.07 JJ N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

Matched VBN o
HR NNP o
for IN o
death NN o
due JJ o
to TO o
cardiovascular JJ o
causes NNS o
and CC o
progressive JJ o
HF NNP o
were VBD N
respectively RB N
1.24 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
1.09-1.40 JJ N
; : N
P NNP N
= NNP N
0.001 CD N
) ) N
and CC N
1.42 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
1.16-1.72 JJ N
; : N
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

CONCLUSION NNP N
CKD NNP i
was VBD N
associated VBN N
with IN N
increased JJ N
mortality NN o
and CC o
hospitalization NN o
in IN N
ambulatory JJ p
patients NNS p
with IN p
chronic JJ p
HF NNP p
, , N
which WDT N
increased VBD N
progressively RB N
with IN N
worsening VBG N
kidney NN o
function NN o
. . o

-DOCSTART- -18547294- O O

The DT N
effect NN N
of IN N
intravenous JJ N
lidocaine NN i
on IN N
QT NNP o
changes NNS o
during IN N
tracheal JJ p
intubation NN p
. . p

Laryngoscopy NNP p
and CC p
tracheal JJ p
intubation NN p
may MD N
provoke VB N
changes NNS N
of IN N
cardiac JJ o
repolarisation NN o
. . o

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
effect NN N
of IN N
intravenous JJ N
lidocaine NN i
on IN N
the DT N
ECG NNP o
changes NNS o
induced VBN N
by IN N
laryngoscopy NN p
and CC p
tracheal JJ p
intubation NN p
. . p

Forty-three JJ p
female JJ p
patients NNS p
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
lidocaine NN i
( ( N
1.5 CD N
mg.kg NN N
( ( N
-1 NNP N
) ) N
) ) N
or CC N
placebo VB i
immediately RB N
after IN N
induction NN N
of IN N
anaesthesia NN N
and CC N
changes NNS N
in IN N
the DT N
ECG NNP o
and CC o
arterial JJ o
blood NN o
pressure NN o
were VBD N
recorded VBN N
. . N

Correction NN N
of IN N
QT NNP o
interval NN o
was VBD N
calculated VBN N
using VBG N
Bazett NNP N
's POS N
formula NN N
( ( N
QTcb NNP N
) ) N
, , N
Fridericia NNP N
's POS N
correction NN N
( ( N
QTcf NNP N
) ) N
, , N
and CC N
Framingham NNP N
formula NN N
( ( N
QTcF NNP N
) ) N
. . N

Transmural JJ o
dispersion NN o
of IN o
repolarisation NN o
( ( o
TDR NNP o
) ) o
was VBD N
determined VBN N
as IN N
Tpeak-Tend JJ N
time NN N
. . N

There EX N
were VBD N
no DT N
changes NNS N
in IN N
the DT N
QTc NNP o
value NN o
in IN N
the DT N
lidocaine NN i
group NN N
. . N

In IN N
the DT N
placebo NN i
group NN N
, , N
significant JJ N
increases NNS N
in IN N
QTcb NNP o
, , o
QTcf NNP o
and CC o
QTcF NNP o
values NNS o
were VBD N
observed VBN N
after IN N
intubation NN N
compared VBN N
to TO N
either DT N
control NN N
measurements VBZ N
or CC N
to TO N
comparative JJ N
measurements NNS N
in IN N
the DT N
lidocaine NN i
group NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
TDR NNP o
either CC N
between IN N
or CC N
within IN N
the DT N
groups NNS N
. . N

Lidocaine NNP i
diminishes VBZ N
prolongation NN N
of IN N
QTc NNP o
, , N
induced VBN N
by IN N
tracheal JJ p
intubation NN p
but CC N
there EX N
is VBZ N
no DT N
effect NN N
of IN N
intubation NN N
on IN N
TDR NNP o
. . o

-DOCSTART- -19911168- O O

Dose-dependent JJ N
effects NNS o
of IN N
the DT N
CRF NNP i
( ( i
1 CD i
) ) i
receptor NN i
antagonist JJ i
R317573 NNP i
on IN N
regional JJ N
brain NN N
activity NN N
in IN N
healthy JJ p
male JJ p
subjects NNS p
. . p

BACKGROUND NNP N
Corticotropin-releasing NNP i
factor NN i
receptor NN i
type NN i
1 CD i
( ( i
CRF NNP i
( ( i
1 CD i
) ) i
) ) i
antagonists NNS N
have VBP N
been VBN N
proposed VBN N
as IN N
therapeutic JJ N
agents NNS N
in IN N
the DT N
treatment NN N
of IN N
mood NN N
and CC N
anxiety NN N
disorders NNS N
although IN N
clinical JJ N
evidence NN N
supporting VBG N
their PRP$ N
development NN N
and CC N
understanding NN N
of IN N
a DT N
dose-response JJ N
relationship NN N
has VBZ N
been VBN N
lacking VBG N
. . N

METHODS NNP N
We PRP N
tested VBD N
two CD N
doses NNS N
of IN N
the DT N
CRF NNP i
( ( i
1 CD i
) ) i
antagonist NN i
R317573 NNP i
for IN N
effects NNS N
on IN N
regional JJ o
cerebral JJ o
glucose NN o
metabolism NN o
( ( o
rCMglu NN o
) ) o
using VBG N
[ NNP i
( ( i
18 CD i
) ) i
F NNP i
] JJ i
fluoro-2-deoxy-D NN i
: : i
-glucose NN i
( ( i
FDG NNP i
) ) i
positron NN i
emission NN i
tomography NN i
( ( i
PET NNP i
) ) i
following VBG N
single-dose JJ N
challenges NNS N
in IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
cross-over JJ N
design NN N
, , N
in IN N
12 CD p
healthy JJ p
male NN p
volunteers NNS p
. . p

RESULTS NNP N
Single NNP N
30- JJ N
and CC N
200-mg JJ N
doses NNS N
of IN N
R317573 NNP i
resulted VBD N
in IN N
dose-related JJ N
changes NNS N
in IN N
rCMglu NN o
. . o

Relative JJ N
increases NNS N
in IN N
rCMglu NN o
were VBD N
observed VBN N
in IN N
frontal JJ N
cortical JJ N
regions NNS N
while IN N
relative JJ N
decreases NNS N
occurred VBD N
in IN N
the DT N
putamen NNS N
and CC N
right JJ N
amygdala NN N
after IN N
both DT N
doses NNS N
. . N

Relative JJ N
decreases NNS N
occurred VBD N
in IN N
cerebellum NN N
and CC N
right JJ N
parahippocampal NN N
gyrus NN N
following VBG N
the DT N
higher JJR N
dose NN N
. . N

CONCLUSIONS NNP N
R317573 NNP i
appears VBZ N
to TO N
produce VB N
acute JJ N
dose-dependent JJ N
changes NNS N
in IN N
rCMglu NN N
. . N

Effects NNS N
occurred VBD N
in IN N
regions NNS N
that WDT N
may MD N
be VB N
behaviorally RB N
relevant JJ N
to TO N
mood NN N
and CC N
anxiety NN N
disorders NNS N
. . N

In IN N
some DT N
regions NNS N
, , N
these DT N
effects NNS N
may MD N
be VB N
related VBN N
to TO N
the DT N
receptor NN N
( ( N
target NN N
) ) N
density NN N
. . N

Measuring VBG N
acute JJ N
effects NNS N
on IN N
rCMglu NN i
with IN N
FDG-PET NNP i
may MD N
offer VB N
a DT N
method NN N
for IN N
defining VBG N
pharmacologically RB N
active JJ N
doses NNS N
for IN N
central JJ N
nervous JJ N
system NN N
targets NNS N
for IN N
which WDT N
selective JJ N
radiotracers NNS N
are VBP N
lacking VBG N
. . N

-DOCSTART- -3117477- O O

Metabolic NNP N
and CC N
ventilatory JJ N
responses NNS N
during IN N
very RB i
low JJ i
level NN i
exercise NN i
. . i

1 CD N
. . N

Nine NNP p
male NN p
and CC p
six CD p
female JJ p
healthy JJ p
subjects NNS p
were VBD p
studied VBN p
during IN p
supine JJ i
bicycle NN i
exercise NN i
at IN p
workloads NNS p
of IN p
12 CD p
and CC p
37 CD p
W NNP p
; : p
pedalling VBG p
rates NNS p
varied VBD p
between IN p
30 CD p
and CC p
50 CD p
cycles/min NN p
at IN p
each DT p
workload NN p
. . p

Measurements NNS N
were VBD N
made VBN N
of IN N
oxygen NN o
consumption NN o
( ( o
VO2 NNP o
) ) o
, , o
carbon NN o
dioxide NN o
production NN o
( ( o
VCO2 NNP o
) ) o
, , o
minute JJ o
ventilation NN o
( ( o
VE NNP o
) ) o
, , o
tidal JJ o
volume NN o
( ( o
VT NNP o
) ) o
, , o
respiratory JJ o
frequency NN o
( ( o
fR NN o
) ) o
, , o
inspiratory JJ o
and CC o
expiratory JJ o
time NN o
( ( o
TI NNP o
, , o
TE NNP o
) ) o
and CC o
mean JJ o
inspiratory NN o
flow NN o
( ( o
VT/TI NNP o
) ) o
using VBG N
a DT N
non-invasive JJ N
canopy-computer-spirometer NN N
system NN N
. . N

2 CD N
. . N

At IN N
rest NN N
, , N
males NNS N
had VBD N
greater JJR N
values NNS N
of IN N
VE NNP o
, , o
VT NNP o
, , o
TI NNP o
, , o
inspiratory JJ o
duty NN o
cycle NN o
( ( o
TI/TTOT NNP o
) ) o
, , o
VCO2 NNP o
and CC o
VO2 NNP o
, , o
and CC o
a DT o
lower JJR o
fR NN o
, , N
than IN N
females NNS N
. . N

3 CD N
. . N

At IN N
the DT N
lower JJR N
workload NN N
, , N
VO2 NNP o
, , o
VCO2 NNP o
, , o
VE NNP o
, , o
VT NNP o
and CC o
VT/TI NNP o
increased VBD N
linearly RB N
with IN N
increasing VBG N
pedalling VBG N
rate NN N
, , N
whereas WP N
at IN N
the DT N
higher JJR N
workload NN N
there EX N
was VBD N
a DT N
decrease NN N
in IN N
VO2 NNP o
and CC N
little JJ N
or CC N
no DT N
change NN N
in IN N
ventilatory NN o
parameters NNS o
from IN N
30 CD N
to TO N
50 CD N
cycles/min NN N
except IN N
for IN N
an DT N
increase NN N
in IN N
fR NN o
in IN N
females NNS N
. . N

4 CD N
. . N

While IN N
performing VBG N
supine JJ i
exercise NN i
, , N
there EX N
was VBD N
an DT N
effect NN N
of IN N
pedalling VBG o
rate NN o
on IN o
ventilatory NN o
and CC o
metabolic JJ o
parameters NNS o
at IN N
the DT N
low JJ N
workload NN N
( ( N
12 CD N
W NNP N
) ) N
which WDT N
diminished VBD N
at IN N
the DT N
higher JJR N
workload NN N
( ( N
37 CD N
W NNP N
) ) N
. . N

An DT N
increase NN N
in IN N
pedalling VBG o
rate NN o
appears VBZ N
to TO N
enhance VB N
efficiency NN N
at IN N
these DT N
low JJ N
workloads NNS N
. . N

5 CD N
. . N

Differences NNS N
between IN N
the DT N
sexes NNS N
during IN N
exercise NN N
generally RB N
include VBP N
: : N
( ( N
a DT N
) ) N
a DT N
higher JJR o
breathing NN o
frequency NN o
, , o
( ( o
b NN o
) ) o
a DT o
greater JJR o
mechanical JJ o
efficiency NN o
, , o
and CC o
( ( o
c NN o
) ) o
lower JJR o
ventilatory NN o
equivalents NNS o
of IN o
O2 NNP o
and CC o
CO2 NNP o
( ( o
VE/VO2 NNP o
and CC o
VE/VCO2 NNP o
) ) o
during IN N
the DT N
higher JJR N
workload NN N
in IN N
females NNS N
than IN N
males NNS N
. . N

-DOCSTART- -24435893- O O

Early JJ N
psychosocial JJ N
intervention NN N
in IN N
Alzheimer NNP p
's POS p
disease NN p
: : p
cost NN i
utility NN i
evaluation NN i
alongside IN N
the DT N
Danish NNP p
Alzheimer NNP N
's POS N
Intervention NNP N
Study NNP N
( ( N
DAISY NNP N
) ) N
. . N

OBJECTIVE UH N
To TO N
assess VB N
the DT N
cost NN i
utility NN i
of IN N
early JJ N
psychosocial JJ N
intervention NN N
for IN N
patients NNS p
with IN p
Alzheimer NNP p
's POS p
disease NN p
and CC p
their PRP$ p
primary JJ p
caregivers NNS p
. . p

DESIGN NN N
Cost NNP i
utility NN i
evaluation NN N
alongside IN N
a DT N
multicentre NN N
, , N
randomised VBD N
controlled VBN N
trial NN N
with IN N
3 CD N
years NNS N
of IN N
follow-up NN N
. . N

SETTING NN N
Primary NNP p
care NN p
and CC p
memory NN p
clinics NNS p
in IN p
five CD p
Danish JJ p
districts NNS p
. . p

PARTICIPANTS VB N
330 CD p
community-dwelling JJ p
patients NNS p
and CC p
their PRP$ p
primary JJ p
caregivers NNS p
. . p

INTERVENTION NNP N
Psychosocial NNP i
counselling NN i
and CC i
support NN i
lasting VBG N
8-12 JJ N
months NNS N
after IN N
diagnosis NN N
and CC N
follow-up NN i
at IN N
3 CD N
, , N
6 CD N
, , N
12 CD N
and CC N
36 CD N
months NNS N
in IN N
the DT N
intervention NN N
group NN N
or CC N
follow-up NN N
only RB N
in IN N
the DT N
control NN i
group NN i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
the DT N
cost NN o
of IN o
additional JJ o
quality-adjusted JJ o
life NN o
years NNS o
( ( o
QALYs NNP o
) ) o
. . o

Costs NNS o
were VBD N
measured VBN N
from IN N
a DT N
societal JJ N
perspective NN N
, , N
including VBG N
the DT N
costs NNS o
of IN o
healthcare NN o
, , o
social JJ o
care NN o
, , o
informal JJ o
care NN o
and CC o
production NN o
loss NN o
. . o

QALYs NNP o
were VBD N
estimated VBN N
separately RB N
for IN N
the DT N
patient NN N
and CC N
the DT N
caregiver NN N
before IN N
aggregation NN N
for IN N
the DT N
main JJ N
analysis NN N
. . N

RESULTS NNP N
None NN N
of IN N
the DT N
observed JJ N
cost NN o
and CC o
QALY NNP o
measures NNS o
were VBD N
significantly RB N
different JJ N
between IN N
the DT N
intervention NN N
and CC N
control NN i
groups NNS i
, , N
although IN N
a DT N
tendency NN N
was VBD N
noted VBN N
for IN N
psychosocial JJ N
care NN N
leading VBG N
to TO N
cost NN N
increases NNS N
with IN N
informal JJ N
care NN N
that WDT N
was VBD N
not RB N
outweighed VBN N
by IN N
the DT N
tendency NN N
for IN N
cost NN N
savings NNS N
with IN N
formal JJ N
care NN N
. . N

The DT N
probability NN N
of IN N
psychosocial JJ N
intervention NN N
being VBG N
cost-effective JJ o
did VBD N
not RB N
exceed VB N
36 CD N
% NN N
for IN N
any DT N
threshold JJ N
value NN N
. . N

The DT N
alternative JJ N
scenario NN N
analysis NN N
showed VBD N
that IN N
the DT N
probability NN o
of IN o
cost-effectiveness NN o
increased VBN o
over IN N
the DT N
range NN N
of IN N
threshold NN N
values NNS N
used VBN N
if IN N
the DT N
cost NN N
perspective NN N
was VBD N
restricted VBN N
to TO N
formal JJ N
healthcare NN N
. . N

CONCLUSIONS VB N
A NNP N
multifaceted JJ N
, , N
psychosocial JJ N
intervention NN N
programme NN N
was VBD N
found VBN N
unlikely RB N
to TO N
be VB N
cost-effective JJ o
from IN N
a DT N
societal JJ N
perspective NN N
. . N

The DT N
recommendation NN N
for IN N
practice NN N
in IN N
settings NNS N
that WDT N
are VBP N
similar JJ N
to TO N
the DT N
Danish JJ N
setting NN N
is VBZ N
to TO N
provide VB N
follow-up JJ N
with IN N
referral JJ N
to TO N
available JJ N
local JJ N
support NN N
programmes NNS N
when WRB N
needed VBN N
, , N
and CC N
to TO N
restrict VB N
large JJ N
multifaceted VBN N
intervention NN N
programmes NNS N
to TO N
patients NNS p
and CC p
caregivers NNS p
with IN p
special JJ p
needs NNS p
until IN N
further JJ N
evidence NN N
for IN N
cost-effectiveness JJ N
emerges NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
The DT N
study NN N
was VBD N
registered VBN N
in IN N
the DT N
Clinical JJ N
Trial NNP N
Database NNP N
as IN N
ISRCTN74848736 NNP N
. . N

-DOCSTART- -22277317- O O

Randomized NNP N
comparison NN N
of IN N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
zotarolimus-eluting JJ i
stents NNS i
vs. IN N
sirolimus-eluting JJ i
stents NNS i
for IN N
percutaneous JJ p
coronary JJ p
intervention NN p
in IN p
chronic JJ p
total JJ p
occlusion NN p
-- : p
CAtholic NNP p
Total NNP p
Occlusion NNP p
Study NNP p
( ( p
CATOS NNP p
) ) p
trial NN p
. . p

BACKGROUND NNP N
Limited NNP N
data NNS N
are VBP N
available JJ N
regarding VBG N
the DT N
direct JJ N
comparison NN N
of IN N
angiographic JJ N
and CC N
clinical JJ N
outcomes NNS N
after IN N
percutaneous JJ N
coronary JJ N
intervention NN N
( ( N
PCI NNP N
) ) N
with IN N
drug-eluting JJ i
stents NNS i
( ( N
DESs NNP N
) ) N
for IN N
chronic JJ p
total JJ p
occlusion NN p
( ( p
CTO NNP p
) ) p
. . p

METHODS NNP N
AND NNP N
RESULTS NNP N
A NNP N
prospective JJ N
, , N
randomized VBN N
, , N
multicenter RBR N
trial NN N
was VBD N
conducted VBN N
to TO N
evaluate VB N
the DT N
non-inferiority NN N
of IN N
a DT N
zotarolimus-eluting JJ i
stent NN i
( ( i
ZES NNP i
; : i
Endeavor NNP i
Sprint? NNP i
, , i
n=80 RB N
) ) N
to TO N
a DT N
sirolimus-eluting JJ i
stent NN i
( ( i
SES NNP i
; : i
Cypher? NNP i
, , i
n=80 NN N
) ) N
in IN N
patients NNS p
with IN p
CTO NNP p
lesion NN p
with IN p
a DT p
reference NN p
vessel NN p
diameter NN p
? . p
2.5mm CD p
. . p

The DT p
primary JJ N
endpoint NN N
was VBD N
in-segment JJ o
binary JJ o
restenosis NN o
rate NN o
at IN o
9-month JJ N
angiographic JJ N
follow-up NN N
. . N

Key NNP N
secondary JJ N
endpoints NNS N
included VBD o
target NN o
vessel NN o
failure NN o
( ( o
TVF NNP o
; : o
including VBG o
cardiac JJ o
death NN o
, , o
myocardial JJ o
infarction NN o
, , o
and CC o
target VB o
vessel JJ o
revascularization NN o
) ) o
and CC o
Academic NNP o
Research NNP o
Consortium-defined NNP o
definite/probable JJ o
stent NN o
thrombosis NN o
( ( o
ST NNP o
) ) o
within IN o
12 CD N
months NNS N
. . N

The DT N
ZES NNP N
was VBD N
non-inferior JJ N
to TO N
the DT N
SES NNP N
with IN N
respect NN N
to TO N
the DT N
primary JJ N
endpoint NN o
, , o
which WDT o
occurred VBD N
in IN N
14.1 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NN N
: : N
6.0-22.2 JJ N
) ) N
and CC N
in IN N
13.7 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
: : N
5.8-21.6 JJ N
) ) N
of IN N
patients NNS N
, , N
respectively RB N
( ( N
non-inferiority JJ N
margin NN N
, , N
15.0 CD N
% NN N
; : N
P NNP N
for IN N
non-inferiority JJ N
< NNP N
0.001 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
between-group JJ N
differences NNS N
in IN N
the DT N
rate NN o
of IN o
TVF NNP o
( ( N
10.0 CD N
% NN N
vs. FW N
17.5 CD N
% NN N
; : N
P=0.168 NNP N
) ) N
nor CC N
in IN N
the DT N
rate NN N
of IN N
ST NNP N
( ( N
0.0 CD N
% NN N
vs. FW N
1.3 CD N
% NN N
; : N
P=0.316 NNP N
) ) N
during IN N
the DT N
12-month JJ N
clinical JJ N
follow-up NN N
. . N

CONCLUSIONS VB N
The DT N
effectiveness NN N
and CC N
safety NN N
of IN N
ZES NNP N
are VBP N
similar JJ N
to TO N
those DT N
of IN N
SES NNP N
and CC N
therefore VB N
it PRP N
is VBZ N
a DT N
good JJ N
treatment NN N
option NN p
in IN p
patients NNS p
undergoing VBG p
PCI NNP p
for IN p
CTO NNP p
with IN p
DESs NNP p
. . p

-DOCSTART- -8179563- O O

Ketorolac NNP i
versus NN i
fentanyl NN i
for IN N
gynaecological JJ p
day-case NN p
surgery NN p
. . p

The DT N
effectiveness NN N
of IN N
fentanyl NN i
and CC N
ketorolac NN i
in IN N
providing VBG N
analgesia NN N
for IN N
day-case JJ p
gynaecological JJ p
procedures NNS p
was VBD p
evaluated VBN p
in IN p
55 CD p
healthy JJ p
volunteers NNS p
in IN p
a DT p
single JJ p
blinded JJ p
fashion NN p
. . p

Fentanyl NNP i
( ( N
1 CD N
mcg/kg RB N
iv NN N
) ) N
and CC N
ketorolac NN i
( ( N
30 CD N
mg RB N
im NN N
) ) N
were VBD N
administered VBN N
immediately RB N
following VBG N
induction NN N
of IN N
anaesthesia NN N
. . N

Anaesthesia NNP N
was VBD N
standardized VBN N
with IN N
propofol NN i
, , i
nitrous JJ i
oxide NN i
and CC i
enflurane NN i
. . i

Outcome NNP N
variables NNS N
assessed VBN N
were VBD N
pain RB o
, , o
additional JJ o
analgesic NN o
requirements NNS o
, , o
and CC o
incidence NN o
of IN o
postoperative JJ o
nausea NN o
and CC o
vomiting NN o
. . o

All DT N
variables NNS N
were VBD N
recorded VBN N
at IN N
15 CD N
minutes NNS N
, , N
2 CD N
hours NNS N
and CC N
24 CD N
hours NNS N
postoperatively RB N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
2 CD N
groups NNS N
with IN N
respect NN N
to TO N
any DT N
of IN N
the DT N
measured JJ N
variables NNS N
. . N

Both DT N
drugs NNS N
were VBD N
ineffective JJ o
as IN N
sole JJ o
analgesic JJ o
agents NNS o
in IN N
half NN N
of IN N
their PRP$ N
respective JJ N
groups NNS N
. . N

It PRP N
may MD N
be VB N
that IN N
a DT N
combination NN N
of IN N
these DT N
drugs NNS N
, , N
providing VBG N
a DT N
multireceptor NN N
approach NN N
to TO N
analgesia VB N
, , N
will MD N
prove VB N
to TO N
be VB N
more RBR N
effective JJ N
. . N

-DOCSTART- -20535539- O O

Melatonin NNP i
versus NN i
placebo NN i
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
conditions NNS p
and CC p
severe JJ p
sleep NN p
problems NNS p
not RB p
amenable JJ p
to TO p
behaviour VB p
management NN p
strategies NNS p
: : p
a DT N
randomised JJ N
controlled VBN N
crossover NN N
trial NN N
. . N

Twenty-two JJ p
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
who WP p
had VBD p
not RB p
responded VBN p
to TO p
supported VB p
behaviour JJ p
management NN p
strategies NNS p
for IN p
severe JJ p
dysomnias NN p
entered VBD N
a DT N
double JJ N
blind NN N
, , N
randomised VBN N
, , N
controlled VBD N
crossover RB N
trial NN N
involving VBG N
3 CD N
months NNS N
of IN N
placebo NN i
versus IN N
3 CD N
months NNS N
of IN N
melatonin NN i
to TO N
a DT N
maximum JJ N
dose NN N
of IN N
10 CD N
mg. NNS N
17 CD p
children NNS p
completed VBD p
the DT p
study NN p
. . p

There EX N
were VBD N
no DT o
significant JJ o
differences NNS o
between IN N
sleep JJ o
variables NNS o
at IN N
baseline NN N
. . N

Melatonin NNP i
significantly RB N
improved VBD o
sleep JJ o
latency NN o
( ( N
by IN N
an DT N
average NN N
of IN N
47 CD N
min NN N
) ) N
and CC N
total JJ o
sleep NN o
( ( N
by IN N
an DT N
average NN N
of IN N
52 CD N
min NN N
) ) N
compared VBN N
to TO N
placebo VB i
, , N
but CC N
not RB N
number NN N
of IN N
night NN N
wakenings NNS N
. . N

The DT N
side NN o
effect NN o
profile NN o
was VBD N
low JJ o
and CC o
not RB o
significantly RB o
different JJ o
between IN N
the DT N
two CD N
arms NNS N
. . N

-DOCSTART- -8458681- O O

Hypotensive JJ N
effects NNS N
and CC N
influence NN N
on IN N
serum NN o
lipids NNS o
of IN N
SQ29,852 NNP i
, , i
a DT i
new JJ i
angiotensin NN i
converting VBG i
enzyme JJ i
inhibitor NN i
, , N
in IN N
patients NNS p
with IN p
essential JJ p
hypertension NN p
: : p
a DT N
comparison NN N
with IN N
atenolol NN i
. . i

The DT N
effects NNS N
of IN N
SQ29,852 NNP i
( ( N
n JJ N
= NNP N
24 CD N
) ) N
, , N
a DT N
new JJ N
angiotensin NN i
converting VBG i
enzyme JJ i
inhibitor NN i
, , N
and CC N
atenolol NN i
( ( N
n JJ N
= NNP N
22 CD N
) ) N
, , N
monotherapies NNS N
were VBD N
compared VBN N
in IN N
46 CD p
patients NNS p
with IN p
mild JJ p
to TO p
moderate VB p
essential JJ p
hypertension NN p
. . p

Both DT N
SQ29,852 NNP i
( ( N
mean VBP N
dose RB N
15.0 CD N
+/- JJ N
5.1 CD N
mg/day NN N
) ) N
and CC N
atenolol $ i
( ( N
mean VB N
dose RB N
37.5 CD N
+/- JJ N
18.5 CD N
mg/day NN N
) ) N
significantly RB N
decreased VBN N
both DT N
systolic JJ o
and CC o
diastolic JJ o
blood NN o
pressures NNS o
. . o

There EX N
were VBD N
no DT N
significant JJ N
changes NNS N
in IN N
serum NN o
lipids NNS o
, , o
apolipoproteins NNS o
, , o
lipoproteins VBZ o
or CC o
atherosclerotic JJ o
indices NNS o
after IN N
both DT N
SQ29,852 NNP i
and CC N
atenolol RB i
. . i

There EX N
were VBD N
also RB N
no DT o
significant JJ o
inter-group JJ o
differences NNS o
. . o

There EX N
were VBD N
no DT N
serious JJ o
side NN o
effects NNS o
or CC o
abnormal JJ o
laboratory NN o
tests NNS o
in IN N
both DT N
treatment NN N
groups NNS N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
SQ29,852 NNP i
is VBZ N
an DT N
effective JJ N
antihypertensive JJ N
drug NN N
without IN N
adverse JJ o
effect NN o
on IN N
lipid JJ N
metabolism NN N
. . N

-DOCSTART- -3538985- O O

Transcutaneous JJ i
electrical JJ i
nerve NN i
stimulation NN i
following VBG p
appendicectomy NN p
: : p
the DT N
placebo NN N
effect NN N
. . N

A DT N
controlled JJ N
trial NN N
was VBD N
undertaken VBN N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
transcutaneous JJ i
electrical JJ i
nerve NN i
stimulation NN i
( ( i
TENS NNP i
) ) i
with IN i
standard JJ i
intramuscular JJ i
opiate NN i
analgesia NN i
in IN N
the DT N
management NN N
of IN N
postoperative JJ N
pain NN N
following VBG p
appendicectomy NN p
. . p

Consecutive JJ p
patients NNS p
undergoing VBG p
emergency NN i
appendicectomy NN i
were VBD N
randomised VBN N
into IN N
control NN N
, , N
sham NN i
TENS NNP i
and CC i
active JJ i
TENS NNP i
groups NNS i
. . i

There EX N
was VBD N
a DT N
significant JJ N
decrease NN N
in IN N
pain NN o
severity NN o
and CC o
analgesic JJ o
intake NN o
in IN N
both DT N
active JJ i
and CC i
sham JJ i
TENS NNP i
groups NNS N
when WRB N
compared VBN N
with IN N
the DT N
control NN i
group NN i
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

No DT N
difference NN N
was VBD N
demonstrated VBN N
in IN N
pain NN o
severity NN o
between IN N
active JJ i
and CC i
sham JJ i
TENS NNP i
groups NNS N
but CC N
the DT N
active JJ i
TENS NNP i
group NN N
required VBD N
slightly RB N
less JJR N
analgesia NN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
the DT N
major JJ N
benefit NN N
of IN N
TENS NNP i
in IN N
the DT N
postappendicectomy NN p
patient NN p
is VBZ N
due JJ N
to TO N
its PRP$ N
'placebo JJ N
effect NN N
' POS N
and CC N
its PRP$ N
use NN N
in IN N
this DT N
situation NN N
can MD N
not RB N
be VB N
recommended VBN N
. . N

-DOCSTART- -7048172- O O

Non-Hodgkin NNP N
's POS N
malignant JJ N
lymphomas NN N
: : N
treatment NN N
of IN N
localized JJ N
relapses NNS N
with IN N
chemo NN i
+ NN i
radio NN i
+ NNP i
BCG-therapy NNP i
. . i

16 CD p
patients NNS p
with IN p
relapsing VBG p
non-Hodgkin NN p
's POS p
malignant JJ p
lymphomas NN p
considered VBN p
as IN p
clinical JJ p
stage NN p
I PRP p
or CC p
II NNP p
were VBD N
treated VBN N
by IN N
an DT N
association NN N
of IN N
chemo NN i
+ NNP i
radiotherapy NN i
and CC i
thereafter RB i
by IN i
maintenance NN i
BCG NNP i
therapy NN i
. . i

5 CD p
of IN p
them PRP p
were VBD p
included VBN p
in IN p
a DT p
randomized JJ p
trial NN p
and CC N
have VB N
a DT N
significantly RB N
different JJ N
disease-free JJ o
survival NN o
from IN N
patients NNS N
receiving VBG N
the DT N
same JJ N
treatment NN N
but CC N
without IN N
BCG NNP i
. . i

11 CD p
were VBD p
systematically RB p
treated VBN p
by IN p
BCG NNP i
and CC N
they PRP N
also RB N
have VBP N
a DT N
fairly RB N
good JJ N
disease-free JJ o
survival NN o
. . o

Such PDT N
a DT N
treatment NN N
appears VBZ N
to TO N
be VB N
of IN N
value NN N
in IN N
treating VBG N
these DT N
patients NNS N
and CC N
even RB N
probably RB N
of IN N
curing VBG N
some DT N
of IN N
them PRP N
. . N

-DOCSTART- -8274583- O O

Noradrenergic NNP o
response NN o
to TO N
intravenous JJ i
yohimbine NN i
in IN N
patients NNS p
with IN p
depression NN p
and CC p
comorbidity NN p
of IN p
depression NN p
and CC p
panic NN p
. . p

Adrenergic NNP o
response NN o
following VBG N
infusions NNS N
of IN N
yohimbine NN i
or CC i
normal JJ i
saline NN i
was VBD N
evaluated VBN N
in IN N
9 CD p
control NN p
subjects NNS p
, , p
8 CD p
patients NNS p
suffering VBG p
from IN p
a DT p
major JJ p
depressive JJ p
episode NN p
( ( p
MDE NNP p
) ) p
, , p
and CC p
12 CD p
patients NNS p
suffering VBG p
from IN p
concurrent JJ p
MDE NNP p
and CC p
panic JJ p
disorder NN p
( ( p
MDE NNP p
+ NNP p
P NNP p
) ) p
. . p

Blood NN N
was VBD N
drawn VBN N
at IN N
-20 NNP N
, , N
0 CD N
, , N
5 CD N
, , N
10 CD N
, , N
20 CD N
, , N
45 CD N
, , N
and CC N
90 CD N
min NN N
following VBG N
the DT N
infusions NNS N
, , N
and CC N
assayed VBD N
for IN N
norepinephrine NN o
( ( o
NE NNP o
) ) o
and CC o
3-methoxy-4-hydroxy-phenyl JJ o
glycol NN o
( ( o
MHPG NNP o
) ) o
. . o

Although IN N
the DT N
patient NN N
groups NNS N
exhibited VBD N
higher JJR N
baseline NN o
NE NNP o
concentrations NNS o
, , N
and CC N
a DT N
greater JJR N
NE NNP o
area NN o
under IN o
the DT o
plasma JJ o
concentration NN o
versus NN o
time NN o
curve NN o
( ( N
AUC0-90 NNP N
) ) N
during IN N
the DT N
yohimbine JJ i
infusion NN N
, , N
the DT N
differences NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
. . N

Baseline NNP o
NE NNP o
was VBD N
significantly RB N
correlated VBN N
with IN N
the DT N
NE NNP o
AUC0-90 NNP o
in IN N
all DT N
three CD N
groups NNS N
, , N
suggesting VBG N
that IN N
, , N
although IN N
the DT N
NE NNP N
system NN N
may MD N
be VB N
dysregulated VBN N
in IN N
the DT N
MDE NNP N
and CC N
MDE NNP N
+ NNP N
P NNP N
patients NNS N
, , N
the DT N
NE NNP N
system NN N
still RB N
appears VBZ N
to TO N
respond VB N
somewhat RB N
predictably RB N
following VBG N
a DT N
challenge NN N
, , N
even RB N
though IN N
the DT N
actual JJ N
magnitude NN N
of IN N
response NN N
may MD N
vary VB N
. . N

-DOCSTART- -12638834- O O

Evaluation NN N
of IN N
25-gauge JJ i
Quincke NNP i
and CC i
24-gauge JJ i
Gertie NNP i
Marx NNP i
needles NNS N
for IN N
spinal JJ p
anaesthesia NN p
for IN p
caesarean JJ p
section NN p
. . p

OBJECTIVE UH N
To TO N
compare VB N
the DT N
insertion NN N
characteristics NNS N
and CC N
rate NN N
of IN N
complications NNS N
between IN N
25-gauge JJ i
Quincke NNP i
and CC i
24-gauge JJ i
Gertie NNP i
Marx NNP i
needles NNS i
. . N

DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
study NN N
. . N

SETTING NNP N
University NNP N
of IN N
Benin NNP N
Teaching NNP N
Hospital NNP N
; : N
a DT N
university-affiliated JJ N
tertiary JJ N
centre NN N
. . N

SUBJECTS JJ N
Parturients NNPS p
( ( p
ASA NNP p
1 CD p
and CC p
2 CD p
) ) p
scheduled VBN p
for IN p
elective JJ p
caesarean JJ p
section NN p
. . p

They PRP N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
spinal JJ i
anaesthesia NN i
with IN i
either DT i
25-gauge JJ i
Quincke NNP i
needle NN i
or CC i
24-gauge JJ i
Gertie NNP i
Marx NNP i
needle NN i
. . i

The DT p
patients NNS p
with IN p
abnormal JJ p
spaces NNS p
, , p
coagulopathy NN p
, , p
infection NN p
, , p
pre-eclampsia/eclampsia NN p
or CC p
obesity NN p
were VBD p
excluded VBN p
. . p

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
number NN o
of IN o
attempts NNS o
at IN o
successful JJ o
identification NN o
of IN o
the DT o
spinal JJ o
space NN o
, , o
intraoperative JJ o
complications NNS o
, , o
incidence NN o
of IN o
postdural JJ o
puncture NN o
headache NN o
( ( o
PDPH NNP o
) ) o
, , o
non-postdural JJ o
puncture NN o
headache NN o
( ( o
NPDPH NNP o
) ) o
and CC o
backache NN o
. . o

RESULTS NNP N
Sixty NNP p
women NNS p
were VBD p
studied VBN p
. . p

The DT N
24-gauge JJ N
Gertie NNP N
Marx NNP N
needle RB N
resulted VBD N
in IN N
more RBR N
successful JJ o
location NN o
of IN o
the DT o
spinal JJ o
space NN o
on IN N
the DT N
second JJ N
attempt NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Non-postdural JJ o
puncture NN o
headache NN o
was VBD N
seen VBN N
in IN N
43 CD N
% NN N
of IN N
the DT N
study NN N
population NN N
. . N

PDPH NNP o
was VBD N
seen VBN N
in IN N
10 CD N
% NN N
of IN N
the DT N
Quincke NNP N
group NN N
and CC N
none NN N
in IN N
the DT N
Gertie NNP N
Marx NNP N
group NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
incidence NN N
of IN N
backache NN o
in IN N
both DT N
groups NNS N
. . N

CONCLUSION NNP N
The DT N
ease NN N
of IN N
insertion NN N
and CC N
low JJ N
incidence NN N
of IN N
PDPH NNP o
with IN N
the DT N
Gertie NNP N
Marx NNP N
needle NN N
may MD N
encourage VB N
trainee NN N
anaesthetists NNS N
to TO N
use VB N
this DT N
needle NN N
for IN N
caesarean JJ N
section NN N
. . N

-DOCSTART- -1992319- O O

A DT N
placebo-controlled JJ i
trial NN N
of IN N
maintenance NN N
therapy NN N
with IN N
fluconazole JJ i
after IN p
treatment NN p
of IN p
cryptococcal JJ p
meningitis NN p
in IN p
the DT p
acquired JJ p
immunodeficiency NN p
syndrome NN p
. . p

California NNP N
Collaborative NNP N
Treatment NNP N
Group NNP N
. . N

BACKGROUND NNP N
AND NNP N
METHODS NNP N
In IN N
patients NNS p
with IN p
the DT p
acquired JJ p
immunodeficiency NN p
syndrome NN p
( ( p
AIDS NNP p
) ) p
, , N
the DT N
rate NN N
of IN N
relapse NN N
after IN N
primary JJ N
treatment NN N
for IN N
cryptococcal JJ N
meningitis NN N
remains VBZ N
high JJ N
. . N

We PRP N
conducted VBD N
a DT N
controlled VBN N
, , N
double-blind JJ N
trial NN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
maintenance NN N
therapy NN N
with IN N
fluconazole NN N
. . N

At IN N
entry NN N
into IN N
the DT N
study NN N
, , N
all DT p
participants NNS p
had VBD p
sterile JJ p
cultures NNS p
of IN p
cerebrospinal JJ p
fluid NN p
, , p
blood NN p
, , p
and CC p
urine JJ p
after IN p
following VBG p
a DT p
standardized JJ p
course NN p
of IN p
therapy NN p
for IN p
culture-proved JJ p
cryptococcal JJ p
meningitis NN p
. . p

The DT N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
take VB N
either DT N
fluconazole NN i
or CC i
placebo NN i
as IN N
maintenance NN N
therapy NN N
. . N

The DT N
dose NN N
of IN N
fluconazole NN i
was VBD N
100 CD N
mg JJ N
daily RB N
in IN N
the DT N
first JJ N
phase NN N
of IN N
study NN N
and CC N
200 CD N
mg NNS N
daily RB N
in IN N
the DT N
second JJ N
phase NN N
. . N

RESULTS NNP N
Of IN p
84 CD p
patients NNS p
initially RB p
enrolled VBD p
, , p
16 CD p
( ( p
19 CD p
percent NN p
) ) p
were VBD p
found VBN p
to TO p
have VB p
silent JJ p
, , p
persistent JJ p
infection NN p
on IN p
the DT p
basis NN p
of IN p
cultures NNS p
that WDT p
became VBD p
positive JJ p
after IN p
entry NN p
into IN p
the DT p
study NN p
; : p
7 CD p
other JJ p
patients NNS p
were VBD p
lost VBN p
to TO p
follow-up NNS p
shortly RB p
after IN p
entry NN p
. . N

Of IN N
the DT N
remaining VBG p
61 CD p
patients NNS p
, , N
10 CD N
of IN N
27 CD N
assigned VBN N
to TO N
placebo VB i
( ( N
37 CD N
percent NN N
) ) N
and CC N
1 CD N
of IN N
34 CD N
assigned VBN N
to TO N
fluconazole VB i
( ( N
3 CD N
percent NN N
) ) N
had VBD N
a DT N
recurrence NN o
of IN o
cryptococcal JJ o
infection NN o
at IN o
any DT o
site NN o
( ( N
difference NN N
in IN N
risk NN N
, , N
34 CD N
percent NN N
; : N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
15 CD N
to TO N
53 CD N
) ) N
. . N

Of IN N
the DT N
11 CD N
recurrent NN N
infections NNS N
, , N
7 CD N
were VBD N
detected VBN N
in IN N
urine NN N
obtained VBN N
after IN N
prostatic JJ N
massage NN N
. . N

There EX N
were VBD N
four CD N
recurrent NN o
meningeal NN o
infections NNS o
in IN N
the DT N
patients NNS N
taking VBG N
placebo NN i
, , N
but CC N
none NN N
in IN N
those DT N
taking VBG N
fluconazole JJ i
( ( N
mean JJ N
duration NN N
of IN N
follow-up NN N
, , N
164 CD N
days NNS N
) ) N
( ( N
P NNP N
= NNP N
0.03 CD N
) ) N
. . N

In IN N
multivariate NN N
analyses NNS N
, , N
the DT N
best JJS N
predictors NNS N
of IN N
recurrence-free JJ o
survival NN o
were VBD N
fluconazole JJ i
treatment NN i
( ( N
P NNP N
= NNP N
0.02 CD N
; : N
relative JJ N
hazard NN N
, , N
13.2 CD N
) ) N
, , N
a DT N
lower JJR N
serum NN N
cryptococcal-antigen NN N
titer NN N
( ( N
P NNP N
= NNP N
0.05 CD N
; : N
relative JJ N
hazard NN N
, , N
1.2 CD N
) ) N
, , N
and CC N
more JJR N
prolonged JJ N
primary JJ N
therapy NN N
with IN N
flucytosine NN N
( ( N
P NNP N
= NNP N
0.09 CD N
; : N
relative JJ N
hazard NN N
, , N
1.1 CD N
) ) N
. . N

Survival NNP o
and CC o
toxicity NN o
were VBD N
similar JJ N
in IN N
the DT N
two CD N
maintenance-treatment JJ N
groups NNS N
. . N

CONCLUSIONS NNP N
In IN N
patients NNS p
with IN p
AIDS NNP p
, , N
silent JJ N
persistent JJ N
infection NN N
is VBZ N
common JJ N
after IN N
clinically RB N
successful JJ N
treatment NN N
for IN N
cryptococcal JJ N
meningitis NN N
. . N

Maintenance NNP N
therapy NN N
with IN N
fluconazole NN i
is VBZ N
highly RB N
effective JJ N
in IN N
preventing VBG N
recurrent JJ N
cryptococcal JJ N
infection NN N
. . N

-DOCSTART- -24402830- O O

A DT N
phase NN N
II NNP N
, , N
randomized VBD N
, , N
multicenter NN N
study NN N
evaluating VBG N
the DT N
combination NN N
of IN N
lapatinib NN N
and CC N
vinorelbine NN N
in IN N
women NNS p
with IN p
ErbB2 NNP p
overexpressing VBG p
metastatic JJ p
breast NN p
cancer NN p
. . p

Lapatinib NNP N
is VBZ N
approved VBN N
in IN N
combination NN N
with IN N
capecitabine NN N
for IN N
treatment NN N
of IN N
patients NNS p
with IN p
human JJ p
epidermal JJ p
growth NN p
factor NN p
receptor NN p
2 CD p
( ( p
HER2 NNP p
) ) p
-positive VBP p
metastatic JJ p
breast NN p
cancer NN p
( ( p
MBC NNP p
) ) p
who WP N
have VBP N
progressed VBN N
on IN N
prior JJ N
trastuzumab NN N
in IN N
the DT N
metastatic JJ N
setting NN N
. . N

Vinorelbine NNP N
is VBZ N
an DT N
important JJ N
chemotherapy NN N
option NN N
for IN N
MBC NNP N
. . N

We PRP N
evaluated VBD N
efficacy NN N
and CC N
safety NN N
of IN N
lapatinib JJ N
plus CC N
vinorelbine JJ N
, , N
compared VBN N
with IN N
lapatinib JJ N
plus CC N
capecitabine JJ N
, , N
in IN N
women NNS p
with IN p
HER2-positive JJ p
MBC NNP p
. . p

In IN p
this DT p
open-label JJ p
, , p
multicenter NN p
, , p
phase NN p
II NNP p
study NN p
, , p
eligible JJ p
patients NNS p
( ( p
N NNP p
= NNP p
112 CD p
) ) p
were VBD N
randomized VBN N
2:1 CD N
to TO N
lapatinib VB i
plus JJ i
vinorelbine NN i
[ NNP i
( ( i
N NNP i
= NNP i
75 CD i
) ) i
1,250 CD i
mg NN i
orally RB i
once RB i
daily JJ i
( ( i
QD NNP i
) ) i
continuously RB i
plus CC i
20 CD i
mg/m NN i
( ( i
2 CD i
) ) i
/day NN i
intravenously RB i
] VBZ i
or CC i
lapatinib JJ i
plus CC i
capecitabine JJ i
[ NNP i
( ( i
N NNP i
= NNP i
37 CD i
) ) i
1,250 CD i
mg NN i
orally RB i
QD NNP i
continuously RB i
plus CC i
2,000 CD i
mg/m NN i
( ( i
2 CD i
) ) i
/day NN i
orally RB i
, , i
2 CD i
doses NNS i
] RB i
. . i

The DT N
primary JJ N
endpoint NN N
was VBD N
progression-free JJ o
survival NN o
( ( o
PFS NNP o
) ) o
. . o

Other JJ N
endpoints NNS N
included VBD N
overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
and CC o
safety NN o
. . o

Patients NNS N
progressing VBG N
within IN N
the DT N
study NN N
were VBD N
given VBN N
the DT N
option NN N
of IN N
crossover NN N
to TO N
the DT N
other JJ N
treatment NN N
arm NN N
; : N
time NN N
to TO N
second JJ N
progression NN N
was VBD N
an DT N
exploratory JJ N
endpoint NN N
. . N

Patient JJ o
demographics NNS o
, , o
stratification NN o
, , o
and CC o
prognostic JJ o
factors NNS o
were VBD N
well RB N
balanced VBN N
between IN N
treatments NNS N
. . N

Median JJ o
PFS NNP o
in IN N
both DT N
arms NNS N
was VBD N
6.2 CD N
months NNS N
[ RB N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
4.2 CD N
, , N
8.8 CD N
( ( N
lapatinib JJ N
plus CC N
vinorelbine JJ N
) ) N
; : N
4.4 CD N
, , N
8.3 CD N
( ( N
lapatinib JJ N
plus CC N
capecitabine NN N
) ) N
] NN N
. . N

Median JJ o
OS NNP o
on IN N
lapatinib JJ N
plus CC N
vinorelbine NN N
was VBD N
24.3 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
16.4 CD N
, , N
NE NNP N
) ) N
and CC N
19.4 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
16.4 CD N
, , N
27.2 CD N
) ) N
on IN N
lapatinib NN N
plus CC N
capecitabine NN N
. . N

In IN N
total JJ N
, , N
42 CD N
patients NNS N
opted VBN N
to TO N
cross VB N
over RP N
; : N
median JJ N
PFS NNP N
was VBD N
3.2 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
1.7 CD N
, , N
5.1 CD N
) ) N
on IN N
lapatinib NN N
plus CC N
vinorelbine NN N
and CC N
4.0 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
2.1 CD N
, , N
5.8 CD N
) ) N
on IN N
lapatinib NN N
plus CC N
capecitabine NN N
. . N

Lapatinib NNP N
plus CC N
vinorelbine NN N
offers NNS N
an DT N
effective JJ N
treatment NN N
option NN N
for IN N
patients NNS p
with IN p
HER2-overexpressing NNP p
MBC NNP p
, , N
having VBG N
displayed VBN N
comparable JJ N
efficacy NN N
and CC N
tolerability NN N
rates NNS N
to TO N
lapatinib VB N
plus JJ N
capecitabine NN N
. . N

-DOCSTART- -16961674- O O

Effectiveness NN o
of IN N
written VBN N
guidelines NNS N
on IN N
the DT N
appropriateness NN N
of IN N
thromboprophylaxis JJ i
prescriptions NNS i
for IN p
medical JJ p
patients NNS p
: : p
a DT N
prospective JJ N
randomized NN N
study NN N
. . N

OBJECTIVE NNP N
To TO N
assess VB N
the DT N
effectiveness NN o
of IN N
providing VBG N
doctors NNS N
with IN N
written VBN N
thromboprophylaxis JJ i
prescription NN i
aids NNS i
based VBN N
on IN N
current JJ N
recommendations NNS N
. . N

DESIGN VB N
A DT N
prospective JJ N
trial NN N
of IN N
specific JJ N
anticoagulant JJ N
prescription NN N
forms NNS N
: : N
a DT N
1-day JJ N
survey NN N
before IN N
and CC N
after IN N
the DT N
intervention NN N
in IN N
each DT N
centre NN N
. . N

SETTING CC N
30 CD p
Internal NNP p
Medicine NNP p
departments NNS p
of IN p
Assistance NNP p
Publique-H?pitaux NNP p
de IN p
Paris NNP p
. . p

SUBJECTS NNP p
All DT p
inpatients NNS p
were VBD p
included VBN p
, , p
except IN p
those DT p
who WP p
were VBD p
either RB p
admitted VBN p
or CC p
discharged VBN p
on IN p
the DT p
day NN p
of IN p
the DT p
survey NN p
, , p
and CC p
those DT p
receiving VBG p
curative JJ i
anticoagulant JJ i
treatment NN p
. . p

INTERVENTIONS VBZ N
The DT N
study NN N
included VBD N
three CD N
parts NNS N
: : N
( ( N
i NN N
) ) N
a DT N
1-day JJ N
baseline NN N
survey NN N
; : N
( ( N
ii NN N
) ) N
over IN N
the DT N
following JJ N
3-month JJ N
period NN N
, , N
departments NNS N
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
: : N
all DT N
practitioners NNS N
in IN N
wards NNS N
allocated VBN N
to TO N
the DT N
intervention NN N
group NN N
were VBD N
required VBN N
to TO N
systematically RB N
use VB N
specific JJ i
anticoagulant JJ i
prescription NN N
forms NNS N
, , N
whilst NN N
doctors NNS N
in IN N
the DT N
control NN N
group NN N
continued VBD N
prescribing VBG N
according VBG N
to TO N
their PRP$ i
usual JJ i
practices NNS i
and CC N
( ( N
iii NN N
) ) N
a DT N
1-day JJ N
postintervention NN N
survey NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURE NNP o
The DT o
proportion NN o
of IN o
prescriptions NNS o
in IN o
accordance NN o
with IN o
the DT o
recommendations NNS o
. . o

RESULTS VB p
1,469 CD p
patients NNS p
were VBD p
included VBN p
. . p

The DT N
intervention NN N
produced VBD N
a DT N
significant JJ o
reduction NN o
in IN N
the DT o
frequency NN o
of IN o
over-prescriptions NNS o
, , o
from IN N
25 CD N
% NN N
to TO N
14 CD N
% NN N
of IN N
the DT N
patients NNS N
who WP N
did VBD N
not RB N
meet VB N
the DT N
guideline NN N
criteria NNS N
( ( N
adjusted VBN N
OR NNP N
: : N
0.3 CD N
; : N
95 CD N
% NN N
CI NNP N
: : N
0.1-0.8 NN N
) ) N
. . N

Using VBG o
specific JJ o
forms NNS o
did VBD N
not RB o
improve VB o
under-prescription NN o
of IN o
anticoagulants NNS o
. . o

A DT N
little JJ N
over IN N
60 CD N
% NN N
of IN N
the DT N
patients NNS N
who WP N
met VBD N
guideline NN N
criteria NNS N
for IN N
thromboprophylaxis NN N
were VBD o
prescribed JJ o
anticoagulants NNS o
in IN N
both DT N
intervention NN N
and CC N
control NN N
wards NNS N
, , N
either RB N
at IN N
baseline NN N
or CC N
after IN N
intervention NN N
. . N

CONCLUSIONS NNP i
Multitargeted VBD i
interventions NNS i
using VBG N
a DT N
variety NN N
of IN N
means NNS N
and CC N
strategies NNS N
should MD N
still RB N
be VB N
considered VBN N
to TO o
improve VB o
prescriptions NNS o
that WDT N
may MD N
have VB N
a DT N
significant JJ o
impact NN o
on IN o
health NN o
expenses NNS o
and CC N
, , N
most RBS N
importantly RB N
, , N
on IN o
patients NNS o
outcomes NNS o
. . o

-DOCSTART- -11238483- O O

Effect NN N
of IN N
protein NN i
ingestion NN i
on IN N
the DT N
glucose JJ o
appearance NN o
rate NN o
in IN N
people NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
. . p

Amino NNP N
acids NNS N
derived VBD N
from IN N
ingested VBN N
protein NN N
are VBP N
potential JJ N
substrates NNS N
for IN N
gluconeogenesis NN N
. . N

However RB N
, , N
several JJ N
laboratories NNS N
have VBP N
reported VBN N
that IN N
protein JJ N
ingestion NN N
does VBZ N
not RB N
result VB N
in IN N
an DT N
increase NN N
in IN N
the DT N
circulating NN o
glucose JJ o
concentration NN o
in IN N
people NNS N
with IN N
or CC N
without IN N
type JJ p
2 CD p
diabetes NNS p
. . p

The DT N
reason NN N
for IN N
this DT N
has VBZ N
remained VBN N
unclear JJ N
. . N

In IN N
people NNS N
without IN N
diabetes NNS N
it PRP N
seems VBZ N
to TO N
be VB N
due JJ N
to TO N
less RBR N
glucose JJ N
being VBG N
produced VBN N
and CC N
entering VBG N
the DT N
circulation NN N
than IN N
the DT N
calculated JJ N
theoretical JJ N
amount NN N
. . N

Therefore RB N
, , N
we PRP N
were VBD N
interested JJ N
in IN N
determining VBG N
whether IN N
this DT N
also RB N
was VBD N
the DT N
case NN N
in IN N
people NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
. . p

Ten CD p
male JJ p
subjects NNS p
with IN p
untreated JJ p
type NN p
2 CD p
diabetes NNS p
were VBD N
given VBN N
, , N
in IN N
random JJ N
sequence NN N
, , N
50 CD i
g NN i
protein NN i
in IN i
the DT i
form NN i
of IN i
very RB i
lean JJ i
beef NN i
or CC i
only RB i
water NN i
at IN i
0800 CD i
h NN i
and CC i
studied VBN i
over IN i
the DT i
subsequent JJ i
8 CD i
h. NN i
Protein NNP i
ingestion NN N
resulted VBD N
in IN N
an DT N
increase NN N
in IN N
circulating VBG o
insulin NN o
, , o
C-peptide NNP o
, , o
glucagon NN o
, , o
alpha NN o
amino NN o
and CC o
urea JJ o
nitrogen NN o
, , o
and CC o
triglycerides NNS o
; : o
a DT o
decrease NN o
in IN o
nonesterified JJ o
fatty JJ o
acids NNS o
; : o
and CC o
a DT o
modest JJ o
increase NN o
in IN o
respiratory JJ o
quotient NN o
. . o

The DT N
total JJ N
amount NN N
of IN N
protein NN o
deaminated VBN o
and CC o
the DT o
amino NN o
groups NNS o
incorporated VBD o
into IN o
urea NN o
was VBD N
calculated VBN N
to TO N
be VB N
approximately RB N
20-23 JJ N
g. VBP N
The DT N
net JJ N
amount NN N
of IN N
glucose NN o
estimated VBN N
to TO N
be VB N
produced VBN N
, , N
based VBN N
on IN N
the DT N
quantity NN o
of IN o
amino JJ o
acids NNS o
deaminated VBD o
, , N
was VBD N
approximately RB N
11-13 JJ N
g. NN N
However RB N
, , N
the DT N
amount NN o
of IN o
glucose JJ o
appearing VBG o
in IN o
the DT o
circulation NN o
was VBD N
only RB N
approximately RB N
2 CD N
g. VBD N
The DT N
peripheral JJ o
plasma NN o
glucose JJ o
concentration NN o
decreased VBN N
by IN N
approximately RB N
1 CD N
mM NNS N
after IN N
ingestion NN N
of IN N
either DT N
protein NN N
or CC N
water NN N
, , N
confirming VBG N
that IN N
ingested JJ N
protein NN N
does VBZ N
not RB N
result VB N
in IN N
a DT N
net JJ N
increase NN N
in IN N
glucose JJ o
concentration NN o
, , N
and CC N
results NNS N
in IN N
only RB N
a DT N
modest JJ N
increase NN N
in IN N
the DT N
rate NN o
of IN o
glucose JJ o
disappearance NN o
. . o

-DOCSTART- -22414705- O O

Noradrenergic NNP N
moderation NN o
of IN N
working VBG N
memory NN N
impairments NNS N
in IN N
adults NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

In IN N
addition NN N
to TO N
having VBG N
difficulties NNS N
with IN N
social JJ N
communications NNS N
, , N
individuals NNS p
with IN p
an DT p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
often RB N
also RB N
experience JJ N
impairment NN o
in IN o
higher-order NN o
, , o
executive NN o
skills NNS o
. . o

The DT N
present JJ N
study NN N
examined VBD N
the DT N
effects NNS N
of IN N
pharmacological JJ N
modulation NN N
of IN N
the DT N
norepinephrine NN N
system NN N
on IN N
the DT N
severity NN N
of IN N
such JJ N
impairments NNS N
. . N

A DT N
sample NN N
of IN N
14 CD p
high-functioning JJ p
adults NNS p
with IN p
ASD NNP p
and CC p
a DT p
demographically-matched JJ p
comparison NN p
group NN p
of IN p
13 CD p
typically RB p
developing VBG p
individuals NNS p
participated VBN p
. . p

An DT N
AX NNP o
continuous JJ o
performance NN o
test NN o
( ( o
AX-CPT NNP o
) ) o
was VBD N
used VBN N
to TO N
evaluate VB N
working VBG N
memory NN N
and CC N
inhibitory NN N
control NN N
. . N

AX-CPT JJ o
performance NN o
was VBD N
assessed VBN N
following VBG N
administration NN N
of IN N
a DT N
single JJ N
dose NN N
of IN N
propranolol NN i
( ( i
a DT i
beta NN i
adrenergic JJ i
antagonist NN i
) ) i
and CC i
following VBG i
placebo NN i
( ( N
sugar NN N
pill NN N
) ) N
administration NN N
. . N

Individuals NNS p
with IN p
ASD NNP p
performed VBD o
more RBR N
poorly RB N
than IN N
non-ASD JJ N
individuals NNS N
in IN N
the DT N
working JJ N
memory NN N
condition NN N
( ( N
BX NNP N
trials NNS N
) ) N
. . N

Importantly RB N
, , N
administration NN N
of IN N
propranolol NN i
attenuated VBN o
this DT o
impairment NN o
, , N
with IN N
the DT N
ASD NNP N
group NN N
performing VBG o
significantly RB N
better RBR N
in IN N
the DT N
propranolol NN N
condition NN N
than IN N
the DT N
placebo JJ N
condition NN N
. . N

Working VBG o
memory NN o
performance NN o
of IN N
the DT N
non-ASD JJ N
group NN N
was VBD N
unaffected VBN N
by IN N
propranolol/placebo JJ N
administration NN N
. . N

No DT N
group NN N
or CC N
medication NN N
effects NNS o
were VBD N
observed VBN N
for IN N
the DT N
inhibition NN o
condition NN o
( ( N
AY NNP N
trials NNS N
) ) N
. . N

The DT N
present JJ N
findings NNS N
suggest VBP N
that IN N
norepinephrine NN N
may MD N
play VB N
a DT N
role NN N
in IN N
some DT N
, , N
but CC N
not RB N
necessarily RB N
all RB N
, , N
cognitive JJ o
impairments NNS o
associated VBN N
with IN N
ASD NNP N
. . N

Additional NNP N
research NN N
is VBZ N
needed VBN N
to TO N
fully RB N
understand VB N
whether IN N
this DT N
role NN N
is VBZ N
primarily RB N
causal JJ N
or CC N
compensatory NN N
in IN N
nature NN N
. . N

-DOCSTART- -3950826- O O

Nutrient JJ N
retention NN N
in IN N
preterm JJ p
infants NNS p
fed VBN p
standard JJ p
infant NN p
formulas NN p
. . p

Our PRP$ N
purpose NN N
was VBD N
to TO N
compare VB o
nitrogen NN o
, , o
mineral NN o
, , o
and CC o
zinc NN o
balance NN o
in IN N
preterm JJ p
infants NNS p
fed VBN p
standard JJ i
infant NN i
formulas NNS i
, , i
Similac NNP i
With IN i
Iron NNP i
and CC i
Similac NNP i
With IN i
Whey NNP i
+ NNP i
Iron NNP i
. . i

Nitrogen NNP o
and CC o
magnesium NN o
balances NNS o
were VBD N
similar JJ N
during IN N
both DT N
feeds NNS N
, , N
and CC N
met VBD N
estimated VBN N
fetal JJ N
requirements NNS N
. . N

Infants NNS N
absorbed VBD N
and CC N
retained VBD N
( ( N
milligrams FW N
per IN N
kilogram FW N
per IN N
day NN N
) ) N
more JJR N
calcium NN o
, , o
phosphorus NN o
, , o
and CC o
zinc NN o
when WRB N
fed VBN N
Similac NNP i
With IN i
Iron NNP i
. . i

However RB N
, , N
retention NN o
of IN o
calcium NN o
, , o
phosphorus NN o
( ( o
both DT o
formulas NN o
) ) o
, , o
and CC o
zinc NN o
( ( N
Similac NNP N
With IN N
Whey NNP N
+ NNP N
Iron NNP N
) ) N
was VBD N
inadequate JJ N
to TO N
meet VB N
estimated JJ N
fetal JJ N
requirements NNS N
. . N

These DT N
findings NNS N
are VBP N
important JJ N
in IN N
the DT N
rapidly RB p
growing VBG p
preterm JJ p
infant NN p
, , N
who WP N
is VBZ N
already RB N
at IN N
risk NN N
for IN N
the DT N
development NN N
of IN N
rickets NNS N
and CC N
zinc NN N
deficiency NN N
and CC N
may MD N
be VB N
fed VBN N
either DT N
formula NN N
on IN N
discharge NN N
from IN N
the DT N
newborn JJ N
nursery NN N
. . N

-DOCSTART- -25286703- O O

[ VB N
A DT N
clinical JJ N
trial NN N
of IN N
ultrasound-guided JJ i
facet NNS i
joint JJ i
block NN i
in IN N
the DT N
lumbar NN N
spine NN N
to TO N
treat VB N
facet JJ p
joint NN p
related VBD p
low JJ p
back RB p
pain NN p
] NN p
. . N

OBJECTIVE UH N
To TO N
determine VB N
the DT N
feasibility NN N
and CC N
clinical JJ N
efficacy NN N
of IN N
ultrasound-guided JJ i
facet NNS i
joint JJ i
injection NN i
and CC N
nerve NN i
block NN i
in IN i
lumbar NN i
facet NN i
joint NN i
for IN N
the DT N
treatment NN N
of IN N
facet-joint NN p
related VBN p
low JJ p
back RB p
pain NN p
. . p

METHODS NNP N
20 CD p
patients NNS p
with IN p
facet-joint JJ p
pain NN p
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
received VBD N
block RB i
blindly RB i
( ( i
B NNP i
group NN i
) ) i
or CC i
guided VBN i
by IN i
ultrasound NN i
( ( i
US NNP i
group NN i
) ) i
respectively RB i
. . i

The DT N
location NN N
of IN N
needle JJ N
tip NN N
was VBD N
confirmed VBN N
by IN N
CT NNP N
in IN N
both DT N
groups NNS N
, , N
and CC N
the DT N
accuracy NN N
was VBD N
computed VBN N
afterwards NNS N
. . N

VAS NNP o
score NN o
, , o
puncture NN o
time NN o
and CC o
one-time JJ o
puncture NN o
success NN o
rate NN o
( ( N
% NN N
) ) N
were VBD N
recorded VBN N
. . N

VAS NNP o
scores NNS o
and CC o
pain VB o
remission NN o
rates NNS o
in IN N
both DT N
groups NNS N
were VBD N
recorded VBN N
at IN N
30 CD N
min NN N
, , N
1 CD N
d NN N
, , N
2 CD N
d NN N
, , N
6 CD N
weeks NNS N
after IN N
the DT N
block NN N
. . N

RESULTS VB N
The DT N
VAS NNP o
scores NNS o
were VBD N
3.3 CD N
+/- JJ N
0.4 CD N
in IN N
US NNP N
group NN N
and CC N
1.2 CD N
+/- JJ N
0.3 CD N
in IN N
B NNP N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
puncture NN o
time NN o
was VBD N
( ( N
206 CD N
+/- JJ N
27 CD N
) ) N
s NN N
in IN N
US NNP N
group NN N
while IN N
( ( N
397 CD N
+/- JJ N
31 CD N
) ) N
s NN N
in IN N
B NNP N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
were VBD N
37 CD N
facet JJ i
joint NN i
blocks NNS i
guided VBN i
by IN i
ultrasound NN i
, , N
in IN N
which WDT N
32 CD N
were VBD N
correctly RB N
targeted VBN N
with IN N
the DT N
first JJ N
puncture NN N
. . N

The DT N
success NN o
rate NN o
is VBZ N
86.5 CD N
% NN N
. . N

There EX N
were VBD N
35 CD N
facet JJ i
joint NN i
blocks NNS i
blindly RB i
, , N
in IN N
which WDT N
11 CD N
were VBD N
correctly RB N
targeted VBN N
with IN N
the DT N
first JJ N
puncture NN N
. . N

The DT N
success NN o
rate NN o
is VBZ N
31.4 CD N
% NN N
. . N

The DT N
difference NN N
of IN N
one-time JJ o
puncture NN o
success NN o
rate NN o
between IN N
the DT N
two CD N
groups NNS N
was VBD N
significant JJ o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Differences NNS N
of IN N
VAS NNP o
and CC o
pain VB o
remission NN o
rate NN o
at IN N
half PDT N
an DT N
hour NN N
after IN N
facet JJ N
joint JJ N
injection NN N
between IN N
B NNP N
group NN N
and CC N
US NNP N
group NN N
were VBD N
significant JJ N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
were VBD N
8 CD N
, , N
9 CD N
, , N
9 CD N
, , N
and CC N
9 CD N
patients NNS N
in IN N
US NNP N
group NN N
obtaining VBG N
a DT N
reduction NN o
in IN N
VAS NNP o
scores NNS o
> VBP N
or CC N
= VBP N
3 CD N
at IN N
30 CD N
min NN N
, , N
1 CD N
d NN N
, , N
2 CD N
d NN N
and CC N
6 CD N
weeks NNS N
after IN N
the DT N
procedure NN N
respectively RB N
, , N
while IN N
the DT N
numbers NNS N
of IN N
such JJ N
patients NNS N
were VBD N
5 CD N
, , N
6 CD N
, , N
5 CD N
, , N
5 CD N
in IN N
B NNP N
group NN N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

After IN N
6 CD N
weeks NNS N
of IN N
follow-up NN N
, , N
the DT N
overall JJ o
remission NN o
rates NNS o
were VBD N
( ( N
72.3 CD N
+/- JJ N
14.0 CD N
) ) N
% NN N
in IN N
US NNP N
group NN N
, , N
and CC N
( ( N
56.7 CD N
+/- JJ N
11.0 CD N
) ) N
% NN N
in IN N
B NNP N
group NN N
, , N
there EX N
was VBD N
no DT o
significant JJ o
difference NN o
between IN N
the DT N
two CD N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
ultrasound-guided JJ i
lumbar NN i
facet NN i
joint JJ i
injection NN i
technique NN i
had VBD N
a DT N
high JJ N
feasibility NN N
and CC N
accuracy NN N
, , N
and CC N
had VBD N
better RBR N
clinical JJ N
efficacy NN N
than IN N
block NN i
blindly RB i
. . i

-DOCSTART- -12005275- O O

Rizatriptan NNP i
5 CD N
mg NN N
for IN N
the DT N
acute JJ N
treatment NN N
of IN N
migraine NN o
in IN p
adolescents NNS p
: : p
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
study NN N
. . N

OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
tolerability NN o
and CC o
efficacy NN o
of IN N
rizatriptan JJ i
5 CD N
mg NN N
in IN N
adolescent JJ p
migraineurs NNS p
. . p

METHODS NNP N
Randomized NNP N
, , N
double-blind NN N
, , N
placebo-controlled JJ N
study NN N
. . N

Patients NNS p
aged VBD p
12 CD p
to TO p
17 CD p
years NNS p
received VBD p
rizatriptan JJ i
5 CD p
mg NN p
( ( p
n JJ p
= NNP p
149 CD p
) ) p
or CC p
placebo NN i
( ( p
n JJ p
= NNP p
147 CD p
) ) p
for IN N
a DT N
moderate JJ N
or CC N
severe JJ N
headache NN N
and CC N
for IN N
up RB N
to TO N
two CD N
recurrences NNS N
. . N

Headache NNP o
severity NN o
, , o
presence NN o
or CC o
absence NN o
of IN o
associated VBN o
symptoms NNS o
, , o
and CC o
functional JJ o
disability NN o
were VBD o
assessed VBN o
over IN o
a DT o
4-hour JJ o
postdose JJ o
period NN o
, , N
and CC N
any DT N
adverse JJ o
events NNS o
were VBD N
recorded VBN N
. . N

The DT N
primary JJ N
efficacy NN N
measure NN N
was VBD N
pain-free JJ o
status NN o
at IN o
2 CD o
hours NNS o
postdose RB o
. . o

RESULTS NNP N
Rizatriptan NNP i
5 CD N
mg NN N
was VBD N
well RB N
tolerated VBN N
. . N

The DT N
most RBS N
commonly RB N
reported VBD N
adverse JJ o
events NNS o
( ( N
all DT N
with IN N
incidence NN N
of IN N
5 CD N
% NN N
or CC N
less JJR N
) ) N
among IN N
patients NNS N
receiving VBG N
rizatriptan NNS i
were VBD N
dry JJ o
mouth NN o
, , o
dizziness NN o
, , o
asthenia/fatigue NN o
, , o
nausea NN o
, , o
and CC o
somnolence NN o
. . o

The DT N
percentage NN N
of IN N
patients NNS N
pain-free JJ o
at IN N
2 CD N
hours NNS N
was VBD N
32 CD N
% NN N
for IN N
rizatriptan JJ N
5 CD N
mg NN N
versus NN N
28 CD N
% NN N
for IN N
placebo NN N
( ( N
P=.474 NNP N
) ) N
. . N

The DT N
percentage NN o
of IN o
patients NNS o
with IN o
pain NN o
relief NN o
( ( N
reduction NN N
of IN N
predose JJ o
pain NN o
intensity NN o
to TO N
mild VB N
or CC N
none NN N
) ) N
at IN N
2 CD N
hours NNS N
was VBD N
66 CD N
% NN N
for IN N
rizatriptan JJ i
versus NN N
56 CD N
% NN N
for IN N
placebo NN i
( ( N
P=.079 NNP N
) ) N
. . N

Placebo NNP o
response NN o
rates NNS o
were VBD N
higher JJR N
than IN N
those DT N
typically RB N
observed VBN N
in IN N
previous JJ N
studies NNS N
of IN N
rizatriptan NN i
in IN N
adults NNS N
. . N

Compared VBN N
with IN N
placebo NN i
, , i
rizatriptan VBP i
significantly RB N
improved VBN N
functional JJ o
disability NN o
at IN N
1.5 CD N
and CC N
2 CD N
hours NNS N
, , N
and CC N
nausea NN o
at IN N
1 CD N
and CC N
1.5 CD N
hours NNS N
. . N

Post NNP N
hoc NN N
analysis NN N
showed VBD N
a DT N
significant JJ N
benefit NN N
of IN N
rizatriptan JJ N
versus NN N
placebo NN N
in IN N
the DT N
percentage NN N
of IN N
patients NNS N
who WP N
had VBD N
pain NN o
relief NN o
when WRB N
their PRP$ N
migraine NN N
attacks NNS N
were VBD N
treated VBN N
on IN N
weekends NNS N
( ( N
65 CD N
% NN N
versus IN N
36 CD N
% NN N
, , N
P=.046 NNP N
) ) N
compared VBN N
with IN N
weekdays NNS N
( ( N
66 CD N
% NN N
versus IN N
61 CD N
% NN N
, , N
P=.365 NNP N
) ) N
, , N
and CC N
the DT N
weekend NN N
placebo NN N
response NN o
rate NN o
was VBD N
similar JJ N
to TO N
that DT N
seen VBN N
in IN N
adults NNS N
. . N

CONCLUSIONS NNP N
Rizatriptan NNP N
5 CD N
mg NN N
was VBD N
well RB N
tolerated VBN o
and CC o
effective JJ o
on IN N
some DT N
measures NNS N
when WRB N
used VBN N
in IN N
adolescents NNS p
for IN p
the DT p
treatment NN p
of IN p
a DT p
migraine JJ p
attack NN p
. . p

-DOCSTART- -22490110- O O

A DT N
web-based JJ N
computer-tailored JJ N
smoking NN i
prevention NN i
programme NN i
for IN N
primary JJ p
school NN p
children NNS p
: : p
intervention NN N
design NN N
and CC N
study NN N
protocol NN N
. . N

BACKGROUND NNP N
Although IN N
the DT N
number NN N
of IN N
smokers NNS N
has VBZ N
declined VBN N
in IN N
the DT N
last JJ N
decade NN N
, , N
smoking NN N
is VBZ N
still RB N
a DT N
major JJ N
health NN N
problem NN N
among IN N
youngsters NNS p
and CC p
adolescents NNS p
. . p

For IN N
this DT N
reason NN N
, , N
there EX N
is VBZ N
a DT N
need NN N
for IN N
effective JJ N
smoking NN N
prevention NN N
programmes VBZ N
targeting VBG N
primary JJ p
school NN p
children NNS p
. . p

A DT N
web-based JJ N
computer-tailored JJ N
feedback NN i
programme NN i
may MD N
be VB N
an DT N
effective JJ N
intervention NN N
to TO N
stimulate VB N
youngsters NNS N
not RB N
to TO N
start VB N
smoking NN N
, , N
and CC N
increase VB N
their PRP$ N
knowledge NN o
about IN o
the DT o
adverse JJ o
effects NNS o
of IN o
smoking NN o
and CC N
their PRP$ N
attitudes NNS N
and CC N
self-efficacy NN N
regarding VBG N
non-smoking JJ N
. . N

METHODS NNP N
& CC N
DESIGN NNP N
This DT N
paper NN N
describes VBZ N
the DT N
development NN N
and CC N
evaluation NN N
protocol NN N
of IN N
a DT N
web-based JJ i
out-of-school JJ i
smoking NN i
prevention NN i
programme NN i
for IN N
primary JJ p
school NN p
children NNS p
( ( p
age NN p
10-13 CD p
years NNS p
) ) p
entitled VBD p
'Fun CD p
without IN p
Smokes NNP p
' POS p
. . N

It PRP N
is VBZ N
a DT N
transformation NN N
of IN N
a DT N
postal JJ N
mailed VBN N
intervention NN N
to TO N
a DT N
web-based JJ N
intervention NN N
. . N

Besides IN N
this DT N
transformation NN N
the DT N
effects NNS N
of IN N
prompts NNS N
will MD N
be VB N
examined VBN N
. . N

This DT N
web-based JJ N
intervention NN N
will MD N
be VB N
evaluated VBN N
in IN N
a DT N
2-year JJ N
cluster NN N
randomised VBD N
controlled VBN N
trial NN N
( ( N
c-RCT JJ N
) ) N
with IN N
three CD N
study NN N
arms NNS N
. . N

An DT N
intervention NN N
and CC N
intervention NN N
+ NNP N
prompt JJ N
condition NN N
will MD N
be VB N
evaluated VBN N
for IN N
effects NNS N
on IN N
smoking VBG o
behaviour NN o
, , N
compared VBN N
with IN N
a DT N
no DT N
information NN N
control NN N
condition NN N
. . N

Information NN N
about IN N
pupils NNS o
' POS o
smoking NN o
status NN o
and CC N
other JJ N
factors NNS N
related VBN N
to TO N
smoking NN N
will MD N
be VB N
obtained VBN N
using VBG N
a DT N
web-based JJ N
questionnaire NN N
. . N

After IN N
completing VBG N
the DT N
questionnaire NN N
pupils VBZ N
in IN N
both DT N
intervention NN N
conditions NNS N
will MD N
receive VB N
three CD N
computer-tailored JJ N
feedback NN N
letters NNS N
in IN N
their PRP$ N
personal JJ N
e-mail NN N
box NN N
. . N

Attitudes NNS o
, , o
social JJ o
influences NNS o
and CC o
self-efficacy JJ o
expectations NNS o
will MD N
be VB N
the DT N
content NN N
of IN N
these DT N
personalised VBN N
feedback NN N
letters NNS N
. . N

Pupils NNS N
in IN N
the DT N
intervention NN N
+ NNP N
prompt JJ N
condition NN N
will MD N
- : N
in IN N
addition NN N
to TO N
the DT N
personalised VBN N
feedback NN N
letters NNS N
- : N
receive JJ N
e-mail NN N
and CC N
SMS NNP N
messages NNS N
prompting VBG N
them PRP N
to TO N
revisit VB N
the DT N
'Fun CD N
without IN N
Smokes NNP N
' POS N
website NN N
. . N

The DT N
main JJ N
outcome NN N
measures NNS N
will MD N
be VB N
ever RB o
smoking VBG o
and CC o
the DT o
utilisation NN o
of IN o
the DT o
'Fun NN o
without IN o
Smokes NNP o
' POS o
website NN o
. . o

Measurements NNS N
will MD N
be VB N
carried VBN N
out RP N
at IN N
baseline NN N
, , N
12 CD N
months NNS N
and CC N
24 CD N
months NNS N
of IN N
follow-up JJ N
. . N

DISCUSSION VB N
The DT N
present JJ N
study NN N
protocol NN N
describes VBZ N
the DT N
purpose NN N
, , N
intervention NN N
design NN N
and CC N
study NN N
protocol NN N
of IN N
'Fun CD N
without IN N
Smokes NNP N
' POS N
. . N

Expectations NNS N
are VBP N
that IN N
pupils NNS N
receiving VBG N
tailored JJ N
advice NN N
will MD N
be VB N
less RBR N
likely JJ N
to TO N
smoke VB N
after IN N
24 CD N
months NNS N
in IN N
contrast NN N
to TO N
pupils VB N
in IN N
the DT N
control NN N
condition NN N
. . N

Furthermore NNP N
, , N
tailored VBD N
feedback NN N
letters NNS N
and CC N
prompting NN N
is VBZ N
expected VBN N
to TO N
be VB N
more RBR N
effective JJ N
than IN N
providing VBG N
tailored JJ N
feedback NN N
letters NNS N
only RB N
. . N

TRIAL NNP N
REGISTRATION NNP N
Dutch NNP N
Trial NNP N
Register NNP N
NTR3116 NNP N
. . N

-DOCSTART- -3284632- O O

Dysthymia NN N
: : N
a DT N
randomized JJ N
study NN N
of IN N
cognitive JJ N
marital JJ N
therapy NN N
and CC N
antidepressants NNS N
. . N

Preliminary NNP N
data NN N
from IN N
a DT N
randomized VBN N
study NN N
of IN N
the DT N
effectiveness NN N
of IN N
combined JJ i
marital JJ i
therapy NN i
and CC i
antidepressant JJ i
medication NN i
in IN N
the DT N
treatment NN p
of IN p
dysthymic JJ p
married JJ p
women NNS p
is VBZ N
presented VBN N
. . N

The DT N
study NN N
compares VBZ N
doxepin VBZ i
with IN i
placebo NN i
, , i
and CC i
a DT i
marital JJ i
therapy NN i
designed VBN i
to TO i
enhance VB i
intimacy NN i
through IN i
facilitating VBG i
self-disclosure NN i
between IN i
spouses NNS i
with IN i
a DT i
more RBR i
supportive JJ i
and CC i
educational JJ i
therapeutic JJ i
approach NN i
. . i

After IN N
ten JJ N
weeks NNS N
of IN N
combined JJ N
treatment NN N
, , N
the DT N
dysthymic JJ p
women NNS p
show VBP N
statistically RB N
significant JJ N
improvement NN N
on IN N
all PDT N
the DT N
depression NN o
measures VBZ o
as RB N
well RB N
as IN N
on IN N
the DT N
intimacy NN o
scale NN o
. . o

A DT N
trend NN N
is VBZ N
developing VBG N
for IN N
greater JJR N
reduction NN N
of IN N
depressive JJ o
symptomatology NN o
in IN N
the DT N
group NN N
treated VBD N
with IN N
self-disclosure NN N
. . N

The DT N
evidence NN N
appears VBZ N
to TO N
suggest VB N
the DT N
possibility NN N
that IN N
the DT N
presence NN N
of IN N
a DT N
patient NN N
's POS N
husband NN N
as IN N
a DT N
supportive JJ N
figure NN N
may MD N
of IN N
itself PRP N
be VB N
a DT N
potent JJ N
therapeutic JJ N
manoeuvre NN N
in IN N
the DT N
treatment NN N
of IN N
dysthymic JJ N
women NNS N
. . N

-DOCSTART- -24573180- O O

Activation NN N
of IN N
the DT N
carotid NN N
chemoreflex JJ N
secondary JJ N
to TO N
muscle VB o
metaboreflex JJ o
stimulation NN o
in IN N
men NNS p
. . p

Recent JJ N
work NN N
has VBZ N
shown VBN N
that IN N
the DT N
carotid NN N
chemoreceptor NN N
( ( N
CC NNP N
) ) N
contributes VBZ N
to TO N
sympathetic VB N
control NN N
of IN N
cardiovascular JJ N
function NN N
during IN N
exercise NN N
, , N
despite IN N
no DT N
evidence NN N
of IN N
increased JJ N
circulating VBG N
CC NNP N
stimuli NN N
, , N
suggesting VBG N
enhanced VBN N
CC NNP N
activity/sensitivity NN N
. . N

As IN N
interactions NNS N
between IN N
metaboreceptors NNS N
and CC N
chemoreceptors NNS N
have VBP N
been VBN N
previously RB N
observed VBN N
, , N
the DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
isolate VB N
the DT N
metaboreflex NN N
while IN N
acutely RB N
stimulating VBG N
or CC N
inhibiting VBG N
the DT N
CC NNP N
to TO N
determine VB N
whether IN N
the DT N
metaboreflex NN N
increased VBD N
CC NNP N
activity/sensitivity NN N
. . N

Fourteen NNP p
young JJ p
healthy JJ p
men NNS p
( ( p
height NN p
: : p
177.0 CD p
? . p
2.1 CD p
cm NN p
, , p
weight NN p
: : p
85.8 CD p
? . p
5.5 CD p
kg NN p
, , p
age NN p
: : p
24.6 CD p
? . p
1.1 CD p
yr NN p
) ) p
performed VBD p
three CD N
trials NNS N
of IN N
40 CD i
% NN i
maximal JJ i
voluntary JJ i
contraction NN i
handgrip NN i
for IN i
2 CD N
min NN N
, , N
followed VBN N
by IN N
3 CD i
min NN i
of IN i
postexercise NN i
circulatory NN i
occlusion NN i
( ( i
PECO NNP i
) ) i
to TO i
stimulate VB N
the DT N
metaboreflex NN N
. . N

In IN N
random JJ N
order NN N
, , N
subjects VBZ N
either CC N
breathed JJ i
room NN i
air NN i
, , o
hypoxia NN o
( ( o
target VB o
SPo2 NNP N
= NNP N
85 CD N
% NN N
) ) N
, , N
or CC N
hyperoxia NN o
( ( o
FiO2 NNP o
= NNP N
1.0 CD N
) ) N
during IN N
the DT N
PECO NNP N
to TO N
modulate VB N
the DT N
chemoreflex NN N
. . N

After IN N
these DT N
trials NNS N
, , N
a DT N
resting VBG N
hypoxia JJ N
trial NN N
was VBD N
conducted VBN N
without IN N
handgrip NN N
or CC N
PECO NNP o
. . o

Ventilation NNP o
( ( o
Ve NNP o
) ) o
, , o
heart NN o
rate NN o
( ( o
HR NNP o
) ) o
, , o
blood NN o
pressure NN o
, , o
and CC o
muscle NN o
sympathetic JJ o
nervous JJ o
activity NN o
( ( o
MSNA NNP o
) ) o
data NNS o
were VBD o
continuously RB N
obtained VBN N
. . N

Relative JJ N
to TO N
normoxic JJ N
PECO NNP N
, , N
inhibition NN N
of IN N
the DT N
CC NNP N
during IN N
hyperoxic JJ N
PECO NNP N
resulted VBD N
in IN N
lower JJR o
MSNA NNP o
( ( o
P NNP o
= NNP N
0.038 CD N
) ) N
and CC N
HR NNP N
( ( N
P NNP N
= NNP N
0.021 CD N
) ) N
. . N

Relative JJ N
to TO N
normoxic JJ N
PECO NNP N
, , N
stimulation NN N
of IN N
the DT N
CC NNP N
during IN N
hypoxic JJ N
PECO NNP N
resulted VBD N
in IN N
higher JJR o
HR NNP o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
Ve NNP N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
ventilatory NN o
and CC o
MSNA NNP o
responses NNS o
to TO N
hypoxic VB o
PECO NNP o
were VBD o
not RB N
greater JJR N
than IN N
the DT N
sum NN N
of IN N
the DT N
responses NNS N
to TO N
hypoxia VB N
and CC N
PECO NNP N
individually RB N
, , N
indicating VBG N
that IN N
the DT N
CC NNP o
are VBP o
not RB o
sensitized VBN o
during IN o
metaboreflex JJ N
activation NN N
. . N

These DT N
results NNS N
demonstrate VBP N
that IN o
stimulation NN o
of IN o
the DT o
metaboreflex NN o
activates VBZ o
, , o
but CC o
does VBZ N
not RB N
sensitize VB N
the DT N
CC NNP o
, , N
and CC N
help NN N
explain VB N
the DT N
enhanced JJ N
CC NNP N
activity NN N
with IN N
exercise NN N
. . N

-DOCSTART- -3341795- O O

Topical JJ i
fibronectin NN i
therapy NN i
for IN N
treatment NN N
of IN N
a DT N
patient NN p
with IN p
chronic JJ o
stasis NN o
ulcers NNS o
. . o

-DOCSTART- -6397729- O O

[ JJ N
Treatment NNP N
of IN N
essential JJ o
headache NN o
in IN N
developmental JJ p
age NN p
with IN N
L-5-HTP NNP i
( ( N
cross NN N
over IN N
double-blind JJ N
study NN N
versus IN N
placebo NN i
) ) i
] NN i
. . N

Thirty NN p
patients NNS p
( ( p
mean JJ p
age NN p
: : p
10.38 CD p
years NNS p
) ) p
affected VBN p
by IN p
primary JJ o
headache NN o
were VBD p
selected VBN p
for IN N
a DT N
double-blind JJ N
cross-over JJ N
clinical JJ N
trial NN N
. . N

The DT N
patients NNS N
were VBD N
randomized VBN N
into IN N
2 CD N
homogeneous JJ N
groups NNS N
of IN N
15 CD N
and CC N
treated VBD N
for IN N
12 CD N
weeks NNS N
with IN N
L-5-HTP NNP i
( ( N
100 CD N
mg/day NN N
) ) N
and CC N
placebo NN i
as IN N
per IN N
the DT N
following JJ N
design NN N
: : N
placebo NN i
- : i
L-5-HTP NNP i
( ( N
group NN N
A NNP N
) ) N
and CC N
L-5-HTP NNP i
- : i
placebo NN i
( ( N
group NN N
B NNP N
) ) N
. . N

Evaluation NN N
was VBD N
carried VBN N
out IN N
every DT N
3 CD N
weeks NNS N
by IN N
the DT N
Migraine NNP o
Index NNP o
supplying VBG N
a DT N
general JJ o
assessment NN o
of IN o
the DT o
attacks NNS o
, , o
i.e NN o
. . o

severity NN o
, , o
duration NN o
and CC o
frequency NN o
. . o

The DT N
decrease NN N
in IN N
mean JJ o
score NN o
values NNS o
was VBD N
directly RB N
proportional JJ N
to TO N
L-5-HTP NNP i
treatment NN N
, , N
and CC N
statistical JJ N
significance NN N
( ( o
Wilcoxon NNP o
's POS o
test NN o
) ) o
was VBD N
observed VBN N
only RB N
for IN N
L-5-HTP NNP N
in IN N
both DT N
groups NNS N
, , N
from IN N
0.05 CD N
to TO N
0.01 CD N
. . N

Improvement NN N
, , N
as IN N
evaluated VBN N
by IN N
CGI NNP N
on IN N
percentage NN N
distribution NN N
of IN N
the DT N
patients NNS N
, , N
was VBD N
homogeneous JJ N
in IN N
both DT N
groups NNS N
. . N

-DOCSTART- -7218018- O O

Are NNP N
oral JJ N
cathartics NNS N
of IN N
value NN N
in IN N
optimizing VBG N
the DT N
gallium NN N
scan JJ N
? . N
Concise NNP N
communication NN N
. . N

The DT N
normal JJ N
intestinal JJ N
secretion NN N
of IN N
9-15 CD N
% NN N
of IN N
an DT N
administered VBN N
dose NN N
of IN N
gallium-67 NN i
may MD N
prevent VB N
early JJ N
detection NN N
of IN N
intra-abdominal JJ N
disease NN N
. . N

We PRP p
randomized VBD p
50 CD p
patients NNS p
to TO N
receive VB N
either DT N
no DT i
bowel NN i
preparation NN i
or CC i
30 CD i
cc NN i
of IN i
milk NN i
of IN i
magnesia JJ i
plus CC i
5 CD i
cc NN i
of IN i
cascara NN i
. . i

No DT N
significant JJ N
difference NN N
was VBD N
found VBN N
between IN N
the DT N
two CD N
groups NNS N
in IN N
frequency NN o
with IN o
which WDT o
gallium NN o
interfered VBD o
with IN o
readings NNS o
or CC o
time NN o
to TO o
complete VB o
the DT o
study NN o
. . o

-DOCSTART- -3715614- O O

[ NNS N
Randomized NNP N
cooperative JJ N
studies NNS N
of IN N
the DT N
surgical JJ i
treatment NN i
of IN N
cancer NN p
of IN p
the DT p
thyroid JJ p
gland NN p
] NN p
. . N

-DOCSTART- -9700583- O O

A DT N
double JJ N
blind NN N
randomized VBD N
study NN N
of IN N
oral JJ N
clodronate NN i
in IN N
the DT N
treatment NN N
of IN N
bone NN p
metastases NNS p
from IN p
tumors NNS p
poorly RB p
responsive VBP p
to TO p
chemotherapy VB p
. . p

Bisphosphonates NNS i
are VBP N
used VBN N
in IN N
oncology NN N
as IN N
a DT N
means NN N
of IN N
decreasing VBG N
complications NNS N
due JJ N
to TO N
bone VB p
metastases NNS p
, , N
in IN N
association NN N
with IN N
anticancer NN N
treatment NN N
, , N
especially RB N
in IN N
patients NNS N
with IN N
breast NN N
cancer NN N
, , N
prostate NN N
cancer NN N
and CC N
myeloma NN N
. . N

Little JJ N
is VBZ N
known VBN N
about IN N
the DT N
effects NNS N
of IN N
bisphosphonates NNS i
on IN N
bone NN N
metastases NNS N
from IN N
other JJ N
tumors NNS N
and CC N
in IN N
particular JJ N
from IN N
tumors NNS N
for IN N
which WDT N
no DT N
effective JJ N
treatment NN N
is VBZ N
available JJ N
. . N

We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
double-blind JJ N
placebo-controlled JJ i
trial NN N
of IN N
oral JJ i
clodronate NN i
in IN N
patients NNS p
with IN p
bone NN p
metastases NNS p
from IN p
tumors NNS p
poorly RB p
responsive VBP p
to TO p
chemotherapy VB p
, , N
with IN N
the DT N
aims NNS N
of IN N
evaluating VBG N
the DT N
effects NNS o
of IN o
this DT o
drug NN o
on IN o
symptoms NNS o
control NN o
and CC o
bone NN o
metastases NNS o
evolution NN o
. . o

Sixty-six JJ p
patients NNS p
with IN p
poorly JJ p
responsive JJ p
tumors NNS p
such JJ p
as IN p
non-small JJ p
cell NN p
lung NN p
cancer NN p
( ( p
NSCLC NNP p
) ) p
, , p
bladder NN p
cancer NN p
, , p
gastrointestinal JJ p
cancers NNS p
, , p
kidney NN p
cancer NN p
, , p
melanoma NN p
and CC p
metastatic JJ p
carcinoma NN p
of IN p
unknown JJ p
origin NN p
entered VBD p
the DT p
study NN p
. . p

Patients NNS p
were VBD p
randomized VBN p
to TO p
receive VB i
either DT i
clodronate NN i
1,600 CD i
mg/day NN i
for IN i
one CD i
year NN i
or CC i
identical JJ i
placebo-containing JJ i
tablets NNS i
. . i

Various JJ i
parameters NNS i
such JJ i
as IN i
Karnofsky NNP o
performance NN o
status NN o
, , o
pain NN o
score NN o
( ( o
measured VBN o
by IN o
a DT o
visual-analogue JJ o
scale NN o
) ) o
and CC o
analgesic JJ o
requirement NN o
were VBD i
recorded VBN i
at IN i
monthly JJ i
intervals NNS i
. . i

Of IN p
the DT p
66 CD p
patients NNS p
enrolled VBD p
, , p
9 CD p
were VBD p
observed VBN p
for IN p
one CD p
month NN p
or CC p
less JJR p
; : p
7 CD p
were VBD p
followed VBN p
for IN p
two CD p
months NNS p
; : p
only RB p
50 CD p
patients NNS p
were VBD p
followed VBN p
for IN p
more JJR p
than IN p
2 CD p
months NNS p
and CC p
could MD p
be VB p
adequately RB p
evaluated VBN p
. . p

At IN N
3 CD N
months NNS N
both DT N
clodronate NN i
and CC N
placebo-treated JJ i
patients NNS N
had VBD N
a DT N
decrease NN o
in IN o
Karnofsky NNP o
performance NN o
status NN o
, , N
with IN N
the DT N
decrease NN N
being VBG N
more RBR N
evident JJ N
in IN N
the DT N
placebo NN N
group NN N
. . N

Mean NNP o
pain NN o
scores NNS o
showed VBD N
an DT N
increase NN o
of IN o
pain NN o
in IN N
patients NNS N
receiving VBG N
placebo NN i
and CC N
a DT N
decrease NN N
of IN N
pain NN N
in IN N
patients NNS N
receiving VBG N
clodronate NN i
, , N
although IN N
the DT N
difference NN N
failed VBD N
to TO N
be VB N
statistically RB N
significant JJ N
. . N

Analgesics NNPS o
requirement NN o
increased VBN N
in IN N
both DT N
groups NNS N
, , N
but CC N
significantly RB N
more RBR N
in IN N
patients NNS N
receiving VBG N
placebo NN i
( ( N
p JJ N
= NNP N
0.042 CD N
) ) N
, , N
in IN N
whom WP N
increase NN N
in IN N
opioid JJ N
requirements NNS N
was VBD N
particularly RB N
evident JJ N
. . N

Toxicity NNP o
was VBD o
low JJ o
, , N
with IN N
occasional JJ o
gastroenteric JJ o
discomfort NN o
in IN N
both DT N
groups NNS N
. . N

The DT N
main JJ N
problem NN N
of IN N
this DT N
study NN N
was VBD N
the DT N
difficulty NN N
in IN N
recruiting VBG N
an DT N
adequate JJ N
number NN N
of IN N
patients NNS N
and CC N
following VBG N
them PRP N
for IN N
a DT N
sufficient JJ N
period NN N
of IN N
time NN N
: : N
general JJ N
conditions NNS N
rapidly RB N
deteriorated VBD N
in IN N
many JJ N
patients NNS N
, , N
and CC N
approximately RB N
25 CD N
% NN N
of IN N
the DT N
66 CD N
enrolled NNS N
were VBD N
not RB N
considered VBN N
evaluable JJ N
; : N
few JJ N
patients NNS N
survived VBD N
for IN N
the DT N
length NN N
of IN N
the DT N
study NN N
, , N
one CD N
year NN N
. . N

This DT N
might MD N
partly RB N
account VB N
for IN N
the DT N
lack NN N
of IN N
significance NN N
of IN N
some DT N
of IN N
the DT N
parameters NNS N
under IN N
study NN N
. . N

With IN N
these DT N
limits NNS N
, , N
oral JJ N
clodronate NN N
demonstrated VBD N
some DT N
efficacy NN N
in IN N
symptom NN N
control NN N
and CC N
in IN N
reducing VBG N
the DT N
need NN N
for IN N
analgesics NNS N
. . N

-DOCSTART- -6363798- O O

A DT N
controlled VBN N
study NN N
of IN N
the DT N
effect NN o
of IN N
indomethacin NN i
in IN N
uremic JJ o
pericarditis NN o
. . o

To TO N
determine VB N
the DT N
impact NN N
of IN N
indomethacin NN i
on IN N
the DT N
course NN N
of IN N
uremic JJ N
pericarditis NN N
we PRP N
performed VBD N
a DT N
prospective JJ N
, , N
double JJ N
blind NN N
study NN N
in IN N
which WDT N
24 CD p
patients NNS p
with IN p
endstage NN p
chronic JJ p
renal JJ p
failure NN p
and CC p
pericarditis NN p
randomly RB p
received VBD p
indomethacin JJ i
, , p
25 CD p
mg NN p
four CD p
times NNS p
daily RB p
, , p
( ( p
11 CD p
patients NNS p
) ) p
or CC p
a DT p
placebo NN i
( ( p
13 CD p
patients NNS p
) ) p
for IN N
a DT N
3-week JJ N
period NN N
. . N

All DT N
patients NNS p
received VBN p
peritoneal JJ p
or CC p
hemodialysis NN p
treatment NN p
concurrently RB p
with IN N
the DT N
study NN N
drug NN N
. . N

In IN N
contrast NN N
to TO N
the DT N
placebo NN i
, , i
indomethacin NN i
produced VBD N
an DT N
immediate JJ N
and CC N
sustained JJ N
reduction NN o
of IN o
fever NN o
in IN N
all DT N
but CC N
one CD N
patient NN N
. . N

On IN N
the DT N
other JJ N
hand NN N
, , N
indomethacin NN i
had VBD N
no DT N
effect NN N
on IN N
the DT N
duration NN o
of IN o
chest NN o
pain NN o
( ( N
mean JJ N
days NNS N
+/- JJ N
SE NNP N
: : N
placebo NN i
1.4 CD N
+/- JJ N
0.6 CD N
, , N
indomethacin JJ i
5.5 CD N
+/- JJ N
3.3 CD N
) ) N
, , N
duration NN N
of IN N
pericardial JJ o
friction NN o
rub NN o
( ( N
placebo JJ N
10.3 CD N
+/- JJ N
1.7 CD N
, , N
indomethacin JJ i
16.0 CD N
+/- JJ N
3.8 CD N
) ) N
, , N
or CC N
on IN N
the DT N
amount NN N
of IN N
pericardial JJ o
effusion NN o
. . o

Further NNP N
, , N
indomethacin NN N
did VBD N
not RB N
diminish VB N
the DT N
need NN o
for IN o
invasive JJ o
surgical JJ o
procedures NNS o
for IN o
relief NN o
of IN o
tamponade NN o
( ( N
three CD N
of IN N
13 CD N
placebo NN N
patients NNS N
, , N
two CD N
of IN N
11 CD N
indomethacin JJ N
patients NNS N
) ) N
or CC N
result NN N
in IN N
decreased JJ N
mortality NN o
rate NN o
. . o

Death NNP o
( ( N
not RB N
due RB N
to TO N
pericarditis NN N
) ) N
occurred VBD N
in IN N
two CD N
patients NNS N
treated VBN N
with IN N
indomethacin NN N
and CC N
one CD N
patient NN N
who WP N
received VBD N
the DT N
placebo NN i
. . i

In IN N
our PRP$ N
patients NNS N
pericarditis VBP N
encompassed VBD N
a DT N
wide JJ N
spectrum NN N
ranging VBG N
from IN N
a DT N
mild JJ o
illness NN o
of IN o
several JJ o
days NNS o
duration NN o
to TO N
a DT N
painful JJ o
and CC o
debilitating JJ o
disease NN o
lasting JJ o
weeks NNS o
and CC N
requiring VBG N
surgical JJ o
intervention NN o
. . o

Although IN N
the DT N
size NN N
of IN N
our PRP$ N
population NN N
prohibits VBZ N
definitive JJ N
conclusions NNS N
, , N
it PRP N
would MD N
appear VB N
that IN N
, , N
except IN N
for IN N
fever NN N
, , N
the DT N
manifestations NNS N
and CC N
natural JJ N
history NN N
of IN N
this DT N
illness NN o
are VBP N
unaffected VBN N
by IN N
indomethacin NN i
. . i

-DOCSTART- -12452980- O O

Investigation NN N
of IN N
the DT N
effect NN N
of IN N
FK506 NNP i
( ( i
tacrolimus NN i
) ) i
and CC i
cyclosporin NN i
on IN N
gingival JJ N
overgrowth NN N
following VBG N
paediatric JJ p
liver JJ p
transplantation NN p
. . p

INTRODUCTION NNP N
Gingival NNP N
overgrowth NN N
associated VBN N
with IN N
immunosuppression NN N
following VBG N
liver JJ N
transplantation NN N
is VBZ N
a DT N
commonly RB N
recognized VBN N
clinical JJ N
problem NN N
. . N

The DT N
aims NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
determine VB N
the DT N
incidence NN N
of IN N
gingival JJ N
overgrowth NN N
in IN N
a DT N
group NN p
of IN p
children NNS p
post VBN p
liver JJ p
transplantation NN p
and CC N
to TO N
compare VB N
gingival JJ p
overgrowth NN p
in IN p
children NNS p
receiving VBG p
FK506 NNP i
with IN N
those DT N
receiving VBG N
cyclosporin NN i
. . i

METHODS NNP N
Seventy-nine JJ p
children NNS p
( ( p
aged VBN p
15-196 CD p
months NNS p
) ) p
undergoing VBG p
liver JJ p
transplantation NN p
at IN p
Birmingham NNP p
Children NNP p
's POS p
Hospital NNP p
between IN p
October NNP p
1998 CD p
and CC p
October NNP p
2000 CD p
were VBD N
studied VBN N
. . N

Gingival NNP o
overgrowth NN o
was VBD N
assessed VBN N
in IN N
a DT N
blinded JJ N
fashion NN N
and CC N
scored VBN N
in IN N
a DT N
previously RB N
validated VBN N
manner NN N
. . N

Gingival NNP o
overgrowth NN o
scores NNS N
of IN N
the DT N
patients NNS N
on IN N
each DT N
immunosuppressant JJ N
drug NN N
were VBD N
then RB N
compared VBN N
. . N

RESULTS NNP N
Fifty-two JJ p
patients NNS p
were VBD N
treated VBN N
with IN N
cyclosporin NN i
and CC N
27 CD N
treated VBN N
with IN N
tacrolimus NN i
. . i

Eighteen JJ p
children NNS p
were VBD N
also RB N
receiving VBG N
nifedipine NN i
( ( N
also RB N
known VBN N
to TO N
cause VB N
gingival JJ o
overgrowth NN o
) ) o
and CC N
were VBD N
considered VBN N
separately RB N
. . N

Of IN N
the DT N
41 CD p
children NNS p
receiving VBG p
cyclosporin NN i
alone RB p
, , p
26 CD p
exhibited VBD p
gingival NN o
overgrowth NN o
compared VBN p
to TO p
zero CD p
of IN p
20 CD p
patients NNS p
receiving VBG p
tacrolimus JJ i
alone RB p
. . p

Those DT N
children NNS p
treated VBN p
with IN p
immunosuppression NN p
plus CC N
nifedipine NN N
developed VBD N
gingival JJ o
overgrowth NN o
, , N
however RB N
, , N
this DT N
was VBD N
much RB N
less JJR N
marked VBN N
in IN N
the DT N
tacrolimus NN i
group NN N
. . N

CONCLUSION NNP N
Tacrolimus NNP i
, , N
unlike IN N
cyclosporin NN i
, , N
is VBZ N
not RB N
associated VBN N
with IN N
gingival NN o
overgrowth NN o
when WRB N
used VBN N
for IN N
immunosuppression NN N
following VBG N
liver JJ p
transplantation NN p
in IN p
children NNS p
, , N
and CC N
may MD N
be VB N
the DT N
drug NN N
of IN N
choice NN N
for IN N
children NNS N
. . N

-DOCSTART- -11709366- O O

Pharmacokinetic NNP o
study NN N
of IN N
human JJ p
immunodeficiency NN p
virus NN p
protease NN i
inhibitors NNS i
used VBN i
in IN i
combination NN i
with IN i
amprenavir NN i
. . i

In IN N
an DT N
open-label JJ N
, , N
randomized VBN N
, , N
multicenter RBR N
, , N
multiple-dose JJ N
pharmacokinetic JJ N
study NN N
, , N
we PRP N
determined VBD N
the DT N
steady-state JJ o
pharmacokinetics NNS o
of IN N
amprenavir NN i
with IN i
and CC i
without IN i
coadministration NN i
of IN i
indinavir NN i
, , i
nelfinavir NN i
, , i
or CC i
saquinavir VB i
soft JJ i
gel NNS i
formulation NN i
in IN N
31 CD p
human JJ p
immunodeficiency NN p
virus NN p
type JJ p
1-infected JJ p
subjects NNS p
. . p

The DT N
results NNS N
indicated VBD N
that IN N
amprenavir NN o
plasma NN o
concentrations NNS o
were VBD N
decreased VBN N
by IN N
saquinavir JJ i
soft JJ N
gel NN N
capsule NN N
( ( N
by IN N
32 CD N
% NN N
for IN N
area NN N
under IN N
the DT N
concentration-time JJ o
curve NN o
at IN o
steady JJ o
state NN o
[ NNS N
AUC NNP N
( ( N
ss NN N
) ) N
] NN N
and CC N
37 CD N
% NN N
for IN N
peak NN o
plasma NN o
concentration NN o
at IN o
steady JJ o
state NN o
[ NNS N
C NNP N
( ( N
max NN N
, , N
ss NN N
) ) N
] NN N
) ) N
and CC N
increased VBN N
by IN N
indinavir NN i
( ( N
33 CD N
% NN N
for IN N
AUC NNP N
( ( N
ss NN N
) ) N
) ) N
. . N

Nelfinavir NNP i
significantly RB N
increased VBD N
amprenavir JJ o
minimum JJ o
drug NN o
concentration NN o
at IN N
steady JJ N
state NN N
( ( N
by IN N
189 CD N
% NN N
) ) N
but CC N
did VBD N
not RB N
affect VB N
amprenavir NN i
AUC NNP o
( ( o
ss NN o
) ) o
or CC N
C NNP o
( ( o
max NN o
, , o
ss NN o
) ) o
. . o

Nelfinavir NNP i
and CC N
saquinavir JJ i
steady-state JJ o
pharmacokinetics NNS o
were VBD N
unchanged JJ N
by IN N
coadministration NN N
with IN N
amprenavir NNS i
compared VBN N
with IN N
the DT N
historical JJ N
monotherapy NN N
data NNS N
. . N

Concentrations NNS o
of IN o
indinavir NN o
, , o
coadministered VBN o
with IN o
amprenavir NN o
, , o
in IN o
plasma NN o
decreased VBN N
in IN N
both DT N
single-dose JJ N
and CC N
steady-state JJ N
evaluations NNS N
. . N

The DT N
changes NNS N
in IN N
amprenavir JJ i
steady-state JJ o
pharmacokinetic JJ o
parameters NNS o
, , N
relative JJ N
to TO N
those DT N
for IN N
amprenavir JJ i
alone RB N
, , N
were VBD N
not RB N
consistent JJ N
among IN N
protease JJ N
inhibitors NNS N
, , N
nor CC N
were VBD N
the DT N
changes NNS N
consistent VBP N
with IN N
potential JJ N
interactions NNS N
in IN N
CYP3A4 NNP N
metabolism NN N
or CC N
P-glycoprotein JJ N
transport NN N
. . N

No UH N
dose JJ N
adjustment NN N
of IN N
either DT N
protease NN N
inhibitor NN N
in IN N
any DT N
of IN N
the DT N
combinations NNS N
studied VBN N
is VBZ N
needed VBN N
. . N

-DOCSTART- -16730541- O O

Thermal JJ i
welding VBG i
versus NN i
bipolar JJ i
tonsillectomy NN i
: : i
a DT N
comparative JJ N
study NN N
. . N

OBJECTIVE NNP N
To TO N
compare VB N
thermal JJ i
welding VBG i
tonsillectomy NN i
( ( i
TWT NNP i
) ) i
with IN i
bipolar JJ i
electrocautery NN i
tonsillectomy NN i
( ( i
BET NNP i
) ) i
procedure NN i
. . i

STUDY NNP N
DESIGN NNP N
AND NNP N
SETTING NNP N
A NNP N
prospective JJ N
randomized NN N
study NN N
was VBD N
conducted VBN N
on IN N
150 CD p
consecutive JJ p
adult NN p
patients NNS p
undergoing VBG p
tonsillectomy NN i
. . i

Indications NNS p
included VBD p
chronic JJ p
tonsillitis NN p
and CC p
obstructive JJ p
sleep NN p
apnea NN p
syndrome NN p
. . p

Exclusion NN p
criteria NNS p
included VBD p
peritonsillar JJ p
abscess NN p
history NN p
, , p
bleeding VBG p
disorders NNS p
, , p
and CC p
any DT p
other JJ p
procedure NN p
together RB p
with IN p
tonsillectomy NN p
. . p

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
TWT NNP i
or CC N
BET NNP i
groups NNS N
. . N

Intraoperative JJ o
bleeding NN o
, , o
operative JJ o
time NN o
, , o
postoperative JJ o
pain NN o
, , o
complication NN o
rates NNS o
, , o
and CC o
return VB o
to TO o
normal JJ o
diet JJ o
were VBD N
evaluated VBN N
. . N

RESULTS NNP N
In IN N
the DT N
TWT NNP i
group NN N
there EX N
was VBD N
no DT N
measurable JJ N
intraoperative JJ o
bleeding NN o
, , N
while IN N
mean JJ o
bleeding NN o
for IN N
BET NNP i
group NN N
was VBD N
16 CD N
mL NN N
. . N

No DT N
significant JJ N
difference NN N
regarding VBG N
mean JJ o
operative JJ o
time NN o
was VBD N
noticed VBN N
. . N

Mean NNP o
postoperative JJ o
pain NN o
score NN o
and CC o
mean JJ o
time NN o
for IN o
return NN o
to TO o
normal JJ o
diet JJ o
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
TWT NNP i
group NN N
. . N

Primary JJ o
hemorrhage NN o
occurred VBD N
in IN N
1 CD N
subject NN N
of IN N
the DT N
BET NNP i
group NN N
. . N

Secondary JJ o
postoperative JJ o
hemorrhage NN o
was VBD N
noticed VBN N
in IN N
1 CD N
subject NN N
of IN N
the DT N
TWT NNP i
group NN N
and CC N
3 CD N
subjects NNS N
of IN N
the DT N
BET NNP i
group NN N
. . N

CONCLUSION NNP N
Thermal NNP i
welding VBG i
tonsillectomy JJ i
procedure NN i
provides VBZ N
sufficient JJ N
hemostasis NN o
, , N
lower JJR N
postoperative NN o
pain NN o
, , N
and CC N
quick JJ o
return NN o
to TO o
normal JJ o
diet JJ o
. . o

EBM JJ N
RATING NNP N
A-1b NNP N
. . N

-DOCSTART- -17666359- O O

[ JJ N
Application NNP N
of IN N
tacrolimus NN i
and CC i
cyclosporine VB i
A NNP i
in IN N
HBV-carrying NNP p
renal JJ p
transplant NN p
recipients NNS p
] VBP p
. . N

OBJECTIVE NNP N
To TO N
compare VB N
the DT N
long-term JJ N
effect NN N
and CC N
safety NN N
of IN N
tacrolimus NN i
( ( i
FK506 NNP i
) ) i
and CC i
cyclosporine NN i
( ( i
CsA NNP i
) ) i
in IN N
kidney NN p
transplant NN p
( ( p
KT NNP p
) ) p
recipients VBZ p
carrying VBG p
hepatitis NN p
B NNP p
Virus NNP p
( ( p
HBV NNP p
) ) p
. . p

METHODS CC N
A DT N
total NN N
of IN N
109 CD p
patients NNS p
with IN p
HBV NNP p
were VBD N
randomized VBN N
into IN N
FK506 NNP i
group NN N
( ( N
52 CD N
cases NNS N
) ) N
and CC N
CsA NNP i
group NN N
( ( N
57 CD N
cases NNS N
) ) N
after IN N
KT NNP N
, , N
and CC N
a DT N
2-year-long JJ N
follow-up NN N
of IN N
the DT N
patients NNS N
was VBD N
conducted VBN N
to TO N
record VB N
the DT N
patient NN o
and CC o
graft NN o
survival NN o
, , o
incidence NN o
of IN o
acute NN o
graft NN o
rejection NN o
and CC N
postoperative JJ o
liver NN o
function NN o
. . o

RESULTS VB N
The DT N
2-year JJ o
patient/graft NN o
survival NN o
was VBD N
86.0 CD N
% NN N
/73.7 CC N
% NN N
and CC N
94.2 CD N
% NN N
/90.3 CD N
% NN N
in IN N
CsA NNP N
and CC N
FK506 NNP N
groups NNS N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
with IN N
incidence NN N
of IN N
acute JJ o
rejection NN o
of IN N
10.5 CD N
% NN N
and CC N
9.6 CD N
% NN N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
, , N
and CC N
rate NN N
of IN N
abnormal JJ o
liver NN o
function NN o
of IN N
26.3 CD N
% NN N
and CC N
15.4 CD N
% NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
respectively RB N
. . N

Eight CD N
patients NNS N
( ( N
14.4 CD N
% NN N
) ) N
in IN N
CsA NNP N
group NN N
required VBD N
a DT N
drug NN N
conversion NN N
but CC N
none NN N
in IN N
FK506 NNP N
group NN N
. . N

The DT N
drug NN N
conversion NN N
resulted VBD N
in IN N
significant JJ N
reduction NN N
of IN N
ALT/AST NNP o
level NN o
from IN N
255.13+/-31.38/201.88+/-21.25 JJ N
U/L NNP N
to TO N
31.25+/-11.50/25.13+/-9.68 JJ N
U/L NNP N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSION NNP N
For IN N
HBV-carrying NNP p
renal JJ p
transplant NN p
recipients NNS p
, , N
FK506 NNP i
as IN N
the DT N
primary JJ N
choice NN N
of IN N
immunosuppressant NN N
can MD N
be VB N
more RBR N
effective JJ N
and CC N
safer JJR N
than IN N
CsA NNP N
. . N

-DOCSTART- -19552744- O O

Pharmacokinetic- JJ N
pharmacodynamic JJ N
analysis NN N
of IN N
the DT N
role NN N
of IN N
CYP2C19 NNP N
genotypes NNS N
in IN N
short-term JJ N
rabeprazole-based JJ i
triple JJ i
therapy NN i
against IN N
Helicobacter NNP N
pylori NN N
. . N

AIMS IN N
The DT N
aim NN N
was VBD N
to TO N
explore VB N
the DT N
role NN N
of IN N
CYP2C19 NNP N
polymorphism NN N
in IN N
short-term JJ N
rabeprazole-based JJ i
triple JJ i
therapy NN i
against IN N
Helicobacter NNP p
pylori JJ p
infection NN p
. . p

METHODS NNP N
Patients NNPS p
with IN p
H. NNP p
pylori FW p
infection NN p
were VBD N
tested VBN N
for IN N
CYP2C19 NNP N
genotype NN N
as IN N
poor JJ N
metabolizers NNS N
( ( N
PMs NNP N
) ) N
or CC N
extensive JJ N
metabolizers NNS N
( ( N
EMs NNP N
, , N
homozygous JJ N
EM NNP N
or CC N
heterozygous JJ N
EM NNP N
) ) N
and CC N
given VBN N
rabeprazole NN i
for IN N
7 CD N
days NNS N
. . N

Antibiotics NNS i
( ( i
clarithromycin NN i
and CC i
amoxicillin NN i
) ) i
were VBD N
given VBN N
on IN N
days NNS N
1-4 CD N
, , N
days NNS N
4-7 CD N
, , N
or CC N
days NNS N
1-7 RB N
. . N

A DT N
direct JJ N
link NN N
model NN N
with IN N
an DT N
effect NN N
compartment NN N
was VBD N
used VBN N
in IN N
the DT N
population NN N
pharmacokinetic-pharmacodynamic JJ N
analysis NN N
. . N

The DT N
status NN N
of IN N
H. NNP o
pylori FW o
infection NN o
was VBD N
evaluated VBN N
. . N

RESULTS NNP N
Rabeprazole NNP o
clearance NN o
was VBD N
lower JJR N
in IN N
CYP2C19 NNP N
PMs NNP N
than IN N
in IN N
EMs NNP N
( ( N
with IN N
average NN N
values NNS N
of IN N
10.7 CD N
vs. FW N
16.8 CD N
l NN N
h NN N
( ( N
-1 NNP N
) ) N
in IN N
PMs NNP N
and CC N
EMs NNP N
, , N
respectively RB N
) ) N
, , N
resulting VBG N
in IN N
higher JJR N
plasma NN N
levels NNS N
in IN N
the DT N
former JJ N
group NN N
. . N

The DT N
values NNS o
of IN o
EC NNP o
( ( o
50 CD o
) ) o
and CC o
k $ o
( ( o
eo NN o
) ) o
of IN o
gastrin JJ o
response NN o
increased VBD N
with IN N
multiple JJ N
doses NNS N
of IN N
rabeprazole NN i
. . i

The DT N
k NN o
( ( o
eo NN o
) ) o
values NNS o
were VBD N
lower JJR N
in IN N
CYP2C19 NNP N
PMs NNP N
than IN N
in IN N
EMs NNP N
on IN N
day NN N
1 CD N
( ( N
0.012 CD N
vs. FW N
0.017 CD N
x $ N
10 CD N
( ( N
-4 NN N
) ) N
l NN N
min NN N
( ( N
-1 NNP N
) ) N
) ) N
, , N
and CC N
higher JJR N
than IN N
in IN N
EMs NNP N
on IN N
day NN N
4 CD N
( ( N
0.804 CD N
vs. FW N
0.169 CD N
x $ N
10 CD N
( ( N
-4 NN N
) ) N
l NN N
min NN N
( ( N
-1 NNP N
) ) N
) ) N
of IN N
rabeprazole NN i
treatment NN N
. . N

The DT N
predicted JJ o
gastrin-time NN o
profile NN o
showed VBD N
a DT N
higher JJR N
response NN N
in IN N
CYP2C19 NNP N
PMs NNP N
than IN N
in IN N
EMs NNP N
on IN N
days NNS N
4 CD N
and CC N
7 CD N
. . N

Helicobacter NNP o
pylori NN o
was VBD o
eradicated VBN o
in IN N
all DT N
CYP2C19 NNP N
PMs NNP N
except IN N
in IN N
one CD N
patient NN N
infected VBN N
by IN N
a DT N
resistant JJ N
strain NN N
. . N

In IN N
contrast NN N
, , N
in IN N
CYP2C19 NNP N
EMs NNP N
the DT N
eradication NN o
rates NNS o
ranged VBD N
from IN N
58 CD N
to TO N
85 CD N
% NN N
. . N

CONCLUSIONS NNP N
CYP2C19 NNP N
genotypes VBZ N
play VB N
a DT N
role NN N
in IN N
H. NNP N
pylori FW N
eradication NN N
therapy NN N
. . N

Rabeprazole-based JJ i
short-term JJ i
triple JJ i
therapy NN i
may MD N
be VB N
applicable JJ N
in IN N
CYP2C19 NNP N
PMs NNP N
for IN N
H. NNP N
pylori JJ N
eradication NN N
. . N

-DOCSTART- -12193353- O O

Local JJ N
warming NN N
and CC N
insertion NN N
of IN N
peripheral JJ N
venous JJ N
cannulas NNS N
: : N
single JJ N
blinded VBD N
prospective JJ N
randomised VBN N
controlled VBN N
trial NN N
and CC N
single JJ N
blinded VBD N
randomised VBN N
crossover RB N
trial NN N
. . N

OBJECTIVE NN N
To TO N
determine VB N
whether IN N
local JJ N
warming NN N
of IN N
the DT N
lower JJR N
arm NN N
and CC N
hand NN N
facilitates NNS N
peripheral VBP o
venous JJ o
cannulation NN o
. . o

DESIGN NNP N
Single NNP N
blinded VBD N
prospective JJ N
randomised VBN N
controlled VBN N
trial NN N
and CC N
single JJ N
blinded VBD N
randomised VBN N
crossover RB N
trial NN N
. . N

SETTING NNP N
Neurosurgical JJ p
unit NN p
and CC p
haematology NN p
ward NN p
of IN p
university NN p
hospital NN p
. . p

PARTICIPANTS CC N
100 CD p
neurosurgical JJ p
patients NNS p
and CC p
40 CD p
patients NNS p
with IN p
leukaemia NNS p
who WP p
required VBD p
chemotherapy NN p
. . p

INTERVENTIONS NNP N
Neurosurgical JJ N
patients NNS N
' POS N
hands NNS i
and CC i
forearms NNS i
were VBD i
covered VBN i
for IN i
15 CD i
minutes NNS i
with IN i
a DT i
carbon NN i
fibre NN i
heating VBG i
mitt NN i
. . i

Patients NNS N
were VBD N
assigned VBN N
randomly RB N
to TO N
active JJ i
warming NN i
at IN i
52 CD i
degrees NNS i
C NNP i
or CC i
passive JJ i
insulation NN i
( ( N
heater NN N
not RB N
activated VBN N
) ) N
. . N

The DT N
same JJ N
warming NN N
system NN N
was VBD N
used VBN N
for IN N
10 CD N
minutes NNS N
in IN N
patients NNS N
with IN N
leukaemia NN N
. . N

They PRP N
were VBD N
assigned VBN N
randomly RB N
to TO N
active JJ N
warming NN N
or CC N
passive JJ N
insulation NN N
on IN N
day NN N
1 CD N
and CC N
given VBN N
alternative JJ N
treatment NN N
during IN N
the DT N
subsequent JJ N
visit NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
PRIMARY NNP N
: : N
success NN o
rate NN o
for IN o
insertion NN o
of IN o
18 CD o
gauge NN o
cannula NN o
into IN o
vein NN o
on IN o
back NN o
of IN o
hand NN o
. . o

SECONDARY NN N
: : N
time NN o
required VBN o
for IN o
successful JJ o
cannulation NN o
. . o

RESULTS NNP N
In IN N
neurosurgical JJ N
patients NNS N
, , N
it PRP N
took VBD N
36 CD N
seconds NNS N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
31 CD N
to TO N
40 CD N
seconds NNS N
) ) N
to TO N
insert VB o
a DT o
cannula NN o
in IN N
the DT N
active JJ N
warming NN N
group NN N
and CC N
62 CD N
( ( N
50 CD N
to TO N
74 CD N
) ) N
seconds NNS N
in IN N
the DT N
passive JJ N
insulation NN N
group NN N
( ( N
P=0.002 NNP N
) ) N
. . N

Three NNP N
( ( N
6 CD N
% NN N
) ) N
first RB N
attempts VBZ N
failed VBN o
in IN N
the DT N
active JJ N
warming VBG N
group NN N
compared VBN N
with IN N
14 CD N
( ( N
28 CD N
% NN N
) ) N
in IN N
the DT N
passive JJ N
insulation NN N
group NN N
( ( N
P=0.008 NNP N
) ) N
. . N

The DT N
crossover NN N
study NN N
in IN N
patients NNS N
with IN N
leukaemia NN N
showed VBD N
that IN N
insertion NN o
time NN o
was VBD N
reduced VBN N
by IN N
20 CD N
seconds NNS N
( ( N
8 CD N
to TO N
32 CD N
, , N
P=0.013 NNP N
) ) N
with IN N
active JJ N
warming NN N
and CC N
that IN N
failure NN o
rates NNS o
at IN o
first JJ o
attempt NN o
were VBD N
6 CD N
% NN N
with IN N
warming VBG N
and CC N
30 CD N
% NN N
with IN N
passive JJ N
insulation NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSIONS NNP N
Local NNP N
warming VBG N
facilitates VBZ N
the DT N
insertion NN o
of IN o
peripheral JJ o
venous JJ o
cannulas NNS o
, , N
reducing VBG N
both DT N
time NN o
and CC o
number NN o
of IN o
attempts NNS o
required VBN o
. . o

This DT N
may MD N
decrease VB N
the DT N
time NN o
staff NN N
spend VBP N
inserting VBG o
cannulas NN o
, , N
reduce VB N
supply NN o
costs NNS o
, , N
and CC N
improve VB N
patient JJ N
satisfaction NN N
. . N

-DOCSTART- -26156941- O O

Physical JJ i
exercise NN i
at IN i
the DT i
workplace NN i
reduces VBZ N
perceived JJ N
physical JJ N
exertion NN N
during IN N
healthcare JJ N
work NN N
: : N
cluster NN N
randomized VBD N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
High NNP i
physical JJ i
exertion NN i
during IN N
work NN N
is VBZ N
a DT N
risk NN N
factor NN N
for IN N
musculoskeletal JJ N
pain NN N
and CC N
long-term JJ N
sickness NN N
absence NN N
. . N

Physical JJ N
exertion NN N
( ( N
RPE NNP N
) ) N
reflects VBZ N
the DT N
balance NN N
between IN N
physical JJ N
work NN N
demands NNS N
and CC N
physical JJ N
capacity NN N
of IN N
the DT N
individual NN N
. . N

Thus RB N
, , N
increasing VBG N
the DT N
physical JJ N
capacity NN N
through IN N
physical JJ N
exercise NN N
may MD N
decrease VB N
physical JJ N
exertion NN N
during IN N
work NN N
. . N

This DT N
study NN N
investigates VBZ N
the DT N
effect NN o
of IN N
workplace-based JJ N
versus NN N
home-based JJ N
physical JJ N
exercise NN N
on IN N
physical JJ N
exertion NN N
during IN N
work NN N
( ( N
WRPE NNP N
) ) N
among IN N
healthcare JJ p
workers NNS p
. . p

METHODS NNP N
200 CD p
female NN p
healthcare NN p
workers NNS p
( ( p
age NN p
: : p
42.0 CD p
, , p
body NN p
mass NN p
index NN p
: : p
24.1 CD p
, , p
average JJ p
pain NN p
intensity NN p
: : p
3.1 CD p
on IN p
a DT p
scale NN p
of IN p
0 CD p
to TO p
10 CD p
, , p
average JJ p
WRPE NNP p
: : p
3.6 CD p
on IN p
a DT p
scale NN p
of IN p
0 CD p
to TO p
10 CD p
) ) p
from IN p
18 CD p
departments NNS p
at IN p
three CD p
participating VBG p
hospitals NNS p
. . p

Participants NNS p
were VBD p
randomly RB p
allocated VBN p
at IN p
the DT p
cluster NN p
level NN p
to TO N
10 CD N
weeks NNS N
of IN N
: : N
( ( i
1 CD i
) ) i
workplace NN i
physical JJ i
exercise NN i
( ( i
WORK NNP i
) ) i
performed VBD i
in IN i
groups NNS i
during IN i
working VBG i
hours NNS i
for IN i
5?10 CD i
minutes NNS i
per IN i
week NN i
and CC i
up RB i
to TO i
five CD i
group-based JJ i
coaching NN i
sessions NNS i
on IN i
motivation NN i
for IN i
regular JJ i
physical JJ i
exercise NN i
, , i
or CC i
( ( i
2 CD i
) ) i
home-based JJ i
physical JJ i
exercise NN i
( ( i
HOME NNP i
) ) i
performed VBD i
during IN i
leisure NN i
time NN i
for IN i
5?10 CD i
minutes NNS i
per IN i
week NN o
. . o

Physical JJ o
exertion NN o
was VBD o
assessed VBN N
at IN N
baseline NN N
and CC N
at IN N
10-week JJ N
follow-up NN N
. . N

RESULTS VB N
2.2 CD N
( ( N
SD NNP N
: : N
1.1 CD N
) ) N
and CC N
1.0 CD N
( ( N
SD NNP N
: : N
1.2 CD N
) ) N
training NN N
sessions NNS N
were VBD N
performed VBN N
per IN N
week NN N
in IN N
WORK NNP N
and CC N
HOME NNP N
, , N
respectively RB o
. . o

Physical JJ o
exertion NN o
was VBD o
reduced VBN o
more RBR o
in IN N
WORK NNP N
than IN N
HOME NNP N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
. . N

Between-group JJ N
differences NNS N
in IN N
physical JJ o
exertion NN o
at IN o
follow-up NN N
( ( N
WORK NNP N
vs. NNP N
HOME NNP N
) ) N
was VBD N
-0.5 JJ N
points NNS N
( ( N
95 CD N
% NN N
CI NNP N
-0.8 NNP N
to TO N
-0.2 VB N
) ) N
. . N

Within-group JJ o
effect NN o
size NN o
( ( o
Cohen NNP o
's POS o
d NN o
) ) o
in IN o
WORK NNP N
and CC N
HOME NNP N
was VBD N
0.43 CD N
and CC N
0.13 CD N
, , N
respectively RB N
. . N

CONCLUSIONS NNP i
Physical NNP i
exercise NN i
performed VBN i
at IN N
the DT N
workplace NN N
appears VBZ N
more RBR N
effective JJ N
than IN i
home-based JJ i
exercise NN i
in IN i
reducing VBG N
physical JJ N
exertion NN N
during IN N
daily JJ N
work NN N
tasks NNS N
in IN N
healthcare JJ p
workers NNS p
. . p

-DOCSTART- -11305684- O O

Effectiveness NN o
of IN N
N NNP N
, , N
N-dimethylglycine NNP N
in IN N
autism NN p
and CC p
pervasive JJ p
developmental JJ p
disorder NN p
. . p

N NNP i
, , i
N-dimethylglycine NNP i
, , N
a DT N
dietary JJ N
supplement NN N
, , N
has VBZ N
been VBN N
reported VBN N
to TO N
be VB N
beneficial JJ N
in IN N
children NNS p
with IN p
autism NN p
and CC p
pervasive JJ p
developmental JJ p
disorder NN p
. . p

We PRP N
examined VBD N
the DT N
effectiveness NN N
of IN N
dimethylglycine NN N
in IN N
children NNS p
with IN p
autism NN p
and CC p
pervasive JJ p
developmental NN p
disorder NN p
in IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
. . N

Thirty-seven JJ p
children NNS p
between IN p
3 CD p
and CC p
11 CD p
years NNS p
of IN p
age NN p
with IN p
a DT p
diagnosis NN p
of IN p
autism NN p
and/or JJ p
pervasive JJ p
developmental NN p
disorder NN p
were VBD N
gender JJR N
and CC N
age NN N
matched VBN N
and CC N
randomly RB N
assigned VBN N
to TO N
receive VB i
either DT i
placebo NN i
or CC i
dimethylglycine NN i
for IN i
4 CD i
weeks NNS i
. . i

All DT N
children NNS N
were VBD N
assessed VBN N
before IN N
and CC N
after IN N
treatment NN N
on IN N
two CD i
behavioral JJ i
measures NNS i
, , i
the DT i
Vineland NNP o
Maladaptive NNP o
Behavior NNP o
Domain NNP o
and CC o
the DT o
Aberrant NNP o
Behavior NNP o
Checklist NNP o
. . o

Standardized NNP o
neurologic JJ o
examinations NNS o
before IN o
and CC o
after IN o
treatment NN o
on IN N
33 CD N
children NNS N
showed VBD N
no DT N
change NN N
. . N

An DT N
overall JJ N
improvement NN N
on IN N
all DT o
behavioral JJ o
measures NNS o
was VBD N
observed VBN N
for IN N
both DT N
the DT N
placebo NN N
and CC N
the DT N
dimethylglycine NN N
groups NNS N
. . N

However RB N
, , N
the DT N
improvement NN N
among IN N
the DT N
children NNS N
who WP N
received VBD N
dimethylglycine NN N
was VBD N
not RB N
statistically RB N
different JJ N
from IN N
the DT N
improvement NN N
observed VBD N
among IN N
the DT N
children NNS N
who WP N
received VBD N
the DT N
placebo NN N
. . N

The DT N
children NNS p
who WP p
participated VBD p
in IN p
this DT p
study NN p
were VBD p
a DT p
heterogeneous JJ p
group NN p
, , N
and CC N
their PRP$ N
apparent JJ N
responses NNS N
to TO N
the DT N
dimethylglycine NN N
varied VBN N
. . N

Some DT N
children NNS N
appeared VBD N
to TO N
respond VB N
positively RB N
to TO N
the DT N
dimethylglycine NN N
, , N
and CC N
there RB N
was VBD N
a DT N
smaller JJR N
proportion NN N
of IN N
negative JJ N
changes NNS N
in IN N
the DT N
dimethylglycine NN N
group NN N
, , N
but CC N
the DT N
quantitative JJ N
changes NNS N
in IN N
the DT N
dimethylglycine JJ N
behavioral JJ N
assessments NNS N
were VBD N
not RB N
significantly RB N
different JJ N
from IN N
what WP N
was VBD N
observed VBN N
among IN N
children NNS N
who WP N
received VBD N
placebo NN N
. . N

-DOCSTART- -25234479- O O

Successful JJ N
face NN o
recognition NN o
is VBZ N
associated VBN N
with IN N
increased JJ N
prefrontal JJ N
cortex NN N
activation NN N
in IN N
autism NN p
spectrum NN p
disorder NN p
. . p

This DT N
study NN N
examines VBZ N
whether IN N
deficits NNS N
in IN N
visual JJ o
information NN o
processing NN o
in IN N
autism-spectrum JJ p
disorder NN p
( ( p
ASD NNP p
) ) p
can MD N
be VB N
offset VBN N
by IN N
the DT N
recruitment NN N
of IN N
brain NN N
structures NNS N
involved VBN N
in IN N
selective JJ N
attention NN N
. . N

During IN N
functional JJ i
MRI NNP i
, , N
12 CD p
children NNS p
with IN p
ASD NNP p
and CC p
19 CD p
control NN p
participants NNS p
completed VBD N
a DT N
selective JJ o
attention NN o
one-back NN i
task NN i
in IN N
which WDT N
images NNS i
of IN i
faces VBZ i
and CC i
houses NNS i
were VBD i
superimposed VBN i
. . i

When WRB N
attending VBG N
to TO N
faces VBZ N
, , N
the DT N
ASD NNP N
group NN N
showed VBD N
increased VBN N
activation NN o
relative NN N
to TO N
control VB N
participants NNS N
within IN N
multiple JJ N
prefrontal JJ o
cortex NN o
areas NNS o
, , N
including VBG N
dorsolateral JJ o
prefrontal JJ o
cortex NN o
( ( N
DLPFC NNP N
) ) N
. . N

DLPFC NNP N
activation NN N
in IN N
ASD NNP N
was VBD N
associated VBN N
with IN N
increased VBN N
response NN o
times NNS o
for IN o
faces VBZ o
. . o

These DT N
data NNS N
suggest VBP N
that IN N
prefrontal JJ o
cortex JJ o
activation NN o
may MD N
represent VB N
a DT N
compensatory NN N
mechanism NN N
for IN N
diminished JJ N
visual JJ o
information NN o
processing NN o
abilities NNS o
in IN N
ASD NNP p
. . p

-DOCSTART- -15224627- O O

Public NNP N
and CC N
private JJ N
heart NN N
rate NN N
feedback NN N
in IN N
social JJ i
phobia NN i
: : i
a DT N
manipulation NN N
of IN N
anxiety NN o
visibility NN o
. . o

According VBG N
to TO N
cognitive JJ N
behavioural JJ N
models NNS N
of IN N
social JJ i
phobia NN i
, , N
bodily RB o
symptoms NNS o
are VBP N
the DT N
main JJ N
source NN N
of IN N
information NN N
concerning VBG N
social JJ o
evaluation NN o
for IN N
social JJ i
phobics NNS i
. . i

Experience NN N
and CC N
perception NN N
of IN N
bodily RB N
symptoms NNS N
therefore RB N
play VBP N
an DT N
important JJ N
role NN N
in IN N
social JJ N
anxiety NN N
. . N

In IN N
this DT N
study NN N
we PRP N
evaluated VBD N
the DT N
effects NNS N
of IN N
anxiety NN o
visibility NN o
on IN N
patients NNS p
and CC p
controls NNS p
using VBG N
feedback NN N
of IN N
veridical JJ N
heart NN N
sounds VBZ N
. . N

A DT p
total NN p
of IN p
32 CD p
social JJ i
phobics NNS i
and CC p
32 CD p
controls NNS p
were VBD N
asked VBN N
twice RB N
to TO N
sit VB N
in IN N
a DT N
chair NN N
and CC N
appear VB N
relaxed VBN N
while IN N
being VBG N
evaluated VBN N
. . N

Half NN N
of IN N
the DT N
participants NNS i
heard VBP i
their PRP$ i
heart NN i
sounds VBZ i
first JJ i
via IN i
headphones NNS i
and CC i
then RB i
via IN i
loudspeakers NNS i
which WDT i
were VBD i
also RB i
audible JJ i
to TO i
observers NNS i
. . i

The DT N
presentation NN N
order NN N
of IN N
the DT N
heart NN o
sound NN o
was VBD N
reversed VBN N
for IN N
the DT N
other JJ N
half NN N
of IN N
the DT N
subjects NNS N
. . N

Social NNP i
phobics NNS i
reported VBD N
substantially RB N
more JJR N
anxiety NN o
than IN N
controls NNS N
. . N

Both DT N
groups NNS N
showed VBD N
habituation NN o
in IN o
heart NN o
rate NN o
from IN N
the DT N
first JJ N
to TO N
the DT N
second JJ N
presentation NN N
, , N
and CC N
both DT N
groups NNS N
reported VBD N
perception NN N
of IN N
a DT N
higher JJR o
heart NN o
rate NN o
, , N
but CC N
only RB N
social JJ N
phobics NNS N
reported VBD N
significantly RB N
more JJR N
anxiety NN o
and CC N
were VBD N
more JJR N
worried JJ o
about IN o
their PRP$ o
heart NN o
rates NNS o
in IN N
the DT N
public NN N
than IN N
in IN N
the DT N
private JJ N
condition NN N
. . N

These DT N
effects NNS N
were VBD N
in IN N
excess NN N
of IN N
actual JJ o
heart NN o
rate NN o
differences NNS o
. . o

In IN N
conclusion NN N
, , N
social JJ i
phobics NNS i
worried VBD o
about IN N
the DT N
broadcast NN N
of IN N
a DT N
bodily JJ o
anxiety NN o
symptom NN o
, , N
whereas JJ N
controls NNS i
did VBD N
not RB N
. . N

Information NN N
about IN N
arousal NN N
made VBN N
public NN N
has VBZ N
a DT N
strong JJ N
potential NN N
to TO N
increase VB N
anxiety NN o
levels NNS o
in IN N
social JJ N
phobics NNS N
. . N

-DOCSTART- -24252844- O O

The DT N
peroxisome JJ N
proliferator NN N
activated VBD N
receptor-? JJ i
pioglitazone NN i
improves VBZ N
vascular JJ N
function NN N
and CC N
decreases VBZ N
disease NN N
activity NN N
in IN p
patients NNS p
with IN p
rheumatoid JJ p
arthritis NN p
. . p

BACKGROUND NNP N
Rheumatoid NNP N
arthritis NN N
( ( N
RA NNP N
) ) N
is VBZ N
associated VBN N
with IN N
heightened JJ N
mortality NN N
due JJ N
to TO N
atherosclerotic JJ N
cardiovascular JJ N
disease NN N
( ( N
CVD NNP N
) ) N
. . N

Inflammatory NNP N
pathways NNS N
in IN N
RA NNP N
negatively RB N
affect VBP N
vascular JJ N
physiology NN N
and CC N
promote VB N
metabolic JJ N
disturbances NNS N
that WDT N
contribute VBP N
to TO N
CVD NNP N
. . N

We PRP N
hypothesized VBD N
that IN N
the DT N
peroxisome JJ N
proliferator NN N
activated VBD N
receptor-? JJ N
( ( N
PPAR-? NNP i
) ) i
pioglitazone NN i
could MD i
promote VB N
potent JJ N
vasculoprotective JJ N
and CC N
anti-inflammatory JJ N
effects NNS N
in IN N
RA NNP N
. . N

METHODS NNP N
AND CC N
RESULTS NNP p
One CD p
hundred VBD p
forty-three JJ p
non-diabetic JJ p
adult NN p
RA NNP p
patients NNS p
( ( p
76.2 CD p
% NN p
female NN p
, , p
age NN p
55.2 CD p
? . p
12.1 CD p
[ JJ p
mean NN p
? . p
SD NNP p
] NNP p
) ) p
on IN p
stable JJ p
RA NNP p
standard NN p
of IN p
care NN p
treatment NN p
were VBD p
enrolled VBN N
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
placebo NN N
controlled VBD N
crossover JJ N
trial NN N
of IN i
45 CD i
mg JJ i
daily JJ i
pioglitazone NN i
versus NN i
placebo NN i
, , i
with IN i
a DT i
3-month JJ i
duration/arm NN i
and CC i
a DT i
2-month JJ i
washout NN i
period NN o
. . o

Pulse NNP o
wave VBP o
velocity NN o
of IN o
the DT o
aorta NN o
( ( o
PWV NNP o
) ) o
, , o
brachial JJ o
artery NN o
flow NN o
mediated VBN o
dilatation NN o
( ( o
FMD NNP o
) ) o
, , o
nitroglycerin RB o
mediated VBN o
dilatation NN o
( ( o
NMD NNP o
) ) o
, , o
microvascular JJ o
endothelial JJ o
function NN o
( ( o
reactive JJ o
hyperemia NN o
index NN o
[ NNP o
RHI NNP o
] NNP o
) ) o
, , o
and CC o
circulating VBG o
biomarkers NNS o
of IN o
inflammation NN o
, , o
insulin NN o
resistance NN o
, , o
and CC o
atherosclerosis NN o
risk NN o
all DT N
were VBD N
quantified VBN N
. . N

RA NNP N
disease NN N
activity NN N
was VBD N
assessed VBN N
with IN N
the DT o
28-Joint JJ o
Count NNP o
Disease NNP o
Activity NNP o
Score NNP o
( ( o
DAS-28 NNP o
) ) o
C-reactive JJ o
protein NN o
( ( o
CRP NNP o
) ) o
and CC o
the DT o
Short NNP o
Form NNP o
( ( o
36 CD o
) ) o
Health NNP o
Survey NNP o
quality NN o
of IN o
life NN o
questionnaire NN o
. . o

When WRB o
added VBD N
to TO N
standard VB N
of IN N
care NN N
RA NNP N
treatment NN i
, , i
pioglitazone NN i
significantly RB i
decreased VBD o
pulse JJ o
wave NN o
velocity NN o
( ( o
ie JJ o
, , o
aortic JJ N
stiffness NN N
) ) N
( ( N
P=0.01 NNP N
) ) N
, , N
while IN N
FMD NNP N
and CC N
RHI NNP N
remained VBD N
unchanged JJ N
when WRB N
compared VBN N
to TO N
treatment NN N
with IN N
placebo NN i
. . i

Further NNP i
, , i
pioglitazone NN i
significantly RB i
reduced VBN o
RA NNP o
disease NN o
activity NN o
( ( o
P=0.02 NNP o
) ) o
and CC o
CRP NNP o
levels NNS o
( ( o
P=0.001 NNP o
) ) N
, , N
while IN N
improving VBG N
lipid JJ N
profiles NNS N
. . N

The DT N
drug NN N
was VBD N
well RB N
tolerated VBN o
. . o

CONCLUSIONS NNP o
Addition NNP i
of IN i
pioglitazone NN i
to TO i
RA NNP i
standard NN N
of IN N
care NN N
significantly RB N
improves VBZ N
aortic JJ N
elasticity NN N
and CC N
decreases VBZ N
inflammation NN N
and CC N
disease NN N
activity NN N
with IN N
minimal JJ N
safety NN N
issues NNS N
. . N

The DT N
clinical JJ N
implications NNS N
of IN N
these DT N
findings NNS N
remain VBP N
to TO N
be VB N
established VBN N
. . N

CLINICAL NNP N
TRIAL NNP N
REGISTRATION NNP N
URL NNP N
ClinicalTrials.gov NNP N
Unique NNP N
Identifier NNP N
: : N
NCT00554853 NN N
. . N

-DOCSTART- -25516338- O O

Exploratory JJ N
Subset NNP N
Analysis NNP N
of IN N
African JJ p
Americans NNPS p
From IN p
the DT p
PointBreak NNP p
Study NNP p
: : p
Pemetrexed-Carboplatin-Bevacizumab JJ i
Followed NNP i
by IN i
Maintenance NNP i
Pemetrexed-Bevacizumab NNP i
Versus NNP N
Paclitaxel-Carboplatin-Bevacizumab NNP i
Followed NNP i
by IN i
Maintenance NNP i
Bevacizumab NNP i
in IN p
Patients NNP p
With IN p
Stage NNP p
IIIB/IV NNP p
Nonsquamous NNP p
Non-Small-Cell NNP p
Lung NNP p
Cancer NNP p
. . p

INTRODUCTION NNP p
African JJ p
Americans NNPS p
have VBP p
a DT p
greater JJR p
incidence NN p
of IN p
lung NN p
cancer NN p
than IN p
whites NNS p
and CC N
have VBP N
been VBN N
underrepresented VBN N
in IN N
clinical JJ N
trials NNS N
. . N

In IN N
the DT N
PointBreak NNP N
trial NN N
( ( N
pemetrexed-carboplatin-bevacizumab JJ i
and CC i
maintenance JJ i
pemetrexed-bevacizumab JJ i
[ NN i
PemCBev NNP i
] NNP i
vs. IN N
paclitaxel-carboplatin-bevacizumab NN i
and CC i
maintenance NN i
bevacizumab NN i
[ NNP i
PacCBev NNP i
] NNP i
) ) i
, , i
10 CD p
% NN p
of IN p
the DT p
patients NNS p
were VBD p
African JJ p
American NNP p
. . p

PointBreak NNP N
had VBD N
negative JJ N
findings NNS N
; : N
PemCBev NNP N
did VBD N
not RB N
demonstrate VB o
superior JJ o
overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
. . o

MATERIALS NNP N
AND CC N
METHODS NNP N
PointBreak NNP N
subgroup NN o
efficacy NN o
and CC o
safety NN o
data NNS N
were VBD N
retrospectively RB N
analyzed VBN p
: : p
African JJ p
Americans NNPS p
versus VBP p
whites NNS p
for IN i
PemCBev NNP i
; : i
PemCBev NNP p
versus NN i
PacCBev NNP i
in IN p
African NNP p
Americans NNPS p
; : p
and CC p
academic JJ p
versus NN p
community NN p
settings NNS p
for IN p
African JJ p
Americans NNPS p
. . p

Hazard NNP o
ratios NNS o
( ( o
HRs NNP o
) ) o
and CC o
P NNP o
values NNS o
were VBD N
derived VBN N
from IN N
a DT N
multivariate NN o
Cox NNP o
proportional JJ N
hazards NNS N
model NN N
after IN N
adjusting VBG N
for IN N
covariates NNS N
. . N

RESULTS NNP p
Of IN p
939 CD p
intent-to-treat NN p
( ( p
ITT NNP p
) ) p
patients NNS p
, , p
94 CD p
were VBD p
African JJ p
American NNP p
and CC p
805 CD p
were VBD p
white JJ p
. . p

African-American JJ p
enrollment NN N
was VBD N
uniform JJ N
across IN N
the DT N
study NN N
sites NNS N
( ( N
median JJ N
, , N
1 CD N
African JJ N
American NNP N
per IN N
site NN N
) ) N
. . N

In IN N
the DT N
PemCBev NNP N
arm NN N
, , N
OS NNP N
( ( N
HR NNP N
, , N
1.125 CD N
; : N
P NNP N
= NNP N
.525 NNP o
) ) o
, , o
progression-free JJ o
survival NN o
( ( o
PFS NNP o
) ) o
( ( o
HR NNP N
, , N
1.229 CD N
; : N
P NNP N
= NNP N
.251 NNP o
) ) o
, , o
response NN o
( ( o
P NNP o
= NNP N
.607 NNP N
) ) N
, , N
and CC N
toxicity NN o
profiles NNS o
were VBD o
similar JJ N
in IN N
African JJ N
Americans NNPS N
versus NN N
whites NNS N
. . N

For IN N
African JJ N
Americans NNPS o
, , o
OS NNP o
( ( N
HR NNP N
, , N
1.375 CD N
; : N
P NNP N
= NNP N
.209 NNP N
) ) N
, , o
PFS NNP o
( ( N
HR NNP N
, , N
0.902 CD N
; : N
P NNP N
= NNP N
.670 NNP N
) ) N
, , N
response NN N
( ( N
P NNP N
= NNP N
1.000 CD N
) ) N
, , N
and CC o
toxicity NN o
profiles NNS o
were VBD o
similar JJ o
in IN N
the DT N
PemCBev NNP N
versus NN N
PacCBev NNP N
arm NN N
. . N

For IN N
African JJ N
Americans NNPS N
, , N
no DT N
significant JJ N
differences NNS N
were VBD N
seen VBN N
in IN N
OS NNP o
( ( N
HR NNP N
, , N
0.661 CD N
; : N
P NNP N
= NNP N
.191 NNP N
) ) N
or CC N
PFS NNP o
( ( N
HR NNP N
, , N
0.969 CD N
; : N
P NNP N
= NNP N
.915 NNP N
) ) N
in IN N
academic JJ N
versus NN N
community NN N
practice NN N
settings NNS N
. . N

CONCLUSION NNP N
In IN N
the DT N
PemCBev NNP N
arm NN N
, , N
this DT N
exploratory NN N
analysis NN N
showed VBD N
no DT N
significant JJ N
differences NNS p
between IN p
African JJ p
Americans NNPS p
and CC p
whites NNS p
for IN o
the DT o
efficacy NN o
outcomes VBZ o
or CC o
toxicity NN o
profiles NNS o
. . N

Consistent JJ N
with IN N
the DT N
ITT NNP N
population NN N
negative JJ N
trial NN N
result NN N
, , N
for IN p
African JJ p
Americans NNPS p
, , p
the DT p
median JJ p
OS NNP N
was VBD N
not RB N
superior JJ N
for IN N
either DT N
arm NN N
. . N

For IN N
African JJ p
Americans NNPS p
, , p
PFS NNP p
and CC p
OS NNP N
were VBD N
similar JJ N
in IN N
the DT N
academic JJ N
and CC N
community NN N
settings NNS N
. . N

Additional JJ N
outcomes NNS N
data NNS p
for IN p
African JJ p
Americans NNPS p
should MD N
be VB N
collected VBN N
in IN N
lung NN N
cancer NN N
studies NNS N
. . N

-DOCSTART- -14732749- O O

Outcomes NNS p
in IN p
patients NNS p
with IN p
diabetes NNS p
mellitus VBP p
undergoing VBG p
percutaneous JJ i
coronary JJ i
intervention NN i
in IN p
the DT p
current JJ p
era NN p
: : p
a DT N
report NN N
from IN N
the DT N
Prevention NNP N
of IN N
REStenosis NNP N
with IN N
Tranilast NNP N
and CC N
its PRP$ N
Outcomes NNP N
( ( N
PRESTO NNP N
) ) N
trial NN N
. . N

BACKGROUND NNP N
Diabetes NNP N
portends VBZ N
an DT N
adverse JJ N
prognosis NN N
in IN N
patients NNS p
undergoing VBG p
percutaneous JJ i
coronary JJ i
intervention NN i
( ( i
PCI NNP i
) ) i
. . i

Whether PRP$ N
improvements NNS N
in IN N
current JJ N
clinical JJ N
practice NN N
( ( N
stents NNS N
, , N
IIb/IIIa NNP N
antagonists VBZ N
) ) N
have VBP N
resulted VBN N
in IN N
substantial JJ N
improvement NN N
of IN N
these DT N
outcomes NNS N
remains VBZ N
an DT N
issue NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
influence NN N
of IN N
diabetes NNS N
on IN N
9-month JJ N
outcomes NNS N
of IN N
patients NNS p
undergoing VBG p
PCI NNP i
in IN p
the DT p
current JJ p
era NN p
. . p

METHODS NNP N
AND CC N
RESULTS NNP N
The DT p
11 CD p
482 CD p
patients NNS p
enrolled VBN p
in IN p
the DT p
Prevention NNP i
of IN i
REStenosis NNP i
with IN i
Tranilast NNP i
and CC i
its PRP$ i
Outcomes NNP i
( ( i
PRESTO NNP i
) ) i
Trial NNP i
were VBD N
stratified VBN N
according VBG N
to TO N
the DT N
presence NN N
( ( N
n=2694 JJ N
) ) N
or CC N
absence NN N
( ( N
n=8798 JJ N
) ) N
of IN N
diabetes NNS N
. . N

Diabetic JJ N
patients NNS N
were VBD N
older JJR N
; : N
were VBD N
more RBR N
likely JJ N
to TO N
be VB N
female JJ N
; : N
had VBD N
a DT N
higher JJR N
proportion NN N
of IN N
congestive JJ o
failure NN o
, , o
hypertension NN o
, , o
prior JJ o
CABG NNP o
, , o
and CC o
unstable JJ o
angina NN o
; : o
and CC N
had VBD N
higher JJR N
body NN o
mass NN o
index NN o
and CC N
lower JJR N
ejection NN o
fraction NN o
than IN N
nondiabetic JJ N
patients NNS N
( ( N
P NNP N
< VBZ N
0.01 CD N
for IN N
all DT N
comparisons NNS N
) ) N
. . N

The DT N
degree NN o
of IN o
multivessel NN o
disease NN o
was VBD N
similar JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

American JJ N
College NNP N
of IN N
Cardiology/American NNP N
Heart NNP N
Association NNP N
type VBD o
C NNP o
lesions NNS o
were VBD N
more JJR N
common JJ N
in IN N
diabetic JJ N
patients NNS N
( ( N
17 CD N
% NN N
versus IN N
15 CD N
% NN N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Angiographic NNP o
and CC o
procedural JJ o
success NN o
rates NNS o
and CC N
in-hospital JJ o
events NNS o
were VBD N
similar JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

The DT N
primary JJ N
end NN N
point NN N
of IN N
death NN o
, , o
myocardial JJ o
infarction NN o
, , o
or CC o
target VB o
vessel JJ o
revascularization NN o
( ( o
TVR NNP o
) ) o
was VBD N
analyzed VBN N
as IN N
time-to-first JJ N
event NN N
within IN N
9 CD N
months NNS N
of IN N
the DT N
index NN N
PCI NNP i
. . i

After IN N
adjusting VBG N
for IN N
certain JJ N
baseline NN N
characteristics NNS N
, , N
diabetes NNS N
was VBD N
independently RB N
associated VBN N
with IN N
death NN o
at IN N
9 CD N
months NNS N
( ( N
relative JJ N
risk NN N
[ NNP N
RR NNP N
] NNP N
, , N
1.87 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.31 CD N
to TO N
2.68 CD N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
with IN N
an DT N
increased VBN N
likelihood NN N
of IN N
TVR NNP o
( ( N
RR NNP N
, , N
1.27 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.14 CD N
to TO N
1.42 CD N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
as RB N
well RB N
as IN N
the DT N
composite JJ N
end NN N
point NN N
of IN N
death/myocardial JJ o
infarction/TVR NN o
( ( N
RR NNP N
, , N
1.26 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.13 CD N
to TO N
1.40 CD N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSIONS NNP N
Despite IN N
advances NNS N
in IN N
interventional JJ N
techniques NNS N
, , N
diabetes VBZ N
remains VBZ N
a DT N
significant JJ N
independent JJ N
predictor NN N
of IN N
adverse JJ N
events NNS N
in IN N
the DT N
intermediate JJ N
term NN N
after IN N
PCI NNP i
. . i

-DOCSTART- -22147942- O O

Predictive JJ N
and CC N
prognostic JJ N
roles NNS N
of IN N
BRAF NNP p
mutation NN p
in IN p
stage NN p
III NNP p
colon NN p
cancer NN p
: : p
results NNS N
from IN N
intergroup JJ N
trial NN N
CALGB NNP N
89803 CD N
. . N

PURPOSE NNP N
Alterations NNPS N
in IN N
the DT N
RAS-RAF-MAP2K NNP N
( ( N
MEK NNP N
) ) N
-MAPK VBP N
signaling VBG N
pathway NN N
are VBP N
major JJ N
drivers NNS N
in IN N
colorectal JJ p
carcinogenesis NN p
. . p

In IN N
colorectal JJ N
cancer NN N
, , N
BRAF NNP N
mutation NN N
is VBZ N
associated VBN N
with IN N
microsatellite JJ N
instability NN N
( ( N
MSI NNP N
) ) N
, , N
and CC N
typically RB N
predicts VBZ N
inferior JJ N
prognosis NN N
. . N

We PRP N
examined VBD N
the DT N
effect NN N
of IN N
BRAF NNP N
mutation NN N
on IN N
survival NN N
and CC N
treatment NN N
efficacy NN N
in IN N
patients NNS p
with IN p
stage NN p
III NNP p
colon NN p
cancer NN p
. . p

METHODS NNP N
We PRP N
assessed VBD N
status NN i
of IN i
BRAF NNP i
c.1799T NN i
> VBZ i
A NNP i
( ( i
p.V600E NN i
) ) i
mutation NN i
and CC i
MSI NNP i
in IN N
506 CD p
stage NN p
III NNP p
colon NN p
cancer NN p
patients NNS p
enrolled VBN p
in IN p
a DT p
randomized JJ p
adjuvant NN p
chemotherapy NN i
trial NN i
[ NNP i
5-fluorouracil CD i
and CC i
leucovorin NN i
( ( i
FU/LV NNP i
) ) i
vs. FW i
irinotecan JJ i
( ( i
CPT11 NNP i
) ) i
, , i
FU NNP i
and CC i
LV NNP i
( ( i
IFL NNP i
) ) i
; : i
CALGB $ N
89803 CD N
] NNP N
. . N

Cox NNP N
proportional JJ N
hazards NNS N
model NN N
was VBD N
used VBN N
to TO N
assess VB N
the DT N
prognostic JJ N
role NN N
of IN N
BRAF NNP N
mutation NN N
, , N
adjusting VBG N
for IN N
clinical JJ N
features NNS N
, , N
adjuvant JJ N
chemotherapy NN i
arm NN N
, , N
and CC N
MSI NNP N
status NN N
. . N

RESULTS NNP N
Compared VBD N
with IN N
431 CD N
BRAF NNP N
wild-type JJ N
patients NNS N
, , N
75 CD p
BRAF-mutated JJ p
patients NNS p
experienced VBD N
significantly RB N
worse JJR N
overall JJ o
survival NN o
[ NNP o
OS NNP o
; : o
log-rank JJ N
P NNP N
= NNP N
0.015 CD N
; : N
multivariate NN N
HR NNP N
= NNP N
1.66 CD N
; : N
95 CD N
% NN N
CI NNP N
: : N
1.05-2.63 JJ N
] NN N
. . N

By IN N
assessing VBG N
combined JJ N
status NN N
of IN N
BRAF NNP N
and CC N
MSI NNP N
, , N
it PRP N
seemed VBD N
that IN N
BRAF-mutated NNP N
MSS NNP N
( ( N
microsatellite JJ N
stable NN N
) ) N
tumor NN N
was VBD N
an DT N
unfavorable JJ N
subtype NN N
, , N
whereas JJ N
BRAF NNP N
wild-type JJ N
MSI-high NNP N
tumor NN N
was VBD N
a DT N
favorable JJ N
subtype NN N
, , N
and CC N
BRAF-mutated JJ N
MSI-high JJ N
tumor NN N
and CC N
BRAF NNP N
wild-type JJ N
MSS NNP N
tumor NN N
were VBD N
intermediate JJ N
subtypes NNS N
. . N

Among IN N
patients NNS N
with IN N
BRAF-mutated JJ N
tumors NNS N
, , N
a DT N
nonsignificant JJ N
trend NN N
toward IN N
improved JJ N
OS NNP o
was VBD N
observed VBN N
for IN N
IFL NNP i
versus NN N
FU/LV NNP i
arm NN N
( ( N
multivariate JJ N
HR NNP N
= NNP N
0.52 CD N
; : N
95 CD N
% NN N
CI NNP N
: : N
0.25-1.10 NN N
) ) N
. . N

Among IN N
patients NNS N
with IN N
BRAF NNP N
wild-type JJ N
cancer NN N
, , N
IFL NNP i
conferred VBD N
no DT N
suggestion NN N
of IN N
benefit NN N
beyond IN N
FU/LV NNP i
alone RB N
( ( N
multivariate JJ N
HR NNP N
= NNP N
1.02 CD N
; : N
95 CD N
% NN N
CI NNP N
: : N
0.72-1.46 NN N
) ) N
. . N

CONCLUSIONS NNP N
BRAF NNP N
mutation NN N
is VBZ N
associated VBN N
with IN N
inferior JJ N
survival NN o
in IN N
stage NN p
III NNP p
colon NN p
cancer NN p
. . p

Additional JJ N
studies NNS N
are VBP N
necessary JJ N
to TO N
assess VB N
whether IN N
there EX N
is VBZ N
any DT N
predictive JJ N
role NN N
of IN N
BRAF NNP N
mutation NN N
for IN N
irinotecan-based JJ i
therapy NN i
. . i

-DOCSTART- -15055890- O O

Perispinal JJ N
analgesia NN N
for IN N
labour NN p
followed VBN N
by IN N
patient-controlled JJ N
infusion NN N
with IN N
bupivacaine NN i
and CC N
sufentanil NN i
: : i
combined VBN i
spinal-epidural JJ i
vs. FW i
epidural JJ i
analgesia NN N
alone RB N
. . N

BACKGROUND NNP N
AND NNP N
OBJECTIVE NNP N
Combined NNP N
spinal-epidural JJ N
is VBZ N
an DT N
alternative JJ N
technique NN N
to TO N
epidural JJ N
analgesia NN N
for IN N
labour NN N
, , N
but CC N
its PRP$ N
benefits NNS N
are VBP N
not RB N
clearly RB N
identified VBN N
. . N

METHODS VB N
A DT N
prospective JJ N
, , N
blinded VBD N
, , N
randomized VBD N
study NN N
was VBD N
undertaken JJ N
involving VBG N
113 CD p
women NNS p
attending VBG p
a DT p
university NN p
hospital NN p
obstetric JJ p
department NN p
. . p

Analgesia NNP N
was VBD N
initiated VBN i
with IN i
intrathecal JJ i
bupivacaine NN i
0.25 CD i
% NN i
1 CD i
mL NN i
+ NNP i
sufentanil VBD i
5 CD i
microg NN i
in IN i
the DT i
combined JJ i
spinal-epidural JJ i
group NN i
( ( i
n JJ i
= NNP i
54 CD i
) ) i
, , i
and CC i
with IN i
bupivacaine JJ i
0.125 CD i
% NN i
+ JJ i
epinephrine NN i
2.5 CD i
microg NN i
mL NN i
( ( i
-1 NNP i
) ) i
+ VBD i
sufentanil $ i
7.5 CD i
microg NN i
in IN i
the DT i
epidural JJ i
group NN i
( ( i
n JJ i
= NNP i
59 CD i
) ) i
. . i

In IN i
both DT i
cases NNS i
this DT i
was VBD i
followed VBN i
by IN i
patient-controlled JJ i
epidural JJ i
analgesia NN i
with IN i
bupivacaine JJ i
0.125 CD i
% NN i
( ( i
+ JJ i
sufentanil NN i
0.25 CD i
microg NN i
mL NN i
( ( i
-1 NNP i
) ) i
) ) i
. . i

Duration NN N
of IN N
labour NN N
, , N
quality NN o
of IN o
analgesia NN o
and CC o
side-effects NNS o
were VBD N
compared VBN N
between IN N
groups NNS N
. . N

RESULTS NNP N
In IN N
the DT N
combined JJ N
spinal-epidural JJ N
group NN N
, , N
the DT N
onset NN o
of IN o
analgesia NN o
was VBD o
faster RBR o
( ( N
5 CD N
vs. FW N
15 CD N
min NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
the DT N
consumption NN o
of IN o
bupivacaine NN o
was VBD o
lower JJR o
( ( N
7.5 CD N
vs. FW N
11.3 CD N
mg NN N
h NN N
( ( N
-1 NNP N
) ) N
, , N
P NNP N
= NNP N
0.003 CD N
) ) N
and CC N
there EX N
was VBD N
less JJR o
unilateral JJ o
analgesia NN o
( ( N
14.8 CD N
% NN N
vs. FW N
40.7 CD N
% NN N
, , N
P NNP N
= NNP N
0.002 CD N
) ) N
than IN N
in IN N
the DT N
epidural JJ N
group NN N
. . N

The DT p
characteristics NNS o
of IN o
labour NN o
were VBD p
similar JJ p
in IN p
both DT p
groups NNS p
. . p

However RB N
, , N
in IN N
the DT N
combined JJ N
spinal-epidural JJ N
group NN N
, , N
there EX N
was VBD N
a DT N
higher JJR o
incidence NN o
of IN o
posterior JJ o
presentation NN o
( ( N
25.9 CD N
% NN N
vs. FW N
10 CD N
% NN N
, , N
P NNP N
= NNP N
0.03 CD N
) ) N
, , N
pruritus NN o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
hypotension NN o
( ( N
P NNP N
= NNP N
0.002 CD N
) ) N
, , N
somnolence NN o
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
, , N
nausea NN o
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
and CC N
one CD N
case NN N
of IN N
meningitis NN o
. . o

CONCLUSIONS VB N
The DT N
combined JJ N
spinal-epidural JJ N
technique NN N
provided VBD N
more RBR N
effective JJ N
analgesia NN N
during IN p
labour JJR p
than IN N
epidural JJ N
analgesia NN N
alone RB N
but CC N
offered VBN N
no DT N
other JJ N
advantage NN N
. . N

It PRP N
induced VBD N
more RBR N
adverse JJ N
effects NNS N
and CC N
this DT N
should MD N
be VB N
considered VBN N
before IN N
routinely RB N
using VBG N
the DT N
combined JJ N
spinal-epidural JJ N
technique NN N
. . N

-DOCSTART- -22583459- O O

Mapping VBG N
from IN N
disease-specific JJ N
measures NNS N
to TO N
health-state JJ N
utility NN N
values NNS N
in IN N
individuals NNS p
with IN p
migraine NN p
. . p

OBJECTIVE CC N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
develop VB N
empirical JJ N
algorithms NN N
that WDT N
estimate VBP N
health-state JJ N
utility NN N
values NNS N
from IN N
disease-specific JJ N
quality-of-life JJ N
scores NNS N
in IN N
individuals NNS p
with IN p
migraine NN p
. . p

METHODS NNP N
Data NNP N
from IN N
a DT N
cross-sectional JJ N
, , N
multicountry NN N
study NN N
were VBD N
used VBN N
. . N

Individuals NNS p
with IN p
episodic NN p
and CC p
chronic JJ p
migraine NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
training NN N
or CC N
validation NN N
samples NNS N
. . N

Spearman NNP o
's POS o
correlation NN o
coefficients NNS o
between IN N
paired VBN N
EuroQol NNP i
five-dimensional JJ i
( ( i
EQ-5D NNP i
) ) i
questionnaire NN i
utility NN N
values NNS N
and CC N
both DT N
Headache NNP o
Impact NNP o
Test NNP o
( ( o
HIT-6 NNP o
) ) o
scores NNS N
and CC N
Migraine-Specific NNP o
Quality-of-Life NNP o
Questionnaire NNP o
version NN o
2.1 CD o
( ( o
MSQ NNP o
) ) o
domain NN o
scores NNS o
( ( N
role NN N
restrictive NN N
, , N
role NN N
preventive NN N
, , N
and CC N
emotional JJ N
function NN N
) ) N
were VBD N
examined VBN N
. . N

Regression NN N
models NNS N
were VBD N
constructed VBN N
to TO N
estimate VB N
EQ-5D NNP N
questionnaire NN N
utility NN N
values NNS N
from IN N
the DT N
HIT-6 NNP N
score NN N
or CC N
the DT N
MSQ NNP N
domain NN N
scores NNS N
. . N

Preferred VBN N
algorithms NNS N
were VBD N
confirmed VBN N
in IN N
the DT N
validation NN N
samples NNS N
. . N

RESULTS NNP N
In IN N
episodic JJ N
migraine NN N
, , N
the DT N
preferred JJ N
HIT-6 NNP i
and CC N
MSQ NNP i
algorithms VBP i
explained VBD N
22 CD N
% NN N
and CC N
25 CD N
% NN N
of IN N
the DT N
variance NN N
( ( N
R NNP N
( ( N
2 CD N
) ) N
) ) N
in IN N
the DT N
training NN N
samples NNS N
, , N
respectively RB N
, , N
and CC N
had VBD N
similar JJ N
prediction NN N
errors NNS N
( ( N
root JJ N
mean NN N
square JJ N
errors NNS N
of IN N
0.30 CD N
) ) N
. . N

In IN N
chronic JJ N
migraine NN N
, , N
the DT N
preferred JJ N
HIT-6 NNP i
and CC i
MSQ NNP i
algorithms VBP i
explained VBD N
36 CD N
% NN N
and CC N
45 CD N
% NN N
of IN N
the DT N
variance NN N
in IN N
the DT N
training NN N
samples NNS N
, , N
respectively RB N
, , N
and CC N
had VBD N
similar JJ N
prediction NN N
errors NNS N
( ( N
root JJ N
mean NN N
square JJ N
errors NNS N
0.31 CD N
and CC N
0.29 CD N
) ) N
. . N

In IN N
episodic JJ N
and CC N
chronic JJ N
migraine NN N
, , N
no DT N
statistically RB N
significant JJ N
differences NNS N
were VBD N
observed VBN N
between IN N
the DT N
mean NN o
observed VBD o
and CC o
the DT o
mean NN o
estimated VBD o
EQ-5D NNP o
questionnaire NN o
utility NN o
values NNS o
for IN N
the DT N
preferred JJ N
HIT-6 NNP i
and CC N
MSQ NNP i
algorithms NN N
in IN N
the DT N
validation NN N
samples NNS N
. . N

CONCLUSIONS VB N
The DT N
relationship NN N
between IN N
the DT N
EQ-5D NNP N
questionnaire NN N
and CC N
the DT N
HIT-6 NNP N
or CC N
the DT N
MSQ NNP N
is VBZ N
adequate JJ N
to TO N
use VB N
regression NN N
equations NNS N
to TO N
estimate VB N
EQ-5D NNP N
questionnaire NN N
utility NN N
values NNS N
. . N

The DT N
preferred JJ N
HIT-6 NNP i
and CC i
MSQ NNP i
algorithms NN N
will MD N
be VB N
useful JJ N
in IN N
estimating VBG N
health-state JJ N
utilities NNS N
in IN N
migraine NN N
trials NNS N
in IN N
which WDT N
no DT N
preference-based JJ N
measure NN N
is VBZ N
present JJ N
. . N

-DOCSTART- -25526831- O O

Cognitive JJ i
behavioral JJ i
therapy NN i
for IN N
early JJ p
adolescents NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
and CC p
clinical JJ p
anxiety NN p
: : p
a DT N
randomized NN N
, , N
controlled VBN N
trial NN N
. . N

Clinically RB N
elevated JJ N
anxiety NN N
is VBZ N
a DT N
common JJ N
, , N
impairing JJ N
feature NN N
of IN N
autism NN N
spectrum NN N
disorders NNS N
( ( N
ASD NNP N
) ) N
. . N

A DT N
modular JJ N
CBT NNP i
program NN N
designed VBN N
for IN N
preteens NNS p
with IN p
ASD NNP p
, , N
Behavioral NNP i
Interventions NNP i
for IN N
Anxiety NNP N
in IN N
Children NNP N
with IN N
Autism NNP N
( ( N
BIACA NNP N
; : N
Wood NNP N
et FW N
al. NN N
, , N
2009 CD N
) ) N
was VBD N
enhanced VBN N
and CC N
modified VBN N
to TO N
address VB N
the DT N
developmental JJ N
needs NNS N
of IN N
early JJ p
adolescents NNS p
with IN p
ASD NNP p
and CC p
clinical JJ p
anxiety NN p
. . p

Thirty-three JJ p
adolescents NNS p
( ( p
11-15 CD p
years NNS p
old JJ p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
16 CD N
sessions NNS N
of IN N
CBT NNP i
or CC N
an DT N
equivalent JJ i
waitlist NN i
period NN i
. . i

The DT N
CBT NNP i
model NN N
emphasized VBD N
exposure NN i
, , i
challenging VBG i
irrational JJ i
beliefs NNS i
, , N
and CC N
behavioral JJ i
supports NNS i
provided VBN N
by IN N
caregivers NNS N
, , N
as RB N
well RB N
as IN N
numerous JJ N
ASD-specific JJ N
treatment NN N
elements NNS N
. . N

Independent JJ N
evaluators NNS N
, , N
parents NNS N
, , N
and CC N
adolescents NNS N
rated VBN N
symptom JJ o
severity NN o
at IN N
baseline NN N
and CC N
posttreatment/postwaitlist NN N
. . N

In IN N
intent-to-treat JJ N
analyses NNS N
, , N
the DT N
CBT NNP i
group NN N
outperformed VBD N
the DT N
waitlist NN N
group NN N
on IN N
independent JJ N
evaluators NNS N
' POS N
ratings NNS o
of IN o
anxiety NN o
severity NN o
on IN o
the DT o
Pediatric NNP o
Anxiety NNP o
Rating NNP o
Scale NNP o
( ( o
PARS NNP o
) ) o
and CC N
79 CD N
% NN N
of IN N
the DT N
CBT NNP N
group NN N
met VBD N
Clinical JJ o
Global NNP o
Impressions-Improvement NNP o
scale NN o
criteria NNS N
for IN N
positive JJ N
treatment NN N
response NN N
at IN N
posttreatment NN N
, , N
as IN N
compared VBN N
to TO N
only RB N
28.6 CD N
% NN N
of IN N
the DT N
waitlist NN N
group NN N
. . N

Group NNP N
differences NNS N
were VBD N
not RB N
found VBN N
for IN N
diagnostic JJ o
remission NN o
or CC o
questionnaire NN o
measures NNS o
of IN o
anxiety NN o
. . o

However RB N
, , N
parent-report JJ o
data NNS o
indicated VBD N
that IN N
there EX N
was VBD N
a DT N
positive JJ o
treatment NN o
effect NN o
of IN o
CBT NNP o
on IN o
autism NN o
symptom JJ o
severity NN o
. . o

The DT N
CBT NNP i
manual JJ N
under IN N
investigation NN N
, , N
enhanced VBD N
for IN N
early JJ N
adolescents NNS N
with IN N
ASD NNP N
, , N
yielded VBD N
meaningful JJ N
treatment NN N
effects NNS N
on IN N
the DT N
primary JJ N
outcome NN N
measure NN N
( ( N
PARS NNP N
) ) N
, , N
although IN N
additional JJ N
developmental JJ N
modifications NNS N
to TO N
the DT N
manual NN N
are VBP N
likely JJ N
warranted VBN N
. . N

Future JJ N
studies NNS N
examining VBG N
this DT N
protocol NN N
relative NN N
to TO N
an DT N
active JJ N
control NN N
are VBP N
needed VBN N
. . N

-DOCSTART- -3548346- O O

Hepatorenal JJ N
syndrome NN N
. . N

Studies NNS N
of IN N
the DT N
effect NN N
of IN N
vascular JJ N
volume NN N
and CC N
intraperitoneal JJ N
pressure NN N
on IN N
renal JJ o
and CC o
hepatic JJ o
function NN o
. . o

Eleven JJ p
patients NNS p
with IN p
well-documented JJ p
hepatorenal JJ p
syndrome NN p
were VBD N
studied VBN N
by IN N
measurement NN N
of IN N
blood NN o
volume NN o
, , o
glomerular JJ o
filtration NN o
rate NN o
, , o
renal JJ o
plasma NN o
flow NN o
, , o
plasma VBP o
aldosterone JJ o
concentration NN o
, , o
renin JJ o
substrate NN o
concentration NN o
, , o
and CC o
plasma JJ o
renin NN o
activity NN o
. . o

They PRP N
were VBD N
then RB N
given VBN N
750 CD i
ml NN i
of IN i
stored JJ i
plasma NN i
, , i
750 CD i
ml NN i
of IN i
fresh JJ i
frozen JJ i
plasma NN i
, , i
and CC i
then RB i
an DT i
infusion NN i
of IN i
angiotensin NN i
II NNP i
, , N
in IN N
random JJ N
order NN N
on IN N
successive JJ N
days NNS N
. . N

Infusion NN i
of IN i
fresh JJ i
frozen JJ i
plasma NN i
improved VBD N
function NN N
more RBR N
than IN N
did VBD N
stored VBN N
plasma NN N
and CC N
in IN N
addition NN N
returned VBD N
a DT N
very RB N
low JJ N
filtration NN N
fraction NN N
toward IN N
normal JJ N
. . N

Angiotensin NNP i
II NNP i
infusion NN i
increased VBD N
filtration NN o
fraction NN o
, , N
but CC N
decreased VBD N
glomerular JJ o
filtration NN o
rate NN o
, , o
renal JJ o
plasma NN o
flow NN o
, , o
and CC o
urine JJ o
flow NN o
sharply RB N
. . N

Patients NNS N
were VBD N
then RB N
given VBN N
a DT N
daily JJ N
infusion NN N
of IN N
1,000 CD i
ml NNS i
of IN i
fresh JJ i
frozen JJ i
plasma NN i
for IN N
seven CD N
to TO N
18 CD N
days NNS N
to TO N
expand VB N
the DT N
blood NN N
volume NN N
to TO N
supranormal JJ N
levels NNS N
as IN N
assayed VBN N
by IN N
serial JJ N
measurement NN N
of IN N
blood NN N
volume NN N
. . N

Plasma NNP o
aldosterone NN o
levels NNS o
decreased VBN N
to TO N
a DT N
normal JJ N
range NN N
, , N
glomerular JJ o
filtration NN o
rate NN o
and CC o
renal JJ o
plasma NN o
flow NN o
both DT N
increased VBN N
, , N
and CC N
urinary JJ o
excretion NN o
of IN o
sodium NN o
and CC o
potassium NN o
both DT N
returned VBN N
toward IN N
normal JJ N
. . N

The DT N
effect NN N
of IN N
intraperitoneal JJ o
pressure NN o
was VBD N
then RB N
studied VBN N
by IN N
measuring VBG N
glomerular JJ o
filtration NN o
rate NN o
, , o
renal JJ o
plasma NN o
flow NN o
, , o
pressure NN o
in IN o
the DT o
vena NN o
cava NN o
, , o
hepatic JJ o
vein NN o
free JJ o
flow NN o
, , o
and CC o
hepatic JJ o
vein NNS o
wedged VBD o
pressure NN o
before IN N
, , N
during IN N
, , N
and CC N
after IN N
paracentesis NN N
to TO N
reduce VB N
the DT N
intraperitoneal JJ N
pressure NN N
from IN N
30 CD N
to TO N
40 CD N
cm NNS N
H2O NNP N
to TO N
12 CD N
to TO N
17 CD N
cm NN N
H2O NNP N
. . N

Venous JJ o
pressures NNS o
moved VBD N
parallel RB N
to TO N
ascitic JJ o
fluid NN o
pressures NNS o
, , N
and CC N
glomerular JJ o
filtration NN o
rate NN o
, , o
renal JJ o
plasma NN o
flow NN o
, , o
and CC o
urine JJ o
flow NN o
all DT N
improved VBD N
sharply RB N
; : N
then RB N
, , N
as IN N
ascitic JJ N
fluid NN N
continued VBD N
to TO N
form VB N
, , N
reducing VBG N
vascular JJ o
volume NN o
, , o
urine JJ o
flow NN o
, , o
glomerular JJ o
filtration NN o
rate NN o
, , o
and CC o
renal JJ o
plasma NN o
flow NN o
all DT N
decreased VBD N
slowly RB N
. . N

Six CD N
patients NNS N
then RB N
underwent JJ N
placement NN N
of IN N
a DT N
LeVeen NNP N
shunt NN N
. . N

Improvement NN N
in IN N
glomerular JJ o
filtration NN o
rate NN o
and CC o
renal JJ o
plasma NN o
flow NN o
and CC o
clinical JJ o
condition NN o
was VBD N
dramatic JJ N
. . N

During IN N
postoperative JJ N
observation NN N
of IN N
up IN N
to TO N
two CD N
years NNS N
, , N
progressive JJ N
improvement NN N
in IN N
hepatic JJ o
function NN o
has VBZ N
occurred VBN N
. . N

-DOCSTART- -2691974- O O

[ NNS N
Are VBP N
there EX N
indications NNS N
for IN N
adjuvant JJ i
chemotherapy NN i
after IN i
excision NN p
of IN p
colorectal JJ p
cancer NN p
? . N
] UH N
. . N

-DOCSTART- -20155309- O O

Pilot NNP N
randomized VBD N
controlled VBN N
trial NN N
of IN N
Reciprocal NNP i
Imitation NNP i
Training NNP i
for IN N
teaching VBG N
elicited VBN N
and CC N
spontaneous JJ o
imitation NN o
to TO N
children NNS p
with IN p
autism NN p
. . p

Children NNP p
with IN p
autism NN p
exhibit NN N
significant JJ N
deficits NNS N
in IN N
imitation NN o
skills NNS o
. . o

Reciprocal JJ i
Imitation NNP i
Training NNP i
( ( i
RIT NNP i
) ) i
, , N
a DT N
naturalistic JJ N
imitation NN N
intervention NN N
, , N
was VBD N
developed VBN N
to TO N
teach VB N
young JJ p
children NNS p
with IN p
autism NN p
to TO N
imitate VB N
during IN N
play NN N
. . N

This DT N
study NN N
used VBD N
a DT N
randomized JJ N
controlled VBN N
trial NN N
to TO N
evaluate VB N
the DT N
efficacy NN o
of IN N
RIT NNP N
on IN N
elicited VBN N
and CC N
spontaneous JJ N
imitation NN o
skills NNS o
in IN N
21 CD p
young JJ p
children NNS p
with IN p
autism NN p
. . p

Results NNP N
found VBD N
that IN N
children NNS N
in IN N
the DT N
treatment NN N
group NN N
made VBD N
significantly RB o
more RBR o
gains NNS o
in IN N
elicited JJ o
and CC o
spontaneous JJ o
imitation NN o
, , N
replicating VBG N
previous JJ N
single-subject JJ N
design NN N
studies NNS N
. . N

Number NNP o
of IN o
spontaneous JJ o
play NN o
acts NNS o
at IN N
pre-treatment NN N
was VBD N
related VBN N
to TO N
improvements NNS N
in IN N
imitation NN o
during IN N
the DT N
intervention NN N
, , N
suggesting VBG N
that IN N
children NNS N
with IN N
a DT N
greater JJR N
play NN N
repertoire NN N
make VBP N
greater JJR N
gains NNS N
during IN N
RIT NNP N
. . N

-DOCSTART- -15816586- O O

Stress NNP N
reduction NN N
and CC N
analgesia NN N
in IN N
patients NNS p
exposed VBN N
to TO N
calming VBG N
music NN N
postoperatively RB N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
AND CC N
OBJECTIVES NNP N
This DT N
randomized VBD N
controlled JJ N
trial NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
, , N
first RB N
, , N
whether IN N
intra- JJ N
or CC N
postoperative JJ N
music NN N
therapy NN N
could MD N
influence VB N
stress NN o
and CC N
immune JJ o
response NN o
during IN N
and CC N
after IN N
general JJ N
anaesthesia NN N
and CC N
second JJ N
, , N
if IN N
there EX N
was VBD N
a DT N
different JJ N
response NN N
between IN N
patients NNS N
exposed VBN N
to TO N
music NN N
intra- NN N
or CC N
postoperatively RB N
. . N

METHOD NNP N
Seventy-five JJ p
patients NNS p
undergoing VBG p
open JJ p
hernia NN p
repair NN p
as IN p
day NN p
care NN p
surgery NN p
were VBD N
randomly RB i
allocated VBN i
to TO i
three CD i
groups NNS i
: : i
intraoperative JJ i
music NN i
, , i
postoperative JJ i
music NN i
and CC i
silence NN i
( ( i
control VB i
group NN i
) ) i
. . i

Anaesthesia NNP i
and CC i
postoperative JJ i
analgesia NN i
were VBD i
standardized VBN i
and CC i
the DT i
same JJ i
surgeon NN i
performed VBD i
all PDT i
the DT i
operations NNS i
. . i

Stress NNP o
response NN o
was VBD i
assessed VBN i
during IN i
and CC i
after IN i
surgery NN i
by IN i
determining VBG i
the DT i
plasma NN o
cortisol NN o
and CC o
blood NN o
glucose NN o
levels NNS o
. . o

Immune NNP o
function NN o
was VBD i
evaluated VBN i
by IN i
studying VBG i
immunoglobulin NN o
A NNP o
( ( o
IgA NNP o
) ) o
levels NNS o
. . o

Patients NNS o
' POS o
postoperative JJ o
pain NN o
, , o
anxiety NN o
, , o
blood NN o
pressure NN o
( ( o
BP NNP o
) ) o
, , o
heart NN o
rate NN o
( ( o
HR NNP o
) ) o
and CC o
oxygen JJ o
saturation NN o
were VBD o
also RB o
studied VBN o
as IN o
stress NN o
markers NNS o
. . o

RESULTS NNP N
There EX N
was VBD N
a DT N
significantly RB N
greater JJR N
decrease NN N
in IN N
the DT N
level NN o
of IN o
cortisol NN o
in IN N
the DT N
postoperative JJ N
music NN N
group NN N
vs. IN N
the DT N
control NN N
group NN N
( ( N
206 CD N
and CC N
72 CD N
mmol NN N
L NNP N
( ( N
-1 NNP N
) ) N
decreases VBZ N
, , N
respectively RB N
) ) N
after IN N
2 CD N
h NN N
in IN N
the DT N
post NN N
anaesthesia NN N
care NN N
unit NN N
. . N

The DT N
postoperative JJ N
music NN N
group NN N
had VBD N
less JJR N
anxiety NN o
and CC o
pain NN o
and CC N
required VBD N
less JJR N
morphine NN o
after IN N
1 CD N
h NNS N
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

In IN N
the DT N
postoperative JJ N
music NN N
group NN N
the DT N
total JJ N
requirement NN N
of IN N
morphine NN o
was VBD N
significantly RB N
lower JJR N
than IN N
in IN N
the DT N
control NN N
group NN N
. . N

The DT N
intraoperative JJ N
music NN N
group NN N
reported VBD N
less JJR N
pain NN o
after IN N
1 CD N
h NN N
in IN N
the DT N
post NN N
anaesthesia NN N
care NN N
unit NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
IgA NNP o
, , o
blood NN o
glucose NN o
, , o
BP NNP o
, , o
HR NNP o
and CC o
oxygen NN o
saturation NN o
between IN N
the DT N
groups NNS N
. . N

CONCLUSION NNP N
This DT N
study NN N
suggests VBZ N
that IN N
intraoperative JJ N
music NN N
may MD N
decrease VB N
postoperative JJ N
pain NN N
, , N
and CC N
that IN N
postoperative JJ N
music NN N
therapy NN N
may MD N
reduce VB N
anxiety NN o
, , o
pain NN o
and CC N
morphine NN o
consumption NN o
. . o

-DOCSTART- -23361389- O O

Effects NNS N
of IN N
a DT N
dietetic JJ i
treatment NN i
in IN N
older JJR p
, , p
undernourished JJ p
, , p
community-dwelling JJ p
individuals NNS p
in IN p
primary JJ p
care NN p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

PURPOSE NNP N
Undernutrition NNP N
is VBZ N
a DT N
prevalent NN N
problem NN N
in IN N
older JJR p
, , p
community-dwelling JJ p
individuals NNS p
. . p

Aim NNP N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
effects NNS N
of IN N
a DT N
dietetic JJ i
treatment NN i
in IN N
older JJR p
, , p
undernourished JJ p
, , p
community-dwelling JJ p
individuals NNS p
. . p

METHODS NNP N
A NNP N
parallel JJ N
randomized VBN N
controlled JJ N
trial NN N
was VBD N
performed VBN N
in IN N
146 CD p
non-institutionalized JJ p
, , p
undernourished JJ p
individuals NNS p
aged VBN p
?65 CD p
years NNS p
in IN p
primary JJ p
care NN p
. . p

Participants NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT i
intervention NN i
( ( i
referral JJ i
to TO i
and CC i
treatment NN i
by IN i
a DT i
trained JJ i
dietitian NN i
) ) i
or CC i
control VB i
group NN i
( ( i
no DT i
referral NN o
) ) o
. . o

Body NNP o
weight VBD o
, , o
physical JJ o
performance NN o
, , o
handgrip JJ o
strength NN o
, , o
energy NN o
intake NN o
, , o
protein JJ o
intake NN o
and CC o
fat-free JJ o
mass NN o
were VBD o
assessed VBN N
at IN N
baseline NN N
, , N
after IN N
3 CD N
months NNS N
and CC N
after IN N
6 CD N
months NNS N
. . N

RESULTS NNP N
All NNP N
randomized VBD N
participants NNS N
( ( N
n JJ N
= NNP N
146 CD N
) ) N
were VBD N
included VBN N
in IN N
the DT N
intention-to-treat JJ N
generalized JJ N
estimating NN N
equations NNS N
analysis NN N
( ( N
72 CD N
in IN N
intervention NN N
and CC N
74 CD N
in IN N
control NN N
group NN N
) ) N
. . N

No DT N
treatment NN N
effect NN N
was VBD N
found VBN N
on IN N
the DT N
primary JJ N
outcomes NNS o
body NN o
weight NN o
( ( o
? . N
= $ N
0.49 CD N
kg NN N
, , N
95 CD N
% NN N
CI NNP N
: : N
-0.15-1.12 NN o
) ) o
, , o
physical JJ o
performance NN o
( ( o
? . o
= RB N
0.15 CD N
points NNS N
, , N
95 CD N
% NN N
CI NNP N
: : N
-0.33-0.64 NN N
) ) N
and CC N
handgrip JJ o
strength NN o
( ( o
? . o
= $ N
0.49 CD N
kg NN N
, , N
95 CD N
% NN N
CI NNP N
: : N
-0.62-1.60 NN N
) ) N
. . N

Furthermore NNP N
, , N
no DT N
treatment NN N
effect NN N
was VBD N
found VBN N
for IN N
the DT N
secondary JJ N
outcomes NNS N
. . N

Predefined VBN N
subgroup NN N
analyses VBZ N
showed VBD N
a DT N
treatment NN N
effect NN o
on IN o
body NN o
weight NN o
in IN o
physically RB o
active JJ N
participants NNS N
( ( N
? . N
= $ N
1.25 CD N
kg NN N
, , N
95 CD N
% NN N
CI NNP N
: : N
0.70-2.11 NN N
) ) N
and CC N
not RB N
in IN N
inactive JJ N
participants NNS N
( ( N
? . N
= '' N
-0.20 JJ N
kg NN N
, , N
95 CD N
% NN N
CI NNP N
: : N
-1.16-0.75 NN N
) ) N
. . N

CONCLUSIONS NNP N
After IN N
6 CD N
months NNS N
, , N
a DT i
dietetic JJ i
treatment NN i
by IN i
trained JJ i
dietitians NNS i
does VBZ i
not RB i
lead VB N
to TO N
increases NNS N
in IN N
body NN N
weight NN N
and CC N
physical JJ N
functioning NN p
in IN p
older JJR p
, , p
undernourished JJ p
, , p
community-dwelling JJ p
individuals NNS p
. . p

-DOCSTART- -21106341- O O

The DT N
Toronto NNP N
prehospital NN N
hypertonic JJ N
resuscitation NN p
-- : p
head JJ p
injury NN N
and CC N
multiorgan JJ N
dysfunction NN N
trial NN N
: : N
feasibility NN N
study NN N
of IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

OBJECTIVE CC N
The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
feasibility NN N
of IN N
a DT N
prehospital JJ N
trial NN N
comparing VBG N
hypertonic JJ i
saline NN i
and CC i
dextran NN i
( ( i
HSD NNP i
) ) i
with IN i
normal JJ i
saline NN i
( ( i
NS NNP i
) ) i
in IN N
blunt NN p
head NN p
injury NN p
patients NNS p
. . p

DESIGN NNP N
The DT N
study NN N
used VBD N
a DT N
double JJ N
blind NN N
randomized VBN N
trial NN N
. . N

SETTING VB N
The DT N
study NN N
was VBD N
conducted VBN N
in IN N
air NN p
and CC p
land NN p
emergency NN p
medical JJ p
services NNS p
and CC p
2 CD p
trauma NN p
centers NNS p
serving VBG p
a DT p
population NN p
of IN p
4 CD p
million CD p
people NNS p
. . p

PATIENTS VB N
The DT N
study NN p
population NN p
consisted VBD p
of IN p
head NN p
injured VBN p
, , p
blunt VB p
trauma JJ p
adult NN p
patients NNS p
with IN p
a DT p
Glasgow NNP p
Coma NNP p
Scale NNP p
of IN p
lower JJR p
than IN p
9 CD p
. . p

INTERVENTIONS NN N
We PRP N
used VBD N
250 CD i
mL NN i
of IN i
HSD NNP i
vs FW i
NS NNP i
given VBN N
within IN N
4 CD N
hours NNS N
of IN N
the DT N
accident NN N
. . N

MEASUREMENTS PDT N
The DT N
specific JJ N
objectives NNS N
were VBD N
to TO N
assess VB o
protocol-related JJ o
logistical JJ o
issues NNS o
, , o
randomization NN o
, , o
HSD NNP o
safety NN o
, , o
and CC o
follow VB o
up RP o
rates NNS o
and CC N
to TO N
obtain VB N
survival JJ o
and CC o
neurocognitive JJ o
end NN o
point NN o
estimates NNS o
. . o

MAIN NNP N
RESULTS NNP N
Of IN N
132 CD p
eligible JJ p
patients NNS p
, , p
113 CD p
were VBD p
randomized VBN p
. . p

Nineteen NNP p
eligible JJ p
patients NNS p
were VBD N
missed VBN N
because IN N
of IN N
lack NN N
of IN N
time NN N
( ( N
9 CD N
[ RB N
22 CD N
% NN N
] NN N
) ) N
, , N
paramedic JJ N
discretion NN N
( ( N
3 CD N
[ RB N
7 CD N
% NN N
] NN N
) ) N
, , N
the DT N
paramedic JJ N
forgot NN N
( ( N
6 CD N
[ RB N
15 CD N
% NN N
] NN N
) ) N
, , N
and CC N
the DT N
paramedic NN N
refused VBD N
( ( N
1 CD N
[ RB N
2 CD N
% NN N
] NN N
) ) N
. . N

Randomization NNP N
compliance NN N
was VBD N
96 CD N
% NN N
( ( N
109/113 CD N
) ) N
. . N

Four CD N
randomized JJ N
cases NNS N
met VBD N
exclusion NN N
criteria NNS N
: : N
penetrating NN N
trauma NN N
( ( N
1 CD N
) ) N
, , N
cardiac JJ N
arrest NN N
( ( N
2 CD N
) ) N
, , N
and CC N
fall NN N
from IN N
standing VBG N
( ( N
1 CD N
) ) N
. . N

Three CD N
randomized JJ N
patients NNS N
were VBD N
excluded VBN N
from IN N
the DT N
final JJ N
analysis NN N
: : N
2 CD N
patients NNS N
received VBD N
less JJR N
than IN N
50 CD N
mL NN N
of IN N
study NN N
solution NN N
due JJ N
to TO N
an DT N
interstitial JJ N
intravenous JJ N
line NN N
and CC N
1 CD N
lost VBN N
randomization NN N
identification NN N
. . N

Fifty JJ N
patients NNS N
( ( N
47 CD N
% NN N
) ) N
were VBD N
randomized VBN N
to TO N
HSD NNP N
and CC N
56 CD N
( ( N
53 CD N
% NN N
) ) N
to TO N
NS NNP N
. . N

Mean NNP o
injury NN o
severity NN o
score NN o
was VBD N
32.7 CD N
for IN N
HSD NNP N
and CC N
32.6 CD N
for IN N
NS NNP N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
length NN o
of IN o
stay NN o
, , o
Sequential NNP o
Organ NNP o
Failure NNP o
Assessment NNP o
maximum NN o
, , o
Multiple NNP o
Organ NNP o
Dysfunction NNP o
Score NNP o
maximum NN o
, , o
delta JJ o
Multiple NNP o
Organ NNP o
Dysfunction NNP o
Score NNP o
, , o
or CC o
Apache NNP o
scores NNS o
. . o

Initial JJ o
head NN o
scans NNS o
scored VBD N
3 CD N
or CC N
higher JJR N
by IN N
Marshall NNP N
classification NN N
for IN N
12 CD N
HSD NNP N
and CC N
11 CD N
NS NNP N
patients NNS N
. . N

Zero NNP N
adverse JJ o
events NNS o
occurred VBD N
, , N
and CC N
follow-up NN N
for IN N
the DT N
primary JJ N
outcome NN N
was VBD N
100 CD N
% NN N
. . N

Alive JJ o
at IN o
30 CD o
days NNS o
for IN N
HSD NNP N
and CC N
NS NNP N
, , N
respectively RB N
, , N
was VBD N
70 CD N
% NN N
( ( N
35/50 CD N
) ) N
and CC N
75 CD N
% NN N
( ( N
42/56 CD N
) ) N
and CC N
at IN N
discharge NN N
was VBD N
68 CD N
% NN N
( ( N
34/50 CD N
) ) N
and CC N
73 CD N
% NN N
( ( N
41/56 CD N
) ) N
. . N

Only RB N
49.3 CD N
% NN N
( ( N
37/77 CD N
) ) N
of IN N
surviving VBG N
patients NNS N
consented VBN N
to TO N
follow-up NN N
at IN N
4 CD N
months NNS N
and CC N
89 CD N
% NN N
( ( N
33/37 CD N
) ) N
completed VBD N
the DT N
assessment NN N
. . N

Disability NN o
rating NN o
scale NN o
( ( N
median JJ N
, , N
interquartile JJ N
range NN N
) ) N
was VBD N
3 CD N
( ( N
0 CD N
, , N
6 CD N
) ) N
for IN N
HSD NNP N
and CC N
was VBD N
0 CD N
( ( N
0 CD N
, , N
6 CD N
) ) N
for IN N
NS NNP N
. . N

Glasgow NNP o
Outcome NNP o
Scale NNP o
Evaluation NNP o
was VBD N
higher JJR N
than IN N
4 CD N
for IN N
HSD NNP N
( ( N
12/12 CD N
[ RB N
100 CD N
% NN N
] NN N
) ) N
and CC N
NS NNP N
( ( N
15/21 CD N
[ RB N
72 CD N
% NN N
] NN N
) ) N
. . N

Functional JJ o
Independence NNP o
Measure NNP o
( ( N
mean NN N
, , N
SD NNP N
) ) N
was VBD N
62 CD N
( ( N
37 CD N
) ) N
for IN N
HSD NNP N
and CC N
80 CD N
( ( N
32 CD N
) ) N
for IN N
NS NNP N
. . N

CONCLUSIONS VB N
It PRP N
is VBZ N
feasible JJ N
to TO N
conduct VB N
a DT N
prehospital JJ N
randomized NN N
controlled VBD N
trial NN N
with IN N
HSD NNP N
for IN N
treatment NN N
of IN N
blunt NN p
trauma NN p
patients NNS p
with IN p
head JJ p
injuries NNS p
; : p
however RB N
, , N
consent NN N
for IN N
neurofunctional JJ N
outcomes NNS N
in IN N
this DT N
cohort NN N
is VBZ N
problematic JJ N
and CC N
threatens VBZ N
the DT N
feasibility NN N
of IN N
definitive JJ N
trials NNS N
using VBG N
these DT N
potentially RB N
meaningful JJ N
end NN N
points NNS N
. . N

-DOCSTART- -3519095- O O

Hexetidine NNP i
( ( i
'Oraldene NNP i
' POS i
) ) i
: : i
a DT N
report NN N
on IN N
its PRP$ N
antibacterial JJ o
and CC o
antifungal JJ o
properties NNS o
on IN N
the DT N
oral JJ N
flora NNS N
in IN N
healthy JJ p
subjects NNS p
. . p

A DT N
randomized JJ N
, , N
double-blind JJ N
crossover NN N
trial NN N
, , N
in IN N
10 CD p
adult NN p
healthy JJ p
subjects NNS p
, , N
was VBD N
carried VBN N
out IN N
to TO N
compare VB N
the DT N
antibacterial JJ o
and CC o
antifungal JJ o
activity NN o
of IN N
a DT N
0.1 CD i
% NN i
solution NN i
of IN i
hexetidine NN i
with IN i
that DT i
of IN i
placebo NN i
. . i

The DT N
pre-dosing JJ N
oral JJ N
flora NN N
of IN N
the DT N
subjects NNS N
was VBD N
assessed VBN N
from IN N
saliva NN o
samples NNS o
cultured VBD N
for IN N
aerobic JJ o
and CC o
anaerobic JJ o
bacteria NNS o
, , N
as RB N
well RB N
as IN N
Candida NNP o
albicans NNS o
. . o

Subjects NNS N
then RB N
rinsed VBD N
their PRP$ N
mouths NNS N
for IN N
1 CD N
minute JJ N
3-times NNS N
a DT N
day NN N
with IN N
15 CD N
ml NNS N
0.1 CD N
% NN N
hexetidine NN i
or CC i
placebo NN i
, , N
saliva NN N
samples NNS N
being VBG N
collected VBN N
at IN N
2 CD N
minutes NNS N
, , N
30 CD N
minutes NNS N
, , N
1 CD N
hour NN N
, , N
3 CD N
hours NNS N
and CC N
5 CD N
hours NNS N
post-dosing JJ N
. . N

Dosing NN N
was VBD N
continued VBN N
for IN N
8 CD N
consecutive JJ N
days NNS N
on IN N
each DT N
treatment NN N
with IN N
an DT N
intervening VBG N
wash-out JJ N
period NN N
of IN N
1 CD N
week NN N
. . N

Hexetidine NNP i
reduced VBD N
aerobic JJ o
bacterial JJ o
counts NNS o
on IN N
Day NNP N
1 CD N
and CC N
Day NNP N
8 CD N
by IN N
a DT N
maximum NN N
of IN N
83 CD N
% NN N
and CC N
86 CD N
% NN N
, , N
respectively RB N
, , N
at IN N
2 CD N
minutes NNS N
post-dosing JJ N
. . N

The DT N
reductions NNS N
were VBD N
statistically RB N
significantly RB N
lower JJR N
than IN N
placebo VB i
up IN N
to TO N
1 CD N
hour NN N
post-dose JJ N
on IN N
Day NNP N
1 CD N
and CC N
up RB N
to TO N
3 CD N
hours NNS N
post-dose JJ N
on IN N
Day NNP N
8 CD N
. . N

Similarly RB N
for IN N
anaerobic JJ o
bacterial JJ o
counts NNS o
, , N
92 CD N
% NN N
and CC N
88 CD N
% NN N
maximum JJ N
reductions NNS N
were VBD N
recorded VBN N
on IN N
Day NNP N
1 CD N
and CC N
Day NNP N
8 CD N
, , N
which WDT N
again RB N
were VBD N
significantly RB N
lower JJR N
than IN N
placebo NN N
for IN N
up IN N
to TO N
3 CD N
hours NNS N
post-dose JJ N
. . N

For IN N
Candida NNP o
albicans NNS o
, , N
however RB N
, , N
the DT N
maximum JJ N
reduction NN N
was VBD N
91 CD N
% NN N
on IN N
the DT N
first JJ N
day NN N
and CC N
67 CD N
% NN N
on IN N
Day NNP N
8 CD N
, , N
maintained VBD N
for IN N
30 CD N
minutes NNS N
post-dosing JJ N
. . N

Although IN N
not RB N
eradicating VBG o
completely RB o
aerobic JJ o
and CC o
anaerobic JJ o
bacteria NNS o
, , N
it PRP N
is VBZ N
concluded VBN N
that IN N
the DT N
substantial JJ N
reduction NN o
in IN N
their PRP$ N
numbers NNS N
should MD N
prove VB N
clinically RB N
useful JJ N
. . N

-DOCSTART- -16238662- O O

A DT N
randomised VBN N
controlled VBN N
trial NN N
of IN N
a DT N
CBT NNP i
intervention NN i
for IN N
anxiety NN p
in IN p
children NNS p
with IN p
Asperger NNP o
syndrome NN o
. . o

BACKGROUND IN N
The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
a DT N
brief JJ i
CBT NNP i
intervention NN i
for IN i
anxiety NN i
with IN N
children NNS p
diagnosed VBN p
with IN p
Asperger NNP p
syndrome NN p
( ( p
AS IN p
) ) p
. . p

A DT N
second JJ N
interest NN N
was VBD N
to TO N
evaluate VB N
whether IN N
more RBR N
intensive JJ N
parent NN N
involvement NN N
would MD N
increase VB N
the DT N
child NN N
's POS N
ability NN N
to TO N
manage VB N
anxiety NN N
outside IN N
of IN N
the DT N
clinic JJ N
setting NN N
. . N

METHODS NNP N
Seventy-one JJ p
children NNS p
aged VBN p
ten NNS p
to TO p
twelve VB p
years NNS p
were VBD p
recruited VBN p
to TO N
participate VB N
in IN N
the DT N
anxiety NN N
programme NN N
. . N

All DT p
children NNS p
were VBD p
diagnosed VBN p
with IN p
AS NNP p
and CC p
the DT p
presence NN p
of IN p
anxiety NN p
symptoms NNS p
was VBD N
accepted VBN N
on IN N
parent NN N
report NN N
via IN N
brief JJ N
interview NN N
. . N

Children NNP N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
conditions NNS N
: : N
intervention NN i
for IN i
child NN i
only RB i
, , i
intervention NN i
for IN i
child NN i
and CC i
parent NN i
, , i
wait-list JJ i
control NN i
. . i

RESULTS VB N
The DT N
two CD N
intervention NN N
groups NNS N
demonstrated VBD N
significant JJ N
decreases NNS N
in IN N
parent-reported JJ o
anxiety NN o
symptoms NNS o
at IN N
follow-up JJ N
and CC N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
child NN N
's POS N
ability NN N
to TO N
generate VB N
positive JJ N
strategies NNS N
in IN N
an DT N
anxiety-provoking JJ N
situation NN N
. . N

There EX N
were VBD N
a DT N
number NN N
of IN N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
interventions NNS N
to TO N
suggest VB N
parent NN N
involvement NN N
as IN N
beneficial JJ N
. . N

CONCLUSIONS VB N
The DT N
sample NN N
of IN N
children NNS N
with IN N
AS NNP N
in IN N
this DT N
study NN N
presented VBD N
with IN N
a DT N
profile NN N
of IN N
anxiety NN N
similar JJ N
to TO N
a DT N
sample NN N
of IN N
clinically RB N
diagnosed VBN N
anxious JJ N
children NNS N
. . N

The DT N
intervention NN N
was VBD N
endorsed VBN N
by IN N
parents NNS N
as IN N
a DT N
useful JJ N
programme NN N
for IN N
children NNS p
diagnosed VBN p
with IN p
Asperger NNP p
syndrome NN p
and CC p
exhibiting VBG p
anxiety NN p
symptoms NNS p
, , N
and CC N
active JJ N
parent NN N
involvement NN N
enhanced VBD N
the DT N
usefulness NN N
of IN N
the DT N
programme NN N
. . N

Limitations NNS N
of IN N
the DT N
study NN N
and CC N
future JJ N
research NN N
are VBP N
discussed VBN N
. . N

-DOCSTART- -12780755- O O

Short-term JJ N
effects NNS N
of IN N
prednisolone NN i
and CC i
dexamethasone NN i
on IN N
circulating VBG o
concentrations NNS o
of IN o
leptin NN o
and CC o
sex NN o
hormone-binding JJ o
globulin NN o
in IN N
children NNS p
being VBG p
treated VBN p
for IN p
acute JJ p
lymphoblastic JJ p
leukaemia NN p
. . p

OBJECTIVE NNP N
Disturbances NNPS N
in IN N
body NN N
weight JJ N
regulation NN N
are VBP N
often RB N
encountered VBN N
during IN N
glucocorticoid JJ i
treatment NN i
and CC N
are VBP N
associated VBN N
with IN N
increased JJ N
insulin NN N
resistance NN N
and CC N
truncal JJ N
fat NN N
accumulation NN N
. . N

Children NNP p
were VBD p
investigated VBN p
who WP p
were VBD p
receiving VBG p
glucocorticoid JJ i
treatment NN i
for IN p
acute JJ p
lymphoblastic JJ p
leukaemia NN p
( ( p
ALL DT p
) ) p
. . p

They PRP N
were VBD N
randomized VBN N
to TO N
receive VB N
either CC N
prednisolone VB i
or CC i
dexamethasone VB i
as IN N
part NN N
of IN N
induction NN N
of IN N
remission NN N
. . N

This DT N
randomization NN N
process NN N
provided VBD N
a DT N
suitable JJ N
opportunity NN N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
these DT N
two CD N
administered VBD N
steroid NN N
on IN N
surrogate JJ N
markers NNS N
of IN N
adipocyte NN N
activity NN N
( ( N
leptin NN N
) ) N
and CC N
hyperinsulinaemia/insulin JJ N
resistance NN N
( ( N
SHBG NNP N
) ) N
. . N

DESIGN NNP N
AND CC N
PATIENTS NNP N
Prospective NNP N
study NN N
over IN N
16 CD N
weeks NNS N
of IN N
children NNS p
randomized VBN N
to TO N
receive VB N
prednisolone NN i
( ( i
40 CD i
mg/m2 NN i
) ) i
or CC i
dexamethasone NN i
( ( i
6.5 CD i
mg/m2 NN i
) ) i
as IN i
part NN i
of IN i
the DT i
MRC-ALL97/99 NNP i
induction NN i
chemotherapy NN i
for IN i
ALL NNP i
. . i

Nineteen NNP p
children NNS p
( ( p
8 CD p
male NN p
, , p
11 CD p
female NN p
) ) p
with IN p
a DT p
median JJ p
age NN p
5.9 CD p
years NNS p
( ( p
range VB p
2.6-13 CD p
years NNS p
) ) p
were VBD p
recruited VBN p
into IN p
the DT p
study NN p
. . p

Main NNP N
outcome JJ N
measures NNS N
were VBD N
body JJ o
mass NN o
index NN o
( ( o
BMI NNP o
) ) o
, , o
serum JJ o
leptin NN o
and CC o
sex NN o
hormone NN o
binding VBG o
globulin NN o
( ( o
SHBG NNP o
) ) o
. . o

RESULTS NNP N
Glucocorticoid NNP N
administration NN N
for IN N
5 CD N
weeks NNS N
resulted VBD N
in IN N
significant JJ N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
increases NNS N
in IN N
BMI NNP o
, , o
leptin NN o
( ( o
corrected VBN o
for IN o
BMI NNP o
) ) o
and CC o
the DT o
leptin NN o
: : o
SHBG NNP o
ratio NN o
and CC o
lowering NN o
of IN o
SHBG NNP o
. . o

Dose NNP N
for IN N
dose NN N
, , N
dexamethasone NN i
was VBD N
significantly RB N
more RBR N
potent JJ N
than IN N
prednisolone NN i
in IN N
altering VBG N
these DT N
parameters NNS N
. . N

CONCLUSIONS NNP N
Short-term JJ N
glucocorticoid NN N
treatment NN N
has VBZ N
significant JJ N
effects NNS N
on IN N
BMI NNP N
, , N
leptin NN N
and CC N
SHBG NNP N
. . N

The DT N
leptin NN N
: : N
SHBG NNP N
ratio NN N
increase NN N
indicates VBZ N
that IN N
this DT N
may MD N
be VB N
a DT N
novel JJ N
and CC N
sensitive JJ N
biochemical JJ N
marker NN N
of IN N
metabolic JJ N
change NN N
. . N

Our PRP$ N
results NNS N
suggest VBP N
that IN N
glucocorticoid JJ i
treatment NN i
regimens NNS i
should MD N
be VB N
kept VBN N
as RB N
short JJ N
as IN N
possible JJ N
to TO N
avoid VB N
possible JJ N
detrimental JJ N
effects NNS N
associated VBN N
with IN N
increased JJ N
adiposity NN N
and CC N
insulin NN N
resistance NN N
. . N

-DOCSTART- -8272303- O O

Ovulation NN N
and CC N
follicular JJ N
development NN N
associated VBN N
with IN N
three CD N
low-dose JJ i
oral JJ i
contraceptives NNS i
: : i
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

OBJECTIVE UH N
To TO N
address VB N
the DT N
hypothesis NN N
that WDT N
multiphasic JJ i
oral JJ i
contraceptives NNS i
( ( i
OCs NNP i
) ) i
increase NN N
rather RB N
than IN N
decrease VB N
the DT N
risk NN o
of IN o
functional JJ o
ovarian JJ o
cysts NNS o
. . o

METHODS NNP N
In IN N
this DT N
single-center NN N
, , N
randomized VBN N
controlled VBD N
study NN N
, , N
women NNS p
were VBD N
assigned VBN N
to TO N
a DT N
multiphasic JJ i
pill NN i
, , i
a DT i
lower-dose JJ i
monophasic NN i
pill NN i
, , i
a DT i
higher-dose JJ i
monophasic NN i
pill NN i
, , i
or CC i
nonsteroidal JJ i
contraception NN i
. . i

Forty JJ p
volunteers NNS p
were VBD p
randomized VBN p
( ( p
ten VB p
each DT p
) ) p
to TO p
three CD i
different JJ i
pill NN i
regimens VBZ i
or CC p
to TO p
nonsteroidal DT i
contraception NN i
. . i

During IN N
6 CD N
months NNS N
of IN N
treatment NN N
, , N
follicular JJ o
development NN o
was VBD N
measured VBN N
by IN N
vaginal JJ N
ultrasonography NN N
and CC N
ovulation NN o
was VBD N
indicated VBN N
by IN N
serum NN N
progesterone NN N
levels NNS N
. . N

RESULTS VB N
The DT N
relative JJ o
risk NN o
( ( o
RR NNP o
) ) o
of IN o
developing VBG o
a DT o
follicular JJ o
structure NN o
greater JJR o
than IN o
30 CD o
mm NN o
in IN o
diameter NN o
during IN N
a DT N
cycle NN N
with IN N
the DT N
higher-dose JJ N
monophasic NN i
pill NN i
was VBD N
0.5 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
0.1-1.9 NN N
; : N
P NNP N
= NNP N
.49 NNP N
) ) N
compared VBN N
with IN N
the DT N
multiphasic NN N
pill NN N
. . N

The DT N
risk NN o
with IN o
the DT o
lower-dose JJ o
monophasic NN o
pill NN o
was VBD N
comparable JJ N
to TO N
that DT N
with IN N
the DT N
multiphasic NN i
pill NN i
( ( N
RR NNP N
1.3 CD N
, , N
95 CD N
% NN N
CI NNP N
0.5-3.6 CD N
; : N
P NNP N
= NNP N
.56 NNP N
) ) N
. . N

With IN N
the DT N
multiphasic NN i
pill NN i
, , N
the DT N
maximum JJ o
ovulation NN o
rate NN o
over IN N
60 CD N
cycles NNS N
was VBD N
1.7 CD N
per IN N
100 CD N
cycles NNS N
( ( N
95 CD N
% NN N
CI NNP N
0.0-8.9 NN N
) ) N
. . N

CONCLUSION VB N
This DT N
multiphasic JJ i
pill NN i
more RBR N
closely RB N
resembled VBN N
the DT N
lower-dose JJ N
monophasic NN i
pill NN i
than IN N
the DT N
higher-dose JJ N
monophasic NN i
pill NN i
in IN N
its PRP$ N
suppression NN o
of IN o
follicular JJ o
development NN o
. . o

-DOCSTART- -12787235- O O

Changing VBG N
Childbirth NN p
: : p
a DT N
pilot NN N
project NN N
. . N

OBJECTIVE UH N
To TO N
compare VB N
the DT N
outcomes NNS N
of IN N
an DT N
adapted JJ N
pilot NN N
Changing NNP i
Childbirth NNP i
initiative JJ i
providing VBG i
continuity NN i
of IN i
care NN i
by IN i
a DT i
group NN i
of IN i
known VBN i
midwives NNS i
with IN i
traditional JJ i
maternity NN i
care NN i
. . i

DESIGN NNP N
Between-groups NNP N
trial NN N
to TO N
compare VB N
levels NNS N
of IN N
satisfaction NN N
and CC N
clinical JJ N
outcomes NNS N
for IN N
two CD p
groups NNS p
of IN p
women NNS p
, , p
cared VBD p
for IN p
either DT p
under IN p
this DT p
Changing NNP i
Childbirth NNP i
scheme NN i
or CC i
the DT i
traditional JJ i
model NN i
of IN i
care NN i
. . i

METHOD NNP N
Of IN N
the DT N
200 CD p
women NNS p
who WP p
agreed VBD p
to TO p
participate VB p
in IN p
the DT p
project NN p
, , p
100 CD p
were VBD p
randomly RB p
allocated VBN p
to TO p
the DT p
pilot NN i
scheme NN i
and CC p
100 CD p
to TO p
the DT p
traditional JJ i
care NN i
package NN i
. . i

During IN N
the DT N
postpartum JJ N
period NN N
, , N
information NN N
was VBD N
collected VBN N
via IN N
a DT N
questionnaire NN N
about IN N
participants NNS N
' POS N
levels NNS N
of IN N
satisfaction NN N
with IN N
a DT N
variety NN N
of IN N
aspects NNS N
of IN N
care NN N
provided VBN N
during IN N
the DT N
antenatal JJ N
, , N
delivery NN N
and CC N
postpartum NN N
periods NNS N
. . N

Data NNS N
about IN N
clinical JJ N
outcomes NNS N
for IN N
the DT N
two CD N
groups NNS N
were VBD N
also RB N
obtained VBN N
. . N

RESULTS JJ N
Women NNP N
in IN N
the DT N
pilot NN N
group NN N
had VBD N
significantly RB N
more RBR N
continuity NN o
of IN o
care NN o
throughout IN N
each DT N
of IN N
the DT N
three CD N
periods NNS N
, , N
were VBD N
generally RB N
more RBR N
satisfied JJ o
with IN N
their PRP$ N
care NN N
, , N
felt VBD N
that IN N
they PRP N
had VBD N
more JJR o
choice NN o
over IN N
a DT N
variety NN o
of IN o
aspects NNS o
of IN o
care NN o
and CC N
experienced VBD N
no DT N
compromise NN o
in IN N
clinical JJ N
outcomes NNS N
( ( N
P NNP N
= VBZ N
0.05 CD N
or CC N
less JJR N
in IN N
each DT N
case NN N
) ) N
. . N

IMPLICATIONS NNP N
FOR NNP N
PRACTICE NNP N
Many NNP N
previous JJ N
attempts NNS N
to TO N
introduce VB N
the DT N
Changing NNP N
Childbirth NNP N
initiative NN N
have VBP N
revealed VBN N
significant JJ N
problems NNS N
, , N
particularly RB N
with IN N
regard NN N
to TO N
the DT N
continuity NN N
of IN N
carer NN N
requirement NN N
. . N

Taking VBG N
account NN N
of IN N
local JJ N
health NN N
care NN N
needs NNS N
and CC N
existing VBG N
provision NN N
, , N
the DT N
present JJ N
study NN N
adapted VBD N
this DT N
concept NN N
to TO N
continuity NN N
of IN N
care NN N
. . N

This DT N
did VBD N
not RB N
apparently RB N
affect VBP N
any DT N
of IN N
the DT N
guiding VBG N
principles NNS N
contained VBN N
in IN N
the DT N
original JJ N
document NN N
, , N
and CC N
yet RB N
enhanced VBN N
satisfaction NN N
. . N

It PRP N
would MD N
appear VB N
that IN N
the DT N
Changing NNP N
Childbirth NNP N
agenda NN N
can MD N
be VB N
adapted VBN N
and CC N
integrated VBN N
with IN N
local JJ N
health NN N
care NN N
situations NNS N
without IN N
sacrificing VBG N
any DT N
of IN N
the DT N
overarching JJ N
principles NNS N
. . N

-DOCSTART- -9314855- O O

The DT N
nature NN N
and CC N
importance NN N
of IN N
changes NNS N
in IN N
toe-brachial JJ N
pressure NN N
indices NNS N
following VBG N
percutaneous JJ i
transluminal JJ i
angioplasty NN i
for IN N
leg NN N
ischaemia NN N
. . N

OBJECTIVES NNP N
To TO N
document VB N
changes NNS N
in IN N
toe-brachial JJ o
pressure NN o
indices NNS o
( ( o
TBPI NNP o
) ) o
during IN N
the DT N
6 CD N
months NNS N
following VBG N
percutaneous JJ i
transluminal JJ i
angioplasty NN i
( ( i
PTA NNP i
) ) i
and CC N
relate VB N
these DT N
changes NNS N
to TO N
restenosis VB N
. . N

Furthermore RB N
, , N
to TO N
ascertain VB N
the DT N
effect NN o
of IN N
administering VBG N
a DT N
vasodilator NN i
, , i
glyceryl JJ i
trinitrate NN i
( ( i
GTN NNP i
) ) i
, , N
immediately RB N
following VBG N
PTA NNP N
. . N

DESIGN NNP N
Eighty-three JJ p
technically RB p
successful JJ p
PTA NNP i
procedures NNS p
were VBD p
studied VBN p
. . p

Fifty-six CD p
were VBD p
for IN p
intermittent JJ p
claudication NN p
, , p
14 CD p
for IN p
ischaemic JJ p
rest NN p
pain NN p
, , p
and CC p
13 CD p
for IN p
non-healing JJ p
ulcers NNS p
. . p

Immediately RB N
following VBG N
balloon NN i
dilatation NN i
an DT i
intra-arterial JJ i
bolus NN i
of IN i
either CC i
150 CD i
micrograms NNS i
GTN NNP i
, , i
with IN i
or CC i
without IN i
a DT i
10 CD i
mg NN i
GTN NNP i
patch NN i
for IN i
24 CD i
h NN i
, , i
or CC i
a DT i
saline JJ i
placebo NN i
was VBD N
administered VBN N
. . N

TBPI NNP o
were VBD N
measured VBN N
before IN N
and CC N
for IN N
6 CD N
h NN N
after IN N
PTA NNP N
and CC N
then RB N
at IN N
24 CD N
h NN N
, , N
1 CD N
week NN N
, , N
1 CD N
month NN N
and CC N
6 CD N
months NNS N
. . N

At IN N
this DT N
time NN N
, , N
patency NN N
at IN N
the DT N
PTA NNP N
site NN N
was VBD N
determined VBN N
by IN N
arteriography NN N
. . N

RESULTS NNP N
There EX N
was VBD N
continuing VBG N
TBPI NNP o
improvement NN N
over IN N
1 CD N
month NN N
in IN N
patients NNS N
given VBN N
saline JJ i
following VBG N
PTA NNP N
. . N

In IN N
patients NNS N
given VBN N
GTN NNP i
, , N
peak NN o
TBPI NNP o
was VBD N
achieved VBN N
by IN N
1 CD N
week NN N
, , N
and CC N
corresponded VBD N
with IN N
the DT N
TBPI NNP o
observed VBD N
immediately RB N
following VBG N
GTN NNP i
administration NN N
. . N

Restenosis NNP o
occurred VBD N
in IN N
27 CD N
( ( N
33 CD N
% NN N
) ) N
patients NNS N
, , N
and CC N
was VBD N
significantly RB N
more RBR N
frequent JJ N
following VBG N
the DT N
procedures NNS N
for IN N
rest NN N
pain NN N
or CC N
ulceration NN N
, , N
or CC N
where WRB N
a DT N
TBPI NNP o
increase NN N
of IN N
more JJR N
than IN N
0.15 CD N
by IN N
1 CD N
week NN N
was VBD N
observed VBN N
. . N

CONCLUSIONS NNP N
Haemodynamic NNP N
changes NNS N
following VBG N
PTA NNP N
continue VBP N
for IN N
at IN N
least JJS N
1 CD N
month NN N
, , N
can MD N
be VB N
modified VBN N
by IN N
GTN NNP i
administration NN N
, , N
and CC N
are VBP N
predictive JJ N
of IN N
subsequent JJ N
restenosis NN N
. . N

Measuring VBG N
the DT N
TBPI NNP o
increase NN N
during IN N
the DT N
first JJ N
week NN N
following VBG N
PTA NNP N
underestimates NNS N
total JJ N
improvement NN N
, , N
and CC N
may MD N
give VB N
false JJ N
reassurance NN N
with IN N
respect NN N
to TO N
recurrent VB N
disease NN N
. . N

-DOCSTART- -3546120- O O

Antihypertensive JJ N
and CC N
volume-depleting JJ N
effects NNS N
of IN N
mild JJ i
exercise NN i
on IN N
essential JJ N
hypertension NN N
. . N

After IN N
a DT N
general JJ N
clinical JJ N
observation NN N
period NN N
of IN N
over IN N
4 CD N
weeks NNS N
, , N
20 CD p
essential JJ p
hypertensive JJ p
subjects NNS p
( ( p
Japanese JJ p
) ) p
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
. . N

One CD p
group NN p
( ( p
n JJ p
= VBZ p
10 CD p
; : p
4 CD p
men NNS p
and CC p
6 CD p
women NNS p
; : p
51.4 CD p
+/- JJ p
2.8 CD p
years NNS p
of IN p
age NN p
) ) p
agreed VBD N
to TO N
physical JJ i
training NN i
using VBG i
bicycle NN i
ergometer NN i
exercise NN i
with IN i
the DT i
intensity NN i
at IN i
blood NN i
lactate NN i
threshold NN i
for IN i
60 CD i
minutes NNS i
three CD i
times NNS i
a DT i
week NN i
for IN i
10 CD i
weeks NNS i
, , N
while IN N
the DT p
other JJ p
group NN p
( ( p
n JJ p
= VBZ p
10 CD p
; : p
4 CD p
men NNS p
and CC p
6 CD p
women NNS p
; : p
51.0 CD p
+/- JJ p
2.9 CD p
years NNS p
of IN p
age NN p
) ) p
did VBD N
no DT i
particular JJ i
physical JJ i
training NN i
and CC N
was VBD N
followed VBN N
once RB N
a DT N
week NN N
as IN N
the DT N
control NN N
. . N

Changes NNS N
in IN N
blood NN o
pressure NN o
, , o
hemodynamics NNS o
, , o
and CC o
humoral JJ o
factors NNS o
of IN N
the DT N
exercised VBN N
group NN N
were VBD N
compared VBN N
with IN N
values NNS N
in IN N
the DT N
controls NNS N
. . N

The DT N
following JJ N
significant JJ N
changes NNS N
were VBD N
found VBN N
only RB N
in IN N
the DT N
exercised JJ N
group NN N
. . N

Blood NNP o
pressure NN o
was VBD N
significantly RB N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
reduced VBN N
. . N

Whole JJ o
blood NN o
and CC o
plasma NN o
volume NN o
indices NNS o
were VBD N
significantly RB N
reduced VBN N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
, , N
p NN N
less JJR N
than IN N
0.01 CD N
, , N
respectively RB N
) ) N
. . N

The DT N
change NN N
in IN N
ratio NN o
of IN o
serum NN o
sodium NN o
to TO o
potassium VB o
positively RB N
correlated VBN N
with IN N
the DT N
change NN N
in IN N
systolic JJ o
blood NN o
pressure NN o
( ( N
r JJ N
= NN N
0.76 CD N
, , N
p NN N
less JJR N
than IN N
0.02 CD N
) ) N
. . N

Plasma NNP o
norepinephrine JJ o
concentrations NNS o
both DT N
at IN N
rest NN N
and CC N
at IN N
the DT N
workload NN N
of IN N
blood NN N
lactate NN N
threshold NN N
during IN N
graded JJ N
exercise NN N
tests NNS N
were VBD N
significantly RB N
reduced VBN N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
, , N
p NN N
less JJR N
than IN N
0.02 CD N
respectively RB N
) ) N
after IN N
10 CD N
weeks NNS N
of IN N
exercise NN i
training NN i
. . i

The DT N
change NN N
in IN N
the DT N
resting VBG o
level NN o
of IN o
plasma JJ o
norepinephrine NN o
positively RB N
correlated VBN N
with IN N
that DT N
in IN N
the DT N
mean JJ o
blood NN o
pressure NN o
. . o

No DT N
such JJ N
changes NNS N
were VBD N
observed VBN N
in IN N
the DT N
control NN N
group NN N
. . N

In IN N
both DT N
groups NNS N
, , N
body NN N
weight NN N
and CC N
urinary JJ N
sodium NN N
excretion NN N
showed VBD N
no DT N
statistically RB N
significant JJ N
changes NNS N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -7003882- O O

[ JJ i
Median NNP i
and CC i
mediolateral JJ i
episiotomy NN i
] NN i
. . p

-DOCSTART- -16603337- O O

The DT N
effect NN N
of IN N
a DT N
parent-implemented JJ i
imitation NN i
intervention NN i
on IN N
spontaneous JJ o
imitation NN o
skills NNS o
in IN N
young JJ p
children NNS p
with IN p
autism NN p
. . p

Children NNP p
with IN p
autism NN p
exhibit NN N
significant JJ N
deficits NNS N
in IN N
their PRP$ N
ability NN N
to TO N
spontaneously RB o
imitate VB o
the DT N
play NN o
actions NNS o
and CC o
descriptive JJ o
gestures NNS o
of IN N
others NNS N
. . N

Reciprocal JJ i
imitation NN i
training NN i
( ( i
RIT NNP i
) ) i
is VBZ i
a DT i
naturalistic JJ i
imitation NN i
intervention NN i
designed VBN N
to TO N
teach VB N
spontaneous JJ o
imitation NN o
skills NNS o
during IN N
play NN N
. . N

This DT N
study NN N
assessed VBD N
the DT N
effectiveness NN o
of IN N
parent-implemented JJ N
RIT NNP i
using VBG N
a DT N
multiple-baseline JJ N
design NN N
across IN N
three CD p
young JJ p
children NNS p
with IN p
autism NN p
and CC p
their PRP$ p
mothers NNS p
. . p

After IN N
an DT N
initial JJ N
baseline NN N
, , N
mothers NNS N
were VBD N
taught VBN N
to TO N
implement VB N
RIT NNP i
techniques NNS N
with IN N
their PRP$ N
child NN N
twice RB N
a DT N
week NN N
for IN N
10 CD N
weeks NNS N
in IN N
a DT N
clinic JJ N
setting NN N
. . N

Two CD N
mothers NNS N
were VBD N
taught VBN N
to TO N
use VB N
RIT NNP i
to TO N
teach VB N
object JJ N
imitation NN N
. . N

The DT N
third JJ N
mother NN N
was VBD N
taught VBN N
to TO N
use VB N
RIT NNP i
to TO N
target VB N
both DT N
object JJ N
and CC N
gesture JJ N
imitation NN N
in IN N
a DT N
multiple-baseline JJ N
design NN N
across IN N
behaviors NNS N
. . N

Generalization NNP N
was VBD N
assessed VBN N
in IN N
the DT N
families NNS N
' POS N
homes NNS N
at IN N
the DT N
end NN N
of IN N
treatment NN N
and CC N
a DT N
1-month JJ N
follow-up NN N
. . N

Parents NNS N
learned VBD o
to TO N
use VB N
the DT N
intervention NN N
strategies NNS N
and CC N
their PRP$ N
children NNS N
exhibited VBN N
increases NNS N
in IN N
spontaneous JJ o
imitation NN o
. . o

These DT N
findings NNS N
replicate VBP N
the DT N
results NNS N
from IN N
previous JJ N
studies NNS N
, , N
indicating VBG N
that IN N
RIT NNP N
is VBZ N
effective JJ N
for IN N
teaching VBG N
imitation NN o
skills NNS o
to TO N
young JJ p
children NNS p
with IN p
autism NN p
in IN N
a DT N
naturalistic JJ N
setting NN N
and CC N
extend VB N
the DT N
findings NNS N
to TO N
parents NNS p
. . p

-DOCSTART- -12050494- O O

Clinically RB N
relevant JJ N
improvement NN N
of IN N
recurrence-free JJ o
survival NN o
with IN N
5-aminolevulinic JJ i
acid NN i
induced VBD N
fluorescence NN N
diagnosis NN N
in IN N
patients NNS p
with IN p
superficial JJ p
bladder NN p
tumors NNS p
. . p

PURPOSES NNP N
Fluorescence NNP N
diagnosis NN N
induced VBN N
by IN N
5-aminolevulinic JJ i
acid NN i
enables VBZ N
more RBR N
thorough JJ N
transurethral JJ N
resection NN N
of IN N
superficial JJ p
bladder NN p
carcinoma NNS p
compared VBN N
with IN N
conventional JJ N
white JJ N
light NN N
. . N

We PRP N
performed VBD N
a DT N
prospective JJ N
, , N
single JJ N
institution NN N
, , N
randomized VBN N
trial NN N
to TO N
investigate VB N
whether IN N
the DT N
residual JJ N
tumor NN N
rate NN N
and CC N
long-term JJ N
tumor NN N
recurrence NN N
can MD N
be VB N
decreased VBN N
by IN N
fluorescence NN i
diagnosis NN i
. . i

MATERIALS NNP N
AND NNP N
METHODS NNP N
A NNP p
total NN p
of IN p
301 CD p
patients NNS p
underwent JJ p
transurethral JJ i
resection NN i
of IN p
bladder NN p
tumors NNS p
with IN p
white JJ i
light NN i
or CC i
fluorescence NN i
diagnosis NN i
. . i

Transurethral JJ i
resection NN i
was VBD N
repeated VBN N
5 CD N
to TO N
6 CD N
weeks NNS N
later RB N
to TO N
evaluate VB N
the DT N
residual JJ N
tumor NN N
rate NN N
. . N

To TO N
determine VB N
recurrence-free JJ o
survival JJ o
patient NN N
followup NN N
was VBD N
performed VBN N
every DT N
3 CD N
months NNS N
by IN N
white JJ i
light JJ i
cystoscopy NN i
and CC N
urine JJ i
cytology NN i
. . i

Recurrence-free JJ o
survival NN o
was VBD N
analyzed VBN N
via IN N
Kaplan-Meier NNP N
methods NNS N
and CC N
multivariable JJ N
Cox NNP N
regression NN N
analysis NN N
. . N

RESULTS VB N
A DT p
total NN p
of IN p
191 CD p
patients NNS p
with IN p
superficial JJ p
bladder NN p
carcinoma NN p
were VBD p
available JJ p
for IN N
efficacy NN N
analysis NN N
. . N

The DT N
residual JJ o
tumor NN o
rate NN o
was VBD N
25.2 CD N
% NN N
in IN N
the DT N
white JJ N
light JJ N
arm NN N
versus NN N
4.5 CD N
% NN N
in IN N
the DT N
fluorescence NN N
diagnosis NN N
arm NN N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

Median JJ N
followup NN N
in IN N
the DT N
white JJ N
light JJ N
arm NN N
in IN N
103 CD N
cases NNS N
was VBD N
21.2 CD N
months NNS N
( ( N
range VB N
4 CD N
to TO N
40 CD N
) ) N
compared VBN N
with IN N
20.5 CD N
( ( N
range NN N
3 CD N
to TO N
40 CD N
) ) N
in IN N
the DT N
88 CD N
in IN N
the DT N
fluorescence NN N
diagnosis NN N
arm NN N
. . N

Recurrence-free JJ o
survival NN o
in IN N
the DT N
fluorescence NN N
diagnosis NN N
group NN N
was VBD N
89.6 CD N
% NN N
after IN N
12 CD N
and CC N
24 CD N
months NNS N
compared VBN N
with IN N
73.8 CD N
% NN N
and CC N
65.9 CD N
% NN N
, , N
respectively RB N
, , N
in IN N
the DT N
white JJ N
light NN N
group NN N
( ( N
p JJ N
= NNP N
0.004 CD N
) ) N
. . N

This DT N
superiority NN N
proved VBD N
to TO N
be VB N
independent JJ N
of IN N
risk NN N
group NN N
. . N

The DT N
adjusted JJ o
hazard NN o
ratio NN o
of IN o
fluorescence NN o
diagnosis NN o
versus IN o
white JJ o
light JJ o
transurethral JJ o
resection NN o
was VBD N
0.33 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
0.16 CD N
to TO N
0.67 CD N
) ) N
. . N

CONCLUSIONS NNP N
Fluorescence NNP N
diagnosis NN N
is VBZ N
significantly RB N
superior JJ N
to TO N
conventional JJ N
white JJ N
light JJ N
transurethral JJ N
resection NN N
with IN N
respect NN N
to TO N
the DT N
residual JJ o
tumor NN o
rate NN o
and CC o
recurrence-free JJ o
survival NN o
. . o

The DT N
differences NNS N
in IN N
recurrence-free JJ o
survival NN o
imply NN N
that WDT N
fluorescence NN N
diagnosis NN N
is VBZ N
a DT N
clinically RB N
relevant JJ N
procedure NN N
for IN N
decreasing VBG N
the DT N
number NN o
of IN o
tumor NN o
recurrences NNS o
. . o

-DOCSTART- -22153696- O O

Significant JJ N
differential JJ N
effects NNS N
of IN N
omega-3 JJ i
fatty JJ i
acids NNS i
and CC N
fenofibrate NN i
in IN N
patients NNS p
with IN p
hypertriglyceridemia NN p
. . p

BACKGROUND NNP N
Omega-3 NNP i
fatty JJ i
acids NNS i
and CC N
fenofibrate NN i
are VBP N
both DT N
used VBN N
to TO N
treat VB N
patients NNS p
with IN p
hypertriglyceridemia NN o
. . o

However RB N
, , N
a DT N
head-to-head JJ N
comparison NN N
of IN N
the DT N
lipoprotein NN N
and CC N
metabolic JJ N
effects NNS N
of IN N
these DT N
two CD N
medicines NNS N
has VBZ N
not RB N
been VBN N
published VBN N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
randomized JJ N
, , N
single-blind JJ N
, , N
placebo-controlled JJ N
, , N
parallel JJ N
study NN N
. . N

Age NNP N
, , N
sex NN N
, , N
and CC N
body NN N
mass NN N
index NN N
were VBD N
matched VBN N
among IN N
groups NNS N
. . N

All DT N
patients NNS N
were VBD N
recommended VBN N
to TO N
maintain VB N
a DT N
low JJ N
fat NN N
diet NN N
. . N

Fifty JJ p
patients NNS p
in IN p
each DT p
group NN p
were VBD N
given VBN N
placebo NNS i
, , i
omega-3 JJ i
fatty JJ i
acids NNS i
2 CD i
g NN i
( ( N
most RBS N
commonly RB N
used JJ N
dosage NN N
in IN N
Korean JJ N
patients NNS N
) ) N
, , N
or CC N
fenofibrate VB i
160 CD i
mg NN i
, , N
respectively RB N
daily JJ N
for IN N
2 CD N
months NNS N
. . N

RESULTS NNP N
Omega-3 JJ i
fatty JJ i
acids NNS i
therapy NN i
decreased VBN N
triglycerides NNS o
by IN N
21 CD N
% NN N
and CC N
triglycerides/HDL NN o
cholesterol NN o
and CC N
improved VBN N
flow-mediated JJ o
dilation NN o
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
however RB N
, , N
did VBD N
not RB N
significantly RB N
change VBP N
insulin NN o
, , o
plasma VBP o
adiponectin NN o
levels NNS o
, , o
and CC o
insulin NN o
sensitivity NN o
( ( N
determined VBN N
by IN N
QUICKI NNP N
) ) N
relative VBP N
to TO N
baseline VB N
measurements NNS N
. . N

Fenofibrate NNP i
therapy NN i
decreased VBD N
total JJ o
cholesterol NN o
, , o
triglycerides NNS o
by IN N
29 CD N
% NN N
, , N
and CC N
triglycerides/HDL-cholesterol NN o
( ( N
all DT N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
improved VBN o
flow-mediated JJ o
dilation NN o
when WRB N
compared VBN N
with IN N
baseline NN N
. . N

When WRB N
compared VBN N
with IN N
placebo NN i
and CC i
omega-3 JJ i
fatty JJ i
acids NNS i
, , i
fenofibrate JJ i
therapy NN i
decreased VBD N
non-HDL JJ o
cholesterol NN o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
triglycerides/HDL $ o
cholesterol NN o
( ( N
P=0.016 NNP N
) ) N
while IN N
increasing VBG N
HDL NNP o
cholesterol NN o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
apolipoprotein JJ o
AI NNP o
( ( N
P=0.001 NNP N
) ) N
. . N

Of IN N
note NN N
, , N
when WRB N
compared VBN N
with IN N
omega-3 JJ N
fatty JJ N
acids NNS N
, , N
fenofibrate JJ N
therapy NN N
decreased VBD N
fasting JJ o
insulin NN o
( ( N
P=0.023 NNP N
) ) N
and CC N
increased VBD N
plasma NN o
adiponectin NN o
( ( N
P=0.002 NNP N
) ) N
and CC N
insulin JJ o
sensitivity NN o
( ( N
P=0.015 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Omega-3 NNP N
fatty JJ N
acids NNS N
and CC N
fenofibrate JJ N
therapy NN N
promoted VBD N
similar JJ N
changes NNS N
in IN N
triglycerides NNS o
and CC o
endothelium-dependent JJ o
dilation NN o
. . o

However RB N
, , N
fenofibrate JJ N
therapy NN N
had VBD N
substantially RB N
better JJR N
effects NNS N
on IN N
lipoprotein NN o
and CC o
metabolic JJ o
profiles NNS o
in IN N
patients NNS p
with IN p
hypertriglyceridemia NN p
. . p

-DOCSTART- -3300436- O O

Outpatient NNP p
management NN p
of IN p
asthma NN p
with IN N
regular JJ N
nebulized JJ N
beta NN N
agonists NNS N
: : N
comparison NN N
of IN N
bitolterol NN i
mesylate NN i
and CC i
isoproterenol NN i
. . i

Nebulized VBN i
bitolterol NN i
solution NN i
and CC i
isoproterenol JJ i
solution NN i
were VBD N
compared VBN N
when WRB N
used VBN N
on IN N
a DT N
regular JJ N
basis NN N
, , N
2.5 CD N
mg NN N
three CD N
times NNS N
a DT N
day NN N
for IN N
1 CD N
month NN N
by IN N
patients NNS p
with IN p
chronic JJ p
asthma NN p
. . p

In IN N
this DT N
multicenter NN N
, , N
double-blind JJ N
trial NN N
; : N
130 CD p
nonsteroid-dependent JJ p
patients NNS p
were VBD p
randomized VBN p
to TO N
receive VB N
one CD N
of IN N
the DT N
two CD N
treatments NNS N
concomitantly RB N
with IN N
their PRP$ N
regular JJ N
asthma NN N
medications NNS N
. . N

On IN N
study NN N
days NNS N
, , N
at IN N
the DT N
beginning NN N
of IN N
the DT N
study NN N
and CC N
after IN N
2 CD N
and CC N
4 CD N
weeks NNS N
, , N
treatments NNS N
were VBD N
given VBN N
in IN N
the DT N
office NN N
or CC N
laboratory NN N
and CC N
patients NNS N
were VBD N
monitored VBN N
with IN N
pulmonary JJ o
function NN o
tests NNS o
for IN N
eight CD N
hours NNS N
. . N

Both DT N
medications NNS N
induced VBD N
rapid JJ o
bronchodilation NN o
that WDT N
had VBD N
a DT N
longer RBR N
duration NN o
after IN N
bitolterol NN N
. . N

The DT N
incidence NN o
of IN o
tremor NN o
was VBD N
similar JJ N
with IN N
the DT N
two CD N
medications NNS N
. . N

Tachycardia NNP o
and CC o
palpitations NNS o
were VBD N
more RBR N
frequent JJ N
following VBG N
isoproterenol NN N
. . N

Bitolterol NNP i
has VBZ N
a DT N
much RB N
longer JJR N
duration NN o
of IN o
action NN o
and CC N
should MD N
be VB N
considered VBN N
as IN N
a DT N
suitable JJ N
bronchodilator NN N
for IN N
regular JJ N
nebulizer JJ N
treatment NN N
of IN N
chronic JJ p
asthma NN p
. . p

-DOCSTART- -24634631- O O

Postoperative JJ N
sleep NN p
disturbances NNS p
after IN N
zolpidem NN i
treatment NN N
in IN N
fast-track JJ N
hip NN N
and CC N
knee VB N
replacement NN N
. . N

STUDY NNP N
OBJECTIVES NNP N
Previous NNP N
studies NNS N
have VBP N
demonstrated VBN N
pronounced JJ N
reduction NN o
of IN o
REM NNP o
sleep NN o
on IN N
the DT N
first JJ N
nights NNS N
following VBG N
major JJ N
surgery NN N
which WDT N
may MD N
influence VB N
pain NN o
, , o
analgesic JJ o
use NN o
, , N
and CC N
recovery NN o
. . o

This DT N
placebo-controlled JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
study NN N
set VBN N
out RP N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
zolpidem NN i
on IN N
sleep JJ N
architecture NN N
in IN N
an DT N
elderly JJ p
population NN p
undergoing VBG p
fast-track JJ p
total JJ p
hip NN p
and CC p
knee NN p
arthroplasty NN p
( ( p
THA/TKA NNP p
) ) p
with IN p
length NN p
of IN p
stay NN p
< IN p
3 CD p
days NNS p
. . p

METHODS NNP N
Twenty NNP p
patients NNS p
( ( p
? . p
60 CD p
years NNS p
) ) p
undergoing VBG p
THA NNP p
or CC p
TKA NNP p
in IN p
a DT p
standardized JJ p
setup NN p
with IN p
spinal JJ p
anesthesia NN p
and CC p
multimodal JJ p
opioid-sparing JJ p
postoperative JJ p
analgesia NN p
were VBD p
included VBN o
. . o

Polysomnography NNP o
measures NNS o
were VBD o
performed VBN N
for IN N
2 CD N
nights NNS N
, , N
1 CD N
night NN N
at IN N
home NN N
prior RB N
to TO N
surgery NN N
and CC N
on IN N
the DT N
first JJ N
night NN N
after IN N
surgery NN N
, , N
when WRB N
the DT N
patient NN N
received VBD i
placebo NN i
or CC i
zolpidem NN i
10 CD i
mg. NN o
Analgesic NNP o
use NN o
, , o
pain NN o
levels NNS o
, , o
and CC o
subjective JJ o
measures NNS o
of IN o
fatigue NN o
and CC o
sleep JJ o
quality NN o
were VBD o
recorded VBN N
. . N

Analysis NN N
of IN N
sleep JJ N
data NN N
was VBD N
performed VBN N
according VBG N
to TO N
the DT o
American JJ o
Academy NNP o
of IN o
Sleep NNP o
Medicine NNP o
manual JJ o
. . o

RESULTS NNP N
Objective JJ N
sleep JJ N
data NNS N
did VBD N
not RB N
show VB N
a DT N
significant JJ N
difference NN N
between IN N
groups NNS N
in IN N
any DT N
of IN N
the DT N
sleep JJ N
stages NNS N
. . N

However RB o
, , o
subjective JJ o
data NNS o
on IN o
sleep JJ o
quality NN o
and CC o
fatigue NN o
showed VBD o
significantly RB N
less JJR o
fatigue NN o
and CC o
better JJR o
sleep NN o
quality NN o
in IN o
the DT i
zolpidem NN i
group NN i
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
, , N
and CC N
reduced VBD N
objectively RB o
recorded JJ o
number NN o
of IN o
arousals NNS o
( ( o
p JJ N
= NNP N
0.004 CD o
) ) o
. . o

Levels NNP o
of IN o
pain NN o
and CC o
opioid NN o
use NN o
were VBD o
similar JJ N
in IN N
the DT N
2 CD N
groups NNS N
. . N

CONCLUSIONS NNP N
Our PRP$ N
objective JJ N
data NNS N
did VBD N
not RB N
support VB N
the DT N
primary JJ N
hypothesis NN N
that WDT N
one CD N
night NN N
's POS N
treatment NN N
with IN i
zolpidem NN i
would MD i
significantly RB N
improve VB N
sleep JJ N
architecture NN N
following VBG N
major JJ N
surgery NN N
, , N
although IN N
there EX N
was VBD N
improved JJ o
feeling NN o
of IN o
sleep JJ o
quality NN o
and CC o
fatigue NN o
associated VBN o
with IN N
fewer JJR N
postoperative JJ N
arousals NNS N
. . N

CITATION NNP N
Krenk NNP N
L NNP N
; : N
Jennum NNP N
P NNP N
; : N
Kehlet NNP N
H. NNP N
Postoperative NNP N
sleep NN N
disturbances NNS N
after IN N
zolpidem NN N
treatment NN N
in IN N
fast-track JJ N
hip NN N
and CC N
knee VB N
replacement NN N
. . N

-DOCSTART- -26135372- O O

Effects NNS o
of IN N
Combined NNP i
Resistive NNP i
Underwater NNP i
Exercises NNP i
and CC i
Interferential NNP i
Current NNP i
Therapy NNP i
in IN N
Patients NNP p
with IN p
Juvenile NNP p
Idiopathic NNP p
Arthritis NNP p
: : p
A DT p
Randomized NNP p
Controlled NNP p
Trial NNP p
. . p

OBJECTIVE CC N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
verify VB N
the DT N
effects NNS o
of IN N
combined JJ i
resistive JJ i
underwater NN i
exercises NNS i
and CC i
interferential JJ i
current JJ i
on IN N
the DT N
peak JJ N
torque NN N
of IN N
the DT N
quadriceps NNS N
and CC N
hamstrings NNS N
and CC N
pain NN N
levels NNS N
in IN N
patients NNS p
with IN p
juvenile JJ p
idiopathic JJ p
arthritis NN p
. . p

DESIGN NNP N
This DT N
is VBZ N
a DT N
randomized JJ N
controlled VBN N
study NN N
; : N
30 CD p
children NNS p
with IN p
polyarticular JJ p
juvenile NN p
idiopathic JJ p
arthritis NN p
were VBD N
randomly RB N
distributed VBN N
into IN N
two CD N
groups NNS N
: : N
the DT N
control NN N
group NN N
( ( N
n JJ N
= NNP N
15 CD N
) ) N
received VBD N
the DT N
traditional JJ i
physical JJ i
therapy NN i
program NN i
and CC N
the DT N
study NN N
group NN N
( ( N
n JJ N
= NNP N
15 CD N
) ) N
received VBD N
resistive JJ i
underwater NN i
exercises NNS i
and CC i
interferential JJ i
current JJ i
therapy NN i
. . i

Peak NNP o
torque NN o
of IN o
the DT o
quadriceps NNS o
and CC o
hamstrings NNS o
and CC o
pain NN o
levels NNS o
were VBD N
evaluated VBN N
before IN N
treatment NN N
, , N
1 CD N
mo NN N
later RB N
, , N
and CC N
after IN N
3 CD N
mos NNS N
using VBG N
the DT N
HUMAC NNP N
NORM NNP N
, , N
CSMI NNP N
Testing NNP N
and CC N
Rehabilitation NNP N
Isokinetic NNP N
System NNP N
and CC N
visual JJ N
analog NN N
scale NN N
, , N
respectively RB N
. . N

RESULTS NNP N
In IN N
the DT N
control NN N
group NN N
, , N
all DT N
measures NNS o
showed VBD N
significant JJ N
differences NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
after IN N
1 CD N
mo NN N
except IN N
peak JJ o
torque NN o
of IN o
left JJ o
quadriceps NNS o
and CC o
pain NN o
levels NNS o
, , N
and CC N
significant JJ N
differences NNS N
were VBD N
found VBN N
after IN N
3 CD N
mos NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
in IN N
all DT N
. . N

In IN N
the DT N
study NN N
group NN N
, , N
all DT N
measures NNS N
showed VBD N
significant JJ N
differences NNS N
after IN N
1 CD N
and CC N
3 CD N
mos NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
there EX N
were VBD N
significant JJ N
differences NNS N
between IN N
groups NNS N
after IN N
1 CD N
and CC N
3 CD N
mos NNS N
in IN N
favor NN N
of IN N
the DT N
study NN N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION VB N
The DT i
combination NN i
of IN i
resistive JJ i
underwater NN i
exercises NNS i
and CC i
interferential JJ i
current JJ i
therapy NN i
is VBZ N
a DT N
potentially RB N
valuable JJ N
treatment NN N
for IN N
patients NNS p
with IN p
juvenile JJ p
idiopathic JJ p
arthritis NN p
. . p

-DOCSTART- -26606872- O O

Effectiveness NN N
of IN N
Neuromuscular NNP i
Electrical NNP i
Stimulation NNP i
on IN N
Patients NNS p
With IN p
Dysphagia NNP p
With IN p
Medullary NNP p
Infarction NNP p
. . p

OBJECTIVE NNP N
To TO N
evaluate VB N
and CC N
compare VB N
the DT N
effects NNS N
of IN N
neuromuscular JJ i
electrical JJ i
stimulation NN i
( ( i
NMES NNP i
) ) i
acting VBG N
on IN N
the DT N
sensory JJ N
input NN N
or CC N
motor NN N
muscle NN N
in IN N
treating VBG N
patients NNS p
with IN p
dysphagia NN p
with IN p
medullary JJ p
infarction NN p
. . p

DESIGN NNP N
Prospective NNP N
randomized VBD N
controlled VBN N
study NN N
. . N

SETTING NNP N
Department NNP N
of IN N
physical JJ N
medicine NN N
and CC N
rehabilitation NN N
. . N

PARTICIPANTS CC N
Patients NNPS p
with IN p
dysphagia NN p
with IN p
medullary JJ p
infarction NN p
( ( p
N=82 NNP p
) ) p
. . p

INTERVENTIONS JJ N
Participants NNS N
were VBD N
randomized VBN N
over IN N
3 CD N
intervention NN N
groups NNS N
: : N
traditional JJ i
swallowing NN i
therapy NN i
, , i
sensory JJ i
approach NN i
combined VBN i
with IN i
traditional JJ i
swallowing VBG i
therapy NN i
, , i
and CC i
motor NN i
approach NN i
combined VBN i
with IN i
traditional JJ i
swallowing VBG i
therapy NN i
. . i

Electrical JJ N
stimulation NN N
sessions NNS N
were VBD N
for IN N
20 CD N
minutes NNS N
, , N
twice RB N
a DT N
day NN N
, , N
for IN N
5d/wk CD N
, , N
over IN N
a DT N
4-week JJ N
period NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Swallowing NNP o
function NN o
was VBD N
evaluated VBN N
by IN N
the DT N
water NN o
swallow JJ o
test NN o
and CC o
Standardized NNP o
Swallowing NNP o
Assessment NNP o
, , o
oral JJ o
intake NN o
was VBD N
evaluated VBN N
by IN N
the DT N
Functional NNP o
Oral NNP o
Intake NNP o
Scale NNP o
, , o
quality NN o
of IN o
life NN o
was VBD N
evaluated VBN N
by IN N
the DT N
Swallowing-Related JJ o
Quality NN o
of IN o
Life NNP o
( ( o
SWAL-QOL NNP o
) ) o
Scale NNP o
, , N
and CC N
cognition NN N
was VBD N
evaluated VBN N
by IN N
the DT N
Mini-Mental JJ o
State NNP o
Examination NNP o
( ( o
MMSE NNP o
) ) o
. . o

RESULTS CC N
There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
groups NNS N
in IN N
age NN N
, , N
sex NN N
, , N
duration NN N
, , N
MMSE NNP o
score NN o
, , o
or CC o
severity NN o
of IN o
the DT o
swallowing VBG o
disorder NN o
( ( N
P NNP N
> NNP N
.05 NNP N
) ) N
. . N

All DT N
groups NNS N
showed VBD N
improved JJ N
swallowing NN o
function NN o
( ( N
P?.01 NNP N
) ) N
; : N
the DT N
sensory JJ N
approach NN N
combined VBN N
with IN N
traditional JJ N
swallowing VBG N
therapy NN N
group NN N
showed VBD N
significantly RB N
greater JJR N
improvement NN N
than IN N
the DT N
other JJ N
2 CD N
groups NNS N
, , N
and CC N
the DT N
motor NN N
approach NN N
combined VBN N
with IN N
traditional JJ N
swallowing VBG N
therapy NN N
group NN N
showed VBD N
greater JJR N
improvement NN N
than IN N
the DT N
traditional JJ N
swallowing NN N
therapy NN N
group NN N
( ( N
P NNP N
< NNP o
.05 NNP o
) ) o
. . o

SWAL-QOL JJ o
Scale JJ o
scores NNS o
increased VBD o
more RBR N
significantly RB N
in IN N
the DT i
sensory JJ i
approach NN i
combined VBN i
with IN i
traditional JJ i
swallowing VBG i
therapy NN i
and CC i
motor NN i
approach NN i
combined VBN i
with IN i
traditional JJ i
swallowing VBG i
therapy NN i
groups NNS i
than IN i
in IN i
the DT i
traditional JJ i
swallowing NN i
therapy NN i
group NN i
, , i
and CC i
the DT i
sensory JJ i
approach NN i
combined VBN i
with IN i
traditional JJ i
swallowing VBG i
therapy NN i
and CC i
motor NN i
approach NN i
combined VBN i
with IN i
traditional JJ i
swallowing VBG i
therapy NN i
groups NNS i
showed VBD N
statistically RB N
significant JJ N
differences NNS N
( ( N
P=.04 NNP N
) ) N
. . N

CONCLUSIONS NNP o
NMES NNP o
that WDT o
targets VBZ N
either CC N
sensory JJ N
input NN N
or CC N
motor NN N
muscle NN N
coupled VBN N
with IN i
traditional JJ i
therapy NN i
is VBZ i
conducive JJ N
to TO N
recovery NN N
from IN N
dysphagia NN N
and CC N
improves VBZ N
quality NN N
of IN N
life NN N
for IN p
patients NNS p
with IN p
dysphagia NN p
with IN p
medullary JJ p
infarction NN p
. . p

A DT N
sensory JJ i
approach NN i
appears VBZ i
to TO N
be VB N
better JJR N
than IN N
a DT N
motor NN N
approach NN N
. . N

-DOCSTART- -15673999- O O

Pilot NNP N
study NN N
of IN N
a DT N
moderate JJ i
dose JJ i
multivitamin/mineral JJ i
supplement NN i
for IN N
children NNS p
with IN p
autistic JJ p
spectrum NN p
disorder NN p
. . p

OBJECTIVE NNP N
Determine NNP N
the DT N
effect NN N
of IN N
a DT N
moderate JJ N
dose JJ N
multivitamin/mineral JJ i
supplement NN i
on IN N
children NNS p
with IN p
autistic JJ p
spectrum NN p
disorder NN p
. . p

DESIGN NNP N
Randomized NNP N
, , N
double-blind NN N
, , N
placebo-controlled JJ i
3-month JJ N
study NN N
. . N

SUBJECTS NNP N
Twenty NNP p
( ( p
20 CD p
) ) p
children NNS p
with IN p
autistic JJ p
spectrum NN p
disorder NN p
, , p
ages VBZ p
3-8 CD p
years NNS p
. . p

RESULTS VB N
A DT N
Global JJ N
Impressions NNP N
parental NN N
questionnaire NN N
found VBD N
that IN N
the DT N
supplement NN N
group NN N
reported VBD N
statistically RB o
significant JJ o
improvements NNS o
in IN N
sleep NN o
and CC o
gastrointestinal JJ o
problems NNS o
compared VBN N
to TO N
the DT N
placebo NN i
group NN N
. . N

An DT N
evaluation NN N
of IN N
vitamin NN o
B NNP o
( ( o
6 CD o
) ) o
levels NNS o
prior RB N
to TO N
the DT N
study NN N
found VBD N
that IN N
the DT N
autistic JJ p
children NNS p
had VBD N
substantially RB o
elevated VBN o
levels NNS o
of IN o
B6 NNP o
compared VBN N
to TO N
a DT N
control NN N
group NN N
of IN N
typical JJ N
children NNS N
( ( N
75 CD N
% NN N
higher JJR N
, , N
p JJ N
< NNP N
0.0000001 CD N
) ) N
. . N

Vitamin NNP o
C NNP o
levels NNS o
were VBD N
measured VBN N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
, , N
and CC N
the DT N
placebo NN N
group NN N
had VBD N
levels NNS N
that WDT N
were VBD N
significantly RB o
below JJ o
average NN o
for IN N
typical JJ N
children NNS N
, , N
whereas IN N
the DT N
supplement NN N
group NN N
had VBD N
near-average JJ N
levels NNS N
. . N

DISCUSSION VB N
The DT N
finding NN N
of IN N
high JJ o
vitamin NN o
B NNP o
( ( o
6 CD o
) ) o
levels NNS o
is VBZ N
consistent JJ N
with IN N
recent JJ N
reports NNS N
of IN N
low JJ N
levels NNS o
of IN o
pyridoxal-5-phosphate NN o
and CC N
low JJ N
activity NN o
of IN o
pyridoxal NN o
kinase NN o
( ( N
i.e. FW N
, , N
pyridoxal NN N
is VBZ N
only RB N
poorly RB N
converted VBN N
to TO N
pyridoxal-5-phosphate NN N
, , N
the DT N
enzymatically RB N
active JJ N
form NN N
) ) N
. . N

This DT N
may MD N
explain VB N
the DT N
functional JJ N
need NN N
for IN N
high-dose JJ N
vitamin NN i
B NNP i
( ( i
6 CD i
) ) i
supplementation NN i
in IN N
many JJ N
children NNS N
and CC N
adults NNS N
with IN N
autism NN N
. . N

-DOCSTART- -24727325- O O

Association NNP N
study NN N
of IN N
the DT N
let-7 JJ N
miRNA-complementary JJ N
site NN N
variant NN N
in IN N
the DT N
3 CD N
' POS N
untranslated JJ N
region NN N
of IN N
the DT N
KRAS NNP N
gene NN N
in IN N
stage NN p
III NNP p
colon NN p
cancer NN p
( ( p
NCCTG NNP p
N0147 NNP p
Clinical NNP p
Trial NNP p
) ) p
. . p

PURPOSE VB N
A DT N
let-7 JJ N
microRNA-complementary JJ N
site NN N
( ( N
LCS6 NNP N
) ) N
polymorphism NN N
in IN N
the DT N
3 CD N
' POS N
untranslated JJ N
region NN N
of IN N
the DT N
KRAS NNP N
gene NN N
has VBZ N
been VBN N
shown VBN N
to TO N
disrupt VB N
let-7 JJ N
binding NN N
and CC N
upregulate JJ N
KRAS NNP N
expression NN N
. . N

We PRP N
evaluated VBD N
the DT N
LCS6 NNP o
genotype NN o
and CC o
its PRP$ o
association NN o
with IN o
KRAS NNP o
mutation NN o
status NN o
, , o
clinicopathologic NN o
features NNS o
, , o
and CC o
disease-free JJ o
survival NN o
( ( o
DFS NNP o
) ) o
in IN N
patients NNS p
with IN p
stage NN p
III NNP p
colon NN p
cancer NN p
who WP p
enrolled VBD p
in IN p
a DT p
phase NN p
III NNP p
clinical JJ p
trial NN p
( ( p
NCCTG NNP p
N0147 NNP p
) ) p
. . p

EXPERIMENTAL NNP N
DESIGN NNP N
The DT N
LCS6 NNP N
genotype NN N
was VBD N
assayed VBN N
by IN N
real-time JJ i
PCR NNP i
in IN i
DNA NNP i
extracted VBD i
from IN i
whole JJ i
blood NN i
( ( i
n JJ i
= NNP i
2,834 CD i
) ) i
and CC i
compared VBN i
with IN i
paired JJ i
tumor NN i
tissue NN i
( ( N
n JJ N
= NNP N
977 CD N
) ) N
. . N

? . N
( ( N
2 CD N
) ) N
and CC N
two-sample JJ N
t NN N
tests NNS N
were VBD N
used VBN N
to TO N
compare VB N
baseline JJ N
factors NNS N
and CC o
KRAS NNP o
mutation NN o
status NN N
between IN p
patients NNS p
defined VBN p
by IN p
LCS6 NNP p
variant NN p
status NN p
. . p

Log-rank JJ N
tests NNS N
and CC N
multivariate VB N
Cox NNP N
models NNS N
assessed VBD N
associations NNS N
between IN N
LCS6 NNP N
status NN N
and CC N
DFS NNP N
, , N
respectively RB N
. . N

RESULTS NNP N
We PRP N
identified VBD N
432 CD N
( ( N
15.2 CD o
% NN o
) ) o
blood NN o
samples NNS o
and CC N
143 CD N
( ( N
14.6 CD o
% NN o
) ) o
tumor NN o
samples NNS o
heterozygous JJ o
or CC o
homozygous JJ o
for IN o
the DT o
LCS6 NNP o
G-allele NNP o
, , o
and CC N
2,402 CD N
of IN N
2,834 CD N
( ( N
84.8 CD N
% NN N
) ) N
blood NN N
samples NNS N
and CC N
834 CD N
of IN N
977 CD N
( ( N
85.4 CD o
% NN o
) ) o
tumor NN o
samples NNS o
homozygous JJ o
for IN o
the DT o
LCS6 NNP o
T-allele NNP o
. . o

Genotype NNP o
results NNS o
were VBD N
highly RB N
concordant JJ N
( ( N
99.8 CD N
% NN N
) ) N
in IN N
cases NNS N
with IN N
paired JJ N
blood NN N
and CC N
tumor NN N
tissue NN N
( ( N
n JJ N
= NNP N
977 CD N
) ) N
. . N

G-allele JJ o
carriers NNS o
were VBD N
significantly RB N
more RBR N
frequent JJ N
in IN p
Caucasians NNPS p
versus IN p
other JJ p
races NNS p
( ( N
? . N
( ( N
2 CD N
) ) N
test NN N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

The DT o
LCS6 NNP o
genotype NN o
was VBD o
not RB N
associated VBN N
with IN o
KRAS NNP o
mutation NN o
status NN o
, , o
clinicopathologic NN o
features NNS o
( ( o
all DT N
P NNP N
> NNP N
0.2 CD N
) ) N
, , N
or CC N
DFS NNP o
( ( o
log-rank JJ N
P NNP N
= NNP N
0.49 CD N
; : N
HR NNP N
, , N
0.929 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.76-1.14 NN N
) ) N
, , N
even RB N
after IN N
combining VBG N
LCS6 NNP N
genotype NN N
with IN o
KRAS NNP o
mutation NN o
status NN o
. . o

CONCLUSIONS NNP N
In IN N
the DT N
largest JJS N
association NN N
study NN N
investigating VBG N
the DT N
LCS6 NNP N
polymorphism NN N
in IN N
colon NN N
cancers NNS N
, , N
the DT N
germline NN N
LCS6 NNP N
genotype NN N
was VBD N
not RB N
associated VBN N
with IN N
KRAS NNP N
mutation NN N
status NN N
or CC N
with IN N
clinical JJ N
outcome NN N
in IN N
patients NNS p
with IN p
stage NN p
III NNP p
tumors NNS p
. . p

-DOCSTART- -21531178- O O

Theory-driven JJ i
intervention NN i
improves VBZ N
calcium JJ o
intake NN o
, , o
osteoporosis NN o
knowledge NN o
, , o
and CC o
self-efficacy NN o
in IN N
community-dwelling JJ p
older JJR p
Black NNP p
adults NNS p
. . p

OBJECTIVE NNP N
To TO N
assess VB N
the DT N
effectiveness NN o
of IN N
an DT N
osteoporosis JJ i
education NN i
program NN i
to TO N
improve VB N
calcium NN o
intake NN o
, , o
knowledge NN o
, , o
and CC o
self-efficacy NN o
in IN N
community-dwelling JJ p
older JJR p
Black NNP p
adults NNS p
. . p

DESIGN NNP N
Randomized NNP N
repeated VBD N
measures NNS N
experimental JJ N
design NN N
. . N

SETTING NN N
Churches NNP p
and CC p
community-based JJ p
organizations NNS p
. . p

PARTICIPANTS NNP N
Men NNP p
and CC p
women NNS p
( ( p
n JJ p
= NNP p
110 CD p
) ) p
50 CD p
years NNS p
old JJ p
and CC p
older JJR p
from IN p
3 CD p
south JJ p
Florida NNP p
counties NNS p
. . p

INTERVENTION NNP N
Participants NNP N
randomly RB N
assigned VBD N
to TO N
either DT N
of IN N
2 CD N
groups NNS N
: : N
Group NNP N
1 CD N
( ( N
experimental JJ N
group NN N
) ) N
or CC N
Group NNP N
2 CD N
( ( i
wait-list JJ i
control NN i
group NN i
) ) i
. . N

Group NNP N
1 CD N
participated VBD N
in IN N
6 CD i
weekly JJ i
education NN i
program NN i
sessions NNS i
immediately RB N
following VBG N
baseline NN i
assessment NN i
, , N
and CC N
Group NNP N
2 CD N
started VBD N
the DT N
program NN N
following VBG N
Group NNP N
1 CD N
's POS N
program NN N
completion NN N
. . N

A DT N
tested JJ N
curriculum NN N
was VBD N
adapted VBN N
to TO N
meet VB N
the DT N
needs NNS N
of IN N
the DT N
target NN N
population NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Dietary NNP o
calcium NN o
intake NN o
, , o
osteoporosis NN o
knowledge NN o
, , o
health NN o
beliefs NNS o
, , o
and CC o
self-efficacy NN o
. . o

ANALYSIS NNP N
Descriptive NNP N
and CC N
summary JJ N
statistics NNS N
, , N
repeated VBD N
measures NNS N
analysis NN N
of IN N
variance NN N
, , N
and CC N
regression NN N
analysis NN N
. . N

RESULTS NNP N
Of IN N
the DT N
total JJ N
participants NNS N
, , N
84.6 CD N
% NN N
completed VBD N
the DT N
study NN N
( ( N
mean JJ N
age NN N
= VBD N
70.2 CD N
years NNS N
) ) N
. . N

Overall UH N
, , N
an DT N
educational JJ i
program NN i
developed VBN N
with IN N
a DT N
theoretical JJ N
background NN N
was VBD N
associated VBN N
with IN N
improvement NN N
in IN N
calcium NN o
intake NN o
, , o
knowledge NN o
, , o
and CC o
self-efficacy NN o
, , N
with IN N
no DT N
effect NN N
on IN N
most JJS N
health NN o
belief NN o
subscales NNS o
. . o

Assigned VBN N
group NN N
was VBD N
the DT N
major JJ N
predictor NN N
of IN N
change NN N
in IN N
calcium NN o
intake NN o
. . o

CONCLUSIONS NNP N
AND NNP N
IMPLICATIONS NNP N
A NNP N
theory-driven JJ N
approach NN N
is VBZ N
valuable JJ N
in IN N
improving VBG N
behavior NN N
to TO N
promote VB N
bone NN N
health NN N
in IN N
this DT N
population NN N
. . N

Health NNP N
professionals NNS N
should MD N
consider VB N
using VBG N
more JJR N
theory-driven JJ N
approaches NNS N
in IN N
intervention NN N
studies NNS N
. . N

-DOCSTART- -3131904- O O

[ JJ N
Supplementary NNP N
treatment NN N
with IN N
Esberitox NNP i
of IN N
female JJ p
patients NNS p
undergoing VBG p
curative JJ i
adjuvant JJ i
irradiation NN i
following VBG p
breast NN p
cancer NN p
] NNP p
. . N

1 CD N
. . N

The DT N
study NN N
was VBD N
supposed VBN N
to TO N
investigate VB N
a DT N
possible JJ N
prevention NN o
or CC o
reduction NN o
of IN o
the DT o
toxicity NN o
of IN N
radiotherapy NN i
by IN N
an DT N
additional JJ N
treatment NN N
with IN N
Esberitox NNP i
. . i

This DT N
question NN N
arose VBD N
when WRB N
performing VBG N
an DT N
investigation NN N
about IN N
the DT N
effect NN N
of IN N
Esberitox NNP i
in IN N
a DT N
combined JJ N
chemo-radiotherapy NN N
. . N

Whereas IN N
the DT N
latter JJ N
induces NNS N
above IN N
all PDT N
a DT N
systemic JJ N
damage NN N
to TO N
the DT N
hemopoietic JJ N
system NN N
, , N
radiotherapy NN N
is VBZ N
a DT N
regional JJ N
noxa NN N
. . N

2 CD N
. . N

The DT N
present JJ N
prospective JJ N
, , N
randomized VBD N
study NN N
was VBD N
conducted VBN N
with IN N
50 CD p
patients NNS p
submitted VBN p
to TO p
curative VB i
adjuvant JJ i
irradiation NN i
following VBG p
surgery NN p
for IN p
mammary JJ p
carcinoma NN p
. . p

The DT N
radiotherapy NN i
was VBD N
performed VBN N
in IN N
the DT N
same JJ N
way NN N
in IN N
all DT N
patients NNS p
with IN p
irradiations NNS p
of IN p
the DT p
thoracic NN p
wall NN p
and CC p
the DT p
regional JJ p
lymph NN p
nodes NNS p
. . p

Two CD N
groups NNS N
were VBD N
built VBN N
by IN N
randomization NN N
. . N

The DT N
study NN N
group NN N
received VBD N
an DT N
additional JJ N
treatment NN N
with IN N
Esberitox NNP i
, , N
the DT N
control NN i
group NN i
did VBD i
not RB i
receive VB i
an DT i
additional JJ i
treatment NN i
. . i

3 CD N
. . N

As IN N
a DT N
result NN N
, , N
no DT N
protective JJ N
influence NN N
of IN N
Esberitox NNP N
could MD N
be VB N
demonstrated VBN N
. . N

The DT N
parameters NNS N
investigated VBN N
were VBD N
the DT N
peripheral JJ o
blood NN o
count NN o
( ( o
leucocytes NNS o
, , o
granulocytes NNS o
, , o
lymphocytes NNS o
, , o
monocytes NNS o
, , o
thrombocytes NNS o
, , o
hemoglobin NN o
, , o
hematocrit NN o
) ) o
and CC o
the DT o
incidence NN o
of IN o
infections NNS o
. . o

4 CD N
. . N

This DT N
result NN N
diverging VBG N
from IN N
literature NN N
is VBZ N
discussed VBN N
. . N

It PRP N
is VBZ N
probably RB N
affected VBN N
by IN N
volume NN N
and CC N
extension NN N
of IN N
the DT N
injury NN N
induced VBN N
by IN N
a DT N
hematotoxic NN N
noxa NN N
and CC N
furthermore NN N
by IN N
the DT N
ability NN N
of IN N
regeneration NN N
. . N

If IN N
this DT N
ability NN N
is VBZ N
exhausted VBN N
, , N
the DT N
protective JJ N
effect NN N
of IN N
Esberitox NNP N
can MD N
act VB N
no DT N
longer JJR N
. . N

Therefore VB N
the DT N
essential JJ N
factor NN N
seems VBZ N
to TO N
be VB N
the DT N
duration NN N
of IN N
exposure NN N
to TO N
the DT N
noxa NN N
. . N

Esberitox NNP N
was VBD N
effective JJ N
in IN N
case NN N
of IN N
a DT N
short JJ N
toxicity NN N
, , N
it PRP N
was VBD N
ineffective JJ N
in IN N
case NN N
of IN N
prolonged JJ N
toxicity NN N
, , N
if IN N
the DT N
treatment NN N
continuity NN N
( ( N
noxa JJ N
) ) N
was VBD N
not RB N
broken VBN N
up RP N
by IN N
some DT N
regeneration NN N
intervals NNS N
. . N

The DT N
radiotherapy NN i
studied VBN N
in IN N
this DT N
trial NN N
had VBD N
a DT N
duration NN N
of IN N
50 CD N
days NNS N
, , N
and CC N
its PRP$ N
effect NN N
was VBD N
that IN N
of IN N
a DT N
longterm JJ N
injury NN N
. . N

-DOCSTART- -25776840- O O

Qingre NNP N
quyu NN N
granule NN N
stabilizes VBZ N
plaques NNS N
through IN N
inhibiting VBG N
the DT N
expression NN N
of IN N
tenascin-C NN N
in IN N
patients NNS p
with IN p
severe JJ p
carotid NN p
stenosis NN p
. . p

OBJECTIVE UH N
To TO N
investigate VB N
the DT N
therapeutic JJ o
effects NNS o
of IN N
Qingre NNP i
Quyu NNP i
Granule NNP i
( ( i
QQG NNP i
) ) i
on IN N
the DT N
patients NNS p
with IN p
severe JJ p
carotid NN p
stenosis NN p
, , N
and CC N
to TO N
explore VB N
the DT N
mechanism NN N
of IN N
it PRP N
. . N

METHODS NNP N
Ninety-six JJ p
patients NNS p
with IN p
severe JJ p
carotid NN p
stenosis NN p
were VBD N
enrolled VBN N
in IN N
the DT N
study NN N
and CC N
were VBD N
classified VBN N
into IN N
a DT N
QQG NNP i
group NN N
( ( N
n=48 CC N
) ) N
and CC N
a DT N
control NN i
group NN i
( ( N
n=48 RB N
) ) N
randomly RB N
using VBG N
consecutively RB N
numbered JJ N
envelopes NNS N
. . N

The DT N
patients NNS N
in IN N
the DT N
QQG NNP i
group NN N
were VBD N
given VBN N
QQG NNP i
and CC N
Western NNP i
medicine NN i
, , N
those DT N
in IN N
the DT N
control NN N
group NN N
were VBD N
given VBN N
Western JJ i
medicine NN i
merely RB N
, , N
the DT N
course NN N
of IN N
treatment NN N
was VBD N
16 CD N
weeks NNS N
. . N

All DT N
patients NNS N
went VBD N
through IN N
endarterectomy NN N
after IN N
treatment NN N
. . N

Plaques NNS N
were VBD N
subjected VBN N
to TO N
the DT N
analysis NN N
of IN N
CD3 NNP N
, , N
CD68 NNP N
, , N
soluble JJ N
intercellular JJ N
adhesion NN N
molecule NN N
1 CD N
( ( N
ICAM-1 NNP N
) ) N
, , N
matrix JJ N
metalloprotease-9 NN N
( ( N
MMP-9 NNP N
) ) N
, , N
CD40L NNP N
, , N
tenascin-C NN N
, , N
and CC N
collagen NN N
content NN N
lipid JJ N
content NN N
by IN N
immunohistochemistry NN N
or CC N
polarized VBN N
light JJ N
analysis NN N
. . N

RESULTS VBN N
By IN N
the DT N
end NN N
of IN N
experiment NN N
, , N
the DT N
expressions NNS o
of IN o
CD3 NNP o
, , o
CD68 NNP o
, , o
ICAM-1 NNP o
, , o
MMP9 NNP o
, , o
CD40L NNP o
and CC o
tenascin-C NN o
on IN N
the DT N
plaques NNS N
were VBD N
statistically RB N
significant JJ N
lower JJR N
in IN N
the DT N
QQG NNP N
group NN N
compared VBN N
with IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
lipid JJ o
content NN o
of IN o
the DT o
plaque NN o
was VBD N
also RB N
significantly RB N
lower JJR N
in IN N
the DT N
QQG NNP i
group NN N
compared VBN N
with IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
interstitial JJ N
collagen NN N
in IN N
the DT N
tissue NN N
sections NNS N
of IN N
the DT N
plaques NNS N
was VBD N
also RB N
significantly RB N
higher RBR N
in IN N
the DT N
QQG NNP i
group NN N
in IN N
comparison NN N
with IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSION NNP N
QQG NNP i
could MD N
stabilize VB N
carotid JJ N
artery NN N
plaques NNS N
through IN N
inhibiting VBG N
pro-inflammation NN N
factors NNS N
and CC N
restraining VBG N
the DT N
tenascin-C NN N
and CC N
MMP9 NNP N
pathway NN N
. . N

-DOCSTART- -7649753- O O

Are NNP N
PRO NNP i
discharge NN i
screens NNS i
associated VBN N
with IN N
postdischarge NN N
adverse JJ N
outcomes NNS N
? . N
OBJECTIVE IN N
We PRP N
evaluate VBP N
whether IN N
patient JJ N
outcomes NNS N
may MD N
be VB N
affected VBN N
by IN N
possible JJ N
errors NNS N
in IN N
care NN N
at IN N
discharge NN N
as IN N
assessed VBN N
by IN N
Peer NNP N
Review NNP N
Organizations NNP N
( ( N
PROs NNP N
) ) N
. . N

DATA NNP N
SOURCES/STUDY NNP N
SETTING NNP N
The DT p
three CD p
data NNS p
sources NNS p
for IN p
the DT p
study NN p
were VBD p
( ( p
1 CD p
) ) p
the DT p
generic JJ i
screen NN i
results NNS i
of IN p
a DT p
3 CD p
percent NN p
random JJ p
sample NN p
of IN p
Medicare NNP p
beneficiaries NNS p
age NN p
65 CD p
years NNS p
or CC p
older JJR p
who WP p
were VBD p
admitted VBN p
to TO p
California NNP p
hospitals NNS p
between IN p
1 CD p
July NNP p
1987 CD p
and CC p
30 CD p
June NNP p
1988 CD p
( ( p
n JJ p
= $ p
20,136 CD p
patients NNS p
) ) p
; : p
( ( p
2 CD p
) ) p
the DT p
1987 CD p
and CC p
1988 CD p
California NNP p
Medicare NNP p
Provided VBD p
Analysis NNP i
and CC i
Review NNP i
( ( i
MEDPAR NNP i
) ) i
data NN i
files NNS i
; : i
and CC p
( ( p
3 CD p
) ) p
the DT p
American NNP i
Hospital NNP i
Association NNP i
( ( i
AHA NNP i
) ) i
1988 CD i
Annual NNP i
Survey NNP i
of IN i
Hospitals NNP i
. . i

STUDY NNP N
DESIGN NNP N
Multivariate NNP i
logistic JJ i
regression NN i
analysis NN i
was VBD N
used VBN N
to TO N
evaluate VB N
the DT N
association NN N
between IN N
the DT N
results NNS N
of IN N
generic JJ N
discharge NN N
administered VBN N
by IN N
the DT N
PROs NNP N
and CC N
two CD N
patient JJ N
outcomes NNS N
: : N
mortality NN N
and CC N
readmission NN N
within IN N
30 CD N
days NNS N
. . N

The DT N
analysis NN N
was VBD N
adjusted VBN N
for IN N
other JJ N
patient JJ N
characteristics NNS N
recorded VBN N
on IN N
the DT N
uniform JJ N
discharge NN N
abstract NN N
. . N

PRINCIPAL NNP N
FINDINGS NNP N
Four NNP N
discharge NN N
screens NNS N
indicated VBD N
an DT N
increased VBN N
risk NN o
of IN o
an DT o
adverse JJ o
outcome-absence NN o
of IN o
documentation NN o
of IN o
discharge NN o
planning NN o
, , o
elevated JJ o
temperature NN o
, , o
abnormal JJ o
pulse NN o
, , o
and CC o
unaddressed JJ o
abnormal JJ o
test NN o
results NNS o
at IN N
discharge NN N
. . N

The DT N
other JJ N
three CD N
discharge NN N
screens NNS N
examined-abnormal JJ o
blood NN o
pressure NN o
, , o
IV NNP o
fluids NNS o
or CC o
drugs NNS o
, , o
and CC o
wound JJ o
drainage NN o
before IN N
discharge-were JJ N
unrelated JJ N
to TO N
postdischarge VB N
adverse JJ N
outcomes NNS N
. . N

CONCLUSIONS NNP N
Generic NNP i
discharge NN i
screens NNS i
based VBN N
on IN N
inadequate JJ N
discharge NN N
planning NN N
, , N
abnormal JJ o
pulse NN o
, , o
increased JJ o
temperature NN o
, , N
or CC N
unaddressed JJ o
abnormal JJ o
tests NNS o
may MD N
be VB N
important JJ N
indicators NNS N
of IN N
substandard NN N
care NN N
. . N

Other JJ N
discharge NN N
screens NNS N
apparently RB N
do VBP N
not RB N
detect VB N
errors NNS N
in IN N
care NN N
associated VBN N
with IN N
major JJ N
consequences NNS N
for IN N
patients NNS N
. . N

-DOCSTART- -20500784- O O

Effects NNS N
of IN N
a DT N
leisure NN i
programme NN i
on IN N
quality NN o
of IN o
life NN o
and CC o
stress NN o
of IN N
individuals NNS p
with IN p
ASD NNP p
. . p

BACKGROUND NNP N
Even RB N
though IN N
there EX N
is VBZ N
research NN N
demonstrating VBG N
a DT N
positive JJ N
relationship NN N
between IN N
leisure NN N
participation NN N
and CC N
the DT N
two CD N
constructs NNS N
of IN N
quality NN o
of IN o
life NN o
and CC o
stress NN o
reduction NN N
, , N
current JJ N
conceptualisation NN N
of IN N
leisure NN N
as IN N
a DT N
contributor NN N
to TO N
quality NN N
of IN N
life NN N
is VBZ N
limited VBN N
. . N

In IN N
addition NN N
, , N
in IN N
spite NN N
of IN N
improvements NNS N
in IN N
accurate JJ N
diagnosis NN N
of IN N
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
at IN N
increasingly RB N
earlier JJR N
ages NNS N
and CC N
proliferation NN N
of IN N
interventions NNS N
, , N
research NN N
associated VBN N
with IN N
leisure NN N
and CC N
quality NN N
of IN N
life NN N
for IN N
people NNS p
with IN p
ASD NNP p
is VBZ N
lacking VBG N
. . N

METHODS NNP N
Therefore NNP N
, , N
a DT N
study NN N
using VBG N
a DT N
repeated JJ N
measures NNS N
design NN N
was VBD N
used VBN N
to TO N
measure VB N
effects NNS N
of IN N
a DT N
1-year JJ i
group NN i
leisure NN i
programme NN i
intended VBN N
to TO N
facilitate VB N
interaction NN i
with IN i
media NNS i
, , i
engagement NN i
in IN i
exercise NN i
, , i
playing VBG i
games NNS i
and CC i
doing VBG i
crafts NNS i
, , i
attending VBG i
events NNS i
, , i
and CC i
participating VBG i
in IN i
other JJ i
recreation NN i
activities NNS i
on IN N
quality NN N
of IN N
life NN N
and CC N
stress NN N
of IN N
37 CD p
participants NNS p
( ( p
22 CD p
male NN p
, , p
15 CD p
female NN p
) ) p
, , p
ages VBZ p
17-39 JJ p
( ( p
M NNP p
= NNP p
31.49 CD p
) ) p
years NNS p
at IN p
the DT p
beginning NN p
of IN p
the DT p
programme NN p
) ) p
diagnosed VBD p
with IN p
an DT p
ASD NNP p
and CC p
a DT p
group NN p
of IN p
34 CD p
adults NNS p
with IN p
ASD NNP p
as IN p
control NN i
group NN i
( ( i
waiting VBG i
list NN i
) ) i
( ( p
19 CD p
male NN p
, , p
15 CD p
female NN p
) ) p
, , p
ages VBZ p
24-38 JJ p
( ( p
M NNP p
= VBZ p
30 CD p
at IN p
programme JJ p
initiation NN p
) ) p
years NNS p
. . p

RESULTS NNP N
There EX N
was VBD N
a DT N
significant JJ N
decrease NN N
in IN N
overall JJ N
scores NNS N
of IN N
stress NN o
levels NNS o
for IN N
participants NNS N
over IN N
the DT N
course NN N
of IN N
the DT N
study NN N
and CC N
there EX N
was VBD N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
four CD N
factors NNS N
of IN N
quality NN o
of IN o
life NN o
that WDT N
were VBD N
measured VBN N
( ( o
satisfaction NN o
, , o
independence NN o
, , o
competence NN o
and CC o
social JJ o
interaction NN o
) ) o
as RB N
well RB N
as IN N
the DT N
total JJ o
score NN o
for IN o
quality NN o
of IN o
life NN o
from IN N
baseline NN N
to TO N
the DT N
end NN N
of IN N
the DT N
intervention NN N
12 CD N
months NNS N
later RB N
. . N

In IN N
contrast NN N
, , N
the DT N
control NN N
group NN N
demonstrated VBD N
no DT N
significant JJ N
improvements NNS N
related VBN N
to TO N
stress VB o
or CC o
quality NN o
of IN o
life NN o
. . o

Implications NNS N
of IN N
these DT N
findings NNS N
to TO N
leisure VB N
services NNS N
and CC N
the DT N
quality NN o
of IN o
life NN o
of IN N
individuals NNS p
with IN p
ASD NNP p
are VBP N
discussed VBN N
. . N

CONCLUSION NNP N
Findings NNP N
support NN N
the DT N
contention NN N
that WDT N
participation NN N
in IN N
recreation NN N
activities NNS N
positively RB N
influenced VBD N
the DT N
stress NN o
and CC o
quality NN o
of IN o
life NN o
of IN N
adults NNS p
with IN p
ASD NNP p
. . p

-DOCSTART- -3085131- O O

Effects NNS N
of IN N
mecamylamine NN i
on IN N
human JJ p
cigarette NN p
smoking NN p
and CC N
subjective JJ N
ratings NNS N
. . N

Multiple JJ N
measures NNS N
of IN N
cigarette NN N
smoking NN N
, , N
subjective JJ N
effect NN N
and CC N
physiological JJ N
effect NN N
were VBD N
collected VBN N
during IN N
90-min JJ N
test NN N
sessions NNS N
in IN N
normal JJ p
volunteers NNS p
. . p

Before IN N
sessions NNS N
subjects NNS N
received VBD N
oral JJ i
doses NNS i
of IN i
mecamylamine NN i
( ( i
2.5 CD i
, , i
5.0 CD i
, , i
10 CD i
, , i
20 CD i
mg NN i
) ) i
or CC i
placebo NN i
. . i

Each DT N
dose NN N
and CC N
placebo NN i
was VBD N
given VBN N
three CD N
times NNS N
in IN N
a DT N
randomized JJ N
block NN N
sequence NN N
. . N

Mecamylamine NNP i
increased VBD N
several JJ N
measures NNS N
of IN N
cigarette NN N
smoking NN N
, , N
including VBG N
number NN o
of IN o
cigarettes NNS o
, , o
number NN o
of IN o
puffs NNS o
per IN o
cigarette NN o
, , o
and CC o
expired VBD o
air NN o
carbon NN o
monoxide NN o
level NN o
. . o

Mecamylamine NNP i
also RB N
produced VBD N
modest JJ N
, , N
dose-related JJ N
decreases NNS N
in IN N
standing VBG N
blood NN o
pressure NN o
and CC N
increases NNS N
in IN N
standing VBG o
heart NN o
rate NN o
. . o

The DT N
subjective JJ N
effects NNS N
produced VBN N
by IN N
mecamylamine NN i
were VBD N
not RB N
characteristic JJ N
of IN N
those DT N
of IN N
psychoactive JJ N
drugs NNS N
. . N

Mecamylamine NNP i
appears VBZ N
to TO N
have VB N
increased VBN N
cigarette NN N
smoking NN N
by IN N
decreasing VBG N
the DT N
effective JJ N
dose JJ N
level NN N
of IN N
nicotine JJ N
available JJ N
from IN N
cigarette NN N
smoking NN N
. . N

-DOCSTART- -17064200- O O

Effect NN N
of IN N
patient NN p
withdrawal NN p
on IN p
a DT p
study NN p
evaluating VBG N
pharmacist JJ i
management NN i
of IN i
hypertension NN i
. . i

STUDY NNP N
OBJECTIVES NNP N
To TO N
examine VB N
potential JJ N
threats NNS N
to TO N
internal JJ N
and CC N
external JJ N
study NN N
validity NN N
caused VBN N
by IN N
differential JJ p
patient NN p
withdrawal NN p
from IN p
a DT p
randomized VBN p
controlled VBN p
trial NN p
evaluating VBG p
pharmacist JJ p
management NN p
of IN p
hypertension NN p
, , p
to TO p
compare VB p
the DT p
characteristics NNS p
of IN p
patients NNS p
who WP p
withdrew VBP p
with IN p
those DT p
of IN p
patients NNS p
who WP p
completed VBD p
the DT p
study NN p
, , p
and CC p
to TO p
identify VB p
characteristics NNS p
that WDT p
predispose VBP p
patients NNS p
to TO p
withdraw VB p
from IN p
hypertension NN p
management NN p
. . p

DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
, , N
comparative JJ N
study NN N
. . N

SETTING NNP N
Network NNP N
of IN N
primary JJ N
care NN N
clinics NNS N
. . N

PATIENTS VB N
Four CD p
hundred JJ p
sixty-three JJ p
patients NNS p
with IN p
a DT p
diagnosis NN p
of IN p
hypertension NN p
and CC p
a DT p
last JJ p
documented JJ p
systolic JJ p
blood NN p
pressure NN p
of IN p
160 CD p
mm NNS p
Hg NNP p
or CC p
greater JJR p
and/or NNS p
diastolic JJ p
blood NN p
pressure NN p
of IN p
100 CD p
mm NNS p
Hg NNP p
or CC p
greater JJR p
. . p

INTERVENTION NN N
Patients NNPS p
were VBD p
randomly RB p
allocated VBN p
to TO p
the DT p
pharmacist NN i
intervention NN i
or CC i
usual-care JJ i
( ( i
control NN i
) ) i
group NN i
. . i

Those DT p
in IN p
the DT p
pharmacist NN p
intervention NN p
group NN p
were VBD N
collaboratively RB i
managed VBN i
by IN i
a DT i
primary JJ i
care NN i
clinical JJ i
pharmacy NN i
specialist NN i
and CC i
their PRP$ i
primary JJ i
care NN i
provider NN i
. . i

Patients NNS p
in IN p
the DT p
control NN p
group NN p
received VBD i
usual JJ i
care NN i
from IN i
only RB i
their PRP$ i
primary JJ i
care NN i
provider NN i
. . i

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Of IN N
the DT N
463 CD p
patients NNS p
, , p
191 CD p
( ( p
41 CD p
% NN p
) ) p
withdrew NN p
from IN p
the DT p
study NN p
after IN p
randomization NN p
and CC p
272 CD p
( ( p
59 CD p
% NN p
) ) p
completed VBD p
the DT p
study NN p
. . p

Patients NNS p
who WP p
withdrew VBP p
from IN p
the DT p
pharmacist NN i
intervention NN i
group NN p
were VBD p
similar JJ p
to TO p
patients NNS p
who WP p
withdrew VBP p
from IN p
the DT p
usual-care JJ p
group NN p
with IN N
respect NN N
to TO N
age NN N
, , N
sex NN N
, , N
insurance NN N
status NN N
, , N
and CC N
chronic JJ N
conditions NNS N
. . N

Patients NNS p
who WP p
smoked VBD p
or CC p
had VBD p
commercial JJ p
insurance NN p
were VBD p
more RBR p
likely JJ p
to TO p
withdraw VB o
from IN p
the DT p
study NN p
than IN p
the DT p
other JJ p
participants NNS p
. . p

However RB N
, , N
multivariate JJ N
analysis NN N
of IN N
all DT N
variables NNS N
, , N
when WRB N
adjusted VBN N
for IN N
the DT N
effect NN N
of IN N
the DT N
intervention NN N
, , N
revealed VBD N
that IN N
insurance NN o
status NN o
was VBD N
the DT N
only JJ N
variable NN N
associated VBN N
with IN N
a DT N
heightened JJ N
probability NN N
of IN N
withdrawal NN o
( ( N
p=0.002 NN N
) ) N
. . N

CONCLUSION NNP N
Although IN N
this DT N
study NN N
had VBD N
a DT N
high JJ N
withdrawal NN N
rate NN N
, , N
between-group JJ p
patient NN p
characteristics NNS p
remained VBD p
balanced JJ p
. . p

Therefore RB N
, , N
internal JJ N
validity NN N
was VBD N
preserved VBN N
, , N
and CC N
outcomes RB N
from IN N
the DT N
study NN N
groups NNS N
could MD N
be VB N
reliably RB N
compared VBN N
. . N

A DT N
lack NN N
of IN N
significant JJ N
differences NNS N
between IN N
patients NNS p
who WP p
withdrew VBD p
versus FW p
those DT p
who WP p
completed VBD p
, , p
with IN p
the DT p
exception NN p
of IN p
insurance NN p
status NN p
, , p
suggests VBZ p
that IN p
external JJ p
validity NN p
was VBD p
not RB p
jeopardized VBN p
. . p

-DOCSTART- -12590404- O O

Fluvoxamine NNP i
as RB N
effective JJ N
as IN N
clomipramine NN i
against IN N
symptoms NNS N
of IN N
severe JJ o
depression NN o
: : o
results NNS N
from IN N
a DT N
multicentre NN N
, , N
double-blind NN N
study NN N
. . N

BACKGROUND NNP N
Although IN N
selective JJ N
serotonin NNS N
reuptake VBP N
inhibitors NNS N
( ( N
SSRIs NNP N
) ) N
are VBP N
better RBR N
tolerated VBN N
than IN N
tricyclic JJ N
antidepressants NNS N
, , N
their PRP$ N
efficacy NN o
in IN N
severe JJ N
depression NN N
remains VBZ N
to TO N
be VB N
further RB N
elucidated VBN N
. . N

METHOD VB N
A DT N
double-blind NN N
, , N
multicentre NN p
study NN p
was VBD p
conducted VBN p
in IN p
86 CD p
severely RB p
depressed JJ p
inpatients NNS p
( ( p
> JJ p
or= RB p
25 CD p
on IN p
the DT p
17-item JJ o
Hamilton NNP o
depression NN o
rating NN o
scale NN o
[ NNP o
HAMD NNP o
] NNP o
total JJ o
score NN o
) ) o
to TO N
compare VB N
the DT N
efficacy NN o
and CC N
safety NN o
of IN N
fluvoxamine NN i
with IN N
that DT N
of IN N
clomipramine NN i
. . i

Following VBG N
placebo JJ i
run-in JJ N
, , N
86 CD p
patients NNS p
were VBD N
randomised VBN N
to TO N
receive VB N
fluvoxamine NN i
or CC i
clomipramine NN i
( ( N
100-250 JJ N
mg/day NN N
) ) N
for IN N
8 CD N
weeks NNS N
. . N

RESULTS NNP N
Fluvoxamine NNP N
and CC N
clomipramine VB N
both DT N
resulted VBN N
in IN N
marked JJ N
improvements NNS o
; : o
there EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
them PRP N
on IN N
the DT N
17-item JJ o
HAMD NNP o
total NN o
score NN o
, , N
the DT N
clinical JJ o
global JJ o
impression NN o
severity NN o
of IN o
illness NN o
or CC N
global JJ o
improvement NN o
items NNS o
or CC o
the DT o
Montgomery-Asberg JJ o
depression NN o
rating NN o
scale NN o
, , N
at IN N
any DT N
visit NN N
. . N

At IN N
the DT N
end NN N
of IN N
the DT N
study NN N
, , N
71 CD N
% NN N
in IN N
the DT N
fluvoxamine NN N
group NN N
and CC N
69 CD N
% NN N
in IN N
the DT N
clomipramine NN N
group NN N
were VBD N
responders NNS N
( ( N
> JJ N
or= RB N
50 CD N
% NN N
decrease NN N
in IN N
17-item JJ o
HAMD NNP o
total NN o
score NN o
) ) o
. . N

However RB N
, , N
fluvoxamine NN N
was VBD N
better RBR N
tolerated VBN o
than IN N
clomipramine NN N
. . N

Clomipramine NNP N
was VBD N
associated VBN N
with IN N
a DT N
higher JJR N
incidence NN N
of IN N
overall JJ N
and CC N
treatment-related JJ N
adverse JJ o
events NNS o
. . o

In IN N
addition NN N
, , N
the DT N
percentage NN N
of IN N
patients NNS N
discontinued VBN o
prematurely RB o
due JJ N
to TO N
adverse JJ o
events NNS o
was VBD N
more JJR N
than IN N
twice RB N
as IN N
high JJ N
with IN N
clomipramine NN N
than IN N
with IN N
fluvoxamine NN N
( ( N
24 CD N
% NN N
vs JJ N
11 CD N
% NN N
) ) N
. . N

CONCLUSION NNP N
Fluvoxamine NNP N
and CC N
clomipramine NN N
are VBP N
equally RB N
effective JJ N
in IN N
severe JJ N
depression NN N
, , N
but CC N
fluvoxamine NN N
has VBZ N
a DT N
better JJR N
safety NN o
and CC N
tolerability NN o
profile NN N
. . N

-DOCSTART- -11069570- O O

Probiotics NNS i
in IN N
the DT N
management NN N
of IN N
atopic NN p
eczema NN p
. . p

BACKGROUND NNP N
Over IN N
the DT N
last JJ N
two CD N
decades IN N
the DT N
incidence NN N
of IN N
allergic JJ N
diseases NNS N
has VBZ N
increased VBN N
in IN N
industrialized JJ N
countries NNS N
, , N
and CC N
consequently RB N
new JJ N
approaches NNS N
have VBP N
to TO N
be VB N
explored VBN N
. . N

OBJECTIVE CC N
The DT N
potential NN N
of IN N
probiotics NNS N
to TO N
control VB N
allergic JJ o
inflammation NN o
at IN p
an DT p
early JJ p
age NN p
was VBD N
assessed VBN N
in IN N
a DT N
randomized JJ N
double-blind JJ N
placebo-controlled JJ N
study NN N
. . N

METHODS NNP N
A NNP p
total NN p
of IN p
27 CD p
infants NNS p
, , p
mean JJ p
age NN p
4.6 CD p
months NNS p
, , p
who WP p
manifested VBD p
atopic JJ p
eczema NN p
during IN p
exclusive JJ p
breast-feeding NN p
and CC p
who WP p
have VBP p
had VBN p
no DT p
exposure NN p
to TO p
any DT p
infant NN p
or CC p
substitute NN p
formula NN p
were VBD N
weaned VBN N
to TO N
probiotic-supplemented JJ i
, , i
Bifidobacterium NNP i
lactis VBZ i
Bb-12 NNP i
or CC i
Lactobacillus NNP i
strain VBP i
GG NNP i
( ( i
ATCC NNP i
53103 CD i
) ) i
, , i
extensively RB i
hydrolysed VBD i
whey JJ i
formulas NNS i
or CC i
to TO i
the DT i
same JJ i
formula NN i
without IN i
probiotics NNS i
. . i

The DT N
extent NN N
and CC N
severity NN N
of IN N
atopic NN N
eczema NN N
, , N
the DT N
growth NN N
and CC N
nutrition NN N
of IN N
infants NNS N
, , N
and CC N
concentrations NNS N
of IN N
circulating VBG N
cytokines/chemokines NNS N
and CC N
soluble JJ N
cell NN N
surface NN N
adhesion NN N
molecules NNS N
in IN N
serum NN N
and CC N
methyl-histamine NN N
and CC N
eosinophilic JJ N
protein NN N
X NN N
in IN N
urine JJ N
were VBD N
determined VBN N
. . N

RESULTS VB N
The DT N
SCORAD NNP o
score NN o
reflecting VBG N
the DT N
extent NN o
and CC o
severity NN o
of IN o
atopic NN o
eczema NN o
was VBD N
16 CD N
( ( N
7-25 JJ N
) ) N
during IN N
breast-feeding NN N
, , N
median JJ N
( ( N
interquartile JJ N
range NN N
) ) N
. . N

After IN N
2 CD N
months NNS N
, , N
a DT N
significant JJ N
improvement NN N
in IN N
skin JJ o
condition NN o
occurred VBD N
in IN N
patients NNS N
given VBN N
probiotic-supplemented JJ N
formulas NNS N
, , N
as IN N
compared VBN N
to TO N
the DT N
unsupplemented JJ N
group NN N
; : N
chi NNS N
( ( N
2 CD N
) ) N
= NN N
12.27 CD N
, , N
P NNP N
= VBZ N
0.002 CD N
. . N

SCORAD NNP o
decreased VBD N
in IN N
the DT N
Bifidobacterium NNP N
lactis VBZ N
Bb-12 NNP N
group NN N
to TO N
0 CD N
( ( N
0-3.8 NN N
) ) N
, , N
and CC N
in IN N
the DT N
Lactobacillus NNP N
GG NNP N
group NN N
to TO N
1 CD N
( ( N
0.1-8.7 NN N
) ) N
, , N
vs RB N
unsupplemented JJ N
13.4 CD N
( ( N
4.5-18.2 JJ N
) ) N
, , N
median JJ N
( ( N
interquartile JJ N
range NN N
) ) N
, , N
in IN N
parallel NN N
with IN N
a DT N
reduction NN N
in IN N
the DT N
concentration NN N
of IN N
soluble JJ N
CD4 NNP o
in IN N
serum NN N
and CC N
eosinophilic JJ N
protein NN N
X NN N
in IN N
urine JJ N
. . N

CONCLUSION VB N
The DT N
results NNS N
provide VBP N
the DT N
first JJ N
clinical JJ N
demonstration NN N
of IN N
specific JJ N
probiotic JJ N
strains NNS N
modifying VBG N
the DT N
changes NNS N
related VBN N
to TO N
allergic JJ o
inflammation NN o
. . o

The DT N
data NN N
further RB N
indicate VBP N
that IN N
probiotics NNS N
may MD N
counteract VB N
inflammatory JJ o
responses NNS o
beyond IN N
the DT N
intestinal JJ N
milieu NN N
. . N

The DT N
combined JJ N
effects NNS N
of IN N
these DT N
probiotic JJ N
strains NNS N
will MD N
guide VB N
infants NNS p
through IN N
the DT N
weaning JJ N
period NN N
, , N
when WRB N
sensitization NN N
to TO N
newly RB N
encountered VBN N
antigens NNS N
is VBZ N
initiated VBN N
. . N

The DT N
probiotic JJ N
approach NN N
may MD N
thus RB N
offer VB N
a DT N
new JJ N
direction NN N
in IN N
the DT N
search NN N
for IN N
future JJ N
foods NNS N
for IN N
allergy JJ N
treatment NN N
and CC N
prevention NN N
strategies NNS N
. . N

-DOCSTART- -25953148- O O

A DT N
Randomized NNP N
Clinical NNP N
Trial NNP N
Comparison NNP N
Between NNP N
Pivotal NNP i
Response NNP i
Treatment NNP i
( ( i
PRT NNP i
) ) i
and CC i
Adult-Driven NNP i
Applied NNP i
Behavior NNP i
Analysis NNP i
( ( i
ABA NNP i
) ) i
Intervention NN i
on IN N
Disruptive JJ o
Behaviors NNS o
in IN p
Public NNP p
School NNP p
Children NNP p
with IN p
Autism NNP p
. . p

Children NNP p
with IN p
autism NN p
often RB N
demonstrate JJ N
disruptive JJ o
behaviors NNS o
during IN N
demanding VBG N
teaching VBG N
tasks NNS N
. . N

Language VB N
intervention NN N
can MD N
be VB N
particularly RB N
difficult JJ N
as IN N
it PRP N
involves VBZ N
social JJ N
and CC N
communicative JJ N
areas NNS N
, , N
which WDT N
are VBP N
challenging VBG N
for IN N
this DT N
population NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
two CD N
intervention NN N
conditions NNS N
, , N
a DT i
naturalistic JJ i
approach NN i
, , i
Pivotal NNP i
Response NNP i
Treatment NNP i
( ( i
PRT NNP i
) ) i
with IN i
an DT i
adult-directed JJ i
ABA NNP i
approach NN i
on IN i
disruptive JJ o
behavior NN o
during IN i
language NN i
intervention NN i
in IN N
the DT N
public JJ N
schools NNS N
. . N

A DT N
randomized JJ N
clinical JJ N
trial NN N
design NN N
was VBD N
used VBN N
with IN N
two CD p
groups NNS p
of IN p
children NNS p
, , p
matched VBD p
according VBG p
to TO p
age NN p
, , p
sex NN p
and CC p
mean JJ p
length NN p
of IN p
utterance NN p
. . p

The DT N
data NN N
showed VBD N
that IN N
the DT N
children NNS N
demonstrated VBD N
significantly RB N
lower JJR N
levels NNS N
of IN N
disruptive JJ o
behavior NN o
during IN N
the DT N
PRT NNP N
condition NN N
. . N

The DT N
results NNS N
are VBP N
discussed VBN N
with IN N
respect NN N
to TO N
antecedent VB N
manipulations NNS N
that WDT N
may MD N
be VB N
helpful JJ N
in IN N
reducing VBG N
disruptive JJ o
behavior NN o
. . o

-DOCSTART- -11132252- O O

Effect NN N
of IN N
secretin NN i
on IN N
children NNS p
with IN p
autism NN p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

To TO N
determine VB N
the DT N
effect NN N
of IN N
intravenous JJ i
porcine NN i
secretin NN i
on IN N
autistic JJ N
behaviours NNS N
in IN N
children NNS p
aged VBD p
2 CD p
to TO p
7 CD p
years NNS p
, , N
the DT N
effects NNS N
of IN N
secretin NN N
on IN N
( ( N
1 CD N
) ) N
performance NN N
on IN N
a DT N
standardized JJ N
language NN N
measure NN N
, , N
and CC N
( ( N
2 CD N
) ) N
autistic JJ N
behaviours NN N
, , N
as IN N
rated VBN N
by IN N
parents NNS N
and CC N
child NN N
development NN N
professionals NNS N
was VBD N
examined VBN N
. . N

Employing VBG N
a DT N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
design NN N
, , N
95 CD p
participants NNS p
were VBD N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
groups NNS N
and CC N
administered VBD N
a DT N
single JJ N
dose NN N
of IN N
either DT N
secretin NN i
or CC i
placebo NN i
. . i

A DT N
follow-up JJ N
assessment NN N
was VBD N
conducted VBN N
3 CD N
weeks NNS N
after IN N
the DT N
injection NN N
. . N

No DT N
significant JJ N
differences NNS N
in IN N
language NN o
or CC o
autistic JJ o
behaviour NN o
measures NNS o
were VBD N
observed VBN N
at IN N
the DT N
3-week JJ N
follow-up NN N
between IN N
the DT N
groups NNS N
. . N

Also RB N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
proportion NN N
of IN N
individuals NNS N
who WP N
improved VBN N
by IN N
> NN o
or CC o
= $ o
6 CD o
points NNS o
on IN o
the DT o
language NN o
measure NN o
at IN N
follow-up NN N
. . N

This DT N
study NN N
showed VBD N
no DT N
significant JJ N
effects NNS N
of IN N
secretin NN N
on IN N
children NNS p
with IN p
autism NN p
. . p

Our PRP$ N
results NNS N
are VBP N
consistent JJ N
with IN N
a DT N
systematic JJ N
review NN N
of IN N
randomized VBN N
controlled JJ N
trials NNS N
evaluating VBG N
the DT N
effect NN N
of IN N
secretin NN N
in IN N
children NNS p
with IN p
autism NN p
. . p

-DOCSTART- -9664917- O O

Diet NNP N
design NN N
for IN N
a DT N
multicenter NN N
controlled VBD N
feeding JJ N
trial NN N
: : N
the DT N
DELTA NNP N
program NN N
. . N

Delta NNP p
Research NNP p
Group NNP p
. . p

OBJECTIVE NNP N
To TO N
describe VB N
the DT N
process NN N
and CC N
results NNS N
of IN N
diet JJ N
standardization NN N
, , N
diet JJ N
validation NN N
, , N
and CC N
monitoring NN N
of IN N
diet JJ N
composition NN N
, , N
which WDT N
were VBD N
key JJ N
components NNS N
of IN N
protocol JJ N
1 CD N
of IN N
Dietary NNP N
Effects NNPS N
on IN N
Lipoproteins NNS N
and CC N
Thrombogenic NNP N
Activity NNP N
( ( N
DELTA-1 NNP N
) ) N
, , N
the DT N
initial JJ N
protocol NN N
in IN N
a DT N
program NN N
of IN N
multicenter NN N
human JJ N
feeding NN N
studies NNS N
designed VBN N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
amount NN N
and CC N
type NN N
of IN N
fat NN N
on IN N
lipoproteins NNS N
and CC N
hemostasis NN N
parameters NNS N
in IN N
various JJ p
demographic JJ p
groups NNS p
. . p

DESIGN NNP N
DELTA-1 NNP N
was VBD N
based VBN N
on IN N
a DT N
randomized VBN N
, , N
blinded VBD N
, , N
crossover JJ N
experimental JJ N
design NN N
. . N

Three CD i
diets NNS i
were VBD N
fed VBN N
for IN N
8 CD N
weeks NNS N
to TO N
103 CD p
healthy JJ p
men NNS p
and CC p
women NNS p
aged VBD p
22 CD p
to TO p
67 CD p
years NNS p
at IN p
4 CD p
field NN p
centers NNS p
. . p

Diet NNP i
A NNP i
, , i
an DT i
average JJ i
American JJ i
diet NN i
, , i
was VBD i
designed VBN i
to TO i
provide VB i
37 CD i
% NN i
of IN i
energy NN i
from IN i
fat JJ i
, , i
16 CD i
% NN i
of IN i
energy NN i
from IN i
saturated VBN i
fatty JJ i
acids NNS i
( ( i
SFAs NNP i
) ) i
; : i
diet JJ i
B NNP i
( ( i
step NN i
1 CD i
diet NN i
) ) i
was VBD i
designed VBN i
to TO i
provide VB i
30 CD i
% NN i
of IN i
energy NN i
from IN i
fat JJ i
, , i
9 CD i
% NN i
of IN i
energy NN i
from IN i
SFA NNP i
; : i
and CC N
diet JJ i
C NNP i
( ( i
low JJ i
SFA NNP i
diet NN i
) ) i
was VBD i
designed VBN i
to TO i
provide VB i
26 CD i
% NN i
of IN i
energy NN i
from IN i
fat JJ i
, , i
5 CD i
% NN i
of IN i
energy NN i
from IN N
SFA NNP N
. . N

Key NNP N
features NNS N
of IN N
diet JJ N
standardization NN N
included VBD N
central JJ N
procurement NN N
of IN N
fat-containing JJ N
foods NNS N
, , N
inclusion NN N
of IN N
standard JJ N
ingredients NNS N
, , N
precision NN N
weighing NN N
of IN N
foods NNS N
-- : N
especially RB N
sources NNS N
of IN N
fat NN N
and CC N
cholesterol NN N
-- : N
and CC N
use NN N
of IN N
standardized JJ N
written VBN N
procedures NNS N
. . N

SETTING NN N
For IN N
menu NN N
validation NN N
, , N
a DT N
set NN N
of IN N
12 CD N
menus NNS N
for IN N
each DT N
diet NN N
was VBD N
prepared VBN N
in IN N
duplicate NN N
and CC N
chemically RB N
assayed VBN N
. . N

For IN N
monitoring NN N
of IN N
diet JJ N
composition NN N
during IN N
the DT N
study NN N
, , N
an DT N
8-day JJ N
diet JJ N
cycle NN N
( ( N
6 CD N
weekday NN N
and CC N
2 CD N
weekend NN N
menus NN N
) ) N
was VBD N
sampled VBN N
by IN N
every DT N
field NN N
center NN N
twice RB N
during IN N
each DT N
of IN N
3 CD N
feeding VBG N
periods NNS N
. . N

STATISTICAL NNP N
ANALYSES NNP N
Means NNP N
( ( N
+/- JJ N
standard NN N
error NN N
) ) N
were VBD N
calculated VBN N
and CC N
compared VBN N
with IN N
target NN N
nutrient JJ N
specifications NNS N
. . N

RESULTS NNP N
DELTA-1 NNP N
was VBD N
able JJ N
to TO N
provide VB N
a DT N
standardized JJ N
diet NN N
that WDT N
met VBD N
nutrient JJ o
specifications NNS o
across IN N
4 CD N
field NN N
centers NNS N
over IN N
24 CD N
weeks NNS N
of IN N
participant JJ N
feeding VBG N
spanning VBG N
a DT N
total NN N
of IN N
8 CD N
months NNS N
. . N

APPLICATIONS NNP N
Prestudy NNP N
chemical JJ N
validation NN N
of IN N
menus NN N
and CC N
continuous JJ N
sampling NN N
and CC N
assay NN N
of IN N
diets NNS N
throughout IN N
the DT N
study NN N
are VBP N
essential JJ N
to TO N
standardize VB N
experimental JJ N
diets NNS N
and CC N
to TO N
ensure VB N
that DT N
nutrient JJ N
target NN N
goals NNS N
are VBP N
met VBN N
and CC N
maintained VBN N
throughout IN N
a DT N
controlled JJ N
multicenter NN N
feeding NN N
study NN N
. . N

-DOCSTART- -24156287- O O

Effect NN N
of IN N
clinical JJ N
context NN N
on IN N
simulator-based JJ N
assessment NN N
of IN N
blood NN o
pressure NN o
taking VBG p
- : N
a DT N
pilot NN N
randomized VBN N
study NN N
. . N

BACKGROUND NNP N
Blood NNP N
pressure NN N
measurement NN N
is VBZ N
an DT N
essential JJ N
clinical JJ N
skill NN N
that WDT N
can MD N
readily RB N
be VB N
assessed VBN N
in IN N
objective JJ N
structured JJ N
clinical JJ N
examination NN N
( ( N
OSCE NNP N
) ) N
. . N

While IN N
the DT N
use NN N
of IN N
simulators NNS i
can MD N
enhance VB N
test NN N
validity NN N
and CC N
reliability NN N
, , N
the DT N
given VBN N
clinical JJ N
context NN N
may MD N
also RB N
affect VB N
student NN N
performance NN N
. . N

AIMS NNP N
To TO N
investigate VB N
the DT N
impact NN N
of IN N
variations NNS N
in IN N
clinical JJ N
context NN N
on IN N
blood NN N
pressure NN N
measurement NN N
in IN N
a DT N
simulator-based JJ i
OSCE NNP i
. . i

METHOD NNP N
We PRP N
randomized VBD p
162 CD p
first-year JJ p
medical JJ p
students NNS p
into IN p
four CD p
groups NNS p
that WDT p
received VBD p
different JJ p
lead-in JJ p
statements NNS p
before IN p
measuring VBG p
blood NN o
pressure NN o
on IN p
a DT p
manikin JJ i
simulator NN i
. . i

These DT N
statements NNS N
described VBD N
hypothetical JJ N
patients NNS N
with IN N
different JJ N
likelihoods NNS N
of IN N
having VBG N
systemic JJ o
hypertension NN o
. . o

RESULTS VB N
The DT N
lead-in JJ N
that WDT N
described VBD N
the DT N
highest JJS N
likelihood NN o
of IN o
hypertension NN o
was VBD N
associated VBN N
with IN N
significantly RB N
higher JJR N
reported VBD o
readings NNS o
and CC o
lower JJR o
accuracy NN o
. . o

The DT N
lead-in NN N
that WDT N
suggested VBD N
normality NN N
yielded VBN N
the DT N
best JJS N
performance NN N
. . N

CONCLUSION NNP N
Student NNP p
performance NN N
in IN N
simulator-based JJ i
OSCE NNP i
may MD N
be VB N
affected VBN N
by IN N
the DT N
clinical JJ N
context NN N
provided VBN N
. . N

However RB N
, , N
we PRP N
argue VBP N
that IN N
construct NN N
validity NN N
should MD N
be VB N
viewed VBN N
in IN N
light NN N
of IN N
the DT N
application NN N
of IN N
a DT N
test NN N
, , N
in IN N
that DT N
patients NNS N
may MD N
also RB N
present VB N
with IN N
different JJ N
cues NNS N
and CC N
likelihoods NNS N
of IN N
having VBG N
hypertension NN N
. . N

Variations NNS N
in IN N
construct NN N
design NN N
should MD N
be VB N
further RB N
explored VBN N
to TO N
enhance VB N
the DT N
training NN N
and CC N
assessment NN N
of IN N
clinical JJ N
competence NN N
that WDT N
reflects VBZ N
the DT N
unpredictability NN N
encountered VBN N
in IN N
daily JJ N
clinical JJ N
practice NN N
. . N

-DOCSTART- -23773944- O O

[ JJ i
Closure NNP i
of IN i
persistent JJ o
foramen NNS o
ovale SYM o
- : N
the DT N
last JJ N
closure NN N
? . N
] NN N
. . N

-DOCSTART- -22526891- O O

Efficacy NN o
and CC N
safety NN o
of IN N
intraseptal JJ N
and CC N
periodontal JJ N
ligament NN N
anesthesia NN N
achieved VBN N
by IN N
computer-controlled JJ i
articaine NN i
+ NNP i
epinephrine NN i
delivery NN i
: : i
a DT N
dose-finding JJ N
study NN N
. . N

OBJECTIVES CC N
The DT N
main JJ N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
dose-dependent JJ N
anesthetic JJ o
efficacy NN o
of IN N
the DT N
intraseptal JJ i
anesthesia NN i
( ( i
ISA NNP i
) ) i
and CC N
periodontal JJ i
ligament NN i
anesthesia NN i
( ( i
PLA NNP i
) ) i
obtained VBD N
with IN N
different JJ N
volumes NNS N
of IN N
4 CD N
% NN N
articaine NN i
and CC N
1:100,000 CD N
epinephrine NN i
( ( i
Ar NNP i
+ NNP i
Ep NNP i
) ) i
in IN N
human JJ N
mandibular JJ N
premolars NNS N
, , N
using VBG N
a DT N
computer-controlled JJ i
local JJ i
anesthetic JJ i
delivery NN i
system NN i
( ( i
CCLADS NNP i
) ) i
. . i

The DT N
safety NN o
profile NN o
of IN N
Ar NNP N
+ NNP N
Ep NNP N
was VBD N
also RB N
studied VBN N
by IN N
investigating VBG N
the DT N
stability NN N
of IN N
cardiovascular JJ N
parameters NNS N
. . N

MATERIAL NNP N
AND CC N
METHODS NNP N
One NNP p
hundred VBD p
and CC p
eighty JJ p
randomly RB p
selected VBN p
healthy JJ p
volunteers NNS p
( ( p
ASA NNP p
I PRP p
) ) p
entered VBD N
the DT N
single-blinded JJ N
study NN N
to TO N
receive VB i
16 CD i
mg NN i
+ VBD i
4 CD i
?g NNP i
, , i
24 CD i
mg NN i
+ VBD i
6 CD i
?g NN i
, , i
and CC i
32 CD i
mg NN i
+ VBD i
8 CD i
?g NN i
of IN i
Ar NNP i
+ NNP i
Ep NNP i
, , i
obtained VBN i
with IN i
different JJ i
volumes NNS i
( ( i
0.4 CD i
, , i
0.6 CD i
, , i
and CC i
0.8 CD i
ml NN i
, , i
respectively RB i
) ) i
, , i
for IN i
the DT i
ISA NNP i
and CC i
PLA NNP i
. . o

Success NNP o
rate NN o
, , o
onset VBN o
, , o
and CC o
duration NN o
of IN o
profound NN o
pulpal JJ o
anesthesia NN o
were VBD o
evaluated VBN i
by IN i
the DT i
electrical JJ o
pulp NN o
tester NN o
, , o
while IN o
the DT i
width NN o
of IN o
the DT o
anesthetic JJ o
field NN o
and CC o
duration NN o
of IN o
soft JJ o
tissue NN o
anesthesia NN o
were VBD o
recorded VBN i
using VBG i
the DT i
pinprick NN o
testing NN o
. . o

A DT o
monitor NN o
was VBD o
used VBN N
for IN N
the DT N
measurement NN N
of IN N
cardiovascular JJ o
parameters NNS o
. . o

RESULTS VB o
A DT N
dose-dependent JJ o
duration NN o
of IN o
pulpal JJ o
and CC o
soft JJ o
tissue NN o
anesthesia NN o
was VBD o
obtained VBN N
only RB N
by IN N
the DT N
ISA NNP i
. . o

Success NNP o
rate NN o
, , o
duration NN o
of IN o
both DT o
pulpal JJ o
and CC o
soft JJ o
tissue NN o
anesthesia NN o
, , o
and CC o
its PRP$ o
width NN o
were VBD o
significantly RB N
better RBR N
in IN N
the DT N
ISA NNP N
compared VBN N
with IN N
the DT N
PLA NNP N
. . N

No NNP N
significant JJ o
cardiovascular JJ o
changes NNS o
were VBD o
seen VBN N
in IN N
both DT N
groups NNS N
. . N

CONCLUSIONS VB N
It PRP N
can MD N
be VB N
suggested VBN N
that IN N
0.6 CD N
and CC N
0.8 CD N
ml NN N
of IN N
4 CD N
% NN N
Ar NNP i
+ NNP N
1:100,000 CD N
Ep NNP i
, , N
delivered VBN N
by IN N
CCLADS NNP N
, , N
offer VBP N
high JJ o
success NN o
rate NN o
and CC o
effective JJ o
clinical JJ o
parameters NNS o
of IN o
ISA NNP N
as IN N
a DT N
primary JJ N
anesthesia NN N
. . N

CLINICAL JJ N
RELEVANCE NN N
It PRP N
seems VBZ N
that IN N
dental NN N
procedures NNS N
requiring VBG N
profound NN N
pulpal NN N
, , N
bone NN N
, , N
and CC N
soft JJ N
tissue NN N
anesthesia NN N
could MD N
be VB N
effectively RB o
and CC o
safely RB o
obtained VBN o
by IN N
mentioned JJ N
anesthetic JJ N
protocol NN N
. . N

-DOCSTART- -10889149- O O

Atrophy NNP N
and CC N
intestinal JJ p
metaplasia NN p
one CD N
year NN N
after IN N
cure NN N
of IN N
H. NNP p
pylori FW p
infection NN p
: : p
a DT N
prospective JJ N
, , N
randomized VBN N
study NN N
. . N

BACKGROUND NNP N
& CC N
AIMS NNP N
Helicobacter NNP N
pylori-infected JJ N
gastric JJ N
mucosa NN N
evolves VBZ N
through IN N
stages NNS N
of IN N
chronic JJ N
gastritis NN N
, , N
intestinal JJ N
metaplasia NN N
( ( N
IM NNP N
) ) N
, , N
glandular JJ N
atrophy NN N
( ( N
GA NNP N
) ) N
, , N
and CC N
dysplasia NN N
before IN N
carcinoma NN N
develops NNS N
. . N

We PRP N
studied VBD N
if IN N
H. NNP N
pylori FW N
eradication NN N
would MD N
alter VB N
the DT N
course NN N
of IN N
premalignant JJ N
histologic NN N
changes NNS N
in IN N
the DT N
stomach NN N
. . N

METHODS NNP N
Volunteers NNPS p
from IN p
the DT p
Yantai NNP p
County NNP p
in IN p
China NNP p
underwent JJ p
upper JJ i
endoscopy NN i
with IN i
biopsy NN i
specimens NNS p
obtained VBN p
from IN p
the DT p
antrum NN p
and CC p
corpus NN p
. . p

H. NNP p
pylori-infected JJ p
subjects NNS p
were VBD N
randomized VBN N
to TO N
receive VB N
either RB N
a DT N
1-week JJ i
course NN i
of IN i
omeprazole JJ i
, , i
amoxicillin NN i
, , i
and CC i
clarithromycin NN i
( ( i
OAC NNP i
) ) i
or CC i
placebo NN i
. . i

At IN N
1 CD N
year NN N
, , N
endoscopies NNS N
with IN N
biopsies NNS N
were VBD N
repeated VBN N
. . N

RESULTS VB N
A DT N
total NN p
of IN p
587 CD p
H. NNP p
pylori-infected JJ p
subjects NNS p
were VBD p
randomized VBN p
to TO p
OAC NNP i
( ( N
n JJ N
= NNP N
295 CD N
) ) N
and CC N
placebo NN N
( ( N
n JJ N
= NNP N
292 CD N
) ) N
. . N

At IN N
1 CD N
year NN N
, , N
H. NNP N
pylori NN N
was VBD N
eradicated VBN N
in IN N
226 CD N
subjects NNS N
assigned VBN N
to TO N
OAC NNP i
. . N

In IN N
the DT N
placebo NN i
group NN N
, , N
245 CD p
patients NNS p
remained VBD p
H. NNP p
pylori NN p
infected VBD p
. . p

Analysis NN N
of IN N
paired JJ N
samples NNS N
obtained VBN N
from IN N
the DT N
same JJ N
patients NNS N
showed VBD N
that IN N
acute NN o
and CC o
chronic JJ o
gastritis NN o
decreased VBN N
in IN N
both DT N
the DT N
antrum NN N
and CC N
corpus NN N
after IN N
H. NNP N
pylori FW N
eradication NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
activity NN o
of IN o
IM NNP o
decreased VBD N
in IN N
antrum NN N
( ( N
P NNP N
= NNP N
0.014 CD N
) ) N
. . N

In IN N
the DT N
H. NNP N
pylori-infected JJ N
group NN N
, , N
antral JJ N
biopsy NN N
specimens NNS N
had VBD N
more RBR N
pronounced JJ N
acute NN o
gastritis NN o
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
, , N
whereas JJ N
corpus NN N
specimens NNS N
showed VBD N
increased VBN N
acute NN o
and CC o
chronic JJ o
gastritis NN o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
a DT N
marginal JJ N
increase NN N
in IN N
GA NNP o
( ( N
P NNP N
= NNP N
0.052 CD N
) ) N
. . N

When WRB N
histologic JJ N
changes NNS N
were VBD N
compared VBN N
between IN N
the DT N
2 CD N
groups NNS N
, , N
decrease NN N
in IN N
acute NN o
and CC o
chronic JJ o
gastritis NN o
was VBD N
more RBR N
frequent JJ N
after IN N
H. NNP N
pylori FW N
eradication NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
but CC N
changes NNS N
in IN N
IM NNP o
were VBD N
similar JJ N
. . N

In IN N
the DT N
H. NNP N
pylori-infected JJ N
group NN N
, , N
increase NN N
in IN N
GA NNP o
was VBD N
seen VBN N
in IN N
the DT N
corpus NN N
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
. . N

CONCLUSIONS NNP N
At IN N
1 CD N
year NN N
, , N
H. NNP N
pylori FW N
eradication NN N
is VBZ N
beneficial JJ N
in IN N
preventing VBG N
progression NN N
of IN N
pathologic JJ o
changes NNS o
of IN N
the DT N
gastric JJ N
mucosa NN N
. . N

-DOCSTART- -25122693- O O

Pathological JJ o
response NN o
and CC o
safety NN o
of IN N
two CD N
neoadjuvant JJ N
strategies NNS N
with IN N
bevacizumab NN i
in IN N
MRI-defined NNP p
locally RB p
advanced VBD p
T3 NNP p
resectable JJ p
rectal JJ p
cancer NN p
: : p
a DT N
randomized JJ N
, , N
noncomparative JJ N
phase NN N
II NNP N
study NN N
. . N

BACKGROUND NNP N
In IN N
T3 NNP N
rectal JJ N
cancer NN N
( ( N
RC NNP N
) ) N
, , N
preoperative JJ N
chemoradiotherapy NN i
[ JJ i
5-fluorouracil JJ i
( ( i
5-FU-RT JJ i
) ) i
] NN i
reduces VBZ N
local JJ o
recurrences NNS o
, , N
but CC N
does VBZ N
not RB N
affect VB N
overall JJ o
survival NN o
. . o

New NNP N
therapeutic JJ N
options NNS N
are VBP N
still RB N
necessary JJ N
to TO N
improve VB N
clinical JJ o
outcomes NNS o
. . o

PATIENTS NNP N
AND CC N
METHODS NNP N
This DT N
randomized VBN N
, , N
noncomparative JJ N
, , N
open-label JJ N
, , N
multicenter NN N
, , N
two CD N
arms NNS N
, , N
phase NN N
II NNP N
study NN N
was VBD N
conducted VBN N
in IN N
MRI-defined NNP p
locally RB p
advanced VBD p
T3 NNP p
resectable JJ p
RC NNP p
. . p

In IN N
arm NN N
A NNP N
, , N
patients NNS N
received VBD N
12-week JJ N
bevacizumab JJ i
plus CC i
5-FU JJ i
, , i
leucovorin JJ i
and CC i
oxaliplatin JJ i
( ( i
Folfox-4 NNP i
) ) i
followed VBD i
with IN i
bevacizumab-5-FU-RT NN i
before IN i
total JJ i
mesorectal JJ i
excision NN i
( ( i
TME NNP i
) ) i
. . i

In IN N
arm NN N
B NNP N
, , N
patients NNS N
received VBD N
only RB N
bevacizumab-5-FU-RT JJ i
before IN i
TME NNP i
. . i

Primary JJ o
end NN o
point NN o
was VBD N
pathological JJ o
complete JJ o
response NN o
( ( o
pCR JJ o
) ) o
rate NN o
. . o

RESULTS NNP N
Forty-six JJ p
patients NNS p
were VBD p
randomized VBN p
in IN p
arm NN p
A NN p
and CC p
45 CD p
patients NNS p
in IN p
arm NN p
B NNP p
. . p

In IN N
arm NN N
A NN N
, , N
the DT N
rate NN o
of IN o
pCR NN o
was VBD N
23.8 CD N
% NN N
[ JJ N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
12.1 CD N
% NN N
to TO N
39.5 CD N
% NN N
] NNP N
statistically RB N
superior VBZ N
to TO N
the DT N
defined VBN N
standard JJ N
rate NN N
of IN N
10 CD N
% NN N
, , N
P NNP N
= VBZ N
0.015 CD N
. . N

In IN N
arm NN N
B NNP N
, , N
the DT N
rate NN o
of IN o
pCR NN o
of IN N
11.4 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
3.8 CD N
% NN N
to TO N
24.6 CD N
% NN N
) ) N
was VBD N
not RB N
different JJ N
from IN N
10 CD N
% NN N
, , N
P NNP N
= VBZ N
0.906 CD N
. . N

No DT N
death NN o
occurred VBD N
during IN N
the DT N
study NN N
period NN N
, , N
from IN N
the DT N
start NN N
until IN N
8 CD N
weeks NNS N
following VBG N
surgery NN N
. . N

Postoperative JJ o
fistulas NNS o
were VBD N
reported VBN N
for IN N
16 CD N
patients NNS N
( ( N
7 CD N
in IN N
arm NN N
A NN N
and CC N
9 CD N
in IN N
arm NN N
B NNP N
) ) N
. . N

CONCLUSION NNP N
Even RB N
if IN N
the DT N
addition NN N
of IN N
bevacizumab NN N
induced VBN N
manageable JJ N
toxicities NNS o
including VBG N
an DT N
increased VBN o
risk NN o
of IN N
postoperative JJ N
fistula NN N
and CC N
no DT N
treatment-related JJ o
death NN o
, , N
arm NN N
B NNP N
did VBD N
not RB N
achieve VB N
the DT N
expected JJ N
pCR NN o
rate NN o
in IN N
the DT N
population NN N
of IN N
patients NNS N
included VBN N
. . N

Induction NNP N
bevacizumab-Folfox-4 NN i
followed VBN N
by IN N
bevacizumab-5-FU-RT NN i
is VBZ N
promising VBG N
. . N

It PRP N
is VBZ N
however RB N
necessary JJ N
to TO N
continue VB N
investigations NNS N
in IN N
the DT N
management NN N
of IN N
locally RB N
advanced JJ N
RC NNP N
. . N

CLINICAL NNP N
TRIALSGOV NNP N
IDENTIFIER NNP N
NCT NNP N
00865189 CD N
. . N

-DOCSTART- -23102530- O O

End-expiratory JJ p
lung NN p
volume NN p
recovers NNS N
more RBR N
slowly RB N
after IN N
closed JJ i
endotracheal NN o
suctioning VBG i
than IN N
after IN N
open JJ i
suctioning NN i
: : i
a DT N
randomized VBN N
crossover NN N
study NN N
. . N

PURPOSE NNP N
Endotracheal NNP N
suctioning VBG N
causes NNS N
significant JJ N
lung JJ N
derecruitment NN N
. . N

Closed VBN i
suction NN o
( ( i
CS NNP i
) ) i
minimizes VBZ N
lung JJ N
volume NN N
loss NN N
during IN N
suction NN N
, , N
and CC N
therefore RB N
, , N
volumes NNS N
are VBP N
presumed VBN N
to TO N
recover VB N
more RBR N
quickly RB N
postsuctioning VBG N
. . N

Conflicting VBG N
evidence NN N
exists VBZ N
regarding VBG N
this DT N
. . N

We PRP N
examined VBD N
the DT N
effects NNS N
of IN N
open JJ i
suction NN i
( ( i
OS NNP i
) ) i
and CC i
CS NNP i
on IN N
lung NN o
volume NN o
loss NN N
during IN N
suctioning NN o
, , N
and CC N
recovery NN N
of IN N
end-expiratory JJ o
lung NN o
volume NN o
( ( o
EELV NNP o
) ) o
up RB N
to TO N
30 CD N
minutes NNS N
postsuction NN N
. . N

MATERIAL NNP N
AND NNP N
METHODS NNP N
Randomized NNP N
crossover NN N
study NN N
examining VBG N
20 CD p
patients NNS p
postcardiac JJ o
surgery NN p
. . p

CS NNP o
and CC N
OS NNP o
were VBD N
performed VBN N
in IN N
random JJ N
order NN N
, , N
30 CD N
minutes NNS N
apart RB N
. . N

Lung NNP o
impedance NN o
was VBD N
measured VBN N
during IN N
suction NN N
, , N
and CC N
end-expiratory JJ N
lung NN N
impedance NN N
was VBD N
measured VBN N
at IN N
baseline NN N
and CC N
postsuctioning VBG N
using VBG N
electrical JJ N
impedance NN N
tomography NN N
. . N

Oximetry NNP o
, , o
partial JJ o
pressure NN o
of IN o
oxygen NN o
in IN o
the DT o
alveoli/fraction NN o
of IN o
inspired JJ o
oxygen NN o
ratio NN o
and CC o
compliance NN o
were VBD N
collected VBN N
. . N

RESULTS JJ N
Reductions NNPS N
in IN N
lung NN N
impedance NN o
during IN N
suctioning VBG N
were VBD N
less JJR N
for IN N
CS NNP i
than IN N
for IN N
OS NNP i
( ( N
mean JJ N
difference NN N
, , N
-905 JJ N
impedance NN N
units NNS N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
-1234 NNP N
to TO N
-587 VB N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

However RB N
, , N
at IN N
all DT N
points NNS N
postsuctioning VBG N
, , N
EELV NNP o
recovered VBD N
more RBR N
slowly RB N
after IN N
CS NNP i
than IN N
after IN N
OS NNP i
. . i

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
the DT N
other JJ N
respiratory NN N
parameters NNS N
. . N

CONCLUSIONS NNP N
Closed VBD i
suctioning VBG i
minimized VBN N
lung NN N
volume NN N
loss NN N
during IN N
suctioning VBG N
but CC N
, , N
counterintuitively RB N
, , N
resulted VBD N
in IN N
slower JJR N
recovery NN N
of IN N
EELV NNP N
postsuction NN N
compared VBN N
with IN N
OS NNP i
. . i

Therefore NNP N
, , N
the DT N
use NN N
of IN N
CS NNP i
can MD N
not RB N
be VB N
assumed VBN N
to TO N
be VB N
protective JJ N
of IN N
lung NN N
volumes NNS N
postsuctioning VBG o
. . o

Consideration NN N
should MD N
be VB N
given VBN N
to TO N
restoring VBG N
EELV NNP N
after IN N
either DT N
suction NN N
method NN N
via IN N
a DT N
recruitment JJ N
maneuver NN N
. . N

-DOCSTART- -12666946- O O

Comparative JJ N
clinical JJ N
and CC N
microbiological JJ N
effects NNS N
of IN N
subgingival JJ N
metronidazole JJ i
application NN N
in IN N
adult NN p
periodontitis NN p
; : p
12-months JJ N
results NNS N
. . N

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
clinical JJ N
and CC N
microbiological JJ N
effects NNS N
of IN N
subgingival JJ N
application NN N
of IN N
25 CD N
% NN N
metronidazole JJ i
dental JJ i
gel NN i
as IN N
an DT N
adjunct NN N
to TO N
scaling NN i
and CC i
root NN i
planing NN i
( ( i
SRP NNP i
) ) i
in IN N
the DT N
treatment NN N
of IN N
adult NN p
periodontitis NN p
. . p

Eighty NNP p
teeth VBZ p
in IN p
18 CD p
patients NNS p
were VBD N
evaluated VBN N
using VBG N
a DT N
split NN N
mouth NN N
design NN N
. . N

The DT N
test NN N
teeth NN N
received VBD N
SRP NNP i
and CC N
a DT N
25 CD N
% NN N
metronidazole JJ i
gel NN i
applied VBN N
subgingivally RB N
on IN N
days NNS N
0 CD N
and CC N
7 CD N
. . N

The DT N
control NN N
teeth VBZ N
received VBN N
SRP NNP i
only RB i
. . i

Clinical JJ N
and CC N
microbiological JJ N
examinations NNS N
were VBD N
carried VBN N
out RP N
before IN N
treatment NN N
and CC N
on IN N
weeks NNS N
1 CD N
, , N
3 CD N
, , N
7 CD N
, , N
13 CD N
, , N
26 CD N
, , N
38 CD N
and CC N
52 CD N
of IN N
the DT N
experimental JJ N
period NN N
. . N

Colony NNP N
forming VBG N
units NNS N
of IN N
Porphyromonas NNP N
gingivalis NN N
and CC N
Prevotella NNP N
intermedia VBP N
/ NNP N
Prevotella NNP N
nigrescens NNS N
were VBD N
determined VBN N
. . N

Both DT N
treatments NNS N
provided VBD N
significant JJ N
improvements NNS N
in IN N
all PDT N
the DT N
clinical JJ o
and CC o
microbiological JJ o
parameters NNS o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

However RB N
, , N
none NN N
of IN N
the DT N
differences NNS N
between IN N
the DT N
study NN N
groups NNS N
were VBD N
statistically RB N
significant JJ N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

As IN N
a DT N
conclusion NN N
, , N
the DT N
present JJ N
study NN N
does VBZ o
not RB o
provide VB o
evidence NN o
in IN o
favour NN o
of IN o
the DT o
routine JJ o
use NN o
of IN o
adjunctive JJ o
metronidazole JJ o
dental NN o
gel NN o
in IN N
the DT N
treatment NN N
of IN N
adult NN o
periodontitis NN o
. . o

-DOCSTART- -16882678- O O

Coenzyme NNP i
Q10 NNP i
and CC N
exercise NN N
training NN N
in IN N
chronic JJ p
heart NN p
failure NN p
. . p

AIMS NNP N
There EX N
is VBZ N
evidence NN N
that IN N
plasma NN N
coenzyme NN o
Q NNP o
( ( o
10 CD o
) ) o
( ( o
CoQ NNP o
( ( o
10 CD o
) ) o
) ) o
levels NNS o
decrease NN N
in IN N
patients NNS p
with IN p
advanced JJ p
chronic JJ p
heart NN p
failure NN p
( ( p
CHF NNP p
) ) p
. . p

However RB N
, , N
it PRP N
is VBZ N
not RB N
known VBN N
whether IN N
oral JJ N
CoQ NNP i
( ( i
10 CD i
) ) i
supplementation NN N
may MD N
improve VB N
cardiocirculatory NN o
efficiency NN o
and CC o
endothelial JJ o
function NN o
in IN N
patients NNS p
with IN p
CHF NNP p
. . p

METHODS NNP N
AND CC N
RESULTS NNP N
We PRP N
studied VBD N
23 CD p
patients NNS p
in IN p
NYHA NNP p
class NN p
II NNP p
and CC p
III NNP p
( ( p
20 CD p
men NNS p
, , p
three CD p
women NNS p
, , p
mean JJ p
age NN p
59+/-9 CD p
years NNS p
) ) p
with IN p
stable JJ p
CHF NNP p
secondary JJ p
to TO p
ischaemic VB p
heart NN p
disease NN p
[ NNP p
ejection NN p
fraction NN p
37+/-7 CD p
% NN p
] NN p
, , N
using VBG N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ N
cross-over NN N
design NN N
. . N

Patients NNS p
were VBD N
assigned VBN N
to TO N
each DT N
of IN N
the DT N
following JJ N
treatments NNS N
: : N
oral JJ i
CoQ NNP i
( ( i
10 CD i
) ) i
( ( i
100 CD i
mg RB i
tid NN i
) ) i
, , i
CoQ NNP i
( ( i
10 CD i
) ) i
plus CC i
supervised JJ i
exercise NN i
training NN i
( ( i
ET NNP i
) ) i
( ( N
60 CD N
% NN N
of IN N
peak NN N
VO NNP N
( ( N
2 CD N
) ) N
, , N
five CD N
times NNS N
a DT N
week NN N
) ) N
, , N
placebo NN i
, , i
and CC i
placebo NN i
plus CC i
ET NNP i
. . i

Each DT N
phase NN N
lasted VBD N
4 CD N
weeks NNS N
. . N

Both DT N
peak JJ o
VO NNP o
( ( o
2 CD o
) ) o
and CC o
endothelium-dependent JJ o
dilation NN o
of IN o
the DT o
brachial JJ o
artery NN o
( ( o
EDDBA NNP o
) ) o
improved VBD N
significantly RB N
after IN N
CoQ NNP i
( ( i
10 CD i
) ) i
and CC N
after IN N
ET NNP i
as IN N
compared VBN N
with IN N
placebo NN i
. . i

CoQ NNP i
( ( i
10 CD i
) ) i
main JJ N
effect NN N
was VBD N
: : N
peak NN o
VO NNP o
( ( o
2 CD o
) ) o
+9 CD o
% NN o
, , o
EDDBA NNP o
+38 NNP N
% NN N
, , N
systolic JJ o
wall NN o
thickening VBG o
score NN o
index NN o
( ( o
SWTI NNP o
) ) o
-12 CD N
% NN N
; : N
ET NNP i
produced VBD N
comparable JJ N
effects NNS N
. . N

CoQ NNP i
( ( i
10 CD i
) ) i
supplementation NN N
resulted VBD N
in IN N
a DT N
four-fold JJ N
increase NN N
in IN N
plasma JJ o
CoQ NNP o
( ( o
10 CD o
) ) o
level NN o
, , N
whereas IN N
the DT N
combination NN N
with IN N
ET NNP i
further RB N
increased VBD N
it PRP N
. . N

No DT N
side NN N
effects NNS N
were VBD N
reported VBN N
with IN N
CoQ NNP i
( ( i
10 CD i
) ) i
. . i

CONCLUSIONS NNP N
Oral NNP i
CoQ NNP i
( ( i
10 CD i
) ) i
improves VBZ N
functional JJ o
capacity NN o
, , o
endothelial JJ o
function NN o
, , o
and CC o
LV NNP o
contractility NN o
in IN N
CHF NNP N
without IN N
any DT N
side NN o
effects NNS o
. . o

The DT N
combination NN N
of IN N
CoQ NNP i
( ( i
10 CD i
) ) i
and CC N
ET NNP i
resulted VBD N
in IN N
higher JJR N
plasma NN o
CoQ NNP o
( ( o
10 CD o
) ) o
levels NNS o
and CC N
more JJR N
pronounced JJ N
effects NNS N
on IN N
all PDT N
the DT N
abovementioned JJ N
parameters NNS N
. . N

However RB N
, , N
significant JJ N
synergistic JJ N
effect NN N
of IN N
CoQ NNP i
( ( i
10 CD i
) ) i
with IN N
ET NNP i
was VBD N
observed VBN N
only RB N
for IN N
peak NN N
SWTI NNP o
suggesting VBG N
that IN N
ET NNP i
amplifies VBZ N
the DT N
already RB N
described JJ N
effect NN N
of IN N
CoQ NNP i
( ( i
10 CD i
) ) i
on IN N
contractility NN o
of IN o
dysfunctional JJ o
myocardium NN o
. . o

-DOCSTART- -12635578- O O

The DT N
effect NN N
of IN N
topical JJ N
nasal NN N
fluticasone NN i
on IN N
objective JJ o
sleep NN o
testing NN o
and CC N
the DT N
symptoms NNS o
of IN o
rhinitis NN o
, , o
sleep NN o
, , o
and CC o
daytime JJ o
somnolence NN o
in IN N
perennial JJ p
allergic JJ p
rhinitis NN p
. . p

Recent NNP N
data NN N
suggested VBD N
that IN N
daytime JJ N
somnolence NN N
in IN N
patients NNS p
with IN p
allergic JJ p
rhinitis NN p
was VBD N
secondary JJ N
to TO N
disrupted VBN o
sleep NN o
caused VBN N
by IN N
nasal JJ N
congestion NN N
. . N

Medications NNS N
, , N
which WDT N
decreased VBD N
congestion NN N
, , N
would MD N
be VB N
expected VBN N
to TO N
improve VB N
sleep NN o
and CC o
daytime JJ o
somnolence NN o
. . o

Previously RB N
, , N
we PRP N
showed VBD N
that IN N
nasal JJ N
steroids NNS N
improved VBD N
all DT N
three CD N
symptoms NNS N
. . N

Presently RB N
, , N
we PRP N
have VBP N
not RB N
performed VBN N
objective JJ N
sleep NN N
testing VBG N
to TO N
determine VB N
if IN N
there EX N
is VBZ N
a DT N
correlation NN N
between IN N
subjective JJ N
improvement NN o
of IN o
congestion NN o
, , o
sleep NN o
, , o
and CC o
daytime JJ o
somnolence NN o
. . o

The DT N
objective NN N
of IN N
this DT N
8-week JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
study NN N
was VBD N
to TO N
determine VB N
if IN N
topical JJ N
nasal NN N
fluticasone NN i
is VBZ N
effective JJ N
at IN N
decreasing VBG N
subjective JJ o
congestion NN o
and CC o
daytime JJ o
somnolence NN o
and CC o
improving VBG o
sleep NN o
and CC N
if IN N
this DT N
improvement NN N
correlated VBD N
with IN N
a DT N
change NN N
in IN N
overnight JJ o
sleep NN o
testing NN o
( ( o
polysomnography NN o
) ) o
. . o

We PRP N
recruited VBD N
32 CD p
subjects NNS p
with IN p
perennial JJ p
allergic JJ p
rhinitis NN p
and CC p
randomized VBD p
them PRP p
in IN p
a DT p
double-blinded JJ p
, , p
cross-over JJ p
fashion NN p
, , N
to TO N
receive VB N
placebo NN i
or CC i
fluticasone NN i
( ( N
50 CD N
micrograms NNS N
a DT N
spray NN N
) ) N
, , N
2 CD N
sprays NNS N
each DT N
side NN N
everyday RB N
, , N
using VBG N
Balaam NNP N
's POS N
design NN N
. . N

Questionnaires NNS o
, , o
quality NN o
of IN o
life NN o
instruments NNS o
, , o
daily JJ o
diary NN o
, , o
Epworth NNP o
Sleepiness NNP o
Scale NNP o
, , o
and CC o
an DT o
overnight JJ o
sleep JJ o
test NN o
with IN o
polysomnograms NNS o
were VBD N
used VBN N
as IN N
tools NNS N
. . N

The DT N
last JJ N
2 CD N
weeks NNS N
of IN N
each DT N
4-week JJ N
treatment NN N
period NN N
were VBD N
summarized VBN N
, , N
scored VBN N
, , N
and CC N
compared VBN N
by IN N
PROC NNP N
MIXED NNP N
in IN N
SAS NNP N
. . N

Correlations NNS N
between IN N
arousals NNS N
on IN N
sleep NN o
tests NNS o
and CC o
subjective JJ o
tests NNS o
were VBD N
performed VBN N
. . N

Fluticasone CD N
improved JJ N
subjective JJ o
sleep NN o
when WRB N
compared VBN N
with IN N
placebo NN N
( ( N
p JJ N
= NNP N
0.04 CD N
) ) N
; : N
however RB N
, , N
there EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
apnea/hypopnea NN o
index NN o
in IN N
those DT N
that WDT N
were VBD N
treated VBN N
. . N

Daytime NNP o
sleepiness NN o
and CC o
fatigue NN o
were VBD N
decreased VBN N
by IN N
> JJ N
10 CD N
% NN N
in IN N
the DT N
treated JJ N
group NN N
; : N
however RB N
, , N
this DT N
was VBD N
not RB N
statistically RB N
significant JJ N
. . N

However RB N
, , N
fluticasone NN N
used VBN N
at IN N
approved JJ N
doses NNS N
improves VBZ N
subjective JJ o
sleep NN o
in IN N
patients NNS p
with IN p
perennial JJ p
allergic JJ p
rhinitis NN p
without IN N
a DT N
change NN N
in IN N
the DT N
apnea/hypopnea NN N
index NN N
. . N

-DOCSTART- -19139601- O O

Principal JJ N
results NNS N
of IN N
the DT N
Japanese JJ p
trial NN N
to TO N
assess VB N
optimal JJ N
systolic JJ N
blood NN N
pressure NN N
in IN N
elderly JJ p
hypertensive JJ p
patients NNS p
( ( p
JATOS NNP p
) ) p
. . N

The DT N
benefits NNS N
of IN N
lowering VBG N
a DT N
systolic JJ N
blood NN N
pressure NN N
below IN N
140 CD N
mmHg NN N
in IN N
elderly JJ p
hypertension NN p
remain VBP N
controversial JJ N
. . N

This DT N
study NN N
is VBZ N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
open-label JJ N
study NN N
with IN N
blinded JJ N
assessment NN N
of IN N
endpoints NNS N
to TO N
compare VB N
the DT N
2-year JJ N
effect NN N
of IN N
strict JJ i
treatment NN i
to TO i
maintain VB i
systolic JJ i
blood NN i
pressure NN i
below IN N
140 CD N
mmHg NN N
with IN N
that DT N
of IN N
mild JJ i
treatment NN i
to TO i
maintain VB i
systolic JJ i
blood NN i
pressure NN i
below IN N
160 CD N
but CC N
at IN N
or CC N
above IN N
140 CD N
mmHg NN N
in IN N
elderly JJ p
hypertensive JJ p
patients NNS p
. . p

Patients NNS p
with IN p
essential JJ p
hypertension NN p
( ( p
65-85 CD p
years NNS p
old JJ p
, , p
with IN p
a DT p
pretreatment JJ p
systolic JJ p
blood NN p
pressure NN p
of IN p
above IN p
160 CD p
mmHg NNS p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
strict JJ i
treatment NN i
( ( i
n=2,212 JJ i
) ) i
or CC i
mild JJ i
treatment NN i
( ( i
n=2,206 JJ i
) ) i
. . N

The DT N
baseline JJ N
drug NN N
was VBD N
efonidipine JJ i
hydrochloride NN i
, , i
a DT i
long-acting JJ i
calcium NN i
antagonist NN i
. . i

The DT N
primary JJ N
endpoint NN N
was VBD N
the DT N
combined JJ o
incidence NN o
of IN o
cardiovascular JJ o
disease NN o
and CC o
renal JJ o
failure NN o
, , N
and CC N
the DT N
secondary JJ N
endpoints NNS N
were VBD N
total JJ o
deaths NNS o
and CC o
any DT o
safety NN o
problems NNS o
. . o

Although IN N
final JJ N
blood NN o
pressures NNS o
( ( o
systolic/diastolic JJ o
) ) o
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
strict-treatment JJ N
group NN N
compared VBN N
with IN N
the DT N
mild-treatment JJ N
group NN N
( ( N
135.9/74.8 CD N
vs. FW N
145.6/78.1 CD N
mmHg NN N
; : N
p CC N
< VB N
0.001 CD N
) ) N
, , N
the DT N
incidence NN N
of IN N
the DT N
primary JJ N
endpoint NN N
was VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
( ( N
86 CD N
patients NNS N
in IN N
each DT N
group NN N
; : N
p=0.99 NN N
) ) N
. . N

Total JJ N
deaths NNS o
were VBD N
54 CD p
in IN p
the DT p
strict-treatment JJ p
group NN p
vs. FW p
42 CD p
in IN p
the DT p
mild-treatment JJ p
group NN p
( ( p
p=0.22 NN p
) ) p
, , p
and CC p
treatment NN p
was VBD p
withdrawn VBN p
because IN p
of IN p
adverse JJ p
events NNS p
in IN p
36 CD p
patients NNS p
in IN p
each DT p
group NN p
( ( p
p=0.99 NN p
) ) p
. . p

An DT N
interaction NN N
between IN N
age NN N
and CC N
treatment NN N
for IN N
the DT N
primary JJ N
endpoints NNS N
( ( N
p=0.03 NN N
) ) N
was VBD N
seen VBN N
. . N

Complex NNP N
clinical JJ N
features NNS N
associated VBN N
with IN N
aging VBG N
seem VBP N
to TO N
have VB N
obscured VBN N
the DT N
difference NN N
in IN N
effect NN N
between IN N
the DT N
two CD N
treatments NNS N
. . N

Further JJ N
studies NNS N
are VBP N
needed VBN N
to TO N
assess VB N
the DT N
optimal JJ N
treatment NN N
strategy NN N
for IN N
hypertension NN p
in IN p
the DT p
elderly JJ p
. . p

-DOCSTART- -11595000- O O

Safety NN N
and CC N
efficacy NN N
of IN N
PNU-142633 NNP i
, , i
a DT i
selective JJ i
5-HT1D JJ i
agonist NN i
, , N
in IN N
patients NNS p
with IN p
acute JJ p
migraine NN p
. . p

In IN N
this DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
parallel-group JJ N
study NN N
, , N
patients NNS p
received VBD N
a DT N
single JJ N
50-mg JJ i
oral JJ i
dose NN i
of IN i
a DT i
5-HT JJ i
( ( i
1D CD i
) ) i
agonist NN i
, , i
PNU-142633 NNP i
( ( i
n JJ i
= NNP i
34 CD i
) ) i
, , i
or CC i
matching VBG i
placebo NN i
( ( N
n JJ N
= NNP N
35 CD N
) ) N
during IN N
an DT N
acute JJ p
migraine NN p
attack NN p
. . p

No DT N
statistically RB N
significant JJ N
treatment NN N
effects NNS N
were VBD N
observed VBN N
at IN N
1 CD N
and CC N
2 CD N
h NN N
after IN N
dosing VBG N
, , N
even RB N
after IN N
stratifying VBG N
by IN N
baseline NN N
headache NN N
intensity NN N
. . N

At IN N
1 CD N
and CC N
2 CD N
h NN N
post-dose JJ N
, , N
8.8 CD N
% NN N
and CC N
29.4 CD N
% NN N
of IN N
the DT N
PNU-142633 NNP i
group NN N
, , N
respectively RB N
, , N
and CC N
8.6 CD N
% NN N
and CC N
40.0 CD N
% NN N
of IN N
the DT N
placebo NN i
group NN N
, , N
respectively RB N
, , N
experienced VBD N
headache NN o
relief NN o
; : o
2.9 CD N
% NN N
and CC N
8.8 CD N
% NN N
of IN N
the DT N
PNU-142633 NNP i
group NN N
and CC N
0 CD N
% NN N
and CC N
5.7 CD N
% NN N
of IN N
the DT N
placebo NN i
group NN N
were VBD N
free JJ o
of IN o
headache NN o
pain NN o
. . o

Adverse JJ o
events NNS o
associated VBN N
with IN N
PNU-142633 NNP i
treatment NN N
included VBD N
chest JJS o
pain NN o
( ( N
two CD N
patients NNS N
) ) N
and CC N
QTc NNP o
prolongation NN o
( ( N
three CD N
patients NNS N
) ) N
. . N

Results NNS N
from IN N
this DT N
study NN N
suggest VBP N
that IN N
anti-migraine JJ N
efficacy NN N
is VBZ N
not RB N
mediated VBN N
solely RB N
through IN N
the DT N
5-HT JJ i
( ( i
1D CD i
) ) i
receptor NN N
subtype NN N
, , N
although IN N
this DT N
receptor NN N
may MD N
contribute VB N
, , N
at IN N
least JJS N
in IN N
part NN N
, , N
to TO N
the DT N
adverse JJ N
cardiovascular JJ N
effects NNS N
observed VBN N
with IN N
5-HT JJ i
agonist JJ i
medications NNS N
. . N

-DOCSTART- -16145415- O O

A DT N
hybrid NN i
technique NN i
using VBG i
bipolar JJ i
energy NN i
in IN i
transurethral JJ i
prostate NN i
surgery NN i
: : i
a DT N
prospective JJ N
, , N
randomized JJ N
comparison NN N
. . N

PURPOSE NNP N
We PRP N
assessed VBD N
the DT N
efficacy NN o
and CC N
safety NN o
of IN N
transurethral JJ i
resection NN i
and CC i
vaporization NN i
with IN i
bipolar JJ i
PlasmaKinetic NNP i
energy NN i
. . i

MATERIALS NNP N
AND CC N
METHODS NNP N
During IN N
a DT N
2-year JJ N
period NN N
101 CD p
men NNS p
with IN p
benign JJ p
prostatic JJ p
hyperplasia NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
PlasmaKinetic NNP i
surgery NN i
or CC i
standard JJ i
transurethral JJ i
prostate NN i
resection NN i
( ( i
TURP NNP i
) ) i
. . i

Patient JJ N
demographics NNS N
, , N
indications NNS N
for IN N
surgery NN N
, , N
preoperative JJ N
and CC N
postoperative JJ N
International NNP N
Prostate NNP N
Symptom NNP N
Score NNP N
, , N
uroflowmetry NN o
scores NNS o
, , o
operative JJ o
time NN o
, , o
catheterization NN o
duration NN o
, , o
hospital NN o
stay NN o
and CC N
complication NN o
rates NNS o
were VBD N
compared VBN N
. . N

RESULTS NNP N
Complete NNP N
data NNS N
on IN N
96 CD p
patients NNS p
with IN p
a DT p
mean JJ p
age NN p
+/- JJ p
SD NNP p
of IN p
69.1 CD p
+/- JJ p
6.1 CD p
years NNS p
was VBD p
available JJ p
at IN N
a DT N
mean JJ N
followup NN N
of IN N
18.3 CD N
+/- JJ N
6.7 CD N
months NNS N
( ( N
range VB N
12 CD N
to TO N
23 CD N
) ) N
. . N

In IN N
the DT N
PlasmaKinetic NNP N
and CC N
TURP NNP N
groups NNS N
mean VBP o
operative JJ o
time NN o
was VBD N
40.3 CD N
+/- JJ N
11.4 CD N
( ( N
range NN N
30 CD N
to TO N
60 CD N
) ) N
and CC N
57.8 CD N
+/- JJ N
13.4 CD N
minutes NNS N
( ( N
range VB N
45 CD N
to TO N
75 CD N
) ) N
, , N
respectively RB N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
mean JJ o
volume NN o
of IN o
saline JJ o
irrigation NN o
during IN o
the DT o
PlasmaKinetic JJ o
procedure NN o
was VBD N
significantly RB N
lower JJR N
than IN N
that DT N
of IN N
hyperosmolar JJ N
solution NN N
irrigation NN N
during IN N
TURP NNP N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Patients NNS N
in IN N
the DT N
PlasmaKinetic NNP N
and CC N
TURP NNP N
groups NNS N
were VBD N
catheterized VBN N
a DT N
mean NN N
of IN N
2.3 CD N
+/- JJ N
0.7 CD N
( ( N
range NN N
2 CD N
to TO N
4 CD N
) ) N
and CC N
3.8 CD N
+/- JJ N
0.7 CD N
days NNS N
( ( N
range VB N
3 CD N
to TO N
5 CD N
) ) N
, , N
respectively RB N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
mean JJ o
improvement NN o
rate NN o
from IN N
baseline NN N
at IN N
month NN N
12 CD N
in IN N
International NNP o
Prostate NNP o
Symptom NNP o
Score NNP o
and CC o
the DT o
maximal JJ o
urinary JJ o
flow NN o
rate NN o
was VBD N
similar JJ N
in IN N
the DT N
2 CD N
groups NNS N
. . N

Severe NNP o
irritative JJ o
symptoms NNS o
were VBD N
the DT N
most RBS N
common JJ N
complaints NNS N
after IN N
PlasmaKinetic JJ N
surgery NN N
, , N
as IN N
observed VBN N
in IN N
6 CD N
cases NNS N
( ( N
12.2 CD N
% NN N
) ) N
. . N

Recatheterization NN o
was VBD N
necessary JJ N
in IN N
3 CD N
cases NNS N
( ( N
6.1 CD N
% NN N
) ) N
cases NNS N
in IN N
the DT N
PlasmaKinetic NNP N
group NN N
and CC N
in IN N
1 CD N
( ( N
2.1 CD N
% NN N
) ) N
in IN N
the DT N
TURP NNP N
group NN N
. . N

During IN N
followup JJ N
urethral JJ o
stricture NN o
formation NN o
was VBD N
observed VBN N
in IN N
3 CD N
patients NNS N
( ( N
6.1 CD N
% NN N
) ) N
cases NNS N
in IN N
the DT N
former JJ N
group NN N
and CC N
in IN N
1 CD N
( ( N
2.1 CD N
% NN N
) ) N
in IN N
the DT N
latter JJ N
group NN N
( ( N
p JJ N
= NNP N
0.002 CD N
) ) N
. . N

Reoperation NN o
was VBD N
required VBN N
in IN N
2 CD N
( ( N
4.1 CD N
% NN N
) ) N
and CC N
1 CD N
( ( N
2.1 CD N
% NN N
) ) N
cases NNS N
in IN N
the DT N
PlasmaKinetic NNP N
and CC N
TURP NNP N
groups NNS N
, , N
respectively RB N
. . N

CONCLUSIONS NN N
: : N
Transurethral JJ N
surgery NN N
with IN N
PlasmaKinetic NNP N
bipolar NN N
energy NN N
seems VBZ N
to TO N
be VB N
a DT N
promising JJ N
alternative NN N
to TO N
prostatic JJ N
tissue NN N
removal NN N
with IN N
shorter RBR N
operative JJ o
, , o
catheterization NN o
and CC o
hospitalization NN o
times NNS o
, , N
although IN N
increased VBN N
rates NNS N
of IN N
postoperative JJ o
irritative NN o
symptoms NNS o
and CC N
urethral JJ o
stricture NN o
formation NN o
must MD N
be VB N
further RB N
evaluated VBN N
. . N

-DOCSTART- -22987106- O O

Junctional NNP o
ectopic NN o
tachycardia NN o
after IN N
congenital JJ N
heart NN N
surgery NN N
in IN N
the DT N
current JJ N
surgical JJ N
era NN N
. . N

To TO N
determine VB N
the DT N
incidence NN N
of IN N
postoperative JJ o
junctional JJ o
ectopic NN o
tachycardia NN o
( ( o
JET NNP o
) ) o
in IN N
a DT N
modern JJ p
cohort NN p
of IN p
pediatric JJ p
patients NNS p
, , N
evaluate VBP N
possible JJ N
risk NN o
factors NNS o
for IN o
JET NNP o
, , N
and CC N
examine VB N
the DT N
effects NNS o
of IN o
JET NNP o
on IN N
postoperative JJ o
morbidity NN o
and CC o
mortality NN o
. . o

JET NN N
is VBZ N
common JJ N
after IN N
congenital JJ N
heart NN N
surgery NN N
. . N

JET-related JJ N
mortality NN N
has VBZ N
been VBN N
a DT N
rare JJ N
event NN N
at IN N
our PRP$ N
center NN N
, , N
which WDT N
is VBZ N
different JJ N
from IN N
previous JJ N
reports NNS N
. . N

We PRP N
reviewed VBD N
records NNS N
for IN N
pediatric JJ p
patients NNS p
who WP p
had VBD p
postoperative JJ p
arrhythmias NN p
between IN p
January NNP p
2006 CD p
and CC p
June NNP p
2010 CD p
at IN p
a DT p
large JJ p
tertiary-care JJ p
children NNS p
's POS p
hospital NN p
. . p

We PRP N
performed VBD N
a DT N
matched VBN N
case-control NN N
study NN N
to TO N
identify VB N
risk NN N
factors NNS N
for IN N
JET NNP N
and CC N
a DT N
matched-cohort NN N
study NN N
to TO N
compare VB N
outcomes NNS N
between IN N
patients NNS N
and CC N
controls NNS N
. . N

Whenever NNP N
possible JJ N
, , N
each DT N
JET NNP N
case NN N
was VBD N
randomly RB N
matched VBN N
to TO N
two CD N
controls NNS N
on IN N
the DT N
basis NN N
of IN N
lesion NN N
, , N
repair NN N
, , N
and CC N
surgical JJ N
period NN N
. . N

We PRP N
identified VBD N
54 CD p
patients NNS p
with IN p
JET NNP p
( ( N
incidence NN N
= RB N
1.4 CD N
% NN N
) ) N
. . N

After IN N
multivariate JJ N
logistic JJ N
regression NN N
analysis NN N
, , N
low JJ o
operative JJ o
weight NN o
, , o
cardiopulmonary JJ o
bypass NN o
( ( o
CPB NNP o
) ) o
duration NN o
> $ N
100 CD N
min NN N
, , N
and CC N
immediate JJ o
postoperative JJ o
serum NN o
lactic JJ o
acid NN o
level NN o
> VBD N
20 CD N
mg/dl NNS N
were VBD N
associated VBN N
with IN N
increased JJ N
odds NNS N
of IN N
developing VBG N
JET NNP N
. . N

Patients NNS p
with IN p
JET NNP i
had VBD N
longer RBR N
mechanical JJ o
ventilation NN o
time NN o
, , o
cardiac JJ o
intensive JJ o
care NN o
unit NN o
( ( o
CICU NNP o
) ) o
stay NN o
, , o
and CC o
hospital NN o
stay NN o
. . o

There EX N
was VBD N
only RB N
one CD N
death NN o
in IN N
JET NNP N
group NN N
( ( N
1.8 CD N
% NN N
) ) N
with IN N
no DT N
significant JJ N
difference NN N
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

JET NNP N
remains VBZ N
a DT N
relatively RB N
common JJ N
postoperative JJ o
arrhythmia NN o
, , N
but CC N
it PRP N
is VBZ N
less RBR N
frequent JJ N
than IN N
previously RB N
reported VBN N
. . N

JET NNP N
occurs VBZ N
more JJR N
commonly RB N
in IN N
smaller JJR p
patients NNS p
with IN p
longer JJR p
CPB NNP p
runs NNS N
and CC N
significant JJ N
postoperative JJ o
lactic JJ o
acidosis NN o
levels NNS o
. . o

Mortality NNP o
associated VBD N
with IN N
JET NNP N
is VBZ N
lower JJR N
than IN N
historically RB N
reported VBN N
, , N
but CC N
morbidity NN o
remains VBZ N
high JJ N
. . N

-DOCSTART- -10408075- O O

[ JJ N
Validity NNP N
of IN N
cardiotocography NN i
in IN N
the DT N
detection NN N
of IN N
umbilical JJ o
cord NN o
complications NNS o
] VBP o
. . N

OBJECTIVE CC N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
validity NN N
of IN N
cardiotocography NN i
for IN N
the DT N
detection NN N
of IN N
cord NN o
complications NNS o
. . o

MATERIAL NNP N
AND NNP N
METHODS NNP N
A NNP p
low-risk JJ p
population NN p
of IN p
4196 CD p
cases NNS p
was VBD p
selected VBN p
in IN p
which WDT p
cord NN p
complications NNS p
have VBP p
been VBN p
recognized VBN p
in IN p
34.3 CD p
% NN p
. . p

Cases VBZ p
with IN p
cord NN p
complications NNS p
and CC p
controls NNS p
were VBD p
paired VBN p
by IN N
parity NN N
, , N
gestational JJ N
age NN N
, , N
maternal JJ N
age NN N
and CC N
mode NN N
of IN N
delivery NN N
. . N

25 CD p
pairs NNS p
were VBD p
randomly RB p
selected VBN p
. . p

50 CD N
tracings NNS N
were VBD N
presented VBN N
twice RB N
to TO N
4 CD N
obstetricians NNS N
in IN N
a DT N
double-blind JJ N
manner NN N
. . N

As IN N
parameters NNS N
for IN N
the DT N
determination NN N
of IN N
the DT N
validity NN N
of IN N
fetal JJ N
monitoring VBG N
the DT N
reliability NN N
, , N
positive JJ N
( ( N
ppv NN N
) ) N
and CC N
negative JJ N
predictive JJ N
value NN N
( ( N
npv JJ N
) ) N
, , N
sensitivity NN N
and CC N
specificity NN N
were VBD N
used VBN N
. . N

Inter- JJ N
and CC N
intra-observer JJ N
variability NN N
were VBD N
also RB N
examined VBN N
. . N

RESULTS NNP N
Reliability NNP o
52 CD N
% NN N
, , N
ppv RB o
52 CD N
% NN N
, , N
npv RB o
52 CD N
% NN N
, , N
sensitivity NN o
46 CD N
% NN N
, , N
specificity NN o
58 CD N
% NN N
. . N

Interobserver NNP N
variability NN N
: : N
All DT N
4 CD N
obstetricians NNS N
agreed VBD N
in IN N
47 CD N
of IN N
100 CD N
evaluations NNS N
. . N

The DT N
level NN o
of IN o
agreement NN o
was VBD N
higher RBR N
in IN N
the DT N
controls NNS N
( ( N
63 CD N
% NN N
) ) N
than IN N
in IN N
the DT N
cord NN N
complication NN N
group NN N
( ( N
56 CD N
% NN N
) ) N
. . N

The DT N
intraobserver NN o
variability NN o
was VBD N
25 CD N
% NN N
. . N

CONCLUSIONS NNP N
Cardiotocography NNP i
is VBZ N
not RB N
useful JJ N
for IN N
the DT N
detection NN o
of IN o
cord NN o
complications NNS o
. . o

The DT N
range NN N
of IN N
possibilities NNS N
has VBZ N
not RB N
been VBN N
exploited VBN N
yet RB N
, , N
even RB N
for IN N
the DT N
evaluation NN N
of IN N
the DT N
fetal JJ N
state NN N
. . N

-DOCSTART- -9351400- O O

Dose-response NNP N
comparison NN N
of IN N
RRR-alpha-tocopherol NNP i
and CC i
all-racemic JJ i
alpha-tocopherol NN i
on IN N
LDL NNP p
oxidation NN p
. . p

Much JJ N
data NNS N
have VBP N
accrued VBN N
in IN N
support NN N
of IN N
the DT N
concept NN N
that IN N
oxidation NN N
of IN N
LDL NNP N
is VBZ N
a DT N
key JJ N
early JJ N
step NN N
in IN N
atherogenesis NN p
. . p

The DT N
most RBS N
consistent JJ N
data NNS N
with IN N
respect NN N
to TO N
micronutrient VB N
antioxidants NNS N
and CC N
atherosclerosis NN N
appear VBP N
to TO N
relate VB N
to TO N
alpha-tocopherol NN i
( ( N
AT NNP N
) ) N
, , N
the DT N
predominant JJ N
lipid-soluble JJ N
antioxidant NN N
in IN N
LDL NNP N
. . N

There EX N
are VBP N
scant JJ N
data NNS N
on IN N
the DT N
direct JJ N
comparison NN N
of IN N
RRR-AT NNP N
and CC N
all-racemic JJ N
( ( N
rac NN N
) ) N
-AT NN N
on IN N
LDL NNP N
oxidizability NN N
. . N

Hence NNP N
, , N
the DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
examine VB N
the DT N
relative JJ N
effects NNS N
of IN N
RRR-AT NNP N
and CC N
all-rac-AT NN N
on IN N
plasma NN N
antioxidant NN N
levels NNS N
and CC N
LDL NNP N
oxidation NN N
in IN N
healthy JJ p
persons NNS p
in IN N
a DT N
dose-response JJ N
study NN N
. . N

The DT N
effect NN N
of IN N
RRR-AT NNP i
and CC i
all-rac-AT NN i
at IN N
doses NNS N
of IN N
100 CD N
, , N
200 CD N
, , N
400 CD N
, , N
and CC N
800 CD N
IU/d NNP N
on IN N
plasma NN N
and CC N
LDL NNP N
AT NNP N
levels NNS N
and CC N
LDL NNP N
oxidation NN N
was VBD N
tested VBN N
in IN N
a DT N
randomized JJ N
, , N
placebo-controlled JJ N
study NN N
of IN N
79 CD p
healthy JJ p
subjects NNS p
. . p

Copper-catalyzed JJ N
oxidation NN N
of IN N
LDL NNP N
was VBD N
monitored VBN N
by IN N
measuring VBG N
the DT N
formation NN N
of IN N
conjugated JJ N
dienes NNS N
and CC N
lipid JJ N
peroxides NNS N
over IN N
an DT N
8-hour JJ N
time NN N
course NN N
at IN N
baseline NN N
and CC N
again RB N
after IN N
8 CD N
weeks NNS N
. . N

Plasma NNP N
AT NNP N
, , N
lipid-standardized JJ N
AT NNP N
, , N
and CC N
LDL NNP N
AT NNP N
levels NNS N
rose VBD N
in IN N
a DT N
dose-dependent JJ N
fashion NN N
in IN N
both DT N
the DT N
RRR-AT NNP N
and CC N
all-rac-AT JJ N
groups NNS N
compared VBN N
with IN N
baseline NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
plasma NN o
, , o
lipid-standardized JJ o
, , o
and CC o
LDL NNP o
AT NNP o
levels NNS o
between IN N
RRR-AT NNP N
and CC N
all-rac-AT JJ N
supplementation NN N
at IN N
any DT N
dose JJ N
comparison NN N
. . N

The DT N
lag NN o
phases NNS o
of IN o
oxidation NN o
were VBD N
significantly RB N
prolonged VBN N
with IN N
doses NNS N
> VBP N
or CC N
= VBP N
400 CD N
IU/d NNP N
of IN N
RRR-AT NNP N
and CC N
all-rac-AT JJ N
, , N
as IN N
measured VBN N
by IN N
conjugated-dienes NNS N
assay NNS N
and CC N
at IN N
400 CD N
IU/d NNP N
of IN N
RRR-AT NNP N
and CC N
800 CD N
IU/d NNP N
of IN N
both DT N
forms NNS N
of IN N
AT NNP N
by IN N
lipid JJ N
peroxide NN N
assay NN N
. . N

Again NNP N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
lag NN o
phase NN o
of IN o
oxidation NN o
at IN N
each DT N
dose NN N
for IN N
RRR-AT NNP N
when WRB N
compared VBN N
with IN N
all-rac-AT NN N
. . N

Also RB N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
LDL NNP o
oxidation NN o
after IN N
in IN N
vitro JJ N
enrichment NN N
of IN N
LDL NNP N
with IN N
RRR-AT NNP N
and CC N
all-rac-AT JJ N
. . N

Thus RB N
, , N
supplementation NN N
with IN N
either DT N
RRR-AT JJ N
or CC N
all-rac-AT JJ N
resulted VBN N
in IN N
similar JJ N
increases NNS N
in IN N
plasma NN N
and CC N
LDL NNP N
AT NNP N
levels NNS N
at IN N
equivalent JJ N
IU NNP N
doses NNS N
, , N
and CC N
the DT N
degree NN N
of IN N
protection NN N
against IN N
copper-catalyzed JJ N
LDL NNP N
oxidation NN N
was VBD N
only RB N
evident JJ N
at IN N
doses NNS N
> VBP N
or CC N
= VBP N
400 CD N
IU/d NNP N
for IN N
both DT N
forms NNS N
. . N

-DOCSTART- -2319047- O O

Methylphenidate NNP i
and CC N
baseball NN N
playing NN N
in IN N
ADHD NNP p
children NNS p
: : p
who WP N
's VBZ N
on IN N
first JJ N
? . N
The DT N
effects NNS N
of IN N
0.3 CD i
and CC i
0.6 CD i
mg/kg NN i
methylphenidate NN i
were VBD N
analyzed VBN N
in IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
cross-over JJ N
study NN N
in IN N
which WDT N
17 CD p
boys NNS p
( ( p
ages IN p
7.8-9.9 CD p
years NNS p
) ) p
with IN p
attention NN p
deficit NN p
hyperactivity NN p
disorder NN p
( ( p
ADHD NNP p
) ) p
played VBD N
in IN N
baseball NN N
games NNS N
. . N

Drug JJ N
effects NNS N
were VBD N
evaluated VBN N
on IN N
children NNS N
's POS N
attention NN o
during IN o
the DT o
game NN o
, , N
as IN N
indicated VBN N
by IN N
their PRP$ N
on-task JJ N
behavior NN N
on IN N
the DT N
field NN N
and CC N
their PRP$ N
ability NN o
to TO o
answer VB o
questions NNS o
about IN N
the DT N
status NN N
of IN N
the DT N
game NN N
at IN N
all DT N
times NNS N
. . N

Judgment NN o
during IN o
batting NN o
, , o
batting VBG o
skill NN o
during IN o
the DT o
game NN o
, , o
and CC o
performance NN o
on IN o
skill NN o
drills NNS o
prior RB o
to TO o
the DT o
game NN o
were VBD N
also RB N
assessed VBN N
as IN N
a DT N
function NN N
of IN N
medication NN N
. . N

Results NNS N
revealed VBD N
that IN N
methylphenidate NN i
had VBD N
a DT N
beneficial JJ N
effect NN N
on IN N
attending VBG N
during IN N
the DT N
game NN N
. . N

-DOCSTART- -18093356- O O

Can MD N
analysis NN N
of IN N
the DT N
bispectral JJ N
index NN N
prove VB N
helpful JJ N
when WRB N
monitoring VBG N
titration NN N
of IN N
doses NNS N
of IN N
midazolam NN i
and CC N
ketamine NN i
for IN N
sedation NN N
during IN N
paediatric JJ o
cardiac JJ o
catheterization NN o
. . o

OBJECTIVE IN N
We PRP N
investigated VBD N
the DT N
use NN N
of IN N
the DT N
bispectral JJ i
index NN i
for IN N
monitoring VBG N
sedation NN i
during IN N
cardiac JJ o
catheterization NN o
. . o

The DT N
scores NNS N
for IN N
the DT N
bispectral JJ N
index NN N
may MD N
not RB N
reflect VB N
correct JJ N
values NNS N
in IN N
children NNS N
, , N
but CC N
may MD N
be VB N
helpful JJ N
during IN N
titration NN N
of IN N
sedatives NNS N
such JJ N
as IN N
midazolam NN i
and CC i
ketamine NN i
. . i

METHODS NNP N
We PRP N
conducted VBD N
a DT N
prospective JJ N
randomized VBN N
clinical JJ N
trial NN N
in IN N
126 CD p
patients NNS p
scheduled VBN p
for IN p
cardiac JJ p
catheterization NN p
in IN p
a DT p
teaching JJ p
hospital NN p
. . p

They PRP p
ranged VBD p
in IN p
age NN p
from IN p
4 CD p
months NNS p
to TO p
15 CD p
years NNS p
. . p

In IN N
66 CD N
patients NNS N
, , N
sedation NN i
was VBD N
performed VBN N
without IN i
use NN i
of IN i
the DT i
bispectral JJ i
index NN i
, , i
while IN i
the DT i
index NN i
was VBD i
used VBN i
in IN i
the DT i
other JJ i
60 CD N
patients NNS N
. . N

The DT N
data NN N
collected VBD N
included JJ N
heart NN N
rate NN N
, , N
mean VBP N
arterial JJ N
pressure NN N
, , N
respiratory NN N
rate NN N
, , N
saturation NN N
of IN N
oxygen NN N
, , N
amount NN N
of IN N
sedatives NNS N
, , N
awakening VBG N
time NN N
and CC N
adverse JJ N
effects NNS N
. . N

We PRP N
subdivided VBD N
the DT N
patients NNS N
into IN N
age-related JJ N
groups NNS N
for IN N
each DT N
parameter NN N
. . N

RESULTS VB N
The DT N
demographic JJ N
data NNS N
were VBD N
not RB N
statistically RB N
different JJ N
. . N

Monitoring VBG N
with IN N
the DT N
bispectral JJ N
index NN N
in IN N
those DT N
aged VBN N
from IN N
1 CD N
to TO N
3 CD N
years NNS N
revealed VBD N
use NN N
of IN N
lower JJR N
doses NNS N
of IN N
midazolam NN N
, , N
at IN N
2.09 CD N
mg NNS N
per IN N
kg NN N
per IN N
hr NN N
, , N
with IN N
standard JJ N
deviation NN N
of IN N
0.36 CD N
, , N
and CC N
similarly RB N
lowers NNS N
doses NNS N
of IN N
ketamine NN N
, , N
at IN N
2.07 CD N
mg NNS N
per IN N
kg NN N
per IN N
hr NN N
, , N
with IN N
standard JJ N
deviation NN N
of IN N
0.22 CD N
, , N
the DT N
values NNS N
in IN N
those DT N
not RB N
monitored VBN N
being VBG N
2.93 CD N
, , N
with IN N
standard JJ N
deviation NN N
of IN N
0.45 CD N
, , N
and CC N
2.96 CD N
with IN N
standard JJ N
deviation NN N
of IN N
0.51 CD N
respectively RB N
, , N
these DT N
difference NN N
being VBG N
statistically RB N
significant JJ N
( ( N
p JJ N
= NN N
0.001 CD N
and CC N
p VB N
= JJ N
0.04 CD N
, , N
respectively RB N
) ) N
. . N

In IN N
those DT N
aged VBN p
from IN p
3 CD p
to TO p
6 CD p
years NNS p
of IN p
age NN p
, , N
dosage NN N
of IN N
midazolam NN N
was VBD N
2.09 CD N
, , N
with IN N
deviation NN N
of IN N
0.36 CD N
, , N
and CC N
of IN N
ketamine NN N
1.78 CD N
, , N
with IN N
deviation NN N
of IN N
0.27 CD N
, , N
following VBG N
use NN N
of IN N
the DT N
bispectral JJ N
index NN N
, , N
compared VBN N
to TO N
2.89 CD N
with IN N
deviation NN N
of IN N
0.28 CD N
, , N
and CC N
2.62 CD N
with IN N
deviation NN N
of IN N
0.69 CD N
respectively RB N
, , N
when WRB N
the DT N
bispectral JJ N
index NN N
was VBD N
not RB N
used VBN N
, , N
these DT N
again RB N
being VBG N
significant JJ N
differences NNS N
( ( N
p JJ N
= NN N
0.033 CD N
and CC N
p VB N
= NNP N
0.04 CD N
) ) N
. . N

The DT o
requirements NNS o
for IN o
respiratory JJ o
support NN o
and CC o
adverse JJ o
effects NNS o
were VBD N
also RB N
significantly RB N
lower JJR N
when WRB N
using VBG N
the DT N
bispectral JJ N
index NN N
( ( N
p IN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
found VBN N
regarding VBG N
dosages NNS N
at IN N
the DT N
ages NNS N
of IN N
4 CD N
months NNS N
to TO N
1 CD N
year NN N
, , N
and CC N
6 CD N
to TO N
15 CD N
years NNS N
. . N

The DT o
awakening JJ o
time NN o
, , N
however RB N
, , N
was VBD N
shorter NN N
with IN N
use NN N
of IN N
the DT N
index NN N
in IN N
those DT N
aged VBN N
from IN N
1 CD N
to TO N
6 CD N
years NNS N
. . N

CONCLUSIONS NN N
When WRB N
using VBG N
the DT N
bispectral JJ N
index NN N
for IN N
monitoring VBG N
sedation NN N
during IN N
catheterization NN N
in IN N
children NNS p
, , N
we PRP N
noted VBD N
decreased JJ o
need NN o
for IN o
doses NNS o
of IN o
midazolam NN o
and CC o
ketamine NN o
, , N
a DT N
lower JJR o
need NN o
for IN o
respiratory JJ o
support NN o
and CC o
less JJR o
adverse JJ o
effects NNS o
. . o

-DOCSTART- -25044819- O O

Reducing VBG N
the DT N
psychological JJ o
distress NN o
of IN N
family NN p
caregivers NNS p
of IN p
home NN p
based VBN p
palliative JJ p
care NN p
patients NNS p
: : p
longer JJR N
term NN N
effects NNS N
from IN N
a DT N
randomised VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Palliative NNP N
care NN N
incorporates VBZ N
comprehensive JJ N
support NN N
of IN N
family NN p
caregivers NNS p
because IN N
many JJ N
of IN N
them PRP N
experience VB N
burden NN N
and CC N
distress NN N
. . N

However RB N
, , N
evidence-based JJ N
support NN N
initiatives NNS N
are VBP N
few JJ N
. . N

PURPOSE NNP N
We PRP N
evaluated VBD N
a DT N
one-to-one JJ i
psychoeducational JJ i
intervention NN N
aimed VBN N
at IN N
mitigating VBG o
the DT o
distress NN o
of IN o
caregivers NNS o
of IN p
patients NNS p
with IN p
advanced JJ p
cancer NN p
receiving VBG p
home-based JJ p
palliative JJ p
care NN p
. . p

We PRP N
hypothesised VBD N
that IN N
caregivers NNS p
would MD N
report VB N
decreased JJ o
distress NN o
as IN o
assessed VBN o
by IN o
the DT o
General NNP o
Health NNP o
Questionnaire NNP o
( ( o
GHQ NNP o
) ) o
. . o

METHOD CC N
A DT N
randomised VBN N
controlled VBN N
trial NN N
comparing VBG N
two CD i
versions NNS i
of IN i
the DT i
delivery NN i
of IN i
the DT i
intervention NN i
( ( i
one CD i
face-to-face NN i
home NN i
visit NN i
plus CC i
telephone NN i
calls VBZ i
versus IN i
two CD i
visits NNS i
) ) i
plus CC i
standard JJ i
care NN i
to TO i
a DT i
control NN i
group NN i
( ( i
standard JJ i
care NN i
only RB i
) ) i
across IN N
four CD p
sites NNS p
in IN p
Australia NNP p
. . p

RESULTS NNP N
Recruitment NNP p
to TO p
the DT p
one CD p
visit NN p
condition NN p
was VBD p
57 CD p
, , p
the DT p
two CD p
visit NN p
condition NN p
93 CD p
, , p
and CC p
the DT p
control NN p
148 CD p
. . p

We PRP N
previously RB N
reported VBD N
non-significant JJ N
changes NNS N
in IN N
distress NN o
between IN N
times NNS N
1 CD N
( ( N
baseline NN N
) ) N
and CC N
2 CD N
( ( N
1-week JJ N
post-intervention NN N
) ) N
but CC N
significant JJ N
gains NNS N
in IN N
competence NN o
and CC o
preparedness NN o
. . o

We PRP N
report VBP N
here RB N
changes NNS N
in IN N
distress NN o
between IN N
times NNS N
1 CD N
and CC N
3 CD N
( ( N
8-week JJ N
post-death NN N
) ) N
. . N

There EX N
was VBD N
significantly RB N
less JJR N
worsening VBG o
in IN o
distress NN o
between IN N
times NNS N
1 CD N
and CC N
3 CD N
in IN N
the DT N
one CD N
visit NN N
intervention NN N
group NN N
than IN N
in IN N
the DT N
control NN N
group NN N
; : N
however RB N
, , N
no DT N
significant JJ N
difference NN N
was VBD N
found VBN N
between IN N
the DT N
two CD N
visit NN N
intervention NN N
and CC N
the DT N
control NN N
group NN N
. . N

CONCLUSIONS NNP N
These DT N
results NNS N
are VBP N
consistent JJ N
with IN N
the DT N
aim NN N
of IN N
the DT N
intervention NN N
, , N
and CC N
they PRP N
support VBP N
existing VBG N
evidence NN N
demonstrating VBG N
that IN N
relatively RB N
short JJ N
psychoeducational JJ N
interventions NNS N
can MD N
help VB N
family NN p
caregivers NNS p
who WP p
are VBP p
supporting VBG p
a DT p
dying VBG p
relative NN p
. . p

The DT N
sustained JJ N
benefit NN N
during IN N
the DT N
bereavement JJ N
period NN N
may MD N
also RB N
have VB N
positive JJ N
resource NN N
implications NNS N
, , N
which WDT N
should MD N
be VB N
the DT N
subject NN N
of IN N
future JJ N
inquiry NN N
. . N

-DOCSTART- -10506815- O O

One-year JJ N
results NNS N
from IN N
the DT N
phase NN N
III NNP N
investigation NN i
of IN i
the DT i
KeraVision NNP i
Intacs NNP i
. . i

BACKGROUND NNP N
Limitations NNP N
of IN N
the DT N
surgical JJ N
correction NN N
for IN N
myopia NN p
include VBP N
inaccuracy NN N
, , N
instability NN N
, , N
treatment NN N
of IN N
the DT N
central JJ N
optical JJ N
zone NN N
, , N
and CC N
lack NN N
of IN N
reversibility NN N
. . N

KeraVision NNP i
Intacs NNP i
offer VBP N
an DT N
alternative NN N
that WDT N
addresses VBZ N
these DT N
shortcomings NNS N
. . N

METHODS NNP N
We PRP N
present VBD N
1 CD N
year NN N
of IN N
follow-up JJ N
information NN N
on IN N
95 CD p
subjects NNS p
enrolled VBN p
in IN p
the DT p
United NNP p
States NNPS p
Food NNP p
and CC p
Drug NNP p
Administration NNP p
Phase NNP p
III NNP p
clinical JJ p
trials NNS p
. . p

RESULTS NNP N
At IN N
1 CD N
year NN N
, , N
99 CD p
% NN p
of IN p
patients NNS p
( ( p
89 CD p
of IN p
90 CD p
) ) p
had VBD p
20/40 CD p
uncorrected JJ p
vision NN p
or CC p
better JJR p
. . p

Ninety-two JJ N
percent NN N
of IN N
eyes NNS N
( ( N
83 CD N
of IN N
90 CD N
) ) N
were VBD N
within IN N
1.00 CD N
D NNP N
of IN N
intended VBN N
correction NN N
and CC N
76 CD N
% NN N
of IN N
eyes NNS N
( ( N
68 CD N
of IN N
90 CD N
) ) N
were VBD N
within IN N
0.50 CD N
D NNP N
of IN N
intended JJ N
correction NN N
. . N

Stability NNP o
was VBD N
achieved VBN N
at IN N
3 CD N
months NNS N
, , N
with IN N
96 CD N
% NN N
of IN N
subjects NNS N
( ( N
86 CD N
of IN N
90 CD N
) ) N
having VBG N
less JJR N
than IN N
1.00 CD N
D NNP N
of IN N
change NN N
from IN N
their PRP$ N
previous JJ N
examination NN N
. . N

In IN N
a DT N
substudy NN N
, , N
89 CD N
% NN N
eyes NNS N
( ( N
58 CD N
of IN N
65 CD N
) ) N
varied VBD N
within IN N
+/- JJ N
0.50 CD N
D NNP N
over IN N
the DT N
course NN N
of IN N
a DT N
day NN N
. . N

Corneal NNP o
curvature NN o
changed VBD N
as IN N
predicted VBN N
, , N
resulting VBG N
in IN N
a DT N
prolate NN N
aspheric JJ N
shape NN N
within IN N
the DT N
central JJ N
optical JJ N
zone NN N
. . N

Most JJS N
complications NNS o
or CC o
adverse JJ o
events NNS o
experienced VBN N
were VBD N
managed VBN N
with IN N
additional JJ N
medication NN N
or CC N
surgical JJ N
intervention NN N
, , N
resulting VBG N
in IN N
a DT N
favorable JJ N
outcome NN N
for IN N
subjects NNS N
. . N

CONCLUSIONS NNP N
KeraVision NNP N
Intacs NNP N
are VBP N
effective JJ o
, , o
predictable JJ o
, , o
stable JJ o
, , o
and CC o
safe JJ o
. . o

This DT N
additive JJ N
technique NN N
may MD N
also RB N
offer VB N
reversibility NN N
. . N

-DOCSTART- -8980774- O O

Single-dose JJ N
pharmacokinetics NNS N
of IN N
delavirdine NN i
mesylate NN i
and CC i
didanosine NN i
in IN N
patients NNS p
with IN p
human JJ o
immunodeficiency NN o
virus NN o
infection NN o
. . o

Delavirdine NNP N
is VBZ N
a DT N
nonnucleoside JJ N
reverse NN N
transcriptase NN N
inhibitor NN N
with IN N
in IN N
vitro JJ N
activity NN N
against IN N
human JJ o
immunodeficiency NN o
virus NN o
type NN o
1 CD o
( ( p
HIV-1 NNP p
) ) p
that WDT N
is VBZ N
currently RB N
being VBG N
evaluated VBN N
in IN N
combination NN N
regimens NNS N
with IN N
various JJ N
nucleoside JJ N
analogs NNS N
, , N
including VBG N
didanosine NN N
. . N

Due NNP N
to TO N
the DT N
pH-dependent JJ N
solubility NN N
of IN N
delavirdine NN N
, , N
the DT N
buffering NN N
agents NNS N
in IN N
didanosine JJ N
formulations NNS N
may MD N
reduce VB N
delavirdine NN N
absorption NN N
. . N

To TO N
evaluate VB N
the DT N
potential JJ N
interaction NN N
between IN N
these DT N
agents NNS N
, , N
12 CD p
HIV-infected JJ p
patients NNS p
( ( p
mean JJ p
[ NNP p
+/- JJ p
standard NN p
deviation NN p
] NNP p
CD4+ NNP p
cell NN p
count NN p
, , p
304 CD p
+/- JJ p
213/mm3 CD p
) ) p
were VBD p
enrolled VBN p
in IN N
a DT N
three-way JJ N
crossover NN N
single-dose JJ N
study NN N
. . N

Didanosine NNP i
( ( N
125 CD N
to TO N
200 CD N
mg NNS N
given VBN N
as IN N
buffered JJ N
tablets NNS N
) ) N
and CC N
delavirdine JJ i
mesylate NN i
( ( N
400 CD N
mg NN N
) ) N
pharmacokinetics NNS N
were VBD N
evaluated VBN N
when WRB N
each DT N
drug NN N
was VBD N
given VBN N
alone RB N
( ( N
treatments NNS N
A DT N
and CC N
B NNP N
, , N
respectively RB N
) ) N
, , N
when WRB N
the DT N
two CD N
drugs NNS N
were VBD N
given VBN N
concurrently RB N
( ( N
treatment NN N
C NNP N
) ) N
, , N
and CC N
when WRB N
didanosine NN i
was VBD N
given VBN N
1 CD N
h NN N
after IN N
delavirdine NN i
( ( N
treatment NN N
D NNP N
) ) N
. . N

Delavirdine NNP o
exposure NN o
was VBD N
reduced VBN N
by IN N
concurrent JJ N
administration NN N
of IN N
didanosine NN i
. . i

The DT N
maximum JJ o
drug NN o
concentration NN o
in IN o
serum NN o
( ( o
Cmax NNP o
) ) o
was VBD N
reduced VBN N
from IN N
7.22 CD N
+/- JJ N
4.0 CD N
to TO N
3.51 CD N
+/- JJ N
1.9 CD N
microM NN N
, , N
and CC N
the DT N
area NN o
under IN o
the DT o
concentration-time JJ o
curve NN o
from IN N
0 CD N
h NN N
to TO N
infinity NN N
( ( N
AUC0 NNP N
-- : N
> JJ N
infinity NN N
) ) N
was VBD N
reduced VBN N
from IN N
22.5 CD N
+/- JJ N
14 CD N
to TO N
14 CD N
+/- JJ N
5.7 CD N
microM.h NN N
. . N

The DT N
extent NN o
of IN o
N-dealkylation NNP o
, , N
as IN N
indicated VBN N
by IN N
the DT N
ratio NN o
of IN o
the DT o
N-dealkylated JJ o
delavirdine NN o
AUC0 NNP o
-- : o
> JJ o
infinity NN o
to TO N
the DT N
delavirdine NN o
AUC0 NNP o
-- : o
> JJ o
infinity NN o
, , N
was VBD N
unchanged JJ N
across IN N
study NN N
treatments NNS N
( ( N
P NNP N
= NNP N
0.708 CD N
) ) N
. . N

Reductions NNPS N
in IN N
didanosine NN o
exposure NN o
were VBD N
observed VBN N
during IN N
concurrent JJ N
administration NN N
with IN N
delavirdine NN N
with IN N
a DT N
Cmax NNP o
reduction NN N
from IN N
4.65 CD N
+/- JJ N
2.0 CD N
to TO N
3.22 CD N
+/- JJ N
0.59 CD N
microM NN N
and CC N
an DT N
AUC0 NNP N
-- : N
> JJ N
infinity NN N
reduction NN N
from IN N
7.93 CD N
+/- JJ N
3.9 CD N
to TO N
6.54 CD N
+/- JJ N
2.3 CD N
microM.h NN N
. . N

Thus RB N
, , N
concurrent JJ N
administration NN N
of IN N
delavirdine NN N
and CC N
didanosine NN N
may MD N
reduce VB N
the DT N
AUC0 NNP o
-- : o
> JJ o
infinity NN o
of IN N
both DT N
drugs NNS N
, , N
although IN N
the DT N
clinical JJ N
significance NN N
of IN N
this DT N
reduction NN N
is VBZ N
unknown JJ N
. . N

Administration NN N
of IN N
delavirdine JJ i
1 CD N
h NN N
before IN N
didanosine NN i
avoided VBD N
the DT N
interaction NN N
. . N

Due NNP N
to TO N
the DT N
single-dose JJ N
nature NN N
of IN N
this DT N
study NN N
, , N
these DT N
findings NNS N
require VBP N
further JJ N
evaluation NN N
at IN N
steady JJ N
state NN N
. . N

-DOCSTART- -11108177- O O

Measurement NN N
of IN N
peptidase NN o
activity NN o
and CC N
evaluation NN N
of IN N
effectiveness NN N
of IN N
administration NN N
of IN N
minocycline NN i
for IN N
treatment NN N
of IN N
dogs NNS p
with IN p
periodontitis NN p
. . p

OBJECTIVE UH N
To TO N
determine VB N
clinical JJ o
, , o
enzymatic JJ o
, , o
and CC o
microbiologic JJ o
effects NNS o
of IN N
controlled-release NN N
localized JJ N
administration NN N
of IN N
minocycline NN i
on IN N
dogs NNS p
with IN p
periodontitis NN p
. . p

ANIMALS NNP N
Five CD p
adult NN p
Beagles NNS p
with IN p
periodontitis NN p
. . p

PROCEDURE NNP N
After IN N
tooth CC N
scaling VBG N
and CC N
root NN N
planing NN N
, , N
2 CD N
treatment NN N
, , N
1 CD N
placebo NN N
, , N
and CC N
1 CD N
control NN N
site NN N
were VBD N
selected VBN N
for IN N
each DT N
dog NN N
. . N

Treatment NN N
sites NNS N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
received VBD N
a DT N
periodontal JJ i
formulation NN i
of IN i
minocycline NN i
hydrochloride NN i
, , i
placebo NN i
sites NNS N
( ( N
5 CD N
) ) N
received VBD i
ointment JJ i
without IN i
minocycline NN i
, , i
and CC i
control VB i
sites NNS i
( ( i
5 CD i
) ) i
did VBD i
not RB i
receive VB i
ointment NN i
. . i

Treatments NNS N
were VBD N
administered VBN N
4 CD N
times NNS N
at IN N
weekly JJ N
intervals NNS N
. . N

Peptidase NNP o
activity NN o
and CC o
clinical JJ o
and CC o
microbiologic JJ o
effects NNS o
were VBD N
evaluated VBN N
and CC N
compared VBN N
among IN N
sites NNS N
for IN N
17 CD N
weeks NNS N
. . N

RESULTS NNP N
Bleeding NNP o
of IN o
the DT o
gums NNS o
on IN o
probing VBG o
( ( o
BOP NNP o
) ) o
and CC o
pocket NN o
depth NN o
( ( o
PD NNP o
) ) o
improved VBD o
at IN N
the DT N
treatment NN N
site NN N
and CC N
were VBD N
maintained VBN N
for IN N
13 CD N
weeks NNS N
after IN N
treatment NN N
. . N

However RB N
, , N
BOP NNP o
and CC o
PD NNP o
in IN N
placebo NN N
and CC N
control VB N
sites NNS N
increased VBN N
from IN N
weeks NNS N
9 CD N
to TO N
17 CD N
Peptidase NNP o
activity NN o
in IN N
the DT N
periodontal JJ N
pocket NN N
decreased VBD N
noticeably RB N
from IN N
week NN N
1 CD N
to TO N
17 CD N
, , N
compared VBN N
with IN N
baseline NN N
values NNS N
for IN N
the DT N
treatment NN N
site NN N
. . N

However RB N
, , N
peptidase NN o
activity NN o
for IN N
placebo NN N
and CC N
control VB N
sites NNS N
increased VBN N
and CC N
were VBD N
above RB N
baseline JJ N
values NNS N
on IN N
week NN N
9 CD N
and CC N
week NN N
13 CD N
, , N
respectively RB N
. . N

Total JJ o
bacterial JJ o
counts NNS o
decreased VBN N
by IN N
90 CD N
% NN N
for IN N
treatment NN N
sites NNS N
and CC N
remained VBD N
at IN N
that DT N
value NN N
for IN N
13 CD N
weeks NNS N
. . N

However RB N
, , N
for IN N
placebo NN N
and CC N
control NN N
sites NNS N
, , N
bacterial JJ o
counts NNS o
increased VBD N
and CC N
reached VBD N
the DT N
baseline NN N
value NN N
on IN N
week NN N
17 CD N
. . N

CONCLUSIONS NNP N
AND NNP N
CLINICAL NNP N
RELEVANCE NNP N
Increased VBD o
peptidase NN o
activity NN o
is VBZ N
correlated VBN N
with IN N
the DT N
progression NN N
of IN N
periodontitis NN p
in IN p
dogs NNS p
. . p

Treatment NN N
with IN N
minocycline NN i
, , N
using VBG N
a DT N
localized VBN N
delivery NN N
system NN N
, , N
was VBD N
effective JJ N
in IN N
dogs NNS N
for IN N
at IN N
least JJS N
13 CD N
weeks NNS N
after IN N
cessation NN N
of IN N
drug NN N
administration NN N
. . N

-DOCSTART- -24291456- O O

Exercise NN i
for IN N
methamphetamine NN i
dependence NN p
: : p
rationale NN N
, , N
design NN N
, , N
and CC N
methodology NN N
. . N

BACKGROUND NNP N
Effective NNP N
pharmacotherapies NNS N
to TO N
treat VB N
methamphetamine NN N
( ( N
MA NNP N
) ) N
dependence NN N
have VBP N
not RB N
been VBN N
identified VBN N
, , N
and CC N
behavioral JJ N
therapies NNS N
are VBP N
marginally RB N
effective JJ N
. . N

Based VBN N
on IN N
behavioral JJ N
studies NNS N
demonstrating VBG N
the DT N
potential JJ N
efficacy NN N
of IN N
aerobic JJ i
exercise NN i
for IN N
improving VBG N
depressive JJ o
symptoms NNS o
, , o
anxiety NN o
, , o
cognitive JJ o
deficits NNS o
, , o
and CC o
substance NN o
use NN o
outcomes NNS o
, , N
the DT N
study NN N
described VBD N
here RB N
is VBZ N
examining VBG N
exercise NN i
as IN N
a DT N
potential JJ N
treatment NN N
for IN N
MA-dependent JJ p
individuals NNS p
. . p

METHODS NNP N
This DT N
study NN N
is VBZ N
randomizing VBG N
150 CD p
participants NNS p
with IN p
MA NNP p
dependence NN p
at IN p
a DT p
residential JJ p
treatment NN p
facility NN p
for IN p
addictive JJ p
disorders NNS p
to TO p
receive VB p
either RB p
a DT p
thrice-weekly JJ i
structured JJ i
aerobic NN i
and CC i
resistance NN i
exercise NN i
intervention NN i
or CC i
a DT i
health NN i
education NN i
condition NN i
. . i

Recruitment NNP N
commenced VBD N
in IN N
March NNP N
, , N
2010 CD N
. . N

Enrollment NN N
and CC N
follow-up JJ N
phases NNS N
are VBP N
ongoing VBG N
, , N
and CC N
recruitment NN N
is VBZ N
exceeding VBG N
targeted VBN N
enrollment JJ N
rates NNS N
. . N

CONCLUSIONS NNP N
Seeking NNP N
evidence NN N
for IN N
a DT N
possibly RB N
effective JJ N
adjunct NN N
to TO N
traditional JJ N
behavioral JJ N
approaches NNS N
for IN N
treatment NN N
of IN N
MA NNP o
dependence NN o
, , N
this DT N
study NN N
is VBZ N
assessing VBG N
the DT N
ability NN N
of IN N
an DT N
8-week JJ N
aerobic NN i
and CC i
resistance NN i
exercise NN i
protocol NN N
to TO N
reduce VB N
relapse NN o
to TO o
MA NNP o
use NN N
during IN N
a DT N
12-week JJ N
follow-up JJ N
period NN N
after IN N
discharge NN N
from IN N
residential-based JJ N
treatment NN N
. . N

The DT N
study NN N
also RB N
is VBZ N
evaluating VBG N
improvements NNS N
in IN N
health NN o
and CC o
functional JJ o
outcomes NNS o
during IN N
and CC N
after IN N
the DT N
protocol NN N
. . N

This DT N
paper NN N
describes VBZ N
the DT N
design NN N
and CC N
methods NNS N
of IN N
the DT N
study NN N
. . N

-DOCSTART- -17322624- O O

Dose-response JJ o
effect NN o
of IN N
flecainide NN i
in IN N
patients NNS p
with IN p
symptomatic JJ p
paroxysmal JJ p
atrial JJ p
fibrillation NN p
and/or NN p
flutter NN p
monitored VBD p
with IN p
trans-telephonic JJ p
electrocardiography NN p
: : p
a DT N
multicenter NN N
, , N
placebo-controlled JJ N
, , N
double-blind JJ N
trial NN N
. . N

BACKGROUND VB N
A DT N
double-blind NN N
, , N
randomized VBN N
, , N
parallel-group JJ N
, , N
placebo-controlled JJ i
trial NN N
was VBD N
conducted VBN N
in IN N
patients NNS p
with IN p
paroxysmal JJ p
atrial JJ p
fibrillation NN p
or CC p
flutter NN p
( ( p
PAF/PAFL NNP p
) ) p
experiencing VBG p
2 CD p
or CC p
more JJR p
episodes NNS p
of IN p
symptomatic JJ p
PAF/PAFL NNP p
during IN p
a DT p
28-day JJ p
observation NN p
period NN p
to TO p
determine VB p
the DT p
dose-response JJ p
effect NN o
and CC o
safety NN o
of IN p
flecainide NN i
. . i

METHODS NNP N
AND NNP N
RESULTS NNP N
A NNP N
total NN N
of IN N
143 CD p
patients NNS p
at IN p
30 CD p
centers NNS p
were VBD N
randomized VBN N
to TO N
receive VB N
25 CD N
, , N
50 CD N
, , N
or CC N
100 CD N
mg NN N
of IN N
flecainide NN i
or CC i
placebo VB i
twice JJ N
daily JJ N
( ( N
BID NNP N
) ) N
. . N

In IN N
123 CD p
patients NNS p
( ( N
per IN N
protocol NN N
set NN N
) ) N
, , N
those DT N
remaining VBG N
free JJ N
from IN N
PAF/PAFL NNP o
after IN N
the DT N
treatment NN N
were VBD N
3.1 CD N
% NN N
on IN N
placebo NN i
, , N
7.7 CD N
% NN N
on IN N
25 CD N
mg/BID NN N
, , N
9.4 CD N
% NN N
on IN N
50 CD N
mg/BID NN N
, , N
and CC N
39.4 CD N
% NN N
on IN N
100 CD N
mg/BID NN N
of IN N
flecainide NN i
. . i

As IN N
a DT N
whole JJ N
group NN N
, , N
a DT N
significant JJ o
linear JJ o
dose-response NN o
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
was VBD N
observed VBN N
and CC N
a DT N
significant JJ N
difference NN N
between IN N
placebo NN N
and CC N
100 CD N
mg/BID NN N
was VBD N
observed VBN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

A DT N
similar JJ N
dose-response NN o
between IN N
the DT N
present JJ N
study NN N
and CC N
Caucasian NNP N
study NN N
was VBD N
demonstrated VBN N
. . N

Although IN N
there EX N
were VBD N
5 CD N
patients NNS N
who WP N
needed VBD N
cardioversion NN o
or CC o
ablation NN o
because IN N
of IN N
frequent JJ N
episodes NNS N
of IN N
PAF/PAFL NNP N
( ( N
2 CD N
in IN N
25 CD N
mg/BID NN N
, , N
1 CD N
in IN N
50 CD N
mg/BID NN N
, , N
and CC N
2 CD N
in IN N
100 CD N
mg/BID NN N
of IN N
flecainide NN i
) ) i
, , N
neither CC N
death NN o
nor CC o
ventricular JJ o
proarrhythmic JJ o
event NN o
was VBD N
reported VBN N
. . N

CONCLUSIONS VB N
This DT N
study NN N
indicated VBD N
that IN N
flecainide NN i
exerted VBD N
a DT N
significant JJ N
dose-dependent JJ N
effect NN N
on IN N
the DT N
prevention NN N
of IN N
symptomatic JJ N
PAF/PAFL NNP N
recurrence NN N
and CC N
showed VBD N
that IN N
there EX N
was VBD N
no DT N
inter-ethnic JJ N
difference NN N
in IN N
the DT N
clinical JJ N
effect NN N
of IN N
flecainide NN i
in IN N
patients NNS p
with IN p
PAF/PAFL NNP p
. . p

-DOCSTART- -11838820- O O

Methodological JJ N
issues NNS N
in IN N
designing VBG N
a DT N
multisite JJ N
trial NN N
of IN N
risperidone NN i
in IN N
children NNS p
and CC p
adolescents NNS p
with IN p
autism NN p
. . p

OBJECTIVE UH N
To TO N
describe VB N
the DT N
methodological JJ N
challenges NNS N
and CC N
decisions NNS N
made VBN N
in IN N
developing VBG N
a DT N
multisite NN N
, , N
controlled VBD N
study NN N
of IN N
risperidone NN i
in IN N
children NNS p
and CC p
adolescents NNS p
with IN p
autism NN p
. . p

METHODS NNP N
Review NNP N
the DT N
design NN N
considerations NNS N
for IN N
clinical JJ N
trials NNS N
in IN N
children NNS p
with IN p
autistic JJ p
disorder NN p
accompanied VBN p
by IN p
severe JJ p
tantrums NNS p
, , p
aggressive JJ p
and/or NN p
self-injurious JJ p
behaviors NNS p
. . p

These DT N
design JJ N
considerations NNS N
include VBP N
the DT N
definition NN N
of IN N
inclusion NN N
criteria NNS N
that WDT N
are VBP N
relevant JJ N
to TO N
clinical JJ N
practice NN N
and CC N
matching VBG N
study NN N
design NN N
to TO N
the DT N
goal NN N
of IN N
evaluating VBG N
short- JJ N
and CC N
long-term JJ N
effects NNS N
. . N

Additional NNP N
ethical JJ N
and CC N
scientific JJ N
issues NNS N
concern NN N
the DT N
length NN N
of IN N
trial NN N
and CC N
sample NN N
size NN N
. . N

RESULTS NNP N
We PRP N
undertook VBD N
a DT N
short-term JJ N
, , N
placebo-controlled JJ i
study NN N
to TO N
evaluate VB N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
risperidone NN i
in IN N
children NNS p
and CC p
adolescents NNS p
with IN p
autistic JJ p
disorder NN p
. . p

This DT N
trial NN N
design NN N
was VBD N
followed VBN N
by IN N
an DT N
extended JJ N
open-label JJ N
maintenance NN N
on IN N
risperidone NN i
to TO N
confirm VB N
durability NN o
of IN N
treatment NN N
effects NNS N
and CC N
to TO N
monitor VB N
safety NN o
. . o

Finally RB N
, , N
a DT N
placebo-controlled JJ N
discontinuation NN N
study NN N
tested VBD N
the DT N
need NN N
for IN N
continuous JJ N
treatment NN N
. . N

CONCLUSIONS NNP N
In IN N
the DT N
absence NN N
of IN N
standard JJ N
pharmacological JJ N
treatment NN N
for IN N
children NNS N
with IN N
autistic JJ N
disorder NN N
, , N
a DT N
placebo-controlled JJ N
study NN N
remains VBZ N
the DT N
most RBS N
appropriate JJ N
method NN N
of IN N
testing VBG N
efficacy NN N
and CC N
safety NN N
. . N

The DT N
clinical JJ N
relevance NN N
of IN N
this DT N
study NN N
is VBZ N
enhanced VBN N
by IN N
the DT N
addition NN N
of IN N
an DT N
extended JJ N
maintenance NN N
phase NN N
followed VBN N
by IN N
a DT N
placebo NN i
discontinuation NN N
. . N

-DOCSTART- -6134180- O O

Gradual NNP N
withdrawal NN N
of IN N
diazepam NN i
after IN N
long-term JJ N
therapy NN N
. . N

41 CD p
outpatients NNS p
who WP p
were VBD p
long-term JJ p
consumers NNS p
of IN p
diazepam NN i
in IN p
therapeutic JJ p
dosage NN p
were VBD p
gradually RB p
withdrawn VBN p
from IN p
the DT p
drug NN p
over IN p
3 CD p
months NNS p
by IN p
stepwise NN p
reduction NN p
. . p

In IN N
a DT N
double-blind JJ N
procedure NN N
half PDT N
the DT N
patients NNS N
began VBD N
withdrawal JJ N
immediately RB N
and CC N
half NN N
after IN N
8 CD N
weeks NNS N
. . N

Of IN N
36 CD p
patients NNS p
who WP p
completed VBD p
treatment NN p
, , N
16 CD N
( ( N
44.4 CD N
% NN N
) ) N
experienced VBD N
true JJ o
withdrawal NN o
phenomena NN o
on IN N
reducing VBG N
their PRP$ N
drugs NNS N
, , N
but CC N
8 CD N
other JJ N
patients NNS N
had VBD N
pseudo-withdrawal JJ o
reactions NNS o
at IN N
a DT N
time NN N
when WRB N
their PRP$ N
drug NN N
treatment NN N
was VBD N
unchanged JJ N
. . N

The DT N
pseudo-withdrawal JJ o
reactions NNS o
consisted VBD N
of IN N
an DT N
increase NN N
in IN N
anxiety NN o
symptoms NNS o
only RB N
, , N
whereas NNS N
true JJ o
withdrawal NN o
symptoms NNS o
also RB N
included VBD N
perceptual JJ o
changes NNS o
and CC o
psychotic JJ o
symptoms NNS o
. . o

Examination NN N
of IN N
pharmacological JJ N
and CC N
clinical JJ N
predictors NNS N
of IN N
withdrawal NN o
phenomena NN o
and CC N
later RB N
relapse NN o
showed VBD N
that IN N
personality NN N
factors NNS N
were VBD N
the DT N
most RBS N
important JJ N
, , N
patients NNS N
with IN N
passive-dependent JJ N
traits NNS N
having VBG N
a DT N
significantly RB N
greater JJR N
prevalence NN N
of IN N
withdrawal NN o
reactions NNS o
. . o

-DOCSTART- -15299181- O O

Concomitant NNP i
radiochemotherapy NN i
vs NN i
radiotherapy NN i
alone RB i
in IN N
patients NNS p
with IN p
head NN p
and CC p
neck NN p
cancer NN p
: : p
a DT N
Hellenic NNP N
Cooperative NNP N
Oncology NNP N
Group NNP N
Phase NNP N
III NNP N
Study NNP N
. . N

The DT N
primary JJ N
objective NN N
of IN N
the DT N
present JJ N
randomized JJ N
phase NN N
III NNP N
trial NN N
was VBD N
to TO N
compare VB N
the DT N
3-yr JJ o
survival NN o
rate NN o
of IN N
patients NNS N
treated VBN N
with IN N
standard JJ i
fractionated VBN i
radiotherapy NN i
( ( i
RT NNP i
) ) i
alone RB N
or CC N
with IN i
the DT i
same JJ i
RT NNP i
concomitantly RB i
with IN i
cisplatin NN i
( ( i
DDP NNP i
) ) i
or CC i
carboplatin NN i
( ( i
Cb NNP i
) ) i
. . i

From IN N
January NNP N
1995 CD N
until IN N
July NNP N
1999 CD N
, , N
124 CD p
patients NNS p
with IN p
histologically RB p
proven VBN p
locally RB p
advanced JJ p
non-nasopharyngeal JJ p
head NN p
and CC p
neck NN p
cancer NN p
( ( p
HNC NNP p
) ) p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
RT NNP i
monotherapy NN i
( ( N
70 CD N
Gy NNP N
, , N
Group NNP N
A NNP N
) ) N
or CC N
the DT N
same JJ N
RT NNP i
concomitantly RB i
with IN i
DDP NNP i
( ( N
100 CD N
mg/m2 NN N
on IN N
d NN N
2 CD N
, , N
22 CD N
, , N
42 CD N
, , N
Group NNP N
B NNP N
) ) N
or CC i
Cb NNP i
( ( N
7 CD N
AUC NNP N
on IN N
d NN N
2 CD N
, , N
22 CD N
, , N
42 CD N
, , N
Group NNP N
C NNP N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
complete JJ o
response NN o
rates NNS o
between IN N
patients NNS N
treated VBN N
with IN N
RT NNP N
alone RB N
or CC N
combined VBN N
chemoradiotherapy NN i
. . i

However RB N
, , N
median JJ o
time NN o
to TO o
progression NN o
( ( o
TTP NNP o
) ) o
and CC o
overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
were VBD N
significantly RB N
longer RBR N
in IN N
patients NNS N
treated VBN N
with IN N
concomitant JJ i
chemoradiotherapy NN i
. . i

Thus RB N
, , N
median JJ o
TTP NNP o
was VBD N
6.3 CD N
, , N
45.2 CD N
, , N
and CC N
17.7 CD N
mo NN N
in IN N
groups NNS N
A NNP N
, , N
B NNP N
, , N
and CC N
C NNP N
respectively RB N
( ( N
p JJ N
= NNP N
0.0002 CD N
) ) N
. . N

Similarly RB N
, , N
median JJ o
OS NNP o
was VBD N
12.2 CD N
, , N
48.6 CD N
, , N
and CC N
24.5 CD N
mo NN N
, , N
respectively RB N
( ( N
p JJ N
= NNP N
0.0003 CD N
) ) N
. . N

At IN N
3 CD N
yr JJ N
follow-up NN N
, , N
17.5 CD N
% NN N
of IN N
patients NNS N
in IN N
group NN N
A NNP N
were VBD N
alive JJ o
compared VBN N
to TO N
52 CD N
% NN N
in IN N
group NN N
B NNP N
and CC N
42 CD N
% NN N
in IN N
group NN N
C NNP N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

Patients NNS N
treated VBD N
with IN N
concomitant JJ i
chemoradiotherapy NN i
experienced VBD N
more RBR N
frequently RB N
severe JJ o
hematological JJ o
toxicity NN o
. . o

Also RB N
, , N
severe JJ o
nausea/vomiting NN o
was VBD N
more RBR N
pronounced JJ N
in IN N
group NN N
B NNP N
, , N
as IN N
expected VBN N
. . N

The DT N
present JJ N
study NN N
clearly RB N
demonstrated VBD N
that IN N
concomitant JJ i
chemoradiotherapy NN i
with IN i
platinum NN i
analogs NNS i
significantly RB N
prolongs VBZ N
3-yr JJ o
survival NN o
and CC o
median JJ o
OS NNP o
in IN N
patients NNS p
with IN p
locally RB p
advanced JJ p
HNC NNP p
compared VBN N
to TO N
conventional JJ N
RT NNP N
alone RB N
. . N

-DOCSTART- -1667693- O O

Evaluation NN N
of IN N
prostaglandin NN i
E1 NNP i
for IN N
prevention NN N
of IN N
respiratory JJ N
failure NN N
in IN N
high JJ p
risk NN p
trauma NN p
patients NNS p
: : p
a DT N
prospective JJ N
clinical JJ N
trial NN N
and CC N
correlation NN N
with IN N
plasma JJ N
suppressive JJ N
factors NNS N
for IN N
neutrophil DT N
activation NN N
. . N

A DT p
group NN p
of IN p
48 CD p
critically RB p
injured JJ p
patients NNS p
were VBD N
entered VBN N
into IN N
a DT N
prospective JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
early JJ i
infusion NN i
of IN i
PGE1 NNP i
for IN N
reducing VBG N
the DT N
incidence NN o
of IN o
severe JJ o
respiratory JJ o
failure NN o
and CC o
mortality NN o
. . o

Secondary JJ N
assessments NNS N
examined VBD N
the DT N
effects NNS N
of IN N
the DT N
PGE1 NNP N
infusion NN N
on IN N
plasma NN N
mediated VBN N
suppression NN N
of IN N
PMN NNP N
superoxide JJ N
production NN N
and CC N
loss NN N
of IN N
PMN NNP N
granule NN N
enzyme NN N
content NN N
. . N

The DT N
incidence NN N
of IN N
severe JJ o
respiratory JJ o
failure NN o
was VBD N
lower JJR N
in IN N
the DT N
PGE1 NNP N
group NN N
-- : N
13 CD N
% NN N
versus IN N
32 CD N
% NN N
, , N
but CC N
this DT N
did VBD N
not RB N
reach VB N
significance NN N
. . N

The DT N
overall JJ N
morality NN N
was VBD N
equivalent JJ N
between IN N
the DT N
two CD N
groups NNS N
-- : N
26 CD N
% NN N
( ( i
PGE1 NNP i
) ) i
versus VBP N
28 CD N
% NN N
( ( i
placebo NN i
) ) i
. . N

The DT N
suppressive JJ N
activity NN N
of IN N
the DT N
patient NN N
plasma NN N
was VBD N
assayed VBN N
by IN N
measurement NN N
of IN N
normal JJ N
PMN NNP N
superoxide NN N
production NN N
relative JJ N
to TO N
normal JJ N
control NN N
plasma NN N
( ( N
ratio JJ N
P NNP N
: : N
C NNP N
) ) N
. . N

The DT N
baseline NN N
ratio NN N
P NNP N
: : N
C NNP N
was VBD N
62 CD N
+/- JJ N
5 CD N
% NN N
in IN N
the DT N
PGE1 NNP N
group NN N
versus VBD N
60 CD N
+/- JJ N
5 CD N
% NN N
in IN N
the DT N
placebo NN N
group NN N
. . N

The DT N
day NN N
1 CD N
plasma NN N
samples NNS N
showed VBD N
significant JJ N
reversal NN N
of IN N
plasma JJ o
suppressive JJ o
activity NN o
in IN N
the DT N
PGE1 NNP N
group NN N
-- : N
ratio JJ N
P NN N
: : N
C $ N
88 CD N
+/- JJ N
5 CD N
% NN N
versus NN N
67 CD N
+/- JJ N
5 CD N
% NN N
in IN N
the DT N
placebo NN N
group NN N
( ( N
P NNP N
less JJR N
than IN N
0.02 CD N
) ) N
. . N

In IN N
patients NNS N
who WP N
received VBD N
the DT N
full JJ N
7 CD N
days NNS N
of IN N
infusion NN N
, , N
the DT N
plasma JJ o
suppressive JJ o
activity NN o
remained VBD N
significantly RB N
diminished VBN N
in IN N
the DT N
PGE1 NNP N
group NN N
-- : N
ratio JJ N
P NN N
: : N
C $ N
77 CD N
+/- JJ N
4 CD N
% NN N
versus NN N
61 CD N
+/- JJ N
5 CD N
% NN N
( ( N
P NNP N
less JJR N
than IN N
0.04 CD N
) ) N
. . N

The DT N
baseline NN N
lysozyme NN N
content NN N
of IN N
patient JJ N
PMN NNP N
's POS N
relative NN N
to TO N
that DT N
of IN N
normal JJ N
control NN N
PMNs NNP N
( ( N
ratio JJ N
P NNP N
: : N
C NNP N
) ) N
was VBD N
119 CD N
+/- JJ N
14 CD N
% NN N
in IN N
the DT N
PGE1 NNP N
group NN N
. . N

A DT N
significant JJ N
loss NN N
of IN N
lysozyme JJ N
content NN N
was VBD N
observed VBN N
in IN N
the DT N
PGE1 NNP N
group NN N
on IN N
day NN N
1 CD N
of IN N
the DT N
infusion NN N
-- : N
ratio JJ N
P NN N
: : N
C $ N
79 CD N
+/- JJ N
8 CD N
% NN N
( ( N
P NNP N
less JJR N
than IN N
0.03 CD N
) ) N
, , N
and CC N
was VBD N
associated VBN N
with IN N
a DT N
reduction NN N
in IN N
the DT N
plasma JJ N
suppressive JJ N
activity NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -20329618- O O

[ JJ N
Effect NNP N
of IN N
zengjing VBG i
no DT i
. . i

1 CD i
capsule NN i
on IN N
morphology NN o
and CC o
motility NN o
of IN o
sperm NN o
in IN N
patients NNS p
with IN p
oligospermia JJ p
] NN p
. . N

OBJECTIVE UH N
To TO N
explore VB N
the DT N
effect NN N
of IN N
Zengjing VBG i
Capsule NNP i
No NNP i
. . i

1 CD i
( ( i
ZJC1 NNP i
) ) i
on IN N
morphology NN N
and CC N
motility NN N
of IN N
sperm NN N
in IN N
patients NNS p
with IN p
oligospermia NN p
( ( p
OSM NNP p
) ) p
. . p

METHODS NNP N
Seventy-two JJ p
OSM NNP p
patients NNS p
were VBD N
assigned VBN N
to TO N
2 CD N
groups NNS N
by IN N
a DT N
randomizing JJ N
digital NN N
table NN N
, , N
the DT N
treated VBN N
group NN N
and CC N
the DT N
control NN N
group NN N
, , N
they PRP N
were VBD N
treated VBN N
respectively RB N
by IN N
ZJC1 NNP i
and CC N
Wuzi NNP i
Yanzong NNP i
Pill NNP i
( ( N
WYP NNP N
) ) N
. . N

The DT N
changes NNS o
of IN o
density NN o
, , o
motility NN o
and CC o
morphology NN o
of IN o
sperm NN o
in IN N
patients NNS N
before IN N
and CC N
after IN N
3-month JJ N
treatment NN N
were VBD N
examined VBN N
using VBG N
computerized JJ N
WLJY-9000 CD N
colour JJ N
semen NNS o
analysis NN o
system NN o
with IN N
refined JJ N
Papanicolaou NNP N
's POS N
stain NN N
. . N

RESULTS VB N
The DT N
density NN o
, , o
motility NN o
and CC o
morphology NN o
of IN o
sperm NN o
were VBD N
improved VBN N
and CC N
sperm JJ o
deformity NN o
rate NN o
was VBD N
significantly RB N
decreased VBN N
after IN N
treatment NN N
in IN N
both DT N
groups NNS N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
but CC N
the DT N
effects NNS N
in IN N
the DT N
treated JJ N
group NN N
were VBD N
better JJR N
than IN N
those DT N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSION NNP N
ZJC1 NNP i
can MD N
enhance VB N
the DT N
density NN o
and CC o
motility NN o
of IN o
sperm NN o
and CC N
reduce VB N
the DT N
sperm JJ o
deformity NN o
rate NN o
in IN N
patients NNS p
with IN p
OSM NNP p
. . p

-DOCSTART- -16418843- O O

The DT N
influence NN N
of IN N
rTMS NN i
over IN N
the DT N
left JJ N
dorsolateral JJ N
prefrontal JJ N
cortex NN N
on IN N
Stroop NNP i
task NN i
performance NN i
. . i

Several JJ N
studies NNS N
have VBP N
demonstrated VBN N
that IN N
repetitive JJ i
transcranial JJ i
magnetic JJ i
stimulation NN i
( ( i
rTMS NN i
) ) i
can MD N
improve VB N
cognitive JJ N
processing NN N
. . N

Neuroimaging VBG N
studies NNS N
have VBP N
shown VBN N
the DT N
engagement NN N
of IN N
the DT N
left JJ N
dorsolateral JJ N
prefrontal NN N
cortex NN N
( ( N
DLPFC NNP N
) ) N
in IN N
executive NN N
functioning NN N
, , N
and CC N
more RBR N
specifically RB N
during IN N
selective JJ N
attention NN N
. . N

In IN N
the DT N
present JJ N
study NN N
, , N
the DT N
influence NN N
of IN N
high-frequency NN i
rTMS NN i
over IN N
the DT N
left JJ N
DLPFC NNP N
on IN N
Stroop NNP N
task NN N
performance NN N
in IN N
healthy JJ p
female NN p
volunteers NNS p
was VBD N
investigated VBN N
. . N

As IN N
expected VBN N
, , N
reaction NN o
time NN o
on IN N
both CC N
the DT N
incongruent NN N
and CC N
congruent NN N
trials NNS N
decreased VBD N
significantly RB N
after IN N
stimulation NN N
, , N
and CC N
there EX N
was VBD N
no DT N
difference NN N
with IN N
regard NN N
to TO N
the DT N
Stroop NNP o
interference NN o
effect NN o
. . o

Mood NNP o
remained VBD N
unchanged JJ N
after IN N
rTMS NN i
. . i

Such PDT N
a DT N
pattern NN N
is VBZ N
consistent JJ N
with IN N
the DT N
role NN N
of IN N
the DT N
left NN N
DLPFC NNP N
in IN N
implementing VBG N
top-down JJ N
attentional JJ N
control NN N
. . N

-DOCSTART- -3586567- O O

Antifibrinolytic JJ i
therapy NN i
for IN N
prevention NN N
of IN N
hemorrhage NN N
during IN N
surgery NN p
of IN p
the DT p
thyroid JJ p
gland NN p
. . p

The DT N
amount NN N
of IN N
fibrinolytic JJ N
activity NN N
in IN N
the DT N
thyroid JJ N
gland NN N
equals NNS N
that WDT N
of IN N
the DT N
prostate NN N
. . N

In IN N
order NN N
to TO N
examine VB N
the DT N
effect NN N
of IN N
the DT N
antifibrinolytic JJ i
drug NN i
tranexemic JJ i
acid NN i
on IN N
perioperative JJ o
bleeding NN o
saline NN i
or CC N
tranexemic JJ i
acid NN i
were VBD N
given VBN N
randomized VBN N
double JJ N
blind NN N
to TO N
76 CD p
consecutive JJ p
patients NNS p
who WP p
came VBD p
for IN p
scheduled VBN p
thyroid NN p
surgery NN p
. . p

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
perioperative JJ o
bleeding NN o
between IN N
patients NNS p
in IN p
the DT p
treatment NN p
group NN p
( ( p
n JJ p
= NNP p
39 CD p
) ) p
and CC p
control NN p
group NN p
( ( p
n JJ p
= NNP p
37 CD p
) ) p
. . N

-DOCSTART- -19861631- O O

Immunologic NNP N
profiles NNS N
of IN N
persons NNS N
recruited VBN N
for IN N
a DT N
randomized JJ N
, , N
placebo-controlled JJ i
clinical JJ N
trial NN N
of IN N
hookworm NN p
infection NN p
. . p

Data NNS N
from IN N
epidemiologic JJ N
studies NNS N
suggest VBP N
that IN N
hookworm NN N
infections NNS N
, , N
in IN N
establishing VBG N
an DT N
immunologic JJ N
phenotype NN N
conducive NN N
to TO N
parasite VB N
survival NN N
, , N
may MD N
protect VB N
against IN N
the DT N
development NN N
of IN N
allergic JJ N
disease NN N
. . N

We PRP N
describe VBP N
immunologic JJ N
findings NNS N
from IN N
a DT N
clinical JJ N
study NN N
designed VBN N
to TO N
investigate VB N
the DT N
safety NN N
of IN N
iatrogenic JJ i
hookworm NN i
infection NN i
in IN N
participants NNS p
with IN p
allergic JJ p
rhinitis NN p
. . p

The DT N
low JJ N
, , N
relatively RB N
safe JJ N
level NN N
of IN N
hookworm NN i
infection NN i
used VBN N
in IN N
this DT N
study NN N
was VBD N
immunogenic JJ N
, , N
inducing VBG N
eosinophilia NNS o
and CC N
a DT N
significant JJ N
specific JJ o
IgG NNP o
response NN o
. . o

Importantly RB N
, , N
no DT N
potentiation NN N
of IN N
IgE NNP o
responses NNS o
to TO o
the DT o
environmental JJ o
allergens NNS o
to TO o
which WDT o
the DT o
participants NNS o
were VBD o
sensitized VBN o
was VBD N
seen VBN N
. . N

However RB N
, , N
no DT N
evidence NN N
of IN N
systemic JJ o
immune JJ o
regulation NN o
was VBD N
seen VBN N
in IN N
infected JJ N
participants NNS N
. . N

This DT N
finding NN N
may MD N
indicate VB N
that IN N
the DT N
level NN o
of IN o
infection NN o
or CC N
the DT N
frequency NN o
of IN o
infection NN o
may MD N
have VB N
to TO N
be VB N
altered VBN N
in IN N
future JJ N
trials NNS N
to TO N
induce VB N
a DT N
therapeutically RB N
conducive JJ N
immunologic NN N
phenotype NN N
. . N

-DOCSTART- -25589191- O O

Afatinib NNP i
versus NN N
cisplatin-based JJ i
chemotherapy NN i
for IN p
EGFR NNP p
mutation-positive JJ p
lung NN p
adenocarcinoma NN p
( ( p
LUX-Lung JJ p
3 CD p
and CC p
LUX-Lung NNP p
6 CD p
) ) p
: : p
analysis NN N
of IN N
overall JJ o
survival NN o
data NNS N
from IN N
two CD N
randomised VBD N
, , N
phase NN N
3 CD N
trials NNS N
. . N

BACKGROUND IN N
We PRP N
aimed VBD N
to TO N
assess VB N
the DT N
effect NN N
of IN N
afatinib NN i
on IN N
overall JJ o
survival NN o
of IN N
patients NNS p
with IN p
EGFR NNP p
mutation-positive JJ p
lung NN p
adenocarcinoma NN p
through IN N
an DT N
analysis NN N
of IN N
data NNS N
from IN N
two CD N
open-label JJ N
, , N
randomised VBN N
, , N
phase VB N
3 CD N
trials NNS N
. . N

METHODS NNP N
Previously RB p
untreated VBD p
patients NNS p
with IN p
EGFR NNP p
mutation-positive JJ p
stage NN p
IIIB NNP p
or CC p
IV NNP p
lung NN p
adenocarcinoma NN p
were VBD p
enrolled VBN p
in IN p
LUX-Lung NNP i
3 CD i
( ( p
n=345 NN p
) ) p
and CC p
LUX-Lung JJ i
6 CD i
( ( p
n=364 NN p
) ) p
. . p

These DT N
patients NNS N
were VBD N
randomly RB i
assigned VBN i
in IN i
a DT i
2:1 CD i
ratio NN i
to TO i
receive VB i
afatinib NN i
or CC i
chemotherapy NN i
( ( i
pemetrexed-cisplatin JJ i
[ NNP i
LUX-Lung NNP i
3 CD i
] NN i
or CC i
gemcitabine-cisplatin JJ i
[ JJ i
LUX-Lung NNP i
6 CD i
] NN i
) ) i
, , i
stratified VBN i
by IN i
EGFR NNP i
mutation NN i
( ( i
exon JJ i
19 CD i
deletion NN i
[ NNP i
del19 NN i
] NNP i
, , i
Leu858Arg NNP i
, , i
or CC i
other JJ i
) ) i
and CC i
ethnic JJ i
origin NN i
( ( i
LUX-Lung NNP i
3 CD i
only RB i
) ) i
. . i

We PRP N
planned VBD N
analyses NNS N
of IN N
mature NN N
overall JJ N
survival NN N
data NNS N
in IN N
the DT N
intention-to-treat JJ N
population NN p
after IN N
209 CD N
( ( N
LUX-Lung NNP N
3 CD N
) ) N
and CC N
237 CD N
( ( N
LUX-Lung NNP N
6 CD N
) ) N
deaths NNS N
. . N

These DT N
ongoing JJ N
studies NNS N
are VBP N
registered VBN N
with IN N
ClinicalTrials.gov NNP N
, , N
numbers NNS N
NCT00949650 NNP N
and CC N
NCT01121393 NNP N
. . N

FINDINGS NNP N
Median JJ N
follow-up NN N
in IN N
LUX-Lung NNP N
3 CD N
was VBD N
41 CD N
months NNS N
( ( N
IQR NNP N
35-44 NNP N
) ) N
; : N
213 CD N
( ( N
62 CD N
% NN N
) ) N
of IN N
345 CD p
patients NNS p
had VBD N
died VBN N
. . N

Median JJ N
follow-up NN N
in IN N
LUX-Lung NNP N
6 CD N
was VBD N
33 CD N
months NNS N
( ( N
IQR NNP N
31-37 NNP N
) ) N
; : N
246 CD N
( ( N
68 CD N
% NN N
) ) N
of IN N
364 CD N
patients NNS N
had VBD N
died VBN N
. . N

In IN N
LUX-Lung NNP N
3 CD N
, , N
median JJ N
overall JJ o
survival NN o
was VBD N
28.2 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
24.6-33.6 CD N
) ) N
in IN N
the DT N
afatinib NN N
group NN N
and CC N
28.2 CD N
months NNS N
( ( N
20.7-33.2 JJ N
) ) N
in IN N
the DT N
pemetrexed-cisplatin JJ N
group NN N
( ( N
HR NNP N
0.88 CD N
, , N
95 CD N
% NN N
CI NNP N
0.66-1.17 CD N
, , N
p=0.39 NN N
) ) N
. . N

In IN N
LUX-Lung NNP N
6 CD N
, , N
median JJ N
overall JJ o
survival NN o
was VBD N
23.1 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
20.4-27.3 CD N
) ) N
in IN N
the DT N
afatinib NN N
group NN N
and CC N
23.5 CD N
months NNS N
( ( N
18.0-25.6 JJ N
) ) N
in IN N
the DT N
gemcitabine-cisplatin JJ N
group NN N
( ( N
HR NNP N
0.93 CD N
, , N
95 CD N
% NN N
CI NNP N
0.72-1.22 CD N
, , N
p=0.61 NN N
) ) N
. . N

However RB N
, , N
in IN N
preplanned JJ N
analyses NNS N
, , N
overall JJ o
survival NN o
was VBD N
significantly RB N
longer JJR N
for IN N
patients NNS N
with IN N
del19-positive JJ N
tumours NNS N
in IN N
the DT N
afatinib NN N
group NN N
than IN N
in IN N
the DT N
chemotherapy NN N
group NN N
in IN N
both DT N
trials NNS N
: : N
in IN N
LUX-Lung NNP N
3 CD N
, , N
median JJ N
overall JJ o
survival NN o
was VBD N
33.3 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
26.8-41.5 CD N
) ) N
in IN N
the DT N
afatinib NN N
group NN N
versus VBD N
21.1 CD N
months NNS N
( ( N
16.3-30.7 JJ N
) ) N
in IN N
the DT N
chemotherapy NN N
group NN N
( ( N
HR NNP N
0.54 CD N
, , N
95 CD N
% NN N
CI NNP N
0.36-0.79 CD N
, , N
p=0.0015 NN N
) ) N
; : N
in IN N
LUX-Lung NNP N
6 CD N
, , N
it PRP N
was VBD N
31.4 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
24.2-35.3 CD N
) ) N
versus NN N
18.4 CD N
months NNS N
( ( N
14.6-25.6 JJ N
) ) N
, , N
respectively RB N
( ( N
HR NNP N
0.64 CD N
, , N
95 CD N
% NN N
CI NNP N
0.44-0.94 CD N
, , N
p=0.023 NN N
) ) N
. . N

By IN N
contrast NN N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
by IN N
treatment NN N
group NN N
for IN N
patients NNS p
with IN p
EGFR NNP p
Leu858Arg-positive JJ N
tumours NNS N
in IN N
either DT N
trial NN N
: : N
in IN N
LUX-Lung NNP N
3 CD N
, , N
median JJ N
overall JJ o
survival NN o
was VBD N
27.6 CD N
months NNS N
( ( N
19.8-41.7 JJ N
) ) N
in IN N
the DT N
afatinib NN N
group NN N
versus VBD N
40.3 CD N
months NNS N
( ( N
24.3-not JJ N
estimable NN N
) ) N
in IN N
the DT N
chemotherapy NN N
group NN N
( ( N
HR NNP N
1.30 CD N
, , N
95 CD N
% NN N
CI NNP N
0.80-2.11 CD N
, , N
p=0.29 NN N
) ) N
; : N
in IN N
LUX-Lung NNP N
6 CD N
, , N
it PRP N
was VBD N
19.6 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
17.0-22.1 CD N
) ) N
versus NN N
24.3 CD N
months NNS N
( ( N
19.0-27.0 JJ N
) ) N
, , N
respectively RB N
( ( N
HR NNP N
1.22 CD N
, , N
95 CD N
% NN N
CI NNP N
0.81-1.83 CD N
, , N
p=0.34 NN N
) ) N
. . N

In IN N
both DT N
trials NNS N
, , N
the DT N
most RBS N
common JJ N
afatinib-related JJ N
grade JJ o
3-4 JJ o
adverse JJ o
events NNS o
were VBD N
rash JJ o
or CC o
acne NN o
( ( N
37 CD N
[ RB N
16 CD N
% NN N
] NN N
of IN N
229 CD p
patients NNS p
in IN p
LUX-Lung NNP p
3 CD p
and CC N
35 CD N
[ JJ N
15 CD N
% NN N
] NN N
of IN N
239 CD p
patients NNS p
in IN p
LUX-Lung NNP p
6 CD N
) ) N
, , N
diarrhoea NN o
( ( N
33 CD N
[ RB N
14 CD N
% NN N
] NN N
and CC N
13 CD N
[ JJ N
5 CD N
% NN N
] NN N
) ) N
, , N
paronychia FW o
( ( N
26 CD N
[ RB N
11 CD N
% NN N
] NN N
in IN N
LUX-Lung NNP N
3 CD N
only RB N
) ) N
, , N
and CC N
stomatitis NN o
or CC o
mucositis NN o
( ( N
13 CD N
[ RB N
5 CD N
% NN N
] NN N
in IN N
LUX-Lung NNP N
6 CD N
only RB N
) ) N
. . N

In IN N
LUX-Lung NNP N
3 CD N
, , N
neutropenia NN o
( ( N
20 CD N
[ RB N
18 CD N
% NN N
] NN N
of IN N
111 CD N
patients NNS N
) ) N
, , N
fatigue NN o
( ( N
14 CD N
[ RB N
13 CD N
% NN N
] NN N
) ) N
and CC N
leucopenia $ o
( ( N
nine CD N
[ RB N
8 CD N
% NN N
] NN N
) ) N
were VBD N
the DT N
most RBS N
common JJ N
chemotherapy-related JJ N
grade JJ N
3-4 JJ N
adverse JJ N
events NNS N
, , N
while IN N
in IN N
LUX-Lung NNP N
6 CD N
, , N
the DT N
most RBS N
common JJ N
chemotherapy-related JJ N
grade JJ o
3-4 JJ o
adverse JJ o
events NNS o
were VBD N
neutropenia RB o
( ( N
30 CD N
[ RB N
27 CD N
% NN N
] NN N
of IN N
113 CD N
patients NNS N
) ) N
, , N
vomiting VBG o
( ( N
22 CD N
[ RB N
19 CD N
% NN N
] NN N
) ) N
, , N
and CC N
leucopenia NN o
( ( N
17 CD N
[ RB N
15 CD N
% NN N
] NN N
) ) N
. . N

INTERPRETATION NNP N
Although IN N
afatinib NN N
did VBD N
not RB N
improve VB N
overall JJ N
survival NN N
in IN N
the DT N
whole JJ N
population NN N
of IN N
either DT N
trial NN N
, , N
overall JJ N
survival NN N
was VBD N
improved VBN N
with IN N
the DT N
drug NN N
for IN N
patients NNS p
with IN p
del19 JJ p
EGFR NNP p
mutations NNS p
. . p

The DT N
absence NN N
of IN N
an DT N
effect NN N
in IN N
patients NNS p
with IN p
Leu858Arg NNP p
EGFR NNP p
mutations NNS p
suggests VBZ N
that IN N
EGFR NNP N
del19-positive JJ N
disease NN N
might MD N
be VB N
distinct JJ N
from IN N
Leu858Arg-positive JJ N
disease NN N
and CC N
that IN N
these DT N
subgroups NNS N
should MD N
be VB N
analysed VBN N
separately RB N
in IN N
future JJ N
trials NNS N
. . N

FUNDING NN N
Boehringer NNP N
Ingelheim NNP N
. . N

-DOCSTART- -24839882- O O

Communication NN i
interventions NNS i
for IN N
minimally RB p
verbal JJ p
children NNS p
with IN p
autism NN p
: : p
a DT N
sequential JJ N
multiple JJ N
assignment NN N
randomized VBN N
trial NN N
. . N

OBJECTIVE VB N
This DT N
study NN N
tested VBD N
the DT N
effect NN N
of IN N
beginning VBG N
treatment NN N
with IN N
a DT N
speech-generating JJ i
device NN i
( ( i
SGD NNP i
) ) i
in IN N
the DT N
context NN N
of IN N
a DT N
blended VBN N
, , N
adaptive JJ N
treatment NN N
design NN N
for IN N
improving VBG N
spontaneous JJ o
, , o
communicative JJ o
utterances NNS o
in IN N
school-aged JJ p
, , p
minimally RB p
verbal JJ p
children NNS p
with IN p
autism NN p
. . p

METHOD NNP N
A NNP p
total NN p
of IN p
61 CD p
minimally RB p
verbal JJ p
children NNS p
with IN p
autism NN p
, , p
aged VBD p
5 CD p
to TO p
8 CD p
years NNS p
, , N
were VBD N
randomized VBN N
to TO N
a DT N
blended JJ i
developmental/behavioral JJ i
intervention NN i
( ( i
JASP+EMT NNP i
) ) i
with IN i
or CC i
without IN i
the DT i
augmentation NN i
of IN i
a DT i
SGD NNP i
for IN N
6 CD N
months NNS N
with IN N
a DT N
3-month JJ N
follow-up NN N
. . N

The DT N
intervention NN N
consisted VBD N
of IN N
2 CD N
stages NNS N
. . N

In IN N
stage NN N
1 CD N
, , N
all DT N
children NNS N
received VBD N
2 CD N
sessions NNS N
per IN N
week NN N
for IN N
3 CD N
months NNS N
. . N

Stage NN N
2 CD N
intervention NN N
was VBD N
adapted VBN N
( ( N
by IN N
increased VBN N
sessions NNS N
or CC N
adding VBG i
the DT i
SGD NNP i
) ) i
based VBN N
on IN N
the DT N
child NN N
's POS N
early JJ N
response NN N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
the DT N
total JJ o
number NN o
of IN o
spontaneous JJ o
communicative JJ o
utterances NNS o
; : o
secondary JJ o
measures NNS o
were VBD o
the DT o
total JJ o
number NN o
of IN o
novel JJ o
words NNS o
and CC o
total JJ o
comments NNS o
from IN o
a DT o
natural JJ o
language NN o
sample NN o
. . o

RESULTS NNP N
Primary NNP N
aim NN N
results NNS N
found VBD N
improvements NNS N
in IN N
spontaneous JJ o
communicative JJ o
utterances NNS o
, , o
novel JJ o
words NNS o
, , o
and CC o
comments NNS o
that IN N
all DT N
favored VBD N
the DT N
blended JJ i
behavioral JJ i
intervention NN i
that WDT i
began VBD i
by IN i
including VBG i
an DT i
SGD NNP i
( ( i
JASP+EMT+SGD NNP i
) ) i
as IN N
opposed VBN N
to TO N
spoken VB i
words NNS i
alone RB i
( ( i
JASP+EMT NNP i
) ) i
. . i

Secondary JJ N
aim NN N
results NNS N
suggest VBP N
that IN N
the DT N
adaptive JJ N
intervention NN N
beginning VBG N
with IN N
JASP+EMT+SGD NNP i
and CC N
intensifying VBG N
JASP+EMT+SGD NNP i
for IN N
children NNS N
who WP N
were VBD N
slow JJ N
responders NNS N
led VBD N
to TO N
better RBR N
posttreatment NN N
outcomes NNS N
. . N

CONCLUSION NNP N
Minimally NNP p
verbal JJ p
school-aged JJ p
children NNS p
can MD N
make VB N
significant JJ N
and CC N
rapid JJ N
gains NNS N
in IN N
spoken JJ o
spontaneous JJ o
language NN o
with IN N
a DT N
novel NN N
, , N
blended VBN N
intervention NN N
that WDT N
focuses VBZ N
on IN N
joint JJ N
engagement NN N
and CC N
play NN N
skills NNS N
and CC N
incorporates VBZ N
an DT N
SGD NNP i
. . i

Future NNP N
studies NNS N
should MD N
further RB N
explore VB N
the DT N
tailoring NN N
design NN N
used VBN N
in IN N
this DT N
study NN N
to TO N
better JJR N
understand VB N
children NNS N
's POS N
response NN N
to TO N
treatment NN N
. . N

Clinical JJ N
trial NN N
registration NN N
information-Developmental JJ N
and CC N
Augmented NNP N
Intervention NNP N
for IN N
Facilitating NNP N
Expressive NNP N
Language NNP N
( ( N
CCNIA NNP N
) ) N
; : N
http NN N
: : N
//clinicaltrials.gov/ NN N
; : N
NCT01013545 NNP N
. . N

-DOCSTART- -9745404- O O

Leptin NNP N
levels NNS N
in IN N
protracted JJ p
critical JJ p
illness NN p
: : p
effects NNS N
of IN N
growth NN i
hormone-secretagogues NNS i
and CC N
thyrotropin-releasing JJ i
hormone NN i
. . i

Prolonged NNP N
critical JJ N
illness NN N
is VBZ N
characterized VBN N
by IN N
feeding-resistant JJ N
wasting NN N
of IN N
protein NN N
, , N
whereas JJ N
reesterification NN N
, , N
instead RB N
of IN N
oxidation NN N
of IN N
fatty JJ N
acids NNS N
, , N
allows VBZ N
fat JJ N
stores NNS N
to TO N
accrue NNS N
and CC N
associate NN N
with IN N
a DT N
low-activity JJ N
status NN N
of IN N
the DT N
somatotropic NN N
and CC N
thyrotropic NN N
axis NN N
, , N
which WDT N
seems VBZ N
to TO N
be VB N
partly RB N
of IN N
hypothalamic JJ N
origin NN N
. . N

To TO N
further JJ N
unravel NN N
this DT N
paradoxical JJ N
metabolic JJ N
condition NN N
, , N
and CC N
in IN N
search NN N
of IN N
potential JJ N
therapeutic JJ N
strategies NNS N
, , N
we PRP N
measured VBD N
serum JJ N
concentrations NNS N
of IN N
leptin NN N
; : N
studied VBD N
the DT N
relationship NN N
with IN N
body NN N
mass NN N
index NN N
, , N
insulin NN N
, , N
cortisol NN N
, , N
thyroid JJ N
hormones NNS N
, , N
and CC N
somatomedins NNS N
; : N
and CC N
documented VBD N
the DT N
effects NNS N
of IN N
hypothalamic JJ N
releasing NN N
factors NNS N
, , N
in IN N
particular JJ N
, , N
GH-secretagogues NNP N
and CC N
TRH NNP N
. . N

Twenty NNP p
adults NNS p
, , p
critically RB p
ill VB p
for IN p
several JJ p
weeks NNS p
and CC p
supported VBD p
with IN p
normocaloric JJ p
, , p
continuously RB p
administered VBN p
parenteral JJ p
and/or JJ p
enteral JJ p
feeding NN p
, , N
were VBD N
studied VBN N
for IN N
45 CD N
h. NN N
They PRP N
had VBD N
been VBN N
randomized VBN N
to TO N
receive VB N
one CD N
of IN N
three CD N
combinations NNS N
of IN N
peptide JJ N
infusions NNS N
, , N
in IN N
random JJ N
order NN N
: : N
TRH NN i
( ( i
one CD i
day NN i
) ) i
and CC i
placebo NN i
( ( N
other JJ N
day NN N
) ) N
; : N
TRH NNP N
+ NNP N
GH-releasing NNP N
peptide NN N
( ( N
GHRP NNP N
) ) N
-2 NN N
and CC N
GHRP-2 NNP N
; : N
TRH NNP N
+ NNP N
GHRH NNP N
+ NNP N
GHRP-2 NNP N
and CC N
GHRH NNP N
+ NNP N
GHRP-2 NNP N
. . N

Peptide NNP i
infusions NNS i
were VBD N
started VBN N
after IN N
a DT N
1-microgram/kg JJ N
bolus NN N
at IN N
0900 CD N
h NN N
and CC N
infused VBN N
( ( N
1 CD N
microgram/kg.h NN N
) ) N
until IN N
0600 CD N
h VBD N
the DT N
next JJ N
morning NN N
. . N

Serum NNP o
concentrations NNS o
of IN o
leptin NN o
, , o
insulin NN o
, , o
cortisol NN o
, , o
T4 NNP o
, , o
T3 NNP o
, , o
insulin-like JJ o
growth NN o
factor NN o
( ( o
IGF NNP o
) ) o
-I NN o
, , o
IGF-binding JJ o
protein-3 NN o
and CC o
the DT o
acid-labile JJ o
subunit NN o
( ( o
ALS NNP o
) ) o
were VBD N
measured VBN N
at IN N
0900 CD N
h NN N
, , N
2100 CD N
h NN N
, , N
and CC N
0600 CD N
h NN N
on IN N
each DT N
of IN N
the DT N
2 CD N
study NN N
days NNS N
. . N

Baseline NNP o
leptin NN o
levels NNS o
( ( N
mean JJ N
+/- JJ N
SEM NN N
: : N
12.4 CD N
+/- JJ N
2.1 CD N
micrograms/L NN N
) ) N
were VBD N
independent JJ N
of IN N
body NN N
mass NN N
index NN N
( ( N
25 CD N
+/- JJ N
1 CD N
kg/m2 NN N
) ) N
, , N
insulin NN N
( ( N
18.6 CD N
+/- JJ N
2.9 CD N
microIU/mL NN N
) ) N
, , N
cortisol NN N
( ( N
504 CD N
+/- JJ N
43 CD N
mmol/L NN N
) ) N
, , N
and CC N
thyroid JJ N
hormones NNS N
( ( N
T4 NNP N
: : N
63 CD N
+/- JJ N
5 CD N
nmol/L NN N
, , N
T3 NNP N
: : N
0.72 CD N
+/- JJ N
0.08 CD N
nmol/L NN N
) ) N
but CC N
correlated VBD N
positively RB N
with IN N
circulating VBG N
levels NNS N
of IN N
IGF-I NNP N
[ NNP N
86 CD N
+/- JJ N
6 CD N
micrograms/L NN N
, , N
determination NN N
coefficient NN N
( ( N
R2 NNP N
) ) N
= VBD N
0.25 CD N
] NN N
and CC N
ALS NNP N
( ( N
7.2 CD N
+/- JJ N
0.6 CD N
mg/L NN N
, , N
R2 NNP N
= NNP N
0.32 CD N
) ) N
. . N

Infusion NN N
of IN N
placebo NN i
or CC N
TRH NNP i
had VBD N
no DT N
effect NN N
on IN N
leptin NN o
. . o

In IN N
contrast NN N
, , N
GH-secretagogues NNP N
elevated VBD N
leptin NN o
levels NNS o
within IN N
12 CD N
h. JJ N
Infusion NNP N
of IN N
GHRP-2 NNP N
alone RB N
induced VBD N
a DT N
maximal JJ o
leptin JJ o
increase NN o
of IN N
+87 NNP N
% NN N
after IN N
24 CD N
h NN N
, , N
whereas WP N
GHRH NNP N
+ VBD N
GHRP-2 NNP N
elevated VBD N
leptin NN o
by IN N
up IN N
to TO N
+157 VB N
% NN N
after IN N
24 CD N
h. VBD N
The DT N
increase NN N
in IN N
leptin NN o
within IN o
12 CD o
h NN o
was VBD N
related VBN N
( ( N
R2 NNP N
= NNP N
0.58 CD N
) ) N
to TO N
the DT N
substantial JJ N
rise NN N
in IN N
insulin NN N
. . N

After IN N
45 CD N
h NN N
, , N
and CC N
having VBG N
reached VBN N
a DT N
plateau NN N
, , N
leptin NN o
was VBD N
related VBN N
to TO N
the DT N
increased VBN o
IGF-I NNP o
( ( N
R2 NNP N
= NNP N
0.37 CD N
) ) N
. . N

In IN N
conclusion NN N
, , N
circulating VBG o
leptin NN o
levels NNS o
during IN N
protracted JJ N
critical JJ N
illness NN N
were VBD N
linked VBN N
to TO N
the DT N
activity NN N
state NN N
of IN N
the DT N
GH/IGF-I NNP N
axis NN N
. . N

Stimulating VBG N
the DT N
GH/IGF-I NNP N
axis NN N
with IN N
GH-secretagogues NNP N
increased VBD N
leptin NN o
levels NNS o
within IN N
12 CD N
h. NN N
Because IN N
leptin NN N
may MD N
stimulate VB N
oxidation NN N
of IN N
fatty JJ N
acids NNS N
, , N
and CC N
because IN N
GH NNP N
, , N
IGF-I NNP N
, , N
and CC N
insulin NN N
have VBP N
a DT N
protein-sparing JJ N
effect NN N
, , N
GH-secretagogue NNP i
administration NN N
may MD N
be VB N
expected VBN N
to TO N
result VB N
in IN N
increased JJ N
utilization NN N
of IN N
fat NN N
as IN N
preferential JJ N
substrate NN N
and CC N
to TO N
restore VB N
protein JJ N
content NN N
in IN N
vital JJ N
tissues NNS N
and CC N
, , N
consequently RB N
, , N
has VBZ N
potential JJ N
as IN N
a DT N
strategy NN N
to TO N
reverse VB N
the DT N
paradoxical JJ N
metabolic JJ N
condition NN N
of IN N
protracted JJ N
critical JJ N
illness NN N
. . N

-DOCSTART- -12160584- O O

Prognostic JJ N
factor NN N
analysis NN N
in IN N
patients NNS p
with IN p
advanced JJ p
prostate NN p
cancer NN p
treated VBN p
by IN p
castration NN i
plus CC i
anandron NN i
or CC i
placebo NN i
: : i
a DT N
final JJ N
update NN N
. . N

PURPOSE NNP N
Different NNP N
outcome NN N
results NNS N
have VBP N
been VBN N
published VBN N
in IN N
trials NNS N
comparing VBG N
maximal JJ N
androgen NN N
blockade NN N
( ( N
MAB NNP N
) ) N
with IN N
chemical NN i
or CC i
surgical JJ i
castration NN i
alone RB i
. . i

The DT N
conflicting NN N
results NNS N
could MD N
be VB N
explained VBN N
by IN N
the DT N
fact NN N
that IN N
patients NNS N
were VBD N
included VBN N
with IN N
different JJ N
prognostic JJ N
factors NNS N
. . N

In IN N
this DT N
new JJ N
analysis NN N
of IN N
the DT N
Anandron NNP N
European NNP N
Study NNP N
, , N
independent JJ N
prognostic JJ N
factors NNS N
have VBP N
been VBN N
evaluated VBN N
in IN N
order NN N
to TO N
identify VB N
those DT N
which WDT N
could MD N
influence VB N
the DT N
study NN N
outcome NN N
and CC N
the DT N
impact NN N
of IN N
the DT N
treatment NN N
. . N

MATERIAL NNP N
AND NNP N
METHODS NNP N
399 CD p
out IN p
of IN p
457 CD p
patients NNS p
recruited VBN p
in IN p
this DT p
study NN p
were VBD p
divided VBN p
in IN p
a DT p
good JJ p
or CC p
poor JJ p
prognostic JJ p
group NN p
depending VBG p
on IN p
the DT p
presence NN p
of IN p
two CD p
or CC p
more JJR p
poor JJ p
prognostic JJ p
factors NNS p
, , p
these DT p
were VBD p
pain NN p
requiring VBG p
treatment NN p
, , p
> VBZ p
5 CD p
bone NN p
metastases NNS p
, , p
hydronephrosis NN p
, , p
and CC p
alkaline JJ p
phosphatase NN p
> VBD p
2 CD p
ULN NNP p
. . p

RESULTS NNP N
When WRB N
expressed VBN N
as IN N
a DT N
percentage NN N
, , N
the DT N
improvement NN o
in IN o
time NN o
to TO o
progression NN o
, , o
overall JJ o
and CC o
cancer NN o
specific JJ o
survival NN o
in IN N
the DT N
Anandron NNP i
treated VBD N
patients NNS N
was VBD N
identical JJ N
in IN N
both DT N
groups NNS N
. . N

In IN N
absolute JJ N
terms NNS N
this DT N
improvement NN N
, , N
however RB N
, , N
was VBD N
greater JJR N
in IN N
the DT N
good JJ N
prognostic JJ N
group NN N
. . N

CONCLUSION NNP N
In IN N
comparison NN N
with IN N
surgical JJ i
castration NN i
MAB NNP i
using VBG i
Anandron NNP i
, , N
in IN N
patients NNS p
with IN p
metastatic JJ p
prostate NN p
cancer NN p
improves VBZ N
the DT N
time NN N
to TO N
objective VB o
progression NN o
, , o
overall JJ o
and CC o
cancer NN o
specific JJ o
survival NN o
, , N
irrespective NN N
of IN N
certain JJ N
poor JJ N
prognostic JJ N
factors NNS N
. . N

-DOCSTART- -12422941- O O

An DT N
exploratory NN N
study NN N
: : N
the DT N
use NN N
of IN N
paroxetine NN i
for IN N
methamphetamine NN o
craving NN o
. . o

Methamphetamine NNP i
abuse NN N
and CC N
dependence NN N
are VBP N
growing VBG N
problems NNS N
nationally RB N
and CC N
worldwide RB N
. . N

There EX N
are VBP N
currently RB N
no DT N
effective JJ N
pharmocologic NN N
treatments NNS N
. . N

Animal NNP N
studies NNS N
with IN N
SSRI NNP N
's POS N
suggest JJS N
that IN N
serotonergic JJ N
modulation NN N
alters NNS N
methamphetamine VBP i
's POS i
behavioral JJ o
effects NNS o
. . o

This DT N
exploratory NN N
study NN N
is VBZ N
a DT N
trial NN N
of IN N
the DT N
effects NNS N
of IN N
the DT N
SSRI NNP i
paroxetine NN i
versus NN i
placebo NN i
( ( N
in IN N
a DT N
double JJ N
blind NN N
design NN N
) ) N
on IN N
craving NN N
and CC N
use NN N
in IN N
a DT N
population NN p
of IN p
methamphetamine NN i
users NNS p
. . p

Many JJ N
subjects NNS N
dropped VBD N
out IN N
of IN N
the DT N
study NN N
, , N
but CC N
those DT N
in IN N
active JJ N
treatment NN N
who WP N
completed VBD N
the DT N
eight CD N
week NN N
trial NN N
had VBD N
a DT N
decrease NN N
in IN N
methamphetamine NN o
craving NN o
compared VBN N
to TO N
the DT N
placebo NN N
treatment NN N
as IN N
measured VBN N
by IN N
the DT N
OCDS NNP N
modified VBD N
for IN N
use NN N
in IN N
this DT N
population NN N
. . N

Statistical JJ N
analyses NNS N
were VBD N
not RB N
performed VBN N
due JJ N
to TO N
the DT N
low JJ N
number NN N
of IN N
subjects NNS N
. . N

The DT N
preliminary JJ N
data NNS N
suggest VBP N
that IN N
serotonergic JJ N
agents NNS N
may MD N
play VB N
a DT N
role NN N
in IN N
the DT N
effective JJ N
treatment NN N
of IN N
methamphetamine NN o
abuse NN o
and CC o
dependence NN o
within IN N
the DT N
context NN N
of IN N
other JJ N
effective JJ N
behavioral JJ N
interventions NNS N
. . N

-DOCSTART- -8976475- O O

Trunk NNP i
exercise NN i
combined VBN i
with IN i
spinal JJ i
manipulative NN i
or CC i
NSAID NNP i
therapy NN i
for IN N
chronic JJ p
low JJ p
back RB p
pain NN p
: : p
a DT N
randomized JJ N
, , N
observer-blinded JJ N
clinical JJ N
trial NN N
. . N

OBJECTIVES UH N
To TO N
study VB N
the DT N
relative JJ N
efficacy NN N
of IN N
three CD N
different JJ N
treatment NN N
for IN N
chronic JJ p
low JJ p
back RB p
pain NN p
( ( p
CLBP NNP p
) ) p
. . p

Two CD N
preplanned JJ N
comparisons NNS N
were VBD N
made VBN N
: : N
( ( N
a DT N
) ) N
Spinal NNP i
manipulative JJ i
therapy NN i
( ( i
SMT NNP i
) ) i
combined VBD i
with IN i
trunk NN i
strengthening VBG i
exercises NNS i
( ( i
TSE NNP i
) ) i
vs. FW i
SMT NNP i
combined VBD i
with IN i
trunk NN i
stretching VBG i
exercises NNS i
, , i
and CC i
( ( N
b NN N
) ) N
SMT NNP i
combined VBN i
with IN i
TSE NNP i
vs. FW i
nonsteroidal JJ i
anti-inflammatory JJ i
drug NN i
( ( i
NSAID NNP i
) ) i
therapy NN i
combined VBN i
with IN i
TSE NNP i
. . i

STUDY NNP N
DESIGN NNP N
Interdisciplinary NNP N
, , N
prospective JJ N
, , N
observer-blinded JJ N
, , N
randomized JJ N
clinical JJ N
trial NN N
with IN N
a DT N
1-yr JJ N
follow-up JJ N
period NN N
. . N

The DT N
trial NN N
evaluated VBD N
therapies NNS N
in IN N
combination NN N
only RB N
and CC N
was VBD N
not RB N
designed VBN N
to TO N
test VB N
the DT N
individual JJ N
treatment NN N
components NNS N
. . N

SETTING NNP N
Primary NNP p
contact NN p
, , p
college NN p
out-patient JJ p
clinic NN p
. . p

PATIENTS NNP N
In IN N
total JJ N
, , N
174 CD p
patients NNS p
aged VBN p
20-60 JJ p
yr NNS p
were VBD N
admitted VBN N
to TO N
the DT N
study NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Patient-rated NNP o
low JJ o
back RB o
pain NN o
, , o
disability NN o
, , o
and CC o
functional JJ o
health NN o
status NN o
at IN N
5 CD N
and CC N
11 CD N
wk NN N
. . N

INTERVENTIONS NNP N
Five NNP N
weeks NNS N
of IN N
SMT NNP i
or CC i
NSAID NNP i
therapy NN i
in IN i
combination NN i
with IN i
supervised JJ i
trunk NN i
exercise NN i
, , N
followed VBN N
by IN N
and CC N
additional JJ N
6 CD N
wk NN N
of IN N
supervised JJ i
exercise NN i
alone RB i
. . i

RESULTS NNP N
Individual NNP N
group NN N
comparisons NNS N
after IN N
5 CD N
and CC N
11 CD N
wk NN N
of IN N
intervention NN N
on IN N
all DT N
three CD o
main JJ o
outcome NN o
measures NNS o
did VBD N
not RB N
reveal VB N
any DT N
clear JJ N
clinically RB N
important JJ N
or CC N
statistically RB N
significant JJ N
differences NNS N
. . N

There EX N
seemed VBD N
to TO N
be VB N
a DT N
sustained JJ N
reduction NN o
in IN o
medication NN o
use NN o
at IN o
the DT o
1-yr JJ o
follow-up NN o
. . o

in IN N
the DT N
SMT/TSE NNP N
group NN N
. . N

Continuance NN N
of IN N
exercise NN N
during IN N
the DT N
follow-up JJ N
year NN N
, , N
regardless RB N
of IN N
type NN N
, , N
was VBD N
associated VBN N
with IN N
a DT N
better JJR N
outcome NN N
. . N

CONCLUSION NNP N
Each DT N
of IN N
the DT N
three CD N
therapeutic JJ N
regimens NNS N
was VBD N
associated VBN N
with IN N
similar JJ N
and CC N
clinically RB N
important JJ N
improvement NN N
over IN N
time NN N
that WDT N
was VBD N
considered VBN N
superior JJ N
to TO N
the DT N
expected JJ N
natural JJ N
history NN N
of IN N
long-standing JJ N
CLBP NNP N
. . N

For IN N
the DT N
management NN N
of IN N
CLBP NNP N
, , N
trunk NN N
exercise NN N
in IN N
combination NN N
with IN N
SMT NNP i
or CC i
NSAID NNP i
therapy NN i
seemed VBD N
to TO N
be VB N
beneficial JJ N
and CC N
worthwhile JJ N
. . N

The DT N
magnitude NN N
of IN N
nonspecific JJ N
therapeutic JJ N
( ( i
placebo NN i
) ) i
effects NNS N
, , N
cost-effectiveness NN N
and CC N
relative JJ N
risks NNS N
of IN N
side NN N
effects NNS N
associated VBN N
with IN N
these DT N
types NNS N
of IN N
therapy NN N
need NN N
to TO N
be VB N
addressed VBN N
in IN N
future JJ N
studies NNS N
. . N

-DOCSTART- -9931687- O O

[ JJ N
Effect NNP N
of IN N
alanyl-glutamine NN i
in IN N
postoperative JJ N
total JJ N
parenteral JJ N
nutrition NN N
on IN N
postoperative JJ N
immunosuppression NN o
and CC o
morbidity NN o
. . o

Preliminary JJ N
results NNS N
of IN N
a DT N
prospective JJ N
randomized NN N
study NN N
] NNP N
. . N

The DT N
impact NN N
of IN N
glutamine JJ i
substitution NN i
on IN N
postoperative JJ N
immunosuppression NN N
and CC N
morbidity NN N
was VBD N
investigated VBN N
in IN N
patients NNS p
with IN p
surgical JJ p
interventions NNS p
and CC p
total JJ p
parenteral JJ p
nutrition NN p
in IN N
a DT N
prospective JJ N
randomized VBN N
trial NN N
. . N

To TO N
analyze VB N
immune JJ N
competence NN N
, , N
the DT N
expression NN N
of IN N
CD3 NNP o
, , o
CD4 NNP o
, , o
and CC o
CD8 NNP o
on IN o
lymphocytes NNS o
and CC o
of IN o
HLA-DR NNP o
and CC o
CD14 NNP o
on IN o
monocytes NNS o
as RB o
well RB o
as IN o
the DT o
plasma NN o
levels NNS o
of IN o
IL-6 NNP o
and CC o
IL-10 NNP o
was VBD N
evaluated VBN N
before RB N
, , N
1 CD N
, , N
2 CD N
, , N
4 CD N
, , N
and CC N
7 CD N
days NNS N
after IN N
surgery NN N
. . N

A DT N
total NN N
of IN N
34 CD p
patients NNS p
have VBP p
been VBN p
included VBN p
( ( i
with IN i
glutamine NN i
: : i
n JJ i
= $ i
18 CD i
; : i
without IN i
glutamine NN i
: : i
n JJ p
= NNP p
16 CD p
) ) p
. . p

Patients NNS p
with IN p
glutamine JJ i
substitution NN i
showed VBD N
decreased JJ o
systemic JJ o
inflammation NN o
, , N
significant JJ N
faster JJR N
compensation NN o
for IN o
postoperative JJ o
immunosuppression NN o
and CC o
a DT o
lower JJR o
incidence NN o
of IN o
postoperative JJ o
complications NNS o
. . o

Patients NNS N
without IN N
postoperative JJ N
complications NNS N
showed VBD N
no DT N
significant JJ N
differences NNS N
in IN N
postoperative JJ N
immunosuppression NN o
. . o

-DOCSTART- -6409006- O O

[ NNS N
Randomized NNP N
controlled VBD N
study NN N
of IN N
OK-432 NNP i
in IN N
the DT N
treatment NN N
of IN N
cancerous JJ o
pleurisy NN o
] NNP o
. . N

A NNP N
randomized VBD N
controlled VBN N
study NN N
was VBD N
performed VBN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
intrapleural JJ N
and CC N
systemic JJ N
administration NN N
of IN N
OK-432 NNP i
, , i
streptococcus NN i
preparation NN i
, , N
in IN N
patients NNS p
with IN p
cancerous JJ p
pleurisy NN p
. . p

A DT p
total NN p
of IN p
53 CD p
patients NNS p
were VBD p
accessed VBN p
to TO p
the DT p
study NN p
: : p
29 CD p
patients NNS p
for IN p
the DT p
OK-432 NNP i
group NN p
and CC p
24 CD p
patients NNS p
for IN p
the DT p
control NN i
group NN i
. . i

Intrapleural NNP N
instillation NN N
of IN N
50 CD i
mg NN i
of IN i
adriamycin NN i
and CC i
a DT i
combination NN i
chemotherapy NN i
of IN i
MFC NNP i
( ( i
mitomycin JJ i
C NNP N
0.08 CD N
mg/kg NN N
, , N
5-FU JJ N
10 CD N
mg/kg NN N
, , N
ara-C JJ i
0.8 CD N
mg/kg NN N
iv NN N
, , N
weekly RB N
) ) N
were VBD N
administered VBN N
in IN N
both DT N
groups NNS N
. . N

In IN N
the DT N
OK-432 NNP N
group NN N
intrapleural JJ N
instillation NN N
of IN N
2 CD N
units NNS N
of IN N
OK-432 NNP i
was VBD N
administered VBN N
daily RB N
until IN N
disappearance NN N
of IN N
pleural JJ N
effusion NN N
; : N
thereafter RB N
, , N
2 CD N
to TO N
5 CD N
units NNS N
of IN N
OK-432 NNP N
were VBD N
administered VBN N
intradermally RB N
every DT N
other JJ N
day NN N
. . N

Patients NNS N
with IN N
stage NN N
III NNP N
in IN N
the DT N
OK-432 NNP N
group NN N
survived VBD o
significantly RB o
longer RBR o
than IN N
those DT N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
, , N
but CC N
there EX N
was VBD N
no DT N
significance NN N
between IN N
in IN N
patients NNS N
with IN N
stage JJ N
IV NNP N
of IN N
both DT N
treatment NN N
groups NNS N
. . N

Also RB N
patients NNS N
with IN N
PPD NNP N
negative JJ N
skin NN N
reaction NN N
at IN N
the DT N
time NN N
of IN N
beginning VBG N
of IN N
treatment NN N
in IN N
the DT N
OK-432 NNP N
group NN N
survived VBD N
significantly RB N
longer RBR N
than IN N
those DT N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
less JJR N
than IN N
0.001 CD N
) ) N
, , N
but CC N
there EX N
was VBD N
no DT N
significance NN N
between IN N
both DT N
treatment NN N
groups NNS N
in IN N
patients NNS N
with IN N
PPD NNP N
positive JJ N
skin NN o
reaction NN o
at IN N
the DT N
time NN N
of IN N
beginning VBG N
of IN N
treatment NN N
. . N

Eighteen NNP N
( ( N
62 CD N
% NN N
) ) N
of IN N
29 CD N
patients NNS N
treated VBN N
with IN N
OK-432 NNP N
had VBD N
a DT N
fever NN N
, , N
but CC N
well RB N
tolerated VBN N
. . N

-DOCSTART- -15131557- O O

Primary JJ i
stenting NN i
of IN N
occluded JJ N
native JJ N
coronary JJ N
arteries NNS N
: : N
final JJ N
results NNS N
of IN N
the DT N
Primary NNP N
Stenting NNP N
of IN N
Occluded NNP p
Native NNP p
Coronary NNP p
Arteries NNP p
( ( p
PRISON NNP p
) ) p
study NN N
. . N

BACKGROUND NNP N
Primary NNP i
intracoronary JJ i
stent NN i
placement NN i
after IN N
successfully RB N
crossing VBG N
chronic JJ N
total JJ p
coronary JJ p
occlusions NNS p
may MD N
decrease VB N
the DT N
high JJ N
restenosis NN o
rate NN o
at IN N
long-term JJ N
follow-up JJ N
compared VBN N
with IN N
conventional JJ i
balloon NN i
angioplasty NN i
. . i

METHODS NNP N
In IN N
a DT N
prospective JJ N
, , N
randomized JJ N
trial NN N
, , N
balloon NN i
angioplasty NN i
was VBD N
compared VBN N
with IN N
stent JJ i
implantation NN i
for IN N
the DT N
treatment NN N
of IN N
chronic JJ p
total JJ p
occlusions NNS p
. . p

Patients NNS N
were VBD N
followed VBN N
for IN N
12 CD N
months NNS N
with IN N
angiographic JJ N
follow-up NN N
at IN N
6 CD N
months NNS N
. . N

Quantitative JJ N
coronary JJ N
analysis NN N
was VBD N
performed VBN N
by IN N
an DT N
independent JJ N
core NN N
lab NN N
. . N

RESULTS VB N
A DT N
total NN N
of IN N
200 CD p
patients NNS p
were VBD p
enrolled VBN p
. . p

Baseline JJ N
characteristics NNS N
were VBD N
evenly RB N
distributed VBN N
. . N

After IN N
the DT N
procedure NN N
the DT N
mean NN o
minimal JJ o
luminal JJ o
diameter NN o
in IN N
the DT N
conventional JJ i
group NN N
was VBD N
2.34 CD N
+/- JJ N
0.46 CD N
mm NN N
versus NN N
2.90 CD N
+/- JJ N
0.41 CD N
mm NN N
in IN N
the DT N
stented VBN i
group NN N
( ( N
P NNP N
< NNP N
.0001 NNP N
) ) N
. . N

The DT N
6-month JJ N
angiographic JJ N
follow-up NN N
showed VBD N
a DT N
mean JJ o
minimal JJ o
luminal JJ o
diameter NN o
of IN N
1.57 CD N
+/- JJ N
0.74 CD N
mm NN N
in IN N
the DT N
conventional JJ N
group NN N
versus VBD N
1.93 CD N
+/- JJ N
0.85 CD N
mm NN N
in IN N
the DT N
stented VBN N
group NN N
( ( N
P NNP N
=.009 NNP N
) ) N
and CC N
a DT N
mean JJ o
diameter NN o
stenosis NN o
of IN N
44.7 CD N
% NN N
+/- JJ N
25.0 CD N
% NN N
versus IN N
35.5 CD N
% NN N
+/- JJ N
26.5 CD N
% NN N
( ( N
P NNP N
=.036 NNP N
) ) N
. . N

Binary JJ o
angiographic JJ o
restenosis NN o
( ( N
> JJ N
50 CD N
% NN N
diameter JJ N
stenosis NN N
) ) N
was VBD N
seen VBN N
in IN N
33 CD N
% NN N
in IN N
the DT N
conventional JJ N
group NN N
versus VBD N
22 CD N
% NN N
in IN N
the DT N
stented VBN i
group NN N
( ( N
P NNP N
=.137 NNP N
) ) N
. . N

The DT N
reocclusion NN o
rates NNS o
were VBD N
7.3 CD N
% NN N
and CC N
8.2 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
1.00 CD N
) ) N
. . N

At IN N
12 CD N
month NN N
follow-up NN N
, , N
the DT N
rate NN o
of IN o
target NN o
lesion NN o
revascularization NN o
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
conventional JJ i
group NN N
( ( N
29 CD N
% NN N
versus IN N
13 CD N
% NN N
, , N
P NNP N
< NNP N
.0001 NNP N
) ) N
. . N

CONCLUSION NNP N
These DT N
data NNS N
demonstrate NN N
that IN N
stenting VBG i
of IN N
chronic JJ p
total JJ p
occlusions NNS p
is VBZ N
superior JJ N
to TO N
balloon VB i
angioplasty JJ i
alone RB i
with IN N
a DT N
statistically RB N
significant JJ N
reduction NN N
in IN N
the DT N
need NN N
for IN N
target NN o
lesion NN o
revascularization NN o
and CC N
a DT N
lower JJR N
, , N
but CC N
not RB N
significant JJ N
, , N
restenosis NN o
rate NN o
. . o

-DOCSTART- -16601648- O O

Risperidone NN i
and CC N
adaptive JJ o
behavior NN o
in IN N
children NNS p
with IN p
autism NN p
. . p

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
impact NN N
of IN N
risperidone NN i
on IN N
adaptive JJ o
behavior NN o
in IN N
children NNS p
with IN p
autistic JJ p
disorder NN p
who WP p
have VBP p
serious JJ p
behavior NN p
problems NNS p
and CC N
to TO N
examine VB N
different JJ N
methods NNS N
of IN N
scoring VBG N
the DT N
Vineland NNP N
Adaptive NNP N
Behavior NNP N
Scales NNP N
to TO N
measure VB N
change NN N
. . N

METHOD NNP N
Forty-eight JJ p
children NNS p
( ( p
5 CD p
years NNS p
to TO p
16 CD p
years NNS p
, , p
5 CD p
months NNS p
) ) p
who WP p
showed VBD p
behavioral JJ p
improvement NN o
during IN p
acute JJ p
treatment NN p
with IN p
risperidone NN i
were VBD i
followed VBN i
for IN i
6 CD i
months NNS i
and CC N
assessed VBN N
with IN N
the DT N
Vineland NNP N
Scales NNP N
. . N

RESULTS NNP N
Raw NNP o
scores VBZ o
, , o
age-equivalents NNS o
, , o
and CC o
special JJ o
norm NN o
percentile NN o
scores VBZ o
all DT N
showed VBD N
significant JJ N
increases NNS N
in IN N
adaptive JJ o
behavior NN o
in IN o
the DT o
areas NNS o
of IN o
communication NN o
, , o
daily JJ o
living NN o
skills NNS o
, , o
and CC o
socialization NN o
( ( N
p JJ N
< NNP N
.01 NNP N
) ) N
. . N

During IN N
a DT N
period NN N
of IN N
6 CD N
to TO N
8 CD N
months NNS N
, , N
children NNS N
gained VBD N
an DT N
average NN N
of IN N
7.8 CD N
age-equivalent JJ N
months NNS N
in IN N
the DT N
area NN o
of IN o
socialization NN o
, , N
a DT N
> JJ N
6 CD N
% NN N
improvement NN N
beyond IN N
what WP N
would MD N
be VB N
expected VBN N
based VBN N
on IN N
baseline JJ N
growth NN N
rates NNS N
. . N

CONCLUSIONS NNP N
Although IN N
limited VBN N
by IN N
the DT N
absence NN N
of IN N
a DT N
control NN N
group NN N
, , N
these DT N
results NNS N
suggest VBP N
that IN N
risperidone NN N
may MD N
improve VB N
adaptive JJ o
skills NNS o
in IN N
children NNS p
with IN p
autistic JJ p
disorder NN p
accompanied VBN N
by IN N
serious JJ N
behavioral JJ N
problems NNS N
. . N

Vineland NNP N
age-equivalent JJ N
scores NNS N
appear VBP N
to TO N
be VB N
most RBS N
useful JJ N
in IN N
assessing VBG N
change NN N
with IN N
treatment NN N
over IN N
time NN N
. . N

-DOCSTART- -4220015- O O

[ JJ i
Prognostic NNP i
experiences NNS i
in IN N
the DT N
long-term JJ i
differential JJ i
therapy NN i
of IN N
chronic JJ p
aggressive JJ p
hepatitides NNS p
] VBP p
. . N

-DOCSTART- -26485385- O O

Preoperative NNP N
Local NNP N
Administration NNP N
of IN N
Morphine NNP i
as IN N
an DT N
Add-on JJ N
Therapy NN N
in IN N
Patients NNS p
Undergoing VBG p
Surgical JJ p
Removal NNP p
of IN p
an DT p
Odontogenic NNP p
Maxillary NNP p
Cyst NNP p
. . p

A NNP N
Randomized NNP N
, , N
Double-Blind NNP N
Pilot NNP N
Study NNP N
. . N

AIMS NNP N
To TO N
evaluate VB N
whether IN N
a DT N
combination NN N
of IN N
locally RB N
administered VBN N
morphine NN i
( ( N
1 CD N
mg NN N
) ) N
and CC N
lidocaine NN i
as IN N
part NN N
of IN N
a DT N
multimodal JJ N
analgesic JJ N
approach NN N
is VBZ N
safe JJ N
, , N
and CC N
whether IN N
it PRP N
improves VBZ N
pain JJ N
control NN N
during IN N
the DT p
first JJ p
24 CD p
hours NNS p
after IN p
odontogenic JJ p
maxillary JJ p
cyst NN p
removal NN p
under IN p
general JJ p
anesthesia NN p
compared VBN N
to TO N
local JJ N
lidocaine NN N
alone RB N
. . N

METHODS NNP N
In IN N
a DT N
double-blind JJ N
, , N
sham-controlled JJ N
, , N
single-center JJ N
trial NN N
, , N
patients NNS p
scheduled VBN p
for IN p
surgical JJ p
removal NN p
of IN p
an DT p
odontogenic JJ p
maxillary JJ p
cyst NN p
under IN p
general JJ p
anesthesia NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
a DT N
local JJ N
injection NN N
of IN N
lidocaine JJ i
solution NN i
with IN i
either DT i
1 CD i
mg NN i
of IN i
morphine NN i
( ( i
MLA NNP i
group NN N
) ) N
or CC i
with IN i
no DT i
morphine NN i
( ( i
LA NNP i
group NN N
) ) N
. . N

Pain NNP N
management NN N
included VBD N
intravenous JJ N
acetaminophen NN i
( ( N
1 CD N
g NN N
every DT N
6 CD N
hours NNS N
) ) N
in IN N
all DT N
patients NNS N
. . N

Upon IN N
request NN N
, , N
the DT N
patients NNS N
could MD N
additionally RB N
receive VB N
ketoprofen NN i
( ( N
first-line JJ N
additional JJ N
analgesia NN N
) ) N
or CC i
tramadol JJ i
( ( N
second-line JJ N
additional JJ N
analgesia NN N
) ) N
. . N

Pain NNP N
intensity NN N
was VBD N
assessed VBN N
using VBG N
a DT N
numeric JJ N
rating NN N
scale NN N
. . N

Primary JJ N
outcome JJ N
measures NNS N
were VBD N
( ( o
1 CD o
) ) o
no DT o
need NN o
for IN o
any DT o
additional JJ o
analgesic JJ o
therapy NN o
and CC o
( ( o
2 CD o
) ) o
time NN o
to TO o
the DT o
first JJ o
rescue NN o
analgesic JJ o
therapy NN o
during IN o
the DT o
first JJ o
24 CD o
hours NNS o
after IN o
the DT o
surgery NN o
. . o

RESULTS NNP N
Of IN N
48 CD p
eligible JJ p
patients NNS p
, , N
24 CD N
were VBD N
allocated VBN N
to TO N
the DT N
MLA NNP N
group NN N
and CC N
24 CD N
to TO N
the DT N
LA NNP N
group NN N
. . N

The DT N
necessity NN N
of IN N
additional JJ o
ketoprofen NN o
therapy NN o
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
groups NNS N
( ( N
25.0 CD N
% NN N
vs JJ N
50.0 CD N
% NN N
, , N
P=.074 NNP N
) ) N
. . N

According VBG N
to TO N
the DT N
Kaplan-Meier NNP N
analysis NN N
, , N
the DT N
probability NN N
of IN N
remaining VBG N
without IN N
additional JJ o
analgesic JJ o
intervention NN o
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
MLA NNP N
group NN N
( ( N
log-rank JJ N
test NN N
, , N
P=.040 NNP N
) ) N
, , N
but CC N
there EX N
were VBD N
no DT N
significant JJ N
( ( N
P NNP N
> NNP N
.05 NNP N
) ) N
differences NNS N
in IN N
overall JJ N
and CC N
maximum JJ N
pain NN o
severity NN o
between IN N
the DT N
two CD N
groups NNS N
. . N

No DT N
adverse JJ o
effects NNS o
of IN N
morphine NN N
were VBD N
recorded VBN N
. . N

CONCLUSION NNP N
Within IN N
the DT N
limitations NNS N
of IN N
this DT N
study NN N
, , N
local JJ N
administration NN N
of IN N
1 CD N
mg NN N
of IN N
morphine NN i
prior RB N
to TO N
the DT N
surgical JJ N
removal NN N
of IN N
an DT N
odontogenic JJ N
maxillary JJ N
cyst NN N
was VBD N
safe JJ N
, , N
but CC N
it PRP N
did VBD N
not RB N
prove VB N
to TO N
be VB N
very RB N
effective JJ N
as IN N
an DT N
add-on JJ N
therapy NN N
for IN N
postoperative JJ N
pain NN N
control NN N
. . N

-DOCSTART- -12576957- O O

Enteral JJ N
nutrition NN N
with IN N
eicosapentaenoic JJ i
acid NN i
, , i
gamma-linolenic JJ i
acid NN i
, , i
and CC i
antioxidants NNS i
reduces NNS N
alveolar JJ N
inflammatory JJ N
mediators NNS N
and CC N
protein NN N
influx NN N
in IN p
patients NNS p
with IN p
acute JJ p
respiratory NN p
distress NN p
syndrome NN p
. . p

OBJECTIVE NNP N
Previously RB N
, , N
we PRP N
showed VBD N
that IN N
acute JJ p
respiratory NN p
distress JJ p
syndrome JJ p
patients NNS p
fed VBD N
an DT N
enteral JJ i
diet NN i
containing VBG i
eicosapentaenoic JJ i
acid NN i
and CC i
gamma-linolenic JJ i
acid NN i
and CC i
elevated JJ i
antioxidants NNS i
( ( i
EPA+GLA NNP i
; : i
Oxepa NNP i
) ) i
had VBD N
significantly RB N
reduced VBN N
pulmonary JJ N
inflammation NN N
, , N
increased JJ N
oxygenation NN N
, , N
and CC N
improved JJ N
clinical JJ N
outcomes NNS N
. . N

In IN N
a DT N
subset NN N
of IN N
acute JJ p
respiratory NN p
distress JJ p
syndrome JJ p
patients NNS p
from IN N
this DT N
trial NN N
, , N
we PRP N
performed VBD N
a DT N
preliminary JJ N
examination NN N
of IN N
the DT N
potential JJ N
mechanisms NN N
underlying VBG N
these DT N
clinical JJ N
improvements NNS N
by IN N
retrospectively RB N
testing VBG N
the DT N
hypothesis NN N
that IN N
enteral JJ N
feeding VBG N
with IN N
EPA+GLA NNP N
could MD N
reduce VB N
alveolar-capillary JJ N
membrane NN N
protein NN N
permeability NN N
and CC N
the DT N
production NN N
of IN N
interleukin NN N
( ( N
IL NNP N
) ) N
-8 NN N
, , N
IL-6 NNP N
, , N
tumor NN N
necrosis NN N
factor-alpha NN N
, , N
and CC N
leukotriene JJ N
B4 NNP N
that WDT N
are VBP N
responsible JJ N
, , N
in IN N
part NN N
, , N
for IN N
pulmonary JJ N
inflammation NN N
. . N

DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
, , N
double-blind NN N
, , N
controlled VBD N
clinical JJ N
trial NN N
. . N

SETTING NN N
Intensive JJ p
Care NNP p
Unit NNP p
of IN p
the DT p
Ohio NNP p
State NNP p
University NNP p
Medical NNP p
Center NNP p
. . p

PATIENTS VB N
A DT p
total NN p
of IN p
67 CD p
patients NNS p
were VBD p
enrolled VBN p
who WP p
met VBD p
defined VBN p
criteria NNS p
for IN p
acute NN p
lung NN p
injury/acute NN p
respiratory NN p
distress JJ p
syndrome NN p
. . p

INTERVENTIONS VBZ N
A DT N
total NN N
of IN N
43 CD N
of IN N
67 CD N
evaluable JJ N
patients NNS N
randomly RB N
received VBD N
either CC N
EPA+GLA NNP i
or CC i
an DT i
isonitrogenous JJ i
, , i
isocaloric JJ i
standard NN i
diet NN i
that WDT N
was VBD N
tube JJ N
fed VBN N
at IN N
a DT N
minimum JJ N
caloric JJ N
delivery NN N
of IN N
75 CD N
% NN N
of IN N
basal NN N
energy NN N
expenditure NN N
times VBZ N
1.33 CD N
for IN N
at IN N
least JJS N
4 CD N
to TO N
7 CD N
days NNS N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Bronchoalveolar NNP o
lavage NN o
( ( o
BAL NNP o
) ) o
was VBD N
performed VBN N
at IN N
baseline NN N
and CC N
study NN N
days NNS N
4 CD N
and CC N
7 CD N
to TO N
obtain VB N
BAL NNP N
fluid NN N
( ( N
BALF NNP N
) ) N
for IN N
measurement NN o
of IN o
total JJ o
protein NN o
, , o
ceruloplasmin NN o
, , o
and CC o
transferrin NN o
, , o
total JJ o
neutrophil NN o
count NN o
, , o
IL-8 NNP o
, , o
IL-6 NNP o
, , o
tumor NN o
necrosis NN o
factor-alpha NN o
, , o
and CC o
leukotriene JJ o
B4 NNP o
. . o

Oxygenation NNP o
, , N
measured VBD N
as IN N
Pao2/Fio2 NNP N
, , N
was VBD N
assessed VBN N
before IN N
BAL NNP N
. . N

Patients NNS N
fed JJ N
EPA+GLA NNP i
had VBD N
a DT N
significant JJ N
reduction NN N
in IN N
BALF NNP o
ceruloplasmin NN o
and CC o
IL-8 NNP o
during IN N
the DT N
study NN N
as IN N
compared VBN N
with IN N
patients NNS N
fed VBP N
the DT N
control NN N
diet NN N
. . N

BALF NNP o
levels NNS o
of IN o
total JJ o
protein NN o
, , o
neutrophils NNS o
, , o
and CC o
leukotriene JJ o
B4 NNP o
tended VBD N
to TO N
decrease VB N
in IN N
EPA+GLA NNP N
patients NNS N
over IN N
the DT N
course NN N
of IN N
the DT N
study NN N
as IN N
compared VBN N
with IN N
control NN N
patients NNS N
. . N

BALF NNP o
levels NNS o
of IN o
IL-6 NNP o
declined VBD N
similarly RB N
during IN N
the DT N
study NN N
in IN N
both DT N
groups NNS N
. . N

A DT N
trend NN N
toward IN N
a DT N
reduction NN N
in IN N
BALF NNP o
tumor NN o
necrosis NN o
factor-alpha NN o
was VBD N
observed VBN N
on IN N
study NN N
day NN N
7 CD N
in IN N
the DT N
EPA+GLA NNP N
group NN N
as IN N
compared VBN N
with IN N
control NN N
patients NNS N
. . N

Significant JJ N
improvements NNS N
in IN N
oxygenation NN o
( ( N
Pao2/Fio2 NNP N
) ) N
occurred VBD N
in IN N
EPA+GLA NNP N
patients NNS N
on IN N
study NN N
day NN N
4 CD N
as IN N
compared VBN N
with IN N
controls NNS N
. . N

Correlation NN N
analysis NN N
revealed VBD N
significant JJ N
relationships NNS N
between IN N
BALF NNP N
neutrophil JJ o
counts NNS N
and CC N
indices NNS N
of IN N
alveolar-capillary JJ N
membrane NN N
protein NN N
permeability NN N
, , N
IL-8 NNP N
, , N
and CC N
leukotriene JJ o
B4 NNP N
. . N

CONCLUSIONS NNP N
This DT N
preliminary JJ N
investigation NN N
showing VBG N
a DT N
decrease NN N
in IN N
BALF NNP N
levels NNS N
of IN N
IL-8 NNP N
and CC N
leukotriene JJ N
B4 NNP N
and CC N
the DT N
associated JJ N
reduction NN N
of IN N
BALF NNP N
neutrophils NNS N
and CC N
alveolar JJ N
membrane NN N
protein NN N
permeability NN N
in IN N
acute JJ N
respiratory NN N
distress JJ N
syndrome JJ N
patients NNS N
fed VBP N
EPA+GLA NNP N
support NN N
, , N
in IN N
part NN N
, , N
the DT N
potential JJ N
mechanisms NN N
underlying VBG N
the DT N
previously RB N
described VBN N
clinical JJ N
improvements NNS N
with IN N
this DT N
diet NN N
. . N

Additional NNP N
controlled VBD N
studies NNS N
are VBP N
needed VBN N
to TO N
confirm VB N
these DT N
findings NNS N
. . N

-DOCSTART- -17366257- O O

Providing VBG N
live JJ i
supervision NN i
via IN i
teleconferencing VBG i
improves JJ N
acquisition NN o
of IN o
motivational JJ o
interviewing NN o
skills NNS o
after IN N
workshop NN N
attendance NN N
. . N

Teleconferencing VBG i
Supervision NNP i
is VBZ N
a DT N
method NN N
for IN N
training VBG N
community-based JJ p
substance NN p
abuse NN p
clinicians NNS p
in IN N
Motivational NNP i
Interviewing NNP i
( ( i
MI NNP i
) ) i
. . i

Following VBG N
a DT N
2-day JJ N
workshop NN N
, , N
13 CD p
clinicians NNS p
received VBD p
live JJ i
supervision NN i
via IN i
telephone NN i
during IN p
5 CD p
counseling VBG p
sessions NNS p
conducted VBN p
at IN p
their PRP$ p
community NN p
treatment NN p
facilities NNS p
. . p

Clinicians NNPS N
were VBD N
assessed VBN N
for IN N
skill JJ o
level NN o
at IN o
post-workshop NN o
, , N
at IN N
post-training NN N
, , N
and CC N
3 CD N
months NNS N
later RB N
; : N
learning VBG N
was VBD N
assessed VBN N
using VBG N
the DT N
MI NNP N
Treatment NNP N
Integrity NNP N
instrument NN N
. . N

All DT N
summary JJ o
scores NNS o
and CC N
therapist JJ o
behavior NN o
frequency NN o
counts NNS o
improved VBN N
by IN N
post-training NN N
or CC N
by IN N
the DT N
3 CD N
month NN N
follow-up RB N
, , N
although IN N
some DT N
gains NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
. . N

Teleconferencing VBG i
Supervision NN i
may MD N
help VB N
facilitate VB N
the DT N
proficient NN N
use NN N
of IN N
MI NNP p
community NN p
clinicians NNS p
following VBG N
workshop NN N
instruction NN N
. . N

-DOCSTART- -20486273- O O

Efficacy NN o
and CC o
safety NN o
of IN N
routine JJ N
blood NN o
pressure NN o
lowering VBG o
in IN N
older JJR p
patients NNS p
with IN p
diabetes NNS p
: : p
results NNS N
from IN N
the DT N
ADVANCE NNP N
trial NN N
. . N

OBJECTIVE CC N
The DT N
efficacy NN o
and CC o
safety NN o
of IN N
blood NN o
pressure NN o
lowering VBG o
in IN N
elderly JJ p
patients NNS p
have VBP N
not RB N
been VBN N
sufficiently RB N
investigated VBN N
in IN N
patients NNS p
with IN p
diabetes NNS p
. . p

Using VBG N
data NNS N
from IN N
the DT N
Action NNP N
in IN N
Diabetes NNP N
and CC N
Vascular NNP N
disease NN N
: : N
preterAx NN N
and CC N
diamicroN-MR NN N
Controlled NNP N
Evaluation NNP N
study NN N
, , N
we PRP N
assessed VBD N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
routine JJ N
blood NN o
pressure NN o
lowering VBG o
to TO N
prevent VB N
major JJ N
clinical JJ N
outcomes NNS N
in IN N
elderly JJ p
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
. . p

METHODS NNP N
Eleven NNP p
thousand VBP p
one CD p
hundred CD p
and CC p
forty JJ p
patients NNS p
aged VBN p
at IN p
least JJS p
55 CD p
years NNS p
with IN p
type NN p
2 CD p
diabetes NNS p
( ( p
mean JJ p
66+/-6 CD p
years NNS p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
perindopril-indapamide JJ i
or CC i
placebo NN i
. . i

The DT N
primary JJ N
endpoint NN N
was VBD N
a DT N
composite NN o
of IN o
major JJ o
macrovascular NN o
and CC o
microvascular JJ o
disease NN o
. . o

The DT N
effects NNS N
of IN N
active JJ N
treatment NN N
on IN N
outcomes NNS N
were VBD N
estimated VBN N
in IN N
subgroups NNS p
according VBG p
to TO p
age NN p
: : p
below IN p
65 CD p
, , p
65-74 JJ p
and CC p
at IN p
least JJS p
75 CD p
years NNS p
. . p

RESULTS NNP N
During IN N
a DT N
mean JJ N
4.3-year JJ N
follow-up NN N
, , N
1799 CD N
( ( N
16.1 CD N
% NN N
) ) N
patients NNS N
experienced VBD N
a DT N
major JJ N
event NN N
. . N

Active JJ N
treatment NN N
produced VBD N
similar JJ N
relative JJ o
risk NN o
reductions NNS o
for IN N
the DT N
primary JJ o
outcome NN o
, , o
major JJ o
macrovascular JJ o
disease NN o
, , o
death NN o
and CC o
renal JJ o
events NNS o
across IN N
age NN N
groups NNS N
( ( N
all DT N
P NNP N
heterogeneity NN N
> NNP N
0.3 CD N
) ) N
. . N

Over IN N
5 CD N
years NNS N
, , N
active JJ N
treatment NN N
was VBD N
estimated VBN N
to TO N
prevent VB N
one CD N
primary JJ o
outcome NN o
in IN N
every DT N
21 CD N
, , N
71 CD N
and CC N
118 CD N
patients NNS N
of IN N
at IN N
least JJS N
75 CD N
, , N
65-74 JJ N
and CC N
below IN N
65 CD N
years NNS N
, , N
respectively RB N
. . N

Similar JJ N
patterns NNS N
of IN N
benefits NNS N
were VBD N
observed VBN N
for IN N
secondary JJ N
outcomes NNS N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
the DT N
tolerability NN o
between IN N
randomized VBN N
allocations NNS N
across IN N
age NN N
groups NNS N
( ( N
all DT N
P NNP N
heterogeneity NN N
> NNP N
0.6 CD N
) ) N
CONCLUSION NNP N
Routine NNP N
administration NN N
of IN N
perindopril-indapamide JJ i
lowers NNS N
blood NN o
pressure NN o
safely RB N
and CC N
reduces VBZ N
the DT N
risk NN o
of IN N
major JJ N
clinical JJ N
outcomes NNS N
in IN N
patients NNS p
of IN p
at IN p
least JJS p
75 CD p
years NNS p
with IN p
type NN p
2 CD p
diabetes NNS p
. . p

The DT N
greater JJR N
absolute JJ N
benefits NNS N
in IN N
older JJR p
patients NNS p
in IN p
this DT p
age NN p
group NN p
were VBD N
not RB N
offset VBN N
by IN N
an DT N
increased VBN N
risk NN N
of IN N
side NN o
effects NNS o
. . o

-DOCSTART- -18357902- O O

[ JJ N
Isometric NNP N
hip NN N
muscle NN N
strength NN N
in IN N
posttraumatic JJ N
below-knee NN p
amputees NNS p
] VBP p
. . N

BACKGROUND/AIM NNP N
Traumas NNP N
and CC N
war NN N
injuries NNS N
, , N
next JJ N
to TO N
chronic JJ N
occlusive JJ N
artery NN N
disease NN N
and CC N
diabetes VBZ N
mellitus-derived JJ N
complications NNS N
, , N
are VBP N
the DT N
most RBS N
frequent JJ N
cause NN N
of IN N
the DT N
lower JJR N
limbs JJ N
amputation NN N
. . N

They PRP N
affect VBP N
mostly RB N
younger JJR p
population NN p
that WDT N
need VBP N
a DT N
higher JJR N
level NN N
of IN N
activities NNS N
as IN N
compared VBN N
with IN N
the DT N
elderly JJ N
. . N

Medical JJ i
rehabilitation NN i
is VBZ N
very RB N
significant JJ N
for IN N
the DT N
muscle NN N
performance NN N
improvement NN N
in IN N
this DT N
population NN N
providing VBG N
their PRP$ N
social JJ N
reintegration NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
below-knee JJ N
amputation NN N
on IN N
the DT N
hip NN N
isometric JJ N
muscle NN N
strength NN N
and CC N
effect NN N
of IN N
rehabilitation NN N
on IN N
improvement NN N
of IN N
hip NN N
muscle NN N
strength NN N
in IN N
below-knee NN p
amputees NNS p
, , p
secondary JJ p
to TO p
war NN p
wounding VBG p
. . p

METHODS NNP N
Forty NNP p
below-knee NN p
amputees NNS p
( ( p
after IN p
war NN p
wounding NN p
) ) p
, , p
average JJ p
age NN p
35.6 CD p
+/- JJ p
10.6 CD p
years NNS p
, , p
that WDT p
were VBD p
included VBN p
in IN p
primary JJ i
rehabilitation NN i
program NN i
with IN i
prosthetics NNS i
, , p
were VBD p
examined VBN p
. . p

Objective JJ N
parameters NNS N
were VBD N
used VBN N
to TO N
evaluate VB N
therapeutical JJ N
effects NNS N
. . N

Isometric NNP o
muscle NN o
strength NN o
of IN o
hip NN o
flexors NNS o
, , o
extensors NNS o
, , o
abductors NNS o
and CC o
adductors NNS o
was VBD o
measured VBN o
by IN o
dynamometer NN o
and CC o
expressed VBN o
in IN o
Newton NNP o
( ( o
N NNP o
) ) o
at IN o
admission NN o
, , o
control NN o
and CC o
discharge NN o
for IN i
each DT i
patient NN i
. . i

Average JJ N
length NN N
of IN N
the DT N
treatment NN N
was VBD N
51 CD N
+/- JJ N
34.1 CD N
days NNS N
. . N

RESULTS NNP N
For IN N
isometric JJ N
hip NN N
flexors NNS N
( ( N
t JJ N
= NNP N
-1.99346 NNP N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
, , N
extensors NNS N
( ( N
t JJ N
= NNP N
-4.629073 NNP N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
abductors NNS N
( ( N
t JJ N
= NNP N
-4.9408 NNP N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
and CC N
adductors NNS N
( ( N
t JJ N
= NNP N
-2.00228 NNP N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
, , N
muscle NN o
strength NN o
was VBD N
significantly RB N
less JJR N
on IN N
the DT N
amputated VBN N
than IN N
on IN N
nonamputated JJ N
side NN N
. . N

The DT N
highest JJS N
differences NNS N
in IN N
muscle NN o
strength NN o
between IN N
amputated VBN N
and CC N
nonamputated VBN N
limbs NNS N
were VBD N
noted VBN N
for IN N
hip NN N
abductors NNS N
( ( N
26.6 CD N
% NN N
) ) N
and CC N
extensors NNS N
( ( N
23.3 CD N
% NN N
) ) N
. . N

There EX N
was VBD N
significant JJ N
improvement NN N
of IN N
mean JJ o
values NNS o
of IN o
strength NN o
for IN N
all DT N
examined VBN N
hip NN N
muscles NNS N
after IN N
rehabilitation NN N
and CC N
prosthetics NNS N
for IN N
both DT N
legs NNS N
in IN N
comparison NN N
to TO N
beginning NN N
of IN N
the DT N
therapy NN N
. . N

The DT N
hip NN N
abductor NN N
on IN N
the DT N
amputated JJ N
side NN N
was VBD N
for IN N
19.4 CD N
% NN N
weaker NN N
after IN N
rehabilitation NN N
in IN N
comparison NN N
to TO N
the DT N
non-amputated JJ N
limb NN N
. . N

CONCLUSION NNP N
Decreases NNP N
of IN N
isometric JJ N
muscle NN N
strength NN N
in IN N
all DT N
examined JJ N
hip NN N
muscles NNS N
were VBD N
observed VBN N
, , N
more RBR N
in IN N
the DT N
amputated JJ N
limb NN N
. . N

Rehabilitation NN N
with IN N
prosthetics NNS N
is VBZ N
a DT N
successful JJ N
method NN N
for IN N
improving VBG N
isometric JJ N
hip NN N
muscle NN N
strength NN N
on IN N
the DT N
both DT N
, , N
amputated VBN p
and CC p
non-amputated JJ p
limbs NNS p
in IN p
war NN p
wounded VBD p
below-knee JJ p
amputees NNS p
. . p

-DOCSTART- -25957107- O O

Effect NN N
of IN N
Chinese NNP i
herbal JJ i
medicine NN i
on IN N
vascular JJ o
functions NNS o
during IN N
60-day JJ N
head-down JJ N
bed NN N
rest NN N
. . N

PURPOSE NNP N
Chinese JJ i
herbal JJ i
medicine NN i
is VBZ N
a DT N
promising JJ N
countermeasure NN N
against IN N
cardiovascular JJ o
dysfunction NN o
associated VBN p
with IN p
a DT p
sedentary JJ p
lifestyle NN p
. . p

We PRP N
examined VBD N
the DT N
impact NN N
of IN N
the DT N
Chinese JJ i
herb NN i
, , i
Taikong NNP i
Yangxin NNP i
, , N
on IN N
the DT N
micro- JJ o
and CC o
macrovascular JJ o
dysfunction NN o
associated VBN N
with IN N
a DT N
60-day JJ p
bed NN p
rest NN p
. . p

METHODS NNP N
Fourteen NNP p
healthy JJ p
men NNS p
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
: : N
those DT N
given VBN N
herbal JJ i
supplement NN i
, , N
and CC N
the DT N
control NN N
group NN N
; : N
the DT N
two CD N
groups NNS N
underwent VBD N
a DT N
60-day JJ i
bed NN i
rest NN i
. . i

The DT N
macrovasculature NN o
was VBD N
assessed VBN N
by IN N
sonography NN N
. . N

Skin NNP o
microvascular JJ o
functions NNS o
were VBD N
assessed VBN N
with IN N
laser NN N
Doppler NNP N
. . N

The DT N
plasma JJ o
level NN o
of IN o
endothelial JJ o
microparticles NNS o
( ( o
EMPs NNP o
) ) o
, , N
markers NNS N
of IN N
endothelial JJ o
injury NN o
, , N
was VBD N
determined VBN N
. . N

RESULTS NNP N
Bed NNP N
rest NN N
induced VBD N
a DT N
33 CD N
% NN N
decrease NN N
in IN N
the DT N
femoral JJ o
artery NN o
diameter NN o
and CC N
compliance NN o
whereas NNS N
carotid VBP o
wall NN o
thickness NN o
, , o
diameter NN o
, , o
and CC o
compliance NN o
remained VBD N
unchanged JJ N
. . N

The DT N
early JJ o
phase NN o
of IN o
endothelium-dependent JJ o
vasodilation NN o
to TO o
ACh NNP o
was VBD N
unmodified VBN N
by IN N
bed NN N
rest NN N
, , N
while IN N
the DT N
late JJ o
phase NN o
was VBD N
reduced VBN N
by IN N
30 CD N
% NN N
along IN N
with IN N
a DT N
twofold JJ N
increase NN N
in IN N
EMPs NNP o
. . o

In IN N
those DT N
given VBN N
Taikong NNP i
Yangxin NNP i
, , N
the DT N
early JJ o
phase NN o
was VBD N
amplified VBN N
by IN N
2.5-fold JJ N
, , N
and CC N
the DT N
effects NNS o
of IN o
bed NN o
rest NN o
on IN N
the DT N
late JJ o
phase NN o
were VBD N
prevented VBN N
. . N

CONCLUSION NNP N
These DT N
findings NNS N
indicate VBP N
that IN N
Taikong NNP N
Yangxin NNP N
ameliorates VBZ N
endothelium-dependent JJ o
vasodilation NN o
, , N
likely RB N
by IN N
improving VBG N
the DT N
NO NNP N
pathway NN N
. . N

The DT N
study NN N
suggests VBZ N
Taikong NNP N
Yangxin NNP N
as IN N
a DT N
new JJ N
countermeasure NN N
to TO N
prevent VB N
the DT N
changes NNS N
in IN N
microvascular JJ o
function NN o
induced VBN N
by IN N
physical JJ N
inactivity NN N
. . N

-DOCSTART- -23562192- O O

Nasal NNP o
eosinophilia NNS o
and CC o
serum NN o
soluble JJ o
intercellular JJ o
adhesion NN o
molecule NN o
1 CD o
in IN N
patients NNS p
with IN p
allergic JJ p
rhinitis NN p
treated VBN N
with IN N
montelukast NN i
alone RB i
or CC N
in IN N
combination NN N
with IN N
desloratadine NN i
or CC N
levocetirizine NN i
. . i

BACKGROUND NNP N
Because IN N
intercellular JJ N
adhesion NN N
molecule NN N
( ( N
ICAM NNP N
) ) N
1 CD N
and CC N
recruitment NN N
of IN N
eosinophils NNS N
are VBP N
crucial JJ N
in IN N
supporting VBG N
allergic JJ N
inflammation NN N
, , N
their PRP$ N
down-regulation NN N
may MD N
bring VB N
additional JJ N
benefits NNS N
in IN N
patients NNS N
' POS N
recovery NN N
. . N

We PRP N
have VBP N
assessed VBN N
nasal JJ o
eosinophilia NNS o
and CC o
serum NN o
soluble JJ o
ICAM-1 NNP o
( ( o
sICAM-1 JJ o
) ) o
concentrations NNS o
in IN N
relation NN N
to TO N
nasal VB o
symptoms NNS o
in IN N
patients NNS p
with IN p
persistent JJ p
allergic JJ p
rhinitis NN p
( ( p
AR NNP p
) ) p
treated VBD N
for IN N
6 CD N
weeks NNS N
with IN N
either DT N
desloratadine NN i
, , i
levocetirizine NN i
, , i
montelukast NN i
alone RB i
, , N
or CC N
in IN N
combination NN i
. . i

METHODS NNP N
In IN N
this DT N
single-center NN p
, , p
randomized VBN p
, , p
double-blind JJ p
, , p
placebo-controlled JJ i
, , p
crossover NN p
, , p
two-arm JJ p
study NN p
, , p
40 CD p
patients NNS p
with IN p
persistent JJ p
AR NNP p
were VBD p
randomized VBN p
to TO N
receive VB N
either DT N
montelukast NN i
and/or JJ i
levocetirizine NN i
or CC i
placebo NN i
( ( N
n JJ N
= NNP N
20 CD N
) ) N
or CC N
to TO N
receive VB N
treatment NN N
with IN N
montelukast NN i
and/or JJ i
desloratadine NN i
or CC N
placebo NN i
( ( N
n JJ N
= NNP N
20 CD N
) ) N
. . N

Nasal NNP o
eosinophilia JJ o
and CC o
concentration NN o
of IN o
sICAM-1 NN o
in IN o
peripheral JJ o
blood NN o
were VBD N
assessed VBN N
before RB N
and CC N
on IN N
the DT N
last JJ N
day NN N
of IN N
each DT N
treatment NN N
period NN N
. . N

RESULTS NNP N
All NNP N
active JJ N
treatments NNS N
in IN N
both DT N
arms NNS N
of IN N
the DT N
study NN N
resulted VBD N
in IN N
the DT N
decrease NN N
of IN N
sICAM-1 JJ o
and CC o
nasal JJ o
eosinophilia NN o
, , N
which WDT N
correlated VBD N
with IN N
the DT N
severity NN o
of IN o
nasal NN o
symptoms NNS o
. . o

In IN N
the DT N
montelukast/levocetirizine NN i
arm NN N
, , N
montelukast NN i
decreased VBD N
nasal JJ o
eosinophilia RB o
more RBR N
significantly RB N
than IN N
levocetirizine NN i
, , N
whereas NNS N
in IN N
reduction NN N
of IN N
sICAM-1 JJ o
all DT N
active JJ N
treatment NN N
options NNS N
were VBD N
equally RB N
effective JJ N
. . N

However RB N
, , N
in IN N
the DT N
desloratadine/montelukast NN i
arm NN N
, , N
the DT N
resulting VBG N
improvement NN N
of IN N
combination NN N
therapy NN N
of IN N
sICAM-1 NN o
and CC N
the DT N
influx NN o
of IN o
eosinophils NNS o
was VBD N
not RB N
statistically RB N
significant JJ N
. . N

CONCLUSION VB N
The DT N
improvement NN N
of IN N
nasal NN o
symptoms NNS o
in IN N
patients NNS p
with IN p
AR NNP p
treated VBD N
with IN N
antihistamines NNS N
, , N
with IN N
or CC N
without IN N
montelukast JJS i
, , N
may MD N
additionally RB N
result VB N
from IN N
the DT N
reduction NN N
of IN N
sICAM-1 NN o
and CC o
nasal JJ o
eosinophilia NN o
. . o

Because IN N
the DT N
combination NN N
therapy NN N
may MD N
bring VB N
inconclusive JJ N
benefits NNS N
in IN N
this DT N
area NN N
there EX N
is VBZ N
a DT N
strong JJ N
need NN N
of IN N
further JJ N
studies NNS N
to TO N
find VB N
mechanisms NN N
that IN N
favor NN N
combination NN N
therapy NN N
. . N

-DOCSTART- -22080777- O O

Instant JJ i
Recess? NNP i
: : i
a DT N
practical JJ N
tool NN N
for IN N
increasing VBG o
physical JJ o
activity NN o
during IN N
the DT N
school NN N
day NN N
. . N

BACKGROUND NNP N
An DT N
increased JJ N
prevalence NN N
of IN p
overweight/obesity NN p
among IN p
children NNS p
has VBZ N
led VBN N
to TO N
school NN N
district NN N
level NN N
policies NNS N
to TO N
increase VB o
physical JJ o
activity NN o
( ( o
PA NNP o
) ) o
among IN p
elementary JJ p
school NN p
students NNS p
. . p

Interventions NNS N
are VBP N
needed VBN N
that IN N
increase NN N
activity NN N
levels NNS N
without IN N
sacrificing VBG N
time NN N
spent VBN N
in IN N
academics NNS N
. . N

OBJECTIVES IN N
We PRP N
evaluated VBD N
a DT N
policy NN i
implementation NN i
intervention NN i
for IN N
to TO N
increase VB N
in-school JJ i
PA NNP i
in IN p
elementary JJ p
schools NNS p
in IN p
Forsyth NNP p
County NNP p
, , p
North NNP p
Carolina NNP p
, , p
in IN N
a DT N
randomized JJ N
study NN N
with IN N
a DT N
delayed JJ N
intervention NN N
control NN N
group NN N
. . N

METHODS NNP p
The DT p
study NN p
included VBD p
third- JJ p
through IN p
fifth-grade JJ p
classrooms NNS p
in IN p
eight CD p
elementary JJ p
schools NNS p
. . p

Instant NNP i
Recess? NNP i
was VBD i
used VBN N
to TO N
introduce VB N
10-minute JJ i
PA NNP i
breaks NNS i
in IN i
classrooms NNS N
on IN N
schedules NNS N
determined VBN N
by IN N
teachers NNS N
. . N

Direct JJ N
observation NN N
was VBD N
used VBN N
to TO N
measure VB o
activity NN o
levels NNS o
, , o
other JJ o
student NN o
behaviors NNS o
, , o
and CC o
teacher NN o
behaviors NNS o
related VBN o
to TO N
PA NNP N
in IN N
the DT N
classrooms NNS N
. . N

RESULTS NNP N
Twenty-eight JJ N
visits NNS N
to TO N
schools NNS N
were VBD N
made VBN N
during IN N
the DT N
spring NN N
and CC N
fall NN N
semesters NNS N
of IN N
2009 CD N
. . N

At IN N
baseline JJ N
11 CD N
% NN N
to TO N
44 CD N
% NN N
of IN N
intervention NN N
and CC N
control NN N
schools NNS N
were VBD N
engaged VBN N
in IN N
classroom-based JJ i
PA. NNP o
PA NNP o
increased VBD o
from IN N
baseline NN N
to TO N
spring VB N
follow-up NN N
in IN N
intervention NN N
schools NNS N
and CC N
was VBD N
maintained VBN N
the DT N
following VBG N
fall NN N
. . N

Control NNP N
schools NNS N
decreased VBD o
PA NNP o
from IN o
baseline NN N
to TO N
spring NN N
and CC N
increased VBD o
PA NNP o
once RB o
they PRP N
began VBD N
the DT N
intervention NN N
. . N

Students NNS N
in IN N
classrooms NNS N
engaged VBN N
in IN N
Instant NNP N
Recess NNP N
exhibited VBD o
statistically RB o
significant JJ o
increases NNS o
in IN o
light NN o
( ( o
51 CD o
% NN o
) ) o
and CC o
moderate-intensity NN o
( ( o
16 CD o
% NN o
) ) o
PA NNP o
and CC o
increases NNS o
in IN o
time NN o
spent VBN o
in IN o
on-task JJ o
behavior NN o
( ( o
11 CD N
% NN N
) ) N
. . N

Control NNP N
schools NNS N
experienced VBD N
similar JJ N
benefits NNS N
after IN N
they PRP N
began VBD N
implementing VBG N
Instant NNP N
Recess NNP N
. . N

CONCLUSIONS NNP N
Instant NNP N
Recess NNP N
is VBZ N
useful JJ N
for IN o
increasing VBG o
PA NNP o
and CC o
improving VBG o
behavior NN o
among IN o
elementary JJ p
school NN p
children NNS p
. . p

Additional NNP N
research NN N
may MD N
be VB N
needed VBN N
to TO N
understand VB N
how WRB N
to TO N
create VB N
policies NNS N
supporting VBG N
classroom NN N
activity NN N
breaks NNS N
and CC N
how WRB N
to TO N
assess VB N
policy NN N
adherence NN N
. . N

-DOCSTART- -25533997- O O

Inverse NNP N
fluoxetine NN N
effects NNS N
on IN N
inhibitory NN o
brain NN o
activation NN o
in IN N
non-comorbid JJ p
boys NNS p
with IN p
ADHD NNP p
and CC p
with IN p
ASD NNP p
. . p

RATIONALE NNP N
Attention NNP N
deficit NN N
hyperactivity NN N
disorder NN N
( ( N
ADHD NNP N
) ) N
and CC N
autism NN N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
are VBP N
often RB N
comorbid JJ N
and CC N
have VBP N
both DT N
performance NN N
and CC N
brain NN N
dysfunctions NNS N
during IN N
motor NN N
response NN N
inhibition NN N
. . N

Serotonin NNP N
agonists VBZ N
modulate VBP N
motor NN o
response NN o
inhibition NN o
and CC N
have VBP N
shown VBN N
positive JJ N
behavioural JJ o
effects NNS o
in IN N
both DT N
disorders NNS N
. . N

AIMS IN N
We PRP N
therefore VBP N
used JJ N
functional JJ i
magnetic JJ i
resonance NN i
imaging NN i
( ( N
fMRI NN N
) ) N
to TO N
investigate VB N
the DT N
so RB N
far RB N
unknown JJ N
shared VBN N
and CC N
disorder-specific JJ N
inhibitory NN o
brain NN o
dysfunctions NNS o
in IN N
these DT N
two CD N
disorders NNS N
, , N
as RB N
well RB N
as IN N
the DT N
effects NNS N
of IN N
a DT N
single JJ N
dose NN N
of IN N
the DT N
selective JJ N
serotonin NN N
reuptake NN N
inhibitor NN N
fluoxetine NN N
. . N

METHODS NNP N
Age-matched JJ p
boys NNS p
with IN p
ADHD NNP p
( ( p
18 CD p
) ) p
, , p
ASD NNP p
( ( p
19 CD p
) ) p
and CC p
healthy JJ p
controls NNS p
( ( p
25 CD p
) ) p
were VBD N
compared VBN i
with IN i
fMRI NN i
during IN i
a DT i
stop JJ i
task NN i
measuring VBG i
motor NN o
inhibition NN o
. . o

Patients NNS N
were VBD N
scanned VBN N
twice RB N
, , N
under IN N
either DT N
an DT i
acute NN i
dose NN i
of IN i
fluoxetine NN i
or CC i
placebo NN i
in IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ i
randomised JJ N
design NN N
. . N

Repeated VBN N
measures NNS N
analyses NNS N
within IN N
patients NNS N
assessed JJ N
drug NN o
effects NNS o
. . o

To TO N
test VB N
for IN N
potential JJ N
normalisation NN o
effects NNS o
of IN N
brain NN N
dysfunctions NNS N
, , N
patients NNS N
under IN N
each DT N
drug NN N
condition NN N
were VBD N
compared VBN N
to TO N
controls NNS N
. . N

RESULTS NNP N
Under IN N
placebo NN N
, , N
relative JJ N
to TO N
controls NNS N
, , N
ASD NNP p
boys VBZ p
showed VBD N
overactivation NN o
in IN o
left NN o
and CC o
right JJ o
inferior JJ o
frontal JJ o
cortex NN o
( ( o
IFC NNP o
) ) o
, , N
while IN N
ADHD NNP p
boys VBZ p
showed VBD N
disorder-specific JJ N
underactivation NN o
in IN o
orbitofrontal JJ o
cortex NN o
( ( o
OFC NNP o
) ) o
and CC o
basal $ o
ganglia NNS o
. . o

Under IN N
fluoxetine NN N
, , N
the DT N
prefrontal JJ o
dysfunctions NNS o
were VBD N
no RB N
longer JJR N
observed VBN N
, , N
due JJ N
to TO N
inverse JJ N
effects NNS N
of IN N
fluoxetine NN N
on IN N
these DT N
activations NNS N
: : N
fluoxetine NN N
downregulated VBD N
IFC NNP o
and CC o
OFC NNP o
activation NN o
in IN N
ASD NNP N
but CC N
upregulated VBD N
them PRP N
in IN N
ADHD NNP N
. . N

CONCLUSIONS NNP N
The DT N
findings NNS N
show VBP N
that IN N
fluoxetine NN N
normalises NNS N
frontal JJ o
lobe NN o
dysfunctions NNS o
in IN N
both DT N
disorders NNS N
via IN N
inverse JJ N
effects NNS N
, , N
downregulating VBG N
abnormally RB N
increased VBN N
frontal JJ o
activation NN o
in IN N
ASD NNP N
and CC N
upregulating VBG N
abnormally RB N
decreased VBN N
frontal JJ o
activation NN o
in IN N
ADHD NNP N
, , N
potentially RB N
reflecting VBG N
inverse JJ N
baseline NN N
serotonin NN N
levels NNS N
in IN N
both DT N
disorders NNS N
. . N

-DOCSTART- -1897766- O O

Comparison NNP N
of IN N
40 CD N
milliliters NNS N
of IN N
0.25 CD N
% NN N
intrapleural JJ N
bupivacaine NN i
with IN N
epinephrine NN i
with IN N
20 CD N
milliliters NNS N
of IN N
0.5 CD N
% NN N
intrapleural JJ N
bupivacaine NN N
with IN N
epinephrine NN N
after IN N
cholecystectomy NN N
. . N

To TO N
determine VB N
the DT N
influence NN N
of IN N
the DT N
volume NN N
of IN N
local JJ N
anesthetic JJ N
injected VBN N
for IN N
intrapleural JJ N
analgesia NN N
, , N
40 CD p
patients NNS p
undergoing JJ p
cholecystectomy NNS p
were VBD p
randomly RB p
allocated VBN p
to TO p
two CD p
groups NNS p
of IN p
20 CD p
patients NNS p
each DT p
. . p

One CD i
group NN i
received VBD i
40 CD i
mL NN i
of IN i
0.25 CD i
% NN i
bupivacaine NN i
with IN i
epinephrine NN i
injected VBN i
intrapleurally RB i
postoperatively RB i
. . i

The DT i
other JJ i
group NN i
received VBD i
20 CD i
mL NN i
of IN i
0.5 CD i
% NN i
bupivacaine NN i
with IN i
epinephrine NN i
. . i

The DT N
onset JJ o
time NN o
of IN o
analgesia NN o
was VBD N
nearly RB N
the DT N
same JJ N
in IN N
both DT N
groups NNS N
and CC N
within IN N
25 CD N
min NNS N
all DT N
patients NNS p
were VBD N
nearly RB N
pain JJ N
free JJ N
. . N

Our PRP$ N
data NNS N
demonstrate NN N
that IN N
100 CD N
mg NN N
of IN N
bupivacaine NN N
with IN N
epinephrine JJ N
elicits NNS N
effective JJ N
analgesia NN N
after IN N
cholecystectomy NN N
. . N

There EX N
are VBP N
only RB N
minor JJ N
differences NNS N
between IN N
20 CD N
and CC N
40 CD N
mL NN N
with IN N
regard NN N
to TO N
pain VB o
relief NN o
. . o

The DT N
authors NNS N
conclude VBP N
that IN N
the DT N
volume NN N
of IN N
local JJ N
anesthetic NN N
within IN N
the DT N
range NN N
of IN N
20-40 JJ N
mL NN N
in IN N
an DT N
adult NN N
has VBZ N
little JJ N
influence NN N
on IN N
the DT N
extent NN N
or CC N
duration NN N
of IN N
intrapleural JJ N
analgesia NN N
. . N

-DOCSTART- -16030622- O O

Trichuris NNP N
infections NNS N
in IN N
pigs NNS p
: : p
a DT N
treatment NN i
trial NN i
in IN N
the DT N
field NN N
. . N

-DOCSTART- -8509099- O O

Recurrence NN o
of IN o
condylomata NNS o
acuminata NNS o
following VBG p
cryotherapy NN i
is VBZ N
not RB N
prevented VBN N
by IN N
systemically RB N
administered VBN N
interferon NN i
. . i

OBJECTIVE UH N
To TO N
determine VB N
whether IN N
interferon JJ i
alpha-2a NN i
, , N
when WRB N
utilised JJ N
as IN N
adjuvant JJ i
chemotherapy NN i
following VBG N
ablation NN N
of IN N
condylomata NN N
acuminata NNS N
( ( N
genital JJ N
warts NNS N
) ) N
by IN N
cryotherapy NN i
, , N
is VBZ N
effective JJ N
in IN N
the DT N
prevention NN N
of IN N
recurrences NNS N
. . N

DESIGN NNP N
Randomised VBD N
, , N
placebo-controlled JJ i
, , N
double-blind JJ N
study NN N
. . N

Statistical JJ N
analysis NN N
was VBD N
by IN N
2-tailed JJ N
Fisher NNP N
's POS N
Exact NNP N
Test NNP N
. . N

PATIENTS CC N
97 CD p
patients NNS p
with IN p
recurrent JJ p
condylomata NN p
acuminata NN p
. . p

INTERVENTION NNP N
49 CD N
patients NNS N
were VBD N
treated VBN N
with IN N
cryotherapy NN i
plus CC i
subcutaneously RB i
administered VBN i
interferon NN i
alpha-2a NN i
, , N
and CC N
48 CD N
received VBD N
cryotherapy NN i
plus CC i
placebo NN i
. . i

Of IN N
these DT N
, , N
36 CD p
and CC p
37 CD p
patients NNS p
, , p
respectively RB p
, , p
completed VBD p
the DT p
study NN p
and CC N
were VBD N
evaluable JJ N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
Clinical NNP o
eradication NN o
of IN o
condylomata NN o
for IN o
six CD o
months NNS o
following VBG o
adjuvant JJ o
chemotherapy NN o
. . o

RESULTS VBN N
By IN N
completion NN N
of IN N
the DT N
adjuvant JJ i
chemotherapy NN i
, , N
10 CD N
( ( N
28 CD N
% NN N
) ) N
interferon NN N
recipients NNS N
and CC N
16 CD N
( ( N
43 CD N
% NN N
) ) N
placebo NN i
recipients NNS N
experienced VBD N
recurrences NNS o
. . o

At IN N
six CD N
months NNS N
follow-up RB N
, , N
25 CD N
( ( N
69 CD N
% NN N
) ) N
interferon NN i
and CC N
27 CD N
( ( N
73 CD N
% NN N
) ) N
placebo NN i
recipients NNS N
experienced VBD o
recurrences NNS o
. . o

In IN N
the DT N
six CD N
months NNS N
following VBG N
interferon NN i
therapy NN i
, , N
only RB N
31 CD N
% NN N
of IN N
interferon NN i
and CC N
27 CD N
% NN N
of IN N
placebo NN i
recipients NNS N
remained VBD N
free JJ o
of IN o
recurrences NNS o
( ( N
p JJ N
= NNP N
0.99 CD N
) ) N
. . N

CONCLUSIONS NNP N
Interferon NNP i
alpha-2a NN i
administered VBD N
subcutaneously RB N
offers VBZ N
no DT N
benefit NN N
as IN N
a DT N
chemotherapeutic JJ i
adjuvant NN i
to TO i
cryotherapy VB i
when WRB N
used VBN N
alone RB N
in IN N
the DT N
therapy NN N
of IN N
genital JJ N
warts NNS N
in IN N
this DT N
population NN p
of IN p
patients NNS p
with IN p
recurrent JJ p
condylomata NNS p
. . p

-DOCSTART- -16431255- O O

Paricalcitol NNP i
capsule NN i
for IN N
the DT N
treatment NN N
of IN N
secondary JJ o
hyperparathyroidism NN o
in IN p
stages NNS p
3 CD p
and CC p
4 CD p
CKD NNP p
. . p

BACKGROUND NNP N
The DT N
safety NN o
and CC o
efficacy NN o
of IN N
paricalcitol NN i
injection NN N
have VBP N
been VBN N
well RB N
established VBN N
for IN N
the DT N
prevention NN N
and CC N
treatment NN N
of IN N
secondary JJ o
hyperparathyroidism NN o
( ( o
SHPT NNP o
) ) o
in IN p
patients NNS p
with IN p
chronic JJ p
kidney NN p
disease NN p
( ( p
CKD NNP p
) ) p
stage NN p
5 CD p
. . p

The DT N
capsule JJ N
form NN N
of IN N
paricalcitol NN N
was VBD N
developed VBN N
to TO N
provide VB N
a DT N
convenient JJ N
dosage NN N
form NN N
for IN N
patients NNS N
with IN N
stages NNS N
3 CD N
and CC N
4 CD N
CKD NNP N
. . N

METHODS NNP N
Three NNP p
randomized VBD p
, , p
placebo-controlled JJ i
, , p
phase-3 JJ p
trials NNS p
were VBD p
conducted VBN p
in IN p
patients NNS p
with IN p
stages NNS p
3 CD p
and CC p
4 CD p
CKD NNP p
with IN p
SHPT NNP p
. . p

Enrollment NNP p
criteria NNS p
included VBD p
an DT p
estimated VBN p
glomerular JJ p
filtration NN p
rate NN p
between IN p
15 CD p
and CC p
60 CD p
mL/min/1.73 NN p
m2 NN p
( ( p
0.25 CD p
and CC p
1.00 CD p
mL/s/1.73 NNS p
m2 NN p
) ) p
, , p
an DT p
average NN p
of IN p
2 CD p
consecutive JJ p
intact JJ p
parathyroid NN p
hormone NN p
( ( p
iPTH NN p
) ) p
levels NNS p
greater JJR p
than IN p
150 CD p
pg/mL NN p
( ( p
ng/L JJ p
) ) p
, , p
2 CD p
consecutive JJ p
serum NN o
calcium NN o
levels NNS o
between IN p
8.0 CD p
and CC p
10.0 CD p
mg/dL NN p
( ( p
2.00 CD p
and CC p
2.50 CD p
mmol/L NN p
) ) p
, , p
and CC p
2 CD p
consecutive JJ p
serum NN o
phosphorus NN o
levels NNS o
of IN p
5.2 CD p
mg/dL NN p
or CC p
less JJR p
( ( p
< NN p
or CC p
= $ p
1.68 CD p
mmol/L NN p
) ) p
. . p

Two CD N
studies NNS N
used VBD N
a DT N
thrice-weekly JJ N
dosing NN N
regimen NNS N
and CC N
1 CD N
study NN N
used VBD N
a DT N
once-daily JJ N
dosing NN N
regimen NNS N
for IN N
24 CD N
weeks NNS N
. . N

Dosing NNP N
was VBD N
based VBN N
on IN N
serum NN N
iPTH NN N
, , N
calcium NN N
, , N
and CC N
phosphorus NN N
levels NNS N
. . N

The DT N
primary JJ N
efficacy JJ N
end NN N
point NN N
is VBZ N
2 CD o
consecutive JJ o
decreases NNS o
in IN o
iPTH NN o
levels NNS o
greater JJR N
than IN N
30 CD N
% NN N
from IN N
baseline NN o
. . o

RESULTS NNP N
Two CD p
hundred VBD p
twenty NN p
patients NNS p
participated VBD p
( ( p
n JJ p
= NN p
107 CD p
, , p
paricalcitol NN p
; : p
n CC p
= $ p
113 CD p
, , p
placebo NN i
) ) i
. . p

At IN N
least JJS N
2 CD N
consecutive JJ N
decreases NNS o
in IN o
iPTH JJ o
levels NNS o
of IN N
30 CD N
% NN N
or CC N
greater JJR N
from IN N
baseline NN N
occurred VBN N
in IN N
91 CD N
% NN N
of IN N
paricalcitol JJ N
versus FW N
13 CD N
% NN N
of IN N
placebo NN N
patients NNS N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Incidences NNS N
of IN N
hypercalcemia NN o
, , o
hyperphosphatemia NN o
, , o
and CC o
elevated VBD o
calcium-phosphorus JJ o
product NN o
levels NNS o
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
groups NNS N
. . N

Similarly RB N
, , N
no DT N
significant JJ N
differences NNS N
in IN N
urinary JJ o
calcium NN o
and CC o
phosphorus JJ o
excretion NN o
or CC o
deterioration NN o
in IN o
kidney NN o
function NN o
were VBD N
detected VBN N
in IN N
patients NNS N
administered VBN N
paricalcitol NNS i
compared VBN N
with IN N
placebo NN i
. . i

CONCLUSION NNP N
Paricalcitol NNP i
capsule NN N
was VBD N
well RB N
tolerated VBN N
and CC N
effectively RB N
decreased VBN N
iPTH NN N
levels NNS N
with IN N
minimal JJ N
or CC N
no DT N
impact NN N
on IN N
calcium NN N
levels NNS N
, , N
phosphorus NN N
balance NN N
, , N
and CC N
kidney NN N
function NN N
in IN N
patients NNS N
with IN N
stages NNS N
3 CD N
and CC N
4 CD N
CKD NNP N
. . N

-DOCSTART- -8686245- O O

[ JJ N
Effectiveness NNP N
of IN N
adjuvant JJ i
hormone NN i
therapy NN i
in IN N
breast NN N
cancer NN N
] NNP N
. . N

A NNP N
third JJ N
series NN N
of IN N
randomized JJ N
tests NNS N
was VBD N
undertaken VBN N
to TO N
evaluate VB o
the DT N
efficacy NN o
of IN N
postoperative JJ N
adjuvant JJ i
hormone NN i
therapy NN i
( ( i
tamoxifen NN i
, , i
diethylstilbestrol NN i
, , i
orimethen VBP i
amino JJ i
glutethymide NN i
) ) i
in IN N
breast NN p
cancer NN p
patients NNS p
. . p

Tamoxifen NNP i
was VBD N
studied VBN N
in IN N
176 CD p
patients NNS p
with IN p
T1-2N0M0 NNP p
tumors NNS p
. . p

Five-year JJ o
recurrence-free JJ o
survival NN o
was VBD N
registered VBN N
in IN N
85.2 CD N
% NN N
of IN N
menopausal NN N
patients NNS N
treated VBN N
with IN N
tamoxifen JJ i
versus NN N
71.1 CD N
% NN N
in IN N
control NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Five-year JJ o
recurrence-free JJ o
survival NN o
in IN N
menopausal NN N
females NNS N
with IN N
breast NN N
tumors NNS N
, , N
stage NN N
IIb NNP N
, , N
was VBD N
71.1 CD N
% NN N
among IN N
those DT N
treated VBN N
with IN N
diethylstilbestrol NN N
and CC N
as RB N
low JJ N
as IN N
57.4 CD N
% NN N
in IN N
the DT N
tamoxifen NN i
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Untoward NNP o
side-effect JJ o
incidence NN o
was VBD N
much JJ o
higher JJR o
in IN N
the DT N
diethylstilbestrol NN N
group NN N
( ( N
30.4 CD N
% NN N
) ) N
as IN N
compared VBN N
with IN N
tamoxifen NN i
( ( N
3.5 CD N
% NN N
) ) N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
found VBN N
for IN N
the DT N
relationship NN N
between IN N
orimethen NN i
and CC N
tamoxifen JJ i
treatment NN N
with IN N
respect NN N
to TO N
5-year JJ o
survival NN o
and CC o
recurrence-free JJ o
survival NN o
. . o

-DOCSTART- -2116385- O O

Cost NNP N
effectiveness NN N
of IN N
training VBG N
incontinent JJ p
elderly RB p
in IN p
nursing VBG p
homes NNS p
: : p
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

This DT N
study NN N
used VBD N
a DT N
randomized JJ N
clinical JJ N
trial NN N
with IN N
133 CD p
incontinent JJ p
elderly RB p
in IN p
seven CD p
nursing NN p
homes NNS p
to TO N
evaluate VB N
the DT N
effectiveness NN o
of IN N
a DT N
behavioral JJ i
training NN i
therapy NN i
and CC N
its PRP$ N
cost NN N
implications NNS N
. . N

The DT N
training NN N
program NN N
lasted VBD N
three CD N
months NNS N
, , N
and CC N
a DT N
22-week JJ N
follow-up JJ N
period NN N
examined VBD N
the DT N
durability NN N
of IN N
the DT N
treatment NN N
effect NN N
. . N

The DT N
therapy NN N
became VBD N
effective JJ N
after IN N
six CD N
weeks NNS N
of IN N
training NN N
. . N

By IN N
the DT N
final JJ N
months NNS N
of IN N
training NN N
, , N
the DT N
treatment NN N
participants NNS N
' POS N
wet NN o
episodes NNS o
had VBD N
been VBN N
reduced VBN N
by IN N
0.6 CD N
episode NNS N
per IN N
day NN N
, , N
or CC N
a DT N
26 CD N
percent NN N
reduction NN N
over IN N
baseline NN N
, , N
and CC N
improvement NN N
was VBD N
maintained VBN N
during IN N
the DT N
follow-up JJ N
period NN N
. . N

Trainees NNS p
with IN p
a DT p
high JJ p
frequency NN p
of IN p
incontinence NN p
during IN p
baseline NN p
, , p
relatively RB p
more RBR p
cognitive JJ p
residents NNS p
, , p
and CC p
residents NNS p
with IN p
a DT p
normal JJ p
bladder NN p
capacity NN p
responded VBD N
better JJR N
to TO N
this DT N
behavioral JJ i
program NN i
. . i

The DT N
cost NN o
of IN o
training NN o
was VBD N
the DT N
equivalent NN N
of IN N
about IN N
one CD N
hour NN N
of IN N
nursing VBG N
aide JJ N
time NN N
per IN N
patient JJ N
day NN N
. . N

The DT N
reduction NN N
in IN N
incontinence NN o
during IN N
the DT N
follow-up JJ N
period NN N
resulted VBD N
in IN N
some DT N
small JJ o
savings NNS o
in IN o
laundry NN o
costs NNS o
and CC o
supplies NNS o
used VBN o
, , N
and CC N
some DT N
quantitatively RB N
unmeasurable JJ N
but CC N
detectable JJ N
improvement NN o
in IN o
psychosocial JJ o
well-being NN o
among IN N
the DT N
trainees NNS N
. . N

Since IN N
the DT N
central JJ N
figure NN N
in IN N
implementing VBG N
this DT N
training NN N
protocol NN N
is VBZ N
the DT N
nursing NN N
aide NN N
, , N
it PRP N
is VBZ N
important JJ N
to TO N
find VB N
an DT N
organizational JJ N
management NN N
scheme NN N
that WDT N
will MD N
stimulate VB N
nursing NN N
aides NNS N
to TO N
reduce VB N
incontinence NN N
among IN N
nursing JJ p
home NN p
residents NNS p
. . p

-DOCSTART- -14995965- O O

Skin NNP o
concentrations NNS o
of IN N
thromboxane NN N
synthetase NN N
inhibitor NN N
after IN N
topical JJ N
application NN N
with IN N
bioelastic JJ N
membrane NN N
. . N

Elevated VBN N
thromboxane NN N
levels NNS N
are VBP N
associated VBN N
with IN N
a DT N
number NN N
of IN N
disease NN N
states NNS N
, , N
including VBG N
dermal JJ N
pressure NN N
ulcers NNS N
. . N

When WRB N
dazmegrel NN i
was VBD i
orally RB i
administered VBN i
to TO i
greyhound VB i
dogs NNS i
wearing VBG i
leg NN i
casts NNS i
, , N
it PRP N
resulted VBD N
in IN N
a DT N
sparring JJ N
effect NN N
on IN N
the DT N
skin JJ N
areas NNS N
of IN N
potential JJ N
pressure NN N
ulcer NN N
development NN N
. . N

The DT N
objective NN N
of IN N
this DT N
research NN N
was VBD N
to TO N
determine VB N
if IN N
bioelastic JJ N
matrices NNS N
could MD N
provide VB N
controlled VBD o
release NN o
of IN N
thromboxane NN N
A2 NNP N
synthetase NN N
inhibitor NN N
( ( N
dazmegrel NN N
) ) N
at IN N
tissue NN N
concentrations NNS N
sufficient NN N
for IN N
inhibition NN N
of IN N
thromboxane NN N
synthesis NN N
. . N

The DT p
animal NN p
used VBN p
for IN p
these DT p
studies NNS p
was VBD p
the DT p
greyhound NN p
, , p
which WDT p
has VBZ p
thin JJ p
skin NN p
, , p
angular JJ p
conformation NN p
, , p
limited JJ p
body NN p
fat JJ p
and CC p
is VBZ p
predisposed VBN p
to TO p
pressure VB p
ulcers NNS p
similar JJ p
to TO p
those DT p
occurring VBG p
in IN p
humans NNS p
. . p

In IN N
vivo JJ N
skin JJ N
penetration NN N
studies NNS N
showed VBD N
that IN N
epidermal JJ N
exposure NN N
to TO N
bioelastic JJ N
thromboxane NN N
synthetase NN N
inhibitor NN N
( ( N
TSI NNP N
) ) N
matrix NN N
resulted VBD N
in IN N
local JJ o
tissue NN o
concentrations NNS o
of IN o
TSI NNP o
sufficient NN N
for IN N
thromboxane NN N
synthetase NN N
inhibition NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
dazmegrel NN N
in IN N
the DT N
skin NN N
layers NNS N
( ( N
epidermis NN N
, , N
dermis NN N
and CC N
subcutaneous JJ N
layers NNS N
) ) N
on IN N
1 CD N
, , N
7 CD N
and CC N
14-day JJ N
exposures NNS N
. . N

-DOCSTART- -15491374- O O

Effects NNS N
of IN N
bifidobacterium NN i
breve VBP i
supplementation NN N
on IN N
intestinal JJ N
flora NNS N
of IN N
low JJ p
birth NN p
weight NN p
infants NNS p
. . p

BACKGROUND IN N
It PRP N
is VBZ N
known VBN N
that IN N
the DT N
bifidobacteria NN N
flora VBP N
play NN N
important JJ N
roles NNS N
in IN N
mucosal NN N
host NN N
defense NN N
and CC N
can MD N
prevent VB N
infectious JJ N
diseases NNS N
. . N

Because IN N
bacterial JJ N
populations NNS N
develop VBP N
during IN N
the DT N
first JJ N
day NN N
of IN N
life NN N
, , N
the DT N
authors NNS N
examined VBD N
whether IN N
the DT N
early JJ N
administration NN N
of IN N
bifidobacteria NN N
has VBZ N
a DT N
positive JJ N
effect NN o
on IN o
the DT o
health NN o
of IN N
low JJ p
birth NN p
weight NN p
infants NNS p
. . p

METHODS NNP N
The DT N
effects NNS N
of IN N
oral JJ N
administration NN N
of IN N
Bifidobacterium NNP i
breve NN i
( ( i
B. NNP i
breve VBP i
) ) i
supplements NNS i
were VBD N
studied VBN N
in IN N
a DT N
controlled JJ N
trial NN N
with IN N
low JJ p
birth NN p
weight NN p
infants NNS p
( ( p
average JJ p
birth NN p
weight NN p
1489 CD p
g NN p
) ) p
. . p

The DT N
infants NNS N
were VBD N
divided VBN N
into IN N
three CD i
groups NNS i
: : i
Group NNP i
A NNP i
and CC i
B NNP i
received VBD i
a DT i
dose NN i
of IN i
1.6 CD i
x NNS i
10 CD i
( ( i
8 CD i
) ) i
cells NNS i
of IN i
B. NNP i
breve VBP i
supplement NN i
twice RB i
a DT i
day NN i
, , i
commencing VBG i
either CC i
from IN i
several JJ i
hours NNS i
after IN i
birth NN i
( ( i
group NN i
A NNP i
) ) i
or CC i
24 CD i
h NN i
after IN i
birth NN i
( ( i
group NN i
B NNP i
) ) i
. . i

Group NNP N
C NNP N
, , N
the DT N
control NN i
group NN i
, , N
received VBD N
no DT i
supplement NN i
. . i

RESULTS CC N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
birth NN o
weight NN o
, , o
treatment NN o
with IN o
antibiotics NNS o
, , o
and CC o
the DT o
starting JJ o
time NN o
of IN o
breast-feeding NN o
among IN N
the DT N
three CD N
groups NNS N
. . N

A DT N
Bifidobacterium-predominant JJ o
flora NN o
was VBD N
formed VBN N
at IN N
an DT N
average NN N
of IN N
2 CD N
weeks NNS N
after IN N
birth NN N
in IN N
group NN N
A NNP N
and CC N
at IN N
an DT N
average NN N
of IN N
4 CD N
weeks NNS N
after IN N
birth NN N
in IN N
group NN N
B NNP N
, , N
while IN N
no DT N
Bifidobacterium NNP o
was VBD N
isolated VBN N
in IN N
eight CD N
out IN N
of IN N
10 CD N
infants NNS N
in IN N
group NN N
C NNP N
during IN N
the DT N
observation NN N
period NN N
of IN N
7 CD N
weeks NNS N
. . N

In IN N
comparison NN N
between IN N
group NN N
A NNP N
and CC N
B NNP N
, , N
Bifidobacterium NNP o
was VBD N
detected VBN o
significantly RB N
earlier RBR N
in IN N
group NN N
A NNP N
, , N
and CC N
the DT N
number NN N
of IN N
Enterobacteriaceae NNP N
present NN N
in IN N
the DT N
infants NNS N
at IN N
2 CD N
weeks NNS N
after IN N
birth NN N
was VBD N
significantly RB N
lower JJR N
in IN N
group NN N
A NNP N
. . N

CONCLUSION NNP N
The DT N
results NNS N
of IN N
the DT N
present JJ N
study NN N
suggest VBP N
that IN N
very RB N
early JJ N
administration NN N
of IN N
B. NNP N
breve VBP N
to TO N
low JJ p
birth NN p
weight NN p
infants NNS p
is VBZ N
useful JJ N
in IN N
promoting VBG N
the DT N
colonization NN N
of IN N
the DT N
Bifidobacterium NNP N
and CC N
the DT N
formation NN N
of IN N
a DT N
normal JJ N
intestinal JJ N
flora NN N
. . N

-DOCSTART- -24675714- O O

Weight NNP o
loss NN o
maintenance NN o
in IN N
overweight JJ p
subjects NNS p
on IN N
ad NN i
libitum NN i
diets NNS i
with IN N
high JJ N
or CC N
low JJ N
protein NN N
content NN N
and CC N
glycemic JJ N
index NN N
: : N
the DT N
DIOGENES NNP N
trial NN N
12-month JJ N
results NNS N
. . N

BACKGROUND NNP N
A NNP i
high JJ i
dietary JJ i
protein NN i
( ( i
P NNP i
) ) i
content NN i
and CC i
low JJ i
glycemic JJ i
index NN i
( ( N
LGI NNP N
) ) N
have VBP N
been VBN N
suggested VBN N
to TO N
be VB N
beneficial JJ N
for IN N
weight JJ N
management NN N
, , N
but CC N
long-term JJ N
studies NNS N
are VBP N
scarce JJ N
. . N

OBJECTIVE IN N
The DT N
DIOGENES NNP N
randomized VBD N
clinical JJ N
trial NN N
investigated VBD N
the DT N
effect NN o
of IN N
P NNP N
and CC N
GI NNP N
on IN N
weight JJ o
loss NN o
maintenance NN o
in IN N
overweight NN p
or CC p
obese JJ p
adults NNS p
in IN p
eight CD p
centers NNS p
across IN p
Europe NNP p
. . p

This DT N
study NN N
reports VBZ N
the DT N
1-year JJ N
results NNS N
in IN N
two CD N
of IN N
the DT N
centers NNS N
that WDT N
extended VBD N
the DT N
intervention NN N
to TO N
1 CD N
year NN N
. . N

METHOD NNP N
After IN N
an DT N
8-week JJ N
low-calorie JJ N
diet NN N
( ( N
LCD NNP N
) ) N
, , N
256 CD p
adults NNS p
( ( p
body NN p
mass NN p
index NN p
> VBD p
27 CD p
kg NNS p
m NN p
( ( p
- : p
) ) p
( ( p
2 CD p
) ) p
) ) p
were VBD p
randomized VBN i
to TO i
five CD i
ad NN i
libitum NN i
diets NNS i
for IN i
12 CD i
months NNS i
: : i
high JJ i
P/LGI NNP i
( ( i
HP/LGI NNP i
) ) i
, , i
HP/high NNP i
GI NNP i
( ( i
HP/HGI NNP i
) ) i
, , i
low JJ i
P/LGI NNP i
( ( i
LP/LGI NNP i
) ) i
, , i
LP/HGI NNP i
and CC i
a DT i
control NN i
diet JJ i
. . i

During IN i
the DT N
first JJ N
6 CD N
months NNS i
, , i
foods NNS i
were VBD i
provided VBN i
for IN i
free JJ i
through IN i
a DT i
shop NN i
system NN i
and CC i
during IN i
the DT i
whole JJ i
12-month JJ i
period NN i
, , i
subjects VBZ i
received VBN i
guidance NN i
by IN i
a DT i
dietician JJ i
. . i

Primary JJ i
outcome NN N
variable NN N
was VBD N
the DT N
change NN o
in IN o
body NN o
weight NN o
over IN o
the DT N
12-month JJ N
intervention NN N
period NN N
. . N

RESULTS NNP N
During IN N
the DT N
LCD NNP N
period NN N
, , N
subjects VBZ N
lost VBN N
11.2 CD N
( ( N
10.8 CD N
, , N
12.0 CD N
) ) N
kg NN N
( ( N
mean JJ N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
) ) N
) ) N
. . N

Average JJ o
weight JJ o
regain NN o
over IN o
the DT N
12-month JJ N
intervention NN N
period NN N
was VBD N
3.9 CD N
( ( N
95 CD N
% NN N
CI NNP N
3.0-4.8 CD N
) ) N
kg NN N
. . N

Subjects NNS N
on IN N
the DT N
HP NNP N
diets NNS N
regained VBD o
less JJR o
weight NN o
than IN o
subjects NNS N
on IN N
the DT N
LP NNP N
diets NNS N
. . N

The DT N
difference NN o
in IN o
weight NN o
regain NN o
after IN o
1 CD N
year NN N
was VBD N
2.0 CD N
( ( N
0.4 CD N
, , N
3.6 CD N
) ) N
kg NN N
( ( N
P=0.017 NNP N
) ) N
( ( N
completers NNS N
analysis NN N
, , N
N=139 NNP N
) ) N
or CC N
2.8 CD N
( ( N
1.4 CD N
, , N
4.1 CD N
) ) N
kg NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
( ( N
intention-to-treat JJ N
analysis NN N
, , N
N=256 NNP N
) ) N
. . N

No DT N
consistent JJ N
effect NN N
of IN N
GI NNP N
on IN o
weight NN o
regain NN o
was VBD o
found VBN N
. . N

There EX N
were VBD N
no DT N
clinically RB N
relevant JJ N
differences NNS N
in IN N
changes NNS N
in IN N
cardiometabolic JJ N
risk NN N
factors NNS N
among IN N
diet JJ N
groups NNS N
. . N

CONCLUSION VB N
A DT N
higher JJR i
protein NN i
content NN i
of IN i
an DT i
ad NN i
libitum NN i
diet JJ i
improves NNS o
weight VBD o
loss NN o
maintenance NN o
in IN p
overweight NN p
and CC p
obese JJ p
adults NNS p
over IN p
12 CD N
months NNS N
. . N

-DOCSTART- -24074927- O O

Early RB N
clinical JJ N
outcomes NNS N
and CC N
toxicity NN N
of IN N
intensity NN N
modulated VBN N
versus IN N
conventional JJ N
pelvic JJ N
radiation NN N
therapy NN N
for IN N
locally RB p
advanced JJ p
cervix NN p
carcinoma NN p
: : p
a DT N
prospective JJ N
randomized NN N
study NN N
. . N

PURPOSE NNP N
To TO N
evaluate VB N
the DT N
toxicity NN o
and CC o
clinical JJ o
outcome NN o
in IN N
patients NNS p
with IN p
locally RB p
advanced JJ p
cervical JJ p
cancer NN p
( ( p
LACC NNP p
) ) p
treated VBD N
with IN N
whole JJ i
pelvic JJ i
conventional JJ i
radiation NN i
therapy NN i
( ( N
WP-CRT NNP N
) ) N
versus NN N
intensity NN i
modulated VBN i
radiation NN i
therapy NN i
( ( N
WP-IMRT NNP N
) ) N
. . N

METHODS NNP N
AND CC N
MATERIALS NNP N
Between NNP p
January NNP p
2010 CD p
and CC p
January NNP p
2012 CD p
, , p
44 CD p
patients NNS p
with IN p
International NNP p
Federation NNP p
of IN p
Gynecology NNP p
and CC p
Obstetrics NNP p
( ( p
FIGO NNP p
2009 CD p
) ) p
stage NN p
IIB-IIIB NNP p
squamous JJ p
cell NN p
carcinoma NN p
of IN p
the DT p
cervix NN p
were VBD p
randomized VBN i
to TO i
receive VB i
50.4 CD i
Gy NNP i
in IN i
28 CD i
fractions NNS i
delivered VBN i
via IN i
either DT i
WP-CRT JJ i
or CC i
WP-IMRT JJ i
with IN i
concurrent JJ i
weekly JJ i
cisplatin NN i
40 CD i
mg/m NN i
( ( i
2 CD i
) ) i
. . i

Acute NNP o
toxicity NN o
was VBD i
graded VBN i
according VBG i
to TO i
the DT i
Common NNP o
Terminology NNP o
Criteria NNP o
for IN o
Adverse NNP o
Events NNP o
, , o
version NN o
3.0 CD o
, , o
and CC o
late JJ o
toxicity NN o
was VBD o
graded VBN o
according VBG o
to TO o
the DT o
Radiation NNP o
Therapy NNP o
Oncology NNP o
Group NNP o
system NN o
. . o

The DT N
primary JJ N
and CC N
secondary JJ N
endpoints NNS N
were VBD N
acute JJ o
gastrointestinal JJ o
toxicity NN o
and CC N
disease-free JJ o
survival NN o
, , N
respectively RB N
. . N

RESULTS NNP N
Of IN N
44 CD N
patients NNS N
, , N
22 CD N
patients NNS N
received VBD N
WP-CRT NNP i
and CC N
22 CD N
received VBD N
WP-IMRT NNP i
. . i

In IN N
the DT N
WP-CRT JJ i
arm NN N
, , N
13 CD N
patients NNS N
had VBD N
stage NN N
IIB NNP N
disease NN N
and CC N
9 CD N
had VBD N
stage NN N
IIIB NNP N
disease NN N
; : N
in IN N
the DT N
IMRT NNP i
arm NN N
, , N
12 CD N
patients NNS N
had VBD N
stage NN N
IIB NNP N
disease NN N
and CC N
10 CD N
had VBD N
stage NN N
IIIB NNP N
disease NN N
. . N

The DT N
median JJ N
follow-up JJ N
time NN N
in IN N
the DT N
WP-CRT JJ N
arm NN N
was VBD N
21.7 CD N
months NNS N
( ( N
range NN N
, , N
10.7-37.4 JJ N
months NNS N
) ) N
, , N
and CC N
in IN N
the DT N
WP-IMRT JJ N
arm NN N
it PRP N
was VBD N
21.6 CD N
months NNS N
( ( N
range NN N
, , N
7.7-34.4 JJ N
months NNS N
) ) N
. . N

At IN N
27 CD N
months NNS N
, , N
disease-free JJ o
survival NN o
was VBD N
79.4 CD N
% NN N
in IN N
the DT N
WP-CRT NNP i
group NN N
versus VBD N
60 CD N
% NN N
in IN N
the DT N
WP-IMRT NNP i
group NN N
( ( N
P=.651 NNP N
) ) N
, , N
and CC N
overall JJ o
survival NN o
was VBD N
76 CD N
% NN N
in IN N
the DT N
WP-CRT NNP N
group NN N
versus VBD N
85.7 CD N
% NN N
in IN N
the DT N
WP-IMRT NNP N
group NN N
( ( N
P=.645 NNP N
) ) N
. . N

Patients NNS N
in IN N
the DT N
WP-IMRT JJ N
arm NN N
experienced VBD N
significantly RB N
fewer JJR N
grade NN o
?2 NNP o
acute VBZ o
gastrointestinal JJ o
toxicities NNS o
( ( o
31.8 CD N
% NN N
vs JJ N
63.6 CD N
% NN N
, , N
P=.034 NNP N
) ) N
and CC N
grade JJ N
?3 NNP N
gastrointestinal JJ o
toxicities NNS o
( ( o
4.5 CD o
% NN N
vs JJ N
27.3 CD N
% NN N
, , N
P=.047 NNP N
) ) N
than IN N
did VBD N
patients NNS N
receiving VBG N
WP-CRT NNP N
and CC N
had VBD N
less JJR N
chronic JJ o
gastrointestinal JJ o
toxicity NN o
( ( o
13.6 CD o
% NN N
vs JJ N
50 CD N
% NN N
, , N
P=.011 NNP N
) ) N
. . N

CONCLUSION NNP i
WP-IMRT NNP i
is VBZ i
associated VBN N
with IN N
significantly RB o
less JJR o
toxicity NN o
compared VBN o
with IN N
WP-CRT NNP i
and CC i
has VBZ N
a DT N
comparable JJ o
clinical JJ o
outcome NN o
. . o

Further JJ o
studies NNS N
with IN N
larger JJR N
sample NN N
sizes NNS N
and CC N
longer JJR N
follow-up JJ N
times NNS N
are VBP N
warranted VBN N
to TO N
justify VB N
its PRP$ N
use NN N
in IN N
routine JJ N
clinical JJ N
practice NN N
. . N

-DOCSTART- -24173178- O O

Comparative NNP N
study NN N
of IN N
actinic JJ p
keratosis NN p
treatment NN N
with IN N
3 CD i
% NN i
diclofenac JJ i
sodium NN i
and CC i
5 CD i
% NN i
5-fluorouracil JJ i
. . i

BACKGROUND NNP N
Actinic NNP p
keratosis NN p
is VBZ N
a DT N
frequent JJ N
lesion NN N
which WDT N
occurs VBZ N
in IN N
sunlight NN N
exposed VBN N
areas NNS N
. . N

Diclofenac NNP i
sodium NN i
and CC i
5-Fluorouracil JJ i
are VBP N
effective JJ N
, , N
non-invasive JJ N
and CC N
easy-to-apply JJ N
topical JJ N
treatment NN N
options NNS N
. . N

OBJECTIVES NNP N
To TO N
assess VB o
and CC o
compare VB o
the DT o
effectiveness NN o
of IN N
3 CD i
% NN i
diclofenac JJ i
sodium NN i
associated VBN N
with IN N
2.5 CD i
% NN i
hyaluronic JJ i
acid NN i
and CC i
of IN i
5 CD i
% NN i
5-Fluorouracil JJ i
for IN N
the DT N
treatment NN N
of IN N
actinic JJ N
keratosis NN N
, , N
as RB N
well RB N
as IN N
the DT N
patient NN N
's POS N
degree NN N
of IN N
satisfaction NN N
and CC N
tolerability NN N
. . N

METHODS NNP N
28 CD p
patients NNS p
with IN p
a DT p
clinical JJ p
diagnosis NN p
of IN p
actinic JJ p
keratosis NN p
were VBD N
randomized VBN N
to TO N
receive VB N
diclofenac JJ i
sodium NN i
or CC i
5-Fluorouracil JJ i
and CC N
were VBD N
clinically RB N
assessed VBN N
before IN N
and CC N
after IN N
treatment NN N
as RB N
well RB N
as IN N
8 CD N
weeks NNS N
after IN N
the DT N
end NN N
of IN N
treatment NN N
. . N

Modified NNP o
versions NNS o
of IN o
the DT o
Investigator NNP o
and CC o
Patient NNP o
Global NNP o
Improvement NNP o
Scores NNP o
were VBD N
used VBN N
. . N

RESULTS VB N
The DT N
average JJ o
number NN o
of IN o
lesions NNS o
in IN o
the DT o
diclofenac NN o
sodium NN o
group NN o
before IN o
and CC o
after IN o
treatment NN o
was VBD N
13.6 CD N
and CC N
6.6 CD N
( ( N
p NN N
< RB N
0,001 CD N
) ) N
, , N
respectively RB N
, , N
while IN N
it PRP N
was VBD N
17.4 CD N
and CC N
3.15 CD N
( ( N
p NN N
< RB N
0.001 CD N
) ) N
in IN N
the DT N
5-Fluorouracil JJ i
group NN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
reduction NN N
in IN N
the DT N
number NN o
of IN o
lesions NNS o
in IN o
the DT o
5-Fluorouracil JJ o
group NN o
in IN N
relation NN N
to TO N
the DT N
diclofenac NN i
sodium NN N
group NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

To TO N
the DT N
non-blinded JJ N
physician NN N
, , N
there EX N
was VBD N
a DT N
higher JJR N
satisfactory JJ N
therapeutic JJ o
response NN o
in IN N
the DT N
5-Fluorouracil JJ i
group NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
; : N
to TO N
the DT N
blinded JJ N
physician NN N
, , N
there EX N
was VBD N
a DT N
higher JJR N
satisfactory JJ N
response NN N
in IN N
this DT N
same JJ N
group NN N
, , N
although IN N
not RB N
statistically RB N
significant JJ N
( ( N
p=0.09 NN N
) ) N
. . N

There EX N
was VBD N
a DT N
high JJ N
degree NN N
of IN N
satisfaction NN N
in IN N
both DT N
groups NNS N
( ( N
73 CD N
% NN N
in IN N
the DT N
diclofenac NN i
sodium NN N
group NN N
and CC N
77 CD N
% NN N
in IN N
the DT N
5-Fluorouracil JJ i
group NN N
; : N
p=0.827 NN N
) ) N
. . N

Regarding VBG N
adverse JJ o
effects NNS o
, , N
the DT N
diclofenac NN i
sodium NN i
group NN N
presented VBD N
a DT N
higher JJR N
degree NN N
of IN N
satisfaction NN N
( ( N
93.3 CD N
% NN N
vs JJ N
38.4 CD N
% NN N
; : N
p=0.008 NN N
) ) N
. . N

Erythema NNP o
, , o
edema NN o
, , o
crusts NNS o
and CC o
itching VBG o
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
5-Fluorouracil JJ i
group NN N
. . N

CONCLUSION NNP N
We PRP N
concluded VBD N
that IN N
5-Fluorouracil NN i
was VBD N
more RBR N
effective JJ N
; : N
however RB N
, , N
it PRP N
showed VBD N
lower JJR N
tolerability NN N
than IN N
diclofenac JJ i
sodium NN i
. . i

-DOCSTART- -9049582- O O

Pharmacokinetic JJ N
properties NNS N
of IN N
YM17E NNP i
, , i
an DT i
inhibitor NN i
of IN i
acyl NN i
coenzyme NN i
A DT N
: : N
cholesterol NN N
acyl NN N
transferase NN N
, , N
and CC N
serum VB o
cholesterol NN o
levels NNS o
in IN N
healthy JJ p
volunteers NNS p
. . p

We PRP N
conducted VBD N
a DT N
single JJ N
and CC N
repeat JJ N
oral JJ N
dose NN i
study NN i
of IN i
YM17E NNP i
, , N
a DT N
novel JJ N
inhibitor NN N
of IN N
acyl NN N
coenzyme NN N
A NNP N
( ( N
CoA NNP N
) ) N
: : N
cholesterol NN N
acyltransferase NN N
, , N
in IN N
healthy JJ p
male NN p
volunteers NNS p
to TO N
evaluate VB N
the DT N
pharmacokinetic JJ o
profile NN o
, , o
tolerability NN o
and CC o
effect NN o
of IN o
the DT o
drug NN o
on IN o
serum NN o
cholesterol NN o
. . o

In IN N
the DT N
single JJ N
administration NN N
study NN N
, , N
YM17E NNP i
was VBD i
administered VBN i
after IN i
a DT i
meal NN i
to TO i
two CD i
groups NNS i
of IN i
subjects NNS i
( ( i
each DT i
containing VBG i
six CD i
subjects NNS i
taking VBG i
the DT i
drug NN i
and CC i
three CD i
taking VBG i
placebo NN i
) ) i
receiving VBG i
3 CD i
, , i
60 CD i
and CC i
300 CD i
mg NN i
or CC i
15 CD i
, , i
60 CD i
and CC i
450 CD i
mg NN i
YM17E NNP i
, , i
respectively RB i
. . i

Plasma NNP o
concentrations NNS o
of IN N
unchanged JJ N
drug NN N
following VBG N
single JJ N
oral JJ N
administration NN N
at IN N
3-300 JJ N
mg NN N
after IN N
a DT N
meal NN N
increased VBN N
with IN N
increasing VBG N
dose NN N
. . N

In IN N
contrast NN N
, , N
plasma NN o
concentrations NNS o
after IN N
administration NN N
of IN N
450 CD N
mg NNS N
were VBD N
almost RB N
the DT N
same JJ N
as IN N
after IN N
300 CD N
mg NN N
. . N

Unchanged VBD N
YM17E NNP i
was VBD N
not RB N
detected VBN N
in IN N
urine NN N
after IN N
single JJ N
administration NN N
, , N
suggesting VBG N
that IN N
it PRP N
was VBD N
excreted VBN N
via IN N
the DT N
bile NN N
or CC N
urine NN N
after IN N
metabolism NN N
. . N

Five CD N
active JJ N
metabolites NNS N
( ( N
M1 NNP N
, , N
M2-a NNP N
, , N
M2-b NNP N
, , N
M3 NNP N
and CC N
M4 NNP N
) ) N
were VBD N
observed VBN N
in IN N
plasma NN N
at IN N
concentrations NNS N
comparable JJ N
to TO N
those DT N
of IN N
unchanged JJ N
YM17E NNP i
. . i

Their PRP$ N
plasma JJ o
concentrations NNS o
increased VBD N
in IN N
a DT N
slightly RB N
greater JJR N
than IN N
dose-dependent JJ N
manner NN N
from IN N
3 CD N
to TO N
300 CD N
mg NN N
. . N

The DT N
effect NN N
of IN N
food NN N
was VBD N
studied VBN N
in IN N
an DT N
open JJ N
crossover NN N
design NN N
with IN N
a DT N
1-week JJ N
washout NN N
period NN N
. . N

Twelve NNP N
subjects VBZ N
received VBD N
150 CD i
mg NNS i
YM17E VBN i
in IN N
both DT N
the DT N
fasted VBN N
and CC N
post-prandial JJ N
states NNS N
. . N

The DT N
AUC NNP o
and CC o
Cmax NNP o
after IN N
fasting VBG N
were VBD N
closely RB N
similar JJ N
to TO N
those DT N
after IN N
a DT N
meal NN N
, , N
showing VBG N
that IN N
bioavailability NN N
was VBD N
not RB N
affected VBN N
by IN N
food NN N
intake NN N
. . N

In IN N
the DT N
repeated JJ N
oral JJ N
dose NN N
study NN N
, , N
the DT N
subjects NNS N
received VBD N
test JJ i
drug NN i
at IN i
150 CD i
mg NN i
or CC i
300 CD i
mg NN i
( ( N
n JJ N
= RB N
6 CD N
each DT N
) ) N
or CC N
placebo NN i
( ( i
n JJ i
= NNP i
3 CD i
) ) i
twice RB i
a DT i
day NN i
( ( N
after IN N
breakfast NN N
and CC N
after IN N
dinner NN N
) ) N
for IN N
7 CD N
days NNS N
. . N

On IN N
days NNS N
1 CD N
and CC N
7 CD N
, , N
the DT N
subjects NNS N
received VBD N
YM17E NNP i
once RB i
a DT i
day NN i
( ( N
after IN N
breakfast NN N
) ) N
for IN N
evaluation NN N
of IN N
pharmacokinetic JJ N
properties NNS N
. . N

After IN N
repeated VBN N
oral JJ N
administration NN N
of IN N
150 CD N
mg NN N
b.d. NN N
, , N
plasma JJ o
concentrations NNS o
reached VBD N
steady JJ N
state NN N
by IN N
day NN N
5 CD N
( ( N
mean JJ N
Cmin NNP N
48.6 CD N
ng.ml-1 NN N
) ) N
. . N

After IN N
repeated JJ N
administration NN N
of IN N
300 CD N
mg NN N
b.d. NN N
, , N
plasma JJ o
concentrations NNS o
prior RB N
to TO N
each DT N
daily JJ N
morning NN N
dose NN N
increased VBD N
up RB N
to TO N
the DT N
5th JJ N
day NN N
( ( N
mean JJ N
Cmin NNP N
166.6 CD N
ng.ml-1 NN N
) ) N
and CC N
then RB N
tended VBD N
to TO N
decrease VB N
until IN N
the DT N
7th JJ N
day NN N
. . N

No DT N
significant JJ o
signs NNS o
, , o
symptoms NNS o
or CC o
changes NNS o
in IN o
serum NN o
cholesterol NN o
levels NNS o
were VBD N
observed VBN N
during IN N
the DT N
single JJ N
and CC N
repeated JJ N
oral JJ N
dose NN N
studies NNS N
at IN N
150 CD N
mg NN N
b.d NN N
. . N

Although IN N
statistical JJ N
analysis NN N
was VBD N
not RB N
conducted VBN N
because IN N
of IN N
the DT N
small JJ p
number NN p
of IN p
subjects NNS p
, , N
all DT N
subjects NNS N
receiving VBG N
repeated VBD N
oral JJ N
administration NN N
of IN N
300 CD N
mg JJ N
twice RB N
daily RB N
showed VBD N
a DT N
25 CD N
% NN N
decrease NN N
in IN N
serum NN o
cholesterol NN o
level NN N
on IN N
day NN N
7 CD N
, , N
but CC N
also RB N
the DT N
simultaneous JJ N
occurrence NN N
of IN N
diarrhoea NN o
. . o

-DOCSTART- -21054362- O O

Antimigraine NNP o
efficacy NN o
of IN N
telcagepant NN i
based VBN N
on IN N
patient NN p
's POS p
historical JJ p
triptan NN i
response NN p
. . p

OBJECTIVE UH N
To TO N
evaluate VB N
whether IN N
the DT N
same JJ N
or CC N
different JJ N
patients NNS p
respond NN o
to TO o
triptans NNS o
and CC i
telcagepant NN i
. . i

BACKGROUND NNP N
Telcagepant NNP i
is VBZ N
an DT N
oral JJ i
calcitonin NN i
gene-related JJ i
peptide NN i
receptor NN i
antagonist NN N
with IN N
acute JJ N
antimigraine NN o
efficacy NN o
comparable JJ N
to TO N
oral JJ i
triptans NNS i
. . i

It PRP N
is VBZ N
currently RB N
unknown JJ N
whether IN N
migraine NN p
patients NNS p
who WP p
can MD p
not RB p
be VB p
adequately RB p
helped VBN p
with IN p
triptans NNS i
might MD N
benefit VB N
from IN N
treatment NN N
with IN N
telcagepant NN i
. . i

METHODS NNP N
Post-hoc JJ N
analysis NN N
of IN N
data NNS N
from IN N
a DT N
randomized VBN N
, , N
controlled VBD N
trial NN N
of IN N
telcagepant NN i
( ( i
150 CD i
mg NN i
, , i
300 CD i
mg NN i
) ) i
zolmitriptan VBZ i
5 CD i
mg NN i
, , i
or CC i
placebo NN i
for IN N
a DT N
moderate/severe JJ N
migraine NN N
. . N

Responder VB N
rates NNS N
were VBD N
analyzed VBN N
according VBG N
to TO N
patients NNS p
' POS p
self-reported JJ o
historical JJ o
triptan NN o
response NN o
( ( o
HTR NNP o
) ) o
: : o
( ( p
1 CD p
) ) p
good JJ p
HTR NNP p
( ( p
N NNP p
= NNP p
660 CD p
) ) p
: : p
response NN p
in IN p
75-100 CD p
% NN p
of IN p
attacks NNS p
; : p
( ( p
2 CD p
) ) p
intermediate NN p
HTR NNP p
( ( p
N NNP p
= NNP p
248 CD p
) ) p
: : p
response NN p
in IN p
25-74 JJ p
% NN p
of IN p
attacks NNS p
; : p
( ( p
3 CD p
) ) p
poor JJ p
HTR/no NNP p
use NN p
( ( p
N NNP p
= NNP p
407 CD p
) ) p
: : p
response NN p
in IN p
< JJ p
25 CD p
% NN p
of IN p
attacks NNS p
, , p
or CC p
patient NN p
did VBD p
not RB p
take VB p
triptans NNS p
. . p

A DT N
limitation NN N
of IN N
the DT N
analysis NN N
is VBZ N
that IN N
the DT p
last JJ p
subgroup NN p
comprised VBD p
mainly RB p
( ( p
91 CD p
% NN p
) ) p
patients NNS p
who WP p
reported VBD p
that IN p
they PRP p
did VBD p
not RB p
take VB p
triptans NNS p
, , p
but CC p
it PRP p
was VBD p
not RB p
known VBN p
whether IN p
these DT p
patients NNS p
were VBD p
triptan-na?ve JJ p
or CC p
had VBD p
previously RB p
used VBN i
triptans NNS i
and CC p
stopped VBD p
taking VBG p
them PRP p
. . p

RESULTS VB N
For IN i
zolmitriptan JJ i
, , i
2-hour JJ o
pain NN o
relief NN o
rates NNS o
were VBD N
higher JJR N
in IN N
the DT N
good JJ N
HTR NNP N
subgroup NN N
( ( N
116/162 CD N
, , N
72 CD N
% NN N
) ) N
than IN N
in IN N
the DT N
intermediate NN N
( ( N
29/62 CD N
, , N
47 CD N
% NN N
) ) N
and CC N
poor/no NN N
use NN N
( ( N
44/111 CD N
, , N
40 CD N
% NN N
) ) N
HTR NNP N
subgroups NNS N
. . N

The DT o
2-hour JJ o
pain NN o
relief NN o
rates NNS o
were VBD N
similar JJ N
across IN N
HTR NNP N
subgroups NNS N
for IN i
telcagepant JJ i
150 CD N
mg NN N
( ( N
48-58 CD N
% NN N
) ) N
, , N
300 CD N
mg NN N
( ( N
52-58 CD N
% NN N
) ) N
, , N
and CC i
placebo NN i
( ( N
26-31 CD N
% NN N
) ) N
. . N

In IN N
the DT N
poor/no NN N
use NN N
HTR NNP N
subgroup NN N
, , N
more JJR N
patients NNS N
receiving VBG i
telcagepant JJ i
300 CD N
mg NN N
( ( N
56/98 CD N
, , N
57.1 CD N
% NN N
) ) N
had VBD o
2-hour JJ o
pain NN o
relief NN o
than IN N
those DT N
receiving VBG i
zolmitriptan NN i
( ( N
44/111 CD N
, , N
39.6 CD N
% NN N
; : N
odds NNS N
ratio VBP N
= $ N
2.11 CD N
[ JJ N
95 CD N
% NN N
CI NNP N
: : N
1.20,3.71 CD N
] NN N
, , N
P NNP N
= NNP N
.009 NNP N
) ) N
; : N
the DT N
percentage NN N
for IN i
telcagepant JJ i
150 CD N
mg NN N
( ( N
57/119 CD N
, , N
47.9 CD N
% NN N
) ) N
was VBD N
not RB N
significantly RB N
different JJ N
from IN i
zolmitriptan NN i
( ( N
odds NNS N
ratio VBP N
= $ N
1.41 CD N
[ JJ N
95 CD N
% NN N
CI NNP N
: : N
0.82 CD N
, , N
2.40 CD N
] NN N
, , N
P NNP N
= NNP N
.211 NNP N
) ) N
. . N

CONCLUSIONS VB N
This DT N
suggests VBZ N
that IN N
different JJ N
patients NNS N
may MD N
respond VB N
to TO i
triptans NNS i
or CC i
telcagepant JJ i
300 CD N
mg NN N
. . N

Caution NN N
should MD N
be VB N
exercised VBN N
in IN N
interpreting VBG N
the DT N
results NNS N
because IN N
of IN N
the DT N
post-hoc JJ N
nature NN N
of IN N
the DT N
analysis NN N
( ( N
clinical JJ N
trial NN N
registry NN N
: : N
NCT00442936 NNP N
) ) N
. . N

-DOCSTART- -21300377- O O

Impact NN N
of IN N
prior JJ N
pharmacotherapy NN i
on IN N
remission NN o
of IN o
psychotic JJ o
depression NN o
in IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

Having VBG N
failed VBN N
to TO N
respond VB N
to TO N
an DT N
adequate JJ N
antidepressant JJ N
treatment NN N
course NN N
predicts VBZ N
poorer JJR N
treatment NN o
outcomes NNS o
in IN N
patients NNS p
with IN p
major JJ p
depression NN p
. . p

However RB N
, , N
little JJ N
is VBZ N
known VBN N
about IN N
the DT N
impact NN N
of IN N
prior JJ N
treatment NN N
on IN N
the DT N
outcome NN o
of IN N
major JJ p
depression NN p
with IN p
psychotic JJ p
features NNS p
( ( p
MDpsy NNP p
) ) p
. . p

We PRP N
examined VBD N
the DT N
effect NN N
of IN N
prior JJ N
treatment NN N
history NN N
on IN N
the DT N
outcome NN o
of IN o
pharmacotherapy NN o
of IN N
MDpsy NNP p
in IN p
patients NNS p
who WP p
participated VBD p
in IN p
the DT p
STOPD-PD NNP p
study NN p
, , p
a DT p
randomized VBN p
, , p
double-blind JJ p
, , p
clinical JJ p
trial NN p
comparing VBG p
a DT p
combination NN N
of IN N
olanzapine JJ i
plus CC i
sertraline JJ i
vs. FW i
olanzapine JJ i
plus CC i
placebo NN i
. . i

The DT N
strength NN N
of IN N
treatment NN N
courses NNS N
received VBD N
prior RB N
to TO N
randomization NN N
was VBD N
classified VBN N
using VBG N
a DT N
validated JJ N
method NN N
. . N

A DT N
hierarchy NN N
of IN N
outcomes NNS o
was VBD N
hypothesized VBN N
based VBN N
on IN N
treatments NNS N
received VBN N
prior RB N
to TO N
randomization NN N
and CC N
randomized JJ N
treatment NN N
. . N

A DT N
high JJ o
remission NN o
rate NN o
was VBD N
observed VBN N
in IN N
subjects NNS p
with IN p
a DT p
history NN p
of IN p
no DT p
prior JJ p
treatment NN p
or CC p
inadequate JJ p
treatment NN p
who WP p
were VBD p
treated VBN p
with IN p
a DT p
combination NN p
of IN p
olanzapine NN i
and CC p
sertraline NN i
. . i

A DT N
low JJ o
remission NN o
rate NN o
was VBD N
observed VBN N
in IN N
subjects NNS p
who WP p
had VBD p
previously RB p
failed VBN p
to TO p
respond VB p
to TO p
an DT p
antidepressant JJ p
alone NN p
and CC p
who WP p
were VBD p
treated VBN p
with IN p
olanzapine JJ i
monotherapy NN p
. . p

A DT N
low JJ o
remission NN o
rate NN o
was VBD N
also RB N
observed VBN N
in IN N
subjects NNS p
who WP p
had VBD p
previously RB p
failed VBN p
to TO p
respond VB p
to TO p
a DT p
combination NN p
of IN p
an DT p
antipsychotic JJ p
and CC p
an DT p
antidepressant NN p
. . p

Similar JJ N
to TO N
patients NNS N
with IN N
major JJ N
depression NN N
, , N
these DT N
results NNS N
emphasize VBP N
the DT N
impact NN o
of IN o
prior JJ o
pharmacotherapy NN o
on IN N
treatment NN o
outcomes NNS o
in IN N
patients NNS p
with IN p
MDpsy NNP p
. . p

-DOCSTART- -19353317- O O

Bridge NNP i
plate NN i
osteosynthesis NN i
using VBG i
dynamic JJ i
condylar JJ i
screw NN i
( ( i
DCS NNP i
) ) i
or CC i
retrograde VBN i
intramedullary JJ i
supracondylar JJ i
nail NN i
( ( i
RIMSN NNP i
) ) i
in IN N
the DT N
treatment NN N
of IN N
distal JJ p
femoral JJ p
fractures NNS p
: : p
comparison NN N
of IN N
two CD N
methods NNS N
in IN N
a DT N
prospective JJ N
randomized NN N
study NN N
. . N

BACKGROUND NNP N
The DT N
treatment NN N
of IN N
distal JJ p
femoral JJ p
fractures NNS p
remains VBZ N
a DT N
significant JJ N
surgical JJ N
challenge NN N
. . N

With IN N
the DT N
rigid JJ N
fixation NN N
of IN N
the DT N
distal JJ N
femoral JJ N
fractures NNS N
, , N
bone NN N
grafting NN N
is VBZ N
frequently RB N
needed VBN N
. . N

Biological JJ N
osteosynthesis NN N
using VBG N
dynamic JJ N
condylar JJ N
screw NN N
( ( N
DCS NNP N
) ) N
and CC N
retrograde JJ N
intramedullary JJ N
supracondylar NN N
nail NN N
( ( N
RIMSN NNP N
) ) N
preserve VBP N
the DT N
blood NN N
supply NN N
and CC N
limit NN N
the DT N
need NN N
for IN N
bone NN N
grafting NN N
. . N

METHODS NNP N
From IN p
September NNP p
2002 CD p
to TO p
December NNP p
2004 CD p
, , p
68 CD p
closed VBD p
fractures NNS p
of IN p
the DT p
distal JJ p
femur NN p
were VBD p
treated VBN p
by IN p
bridge NN i
plate NN i
osteosynthesis NN i
using VBG i
DCS NNP i
in IN i
31 CD i
and CC i
RIMSN NNP i
in IN i
37 CD i
. . i

The DT N
patients NNS N
were VBD N
allocated VBN N
to TO N
one CD N
of IN N
the DT N
two CD N
groups NNS N
randomly RB N
and CC N
followed VBD N
for IN N
24-36 JJ N
months NNS N
( ( N
average JJ N
: : N
30 CD N
months NNS N
) ) N
. . N

RESULTS VBN N
With IN N
respect NN N
to TO N
operation NN N
time NN N
, , N
the DT N
DCS NNP N
group NN N
presented VBD N
significantly RB N
better JJR N
results NNS N
than IN N
the DT N
RIMSN NNP N
group NN N
( ( N
p=0.000 NN N
) ) N
. . N

However RB N
, , N
the DT N
blood NN o
loss NN o
was VBD N
significantly RB N
more RBR N
in IN N
the DT N
DCS NNP N
group NN N
( ( N
p=0.000 NN N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
terms NNS N
of IN N
cumulative JJ o
rate NN o
of IN o
union NN o
( ( N
p=0.855 NN N
) ) N
, , N
range NN o
of IN o
motion NN o
of IN o
the DT o
knee NN o
( ( N
p=0.727 NN N
) ) N
, , N
overall JJ o
results NNS o
( ( N
p=0.925 NN N
) ) N
and CC N
complications NNS o
( ( N
p=0.927 NN N
) ) N
between IN N
the DT N
two CD N
groups NNS N
. . N

CONCLUSION NNP N
No NNP N
implant NN N
or CC N
surgical JJ N
technique NN N
is VBZ N
superior JJ N
to TO N
any DT N
other JJ N
under IN N
all DT N
circumstances NNS N
for IN N
distal JJ N
femoral JJ N
fracture NN N
. . N

RIMSN NNP N
is VBZ N
standard JJ N
care NN N
, , N
yet RB N
the DT N
biological JJ N
osteosynthesis NN N
using VBG N
DCS NNP N
is VBZ N
a DT N
very RB N
good JJ N
alternative NN N
for IN N
the DT N
treatment NN N
of IN N
distal JJ p
femoral JJ p
fractures NNS p
. . p

-DOCSTART- -12356338- O O

Acute NNP N
cardiac JJ N
effects NNS N
of IN N
nicotine NN i
in IN N
healthy JJ p
young JJ p
adults NNS p
. . p

BACKGROUND NNP N
Nicotine NNP N
is VBZ N
known VBN N
to TO N
have VB N
many JJ N
physiologic JJ N
effects NNS N
. . N

The DT N
influence NN N
of IN N
nicotine NN i
delivered VBN N
in IN N
chewing VBG i
gum NN i
upon IN N
cardiac JJ N
hemodynamics NNS N
and CC N
conduction NN N
has VBZ N
not RB N
been VBN N
well-characterized JJ N
. . N

METHODS NNP N
We PRP N
studied VBD N
the DT N
effects NNS N
of IN N
nicotine NN i
in IN N
nonsmoking VBG p
adults NNS p
( ( p
6 CD p
male NN p
, , p
5 CD p
female NN p
; : p
ages VBZ p
23-36 CD p
years NNS p
) ) p
using VBG N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
cross-over JJ N
study NN N
. . N

Subjects NNS N
chewed VBD N
nicotine JJ i
gum NN i
( ( i
4 CD i
mg NN i
) ) i
or CC i
placebo NN i
. . i

After IN N
20 CD N
minutes NNS N
( ( N
approximate JJ N
time NN N
to TO N
peak VB N
nicotine JJ N
levels NNS N
) ) N
, , N
echocardiograms JJ i
and CC i
signal-averaged JJ i
electrocardiograms NNS i
( ( N
SAECG NNP N
) ) N
were VBD N
obtained VBN N
. . N

After IN N
40 CD N
minutes NNS N
, , N
subjects NNS N
were VBD N
again RB N
given VBN N
nicotine JJ i
gum NN i
or CC N
placebo NN i
in IN N
cross-over JJ N
fashion NN N
. . N

Standard NNP N
echocardiographic JJ N
measurements NNS N
were VBD N
made VBN N
from IN N
two-dimensional JJ N
images NNS N
. . N

We PRP N
then RB N
calculated VBD N
end-systolic JJ o
wall NN o
stress NN o
( ( o
ESWS NNP o
) ) o
, , o
shortening VBG o
fraction NN o
( ( o
SF NNP o
) ) o
, , o
systemic JJ o
vascular NN o
resistance NN o
( ( o
SVR NNP o
) ) o
, , o
velocity NN o
for IN o
circumferential JJ o
fiber NN o
shortening NN o
corrected VBN o
for IN o
heart NN o
rate NN o
( ( o
Vcfc NNP o
) ) o
, , o
stroke VBD o
volume NN o
, , o
and CC o
cardiac JJ o
output NN o
. . o

P NNP o
wave NN o
and CC o
QRS NNP o
duration NN o
were VBD N
measured VBN N
from IN N
SAECG NNP N
. . N

RESULTS NNP N
Significant JJ N
differences NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
from IN N
control NN N
or CC N
placebo NN N
were VBD N
found VBN N
for IN N
ESWS NNP o
, , o
mean JJ o
blood NN o
pressure NN o
, , o
cardiac JJ o
output NN o
, , o
SVR NNP o
, , o
heart NN o
rate NN o
, , o
and CC o
P NNP o
wave VBP o
duration NN o
. . o

No DT N
significant JJ N
changes NNS N
were VBD N
seen VBN N
in IN N
left JJ o
ventricular JJ o
ejection NN o
time NN o
( ( o
LVET NNP o
) ) o
, , o
LV NNP o
dimensions NNS o
, , o
SF NNP o
, , o
contractility NN o
( ( o
Vcfc NNP o
) ) o
, , o
or CC o
QRS NNP o
duration NN o
. . o

CONCLUSIONS NNP N
These DT N
results NNS N
suggest VBP N
that IN N
nicotine JJ N
chewing VBG N
gum NN N
increases NNS N
afterload NN o
and CC o
cardiac JJ o
output NN o
. . o

Cardiac JJ o
contractility NN o
does VBZ N
not RB N
change VB N
acutely RB N
in IN N
response NN N
to TO N
nicotine VB N
gum NN N
. . N

Heart NNP o
rate NN o
and CC N
P NNP o
wave VBP o
duration NN o
are VBP N
increased VBN N
by IN N
chewing VBG N
nicotine JJ N
gum NN N
. . N

-DOCSTART- -10197379- O O

Isoniazid NNP i
prophylaxis NN N
for IN N
tuberculosis NN p
in IN p
HIV NNP p
infection NN p
: : p
a DT N
meta-analysis NN N
of IN N
randomized VBN N
controlled JJ N
trials NNS N
. . N

OBJECTIVES NNP N
To TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
isoniazid NN i
for IN N
the DT N
prevention NN N
of IN N
tuberculosis NN N
in IN N
tuberculin JJ p
skin JJ p
test-positive JJ p
and CC p
negative JJ p
individuals NNS p
with IN p
HIV NNP p
infection NN p
. . p

DESIGN NNP N
Meta-analysis NN N
of IN N
randomized VBN N
controlled JJ N
trials NNS N
. . N

SETTING NNP N
Seven NNP p
trials NNS p
from IN p
Mexico NNP p
, , p
Haiti NNP p
, , p
the DT p
United NNP p
States NNPS p
, , p
Zambia NNP p
, , p
Uganda NNP p
and CC p
Kenya NNP p
. . p

PATIENTS NNP N
Individuals NNP p
free JJ p
from IN p
tuberculosis NN p
, , p
2367 CD p
persons NNS p
in IN p
the DT p
intervention NN p
and CC p
2162 CD p
in IN p
the DT p
control NN p
groups NNS p
. . p

INTERVENTION NNP N
Comparison NNP o
of IN o
isoniazid NN o
with IN o
placebo NN o
or CC o
no DT o
prophylaxis NN o
. . o

METHODS NNP N
A NNP N
systematic JJ N
search NN N
of IN N
the DT N
literature NN N
was VBD N
carried VBN N
out IN N
from IN N
1985 CD N
to TO N
October NNP N
1997 CD N
for IN N
randomized VBN N
controlled JJ N
trials NNS N
of IN N
isoniazid JJ i
prophylaxis NN p
in IN p
HIV-infected JJ p
persons NNS p
. . p

Two CD N
reviewers NNS N
evaluated VBD N
the DT N
relevance NN N
of IN N
each DT N
candidate NN N
study NN N
and CC N
the DT N
validity NN N
of IN N
eligible JJ N
trials NNS N
. . N

Studies NNS N
were VBD N
pooled VBN N
using VBG N
a DT N
random JJ N
effect NN N
model NN N
, , N
conducting VBG N
secondary JJ N
analyses NNS N
for IN N
tuberculin JJ N
skin JJ N
test-positive JJ N
and CC N
negative JJ N
persons NNS N
. . N

RESULTS JJ N
Mean JJ N
follow-up NN N
in IN N
trials NNS N
varied VBD N
between IN N
0.4 CD N
and CC N
3.2 CD N
years NNS N
. . N

Pooling VBG N
all DT N
seven CD N
trials NNS N
, , N
a DT N
risk NN o
ratio NN o
was VBD N
found VBN N
for IN N
persons NNS N
treated VBN N
with IN N
isoniazid NN i
for IN N
developing VBG N
tuberculosis NN N
of IN N
0.58 CD N
[ JJ N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
, , N
0.43-0.80 JJ N
] NN N
and CC N
0.94 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.83-1.07 NNP N
) ) N
for IN N
death NN o
. . o

In IN N
groups NNS N
of IN N
tuberculin JJ N
skin JJ N
test-positive JJ N
and CC N
negative JJ N
persons NNS N
, , N
the DT N
risk NN o
ratio NN o
of IN o
tuberculosis NN o
was VBD N
0.40 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.24-0.65 NNP N
) ) N
and CC N
0.84 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.54-1.30 NNP N
) ) N
, , N
respectively RB N
, , N
and CC N
the DT N
difference NN o
in IN o
the DT o
effectiveness NN o
of IN N
isoniazid JJ i
versus NN N
placebo NN i
between IN N
these DT N
groups NNS N
was VBD N
statistically RB N
significant JJ N
( ( N
P NNP N
= NNP N
0.03 CD N
, , N
for IN N
the DT N
difference NN N
of IN N
summary JJ N
estimates NNS N
) ) N
. . N

Consistency NN N
of IN N
results NNS N
was VBD N
found VBN N
across IN N
trials NNS N
( ( N
P NNP N
> NNP N
0.10 CD N
, , N
heterogeneity NN N
value NN N
) ) N
for IN N
all DT N
comparisons NNS N
. . N

CONCLUSIONS NNP N
Prophylaxis NNP N
with IN N
isoniazid JJ i
reduces NNS N
the DT N
risk NN N
of IN N
tuberculosis NN N
in IN N
persons NNS p
with IN p
HIV NNP p
infection NN p
. . p

The DT N
effect NN N
is VBZ N
restricted VBN p
to TO p
tuberculin VB p
skin JJ p
test-positive JJ p
persons NNS p
. . p

-DOCSTART- -22079053- O O

Effect NN N
of IN N
cervical JJ i
spine NN i
manipulative JJ i
therapy NN i
on IN N
judo NN p
athletes NNS p
' POS p
grip NN N
strength NN N
. . N

OBJECTIVE CC N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
perform VB N
an DT N
investigation NN N
evaluating VBG N
if IN N
cervical JJ i
spinal JJ i
manipulative JJ i
therapy NN i
( ( i
SMT NNP i
) ) i
can MD N
increase VB N
grip JJ N
strength NN N
on IN N
judo NN p
athletes NNS p
in IN p
a DT p
top JJ p
10 CD p
national-ranked JJ p
team NN p
. . p

METHODS VB N
A DT N
single-blinded JJ N
, , N
prospective JJ N
, , N
comparative JJ N
, , N
pilot NN N
, , N
randomized VBN N
, , N
clinical JJ N
trial NN N
was VBD N
performed VBN N
with IN N
18 CD p
athletes NNS p
of IN p
both DT p
sexes NNS p
from IN p
a DT p
judo NN p
team NN p
currently RB p
competing VBG p
on IN p
a DT p
national JJ p
level NN p
. . p

The DT N
athletes NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
2 CD N
groups NNS N
: : N
chiropractic JJ i
SMT NNP i
and CC i
sham NN i
. . i

Three CD N
interventions NNS N
were VBD N
performed VBN N
on IN N
each DT N
of IN N
the DT N
athletes NNS N
at IN N
different JJ N
time NN N
points NNS N
. . N

Force NN N
measurements NNS N
were VBD N
obtained VBN N
by IN N
a DT N
hydraulic JJ N
dynamometer NN N
immediately RB N
before IN N
and CC N
after IN N
each DT N
intervention NN N
at IN N
the DT N
same JJ N
period NN N
before IN N
training VBG N
up RP N
to TO N
3 CD N
weeks NNS N
with IN N
at IN N
least JJS N
36 CD N
hours NNS N
between IN N
interventions NNS N
. . N

RESULTS NNP N
Analysis NNP N
of IN N
grip NN o
strength NN o
data NNS o
revealed VBD N
a DT N
statistically RB N
significant JJ N
increase NN N
in IN N
strength NN o
within IN N
the DT N
treatment NN N
group NN N
after IN N
the DT N
first JJ N
intervention NN N
( ( N
6.95 CD N
% NN N
right NN N
, , N
12.61 CD N
% NN N
left NN N
) ) N
as IN N
compared VBN N
with IN N
the DT N
second JJ N
( ( N
11.53 CD N
% NN N
right NN N
, , N
17.02 CD N
% NN N
left NN N
) ) N
and CC N
the DT N
third JJ N
interventions NNS N
( ( N
10.53 CD N
% NN N
right NN N
, , N
16.81 CD N
% NN N
left VBD N
) ) N
. . N

No DT N
statistically RB N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
grip JJ o
strength NN o
comparison NN o
within IN N
the DT N
sham NN N
group NN N
. . N

Overall JJ N
differences NNS o
in IN o
strength NN o
were VBD N
consistently RB N
significant JJ N
between IN N
the DT N
study NN N
groups NNS N
( ( N
P NNP N
= NNP N
.0025 NNP N
) ) N
. . N

CONCLUSION VB N
The DT N
present JJ N
study NN N
suggests VBZ N
that IN N
the DT N
grip NN N
strength NN N
of IN N
national JJ p
level NN p
judo NN p
athletes NNS p
receiving VBG N
chiropractic JJ i
SMT NNP i
improved VBD N
compared VBN N
to TO N
those DT N
receiving VBG N
sham NN N
. . N

-DOCSTART- -23097006- O O

Pulmonary JJ N
vein NN N
re-isolation NN N
for IN N
atrial JJ p
fibrillation NN p
using VBG N
duty-cycled JJ i
phased JJ i
radiofrequency NN i
ablation NN i
: : i
safety NN N
and CC N
efficacy NN N
of IN N
a DT N
primary JJ i
2:1 CD i
bipolar/unipolar JJ i
ablation NN i
mode NN i
. . i

PURPOSE NNP N
Pulmonary NNP i
vein NN i
isolation NN i
( ( i
PVI NNP i
) ) i
using VBG N
phased JJ i
radiofrequency NN i
( ( i
RF NNP i
) ) i
energy NN i
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
effective JJ N
in IN N
the DT N
treatment NN N
of IN N
paroxysmal JJ p
atrial JJ p
fibrillation NN p
( ( p
AF NNP p
) ) p
. . p

We PRP N
characterize VBP N
pulmonary JJ i
vein NN i
( ( i
PV NNP i
) ) i
conduction NN i
at IN i
repeat NN i
ablation NN i
in IN N
patients NNS p
with IN p
AF NNP p
after IN N
an DT N
initial JJ N
successful JJ N
PVI NNP N
using VBG N
phased VBD N
RF NNP N
technology NN N
and CC N
analyze VB N
the DT N
effects NNS N
of IN N
a DT N
primary JJ N
2:1 CD N
ablation NN N
mode NN N
. . N

METHODS NNP N
AND NNP N
RESULTS NNP N
A NNP N
primary JJ N
4:1 CD N
bipolar/unipolar JJ N
mode NN N
in IN N
group NN N
A NNP N
patients NNS N
( ( p
n JJ p
= NNP p
22 CD p
) ) p
was VBD N
compared VBN N
with IN N
a DT N
primary JJ N
2:1 CD N
mode NN N
in IN N
group NN N
B NNP N
( ( p
n JJ p
= NNP p
22 CD p
) ) p
acutely RB N
and CC N
during IN N
follow-up JJ N
. . N

Of IN N
all DT N
PVs NNP N
, , N
81 CD N
% NN N
showed VBD N
reconnection NN N
( ( N
s JJ N
) ) N
; : N
52 CD N
% NN N
of IN N
them PRP N
had VBD N
reconnected VBN N
in IN N
all DT N
PVs NNP N
. . N

PVI NNP N
was VBD N
achieved VBN N
in IN N
all DT N
patients NNS N
without IN N
complications NNS N
. . N

Procedure NN o
and CC o
fluoroscopy NN o
times NNS o
were VBD N
shorter JJR N
in IN N
group NN N
B NNP N
( ( N
108 CD N
? . N
15 CD N
vs. IN N
126 CD N
? . N
24 CD N
min NN N
and CC N
17 CD N
? . N
5 CD N
vs. IN N
23 CD N
? . N
7 CD N
min NN N
, , N
respectively RB N
) ) N
. . N

This DT N
was VBD N
attributed VBN N
to TO N
a DT N
significant JJ N
decrease NN N
of IN N
early JJ o
PV NNP o
reconnections NNS o
within IN o
the DT N
first JJ N
30 CD N
min NN N
in IN N
17 CD N
% NN N
of IN N
group NN N
B NNP N
patients NNS N
vs. FW N
45 CD N
% NN N
of IN N
group NN N
A NNP N
patients NNS N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

After IN N
9.5 CD N
? . N
4 CD N
months NNS N
, , N
recurrence NN o
of IN o
AF NNP o
was VBD o
detected VBN N
in IN N
5 CD N
of IN N
22 CD N
patients NNS N
( ( N
22.7 CD N
% NN N
) ) N
in IN N
group NN N
A NNP N
vs. NN N
3 CD N
of IN N
22 CD N
patients NNS N
( ( N
13.6 CD N
% NN N
) ) N
in IN N
group NN N
B NNP N
( ( N
p JJ N
= NNP N
0.722 CD N
) ) N
. . N

CONCLUSIONS NNP i
Phased VBD i
RF NNP i
energy NN i
applied VBN i
by IN N
a DT N
2:1 CD N
bipolar/unipolar JJ N
mode NN N
seems VBZ N
safe JJ N
and CC N
effective JJ N
in IN N
redo-PVI JJ N
procedures NNS N
, , N
resulting VBG N
in IN N
a DT N
mid-term JJ N
freedom NN N
from IN N
AF NNP N
in IN N
86.4 CD N
% NN N
. . N

Significant JJ N
shorter JJ N
procedure NN N
and CC N
fluoroscopy NN N
times NNS N
compared VBN N
with IN N
a DT N
primary JJ N
4:1 CD N
ablation NN N
mode NN N
during IN N
repeat NN N
PVI NNP N
are VBP N
mainly RB N
attributed VBN N
to TO N
a DT N
lower JJR N
incidence NN N
of IN N
acutely RB N
reconnected VBN N
PVs NNP N
within IN N
the DT N
first JJ N
30 CD N
min NN N
. . N

-DOCSTART- -8589555- O O

Synthetic JJ i
serum NN i
substitute NN i
( ( i
SSS NNP i
) ) i
: : i
a DT N
globulin-enriched JJ N
protein NN N
supplement NN N
for IN N
human JJ p
embryo JJ p
culture NN p
. . p

OBJECTIVE CC N
The DT N
purpose NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
evaluate VB N
whether IN N
an DT N
IVF NNP N
protein NN N
supplement NN N
prepared VBN N
from IN N
human JJ N
serum NN N
albumin NN N
( ( N
HSA NNP N
) ) N
and CC N
human JJ N
globulins NNS N
would MD N
retain VB N
performance NN o
characteristics NNS o
equivalent JJ N
to TO N
those DT N
reported VBN N
for IN N
the DT N
commercial JJ N
plasma NN N
expanders NNS N
, , N
Plasmatein NNP i
( ( N
Alpha NNP N
Therapeutics NNP N
, , N
Los NNP N
Angeles NNP N
, , N
California NNP N
) ) N
and CC N
Plasmanate NNP i
( ( N
Cutter NNP N
Biological NNP N
, , N
Miles NNP N
Inc. NNP N
, , N
Elkhart NNP N
, , N
Indiana NNP N
) ) N
. . N

METHODS NNP N
Pronuclear-stage JJ p
human JJ p
embryos NN p
were VBD N
randomly RB N
divided VBN i
and CC i
cultured VBN i
in IN i
human JJ i
tubal JJ i
fluid NN i
medium NN i
( ( i
HTF NNP i
) ) i
supplemented VBD i
with IN i
either DT i
HSA NNP i
( ( i
5 CD i
mg/mL NN i
) ) i
or CC i
Plasmatein NNP i
( ( i
10 CD i
% NN i
, , i
v/v NN i
; : i
5 CD i
mg/ml NN i
) ) i
as IN i
a DT i
means NN i
of IN i
indirectly RB i
assessing VBG i
the DT i
effect NN i
alpha- JJ i
and CC i
beta-globulins NNS i
have VBP i
on IN i
embryonic JJ i
development NN i
. . i

Those DT N
results NNS N
coupled VBD N
with IN N
the DT N
known VBN N
composition NN N
characteristics NNS N
of IN N
Plasmatein NNP i
were VBD N
used VBN N
as IN N
the DT N
starting VBG N
basis NN N
to TO N
formulate VB N
test JJ N
lots NNS N
of IN N
synthetic JJ N
serum NN N
substitute NN N
( ( N
SSS NNP N
) ) N
. . N

RESULTS NNP N
Significantly NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
more JJR N
of IN N
the DT N
human JJ N
embryos NN N
cultured VBN N
in IN N
Plasmatein NNP i
supplemented VBD N
medium NN N
reached VBD N
the DT N
four-cell NN o
or CC o
greater JJR o
stage NN o
by IN N
40 CD N
hr NNS N
postinsemination NN N
than IN N
a DT N
comparable JJ N
group NN N
cultured VBD N
in IN N
HSA NNP i
alone RB N
. . N

Lot NNP N
1 CD N
of IN N
SSS NNP N
, , N
formulated VBD N
with IN N
HSA NNP N
( ( N
84 CD N
% NN N
of IN N
total JJ N
protein NN N
) ) N
and CC N
human JJ N
globulins NNS N
( ( N
16 CD N
% NN N
of IN N
total JJ N
protein NN N
) ) N
and CC N
an DT N
aqueous JJ N
lipoprotein NN N
fraction NN N
derived VBN N
from IN N
human JJ N
plasma NN N
( ( N
Excyte NNP N
IV NNP N
; : N
Miles NNP N
Diagnostics NNPS N
, , N
Kankakee NNP N
, , N
Illinois NNP N
) ) N
, , N
produced VBD N
accelerated VBN N
early JJ o
embryonic JJ o
growth NN o
relative JJ N
to TO N
control VB N
murine JJ N
embryos NNS N
grown VBN N
in IN N
the DT N
presence NN N
of IN N
Plasmatein NNP N
, , N
however RB N
, , N
the DT N
percentage NN N
of IN N
the DT N
embryos NN N
reaching VBG N
the DT N
hatched JJ N
blastocyst NN N
stage NN N
was VBD N
decreased VBN N
( ( N
45 CD N
vs RB N
100 CD N
% NN N
) ) N
. . N

Human JJ p
embryos NN p
from IN p
seven CD p
patients NNS p
, , N
randomized VBN N
to TO N
HTF NNP N
medium NN N
supplemented VBD N
with IN N
Plasmatein NNP i
or CC N
lot NN N
1 CD N
of IN N
SSS NNP i
, , N
showed VBD N
equivalent JJ N
growth NN o
at IN N
36-40 JJ N
hr NN N
postinsemination NN N
. . N

A DT N
microprecipitate NN N
developed VBN N
in IN N
media NNS N
supplemented VBN N
with IN N
lot NN N
1 CD N
after IN N
several JJ N
days NNS N
of IN N
culture NN N
. . N

The DT N
Excyte NNP o
IV NNP o
concentration NN o
was VBD N
reduced VBN N
and CC N
, , N
ultimately RB N
, , N
eliminated VBN N
from IN N
the DT N
subsequent JJ N
and CC N
final JJ N
prototype NN N
lots NNS N
of IN N
SSS NNP N
. . N

Murine NNP p
embryos JJ p
grown VBN N
in IN N
the DT N
presence NN N
of IN N
lipoprotein JJ N
free JJ N
SSS NNP i
showed VBD N
significantly RB N
accelerated VBN o
( ( o
P NNP o
< NNP o
0.01 CD o
) ) o
growth NN o
at IN N
17 CD N
hr NN N
postthaw NN N
compared VBN N
to TO N
Plasmatein NNP i
and CC N
all DT N
embryos NNS N
progressed VBN N
to TO N
hatching VBG o
by IN N
41 CD N
hr NN N
. . N

Human NNP p
embryos NN p
, , N
randomized VBN N
to TO N
either DT N
Plasmatein NNP i
or CC N
lot NN N
3 CD N
of IN N
SSS NNP i
, , N
showed VBD N
significantly RB N
accelerated VBN o
growth NN o
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
when WRB N
scored VBN N
at IN N
38 CD N
hr NN N
following VBG N
insemination NN N
. . N

CONCLUSION NNP N
Synthetic NNP i
serum NN i
substitute NN i
provides VBZ N
a DT N
convient NN N
, , N
standardized JJ N
means NNS N
of IN N
adding VBG N
protein NN N
to TO N
media NNS N
used VBN N
in IN N
assisted JJ N
reproductive JJ N
technology NN N
( ( N
ART NNP N
) ) N
procedures NNS N
. . N

-DOCSTART- -16671415- O O

Decompressive JJ i
craniectomy NN i
in IN N
traumatic JJ p
brain NN p
injury NN p
: : p
the DT N
randomized JJ N
multicenter NN N
RESCUEicp NNP N
study NN N
( ( N
www.RESCUEicp.com NN N
) ) N
. . N

The DT N
RESCUEicp NNP N
( ( N
Randomized NNP N
Evaluation NNP N
of IN N
Surgery NNP N
with IN N
Craniectomy NNP N
for IN N
Uncontrollable JJ N
Elevation NN N
of IN N
intracranial JJ N
pressure NN N
) ) N
study NN N
has VBZ N
been VBN N
established VBN N
to TO N
determine VB N
whether IN N
decompressive JJ i
craniectomy NN i
has VBZ N
a DT N
role NN N
in IN N
the DT N
management NN N
of IN N
patients NNS p
with IN p
traumatic JJ p
brain NN p
injury NN p
and CC p
raised VBD p
intracranial JJ p
pressure NN p
that WDT p
does VBZ p
not RB p
respond VB p
to TO p
initial JJ p
treatment NN p
measures NNS p
. . p

We PRP N
describe VBP N
the DT N
concept NN N
of IN N
decompressive JJ i
craniectomy NN i
in IN N
traumatic JJ N
brain NN N
injury NN N
and CC N
the DT N
rationale NN N
and CC N
protocol NN N
of IN N
the DT N
RESCUEicp NNP N
study NN N
. . N

-DOCSTART- -18242415- O O

Effect NN N
of IN N
a DT N
nutrition NN i
intervention NN i
during IN N
early JJ N
childhood NN N
on IN N
economic JJ o
productivity NN o
in IN N
Guatemalan NNP p
adults NNS p
. . p

BACKGROUND NNP N
Substantial NNP N
, , N
but CC N
indirect JJ N
, , N
evidence NN N
suggests VBZ N
that IN N
improving VBG N
nutrition NN N
in IN N
early JJ N
childhood NN N
in IN N
developing VBG N
countries NNS N
is VBZ N
a DT N
long-term JJ N
economic JJ N
investment NN N
. . N

We PRP N
investigated VBD N
the DT N
direct JJ N
effect NN N
of IN N
a DT N
nutrition NN i
intervention NN i
in IN N
early JJ N
childhood NN N
on IN N
adult JJ N
economic JJ N
productivity NN N
. . N

METHODS NNP N
We PRP N
obtained VBD N
economic JJ N
data NNS N
from IN N
1424 CD p
Guatemalan NNP p
individuals NNS p
( ( p
aged VBN p
25-42 CD p
years NNS p
) ) p
between IN p
2002 CD p
and CC p
2004 CD p
. . p

They PRP N
accounted VBD p
for IN p
60 CD p
% NN p
of IN p
the DT p
2392 CD p
children NNS p
( ( p
aged VBN p
0-7 CD p
years NNS p
) ) p
who WP p
had VBD p
been VBN p
enrolled VBN p
in IN p
a DT p
nutrition NN i
intervention NN i
study NN p
during IN p
1969-77 JJ p
. . p

In IN N
this DT N
initial JJ N
study NN N
, , N
two CD N
villages NNS N
were VBD N
randomly RB N
assigned VBN N
a DT N
nutritious JJ i
supplement NN i
( ( i
atole JJ i
) ) i
for IN i
all DT i
children NNS i
and CC i
two CD i
villages NNS i
a DT i
less RBR i
nutritious JJ i
one CD i
( ( i
fresco NN i
) ) i
. . i

We PRP N
estimated VBD N
annual JJ N
income NN N
, , N
hours NNS N
worked VBD N
, , N
and CC N
average JJ N
hourly JJ N
wages NNS N
from IN N
all DT N
economic JJ N
activities NNS N
. . N

We PRP N
used VBD N
linear JJ N
regression NN N
models NNS N
, , N
adjusting VBG N
for IN N
potentially RB N
confounding VBG N
factors NNS N
, , N
to TO N
assess VB N
the DT N
relation NN N
between IN N
economic JJ N
variables NNS N
and CC N
exposure NN N
to TO N
atole VB i
or CC N
fresco VB i
at IN N
specific JJ N
ages NNS N
between IN N
birth NN N
and CC N
7 CD N
years NNS N
. . N

FINDINGS NNP N
Exposure NN N
to TO N
atole VB i
before IN N
, , N
but CC N
not RB N
after IN N
, , N
age NN N
3 CD N
years NNS N
was VBD N
associated VBN N
with IN N
higher JJR N
hourly NN o
wages NNS o
, , N
but CC N
only RB N
for IN N
men NNS N
. . N

For IN N
exposure NN N
to TO N
atole VB N
from IN N
0 CD N
to TO N
2 CD N
years NNS N
, , N
the DT N
increase NN N
was VBD N
US NNP N
$ $ N
0.67 CD N
per IN N
hour NN N
( ( N
95 CD N
% NN N
CI NNP N
0.16-1.17 NN N
) ) N
, , N
which WDT N
meant VBD N
a DT N
46 CD N
% NN N
increase NN N
in IN N
average JJ N
wages NNS N
. . N

There EX N
was VBD N
a DT N
non-significant JJ N
tendency NN o
for IN o
hours NNS o
worked VBN o
to TO N
be VB N
reduced VBN N
and CC N
for IN N
annual JJ o
incomes NNS o
to TO N
be VB N
greater JJR N
for IN N
those DT N
exposed VBN N
to TO N
atole VB i
from IN N
0 CD N
to TO N
2 CD N
years NNS N
. . N

INTERPRETATION NNP N
Improving VBG N
nutrition NN N
in IN N
early JJ N
childhood NN N
led VBD N
to TO N
substantial JJ o
increases NNS o
in IN o
wage NN o
rates NNS o
for IN N
men NNS N
, , N
which WDT N
suggests VBZ N
that IN N
investments NNS N
in IN N
early JJ N
childhood NN N
nutrition NN N
can MD N
be VB N
long-term JJ N
drivers NNS N
of IN N
economic JJ N
growth NN N
. . N

-DOCSTART- -22344198- O O

Efficacy NN o
and CC o
safety NN o
of IN N
leuprolide JJ i
acetate JJ i
3-month JJ i
depot NN N
11.25 CD N
milligrams NNS N
or CC N
30 CD N
milligrams NNS N
for IN N
the DT N
treatment NN N
of IN N
central JJ p
precocious JJ p
puberty NN p
. . p

CONTEXT NNP N
GnRH NNP N
agonist NN N
( ( N
GnRHa NNP N
) ) N
monthly JJ N
injections NNS N
are VBP N
frequently RB N
used VBN N
in IN N
the DT N
treatment NN N
of IN N
central JJ p
precocious JJ p
puberty NN p
( ( p
CPP NNP p
) ) p
. . p

The DT N
3-month JJ i
leuprolide NN i
depot NN i
11.25- JJ i
and CC N
30-mg JJ N
formulations NNS N
are VBP N
newly RB N
approved VBN N
treatment NN N
options NNS N
. . N

OBJECTIVE IN N
The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
leuprolide JJ i
acetate JJ i
3-month JJ i
depot NN N
formulations NNS N
for IN N
the DT N
treatment NN N
of IN N
CPP NNP p
in IN p
children NNS p
. . p

DESIGN NN N
This DT N
was VBD N
a DT N
phase NN N
III NNP N
, , N
randomized VBD N
, , N
open-label JJ N
, , N
dose-ranging JJ N
6-month JJ N
study NN N
. . N

SETTING NNP N
Twenty-two JJ p
U.S. NNP p
medical JJ p
centers NNS p
( ( p
including VBG p
Puerto NNP p
Rico NNP p
) ) p
participated VBD p
. . p

PATIENTS NNP N
Children NNP p
diagnosed VBD p
with IN p
CPP NNP p
( ( p
n JJ p
= NNP p
84 CD p
) ) p
, , p
who WP p
were VBD p
either CC p
treatment NN p
naive JJ p
or CC p
previously RB p
treated VBN p
with IN p
GnRHa NNP p
, , p
were VBD p
recruited VBN p
. . p

Chronological JJ p
age NN p
at IN p
onset NN p
of IN p
pubertal JJ p
signs NNS p
was VBD p
less JJR p
than IN p
8 CD p
yr NN p
in IN p
girls NNS p
and CC p
less JJR p
than IN p
9 CD p
yr NN p
in IN p
boys NNS p
, , p
and CC p
bone NN p
age NN p
was VBD p
advanced VBN p
over IN p
chronological JJ p
age NN p
at IN p
least JJS p
1 CD p
yr NN p
. . p

INTERVENTION NNP N
Leuprolide NNP i
acetate NN i
depot NN i
( ( N
11.25 CD N
or CC N
30 CD N
mg NN N
) ) N
was VBD N
administered VBN N
im JJ N
every DT N
3 CD N
months NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Biochemical NNP o
[ NNP o
peak-stimulated JJ o
LH NNP o
, , o
estradiol NN o
( ( o
girls NNS o
) ) o
, , o
and CC o
testosterone NN o
( ( o
boys NNS o
) ) o
] NN o
and CC o
anthropometric JJ o
( ( o
growth NN o
rate NN o
, , o
bone NN o
age NN o
acceleration NN o
, , o
pubertal JJ o
progression NN o
) ) o
parameters NNS o
and CC N
safety NN o
were VBD N
assessed VBN N
. . N

RESULTS NNP N
Peak-stimulated JJ o
LH NNP o
was VBD N
suppressed VBN N
in IN N
the DT N
11.25- JJ N
and CC N
30-mg JJ N
dose NN N
groups NNS N
in IN N
78.4 CD N
and CC N
95.2 CD N
% NN N
, , N
respectively RB N
, , N
of IN N
children NNS N
from IN N
months NNS N
2 CD N
through IN N
6 CD N
. . N

There EX N
were VBD N
nine CD N
treatment NN N
failures NNS N
( ( N
peak-stimulated JJ N
LH NNP N
> NNP N
4 CD N
IU/liter NNP N
) ) N
in IN N
the DT N
11.25-mg JJ N
group NN N
and CC N
two CD N
in IN N
the DT N
30-mg JJ N
group NN N
. . N

Basal NNP o
sex NN o
steroid NN o
suppression NN o
, , o
growth NN o
rates NNS o
, , o
pubertal JJ o
progression NN o
, , o
bone NN o
age NN o
advancement NN o
, , o
and CC o
adverse JJ o
events NNS o
were VBD N
similar JJ N
with IN N
either DT N
dose NN N
. . N

CONCLUSIONS NNP N
Treatment NNP N
with IN N
leuprolide JJ i
acetate JJ i
3-month JJ N
depot NN N
formulations NNS N
( ( N
11.25 CD N
and CC N
30 CD N
mg NN N
) ) N
effectively RB N
suppressed VBD N
the DT N
GnRH NNP N
axis NN N
, , N
was VBD N
well RB N
tolerated VBN N
, , N
and CC N
may MD N
positively RB N
impact VB N
patient JJ N
convenience NN N
and CC N
compliance NN N
. . N

-DOCSTART- -23321692- O O

A DT N
trial NN N
with IN N
3'-azido-2',3'-dideoxythymidine JJ i
and CC N
human JJ N
interferon-? NN i
in IN p
cats NNS p
naturally RB p
infected VBN p
with IN p
feline JJ p
leukaemia NN p
virus NN p
. . p

Feline NNP N
leukaemia NN N
virus NN N
( ( N
FeLV NNP N
) ) N
infection NN N
is VBZ N
still RB N
one CD N
of IN N
the DT N
leading JJ N
causes NNS N
of IN N
infection-related JJ N
deaths NNS N
in IN p
domestic JJ p
cats NNS p
. . p

Treatment NN N
with IN N
various JJ N
drugs NNS N
has VBZ N
been VBN N
attempted VBN N
, , N
but CC N
none NN N
has VBZ N
resulted VBN N
in IN N
cure NN N
or CC N
complete JJ N
virus NN N
elimination NN N
. . N

Human JJ i
interferon-?2a JJ i
( ( i
huIFN-?2a JJ i
) ) i
and CC i
3'-azido-2',3'-dideoxythymidine JJ i
( ( i
AZT NNP i
) ) i
have VBP i
been VBN N
proven VBN N
to TO N
decrease VB N
antigenaemia NN N
in IN N
cats NNS N
infected VBN N
experimentally RB N
with IN N
FeLV NNP N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
efficacy NN o
of IN o
huIFN-?2a NN i
, , i
AZT NNP i
and CC N
a DT N
combination NN N
of IN N
both DT N
drugs NNS N
in IN N
cats NNS N
infected VBN N
naturally RB N
with IN N
FeLV NNP N
in IN N
a DT N
placebo-controlled JJ N
double-blinded JJ N
trial NN p
. . p

Fourty-four CD p
FeLV-infected JJ p
cats NNS p
in IN p
which WDT p
free JJ p
FeLV NNP p
p27 NN p
antigen NN p
was VBD p
detected VBN p
in IN p
serum NN p
by IN p
enzyme-linked JJ p
immunosorbent JJ p
assay NN p
were VBD p
included VBN p
in IN p
the DT p
study NN p
. . p

Cats NNS p
were VBD N
assigned VBN N
to TO N
one CD N
of IN N
four CD N
treatment NN N
groups NNS N
that WDT N
received VBD N
either RB N
high JJ N
dose JJ N
huIFN-?2a NN i
( ( i
10 CD i
( ( i
5 CD N
) ) N
IU/kg NNP N
q24h NN N
; : N
12 CD N
cats NNS N
) ) N
, , i
AZT NNP i
( ( N
5 CD N
mg/kg NN N
q12h NN N
; : N
10 CD N
cats NNS N
, , N
both DT N
of IN N
these DT N
treatments NNS N
( ( N
12 CD N
cats NNS N
) ) N
or CC i
placebo NN i
( ( i
10 CD i
cats NNS N
) ) N
. . N

All DT N
cats NNS N
were VBD N
treated VBN N
for IN N
6 CD N
weeks NNS N
. . N

Clinical JJ N
variables NNS N
, , N
including VBG o
stomatitis NN o
, , o
and CC o
laboratory NN o
parameters NNS o
, , o
such JJ o
as IN o
CD4 NNP o
( ( o
+ NNP o
) ) o
and CC o
CD8 NNP o
( ( o
+ NNP o
) ) o
counts NNS o
and CC o
serum NN o
FeLV NNP o
p VBZ o
27 CD o
antigen NN o
concentration NN o
, , o
were VBD o
recorded VBN N
throughout IN N
the DT N
treatment NN N
period NN o
. . o

No DT o
significant JJ o
difference NN o
among IN o
the DT N
groups NNS N
was VBD N
observed VBN N
during IN N
the DT N
treatment NN N
period NN N
for IN N
any DT N
of IN N
the DT N
parameters NNS N
. . N

Aside RB N
from IN N
anaemia NN o
in IN o
one CD o
cat NN N
treated VBN N
with IN N
AZT NNP N
, , N
no DT o
adverse JJ o
effects NNS o
were VBD o
observed VBN N
. . N

It PRP N
was VBD N
not RB N
possible JJ N
to TO N
demonstrate VB o
efficacy NN o
of IN o
huIFN-?2a NN o
or CC i
AZT NNP i
alone RB N
or CC N
together RB N
in IN N
cats NNS N
infected VBN N
naturally RB N
with IN N
FeLV NNP N
when WRB N
given VBN N
according VBG N
to TO N
this DT N
regimen NNS N
for IN N
6 CD N
weeks NNS N
; : N
however RB o
, , o
no DT o
notable JJ o
side NN o
effects NNS o
were VBD o
detected VBN N
. . N

-DOCSTART- -6360688- O O

Comparison NNP N
of IN N
short-term JJ N
efficacy NN N
of IN N
diltiazem NN i
and CC i
propranolol NN i
in IN N
unstable JJ N
angina NN N
at IN N
rest NN N
-- : N
a DT N
randomized JJ N
trial NN N
in IN N
70 CD p
patients NNS p
. . p

The DT N
short-term JJ N
efficacy NN N
of IN N
diltiazem NN i
( ( i
D NNP i
) ) i
has VBZ N
been VBN N
compared VBN N
to TO N
that DT N
of IN N
propranolol NN i
( ( i
P NNP i
) ) i
, , N
in IN N
a DT N
group NN N
of IN N
70 CD p
patients NNS p
hospitalized VBN p
in IN p
the DT p
Coronary NNP p
Care NNP p
Unit NNP p
for IN p
unstable JJ p
angina NN p
, , p
defined VBN p
as IN p
recent JJ p
( ( p
less JJR p
than IN p
one CD p
month NN p
) ) p
appearance NN p
or CC p
aggravation NN p
of IN p
spontaneous JJ p
chest NN p
pains NNS p
. . p

Among IN p
the DT p
70 CD p
patients NNS p
, , p
24 CD p
had VBD p
angina VBN p
only RB p
at IN p
rest NN p
. . p

The DT N
patients NNS p
have VBP p
been VBN p
divided VBN p
into IN p
two CD p
groups NNS p
according VBG p
to TO p
ST-T JJ p
changes NNS p
during IN p
chest NN p
pain NN p
: : p
29 CD p
with IN p
ST NNP p
elevation NN p
( ( p
group NN p
A NNP p
) ) p
and CC p
41 CD p
with IN p
other JJ p
repolarization NN p
abnormalities NNS p
( ( p
group NN p
B NNP p
) ) p
. . p

Treatment NN N
was VBD N
then RB N
randomized VBN N
in IN N
each DT N
group NN N
. . N

Treatment NNP N
Treatment NNP N
was VBD N
considered VBN N
successful JJ N
only RB N
if IN N
spontaneous JJ N
chest NN o
pains NNS o
disappeared VBD N
completely RB N
. . N

Thirty-four JJ N
patients NNS N
were VBD N
treated VBN N
with IN N
D NNP i
( ( N
282 CD N
+/- JJ N
102 CD N
mg/day NN N
) ) N
and CC N
36 CD N
with IN N
P NNP i
( ( N
158 CD N
+/- JJ N
81 CD N
mg/day NN N
) ) N
. . N

In IN N
the DT N
whole JJ N
group NN N
and CC N
in IN N
groups NNS N
A NNP N
and CC N
B NNP N
considered VBD N
individually RB N
, , N
responses NNS N
to TO N
D NNP i
and CC N
P NNP i
did VBD N
not RB N
differ VB N
. . N

Among IN N
the DT N
24 CD p
patients NNS p
with IN p
angina JJ o
exclusively RB p
at IN p
rest NN p
, , N
nine CD N
successes NNS N
and CC N
four CD N
failures NNS N
were VBD N
observed VBN N
with IN N
D. NNP i
There EX N
was VBD N
no DT o
symptomatic JJ o
relief NN o
among IN N
the DT N
11 CD N
patients NNS N
treated VBN N
by IN N
P NNP i
( ( N
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

Moreover RB N
, , N
the DT N
number NN o
of IN o
episodes NNS o
of IN o
angina NN o
was VBD N
decreased VBN N
by IN N
D NNP i
and CC N
unchanged JJ N
by IN N
P NNP i
, , N
while IN N
eight CD N
out IN N
of IN N
the DT N
11 CD N
failures NNS N
with IN N
P NNP i
were VBD N
immediate JJ N
successes NNS N
when WRB N
treatment NN N
was VBD N
replaced VBN N
with IN N
D. NNP i
These DT N
results NNS N
suggest VBP N
that IN N
D NNP i
is VBZ N
preferable JJ N
to TO N
P VB i
for IN N
management NN N
of IN N
unstable JJ p
angina NNS p
in IN p
patients NNS p
with IN p
angina NN p
which WDT p
is VBZ p
exclusively RB p
spontaneous JJ p
. . p

-DOCSTART- -8689462- O O

Intra-articular JJ N
hyaluronic JJ i
acid NN i
compared VBN N
to TO N
intra-articular JJ N
triamcinolone NN i
hexacetonide NN i
in IN N
inflammatory JJ p
knee NN p
osteoarthritis NN p
. . p

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
comparative JJ N
efficacy NN N
and CC N
safety NN N
of IN N
intra-articular JJ i
( ( i
i/a NN i
) ) i
triamcinolone NN i
. . i

hexacetonide NN i
( ( i
TH NNP i
) ) i
and CC i
i/a JJ i
hyaluronic JJ i
acid NN i
( ( i
HA NNP i
) ) i
in IN N
inflammatory JJ p
knee NN p
osteoarthritis NN p
. . p

A DT N
randomized JJ N
double-blind JJ N
comparative JJ N
trail NN N
was VBD N
carried VBN N
out RP N
in IN N
a DT N
rheumatology NN p
outpatient NN p
department NN p
. . p

There EX N
were VBD N
63 CD p
patients NNS p
( ( p
24 CD p
male NN p
, , p
39 CD p
female NN p
, , p
mean JJ p
age NN p
70.5 CD p
years NNS p
) ) p
with IN p
bilateral JJ p
symptomatic JJ p
knee NN p
osteoarthritis NN p
with IN p
effusion NN p
. . p

Each DT N
was VBD N
given VBN N
five CD i
HA NNP i
injections NNS i
at IN i
weekly JJ i
intervals NNS i
; : i
or CC i
20 CD i
mg NN i
TH NNP i
followed VBN i
by IN i
four CD i
placebo NN i
( ( i
saline NN i
) ) i
injections NNS i
. . i

Patients NNS N
were VBD N
examined JJ N
weekly JJ N
during IN N
the DT N
treatment NN N
period NN N
and CC N
then RB N
at IN N
monthly JJ N
intervals NNS N
for IN N
a DT N
further JJ N
6 CD N
months NNS N
. . N

Assessment NNP N
included VBD N
recording NN N
of IN N
: : N
visual JJ o
analog NN o
scores NNS o
( ( o
VAS NNP o
) ) o
for IN o
pain NN o
; : o
duration NN o
of IN o
stiffness NN o
; : o
range NN o
of IN o
movement NN o
; : o
joint JJ o
effusion NN o
; : o
local JJ o
heat NN o
; : o
synovial JJ o
thickening NN o
; : o
joint-line JJ o
and CC o
periarticular JJ o
tenderness NN o
. . o

The DT N
principal JJ N
outcome JJ N
measure NN N
was VBD N
pain NN o
on IN o
a DT o
self-selected JJ o
activity NN o
assessed VBN o
by IN o
Vas NNP o
. . o

The DT N
two CD p
groups NNS p
were VBD p
comparable JJ p
at IN p
entry NN p
and CC N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
groups NNS N
developed VBD N
at IN N
any DT N
time NN N
during IN N
the DT N
treatment NN N
period NN N
. . N

However RB N
, , N
there EX N
was VBD N
a DT N
high JJ p
drop-out NN p
rate NN p
and CC N
intention NN N
to TO N
treat VB N
analysis NN N
failed VBD N
to TO N
demonstrate VB N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
groups NNS N
. . N

In IN N
patients NNS N
remaining VBG N
in IN N
the DT N
study NN N
, , N
significantly RB N
less JJR N
pain NN o
was VBD N
experienced VBN N
by IN N
the DT N
HA NNP i
group NN N
during IN N
the DT N
6 CD N
month NN N
follow-up JJ N
period NN N
. . N

Other JJ N
parameters NNS N
showed VBD N
a DT N
similar JJ N
trend NN N
in IN N
favor NN N
of IN N
experienced VBN N
by IN N
the DT N
HA NNP i
group NN N
during IN N
the DT N
6 CD N
month NN N
follow-up JJ N
period NN N
. . N

Other JJ N
parameters NNS N
showed VBD N
a DT N
similar JJ N
trend NN N
in IN N
favor NN N
of IN N
HA NNP i
. . i

We PRP N
could MD N
not RB N
, , N
however RB N
, , N
demonstrate JJ N
significant JJ N
differences NNS N
between IN N
the DT N
placebo NN N
and CC N
active JJ N
treatments NNS N
. . N

HA NNP i
may MD N
therefore RB N
be VB N
a DT N
useful JJ N
additional JJ N
therapy NN N
for IN N
symptomatic JJ p
knee NN p
osteoarthritis NN p
and CC N
may MD N
have VB N
a DT N
long JJ N
duration NN N
of IN N
action NN N
. . N

-DOCSTART- -26742304- O O

Effect NN N
of IN N
direct JJ i
current JJ i
pulse NN i
stimulating VBG i
acupoints NNS i
of IN i
JiaJi NNP i
( ( N
T10-13 NNP N
) ) N
and CC N
Ciliao NNP N
( ( N
BL NNP N
32 CD N
) ) N
with IN N
Han NNP i
's POS i
Acupoint NNP i
Nerve NNP i
Stimulator NNP i
on IN N
labour NN o
pain NN o
in IN p
women NNS p
: : p
a DT N
randomized NN N
controlled VBD N
clinical JJ N
study NN N
. . N

OBJECTIVE NNP N
To TO N
assess VB N
the DT N
clinical JJ N
effect NN N
and CC N
safety NN N
of IN N
direct JJ i
current JJ i
( ( i
DC NNP i
) ) i
pulse NN i
produced VBN i
by IN i
Han NNP i
's POS i
Acupoint NNP i
Nerve NNP i
Stimulator NNP i
in IN N
reduction NN N
( ( N
HANS NNP N
) ) N
of IN N
labor NN o
pain NN o
. . o

METHODS NNP N
Totally RB N
120 CD p
participants NNS p
were VBD N
enrolled VBN N
in IN N
this DT N
clinical JJ N
trial NN N
, , N
and CC N
were VBD N
randomly RB N
divided VBN N
into IN N
4 CD N
groups NNS N
including VBG N
: : N
HANS NNP i
group NN i
, , i
patient NN i
controlled VBD i
intravenous JJ i
analgesia NN i
( ( i
PCIA NNP i
) ) i
group NN i
, , i
patient-controlled JJ i
epidural JJ i
analgesia NN i
( ( i
PCEA NNP i
) ) i
group NN N
and CC N
control NN N
group NN N
. . N

The DT N
HANS NNP i
group NN N
was VBD N
treated VBN N
by IN N
stimulating VBG N
the DT N
acupoints NNS i
of IN i
JiaJi NNP i
( ( N
T10-L3 NNP N
) ) N
and CC N
Ciliao NNP i
( ( N
BL NNP N
32 CD N
) ) N
with IN N
DC NNP i
pulse NN i
of IN N
100 CD N
Hz NNP N
and CC N
15-30 JJ N
mA NN N
produced VBN N
by IN N
a DT N
portable JJ i
battery-powered JJ i
Han NNP i
's POS i
Acupoint NNP i
Nerve NNP i
Stimulator NNP i
for IN N
30 CD N
min NN N
. . N

The DT N
PCIA NNP i
group NN N
was VBD N
intravenously RB N
infused VBN N
Ondansetron NNP i
( ( N
8 CD N
mg NN N
) ) N
for IN N
5 CD N
min NNS N
, , N
then RB N
tramadol VB i
injection NN i
( ( N
1.5 CD N
mg/kg NN N
) ) N
was VBD N
slowly RB N
dripped VBN N
by IN N
using VBG N
BaxterAP NNP N
II NNP N
electronic JJ N
pump NN N
with IN N
50 CD N
mL NNS N
tramadol NN i
( ( N
0.70 CD N
% NN N
) ) N
+ NN N
ondansetron NN i
( ( N
8 CD N
mg NN N
) ) N
, , N
background JJ N
infusion NN N
2 CD N
mL/h NN N
, , N
PCA NNP N
dose NN N
of IN N
2 CD N
mL NNS N
, , N
lockout IN N
interval NN N
of IN N
10 CD N
min NN N
. . N

In IN N
PCEA NNP i
group NN N
, , N
women NNS N
received VBD N
intrathecal JJ N
injection NN i
ropivacaine NN i
( ( N
3 CD N
mg NN N
) ) N
in IN N
L2-3 NNP N
, , N
and CC N
epidural JJ N
catheter NN N
was VBD N
connected VBN N
to TO N
BaxterAP NNP N
II NNP N
electronic JJ N
pump NN N
, , N
with IN N
100 CD N
mL NNS N
Ropivacaine NNP i
( ( N
0.1 CD N
% NN N
) ) N
and CC N
Sufentanil NNP i
( ( N
50 CD N
ug NN N
) ) N
, , N
background JJ N
infusion NN N
5 CD N
mL NN N
, , N
Patient NNP i
controlled VBD i
analgesia NN i
( ( i
PCA NNP i
) ) i
dose NN N
of IN N
5 CD N
mL NNS N
, , N
lockout IN N
interval NN N
of IN N
10 CD N
min NN N
. . N

The DT N
control NN N
group NN N
was VBD N
not RB N
received VBN N
analgesia NN N
. . N

The DT o
visual JJ o
analogue NN o
scale NN o
( ( o
VAS NNP o
) ) o
, , o
stage NN o
and CC o
manner NN o
of IN o
labor NN o
, , o
Apgar NNP o
score NN o
of IN o
newborn JJ o
, , o
neonatal JJ o
weights NNS o
, , o
oxytocin JJ o
dosage NN o
, , o
postpartum NN o
hemorrhage NN o
and CC o
side NN o
effects NNS o
were VBD N
monitored VBN N
in IN N
all DT N
groups NNS N
. . N

RESULTS VB N
The DT N
vital JJ N
signs NNS N
were VBD N
all DT N
stable JJ N
in IN N
the DT N
four CD N
analgesic JJ N
groups NNS N
. . N

After IN N
analgesia NN N
, , N
there EX N
was VBD N
statistical JJ N
difference NN N
in IN N
VAS NNP o
score NN o
between IN N
HANS NNP i
group NN N
and CC N
control NN i
group NN N
, , N
between IN N
PCEA NNP i
group NN N
and CC N
the DT N
control NN i
group NN N
, , N
between IN N
PCIA NNP i
group NN N
and CC N
control NN i
group NN N
. . N

The DT N
analgesic JJ o
effect NN o
in IN N
the DT N
PCEA NNP i
group NN N
was VBD N
significantly RB N
better JJR N
than IN N
that DT N
of IN N
other JJ N
two CD N
groups NNS N
. . N

The DT N
second JJ N
stage NN N
of IN N
labor NN N
in IN N
the DT N
PCEA NNP i
group NN N
was VBD N
longer JJR N
than IN N
the DT N
other JJ N
three CD N
groups NNS N
, , N
showing VBG N
significant JJ N
difference NN N
between IN N
them PRP N
. . N

The DT N
Apgar NNP N
score NN N
of IN N
newborn JJ N
1 CD N
min NN N
after IN N
birth NN N
in IN N
the DT N
PCIA NNP i
group NN N
was VBD N
slightly RB N
lower JJR N
than IN N
that DT N
of IN N
the DT N
other JJ N
two CD N
groups NNS N
, , N
showing VBG N
significant JJ N
difference NN N
between IN N
them PRP N
. . N

The DT N
neonatal JJ o
weights NNS o
between IN N
four CD N
groups NNS N
were VBD N
not RB N
significantly RB N
different JJ N
. . N

The DT N
rate NN o
of IN o
cesarean JJ o
section NN o
in IN N
the DT N
control NN N
group NN N
was VBD N
significantly RB N
higher JJR N
than IN N
that DT N
of IN N
the DT N
labor NN N
analgesia NN N
group NN N
, , N
there EX N
was VBD N
statistically RB N
difference NN N
in IN N
four CD N
groups NNS N
. . N

The DT N
number NN N
of IN N
PCIA NNP i
group NN N
that WDT N
used VBD o
oxytocin NN o
was VBD N
lower JJR N
than IN N
that DT N
of IN N
other JJ N
three CD N
groups NNS N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
postpartum JJ o
hemorrhage NN o
between IN N
four CD N
groups NNS N
. . N

The DT N
side NN N
effects NNS N
of IN N
the DT N
PCEA NNP i
group NN N
were VBD N
itching VBG o
, , o
uroschesis NN o
and CC o
neonatal JJ o
asphyxia NN o
and CC N
PCIA NNP i
group NN N
were VBD N
nausea RB o
and CC o
vomiting VBG o
and CC o
neonatal JJ o
asphyxia NN o
. . o

However RB N
, , N
fewer JJR N
side-effects NNS o
were VBD N
observed VBN N
in IN N
the DT N
HANS NNP i
group NN N
. . N

CONCLUSION NNP N
The DT N
DC NNP N
pulse NN N
produced VBN N
by IN N
HANS NNP i
may MD N
be VB N
a DT N
non-pharmacological JJ N
alternative NN N
to TO N
labor NN N
pain NN N
with IN N
fewer JJR N
side NN N
effects NNS N
. . N

-DOCSTART- -19268506- O O

Cardiovascular JJ o
risk NN o
markers NNS o
during IN N
treatment NN N
with IN N
estradiol NN i
and CC i
trimegestone NN i
or CC i
dydrogesterone NN i
. . N

OBJECTIVE UH N
To TO N
study VB N
cardiovascular JJ o
risk NN o
markers NNS o
in IN N
women NNS p
taking VBG p
estradiol/trimegestone NN i
or CC i
estradiol/dydrogesterone NN i
. . i

DESIGN NNP N
Multicenter NNP N
, , N
randomized VBD N
, , N
prospective JJ N
, , N
double-blind JJ N
study NN N
of IN N
184 CD p
healthy JJ p
post-menopausal JJ p
women NNS p
randomized VBD N
to TO N
6 CD i
cycles NNS i
of IN i
either DT i
estradiol NN i
( ( i
2mg CD i
) ) i
+trimegestone NN i
( ( i
0.5mg CD i
) ) i
( ( i
T-group NNP i
) ) i
or CC i
estradiol NN i
( ( i
2mg CD i
) ) i
+dydrogesterone NN i
( ( i
10mg CD i
) ) i
( ( i
DYDR NNP i
group NN i
) ) i
. . i

Cardiovascular JJ o
risk NN o
markers NNS o
were VBD i
measured VBN i
before IN i
, , i
after IN i
cycle NN i
1 CD i
, , i
3 CD i
and CC i
6 CD i
and CC i
at IN i
4 CD i
weeks NNS i
post-treatment JJ i
. . i

RESULTS NNP N
Fibrinogen NNP o
was VBD N
reduced VBN N
in IN N
both DT N
groups NNS N
but CC N
more JJR N
markedly RB N
in IN N
the DT N
DYDR NNP N
group NN N
. . N

Factor NNP o
VIIc NNP o
activity NN o
levels NNS o
decreased VBN N
in IN N
both DT N
groups NNS N
with IN N
a DT N
greater JJR N
change NN N
in IN N
the DT N
T-group NNP N
. . N

Factor NNP o
VII NNP o
antigen NN o
was VBD N
increased VBN N
in IN N
both DT N
groups NNS N
with IN N
a DT N
greater JJR N
increase NN N
in IN N
the DT N
DYDR NNP N
group NN N
. . N

Factor NNP o
VIIa NNP o
was VBD N
increased VBN N
in IN N
the DT N
DYDR NNP N
group NN N
only RB N
. . N

Plasminogen NN o
levels NNS o
were VBD N
also RB N
increased VBN N
in IN N
both DT N
groups NNS N
with IN N
a DT N
greater JJR N
increase NN N
in IN N
the DT N
T-group NNP N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
changes NNS N
in IN N
lipid JJ o
variables NNS o
between IN N
the DT N
different JJ N
regimens NNS N
. . N

Changes NNS N
in IN N
total JJ o
cholesterol NN o
and CC o
LDL NNP o
cholesterol NN o
were VBD N
correlated VBN N
positively RB N
with IN N
changes NNS N
in IN N
factor NN o
VIIc NNP o
in IN N
the DT N
DYDR NNP N
group NN N
and CC N
negatively RB N
with IN N
changes NNS N
in IN N
factor NN o
VIIc NNP o
in IN N
the DT N
T-group NNP N
. . N

Trigemestone NN N
was VBD N
associated VBN N
with IN N
a DT N
better JJR N
bleeding NN o
pattern NN o
. . o

CONCLUSIONS NNP N
Trimegestone NNP N
was VBD N
associated VBN N
with IN N
less RBR N
procoagulant JJ o
changes NNS o
in IN o
factor NN o
VIIa NNP o
and CC N
factor NN o
VIIc NNP o
activity NN o
and CC N
larger JJR N
decrease NN N
in IN N
PAI-1 NNP o
activity NN o
compared VBN N
with IN N
the DT N
dydrogesterone NN N
preparation NN N
. . N

These DT N
results NNS N
reflect VBP N
less JJR N
androgenic JJ o
properties NNS o
of IN N
the DT N
trimegestone NN N
preparation NN N
. . N

The DT N
fibrinogen NN o
level NN o
and CC N
Lp NNP o
( ( o
a DT o
) ) o
were VBD N
more JJR N
decreased JJ N
during IN N
dydrogesterone NN N
treatment NN N
. . N

Further JJ N
investigation NN N
is VBZ N
required VBN N
to TO N
clarify VB N
the DT N
relative JJ N
importance NN N
of IN N
beneficial JJ N
effects NNS N
with IN N
respect NN N
to TO N
cardiovascular JJ N
risk NN N
. . N

-DOCSTART- -16585808- O O

Survey NNP i
response NN N
inducements NNS N
for IN N
registered JJ p
nurses NNS p
. . p

The DT N
past JJ N
20 CD N
years NNS N
have VBP N
seen VBN N
an DT N
overall JJ N
decline NN N
in IN N
survey NN N
response NN N
rates NNS N
and CC N
an DT N
even RB N
more RBR N
pronounced JJ N
decline NN N
in IN N
samples NNS N
of IN N
health NN p
care NN p
professionals NNS p
. . p

The DT N
authors NNS N
tested VBD N
the DT N
use NN N
of IN N
a DT N
thank NN i
you PRP i
or CC i
reminder VB i
postcard NN i
as IN N
a DT N
method NN N
by IN N
which WDT N
to TO N
stem VB N
the DT N
tide NN N
of IN N
declining VBG N
response NN N
rates NNS N
. . N

The DT N
authors NNS N
conducted VBD N
a DT N
mail NN i
and CC i
telephone NN i
survey NN i
of IN p
49,605 CD p
registered JJ p
nurses NNS p
for IN p
the DT p
2000 CD p
National NNP p
Sample NNP p
Survey NNP p
of IN p
Registered NNP p
Nurses NNP p
and CC N
sent VBD N
an DT N
extra JJ N
mailing NN N
to TO N
a DT N
random JJ N
subsample NN N
( ( N
n JJ N
= NNP N
4,968 CD N
) ) N
. . N

They PRP N
then RB N
compared VBN N
response NN o
rates NNS N
for IN N
both DT N
groups NNS N
. . N

Contrary NNP N
to TO N
prior VB N
research NN N
, , N
this DT N
study NN N
found VBD N
that IN N
reminder NN N
postcards NNS N
did VBD N
not RB N
improve VB N
response NN o
rates NNS o
or CC o
rates NNS o
of IN o
return NN o
. . o

There EX N
may MD N
be VB N
several JJ N
reasons NNS N
for IN N
this DT N
finding NN N
, , N
including VBG N
the DT N
general JJ N
familiarity NN N
with IN N
, , N
and CC N
high JJ N
saliency NN N
of IN N
, , N
this DT N
research NN N
project NN N
for IN N
the DT N
nursing NN N
community NN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
even RB N
widely RB N
accepted VBN N
best JJS N
practices NNS N
for IN N
survey NN N
methods NNS N
deserve VBP N
scrutiny NN N
when WRB N
applied VBN N
to TO N
special JJ N
subpopulations NNS N
. . N

-DOCSTART- -25428632- O O

Evaluating VBG N
the DT N
efficacy NN o
of IN N
thoracoscopy NN i
and CC i
talc JJ i
poudrage NN i
versus NN i
pleurodesis NN i
using VBG i
talc JJ i
slurry NN i
( ( N
TAPPS NNP N
trial NN N
) ) N
: : N
protocol NN N
of IN N
an DT N
open-label NN N
randomised VBD N
controlled VBN N
trial NN N
. . N

INTRODUCTION VB N
The DT N
management NN N
of IN N
recurrent NN N
malignant JJ N
pleural JJ N
effusions NNS N
( ( N
MPE NNP N
) ) N
can MD N
be VB N
challenging VBG N
. . N

Various JJ N
options NNS N
are VBP N
available JJ N
, , N
with IN N
the DT N
most RBS N
efficacious JJ N
and CC N
widely RB N
used VBD N
being VBG N
talc JJ i
pleurodesis NN i
. . i

Talc NNP i
can MD N
either RB N
be VB N
applied VBN N
via IN N
a DT N
chest NN N
drain NN N
in IN N
the DT N
form NN N
of IN N
slurry NN N
, , N
or CC N
at IN N
medical JJ i
thoracoscopy NN i
using VBG i
poudrage NN i
. . i

Current JJ N
evidence NN N
regarding VBG N
which WDT N
method NN N
is VBZ N
most RBS N
effective JJ N
is VBZ N
conflicting VBG N
and CC N
often RB N
methodologically RB N
flawed VBN N
. . N

The DT N
TAPPS NNP N
trial NN N
is VBZ N
a DT N
suitably RB N
powered VBN N
, , N
multicentre FW N
, , N
open-label JJ N
, , N
randomised VBD N
controlled VBN N
trial NN N
designed VBN N
to TO N
compare VB N
the DT N
pleurodesis NN N
success NN N
rate NN N
of IN N
medical JJ i
thoracoscopy NN i
and CC i
talc JJ i
poudrage NN i
with IN i
chest NN i
drain NN i
insertion NN i
and CC i
talc NN i
slurry NN i
. . i

METHODS NNP N
AND CC N
ANALYSIS NNP N
330 CD p
patients NNS p
with IN p
a DT p
confirmed JJ p
MPE NNP p
requiring VBG p
intervention NN p
will MD p
be VB p
recruited VBN p
from IN p
UK NNP p
hospitals NNS p
. . p

Patients NNS N
will MD N
be VB N
randomised VBN N
( ( N
1:1 CD N
) ) N
to TO N
undergo VB N
either RB N
small JJ i
bore NN i
( ( i
< JJ i
14 CD i
Fr NNP i
) ) i
Seldinger NNP i
chest JJS i
drain NN i
insertion NN i
followed VBN i
by IN i
instillation NN i
of IN i
sterile JJ i
talc NN i
( ( i
4 CD N
g NN N
) ) N
, , N
or CC N
to TO i
undergo VB i
medical JJ i
thoracoscopy NN i
and CC i
simultaneous JJ i
poudrage NN i
( ( i
4 CD i
g NN N
) ) N
. . N

The DT N
allocated JJ N
procedure NN N
will MD N
be VB N
performed VBN N
as IN N
an DT N
inpatient NN N
within IN N
3 CD N
days NNS N
of IN N
randomisation NN N
taking VBG N
place NN N
. . N

Following VBG N
discharge NN N
, , N
patients NNS N
will MD N
be VB N
followed VBN N
up RP N
at IN N
regular JJ N
intervals NNS N
for IN N
6 CD N
months NNS N
. . N

The DT N
primary JJ N
outcome JJ N
measure NN N
is VBZ N
pleurodesis JJ o
failure NN o
rates NNS o
at IN o
3 CD N
months NNS N
. . N

Pleurodesis NNP o
failure NN o
is VBZ o
defined VBN N
as IN N
the DT N
need NN N
for IN N
further JJ N
pleural JJ N
intervention NN N
for IN N
fluid JJ N
management NN N
on IN N
the DT N
side NN N
of IN N
the DT N
trial NN N
intervention NN N
. . N

ETHICS NNP N
AND CC N
DISSEMINATION NNP N
The DT N
trial NN N
has VBZ N
received VBN N
ethical JJ N
approval NN N
from IN N
the DT N
National NNP N
Research NNP N
Ethics NNP N
Service NNP N
Committee NNP N
North NNP N
West-Preston NNP N
( ( N
12/NW/0467 CD N
) ) N
. . N

There EX N
is VBZ N
a DT N
trial NN N
steering VBG N
committee NN N
which WDT N
includes VBZ N
independent JJ N
members NNS N
and CC N
a DT N
patient NN N
and CC N
public JJ N
representative NN N
. . N

The DT N
trial NN N
results NNS N
will MD N
be VB N
published VBN N
in IN N
a DT N
peer-reviewed JJ N
journal NN N
and CC N
presented VBD N
at IN N
international JJ N
conferences NNS N
, , N
as RB N
well RB N
as IN N
being VBG N
disseminated VBN N
via IN N
local JJ N
and CC N
national JJ N
charities NNS N
and CC N
patient JJ N
groups NNS N
. . N

All DT N
participants NNS N
who WP N
wish VBP N
to TO N
know VB N
the DT N
study NN N
results NNS N
will MD N
also RB N
be VB N
contacted VBN N
directly RB N
on IN N
their PRP$ N
publication NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
NUMBER NNP N
ISRCTN47845793 NNP N
. . N

-DOCSTART- -16104966- O O

Open JJ i
flap NN i
debridement NN i
with IN i
or CC i
without IN i
intentional JJ i
cementum NN i
removal NN i
: : i
a DT N
4-month JJ N
follow-up NN N
. . N

OBJECTIVES IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
influence NN N
of IN N
cementum NN i
removal NN i
on IN i
periodontal JJ i
repair NN i
. . i

MATERIAL NNP N
AND NNP N
METHODS NNP N
Forty NNP p
subjects NNS p
with IN p
chronic JJ p
periodontitis NN p
and CC p
presenting NN p
, , p
at IN p
least JJS p
, , p
two CD p
proximal JJ p
sites NNS p
in IN p
anterior JJ p
teeth NNS p
( ( p
upper JJ p
or CC p
lower JJR p
) ) p
with IN p
probing VBG p
depth JJ p
> NN p
or CC p
=5 JJ p
mm NNS p
were VBD p
selected VBN p
. . p

After IN N
oral JJ N
hygiene NN N
instructions NNS N
and CC N
ultrasonic JJ N
supragingival NN N
instrumentation NN N
, , N
the DT N
subjects NNS N
were VBD N
randomly RB N
assigned VBN N
for IN N
one CD N
of IN N
the DT N
following JJ N
groups NNS N
: : N
CIC NNP i
, , i
scaled VBD i
with IN i
Gracey NNP i
curettes NNS i
; : i
CIUS NNP i
, , i
scaled VBD i
with IN i
ultrasonic JJ i
device NN i
; : i
CDC NNP i
, , i
calculus JJ i
deattachment NN i
with IN i
Gracey NNP i
curettes NNS i
and CC i
brushing VBG i
with IN i
saline JJ i
solution NN i
; : i
and CC i
CDUS NNP i
, , i
calculus JJ i
deattachment NN i
with IN i
ultrasonic JJ i
device NN i
and CC i
brushing VBG i
with IN i
saline JJ i
solution NN i
. . i

Full-thickness JJ N
flaps NNS N
were VBD N
reflected VBN N
and CC N
the DT N
instrumentation NN N
was VBD N
performed VBN N
with IN N
a DT N
clinical JJ N
microscope NN N
. . N

Probing VBG o
depth NN o
( ( o
PD NNP o
) ) o
, , o
relative JJ o
gingival NN o
margin NN o
level NN o
( ( o
RGML NNP o
) ) o
and CC o
relative JJ o
attachment NN o
level NN o
( ( o
RAL NNP o
) ) o
were VBD N
registered VBN N
at IN N
five CD N
experimental JJ N
periods NNS N
: : N
baseline NN N
and CC N
30 CD N
, , N
60 CD N
, , N
90 CD N
and CC N
120 CD N
days NNS N
postoperative JJ N
. . N

RESULTS VB N
All PDT N
the DT N
approaches NNS N
were VBD N
able JJ N
to TO N
markedly RB N
reduce VB N
the DT N
PD NNP N
values NNS N
from IN N
the DT N
baseline NN N
to TO N
the DT N
other JJ N
evaluation NN N
periods NNS N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

The DT N
increase NN N
in IN N
RGML NNP o
values NNS o
was VBD N
statistically RB N
significant JJ N
only RB N
for IN N
the DT N
CDUS NNP i
group NN N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
baseline NN N
and CC N
postoperative JJ N
values NNS N
in IN N
all DT N
groups NNS N
for IN N
the DT N
RAL NNP o
changes NNS o
. . o

The DT N
changes NNS N
in IN N
RAL NNP o
were VBD N
statistically RB N
significant JJ N
only RB N
among IN N
the DT N
groups NNS N
CDC NNP i
and CC N
CDUS NNP i
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
conventional JJ i
scaling NN i
and CC i
root NN i
planing NN i
and CC i
the DT i
calculus JJ i
deattachment NN i
were VBD N
effective JJ N
in IN N
reducing VBG N
the DT N
probing VBG N
depth NN N
values NNS N
, , N
regardless RB N
of IN N
the DT N
instrumentation NN N
method NN N
. . N

-DOCSTART- -20004758- O O

Optimum JJ N
frequency NN N
of IN N
exercise NN i
for IN N
bone NN o
health NN o
: : o
randomised VBN N
controlled VBD N
trial NN N
of IN N
a DT N
high-impact JJ p
unilateral JJ p
intervention NN p
. . p

INTRODUCTION NNP N
Exercise NNP i
can MD N
increase VB N
bone NN o
strength NN o
, , N
but CC N
to TO N
be VB N
effective JJ N
in IN N
reducing VBG N
fracture NN o
risk NN o
, , N
exercise NN i
must MD N
be VB N
feasible JJ N
enough JJ N
to TO N
be VB N
adopted VBN N
into IN N
daily JJ N
life NN N
and CC N
influence NN N
potentially RB N
vulnerable JJ N
skeletal JJ N
sites NNS N
such JJ N
as IN N
the DT N
superolateral JJ N
cortex NN N
of IN N
the DT N
femoral JJ N
neck NN N
, , N
where WRB N
thinning NN N
is VBZ N
associated VBN N
with IN N
increased JJ N
fracture NN o
risk NN o
. . o

Brief NNP i
, , i
high-impact JJ i
exercise NN i
increases VBZ N
femoral JJ o
neck NN o
bone NN o
density NN o
but CC N
the DT N
optimal JJ N
frequency NN N
of IN N
such JJ N
exercise NN N
and CC N
the DT N
location NN N
of IN N
bone NN N
accrual JJ N
is VBZ N
unknown JJ N
. . N

This DT N
study NN N
thus RB N
examined VBN N
( ( N
1 CD N
) ) N
the DT N
effectiveness NN N
of IN N
different JJ N
weekly JJ N
frequencies NNS N
of IN N
exercise NN N
on IN N
femoral JJ o
neck NN o
BMD NNP o
and CC N
( ( N
2 CD N
) ) N
whether IN o
BMD NNP o
change NN o
differed VBD o
between IN o
hip NN o
sites NNS o
using VBG N
a DT N
high-impact JJ N
, , N
unilateral JJ N
intervention NN N
. . N

METHODS NNP N
Healthy NNP p
premenopausal NN p
women NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
exercise VB i
0 CD N
, , N
2 CD N
, , N
4 CD N
, , N
or CC N
7 CD N
days/week NN N
for IN N
6 CD N
months NNS N
. . N

The DT N
exercise NN i
intervention NN i
incorporated VBD N
50 CD N
multidirectional JJ N
hops NNS N
on IN N
one CD N
randomly NN N
selected VBN N
leg NN N
. . N

BMD NNP o
was VBD N
measured VBN N
by IN N
DXA NNP N
at IN N
baseline NN N
and CC N
after IN N
6 CD N
months NNS N
of IN N
exercise NN N
. . N

Changes NNS N
in IN N
the DT N
exercise NN N
leg NN N
were VBD N
compared VBN N
between IN N
groups NNS N
using VBG N
ANCOVA NNP N
, , N
with IN N
change NN N
in IN N
the DT N
control NN N
leg NN N
and CC N
baseline NN N
BMD NNP N
as IN N
covariates NNS N
. . N

RM-MANOVA NNP N
was VBD N
conducted VBN N
to TO N
determine VB N
whether IN N
bone NN o
changes NNS o
from IN N
exercise NN i
differed VBN N
between IN N
hip NN N
sites NNS N
. . N

RESULTS NNP N
61 CD p
women NNS p
( ( p
age NN p
33.6+/-11.1 CD p
years NNS p
) ) p
completed VBD p
the DT p
intervention NN p
. . p

Compliance NNP N
amongst JJ N
exercisers NNS N
was VBD N
86.7+/-10.6 CD N
% NN N
. . N

Peak NNP o
ground NN o
reaction NN o
forces NNS o
during IN N
exercise NN N
increased VBN N
from IN N
2.5 CD N
to TO N
2.8 CD N
times NNS N
body JJ N
weight NN N
. . N

The DT N
change NN o
in IN o
femoral JJ o
neck NN o
BMD NNP o
in IN N
the DT N
exercise NN i
limb NN N
( ( N
adjusted VBN N
for IN N
change NN N
in IN N
the DT N
control NN N
limb NN N
and CC N
baseline VB N
BMD NNP N
) ) N
differed VBD N
between IN N
groups NNS N
( ( N
p=0.015 NN N
) ) N
, , N
being VBG N
-0.3 CD N
% NN N
( ( N
-1.2 CD N
to TO N
0.6 CD N
) ) N
, , N
0.0 CD N
% NN N
( ( N
-1.0 CD N
to TO N
1.0 CD N
) ) N
, , N
0.9 CD N
% NN N
( ( N
-0.1 CD N
to TO N
2.0 CD N
) ) N
and CC N
1.8 CD N
% NN N
( ( N
0.8 CD N
to TO N
2.8 CD N
) ) N
in IN N
those DT N
exercising VBG N
0 CD N
, , N
2 CD N
, , N
4 CD N
and CC N
7 CD N
days NNS N
per IN N
week NN N
, , N
respectively RB N
. . N

When WRB N
BMD NNP o
changes NNS o
at IN o
upper JJ o
neck NN o
, , o
lower JJR o
neck NN o
and CC o
trochanter NN o
were VBD N
compared VBN N
using VBG N
RM-MANOVA NNP N
, , N
a DT N
significant JJ N
exercise NN N
effect NN N
was VBD N
observed VBN N
( ( N
p=0.048 NN N
) ) N
, , N
but CC N
this DT N
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
sites NNS N
( ( N
p=0.439 NN N
) ) N
despite IN N
greatest JJS N
mean NN N
increases NNS N
at IN N
the DT N
upper JJ N
femoral JJ N
neck NN N
. . N

CONCLUSIONS NNP N
Brief NNP N
, , N
daily RB N
hopping VBG N
exercises NNS i
increased VBD N
femoral JJ o
neck NN o
BMD NNP o
in IN N
premenopausal JJ p
women NNS p
but CC N
less JJR N
frequent JJ N
exercise NN N
was VBD N
not RB N
effective JJ N
. . N

Brief JJ i
high-impact JJ i
exercise NN i
may MD N
have VB N
a DT N
role NN N
in IN N
reducing VBG N
hip NN o
fragility NN o
, , N
but CC N
may MD N
need VB N
to TO N
be VB N
performed VBN N
frequently RB N
for IN N
optimal JJ N
response NN N
. . N

-DOCSTART- -161652- O O

Aortic JJ i
valve NN i
replacement NN i
. . i

A DT N
randomized JJ N
study NN N
comparing VBG N
the DT N
Bj?rk-Shiley NNP i
and CC i
Lillehei-Kaster NNP i
disc NN i
valves NNS i
. . i

Late JJ N
haemodynamics NNS N
related VBN N
to TO N
clinical JJ N
results NNS N
. . N

In IN N
this DT N
study NN N
, , N
78 CD p
randomized VBD p
patients NNS p
with IN p
either DT i
Bj?rk-Shiley NNP i
( ( i
B-S NNP i
) ) i
or CC i
Lillehei-Kaster JJ i
( ( i
L-K NNP i
) ) i
aortic JJ i
disc NN i
valve NN i
prostheses NNS i
were VBD i
re-admitted JJ p
for IN p
clinical JJ p
and CC p
haemodynamic JJ p
evaluation NN p
. . p

The DT p
patients NNS p
were VBD p
selected VBN p
that IN p
those DT p
with IN p
narrow JJ p
aortic JJ p
roots NNS p
were VBD p
over-represented JJ i
. . i

Cine-aortography NN i
was VBD i
carried VBN N
out RP N
in IN N
75 CD p
patients NNS p
and CC i
left VBD i
ventricular JJ i
catheterisation NN i
via IN i
the DT i
transseptal JJ i
approach NN i
was VBD i
performed VBN p
in IN p
42 CD p
. . p

The DT o
clinical JJ o
improvement NN o
was VBD o
striking VBG N
, , N
although IN N
the DT o
number NN o
of IN o
patients NNS o
still RB o
incapacitated VBN o
was VBD o
relatively RB N
large JJ N
in IN N
patients NNS N
with IN N
the DT N
small JJ i
L-K JJ i
valves NNS i
( ( i
Nos NNP N
. . N

14 CD N
& CC N
16 CD N
) ) o
. . o

Peak-to-peak JJ o
and CC o
mean JJ o
systolic JJ o
pressure NN o
differences NNS o
across IN o
the DT o
valves NNS o
were VBD o
significantly RB N
lower JJR N
in IN N
the DT i
B-S NNP i
than IN i
in IN N
the DT i
L-K NNP i
valves NNS i
, , N
particularly RB N
when WRB N
the DT N
small JJ N
valve NN N
sizes NNS N
were VBD N
compared VBN o
. . o

Left NNP o
ventricular JJ o
end-diastolic JJ o
pressure NN o
( ( o
LVEDP NNP o
) ) o
, , o
which WDT N
was VBD N
elevated VBN N
in IN N
most JJS N
patients NNS N
before IN N
operation NN N
, , N
decreased VBN N
significantly RB N
to TO N
normal JJ N
levels NNS N
in IN N
the DT N
B-S NNP N
group NN N
. . N

In IN N
the DT i
L-K NNP i
group NN o
, , o
LVEDP NNP o
did VBD o
not RB N
decrease VB N
significantly RB N
and CC N
was VBD N
on IN N
the DT N
average NN N
still RB N
above IN N
the DT N
normal JJ N
level NN N
after IN N
operation NN N
, , N
probably RB N
due JJ N
to TO N
the DT N
relatively RB N
large JJ N
pressure NN N
gradients NNS N
. . N

The DT N
study NN N
indicates VBZ N
that IN N
the DT i
L-K NNP i
valves NNS i
Nos NNP N
. . N

14 CD N
& CC N
16 CD N
in IN N
particular JJ N
represents VBZ N
a DT N
resistance NN N
to TO N
flow VB N
that DT N
is VBZ N
too RB N
large JJ N
to TO N
be VB N
acceptable JJ N
in IN N
clinical JJ N
practice NN N
. . N

-DOCSTART- -16957977- O O

Albumin-glutaraldehyde JJ i
bioadhesive NN i
( ( i
Bioglue NNP i
) ) i
for IN N
prevention NN N
of IN N
postoperative JJ o
complications NNS o
after IN N
stapled VBN N
hemorrhoidopexy NN N
: : N
A DT N
randomized NN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Hemorrhoidopexy NNP N
using VBG N
the DT N
circumferential JJ N
stapler NN N
is VBZ N
an DT N
established JJ N
method NN N
for IN N
surgical JJ N
treatment NN N
of IN N
patients NNS p
with IN p
prolapsing JJ p
hemorrhoids NNS p
. . p

Despite IN N
its PRP$ N
advantages NNS N
, , N
complications NNS N
such JJ N
as IN N
anal JJ N
canal JJ N
stenosis NN N
, , N
hemorrhage NN N
and CC N
anastomosis NN N
leak NN N
with IN N
eventual JJ N
intrapelvic JJ N
sepsis NN N
can MD N
cause VB N
serious JJ N
postoperative JJ N
problems NNS N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
utility NN N
of IN N
a DT N
surgical JJ N
adhesive NN N
, , N
the DT N
biological JJ i
albumin-glutaraldehyde JJ i
glue NN i
Bioglue NNP i
, , N
in IN N
reduction NN N
of IN N
these DT N
postoperative JJ N
complications NNS N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Between NNP p
January NNP p
2002 CD p
and CC p
November NNP p
2004 CD p
, , p
200 CD p
patients NNS p
undergoing VBG p
stapled JJ i
hemorrhoidopexy NN i
were VBD p
enrolled VBN p
in IN N
a DT N
prospective JJ N
, , N
randomized JJ N
clinical JJ N
trial NN N
. . N

One CD p
hundred VBD p
patients NNS p
were VBD p
randomly RB p
assigned VBN p
to TO p
the DT p
control NN i
group NN i
; : i
the DT p
study NN p
group NN p
consisted VBD p
of IN p
100 CD p
patients NNS p
who WP N
received VBD N
Bioglue NNP i
in IN i
the DT i
mucosa NN i
anastomosis NN i
area NN i
. . i

All DT N
patients NNS N
received VBD N
standardized JJ i
postoperative JJ i
analgesic NN i
, , i
laxative JJ i
and CC i
antibiotic JJ i
treatment NN i
. . i

We PRP N
then RB N
evaluated VBD N
the DT N
two CD N
groups NNS N
for IN N
postoperative JJ o
complications NNS o
( ( N
after IN N
surgery NN N
and CC N
6 CD N
months NNS N
postoperatively RB N
) ) N
. . N

RESULTS CC N
From IN N
the DT N
control NN N
group NN N
( ( N
no DT N
Bioglue NNP N
application NN N
) ) N
, , N
two CD N
patients NNS N
presented VBN N
with IN N
anal JJ o
stenosis NN o
, , N
two CD N
with IN N
hemorrhage NN o
, , N
three CD N
had VBD N
anastomosis VBN o
leak NN o
and CC N
one CD N
had VBD N
thrombosis NN o
, , N
whereas IN N
none NN N
of IN N
the DT N
patients NNS N
from IN N
the DT N
Bioglue NNP N
group NN N
had VBD N
any DT N
of IN N
these DT N
complications NNS o
. . o

Both DT N
groups NNS N
had VBD N
patients NNS N
with IN N
severe JJ o
postoperative JJ o
pain NN o
( ( N
3 CD N
each DT N
) ) N
and CC N
fecal JJ o
incontinence NN o
( ( N
1 CD N
patient NN N
each DT N
) ) N
. . N

The DT N
overall JJ o
difference NN o
in IN N
the DT N
number NN o
of IN o
complications NNS o
in IN N
the DT N
two CD N
groups NNS N
was VBD N
statistically RB N
significant JJ N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NN N
In IN N
this DT N
first JJ N
study NN N
using VBG N
Bioglue NNP N
in IN N
patients NNS N
undergoing VBG N
circumferential JJ N
stapled JJ N
hemorrhoidopexy NN N
we PRP N
have VBP N
shown VBN N
that IN N
application NN N
of IN N
the DT N
glue NN N
is VBZ N
effective JJ o
in IN N
reducing VBG o
postoperative JJ o
complications NNS o
. . o

-DOCSTART- -20204689- O O

Promoting VBG i
social JJ i
skill NN i
development NN i
in IN N
children NNS p
with IN p
pervasive JJ p
developmental JJ p
disorders NNS p
: : p
a DT N
feasibility NN N
and CC N
efficacy NN N
study NN N
. . N

A DT N
randomized JJ N
controlled JJ N
design NN N
was VBD N
employed VBN N
to TO N
evaluate VB N
a DT N
social JJ i
skills NNS i
intervention NN i
for IN N
children NNS p
with IN p
pervasive JJ p
developmental NN p
disorders NNS p
. . p

Aims NNP N
included VBD N
evaluating VBG N
the DT N
acceptability NN N
of IN N
the DT N
program NN N
and CC N
gathering VBG N
preliminary JJ N
evidence NN N
on IN N
efficacy NN N
. . N

Forty-four JJ p
children NNS p
, , p
ages VBZ p
8-11 CD p
years NNS p
, , p
were VBD p
randomly RB p
assigned VBN p
to TO p
treatment NN i
or CC p
wait JJ i
list NN i
. . i

Treatment NNP N
consisted VBD N
of IN N
a DT N
16-week JJ N
group NN i
intervention NN i
designed VBN i
to TO i
teach VB i
appropriate JJ i
social JJ i
behavior NN i
. . i

Between NNP N
group NN N
comparisons NNS N
showed VBD N
that IN N
children NNS N
in IN N
treatment NN N
were VBD N
rated VBN N
as IN N
improved VBN N
on IN N
the DT N
primary JJ o
outcome NN o
measure NN o
, , o
( ( o
unblinded JJ o
parent NN o
report NN o
) ) o
, , N
but CC N
not RB N
on IN N
the DT N
secondary JJ N
outcome NN N
measure NN N
, , N
a DT N
parent NN o
questionnaire NN o
. . o

Parents NNS p
reported VBD N
a DT N
high JJ N
level NN o
of IN o
satisfaction NN o
with IN N
the DT N
intervention NN N
. . N

The DT N
study NN N
supports VBZ N
the DT N
feasibility NN N
of IN N
this DT N
intervention NN N
to TO N
families NNS p
and CC N
highlights NNS N
challenges NNS N
for IN N
future JJ N
research NN N
in IN N
social JJ i
skills NNS i
intervention NN i
. . i

-DOCSTART- -16378639- O O

Wavefront-guided JJ i
versus NN i
standard NN i
LASIK NNP i
enhancement NN i
for IN N
residual JJ N
refractive JJ N
errors NNS N
. . N

OBJECTIVE NNP N
To TO N
assess VB N
efficacy NN o
, , o
safety NN o
, , o
predictability NN o
, , o
stability NN o
, , o
and CC o
changes NNS o
in IN o
higher-order NN o
aberrations NNS o
( ( o
HOAs NNP o
) ) o
and CC N
contrast JJ o
sensitivity NN o
( ( o
CS NNP o
) ) o
after IN N
wavefront-guided JJ i
and CC i
standard JJ i
LASIK NNP i
enhancement NN i
for IN N
the DT N
correction NN N
of IN N
residual JJ N
refractive JJ N
errors NNS N
. . N

DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
, , N
comparative JJ N
clinical JJ N
study NN N
. . N

PARTICIPANTS NNP N
Twenty NNP p
eyes NNS p
of IN p
20 CD p
consecutive JJ p
patients NNS p
( ( p
spherical JJ p
equivalent NN p
[ NNP p
SE NNP p
] NNP p
, , p
-2.01+/-1.36 NNP p
diopters NNS p
[ NNP p
D NNP p
] NNP p
) ) p
treated VBD p
with IN p
wavefront-guided JJ i
Zyoptix NNP i
Ablation NNP i
Refinement NNP i
software NN i
( ( i
ZAR NNP i
) ) i
LASIK NNP i
and CC p
20 CD p
eyes NNS p
of IN p
20 CD p
consecutive JJ p
patients NNS p
( ( p
SE NNP p
, , p
-1.81+/-1.21 NNP p
D NNP p
) ) p
treated VBD p
with IN p
standard JJ i
Planoscan NNP i
LASIK NNP i
, , p
both DT p
for IN p
residual JJ p
refractive JJ p
error NN p
enhancement NN p
. . p

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Efficacy NNP o
, , o
safety NN o
, , o
predictability NN o
, , o
stability NN o
, , o
HOAs NNP o
, , o
and CC o
CS NNP o
were VBD N
evaluated VBN N
before IN N
and CC N
after IN N
enhancement NN N
at IN N
6 CD N
months NNS N
' POS N
follow-up NN N
. . N

METHODS NNP N
Uncorrected VBD o
visual JJ o
acuity NN o
( ( o
UCVA NNP o
) ) o
, , o
best-corrected JJ o
visual JJ o
acuity NN o
( ( o
BCVA NNP o
) ) o
, , o
manifest JJS o
refraction NN o
, , o
CS NNP o
by IN o
means NNS o
of IN o
the DT o
Functional NNP o
Acuity NNP o
Contrast NNP o
Test NNP o
, , o
and CC o
HOAs NNP o
by IN o
means NNS o
of IN o
Zywave NNP o
aberrometry NN o
were VBD N
evaluated VBN N
preoperatively RB N
and CC N
6 CD N
months NNS N
after IN N
retreatment NN N
. . N

RESULTS NNP N
At IN N
6 CD N
months NNS N
postoperatively RB N
, , N
UCVA NNP o
was VBD N
20/25 CD N
or CC N
better JJR N
in IN N
100 CD N
% NN N
of IN N
the DT N
eyes NNS N
. . N

Efficacy NN o
indexes NNS o
were VBD N
1.09 CD N
for IN N
ZAR NNP i
patients NNS N
and CC N
0.95 CD N
for IN N
Planoscan JJ i
patients NNS N
. . N

No DT o
eyes NNS o
lost VBN o
> CD N
or CC N
=1 JJ N
line NN N
of IN N
BCVA NNP o
; : o
in IN N
the DT N
ZAR NNP i
group NN N
, , N
2 CD N
eyes NNS N
gained VBD o
1 CD N
line NN N
and CC N
6 CD N
eyes NNS N
gained VBN o
> CD N
or CC N
=2 JJ N
lines NNS N
; : N
in IN N
the DT N
Planoscan NNP i
group NN N
, , N
3 CD N
eyes NNS N
gained VBD N
1 CD N
line NN N
. . N

The DT N
ZAR NNP i
group NN N
showed VBD N
a DT N
percentage NN N
of IN N
eyes NNS N
( ( N
94.4 CD N
% NN N
) ) N
within IN N
the DT N
0.5-D JJ N
range NN N
in IN N
SE NNP N
higher JJR N
than IN N
that DT N
shown VBN N
by IN N
the DT N
Planoscan NNP i
group NN N
( ( N
88.8 CD N
% NN N
) ) N
. . N

After IN N
6 CD N
months NNS N
, , N
the DT N
HOA NNP o
root NN o
mean NN o
square NN o
( ( o
RMS NNP o
) ) o
increased VBD N
on IN N
average NN N
by IN N
a DT N
factor NN N
of IN N
1.44 CD N
for IN N
the DT N
Planoscan NNP i
group NN N
( ( N
P NNP N
= NNP N
0.003 CD N
) ) N
. . N

No UH N
change NN N
or CC N
reduction NN o
in IN o
HOA NNP o
RMS NNP o
was VBD N
found VBN N
in IN N
the DT N
ZAR NNP i
group NN N
( ( N
factor NN N
of IN N
0.96 CD N
; : N
P NNP N
> NNP N
0.01 CD N
) ) N
. . N

Contrast NNP o
sensitivity NN o
was VBD N
reduced VBN N
in IN N
the DT N
Planoscan NNP i
group NN N
only RB N
at IN N
the DT N
highest JJS N
spatial JJ N
frequency NN N
( ( N
18 CD N
cycles NNS N
per IN N
degree NN N
; : N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

There EX N
was VBD N
a DT N
significant JJ N
reduction NN o
of IN o
CS NNP o
as IN o
a DT o
function NN o
of IN o
HOA NNP o
increase NN o
for IN N
the DT N
Planoscan NNP i
group NN N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

No UH N
changes NNS N
were VBD N
observed VBN N
for IN N
the DT N
ZAR NNP i
group NN N
at IN N
any DT N
spatial JJ o
frequency NN o
( ( N
1.5-18 JJ N
cycles NNS N
per IN N
degree NN N
; : N
P NNP N
> NNP N
0.01 CD N
) ) N
. . N

CONCLUSIONS NNP N
Wavefront-guided JJ i
LASIK NNP i
using VBG N
the DT N
ZAR NNP N
algorithm NN N
is VBZ N
an DT N
effective JJ N
and CC N
safe JJ N
procedure NN N
for IN N
treatment NN N
of IN N
residual JJ N
refractive JJ N
errors NNS N
. . N

Wavefront-guided JJ i
LASIK NNP i
does VBZ N
not RB N
increase VB N
HOAs NNP N
and CC N
does VBZ N
not RB N
modify VB N
CS NNP N
compared VBN N
with IN N
preoperative JJ N
values NNS N
. . N

Wavefront-guided JJ i
LASIK NNP i
seems VBZ N
to TO N
be VB N
better JJR N
than IN N
standard JJ N
LASIK NNP i
for IN N
retreatments NNS N
. . N

-DOCSTART- -23326865- O O

Effect NN N
of IN N
aliskiren NN i
on IN N
proteinuria NNS o
in IN N
non-diabetic JJ p
chronic JJ p
kidney NN p
disease NN p
: : p
a DT N
double-blind NN N
, , N
crossover NN N
, , N
randomised VBN N
, , N
controlled VBN N
trial NN N
. . N

AIM NNP N
To TO N
evaluate VB N
the DT N
proteinuria-lowering JJ o
effect NN o
of IN o
a DT o
renin NN o
inhibitor NN o
( ( o
aliskiren NN o
) ) o
, , N
compared VBN N
to TO N
placebo VB i
and CC N
to TO N
an DT N
angiotensin-converting JJ i
enzyme NN i
inhibitor NN i
( ( i
perindopril NN i
) ) i
, , N
in IN N
patients NNS p
with IN p
non-diabetic JJ p
chronic JJ p
kidney NN p
disease NN p
. . p

METHODS NNP N
A DT N
randomised JJ N
, , N
double-blind JJ N
, , N
crossover JJ N
trial NN N
was VBD N
performed VBN N
in IN N
14 CD p
patients NNS p
with IN p
nondiabetic JJ p
chronic JJ p
kidney NN p
disease NN p
with IN p
24-h JJ p
mean JJ p
proteinuria NN p
of IN p
2.01 CD p
g NN p
( ( p
95 CD p
% NN p
CI NNP p
, , p
1.36?2.66 CD p
) ) p
and CC p
estimated VBN p
creatinine JJ p
clearance NN p
of IN p
93?6.8 CD p
ml/min NN p
. . p

The DT p
study NN N
consisted VBD N
of IN N
five CD N
treatment NN N
periods NNS N
. . N

The DT N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB i
aliskiren NNS i
( ( i
150 CD i
mg NN N
) ) N
, , i
aliskiren RB i
( ( i
300 CD i
mg NN N
) ) N
, , i
perindopril NN i
( ( i
5 CD i
mg NN N
) ) N
, , i
perindopril NN i
( ( i
10 CD i
mg NN N
) ) N
or CC N
placebo NN i
. . i

RESULTS NNP i
Aliskiren NNP i
and CC i
perindopril NN i
reduced VBN o
proteinuria NN o
. . o

These DT o
effects NNS N
were VBD N
dose-dependent JJ N
. . N

Furthermore CD o
, , o
24-h JJ o
proteinuria NN o
was VBD o
reduced VBN N
by IN N
23 CD N
% NN N
( ( N
mean JJ N
95 CD N
% NN N
CI NNP N
; : N
2?44 CD N
) ) N
by IN N
treatment NN N
with IN N
aliskiren NNS i
( ( i
150 CD i
mg NN N
) ) N
, , N
by IN N
36 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
17?55 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) i
with IN i
aliskiren NN i
( ( i
300 CD i
mg NN i
) ) N
, , N
by IN N
7.1 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
11?26 CD N
) ) N
with IN i
perindopril NN i
( ( i
5 CD i
mg NN i
) ) i
and CC i
by IN N
25 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
11?39 CD N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
with IN i
perindopril NN i
( ( i
10 CD i
mg NN i
) ) i
, , i
compared VBN i
to TO N
placebo VB i
. . N

No DT N
significant JJ N
difference NN N
was VBD N
found VBN N
between IN N
the DT N
effects NNS N
of IN N
aliskiren NNS i
and CC i
perindopril NN i
. . i

CONCLUSIONS NNP i
Aliskiren NNP i
significantly RB o
reduced VBD o
proteinuria NNS o
. . o

The DT o
antiproteinuric JJ o
effect NN o
is VBZ o
probably RB N
similar JJ N
to TO N
that DT N
of IN N
perindopril NN i
, , i
for IN i
equivalent JJ i
hypotensive JJ N
dosages NNS N
. . N

The DT i
renin JJ i
inhibitor NN i
provides VBZ N
a DT N
promising JJ N
alternative JJ N
approach NN N
for IN N
the DT N
treatment NN N
of IN p
patients NNS p
with IN o
chronic JJ o
proteinuric JJ o
non-diabetic JJ o
kidney NN o
disease NN o
. . o

-DOCSTART- -23512255- O O

Lengthening VBG N
the DT N
moment NN N
arm NN N
of IN N
the DT N
patella NN N
confers NNS N
enhanced VBD N
extensor NN o
mechanism NN o
power NN o
following VBG p
total JJ p
knee JJ p
arthroplasty NN p
. . p

We PRP N
investigated VBD N
whether IN N
a DT N
postulated JJ N
biomechanical JJ N
advantage NN N
conferred VBD N
to TO N
the DT N
extensor NN N
mechanism NN N
by IN N
a DT N
change NN N
in IN N
knee NN N
implant JJ N
design NN N
was VBD N
detectable JJ N
in IN N
patients NNS p
by IN p
direct JJ p
physical JJ p
testing NN p
. . p

212 CD p
TKA JJ p
patients NNS p
were VBD N
enrolled VBN N
in IN N
a DT N
double JJ N
blind NN N
randomized VBD N
controlled VBN N
trial NN N
to TO N
receive VB N
either CC N
a DT N
traditional JJ i
implant NN i
or CC i
one CD i
which WDT i
incorporated VBD i
new JJ i
design NN i
features NNS i
. . i

Extensor NNP o
mechanism NN o
power NN o
output NN o
and CC o
physical JJ o
performance NN o
on IN o
a DT o
battery NN o
of IN o
timed JJ o
functional JJ o
activities NNS o
was VBD N
assessed VBN N
pre-operatively RB N
and CC N
then RB N
at IN N
6 CD N
, , N
26 CD N
, , N
and CC N
52 CD N
weeks NNS N
post-operatively RB N
. . N

Significantly RB N
enhanced JJ N
power NN o
output NN o
was VBD N
observed VBN N
in IN N
both DT N
groups NNS N
post-arthroplasty VBP N
; : N
however RB N
, , N
the DT N
new JJ i
design NN i
implant JJ i
group NN N
demonstrated VBD N
a DT N
greater JJR N
change NN o
in IN o
power NN o
output NN o
than IN N
the DT N
traditional JJ i
implant NN i
group NN N
. . N

Posthoc NNP o
testing VBG o
of IN N
between IN N
group NN N
differences NNS N
highlighted VBD N
greater JJR N
improvement NN N
at IN N
all DT o
post-operative JJ o
assessments NNS o
. . o

At IN N
52 CD N
weeks NNS N
, , N
patients NNS N
receiving VBG N
the DT N
implant NN N
with IN N
the DT N
postulated JJ N
biomechanical JJ N
advantage NN N
achieved VBD N
116 CD N
% NN N
of IN N
the DT N
power NN o
output NN o
of IN o
their PRP$ o
contralateral JJ o
limb NN o
, , N
whereas JJ N
patients NNS N
with IN N
the DT N
traditional JJ N
design NN N
achieved VBD N
90 CD N
% NN N
. . N

No DT N
between IN N
group NN N
difference NN N
was VBD N
detected VBN N
in IN N
the DT N
patient NN N
's POS N
time NN N
to TO N
complete VB N
functional JJ N
tasks NNS N
. . N

Thus RB N
, , N
patients NNS N
receiving VBG N
a DT N
knee NN i
implant NN i
of IN i
a DT i
modern JJ i
design NN i
( ( N
theoretically RB N
able JJ N
to TO N
confer VB N
a DT N
mechanical JJ N
advantage NN N
to TO N
the DT N
extensor NN N
mechanism NN N
) ) N
were VBD N
found VBN N
to TO N
generate VB N
significantly RB N
greater JJR N
extensor NN o
power NN o
than IN N
those DT N
receiving VBG N
a DT N
traditional JJ i
implant NN i
without IN N
the DT N
postulated JJ N
mechanical JJ N
advantage NN N
. . N

-DOCSTART- -11374137- O O

[ JJ N
Advantages NNP N
of IN N
video NN i
assisted VBN i
thoracic NN i
surgery NN i
in IN N
the DT N
treatment NN N
of IN N
spontaneous JJ p
pneumothorax NN p
] NNP p
. . N

Spontaneous JJ p
pneumothorax NN p
( ( p
SP NNP p
) ) p
is VBZ N
a DT N
disabling VBG N
condition NN N
mostly RB N
affecting VBG N
young JJ p
, , p
thin JJ p
and CC p
otherwise RB p
healthy JJ p
males NNS p
. . p

It PRP N
is VBZ N
usually RB N
caused VBN N
by IN N
ruptured JJ N
pleural JJ N
blebs NN N
. . N

The DT N
first JJ N
treatment NN N
is VBZ N
the DT N
insertion NN i
of IN i
a DT i
chest NN i
tube NN i
( ( i
ICT NNP i
) ) i
but CC N
in IN N
a DT N
great JJ N
number NN N
of IN N
patients NNS N
there EX N
is VBZ N
recurrence NN N
of IN N
the DT N
disease NN N
. . N

We PRP N
believe VBP N
that IN N
the DT N
video NN i
assisted VBN i
thoracoscopy NN i
( ( i
VATS NNP i
) ) i
is VBZ N
the DT N
best JJS N
treatment NN N
possible JJ N
because IN N
it PRP N
allows VBZ N
us PRP N
to TO N
treat VB N
the DT N
ruptured JJ N
bleb NN N
radically RB N
avoiding VBG N
any DT N
recurrence NN N
. . N

In IN N
order NN N
to TO N
prove VB N
it PRP N
, , N
40 CD p
patients NNS p
admitted VBN p
in IN p
a DT p
five-year JJ p
period NN p
, , p
with IN p
a DT p
SP NNP p
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
be VB N
treated VBN N
by IN N
ICT NNP i
or CC i
VATS NNP i
. . i

The DT N
ICT JJ i
patients NNS N
were VBD N
in IN N
the DT N
hospital NN N
a DT N
mean JJ o
time NN o
of IN N
7.5 CD N
( ( N
4 CD N
to TO N
15 CD N
) ) N
days NNS N
and CC N
the DT N
VATS NNP i
patients NNS N
, , N
5.3 CD N
( ( N
2 CD N
to TO N
7 CD N
) ) N
days NNS N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

ICT JJ i
patients NNS N
required VBN N
analgesic JJ o
drugs NNS o
during IN N
76.8 CD N
+/- JJ N
31 CD N
hours NNS N
and CC N
VATS NNP i
patients NNS N
38.4 CD N
+/- JJ N
13 CD N
hours NNS N
( ( N
p JJ N
< NNP N
.05 NNP N
) ) N
. . N

From IN N
the DT N
ICT NNP i
group NN N
, , N
8 CD N
( ( N
53 CD N
% NN N
) ) N
patients NNS N
had VBD N
recurrence NN o
of IN o
the DT o
disease NN o
and CC N
6 CD N
( ( N
40 CD N
% NN N
) ) N
had VBD N
a DT N
prolonged JJ N
air NN o
leak NN o
, , N
while IN N
none NN N
of IN N
the DT N
patients NNS N
of IN N
the DT N
VATS NNP i
group NN N
had VBD N
any DT N
complication NN o
( ( N
< NNP N
.001 NNP N
) ) N
. . N

Cost NN o
of IN o
ICT NNP o
and CC o
VATS NNP o
were VBD N
$ $ N
850 CD N
and CC N
$ $ N
1730 CD N
, , N
respectively RB N
. . N

According VBG N
to TO N
these DT N
results NNS N
, , N
VATS NNP i
should MD N
be VB N
the DT N
treatment NN N
of IN N
choice NN N
in IN N
SP NNP N
patients NNS N
. . N

It PRP N
treats VBZ N
the DT N
cause NN N
of IN N
the DT N
disease NN N
. . N

It PRP N
also RB N
reduces VBZ N
the DT N
hospitalization NN o
time NN o
, , N
the DT N
use NN N
of IN N
analgesic JJ N
drugs NNS N
post NN N
surgery NN N
, , N
decreases VBZ N
recurrence NN o
of IN o
the DT o
disease NN o
and CC o
the DT o
cost NN o
of IN o
the DT o
treatment NN o
. . o

Moreover RB N
, , N
the DT N
patients NNS N
were VBD N
back RB N
to TO N
work VB N
in IN N
less JJR N
than IN N
10 CD N
days NNS N
. . N

-DOCSTART- -12084138- O O

A DT N
randomized JJ N
trial NN N
of IN N
a DT N
brief JJ i
alcohol NN i
intervention NN i
for IN N
needle JJ p
exchangers NNS p
( ( N
BRAINE NNP N
) ) N
. . N

AIMS UH N
To TO N
test VB N
motivational JJ i
interviewing NN i
( ( i
MI NNP i
) ) i
as IN N
a DT N
brief JJ N
intervention NN N
for IN N
reducing VBG N
alcohol NN o
use NN o
among IN N
needle JJ p
exchange NN p
clients NNS p
. . p

DESIGN NNP N
Randomized NNP N
clinical JJ N
trial NN N
. . N

SETTING NNP N
Needle NNP N
exchange NN N
program-Providence NN N
, , N
Rhode NNP p
Island NNP p
, , p
USA NNP p
. . p

PARTICIPANTS NNP N
Between NNP p
2/98 CD p
and CC p
10/99 CD p
, , p
we PRP p
recruited VBD p
187 CD p
AUDIT-positive JJ p
( ( p
> JJ p
8 CD p
) ) p
active JJ p
injection NN p
drug NN p
users NNS p
. . p

INTERVENTION NNP N
Those DT N
assigned VBN N
to TO N
a DT N
brief JJ i
motivational JJ i
intervention NN i
( ( i
MI NNP i
) ) i
condition NN N
received VBD N
two CD i
1-hour JJ i
therapist JJ i
sessions NNS i
following VBG i
assessment NN i
visits NNS i
, , N
1 CD N
month NN N
apart RB N
, , N
focusing VBG N
on IN N
alcohol NN N
use NN N
and CC N
HIV NNP N
risk-taking NN N
. . N

MEASUREMENTS NNP N
Control NNP i
and CC N
MI NNP i
subjects NNS N
received VBD N
identical JJ N
research NN N
assessments NNS N
at IN N
baseline NN N
, , N
1 CD N
and CC N
6 CD N
months NNS N
following VBG N
study NN N
enrollment NN N
. . N

At IN N
6 CD N
months NNS N
, , N
study NN N
outcomes NNS N
included VBD N
days NNS o
of IN o
alcohol NN o
use NN o
measured VBD N
using VBG N
the DT N
time-line JJ N
follow-back JJ N
method NN N
. . N

FINDINGS NNP N
Study NNP o
retention NN o
was VBD N
96.8 CD N
% NN N
at IN N
6 CD N
months NNS N
. . N

Participants NNS N
reported VBD N
an DT N
average NN N
of IN N
12.0 CD N
drinking NN o
days NNS o
at IN N
baseline NN N
and CC N
8.3 CD N
at IN N
6 CD N
months NNS N
. . N

Significant JJ N
reductions NNS N
in IN N
drinking NN o
days NNS o
were VBD N
observed VBN N
in IN N
both DT N
treatment NN N
conditions NNS N
. . N

We PRP N
found VBD N
significant JJ N
treatment NN N
x NNP N
baseline NN o
drinking VBG o
day NN o
interaction NN o
effects NNS o
. . o

Tests NNS N
for IN N
simple JJ N
main JJ N
effects NNS N
were VBD N
significant JJ N
for IN N
subjects NNS N
with IN N
above JJ N
median NN o
( ( o
> JJ o
9 CD o
) ) o
baseline NN o
drinking VBG o
day NN o
frequency NN o
, , N
but CC N
not RB N
for IN N
those DT N
with IN N
below JJ N
median JJ N
baseline NN o
drinking NN o
frequency NN o
. . o

Comparisons NNS N
on IN N
dichotomous JJ N
outcomes NNS N
provided VBD N
supporting VBG N
evidence NN N
of IN N
treatment NN o
efficacy NN o
; : o
those DT N
in IN N
MI NNP N
were VBD N
over RB N
two CD N
times NNS N
more RBR N
likely JJ N
than IN N
controls NNS N
to TO N
report VB N
reductions NNS o
of IN o
7 CD o
days NNS o
or CC o
more JJR o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS VB N
This DT N
study NN N
provides VBZ N
the DT N
first JJ N
direct JJ N
evidence NN N
that IN N
brief JJ i
MI NNP i
can MD N
decrease VB N
alcohol NN o
use NN o
among IN N
active JJ N
injection NN p
drug NN p
users NNS p
with IN p
drinking NN p
problems NNS p
. . p

Heavier JJR N
drinkers NNS N
seem VBP N
best RB N
suited VBN N
for IN N
this DT N
intervention NN N
, , N
but CC N
the DT N
optimal JJ N
intensity NN N
of IN N
treatments NNS N
and CC N
which WDT N
components NNS N
of IN N
brief JJ N
intervention NN N
are VBP N
most RBS N
effective JJ N
deserve NN N
further RB N
study NN N
. . N

-DOCSTART- -17009251- O O

Effect NN N
of IN N
hormone NN N
therapy NN N
on IN N
risk NN N
of IN N
hip NN p
and CC p
knee VB p
joint JJ p
replacement NN p
in IN p
the DT p
Women NNP p
's POS p
Health NNP p
Initiative NNP p
. . p

OBJECTIVE NNP N
To TO N
determine VB N
the DT N
effect NN N
of IN N
hormone NN N
therapy NN N
on IN N
arthroplasty JJ o
rates NNS o
. . o

METHODS NNP N
We PRP N
examined VBD N
data NNS p
from IN p
the DT p
Women NNP p
's POS p
Health NNP p
Initiative NNP p
placebo-controlled JJ p
, , p
double-blind JJ p
, , p
randomized JJ p
trials NNS p
. . p

Community-dwelling JJ p
women NNS p
ages VBZ p
50-79 JJ p
years NNS p
were VBD p
enrolled VBN p
at IN p
40 CD p
US NNP p
clinics NNS p
. . p

Women NNS p
with IN p
prior JJ p
arthroplasty NNS p
were VBD p
excluded VBN p
, , p
yielding VBG p
a DT p
sample JJ p
size NN p
of IN p
26,321 CD p
subjects NNS p
. . p

Women NNS p
who WP p
had VBD p
had VBN p
hysterectomies NNS p
( ( N
n JJ N
= NNP N
10,272 CD N
) ) N
were VBD N
randomly RB i
assigned VBN i
to TO i
receive VB i
0.625 CD i
mg/day NN i
conjugated VBD i
equine JJ i
estrogens NNS i
( ( i
n JJ i
= NNP i
5,076 CD i
) ) i
, , i
or CC i
placebo NN i
( ( i
n JJ i
= NNP i
5,196 CD i
) ) i
, , i
with IN i
a DT i
mean JJ i
followup NN i
of IN i
7.1 CD i
years NNS i
. . i

Those DT p
who WP p
had VBD p
not RB p
had VBN p
hysterectomies NNS p
( ( N
n JJ N
= NNP N
16,049 CD N
) ) N
were VBD N
randomly RB i
assigned VBN i
to TO i
receive VB i
estrogen NN i
plus CC i
progestin NN i
( ( i
n JJ i
= NNP i
8,240 CD i
) ) i
, , i
given VBN i
as IN i
0.625 CD i
mg/day NN i
conjugated VBD i
equine JJ i
estrogens NNS i
plus CC i
2.5 CD i
mg/day JJ i
medroxyprogesterone NN i
acetate NN i
, , i
or CC i
placebo NN i
( ( i
n JJ i
= NNP i
7,809 CD i
) ) i
, , i
with IN i
a DT i
mean JJ i
followup NN i
of IN i
5.6 CD i
years NNS i
. . i

Participants NNS N
reported VBD N
hospitalizations NNS o
, , o
and CC o
arthroplasties NNS o
were VBD N
identified VBN N
by IN N
procedure NN o
codes NNS o
. . o

Arthroplasties NNS o
due JJ N
to TO N
hip VB N
fracture NN N
were VBD N
censored VBN N
. . N

Cox NNP N
proportional JJ N
hazards NNS N
regression NN N
was VBD N
used VBN N
to TO N
assess VB N
hazard JJ N
ratios NNS N
( ( N
HRs NNP N
) ) N
and CC N
95 CD N
% NN N
confidence NN N
intervals NNS N
( ( N
95 CD N
% NN N
CIs NNP N
) ) N
using VBG N
intent-to-treat JJ N
methods NNS N
and CC N
outcome NN N
of IN N
time NN N
to TO N
first JJ N
procedure NN N
. . N

RESULTS NNP N
In IN N
the DT N
estrogen-alone JJ N
trial NN N
, , N
women NNS p
receiving VBG N
hormone NN N
therapy NN N
had VBD N
significantly RB N
lower JJR N
rates NNS o
of IN o
any DT o
arthroplasty JJ o
( ( N
HR NNP N
0.84 CD N
[ VBD N
95 CD N
% NN N
CI NNP N
0.70-1.00 CD N
] NNP N
, , N
P NNP N
= NNP N
0.05 CD N
) ) N
. . N

However RB N
, , N
this DT N
effect NN N
was VBD N
borderline JJ N
statistically RB N
significant JJ N
for IN N
hip NN N
arthroplasty NN N
( ( N
HR NNP N
0.73 CD N
[ VBD N
95 CD N
% NN N
CI NNP N
0.52-1.03 CD N
] NNP N
, , N
P NNP N
= NNP N
0.07 CD N
) ) N
, , N
and CC N
not RB N
significant JJ N
for IN N
knee NN N
arthroplasty NN N
( ( N
HR NNP N
0.87 CD N
[ VBD N
95 CD N
% NN N
CI NNP N
0.71-1.07 CD N
] NNP N
, , N
P NNP N
= NNP N
0.19 CD N
) ) N
. . N

In IN N
the DT N
estrogen-plus-progestin JJ N
trial NN N
, , N
there EX N
was VBD N
no DT N
association NN N
for IN N
total JJ o
arthroplasty NN o
( ( N
HR NNP N
0.99 CD N
[ VBD N
95 CD N
% NN N
CI NNP N
0.82-1.20 CD N
] NNP N
, , N
P NNP N
= NNP N
0.92 CD N
) ) N
or CC N
for IN N
individual JJ o
hip NN o
( ( N
HR NNP N
1.14 CD N
[ VBD N
95 CD N
% NN N
CI NNP N
0.83-1.57 CD N
] NNP N
, , N
P NNP N
= NNP N
0.41 CD N
) ) N
or CC N
knee NN o
( ( N
HR NNP N
0.91 CD N
[ VBD N
95 CD N
% NN N
CI NNP N
0.72-1.15 CD N
] NNP N
, , N
P NNP N
= NNP N
0.41 CD N
) ) N
arthroplasties NNS o
. . o

CONCLUSION NNP N
These DT N
data NNS N
suggest VBP N
that IN N
hormone NN N
therapy NN N
may MD N
influence VB N
joint JJ N
health NN N
, , N
but CC N
this DT N
observed JJ N
decrease NN N
in IN N
risk NN N
may MD N
be VB N
limited VBN N
to TO N
unopposed JJ N
estrogen NN N
and CC N
may MD N
possibly RB N
be VB N
more RBR N
important JJ N
in IN N
hip NN N
than IN N
in IN N
knee NN N
osteoarthritis NN N
. . N

-DOCSTART- -24200220- O O

Evaluating VBG N
proton NN i
stereotactic JJ i
body NN i
radiotherapy NN i
to TO N
reduce VB N
chest JJS N
wall NN N
dose NN N
in IN N
the DT N
treatment NN N
of IN N
lung NN p
cancer NN p
. . p

Stereotactic JJ i
body NN i
radiotherapy NN i
( ( i
SBRT NNP i
) ) i
can MD N
produce VB N
excellent JJ N
local JJ N
control NN N
of IN N
several JJ N
types NNS N
of IN N
solid JJ N
tumor NN N
; : N
however RB N
, , N
toxicity NN N
to TO N
nearby RB N
critical JJ N
structures NNS N
is VBZ N
a DT N
concern NN N
. . N

We PRP N
found VBD N
previously RB N
that IN N
in IN N
SBRT NNP i
for IN N
lung NN N
cancer NN N
, , N
the DT N
chest JJS N
wall NN N
( ( N
CW NNP N
) ) N
volume NN N
receiving VBG N
20 CD i
, , i
30 CD i
, , i
or CC i
40Gy CD i
( ( N
V20 NNP N
, , N
V30 NNP N
, , N
or CC N
V40 NNP N
) ) N
was VBD N
linked VBN N
with IN N
the DT N
development NN N
of IN N
neuropathy NN N
. . N

Here RB N
we PRP N
sought VBD N
to TO N
determine VB N
whether IN N
the DT N
dosimetric JJ N
advantages NNS N
of IN N
protons NNS N
could MD N
produce VB N
lower JJR N
CW NNP N
doses NNS N
than IN N
traditional JJ N
photon-based JJ i
SBRT NNP i
. . i

We PRP N
searched VBD N
an DT N
institutional JJ N
database NN N
to TO N
identify VB N
patients NNS p
treated VBN p
with IN p
photon NN i
SBRT NNP i
for IN p
lung NN p
cancer NN p
with IN p
tumors NNS p
within IN p
< JJ p
2.5cm CD p
of IN p
the DT p
CW NNP p
. . p

We PRP N
found VBD N
260 CD p
cases NNS p
; : p
of IN p
these DT p
, , p
chronic NN p
grade NN p
? . p
2 CD p
CW NNP p
pain NN p
was VBD p
identified VBN p
in IN p
23 CD p
patients NNS p
. . p

We PRP N
then RB p
selected VBD p
10 CD p
representative JJ p
patients NNS p
from IN p
this DT p
group NN p
and CC p
generated VBD i
proton NN i
SBRT NNP i
treatment NN i
plans NNS p
, , p
using VBG N
the DT N
identical JJ N
dose NN N
of IN N
50Gy CD N
in IN N
4 CD N
fractions NNS N
, , N
and CC N
assessed VBD N
potential JJ N
differences NNS N
in IN N
CW NNP N
dose NN N
between IN N
the DT N
2 CD N
plans NNS N
. . N

The DT o
proton NN o
SBRT NNP o
plans VBZ o
reduced VBD o
the DT o
CW NNP o
doses NNS o
at IN o
all DT N
dose JJ N
levels NNS N
measured VBN o
. . o

The DT o
median JJ o
CW NNP o
V20 NNP o
was VBD o
364.0cm CD N
( ( N
3 CD N
) ) N
and CC N
160.0cm CD N
( ( N
3 CD N
) ) N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
, , N
V30 NNP N
was VBD N
144.6cm CD N
( ( N
3 CD N
) ) N
vs NN N
77.0cm CD N
( ( N
3 CD N
) ) N
( ( N
p JJ N
= NNP N
0.0012 CD N
) ) N
, , N
V35 NNP N
was VBD N
93.9cm CD N
( ( N
3 CD N
) ) N
vs NN N
57.9cm CD N
( ( N
3 CD N
) ) N
( ( N
p JJ N
= NNP N
0.005 CD N
) ) N
, , N
V40 NNP N
was VBD N
66.5cm CD N
( ( N
3 CD N
) ) N
vs NN N
45.4cm CD N
( ( N
3 CD N
) ) N
( ( N
p JJ N
= NNP N
0.0112 CD N
) ) N
, , N
and CC N
mean JJ N
lung NN N
dose NN N
was VBD N
5.9Gy CD N
vs NN N
3.8Gy CD N
( ( N
p NN N
= RB N
0.0001 CD N
) ) N
for IN N
photons NNS N
and CC N
protons NNS N
, , N
respectively RB N
. . N

Coverage NN N
of IN N
the DT o
planning NN o
target NN o
volume NN o
( ( o
PTV NNP o
) ) o
was VBD o
comparable JJ N
between IN N
the DT N
2 CD N
sets NNS N
of IN N
plans NNS N
( ( N
96.4 CD N
% NN N
for IN N
photons NNS N
and CC N
97 CD N
% NN N
for IN N
protons NNS N
) ) N
. . N

From IN N
a DT N
dosimetric JJ N
standpoint NN i
, , i
proton NN i
SBRT NNP i
can MD i
achieve VB N
the DT N
same JJ N
coverage NN N
of IN N
the DT o
PTV NNP o
while IN o
significantly RB o
reducing VBG o
the DT o
dose NN o
to TO o
the DT o
CW NNP o
and CC o
lung RB o
relative JJ o
to TO o
photon VB o
SBRT NNP o
and CC o
therefore RB N
may MD N
be VB N
beneficial JJ N
for IN N
the DT N
treatment NN N
of IN N
lesions NNS o
closer VBP o
to TO N
critical JJ N
structures NNS N
. . N

-DOCSTART- -8155449- O O

Risk NN N
of IN N
aspiration NN N
with IN N
the DT N
laryngeal NN i
mask NN N
. . N

In IN N
order NN N
to TO N
assess VB N
if IN N
the DT N
use NN N
of IN N
the DT N
laryngeal JJ N
mask NN N
airway NN N
is VBZ N
associated VBN N
with IN N
an DT N
increased VBN N
risk NN N
of IN N
gastric JJ N
regurgitation NN N
during IN N
mechanical JJ N
ventilation NN N
, , N
we PRP N
studied VBD N
50 CD p
patients NNS p
allocated VBD p
randomly RB p
to TO p
undergo VB p
anaesthesia NN i
with IN p
either DT p
artificial JJ i
ventilation NN i
with IN i
isoflurane NN i
and CC i
nitrous JJ i
oxide NN i
in IN i
oxygen NN i
and CC i
atracurium NN i
( ( p
group NN p
A NNP p
) ) p
or CC p
spontaneous JJ i
ventilation NN i
with IN i
isoflurane NN i
and CC i
nitrous JJ i
oxide NN i
in IN i
oxygen NN i
( ( p
group NN p
B NNP p
) ) p
. . p

In IN N
both DT N
groups NNS N
a DT N
laryngeal JJ N
mask NN N
airway NN N
was VBD N
used VBN N
. . N

Regurgitation NNP N
was VBD N
assessed VBN N
by IN N
the DT N
patient NN N
ingesting VBG N
a DT N
methylene NN i
blue JJ i
capsule NN i
10 CD N
min NN N
before IN N
induction NN N
of IN N
anaesthesia NN N
and CC N
examining VBG N
the DT N
oropharynx NN N
by IN N
direct JJ N
laryngoscopy NN N
at IN N
the DT N
end NN N
of IN N
surgery NN N
. . N

In IN N
one CD N
patient NN N
in IN N
each DT N
group NN N
, , N
there EX N
was VBD N
staining VBG o
of IN o
the DT o
oropharynx NN o
with IN N
blue JJ N
dye NN N
at IN N
the DT N
end NN N
of IN N
surgery NN N
. . N

In IN N
the DT N
patient NN N
in IN N
group NN N
A NNP N
, , N
dye NN o
was VBD o
present JJ o
in IN o
the DT o
trachea NN o
and CC o
bronchi NN o
. . N

-DOCSTART- -11931782- O O

Safety NN N
of IN N
intravitreous JJ N
fomivirsen NN i
for IN N
treatment NN N
of IN N
cytomegalovirus NN o
retinitis NN p
in IN p
patients NNS p
with IN p
AIDS NNP p
. . p

PURPOSE NNP N
To TO N
report VB N
data NNS N
regarding VBG N
the DT N
safety NN N
of IN N
intravitreous JJ N
fomivirsen NN i
for IN N
treatment NN N
of IN N
cytomegalovirus NN o
( ( N
CMV NNP N
) ) N
retinitis NN N
in IN N
patients NNS p
with IN p
acquired JJ p
immunodeficiency NN p
syndrome NN p
( ( p
AIDS NNP p
) ) p
. . p

DESIGN NNP N
Critical NNP N
review NN N
of IN N
safety NN N
data NNS N
from IN N
three CD N
randomized NNS N
controlled VBD N
clinical JJ N
trials NNS N
with IN N
supplemental JJ N
information NN N
from IN N
an DT N
expanded VBN N
drug NN N
access NN N
program NN N
. . N

METHODS NNP N
Adverse NNP N
ocular JJ N
events NNS N
reported VBN N
by IN N
clinician JJ N
investigators NNS N
were VBD N
listed VBN N
using VBG N
terms NNS N
modified VBN N
from IN N
the DT N
COSTART NNP N
dictionary NN N
. . N

Data NNP N
for IN N
two CD p
doses NNS p
( ( p
165-microg/injection JJ p
[ NN p
35 CD p
eyes NNS p
, , p
30 CD p
patients NNS p
] JJ p
and CC p
330-microg/injection JJ p
[ NN p
153 CD p
eyes NNS p
, , p
120 CD p
patients NNS p
] JJ p
) ) p
and CC N
two CD N
330-microg/injection JJ N
dose JJ N
schedules NNS N
of IN N
different JJ N
intensity NN N
were VBD N
pooled VBN N
to TO N
calculate VB N
incidence NN N
rates NNS N
for IN N
each DT N
event NN N
. . N

Rates NNS N
were VBD N
calculated VBN N
as IN N
events/patient-year JJ N
( ( N
based VBN N
on IN N
total JJ N
cumulative JJ N
reported VBD N
events NNS N
and CC N
duration NN N
of IN N
treatment NN N
) ) N
for IN N
events NNS N
that WDT N
could MD N
recur VB N
during IN N
treatment NN N
. . N

Rates NNS N
were VBD N
calculated VBN N
as IN N
patients NNS N
with IN N
events/person-year JJ N
for IN N
the DT N
following JJ N
events NNS N
: : N
retinal JJ N
detachment NN N
, , N
cataract NN N
, , N
visual JJ N
field NN N
disturbance NN N
, , N
and CC N
retinal JJ N
pigment NN N
epitheliopathy NN N
. . N

To TO N
assess VB N
the DT N
ability NN N
to TO N
manage VB N
events NNS N
, , N
we PRP N
reviewed VBD N
treatments NNS N
given VBN N
for IN N
two CD N
events NNS N
( ( N
anterior JJ N
chamber NN N
inflammation NN N
, , N
increased VBD N
intraocular JJ N
pressure NN N
) ) N
in IN N
one CD N
trial NN N
. . N

We PRP N
also RB N
report VBP N
an DT N
analysis NN N
comparing VBG N
the DT N
proportion NN N
of IN N
eyes NNS N
that WDT N
developed VBD N
one CD N
or CC N
more JJR N
key JJ N
events NNS N
to TO N
the DT N
cumulative JJ N
number NN N
of IN N
injections NNS N
. . N

RESULTS JJ N
Incidence NN N
rates NNS N
were VBD N
dose JJ N
and CC N
schedule JJ N
dependent NN N
( ( N
165 CD N
microg/injection NN N
, , N
4.06 CD N
events/patient-year JJ N
; : N
330 CD N
microg/injection NN N
, , N
6.58 CD N
events/patient-year JJ N
[ NNP N
less JJR N
intense JJ N
regimen NNS N
] VBP N
and CC N
8.35 CD N
events/patient-year JJ N
[ NNP N
more JJR N
intense JJ N
regimen NNS N
] VBP N
) ) N
. . N

The DT N
most RBS N
frequently RB N
reported VBN N
events NNS N
were VBD N
anterior JJ o
chamber NN o
inflammation NN o
and CC o
increased VBD o
intraocular JJ o
pressure NN o
. . o

We PRP N
found VBD N
no DT N
evidence NN N
that IN N
the DT N
proportion NN o
of IN o
patients NNS o
with IN o
events NNS o
increased VBN N
as IN N
the DT N
number NN o
of IN o
injections NNS o
increased VBN o
. . o

CONCLUSIONS NNP N
Intravitreous NNP N
fomivirsen NN N
is VBZ N
well RB o
tolerated VBN o
with IN o
an DT o
acceptable JJ o
safety NN o
profile NN o
. . o

Adverse JJ o
ocular JJ o
events NNS o
associated VBN N
with IN N
doses NNS N
and CC N
schedules NNS N
used VBN N
clinically RB N
can MD N
be VB N
managed VBN N
successfully RB N
with IN N
medical JJ N
therapy NN N
. . N

-DOCSTART- -10928228- O O

Is VBZ N
a DT N
calculated JJ N
total JJ N
hip NN N
BMD NNP N
of IN N
clinical JJ o
use NN o
? . N
The DT N
diagnosis NN N
of IN N
osteoporosis NN N
is VBZ N
based VBN N
on IN N
bone NN N
mass NN N
measurement NN N
. . N

To TO N
avoid VB N
the DT N
errors NNS N
associated VBN N
with IN N
the DT N
measurement NN N
of IN N
spinal JJ N
bone NN N
density NN N
the DT N
total JJ N
hip NN N
has VBZ N
been VBN N
accepted VBN N
as IN N
the DT N
standard JJ N
measurement NN N
site NN N
. . N

This DT N
information NN N
is VBZ N
not RB N
available JJ N
for IN N
many JJ N
early JJ N
measurements NNS N
. . N

We PRP N
have VBP N
assessed VBN N
whether IN N
it PRP N
is VBZ N
possible JJ N
to TO N
derive VB N
clinically RB N
useful JJ N
information NN N
about IN N
total JJ i
hip NN i
bone NN i
mineral JJ i
density NN i
( ( N
BMD NNP N
) ) N
from IN N
measurements NNS N
at IN N
other JJ N
hip NN N
sites NNS N
. . N

The DT N
bone NN N
mass NN N
measurements NNS N
of IN N
46 CD p
patients NNS p
participating VBG p
in IN p
a DT p
current JJ p
trial NN p
of IN p
therapy NN p
for IN p
osteoporosis NN p
were VBD N
reviewed VBN N
. . N

The DT N
total JJ o
hip NN o
BMD NNP o
as IN N
directly RB N
measured VBN N
was VBD N
compared VBN N
with IN N
that DT N
obtained VBN N
from IN N
the DT N
formula NN N
: : N
Total JJ o
hip NN o
BMD NNP o
= VBZ N
0.48 CD N
x NN N
Neck NNP o
BMD NNP o
+ VBD N
0.62 CD N
x NNP N
Trochanteric NNP o
BMD NNP o
+ VBD N
0.03 CD N
. . N

In IN N
30 CD p
patients NNS p
with IN p
follow-up JJ p
data NNS p
the DT N
rate NN o
of IN o
change NN o
in IN o
hip NN o
BMD NNP o
over IN N
a DT N
year NN N
was VBD N
also RB N
determined VBN N
by IN N
both DT N
methods NNS N
. . N

In IN N
the DT N
pretreatment NN N
state NN N
there EX N
was VBD N
good JJ N
agreement NN o
between IN N
the DT N
two CD N
measures NNS N
( ( N
r2 VB N
= RB N
0.96 CD N
, , N
SEE NNP N
0.012 CD N
g/cm2 NN N
) ) N
. . N

If IN N
the DT N
formula NN N
was VBD N
used VBN N
to TO N
compute VB N
a DT N
change NN o
in IN o
total JJ o
hip NN o
BMD NNP o
, , N
the DT N
agreement NN o
between IN N
both DT N
methods NNS N
remained VBD N
good JJ N
. . N

However RB N
, , N
the DT N
standard JJ o
error NN o
of IN o
the DT o
estimate NN o
of IN o
the DT o
change NN o
represented VBD N
59 CD N
% NN N
of IN N
the DT N
observed JJ N
change NN N
. . N

This DT N
indicates VBZ N
that IN N
the DT N
error NN o
associated VBN o
with IN o
this DT o
estimate NN o
is VBZ N
too RB N
great JJ N
to TO N
allow VB N
clinically RB N
meaningful JJ N
conclusions NNS N
to TO N
be VB N
drawn VBN N
from IN N
calculated VBN o
total JJ o
hip NN o
BMD NNP o
. . o

We PRP N
conclude VBP N
that IN N
, , N
whilst VB N
it PRP N
may MD N
be VB N
possible JJ N
to TO N
obtain VB N
reasonable JJ N
point NN N
estimates NNS N
of IN N
total JJ o
hip NN o
BMD NNP o
from IN N
other JJ N
measures NNS N
in IN N
the DT N
hip NN N
, , N
these DT N
estimates NNS N
are VBP N
too RB N
imprecise JJ N
to TO N
allow VB N
conclusions NNS N
about IN N
change NN o
in IN o
BMD NNP o
to TO N
be VB N
made VBN N
. . N

-DOCSTART- -3503390- O O

Hemolytic JJ i
streptococcus NN i
preparation NN i
OK-432 NNP i
; : i
beneficial JJ N
adjuvant NN N
therapy NN N
in IN N
recurrent NN p
gastric JJ p
carcinoma NN p
. . p

The DT N
administration NN N
of IN N
a DT N
hemolytic JJ i
streptococcus NN i
preparation NN i
, , N
OK-432 NNP N
, , N
is VBZ N
thought VBN N
to TO N
be VB N
of IN N
therapeutic JJ N
value NN N
in IN N
the DT N
treatment NN N
of IN N
cancer NN p
patients NNS p
through IN N
a DT N
stimulatory JJ N
effect NN N
on IN N
the DT N
immune NN N
system NN N
. . N

In IN N
order NN N
to TO N
evaluate VB N
any DT N
beneficial JJ N
effect NN N
of IN N
such JJ N
an DT N
administration NN N
, , N
a DT p
group NN p
of IN p
patients NNS p
with IN p
recurrent JJ p
gastric JJ p
cancer NN p
was VBD N
studied VBN N
. . N

This DT N
group NN N
was VBD N
randomly RB N
subdivided VBN N
into IN N
3 CD i
groups NNS i
: : i
1 CD i
) ) i
Intradermal NNP i
group NN i
( ( i
ID NNP i
Group NNP i
) ) i
, , i
42 CD i
patients NNS i
given VBN i
an DT i
intradermal JJ i
injections NNS i
of IN i
OK-432 NNP i
. . i

2 CD i
) ) i
Intramuscular NNP i
group NN i
( ( i
IM NNP i
Group NNP i
) ) i
, , i
40 CD i
patients NNS i
given VBN i
an DT i
intramuscular JJ i
injections NNS i
of IN i
OK-432 NNP i
. . i

3 CD i
) ) i
Control NNP i
group NN i
( ( i
C NNP i
Group NNP i
) ) i
, , i
39 CD i
patients NNS i
not RB i
given VBN i
injections NNS i
. . i

Each DT N
group NN N
was VBD N
studied VBN N
in IN N
regards NNS N
to TO N
the DT N
length NN o
of IN o
survival NN o
, , N
the DT N
host NN o
immune JJ o
response NN o
and CC o
the DT o
incidence NN o
of IN o
side NN o
effects NNS o
. . o

When WRB N
compared VBN N
to TO N
the DT N
IM NNP N
and CC N
C NNP N
Groups NNP N
, , N
the DT N
ID NNP N
Group NNP N
showed VBD N
improved JJ N
survival NN o
. . o

Accompanying VBG N
this DT N
improved JJ N
survival NN N
, , N
the DT N
ID NNP N
Group NNP N
also RB N
had VBD N
greater JJR N
white JJ o
cell NN o
and CC o
lymphocyte NN o
counts NNS o
, , N
a DT N
greater JJR N
number NN N
of IN N
T NNP o
cells NNS o
, , N
and CC N
a DT N
more RBR N
dramatic JJ o
skin NN o
reaction NN o
to TO N
the DT N
extracted VBN N
cell NN N
wall NN N
polysaccharide NN N
of IN N
hemolytic JJ N
streptococcus NN N
Su-strain NNP N
( ( N
Su-PS NNP N
) ) N
. . N

The DT N
ID NNP N
Group NNP N
, , N
following VBG N
OK-432 JJ N
injection NN N
, , N
had VBD N
a DT N
4.8 CD N
% NN N
incidence NN N
of IN N
fever NN o
and CC N
a DT N
52.4 CD N
% NN N
incidence NN N
of IN N
local JJ o
abscess NN o
formation NN o
at IN N
the DT N
injection NN N
site NN N
. . N

90 CD N
% NN N
of IN N
the DT N
IM NNP N
Group NNP N
developed VBD N
fever RB o
but CC N
abscess JJ o
formation NN o
was VBD N
absent VBN N
in IN N
all DT N
patients NNS N
. . N

From IN N
these DT N
results NNS N
, , N
it PRP N
was VBD N
concluded VBN N
that IN N
in IN N
the DT N
patients NNS N
tested VBN N
, , N
intradermal JJ N
injection NN N
of IN N
OK-432 NNP N
appears VBZ N
to TO N
be VB N
clinically RB N
superior JJ N
to TO N
intramuscular JJ N
injection NN N
. . N

-DOCSTART- -7815983- O O

[ JJ N
Carbohydrate NNP N
substitutes NNS N
: : N
comparative JJ N
study NN N
of IN N
intestinal JJ p
absorption NN p
of IN p
fructose NN i
, , i
sorbitol NN i
and CC i
xylitol NNP i
] NNP i
. . N

BACKGROUND NNP N
The DT N
carbohydrate NN N
substitutes NNS N
fructose VBP i
, , i
sorbitol JJ i
and CC i
xylitol NNS i
are VBP N
gaining VBG N
more JJR N
and CC N
more JJR N
importance NN N
in IN N
the DT N
production NN N
of IN N
dietary JJ N
food NN N
. . N

But CC N
they PRP N
can MD N
provoke VB N
gastrointestinal JJ N
side-effects NNS N
. . N

In IN N
a DT N
randomized JJ N
double JJ N
blind NN N
study VBD N
the DT N
rate NN N
of IN N
malabsorption NN N
of IN N
these DT N
sugars NNS N
was VBD N
compared VBN N
and CC N
the DT N
concomitant NN N
symptoms NNS N
were VBD N
recorded VBN N
. . N

SUBJECTS NNP N
AND NNP N
METHODS NNP N
25 CD p
healthy JJ p
controls NNS p
received VBD N
25 CD i
g NN i
of IN i
each DT i
sugar NN i
within IN N
3 CD N
consecutive JJ N
days NNS N
. . N

The DT N
intestinal JJ o
absorption NN o
was VBD o
determined VBN o
by IN o
H2-exhalation NNP o
tests NNS o
and CC N
the DT N
clinical JJ o
symptoms NNS o
were VBD N
recorded VBN N
. . N

RESULTS VB N
The DT N
rate NN o
of IN o
malabsorption NN o
was VBD N
84 CD N
% NN N
for IN N
sorbitol NN i
, , N
36 CD N
% NN N
for IN N
fructose JJ i
and CC N
12 CD N
% NN N
for IN N
xylitol NNP i
( ( N
p JJ N
< VBP N
0.01 CD N
for IN N
sorbitol NN i
versus NN i
fructose NN i
and CC i
xylitol NN i
) ) i
. . N

57 CD N
% NN N
of IN N
the DT N
participants NNS N
with IN N
pathological JJ N
H2-test NNP N
after IN N
sorbitol NN i
and CC N
56 CD N
% NN N
after IN N
fructose JJ i
reported VBD N
symptoms NNS N
, , N
while IN N
all DT N
of IN N
the DT N
3 CD N
malabsorbers NNS N
of IN N
xylitol NN i
were VBD N
symptomatic JJ N
. . N

CONCLUSIONS NNP N
There EX N
is VBZ N
an DT N
advantage NN N
to TO N
administering VBG N
xylitol NN i
and CC N
fructose JJ i
with IN N
regard NN N
to TO N
the DT N
intestinal JJ o
absorption NN o
and CC N
concomitant NN N
symptoms NNS N
as IN N
compared VBN N
with IN N
sorbitol NN i
. . i

H2-exhalation NN N
tests NNS N
appear VBP N
to TO N
be VB N
a DT N
reliable JJ N
diagnostic JJ N
tool NN N
to TO N
detect VB N
carbohydrate JJ o
malabsorption NN o
and CC N
should MD N
find VB N
broader JJR N
application NN N
in IN N
patients NNS N
suffering VBG N
from IN N
non-specific JJ N
abdominal JJ N
complaints NNS N
. . N

-DOCSTART- -2195054- O O

A DT N
controlled VBN N
crossover NN N
trial NN N
of IN N
fenfluramine NN i
in IN N
autism NN p
. . p

We PRP N
report VBP N
a DT N
12 CD N
month NN N
double-blind JJ N
randomized VBD N
crossover JJ N
trial NN N
of IN N
fenfluramine NN i
in IN N
20 CD p
children NNS p
with IN p
the DT p
syndrome NN p
of IN p
autism NN p
. . p

On IN N
active JJ N
drug NN N
most JJS N
of IN N
the DT N
children NNS p
lost VBD o
weight NN o
and CC o
blood NN o
serotonin NN o
levels NNS o
fell VBD N
by IN N
an DT N
average NN N
of IN N
60 CD N
% NN N
. . N

There EX N
was VBD N
a DT N
fall NN N
in IN N
urinary JJ o
dopamine NN o
( ( o
DA NNP o
) ) o
and CC o
noradrenaline JJ o
( ( o
NA NNP o
) ) o
levels NNS o
and CC o
increased JJ o
excretion NN o
of IN o
homovanillic JJ o
acid NN o
( ( o
HVA NNP o
) ) o
. . o

Some DT N
of IN N
the DT N
children NNS p
showed VBD N
improvement NN N
in IN N
tests NNS o
of IN o
cognitive JJ o
and CC o
language NN o
function NN o
, , N
although IN N
the DT N
results NNS N
did VBD N
not RB N
achieve VB N
overall JJ N
statistical JJ o
significance NN o
. . o

Event-related JJ o
brain NN o
potentials NNS o
( ( o
ERPs NNP o
) ) o
were VBD N
obtained VBN N
in IN N
seven CD N
subjects NNS N
on IN N
an DT N
auditory JJ N
choice NN N
reaction NN N
time NN N
task NN N
. . N

Side JJ o
effects NNS o
of IN N
the DT N
drug NN N
included VBD N
irritability NN o
and CC o
lethargy NN o
. . o

Fenfluramine NN N
may MD N
have VB N
a DT N
limited JJ N
place NN N
in IN N
the DT N
management NN N
of IN N
some DT N
patients NNS p
with IN p
autistic JJ p
disorder NN p
. . p

-DOCSTART- -19282350- O O

FDA NNP N
review NN N
of IN N
a DT N
panitumumab NN i
( ( i
Vectibix NNP i
) ) i
clinical JJ N
trial NN N
for IN N
first-line JJ N
treatment NN N
of IN N
metastatic JJ p
colorectal JJ p
cancer NN p
. . p

On IN N
September NNP N
27 CD N
, , N
2006 CD N
, , N
the DT N
U.S. NNP N
Food NNP N
and CC N
Drug NNP N
Administration NNP N
granted VBD N
accelerated VBD N
approval NN N
to TO N
panitumumab VB i
( ( i
Vectibix NNP i
; : i
Amgen NNP N
, , N
Inc. NNP N
, , N
Thousand NNP N
Oaks NNP N
, , N
CA NNP N
) ) N
for IN N
the DT N
treatment NN N
of IN N
patients NNS p
with IN p
epidermal JJ p
growth NN p
factor NN p
receptor-expressing NN p
, , p
metastatic JJ p
colorectal NN p
carcinoma NN p
with IN p
disease JJ p
progression NN p
on IN p
or CC p
following VBG p
fluoropyrimidine- JJ i
, , i
oxaliplatin- JJ i
, , i
and CC i
irinotecan-containing JJ i
chemotherapy NN i
regimens NNS i
. . i

Accelerated NNP N
approval NN N
was VBD N
based VBN N
on IN N
demonstration NN N
of IN N
a DT N
beneficial JJ N
effect NN N
on IN N
progression-free JJ N
survival NN N
( ( N
PFS NNP N
) ) N
. . N

The DT N
present JJ N
submission NN N
summarizes VBZ N
a DT N
second JJ N
clinical JJ N
trial NN N
, , N
to TO N
be VB N
included VBN N
in IN N
the DT N
panitumumab JJ i
package NN N
insert NN N
in IN N
June NNP N
2008 CD N
, , N
of IN N
chemotherapy NN i
and CC i
bevacizumab NN i
with IN i
and CC i
without IN i
panitumumab NN i
in IN N
the DT N
first-line JJ N
treatment NN N
of IN N
patients NNS p
with IN p
metastatic JJ p
colorectal JJ p
cancer NN p
. . p

The DT N
study NN N
was VBD N
closed VBN N
when WRB N
inferior JJ N
PFS NNP N
and CC N
greater JJR N
toxicity NN N
were VBD N
demonstrated VBN N
at IN N
the DT N
time NN N
of IN N
the DT N
planned VBN N
interim NN N
efficacy NN N
analysis NN N
. . N

Patients NNS p
receiving VBG p
panitumumab NN i
in IN N
combination NN N
with IN N
bevacizumab NN i
and CC i
chemotherapy NN i
experienced VBD N
a DT N
higher JJR N
incidence NN N
of IN N
death NN o
( ( N
9 CD N
% NN N
versus IN N
4 CD N
% NN N
) ) N
and CC N
a DT N
higher JJR N
risk NN N
for IN N
grade NN o
3 CD o
and CC o
4 CD o
toxicities NNS o
than IN N
patients NNS p
receiving VBG p
bevacizumab NN i
and CC i
chemotherapy NN i
alone RB i
. . i

The DT N
incidences NNS o
of IN o
any DT o
Common NNP o
Terminology NNP o
Criteria NNP o
for IN o
Adverse NNP o
Events NNP o
grade VBD o
3 CD o
and CC o
4 CD o
adverse JJ o
events NNS o
( ( o
AEs NNP o
) ) o
were VBD N
87 CD N
% NN N
and CC N
72 CD N
% NN N
in IN N
the DT N
panitumumab NN i
and CC N
control NN N
groups NNS N
, , N
respectively RB N
. . N

Grade VB o
3 CD o
and CC o
4 CD o
AEs NNP o
occurring VBG N
more JJR N
commonly RB N
in IN N
panitumumab-treated JJ i
patients NNS N
included VBD N
rash/acneiform NN o
dermatitis NN o
, , o
diarrhea NN o
, , o
dehydration NN o
, , o
primarily RB o
resulting VBG o
from IN o
diarrhea NN o
, , o
hypokalemia NN o
, , o
stomatitis/mucositis NN o
, , o
and CC o
pulmonary JJ o
embolism NN o
. . o

The DT N
addition NN N
of IN N
panitumumab NN i
to TO i
bevacizumab VB i
and CC i
chemotherapy VB i
for IN N
the DT N
first-line JJ N
treatment NN N
of IN N
metastatic JJ p
colorectal NN p
cancer NN p
was VBD N
harmful JJ N
when WRB N
compared VBN N
with IN N
bevacizumab NN i
and CC i
chemotherapy NN i
alone RB i
. . i

The DT N
use NN N
of IN N
panitumumab NN i
in IN N
this DT N
setting NN N
can MD N
not RB N
be VB N
recommended VBN N
. . N

-DOCSTART- -24835171- O O

Changes NNS N
in IN N
spinal JJ N
inhibitory NN N
networks NNS N
induced VBN N
by IN N
furosemide NN i
in IN N
humans NNS N
. . N

During IN N
neural JJ N
development NN N
in IN N
animals NNS N
, , N
GABAergic NNP N
and CC N
glycinergic JJ N
neurons NNS N
are VBP N
first JJ N
excitatory NN N
, , N
and CC N
then RB N
become VB N
inhibitory NN N
in IN N
the DT N
mature NN N
state NN N
. . N

This DT N
developmental JJ N
shift NN N
is VBZ N
due JJ N
mainly RB N
to TO N
strong JJ N
expression NN N
of IN N
the DT N
cation-chloride JJ N
K-Cl NNP N
cotransporter NN N
2 CD N
( ( N
KCC2 NNP N
) ) N
and CC N
down-regulation NN N
of IN N
Na-K-Cl NNP N
cotransporter NN N
1 CD N
( ( N
NKCC1 NNP N
) ) N
during IN N
maturation NN N
. . N

The DT N
down-regulation NN N
of IN N
co-transporter NN N
KCC2 NNP N
after IN N
spinal JJ N
cord NN N
transection NN N
in IN N
animals NNS N
leads NNS N
to TO N
the DT N
depolarising NN N
( ( N
excitatory NN N
) ) N
action NN N
of IN N
GABA NNP N
and CC N
glycine NN N
and CC N
thus RB N
results NNS N
in IN N
a DT N
reduction NN N
of IN N
inhibitory JJ N
synaptic JJ N
efficiency NN N
. . N

Furosemide NNP i
, , N
a DT N
loop NN N
diuretic NN N
, , N
has VBZ N
been VBN N
shown VBN N
to TO N
selectively RB N
and CC N
reversibly RB N
block VB N
inhibitory NN N
postsynaptic JJ N
potentials NNS N
without IN N
affecting VBG N
excitatory JJ N
postsynaptic JJ N
potentials NNS N
in IN N
animal JJ N
spinal JJ N
neurons NNS N
. . N

Moreover RB N
, , N
this DT N
diuretic NN N
has VBZ N
been VBN N
also RB N
demonstrated VBN N
to TO N
block VB N
the DT N
cation-chloride JJ N
co-transporters NNS N
. . N

Here RB N
, , N
we PRP N
used VBD N
furosemide RB i
to TO N
demonstrate VB N
changes NNS p
in IN p
spinal JJ p
inhibitory NN p
networks NNS p
in IN p
healthy JJ p
human JJ p
subjects NNS p
. . p

Non-invasive JJ N
electrophysiological JJ N
techniques NNS N
were VBD N
used VBN N
to TO N
assess VB N
presynaptic JJ N
inhibition NN N
, , N
postsynaptic JJ N
inhibition NN N
and CC N
the DT N
efficacy NN N
of IN N
synaptic JJ N
transmission NN N
between IN N
muscle NN N
afferent NN N
terminals NNS N
and CC N
soleus JJ N
motoneurons NNS N
in IN N
the DT N
spinal JJ N
cord NN N
. . N

Orally RB i
administered VBN i
furosemide NN i
, , i
at IN i
doses NNS i
commonly RB i
used VBN i
in IN i
the DT i
clinic NN i
( ( i
40 CD i
mg NN i
) ) i
, , N
significantly RB N
reduced VBN N
spinal JJ o
inhibitory JJ o
interneuronal JJ o
activity NN o
for IN N
at IN N
least JJS N
70 CD N
min NN N
from IN N
intake NN N
compared VBN N
to TO N
control VB N
experiments NNS N
in IN N
the DT N
same JJ N
subjects NNS N
while IN N
no DT N
changes NNS N
were VBD N
observed VBN N
in IN N
the DT N
efficacy NN N
of IN N
synaptic JJ N
transmission NN N
between IN N
muscle NN N
afferent NN N
terminals NNS N
and CC N
soleus JJ N
motoneurons NNS N
. . N

The DT N
reduction NN o
of IN o
inhibition NN o
was VBD N
dose-dependent JJ N
. . N

Our PRP$ N
results NNS N
provide VBP N
indirect JJ N
evidence NN N
that IN N
reversible JJ N
changes NNS N
in IN N
the DT N
cation-chloride JJ N
transport NN N
system NN N
induce JJ N
modulations NNS N
of IN N
inhibitory JJ N
neuronal JJ N
activity NN N
at IN N
spinal JJ N
cord NN N
level NN N
in IN N
humans NNS N
. . N

-DOCSTART- -23312881- O O

Intravenous JJ N
aflibercept NN i
administered VBN N
in IN N
combination NN N
with IN N
irinotecan JJ i
, , i
5-fluorouracil JJ i
and CC i
leucovorin JJ i
in IN N
patients NNS p
with IN p
advanced JJ p
solid JJ p
tumours NNS p
: : p
results NNS N
from IN N
the DT N
expansion NN N
cohort NN N
of IN N
a DT N
phase NN N
I PRP N
study VBP N
. . N

BACKGROUND NNP N
Following VBG N
the DT N
dose-escalation NN N
stage NN N
, , N
this DT N
double-blind JJ N
expansion NN N
stage NN N
of IN N
the DT N
phase NN N
I PRP N
study VBP N
evaluated VBD N
the DT N
safety NN N
, , N
pharmacodynamics NNS N
, , N
pharmacokinetics NNS N
, , N
anti-vascular JJ N
effects NNS N
and CC N
antitumour JJ N
activity NN N
of IN N
aflibercept $ i
4 CD N
mg/kg NN N
with IN N
irinotecan JJ i
, , i
5-fluorouracil JJ i
and CC i
leucovorin JJ i
( ( i
LV5FU2 NNP i
) ) i
. . i

PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNP p
with IN p
advanced JJ p
solid JJ p
tumours NNS p
were VBD N
randomised VBN N
at IN N
cycle-1 NN N
to TO N
placebo VB i
or CC i
aflibercept VB i
( ( N
4 CD N
mg/kg NN N
) ) N
on IN N
day NN N
1 CD N
then RB N
irinotecan-LV5FU2 NN i
on IN N
days NNS N
1 CD N
and CC N
2 CD N
. . N

Subsequently RB N
, , N
all DT N
patients NNS N
received VBD N
aflibercept JJ i
with IN N
irinotecan-LV5FU2 JJ i
every DT N
2 CD N
weeks NNS N
. . N

Anti-vascular JJ N
effects NNS N
were VBD N
assessed VBN N
using VBG N
dynamic JJ N
contrast-enhanced JJ N
magnetic JJ N
resonance NN N
imaging NN N
( ( N
DCE-MRI NNP N
) ) N
. . N

RESULTS JJ N
Twenty-seven JJ p
patients NNS p
were VBD p
treated VBN p
; : p
14 CD N
received VBD N
placebo NN i
in IN N
cycle-1 NN N
followed VBN N
by IN N
aflibercept NN i
in IN N
later JJ N
cycles NNS N
and CC N
13 CD N
received VBD N
aflibercept JJ i
4 CD N
mg/kg NN N
upfront NN N
. . N

The DT N
median JJ o
number NN o
of IN o
aflibercept JJ o
cycles NNS o
was VBD N
16 CD N
( ( N
range VB N
1-44 CD N
) ) N
, , N
12 CD N
patients NNS N
received VBD N
?20 JJ N
cycles NNS N
. . N

Most JJS N
frequent JJ N
grade NN N
3/4 CD N
adverse JJ N
events NNS N
were VBD o
neutropenia RB o
( ( o
37 CD o
% NN o
) ) o
, , o
fatigue NN o
( ( o
33 CD N
% NN N
) ) N
and CC o
hypertension NN o
( ( o
30 CD N
% NN N
) ) N
. . N

No DT N
anti-aflibercept JJ N
antibodies NNS N
were VBD N
detected VBN p
. . p

Four CD p
patients NNS p
achieved VBN p
partial JJ p
responses NNS p
and CC p
17 CD N
had VBD N
stable JJ N
disease NN N
, , N
lasting VBG N
> JJ N
3 CD N
months NNS N
in IN N
14 CD N
patients NNS o
. . o

Plasma NNP o
levels NNS o
of IN o
free JJ o
over IN o
vascular JJ o
endothelial JJ o
growth NN o
factor-bound JJ o
aflibercept NN o
were VBD o
adequate JJ N
, , N
with IN N
steady-state JJ N
achieved VBN N
from IN N
cycle-3 NN N
. . N

Exploratory JJ N
DCE-MRI NNP N
showed VBD N
no DT N
significant JJ N
perfusion NN N
changes NNS N
with IN N
aflibercept NN N
. . N

CONCLUSION NNP i
Aflibercept IN i
4 CD i
mg/kg JJ N
plus CC i
irinotecan-LV5FU2 JJ i
every DT i
2 CD N
weeks NNS N
had VBD N
acceptable JJ N
toxicity NN N
and CC N
pharmacokinetics NNS N
, , N
and CC N
showed VBD N
promising JJ N
antitumour JJ N
activity NN N
. . N

-DOCSTART- -19545929- O O

Gemcitabine NNP i
combined VBN i
with IN i
either DT i
pemetrexed NN i
or CC i
paclitaxel NN i
in IN i
the DT N
treatment NN N
of IN N
advanced JJ p
non-small JJ p
cell NN p
lung NN p
cancer NN p
: : p
a DT N
randomized JJ N
phase NN N
II NNP N
SICOG NNP N
trial NN N
. . N

PURPOSE NNP N
To TO N
estimate VB N
the DT N
safety NN o
, , o
activity NN o
, , o
and CC o
impact NN o
on IN o
quality NN o
of IN o
life NN o
of IN N
a DT N
combination NN i
of IN i
gemcitabine NN i
and CC i
pemetrexed NN i
in IN N
patients NNS p
with IN p
locally RB p
advanced JJ p
or CC p
metastatic JJ p
non-small JJ p
cell NN p
lung NN p
cancer NN p
( ( p
NSCLC NNP p
) ) p
in IN N
the DT N
context NN N
of IN N
a DT N
randomized JJ N
two-stage NN N
phase NN N
II NNP N
study NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNPS p
in IN p
stage NN p
IIIB NNP p
or CC p
IV NNP p
NSCLC NNP p
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
either DT i
gemcitabine NN i
1250 CD N
mg/m NN N
( ( N
2 CD N
) ) N
on IN N
day NN N
1 CD N
, , N
and CC i
pemetrexed NN i
( ( N
Alimta NNP N
) ) N
500 CD N
mg/m NN N
( ( N
2 CD N
) ) N
followed VBN i
by IN i
gemcitabine NN i
1250 CD N
mg/m NN N
( ( N
2 CD N
) ) N
on IN N
day NN N
8 CD N
of IN N
a DT N
3-weekly JJ N
cycle NN N
( ( i
GA NNP i
arm NN N
) ) N
, , N
or CC N
paclitaxel VB i
120 CD N
mg/m NN N
( ( N
2 CD N
) ) N
followed VBN i
by IN i
gemcitabine NN i
1000 CD N
mg/m NN N
( ( N
2 CD N
) ) N
, , N
both DT N
given VBN N
on IN N
days NNS N
1 CD N
and CC N
8 CD N
of IN N
a DT N
3-weekly JJ N
cycle NN N
( ( i
PG NNP i
arm NN N
) ) N
. . N

RESULTS $ N
105 CD p
( ( p
GA NNP p
arm NN p
, , p
51 CD p
; : p
PG NNP p
arm NN p
, , p
54 CD p
) ) p
eligible JJ p
patients NNS p
( ( p
stage NN p
IV NNP p
, , p
32 CD p
and CC p
30 CD p
, , p
respectively RB p
) ) p
were VBD N
enrolled VBN N
into IN N
this DT N
study NN N
; : N
thereafter RB N
, , N
accrual JJ N
was VBD N
stopped VBN N
due JJ N
to TO N
first-stage JJ N
analysis NN N
. . N

The DT N
response NN o
rate NN o
was VBD N
20 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
10-33 CD N
% NN N
) ) N
in IN N
the DT N
GA NNP N
arm NN N
, , N
and CC N
32 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
20-46 CD N
% NN N
) ) N
in IN N
the DT N
PG NNP N
arm NN N
. . N

Median JJ o
progression-free JJ o
survival NN o
was VBD N
5.1 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
3.7-6.5 JJ N
) ) N
months NNS N
in IN N
the DT N
GA NNP N
arm NN N
, , N
and CC N
8.3 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
5.9-10.7 JJ N
) ) N
months NNS N
in IN N
the DT N
PG NNP N
arm NN N
, , N
while IN N
median JJ o
overall JJ o
survival NN o
was VBD N
10.5 CD N
( ( N
95 CD N
% NN N
CI NNP N
7.1-13.9 CD N
) ) N
, , N
and CC N
13.3 CD N
( ( N
95 CD N
% NN N
CI NNP N
11.7-14.9 CD N
) ) N
months NNS N
, , N
respectively RB N
. . N

Severe NNP o
neutropenia NN o
( ( N
36 CD N
% NN N
vs JJ N
22 CD N
% NN N
) ) N
, , N
and CC N
febrile JJ o
neutropenia NN o
( ( N
14 CD N
% NN N
vs JJ N
7 CD N
% NN N
) ) N
were VBD N
more RBR N
common JJ N
with IN N
the DT N
GA NNP N
regimen NNS N
, , N
while IN N
hair JJ o
loss NN o
( ( N
52 CD N
% NN N
vs JJ N
16 CD N
% NN N
) ) N
and CC N
any DT o
grade JJ o
peripheral JJ o
neuropathy NN o
( ( N
31 CD N
% NN N
vs JJ N
2 CD N
% NN N
) ) N
occurred VBD N
more RBR N
frequently RB N
with IN N
PG NNP i
regimen NNS i
. . i

Other JJ N
severe JJ o
side NN o
effects NNS o
of IN N
GA NNP i
regimen NNS i
were VBD N
diarrhoea JJ o
( ( N
10 CD N
% NN N
) ) N
, , N
liver RB o
enzyme JJ o
derangement NN o
( ( N
10 CD N
% NN N
) ) N
, , N
and CC N
fatigue NN o
( ( N
8 CD N
% NN N
) ) N
. . N

CONCLUSION VB N
The DT N
GA NNP N
regimen NN N
was VBD N
tolerated VBN o
and CC o
moderately RB o
active JJ o
in IN N
advanced JJ N
or CC N
metastatic JJ N
NSCLC NNP N
. . N

However RB N
, , N
this DT N
combination NN N
did VBD N
not RB N
yield VB N
any DT N
advantage NN N
in IN N
comparison NN N
with IN N
the DT N
PG NNP N
regimen NNS N
, , N
and CC N
does VBZ N
not RB N
deserve VB N
further JJ N
evaluation NN N
. . N

-DOCSTART- -17623816- O O

The DT N
peroxisome JJ N
proliferator-activated JJ N
receptor-gamma JJ N
agonist NN N
pioglitazone NN i
increases VBZ N
number NN o
and CC o
function NN o
of IN o
endothelial JJ o
progenitor NN o
cells NNS o
in IN N
patients NNS p
with IN p
coronary JJ p
artery NN p
disease NN p
and CC p
normal JJ p
glucose JJ p
tolerance NN p
. . p

OBJECTIVE CC N
Peroxisome JJ N
proliferator-activated JJ N
receptor-gamma NN N
( ( N
PPAR NNP N
gamma NN N
) ) N
agonists VBZ N
( ( i
thiazolidinediones NNS i
[ NNP i
TZDs NNP i
] NNP i
) ) i
are VBP N
used VBN N
for IN N
the DT N
treatment NN N
of IN N
diabetes NNS N
. . N

Bone CD N
marrow-derived JJ N
endothelial JJ N
progenitor NN N
cells NNS N
( ( N
EPCs NNP N
) ) N
improve VB N
vascular JJ o
function NN o
and CC N
predict NN N
cardiovascular NN o
risk NN o
. . o

The DT N
effect NN N
of IN N
pioglitazone NN i
therapy NN N
on IN N
EPCs NNP N
was VBD N
examined VBN N
. . N

RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
AND NNP N
RESULTS NNP N
We PRP N
performed VBD N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
study NN N
on IN N
patients NNS p
with IN p
documented JJ p
stable JJ p
coronary JJ p
artery NN p
disease NN p
and CC p
normal JJ p
glucose JJ p
tolerance NN p
. . p

Of IN N
54 CD p
patients NNS p
with IN p
normal JJ p
fasting VBG p
glucose JJ p
levels NNS p
, , p
18 CD p
showed VBD p
impaired JJ p
glucose JJ p
tolerance NN p
and CC p
36 CD p
patients NNS p
with IN p
normal JJ p
glucose JJ p
tolerance NN p
were VBD p
randomized VBN p
to TO N
30-day JJ N
treatment NN N
with IN N
pioglitazone NN i
( ( N
45 CD N
mg NN N
) ) N
or CC i
placebo NN i
in IN i
addition NN i
to TO i
optimal VB i
medical JJ i
therapy NN i
. . i

All DT N
patients NNS N
in IN N
the DT N
TZD NNP i
group NN N
showed VBD N
an DT N
increase NN N
of IN N
adiponectin JJ o
levels NNS o
as IN N
an DT N
indicator NN N
of IN N
compliance NN N
( ( N
11.4 CD N
+/- JJ N
1.1 CD N
to TO N
36.8 CD N
+/- JJ N
2.1 CD N
microg/ml NN N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

TZD NNP i
, , N
but CC N
not RB N
placebo VB i
, , N
decreased VBN N
mean JJ o
high-sensitivity NN o
C-reactive JJ o
protein NN o
to TO N
43 CD N
+/- JJ N
19 CD N
% NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Pioglitazone NN N
increased VBD N
CD34 NNP o
( ( o
+ NNP o
) ) o
/kinase NN o
insert JJ o
domain NN o
receptor NN o
( ( o
+ NNP o
) ) o
EPCs NNP o
to TO N
142 CD N
+/- JJ N
9 CD N
% NN N
and CC N
cultured VBD o
1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine-labeled JJ o
acetylated JJ o
LDL NNP o
( ( o
+ NNP o
) ) o
/lectin NN o
( ( o
+ NNP o
) ) o
EPCs NNP o
to TO N
180 CD N
+/- JJ N
3 CD N
% NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

EPC JJ o
numbers NNS o
were VBD N
not RB N
changed VBN N
in IN N
the DT N
placebo NN N
group NN N
. . N

TZD NNP N
increased VBD N
the DT N
SDF-1-induced NNP o
migratory NN o
capacity NN o
to TO N
146 CD N
+/- JJ N
9 CD N
% NN N
per IN N
EPC NNP N
number NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
upregulated VBD N
the DT N
clonogenic JJ o
potential NN o
of IN o
EPCs NNP o
, , N
increasing VBG N
the DT o
colony-forming JJ o
units NNS o
to TO N
172 CD N
+/- JJ N
12 CD N
% NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

In IN N
cultured JJ N
human JJ N
EPCs NNP N
, , N
TZD NNP i
increased VBD N
EPC NNP o
numbers NNS o
and CC o
migration NN o
and CC o
reduced JJ o
NADPH-oxidase NNP o
activity NN o
. . o

The DT N
TZD NNP i
effect NN N
was VBD N
reversed VBN N
by IN N
the DT N
PPAR NNP N
gamma NN N
antagonist NN N
GW9662 NNP N
and CC N
mimicked VBN N
by IN N
treatment NN N
with IN N
adiponectin NN N
. . N

CONCLUSIONS VB N
The DT N
PPAR NNP N
gamma NN N
agonist NN N
pioglitazone NN i
increases VBZ N
the DT N
number NN o
and CC o
function NN o
of IN o
EPCs NNP o
in IN N
patients NNS p
with IN p
coronary JJ p
artery NN p
disease NN p
. . p

The DT N
effect NN N
represents VBZ N
a DT N
potential JJ N
regenerative NN N
mechanism NN N
in IN N
atherosclerosis NN N
and CC N
is VBZ N
observed VBN N
in IN N
normoglycemic JJ p
individuals NNS p
with IN p
stable JJ p
coronary JJ p
artery NN p
disease NN p
. . p

-DOCSTART- -22906113- O O

Emotion NNP i
regulation NN i
strategies NNS i
that WDT N
promote VBP N
learning NN N
: : N
reappraisal NN N
enhances VBZ N
children NNS o
's POS o
memory NN o
for IN o
educational JJ o
information NN o
. . o

The DT N
link NN N
between IN N
emotion NN i
regulation NN i
and CC N
academic JJ o
achievement NN o
is VBZ N
well RB N
documented VBN N
. . N

Less NNP N
is VBZ N
known VBN N
about IN N
specific JJ N
emotion NN i
regulation NN i
strategies NNS N
that WDT N
promote VBP N
learning VBG N
. . N

Six- JJ p
to TO p
13-year-olds NNS p
( ( p
N NNP p
= NNP p
126 CD p
) ) p
viewed VBD i
a DT i
sad JJ i
film NN i
and CC i
were VBD i
instructed VBN i
to TO i
reappraise VB i
the DT i
importance NN i
, , i
reappraise VB i
the DT i
outcome NN i
, , i
or CC i
ruminate VB i
about IN i
the DT i
sad JJ i
events NNS i
; : i
another DT i
group NN i
received VBD i
no DT i
regulation NN i
instructions NNS i
. . i

Children NNP p
viewed VBD N
an DT N
educational JJ i
film NN i
, , N
and CC N
memory NN N
for IN N
this DT N
was VBD N
later RB N
assessed VBN N
. . N

As IN N
predicted JJ N
, , N
reappraisal JJ N
strategies NNS N
more RBR N
effectively RB N
attenuated JJ N
children NNS o
's POS o
self-reported JJ o
emotional JJ o
processing NN o
. . o

Reappraisal NNP N
enhanced VBD N
memory NN o
for IN o
educational JJ o
details NNS o
relative VBP N
to TO N
no DT N
instructions NNS N
. . N

Rumination NN N
did VBD N
not RB N
lead VB N
to TO N
differences NNS N
in IN N
memory NN o
from IN N
the DT N
other JJ N
instructions NNS N
. . N

Memory NNP o
benefits NNS o
of IN N
effective JJ N
instructions NNS N
were VBD N
pronounced VBN o
for IN N
children NNS p
with IN N
poorer JJR o
emotion NN o
regulation NN o
skill NN o
, , N
suggesting VBG N
the DT N
utility NN N
of IN N
reappraisal NN N
in IN N
learning VBG N
contexts NN N
. . N

-DOCSTART- -3608343- O O

Circadian JJ N
changes NNS N
in IN N
the DT N
pharmacokinetics NNS o
of IN N
oral JJ p
ketoprofen NN i
. . i

Several JJ N
investigations NNS N
which WDT N
have VBP N
taken VBN N
treatment NN N
time NN N
into IN N
account NN N
have VBP N
shown VBN N
that IN N
the DT N
pharmacokinetic JJ N
parameters NNS N
, , N
the DT N
therapeutic JJ o
efficacy NN o
and CC N
even RB N
the DT N
toxicity NN o
of IN N
a DT N
large JJ N
number NN N
of IN N
products NNS N
may MD N
vary VB N
according VBG N
to TO N
the DT N
administration NN N
schedule NN N
. . N

The DT N
present JJ N
study NN N
was VBD N
carried VBN N
out RP N
in IN N
order NN N
to TO N
evaluate VB N
any DT N
circadian JJ N
changes NNS N
in IN N
pharmacokinetic JJ N
parameters NNS N
of IN N
ketoprofen NN i
, , N
a DT N
new JJ N
non-steroidal JJ N
anti-inflammatory JJ N
drug NN N
( ( N
NSAID NNP N
) ) N
. . N

This DT N
randomised VBD N
crossover NN N
study NN N
consisted VBD N
of IN N
a DT N
single JJ N
oral JJ N
dose NN N
of IN N
ketoprofen $ i
100mg CD N
administered VBN N
to TO N
8 CD p
healthy JJ p
male NN p
volunteers NNS p
, , p
mean JJ p
age NN p
27.2 CD p
years NNS p
, , N
at IN N
07.00 CD N
hours NNS N
, , N
13.00 CD N
hours NNS N
, , N
19.00 CD N
hours NNS N
or CC N
01.00 CD N
hours NNS N
in IN N
4 CD N
study NN N
periods NNS N
during IN N
the DT N
first JJ N
3 CD N
months NNS N
of IN N
the DT N
year NN N
. . N

The DT N
order NN N
of IN N
administration NN N
was VBD N
randomised VBN N
, , N
with IN N
each DT N
subject NN N
acting VBG N
as IN N
his PRP$ N
own JJ N
control NN N
. . N

A DT N
total NN N
of IN N
14 CD p
blood NN p
and CC p
4 CD p
urine JJ p
samples NNS p
were VBD N
taken VBN N
over RP N
a DT N
12-hour JJ N
period NN N
. . N

The DT N
peak JJ o
plasma NN o
concentration NN o
was VBD N
twice RB N
as RB N
high JJ N
after IN N
drug NN N
administration NN N
at IN N
07.00 CD N
hours NNS N
( ( N
13.4 CD N
+/- JJ N
1 CD N
mg/L NN N
) ) N
than IN N
after IN N
other JJ N
administration NN N
times NNS N
( ( N
13.00 CD N
hours NNS N
: : N
6.9 CD N
+/- JJ N
1 CD N
; : N
19.00 CD N
hours NNS N
: : N
7.2 CD N
+/- JJ N
0.7 CD N
; : N
01.00 CD N
hours NNS N
: : N
6.3 CD N
+/- JJ N
0.5 CD N
mg/L NN N
) ) N
[ VBZ N
p NN N
less JJR N
than IN N
0.001 CD N
] NN N
. . N

The DT N
time NN o
to TO o
reach VB o
peak JJ o
concentration NN o
was VBD N
much RB N
longer JJR N
after IN N
drug NN N
administration NN N
at IN N
01.00 CD N
hours NNS N
( ( N
135 CD N
+/- JJ N
16.7 CD N
min NN N
) ) N
than IN N
at IN N
07.00 CD N
( ( N
73.1 CD N
+/- JJ N
14.1 CD N
min NN N
) ) N
, , N
13.00 CD N
( ( N
75 CD N
+/- JJ N
16.5 CD N
min NN N
) ) N
or CC N
19.00 CD N
hours NNS N
( ( N
82.5 CD N
+/- JJ N
12.7 CD N
min NN N
) ) N
[ VBZ N
p NN N
less JJR N
than IN N
0.05 CD N
] NN N
. . N

The DT N
lag NN o
time NN o
was VBD N
significantly RB N
longer JJR N
at IN N
01.00 CD N
hours NNS N
than IN N
at IN N
13.00 CD N
hours NNS N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

The DT N
absorption NN o
rate NN o
constant JJ N
after IN N
treatment NN N
at IN N
01.00 CD N
hours NNS N
was VBD N
less JJR N
than IN N
at IN N
the DT N
other JJ N
times NNS N
of IN N
administration NN N
( ( N
p IN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

The DT N
bodyweight-corrected JJ o
area NN o
under IN o
the DT o
curve NN o
( ( o
AUC0-12 NNP o
) ) o
was VBD N
greater JJR N
after IN N
07.00 CD N
hours NNS N
than IN N
after IN N
13.00 CD N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
or CC N
19.00 CD N
hours NNS N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
and CC N
greater JJR N
after IN N
01.00 CD N
hours NNS N
than IN N
after IN N
13.00 CD N
hours NNS N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

The DT N
elimination NN o
half-life NN o
was VBD N
significantly RB N
longer RBR N
after IN N
administration NN N
at IN N
01.00 CD N
hours NNS N
than IN N
after IN N
19.00 CD N
hours NNS N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
, , N
while IN N
the DT N
total JJ o
clearance NN o
was VBD N
lowest VBN N
at IN N
07.00 CD N
hours NNS N
. . N

Cosinor NNP N
analysis NN N
demonstrated VBD N
statistically RB N
significant JJ N
circadian JJ o
rhythms NN o
for IN N
all DT N
pharmacokinetic JJ N
parameters NNS N
described VBN N
above IN N
. . N

The DT N
amount NN N
of IN N
ketoprofen NN i
eliminated VBN N
in IN N
the DT N
urine NN N
was VBD N
delayed VBN N
, , N
and CC N
was VBD N
significantly RB N
greater JJR N
after IN N
the DT N
administration NN N
at IN N
01.00 CD N
hours NNS N
than IN N
07.00 CD N
hours NNS N
or CC N
19.00 CD N
hours NNS N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

The DT N
relationship NN N
between IN N
absorption NN N
, , N
diffusion NN N
and/or NN N
elimination NN N
mechanisms NNS N
of IN N
the DT N
drug NN N
are VBP N
discussed VBN N
. . N

-DOCSTART- -22092941- O O

Maintaining VBG N
tissue NN N
orientation NN N
during IN N
mohs JJ i
micrographic JJ i
surgery NN i
: : i
scalpel NN i
versus NN i
marker NN i
. . i

BACKGROUND NNP N
Critical NNP N
to TO N
the DT N
accuracy NN N
of IN N
Mohs NNP i
surgery NN i
is VBZ N
the DT N
ability NN N
to TO N
maintain VB N
proper JJ N
orientation NN N
of IN N
excised JJ N
tissue NN N
with IN N
respect NN N
to TO N
the DT N
surrounding VBG N
skin NN N
. . N

Several JJ N
techniques NNS N
have VBP N
been VBN N
described VBN N
for IN N
maintaining VBG N
this DT N
orientation NN N
, , N
although IN N
no DT N
prior JJ N
investigations NNS N
directly RB N
compare VBP N
these DT N
techniques NNS N
. . N

OBJECTIVE NNP N
To TO N
compare VB N
the DT N
incidence NN N
of IN N
tissue NN N
orientation NN N
loss NN N
resulting VBG N
from IN N
inability NN N
to TO N
identify VB N
skin JJ N
score NN N
marks NNS N
with IN N
that DT N
occurring VBG N
from IN N
failure NN N
to TO N
identify VB N
marks NNS N
made VBN N
using VBG N
a DT N
gentian JJ i
violet NN i
marker NN i
during IN N
Mohs NNP i
micrographic JJ i
surgery NN i
( ( i
MMS NNP i
) ) i
. . i

We PRP N
also RB N
sought VBD N
to TO N
determine VB N
the DT N
incidence NN N
of IN N
scars NNS N
resulting VBG N
from IN N
skin NN N
scoring NN N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Patients NNP p
undergoing VBG p
MMS NNP i
were VBD N
prospectively RB N
randomized VBN N
to TO N
have VB N
their PRP$ N
tissue NN i
margins NNS i
oriented VBN i
using VBG i
light JJ i
scoring VBG i
using VBG i
a DT i
scalpel JJ i
versus NN i
marking VBG i
them PRP i
using VBG i
a DT i
gentian JJ i
violet NN i
marker NN i
. . i

Incidence NN N
of IN N
scoring VBG N
scars NNS N
and CC N
tissue NN N
orientation NN N
loss NN N
were VBD N
the DT N
primary JJ N
outcome NN N
measures NNS N
. . N

RESULTS NNP N
Data NNP p
were VBD p
analyzed VBN p
for IN p
101 CD p
tumors NNS p
. . p

There EX N
were VBD N
no DT N
instances NNS N
of IN N
tissue NN o
orientation NN o
loss NN o
in IN N
the DT N
scalpel NN N
or CC N
marker NN N
arms NNS N
, , N
nor CC N
were VBD N
there EX N
any DT N
visible JJ o
score NN o
mark NN o
scars NNS o
at IN N
follow-up NN N
. . N

CONCLUSION NNP N
Incidence NNP N
of IN N
excessive JJ o
scars NNS o
resulting VBG N
from IN N
lightly RB N
scored VBN N
tissue NN N
or CC N
loss NN N
of IN N
tissue NN N
orientation NN N
caused VBN N
by IN N
lost VBN N
gentian JJ N
violet NN N
markings NNS N
appears VBZ N
to TO N
be VB N
low JJ N
. . N

Both DT N
methods NNS N
worked VBN N
well RB N
within IN N
the DT N
confines NNS N
of IN N
this DT N
study NN N
. . N

-DOCSTART- -3382462- O O

Effect NN N
of IN N
nimodipine JJ i
upon IN N
electroencephalographic JJ o
vigilance NN o
in IN N
elderly JJ p
persons NNS p
with IN p
minor JJ p
impairment NN p
of IN p
brain NN p
functions NNS p
. . p

10 CD p
volunteers NNS p
( ( p
61-78 CD p
years NNS p
) ) p
with IN p
minor JJ p
impairment NN p
of IN p
brain NN p
function NN p
were VBD N
given VBN N
placebo NNS i
, , N
40 CD N
mg NN N
and CC N
60 CD N
mg NNS N
nimodipine JJ i
( ( i
Nimotop NNP i
) ) i
in IN N
single JJ N
doses NNS N
with IN N
intervals NNS N
of IN N
3 CD N
medication-free JJ N
days NNS N
between IN N
medications NNS N
under IN N
double-blind JJ N
conditions NNS N
. . N

Consecutive JJ N
2-s JJ N
epochs NN N
of IN N
a DT N
10-min JJ i
EEG NN i
record NN N
( ( N
resting VBG N
conditions NNS N
) ) N
of IN N
F3/C3-F4/C4-P3/01-P4/02 NNP N
were VBD N
subjected VBN N
to TO N
FFT NNP N
( ( N
Fast NNP N
Fourier NNP N
Transform NNP N
) ) N
. . N

Using VBG N
the DT N
information NN N
given VBN N
by IN N
the DT N
4 CD N
leads NNS N
for IN N
each DT N
minute NN N
of IN N
recording VBG N
the DT N
number NN o
of IN o
epochs NN o
which WDT N
correspond NN N
to TO N
a DT N
stage NN N
A DT N
or CC N
non-A JJ N
were VBD N
determined VBN N
. . N

In IN N
order NN N
to TO N
evaluate VB N
subtle JJ N
effects NNS N
on IN N
electroencephalographic JJ N
vigilance NN N
within IN N
stage NN N
A NNP N
, , N
also RB N
the DT N
anterior-posterior JJ o
and CC o
left-right JJ o
relations NNS o
of IN o
absolute JJ o
alpha-power NN o
were VBD N
calculated VBN N
. . N

Since IN N
previous JJ N
findings NNS N
suggested VBD N
that IN N
a DT N
nimodipine JJ N
effect NN N
can MD N
only RB N
be VB N
demonstrated VBN N
when WRB N
individual JJ N
differences NNS N
in IN N
the DT N
baseline-EEG NN o
are VBP N
considered VBN N
, , N
the DT N
subjects NNS N
were VBD N
subdivided VBN N
in IN N
equal JJ N
subgroups NNS N
according VBG N
to TO N
the DT N
number NN N
of IN N
non-A JJ N
epochs NN N
under IN N
placebo NN N
. . N

The DT N
rationale NN N
for IN N
this DT N
is VBZ N
the DT N
finding NN N
that IN N
in IN N
geriatric JJ p
patients NNS p
two CD N
electroencephalographically RB N
distinguishable JJ N
forms NNS o
of IN N
dissolution NN N
can MD N
be VB N
observed VBN N
. . N

Under IN N
both DT N
40 CD N
mg NN N
and CC N
60 CD N
mg NNS N
nimodipine VBP i
the DT N
subgroup NN N
with IN N
a DT N
prevalence NN N
of IN N
non-A JJ o
epochs NN o
( ( N
poor JJ N
alpha-activity NN o
) ) o
showed VBD N
a DT N
decrease NN N
of IN N
non-A JJ o
epochs NN o
; : o
the DT N
subgroup NN N
with IN N
a DT N
prevalence NN o
of IN o
A-epochs NNP o
( ( o
abundant JJ o
alpha-activity NN o
) ) o
, , N
an DT N
increase NN N
. . N

Opposite JJ N
results NNS N
for IN N
the DT N
two CD N
subgroups NNS N
were VBD N
also RB N
obtained VBN N
for IN N
the DT N
left-right JJ o
relations NNS o
of IN o
alpha-power NN o
over IN N
the DT N
anterior JJ N
regions NNS N
. . N

Under IN N
40 CD N
mg NNS N
nimodipine VBP i
the DT N
subgroup NN N
with IN N
poor JJ N
alpha-activity NN o
showed VBD N
a DT N
shift NN o
to TO o
the DT o
left NN o
; : o
the DT N
subgroup NN N
with IN N
abundant JJ N
alpha-activity NN o
to TO o
the DT o
right NN o
. . o

Under IN N
60 CD N
mg NN N
nimodipine JJ i
both DT N
subgroups NNS N
showed VBD N
a DT N
shift NN o
to TO o
the DT o
left NN o
. . o

The DT N
results NNS N
confirm VBP N
findings NNS N
that WDT N
nimodipine VBP N
stabilizes VBZ N
electroencephalographic JJ o
vigilance NN o
at IN N
a DT N
medium NN N
level NN N
. . N

Moreover RB N
they PRP N
suggest VBP N
a DT N
dose JJ N
dependence NN N
of IN N
the DT N
effect NN N
, , N
i.e. FW N
, , N
at IN N
higher JJR N
doses NNS N
nimodipine VBP i
seems VBZ N
to TO N
act VB N
as IN N
a DT N
sedative NN N
. . N

-DOCSTART- -15975721- O O

Removal NN N
of IN N
inflammatory JJ N
cytokines NNS N
and CC N
endotoxin NN N
by IN N
veno-venous JJ i
continuous JJ i
renal JJ i
replacement NN i
therapy NN i
for IN N
burned JJ p
patients NNS p
with IN p
sepsis NN p
. . p

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
veno-venous JJ i
continuous JJ i
renal JJ i
replacement NN i
therapy NN i
( ( i
CRRT NNP i
) ) i
on IN N
the DT N
plasma NN N
levels NNS N
of IN N
endotoxin NN N
and CC N
cytokines NNS N
in IN N
severely RB p
burned VBN p
patients NNS p
with IN p
sepsis NN p
. . p

METHODS NNP N
Twenty NNP p
adult NN p
severely RB p
burned VBD p
patients NNS p
with IN p
sepsis NN p
were VBD p
studied VBN p
. . p

For IN N
the DT N
diagnosis NN N
of IN N
sepsis NN N
, , N
patients NNS N
were VBD N
randomly RB N
divided VBN N
into IN N
CRRT NNP i
( ( N
n=10 NN N
) ) N
and CC N
Control NNP i
( ( N
n=10 RB N
) ) N
. . N

Both DT N
groups NNS N
received VBD N
conventional JJ i
therapy NN i
after IN N
admission NN N
. . N

Veno-venous JJ i
CRRT NNP i
was VBD N
administered VBN N
to TO N
10 CD N
patients NNS N
in IN N
the DT N
CRRT NNP N
group NN N
whenever WDT N
patients NNS N
were VBD N
determined VBN N
to TO N
be VB N
septic JJ N
. . N

The DT N
plasma JJ N
level NN N
of IN N
endotoxin NN N
, , N
TNF-alpha NNP N
, , N
IL-1 NNP N
beta NN N
, , N
IL-6 NNP N
and CC N
IL-8 NNP N
were VBD N
measured VBN N
at IN N
0 CD N
, , N
1 CD N
, , N
2 CD N
, , N
6 CD N
, , N
12 CD N
, , N
36 CD N
and CC N
60 CD N
h NN N
after IN N
CRRT NNP N
initiation NN N
, , N
and CC N
at IN N
0 CD N
, , N
12 CD N
, , N
36 CD N
and CC N
60 CD N
h NN N
after IN N
the DT N
patients NNS N
were VBD N
diagnosed VBN N
as IN N
having VBG N
sepsis NN N
in IN N
the DT N
Control NNP N
group NN N
. . N

MAIN NNP N
RESULTS NNP N
Plasma NNP o
level NN o
of IN o
endotoxin NN o
and CC o
all PDT o
the DT o
cytokines NNS o
after IN o
CRRT NNP o
initiation NN o
were VBD N
significantly RB N
lower JJR N
than IN N
those DT N
before IN N
the DT N
treatment NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
serial JJ o
change NN o
of IN o
endotoxin NN o
, , o
IL-1 NNP o
beta NN o
, , o
IL-6 NNP o
and CC o
IL-8 NNP o
was VBD N
significantly RB N
lower JJR N
at IN N
12 CD N
, , N
36 CD N
and CC N
60 CD N
h NN N
after IN N
treatment NN N
compared VBN N
with IN N
Control NNP N
groups NNS N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

A DT N
significant JJ N
decrease NN N
in IN N
plasma JJ o
TNF-alpha JJ o
levels NNS o
was VBD N
seen VBN N
at IN N
36 CD N
and CC N
60 CD N
h NN N
after IN N
treatment NN N
compared VBN N
with IN N
Control NNP N
groups NNS N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSION NNP N
Plasma NNP N
endotoxin NN N
and CC N
cytokines NNS N
( ( N
TNF-alpha NNP N
, , N
IL-1 NNP N
beta NN N
, , N
IL-6 NNP N
and CC N
IL-8 NNP N
) ) N
can MD N
be VB N
removed VBN N
effectively RB N
with IN N
CRRT NNP i
in IN N
severely RB N
burned VBN N
patients NNS N
with IN N
sepsis NN N
. . N

-DOCSTART- -10094243- O O

Epinephrine-induced JJ N
panic NN N
attacks NNS N
and CC N
hyperventilation NN N
. . N

To TO N
assess VB N
the DT N
effects NNS N
of IN N
epinephrine NN i
on IN N
ventilation NN N
in IN N
patients NNS p
with IN p
panic JJ p
disorder NN p
and CC p
in IN p
social JJ p
phobics NNS p
, , N
analyses NNS N
were VBD N
performed VBN N
on IN N
pooled VBN N
data NNS N
from IN N
two CD N
previous JJ N
infusion NN N
studies NNS N
. . N

Throughout IN N
the DT N
infusion NN N
, , N
changes NNS o
in IN o
transcutaneous JJ o
PCO2 NNP o
( ( o
tcPCO2 NN o
) ) o
, , o
subjective JJ o
anxiety NN o
, , o
heart NN o
rate NN o
and CC o
blood NN o
pressure NN o
were VBD N
recorded VBN N
continuously RB N
. . N

Twenty-nine JJ p
patients NNS p
received VBD p
epinephrine JJ i
, , p
ten JJ p
patients NNS p
received VBD p
placebo NN i
. . i

Thirteen JJ N
patients NNS N
( ( N
45 CD N
% NN N
) ) N
had VBD N
a DT N
panic JJ N
attack NN N
during IN N
epinephrine NN i
. . i

The DT N
fall NN o
in IN o
tcPCO2 NN o
and CC o
the DT o
cardiovascular JJ o
response NN o
was VBD N
greater JJR N
in IN N
panicking VBG N
patients NNS N
than IN N
patients NNS N
who WP N
did VBD N
not RB N
panic JJ N
. . N

Although IN N
the DT N
fall NN N
in IN N
tcPCO2 NN o
associated VBN N
with IN N
panic NN N
was VBD N
not RB N
substantial JJ N
and CC N
did VBD N
not RB N
indicate VB N
clinically RB N
significant JJ N
acute JJ o
hyperventilation NN o
, , N
it PRP N
appears VBZ N
to TO N
be VB N
a DT N
sensitive JJ N
index NN N
for IN N
epinephrine-induced JJ N
panic NN N
. . N

The DT N
fall NN o
in IN o
tcPCO2 NN o
was VBD N
predicted VBN N
rather RB N
by IN N
the DT N
frequency NN N
of IN N
occurrence NN o
of IN o
anxiety-related JJ o
somatic NN o
symptoms NNS o
than IN N
by IN N
the DT N
fear NN N
of IN N
these DT N
symptoms NNS N
. . N

These DT N
findings NNS N
further RB N
reduce VB N
a DT N
role NN N
for IN N
fear NN N
of IN N
bodily JJ N
sensations NNS N
in IN N
epinephrine-induced JJ i
panic NN N
attacks NNS N
and CC N
favor VBP N
a DT N
biological JJ N
sensitivity NN N
to TO N
sympathetic JJ N
stimulation NN N
. . N

-DOCSTART- -24229362- O O

Study NNP N
protocol NN N
: : N
Rehabilitation NN i
including VBG i
Social NNP i
and CC i
Physical NNP i
activity NN i
and CC i
Education NN i
in IN N
Children NNP p
and CC p
Teenagers NNP p
with IN p
Cancer NNP p
( ( N
RESPECT NNP N
) ) N
. . N

BACKGROUND NNP N
During IN N
cancer NN N
treatment NN N
children NNS p
have VBP p
reduced VBN p
contact NN p
with IN p
their PRP$ p
social JJ p
network NN p
of IN p
friends NNS p
, , p
and CC p
have VBP p
limited VBN p
participation NN p
in IN p
education NN p
, , p
sports NNS p
, , p
and CC p
leisure NN p
activities NNS p
. . p

During IN N
and CC N
following VBG N
cancer NN N
treatment NN N
, , N
children NNS p
describe VBP N
school NN N
related VBN N
problems NNS N
, , N
reduced VBD N
physical JJ N
fitness NN N
, , N
and CC N
problems NNS N
related VBN N
to TO N
interaction NN N
with IN N
peers NNS N
. . N

METHODS/DESIGN NNP N
The DT N
RESPECT NNP N
study NN N
is VBZ N
a DT N
nationwide JJ p
population-based JJ N
prospective NN N
, , N
controlled VBN N
, , N
mixed-methods NNS N
intervention NN N
study NN N
looking VBG N
at IN N
children NNS p
aged VBN p
6-18 CD p
years NNS p
newly RB p
diagnosed VBN p
with IN p
cancer NN p
in IN p
eastern JJ p
Denmark NNP p
( ( p
n=120 NN p
) ) p
and CC p
a DT p
matched JJ p
control NN p
group NN p
in IN p
western JJ p
Denmark NNP p
( ( p
n=120 NN p
) ) p
. . p

RESPECT NNP N
includes VBZ p
Danish-speaking NNP p
children NNS p
diagnosed VBD p
with IN p
cancer NN p
and CC p
treated VBN p
at IN p
pediatric JJ p
oncology NN p
units NNS p
in IN p
Denmark NNP p
. . p

Primary JJ N
endpoints NNS N
are VBP N
the DT N
level NN o
of IN o
educational JJ o
achievement NN o
one CD o
year NN o
after IN o
the DT o
cessation NN o
of IN o
first-line JJ o
cancer NN o
therapy NN o
, , o
and CC o
the DT o
value NN o
of IN o
VO2max NNP o
one CD o
year NN o
after IN o
the DT o
cessation NN o
of IN o
first-line JJ o
cancer NN o
therapy NN o
. . o

Secondary JJ N
endpoints NNS N
are VBP N
quality NN o
of IN o
life NN o
measured VBN o
by IN o
validated JJ o
questionnaires NNS o
and CC o
interviews NNS o
, , o
and CC o
physical JJ o
performance NN o
. . o

RESPECT NNP N
includes VBZ N
a DT N
multimodal JJ i
intervention NN i
program NN i
, , i
including VBG i
ambassador-facilitated JJ i
educational JJ i
, , i
physical JJ i
, , i
and CC i
social JJ i
interventions NNS i
. . i

The DT N
educational JJ i
intervention NN i
includes VBZ N
an DT N
educational JJ i
program NN i
aimed VBN N
at IN N
the DT N
child NN p
with IN p
cancer NN p
, , N
the DT N
child NN N
's POS N
schoolteachers NNS N
and CC N
classmates NNS N
, , N
and CC N
the DT N
child NN N
's POS N
parents NNS N
. . N

Children NNP p
with IN p
cancer NN p
will MD N
each DT N
have VB N
two CD N
ambassadors NNS N
assigned VBD N
from IN N
their PRP$ N
class NN N
. . N

The DT N
ambassadors NNS N
visit VBP i
the DT i
child NN i
with IN i
cancer NN i
at IN N
the DT N
hospital NN N
at IN N
alternating VBG N
2-week JJ N
intervals NNS N
and CC i
participate VB i
in IN i
the DT i
intervention NN i
program NN i
. . i

The DT N
physical JJ i
and CC i
social JJ i
intervention NN i
examines VBZ N
the DT N
effect NN N
of IN N
early JJ N
, , N
structured VBN N
, , N
individualized VBN N
, , N
and CC N
continuous JJ N
physical JJ N
activity NN N
from IN N
diagnosis NN N
throughout IN N
the DT N
treatment NN N
period NN N
. . N

The DT N
patients NNS p
are VBP N
tested VBN N
at IN N
diagnosis NN N
, , N
at IN N
3 CD N
and CC N
6 CD N
months NNS N
after IN N
diagnosis NN N
, , N
and CC N
one CD N
year NN N
after IN N
the DT N
cessation NN N
of IN N
treatment NN N
. . N

The DT N
study NN N
is VBZ N
powered VBN N
to TO N
quantify VB N
the DT N
impact NN N
of IN N
the DT N
combined JJ N
educational JJ i
, , i
physical JJ i
, , i
and CC i
social JJ i
intervention NN i
programs NNS i
. . i

DISCUSSION NNP N
RESPECT NNP N
is VBZ N
the DT N
first JJ N
population-based JJ N
study NN N
to TO N
examine VB N
the DT N
effect NN N
of IN N
early JJ N
rehabilitation NN N
for IN N
children NNS N
with IN N
cancer NN N
, , N
and CC N
to TO N
use VB N
healthy JJ N
classmates NNS i
as IN i
ambassadors NNS i
to TO N
facilitate VB N
the DT N
normalization NN N
of IN N
social JJ N
life NN N
in IN N
the DT N
hospital NN N
. . N

For IN N
children NNS p
with IN p
cancer NN p
, , N
RESPECT NNP N
contributes VBZ N
to TO N
expanding VBG N
knowledge NN N
on IN N
rehabilitation NN N
that WDT N
can MD N
also RB N
facilitate VB N
rehabilitation NN N
of IN N
other JJ N
children NNS N
undergoing VBG N
hospitalization NN N
for IN N
long-term JJ N
illness NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
Clinical NNP N
Trials.gov NNP N
: : N
file NN N
. . N

NCT01772849 NNP N
and CC N
NCT01772862 NNP N
. . N

-DOCSTART- -22392415- O O

A DT N
double-blind JJ N
placebo NN i
controlled VBD N
trial NN N
of IN N
Ginkgo NNP i
biloba NN i
added VBD N
to TO N
risperidone VB i
in IN N
patients NNS p
with IN p
autistic JJ p
disorders NNS p
. . p

Ginkgo NNP N
biloba NN N
has VBZ N
been VBN N
reported VBN N
to TO N
affect VB N
the DT N
neurotransmitter NN N
system NN N
and CC N
to TO N
have VB N
antioxidant JJ N
properties NNS N
that WDT N
could MD N
impact VB N
the DT N
pathogenesis NN N
of IN N
Autism NNP p
Spectrum NNP p
Disorder NNP p
. . p

Based VBN N
on IN N
these DT N
studies NNS N
, , N
we PRP N
decided VBD N
to TO N
assess VB N
the DT N
effectiveness NN N
of IN N
Ginkgo NNP i
biloba NN i
extract NN N
( ( N
Ginko NNP N
T.D. NNP N
, , N
Tolidaru NNP N
, , N
Iran NNP N
) ) N
as IN N
an DT N
adjunctive JJ N
agent NN N
to TO N
risperidone VB N
in IN N
the DT N
treatment NN N
of IN N
autism NN N
. . N

Forty-seven JJ p
outpatients NNS p
with IN p
a DT p
DSM-IV-TR JJ p
diagnosis NN p
of IN p
autism NN p
ages NNS p
between IN p
4 CD p
and CC p
12 CD p
years NNS p
were VBD N
assigned VBN N
to TO N
this DT N
double NN N
blinded VBD N
clinical JJ N
trial NN N
and CC N
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
. . N

One CD N
group NN N
received VBD N
risperidone JJ i
plus CC i
Ginko NNP i
T.D NNP i
and CC i
the DT i
other JJ i
received VBD i
risperidone JJ i
plus CC i
placebo NN i
. . i

The DT N
dose NN N
of IN N
risperidone NN i
was VBD N
1-3 JJ N
mg/day NN N
and CC N
the DT N
dose NN N
of IN N
Ginko NNP i
T.D NNP i
. . i

was VBD N
80 CD N
mg/day NN N
for IN N
patients NNS p
under IN p
30 CD p
kg NNS p
and CC N
120 CD N
mg/day NN N
for IN N
patients NNS p
above IN p
30 CD p
kg NNS p
. . p

Patients NNS N
were VBD N
assessed VBN N
using VBG N
Aberrant JJ o
Behavior NNP o
Checklist-Community NNP o
( ( o
ABC-C NNP o
) ) o
rating NN o
scale NN o
and CC o
the DT o
side NN o
effect NN o
check NN o
list NN o
every DT N
2 CD N
weeks NNS N
until IN N
the DT N
endpoint NN N
. . N

None NN N
of IN N
the DT N
5 CD N
subscales NNS N
of IN N
ABC-C NNP o
rating NN o
scale NN o
showed VBD N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
. . N

Incidents NNS o
of IN o
side NN o
effects NNS o
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

Adding VBG N
Ginkgo NNP i
biloba NN i
to TO i
risperidone VB i
did VBD N
not RB N
affect VB N
the DT N
treatment NN N
outcome NN N
of IN N
ADs NNP o
. . o

Nevertheless NNP N
, , N
further JJ N
observations NNS N
are VBP N
needed VBN N
to TO N
confirm VB N
this DT N
result NN N
. . N

-DOCSTART- -21309374- O O

Effectiveness NN N
of IN N
sensory JJ i
integration NN i
interventions NNS i
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
: : p
a DT N
pilot NN N
study NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
pilot NN N
study NN N
was VBD N
to TO N
establish VB N
a DT N
model NN N
for IN N
randomized VBN N
controlled JJ N
trial NN N
research NN N
, , N
identify VB N
appropriate JJ N
outcome NN N
measures NNS N
, , N
and CC N
address VB N
the DT N
effectiveness NN N
of IN N
sensory JJ i
integration NN i
( ( i
SI NNP i
) ) i
interventions NNS N
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
) ) p
. . p

Children NNP p
ages VBZ p
6-12 NN p
with IN p
ASD NNP p
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
fine JJ i
motor NN i
or CC N
SI NNP i
treatment NN i
group NN N
. . N

Pretests NNS N
and CC N
posttests NNS N
measured VBD N
social JJ o
responsiveness NN o
, , o
sensory JJ o
processing NN o
, , o
functional JJ o
motor NN o
skills NNS o
, , o
and CC o
social-emotional JJ o
factors NNS o
. . o

Results NNS N
identified VBD N
significant JJ N
positive JJ N
changes NNS N
in IN N
Goal NNP o
Attainment NNP o
Scaling NNP o
scores NNS o
for IN N
both DT N
groups NNS N
; : N
more RBR N
significant JJ N
changes NNS N
occurred VBD N
in IN N
the DT N
SI NNP N
group NN N
, , N
and CC N
a DT N
significant JJ N
decrease NN N
in IN N
autistic JJ o
mannerisms NNS o
occurred VBD N
in IN N
the DT N
SI NNP N
group NN N
. . N

No DT N
other JJ N
results NNS N
were VBD N
significant JJ N
. . N

The DT N
study NN N
discusses VBZ N
considerations NNS N
for IN N
designing VBG N
future JJ N
outcome NN N
studies NNS N
for IN N
children NNS p
with IN p
ASD NNP p
. . p

-DOCSTART- -17410213- O O

Effects NNS N
of IN N
application NN N
in IN N
spring NN N
of IN N
urea JJ i
fertiliser NN i
on IN N
aspects NNS N
of IN N
reproductive JJ N
performance NN N
of IN N
pasture-fed JJ p
dairy NN p
cows NNS p
. . p

AIMS NNP N
To TO N
assess VB N
if IN N
raising VBG N
concentrations NNS N
of IN N
crude NN N
protein NN N
( ( N
CP NNP N
) ) N
in IN N
pasture NN N
in IN N
spring NN N
by IN N
the DT N
frequent JJ N
application NN N
of IN N
urea JJ i
fertiliser NN i
would MD N
affect VB N
ovarian JJ o
follicular JJ o
dynamics NNS o
, , o
luteal JJ o
function NN o
, , o
onset NN o
of IN o
oestrus NN o
and CC o
reproductive JJ o
performance NN o
of IN N
dairy NN p
cows NNS p
under IN p
farming VBG p
conditions NNS p
in IN p
New NNP p
Zealand NNP p
. . p

METHODS NNP N
Spring-calved JJ p
dairy NN p
cows NNS p
were VBD p
grazed VBN p
for IN p
101 CD p
days NNS p
in IN p
paddocks NNS p
that WDT p
were VBD p
either RB p
not RB i
fertilised VBN i
( ( p
Control NNP p
; : p
n=20 CC p
) ) p
during IN p
the DT p
course NN p
of IN p
the DT p
study NN p
, , p
or CC p
were VBD p
fertilised VBN i
with IN p
40-50 JJ i
kg NNS i
nitrogen NN i
( ( p
N NNP p
) ) p
/ha VBP p
every DT p
4-6 JJ p
weeks NNS p
( ( p
High-N NNP p
; : p
n=20 NN p
) ) p
. . p

Similar JJ N
generous JJ N
pasture NN N
allowances NNS N
were VBD N
offered VBN N
to TO N
both DT N
groups NNS N
. . N

Concentrations NNS o
of IN o
CP NNP o
in IN o
pasture NN o
, , o
urea JJ o
in IN o
serum NN o
and CC o
progesterone NN o
in IN o
milk NN o
were VBD N
measured VBN N
. . N

Ovarian JJ o
follicular NN o
and CC o
luteal JJ o
dynamics NNS o
were VBD N
determined VBN N
using VBG N
ultrasonography NN N
. . N

Oestrous JJ o
behaviour NN o
and CC o
the DT o
number NN o
, , o
time NN o
and CC o
outcome NN o
of IN o
inseminations NNS o
were VBD N
also RB N
recorded VBN N
. . N

RESULTS JJ N
Mean JJ o
concentrations NNS o
of IN o
CP NNP o
in IN o
pasture NN o
and CC o
urea NN o
in IN o
serum NN o
was VBD N
higher RBR N
in IN N
the DT N
High-N NNP N
than IN N
the DT N
Control NNP N
group NN N
( ( N
25.2 CD N
vs NN N
21.6 CD N
and CC N
8.3 CD N
vs NN N
5.4 CD N
mmol/L NN N
for IN N
CP NNP N
and CC N
urea JJ N
, , N
respectively RB N
; : N
p VB N
< $ N
0.001 CD N
) ) N
. . N

Intervals NNS o
between IN o
calving VBG o
and CC o
first JJ o
oestrus NN o
, , o
first JJ o
insemination NN o
and CC o
conception NN o
, , o
the DT o
time NN o
of IN o
first JJ o
emergence NN o
of IN o
a DT o
dominant JJ o
follicle NN o
, , o
milk NN o
progesterone NN o
concentration NN o
, , o
and CC o
the DT o
diameter NN o
of IN o
the DT o
corpus NN o
luteum NN o
( ( o
CL NNP o
) ) o
in IN o
the DT o
first JJ o
luteal JJ o
phase NN o
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
groups NNS N
. . N

The DT N
interval NN o
from IN o
calving VBG o
to TO o
first JJ o
ovulation NN o
tended VBN N
( ( N
p=0.10 NN N
) ) N
to TO N
be VB N
lower JJR N
and CC N
the DT N
diameter NN o
of IN o
the DT o
dominant JJ o
follicle NN o
of IN o
the DT o
oestrous JJ o
cycle NN o
at IN o
which WDT o
cows VBZ o
conceived VBN o
was VBD N
greater JJR N
( ( N
p=0.02 NN N
) ) N
in IN N
Control NNP N
than IN N
High-N NNP N
cows NNS N
. . N

CONCLUSIONS VB N
The DT N
use NN N
of IN N
large JJ N
amounts NNS N
of IN N
urea JJ i
fertiliser NN i
during IN N
spring NN N
and CC N
the DT N
consequent NN N
increases NNS N
in IN N
concentrations NNS o
of IN o
CP NNP o
in IN o
pasture NN o
and CC o
urea NN o
in IN o
serum NN o
did VBD N
not RB N
negatively RB N
affect JJ N
any DT N
of IN N
the DT N
parameters NNS N
of IN N
reproductive JJ o
performance NN o
of IN N
pasture-fed JJ p
dairy NN p
cows NNS p
that WDT N
were VBD N
assessed VBN N
in IN N
this DT N
study NN N
. . N

-DOCSTART- -14609821- O O

Evaluation NN N
of IN N
umbilical JJ i
cord NN i
serum NN i
therapy NN i
for IN N
persistent JJ p
corneal JJ p
epithelial JJ p
defects NNS p
. . p

AIMS NNP N
To TO N
evaluate VB N
umbilical JJ i
cord NN i
serum NN i
therapy NN i
as IN N
a DT N
means NN N
of IN N
promoting VBG N
the DT N
healing NN N
of IN N
persistent JJ o
corneal JJ o
epithelial JJ o
defects NNS o
. . o

METHODS NNP N
Umbilical NNP i
cord NN i
serum NN i
or CC i
autologous JJ i
serum NN i
drops NNS i
were VBD N
used VBN N
to TO N
promote VB N
the DT N
healing NN N
of IN N
persistent JJ o
epithelial JJ o
defects NNS o
. . o

The DT N
study NN N
design NN N
was VBD N
a DT N
prospective JJ N
randomised VBN N
controlled VBD N
clinical JJ N
trial NN N
. . N

60 CD p
eyes NNS p
of IN p
59 CD p
patients NNS p
were VBD N
divided VBN N
into IN N
two CD N
groups NNS N
, , N
31 CD N
in IN N
the DT N
cord NN i
serum NN i
group NN N
and CC N
29 CD N
in IN N
the DT N
autologous JJ i
serum NN i
control NN i
group NN i
. . i

Epithelial JJ N
defects NNS N
measuring VBG N
at IN N
least JJS N
2 CD N
mm NN N
in IN N
linear JJ N
dimension NN N
resistant NN N
to TO N
conventional JJ N
medical JJ N
management NN N
were VBD N
included VBN N
. . N

Serial JJ N
measurements NNS N
of IN N
the DT N
size NN N
of IN N
the DT N
epithelial JJ N
defects-namely RB N
, , N
two CD N
maximum JJ N
linear JJ N
dimensions NNS N
perpendicular VBP N
to TO N
each DT N
other JJ N
, , N
and CC N
the DT N
area NN N
and CC N
perimeter NN N
was VBD N
done VBN N
at IN N
start NN N
of IN N
therapy NN N
and CC N
follow VB N
up RP N
days NNS N
3 CD N
, , N
7 CD N
, , N
14 CD N
, , N
21 CD N
. . N

Rate NN o
of IN o
healing NN o
of IN o
the DT o
epithelial JJ o
defects NNS o
were VBD N
measured VBN N
as IN N
percentage NN N
decrease NN N
from IN N
the DT N
baseline NN N
parameter NN N
at IN N
each DT N
subsequent NN N
follow VBP N
up RB N
. . N

The DT N
data NNS N
were VBD N
analysed VBN N
by IN N
the DT N
non-parametric JJ N
Wilcoxon NNP N
rank NN N
sum NN N
test NN N
using VBG N
STATA NNP N
7.0 CD N
. . N

RESULTS VB N
The DT N
median JJ N
percentage NN N
decrease NN o
in IN o
the DT o
size NN o
of IN o
the DT o
epithelial JJ o
defect NN o
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
cord NN i
serum NN i
group NN N
at IN N
days NNS N
7 CD N
, , N
14 CD N
and CC N
21 CD N
( ( N
p NN N
< RB N
0.05 CD N
) ) N
when WRB N
measured VBN N
in IN N
terms NNS N
of IN N
the DT N
area NN N
and CC N
perimeter NN N
. . N

A DT N
greater JJR N
number NN N
of IN N
patients NNS N
showed VBD N
complete JJ o
re-epithelialisation NN o
with IN N
umbilical JJ N
cord NN i
serum NN i
( ( N
n JJ N
= NNP N
18 CD N
) ) N
than IN N
with IN N
autologous JJ N
serum NN N
( ( N
n JJ N
= NNP N
11 CD N
) ) N
( ( N
Pearson NNP N
chi VBZ N
= NNP N
0.19 CD N
) ) N
. . N

None NN N
of IN N
the DT N
patients NNS N
reported VBD N
any DT N
side NN N
effects NNS N
or CC N
discomfort NN N
with IN N
either DT N
treatment NN N
. . N

CONCLUSIONS NNP N
Umbilical NNP i
cord NN i
serum NN i
leads VBZ N
to TO N
faster RBR o
healing NN o
of IN o
the DT o
persistent JJ o
corneal NN o
epithelial JJ o
defects NNS o
refractory NN N
to TO N
all DT N
medical JJ N
management NN N
compared VBN N
to TO N
autologous JJ i
serum NN i
. . i

-DOCSTART- -8133853- O O

A DT N
controlled JJ N
trial NN N
of IN N
intravenous JJ N
immune JJ i
globulin NN i
to TO N
reduce VB N
nosocomial JJ o
infections NNS o
in IN N
very-low-birth-weight JJ p
infants NNS p
. . p

National NNP N
Institute NNP N
of IN N
Child NNP N
Health NNP N
and CC N
Human NNP N
Development NNP N
Neonatal NNP N
Research NNP N
Network NNP N
. . N

BACKGROUND NNP N
Nosocomial NNP o
infections NNS o
are VBP N
a DT N
major JJ N
cause NN N
of IN N
morbidity NN N
and CC N
mortality NN N
in IN N
premature JJ p
infants NNS p
. . p

As IN N
a DT N
rule NN N
, , N
their PRP$ N
low JJ N
serum NN N
gamma NN N
globulin NN N
levels NNS N
at IN N
birth NN N
subsequently RB N
decline VBZ N
to TO N
hypogammaglobulinemic VB N
values NNS N
; : N
hence NN N
, , N
prophylactic JJ N
administration NN N
of IN N
intravenous JJ N
immune NNS i
globulin NN i
may MD N
reduce VB N
the DT N
rate NN N
of IN N
hospital-acquired JJ N
infections NNS N
. . N

METHODS NNP N
In IN N
this DT N
prospective JJ N
, , N
multicenter NN N
, , N
two-phase NN N
controlled VBD N
trial NN N
, , N
2416 CD p
infants NNS p
were VBD p
stratified VBN p
according VBG p
to TO p
birth NN p
weight NN p
( ( p
501 CD p
to TO p
1000 CD p
g NN p
and CC p
1001 CD p
to TO p
1500 CD p
g NN p
) ) p
and CC N
randomly RB N
assigned VBN N
to TO N
an DT N
intravenous JJ i
immune JJ i
globulin NN i
group NN i
( ( N
n IN N
= NNP N
1204 CD N
) ) N
or CC N
a DT N
control NN i
group NN i
( ( N
n IN N
= NNP N
1212 CD N
) ) N
. . N

Control NN p
infants NNS p
were VBD N
given VBN N
placebo JJ N
infusions NNS N
during IN N
phase NN N
1 CD N
of IN N
the DT N
study NN N
( ( N
n JJ N
= NNP N
623 CD N
) ) N
but CC N
were VBD N
not RB N
given VBN N
any DT N
infusions NNS N
during IN N
phase NN N
2 CD N
( ( N
n JJ N
= NNP N
589 CD N
) ) N
. . N

Infants NNS p
weighing VBG p
501 CD p
to TO p
1000 CD p
g NN p
at IN p
birth NN p
were VBD N
given VBN N
900 CD N
mg NN N
of IN N
immune JJ i
globulin NN i
per IN N
kilogram NN N
of IN N
body NN N
weight NN N
, , N
and CC N
infants NNS N
weighing VBG N
1001 CD N
to TO N
1500 CD N
g NN N
at IN N
birth NN N
were VBD N
given VBN N
a DT N
dose NN N
of IN N
700 CD N
mg NNS N
per IN N
kilogram NN N
. . N

The DT N
immune JJ i
globulin NN i
infusions NNS N
were VBD N
repeated VBN N
every DT N
14 CD N
days NNS N
until IN N
the DT N
infants NNS N
weighed VBD N
1800 CD N
g NN N
, , N
were VBD N
transferred VBN N
to TO N
another DT N
center NN N
, , N
died VBD N
, , N
or CC N
were VBD N
sent VBN N
home NN N
from IN N
the DT N
hospital NN N
. . N

RESULTS NNP N
Nosocomial JJ o
infections NNS o
of IN o
the DT o
blood NN o
, , o
meninges NNS o
, , o
or CC o
urinary JJ o
tract NN o
occurred VBD N
in IN N
439 CD N
of IN N
the DT N
2416 CD N
infants NNS N
( ( N
18.2 CD N
percent NN N
) ) N
: : N
208 CD N
( ( N
17.3 CD N
percent NN N
) ) N
in IN N
the DT N
immune JJ N
globulin NN N
group NN N
and CC N
231 CD N
( ( N
19.1 CD N
percent NN N
) ) N
in IN N
the DT N
control NN N
group NN N
( ( N
relative JJ N
risk NN N
, , N
0.91 CD N
; : N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
0.77 CD N
to TO N
1.08 CD N
) ) N
. . N

Septicemia NNP o
occurred VBD N
in IN N
15.5 CD N
percent NN N
of IN N
the DT N
immune JJ N
globulin NN N
recipients NNS N
and CC N
17.2 CD N
percent NN N
of IN N
the DT N
controls NNS N
. . N

During IN N
phase NN N
1 CD N
the DT N
rate NN N
of IN N
nosocomial JJ o
infections NNS o
was VBD N
13.4 CD N
percent NN N
in IN N
the DT N
immune JJ N
globulin NN N
group NN N
and CC N
17.8 CD N
percent NN N
in IN N
the DT N
control NN N
group NN N
; : N
the DT N
respective JJ N
rates NNS N
during IN N
phase NN N
2 CD N
were VBD N
21.0 CD N
percent NN N
and CC N
20.4 CD N
percent NN N
. . N

The DT N
predominant JJ N
organisms NNS N
included VBD N
gram-positive JJ N
cocci NN N
( ( N
53.0 CD N
percent NN N
) ) N
, , N
gram-negative JJ N
bacilli NN N
( ( N
22.4 CD N
percent NN N
) ) N
, , N
and CC N
candida NN N
species NNS N
( ( N
16.0 CD N
percent NN N
) ) N
. . N

Adverse JJ o
reactions NNS o
were VBD N
rarely RB N
observed VBN N
during IN N
the DT N
infusions NNS N
. . N

Immune NNP N
globulin NN N
therapy NN N
had VBD N
no DT N
effect NN N
on IN N
respiratory NN o
distress NN o
syndrome NN o
, , o
bronchopulmonary JJ o
dysplasia NN o
, , o
intracranial JJ o
hemorrhage NN o
, , o
the DT o
duration NN o
of IN o
hospitalization NN o
, , o
or CC o
mortality NN o
. . o

The DT N
incidence NN N
of IN N
necrotizing VBG o
enterocolitis NN o
was VBD N
12.0 CD N
percent NN N
in IN N
the DT N
immune JJ N
globulin NN N
group NN N
and CC N
9.5 CD N
percent NN N
in IN N
the DT N
control NN N
group NN N
. . N

CONCLUSIONS NNP N
Prophylactic NNP N
use NN N
of IN N
intravenous JJ N
immune JJ N
globulin NN N
failed VBD N
to TO N
reduce VB N
the DT N
incidence NN N
of IN N
hospital-acquired JJ o
infections NNS o
in IN N
very-low-birth-weight JJ p
infants NNS p
. . p

-DOCSTART- -8832772- O O

Effects NNS N
of IN N
ORG-2766 NNP i
on IN N
brain NN N
event-related JJ N
potentials NNS N
of IN N
autistic JJ p
children NNS p
. . p

A DT N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
examined VBD N
the DT N
effects NNS N
of IN N
6 CD N
weeks NNS N
of IN N
treatment NN N
with IN N
the DT N
adrenocorticotropin4-9 JJ i
analogue NN i
ORG-2766 NNP i
( ( N
40 CD N
mg/day NN N
) ) N
on IN N
brain NN N
event-related JJ N
potentials NNS N
( ( N
ERPs NNP N
) ) N
of IN N
autistic JJ p
children NNS p
. . p

In IN N
visual JJ N
and CC N
auditory JJ N
oddball NN N
paradigms NN N
( ( N
with IN N
task NN N
and CC N
nontask JJ N
conditions NNS N
) ) N
, , N
standard JJ N
( ( N
80 CD N
% NN N
) ) N
, , N
target NN N
( ( N
10 CD N
% NN N
) ) N
, , N
and CC N
unexpected JJ N
novel NN N
stimuli NNS N
( ( N
10 CD N
% NN N
) ) N
were VBD N
presented VBN N
. . N

ORG-2766 NNP N
( ( N
a DT N
) ) N
increased VBD o
the DT o
occipital JJ o
P3 NNP o
component NN o
of IN o
the DT o
ERP NNP o
to TO o
visual JJ o
targets NNS o
, , o
( ( o
b NN o
) ) o
decreased VBD o
the DT o
occipital JJ o
P3 NNP o
component NN o
of IN o
the DT o
ERP NNP o
to TO o
auditory JJ o
targets NNS o
, , o
( ( o
c NN o
) ) o
did VBD o
not RB o
affect VB o
visual JJ o
and CC o
auditory JJ o
parietal JJ o
target NN o
P3 NNP o
components NNS o
, , o
and CC o
( ( o
d NN o
) ) o
also RB o
did VBD o
not RB o
affect VB o
the DT o
A/Pcz/300 NNP o
to TO o
auditory VB o
novel JJ o
stimuli NNS o
. . o

In IN N
addition NN N
, , N
ORG-2766 NNP N
treatment NN N
increased VBD o
the DT o
N1 NNP o
component NN o
of IN o
the DT o
ERP NNP o
to TO o
task-irrelevant JJ o
auditory NN o
stimuli NNS o
. . o

-DOCSTART- -12406050- O O

Adherence NN N
to TO N
moderate-intensity NN i
exercise NN i
during IN N
breast NN i
cancer NN i
therapy NN i
. . i

PURPOSE VB N
The DT N
aims NNS N
of IN N
this DT N
pilot NN N
study NN N
were VBD N
the DT N
following JJ N
: : N
1 CD N
) ) N
to TO N
examine VB N
patterns NNS N
of IN N
adherence NN N
to TO N
a DT N
brisk JJ i
walking VBG i
program NN i
in IN N
women NNS p
receiving VBG p
adjuvant JJ i
chemotherapy NN i
or CC i
radiation NN i
therapy NN i
for IN p
newly RB p
diagnosed VBN p
breast NN p
cancer NN p
using VBG N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
controlled VBD N
experimental JJ N
design NN N
; : N
2 CD N
) ) N
to TO N
examine VB N
the DT N
influence NN N
of IN N
disease NN N
symptoms NNS N
and CC N
treatment NN N
side NN N
effects NNS N
on IN N
exercise NN i
levels NNS N
; : N
and CC N
3 CD N
) ) N
to TO N
suggest VB N
methods NNS N
that WDT N
may MD N
improve VB N
future NN N
clinical JJ N
trials NNS N
of IN N
moderate-intensity NN N
exercise NN N
in IN N
similar JJ N
populations NNS N
. . N

DESCRIPTION NNP N
OF IN N
STUDY NNP N
Fifty-two NNP p
patients NNS p
with IN p
newly RB p
diagnosed VBN p
breast NN p
cancer NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
treatment NN N
arms NNS N
: : N
usual JJ i
care NN i
or CC N
usual JJ i
care NN i
plus CC i
exercise NN i
. . i

Those DT N
assigned VBN N
to TO N
the DT N
exercise NN i
group NN N
received VBD N
a DT N
standardized JJ i
, , i
self-administered JJ i
, , i
home-based JJ i
brisk NN i
walking VBG i
intervention NN i
in IN N
addition NN N
to TO N
usual JJ N
care NN N
. . N

Each DT N
day NN N
subjects VBZ N
completed VBN N
self-report JJ N
diary JJ N
forms NNS N
that WDT N
elicited VBD N
information NN N
about IN N
activity NN N
levels NNS N
, , N
and CC N
the DT N
occurrence NN N
of IN N
symptoms NNS N
and CC N
side JJ N
effects NNS N
during IN N
cancer NN N
treatment NN N
. . N

RESULTS NNP N
Analyses NNP N
of IN N
self-reported JJ N
daily JJ N
activity NN N
levels NNS N
revealed VBD N
a DT N
diffusion NN N
of IN N
treatment NN N
effect NN N
. . N

Fifty NNP N
percent NN N
of IN N
the DT N
usual-care JJ N
group NN N
reported VBD N
maintaining NN o
or CC o
increasing VBG o
their PRP$ o
physical JJ o
activity NN o
to TO o
a DT o
moderate-intensity JJ o
level NN o
, , N
while IN N
33 CD N
% NN N
of IN N
the DT N
exercise NN N
group NN N
did VBD N
not RB N
exercise NN N
at IN N
the DT N
prescribed NN N
levels NNS N
. . N

Analyses NNS N
of IN N
self-reported JJ o
disease NN o
symptoms NNS o
and CC o
treatment NN o
side NN o
effects NNS o
did VBD N
not RB N
reveal VB N
clinically RB N
meaningful JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
. . N

CLINICAL JJ N
IMPLICATIONS NNP N
The DT N
results NNS N
of IN N
this DT N
study NN N
suggest VBP N
that IN N
women NNS p
who WP N
exercised VBD N
regularly RB N
before RB N
receiving VBG N
a DT N
breast NN N
cancer NN N
diagnosis NN N
attempted VBD N
to TO N
maintain VB N
their PRP$ N
exercise NN i
programs NNS i
. . i

Women NNS p
who WP N
lead VBP N
sedentary JJ N
lifestyles NNS N
may MD N
benefit VB N
from IN N
a DT N
structured JJ i
exercise NN i
program NN i
that WDT N
includes VBZ N
information NN N
and CC N
support NN N
related VBN N
to TO N
exercise VB N
adherence NN N
strategies NNS N
. . N

-DOCSTART- -18684258- O O

A DT N
pilot NN N
study NN N
of IN N
a DT N
low-tilt JJ N
biphasic JJ N
waveform NN N
for IN N
transvenous JJ N
cardioversion NN N
of IN N
atrial JJ p
fibrillation NN p
: : p
improved VBN N
efficacy NN o
compared VBN N
with IN N
conventional JJ N
capacitor-based JJ N
waveforms NNS N
in IN N
patients NNS N
. . N

BACKGROUND NNP N
The DT N
optimal JJ N
waveform NN N
tilt NN N
for IN N
defibrillation NN N
is VBZ N
not RB N
known VBN N
. . N

Most JJS N
modern JJ N
defibrillators NNS N
used VBN N
for IN N
the DT N
cardioversion NN N
of IN N
atrial JJ N
fibrillation NN N
( ( N
AF NNP N
) ) N
employ VBD N
high-tilt JJ N
, , N
capacitor-based JJ N
biphasic JJ N
waveforms NNS N
. . N

METHODS NNP N
We PRP N
have VBP N
developed VBN N
a DT N
low-tilt JJ i
biphasic JJ i
waveform NN i
for IN N
defibrillation NN N
. . N

This DT N
low-tilt JJ i
waveform NN i
was VBD N
compared VBN N
with IN N
a DT N
conventional JJ i
waveform NN i
of IN N
equivalent JJ N
duration NN N
and CC N
voltage NN N
in IN N
patients NNS p
with IN p
AF NNP p
. . p

Patients NNS p
with IN p
persistent JJ p
AF NNP p
or CC p
AF NNP p
induced VBD p
during IN p
a DT p
routine JJ p
electrophysiology NN p
study NN p
( ( p
EPS NNP p
) ) p
were VBD N
randomized VBN N
to TO N
receive VB N
either RB N
the DT N
low-tilt JJ i
waveform NN i
or CC N
a DT N
conventional JJ i
waveform NN i
. . i

Defibrillation NNP N
electrodes NNS N
were VBD N
positioned VBN N
in IN N
the DT N
right JJ N
atrial JJ N
appendage NN N
and CC N
distal JJ N
coronary JJ N
sinus NN N
. . N

Phase VB N
1 CD N
peak JJ N
voltage NN N
was VBD N
increased VBN N
in IN N
a DT N
stepwise NN N
progression NN N
from IN N
50 CD N
V NNP N
to TO N
300V CD N
. . N

Shock NNP N
success NN N
was VBD N
defined VBN N
as IN N
return NN o
of IN o
sinus NN o
rhythm NN o
for IN N
> NNP N
/=30 NNP N
seconds NNS N
. . N

RESULTS VB N
The DT N
low-tilt JJ i
waveform NN i
produced VBN N
successful JJ N
termination NN o
of IN o
persistent JJ o
AF NNP o
at IN N
a DT N
mean JJ N
voltage NN N
of IN N
223 CD N
V NNP N
( ( N
8.2 CD N
J NNP N
) ) N
versus VBD N
270 CD N
V NNP N
( ( N
6.7 CD N
J NNP N
) ) N
with IN N
the DT N
conventional JJ i
waveform NN i
( ( N
P NNP N
= VBZ N
0.002 CD N
for IN N
voltage NN N
, , N
P NNP N
= NNP N
ns NN N
for IN N
energy NN N
) ) N
. . N

In IN N
patients NNS p
with IN p
induced JJ p
AF NNP p
the DT N
mean JJ o
voltage NN o
for IN N
the DT N
low-tilt JJ N
waveform NN N
was VBD N
91V CD N
( ( N
1.6 CD N
J NNP N
) ) N
and CC N
for IN N
the DT N
conventional JJ N
waveform NN N
was VBD N
158 CD N
V NNP N
( ( N
2.0 CD N
J NNP N
) ) N
( ( N
P NNP N
= VBZ N
0.005 CD N
for IN N
voltage NN N
, , N
P NNP N
= NNP N
ns NN N
for IN N
energy NN N
) ) N
. . N

The DT N
waveform NN N
was VBD N
much RB N
more RBR N
successful JJ N
at IN N
very RB N
low JJ N
voltages NNS N
( ( N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
100 CD N
V NNP N
) ) N
compared VBN N
with IN N
the DT N
conventional JJ N
waveform NN N
( ( N
Novel NNP N
: : N
82 CD N
% NN N
vs JJ N
Conventional NNP N
22 CD N
% NN N
, , N
P NNP N
= NNP N
0.008 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
low-tilt JJ i
biphasic JJ i
waveform NN i
was VBD N
more RBR N
successful JJ N
for IN N
the DT N
internal JJ N
cardioversion NN N
of IN N
both DT N
persistent JJ N
and CC N
induced JJ N
AF NNP p
in IN p
patients NNS p
( ( N
in IN N
terms NNS N
of IN N
leading VBG N
edge NN N
voltage NN N
) ) N
. . N

-DOCSTART- -26650831- O O

Ultrasound NN i
is VBZ N
at IN N
least JJS N
as RB N
good JJ N
as IN N
magnetic JJ i
resonance NN i
imaging NN i
in IN N
predicting VBG o
tumour JJ o
size NN o
post-neoadjuvant JJ N
chemotherapy NN p
in IN p
breast NN p
cancer NN p
. . p

BACKGROUND IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
accuracy NN o
of IN N
clinical JJ N
imaging NN N
of IN N
the DT N
primary JJ i
breast NN i
tumour JJ i
post-neoadjuvant JJ i
chemotherapy NN i
( ( i
NAC NNP i
) ) i
related VBD N
to TO N
the DT N
post-neoadjuvant JJ N
histological JJ N
tumour NN N
size NN N
( ( N
gold JJ N
standard NN N
) ) N
and CC N
whether IN N
this DT N
varies NNS N
with IN N
breast NN p
cancer NN p
subtype NN p
. . p

In IN N
this DT N
study NN N
, , N
results NNS N
of IN N
both DT N
magnetic JJ i
resonance NN i
imaging NN i
( ( i
MRI NNP i
) ) i
and CC i
ultrasound NN i
( ( i
US NNP i
) ) i
were VBD N
reported VBN N
. . N

METHODS NNP N
Patients NNPS p
with IN p
invasive JJ p
breast NN p
cancer NN p
were VBD p
enrolled VBN p
in IN p
the DT p
INTENS NNP p
study NN p
between IN p
2006 CD p
and CC p
2009 CD p
. . p

We PRP p
included VBD p
182 CD p
patients NNS p
, , p
of IN p
whom WP p
data NNS p
were VBD p
available JJ p
for IN p
post-NAC JJ p
MRI NNP i
( ( p
n=155 NN p
) ) p
, , p
US NNP i
( ( p
n=123 NN p
) ) p
, , p
and CC p
histopathological JJ p
tumour NN p
size NN p
. . p

RESULTS NNP N
MRI NNP N
estimated VBD N
residual JJ o
tumour NN o
size NN o
with IN N
< JJ N
10-mm JJ N
discordance NN N
in IN N
54 CD N
% NN N
of IN N
patients NNS N
, , N
overestimated VBN N
size NN N
in IN N
28 CD N
% NN N
and CC N
underestimated JJ N
size NN N
in IN N
18 CD N
% NN N
of IN N
patients NNS N
. . N

With IN N
US NNP N
, , N
this DT N
was VBD N
63 CD N
% NN N
, , N
20 CD N
% NN N
and CC N
17 CD N
% NN N
, , N
respectively RB N
. . N

The DT N
negative JJ N
predictive JJ N
value NN N
in IN N
hormone JJ N
receptor-positive JJ N
tumours NN N
for IN N
both DT N
MRI NNP N
and CC N
US NNP N
was VBD N
low JJ N
, , N
26 CD N
% NN N
and CC N
33 CD N
% NN N
, , N
respectively RB N
. . N

The DT N
median JJ o
deviation NN o
in IN o
clinical JJ o
tumour NN o
size NN o
as IN o
percentage NN o
of IN o
pathological JJ o
tumour NN o
was VBD N
63 CD N
% NN N
( ( N
P25=26 NNP N
, , N
P75=100 NNP N
) ) N
and CC N
49 CD N
% NN N
( ( N
P25=22 NNP N
, , N
P75=100 NNP N
) ) N
for IN N
MRI NNP N
and CC N
US NNP N
, , N
respectively RB N
( ( N
P=0.06 NNP N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
this DT N
study NN N
, , N
US NNP N
was VBD N
at IN N
least JJS N
as RB N
good JJ N
as IN N
breast NN N
MRI NNP N
in IN N
providing VBG N
information NN N
on IN N
residual JJ N
tumour NN N
size NN N
post-neoadjuvant JJ N
chemotherapy NN N
. . N

However RB N
, , N
both DT N
modalities NNS N
suffered VBD N
from IN N
a DT N
substantial JJ N
percentage NN N
of IN N
over- JJ N
and CC N
underestimation NN N
of IN N
tumour JJ N
size NN N
and CC N
in IN N
addition NN N
both DT N
showed VBD N
a DT N
low JJ N
negative JJ o
predictive JJ o
value NN o
of IN o
pathologic JJ o
complete JJ o
remission NN o
( ( N
Gov NNP N
nr NN N
: : N
NCT00314977 NNP N
) ) N
. . N

-DOCSTART- -16220761- O O

Adhesion-prevention JJ o
effects NNS o
of IN N
fibrin NN i
sealants NNS i
after IN p
laparoscopic JJ i
myomectomy NN i
as IN N
determined VBN N
by IN N
second-look JJ N
laparoscopy NN N
: : N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
controlled VBN N
study NN N
. . N

OBJECTIVE NNP N
To TO N
examine VB N
the DT N
adhesion NN o
prevention NN o
effects NNS o
of IN N
2 CD N
types NNS N
of IN N
fibrin NN i
sealant NN i
after IN i
laparoscopic JJ i
myomectomy NN i
( ( i
LM NNP i
) ) i
. . i

STUDY NNP N
DESIGN NNP N
A NNP N
prospective JJ N
, , N
randomized VBN N
study NN N
( ( p
Canadian JJ p
Task NNP p
Force NNP p
I PRP p
) ) p
was VBD N
conducted VBN N
at IN N
a DT N
University-affiliated JJ p
hospital NN p
. . p

A DT p
total NN p
of IN p
91 CD p
patients NNS p
showing VBG p
a DT p
minimal JJ p
myoma NN p
> VBD p
5 CD p
cm NN p
, , p
excluding VBG p
pedunculated VBN p
myomas NN p
, , p
underwent JJ p
LM NNP i
alone RB p
: : p
32 CD p
patients NNS p
in IN p
the DT p
control NN p
group NN p
, , p
29 CD p
in IN p
the DT p
fibrin NN i
gel NN i
group NN p
and CC p
30 CD p
patients NNS p
in IN p
the DT p
fibrin JJ i
sheet NN i
group NN i
. . i

After IN N
LM NNP N
, , N
postoperative JJ o
adhesions NNS o
were VBD N
evaluated VBN N
by IN N
second-look JJ o
laparoscopy NN o
. . o

The DT o
frequency NN o
of IN o
postoperative JJ o
adhesions NNS o
was VBD N
the DT N
main JJ N
outcome NN N
. . N

RESULTS VB N
The DT N
frequency NN o
of IN o
postoperative JJ o
adhesions NNS o
of IN o
the DT o
uterus NN o
was VBD N
significantly RB N
lower JJR N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
in IN N
the DT N
fibrin NN i
gel NN i
group NN N
, , N
with IN N
20/32 CD N
( ( N
62.5 CD N
% NN N
) ) N
in IN N
the DT N
control NN N
group NN N
, , N
10/29 CD N
( ( N
34.5 CD N
% NN N
) ) N
in IN N
the DT N
fibrin NN i
gel NN i
group NN N
and CC N
20/30 CD N
( ( N
67.7 CD N
% NN N
) ) N
in IN N
the DT N
fibrin JJ i
sheet NN i
group NN N
. . N

Although IN N
no DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
the DT N
incidence NN o
of IN o
de FW o
novo FW o
adnexal JJ o
adhesions NNS o
, , N
the DT N
lowest JJS N
rate NN N
was VBD N
found VBN N
in IN N
the DT N
fibrin NN i
gel NN i
group NN N
, , N
with IN N
4/32 CD N
patients NNS N
( ( N
12.5 CD N
% NN N
) ) N
in IN N
the DT N
control NN N
group NN N
, , N
2/29 CD N
patients NNS N
( ( N
6.8 CD N
% NN N
) ) N
in IN N
the DT N
fibrin NN i
gel NN i
group NN N
and CC N
5/30 CD N
patients NNS N
( ( N
16.7 CD N
% NN N
) ) N
in IN N
the DT N
fibrin JJ N
sheet NN N
group NN N
. . N

No DT o
bilateral JJ o
adnexal NN o
adhesions NNS o
were VBD N
observed VBN N
in IN N
the DT N
3 CD N
groups NNS N
. . N

CONCLUSION NNP N
After IN N
LM NNP N
for IN N
myomas NN N
as RB N
large JJ N
as IN N
> NN N
or CC N
= $ N
5 CD N
cm NN N
, , N
postoperative JJ o
adhesions NNS o
were VBD N
observed VBN N
in IN N
> NN N
or CC N
= VB N
50 CD N
% NN N
of IN N
patients NNS N
. . N

The DT N
use NN N
of IN N
fibrin NN i
gel NN i
after IN N
LM NNP N
is VBZ N
recommended VBN N
. . N

-DOCSTART- -10036953- O O

[ JJ N
Triple NNP N
therapy NN N
regimens VBZ N
involving VBG N
H2 NNP i
blockaders NNS i
for IN N
therapy NN N
of IN N
Helicobacter NNP o
pylori FW o
infections NNS o
] VBP o
. . N

Comparison NNP o
of IN N
ranitidine NN i
and CC N
lansoprazole NN i
in IN N
short-term JJ N
low-dose JJ N
triple NN N
therapy NN N
for IN N
Helicobacter NNP N
pylori JJ N
infection NN N
. . N

To TO N
evaluate VB N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
two CD N
1-week JJ N
low-dose JJ N
triple-therapy JJ N
drug NN N
regimens NNS N
involving VBG N
antisecretory NN i
drugs NNS i
for IN N
Helicobacter NNP N
pylori JJ N
infection NN N
, , N
99 CD p
patients NNS p
with IN p
H. NNP p
pylori FW p
infection NN p
were VBD p
treated VBN N
with IN N
either DT N
lansoprazole NN i
( ( N
LPZ NNP N
) ) N
or CC N
ranitidine NN i
( ( N
RNT NNP N
) ) N
used VBD N
together RB N
with IN N
clarithromycin NN i
( ( i
CAM NNP i
) ) i
and CC N
metrinidazole $ i
( ( i
MTZ NNP i
) ) i
. . N

The DT N
drug NN N
combination NN N
and CC N
administration NN N
periods NNS N
in IN N
the DT N
PPI NNP N
group NN N
were VBD N
LPZ NNP i
30 CD N
mg NN N
, , N
CAM NNP i
400 CD N
mg NN N
, , N
MTZ NNP i
500 CD N
mg NN N
( ( N
LCM NNP N
group NN N
) ) N
. . N

The DT N
ranitidine NN i
group NN N
received VBD N
RNT NNP i
300 CD N
mg NN N
, , N
CAM NNP i
400 CD N
mg NN N
, , N
MTZ NNP i
500 CD N
mg NN N
( ( N
RCM NNP N
group NN N
) ) N
. . N

The DT N
cure NN o
rate NN o
of IN o
H. NNP o
pylori FW o
infection NN o
was VBD N
88 CD N
% NN N
in IN N
the DT N
LCM NNP i
group NN N
; : N
95 CD N
% NN N
CI NNP N
79-97 CD N
and CC N
92 CD N
% NN N
in IN N
the DT N
RCM NNP i
group NN N
; : N
95 CD N
% NN N
CI NNP N
84-99 CD N
. . N

-DOCSTART- -7892971- O O

Peritonsillar JJ N
infiltration NN N
with IN N
bupivacaine NN i
for IN N
paediatric JJ p
tonsillectomy NN p
. . p

In IN N
a DT N
double-blind JJ N
study NN N
forty-two JJ p
children NNS p
scheduled VBN p
for IN p
elective JJ p
adenotonsillectomy NN p
were VBD N
randomized VBN N
to TO N
receive VB N
peritonsillar JJ N
infiltration NN i
, , N
following VBG N
induction NN N
of IN N
anaesthesia NN N
, , N
with IN N
either DT N
0.25 CD i
% NN i
plain NN i
bupivacaine NN i
or CC i
0.9 CD i
% NN i
saline NN i
, , N
0.5 CD N
ml/kg NN N
to TO N
a DT N
maximum NN N
of IN N
10 CD N
ml NN N
. . N

The DT N
children NNS p
were VBD N
assessed VBN N
on IN N
awakening NN o
, , N
and CC N
then RB N
10 CD N
minutes NNS N
, , N
1 CD N
hour NN N
, , N
4 CD N
hours NNS N
and CC N
24 CD N
hours NNS N
later RB N
. . N

On IN N
each DT N
occasion NN N
the DT N
observer NN N
gave VBD N
the DT N
child NN N
a DT N
pain NN o
score NN o
from IN N
1 CD N
( ( N
no DT N
pain NN N
) ) N
to TO N
5 CD N
( ( N
severe JJ N
pain NN N
) ) N
. . N

The DT N
scores NNS o
on IN o
awakening VBG o
and CC N
after IN N
10 CD N
minutes NNS N
were VBD N
significantly RB o
lower JJR o
in IN N
the DT N
bupivacaine NN i
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
, , N
Mann-Whitney NNP N
U NNP N
test NN N
) ) N
. . N

Thereafter RB N
there EX N
was VBD N
no DT N
difference NN N
between IN N
the DT N
groups NNS N
. . N

The DT N
authors NNS N
conclude VBP N
that IN N
peritonsillar JJ N
infiltration NN N
with IN N
bupivacaine NN i
is VBZ N
only RB N
moderately RB N
useful JJ N
as IN N
analgesia NN N
for IN N
children NNS p
having VBG p
tonsillectomy NN p
. . p

-DOCSTART- -24913600- O O

A DT N
brief JJ i
adherence NN i
intervention NN i
that WDT N
improved VBD N
glycemic JJ o
control NN o
: : o
mediation NN N
by IN N
patterns NNS N
of IN N
adherence NN N
. . N

This DT N
study NN N
examined VBD N
whether IN N
longitudinal JJ N
adherence NN N
profiles NNS N
mediated VBD N
the DT N
relationship NN N
between IN N
a DT p
brief JJ p
adherence NN i
intervention NN i
and CC p
glycemic JJ p
control NN p
among IN p
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
. . p

Adherence NNP i
was VBD N
assessed VBN N
using VBG N
the DT N
Medication NNP N
Event NNP N
Monitoring NNP N
System NNP N
. . N

Longitudinal JJ N
analysis NN N
via IN N
growth NN N
curve VBP N
mixture NN N
modeling NN N
was VBD N
carried VBN N
out IN N
to TO N
classify VB N
patients NNS N
according VBG N
to TO N
patterns NNS N
of IN N
adherence NN i
to TO i
oral JJ i
hypoglycemic JJ i
agents NNS i
. . i

Hemoglobin NNP N
A1c NNP N
assays NNS N
were VBD N
used VBN N
to TO N
measure VB N
glycemic JJ o
control NN o
as IN N
the DT N
clinical JJ N
outcome NN N
. . N

Across IN N
the DT N
whole JJ N
sample NN N
, , N
longitudinal JJ N
adherence NN N
profiles NNS N
mediated VBD N
35.2 CD N
% NN N
( ( N
13.2 CD N
, , N
81.0 CD N
% NN N
) ) N
of IN N
the DT N
effect NN N
of IN N
a DT N
brief JJ N
adherence NN i
intervention NN i
on IN N
glycemic JJ o
control NN o
[ NN N
from IN N
odds NNS N
ratio NN N
( ( N
OR NNP N
) ) N
= VBZ N
8.48 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
( ( N
3.24 CD N
, , N
22.2 CD N
) ) N
to TO N
4.00 CD N
, , N
95 CD N
% NN N
CI NNP N
( ( N
1.34 CD N
, , N
11.93 CD N
) ) N
] NN N
. . N

Our PRP$ N
results NNS N
suggest VBP N
that IN N
patients NNS N
in IN N
the DT N
intervention NN N
had VBD N
better JJR N
glycemic JJ o
control NN o
largely RB N
due JJ N
to TO N
their PRP$ N
greater JJR N
likelihood NN N
of IN N
adherence NN N
to TO N
oral JJ N
hypoglycemic JJ N
agents NNS N
. . N

-DOCSTART- -18761646- O O

Short-term JJ o
metabolic NN o
and CC o
cardiovascular JJ o
effects NNS o
of IN N
metformin NN i
in IN N
markedly RB p
obese JJ p
adolescents NNS p
with IN p
normal JJ p
glucose JJ p
tolerance NN p
. . p

OBJECTIVE CC N
Although IN N
metformin NN i
( ( N
MET NNP N
) ) N
is VBZ N
an DT N
insulin JJ N
sensitizer NN N
currently RB N
used VBN N
as IN N
an DT N
adjunct NN N
to TO N
the DT N
treatment NN N
of IN N
some DT N
of IN N
the DT N
complications NNS N
of IN N
childhood NN N
obesity NN N
besides IN N
type JJ N
2 CD N
diabetes NNS N
mellitus NN N
, , N
few JJ N
studies NNS N
have VBP N
comprehensively RB N
examined VBN N
its PRP$ N
metabolic NN N
and CC N
clinical JJ N
effects NNS N
in IN N
obese JJ N
children NNS N
with IN N
normal JJ N
glucose JJ N
tolerance NN N
( ( N
NGT NNP N
) ) N
. . N

METHODS NNP N
We PRP N
therefore RB N
conducted VBD N
a DT N
4-month JJ N
double-blind JJ N
clinical JJ N
trial NN N
in IN N
28 CD p
obese JJ p
[ JJ p
mean NN p
body NN o
mass NN o
index NN o
( ( o
BMI NNP o
) ) o
: : o
40.3 CD p
+/- JJ p
5.7 CD p
kg/m NN p
( ( p
2 CD p
) ) p
] NN p
, , p
insulin-resistant JJ p
[ JJ p
homeostasis NN p
model NN p
assessment JJ p
- : p
insulin NN p
resistance NN p
: : p
7.6 CD p
+/- JJ p
2.8 CD p
and CC p
whole JJ p
body NN p
insulin JJ p
sensitivity NN p
index NN p
( ( p
WBISI NNP p
) ) p
: : p
1.5 CD p
+/- JJ p
0.7 CD p
] JJ p
adolescents NNS p
( ( p
age NN p
15.0 CD p
+/- JJ p
1.3 CD p
yr NN p
) ) p
randomized VBD p
to TO p
MET NNP p
( ( p
n JJ p
= NN p
15 CD p
, , p
dose JJ p
1500 CD p
mg JJ p
daily JJ p
) ) p
or CC p
placebo NN i
( ( p
n JJ p
= NNP p
13 CD p
) ) p
. . p

RESULTS VB N
The DT N
treatment NN N
with IN N
MET NNP N
was VBD N
well RB N
tolerated VBN N
. . N

MET NNP N
treatment NN N
was VBD N
associated VBN N
with IN N
a DT N
decreased JJ N
BMI NNP o
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
as RB N
well RB N
as IN N
with IN N
a DT N
reduction NN N
in IN N
subcutaneous JJ o
fat NN o
( ( N
p JJ N
= NNP N
0.03 CD N
) ) N
, , N
particularly RB N
the DT N
deep JJ o
subcutaneous JJ o
fat NN o
( ( N
p JJ N
= NNP N
0.04 CD N
) ) N
as IN N
assessed VBN N
by IN N
magnetic JJ N
resonance NN N
imaging NN N
. . N

Postintervention NN N
, , N
the DT N
MET NNP N
group NN N
had VBD N
a DT N
35 CD N
% NN N
improvement NN N
in IN N
insulin NN o
sensitivity NN o
( ( o
WBISI NNP o
) ) o
compared VBN N
with IN N
the DT N
placebo NN i
group NN N
( ( N
p JJ N
= NNP N
0.008 CD N
) ) N
. . N

However RB N
, , N
significance NN N
was VBD N
lost VBN N
with IN N
adjustments NNS N
for IN N
differences NNS N
in IN N
baseline JJ N
insulin NN o
sensitivity NN o
( ( N
p JJ N
= NNP N
0.09 CD N
) ) N
. . N

While IN N
there EX N
was VBD N
no DT N
change NN N
in IN N
inflammatory JJ o
cytokines NNS o
or CC o
lipid JJ o
parameters NNS o
, , o
cardiovascular JJ o
function NN o
as IN N
assessed VBN N
by IN N
heart NN o
rate NN o
recovery NN o
after IN N
exercise NN N
improved VBN N
with IN N
MET NNP N
and CC N
worsened VBN N
in IN N
placebo NN N
( ( N
p JJ N
= NNP N
0.03 CD N
) ) N
. . N

CONCLUSION NNP N
Short-term NNP N
use NN N
of IN N
MET NNP N
is VBZ N
well RB N
tolerated VBN o
by IN N
obese JJ p
children NNS p
with IN p
NGT NNP p
and CC N
has VBZ N
a DT N
beneficial JJ N
effect NN N
on IN N
BMI NNP N
and CC N
autonomic JJ N
control NN N
of IN N
the DT N
heart NN N
as RB N
well RB N
as IN N
a DT N
trend NN N
toward IN N
improved JJ N
insulin NN o
sensitivity NN o
. . o

Thus RB N
, , N
long-term JJ N
treatment NN N
with IN N
MET NNP N
may MD N
provide VB N
a DT N
means NN N
to TO N
ameliorate VB N
the DT N
cardio-metabolic JJ o
consequences NNS o
of IN o
adolescent JJ o
obesity NN o
. . o

-DOCSTART- -18339093- O O

Teaching VBG N
picture-to-object JJ N
relations NNS N
in IN N
picture-based JJ N
requesting NN N
by IN N
children NNS p
with IN p
autism NN p
: : p
a DT N
comparison NN o
between IN N
error NN i
prevention NN i
and CC N
error NN i
correction NN i
teaching NN i
procedures NNS i
. . i

BACKGROUND NNP N
Children NNP p
who WP p
have VBP p
a DT p
combination NN p
of IN p
language NN p
and CC p
developmental JJ p
disabilities NNS p
with IN p
autism NN p
often RB N
experience JJ N
major JJ N
difficulties NNS N
in IN N
learning VBG N
relations NNS N
between IN N
objects NNS N
and CC N
their PRP$ N
graphic JJ N
representations NNS N
. . N

Therefore RB N
, , N
they PRP N
would MD N
benefit VB N
from IN N
teaching VBG i
procedures NNS i
that WDT N
minimize VBP N
their PRP$ N
difficulties NNS N
in IN N
acquiring VBG N
these DT N
relations NNS N
. . N

This DT N
study NN N
compared VBN N
two CD N
teaching NN i
procedures NNS i
, , i
an DT i
error NN i
prevention NN i
procedure NN i
and CC i
an DT i
error NN i
correction NN i
procedure NN i
, , i
for IN i
teaching VBG i
relations NNS i
between IN i
objects NNS i
and CC i
pictures NNS i
. . i

METHOD JJ N
Participants NNS p
were VBD p
two CD p
groups NNS p
of IN p
children NNS p
with IN p
autism NN p
, , p
aged VBD p
between IN p
3 CD p
and CC p
7 CD p
years NNS p
. . p

In IN N
the DT N
context NN N
of IN N
picture-to-object JJ N
requesting NN N
, , N
one CD N
group NN N
was VBD N
taught VBN N
using VBG N
an DT i
error NN i
correction NN i
method NN i
and CC N
the DT N
other JJ N
group NN N
with IN N
an DT i
error NN i
prevention NN i
method NN i
. . i

The DT N
measures NNS N
for IN N
each DT N
child NN N
were VBD N
accuracy NN o
of IN o
correspondences NNS o
between IN o
taught JJ o
picture NN o
and CC o
object JJ o
pairs NNS o
and CC o
accuracy NN o
of IN o
delayed JJ o
correspondences NNS o
in IN o
learning VBG o
outcome JJ o
tests NNS o
with IN o
all DT o
combinations NNS o
of IN o
object NN o
and CC o
picture NN o
pairs NNS o
presented VBN o
to TO N
them PRP N
throughout IN N
the DT N
study NN N
. . N

RESULTS NNP N
The DT N
group NN N
receiving VBG N
the DT N
error NN N
prevention-based JJ i
teaching NN i
made VBN N
significantly RB N
fewer JJR N
errors NNS o
during IN N
the DT N
teaching NN N
phases NNS N
and CC N
in IN N
their PRP$ N
learning NN N
outcome NN N
test NN N
for IN N
correspondences NNS N
between IN N
all DT N
combinations NNS N
of IN N
pictures NNS N
and CC N
objects NNS N
. . N

CONCLUSIONS VB N
The DT N
error NN N
prevention NN i
teaching NN i
procedure NN i
would MD N
seem VB N
to TO N
provide VB N
a DT N
more RBR N
efficient JJ N
and CC N
ecologically RB N
valid JJ N
method NN N
than IN N
the DT N
error NN N
correction NN N
procedure NN N
for IN N
teaching VBG N
relations NNS N
between IN N
objects NNS N
and CC N
their PRP$ N
graphic-based JJ N
referents NNS N
. . N

Improvements NNS N
in IN N
the DT N
methodology NN N
were VBD N
suggested VBN N
for IN N
providing VBG N
a DT N
stronger JJR N
basis NN N
for IN N
comparison NN N
between IN N
error NN N
correction NN N
and CC N
error NN N
prevention NN N
teaching VBG N
methods NNS N
. . N

-DOCSTART- -20042310- O O

A DT N
phase NN N
II NNP N
study NN N
of IN N
cetuximab NN i
, , i
capecitabine NN i
and CC N
radiotherapy NN i
in IN N
neoadjuvant JJ N
treatment NN N
of IN N
patients NNS p
with IN p
locally RB p
advanced VBN p
resectable JJ p
rectal JJ p
cancer NN p
. . p

BACKGROUND NNP N
Neoadjuvant NNP N
chemoradiotherapy NN i
( ( i
CRT NNP i
) ) i
reduces VBZ N
local JJ N
tumor NN N
recurrence NN N
in IN N
locally RB N
advanced JJ N
rectal JJ N
cancer NN N
( ( N
LARC NNP N
) ) N
. . N

This DT N
phase NN N
II NNP N
study NN N
assessed VBD N
neoadjuvant JJ N
cetuximab NN N
with IN N
capecitabine-based JJ N
CRT NNP N
in IN N
LARC NNP N
. . N

METHODS NNP N
Patients NNPS p
with IN p
stage NN p
II/III NNP p
LARC NNP p
received VBD N
capecitabine JJ i
1250 CD N
mg/m NN N
( ( N
2 CD N
) ) N
twice RB N
daily RB N
for IN N
2 CD N
weeks NNS N
followed VBN N
by IN N
intravenous JJ i
cetuximab NNS i
400 CD N
mg/m NN N
( ( N
2 CD N
) ) N
at IN N
week NN N
3 CD N
, , N
then RB N
weekly RB N
intravenous JJ N
250 CD N
mg/m NN N
( ( N
2 CD N
) ) N
cetuximab NN i
plus CC i
CRT NNP i
including VBG N
capecitabine NN i
825 CD N
mg/m NN N
( ( N
2 CD N
) ) N
twice RB N
daily RB N
( ( N
including VBG N
weekends NNS N
during IN N
radiotherapy NN N
) ) N
with IN N
radiotherapy NN i
of IN N
45 CD N
Gy NNP N
( ( N
25 CD N
x RB N
1.8 CD N
Gy NNP N
) ) N
, , N
5 CD N
days NNS N
a DT N
week NN N
for IN N
5 CD N
weeks NNS N
. . N

Total JJ N
mesorectal JJ N
excision NN N
was VBD N
scheduled VBN N
4-6 JJ N
weeks NNS N
following VBG N
completion NN N
of IN N
CRT NNP N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
pathological JJ o
complete JJ o
response NN o
( ( o
pCR NN o
) ) o
. . N

RESULTS JJ N
Thirty-seven JJ p
patients NNS p
were VBD p
eligible JJ p
for IN N
safety NN o
and CC o
efficacy NN o
. . o

TMN NNP o
staging VBG N
at IN N
baseline NN N
was VBD N
: : N
T4N2 NNP N
, , N
11 CD N
% NN N
; : N
T3N2 NNP N
, , N
40 CD N
% NN N
; : N
T2N2 NNP N
, , N
3 CD N
% NN N
; : N
T3N1 NNP N
, , N
35 CD N
% NN N
; : N
T2N1 NNP N
, , N
3 CD N
% NN N
and CC N
T3N0 NNP N
8 CD N
% NN N
. . N

The DT N
most RBS N
common JJ N
adverse JJ N
events NNS N
included VBD N
, , N
grade VBD o
1/2 CD o
acneiform NN o
skin NN o
rash NN o
( ( N
86 CD N
% NN N
) ) N
, , N
and CC N
grade VBD o
3 CD o
radiodermatitis NN o
, , N
( ( N
16 CD N
% NN N
) ) N
, , N
diarrhea NN o
( ( N
11 CD N
% NN N
) ) N
and CC N
hypersensitivity NN o
( ( N
5 CD N
% NN N
) ) N
. . N

pCR NN o
was VBD N
achieved VBN N
in IN N
3 CD N
patients NNS N
( ( N
8 CD N
% NN N
) ) N
. . N

Overall- JJ N
, , N
T- JJ o
and CC o
N-downstaging JJ o
rates NNS o
were VBD N
73 CD N
% NN N
, , N
57 CD N
% NN N
and CC N
81 CD N
% NN N
respectively RB N
. . N

Total JJ o
sphincter JJ o
preservation NN o
rate NN o
was VBD N
76 CD N
% NN N
, , N
and CC N
53 CD N
% NN N
in IN N
17 CD p
patients NNS p
whose WP$ N
tumors NNS N
were VBD N
located VBN N
within IN N
5 CD N
cm NN N
from IN N
the DT N
anal JJ N
verge NN N
. . N

Non-fatal JJ o
perioperative JJ o
complications NNS o
occurred VBD N
in IN N
13 CD p
patients NNS p
( ( N
35 CD N
% NN N
) ) N
with IN N
delayed VBN o
wound NN o
healing VBG o
occurring VBG N
in IN N
6 CD p
patients NNS p
( ( N
16 CD N
% NN N
) ) N
. . N

One CD N
death NN N
was VBD N
recorded VBN N
due JJ N
to TO N
sepsis VB N
following VBG N
colonic JJ N
necrosis NN N
. . N

CONCLUSION NNP N
Neoadjuvant NNP N
cetuximab NN i
with IN i
capecitabine-based JJ i
CRT NNP i
is VBZ N
tolerable JJ N
in IN N
patients NNS p
with IN p
resectable JJ p
LARC NNP p
. . p

Whilst NNP N
the DT N
pCR NN N
rate NN N
was VBD N
similar JJ N
to TO N
recent JJ N
reports NNS N
, , N
a DT N
high JJ N
pathological JJ N
downstaging VBG N
rate NN N
was VBD N
achieved VBN N
. . N

-DOCSTART- -18781287- O O

Efficacy NN o
of IN N
topical JJ N
azithromycin NN i
ophthalmic JJ N
solution NN N
1 CD N
% NN N
in IN N
the DT N
treatment NN N
of IN N
posterior JJ p
blepharitis NN p
. . p

INTRODUCTION NNP N
Azithromycin NNP i
, , N
a DT N
broad-spectrum JJ N
antibiotic JJ N
with IN N
potent JJ N
anti-inflammatory JJ N
activities NNS N
, , N
has VBZ N
the DT N
potential JJ N
to TO N
effectively RB N
treat VB N
blepharitis NN o
, , p
an DT p
inflammatory JJ p
disease NN p
of IN p
the DT p
eyelid JJ p
with IN p
abnormal JJ p
eyelid JJ p
flora NN p
as IN p
an DT p
etiologic JJ p
determinant NN p
. . p

The DT N
present JJ N
study NN N
compared VBN N
the DT N
efficacy NN o
of IN N
topical JJ N
azithromycin NN i
ophthalmic JJ N
solution NN N
1 CD N
% NN N
( ( N
AzaSite NNP N
; : N
Inspire NNP N
Pharmaceuticals NNP N
, , N
Inc NNP N
, , N
NC NNP N
, , N
USA NNP N
) ) N
combined VBD N
with IN N
warm JJ N
compresses NNS N
( ( N
azithromycin JJ N
group NN N
) ) N
to TO N
warm JJ N
compresses NNS N
alone RB N
( ( N
compress JJ N
group NN N
) ) N
in IN N
patients NNS N
with IN N
posterior JJ N
blepharitis NN N
. . N

METHODS NNP N
Twenty-one CD p
patients NNS p
diagnosed VBN p
with IN p
posterior JJ p
blepharitis NN p
were VBD N
randomized VBN N
in IN N
an DT N
open-label JJ N
study NN N
to TO N
receive VB N
either DT N
azithromycin NN i
plus CC i
warm JJ i
compresses NNS i
( ( N
10 CD N
patients NNS N
) ) N
, , N
or CC N
compresses VBZ N
alone RB N
( ( N
11 CD N
patients NNS N
) ) N
. . N

All DT N
patients NNS N
were VBD N
instructed VBN N
to TO N
apply VB N
compresses NNS N
to TO N
each DT N
eye NN N
for IN N
5-10 JJ N
minutes NNS N
twice RB N
daily RB N
for IN N
14 CD N
days NNS N
. . N

Each DT N
eye NN N
in IN N
the DT N
azithromycin NN i
group NN N
also RB N
received VBD N
azithromycin JJ N
solution NN N
( ( N
1 CD N
drop NN N
) ) N
twice RB N
daily RB N
for IN N
the DT N
first JJ N
2 CD N
days NNS N
followed VBN N
by IN N
once RB N
daily JJ N
for IN N
the DT N
next JJ N
12 CD N
days NNS N
. . N

Patients NNS N
were VBD N
evaluated VBN N
at IN N
study NN N
initiation NN N
( ( N
visit IN N
1 CD N
) ) N
and CC N
at IN N
end NN N
of IN N
treatment NN N
( ( N
visit IN N
2 CD N
) ) N
for IN N
the DT N
severity NN N
of IN N
five CD N
clinical JJ N
signs NNS N
: : N
eyelid JJ o
debris NN o
, , o
eyelid JJ o
redness NN o
, , o
eyelid JJ o
swelling NN o
, , o
meibomian JJ o
gland NN o
( ( o
MG NNP o
) ) o
plugging NN o
, , o
and CC o
the DT o
quality NN o
of IN o
MG NNP o
secretion NN o
. . o

At IN N
visit NN N
2 CD N
, , N
patients NNS N
also RB N
rated VBD N
their PRP$ N
degree NN N
of IN N
overall JJ o
symptomatic JJ o
relief NN o
. . o

RESULTS NNP N
Twenty NNP p
patients NNS p
completed VBD p
the DT p
study NN p
. . p

At IN N
visit NN N
2 CD N
, , N
patients NNS N
in IN N
the DT N
azithromycin NN i
group NN N
demonstrated VBD N
significant JJ o
improvements NNS o
in IN N
MG NNP o
plugging NN o
, , o
MG NNP o
secretions NNS o
, , o
and CC o
eyelid JJ o
redness NN o
as IN N
compared VBN N
with IN N
the DT N
compress NN N
group NN N
. . N

In IN N
the DT N
azithromycin NN i
group NN N
, , N
MG NNP o
plugging VBG o
resolved VBN N
completely RB N
in IN N
three CD N
patients NNS N
and CC N
MG NNP o
secretion NN o
returned VBD o
to TO o
normal JJ o
in IN N
two CD N
patients NNS N
; : N
no DT N
such JJ N
results NNS N
were VBD N
seen VBN N
in IN N
the DT N
compress NN N
group NN N
. . N

Furthermore RB N
, , N
a DT N
higher JJR N
percentage NN N
of IN N
patients NNS N
in IN N
the DT N
azithromycin NN N
group NN N
rated VBD N
overall JJ o
symptomatic JJ o
relief NN o
as IN N
excellent NN N
or CC N
good JJ N
. . N

Visual JJ o
acuity NN o
measurements NNS o
and CC o
biomicroscopic JJ o
evaluation NN o
revealed VBD N
no DT o
ocular JJ o
safety NN o
issues NNS o
. . o

CONCLUSION NNP N
Azithromycin NNP i
ophthalmic JJ N
solution NN N
in IN N
combination NN N
with IN N
warm JJ N
compresses NNS N
provided VBD N
a DT N
significantly RB o
greater JJR o
clinical JJ o
benefit NN o
than IN N
warm JJ N
compresses NNS N
alone RB N
in IN N
treating VBG N
the DT N
signs NNS o
and CC o
symptoms NNS o
of IN o
posterior JJ o
blepharitis NN o
. . o

-DOCSTART- -18802980- O O

CASTLE NNP i
data NNS i
show VBP p
no DT p
gender NN p
differences NNS p
. . p

-DOCSTART- -25681235- O O

Assessment NN N
of IN N
paravalvular JJ N
aortic JJ N
regurgitation NN N
after IN N
transcatheter NN i
aortic JJ i
valve NN i
replacement NN i
: : i
intra-core JJ N
laboratory NN N
variability NN N
. . N

BACKGROUND NNP N
There EX N
is VBZ N
significant JJ N
disparity NN N
in IN N
the DT N
reported JJ N
incidence NN N
of IN N
moderate JJ p
and CC p
severe JJ p
paravalvular JJ o
aortic JJ o
regurgitation NN o
( ( o
PAR NNP o
) ) o
between IN N
the DT N
Placement NNP p
of IN p
Aortic NNP p
Transcatheter NNP p
Valves NNP p
( ( p
PARTNER NNP p
) ) p
I PRP p
and CC p
PARTNER NNP p
II NNP p
trials NNS p
, , N
which WDT N
may MD N
be VB N
related VBN N
to TO N
the DT N
echocardiographic JJ N
methodologies NNS N
used VBN N
by IN N
separate JJ N
core NN N
laboratories NNS N
. . N

To TO N
further RBR N
explore VB N
the DT N
variability NN N
in IN N
echocardiographic JJ N
interpretation NN N
of IN N
PAR NNP N
, , N
agreement NN N
between IN N
the DT N
grading NN N
of IN N
PAR NNP N
by IN N
the DT N
core NN N
laboratory NN N
of IN N
PARTNER NNP N
IIB NNP N
was VBD N
compared VBN N
with IN N
that DT N
by IN N
a DT N
consortium NN N
of IN N
echocardiography NN N
core NN N
laboratory NN N
directors NNS N
. . N

METHODS NNP N
The DT N
PARTNER NNP N
IIB NNP N
core NN N
laboratory NN N
reevaluated VBD N
patients NNS N
using VBG N
primarily RB N
the DT N
circumferential JJ N
extent NN N
of IN N
the DT N
regurgitant NN N
jet NN N
for IN N
PAR NNP o
. . o

A NNP N
consortium NN p
of IN p
echocardiography NN p
core NN p
laboratory NN p
directors NNS p
was VBD N
formed VBN N
to TO N
evaluate VB N
the DT N
echocardiographic JJ i
images NNS i
and CC N
to TO N
grade VB N
PAR NNP o
and CC N
central JJ N
and CC N
total JJ N
aortic JJ N
regurgitation NN N
in IN N
a DT N
randomly JJ p
chosen NN p
subset NN p
of IN p
the DT p
randomized JJ p
patients NNS p
in IN p
the DT p
PARTNER NNP p
IIB NNP p
trial NN p
using VBG p
a DT p
multiwindow NN p
, , p
multiparametric JJ p
approach NN p
. . p

Both CC N
a DT N
four-class JJ N
scale NN N
( ( N
none NN N
or CC N
trace NN N
, , N
mild NN N
, , N
moderate JJ N
, , N
and CC N
severe RB N
) ) N
and CC N
a DT N
seven-class NN N
( ( N
none NN N
, , N
trace NN N
, , N
mild NN N
, , N
mild NN N
to TO N
moderate VB N
, , N
moderate VB N
, , N
moderate VB N
to TO N
severe VB N
, , N
and CC N
severe RB N
) ) N
scale NN N
were VBD N
used VBN N
. . N

Levels NNP N
of IN N
grading VBG N
agreement NN N
between IN N
the DT N
consortium NN N
and CC N
original JJ N
core NN N
laboratory NN N
in IN N
both DT N
scales NNS N
were VBD N
determined VBN N
using VBG N
weighted VBN N
? . N
statistics NNS N
. . N

RESULTS NNP p
Only RB p
87 CD p
patients NNS p
assessed VBN p
for IN o
PAR NNP o
by IN p
the DT p
consortium NN p
could MD p
be VB p
paired VBN p
with IN p
readings NNS p
by IN p
the DT p
PARTNER NNP p
IIB NNP p
core NN p
laboratory NN p
. . p

Using VBG N
the DT N
four-class NN N
grading VBG N
scheme NN N
the DT o
weighted VBN o
? . o
statistic JJ o
for IN o
PAR NNP o
was VBD o
0.481 CD N
( ( N
95 CD N
% NN N
confidence NN N
limits NNS N
, , N
0.367 CD N
, , N
0.595 CD N
) ) N
. . N

Using VBG N
the DT N
seven-class JJ N
scale NN N
, , N
the DT o
weighted VBN o
? . o
statistic JJ o
for IN o
PAR NNP o
was VBD o
0.517 CD N
( ( N
95 CD N
% NN N
confidence NN N
limits NNS N
, , N
0.431 CD N
, , N
0.607 CD N
) ) N
. . N

For IN N
either DT N
grading VBG N
scheme NN N
, , N
15.9 CD N
% NN N
of IN N
patients NNS N
graded VBN N
by IN N
the DT N
PARTNER NNP N
IIB NNP N
core NN N
laboratory NN N
as IN N
having VBG N
moderate JJ o
PAR NNP o
would MD o
have VB N
been VBN N
graded VBN N
as IN N
having VBG N
mild JJ o
PAR NNP o
using VBG o
the DT N
multiparametric JJ N
approach NN N
. . N

Similar JJ N
results NNS N
were VBD N
seen VBN N
for IN N
central JJ o
and CC o
total JJ o
aortic JJ o
regurgitation NN o
assessments NNS o
. . N

CONCLUSIONS NNP N
Using NNP N
primarily RB N
the DT N
circumferential JJ N
extent NN N
criteria NNS N
, , N
the DT N
PARTNER NNP N
IIB NNP N
core NN N
laboratory NN N
overestimated VBD N
the DT N
severity NN N
of IN N
PAR NNP o
compared VBN o
to TO N
the DT N
consortium NN N
using VBG N
a DT N
multi-parametric JJ N
approach NN N
. . N

Although IN N
a DT N
more RBR N
granular JJ N
classification NN N
scheme NN N
for IN N
PAR NNP N
may MD N
slightly RB N
improve VB N
concordance NN N
between IN N
core NN N
laboratories NNS N
, , N
differences NNS N
in IN N
the DT N
incidence NN N
of IN N
moderate JJ N
or CC N
severe JJ o
PAR NN o
are VBP o
likely JJ N
related VBN N
to TO N
differences NNS N
in IN N
grading VBG N
methodology NN N
. . N

A DT N
multiparametric JJ N
approach NN N
is VBZ N
advocated VBN N
, , N
and CC N
other JJ N
echocardiographic JJ N
methods NNS N
for IN N
assessing VBG N
PAR NNP N
deserve VB N
further RB N
study NN N
. . N

-DOCSTART- -25359159- O O

Comparison NNP N
of IN N
insulin NN i
glargine NN i
and CC i
liraglutide NN i
added VBD N
to TO N
oral JJ N
agents NNS N
in IN N
patients NNS p
with IN p
poorly RB p
controlled VBN p
type NN p
2 CD p
diabetes NNS p
. . p

AIM NNP N
To TO N
compare VB N
safety NN N
and CC N
efficacy NN N
of IN N
insulin NN i
glargine NN i
and CC i
liraglutide NN i
in IN N
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
( ( p
T2DM NNP p
) ) p
. . p

METHODS NNP N
This DT N
randomized VBN N
, , N
multinational JJ N
, , N
open-label JJ N
trial NN N
included VBD N
subjects NNS p
treated VBN p
for IN p
T2DM NNP p
with IN p
metformin NN i
? . i
sulphonylurea NN i
, , i
who WP i
had VBD p
glycated VBN p
haemoglobin NN p
( ( p
HbA1c NNP p
) ) p
levels NNS p
of IN p
7.5-12 CD p
% NN p
. . p

Subjects NNS p
were VBD N
assigned VBN N
to TO N
24 CD N
weeks NNS i
of IN i
insulin NN i
glargine NN i
, , i
titrated VBN i
to TO N
target VB N
fasting VBG N
plasma JJ N
glucose NN N
of IN N
4.0-5.5 JJ N
mmol/L NN i
or CC i
liraglutide NN i
, , i
escalated VBN i
to TO N
the DT N
highest JJS N
approved JJ N
clinical JJ N
dose NN N
of IN N
1.8 CD N
mg JJ N
daily RB N
. . N

The DT N
trial NN N
was VBD N
powered VBN N
to TO N
detect VB N
superiority NN N
of IN i
glargine NN i
over IN i
liraglutide NN i
in IN i
percentage NN i
of IN N
people NNS N
reaching VBG N
HbA1c NNP N
< $ N
7 CD N
% NN N
. . N

RESULTS VB p
The DT p
mean JJ p
[ NNP p
standard NN p
deviation NN p
( ( p
s.d JJ p
. . p

) ) p
] JJ p
age NN p
of IN p
the DT p
participants NNS p
was VBD p
57 CD p
( ( p
9 CD p
) ) p
years NNS p
, , p
the DT p
duration NN p
of IN p
diabetes NNS p
was VBD p
9 CD p
( ( p
6 CD p
) ) p
years NNS p
, , p
body NN p
mass NN p
index NN p
was VBD p
31.9 CD p
( ( p
4.2 CD p
) ) p
kg/m NN p
( ( p
2 CD p
) ) p
and CC p
HbA1c NNP p
level NN p
was VBD p
9.0 CD p
( ( p
1.1 CD p
) ) p
% NN p
. . p

Equal JJ p
numbers NNS p
( ( p
n JJ p
= NNP p
489 CD p
) ) p
were VBD p
allocated VBN p
to TO N
glargine VB N
and CC N
liraglutide VB p
. . p

Similar JJ p
numbers NNS p
of IN p
subjects NNS p
in IN p
both DT p
groups NNS p
attained VBD p
an DT o
HbA1c NNP o
level NN o
of IN o
< JJ o
7 CD o
% NN N
( ( N
48.4 CD N
vs. FW N
45.9 CD N
% NN N
) ) N
; : N
therefore RB N
, , N
superiority NN N
of IN N
glargine NN N
over IN N
liraglutide NN N
was VBD N
not RB N
observed VBN N
( ( N
p JJ N
= NNP N
0.44 CD N
) ) N
. . N

Subjects NNS p
treated VBD p
with IN p
glargine NN p
had VBD p
greater JJR N
reductions NNS N
of IN N
HbA1c NNP o
[ NNP o
-1.94 NNP o
% NN N
( ( N
0.05 CD N
) ) N
and CC N
-1.79 $ N
% NN N
( ( N
0.05 CD N
) ) N
; : N
p CC N
= $ N
0.019 CD N
] NN N
and CC o
fasting VBG o
plasma NN o
glucose JJ o
[ JJ o
6.2 CD N
( ( N
1.6 CD N
) ) N
and CC N
7.9 CD N
( ( N
2.2 CD N
) ) N
mmol/L NN N
; : N
p CC N
< $ N
0.001 CD N
] NN N
than IN N
those DT N
receiving VBG N
liraglutide RB N
. . N

The DT N
liraglutide NN p
group NN p
reported VBD p
a DT N
greater JJR o
number NN o
of IN o
gastrointestinal JJ o
treatment-emergent JJ o
adverse JJ o
events NNS o
( ( o
p JJ o
< NNP o
0.001 CD o
) ) o
. . o

The DT o
mean NN o
( ( o
s.d NN o
. . o

) ) o
weight VBD o
change NN o
was VBD o
+2.0 NNP o
( ( N
4.0 CD N
) ) N
kg NN N
for IN N
glargine NN N
and CC N
-3.0 NNP N
( ( N
3.6 CD N
) ) N
kg NN N
for IN N
liraglutide NN N
( ( N
p JJ N
< NNP N
0.001 CD o
) ) o
. . o

Symptomatic JJ o
hypoglycaemia NN o
was VBD o
more RBR N
common JJ N
with IN N
glargine NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

A DT N
greater JJR N
number NN N
of IN N
subjects NNS N
in IN N
the DT N
liraglutide JJ N
arm NN N
withdrew NN N
as IN N
a DT N
result NN N
of IN N
adverse JJ N
events NNS N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSION NNP N
Adding NNP N
either CC N
insulin JJ N
glargine NN N
or CC N
liraglutide NN p
to TO p
subjects NNS p
with IN p
poorly RB N
controlled VBN N
T2DM NNP N
reduces NNS N
HbA1c NNP N
substantially RB N
, , N
with IN N
nearly RB N
half NN N
of IN N
subjects NNS N
reaching VBG N
target NN N
levels NNS N
of IN N
7 CD N
% NN N
. . N

-DOCSTART- -22695168- O O

The DT N
effects NNS N
of IN N
orthotic JJ i
heel NN i
lifts NNS i
on IN N
Achilles NNP o
tendon NNP o
force NN o
and CC o
strain NN o
during IN N
running VBG N
. . N

This DT N
study NN N
assessed VBD N
the DT N
effects NNS N
of IN N
orthotic JJ i
heel NN i
lifts NNS i
on IN N
Achilles NNP o
tendon NN o
( ( o
AT NNP o
) ) o
force NN o
and CC o
strain NN o
during IN N
running VBG N
. . N

Ten CD p
females NNS p
ran VBD p
barefoot NN p
over IN p
a DT p
force NN p
plate NN p
in IN p
three CD p
conditions NNS p
: : p
no DT i
heel NN i
lifts NNS i
( ( p
NHL NNP p
) ) p
, , p
with IN p
12 CD i
mm NNS i
heel JJ i
lifts NNS i
( ( p
12HL CD p
) ) p
and CC p
with IN p
18 CD i
mm NNS i
heel JJ i
lifts NNS i
( ( p
18HL CD p
) ) p
. . p

Kinematics NNS o
for IN o
the DT o
right JJ o
lower JJR o
limb NN o
were VBD N
collected VBN N
( ( N
200 CD N
Hz NNP N
) ) N
. . N

AT NNP o
force NN o
was VBD N
calculated VBN N
from IN N
inverse JJ N
dynamics NNS N
. . N

AT NNP o
strain NN o
was VBD N
determined VBN N
from IN N
kinematics NNS N
and CC N
ultrasound JJ N
images NNS N
of IN N
medial JJ N
gastrocnemius NN N
( ( N
50 CD N
Hz NNP N
) ) N
. . N

Peak NNP o
AT NNP o
strain NN o
was VBD N
less JJR N
for IN N
18HL CD N
( ( N
5.5 CD N
? . N
4.4 CD N
% NN N
) ) N
than IN N
for IN N
NHL NNP N
( ( N
7.4 CD N
? . N
4.2 CD N
% NN N
) ) N
( ( N
p JJ N
= NNP N
.029 NNP N
, , N
effect NN N
size NN N
[ NNP N
ES NNP N
] NNP N
= NNP N
0.44 CD N
) ) N
but CC N
not RB N
for IN N
12HL CD N
( ( N
5.8 CD N
? . N
4.8 CD N
% NN N
) ) N
versus NN N
NHL NNP N
( ( N
ES NNP N
= NNP N
0.35 CD o
) ) o
. . o

Peak NNP o
AT NNP o
force NN o
was VBD o
significantly RB N
( ( N
p JJ N
= NNP N
.024 NNP N
, , N
ES NNP N
= NNP N
0.42 CD N
) ) N
less JJR N
for IN N
18HL CD N
( ( N
2382 CD N
? . N
717 CD N
N NNP N
) ) N
than IN N
for IN N
NHL NNP N
( ( N
2710 CD N
? . N
830 CD N
N NNP N
) ) N
but CC N
not RB N
for IN N
12HL CD N
( ( N
2538 CD N
? . N
823 CD N
N NNP N
, , N
ES NNP N
= NNP N
0.21 CD N
) ) N
. . N

The DT N
18HL CD N
reduced VBD o
ankle JJ o
dorsiflexion NN o
but CC o
not RB o
flexion-extension JJ o
ankle NN o
moments NNS o
and CC o
increased VBD o
the DT o
AT NNP o
moment NN o
arm NN o
compared VBN o
with IN N
NHL NNP N
. . N

Thus NNP N
, , N
18HL CD N
reduced VBN o
force NN o
and CC o
strain NN o
on IN o
the DT o
AT NNP N
during IN N
running VBG N
via IN N
a DT N
reduction NN o
in IN o
dorsiflexion NN o
, , o
which WDT o
lengthened VBD o
the DT o
AT NNP o
moment NN o
arm NN o
. . o

Therefore RB i
, , i
heel NN i
lifts NNS i
could MD N
be VB N
used VBN N
to TO N
reduce VB N
AT NNP o
loading NN o
and CC o
strain NN o
during IN o
the DT N
rehabilitation NN N
of IN N
AT NNP N
injuries NNS N
. . N

-DOCSTART- -8277075- O O

Altered NNP N
peripheral JJ o
vasodilator NN o
profile NN o
of IN N
nitroglycerin JJ N
during IN N
long-term JJ N
infusion NN N
of IN N
N-acetylcysteine NNP N
. . N

OBJECTIVES NNP N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
short- JJ o
and CC o
long-term JJ o
effects NNS o
of IN N
intravenous JJ i
nitroglycerin JJ i
plus CC i
placebo JJ i
and CC N
nitroglycerin JJ i
plus CC i
N-acetylcysteine JJ i
on IN N
peripheral JJ N
arteries NNS N
, , N
veins NNS N
and CC N
microcirculation NN N
in IN N
humans NNS N
. . N

BACKGROUND IN N
The DT N
thiol JJ N
donor JJ N
N-acetylcysteine NN i
may MD N
potentiate VB N
the DT N
hemodynamic JJ N
response NN N
to TO N
nitrates NNS N
in IN N
nitrate-tolerant JJ N
and CC N
nontolerant JJ N
patients NNS N
. . N

The DT N
vascular JJ N
changes NNS N
responsible JJ N
for IN N
this DT N
effect NN N
are VBP N
not RB N
clear JJ N
. . N

METHODS NNP N
Eight NNP p
male NN p
volunteers NNS p
were VBD N
treated VBN N
with IN N
nitroglycerin NN i
( ( i
0.1 CD i
microgram/kg NN i
per IN i
min NN i
) ) i
combined VBN i
with IN i
N-acetylcysteine NNP i
( ( N
2 CD N
g NN N
intravenously RB N
, , N
followed VBN N
by IN N
5 CD N
mg/kg NNS N
per IN N
h NN N
) ) N
or CC N
placebo NN i
for IN N
23 CD N
h NN N
in IN N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
crossover NN N
study NN N
. . N

Venous JJ o
volume NN o
, , N
the DT N
diameter NN o
of IN o
the DT o
radial NN o
and CC o
temporal JJ o
arteries NNS o
, , o
calf NN o
blood NN o
flow NN o
and CC N
subcutaneous JJ o
blood NN o
flow NN o
were VBD N
measured VBN N
at IN N
baseline NN N
and CC N
repeated VBD N
after IN N
1 CD N
and CC N
23 CD N
h NN N
of IN N
infusion NN N
. . N

RESULTS NNP N
Prolonged VBD N
coadministration NN N
of IN N
N-acetylcysteine NNP i
and CC i
nitroglycerin RB i
potentiated VBD N
the DT N
acute JJ o
venodilator NN o
effect NN o
of IN N
nitroglycerin NN N
as IN N
estimated VBN N
by IN N
changes NNS o
in IN o
venous JJ o
volume NN o
( ( i
nitroglycerin JJ i
plus CC i
N-acetylcysteine JJ i
, , N
4.45 CD N
+/- JJ N
0.36 CD N
ml/100 NN N
g NN N
; : N
nitroglycerin CC i
plus CC i
placebo NN i
, , N
3.65 CD N
+/- JJ N
0.46 CD N
ml/100 NN N
g NN N
, , N
mean JJ N
+/- JJ N
SEM NNP N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
and CC N
prevented VBD N
development NN o
of IN o
tolerance NN o
as IN N
seen VBN N
after IN N
23 CD N
h NN N
of IN N
treatment NN N
with IN N
nitroglycerin JJ N
plus CC N
placebo NN N
( ( N
4.35 CD N
+/- JJ N
0.25 CD N
vs. FW N
3.47 CD N
+/- JJ N
0.41 CD N
ml/100 NN N
g NN N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
. . N

N-acetylcysteine NNP i
had VBD N
no DT N
effect NN N
on IN N
nitroglycerin-induced JJ o
changes NNS o
in IN o
arterial JJ o
diameters NNS o
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
but CC N
significantly RB N
increased VBD N
microcirculatory JJ o
subcutaneous JJ o
blood NN o
flow NN o
after IN o
1 CD o
h NN o
( ( i
nitroglycerin JJ i
plus CC i
N-acetylcysteine JJ i
: : i
6.3 CD N
+/- JJ N
1.3 CD N
ml/100 NN N
g NN N
per IN N
min NN N
vs. FW N
nitroglycerin JJ i
plus CC i
placebo NN i
: : i
3.5 CD N
+/- JJ N
0.3 CD N
ml/100 NN N
g NN N
per IN N
min NN N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
and CC N
after IN N
23 CD N
h NN N
( ( N
4.4 CD N
+/- JJ N
0.6 CD N
vs. FW N
3.1 CD N
+/- JJ N
0.5 CD N
ml/100 NN N
g NN N
per IN N
min NN N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS VB N
The DT N
results NNS N
suggest VBP N
that IN N
coadministration NN N
of IN N
nitroglycerin JJ i
and CC i
N-acetylcysteine JJ i
in IN N
humans NNS N
1 CD N
) ) N
potentiates NNS N
and CC N
preserves VBZ N
nitroglycerin-induced JJ o
venodilation NN o
and CC N
2 CD N
) ) N
augments VBZ N
the DT N
effect NN o
of IN o
nitroglycerin NN o
on IN o
small JJ o
resistance NN o
vessels NNS o
( ( o
regulating VBG o
subcutaneous JJ o
blood NN o
flow NN o
) ) o
without IN o
affecting VBG o
the DT o
response NN o
to TO o
nitroglycerin VB o
in IN o
middle-sized JJ o
arteries NNS o
. . o

Both CC N
the DT N
development NN N
of IN N
nitrate JJ o
tolerance NN o
and CC N
the DT N
administration NN N
of IN N
N-acetylcysteine NNP i
significantly RB N
change VBP N
the DT N
normal JJ N
vasodilator NN o
profile NN o
of IN N
nitroglycerin NN i
in IN N
humans NNS N
. . N

-DOCSTART- -24554519- O O

Psychological JJ N
functioning NN N
1 CD N
year NN N
after IN N
a DT N
brief JJ N
intervention NN N
using VBG N
micronutrients NNS i
to TO N
treat VB N
stress NN o
and CC p
anxiety NN o
related VBN p
to TO p
the DT p
2011 CD p
Christchurch NNP p
earthquakes NNS p
: : p
a DT N
naturalistic JJ N
follow-up NN N
. . N

OBJECTIVE IN N
We PRP N
investigated VBD N
whether IN N
micronutrients NNS i
given VBN N
acutely RB N
following VBG N
the DT N
Christchurch NNP p
earthquakes NNS N
continued VBD N
to TO N
confer VB N
benefit NN N
1 CD N
year NN N
following VBG N
the DT N
treatment NN N
. . N

METHODS NNP N
Sixty-four JJ p
adults NNS p
from IN p
the DT p
original JJ p
91 CD p
participants NNS p
experiencing VBG p
heightened VBN p
anxiety NN p
or CC p
stress JJ p
2-3 JJ p
months NNS p
following VBG p
the DT p
22nd CD p
February NNP p
2011 CD p
earthquake NN p
and CC p
who WP p
had VBD p
been VBN p
randomized VBN p
to TO p
receive VB p
three CD i
different JJ i
doses NNS i
of IN i
micronutrients NNS i
completed VBN p
on-line JJ p
questionnaires NNS p
assessing VBG p
mood NN o
, , o
anxiety NN o
, , o
stress NN o
, , o
and CC o
symptoms NNS o
associated VBN o
with IN o
post-traumatic JJ o
stress NN o
disorder NN o
1 CD p
year NN p
after IN p
completing VBG p
the DT p
initial JJ p
study NN p
. . p

Twenty-one CD p
out IN p
of IN p
29 CD p
nonrandomized JJ p
controls NNS p
who WP p
did VBD p
not RB p
receive VB p
the DT p
treatment NN p
also RB p
completed VBD p
the DT p
questionnaires NNS p
. . N

RESULTS NNP N
Both NNP N
the DT N
treated VBN N
and CC N
control VB N
groups NNS N
experienced JJ N
significant JJ N
improvement NN N
in IN N
psychological JJ o
functioning NN o
compared VBN N
with IN N
end-of-trial JJ N
. . N

However RB N
, , N
treated VBD N
participants NNS N
had VBD N
better RBR N
long-term JJ o
outcomes NNS o
on IN N
most JJS N
measures NNS N
compared VBN N
with IN N
controls NNS N
( ( N
ES=0.69-1.31 NNP N
) ) N
. . N

Those DT N
who WP N
stayed VBD N
on IN N
micronutrients NNS N
through IN N
to TO N
follow-up JJ N
or CC N
stopped VBD N
all DT N
treatment NN N
reported VBD N
better RBR N
psychological JJ o
functioning NN o
than IN N
those DT N
who WP N
switched VBD N
to TO N
other JJ N
treatments NNS N
including VBG N
medications NNS N
. . N

About IN N
10 CD N
% NN N
of IN N
the DT N
sample NN N
continued VBD N
to TO N
have VB N
post-traumatic JJ o
stress NN o
disorder NN o
symptoms NNS o
. . o

CONCLUSIONS NNP N
Disaster NNP p
survivors NNS p
improve VBP N
psychologically RB N
over IN N
time NN N
regardless NN N
of IN N
receiving VBG N
intervention NN N
; : N
however RB N
, , N
those DT N
taking VBG N
micronutrients NNS i
during IN N
the DT N
acute JJ N
phase NN N
following VBG N
a DT N
disaster NN N
show NN N
better RBR N
outcomes RB o
, , N
identifying VBG N
micronutrients NNS i
as IN N
a DT N
viable JJ N
treatment NN N
for IN N
acute JJ o
stress NN o
following VBG N
a DT N
natural JJ N
disaster NN N
with IN N
maintenance NN N
of IN N
benefits NNS N
1 CD N
year NN N
later RB N
. . N

ACTRN $ N
12611000460909 CD N
-DOCSTART- -24290135- O O

A DT N
novel JJ N
methodology NN N
for IN N
generating VBG N
3D CD i
finite JJ i
element NN i
models NNS i
of IN p
the DT p
hip NN p
from IN N
2D CD i
radiographs NN i
. . i

Finite NNP i
element NN i
( ( i
FE NNP i
) ) i
modelling NN i
has VBZ N
been VBN N
proposed VBN N
as IN N
a DT N
tool NN N
for IN N
estimating VBG N
fracture NN o
risk NN o
and CC N
patient-specific JJ i
FE NNP i
models NNS i
are VBP N
commonly RB N
based VBN N
on IN N
computed JJ i
tomography NN i
( ( N
CT NNP N
) ) N
. . N

Here RB N
, , N
we PRP N
present VBP N
a DT N
novel JJ N
method NN N
to TO N
automatically RB N
create VB i
personalised VBD i
3D CD i
models NNS i
from IN i
standard JJ i
2D CD i
hip NN i
radiographs NN i
. . i

A DT N
set NN N
of IN N
geometrical JJ N
parameters NNS N
of IN N
the DT N
femur NN N
were VBD N
determined VBN N
from IN N
seven CD p
a-p JJ i
hip NN i
radiographs NN i
and CC N
compared VBN N
to TO N
the DT N
3D CD i
femoral JJ i
shape NN i
obtained VBN i
from IN i
CT NNP i
as IN N
training VBG N
material NN N
; : N
the DT N
error NN N
in IN N
reconstructing VBG N
the DT N
3D CD N
model NN N
from IN N
the DT N
2D CD N
radiographs NN N
was VBD N
assessed VBN N
. . N

Using VBG N
the DT N
geometry NN N
parameters NNS N
as IN N
the DT N
input NN N
, , N
the DT N
3D CD N
shape NN N
of IN N
another DT N
21 CD p
femora NN p
was VBD p
built VBN p
and CC p
meshed VBN p
, , N
separating VBG N
a DT N
cortical JJ N
and CC N
trabecular JJ N
compartment NN N
. . N

The DT N
material NN N
properties NNS N
were VBD N
derived VBN N
from IN N
the DT N
homogeneity NN o
index NN o
assessed VBN N
by IN N
texture NN N
analysis NN N
of IN N
the DT N
radiographs NN N
, , N
with IN N
focus NN N
on IN N
the DT N
principal NN N
tensile NN N
and CC N
compressive JJ N
trabecular JJ N
systems NNS N
. . N

The DT N
ability NN N
of IN N
these DT N
FE NNP i
models NNS i
to TO N
predict VB N
failure NN o
load NN o
as IN N
determined VBN N
by IN N
experimental JJ N
biomechanical JJ N
testing NN N
was VBD N
evaluated VBN N
and CC N
compared VBN N
to TO N
the DT N
predictive JJ N
ability NN N
of IN N
DXA NNP N
. . N

The DT N
average JJ o
reconstruction NN o
error NN o
of IN N
the DT N
3D CD N
models NNS N
was VBD N
1.77 CD N
mm NN N
( ( N
?1.17 NNP N
mm NN N
) ) N
, , N
with IN N
the DT N
error NN N
being VBG N
smallest JJS N
in IN N
the DT N
femoral JJ N
head NN N
and CC N
neck NN N
, , N
and CC N
greatest JJS N
in IN N
the DT N
trochanter NN N
. . N

The DT o
correlation NN o
of IN N
the DT o
FE NNP o
predicted VBD o
failure NN o
load NN o
with IN N
the DT o
experimental JJ o
failure NN o
load NN o
was VBD N
r NN N
( ( N
2 CD N
) ) N
=64 CD N
% NN N
for IN N
the DT N
reconstruction NN N
FE NNP N
model NN N
, , N
which WDT N
was VBD N
significantly RB N
better JJR N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
than IN N
that DT N
for IN N
DXA NNP N
( ( N
r NN N
( ( N
2 CD N
) ) N
=24 CD N
% NN N
) ) N
. . N

This DT N
novel JJ N
method NN N
for IN N
automatically RB N
constructing VBG N
a DT N
patient-specific JJ i
3D CD i
finite JJ i
element NN i
model NN i
from IN i
standard JJ i
2D CD i
radiographs NN i
shows NNS o
encouraging VBG o
results NNS o
in IN N
estimating VBG o
patient-specific JJ o
failure NN o
loads NNS o
. . o

-DOCSTART- -9006472- O O

Feasibility NN o
and CC o
effects NNS o
of IN N
nurse JJ i
run NN i
clinics NNS i
for IN p
patients NNS p
with IN p
epilepsy NN p
in IN p
general JJ p
practice NN p
: : p
randomised VBN N
controlled JJ N
trial NN N
. . N

Epilepsy NNP N
Care NNP N
Evaluation NNP N
Group NNP N
. . N

OBJECTIVE NNP N
To TO N
test VB N
the DT N
feasibility NN o
and CC o
effect NN o
of IN N
nurse JJ i
run NN i
epilepsy NN i
clinics NNS i
in IN p
primary JJ p
care NN p
. . p

DESIGN VB N
A DT N
randomised JJ N
controlled JJ N
trial NN N
of IN N
nurse JJ i
run NN i
clinics NNS i
versus VBP p
usual JJ i
care NN i
. . i

SETTING NN N
Six NNP p
general JJ p
practices NNS p
in IN p
the DT p
South NNP p
Thames NNPS p
region NN p
. . p

SUBJECTS NNP N
251 CD p
patients NNS p
aged VBN p
over IN p
15 CD p
years NNS p
who WP p
were VBD p
taking VBG p
anti-epileptic JJ p
drugs NNS p
or CC p
had VBD p
a DT p
diagnosis NN p
of IN p
epilepsy NN p
and CC p
an DT p
attack NN p
in IN p
the DT p
past JJ p
two CD p
years NNS p
who WP p
met VBD p
specified VBN p
inclusion NN p
criteria NNS p
and CC p
had VBD p
responded VBN p
to TO p
a DT p
questionnaire NN p
. . p

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Questionnaire NNP i
responses NNS i
and CC N
recording NN N
of IN N
key JJ N
variables NNS N
extracted VBN N
from IN N
the DT N
clinical JJ N
records NNS N
before IN N
and CC N
after IN N
the DT N
intervention NN N
. . N

RESULTS CC N
127 CD p
patients NNS p
were VBD N
randomised VBN N
to TO N
a DT N
nurse JJ N
run NN N
clinic NN N
, , N
of IN N
whom WP N
106 CD N
( ( N
83 CD N
% NN N
) ) N
attended VBD N
. . N

The DT N
nurse JJ N
wrote VBD N
28 CD N
letters NNS N
to TO N
the DT N
general JJ N
practitioners NNS N
suggesting VBG N
changes NNS i
in IN i
epilepsy NN i
management NN i
. . i

For IN N
this DT N
intervention NN N
group NN N
compared VBN N
with IN N
the DT N
usual JJ i
care NN i
group NN N
there EX N
was VBD N
a DT N
highly RB N
significant JJ N
improvement NN N
in IN N
the DT N
level NN o
of IN o
advice NN o
recorded VBN o
as IN N
having VBG N
been VBN N
given VBN N
on IN N
drug NN o
compliance NN o
, , o
adverse JJ o
drug NN o
effects NNS o
, , o
driving VBG o
, , o
alcohol NN o
intake NN o
, , o
and CC o
self PRP o
help VBP o
groups NNS N
. . N

CONCLUSIONS NNP N
Nurse NNP i
run VBP i
clinics NNS i
for IN p
patients NNS p
with IN p
epilepsy NN p
were VBD N
feasible JJ o
and CC o
well RB o
attended VBD o
. . o

Such JJ N
clinics NNS N
can MD N
significantly RB N
improve VB o
the DT o
level NN o
of IN o
advice NN o
and CC o
drug NN o
management NN o
recorded VBN N
. . N

-DOCSTART- -8421029- O O

Timing NN N
of IN N
antibiotic JJ i
administration NN i
in IN N
knee JJ p
replacement NN p
under IN p
tourniquet NN p
. . p

Cephamandole NNP o
levels NNS o
in IN o
serum NN o
and CC o
drain NN o
fluid NN o
were VBD N
measured VBN N
in IN N
32 CD p
knee JJ p
replacement NN p
operations NNS p
to TO N
determine VB N
the DT N
benefit NN N
of IN N
an DT N
intravenous JJ N
dose NN N
of IN N
antibiotic JJ N
at IN N
the DT N
time NN N
of IN N
tourniquet JJ N
deflation NN N
. . N

Concentrations NNS N
of IN N
cephamandole NN o
in IN o
drain NN o
fluid NN o
were VBD N
directly RB N
proportional JJ N
to TO N
the DT N
serum NN N
concentration NN N
at IN N
the DT N
time NN N
of IN N
tourniquet JJ N
release NN N
. . N

A DT N
'tourniquet-release JJ i
' POS i
dose NN i
of IN i
antibiotic JJ i
increased VBD N
drain NN o
fluid NN o
concentration NN o
threefold NN N
. . N

-DOCSTART- -11535502- O O

Relationships NNS N
between IN N
age NN N
at IN N
diagnosis NN N
, , N
clinical JJ N
features NNS N
, , N
and CC N
outcome NN N
of IN N
therapy NN N
in IN N
children NNS p
treated VBN p
in IN p
the DT p
Medical NNP p
Research NNP p
Council NNP p
AML NNP p
10 CD p
and CC p
12 CD p
trials NNS p
for IN p
acute JJ p
myeloid NN p
leukemia NN p
. . p

Between NNP p
May NNP p
1988 CD p
and CC p
June NNP p
2000 CD p
, , p
698 CD p
children NNS p
were VBD p
treated VBN p
in IN p
the DT p
Medical NNP p
Research NNP p
Council NNP p
acute VBZ p
myeloid JJ p
leukemia NN p
10 CD p
and CC p
12 CD p
trials NNS p
. . p

The DT N
presenting NN N
features NNS i
and CC i
outcomes NNS i
of IN i
therapy NN i
in IN i
these DT i
children NNS i
were VBD i
compared VBN i
by IN i
age NN i
. . i

Although IN N
there EX N
was VBD N
no DT N
single JJ N
cutoff NN N
in IN N
age NN N
, , N
younger JJR N
children NNS N
were VBD N
more RBR N
likely JJ N
to TO N
have VB N
intermediate JJ N
risk NN N
and CC N
less RBR N
likely JJ N
to TO N
have VB N
favorable JJ o
cytogenetics NNS o
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
and CC N
they PRP N
had VBD N
a DT N
higher JJR N
incidence NN o
of IN o
translocations NNS o
involving VBG o
chromosome NN o
11q23 CD o
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

The DT N
distribution NN N
of IN N
French-American-British NNP N
( ( N
FAB NNP N
) ) N
types NNS N
also RB N
varied VBD N
with IN N
age NN N
; : N
FAB NNP o
types VBZ o
M5 NNP o
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
and CC N
M7 NNP o
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
were VBD N
more JJR N
common JJ N
in IN N
early JJ N
childhood NN N
, , N
whereas IN N
older JJR N
children NNS N
were VBD N
more RBR N
likely JJ N
to TO N
have VB N
FAB NNP o
types NNS o
M0 NNP o
( ( N
P NNP N
=.03 NNP N
) ) N
, , N
M1 NNP N
( ( N
P NNP N
=.04 NNP N
) ) N
, , N
M2 NNP o
( ( N
P NNP N
=.005 NNP N
) ) N
, , N
and CC N
M3 NNP o
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Involvement NN o
of IN o
the DT o
central JJ o
nervous JJ o
system NN o
at IN N
diagnosis NN N
was VBD N
also RB N
more JJR N
common JJ N
in IN N
the DT N
youngest JJS N
children NNS N
( ( N
P NNP N
=.01 NNP N
) ) N
. . N

Younger JJR N
children NNS N
had VBD N
more RBR N
severe JJ o
diarrhea NN o
( ( N
P NNP N
=.002 NNP N
) ) N
, , N
whereas JJ N
older JJR N
children NNS N
had VBD N
worse JJR N
nausea NN o
and CC o
vomiting NN o
( ( N
P NNP N
=.01 NNP N
) ) N
after IN N
chemotherapy NN N
. . N

When WRB N
adjusted VBN N
for IN N
other JJ N
important JJ N
factors NNS N
, , N
complete JJ o
remission NN o
rates NNS o
were VBD N
similar JJ N
( ( N
P NNP N
=.5 NNP N
) ) N
and CC N
although IN N
there EX N
was VBD N
less RBR N
resistant JJ N
disease NN N
in IN N
younger JJR N
children NNS N
( ( N
P NNP N
=.003 NNP N
) ) N
, , N
this DT N
was VBD N
partially RB N
balanced VBN N
by IN N
a DT N
slight JJ N
increase NN N
in IN N
deaths NNS o
during IN N
induction NN N
therapy NN N
in IN N
younger JJR N
patients NNS N
( ( N
P NNP N
=.06 NNP N
) ) N
. . N

On IN N
multivariate NN N
analysis NN N
overall JJ o
survival NN o
( ( N
P NNP N
=.02 NNP N
) ) N
, , N
event-free JJ o
survival NN o
( ( N
P NNP N
=.02 NNP N
) ) N
, , N
and CC N
disease-free JJ o
survival NN o
were VBD N
better JJR N
( ( N
P NNP N
=.06 NNP N
) ) N
in IN N
younger JJR N
children NNS N
due JJ N
to TO N
a DT N
lower JJR N
relapse NN o
rate NN o
( ( N
P NNP N
=.02 NNP N
) ) N
especially RB N
in IN N
the DT N
bone NN N
marrow NN N
( ( N
P NNP N
=.02 NNP N
) ) N
. . N

-DOCSTART- -8708726- O O

Randomized VBN N
trial NN N
comparing VBG N
induction NN i
chemotherapy NN i
versus NN N
induction NN i
chemotherapy NN i
followed VBN i
by IN i
maintenance NN i
chemotherapy NN i
in IN N
small-cell JJ p
lung NN p
cancer NN p
. . p

European JJ N
Lung NNP N
Cancer NNP N
Working NNP N
Party NNP N
. . N

PURPOSE NNP N
AND CC N
METHODS NNP N
The DT N
European NNP N
Lung NNP N
Cancer NNP N
Working NNP N
Party NNP N
( ( N
ELCWP NNP N
) ) N
performed VBD N
a DT N
randomized JJ N
trial NN N
with IN N
the DT N
primary JJ N
end NN N
point NN N
to TO N
determine VB N
if IN N
maintenance NN N
chemotherapy NN N
with IN N
12 CD N
courses NNS N
of IN N
etoposide NN i
( ( N
120 CD N
mg/m2 NN N
on IN N
days NNS N
1 CD N
and CC N
3 CD N
) ) N
and CC N
vindesine NN i
( ( N
3 CD N
mg/m2 NN N
on IN N
day NN N
3 CD N
) ) N
could MD N
improve VB N
progression-free JJ o
survival NN o
in IN N
small-cell JJ p
lung NN p
cancer NN p
( ( p
SCLC NNP p
) ) p
patients NNS p
who WP p
responded VBD p
to TO p
six CD p
courses NNS p
of IN p
induction NN i
chemotherapy NN i
with IN i
ifosfamide NN i
, , i
etoposide RB i
, , i
and CC i
an DT i
anthracycline NN i
( ( i
doxorubicin NN i
or CC i
epirubicin NN i
) ) i
. . i

RESULTS NNP N
Among IN p
235 CD p
eligible JJ p
patients NNS p
initially RB p
registered VBD p
, , p
91 CD p
were VBD p
randomized VBN p
to TO p
receive VB p
maintenance NN p
therapy NN p
, , p
including VBG p
seven CD p
patients NNS p
who WP p
were VBD p
no RB p
longer RBR p
responding VBG p
. . p

Among IN N
84 CD N
randomized JJ N
responders NNS N
, , N
progression-free JJ o
survival NN o
was VBD N
significantly RB N
improved VBN N
( ( N
P NNP N
= NNP N
.003 NNP N
) ) N
by IN N
maintenance NN N
therapy NN N
, , N
with IN N
median JJ N
durations NNS N
( ( N
maintenance NN N
v IN N
follow-up JJ N
) ) N
of IN N
25 CD N
versus NNS N
12 CD N
weeks NNS N
after IN N
the DT N
second JJ N
randomization NN N
, , N
but CC N
survival NN o
was VBD N
not RB N
significantly RB N
increased VBN N
( ( N
P NNP N
= NNP N
.10 NNP N
) ) N
, , N
with IN N
median JJ N
durations NNS N
of IN N
48 CD N
and CC N
38 CD N
weeks NNS N
. . N

However RB N
, , N
in IN N
a DT N
multi-variate JJ N
analysis NN N
that WDT N
took VBD N
into IN N
account NN o
disease NN o
extent NN o
, , o
maintenance NN o
therapy NN o
, , o
Karnofsky NNP o
performance NN o
status NN o
( ( o
PS NNP o
) ) o
, , o
and CC o
absolute JJ o
dose-intensity NN o
( ( o
ADI NNP o
) ) o
of IN o
anthracycline NN o
given VBN N
during IN N
induction NN N
, , N
limited JJ o
disease NN o
( ( o
LD NNP o
) ) o
and CC o
maintenance NN o
were VBD N
found VBN N
to TO N
be VB N
independent JJ N
positive JJ N
predictors NNS N
of IN N
survival NN o
. . o

CONCLUSION NNP N
We PRP N
conclude VBP N
that DT N
maintenance NN N
chemotherapy NN N
in IN N
responding VBG N
patients NNS N
is VBZ N
beneficial JJ N
in IN N
SCLC NNP N
. . N

-DOCSTART- -19182698- O O

MF101 NNP i
, , i
a DT i
selective JJ i
estrogen NN i
receptor NN i
beta NN N
modulator NN N
for IN N
the DT N
treatment NN N
of IN N
menopausal NN N
hot JJ N
flushes NNS N
: : N
a DT N
phase NN N
II NNP N
clinical JJ N
trial NN N
. . N

OBJECTIVE NN N
To TO N
determine VB N
the DT N
optimal JJ N
dose NN N
, , N
safety NN N
, , N
and CC N
efficacy NN N
of IN N
an DT N
estrogen NN i
receptor NN i
beta NN i
selective JJ i
Chinese NNP i
herbal NN i
extract NN i
, , i
menopausal JJ i
formula NN i
101 CD i
( ( N
MF101 NNP N
) ) N
, , N
for IN N
treating VBG N
hot JJ N
flushes NNS N
. . N

METHODS NNP N
A NNP N
randomized NN p
, , p
blinded VBD p
trial NN p
in IN p
217 CD p
postmenopausal JJ p
women NNS p
with IN p
hot JJ p
flushes NNS p
randomized VBD p
to TO p
5 CD p
or CC p
10 CD p
g/day NN p
of IN p
MF101 NNP i
or CC i
placebo NN i
for IN p
12 CD p
weeks NNS p
. . p

RESULTS VB N
The DT N
effects NNS N
of IN N
5 CD N
g/day NN N
of IN N
MF101 NNP N
did VBD N
not RB N
differ VB N
from IN N
those DT N
of IN N
placebo NN i
. . i

After IN N
12 CD N
weeks NNS N
, , N
the DT N
mean JJ o
percent NN o
decrease NN o
in IN o
frequency NN o
of IN o
hot JJ o
flushes NNS o
in IN N
the DT N
10 CD N
g/day NN N
group NN N
was VBD N
12.9 CD N
% NN N
greater JJR N
than IN N
that DT N
in IN N
the DT N
placebo NN i
group NN N
( ( N
P NNP N
= NNP N
0.15 CD N
) ) N
, , N
the DT N
median JJ N
percent NN N
decrease NN N
was VBD N
11.7 CD N
% NN N
greater JJR N
than IN N
that DT N
in IN N
the DT N
placebo NN N
group NN N
( ( N
P NNP N
= NNP N
0.05 CD N
) ) N
, , N
and CC N
the DT N
proportion NN o
of IN o
women NNS o
with IN o
at IN o
least JJS o
a DT o
50 CD o
% NN o
reduction NN o
in IN o
hot JJ o
flushes NNS o
was VBD N
16.2 CD N
% NN N
greater JJR N
than IN N
that DT N
in IN N
the DT N
placebo NN N
group NN N
( ( N
P NNP N
= NNP N
0.03 CD N
) ) N
. . N

CONCLUSIONS NNP N
Treatment NNP N
with IN N
10 CD N
g/day NN N
of IN N
MF101 NNP i
reduces VBZ N
the DT N
frequency NN N
of IN N
hot JJ N
flushes NNS N
. . N

Trials NNS N
with IN N
higher JJR N
doses NNS N
are VBP N
planned VBN N
. . N

-DOCSTART- -22683613- O O

Plerixafor NNP i
plus CC i
granulocyte JJ i
colony-stimulating JJ i
factor NN i
versus NN i
placebo NN i
plus CC i
granulocyte JJ i
colony-stimulating JJ i
factor NN i
for IN N
mobilization NN N
of IN N
CD34 NNP N
( ( N
+ NNP N
) ) N
hematopoietic JJ N
stem NN N
cells NNS N
in IN N
patients NNS p
with IN p
multiple JJ p
myeloma NNS p
and CC p
low JJ p
peripheral JJ p
blood NN p
CD34 NNP p
( ( p
+ NNP p
) ) p
cell NN p
count NN p
: : p
results NNS N
of IN N
a DT N
subset JJ N
analysis NN N
of IN N
a DT N
randomized JJ N
trial NN N
. . N

Preapheresis NNP N
peripheral JJ N
blood NN N
( ( N
PB NNP N
) ) N
CD34 NNP N
( ( N
+ NNP N
) ) N
cell NN N
count NN N
is VBZ N
a DT N
strong JJ N
predictor NN N
of IN N
hematopoietic JJ N
stem NN N
cell NN N
( ( N
HSC NNP N
) ) N
mobilization NN N
and CC N
is VBZ N
routinely RB N
used VBN N
to TO N
optimize VB N
the DT N
timing NN N
, , N
cost NN N
, , N
and CC N
success NN N
of IN N
HSC NNP N
collection NN N
in IN N
patients NNS p
with IN p
multiple JJ p
myeloma NN p
. . p

However RB N
, , N
a DT N
uniform JJ N
PB NNP N
CD34 NNP N
( ( N
+ NNP N
) ) N
cell NN N
count NN N
that WDT N
predicts VBZ N
mobilization NN N
failure NN N
has VBZ N
not RB N
been VBN N
defined VBN N
, , N
resulting VBG N
in IN N
the DT N
development NN N
of IN N
institute-specific JJ N
algorithms NN N
for IN N
mobilization NN N
, , N
particularly RB N
regarding VBG N
the DT N
decision NN N
of IN N
when WRB N
to TO N
use VB N
the DT N
novel JJ N
stem NN N
cell NN N
mobilization NN N
agent NN N
plerixafor NN N
. . N

In IN N
this DT N
post NN N
hoc NN N
analysis NN N
, , N
we PRP N
evaluated VBD N
the DT N
mobilization NN N
efficacy NN N
of IN N
plerixafor JJ i
plus CC i
granulocyte JJ i
colony-stimulating JJ i
factor NN i
( ( i
G-CSF NNP i
) ) i
versus NN i
placebo JJ i
plus CC i
G-CSF JJ i
in IN N
patients NNS p
with IN p
multiple JJ p
myeloma NN p
, , p
stratified VBN p
by IN p
preapheresis NN p
PB NNP p
CD34 NNP p
( ( p
+ NNP p
) ) p
cell NN p
count NN p
: : p
< JJ p
10 CD p
, , p
< FW p
15 CD p
, , p
< FW p
20 CD p
, , p
and CC p
?20 NNP p
cells/?L NN p
. . p

Regardless NNP p
of IN N
the DT N
PB NNP N
CD34 NNP N
( ( N
+ NNP N
) ) N
cell NN N
count NN N
, , N
the DT N
total JJ N
yield NN N
of IN N
CD34 NNP N
( ( N
+ NNP N
) ) N
cells NNS N
from IN N
apheresis NN N
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
plerixafor NN i
group NN i
than IN N
in IN N
the DT N
placebo NN i
group NN i
, , N
and CC N
significantly RB N
more JJR N
patients NNS N
in IN N
the DT N
plerixafor NN i
group NN i
collected VBD N
the DT N
minimum NN N
( ( N
?2 VB N
? . N
10 CD N
( ( N
6 CD N
) ) N
cells/kg NN N
) ) N
and CC N
optimum JJ N
( ( N
?6 VB N
? . N
10 CD N
( ( N
6 CD N
) ) N
cells/kg NN N
) ) N
stem NN N
cell NN N
yields NNS N
on IN N
each DT N
day NN N
of IN N
apheresis NN N
. . N

As IN N
a DT N
corollary NN N
, , N
the DT N
greater JJR o
stem NN o
cell NN o
collection NN o
in IN o
plerixafor-treated JJ o
patients NNS i
resulted VBD N
in IN N
the DT N
need NN N
for IN N
significantly RB N
fewer JJR N
days NNS N
of IN N
apheresis NN N
to TO N
reach VB N
minimum JJ N
and CC N
optimum JJ N
cell NN N
doses NNS N
across IN N
all DT N
cell NN N
count NN N
groups NNS N
. . N

For IN N
all DT N
CD34 NNP N
( ( N
+ NNP N
) ) N
cell NN N
count NN N
groups NNS N
, , N
the DT o
proportion NN o
of IN o
patients NNS o
proceeding VBG o
to TO o
transplantation NN o
and CC o
the DT o
median JJ o
time NN o
to TO o
platelet VB o
and CC o
neutrophil VB o
engraftment NN o
were VBD o
similar JJ o
in IN i
the DT i
plerixafor NN i
and CC i
placebo NN i
groups NNS N
. . N

Our PRP$ N
findings NNS N
demonstrate VBP N
that IN N
in IN N
patients NNS N
with IN N
multiple JJ N
myeloma NNS N
who WP N
might MD N
be VB N
predicted VBN N
to TO N
fail VB N
mobilization NN N
based VBN N
on IN N
low JJ N
PB NNP N
CD34 NNP N
( ( N
+ NNP N
) ) N
cell NN N
count NN N
, , N
the DT N
addition NN N
of IN N
plerixafor NN N
to TO N
G-CSF NNP N
allows NNS N
for IN N
collection NN N
of IN N
the DT N
minimal JJ N
and CC N
optimal JJ N
cell NN N
doses NNS N
in IN N
a DT N
greater JJR N
proportion NN N
of IN N
patients NNS N
compared VBN N
with IN N
G-CSF NNP N
alone RB N
. . N

In IN N
addition NN N
, , N
plerixafor JJ i
plus CC i
G-CSF NNP i
significantly RB i
improves VBZ N
the DT N
likelihood NN N
of IN N
optimal JJ N
HSC NNP N
collection NN N
in IN N
patients NNS N
with IN N
higher JJR N
preapheresis NN N
PB NNP N
CD34 NNP N
( ( N
+ NNP N
) ) N
cell NN N
counts NNS N
( ( N
?20 NNP N
cells/?L NN N
) ) N
compared VBN N
with IN N
placebo JJ N
plus CC N
G-CSF NNP N
. . N

Collectively RB N
, , N
this DT N
analysis NN N
of IN N
predicted JJ N
poor JJ N
mobilizers NNS N
validates VBZ N
the DT N
superiority NN N
of IN i
plerixafor JJ i
plus CC i
G-CSF JJ i
compared VBN N
with IN i
G-CSF NNP i
alone RB N
, , N
which WDT N
had VBD N
been VBN N
demonstrated VBN N
previously RB N
in IN N
the DT N
overall JJ N
patient JJ N
population NN N
. . N

-DOCSTART- -15055365- O O

Reflexive JJ o
orienting VBG o
in IN N
response NN N
to TO N
eye NN N
gaze NN N
and CC N
an DT N
arrow NN i
in IN N
children NNS p
with IN p
and CC p
without IN p
autism NN p
. . p

BACKGROUND NNP N
This DT N
study NN N
investigated VBD N
whether IN N
another DT N
person NN N
's POS N
social JJ N
attention NN o
, , N
specifically RB N
the DT N
direction NN N
of IN N
their PRP$ N
eye NN N
gaze NN N
, , N
and CC N
a DT N
non-social JJ N
directional JJ N
cue NN N
, , N
an DT N
arrow NN N
, , N
triggered VBD N
reflexive JJ o
orienting NN o
in IN N
children NNS p
with IN p
and CC p
without IN p
autism NN p
in IN N
an DT N
experimental JJ N
situation NN N
. . N

METHODS NNP N
Children NNP p
with IN p
autism NN p
and CC p
typically RB p
developed JJ p
children NNS p
participated VBN p
in IN N
one CD N
of IN N
two CD N
experiments NNS N
. . N

Both DT N
experiments NNS N
involved VBD N
the DT N
localization NN i
of IN i
a DT i
target NN i
that WDT i
appeared VBD i
to TO i
the DT i
left NN i
or CC i
right NN i
of IN i
the DT i
fixation NN i
point NN i
. . i

Before IN N
the DT N
target NN N
appeared VBD N
, , N
the DT i
participant NN i
's POS i
attention NN i
was VBD i
cued VBN i
to TO i
the DT i
left NN i
or CC i
right NN i
by IN i
either DT i
an DT i
arrow NN i
or CC i
the DT i
direction NN i
of IN i
eye NN i
gaze NN i
on IN i
a DT i
computerized JJ i
face NN i
. . i

RESULTS NNP N
Children NNP p
with IN p
autism NN p
were VBD N
slower JJR o
to TO o
respond VB o
, , N
which WDT N
suggests VBZ N
a DT N
slight JJ N
difference NN N
in IN N
the DT N
general JJ N
cognitive JJ o
ability NN o
of IN N
the DT N
groups NNS N
. . N

In IN N
Experiment JJ N
1 CD N
, , N
although IN N
the DT N
participants NNS N
were VBD N
instructed VBN N
to TO N
disregard VB N
the DT N
cue NN N
and CC N
the DT N
target NN N
was VBD N
correctly RB N
cued VBN N
in IN N
only RB N
50 CD N
% NN N
of IN N
the DT N
trials NNS N
, , N
both DT N
groups NNS N
of IN N
children NNS N
responded VBD o
significantly RB N
faster RBR N
to TO N
cued VB N
targets NNS N
than IN N
to TO N
uncued JJ N
targets NNS N
, , N
regardless RB N
of IN N
the DT N
cue NN N
. . N

In IN N
Experiment JJ N
2 CD N
, , N
children NNS N
were VBD N
instructed VBN N
to TO N
attend VB N
to TO N
the DT N
direction NN N
opposite IN N
that DT N
of IN N
the DT N
cues NNS N
and CC N
the DT N
target NN N
was VBD N
correctly RB N
cued VBN N
in IN N
only RB N
20 CD N
% NN N
of IN N
the DT N
trials NNS N
. . N

Typically RB N
developed JJ N
children NNS N
located VBN o
targets NNS o
cued VBN o
by IN o
eye NN o
gaze NNS o
more RBR N
quickly RB N
, , N
while IN N
the DT N
arrow NN N
cue NN N
did VBD N
not RB N
trigger VB N
such JJ N
reflexive JJ o
orienting NN o
in IN N
these DT N
children NNS N
. . N

However RB N
, , N
both DT N
social JJ N
and CC N
non-social JJ N
cues NNS N
shifted VBD N
attention NN o
to TO N
the DT N
cued VBN N
location NN N
in IN N
children NNS N
with IN N
autism NN N
. . N

CONCLUSION NNP N
These DT N
results NNS N
indicate VBP N
that IN N
eye NN N
gaze NN N
attracted VBD N
attention NN o
more RBR N
effectively RB N
than IN N
the DT N
arrow NN N
in IN N
typically RB p
developed JJ p
children NNS p
, , N
while IN N
children NNS p
with IN p
autism NN p
shifted VBN N
their PRP$ N
attention NN N
equally RB N
in IN N
response NN N
to TO N
eye NN N
gaze NN N
and CC N
arrow JJ N
direction NN N
, , N
failing VBG N
to TO N
show VB N
preferential JJ N
sensitivity NN o
to TO N
the DT N
social JJ N
cue NN N
. . N

Difficulty NN N
in IN N
shifting VBG N
controlled JJ N
attention NN o
to TO N
the DT N
instructed JJ N
side NN N
was VBD N
also RB N
found VBN N
in IN N
children NNS p
with IN p
autism NN p
. . p

-DOCSTART- -25045936- O O

Egg NNP i
intake NN i
during IN N
carbohydrate JJ N
restriction NN N
alters NNS N
peripheral JJ N
blood NN N
mononuclear NN N
cell NN N
inflammation NN N
and CC N
cholesterol NN N
homeostasis NN N
in IN N
metabolic JJ N
syndrome NN N
. . N

Egg NNP N
yolk NN N
contains NNS N
bioactive JJ N
components NNS N
that WDT N
improve VBP N
plasma NN N
inflammatory NN N
markers NNS N
and CC N
HDL NNP N
profiles NNS N
in IN N
metabolic JJ N
syndrome NN N
( ( N
MetS NNP N
) ) N
under IN N
carbohydrate NN N
restriction NN N
. . N

We PRP N
further RB N
sought VBD N
to TO N
determine VB N
whether IN N
egg NN i
yolk NNS i
intake VBP i
affects NNS N
peripheral JJ o
blood NN o
mononuclear NN o
cell NN o
( ( o
PBMC NNP o
) ) o
inflammation NN o
and CC N
cholesterol NN N
homeostasis NN N
in IN N
MetS NNP N
, , N
as IN N
HDL NNP N
and CC N
its PRP$ N
associated JJ N
lipid JJ N
transporter NN N
ATP-binding NNP N
cassette NN N
transporter NN N
A1 NNP N
( ( N
ABCA1 NNP N
) ) N
reduce VB N
the DT N
inflammatory JJ N
potential NN N
of IN N
leukocytes NNS N
through IN N
modulation NN N
of IN N
cellular JJ N
cholesterol NN N
content NN N
and CC N
distribution NN N
. . N

Thirty-seven JJ p
men NNS p
and CC p
women NNS p
classified VBN p
with IN p
MetS NNP p
consumed VBD N
a DT N
moderate JJ i
carbohydrate-restricted JJ i
diet NN i
( ( N
25 CD N
% NN N
-30 CD N
% NN N
of IN N
energy NN N
) ) N
for IN N
12 CD N
weeks NNS N
, , N
in IN N
addition NN N
to TO N
consuming VBG N
either DT i
three CD i
whole JJ i
eggs NNS i
per IN i
day NN i
( ( i
EGG NNP i
) ) i
or CC i
the DT i
equivalent JJ i
amount NN i
of IN i
yolk-free JJ i
egg NN i
substitute NN i
( ( i
SUB NNP i
) ) i
. . N

Interestingly RB N
, , N
lipopolysaccharide-induced JJ o
PBMC NNP o
IL-1? NNP o
and CC o
TNF? NNP o
secretion NN o
increased VBD o
from IN o
baseline NN N
to TO N
week NN N
12 CD N
in IN N
the DT N
SUB NNP N
group NN N
only RB N
, , N
despite IN N
increases NNS N
in IN N
PBMC NNP o
toll-like JJ o
receptor NN o
4 CD o
( ( o
TLR4 NNP o
) ) o
mRNA NN o
expression NN o
in IN o
the DT N
EGG NNP N
group NN N
. . N

Compared VBN N
to TO N
baseline VB o
, , o
ABCA1 NNP o
and CC o
3-hydroxy-3-methyl-glutaryl NNP o
( ( o
HMG NNP o
) ) o
-CoA VBP o
reductase NN o
mRNA JJ o
expression NN o
increased VBN o
by IN o
week NN N
12 CD N
in IN N
the DT N
EGG NNP N
group NN N
only RB N
, , N
whereas NNS N
changes NNS N
in IN N
PBMC NNP o
total JJ o
cholesterol NN o
positively RB o
correlated VBN N
with IN N
changes NNS N
in IN N
lipid JJ N
raft NN N
content NN N
. . N

Together RB N
, , N
these DT N
findings NNS N
suggest VBP N
that IN N
intake NN N
of IN N
whole JJ N
eggs NNS N
during IN N
carbohydrate JJ N
restriction NN N
alters NNS o
PBMC NNP o
inflammation NN o
and CC o
cholesterol NN o
homeostasis NN o
in IN o
MetS NNP N
. . N

-DOCSTART- -24722763- O O

Directed VBN i
forgetting NN i
in IN N
high-functioning JJ p
adults NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

Rehearsal NNP N
strategies NNS N
of IN N
adults NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASDs NNP p
) ) p
and CC p
demographically RB p
matched VBN p
typically RB p
developed VBN p
( ( p
TD NNP p
) ) p
adults NNS p
were VBD N
strategically RB N
manipulated VBN N
by IN N
cueing VBG N
participants NNS N
to TO N
either DT N
learn NN i
, , N
or CC N
forget VB i
each DT N
list NN N
word NN N
prior RB N
to TO N
a DT N
recognition NN i
task NN i
. . i

Participants NNS N
were VBD N
also RB N
asked VBN N
to TO N
distinguish VB N
between IN N
autonoetic JJ N
and CC N
noetic JJ N
states NNS N
of IN N
awareness NN N
using VBG N
the DT N
Remember/Know NNP N
paradigm NN N
. . N

The DT N
ASD NNP p
group NN p
recognised VBD N
a DT N
similar JJ N
number NN N
of IN N
to-be-forgotten JJ o
words NNS o
as IN N
the DT N
TD NNP N
group NN N
, , N
but CC N
significantly RB N
fewer JJR N
to-be-learned JJ o
words NNS o
. . o

This DT N
deficit NN o
was VBD N
only RB N
evident JJ o
in IN o
Remember NNP o
responses NNS o
that WDT N
reflect VBP N
autonoetic JJ o
awareness NN o
, , o
or CC o
episodic JJ o
memory NN o
, , o
and CC o
not RB o
Know NNP o
responses VBZ o
. . o

These DT N
findings NNS o
support VBP o
the DT N
elaborative JJ N
encoding NN N
deficit NN N
hypothesis NN N
and CC N
provide VB N
a DT N
link NN o
between IN o
the DT o
previously RB o
established VBN o
mild JJ o
episodic JJ o
memory NN o
impairments NNS o
in IN o
adults NNS o
with IN o
high JJ o
functioning VBG o
autism NN o
and CC o
the DT o
encoding NN o
strategies NNS o
employed VBN N
. . N

-DOCSTART- -22092536- O O

Paracetamol NNP i
and CC N
opioid JJ N
pathways NNS N
: : N
a DT N
pilot NN N
randomized VBN N
clinical JJ N
trial NN N
. . N

Previous JJ N
studies NNS N
suggest VBP N
that IN N
the DT N
antinociceptive JJ N
action NN N
of IN N
paracetamol NN i
( ( i
acetaminophen NN i
, , i
APAP NNP i
) ) i
might MD N
involve VB N
descending VBG N
inhibitory JJ N
pain NN N
pathways NNS N
and CC N
the DT N
opioidergic JJ N
system NN N
: : N
this DT N
study NN N
explores VBZ N
this DT N
issue NN N
in IN p
humans NNS p
with IN p
naloxone NN i
, , i
the DT i
opioid JJ i
antagonist NN i
. . i

After IN N
ethical JJ N
approval NN N
, , N
12 CD p
healthy JJ p
male NN p
volunteers NNS p
were VBD p
included VBN p
in IN N
this DT N
randomized VBN N
, , N
controlled VBN N
, , N
double-blind NN N
, , N
crossover NN N
, , N
four-arm JJ N
study NN N
. . N

They PRP N
were VBD N
administered VBN N
intravenous JJ i
paracetamol NN i
( ( i
APAP NNP i
1 CD i
g NN i
) ) i
or CC i
saline NN i
( ( i
placebo NN i
, , i
pl NN i
) ) i
followed VBD N
at IN N
100 CD N
min NN N
with IN N
IV NNP i
naloxone NN i
( ( i
Nal NNP i
8 CD i
mg NN i
) ) i
or CC i
saline NN i
, , N
every DT N
week NN N
for IN N
4 CD N
weeks NNS N
. . N

The DT N
amplitude NN o
of IN o
cerebral JJ o
potentials NNS o
evoked VBN o
by IN N
thermal/painful JJ N
stimuli NNS N
applied VBN N
on IN N
the DT N
arm NN N
was VBD N
recorded VBN N
nine CD N
times NNS N
over IN N
150 CD N
min NNS N
, , N
witnessing VBG N
of IN N
pain NN N
integration NN N
at IN N
central JJ N
level NN N
. . N

Amplitude NNP o
changes NNS o
as RB o
well RB o
as IN o
areas NNS o
under IN o
the DT o
curve NN o
( ( o
AUCs NNP o
) ) o
over IN N
150 CD N
min NNS N
were VBD N
compared VBN N
for IN N
the DT N
four CD N
treatments NNS N
by IN N
repeated JJ N
measures NNS N
ANOVA NNP N
( ( N
significance NN N
0.05 CD N
) ) N
. . N

Amplitude NNP o
changes NNS o
were VBD N
significant JJ N
for IN N
APAP/pl NNP i
vs. FW N
pl/pl NN N
at IN N
t150 NN N
: : N
-44 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
-58 NNP N
to TO N
-30 VB N
) ) N
vs. FW N
-27 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
-37 NNP N
to TO N
-17 VB N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
but CC N
not RB N
vs. IN N
APAP/Nal NNP i
. . i

AUC NNP o
( ( N
0-150 JJ N
) ) N
of IN N
APAP/pl NNP N
is VBZ N
significantly RB N
different JJ N
from IN N
pl/pl NN N
( ( N
-3452 CD N
% NN N
.min NNP N
( ( N
95 CD N
% NN N
CI NNP N
-4705 NNP N
to TO N
-2199 VB N
) ) N
vs. FW N
-933 CD N
% NN N
min NN N
( ( N
95 CD N
% NN N
CI NNP N
-2273 NNP N
to TO N
407 CD N
; : N
P NNP N
= NNP N
0.015 CD N
) ) N
but CC N
not RB N
from IN N
APAP/Nal NNP i
( ( N
-1731 CD N
% NN N
min NN N
( ( N
95 CD N
% NN N
CI NNP N
-3676 NNP N
to TO N
214 CD N
; : N
P NNP N
= NNP N
0.08 CD N
) ) N
and CC N
other JJ N
treatments NNS N
. . N

AUC NNP o
( ( N
90-150 CD N
) ) N
is VBZ N
not RB N
significantly RB N
different JJ N
. . N

This DT N
pilot NN N
study NN N
shows VBZ N
for IN N
the DT N
first JJ N
time NN N
in IN N
human JJ p
volunteers NNS p
that WDT N
naloxone RB i
does VBZ N
not RB N
inhibit VB o
paracetamol JJ o
antinociception NN o
, , N
suggesting VBG N
no DT N
significant JJ N
implication NN N
of IN N
the DT N
opioid NN N
system NN N
in IN N
paracetamol JJ i
mechanism NN N
of IN N
action NN N
: : N
this DT N
needs VBZ N
be VB N
confirmed VBN N
on IN N
a DT N
larger JJR N
number NN N
of IN N
subjects NNS N
. . N

-DOCSTART- -15200727- O O

Patterning VBG N
of IN N
pain NN o
and CC o
power NN o
with IN N
guided JJ i
imagery NN i
. . i

Using VBG N
Martha NNP N
Rogers NNP N
' POS N
science NN N
of IN N
unitary JJ N
human JJ N
beings NNS N
, , N
changes NNS N
in IN N
pain NN o
and CC o
power NN o
among IN N
42 CD p
patients NNS p
were VBD N
examined VBN N
in IN N
relation NN N
to TO N
the DT N
use NN N
of IN N
a DT N
guided JJ i
imagery NN i
modality NN i
. . i

Participants NNS p
were VBD p
randomly RB p
assigned VBN p
to TO p
treatment NN i
and CC i
control NN i
groups NNS i
and CC N
repeated VBD N
measures NNS N
MANCOVA NNP N
was VBD N
used VBN N
to TO N
detect VB N
differences NNS N
in IN N
pain NN o
and CC o
power NN o
over IN N
a DT i
4-day JJ i
period NN i
of IN i
time NN i
. . i

The DT N
treatment NN N
group NN N
's POS N
pain NN o
decreased VBD N
during IN N
the DT N
last JJ N
2 CD N
days NNS N
of IN N
the DT N
study NN N
. . N

No DT N
differences NNS N
in IN N
power NN o
emerged VBN N
. . N

Guided VBN i
imagery NN i
appeared VBD N
to TO N
have VB N
potential JJ N
as IN N
a DT N
useful JJ N
nursing NN p
modality NN p
for IN p
chronic JJ p
pain NN p
sufferers NNS p
. . p

-DOCSTART- -18470779- O O

Science NN N
to TO N
practice NN N
in IN N
underserved JJ N
communities NNS N
: : N
the DT N
effectiveness NN o
of IN N
school NN i
mental JJ i
health NN i
programming NN i
. . i

This DT N
study NN N
examined VBD N
the DT N
effectiveness NN N
of IN N
a DT N
treatment NN i
program NN i
comprised VBN i
of IN i
several JJ i
components NNS i
based VBN i
on IN i
evidence-based JJ i
treatments NNS i
( ( i
EBTs NNP i
) ) i
for IN i
disruptive JJ i
behavior NN i
problems NNS i
delivered VBN N
to TO N
youth VB p
participating VBG p
in IN p
a DT p
school NN p
mental JJ p
health NN p
program NN p
in IN p
an DT p
underserved JJ p
community NN p
in IN p
the DT p
Appalachian JJ p
region NN p
. . p

Participants NNS N
were VBD N
117 CD p
children NNS p
in IN p
kindergarten VBN p
through IN p
6th CD p
grade NN p
including VBG p
91 CD p
children NNS p
( ( p
78 CD p
% NN p
male NN p
) ) p
from IN p
5 CD p
schools NNS p
who WP p
were VBD p
consecutively RB p
referred VBN p
to TO p
the DT p
intervention NN i
program NN i
and CC p
26 CD p
children NNS p
( ( p
73 CD p
% NN p
male NN p
) ) p
from IN p
3 CD p
schools NNS p
in IN p
which WDT p
program NN p
implementation NN p
was VBD p
delayed VBN p
for IN p
1 CD p
year NN p
. . p

Treatment NNP N
outcome NN N
was VBD N
measured VBN N
via IN N
parent NN o
and CC o
teacher JJ o
ratings NNS o
of IN o
child NN o
symptoms NNS o
and CC o
functioning VBG o
. . o

The DT N
treatment NN N
condition NN N
resulted VBD N
in IN N
significant JJ N
reduction NN N
in IN N
hyperactivity/impulsivity NN o
and CC o
early JJ o
aggressive JJ o
and CC o
delinquent JJ o
behavior NN o
, , o
as RB o
well RB o
as IN o
significant JJ o
improvement NN o
in IN o
several JJ o
other JJ o
functional JJ o
domains NNS o
. . o

Results VB N
suggest JJS N
that IN N
EBTs NNP i
can MD N
retain VB N
their PRP$ N
effectiveness NN o
when WRB N
transported VBN N
to TO N
a DT N
community NN N
context NN N
. . N

-DOCSTART- -15857741- O O

Acustimulation NNP i
wrist NN i
bands NNS i
are VBP N
not RB N
effective JJ N
for IN N
the DT N
control NN N
of IN N
chemotherapy-induced JJ o
nausea NN o
in IN N
women NNS p
with IN p
breast NN p
cancer NN p
. . p

This DT N
experiment NN N
examined VBD N
the DT N
efficacy NN N
of IN N
an DT N
acustimulation NN i
wrist NN i
band NN i
for IN N
the DT N
relief NN N
of IN N
chemotherapy-induced JJ o
nausea NN o
using VBG N
a DT N
randomized JJ N
three-arm JJ N
clinical JJ N
trial NN N
( ( i
active JJ i
acustimulation NN i
, , i
sham JJ i
acustimulation NN i
, , N
and CC N
no DT i
acustimulation NN i
) ) i
in IN N
96 CD p
women NNS p
with IN p
breast NN p
cancer NN p
who WP p
experienced VBD p
nausea NN p
at IN p
their PRP$ p
first JJ p
chemotherapy NN i
treatment NN i
. . i

Five CD N
outcomes NNS N
related VBN N
to TO N
wrist VB o
band NN o
efficacy NN o
( ( o
acute JJ o
nausea NN o
, , o
delayed VBN o
nausea NN o
, , o
vomiting VBG o
, , o
QOL NNP o
, , o
and CC o
total JJ o
amount NN o
of IN o
antiemetic JJ o
medication NN o
used VBN o
) ) o
were VBD N
examined VBN N
. . N

The DT N
five CD N
outcomes NNS N
were VBD N
examined VBN N
separately RB N
using VBG N
analysis NN N
of IN N
covariance NN N
controlling VBG N
for IN N
age NN N
and CC N
severity NN o
of IN o
past JJ o
nausea NN o
. . o

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
any DT N
of IN N
these DT N
study NN N
measures NNS N
among IN N
the DT N
three CD N
treatment NN N
conditions NNS N
( ( N
P NNP N
> VBZ N
0.1 CD N
for IN N
all DT N
) ) N
. . N

Study NNP N
results NNS N
do VBP N
not RB N
support VB N
the DT N
hypothesis NN N
that WDT N
acustimulation NN i
bands NNS i
are VBP N
efficacious JJ N
as IN N
an DT N
adjunct NN N
to TO N
pharmacological JJ N
antiemetics NNS N
for IN N
control NN N
of IN N
chemotherapy-related JJ o
nausea NN o
in IN N
female JJ p
breast NN p
cancer NN p
patients NNS p
. . p

-DOCSTART- -10693733- O O

Sun NNP i
protection NN i
counseling VBG i
for IN i
children NNS i
: : i
primary NN N
care NN N
practice NN N
patterns NNS N
and CC N
effect NN N
of IN N
an DT N
intervention NN N
on IN N
clinicians NNS p
. . p

OBJECTIVES NNP N
To TO N
describe VB N
current JJ N
primary JJ i
care NN i
sun NN i
protection NN i
advice NN p
for IN p
children NNS p
and CC N
assess VB N
the DT N
effect NN o
on IN o
clinicians NNS o
of IN N
an DT N
intervention NN N
to TO N
enhance VB N
their PRP$ N
sun NN o
protection NN o
advocacy NN o
. . o

SETTING NN N
Primary NNP p
care NN p
practices NNS p
caring VBG p
for IN p
children NNS p
in IN p
New NNP p
Hampshire NNP p
with IN p
special JJ p
attention NN p
to TO p
clinicians NNS p
serving VBG p
10 CD p
towns NNS p
that WDT p
were VBD p
involved VBN p
in IN p
a DT p
randomized NN p
controlled VBN p
trial NN p
of IN p
the DT p
multicomponent NN p
SunSafe NNP i
intervention NN p
involving VBG p
schools NNS p
, , p
recreation NN p
areas NNS p
, , p
and CC p
primary JJ p
care NN p
practices NNS p
. . p

DESIGN/INTERVENTION VB N
A NNP N
statewide JJ N
survey NN N
of IN N
all DT p
primary JJ p
care NN p
clinicians NNS p
serving VBG p
children NNS p
addressed VBD N
their PRP$ N
self-reported JJ N
sun NN o
protection NN o
advocacy NN o
practices NNS o
. . o

Clinicians NNPS p
in IN p
10 CD p
systematically RB p
selected VBN p
rural JJ p
towns NNS p
were VBD N
involved VBN N
in IN N
the DT N
subsequent JJ N
intervention NN N
study NN N
. . N

The DT N
primary JJ i
care NN i
intervention NN i
provided VBD i
assistance NN i
to TO i
practices NNS i
in IN i
establishing VBG i
an DT i
office NN i
system NN i
that WDT i
promoted VBD i
sun JJ i
protection NN i
advice NN i
to TO i
children NNS i
and CC i
their PRP$ i
parents NNS i
during IN i
office NN i
visits NNS i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Sun NNP o
protection NN o
promotion NN o
activities NNS o
of IN N
primary JJ N
care NN N
clinicians NNS N
as IN N
determined VBN N
by IN N
their PRP$ N
self JJ N
report NN N
, , N
research NN N
assistant NN N
observation NN N
, , N
and CC N
parent NN N
interviews NNS N
. . N

RESULTS NNP N
Of IN N
261 CD p
eligible JJ p
clinicians NNS p
responding VBG p
to TO p
the DT p
statewide NN p
survey NN p
, , N
about IN N
half PDT N
provide JJ o
sun NN o
protection NN o
counseling VBG o
most JJS o
of IN o
the DT o
time NN o
or CC o
almost RB o
always RB o
during IN N
summer NN N
well RB N
care VB N
visits NNS N
. . N

Pediatricians NNPS N
do VBP N
so RB N
more RBR N
often RB N
than IN N
family NN N
physicians NNS N
. . N

Clinicians NNPS N
involved VBN N
in IN N
the DT N
intervention NN N
increased VBD N
their PRP$ N
use NN o
of IN o
handouts NNS o
, , o
waiting VBG o
room NN o
educational JJ o
materials NNS o
, , o
and CC o
sunscreen JJ o
samples NNS o
. . o

Compared VBN N
with IN N
control NN N
town NN N
parents NNS N
, , N
parents NNS N
in IN N
intervention NN N
towns NNS N
reported VBD N
an DT N
increase NN N
in IN N
clinician JJ o
sun NN o
protection NN o
advice NN o
. . o

CONCLUSIONS VB N
The DT N
SunSafe NNP N
primary JJ N
care NN N
intervention NN N
increased VBD N
sun JJ o
protection NN o
counseling VBG o
activities NNS o
of IN N
participating VBG p
clinicians NNS p
. . p

A DT N
single-focus JJ N
preventive JJ N
service NN N
office NN N
system NN N
is VBZ N
feasible JJ o
to TO N
include VB N
in IN N
community NN N
interventions NNS N
to TO N
promote VB N
sun JJ o
protection NN o
. . o

-DOCSTART- -23588127- O O

Prevalence NN N
and CC N
treatment NN N
outcome NN N
of IN N
cervicitis NN o
of IN p
unknown JJ p
etiology NN p
. . p

BACKGROUND NNP N
Mucopurulent NNP N
cervicitis NN N
( ( N
MPC NNP N
) ) N
is VBZ N
a DT N
clinical JJ N
syndrome NN N
characterized VBN N
by IN N
mucopurulent JJ N
discharge NN N
from IN N
the DT N
cervix NN N
and CC N
other JJ N
signs NNS N
of IN N
inflammation NN N
. . N

This DT N
was VBD N
a DT N
phase NN N
III NNP N
, , N
multicenter NN N
study NN N
designed VBN N
to TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
placebo NN i
versus NN N
empiric JJ i
antibiotic JJ i
treatment NN i
for IN N
clinical JJ N
cure NN N
of IN N
MPC NNP o
of IN N
unknown JJ N
etiology NN N
at IN N
2-month JJ N
follow-up NN N
. . N

Unfortunately RB N
, , N
enrollment NN N
was VBD N
terminated VBN N
because IN N
of IN N
low JJ N
accrual NNS N
of IN N
women NNS p
with IN p
cervicitis NN p
of IN p
unknown JJ p
etiology NN p
, , N
but CC N
important JJ N
prevalence NN N
and CC N
outcome NN N
data NNS N
were VBD N
obtained VBN N
. . N

METHODS NNP N
Five CD p
hundred VBD p
seventy-seven JJ p
women NNS p
were VBD p
screened VBN p
for IN p
MPC NNP p
. . p

Women NNP p
with IN p
MPC NNP p
were VBD N
randomized VBN N
to TO N
the DT N
treatment NN N
or CC N
placebo NN i
arm NN N
of IN N
the DT N
study NN N
, , N
and CC N
the DT N
2 CD N
arms NNS N
were VBD N
evaluated VBN N
based VBN N
on IN N
the DT N
etiology NN o
, , o
clinical JJ o
cure NN o
rates NNS o
, , o
adverse JJ o
events NNS o
( ( o
AEs NNP o
) ) o
, , o
and CC o
rates NNS o
of IN o
pelvic JJ o
inflammatory JJ o
disease NN o
. . o

RESULTS NNP N
One CD p
hundred VBD p
thirty-one NN p
( ( p
23 CD p
% NN p
[ CC p
131/577 CD p
] NN p
) ) p
screened VBD p
women NNS p
were VBD N
found VBN N
to TO N
have VB N
MPC NNP N
. . N

Eighty-seven NNP p
were VBD p
enrolled VBN p
and CC N
randomized VBN N
. . N

After IN N
excluding VBG N
women NNS N
with IN N
sexually RB N
transmitted VBN N
infections NNS N
and CC N
other JJ N
exclusions NNS N
, , N
61 CD N
% NN N
( ( N
53/87 CD N
) ) N
had VBD N
cervicitis NN o
of IN N
unknown JJ N
etiology NN N
. . N

The DT N
overall JJ o
clinical JJ o
failure NN o
rate NN o
was VBD N
30 CD N
% NN N
( ( N
10/33 CD N
) ) N
, , N
and CC N
the DT N
clinical JJ o
cure NN o
rate NN o
was VBD N
only RB N
24 CD N
% NN N
( ( N
8/33 CD N
) ) N
. . N

Rates NNS N
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
arms NNS N
. . N

There EX N
were VBD N
24 CD N
gastrointestinal JJ o
AEs NNP o
in IN N
the DT N
treatment NN N
arm NN N
compared VBN N
with IN N
1 CD N
AE NNP N
in IN N
the DT N
placebo NN i
arm NN N
. . N

CONCLUSIONS NNP N
More JJR N
than IN N
half NN N
of IN N
the DT N
cases NNS N
of IN N
MPC NNP N
were VBD N
of IN N
unknown JJ N
etiology NN N
. . N

Clinical JJ o
cure NN o
rates NNS o
for IN N
the DT N
placebo NN i
and CC N
treatment NN N
arms NNS N
were VBD N
extremely RB N
low JJ N
, , N
with IN N
most JJS N
women NNS N
concluding VBG N
the DT N
study NN N
with IN N
a DT N
partial JJ N
response NN N
. . N

Gastrointestinal JJ o
AEs NNP o
were VBD N
higher JJR N
in IN N
the DT N
treatment NN N
arm NN N
. . N

-DOCSTART- -24534270- O O

Accumulated VBN i
brisk JJ i
walking NN i
reduces NNS N
arterial JJ N
stiffness NN N
in IN p
overweight JJ p
adults NNS p
: : p
evidence NN N
from IN N
a DT N
randomized VBN N
control NN N
trial NN N
. . N

Arterial JJ N
stiffness NN N
is VBZ N
a DT N
major JJ N
contributor NN N
to TO N
the DT N
development NN N
of IN N
atherosclerosis NN N
and CC N
consequently RB N
cardiovascular JJ N
disease NN N
. . N

This DT N
study NN N
aimed VBD N
to TO N
examine VB N
whether IN N
6 CD N
months NNS N
of IN N
accumulated VBN N
( ( N
3 CD N
? . N
10 CD N
minutes NNS N
, , N
5 CD N
days/week NN i
) ) i
brisk NN i
walking NN i
was VBD N
sufficient JJ N
to TO N
reduce VB N
arterial JJ N
stiffness NN p
in IN p
sedentary JJ p
, , p
overweight JJ p
individuals NNS p
. . p

Seventy-seven JJ p
individuals NNS p
( ( p
19 CD p
men NNS p
, , p
58 CD p
women NNS p
; : p
age NN p
, , p
30-55 CD p
years NNS p
) ) p
were VBD N
randomly RB N
allocated VBN N
to TO N
one CD N
of IN N
three CD N
groups NNS p
; : p
two CD p
groups NNS p
completed VBD i
30 CD i
minutes NNS i
of IN i
accumulated JJ i
walking VBG i
with IN i
either DT i
monthly JJ i
or CC i
weekly JJ i
telephone NN i
support NN i
; : i
the DT p
third JJ i
group NN i
( ( i
control NN i
) ) i
performed VBD i
stretching VBG i
exercises NNS i
. . i

The DT p
walking VBG p
groups NNS p
were VBD N
combined VBN N
and CC N
telephone NN N
support NN N
included VBD N
as IN N
a DT N
covariate NN N
. . N

Anthropometry NNP o
, , o
blood NN o
pressure NN o
( ( o
BP NNP o
) ) o
, , o
blood NN o
lipids NNS o
, , o
pulse RB o
wave VBP o
velocity NN o
( ( o
PWV NNP o
) ) o
, , o
and CC o
NOx NNP o
( ( o
surrogate JJ o
marker NN o
for IN o
nitric JJ o
oxide NN o
) ) o
were VBD N
measured VBN N
at IN N
baseline NN N
, , N
post-intervention NN N
and CC N
4 CD N
months NNS N
post-intervention NN N
. . N

No CC N
changes NNS N
were VBD N
observed VBN N
for IN o
anthropometry NN o
, , o
BP NNP o
, , o
or CC o
lipids NNS o
. . o

However RB N
, , N
at IN N
the DT N
end NN N
of IN N
the DT N
intervention NN N
, , N
there EX N
was VBD N
a DT N
decrease NN N
in IN o
PWV NNP o
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
accompanied VBN N
by IN N
an DT N
increase NN N
in IN o
NOx NNP o
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
with IN N
changes NNS N
maintained VBD N
4 CD N
months NNS N
post-intervention NN N
. . N

A NNP N
strong JJ N
negative JJ N
correlation NN N
between IN o
PWV NNP o
and CC o
NOx NNP o
was VBD N
also RB N
observed VBN N
( ( N
P NNP N
< NNP N
.001 NNP N
; : N
r NN N
= NNP N
-0.65 NNP N
) ) N
. . N

A DT N
lifestyle JJ N
approach NN N
to TO N
meeting VBG N
current JJ i
physical JJ i
activity NN i
guidelines NNS N
results NNS N
in IN N
favorable JJ N
alterations NNS N
in IN N
arterial JJ N
function NN N
in IN p
overweight JJ p
individuals NNS p
. . p

-DOCSTART- -8292465- O O

The DT N
incidence NN N
of IN N
first-dose JJ N
hypotension NN N
with IN N
quinapril NN i
in IN N
patients NNS p
with IN p
mild JJ p
to TO p
moderate VB p
hypertension NN p
. . p

A DT p
total NN p
of IN p
2242 CD p
patients NNS p
with IN p
mild JJ p
to TO p
moderate VB p
hypertension NN p
( ( p
diastolic JJ p
pressure NN p
95-120 CD p
mmHg NN p
) ) p
were VBD N
randomised VBN N
on IN N
a DT N
double-blind JJ N
basis NN N
to TO N
receive VB N
a DT N
single JJ N
dose NN N
of IN N
placebo NN i
, , i
5 CD i
mg NN i
quinapril NN i
or CC i
10 CD i
mg JJ i
quinapril NN i
. . i

Patients NNS p
were VBD p
identified VBN p
who WP p
: : p
( ( p
a DT p
) ) p
met VBD p
the DT p
blood NN o
pressure NN o
( ( p
BP NNP p
) ) p
criteria NNS p
for IN p
first-dose JJ p
hypotension NN p
( ( p
sitting VBG p
or CC p
standing VBG p
systolic JJ p
BP NNP p
< NNP p
100 CD p
mmHg NN p
, , p
or CC p
a DT p
fall NN p
in IN p
systolic JJ p
BP NNP p
> NN p
or CC p
= $ p
20 CD p
mmHg NN p
on IN p
standing VBG p
) ) p
; : p
( ( p
b NN p
) ) p
had VBD p
symptoms NNS p
suggestive JJ p
of IN p
hypotension NN p
; : p
and CC p
( ( p
c NN p
) ) p
met VBD p
the DT p
BP NNP p
criteria NNS p
and CC p
had VBD p
symptoms NNS p
. . p

In IN N
all DT N
three CD N
classifications NNS N
there EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
incidences NNS N
in IN N
placebo NN N
and CC N
combined VBD N
active JJ N
treatment NN N
groups NNS N
, , N
or CC N
between IN N
those DT N
in IN N
the DT N
two CD N
quinapril NN N
groups NNS N
. . N

No RB N
associated JJ o
serious JJ o
adverse JJ o
events NNS o
were VBD N
reported VBN N
. . N

In IN N
the DT N
low-risk JJ p
population NN p
studied VBD N
, , N
it PRP N
would MD N
appear VB N
that IN N
the DT N
incidence NN N
of IN N
first-dose JJ N
hypotension NN N
with IN N
quinapril NN N
is VBZ N
similar JJ N
to TO N
placebo VB N
and CC N
is VBZ N
not RB N
dose-related JJ N
. . N

-DOCSTART- -16253098- O O

Oral NNP N
health NN N
impacts NNS N
on IN N
daily JJ N
living NN N
related VBN N
to TO N
four CD N
different JJ N
treatment NN N
protocols NNS N
for IN N
chronic JJ p
periodontitis NN p
. . p

BACKGROUND IN N
The DT N
aims NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
evaluate VB N
the DT N
oral JJ N
health NN N
impacts NNS N
perceived VBN N
by IN N
patients NNS p
submitted VBN p
to TO p
different JJ p
treatments NNS p
of IN p
chronic JJ p
periodontitis NN p
and CC p
their PRP$ p
association NN p
with IN p
clinical JJ p
parameters NNS p
. . p

METHODS NNP N
Sixty NNP p
patients NNS p
were VBD p
assigned VBN p
to TO N
one CD N
of IN N
the DT N
following JJ N
therapeutic JJ N
groups NNS N
: : N
control NN i
, , i
treated VBN i
with IN i
full-mouth JJ i
scaling NN i
and CC i
root NN i
planing NN i
( ( i
SRP NNP i
) ) i
; : i
test $ N
1 CD N
, , N
treated VBN i
with IN i
SRP NNP i
and CC i
400 CD i
mg NNS i
systemically RB i
administered VBN i
metronidazole NN i
( ( i
MET NNP i
) ) i
three CD N
times NNS N
per IN N
day NN N
for IN N
10 CD N
days NNS N
; : N
test JJS N
2 CD N
, , N
treated VBN i
with IN i
SRP NNP i
and CC i
professional JJ i
supragingival NN i
plaque NN i
removal NN i
( ( i
PP NNP i
) ) i
every DT N
week NN N
for IN N
3 CD N
months NNS N
; : N
and CC N
test VB N
3 CD N
, , N
treated VBN N
with IN N
SRP NNP i
and CC i
MET NNP i
plus CC i
PP NNP i
. . i

Clinical NNP N
periodontal JJ N
measurements NNS N
and CC N
data NNS N
regarding VBG N
patients NNS N
' POS N
oral JJ o
health NN o
impacts NNS o
( ( o
perceived VBN o
impacts NNS o
on IN o
bleeding VBG o
gums NNS o
, , o
gingival JJ o
recession NN o
, , o
sensitivity NN o
to TO o
cold VB o
, , o
packing VBG o
foods NNS o
, , o
aesthetics NNS o
, , o
bad JJ o
breath NN o
, , o
and CC o
tooth DT o
mobility NN o
) ) o
were VBD N
collected VBN N
at IN N
baseline NN N
and CC N
3 CD N
months NNS N
after IN N
therapy NN N
. . N

RESULTS NNP N
All NNP N
groups NNS N
presented VBD N
significant JJ N
improvement NN N
in IN N
oral JJ o
health NN o
perceived VBD o
impacts NNS o
. . o

There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
in IN N
the DT N
improvement NN N
of IN N
oral JJ o
health NN o
impacts NNS o
among IN N
groups NNS N
subjected VBN N
to TO N
different JJ N
treatments NNS N
. . N

The DT N
clinical JJ N
data NNS N
of IN N
percentage NN N
of IN N
deep JJ o
probing VBG o
depth NN o
, , o
deep JJ o
clinical JJ o
attachment NN o
level NN o
, , o
and CC o
bleeding VBG o
on IN o
probing VBG o
were VBD N
found VBN N
to TO N
be VB N
correlated VBN N
significantly RB N
with IN N
oral JJ N
health NN N
impacts NNS N
. . N

CONCLUSIONS NNP N
Periodontal NNP i
treatment NN i
leads VBZ N
to TO N
a DT N
significant JJ N
reduction NN N
of IN N
self-perceived JJ o
impacts NNS o
regardless RB N
of IN N
the DT N
non-surgical JJ N
treatment NN N
protocol NN N
employed VBN N
. . N

Most JJS N
of IN N
the DT N
clinical JJ N
data NNS N
were VBD N
associated VBN N
with IN N
oral JJ N
health NN N
impacts NNS N
. . N

-DOCSTART- -3287226- O O

[ JJ o
Prevention NNP o
of IN o
thromboembolism NN o
in IN N
patients NNS p
operated VBN p
on IN p
for IN p
hip NN p
prosthesis NN p
] NNP p
. . N

The DT N
latest JJS N
research NN N
into IN N
the DT N
prevention NN o
of IN o
peri- NN o
and CC o
postoperative JJ o
thromboembolic NN o
disease NN o
has VBZ N
found VBN N
orthopaedic JJ N
surgery NN N
patients NNS N
to TO N
be VB N
most VBN N
at IN N
risk NN N
. . N

As IN N
the DT N
genesis NN N
of IN N
deep JJ N
venous JJ N
thrombosis NN N
( ( N
DVT NNP N
) ) N
is VBZ N
due JJ N
to TO N
haemodynamic VB N
, , N
hemorheologic NN N
and CC N
parietal JJ N
factors NNS N
, , N
various JJ N
prophylactic JJ N
measures NNS N
have VBP N
been VBN N
considered VBN N
in IN N
the DT N
past NN N
, , N
measures NNS N
which WDT N
have VBP N
not RB N
proved VBN N
able JJ N
to TO N
provide VB N
satisfactory JJ N
protection NN N
in IN N
orthopaedics NNS N
. . N

The DT N
results NNS N
obtained VBD N
with IN N
Defibrotide NNP i
in IN N
a DT N
random NN N
and CC N
controlled VBD N
clinical JJ N
study NN N
versus IN N
calcium NN i
heparin NN i
involving VBG N
211 CD p
patients NNS p
of IN p
both DT p
sexes NNS p
candidates NNS p
to TO p
receive VB p
total JJ p
hip NN p
arthroplasty NN p
and CC p
presenting NN p
at IN p
least JJS p
one CD p
major JJ p
thromboembolic NN p
risk NN p
factor NN p
are VBP N
reported VBN N
. . N

The DT N
patients NNS N
were VBD N
assigned VBN N
at IN N
random NN N
to TO N
one CD N
of IN N
the DT N
following JJ N
treatments NNS N
: : N
1 CD N
) ) N
Defibrotide NN i
at IN i
a DT i
dose NN i
of IN i
400 CD i
mg NN i
b.i.d NN i
. . i

i.v NN i
. . i

in IN i
50 CD i
ml JJ i
phleboclysis NN i
in IN i
5 CD i
minutes NNS i
( ( i
n JJ i
= NNP i
108 CD i
) ) i
; : i
2 CD i
) ) i
calcium NN i
heparin NN i
at IN i
a DT i
dose NN i
of IN i
5000 CD i
IU NNP i
t.i.d NN i
. . i

subcutaneously RB i
( ( i
n JJ i
= NNP i
103 CD i
) ) i
. . N

The DT i
treatment NN i
began VBD i
the DT i
day NN i
before IN i
operation NN i
and CC i
continued VBN i
on IN i
average NN i
up RB i
to TO i
the DT i
eighth JJ i
day NN i
for IN i
the DT i
Defibrotide NNP i
group NN i
. . i

With IN N
the DT N
control NN N
group NN N
it PRP N
continued VBD N
until IN N
discharge NN N
( ( N
usually RB N
on IN N
the DT N
15th JJ N
day NN N
) ) N
and CC N
at IN N
home NN N
for IN N
about RB N
three CD N
weeks NNS N
until IN N
the DT N
completion NN N
of IN N
the DT N
physiotherapy NN N
cycle NN N
. . N

In IN N
the DT N
108 CD N
patients NNS N
treated VBN N
with IN N
Defibrotide NNP i
only RB N
one CD N
case NN N
of IN N
DVT NNP o
was VBD N
reported VBN N
and CC N
in IN N
none NN N
of IN N
these DT N
patients NNS N
were VBD N
symptoms NNS o
or CC o
signs NNS o
of IN o
pulmonary JJ o
embolism NN o
encountered VBN N
. . N

In IN N
the DT N
group NN N
treated VBD N
with IN N
calcium NN N
heparin NN N
2 CD N
cases NNS N
of IN N
clinically RB N
and CC N
radiologically RB o
diagnosed VBD o
pulmonary JJ o
embolism NN o
and CC N
4 CD N
cases NNS o
of IN o
DVT NNP o
were VBD N
observed VBN N
. . N

Although IN N
the DT N
differences NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
, , N
the DT N
tendency NN N
favours VBZ N
Defibrotide NNP N
. . N

Statistically NNP N
significant JJ N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
was VBD N
the DT N
difference NN N
in IN N
postoperative JJ o
bleeding NN o
evaluated VBN o
with IN N
particular JJ N
attention NN N
in IN N
patients NNS N
of IN N
advanced JJ N
age NN N
. . N

Further NNP N
, , N
in IN N
the DT N
Defibrotide NNP i
group NN N
, , N
scarring VBG o
was VBD N
considered VBN N
excellent JJ N
in IN N
96 CD N
% NN N
of IN N
cases NNS N
while IN N
in IN N
the DT N
heparin NN N
group NN N
scarring VBG o
was VBD N
excellent JJ N
in IN N
85 CD N
% NN N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

To TO N
conclude VB N
, , N
the DT N
sure JJ N
clinical JJ o
effectiveness NN o
, , o
tolerance NN o
, , o
handiness NN o
and CC o
lack NN o
of IN o
interference NN o
with IN o
clotting VBG o
functions NNS o
make VBP N
Defibrotide VB i
a DT N
really RB N
useful JJ N
drug NN N
for IN N
the DT N
prevention NN N
of IN N
thromboembolic JJ o
episodes NNS N
in IN N
patients NNS p
undergoing VBG p
major JJ p
orthopaedic JJ p
surgery NN p
. . p

-DOCSTART- -9134405- O O

A DT N
randomised JJ N
trial NN N
evaluating VBG N
pain NN o
and CC o
bleeding NN o
after IN p
a DT p
first JJ p
trimester NN p
miscarriage NN p
treated VBD p
surgically RB p
or CC p
medically RB p
. . p

Miscarriage NN N
treated VBD N
surgically RB i
and CC i
medically RB i
were VBD N
compared VBN N
in IN N
a DT N
randomised JJ N
controlled VBN N
trial NN N
evaluating VBG N
pain NN o
and CC o
bleeding NN o
. . o

Surgery NN N
is VBZ N
associated VBN N
with IN N
less JJR o
pain NN o
( ( N
P NNP N
< NNP N
0.03 CD N
) ) N
and CC N
vaginal JJ o
bleeding NN o
( ( N
duration NN N
and CC N
severity NN N
, , N
P NNP N
= NNP N
0.001 CD N
) ) N
than IN N
medical JJ N
treatment NN N
, , N
fewer JJR o
daily JJ o
hospital NN o
attendances NNS o
( ( N
2.5 CD N
compared VBN N
with IN N
three CD N
, , N
P NNP N
= NNP N
0.04 CD N
) ) N
but CC N
a DT N
greater JJR N
drop NN N
in IN N
haemoglobin JJ N
concentration NN N
( ( N
difference NN N
, , N
1 CD N
g/dl NN N
; : N
CI95 NNP N
% NN N
= NNP N
0.3-1.6 NN N
) ) N
. . N

-DOCSTART- -17972479- O O

Hitting VBG N
the DT N
target NN N
: : N
relatively RB N
easy JJ N
, , N
yet RB N
absolutely RB N
difficult JJ N
. . N

It PRP N
is VBZ N
generally RB N
agreed VBN N
that IN N
absolute-direction NN p
judgments NNS p
require VBP N
information NN N
about IN N
eye NN N
position NN N
, , N
whereas JJ N
relative-direction NN N
judgments NNS N
do VBP N
not RB N
. . N

The DT N
source NN N
of IN N
this DT N
eye-position JJ N
information NN N
, , N
particularly RB N
during IN N
monocular JJ N
viewing NN N
, , N
is VBZ N
a DT N
matter NN N
of IN N
debate NN N
. . N

It PRP N
may MD N
be VB N
either CC N
binocular VB N
eye NN N
position NN N
, , N
or CC N
the DT N
position NN N
of IN N
the DT N
viewing-eye JJ N
only RB N
, , N
that DT N
is VBZ N
crucial JJ N
. . N

Using VBG N
more RBR N
ecologically RB N
valid JJ N
stimulus NN N
situations NNS N
than IN N
the DT N
traditional JJ N
LED NNP N
in IN N
the DT N
dark NN N
, , N
we PRP N
performed VBD N
two CD N
experiments NNS N
. . N

In IN N
experiment JJ N
1 CD N
, , N
observers NNS i
threw VBD i
darts NNS i
at IN i
targets NNS i
that WDT i
were VBD i
fixated VBN i
either RB i
monocularly RB i
or CC i
binocularly RB i
. . i

In IN N
experiment JJ N
2 CD N
, , N
observers NNS i
aimed VBD i
a DT i
laser NN i
gun NN i
at IN i
targets NNS i
while IN i
fixating VBG i
either CC i
the DT i
rear NN i
or CC i
the DT i
front JJ i
gunsight NN i
monocularly RB i
, , i
or CC i
the DT i
target NN i
either CC i
monocularly JJ i
or CC i
binocularly RB i
. . i

We PRP N
measured VBD N
the DT N
accuracy NN o
and CC o
precision NN o
of IN N
the DT N
observers NNS N
' POS N
absolute- JJ N
and CC N
relative-direction JJ N
judgments NNS N
. . N

We PRP N
found VBD N
that IN N
( ( N
a DT N
) ) N
relative-direction NN N
judgments NNS N
were VBD N
precise JJ N
and CC N
independent JJ N
of IN N
phoria NN N
, , N
and CC N
( ( N
b NN N
) ) N
monocular JJ N
absolute-direction NN N
judgments NNS N
were VBD N
inaccurate JJ o
, , N
and CC N
the DT N
magnitude NN N
of IN N
the DT N
inaccuracy NN o
was VBD N
predictable JJ N
from IN N
the DT N
magnitude NN N
of IN N
phoria NN N
. . N

These DT N
results NNS N
confirm VBP N
that IN N
relative-direction NN N
judgments NNS N
do VBP N
not RB N
require VB N
information NN N
about IN N
eye NN N
position NN N
. . N

Moreover RB N
, , N
they PRP N
show VBP N
that IN N
binocular JJ N
eye-position NN N
information NN N
is VBZ N
crucial JJ N
when WRB N
judging VBG N
the DT N
absolute JJ N
direction NN N
of IN N
both DT N
monocular JJ N
and CC N
binocular JJ N
targets NNS N
. . N

-DOCSTART- -7104637- O O

Intraoperative JJ i
microscopy NN i
of IN p
bile NN p
-- : p
is VBZ p
it PRP N
useful JJ N
? . N
Direct JJ i
microscopy NN i
of IN i
the DT i
bile NN i
was VBD N
performed VBN N
during IN p
cholecystectomy NN i
in IN p
111 CD p
patients NNS p
in IN p
an DT N
attempt NN N
to TO N
identify VB N
those DT N
with IN N
a DT N
high JJ N
risk NN N
of IN N
wound JJ N
infection NN N
. . N

Bacteria NNP N
were VBD N
identified VBN N
in IN N
23 CD p
patients NNS p
, , p
11 CD p
of IN p
83 CD p
undergoing JJ p
cholecystectomy NN i
alone RB p
and CC p
12 CD p
of IN p
28 CD p
undergoing JJ p
exploration NN p
of IN p
the DT p
common JJ p
bile NN p
duct NN p
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

These DT N
23 CD p
patients NNS p
were VBD p
randomly RB p
allocated VBN p
to TO p
an DT p
antibiotic JJ i
group NN i
or CC p
a DT p
control NN p
group NN p
; : p
there EX N
was VBD N
one CD N
wound NN N
infection NN N
in IN N
the DT N
antibiotic JJ i
group NN i
and CC N
two CD N
in IN N
the DT N
control NN i
group NN i
. . i

A DT N
total NN N
of IN N
14 CD p
patients NNS p
developed VBD N
wound JJ o
sepsis NN o
. . o

Infection NN o
was VBD N
more RBR N
likely JJ N
if IN N
the DT N
common JJ N
bile NN N
duct NN N
was VBD N
explored VBN N
( ( N
6 CD N
of IN N
28 CD N
) ) N
rather RB N
than IN N
cholecystectomy VB i
alone JJ N
( ( N
8 CD N
of IN N
83 CD N
) ) N
. . N

There EX N
was VBD N
a DT N
poor JJ N
correlation NN N
between IN N
microscopy NN N
and CC N
culture NN N
of IN N
the DT N
bile NN N
for IN N
bacteria NNS o
and CC N
there EX N
was VBD N
no DT N
increase NN N
in IN N
sepsis NN o
when WRB N
bacteria NNS N
were VBD N
observed VBN N
on IN N
microscopy NN N
. . N

We PRP N
were VBD N
not RB N
able JJ N
to TO N
identify VB N
a DT N
high JJ N
risk NN N
group NN N
of IN N
patients NNS N
by IN N
intraoperative JJ p
microscopy NN p
of IN p
bile NN p
. . p

-DOCSTART- -7799030- O O

Cytokine NN o
levels NNS o
and CC o
systemic JJ o
toxicity NN o
in IN N
patients NNS p
undergoing VBG p
isolated JJ i
limb NN i
perfusion NN i
with IN i
high-dose JJ i
tumor NN i
necrosis NN i
factor NN i
, , i
interferon NN i
gamma NN i
, , i
and CC i
melphalan NN i
. . i

PURPOSE NNP N
Isolated NNP i
limb NN i
perfusion NN i
( ( i
ILP NNP i
) ) i
with IN i
tumor NN i
necrosis NN i
factor NN i
( ( i
TNF NNP i
) ) i
, , i
interferon JJ i
gamma NN i
, , i
and CC i
melphalan NN i
( ( i
M NNP i
) ) i
has VBZ N
been VBN N
reported VBN N
to TO N
result VB N
in IN N
high JJ N
response NN o
rates NNS o
for IN N
extremity NN N
melanoma NN N
and CC N
sarcoma NN N
. . N

We PRP N
have VBP N
evaluated VBN N
the DT N
relationship NN N
of IN N
systemic JJ N
TNF NNP N
exposure NN N
to TO N
induction NN N
of IN N
several JJ N
secondary JJ o
mediators NNS o
and CC N
incidence NN N
of IN N
systemic JJ o
toxicity NN o
. . o

PATIENTS NNP N
AND CC N
METHODS NNP N
Nineteen NNP p
patients NNS p
with IN p
extremity NN p
melanoma NN p
( ( p
n JJ p
= NNP p
16 CD p
) ) p
or CC p
sarcoma NN p
( ( p
n JJ p
= NNP p
3 CD p
) ) p
, , N
underwent JJ N
90-minute JJ N
ILP NNP i
with IN i
TNF-alpha NNP i
, , i
interferon NN i
gamma NN i
( ( N
0.2 CD N
mg NN N
) ) N
, , N
and CC i
M NNP i
( ( N
10 CD N
to TO N
13 CD N
mg/L NN N
of IN N
limb NN N
volume NN N
) ) N
( ( i
TNF/IFN/M NNP i
) ) i
( ( N
n JJ N
= NNP N
12 CD N
) ) N
, , N
or CC i
M NNP i
alone RB i
( ( N
n JJ N
= NNP N
7 CD N
) ) N
. . N

Continuous JJ N
intraoperative JJ N
monitoring NN N
( ( N
CIM NNP N
) ) N
for IN N
systemic JJ N
leak NN N
from IN N
the DT N
perfusion NN N
circuit NN N
was VBD N
performed VBN N
using VBG N
radioactive JJ N
iodine-131 JJ i
albumin NN i
. . i

Cytokine NN N
levels NNS N
in IN N
the DT N
perfusate NN N
and CC N
systemic JJ N
circulation NN N
during IN N
and CC N
after IN N
ILP NNP N
were VBD N
measured VBN N
by IN N
enzyme-linked JJ i
immunosorbent NN i
assay NN i
. . i

RESULTS NNP N
Systemic NNP o
leaks VBZ o
> CD o
or CC o
= VB o
1 CD o
% NN o
from IN N
the DT N
perfusion NN o
circuit NN o
occurred VBD N
in IN N
six CD N
patients NNS N
who WP N
received VBD N
TNF/IFN/M NNP N
and CC N
in IN N
four CD N
who WP N
received VBD N
M NNP N
alone RB N
. . N

Hypotension NNP o
that IN o
required VBD o
vasopressor NN o
support NN o
occurred VBD N
in IN N
six CD N
of IN N
six CD N
patients NNS N
with IN N
evidence NN N
of IN N
a DT N
leak NN N
( ( N
> CD N
or CC N
= VB N
1 CD N
% NN N
) ) N
and CC N
zero CD N
of IN N
six CD N
patients NNS N
without IN N
a DT N
leak NN N
( ( N
< JJ N
1 CD N
% NN N
) ) N
. . N

These DT N
six CD N
patients NNS N
had VBD N
significantly RB N
higher JJR N
peak JJ o
systemic JJ o
TNF NNP o
levels NNS o
during IN N
and CC N
after IN N
perfusion NN N
than IN N
patients NNS N
without IN N
a DT N
leak NN N
( ( N
2.8 CD N
and CC N
8.2 CD N
ng/mL JJ N
v NN N
0.7 CD N
and CC N
2.0 CD N
ng/mL NN N
, , N
respectively RB N
; : N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

All PDT N
patients NNS N
who WP N
received VBD N
TNF/IFN/M NNP N
had VBD N
significantly RB N
greater JJR N
increases NNS N
in IN N
systemic JJ o
interleukin-6 JJ o
( ( o
IL-6 NNP o
) ) o
levels NNS o
than IN N
in IN N
patients NNS N
with IN N
M NNP N
alone RB N
( ( N
12,395 CD N
+/- JJ N
10,374 CD N
pg/mL NN N
v NN N
79.4 CD N
+/- JJ N
7.2 CD N
pg/mL NN N
, , N
respectively RB N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Intracellular JJ o
adhesion NN o
molecule NN o
( ( o
ICAM NNP o
) ) o
, , o
IL-8 NNP o
, , o
and CC o
TNF-R JJ o
levels NNS o
were VBD N
also RB N
increased VBN N
after IN N
ILP NNP N
with IN N
TNF/IFN/M NNP N
. . N

CONCLUSION NNP N
ILP NNP N
with IN N
TNF/IFN/M NNP N
can MD N
be VB N
safely RB N
performed VBN N
, , N
as IN N
I131 NNP N
albumin VBP N
provides VBZ N
a DT N
sensitive JJ N
measure NN N
of IN N
systemic JJ N
leakage NN N
from IN N
the DT N
perfusion NN N
circuit NN N
. . N

Patients NNS N
with IN N
a DT N
measured JJ N
leak NN N
of IN N
> NN N
or CC N
= VB N
1 CD N
% NN N
develop NN N
mild NN N
and CC N
transient JJ N
postoperative JJ N
hypotension NN N
with IN N
significantly RB N
higher JJR N
systemic JJ N
TNF NNP N
levels NNS N
and CC N
lower JJR N
perfusate NN N
TNF NNP N
levels NNS N
than IN N
in IN N
patients NNS N
without IN N
leaks NNS N
. . N

-DOCSTART- -19884541- O O

Comparison NNP N
of IN N
neurocognitive JJ o
functioning NN o
in IN N
children NNS p
previously RB p
randomly RB p
assigned VBN p
to TO p
intrathecal JJ i
methotrexate NN i
compared VBN N
with IN N
triple JJ i
intrathecal JJ i
therapy NN i
for IN N
the DT N
treatment NN N
of IN N
childhood NN p
acute NN p
lymphoblastic JJ p
leukemia NN p
. . p

PURPOSE NNP N
For IN N
the DT N
majority NN N
of IN N
children NNS p
with IN p
acute JJ p
lymphoblastic JJ p
leukemia NN p
( ( p
ALL NNP p
) ) p
, , p
CNS NNP p
prophylaxis NN p
consists VBZ p
of IN p
either DT p
intrathecal JJ i
( ( i
IT NNP i
) ) i
methotrexate NN i
or CC i
triple VB i
IT NNP i
therapy NN i
( ( i
ie JJ i
, , i
methotrexate NN i
with IN i
both DT i
cytarabine NN i
and CC i
hydrocortisone NN i
) ) i
. . i

The DT N
long-term JJ N
neurotoxicities NNS N
of IN N
these DT N
two CD N
IT NNP N
strategies NNS N
have VBP N
not RB N
yet RB N
been VBN N
directly RB N
compared VBN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
In IN N
this DT N
multisite NN N
study NN N
, , N
171 CD p
children NNS p
with IN p
standard-risk JJ p
ALL NNP p
, , p
age NN p
1 CD p
to TO p
9.99 CD p
years NNS p
at IN p
diagnosis NN p
, , p
previously RB p
randomly RB p
assigned VBN p
to TO p
IT NNP i
methotrexate NNP i
( ( p
n JJ p
= NNP p
82 CD p
) ) p
or CC p
to TO p
triple VB i
IT NNP i
therapy NN i
( ( p
n JJ p
= NNP p
89 CD p
) ) p
on IN p
CCG NNP p
1952 CD p
, , p
underwent JJ p
neurocognitive JJ p
evaluation NN p
by IN p
a DT p
licensed JJ p
psychologist NN p
at IN p
a DT p
mean NN p
of IN p
5.9 CD p
years NNS p
after IN p
random JJ p
assignment NN p
. . p

RESULTS JJ N
Patients NNPS p
who WP p
received VBD p
IT NNP i
methotrexate NNP i
had VBD N
a DT N
mean JJ o
Processing NNP o
Speed NNP o
Index NNP o
that WDT N
was VBD N
3.6 CD N
points NNS N
lower JJR N
, , N
about IN N
one CD N
fourth JJ N
of IN N
a DT N
standard JJ N
deviation NN N
, , N
than IN N
those DT N
who WP N
received VBD N
triple JJ i
IT NNP i
therapy NN i
( ( N
P NNP N
= NNP N
.04 NNP N
) ) N
after IN N
analysis NN N
was VBD N
adjusted VBN N
for IN N
age NN N
, , N
sex NN N
, , N
and CC N
time NN N
since IN N
diagnosis NN N
. . N

Likewise NNP N
, , N
19.5 CD p
% NN p
of IN p
children NNS p
in IN p
the DT p
IT NNP i
methotrexate NNP i
group NN p
had VBD N
a DT N
Processing NNP o
Speed NNP o
Index NNP o
score NN o
in IN N
the DT N
below-average NN N
range NN N
compared VBN N
with IN N
6.9 CD N
% NN N
in IN N
the DT N
triple NN i
IT NNP i
therapy NN i
group NN i
( ( N
P NNP N
= NNP N
.02 NNP N
) ) N
. . N

Otherwise UH N
, , N
the DT N
groups NNS N
performed VBD N
similarly RB N
on IN N
tests NNS o
of IN o
full-scale JJ o
intelligence NN o
quotient NN o
, , o
academic JJ o
achievement NN o
, , o
attention/concentration NN o
, , o
memory NN o
, , o
and CC o
visual JJ o
motor NN o
integration NN o
. . o

The DT N
association NN N
of IN N
treatment NN N
with IN N
measures NNS o
of IN o
cognitive JJ o
functioning NN o
was VBD N
not RB N
modified VBN N
by IN N
sex NN p
or CC p
age NN p
at IN p
diagnosis NN p
. . p

In IN N
the DT N
post-therapy JJ N
period NN N
, , N
there EX N
were VBD N
no DT N
group NN N
differences VBZ N
in IN N
special JJ o
education NN o
services NNS o
, , o
neurologic JJ o
events NNS o
, , o
or CC o
use NN o
of IN o
psychotropic NN o
medications NNS o
. . o

CONCLUSION NNP N
This DT N
study NN N
did VBD N
not RB N
show VB N
any DT N
clinically RB N
meaningful JJ N
differences NNS N
in IN N
neurocognitive JJ o
functioning NN o
between IN N
patients NNS N
previously RB N
randomly RB N
assigned VBN N
to TO N
IT NNP i
methotrexate NN i
or CC N
triple VB i
IT NNP i
therapy NN i
except IN N
for IN N
a DT N
small JJ N
difference NN N
in IN N
processing VBG o
speed NN o
in IN N
the DT N
IT NNP i
methotrexate NNP i
group NN i
. . i

-DOCSTART- -2195532- O O

[ JJ N
Methodologic NNP N
comparison NN N
of IN N
the DT N
polyfrequency NN i
oscillation NN i
method NN i
, , N
transcutaneous JJ N
oxygen NN N
pressure NN N
measurement NN N
and CC N
body NN N
plethysmography NN N
in IN N
bronchial JJ p
provocation NN p
with IN p
methacholine JJ i
] NN i
. . N

A DT p
bronchial JJ p
provocation NN p
challenge NN p
test NN p
was VBD p
conducted VBN p
with IN p
30 CD p
subjects NNS p
using VBG p
metacholin NN i
. . i

In IN N
randomised JJ N
sequence NN N
lung NN N
function NN N
analysis NN N
tests NNS N
were VBD N
carried VBN N
out RP N
with IN N
the DT N
bodyplethysmograph NN i
( ( N
Raw NNP N
, , N
FEV1 NNP N
) ) N
and CC N
the DT N
polyfrequent JJ N
oscillation NN N
method NN N
( ( N
resistance NN N
, , N
reactance NN N
between IN N
2 CD N
and CC N
52 CD N
Hz NNP N
) ) N
, , N
whereas IN N
the DT N
transcutaneous JJ i
oxygen NN i
pressure NN i
( ( N
tc-PO2 JJ N
) ) N
was VBD N
measured VBN N
continuously RB N
. . N

Correlations NNS N
between IN N
the DT N
various JJ N
parameters NNS N
, , N
the DT N
change NN N
of IN N
the DT N
values NNS N
at IN N
PD60 NNP N
sGaw NN N
in IN N
relation NN N
to TO N
the DT N
initial JJ N
values NNS N
, , N
the DT N
interindividual JJ N
variability NN N
and CC N
the DT N
reactivity NN N
were VBD N
determined VBN N
. . N

Medium JJ N
correlations NNS N
were VBD N
found VBN N
for IN N
the DT N
oscillatory NN o
parameters NNS o
and CC o
Raw NNP o
, , N
whereas IN N
for IN N
tc-PO2 NN o
and CC o
Raw NNP o
the DT N
correlation NN N
was VBD N
markedly RB N
lower JJR N
. . N

In IN N
terms NNS N
of IN N
percentage NN N
the DT N
greatest JJS o
change NN o
was VBD N
found VBN N
in IN N
reactance NN o
, , N
in IN N
relation NN N
to TO N
the DT N
initial JJ N
value NN N
, , N
followed VBN N
by IN N
Raw NNP o
and CC o
FEV1 NNP o
. . o

The DT N
interindividual JJ N
variability NN N
resulted VBD N
in IN N
the DT N
highest JJS o
values NNS o
for IN N
the DT N
reactance NN o
, , N
followed VBN N
by IN N
Raw NNP o
and CC N
FEV1 NNP o
. . o

Interindividual NNP N
variability NN o
showed VBD N
the DT N
highest JJS N
values NNS N
for IN N
the DT N
reactance NN o
before IN N
oscillatory JJ o
resistance NN o
and CC o
Raw NNP o
. . o

In IN N
respect NN N
of IN N
reactivity NN N
, , N
reactance NN o
also RB N
had VBD N
the DT N
highest JJS N
values NNS N
. . N

Overall JJ N
evaluation NN N
showed VBD N
that IN N
bodyplethysmography NN i
and CC N
the DT N
polyfrequent JJ i
oscillation NN i
method NN i
( ( N
reactance NN N
or CC N
resonance NN N
frequency NN N
) ) N
are VBP N
comparably RB N
sensitive JJ N
. . N

-DOCSTART- -17467265- O O

Chemoradiation NN N
comparing VBG N
cisplatin JJ i
versus NN N
carboplatin NN i
in IN N
locally RB p
advanced JJ p
nasopharyngeal JJ p
cancer NN p
: : p
randomised VBN N
, , N
non-inferiority NN N
, , N
open JJ N
trial NN N
. . N

PURPOSE VB N
This DT N
single JJ p
centre NN p
, , N
open JJ N
labelled VBD N
, , N
randomised VBD N
non-inferiority JJ N
trial NN N
compared VBN N
concurrent JJ N
chemoradiotherapy NN i
with IN i
carboplatin JJ i
versus JJ N
standard NN i
concurrent NN i
chemoradiotherapy NN i
with IN i
cisplatin NN i
in IN N
patients NNS p
with IN p
locoregionally RB p
advanced JJ p
nasopharyngeal JJ p
cancer NN p
( ( N
NPC NNP N
) ) N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
From NNP p
August NNP p
1999 CD p
to TO p
December NNP p
2004 CD p
, , p
206 CD p
patients NNS p
with IN p
locally RB p
advanced JJ p
NPC NNP p
were VBD p
randomised VBN p
with IN p
101 CD i
to TO i
cisplatin VB i
arm NN i
and CC i
105 CD i
to TO i
carboplatin VB i
arm NN p
. . p

Planned VBD i
radiotherapy NN i
was VBD N
the DT N
same JJ N
in IN N
both DT N
groups NNS N
. . N

All PDT N
the DT N
patients NNS N
were VBD N
evaluated VBN N
for IN N
toxicity NN o
and CC o
survival NN o
according VBG N
to TO N
the DT N
as-treated JJ N
principle NN N
. . N

RESULTS NNP N
With IN N
a DT N
median JJ N
follow-up NN N
of IN N
26.3 CD N
months NNS N
( ( N
range VB N
3-74.6 JJ N
months NNS N
) ) N
, , N
59 CD N
% NN N
of IN N
patients NNS N
in IN N
the DT N
cisplatin NN N
arm NN N
completed VBD N
the DT N
planned VBN N
concurrent NN N
chemoradiation NN N
treatment NN N
, , N
compared VBN N
to TO N
73 CD N
% NN N
in IN N
the DT N
carboplatin NN N
arm NN N
. . N

Forty-two JJ N
percent NN N
of IN N
cisplatin NN N
patients NNS N
completed VBD N
the DT N
3 CD o
cycles NNS o
of IN o
adjuvant JJ o
therapy NN o
compared VBN N
to TO N
70 CD N
% NN N
in IN N
the DT N
carboplatin NN N
group NN N
. . N

There EX N
were VBD N
more JJR N
renal JJ o
toxicity NN o
, , o
leucopenia NN o
, , o
and CC o
anaemia NN o
in IN N
the DT N
cisplatin NN N
group NN N
, , N
and CC N
more JJR N
thrombocytopenia NN o
in IN N
the DT N
carboplatin NN N
arm NN N
. . N

The DT N
3 CD o
year NN o
disease NN o
free JJ o
survival NN o
rates NNS o
were VBD N
63.4 CD N
% NN N
for IN N
the DT N
cisplatin NN N
group NN N
and CC N
60.9 CD N
% NN N
for IN N
the DT N
carboplatin NN N
group NN N
( ( N
p=0.9613 NN N
) ) N
( ( N
HR $ N
0.70 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
: : N
0.50-0.98 JJ N
) ) N
. . N

The DT N
3 CD o
year NN o
overall JJ o
survival NN o
rates NNS o
were VBD N
77.7 CD N
% NN N
and CC N
79.2 CD N
% NN N
for IN N
cisplatin NN N
and CC N
carboplatin NN N
groups NNS N
, , N
respectively RB N
( ( N
p=0.9884 NN N
) ) N
( ( N
HR $ N
0.83 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
0.63-1.010 NN N
) ) N
. . N

CONCLUSION NNP N
We PRP N
concluded VBD N
that IN N
the DT N
tolerability NN o
of IN o
carboplatin NN o
based VBN o
regimen NNS o
is VBZ N
better JJR N
than IN N
that DT N
of IN N
the DT N
cisplatin NN i
regimen NN N
. . N

Moreover RB N
, , N
the DT N
treatment NN N
efficacy NN N
of IN N
carboplatin NN N
arm NN N
is VBZ N
not RB N
different JJ N
from IN N
the DT N
standard JJ N
regimen NNS N
in IN N
the DT N
treatment NN N
of IN N
locoregional JJ p
advanced JJ p
stage NN p
NPC NNP p
. . p

-DOCSTART- -10560780- O O

Barriers NNS N
to TO N
hypertension NN N
care NN N
and CC N
control NN N
in IN N
young JJ p
urban JJ p
black JJ p
men NNS p
. . p

Barriers NNS N
to TO N
high JJ o
blood NN o
pressure NN o
( ( N
HBP NNP N
) ) N
care NN N
and CC N
control NN N
have VBP N
been VBN N
reported VBN N
in IN N
the DT N
literature NN N
for IN N
> $ N
30 CD N
years NNS N
. . N

Few JJ N
reports NNS N
on IN N
barriers NNS N
, , N
however RB N
, , N
have VBP N
focused VBN N
on IN N
the DT N
young JJ p
black JJ p
man NN p
with IN p
HBP NNP p
, , N
the DT N
age/sex/race NN N
group NN N
with IN N
the DT N
highest JJS N
rates NNS N
of IN N
early JJ N
severe JJ N
and CC N
complicated JJ N
HBP NNP N
and CC N
the DT N
lowest JJS N
rates NNS N
of IN N
awareness NN N
, , N
treatment NN N
, , N
and CC N
control NN N
. . N

In IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
of IN N
comprehensive JJ N
care NN N
for IN N
hypertensive JJ p
young JJ p
urban JJ p
black JJ p
men NNS p
, , N
factors NNS N
potentially RB N
associated VBN N
with IN N
care NN N
and CC N
control NN N
were VBD N
assessed VBN N
at IN N
baseline NN N
for IN N
the DT N
309 CD p
enrolled VBD p
men NNS p
. . p

A DT p
majority NN p
of IN p
the DT p
men NNS p
encountered VBD p
a DT p
variety NN p
of IN p
barriers NNS p
including VBG p
economic JJ p
, , p
social JJ p
, , p
and CC p
lifestyle JJ p
obstacles NNS p
to TO p
adequate VB p
BP NNP p
care NN p
and CC p
control NN p
, , p
including VBG p
no DT o
current JJ o
HBP NNP o
care NN o
( ( p
49 CD p
% NN p
) ) p
, , p
risk NN o
of IN o
alcoholism NN o
( ( p
62 CD p
% NN p
) ) p
, , p
use NN o
of IN o
illicit NN o
drugs NNS o
( ( p
45 CD p
% NN p
) ) p
, , p
social JJ o
isolation NN o
( ( p
47 CD p
% NN p
) ) p
, , p
unemployment NN o
( ( p
40 CD p
% NN p
) ) p
, , p
and CC p
lack NN o
of IN o
health NN o
insurance NN o
( ( p
51 CD p
% NN p
) ) p
. . p

Having VBG o
health NN o
insurance NN o
( ( N
odds NNS N
ratio VBP N
= JJ N
7.20 CD N
, , N
P NNP N
= NNP N
.00 NNP N
) ) N
and CC N
a DT N
negative JJ o
urine JJ o
drug NN o
screen NN o
( ( N
odds NNS N
ratio VBP N
= JJ N
.56 NNP N
, , N
P NNP N
= NNP N
.04 NNP N
) ) N
were VBD N
significant JJ N
predictors NNS N
of IN N
being VBG N
in IN N
HBP NNP N
care NN N
. . N

Low JJ o
alcoholism NN o
risk NN o
and CC o
employment NN o
were VBD N
identified VBN N
as IN N
significant JJ N
predictors NNS N
of IN N
compliance NN N
with IN N
HBP NNP N
medication-taking JJ N
behavior NN N
. . N

Men NNP p
currently RB p
using VBG o
illicit JJ o
drugs NNS o
were VBD N
2.64 CD N
times NNS N
less RBR N
likely JJ N
to TO N
have VB N
controlled VBN o
BP NNP o
compared VBN N
with IN N
their PRP$ N
counterparts NNS p
who WP p
did VBD p
not RB p
use VB p
illicit JJ p
drugs NNS p
, , N
and CC N
men NNS p
currently RB p
taking VBG o
HBP NNP o
medication NN o
were VBD N
63 CD N
times NNS N
more RBR N
likely JJ N
have VBP N
controlled VBN o
BP NNP o
compared VBN N
with IN N
men NNS p
not RB p
taking VBG p
HBP NNP p
medication NN p
. . p

Comprehensive JJ i
interventions NNS i
are VBP N
needed VBN N
to TO N
address VB N
socioeconomic JJ N
and CC N
lifestyle JJ N
issues NNS N
as RB N
well RB N
as IN N
other JJ N
barriers NNS N
to TO N
care VB N
and CC N
treatment NN N
, , N
if IN N
HBP NNP N
care NN N
is VBZ N
to TO N
be VB N
salient JJ N
and CC N
effective JJ N
in IN N
this DT N
high JJ p
risk NN p
group NN p
. . p

-DOCSTART- -12738312- O O

Comparison NNP N
of IN N
the DT N
comet NN N
assay NN N
and CC N
the DT N
oxygen NN N
microelectrode NN N
for IN N
measuring VBG N
tumor NN o
oxygenation NN o
in IN N
head-and-neck JJ p
cancer NN p
patients NNS p
. . p

PURPOSE NNP N
To TO N
compare VB N
the DT N
Eppendorf NNP i
PO2 NNP i
histograph NN i
and CC N
the DT N
alkaline NN i
comet NN i
assay VBP i
as IN N
methods NNS N
of IN N
measuring VBG N
tumor NN o
hypoxia NN o
in IN N
patients NNS p
with IN p
head-and-neck JJ p
squamous JJ p
cell NN p
carcinomas NN p
. . p

MATERIALS NNP N
AND CC N
METHODS NNP N
As IN N
part NN N
of IN N
a DT N
larger JJR N
clinical JJ N
trial NN N
, , N
65 CD p
patients NNS p
with IN p
head-and-neck JJ p
squamous JJ p
cell NN p
carcinoma NN p
nodal JJ p
metastasis NN p
underwent JJ N
tumor NN o
oxygenation NN o
measurements NNS o
with IN o
Eppendorf NNP o
PO2 NNP o
histographs NN o
and CC o
comet NN o
assays NNS o
, , i
performed VBN i
on IN i
fine-needle JJ i
aspirates NNS i
at IN i
1 CD i
and CC i
2 CD i
min NN i
after IN i
5 CD i
Gy NNP i
. . i

Fifty-four CD p
patients NNS p
had VBD p
sufficient JJ p
tumor NN p
cells NNS p
for IN p
comet JJ p
analysis NN p
at IN N
1 CD N
min NN N
and CC N
26 CD N
at IN N
both DT N
1 CD N
and CC N
2 CD N
min NN N
. . N

Individual JJ N
cells NNS N
were VBD N
examined VBN i
for IN i
DNA NNP i
single-strand NN i
breaks NNS i
by IN i
alkaline JJ i
gel NN i
electrophoresis NN i
, , i
and CC i
the DT i
distribution NN i
of IN i
values NNS i
was VBD i
quantified VBN i
using VBG i
median JJ i
tail NN i
moment NN i
( ( i
MTM NNP i
) ) i
. . N

Nonirradiated VBN N
tumor NN N
cells NNS N
from IN N
pretreatment JJ N
fine-needle JJ N
aspirates NNS N
received VBD N
5 CD i
Gy NNP i
in IN i
vitro NN i
to TO N
establish VB N
the DT N
oxygenated JJ N
response NN N
. . N

RESULTS NNP N
There EX N
was VBD N
a DT N
significant JJ N
correlation NN N
between IN N
the DT N
1- JJ N
and CC N
2-min JJ N
MTM NNP N
( ( N
slope VBP N
= RB N
0.77 CD N
+/- JJ N
0.03 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
relationship NN N
between IN N
DNA NNP o
damage NN o
in IN o
tumor NN o
cells NNS o
irradiated VBN N
in IN N
vitro NN N
and CC N
in IN N
vivo NN N
. . N

No DT N
correlation NN N
was VBD N
found VBN N
between IN N
Eppendorf NNP o
PO2 NNP o
measurements NNS o
and CC o
comet VBD o
MTM NNP o
. . o

There EX N
was VBD N
a DT N
statistically RB N
significant JJ N
correlation NN N
between IN N
the DT N
treatment NN N
response NN N
in IN N
the DT N
node NN N
studied VBD N
and CC N
comet VBD N
MTMs NNP N
, , N
whereas VBZ N
no DT N
correlation NN N
was VBD N
observed VBN N
between IN N
treatment NN N
response NN N
and CC N
Eppendorf NNP N
measurements NNS N
. . N

CONCLUSIONS NNP N
Comet NNP N
assays NNS N
are VBP N
reproducible JJ N
, , N
as IN N
shown VBN N
by IN N
biopsies NNS N
at IN N
1 CD N
and CC N
2 CD N
min NN N
. . N

Intertumor NNP N
variation NN N
in IN N
the DT N
MTM NNP N
is VBZ N
not RB N
a DT N
result NN N
of IN N
intrinsic JJ N
radiosensitivity NN N
but CC N
of IN N
tumor NN N
hypoxia NN N
. . N

There EX N
was VBD N
no DT N
correlation NN N
between IN N
Eppendorf NNP N
PO2 NNP N
measurements NNS N
and CC N
comet VBD N
MTM NNP N
. . N

Comet NNP N
assays NNS N
were VBD N
better JJR N
than IN N
Eppendorf NNP N
in IN N
predicting VBG N
treatment NN N
response NN N
as IN N
an DT N
end NN N
point NN N
for IN N
short-term JJ N
outcome NN N
. . N

Longer JJR N
follow-up NN N
is VBZ N
needed VBN N
to TO N
determine VB N
the DT N
role NN N
of IN N
the DT N
comet NN N
assay NN N
as IN N
a DT N
predictor NN N
for IN N
locoregional JJ N
tumor NN N
control NN N
and CC N
survivals NNS N
. . N

-DOCSTART- -22732966- O O

Nutritional JJ N
orientation NN N
, , N
knowledge NN N
and CC N
quality NN N
of IN N
diet NN N
in IN N
heart NN p
failure NN p
: : p
randomized JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
Non-pharmacological JJ N
measures NNS N
are VBP N
recommended VBN N
for IN N
heart NN p
failure NN p
patients NNS p
. . p

However RB N
, , N
most JJS N
studies NNS N
evaluate VBP N
low JJ N
sodium NN N
diet NN N
, , N
while IN N
little JJ N
is VBZ N
known VBN N
about IN N
the DT N
effects NNS N
of IN N
interventions NNS N
to TO N
improve VB N
adherence NN N
and CC N
knowledge NN N
of IN N
patients NNS N
about IN N
diet JJ N
content NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
if IN N
a DT N
global JJ N
nutritional JJ i
orientation NN i
could MD N
affect VB N
nutritional JJ o
knowledge NN o
, , o
adherence NN o
to TO o
food NN o
guidelines NNS o
, , o
anthropometrics NNS o
and CC o
quality NN o
of IN o
life NN o
in IN N
heart NN p
failure NN p
patients NNS p
. . p

METHODS NNP N
Forty NNP p
six CD p
patients NNS p
were VBD N
randomized VBN N
to TO N
intervention VB N
or CC N
control VB N
group NN N
. . N

Both DT N
groups NNS N
received VBD N
usual JJ i
care NN i
with IN i
medical JJ i
and CC i
nursing JJ i
staff NN i
; : i
the DT i
intervention NN i
group NN i
received VBD i
additional JJ i
nutritional JJ i
guidance NN i
about IN i
diet JJ i
and CC i
its PRP$ i
relationship NN i
with IN i
disease NN i
, , i
sources NNS i
of IN i
nutrients NNS i
, , i
and CC i
reduction NN i
of IN i
dietary JJ i
sodium NN i
and CC i
fats NNS i
. . i

Enforcement NN i
of IN i
the DT i
nutritional JJ i
guidance NN i
was VBD i
performed VBN i
after IN i
4 CD i
weeks NNS i
. . i

Both DT i
groups NNS i
were VBD i
evaluated VBN i
at IN i
baseline NN i
, , i
and CC i
after IN i
6 CD i
weeks NNS i
and CC i
6 CD i
months NNS i
. . i

Evaluations NNS N
included VBD N
anthropometric JJ o
parameters NNS o
, , o
sodium NN o
excretion NN o
in IN o
24-hour JJ o
urine NN o
, , o
dietary JJ o
recall NN o
, , o
nutrition NN o
knowledge NN o
and CC o
quality NN o
of IN o
life NN o
questionnaires NNS o
. . o

RESULTS NNP N
Mean NNP p
age NN p
of IN p
included JJ p
patients NNS p
was VBD p
58 CD p
? . p
10 CD p
years NNS p
and CC p
70 CD p
% NN p
were VBD p
male JJ p
. . p

After IN N
6 CD N
months NNS N
of IN N
follow-up NN N
, , N
the DT o
nutritional JJ o
knowledge NN o
of IN N
intervention NN N
group NN N
increased VBD N
compared VBN N
to TO N
control VB N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Caloric NNP o
, , o
fat NN o
and CC o
sodium NN o
intake NN o
decreased VBN N
in IN N
the DT N
intervention NN N
group NN N
compared VBN N
to TO N
control VB N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
seen VBN N
in IN o
quality NN o
of IN o
life NN o
or CC o
anthropometric JJ o
parameters NNS o
. . o

CONCLUSIONS NNP i
Nutritional NNP i
orientation NN i
was VBD N
effective JJ N
to TO N
modify VB N
1 CD N
) ) o
knowledge NN o
about IN o
food NN o
and CC o
nutrition NN o
, , o
and CC N
2 CD N
) ) o
quality NN o
of IN o
diet NN o
in IN p
outpatients NNS p
with IN p
heart NN p
failure NN p
. . p

Further JJ N
studies NNS N
are VBP N
necessary JJ N
to TO N
evaluate VB N
the DT N
benefits NNS N
on IN o
quality NN o
of IN o
life NN o
and CC o
prognosis NN o
. . o

-DOCSTART- -18353086- O O

Does NNP N
surface VB N
preparation NN N
alter NN N
ALA NNP o
uptake NN o
in IN N
superficial JJ N
non-melanoma JJ p
skin NN p
cancer NN p
in IN N
vivo NN N
? . N
BACKGROUND/PURPOSE NNP N
Photodynamic NNP N
therapy NN N
( ( N
PDT NNP N
) ) N
using VBG N
aminolaevulinic JJ i
acid NN i
( ( i
ALA NNP i
) ) i
is VBZ N
widely RB N
used VBN N
in IN N
the DT N
treatment NN N
of IN N
non-melanoma JJ p
skin NN p
cancer NN p
. . p

Surface NNP i
preparation NN i
of IN N
the DT N
lesion NN N
is VBZ N
commonly RB N
performed VBN N
before IN N
application NN N
of IN N
ALA NNP N
but CC N
the DT N
extent NN N
of IN N
the DT N
preparation NN N
varies NNS N
from IN N
centre NN N
to TO N
centre VB N
and CC N
there EX N
has VBZ N
been VBN N
no DT N
study NN N
of IN N
its PRP$ N
effects NNS N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
examine VB N
the DT N
effects NNS N
of IN N
surface NN i
preparation NN i
on IN N
the DT N
local JJ N
uptake NN o
of IN o
ALA NNP o
by IN N
recording VBG N
fluorescence NN N
from IN N
accumulated VBN N
protoporphyrin NN N
IX NNP N
( ( N
PPIX NNP N
) ) N
. . N

METHODS PDT N
The DT N
study NN N
was VBD N
performed VBN N
on IN N
16 CD p
lesions NNS p
, , p
either RB p
superficial JJ p
basal NN p
cell NN p
carcinoma NN p
( ( p
BCC NNP p
) ) p
or CC p
Bowen NNP p
's POS p
disease NN p
( ( p
BD NNP p
) ) p
. . p

Each DT N
half NN N
of IN N
the DT N
lesion NN N
was VBD N
randomly RB N
assigned VBN N
to TO N
( ( i
a DT i
) ) i
no DT i
surface NN i
preparation NN i
or CC i
( ( i
b NN i
) ) i
surface NN i
preparation NN i
( ( i
randomly RB i
allocated VBN i
to TO i
gentle VB i
curettage NN i
or CC i
abrasion NN i
with IN i
a DT i
spatula NN i
) ) i
. . N

ALA NNP N
was VBD N
left VBN N
for IN N
4 CD N
h NN N
( ( N
BCC NNP N
) ) N
or CC N
6 CD N
h NN N
( ( N
BD NNP N
) ) N
. . N

PPIX NNP o
fluorescence NN o
was VBD N
measured VBN N
using VBG N
an DT N
excitation NN N
wavelength NN N
of IN N
405+/-5 JJ N
nm NN N
and CC N
emission NN N
spectrum NN N
recorded VBD N
using VBG N
a DT N
photodiode JJ i
array NN i
. . i

Spectra NNP N
were VBD N
measured VBN N
( ( N
a DT N
) ) N
before IN N
and CC N
( ( N
b NN N
) ) N
after IN N
surface NN N
preparation NN N
, , N
( ( N
c NN N
) ) N
immediately RB N
before IN N
and CC N
( ( N
d NN N
) ) N
after IN N
laser NN i
irradiation NN i
at IN N
630 CD N
nm NNS N
. . N

RESULTS VB N
The DT N
ratio NN o
of IN o
fluorescence NN o
after IN o
incubation NN o
to TO N
that DT N
before IN N
incubation NN N
was VBD N
6.1+/-1.2 JJ N
in IN N
the DT N
non-prepared JJ N
section NN N
. . N

This DT N
increased VBD N
slightly RB N
but CC N
not RB N
significantly RB N
to TO N
6.8 CD N
+/-1.8 NN N
in IN N
the DT N
prepared JJ N
section NN N
( ( N
P NNP N
< NNP N
0.1 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
curettage NN o
and CC o
abrasion NN o
. . o

There EX N
was VBD N
also RB N
no DT N
significant JJ N
difference NN N
in IN N
outcome NN o
after IN N
PDT NNP N
. . N

CONCLUSIONS NNP N
The DT N
clinical JJ N
assessment NN N
agrees VBZ N
with IN N
the DT N
fluorescence NN N
data NNS N
as IN N
no DT N
significant JJ N
difference NN N
was VBD N
seen VBN N
between IN N
prepared JJ N
and CC N
unprepared JJ N
halves NNS N
of IN N
the DT N
lesion NN N
12 CD N
months NNS N
after IN N
PDT NNP N
. . N

Overall VB N
our PRP$ N
data NNS N
seem VBP N
to TO N
suggest VB N
that DT N
for IN N
most JJS N
BCC NNP N
and CC N
BD NNP N
lesions NNS N
, , N
surface NN N
preparation NN N
did VBD N
not RB N
increase VB N
ALA NNP o
uptake JJ o
. . o

-DOCSTART- -12680863- O O

A DT N
single JJ i
nasal NN i
allergen NN i
challenge NN i
increases NNS N
induced VBD N
sputum JJ o
inflammatory JJ o
markers NNS o
in IN N
non-asthmatic JJ p
subjects NNS p
with IN p
seasonal JJ p
allergic JJ p
rhinitis NN p
: : p
correlation NN N
with IN N
plasma JJ N
interleukin-5 JJ N
. . N

BACKGROUND NNP N
Seasonal NNP N
allergic JJ N
rhinitis NN N
( ( N
SAR NNP N
) ) N
is VBZ N
a DT N
risk NN p
factor NN p
for IN p
asthma NN p
in IN p
affected JJ p
individuals NNS p
. . p

Nasal NNP N
allergic JJ N
inflammation NN N
enhances VBZ N
bone-marrow JJ N
eosinophil NN N
production NN N
, , N
mainly RB N
via IN N
IL-5 NNP N
, , N
and CC N
rhinitis NN N
patients NNS N
have VBP N
increased VBN N
airway JJ N
inflammation NN N
during IN N
the DT N
pollen NN N
season NN N
. . N

OBJECTIVE UH N
To TO N
assess VB N
the DT N
impact NN N
of IN N
nasal NN N
allergy NN N
on IN N
sputum NN o
inflammatory NN o
markers NNS o
. . o

METHODS NNP N
In IN N
an DT N
open-labelled JJ N
, , N
randomized VBN N
, , N
placebo-controlled JJ i
cross-over NN N
study NN N
with IN N
16 CD p
non-asthmatic JJ p
SAR NNP p
patients NNS p
( ( p
median JJ p
age NN p
25 CD p
years NNS p
, , p
56 CD p
% NN p
males NNS p
) ) p
, , N
the DT N
effect NN N
of IN N
a DT N
single JJ i
nasal NN i
allergen NN i
challenge NN i
performed VBD N
out IN N
of IN N
season NN N
on IN N
induced JJ N
sputum NN o
inflammatory NN o
parameters NNS N
was VBD N
evaluated VBN N
. . N

SAR JJ p
patients NNS p
were VBD p
identified VBN p
by IN p
history NN p
, , p
skin-prick JJ p
test NN p
and CC p
specific JJ p
IgE NNP p
. . p

All DT p
patients NNS p
had VBD p
normal JJ p
lung JJ p
function/bronchial JJ p
hyper-responsiveness NN p
out IN p
of IN p
season NN p
and CC p
a DT p
negative JJ p
asthma/wheezing NN p
history NN p
. . p

Sputum NNP o
cells NNS o
and CC o
supernatant JJ o
levels NNS o
of IN o
ECP NNP o
, , o
sICAM NN o
, , o
IL-5 NNP o
and CC o
IL-10 NNP o
, , o
and CC o
plasma NN o
levels NNS o
of IN o
IL-5 NNP o
and CC o
ECP NNP o
, , i
were VBD i
measured VBN i
before IN i
and CC i
24 CD i
h NN i
after IN i
nasal JJ i
allergen NN i
challenge NN i
. . i

After IN i
a DT i
washout JJ i
period NN i
of IN i
at IN i
least JJS i
4 CD i
weeks NNS i
, , i
the DT i
procedure NN i
was VBD i
repeated VBN i
with IN i
placebo NN i
challenge NN i
( ( i
diluent NN i
) ) i
. . i

RESULTS NNP N
Nasal NNP N
allergen VBZ N
challenge NN N
led VBD N
to TO N
an DT N
increase NN N
in IN N
sputum JJ o
ECP NNP o
( ( N
pre JJ N
= $ N
60 CD N
+/- JJ N
12 CD N
, , N
post NN N
= VBD N
212 CD N
+/- JJ N
63 CD N
micro NN N
g/L NN N
, , N
P NNP N
= VBZ N
0.02 CD N
vs. FW N
placebo NN N
) ) N
, , N
and CC N
sICAM NN o
( ( N
4.8 CD N
+/- JJ N
2.7 CD N
to TO N
6.5 CD N
+/- JJ N
2.9 CD N
ng/mL NN N
, , N
P NNP N
= VBZ N
0.02 CD N
vs. FW N
placebo NN N
) ) N
, , N
whereas JJ N
IL-10 NNP o
decreased VBD N
after IN N
provocation NN N
( ( N
44 CD N
+/- JJ N
11 CD N
to TO N
29 CD N
+/- JJ N
6 CD N
pg/mL NN N
, , N
P NNP N
= VBZ N
0.06 CD N
vs. FW N
placebo NN N
) ) N
. . N

Sputum NNP o
IL-5 NNP o
was VBD N
undetectable JJ N
in IN N
all DT N
patients NNS N
. . N

The DT N
absolute JJ N
number NN N
of IN N
blood NN o
and CC o
sputum NN o
eosinophils NNS o
did VBD N
not RB N
change VB N
significantly RB N
after IN N
allergen NN N
or CC N
placebo NN N
challenge NN N
( ( N
P NNP N
> NNP N
0.07 CD N
, , N
both DT N
comparisons NNS N
) ) N
. . N

Plasma NNP o
levels NNS o
of IN o
IL-5 NNP o
increased VBD N
after IN N
allergen NN N
challenge NN N
( ( N
8.7 CD N
+/- JJ N
2.9 CD N
to TO N
14.5 CD N
+/- JJ N
3.9 CD N
pg/mL NN N
, , N
P NNP N
= NNP N
0.001 CD N
) ) N
, , N
and CC N
the DT N
increase NN N
in IN N
plasma JJ N
IL-5 NNP N
was VBD N
positively RB N
correlated VBN N
with IN N
the DT N
rise NN N
in IN N
sputum NN o
ECP NNP o
in IN N
a DT N
subgroup NN N
of IN N
'responders NNS N
' POS N
( ( N
n JJ N
= NN N
12 CD N
, , N
r NN N
= VBD N
0.71 CD N
, , N
P NNP N
= NNP N
0.01 CD N
) ) N
. . N

CONCLUSIONS VB N
A DT N
single JJ i
nasal NN i
allergen NN i
challenge NN i
in IN N
SAR NNP p
patients NNS p
increased VBD N
markers NNS N
of IN N
allergic JJ o
inflammation NN o
in IN N
the DT N
lower JJR N
respiratory NN N
tract NN N
, , N
possibly RB N
via IN N
pronounced JJ N
activation NN N
of IN N
inflammatory NN N
cells NNS N
through IN N
circulating VBG N
immediate-type JJ N
reaction NN N
cytokines NNS N
like IN N
IL-5 NNP N
. . N

These DT N
findings NNS N
may MD N
provide VB N
additional JJ N
explanatory NN N
data NNS N
for IN N
the DT N
high JJ N
susceptibility NN N
of IN N
SAR NNP p
patients NNS p
to TO N
incident VB N
asthma NN N
. . N

-DOCSTART- -18582177- O O

Cognitive JJ N
effects NNS N
of IN N
risperidone NN i
in IN N
children NNS p
with IN p
autism NN p
and CC p
irritable JJ p
behavior NN p
. . p

OBJECTIVE CC N
The DT N
objective NN N
of IN N
this DT N
research NN N
was VBD N
to TO N
explore VB N
the DT N
effects NNS N
of IN N
risperidone NN i
on IN N
cognitive JJ o
processes NNS o
in IN N
children NNS p
with IN p
autism NN p
and CC p
irritable JJ p
behavior NN p
. . p

METHOD NNP N
Thirty-eight JJ p
children NNS p
, , p
ages VBZ p
5-17 CD p
years NNS p
with IN p
autism NN p
and CC p
severe JJ p
behavioral JJ p
disturbance NN p
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
risperidone VB i
( ( N
0.5 CD N
to TO N
3.5 CD N
mg/day NN N
) ) N
or CC i
placebo NN i
for IN N
8 CD N
weeks NNS N
. . N

This DT p
sample NN p
of IN p
38 CD p
was VBD p
a DT p
subset NN p
of IN p
101 CD p
subjects NNS p
who WP p
participated VBD p
in IN p
the DT p
clinical JJ p
trial NN p
; : p
63 CD p
were VBD p
unable JJ p
to TO p
perform VB p
the DT p
cognitive JJ p
tasks NNS p
. . p

A DT N
double-blind JJ N
placebo-controlled JJ N
parallel NN N
groups NNS N
design NN N
was VBD N
used VBN N
. . N

Dependent JJ N
measures NNS N
included VBD N
tests NNS o
of IN o
sustained JJ o
attention NN o
, , o
verbal JJ o
learning NN o
, , o
hand-eye JJ o
coordination NN o
, , o
and CC o
spatial JJ o
memory NN o
assessed VBN o
before IN o
, , o
during IN o
, , o
and CC o
after IN o
the DT o
8-week JJ o
treatment NN o
. . o

Changes NNS N
in IN N
performance NN N
were VBD N
compared VBN N
by IN N
repeated JJ N
measures NNS N
ANOVA NNP o
. . o

RESULTS NNP N
Twenty-nine JJ p
boys NNS p
and CC p
9 CD p
girls NNS p
with IN p
autism NN p
and CC p
severe JJ p
behavioral JJ p
disturbance NN p
and CC p
a DT p
mental JJ p
age NN p
> NNP p
or=18 JJ p
months NNS p
completed VBN p
the DT p
cognitive JJ p
part NN p
of IN p
the DT p
study NN p
. . p

No DT N
decline NN N
in IN N
performance NN N
occurred VBD N
with IN N
risperidone NN N
. . N

Performance NN N
on IN N
a DT N
cancellation NN o
task NN o
( ( o
number NN o
of IN o
correct JJ o
detections NNS o
) ) o
and CC N
a DT N
verbal JJ o
learning NN o
task NN o
( ( o
word NN o
recognition NN o
) ) o
was VBD N
better RBR N
on IN N
risperidone NN i
than IN N
on IN N
placebo NN i
( ( N
without IN N
correction NN N
for IN N
multiplicity NN N
) ) N
. . N

Equivocal JJ o
improvement NN o
also RB N
occurred VBD N
on IN N
a DT N
spatial JJ o
memory NN o
task NN o
. . o

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
treatment NN N
conditions NNS N
on IN N
the DT N
Purdue NNP o
Pegboard NNP o
( ( o
hand-eye JJ o
coordination NN o
) ) o
task NN N
or CC N
the DT N
Analog NNP o
Classroom NNP o
Task NNP o
( ( o
timed VBN o
math RB o
test NN o
) ) o
. . N

CONCLUSION NNP N
Risperidone NNP i
given VBN N
to TO N
children NNS p
with IN p
autism NN p
at IN N
doses VBZ N
up RB N
to TO N
3.5 CD N
mg NN N
for IN N
up IN N
to TO N
8 CD N
weeks NNS N
appears VBZ N
to TO N
have VB N
no DT N
detrimental JJ N
effect NN N
on IN N
cognitive JJ o
performance NN o
. . o

-DOCSTART- -9058626- O O

Soluble JJ i
intercellular JJ i
adhesion NN i
molecule-1 NN i
in IN N
primary JJ p
biliary JJ p
cirrhosis NN p
: : p
effect NN N
of IN N
ursodeoxycholic JJ i
acid NN i
and CC N
immunosuppressive JJ i
therapy NN i
. . i

OBJECTIVES NNP N
Soluble JJ i
intercellular JJ i
adhesion NN i
molecule-1 NN i
( ( i
sICAM-1 JJ i
) ) i
is VBZ N
thought VBN N
to TO N
be VB N
released VBN N
by IN N
a DT N
variety NN N
of IN N
cells NNS N
at IN N
sites NNS N
of IN N
inflammation NN N
, , N
and CC N
their PRP$ N
serum NN N
levels NNS N
have VBP N
been VBN N
used VBN N
as IN N
markers NNS N
of IN N
inflammatory NN N
and CC N
immune JJ N
activity NN N
. . N

Our PRP$ N
aim NN N
was VBD N
to TO N
determine VB N
the DT N
effect NN N
of IN N
therapy NN N
with IN N
ursodeoxycholic JJ i
acid NN i
alone RB i
and CC N
in IN N
combination NN N
with IN N
azathioprine NN i
and CC i
prednisone NN i
on IN N
serum JJ o
sICAM-1 JJ o
levels NNS o
in IN N
primary JJ N
biliary JJ N
cirrhosis NN N
. . N

DESIGN/METHODS NNP N
Twenty-four JJ p
patients NNS p
with IN p
primary JJ p
biliary JJ p
cirrhosis NN p
and CC p
17 CD p
healthy JJ p
subjects NNS p
were VBD p
studied VBN p
. . p

Primary JJ p
biliary JJ p
cirrhosis NN p
patients NNS p
received VBD N
ursodeoxycholic JJ i
acid NN i
for IN N
12 CD N
months NNS N
and CC N
were VBD N
then RB N
randomized VBN N
in IN N
a DT N
double-blind JJ N
fashion NN N
to TO N
receive VB N
prednisone NN i
and CC i
azathioprine NN i
, , i
or CC i
placebo NN i
in IN i
addition NN i
to TO i
ursodeoxycholic JJ i
acid NN i
. . i

RESULTS NNP N
sICAM-1 JJ o
levels NNS o
were VBD N
significantly RB N
higher JJR N
in IN N
primary JJ p
biliary JJ p
cirrhosis NN p
patients NNS p
than IN N
healthy JJ p
subjects NNS p
and CC N
fell VBD N
by IN N
a DT N
median NN N
of IN N
20 CD N
% NN N
after IN N
12 CD N
months NNS N
' POS N
therapy NN N
with IN N
ursodeoxycholic JJ i
acid NN i
( ( N
P NNP N
< NNP N
0.0004 CD N
) ) N
. . N

Addition NN N
of IN N
azathioprine NN i
and CC i
prednisone NN i
to TO N
ursodeoxycholic JJ i
acid NN i
resulted VBD N
in IN N
a DT N
further JJ N
reduction NN N
of IN N
sICAM-1 JJ o
levels NNS o
by IN N
a DT N
median NN N
of IN N
25 CD N
% NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Reductions NNPS N
in IN N
sICAM-1 JJ o
were VBD N
accompanied VBN N
by IN N
improvement NN N
in IN N
liver JJ o
function NN o
tests NNS o
but CC N
not RB N
in IN N
the DT N
lymphocyte JJ o
activation NN o
marker NN o
, , o
soluble JJ o
interleukin-2 JJ o
receptor NN o
. . o

CONCLUSION NNP N
sICAM-1 JJ o
levels NNS o
in IN N
primary JJ N
biliary JJ N
cirrhosis NN N
are VBP N
reduced VBN N
by IN N
ursodeoxycholic JJ i
acid NN i
. . i

Further JJ N
reductions NNS N
were VBD N
achieved VBN N
by IN N
adding VBG N
prednisone NN i
and CC i
azathioprine NN i
. . i

These DT N
reductions NNS N
probably RB N
reflect VBP N
an DT N
improvement NN N
in IN N
hepatobiliary JJ o
excretion NN o
and CC N
a DT N
reduction NN o
in IN o
cellular JJ o
production NN o
of IN o
sICAM-1 NN o
. . o

-DOCSTART- -17050770- O O

Classroom NNP i
intervention NN i
for IN N
illness-related JJ N
problem NN N
behavior NN N
in IN N
children NNS p
with IN p
developmental JJ p
disabilities NNS p
. . p

There EX N
is VBZ N
growing VBG N
evidence NN N
of IN N
an DT N
association NN N
between IN N
physical JJ N
illness NN N
and CC N
problem NN N
behavior NN N
in IN N
children NNS p
with IN p
developmental JJ p
disabilities NNS p
. . p

Such JJ N
behavior NN N
can MD N
compromise VB N
school NN N
performance NN N
. . N

Therefore RB N
, , N
the DT N
purpose NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
evaluate VB N
, , N
using VBG N
a DT N
group NN N
design NN N
, , N
the DT N
effectiveness NN N
of IN N
medical JJ i
intervention NN i
alone RB i
( ( N
N NNP N
= NNP N
11 CD N
) ) N
versus NN N
behavioral JJ i
plus CC i
medical JJ i
intervention NN i
( ( N
N NNP N
= NNP N
10 CD N
) ) N
for IN N
illness-related JJ N
problem NN N
behavior NN N
in IN N
a DT N
school NN N
setting VBG N
. . N

Following VBG N
intervention NN N
, , N
the DT N
behavioral JJ N
plus CC N
medical JJ N
intervention NN N
group NN N
showed VBD N
lower JJR N
levels NNS N
of IN N
problem NN o
behavior NN o
and CC N
completed VBD o
more JJR o
academic JJ o
tasks NNS o
than IN N
did VBD N
the DT N
medical JJ N
intervention NN N
alone RB N
group NN N
. . N

The DT N
results NNS N
are VBP N
discussed VBN N
with IN N
respect NN N
to TO N
the DT N
concept NN o
of IN o
illness NN o
and CC o
pain NN o
as IN N
a DT N
setting NN N
event NN N
for IN N
problem NN N
behavior NN N
. . N

The DT N
need NN N
for IN N
research NN N
to TO N
develop VB N
algorithms NN N
that WDT N
allow VBP N
one CD N
to TO N
select VB N
the DT N
best JJS N
combination NN N
of IN N
medical JJ i
and CC i
behavioral JJ i
interventions NNS i
for IN N
specific JJ N
illnesses NNS N
and CC N
contexts NN N
is VBZ N
noted VBN N
. . N

-DOCSTART- -19515873- O O

Folic JJ i
acid-based JJ i
intervention NN i
in IN N
non-ST JJ p
elevation NN p
acute NN p
coronary JJ p
syndromes NNS o
. . o

Homocysteinemia NNP N
is VBZ N
a DT N
risk NN N
factor NN N
for IN N
cardiovascular JJ N
diseases NNS N
. . N

Folic NNP i
acid NN i
combined VBN i
with IN i
vitamins NNS i
B NNP i
( ( i
6 CD i
) ) i
and CC i
B NNP i
( ( i
12 CD i
) ) i
is VBZ N
effective JJ N
in IN N
lowering VBG N
homocysteine NN o
levels NNS o
. . o

This DT N
randomized VBD N
placebo-controlled JJ i
study NN N
was VBD N
designed VBN N
to TO N
determine VB N
the DT N
effect NN N
of IN N
a DT N
folic JJ i
acid-based JJ i
supplement NN i
on IN N
secondary JJ N
prevention NN N
of IN N
clinical JJ N
events NNS N
in IN N
non-ST-segment JJ p
elevation NN p
acute NN p
coronary JJ p
syndromes NNS p
. . p

The DT N
study NN N
comprised VBD N
240 CD p
patients NNS p
with IN p
either DT p
unstable JJ p
angina NN p
or CC p
non-ST-elevation JJ p
myocardial JJ p
infarction NN p
in IN p
the DT p
previous JJ p
2 CD p
weeks NNS p
who WP N
were VBD N
randomized VBN N
to TO N
a DT N
folate NN i
group NN N
( ( N
n JJ N
=116 NN N
) ) N
or CC N
a DT N
placebo NN i
group NN i
( ( N
n JJ N
=124 NN N
) ) N
. . N

The DT N
folate NN N
group NN N
received VBD N
1 CD N
mg NNS N
folic JJ i
acid RB i
, , N
400 CD N
microg NN N
vitamin NN i
B NNP i
( ( i
12 CD i
) ) i
, , N
and CC N
10 CD N
mg NN N
vitamin NN i
B NNP i
( ( i
6 CD i
) ) i
daily RB N
. . N

Clinical JJ o
outcomes NNS o
within IN N
6 CD N
months NNS N
were VBD N
assessed VBN N
. . N

The DT N
composite JJ N
endpoint NN o
of IN N
death NN o
, , o
nonfatal JJ o
acute NN o
coronary JJ o
syndrome NN o
, , o
and CC o
serious JJ o
re-hospitalization NN o
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
folate NN N
group NN N
; : N
serious JJ N
re-hospitalization NN N
alone NN N
was VBD N
significantly RB N
higher JJR N
in IN N
this DT N
group NN N
. . N

Advanced NNP o
age NN o
and CC o
diabetes NNS o
increased VBD N
susceptibility NN N
to TO N
the DT N
composite JJ N
outcome NN N
. . N

Folic JJ i
acid-based JJ i
supplementation NN i
is VBZ N
not RB o
beneficial JJ o
and CC o
may MD o
even RB o
be VB o
harmful JJ o
in IN N
the DT N
secondary JJ N
prevention NN o
of IN o
cardiovascular JJ o
events NNS o
in IN N
patients NNS N
with IN N
unstable JJ N
angina NNS N
and CC N
non-ST-elevation JJ N
myocardial JJ N
infarction NN N
. . N

Further JJ N
studies NNS N
on IN N
the DT N
safety NN N
of IN N
such JJ N
supplements NNS N
are VBP N
suggested VBN N
. . N

Controlled VBN N
Clinical JJ N
Trials NNS N
Registry NNP N
no DT N
. . N

ISRCTN30249553 NNP N
. . N

-DOCSTART- -22475864- O O

Pre-vaccination NNP N
immunity NN N
and CC N
immune JJ N
responses NNS N
to TO N
a DT N
cell NN N
culture-derived JJ N
whole-virus JJ N
H1N1 NNP N
vaccine NN N
are VBP N
similar JJ N
to TO N
a DT N
seasonal JJ N
influenza NN N
vaccine NN N
. . N

BACKGROUND NNP N
Immune NNP N
responses VBZ N
to TO N
novel VB N
pandemic JJ N
influenza NN N
vaccines NNS N
may MD N
be VB N
influenced VBN N
by IN N
previous JJ N
exposure NN N
to TO N
antigenically RB N
similar JJ N
seasonal JJ N
strains NNS N
. . N

METHODS NNP N
An DT N
open-label JJ N
, , N
randomized VBN N
, , N
phase VB N
I/II NNP N
study NN N
was VBD N
conducted VBN N
to TO N
assess VB N
the DT N
immunogenicity NN N
and CC N
safety NN N
of IN N
a DT N
non-adjuvanted JJ N
, , N
inactivated JJ i
whole-virus JJ i
H1N1 NNP i
A/California/07/2009 NNP i
vaccine NN i
. . i

408 CD p
subjects NNS p
were VBD p
stratified VBN p
by IN p
age NN p
( ( p
18-59 JJ p
and CC p
> JJ p
60 CD p
years NNS p
) ) p
and CC N
randomized $ N
1:1 CD N
to TO N
receive VB N
two CD N
vaccinations NNS N
with IN N
either DT N
3.75 CD i
or CC i
7.5 CD i
?g JJ i
hemagglutinin NN i
antigen NN i
21 CD i
days NNS i
apart RB i
. . i

Safety NNP N
, , N
immunogenicity NN N
and CC N
the DT N
influence NN N
of IN N
seasonal JJ N
influenza JJ N
vaccination NN N
and CC N
antibody NN N
cross-reactivity NN N
with IN N
a DT N
seasonal JJ N
H1N1 NNP N
strain NN N
was VBD N
assessed VBN N
. . N

RESULTS VB N
A DT N
single JJ N
vaccination NN N
with IN N
either DT N
dose NN N
induced VBD N
substantial JJ N
increases NNS N
in IN o
H1N1 NNP o
A/California/07/2009 NNP o
hemagglutination NN o
inhibition NN o
( ( o
HI NNP o
) ) o
and CC o
neutralizing VBG o
( ( o
MN NNP o
) ) o
antibody NN o
titers NNS o
in IN N
both DT N
adult NN N
and CC N
elderly JJ N
subjects NNS N
. . N

A DT N
single JJ N
7.5 CD N
?g NN N
dose NN N
induced JJ o
seroprotection NN o
rates NNS o
of IN o
86.9 CD N
% NN N
in IN N
adults NNS N
and CC N
75.2 CD N
% NN N
in IN N
elderly JJ N
subjects NNS N
. . N

Two CD N
7.5 CD N
?g JJ N
vaccinations NNS N
induced JJ o
seroprotection NN o
rates NNS o
in IN o
adult NN N
and CC N
elderly JJ N
subjects NNS N
of IN N
90.9 CD N
% NN N
and CC N
89.1 CD N
% NN N
, , N
respectively RB N
. . N

The DT N
robust JJ N
immune NN N
response NN N
to TO N
vaccination NN N
was VBD N
confirmed VBN N
by IN N
analyses NNS N
of IN N
neutralizing VBG N
antibody NN N
titers NNS N
. . N

Both DT o
HI NNP o
and CC o
MN NNP o
antibodies NNS o
persisted VBD o
for IN N
? . N
6 CD N
months NNS N
post-vaccination NN N
. . N

Between VB N
34 CD N
% NN N
and CC N
49 CD N
% NN N
of IN N
subjects NNS o
had VBD o
seroprotective JJ o
levels NNS o
of IN o
H1N1 NNP o
A/California/07/2009 NNP o
antibodies NNS o
at IN o
baseline NN o
. . o

Higher JJR o
baseline NN o
HI NNP o
titers NNS o
were VBD o
associated VBN N
with IN N
receipt NN N
of IN N
the DT N
2008-09 JJ N
or CC N
2009-10 JJ N
seasonal JJ N
influenza NN N
vaccine NN N
. . N

High JJ N
baseline NN o
A/California/07/2009 NNP o
neutralizing VBG o
antibody NN o
titers NNS o
were VBD o
also RB N
associated VBN N
with IN N
high JJ N
baseline NN N
titers NNS N
against IN N
A/New NNP N
Caledonia/20/99 NNP N
, , N
a DT N
seasonal JJ N
H1N1 NNP N
strain NN N
which WDT N
circulated VBD N
and CC N
was VBD N
included VBN N
in IN N
the DT N
seasonal JJ N
vaccine NN N
from IN N
2000-01 JJ N
to TO N
2006-07 JJ N
. . N

Pre-adsorption NN N
with IN N
A/H1N1/New NNP N
Caledonia/20/99 NNP N
antigen NN N
reduced VBD o
A/H1N1/California/07/2009 NNP o
baseline NN o
titers NNS o
in IN o
55 CD o
% NN N
of IN N
tested JJ N
sera NN N
. . N

The DT N
vaccine NN N
was VBD N
well RB N
tolerated VBN o
with IN o
low JJ N
rates NNS N
of IN N
fever NN N
. . N

CONCLUSIONS VB N
A DT N
whole-virus JJ N
H1N1 NNP N
A/California/07/2009 NNP N
vaccine NN N
was VBD N
safe JJ N
and CC N
well RB N
tolerated VBN N
and CC N
a DT N
single JJ N
dose NN N
induced VBN N
substantial JJ N
immune NN N
responses NNS N
similar JJ N
to TO N
seasonal JJ N
influenza NN N
vaccines NNS N
, , N
probably RB N
due JJ N
to TO N
immunological JJ N
priming NN N
by IN N
previous JJ N
seasonal JJ N
influenza NN N
vaccines NNS N
or CC N
infections NNS N
. . N

-DOCSTART- -1370735- O O

Different NNP i
aprotinin NN i
applications NNS i
influencing VBG N
hemostatic JJ N
changes NNS N
in IN N
orthotopic NN p
liver NN p
transplantation NN p
. . p

The DT N
effect NN N
of IN N
different JJ N
aprotinin NN i
applications NNS i
on IN N
hemostatic JJ N
changes NNS N
and CC N
blood NN N
product NN N
requirements NNS N
in IN N
orthotopic JJ p
liver NN p
transplantation NN p
was VBD N
investigated VBN N
in IN N
a DT N
prospective JJ N
, , N
open JJ N
, , N
and CC N
randomized VBD N
study NN N
. . N

From IN p
November NNP p
1989 CD p
to TO p
June NNP p
1990 CD p
, , p
13 CD p
patients NNS p
received VBD N
aprotinin RB i
as IN N
a DT N
bolus NN i
of IN i
0.5 CD i
Mill NNP i
. . i

Kallikrein NNP N
inactivator JJ N
units NNS N
( ( N
KIU NNP N
) ) N
on IN N
three CD N
occasions NNS N
in IN N
the DT N
course NN N
of IN N
an DT N
OLT NNP N
, , N
whereas RB N
10 CD N
other JJ N
patients NNS N
were VBD N
treated VBN N
with IN N
continuous JJ i
aprotinin JJ i
infusion NN i
of IN i
0.1-0.4 JJ i
Mill NNP i
. . i

KIU/hr NNP N
. . N

Before IN N
and CC N
after IN N
reperfusion NN N
of IN N
the DT N
graft NN o
liver NN o
, , o
signs NNS o
of IN o
hyperfibrinolysis NN o
, , N
measured VBN N
by IN N
thrombelastography NN N
, , N
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
infusion NN N
group NN N
. . N

Tissue-type JJ o
plasminogen NN o
activator NN o
( ( o
t-PA JJ o
) ) o
activity NN o
increased VBD N
during IN N
the DT N
anhepatic JJ N
phase NN N
but CC N
to TO N
a DT N
significantly RB N
lesser JJR N
extent NN N
in IN N
the DT N
infusion NN N
group NN N
. . N

Blood NNP o
product NN o
requirements NNS o
during IN N
OLT NNP N
were VBD N
tendentiously RB N
higher JJR N
in IN N
the DT N
bolus NN N
group NN N
but CC N
not RB N
significantly RB N
so RB N
. . N

However RB N
, , N
the DT N
use NN N
of IN N
packed JJ o
red JJ o
blood NN o
cells NNS o
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
postoperative JJ N
period NN N
, , N
whereas IN N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
fresh JJ N
frozen NN N
plasma NN o
requirements NNS o
between IN N
the DT N
two CD N
groups NNS N
. . N

All DT N
23 CD p
patients NNS p
have VBP N
survived VBN o
, , N
and CC N
only RB N
one CD N
woman NN N
of IN N
each DT N
group NN N
required VBN N
retransplantation NN o
due JJ N
to TO N
severe VB N
host-versus-graft JJ o
reactions NNS o
. . o

Furthermore RB N
, , N
we PRP N
investigated VBD N
the DT N
perfusate NN N
of IN N
the DT N
graft NN N
liver NN N
in IN N
both DT N
groups NNS N
and CC N
detected JJ N
signs NNS N
of IN N
a DT N
decreased JJ N
t-PA JJ o
release NN o
in IN N
the DT N
infusion NN N
group NN N
. . N

Our PRP$ N
results NNS N
demonstrate VBP N
an DT N
advantage NN N
of IN N
aprotinin NN i
given VBN N
as IN N
continuous JJ N
infusion NN N
over IN N
bolus JJ N
application NN N
in IN N
OLT NNP N
. . N

-DOCSTART- -7761019- O O

[ JJ N
Effects NNS N
of IN N
betamethasone NN i
on IN N
neuromuscular JJ o
blockade NN o
induced VBN N
by IN N
vecuronium NN i
in IN N
continuous JJ N
infusion NN N
] NN N
. . N

The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
determine VB N
a DT N
possible JJ N
interaction NN N
between IN N
a DT N
corticosteroid NN i
( ( i
betamethasone NN i
) ) i
and CC i
vecuronium NN i
, , N
a DT N
nondepolarizing JJ i
muscle NN i
relaxant NN i
. . i

The DT N
authors NNS N
studied VBD N
20 CD p
patients NNS p
, , p
ASA NNP p
I-II NNP p
, , p
aged VBD p
20-54 JJ p
, , p
both DT p
sexes NNS p
, , p
scheduled VBN p
for IN p
abdominal JJ i
surgery NN i
. . i

Mechanomyographic NNP o
and CC o
clinical JJ o
evaluation NN o
by IN o
single JJ o
twitch NN o
and CC o
TOF NNP o
stimulation NN o
of IN o
the DT o
ulnar JJ o
nerve NN o
at IN o
the DT o
wrist NN o
and CC N
measurement NN N
of IN N
the DT N
concomitant JJ o
abductor NN o
pollicis NN o
muscle NN o
was VBD N
applied VBN N
. . N

The DT N
onset JJ o
time NN o
of IN N
vecuronium NN i
after IN N
a DT N
single JJ N
bolus NN N
dose NN N
of IN N
0.08 CD N
mg/kg NN N
, , N
duration NN o
of IN o
action NN o
to TO N
10 CD N
% NN N
single JJ o
twitch NN o
recovery NN o
, , N
duration NN N
of IN N
continuous JJ N
infusion NN N
of IN N
0.4-0.5 JJ N
micrograms/kg/min NN N
of IN N
vecuronium NN i
started VBN N
at IN N
10 CD N
% NN N
single JJ o
twitch NN o
recovery NN o
, , N
and CC N
the DT N
effects NNS N
of IN N
0.1 CD N
mg/kg NNS N
betamethasone CD i
administration NN N
10 CD N
min NN N
after IN N
continuous JJ N
infusion NN N
were VBD N
evaluated VBN N
. . N

The DT N
recovery NN o
rate NN o
of IN o
vecuronium NN o
after IN N
stopping VBG N
infusion NN N
at IN N
10 CD N
% NN N
recovery NN N
was VBD N
also RB N
evaluated VBN N
. . N

Corticosteroids NNS i
may MD N
interact VB N
with IN N
non-depolarizing JJ i
muscle NN i
relaxants NNS i
both DT N
in IN N
prejunctional NN N
and CC N
postjunctional JJ N
acetylcholine NN N
receptors NNS N
by IN N
several JJ N
mechanisms NNS N
of IN N
action NN N
. . N

-DOCSTART- -1634173- O O

[ JJ i
Local NNP i
therapy NN i
of IN i
grade NN i
1 CD i
and CC i
2 CD i
hemorrhoids NNS i
. . i

Effectiveness NN N
of IN N
a DT N
combination NN i
preparation NN i
with IN i
standardized JJ i
blood NN i
leech NN i
extract NN i
] NNP i
. . N

AIMS NNP N
Testing VBG N
the DT N
effectiveness NN N
of IN N
a DT N
topical JJ i
combination NN i
preparation NN i
containing VBG i
standardized VBN i
leech JJ i
extract NN i
, , i
polidocanol NN i
and CC i
allantoin NN i
. . i

STUDY NNP N
DESIGN NNP N
Placebo-controlled NNP i
, , N
double-blind NN N
study NN N
in IN N
80 CD p
patients NNS p
with IN p
first JJ p
and CC p
second JJ p
degree NN p
hemorrhoids NNS p
; : p
duration NN N
of IN N
treatment NN N
one CD N
week NN N
; : N
examinations NNS N
performed VBD N
on IN N
admission NN N
and CC N
on IN N
days NNS N
3 CD N
, , N
4 CD N
, , N
5 CD N
and CC N
8 CD N
. . N

RESULTS VB N
Both DT N
the DT N
subjective NN o
and CC o
objective JJ o
symptoms NNS o
and CC o
signs NNS o
improved VBN o
during IN N
the DT N
one CD N
week NN N
of IN N
treatment NN N
statistically RB N
significantly RB N
more RBR N
rapidly RB N
under IN N
the DT N
test NN i
preparation NN i
as IN N
compared VBN N
with IN N
placebo NN i
. . i

Histologically NNP o
demonstrable JJ o
signs NNS o
of IN o
inflammation NN o
were VBD N
more JJR N
clearly RB N
improved VBN N
in IN N
the DT N
preparation NN i
group NN N
than IN N
in IN N
the DT N
placebo NN i
group NN N
. . N

No DT o
side NN o
effects NNS o
were VBD N
observed VBN N
. . N

CONCLUSIONS VB N
The DT N
good JJ N
efficacy NN N
and CC N
tolerability NN N
of IN N
a DT N
topical JJ i
therapeutic JJ i
preparation NN i
in IN N
first JJ p
and CC p
second JJ p
degree NN p
hemorrhoids NNS p
have VBP N
been VBN N
convincingly RB N
demonstrated VBN N
. . N

-DOCSTART- -8436744- O O

Clinical JJ N
and CC N
prognostic JJ N
significance NN N
of IN N
serum NN N
magnesium NN N
concentration NN N
in IN N
patients NNS p
with IN p
severe JJ p
chronic JJ p
congestive JJ p
heart NN p
failure NN p
: : p
the DT N
PROMISE NNP N
Study NNP N
. . N

OBJECTIVES NNP N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
prognostic JJ N
significance NN N
of IN N
alterations NNS N
in IN N
serum JJ N
magnesium NN N
in IN N
patients NNS p
with IN p
moderate JJ p
to TO p
severe VB p
congestive JJ p
heart NN p
failure NN p
. . p

BACKGROUND NNP N
Reductions NNPS N
in IN N
serum NN N
magnesium NN N
have VBP N
been VBN N
postulated VBN N
to TO N
play VB N
a DT N
role NN N
in IN N
promoting VBG N
arrhythmias NN N
and CC N
to TO N
have VB N
an DT N
adverse JJ N
impact NN N
on IN N
survival NN N
in IN N
congestive JJ N
heart NN N
failure NN N
, , N
although IN N
support NN N
for IN N
this DT N
postulate NN N
is VBZ N
lacking VBG N
. . N

METHODS NNP N
Serum NNP o
magnesium NN o
levels NNS o
were VBD o
measured VBN o
in IN N
1,068 CD p
patients NNS p
enrolled VBN p
in IN p
a DT p
survival NN p
study NN p
of IN p
class NN p
III NNP p
or CC p
IV NNP p
heart NN p
failure NN p
at IN p
the DT p
time NN p
of IN p
double-blind JJ p
randomization NN p
to TO p
milrinone VB i
, , i
a DT i
phosphodiesterase NN i
inhibitor NN i
, , i
or CC i
placebo NN i
. . i

All DT N
patients NNS N
received VBD N
conventional JJ i
therapy NN i
with IN i
digoxin NN i
, , i
diuretic JJ i
drugs NNS i
and CC i
a DT i
converting VBG i
enzyme NN i
inhibitor NN i
throughout IN N
the DT N
trial NN N
. . N

The DT N
median JJ N
follow-up JJ N
period NN N
was VBD N
6.1 CD N
months NNS N
( ( N
range VB N
1 CD N
day NN N
to TO N
20 CD N
months NNS N
) ) N
. . N

RESULTS JJ N
Patients NNS N
with IN N
high JJ N
serum NN N
magnesium NN N
( ( N
defined VBN N
as IN N
> NN N
or CC N
= $ N
1.9 CD N
mEq/liter NN N
, , N
n JJ N
= NNP N
242 CD N
) ) N
were VBD N
less RBR N
likely JJ N
to TO N
survive VB o
than IN N
were VBD N
patients NNS N
with IN N
a DT N
normal JJ N
magnesium NN N
level NN N
( ( N
n JJ N
= NNP N
627 CD N
) ) N
( ( N
p JJ N
< NN N
0.05 CD N
, , N
risk NN N
ratio NN N
= NNP N
1.41 CD N
) ) N
. . N

Patients NNS N
with IN N
a DT N
low JJ N
magnesium NN N
level NN N
( ( N
defined VBN N
as IN N
< NN N
or CC N
= $ N
1.5 CD N
mEq/liter NN N
, , N
n JJ N
= NNP N
199 CD N
) ) N
had VBD N
no DT N
difference NN N
in IN N
survival NN o
compared VBN N
with IN N
the DT N
group NN N
with IN N
a DT N
normal JJ N
magnesium NN N
level NN N
( ( N
p JJ N
= NNP N
NS NNP N
, , N
risk NN N
ratio NN N
= NNP N
0.89 CD N
) ) N
. . N

At IN N
baseline NN N
, , N
the DT N
patients NNS N
in IN N
the DT N
high JJ N
magnesium NN N
group NN N
were VBD N
older JJR N
and CC N
had VBD N
more RBR N
severe JJ N
functional JJ o
and CC o
renal JJ o
impairment NN o
. . o

An DT N
analysis NN N
after IN N
adjustment NN N
for IN N
these DT N
variables NNS N
demonstrated VBD N
no DT N
difference NN N
in IN N
survival NN o
comparing VBG N
the DT N
low JJ N
, , N
normal JJ N
and CC N
high JJ N
magnesium NN N
groups NNS N
. . N

Although IN N
the DT N
three CD N
groups NNS N
had VBD N
no DT N
difference NN N
in IN N
frequency NN N
of IN N
ventricular JJ o
tachycardia NN o
, , o
length NN o
of IN o
longest JJS o
run NN o
or CC o
frequency NN o
of IN o
ventricular JJ o
premature NN o
beats NNS o
on IN N
baseline NN o
Holter NNP o
monitoring NN o
, , N
the DT N
group NN N
with IN N
hypomagnesemia NN N
had VBD N
more RBR N
frequent JJ N
ventricular JJ N
couplets NNS N
. . N

CONCLUSIONS NNP N
Serum NNP N
magnesium NN N
does VBZ N
not RB N
appear VB N
to TO N
be VB N
an DT N
independent JJ N
risk NN N
factor NN N
for IN N
either DT N
sudden JJ o
death NN o
or CC o
death NN o
due JJ N
to TO N
all DT N
causes NNS N
in IN N
patients NNS N
with IN N
moderate JJ N
to TO N
severe VB N
heart NN N
failure NN N
. . N

Hypomagnesemia NNP N
is VBZ N
associated VBN N
with IN N
an DT N
increase NN N
in IN N
the DT N
frequency NN N
of IN N
certain JJ N
forms NNS N
of IN N
ventricular JJ o
ectopic NN o
activity NN o
, , N
but CC N
this DT N
is VBZ N
not RB N
associated VBN N
with IN N
an DT N
increase NN N
in IN N
clinical JJ N
events NNS N
. . N

The DT N
higher JJR N
mortality NN N
rate NN N
among IN N
the DT N
patients NNS N
with IN N
hypermagnesemia NN N
is VBZ N
attributable JJ N
to TO N
older JJR N
age NN N
, , N
more RBR N
advanced JJ N
heart NN N
failure NN N
and CC N
renal JJ N
insufficiency NN N
. . N

-DOCSTART- -10439497- O O

Treatment NN N
of IN N
hypertensive JJ p
and CC p
hypercholesterolaemic JJ p
patients NNS p
in IN N
general JJ N
practice NN N
. . N

The DT N
effect NN N
of IN N
captopril NN i
, , i
atenolol NN i
and CC i
pravastatin NN i
combined VBN i
with IN i
life NN i
style NN i
intervention NN i
. . i

OBJECTIVE UH N
To TO N
elucidate VB N
the DT N
effect NN N
on IN N
blood NN N
pressure NN N
and CC N
blood NN N
lipids NNS N
of IN N
an DT N
angiotensin NN i
converting VBG i
enzyme JJ i
inhibitor NN i
( ( i
captopril NN i
) ) i
, , i
and CC i
a DT i
beta-receptor NN i
blocking NN i
agent NN i
( ( i
atenolol NN i
) ) i
, , i
given VBN i
alone RB i
or CC i
in IN i
combination NN i
with IN i
a DT i
cholesterol NN i
reducing VBG i
drug NN i
, , i
the DT i
beta-hydroxy-methylglutaryl-coenzyme NN i
A DT i
reductase NN i
inhibitor NN i
pravastatin NN i
, , N
in IN N
patients NNS p
who WP p
were VBD i
also RB i
encouraged VBN i
to TO i
improve VB i
their PRP$ i
lifestyle NN i
. . i

DESIGN VB N
A DT N
longitudinal JJ N
study NN N
consisting VBG N
of IN N
three CD N
phases NNS N
. . N

I PRP N
: : N
Lifestyle JJ i
intervention NN i
alone RB i
. . i

II NN N
: : N
Continued JJ i
lifestyle JJ i
intervention NN i
combined VBN i
with IN i
captopril NN i
or CC i
atenolol NN i
. . i

III NN N
: : N
Continued JJ i
lifestyle JJ i
intervention NN i
combined VBN i
with IN i
the DT i
same JJ i
drugs NNS i
as IN i
in IN i
phase NN i
II NNP i
and CC i
in IN i
addition NN i
pravastatin NN i
or CC i
placebo NN i
. . i

SETTING CC N
Fifty-four JJ p
general JJ p
practice NN p
surgeries NNS p
in IN p
Norway NNP p
. . p

PARTICIPANTS NNP N
Hypertensive JJ p
patients NNS p
, , p
210 CD p
females NNS p
and CC p
160 CD p
males NNS p
, , p
treated VBD p
or CC p
untreated JJ p
with IN p
antihypertensive JJ p
drugs NNS p
with IN p
a DT p
sitting VBG p
diastolic JJ p
blood NN p
pressure NN p
between IN p
95 CD p
and CC p
115 CD p
mmHg NN p
and CC p
a DT p
serum JJ p
total NN p
cholesterol NN p
between IN p
6.5 CD p
mmol/l NNS p
( ( p
7.0 CD p
for IN p
those DT p
age NN p
60-67 JJ p
years NNS p
) ) p
and CC p
9.0 CD p
mmol/l NN p
. . p

RESULTS VB N
The DT N
antihypertensive JJ N
effect NN N
of IN N
captopril NN i
and CC i
atenolol NN i
was VBD N
not RB N
influenced VBN N
by IN N
concurrent JJ N
administration NN N
of IN N
pravastatin NN i
. . i

The DT N
effect NN N
of IN N
pravastatin NN i
was VBD N
not RB N
limited VBN N
by IN N
concurrent JJ N
medication NN N
with IN N
captopril NN i
or CC i
atenolol NN i
. . i

Improvement NN o
in IN o
lifestyle NN o
seemed VBD N
to TO N
reduce VB N
the DT N
need NN N
for IN N
supplementary JJ o
treatment NN o
with IN o
diuretics NNS o
. . o

CONCLUSION NNP N
Pravastatin NNP i
can MD N
be VB N
used VBN N
in IN N
combination NN N
with IN N
captopril NN i
or CC i
atenolol NN i
in IN N
the DT N
treatment NN N
of IN N
hypertensive JJ p
and CC p
hypercholesterolaemic JJ p
patients NNS p
. . p

-DOCSTART- -7654128- O O

Failure NN N
of IN N
naltrexone NN i
hydrochloride NN i
to TO N
reduce VB N
self-injurious JJ p
and CC p
autistic JJ p
behavior NN p
in IN p
mentally RB p
retarded JJ p
adults NNS p
. . p

Double-blind JJ N
placebo-controlled JJ i
studies NNS N
. . N

BACKGROUND IN N
It PRP N
is VBZ N
hypothesized VBN N
that IN N
self-injurious JJ N
behavior NN N
( ( N
SIB NNP N
) ) N
and CC N
symptoms NNS N
of IN N
autism NN N
may MD N
be VB N
due JJ N
to TO N
overactivity NN N
in IN N
some DT N
opioid JJ N
systems NNS N
in IN N
the DT N
brain NN N
. . N

We PRP N
examined VBD N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
naltrexone JJ i
hydrochloride NN i
, , N
an DT N
opioid JJ N
antagonist NN N
, , N
in IN N
the DT N
treatment NN N
of IN N
SIB NNP p
and CC p
autism NN p
in IN p
mentally RB p
retarded JJ p
adults NNS p
. . p

METHOD NNP N
Thirty-three NNP p
mentally RB p
retarded VBD p
adults NNS p
with IN p
autism NN p
and/or NN p
SIB NNP p
participated VBD p
in IN p
double-blind NN p
, , p
placebo-controlled JJ i
crossover NN p
studies NNS p
. . p

Active JJ N
treatment NN N
was VBD N
first RB N
a DT N
single JJ N
100-mg JJ N
dose NN N
of IN N
naltrexone JJ i
hydrochloride NN i
. . i

Subsequently NNP N
, , N
19 CD N
subjects NNS N
were VBD N
treated VBN N
with IN N
50 CD N
mg/d NNS N
and CC N
14 CD N
with IN N
150 CD N
mg/d NNS N
of IN N
naltrexone NN i
hydrochloride NN i
for IN N
4 CD N
weeks NNS N
. . N

The DT N
outcome NN N
was VBD N
assessed VBN N
by IN N
means NNS N
of IN N
direct JJ N
observations NNS N
( ( N
n JJ N
= NNP N
11 CD N
) ) N
and CC N
on IN N
the DT N
basis NN N
of IN N
scores NNS N
on IN N
a DT N
list NN o
of IN o
target NN o
behaviors NNS o
, , o
the DT o
Aberrant NNP o
Behavior NNP o
Checklist NNP o
, , o
and CC o
the DT o
Clinical NNP o
Global NNP o
Impression NNP o
Scale NNP o
. . o

RESULTS NNP N
Thirty-two JJ N
subjects NNS N
( ( N
seven CD N
with IN N
autism NN N
, , N
16 CD N
with IN N
autism NN N
and CC N
SIB NNP N
, , N
and CC N
nine CD N
with IN N
SIB NNP N
) ) N
completed VBD N
the DT N
trial NN N
. . N

Naltrexone CD i
treatment NN N
failed VBD o
to TO N
have VB N
therapeutic JJ N
effects NNS N
on IN N
SIB NNP N
and CC N
autism NN N
. . N

On IN N
the DT N
contrary JJ N
, , N
naltrexone RB i
increased VBD o
the DT o
incidence NN o
of IN o
stereotypic JJ o
behavior NN o
on IN o
the DT o
Aberrant NNP o
Behavior NNP o
Checklist NNP o
, , N
and CC N
the DT N
care NN N
staff NN N
evaluated VBD N
the DT N
effect NN N
of IN N
the DT N
50-mg/d JJ N
treatment NN N
as IN N
being VBG N
significantly RB o
worse JJR o
than IN N
that DT N
of IN N
the DT N
placebo NN N
treatment NN N
as IN N
measured VBN N
by IN N
the DT N
Clinical NNP o
Global NNP o
Impression NNP o
Scale NNP o
. . o

CONCLUSION NNP N
Our PRP$ N
findings NNS N
suggest VBP N
that IN N
naltrexone NN N
has VBZ N
no DT N
clinical JJ N
value NN N
for IN N
a DT N
broad JJ N
group NN N
of IN N
mentally RB N
retarded JJ N
subjects NNS N
with IN N
SIB NNP N
and/or JJ N
autism NN N
. . N

-DOCSTART- -11549300- O O

Dipyridamole NNP i
in IN N
chronic JJ p
stable JJ p
angina NN p
pectoris NN p
; : p
a DT N
randomized VBN N
, , N
double JJ N
blind NN N
, , N
placebo-controlled JJ N
, , N
parallel JJ N
group NN N
study NN N
. . N

BACKGROUND NNP N
Oral NNP N
dipyridamole NN i
induces NNS N
accumulation NN N
of IN N
endogenous JJ N
adenosine NN N
, , N
which WDT N
in IN N
a DT N
hypoxic NN N
milieu NN N
exerts VBZ N
experimentally RB N
an DT N
angiogenic JJ N
effect NN N
on IN N
coronary JJ N
collateral NN N
circulation NN N
. . N

A DT N
meta-analysis NN N
of IN N
13 CD N
randomized JJ N
placebo-controlled JJ N
trials NNS N
published VBN N
between IN N
1960 CD N
and CC N
1992 CD N
showed VBD N
evidence NN N
of IN N
benefit NN N
for IN N
dipyridamole NN i
in IN N
the DT N
treatment NN N
of IN N
angina JJ N
pectoris NN N
, , N
especially RB N
with IN N
longer JJR N
duration NN N
of IN N
treatment NN N
. . N

Aim NNP N
To TO N
assess VB N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
dipyridamole NN N
in IN N
the DT N
treatment NN N
of IN N
patients NNS p
with IN p
chronic JJ p
stable JJ p
angina NN p
in IN p
a DT p
large JJ p
scale NN p
, , p
international JJ p
, , N
randomized VBN N
, , N
placebo-controlled JJ N
, , N
parallel JJ N
group NN N
study NN N
. . N

METHODS NNP N
Four CD p
hundred VBD p
patients NNS p
with IN p
chronic JJ p
stable JJ p
angina NN p
pectoris NN p
and CC p
a DT p
positive JJ p
treadmill NN p
exercise NN p
test NN p
were VBD p
randomized VBN p
to TO N
receive VB N
either RB N
modified JJ i
release NN i
dipyridamole NN i
( ( N
200 CD N
mg NN N
b.i.d NN N
. . N

p.o. NN N
, , N
n=198 NN N
) ) N
or CC N
corresponding VBG i
placebo NN i
( ( N
n=202 JJ N
) ) N
, , N
for IN N
24 CD N
weeks NNS N
as IN N
an DT N
add-on JJ N
to TO N
conventional JJ i
antianginal JJ i
therapy NN i
and CC N
for IN N
4 CD N
additional JJ N
weeks NNS N
as IN N
monotherapy NN N
-- : N
the DT N
latter NN N
after IN N
withdrawal NN i
of IN i
standard JJ i
treatment NN i
with IN i
calcium NN i
antagonists NNS i
and/or VBP i
beta-blockers NNS i
and/or JJ i
long-acting JJ i
( ( i
prophylactic JJ i
) ) i
nitrates NNS i
. . i

RESULTS NNP N
Of IN N
the DT N
198 CD p
patients NNS p
randomized VBN N
to TO N
dipyridamole VB i
, , N
134 CD N
completed VBD N
the DT N
add-on NN N
and CC N
only RB N
12 CD N
the DT N
monotherapy NN N
phase NN N
. . N

Of IN N
the DT N
202 CD N
patients NNS N
randomized VBN N
to TO N
placebo VB i
, , N
162 CD N
reached VBD N
the DT N
add-on JJ N
and CC N
only RB N
12 CD N
the DT N
monotherapy NN N
phase NN N
. . N

Serious JJ o
adverse JJ o
events NNS o
occurred VBD N
in IN N
15 CD N
patients NNS N
with IN N
dipyridamole JJ N
and CC N
in IN N
12 CD N
with IN N
placebo NN N
( ( N
7.6 CD N
% NN N
vs NN N
6.0 CD N
, , N
P=0.52 NNP N
) ) N
. . N

Increase NN o
over IN o
the DT o
baseline NN o
treadmill NN o
exercise NN o
test NN o
was VBD N
similar JJ N
in IN N
the DT N
treatment NN N
groups NNS N
at IN N
each DT N
stage NN N
of IN N
the DT N
trial NN N
for IN N
all PDT N
the DT N
main JJ N
efficacy NN N
parameters NNS N
: : N
total JJ o
treadmill NN o
exercise NN o
test NN o
duration NN o
; : o
time NN o
to TO o
first JJ o
anginal JJ o
pain NN o
( ( N
except IN N
for IN N
a DT N
-13 NN N
s NN N
difference NN N
in IN N
favour NN N
of IN N
placebo NN N
at IN N
week NN N
24 CD N
; : N
P=0.040 NNP N
) ) N
; : N
time NN o
to TO o
ST NNP o
segment NN o
depression NN o
> VBD N
0.1 CD N
mVolt NN o
( ( N
except IN N
for IN N
a DT N
+21 JJ N
s NN N
difference NN N
in IN N
favour NN N
of IN N
dipyridamole NN N
at IN N
week NN N
8 CD N
; : N
P=0.024 NNP N
; : N
this DT N
latter JJ N
difference NN N
was VBD N
totally RB N
attributable JJ N
to TO N
patients NNS N
with IN N
lower JJR N
exercise NN N
tolerance NN N
-- : N
Bruce NNP N
stage NN N
II NNP N
at IN N
study NNP N
entry NN N
) ) N
. . N

CONCLUSION NNP N
In IN N
patients NNS p
with IN p
chronic JJ p
stable JJ p
angina NN p
treated VBN p
with IN p
regular JJ p
antianginal JJ p
background NN p
medication NN p
, , N
the DT N
use NN N
of IN N
oral JJ N
dipyridamole NN i
is VBZ N
safe JJ o
and CC N
well RB N
tolerated VBN o
. . o

Antianginal NNP N
and CC N
antiischaemic JJ N
efficacy NN N
, , N
as IN N
assessed VBN N
by IN N
exercise NN N
testing NN N
, , N
is VBZ N
comparable JJ N
to TO N
placebo VB N
, , N
except IN N
for IN N
a DT N
beneficial JJ N
effect NN N
on IN N
time NN N
to TO N
ischaemia VB N
after IN N
2 CD N
months NNS N
, , N
totally RB N
attributable JJ N
to TO N
patients NNS N
with IN N
lower JJR N
exercise NN N
tolerance NN N
at IN N
study NN N
entry NN N
. . N

-DOCSTART- -16238797- O O

Bronchial NNP o
matrix NN o
and CC o
inflammation NN o
respond NN N
to TO N
inhaled VB i
steroids NNS i
despite IN N
ongoing VBG N
allergen NN N
exposure NN N
in IN N
asthma NN p
. . p

BACKGROUND NNP N
Inflammatory NNP o
and CC o
structural JJ o
changes NNS o
of IN o
the DT o
airway NN o
mucosa NN o
are VBP N
chronic JJ N
features NNS N
of IN N
asthma NN N
. . N

The DT N
mechanisms JJ N
underlying VBG N
these DT N
changes NNS N
and CC N
their PRP$ N
modulation NN N
by IN N
steroid JJ i
prophylaxis NNS N
have VBP N
not RB N
been VBN N
clarified VBN N
. . N

OBJECTIVE IN N
We PRP N
postulated VBD N
that IN N
asymptomatic JJ N
ongoing VBG N
allergen NN N
exposure NN N
could MD N
drive VB N
airway RP N
inflammation NN N
as RB N
well RB N
as IN N
changes NNS N
in IN N
the DT N
extracellular JJ N
matrix NN N
( ( N
ECM NNP N
) ) N
, , N
and CC N
that IN N
inhaled JJ i
steroids NNS i
could MD N
prevent VB N
this DT N
. . N

METHODS NNP N
Therefore RB N
, , N
we PRP N
exposed VBD N
patients NNS p
with IN p
mild JJ p
asthma NNS p
to TO N
2 CD i
weeks NNS i
of IN i
repeated VBN i
low-dose JJ i
allergen NN i
, , i
with IN i
concomitant NN i
inhaled VBN i
steroid NN i
or CC i
placebo NN i
treatment NN i
. . i

Bronchial JJ i
biopsies NNS i
, , N
which WDT N
were VBD N
taken VBN N
before RB N
and CC N
after IN N
this DT N
exposure NN N
, , N
were VBD N
stained VBN N
and CC N
digitally RB N
analysed VBN N
. . N

The DT N
ECM NNP N
proteins NNS N
in IN N
asthmatics NNS N
were VBD N
also RB N
compared VBN N
with IN N
a DT N
normal JJ N
control NN N
group NN N
. . N

RESULTS NNP N
Low-dose JJ N
allergen NN N
exposure NN N
alone RB N
resulted VBD N
in IN N
a DT N
significant JJ N
increase NN N
of IN N
bronchial JJ o
epithelial JJ o
macrophages NNS o
. . o

Despite IN N
ongoing VBG N
allergen NN N
exposure NN N
, , N
inhaled JJ i
steroids NNS i
reduced VBD N
the DT N
numbers NNS o
of IN o
mucosal NN o
eosinophils NNS o
, , o
neutrophils NNS o
and CC o
T NNP o
lymphocytes VBZ o
. . o

At IN N
baseline NN N
, , N
the DT N
mean JJ N
density NN o
of IN o
the DT o
proteoglycans NNS o
( ( o
PGS NNP o
) ) o
biglycan NN o
and CC o
decorin NN o
were VBD N
, , N
respectively RB N
, , N
higher JJR N
and CC N
lower RBR N
in IN N
the DT N
bronchial JJ N
mucosa NN N
of IN N
asthmatics NNS N
as IN N
compared VBN N
with IN N
normal JJ N
controls NNS N
. . N

Steroid NNP i
treatment NN i
, , N
during IN N
allergen NN N
exposure NN N
, , N
increased VBD N
the DT N
mean JJ o
density NN o
of IN o
the DT o
PGS NNP o
biglycan NN o
and CC o
versican JJ o
. . o

CONCLUSION NNP N
We PRP N
conclude VBP N
that DT N
chronic JJ N
allergen NN N
exposure NN N
induces VBZ N
inflammatory JJ N
changes NNS N
in IN N
the DT N
bronchial JJ N
mucosa NN N
. . N

Despite IN N
ongoing VBG N
allergen NN N
exposure NN N
, , N
steroid JJ i
treatment NN i
decreases VBZ N
mucosal JJ o
inflammatory JJ o
cells NNS o
while IN N
altering VBG N
PG NNP N
density NN N
. . N

The DT N
latter JJ N
observation NN N
highlights NNS N
the DT N
need NN N
to TO N
examine VB N
steroid-induced JJ o
changes NNS o
closely RB N
in IN N
the DT N
airway NN N
structure NN N
in IN N
patients NNS p
with IN p
asthma NN p
. . p

-DOCSTART- -20592840- O O

Field NNP N
efficacy NN o
of IN o
an DT o
inactivated JJ o
bivalent NN o
influenza NN o
vaccine NN o
in IN N
a DT N
multi-site JJ p
swine NN p
production NN p
system NN p
during IN p
an DT p
outbreak NN p
of IN p
systemic JJ p
porcine NN p
circovirus NN p
associated VBN p
disease NN p
. . p

Swine NNP N
influenza NN N
( ( N
SI NNP N
) ) N
is VBZ N
a DT N
disease NN N
of IN N
significance NN N
for IN N
the DT N
swine NN N
industry NN N
, , N
and CC N
vaccination NN N
is VBZ N
often RB N
recommended VBN N
as IN N
a DT N
way NN N
to TO N
reduce VB N
its PRP$ N
impact NN N
on IN N
production NN N
. . N

The DT N
efficacy NN N
of IN N
SI NNP i
vaccines NNS i
is VBZ N
well RB N
established VBN N
under IN N
experimental JJ N
conditions NNS N
, , N
but CC N
information NN N
about IN N
field NN N
efficacy NN N
is VBZ N
scarce JJ N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
a DT N
commercial JJ i
inactivated JJ i
bivalent NN i
( ( i
H1N1/H3N2 NNP i
) ) i
vaccine NN i
under IN N
conditions NNS N
of IN N
natural JJ N
exposure NN N
to TO N
a DT N
field NN i
SI NNP i
variant NN i
. . i

To TO N
accomplish VB N
our PRP$ N
goal NN N
we PRP N
used VBD N
a DT N
randomized JJ N
, , N
blinded VBD N
, , N
field NN N
trial NN N
in IN N
2 CD p
cohorts NNS p
of IN p
finisher NN p
pigs NNS p
in IN p
a DT p
multi-site JJ p
swine NN p
production NN p
system NN p
located VBN p
in IN p
southern JJ p
Ontario NNP p
. . p

During IN N
the DT N
trial NN N
, , N
this DT N
herd NN N
experienced VBD N
an DT N
outbreak NN N
of IN N
porcine NN N
circovirus NN N
associated VBN N
disease NN N
( ( N
PCVAD NNP N
) ) N
. . N

The DT N
efficacy NN o
of IN o
the DT o
SI NNP o
vaccine NN o
was VBD N
assessed VBN N
through IN N
its PRP$ N
effect NN N
on IN N
average JJ o
daily JJ o
weight NN o
gain NN o
, , o
and CC o
serological JJ o
responses NNS o
to TO o
SI VB o
over IN o
time NN o
. . o

The DT N
effect NN o
of IN o
vaccination NN o
on IN N
pig NN o
growth NN o
was VBD N
different JJ N
in IN N
the DT N
2 CD p
cohorts NNS p
. . p

Weight NNP o
gain NN o
was VBD N
higher RBR N
in IN N
vaccinated JJ N
pigs NNS p
than IN N
in IN N
control NN N
pigs NNS N
in IN N
Cohort NNP N
1 CD N
, , N
but CC N
was VBD N
numerically RB N
higher JJR N
for IN N
control NN N
pigs NNS N
than IN N
for IN N
vaccinated JJ N
pigs NNS N
in IN N
Cohort NNP N
2 CD N
. . N

Vaccination NN i
against IN N
swine NN N
influenza NN N
, , N
in IN N
a DT N
herd NN p
experiencing VBG p
an DT p
outbreak NN p
of IN p
PCVAD NNP p
, , N
was VBD N
of IN N
questionable JJ N
value NN N
. . N

-DOCSTART- -15734707- O O

The DT N
effect NN N
of IN N
vitamin JJ i
A-fortified NNP i
coconut NN i
cooking VBG i
oil NN i
on IN N
the DT N
serum NN o
retinol JJ o
concentration NN o
of IN p
Filipino NNP p
children NNS p
4-7 CD p
years NNS p
old JJ p
. . p

A DT N
6-month JJ N
intervention NN N
trial NN N
was VBD N
conducted VBN N
among IN N
542 CD p
Filipino NNP p
children NNS p
aged VBD p
4 CD p
to TO p
7 CD p
years NNS p
to TO N
determine VB N
the DT N
effect NN N
of IN N
vitamin JJ i
A-fortified NNP i
coconut NN i
cooking VBG i
oil NN i
intake NN N
on IN N
their PRP$ N
vitamin NN N
A DT N
status NN N
and CC N
to TO N
identify VB N
factors NNS N
that WDT N
influence NN N
this DT N
. . N

Children NNP N
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
Experimental NNP N
group NN N
, , N
with IN N
vitamin JJ i
A-fortified JJ i
cooking NN i
oil NN i
ration NN N
; : N
to TO N
Control-1 NNP N
group NN N
with IN N
unfortified JJ i
cooking NN i
oil NN i
ration NN i
; : i
and CC N
to TO N
Control-2 NNP N
group NN N
without IN i
cooking VBG i
oil NN i
ration NN i
. . i

In IN N
all DT N
groups NNS N
, , N
children NNS N
's POS N
serum NN N
retinol NN o
concentration NN o
improved VBN N
. . N

Relative JJ N
change NN N
in IN N
serum NN o
retinol NN o
concentration NN o
was VBD N
significantly RB N
higher JJR N
among IN N
the DT N
Experimental NNP N
group NN N
, , N
with IN N
one-third NN N
of IN N
total JJ N
vitamin FW N
A DT N
intake NN N
coming VBG N
from IN N
vitamin JJ i
A-fortified JJ i
cooking NN i
oil NN i
intake NN N
, , N
than IN N
in IN N
the DT N
Control NNP N
groups NNS N
, , N
with IN N
more JJR N
than IN N
half NN N
of IN N
intake NN N
from IN N
other JJ N
vitamin JJ N
A-rich JJ N
foods NNS N
. . N

Determinants NNS N
of IN N
post-intervention NN N
serum NN N
retinol NN N
concentration NN N
included VBD N
baseline JJ N
serum NN N
retinol NN N
concentration NN N
, , N
caregiver NN N
's POS N
education NN N
, , N
receipt NN N
of IN N
high-dose JJ N
vitamin NN N
A NNP N
capsule NN N
, , N
interaction NN N
between IN N
consumption NN N
of IN N
vitamin JJ N
A-fortified JJ N
cooking NN N
oil NN N
and CC N
of IN N
other JJ N
vitamin JJ N
A-rich NNP N
foods NNS N
, , N
and CC N
between IN N
households NNS N
purchasing VBG N
cooking JJ N
oil NN N
and CC N
food NN N
expenditure NN N
. . N

Intake NNP N
of IN N
vitamin JJ i
A-fortified JJ i
cooking NN i
oil NN i
combined VBN N
with IN N
vitamin JJ N
A-rich NNP N
foods NNS N
was VBD N
necessary JJ N
to TO N
increase VB N
serum NN o
retinol JJ o
concentration NN o
. . o

It PRP N
is VBZ N
recommended VBN N
to TO N
vigorously RB N
promote VB N
the DT N
consumption NN N
of IN N
vitamin JJ i
A-fortified JJ i
cooking NN i
oil NN i
together RB N
with IN N
other JJ N
vitamin JJ N
A-rich JJ N
sources NNS N
to TO N
sustain VB N
the DT N
prevention NN o
and CC N
control NN o
of IN N
vitamin FW N
A DT N
deficiency NN o
. . o

-DOCSTART- -22349989- O O

ApoA-I JJ i
induction NN N
as IN N
a DT N
potential JJ N
cardioprotective JJ N
strategy NN N
: : N
rationale NN N
for IN N
the DT N
SUSTAIN NNP N
and CC N
ASSURE NNP N
studies NNS N
. . N

BACKGROUND NNP N
Considerable JJ N
interest NN N
has VBZ N
focused VBN N
on IN N
the DT N
development NN N
of IN N
therapies NNS N
that WDT N
target VBP N
the DT N
functionality NN N
of IN N
high-density NN N
lipoproteins NNS N
( ( N
HDL NNP N
) ) N
. . N

Upregulation NN N
of IN N
endogenous JJ N
synthesis NN N
of IN N
the DT N
major JJ N
protein NN N
on IN N
HDL NNP N
particles NNS N
, , N
apolipoprotein RB i
A-I NNP i
( ( N
apoA-I NN N
) ) N
, , N
represents VBZ N
a DT N
novel JJ N
approach NN N
to TO N
generation NN N
of IN N
new JJ N
HDL NNP N
particles NNS N
. . N

The DT N
Study NNP N
of IN N
Quantitative NNP N
Serial NNP N
Trends NNP N
in IN N
Lipids NNP N
with IN N
Apolipoprotein NNP i
A-I NNP i
Stimulation NNP i
( ( N
SUSTAIN NNP N
, , N
NCT01423188 NNP N
) ) N
study NN N
aims VBZ N
to TO N
evaluate VB N
the DT N
lipid JJ o
efficacy NN o
, , o
safety NN o
and CC N
tolerability NN o
of IN N
an DT N
apoA-I JJ i
inducer NN i
( ( i
RVX-208 NNP i
) ) i
. . N

The DT N
ApoA-I JJ N
Synthesis NNP N
Stimulation NNP N
and CC N
Intravascular NNP i
Ultrasound NNP i
for IN N
Coronary NNP N
Atheroma NNP N
Regression NNP N
Evaluation NNP N
( ( N
ASSURE NNP N
, , N
NCT01067820 NNP N
) ) N
study NN N
aims VBZ N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
RVX-208 NNP N
on IN N
plaque NN N
burden NN N
. . N

METHODS NNP N
In IN p
SUSTAIN NNP p
, , p
172 CD p
patients NNS p
with IN p
low JJ p
levels NNS p
of IN p
HDL-C NNP p
will MD p
be VB p
randomized VBN p
to TO N
receive VB N
RVX-208 NNP i
100 CD N
mg NN N
bid NN N
or CC N
placebo NN i
for IN N
24 CD N
weeks NNS N
. . N

The DT N
primary JJ N
efficacy NN N
parameter NN N
will MD N
be VB N
the DT N
percentage NN o
change NN o
in IN o
HDL-C NNP o
levels NNS o
. . o

In IN p
ASSURE NNP p
, , p
310 CD p
patients NNS p
with IN p
angiographic JJ p
coronary JJ p
artery NN p
disease NN p
and CC p
low JJ p
HDL-C NNP p
levels NNS p
will MD p
be VB p
randomized VBN p
to TO N
receive VB N
RVX-208 NNP i
100 CD N
mg NN N
bid NN N
or CC N
placebo NN i
for IN N
26 CD N
weeks NNS N
. . N

The DT N
primary JJ N
efficacy NN N
parameter NN N
will MD N
be VB N
the DT N
nominal JJ N
change NN N
in IN N
percent NN o
atheroma NN o
volume NN o
( ( o
PAV NNP o
) ) o
, , N
determined VBN N
by IN N
analysis NN N
of IN N
intravascular JJ N
ultrasound NN N
( ( N
IVUS NNP N
) ) N
images NNS N
of IN N
matched JJ N
coronary JJ N
artery NN N
segments NNS N
acquired VBD N
at IN N
baseline NN N
and CC N
at IN N
26-week JJ N
follow-up NN N
. . N

The DT N
effect NN N
of IN N
RVX-208 NNP i
on IN N
other JJ N
lipid JJ o
and CC o
inflammatory JJ o
markers NNS o
, , o
safety NN o
and CC o
tolerability NN o
will MD N
also RB N
be VB N
assessed VBN N
in IN N
both DT N
studies NNS N
. . N

CONCLUSION NNP N
ApoA-I NNP i
induction NN N
represents VBZ N
a DT N
potential JJ N
novel NN N
strategy NN N
to TO N
reduce VB N
cardiovascular JJ o
risk NN o
, , N
by IN N
generating VBG N
nascent JJ N
HDL NNP N
particles NNS N
. . N

These DT N
studies NNS N
will MD N
provide VB N
early JJ N
evaluation NN N
of IN N
the DT N
effects NNS N
of IN N
RVX-208 NNP i
on IN N
lipids NNS N
and CC N
atherosclerotic JJ N
plaque NN N
. . N

-DOCSTART- -3895875- O O

Prophylactic JJ i
lidocaine NN i
in IN N
the DT N
early JJ N
phase NN N
of IN N
suspected JJ N
myocardial JJ N
infarction NN N
. . N

Four CD p
hundred VBD p
two CD p
patients NNS p
with IN p
suspected JJ p
myocardial JJ p
infarction NN p
seen VBN p
within IN p
6 CD p
hours NNS p
of IN p
the DT p
onset NN p
of IN p
symptoms NNS p
entered VBD N
a DT N
double-blind JJ N
randomized JJ N
trial NN N
of IN N
lidocaine NN i
vs NN i
placebo NN i
. . i

During IN N
the DT N
1 CD N
hour NN N
after IN N
administration NN N
of IN N
the DT N
drug NN N
the DT N
incidence NN o
of IN o
ventricular JJ o
fibrillation NN o
or CC o
sustained VBN o
ventricular JJ o
tachycardia NN o
among IN N
the DT N
204 CD p
patients NNS p
with IN p
acute JJ p
myocardial JJ p
infarction NN p
was VBD N
low JJ N
, , N
1.5 CD N
% NN N
. . N

Lidocaine NNP i
, , N
given VBN N
in IN N
a DT N
300 CD N
mg NN N
dose VBD N
intramuscularly RB N
followed VBN N
by IN N
100 CD N
mg NN N
intravenously RB N
, , N
did VBD N
not RB N
prevent VB N
sustained JJ o
ventricular JJ o
tachycardia NN o
, , N
although IN N
there EX N
was VBD N
a DT N
significant JJ N
reduction NN N
in IN N
the DT N
number NN o
of IN o
patients NNS o
with IN o
warning VBG o
arrhythmias NNS o
between IN N
15 CD N
and CC N
45 CD N
minutes NNS N
after IN N
the DT N
administration NN N
of IN N
lidocaine NN i
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

The DT N
average JJ o
plasma JJ o
lidocaine JJ o
level NN o
10 CD N
minutes NNS o
after IN o
administration NN N
for IN N
patients NNS N
without IN N
a DT N
myocardial JJ N
infarction NN N
was VBD N
significantly RB N
higher JJR N
than IN N
that DT N
for IN N
patients NNS N
with IN N
an DT N
acute JJ N
infarction NN N
. . N

The DT N
mean JJ o
plasma NN o
lidocaine JJ o
level NN o
of IN N
patients NNS N
on IN N
beta-blocking JJ N
agents NNS N
was VBD N
no DT N
different JJ N
from IN N
that DT N
in IN N
patients NNS N
not RB N
on IN N
beta NN N
blocking VBG N
agents NNS N
. . N

During IN N
the DT N
1-hour JJ N
study NN N
period NN N
, , N
the DT N
incidence NN o
of IN o
central JJ o
nervous JJ o
system NN o
side NN o
effects NNS o
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
lidocaine NN N
group NN N
, , N
hypotension NN o
occurred VBD N
in IN N
11 CD N
patients NNS N
, , N
nine CD N
of IN N
whom WP N
had VBD N
received VBN N
lidocaine NN N
, , N
and CC N
four CD p
patients NNS p
died VBD o
from IN N
asystole NN N
, , N
three CD N
of IN N
whom WP N
had VBD N
had VBN N
lidocaine NN i
. . i

We PRP N
can MD N
not RB N
advocate VB N
the DT N
administration NN N
of IN N
lidocaine JJ i
prophylactically RB N
in IN N
the DT N
early JJ N
hours NNS N
of IN N
suspected JJ N
myocardial JJ N
infarction NN N
. . N

-DOCSTART- -8091822- O O

[ VB N
The DT N
anti-ischemic JJ o
effect NN o
of IN N
phosphodiesterase NN N
III NNP N
inhibitors NNS N
] NNP N
. . N

When WRB N
enoximone NN i
is VBZ N
acutely RB N
administered VBN N
to TO N
patients NNS p
with IN p
stable JJ p
angina NNS p
and CC p
angiographically RB p
proven JJ p
relevant JJ p
coronary JJ p
stenosis NN p
i.v NN p
. . p

application NN p
of IN p
0.75 CD p
mg/kg NN p
exhibits NNS N
pronounced VBD N
antiischemic JJ o
effects NNS o
. . o

This DT N
could MD N
be VB N
observed VBN N
in IN N
patients NNS N
during IN N
exercise NN N
and CC N
in IN N
those DT N
in IN N
whom WP N
the DT N
ischemia NN o
was VBD N
provoked VBN N
by IN N
rapid JJ N
cardiac JJ N
stimulation NN N
. . N

The DT N
antiischemic JJ o
effects NNS o
were VBD N
documented VBN N
by IN N
relief NN o
of IN o
symptoms NNS o
, , N
reduction NN N
of IN N
ST-depression NNP o
, , N
improvement NN N
of IN N
impaired JJ N
myocardial JJ o
wall NN o
motion NN o
, , N
decrease NN N
to TO N
normalization NN N
of IN N
pathologically RB o
elevated VBN o
filling JJ o
pressure NN o
, , o
amelioration NN o
of IN o
coronary JJ o
blood NN o
flow NN o
as IN N
evidenced VBN N
by IN N
myocard NN o
scintigraphy NN o
and CC N
washout NN o
time NN o
of IN N
an DT N
intracoronarily JJ N
injected VBN N
echo-contrast JJ N
medium NN N
. . N

There EX N
was VBD N
also RB N
a DT N
definite JJ N
improvement NN N
of IN N
ischemia-caused JJ o
mitral JJ o
regurgitation NN o
. . o

Similar JJ N
observations NNS N
were VBD N
found VBN N
when WRB N
the DT N
drug NN N
was VBD N
injected VBN N
in IN N
the DT N
diseased JJ N
coronary JJ N
arteries NNS N
in IN N
a DT N
small JJ N
dose NN N
( ( N
0.075 CD N
mg/kg NN N
) ) N
so IN N
that DT N
peripheral JJ o
effects NNS o
were VBD N
not RB N
present JJ N
. . N

In IN N
comparison NN N
to TO N
the DT N
Ca NNP N
( ( N
++ NNP N
) ) N
-blocker NN N
Gallopamil NNP i
the DT N
antiischemic JJ o
effects NNS o
of IN N
Enoximone NNP i
were VBD N
more RBR N
pronounced JJ N
, , N
a DT N
synergistic JJ o
action NN o
was VBD N
, , N
however RB N
, , N
observed JJ N
. . N

Negative JJ o
dromotropic JJ o
effects NNS o
of IN N
Gallopamil NNP i
could MD N
be VB N
abolished VBN N
by IN N
Enoximone NNP i
. . i

With IN N
oral JJ N
administration NN N
of IN N
the DT N
drug NN N
over IN N
a DT N
period NN N
of IN N
one CD N
week NN N
antiischemic JJ o
effects NNS o
could MD N
also RB N
be VB N
documented VBN N
with IN N
Holter NNP o
monitoring NN o
as RB N
well RB N
as IN N
during IN N
exercise NN N
. . N

There EX N
was VBD N
a DT N
reduction NN N
of IN N
ST-depression NNP o
both DT N
at IN N
spontaneously RB N
occurring VBG N
ischemic JJ N
episodes NNS N
and CC N
during IN N
exercise NN N
, , N
in IN N
the DT N
number NN o
and CC o
duration NN o
of IN o
episodes NNS o
of IN o
silent JJ o
ischemia NN o
, , N
particularly RB N
, , N
however RB N
, , N
a DT N
decrease NN N
in IN N
symptomatic JJ o
episodes NNS o
. . o

In IN N
none NN N
of IN N
the DT N
patients NNS N
under IN N
study NN N
proarrhythmic JJ o
effects NNS o
were VBD N
observed VBN N
. . N

-DOCSTART- -7134226- O O

Inhibition NN N
of IN N
spontaneous JJ N
platelet NN o
aggregation NN o
and CC o
adhesion NN o
by IN N
indobufen NN i
( ( i
K NNP i
3920 CD i
) ) i
. . i

A DT N
randomized JJ N
, , N
double-blind JJ N
crossover NN N
study NN N
on IN N
platelet NN N
, , N
coagulation NN N
and CC N
fibrinolysis NN N
function NN N
tests NNS N
. . N

In IN N
a DT N
randomized JJ N
double-blind NN N
crossover NN N
study NN N
in IN p
12 CD p
patients NNS p
with IN p
atherosclerotic JJ p
disease NN p
, , N
the DT N
effect NN N
of IN N
2 CD N
dosages NNS N
( ( N
100 CD N
and CC N
200 CD N
mg NN N
twice RB N
daily RB N
) ) N
of IN N
indobufen NN i
, , N
a DT N
new JJ N
synthetic JJ N
inhibition NN N
of IN N
platelet NN N
aggregation NN N
, , N
on IN N
some DT N
platelet NN o
functions NNS o
, , o
coagulation NN o
and CC o
fibrinolysis NN o
tests NNS o
was VBD N
investigated VBN N
. . N

Regardless NNP N
of IN N
the DT N
dosage NN N
used VBN N
, , N
indobufen NN i
was VBD N
shown VBN N
to TO N
induce VB N
a DT N
prompt JJ N
normalization NN N
of IN N
the DT N
enhanced JJ o
platelet NN o
aggregation NN o
of IN N
these DT N
patients NNS N
. . N

The DT N
effect NN N
lasted VBD N
for IN N
the DT N
entire JJ N
period NN N
of IN N
drug NN N
administration NN N
and CC N
in IN N
50 CD N
% NN N
of IN N
patients NNS N
a DT N
normal JJ N
platelet NN N
aggregation NN N
was VBD N
maintained VBN N
until IN N
the DT N
fourth JJ N
day NN N
after IN N
discontinuation NN N
of IN N
the DT N
drug NN N
. . N

Indobufen NNP i
was VBD N
also RB N
able JJ N
to TO N
reduce VB N
platelet NN o
adhesiveness NN o
and CC N
to TO N
lengthen VB N
bleeding NN o
time NN o
, , N
especially RB N
when WRB N
the DT N
higher JJR N
dosage NN N
was VBD N
used VBN N
. . N

-DOCSTART- -20484620- O O

Clonidine JJ o
clearance NN o
matures NNS N
rapidly RB N
during IN N
the DT N
early JJ N
postnatal JJ N
period NN N
: : N
a DT N
population NN N
pharmacokinetic JJ N
analysis NN N
in IN N
newborns NNS p
with IN p
neonatal JJ p
abstinence NN p
syndrome NN p
. . p

The DT N
population NN N
pharmacokinetic NN o
( ( o
PK NNP o
) ) o
profile NN o
of IN N
oral JJ i
clonidine NN i
was VBD N
characterized VBN N
in IN N
newborns NNS p
with IN p
neonatal JJ p
abstinence NN p
syndrome NN p
, , N
and CC N
significant JJ N
covariates NNS N
affecting VBG N
its PRP$ N
PK NNP N
parameters NNS N
were VBD N
identified VBN N
. . N

Plasma NNP o
clonidine JJ o
concentration NN o
data NNS o
were VBD N
obtained VBN N
from IN N
a DT N
clinical JJ N
trial NN N
in IN N
which WDT N
36 CD p
newborns NNS p
, , p
aged VBD p
1 CD p
to TO p
25 CD p
days NNS p
( ( p
postnatal JJ p
age NN p
, , p
PNA NNP p
) ) p
and CC p
weighing VBG p
2.1 CD p
to TO p
3.9 CD p
kg NNS p
, , N
were VBD N
enrolled VBN N
to TO N
take VB N
multiple JJ N
oral JJ N
doses NNS N
of IN N
clonidine NN N
. . N

The DT N
population NN N
PK NNP o
model NN o
of IN o
clonidine NN o
was VBD N
developed VBN N
by IN N
NONMEM NNP N
, , N
and CC N
significant JJ N
covariates NNS N
were VBD N
identified VBN N
, , N
followed VBN N
by IN N
nonparametric JJ N
bootstraps NNS N
( ( N
2000 CD N
replicates NNS N
) ) N
and CC N
simulation NN N
experiments NNS N
. . N

A DT N
1-compartment JJ N
open JJ N
linear NN N
PK NNP N
model NN N
was VBD N
chosen VBN N
to TO N
describe VB N
plasma JJ o
concentrations NNS o
of IN o
clonidine NN o
, , N
and CC N
body NN o
weight NN o
and CC o
PNA NNP o
were VBD N
significant JJ N
covariates NNS N
for IN N
apparent JJ o
clearance NN o
( ( N
CL/F NNP N
) ) N
as IN N
follows VBZ N
: : N
CL/F NNP N
( ( N
L/h NNP N
) ) N
= VBD N
15.2 CD N
? . N
[ VB N
body NN N
weight NN N
( ( N
kg NN N
) ) N
/70 NN N
] NNP N
( ( N
0.75 CD N
) ) N
? . N
[ JJ N
PNA NNP N
( ( N
day NN N
) ) N
( ( N
0.441 CD N
) ) N
/ NN N
( ( N
4.06 CD N
( ( N
0.441 CD N
) ) N
+ NN N
PNA NNP N
( ( N
day NN N
) ) N
( ( N
0.441 CD N
) ) N
) ) N
] NN N
. . N

Furthermore NNP o
, , o
CL/F NNP o
of IN o
clonidine NN o
increased VBN o
rapidly RB N
with IN N
PNA NNP N
during IN N
the DT N
first JJ N
month NN N
of IN N
life NN N
after IN N
body NN N
weight NN N
was VBD N
adjusted VBN N
. . N

Any DT N
optimal JJ N
dosage NN N
regimen NNS N
for IN i
clonidine NN i
in IN i
term NN N
neonates NNS N
should MD N
be VB N
based VBN N
on IN N
infant NN N
's POS N
age NN N
and CC N
body NN N
weight NN N
, , N
and CC N
1.5 CD N
?g/kg NN N
every DT N
4 CD N
hours NNS N
is VBZ N
proposed VBN N
starting VBG N
the DT N
second JJ N
week NN N
of IN N
life NN N
based VBN N
on IN N
the DT N
simulation NN N
results NNS N
. . N

-DOCSTART- -23477890- O O

The DT N
addition NN N
of IN N
amifostine NN i
to TO i
carboplatin VB i
and CC i
paclitaxel VB i
based VBN i
chemoradiation NN i
in IN N
locally RB p
advanced JJ p
non-small JJ p
cell NN p
lung NN p
cancer NN p
: : p
long-term JJ N
follow-up NN N
of IN N
Radiation NNP N
Therapy NNP N
Oncology NNP N
Group NNP N
( ( N
RTOG NNP N
) ) N
randomized VBD N
trial NN N
9801 CD N
. . N

INTRODUCTION NNP N
We PRP N
report VBP N
the DT N
long-term JJ N
results NNS N
of IN N
RTOG NNP N
9801 CD N
, , N
a DT N
randomized JJ N
trial NN N
investigating VBG N
the DT N
ability NN N
of IN N
amifostine NN i
, , N
a DT N
radioprotector NN N
, , N
to TO N
reduce VB N
chemoradiation-induced JJ N
esophagitis NN N
. . N

METHODS NNP N
Patients NNPS p
with IN p
stages NNS p
II NNP p
and CC p
IIIA/B NNP p
non-small-cell JJ p
lung NN p
cancer NN p
received VBD N
induction NN N
paclitaxel NN i
225 CD N
mg/m2 NN N
intravenously RB N
( ( N
IV NNP N
) ) N
and CC N
carboplatin JJ i
area NN N
under IN N
the DT N
curve NN N
( ( N
AUC NNP N
) ) N
6 CD N
both DT N
days NNS N
1 CD N
and CC N
22 CD N
, , N
followed VBN N
by IN N
concurrent JJ N
weekly JJ N
paclitaxel NN i
( ( N
50 CD N
mg/m2 NN N
) ) N
and CC N
carboplatin NN i
( ( N
AUC NNP N
2 CD N
) ) N
, , N
with IN N
hyperfractionated VBN i
radiation NN i
therapy NN i
( ( N
69.6 CD N
Gy NNP N
at IN N
1.2 CD N
Gy NNP N
BID NNP N
) ) N
. . N

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
amifostine VB i
( ( N
AM NNP N
) ) N
500 CD N
mg JJ N
IV NNP N
four CD N
times NNS N
per IN N
week NN N
or CC N
no-AM JJ N
during IN N
chemoradiotherapy NN N
. . N

Stratification NN N
factors NNS N
included VBD N
age NN N
( ( N
< JJ N
70 CD N
vs. FW N
?70 CD N
years NNS N
) ) N
, , N
stage NN N
and CC N
performance NN N
status NN N
. . N

RESULTS VB p
243 CD p
patients NNS p
( ( p
pts NNS p
) ) p
were VBD p
enrolled VBN p
; : p
120 CD p
received VBD p
AM NNP p
, , p
123 CD p
received VBD p
no-AM JJ p
. . p

Two CD p
pts NNS p
on IN p
each DT p
arm NN p
were VBD p
found VBN p
ineligible JJ p
. . p

Overall JJ p
, , p
85 CD p
% NN p
of IN p
patients NNS p
were VBD p
?70 JJ p
years NNS p
; : p
75 CD p
% NN p
had VBD p
a DT p
KPS NNP p
?90 NNP p
. . p

34 CD p
% NN p
had VBD o
squamous JJ o
histology NN o
. . o

With IN o
median JJ N
follow-up NN N
of IN N
96.3 CD N
months NNS N
( ( N
for IN N
patients NNS N
still RB N
alive JJ N
) ) N
, , o
overall JJ o
survival NN o
was VBD o
identical JJ o
( ( N
hazard JJ N
ratio NN N
1.03 CD N
( ( N
0.79-1.34 NN N
) ) N
, , N
NS NNP N
) ) N
: : N
five-year JJ o
survival JJ o
17 CD o
% NN o
in IN o
both DT N
arms NNS N
. . N

The DT o
incidence NN o
of IN o
late JJ o
grade NN o
3-5 JJ o
toxicities NNS o
was VBD o
16 CD o
% NN N
in IN N
the DT N
AM NNP N
arm NN N
and CC N
19 CD N
% NN N
in IN N
the DT N
control NN N
arm NN N
( ( N
hazard JJ N
ratio NN N
1.24 CD N
( ( N
0.66-2.32 NN N
) ) N
, , N
NS NNP N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
arms NNS N
regarding VBG o
overall JJ o
survival NN o
, , o
disease-free JJ o
survival NN o
or CC o
long-term JJ o
toxicity NN o
. . o

CONCLUSION VB o
The DT N
chemoradiation NN N
regimen NNS i
of IN i
carboplatin NN i
and CC i
paclitaxel NN i
produced VBN i
long-term JJ N
results NNS N
in IN N
the DT N
multi-institutional JJ N
setting NN N
comparable JJ N
to TO N
other JJ N
regimens NNS i
. . i

Amifostine NNP i
did VBD i
not RB i
appear VB N
to TO N
compromise VB o
survival NN o
. . o

As IN o
done VBN o
in IN N
RTOG NNP N
9801 CD N
, , N
more RBR N
consistent JJ N
reporting NN N
of IN N
long JJ N
term NN o
toxicity NN o
is VBZ o
needed VBN o
for IN N
comparison NN N
of IN N
different JJ N
chemoradiation NN N
regimens NNS N
. . N

-DOCSTART- -1922235- O O

A DT N
comparison NN N
of IN N
single-dose JJ N
cefixime NN i
with IN N
ceftriaxone NN i
as IN N
treatment NN N
for IN N
uncomplicated JJ o
gonorrhea NN o
. . o

The DT N
Gonorrhea NNP N
Treatment NNP N
Study NNP N
Group NNP N
. . N

BACKGROUND NNP N
Because IN N
of IN N
the DT N
widespread JJ N
existence NN N
of IN N
Neisseria NNP N
gonorrhoeae NN N
resistant NN N
to TO N
penicillin VB N
or CC N
tetracycline VB N
, , N
ceftriaxone NN N
is VBZ N
now RB N
recommended VBN N
for IN N
the DT N
treatment NN N
of IN N
gonorrhea NN o
. . o

There EX N
is VBZ N
, , N
however RB N
, , N
a DT N
need NN N
for IN N
effective JJ N
antibiotics NNS N
that WDT N
can MD N
be VB N
administered VBN N
orally RB N
as IN N
an DT N
alternative NN N
to TO N
ceftriaxone NN i
, , N
which WDT N
requires VBZ N
intramuscular JJ N
administration NN N
. . N

Cefixime NNP N
is VBZ N
an DT N
orally RB N
absorbed JJ N
cephalosporin NN N
that WDT N
is VBZ N
active JJ N
against IN N
resistant JJ N
gonococci NN N
and CC N
has VBZ N
pharmacokinetic JJ N
activity NN N
suitable JJ N
for IN N
single-dose JJ N
administration NN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
In IN N
a DT N
randomized JJ N
, , N
unblinded JJ p
multicenter NN p
study NN p
of IN p
209 CD p
men NNS p
and CC p
124 CD p
women NNS p
with IN p
uncomplicated JJ p
gonorrhea NN p
, , N
we PRP N
compared VBN N
three CD N
single-dose JJ N
treatment NN N
regimens NNS N
: : N
400 CD i
mg NN i
or CC i
800 CD i
mg NN i
of IN i
cefixime NN i
, , i
administered VBN i
orally RB i
, , i
and CC i
250 CD i
mg NN i
of IN i
ceftriaxone NN i
administered VBN N
intramuscularly RB N
. . N

The DT N
overall JJ o
cure NN o
rates NNS o
were VBD N
96 CD N
percent NN N
for IN N
the DT N
400-mg JJ N
dose NN N
of IN N
cefixime NN i
( ( N
89 CD N
of IN N
93 CD N
patients NNS N
) ) N
( ( N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
93.5 CD N
percent NN N
to TO N
97.8 CD N
percent NN N
) ) N
; : N
98 CD N
percent NN N
for IN N
the DT N
800-mg JJ N
dose NN N
of IN N
cefixime NN i
( ( N
86 CD N
of IN N
88 CD N
patients NNS N
) ) N
( ( N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
94.6 CD N
percent NN N
to TO N
100 CD N
percent NN N
) ) N
; : N
and CC N
98 CD N
percent NN N
for IN N
ceftriaxone NN i
( ( N
92 CD N
of IN N
94 CD N
patients NNS N
) ) N
( ( N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
94.9 CD N
to TO N
100 CD N
percent NN N
) ) N
. . N

The DT N
cure NN o
rates NNS o
were VBD N
similar JJ N
in IN N
men NNS N
and CC N
women NNS N
, , N
and CC N
pharyngeal JJ o
infection NN o
was VBD N
eradicated VBN N
in IN N
20 CD N
of IN N
22 CD N
patients NNS N
( ( N
91 CD N
percent NN N
) ) N
. . N

Thirty-nine JJ N
percent NN N
of IN N
303 CD N
pretreatment JJ N
gonococcal JJ N
isolates NNS N
had VBD N
one CD N
or CC N
more JJR N
types NNS N
of IN N
antimicrobial JJ N
resistance NN N
; : N
the DT N
efficacy NN o
of IN N
all DT N
three CD N
regimens NNS N
was VBD N
independent JJ N
of IN N
the DT N
resistance NN N
pattern NN N
. . N

Chlamydia NNP o
trachomatis NN o
infection NN o
persisted VBN N
in IN N
at IN N
least JJS N
half PDT N
the DT N
patients NNS N
infected VBN N
in IN N
each DT N
treatment NN N
group NN N
. . N

All DT N
three CD N
regimens NNS N
were VBD N
well RB N
tolerated VBN o
. . o

CONCLUSIONS NNP N
In IN N
the DT N
treatment NN N
of IN N
uncomplicated JJ o
gonorrhea NN o
, , N
a DT N
single JJ N
dose NN N
of IN N
cefixime NN i
( ( N
400 CD N
or CC N
800 CD N
mg NN N
) ) N
given VBN N
orally RB N
appears VBZ N
to TO N
be VB N
as RB N
effective JJ o
as IN N
the DT N
currently RB N
recommended VBN N
regimen NNS N
of IN N
ceftriaxone NN i
( ( N
250 CD N
mg NN N
given VBN N
intramuscularly RB N
) ) N
. . N

-DOCSTART- -350565- O O

Tinidazole NNP i
and CC i
metronidazole NN i
in IN N
hepatic JJ p
amoebiasis NN p
. . p

The DT N
efficacy NN N
of IN N
metronidazole NN i
and CC N
tinidazole NN i
has VBZ N
been VBN N
compared VBN N
in IN N
31 CD p
patients NNS p
with IN p
hepatic JJ p
amoebiasis NN p
. . p

Only RB p
those DT p
with IN p
unequivocal JJ p
clinical JJ p
, , p
radiological JJ p
and CC p
laboratory JJ p
evidence NN p
of IN p
hepatic JJ p
amoebiasis NN p
were VBD N
included VBN N
; : N
diagnostic JJ N
and CC N
therapeutic JJ N
aspiration NN N
was VBD N
performed VBN N
where WRB N
necessary JJ N
. . N

15 CD p
patients NNS p
received VBN p
metronidazole JJ i
and CC i
16 CD i
tinidazole NN i
, , p
in IN p
random JJ p
order NN p
. . p

The DT N
2 CD N
groups NNS N
were VBD N
comparable JJ N
. . N

Both DT N
drugs NNS N
were VBD N
given VBN N
orally RB N
in IN N
a DT N
single JJ N
daily JJ N
dose NN N
of IN N
2g CD N
for IN N
a DT N
minimum NN N
of IN N
3 CD N
days NNS N
, , N
with IN N
treatment NN N
extended VBN N
if IN N
considered VBN N
clinically RB N
advisable JJ N
. . N

12 CD N
of IN N
15 CD N
patients NNS N
( ( N
80 CD N
% NN N
) ) N
were VBD N
cured VBN o
with IN N
metronidazole JJ i
given VBN N
for IN N
an DT N
average JJ N
period NN N
of IN N
7 CD N
days NNS N
( ( N
range VB N
4 CD N
to TO N
14 CD N
days NNS N
) ) N
. . N

15 CD N
of IN N
16 CD N
patients NNS N
( ( N
93.8 CD N
% NN N
) ) N
given VBN N
tinidazole NNS i
were VBD N
cured VBN o
and CC N
the DT N
mean JJ o
duration NN o
of IN o
treatment NN o
was VBD N
4 CD N
days NNS N
( ( N
range VB N
3 CD N
to TO N
6 CD N
days NNS N
) ) N
. . N

There EX N
were VBD N
fewer JJR o
side-effects NNS o
with IN N
tinidazole NN i
. . i

In IN N
this DT N
study NN N
of IN N
hepatic JJ p
amoebiasis NN p
in IN p
Bangladesh NNP p
, , N
tinidazole NN N
was VBD N
found VBN N
to TO N
be VB N
superior JJ N
to TO N
metronidazole VB i
in IN N
overall JJ o
efficacy NN o
because IN N
a DT N
shorter JJR N
course NN N
of IN N
treatment NN N
was VBD N
necessary JJ N
and CC N
it PRP N
caused VBD N
fewer JJR N
side-effects NNS o
. . o

-DOCSTART- -9430799- O O

A DT N
carbohydrate NN i
meal NN i
attenuates VBZ N
the DT N
forearm NN N
vasoconstrictor NN N
response NN N
to TO N
lower VB N
body NN N
subatmospheric JJ N
pressure NN N
in IN N
healthy JJ p
young JJ p
adults NNS p
. . p

The DT N
cardiovascular NN N
( ( N
CV NNP N
) ) N
responses VBZ N
to TO N
meal VB i
ingestion NN i
and CC N
orthostasis NN N
are VBP N
well RB N
established VBN N
. . N

The DT N
effect NN N
of IN N
meal NN N
ingestion NN N
and CC N
meal JJ N
composition NN N
on IN N
the DT N
CV NNP N
responses NNS N
to TO N
orthostasis NNS N
are VBP N
unknown JJ N
. . N

The DT N
effect NN N
of IN N
high JJ i
carbohydrate NN i
( ( i
HC NNP i
) ) i
and CC i
high JJ i
fat NN i
( ( i
HF NNP i
) ) i
meal NN i
ingestion NN i
on IN N
the DT N
CV NNP N
responses NNS N
to TO N
simulated VBN N
orthostatic JJ N
stress NN N
( ( N
using VBG N
graded VBN N
lower JJR N
body NN N
subatmospheric JJ N
pressure NN N
( ( N
LBSP NNP N
) ) N
) ) N
was VBD N
assessed VBN N
in IN N
nine CD p
healthy JJ p
young JJ p
volunteers NNS p
. . p

Cardiac NNP o
output NN o
( ( o
CO NNP o
) ) o
, , o
forearm JJ o
blood NN o
flow NN o
( ( o
FABF NNP o
) ) o
heart NN o
rate NN o
( ( o
HR NNP o
) ) o
and CC o
blood NN o
pressure NN o
( ( o
BP NNP o
) ) o
were VBD N
measured VBN N
before IN N
and CC N
during IN N
LBSP NNP N
while IN N
fasted VBN N
and CC N
after IN N
eating VBG i
HC NNP i
and CC i
HF NNP i
meals NNS i
. . i

Ingestion NN N
of IN N
both DT N
meals NNS N
led VBD N
to TO N
an DT N
increase NN N
in IN N
CO NNP o
and CC o
HR NNP o
. . o

Both DT N
meals NNS N
resulted VBD N
in IN N
a DT N
fall NN N
in IN N
total JJ o
peripheral JJ o
resistance NN o
but CC N
only RB N
HC NNP N
led VBD N
to TO N
a DT N
significant JJ N
fall NN N
in IN N
BP NNP o
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

HF NNP N
had VBD N
no DT N
effect NN N
on IN N
the DT N
CV NNP N
responses NNS N
to TO N
LBSP NNP o
, , N
whereas IN N
HC NNP N
resulted VBD N
in IN N
attenuated JJ o
FABF NNP o
and CC o
forearm JJ o
vascular NN o
resistance NN o
responses NNS o
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Thus RB N
, , N
ingestion NN N
of IN N
an DT N
HC NNP i
meal NN i
significantly RB N
attenuates VBZ N
the DT N
forearm NN N
vascular NN N
response NN N
to TO N
orthostatic JJ N
stress NN N
and CC N
the DT N
hypotensive JJ N
effect NN N
of IN N
orthostasis NN N
is VBZ N
additive JJ N
to TO N
that DT N
occurring VBG N
after IN N
an DT N
HC NNP N
meal NN N
. . N

-DOCSTART- -23931247- O O

Ilioinguinal-iliohypogastric JJ N
nerve NN N
block NN N
within IN N
travenous JJ N
dexketoprofen NN i
improves VBZ N
postoperative JJ N
analgesia NN N
in IN N
abdominal JJ p
hysterectomies NNS p
. . p

BACKGROUND NNP N
AND NNP N
OBJECTIVE NNP N
In IN N
this DT N
study NN N
, , N
our PRP$ N
aim NN N
was VBD N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
intravenous JJ N
dexketoprofen NNS i
trometamol VBP i
with IN N
ilioinguinal JJ N
and CC N
iliohypogastric JJ N
nerve NN N
block NN N
on IN N
analgesic JJ N
quality NN N
and CC N
morphine NN N
consumption NN N
after IN N
total JJ p
abdominal JJ p
hysterectomy NN p
operations NNS p
. . p

METHODS NNP N
We PRP p
conducted VBD p
this DT p
randomized VBN p
controlled VBD p
clinical JJ p
study NN p
on IN p
61 CD p
patients NNS p
. . p

The DT p
study NN p
was VBD p
conducted VBN p
in IN p
the DT p
operation NN p
room NN p
, , p
post-anesthesia JJ p
care NN p
unit NN p
, , p
and CC p
inpatient JJ p
clinic NN p
. . p

We PRP N
randomly RB N
grouped VBD N
the DT N
61 CD p
patients NNS p
into IN p
control NN i
group NN i
( ( p
group NN p
C NNP p
) ) p
, , p
block NN i
group NN i
( ( p
group NN p
B NNP p
) ) p
and CC p
dexketoprofen-block JJ i
group NN i
( ( p
group NN p
DB NNP p
) ) p
. . N

Before IN N
the DT N
skin NN N
incision NN N
performed VBD N
after IN N
anesthesia JJ N
induction NN N
, , N
we PRP N
performed VBD N
ilioinguinal JJ i
iliohypogastric JJ i
block NN i
( ( N
group NN N
C NNP N
given VBN N
saline NN i
and CC N
group NN N
P NNP N
and CC N
DB NNP i
given VBN N
levobupivacaine NN i
) ) i
. . N

In IN N
contrast NN N
to TO N
group NN N
C NNP N
and CC N
B NNP N
, , N
group NN N
DB NNP N
was VBD N
given VBN N
dexketoprofen RB i
. . i

We PRP N
administered VBD N
morphine JJ i
analgesia NN i
to TO N
all DT N
patients NNS N
by IN N
patient-controlled JJ N
analgesia NN N
( ( N
PCA NNP N
) ) N
during IN N
the DT N
postoperative JJ N
24 CD N
hours NNS N
. . N

We PRP N
recorded VBD N
Visual NNP o
Analogue NNP o
Scale NNP o
( ( o
VAS NNP o
) ) o
, , o
satisfaction NN o
scores NNS o
, , o
morphine NN o
consumption NN o
and CC o
side NN o
effects NNS o
during IN N
postoperative JJ N
24 CD N
hours NNS N
. . N

RESULTS NNP N
We PRP N
found VBD N
the DT N
DB NNP N
group?s NN o
VAS NNP o
scores VBZ o
to TO o
be VB N
lower JJR N
than IN N
the DT N
control NN N
group NN N
and CC N
block NN N
group?s NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
values NNS N
at IN N
postoperative JJ N
1st CD N
, , N
2nd CD N
, , N
6th CD N
and CC N
12th CD N
hours NNS o
. . o

VAS NNP o
scores NNS o
of IN o
group NN N
C NNP N
were VBD N
higher JJR N
than IN N
of IN N
group NN N
B NNP N
at IN N
postoperative JJ N
fi NN N
rst VBD N
2 CD N
hours NNS N
. . N

Time NNP N
to TO N
fi VB N
rst JJ N
PCA NNP N
demand NN N
was VBD N
longer RBR o
, , o
morphine JJ o
consumption NN o
values NNS o
were VBD o
lower JJR N
and CC N
satisfaction NN o
scores NNS o
were VBD o
higher JJR N
in IN N
group NN N
DB NNP N
than IN N
in IN N
the DT N
other JJ N
two CD N
groups NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
Ilioinguinal-iliohypogastric JJ N
nerve NN N
block NN N
with IN N
IV NNP i
dexketoprofen NN i
increases NNS i
patient JJ N
satisfaction NN N
by IN N
decreasing VBG N
opioid JJ N
consumption NN N
, , N
increasing VBG N
patient JJ N
satisfaction NN N
, , N
which WDT N
suggests VBZ N
that IN N
dexketoprofen NN N
trometamol NN N
is VBZ N
an DT N
effective JJ N
non-steroidal JJ N
anti-inflammatory JJ N
analgesic NN N
in IN N
postoperative JJ N
analgesia NN N
. . N

-DOCSTART- -9023640- O O

Effects NNS N
of IN N
omeprazole NN i
and CC N
amoxycillin NN i
on IN N
the DT N
human JJ N
oral JJ N
and CC N
gastrointestinal JJ N
microflora NNS N
in IN N
patients NNS p
with IN p
Helicobacter NNP p
pylori JJ p
infection NN p
. . p

Fourteen JJ p
patients NNS p
with IN p
Helicobacter NNP p
pylori FW p
infection NN p
were VBD N
treated VBN N
with IN N
omeprazole JJ i
capsules NNS N
20 CD N
mg NNS N
and CC N
amoxycillin NN i
capsules NNS N
1000 CD N
mg JJ N
twice RB N
daily RB N
for IN N
14 CD N
days NNS N
and CC N
14 CD N
patients NNS N
with IN N
omeprazole JJ i
capsules NNS N
20 CD N
mg NNS N
and CC N
placebo VB i
twice RB N
daily RB N
for IN N
14 CD N
days NNS N
. . N

Samples NNS N
from IN N
saliva NN N
, , N
dental JJ N
plaque NN N
and CC N
faeces NNS N
and CC N
biopsies NNS N
from IN N
antrum NN N
and CC N
corpus NN N
were VBD N
analysed VBN N
in IN N
order NN N
to TO N
determine VB N
the DT N
ecological JJ N
changes NNS N
in IN N
the DT N
normal JJ N
microflora NN N
. . N

Several JJ N
microorganisms NNS N
were VBD N
affected VBN N
by IN N
both DT N
treatment NN N
regimens NNS N
. . N

Two CD N
patients NNS N
were VBD N
colonised VBN N
with IN N
enterobacteria NNS N
in IN N
the DT N
oral JJ N
cavity NN N
and CC N
stomach NN N
during IN N
the DT N
omeprazole JJ i
plus CC i
amoxycillin JJ i
treatment NN N
. . N

A DT N
general JJ o
increase NN o
in IN o
the DT o
number NN o
of IN o
microorganisms NNS o
from IN o
gastric JJ o
mucosa NN o
was VBD N
observed VBN N
in IN N
both DT N
treatment NN N
groups NNS N
. . N

A DT N
selection NN o
of IN o
resistant JJ o
enterobacteria NN o
and CC N
an DT N
increase NN o
in IN o
beta-lactamase JJ o
production NN o
was VBD N
observed VBN N
in IN N
the DT N
faecal JJ N
samples NNS N
during IN N
the DT N
omeprazole JJ i
plus CC i
amoxycillin JJ i
treatment NN N
. . N

Eradication NN o
of IN o
H. NNP o
pylori NN o
in IN o
the DT o
omeprazole-amoxycillin JJ o
group NN o
was VBD N
50 CD N
% NN N
and CC N
in IN N
the DT N
omeprazole JJ i
placebo NN i
group NN N
0 CD N
% NN N
four CD N
weeks NNS N
after IN N
treatment NN N
. . N

No DT o
viable JJ o
H. NNP o
pylori NN o
were VBD N
cultivated VBN N
in IN N
the DT N
saliva NN o
, , o
dental JJ o
plaque NN o
or CC o
faecal JJ o
samples NNS o
. . o

Treatment NN N
with IN N
omeprazole JJ i
20 CD N
mg NN N
and CC N
amoxycillin NN i
1000 CD N
mg NN N
twice RB N
daily RB N
for IN N
14 CD N
days NNS N
altered VBD N
the DT N
normal JJ N
microflora NN N
in IN N
the DT N
oral JJ N
, , N
gastric JJ N
and CC N
intestinal JJ N
tract NN N
and CC N
antibiotic JJ N
resistant JJ N
microorganisms NNS N
increased VBD N
in IN N
numbers NNS N
in IN N
the DT N
intestinal JJ o
microflora NN o
. . o

-DOCSTART- -3447334- O O

A DT N
prospective JJ N
, , N
randomized JJ N
study NN N
of IN N
5-fluorouracil JJ i
and CC i
filtration NN i
surgery NN i
. . i

Our PRP$ N
study NN N
shows VBZ N
that IN N
use NN N
of IN N
a DT N
small JJ N
dose NN N
of IN N
subconjunctival JJ i
5-FU JJ i
provides VBZ N
significantly RB N
lower JJR N
postoperative JJ o
intraocular JJ o
pressure NN o
than IN N
does VBZ N
no DT i
antimetabolite JJ i
treatment NN i
. . N

Morphology NNP N
of IN N
the DT N
postoperative JJ p
blebs NN p
suggests VBZ N
that IN N
increased VBD N
filtration NN N
results NNS N
in IN N
lower JJR N
intraocular JJ o
pressure NN o
in IN N
the DT N
5-FU JJ i
group NN p
. . p

Corneal NNP o
epithelial JJ o
defects NNS o
were VBD N
as IN N
common JJ N
with IN N
a DT N
low JJ N
dose NN N
as IN N
with IN N
higher JJR N
doses NNS N
previously RB N
described VBN N
. . N

-DOCSTART- -6337497- O O

A DT N
dose-response JJ N
study NN N
of IN N
the DT N
effect NN N
of IN N
levobunolol NN i
on IN N
ocular JJ o
hypertension NN o
. . o

We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
double-masked JJ N
, , N
dose-response JJ N
study NN N
of IN N
the DT N
ocular JJ o
hypotensive JJ o
effect NN o
of IN N
the DT N
beta-adrenergic JJ N
blocker NN N
, , N
levobunolol NN N
. . N

A DT N
single JJ N
drop NN N
of IN N
placebo NN i
or CC i
levobunolol NN i
( ( N
at IN N
concentrations NNS N
of IN N
0.03 CD N
% NN N
, , N
0.3 CD N
% NN N
, , N
0.6 CD N
% NN N
, , N
1 CD N
% NN N
, , N
and CC N
2 CD N
% NN N
) ) N
was VBD N
administered VBN N
to TO N
one CD p
eye NN p
of IN p
each DT p
of IN p
48 CD p
patients NNS p
with IN p
ocular JJ p
hypertension NN p
. . p

The DT N
0.3 CD N
% NN N
and CC N
0.6 CD N
% NN N
concentrations NNS N
decreased VBD N
intraocular JJ o
pressure NN o
significantly RB N
from IN N
baseline NN N
levels NNS N
compared VBN N
to TO N
placebo VB N
at IN N
one CD N
, , N
two CD N
, , N
and CC N
four CD N
hours NNS N
after IN N
treatment NN N
. . N

The DT N
1 CD N
% NN N
and CC N
2 CD N
% NN N
concentrations NNS N
decreased VBD N
intraocular JJ o
pressure NN o
significantly RB o
from IN N
baseline NN N
compared VBN N
to TO N
placebo VB N
at IN N
one CD N
, , N
two CD N
, , N
four CD N
, , N
six CD N
, , N
eight CD N
, , N
and CC N
12 CD N
hours NNS N
after IN N
administration NN N
. . N

No DT N
objective JJ o
or CC o
subjective JJ o
side NN o
effects NNS o
were VBD N
noted VBN N
, , N
and CC N
no DT N
substantial JJ o
changes NNS o
in IN o
visual JJ o
acuity NN o
, , o
pupil NN o
diameter NN o
, , o
pulse JJ o
rate NN o
, , o
or CC o
blood NN o
pressure NN o
were VBD N
recorded VBN N
during IN N
the DT N
study NN N
. . N

These DT N
results NNS N
appear VBP N
to TO N
justify VB N
long-term JJ N
studies NNS N
of IN N
levobunolol NN i
for IN N
the DT N
treatment NN N
of IN N
increased JJ N
intraocular JJ o
pressure NN o
. . o

-DOCSTART- -20537413- O O

Comparing VBG N
the DT N
effectiveness NN o
of IN N
peer NN i
mentoring NN i
and CC N
student NN i
mentoring NN i
in IN N
a DT N
35-week JJ N
fitness NN N
program NN N
for IN N
older JJR p
adults NNS p
. . p

To TO N
investigate VB N
the DT N
applicability NN o
and CC N
effectiveness NN o
of IN N
a DT N
peer-mentored JJ i
exercise NN i
program NN i
, , N
this DT N
study NN N
compared VBN N
the DT N
retention NN o
and CC o
participation NN o
rates NNS o
, , N
and CC N
physical JJ o
improvements NNS o
of IN N
older JJR p
adults NNS p
trained VBN i
by IN i
peer NN i
mentors NNS i
( ( i
PM NNP i
) ) i
to TO i
a DT i
group NN i
trained VBN i
by IN i
young JJ i
qualified JJ i
student NN i
mentors NNS i
( ( i
SM NNP i
) ) i
. . i

A DT N
group NN N
of IN N
older JJR p
adults NNS p
were VBD N
prepared VBN N
as IN N
peer NN N
mentors NNS N
through IN N
a DT N
30-week JJ N
preparation NN N
program NN N
. . N

Later NNP N
, , N
60 CD p
older JJR p
adults NNS p
( ( p
mean VB p
? . p
SD NNP p
age NN p
: : p
68.7 CD p
? . p
6.1 CD p
years NNS p
) ) p
were VBD p
recruited VBN N
and CC N
randomly RB N
assigned VBN N
to TO N
either CC N
the DT N
PM NNP N
or CC N
SM NNP N
group NN N
. . N

Both DT N
groups NNS N
completed VBD N
an DT N
identical JJ N
35-week JJ N
fitness NN N
program NN N
. . N

Pre- NNP N
, , N
midterm- JJ N
and CC N
post-training JJ o
assessments NNS o
of IN o
fitness NN o
were VBD o
completed VBN N
and CC o
rates NNS o
of IN o
participation NN o
and CC o
retention NN o
were VBD o
documented VBN N
. . N

The DT N
same JJ N
retention NN N
rates NNS N
were VBD N
observed VBN N
in IN N
the DT N
two CD N
groups NNS N
, , N
but CC N
SM NNP N
group NN N
had VBD o
higher JJR o
participation NN o
. . o

Both DT N
groups NNS o
improved VBN o
significantly RB o
in IN o
all DT o
measures NNS o
of IN o
fitness NN o
and CC o
there EX N
were VBD N
no DT N
significant JJ N
post-test JJ N
differences NNS N
between IN N
the DT N
groups NNS N
in IN N
the DT N
fitness NN N
measures NNS N
. . N

Findings NNS N
suggest VBP N
that IN N
the DT N
peer NN N
mentor NN N
model NN N
is VBZ N
applicable JJ N
in IN N
an DT N
older JJR p
adult NN p
exercise NN p
program NN p
and CC p
may MD N
be VB N
as RB N
effective JJ N
as IN N
a DT N
program NN N
mentored VBN N
by IN N
young JJ N
professionals NNS N
. . N

-DOCSTART- -24408892- O O

A DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
the DT N
Korean JJ i
version NN i
of IN i
the DT i
PEERS NNP i
( ( i
? . i
) ) i
parent-assisted JJ i
social JJ i
skills NNS i
training VBG i
program NN i
for IN p
teens NNS p
with IN p
ASD NNP p
. . p

Impaired NNP N
social JJ N
functioning NN N
is VBZ N
a DT N
hallmark JJ N
feature NN N
of IN N
autism NN N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
, , N
often RB N
requiring VBG N
treatment NN N
throughout IN N
the DT N
life NN N
span NN N
. . N

PEERS NNS i
( ( i
? . i
) ) i
( ( i
Program NNP i
for IN i
the DT i
Education NNP i
and CC i
Enrichment NNP i
of IN i
Relational NNP i
Skills NNP i
) ) i
is VBZ i
a DT N
parent-assisted JJ p
social JJ p
skills NNS p
training VBG p
for IN p
teens NNS p
with IN p
ASD NNP p
. . p

Although IN N
PEERS NNP N
( ( N
? . N
) ) N
has VBZ N
an DT N
established VBN N
evidence NN N
base NN N
in IN N
improving VBG N
the DT N
social JJ N
skills NNS N
of IN N
adolescents NNS N
and CC N
young JJ N
adults NNS N
with IN N
ASD NNP N
in IN N
North NNP N
America NNP N
, , N
the DT N
efficacy NN N
of IN N
this DT N
treatment NN N
has VBZ N
yet RB N
to TO N
be VB N
established VBN N
in IN N
cross-cultural JJ N
validation NN N
trials NNS N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
examine VB N
the DT N
feasibility NN N
and CC N
treatment NN N
efficacy NN N
of IN N
a DT i
Korean JJ i
version NN i
of IN i
PEERS NNP i
( ( i
? . i
) ) i
for IN i
enhancing VBG N
social JJ N
skills NNS N
through IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
( ( N
RCT NNP N
) ) N
.The VBP N
English JJ N
version NN N
of IN N
the DT N
PEERS NNP i
( ( i
? . i
) ) i
Treatment NN i
Manual NNP N
( ( N
Laugeson NNP N
& CC N
Frankel NNP N
, , N
2010 CD N
) ) N
was VBD N
translated VBN N
into IN N
Korean NNP p
and CC p
reviewed VBN p
by IN p
21 CD p
child JJ p
mental JJ p
health NN p
professionals NNS p
. . p

Items NNP p
identified VBD N
as IN N
culturally RB N
sensitive JJ N
were VBD N
surveyed VBN p
by IN p
447 CD p
middle JJ p
school NN p
students NNS p
, , p
and CC p
material NN N
was VBD N
modified VBN N
accordingly RB p
. . p

Participants NNS p
included VBD p
47 CD p
teens NNS p
between IN p
12 CD p
and CC p
18 CD p
years NNS p
of IN p
age NN p
with IN p
a DT p
diagnosis NN p
of IN p
ASD NNP p
and CC p
a DT p
verbal JJ p
intelligence NN p
quotient NN p
( ( p
IQ NNP p
) ) p
? . p
65 CD p
. . N

Eligible JJ N
teens NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
treatment NN N
group NN N
( ( N
TG NNP N
) ) N
or CC N
delayed VBN i
treatment NN i
control NN i
group NN i
( ( N
CG NNP N
) ) N
. . N

Primary JJ N
outcome NN N
measures NNS N
included VBD N
questionnaires NNS N
and CC N
direct JJ N
observations NNS N
quantifying VBG N
social JJ N
ability NN N
and CC N
problems NNS N
directly RB N
related VBN N
to TO N
ASD NNP N
. . N

Secondary NNP N
outcome NN N
measures NNS N
included VBD N
scales NNS N
for IN N
depressive NN N
symptoms NNS N
, , N
anxiety NN N
, , N
and CC N
other JJ N
behavioral JJ N
problems NNS N
. . N

Rating VBG N
scales NNS N
for IN N
parental JJ N
depressive NN N
symptoms NNS N
and CC N
anxiety NN N
were VBD N
examined VBN N
to TO N
detect VB N
changes NNS N
in IN N
parental JJ N
psychosocial JJ N
functioning NN N
throughout IN N
the DT N
PEERS NNP N
( ( N
? . N
) ) N
treatment NN N
. . N

Independent JJ N
samples NNS N
t-tests NNS N
revealed VBD N
no DT o
significant JJ o
differences NNS o
at IN o
baseline NN o
across IN o
the DT o
TG NNP o
and CC o
CG NNP o
conditions NNS N
with IN N
regard NN N
to TO N
age NN N
( ( N
14.04 CD N
? . N
1.64 CD N
and CC N
13.54 CD N
? . N
1.50 CD N
years NNS N
) ) N
, , N
IQ NNP N
( ( N
99.39 CD N
? . N
18.09 CD N
& CC N
100.67 CD N
? . N
16.97 CD N
) ) N
, , N
parental JJ N
education NN N
, , N
socioeconomic JJ N
status NN N
, , N
or CC N
ASD NNP N
symptoms NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
, , N
respectively RB N
. . N

Results NNS N
for IN N
treatment NN N
outcome NN N
suggest VBP N
that IN N
the DT o
TG NNP o
showed VBD o
significant JJ o
improvement NN o
in IN o
communication NN o
and CC o
social JJ o
interaction NN o
domain NN o
scores NNS o
on IN o
the DT o
Autism NNP o
Diagnostic NNP o
Observation NNP o
Schedule NNP o
, , o
interpersonal JJ o
relationship NN o
and CC o
play/leisure NN o
time NN o
on IN o
the DT o
subdomain NN o
scores NNS o
of IN o
the DT o
Korean JJ o
version NN o
of IN o
the DT o
Vineland NNP o
Adaptive NNP o
Behavior NNP o
Scale NNP o
( ( o
p NN o
's POS o
< NNP o
0.01 CD o
) ) o
, , o
social JJ o
skills NNS o
knowledge VBP o
total JJ o
scores NNS o
on IN o
the DT o
Test NNP o
of IN o
Adolescent NNP o
Social NNP o
Skills NNP o
Knowledge-Revised JJ o
( ( o
p JJ o
< NNP o
0.01 CD o
) ) o
, , o
and CC o
decreased VBD o
depressive JJ o
symptoms NNS o
on IN o
the DT o
Child NNP o
Depression NNP o
Inventory NNP o
following VBG o
treatment NN o
( ( o
p JJ o
< NNP o
0.05 CD o
) ) o
. . o

Analyses NNS N
of IN N
parental JJ N
outcome NN N
reveal NN o
a DT o
significant JJ o
decrease NN o
in IN o
maternal JJ o
state NN o
anxiety NN o
in IN o
the DT o
TG NNP o
after IN o
controlling VBG N
for IN N
potential JJ N
confounding NN N
variables NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Despite IN N
cultural JJ N
and CC N
linguistic JJ N
differences NNS N
, , N
the DT N
PEERS NNP N
( ( N
? . N
) ) N
social JJ N
skills NNS N
intervention NN N
appears VBZ N
to TO N
be VB N
efficacious JJ o
for IN o
teens NNS o
with IN o
ASD NNP o
in IN o
Korea NNP p
with IN N
modest JJ N
cultural JJ N
adjustment NN N
. . N

In IN N
an DT N
RCT NNP N
, , N
participants NNS N
receiving VBG N
the DT N
PEERS NNP N
( ( N
? . N
) ) N
treatment NN N
showed VBD o
significant JJ o
improvement NN o
in IN o
social JJ o
skills NNS o
knowledge NN o
, , o
interpersonal JJ o
skills NNS o
, , o
and CC o
play/leisure NN o
skills NNS o
, , o
as RB o
well RB o
as IN o
a DT o
decrease NN o
in IN o
depressive JJ o
symptoms NNS o
and CC o
ASD NNP o
symptoms NNS o
. . o

This DT N
study NN N
represents VBZ N
one CD N
of IN N
only RB N
a DT N
few JJ N
cross-cultural JJ N
validation NN N
trials NNS N
of IN N
an DT N
established VBN N
evidence-based JJ N
treatment NN N
for IN N
adolescents NNS p
with IN p
ASD NNP p
. . p

-DOCSTART- -25560349- O O

Aloe NNP i
vera NN i
gel NN i
and CC N
cesarean NN o
wound NN o
healing NN o
; : o
a DT N
randomized VBN N
controlled JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
Failure NNP N
in IN N
complete JJ N
healing NN o
of IN N
the DT N
wound NN N
is VBZ N
one CD N
of IN N
the DT N
probable JJ N
complications NNS N
of IN N
cesarean NN N
. . N

The DT N
present JJ N
study NN N
aimed VBN N
to TO N
determine VB N
the DT N
effectiveness NN N
of IN N
dressing VBG N
with IN N
aloe JJ i
vera NN i
gel NN i
in IN N
healing NN o
of IN o
cesarean JJ o
wound NN o
. . o

METHODS NNP N
This DT N
prospective JJ N
randomized VBN N
double-blind JJ N
clinical JJ N
trial NN N
was VBD N
conducted VBN N
on IN N
90 CD p
women NNS p
who WP p
had VBD p
undergone JJ p
cesarean JJ p
operation NN p
in IN p
Amir-al-Momenin NNP p
hospital NN p
( ( p
Gerash NNP p
, , p
Iran NNP p
) ) p
. . p

The DT N
participants NNS p
were VBD p
randomly RB p
divided VBN p
into IN p
two CD p
groups NNS p
each DT p
containing VBG p
45 CD p
patients NNS p
. . p

In IN N
one CD N
group NN N
, , N
the DT N
wound NN N
was VBD N
dressed VBN i
with IN i
aloe JJ i
vera NN i
gel NN i
, , N
while IN N
simple JJ i
dressing NN i
was VBD N
used VBN N
in IN N
the DT N
control NN N
group NN N
. . N

Wound IN o
healing NN o
was VBD N
assessed VBN N
24 CD N
hours NNS N
and CC N
8 CD N
days NNS N
after IN N
the DT N
cesarean JJ N
operation NN N
using VBG N
REEDA NNP o
scale NN o
. . o

The DT N
data NNS N
were VBD N
analyzed VBN N
through IN N
Chi-square NNP N
and CC N
t-test JJ N
. . N

RESULTS VB N
The DT p
participants NNS p
' POS p
mean JJ p
age NN p
was VBD p
27.56?4.20 CD p
in IN p
the DT p
aloe NN p
vera NN p
group NN p
and CC p
26.62?4.88 CD p
in IN p
the DT p
control NN p
group NN p
, , p
but CC N
the DT N
difference NN N
was VBD N
not RB N
statistically RB N
significant JJ N
. . N

However RB N
, , N
a DT N
significant JJ N
difference NN N
was VBD N
found VBN N
between IN N
the DT N
two CD N
groups NNS N
concerning VBG o
body NN o
mass NN o
index NN o
, , o
heart NN o
rate NN o
, , o
and CC o
systolic JJ o
blood NN o
pressure NN o
( ( o
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Also RB N
, , N
a DT N
significant JJ N
difference NN N
was VBD N
observed VBN N
between IN N
the DT N
two CD N
groups NNS N
with IN N
respect NN N
to TO N
the DT o
wound NN o
healing VBG o
score RB o
24 CD o
hours NNS o
after IN o
the DT o
operation NN o
( ( o
P=0.003 NNP N
) ) N
. . N

After IN N
8 CD N
days NNS N
, , N
however RB N
, , N
the DT N
difference NN N
in IN N
the DT o
wound NN o
healing VBG o
score NN o
was VBD o
not RB N
significant JJ N
( ( N
P=0.283 NNP N
) ) N
. . N

Overall JJ N
, , N
45 CD N
participants NNS N
in IN N
the DT N
aloe NN N
vera NN N
group NN N
and CC N
35 CD N
ones NNS N
in IN N
the DT N
control NN N
group NN N
had VBD N
obtained VBN N
a DT N
zero CD N
score NN N
24 CD N
hours NNS N
after IN N
the DT N
operation NN N
. . N

These DT N
measures NNS N
were VBD N
respectively RB N
obtained VBN N
as IN N
42 CD N
and CC N
41eight CD N
days NNS N
after IN N
the DT N
operation NN N
. . N

CONCLUSION NNP N
According VBG N
to TO N
the DT N
findings NNS N
of IN N
this DT N
study NN N
, , N
the DT p
women NNS p
are VBP p
recommended VBN N
to TO N
be VB N
informed VBN N
regarding VBG N
the DT N
positive JJ o
effects NNS o
of IN o
dressing VBG N
with IN i
aloe JJ i
vera NN i
gel NN i
. . N

-DOCSTART- -12356631- O O

7-hexanoyltaxol-eluting JJ i
stent NN i
for IN N
prevention NN N
of IN N
neointimal JJ N
growth NN N
: : N
an DT N
intravascular JJ N
ultrasound NN N
analysis NN N
from IN N
the DT N
Study NNP N
to TO N
COmpare NNP N
REstenosis NNP N
rate NN N
between IN N
QueST NNP N
and CC N
QuaDS-QP2 NNP N
( ( N
SCORE NNP N
) ) N
. . N

BACKGROUND NNP N
Inhibition NNP N
of IN N
neointimal JJ N
tissue NN N
growth NN N
has VBZ N
been VBN N
demonstrated VBN N
in IN N
preliminary JJ N
human JJ N
feasibility NN N
studies NNS N
with IN N
a DT N
stent-based JJ i
polymer NN i
sleeve NN i
delivering VBG i
7-hexanoyltaxol JJ i
. . i

The DT N
Study NNP N
to TO N
COmpare NNP N
REstenosis NNP N
rate NN N
between IN N
QueST NNP N
and CC N
QuaDS-QP2 NNP N
( ( N
SCORE NNP N
) ) N
trial NN N
is VBZ N
a DT N
human JJ p
, , N
randomized VBN N
, , N
multicenter RBR N
trial NN N
comparing VBG N
7-hexanoyltaxol JJ i
( ( i
QP2 NNP i
) ) i
-eluting VBG i
stents NNS i
( ( i
qDES NN i
) ) i
with IN i
bare NN i
metal NN i
stents NNS i
( ( i
BMS NNP i
) ) i
in IN N
the DT N
treatment NN p
of IN p
de FW p
novo FW p
coronary JJ p
lesions NNS p
. . p

The DT N
purpose NN N
of IN N
this DT N
substudy NN N
was VBD N
to TO N
evaluate VB N
the DT N
acute JJ o
expansion NN o
property NN o
and CC o
long-term JJ o
neointimal JJ o
responses NNS o
of IN N
qDES NNS i
compared VBN N
with IN N
BMS NNP i
as IN N
assessed VBN N
by IN N
intravascular JJ N
ultrasound NN N
( ( N
IVUS NNP N
) ) N
. . N

METHODS NNP N
AND NNP N
RESULTS NNP N
A NNP p
total NN p
of IN p
122 CD p
( ( p
qDES JJ p
66 CD p
, , p
BMS NNP p
56 CD p
) ) p
patients NNS p
were VBD N
enrolled VBN N
into IN N
the DT N
IVUS NNP N
substudy NN N
. . N

All DT N
IVUS NNP N
images NNS N
( ( N
immediately RB N
after IN N
the DT N
procedure NN N
and CC N
at IN N
6-month JJ N
follow-up NN N
) ) N
were VBD N
analyzed VBN N
at IN N
an DT N
independent JJ N
core NN N
laboratory NN N
in IN N
a DT N
blind JJ N
manner NN N
. . N

At IN N
baseline NN N
, , N
qDES RB i
achieved VBN N
stent JJ o
expansion NN o
similar JJ N
to TO N
BMS NNP N
. . N

At IN N
follow-up JJ N
, , N
qDES NN i
showed VBD N
reduced VBN N
neointimal JJ o
growth NN o
by IN N
70 CD N
% NN N
at IN N
the DT N
tightest JJS N
cross NN N
section NN N
and CC N
by IN N
68 CD N
% NN N
over IN N
the DT N
stented VBN N
segment NN N
( ( N
P NNP N
< VBZ N
0.0001 CD N
for IN N
both DT N
) ) N
, , N
resulting VBG N
in IN N
a DT N
significantly RB N
larger JJR N
lumen NNS N
in IN N
qDES NN N
than IN N
in IN N
BMS NNP N
. . N

Unlike IN N
intracoronary JJ N
brachytherapy NN N
, , N
there EX N
was VBD N
no DT N
evidence NN N
of IN N
negative JJ o
edge NN o
effects NNS o
, , o
unhealed JJ o
dissections NNS o
, , o
or CC o
late RB o
stent-vessel JJ o
wall NN o
malapposition NN o
over IN N
the DT N
stented JJ N
and CC N
adjacent JJ N
references NNS N
segments NNS N
in IN N
either DT N
group NN N
. . N

CONCLUSIONS NNP N
Detailed NNP N
IVUS NNP N
analysis NN N
revealed VBD N
that IN N
qDES NN i
had VBD N
comparable JJ N
acute JJ N
mechanical NN N
and CC N
superior JJ N
long-term JJ N
biological JJ N
effects NNS N
to TO N
BMS NNP i
. . i

Although IN N
the DT N
long-term JJ N
benefits NNS N
and CC N
limitations NNS N
of IN N
this DT N
technology NN N
require VB N
further JJ N
investigation NN N
, , N
the DT N
reduction NN N
in IN N
neointimal JJ N
thickenings NNS N
demonstrated VBD N
that IN N
local JJ N
delivery NN N
of IN N
7-hexanoyltaxol NNP i
through IN N
polymer NN N
sleeves NNS N
augments NNS N
conventional JJ N
mechanical JJ N
treatment NN N
of IN N
atherosclerotic JJ p
disease NN p
. . p

-DOCSTART- -25622776- O O

Using VBG N
behavioral JJ N
economics NNS N
to TO N
predict VB N
opioid JJ N
use NN N
during IN p
prescription NN p
opioid JJ p
dependence NN p
treatment NN p
. . p

BACKGROUND NNP N
Research NNP N
grounded VBD N
in IN N
behavioral JJ N
economics NNS N
has VBZ N
previously RB N
linked VBN N
addictive JJ N
behavior NN N
to TO N
disrupted VBN N
decision-making NN N
and CC N
reward-processing NN N
, , N
but CC N
these DT N
principles NNS N
have VBP N
not RB N
been VBN N
examined VBN N
in IN N
prescription NN N
opioid JJ N
addiction NN N
, , N
which WDT N
is VBZ N
currently RB N
a DT N
major JJ N
public JJ N
health NN N
problem NN N
. . N

This DT N
study NN N
examined VBD N
whether IN N
pre-treatment JJ N
drug NN N
reinforcement NN N
value NN N
predicted VBD N
opioid JJ o
use NN o
during IN N
outpatient JJ p
treatment NN N
of IN N
prescription NN N
opioid JJ N
addiction NN N
. . N

METHODS NNP N
Secondary JJ N
analyses NNS N
examined VBD N
participants NNS p
with IN p
prescription NN p
opioid JJ p
dependence NN p
who WP p
received VBD p
12 CD p
weeks NNS p
of IN p
buprenorphine-naloxone NN i
and CC i
counseling NN i
in IN p
a DT p
multi-site JJ p
clinical JJ p
trial NN p
( ( p
N=353 NNP p
) ) p
. . p

Baseline NNP N
measures NNS N
assessed VBD N
opioid JJ o
source NN o
and CC N
indices NNS o
of IN o
drug NN o
reinforcement NN o
value NN o
, , N
including VBG N
the DT N
total JJ N
amount NN N
and CC N
proportion NN N
of IN N
income NN N
spent VBN N
on IN N
drugs NNS N
. . N

Weekly JJ o
urine JJ o
drug NN o
screens NNS o
measured VBN N
opioid JJ N
use NN N
. . N

RESULTS NNP N
Obtaining VBG N
opioids NNS N
from IN N
doctors NNS N
was VBD N
associated VBN N
with IN N
lower JJR N
pre-treatment JJ N
drug NN N
spending NN N
, , N
while IN N
obtaining VBG N
opioids NNS N
from IN N
dealers/patients NNS N
was VBD N
associated VBN N
with IN N
greater JJR N
spending NN N
. . N

Controlling VBG N
for IN N
demographics NNS N
, , N
opioid JJ N
use NN N
history NN N
, , N
and CC N
opioid JJ N
source NN N
frequency NN N
, , N
patients NNS N
who WP N
spent VBD N
a DT N
greater JJR N
total JJ N
amount NN N
( ( N
OR=1.30 NNP N
, , N
p NN N
< NNP N
.001 NNP N
) ) N
and CC N
a DT N
greater JJR N
proportion NN N
of IN N
their PRP$ N
income NN N
on IN N
drugs NNS N
( ( N
OR=1.31 NNP N
, , N
p NN N
< NNP N
.001 NNP N
) ) N
were VBD N
more RBR N
likely JJ N
to TO N
use VB N
opioids NNS N
during IN N
treatment NN N
. . N

CONCLUSIONS NNP N
Individual NNP N
differences NNS N
in IN N
drug NN N
reinforcement NN N
value NN N
, , N
as IN N
indicated VBN N
by IN N
pre-treatment JJ N
allocation NN N
of IN N
economic JJ N
resources NNS N
to TO N
drugs NNS N
, , N
reflects VBZ N
propensity NN N
for IN N
continued JJ N
opioid JJ N
use NN N
during IN N
treatment NN N
among IN N
individuals NNS p
with IN p
prescription NN p
opioid JJ p
addiction NN p
. . p

Future JJ N
studies NNS N
should MD N
examine VB N
disrupted VBN o
decision-making JJ o
and CC N
reward-processing JJ o
in IN N
prescription NN N
opioid NN N
users NNS N
more RBR N
directly RB N
and CC N
test VB N
whether IN N
reinforcer NN N
pathology NN N
can MD N
be VB N
remediated VBN N
in IN N
this DT N
population NN N
. . N

-DOCSTART- -18629569- O O

Effects NNS N
of IN N
a DT N
long-term JJ N
vitamin NN i
D NNP i
and CC N
calcium NN i
supplementation NN i
on IN N
falls NNS o
and CC o
parameters NNS o
of IN o
muscle NN o
function NN o
in IN N
community-dwelling JJ p
older NN p
individuals NNS p
. . p

UNLABELLED NN N
In IN N
242 CD p
community-dwelling JJ p
seniors NNS p
, , N
supplementation NN N
with IN N
either DT N
1000 CD N
mg NN N
of IN N
calcium NN i
or CC N
1000 CD N
mg NN N
of IN N
calcium NN i
plus CC i
vitamin NN i
D NNP i
resulted VBD N
in IN N
a DT N
decrease NN N
in IN N
the DT N
number NN N
of IN N
subjects NNS N
with IN N
first JJ N
falls NNS N
of IN N
27 CD N
% NN N
at IN N
month NN N
12 CD N
and CC N
39 CD N
% NN N
at IN N
month NN N
20 CD N
. . N

Additionally RB N
, , N
parameters NNS N
of IN N
muscle NN o
function NN o
improved VBD N
significantly RB N
. . N

INTRODUCTION NNP N
The DT N
efficacy NN N
of IN N
vitamin NN i
D NNP i
and CC N
calcium NN i
supplementation NN N
on IN N
risk NN o
of IN o
falling VBG o
in IN N
the DT N
elderly JJ N
is VBZ N
discussed VBN N
controversially RB N
. . N

Randomized NNP N
controlled VBD N
trials NNS N
using VBG N
falls NNS N
as IN N
primary JJ N
outcome NN N
are VBP N
needed VBN N
. . N

We PRP N
investigated VBD N
long-term JJ N
effects NNS N
of IN N
calcium NN i
and CC N
vitamin NN i
D NNP i
on IN N
falls NNS o
and CC o
parameters NNS o
of IN o
muscle NN o
function NN o
in IN N
community-dwelling JJ p
elderly JJ p
women NNS p
and CC p
men NNS p
. . p

METHODS NNP N
Our PRP$ N
study NN N
population NN N
consisted VBD N
of IN N
242 CD p
individuals NNS p
recruited VBN p
by IN p
advertisements NNS p
and CC p
mailing VBG p
lists NNS p
( ( p
mean JJ p
[ NNP p
+/- NN p
SD NNP p
] NNP p
age NN p
, , p
77 CD p
+/- JJ p
4 CD p
years NNS p
) ) p
. . p

All DT p
serum JJ p
25-hydroxyvitamin JJ p
D NNP p
( ( p
25 CD p
[ NNP p
OH NNP p
] NNP p
D NNP p
) ) p
levels NNS p
were VBD p
below IN p
78 CD p
nmol/l NN p
. . p

Individuals NNS N
received VBD N
in IN N
a DT N
double JJ N
blinded JJ N
fashion NN N
either DT N
1000 CD N
mg NN N
of IN N
calcium NN i
or CC N
1000 CD N
mg NN N
of IN N
calcium NN i
plus CC N
800 CD N
IU NNP N
of IN N
vitamin NNP i
D NNP i
per IN N
day NN N
over IN N
a DT N
treatment NN N
period NN N
of IN N
12 CD N
months NNS N
, , N
which WDT N
was VBD N
followed VBN N
by IN N
a DT N
treatment-free JJ N
but CC N
still RB N
blinded VBD N
observation JJ N
period NN N
of IN N
8 CD N
months NNS N
. . N

Falls NNP o
were VBD N
documented VBN N
using VBG N
diaries NNS N
. . N

The DT p
study NN p
took VBD p
place NN p
in IN p
Bad NNP p
Pyrmont NNP p
, , p
Germany NNP p
( ( p
latitude VBP p
52 CD p
degrees NNS p
) ) p
and CC p
Graz NNP p
, , p
Austria NNP p
( ( p
latitude VBP p
46 CD p
degrees NNS p
) ) p
. . p

RESULTS $ N
Compared VBD N
to TO N
calcium VB N
mono NN N
, , N
supplementation NN N
with IN N
calcium NN N
plus CC N
vitamin NN i
D NNP i
resulted VBD N
in IN N
a DT N
significant JJ N
decrease NN N
in IN N
the DT N
number NN N
of IN N
subjects NNS o
with IN o
first JJ o
falls NNS o
of IN N
27 CD N
% NN N
at IN N
month NN N
12 CD N
( ( N
RR NNP N
= NNP N
0.73 CD N
; : N
CI NNP N
= NNP N
0.54-0.96 NN N
) ) N
and CC N
39 CD N
% NN N
at IN N
month NN N
20 CD N
( ( N
RR NNP N
= NNP N
0.61 CD N
; : N
CI NNP N
= NNP N
0.34-0.76 NN N
) ) N
. . N

Concerning VBG N
secondary JJ N
endpoints NNS N
, , N
we PRP N
observed VBD N
significant JJ N
improvements NNS o
in IN o
quadriceps JJ o
strength NN o
of IN N
8 CD N
% NN N
, , N
a DT N
decrease NN N
in IN N
body NN o
sway NN o
of IN N
28 CD N
% NN N
, , N
and CC N
a DT N
decrease NN N
in IN N
time NN o
needed VBN o
to TO o
perform VB o
the DT o
TUG NNP o
test NN o
of IN N
11 CD N
% NN N
. . N

DISCUSSION NNP N
Combined NNP N
calcium NN i
and CC N
vitamin NN i
D NNP i
supplementation NN N
proved VBD N
superior JJ N
to TO N
calcium VB N
alone RB N
in IN N
reducing VBG N
the DT N
number NN o
of IN o
falls NNS o
and CC N
improving VBG N
muscle NN o
function NN o
in IN N
community-dwelling JJ p
older NN p
individuals NNS p
. . p

-DOCSTART- -16822100- O O

Randomized NNP N
comparison NN N
of IN N
two CD i
communication NN i
interventions NNS i
for IN N
preschoolers NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

This DT N
randomized JJ N
group NN N
experiment NN N
compared VBN N
the DT N
efficacy NN N
of IN N
2 CD i
communication NN i
interventions NNS i
( ( i
Responsive JJ i
Education NN i
and CC i
Prelinguistic NNP i
Milieu NNP i
Teaching NNP i
[ NNP i
RPMT NNP i
] NNP i
and CC i
the DT i
Picture NNP i
Exchange NNP i
Communication NNP i
System NNP i
[ NNP i
PECS NNP i
] NNP i
) ) i
in IN N
36 CD p
preschoolers NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

Each DT N
treatment NN N
was VBD N
delivered VBN N
3 CD N
times NNS N
per IN N
week NN N
, , N
in IN N
20-min JJ N
sessions NNS N
, , N
for IN N
6 CD N
months NNS N
. . N

The DT N
results NNS N
revealed VBD N
that IN N
the DT N
RPMT NNP i
facilitated VBD N
the DT N
frequency NN o
of IN o
generalized JJ o
turn NN o
taking VBG o
and CC o
generalized VBN o
initiating NN o
joint JJ o
attention NN o
more RBR N
than IN N
did VBD N
the DT N
PECS NNP N
. . N

The DT N
latter JJ N
effect NN N
occurred VBD N
only RB N
for IN N
children NNS N
who WP N
began VBD N
treatment NN N
with IN N
at IN N
least JJS N
some DT N
initiating VBG o
joint JJ o
attention NN o
. . o

In IN N
contrast NN N
, , N
the DT N
PECS NNP i
facilitated VBD N
generalized JJ o
requests NNS o
more RBR N
than IN N
the DT N
RPMT NNP N
in IN N
children NNS N
with IN N
very RB N
little JJ N
initiating VBG o
joint JJ o
attention NN o
prior RB N
to TO N
treatment NN N
. . N

These DT N
effect NN o
sizes NNS o
were VBD N
large JJ o
. . o

-DOCSTART- -24431427- O O

Multisensory JJ i
temporal JJ i
integration NN i
in IN N
autism NN p
spectrum NN p
disorders NNS p
. . p

The DT N
new JJ N
DSM-5 NNP i
diagnostic JJ N
criteria NNS N
for IN N
autism NN N
spectrum NN N
disorders NNS N
( ( N
ASDs NNP N
) ) N
include VBP N
sensory JJ N
disturbances NNS N
in IN N
addition NN N
to TO N
the DT N
well-established JJ N
language NN N
, , N
communication NN N
, , N
and CC N
social JJ N
deficits NNS N
. . N

One CD N
sensory NN N
disturbance NN N
seen VBN N
in IN N
ASD NNP N
is VBZ N
an DT N
impaired JJ N
ability NN N
to TO N
integrate VB N
multisensory JJ N
information NN N
into IN N
a DT N
unified JJ N
percept NN N
. . N

This DT N
may MD N
arise VB N
from IN N
an DT N
underlying JJ N
impairment NN N
in IN N
which WDT N
individuals NNS p
with IN p
ASD NNP p
have VBP N
difficulty NN N
perceiving VBG N
the DT N
temporal JJ N
relationship NN N
between IN N
cross-modal JJ N
inputs NNS N
, , N
an DT N
important JJ N
cue NN N
for IN N
multisensory JJ N
integration NN N
. . N

Such JJ N
impairments NNS N
in IN N
multisensory NN N
processing NN N
may MD N
cascade VB N
into IN N
higher-level JJ N
deficits NNS N
, , N
impairing VBG N
day-to-day JJ N
functioning NN N
on IN N
tasks NNS N
, , N
such JJ N
as IN N
speech JJ N
perception NN N
. . N

To TO N
investigate VB N
multisensory JJ N
temporal JJ N
processing VBG N
deficits NNS N
in IN N
ASD NNP N
and CC N
their PRP$ N
links NNS N
to TO N
speech VB N
processing NN N
, , N
the DT N
current JJ N
study NN N
mapped VBD N
performance NN N
on IN N
a DT N
number NN N
of IN N
multisensory JJ i
temporal JJ i
tasks NNS i
( ( i
with IN i
both DT i
simple JJ i
and CC i
complex JJ i
stimuli NN i
) ) i
onto IN N
the DT N
ability NN N
of IN N
individuals NNS p
with IN p
ASD NNP p
to TO N
perceptually RB N
bind VB N
audiovisual JJ N
speech NN N
signals NNS N
. . N

High-functioning JJ p
children NNS p
with IN p
ASD NNP p
were VBD N
compared VBN N
with IN N
a DT p
group NN p
of IN p
typically RB p
developing VBG p
children NNS p
. . p

Performance NN N
on IN N
the DT N
multisensory JJ i
temporal JJ i
tasks NNS i
varied VBN N
with IN N
stimulus JJ N
complexity NN N
for IN N
both DT N
groups NNS N
; : N
less CC N
precise JJ N
temporal JJ o
processing NN o
was VBD N
observed VBN N
with IN N
increasing VBG N
stimulus JJ N
complexity NN N
. . N

Notably RB N
, , N
individuals NNS p
with IN p
ASD NNP p
showed VBD N
a DT N
speech-specific JJ o
deficit NN o
in IN o
multisensory JJ o
temporal JJ o
processing NN o
. . o

Most JJS N
importantly RB N
, , N
the DT N
strength NN o
of IN o
perceptual JJ o
binding NN o
of IN o
audiovisual JJ o
speech NN o
observed VBN N
in IN N
individuals NNS p
with IN p
ASD NNP p
was VBD N
strongly RB N
related VBN N
to TO N
their PRP$ N
low-level JJ N
multisensory JJ N
temporal JJ N
processing NN N
abilities NNS N
. . N

Collectively RB N
, , N
the DT N
results NNS N
represent VBP N
the DT N
first JJ N
to TO N
illustrate VB N
links NNS N
between IN N
multisensory JJ N
temporal JJ N
function NN N
and CC N
speech NN N
processing NN N
in IN N
ASD NNP N
, , N
strongly RB N
suggesting VBG N
that IN N
deficits NNS N
in IN N
low-level JJ N
sensory JJ N
processing NN N
may MD N
cascade VB N
into IN N
higher-order NN N
domains NNS N
, , N
such JJ N
as IN N
language NN o
and CC o
communication NN o
. . o

-DOCSTART- -1725537- O O

Role NNP N
of IN N
diltiazem NN i
in IN N
the DT N
treatment NN N
of IN N
silent JJ N
myocardial JJ N
ischemia NN N
. . N

Silent JJ N
myocardial JJ N
ischemia NN N
is VBZ N
a DT N
frequent JJ N
finding NN N
when WRB N
Holter NNP N
monitoring NN N
is VBZ N
done VBN N
in IN N
patients NNS p
with IN p
advanced JJ p
coronary JJ p
disease NN p
. . p

Silent JJ N
ischemia NN N
is VBZ N
associated VBN N
with IN N
a DT N
worse JJR N
prognosis NN N
in IN N
patients NNS N
with IN N
stable JJ N
or CC N
unstable JJ N
angina NN N
, , N
survivors NNS N
of IN N
myocardial JJ N
infarction NN N
, , N
and CC N
populations NNS N
at IN N
risk NN N
for IN N
coronary JJ N
disease NN N
. . N

Whether NNP N
medical JJ N
therapy NN N
for IN N
silent JJ N
ischemia NN N
improves VBZ N
prognosis NN N
is VBZ N
not RB N
known VBN N
. . N

In IN N
a DT N
randomized JJ N
, , N
placebo-controlled JJ i
, , N
multicenter JJ N
trial NN N
of IN N
60 CD p
patients NNS p
with IN p
documented JJ p
coronary JJ p
disease NN p
, , p
positive JJ p
exercise NN p
tests NNS p
, , p
and CC p
ischemic JJ p
episodes NNS p
on IN p
Holter NNP p
monitoring NN p
, , N
long-acting JJ N
diltiazem NN i
reduced VBD N
ischemic JJ o
episodes NNS o
by IN N
50 CD N
% NN N
compared VBN N
to TO N
placebo VB i
, , N
from IN N
a DT N
mean NN N
of IN N
5.6 CD N
to TO N
2.8 CD N
( ( N
p NN N
less JJR N
than IN N
0.0001 CD N
) ) N
. . N

Efficacy NN o
was VBD N
maintained VBN N
over IN N
24 CD N
h NNS N
and CC N
diltiazem NN i
also RB N
significantly RB N
improved VBN N
exercise NN o
test NN o
parameters NNS o
. . o

Three CD N
smaller JJR N
studies NNS N
also RB N
demonstrated VBD N
that IN N
diltiazem NN i
effectively RB N
reduces VBZ N
ambulatory JJ o
ischemia NN o
; : o
however RB N
, , N
results NNS N
with IN N
nifedipine JJ N
are VBP N
conflicting VBG N
, , N
with IN N
several JJ N
studies NNS N
showing VBG N
no DT N
benefit NN N
. . N

In IN N
contrast NN N
, , N
beta-blockers NNS N
reliably RB N
reduce VB N
ischemic JJ o
episodes NNS o
. . o

The DT N
role NN N
of IN N
medical JJ N
therapy NN N
for IN N
silent JJ N
ischemia NN N
will MD N
be VB N
clarified VBN N
only RB N
when WRB N
its PRP$ N
effect NN N
upon IN N
morbidity NN N
and CC N
mortality NN N
are VBP N
determined VBN N
. . N

-DOCSTART- -26068086- O O

Improvement NN N
in IN N
Patient-Reported NNP p
Visual NNP p
Function NNP p
After IN p
Ocriplasmin NNP i
for IN p
Vitreomacular NNP p
Adhesion NNP p
: : p
Results NNS N
of IN N
the DT N
Microplasmin NNP i
for IN i
Intravitreous NNP i
Injection-Traction NNP i
Release NNP N
Without NNP N
Surgical NNP N
Treatment NNP N
( ( N
MIVI-TRUST NNP N
) ) N
Trials NNPS N
. . N

IMPORTANCE VB N
The DT N
impact NN N
of IN N
vitreomacular JJ i
adhesion NN i
( ( i
VMA NNP i
) ) i
resolution NN N
on IN N
patient-reported JJ p
visual JJ p
function NN p
in IN p
symptomatic JJ p
VMA/vitreomacular NNP p
traction NN p
( ( p
VMT NNP p
) ) p
has VBZ N
not RB N
yet RB N
been VBN N
documented VBN N
, , N
to TO N
our PRP$ N
knowledge NN N
. . N

OBJECTIVE UH N
To TO N
determine VB N
the DT N
impact NN N
of IN N
intravitreal JJ i
ocriplasmin NNS i
on IN N
patient-reported JJ N
visual JJ o
function NN o
using VBG N
the DT N
25-item JJ N
National NNP N
Eye NNP N
Institute NNP N
Visual NNP N
Function NNP N
Questionnaire NNP N
( ( i
NEI NNP i
VFQ-25 NNP i
) ) i
during IN N
a DT N
6-month JJ N
follow-up NN N
in IN N
patients NNS p
with IN p
symptomatic JJ p
VMA NNP p
. . p

DESIGN NNP N
, , N
SETTING NNP N
, , N
AND NNP N
PARTICIPANTS NNP N
Two CD N
multicenter NN N
, , N
randomized VBN N
, , N
masked VBN N
, , N
phase VB N
3 CD N
clinical JJ N
trials NNS N
( ( N
studies NNS N
TG-MV-006 NNP N
[ NN N
between IN N
December NNP N
2008 CD N
and CC N
April NNP N
2010 CD N
] NNP N
and CC N
TG-MV-007 NNP N
[ NNP N
between IN N
December NNP N
2008 CD N
and CC N
July NNP N
2010 CD N
] NN N
) ) N
at IN N
clinic-based JJ N
centers NNS N
in IN N
the DT N
United NNP N
States NNPS N
and CC N
Europe NNP N
. . N

A NNP p
total NN p
of IN p
652 CD p
patients NNS p
with IN p
symptomatic JJ p
VMA/VMT NNP p
, , p
including VBG p
when WRB p
associated VBN p
with IN p
a DT p
macular JJ p
hole NN p
400 CD p
?m NN p
or CC p
smaller JJR p
, , p
were VBD N
studied VBN N
. . N

Analysis NN N
was VBD N
by IN N
intent-to-treat JJ N
population NN N
and CC N
performed VBN N
in IN N
May NNP N
2013 CD N
. . N

INTERVENTIONS JJ p
Patients NNS p
with IN p
symptomatic JJ p
VMA/VMT NNP p
were VBD N
randomly RB N
assigned VBN N
( ( N
2:1 CD N
or CC N
3:1 CD N
in IN N
study NN N
TG-MV-006 NNP N
and CC N
study VB N
TG-MV-007 NNP N
, , N
respectively RB N
) ) N
to TO N
receive VB N
a DT N
single JJ N
intravitreal NN N
injection NN N
of IN i
ocriplasmin NN i
, , i
125 CD N
?g NN N
, , N
or CC N
placebo-injected JJ i
vehicle NN i
( ( i
placebo NN i
) ) i
. . i

The DT i
NEI NNP i
VFQ-25 NNP i
was VBD i
administered VBN N
at IN N
baseline NN N
and CC N
6 CD N
months NNS N
following VBG i
ocriplasmin JJ i
injection NN i
. . N

MAIN NNP N
OUTCOMES NNP N
AND NNP N
MEASURES NNP o
Mean NNP o
changes NNS o
between IN o
baseline NN o
and CC o
6-month JJ o
follow-up JJ o
NEI NNP o
VFQ-25 NNP o
composite JJ o
and CC o
subscale JJ o
scores NNS o
and CC o
the DT o
proportion NN o
of IN o
patients NNS o
with IN o
a DT o
clinically RB o
meaningful JJ o
change NN o
( ( o
?5 JJ o
points NNS o
) ) o
in IN o
scores NNS o
. . o

RESULTS NNP o
Across IN N
the DT N
2 CD N
studies NNS p
, , p
464 CD p
patients NNS p
received VBN i
ocriplasmin JJ i
and CC i
188 CD p
received VBD i
placebo NN i
. . i

At IN i
6 CD N
months NNS N
, , N
the DT N
ocriplasmin NN N
group NN N
reported VBD N
greater JJR o
mean JJ o
improvements NNS o
from IN o
baseline NN o
in IN o
the DT N
NEI NNP o
VFQ-25 NNP o
composite JJ o
score NN o
than IN o
the DT N
placebo NN i
group NN i
( ( N
mean JJ N
change NN N
, , N
3.4 CD N
vs NN N
0.7 CD N
, , N
respectively RB N
; : N
P NNP N
= NNP N
.005 NNP N
) ) N
. . N

Improvements NNS N
were VBD N
also RB N
noted VBN N
in IN N
subscale JJ o
scores NNS o
, , o
with IN N
the DT N
following VBG N
respective JJ N
mean JJ N
changes NNS N
for IN N
the DT N
ocriplasmin NN i
vs NN i
placebo NN i
groups NNS N
: : N
vision-related JJ N
dependency NN N
, , N
1.7 CD N
vs NN N
-2.1 NNP N
( ( N
P NNP N
= NNP N
.009 NNP N
) ) N
; : N
driving VBG N
difficulty NN N
, , N
2.7 CD N
vs NN N
-1.5 NNP N
( ( N
P NNP N
= NNP N
.03 NNP N
) ) N
; : N
distance NN N
vision NN N
activities NNS N
, , N
4.1 CD N
vs NN N
0.8 CD N
( ( N
P NNP N
= NNP N
.03 NNP N
) ) N
; : N
and CC N
general JJ N
vision NN N
, , N
6.1 CD N
vs NN N
2.1 CD N
( ( N
P NNP N
= NNP N
.003 NNP N
) ) N
. . N

A DT N
higher JJR N
proportion NN N
of IN N
the DT N
ocriplasmin NN i
group NN i
had VBD N
a DT N
clinically RB N
meaningful JJ N
( ( N
?5-point JJ N
) ) N
improvement NN N
in IN o
NEI NNP o
VFQ-25 NNP o
composite JJ o
score NN o
from IN o
baseline NN N
than IN N
the DT N
placebo NN N
group NN N
( ( N
36.0 CD N
% NN N
vs JJ N
27.2 CD N
% NN N
, , N
respectively RB N
; : N
P NNP N
= NNP N
.03 NNP N
) ) N
. . N

Fewer JJR i
ocriplasmin-treated JJ i
patients NNS i
had VBD N
a DT N
clinically RB N
meaningful JJ N
worsening VBG N
in IN N
their PRP$ N
visual JJ o
function NN o
than IN o
the DT N
placebo NN i
group NN i
( ( N
15.0 CD N
% NN N
vs JJ N
24.3 CD N
% NN N
, , N
respectively RB N
; : N
P NNP N
= NNP N
.005 NNP N
) ) N
. . N

Changes NNS o
in IN o
NEI NNP o
VFQ-25 NNP o
composite JJ o
score NN o
and CC o
various JJ o
subscale JJ o
scores NNS o
were VBD N
observed VBN i
in IN i
ocriplasmin-treated JJ i
patients NNS N
who WP N
achieved VBD N
VMA NNP N
resolution NN N
at IN N
day NN N
28 CD N
. . N

CONCLUSIONS NNP N
AND CC N
RELEVANCE NNP N
Ocriplasmin NNP i
produces VBZ i
clinically RB N
meaningful JJ N
improvement NN N
in IN N
patient-reported JJ N
visual JJ N
function NN N
in IN p
symptomatic JJ p
VMA/VMT NNP p
. . p

TRIAL NNP N
REGISTRATION NNP N
clinicaltrials.gov NN N
Identifiers NNS N
: : N
NCT00781859 NNP N
and CC N
NCT00798317 NNP N
. . N

-DOCSTART- -1573044- O O

Comparative JJ N
drug NN p
effects NNS p
and CC p
abuse NN p
liability NN p
of IN N
lorazepam NN i
, , i
buspirone NN i
, , i
and CC i
secobarbital NN i
in IN p
nondependent JJ p
subjects NNS p
. . p

The DT N
pharmacologic JJ N
effects NNS N
of IN N
lorazepam NN i
( ( N
2 CD N
mg NN N
) ) N
, , N
buspirone NN i
( ( N
20 CD N
mg NN N
, , N
10 CD N
mg NN N
) ) N
, , N
secobarbital JJ i
( ( N
100 CD N
mg NN N
) ) N
, , N
and CC i
placebo NN i
were VBD N
compared VBN N
in IN N
15 CD p
male NN p
, , p
experienced VBD p
, , p
intermittent JJ p
nontherapeutic JJ p
drug NN p
users NNS p
. . p

All DT N
drugs NNS N
produced VBD N
a DT N
drug NN N
effect NN N
, , N
however RB N
, , N
buspirone RB i
20 CD i
mg NN N
was VBD N
significantly RB N
less JJR N
liked JJ N
than IN N
were VBD N
lorazepam JJ i
, , i
secobarbital JJ i
, , i
or CC i
buspirone RB i
10 CD i
mg NN i
( ( N
p NN N
less JJR N
than IN N
.05 NN N
) ) N
but CC N
not RB N
placebo VB i
. . i

Lorazepam NNP i
was VBD N
liked VBN N
better RBR N
than IN N
were VBD N
other JJ N
drugs NNS N
only RB N
at IN N
1 CD N
hour NN N
and CC N
only RB N
compared VBN N
with IN N
buspirone NN i
20 CD N
and CC N
placebo NN i
. . i

Compared VBN N
with IN N
other JJ N
drugs NNS N
, , N
lorazepam JJ i
drug NN o
effects NNS o
were VBD N
greater JJR o
and CC N
resulted VBD N
in IN N
more RBR N
prolonged JJ o
impairment NN o
of IN N
a DT N
motor NN o
tracking VBG o
task NN o
, , o
standing VBG o
steadiness NN o
, , o
and CC o
memory NN o
. . o

Buspirone CD i
20 CD N
mg NNS N
significantly RB o
impaired JJ o
memory NN o
at IN N
1 CD N
hour NN N
compared VBN N
with IN N
placebo NN i
. . i

Subjects NNS N
were VBD N
more RBR N
likely JJ N
to TO N
identify VB N
buspirone NN i
as IN N
unfamiliar JJ o
. . o

Because IN N
buspirone NN i
20 CD N
mg NN N
was VBD N
less JJR N
liked JJ N
than IN N
were VBD N
other JJ N
drugs NNS N
, , N
dose JJ N
escalation NN N
as IN N
part NN N
of IN N
drug NN o
abuse NN o
is VBZ N
not RB N
likely JJ N
to TO N
occur VB N
. . N

Lorazepam NNP i
also RB N
was VBD N
not RB o
particularly RB o
liked VBN o
and CC N
was VBD N
not RB o
different JJ o
from IN N
placebo NN i
on IN N
most JJS o
subjective JJ o
abuse-relevant JJ o
measures NNS o
. . o

-DOCSTART- -19729979- O O

Weekly JJ N
docetaxel NN i
with IN N
or CC N
without IN N
gemcitabine JJ i
as IN N
second-line JJ i
chemotherapy NN i
in IN N
paclitaxel-pretreated JJ i
patients NNS p
with IN p
metastatic JJ p
breast NN p
cancer NN p
: : p
a DT N
randomized JJ N
phase NN N
II NNP N
study NN N
conducted VBN N
by IN N
the DT N
Hellenic NNP N
Co-Operative NNP N
Oncology NNP N
Group NNP N
. . N

OBJECTIVE CC N
A DT N
randomized JJ N
phase NN N
II NNP N
trial NN N
was VBD N
conducted VBN N
to TO N
test VB N
whether IN N
the DT N
addition NN N
of IN N
gemcitabine NN i
to TO N
weekly VB N
docetaxel NN i
could MD N
improve VB N
the DT N
objective JJ o
response NN o
rate NN o
and CC o
survival NN o
outcomes NNS o
as IN N
second-line JJ N
chemotherapy NN N
in IN N
patients NNS p
with IN p
metastatic JJ p
breast NN p
cancer NN p
who WP p
have VBP p
failed VBN p
a DT p
paclitaxel-containing JJ i
regimen NN p
. . p

METHODS JJ N
Patients NNPS N
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
weekly JJ N
docetaxel NN i
40 CD i
mg/m NN i
( ( i
2 CD i
) ) i
( ( N
group NN N
A NNP N
, , N
n JJ N
= NNP N
34 CD N
) ) N
or CC N
the DT N
combination NN N
of IN N
weekly JJ N
docetaxel NN i
35 CD i
mg/m NN i
( ( i
2 CD i
) ) i
with IN i
gemcitabine NN i
600 CD N
mg/m NN N
( ( N
2 CD N
) ) N
( ( N
group NN N
B NNP N
, , N
n JJ N
= NNP N
41 CD N
) ) N
. . N

Three CD N
consecutive JJ N
weekly JJ N
infusions NNS N
followed VBN N
by IN N
a DT N
1-week JJ N
rest NN N
period NN N
represented VBD N
1 CD N
chemotherapy NN i
cycle NN N
. . N

RESULTS VB N
The DT N
objective JJ o
response NN o
rate NN o
was VBD N
18 CD N
% NN N
and CC N
27.5 CD N
% NN N
in IN N
group NN N
A NNP N
and CC N
B NNP N
, , N
respectively RB N
( ( N
p JJ N
= NNP N
0.413 CD N
) ) N
. . N

No DT N
statistically RB N
significant JJ N
differences NNS N
were VBD N
demonstrated VBN N
in IN N
terms NNS N
of IN N
median JJ o
overall JJ o
survival NN o
and CC o
time NN o
to TO o
disease VB o
progression NN o
. . o

The DT N
rate NN o
and CC o
grade NN o
3 CD o
and CC o
4 CD o
neutropenia NNS o
were VBD N
higher JJR N
in IN N
group NN N
B NNP N
( ( N
23 CD N
vs. FW N
3 CD N
% NN N
) ) N
. . N

CONCLUSIONS VB N
The DT N
weekly JJ N
administration NN N
of IN N
docetaxel NN i
and CC N
gemcitabine NN i
did VBD N
not RB N
result VB N
in IN N
superior JJ N
clinical JJ o
outcomes NNS o
over IN N
weekly JJ N
docetaxel NN N
. . N

-DOCSTART- -18540211- O O

Use NNP N
of IN N
topical JJ N
selamectin NN i
for IN N
the DT N
treatment NN N
of IN N
Syphacia NNP p
muris NNP p
infection NN p
in IN p
laboratory NN p
rats NNS p
. . p

Efficacy NN o
of IN N
selamectin NN i
was VBD N
studied VBN N
in IN N
naturally RB p
acquired VBN p
S. NNP p
muris JJ p
infections NNS p
in IN N
rats NNS p
. . p

Fourty-eight JJ p
S. NNP p
muris-positive JJ p
rats NNS p
were VBD N
divided VBN N
into IN N
six CD N
treated JJ N
and CC N
two CD N
control NN N
groups NNS N
. . N

Selamectin NNP i
( ( N
6 CD N
mg/kg NN N
) ) N
was VBD N
applied VBN N
topically RB N
to TO N
the DT N
skin NN N
in IN N
a DT N
single JJ N
spot NN N
at IN N
the DT N
base NN N
of IN N
the DT N
neck NN N
in IN N
the DT N
treatment NN N
group NN N
. . N

The DT N
rats NNS N
of IN N
treated JJ N
and CC N
control NN N
groups NNS N
were VBD N
necropsied VBN N
on IN N
the DT N
24th CD N
day NN N
after IN N
the DT N
treatment NN N
. . N

Topical NNP N
selamectin NN i
was VBD N
found VBN N
to TO N
be VB N
40.7-63.3 JJ N
% NN N
effective JJ o
( ( o
based VBN o
on IN o
egg NN o
per IN o
gram NN o
method NN o
) ) o
in IN o
eliminating VBG o
S. NNP o
muris JJ o
infection NN o
in IN N
rats NNS N
. . N

The DT N
efficacy NN o
of IN o
the DT o
treatment NN o
against IN N
S. NNP N
muris NNP N
( ( N
based VBN N
on IN N
adult NN N
worm NN N
counts NNS N
) ) N
in IN N
male NN p
and CC p
female JJ p
rats NNS p
was VBD N
35.14-58.88 JJ N
% NN N
, , N
respectively RB N
( ( N
mean JJ N
48.39 CD N
% NN N
) ) N
. . N

-DOCSTART- -10410152- O O

[ JJ N
Efficacy NNP N
of IN N
combination NN N
with IN N
granisetron NN i
and CC i
methylprednisolone NN i
for IN N
nausea NN o
, , o
vomiting VBG o
and CC o
appetite JJ o
loss NN o
in IN p
remission NN p
induction NN p
chemotherapy NN p
of IN p
acute JJ p
myeloid NN p
leukemia NN p
-- : p
a DT p
randomized JJ N
comparative JJ N
trial NN N
between IN N
granisetron NN i
alone RB i
and CC i
granisetron JJ i
plus CC i
methylprednisolone JJ i
] NN i
. . N

The DT N
prevention NN N
of IN N
nausea NN o
, , o
vomiting VBG o
and CC o
appetite JJ o
loss NN o
induced VBN N
by IN N
remission NN N
induction NN N
chemotherapy NN N
for IN N
acute JJ p
myeloid NN p
leukemia NN p
was VBD N
compared VBN N
by IN N
randomization NN N
between IN N
granisetron NN i
alone RB i
and CC p
combination NN p
with IN p
granisetron NN i
plus CC i
methylprednisolone NN i
. . i

Granisetron NNP i
was VBD N
administered VBN N
at IN N
40 CD i
micrograms/kg NN i
during IN i
chemotherapy NN i
, , i
and CC i
methylprednisolone NN i
was VBD N
administered VBN N
concomitantly RB N
at IN N
125 CD N
mg/body NN N
for IN N
3 CD N
days NNS N
or CC N
more JJR N
in IN N
the DT N
combination NN p
group NN p
. . p

The DT p
single JJ p
and CC p
combination NN p
groups NNS p
comprised VBD p
14 CD p
and CC p
13 CD p
patients NNS p
, , p
respectively RB p
, , p
and CC p
there EX p
was VBD p
no DT p
significant JJ p
difference NN p
between IN p
the DT p
background NN p
of IN p
both DT p
groups NNS p
. . p

To TO N
evaluate VB N
the DT N
effect NN N
they PRP N
were VBD N
scored VBN N
according VBG N
to TO N
4 CD N
grades NNS N
, , N
and CC N
evaluated VBD N
every DT N
24 CD N
hours NNS N
from IN N
the DT N
start NN N
of IN N
chemotherapy NN N
to TO N
5 CD N
days NNS N
after IN N
its PRP$ N
completion NN N
. . N

The DT N
complete JJ o
inhibition NN o
rate NN o
of IN o
vomiting VBG o
was VBD N
as RB N
high JJ N
as IN N
71.4 CD N
% NN N
and CC N
92.3 CD N
% NN N
in IN N
the DT N
single JJ N
and CC N
combination NN N
groups NNS N
, , N
respectively RB N
, , N
showing VBG N
no DT N
significant JJ N
difference NN N
. . N

The DT N
grade NN o
of IN o
vomiting VBG o
was VBD N
mild VBN N
in IN N
both DT N
groups NNS N
. . N

Nausea NN o
was VBD N
noted VBN N
in IN N
71.4 CD N
% NN N
and CC N
46.2 CD N
% NN N
, , N
respectively RB N
, , N
and CC N
the DT N
inhibitory JJ N
effect NN N
tended VBD N
to TO N
be VB N
higher JJR N
in IN N
the DT N
combination NN N
group NN N
. . N

Appetite NNP o
loss NN o
developed VBD N
in IN N
92.9 CD N
% NN N
and CC N
41.7 CD N
% NN N
, , N
respectively RB N
, , N
and CC N
the DT N
prevention NN N
effect NN N
was VBD N
clearly RB N
higher JJR N
in IN N
the DT N
combination NN N
group NN N
. . N

The DT N
prevention NN N
effects NNS N
on IN N
nausea NN o
7 CD N
, , N
8 CD N
and CC N
10 CD N
days NNS N
after IN N
the DT N
start NN N
of IN N
chemotherapy NN N
, , N
on IN o
appetite JJ o
loss NN o
2-10 JJ N
days NNS N
after IN N
it PRP N
, , N
and CC N
2-5 JJ N
days NNS N
after IN N
its PRP$ N
completion NN N
, , N
were VBD N
higher JJR N
in IN N
the DT N
combination NN N
group NN N
. . N

Granisetron NNP i
revealed VBD N
an DT N
excellent JJ N
inhibitory NN o
effect NN o
on IN o
vomiting VBG o
induced VBN N
by IN N
remission NN N
induction NN N
chemotherapy NN N
for IN N
acute JJ N
myeloid NN N
leukemia NN N
, , N
but CC N
combination NN N
with IN N
granisetron NN i
and CC i
methylprednisolone NN i
was VBD N
considered VBN N
useful JJ N
for IN N
nausea NN o
in IN N
the DT N
latter JJ N
half NN N
of IN N
the DT N
treatment NN N
period NN N
and CC N
for IN N
appetite JJ o
loss NN o
during IN N
the DT N
whole JJ N
period NN N
. . N

-DOCSTART- -1997878- O O

Sinemet NNP i
CR NNP i
in IN p
Parkinson NNP p
's POS p
disease NN p
. . p

Sinemet NNP i
CR NNP i
, , N
a DT N
controlled JJ N
release NN N
carbidopa/levodopa NN i
preparation NN i
, , N
was VBD N
compared VBN N
to TO N
conventional JJ N
carbidopa/levodopa NN i
in IN N
a DT N
double JJ N
blind NN N
, , N
placebo-controlled JJ i
trial NN N
. . N

Comparable JJ o
clinical JJ o
benefits NNS o
and CC o
adverse JJ o
effects NNS o
were VBD N
noted VBN N
with IN N
the DT N
two CD N
medications NNS N
. . N

However RB N
significantly RB N
less RBR N
frequent JJ N
dosing NN N
was VBD N
necessary JJ N
with IN N
Sinemet NNP N
CR NNP N
. . N

-DOCSTART- -12974687- O O

Abrasive JJ o
wear NN o
on IN N
eroded JJ p
root NN p
dentine NN p
after IN N
different JJ N
periods NNS N
of IN N
exposure NN N
to TO N
saliva VB i
in IN N
situ NN N
. . N

The DT N
effect NN N
of IN N
salivary JJ i
exposure NN N
time NN N
on IN N
the DT N
abrasive JJ o
wear NN o
of IN N
acid-eroded JJ p
dentine NN p
was VBD N
evaluated VBN N
in IN N
situ NN N
. . N

One-hundred JJ p
and CC p
twenty JJ p
bovine NN p
root NN p
dentine NN p
slabs NN p
were VBD N
randomly RB N
assigned VBN N
into IN N
six CD N
groups NNS N
( ( N
A-F NNP N
) ) N
and CC N
placed VBN N
in IN N
intraoral JJ N
palatal JJ N
devices NNS N
, , N
which WDT N
were VBD N
worn VBN N
by IN N
10 CD p
volunteers NNS p
for IN N
4 CD N
d. NN N
On IN N
the DT N
first JJ N
day NN N
, , N
no DT N
erosive/abrasive JJ N
procedures NNS N
were VBD N
carried VBN N
out RP N
. . N

On IN N
the DT N
following VBG N
3 CD N
d NN N
, , N
erosive JJ i
challenges NNS i
were VBD N
performed VBN N
extraorally RB N
, , N
two CD N
times NNS N
per IN N
day NN N
, , N
by IN N
immersing VBG N
the DT N
device NN N
for IN N
90 CD N
s NN N
in IN N
a DT N
soft JJ N
drink NN N
. . N

Subsequently RB N
, , N
the DT N
group NN N
A DT N
specimens NNS N
were VBD N
immediately RB N
brushed VBN N
( ( N
40 CD N
strokes NNS N
) ) N
, , N
and CC N
the DT N
others NNS N
were VBD N
brushed VBN N
after IN N
the DT N
following JJ N
times NNS N
: : N
B NNP N
, , N
20 CD N
min NN N
; : N
C NNP N
, , N
40 CD N
min NN N
; : N
and CC N
D NNP N
, , N
60 CD N
min NN N
. . N

Group NNP N
E NNP N
specimens NNS N
were VBD N
only RB N
acid-eroded JJ N
and CC N
those DT N
of IN N
group NN N
F NNP N
were VBD N
only RB N
brushed VBN N
. . N

Dentine NNP o
wear NN o
was VBD N
measured VBN N
with IN N
a DT N
profilometer NN N
. . N

anova NN N
and CC N
Dunnett NNP N
's POS N
test NN N
showed VBD N
that IN N
groups NNS N
A-D NNP N
did VBD N
not RB N
differ VB N
statistically RB N
from IN N
the DT N
control NN N
group NN N
E NNP N
but CC N
differed VBD N
from IN N
the DT N
control NN N
group NN N
F. NNP N
The DT N
lowest JJS N
mean JJ N
value NN N
was VBD N
found VBN N
for IN N
group NN N
F. NNP N
Regression NNP N
analysis NN N
was VBD N
unable JJ N
to TO N
show VB N
salivary JJ i
effect NN N
on IN N
dentine NN o
wear NN o
reduction NN o
. . o

The DT N
data NN N
suggest NN N
that IN N
the DT N
exposure NN N
time NN N
of IN N
saliva NN N
of IN N
up IN N
to TO N
60 CD N
min NN N
has VBZ N
no DT N
effect NN N
on IN N
reducing VBG N
the DT N
eroded JJ o
dentine NN o
wear NN o
by IN N
toothbrushing VBG N
. . N

-DOCSTART- -14589718- O O

Fake NNP p
bad JJ p
test NN p
response NN p
bias NN p
effects NNS p
on IN N
the DT N
test NN o
of IN o
variables NNS o
of IN o
attention NN o
. . o

This DT N
study NN N
investigated VBD N
the DT N
effects NNS N
of IN N
faking VBG i
bad JJ i
( ( i
FB NNP i
) ) i
on IN i
the DT i
Test NNP i
of IN i
Variables NNP i
of IN i
Attention NNP i
( ( i
TOVA NNP i
) ) i
using VBG p
subjects NNS p
randomly RB N
placed VBN N
into IN N
two CD N
groups NNS N
. . N

Subjects NNS N
in IN N
Group NNP N
1 CD N
took VBD N
the DT N
TOVA NNP i
under IN i
normal JJ i
conditions NNS i
( ( i
NC NNP i
) ) i
first RB N
; : N
they PRP N
were VBD N
then RB N
requested VBN N
to TO N
subtly RB i
fake VB i
bad JJ i
. . i

Group NNP N
2 CD N
subjects NNS N
took VBD N
the DT N
TOVA NNP i
under IN i
the DT i
same JJ i
fake JJ i
bad JJ i
instructions NNS i
first RB i
, , i
then RB i
took VBD i
the DT i
test NN i
under IN i
normal JJ i
conditions NNS i
the DT i
second JJ i
time NN i
. . i

An DT N
analysis NN N
of IN N
the DT N
effects NNS N
of IN N
test NN N
order NN N
yielded VBN N
non-significant JJ N
differences NNS N
for IN N
basic JJ N
TOVA NNP o
variables NNS o
across IN N
all DT N
four CD N
quarters NNS N
, , N
both DT N
halves NNS N
and CC N
the DT N
total JJ N
score NN N
. . N

An DT N
analysis NN N
for IN N
group NN N
mean NN N
differences NNS N
between IN N
the DT N
NC NNP N
and CC N
the DT N
FB NNP N
instructions NNS N
yielded VBD N
significant JJ N
differences NNS N
across IN N
the DT N
basic JJ o
TOVA NNP o
variables NNS o
across IN N
the DT N
four CD N
quarters NNS N
, , N
two CD N
halves NNS N
and CC N
total JJ N
score NN N
. . N

The DT N
FB NNP N
group NN N
had VBD N
excessive JJ N
amounts NNS o
of IN o
omission NN o
and CC o
commission NN o
errors NNS o
, , N
a DT N
greater JJR N
response NN o
time NN o
mean NN o
( ( N
i.e. FW N
, , N
slower JJR N
to TO N
respond VB N
) ) N
and CC N
had VBD N
greater JJR N
variance NN o
around IN o
their PRP$ o
mean JJ o
response NN o
time NN o
. . o

The DT N
study NN N
affirms VBZ N
that IN N
the DT N
professional JJ N
using VBG N
the DT N
TOVA NNP N
needs VBZ N
to TO N
carefully RB N
eliminate VB N
a DT N
fake JJ N
bad JJ N
test-taking NN N
bias NN N
when WRB N
subjects NNS N
produce VBP N
excessive JJ N
test NN N
results NNS N
. . N

-DOCSTART- -15165532- O O

Mouth NNP N
closing NN N
device NN N
( ( N
chinstrap NN N
) ) N
reduces VBZ N
mouth JJ o
leak NN o
during IN N
nasal JJ p
CPAP NNP p
. . p

BACKGROUND NNP N
AND CC N
PURPOSE NNP N
Mouth NNP N
leak VBP N
occasionally RB N
complicates VBZ N
continuous JJ N
positive JJ N
airway NN N
pressure NN N
( ( p
CPAP NNP p
) ) p
therapy NN p
, , N
which WDT N
leads VBZ N
to TO N
discomfort VB N
. . N

While IN N
a DT N
chinstrap NN N
prevents VBZ N
the DT N
mouth NN N
from IN N
opening VBG N
during IN N
sleep NN N
, , N
its PRP$ N
efficacy NN N
in IN N
diminishing VBG N
mouth NN N
leak NN N
has VBZ N
not RB N
been VBN N
studied VBN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Fifteen NNP p
patients NNS p
with IN p
mouth JJ p
leak JJ p
complaining NN p
of IN p
mouth NN p
dryness NN p
and CC p
nasal JJ p
obstruction NN p
underwent JJ N
two CD i
consecutive JJ i
overnight JJ i
polysomnographies NNS i
, , i
one CD i
with IN i
a DT i
chinstrap NN i
, , i
in IN i
random JJ i
order NN i
. . i

Cephalometry NN o
with IN i
and CC i
without IN i
a DT i
chinstrap NN i
was VBD N
randomly RB N
performed VBN N
on IN N
six CD p
patients NNS p
. . p

RESULTS NNP N
With IN N
the DT N
chinstrap NN N
, , N
both DT N
mouth FW o
leak NN o
and CC o
the DT o
arousal NN o
index NN o
decreased VBD N
significantly RB N
, , N
from IN N
( ( N
mean+/-SD JJ N
) ) N
42.9+/-23.5 CD N
to TO N
23.8+/-13.3 CD N
% NN N
of IN N
total JJ o
sleep JJ o
time NN o
( ( N
TST NNP N
) ) N
, , N
and CC N
from IN N
33.4+/-18.6 JJ N
to TO N
23.6+/-9.3/sleep JJ N
hour NN N
, , N
respectively RB N
. . N

However RB N
, , N
snoring VBG o
time NN o
showed VBD N
a DT N
concomitant JJ N
increase NN N
from IN N
6.7+/-14.3 JJ N
to TO N
24.0+/-13.2 CD N
% NN N
of IN N
TST NNP N
. . N

The DT N
arousal JJ o
index NN o
was VBD N
significantly RB N
higher JJR N
during IN N
leak JJR N
periods NNS N
, , N
and CC N
its PRP$ N
changes NNS N
correlated VBN N
positively RB N
with IN N
changes NNS N
in IN N
mouth NN o
leak NN o
. . o

Cephalometric JJ o
measures NNS o
showed VBD N
a DT N
significant JJ N
decrease NN N
in IN N
anterior JJ o
lower JJR o
facial JJ o
height NN o
. . o

CONCLUSIONS VB N
The DT N
chinstrap NN N
, , N
by IN N
closing VBG N
the DT N
mouth NN N
during IN N
CPAP NNP N
, , N
reduces VBZ N
mouth JJ N
leak NN N
and CC N
therefore RB N
the DT N
arousal NN N
index NN N
in IN N
most JJS N
patients NNS N
. . N

Nevertheless NNP N
, , N
the DT N
indices NNS N
remained VBD N
unacceptably RB N
high JJ N
. . N

The DT N
chinstrap NN N
may MD N
also RB N
increase VB N
snoring NN N
and CC N
, , N
in IN N
rare JJ N
cases NNS N
, , N
can MD N
worsen VB N
the DT N
respiratory NN N
disturbance NN N
index NN N
. . N

Consideration NN N
of IN N
these DT N
potential JJ N
effects NNS N
is VBZ N
important JJ N
before IN N
instituting VBG N
regular JJ N
home NN N
use NN N
of IN N
the DT N
chinstrap NN N
. . N

-DOCSTART- -15274670- O O

Effect NN N
of IN N
the DT N
motilin NN N
agonist NN N
KC NNP i
11458 CD i
on IN N
gastric JJ N
emptying VBG N
in IN N
diabetic JJ N
gastroparesis NN N
. . N

BACKGROUND NNP N
KC NNP i
11458 CD i
, , N
a DT N
motilin JJ N
agonist NN N
without IN N
antibiotic JJ N
properties NNS N
, , N
accelerates VBZ N
gastric JJ N
emptying VBG N
in IN N
animals NNS p
and CC p
healthy JJ p
humans NNS p
. . p

AIM NNP N
To TO N
evaluate VB N
the DT N
acute JJ N
effects NNS N
of IN N
KC NNP i
11458 CD i
on IN N
gastric JJ N
emptying VBG N
in IN N
diabetic JJ N
gastroparesis NN N
. . N

METHODS NNP N
Twenty-nine JJ p
patients NNS p
( ( p
6 CD p
type NN p
1 CD p
and CC p
23 CD p
type NN p
2 CD p
) ) p
with IN p
gastroparesis NN p
underwent JJ N
assessments NNS N
of IN N
: : N
( ( N
i NN N
) ) N
gastric NN o
emptying NN o
of IN N
a DT N
solid/liquid JJ N
meal NN N
using VBG N
scintigraphy NN N
, , N
( ( N
ii NN N
) ) N
glycaemic FW N
control NN N
( ( N
blood NN N
glucose NN N
at IN N
0 CD N
, , N
30 CD N
, , N
60 CD N
, , N
90 CD N
and CC N
120 CD N
min NN N
during IN N
the DT N
gastric JJ N
emptying VBG N
measurement NN N
) ) N
and CC N
( ( N
iii NN N
) ) N
upper IN N
gastrointestinal JJ N
and CC N
'meal-related JJ N
' '' N
symptoms NNS N
( ( N
questionnaire NN N
) ) N
, , N
at IN p
baseline NN p
and CC p
after IN p
treatment NN p
with IN p
KC NNP i
11458 CD i
in IN p
a DT p
dose NN p
of IN p
8 CD p
mg NNS p
t.d.s. NN p
, , N
or CC i
placebo NN i
for IN p
8 CD p
days NNS p
. . p

RESULTS NNP N
KC NNP i
11458 CD i
had VBD N
no DT N
statistically RB N
significant JJ N
or CC N
clinically RB N
relevant JJ N
effect NN N
on IN N
gastric JJ o
emptying NN o
of IN N
either CC N
the DT N
solid JJ N
intragastric JJ N
retention NN N
at IN N
100 CD N
min NN N
( ( N
T100 NNP N
) ) N
( ( N
P NNP N
= NNP N
0.87 CD N
) ) N
or CC N
liquid $ N
50 CD N
% NN N
emptying JJ N
time NN N
( ( N
T50 NNP N
) ) N
( ( N
P NNP N
= NNP N
0.17 CD N
) ) N
components NNS N
of IN N
the DT N
meal NN N
. . N

KC NNP i
11458 CD i
slightly RB N
worsened VBN N
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
upper JJ o
gastrointestinal NN o
symptoms NNS o
when WRB N
compared VBN N
with IN N
placebo NN i
. . i

The DT N
magnitude NN N
of IN N
the DT N
change NN N
in IN N
solid JJ o
gastric JJ o
emptying VBG o
correlated VBN N
with IN N
the DT N
change NN N
in IN N
the DT N
blood NN o
glucose JJ o
concentration NN o
( ( N
r JJ N
= VBZ N
0.49 CD N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
KC NNP i
11458 CD i
, , N
in IN N
a DT N
dose NN N
of IN N
8 CD N
mg NN N
t.d.s NN N
. . N

for IN N
8 CD N
days NNS N
, , N
does VBZ N
not RB N
accelerate VB N
gastric JJ o
emptying VBG o
in IN N
patients NNS N
with IN N
diabetic JJ N
gastroparesis NN N
. . N

The DT N
absence NN N
of IN N
efficacy NN N
may MD N
relate VB N
to TO N
an DT N
effect NN N
of IN N
hyperglycaemia NN N
. . N

-DOCSTART- -10993031- O O

Sublingual JJ N
administration NN N
of IN N
micronized JJ i
estradiol NN i
and CC i
progesterone NN i
, , N
with IN N
and CC N
without IN N
micronized VBN i
testosterone NN i
: : i
effect NN N
on IN N
biochemical JJ p
markers NNS p
of IN p
bone NN o
metabolism NN p
and CC o
bone JJ o
mineral JJ o
density NN o
. . o

OBJECTIVES CC N
The DT N
purpose NN N
of IN N
this DT N
investigation NN N
was VBD N
to TO N
evaluate VB N
the DT N
relative JJ N
efficacy NN N
of IN N
the DT N
sublingual JJ N
administration NN N
of IN N
micronized JJ i
estradiol NN i
( ( i
E2 NNP i
) ) i
, , i
progesterone NN i
( ( i
P4 NNP i
) ) i
, , i
and CC i
testosterone NN i
( ( i
T NNP i
) ) i
on IN N
bone NN p
mineral JJ p
density NN p
and CC p
biochemical JJ p
markers NNS p
of IN p
bone NN p
metabolism NN p
. . p

DESIGN NN N
In IN N
this DT N
double-blind NN N
, , N
prospective JJ N
study NN N
, , N
postmenopausal JJ p
women NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
four CD p
treatment NN p
groups NNS p
: : p
hysterectomized VBN p
women NNS p
were VBD N
assigned VBN N
to TO N
either DT N
1 CD N
) ) N
micronized VBN i
E2 NNP i
( ( N
0.5 CD N
mg NN N
) ) N
or CC N
2 CD N
) ) N
micronized VBN i
E2 NNP i
( ( N
0.5 CD N
mg NN N
) ) N
+ VBZ N
micronized VBN i
T NNP i
( ( N
1.25 CD N
mg NN N
) ) N
. . N

Women NNS p
with IN p
intact JJ p
uteri NNS p
were VBD N
assigned VBN N
to TO N
either DT N
3 CD N
) ) N
micronized VBN i
E2 NNP i
( ( N
0.5 CD N
mg NN N
) ) N
+ VBZ N
micronized VBN i
P4 NNP i
( ( N
100 CD N
mg NN N
) ) N
or CC N
4 CD N
) ) N
micronized VBN i
E2 NNP i
( ( N
0.5 CD N
mg NN N
) ) N
+ VBZ i
micronized VBN i
P4 NNP i
( ( N
100 CD N
mcg NN N
) ) N
+ VBZ i
micronized VBN i
T NNP i
( ( N
1.25 CD N
mg NN N
) ) N
. . N

For IN N
the DT N
purpose NN N
of IN N
this DT N
study NN N
, , N
the DT N
four CD N
treatment NN N
groups NNS N
were VBD N
combined VBN N
into IN N
two CD N
groups NNS N
for IN N
all DT N
comparisons NNS N
. . N

The DT N
E2 NNP i
and CC N
E2+P4 NNP i
groups NNS N
were VBD N
combined VBN N
into IN N
the DT N
HRT NNP p
alone RB p
group NN p
( ( p
n=30 NN p
) ) p
, , N
and CC N
the DT N
E2+T NNP i
and CC N
E2+P4+T NNP i
groups NNS N
were VBD N
combined VBN N
into IN N
the DT N
HRT NNP i
+ NNP i
T NNP i
group NN p
( ( p
n=27 RB p
) ) p
. . p

Hormones NNPS N
were VBD N
administered VBN N
sublingually RB N
as IN N
a DT N
single JJ N
tablet NN N
twice RB N
a DT N
day NN N
for IN N
12 CD N
months NNS N
. . N

Bone NNP o
mineral JJ o
density NN o
was VBD N
measured VBN N
in IN N
the DT N
anterior-posterior JJ N
lumbar NN N
spine NN N
and CC N
total JJ N
left JJ N
hip NN N
via IN N
dual JJ N
energy NN N
x-ray JJ N
absorptiometry NN N
. . N

Bone NNP o
metabolism NN o
was VBD N
assessed VBN N
via IN N
serum JJ N
bone-specific JJ N
alkaline NN N
phosphatase NN N
and CC N
urinary JJ N
deoxypyridinoline NN N
and CC N
cross-linked JJ N
N-telopeptide NNP N
of IN N
type NN N
I PRP N
collagen VBP N
, , N
both DT N
normalized VBN N
to TO N
creatinine VB N
. . N

Data NNP N
were VBD N
analyzed VBN N
via IN N
a DT N
repeated JJ N
measures NNS N
analysis NN N
of IN N
variance NN N
and CC N
a DT N
Student NN N
's POS N
t JJ N
test NN N
( ( N
alpha=0.05 NN N
) ) N
. . N

RESULTS VB N
The DT p
subjects NNS p
were VBD p
of IN p
similar JJ p
age NN p
( ( p
54.0 CD p
+/- JJ p
0.8 CD p
years NNS p
) ) p
, , p
height VBD p
( ( p
64.0 CD p
+/- JJ p
0.3 CD p
in IN p
) ) p
, , p
weight VBD p
( ( p
157.6 CD p
+/- JJ p
4.2 CD p
lb NN p
) ) p
, , p
and CC p
had VBD p
similar JJ p
baseline NN p
follicle-stimulating NN p
hormone NN p
( ( p
66.4 CD p
+/- JJ p
3.2 CD p
mIU/L NN p
) ) p
, , p
E2 NNP p
( ( p
26.4 CD p
+/- JJ p
1.5 CD p
pg/ml NN p
) ) p
, , p
P4 NNP p
( ( p
0.3 CD p
+/- JJ p
0.1 CD p
ng/ml NN p
) ) p
, , p
total JJ p
T NNP p
( ( p
19.0 CD p
+/- JJ p
1.5 CD p
ng/dL NN p
) ) p
, , p
and CC p
bioavailable JJ p
T NNP p
( ( p
3.7 CD p
+/- JJ p
0.3 CD p
ng/dL NN p
) ) p
levels NNS p
. . p

During IN N
therapy NN N
, , N
serum NN N
levels NNS N
increased VBN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
for IN N
each DT N
hormone NN N
. . N

Bone NNP o
mineral JJ o
density NN o
and CC o
bone NN o
markers NNS o
at IN N
baseline NN N
were VBD N
similar JJ N
for IN N
each DT N
treatment NN N
group NN N
. . N

Bone-specific JJ o
alkaline JJ o
phosphatase NN o
decreased VBN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
by IN N
-14.3 JJ N
+/- JJ N
4.1 CD N
% NN N
in IN N
the DT N
HRT NNP i
alone RB N
group NN N
and CC N
by IN N
-8.2 NNP N
+/- JJ N
4.6 CD N
% NN N
in IN N
the DT N
HRT NNP i
+ NNP i
T NNP i
group NN N
. . N

Deoxypyridinoline NNP N
levels NNS o
decreased VBN N
significantly RB N
in IN N
the DT N
HRT NNP i
alone RB i
and CC N
HRT NNP i
+ NNP i
T NNP i
groups NNS N
, , N
- : N
14.4 CD N
+/- JJ N
6.8 CD N
% NN N
and CC N
-26.9 JJ N
+/- JJ N
7.6 CD N
% NN N
, , N
respectively RB N
. . N

Significant JJ N
reductions NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
in IN N
cross-linked JJ o
N-telopeptide NNP o
of IN o
type NN o
I PRP o
collagen VBP o
were VBD N
also RB N
observed VBN N
in IN N
both DT N
groups NNS N
, , N
-24.4 VBD N
+/- JJ N
6.5 CD N
% NN N
and CC N
-39.5 JJ N
+/- JJ N
8.6 CD N
% NN N
, , N
respectively RB N
. . N

Bone NNP o
mineral JJ o
density NN o
in IN o
the DT o
lumbar NN o
spine NN o
increased VBN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
by IN N
+2.2 JJ N
+/- JJ N
0.5 CD N
% NN N
the DT N
HRT NNP i
alone RB i
group NN N
and CC N
by IN N
+ JJ N
1.8 CD N
+/- JJ N
0.6 CD N
% NN N
in IN N
the DT N
HRT NNP i
+ NNP i
T NNP i
group NN N
. . N

Total JJ o
hip NN o
bone NN o
mineral JJ o
density NN o
was VBD N
maintained VBN N
in IN N
the DT N
HRT NNP i
alone RB i
group NN N
( ( N
+0.4 JJ N
+/- JJ N
0.4 CD N
% NN N
) ) N
and CC N
increased VBN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
in IN N
the DT N
HRT NNP i
+ NNP i
T NNP i
group NN N
( ( N
+ JJ N
1.8 CD N
+/- JJ N
0.5 CD N
% NN N
) ) N
. . N

CONCLUSIONS NNP N
Sublingual NNP N
micronized VBD N
HRT NNP i
favorably RB N
decreases VBZ N
serum NN o
and CC o
urine JJ o
markers NNS o
of IN o
bone NN o
metabolism NN o
, , N
prevents VBZ N
bone JJ o
loss NN o
, , N
and CC N
results NNS N
in IN N
a DT N
slight JJ N
increase NN N
in IN N
spine NN o
and CC o
hip NN o
bone NN o
mineral JJ o
density NN o
. . o

Although IN N
the DT N
addition NN N
of IN N
testosterone NN N
to TO N
HRT NNP i
for IN N
1 CD N
year NN N
did VBD N
not RB N
result VB N
in IN N
added JJ N
benefit NN N
to TO N
the DT N
spine NN o
bone NN o
mineral JJ o
density NN o
, , N
it PRP N
did VBD N
result VB N
in IN N
a DT N
significant JJ N
increase NN N
in IN N
hip NN o
bone NN o
mineral JJ o
density NN o
. . o

Longer JJR N
duration NN N
of IN N
therapy NN N
may MD N
have VB N
further JJR N
improved VBN N
these DT N
outcomes NNS N
. . N

-DOCSTART- -12073766- O O

Heparan NNP i
sulfate NN i
in IN N
the DT N
treatment NN N
of IN N
intermittent JJ p
claudication NN p
: : p
results NNS N
of IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
multicenter NN N
trial NN N
. . N

Peripheral JJ N
arterial JJ N
disease NN N
( ( N
PAD NNP N
) ) N
is VBZ N
by IN N
far RB N
the DT N
most RBS N
common JJ N
cause NN N
of IN N
intermittent JJ p
claudication NN p
. . p

This DT N
disease NN N
can MD N
greatly RB N
reduce VB N
the DT N
affected JJ N
individual NN N
's POS N
walking NN N
capacity NN N
and CC N
can MD N
seriously RB N
affect VB N
daily JJ N
life NN N
activities NNS N
. . N

Few NNP N
therapeutic JJ N
options NNS N
are VBP N
aimed VBN N
at IN N
improving VBG N
walking VBG o
capacity NN o
. . o

This DT N
was VBD N
a DT N
randomized JJ N
, , N
doubleblind VB N
, , N
placebo-controlled JJ N
, , N
multicenter JJ p
trial NN p
, , p
performed VBN p
in IN p
24 CD p
Italian JJ p
centers NNS p
. . p

Two CD p
hundred VBD p
seventeen JJ p
patients NNS p
with IN p
intermittent JJ p
claudication NN p
( ( p
stages NNS p
IIa NNP p
and CC p
IIb NNP p
of IN p
Fontaine NNP p
's POS p
PAD NNP p
classification NN p
) ) p
were VBD N
randomly RB i
assigned VBN i
to TO i
heparan VB i
sulfate NN i
( ( i
40 CD i
mg NN i
orally RB i
twice RB i
a DT i
day NN i
) ) i
or CC i
placebo NN i
for IN i
6 CD i
months NNS i
. . i

The DT N
primary JJ N
end-point NN N
was VBD N
an DT N
increase NN N
in IN N
pain-free JJ o
walking NN o
distance NN o
[ NNP N
initial JJ N
claudication NN o
distance NN o
( ( o
ICD NNP o
) ) o
] NN o
during IN N
the DT N
24 CD N
weeks NNS N
of IN N
treatment NN N
. . N

The DT N
pain-free JJ o
and CC o
the DT o
absolute NN o
walking VBG o
distance NN o
( ( o
ACD NNP o
) ) o
were VBD N
monitored VBN N
by IN N
standardized JJ N
treadmill JJ N
test NN N
at IN N
baseline NN N
and CC N
at IN N
4 CD N
, , N
12 CD N
and CC N
24 CD N
weeks NNS N
. . N

The DT N
change NN N
in IN N
initial JJ N
claudication NN o
distance NN o
during IN N
treatment NN N
, , N
expressed VBN N
as IN N
integrated JJ N
change NN N
over IN N
time NN N
, , N
was VBD N
significantly RB N
greater JJR N
with IN N
heparan NN i
sulfate NN i
than IN N
with IN N
placebo NN N
( ( N
306 CD N
+/- JJ N
494 CD N
vs. FW N
250 CD N
+/- JJ N
510 CD N
meters NNS N
x JJ N
months NNS N
, , N
p VBP N
= RB N
0.019 CD N
) ) N
. . N

Significantly RB N
fewer JJR N
treated JJ N
patients NNS N
worsened VBD N
during IN N
treatment NN N
( ( N
decreased JJ N
initial JJ o
claudication NN o
distance NN o
) ) o
compared VBN N
with IN N
controls NNS N
( ( N
9.1 CD N
% NN N
vs. FW N
19.6 CD N
% NN N
; : N
p CC N
= VB N
0.027 CD N
) ) N
. . N

Functional JJ o
recovery NN o
in IN N
the DT N
most RBS N
severely RB N
affected JJ N
subgroup NN N
of IN N
patients NNS N
( ( N
stage JJ N
IIb NNP N
of IN N
Fontaine NNP N
's POS N
classification NN N
) ) N
was VBD N
more RBR N
clearly RB N
detected VBN N
and CC N
significantly RB N
greater JJR N
among IN N
treated VBN N
than IN N
among IN N
control NN N
patients NNS N
( ( N
absolute JJ N
increase NN N
in IN N
ICD NNP N
: : N
70 CD N
+/- JJ N
113 CD N
vs. FW N
58 CD N
+/- JJ N
172 CD N
meters NNS N
, , N
p VBP N
= JJ N
0.028 CD N
; : N
integrated VBN N
increase NN N
: : N
304 CD N
+/- JJ N
422 CD N
vs. FW N
208 CD N
+/- JJ N
503 CD N
meters NNS N
x JJ N
months NNS N
; : N
p CC N
= VB N
0.004 CD N
) ) N
. . N

Heparan NNP N
sulfate NN N
appeared VBD N
to TO N
increase VB N
the DT N
walking JJ o
capacity NN o
of IN N
patients NNS p
with IN p
intermittent JJ p
claudication NN p
to TO N
a DT N
significantly RB N
greater JJR N
extent NN N
than IN N
did VBD N
placebo NN N
. . N

The DT N
treatment NN N
was VBD N
well RB N
tolerated VBN N
. . N

-DOCSTART- -12462350- O O

Secretin NNP i
and CC N
sleep NN N
in IN N
children NNS p
with IN p
autism NN p
. . p

The DT N
objectives NNS N
of IN N
this DT N
pilot NN N
study NN N
were VBD N
1 CD N
) ) N
to TO N
examine VB N
possible JJ N
effects NNS N
of IN N
secretin JJ i
infusions NNS N
on IN N
sleep-wake JJ N
state NN N
organization NN N
in IN N
children NNS p
with IN p
autism NN p
, , p
and CC p
2 CD p
) ) p
to TO p
assess VB p
the DT p
feasibility NN p
of IN p
home NN p
recordings NNS p
using VBG p
time-lapse JJ p
videosomnography NN p
in IN p
children NNS p
with IN p
autism NN p
. . p

Participants NNS p
were VBD p
a DT p
subset NN p
of IN p
subjects NNS p
from IN p
two CD p
double JJ p
blind NN p
, , p
placebo-control NN p
, , p
multi-center JJ p
clinical JJ p
trials NNS p
. . p

One CD N
trial NN N
, , N
the DT N
UC NNP N
Irvine NNP N
study NN N
, , N
assessed VBD N
the DT N
effects NNS N
of IN N
porcine NN i
secretin NN i
vs. FW i
saline NN i
infusions NNS i
on IN N
children NNS N
's POS N
behavior NN o
, , o
language NN o
and CC N
IQ NNP o
. . o

The DT N
UC NNP N
Davis NNP N
trial NN N
assessed VBD N
the DT N
effects NNS N
of IN N
synthetic JJ i
human JJ i
secretin NN i
vs. FW i
saline NN i
infusions NNS i
on IN N
behavior NN o
, , o
language NN o
and CC N
gastrointestinal JJ o
function NN o
. . o

The DT N
sleep NN N
study NN N
enrolled VBD p
some DT p
of IN p
the DT p
children NNS p
from IN p
each DT p
of IN p
the DT p
two CD p
trials NNS p
to TO N
observe VB N
possible JJ N
secretin JJ N
effects NNS N
on IN N
sleep NN N
. . N

To TO N
examine VB N
sleep NN N
, , N
the DT N
UC NNP N
Irvine NNP N
trial NN N
used VBD N
the DT N
Children NNP o
's POS o
Sleep NNP o
Habits NNP o
Questionnaire NNP o
and CC o
daily JJ o
sleep NN o
diaries NNS o
, , N
whereas IN N
the DT N
UC NNP N
Davis NNP N
study NN N
used VBD N
home-recorded JJ o
time-lapse JJ o
videosomnography NN o
. . o

Because IN N
of IN N
the DT N
small JJ N
sample NN N
size NN N
, , N
the DT N
results NNS N
from IN N
both DT N
trials NNS N
are VBP N
preliminary JJ N
. . N

They PRP N
suggest VBP N
that IN N
secretin NN i
, , i
porcine NN i
or CC i
synthetic JJ i
, , N
does VBZ N
not RB N
improve VB N
sleep-wake NN o
state NN o
organization NN o
dramatically RB N
. . N

-DOCSTART- -11465651- O O

Valsartan NNP N
alone RB N
or CC N
with IN N
a DT N
diuretic JJ N
or CC N
ACE NNP N
inhibitor NN i
as IN N
treatment NN N
for IN N
African JJ p
American JJ p
hypertensives NNS p
: : p
relation NN N
to TO N
salt VB N
intake NN N
. . N

Previous JJ N
clinical JJ N
trials NNS N
have VBP N
demonstrated VBN N
the DT N
important JJ N
influence NN N
of IN N
ethnicity NN N
and CC N
dietary JJ N
salt NN N
on IN N
the DT N
antihypertensive JJ N
efficacy NN N
of IN N
drugs NNS N
that WDT N
block VBP N
the DT N
renin NN N
angiotensin NN N
system NN N
. . N

Angiotensin NNP N
II NNP N
receptor NN N
blockers NNS N
are VBP N
a DT N
new JJ N
therapeutic JJ N
entity NN N
that WDT N
have VBP N
not RB N
been VBN N
widely RB N
studied VBN N
in IN N
African JJ N
American JJ N
hypertensives NNS N
, , N
either RB N
alone RB N
, , N
or CC N
in IN N
combination NN N
with IN N
other JJ N
therapies NNS N
such JJ N
as IN N
diuretics NNS N
or CC N
angiotensin NN N
converting VBG N
enzyme JJ N
inhibitors NNS N
. . N

We PRP N
performed VBD N
a DT N
pilot NN N
, , N
prospective JJ N
, , N
open JJ N
label NN N
, , N
randomized VBN N
design NN N
clinical JJ N
trial NN N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
the DT N
angiotensin NN i
II NNP i
receptor NN i
blocker NN i
valsartan NN i
( ( N
160 CD N
mg NN N
once RB N
a DT N
day NN N
) ) N
on IN N
systolic NN o
and CC o
diastolic JJ o
blood NN o
pressure NN o
in IN N
hypertensive JJ p
African JJ p
Americans NNPS p
( ( p
n JJ p
= NNP p
88 CD p
) ) p
on IN p
a DT p
low JJ i
salt NN i
( ( i
100 CD i
mEq NNS i
Na+/day NNP i
) ) i
for IN i
2 CD i
weeks NNS i
and CC i
the DT i
same JJ i
diet NN i
supplemented VBN i
by IN i
100 CD i
mEq NNS i
Na+ NNP i
for IN i
4 CD i
weeks NNS i
. . i

After IN N
this DT N
evaluation NN N
, , N
while IN N
continuing VBG N
the DT N
Na+ NNP N
supplementation NN N
, , N
patients NNS N
were VBD N
randomized VBN i
to TO i
valsartan VB i
320 CD i
mg/day NN i
( ( i
n JJ i
= NNP i
28 CD i
) ) i
, , i
or CC i
the DT i
addition NN i
of IN i
hydrochlorothiazide NN i
( ( i
HCTZ NNP i
) ) i
12.5 CD i
mg/day NN i
( ( i
n JJ i
= NNP i
30 CD i
) ) i
, , i
or CC i
benazepril VB i
20 CD i
mg/day NN i
to TO i
the DT i
valsartan NN i
160 CD i
mg/day NN i
for IN i
an DT i
additional JJ i
6 CD i
weeks NNS i
. . i

Valsartan NNP N
( ( N
160 CD N
mg/day NN N
) ) N
lowered VBD N
blood NN o
pressure NN o
significantly RB N
in IN N
African JJ N
American JJ N
patients NNS N
on IN N
both DT N
low JJ N
salt NN N
( ( N
-6.4/-4.8 JJ N
mm NN N
Hg NNP N
: : N
P NNP N
< NNP N
.001 NNP N
) ) N
and CC N
a DT N
high JJ N
salt NN N
diet NN N
( ( N
-4.9/-3.8 JJ N
mm NN N
Hg NNP N
: : N
P NNP N
= NNP N
.01 NNP N
) ) N
. . N

The DT N
high JJ N
salt NN N
diet NN N
attenuated VBD N
the DT N
antihypertensive JJ o
effect NN o
slightly RB N
( ( N
1.6/1.3 CD N
mm NN N
Hg NNP N
, , N
P NNP N
= NNP N
not RB N
significant JJ N
) ) N
. . N

When WRB N
comparing VBG N
the DT N
efficacy NN N
of IN N
the DT N
three CD N
randomized VBN N
therapeutic JJ N
regimens NNS N
while IN N
on IN N
the DT N
Na+ NNP N
supplement NN N
, , N
the DT N
valsartan NN N
160 CD N
mg/HCTZ NN N
12.5 CD N
mg NN N
was VBD N
the DT N
most RBS N
effective JJ N
therapy NN N
with IN N
an DT N
incremental JJ N
reduction NN N
in IN N
blood NN o
pressure NN o
of IN N
-10.5/-6.9 NNP N
mm FW N
Hg NNP N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
, , N
compared VBN N
to TO N
valsartan VB N
160 CD N
mg/day JJ N
alone RB N
. . N

Doubling VBG N
the DT N
dose NN N
of IN N
valsartan NN N
to TO N
320 CD N
mg NNS N
incrementally RB N
lowered VBD N
blood NN o
pressure NN o
by IN N
-3.8/-3.3 NNP N
mm NN N
Hg NNP N
( ( N
P NNP N
= NNP N
not RB N
significant JJ N
) ) N
. . N

The DT N
least JJS N
effective JJ N
approach NN N
was VBD N
adding VBG N
benazepril RB N
20 CD N
mg/day NN N
to TO N
valsartan VB N
160 CD N
mg/day NN N
with IN N
no DT N
incremental JJ N
reduction NN N
in IN N
systolic JJ o
blood NN o
pressure NN o
and CC o
diastolic JJ o
blood NN o
pressure NN o
reduction NN N
of IN N
only RB N
1.7 CD N
mm NNS N
Hg NNP N
( ( N
P NNP N
= NNP N
not RB N
significant JJ N
) ) N
. . N

We PRP N
conclude VBP N
that IN N
in IN N
our PRP$ N
open JJ N
label NN N
pilot NN N
study NN N
, , N
the DT N
antihypertensive JJ N
activity NN N
of IN N
valsartan NN N
is VBZ N
not RB N
significantly RB N
attenuated VBN N
by IN N
supplemented JJ N
salt NN N
diet NN N
in IN N
hypertensive JJ p
African JJ p
Americans NNPS p
. . p

Moreover RB N
, , N
adding VBG N
a DT N
low JJ N
dose NN N
of IN N
HCTZ NNP N
appears VBZ N
to TO N
be VB N
the DT N
most RBS N
effective JJ N
strategy NN N
in IN N
enhancing VBG N
the DT N
antihypertensive JJ N
activity NN N
of IN N
this DT N
angiotensin NN N
II NNP N
receptor NN N
blocker NN N
in IN N
contrast NN N
to TO N
either DT N
doubling VBG N
the DT N
dose NN N
or CC N
adding VBG N
an DT N
angiotensin NN N
converting VBG N
enzyme JJ N
inhibitor NN N
. . N

-DOCSTART- -10211492- O O

Local JJ N
injection NN N
of IN N
bupivacaine NN i
after IN p
rubber NN p
band NN p
ligation NN p
of IN p
hemorrhoids NNS p
: : p
prospective JJ N
, , N
randomized VBN N
study NN N
. . N

PURPOSE VB N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
if IN N
local JJ N
injection NN N
of IN N
bupivacaine NN i
after IN N
hemorrhoidal JJ N
banding NN N
causes VBZ N
a DT N
decrease NN o
in IN o
pain NN o
and CC o
in IN o
the DT o
incidence NN o
of IN o
associated VBN o
symptoms NNS o
. . o

METHODS NNP N
After IN p
hemorrhoidal JJ p
banding NN p
, , p
patients NNS p
were VBD N
randomly RB i
assigned VBN i
to TO i
receive VB i
a DT i
local JJ i
injection NN i
of IN i
bupivacaine NN i
with IN i
1:200,000 CD i
epinephrine NN i
, , i
an DT i
injection NN i
of IN i
normal JJ i
saline NN i
, , i
or CC i
no DT i
injection NN i
, , i
just RB i
superior JJ i
to TO i
each DT i
band NN i
. . i

Pain NN o
was VBD i
graded VBN i
by IN i
the DT i
patient NN i
and CC i
by IN i
the DT i
study NN i
nurse NN i
within IN i
30 CD i
minutes NNS i
, , i
and CC i
any DT i
associated VBN o
symptoms NNS o
were VBD i
recorded VBN i
. . i

At IN i
intervals NNS i
6 CD i
, , i
24 CD i
, , i
and CC i
48 CD i
hours NNS i
postbanding VBG i
, , i
the DT i
patient NN i
recorded VBD i
pain NN o
, , o
limitation NN o
of IN o
activities NNS o
, , o
and CC o
analgesic JJ o
requirements NNS o
. . o

Associated VBN o
symptoms NNS o
while IN N
at IN N
home NN N
were VBD N
recorded VBN N
. . N

RESULTS NNP N
Of IN N
115 CD p
patients NNS p
studied VBN p
, , N
42 CD N
received VBD N
bupivacaine NN i
injection NN N
, , N
42 CD N
received VBD N
normal JJ i
saline JJ i
injection NN N
, , N
and CC N
31 CD N
received VBD N
no DT i
injection NN i
. . i

In IN N
patients NNS N
receiving VBG N
bupivacaine NN i
compared VBN N
with IN N
no DT N
injection NN N
, , N
within IN N
30 CD N
minutes NNS N
postbanding VBG N
there RB N
was VBD N
a DT N
significant JJ N
reduction NN o
in IN o
pain NN o
graded VBN N
by IN N
the DT N
patient NN N
( ( N
P NNP N
= NNP N
0.000002 CD N
) ) N
and CC N
by IN N
the DT N
nurse NN N
( ( N
P NNP N
= NNP N
0.000005 CD N
) ) N
and CC N
a DT N
significant JJ N
reduction NN N
in IN N
incidence NN o
of IN o
nausea NN o
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
and CC N
shaking VBG N
( ( N
P NNP N
= NNP N
0.008 CD N
) ) N
. . N

However RB N
, , N
in IN N
the DT N
bupivacaine NN i
group NN N
compared VBN N
with IN N
the DT N
other JJ N
two CD N
groups NNS N
, , N
at IN N
the DT N
intervals NNS N
of IN N
6 CD N
, , N
24 CD N
, , N
and CC N
48 CD N
hours NNS N
postbanding VBG N
there EX N
was VBD N
no DT N
sustained JJ N
reduction NN N
in IN N
the DT N
severity NN o
of IN o
pain NN o
and CC N
no DT N
reduction NN N
in IN N
analgesic JJ o
requirements NNS o
or CC o
limitation NN o
of IN o
normal JJ o
activities NNS o
. . o

In IN N
the DT N
week NN N
after IN N
banding VBG N
, , N
there EX N
was VBD N
no DT N
difference NN N
between IN N
groups NNS N
in IN N
symptoms NNS N
of IN N
nausea NN o
, , o
shaking NN o
, , o
lightheadedness NN o
, , o
urinary JJ o
retention NN o
, , o
or CC o
bleeding VBG o
. . o

CONCLUSIONS NNP N
Bupivacaine NNP i
injection NN N
may MD N
be VB N
useful JJ N
for IN N
reducing VBG N
pain NN N
and CC N
associated VBD N
symptoms NNS N
long RB N
enough RB N
to TO N
tolerate VB N
a DT N
trip NN N
home NN N
from IN N
the DT N
outpatient JJ N
department NN N
but CC N
does VBZ N
not RB N
show VB N
a DT N
sustained JJ N
effect NN N
. . N

-DOCSTART- -6108319- O O

Double-blind NNP N
comparison NN N
of IN N
ketazolam NN i
, , i
diazepam NN i
and CC i
placebo NN i
in IN N
once-a-day JJ N
vs NN N
t.i.d NN N
. . N

dosing VBG N
. . N

Comparison NNP N
of IN N
ketazolam NNP i
given VBN N
once-a-day JJ N
with IN N
diazepam NN i
given VBN N
three CD N
times NNS N
a DT N
day NN N
and CC i
placebo VB i
given VBN N
either DT N
once RB N
or CC N
3 CD N
times NNS N
a DT N
day NN N
in IN N
101 CD p
anxious JJ p
outpatients NNS p
showed VBD N
ketazolam NNS N
to TO N
be VB N
significantly RB N
better JJR N
than IN N
placebo NN N
in IN N
alleviating VBG N
the DT N
symptoms NNS p
of IN p
anxiety NN p
and CC N
, , N
on IN N
several JJ N
measures NNS N
of IN N
efficacy NN N
, , N
better JJR N
than IN N
diazepam NN N
as IN N
well RB N
. . N

Significantly RB N
fewer JJR N
patients NNS p
on IN p
ketazolam NN i
dropped VBD p
out IN p
of IN p
the DT p
study NN p
due JJ N
to TO N
ineffective JJ N
medication NN N
than IN N
on IN N
the DT N
other JJ N
3 CD N
treatments NNS N
. . N

The DT N
incidence NN o
of IN o
side NN o
effects NNS o
was VBD o
lowest JJS o
in IN N
the DT N
ketazolam NN N
group NN N
. . N

Of IN N
particular JJ N
note NN N
, , N
drowsiness NN o
was VBD N
reported VBN N
twice RB N
as RB N
often RB N
by IN N
diazepam JJ i
patients NNS N
as IN N
by IN N
ketazolam NN i
patients NNS N
. . N

-DOCSTART- -2148830- O O

A DT N
randomized VBN N
study NN N
on IN N
hormone-resistant JJ p
prostatic JJ p
cancer NN p
: : p
estramustine JJ i
phosphate NN i
versus NN N
low JJ i
dose JJ i
epirubicin NN i
with IN i
or CC i
without IN i
medroxyprogesterone JJ i
acetate NN i
. . i

A DT N
Norwegian JJ N
multicenter NN N
study NN N
. . N

A DT N
prospective JJ N
randomized NN N
study NN N
has VBZ N
been VBN N
carried VBN N
out RP N
in IN N
order NN N
to TO N
compare VB N
three CD N
different JJ N
treatment NN N
modalities NNS N
for IN N
symptomatic JJ p
metastatic JJ p
hormone-resistant JJ p
prostatic JJ p
cancer NN p
. . p

A DT N
total NN p
of IN p
79 CD p
patients NNS p
were VBD p
included VBN p
. . p

One CD N
group NN N
was VBD N
treated VBN i
with IN i
estramustine JJ i
phosphate NN i
, , i
another DT i
with IN i
Epirubicin NNP i
plus CC i
Medroxyprogesterone NNP i
acetate NN i
( ( i
MPA NNP i
) ) i
, , i
while IN i
the DT i
third JJ i
arm NN i
consisted VBD i
of IN i
Epirubicin NNP i
plus CC i
placebo NN i
. . i

Best JJS o
palliation NN o
was VBD N
obtained VBN N
by IN N
the DT N
combination NN N
of IN N
Epirubicin NNP i
and CC i
MPA NNP i
. . i

This DT N
combination NN N
also RB N
seemed VBD N
to TO N
be VB N
associated VBN N
with IN N
the DT N
longest JJS N
response NN N
duration NN N
. . N

-DOCSTART- -23016708- O O

Improving VBG N
RBC NNP N
K NNP N
transport NN N
and CC N
hemoglobin-O2 JJ N
binding NN N
by IN N
amiloride NN i
: : i
A DT N
novel JJ N
therapeutic JJ N
approach NN N
for IN N
reversion NN N
of IN N
angina NN N
and CC N
myocardial JJ N
ischemia NN N
in IN N
coronary JJ p
heart NN p
diseases NNS p
. . p

UNLABELLED NNP N
Coronary NNP N
heart NN N
disease NN N
( ( N
CHD NNP N
) ) N
is VBZ N
the DT N
leading VBG N
cause NN N
of IN N
morbidity NN N
and CC N
mortality NN N
across IN N
the DT N
entire JJ N
world NN N
, , N
in IN N
which WDT N
reversion NN N
of IN N
angina NN N
or CC N
improvement NN N
of IN N
ECG NNP N
remains VBZ N
an DT N
unrealistic JJ N
therapeutic JJ N
option NN N
for IN N
most JJS N
patients NNS N
, , N
suggesting VBG N
that IN N
microvascular JJ N
dysfunction NN N
or CC N
impaired JJ N
oxygen NN N
delivery NN N
might MD N
be VB N
critical JJ N
factors NNS N
in IN N
CHD NNP N
. . N

This DT N
research NN N
article NN N
, , N
thus RB N
presents VBZ N
the DT N
rationale JJ N
basis NN N
, , N
clinical JJ N
and CC N
experimental JJ N
, , N
for IN N
the DT N
first JJ N
therapeutic JJ N
innovation NN N
addressing VBG N
the DT N
role NN N
of IN N
red JJ N
blood NN N
cell NN N
( ( N
RBC NNP N
) ) N
H/K NNP N
and CC N
O2/CO2 NNP N
exchanges NNS N
in IN N
CHD NNP N
. . N

It PRP N
is VBZ N
followed VBN N
by IN N
a DT N
randomized JJ N
single-blind JJ N
trial NN N
of IN N
Amiloride NNP i
and CC i
Optimal NNP i
Medical NNP i
Therapy NNP i
( ( p
OMT NNP p
, , p
n=35 JJ p
cases NNS p
) ) p
vs VBP p
OMT NNP i
alone RB i
( ( p
n=35 JJ p
cases NNS p
) ) p
in IN p
patients NNS p
having VBG p
angina RB p
, , p
ST-T JJ p
alteration NN p
and CC p
a DT p
defective JJ p
RBC-K JJ p
transport NN p
. . p

All DT p
patients NNS p
had VBD p
serial JJ p
clinical JJ p
evaluation NN p
, , p
Ion NNP p
Transport NNP p
Studies NNP p
, , p
ECGs NNP p
and CC p
non-invasive JJ p
aortic JJ p
waveform NN p
and CC p
cardiovascular JJ p
hemodynamic JJ p
recordings NNS p
. . p

Statistical JJ N
analysis NN N
was VBD N
performed VBN N
by IN N
SAS NNP N
. . N

RESULTS NNP N
Amiloride NNP N
rapidly RB N
improved VBD N
RBC-K NNP N
( ( N
93.5 CD N
?4 NNP N
vs NN N
84.5 CD N
?4 NN N
mmol/lc NN N
, , N
p= NN N
< NNP N
0.001 CD N
) ) N
, , N
angina RB N
( ( N
80 CD N
% NN N
of IN N
cases NNS N
, , N
1.5 CD N
?0.3 JJ N
weeks NNS N
, , N
CI:1.72 NNP N
to TO N
1.45 CD N
) ) N
, , N
CCS NNP N
Class NNP N
( ( N
1.3 CD N
?0.5 NNP N
vs NN N
3.1 CD N
?0.8 NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
vs NN N
patients NNS N
with IN N
OMT NNP N
alone RB N
CCS NNP N
Class NNP N
( ( N
3.2 CD N
? . N
0.4 CD N
vs NN N
3.3 CD N
? . N
0.5 CD N
, , N
p FW N
=0.21 NN N
) ) N
. . N

Reversion NN N
of IN N
angina NN N
was VBD N
sustained VBN N
through IN N
the DT N
next JJ N
6-months JJ N
( ( N
87 CD N
% NN N
vs JJ N
26 CD N
% NN N
in IN N
OMT NNP N
, , N
RR NNP N
2.1 CD N
, , N
odds NNS N
ratio VBP N
6.31 CD N
, , N
Pearson NNP N
x2 NNP N
34.6 CD N
, , N
p NN N
< VBD N
0.0001 CD N
at IN N
95 CD N
% NN N
CI NNP N
) ) N
and CC N
1-year JJ N
( ( N
85 CD N
% NN N
vs JJ N
37 CD N
% NN N
OMT NNP N
) ) N
. . N

At IN N
6-months JJ N
of IN N
amiloride NN N
, , N
ECG NNP N
became VBD N
normal JJ N
( ( N
29 CD N
% NN N
vs JJ N
0 CD N
% NN N
, , N
RR NNP N
? . N
uncalculated-time JJ N
, , N
odds NNS N
ratio NN N
? . N
, , N
Pearson NNP N
x2 VBD N
42.4 CD N
at IN N
95 CD N
% NN N
CI NNP N
, , N
p NN N
< NNP N
0.0001 CD N
) ) N
, , N
improved VBN N
( ( N
55 CD N
% NN N
vs JJ N
29 CD N
% NN N
; : N
RR2.1 NNP N
, , N
odds VBZ N
ratio NN N
3.16 CD N
, , N
95 CD N
% NN N
CI NNP N
, , N
p NN N
< NNP N
0.0001 CD N
) ) N
or CC N
unchanged JJ N
( ( N
15 CD N
% NN N
vs JJ N
67 CD N
% NN N
OMT NNP N
) ) N
. . N

At IN N
1-year JJ N
, , N
seven CD N
patients NNS N
on IN N
amiloride NN N
( ( N
18 CD N
% NN N
) ) N
exhibited VBD N
evidence NN N
of IN N
electrical JJ N
regeneration NN N
of IN N
the DT N
heart NN N
, , N
not RB N
observed VBN N
with IN i
placebo NN i
. . i

IN NNP i
CONCLUSION NNP N
This DT N
therapeutical JJ N
innovation NN N
of IN N
amiloride JJ N
improves NNS N
RBC NNP N
H/K NNP N
and CC N
O2/CO2 NNP N
function NN N
, , N
and CC N
reverses VBZ N
angina NNS N
, , N
ST-T JJ N
alterations NNS N
while IN N
inducing VBG N
electrical JJ N
regeneration NN N
of IN N
the DT N
heart NN N
, , N
in IN p
patients NNS p
receiving VBG p
optimal JJ p
medical JJ p
treatment NN p
for IN p
angina NN p
. . N

The DT N
article NN N
has VBZ N
short JJ N
discussion NN N
on IN N
the DT N
relevant JJ N
patents NNS N
to TO N
the DT N
topic NN N
. . N

-DOCSTART- -16048456- O O

Autism-Spectrum JJ i
Quotient-Japanese JJ i
version NN N
and CC N
its PRP$ N
short JJ N
forms NNS N
for IN N
screening VBG p
normally RB p
intelligent JJ p
persons NNS p
with IN p
pervasive JJ p
developmental NN p
disorders NNS p
. . p

A DT N
Japanese JJ i
version NN i
of IN i
the DT i
Autism NNP i
Spectrum NNP i
Quotient NNP i
( ( i
AQ NNP i
) ) i
, , i
AQ-J NNP i
was VBD N
administered VBN N
to TO N
25 CD p
normally RB p
intelligent JJ p
high-functioning JJ p
pervasive JJ p
developmental NN p
disorder NN p
( ( p
HPDD NNP p
) ) p
patients NNS p
( ( p
mean JJ p
age NN p
, , p
24.2 CD p
years NNS p
; : p
24 CD p
male NN p
, , p
one CD p
female NN p
) ) p
and CC p
215 CD p
controls NNS p
( ( p
mean JJ p
age NN p
, , p
30.4 CD p
years NNS p
; : p
86 CD p
male NN p
, , p
129 CD p
female NN p
) ) p
randomly RB p
selected VBN p
from IN p
the DT p
general JJ p
population NN p
. . p

The DT N
AQ-J NNP i
had VBD N
satisfactory JJ o
internal JJ o
consistency NN o
reliability NN o
( ( N
Cronbach NNP N
's POS N
alpha NN N
> VBD N
0.70 CD N
in IN N
the DT N
two CD N
groups NNS N
) ) N
, , N
test-retest JJ o
reliability NN o
, , o
and CC o
discriminant JJ o
validity NN o
[ NNP N
i.e NN N
. . N

the DT N
AQ-J NNP N
score NN N
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
HPDD NNP N
( ( N
mean NN N
, , N
29.6 CD N
) ) N
than IN N
controls NNS N
( ( N
mean VB N
, , N
22.2 CD N
) ) N
] NN N
. . N

At IN N
a DT N
cut-off NN N
of IN N
26 CD N
, , N
the DT N
AQ-J NNP o
had VBD N
satisfactory JJ o
sensitivity NN o
, , o
specificity NN o
, , o
and CC o
negative JJ o
predictive JJ o
value NN o
, , N
but CC N
it PRP N
had VBD N
low JJ o
positive JJ o
predictive NN o
value NN o
( ( N
0.24 CD N
) ) N
possibly RB N
due JJ N
to TO N
the DT N
facts NNS N
that IN N
the DT N
25 CD N
mild JJ N
HPDD NNP N
patients NNS N
scored VBD N
lower JJR N
and CC N
the DT N
controls NNS N
scored VBD N
higher JJR N
on IN N
the DT N
AQ-J NNP i
than IN N
British NNP N
counterparts NNS N
on IN N
the DT N
AQ NNP N
. . N

The DT N
AQ-J-21 NNP o
( ( o
consisting VBG o
of IN o
21 CD o
items NNS o
significantly RB o
associated VBN o
with IN o
HPDD NNP o
diagnosis NN o
) ) o
and CC N
the DT N
AQ-J-10 NNP o
( ( o
consisting VBG o
of IN o
10 CD o
of IN o
the DT o
21 CD o
items NNS o
with IN o
an DT o
effect NN o
size NN o
> NNP o
0.17 CD o
) ) o
had VBD N
higher JJR o
, , N
although IN N
not RB o
satisfactory JJ o
, , o
positive JJ o
predictive JJ o
values NNS o
of IN N
0.35 CD N
and CC N
0.46 CD N
at IN N
cut-offs NNS N
of IN N
12 CD N
and CC N
7 CD N
, , N
respectively RB N
, , N
than IN N
the DT N
AQ-J NNP i
. . i

The DT N
AQ-J JJ i
and CC N
two CD N
short JJ N
forms NNS N
are VBP N
useful JJ N
not RB N
to TO N
predict VB N
but CC N
to TO N
rule VB N
out RP N
mild NN o
HPDD NNP o
, , N
the DT N
most RBS N
difficult JJ N
part NN N
of IN N
HPDD NNP N
to TO N
be VB N
distinguished VBN N
from IN N
non-PDD JJ N
conditions NNS N
, , N
in IN N
persons NNS N
scoring VBG N
under IN N
the DT N
cut-offs NNS N
and CC N
to TO N
consider VB N
professionals NNS N
' POS N
examination NN N
of IN N
HPDD NNP N
in IN N
persons NNS N
scoring VBG N
over IN N
them PRP N
, , N
because IN N
their PRP$ N
negative JJ N
predictive JJ N
values NNS N
were VBD N
satisfactory JJ N
. . N

-DOCSTART- -7056921- O O

Effects NNS N
of IN N
vicarious JJ i
reinforcement NN i
in IN p
normal JJ p
and CC p
severely RB p
disturbed JJ p
children NNS p
. . p

-DOCSTART- -20504165- O O

Improving VBG N
the DT N
immunogenicity NN o
of IN N
pneumococcal JJ N
conjugate NN N
vaccine NN N
in IN N
HIV-infected NNP p
adults NNS p
with IN p
a DT p
toll-like JJ p
receptor NN p
9 CD p
agonist NN p
adjuvant NN p
: : p
a DT N
randomized NN N
, , N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Persons NNP p
infected VBD p
with IN p
human JJ p
immunodeficiency NN p
virus NN p
( ( p
HIV NNP p
) ) p
are VBP N
often RB N
hyporesponsive JJ N
to TO N
immunization NN N
, , N
including VBG N
pneumococcal JJ N
vaccines NNS N
. . N

We PRP N
hypothesized VBD N
that IN N
adding VBG N
CPG NNP N
7909 CD N
, , N
a DT N
toll-like JJ N
receptor NN N
9 CD N
( ( N
TLR9 NNP N
) ) N
agonist NN N
and CC N
vaccine NN N
adjuvant NN N
, , N
to TO N
7-valent JJ N
pneumococcal JJ N
conjugate NN N
vaccine NN N
( ( N
7vPnC CD N
) ) N
would MD N
increase VB N
its PRP$ N
immunogenicity NN N
in IN N
HIV-infected NNP p
adults NNS p
. . p

METHODS NNP N
We PRP N
performed VBD N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
phase VB N
1b/2a CD N
trial NN N
randomizing VBG N
HIV-positive JJ p
patients NNS p
to TO N
receive VB N
double JJ N
doses NNS N
of IN N
7vPnC CD i
( ( i
Prevnar NNP i
) ) i
at IN N
0 CD N
and CC N
3 CD N
months NNS N
and CC N
1 CD N
dose NN N
of IN N
23-valent JJ i
pneumococcal JJ i
polysaccharide NN i
vaccine NN i
( ( i
PPV-23 NNP i
; : i
Pneumo NNP i
Novum NNP i
) ) i
at IN N
9 CD N
months NNS N
, , N
with IN N
experimental JJ N
patients NNS N
receiving VBG N
1 CD N
mg NN N
of IN N
CPG NNP i
7909 CD i
added VBD N
to TO N
each DT N
of IN N
their PRP$ N
3 CD N
vaccine NN N
doses NNS N
; : N
control NN N
patients NNS N
had VBD N
phosphate-buffered JJ i
saline NN i
added VBN N
instead RB N
. . N

Immunogenicity NNP o
and CC o
safety NN o
were VBD N
evaluated VBN N
for IN N
up RB N
to TO N
10 CD N
months NNS N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
the DT N
proportion NN o
of IN o
vaccine NN o
high JJ o
responders NNS o
at IN o
9 CD o
months NNS o
, , N
defined VBD N
as IN N
a DT N
2-fold JJ N
increase NN N
in IN N
IgG NNP N
levels NNS N
to TO N
> VB N
or CC N
= VB N
1 CD N
microg/mL NN N
for IN N
at IN N
least JJS N
5 CD N
of IN N
7 CD N
of IN N
the DT N
7vPnC CD N
serotypes NNS N
. . N

RESULTS NNP N
Ninety-seven JJ p
participants NNS p
were VBD p
included VBN p
in IN p
the DT p
study NN p
. . p

The DT N
proportion NN o
of IN o
vaccine NN o
high JJ o
responders NNS o
was VBD N
higher RBR N
in IN N
the DT N
experimental JJ N
group NN N
( ( N
n JJ N
= NNP N
48 CD N
) ) N
than IN N
among IN N
controls NNS N
( ( N
n JJ N
= VBZ N
49 CD N
; : N
48.8 CD N
% NN N
vs JJ N
25.0 CD N
% NN N
; : N
P NNP N
= NNP N
.02 NNP N
) ) N
at IN N
9 CD N
months NNS N
. . N

Greater NNP N
proportions NNS o
of IN o
high JJ o
responders NNS o
were VBD N
also RB N
observed VBN N
at IN N
3 CD N
( ( N
51.1 CD N
% NN N
vs JJ N
39.6 CD N
% NN N
; : N
P NNP N
= NNP N
.26 NNP N
) ) N
, , N
4 CD N
( ( N
77.3 CD N
% NN N
vs JJ N
56.3 CD N
% NN N
; : N
P NNP N
= NNP N
.03 NNP N
) ) N
, , N
and CC N
10 CD N
months NNS N
( ( N
87.8 CD N
% NN N
vs JJ N
51.1 CD N
% NN N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Mild NNP o
systemic JJ o
and CC o
injection NN o
site NN o
reactions NNS o
to TO N
7vPnC CD i
were VBD N
more JJR N
common JJ N
in IN N
the DT N
experimental JJ N
group NN N
than IN N
the DT N
control NN N
group NN N
( ( N
100 CD N
% NN N
vs JJ N
81.3 CD N
% NN N
; : N
P NNP N
= NNP N
.002 NNP N
) ) N
. . N

CPG JJ N
7909 CD N
did VBD N
not RB N
increase VB N
non-7vPnC JJ o
IgG NNP o
levels NNS o
after IN N
PPV-23 NNP i
immunization NN N
. . N

No DT N
adverse JJ N
effects NNS N
on IN N
CD4 NNP o
( ( o
+ NNP o
) ) o
cell NN o
count NN o
or CC o
organ JJ o
functions NNS o
occurred VBD N
in IN N
either DT N
group NN N
. . N

CONCLUSIONS VB N
The DT N
addition NN N
of IN N
a DT N
TLR9 NNP i
agonist NN N
to TO N
7vPnC CD i
significantly RB N
enhanced VBD N
the DT N
proportion NN N
of IN N
vaccine NN o
high JJ o
responders NNS o
. . o

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
identifier NN N
: : N
NCT00562939 NNP N
. . N

-DOCSTART- -22617130- O O

Phase NNP N
II NNP N
multi-institutional JJ N
prospective NN N
randomised VBN N
trial NN N
comparing VBG N
S-1+paclitaxel JJ i
with IN N
S-1+cisplatin NNP i
in IN N
patients NNS p
with IN p
unresectable JJ p
and/or JJ p
recurrent NN p
advanced VBD p
gastric JJ p
cancer NN p
. . p

BACKGROUND VB N
A DT N
combination NN N
of IN N
S-1 NNP i
and CC N
cisplatin NN i
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
effective JJ N
with IN N
acceptable JJ N
safety NN N
for IN N
the DT N
first-line JJ N
treatment NN N
of IN N
far-advanced JJ N
gastric JJ N
cancer NN N
in IN N
Japan NNP N
. . N

This DT N
is VBZ N
the DT N
first JJ N
randomised JJ N
phase NN N
II NNP N
trial NN N
to TO N
compare VB N
S-1+paclitaxel JJ N
with IN N
S-1+cisplatin NNP N
in IN N
this DT N
setting NN N
. . N

METHODS NNP N
Patients NNPS p
with IN p
unresectable JJ p
and/or JJ p
recurrent NN p
advanced VBD p
gastric JJ p
cancer NN p
were VBD p
randomly RB p
assigned VBN p
to TO p
receive VB p
one CD p
of IN p
the DT p
two CD p
regimens NNS p
: : p
S-1 NNP i
( ( i
40 CD i
mg NN i
m NN i
( ( i
-2 NNP i
) ) i
twice RB i
daily RB i
) ) i
on IN i
days NNS i
1-14 JJ i
plus JJ i
paclitaxel NN i
( ( i
60 CD i
mg NN i
m NN i
( ( i
-2 NNP i
) ) i
) ) i
on IN i
days NNS i
1 CD i
, , i
8 CD i
, , i
and CC i
15 CD i
of IN i
a DT i
4-week JJ i
cycle NN i
( ( i
S-1+paclitaxel NNP i
) ) i
or CC i
S-1 NNP i
( ( i
40 CD i
mg NN i
m NN i
( ( i
-2 NNP i
) ) i
twice RB i
daily RB i
) ) i
on IN i
days NNS i
1-21 JJ i
plus JJ i
cisplatin NN i
( ( i
60 CD i
mg NN i
m NN i
( ( i
-2 NNP i
) ) i
) ) i
on IN i
day NN i
8 CD i
of IN i
a DT i
5-week JJ i
cycle NN i
( ( i
S-1+cisplatin NNP i
) ) i
. . i

The DT N
primary JJ N
end NN N
point NN N
was VBD N
the DT N
response NN o
rate NN o
( ( o
RR NNP o
) ) o
. . N

Secondary JJ N
end NN N
points NNS N
included VBD N
progression-free JJ o
survival NN o
( ( o
PFS NNP o
) ) o
, , o
overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
, , o
and CC o
safety NN o
. . o

RESULTS VB N
A DT N
total NN N
of IN N
83 CD p
patients NNS p
were VBD N
eligible JJ N
for IN N
safety NN N
and CC N
efficacy NN N
analyses NNS N
. . N

In IN N
the DT N
S-1+paclitaxel NNP i
and CC N
S-1+cisplatin NNP i
groups NNS N
, , N
RRs NNP o
( ( N
52.3 CD N
% NN N
vs JJ N
48.7 CD N
% NN N
; : N
P=0.74 NNP N
) ) N
and CC N
median JJ N
PFS NNP N
( ( N
9 CD N
vs RB N
6 CD N
months NNS N
; : N
P=0.50 NNP N
) ) N
were VBD N
similar JJ N
. . N

The DT N
median JJ o
OS NNP o
was VBD N
similar JJ N
in IN N
the DT N
S-1+paclitaxel NNP N
and CC N
S-1+cisplatin NNP N
groups NNS N
( ( N
16 CD N
vs RB N
17 CD N
months NNS N
; : N
P=0.84 NNP N
) ) N
. . N

The DT N
incidence NN o
of IN o
grade NN o
3 CD o
or CC o
higher JJR o
haematological JJ o
toxicity NN o
was VBD N
19.0 CD N
% NN N
with IN N
S-1+paclitaxel NNP N
and CC N
19.5 CD N
% NN N
with IN N
S-1+cisplatin NNP i
. . i

The DT N
incidence NN o
of IN o
grade NN o
3 CD o
or CC o
higher JJR o
non-haematological JJ o
toxicity NN o
was VBD N
14.2 CD N
% NN N
with IN N
S-1+paclitaxel NNP N
and CC N
17.1 CD N
% NN N
with IN N
S-1+cisplatin NNP i
. . i

CONCLUSION NNP N
S-1+paclitaxel NNP i
was VBD N
suggested VBN N
to TO N
be VB N
a DT N
feasible JJ N
and CC N
effective JJ N
non-platinum-based JJ i
regimen NNS i
for IN N
chemotherapy NN N
in IN N
patients NNS p
with IN p
advanced JJ p
gastric JJ p
cancer NN p
. . p

Our PRP$ N
results NNS N
should MD N
be VB N
confirmed VBN N
in IN N
multicenter NN N
, , N
phase VB N
III-controlled NNP N
clinical JJ N
trials NNS N
. . N

-DOCSTART- -16483029- O O

Evaluating VBG o
erectile JJ p
dysfunction NN p
: : p
oral JJ N
sildenafil NN N
versus NN N
intracavernosal JJ N
injection NN N
of IN N
papaverine NN N
. . N

BACKGROUND NNP N
Intracavernosal NNP N
injection NN N
of IN N
vasoactive JJ N
drugs NNS N
is VBZ N
an DT N
established JJ N
method NN N
of IN N
evaluating VBG N
erectile JJ N
dysfunction NN N
. . N

However RB N
, , N
it PRP N
is VBZ N
invasive JJ N
and CC N
may MD N
be VB N
associated VBN N
with IN N
pain NN N
and CC N
priapism NN N
. . N

We PRP N
investigated VBD N
the DT N
use NN N
of IN N
oral JJ N
sildenafil NN N
as IN N
a DT N
possible JJ N
substitute NN N
for IN N
intracavernosal JJ N
agents NNS N
. . N

METHODS NNP N
Men NNP p
with IN p
erectile JJ p
dysfunction NN p
were VBD p
randomized VBN p
into IN p
two CD p
groups NNS p
of IN p
25 CD p
each DT p
. . p

One CD N
group NN N
of IN N
25 CD p
men NNS p
received VBN N
injection NN i
papaverine NN i
initially RB i
followed VBN i
by IN i
oral JJ i
sildenafil NN i
, , N
and CC N
another DT N
25 CD N
received VBD N
oral JJ i
sildenafil NN i
followed VBN i
by IN i
injection NN i
papaverine NN i
. . i

Genital JJ N
self-stimulation NN N
was VBD N
used VBN N
in IN N
both DT N
the DT N
groups NNS N
. . N

Penile NNP o
length NN o
and CC o
circumference NN o
as RB o
well RB o
as IN o
angle NN o
of IN o
erection NN o
, , N
before IN N
and CC N
after IN N
each DT N
medication NN N
, , N
were VBD N
recorded VBN N
. . N

Two CD N
days NNS N
later RB N
, , N
the DT N
intervention NN N
arms NNS N
were VBD N
crossed VBN N
over IN N
. . N

Subjective JJ o
responses NNS o
were VBD N
obtained VBN N
. . N

The DT N
effect NN N
of IN N
medication NN N
on IN N
each DT N
outcome NN N
variable NN N
was VBD N
studied VBN N
by IN N
using VBG N
analysis NN o
of IN o
variance NN o
models NNS o
in IN N
relation NN N
to TO N
patient VB N
, , N
period NN N
and CC N
medication NN N
. . N

RESULTS NNP N
There EX N
was VBD N
statistically RB N
significant JJ N
improvement NN N
from IN N
the DT N
baseline NN N
value NN N
in IN N
both CC N
the DT N
arms NNS N
, , N
i.e JJ N
injection NN N
papaverine NN N
and CC N
oral JJ N
sildenafil NN N
( ( N
p JJ N
< NN N
0.001 CD N
, , N
p NN N
< VBD N
0.001 CD N
, , N
respectively RB N
) ) N
for IN N
both DT N
penile JJ o
length NN o
and CC o
circumference NN o
. . o

No DT N
significant JJ N
difference NN o
was VBD N
observed VBN N
between IN N
the DT N
two CD N
medications NNS N
in IN N
the DT N
outcome NN N
measures NNS N
. . N

CONCLCUSION NN N
: : N
Oral JJ N
sildenafil NN N
was VBD N
as RB N
effective JJ N
as IN N
injection NN N
papaverine NN N
in IN N
evaluating VBG N
erectile JJ p
dysfunction NN p
. . p

-DOCSTART- -11705818- O O

Acute NNP o
hemodynamic JJ o
effects NNS o
of IN N
conivaptan NN i
, , N
a DT N
dual JJ N
V NNP N
( ( N
1A CD N
) ) N
and CC N
V NNP N
( ( N
2 CD N
) ) N
vasopressin NN N
receptor NN N
antagonist NN N
, , N
in IN N
patients NNS p
with IN p
advanced JJ p
heart NN p
failure NN p
. . p

BACKGROUND NNP N
Arginine NNP N
vasopressin NN N
may MD N
contribute VB N
to TO N
abnormalities NNS o
in IN o
hemodynamics NNS o
and CC o
fluid JJ o
balance NN o
in IN N
heart NN N
failure NN N
through IN N
its PRP$ N
actions NNS N
on IN N
V NNP o
( ( o
1A CD o
) ) o
( ( o
vascular JJ o
and CC o
myocardial JJ o
effects NNS o
) ) o
and CC o
V NNP o
( ( o
2 CD o
) ) o
receptors NNS o
( ( o
renal JJ o
effects NNS o
) ) o
. . o

Inhibiting VBG N
the DT N
action NN N
of IN N
vasopressin NN N
may MD N
be VB N
beneficial JJ N
in IN N
patients NNS p
with IN p
heart NN p
failure NN p
. . p

METHODS NNP N
AND NNP N
RESULTS NNP N
A NNP N
total NN N
of IN N
142 CD p
patients NNS p
with IN p
symptomatic JJ p
heart NN p
failure NN p
( ( p
New NNP p
York NNP p
Heart NNP p
Association NNP p
class NN p
III NNP p
and CC p
IV NNP p
) ) p
were VBD N
randomized VBN N
to TO N
double-blind VB N
, , N
short-term JJ N
treatment NN N
with IN N
conivaptan NN i
, , N
a DT N
dual JJ N
V NNP N
( ( N
1a CD N
) ) N
/V NN N
( ( N
2 CD N
) ) N
vasopressin NN i
receptor NN N
antagonist NN N
, , N
at IN N
a DT N
single JJ N
intravenous JJ N
dose NN N
( ( N
10 CD N
, , N
20 CD N
, , N
or CC N
40 CD N
mg NN N
) ) N
or CC N
placebo NN i
. . i

Compared VBN N
with IN N
placebo NN N
, , N
conivaptan NN N
at IN N
20 CD N
and CC N
40 CD N
mg NN N
significantly RB N
reduced VBD N
pulmonary JJ o
capillary JJ o
wedge NN o
pressure NN o
( ( N
-2.6+/-0.7 UH N
, , N
-5.4+/-0.7 NNP N
, , N
and CC N
-4.6+/-0.7 NNP N
mm VBP N
Hg NNP N
for IN N
placebo NN N
and CC N
20 CD N
and CC N
40 CD N
mg NN N
groups NNS N
, , N
respectively RB N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
right JJ o
atrial JJ o
pressure NN o
( ( N
-2.0+/-0.4 UH N
, , N
-3.7+/-0.4 NNP N
, , N
and CC N
-3.5+/-0.4 NNP N
mm VBP N
Hg NNP N
for IN N
placebo NN N
and CC N
20 CD N
and CC N
40 CD N
mg NN N
groups NNS N
, , N
respectively RB N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
during IN N
the DT N
3- JJ N
to TO N
6-hour JJ N
interval NN N
after IN N
intravenous JJ N
administration NN N
. . N

Conivaptan NNP i
significantly RB N
increased VBD N
urine JJ o
output NN o
in IN N
a DT N
dose-dependent JJ N
manner NN N
( ( N
-11+/-17 JJ N
, , N
68+/-17 JJ N
, , N
152+/-19 JJ N
, , N
and CC N
176+/-18 JJ N
mL/hour NN N
for IN N
placebo NN N
and CC N
10 CD N
, , N
20 CD N
, , N
and CC N
40 CD N
mg NN N
groups NNS N
, , N
respectively RB N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
during IN N
the DT N
first JJ N
4 CD N
hours NNS N
after IN N
the DT N
dose NN N
. . N

Changes NNS N
in IN N
cardiac JJ o
index NN o
, , o
systemic JJ o
and CC o
pulmonary JJ o
vascular NN o
resistance NN o
, , o
blood NN o
pressure NN o
, , o
and CC o
heart NN o
rate NN o
did VBD N
not RB N
significantly RB N
differ VBP N
from IN N
placebo NN N
. . N

CONCLUSIONS NNP N
In IN N
patients NNS p
with IN p
advanced JJ p
heart NN p
failure NN p
, , N
vasopressin NN N
receptor NN N
antagonism NN N
with IN N
conivaptan NN i
resulted VBN N
in IN N
favorable JJ N
changes NNS N
in IN N
hemodynamics NNS o
and CC o
urine JJ o
output NN o
without IN N
affecting VBG N
blood NN o
pressure NN o
or CC o
heart NN o
rate NN o
. . o

These DT N
data NNS N
suggest VBP N
that IN N
vasopressin NN N
is VBZ N
functionally RB N
significant JJ N
in IN N
advanced JJ N
heart NN N
failure NN N
and CC N
that IN N
further JJ N
investigations NNS N
are VBP N
warranted VBN N
to TO N
examine VB N
the DT N
effects NNS N
of IN N
conivaptan NN N
on IN N
symptom JJ N
relief NN N
and CC N
natural JJ N
history NN N
in IN N
such JJ N
patients NNS N
. . N

-DOCSTART- -9499947- O O

[ JJ N
Value NNP N
of IN N
absorbable JJ i
clips NNS i
in IN N
laparoscopic JJ i
cholecystectomy NN i
. . i

A DT N
randomized JJ N
prospective JJ N
study NN N
] NNP N
. . N

Most JJS N
surgeons NNS N
use VBP N
metal JJ N
clips NNS N
in IN N
laparoscopic JJ i
cholecystectomy NN i
. . i

The DT N
aim NN N
of IN N
this DT N
prospective JJ N
randomized NN N
controlled VBD N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
efficacy NN o
of IN o
absorbable JJ o
clips NNS o
in IN N
elective JJ o
laparoscopic NN o
cholecystectomy NN o
. . o

One CD p
hundred VBD p
consecutive JJ p
patients NNS p
with IN p
symptomatic JJ p
gallstones NNS p
without IN p
complications NNS p
were VBD p
randomized VBN p
into IN p
groups NNS p
; : p
group NN p
T NNP p
had VBD N
two CD i
metal JJ i
clips NNS i
( ( i
titan JJ i
clip NN i
ETHICONR NNP i
) ) i
, , N
group NN p
R NNP p
( ( i
laproclipR JJ i
Davis NNP i
and CC i
Geck NNP i
) ) i
had VBD N
one CD i
absorbable JJ i
clip NN i
applied VBN i
on IN i
the DT i
cystic JJ i
duct NN i
and CC i
cystic JJ i
artery NN i
. . i

The DT p
patients NNS p
were VBD N
followed VBN N
for IN N
one CD N
year NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
concerning VBG N
operative JJ o
time NN o
, , o
hospital NN o
stay NN o
and CC o
postoperative JJ o
complications NNS o
. . o

The DT N
absorbable JJ o
clips NNS o
seem VBP o
to TO o
be VB o
as RB o
effective JJ o
as IN o
metal NN o
clips NNS o
in IN N
providing VBG N
hemostasis NN o
in IN N
cystic JJ N
artery NN N
and CC N
in IN N
cystic JJ N
duct NN N
ligation NN N
. . N

-DOCSTART- -26678641- O O

Efficacy NN N
of IN N
colchicine NN i
versus NN N
placebo NN i
for IN N
the DT N
treatment NN N
of IN N
pericardial JJ p
effusion NN p
after IN p
open-heart JJ p
surgery NN p
: : p
A DT N
randomized JJ N
, , N
placebo-controlled JJ N
trial NN N
. . N

BACKGROUND NNP N
Pericardial NNP o
effusion NN o
( ( o
PE NNP o
) ) o
, , N
a DT N
common JJ N
complication NN N
after IN N
open-heart JJ N
surgery NN N
, , N
accounts NNS N
for IN N
50 CD N
% NN N
to TO N
85 CD N
% NN N
of IN N
patients NNS N
. . N

Although IN N
reversible JJ N
in IN N
most JJS N
of IN N
the DT N
cases NNS N
, , N
it PRP N
could MD N
be VB N
life NN N
threatening VBG N
in IN N
the DT N
occurrence NN N
of IN N
tamponade NN N
in IN N
large JJ N
effusions NNS N
. . N

We PRP N
aimed VBD N
to TO N
determine VB N
the DT N
therapeutic JJ N
efficacy NN N
of IN N
colchicine NN N
on IN N
PE NNP o
after IN p
open-heart JJ p
surgery NN p
. . p

METHODS NNP N
The DT N
study NN N
is VBZ N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
triple-blind JJ N
, , N
placebo-controlled JJ i
single-center JJ p
trial NN p
at IN p
Tehran NNP p
Heart NNP p
Center NNP p
. . p

A NNP p
total NN p
of IN p
149 CD p
patients NNS p
with IN p
mild JJ p
or CC p
moderate JJ p
PE NNP p
in IN p
transthoracic NN p
echocardiography NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB i
1 CD i
mg/d NNS i
colchicine NN i
( ( i
n JJ i
= NNP i
74 CD i
) ) i
or CC i
1 CD i
tablet NN i
of IN i
placebo NN i
( ( i
n JJ i
= NNP i
75 CD i
) ) i
for IN i
2 CD i
weeks NNS i
and CC i
then RB i
underwent JJ i
follow-up JJ i
echocardiography NN i
. . i

RESULTS NNP N
Baseline NNP N
and CC N
clinical JJ N
characteristics NNS N
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
2 CD N
study NN N
groups NNS N
except IN N
for IN N
age NN N
( ( N
P NNP N
= NNP N
.02 NNP N
) ) N
and CC N
graft JJ N
numbers NNS N
( ( N
P NNP N
= NNP N
.005 NNP N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
pretreatment NN N
and CC N
posttreatment NN N
PE NNP o
sizes VBZ o
between IN N
the DT N
2 CD N
study NN N
groups NNS N
( ( N
P NNP N
= NNP N
.440 NNP N
and CC N
.844 NNP N
, , N
respectively RB N
) ) N
. . N

Median JJ N
( ( N
25th-75th JJ N
percentiles NNS N
) ) N
of IN N
effusion NN o
changes NNS o
was VBD N
5 CD N
mm NN N
( ( N
1-7.6 JJ N
mm NN N
) ) N
in IN N
the DT N
colchicine NN i
group NN N
and CC N
5 CD N
mm NN N
( ( N
1-6.6 JJ N
mm NN N
) ) N
in IN N
the DT N
placebo NN i
group NN N
( ( N
P NNP N
= NNP N
.932 NNP N
) ) N
. . N

Intervention NNP N
had VBD N
no DT N
significant JJ N
impact NN N
on IN N
pretreatment NN N
and CC N
posttreatment JJ o
effusion NN o
values NNS o
and CC o
changes NNS o
in IN N
isolated JJ o
coronary JJ o
artery NN o
bypass NN o
graft NN o
surgery NN o
patients NNS o
( ( N
P NNP N
= NNP N
.607 NNP N
, , N
.539 NNP N
, , N
and CC N
.628 NNP N
, , N
respectively RB N
) ) N
. . N

After IN N
adjustment NN N
for IN N
possible JJ N
confounders NNS N
, , N
there EX N
was VBD N
still RB N
no DT N
significant JJ N
difference NN N
in IN N
postoperative JJ N
PE NNP o
between IN N
the DT N
2 CD N
study NN N
groups NNS N
( ( N
t JJ N
= NNP N
-0.285 NNP N
, , N
P NNP N
= NNP N
.776 NNP N
) ) N
. . N

CONCLUSION NNP N
We PRP N
concluded VBD N
that IN N
prescription NN N
of IN N
colchicine NN i
does VBZ N
not RB N
seem VB N
to TO N
be VB N
effective JJ N
in IN N
treatment NN N
of IN N
asymptomatic JJ o
postoperative JJ o
PE NNP o
. . o

This DT N
could MD N
be VB N
justified VBN N
in IN N
case NN N
that IN N
the DT N
etiology NN N
of IN N
most JJS N
of IN N
the DT N
PEs NNP p
might MD N
be VB N
contribution NN N
of IN N
noninflammatory JJ N
factors NNS N
which WDT N
are VBP N
better JJR N
to TO N
be VB N
dealt VBN N
with IN N
observational JJ N
approaches NNS N
. . N

-DOCSTART- -24011178- O O

Benefits NNS N
and CC N
costs NNS N
of IN N
home-based JJ i
pulmonary JJ i
rehabilitation NN i
in IN N
chronic JJ p
obstructive JJ p
pulmonary JJ p
disease NN p
- : N
a DT N
multi-centre JJ N
randomised VBN N
controlled VBN N
equivalence NN N
trial NN N
. . N

BACKGROUND NNP N
Pulmonary NNP i
rehabilitation NN i
is VBZ N
widely RB N
advocated VBN N
for IN N
people NNS p
with IN p
chronic JJ p
obstructive JJ p
pulmonary JJ p
disease NN p
( ( p
COPD NNP p
) ) p
to TO N
improve VB N
exercise NN N
capacity NN N
, , N
symptoms NNS N
and CC N
quality NN N
of IN N
life NN N
, , N
however RB N
only RB N
a DT N
minority NN N
of IN N
individuals NNS N
with IN N
COPD NNP N
are VBP N
able JJ N
to TO N
participate VB N
. . N

Travel NNP N
and CC N
transport NN N
are VBP N
frequently RB N
cited VBN N
as IN N
barriers NNS N
to TO N
uptake VB N
of IN N
centre-based JJ N
programs NNS N
. . N

Other JJ N
models NNS N
of IN N
pulmonary JJ i
rehabilitation NN i
, , N
including VBG N
home-based JJ N
programs NNS N
, , N
have VBP N
been VBN N
proposed VBN N
in IN N
order NN N
to TO N
improve VB N
access NN N
to TO N
this DT N
important JJ N
treatment NN N
. . N

Previous JJ N
studies NNS N
of IN N
home-based JJ i
pulmonary JJ i
rehabilitation NN i
in IN N
COPD NNP N
have VBP N
demonstrated VBN N
improvement NN N
in IN N
exercise NN N
capacity NN N
and CC N
quality NN N
of IN N
life NN N
, , N
but CC N
not RB N
all DT N
elements NNS N
of IN N
the DT N
program NN N
were VBD N
conducted VBN N
in IN N
the DT N
home NN N
environment NN N
. . N

It PRP N
is VBZ N
uncertain JJ N
whether IN N
a DT N
pulmonary JJ i
rehabilitation NN i
program NN i
delivered VBN N
in IN N
its PRP$ N
entirety NN N
at IN N
home NN N
is VBZ N
cost VBN o
effective JJ o
and CC N
equally RB N
capable JJ N
of IN N
producing VBG N
benefits NNS N
in IN N
exercise NN N
capacity NN N
, , N
symptoms NNS N
and CC N
quality NN N
of IN N
life NN N
as IN N
a DT N
hospital-based JJ i
program NN i
. . i

The DT N
aim NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
compare VB N
the DT N
costs NNS N
and CC N
benefits NNS N
of IN N
home-based JJ i
and CC i
hospital-based JJ i
pulmonary JJ i
rehabilitation NN i
for IN N
people NNS p
with IN p
COPD NNP p
. . p

METHODS/DESIGN NNP N
This DT N
randomised VBD N
, , N
controlled VBD N
, , N
equivalence NN N
trial NN N
conducted VBN N
at IN p
two CD p
centres NNS p
will MD p
recruit VB p
166 CD p
individuals NNS p
with IN p
spirometrically RB p
confirmed VBN p
COPD NNP p
. . p

Participants NNS p
will MD p
be VB p
randomly RB p
allocated VBN p
to TO p
hospital-based JJ i
or CC i
home-based JJ i
pulmonary JJ i
rehabilitation NN i
. . i

Hospital JJ N
programs NNS N
will MD N
follow VB N
the DT N
traditional JJ N
outpatient NN N
model NN N
consisting VBG N
of IN N
twice JJ N
weekly NNS N
supervised VBD N
exercise NN N
training NN N
and CC N
education NN N
for IN N
eight CD N
weeks NNS N
. . N

Home-based JJ i
programs NNS i
will MD N
involve VB N
one CD i
home NN i
visit NN i
followed VBN i
by IN i
seven CD i
weekly JJ i
telephone NN i
calls NNS i
, , i
using VBG i
a DT i
motivational JJ i
interviewing NN i
approach NN i
to TO N
enhance VB N
exercise NN N
participation NN N
and CC N
facilitate VB N
self JJ i
management NN i
. . N

The DT N
primary JJ N
outcome NN N
is VBZ N
change VBN o
in IN o
6-minute JJ o
walk NN o
distance NN o
immediately RB N
following VBG N
intervention NN N
. . N

Measurements NNS N
of IN N
exercise NN o
capacity NN o
, , o
physical JJ o
activity NN o
, , o
symptoms NNS o
and CC o
quality NN o
of IN o
life NN o
will MD N
be VB N
taken VBN N
at IN N
baseline NN N
, , N
immediately RB N
following VBG N
the DT N
intervention NN N
and CC N
at IN N
12 CD N
months NNS N
, , N
by IN N
a DT N
blinded JJ N
assessor NN N
. . N

Completion NN o
rates NNS o
will MD N
be VB N
compared VBN N
between IN N
programs NNS N
. . N

Direct NNP o
healthcare NN o
costs NNS o
and CC o
indirect JJ o
( ( o
patient-related JJ o
) ) o
costs NNS o
will MD N
be VB N
measured VBN N
to TO N
compare VB N
the DT N
cost-effectiveness NN N
of IN N
each DT N
program NN N
. . N

DISCUSSION NNP N
This DT N
trial NN N
will MD N
identify VB N
whether IN N
home-based JJ i
pulmonary JJ i
rehabilitation NN i
can MD N
deliver VB N
equivalent JJ N
benefits NNS N
to TO N
centre-based JJ N
pulmonary JJ N
rehabilitation NN N
in IN N
a DT N
cost NN N
effective JJ N
manner NN N
. . N

The DT N
results NNS N
of IN N
this DT N
study NN N
will MD N
contribute VB N
new JJ N
knowledge NN N
regarding VBG N
alternative JJ N
models NNS N
of IN N
pulmonary JJ N
rehabilitation NN N
and CC N
will MD N
inform VB N
pulmonary JJ N
rehabilitation NN N
guidelines NNS N
for IN N
COPD NNP N
. . N

-DOCSTART- -21705084- O O

Adjusting VBG N
intraocular JJ N
pressure NN N
for IN N
central JJ N
corneal JJ N
thickness NN N
does VBZ N
not RB N
improve VB N
prediction NN N
models NNS N
for IN N
primary JJ N
open-angle JJ N
glaucoma NN N
. . N

PURPOSE NNP N
To TO N
determine VB N
if IN N
the DT N
accuracy NN N
of IN N
the DT N
baseline NN N
prediction NN N
model NN N
for IN N
the DT N
development NN N
of IN N
primary JJ N
open-angle JJ N
glaucoma NN N
( ( N
POAG NNP N
) ) N
in IN N
patients NNS p
with IN p
ocular JJ p
hypertension NN p
can MD N
be VB N
improved VBN N
by IN N
correcting VBG N
intraocular JJ i
pressure NN i
( ( i
IOP NNP i
) ) i
for IN i
central JJ i
corneal NN i
thickness NN i
( ( i
CCT NNP i
) ) i
. . i

DESIGN NNP N
Reanalysis NNP N
of IN N
the DT N
baseline NN i
prediction NN i
model NN i
for IN N
the DT N
development NN N
of IN N
POAG NNP N
from IN N
the DT N
Ocular NNP N
Hypertension NNP N
Treatment NNP N
Study NNP N
( ( N
OHTS NNP N
) ) N
substituting VBG N
IOP NNP N
adjusted VBD N
for IN N
CCT NNP N
using VBG N
5 CD N
different JJ N
correction NN N
formulae NN N
for IN N
unadjusted JJ N
IOP NNP N
. . N

PARTICIPANTS VB N
A DT p
total NN p
of IN p
1433 CD p
of IN p
1636 CD p
participants NNS p
randomized VBN p
to TO p
OHTS NNP p
who WP p
had VBD p
complete JJ p
baseline NN p
data NNS p
for IN p
factors NNS p
in IN p
the DT p
prediction NN p
model NN p
: : p
age NN p
, , p
IOP NNP p
, , p
CCT NNP p
, , p
vertical JJ p
cup-to-disc NN p
ratio NN p
( ( p
VCDR NNP p
) ) p
, , p
and CC p
pattern JJ p
standard JJ p
deviation NN p
( ( p
PSD NNP p
) ) p
. . p

METHODS NNP N
Reanalysis NNP N
of IN N
the DT N
prediction NN i
model NN i
for IN N
the DT N
risk NN N
of IN N
developing VBG N
POAG NNP N
using VBG N
the DT N
same JJ N
baseline NN N
variables NNS N
( ( N
age NN N
, , N
IOP NNP N
, , N
CCT NNP N
, , N
VCDR NNP N
, , N
and CC N
PSD NNP N
) ) N
except IN N
that DT N
IOP NNP N
was VBD N
adjusted VBN N
for IN N
CCT NNP N
using VBG N
correction NN N
formulae NN N
. . N

A DT N
separate JJ N
Cox NNP N
proportional NN N
hazards NNS N
model NN N
was VBD N
run VBN N
using VBG N
IOP NNP N
adjusted VBD N
for IN N
CCT NNP N
by IN N
each DT N
of IN N
the DT N
5 CD N
formulae NN N
published VBN N
to TO N
date NN N
. . N

Models NNS N
were VBD N
run VBN N
including VBG N
and CC N
excluding VBG N
CCT NNP N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Predictive NNP o
accuracy NN o
of IN o
each DT o
Cox NNP o
proportional JJ o
hazards NNS o
model NN o
was VBD N
assessed VBN N
using VBG N
the DT o
c-statistic JJ o
and CC o
calibration JJ o
chi-square NN o
. . o

RESULTS NNP N
C-statistics NNPS N
for IN N
prediction NN N
models NNS N
that IN N
used VBD N
IOP NNP N
adjusted VBD N
for IN N
CCT NNP N
by IN N
various JJ N
formulas NNS N
ranged VBD N
from IN N
0.75 CD N
to TO N
0.77 CD N
, , N
no DT N
better JJR N
than IN N
the DT N
original JJ N
prediction NN N
model NN N
( ( N
0.77 CD N
) ) N
that WDT N
did VBD N
not RB N
adjust VB N
IOP NNP N
for IN N
CCT NNP N
. . N

Calibration NNP N
chi-square NN N
was VBD N
acceptable JJ N
for IN N
all DT N
models NNS N
. . N

Baseline NNP o
IOP NNP o
, , N
whether IN N
adjusted VBN N
for IN N
CCT NNP N
or CC N
not RB N
, , N
was VBD N
statistically RB N
significant JJ N
in IN N
all DT N
models NNS N
including VBG N
those DT N
with IN N
CCT NNP N
in IN N
the DT N
same JJ N
model NN N
. . N

The DT N
CCT NNP o
was VBD N
statistically RB N
significant JJ N
in IN N
all DT N
models NNS N
including VBG N
those DT N
with IN N
IOP NNP N
adjusted VBD N
for IN N
CCT NNP N
in IN N
the DT N
same JJ N
model NN N
. . N

CONCLUSIONS VB N
The DT N
calculation NN N
of IN N
individual JJ N
risk NN N
for IN N
developing VBG N
POAG NNP N
in IN N
ocular JJ p
hypertensive JJ p
individuals NNS p
is VBZ N
simpler JJR N
and CC N
equally RB N
accurate JJ N
using VBG N
IOP NNP N
and CC N
CCT NNP N
as IN N
measured VBN N
, , N
rather RB N
than IN N
applying VBG N
an DT N
adjustment NN N
formula NN N
to TO N
correct VB N
IOP NNP N
for IN N
CCT NNP N
. . N

-DOCSTART- -19247233- O O

Using VBG N
a DT N
novel NN N
wound NN N
model NN N
to TO N
investigate VB N
the DT N
healing NN o
properties NNS o
of IN N
products NNS N
for IN N
superficial JJ N
wounds NNS N
. . N

OBJECTIVE NNP N
To TO N
establish VB N
a DT N
new JJ N
wound NN N
model NN N
that WDT N
can MD N
induce VB N
uniform JJ N
abrasions NNS N
and CC N
use VB N
it PRP N
to TO N
assess VB N
the DT N
healing NN o
properties NNS o
of IN N
a DT N
range NN N
of IN N
products NNS N
commonly RB N
applied VBD N
to TO N
these DT N
wounds NNS N
. . N

METHOD NNP N
Ten NNP p
healthy JJ p
volunteers NNS p
were VBD N
enrolled VBN N
into IN N
an DT N
open-label JJ N
, , N
randomised JJ N
, , N
intra-individual JJ N
comparison NN N
pilot NN N
study NN N
. . N

Five CD N
standardised JJ N
, , N
superficial JJ N
abrasions NNS N
were VBD N
induced VBN N
on IN N
their PRP$ N
forearms NNS N
by IN N
repeatedly RB N
scrubbing VBG N
the DT N
skin NN N
with IN N
a DT N
surgical JJ N
brush NN N
until IN N
the DT N
first JJ N
signs NNS N
of IN N
uniform JJ N
glistening NN N
and CC N
punctuate NN N
bleeding NN N
were VBD N
observed VBN N
. . N

Three CD N
products NNS N
that WDT N
promote VBP N
a DT N
moist NN N
wound NN N
environment NN N
( ( i
polyurethane NN i
, , i
hydrocolloid NN i
, , i
hydrogel NN i
) ) i
and CC N
two CD i
standard JJ i
plasters NNS i
were VBD N
randomly RB N
allocated VBN N
to TO N
the DT N
test NN N
areas NNS N
. . N

RESULTS NNP N
Evaluation NNP o
of IN o
wound NN o
healing VBG o
on IN N
days NNS N
2 CD N
, , N
5 CD N
, , N
8 CD N
and CC N
14 CD N
+/- JJ N
1 CD N
showed VBD N
best RBS N
results NNS N
for IN N
the DT N
polyurethane NN i
and CC N
hydrocolloid JJ i
plasters NNS N
. . N

Visible JJ o
re-epithelialisation NN o
was VBD N
recorded VBN N
on IN N
days NNS N
5 CD N
and CC N
8 CD N
. . N

More JJR N
than IN N
50 CD N
% NN N
of IN N
the DT N
wound JJ o
area NN o
had VBD o
closed VBN o
. . o

Video NNP N
microscope NN N
images VBZ N
support VB N
these DT N
findings NNS N
. . N

The DT N
investigator NN N
and CC N
volunteers NNS N
assessed VBD N
cosmetic JJ o
outcomes NNS o
on IN N
day NN N
31 CD N
+/- JJ N
2 CD N
. . N

Best JJS N
results NNS N
were VBD N
obtained VBN N
for IN N
the DT N
polyurethane NN N
and CC N
hydrocolloid NN N
products NNS N
, , N
which WDT N
had VBD N
high JJ o
mean NN o
scores NNS o
close RB N
to TO N
the DT N
maximum NN N
of IN N
10 CD N
. . N

Histological JJ o
examination NN o
of IN o
biopsies NNS o
taken VBN N
from IN N
the DT N
abrasions NNS N
of IN N
two CD N
volunteers NNS N
showed VBD N
the DT N
dermis NN o
remained VBD o
intact JJ o
, , N
making VBG N
the DT N
model NN N
highly RB N
suitable JJ N
for IN N
the DT N
study NN N
of IN N
superficial JJ N
wounds NNS N
. . N

CONCLUSION NNP N
Uniform NNP N
and CC N
identical JJ N
standardised VBD N
wounds NNS N
created VBN N
using VBG N
an DT N
abrasive JJ N
brush NN N
technique NN N
can MD N
be VB N
used VBN N
to TO N
reliably VB N
detect JJ N
differences NNS N
in IN N
the DT N
performance NN o
of IN o
plasters NNS o
intended VBN N
for IN N
superficial JJ p
wounds NNS p
. . p

In IN N
general JJ N
, , N
products NNS N
that IN N
promote VBP N
a DT N
moist NN N
wound NN N
environment NN N
produced VBD N
better JJR N
results NNS N
than IN N
those DT N
that WDT N
promote VBP N
a DT N
dry JJ N
wound NN N
environment NN N
, , N
with IN N
an DT N
earlier JJR N
onset NN N
of IN N
healing NN o
and CC N
better JJR N
healing VBG o
outcomes NNS o
. . o

Superficial NNP N
cutaneous JJ N
wounds NNS N
treated VBN N
with IN N
polyurethane NN i
or CC N
hydrocolloid NN i
products NNS N
demonstrated VBD N
superior JJ N
rates NNS N
of IN N
re-epithelialisation NN o
and CC o
overall JJ o
cosmetic JJ o
outcomes NNS o
. . o

DECLARATION NNP N
OF IN N
INTEREST NNP N
This DT N
study NN N
was VBD N
funded VBN N
by IN N
Beiersdorf NNP N
AG NNP N
. . N

Neither CC N
author NN N
has VBZ N
any DT N
interest NN N
in IN N
the DT N
sponsor NN N
's POS N
commercial JJ N
activities NNS N
. . N

-DOCSTART- -21304253- O O

[ JJ N
Efficacy NNP N
of IN N
naftopidil NN i
in IN N
patients NNS p
with IN p
overactive JJ p
bladder NN p
associated VBN p
with IN p
benign JJ p
prostatic JJ p
hyperplasia NN p
: : p
prospective JJ N
randomized NN N
controlled VBD N
study NN N
to TO N
compare VB N
differences NNS N
in IN N
efficacy NN N
between IN N
morning NN N
and CC N
evening VBG N
medication NN N
] NNP N
. . N

A NNP N
total NN p
of IN p
100 CD p
patients NNS p
with IN p
benign JJ p
prostatic JJ p
hyperplasia NN p
( ( p
BPH NNP p
) ) p
and CC p
overactive JJ p
bladder NN p
( ( p
OAB NNP p
) ) p
symptoms NNS p
( ( p
BPH/OAB NNP p
) ) p
, , p
enrolled VBN p
between IN p
June NNP p
2006 CD p
to TO p
March NNP p
2008 CD p
, , N
were VBD N
randomly RB N
divided VBN N
into IN N
2 CD N
groups NNS N
of IN N
morning NN N
medication NN N
( ( N
M NNP N
) ) N
and CC N
evening VBG N
medication NN N
( ( N
E NNP N
) ) N
groups NNS N
, , N
then RB i
50 CD i
mg NN i
of IN i
naftopidil NN i
was VBD i
given VBN i
once RB i
a DT i
day NN i
after IN i
breakfast NN i
or CC i
supper NN i
for IN i
8 CD i
weeks NNS i
. . i

Data NNS N
were VBD N
available JJ N
for IN N
efficacy NN N
analysis NN N
on IN N
80 CD N
patients NNS N
( ( N
M NNP N
group NN N
; : N
43 CD N
, , N
E NNP N
group NN N
; : N
37 CD N
) ) N
. . N

Naftopidil NNP i
significantly RB N
improved VBD N
the DT N
overall JJ o
international JJ o
prostatic JJ o
symptom NN o
score NN o
; : N
from IN N
19.2?7.9 CD N
to TO N
11.7?5.8 CD N
in IN N
the DT N
M NNP N
group NN N
and CC N
from IN N
19.4?6.4 CD N
to TO N
12.3?6.8 CD N
in IN N
the DT N
E NNP N
group NN N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
, , N
QOL NNP N
score NN N
from IN N
4.9?0.8 CD N
to TO N
3.2?1.4 CD N
in IN N
the DT N
M NNP N
group NN N
and CC N
from IN N
5.0?0.8 CD N
to TO N
3.6?1.3 CD N
in IN N
the DT N
E NNP N
group NN N
( ( N
p JJ N
< NNP N
0.0001 CD o
) ) o
, , o
and CC o
OAB NNP o
symptom VBD o
score NN o
from IN o
7.8?2.6 CD N
to TO N
5.0?2.5 CD N
in IN N
the DT N
M NNP N
group NN N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
and CC N
from IN N
8.6?2.9 CD N
to TO N
5.8? CD N
3.3 CD N
in IN N
the DT N
E NNP N
group NN N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
incidence NN N
of IN N
adverse JJ o
effects NNS o
between IN o
the DT N
M NNP N
group NN N
( ( N
6.1 CD N
% NN N
) ) N
and CC N
E NNP N
group NN N
( ( N
2.2 CD N
% NN N
) ) N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
naftopidil JJ N
improves NNS o
storage NN o
symptoms NNS o
as RB o
well RB o
as IN o
voiding VBG o
symptoms NNS o
regardless RB o
of IN N
timing NN N
of IN N
administration NN N
. . N

-DOCSTART- -10100592- O O

A DT N
comparative JJ N
study NN N
of IN N
administration NN N
methods NNS N
of IN N
granisetron NN i
injection NN i
used VBN N
to TO N
treat VB N
nausea/vomiting VBG N
induced VBN N
by IN N
cancer NN N
chemotherapy NN N
without IN N
cisplatin NN N
in IN N
tumors NNS p
of IN p
hematopoietic JJ p
organs NNS p
. . p

Keihanshin NNP N
Study NNP N
Group NNP N
of IN N
Hematological NNP N
Malignancies NNP N
. . N

PURPOSE VB N
The DT N
antiemetic JJ N
effect NN N
of IN N
granisetron NN i
injection NN i
at IN N
a DT N
dose NN N
of IN N
40 CD N
microg/kg NNS N
used VBN N
in IN N
the DT N
treatment NN N
of IN N
nausea/vomiting VBG N
induced VBN N
by IN N
multidrug NN i
combined VBN i
cancer NN i
chemotherapy NN i
excluding VBG i
cisplatin NN i
in IN N
patients NNS p
with IN p
tumors NNS p
of IN p
hematopoietic JJ p
organs NNS p
was VBD N
evaluated VBN N
by IN N
comparing VBG N
a DT N
30-min JJ N
infusion NN N
and CC N
a DT N
slow JJ N
intravenous JJ N
injection NN N
given VBN N
over IN N
30 CD N
s. JJ N
METHODS NNP N
A DT N
two-group JJ N
random-allocation NN N
comparative NN N
study NN N
was VBD N
performed VBN N
with IN N
the DT N
cooperation NN N
of IN N
multiple JJ p
institutions NNS p
using VBG p
a DT p
central JJ p
registration NN p
system NN p
. . p

RESULTS NNP N
In IN N
the DT N
treatment NN N
of IN N
acute JJ N
clinical JJ N
symptoms NNS N
, , N
appetite NN o
was VBD N
described VBN N
as IN N
similar JJ N
to TO N
that IN N
during IN N
good JJ N
health NN N
by IN N
61.1 CD N
% NN N
of IN N
patients NNS N
( ( p
55/93 CD p
) ) p
in IN N
the DT N
instillation NN N
group NN N
and CC N
by IN N
47.3 CD N
% NN N
( ( p
44/93 CD p
) ) p
in IN N
the DT N
slow JJ N
injection NN N
group NN N
, , N
a DT N
significant JJ N
advantage NN N
in IN N
the DT N
infusion NN N
group NN N
. . N

However RB N
, , N
no DT o
significant JJ o
differences NNS o
in IN N
the DT N
number NN o
of IN o
episodes NNS o
of IN o
vomiting NN o
, , o
the DT o
severity NN o
of IN o
nausea NN o
or CC o
clinical JJ o
efficacy NN o
were VBD N
found VBN N
. . N

In IN N
the DT N
final JJ N
clinical JJ N
evaluation NN N
and CC N
assessment NN N
of IN N
usefulness NN N
based VBN N
on IN N
the DT N
subjective JJ N
judgement NN N
of IN N
physicians NNS N
throughout IN N
the DT N
entire JJ N
therapeutic JJ N
period NN N
, , N
no DT N
differences NNS N
were VBD N
discernible JJ N
. . N

No DT N
side NN N
effects NNS N
were VBD N
reported VBN N
for IN N
either DT N
method NN N
and CC N
there EX N
was VBD N
no DT N
indication NN N
of IN N
a DT N
sex NN N
difference NN N
concerning VBG N
efficacy NN N
. . N

However RB N
, , N
the DT N
efficacy NN o
in IN o
patients NNS o
with IN N
an DT N
anemic JJ N
tendency NN N
was VBD N
slightly RB o
inferior JJ o
. . o

CONCLUSIONS VB N
The DT N
maintenance NN N
of IN N
appetite NN N
during IN N
the DT N
administration NN N
of IN N
anticancer NN N
drugs NNS N
is VBZ N
very RB N
important JJ N
to TO N
maintain VB N
patients NNS N
' POS N
daily JJ N
activities NNS N
and CC N
quality NN N
of IN N
life NN N
. . N

The DT N
present JJ N
results NNS N
support VB N
the DT N
usefulness NN N
of IN N
infusion NN N
of IN N
granisetron NN i
as IN N
an DT N
administration NN N
method NN N
during IN N
chemotherapy NN N
for IN N
malignant JJ N
hemopathy NN N
. . N

-DOCSTART- -26316279- O O

Use NNP N
of IN N
the DT N
learning VBG i
conversation NN i
improves NNS N
instructor VBP p
confidence NN p
in IN p
life NN p
support NN p
training NN p
: : p
An DT N
open JJ N
randomised VBN N
controlled VBD N
cross-over JJ N
trial NN N
comparing VBG N
teaching VBG N
feedback NN N
mechanisms NN N
. . N

AIMS NNP N
Feedback NNP N
is VBZ N
vital JJ N
for IN N
the DT N
effective JJ N
delivery NN N
of IN N
skills-based JJ N
education NN N
. . N

We PRP N
sought VBD N
to TO N
compare VB N
the DT N
sandwich NN i
technique NN i
and CC N
learning VBG i
conversation NN i
structured VBD N
methods NNS N
of IN N
feedback NN N
delivery NN N
in IN N
competency-based JJ N
basic JJ N
life NN N
support NN N
( ( N
BLS NNP N
) ) N
training NN N
. . N

METHODS NNP N
Open NNP N
randomised VBD N
crossover NN N
study NN N
undertaken VBP N
between IN p
October NNP p
2014 CD p
and CC p
March NNP p
2015 CD p
at IN p
the DT p
University NNP p
of IN p
Birmingham NNP p
, , p
United NNP p
Kingdom NNP p
. . p

Six-hundred NNP p
and CC p
forty NN p
healthcare NN p
students NNS p
undertaking VBG p
a DT p
European JJ p
Resuscitation NNP p
Council NNP p
( ( p
ERC NNP p
) ) p
BLS NNP p
course NN p
were VBD p
enrolled VBN p
, , p
each DT p
of IN p
whom WP p
was VBD p
randomised VBN p
to TO p
receive VB p
teaching VBG i
using VBG i
either CC i
the DT i
sandwich NN i
technique NN i
or CC i
the DT i
learning JJ i
conversation NN i
. . i

Fifty-eight JJ p
instructors NNS p
were VBD p
randomised VBN p
to TO p
initially RB p
teach VB p
using VBG p
either CC p
the DT p
learning JJ i
conversation NN i
or CC i
sandwich NN i
technique NN i
, , N
prior RB N
to TO N
crossing-over NN N
and CC N
teaching NN N
with IN N
the DT N
alternative NN N
technique NN N
after IN N
a DT N
pre-defined JJ N
time NN N
period NN N
. . N

Outcome NNP N
measures NNS N
included VBD N
skill JJ o
acquisition NN o
as IN o
measured VBN o
by IN o
an DT o
end-of-course JJ o
competency NN o
assessment NN o
, , o
instructors NNS o
' POS o
perception NN o
of IN o
teaching VBG o
with IN o
each DT o
feedback NN o
technique NN o
and CC o
candidates NNS o
' POS o
perception NN o
of IN o
the DT o
feedback NN o
they PRP o
were VBD o
provided VBN o
with IN o
. . o

RESULTS NNP N
Scores NNP N
assigned VBD N
to TO N
use VB N
of IN N
the DT N
learning VBG N
conversation NN N
by IN N
instructors NNS N
were VBD N
significantly RB N
more RBR N
favourable JJ N
than IN N
for IN N
the DT N
sandwich NN N
technique NN N
across IN N
all DT N
but CC N
two CD N
assessed VBD N
domains NNS N
relating VBG N
to TO N
instructor VB o
perception NN o
of IN o
the DT o
feedback NN o
technique NN o
, , N
including VBG N
all DT N
skills-based JJ N
domains NNS N
. . N

No DT N
difference NN N
was VBD N
seen VBN N
in IN N
either DT N
assessment JJ o
pass NN o
rates NNS o
( ( N
80.9 CD N
% NN N
sandwich NN N
technique NN N
vs. FW N
77.2 CD N
% NN N
learning JJ N
conversation NN N
; : N
OR CC N
1.2 CD N
, , N
95 CD N
% NN N
CI NNP N
0.85-1.84 CD N
; : N
p=0.29 NN N
) ) N
or CC N
any DT N
domain NN N
relating NN N
to TO N
candidates NNS N
' POS N
perception NN N
of IN N
their PRP$ N
teaching NN N
technique NN N
. . N

CONCLUSIONS NNP N
& CC N
RELEVANCE NNP N
This DT N
is VBZ N
the DT N
first JJ N
direct JJ N
comparison NN N
of IN N
two CD N
feedback NN N
techniques NNS N
in IN N
clinical JJ N
medical JJ N
education NN N
using VBG N
both DT N
quantitative JJ N
and CC N
qualitative JJ N
methodology NN N
. . N

The DT N
learning JJ i
conversation NN i
is VBZ N
preferred VBN N
by IN N
instructors NNS p
providing VBG p
competency-based JJ p
life NN p
support NN p
training NN p
and CC N
is VBZ N
perceived VBN N
to TO N
favour VB N
skills NNS N
acquisition NN N
. . N

-DOCSTART- -17466465- O O

Development NNP N
, , N
description NN N
, , N
and CC N
acceptability NN N
of IN N
a DT N
small-group NN i
, , i
behavioral JJ i
intervention NN i
to TO N
prevent VB N
HIV NNP N
and CC N
hepatitis NN N
C NNP N
virus NN N
infections NNS N
among IN N
young JJ p
adult NN p
injection JJ p
drug NN p
users NNS p
. . p

Young NNP p
injection NN p
drug NN p
users NNS p
( ( p
IDUs NNP p
) ) p
who WP p
are VBP p
not RB p
infected VBN p
with IN p
HIV NNP p
or CC p
hepatitis NN p
C NNP p
virus NN p
are VBP N
at IN N
great JJ N
risk NN N
of IN N
acquiring VBG N
one CD N
or CC N
both DT N
of IN N
these DT N
infections NNS N
through IN N
their PRP$ N
sexual JJ N
or CC N
injection NN N
behaviors NNS N
. . N

We PRP N
describe VBP N
the DT N
development NN N
of IN N
a DT N
behavioral JJ N
intervention NN N
designed VBN N
to TO N
decrease VB N
sexual JJ o
and CC o
injection NN o
risk NN o
behaviors NNS o
among IN N
young JJ p
IDUs NNP p
. . p

The DT N
intervention NN N
was VBD N
developed VBN N
through IN N
a DT N
dynamic JJ N
and CC N
iterative JJ N
process NN N
that WDT N
involved VBD N
extensive JJ N
development NN N
activities NNS N
, , N
focus NN N
groups NNS N
with IN N
the DT N
target NN N
population NN N
to TO N
pilot VB N
individual JJ N
activities NNS N
and CC N
intervention NN N
sessions NNS N
, , N
and CC N
later RB N
, , N
pilot NN N
testing NN N
of IN N
the DT N
entire JJ N
intervention NN N
. . N

The DT N
six-session NN N
intervention NN N
that WDT N
emerged VBD N
from IN N
the DT N
development NN N
process NN N
relied VBN N
on IN N
both DT N
social-cognitive JJ i
theories NNS i
and CC i
peer VB i
influence NN i
models NNS i
. . i

We PRP N
also RB N
designed VBD N
a DT N
control NN N
intervention NN N
, , N
trained VBD N
facilitators NNS N
to TO N
deliver VB N
the DT N
interventions NNS N
, , N
and CC N
conducted VBD N
quality NN N
assurance NN N
of IN N
intervention NN N
delivery NN N
. . N

To TO N
better JJR N
understand VB N
intervention NN N
trial NN N
findings NNS N
, , N
we PRP N
asked VBD N
participants NNS N
about IN N
their PRP$ N
intervention NN N
experiences NNS N
and CC N
examined VBD N
potential JJ N
contamination NN N
across IN N
arms NNS N
. . N

Both DT N
interventions NNS N
were VBD N
delivered VBN N
with IN N
high JJ N
fidelity NN N
and CC N
participants NNS N
in IN N
both DT N
groups NNS N
reported VBD N
positive JJ N
experiences NNS N
. . N

More JJR N
perceived JJ o
impact NN o
was VBD N
reported VBN N
for IN N
injection NN o
risk NN o
behaviors NNS o
than IN N
for IN N
sexual JJ o
risk NN o
behaviors NNS o
among IN N
participants NNS N
in IN N
the DT N
intervention NN N
arm NN N
. . N

Minimal JJ N
evidence NN N
of IN N
contamination NN o
was VBD N
found VBN N
. . N

Lessons NNS N
learned VBD N
can MD N
help VB N
future VB N
researchers NNS N
to TO N
develop VB N
stronger JJR N
interventions NNS N
for IN N
this DT N
high-need JJ N
population NN N
. . N

-DOCSTART- -24035299- O O

Effect NN N
of IN N
phrenic JJ N
nerve NN N
palsy NN N
on IN N
early JJ N
postoperative JJ N
lung NN N
function NN N
after IN N
pneumonectomy NN p
: : p
a DT N
prospective JJ N
study NN N
. . N

BACKGROUND NNP N
The DT N
issue NN N
of IN N
phrenic JJ N
nerve NN N
preservation NN N
during IN N
pneumonectomy NN i
is VBZ N
still RB N
an DT N
unanswered JJ N
question NN N
. . N

So RB N
far RB N
, , N
its PRP$ N
direct JJ N
effect NN N
on IN N
immediate JJ N
postoperative JJ N
pulmonary NN N
lung NN N
function NN N
has VBZ N
never RB N
been VBN N
evaluated VBN N
in IN N
a DT N
prospective JJ N
trial NN N
. . N

METHODS NNP N
We PRP N
conducted VBD N
a DT N
prospective JJ N
crossover NN N
study NN N
including VBG N
10 CD p
patients NNS p
undergoing JJ p
pneumonectomy NN i
for IN p
lung NN p
cancer NN p
between IN p
July NNP p
2011 CD p
and CC p
July NNP p
2012 CD p
. . p

After IN N
written VBN N
informed JJ N
consent NN N
, , N
all DT p
consecutive JJ p
patients NNS p
who WP p
agreed VBD p
to TO p
take VB p
part NN p
in IN p
the DT p
study NN p
and CC p
in IN p
whom WP p
preservation NN p
of IN p
the DT p
phrenic JJ p
nerve NN p
during IN p
operation NN p
was VBD p
possible JJ p
, , p
were VBD p
included VBN p
in IN p
the DT p
study NN p
. . p

Upon IN N
completion NN N
of IN N
lung NN N
resection NN N
, , N
a DT N
catheter NN N
was VBD N
placed VBN N
in IN N
the DT N
proximal JJ N
paraphrenic JJ N
tissue NN N
on IN N
the DT N
pericardial JJ N
surface NN N
. . N

After IN N
an DT N
initial JJ N
phase NN N
of IN N
recovery NN N
of IN N
5 CD N
days NNS N
all DT N
patients NNS N
underwent JJ N
ultrasonographic JJ i
assessment NN N
of IN N
diaphragmatic JJ N
motion NN N
followed VBN N
by IN N
lung NN N
function NN N
testing VBG N
with IN N
and CC N
without IN N
induced JJ N
phrenic JJ N
nerve NN N
palsy NN N
. . N

The DT N
controlled VBN N
, , N
temporary JJ N
paralysis NN N
of IN N
the DT N
ipsilateral JJ N
hemidiaphragm NN N
was VBD N
achieved VBN N
by IN N
local JJ N
administration NN N
of IN i
lidocaine JJ i
1 CD i
% NN i
at IN N
a DT N
rate NN N
of IN N
3 CD N
mL/h NN N
( ( N
30 CD N
mg/h NN N
) ) N
via IN N
the DT N
above-mentioned JJ N
catheter NN N
. . N

RESULTS NNP o
Temporary NNP o
phrenic JJ o
nerve NN o
palsy NN o
was VBD N
accomplished VBN N
in IN N
all DT N
but CC N
1 CD N
patient NN N
with IN N
suspected JJ N
catheter NN N
dislocation NN N
. . N

Spirometry NN N
showed VBD N
a DT N
significant JJ N
decrease NN N
in IN o
dynamic JJ o
lung NN o
volumes NNS o
( ( N
forced JJ N
expiratory NN N
volume NN N
in IN N
1 CD N
second JJ N
and CC N
forced JJ N
vital JJ N
capacity NN N
; : N
p CC N
< VB N
0.05 CD N
) ) N
with IN N
the DT N
paralyzed JJ N
hemidiaphragm NN N
. . N

Blood NNP o
oxygen NN o
saturation NN o
levels NNS o
did VBD N
not RB N
change VB N
significantly RB N
. . N

CONCLUSIONS VB N
Our PRP$ N
results NNS N
show VBP N
that IN N
phrenic JJ N
nerve NN N
palsy NN N
causes VBZ N
a DT N
significant JJ N
impairment NN N
of IN o
dynamic JJ o
lung NN o
volumes NNS o
during IN N
the DT N
early JJ N
postoperative JJ N
period NN N
after IN i
pneumonectomy NN i
. . i

Therefore RB N
, , N
in IN N
these DT N
already RB N
compromised JJ N
patients NNS N
, , N
intraoperative JJ N
phrenic NN N
nerve NN N
injury NN N
should MD N
be VB N
avoided VBN N
whenever WRB N
possible JJ N
. . N

-DOCSTART- -15769918- O O

Controlled VBN N
clinical JJ N
trial NN N
of IN N
IV NNP N
cyclophosphamide NN i
versus NN N
IV NNP N
methylprednisolone NN i
in IN N
severe JJ p
neurological JJ p
manifestations NNS p
in IN p
systemic JJ p
lupus NN p
erythematosus NN p
. . p

BACKGROUND NNP N
Severe NNP p
neurological JJ p
involvement NN p
in IN p
systemic JJ p
lupus NN p
erythematosus NN p
( ( p
NPSLE NNP p
) ) p
is VBZ N
one CD N
of IN N
the DT N
most RBS N
dreadful JJ N
complications NNS N
of IN N
the DT N
disease NN N
. . N

OBJECTIVE UH N
To TO N
identify VB N
the DT N
best JJS N
drug NN N
, , N
dose NN N
, , N
and CC N
treatment NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
The DT N
study NN N
was VBD N
a DT N
controlled JJ N
clinical JJ N
trial NN N
at IN N
two CD p
tertiary JJ p
care NN p
centres NNS p
of IN p
patients NNS p
with IN p
SLE NNP p
according VBG p
to TO p
the DT p
ACR NNP p
criteria NNS p
, , p
with IN p
incident NN p
( ( p
no DT p
more JJR p
than IN p
15 CD p
days NNS p
) ) p
onset NN p
of IN p
severe JJ p
NP NNP p
manifestations NNS p
such JJ p
as IN p
seizures NNS p
, , p
optic JJ p
neuritis NN p
, , p
peripheral JJ p
or CC p
cranial JJ p
neuropathy NN p
, , p
coma NN p
, , p
brainstem NN p
disease NN p
, , p
or CC p
transverse JJ p
myelitis NN p
. . p

Induction NNP N
treatment NN N
with IN N
3 CD N
g NN N
of IN N
IV NNP N
methylprednisolone NN i
( ( N
MP NNP N
) ) N
followed VBN N
by IN N
either DT N
IV NNP N
monthly JJ N
cyclophosphamide NN i
( ( N
Cy NNP N
) ) N
versus NN N
IV NNP i
MP NNP i
bimonthly RB i
every DT N
4 CD N
months NNS N
for IN N
1 CD N
year NN N
and CC N
then RB N
IV NNP N
Cy NNP N
or CC N
IV NNP N
MP NNP N
every DT N
3 CD N
months NNS N
for IN N
another DT N
year NN N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
response NN o
to TO o
treatment NN o
: : o
at IN N
least JJS N
20 CD o
% NN o
improvement NN o
from IN o
basal JJ o
conditions NNS o
on IN N
clinical JJ o
, , o
laboratory NN o
, , o
or CC o
specific JJ o
neurological JJ o
testing NN o
variables NNS o
. . o

RESULTS NNP N
Overall NNP N
, , N
a DT N
response NN o
rate NN o
of IN N
75 CD N
% NN N
was VBD N
observed VBN N
. . N

Of IN N
the DT N
32 CD p
patients NNS p
studied VBN p
, , N
18/19 CD N
receiving VBG N
Cy NNP N
and CC N
7/13 CD N
receiving VBG N
MP NNP N
responded VBD N
to TO N
treatment NN N
( ( N
p JJ N
< NNP N
0.03 CD N
) ) N
. . N

CONCLUSIONS NNP N
Cy NNP N
seems VBZ N
to TO N
be VB N
more RBR N
effective JJ o
than IN N
MP NNP N
in IN N
the DT N
treatment NN N
of IN N
acute NN N
, , N
severe JJ N
NPSLE NNP N
. . N

-DOCSTART- -22020134- O O

Docosahexaenoic NNP i
acid-rich JJ i
fish JJ i
oil NN i
modulates VBZ N
the DT N
cerebral JJ o
hemodynamic JJ o
response NN o
to TO N
cognitive JJ N
tasks NNS N
in IN N
healthy JJ p
young JJ p
adults NNS p
. . p

A DT N
number NN N
of IN N
recent JJ N
studies NNS N
have VBP N
assessed VBN N
the DT N
impact NN N
of IN N
dietary JJ N
omega-3 JJ N
polyunsaturated VBN N
fatty JJ N
acids NNS N
( ( N
n-3 JJ N
PUFAs NNP N
) ) N
on IN N
behavioral JJ N
outcomes NNS N
; : N
however RB N
, , N
very RB N
little JJ N
attention NN N
has VBZ N
been VBN N
given VBN N
to TO N
their PRP$ N
impact NN N
upon IN N
brain NN N
function NN N
in IN N
physiological JJ N
terms NNS N
. . N

Sixty-five JJ p
healthy JJ p
adults NNS p
aged VBD p
18-29yrs JJ p
took VBD N
part NN N
in IN N
this DT N
double-blind NN N
, , N
placebo-controlled JJ i
study NN N
assessing VBG N
the DT N
effects NNS N
of IN N
12 CD N
weeks NNS N
daily RB N
dietary JJ N
supplementation NN N
with IN N
docosahexaenoic JJ i
acid-rich JJ i
fish JJ i
oil NN i
( ( N
1g CD N
, , N
2g CD N
) ) N
or CC i
placebo NN i
( ( i
olive JJ i
oil NN i
) ) i
. . i

Relative JJ N
changes NNS N
in IN N
the DT N
concentration NN o
of IN o
oxyhemoglobin NN o
and CC o
deoxyhemoglobin NN o
were VBD N
assessed VBN N
in IN N
the DT N
prefrontal JJ N
cortex NN N
using VBG N
near-infrared JJ N
spectroscopy NN N
during IN N
performance NN N
of IN N
nine CD N
computerized JJ N
cognitive JJ N
tasks NNS N
. . N

Supplementation NN N
with IN N
both DT N
doses NNS N
of IN N
fish JJ N
oil NN N
, , N
in IN N
comparison NN N
with IN N
placebo NN N
, , N
resulted VBD N
in IN N
significantly RB N
increased JJ N
concentrations NNS o
of IN o
oxyhemoglobin NN o
and CC o
total JJ o
levels NNS o
of IN o
hemoglobin NN o
, , N
indicative JJ N
of IN N
increased JJ N
cerebral JJ o
blood NN o
flow NN o
, , N
during IN N
the DT N
cognitive JJ N
tasks NNS N
. . N

Changes NNS N
in IN N
hemodynamic JJ o
response NN N
to TO N
tasks NNS N
were VBD N
not RB N
accompanied VBN N
by IN N
consistent JJ N
changes NNS N
in IN N
cognitive JJ o
performance NN o
. . o

-DOCSTART- -16198776- O O

Pulse NNP i
versus NN i
continuous JJ i
terbinafine NN i
for IN N
onychomycosis NN p
: : p
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
controlled JJ N
trial NN N
. . N

BACKGROUND NNP N
Effective NNP N
treatments NNS N
for IN N
onychomycosis NN N
are VBP N
expensive JJ N
. . N

Previous JJ N
studies NNS N
suggest VBP N
that IN N
less JJR N
costly JJ N
, , N
pulsed JJ N
doses NNS N
of IN N
antifungal JJ i
medications NNS i
may MD N
be VB N
as RB N
effective JJ N
as IN N
standard NN N
, , N
continuous JJ N
doses NNS N
. . N

Terbinafine NNP N
is VBZ N
the DT N
current JJ N
treatment NN N
of IN N
choice NN N
for IN N
toenail JJ N
onychomycosis NN N
. . N

OBJECTIVE CC N
Our PRP$ N
purpose NN N
was VBD N
to TO N
determine VB N
whether IN N
pulse-dose JJ i
terbinafine NN i
is VBZ N
as RB N
effective JJ N
as IN N
standard JJ i
continuous-dose JJ i
terbinafine NN i
for IN N
treatment NN N
of IN N
toenail JJ N
onychomycosis NN N
. . N

METHODS NNP N
We PRP N
conducted VBD N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
noninferiority NN N
, , N
clinical JJ N
intervention NN N
trial NN N
in IN N
the DT N
Minneapolis NNP p
Veterans NNP p
Affairs NNP p
Medical NNP p
Center NNP p
. . p

The DT p
main JJ p
inclusion NN p
criteria NNS p
for IN p
participants NNS p
were VBD p
a DT p
positive JJ p
dermatophyte NN p
culture NN p
and CC p
at IN p
least JJS p
25 CD p
% NN p
distal JJ p
subungual JJ p
clinical JJ p
involvement NN p
. . p

Six CD p
hundred VBD p
eighteen JJ p
volunteers NNS p
were VBD p
screened VBN p
; : p
306 CD p
were VBD p
randomized VBN p
. . p

Terbinafine NNP i
, , N
250 CD N
mg NNS N
daily RB N
for IN N
3 CD N
months NNS N
( ( N
continuous JJ N
) ) N
or CC N
terbinafine NN i
, , N
500 CD N
mg NNS N
daily RB N
for IN N
1 CD N
week NN N
per IN N
month NN N
for IN N
3 CD N
months NNS N
( ( N
pulse NN N
) ) N
was VBD N
administered VBN N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
mycological JJ o
cure NN o
of IN o
the DT o
target NN o
toenail NN o
at IN o
18 CD o
months NNS o
. . o

Secondary JJ N
outcome NN N
measures NNS N
included VBD N
clinical JJ o
cure NN o
and CC o
complete JJ o
( ( o
clinical JJ o
plus CC o
mycological JJ o
) ) o
cure NN o
of IN o
the DT o
target NN o
toenail NN o
and CC o
complete JJ o
cure NN o
of IN o
all DT o
10 CD o
toenails NNS o
. . o

RESULTS NNP N
Results NNP N
of IN N
an DT N
intent-to-treat JJ N
analysis NN N
did VBD N
not RB N
meet VB N
the DT N
prespecified JJ N
criterion NN N
for IN N
noninferiority NN N
but CC N
did VBD N
demonstrate VB N
the DT N
superiority NN N
of IN N
continuous-dose JJ i
terbinafine NN i
for IN N
: : N
mycological JJ o
cure NN o
of IN N
the DT N
target NN N
toenail NN N
( ( N
70.9 CD N
% NN N
[ CC N
105/148 CD N
] JJ N
vs RB N
58.7 CD N
% NN N
[ CC N
84/143 CD N
] NN N
; : N
P NNP N
=.03 NNP N
, , N
relative JJ o
risk NN o
[ NNP N
RR NNP N
] NNP N
of IN N
1.21 CD N
[ JJ N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
, , N
1.02-1.43 JJ N
] NN N
) ) N
; : N
clinical JJ o
cure NN o
of IN N
the DT N
target NN N
toenail NN N
( ( N
44.6 CD N
% NN N
[ CC N
66/148 CD N
] JJ N
vs RB N
29.3 CD N
% NN N
[ CC N
42/143 CD N
] NN N
; : N
P NNP N
=.007 NNP N
, , N
RR NNP N
=1.52 NNP N
[ VBD N
95 CD N
% NN N
CI NNP N
, , N
1.11-2.07 JJ N
) ) N
; : N
complete JJ o
cure NN o
of IN N
the DT N
target NN N
toenail NN N
( ( N
40.5 CD N
% NN N
[ CC N
60/148 CD N
] JJ N
vs RB N
28.0 CD N
% NN N
[ CC N
40/143 CD N
] NN N
; : N
P NNP N
=.02 NNP N
, , N
RR=1.45 NNP N
[ VBD N
95 CD N
% NN N
CI NNP N
, , N
1.04-2.01 JJ N
) ) N
; : N
and CC N
complete JJ o
cure NN o
of IN N
all DT N
10 CD N
toenails NNS N
( ( N
25.2 CD N
% NN N
[ CC N
36/143 CD N
] JJ N
vs RB N
14.7 CD N
% NN N
[ CC N
21/143 CD N
] NN N
; : N
P NNP N
=.03 NNP N
, , N
RR NNP N
=1.71 NNP N
[ VBD N
95 CD N
% NN N
CI NNP N
, , N
1.05-2.79 JJ N
) ) N
. . N

Tolerability NN o
of IN N
the DT N
regimens NNS N
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
groups NNS N
( ( N
chi2 JJ N
=1.63 NN N
; : N
P NNP N
=.65 NNP N
) ) N
. . N

LIMITATIONS VB N
The DT p
study NN p
population NN p
primarily RB p
consisted VBN p
of IN p
older JJR p
men NNS p
with IN p
severe JJ p
onychomycosis NN p
. . p

CONCLUSIONS VB N
This DT N
study NN N
demonstrated VBD N
the DT N
superiority NN N
of IN N
continuous- NN N
over IN N
pulse-dose JJ i
terbinafine NN i
. . i

We PRP N
also RB N
found VBD N
this DT N
expensive JJ N
therapy NN N
to TO N
be VB N
much RB N
less RBR N
effective JJ o
than IN N
previously RB N
believed VBN N
, , N
particularly RB N
for IN N
achieving VBG N
complete JJ N
cure NN N
of IN N
all DT N
10 CD N
toenails NNS N
. . N

-DOCSTART- -8063348- O O

Effects NNS N
of IN N
short-term JJ N
isotonic JJ i
& CC i
isometric JJ i
training NN i
on IN N
cardiovascular JJ o
& CC o
pulmonary JJ o
function NN o
. . o

A DT N
randomised JJ N
control NN N
trial NN N
of IN N
short-term JJ i
exercises NNS i
on IN N
specific JJ N
cardiovascular JJ N
and CC N
respiratory JJ N
parameters NNS N
was VBD N
undertaken VBN N
in IN p
normal JJ p
male JJ p
college NN p
students NNS p
. . p

The DT N
effects NNS N
of IN N
isotonic JJ i
training NN i
( ( i
5BX CD i
programme NN i
) ) i
and CC i
isometric JJ i
training NN i
( ( i
a DT i
programme NN i
of IN i
isometric JJ i
exercises NNS i
working VBG i
all DT i
major JJ i
groups NNS i
of IN i
muscles NNS i
) ) i
were VBD N
compared VBN N
with IN i
a DT i
control NN i
group NN i
with IN N
no DT N
specific JJ N
workout NN N
. . N

Both DT N
isotonic JJ i
and CC i
isometric JJ i
training NN i
resulted VBD N
in IN N
significant JJ o
cardiovascular JJ o
improvement NN o
but CC N
seemed VBD N
inadequate JJ N
to TO N
improve VB N
vital JJ o
capacity NN o
and CC o
flow NN o
rates NNS o
. . o

Isotonic JJ i
training NN i
in IN N
addition NN N
, , N
improved JJ N
ventilatory NN o
efficiency NN o
. . o

It PRP N
is VBZ N
concluded VBN N
that IN N
such JJ N
isotonic JJ i
or CC i
isometric JJ i
training NN i
of IN N
thrice NN N
a DT N
week NN N
for IN N
ten JJ N
weeks NNS N
, , N
requiring VBG N
no DT N
equipment NN N
, , N
less JJR N
time NN N
and CC N
space NN N
can MD N
be VB N
promoted VBN N
to TO N
improve VB N
physical JJ o
fitness NN o
. . o

-DOCSTART- -12236273- O O

Boosting VBG N
uptake NN o
of IN N
influenza JJ N
immunisation NN N
: : N
a DT N
randomised JJ N
controlled JJ N
trial NN N
of IN N
telephone NN i
appointing VBG i
in IN N
general JJ N
practice NN N
. . N

BACKGROUND NNP N
Immunisation NNP N
against IN N
influenza NN N
is VBZ N
an DT N
effective JJ N
intervention NN N
that WDT N
reduces VBZ N
serologically RB N
confirmed VBN N
cases NNS N
by IN N
between IN N
60 CD N
% NN N
and CC N
70 CD N
% NN N
. . N

Almost NNP N
all DT N
influenza JJ N
immunisation NN N
in IN N
the DT N
UK NNP p
is VBZ N
done VBN N
within IN N
general JJ N
practice NN N
. . N

Current JJ N
evidence NN N
on IN N
the DT N
effectiveness NN N
of IN N
patient JJ N
reminders NNS N
for IN N
all DT N
types NNS N
of IN N
immunisation NN N
programmes NNS N
is VBZ N
largely RB N
based VBN N
on IN N
North JJ N
American JJ N
studies NNS N
. . N

AIM NNP N
To TO N
determine VB N
whether IN N
telephone NN i
appointments NNS i
offered VBD N
bygeneral JJ N
practice NN N
receptionists NNS N
increase VBP N
the DT N
uptake NN o
of IN o
irfluenza JJ o
immunisation NN o
among IN N
the DT N
registered JJ p
population NN p
aged VBD p
over IN p
65 CD p
years NNS p
in IN p
east JJ p
London NNP p
practices NNS p
. . p

DESIGN NNP N
OF NNP N
STUDY NNP N
Randomised VBD N
controlled VBN N
trial NN N
. . N

SETTING NNP N
Three NNP N
research NN N
general JJ N
practices NNS N
within IN N
the DT N
East NNP p
London NNP p
and CC p
Essex NNP p
network NN p
of IN p
researchers NNS p
( ( p
ELENoR NNP p
) ) p
. . p

METHOD JJ N
Participants NNS p
were VBD p
1,820 CD p
low-risk JJ p
patients NNS p
aged VBD p
65 CD p
to TO p
74 CD p
years NNS p
who WP p
had VBD p
not RB p
previously RB p
been VBN p
in IN p
a DT p
recall NN p
system NN p
for IN p
influenza JJ p
immunisation NN p
at IN p
their PRP$ p
general JJ p
practice NN p
. . p

The DT N
intervention NN N
, , N
during IN N
October NNP N
2000 CD N
, , N
was VBD N
a DT N
telephone NN i
call NN i
from IN i
the DT i
practice NN i
receptionist NN i
to TO N
intervention NN i
group NN N
households NNS N
, , N
offering VBG N
an DT N
appointment NN N
for IN N
influenza JJ N
immunisation NN N
at IN N
a DT N
nurse-run JJ N
. . N

clinic JJ N
Main NNP N
outcome NN N
measures NNS N
were VBD N
the DT N
numbers NNS o
of IN o
individuals NNS o
in IN o
each DT o
group NN o
receiving VBG o
immunisation NN o
, , o
and CC o
practice NN o
costs NNS o
of IN o
a DT o
telephone-appointing JJ o
programme NN o
. . o

RESULTS NNP N
intention NN N
to TO N
treat VB N
analysis NN N
showed VBD N
an DT N
immunisation NN o
rate NN o
in IN N
the DT N
control NN i
group NN N
of IN N
44 CD N
% NN N
, , N
compared VBN N
with IN N
50 CD N
% NN N
in IN N
the DT N
intervention NN i
group NN i
( ( N
odds NNS N
ratio VBP N
= JJ N
1.29 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
= VBD N
1.03 CD N
to TO N
1.63 CD N
) ) N
. . N

Of IN N
the DT N
patients NNS p
making VBG p
a DT p
telephone NN i
appointment NN i
, , N
88 CD N
% NN N
recieved JJ N
immunisation NN o
, , N
while IN N
22 CD N
% NN N
of IN N
those DT N
not RB N
wanting VBG N
an DT N
appointment NN N
went VBD N
on IN N
to TO N
be VB N
immunised VBN N
. . N

In IN N
the DT N
controlgroup NN i
, , N
income NN o
generated VBD o
was VBD N
11.35 CD N
pounds NNS N
per IN N
immunisation NN N
, , N
for IN N
each DT N
additional JJ N
immunisation NN N
in IN N
the DT N
intervention NN N
group NN N
the DT N
income NN N
was VBD N
5.20 CD N
pounds NNS N
. . N

The DT N
'number NNP o
needed VBD o
to TO o
telephone NN o
' '' o
was VBD N
17 CD N
. . N

CONCLUSION NNP N
Uptake NNP N
of IN N
influenza JJ N
immunisation NN o
among IN N
the DT N
low-risk JJ p
older JJR p
population NN p
in IN p
inner-city JJ p
areas NNS p
can MD N
be VB N
boosted VBN N
by IN N
around IN N
6 CD N
% NN N
using VBG N
a DT N
simple JJ N
intervention NN i
by IN N
receptionists NNS N
. . N

Immunisation NN o
rates NNS o
in IN N
this DT N
low-risk JJ N
group NN N
fell VBD N
well RB N
short RB N
of IN N
the DT N
60 CD N
% NN N
government NN N
target NN N
. . N

Improving VBG N
immunisation NN o
rates NNS o
will MD N
require VB N
a DT N
sustained JJ N
public JJ N
health NN N
campaign NN N
. . N

Retaining VBG N
the DT N
item-of-service JJ N
payments NNS N
to TO N
practices NNS N
should MD N
support VB N
costs NNS N
of IN N
practice-based JJ N
interventions NNS N
. . N

-DOCSTART- -10832774- O O

Assessment NN N
in IN N
multisite JJ N
randomized JJ N
clinical JJ N
trials NNS N
of IN N
patients NNS p
with IN p
autistic JJ o
disorder NN o
: : o
the DT p
Autism NNP p
RUPP NNP p
Network NNP p
. . p

Research NNP N
Units VBZ N
on IN N
Pediatric NNP N
Psychopharmacology NNP N
. . N

Assessment NNP N
of IN N
autistic JJ o
disorder NN o
( ( o
autism NN o
) ) o
symptoms NNS o
, , o
primary JJ o
and CC o
secondary JJ o
, , N
poses VBZ N
more RBR N
challenging JJ N
problems NNS N
than IN N
ordinarily RB N
found VBN N
in IN N
multisite JJ N
randomized JJ N
clinical JJ N
trial NN N
( ( N
RCT NNP N
) ) N
assessments NNS N
. . N

For IN N
example NN N
, , N
subjects NNS N
may MD N
be VB N
uncommunicative JJ p
and CC p
extremely RB p
heterogeneous JJ p
in IN p
problem NN p
presentation NN p
, , N
and CC N
current JJ N
pharmacological JJ N
treatments NNS N
are VBP N
not RB N
likely JJ N
to TO N
alter VB N
most JJS N
core NN N
features NNS N
of IN N
autism NN N
. . N

The DT N
Autism NNP N
Research NNP N
Units NNP N
on IN N
Pediatric NNP N
Psychopharmacology NNP N
( ( N
RUPP NNP N
Autism NNP N
Network NNP N
) ) N
resolved VBD N
some DT N
of IN N
these DT N
problems NNS N
during IN N
the DT N
design NN N
of IN N
a DT N
risperidone NN i
RCT NNP i
in IN N
children/adolescents NNS p
. . p

The DT N
inappropriateness NN N
of IN N
the DT N
usual JJ N
anchors NNS N
for IN N
a DT N
Clinical JJ N
Global NNP N
Impression NNP N
of IN N
Severity NNP N
( ( N
CGI-S NNP N
) ) N
was VBD N
resolved VBN N
by IN N
defining VBG N
uncomplicated JJ p
autism NN p
without IN p
secondary JJ p
symptoms NNS p
as IN p
a DT p
CGI-S NNP p
of IN p
3 CD p
, , p
mildly RB p
ill JJ p
. . p

The DT N
communication NN o
problems NNS o
, , N
compromising VBG N
use NN N
of IN N
the DT N
patient NN N
as IN N
an DT N
informant NN N
, , N
were VBD N
addressed VBN N
by IN N
several JJ N
strategies NNS N
, , N
including VBG N
careful JJ o
questioning NN o
of IN o
care NN o
providers NNS o
, , o
rating NN o
scales NNS o
, , o
laboratory NN o
tests NNS o
, , i
and CC i
physical JJ o
exams NN o
. . o

The DT N
broad JJ N
subject JJ N
heterogeneity NN N
requires VBZ N
outcome JJ N
measures NNS N
sensitive JJ N
to TO N
individual JJ N
change NN N
over IN N
a DT N
wide JJ N
spectrum NN N
of IN N
treatment NN N
response NN o
and CC N
side NN o
effects NNS o
. . o

The DT N
problems NNS N
of IN N
neuropsychologically RB N
testing VBG N
nonverbal JJ p
, , p
lower JJR p
functioning NN p
, , p
sometimes RB p
noncompliant JJ p
subjects NNS p
requires VBZ N
careful JJ N
instrument JJ N
selection/adaptation NN N
and CC N
flexible JJ N
administration NN N
techniques NNS N
. . N

The DT N
problems NNS N
of IN N
assessing VBG N
low-end JJ o
IQs NNP o
, , N
neglected VBN N
by IN N
most JJS N
standardized JJ N
test NN N
developers NNS N
, , N
was VBD N
resolved VBN N
by IN N
an DT N
algorithm NN N
of IN N
test NN N
hierarchy NN N
. . N

Scarcity NN N
of IN N
other JJ N
autism-adapted JJ N
cognitive NN N
and CC N
neuropsychological JJ N
tests NNS N
and CC N
lack NN N
of IN N
standardization NN N
required VBN N
development NN N
of IN N
a DT N
new JJ N
, , N
specially RB N
adapted VBN N
battery NN N
. . N

Reliability NN N
on IN N
the DT N
Autism NNP o
Diagnostic NNP o
Interview NNP o
( ( N
currently RB N
the DT N
most RBS N
valid JJ N
diagnostic JJ N
instrument NN N
) ) N
and CC N
other JJ N
clinician JJ N
instruments NNS N
required VBN N
extensive JJ N
cross-site JJ N
training NN N
( ( N
in-person JJ N
, , N
videotape NN N
, , N
and CC N
teleconference NN N
sessions NNS N
) ) N
. . N

Definition NN N
of IN N
a DT N
treatment NN N
responder NN N
required VBN N
focus NN N
on IN N
individually RB N
relevant JJ N
target NN N
symptoms NNS N
, , N
synthesis NN N
of IN N
possible JJ N
modest JJ N
improvements NNS N
in IN N
many JJ N
domains NNS N
, , N
and CC N
acceptance NN N
of IN N
attainable JJ N
though IN N
imperfect JJ N
goals NNS N
. . N

The DT N
assessment NN i
strategy NN i
developed VBD N
is VBZ N
implemented VBN N
in IN N
a DT N
RCT NNP N
of IN N
risperidone NN i
( ( N
McDougle NNP N
et RB N
al. RB N
, , N
2000 CD N
) ) N
for IN N
which WDT N
the DT N
design NN N
and CC N
other JJ N
methodological JJ N
challenges NNS N
are VBP N
described VBN N
elsewhere RB N
( ( N
Scahill NNP N
et VBZ N
al. RB N
, , N
2000 CD N
) ) N
. . N

Some DT N
of IN N
these DT N
problems NNS N
and CC N
solutions NNS N
are VBP N
partially RB N
shared VBN N
with IN N
RCTs NNP N
of IN N
other JJ N
treatments NNS N
and CC N
other JJ N
disorders NNS N
. . N

-DOCSTART- -17133499- O O

Impact NN N
of IN N
disease NN N
severity NN N
on IN N
outcome NN N
of IN N
antiviral JJ i
therapy NN i
for IN N
chronic JJ p
hepatitis NN p
C NNP p
: : p
Lessons NNS N
from IN N
the DT N
HALT-C NNP N
trial NN N
. . N

In IN N
patients NNS p
with IN p
chronic JJ p
hepatitis NN p
C NNP p
, , p
advanced VBD p
fibrosis NN p
and CC p
cirrhosis NN p
are VBP p
associated VBN p
with IN p
lower JJR p
rates NNS p
of IN p
sustained JJ o
virologic JJ o
response NN o
( ( o
SVR NNP o
) ) o
to TO p
interferon VB p
( ( p
IFN NNP p
) ) p
-based VBD p
therapy NN p
. . p

In IN N
this DT N
study NN N
, , N
we PRP N
assessed VBD N
virologic JJ o
response NN o
to TO N
retreatment VB N
with IN N
peginterferon JJ i
alfa-2a JJ i
and CC i
ribavirin NN i
( ( i
RBV NNP i
) ) i
, , N
as IN N
a DT N
function NN N
of IN N
the DT N
baseline NN N
fibrosis NN N
score NN N
( ( N
Ishak NNP N
staging VBG N
) ) N
and CC N
platelet NN N
count NN N
, , N
in IN N
1,046 CD p
patients NNS p
enrolled VBN p
in IN p
the DT p
Hepatitis NNP p
C NNP p
Antiviral NNP p
Long-term NNP p
Treatment NNP p
against IN p
Cirrhosis NNP p
( ( p
HALT-C NNP p
) ) p
Trial NNP p
. . p

All DT p
patients NNS p
had VBD p
failed VBN p
prior RB p
treatment NN p
with IN p
IFN NNP i
or CC p
peginterferon VB i
+/- JJ i
RBV NNP i
and CC p
had VBD p
Ishak NNP p
fibrosis NN p
scores VBZ p
> CD p
or CC p
= VB p
3 CD p
. . p

Four CD p
groups NNS p
of IN p
patients NNS p
with IN p
increasingly RB p
severe JJ p
liver NN p
disease NN p
were VBD p
compared VBN p
: : p
( ( N
A DT N
) ) N
bridging NN N
fibrosis NN N
( ( N
Ishak NNP N
3 CD N
and CC N
4 CD N
) ) N
with IN N
platelet NN N
counts NNS N
> VBP N
125,000/mm3 CD N
( ( N
n JJ N
= NNP N
559 CD N
) ) N
; : N
( ( N
B NNP N
) ) N
bridging VBG N
fibrosis NN N
with IN N
platelet NN N
counts NNS N
< VBP N
or CC N
=125,000/mm3 NNP N
( ( N
n JJ N
= NNP N
96 CD N
) ) N
; : N
( ( N
C NNP N
) ) N
cirrhosis NN N
( ( N
Ishak NNP N
5 CD N
and CC N
6 CD N
) ) N
with IN N
platelet NN N
counts NNS N
> VBP N
125,000/mm3 CD N
( ( N
n JJ N
= NNP N
198 CD N
) ) N
; : N
and CC N
( ( N
D NNP N
) ) N
cirrhosis NN N
with IN N
platelet NN N
counts NNS N
< VBP N
or CC N
=125,000/mm3 NNP N
( ( N
n JJ N
= NNP N
193 CD N
) ) N
. . N

SVR JJ o
rates NNS o
were VBD N
23 CD N
% NN N
, , N
17 CD N
% NN N
, , N
10 CD N
% NN N
, , N
and CC N
9 CD N
% NN N
in IN N
groups NNS N
A NNP N
, , N
B NNP N
, , N
C NNP N
, , N
and CC N
D NNP N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
.0001 NNP N
for IN N
trend NN N
) ) N
. . N

Reduction NN o
in IN o
SVR NNP o
as IN N
a DT N
function NN N
of IN N
increasingly RB N
severe JJ N
disease NN N
was VBD N
independent JJ N
of IN N
age NN N
, , N
percent JJ N
African JJ N
American NNP N
, , N
HCV NNP N
genotype NN N
, , N
HCV NNP N
level NN N
, , N
and CC N
type NN N
of IN N
prior JJ N
therapy NN N
. . N

Dose NNP N
reduction NN N
lowered VBD N
SVR NNP o
frequencies NNS o
, , N
but CC N
to TO N
a DT N
lesser JJR N
extent NN N
than IN N
disease NN N
severity NN N
. . N

By IN N
logistic JJ N
regression NN N
, , N
cirrhosis NN o
( ( N
P NNP N
< NNP N
.0001 NNP N
) ) N
was VBD N
the DT N
major JJ N
determinant NN N
that WDT N
impaired VBD N
virologic JJ o
response NN o
, , N
independent JJ N
of IN N
dose JJ N
reduction NN N
or CC N
platelet NN N
count NN N
. . N

In IN N
conclusion NN N
, , N
disease NN N
severity NN N
is VBZ N
a DT N
major JJ N
independent JJ N
determinant NN N
of IN N
rate NN o
of IN o
SVR NNP o
in IN N
patients NNS p
with IN p
advanced JJ p
chronic JJ p
hepatitis NN p
C. NNP p
New NNP N
strategies NNS N
are VBP N
needed VBN N
to TO N
optimize VB N
antiviral JJ N
therapy NN N
in IN N
these DT N
difficult-to-cure JJ p
patients NNS p
. . p

-DOCSTART- -24366350- O O

Households NNS p
with IN p
young JJ p
children NNS p
and CC p
use NN p
of IN p
freely RB p
distributed VBN p
bednets NNS i
in IN p
rural JJ p
Madagascar NNP p
. . p

BACKGROUND NNP N
Malaria NNP N
infections NNS N
are VBP N
the DT N
leading VBG N
cause NN N
of IN N
death NN N
for IN N
children NNS p
in IN p
Madagascar NNP p
. . p

Insecticide-treated JJ i
bednets NNS i
offer VBP N
effective JJ N
prevention NN N
, , N
but CC N
it PRP N
is VBZ N
unclear JJ N
how WRB N
well RB N
free JJ i
bednet NN i
distribution NN i
programs NNS i
reach VBP N
young JJ p
children NNS p
. . p

METHODS NNP N
We PRP N
conducted VBD N
a DT N
secondary JJ N
analysis NN N
of IN N
a DT N
free JJ i
bednet NN i
distribution NN i
program NN i
in IN p
Madagascar NNP p
from IN p
2007-2008 JJ p
. . p

Interviews NNS i
were VBD N
performed VBN N
at IN N
baseline NN N
and CC N
6 CD N
months NNS N
. . N

Principal JJ N
components NNS N
analysis NN N
was VBD N
used VBN N
to TO N
construct VB N
a DT N
wealth NN N
and CC N
malaria NNS N
knowledge VBP N
index NN N
. . N

Coverage NNP N
efficiency NN N
was VBD N
calculated VBN N
as IN N
coverage NN i
of IN i
children NNS i
per IN i
bednet NN i
owned VBN i
. . i

Univariable JJ N
and CC N
multivariable JJ N
regressions NNS N
were VBD N
used VBN N
to TO N
determine VB N
predictors NNS N
of IN N
bednet NN i
use NN N
. . N

RESULTS NNP N
Bednet NNP o
use NN o
, , N
among IN N
the DT N
560 CD p
households NNS p
in IN p
the DT p
study NN p
, , N
increased VBD N
from IN N
6 CD N
to TO N
91 CD N
% NN N
after IN N
6 CD N
months NNS N
. . N

Coverage NNP o
efficiency NN o
increased VBD N
from IN N
1.29 CD N
to TO N
1.56 CD N
children NNS N
covered VBN N
per IN N
bednet NN N
owned VBN N
. . N

In IN N
multivariable JJ N
analysis NN N
, , N
having VBG N
a DT N
child NN p
under IN p
5 CD p
years NNS p
of IN p
age NN p
was VBD N
the DT N
only JJ N
variable NN N
associated VBN N
with IN N
bednet NN N
use NN N
( ( N
OR CC N
9.10 CD N
; : N
p=0.001 NN N
) ) N
, , N
yielding VBG N
a DT N
99 CD N
% NN N
likelihood NN N
of IN N
using VBG N
a DT N
bednet NN N
( ( N
95 CD N
% NN N
CI NNP N
96.4 CD N
to TO N
99.9 CD N
% NN N
) ) N
versus VBZ N
82 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
72.2 CD N
to TO N
88.4 CD N
% NN N
) ) N
in IN N
households NNS N
without IN N
young JJ N
children NNS N
. . N

CONCLUSION VB N
This DT N
free JJ i
bednet NN i
distribution NN i
program NN i
achieved VBN N
high JJ N
levels NNS N
of IN N
adherence NN N
after IN N
6 CD N
months NNS N
. . N

Household NNP N
presence NN N
of IN N
children NNS p
was VBD N
associated VBN N
with IN N
bednet NN N
use NN N
, , N
but CC N
not RB N
household JJ N
income NN N
or CC N
education NN N
, , N
suggesting VBG N
that IN N
distribution NN N
to TO N
priority NN N
groups NNS N
may MD N
help VB N
overcome VB N
traditional JJ N
barriers NNS N
to TO N
adoption NN N
in IN N
some DT N
settings NNS N
. . N

-DOCSTART- -7298122- O O

Changing VBG N
sodium NN N
intake NN N
in IN N
children NNS p
. . p

The DT N
Minneapolis NNP N
Children NNP N
's POS N
Blood NNP N
Pressure NN N
Study NNP N
. . N

To TO N
assess VB N
the DT N
effects NNS N
of IN N
modifying VBG N
dietary JJ N
sodium NN N
intake NN N
, , N
80 CD p
school NN p
children NNS p
with IN p
blood NN p
pressures NNS p
above IN p
the DT p
95th CD p
percentile NN p
for IN p
age NN p
and CC p
sex NN p
but CC p
below IN p
130/90 CD p
mm NN p
Hg NNP p
at IN p
school NN p
screening VBG p
were VBD N
randomized VBN N
to TO N
a DT N
family NN i
intervention NN i
program NN i
or CC N
a DT N
control NN i
group NN i
. . i

Twenty NNP p
children NNS p
aged VBD p
6 CD p
to TO p
9 CD p
years NNS p
and CC p
their PRP$ p
families NNS p
began VBD N
a DT N
program NN N
to TO N
modify VB N
the DT N
family NN N
diet VBZ N
toward IN N
a DT N
goal NN N
of IN N
70 CD N
mEq JJ N
sodium NN N
per IN N
person NN N
per IN N
day NN N
. . N

Adherence NNP o
was VBD N
assessed VBN N
by IN N
3-day JJ o
food NN o
records NNS o
and CC o
urine JJ o
collections NNS o
in IN o
children NNS o
and CC o
adults NNS o
. . o

The DT N
sodium NN o
intakes NNS o
and CC o
blood NN o
pressures NNS o
of IN N
the DT N
intervention NN N
and CC N
control NN N
group NN N
were VBD N
compared VBN N
1 CD N
year NN N
after IN N
randomization NN N
. . N

Sodium NNP o
intake NN o
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
intervention NN N
group NN N
only RB N
in IN N
the DT N
active JJ N
participants NNS N
as IN N
compared VBN N
to TO N
dropouts NNS N
and CC N
controls NNS N
( ( N
87 CD N
vs NN N
130 CD N
and CC N
133 CD N
mmoles/24 NNS N
hr NN N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
groups NNS N
in IN N
height NN o
, , o
weight NN o
, , o
or CC o
blood NN o
pressure NN o
. . o

-DOCSTART- -9652561- O O

Randomised VBN N
placebo-controlled JJ i
trial NN N
of IN N
rhesus-human JJ i
reassortant JJ i
rotavirus NN i
vaccine NN i
for IN N
prevention NN N
of IN N
severe JJ o
rotavirus NN o
gastroenteritis NN o
. . o

BACKGROUND NNP N
Rotavirus NNP N
is VBZ N
the DT N
most RBS N
common JJ N
cause NN N
of IN N
acute JJ N
childhood NN N
gastroenteritis NN N
. . N

Vaccination NN N
with IN N
live JJ N
oral JJ N
heterologous JJ N
rotavirus NN N
vaccines NNS N
may MD N
prevent VB N
rotavirus NN N
gastroenteritis NN N
. . N

We PRP N
assessed VBD N
the DT N
efficacy NN o
of IN N
rhesus-human JJ i
reassortant JJ i
rotavirus NN i
tetravalent NN i
vaccine NN i
( ( i
RRV-TV NNP i
) ) i
against IN N
severe JJ N
rotavirus NN N
gastroenteritis NN N
in IN N
Finnish JJ p
children NNS p
in IN N
a DT N
randomised JJ N
placebo-controlled JJ i
double-blind JJ N
trial NN N
. . N

METHODS NNP N
Placebo NNP i
or CC i
RRV-TV NNP i
( ( N
titre JJ N
4x10 CD N
( ( N
5 CD N
) ) N
plaque-forming JJ N
units NNS N
) ) N
was VBD N
given VBN N
to TO N
infants NNS p
at IN p
ages NNS p
2 CD p
, , p
3 CD p
, , p
and CC p
5 CD p
months NNS p
. . p

The DT N
children NNS N
were VBD N
followed VBN N
up RP N
for IN N
one CD N
or CC N
two CD N
rotavirus JJ N
epidemic JJ N
seasons NNS N
. . N

The DT N
main JJ N
outcome NN N
measure NN N
was VBD N
protection NN o
against IN o
severe JJ o
rotavirus NN o
gastroenteritis NN o
( ( N
score JJ N
> NN N
or CC N
=11 NN N
on IN N
a DT N
20-point JJ N
severity NN N
scale NN N
) ) N
. . N

2398 CD p
children NNS p
were VBD p
enrolled VBN p
and CC N
received VBN N
at IN N
least JJS N
one CD N
dose NN N
of IN N
RRV-TV NNP N
( ( N
n=1191 NN N
) ) N
or CC N
placebo NN i
( ( N
n=1207 JJ N
) ) N
. . N

The DT N
primary JJ N
efficacy NN N
analysis NN N
was VBD N
based VBN N
on IN N
children NNS N
who WP N
received VBD N
three CD N
doses NNS N
of IN N
RRV-TV NNP N
( ( N
n=1128 NN N
) ) N
or CC N
placebo NN N
( ( N
n=1145 JJ N
) ) N
. . N

FINDINGS $ N
256 CD N
episodes NNS N
of IN N
rotavirus NN N
gastroenteritis NN N
occurred VBD N
at IN N
any DT N
time NN N
during IN N
the DT N
study NN N
; : N
65 CD N
were VBD N
among IN N
1191 CD N
RRV-TV JJ i
recipients NNS N
, , N
and CC N
191 CD N
among IN N
1207 CD N
placebo NN i
recipients NNS N
( ( N
vaccine JJ N
efficacy NN N
66 CD N
% NN N
[ JJ N
95 CD N
% NN N
CI NNP N
55-74 JJ N
] NN N
; : N
intention-to-treat JJ N
analysis NN N
) ) N
. . N

226 CD N
episodes NNS N
were VBD N
included VBN N
in IN N
the DT N
primary JJ N
efficacy NN o
analysis NN N
of IN N
fully RB N
vaccinated VBN N
children NNS N
( ( N
54 CD N
among IN N
1128 CD N
RRV-TV JJ N
recipients NNS N
, , N
172 CD N
among IN N
1145 CD N
placebo NN N
recipients NNS N
; : N
vaccine VB N
efficacy NN N
68 CD N
% NN N
[ JJ N
57-76 JJ N
] NN N
) ) N
. . N

100 CD N
episodes NNS N
were VBD N
severe JJ N
, , N
eight CD N
in IN N
RRV-TV NNP i
recipients NNS N
and CC N
92 CD N
in IN N
placebo NN N
recipients NNS N
( ( N
vaccine JJ N
efficacy NN N
91 CD N
% NN N
[ JJ N
82-96 JJ N
] NN N
) ) N
. . N

INTERPRETATION NNP N
RRV-TV NNP i
vaccine NN i
was VBD N
highly RB N
effective JJ N
against IN N
severe JJ N
rotavirus NN N
gastroenteritis NN N
in IN N
young JJ p
children NNS p
. . p

Incorporation NN N
of IN N
this DT N
vaccine NN N
into IN N
routine JJ N
immunisation NN N
schedules NNS N
of IN N
infants NNS N
could MD N
reduce VB N
severe JJ o
rotavirus NN o
gastroenteritis NN o
by IN N
90 CD N
% NN N
and CC N
severe JJ o
gastroenteritis NN o
of IN N
all DT N
causes NNS N
in IN N
young JJ N
children NNS N
by IN N
60 CD N
% NN N
. . N

-DOCSTART- -11994052- O O

Metformin NNP i
does VBZ N
not RB N
enhance VB N
ovulation NN N
induction NN N
in IN N
clomiphene NN p
resistant JJ p
polycystic JJ p
ovary JJ p
syndrome NN p
in IN N
clinical JJ N
practice NN N
. . N

AIMS NNP N
To TO N
determine VB N
whether IN N
metformin NN i
pretreatment NN i
has VBZ N
beneficial JJ o
effects NNS o
in IN N
clomiphene NN p
resistant JJ p
infertile JJ p
women NNS p
with IN p
polycystic JJ p
ovary JJ p
syndrome NN p
( ( p
PCOS NNP p
) ) p
in IN p
an DT p
infertility NN p
clinic NN p
. . p

METHODS NNP N
This DT N
was VBD N
a DT N
randomized JJ N
placebo NN N
controlled VBD N
double-blind NN N
crossover NN N
study NN N
of IN N
3 CD N
months NNS N
metformin RB i
( ( N
1500 CD N
mg IN N
day-1 NN i
) ) i
/placebo NN i
, , N
followed VBN N
by IN N
3 CD N
months NNS N
metformin/placebo VBN i
together RB i
with IN i
clomiphene NN i
( ( N
50-100 JJ N
mg NN N
for IN N
5 CD N
days NNS N
) ) N
for IN N
three CD N
cycles NNS N
in IN N
clomiphene NN p
resistant JJ p
women NNS p
with IN p
PCOS NNP p
. . p

The DT N
primary JJ N
outcomes NNS N
were VBD N
restoration NN o
of IN o
spontaneous JJ o
menses NNS o
, , o
ovulation NN o
induction NN o
( ( o
spontaneous JJ o
or CC o
clomiphene NN o
induced VBN o
) ) o
and CC o
pregnancy NN o
. . o

Secondary JJ o
endpoints NNS o
were VBD N
changes NNS N
in IN N
biochemical JJ N
parameters NNS N
related VBN N
to TO N
androgens NNS N
and CC N
insulin NN N
. . N

RESULTS NNP N
Twelve NNP p
women NNS p
completed VBD p
the DT p
metformin NN i
arm NN p
and CC p
14 CD p
the DT p
placebo NN i
arm NN p
. . p

Spontaneous JJ o
menstruation NN o
resumed VBD N
in IN N
five CD N
metformin NNS i
treated VBD N
patients NNS N
and CC N
in IN N
six CD N
placebo NN i
treated VBN N
women NNS N
, , N
P=0.63 NNP N
. . N

No NNP N
women NNS N
given VBN N
metformin NNS N
spontaneously RB o
ovulated VBD o
, , N
although IN N
one CD N
patient NN N
given VBN N
placebo NN i
did VBD N
, , N
P=0.30 NNP N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
efficacy NN o
of IN o
clomiphene NN o
between IN N
the DT N
two CD N
groups NNS N
with IN N
ovulation NN o
being VBG o
induced VBN o
in IN N
five CD N
( ( N
out IN N
of IN N
12 CD N
) ) N
metformin NN i
treated VBN N
women NNS N
and CC N
four CD N
( ( N
out IN N
of IN N
14 CD N
) ) N
placebo NN i
treated VBN N
women NNS N
, , N
P=0.63 NNP N
. . N

Pregnancy NN o
occurred VBD N
in IN N
three CD N
( ( N
out IN N
of IN N
12 CD N
) ) N
women NNS N
given VBN N
metformin NNS i
and CC N
two CD N
( ( N
out IN N
of IN N
14 CD N
) ) N
women NNS N
given VBN N
placebo NNS i
, , N
P=0.59 NNP N
. . N

CONCLUSIONS NNP N
Metformin NNP i
is VBZ N
not RB N
always RB N
beneficial JJ N
when WRB N
given VBN N
to TO N
clomiphene VB p
resistant JJ p
infertile JJ p
women NNS p
with IN p
PCOS NNP p
in IN N
clinical JJ N
practice NN N
. . N

-DOCSTART- -12790985- O O

Stapled JJ i
mucosectomy NN i
for IN N
acute NN N
thrombosed VBN N
circumferentially RB N
prolapsed JJ N
piles NNS N
: : N
a DT N
prospective JJ N
randomized VBN N
comparison NN N
with IN N
conventional JJ i
haemorrhoidectomy NN i
. . i

OBJECTIVE NNP N
Stapled NNP i
mucosectomy NN i
has VBZ N
been VBN N
developed VBN N
as IN N
an DT N
alternative NN N
to TO N
conventional JJ i
haemorrhoidectomy NN i
for IN N
the DT N
elective JJ N
treatment NN N
of IN N
haemorrhoids NNS N
, , N
but CC N
has VBZ N
not RB N
been VBN N
assessed VBN N
in IN N
the DT N
emergency NN N
setting VBG N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
this DT N
technique NN N
with IN N
a DT N
conventional JJ i
procedure NN i
for IN N
acute NN N
thrombosed VBN N
circumferential JJ N
prolapsed JJ N
haemorrhoids NNS N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
A NNP N
prospective JJ N
randomized VBN N
comparison NN N
of IN N
conventional JJ i
Milligan-Morgan JJ i
haemorrhoidectomy NN i
and CC i
stapled VBD i
mucosectomy NN i
was VBD N
carried VBN N
out RP N
on IN N
35 CD p
consecutive JJ p
patients NNS p
presenting VBG p
with IN p
acute NN p
thrombosed VBN p
circumferential JJ p
prolapsed JJ p
haemorrhoids NNS p
. . p

Operative NNP o
data NN o
, , o
postoperative JJ o
stay NN o
, , o
pain NN o
assessment NN o
and CC o
persistent NN o
symptoms NNS o
were VBD N
compared VBN N
at IN N
discharge NN N
and CC N
at IN N
2 CD N
week NN N
and CC N
6 CD N
week NN N
review NN N
. . N

Additionally RB N
at IN N
6 CD N
week NN N
review VB N
the DT N
time NN N
to TO N
return VB N
to TO N
work VB N
was VBD N
recorded VBN N
and CC N
an DT N
endoanal JJ o
ultrasound NN o
was VBD N
carried VBN N
out RP N
. . N

RESULTS NNP N
Thirty NNP p
patients NNS p
were VBD N
randomized VBN N
and CC N
followed VBN N
up RP N
for IN N
six CD N
weeks NNS N
. . N

Although IN N
postoperative JJ o
stay NN o
and CC o
in-hospital JJ o
analgesia NN o
were VBD N
the DT N
same JJ N
, , N
patients NNS p
from IN N
the DT N
stapled VBN i
group NN i
reported VBD N
significantly RB N
more RBR N
pain NN N
at IN N
discharge NN N
. . N

However RB N
, , N
by IN N
2 CD N
weeks NNS N
the DT N
conventional JJ i
group NN i
reported VBD N
significantly RB N
higher JJR o
pain NN o
scores NNS o
particularly RB N
on IN N
passing VBG N
stool NN N
. . N

By IN N
this DT N
stage NN N
over IN N
half PDT N
the DT N
stapled JJ p
group NN p
patients NNS p
reported VBD N
no DT o
pain NN o
at IN N
all DT N
. . N

More JJR p
patients NNS p
in IN p
the DT p
conventional JJ i
group NN i
complained VBD p
of IN p
persistent JJ o
symptoms NNS o
of IN o
pain NN o
, , o
bleeding NN o
and CC o
discharge NN o
at IN p
2 CD p
week NN p
and CC p
6 CD p
week NN p
review NN p
with IN p
20 CD p
% NN p
requiring VBG p
readmission NN p
compared VBN p
with IN p
none NN p
in IN p
the DT p
stapled JJ p
group NN p
. . p

The DT N
median JJ o
return NN o
to TO o
work VB o
was VBD o
significantly RB o
shorter JJR o
for IN N
the DT N
stapled VBN i
group NN i
( ( N
14 CD N
days NNS N
vs RB N
28 CD N
days NNS N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Although IN N
all DT N
patients NNS N
claimed VBD N
to TO N
be VB N
continent JJ N
, , N
two CD p
patients NNS p
from IN p
each DT p
group NN p
had VBD p
ultrasonic JJ p
evidence NN p
of IN N
internal JJ o
sphincter NN o
damage NN o
. . o

CONCLUSION NNP N
Stapled VBD i
mucosectomy NN i
for IN N
acute NN N
thrombosed VBN N
circumferential JJ N
piles NNS N
is VBZ N
feasible JJ N
and CC N
may MD N
result VB N
in IN N
less JJR o
pain NN o
, , N
a DT N
more RBR N
rapid JJ N
resolution NN N
of IN N
symptoms NNS N
and CC N
an DT N
earlier JJR N
return NN N
to TO N
work VB N
compared VBN N
with IN N
a DT N
conventional JJ i
procedure NN i
. . i

-DOCSTART- -21767149- O O

A DT N
feasibility NN N
study NN N
exploring VBG N
the DT N
role NN N
of IN N
Chinese JJ i
herbal JJ i
medicine NN i
in IN N
the DT N
treatment NN N
of IN N
endometriosis NN N
. . N

BACKGROUND NNP N
Endometriosis NNP N
is VBZ N
a DT N
common JJ N
and CC N
disabling VBG N
gynecologic JJ N
condition NN N
affecting VBG N
between IN N
5 CD N
% NN N
and CC N
15 CD N
% NN N
of IN N
women NNS N
of IN N
childbearing VBG N
age NN N
. . N

Conventional NNP N
medical JJ N
intervention NN N
has VBZ N
unpleasant JJ N
side-effects NNS N
, , N
and CC N
symptoms NNS N
frequently RB N
return VBP N
after IN N
treatment NN N
. . N

Preliminary JJ N
evidence NN N
suggests VBZ N
Chinese NNP i
herbal JJ i
medicine NN i
( ( i
CHM NNP i
) ) i
may MD N
contribute VB N
to TO N
the DT N
treatment NN N
of IN N
endometriosis NN N
. . N

OBJECTIVES CC N
The DT N
aims NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
test VB N
the DT N
feasibility NN N
of IN N
a DT N
novel JJ N
methodology NN N
for IN N
investigating VBG N
individualized JJ N
decoctions NNS N
of IN N
CHM NNP N
rigorously RB N
and CC N
to TO N
gather VB N
preliminary JJ N
data NNS N
on IN N
the DT N
treatment NN N
effect NN N
of IN N
CHM NNP N
for IN N
a DT N
larger JJR N
definitive JJ N
trial NN N
. . N

DESIGN VB N
This DT N
was VBD N
a DT N
16-week JJ N
prospective JJ N
, , N
double JJ N
blinded VBN N
, , N
randomized VBN N
controlled VBD N
trial NN N
of IN N
40 CD p
women NNS p
with IN p
laparoscopically RB p
confirmed VBN p
endometriosis NN p
. . p

SETTINGS VB N
The DT p
trial NN p
was VBD p
conducted VBN p
at IN p
a DT p
private JJ p
CHM NNP p
clinic NN p
in IN p
Hove NNP p
( ( p
U.K. NNP p
) ) p
and CC p
at IN p
a DT p
National NNP p
Health NNP p
Service NNP p
outpatient NN p
clinic NN p
in IN p
London NNP p
( ( p
U.K. NNP p
) ) p
. . p

INTERVENTIONS JJ N
Participants NNS i
were VBD i
initially RB i
randomized VBN i
to TO i
either DT i
wait-list JJ i
control NN i
( ( i
WLC NNP i
) ) i
or CC i
treatment NN i
groups NNS i
to TO i
receive VB i
either DT i
individualized JJ i
CHM NNP i
decoctions NNS i
or CC i
a DT i
therapeutically RB i
inert JJ i
placebo NN i
decoction NN i
. . i

OUTCOME NNP N
MEASURES NNP N
Four NNP N
10-cm JJ N
visual JJ N
analogue NN N
scales NNS N
( ( N
VAS NNP N
) ) N
were VBD N
used VBN N
to TO N
measure VB o
menstrual JJ o
pain NN o
, , o
daily RB o
pain NN o
, , o
and CC o
pain NN o
on IN o
intercourse NN o
and CC o
bowel NN o
movement NN o
; : o
these DT N
measurements NNS N
were VBD N
recorded VBN N
weekly RB N
. . N

The DT N
Endometriosis NNP o
Health NNP o
Profile-30 NNP o
( ( o
EHP-30 NNP o
) ) o
endometriosis-specific JJ o
quality-of-life JJ o
questionnaire NN o
was VBD N
completed VBN N
at IN N
the DT N
beginning NN N
and CC N
at IN N
the DT N
end NN N
of IN N
the DT N
trial NN N
. . N

The DT N
Measure NN o
Yourself NNP o
Medical NNP o
Outcomes NNP o
Profile NNP o
( ( o
MYMOP NNP o
) ) o
a DT o
patient-centered JJ o
health NN o
questionnaire NN o
was VBD N
completed VBN N
monthly RB N
. . N

Liver NNP o
and CC o
renal JJ o
function NN o
was VBD N
measured VBN N
at IN N
0 CD N
, , N
4 CD N
, , N
8 CD N
, , N
and CC N
16 CD N
weeks NNS N
. . N

RESULTS NNP N
Twenty-eight NNP p
( ( p
28 CD p
) ) p
women NNS p
completed VBD p
the DT p
trial NN p
. . p

High JJ N
dropout NN N
rates NNS N
led VBD N
to TO N
the DT N
suspension NN N
of IN N
the DT N
WLC NNP N
. . N

Randomization NNP N
, , N
double JJ N
blinding NN N
, , N
and CC N
allocation NN N
concealment NN N
was VBD N
achieved VBN N
successfully RB N
. . N

Adjusted VBN N
mean JJ N
differences NNS N
favored VBD N
the DT N
active JJ N
treatment NN N
in IN N
the DT N
EHP-30 NNP o
and CC o
MYMOP NNP o
scores NNS o
. . o

VAS NNP o
scores VBZ o
favored VBD N
the DT N
active JJ N
treatment NN N
for IN N
relief NN N
of IN N
menstrual JJ N
pain NN N
and CC N
the DT N
placebo NN N
group NN N
for IN N
reduction NN N
of IN N
daily JJ N
pain NN N
. . N

CONCLUSIONS VB N
the DT N
methodology NN N
successfully RB N
allowed VBN N
individualized JJ N
CHM NNP N
decoctions NNS N
to TO N
be VB N
tested VBN N
rigorously RB N
. . N

There EX N
are VBP N
nonspecific JJ N
contextual JJ N
effects NNS N
from IN N
CHM NNP N
that IN N
require VBP N
further JJ N
investigation NN N
. . N

Provisional NNP N
data NNS N
were VBD N
generated VBN N
to TO N
warrant VB N
a DT N
larger JJR N
, , N
more-definitive JJ N
study NN N
. . N

-DOCSTART- -4678681- O O

Joint NNP N
study NN N
of IN N
extracranial JJ N
arterial JJ N
occlusion NN N
. . N

VI NNP N
. . N

Racial JJ N
differences NNS N
in IN N
hospitalized JJ p
patients NNS p
with IN p
ischemic JJ p
stroke NN p
. . p

-DOCSTART- -7644960- O O

A DT N
randomized JJ N
trial NN N
of IN N
exercise NN i
therapy NN i
in IN p
patients NNS p
with IN p
acute JJ p
low JJ p
back RB p
pain NN p
. . p

Efficacy NN N
on IN N
sickness JJ o
absence NN o
. . o

STUDY NNP N
DESIGN NNP N
A NNP N
randomized JJ N
, , N
placebo-controlled JJ i
trial NN N
in IN N
which WDT N
patients NNS N
received VBD N
either RB N
usual JJ i
care NN i
by IN N
a DT N
general JJ N
practitioner NN N
( ( N
information NN N
and CC N
analgesics NNS N
) ) N
, , N
or CC N
placebo NN i
physiotherapy NN i
given VBN N
by IN N
a DT N
physiotherapist NN N
, , N
or CC N
exercise NN i
therapy NN i
given VBN N
by IN N
a DT N
physiotherapist NN N
. . N

OBJECTIVE UH N
To TO N
assess VB N
the DT N
efficacy NN N
of IN N
exercise NN i
therapy NN i
on IN N
sickness JJ o
absence NN o
from IN o
work NN o
in IN N
patients NNS p
with IN p
acute JJ p
low JJ p
back RB p
pain NN p
. . p

SUMMARY NNP N
OF IN N
BACKGROUND NNP N
DATA NNP N
Exercise NNP i
therapy NN i
during IN N
the DT N
nonchronic JJ N
phase NN N
of IN N
back JJ N
pain NN N
is VBZ N
considered VBN N
to TO N
reduce VB N
sickness JJ o
absence NN o
, , N
but CC N
this DT N
opinion NN N
is VBZ N
controversial JJ N
. . N

METHODS JJ N
Patients NNS p
with IN p
acute JJ p
nonspecific NN p
low JJ p
back RB p
pain NN p
and CC p
a DT p
paid VBN p
job NN p
were VBD p
included VBN p
for IN p
analysis NN p
. . p

Sickness JJ o
absence NN o
( ( o
number NN o
of IN o
days NNS o
) ) o
was VBD N
checked VBN N
monthly RB N
during IN N
the DT N
1-year JJ N
follow-up JJ N
period NN N
and CC N
compliance NN o
was VBD N
also RB N
assessed VBN N
. . N

RESULTS NNP N
From IN N
40 CD p
general JJ p
practices NNS p
363 CD p
patients NNS p
who WP p
were VBD p
gainfully RB p
employed VBN p
were VBD p
included VBN p
. . p

In IN N
the DT N
exercise NN i
therapy NN i
group NN N
the DT N
percentage NN N
of IN N
patients NNS N
with IN N
sickness JJ o
absence NN o
was VBD N
higher JJR N
and CC N
the DT N
duration NN o
of IN o
absence NN o
was VBD N
longer JJR N
than IN N
in IN N
the DT N
placebo NN i
and CC N
usual JJ i
care NN i
groups NNS N
, , N
but CC N
these DT N
differences NNS N
were VBD N
not RB N
significant JJ N
. . N

Indications NNS N
of IN N
more JJR N
absence NN o
in IN N
the DT N
exercise NN i
therapy NN i
group NN i
appeared VBD N
to TO N
be VB N
based VBN N
largely RB N
on IN N
a DT N
greater JJR N
number NN N
of IN N
patients NNS N
with IN N
absences NNS N
during IN N
the DT N
first JJ N
3 CD N
months NNS N
. . N

Patients NNS N
in IN N
the DT N
exercise NN i
group NN i
who WP N
had VBD N
not RB N
reported VBN N
sick NN N
at IN N
entry NN N
had VBD N
more JJR N
sickness JJ o
absences NNS o
during IN N
the DT N
follow-up JJ N
year NN N
than IN N
patients NNS N
in IN N
the DT N
usual JJ i
care NN i
and CC N
placebo NN i
group NN N
. . N

Good JJ N
compliance NN o
did VBD N
not RB N
affect VB N
the DT N
results NNS N
. . N

CONCLUSIONS NNP N
Exercise NNP i
therapy NN i
for IN N
patients NNS p
with IN p
acute JJ p
low JJ p
back RB p
pain NN p
does VBZ N
not RB N
reduce VB N
sickness NN o
absence NN o
. . o

-DOCSTART- -15327617- O O

A DT N
prospective JJ N
randomised JJ N
comparison NN N
of IN N
sublingual JJ i
and CC i
vaginal JJ i
misoprostol NN i
in IN p
second JJ p
trimester NN p
termination NN p
of IN p
pregnancy NN p
. . p

OBJECTIVE UH N
To TO N
compare VB N
the DT N
efficacy NN o
, , o
side NN o
effects NNS o
and CC o
acceptability NN o
of IN N
sublingual JJ i
and CC i
vaginal JJ i
misoprostol NN i
for IN N
second JJ p
trimester NN p
medical JJ p
abortion NN p
. . p

DESIGN NNP N
Prospective NNP N
randomised VBD N
controlled VBN N
trial NN N
. . N

SETTING NN N
Tertiary JJ p
referral JJ p
unit NN p
and CC p
a DT p
teaching JJ p
hospital NN p
. . p

POPULATION NNP N
Two CD p
hundred VBD p
and CC p
twenty-four JJ p
women NNS p
at IN p
12 CD p
to TO p
20 CD p
weeks NNS p
of IN p
gestation NN p
. . p

METHODS NNP N
The DT N
women NNS N
were VBD N
randomised VBN N
to TO N
receive VB N
either DT N
sublingual JJ i
or CC i
vaginal JJ i
misoprostol NN i
400 CD i
microg NN i
every DT N
3 CD N
hours NNS N
for IN N
a DT N
maximum NN N
of IN N
five CD N
doses NNS N
. . N

The DT N
course NN N
of IN N
misoprostol NN i
was VBD N
repeated VBN N
if IN N
the DT N
woman NN N
did VBD N
not RB N
abort VB N
within IN N
24 CD N
hours NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT o
success NN o
rate NN o
at IN o
48 CD o
hours NNS o
, , o
induction-to-abortion NN o
interval NN o
and CC o
the DT o
side NN o
effects NNS o
. . o

RESULTS NNP N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT o
success NN o
rate NN o
at IN o
48 CD o
hours NNS o
( ( N
sublingual JJ N
: : N
91 CD N
% NN N
; : N
vaginal JJ N
: : N
95 CD N
% NN N
) ) N
. . N

However RB N
, , N
the DT N
success NN o
rate NN o
at IN o
24 CD o
hours NNS o
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
vaginal JJ N
group NN N
( ( N
85 CD N
% NN N
) ) N
compared VBN N
with IN N
the DT N
sublingual JJ N
group NN N
( ( N
64 CD N
% NN N
) ) N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT o
median JJ o
induction-to-abortion NN o
interval NN o
( ( N
sublingual JJ N
: : N
13.8 CD N
hours NNS N
; : N
vaginal JJ N
: : N
12.0 CD N
hours NNS N
) ) N
. . N

Significantly RB N
more JJR N
women NNS N
in IN N
the DT N
sublingual JJ N
group NN N
preferred VBD o
the DT o
route NN o
to TO o
which WDT o
they PRP o
were VBD o
assigned VBN o
when WRB N
compared VBN N
with IN N
the DT N
vaginal JJ N
group NN N
. . N

The DT o
incidence NN o
of IN o
fever NN o
was VBD N
also RB N
less RBR N
in IN N
the DT N
sublingual JJ N
group NN N
. . N

CONCLUSION NNP N
The DT N
use NN N
of IN N
vaginal JJ i
misoprostol NN i
for IN N
second JJ N
trimester NN N
medical JJ N
abortion NN N
resulted VBD N
in IN N
a DT N
higher JJR N
success NN o
rate NN o
than IN N
sublingual JJ N
misoprostol NN i
at IN N
24 CD N
hours NNS N
but CC N
the DT N
abortion NN o
rate NN o
was VBD N
similar JJ N
at IN N
48 CD N
hours NNS N
. . N

Vaginal NNP i
misoprostol NN i
should MD N
be VB N
the DT N
regimen NNS N
of IN N
choice NN N
but CC N
sublingual JJ i
misoprostol NN i
is VBZ N
also RB N
an DT N
effective JJ N
alternative NN N
. . N

-DOCSTART- -12033348- O O

Lack NN N
of IN N
benefit NN N
of IN N
an DT N
active JJ i
pectoral JJ i
pulse NN i
generator NN i
on IN N
atrial JJ N
defibrillation NN N
thresholds NNS N
. . N

INTRODUCTION NNP N
Atrial NNP N
defibrillation NN N
can MD N
be VB N
achieved VBN N
with IN N
standard JJ N
implantable JJ N
cardioverter NN N
defibrillator NN N
leads VBZ N
, , N
which WDT N
has VBZ N
led VBN N
to TO N
the DT N
development NN N
of IN N
combined JJ N
atrial JJ N
and CC N
ventricular JJ N
devices NNS N
. . N

For IN N
ventricular JJ N
defibrillation NN N
, , N
use NN N
of IN N
an DT N
active JJ i
pectoral JJ i
electrode NN i
( ( i
active JJ i
can MD i
) ) i
in IN N
the DT N
shocking VBG N
pathway RB N
markedly RB N
reduces VBZ N
defibrillation NN N
thresholds NNS N
( ( N
DFTs NNP N
) ) N
. . N

However RB N
, , N
the DT N
effect NN N
of IN N
an DT N
active JJ i
pectoral NN i
can MD i
on IN N
atrial JJ N
defibrillation NN N
is VBZ N
unknown JJ N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
This DT N
study NN N
was VBD N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
paired VBD N
comparison NN i
of IN i
two CD i
shock NN i
configurations NNS i
on IN N
atrial JJ p
DFTs NNP p
in IN p
33 CD p
patients NNS p
. . p

The DT N
lead NN N
system NN N
evaluated VBD N
was VBD N
a DT N
dual-coil JJ i
transvenous JJ i
defibrillation NN i
lead NN i
with IN i
a DT i
left JJ i
pectoral JJ i
pulse NN i
generator NN i
emulator NN i
. . N

Shocks NNS N
were VBD N
delivered VBN N
either RB N
between IN N
the DT N
right JJ i
ventricular NN i
coil NN i
and CC i
proximal JJ i
atrial JJ i
coil NN i
( ( i
lead JJ i
) ) i
or CC i
between IN i
the DT i
right JJ i
ventricular NN i
coil NN i
and CC i
an DT i
active JJ i
can MD i
in IN i
common JJ i
with IN i
the DT i
atrial JJ i
coil NN i
( ( N
active JJ N
can MD N
) ) N
. . N

Delivered VBN o
energy NN o
at IN o
DFT NNP o
was VBD N
4.2 CD N
+/- JJ N
4.1 CD N
J NNP N
in IN N
the DT N
lead NN N
configuration NN N
and CC N
5.0 CD N
+/- JJ N
3.7 CD N
J NNP N
in IN N
the DT N
active JJ i
can MD i
configuration NN N
( ( N
P NNP N
= NNP N
NS NNP N
) ) N
. . N

Peak NNP o
current JJ o
was VBD N
32 CD N
% NN N
higher JJR N
with IN N
an DT N
active JJ i
can MD i
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
whereas JJ N
shock NN o
impedance NN o
was VBD N
18 CD N
% NN N
lower JJR N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Moreover RB N
, , N
a DT N
low JJ o
threshold NN o
( ( N
< CD N
or CC N
= VB N
3 CD N
J NNP N
) ) N
was VBD N
observed VBN N
in IN N
61 CD N
% NN N
of IN N
subjects NNS N
in IN N
the DT N
lead JJ N
configuration NN N
but CC N
in IN N
only RB N
36 CD N
% NN N
in IN N
the DT N
active JJ i
can MD i
configuration NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
were VBD N
no DT o
clinical JJ o
predictors NNS o
of IN N
the DT N
atrial JJ N
DFT NNP N
. . N

CONCLUSION NNP N
These DT N
results NNS N
indicate VBP N
that IN N
low JJ N
atrial JJ N
DFTs NN N
can MD N
be VB N
achieved VBN N
using VBG N
a DT N
transvenous JJ N
ventricular JJ N
defibrillation NN N
lead NN N
. . N

Because IN N
no DT N
benefit NN N
was VBD N
observed VBN N
with IN N
the DT N
use NN N
of IN N
an DT N
active JJ i
pectoral JJ i
electrode NN i
for IN N
atrial JJ N
defibrillation NN N
, , N
programmable JJ N
shock NN N
vectors NNS N
may MD N
be VB N
useful JJ N
for IN N
dual-chamber JJ N
implantable JJ N
cardioverter NN N
defibrillators NNS N
. . N

-DOCSTART- -6455048- O O

Relief NN N
of IN N
osteoporotic JJ o
backache NN o
with IN N
fluoride NN i
, , i
calcium NN i
, , i
and CC i
calciferol NN i
. . i

In IN N
a DT N
prospective JJ N
randomized VBN N
clinical JJ N
trial NN N
comprising VBG N
22 CD p
postmenopausal JJ p
women NNS p
with IN p
backache NN p
and CC p
a DT p
halisteretic JJ p
spine NN p
with IN p
crush JJ p
fracture NN p
( ( p
s NN p
) ) p
, , p
12 CD p
women NNS p
completed VBD p
a DT p
12-week JJ p
therapy NN p
with IN p
sodium NN i
fluoride NN i
, , i
calcium NN i
and CC i
calciferol NN i
and CC N
10 CD N
with IN N
placebo NN i
. . i

A DT N
statistically RB N
significant JJ N
improvement NN N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
, , N
evaluated VBN N
by IN N
a DT N
four-stage JJ o
scale NN o
on IN o
pains NNS o
, , o
infirmity NN o
, , o
and CC o
consumption NN o
of IN o
analgesics NNS o
, , N
was VBD N
observed VBN N
in IN N
the DT N
actively RB N
treated JJ N
patients NNS N
. . N

-DOCSTART- -15894770- O O

Effects NNS N
of IN N
congestive JJ N
heart NN N
failure NN N
on IN N
plasma NN o
von NN o
Willebrand NNP o
factor NN o
and CC N
soluble JJ o
P-selectin JJ o
concentrations NNS o
in IN N
patients NNS p
with IN p
non-valvar JJ p
atrial JJ p
fibrillation NN p
. . p

OBJECTIVE UH N
To TO N
examine VB N
further RB N
the DT N
relations NNS N
of IN N
plasma NN o
von NN o
Willebrand NNP o
factor NN o
( ( o
vWf NN o
, , o
an DT o
index NN o
of IN o
endothelial JJ o
damage NN o
and CC o
dysfunction NN o
) ) o
and CC N
soluble JJ o
P-selectin NNP o
( ( o
sP-sel NN o
, , o
an DT o
index NN o
of IN o
platelet NN o
activation NN o
) ) o
concentrations NNS N
to TO N
the DT N
presence NN N
and CC N
onset NN N
of IN N
clinical JJ N
congestive JJ N
heart NN N
failure NN N
( ( N
CHF NNP N
) ) N
and CC N
the DT N
degree NN N
of IN N
left NN N
ventricular NN N
( ( N
LV NNP N
) ) N
dysfunction NN N
in IN N
patients NNS p
taking VBG p
part NN p
in IN p
the DT p
SPAF NNP p
( ( p
stroke JJ p
prevention NN p
in IN p
atrial JJ p
fibrillation NN p
) ) p
study NN p
. . p

METHODS NNP N
Plasma NNP o
concentrations NNS o
of IN o
vWf NN o
and CC o
sP-sel NN o
were VBD N
measured VBN N
by IN N
enzyme NN N
linked VBN N
immunosorbent JJ N
assay NN N
( ( N
ELISA NNP N
) ) N
in IN N
1321 CD p
participants NNS p
in IN p
the DT p
SPAF NNP p
III NNP p
study NN p
and CC N
related VBN N
to TO N
the DT N
presence NN N
and CC N
onset NN N
of IN N
clinical JJ N
CHF NNP N
, , N
as RB N
well RB N
as IN N
echocardiographic JJ N
findings NNS N
. . N

Of IN N
the DT N
1321 CD p
patients NNS p
with IN p
atrial JJ p
fibrillation NN p
( ( p
AF NNP p
) ) p
, , p
331 CD p
( ( p
25 CD p
% NN p
) ) p
had VBD p
a DT p
documented JJ p
history NN p
of IN p
clinical JJ p
heart NN p
failure NN p
, , p
of IN p
which WDT p
168 CD p
cases NNS p
were VBD p
related VBN p
to TO p
a DT p
new JJ p
or CC p
recurrent JJ p
episode NN p
of IN p
acute NN p
decompensated VBN p
heart NN p
failure NN p
occurring VBG p
within IN p
the DT p
preceding VBG p
three CD p
months NNS p
. . p

RESULTS NNP N
Mean NNP o
plasma NN o
vWf NN o
was VBD N
higher JJR N
among IN N
patients NNS N
with IN N
AF NNP N
and CC N
CHF NNP N
( ( N
154 CD N
( ( N
29 CD N
) ) N
v NN N
144 CD N
( ( N
31 CD N
) ) N
IU/dl NNP N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
particularly RB N
those DT N
with IN N
acute NN N
or CC N
recent JJ N
decompensated VBN N
symptoms NNS N
. . N

Patients NNS p
with IN p
severe JJ o
LV NNP o
dysfunction NN o
on IN p
two CD p
dimensional JJ p
echocardiography NN p
and CC p
low JJ p
fractional JJ p
shortening NN p
also RB N
had VBD N
significantly RB N
higher JJR N
vWf NN o
concentrations NNS o
than IN N
those DT N
with IN N
no DT N
LV NNP N
dysfunction NN N
. . N

CHF NNP N
patients NNS N
with IN N
clinical JJ N
features NNS N
-- : N
with IN N
( ( N
156 CD N
( ( N
28 CD N
) ) N
IU/dl NNP N
) ) N
and CC N
without IN N
( ( N
152 CD N
( ( N
31 CD N
) ) N
IU/dl NNP N
) ) N
LV NNP N
dysfunction NN N
-- : N
also RB N
had VBD N
higher JJR N
mean JJ o
vWf NN o
concentrations NNS o
than IN N
patients NNS N
with IN N
asymptomatic JJ N
LV NNP N
dysfunction NN N
( ( N
146 CD N
( ( N
31 CD N
) ) N
IU/dl NNP N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
presence NN N
of IN N
mitral JJ o
regurgitation NN o
in IN o
CHF NNP o
was VBD N
associated VBN N
with IN N
lower JJR N
vWf NN N
concentrations NNS N
. . N

Plasma NNP o
sP-sel JJ o
concentrations NNS o
were VBD N
not RB N
affected VBN N
by IN N
presence NN N
, , N
onset NN N
, , N
or CC N
severity NN N
of IN N
heart NN N
failure NN N
. . N

CONCLUSIONS NNP N
CHF NNP N
may MD N
contribute VB N
to TO N
hypercoagulability NN N
and CC N
thrombotic JJ N
risk NN N
in IN N
AF NNP N
through IN N
increased VBN N
endothelial JJ o
damage NN o
and CC o
dysfunction NN o
. . o

Patients NNS p
with IN p
acute NN p
or CC p
recent JJ p
decompensated VBN p
features NNS p
have VBP N
the DT N
highest JJS N
degree NN N
of IN N
endothelial JJ o
damage NN o
and CC o
dysfunction NN o
. . o

The DT N
presence NN N
of IN N
CHF NNP N
clinical JJ N
features NNS N
was VBD N
an DT N
important JJ N
determinant NN N
of IN N
plasma NN N
vWf NN N
concentrations NNS N
. . N

-DOCSTART- -21334061- O O

Comparison NNP N
of IN N
adaptive JJ i
pacing NN i
therapy NN i
, , i
cognitive JJ i
behaviour NN i
therapy NN i
, , i
graded VBD i
exercise NN i
therapy NN i
, , N
and CC N
specialist VB i
medical JJ i
care NN i
for IN N
chronic JJ p
fatigue NN p
syndrome NN p
( ( N
PACE NNP N
) ) N
: : N
a DT N
randomised JJ N
trial NN N
. . N

BACKGROUND NNP N
Trial NNP N
findings NNS N
show VBP N
cognitive JJ i
behaviour NN i
therapy NN i
( ( i
CBT NNP i
) ) i
and CC N
graded VBN i
exercise NN i
therapy NN i
( ( i
GET NNP i
) ) i
can MD N
be VB N
effective JJ N
treatments NNS N
for IN N
chronic JJ N
fatigue NN N
syndrome NN N
, , N
but CC N
patients NNS N
' POS N
organisations NNS N
have VBP N
reported VBN N
that IN N
these DT N
treatments NNS N
can MD N
be VB N
harmful JJ N
and CC N
favour JJ N
pacing NN i
and CC N
specialist NN i
health NN i
care NN i
. . i

We PRP N
aimed VBD N
to TO N
assess VB N
effectiveness NN o
and CC o
safety NN o
of IN N
all DT N
four CD N
treatments NNS N
. . N

METHODS NNP N
In IN N
our PRP$ N
parallel-group NN N
randomised VBN N
trial NN N
, , N
patients NNS p
meeting NN p
Oxford NNP p
criteria NN p
for IN p
chronic JJ p
fatigue NN p
syndrome NN p
were VBD p
recruited VBN p
from IN p
six CD i
secondary-care JJ i
clinics NNS i
in IN i
the DT i
UK NNP i
and CC i
randomly RB i
allocated VBN i
by IN i
computer-generated JJ i
sequence NN i
to TO i
receive VB i
specialist NN i
medical JJ i
care NN i
( ( i
SMC NNP i
) ) i
alone RB i
or CC i
with IN i
adaptive JJ i
pacing VBG i
therapy NN i
( ( i
APT NNP i
) ) i
, , i
CBT NNP i
, , i
or CC i
GET NNP i
. . i

Primary NNP N
outcomes NNS N
were VBD N
fatigue JJ o
( ( o
measured VBN o
by IN o
Chalder NNP o
fatigue NN o
questionnaire NN o
score NN o
) ) o
and CC o
physical JJ o
function NN o
( ( o
measured VBN o
by IN o
short JJ o
form-36 JJ o
subscale NN o
score NN o
) ) o
up IN N
to TO N
52 CD N
weeks NNS N
after IN N
randomisation NN N
, , N
and CC N
safety NN N
was VBD N
assessed VBN N
primarily RB N
by IN N
recording VBG N
all DT N
serious JJ o
adverse JJ o
events NNS o
, , N
including VBG N
serious JJ o
adverse JJ o
reactions NNS o
to TO N
trial NN N
treatments NNS N
. . N

Primary JJ N
outcomes NNS N
were VBD N
rated VBN N
by IN N
participants NNS N
, , N
who WP N
were VBD N
necessarily RB N
unmasked VBN N
to TO N
treatment NN N
assignment NN N
; : N
the DT N
statistician NN N
was VBD N
masked VBN N
to TO N
treatment NN N
assignment NN N
for IN N
the DT N
analysis NN N
of IN N
primary JJ N
outcomes NNS N
. . N

We PRP N
used VBD N
longitudinal JJ i
regression NN i
models NNS i
to TO i
compare VB i
SMC NNP i
alone RB i
with IN i
other JJ i
treatments NNS i
, , i
APT NNP i
with IN i
CBT NNP i
, , i
and CC i
APT NNP i
with IN i
GET NNP i
. . i

The DT N
final JJ N
analysis NN N
included VBD N
all DT N
participants NNS N
for IN N
whom WP N
we PRP N
had VBD N
data NNS N
for IN N
primary JJ N
outcomes NNS N
. . N

This DT N
trial NN N
is VBZ N
registered VBN N
at IN N
http NN N
: : N
//isrctn.org NN N
, , N
number NN N
ISRCTN54285094 NNP N
. . N

FINDINGS NNP N
We PRP N
recruited VBD N
641 CD p
eligible JJ p
patients NNS p
, , N
of IN N
whom WP N
160 CD N
were VBD N
assigned VBN N
to TO N
the DT N
APT NNP N
group NN N
, , N
161 CD N
to TO N
the DT N
CBT NNP N
group NN N
, , N
160 CD N
to TO N
the DT N
GET NNP N
group NN N
, , N
and CC N
160 CD N
to TO N
the DT N
SMC-alone NNP i
group NN N
. . N

Compared VBN N
with IN N
SMC NNP N
alone RB N
, , N
mean JJ o
fatigue NN o
scores NNS o
at IN N
52 CD N
weeks NNS N
were VBD N
3?4 CD N
( ( N
95 CD N
% NN N
CI NNP N
1?8 CD N
to TO N
5?0 CD N
) ) N
points NNS N
lower JJR N
for IN N
CBT NNP N
( ( N
p JJ N
= NNP N
0?0001 CD N
) ) N
and CC N
3?2 CD N
( ( N
1?7 CD N
to TO N
4?8 CD N
) ) N
points NNS N
lower JJR N
for IN N
GET NNP N
( ( N
p JJ N
= NNP N
0?0003 CD N
) ) N
, , N
but CC N
did VBD N
not RB N
differ VB N
for IN N
APT NNP N
( ( N
0?7 CD N
[ RB N
-0?9 NN N
to TO N
2?3 CD N
] NN N
points NNS N
lower JJR N
; : N
p VB N
= $ N
0?38 CD N
) ) N
. . N

Compared VBN N
with IN N
SMC NNP N
alone RB N
, , N
mean JJ N
physical JJ o
function NN o
scores NNS o
were VBD N
7?1 CD N
( ( N
2?0 CD N
to TO N
12?1 CD N
) ) N
points NNS N
higher JJR N
for IN N
CBT NNP N
( ( N
p JJ N
= NNP N
0?0068 CD N
) ) N
and CC N
9?4 CD N
( ( N
4?4 CD N
to TO N
14?4 CD N
) ) N
points NNS N
higher JJR N
for IN N
GET NNP N
( ( N
p JJ N
= NNP N
0?0005 CD N
) ) N
, , N
but CC N
did VBD N
not RB N
differ VB N
for IN N
APT NNP N
( ( N
3?4 CD N
[ RB N
-1?6 NN N
to TO N
8?4 CD N
] NN N
points NNS N
lower JJR N
; : N
p=0?18 NN N
) ) N
. . N

Compared VBN N
with IN N
APT NNP N
, , N
CBT NNP N
and CC N
GET NNP N
were VBD N
associated VBN N
with IN N
less JJR o
fatigue NN o
( ( o
CBT NNP o
p VBZ N
= JJ N
0?0027 CD N
; : N
GET NNP N
p VBP N
= NNP N
0?0059 CD N
) ) N
and CC N
better JJR o
physical JJ o
function NN o
( ( N
CBT NNP N
p=0?0002 NN N
; : N
GET NNP N
p VBP N
< NNP N
0?0001 CD N
) ) N
. . N

Subgroup NNP N
analysis NN N
of IN N
427 CD N
participants NNS N
meeting VBG N
international JJ N
criteria NNS p
for IN p
chronic JJ o
fatigue NN o
syndrome NN o
and CC p
329 CD N
participants NNS N
meeting VBG N
London NNP N
criteria NNS N
for IN N
myalgic JJ N
encephalomyelitis NN N
yielded VBN N
equivalent JJ N
results NNS N
. . N

Serious JJ N
adverse JJ o
reactions NNS o
were VBD N
recorded VBN N
in IN N
two CD N
( ( N
1 CD N
% NN N
) ) N
of IN N
159 CD N
participants NNS N
in IN N
the DT N
APT NNP N
group NN N
, , N
three CD N
( ( N
2 CD N
% NN N
) ) N
of IN N
161 CD N
in IN N
the DT N
CBT NNP N
group NN N
, , N
two CD N
( ( N
1 CD N
% NN N
) ) N
of IN N
160 CD N
in IN N
the DT N
GET NNP N
group NN N
, , N
and CC N
two CD N
( ( N
1 CD N
% NN N
) ) N
of IN N
160 CD N
in IN N
the DT N
SMC-alone NNP N
group NN N
. . N

INTERPRETATION NNP N
CBT NNP N
and CC N
GET NNP N
can MD N
safely RB N
be VB N
added VBN N
to TO N
SMC NNP N
to TO N
moderately RB N
improve VB N
outcomes NNS N
for IN N
chronic JJ N
fatigue NN o
syndrome NN o
, , N
but CC N
APT NNP N
is VBZ N
not RB N
an DT N
effective JJ N
addition NN N
. . N

FUNDING NN N
UK NNP N
Medical NNP N
Research NNP N
Council NNP N
, , N
Department NNP N
of IN N
Health NNP N
for IN N
England NNP N
, , N
Scottish NNP N
Chief NNP N
Scientist NNP N
Office NNP N
, , N
Department NNP N
for IN N
Work NNP N
and CC N
Pensions NNP N
. . N

-DOCSTART- -16730335- O O

Effects NNS N
of IN N
short- JJ N
and CC N
long-term JJ N
risperidone NN i
treatment NN p
on IN p
prolactin NN o
levels NNS o
in IN p
children NNS p
with IN p
autism NN p
. . p

BACKGROUND IN N
The DT N
effects NNS N
of IN N
short- JJ N
and CC N
long-term JJ N
risperidone NN i
treatment NN N
on IN N
serum NN N
prolactin NN N
were VBD N
assessed VBN N
in IN N
children NNS p
and CC p
adolescents NNS p
with IN p
autism NN p
. . p

METHODS NNP N
Patients NNPS p
with IN p
autism NN p
( ( p
N NNP p
= NNP p
101 CD p
, , p
5-17 CD p
years NNS p
of IN p
age NN p
) ) p
were VBD N
randomized VBN N
to TO N
an DT N
8-week JJ N
trial NN N
of IN N
risperidone NN i
or CC i
placebo NN i
and CC N
63 CD p
then RB p
took VBD p
part NN p
in IN p
a DT p
4-month JJ p
open-label JJ p
follow-up JJ p
phase NN p
. . p

Serum NNP N
samples NNS N
were VBD N
obtained VBN N
at IN N
Baseline NNP N
and CC N
Week-8 NNP N
( ( N
N NNP N
= NNP N
78 CD N
) ) N
, , N
and CC N
at IN N
6-month JJ N
( ( N
N NNP N
= NNP N
43 CD N
) ) N
and CC N
22-month JJ N
( ( N
N NNP N
= NNP N
30 CD N
) ) N
follow-up NN N
. . N

Serum NNP N
prolactin NN N
was VBD N
determined VBN N
by IN N
immunoradiometric JJ N
assay NN N
; : N
dopamine JJ o
type-2 JJ o
receptor NN o
( ( o
DRD2 NNP o
) ) o
polymorphisms NNS o
were VBD o
genotyped VBN o
. . o

RESULTS NNP N
Baseline NNP o
prolactin NN o
levels NNS o
were VBD N
similar JJ N
in IN N
the DT N
risperidone NN i
( ( N
N NNP N
= NNP N
42 CD N
) ) N
and CC N
placebo NN i
( ( N
N NNP N
= NNP N
36 CD N
) ) N
groups NNS N
( ( N
9.3 CD N
+/- JJ N
7.5 CD N
and CC N
9.3 CD N
+/- JJ N
7.6 CD N
ng/ml NN N
, , N
respectively RB N
) ) N
. . N

After IN N
8 CD N
weeks NNS N
of IN N
risperidone NN i
, , N
prolactin NN o
increased VBD N
to TO N
39.0 CD N
+/- JJ N
19.2 CD N
ng/ml NN N
, , N
compared VBN N
with IN N
10.1 CD N
+/- JJ N
8.8 CD N
ng/ml NN N
for IN N
placebo NN N
( ( N
p JJ N
< NNP N
.0001 NNP N
) ) N
. . N

Prolactin NN o
levels NNS o
were VBD N
also RB N
significantly RB N
increased VBN N
at IN N
6 CD N
months NNS N
( ( N
32.4 CD N
+/- JJ N
17.8 CD N
ng/ml NN N
; : N
N NNP N
= VBZ N
43 CD N
, , N
p NN N
< NNP N
.0001 NNP N
) ) N
and CC N
at IN N
22 CD N
months NNS N
( ( N
N NNP N
= NNP N
30 CD N
, , N
25.3 CD N
+/- JJ N
15.6 CD N
ng/ml NN N
, , N
p NN N
< NNP N
.0001 NNP N
) ) N
. . N

Prolactin NN o
levels NNS o
were VBD N
not RB N
associated VBN N
with IN N
adverse JJ N
effects NNS N
and CC N
DRD2 NNP N
alleles NNS N
( ( N
Taq1A NNP N
, , N
-141C NNP N
Ins/Del NNP N
, , N
C957T NNP N
) ) N
did VBD N
not RB N
significantly RB N
influence VB N
baseline NN N
levels NNS N
or CC N
risperidone-induced JJ N
increases NNS N
in IN N
prolactin NN N
. . N

CONCLUSIONS NNP N
Risperidone NNP i
treatment NN N
was VBD N
associated VBN N
with IN N
two- JJ N
to TO N
four-fold JJ N
mean NN N
increases NNS N
in IN N
serum NN N
prolactin NN N
in IN N
children NNS p
with IN p
autism NN p
. . p

Although IN N
risperidone-induced JJ N
increases NNS N
tended VBD N
to TO N
diminish VB N
with IN N
time NN N
, , N
further JJ N
research NN N
on IN N
the DT N
consequences NNS N
of IN N
long-term JJ N
prolactin NN N
elevations NNS N
in IN N
children NNS p
and CC p
adolescents NNS p
is VBZ N
needed VBN N
. . N

-DOCSTART- -20635521- O O

Effect NN N
of IN N
developmental JJ i
speech NN i
and CC i
language NN i
training NN i
through IN i
music NN i
on IN N
speech NN o
production NN o
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

The DT N
study NN N
compared VBN N
the DT N
effect NN N
of IN N
music NN i
training NN i
, , i
speech NN i
training NN i
and CC N
no-training NN i
on IN N
the DT N
verbal JJ N
production NN N
of IN N
children NNS p
with IN p
Autism NNP p
Spectrum NNP p
Disorders NNP p
( ( p
ASD NNP p
) ) p
. . p

Participants NNS p
were VBD p
50 CD p
children NNS p
with IN p
ASD NNP p
, , p
age NN p
range NN p
3 CD p
to TO p
5 CD p
years NNS p
, , p
who WP p
had VBD p
previously RB p
been VBN p
evaluated VBN p
on IN p
standard JJ p
tests NNS p
of IN p
language NN p
and CC p
level NN p
of IN p
functioning VBG p
. . p

They PRP N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
3-day JJ N
conditions NNS N
. . N

Participants NNS N
in IN N
music NN i
training NN i
( ( N
n JJ N
= NNP N
18 CD N
) ) N
watched VBD N
a DT N
music NN i
video NN i
containing VBG i
6 CD i
songs NNS i
and CC i
pictures NNS i
of IN i
the DT i
36 CD i
target NN i
words NNS i
; : i
those DT N
in IN N
speech JJ i
training NN i
( ( N
n JJ N
= NNP N
18 CD N
) ) N
watched VBD N
a DT N
speech NN i
video NN i
containing VBG i
6 CD i
stories NNS i
and CC i
pictures NNS i
, , N
and CC N
those DT N
in IN N
the DT N
control NN i
condition NN i
( ( N
n JJ N
= NNP N
14 CD N
) ) N
received VBD N
no DT i
treatment NN i
. . i

Participants NNS N
' POS N
verbal JJ N
production NN N
including VBG N
semantics NNS N
, , N
phonology NN N
, , N
pragmatics NNS N
, , N
and CC N
prosody NN N
was VBD N
measured VBN N
by IN N
an DT N
experimenter NN N
designed VBN N
verbal JJ N
production NN N
evaluation NN N
scale NN N
. . N

Results NNS N
showed VBD N
that IN N
participants NNS N
in IN N
both DT N
music NN i
and CC N
speech NN i
training NN i
significantly RB N
increased VBD N
their PRP$ N
pre NN o
to TO o
posttest VB o
verbal JJ o
production NN o
. . o

Results NNP N
also RB N
indicated VBD N
that IN N
both DT N
high JJ N
and CC N
low JJ N
functioning NN N
participants NNS N
improved VBD N
their PRP$ N
speech NN o
production NN o
after IN N
receiving VBG N
either CC N
music NN N
or CC N
speech NN N
training NN N
; : N
however RB N
, , N
low JJ N
functioning NN N
participants NNS N
showed VBD N
a DT N
greater JJR o
improvement NN o
after IN N
the DT N
music NN i
training NN i
than IN N
the DT N
speech NN N
training NN N
. . N

Children NNP p
with IN p
ASD NNP p
perceive JJ N
important JJ N
linguistic JJ N
information NN N
embedded VBN N
in IN N
music NN N
stimuli NNS N
organized VBN N
by IN N
principles NNS N
of IN N
pattern JJ N
perception NN N
, , N
and CC N
produce VBP N
the DT N
functional JJ N
speech NN N
. . N

-DOCSTART- -16381993- O O

GH NNP N
effect NN N
on IN N
enzyme NN o
activity NN o
of IN o
11betaHSD CD o
in IN N
abdominal JJ N
obesity NN N
is VBZ N
dependent JJ N
on IN N
treatment NN N
duration NN N
. . N

OBJECTIVE NNP N
In IN N
the DT N
past JJ N
years NNS N
the DT N
interaction NN N
of IN N
GH NNP i
and CC N
11beta CD N
hydroxysteroid JJ N
dehydrogenase NN N
( ( N
11betaHSD CD N
) ) N
in IN N
the DT N
pathogenesis NN N
of IN N
central JJ N
obesity NN N
has VBZ N
been VBN N
suggested VBN N
. . N

DESIGN NNP N
We PRP N
studied VBD N
the DT N
effects NNS N
of IN N
9 CD N
months NNS N
of IN N
GH NNP i
treatment NN i
on IN N
11betaHSD CD N
activity NN N
and CC N
its PRP$ N
relationship NN N
with IN N
body NN o
composition NN o
and CC o
insulin NN o
sensitivity NN o
in IN N
30 CD p
men NNS p
with IN p
abdominal JJ p
obesity NN p
, , p
aged VBN p
48-66 CD p
years NNS p
, , N
in IN N
a DT N
randomised JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
. . N

METHODS NNP N
Urinary NNP i
steroid NN i
profile NN i
was VBD i
used VBN i
to TO i
estimate VB i
11betaHSD CD o
type NN o
1 CD o
and CC o
2 CD o
( ( o
11betaHSD1 CD o
and CC o
11betaHSD2 CD o
) ) o
activities NNS o
. . o

Abdominal NNP o
s.c. NN o
and CC o
visceral JJ o
adipose JJ o
tissues NNS o
were VBD i
measured VBN i
using VBG i
computed VBN i
tomography NN i
. . i

Glucose NNP o
disposal NN o
rate NN o
( ( o
GDR NNP o
) ) o
obtained VBD i
during IN i
a DT i
euglycaemic-hyperinsulinaemic JJ i
glucose NN i
clamp NN i
was VBD i
used VBN i
to TO i
assess VB i
insulin JJ o
sensitivity NN o
. . o

RESULTS NNP N
In IN N
the DT N
GH-treated NNP N
group NN N
the DT N
11betaHSD1 CD o
activity NN o
decreased VBN N
transiently RB N
after IN N
6 CD N
weeks NNS N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
whereas VBD N
11betaHSD2 CD N
increased VBD N
after IN N
9 CD N
months NNS N
of IN N
treatment NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Between $ N
6 CD N
weeks NNS N
and CC N
9 CD N
months NNS N
, , N
GDR NNP o
increased VBD N
and CC N
visceral JJ o
fat JJ o
mass NN o
decreased VBN N
. . N

Changes NNS N
in IN N
11betaHSD1 CD o
correlated VBN N
with IN N
changes NNS N
in IN N
visceral JJ o
fat JJ o
mass NN o
between IN N
baseline NN N
and CC N
6 CD N
weeks NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
correlations NNS N
between IN N
11betaHSD1 CD o
and CC N
11betaHSD CD o
2 CD o
and CC N
changes NNS N
in IN N
GDR NNP o
. . o

DISCUSSION NNP N
The DT N
study NN N
demonstrates VBZ N
that IN N
short- JJ N
and CC N
long-term JJ N
GH NNP N
treatment NN N
has VBZ N
different JJ N
effects NNS N
on IN N
11betaHSD1 CD o
and CC o
11betaHSD2 CD o
activity NN o
. . o

Moreover RB N
, , N
the DT N
data NNS N
do VBP N
not RB N
support VB N
that IN N
long-term JJ N
metabolic JJ N
effects NNS N
of IN N
GH NNP N
are VBP N
mediated VBN N
through IN N
its PRP$ N
action NN N
on IN N
11betaHSD CD N
. . N

-DOCSTART- -16275661- O O

Mending VBG N
the DT N
rhythm NN N
does VBZ N
not RB N
improve VB N
prognosis NN N
in IN N
patients NNS p
with IN p
persistent JJ p
atrial JJ p
fibrillation NN p
: : p
a DT N
subanalysis NN N
of IN N
the DT N
RACE NNP N
study NN N
. . N

AIMS NNP N
To TO N
compare VB N
outcome NN N
of IN N
AF NNP p
patients NNS p
with IN p
effective JJ p
rhythm NNS p
control NN p
with IN N
patients NNS p
treated VBN p
with IN p
rate NN p
control NN p
. . p

METHODS NNP N
AND CC N
RESULTS NNP N
Out NNP N
of IN N
the DT N
266 CD p
AF NNP p
patients NNS p
randomized VBD p
to TO p
rhythm VB i
control NN i
in IN p
the DT p
RACE NNP p
study NN p
, , p
49 CD p
patients NNS p
turned VBD p
to TO p
long-term JJ i
sinus NN i
rhythm NN i
and CC p
were VBD p
continuously RB p
treated VBN p
with IN p
oral JJ i
anticoagulation NN i
. . i

The DT N
incidence NN N
of IN N
the DT N
primary JJ N
endpoint NN N
in IN N
these DT N
patients NNS N
was VBD N
compared VBN N
to TO N
that DT N
in IN N
178 CD N
patients NNS N
out IN N
of IN N
the DT N
initial JJ N
256 CD p
rate-control JJ p
patients NNS p
of IN p
RACE NNP p
who WP N
were VBD N
in IN N
AF NNP N
and CC N
using VBG N
oral JJ N
anticoagulation NN N
continuously RB N
. . N

Baseline NNP N
characteristics NNS N
of IN N
both DT N
groups NNS N
were VBD N
not RB N
different JJ N
. . N

After IN N
a DT N
mean JJ N
follow-up NN N
of IN N
2.3+/-0.6 CD N
years NNS N
, , N
the DT N
primary JJ N
endpoint NN N
( ( N
a DT N
composite NN o
of IN o
cardiovascular JJ o
mortality NN o
, , o
heart NN o
failure NN o
, , o
thrombo-embolic JJ o
complications NNS o
( ( o
TECs NNP o
) ) o
, , o
bleeding VBG o
, , o
serious JJ o
adverse JJ o
effects NNS o
of IN o
antiarrhythmic JJ o
drugs NNS o
and CC o
pacemaker NN o
implants NNS o
) ) o
was VBD N
22.4 CD N
% NN N
in IN N
the DT N
rhythm-control NN N
group NN N
vs. FW N
15.2 CD N
% NN N
in IN N
the DT N
rate-control NN N
group NN N
. . N

Multivariable JJ N
regression NN N
analysis NN N
indicated VBD N
coronary JJ o
artery NN o
disease NN o
, , o
heart NN o
failure NN o
, , o
and CC o
digitalis RB o
as IN N
independent JJ N
risk NN N
indicators NNS N
of IN N
cardiovascular JJ N
morbidity NN N
and CC N
mortality NN N
. . N

Chronic NNP o
sinus NN o
rhythm NN o
did VBD N
not RB N
matter NN N
. . N

CONCLUSION NNP N
Among IN N
patients NNS p
who WP p
remained VBD p
on IN p
warfarin NN i
, , N
those DT N
who WP N
mostly RB N
were VBD N
maintained VBN N
in IN N
sinus NN N
rhythm NN N
under IN N
a DT N
rhythm-control JJ N
strategy NN N
did VBD N
not RB N
have VB N
a DT N
superior JJ N
prognosis NN N
compared VBN N
to TO N
those DT N
who WP N
remained VBD N
in IN N
AF NNP N
under IN N
a DT N
rate-control JJ N
strategy NN N
. . N

-DOCSTART- -19713225- O O

Arterial NNP N
cardiovascular JJ N
risk NN N
factors NNS N
and CC N
venous JJ p
thrombosis NN p
: : p
results NNS N
from IN N
a DT N
population-based JJ N
, , N
prospective JJ N
study NN N
( ( N
the DT N
HUNT NNP N
2 CD N
) ) N
. . N

BACKGROUND NNP N
An DT N
explanation NN N
for IN N
the DT N
increased VBN N
risk NN N
of IN N
myocardial JJ N
infarction NN N
and CC N
stroke NN N
in IN N
patients NNS p
with IN p
venous JJ p
thrombosis NN p
is VBZ N
lacking VBG N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
whether IN N
risk NN N
factors NNS N
for IN N
arterial JJ N
cardiovascular JJ N
disease NN N
also RB N
increase VBZ N
the DT N
risk NN N
of IN N
venous JJ N
thrombosis NN N
. . N

DESIGN NNP N
AND CC N
METHODS NNP N
Cases NNP p
who WP p
had VBD p
a DT p
first JJ p
venous JJ p
thrombosis NN p
( ( p
n=515 JJ p
) ) p
and CC p
matched VBN p
controls NNS p
( ( p
n=1,505 NN p
) ) p
were VBD p
identified VBN p
from IN p
a DT p
population-based JJ p
, , p
nested JJ p
, , p
case-cohort JJ p
study NN p
( ( p
the DT p
HUNT NNP p
2 CD p
study NN p
) ) p
comprising VBG p
71 CD p
% NN p
( ( p
n=66,140 JJ p
) ) p
of IN p
the DT p
adult NN p
residents NNS p
of IN p
Nord-Tr?ndelag NNP p
County NNP p
in IN p
Norway NNP p
. . p

RESULTS VB N
The DT N
age- JJ N
and CC N
sex-adjusted JJ N
odds NNS N
ratio NN N
of IN o
venous JJ o
thrombosis NN o
for IN p
subjects NNS p
with IN p
concentrations NNS p
of IN p
C-reactive JJ p
protein NN p
in IN p
the DT p
highest JJS p
quintile NN p
was VBD N
1.6 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
: : N
1.2-2.2 JJ N
) ) N
compared VBN N
to TO N
subjects NNS N
with IN o
C-reactive JJ o
protein NN o
in IN N
the DT N
lowest JJS N
quintile NN N
. . N

This DT N
association NN N
was VBD N
strongest VBN N
in IN p
subjects NNS p
who WP p
experienced VBD p
venous JJ p
thrombosis NN p
within IN p
a DT p
year NN p
after IN p
blood NN p
sampling VBG p
with IN N
a DT N
three-fold JJ N
increased JJ N
risk NN N
of IN N
participants NNS N
in IN N
the DT N
highest JJS N
versus NN N
the DT N
lowest JJS N
quintile NN N
. . N

Having VBG N
first JJ N
degree JJ N
relatives NNS N
who WP N
had VBD N
a DT N
myocardial JJ N
infarction NN N
before IN N
the DT N
age NN N
of IN N
60 CD N
years NNS N
was VBD N
positively RB N
associated VBN N
with IN o
venous JJ o
thrombosis NN o
compared VBN N
to TO N
not RB N
having VBG N
a DT N
positive JJ N
family NN N
history NN N
[ NNP N
odds VBZ N
ratio NN N
1.3 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
: : N
1.1-1.6 JJ N
) ) N
] NN N
. . N

Subjects NNS N
with IN o
blood NN o
pressure NN o
in IN N
the DT N
highest JJS N
quintile NN N
had VBD N
half PDT N
the DT N
risk NN N
of IN N
developing VBG o
venous JJ o
thrombosis NN o
compared VBN N
to TO N
subjects NNS N
whose WP$ N
blood NN N
pressure NN N
was VBD N
in IN N
the DT N
lowest JJS N
quintile NN N
. . N

There EX N
were VBD N
no DT N
associations NNS N
between IN N
the DT o
risk NN o
of IN o
venous JJ o
thrombosis NN o
and CC o
total JJ o
cholesterol NN o
, , o
low JJ o
density NN o
lipoprotein-cholesterol NN o
, , o
high JJ o
density NN o
lipoprotein-cholesterol NN o
, , o
triglycerides NNS o
, , o
glucose NN o
or CC o
smoking NN o
. . o

We PRP N
confirmed VBD N
the DT N
positive JJ N
association NN N
between IN o
obesity NN o
and CC o
venous JJ o
thrombosis NN o
. . o

CONCLUSIONS NNP N
C-reactive JJ N
protein NN N
and CC N
a DT N
family NN N
history NN N
of IN N
myocardial JJ N
infarction NN N
were VBD N
positively RB N
associated VBN N
with IN N
subsequent JJ o
venous JJ o
thrombosis NN o
. . o

Blood NNP o
pressure NN o
was VBD N
inversely RB N
correlated VBN N
to TO p
venous JJ p
thrombosis NN p
. . p

These DT N
findings NNS N
should MD N
be VB N
confirmed VBN N
by IN N
further JJ N
investigations NNS N
. . N

-DOCSTART- -22574591- O O

[ JJ N
Effects NNS N
of IN N
shuxuening VBG i
injection NN i
on IN N
the DT N
levels NNS N
of IN N
serum NN o
matrix RBS o
metalloproteinase-9 JJ o
and CC N
tissue JJ o
inhibitor NN o
of IN o
metalloproteinase-1 NN o
in IN N
acute NN p
exacerbated VBD p
chronic JJ p
obstructive JJ p
pulmonary JJ p
disease NN p
patients NNS p
] VBP p
. . N

OBJECTIVE NNP N
To TO N
observe VB N
the DT N
effects NNS N
of IN N
Shuxuening VBG i
Injection NNP i
( ( i
SI NNP i
) ) i
on IN N
the DT N
levels NNS N
of IN N
serum NN o
matrix NN o
metalloproteinase-9 NN o
( ( o
MMP-9 NNP o
) ) o
and CC N
tissue NN o
inhibitor NN o
of IN o
metalloproteinase NN o
( ( o
TIMP-1 NNP o
) ) o
in IN N
acute NN p
exacerbated VBD p
chronic JJ p
obstructive JJ p
pulmonary JJ p
disease NN p
( ( p
COPD NNP p
) ) p
patients NNS p
. . p

METHODS NNP N
Seventy-nine JJ p
patients NNS p
with IN p
acute JJ p
exacerbated VBN p
COPD NNP p
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
treatment NN N
group NN N
( ( N
39 CD N
cases NNS N
) ) N
and CC N
the DT N
control NN N
group NN N
( ( N
40 CD N
cases NNS N
) ) N
. . N

Routine JJ i
therapies NNS i
for IN i
COPD NNP i
were VBD N
given VBN N
to TO N
patients NNS N
in IN N
the DT N
control NN N
group NN N
, , N
while IN i
15 CD i
mL NNS i
SI NNP i
was VBD i
given VBN i
to TO i
those DT i
in IN i
the DT i
treatment NN i
group NN i
by IN i
intravenous JJ i
dripping NN i
, , i
twice RB i
daily RB i
for IN i
total JJ i
14 CD i
days NNS i
. . i

The DT N
forced JJ o
expiratory NN o
volume NN o
in IN o
one CD o
second NN o
( ( o
FEV1 NNP o
) ) o
and CC i
forced VBN o
vital JJ o
capacity NN o
( ( o
FVC NNP o
) ) o
were VBD i
detected VBN i
by IN i
Spirometer NNP i
. . i

The DT N
FEV1/FVC NNP N
( ( N
% NN N
) ) N
and CC N
the DT N
FEV1 NNP N
% NN N
were VBD N
calculated VBN N
. . N

The DT N
levels NNS o
of IN o
serum NN o
MMP-9 NNP o
and CC o
TIMP-1 NNP o
were VBD N
detected VBN N
using VBG N
ELISA NNP N
before IN N
and CC N
after IN N
treatment NN N
, , N
and CC N
compared VBN N
with IN N
20 CD N
healthy JJ N
subjects NNS N
as IN N
the DT N
control NN N
. . N

RESULTS VB N
The DT N
FEV1 NNP o
, , o
FVC NNP o
, , o
FEV1/FVC NNP o
( ( o
% NN o
) ) o
, , o
and CC o
FEV1 NNP o
% NN o
were VBD N
significantly RB N
improved VBN N
after IN N
treatment NN N
in IN N
the DT N
treatment NN N
group NN N
when WRB N
compared VBN N
with IN N
before RB N
treatment NN N
and CC N
with IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

When WRB N
compared VBN N
with IN N
before RB N
treatment NN N
and CC N
with IN N
the DT N
control NN N
group NN N
, , N
the DT N
levels NNS N
of IN N
serum NN o
MMP-9 NNP o
, , o
TIMP-1 NNP o
, , o
and CC o
the DT o
ratio NN o
of IN o
MMP-9/TIMP-1 NNP o
decreased VBD N
more RBR N
significantly RB N
in IN N
the DT N
treatment NN N
group NN N
after IN N
treatment NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Correlation NN N
analyses VBZ N
showed VBD N
that IN N
obvious JJ N
negative JJ N
correlation NN N
existed VBD N
between IN N
the DT N
levels NNS N
of IN N
serum NN o
MMP-9 NNP o
and CC o
TIMP-1 NNP o
and CC o
FEV1/FVC NNP o
( ( o
% NN o
) ) o
( ( N
r JJ N
= NNP N
-0.677 NNP N
, , N
-0.629 NNP N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Obvious JJ N
negative JJ N
correlation NN N
existed VBD N
between IN N
the DT N
levels NNS N
of IN N
serum NN o
MMP-9 NNP o
and CC o
TIMP-1 NNP o
and CC o
FEV1 NNP o
% NN o
( ( N
r JJ N
= NNP N
-0.562 NNP N
, , N
-0.661 NNP N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Furthermore UH N
, , N
obvious JJ N
negative JJ N
correlation NN N
also RB N
existed VBD N
between IN N
the DT N
ratio NN N
of IN N
MMP-9/ NNP N
TIMP-1 NNP N
and CC N
FEV1 NNP N
% NN N
, , N
as RB N
well RB N
as IN N
FEV1/FVC NNP N
( ( N
% NN N
) ) N
( ( N
r JJ N
= NNP N
-0.732 NNP N
, , N
-0.891 NNP N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSIONS NNP N
SI NNP i
could MD N
improve VB N
the DT N
pulmonary JJ N
ventilation NN N
function NN N
of IN N
acute NN p
exacerbated VBN p
COPD NNP p
patients NNS p
. . p

One CD N
of IN N
its PRP$ N
mechanisms NNS N
might MD N
be VB N
correlated VBN N
with IN N
lowering VBG N
the DT N
serum NN N
levels NNS N
of IN N
MMP-9 NNP N
and CC N
TIMP-1 NNP N
, , N
and CC N
correcting VBG N
the DT N
imbalance NN N
of IN N
MMP-9/TIMP-1 NNP N
. . N

-DOCSTART- -22045148- O O

A DT N
simplified VBN N
score NN N
for IN N
transfer NN N
of IN N
patients NNS p
requiring VBG p
mechanical JJ i
ventilation NN i
to TO N
a DT N
long-term JJ N
care NN N
hospital NN N
. . N

BACKGROUND NNP N
Long-term NNP N
care NN N
hospitals NNS N
are VBP N
Medicare NNP N
providers NNS N
of IN N
postacute NN p
care NN p
that WDT N
have VBP N
a DT p
mean JJ p
length NN p
of IN p
stay NN p
of IN p
25 CD p
days NNS p
or CC p
more JJR p
. . p

Early JJ N
identification NN N
and CC N
timely JJ N
transfer NN N
of IN N
patients NNS p
requiring VBG p
mechanical JJ p
ventilation NN p
to TO N
such JJ N
hospitals NNS N
may MD N
improve VB N
the DT N
efficiency NN o
of IN N
inpatient NN N
care NN N
. . N

OBJECTIVES NNP N
To TO N
develop VB N
a DT N
predictive JJ i
model NN i
and CC N
a DT N
simplified VBN N
score NN N
for IN N
use NN N
on IN N
day NN N
7 CD N
of IN N
hospitalization NN N
to TO N
assess VB N
whether IN N
a DT N
patient NN p
receiving VBG p
mechanical JJ i
ventilation NN i
is VBZ N
likely JJ N
to TO N
require VB N
an DT N
additional JJ N
25 CD N
days NNS N
of IN N
hospitalization NN N
( ( N
ie JJ N
, , N
would MD N
qualify VB N
for IN N
transfer NN N
to TO N
a DT N
long-term JJ N
care NN N
hospital NN N
) ) N
. . N

METHODS CC N
A DT N
retrospective JJ N
, , N
cross-sectional JJ N
study NN N
using VBG N
hospital JJ p
discharge NN p
and CC p
billing NN p
data NNS p
from IN p
the DT p
2005 CD p
Nationwide NNP p
Inpatient NNP p
Sample NNP p
for IN p
54 CD p
686 CD p
Medicare NNP p
beneficiaries NNS p
admitted VBD p
to TO p
US NNP p
community NN p
hospitals NNS p
who WP p
met VBD p
the DT p
study NN p
's POS p
eligibility NN p
criteria NNS p
. . p

The DT N
outcome NN N
was VBD N
overall JJ o
length NN o
of IN o
stay NN o
( ( N
?32 JJ N
vs NN N
< $ N
32 CD N
days NNS N
) ) N
. . N

Split-sample JJ N
validation NN N
was VBD N
used VBN N
. . N

Multivariable JJ N
survey-logistic JJ N
regression NN N
analyses NNS N
were VBD N
performed VBN N
to TO N
assess VB N
predictors NNS N
and CC N
probability NN N
of IN N
the DT N
outcome NN N
. . N

A DT N
simplified JJ o
score NN o
was VBD o
derived VBN N
from IN N
the DT N
final JJ N
predictive NN N
model NN N
. . N

RESULTS VB N
The DT N
discriminatory JJ N
power NN N
of IN N
the DT o
predictive JJ o
model NN o
was VBD o
0.75 CD N
and CC N
that IN N
of IN N
the DT o
simplified VBN o
score NN o
was VBD o
0.72 CD N
. . N

The DT N
model NN N
calibrated VBN N
well RB N
. . N

All DT N
predictors NNS N
were VBD N
significantly RB N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
associated VBN N
with IN N
a DT N
hospitalization NN o
of IN o
32 CD o
days NNS o
or CC o
longer JJR o
; : o
having VBG o
a DT N
tracheostomy NN N
was VBD N
the DT N
strongest JJS N
predictor NN N
( ( N
odds NNS N
ratio NN N
, , N
4.74 CD N
) ) N
. . N

The DT N
simplified JJ N
scores NNS N
ranged VBD N
from IN N
-5 NN N
to TO N
110 CD N
points NNS N
and CC N
were VBD N
categorized VBN N
into IN N
3 CD N
classes NNS N
of IN N
risk NN N
. . N

CONCLUSIONS NNP N
Efforts NNPS N
to TO N
aid VB N
discharge NN N
decision NN N
making NN N
and CC N
optimize VB N
hospital JJ N
resource NN N
planning NN N
could MD N
take VB N
advantage NN N
of IN N
our PRP$ N
predictive JJ N
model NN N
and CC N
the DT N
simplified JJ N
scoring NN N
tool NN N
. . N

-DOCSTART- -9828635- O O

[ JJ i
Radiotherapy NNP i
for IN N
choroidal JJ N
neovascularization NN N
in IN N
age-related JJ N
macular JJ N
degeneration NN N
. . N

A DT N
pilot NN N
study NN N
using VBG N
low- JJ i
versus NN i
high-dose JJ i
photon NN i
bean NN i
radiation NN i
] NN i
. . N

PURPOSE NNP N
Several JJ N
pilot NN N
studies NNS N
have VBP N
indicated VBN N
that IN N
low-dose JJ i
radiation NN i
therapy NN i
might MD N
have VB N
a DT N
beneficial JJ N
effect NN N
on IN N
the DT N
course NN N
of IN N
choroidal JJ N
neovascularization NN N
( ( N
CNV NNP N
) ) N
in IN N
age-related JJ p
macular JJ p
degeneration NN p
( ( p
AMD NNP p
) ) p
. . p

This DT N
study NN N
aimed VBD N
to TO N
ascertain VB N
whether IN N
such JJ N
treatment NN N
might MD N
halt VB N
the DT N
progression NN N
of IN N
neovascular JJ N
AMD NNP N
and CC N
whether IN N
a DT N
low JJ N
or CC N
a DT N
high JJ N
radiation NN N
dose NN N
should MD N
be VB N
applied VBN N
. . N

PATIENTS VB N
The DT N
patients NNS p
comprised VBD p
some DT p
randomized VBN p
to TO p
0 CD i
vs NNS i
10 CD i
vs NNS i
36 CD i
Gy NNP i
of IN i
radiation NN i
and CC p
( ( p
after IN p
a DT p
change NN p
of IN p
the DT p
study NN p
protocol NN p
became VBD p
necessary JJ p
) ) p
others NNS p
who WP p
participated VBD p
in IN p
a DT p
prospective JJ p
, , p
controlled VBD p
non-randomized JJ p
pilot NN p
study NN p
. . p

Enclosed VBN N
were VBD N
eyes NNS p
with IN p
visual JJ p
acuity NN p
of IN p
> NN p
or CC p
= VB p
0.1 CD p
and CC p
< NNP p
or CC p
= $ p
0.6 CD p
revealing VBG p
a DT p
juxta-subfoveal JJ p
CNV NNP p
either NN p
of IN p
the DT p
occult NN p
type NN p
( ( p
type JJ p
1 CD p
) ) p
or CC p
the DT p
classic JJ p
type NN p
( ( p
isolated JJ p
or CC p
as IN p
part NN p
of IN p
a DT p
predominantly RB p
occult JJ p
lesion NN p
) ) p
. . p

RESULTS NNP N
Eyes NNP N
treated VBD N
with IN N
10 CD i
Gy NNP i
for IN N
occult NN N
CNV NNP N
( ( N
n JJ N
= NNP N
12 CD N
) ) N
were VBD N
subject JJ N
to TO N
severe JJ o
visual JJ o
loss NN o
in IN N
41.6 CD N
% NN N
of IN N
the DT N
cases NNS N
compared VBN N
to TO N
38.5 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
( ( N
n JJ N
= NNP N
13 CD N
) ) N
at IN N
12 CD N
months NNS N
of IN N
follow-up NN N
. . N

For IN N
eyes NNS N
treated VBN N
with IN N
10 CD i
Gy NNP i
because IN N
of IN N
classic JJ N
CNV NNP N
, , N
the DT N
corresponding JJ N
figures NNS N
were VBD N
33 CD N
% NN N
( ( N
n JJ N
= NNP N
18 CD N
) ) N
and CC N
57 CD N
% NN N
( ( N
n JJ N
= NNP N
14 CD N
) ) N
respectively RB N
. . N

At IN N
18 CD N
months NNS N
of IN N
follow-up NN N
, , N
the DT N
percentages NNS N
were VBD N
63 CD N
% NN N
and CC N
75 CD N
% NN N
respectively RB N
. . N

Fluorescein NNP o
angiographic JJ o
growth NN o
of IN o
classic JJ o
and CC o
occult NN o
CNV NNP o
could MD N
not RB N
be VB N
halted VBN N
by IN N
10 CD N
Gy NNP N
, , N
while IN N
a DT N
temporary JJ o
growth NN o
retardation NN o
was VBD N
observed VBN N
in IN N
cases NNS N
irradiated VBN N
with IN N
36 CD i
Gy NNP i
. . i

CONCLUSION NNP N
In IN N
the DT N
study NN N
presented VBD N
, , N
the DT N
natural JJ N
course NN N
of IN N
occult NN N
CNV NNP N
could MD N
not RB N
be VB N
improved VBN N
by IN N
irradiation NN N
with IN N
10 CD i
or CC i
36 CD i
Gy NNP i
. . i

In IN N
cases NNS N
of IN N
classic JJ N
CNV NNP N
, , N
low-dose JJ N
irradiation NN N
with IN N
10 CD i
Gy NNP i
postponed VBD N
severe JJ o
visual JJ o
loss NN o
by IN N
a DT N
maximum NN N
of IN N
18 CD N
months NNS N
. . N

A DT N
positive JJ N
treatment NN N
effect NN N
was VBD N
also RB N
observed VBN N
in IN N
cases NNS N
irradiated VBN N
with IN N
36 CD i
Gy NNP i
; : i
however RB N
, , N
a DT N
25 CD N
% NN N
incidence NN N
of IN N
radiation NN N
retinopathy NN N
seems VBZ N
unacceptable JJ N
. . N

-DOCSTART- -16548702- O O

Resisting VBG N
good JJ N
news NN N
: : N
reactions NNS N
to TO N
breast VB p
cancer NN p
risk NN p
communication NN N
. . N

Many JJ N
women NNS N
overestimate VBP N
their PRP$ N
percentage NN N
risk NN N
of IN N
breast NN N
cancer NN N
, , N
even RB N
after IN N
they PRP N
have VBP N
received VBN N
careful JJ i
estimates NNS i
from IN N
health NN N
professionals NNS N
. . N

In IN N
2 CD N
experiments NNS N
with IN N
134 CD p
young JJ p
adult NN p
women NNS p
, , p
6 CD p
variables NNS p
were VBD N
explored VBN N
that IN N
might MD N
influence VB N
such JJ N
risk NN o
perception NN o
persistence NN N
. . N

In IN N
Study NNP N
1 CD N
, , N
each DT N
of IN N
the DT N
following JJ N
explanations NNS N
was VBD N
unrelated JJ N
to TO N
persistence VB o
: : o
public JJ i
commitment NN i
, , i
self-consistency NN i
, , N
and CC N
unique JJ i
causal NN i
risk NN i
models NNS i
. . i

In IN N
Study NNP N
2 CD N
, , N
two CD N
individual JJ N
difference NN N
measures NNS N
, , N
pessimism NN N
and CC N
differences NNS N
in IN N
understanding JJ N
percentages NNS N
, , N
were VBD N
unrelated JJ N
to TO N
risk VB o
perception NN o
persistence NN o
. . o

However RB N
, , N
providing VBG N
a DT N
risk NN i
anchor NN i
based VBN i
on IN i
downward JJ i
social JJ i
comparison NN i
processes NNS i
resulted VBD N
in IN N
better JJR N
risk NN o
acceptance NN o
at IN N
posttest JJS N
that IN N
persisted VBD N
at IN N
a DT N
2-week JJ N
follow-up JJ N
assessment NN N
. . N

This DT N
article NN N
discusses VBZ N
why WRB N
comparison NN i
anchors NNS i
might MD N
be VB N
important JJ N
in IN N
risk NN N
feedback NN N
situations NNS N
and CC N
concludes NNS N
with IN N
recommendations NNS N
for IN N
professionals NNS N
who WP N
wish VBP N
to TO N
provide VB N
accurate NN N
risk NN N
information NN N
and CC N
have VBP N
patients NNS N
adopt VB N
that DT N
information NN N
. . N

-DOCSTART- -787788- O O

Vitamin NNP i
C NNP i
and CC N
acute JJ N
illness NN N
in IN N
Navajo NNP p
school NN p
children NNS p
. . p

To TO N
evaluate VB N
earlier JJR N
observations NNS N
, , N
including VBG N
our PRP$ N
own JJ N
, , N
showing VBG N
usefulness NN N
of IN N
vitamin NN i
C NNP i
for IN N
managing VBG N
the DT N
common JJ N
cold NN N
, , N
we PRP N
performed VBD N
a DT N
double-blind JJ N
trial NN N
of IN N
vitamin NN i
C NNP i
versus NN i
placebo NN i
in IN N
868 CD p
children NNS p
. . p

There EX N
was VBD N
no DT N
difference NN N
in IN N
number NN o
becoming VBG o
ill JJ o
( ( N
133 CD N
versus IN N
129 CD N
) ) N
, , N
number NN o
of IN o
episodes NNS o
( ( N
166 CD N
versus IN N
159 CD N
) ) N
or CC N
mean JJ o
illness JJ o
duration NN o
( ( N
5.5 CD N
versus NN N
5.8 CD N
days NNS N
) ) N
between IN N
the DT N
groups NNS N
. . N

Children NNP p
receiving VBG p
vitamin NN p
C NNP p
had VBD N
fewer JJR N
throat NN o
cultures NNS o
yielding VBG N
beta-hemolytic JJ o
streptococcus NN o
( ( N
six CD N
versus NN N
13 CD N
, , N
P NNP N
less JJR N
than IN N
0.10 CD N
) ) N
, , N
but CC N
no DT N
difference NN N
in IN N
overall JJ o
complicated JJ o
illness NN o
rate NN o
( ( N
24 CD N
versus IN N
25 CD N
) ) N
. . N

Plasma NNP o
ascorbic JJ o
acid NN o
levels NNS o
were VBD N
higher JJR N
in IN N
the DT N
vitamin NN p
group NN p
24 CD N
to TO N
26 CD N
hours NNS N
after IN N
supplementation NN N
( ( N
1.28 CD N
versus NN N
1.04 CD N
mg NN N
per IN N
100 CD N
ml NN N
, , N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

Children NNP p
with IN p
high JJ p
plasma NN p
ascorbic JJ p
acid JJ p
concentrations NNS N
had VBD N
longer RBR N
mean JJ o
illness NN o
( ( N
6.8 CD N
versus NN N
4.0 CD N
days NNS N
, , N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
than IN N
those DT N
with IN N
low JJ N
levels NNS N
. . N

Vitamin NNP i
C NNP i
does VBZ N
not RB N
seem VB N
to TO N
be VB N
an DT N
effective JJ N
prophylactic NN N
or CC N
therapeutic JJ N
agent NN N
for IN N
upper JJ N
respiratory NN N
illness NN N
. . N

-DOCSTART- -1640362- O O

Performance NN N
of IN N
a DT N
modified VBN i
starch NN i
hydrophilic NN i
matrix NN i
for IN i
the DT i
sustained JJ i
release NN i
of IN i
theophylline NN i
in IN N
healthy JJ p
volunteers NNS p
. . p

Two CD N
experimental JJ N
formulations NNS N
of IN N
theophylline NN i
with IN i
a DT i
hydrophilic JJ i
starch NN i
matrix NN i
were VBD N
evaluated VBN N
for IN N
their PRP$ N
sustained-release JJ N
characteristics NNS N
after IN N
single JJ N
administration NN N
in IN N
healthy JJ p
human JJ p
volunteers NNS p
. . p

Theo-dur NN i
was VBD N
chosen VBN N
as IN N
a DT N
reference NN N
sustained-release JJ N
formulation NN N
. . N

In IN N
a DT N
first JJ N
study NN N
, , N
the DT N
extent NN N
of IN N
absorption NN N
was VBD N
similar JJ N
for IN N
a DT N
syrup NN N
, , N
for IN N
Theo-dur NNP i
, , N
and CC N
for IN N
the DT N
experimental JJ N
formulation NN N
of IN N
theophylline NN i
with IN i
70 CD i
% NN i
drum-dried JJ i
corn NN i
starch NN i
as IN i
the DT i
sustained-release JJ i
agent NN i
( ( i
DDCS-70 NNP i
) ) i
. . N

The DT N
maximal JJ o
plasma NN o
concentration NN o
( ( o
Cmax NNP o
) ) o
was VBD N
significantly RB N
lower JJR N
, , N
and CC N
the DT N
time NN o
to TO o
reach VB o
Cmax NNP o
as RB N
well RB N
as IN N
the DT N
time NN N
span NN N
during IN N
which WDT N
the DT N
plasma NN o
concentration NN o
was VBD N
at IN N
least JJS N
75 CD N
% NN N
of IN N
the DT N
Cmax NNP N
were VBD N
significantly RB N
higher JJR N
for IN N
Theo-dur NNP N
than IN N
for IN N
the DT N
DDCS-70 NNP N
formulation NN N
. . N

A DT N
sustained-release JJ N
profile NN N
, , N
as IN N
for IN N
Theo-dur NNP i
, , N
was VBD N
not RB N
reached VBN N
for IN N
DDCS-70 NNP N
. . N

In IN N
a DT N
second JJ N
study NN N
the DT N
influence NN N
of IN N
the DT N
starch NN N
: : N
drug NN N
ratio NN N
on IN N
the DT N
bioavailability NN N
was VBD N
investigated VBN N
. . N

The DT N
decrease NN N
in IN N
starch NN N
content NN N
from IN N
70 CD N
to TO N
50 CD N
% NN N
of IN N
the DT N
formulation NN N
did VBD N
not RB N
improve VB N
the DT N
plasma NN o
concentration-time JJ o
profile NN N
towards NNS N
a DT N
sustained-release JJ N
profile NN N
. . N

-DOCSTART- -20863389- O O

A DT N
phase NN N
II NNP N
randomized VBD N
trial NN N
comparing VBG N
radiotherapy NN i
with IN N
concurrent JJ N
weekly JJ N
cisplatin NN i
or CC N
weekly JJ N
paclitaxel NN i
in IN N
patients NNS p
with IN p
advanced JJ p
cervical JJ p
cancer NN p
. . p

PURPOSE/OBJECTIVE VB N
This DT N
is VBZ N
a DT N
prospective JJ N
comparison NN N
of IN N
weekly JJ N
cisplatin NN i
to TO N
weekly VB N
paclitaxel NN i
as IN N
concurrent JJ N
chemotherapy NN N
with IN N
standard JJ i
radiotherapy NN i
for IN N
locally RB N
advanced JJ p
cervical JJ p
carcinoma NN p
. . p

MATERIALS/METHODS NNP N
Between NNP p
May NNP p
2000 CD p
and CC p
May NNP p
2004 CD p
, , p
31 CD p
women NNS p
with IN p
FIGO NNP p
stage NN p
IB2-IVA NNP p
cervical JJ p
cancer NN p
or CC p
with IN p
postsurgical JJ p
pelvic JJ p
recurrence NN p
were VBD p
enrolled VBN p
into IN p
this DT p
phase NN p
II NNP p
study NN p
and CC N
randomized VBN N
to TO N
receive VB N
on IN N
a DT N
weekly JJ N
basis NN N
either CC N
40 CD i
mg/m? NN i
Cisplatin NNP i
( ( i
group NN i
I PRP i
; : i
16 CD i
patients NNS i
) ) i
or CC i
50 CD i
mg/m? NNS i
paclitaxel NN i
( ( i
group NN i
II NNP i
; : i
15 CD i
patients NNS i
) ) i
concurrently RB i
with IN i
radiotherapy NN i
. . i

Median JJ N
total NN N
dose NN N
to TO N
point VB N
A NNP N
was VBD N
74 CD N
Gy NNP N
( ( N
range NN N
: : N
66-92 JJ N
Gy NNP N
) ) N
for IN N
group NN N
I PRP N
and CC N
66 CD N
Gy NNP N
( ( N
range NN N
: : N
40-98 JJ N
Gy NNP N
) ) N
for IN N
group NN N
II NNP N
. . N

Median JJ N
follow-up JJ N
time NN N
was VBD N
46 CD N
months NNS N
. . N

RESULTS NNP p
Patient NNP p
and CC p
tumor NN p
characteristics NNS p
were VBD p
similar JJ N
in IN N
both DT N
groups NNS N
. . N

The DT o
mean JJ o
number NN o
of IN o
chemotherapy NN o
cycles NNS o
was VBD o
also RB N
comparable JJ N
with IN N
87 CD N
% NN N
and CC N
80 CD N
% NN N
of IN N
patients NNS N
receiving VBG N
at IN N
least JJS N
4 CD N
doses NNS N
in IN N
groups NNS N
I PRP N
and CC N
II NNP N
, , N
respectively RB N
. . N

Seven JJ N
patients NNS N
( ( N
44 CD N
% NN N
) ) N
of IN N
group NN N
I PRP N
and CC N
8 CD N
patients NNS N
( ( N
53 CD N
% NN N
) ) N
of IN N
group NN N
II NNP N
developed VBD o
tumor NN o
recurrence NN o
. . o

The DT o
Median JJ o
Survival NNP o
time NN o
was VBD o
not RB N
reached VBN N
for IN N
Group NNP N
I PRP N
and CC N
53 CD N
months NNS N
for IN N
group NN N
II NNP N
. . N

The DT o
proportion NN o
of IN o
patients NNS o
surviving VBG o
at IN o
2 CD N
and CC N
5 CD N
years NNS N
was VBD N
78 CD N
% NN N
and CC N
54 CD N
% NN N
for IN N
group NN N
I PRP N
and CC N
73 CD N
% NN N
and CC N
43 CD N
% NN N
for IN N
group NN N
II NNP N
respectively RB N
. . N

CONCLUSIONS VB N
This DT N
small JJ N
prospective JJ N
study NN N
shows NNS N
that WDT N
weekly VBP i
paclitaxel NN i
does VBZ i
not RB N
provide VB N
any DT o
clinical JJ o
advantage NN o
over IN o
weekly JJ i
cisplatin NN i
for IN i
concurrent JJ i
chemoradiation NN i
for IN i
advanced JJ p
carcinoma NN p
of IN p
the DT p
cervix NN p
. . p

-DOCSTART- -22156967- O O

A DT N
randomized JJ N
trial NN N
of IN N
a DT N
behavioral JJ i
intervention NN i
for IN N
black JJ p
MSM NNP p
: : p
the DT N
DiSH NNP N
study NN N
. . N

OBJECTIVE NNP N
To TO N
test VB N
a DT N
new JJ N
behavioral JJ N
intervention NN N
for IN N
black JJ p
MSM NNP p
in IN N
reducing VBG N
sexual JJ N
risk NN N
and CC N
increasing VBG N
social JJ N
support NN N
and CC N
intentions NNS N
to TO N
use VB N
condoms NNS N
. . N

DESIGN VB N
A DT N
single-site JJ N
, , N
unblinded JJ N
randomized VBN N
trial NN N
in IN N
New NNP p
York NNP p
City NNP p
with IN N
3-month JJ N
follow-up NN N
. . N

METHODS NNP N
Participants NNP p
( ( p
n JJ p
= NNP p
283 CD p
) ) p
reporting NN p
at IN p
least JJS p
two CD p
sexual JJ p
partners NNS p
and CC p
unprotected JJ p
anal JJ p
intercourse NN p
with IN p
a DT p
man NN p
in IN p
the DT p
past JJ p
3 CD p
months NNS p
were VBD N
enrolled VBN N
and CC N
randomized VBN N
to TO N
a DT N
social-cognitive JJ i
theory-based JJ i
intervention NN i
or CC i
control NN i
comparison NN i
. . i

Men NN N
in IN N
the DT N
intervention NN N
group NN N
participated VBD N
in IN N
five CD N
2-h JJ N
group NN N
sessions NNS N
focused VBD N
on IN N
creating VBG N
a DT N
group NN N
environment NN N
with IN N
sexual JJ N
risk-reduction NN N
information NN N
and CC N
exercises VBZ N
woven VBN N
into IN N
joint JJ N
meal JJ N
preparation NN N
and CC N
sharing NN N
activities NNS N
, , N
while IN N
exploring VBG N
self-efficacy JJ N
perceptions NNS N
and CC N
outcome JJ N
expectancies NNS N
. . N

Intervention NNP N
( ( N
n JJ N
= NNP N
142 CD N
) ) N
and CC N
control NN N
( ( N
n JJ N
= NNP N
141 CD N
) ) N
groups NNS N
received VBD N
standard JJ N
HIV NNP N
counseling NN N
and CC N
testing VBG N
at IN N
baseline NN N
. . N

RESULTS NNP N
No NNP N
significant JJ N
differences NNS N
were VBD N
found VBN N
between IN N
study NN N
arms NNS N
at IN N
3 CD N
months NNS N
in IN N
number NN o
of IN o
male JJ o
partners NNS o
, , o
number NN o
of IN o
unprotected JJ o
anal JJ o
intercourse NN o
partners NNS o
, , o
proportion NN o
reporting NN o
unprotected JJ o
sex NN o
, , o
number NN o
of IN o
acts NNS o
protected VBN o
by IN o
condoms NNS o
, , o
self-efficacy NN o
, , o
condom NN o
attitudes NNS o
, , o
condom NN o
intentions NNS o
, , o
social JJ o
isolation NN o
and CC o
psychological JJ o
distress NN o
. . o

In IN N
both DT N
arms NNS N
combined VBN N
, , N
declines NNS N
from IN N
baseline NN N
to TO N
3 CD N
months NNS N
were VBD N
observed VBN N
in IN N
sexual JJ o
risk NN o
behaviors NNS o
, , o
social JJ o
isolation NN o
and CC o
psychological JJ o
distress NN o
, , N
whereas IN N
self-efficacy NN o
, , o
condom NN o
attitudes NNS o
and CC o
condom NN o
intentions NNS N
improved VBN N
. . N

CONCLUSION NNP N
As IN N
the DT N
HIV NNP N
epidemic JJ N
continues VBZ N
to TO N
have VB N
a DT N
dramatic JJ N
impact NN N
on IN N
black JJ p
MSM NNP p
in IN p
the DT p
USA NNP p
, , N
the DT N
urgency NN N
to TO N
design VB N
innovative JJ N
interventions NNS N
continues VBZ N
. . N

-DOCSTART- -23385110- O O

Wheelchair NNP i
skills VBZ i
training NN i
to TO N
improve VB N
confidence NN o
with IN N
using VBG N
a DT N
manual JJ N
wheelchair NN N
among IN N
older JJR p
adults NNS p
: : p
a DT N
pilot NN N
study NN N
. . N

OBJECTIVE NNP N
To TO N
examine VB N
the DT N
effects NNS N
of IN N
wheelchair NN i
skills NNS i
training VBG i
on IN N
confidence NN o
in IN N
older JJR p
adults NNS p
who WP p
are VBP p
inexperienced VBN p
wheelchair JJ p
users NNS p
. . p

DESIGN NNP N
Parallel NNP N
group NN N
, , N
single-blind JJ N
randomized VBD N
controlled JJ N
trial NN N
. . N

SETTING NNP N
Research NNP N
laboratory NN N
in IN N
a DT N
rehabilitation NN N
hospital NN N
. . N

PARTICIPANTS JJ N
Participants NNS p
( ( p
N=20 NNP p
) ) p
who WP p
were VBD p
community-living JJ p
older JJR p
adults NNS p
at IN p
least JJS p
65 CD p
years NNS p
old JJ p
( ( p
mean JJ p
age NN p
, , p
70y CD p
) ) p
, , p
50 CD p
% NN p
women NNS p
, , p
and CC p
who WP p
had VBD p
no DT p
experience NN p
of IN p
using VBG p
a DT p
wheelchair NN p
were VBD N
randomly RB N
allocated VBN N
to TO N
an DT N
intervention NN N
( ( N
n=10 JJ N
) ) N
or CC N
control NN N
( ( N
n=10 JJ N
) ) N
group NN N
. . N

INTERVENTIONS VBZ N
The DT N
intervention NN N
group NN N
received VBD N
two CD i
1-hour JJ i
training NN i
sessions NNS i
that WDT i
followed VBD i
the DT i
Wheelchair NNP i
Skills NNP i
Training NNP i
Program NNP i
( ( i
WSTP NNP i
) ) i
protocol NN i
. . i

The DT N
control NN N
group NN N
received VBD N
a DT N
single JJ i
socialization NN i
contact NN i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
The DT N
Wheelchair NNP o
Use NNP o
Confidence NNP o
Scale-Manual JJ o
( ( o
WheelCon-M NNP o
) ) o
was VBD N
used VBN N
to TO N
evaluate VB o
confidence NN o
with IN N
using VBG N
a DT N
manual JJ N
wheelchair NN N
. . N

The DT N
WheelCon-M NNP N
is VBZ N
a DT N
self-report JJ N
questionnaire NN N
that WDT N
comprises VBZ N
65 CD N
items NNS N
in IN N
6 CD N
conceptual JJ N
areas NNS N
. . N

RESULTS VB N
A DT N
1-way JJ N
between-groups JJ N
analysis NN N
of IN N
covariance NN N
revealed VBD N
a DT N
significant JJ o
difference NN o
in IN N
postintervention NN o
WheelCon-M JJ o
scores NNS o
between IN N
the DT N
intervention NN N
and CC N
control NN N
groups NNS N
( ( N
F1,17=10.9 NNP N
, , N
P=.004 NNP N
) ) N
after IN N
controlling VBG N
for IN N
baseline JJ N
WheelCon-M JJ N
scores NNS N
. . N

A DT N
large JJ N
effect NN o
size NN o
was VBD N
also RB N
observed VBN N
( ( N
partial JJ N
? . N
( ( N
2 CD N
) ) N
=.39 NN N
) ) N
. . N

Secondary JJ N
analyses NNS N
revealed VBD N
that IN N
the DT N
WSTP NNP N
had VBD N
greater JJR o
effects NNS o
on IN o
confidence NN o
in IN o
areas NNS o
related VBN o
to TO o
maneuvering VBG o
around IN o
the DT o
physical JJ o
environment NN o
, , o
knowledge NN o
and CC o
problem NN o
solving NN o
, , o
advocacy NN o
, , o
and CC o
managing VBG o
emotions NNS o
than IN o
in IN o
areas NNS o
related VBN o
to TO o
performing VBG o
activities NNS o
and CC o
behaving VBG o
in IN o
social JJ o
situations NNS o
. . o

CONCLUSION NNP N
Two CD N
1-hour JJ N
WSTP NNP N
sessions NNS N
improve VBP o
confidence NN o
with IN o
using VBG o
a DT o
manual JJ o
wheelchair NN o
among IN p
older JJR p
adults NNS p
who WP p
are VBP p
inexperienced VBN p
wheelchair JJ p
users NNS p
. . p

-DOCSTART- -21720441- O O

Beverage NNP i
vs. FW i
solid JJ i
fruits NNS i
and CC i
vegetables NNS i
: : i
effects NNS N
on IN N
energy NN N
intake NN N
and CC N
body NN o
weight NN o
. . o

Beverage NN N
consumption NN N
has VBZ N
been VBN N
implicated VBN N
in IN N
weight NN N
gain NN N
, , N
but CC N
questions NNS N
remain VBP N
about IN N
the DT N
veracity NN N
of IN N
the DT N
association NN N
, , N
whether IN N
the DT N
relationship NN N
is VBZ N
causal JJ N
and CC N
what WP N
property NN N
of IN N
beverages NNS N
is VBZ N
responsible JJ N
. . N

It PRP N
was VBD N
hypothesized VBN N
that IN N
food NN N
form NN N
is VBZ N
the DT N
most RBS N
salient JJ N
attribute NN N
. . N

Thus RB N
, , N
a DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
food NN N
form NN N
was VBD N
conducted VBN N
. . N

Energy-matched JJ i
beverage NN i
or CC i
solid JJ i
forms NNS i
of IN i
fruits NNS i
and CC i
vegetables NNS i
were VBD N
provided VBN N
to TO N
34 CD p
, , p
lean JJ p
or CC p
overweight/obese JJ p
adults NNS p
for IN N
two CD N
8-week JJ N
periods NNS N
with IN N
a DT N
3-week JJ N
washout NN N
interspersed VBN N
. . N

Dietary JJ o
compensation NN o
was VBD N
incomplete JJ N
( ( N
beverage VB N
53 CD N
% NN N
; : N
solid JJ N
78 CD N
% NN N
) ) N
and CC N
body JJ o
weight NN o
increased VBD N
after IN N
the DT N
beverage NN N
( ( N
1.95 CD N
? . N
0.33 CD N
kg NN N
) ) N
( ( N
77 CD N
% NN N
fat JJ N
mass NN N
) ) N
and CC N
solid JJ N
( ( N
1.36 CD N
? . N
0.30 CD N
kg NN N
) ) N
( ( N
85 CD N
% NN N
fat JJ N
mass NN N
) ) N
treatments NNS N
( ( N
both DT N
P NNP N
< NNP N
0.0005 CD N
) ) N
. . N

Differences NNS N
between IN N
food NN N
forms NNS N
were VBD N
not RB N
significant JJ N
. . N

The DT N
lean JJ N
group NN N
had VBD N
the DT N
highest JJS o
dietary JJ o
compensation NN o
( ( o
119 CD N
% NN N
) ) N
and CC N
no DT N
significant JJ o
weight NN o
change NN o
( ( o
0.84 CD N
? . N
0.53 CD N
kg NN N
) ) N
after IN N
consuming VBG N
the DT N
solid JJ N
fruits NNS N
and CC N
vegetables NNS N
whereas VBP N
the DT N
overweight/obese JJ N
group NN N
had VBD N
lower JJR o
compensation NN o
and CC o
significant JJ o
weight JJ o
gain NN o
during IN o
the DT N
solid JJ N
arm NN N
( ( N
46 CD N
% NN N
, , N
1.77 CD N
? . N
0.32 CD N
kg NN N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

In IN N
contrast NN N
, , N
incomplete JJ o
dietary JJ o
compensation NN o
and CC o
weight JJ o
gain NN o
occurred VBD o
in IN N
both CC N
the DT N
lean NN N
( ( N
43 CD N
% NN N
, , N
1.61 CD N
? . N
0.44 CD N
kg NN N
, , N
P NNP N
= NNP N
0.003 CD N
) ) N
and CC N
overweight/obese JJ N
( ( N
61 CD N
% NN N
, , N
2.22 CD N
? . N
0.47 CD N
kg NN N
, , N
P NNP N
< NNP N
0.0005 CD N
) ) N
groups NNS N
during IN N
the DT N
beverage NN N
arm NN N
. . N

Secondary JJ N
analyses NNS N
revealed VBD p
the DT p
obese JJ p
group NN p
gained VBD N
more JJR N
weight NN N
than IN N
the DT p
lean JJ p
and CC p
overweight JJ p
groups NNS p
during IN N
the DT N
beverage NN N
intervention NN N
( ( N
P NNP N
= NNP N
0.024 CD N
) ) N
. . N

These DT N
data NNS N
demonstrate VBP N
energy NN N
consumed VBN N
as IN N
beverages NNS N
may MD N
be VB N
especially RB N
problematic JJ o
for IN o
weight JJ o
gain NN o
. . o

They PRP N
also RB N
indicate VBP N
that IN N
advice NN N
to TO N
increase VB N
fruit NN N
and CC N
vegetable JJ N
consumption NN N
should MD N
emphasize VB N
total JJ N
energy NN N
intake NN N
because IN N
the DT N
additional JJ N
energy NN N
contributed VBD N
may MD N
promote VB o
weight NN o
gain NN o
, , o
especially RB N
among IN N
overweight JJ p
and CC p
obese JJ p
individuals NNS p
. . p

-DOCSTART- -8376638- O O

Coping VBG N
with IN N
distress NN N
and CC N
self JJ N
harm NN N
: : N
the DT N
impact NN N
of IN N
a DT N
primary JJ i
prevention NN i
program NN i
among IN N
adolescents NNS p
. . p

The DT N
effectiveness NN N
of IN N
a DT N
school-based JJ i
primary JJ i
prevention NN i
psychological JJ i
program NN i
is VBZ N
assessed VBN N
in IN N
the DT N
present JJ N
study NN N
. . N

The DT N
program NN N
was VBD N
designed VBN N
to TO N
( ( N
a DT N
) ) N
improve NN N
students NNS N
' POS N
distress-coping NN o
, , N
( ( N
b NN N
) ) N
prepare VB N
them PRP N
as IN N
gatekeepers NNS o
with IN o
regard NN o
to TO o
self-destructive JJ o
behavior NN o
of IN o
peers NNS o
and CC N
( ( N
c NN N
) ) N
assess IN N
the DT N
program NN N
's POS N
face NN o
validity NN o
and CC N
social JJ o
validity NN o
. . o

The DT N
program NN N
was VBD N
primarily RB N
based VBN N
on IN N
cognitive-behavioral JJ N
modification NN N
principles NNS N
, , N
procedures NNS N
and CC N
techniques NNS N
. . N

Two CD p
hundred CD p
and CC p
thirty-seven JJ p
students NNS p
, , p
drawn NN p
from IN p
six CD p
homeroom NN p
grade NN p
eight CD p
classes NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
experimental VB N
and CC N
control VB N
( ( N
no DT N
intervention NN N
) ) N
conditions NNS N
. . N

The DT N
program NN N
consisted VBN N
of IN N
seven CD N
units NNS N
passed VBN N
during IN N
twelve JJ N
weekly JJ N
one-hour JJ N
sessions NNS N
. . N

Overall NNP N
, , N
the DT N
program NN N
had VBD N
a DT N
positive JJ N
effect NN N
on IN N
attitudes NNS o
, , o
emotions NNS o
, , o
knowledge NN o
and CC o
awareness NN o
of IN o
distress NN o
coping VBG o
skills NNS o
. . o

In IN N
addition NN N
, , N
it PRP N
had VBD N
some DT N
degree NN N
of IN N
face NN o
validity NN o
and CC o
social JJ o
validity NN o
from IN N
the DT N
students NNS N
' POS N
vantage NN N
point NN N
. . N

These DT N
results NNS N
lend VBP N
support NN N
to TO N
the DT N
feasibility NN N
of IN N
a DT N
cognitive-behavioral JJ o
, , o
school-based JJ o
prevention NN o
program NN o
for IN N
students NNS N
' POS N
distress-coping JJ N
enhancement NN N
. . N

-DOCSTART- -12569977- O O

Liposome-entrapped JJ i
D. NNP i
pteronyssinus NN i
vaccination NN i
in IN N
mild JJ p
asthma JJ p
patients NNS p
: : p
effect NN N
of IN N
1-year JJ N
double-blind NN N
, , N
placebo-controlled JJ i
trial NN N
on IN N
inflammation NN N
, , N
bronchial JJ N
hyperresponsiveness NN N
and CC N
immediate JJ N
and CC N
late JJ N
bronchial NN N
responses NNS N
to TO N
the DT N
allergen NN N
. . N

BACKGROUND NNP N
Allergen NNP N
vaccination NN N
is VBZ N
effective JJ N
in IN N
mite-allergic JJ p
asthma NN p
. . p

Liposomes NNS N
are VBP N
immunological JJ N
adjuvants NNS N
that WDT N
can MD N
act VB N
as IN N
allergen NN N
carriers NNS N
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
immunological JJ N
and CC N
functional JJ N
effects NNS N
of IN N
a DT N
liposome-entrapped JJ i
D. NNP i
pteronyssinus NN i
vaccine NN i
on IN N
mite JJ p
monosensitive NN p
, , p
mild JJ p
asthma NN p
patients NNS p
. . p

METHODS VB N
A DT N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
was VBD N
conducted VBN N
on IN N
26 CD p
asthma JJ p
patients NNS p
who WP p
randomly VBP p
received VBN p
vaccination NN p
or CC p
placebo NN i
for IN p
1 CD p
year NN p
. . p

The DT N
levels NNS N
of IN N
exposure NN N
to TO N
Der NNP N
p NN N
1 CD N
allergen NN N
were VBD N
constant JJ N
during IN N
the DT N
study NN N
. . N

Allergen NNP N
bronchial JJ N
challenge NN N
was VBD N
made VBN N
at IN N
the DT N
beginning NN N
( ( N
T0 NNP N
) ) N
and CC N
after IN N
1 CD N
year NN N
of IN N
treatment NN N
( ( N
T12 NNP N
) ) N
. . N

The DT N
day NN N
before IN N
and CC N
24 CD N
h NN N
after IN N
the DT N
allergen NN N
provocation NN N
, , N
patients NNS N
were VBD N
challenged VBN N
with IN N
methacholine NN i
( ( N
Mth NNP N
) ) N
( ( N
until IN N
FEV1 NNP N
fell VBD N
by IN N
40 CD N
% NN N
) ) N
and CC N
blood NN N
and CC N
sputum NN N
samples NNS N
were VBD N
obtained VBN N
. . N

Dose-response JJ N
curves NNS N
to TO N
Mth NNP N
were VBD N
evaluated VBN N
in IN N
terms NNS N
of IN N
Mth-PD20 NNP N
( ( N
dose NN N
of IN N
Mth NNP N
that WDT N
induced VBD N
20 CD N
% NN N
drop NN N
in IN N
FEV1 NNP N
) ) N
, , N
slope NN N
( ( N
Mth-DRS NNP N
) ) N
and CC N
level NN N
of IN N
plateau NN N
. . N

Blood NNP o
and CC o
sputum NN o
eosinophils NNS o
and CC o
serum NN o
levels NNS o
of IN o
eosinophil NN o
cationic JJ o
protein NN o
( ( o
ECP NNP o
) ) o
and CC o
intercellular JJ o
adhesion NN o
molecule-1 NN o
( ( o
ICAM-1 NNP o
) ) o
were VBD N
measured VBN N
. . N

RESULTS NNP N
Groups NNP N
were VBD N
comparable JJ N
at IN N
the DT N
start NN N
of IN N
the DT N
trial NN N
. . N

At IN N
TI2 NNP N
, , N
previous JJ N
to TO N
the DT N
allergen NN N
challenge NN N
, , N
the DT N
active JJ N
group NN N
showed VBD N
higher JJR N
values NNS N
of IN N
both DT N
FEV1 NNP o
and CC o
Mth-PD20 NNP o
and CC N
lower JJR N
values NNS N
of IN N
Mth-DRS NNP o
. . o

The DT N
number NN o
of IN o
patients NNS o
presenting VBG o
a DT o
level NN o
of IN o
plateau NN o
increased VBN N
in IN N
the DT N
active JJ N
group NN N
( ( N
from IN N
two CD N
to TO N
four CD N
) ) N
and CC N
decreased VBN N
in IN N
the DT N
placebo NN N
group NN N
( ( N
from IN N
two CD N
to TO N
one CD N
) ) N
. . N

At IN N
T12 NNP N
, , N
before IN N
the DT N
allergen NN N
challenge NN N
, , N
serum NN o
ECP NNP o
levels NNS o
increased VBN N
in IN N
the DT N
placebo NN N
group NN N
and CC N
blood NN N
eosinophils NNS N
showed VBD N
a DT N
trend NN N
towards NNS N
lower JJR N
numbers NNS N
in IN N
the DT N
active JJ N
one NN N
. . N

The DT N
immediate JJ N
response NN N
and CC N
the DT N
changes NNS N
in IN N
Mth-DRS NNP o
values NNS o
, , o
sputum NN o
eosinophils NNS o
and CC o
serum VB o
ECP NNP o
levels NNS o
following VBG N
the DT N
allergen NN N
challenge NN N
were VBD N
attenuated VBN N
in IN N
the DT N
active JJ N
group NN N
. . N

CONCLUSION NNP N
Liposome-entrapped NNP N
D. NNP N
Pteronyssinus NNP N
vaccination NN N
: : N
( ( N
i NN N
) ) N
protects VBZ N
mild JJ p
asthma JJ p
patients NNS p
from IN N
the DT N
worsening NN N
of IN N
asthma NNS N
due JJ N
to TO N
sustained VBN N
mite JJ N
exposure NN N
; : N
and CC N
( ( N
ii NN N
) ) N
reduces VBZ N
the DT N
functional JJ N
and CC N
inflammatory JJ N
changes NNS N
induced VBN N
by IN N
allergen NN N
bronchial JJ N
provocation NN N
. . N

-DOCSTART- -3286673- O O

Pulsatile NNP o
insulin NN o
delivery NN o
is VBZ N
more RBR N
efficient JJ N
than IN N
continuous JJ i
infusion NN i
in IN N
modulating VBG N
islet NN N
cell NN N
function NN N
in IN N
normal JJ p
subjects NNS p
and CC p
patients NNS p
with IN p
type JJ p
1 CD p
diabetes NNS p
. . p

The DT N
respective JJ N
modulating NN N
effects NNS N
of IN N
continuous JJ i
and CC i
intermittent JJ i
insulin NN i
delivery NN i
on IN N
pancreatic JJ N
islet NN N
cell NN N
function NN N
were VBD N
studied VBN N
in IN N
seven CD p
normal JJ p
men NNS p
and CC p
nine CD p
insulin-dependent NN p
( ( p
type JJ p
1 CD p
) ) p
diabetic JJ p
patients NNS p
. . p

In IN N
the DT N
normal JJ p
men NNS p
, , N
saline NN i
or CC i
continuous JJ i
( ( N
0.8 CD N
mU RB N
kg-1 JJ N
min-1 NN N
) ) N
or CC i
pulsatile NN i
( ( N
5.2 CD N
mU RB N
kg-1 JJ N
min-1 NNS N
, , N
with IN N
a DT N
switching VBG N
on/off RP N
length NN N
of IN N
2/11 CD N
min NN N
) ) N
human JJ i
insulin NN i
were VBD N
delivered VBN N
on IN N
different JJ N
days NNS N
and CC N
in IN N
random JJ N
order NN N
. . N

Despite IN N
hyperinsulinemia NN N
, , N
blood NN N
glucose NN N
was VBD N
kept VBN N
close RB N
to TO N
its PRP$ N
basal NN N
value NN N
by IN N
the DT N
glucose JJ N
clamp NN N
technique NN N
. . N

The DT N
diabetic JJ p
patients NNS p
also RB N
were VBD N
infused VBN N
in IN N
random JJ N
order NN N
and CC N
on IN N
different JJ N
days NNS N
with IN N
either DT N
saline NN i
or CC N
a DT N
smaller JJR i
amount NN i
of IN i
insulin NN i
delivered VBN i
continuously RB i
( ( N
0.15 CD N
mU RB N
kg-1 JJ N
min-1 NN N
) ) N
or CC i
in IN i
a DT i
pulsatile JJ i
manner NN i
( ( N
0.97 CD N
mU RB N
kg-1 JJ N
min-1 NN N
for IN N
2 CD N
min NN N
, , N
followed VBN N
by IN N
11 CD N
min NNS N
during IN N
which WDT N
no DT N
insulin NN N
was VBD N
infused VBN N
) ) N
. . N

In IN N
all DT N
experiments NNS N
, , N
5 CD N
g NN N
arginine NN i
were VBD N
given VBN N
iv NNS N
as IN N
a DT N
bolus NN N
dose JJ N
30 CD N
min NN N
before IN N
the DT N
end NN N
of IN N
the DT N
study NN N
, , N
and CC N
plasma VB o
C-peptide NNP o
and CC o
glucagon NN o
levels NNS o
were VBD N
determined VBN N
to TO N
assess VB N
islet NN N
cell NN N
function NN N
. . N

In IN N
the DT N
normal JJ p
men NNS p
, , N
insulin NN N
administration NN N
resulted VBD N
in IN N
a DT N
significant JJ N
decline NN N
of IN N
basal NN o
plasma NN o
glucagon NN o
and CC o
C-peptide JJ o
levels NNS o
and CC N
in IN N
a DT N
clear-cut JJ N
decrease NN N
in IN N
the DT N
arginine-induced JJ o
glucagon NN o
response NN o
. . o

These DT N
effects NNS N
of IN N
insulin NN N
were VBD N
significantly RB N
more RBR N
marked JJ N
when WRB N
insulin NN N
was VBD N
delivered VBN N
in IN N
a DT N
pulsatile NN N
rather RB N
than IN N
a DT N
continuous JJ N
manner NN N
. . N

In IN N
the DT N
insulin-dependent JJ p
diabetic JJ p
patients NNS p
, , N
the DT N
lower JJR N
dose NN N
of IN N
insulin NN N
infused VBN N
continuously RB N
did VBD N
not RB N
alter VB N
the DT N
basal NN o
or CC o
arginine-stimulated JJ o
glucagon NN o
response NN o
. . o

In IN N
contrast NN N
, , N
when WRB N
the DT N
same JJ N
amount NN N
of IN N
insulin NN N
was VBD N
delivered VBN N
intermittently RB N
, , N
arginine-induced JJ o
glucagon NN o
release NN o
was VBD N
greatly RB N
reduced VBN N
. . N

Thus RB N
, , N
these DT N
data NNS N
support NN N
the DT N
concept NN N
that WDT N
insulin VBZ N
per IN N
se NN N
is VBZ N
a DT N
potent JJ N
physiological JJ o
modulator NN o
of IN o
islet NN o
A- NNP o
and CC o
B-cell NNP o
function NN o
. . o

Furthermore RB N
, , N
they PRP N
suggest VBP N
that IN N
these DT N
effects NNS N
of IN N
insulin NN N
are VBP N
reinforced VBN N
when WRB N
the DT N
hormone NN N
is VBZ N
administered VBN N
in IN N
an DT N
intermittent JJ N
manner NN N
in IN N
an DT N
attempt NN N
to TO N
reproduce VB N
the DT N
pulsatile NN o
physiological JJ o
release NN o
of IN o
insulin NN o
. . o

-DOCSTART- -16739368- O O

[ JJ o
Rapidity NNP o
of IN o
pain NN o
relief NN o
, , o
medication NN o
requirement NN o
and CC o
patient JJ o
satisfaction NN o
with IN p
reflux JJ p
treatment NN p
in IN N
the DT N
physician NN N
's POS N
office NN N
] NN N
. . N

Treatment NN N
of IN N
gastroesophageal NN o
reflux NN o
disease NN o
( ( o
GERD NNP o
) ) o
with IN N
proton NN o
pump NN o
inhibitors NNS o
was VBD N
investigated VBN N
in IN N
three CD N
controlled VBD N
prospective JJ N
, , N
randomized JJ N
open JJ N
studies NNS N
. . N

Lansoprazole NNP i
, , i
omeprazole JJ i
MUPS NNP i
and CC i
esomeprazole NN i
were VBD N
compared VBN N
under IN N
doctor NN N
's POS N
office NN N
conditions NNS N
. . N

The DT N
outcomes NNS N
of IN N
interest NN N
were VBD N
the DT N
rapidity NN o
of IN o
pain NN o
relief NN o
achieved VBN N
with IN N
a DT N
single JJ o
dose NN o
, , o
effectiveness NN o
and CC o
patient JJ o
satisfaction NN o
with IN N
on IN N
demand NN N
therapy NN N
. . N

In IN N
the DT N
first JJ N
study NN N
, , N
180 CD p
patients NNS p
with IN p
chronic JJ p
and CC p
prolonged JJ p
episodes NNS p
of IN p
reflux NN p
were VBD p
investigated VBN p
. . p

Time NN N
to TO N
pain VB o
relief NN o
following VBG N
a DT N
single JJ N
dose NN N
was VBD N
1.1 CD N
+/- JJ N
0.8 CD N
hours NNS N
with IN N
30 CD N
mg NNS N
lansoprazole JJ i
, , N
3.0 CD N
+/- JJ N
2.5 CD N
hours NNS N
with IN N
20 CD N
mgomeprazole JJ i
MUPS NNP N
and CC N
2.1 CD N
+/- JJ N
1.2 CD N
hours NNS N
with IN N
40 CD N
mg NNS N
esomeprazole JJ i
. . i

Studies NNS N
2 CD N
and CC N
3 CD N
were VBD N
designed VBN N
as IN N
cross-over NN N
studies NNS N
intended VBN N
to TO N
investigate VB N
drug NN o
consumption NN o
. . o

In IN N
study NN N
2 CD N
, , N
the DT N
amount NN o
of IN o
lansoprazole NN o
consumed VBN o
was VBD N
approximately RB N
50 CD N
% NN N
less JJR N
than IN N
that DT N
of IN N
omeprazole NN i
, , N
and CC N
this DT N
translated VBN N
to TO N
81 CD N
% NN N
patient JJ o
satisfaction NN o
with IN N
lansoprazole JJ i
compared VBN N
with IN N
only RB N
9.5 CD N
% NN N
for IN N
omeprazole NN i
. . i

In IN N
study NN N
3 CD N
comparing VBG N
lansoprazole NN N
and CC N
esomeprazole NN i
, , N
consumption NN o
of IN N
the DT N
former JJ N
was VBD N
85 CD N
% NN N
that WDT N
of IN N
the DT N
latter NN N
. . N

58 CD N
% NN N
of IN N
the DT N
patients NNS N
opted VBD N
to TO N
continuetreatment VB o
with IN N
lansoprazole NN i
, , N
compared VBN N
with IN N
only RB N
25 CD N
% NN N
in IN N
the DT N
case NN N
of IN N
esomeprazole NN i
. . N

The DT N
appreciably RB N
greater JJR N
patient JJ o
satisfaction NN o
with IN N
lansoprazole NN i
was VBD N
due JJ N
tothe NN N
faster RBR o
pain NN o
relief NN o
achieved VBN N
with IN N
this DT N
drug NN N
. . N

-DOCSTART- -22578685- O O

Carbon NNP i
dioxide NN i
insufflation NN i
in IN N
open-chamber JJ N
cardiac JJ N
surgery NN N
: : N
a DT N
double-blind NN N
, , N
randomized VBD N
clinical JJ N
trial NN N
of IN N
neurocognitive JJ N
effects NNS N
. . N

OBJECTIVE IN N
The DT N
aims NNS N
of IN N
this DT N
study NN N
were VBD N
first RB N
to TO N
analyze VB N
neurocognitive JJ o
outcomes NNS o
of IN N
patients NNS p
after IN p
open-chamber JJ p
cardiac JJ p
surgery NN p
to TO N
determine VB N
whether IN N
carbon NN i
dioxide NN i
pericardial JJ i
insufflation NN i
reduces NNS N
incidence NN N
of IN N
neurocognitive JJ o
decline NN o
( ( N
primary JJ N
end NN N
point NN N
) ) N
as IN N
measured VBN N
6 CD N
weeks NNS N
postoperatively RB N
and CC N
second JJ N
to TO N
assess VB N
the DT N
utility NN N
of IN N
carbon NN i
dioxide NN i
insufflation NN i
in IN N
cardiac JJ N
chamber NN N
deairing NN N
as IN N
assessed VBN N
by IN N
transesophageal JJ N
echocardiography NN N
. . N

METHODS NNP N
A NNP N
multicenter NN N
, , N
prospective JJ N
, , N
double-blind JJ N
, , N
randomized VBN N
, , N
controlled VBN N
trial NN N
compared VBN N
neurocognitive JJ N
outcomes NNS N
in IN N
patients NNS p
undergoing VBG p
open-chamber JJ p
( ( p
left-sided JJ p
) ) p
cardiac NN p
surgery NN p
who WP p
were VBD p
assigned VBN p
carbon NN i
dioxide NN i
insufflation NN i
or CC i
placebo NN i
( ( p
control VB p
group NN p
) ) p
in IN p
addition NN p
to TO p
standardized VB p
mechanical JJ p
deairing VBG p
maneuvers NNS p
. . p

RESULTS NNP N
One CD p
hundred VBD p
twenty-five JJ p
patients NNS p
underwent JJ p
surgery NN p
and CC N
were VBD N
randomly RB N
allocated VBN N
. . N

Neurocognitive JJ N
testing NN N
showed VBD N
no DT N
clinically RB N
significant JJ N
differences NNS N
in IN N
z NN o
scores NNS o
between IN N
preoperative JJ N
and CC N
postoperative JJ N
testing NN N
. . N

Linear JJ N
regression NN N
was VBD N
used VBN N
to TO N
identify VB N
factors NNS N
associated VBN N
with IN N
neurocognitive JJ N
decline NN N
. . N

Factors NNS p
most RBS p
strongly RB p
associated VBN p
with IN p
neurocognitive JJ p
decline NN p
were VBD p
hypercholesterolemia JJ o
, , o
aortic JJ o
atheroma NN o
grade NN o
, , o
and CC o
coronary JJ o
artery NN o
disease NN o
. . o

There EX N
was VBD N
significantly RB N
more JJR N
intracardiac JJ o
gas NN o
noted VBD N
on IN N
intraoperative JJ N
transesophageal NN N
echocardiography NN N
in IN N
all DT N
cardiac JJ N
chambers NNS N
( ( N
left JJ N
atrium NN N
, , N
left VBD N
ventricle NN N
, , N
and CC N
aorta NN N
) ) N
at IN N
all DT N
measured VBN N
times NNS N
( ( N
after IN N
crossclamp NN N
removal NN N
, , N
during IN N
weaning VBG N
from IN N
cardiopulmonary JJ N
bypass NN N
, , N
and CC N
at IN N
declaration NN N
of IN N
adequate JJ N
deairing NN N
by IN N
the DT N
anesthetist NN N
) ) N
in IN N
the DT N
control NN N
group NN N
than IN N
in IN N
the DT N
carbon NN N
dioxide NN N
group NN N
( ( N
P NNP N
< NNP N
.04 NNP N
) ) N
. . N

Deairing VBG o
time NN o
was VBD N
also RB N
significantly RB N
longer RBR N
in IN N
the DT N
control NN N
group NN N
( ( N
12 CD N
minutes NNS N
[ VBP N
interquartile JJ N
range NN N
, , N
9-18 CD N
] NNP N
versus NN N
9 CD N
minutes NNS N
[ VBP N
interquartile JJ N
range NN N
, , N
7-14 JJ N
minutes NNS N
] VBP N
; : N
P NNP N
= NNP N
.002 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Carbon NNP i
dioxide IN i
pericardial JJ N
insufflation NN N
in IN N
open-chamber JJ N
cardiac JJ N
surgery NN N
does VBZ N
not RB N
affect VB N
postoperative JJ N
neurocognitive JJ o
decline NN o
. . o

The DT p
most RBS p
important JJ p
factor NN p
is VBZ p
atheromatous JJ p
vascular JJ p
disease NN p
. . p

-DOCSTART- -22511135- O O

Right RB N
ventricular JJ N
function NN N
during IN N
high-frequency JJ i
oscillatory JJ i
ventilation NN i
in IN N
adults NNS p
with IN p
acute JJ p
respiratory NN p
distress NN p
syndrome NN p
. . p

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
mean JJ N
airway JJ N
pressure NN N
under IN N
high-frequency NN i
oscillatory NN i
ventilation NN i
on IN N
right JJ N
ventricular JJ N
function NN N
. . N

DESIGN NNP N
Prospective NNP N
randomized VBD N
study NN N
. . N

SETTING NNP N
Intensive NNP N
care NN N
unit NN N
of IN N
a DT N
tertiary JJ N
care NN N
hospital NN N
. . N

PATIENTS NNP N
Sixteen NNP p
consecutive JJ p
patients NNS p
within IN p
the DT p
first JJ p
48 CD p
hrs NN p
of IN p
mainly RB p
pulmonary JJ p
acute NN p
respiratory NN p
distress JJ p
syndrome NN p
. . p

INTERVENTIONS NNP N
After IN N
a DT N
6-hr-period JJ N
of IN N
protective JJ i
conventional JJ i
mechanical JJ i
ventilation NN i
, , N
patients NNS N
were VBD N
submitted VBN N
to TO N
three CD i
1-hr JJ i
periods NNS i
of IN i
high-frequency NN i
oscillatory NN i
ventilation NN i
( ( N
+5 JJ N
, , N
+10 NNP N
, , N
+15 NNP N
) ) N
in IN N
a DT N
randomized JJ N
order NN N
, , N
with IN N
a DT N
mean JJ N
airway NN N
pressure NN N
level NN N
determined VBN N
by IN N
adding VBG N
5 CD i
, , i
10 CD i
, , i
or CC i
15 CD i
cm NNS i
H2O NNP i
to TO N
the DT N
mean JJ N
airway NN N
pressure NN N
recorded VBN N
during IN N
conventional JJ N
mechanical JJ N
ventilation NN N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Mean NNP o
airway JJ o
pressure NN o
was VBD N
18?3 CD N
cm JJ N
H2O NNP N
during IN i
conventional JJ i
mechanical JJ i
ventilation NN i
and CC N
was VBD N
increased VBN N
until IN N
33?3 CD N
cm NNS N
H2O NNP N
at IN N
high-frequency NN i
oscillatory NN i
ventilation+15 NN o
. . o

Right NNP o
ventricular JJ o
function NN o
was VBD o
assessed VBN N
using VBG o
transesophageal JJ o
echocardiography NN o
. . o

During IN i
conventional JJ i
mechanical JJ i
ventilation NN i
, , i
nine CD N
patients NNS N
presented VBD N
a DT N
right JJ o
ventricular NN o
dysfunction NN o
( ( o
right JJ N
ventricular NN N
end-diastolic JJ N
area/left NN N
ventricular JJ N
end-diastolic JJ N
area NN N
ratio NN N
> NNP N
0.6 CD N
) ) N
of IN N
whom WP N
four CD N
patients NNS N
had VBD N
a DT N
right JJ o
ventricular NN o
failure NN o
( ( o
right JJ N
ventricular NN N
end-diastolic JJ N
area/left NN N
ventricular JJ N
end-diastolic JJ N
area NN N
ratio NN i
> NNP i
0.9 CD i
) ) i
. . i

High-frequency NNP i
oscillatory JJ i
ventilation+10 NN i
and CC i
+15 VB N
further RB o
worsened VBN o
right JJ o
ventricular NN o
function NN o
, , o
resulting VBG N
in IN N
about IN N
a DT N
40 CD N
% NN N
increase NN N
in IN N
right JJ o
ventricular JJ o
end-diastolic JJ o
area/left NN o
ventricular JJ o
end-diastolic JJ o
area NN o
ratio NN o
and CC o
a DT N
30 CD N
% NN N
increase NN N
in IN N
end-diastolic JJ o
eccentricity NN o
index NN o
when WRB o
compared VBN N
with IN i
conventional JJ i
mechanical JJ i
ventilation NN i
or CC i
high-frequency NN i
oscillatory NN i
ventilation+5 NN i
periods NNS i
. . N

At IN N
high-frequency JJ N
oscillatory NN N
ventilation+15 NN N
, , N
15 CD N
patients NNS N
had VBD o
right JJ o
ventricular JJ o
dysfunction NN o
and CC o
nine CD N
had VBD o
right JJ o
ventricular JJ o
failure NN o
. . o

High-frequency NNP N
oscillatory JJ N
ventilation NN N
did VBD N
not RB o
improve VB o
oxygenation NN o
whatever IN o
the DT N
mean JJ N
airway NN N
pressure NN N
level NN N
. . N

A DT N
significant JJ N
redistribution NN N
of IN N
tidal JJ N
variation NN N
to TO N
the DT N
posterior JJ N
parts NNS N
of IN N
the DT N
lung NN N
was VBD N
observed VBN N
on IN N
electrical JJ N
impedance NN N
tomography NN N
measurements NNS N
when WRB o
increasing VBG o
mean VB o
airway JJ o
pressure NN o
. . o

However RB N
, , N
this DT N
redistribution NN N
was VBD N
not RB N
observed VBN N
in IN N
patients NNS N
who WP N
presented VBD N
a DT N
worsening NN o
of IN o
right JJ o
ventricular JJ o
function NN o
( ( o
right JJ N
ventricular NN N
end-diastolic JJ N
area/left NN N
ventricular JJ N
end-diastolic JJ N
area NN N
increase NN N
> VBD N
40 CD N
% NN N
) ) N
at IN N
high-frequency NN i
oscillatory NN i
ventilation+15 NN i
. . i

CONCLUSIONS NNP N
In IN N
patients NNS p
with IN p
mainly RB p
pulmonary JJ p
acute NN p
respiratory NN p
distress NN p
syndrome NN p
, , p
using VBG N
high JJ N
mean JJ N
airway NN N
pressure NN N
under IN i
high-frequency NN i
oscillatory JJ i
ventilation NN i
can MD o
worsen VB o
right JJ o
ventricular NN o
function NN o
when WRB o
compared VBN N
with IN i
protective JJ i
conventional JJ i
mechanical JJ i
ventilation NN i
, , i
notably RB N
in IN N
patients NNS N
in IN N
whom WP N
high-frequency NN N
oscillatory NN N
ventilation NN N
produced VBD N
less JJR N
alveolar JJ N
recruitment NN N
of IN N
the DT N
posterior JJ N
parts NNS N
of IN N
the DT N
lungs NNS N
. . N

This DT N
study NN N
highlights VBZ N
the DT N
interest NN N
of IN N
monitoring VBG N
right JJ N
ventricular JJ N
function NN N
during IN i
high-frequency JJ i
oscillatory JJ i
ventilation NN i
. . i

-DOCSTART- -25798575- O O

Safety NN N
and CC N
benefit NN N
of IN N
discontinuing VBG N
statin JJ i
therapy NN i
in IN N
the DT N
setting NN N
of IN N
advanced JJ p
, , p
life-limiting JJ p
illness NN p
: : p
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

IMPORTANCE NNP N
For IN N
patients NNS p
with IN p
limited JJ p
prognosis NN p
, , N
some DT N
medication NN N
risks NNS N
may MD N
outweigh VB N
the DT N
benefits NNS N
, , N
particularly RB N
when WRB N
benefits NNS N
take VBP N
years NNS N
to TO N
accrue VB N
; : N
statins NNS N
are VBP N
one CD N
example NN N
. . N

Data NNS N
are VBP N
lacking VBG N
regarding VBG N
the DT N
risks NNS N
and CC N
benefits NNS N
of IN N
discontinuing VBG N
statin JJ N
therapy NN N
for IN N
patients NNS p
with IN p
limited JJ p
life NN p
expectancy NN p
. . p

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
safety NN N
, , N
clinical JJ N
, , N
and CC N
cost NN N
impact NN N
of IN N
discontinuing VBG N
statin JJ i
medications NNS N
for IN N
patients NNS p
in IN p
the DT p
palliative JJ p
care NN p
setting VBG p
. . p

DESIGN NNP N
, , N
SETTING NNP N
, , N
AND NNP N
PARTICIPANTS NNP N
This DT N
was VBD N
a DT N
multicenter NN N
, , N
parallel-group NN N
, , N
unblinded JJ N
, , N
pragmatic JJ N
clinical JJ N
trial NN N
. . N

Eligibility NNP p
included VBD p
adults NNS p
with IN p
an DT p
estimated JJ p
life NN p
expectancy NN p
of IN p
between IN p
1 CD p
month NN p
and CC p
1 CD p
year NN p
, , p
statin NN p
therapy NN p
for IN p
3 CD p
months NNS p
or CC p
more JJR p
for IN p
primary JJ p
or CC p
secondary JJ p
prevention NN p
of IN p
cardiovascular JJ p
disease NN p
, , p
recent JJ p
deterioration NN p
in IN p
functional JJ p
status NN p
, , p
and CC p
no DT p
recent JJ p
active JJ p
cardiovascular JJ p
disease NN p
. . p

Participants NNS N
were VBD N
randomized VBN N
to TO N
either DT N
discontinue NN i
or CC i
continue VB i
statin JJ i
therapy NN i
and CC N
were VBD N
monitored VBN N
monthly RB N
for IN N
up IN N
to TO N
1 CD N
year NN N
. . N

The DT N
study NN N
was VBD N
conducted VBN p
from IN p
June NNP p
3 CD p
, , p
2011 CD p
, , p
to TO p
May NNP p
2 CD p
, , p
2013 CD p
. . p

All DT N
analyses NNS N
were VBD N
performed VBN N
using VBG N
an DT N
intent-to-treat JJ N
approach NN N
. . N

INTERVENTIONS NNP N
Statin NNP i
therapy NN i
was VBD N
withdrawn VBN N
from IN N
eligible JJ N
patients NNS N
who WP N
were VBD N
randomized VBN N
to TO N
the DT N
discontinuation NN N
group NN N
. . N

Patients NNS N
in IN N
the DT N
continuation NN N
group NN N
continued VBD N
to TO N
receive VB i
statins NNS i
. . i

MAIN NNP N
OUTCOMES NNP N
AND NNP N
MEASURES NNP N
Outcomes NNP N
included VBD N
death NN o
within IN o
60 CD o
days NNS o
( ( o
primary JJ o
outcome NN o
) ) o
, , o
survival JJ o
, , o
cardiovascular JJ o
events NNS o
, , o
performance NN o
status NN o
, , o
quality NN o
of IN o
life NN o
( ( o
QOL NNP o
) ) o
, , o
symptoms NNS o
, , o
number NN o
of IN o
nonstatin JJ o
medications NNS o
, , o
and CC o
cost NN o
savings NNS o
. . o

RESULTS VB N
A DT p
total NN p
of IN p
381 CD p
patients NNS p
were VBD p
enrolled VBN p
; : p
189 CD N
of IN N
these DT N
were VBD N
randomized VBN N
to TO N
discontinue VB N
statins NNS i
, , N
and CC N
192 CD N
were VBD N
randomized VBN N
to TO N
continue VB N
therapy NN N
. . N

Mean NNP o
( ( o
SD NNP o
) ) o
age NN o
was VBD p
74.1 CD p
( ( p
11.6 CD p
) ) p
years NNS p
, , p
22.0 CD p
% NN p
of IN p
the DT p
participants NNS p
were VBD p
cognitively RB p
impaired VBN p
, , p
and CC p
48.8 CD p
% NN p
had VBD p
cancer NN p
. . p

The DT N
proportion NN N
of IN N
participants NNS N
in IN N
the DT N
discontinuation NN N
vs NN N
continuation NN N
groups NNS N
who WP N
died VBD N
within IN N
60 CD N
days NNS N
was VBD N
not RB N
significantly RB N
different JJ N
( ( N
23.8 CD N
% NN N
vs JJ N
20.3 CD N
% NN N
; : N
90 CD N
% NN N
CI NNP N
, , N
-3.5 NNP N
% NN N
to TO N
10.5 CD N
% NN N
; : N
P=.36 NNP N
) ) N
and CC N
did VBD N
not RB N
meet VB N
the DT N
noninferiority JJ N
end NN N
point NN N
. . N

Total JJ o
QOL NNP o
was VBD N
better RBR N
for IN N
the DT N
group NN N
discontinuing VBG N
statin JJ N
therapy NN N
( ( N
mean JJ N
McGill NNP N
QOL NNP N
score NN N
, , N
7.11 CD N
vs NN N
6.85 CD N
; : N
P=.04 NNP N
) ) N
. . N

Few JJ N
participants NNS N
experienced VBD N
cardiovascular JJ o
events NNS o
( ( N
13 CD N
in IN N
the DT N
discontinuation NN N
group NN N
vs VBD N
11 CD N
in IN N
the DT N
continuation NN N
group NN N
) ) N
. . N

Mean JJ o
cost NN o
savings NNS o
were VBD N
$ $ N
3.37 CD N
per IN N
day NN N
and CC N
$ $ N
716 CD N
per IN N
patient NN N
. . N

CONCLUSIONS NNP N
AND CC N
RELEVANCE NNP N
This DT N
pragmatic JJ N
trial NN N
suggests VBZ N
that IN N
stopping VBG N
statin JJ N
medication NN N
therapy NN N
is VBZ N
safe JJ N
and CC N
may MD N
be VB N
associated VBN N
with IN N
benefits NNS N
including VBG N
improved JJ o
QOL NNP o
, , o
use NN o
of IN o
fewer JJR o
nonstatin NN o
medications NNS o
, , o
and CC o
a DT o
corresponding JJ o
reduction NN o
in IN o
medication NN o
costs NNS o
. . o

Thoughtful JJ N
patient-provider JJ N
discussions NNS N
regarding VBG N
the DT N
uncertain JJ N
benefit NN N
and CC N
potential JJ N
decrement NN N
in IN N
QOL NNP N
associated VBD N
with IN N
statin JJ N
continuation NN N
in IN N
this DT N
setting NN N
are VBP N
warranted VBN N
. . N

TRIAL NNP N
REGISTRATION NNP N
clinicaltrials.gov NN N
Identifier NNP N
: : N
NCT01415934 NN N
. . N

-DOCSTART- -6764321- O O

Two CD N
blind JJ N
randomized VBD N
cross-over JJ N
trials NNS N
in IN N
the DT N
treatment NN p
of IN p
primary JJ o
open JJ o
angle NN o
glaucoma NN o
. . o

We PRP N
present VBD N
the DT N
results NNS N
of IN N
two CD N
blind NNS N
randomized JJ N
trials NNS N
comparing VBG N
both DT N
guanethidine JJ i
3 CD i
per IN i
cent NN i
and CC i
adrenaline VB i
0.5 CD i
per IN i
cent NN i
( ( i
Ganda NNP i
3.0/0.5 CD i
) ) i
and CC N
guanethidine $ i
1 CD i
per IN i
cent NN i
and CC N
adrenaline VB i
0.2 CD i
per IN i
cent NN i
( ( i
Ganda NNP i
1.0/0.2 CD i
) ) i
in IN N
single JJ N
drop NN N
form NN N
with IN N
Timolol NNP i
( ( i
Timoptol NNP i
) ) i
0.25 CD i
per IN i
cent NN i
. . i

Results NNS N
of IN N
48-hour JJ N
phasing NN N
at IN N
the DT N
end NN N
of IN N
one CD N
month NN N
's POS N
treatment NN N
demonstrated VBD N
a DT N
significantly RB N
greater JJR N
fall NN o
in IN o
intraocular JJ o
pressure NN o
with IN N
Ganda NNP i
3.0/0.5 CD i
( ( N
9.8 CD N
mm RB N
Hg NNP N
) ) N
than IN N
with IN N
Timolol NNP i
0.25 CD i
per IN i
cent NN i
( ( N
7.67 CD N
mm RB N
Hg NNP N
) ) N
P NNP N
less JJR N
than IN N
0.001 CD N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
fall NN o
in IN o
intraocular JJ o
pressure NN o
between IN N
Ganda NNP i
1.0/0.2 CD i
( ( N
8.87 CD N
mm RB N
Hg NNP N
) ) N
and CC N
Timolol $ i
0.25 CD i
per IN i
cent NN i
( ( N
8.24 CD N
mm RB N
Hg NNP N
) ) N
. . N

-DOCSTART- -23107353- O O

Acceleration NN N
of IN N
insulin NN N
pharmacodynamic JJ N
profile NN N
by IN N
a DT N
novel JJ N
insulin NN i
infusion NN i
site NN i
warming VBG i
device NN i
. . i

BACKGROUND NNP N
AND NNP N
OBJECTIVE NNP N
Subcutaneously NNP N
injected VBD N
rapid-acting JJ N
insulin NN N
analogs NNS N
do VBP N
not RB N
replicate VB N
physiologic JJ N
insulin NN N
action NN N
due JJ N
to TO N
delays NNS N
in IN N
their PRP$ N
onset NN N
and CC N
peak JJ N
action NN N
resulting VBG N
in IN N
postprandial JJ N
glucose JJ N
excursions NNS N
. . N

The DT i
InsuPatch NNP i
( ( i
IP NNP i
) ) i
is VBZ N
a DT N
novel JJ N
insulin NN N
infusion NN N
site NN N
warming VBG N
device NN N
developed VBD N
to TO N
accelerate VB N
insulin NN N
action NN N
by IN N
increasing VBG N
blood NN N
flow NN N
to TO N
the DT N
area NN N
of IN N
insulin NN N
absorption NN N
. . N

Thirteen JJ p
adolescents NNS p
with IN p
type JJ p
1 CD p
diabetes NNS p
( ( p
T1D NNP p
, , p
mean JJ p
age NN p
14 CD p
? . p
4 CD p
yr NN p
) ) p
were VBD p
enrolled VBN p
in IN N
this DT N
study NN N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
the DT N
IP NNP i
on IN N
the DT N
pharmacodynamics NNS N
and CC N
pharmacokinetics NNS N
of IN N
a DT N
0.2 CD N
unit/kg JJ N
bolus NN N
dose NN i
of IN i
aspart JJ i
insulin NN i
using VBG i
the DT i
euglycemic JJ i
clamp NN i
technique NN i
. . i

RESEARCH NNP i
DESIGN NNP N
AND NNP N
METHODS NNP N
Each DT N
subject JJ N
underwent JJ N
two CD i
euglycemic JJ i
clamp NN i
procedures NNS i
on IN i
separate JJ i
occasions NNS N
: : N
one CD N
with IN N
IP NNP i
and CC N
one CD i
without IN i
IP NNP i
activation NN i
in IN N
random JJ N
order NN N
. . N

RESULTS VB N
When WRB N
the DT N
insulin NN N
bolus NN N
was VBD N
given VBN N
with IN N
IP NNP N
activation NN N
as IN N
compared VBN N
to TO N
without IN N
IP NNP N
activation NN o
, , o
time NN o
to TO o
reach VB o
maximum JJ o
insulin JJ o
action NN o
( ( o
T NNP o
( ( o
GIRmax NNP o
) ) o
) ) o
and CC o
to TO o
reach VB o
50 CD N
% NN N
maximum JJ o
action NN o
( ( o
T NNP N
( ( N
50 CD N
% NN N
GIRmax NNP N
) ) N
) ) N
were VBD N
35 CD N
and CC N
18 CD N
min NNS N
earlier RB N
( ( N
125 CD N
? . N
8 CD N
min NN N
vs. FW N
90 CD N
? . N
6 CD N
min NN N
, , N
p NN N
= VBD N
0.002 CD N
and CC N
58 CD N
? . N
5 CD N
min NN N
. . N

vs. FW N
40 CD N
? . N
3 CD N
min NN N
, , N
p NN N
= VBD N
0.01 CD N
, , N
respectively RB N
) ) N
, , N
and CC o
the DT o
area NN o
under IN o
curve NN o
, , o
AUC NNP o
( ( o
GIR NNP N
0-90 NNP N
min NN N
) ) N
, , N
reflecting VBG N
early JJ o
glucodynamic JJ o
action NN o
, , o
was VBD o
significantly RB N
greater JJR N
( ( N
p JJ N
= NNP N
0.001 CD N
) ) N
. . N

IP NNP N
activation NN N
also RB N
accelerated VBD N
the DT N
rise NN o
in IN o
plasma JJ o
insulin NN o
levels NNS o
after IN N
the DT N
bolus NN N
( ( N
p JJ N
= NNP N
0.03 CD N
) ) N
and CC N
resulted VBN N
in IN N
a DT N
higher JJR N
peak NN o
( ( N
p JJ N
= NNP N
0.04 CD N
) ) N
and CC o
greater JJR o
overall JJ o
increase NN o
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
in IN o
plasma JJ o
insulin NN o
levels NNS o
. . o

CONCLUSIONS NNP o
Our PRP$ N
results NNS i
show VBP i
that IN i
insulin NN i
infusion NN i
site NN N
warming VBG N
with IN N
IP NNP N
activation NN N
accelerates VBZ o
the DT o
time NN o
action NN o
profile NN o
of IN o
aspart NN o
insulin NN o
which WDT o
may MD o
be VB N
of IN N
benefit NN N
to TO N
current JJ N
open-loop JJ N
and CC N
future JJ N
closed-loop JJ N
insulin NN N
delivery NN N
in IN N
patients NNS p
with IN p
T1D NNP p
. . p

-DOCSTART- -22320409- O O

Comparison NNP N
of IN N
sedative JJ i
drugs NNS i
under IN N
peribulbar NN N
or CC N
topical JJ N
anesthesia NN N
during IN N
phacoemulsification NN p
. . p

BACKGROUND NNP N
AND NNP N
OBJECTIVE NNP N
To TO N
compare VB N
dexmedetomidine NN i
and CC i
midazolam+fentanyl JJ i
sedation NN i
primarily RB N
based VBN N
on IN N
patient JJ N
satisfaction NN N
during IN N
phacoemulsification NN N
under IN N
topical JJ N
and CC N
peribulbar JJ N
anesthesia NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Prospective NNP N
, , N
randomized VBN N
, , N
and CC N
double-blind NN N
study NN N
of IN N
80 CD p
American JJ p
Society NNP p
of IN p
Anesthesiology NNP p
grade VBD p
I-II NNP p
patients NNS p
who WP p
underwent JJ p
phacoemulsification NN p
with IN p
local JJ p
anesthesia NN p
under IN p
sedation NN p
. . p

Patients NNS N
were VBD N
divided VBN N
into IN N
four CD p
groups NNS p
( ( p
20 CD p
patients NNS p
for IN p
each DT p
) ) p
: : p
dexmedetomidine NN i
and CC i
topical JJ i
anesthesia NN i
, , i
dexmedetomidine NN i
and CC i
peribulbar NN i
anesthesia NN i
, , i
midazolam+fentanyl NN i
and CC i
topical JJ i
anesthesia NN i
, , N
and CC N
midazolam+fentanyl NN i
and CC i
peribulbar NN i
anesthesia NN i
. . i

Patient NNP N
and CC N
surgeon JJ N
satisfaction NN N
were VBD N
determined VBN N
on IN N
a DT N
5-point JJ N
scale NN N
. . N

The DT N
pain NN N
was VBD N
determined VBN N
by IN N
verbal JJ N
pain NN N
scale NN N
intraoperatively RB N
and CC N
postoperatively RB N
. . N

Drugs NNS N
were VBD N
given VBN N
to TO N
a DT N
Ramsay NNP N
sedation NN N
scale NN N
of IN N
3 CD N
. . N

Topical JJ N
and CC N
peribulbar JJ N
anesthesia NN N
were VBD N
performed VBN N
by IN N
an DT N
ophthalmologist NN N
. . N

Hemodynamic NNP N
, , N
respiratory NN N
, , N
and CC N
intraocular JJ N
pressure NN N
monitoring NN N
was VBD N
done VBN N
. . N

Operative NNP N
and CC N
recovery NN N
times NNS N
were VBD N
recorded VBN N
. . N

RESULTS NNP N
In IN N
the DT N
midazolam+fentanyl NN i
groups NNS N
, , N
better JJR N
patient NN o
and CC o
surgeon JJ o
satisfaction NN o
scores NNS o
were VBD N
obtained VBN N
( ( N
P NNP N
< NNP N
.005 NNP N
) ) N
, , N
verbal JJ o
pain NN o
scale NN o
scores NNS o
were VBD N
significantly RB N
lower JJR N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
and CC N
patients NNS N
needed VBN N
less RBR N
postoperative JJ o
analgesia NN o
. . o

Ramsay NNP o
sedation NN o
scale NN o
scores NNS o
were VBD N
between IN N
3 CD N
and CC N
4 CD N
in IN N
all DT N
patients NNS N
and CC N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
. . N

Intraocular JJ o
pressure NN o
alterations NNS o
were VBD N
similar JJ N
between IN N
groups NNS N
. . N

Recovery JJ o
time NN o
was VBD N
longer RBR N
in IN N
the DT N
dexmedetomidine NN N
groups NNS N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

CONCLUSION VB N
The DT N
study NN N
demonstrated VBD N
that IN N
the DT N
midazolam+fentanyl NN i
combination NN i
provided VBD N
high-level JJ N
patient JJ o
satisfaction NN o
scores NNS o
, , N
low-level JJ N
pain NN o
scores NNS o
, , N
and CC N
shorter JJR N
recovery NN o
time NN o
. . o

Also RB N
, , N
both DT N
of IN N
the DT N
peribulbar NN N
and CC N
topical JJ N
anesthesia NN N
procedures NNS N
showed VBD N
similar JJ N
efficiency NN N
. . N

-DOCSTART- -3305203- O O

Therapeutic JJ N
strategies NNS N
in IN N
acute JJ p
myelocytic JJ p
leukemia NN p
: : p
a DT N
status NN N
report NN N
of IN N
the DT N
experience NN N
of IN N
CALGB NNP N
. . N

Cancer NNP p
and CC p
Leukemia NNP p
Group NNP N
B NNP N
. . N

-DOCSTART- -17481800- O O

Dissociation NN N
between IN N
cortical JJ N
activation NN N
and CC N
cognitive JJ N
performance NN N
under IN N
pharmacological JJ N
blood NN N
pressure NN N
elevation NN N
in IN N
chronic JJ N
hypotension NN N
. . N

The DT N
present JJ N
study NN N
explored VBD N
the DT N
impact NN N
of IN N
pharmacological JJ i
blood NN i
pressure NN i
elevation NN i
on IN N
cortical JJ N
activation NN N
and CC N
reaction NN N
time NN N
in IN N
chronic JJ p
hypotension NN p
. . p

Effects NNS N
of IN N
the DT N
sympathomimetic JJ i
etilefrine NN i
were VBD N
investigated VBN N
in IN N
50 CD p
hypotensive JJ p
persons NNS p
based VBN N
on IN N
a DT N
randomized VBN N
, , N
placebo-controlled JJ i
double JJ N
blind NN N
design NN N
. . N

As IN N
an DT N
indicator NN N
of IN N
cortical JJ N
excitability NN N
, , N
the DT N
contingent NN N
negative JJ N
variation NN N
( ( N
CNV NNP N
) ) N
, , N
induced VBN N
by IN N
a DT N
constant JJ N
foreperiod NN N
reaction NN N
time NN N
task NN N
, , N
was VBD N
assessed VBN N
at IN N
frontal JJ N
( ( N
F3 NNP N
, , N
Fz NNP N
, , N
F4 NNP N
) ) N
and CC N
central JJ N
( ( N
C3 NNP N
, , N
Cz NNP N
, , N
C4 NNP N
) ) N
scalp NN N
sites NNS N
. . N

Etilefrine NNP i
provoked VBD N
a DT N
decrease NN N
in IN N
the DT N
frontal NN o
and CC o
central JJ o
CNV NNP o
. . o

In IN N
contrast NN N
, , N
shorter JJR N
reaction NN o
times NNS o
were VBD N
observed JJ N
following JJ N
drug NN N
administration NN N
. . N

The DT N
degree NN o
of IN N
pharmacologically RB N
induced VBN o
blood NN o
pressure NN o
elevation NN o
was VBD N
correlated VBN N
to TO N
CNV NNP N
attrition NN N
as RB N
well RB N
as IN N
to TO N
performance NN N
enhancement NN N
. . N

Inhibitory JJ N
effects NNS N
of IN N
baroreceptor NN N
activation NN N
on IN N
cortical JJ N
excitability NN N
and CC N
enhanced VBD N
cerebral JJ N
blood NN N
flow NN N
are VBP N
considered VBN N
to TO N
be VB N
involved VBN N
in IN N
mediating VBG N
the DT N
effects NNS N
of IN N
blood NN o
pressure NN o
elevation NN o
on IN N
cerebral JJ N
functioning NN N
. . N

Implications NNS N
for IN N
the DT N
treatment NN N
of IN N
chronic JJ o
hypotension NN o
are VBP N
discussed VBN N
. . N

-DOCSTART- -9757955- O O

Compliance NN N
with IN N
depot NN i
medroxyprogesterone NN i
acetate NN i
: : i
a DT N
randomized NN N
, , N
controlled VBD N
trial NN N
of IN N
intensive JJ N
reminders NNS N
. . N

We PRP N
enrolled VBD N
women NNS p
in IN N
a DT N
prospective JJ N
, , N
randomized VBN N
study NN N
to TO N
determine VB N
whether IN N
an DT N
intensive JJ N
reminder NN N
system NN N
would MD N
improve VB N
compliance NN N
in IN N
women NNS p
receiving VBG p
depot NN i
medroxyprogesterone NN i
injections NNS p
. . p

Women NNP N
selecting VBG N
this DT N
treatment NN N
were VBD N
assigned VBN N
to TO N
a DT N
group NN N
that WDT N
received VBD N
both DT N
mail NN i
and CC i
telephone NN i
reminders NNS i
or CC N
to TO N
a DT N
second JJ N
group NN N
that WDT N
received VBD N
only RB i
a DT i
scheduled JJ i
appointment NN i
at IN i
the DT i
time NN i
of IN i
the DT i
previous JJ i
injection NN i
. . i

The DT N
rate NN o
of IN o
continuation NN o
and CC N
the DT N
rate NN o
of IN o
on-time JJ o
injections NNS o
did VBD N
not RB N
differ VB N
between IN N
groups NNS N
. . N

Women NNS N
who WP N
had VBD N
prolonged VBN o
bleeding NN o
were VBD N
more RBR N
likely JJ N
to TO N
discontinue VB N
depot VB N
medroxyprogesterone JJ N
injections NNS N
. . N

-DOCSTART- -22587862- O O

Effect NN N
of IN N
a DT N
mobile JJ i
safety NN i
alarm NN i
on IN N
going VBG o
outside JJ o
, , o
feeling JJ o
safe JJ o
, , o
fear NN o
of IN o
falling VBG o
, , o
and CC o
quality NN o
of IN o
life NN o
in IN N
community-living JJ p
older NN p
persons NNS p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

-DOCSTART- -10770979- O O

Lack NN N
of IN N
effect NN N
of IN N
a DT N
low-fat JJ i
, , i
high-fiber JJ i
diet NN i
on IN N
the DT N
recurrence NN o
of IN o
colorectal JJ o
adenomas NN o
. . o

Polyp NNP N
Prevention NNP N
Trial NNP N
Study NNP N
Group NNP N
. . N

BACKGROUND NNP N
We PRP N
tested VBD N
the DT N
hypothesis NN N
that WDT N
dietary JJ N
intervention NN N
can MD N
inhibit VB N
the DT N
development NN o
of IN o
recurrent NN o
colorectal NN o
adenomas NN o
, , N
which WDT N
are VBP N
precursors NNS N
of IN N
most JJS N
large-bowel JJ N
cancers NNS N
. . N

METHODS NNP N
We PRP N
randomly RB N
assigned VBD N
2079 CD p
men NNS p
and CC p
women NNS p
who WP p
were VBD p
35 CD p
years NNS p
of IN p
age NN p
or CC p
older JJR p
and CC p
who WP p
had VBD p
had VBN p
one CD p
or CC p
more JJR p
histologically RB p
confirmed VBN p
colorectal JJ p
adenomas NN p
removed VBD p
within IN p
six CD p
months NNS p
before IN p
randomization NN p
to TO N
one CD N
of IN N
two CD N
groups NNS N
: : N
an DT i
intervention NN i
group NN i
given VBN i
intensive JJ i
counseling NN i
and CC i
assigned VBD i
to TO i
follow VB i
a DT i
diet NN i
that WDT i
was VBD i
low JJ i
in IN i
fat NN i
( ( i
20 CD i
percent NN i
of IN i
total JJ i
calories NNS i
) ) i
and CC i
high JJ i
in IN i
fiber NN i
( ( i
18 CD i
g NN i
of IN i
dietary JJ i
fiber NN i
per IN i
1000 CD i
kcal NN i
) ) i
and CC i
fruits NNS i
and CC i
vegetables NNS i
( ( i
3.5 CD i
servings NNS i
per IN i
1000 CD i
kcal NN i
) ) i
, , i
and CC i
a DT i
control NN i
group NN i
given VBN i
a DT i
standard JJ i
brochure NN i
on IN i
healthy JJ i
eating NN i
and CC i
assigned VBD i
to TO i
follow VB i
their PRP$ i
usual JJ i
diet NN i
. . i

Subjects NNS N
entered VBD N
the DT N
study NN N
after IN N
undergoing VBG N
complete JJ N
colonoscopy NN N
and CC N
removal NN N
of IN N
adenomatous JJ N
polyps NNS N
; : N
they PRP N
remained VBD N
in IN N
the DT N
study NN N
for IN N
approximately RB N
four CD N
years NNS N
, , N
undergoing VBG N
colonoscopy NN N
one CD N
and CC N
four CD N
years NNS N
after IN N
randomization NN N
. . N

RESULTS VB N
A DT p
total NN p
of IN p
1905 CD p
of IN p
the DT p
randomized JJ p
subjects NNS p
( ( p
91.6 CD p
percent NN p
) ) p
completed VBD p
the DT p
study NN p
. . p

Of IN N
the DT N
958 CD N
subjects NNS N
in IN N
the DT N
intervention NN N
group NN N
and CC N
the DT N
947 CD N
in IN N
the DT N
control NN N
group NN N
who WP N
completed VBD N
the DT N
study NN N
, , N
39.7 CD N
percent NN N
and CC N
39.5 CD N
percent NN N
, , N
respectively RB N
, , N
had VBD N
at IN N
least JJS N
one CD o
recurrent NN o
adenoma NN o
; : o
the DT N
unadjusted JJ o
risk NN o
ratio NN o
was VBD N
1.00 CD N
( ( N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
0.90 CD N
to TO N
1.12 CD N
) ) N
. . N

Among IN N
subjects NNS N
with IN N
recurrent NN N
adenomas NN N
, , N
the DT N
mean NN o
( ( o
+/-SE JJ o
) ) o
number NN o
of IN o
such JJ o
lesions NNS o
was VBD N
1.85+/-0.08 JJ N
in IN N
the DT N
intervention NN N
group NN N
and CC N
1.84+/-0.07 NNS N
in IN N
the DT N
control NN N
group NN N
. . N

The DT N
rate NN o
of IN o
recurrence NN o
of IN o
large JJ o
adenomas NNS o
( ( N
with IN N
a DT N
maximal JJ N
diameter NN N
of IN N
at IN N
least JJS N
1 CD N
cm NN N
) ) N
and CC N
advanced JJ o
adenomas NN o
( ( N
defined VBN N
as IN N
lesions NNS N
that WDT N
had VBD N
a DT N
maximal JJ N
diameter NN N
of IN N
at IN N
least JJS N
1 CD N
cm NN N
or CC N
at IN N
least JJS N
25 CD N
percent NN N
villous JJ N
elements NNS N
or CC N
evidence NN N
of IN N
high-grade JJ N
dysplasia NN N
, , N
including VBG N
carcinoma NN N
) ) N
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
two CD N
groups NNS N
. . N

CONCLUSIONS NNP N
Adopting VBG N
a DT N
diet NN N
that WDT N
is VBZ N
low JJ N
in IN N
fat NN N
and CC N
high JJ N
in IN N
fiber NN N
, , N
fruits NNS N
, , N
and CC N
vegetables NNS N
does VBZ N
not RB N
influence VB N
the DT N
risk NN o
of IN o
recurrence NN o
of IN N
colorectal JJ N
adenomas NN N
. . N

-DOCSTART- -11501687- O O

Olanzapine NNP i
versus NN i
haloperidol NN i
in IN N
children NNS p
with IN p
autistic JJ o
disorder NN o
: : o
an DT N
open JJ N
pilot NN N
study NN N
. . N

OBJECTIVES NNP N
Conventional NNP N
neuroleptics NNS i
ameliorate VBP N
symptoms NNS N
in IN N
children NNS p
with IN p
autistic JJ p
disorder NN p
; : p
however RB N
, , N
they PRP N
are VBP N
known VBN N
to TO N
cause VB N
dyskinesias NN N
. . N

Atypical JJ i
neuroleptics NNS i
, , N
including VBG N
olanzapine NN N
, , N
may MD N
have VB N
less JJR N
risk NN N
for IN N
dyskinesia NN N
, , N
but CC N
their PRP$ N
efficacy NN N
in IN N
autistic JJ N
disorder NN N
is VBZ N
not RB N
established VBN N
. . N

This DT N
study NN N
was VBD N
designed VBN N
to TO N
investigate VB N
the DT N
safety NN N
and CC N
effectiveness NN N
of IN N
open-label JJ N
olanzapine NN i
as IN N
a DT N
treatment NN N
for IN N
children NNS p
with IN p
autistic JJ p
disorder NN p
by IN N
using VBG N
haloperidol NN i
as IN N
a DT N
standard JJ N
comparator NN N
treatment NN N
. . N

METHOD NNP N
In IN N
a DT N
parallel JJ p
groups NNS p
design NN p
, , p
12 CD p
children NNS p
with IN p
DSM-IV NNP p
autistic JJ p
disorder NN p
( ( p
mean JJ p
age NN p
7.8+/-2.1 CD p
years NNS p
) ) p
were VBD p
randomized VBN p
to TO N
6 CD N
weeks NNS N
of IN N
open JJ i
treatment NN i
with IN i
olanzapine NN i
or CC i
haloperidol NN i
. . i

Mean NNP N
final JJ N
dosages NNS N
were VBD N
7.9+/-2.5 JJ N
mg/day NN N
for IN N
olanzapine NN i
and CC N
1.4+/-0.7 JJ N
mg/day NN N
for IN N
haloperidol NN i
. . i

Outcome NNP N
measures NNS N
included VBD N
the DT N
Clinical NNP o
Global NNP o
Impressions NNP o
( ( o
CGI NNP o
) ) o
and CC o
the DT o
Children NNP o
's POS o
Psychiatric NNP o
Rating NNP o
Scale NNP o
( ( o
CPRS NNP o
) ) o
. . o

RESULTS NNP N
Both NNP N
groups NNS N
had VBD N
symptom VBN o
reduction NN o
. . o

Five CD N
of IN N
six CD N
in IN N
the DT N
olanzapine NN i
group NN N
and CC N
three CD N
of IN N
six CD N
in IN N
the DT N
haloperidol NN i
group NN N
were VBD N
rated VBN N
as IN N
responders NNS N
according VBG N
to TO N
the DT N
CGI NNP o
Improvement NNP N
item NN N
. . N

Subjects NNS N
showed VBD N
improvement NN N
on IN N
the DT N
CPRS NNP o
Autism NNP o
Factor NNP o
( ( N
F1,9 NNP N
= NNP N
24.4 CD N
, , N
p NN N
= NNP N
.0008 NNP N
) ) N
. . N

Side JJ N
effects NNS N
included VBD N
drowsiness NN o
and CC o
weight JJ o
gain NN o
. . o

CONCLUSIONS VB N
The DT N
findings NNS N
suggest VBP N
that IN N
olanzapine NN i
is VBZ N
a DT N
promising JJ N
treatment NN o
for IN N
children NNS p
with IN p
autistic JJ p
disorder NN p
. . p

Further JJ N
placebo-controlled JJ N
and CC N
long-term JJ N
studies NNS N
of IN N
olanzapine NN i
in IN N
autistic JJ N
disorder NN N
are VBP N
required VBN N
. . N

-DOCSTART- -3553277- O O

Comparison NNP N
of IN N
inhaled JJ i
albuterol NN i
powder NN i
and CC i
aerosol NN i
in IN N
asthma NN p
. . p

In IN N
this DT N
multicenter NN N
, , N
randomized VBN N
, , N
double-blind JJ N
study NN N
comparing VBG N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
aerosolized JJ i
albuterol NN i
with IN i
the DT i
dry JJ i
powder NN i
formulation NN i
, , N
231 CD p
patients NNS p
with IN p
chronic JJ p
reversible JJ p
obstructive JJ p
airway NN p
disease NN p
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
either DT N
placebo NN i
albuterol NN i
aerosol NN i
followed VBD N
immediately RB N
by IN N
active JJ i
albuterol NN i
powder NN i
( ( N
200 CD N
micrograms NNS N
) ) N
or CC N
active JJ i
albuterol NN i
aerosol NN i
( ( N
two CD N
puffs NNS N
, , N
180 CD N
micrograms NNS N
) ) N
followed VBD N
immediately RB N
by IN N
placebo NN i
lactose JJ i
powder NN i
four CD N
times NNS N
a DT N
day NN N
for IN N
a DT N
period NN N
of IN N
12 CD N
weeks NNS N
. . N

No DT N
statistically RB N
significant JJ N
differences NNS N
were VBD N
found VBN N
between IN N
the DT N
powder NN i
and CC N
aerosol JJ i
formulations NNS N
with IN N
respect NN N
to TO N
pulmonary JJ o
function NN o
, , o
length NN o
of IN o
time NN o
mean JJ o
FEV1 NNP o
remained VBD N
greater JJR N
than IN N
or CC N
equal JJ N
to TO N
15 CD N
% NN N
above IN N
baseline NN N
, , N
physicians NNS o
' POS o
assessments NNS o
of IN o
patients NNS o
' POS o
clinical JJ o
response NN o
, , N
or CC N
patients NNS o
' POS o
subjective JJ o
symptom NN o
scores NNS o
. . o

There EX N
were VBD N
also RB N
no DT N
significant JJ N
differences NNS N
between IN N
treatment NN N
groups NNS N
in IN N
cardiovascular JJ o
effects NNS o
, , o
laboratory NN o
values NNS o
, , o
or CC o
adverse JJ o
events NNS o
. . o

Among IN N
patients NNS N
who WP N
expressed VBD N
a DT N
preference NN o
for IN o
one CD o
of IN o
the DT o
delivery NN o
systems NNS o
, , N
half NN p
preferred VBD p
using VBG p
the DT p
powder NN p
. . p

Results NNS N
of IN N
this DT N
study NN N
demonstrate NN N
that IN N
200 CD N
micrograms NNS N
of IN N
albuterol NN i
powder NN i
is VBZ N
as IN N
safe JJ N
and CC N
effective JJ N
as IN N
180 CD N
micrograms NNS N
of IN N
albuterol NN i
aerosol NN i
. . i

-DOCSTART- -20204691- O O

Digestive JJ i
enzyme NN i
supplementation NN i
for IN N
autism NN p
spectrum NN p
disorders NNS p
: : p
a DT N
double-blind JJ N
randomized NN N
controlled VBD N
trial NN N
. . N

To TO N
examine VB N
the DT N
effects NNS N
of IN N
a DT N
digestive JJ i
enzyme NN i
supplement NN i
in IN N
improving VBG N
expressive JJ o
language NN o
, , o
behaviour NN o
and CC o
other JJ o
symptoms NNS o
in IN N
children NNS p
with IN p
Autism NNP p
Spectrum NNP p
Disorder NNP p
. . p

Randomized VBN N
, , N
double-blind JJ N
placebo-controlled JJ i
trial NN N
using VBG N
crossover NN N
design NN N
over IN N
6 CD N
months NNS N
for IN N
43 CD p
children NNS p
, , p
aged VBN p
3-8 CD p
years NNS p
. . p

Outcome NNP N
measurement NN N
tools NNS N
included VBD N
monthly JJ N
Global NNP o
Behaviour NNP o
Rating NNP o
Scales NNP o
, , o
Additional NNP o
Rating NNP o
Scales NNP o
of IN o
other JJ o
symptoms NNS o
by IN o
parents NNS o
and CC o
therapists NNS o
, , N
and CC N
monthly JJ o
completion NN o
of IN o
the DT o
Rescorla NNP o
Language NNP o
Development NNP o
Survey NNP o
. . o

Compared VBN N
with IN N
placebo NN i
, , N
treatment NN N
with IN N
enzyme NN i
was VBD N
not RB N
associated VBN N
with IN N
clinically RB N
significant JJ o
improvement NN o
in IN o
behaviour NN o
, , o
food NN o
variety NN o
, , o
gastrointestinal JJ o
symptoms NNS o
, , o
sleep JJ o
quality NN o
, , o
engagement NN o
with IN o
therapist NN o
, , o
or CC o
the DT o
Language NNP o
Development NNP o
Survey NNP o
Vocabulary NNP o
or CC o
Sentence NNP o
Complexity NNP o
Scores NNP o
. . o

A NNP N
small JJ N
statistically RB N
significant JJ o
improvement NN o
on IN N
enzyme NN N
therapy NN N
was VBD N
seen VBN N
for IN N
the DT N
food NN N
variety NN N
scores NNS N
. . N

No DT N
clinically RB N
significant JJ N
effect NN N
improvement NN N
of IN N
autism NN o
symptoms NNS o
with IN N
enzyme NN N
use NN N
was VBD N
shown VBN N
with IN N
this DT N
trial NN N
, , N
however RB N
, , N
possible JJ N
effects NNS N
on IN N
improvement NN o
in IN o
food NN o
variety NN o
warrants NNS N
further RBR N
detailed JJ N
investigation NN N
. . N

-DOCSTART- -20675425- O O

The DT N
effectiveness NN o
of IN N
a DT N
calcium NN N
sodium NN N
phosphosilicate NN N
desensitizer NN N
in IN N
reducing VBG N
cervical JJ p
dentin NN p
hypersensitivity NN p
: : p
a DT N
pilot NN N
study NN N
. . N

BACKGROUND NNP N
NovaMin NNP N
( ( N
NovaMin NNP N
Technology NNP N
, , N
Alachua NNP N
, , N
Fla. NNP N
) ) N
was VBD N
introduced VBN N
into IN N
the DT N
dental JJ N
market NN N
as IN N
a DT N
desensitizer NN N
in IN N
December NNP N
2004 CD N
. . N

However RB N
, , N
to TO N
the DT N
authors NNS N
' POS N
knowledge NN N
, , N
no DT N
researchers NNS N
yet RB N
have VBP N
evaluated VBN N
the DT N
effectiveness NN N
of IN N
100 CD N
percent NN N
NovaMin NNP N
powder NN N
with IN N
NovaMin-containing NNP N
toothpaste NN N
in IN N
reducing VBG N
dentin JJ N
hypersensitivity NN N
compared VBN N
with IN N
the DT N
effectiveness NN N
of IN N
NovaMin-containing NNP N
toothpaste NN N
only RB N
and CC N
a DT N
desensitizing NN N
toothpaste NN N
containing VBG N
potassium NN N
nitrate NN N
as IN N
a DT N
control NN N
. . N

METHODS NNP N
The DT N
authors NNS N
divided VBD N
60 CD p
participants NNS p
randomly RB N
into IN N
three CD N
groups NNS N
: : N
NovaMin NNP i
powder NN i
with IN i
NovaMin-containing NNP i
toothpaste NN i
( ( i
group NN i
1 CD i
) ) i
, , i
a DT i
placebo NN i
powder NN i
with IN i
NovaMin-containing NNP i
toothpaste NN i
( ( i
group NN i
2 CD i
) ) i
and CC i
a DT i
placebo NN i
powder NN i
with IN i
the DT i
control NN i
toothpaste NN i
( ( i
group NN i
3 CD i
) ) i
. . i

The DT N
authors NNS N
used VBN N
tactile NN o
and CC o
cold JJ o
stimuli NN o
and CC o
a DT o
visual JJ o
analog NN o
scale NN o
to TO o
evaluate VB N
participants NNS N
' POS N
pain NN N
at IN N
baseline NN N
, , N
immediately RB N
after IN N
powder NN N
application NN N
and CC N
at IN N
one CD N
week NN N
, , N
two CD N
weeks NNS N
and CC N
four CD N
weeks NNS N
after IN N
powder NN N
application NN N
. . N

They PRP N
analyzed VBD N
data NNS N
by IN N
using VBG N
Friedman NNP o
and CC o
Wilcoxon NNP o
signed-rank JJ o
tests NNS o
for IN N
within-group JJ N
comparison NN N
. . N

They PRP N
used VBD N
Kruskal-Wallis NNP o
and CC o
Mann-Whitney NNP o
U NNP o
tests NNS o
for IN N
between-group JJ N
comparison NN N
. . N

They PRP N
considered VBD N
P NNP N
< NNP N
.05 NNP N
to TO N
be VB N
statistically RB N
significant JJ N
. . N

RESULTS NNP N
Groups NNP N
1 CD N
and CC N
2 CD N
showed VBD N
significant JJ N
hypersensitivity NN o
reduction NN o
over IN N
baseline NN N
at IN N
all DT N
time NN N
points NNS N
. . N

Group NNP N
3 CD N
showed VBD N
significant JJ N
hypersensitivity NN o
reduction NN o
at IN N
one CD N
week NN N
onward RB N
. . N

Group NNP N
1 CD N
showed VBD N
significant JJ N
improvement NN N
compared VBN N
with IN N
groups NNS N
2 CD N
and CC N
3 CD N
, , N
except IN N
for IN N
response NN N
to TO N
tactile VB o
stimulus NN o
at IN N
four CD N
weeks NNS N
with IN N
group NN N
2 CD N
. . N

Between NNP N
groups NNS N
2 CD N
and CC N
3 CD N
, , N
there EX N
were VBD N
significant JJ N
differences NNS N
at IN N
two CD N
and CC N
four CD N
weeks NNS N
. . N

CONCLUSIONS NNP N
and CC N
CLINICAL NNP N
IMPLICATIONS NNP N
The DT N
use NN N
of IN N
NovaMin NNP N
powder NN N
and CC N
NovaMin-containing NNP N
toothpaste NN N
for IN N
hypersensitivity NN N
reduction NN N
is VBZ N
more RBR N
effective JJ N
than IN N
the DT N
use NN N
of IN N
a DT N
desensitizing VBG N
toothpaste NN N
containing VBG N
potassium NN N
nitrate NN N
and CC N
fluoride NN N
. . N

-DOCSTART- -7200736- O O

Prostaglandin NNP p
E1 NNP p
as IN p
a DT p
hypotensive JJ p
drug NN p
during IN p
general JJ p
anaesthesia NN p
. . p

Hypotension NNP o
induced VBN N
by IN N
prostaglandin NN i
E1 NNP i
( ( i
PGE1 NNP i
) ) i
infusion NN i
( ( N
100-150 JJ N
ng/kg/minute NN N
) ) N
during IN N
halothane NN i
anaesthesia NN i
to TO N
reduce VB N
operative JJ N
blood NN N
loss NN N
during IN p
mastectomy NN p
was VBD N
investigated VBN N
. . N

PGE1 NNP N
decreased VBD N
systolic JJ o
arterial JJ o
pressure NN o
approximately RB N
34 CD N
% NN N
from IN N
pre-administration NN N
values NNS N
. . N

The DT N
duration NN N
of IN N
induced JJ p
hypotension NN p
was VBD N
about IN N
75 CD N
minutes NNS N
. . N

When WRB N
the DT N
infusion NN N
was VBD N
stopped VBN N
, , N
blood NN o
pressure NN o
returned VBD N
to TO N
within IN N
15 CD N
% NN N
of IN N
the DT N
control NN N
with IN N
15 CD N
minutes NNS N
. . N

Heart NNP o
rate NN o
did VBD N
not RB N
change VB N
significantly RB N
during IN N
PGE1 NNP N
infusion NN N
; : N
the DT N
pre-ejection NN o
period NN o
and CC N
left VBD o
ventricular JJ o
ejection NN o
period NN N
were VBD N
shortened VBN N
. . N

Renal JJ o
function NN o
during IN N
the DT N
hypotensive JJ N
period NN N
was VBD N
well RB N
maintained VBN N
. . N

Blood NNP o
loss NN o
during IN N
surgery NN N
was VBD N
significantly RB N
decreased VBN N
. . N

These DT N
findings NNS N
suggest VBP N
that IN N
PGE1 NNP N
can MD N
be VB N
used VBN N
safely RB N
to TO N
control VB N
arterial JJ o
pressure NN o
during IN N
surgery NN N
. . N

-DOCSTART- -9394942- O O

Naltrexone NN i
in IN N
young JJ p
autistic JJ p
children NNS p
: : p
replication NN N
study NN N
and CC N
learning NN N
measures NNS N
. . N

OBJECTIVE NNP N
This DT N
study NN N
expanded VBD N
upon RB N
previous JJ N
work NN N
on IN N
naltrexone JJ i
efficacy NN N
and CC N
safety NN N
in IN N
young JJ p
autistic JJ p
children NNS p
and CC N
assessed JJ N
performance NN N
on IN N
learning VBG N
measures NNS N
. . N

METHOD NNP N
Eleven NNP p
children NNS p
with IN p
autistic JJ p
disorder NN p
, , p
aged VBD p
3.0 CD p
to TO p
8.3 CD p
years NNS p
, , N
were VBD N
studied VBN N
in IN N
home NN N
, , N
school NN N
, , N
and CC N
outpatient JJ N
laboratory NN N
, , N
bringing VBG N
to TO N
24 CD N
the DT N
combined VBN N
study NN N
sample NN N
. . N

Naltrexone NNP i
, , N
1.0 CD N
mg/kg NN N
, , N
was VBD N
given VBN N
daily RB N
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
crossover JJ N
design NN N
. . N

Dependent JJ N
measures NNS N
were VBD N
parent NN N
and CC N
teacher RB N
Clinical JJ o
Global NNP o
Impressions NNP o
( ( o
CGI NNP o
) ) o
and CC N
Naltrexone NNP o
Side NNP o
Effects NNP o
Rating NNP o
Scale NNP o
( ( o
SE NNP o
) ) o
, , o
Conners NNPS o
Parent NNP o
Impulsivity/Hyperactivity NNP o
Factor NNP o
, , o
Teacher NNP o
Hyperactivity NNP o
Factor NNP o
, , N
laboratory NN N
CGI NNP N
, , N
and CC N
analysis NN N
of IN N
videotaped JJ N
behavior NN N
. . N

Learning VBG N
measures NNS N
were VBD N
the DT N
Early JJ o
Intervention NNP o
Developmental NNP o
Profile-Language NNP o
and CC N
paired-associate JJ o
learning NN o
. . o

RESULTS JJ N
Comparisons NNPS N
between IN N
naltrexone NN i
and CC N
baseline NN N
, , N
but CC N
not RB N
naltrexone RB i
and CC N
placebo NN i
, , N
on IN N
parent NN N
and CC N
teacher NN N
ratings NNS N
showed VBD N
statistical JJ N
significance NN N
. . N

Three CD N
of IN N
11 CD N
subjects NNS N
improved VBN N
in IN N
two CD N
or CC N
more JJR N
settings NNS N
. . N

Side JJ o
effects NNS o
were VBD N
mild JJ N
. . N

Administering VBG N
naltrexone NN i
was VBD N
a DT N
challenge NN N
. . N

The DT N
combined JJ N
study NN N
sample NN N
showed VBD N
improvement NN N
on IN N
all DT N
parent NN o
measures NNS o
and CC N
on IN N
Teacher NNP o
CGI NNP o
and CC N
SE-Restlessness NNP o
compared VBN N
with IN N
baseline NN N
and CC N
placebo NN i
. . i

Eleven NNP N
of IN N
the DT N
24 CD p
children NNS p
improved VBN N
in IN N
two CD N
or CC N
more JJR N
settings NNS N
. . N

Scores NNS N
on IN N
learning VBG o
measures NNS o
did VBD N
not RB N
change VB N
across IN N
conditions NNS N
. . N

CONCLUSIONS NNP N
Naltrexone NNP i
was VBD N
associated VBN N
with IN N
modest JJ N
improvement NN N
of IN N
behavior NN o
in IN N
11 CD N
of IN N
24 CD N
children NNS N
, , N
but CC N
learning VBG o
did VBD N
not RB N
improve VB N
. . N

-DOCSTART- -26035186- O O

A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
study NN N
of IN N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
2 CD N
doses NNS N
of IN N
vortioxetine NN i
in IN N
adults NNS p
with IN p
major JJ p
depressive JJ p
disorder NN p
. . p

BACKGROUND VB N
This DT N
8-week JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
study NN N
, , N
conducted VBN N
August NNP N
2010-May JJ N
2012 CD N
in IN N
the DT N
United NNP N
States NNPS N
, , N
evaluated VBD N
the DT N
safety NN o
and CC o
efficacy NN o
of IN N
vortioxetine NN i
10 CD N
mg NN N
and CC N
15 CD N
mg NNS N
in IN N
patients NNS p
with IN p
major JJ p
depressive JJ p
disorder NN p
( ( p
MDD NNP p
) ) p
. . p

The DT N
mechanism NN N
of IN N
action NN N
of IN N
vortioxetine NN i
is VBZ N
thought VBN N
to TO N
be VB N
related VBN N
to TO N
direct JJ N
modulation NN N
of IN N
serotonin NN o
( ( o
5-HT JJ o
) ) o
receptor NN o
activity NN o
and CC N
inhibition NN N
of IN N
the DT N
serotonin NN o
transporter NN o
. . o

METHOD NNP N
Adults NNP p
aged VBD p
18-75 CD p
years NNS p
with IN p
MDD NNP p
( ( p
DSM-IV-TR NNP p
) ) p
and CC p
Montgomery-Asberg NNP p
Depression NNP p
Rating NNP p
Scale NNP p
( ( p
MADRS NNP p
) ) p
total NN p
score NN p
? . p
26 CD p
were VBD p
randomized VBN p
( ( p
1:1:1 CD p
) ) p
to TO p
receive VB i
vortioxetine NN i
10 CD i
mg NN N
or CC N
15 CD N
mg NN N
or CC N
placebo NN i
once RB i
daily JJ N
, , N
with IN N
the DT o
primary JJ o
efficacy JJ o
end NN o
point NN o
being VBG o
change NN o
from IN o
baseline NN o
at IN o
week NN o
8 CD o
in IN o
MADRS NNP o
analyzed VBN o
by IN N
mixed JJ N
model NN N
for IN N
repeated JJ N
measures NNS o
. . o

Adverse JJ o
events NNS o
were VBD o
recorded VBN N
during IN N
the DT N
study NN o
, , o
suicidal JJ o
ideation NN o
and CC o
behavior NN o
were VBD o
assessed VBN o
using VBG o
the DT o
Columbia-Suicide JJ o
Severity NNP o
Rating NNP o
Scale NNP o
( ( o
C-SSRS NNP o
) ) o
, , o
and CC o
sexual JJ o
dysfunction NN o
was VBD o
assessed VBN o
using VBG o
the DT o
Arizona NNP o
Sexual NNP o
Experience NNP o
( ( o
ASEX NNP o
) ) o
scale NN o
. . o

RESULTS NNP p
Of IN p
the DT p
1,111 CD p
subjects NNS p
screened VBN p
, , p
469 CD p
subjects NNS p
were VBD p
randomized VBN p
: : p
160 CD p
to TO p
placebo VB i
, , i
157 CD p
to TO p
vortioxetine VB i
10 CD i
mg NN p
, , p
and CC p
152 CD p
to TO p
vortioxetine VB i
15 CD i
mg NN p
. . p

Differences NNS N
from IN i
placebo NN i
in IN i
the DT o
primary JJ o
efficacy JJ o
end NN o
point NN o
were VBD o
not RB N
statistically RB N
significant JJ N
for IN i
vortioxetine NN i
10 CD i
mg NN N
or CC N
vortioxetine NN N
15 CD N
mg. NN o
Nausea NNP o
, , o
headache NN o
, , o
dry JJ o
mouth NN o
, , o
constipation NN o
, , o
diarrhea NN o
, , o
vomiting VBG o
, , o
dizziness NN o
, , o
and CC o
flatulence NN o
were VBD o
reported VBN N
in IN N
? . N
5 CD N
% NN N
of IN N
subjects NNS N
receiving VBG N
vortioxetine NN N
. . N

Discontinuation NN N
due JJ N
to TO o
adverse JJ o
events NNS o
occurred VBD o
in IN N
7 CD N
subjects NNS N
( ( N
4.4 CD N
% NN N
) ) N
in IN N
the DT N
placebo NN i
group NN i
, , N
8 CD N
( ( N
5.2 CD N
% NN N
) ) N
in IN N
the DT N
vortioxetine NN i
10 CD i
mg NN N
group NN N
, , N
and CC N
12 CD N
( ( N
7.9 CD N
% NN N
) ) N
in IN N
the DT N
vortioxetine NN i
15 CD i
mg NN N
group NN N
. . N

ASEX NNP N
total JJ N
scores NNS N
were VBD N
similar JJ N
across IN N
groups NNS N
. . N

There EX N
were VBD N
no DT N
clinically RB N
significant JJ N
trends NNS N
within IN N
or CC N
between IN N
treatment NN N
groups NNS N
on IN N
the DT N
C-SSRS NNP o
, , o
laboratory NN o
values NNS o
, , o
electrocardiogram NN o
, , o
or CC o
vital JJ o
sign NN o
parameters NNS o
. . o

CONCLUSIONS NNP o
In IN N
this DT N
study NN i
, , i
vortioxetine NN i
did VBD i
not RB N
differ VB N
significantly RB N
from IN N
placebo NN i
on IN i
MADRS NNP N
total NN N
score NN N
after IN N
8 CD N
weeks NNS N
of IN N
treatment NN N
in IN N
MDD NNP N
subjects NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
identifier NN N
: : N
NCT01179516 NNP N
. . N

-DOCSTART- -12793516- O O

Service NNP N
variation NN N
in IN N
baseline NN N
variables NNS N
and CC N
prediction NN N
of IN N
risk NN N
in IN N
a DT N
randomised JJ N
controlled JJ N
trial NN N
of IN N
psychological JJ i
treatment NN i
in IN N
repeated JJ N
parasuicide NN N
: : N
the DT N
POPMACT NNP N
Study NNP N
. . N

The DT N
treatment NN N
protocol NN N
and CC N
baseline NN N
characteristics NNS N
of IN N
480 CD p
subjects NNS p
with IN p
a DT p
history NN p
of IN p
repeated VBN p
parasuicide NN p
recruited VBN N
in IN N
five CD N
centres NNS N
to TO N
a DT N
randomised VBN N
therapeutic JJ N
trial NN N
of IN N
manual JJ i
assisted VBN i
cognitive-behaviour JJ i
therapy NN i
( ( i
MACT NNP i
) ) i
and CC i
treatment NN i
as IN i
usual JJ i
( ( i
TAU NNP i
) ) i
are VBP N
described VBN N
. . N

Most JJS p
patients NNS p
had VBD p
significant JJ p
anxiety NN o
and CC o
depressive JJ o
disturbance NN o
with IN p
42 CD p
% NN p
having VBG p
a DT p
personality NN p
disorder NN p
. . p

Variation NNP N
in IN N
service NN N
policies NNS N
influenced VBD N
recruitment NN N
, , N
with IN N
earlier RBR N
assessment JJ N
centres NNS N
seeing VBG N
people NNS N
with IN N
more RBR N
frequent JJ N
episodes NNS o
of IN o
self-harm NN o
and CC N
greater JJR N
parasuicide NN o
risk NN o
than IN N
later JJR N
ones NNS N
. . N

Parasuicide NNP o
risk NN o
was VBD N
also RB N
significantly RB N
greater JJR N
in IN N
those DT N
with IN N
their PRP$ N
first JJ N
parasuicide NN N
episode NN N
at IN N
an DT N
earlier JJR N
age NN N
and CC N
in IN N
those DT N
with IN N
a DT N
more RBR N
recent JJ N
latest JJS N
episode NN N
. . N

-DOCSTART- -17852793- O O

New NNP i
mini-extracorporeal JJ i
circulation NN i
system NN i
( ( i
ECC.O NNP i
) ) i
is VBZ N
a DT N
safe JJ N
technique NN N
in IN N
coronary JJ N
surgery NN N
. . N

OBJECTIVES NNP N
Cardiopulmonary NNP i
bypass NN i
( ( i
CPB NNP i
) ) i
is VBZ N
known VBN N
to TO N
cause VB N
the DT N
systemic JJ N
inflammatory NN N
reaction NN N
after IN N
cardiac JJ N
surgery NN N
. . N

New NNP N
coated VBD N
and CC N
closed VBD N
loop NN N
circuit NN N
systems NNS N
may MD N
reduce VB N
this DT N
inflammation NN o
response NN o
and CC o
improve VB o
the DT o
surgical JJ o
outcome NN o
. . o

This DT N
study NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
the DT N
mini-extracorporeal JJ i
circulation NN i
system NN i
( ( i
ECC.O NNP i
) ) i
in IN N
CABG NNP p
patients NNS p
. . p

DESIGN NNP N
Forty NNP p
patients NNS p
undergoing VBG p
elective JJ p
coronary JJ p
surgery NN p
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
, , N
the DT N
ECC.O NNP i
group NN i
and CC i
the DT i
standard JJ i
CPB NNP i
group NN i
. . i

Routine NNP N
hemodynamic JJ N
monitoring NN N
and CC N
biochemical JJ N
measurements NNS N
were VBD N
registered VBN N
according VBG N
to TO N
the DT N
hospital NN N
practice NN N
. . N

RESULTS VB N
The DT N
clinical JJ N
outcome NN N
of IN N
the DT N
patients NNS N
was VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
groups NNS N
in IN N
the DT N
duration NN o
of IN o
intubation NN o
following VBG o
surgery NN o
, , o
the DT o
length NN o
of IN o
intensive JJ o
care NN o
unit-stay JJ o
or CC o
the DT o
total JJ o
hospital NN o
stay NN o
. . o

The DT N
haemoglobin JJ o
level NN o
was VBD N
significantly RB N
higher JJR N
( ( N
p=0.0069 NN N
) ) N
during IN N
and CC N
after IN N
the DT N
perfusion NN N
in IN N
the DT N
ECC.O NNP i
group NN N
. . N

CONCLUSIONS VB N
The DT N
ECC.O NNP i
system NN N
can MD N
be VB N
safely RB N
used VBN N
in IN N
CABG NNP p
patients NNS p
and CC N
it PRP N
maintains VBZ N
haemoglobin JJ N
level NN N
better RBR N
than IN N
conventional JJ N
CPB NNP i
. . i

-DOCSTART- -9178124- O O

Field NNP N
trials NNS N
of IN N
a DT N
vaccine NN i
against IN N
bovine NN N
mastitis NN N
. . N

1 CD N
. . N

Evaluation NN N
in IN N
heifers NNS p
. . p

A DT N
vaccine NN i
was VBD N
developed VBN N
against IN N
bovine NN N
mastitis NN N
based VBN N
on IN N
inactivated JJ N
, , N
highly RB N
encapsulated JJ N
Staphylococcus NNP N
aureus NN N
cells NNS N
; : N
a DT N
crude NN N
extract NN N
of IN N
Staph NNP N
. . N

aureus NN N
exopolysaccharides NNS N
; : N
and CC N
inactivated VBD N
, , N
unencapsulated JJ N
Staph NNP N
, , N
aureus NN N
and CC N
Streptococcus NNP N
spp NN N
. . N

cells NNS N
. . N

This DT N
vaccine NN i
was VBD N
tested VBN N
on IN N
30 CD p
heifers NNS p
during IN N
a DT N
7-mo JJ N
period NN N
. . N

The DT N
30 CD p
heifers NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
three CD N
groups NNS N
of IN N
10 CD N
heifers NNS N
each DT N
. . N

The DT N
prepartum NN N
group NN N
received VBD N
two CD N
injections NNS N
of IN N
the DT N
vaccine NN i
at IN N
8 CD N
and CC N
4 CD N
wk NN N
before IN N
calving NN N
, , N
and CC N
the DT N
postpartum NN N
group NN N
received VBD N
two CD N
injections NNS N
at IN N
1 CD N
and CC N
5 CD N
wk NN N
after IN N
calving VBG N
. . N

The DT N
control NN N
group NN N
received VBD N
two CD N
injections NNS N
of IN N
a DT N
placebo NN N
at IN N
8 CD N
and CC N
4 CD N
wk NN N
before IN N
calving VBG N
. . N

The DT N
vaccine NN i
or CC N
the DT N
placebo NN i
was VBD N
administered VBN N
subcutaneously RB N
in IN N
the DT N
brachiocephalicus NN N
muscle NN N
of IN N
the DT N
neck NN N
. . N

The DT N
frequencies NNS o
of IN o
intramammary JJ o
infections NNS o
caused VBN o
by IN o
Staph NNP o
. . o

aureus NN o
were VBD N
reduced VBN N
from IN N
18.8 CD N
% NN N
for IN N
heifers NNS N
in IN N
the DT N
control NN N
group NN N
to TO N
6.7 CD N
and CC N
6.0 CD N
% NN N
for IN N
heifers NNS N
in IN N
the DT N
prepartum NN N
and CC N
postpartum NN N
groups NNS N
, , N
respectively RB N
. . N

This DT N
protective JJ o
effect NN o
was VBD N
maintained VBN N
for IN N
at IN N
least JJS N
6 CD N
mo NN N
. . N

The DT N
relative JJ o
risk NN o
of IN o
mastitis NN o
caused VBN o
by IN o
Staph NNP o
. . o

aureus NN o
was VBD N
0.31 CD N
and CC N
0.28 CD N
for IN N
heifers NNS N
in IN N
the DT N
prepartum NN N
and CC N
postpartum NN N
groups NNS N
, , N
respectively RB N
, , N
compared VBN N
with IN N
that DT N
for IN N
heifers NNS N
in IN N
the DT N
control NN N
group NN N
. . N

The DT N
results NNS o
of IN o
the DT o
trial NN o
indicated VBD o
the DT o
effectiveness NN o
of IN o
the DT o
vaccine NN o
in IN N
decreasing VBG N
the DT N
incidence NN N
of IN N
intrammammary JJ N
infections NNS N
caused VBN N
by IN N
Staph NNP N
. . N

aureus NN N
. . N

A DT N
slight JJ N
but CC N
nonsignificant JJ N
increase NN N
occurred VBD N
in IN N
fat JJ o
production NN o
in IN N
the DT N
milk NN N
of IN N
vaccinated JJ N
cows NNS N
. . N

The DT N
vaccine NN N
had VBD N
no DT N
observable JJ N
effect NN N
on IN N
somatic JJ N
cell NN N
count NN N
or CC N
streptococcal JJ N
infections NNS N
. . N

-DOCSTART- -20506785- O O

[ JJ i
Pleural NNP i
tent NN i
after IN N
upper JJ p
lobectomy NN p
-- : p
randomized VBD p
study NN N
of IN N
it PRP N
's VBZ N
efficacy NN N
and CC N
duration NN N
of IN N
the DT N
effect NN N
] NNP N
. . N

UNLABELLED IN N
The DT N
aim NN N
of IN N
our PRP$ N
study NN N
is VBZ N
to TO N
evaluate VB N
the DT N
safety NN o
, , o
efficacy NN o
and CC o
also RB o
the DT o
maximum JJ o
duration NN o
of IN o
effect NN o
of IN o
the DT o
pleural JJ o
tent NN o
in IN N
reducing VBG N
the DT N
incidence NN N
of IN N
air NN N
leak NN N
after IN N
upper JJ N
lobectomy NN N
. . N

METHODS NNP N
Sixty NNP p
patients NNS p
who WP p
underwent VBP p
upper JJ p
lobectomy NN p
were VBD N
prospectively RB N
randomized VBN N
into IN N
two CD N
groups NNS N
: : N
30 CD p
patients NNS p
had VBD N
creation NN i
of IN i
pleural JJ i
tent NN i
( ( N
group NN N
1 CD N
) ) N
and CC N
30 CD N
did VBD i
not RB i
( ( N
group NN N
2 CD N
) ) N
. . N

The DT N
preoperative JJ N
, , N
operative JJ N
, , N
and CC N
postoperative JJ N
characteristics NNS N
of IN N
both DT N
groups NNS N
were VBD N
compared VBN N
. . N

Then RB N
multivariate JJ N
analyses NNS N
were VBD N
used VBN N
to TO N
identify VB N
factors NNS N
predictive CD N
of IN N
prolonged JJ N
air NN N
leaks NNS N
and CC N
their PRP$ N
duration NN N
. . N

The DT N
reduction NN N
of IN N
incidences NNS o
of IN o
air NN o
leak NN o
in IN N
the DT N
two CD N
groups NNS N
was VBD N
subsequently RB N
compared VBN N
during IN N
successive JJ N
postoperative JJ N
periods NNS N
. . N

RESULTS NNP N
Demographic NNP N
and CC N
clinical JJ N
profiles NNS N
of IN N
both DT N
groups NNS N
were VBD N
not RB N
statistically RB N
different JJ N
. . N

The DT N
tented JJ N
patients NNS N
had VBD N
statistically RB N
significant JJ N
reduction NN N
of IN N
mean JJ o
duration NN o
of IN o
air NN o
leak NN o
in IN N
days NNS N
( ( N
4.9 CD N
+/- JJ N
1.79 CD N
vs JJ N
8.2 CD N
+/- JJ N
4.2 CD N
) ) N
, , N
the DT N
number NN o
of IN o
days NNS o
of IN o
a DT o
chest NN o
tube NN o
duration NN o
( ( N
7.3 CD N
+/- JJ N
1.14 CD N
vs JJ N
12.46 CD N
+/- JJ N
3.6 CD N
) ) N
, , N
the DT N
length NN o
of IN o
postoperative JJ o
in-hospital JJ o
stay NN o
in IN o
days NNS o
( ( N
9.4 CD N
+/- JJ N
1.86 CD N
vs JJ N
13.6 CD N
+/- JJ N
2.49 CD N
) ) N
, , N
and CC N
the DT N
hospital NN o
stay NN o
cost NN o
per IN o
patient NN o
( ( N
leva NN N
, , N
3840 CD N
+/- JJ N
298 CD N
vs JJ N
5160 CD N
+/- JJ N
3890 CD N
) ) N
. . N

Logistic JJ N
regression NN N
analyses NNS N
showed VBD N
that IN N
no DT N
having VBG N
creation NN N
a DT N
pleural JJ i
tent NN i
procedure NN N
was VBD N
the DT N
most RBS N
significant JJ N
predictive JJ N
factor NN N
of IN N
the DT N
occurrence NN o
and CC o
duration NN o
of IN o
prolonged JJ o
air NN o
leaks NNS o
. . o

A DT N
greater JJR N
reduction NN N
in IN N
the DT N
duration NN o
of IN o
air NN o
leaks NNS o
was VBD N
observed VBN N
before IN N
postoperative JJ N
day NN N
4 CD N
in IN N
group NN N
1 CD N
, , N
and CC N
logistic JJ N
regression NN N
analysis NN N
showed VBD N
that IN N
having VBG N
a DT N
pleural JJ N
tent NN N
procedure NN N
was VBD N
the DT N
most RBS N
significant JJ N
predictive JJ N
factor NN N
of IN N
air NN o
leaks NNS o
that WDT N
persisted VBD N
for IN N
less JJR N
than IN N
4 CD N
days NNS N
. . N

CONCLUSIONS NNP N
Pleural NNP N
tent NN N
creation NN N
after IN N
upper JJ N
lobectomy NN N
is VBZ N
a DT N
simple JJ o
and CC o
safe JJ o
procedure NN o
that WDT N
reduces VBZ N
the DT N
duration NN o
of IN o
air NN o
leaks NNS o
and CC N
the DT N
hospital NN o
stay NN o
costs NNS o
. . o

The DT N
benefit NN N
from IN N
that DT N
procedure NN N
is VBZ N
achieved VBN N
before IN N
postoperative JJ N
day NN N
4 CD N
. . N

-DOCSTART- -7942578- O O

Effects NNS N
of IN N
a DT N
fish-oil JJ i
and CC i
vegetable-oil JJ i
formula NN i
on IN N
aggregation NN N
and CC N
ethanolamine-containing JJ N
lysophospholipid JJ o
generation NN o
in IN N
activated JJ N
human JJ N
platelets NNS N
and CC N
on IN N
leukotriene JJ o
production NN o
in IN N
stimulated JJ N
neutrophils NNS N
. . N

The DT N
effects NNS N
of IN N
consuming VBG N
a DT N
liquid JJ i
formula NN i
containing VBG i
either CC i
fish JJ i
oil NN i
enriched VBN i
in IN i
omega-3 JJ i
fatty JJ i
acids NNS i
or CC i
vegetable JJ i
oil NN i
enriched VBN i
in IN i
oleic JJ i
acid NN i
was VBD N
evaluated VBN N
in IN N
20 CD p
male JJ p
subjects NNS p
randomly RB N
allocated VBN N
into IN N
two CD i
groups NNS i
over IN i
a DT i
42-d JJ i
period NN i
. . i

A DT N
decrease NN N
in IN N
collagen-induced JJ o
aggregation NN o
by IN N
using VBG N
washed JJ N
platelet NN N
suspensions NNS N
was VBD N
found VBN N
in IN N
both DT N
groups NNS N
after IN N
nutritional JJ N
supplementation NN N
. . N

A DT N
considerable JJ N
rise NN N
in IN N
omega-3 JJ o
and CC N
a DT N
decrease NN N
in IN N
omega-6 JJ o
fatty JJ o
acids NNS o
occurred VBD N
in IN N
the DT N
platelet NN N
phospholipid JJ N
with IN N
fish-oil JJ i
consumption NN i
. . i

The DT N
degree NN N
of IN N
eicosapentaenoic NN o
acid NN o
( ( N
EPA NNP N
, , N
20:5n-3 JJ N
) ) N
enrichment NN N
( ( N
fish-oil JJ N
group NN N
) ) N
was VBD N
dramatically RB N
greater JJR N
in IN N
the DT N
ether-containing JJ N
plasmenylethanolamine NN N
( ( N
13.5 CD N
mol CD N
% NN N
of IN N
fatty JJ N
acids NNS N
; : N
mol CD N
% NN N
of IN N
fatty JJ N
acids NNS N
= VBP N
moles NNS N
per IN N
100 CD N
moles NNS N
of IN N
total JJ N
fatty JJ N
acids NNS N
) ) N
than IN N
in IN N
phosphatidylethanolamine NN N
( ( N
2.8 CD N
mol CD N
% NN N
) ) N
or CC N
phosphatidylcholine NN N
( ( N
2.9 CD N
mol CD N
% NN N
) ) N
. . N

Neither CC N
treatment NN N
significantly RB N
influenced VBD N
the DT N
agonist-induced JJ o
accumulation NN o
of IN o
lysoplasmenylethanolamine NN o
as IN N
derived JJ N
via IN N
phospholipase NN N
A2 NNP N
hydrolysis NN N
of IN N
plasmenylethanolamine NN N
. . N

HPLC NNP o
measurements NNS o
of IN N
eicosanoid JJ o
production NN o
in IN N
A23187-stimulated NNP N
neutrophils NNS N
revealed VBD N
a DT N
considerable JJ N
decrease NN N
in IN N
the DT N
formation NN o
of IN o
arachidonic JJ o
acid-derived JJ o
leukotriene NN o
B4 NNP o
( ( N
LTB4 NNP N
) ) N
, , N
by IN N
41 CD N
% NN N
, , N
and CC N
5-HETE JJ o
( ( o
5-hydroxyeicosatetraenoic JJ o
acid NN o
) ) o
, , N
by IN N
30 CD N
% NN N
, , N
in IN N
the DT N
fish-oil JJ N
group NN N
along IN N
with IN N
the DT N
appearance NN N
of IN N
the DT N
corresponding JJ N
EPA-derived JJ N
products NNS N
[ JJ N
LTB5 NNP N
and CC N
5-HEPE JJ N
( ( N
5-hydroxyeicosapentaenoic JJ N
acid NN N
) ) N
] NN N
. . N

No DT N
such JJ N
alterations NNS N
in IN N
the DT N
formation NN N
of IN N
lipoxygenase NN N
products NNS N
were VBD N
found VBN N
with IN N
the DT N
vegetable JJ i
oil NN i
treatment NN i
. . i

-DOCSTART- -8018457- O O

Interactive JJ N
effects NNS N
of IN N
indomethacin NN i
, , i
angiotensin NN i
II NNP i
and CC i
frusemide VB i
on IN N
renal JJ p
haemodynamics NNS p
and CC p
natriuresis NN p
in IN p
man NN p
. . p

The DT N
responses NNS N
of IN N
renal JJ N
haemodynamic NN N
and CC N
natriuretic JJ N
indices NNS N
to TO N
the DT N
oral JJ N
prostaglandin NN N
synthetase NN N
inhibitor NN N
indomethacin NN i
( ( i
200 CD i
mg NN i
) ) i
, , i
to TO i
infused VBN i
angiotensin NN i
II NNP i
( ( N
1 CD N
ng RB N
min-1 JJ N
kg-1 NN N
) ) N
and CC N
to TO N
the DT N
combination NN N
of IN N
the DT N
two CD N
were VBD N
studies NNS N
in IN N
placebo-controlled JJ i
fashion NN N
in IN N
eight CD p
normal JJ p
male JJ p
subjects NNS p
both DT p
prior JJ p
to TO p
and CC p
following VBG p
administration NN p
of IN p
intravenous JJ i
frusemide NN i
( ( p
20 CD p
mg NN p
) ) p
. . p

As IN N
compared VBN N
with IN N
placebo NN i
, , i
angiotensin NN i
II NNP i
infusion NN i
alone RB N
caused VBD N
significant JJ N
reductions NNS N
in IN N
absolute JJ o
rate NN o
of IN o
sodium NN o
excretion NN o
, , o
fractional JJ o
sodium NN o
excretion NN o
, , o
urine JJ o
flow NN o
rate NN o
and CC o
effective JJ o
renal JJ o
plasma NN o
flow NN o
( ( N
all DT N
P NNP N
< NNP N
0.001 CD N
vs NN N
placebo NN N
) ) N
but CC N
had VBD N
no DT N
effect NN N
on IN N
glomerular JJ o
filtration NN o
rate NN o
. . o

The DT N
only JJ N
change NN N
observed VBD N
in IN N
these DT N
parameters NNS N
with IN N
indomethacin JJ i
alone NN N
was VBD N
a DT N
small JJ N
but CC N
significant JJ N
reduction NN N
in IN N
urine JJ o
flow NN o
rate NN o
( ( N
P NNP N
< VBZ N
0.005 CD N
vs NN N
placebo NN N
) ) N
. . N

As IN N
compared VBN N
with IN N
the DT N
effects NNS N
of IN N
angiotensin JJ N
II NNP N
alone RB N
, , N
indomethacin JJ i
pre-treatment NN N
followed VBN N
by IN N
angiotensin NN i
II NNP i
infusion NN i
led VBD N
to TO N
much RB N
greater JJR N
falls NNS o
in IN N
absolute JJ o
rate NN o
of IN o
sodium NN o
excretion NN o
, , o
fractional JJ o
sodium NN o
excretion NN o
, , o
urine JJ o
flow NN o
rate NN o
and CC o
effective JJ o
renal JJ o
plasma NN o
flow NN o
( ( N
all DT N
P NNP N
< NNP N
0.0001 CD N
vs NN N
placebo NN i
) ) i
associated VBN N
with IN N
a DT N
significant JJ N
reduction NN N
in IN N
glomerular JJ o
filtration NN o
rate NN o
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
not RB N
observed VBN N
with IN N
angiotensin JJ N
II NNP N
alone RB N
. . N

Frusemide NNP i
administration NN N
at IN N
the DT N
midpoint NN N
of IN N
each DT N
study NN N
limb NN N
resulted VBD N
in IN N
each DT N
case NN N
in IN N
a DT N
prompt JJ N
15 CD N
to TO N
20 CD N
fold JJ N
increase NN N
in IN N
natriuresis NN o
. . o

The DT N
renal JJ o
haemodynamic NN o
and CC o
natriuretic JJ o
effects NNS o
of IN N
angiotensin NN N
II NNP N
, , N
indomethacin NN N
and CC N
their PRP$ N
combination NN N
were VBD N
not RB N
qualitatively RB N
different JJ N
from IN N
those DT N
observed VBN N
in IN N
the DT N
pre-frusemide JJ i
phase NN N
. . N

Our PRP$ N
findings NNS N
provide VBP N
a DT N
clear JJ N
demonstration NN N
in IN N
man NN p
of IN N
the DT N
important JJ N
homeostatic JJ o
role NN o
of IN N
renal JJ N
prostaglandins NNS N
in IN N
preserving VBG N
renal JJ o
function NN o
, , o
particularly RB o
glomerular JJ o
filtration NN o
, , N
under IN N
conditions NNS N
of IN N
elevated JJ N
circulating VBG N
angiotensin NN N
II NNP N
. . N

-DOCSTART- -24286965- O O

Continuous JJ N
glucose JJ N
monitoring NN N
in IN N
acute JJ p
coronary JJ p
syndrome NN p
. . p

BACKGROUND NNP N
Diabetes NNP p
mellitus NN p
is VBZ N
an DT N
independent JJ N
risk NN N
factor NN N
for IN N
cardiovascular JJ p
disease NN p
. . p

OBJECTIVE UH N
To TO N
compare VB N
the DT N
efficacy NN o
of IN o
devices NNS o
for IN N
continuous JJ N
glucose JJ N
monitoring NN N
and CC N
capillary JJ N
glucose NN N
monitoring NN N
in IN N
hospitalized JJ p
patients NNS p
with IN p
acute JJ p
coronary JJ p
syndrome NN p
using VBG N
the DT N
following JJ N
parameters NNS N
: : N
time NN o
to TO o
achieve VB o
normoglycemia NN o
, , o
period NN o
of IN o
time NN o
in IN o
normoglycemia NN o
, , o
and CC o
episodes NNS o
of IN o
hypoglycemia NN o
. . o

METHODS NNP N
We PRP N
performed VBD N
a DT N
pilot NN N
, , N
non-randomized JJ N
, , N
unblinded JJ N
clinical JJ N
trial NN N
that WDT N
included VBD N
16 CD p
patients NNS p
with IN p
acute JJ p
coronary JJ p
artery NN p
syndrome NN p
, , p
a DT p
capillary JJ p
or CC p
venous JJ p
blood NN p
glucose NN p
? . p
140 CD p
mg/dl NN p
, , p
and CC p
treatment NN p
with IN p
a DT p
continuous JJ p
infusion NN p
of IN p
fast JJ p
acting VBG p
human JJ i
insulin NN i
. . i

These DT N
patients NNS N
were VBD N
randomized VBN N
into IN N
2 CD N
groups NNS N
: : N
a DT N
conventional JJ N
group NN N
, , N
in IN N
which WDT i
capillary JJ i
measurement NN i
and CC i
recording NN i
as RB i
well RB i
as IN i
insulin NN i
adjustment NN i
were VBD i
made VBN N
every DT N
4h CD N
, , N
and CC N
an DT N
intervention NN N
group NN N
, , N
in IN N
which WDT i
measurement NN i
and CC i
recording NN i
as RB i
well RB i
as IN i
insulin NN i
adjustment NN i
were VBD i
made VBN i
every DT i
hour NN i
with IN i
a DT i
subcutaneous JJ i
continuous JJ i
monitoring NN i
system NN o
. . o

Student NN o
's POS o
t-test NN o
was VBD o
applied VBN N
for IN N
mean JJ N
differences NNS N
and CC N
the DT o
X NNP o
( ( o
2 CD o
) ) o
test NN o
for IN o
qualitative JJ N
variables NNS N
. . N

RESULTS NNP N
We PRP N
observed VBD N
a DT N
statistically RB N
significant JJ N
difference NN N
in IN N
the DT o
mean JJ o
time NN o
for IN o
achieving VBG o
normoglycemia NN o
, , o
favoring VBG N
the DT N
conventional JJ N
group NN N
with IN N
a DT N
P NNP N
= NN N
0.02 CD N
. . N

CONCLUSION NNP N
Continuous NNP N
monitoring VBG N
systems NNS N
are VBP N
as RB N
useful JJ N
as IN N
capillary JJ N
monitoring NN N
for IN N
achieving VBG N
normoglycemia NN N
. . N

-DOCSTART- -9070546- O O

Comparison NNP N
of IN N
arbutamine NN i
and CC N
exercise NN i
echocardiography NN i
in IN N
diagnosing VBG p
myocardial JJ p
ischemia NN p
. . p

Arbutamine NNP i
is VBZ N
a DT N
new JJ N
catecholamine NN N
designed VBN N
for IN N
use NN N
as IN N
a DT N
pharmacologic JJ N
stress NN N
agent NN N
. . N

This DT N
study NN N
compared VBN N
the DT N
sensitivity NN N
of IN N
arbutamine NN i
with IN N
symptom-limited JJ i
exercise NN i
to TO N
induce VB N
echocardiographic JJ o
signs NNS o
of IN o
ischemia NN o
. . o

Arbutamine NNP i
was VBD N
administered VBN N
by IN N
a DT N
computerized JJ N
closed-loop NN N
delivery NN N
system NN N
that WDT N
controls VBZ N
the DT N
infusion NN N
rate NN N
of IN N
arbutamine NN i
toward IN N
a DT N
predefined JJ N
rate NN N
of IN N
heart NN N
rate NN N
increase NN N
and CC N
maximum JJ N
heart NN N
rate NN N
limit NN N
. . N

Beta NNP N
blockers NNS N
were VBD N
stopped VBN N
> CD N
or CC N
= VB N
48 CD N
hours NNS N
before IN N
both DT N
tests NNS N
. . N

Stress NN N
was VBD N
stopped VBN N
for IN N
intolerable JJ N
symptoms NNS N
, , N
or CC N
clinical JJ N
, , N
electrocardiographic JJ N
or CC N
echocardiographic JJ N
signs NNS N
of IN N
ischemia NN N
( ( N
new JJ N
or CC N
worsening VBG N
wall JJ N
motion NN N
abnormality NN N
) ) N
, , N
target VB N
heart NN N
rate NN N
( ( N
> CD N
or CC N
= VB N
85 CD N
% NN N
age NN N
predicted VBD N
maximum JJ N
heart NN N
rate NN N
) ) N
, , N
or CC N
plateau NN N
of IN N
heart NN N
rate NN N
response NN N
. . N

Thirty-seven JJ p
patients NNS p
were VBD p
entered VBN p
into IN p
the DT p
study NN p
( ( p
35 CD p
arbutamine NN i
and CC p
exercise NN i
, , p
1 CD p
arbutamine NN i
only RB p
, , p
1 CD p
exercise NN i
only RB p
) ) p
, , p
of IN p
which WDT p
30 CD p
had VBD p
angiographic JJ p
evidence NN p
of IN p
coronary JJ p
artery NN p
disease NN p
( ( p
> CD p
or CC p
= VB p
50 CD p
% NN p
lumen NNS p
diameter RB p
narrowing VBG p
) ) p
. . p

Rate-pressure JJ o
product NN o
increased VBN N
significantly RB N
in IN N
response NN N
to TO N
both DT N
stress JJ N
modalities NNS N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
and CC N
was VBD N
significantly RB N
greater JJR N
with IN N
exercise NN N
( ( N
11,308 CD N
+/- JJ N
2,443 CD N
) ) N
than IN N
with IN N
arbutamine NN N
( ( N
9,486 CD N
+/- JJ N
2,479 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
time NN o
to TO o
maximum VB o
heart NN o
rate NN o
was VBD N
longer RBR N
during IN N
arbutamine JJ i
stress NN N
echocardiography NN N
than IN N
during IN N
exercise NN i
testing NN N
( ( N
17.3 CD N
+/- JJ N
9.4 CD N
versus NN N
9.3 CD N
+/- JJ N
4.2 CD N
minutes NNS N
, , N
respectively RB N
, , N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

There EX N
were VBD N
more JJR N
patients NNS N
with IN N
interpretable JJ N
echo NN N
data NNS N
for IN N
arbutamine NN i
( ( N
82 CD N
% NN N
) ) N
than IN N
for IN N
exercise NN i
( ( N
67 CD N
% NN N
) ) N
. . N

Sensitivity NN o
for IN o
recognition NN o
of IN o
myocardial JJ o
ischemia NN o
was VBD N
94 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval JJ N
70 CD N
% NN N
to TO N
100 CD N
% NN N
) ) N
and CC N
88 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval JJ N
62 CD N
% NN N
to TO N
98 CD N
% NN N
) ) N
, , N
respectively RB N
. . N

The DT N
most RBS N
frequent JJ N
adverse JJ o
events NNS o
during IN N
arbutamine NN i
( ( N
n JJ N
= NNP N
36 CD N
) ) N
were VBD N
dyspnea VBN o
( ( N
5.6 CD N
% NN N
) ) N
and CC N
tremor NN o
( ( N
5.6 CD N
% NN N
) ) N
. . N

Two CD N
arbutamine JJ i
stress NN N
tests NNS N
were VBD N
discontinued VBN N
due JJ N
to TO N
arrhythmias VB o
: : o
1 CD N
patient NN N
had VBD N
premature JJ o
atrial JJ o
and CC o
ventricular JJ o
beats NNS o
, , N
and CC N
the DT N
other JJ N
had VBD N
premature JJ o
atrial JJ o
contractions NNS o
and CC o
atrial JJ o
fibrillation NN o
. . o

Arrhythmias NNP o
were VBD o
well RB o
tolerated VBN o
and CC o
resolved VBN o
without IN N
sequelae NN N
. . N

In IN N
conclusion NN N
, , N
the DT N
sensitivity NN N
of IN N
arbutamine NN i
to TO N
induce VB N
echocardiographic JJ o
signs NNS o
of IN o
ischemia NN o
was VBD N
similar JJ N
to TO N
that DT N
of IN N
exercise NN i
despite IN N
a DT N
lower JJR N
rate-pressure NN o
product NN o
. . o

Arbutamine NNP i
was VBD N
well RB o
tolerated JJ o
and CC o
provides VBZ o
a DT o
reliable JJ o
alternative NN o
to TO o
exercise VB o
echocardiography NN o
. . o

-DOCSTART- -12925182- O O

Reduction NN N
of IN N
isoflurane NN N
MAC NNP N
by IN N
fentanyl NN i
or CC N
remifentanil NN i
in IN N
rats NNS p
. . p

OBJECTIVE IN N
The DT N
main JJ N
objective NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
effects NNS N
of IN N
three CD N
different JJ N
infusion NN N
rates NNS N
of IN N
fentanyl NN i
and CC i
remifentanil NN i
on IN N
the DT N
minimum JJ N
alveolar JJ N
concentration NN N
( ( N
MAC NNP N
) ) N
of IN N
isoflurane NN N
in IN N
the DT N
rat NN p
. . p

A DT N
secondary JJ N
objective NN N
was VBD N
to TO N
assess VB N
the DT N
cardiovascular NN N
and CC N
respiratory JJ N
effects NNS N
of IN N
the DT N
two CD N
opioid JJ N
drugs NNS N
. . N

ANIMAL NNP N
POPULATION NNP N
Thirty-seven NNP p
male NN p
Wistar NNP p
rats NNS p
were VBD N
randomly RB N
allocated VBN N
to TO N
one CD N
of IN N
six CD N
treatment NN N
groups NNS N
. . N

MATERIAL NNP N
AND NNP N
METHODS NNP N
For IN N
all DT N
treatment NN N
groups NNS N
anaesthesia NN N
was VBD N
induced VBN N
with IN N
5 CD N
% NN N
isoflurane NN i
in IN i
oxygen NN i
using VBG N
an DT N
induction NN N
chamber NN N
. . N

A DT N
14-gauge JJ N
catheter NN N
was VBD N
used VBN N
for IN N
endotracheal JJ N
intubation NN N
, , N
and CC N
anaesthesia NN N
was VBD N
maintained VBN N
with IN N
isoflurane NN N
delivered VBN N
in IN N
oxygen NN N
via IN N
a DT N
T-piece NNP N
breathing NN N
system NN N
. . N

A DT N
baseline JJ N
determination NN N
of IN N
the DT N
minimum JJ N
alveolar JJ N
concentration NN N
of IN N
isoflurane NN N
( ( N
MACISO NNP N
) ) N
was VBD N
made VBN N
for IN N
each DT N
animal NN N
. . N

Fentanyl NNP i
( ( N
15 CD N
, , N
30 CD N
, , N
60 CD N
micro NN N
g JJ N
kg-1 JJ N
hour-1 NN N
) ) N
or CC N
remifentanil NN i
( ( N
60 CD N
, , N
120 CD N
, , N
240 CD N
micro NN N
g JJ N
kg-1 JJ N
hour-1 NN N
) ) N
were VBD N
infused VBN N
intravenously RB N
into IN N
a DT N
previously RB N
cannulated VBN N
tail NN N
vein NN N
. . N

Thirty NNP N
minutes NNS N
after IN N
the DT N
infusion NN N
started VBD N
, , N
a DT N
second JJ N
MACISO NNP N
( ( N
MACISO+drug NNP N
) ) N
was VBD N
determined VBN N
. . N

The DT N
carotid NN N
artery NN N
was VBD N
cannulated VBN N
to TO N
monitor VB N
the DT N
arterial JJ o
pressure NN o
and CC N
to TO N
take VB N
samples NNS N
for IN N
arterial JJ o
gas NN o
measurements NNS o
. . o

Cardiovascular NNP o
( ( o
heart NN o
rate NN o
and CC o
arterial JJ o
pressure NN o
) ) o
and CC o
respiratory NN o
( ( o
respiratory JJ o
rate NN o
and CC o
presence/absence NN o
of IN o
apnoea NN o
) ) o
effects NNS o
after IN N
opioid JJ N
infusion NN N
were VBD N
also RB N
recorded VBN N
. . N

RESULTS NNP N
Fentanyl NNP i
( ( N
15 CD N
, , N
30 CD N
, , N
60 CD N
micro NN N
g JJ N
kg-1 JJ N
hour-1 NN N
) ) N
and CC N
remifentanil NN i
( ( N
60 CD N
, , N
120 CD N
, , N
240 CD N
micro NN N
g JJ N
kg-1 JJ N
hour-1 NN N
) ) N
similarly RB N
reduced VBN N
isoflurane NN N
MAC NNP N
in IN N
a DT N
dose-dependent JJ N
fashion NN N
: : N
by IN N
10 CD N
% NN N
at IN N
lower JJR N
doses NNS N
, , N
25 CD N
% NN N
at IN N
medium NN N
doses NNS N
and CC N
by IN N
60 CD N
% NN N
at IN N
higher JJR N
doses NNS N
of IN N
both DT N
the DT N
drugs NNS N
. . N

Both DT N
opioids NNS N
reduced VBD N
the DT N
respiratory NN N
rate NN N
in IN N
a DT N
similar JJ N
way NN N
for IN N
all DT N
doses NNS N
tested VBN N
. . N

No DT N
episodes NNS N
of IN N
apnoea NN N
were VBD N
recorded VBN N
in IN N
the DT N
remifentanil NN i
groups NNS N
, , N
while IN N
administration NN N
of IN N
fentanyl NN N
resulted VBN N
in IN N
apnoea NN N
in IN N
three CD N
animals NNS N
( ( N
one CD N
at IN N
each DT N
dose JJ N
level NN N
) ) N
. . N

The DT N
effects NNS N
on IN N
the DT N
cardiovascular JJ N
system NN N
were VBD N
similar JJ N
with IN N
both DT N
drugs NNS N
. . N

CONCLUSIONS NNP N
We PRP N
conclude VBP N
that IN N
the DT N
intraoperative JJ N
use NN N
of IN N
remifentanil NN i
in IN N
the DT N
rat NN N
reduces VBZ N
the DT N
MAC NNP N
of IN N
isoflurane NN N
, , N
and CC N
that IN N
this DT N
anaesthetic JJ N
sparing NN N
effect NN N
is VBZ N
dose-dependent JJ N
and CC N
similar JJ N
to TO N
that DT N
produced VBN N
by IN N
fentanyl NN N
at IN N
the DT N
doses NNS N
tested VBN N
. . N

CLINICAL JJ N
RELEVANCE NNP N
The DT N
use NN N
of IN N
remifentanil NN i
during IN N
inhalant JJ N
anaesthesia NN N
in IN N
the DT N
rat NN N
can MD N
be VB N
considered VBN N
an DT N
intravenous JJ N
alternative NN N
to TO N
fentanyl VB i
, , N
providing VBG N
similar JJ N
reduction NN N
in IN N
isoflurane NN N
requirements NNS N
. . N

Due NNP N
to TO N
its PRP$ N
rapid JJ N
offset NN N
, , N
it PRP N
is VBZ N
recommended VBN N
that IN N
alternative JJ N
pain NN N
relief NN N
be VB N
instituted VBN N
before IN N
it PRP N
is VBZ N
discontinued VBN N
. . N

-DOCSTART- -12045163- O O

Prospective JJ N
study NN N
of IN N
C-reactive NNP o
protein NN o
, , o
homocysteine NN o
, , o
and CC o
plasma VB o
lipid JJ o
levels NNS o
as IN N
predictors NNS N
of IN N
sudden JJ N
cardiac JJ N
death NN N
. . N

BACKGROUND NNP N
Sudden NNP o
cardiac JJ o
death NN o
( ( o
SCD NNP o
) ) o
is VBZ N
an DT N
important JJ N
cause NN N
of IN N
mortality NN N
even RB N
among IN N
apparently RB N
healthy JJ N
populations NNS N
. . N

However RB N
, , N
our PRP$ N
ability NN N
to TO N
identify VB N
those DT N
at IN N
risk NN N
for IN N
SCD NNP N
in IN N
the DT N
general JJ N
population NN N
is VBZ N
poor JJ N
, , N
and CC N
more RBR N
specific JJ N
markers NNS N
are VBP N
needed VBN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
To TO N
compare VB N
and CC N
contrast VB N
the DT N
relative JJ N
importance NN N
of IN N
C-reactive JJ o
protein NN o
( ( o
CRP NNP o
) ) o
, , o
homocysteine NN o
, , o
and CC o
lipids NNS o
as IN N
long-term JJ N
predictors NNS N
of IN N
SCD NNP N
, , N
we PRP N
performed VBD N
a DT N
prospective JJ N
, , N
nested JJ N
, , N
case-control JJ N
analysis NN N
involving VBG N
97 CD p
cases NNS p
of IN p
SCD NNP p
among IN p
apparently RB p
healthy JJ p
men NNS p
enrolled VBN p
in IN p
the DT p
Physician NNP p
's POS p
Health NNP p
Study NNP p
. . p

Of IN N
these DT N
plasma JJ N
markers NNS N
measured VBD N
, , N
only RB N
baseline JJ N
CRP NNP o
levels NNS o
were VBD N
significantly RB N
associated VBN N
with IN N
the DT N
risk NN N
of IN N
SCD NNP N
over IN N
the DT N
ensuing VBG N
17 CD N
years NNS N
of IN N
follow-up NN N
( ( N
P NNP N
for IN N
trend=0.001 NN N
) ) N
. . N

The DT N
increase NN N
in IN N
risk NN N
associated VBN N
with IN N
CRP NNP o
levels NNS o
was VBD N
primarily RB N
seen VBN N
among IN N
men NNS N
in IN N
the DT N
highest JJS N
quartile NN N
, , N
who WP N
were VBD N
at IN N
a DT N
2.78-fold JJ N
increased JJ N
risk NN N
of IN N
SCD NNP o
( ( N
95 CD N
% NN N
CI NNP N
1.35 CD N
to TO N
5.72 CD N
) ) N
compared VBN N
with IN N
men NNS N
in IN N
the DT N
lowest JJS N
quartile NN N
. . N

These DT N
results NNS N
were VBD N
not RB N
significantly RB N
altered VBN N
in IN N
analyses NNS N
that WDT N
( ( N
in IN N
addition NN N
to TO N
the DT N
matching JJ N
variables NNS N
of IN N
age NN N
and CC N
smoking NN N
status NN N
) ) N
controlled VBD N
for IN N
lipid JJ o
parameters NNS o
, , o
homocysteine NN o
, , o
and CC o
multiple JJ o
cardiac JJ o
risk NN o
factors NNS o
( ( N
relative JJ N
risk NN N
for IN N
highest JJS N
versus NN N
lowest JJS N
quartile NN N
2.65 CD N
, , N
95 CD N
% NN N
CI NNP N
0.79 CD N
to TO N
8.83 CD N
; : N
P NNP N
for IN N
trend=0.03 NN N
) ) N
. . N

In IN N
contrast NN N
to TO N
the DT N
positive JJ N
relationship NN N
observed VBD N
for IN N
CRP NNP i
, , N
neither DT N
homocysteine NN N
nor CC N
lipid JJ N
levels NNS N
were VBD N
significantly RB N
associated VBN N
with IN N
risk NN N
of IN N
SCD NNP o
. . o

CONCLUSIONS NNP N
These DT N
prospective JJ N
data NNS N
suggest VBP N
that IN N
CRP NNP N
levels NNS N
may MD N
be VB N
useful JJ N
in IN N
identifying VBG N
apparently RB p
healthy JJ p
men NNS p
who WP p
are VBP p
at IN p
an DT p
increased VBN p
long-term JJ o
risk NN o
of IN o
SCD NNP o
. . o

-DOCSTART- -22185349- O O

Non-verbal JJ i
communication NN i
of IN i
compassion NN i
: : i
measuring NN N
psychophysiologic JJ N
effects NNS N
. . N

BACKGROUND NNP N
Calm NNP N
, , N
compassionate NN N
clinicians NNS N
comfort VBP N
others NNS N
. . N

To TO N
evaluate VB N
the DT N
direct JJ N
psychophysiologic JJ N
benefits NNS N
of IN N
non-verbal JJ i
communication NN i
of IN i
compassion NN i
( ( i
NVCC NNP i
) ) i
, , N
it PRP N
is VBZ N
important JJ N
to TO N
minimize VB N
the DT N
effect NN N
of IN N
subjects NNS N
' POS N
expectation NN N
. . N

This DT N
preliminary JJ N
study NN N
was VBD N
designed VBN N
to TO N
a DT N
) ) N
test NN N
the DT N
feasibility NN N
of IN N
two CD N
strategies NNS N
for IN N
maintaining VBG N
subject JJ N
blinding VBG N
to TO N
non-verbal JJ i
communication NN i
of IN i
compassion NN i
( ( i
NVCC NNP i
) ) i
, , N
and CC N
b NN N
) ) N
determine NN N
whether IN N
blinded JJ N
subjects NNS N
would MD N
experience VB N
psychophysiologic JJ N
effects NNS N
from IN N
NVCC NNP N
. . N

METHODS NNP N
Subjects NNPS p
were VBD p
healthy JJ p
volunteers NNS p
who WP p
were VBD p
told VBN p
the DT p
study NN p
was VBD p
evaluating VBG p
the DT p
effect NN p
of IN p
time NN p
and CC p
touch NN p
on IN p
the DT p
autonomic JJ p
nervous JJ p
system NN p
. . p

The DT p
practitioner NN p
had VBD p
more JJR p
than IN p
10 CD p
years NNS p
' POS p
experience NN p
with IN p
loving-kindness JJ i
meditation NN i
( ( p
LKM NNP p
) ) p
, , p
a DT p
form NN p
of IN p
NVCC NNP i
. . i

Subjects NNS N
completed VBD N
10-point JJ o
visual JJ o
analog NN o
scales NNS o
( ( o
VAS NNP o
) ) o
for IN o
stress NN o
, , o
relaxation NN o
, , o
and CC o
peacefulness NN o
before IN N
and CC N
after IN N
LKM NNP N
. . N

To TO N
assess VB N
physiologic JJ o
effects NNS o
, , N
practitioners NNS N
and CC N
subjects NNS N
wore VBP N
cardiorespiratory JJ o
monitors NNS o
to TO o
assess VB o
respiratory JJ o
rate NN o
( ( o
RR NNP o
) ) o
, , o
heart NN o
rate NN o
( ( o
HR NNP o
) ) o
and CC o
heart NN o
rate NN o
variability NN o
( ( o
HRV NNP o
) ) o
throughout IN N
the DT N
4 CD N
10-minute JJ N
study NN N
periods NNS N
: : N
Baseline NNP N
( ( N
both DT N
practitioner NN i
and CC i
subjects NNS i
read VBP i
neutral JJ i
material NN i
) ) i
; : i
non-tactile-LKM JJ N
( ( i
subjects NNS i
read VBP i
while IN i
the DT i
practitioner NN i
practiced VBD i
LKM NNP i
while IN i
pretending VBG i
to TO i
read VB i
) ) i
; : i
tactile-LKM JJ N
( ( i
subjects NNS i
rested VBN i
while IN i
the DT i
practitioner NN i
practiced VBD i
LKM NNP i
while IN i
lightly RB i
touching VBG i
the DT i
subject NN i
on IN i
arms NNS i
, , i
shoulders NNS i
, , i
hands NNS i
, , i
feet NNS i
, , i
and CC i
legs NNS i
) ) i
; : i
Post-Intervention JJ N
Rest NNP N
( ( i
subjects NNS i
rested VBN i
; : i
the DT i
practitioner NN i
read NN i
) ) i
. . N

To TO N
assess VB N
blinding NN N
, , N
subjects NNS N
were VBD N
asked VBN N
after IN N
the DT N
interventions NNS N
what WP N
the DT N
practitioner NN N
was VBD N
doing VBG N
during IN N
each DT N
period NN N
( ( N
reading NN N
, , N
touch NN N
, , N
or CC N
something NN N
else RB N
) ) N
. . N

RESULTS JJ N
Subjects NNPS p
' POS p
mean JJ p
age NN p
was VBD p
43.6 CD p
years NNS p
; : p
all DT p
were VBD p
women NNS p
. . p

Blinding NNP N
was VBD N
maintained VBN N
and CC N
the DT N
practitioner NN N
was VBD N
able JJ N
to TO N
maintain VB N
meditation NN o
for IN N
both DT N
tactile JJ N
and CC N
non-tactile JJ N
LKM NNP N
interventions NNS N
as IN N
reflected VBN N
in IN N
significantly RB N
reduced VBN N
RR NNP o
. . o

Despite IN N
blinding NN N
, , N
subjects NNS N
' POS N
VAS NNP o
scores NNS o
improved VBN N
from IN N
baseline NN N
to TO N
post-intervention NN N
for IN N
stress NN o
( ( N
5.5 CD N
vs. FW N
2.2 CD N
) ) N
, , N
relaxation NN o
( ( N
3.8 CD N
vs. FW N
8.8 CD N
) ) N
and CC N
peacefulness NN o
( ( N
3.8 CD N
vs. FW N
9.0 CD N
, , N
P NNP N
< VBZ N
0.05 CD N
for IN N
all DT N
comparisons NNS N
) ) N
. . N

Subjects NNS N
also RB N
had VBD N
significant JJ N
reductions NNS N
in IN N
RR NNP o
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
and CC N
improved VBN o
HRV NNP o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
with IN N
both DT N
tactile JJ N
and CC N
non-tactile JJ N
LKM NNP N
. . N

CONCLUSION NNP N
It PRP N
is VBZ N
possible JJ N
to TO N
test VB N
the DT N
effects NNS N
of IN N
LKM NNP N
with IN N
tactile JJ N
and CC N
non-tactile JJ N
blinding NN N
strategies NNS N
; : N
even RB N
with IN N
blinding VBG N
in IN N
this DT N
small JJ N
preliminary JJ N
study NN N
, , N
subjects NNS N
reported VBD N
significant JJ N
improvements NNS N
in IN N
well-being NN N
which WDT N
were VBD N
reflected VBN N
in IN N
objective JJ N
physiologic JJ N
measures NNS N
of IN N
autonomic JJ N
activity NN N
. . N

Extending VBG N
compassion NN N
is VBZ N
not RB N
only RB N
good JJ N
care NN N
; : N
it PRP N
may MD N
also RB N
be VB N
good JJ N
medicine NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
NUMBER NNP N
US NNP N
National NNP N
ClinicalTrials.gov NNP N
registration NN N
number NN N
, , N
NCT01428674 NNP N
. . N

-DOCSTART- -21126245- O O

Intervention NN i
targeting VBG N
development NN N
of IN N
socially RB N
synchronous JJ N
engagement NN N
in IN N
toddlers NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Social NNP N
and CC N
communication NN N
impairments NNS N
are VBP N
core JJ N
deficits NNS N
and CC N
prognostic JJ N
indicators NNS N
of IN N
autism NN N
. . N

We PRP N
evaluated VBD N
the DT N
impact NN N
of IN N
supplementing VBG N
a DT N
comprehensive JJ i
intervention NN i
with IN N
a DT N
curriculum NN N
targeting VBG N
socially RB N
synchronous JJ N
behavior NN N
on IN N
social JJ N
outcomes NNS N
of IN N
toddlers NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
) ) p
. . p

METHODS NNP N
Fifty NNP p
toddlers NNS p
with IN p
ASD NNP p
, , p
ages VBZ p
21 CD p
to TO p
33 CD p
months NNS p
, , N
were VBD N
randomized VBN N
to TO N
one CD N
of IN N
two CD N
six-month JJ N
interventions NNS N
: : N
Interpersonal NNP i
Synchrony NNP i
or CC N
Non-Interpersonal JJ i
Synchrony NNP i
. . i

The DT N
interventions NNS N
provided VBD N
identical JJ N
intensity NN N
( ( N
10 CD N
hours NNS N
per IN N
week NN N
in IN N
classroom NN N
) ) N
, , N
student-to-teacher JJ N
ratio NN N
, , N
schedule NN N
, , N
home-based JJ N
parent NN N
training NN N
( ( N
1.5 CD N
hours NNS N
per IN N
month NN N
) ) N
, , N
parent JJ N
education NN N
( ( N
38 CD N
hours NNS N
) ) N
, , N
and CC N
instructional JJ N
strategies NNS N
, , N
except IN N
the DT N
Interpersonal NNP N
Synchrony NNP N
condition NN N
provided VBD N
a DT N
supplementary JJ N
curriculum NN N
targeting VBG N
socially RB N
engaged VBN N
imitation NN N
, , N
joint JJ N
attention NN N
, , N
and CC N
affect JJ N
sharing NN N
; : N
measures NNS N
of IN N
these DT N
were VBD N
primary JJ N
outcomes NNS N
. . N

Assessments NNS N
were VBD N
conducted VBN N
pre-intervention NN N
, , N
immediately RB N
post-intervention NN N
, , N
and CC N
, , N
to TO N
assess VB N
maintenance NN N
, , N
at IN N
six-month JJ N
follow-up NN N
. . N

Random NNP N
effects NNS N
models NNS N
were VBD N
used VBN N
to TO N
examine VB N
differences NNS N
between IN N
groups NNS N
over IN N
time NN N
. . N

Secondary JJ N
analyses NNS N
examined VBD N
gains NNS o
in IN o
expressive JJ o
language NN o
and CC o
nonverbal JJ o
cognition NN o
, , N
and CC N
time NN o
effects NNS o
during IN N
the DT N
intervention NN N
and CC N
follow-up JJ N
periods NNS N
. . N

RESULTS VB N
A DT N
significant JJ N
treatment NN N
effect NN N
was VBD N
found VBN N
for IN N
socially RB N
engaged VBN N
imitation NN N
( ( N
p JJ N
= NNP N
.02 NNP N
) ) N
, , N
with IN N
more JJR N
than IN N
doubling VBG N
( ( N
17 CD N
% NN N
to TO N
42 CD N
% NN N
) ) N
of IN N
imitated JJ N
acts NNS N
paired VBN N
with IN N
eye NN N
contact NN N
in IN N
the DT N
Interpersonal NNP N
Synchrony NNP N
group NN N
after IN N
the DT N
intervention NN N
. . N

This DT N
skill NN N
was VBD N
generalized VBN N
to TO N
unfamiliar VB N
contexts NN N
and CC N
maintained VBD N
through IN N
follow-up NN N
. . N

Similar JJ N
gains NNS N
were VBD N
observed VBN N
for IN N
initiation NN N
of IN N
joint JJ o
attention NN o
and CC N
shared VBD N
positive JJ N
affect NN N
, , N
but CC N
between-group JJ N
differences NNS N
did VBD N
not RB N
reach VB N
statistical JJ N
significance NN N
. . N

A DT N
significant JJ N
time NN N
effect NN N
was VBD N
found VBN N
for IN N
all DT N
outcomes NNS N
( ( N
p JJ N
< NNP N
.001 NNP N
) ) N
; : N
greatest JJS N
change NN N
occurred VBD N
during IN N
the DT N
intervention NN N
period NN N
, , N
particularly RB N
in IN N
the DT N
Interpersonal NNP N
Synchrony NNP N
group NN N
. . N

CONCLUSIONS NNP N
This DT N
is VBZ N
the DT N
first JJ N
ASD NNP N
randomized VBN N
trial NN N
involving VBG N
toddlers NNS p
to TO N
identify VB N
an DT N
active JJ N
ingredient NN N
for IN N
enhancing VBG N
socially RB N
engaged VBN N
imitation NN N
. . N

Adding VBG N
social JJ N
engagement JJ N
targets NNS N
to TO N
intervention VB N
improves NNS N
short-term JJ N
outcome NN N
at IN N
no DT N
additional JJ N
cost NN N
to TO N
the DT N
intervention NN N
. . N

The DT N
social JJ N
, , N
language NN N
, , N
and CC N
cognitive JJ N
gains NNS N
in IN N
our PRP$ N
participants NNS N
provide VBP N
evidence NN N
for IN N
plasticity NN N
of IN N
these DT N
developmental JJ N
systems NNS N
in IN N
toddlers NNS p
with IN p
ASD NNP p
. . p

http NN N
: : N
//www.clinicaltrials.gov/ct2/show/NCT00106210 NN N
? . N
term NN N
= NNP N
landa NN N
& CC N
rank NN N
= NN N
3 CD N
. . N

-DOCSTART- -3690941- O O

The DT N
additive JJ N
analgesic JJ N
efficacy NN N
of IN N
acetaminophen NN i
, , N
1000 CD N
mg NN N
, , N
and CC N
codeine NN i
, , N
60 CD N
mg NN N
, , N
in IN N
dental JJ p
pain NN p
. . p

In IN N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
single-dose JJ N
trial NN N
the DT N
analgesic JJ N
contribution NN N
of IN N
acetaminophen NN i
, , i
1000 CD i
mg NN i
, , i
and CC i
codeine NN i
, , i
60 CD i
mg NN i
, , N
was VBD N
determined VBN N
. . N

The DT N
study NN N
was VBD N
a DT N
2 CD N
X NN N
2 CD N
factorial JJ N
experiment NN N
in IN N
which WDT N
120 CD p
patients NNS p
suffering VBG p
from IN p
pain NN p
as IN p
a DT p
result NN p
of IN p
oral JJ p
surgery NN p
rated VBD N
their PRP$ N
pain NN o
intensity NN o
and CC o
pain NN o
relief NN o
for IN N
up IN N
to TO N
5 CD N
hours NNS N
after IN N
a DT N
single JJ N
dose NN N
of IN N
one CD N
of IN N
: : N
1000 CD N
mg NN N
acetaminophen NN i
, , N
60 CD N
mg NN N
codeine NN i
, , N
1000 CD N
mg NN N
acetaminophen NN i
plus CC i
60 CD i
mg NN i
codeine NN i
, , N
or CC N
placebo NN i
. . i

The DT N
factorial JJ N
analysis NN N
showed VBD N
that IN N
both DT N
1000 CD N
mg NN N
acetaminophen NN i
and CC N
60 CD N
mg NN N
codeine NN i
made VBD N
a DT N
statistically RB N
significant JJ N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
contribution NN N
to TO N
the DT N
analgesic JJ o
effectiveness NN o
of IN o
the DT o
combination NN o
on IN o
all DT o
measures NNS o
of IN o
efficacy NN o
( ( o
sum NN o
of IN o
pain NN o
intensity NN o
differences NNS o
, , o
largest JJS o
pain NN o
intensity NN o
difference NN o
, , o
total JJ o
pain NN o
relief NN o
, , o
largest JJS o
pain NN o
relief NN o
, , o
and CC o
time NN o
to TO o
remedication NN o
) ) o
. . o

The DT N
incidence NN o
of IN o
adverse JJ o
effects NNS o
did VBD N
not RB N
appear VB N
to TO N
differ VB N
among IN N
the DT N
treatments NNS N
, , N
including VBG N
placebo NN i
. . i

-DOCSTART- -18488812- O O

Comparative JJ N
bioavailability NN N
study NN N
with IN N
two CD N
pantoprazole JJ i
delayed-released JJ N
tablet NN N
formulations NNS N
administered VBN N
with IN N
and CC N
without IN N
food NN N
in IN N
healthy JJ p
subjects NNS p
. . p

OBJECTIVE NNP N
To TO N
assess VB N
the DT N
comparative JJ o
bioavailability NN o
of IN N
two CD N
formulations NNS N
( ( i
40 CD i
mg RB i
delayed-released JJ i
[ NNP i
DR NNP i
] NNP i
tablet NN i
; : i
test NN i
and CC i
reference NN i
) ) i
of IN i
pantoprazole NN i
( ( N
CAS NNP N
102625-70-7 CD N
) ) N
in IN N
healthy JJ p
volunteers NNS p
of IN p
both DT p
sexes NNS p
, , N
with IN N
and CC N
without IN N
food NN N
. . N

METHODS NNP N
The DT N
study NN N
was VBD N
conducted VBN N
using VBG N
an DT N
open JJ N
, , N
randomized VBN N
, , N
two-period JJ N
crossover NN N
design NN N
with IN N
a DT N
1-week JJ N
washout NN N
interval NN N
, , N
in IN N
two CD N
groups NNS N
, , N
with IN N
and CC N
without IN N
food NN N
. . N

Plasma NNP N
samples NNS N
were VBD N
obtained VBN N
for IN N
up RB N
to TO N
24 CD N
h NNS N
post NN N
dose NN N
. . N

Plasma NNP N
pantoprazole JJ i
concentrations NNS N
were VBD N
analyzed VBN N
by IN N
liquid NN N
chromatography NN N
coupled VBD N
to TO N
tandem VB N
mass NN N
spectrometry NN N
( ( N
LC-MS-MS NNP N
) ) N
with IN N
positive JJ N
ion NN N
electrospray NN N
ionization NN N
using VBG N
multiple JJ N
reactions NNS N
monitoring NN N
( ( N
MRM NNP N
) ) N
. . N

From IN N
the DT N
pantoprazole NN i
plasma NN N
concentration NN N
vs. FW N
time NN N
curves NNS N
, , N
the DT N
pharmacokinetic JJ N
parameters NNS N
AUC NNP N
( ( N
last JJ N
) ) N
and CC N
C NNP N
( ( N
max NN N
) ) N
were VBD N
obtained VBN N
, , N
with IN N
and CC N
without IN N
food NN N
. . N

RESULTS VB N
The DT N
limit NN o
of IN o
quantification NN o
was VBD N
5 CD N
ng/mL NN N
for IN N
plasma JJ N
pantoprazole JJ N
analysis NN N
. . N

The DT N
geometric JJ o
mean NN o
and CC o
90 CD o
% NN o
confidence NN o
interval JJ o
CI NNP o
of IN o
test/reference NN o
percent NN o
ratios NNS o
were VBD N
, , N
without IN N
and CC N
with IN N
food NN N
, , N
respectively RB N
: : N
104.6540 CD N
% NN N
( ( N
90.8616 CD N
% NN N
-120.5401 NNP N
% NN N
) ) N
and CC N
99.9708 CD N
% NN N
( ( N
90.9987 CD N
% NN N
-109.8275 NNP N
% NN N
) ) N
for IN N
C NNP o
( ( o
max NN o
) ) o
, , N
95.6634 CD N
% NN N
( ( N
85.2675 CD N
% NN N
-107.3267 NNP N
% NN N
) ) N
and CC N
89.3500 CD N
% NN N
( ( N
83.6630 CD N
% NN N
-95.4237 NNP N
% NN N
) ) N
for IN N
AUC NNP N
( ( N
last JJ N
) ) N
. . N

CONCLUSION NNP N
Since IN N
the DT N
90 CD N
% NN N
CI NNP N
for IN N
AUC NNP o
( ( o
last JJ o
) ) o
and CC N
C NNP o
( ( o
max NN o
) ) o
ratios NNS o
were VBD N
within IN N
the DT N
80-125 JJ N
% NN N
interval NN N
proposed VBN N
by IN N
the DT N
US NNP N
FDA NNP N
, , N
it PRP N
was VBD N
concluded VBN N
that IN N
pantoprazole JJ i
40 CD N
mg NN N
DR NNP N
tablet NN N
( ( N
test JJS N
formulation NN N
) ) N
with IN N
and CC N
without IN N
food NN N
was VBD N
bioequivalent NN N
to TO N
the DT N
reference NN N
40 CD N
mg NN N
DR NNP N
tablet NN N
for IN N
both DT N
the DT N
rate NN N
and CC N
extent NN N
of IN N
absorption NN N
. . N

-DOCSTART- -15608043- O O

Randomized VBN N
, , N
double-blind JJ N
, , N
phase JJ N
III NNP N
, , N
controlled VBD N
trial NN N
comparing VBG N
levobupivacaine JJ i
0.25 CD N
% NN N
, , N
ropivacaine VB i
0.25 CD N
% NN N
and CC N
bupivacaine VB i
0.25 CD N
% NN N
by IN N
the DT N
caudal JJ p
route NN p
in IN p
children NNS p
. . p

BACKGROUND IN N
The DT N
rationale NN N
for IN N
replacing VBG N
racemic JJ i
bupivacaine NN i
with IN N
the DT N
s-enantiomers NNS i
levobupivacaine NN i
and CC N
ropivacaine NN i
is VBZ N
to TO N
provide VB N
a DT N
wider JJR N
margin NN N
of IN N
safety NN N
with IN N
the DT N
same JJ N
analgesic JJ o
efficacy NN o
and CC N
less RBR N
postoperative JJ o
motor NN o
block NN o
. . o

In IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
phase JJ N
III NNP N
, , N
controlled VBD N
trial NN N
we PRP N
compared VBN N
the DT N
caudal JJ N
administration NN N
of IN N
levobupivacaine JJ i
0.25 CD N
% NN N
and CC N
ropivacaine VB i
0.25 CD N
% NN N
with IN N
bupivacaine JJ i
0.25 CD N
% NN N
in IN N
children NNS p
. . p

METHODS NNP N
Ninety-nine JJ p
ASA NNP p
I-II NNP p
children NNS p
less JJR p
than IN p
10 CD p
yr JJ p
old JJ p
scheduled VBN p
for IN p
elective JJ p
sub-umbilical JJ p
surgery NN p
were VBD N
randomized VBN N
to TO N
receive VB N
caudal JJ N
block NN N
with IN N
bupivacaine JJ i
0.25 CD N
% NN N
, , N
ropivacaine VB i
0.25 CD N
% NN N
or CC N
levobupivacaine VB i
0.25 CD N
% NN N
. . N

The DT N
primary JJ N
outcome NN N
of IN N
the DT N
study NN N
was VBD N
the DT N
clinical JJ o
efficacy NN o
of IN o
the DT o
caudal JJ o
block NN o
during IN o
the DT o
operation NN o
. . o

Secondary JJ N
outcome NN N
measures NNS N
were VBD N
analgesic JJ o
onset JJ o
time NN o
, , o
pain NN o
relief NN o
after IN o
the DT o
operation NN o
and CC o
residual JJ o
motor NN o
blockade NN o
. . o

RESULTS VB N
The DT N
proportion NN N
of IN N
children NNS N
with IN N
effective JJ N
analgesia NN N
during IN N
the DT N
operation NN N
was VBD N
similar JJ N
among IN N
groups NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
analgesic JJ N
onset NN N
time NN N
of IN N
the DT N
caudal NN N
block NN N
. . N

Bupivacaine NNP N
produced VBD N
a DT N
significant JJ N
incidence NN N
of IN N
residual JJ o
motor NN o
block NN o
compared VBN N
with IN N
levobupivacaine NN N
or CC N
ropivacaine NN N
at IN N
wake-up NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
number NN N
of IN N
patients NNS N
receiving VBG N
rescue NN N
analgesia NN N
after IN N
surgery NN N
. . N

However RB N
, , N
analgesic JJ N
block NN N
lasted VBD N
significantly RB N
longer RBR N
in IN N
patients NNS N
receiving VBG N
bupivacaine NN N
( ( N
P=0.03 NNP N
) ) N
. . N

CONCLUSION NNP N
During IN N
sub-umbilical JJ N
surgery NN N
, , N
caudal JJ N
levobupivacaine NN N
, , N
ropivacaine NN N
and CC N
bupivacaine NN N
provided VBN N
comparable JJ N
analgesic JJ o
efficacy NN o
. . o

Bupivacaine NNP N
produced VBD N
a DT N
higher JJR N
incidence NN o
of IN o
residual JJ o
motor NN o
blockade NN o
and CC N
a DT N
longer RBR N
analgesic JJ o
block NN o
than IN N
ropivacaine NN N
and CC N
levobupivacaine NN N
. . N

-DOCSTART- -9269786- O O

Association NNP N
of IN N
PML-RAR NNP N
alpha JJ N
fusion NN N
mRNA NN N
type NN N
with IN N
pretreatment JJ N
hematologic JJ o
characteristics NNS o
but CC N
not RB N
treatment NN N
outcome NN N
in IN N
acute JJ p
promyelocytic JJ p
leukemia NN p
: : p
an DT N
intergroup NN N
molecular NN N
study NN N
. . N

In IN N
each DT N
case NN N
of IN N
acute JJ p
promyelocytic JJ p
leukemia NN p
( ( p
APL NNP p
) ) p
one CD N
of IN N
three CD N
PML-RAR JJ N
alpha NN N
mRNA NN N
types NNS N
is VBZ N
produced VBN N
, , N
depending VBG N
on IN N
the DT N
break/fusion NN N
site NN N
in IN N
the DT N
PML NNP N
gene NN N
that WDT N
is VBZ N
linked VBN N
to TO N
a DT N
common JJ N
RAR NNP N
alpha JJ N
gene NN N
segment NN N
: : N
a DT N
short JJ N
( ( N
S NNP N
) ) N
-form NN N
type NN N
, , N
PML NNP N
exon VBZ N
3 CD N
RAR NNP N
alpha NN N
exon VBZ N
3 CD N
; : N
a DT N
long JJ N
( ( N
L NNP N
) ) N
-form NN N
type NN N
, , N
PML NNP N
exon VBZ N
6 CD N
RAR NNP N
alpha NN N
exon VBZ N
3 CD N
; : N
or CC N
a DT N
variable JJ N
( ( N
V NNP N
) ) N
-form NN N
type NN N
, , N
variably RB N
deleted VBD N
PML NNP N
exon VBD N
6 CD N
RAR NNP N
alpha NN N
exon VBD N
3 CD N
. . N

We PRP N
evaluated VBD N
whether IN N
PML-RAR NNP N
alpha NN N
mRNA NN N
type NN N
is VBZ N
associated VBN N
with IN N
distinct JJ N
pretreatment JJ N
clinical JJ N
characteristics NNS N
and CC N
therapeutic JJ N
outcome NN N
in IN N
previously RB p
untreated VBN p
adult NN p
APL NNP p
patients NNS p
registered VBD p
to TO p
protocol VB p
INT NNP p
0129 CD p
by IN p
the DT p
Eastern NNP p
Cooperative NNP p
Oncology NNP p
Group NNP p
, , p
the DT p
Southwest NNP p
Oncology NNP p
Group NNP p
, , p
and CC p
the DT p
Cancer NNP p
and CC p
Leukemia NNP p
Group NNP p
B NNP p
. . p

Of IN p
279 CD p
clinically RB p
eligible JJ p
cases NNS p
, , p
230 CD p
were VBD p
molecularly RB i
evaluable JJ i
, , N
and CC N
of IN N
these DT N
, , N
111 CD N
were VBD N
randomized VBN N
to TO N
receive VB i
remission NN i
induction NN i
therapy NN i
with IN i
all-trans NNS i
retinoic JJ i
acid NN i
( ( i
ATRA NNP i
) ) i
and CC N
119 CD N
with IN N
conventional JJ i
chemotherapy NN i
. . i

Nine NNP N
cases NNS N
not RB N
excluded VBN N
by IN N
central JJ N
pathology NN N
review NN N
were VBD N
PML-RAR NNP o
alpha JJ o
negative JJ o
, , N
and CC N
notably RB N
, , N
none NN N
of IN N
five CD N
of IN N
these DT N
cases NNS N
treated VBD N
with IN N
ATRA NNP N
achieved VBD N
complete JJ o
remission NN o
( ( N
CR NNP N
) ) N
. . N

Among IN N
221 CD N
PML-RAR JJ N
alpha-positive JJ N
cases NNS N
, , N
there EX N
were VBD N
82 CD N
S-form JJ N
cases NNS N
( ( N
37 CD N
% NN N
) ) N
, , N
121 CD N
L-form JJ N
cases NNS N
( ( N
55 CD N
% NN N
) ) N
, , N
and CC N
18 CD N
V-form JJ N
cases NNS N
( ( N
8 CD N
% NN N
) ) N
. . N

Before IN N
any DT N
antileukemic JJ N
therapy NN N
, , N
the DT N
S-form NNP N
type NN N
, , N
compared VBN N
with IN N
the DT N
L-form NNP N
type NN N
, , N
was VBD N
associated VBN N
with IN N
higher JJR N
values NNS N
for IN N
the DT N
white JJ o
blood NN o
cell NN o
( ( o
WBC NNP o
) ) o
count NN o
( ( N
median JJ N
2,500/microL CD N
v NN N
1,600/microL CD N
; : N
P NNP N
= NNP N
.009 NNP N
) ) N
, , N
the DT N
percentage NN N
of IN N
blood NN o
blasts NNS o
plus CC o
promyelocytes NNS o
( ( N
median JJ N
29 CD N
% NN N
v JJ N
8.5 CD N
% NN N
; : N
P NNP N
= NNP N
.03 NNP N
) ) N
, , N
and CC N
the DT N
absolute JJ o
blood NN o
blasts NNS o
plus CC o
promyelocytes NNS o
( ( N
884/microL CD N
v RB N
126/microL CD N
; : N
P NNP N
= NNP N
.019 NNP N
) ) N
. . N

Also RB N
, , N
an DT N
increased JJ N
percentage NN N
of IN N
S-form NNP N
versus IN N
L-form NNP N
cases NNS N
had VBD N
the DT N
M3 NNP o
variant NN o
phenotype NN o
, , N
24 CD N
% NN N
v JJ N
12 CD N
% NN N
( ( N
P NNP N
= NNP N
.036 NNP N
) ) N
. . N

There EX N
were VBD N
no DT N
differences NNS N
between IN N
S-form NNP N
and CC N
L-form NNP N
cases NNS N
in IN N
either DT N
CR NNP o
rate NN o
( ( N
79 CD N
% NN N
v JJ N
69 CD N
% NN N
; : N
P NNP N
= NNP N
.14 NNP N
) ) N
or CC N
disease JJ o
free JJ o
survival NN o
distribution NN o
( ( N
multivariate JJ N
analysis NN N
adjusting VBG N
for IN N
the DT N
association NN N
of IN N
S-form NNP N
type NN N
and CC N
higher JJR N
WBC NNP N
count NN N
; : N
P NNP N
= NNP N
.40 NNP N
) ) N
. . N

We PRP N
conclude VBP N
that IN N
the DT N
S-form NNP N
type NN N
is VBZ N
associated VBN N
with IN N
previously-identified JJ N
adverse JJ N
risk NN N
WBC NNP N
parameters NNS N
but CC N
that IN N
the DT N
identification NN N
of IN N
the DT N
S-form NNP N
or CC N
L-form NNP N
type NN N
of IN N
PML-RAR NNP N
alpha NN N
mRNA NN N
, , N
per IN N
se FW N
, , N
does VBZ N
not RB N
predict VB N
clinical JJ N
outcome NN N
or CC N
add VB N
to TO N
the DT N
value NN N
of IN N
an DT N
increased VBN N
WBC NNP N
count NN N
as IN N
a DT N
negative JJ N
prognostic JJ N
indicator NN N
in IN N
APL NNP p
patients NNS p
. . p

-DOCSTART- -18035192- O O

Results NNS N
of IN N
a DT N
phase NN N
III NNP N
, , N
8-week JJ N
, , N
multicenter NN N
, , N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
parallel-group JJ N
clinical JJ N
trial NN N
to TO N
assess VB N
the DT N
effects NNS N
of IN N
amlodipine JJ i
camsylate NN i
versus NN N
amlodipine NN i
besylate NN i
in IN N
Korean JJ p
adults NNS p
with IN p
mild NN p
to TO p
moderate VB p
hypertension NN p
. . p

BACKGROUND NNP N
Amlodipine NNP i
besylate NN i
has VBZ N
been VBN N
used VBN N
in IN N
Korea NNP N
for IN N
the DT N
treatment NN N
of IN N
hypertension NN N
for IN N
> $ N
17 CD N
years NNS N
, , N
with IN N
well-established JJ N
efficacy NN N
and CC N
tolerability NN N
. . N

Amlodipine NNP i
camsylate NN i
is VBZ N
a DT N
newer JJR N
formulation NN N
developed VBD N
for IN N
generic JJ N
use NN N
. . N

It PRP N
has VBZ N
been VBN N
assessed VBN N
in IN N
terms NNS N
of IN N
physical JJ N
stability NN N
and CC N
pharmacokinetic JJ N
and CC N
pharmacodynamic JJ N
properties NNS N
and CC N
been VBN N
found VBN N
to TO N
be VB N
effective JJ N
in IN N
lowering VBG N
blood NN N
pressure NN N
in IN N
preclinical JJ N
and CC N
Phase NNP N
I PRP N
and CC N
II NNP N
trials NNS N
. . N

However RB N
, , N
to TO N
date NN N
, , N
no DT N
studies NNS N
have VBP N
compared VBN N
the DT N
clinical JJ N
effectiveness NN N
of IN N
amlodipine JJ i
camsylate NN i
and CC N
amlodipine JJ i
besylate NN i
in IN N
treating VBG N
hypertension NN N
. . N

OBJECTIVE CC N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
determine VB N
the DT N
effectiveness NN o
and CC o
tolerability NN o
of IN N
amlodipine JJ i
camsylate NN i
compared VBN N
with IN N
amlodipine JJ i
besylate NN i
in IN N
Korean JJ p
patients NNS p
with IN p
mild JJ p
to TO p
moderate VB p
hypertension NN p
. . p

METHODS NNP N
This DT N
Phase NNP N
III NNP N
, , N
8-week JJ N
, , N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
parallel-group JJ N
study NN N
was VBD N
conducted VBN N
in IN N
13 CD p
cardiology NN p
centers NNS p
across IN p
the DT p
Republic NNP p
of IN p
Korea NNP p
. . p

Male NNP p
and CC p
female JJ p
Korean JJ p
patients NNS p
aged VBD p
18 CD p
to TO p
75 CD p
years NNS p
having VBG p
uncomplicated JJ p
, , p
mild JJ p
to TO p
moderate VB p
, , p
essential JJ p
hypertension NN p
( ( p
sitting VBG p
diastolic JJ p
blood NN p
pressure NN p
[ NNP p
SiDBP NNP p
] NNP p
90- CD p
< NNP p
110 CD p
mm NN p
Hg NNP p
) ) p
and CC p
receiving VBG p
no DT p
antihypertensives NNS p
in IN p
the DT p
2 CD p
weeks NNS p
before IN p
randomization NN p
were VBD p
eligible JJ p
. . p

Patients NNS N
were VBD N
randomly RB i
assigned VBN i
to TO i
receive VB i
oral JJ i
treatment NN i
with IN i
amlodipine JJ i
camsylate NN i
or CC i
amlodipine JJ i
besylate NN i
. . i

For IN i
the DT i
first JJ i
4 CD i
weeks NNS i
, , i
patients NNS i
received VBD i
amlodipine JJ i
5 CD i
mg NN i
QD NNP i
( ( i
morning NN i
) ) i
. . i

After IN i
4 CD i
weeks NNS i
, , i
if IN i
either DT i
blood NN o
pressure NN o
was VBD i
> JJ i
or CC i
=140/ JJ i
> NN i
or CC i
=90 VB i
mm JJ i
Hg NNP i
or CC i
SiDBP NNP i
had VBD i
not RB i
decreased VBN i
by IN i
> NN i
or CC i
=10 VB i
mm JJ i
Hg NNP i
from IN i
baseline NN i
, , i
the DT i
dose NN i
of IN i
amlodipine NN i
was VBD i
increased VBN i
to TO i
10 CD i
mg NNS i
QD NNP i
for IN i
4 CD i
weeks NNS i
. . i

Trough NNP o
blood NN o
pressure NN o
and CC o
heart NN o
rate NN o
were VBD i
measured VBN i
in IN i
duplicate NN i
with IN i
the DT i
patient NN i
in IN i
the DT i
sitting VBG i
position NN i
at IN i
each DT i
clinic JJ i
visit NN i
( ( i
baseline JJ i
[ NNP i
week NN i
0 CD i
] NN i
and CC i
weeks NNS i
4 CD i
and CC i
8 CD i
of IN i
treatment NN i
) ) i
; : i
mean JJ i
values NNS i
were VBD i
calculated VBN i
and CC i
recorded VBN i
. . i

At IN i
weeks NNS i
4 CD i
and CC i
8 CD i
, , i
tolerability NN o
was VBD i
assessed VBN i
using VBG i
history NN i
taking NN i
and CC i
laboratory NN i
analysis NN i
, , i
and CC i
compliance NN i
was VBD i
assessed VBN i
using VBG i
pill NN i
counts NNS i
. . i

The DT N
primary JJ N
end NN N
point NN N
was VBD N
change NN N
from IN N
baseline NN N
in IN N
SiDBP NNP o
at IN N
week NN N
8 CD N
. . N

Secondary JJ N
end NN N
points NNS N
were VBD N
change NN N
from IN N
baseline NN N
in IN N
sitting VBG o
systolic JJ o
blood NN o
pressure NN o
( ( N
SiSBP NNP N
) ) N
at IN N
week NN N
8 CD N
in IN N
the DT N
total JJ N
population NN N
and CC N
in IN N
the DT N
subgroup NN N
of IN N
patients NNS N
who WP N
had VBD N
previously RB N
received VBN N
antihypertensive JJ N
treatment NN N
versus IN N
those DT N
who WP N
had VBD N
not RB N
. . N

RESULTS VB N
A DT p
total NN p
of IN p
189 CD p
patients NNS p
were VBD p
enrolled VBN p
( ( p
mean JJ p
age NN p
, , p
53 CD p
years NNS p
; : p
105 CD p
women NNS p
, , p
84 CD p
men NNS p
; : p
mean VB p
body NN p
weight NN p
, , p
65.8 CD p
kg NN p
) ) p
. . p

One CD N
patient NN N
in IN N
the DT N
amlodipine JJ i
camsylate NN i
group NN N
dropped VBD N
out IN N
of IN N
the DT N
study NN N
at IN N
week NN N
0 CD N
of IN N
treatment NN N
( ( N
this DT N
patient NN N
did VBD N
not RB N
use VB N
any DT N
study NN N
medication NN N
) ) N
and CC N
was VBD N
excluded VBN N
from IN N
the DT N
modified VBN N
intent-to-treat NN N
( ( N
ITT NNP N
) ) N
analysis NN N
. . N

Thus RB N
, , N
188 CD p
patients NNS p
were VBD p
treated VBN p
and CC p
included VBN p
in IN p
the DT p
ITT NNP p
analysis NN p
( ( N
94 CD N
patients NNS N
per IN N
treatment NN N
group NN N
; : N
ITT NNP N
analysis NN N
) ) N
; : N
161 CD N
patients NNS N
were VBD N
included VBN N
in IN N
the DT N
perprotocol NN N
( ( N
PP NNP N
) ) N
analysis NN N
( ( N
n JJ N
= VBP N
80 CD N
for IN N
amlodipine NN i
camsylate NN i
, , N
n JJ N
= VBP N
81 CD N
for IN N
amlodipine JJ i
besylate NN i
) ) i
( ( N
14 CD N
patients NNS N
in IN N
the DT N
amlodipine JJ i
camsylate NN i
group NN N
and CC N
13 CD N
patients NNS N
in IN N
the DT N
amlodipine JJ i
besylate NN i
group NN N
were VBD N
excluded VBN N
from IN N
the DT N
PP NNP N
analysis NN N
due JJ N
to TO N
consistent JJ N
withdrawal NN N
or CC N
protocol JJ N
violation NN N
) ) N
. . N

Mean NNP o
( ( o
SD NNP o
) ) o
SiSBP NNP o
and CC o
SiDBP NNP o
were VBD N
significantly RB N
decreased VBN N
from IN N
baseline NN N
in IN N
both DT N
groups NNS N
( ( i
amlodipine JJ i
camsylate NN i
, , N
from IN N
146.7 CD N
[ $ N
12.3 CD N
] NNP N
/96.6 NNP N
[ VBD N
5.4 CD N
] NN N
to TO N
127.9 CD N
[ NNS N
14.8 CD N
] JJ N
/83.4 NNP N
[ NNP N
7.7 CD N
] NNP N
mm NN N
Hg NNP N
[ NNP N
both DT N
, , N
P NNP N
< VBZ N
0.001 CD N
] NN N
; : N
amlodipine JJ i
besylate NN i
, , N
from IN N
146.8 CD N
[ $ N
12.8 CD N
] NNP N
/96.7 NNP N
[ VBD N
5.1 CD N
] NN N
to TO N
128.0 CD N
[ NNS N
10.1 CD N
] JJ N
/83.8 NNP N
[ NNP N
7.5 CD N
] NNP N
mm NN N
Hg NNP N
[ NNP N
both DT N
, , N
P NNP N
< VBZ N
0.001 CD N
] NN N
) ) N
. . N

The DT N
differences NNS N
in IN N
SiSBP/SiDBP NNP o
between IN N
the DT N
2 CD N
groups NNS N
at IN N
week NN N
8 CD N
were VBD N
not RB N
significant JJ N
. . N

The DT N
SiDBP NNP o
response NN o
rates NNS o
in IN N
the DT N
subgroups NNS N
that WDT N
had VBD N
and CC N
had VBD N
not RB N
been VBN N
previously RB N
treated VBN N
with IN N
antihypertensives NNS N
were VBD N
statistically RB N
similar JJ N
( ( N
56/69 CD N
[ RB N
81.2 CD N
% NN N
] NN N
and CC N
83/92 CD N
[ JJ N
90.2 CD N
% NN N
] NN N
, , N
respectively RB N
) ) N
. . N

The DT N
prevalences NNS N
of IN N
clinical JJ o
adverse JJ o
events NNS o
( ( N
AEs NNP N
) ) N
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
2 CD N
treatment NN N
groups NNS N
( ( i
amlodipine JJ i
camsylate NN i
, , N
27.3 CD N
% NN N
; : N
amlodipine JJ i
besylate NN i
, , N
28.7 CD N
% NN N
) ) N
. . N

The DT N
most RBS N
common JJ N
AEs NNP N
were VBD N
dizziness JJ o
and CC o
dyspnea NN o
( ( N
both DT N
in IN N
3/94 CD N
[ JJ N
3.2 CD N
% NN N
] NN N
and CC N
1/94 CD N
[ JJ N
1.1 CD N
% NN N
] JJ N
patients NNS N
who WP N
received VBD N
amlodipine JJ i
camsylate NN i
and CC N
amlodipine NN i
besylate NN i
, , N
respectively RB N
) ) N
. . N

CONCLUSION VB N
The DT N
effectiveness NN N
and CC N
tolerability NN N
of IN N
amlodipine JJ i
camsylate NN i
were VBD N
not RB N
significantly RB N
different JJ N
from IN N
those DT N
of IN N
amlodipine JJ i
besylate NN i
in IN N
these DT N
Korean JJ p
adults NNS p
with IN p
mild NN p
to TO p
moderate VB p
hypertension NN p
. . p

-DOCSTART- -2182521- O O

The DT N
clinician NN N
's POS N
decision NN N
of IN N
whether IN N
CHOP NNP i
chemotherapy NN i
should MD N
be VB N
standard JJ N
therapy NN N
for IN N
treatment NN o
of IN o
patients NNS o
with IN o
diffuse NN o
histiocytic JJ o
lymphoma NN o
. . o

-DOCSTART- -19552904- O O

Short-term JJ N
metformin NN i
treatment NN N
for IN N
clomiphene JJ p
citrate-resistant JJ p
women NNS p
with IN p
polycystic JJ p
ovary JJ p
syndrome NN p
. . p

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
a DT N
short-course JJ N
pretreatment NN N
with IN N
metformin NN i
on IN N
hyperandrogenism NN o
, , o
insulin NN o
resistance NN o
, , o
cervical JJ o
scores NNS o
, , o
and CC o
pregnancy NN o
rates NNS o
in IN N
women NNS p
with IN p
clomiphene JJ i
citrate NN i
( ( p
CC NNP p
) ) p
-resistant VBP p
polycystic JJ p
ovary JJ p
syndrome NN p
( ( p
PCOS NNP p
) ) p
. . p

METHODS NNP N
Thirty-seven JJ p
women NNS p
with IN p
CC-resistant JJ p
PCOS NNP p
were VBD p
randomly RB p
assigned VBN p
to TO N
be VB N
pretreated VBN N
with IN N
500 CD N
mg NNS N
of IN N
metformin NN i
or CC i
placebo NN i
3 CD N
times NNS N
per IN N
day NN N
for IN N
2 CD N
cycles NNS N
, , N
and CC N
100 CD N
mg NN N
of IN N
CC NNP i
was VBD N
given VBN N
on IN N
days NNS N
5 CD N
through IN N
9 CD N
of IN N
the DT N
second JJ N
cycle NN N
in IN N
both DT N
groups NNS N
. . N

Luteinizing VBG o
hormone NN o
( ( o
LH NNP o
) ) o
, , o
follicle NN o
stimulating VBG o
hormone NN o
( ( o
FSH NNP o
) ) o
, , o
dehydroepiandrostendione JJ o
sulfate NN o
( ( o
DHEAS NNP o
) ) o
, , o
total JJ o
testosterone NN o
( ( o
T NNP o
) ) o
, , o
glucose JJ o
, , o
and CC o
insulin NN o
levels NNS o
were VBD N
measured VBN N
at IN N
baseline NN N
and CC N
after IN N
the DT N
first JJ N
cycle NN N
, , N
as RB N
well RB N
as IN N
body NN o
mass NN o
index NN o
( ( o
BMI NNP o
) ) o
, , o
cervical JJ o
score NN o
, , o
and CC o
pregnancy NN o
rate NN o
. . o

RESULTS NNP N
After IN N
1 CD N
cycle NN N
, , N
BMI NNP o
, , o
total JJ o
T NNP o
level NN o
, , o
and CC o
percentage NN o
of IN o
participants NNS o
with IN o
insulin NN o
resistance NN o
were VBD N
significantly RB N
decreased VBN N
in IN N
the DT N
metformin NN i
group NN N
, , N
without IN N
any DT N
significant JJ N
decrease NN N
in IN N
LH NNP o
, , o
FSH NNP o
, , o
and CC o
DHEAS NNP o
levels NNS o
; : o
and CC N
in IN N
the DT N
second JJ N
cycle NN N
, , N
CC NNP i
treatment NN N
resulted VBD N
in IN N
a DT N
higher JJR N
ovulation NN o
rate NN o
and CC o
a DT o
thicker NN o
endometrium NN o
in IN N
the DT N
metformin NN i
group NN N
. . N

The DT N
pregnancy NN o
rate NN o
and CC o
cervical JJ o
scores NNS o
were VBD N
also RB N
higher JJR N
in IN N
that DT N
group NN N
. . N

CONCLUSION VB N
The DT N
short-course JJ N
pretreatment NN N
with IN N
metformin NNS i
decreased VBN N
hyperandrogenism NN o
and CC o
insulin NN o
resistance NN o
and CC N
improved JJ N
cervical JJ o
sores NNS o
, , o
ovulation NN o
rate NN o
, , o
and CC o
pregnancy NN o
rate NN o
among IN N
women NNS p
with IN p
CC-resistant JJ p
PCOS NNP p
. . p

-DOCSTART- -24356715- O O

12-week JJ N
, , N
placebo-controlled JJ i
trial NN N
of IN N
add-on JJ N
riluzole NN i
in IN N
the DT N
treatment NN N
of IN N
childhood-onset JJ p
obsessive-compulsive JJ p
disorder NN p
. . p

Many JJ N
children NNS p
with IN p
childhood-onset JJ p
obsessive-compulsive JJ p
disorder NN p
( ( p
OCD NNP p
) ) p
fail VBP N
to TO N
respond VB N
adequately RB N
to TO N
standard VB N
therapies NNS N
. . N

Evidence NN N
from IN N
preclinical JJ N
and CC N
clinical JJ N
studies NNS N
suggests VBZ N
that IN N
the DT N
glutamatergic NN N
neurotransmitter NN N
system NN N
might MD N
be VB N
an DT N
alternative JJ N
treatment NN N
target NN N
. . N

This DT N
study NN N
examined VBD N
the DT N
efficacy NN N
of IN N
riluzole NN i
, , N
a DT N
glutamatergic JJ N
modulator NN N
, , N
as IN N
an DT N
adjunctive JJ N
therapy NN N
for IN N
children NNS p
with IN p
treatment-resistant JJ p
OCD NNP p
. . p

In IN N
a DT N
12-week JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
study NN N
, , N
60 CD p
treatment-resistant JJ p
children NNS p
and CC p
adolescents NNS p
( ( p
mean VB p
age=14.5 RB p
? . p
2.4 CD p
years NNS p
) ) p
, , p
with IN p
moderate JJ p
to TO p
severe VB p
OCD NNP p
( ( p
mean JJ p
Children NNP p
's POS p
Yale-Brown JJ p
Obsessive-Compulsive JJ p
Scale NNP p
( ( p
CY-BOCS NNP p
) ) p
=28.2 NN p
? . p
3.7 CD p
) ) p
, , p
17 CD p
of IN p
whom WP p
also RB p
had VBD p
concomitant JJ p
autism NN p
spectrum NN p
disorder NN p
, , p
were VBD N
randomized VBN N
to TO N
receive VB i
riluzole NN i
( ( i
final JJ i
dose NN i
of IN i
100 CD i
mg/day NN i
) ) i
or CC i
placebo NN i
in IN i
addition NN N
to TO N
the DT N
existing VBG N
treatment NN N
regimen NNS p
. . p

Fifty-nine JJ p
subjects NNS p
completed VBD p
the DT p
randomized JJ N
trial NN N
. . N

Primary JJ N
outcome JJ N
measures NNS N
were VBD N
changes NNS N
on IN N
the DT o
CY-BOCS NNP o
, , o
the DT o
Clinical NNP o
Global NNP o
Impressions NNP o
Scale NNP o
, , o
and CC o
the DT o
Children NNP o
's POS o
Global NNP o
Assessment NNP o
Scale NNP o
. . o

Riluzole NNP N
was VBD N
fairly RB N
well RB o
tolerated VBN o
, , o
although IN N
it PRP N
was VBD N
associated VBN N
with IN N
one CD N
case NN N
of IN N
pancreatitis NN o
and CC o
five CD N
instances NNS N
of IN N
slight JJ N
increases NNS N
in IN N
transaminases NNS o
. . o

All DT N
subjects NNS N
showed VBD N
significant JJ N
reductions NNS N
in IN N
CY-BOCS NNP o
scores NNS o
during IN o
treatment NN N
; : N
however RB N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
placebo NN N
and CC N
riluzole NN N
on IN N
any DT N
of IN N
the DT N
primary JJ N
or CC N
secondary JJ N
outcome NN N
measures NNS N
. . N

The DT N
study NN N
failed VBD N
to TO N
demonstrate VB N
superiority NN N
of IN N
riluzole NN N
over RB N
placebo RB N
as IN N
an DT N
adjunctive JJ N
treatment NN N
for IN p
children NNS p
with IN p
childhood-onset JJ p
OCD NNP p
. . p

However RB N
, , N
future JJ N
studies NNS N
may MD N
show VB N
benefits NNS N
for IN N
less JJR N
treatment-refractory JJ p
children NNS p
with IN p
fewer JJR p
concomitant NN p
medications NNS p
. . p

-DOCSTART- -20697791- O O

Promoting VBG N
imitation NN N
in IN N
young JJ p
children NNS p
with IN p
autism NN p
: : p
a DT N
comparison NN N
of IN N
reciprocal JJ i
imitation NN i
training NN i
and CC N
video NN i
modeling NN i
. . i

The DT N
inability NN N
to TO N
imitate VB N
is VBZ N
a DT N
salient JJ N
diagnostic JJ N
marker NN N
for IN N
autism NN p
. . p

It PRP N
has VBZ N
been VBN N
suggested VBN N
that IN N
for IN N
children NNS p
with IN p
autism NN p
, , N
imitation NN N
may MD N
be VB N
a DT N
prerequisite NN N
skill NN N
that WDT N
can MD N
assist VB N
in IN N
the DT N
development NN N
of IN N
various JJ N
skills NNS N
. . N

Using VBG N
a DT N
multiple JJ N
baseline NN N
design NN N
across IN N
subjects NNS N
, , N
the DT N
purpose NN N
of IN N
this DT N
research NN N
was VBD N
to TO N
determine VB N
if IN N
two CD N
interventions NNS N
, , N
reciprocal JJ i
imitation NN i
training NN i
and CC i
video NN i
modeling NN i
were VBD N
effective JJ N
in IN N
promoting VBG o
imitation NN o
acquisition NN o
in IN N
young JJ N
children NNS N
with IN N
autism NN N
. . N

Six NNP p
boys NNS p
were VBD p
matched VBN p
across IN p
various JJ p
features NNS p
( ( p
i.e. FW p
, , N
age NN p
, , p
language NN p
, , p
autism NN p
severity NN p
) ) p
and CC N
randomly RB N
placed VBN N
in IN N
a DT N
treatment NN N
condition NN N
. . N

Results NNS N
indicated VBD N
that IN N
all DT N
six CD N
participants NNS N
increased VBD N
their PRP$ N
imitation NN o
skills NNS o
to TO N
varying VBG N
degrees NNS N
in IN N
both DT N
conditions NNS N
, , N
and CC N
imitation NN N
maintained VBD N
and CC N
generalized VBD N
at IN N
higher JJR N
than IN N
baseline NN N
levels NNS N
post NN N
treatment NN N
. . N

-DOCSTART- -8378411- O O

Video NNP N
rating NN N
analysis NN N
of IN N
effect NN N
of IN N
maprotiline NN N
in IN N
patients NNS p
with IN p
dementia NN p
and CC p
depression NN p
. . p

In IN N
patients NNS p
with IN p
dementia NN p
and CC p
mild JJ p
depression NN p
( ( p
DSM-III-R NNP p
290.21 CD p
) ) p
, , N
the DT N
effect NN N
of IN N
low JJ N
doses NNS N
of IN N
the DT N
antidepressant JJ N
maprotiline NN i
( ( N
up IN N
to TO N
75 CD N
mg/d NN N
) ) N
was VBD N
examined VBN N
. . N

The DT N
main JJ N
parameter NN N
was VBD N
a DT N
video NN N
rating NN N
of IN N
global JJ N
impression NN N
. . N

The DT N
Mini-Mental JJ o
State NNP o
Examination NNP o
( ( i
MMS NNP i
) ) i
and CC N
the DT N
Geriatric NNP o
Depression NNP o
Scale NNP o
( ( i
GDS NNP i
) ) i
were VBD N
applied VBN N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
maprotiline NN N
on IN N
cognitive JJ N
and CC N
depressive JJ N
symptoms NNS N
. . N

The DT N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
was VBD N
of IN N
eight CD N
weeks NNS N
' POS N
duration NN N
and CC N
included VBD N
127 CD p
patients NNS p
, , N
randomized VBN N
in IN N
two CD N
groups NNS N
. . N

The DT N
antidepressant JJ N
effect NN N
of IN N
maprotiline NN i
was VBD N
reflected VBN N
in IN N
the DT N
GDS NNP N
. . N

There EX N
was VBD N
, , N
however RB N
, , N
no DT N
indication NN N
of IN N
an DT N
effect NN N
of IN N
maprotiline NN N
on IN N
cognitive JJ o
performance NN o
. . o

The DT N
global JJ N
impression NN N
, , N
evaluated VBN N
by IN N
video NN N
rating NN N
, , N
gave VBD N
no DT N
indication NN N
as IN N
to TO N
a DT N
beneficial JJ N
effect NN N
of IN N
the DT N
treatment NN N
. . N

- : N
The DT N
video NN N
analysis NN N
showed VBD N
a DT N
significant JJ N
interrater NN N
reliability NN o
. . o

The DT N
discrepancy NN N
between IN N
the DT N
results NNS N
of IN N
the DT N
video NN N
rating NN N
and CC N
the DT N
GDS NNP N
is VBZ N
discussed VBN N
. . N

- : N
The DT N
results NNS N
confirm VBP N
similar JJ N
findings NNS N
of IN N
other JJ N
authors NNS N
; : N
i.e. NN N
, , N
that IN N
a DT N
sedating VBG N
antidepressant NN N
with IN N
some DT N
anticholinergic JJ N
effects NNS N
can MD N
not RB N
be VB N
expected VBN N
to TO N
improve VB N
cognitive JJ o
functions NNS o
despite IN N
its PRP$ N
antidepressant JJ N
effect NN N
. . N

The DT N
main JJ N
interest NN N
of IN N
this DT N
study NN N
, , N
however RB N
, , N
lies VBZ N
in IN N
its PRP$ N
methodology NN N
( ( N
video JJ N
analysis NN N
) ) N
. . N

-DOCSTART- -1880321- O O

Methotrexate NNP i
in IN N
the DT N
treatment NN N
of IN N
steroid-dependent JJ p
asthma NN p
. . p

A DT N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
crossover NN N
study NN N
was VBD N
designed VBN N
to TO N
compare VB N
steroid JJ o
requirements NNS o
between IN N
placebo NN i
and CC N
methotrexate NN i
( ( N
MTX NNP N
) ) N
treatment NN N
in IN N
subjects NNS p
with IN p
corticosteroid-requiring JJ p
asthma NN p
. . p

Subjects NNS N
began VBD N
with IN N
a DT N
steroid JJ N
taper NN N
and CC N
then RB N
were VBD N
randomized VBN N
to TO N
a DT N
3-month JJ N
trial NN N
of IN N
drug NN N
or CC N
placebo NN i
therapy NN i
. . i

Subjects NNS N
received VBD N
15 CD N
mg NN N
of IN N
MTX NNP i
a DT N
week NN N
or CC N
identical JJ N
placebo NN i
. . i

A DT N
1-month JJ N
washout NN N
period NN N
was VBD N
completed VBN N
before IN N
the DT N
crossover NN N
trial NN N
. . N

Symptom NNP o
scores NNS o
, , o
peak NN o
flow NN o
rates NNS o
, , o
spirometry NN o
, , o
and CC o
beta-agonist JJ o
frequency NN o
were VBD N
closely RB N
monitored VBN N
. . N

Ten CD p
subjects NNS p
completed VBD p
the DT p
study NN p
. . p

The DT N
average JJ N
dose NN N
of IN N
prednisone NN N
during IN N
the DT N
placebo-treatment JJ i
period NN N
was VBD N
11.97 CD N
mg/day NN N
compared VBN N
to TO N
8.37 CD N
mg/day NNS N
while IN N
subjects NNS N
were VBD N
taking VBG N
MTX NNP i
. . i

This DT N
was VBD N
a DT N
30 CD N
% NN N
reduction NN N
in IN N
daily JJ o
steroid JJ o
requirement NN o
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

Symptom JJ o
scores NNS o
and CC o
spirometry NN o
did VBD N
not RB N
differ VB N
between IN N
the DT N
crossover NN N
trials NNS N
, , N
and CC N
overall JJ N
clinical JJ N
status NN N
was VBD N
not RB N
altered VBN N
. . N

Complications NNS o
from IN o
MTX NNP o
were VBD N
mild JJ N
and CC N
included VBD N
anorexia NN o
, , o
alopecia NN o
, , o
and CC o
stomatitis NN o
. . o

All DT N
complications NNS o
resolved VBN N
with IN N
dose JJ N
reduction NN N
or CC N
when WRB N
MTX NNP i
was VBD N
stopped VBN N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
. . N

No DT N
subjects NNS N
withdrew VBD N
from IN N
the DT N
study NN N
because IN N
of IN N
MTX NNP i
complications NNS N
. . N

Low-dose JJ N
MTX NNP i
significantly RB N
reduced VBD N
the DT N
steroid JJ o
requirement NN o
in IN N
this DT N
group NN N
of IN N
subjects NNS p
with IN p
steroid-dependent JJ p
asthma NN p
. . p

This DT N
reduction NN o
in IN o
steroid JJ o
requirement NN o
was VBD N
obtained VBN N
without IN N
altering VBG N
clinical JJ N
status NN N
and CC N
without IN N
significant JJ N
complication NN N
. . N

-DOCSTART- -4615718- O O

[ JJ N
Psychoexperimental NNP N
studies NNS N
on IN N
the DT N
effect NN N
of IN N
a DT N
valepotriate JJ i
combination NN i
as RB p
well RB p
as IN p
the DT p
combined JJ p
effects NNS p
of IN p
valtratum NN i
and CC i
alcohol NN i
] NN i
. . N

-DOCSTART- -15653006- O O

Low-dose JJ N
, , N
vaginally RB N
administered VBN N
estrogens NNS i
may MD N
enhance VB N
local JJ N
benefits NNS N
of IN N
systemic JJ N
therapy NN N
in IN N
the DT N
treatment NN N
of IN N
urogenital JJ p
atrophy NN p
in IN p
postmenopausal JJ p
women NNS p
on IN p
hormone NN p
therapy NN p
. . p

BACKGROUND NNP N
When WRB N
genital JJ N
atrophy NN N
exists NNS N
, , N
systemic JJ i
hormone NN i
therapy NN i
( ( i
HT NNP i
) ) i
has VBZ N
a DT N
timing NN N
until IN N
to TO N
induce VB N
vaginal JJ N
proliferation NN N
and CC N
symptomatic JJ N
relieve NN N
. . N

Thus RB N
, , N
in IN N
order NN N
to TO N
obtain VB N
a DT N
prompt JJ N
improvement NN N
, , N
the DT N
association NN N
of IN N
local JJ N
therapy NN N
acting VBG N
on IN N
the DT N
genital JJ N
epithelium NN N
to TO N
the DT N
systemic JJ N
treatment NN N
should MD N
be VB N
considered VBN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
effects NNS N
of IN N
a DT N
combined JJ N
therapy NN N
consisting NN N
of IN N
vaginal JJ N
estriol NN N
with IN N
transdermal JJ N
17-beta-estradiol JJ N
( ( N
50 CD N
microg/day NN N
) ) N
plus CC N
medroxyprogesterone JJ N
acetate NN N
( ( N
5 CD N
mg/day NN N
) ) N
per IN N
os NN N
in IN N
shortening VBG N
the DT N
period NN N
of IN N
uro-genital JJ N
symptoms NNS N
. . N

SUBJECTS NNP N
AND NNP N
METHODS NNP N
In IN N
a DT N
randomized JJ N
, , N
double JJ N
blind NN N
, , N
controlled VBN N
with IN N
placebo NN i
study NN N
, , N
27 CD p
women NNS p
with IN p
climacteric JJ p
symptoms NNS p
and CC p
atrophic JJ p
vaginitis NN p
were VBD N
treated VBN N
for IN N
4 CD N
months NNS N
with IN N
HT NNP i
plus CC i
vaginal JJ i
estriol NN i
0.5 CD i
mg/day NN i
( ( N
group NN N
E NNP N
) ) N
or CC N
placebo NN i
( ( N
group NN N
P NNP N
) ) N
. . N

Patients NNS N
use VBP N
the DT N
local JJ N
medication NN N
daily RB N
for IN N
the DT N
first JJ N
3 CD N
weeks NNS N
and CC N
twice-weekly JJ N
thereafter NN N
. . N

Before IN N
entering VBG N
in IN N
the DT N
study NN N
, , N
patients NNS N
were VBD N
asked VBN N
about IN N
HT NNP N
and CC N
selected VBN N
for IN N
inclusion NN N
. . N

In IN N
the DT N
first JJ N
visit NN N
, , N
electible JJ N
patients NNS N
after IN N
written VBN N
informed JJ N
consent NN N
were VBD N
randomized VBN N
to TO N
receive VB p
HT NNP i
plus CC i
local JJ i
estriol NN i
or CC p
placebo NN i
. . i

All PDT N
the DT N
subjects NNS N
had VBD N
baseline NN N
studies NNS N
, , N
including VBG N
medical JJ N
history NN N
, , N
physical JJ N
examination NN N
, , N
blood NN N
and CC N
urine JJ N
analysis NN N
. . N

In IN N
order NN N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
local JJ N
treatment NN N
on IN N
urinary JJ N
and CC N
genital JJ N
symptoms NNS N
, , N
a DT N
score NN N
for IN N
genital NN N
, , N
urinary JJ N
and CC N
colposcopic JJ N
complaints NNS N
( ( N
0 CD N
minimum-100 JJ N
maximum NN N
) ) N
was VBD N
developed VBN N
. . N

This DT N
score NN N
and CC N
Blatt-Kuperman NNP N
were VBD N
recorded VBN N
and CC N
performed VBN N
in IN N
every DT N
control NN N
. . N

RESULTS CC N
There EX N
were VBD N
no DT o
differences NNS o
on IN o
climacteric NN o
symptoms NNS o
relief NN o
between IN o
the DT o
two CD o
groups NNS o
. . o

Additionally RB N
, , N
the DT N
improvement NN o
in IN o
urinary JJ o
symptoms NNS o
at IN o
the DT o
end NN o
of IN o
the DT o
study NN o
was VBD o
similar JJ o
for IN o
both DT o
groups NNS o
( ( N
from IN N
16.5 CD N
+/- JJ N
6.1 CD N
to TO N
8.5 CD N
+/- JJ N
2.4 CD N
for IN N
E NNP N
group NN N
and CC N
from IN N
15.8 CD N
+/- JJ N
7.8 CD N
to TO N
8.8 CD N
+/- JJ N
2.7 CD N
for IN N
P NNP N
group NN N
; : N
P NNP N
< VBD N
0.01 CD N
versus NN N
basal NN N
) ) N
; : N
however RB N
, , N
those DT N
women NNS o
in IN o
group NN o
E NNP o
reached VBD o
significant JJ o
improvement NN o
on IN o
urinary JJ o
complaints NNS o
since IN o
the DT o
first JJ o
month NN o
of IN o
treatment NN o
. . o

Additionally RB N
, , N
a DT N
significant JJ o
difference NN o
between IN o
E NNP o
and CC o
P NNP o
was VBD o
observed VBN o
at IN o
months NNS o
2 CD o
and CC o
3 CD o
, , o
although IN o
no DT o
differences NNS o
were VBD o
detected VBN o
at IN o
the DT o
end NN o
of IN o
the DT o
study NN o
. . o

Papanicolaou NNP o
smear JJ o
showed VBD o
reactive JJ o
or CC o
reparative JJ o
changes NNS o
and CC o
karyopyknotic JJ o
index NN o
exhibited VBD o
a DT o
significant JJ o
increase NN o
in IN o
superficial JJ o
cells NNS o
in IN o
both DT o
groups NNS o
and CC o
at IN o
the DT o
end NN o
of IN o
the DT o
study NN o
. . o

CONCLUSIONS NNP N
Adding NNP N
vaginal JJ N
estriol NN N
to TO N
HRT NNP N
may MD N
shorten VB N
the DT N
latency NN N
period NN N
for IN N
urinary JJ N
symptoms NNS N
. . N

-DOCSTART- -22401811- O O

Efficiency NN o
of IN N
slush NN i
nitrogen NN i
vitrification NN i
of IN N
human JJ N
oocytes NNS N
vitrified VBN i
with IN i
or CC i
without IN i
cumulus JJ i
cells NNS i
in IN N
relation NN N
to TO N
survival VB o
rate NN o
and CC N
meiotic JJ o
spindle NN o
competence NN o
. . o

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
efficiency NN o
of IN N
slush NN i
nitrogen NN i
vitrification NN i
of IN N
human JJ p
oocytes NNS p
with IN i
or CC i
without IN i
cumulus JJ i
cells NNS i
in IN N
terms NNS N
of IN N
survival NN o
rate NN o
and CC N
maintenance NN o
of IN o
meiotic JJ o
spindle NN o
. . o

DESIGN NNP N
Randomized NNP N
, , N
comparative JJ N
study NN N
. . N

SETTING NNP N
Medical NNP N
center NN N
. . N

PATIENT NNP N
( ( N
S NNP N
) ) N
A NNP N
total NN N
of IN N
274 CD p
oocytes NNS p
obtained VBN p
from IN p
46 CD p
couples NNS p
undergoing JJ p
infertility NN p
treatment NN p
. . p

INTERVENTION NNP N
( ( N
S NNP N
) ) N
Metaphase NNP N
II NNP N
oocytes NNS N
were VBD N
divided VBN N
into IN N
groups NNS N
A NNP N
and CC N
B NNP N
, , N
vitrified VBD i
with IN i
and CC i
without IN i
cumulus JJ i
cells NNS i
, , N
respectively RB N
. . N

MAIN NNP N
OUTCOMES NNP N
MEASURE NNP N
( ( N
S NNP N
) ) N
Survival NNP o
rates NNS o
and CC o
maintenance NN o
of IN o
meiotic JJ o
spindle NN o
observed VBD o
immediately RB o
after IN o
warming VBG o
and CC o
3 CD o
hours NNS o
after IN o
incubation NN o
. . o

RESULT NNP N
( ( N
S NNP N
) ) N
No NNP N
statistically RB N
significant JJ N
difference NN N
was VBD N
detected VBN N
between IN N
the DT N
two CD N
groups NNS N
in IN N
terms NNS N
of IN N
survival NN o
rate NN o
, , N
but CC N
a DT N
significantly RB N
higher JJR N
percentage NN N
of IN N
detectable JJ o
spindle NN o
was VBD N
observed VBN N
in IN N
group NN N
B NNP N
( ( N
completely RB N
denuded VBN N
oocytes NNS N
) ) N
, , N
either RB N
immediately RB N
after IN N
warming VBG N
or CC N
3 CD N
hours NNS N
after IN N
incubation NN N
. . N

CONCLUSION NNP N
( ( N
S NNP N
) ) N
Complete NNP N
denudation NN N
of IN N
oocytes NNS N
before IN N
slush JJ N
nitrogen NN N
vitrification NN N
does VBZ N
not RB N
influence VB N
survival JJ o
rates NNS o
but CC N
positively RB N
affects VBZ N
oocyte JJ N
meiotic JJ o
spindle NN o
competence NN o
. . o

These DT N
data NNS N
support NN N
the DT N
hypothesis NN N
that WDT N
cumulus VBZ N
cells NNS N
during IN N
vitrification NN N
represent VBP N
an DT N
obstacle NN N
to TO N
cryoprotectant VB N
penetration NN N
more JJR N
than IN N
having VBG N
a DT N
protective JJ N
role NN N
for IN N
the DT N
oocyte NN N
. . N

-DOCSTART- -11378004- O O

Carvedilol NNP i
increases VBZ N
plasma JJ o
vascular JJ o
endothelial JJ o
growth NN o
factor NN o
( ( o
VEGF NNP o
) ) o
in IN N
patients NNS p
with IN p
chronic JJ p
heart NN p
failure NN p
. . p

-DOCSTART- -8334086- O O

A DT N
randomised JJ N
prospective JJ N
study NN N
comparing VBG N
the DT N
new JJ N
vacuum NN N
extractor NN N
policy NN N
with IN N
forceps JJ N
delivery NN N
. . N

OBJECTIVE UH N
To TO N
compare VB N
assisted JJ N
vaginal JJ N
delivery NN N
by IN N
forceps NNS N
with IN N
delivery NN N
by IN N
vacuum NN N
extractor NN N
, , N
where WRB N
a DT N
new JJ N
vacuum NN N
extractor NN N
policy NN N
was VBD N
employed VBN N
which WDT N
dictated VBD N
the DT N
cup NN N
to TO N
be VB N
used VBN N
in IN N
specific JJ N
situations NNS N
. . N

DESIGN NNP N
Multicentre NNP N
randomised VBD N
controlled VBN N
trial NN N
. . N

SETTING VB N
Four CD p
district NN p
general JJ p
hospitals NNS p
in IN p
the DT p
West NNP p
Midlands NNPS p
. . p

SUBJECTS NNP N
Six NNP p
hundred-seven JJ p
women NNS p
requiring VBG p
assisted VBD p
vaginal JJ p
delivery NN p
, , N
of IN N
whom WP N
296 CD p
were VBD p
allocated VBN i
to TO i
vacuum VB i
extractor JJ i
delivery NN i
and CC i
311 CD i
to TO i
forceps NNS i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Delivery NNP o
success NN o
rate NN o
, , o
maternal JJ o
perineal NN o
and CC o
vaginal JJ o
injuries NNS o
, , o
maternal JJ o
anaesthetic JJ o
requirements NNS o
, , o
neonatal JJ o
scalp NN o
and CC o
facial JJ o
injuries NNS o
. . o

RESULTS NNP N
Of IN N
the DT N
vacuum NN N
extractor NN N
group NN N
, , N
85 CD N
% NN N
were VBD N
delivered VBN N
by IN N
the DT N
allocated JJ N
instrument NN N
compared VBN N
to TO N
90 CD N
% NN N
in IN N
the DT N
forceps NNS N
group NN N
( ( N
odds NNS N
ratio NN N
( ( N
OR NNP N
) ) N
0.64 CD N
; : N
95 CD N
% NN N
confidence NN N
intervals NNS N
( ( N
CI NNP N
) ) N
0.4-1.04 NN N
) ) N
. . N

However RB N
, , N
more JJR N
women NNS N
in IN N
the DT N
vacuum NN N
extractor NN N
group NN N
were VBD N
delivered VBN N
vaginally RB N
( ( N
98 CD N
% NN N
) ) N
than IN N
in IN N
the DT N
forceps NNS N
group NN N
( ( N
96 CD N
% NN N
) ) N
. . N

There EX N
were VBD N
significantly RB N
fewer JJR N
women NNS N
with IN N
anal JJ o
sphincter NN o
damage NN o
or CC o
upper JJ o
vaginal JJ o
extensions NNS o
in IN N
the DT N
vacuum NN N
extractor NN N
group NN N
( ( N
11 CD N
% NN N
vs JJ N
17 CD N
% NN N
, , N
OR NNP N
0.6 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.38-0.97 NN N
) ) N
. . N

There EX N
were VBD N
significantly RB N
fewer JJR N
women NNS N
in IN N
the DT N
vacuum NN N
extractor NN N
group NN N
requiring VBG N
epidural JJ o
or CC o
spinal JJ o
anaesthetics NNS o
( ( N
25.4 CD N
% NN N
vs JJ N
32.7 CD N
% NN N
, , N
OR NNP N
0.69 CD N
; : N
95 CD N
% NN N
CI NNP N
0.49-0.99 NN N
) ) N
or CC N
general JJ o
anaesthetics NNS o
( ( N
1 CD N
% NN N
vs JJ N
4 CD N
% NN N
, , N
OR NNP N
0.17 CD N
; : N
95 CD N
% NN N
CI NNP N
0.04-0.76 NN N
) ) N
. . N

Although IN N
there EX N
were VBD N
significantly RB N
more JJR N
babies NNS p
in IN N
the DT N
vacuum NN N
extractor NN N
group NN N
with IN N
cephalhaematomata NNS o
( ( N
9 CD N
% NN N
vs JJ N
3 CD N
% NN N
, , N
OR NNP N
3.3 CD N
; : N
95 CD N
% NN N
CI NNP N
1.4-7.4 CD N
) ) N
there EX N
were VBD N
fewer JJR N
babies NNS N
in IN N
the DT N
vacuum NN N
extractor NN N
group NN N
with IN N
other JJ N
facial JJ o
injuries NNS o
. . o

There EX N
were VBD N
three CD N
babies NNS N
in IN N
the DT N
forceps NNS N
group NN N
with IN N
unexplained JJ o
neonatal JJ o
convulsions NNS o
. . o

CONCLUSIONS NNP N
Assisted NNP N
vaginal JJ N
delivery NN N
using VBG N
the DT N
new JJ N
vacuum NN N
extractor NN N
policy NN N
is VBZ N
associated VBN N
with IN N
significantly RB N
less RBR N
maternal JJ o
trauma NN o
than IN N
with IN N
forceps NNS N
. . N

Further JJ N
studies NNS N
are VBP N
required VBN N
to TO N
assess VB N
neonatal JJ N
morbidity NN N
adequately RB N
. . N

-DOCSTART- -1445476- O O

Controlled VBN N
study NN N
on IN N
the DT N
therapeutic JJ o
efficacy NN o
of IN N
propionyl-L-carnitine NN N
in IN N
patients NNS p
with IN p
congestive JJ p
heart NN p
failure NN p
. . p

A DT N
double-blind JJ N
phase NN N
II NNP N
study NN N
of IN N
propionyl-L-carnitine NN N
( ( N
CAS NNP N
17298-37-2 CD N
) ) N
versus NN N
placebo NN N
was VBD N
carried VBN N
out RP N
on IN N
a DT N
group NN N
of IN N
60 CD p
patients NNS p
with IN p
mild JJ p
to TO p
moderate VB p
( ( p
II NNP p
and CC p
III NNP p
NYHA NNP p
class NN p
) ) p
congestive JJ p
heart NN p
failure NN p
. . p

The DT p
group NN p
was VBD p
made VBN p
up IN p
of IN p
men NNS p
and CC p
women NNS p
aged VBD p
between IN p
48 CD p
and CC p
73 CD p
years NNS p
in IN p
chronic JJ p
treatment NN p
with IN p
digitalis NN p
and CC p
diuretics NNS p
for IN p
at IN p
least JJS p
3 CD p
months NNS p
and CC p
who WP p
still RB p
displayed VBD p
symptoms NNS p
. . p

Thirty NN N
of IN N
these DT N
patients NNS N
were VBD N
chosen VBN i
randomly RB i
and CC i
for IN i
180 CD i
days NNS i
, , i
500 CD i
mg NN i
of IN i
propionyl-L-carnitine NN i
was VBD i
orally RB i
administered VBN i
, , i
3 CD i
times NNS i
a DT i
day NN i
in IN i
addition NN i
to TO i
their PRP$ i
usual JJ i
treatment NN i
. . i

At IN i
basal JJ i
conditions NNS i
and CC i
after IN i
30 CD i
, , i
90 CD i
and CC i
180 CD i
days NNS i
the DT i
maximum JJ o
exercise NN o
time NN o
was VBD o
evaluated VBN o
using VBG o
an DT o
exercise NN o
tolerance NN o
test NN o
performed VBD i
on IN i
an DT i
ergometer NN i
bicycle NN i
and CC i
the DT i
left JJ o
ventricular JJ o
ejection NN o
fraction NN o
was VBD i
tested VBN i
by IN i
means NNS i
of IN i
bidimensional JJ o
echocardiography NN o
. . o

After IN N
one CD N
month NN N
of IN N
treatment NN N
, , N
the DT N
patients NNS N
treated VBN N
with IN N
propionyl-L-carnitine NN N
, , N
compared VBN N
to TO N
the DT N
control NN N
group NN N
, , N
showed VBD N
significant JJ N
increases NNS N
in IN N
the DT N
values NNS o
of IN o
both DT o
tests NNS o
, , N
increases NNS N
which WDT N
became VBD N
even RB N
more RBR N
evident JJ N
after IN N
90 CD N
and CC N
180 CD N
days NNS N
. . N

At IN N
the DT N
stated VBN N
times NNS N
the DT N
increases NNS N
in IN N
the DT N
maximum JJ o
exercise NN o
time NN o
were VBD N
16.4 CD N
% NN N
, , N
22.9 CD N
% NN N
, , N
and CC N
25.9 CD N
% NN N
, , N
respectively RB N
. . N

The DT N
ventricular JJ o
ejection NN o
fraction NN o
increased VBN N
by IN N
8.4 CD N
% NN N
, , N
11.6 CD N
% NN N
and CC N
13.6 CD N
% NN N
, , N
respectively RB N
. . N

On IN N
the DT N
basis NN N
of IN N
these DT N
results NNS N
, , N
having VBG N
studied VBN N
the DT N
particular JJ N
mechanism NN N
of IN N
action NN N
of IN N
propionyl-L-carnitine NN N
the DT N
authors NNS N
conclude VBP N
that IN N
it PRP N
represents VBZ N
a DT N
drug NN N
of IN N
undoubted JJ N
therapeutic JJ N
interest NN N
in IN N
patients NNS p
with IN p
congestive JJ p
heart NN p
failure NN p
, , N
in IN N
whom WP N
it PRP N
could MD N
be VB N
efficaciously RB o
administered VBN N
along IN N
with IN N
a DT N
standard JJ N
pharmacological JJ N
therapy NN N
. . N

-DOCSTART- -7492158- O O

The DT N
effect NN o
of IN N
iron NN i
in IN N
formula NN N
milk NN N
after IN N
6 CD N
months NNS N
of IN N
age NN N
. . N

Ninety NNP p
two CD p
normal JJ p
birthweight JJ p
infants NNS p
aged VBD p
6 CD p
months NNS p
entered VBD N
a DT N
double JJ N
blind NN N
controlled VBD N
trial NN N
which WDT N
compared VBN N
a DT N
follow NN N
on IN N
formula NN i
milk NN i
with IN i
no DT i
added JJ i
iron NN i
against IN i
the DT i
same JJ i
formula NN i
milk NN i
containing VBG i
1.2 CD i
mg NN i
of IN i
iron NN i
per IN i
100 CD i
ml NN i
. . i

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
social JJ N
class NN N
or CC N
demographic JJ N
characteristics NNS N
of IN N
the DT N
two CD N
treatment NN N
groups NNS N
or CC N
in IN N
the DT N
proportion NN N
of IN N
each DT N
group NN N
completing VBG N
the DT N
trial NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
in IN N
the DT N
quantity NN o
of IN o
milk NN o
taken VBN o
but CC N
the DT N
amounts NNS N
taken VBN N
lessened VBD N
between IN N
6 CD N
and CC N
18 CD N
months NNS N
of IN N
age NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
with IN N
respect NN N
to TO N
mean VB o
haemoglobin NN o
and CC o
median JJ o
serum NN o
ferritin NN o
at IN N
6 CD N
, , N
9 CD N
, , N
12 CD N
, , N
15 CD N
, , N
and CC N
18 CD N
months NNS N
of IN N
age NN N
. . N

Very RB N
few JJ N
infants NNS N
developed VBD N
iron NN o
deficiency NN o
anaemia NN o
in IN N
either CC N
group NN N
but CC N
there EX N
was VBD N
a DT N
tendency NN N
for IN N
serum NN o
ferritin NN o
levels NNS o
to TO N
fall VB N
between IN N
6 CD N
and CC N
18 CD N
months NNS N
of IN N
age NN N
in IN N
both DT N
groups NNS N
. . N

The DT N
results NNS N
suggest VBP N
that IN N
iron NN i
added VBD N
to TO N
follow VB N
on IN N
milk NN N
was VBD N
not RB N
an DT N
important JJ N
source NN N
of IN N
dietary JJ N
iron NN i
in IN N
the DT N
infants NNS N
studied VBN N
. . N

-DOCSTART- -12653872- O O

Multiple NNP i
risk NN i
factor NN i
intervention NN i
reduces VBZ N
cardiovascular JJ N
risk NN N
in IN N
hypertensive JJ p
patients NNS p
with IN p
echolucent JJ p
plaques NNS p
in IN p
the DT p
carotid NN p
artery NN p
. . p

OBJECTIVE NNP N
In IN N
a DT N
previously RB N
published VBN N
randomized VBN N
6-year JJ N
study NN N
we PRP N
observed VBD N
that IN N
multiple JJ i
risk NN i
factor NN i
intervention NN i
reduced VBD N
cardiovascular JJ N
risk NN N
in IN N
high-risk JJ p
hypertensive JJ p
men NNS p
, , N
and CC N
that IN N
this DT N
effect NN N
was VBD N
confined VBN N
to TO N
patients NNS p
with IN p
carotid JJ p
artery NN p
plaques NNS p
. . p

Hypothetically RB N
, , N
the DT N
underlying VBG N
mechanism NN N
might MD N
have VB N
been VBN N
a DT N
stabilization NN N
of IN N
echolucent NN N
, , N
instable JJ N
, , N
rupture-prone JJ N
plaques NNS N
. . N

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
examine VB N
plaque NN o
characteristics NNS o
by IN N
B-mode NNP i
ultrasound NN i
in IN N
the DT N
previous JJ N
intervention NN N
study NN N
, , N
and CC N
also RB N
to TO N
investigate VB N
the DT N
relationship NN N
between IN N
plaque NN o
characteristics NNS o
at IN N
baseline NN N
and CC N
cardiovascular JJ o
events NNS o
during IN N
the DT N
6-year JJ N
follow-up NN N
in IN N
the DT N
two CD N
randomization NN N
groups NNS N
. . N

METHODS NNP N
High NNP i
resolution NN i
B-mode NNP i
ultrasound NN i
was VBD N
used VBN N
to TO N
characterize VB o
plaque JJ o
echogenicity NN o
in IN N
four CD N
subgroups NNS N
- : N
dominantly RB N
echolucent NN N
, , N
substantially RB N
echolucent JJ N
, , N
dominantly RB N
echogenic JJ N
, , N
and CC N
uniformly RB N
echogenic JJ N
. . N

RESULTS NNP N
In IN N
the DT N
usual JJ i
care NN i
group NN i
17 CD p
of IN p
32 CD p
( ( p
53 CD p
% NN p
) ) p
patients NNS p
with IN p
echolucent JJ o
plaques NNS o
at IN p
baseline NN p
suffered VBN N
from IN N
a DT N
combined VBN N
end-point NN N
( ( N
any DT N
death NN o
or CC o
nonfatal JJ o
myocardial JJ o
infarction NN o
or CC o
nonfatal JJ o
stroke NN o
) ) o
during IN N
follow-up JJ N
compared VBN N
with IN N
seven CD N
of IN N
28 CD N
( ( N
25 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
intervention NN i
group NN i
( ( N
P NNP N
= NNP N
0.036 CD N
) ) N
. . N

The DT N
corresponding JJ o
numbers NNS o
in IN N
patients NNS N
with IN N
echogenic JJ o
plaques NNS o
were VBD N
n JJ N
= JJ N
4/13 CD N
( ( N
31 CD N
% NN N
) ) N
and CC N
n JJ N
= NN N
4/17 CD N
( ( N
24 CD N
% NN N
) ) N
, , N
respectively RB N
( ( N
NS NNP N
) ) N
. . N

In IN N
the DT N
usual JJ i
care NN i
group NN i
11 CD N
of IN N
33 CD N
( ( N
33 CD N
% NN N
) ) N
patients NNS N
with IN N
no DT N
plaques NNS N
suffered VBD N
from IN N
a DT N
combined JJ N
end-point NN N
during IN N
follow-up JJ N
compared VBN N
with IN N
11 CD N
of IN N
30 CD N
( ( N
37 CD N
% NN N
) ) N
in IN N
the DT N
intervention NN i
group NN i
. . i

CONCLUSION NNP N
Our PRP$ N
data NNS N
indicate VBP N
that IN N
the DT N
beneficial JJ o
effect NN o
of IN N
the DT N
multiple NN i
risk NN i
intervention NN i
programme NN i
was VBD N
confined VBN N
to TO N
those DT N
patients NNS N
with IN N
echolucent JJ N
plaques NNS N
. . N

The DT N
data NNS N
have VBP N
to TO N
be VB N
confirmed VBN N
with IN N
a DT N
large-scale JJ N
trial NN N
. . N

-DOCSTART- -2067508- O O

Tracheal NNP N
soiling VBG N
with IN N
blood NN N
during IN N
intranasal NN i
surgery NN i
-- : i
comparison NN i
of IN N
two CD N
endotracheal JJ N
tubes NNS N
. . N

Sixty NNP p
adult NN p
patients NNS p
, , p
ASA NNP p
Classes NNP p
I PRP p
& CC p
II NNP p
, , N
were VBD N
involved VBN N
in IN N
a DT N
study NN N
to TO N
compare VB N
the DT N
effectiveness NN N
of IN N
Mallinckrodt NNP i
Hi-Lo-Evac NNP i
tube NN i
and CC i
Portex NNP i
blue JJ i
line NN i
tube NN i
in IN N
preventing VBG N
soiling NN N
of IN N
the DT N
lower JJR N
airways NNS N
during IN N
intranasal NN N
surgery NN N
. . N

The DT N
Hi-Lo-Evac JJ N
tube NN N
with IN N
and CC N
without IN N
pack NN N
was VBD N
significantly RB N
more RBR N
effective JJ o
than IN N
the DT N
Portex NNP N
tube NN N
with IN N
pharyngeal JJ N
pack NN N
( ( N
P NNP N
less JJR N
than IN N
0.002 CD N
) ) N
and CC N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
respectively RB N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
when WRB N
the DT N
Hi-Lo-Evac NNP N
tube NN N
was VBD N
used VBN N
with IN N
or CC N
without IN N
a DT N
pack NN N
( ( N
P NNP N
greater JJR N
than IN N
0.2 CD N
) ) N
. . N

The DT N
more RBR N
effective JJ o
protection NN o
of IN o
the DT o
lower JJR o
airways NNS o
by IN N
the DT N
Hi-Lo-Evac NNP N
tube NN N
is VBZ N
attributed VBN N
to TO N
the DT N
facility NN N
of IN N
subglottic JJ N
aspiration NN N
during IN N
surgery NN N
. . N

It PRP N
is VBZ N
suggested VBN N
that IN N
the DT N
Hi-Lo-Evac NNP N
tube NN N
could MD N
be VB N
used VBN N
with IN N
safety NN o
during IN N
intranasal JJ N
surgery NN N
in IN N
order NN N
to TO N
reduce VB N
postoperative JJ o
morbidity NN o
associated VBN N
with IN N
the DT N
use NN N
of IN N
pharyngeal JJ N
pack NN N
. . N

-DOCSTART- -11104595- O O

Perioperative JJ i
enteral JJ i
nutrition NN i
and CC N
quality NN o
of IN o
life NN o
of IN N
severely RB p
malnourished VBN p
head NN p
and CC p
neck NN p
cancer NN p
patients NNS p
: : p
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
AND CC N
AIMS NNP N
This DT N
study NN N
evaluated VBD N
the DT N
use NN N
of IN N
perioperative JJ i
nutritional JJ i
support NN i
on IN N
Quality NN o
of IN o
Life NNP o
( ( o
QOL NNP o
) ) o
in IN N
malnourished VBN p
head NN p
and CC p
neck NN p
cancer NN p
patients NNS p
undergoing VBG p
surgery NN p
. . p

METHODS NNP N
49 CD p
Malnourished NNP p
( ( p
weight JJ p
loss NN p
> VBZ p
10 CD p
% NN p
) ) p
head NN p
and CC p
neck NN p
cancer NN p
patients NNS p
who WP p
were VBD p
included VBN p
in IN p
a DT p
nutrition NN p
intervention NN p
trial NN p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
no DT i
preoperative JJ i
and CC i
standard JJ i
postoperative JJ i
tube-feeding NN i
( ( i
group NN i
I PRP i
) ) i
, , i
standard JJ i
preoperative NN i
and CC i
postoperative JJ i
tube-feeding NN i
( ( i
group NN i
II NNP i
) ) i
or CC N
arginine-supplemented JJ i
preoperative NN i
and CC i
postoperative JJ i
tube-feeding NN i
( ( N
group NN N
III NNP N
) ) N
. . N

Of IN N
these DT N
patients NNS p
, , N
31 CD N
completed VBD N
a DT N
full JJ N
QOL NNP o
assessment NN o
on IN N
the DT N
first JJ N
day NN N
of IN N
preoperative JJ N
nutritional JJ N
support NN N
, , N
one CD N
day NN N
before IN N
surgery NN N
, , N
and CC N
6 CD N
months NNS N
after IN N
surgery NN N
. . N

Both CC N
a DT N
disease-specific NN N
( ( N
EORTC NNP N
QLQ-C30 NNP N
) ) N
and CC N
a DT N
generic JJ N
questionnaire NN N
( ( N
COOP-WONCA NNP N
) ) N
were VBD N
used VBN N
. . N

One CD N
way NN N
analysis NN N
of IN N
variance NN N
( ( N
ANOVA NNP N
) ) N
and CC N
the DT N
Kruskal-Wallis NNP N
test NN N
were VBD N
applied VBN N
for IN N
testing VBG N
differences NNS N
in IN N
scores NNS N
between IN N
groups NNS N
. . N

RESULTS NNP N
Between NNP N
baseline NN N
and CC N
the DT N
day NN N
before IN N
surgery NN N
, , N
both DT N
preoperatively RB i
fed VBN i
groups NNS N
revealed VBD N
a DT N
positive JJ N
change NN N
for IN N
the DT N
dimensions NNS N
physical JJ o
and CC o
emotional JJ o
functioning NN o
and CC o
dyspnea NN o
( ( N
with IN N
significance NN N
in IN N
group NN N
II NNP N
, , N
P=0.050,0.031,0.045 NNP N
respectively RB N
) ) N
. . N

Group NNP N
III NNP N
showed VBD N
a DT N
negative JJ N
change NN N
in IN N
appetite NN o
( ( N
P=0.049 NNP N
) ) N
. . N

Between NNP N
baseline NN N
and CC N
6 CD N
months NNS N
after IN N
surgery NN N
, , N
there EX N
were VBD N
no DT N
differences NNS N
between IN N
group NN N
I PRP N
and CC N
both DT i
pre-fed JJ i
groups NNS i
. . i

There EX N
were VBD N
no DT N
differences NNS N
in IN N
favour NN N
of IN N
group NN N
III NNP N
compared VBN N
to TO N
group NN N
II NNP N
. . N

CONCLUSION NNP N
Enteral NNP i
nutrition NN i
improves VBZ N
QOL NNP o
of IN N
severely RB N
malnourished VBN N
head NN N
and CC N
neck NN N
cancer NN N
patients NNS N
in IN N
the DT N
period NN N
preceding VBG N
surgery NN N
. . N

No DT N
benefit NN N
of IN N
preoperative JJ i
enteral JJ i
feeding NN i
on IN N
QOL NNP o
could MD N
be VB N
demonstrated VBN N
6 CD N
months NNS N
after IN N
surgery NN N
. . N

-DOCSTART- -12855087- O O

Virtual JJ i
reality NN i
intervention NN i
for IN N
older JJR p
women NNS p
with IN p
breast NN p
cancer NN p
. . p

This DT N
study NN N
examined VBD N
the DT N
effects NNS N
of IN N
a DT N
virtual JJ i
reality NN i
distraction NN i
intervention NN i
on IN N
chemotherapy-related JJ p
symptom NN o
distress NN o
levels NNS p
in IN p
16 CD p
women NNS p
aged VBD p
50 CD p
and CC p
older JJR p
. . p

A DT N
cross-over JJ N
design NN N
was VBD N
used VBN N
to TO N
answer VB N
the DT N
following JJ N
research NN N
questions NNS N
: : N
( ( N
1 CD N
) ) N
Is VBZ N
virtual JJ N
reality NN N
an DT N
effective JJ N
distraction NN N
intervention NN N
for IN N
reducing VBG N
chemotherapy-related JJ N
symptom NN N
distress NN N
levels NNS N
in IN N
older JJR p
women NNS p
with IN p
breast NN p
cancer NN p
? . N
( ( N
2 CD N
) ) N
Does NNP N
virtual JJ i
reality NN i
have VBP N
a DT N
lasting JJ N
effect NN N
? . N
Chemotherapy NN N
treatments NNS N
are VBP N
intensive JJ N
and CC N
difficult JJ N
to TO N
endure VB N
. . N

One CD N
way NN N
to TO N
cope VB N
with IN N
chemotherapy-related JJ N
symptom NN N
distress NN N
is VBZ N
through IN N
the DT N
use NN N
of IN N
distraction NN N
. . N

For IN N
this DT N
study NN N
, , N
a DT i
head-mounted JJ i
display NN i
( ( i
Sony NNP i
PC NNP i
Glasstron NNP i
PLM NNP i
- : i
S700 NN i
) ) i
was VBD i
used VBN i
to TO i
display VB i
encompassing VBG i
images NNS i
and CC i
block NN i
competing VBG i
stimuli NNS i
during IN i
chemotherapy JJ i
infusions NNS i
. . i

The DT N
Symptom NNP o
Distress NNP o
Scale NNP o
( ( o
SDS NNP o
) ) o
, , o
Revised VBN o
Piper NNP o
Fatigue NNP o
Scale NNP o
( ( o
PFS NNP o
) ) o
, , o
and CC o
the DT o
State NNP o
Anxiety NNP o
Inventory NNP o
( ( o
SAI NNP o
) ) o
were VBD i
used VBN i
to TO i
measure VB i
symptom JJ i
distress NN i
. . i

For IN N
two CD N
matched JJ N
chemotherapy NN N
treatments NNS N
, , N
one CD N
pre-test NN N
and CC N
two CD N
post-test JJ N
measures NNS N
were VBD N
employed VBN N
. . N

Participants NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
the DT N
VR NNP i
distraction NN i
intervention NN i
during IN i
one CD i
chemotherapy NN i
treatment NN i
and CC i
received VBD i
no DT i
distraction NN i
intervention NN i
( ( i
control VB i
condition NN i
) ) i
during IN i
an DT i
alternate JJ i
chemotherapy NN i
treatment NN i
. . i

Analysis NN N
using VBG N
paired VBN N
t-tests NNS N
demonstrated VBD N
a DT N
significant JJ N
decrease NN o
in IN N
the DT N
SAI NNP o
( ( N
p JJ N
= NNP N
0.10 CD N
) ) N
scores NNS N
immediately RB N
following VBG N
chemotherapy NN N
treatments NNS N
when WRB N
participants NNS N
used VBD N
VR NNP N
. . N

No NNP N
significant JJ N
changes NNS N
were VBD N
found VBN N
in IN N
SDS NNP o
or CC o
PFS NNP o
values NNS o
. . o

There EX N
was VBD N
a DT N
consistent JJ N
trend NN N
toward IN N
improved VBN o
symptoms NNS o
on IN N
all DT N
measures NNS N
48 CD N
h NN N
following VBG N
completion NN N
of IN N
chemotherapy NN N
. . N

Evaluation NN N
of IN N
the DT N
intervention NN N
indicated VBD N
that IN N
women NNS p
thought VBD N
the DT N
head NN N
mounted VBD N
device NN N
was VBD N
easy JJ N
to TO N
use VB N
, , N
they PRP N
experienced VBD N
no DT N
cybersickness NN o
, , N
and CC N
100 CD N
% NN N
would MD N
use VB N
VR NNP N
again RB N
. . N

-DOCSTART- -19718941- O O

A DT N
comparison NN N
of IN N
a DT N
spiritually RB i
based VBN i
and CC i
non-spiritually RB i
based VBN i
educational JJ i
intervention NN i
for IN N
informed JJ N
decision NN N
making NN N
for IN N
prostate NN N
cancer NN N
screening VBG N
among IN N
church-attending JJ p
African-American JJ p
men NNS p
. . p

INTRODUCTION NNP N
Health NNP i
communication NN i
interventions NNS i
have VBP N
been VBN N
modestly RB N
effective JJ N
for IN N
increasing VBG N
informed JJ N
decision NN N
making NN N
for IN N
prostate NN N
cancer NN N
screening VBG N
among IN p
African-American JJ p
men NNS p
; : p
however RB N
, , N
knowledge NN N
and CC N
informed JJ N
decision NN N
making NN N
is VBZ N
still RB N
questionable JJ N
even RB N
with IN N
screening VBG N
. . N

Church-based JJ N
programs NNS N
may MD N
be VB N
more RBR N
effective JJ N
if IN N
they PRP N
are VBP N
spiritually RB N
based VBN N
in IN N
nature NN N
. . N

OBJECTIVE CC N
The DT N
aims NNS N
of IN N
the DT N
present JJ N
study NN N
were VBD N
to TO N
implement VB N
and CC N
provide VB N
an DT N
initial JJ N
evaluation NN N
of IN N
a DT N
spiritually RB N
based VBN N
prostate NN N
cancer NN N
screening VBG N
informed JJ N
decision NN N
making VBG N
intervention NN N
for IN N
African-American JJ p
men NNS p
who WP p
attend VBP p
church NN p
, , N
and CC N
determine VB N
its PRP$ N
efficacy NN N
for IN N
increasing VBG N
informed JJ N
decision NN N
making NN N
. . N

DESIGN NNP N
AND CC N
METHOD NNP N
Churches NNP p
were VBD N
randomized VBN N
to TO N
receive VB N
either CC N
the DT N
spiritually RB i
based VBN i
or CC i
the DT i
non-spiritual JJ i
intervention NN i
. . i

Trained NNP N
community NN N
health NN N
advisors NNS N
, , N
who WP N
were VBD N
African-American JJ N
male JJ N
church NN N
members NNS N
, , N
led VBD N
an DT N
educational JJ i
session NN i
and CC N
distributed VBD i
educational JJ i
print NN i
materials NNS i
. . i

Participants NNS N
completed VBD N
baseline NN N
and CC N
immediate JJ N
follow-up JJ N
surveys NNS N
to TO N
assess VB N
the DT N
intervention NN N
impact NN N
on IN N
study NN N
outcomes NNS N
. . N

RESULTS VB N
The DT N
spiritually RB N
based VBN N
intervention NN N
appeared VBD N
to TO N
be VB N
more RBR N
effective JJ N
in IN N
areas NNS N
such JJ N
as IN N
knowledge NN N
, , N
and CC N
men NNS N
read VBP N
more JJR N
of IN N
their PRP$ N
materials NNS o
in IN N
the DT N
spiritually RB N
based VBN N
group NN N
than IN N
in IN N
the DT N
non-spiritual JJ N
group NN N
. . N

CONCLUSIONS NNP N
Further NNP N
examination NN N
of IN N
the DT N
efficacy NN o
of IN N
the DT N
spiritually RB N
based VBN N
approach NN N
to TO N
health NN N
communication NN N
is VBZ N
warranted VBN N
. . N

-DOCSTART- -21721430- O O

Validity NNP o
and CC o
reliability NN o
assessment NN N
of IN N
the DT N
Siriraj NNP i
Asthma NNP i
Control NNP i
Questionnaire NNP i
. . i

OBJECTIVE CC N
The DT N
present JJ N
study NN N
assessed VBD N
the DT N
validity NN o
and CC N
reliability NN o
of IN N
the DT N
Siriraj NNP i
Asthma NNP i
Control NNP i
Questionnaire NNP i
in IN N
Asthma NNP N
Clinic NNP N
, , N
Siriraj NNP p
Hospital NNP p
. . p

MATERIAL NNP N
AND CC N
METHOD NNP N
The DT N
data NN N
of IN N
the DT N
questionnaire NN N
responses NNS N
and CC N
spirometric JJ N
results NNS N
from IN N
20 CD p
randomized JJ p
asthmatic JJ p
patients NNS p
in IN p
the DT p
clinic NN p
including VBG p
the DT p
record NN p
of IN p
3 CD p
visits NNS p
for IN p
each DT p
subject NN p
. . p

The DT N
validation NN N
was VBD N
performed VBN N
by IN N
Kruskal-Wallis NNP i
test NN i
comparing VBG N
the DT N
scores NNS N
with IN N
the DT N
level NN N
of IN N
asthma NNS N
control NN N
determined VBN N
by IN N
physicians NNS N
according VBG N
to TO N
GINA NNP N
guideline NN N
. . N

Internal NNP N
consistency NN N
reliability NN N
was VBD N
analyzed VBN N
by IN N
Cronbach NNP N
's POS N
alpha NN N
. . N

RESULTS NNP N
Sixty NNP N
questionnaires VBZ N
from IN N
20 CD p
patients NNS p
with IN p
age NN p
29-73 CD p
years NNS p
were VBD N
analyzed VBN N
. . N

There EX N
were VBD N
40 CD N
controlled VBN N
, , N
7 CD N
partly RB N
controlled VBN N
and CC N
13 CD N
uncontrolled JJ N
visits NNS N
. . N

The DT N
scores NNS o
from IN o
5-items JJ o
questionnaires NNS o
and CC o
6-items JJ o
clinical JJ o
score NN o
were VBD N
significantly RB N
associated VBN N
with IN N
the DT N
physician-diagnosed JJ N
groups NNS N
( ( N
i.e. FW N
, , N
controlled VBD N
, , N
partly RB N
controlled VBN N
and CC N
uncontrolled JJ N
groups NNS N
) ) N
. . N

Median JJ o
scores NNS o
( ( o
min NN o
, , o
max NN o
) ) o
were VBD N
0 CD N
( ( N
0 CD N
, , N
5 CD N
) ) N
, , N
2 CD N
( ( N
0 CD N
, , N
6 CD N
) ) N
, , N
4 CD N
( ( N
0 CD N
, , N
12 CD N
) ) N
respectively RB N
, , N
( ( N
5-items CD N
, , N
p VBZ N
< NNP N
0.001 CD N
) ) N
and CC N
2 CD N
( ( N
0 CD N
, , N
7 CD N
) ) N
, , N
3 CD N
( ( N
1 CD N
, , N
7 CD N
) ) N
, , N
6 CD N
( ( N
2,15 CD N
) ) N
respectively RB N
, , N
( ( N
6-items CD N
, , N
p VBZ N
< NNP N
0.001 CD N
) ) N
. . N

Internal NNP o
consistency NN o
reliability NN o
of IN N
both DT N
5-items JJ N
questionnaire NN N
and CC N
6-items JJ N
clinical JJ N
score NN N
were VBD N
within IN N
the DT N
acceptable JJ N
range NN N
( ( N
0.829 CD N
and CC N
0.708 CD N
respectively RB N
) ) N
. . N

5-items JJ o
questionnaire NN o
is VBZ N
more RBR N
associated JJ N
with IN N
the DT N
physician NN N
diagnosed VBN N
group NN N
and CC N
more JJR N
consistent JJ o
than IN N
6-items JJ o
clinical JJ o
score NN o
. . o

Further JJ N
analysis NN N
revealed VBD N
cutoff NN N
point NN N
at IN N
2.5 CD N
to TO N
separate VB N
uncontrolled JJ N
from IN N
controlled VBN N
or CC N
partly RB N
controlled VBN N
patient NN N
with IN N
sensitivity NN o
76.9 CD N
% NN N
and CC N
specificity NN o
89.4 CD N
% NN N
and CC N
cutoff NN o
point NN o
at IN N
1.5 CD N
to TO N
separate VB N
uncontrolled JJ N
or CC N
partly RB N
controlled VBN N
from IN N
controlled VBN N
patient NN N
with IN N
sensitivity NN o
70.0 CD N
% NN N
and CC N
specificity NN o
85.0 CD N
% NN N
. . N

CONCLUSION NNP N
The DT N
validity NN o
and CC o
reliability NN o
of IN N
Siriraj NNP i
Asthma NNP i
Control NNP i
Questionnaire NNP i
is VBZ N
acceptable JJ N
and CC N
might MD N
be VB N
used VBN N
in IN N
the DT N
clinical JJ N
practice NN N
and CC N
research NN N
in IN N
Thai NNP p
asthmatic JJ p
patients NNS p
. . p

-DOCSTART- -20615885- O O

Human NNP N
papillomavirus NN N
genotypes NNS N
in IN N
cervical JJ p
intraepithelial JJ p
neoplasia NN p
grade VBD p
3 CD p
. . p

BACKGROUND VB N
There EX N
are VBP N
few JJ N
large JJ N
case NN N
series NN N
describing VBG N
the DT N
human JJ o
papillomavirus NN o
( ( o
HPV NNP o
) ) o
genotypes VBZ N
found VBN N
in IN N
women NNS N
diagnosed VBN N
with IN N
rigorously RB N
reviewed VBN N
cervical JJ p
intraepithelial JJ p
neoplasia NN p
grade VBD p
3 CD p
( ( p
CIN3 NNP p
) ) p
, , p
cervical JJ p
precancer NN p
. . p

METHODS NNP N
The DT N
Atypical NNP N
Squamous NNP N
Cells NNP N
of IN N
Undetermined VBN N
Significance NNP N
( ( N
ASCUS NNP N
) ) N
and CC N
Low-Grade NNP N
Squamous NNP N
Intraepithelial NNP N
Lesion NNP N
( ( N
LSIL NNP N
) ) N
Triage NN N
Study NNP N
( ( N
ALTS NNP N
) ) N
was VBD N
a DT N
clinical JJ N
trial NN N
to TO N
evaluate VB N
the DT N
best JJS N
management NN N
strategies NNS N
for IN N
women NNS p
with IN p
equivocal JJ p
( ( p
ASCUS NNP p
) ) p
or CC p
mildly RB p
abnormal JJ p
( ( p
LSIL NNP p
) ) p
Pap NNP p
tests NNS p
. . p

During IN N
enrollment NN N
and CC N
the DT N
2-year JJ N
follow-up NN N
, , N
608 CD p
women NNS p
had VBD p
a DT p
histopathologic JJ p
diagnosis NN p
of IN p
CIN3 NNP p
and CC p
PCR-based JJ i
HPV NNP i
genotyping VBG i
results NNS i
on IN p
cervical JJ p
specimens NNS p
. . p

The DT N
genotyping VBG N
results NNS N
were VBD N
ranked VBN N
hierarchically RB N
according VBG N
to TO N
cancer NN N
risk NN N
: : N
HPV16 NNP N
> VBZ N
other JJ N
carcinogenic JJ N
HPV NNP N
> NNP N
noncarcinogenic JJ N
HPV NNP N
> NNP N
PCR NNP N
negative JJ N
. . N

RESULTS NNP N
Among IN N
the DT N
608 CD p
women NNS p
diagnosed VBN p
with IN p
CIN3 NNP p
, , N
601 CD N
( ( N
98.8 CD N
% NN N
) ) N
cases NNS N
were VBD N
positive JJ N
for IN N
any DT N
HPV NNP N
genotype NN N
and CC N
95.4 CD N
% NN N
for IN N
any DT N
carcinogenic JJ o
HPV NNP o
. . o

HPV16 NNP o
( ( N
59.9 CD N
% NN N
) ) N
, , N
HPV31 NNP o
( ( N
18.1 CD N
% NN N
) ) N
, , N
HPV52 NNP o
( ( N
14.8 CD N
% NN N
) ) N
, , N
HPV51 NNP o
( ( N
14.0 CD N
% NN N
) ) N
, , N
and CC N
HPV18 NNP o
( ( N
13.2 CD N
% NN N
) ) N
were VBD N
the DT N
five CD N
most JJS N
common JJ N
HPV NNP N
genotypes NNS N
detected VBD N
. . N

Younger JJR o
age NN o
, , o
consensus NN o
histologic JJ o
confirmation NN o
, , o
smoking NN o
, , o
and CC o
multiparity NN o
increased VBD N
the DT N
likelihood NN N
of IN N
testing VBG o
HPV NNP o
16 CD o
positive JJ o
. . o

Specifically RB N
, , N
HPV16-positive JJ o
CIN3 NNP o
occurred VBD N
at IN N
a DT N
younger JJR N
age NN N
than IN N
CIN3 NNP o
positive JJ o
for IN N
other JJ N
carcinogenic JJ o
HPV NNP o
genotypes NNS o
( ( N
median NN N
of IN N
23.5 CD N
years NNS N
versus IN N
25 CD N
years NNS N
, , N
respectively RB N
; : N
P NNP N
= VBZ N
0.0003 CD N
, , N
Kruskal-Wallis NNP N
) ) N
. . N

CONCLUSIONS NNP N
HPV16-positive JJ o
CIN3 NNP o
was VBD N
more RBR N
commonly RB N
diagnosed VBN N
in IN N
younger JJR N
women NNS N
( ( N
versus IN N
older JJR N
women NNS N
) ) N
, , N
with IN N
consensus NN N
diagnosis NN N
( ( N
versus IN N
some DT N
disagreement NN N
between IN N
reviewers NNS N
) ) N
, , N
and CC N
in IN N
smokers NNS N
( ( N
versus IN N
nonsmokers NNS N
) ) N
, , N
and CC N
was VBD N
less JJR N
commonly RB N
diagnosed VBN N
in IN N
multiparous JJ N
women NNS N
compared VBN N
CIN3 NNP o
positive JJ o
for IN N
other JJ N
carcinogenic JJ o
HPV NNP o
genotypes NNS o
. . o

IMPACT NNP N
In IN N
populations NNS N
vaccinated VBN N
against IN N
HPV16 NNP i
( ( i
and CC i
HPV18 NNP i
) ) i
, , N
the DT N
median JJ N
age NN N
of IN N
CIN3 NNP N
in IN N
women NNS N
with IN N
ASCUS NNP N
and CC N
LSIL NNP N
cytology NN N
should MD N
shift VB N
to TO N
older JJR N
ages NNS N
, , N
possibly RB N
permitting VBG N
later RB N
age NN N
at IN N
first JJ N
screening NN N
. . N

-DOCSTART- -23992605- O O

A DT N
comparison NN N
of IN N
Villalta-Prandoni NNP i
scale NN i
and CC N
venous JJ i
clinical JJ i
severity NN i
score NN i
in IN N
the DT N
assessment NN N
of IN N
post NN o
thrombotic JJ o
syndrome NN o
. . o

BACKGROUND NNP N
Post-thrombotic JJ N
syndrome NN N
( ( N
PTS NNP N
) ) N
is VBZ N
the DT N
most RBS N
important JJ N
late JJ N
complication NN N
of IN N
acute JJ p
deep JJ p
venous JJ p
thrombosis NN p
( ( p
DVT NNP p
) ) p
, , N
with IN N
as RB N
many JJ N
as IN N
two-thirds NNS N
of IN N
patients NNS N
developing VBG N
symptoms NNS N
of IN N
pain NN o
, , o
edema NN o
, , o
hyperpigmentation NN o
, , N
or CC N
ulceration NN o
. . o

Although IN N
several JJ N
instruments NNS N
are VBP N
available JJ N
for IN N
evaluation NN N
of IN N
the DT N
severity NN N
of IN N
PTS NNP N
, , N
including VBG N
the DT N
Villalta-Prandoni NNP o
scale NN o
( ( o
VPS NNP o
) ) o
and CC N
Venous JJ o
Clinical NNP o
Severity NNP o
Score NNP o
( ( o
VCSS NNP o
) ) o
, , N
no DT N
studies NNS N
have VBP N
yet RB N
compared VBN N
the DT N
2 CD N
instruments NNS N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
compare VB N
the DT N
2 CD N
instruments NNS N
as IN N
part NN N
of IN N
a DT N
larger JJR N
randomized VBN N
controlled VBD N
study NN N
that WDT N
assessed VBD N
the DT N
impact NN N
of IN N
graduated JJ i
compressive JJ i
stockings NNS i
in IN N
the DT N
prevention NN N
of IN N
PTS NNP N
. . N

METHODS NNP N
Sixty-nine JJ p
consecutive JJ p
patients NNS p
with IN p
acute JJ p
DVT NNP p
documented VBN p
by IN p
duplex JJ p
ultrasonography NN p
were VBD N
randomized VBN N
to TO N
treatment NN N
with IN N
30-40 JJ i
mm NN i
Hg NNP i
graduated VBD i
compressive JJ i
stockings NNS i
( ( i
GCS NNP i
) ) i
or CC i
no DT i
stockings NNS i
. . i

Patients NNS p
were VBD p
followed VBN p
clinically RB p
at IN p
months NNS p
1 CD p
, , p
3 CD p
, , p
6 CD p
, , p
12 CD p
, , p
18 CD p
, , p
and CC p
24 CD p
after IN p
the DT p
diagnosis NN p
of IN p
DVT NNP p
. . p

PTS NNP N
as IN N
defined VBN N
by IN N
the DT N
VPS NNP N
and CC N
VCSS NNP N
were VBD N
assessed VBN N
at IN N
these DT N
follow-up JJ N
visits NNS N
. . N

Based VBN N
upon IN N
the DT N
VPS NNP N
, , N
PTS NNP N
was VBD N
scored VBN N
as IN N
absent NN N
( ( N
score NN N
< VBZ N
3 CD N
or CC N
3 CD N
without IN N
objective JJ N
criteria NNS N
) ) N
, , N
mild FW N
to TO N
moderate VB N
( ( N
score NN N
?3 NN N
with IN N
1 CD N
objective JJ N
criteria NNS N
) ) N
, , N
or CC N
severe RB N
( ( N
score VB N
?4 NN N
) ) N
. . N

For IN N
the DT N
VCSS NNP N
, , N
PTS NNP N
was VBD N
considered VBN N
to TO N
be VB N
absent JJ N
( ( N
score VB N
?3 NN N
) ) N
, , N
mild FW N
to TO N
moderate VB N
( ( N
score VB N
4-7 NN N
) ) N
, , N
or CC N
severe RB N
( ( N
score VB N
?8 NN N
) ) N
. . N

The DT N
2 CD N
instruments NNS N
were VBD N
compared VBN N
for IN N
mild NN N
to TO N
moderate VB N
and CC N
severe JJ N
disease NN N
using VBG N
the DT N
Pearson NNP N
chi-squared JJ N
test NN N
and CC N
gamma NN N
statistic NN N
. . N

RESULTS NNP N
Good JJ N
correlation NN N
was VBD N
detected VBN N
in IN N
the DT N
ability NN N
of IN N
VPS NNP N
and CC N
VCSS NNP N
instruments NNS N
to TO N
detect VB N
mild NN N
to TO N
moderate VB N
disease NN N
( ( N
gamma JJ N
statistic JJ N
= NNP N
0.71-0.98 NN N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

For IN N
severe JJ N
disease NN N
, , N
a DT N
statistically RB N
significant JJ N
correlation NN N
was VBD N
not RB N
found VBN N
in IN N
the DT N
ability NN N
of IN N
the DT N
2 CD N
instruments NNS N
to TO N
detect VB N
disease NN N
( ( N
gamma JJ N
statistic JJ N
= NNP N
0.5-0.98 NN N
; : N
P NNP N
> NNP N
0.05 CD N
) ) N
, , N
especially RB N
at IN N
12 CD N
and CC N
24 CD N
months NNS N
. . N

CONCLUSION NNP i
Both NNP i
VPS NNP i
and CC i
the DT N
VCSS NNP i
scoring VBG i
systems NNS N
are VBP N
important JJ N
tools NNS N
in IN N
the DT N
identification NN N
and CC N
follow-up NN N
of IN N
PTS NNP N
. . N

There EX N
exists VBZ N
agreement NN N
between IN N
the DT N
2 CD N
instruments NNS N
for IN N
detecting VBG N
mild NN N
to TO N
moderate VB N
disease NN N
. . N

For IN N
severe JJ N
disease NN N
however RB N
, , N
VCSS NNP N
may MD N
possibly RB N
be VB N
a DT N
more RBR N
sensitive JJ N
instrument NN N
. . N

-DOCSTART- -7612555- O O

Prospective JJ N
trial NN N
of IN N
intraoperative JJ i
mitomycin NN i
C NNP i
in IN N
the DT N
treatment NN N
of IN N
primary JJ p
pterygium NN p
. . p

AIMS VB N
A NNP N
prospective JJ N
, , N
randomised VBD N
, , N
double JJ N
blind NN N
, , N
placebo NN i
controlled VBD N
study NN N
of IN N
intraoperative JJ i
mitomycin NN i
C NNP i
as IN N
adjunctive JJ N
treatment NN N
of IN N
primary JJ p
pterygium NN p
was VBD N
conducted VBN N
. . N

METHODS NNP N
A NNP p
total NN p
of IN p
66 CD p
eyes NNS p
of IN p
54 CD p
patients NNS p
with IN p
primary JJ p
pterygium NN p
were VBD N
treated VBN N
with IN N
excision NN i
, , i
with IN i
or CC i
without IN i
a DT i
single JJ i
intraoperative JJ i
application NN i
of IN i
mitomycin NN i
C NNP i
( ( N
0.1 CD N
mg/ml NN N
for IN N
5 CD N
minutes NNS N
) ) N
to TO N
evaluate VB N
the DT N
efficacy NN o
and CC o
toxicity NN o
of IN N
this DT N
adjunctive JJ N
treatment NN N
. . N

The DT N
mean NN N
follow VBP N
up RB N
was VBD N
14.1 CD N
months NNS N
( ( N
range VB N
12-23 JJ N
months NNS N
) ) N
. . N

RESULTS NNP N
Of IN N
the DT N
36 CD N
eyes NNS N
that WDT N
underwent JJ N
simple JJ N
excision NN N
, , N
14 CD N
( ( N
38.8 CD N
% NN N
) ) N
exhibited VBD N
recurrences NNS o
whereas IN N
only RB N
one CD N
of IN N
30 CD N
eyes NNS N
( ( N
3.33 CD N
% NN N
) ) N
treated VBD N
with IN N
excision NN N
and CC N
intraoperative JJ N
application NN N
of IN N
mitomycin NN i
C NNP i
had VBD N
recurrence NN o
( ( N
p JJ N
= NNP N
0.0006 CD N
) ) N
. . N

Neither CC N
serious JJ N
ocular JJ o
complications NNS o
nor CC o
systemic JJ o
toxicity NN o
were VBD N
noted VBN N
in IN N
the DT N
mitomycin NN i
C NNP i
treated VBD N
group NN N
. . N

CONCLUSION NNP N
Intraoperative NNP N
mitomycin NN i
C NNP i
appears VBZ N
to TO N
be VB N
an DT N
effective JJ N
and CC N
safe JJ N
adjunctive JJ N
treatment NN N
of IN N
primary JJ p
pterygium NN p
. . p

-DOCSTART- -25801501- O O

The DT N
Effects NNPS N
of IN N
Naltrexone NNP i
on IN N
Subjective NNP N
Response NNP N
to TO N
Methamphetamine NNP i
in IN N
a DT N
Clinical JJ p
Sample NN p
: : p
a DT N
Double-Blind NNP N
, , N
Placebo-Controlled NNP N
Laboratory NNP N
Study NNP N
. . N

Methamphetamine NNP i
( ( p
MA NNP p
) ) p
use NN p
disorder NN p
is VBZ N
a DT N
serious JJ N
psychiatric JJ N
condition NN N
for IN N
which WDT N
there EX N
are VBP N
no DT N
FDA-approved JJ N
medications NNS N
. . N

Naltrexone NNP i
( ( N
NTX NNP N
) ) N
is VBZ N
an DT N
opioid JJ N
receptor NN N
antagonist NN N
with IN N
demonstrated JJ N
efficacy NN N
, , N
albeit IN N
moderate JJ N
, , N
for IN N
the DT N
treatment NN N
of IN N
alcoholism NN N
and CC N
opioid JJ N
dependence NN N
. . N

Preclinical NNP N
and CC N
clinical JJ N
studies NNS N
suggest VBP N
that IN N
NTX NNP N
may MD N
be VB N
useful JJ N
for IN N
the DT N
treatment NN N
of IN N
MA NNP N
use NN N
disorder NN N
. . N

To TO N
inform VB N
treatment NN N
development NN N
, , N
we PRP N
conducted VBD N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
crossover NN N
, , N
placebo-controlled JJ N
human JJ N
laboratory NN N
study NN N
of IN N
NTX NNP N
. . N

Non-treatment-seeking JJ p
individuals NNS p
meeting VBG p
DSM-IV NNP p
criteria NNS p
for IN p
MA NNP p
abuse NN p
or CC p
dependence NN p
( ( p
n=30 NN p
) ) p
completed VBD p
two CD p
separate JJ p
5-day JJ p
inpatient NN p
stays NNS p
. . p

During IN N
each DT N
admission NN N
, , N
participants NNS N
completed VBD N
testing VBG N
sessions NNS N
comprised VBN N
of IN N
MA NNP i
cue-reactivity NN N
and CC N
intravenous JJ i
MA NNP i
administration NN i
( ( i
30 CD i
mg NN i
) ) i
after IN i
receiving VBG i
oral JJ i
NTX NNP i
( ( i
50 CD i
mg NN i
) ) i
or CC i
placebo NN i
for IN i
4 CD N
days NNS N
. . N

This DT N
study NN N
tested VBD N
the DT N
hypotheses NNS N
that WDT N
NTX NNP N
would MD N
( ( N
a DT N
) ) N
attenuate NN N
cue-induced JJ N
MA NNP N
craving NN N
, , N
and CC N
( ( N
b NN N
) ) N
reduce VB N
subjective JJ N
responses NNS N
to TO N
MA NNP N
administration NN N
. . N

Results NNP N
largely RB N
supported VBD N
the DT N
study NN N
hypotheses NNS N
such JJ N
that IN N
( ( N
a DT N
) ) N
NTX NNP N
significantly RB N
blunted VBD N
cue-induced JJ N
craving NN N
for IN N
MA NNP N
and CC N
( ( N
b NN N
) ) N
attenuated VBD N
several JJ N
of IN N
the DT N
hedonic JJ N
subjective JJ N
effects NNS N
of IN N
MA NNP N
, , N
including VBG N
craving NN N
, , N
during IN N
controlled VBN N
MA NNP N
administration NN N
and CC N
as IN N
compared VBN N
with IN N
placebo NN i
. . i

NTX NNP i
decreased VBD N
overall JJ o
subjective JJ o
ratings NNS o
of IN o
'crave JJ o
drug NN o
, , o
' '' o
'stimulated VBN o
, , o
' '' o
and CC o
'would MD o
like VB o
drug NN o
access NN o
, , o
' '' o
decreased VBD o
the DT N
the DT N
post-MA JJ N
administration NN N
timecourse NN o
of IN o
'anxious JJ o
' POS o
and CC o
increased VBD o
ratings NNS o
of IN o
'bad JJ o
drug NN o
effects NNS o
, , o
' '' o
as IN o
compared VBN N
with IN N
placebo NN i
. . i

These DT i
findings NNS N
support VBP N
a DT N
potential JJ N
mechanism NN N
of IN N
action NN N
by IN N
showing VBG N
that IN N
NTX NNP N
reduced VBD o
cue-induced JJ o
craving NN o
and CC o
subjective JJ o
responses NNS o
to TO o
MA NNP o
. . o

This DT N
is VBZ N
consistent JJ N
with IN N
positive JJ N
treatment NN N
studies NNS i
of IN i
NTX NNP i
for IN N
amphetamine JJ i
dependence NN i
, , N
as RB N
well RB N
as IN N
ongoing VBG N
clinical JJ N
trials NNS N
for IN N
MA NNP N
. . N

-DOCSTART- -19481433- O O

Clinical JJ N
impact NN N
of IN N
leak JJ N
compensation NN N
during IN N
non-invasive JJ N
ventilation NN N
. . N

BACKGROUND NNP N
This DT N
study NN N
aimed VBD N
to TO N
assess VB N
the DT N
impact NN N
of IN N
leak JJ N
compensation NN N
capabilities NNS N
during IN N
pressure- JJ i
and CC i
volume-limited JJ i
non-invasive JJ i
positive-pressure NN i
ventilation NN i
( ( i
NPPV NNP i
) ) i
in IN N
COPD NNP N
patients NNS N
. . N

METHODS NNP N
Fourteen NNP p
patients NNS p
with IN p
stable JJ p
hypercapnic JJ p
COPD NN p
who WP p
were VBD p
receiving VBG p
long-term JJ p
NPPV NNP p
were VBD p
included VBN p
in IN p
the DT p
study NN p
. . p

For IN N
both DT N
modes NNS N
of IN N
NPPV NNP N
, , N
a DT N
full JJ i
face NN i
mask NN i
and CC i
an DT i
artificial JJ i
leak NN i
in IN i
the DT i
ventilatory NN i
circuit NN i
were VBD N
used VBN N
at IN N
three CD N
different JJ N
settings NNS N
, , N
and CC N
applied VBD N
during IN N
daytime JJ N
NPPV NNP N
, , N
either RB i
without IN i
leakage NN i
( ( i
setting VBG i
I PRP i
) ) i
, , i
with IN i
leakage NN i
during IN i
inspiration NN i
only RB i
( ( i
setting VBG i
II NNP i
) ) i
, , i
and CC i
with IN i
leakage NN i
during IN i
inspiration NN i
and CC i
expiration NN i
( ( i
setting VBG i
III NNP i
) ) i
. . i

Ventilation NNP o
pattern NN o
was VBD N
pneumotachy-graphically RB N
recorded VBN N
. . N

RESULTS NNP N
NPPV NNP N
was VBD N
feasible JJ N
with IN N
negligible JJ N
leak NN o
volumes NNS o
, , N
indicating VBG N
optimal JJ N
mask NN N
fitting VBG N
during IN N
the DT N
daytime NN N
( ( N
setting VBG N
I PRP N
) ) N
. . N

In IN N
the DT N
presence NN N
of IN N
leakage NN o
( ( N
settings NNS N
II NNP N
and CC N
III NNP N
) ) N
, , N
the DT N
attempt NN N
to TO N
compensate VB N
for IN N
leak NN N
was VBD N
only RB N
evident JJ N
during IN N
pressure-limited JJ N
NPPV NNP N
, , N
since IN N
inspiratory NN o
volumes NNS o
delivered VBN o
by IN o
the DT o
ventilator NN o
increased VBD N
from IN N
726+/-129 NNP N
( ( N
setting VBG N
I PRP N
) ) N
to TO N
1104+/-164 JJ N
( ( N
setting VBG N
II NNP N
) ) N
, , N
and CC N
to TO N
1257+/-166 JJ N
( ( N
setting VBG N
III NNP N
) ) N
ml NN N
during IN N
pressure-limited JJ N
NPPV NNP N
, , N
respectively RB N
( ( N
all DT N
p VBP N
< $ N
0.001 CD N
) ) N
; : N
however RB N
, , N
they PRP N
remained VBD N
stable JJ N
during IN N
volume-limited JJ N
NPPV NNP N
. . N

Leak NNP N
compensation NN N
resulted VBD N
in IN N
a DT N
decrease NN N
in IN N
leakage-induced JJ o
dyspnea NN o
. . o

However RB N
, , N
83 CD N
% NN N
/87 CD N
% NN N
( ( N
setting VBG N
II/III NNP N
) ) N
of IN N
the DT N
additionally-delivered JJ N
inspiratory NN N
volume NN N
during IN N
pressure-limited JJ N
NPPV NNP N
was VBD N
also RB N
lost VBN N
via IN N
leakage NN N
. . N

Expiratory JJ o
volume NN o
was VBD N
higher RBR N
in IN N
setting VBG N
II NNP N
compared VBN N
to TO N
setting VBG N
III NNP N
( ( N
both DT N
p VBP N
< $ N
0.001 CD N
) ) N
, , N
indicating VBG N
the DT N
presence NN N
of IN N
significant JJ N
expiratory JJ N
leakage NN N
. . N

CONCLUSIONS VB N
The DT N
attempt NN N
at IN N
leak JJ N
compensation NN N
largely RB N
feeds VBZ N
the DT N
leakage NN N
itself PRP N
and CC N
only RB N
results NNS N
in IN N
a DT N
marginal JJ N
increase NN N
of IN N
tidal JJ N
volume NN N
. . N

However RB N
, , N
pressure-limited JJ N
-- : N
but CC N
not RB N
volume-limited JJ N
-- : N
NPPV JJ N
results NNS N
in IN N
a DT N
clinically-important JJ N
leak JJ N
compensation NN N
in IN N
vivo NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
www.uniklinik-freiburg.de/zks/live/uklregister/Oeffentlich.html JJ N
Identifier NNP N
: : N
UKF001272 NN N
. . N

-DOCSTART- -7326194- O O

Lower JJR N
relapse NN N
rates NNS N
after IN N
neighbourhood JJ N
injection NN N
of IN N
Corynebacterium NNP i
parvum NN i
in IN N
operable JJ N
cervix NN N
carcinoma NN N
. . N

The DT N
effect NN N
of IN N
adjuvant JJ N
immunotherapy NN N
with IN N
a DT N
single JJ i
neighbourhood NN i
injection NN i
of IN i
2 CD i
mg NNS i
C. NNP i
parvum NN i
( ( i
CP NNP i
) ) i
was VBD N
investigated VBN N
in IN N
a DT N
randomized JJ N
study NN N
involving VBG N
43 CD p
patients NNS p
with IN p
carcinoma NN p
of IN p
the DT p
cervix NN p
uteri NN p
, , p
all DT p
of IN p
whom WP p
were VBD p
treated VBN p
by IN p
radical JJ i
surgery NN i
. . i

All DT p
patients NNS p
had VBD p
carcinoma NNS p
confined VBN p
to TO p
the DT p
cervix NN p
, , p
the DT p
upper JJ p
part NN p
of IN p
the DT p
vagina NN p
or CC p
the DT p
parametrial JJ p
region NN p
. . p

When WRB p
the DT p
malignancy NN p
had VBD p
spread VBN p
to TO p
the DT p
parametrial JJ p
region NN p
, , p
additional JJ p
postoperative NN i
radiotherapy NN i
was VBD p
given VBN p
. . p

22 CD p
patients NNS p
received VBD p
immunotherapy JJ i
10 CD p
days NNS p
before RB p
surgery NN p
, , p
whereas IN p
the DT p
remaining VBG p
21 CD p
control NN p
patients NNS p
received VBD p
no DT i
immune JJ i
stimulation NN i
. . i

Only RB N
minor JJ N
side NN o
effects NNS o
of IN N
CP NNP N
were VBD N
encountered VBN N
. . N

Follow-up NN N
shows VBZ N
a DT N
relapse NN o
rate NN o
of IN N
5 CD N
% NN N
in IN N
the DT N
CP NNP N
treated VBD N
group NN N
and CC N
of IN N
29 CD N
% NN N
in IN N
the DT N
controls NNS N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

A DT N
further JJ N
15 CD p
patients NNS p
with IN p
more RBR p
advanced JJ p
malignancies NNS p
were VBD p
added VBN p
to TO p
our PRP$ p
studies NNS p
. . p

In IN N
these DT N
, , N
CP NNP i
stimulation NN i
had VBD N
no DT N
effect NN N
on IN N
relapse NN o
rates NNS o
, , N
but CC N
the DT N
relapse-free JJ o
intervals NNS o
were VBD N
longer RB N
after IN N
immune JJ i
stimulation NN i
: : i
control NN N
3.5 CD N
months NNS N
( ( N
mean JJ N
) ) N
+/- JJ N
1.5 CD N
( ( N
s.d NN N
. . N

) ) N
, , N
CP NNP N
13.0 CD N
months NNS N
+/- JJ N
7.0 CD N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

The DT N
number NN o
of IN o
peripheral JJ o
T NNP o
cells NNS o
and CC o
the DT o
ability NN o
to TO o
become VB o
sensitized JJ o
to TO o
DNCB NNP o
were VBD N
increased VBN N
after IN N
CP NNP i
stimulation NN i
. . i

A DT N
decrease NN N
was VBD N
found VBN N
in IN N
the DT N
number NN o
of IN o
blood NN o
monocytes NNS o
and CC o
the DT o
number NN o
of IN o
monocytes NNS o
capable JJ o
of IN o
transforming VBG o
into IN o
active JJ o
macrophages NNS o
, , N
indicating VBG N
a DT N
possible JJ N
sequestration NN N
of IN N
these DT N
cells NNS N
in IN N
the DT N
tissues NNS N
. . N

-DOCSTART- -10871578- O O

Plasma NNP N
antioxidant NN N
status NN N
after IN N
high-dose JJ i
chemotherapy NN i
: : i
a DT N
randomized JJ N
trial NN N
of IN N
parenteral JJ N
nutrition NN N
in IN N
bone NN p
marrow NN p
transplantation NN p
patients NNS p
. . p

BACKGROUND NNP N
Chemotherapy NNP i
and CC i
radiation NN i
therapy NN i
result NN N
in IN N
increased JJ N
free JJ N
radical JJ N
formation NN N
and CC N
depletion NN N
of IN N
tissue NN N
antioxidants NNS N
. . N

It PRP N
is VBZ N
not RB N
known VBN N
whether IN N
parenteral JJ i
nutrition NN i
( ( i
PN NNP i
) ) i
administered VBD N
during IN N
bone NN i
marrow NN i
transplantation NN i
( ( i
BMT NNP i
) ) i
supports VBZ N
systemic JJ N
antioxidant NN N
status NN N
. . N

OBJECTIVE CC N
The DT N
aims NNS N
of IN N
the DT N
study NN N
were VBD N
to TO N
determine VB N
1 CD N
) ) N
whether IN N
high-dose JJ i
chemotherapy NN i
decreases VBZ N
concentrations NNS N
of IN N
major JJ N
circulating VBG N
antioxidants NNS N
in IN N
patients NNS p
undergoing VBG p
BMT NNP i
and CC N
2 CD N
) ) N
whether IN N
administration NN N
of IN N
standard JJ N
PN NNP i
maintains VBZ N
systemic JJ N
antioxidant JJ N
concentrations NNS N
compared VBN N
with IN N
PN NNP i
containing VBG N
micronutrients NNS N
and CC N
minimal JJ N
lipids NNS N
alone RB N
. . N

DESIGN NNP N
Twenty-four JJ p
BMT NNP i
patients NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
standard JJ i
PN NNP i
containing VBG i
conventional JJ i
amounts NNS i
of IN i
dextrose NN i
, , i
amino JJ i
acids NNS i
, , i
micronutrients NNS i
, , i
and CC i
lipid JJ i
( ( N
120 CD N
kJ/d NN N
) ) N
or CC N
a DT N
solution NN i
containing VBG i
only JJ i
micronutrients NNS i
( ( N
identical JJ N
to TO N
those DT N
in IN N
standard JJ N
PN NNP N
) ) N
and CC N
a DT N
small JJ N
amount NN N
of IN N
lipid JJ N
( ( N
12 CD N
kJ/d NN N
) ) N
. . N

Plasma NNP o
antioxidant JJ o
status NN o
was VBD N
measured VBN N
before IN N
conditioning VBG N
therapy NN N
and CC N
serially RB N
at IN N
days NNS N
1 CD N
, , N
3 CD N
, , N
7 CD N
, , N
10 CD N
, , N
and CC N
14 CD N
after IN N
BMT NNP N
. . N

RESULTS NNP N
Plasma NNP o
glutathione NN o
( ( o
GSH NNP o
) ) o
and CC o
alpha- JJ o
and CC o
gamma-tocopherol JJ o
concentrations NNS o
decreased VBN N
and CC N
the DT N
GSH NNP o
redox NN o
state NN o
became VBD N
more RBR N
oxidized JJ N
after IN N
conditioning VBG N
chemotherapy NN N
. . N

Plasma NNP o
cysteine JJ o
concentrations NNS o
were VBD N
unchanged JJ N
, , N
whereas JJ N
cystine NN N
concentrations NNS N
increased VBD N
. . N

Plasma NNP o
vitamin JJ o
C NNP o
and CC o
zinc NNP o
concentrations NNS o
and CC o
GSH NNP o
peroxidase NN o
activity NN o
increased VBD N
over IN N
time NN N
. . N

Plasma VB o
alpha-tocopherol JJ o
concentrations NNS o
were VBD N
lower JJR N
in IN N
patients NNS N
given VBN N
standard JJ N
PN NNP N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
other JJ N
plasma JJ o
antioxidants NNS o
between IN N
groups NNS N
. . N

CONCLUSIONS VB N
A DT N
significant JJ N
decline NN N
in IN N
GSH-glutathione NNP o
disulfide NN o
, , o
cysteine-cystine NN o
, , o
and CC o
vitamin FW o
E NNP o
status NN o
occurs VBZ N
after IN N
chemotherapy NN i
and CC i
BMT NNP i
. . i

Standard NNP N
PN NNP N
does VBZ N
not RB N
improve VB N
antioxidant NN N
status NN N
compared VBN N
with IN N
administration NN N
of IN N
micronutrients NNS N
alone RB N
. . N

Further JJ N
evaluation NN N
of IN N
PN NNP N
formulations NNS N
to TO N
support VB N
patients NNS p
undergoing VBG p
high-dose JJ i
chemotherapy NN i
and CC N
BMT NNP i
are VBP N
needed VBN N
. . N

-DOCSTART- -4101734- O O

Fluorouracil NNP i
as IN N
an DT N
adjuvant NN N
to TO N
surgery VB i
in IN N
carcinoma NN p
of IN p
the DT p
colon NN p
. . p

-DOCSTART- -24641638- O O

Prophylactic JJ i
vs NN i
therapeutic JJ i
blood NN i
patch NN i
for IN N
obstetric JJ p
patients NNS p
with IN p
accidental JJ p
dural JJ p
puncture NN p
-- : p
a DT p
randomised JJ N
controlled VBN N
trial NN N
. . N

Epidural JJ i
blood NN i
patch NN i
is VBZ N
a DT N
standard JJ N
treatment NN N
for IN N
obstetric JJ p
patients NNS p
experiencing VBG p
a DT p
severe JJ p
post-dural JJ p
puncture NN p
headache NN p
. . p

Patients NNS p
who WP p
sustained VBD p
an DT p
accidental JJ p
dural JJ p
puncture NN p
during IN p
establishment NN p
of IN p
epidural JJ p
analgesia NN p
during IN p
labour NN p
or CC p
at IN p
caesarean JJ p
delivery NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
a DT N
prophylactic JJ i
epidural JJ i
blood NN i
patch NN i
or CC N
conservative JJ i
treatment NN i
with IN i
a DT i
therapeutic JJ i
epidural JJ i
blood NN i
patch NN i
if IN i
required VBN i
. . i

Eleven NNP p
of IN p
60 CD p
( ( p
18.3 CD p
% NN p
) ) p
patients NNS p
in IN N
the DT N
prophylactic JJ i
epidural JJ i
blood NN i
patch NN i
group NN N
developed VBD N
a DT N
post-dural JJ o
puncture NN o
headache NN o
compared VBN N
with IN N
39 CD p
of IN p
49 CD p
( ( p
79.6 CD p
% NN p
) ) p
in IN N
the DT N
therapeutic JJ i
epidural JJ i
blood NN i
patch NN i
group NN N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

A DT N
blood NN N
patch NN N
was VBD N
performed VBN N
in IN N
36 CD N
( ( N
73.4 CD N
% NN N
) ) N
of IN N
patients NNS N
in IN N
the DT N
therapeutic JJ N
group NN N
. . N

The DT N
number NN o
of IN o
patients NNS o
who WP o
needed VBD o
a DT o
second JJ o
blood NN o
patch NN o
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
two CD N
groups NNS N
: : N
6 CD N
( ( N
10.0 CD N
% NN N
) ) N
for IN N
prophylactic JJ i
epidural JJ i
blood NN i
patch NN i
and CC N
4 CD N
( ( N
11.1 CD N
% NN N
) ) N
for IN N
therapeutic JJ i
epidural JJ i
blood NN i
patch NN i
. . i

We PRP N
conclude VBP N
that IN N
prophylactic JJ i
epidural JJ i
blood NN i
patch NN N
is VBZ N
an DT N
effective JJ o
method NN N
to TO N
reduce VB N
the DT N
development NN N
of IN N
post-dural JJ N
puncture NN N
headache NN N
in IN N
obstetric JJ p
patients NNS p
. . p

-DOCSTART- -8616024- O O

Measurement NN N
of IN N
health-related JJ o
quality NN o
of IN o
life NN o
in IN N
multiple JJ p
myeloma NN p
. . p

Nordic NNP N
Myeloma NNP N
Study NNP N
Group NNP N
. . N

When WRB N
a DT N
randomized VBN N
trial NN N
( ( N
NMSG NNP N
4/90 CD N
) ) N
comparing VBG N
treatment NN N
with IN N
melphalan/prednisone NN i
to TO N
melphalan/ VB i
prednisone NN i
+ NNP i
interferon VBZ i
alpha-2b NN i
in IN N
newly RB p
diagnosed VBN p
multiple JJ p
myeloma NN p
was VBD N
initiated VBN N
in IN N
1990 CD N
, , N
a DT N
quality-of-life JJ o
assessment NN o
was VBD N
integrated VBN N
into IN N
the DT N
study NN N
. . N

We PRP N
used VBD N
the DT N
questionnaire NN N
( ( N
QLQ-C30 NNP N
) ) N
developed VBN N
by IN N
the DT N
European JJ N
Organization NNP N
of IN N
Research NNP N
and CC N
Treatment NNP N
of IN N
Cancer NNP N
( ( N
EORTC NNP N
) ) N
Study NNP N
Group NNP N
on IN N
Quality NNP o
of IN o
Life NNP o
. . o

The DT N
QLQ-C30 JJ N
incorporates NNS N
five CD N
functional JJ N
scales NNS N
, , N
three CD N
symptom NN N
scales NNS N
, , N
a DT N
global JJ N
health NN N
and CC N
quality-of JJ o
life NN o
scale NN o
and CC N
some DT N
single JJ N
symptom NN N
measures NNS N
. . N

The DT N
questionnaire NN N
was VBD N
completed VBN N
prior JJ N
to TO N
treatment NN N
and CC N
after IN N
1 CD N
, , N
6 CD N
, , N
12 CD N
, , N
24 CD N
, , N
36 CD N
and CC N
48 CD N
months NNS N
. . N

524 CD p
( ( p
90.2 CD p
% NN p
) ) p
of IN p
581 CD p
patients NNS p
enrolled VBN p
in IN p
the DT p
NMSG NNP p
4/90 CD p
completed VBD p
the DT p
first JJ p
questionnaire NN p
, , p
and CC p
484 CD p
( ( p
83.3 CD p
% NN p
) ) p
completed VBD p
all DT p
questionnaires NNS p
given VBN p
to TO p
them PRP p
. . p

All DT N
but CC N
one CD N
of IN N
the DT N
scales NNS N
met VBD N
the DT N
minimum JJ N
criteria NNS N
of IN N
reliability NN N
( ( N
Cronbach NNP N
's POS N
alpha NN N
> NNP N
/ NNP N
0.70 CD N
) ) N
. . N

Validity NNP N
was VBD N
shown VBN N
by IN N
( ( N
1 CD N
) ) N
the DT N
ability NN N
of IN N
the DT N
scales NNS N
to TO N
discriminate VB N
clearly RB N
between IN N
patients NNS N
differing VBG N
in IN N
clinical JJ N
status NN N
as IN N
defined VBN N
by IN N
pretreatment NN N
W.H.O NNP N
. . N

performance NN N
index NN N
and CC N
Durie NNP N
& CC N
Salmon NNP N
stage NN N
, , N
and CC N
( ( N
2 CD N
) ) N
the DT N
sensitivity NN N
to TO N
changes NNS N
in IN N
objective JJ N
disease NN N
status NN N
( ( N
response NN N
and CC N
relapse NN N
) ) N
. . N

This DT N
is VBZ N
the DT N
first JJ N
report NN N
of IN N
the DT N
measurement NN N
of IN N
health-related JJ o
quality NN o
of IN o
life NN o
in IN N
a DT N
prospective JJ N
clinical JJ N
trial NN N
in IN N
multiple JJ N
myeloma NN N
. . N

The DT o
results NNS o
demonstrate VBP o
that IN o
the DT o
QLQ-C30 NNP o
is VBZ o
a DT o
reliable JJ o
and CC o
valid JJ o
instrument NN o
for IN o
the DT o
measurement NN o
of IN o
quality NN o
of IN o
life NN o
in IN o
these DT o
patients NNS o
. . o

The DT N
data NN N
will MD N
be VB N
used VBN N
for IN N
a DT N
cost-utility JJ N
analysis NN N
of IN N
the DT N
results NNS N
of IN N
the DT N
NMSG NNP N
4/90 CD N
trial NN N
. . N

-DOCSTART- -18161643- O O

Improving VBG N
the DT N
transition NN p
from IN p
residential JJ i
to TO i
outpatient JJ i
addiction NN i
treatment NN i
: : i
gender NN N
differences NNS N
in IN N
response NN N
to TO N
supportive VB N
telephone NN N
calls NNS N
. . N

Substance NN N
use NN N
relapse NN N
rates NNS N
are VBP N
often RB N
high JJ N
in IN N
the DT N
first JJ N
months NNS N
after IN N
discharge NN N
from IN N
inpatient JJ i
substance NN i
abuse NN i
treatment NN i
, , N
and CC N
patient JJ o
adherence NN o
to TO o
aftercare VB o
plans NNS N
is VBZ N
often RB N
low JJ N
. . N

Four CD p
residential JJ p
addiction NN p
treatment NN p
centers NNS p
participated VBD N
in IN N
a DT N
feasibility NN N
study NN N
designed VBN N
to TO N
estimate VB N
the DT N
efficacy NN o
of IN N
a DT N
post-discharge JJ i
telephone NN i
intervention NN i
intended VBN i
to TO i
encourage VB i
compliance NN i
with IN i
aftercare NN i
. . i

A DT p
total NN p
of IN p
282 CD p
participants NNS p
( ( p
100 CD p
women NNS p
, , p
182 CD p
men NNS p
) ) p
with IN p
substance NN p
use NN p
disorders NNS p
were VBD p
included VBN p
in IN p
this DT p
secondary JJ p
analysis NN p
. . p

The DT N
findings NNS N
revealed VBD N
that IN N
women NNS N
were VBD N
more RBR N
likely JJ N
than IN N
men NNS N
to TO N
attend VB o
aftercare NN o
. . o

This DT N
gender NN N
effect NN N
persisted VBN N
after IN N
adjustment NN N
for IN N
a DT N
number NN N
of IN N
potential JJ N
mediators NNS N
. . N

-DOCSTART- -23381958- O O

Drug-drug JJ N
interaction NN N
study NN N
of IN N
ACT-178882 NNP N
, , N
a DT N
new JJ N
renin NN N
inhibitor NN N
, , N
and CC N
diltiazem NN N
in IN N
healthy JJ p
subjects NNS p
. . p

BACKGROUND NNP N
AND CC N
OBJECTIVE NNP N
The DT N
cytochrome NN N
P450 NNP N
( ( N
CYP NNP N
) ) N
enzyme NN N
, , N
CYP3A4 NNP N
, , N
metabolizes VBZ N
ACT-178882 NNP N
, , N
a DT N
new JJ N
direct JJ N
renin NN N
inhibitor NN N
. . N

This DT N
study NN N
investigated VBD N
the DT N
effect NN o
of IN N
diltiazem NN i
, , N
a DT N
moderate JJ N
inhibitor NN N
of IN N
CYP3A4 NNP N
, , N
on IN N
the DT N
single-dose JJ N
pharmacokinetics NNS N
of IN N
ACT-178882 NNP N
in IN N
healthy JJ p
subjects NNS p
. . p

METHODS NNP N
In IN N
this DT N
open-label JJ N
, , N
two-way JJ N
crossover NN N
, , N
drug-drug JJ N
interaction NN N
study NN N
, , N
healthy JJ p
young JJ p
male JJ p
subjects NNS p
received VBD N
treatments NNS N
A NNP N
and CC N
B NNP N
in IN N
a DT N
randomized JJ N
fashion NN N
. . N

Treatment VB N
A NNP N
consisted NN N
of IN N
a DT N
single JJ i
dose NN i
of IN i
100 CD i
mg JJ i
ACT-178882 NNP i
and CC i
treatment NN i
B NNP i
of IN i
diltiazem NN i
300 CD i
mg NN i
once RB i
a DT i
day NN i
for IN i
13 CD i
days NNS i
and CC i
a DT i
single JJ i
dose NN i
of IN i
100 CD i
mg JJ i
ACT-178882 JJ i
on IN i
day NN i
4 CD i
. . i

Serial JJ N
blood NN N
samples NNS N
for IN N
the DT N
measurement NN N
of IN N
ACT-178882 NNP N
were VBD N
drawn VBN N
pre-dose NN N
and CC N
up RB N
to TO N
120 CD N
h JJ N
post-dose JJ N
during IN N
treatment NN N
A NNP N
and CC N
pre-dose JJ N
ACT-178882 NNP N
and CC N
up RB N
to TO N
240 CD N
h JJ N
post-dose JJ N
during IN N
treatment NN N
B. NNP N
Trough NNP N
blood NN o
samples NNS o
for IN o
the DT o
measurement NN N
of IN N
diltiazem NN N
were VBD N
taken VBN N
on IN N
days NNS N
1-5 CD N
of IN N
dosing VBG N
during IN N
treatment NN o
B NNP o
. . o

Safety NNP o
was VBD o
assessed VBN o
by IN o
recording VBG o
of IN o
vital JJ o
signs NNS o
and CC o
electrocardiogram NN o
, , o
clinical JJ o
laboratory NN o
tests NNS o
and CC o
adverse JJ o
event NN o
reporting NN o
. . o

RESULTS NNP o
Fourteen JJ p
subjects NNS p
were VBD p
enrolled VBN p
and CC p
completed VBN p
the DT p
study NN p
. . N

In IN N
the DT N
absence NN N
of IN N
diltiazem NN N
, , N
the DT N
mean NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
) ) N
maximum NN N
concentration NN N
( ( N
Cmax NNP N
) ) N
and CC N
area NN N
under IN N
the DT N
curve NN N
from IN N
time NN N
zero CD N
to TO N
infinity NN N
( ( N
AUC? NNP N
) ) N
were VBD N
26.8 CD N
( ( N
20.1-35.8 JJ N
) ) N
ng/mL NN N
and CC N
454 CD N
( ( N
351-587 CD N
) ) N
ng?h/mL NN N
, , N
respectively RB N
. . N

In IN N
the DT N
presence NN N
of IN N
diltiazem NN N
these DT N
values NNS N
were VBD N
43.5 CD N
( ( N
36.8-51.4 CD N
) ) N
ng/mL NN N
and CC N
918 CD N
( ( N
781-1078 CD N
) ) N
ng?h/mL NN N
, , N
respectively RB o
. . o

The DT o
median JJ o
time NN o
to TO o
Cmax NNP o
( ( o
tmax NN o
) ) o
for IN o
ACT-178882 NNP N
was VBD N
prolonged VBN N
from IN N
3.5 CD N
to TO N
5.0 CD N
h NN N
by IN N
diltiazem JJ N
whereas NNS N
its PRP$ N
apparent JJ o
terminal JJ o
half-life NN o
( ( o
t? NN o
) ) o
was VBD o
unaffected VBN o
by IN N
diltiazem NN N
, , N
22.9 CD N
and CC N
24.2 CD N
h NN N
for IN N
treatments NNS N
A NNP N
and CC N
B NNP N
, , N
respectively RB N
. . N

Using VBG N
treatment NN N
A NNP N
as IN N
reference NN N
, , N
the DT o
geometric JJ o
mean NN o
ratio NN o
( ( o
90 CD N
% NN N
CI NNP N
) ) N
was VBD N
1.62 CD N
( ( N
1.36-1.94 CD N
) ) N
for IN o
Cmax NNP o
and CC o
2.02 CD N
( ( N
1.75-2.34 CD N
) ) N
for IN N
AUC? NNP N
, , N
indicating VBG N
a DT N
significant JJ N
interaction NN N
between IN N
ACT-178882 NNP N
and CC N
diltiazem NN N
. . N

One CD N
( ( N
7.1 CD N
% NN N
) ) N
and CC N
3 CD N
( ( N
21.3 CD N
% NN N
) ) N
of IN N
14 CD N
subjects NNS N
reported VBD o
an DT o
adverse JJ o
event NN o
during IN N
treatment NN N
A NNP N
and CC N
B NNP N
, , N
respectively RB N
, , N
with IN o
headache NN o
being VBG N
the DT N
most RBS N
frequently RB N
reported VBN N
, , N
with IN N
three CD N
events NNS N
. . N

There EX N
were VBD N
no DT N
clinically RB N
relevant JJ N
effects NNS N
of IN N
treatments NNS N
on IN N
vital JJ N
signs NNS N
, , N
electrocardiogram NN N
or CC N
clinical JJ N
laboratory NN N
variables NNS N
. . N

CONCLUSION NNP N
Concomitant NNP N
administration NN N
of IN N
diltiazem NN N
doubled VBD N
the DT N
exposure NN N
to TO N
ACT-178882 NNP N
without IN N
affecting VBG N
t? NN N
. . N

The DT N
clinical JJ N
significance NN N
of IN N
this DT N
increase NN N
is VBZ N
at IN N
present JJ N
unknown JJ N
and CC N
will MD N
need VB N
to TO N
be VB N
investigated VBN N
in IN N
future JJ N
clinical JJ N
studies NNS N
. . N

Treatment NN N
with IN N
ACT-178882 NNP N
alone RB N
or CC N
in IN N
combination NN N
with IN N
diltiazem NN N
was VBD N
safe JJ N
and CC N
well RB N
tolerated VBN N
. . N

-DOCSTART- -23436524- O O

Modulation NN N
of IN N
the DT N
intestinal JJ N
environment NN N
, , N
innate VB N
immune JJ N
response NN N
, , N
and CC N
barrier JJR N
function NN N
by IN N
dietary JJ i
threonine NN i
and CC i
purified JJ i
fiber NN i
during IN N
a DT N
coccidiosis NN N
challenge NN N
in IN N
broiler NN p
chicks NNS p
. . p

Coccidiosis NN N
is VBZ N
a DT N
major JJ N
contributor NN N
to TO N
economic JJ N
losses NNS N
in IN N
the DT N
poultry NN p
industry NN N
due JJ N
to TO N
its PRP$ N
detrimental JJ N
effects NNS N
on IN N
growth NN N
performance NN N
and CC N
nutrient JJ N
utilization NN N
. . N

We PRP N
hypothesized VBD N
that IN N
the DT N
combined JJ N
effects NNS N
of IN N
supplemental JJ i
dietary JJ i
Thr NNP i
and CC i
purified VBD i
fiber NN i
may MD N
modulate VB N
the DT N
intestinal JJ N
environment NN N
and CC N
positively RB N
affect JJ N
intestinal JJ N
immune NN N
responses NNS N
and CC N
barrier JJR N
function NN N
in IN N
broiler NN p
chicks NNS p
infected VBN p
with IN p
Eimeria NNP p
maxima NN p
. . p

A DT N
Thr-deficient JJ i
basal NN i
diet NN N
( ( N
3.1 CD N
g NN N
of IN N
Thr/kg NNP N
of IN N
diet NN N
) ) N
was VBD N
supplemented VBN N
with IN N
70 CD i
g/kg NN i
of IN i
silica NN i
sand NN i
( ( i
control NN i
) ) i
or CC i
high-methoxy JJ i
pectin NN i
and CC i
1 CD i
of IN i
2 CD i
concentrations NNS i
of IN i
Thr NNP i
( ( N
1.8 CD N
or CC N
5.3 CD N
g/kg NN N
of IN N
diet JJ N
; : N
4 CD N
diets NNS N
total JJ N
) ) N
, , N
and CC N
fed VBD N
to TO N
chicks NNS p
from IN p
hatch NN p
to TO p
d VB p
16 CD p
posthatch NN p
. . p

On IN N
d NN N
10 CD N
posthatch NN N
, , N
chicks NNS N
received VBD N
0.5 CD i
mL NN i
of IN i
distilled JJ i
water NN i
or CC i
an DT i
acute JJ i
dose NN i
of IN i
Eimeria NNP i
maxima NNP i
( ( N
1.5 CD N
? . N
10 CD N
( ( N
3 CD N
) ) N
sporulated VBN N
oocytes NNS N
) ) N
with IN N
6 CD N
replicate NN N
pens NNS N
of IN N
6 CD N
chicks NNS N
per IN N
each DT N
of IN N
8 CD N
treatment NN N
combinations NNS N
( ( N
4 CD N
diets NNS N
and CC N
2 CD N
inoculation NN N
states NNS N
) ) N
. . N

Body NNP o
weight VBD o
gain NN o
, , o
feed JJ o
intake NN o
, , o
and CC o
G NNP o
: : o
F NN o
increased VBD N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
with IN N
addition NN N
of IN N
5.3 CD N
g NN N
of IN N
Thr/kg NNP N
of IN N
diet JJ N
. . N

Eimeria NNP o
maxima JJ o
schizonts NNS o
were VBD N
present JJ N
only RB N
in IN N
intestinal JJ N
tissue NN N
sampled VBN N
from IN N
infected VBN N
birds NNS N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Weights NNS o
of IN o
cecal JJ o
digesta NN o
were VBD N
highest JJS N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
in IN N
pectin-fed JJ N
birds NNS N
, , N
and CC N
ceca NN N
with IN N
the DT N
heaviest JJS N
weights NNS N
also RB N
had VBD N
the DT N
highest JJS N
concentrations NNS N
of IN N
total JJ N
short-chain JJ N
fatty JJ N
acids NNS N
. . N

Expression NN o
of IN o
interleukin-12 NN o
in IN o
ileal JJ o
mucosa NN o
was VBD N
highest JJS N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
in IN N
infected JJ N
birds NNS N
receiving VBG N
the DT N
control NN N
diet JJ N
with IN N
5.3 CD N
g NN N
of IN N
supplemental JJ N
Thr/kg NNP N
. . N

In IN N
cecal JJ N
tonsils NNS N
, , N
interferon-? JJ o
expression NN o
was VBD o
highest JJS N
in IN N
infected JJ N
birds NNS N
receiving VBG N
the DT N
control NN N
diet NN N
( ( N
fiber VB N
? . N
infection NN N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
; : N
interferon-? JJ N
expression NN N
was VBD N
lowest JJS N
in IN N
infected JJ N
birds NNS N
fed VBD N
the DT N
high JJ N
Thr NNP N
diet NN N
( ( N
Thr NNP N
? . N
infection NN N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
differences NNS N
due RB N
to TO N
infection NN i
or CC i
Thr NNP i
supplementation NN i
for IN i
cytokine JJ N
expression NN N
in IN N
birds NNS N
fed VBN N
pectin-containing JJ N
treatments NNS N
. . N

Overall JJ N
, , N
we PRP N
conclude VBP N
that IN N
although IN N
pectin NN N
has VBZ N
some DT N
protective JJ N
function NN N
against IN N
coccidiosis NN N
, , N
Thr NNP N
supplementation NN N
had VBD N
the DT N
greatest JJS N
effect NN N
on IN N
intestinal JJ N
immune JJ N
response NN N
and CC N
maintenance NN N
of IN N
near IN N
normal JJ N
growth NN p
in IN p
young JJ p
broiler NN p
chicks NNS p
infected VBN p
with IN p
E. NNP p
maxima NNS p
. . p

-DOCSTART- -7381634- O O

Is VBZ N
anti-Pseudomonas JJ N
therapy NN N
warranted VBN N
in IN N
acute JJ N
respiratory NN o
exacerbations NNS o
in IN N
children NNS p
with IN p
cystic JJ p
fibrosis NN p
? . N
A DT N
controlled JJ N
study NN N
was VBD N
designed VBN N
to TO N
clarify VB N
the DT N
indications NNS N
for IN N
antibiotic JJ N
therapy NN N
in IN N
children NNS p
with IN p
advanced JJ p
cystic JJ p
fibrosis NN p
hospitalized VBN p
with IN p
respiratory JJ p
exacerbations NNS p
. . p

Twenty-two JJ p
children NNS p
with IN p
severe JJ p
CF NNP p
and CC p
signs NNS p
of IN p
acute NN p
lower JJR p
respiratory NN p
infection NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
cloxacillin NN i
or CC i
carbenicillin NN i
plus CC i
gentamicin NN i
administered VBD N
intravenously RB N
for IN N
ten JJ N
days NNS N
. . N

Other JJ N
aspects NNS N
of IN N
therapy NN N
were VBD N
constant JJ N
. . N

The DT N
groups NNS N
were VBD N
comparable JJ N
in IN N
all DT N
respects NNS N
and CC N
Pseudomonas NNP p
aeruginosa NN p
was VBD p
the DT p
predominant JJ p
sputum NN p
pathogen NN p
in IN p
most JJS p
patients NNS p
. . p

Clinical JJ o
improvement NN o
, , o
chest VBP o
radiograph NN o
changes NNS o
, , o
evidence NN o
of IN o
airway JJ o
obstruction NN o
, , o
and CC o
bacteriologic JJ o
flora NNS o
of IN o
sputum NN o
were VBD N
no DT N
different JJ N
regardless NN N
of IN N
the DT N
regimen NNS N
used VBN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
the DT N
use NN N
of IN N
anti-Pseudomonas JJ N
medication NN N
in IN N
these DT N
children NNS N
may MD N
not RB N
always RB N
be VB N
necessary JJ N
. . N

These DT N
observations NNS N
need VBP N
to TO N
be VB N
confirmed VBN N
by IN N
blind-controlled JJ N
studies NNS N
in IN N
larger JJR N
numbers NNS N
of IN N
patients NNS N
with IN N
mild JJ N
as RB N
well RB N
as IN N
severe JJ N
respiratory NN N
involvement NN N
. . N

-DOCSTART- -22525955- O O

Longitudinal JJ N
follow-up NN N
of IN N
children NNS p
with IN p
autism NN p
receiving VBG p
targeted VBN p
interventions NNS p
on IN p
joint JJ i
attention NN i
and CC i
play NN i
. . i

OBJECTIVE CC N
This DT N
study NN N
examines VBZ N
the DT N
cognitive NN o
and CC o
language NN o
outcomes NNS o
of IN N
children NNS p
with IN p
an DT p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
over IN p
a DT p
5-year JJ p
period NN p
after IN p
receiving VBG p
targeted VBD i
early JJ i
interventions NNS i
that WDT i
focused VBD i
on IN i
joint JJ i
attention NN i
and CC i
play NN i
skills NNS i
. . i

METHOD NNP N
Forty NNP p
children NNS p
from IN p
the DT p
original JJ p
study NN p
( ( p
n JJ p
= NNP p
58 CD p
) ) p
had VBD p
complete JJ p
data NNS p
at IN p
the DT p
5-year JJ p
follow-up NN p
. . p

RESULTS NNP N
In IN N
all DT N
, , N
80 CD N
% NN N
of IN N
children NNS N
had VBD N
achieved VBN N
functional JJ o
use NN o
of IN o
spoken JJ o
language NN o
with IN N
baseline JJ N
play NN N
level NN N
predicting VBG N
spoken JJ N
language NN N
at IN N
the DT N
5-year JJ N
follow-up NN N
. . N

Of IN N
children NNS N
who WP N
were VBD N
using VBG N
spoken JJ N
language NN N
at IN N
age NN N
8 CD N
years NNS N
, , N
several JJ N
baseline NN N
behaviors NNS N
predicted VBD N
their PRP$ N
later JJ N
ability NN N
, , N
including VBG N
earlier JJR N
age NN N
of IN N
entry NN N
into IN N
the DT N
study NN N
, , N
initiating VBG N
joint JJ o
attention NN o
skill NN o
, , o
play VB o
level NN o
, , N
and CC N
assignment NN N
to TO N
either VB N
the DT N
joint JJ i
attention NN i
or CC i
symbolic JJ i
play NN i
intervention NN N
group NN N
. . N

Only RB N
baseline JJ N
play NN N
diversity NN N
predicted VBD N
cognitive JJ N
scores NNS N
at IN N
age NN N
8 CD N
years NNS N
. . N

CONCLUSIONS VB N
This DT N
study NN N
is VBZ N
one CD N
of IN N
the DT N
only JJ N
long-term JJ N
follow-up JJ N
studies NNS N
of IN N
children NNS p
who WP p
participated VBD p
in IN p
preschool NN p
early JJ p
interventions NNS p
aimed VBN p
at IN p
targeting VBG p
core NN p
developmental NN p
difficulties NNS p
. . p

The DT N
study NN N
findings NNS N
suggest VBP N
that IN N
focusing VBG N
on IN N
joint JJ N
attention NN N
and CC N
play NN N
skills NNS N
in IN N
comprehensive JJ N
treatment NN N
models NNS N
is VBZ N
important JJ N
for IN N
long-term JJ o
spoken JJ o
language NN o
outcomes NNS o
. . o

-DOCSTART- -7956382- O O

Effect NN N
of IN N
TENS NNP N
on IN N
pain NN o
, , o
medications NNS o
, , o
and CC o
pulmonary JJ o
function NN o
following VBG p
coronary JJ p
artery JJ p
bypass NN p
graft NN p
surgery NN p
. . p

The DT N
efficacy NN N
of IN N
transcutaneous JJ i
electrical JJ i
nerve NN i
stimulation NN i
( ( i
TENS NNP i
) ) i
as IN N
an DT N
adjunct NN N
to TO N
narcotic JJ N
medications NNS N
for IN N
the DT N
management NN N
of IN N
postoperative JJ o
pain NN o
was VBD N
assessed VBN N
in IN N
a DT N
prospective JJ p
, , p
randomized VBN p
, , p
controlled VBD p
study NN p
of IN p
patients NNS p
following VBG p
coronary JJ p
artery JJ p
bypass NN p
graft NN p
( ( p
CABG NNP p
) ) p
surgery NN p
with IN p
the DT p
right NN p
or CC p
left VBD p
internal JJ p
thoracic NN p
artery NN p
( ( p
ITA NNP p
) ) p
. . p

Forty-five JJ p
male JJ p
patients NNS p
( ( p
mean JJ p
age NN p
, , p
57 CD p
+/- JJ p
6 CD p
years NNS p
) ) p
were VBD p
randomly RB p
assigned VBN p
to TO N
( ( N
1 CD N
) ) N
TENS NN i
, , N
( ( N
2 CD N
) ) N
placebo NN i
TENS NNP i
, , i
or CC i
( ( i
3 CD i
) ) i
control NN i
treatments NNS i
( ( N
n JJ N
= RB N
15 CD N
each DT N
) ) N
, , N
following VBG N
extubation NN N
and CC N
during IN N
the DT N
24- JJ N
to TO N
72-h JJ N
postoperative JJ N
period NN N
. . N

Two-way JJ N
analysis NN N
of IN N
variance NN N
tests NNS N
indicated VBD N
no DT N
significant JJ N
differences NNS N
among IN N
treatment NN N
groups NNS N
for IN N
( ( o
1 CD o
) ) o
pain NN o
with IN o
cough NN o
, , o
( ( o
2 CD o
) ) o
narcotic JJ o
medication NN o
intake NN o
, , o
( ( o
3 CD o
) ) o
FVC NNP o
, , o
( ( o
4 CD o
) ) o
FEV1 NNP o
, , o
and CC o
( ( o
5 CD o
) ) o
PEFR NNP o
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

However RB N
, , N
pain VBP o
at IN o
rest NN o
reported VBN N
by IN N
the DT N
TENS NNP p
group NN p
was VBD N
significantly RB N
lower JJR N
than IN N
that DT N
reported VBN N
by IN N
the DT N
control NN N
group NN N
( ( N
treatment NN N
main JJ N
effect NN N
; : N
p CC N
< VB N
0.04 CD N
) ) N
, , N
although IN N
no DT N
significant JJ N
differences NNS N
were VBD N
observed VBN N
between IN N
the DT N
TENS NNP N
and CC N
placebo NN N
or CC N
between IN N
the DT N
placebo NN N
and CC N
control NN N
groups NNS N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

All DT N
six CD N
criterion NN N
measures NNS N
were VBD N
characterized VBN N
by IN N
significant JJ N
changes NNS N
over IN N
time NN N
for IN N
the DT N
entire JJ N
group NN N
( ( N
n JJ N
= VBZ N
45 CD N
; : N
time NN N
main JJ N
effect NN N
; : N
p CC N
< VB N
0.01 CD N
) ) N
, , N
as IN N
follows VBZ N
: : N
pain NN o
and CC o
medication NN o
intake NN o
were VBD N
similar JJ N
on IN N
days NNS N
1 CD N
and CC N
2 CD N
, , N
but CC N
were VBD N
significantly RB N
less JJR N
on IN N
day NN N
3 CD N
, , N
and CC N
pulmonary JJ o
functions NNS o
were VBD N
significantly RB N
lower JJR N
than IN N
preoperatively RB N
on IN N
day NN N
1 CD N
, , N
decreased VBD N
further RBR N
on IN N
day NN N
2 CD N
, , N
and CC N
despite IN N
an DT N
improvement NN N
on IN N
day NN N
3 CD N
, , N
remained VBD N
significantly RB N
lower JJR N
than IN N
preoperative JJ N
values NNS N
( ( N
p VB N
< RB N
0.01 CD N
) ) N
. . N

This DT N
study NN N
suggests VBZ N
that IN N
the DT N
addition NN N
of IN N
TENS NNP i
, , N
applied VBD N
continuously RB N
during IN N
the DT N
immediate JJ N
postoperative JJ N
period NN N
following VBG N
CABG NNP N
with IN N
ITA NNP N
, , N
may MD N
not RB N
be VB N
advantageous JJ N
in IN N
pain NN o
management NN o
or CC N
the DT N
prevention NN N
of IN N
pulmonary JJ o
dysfunction NN o
. . o

-DOCSTART- -20548043- O O

Cognitive-behavioral JJ i
therapy NN i
for IN N
psychogenic JJ p
nonepileptic JJ p
seizures NNS p
: : p
a DT N
pilot NN N
RCT NNP N
. . N

OBJECTIVE NNP N
To TO N
compare VB N
cognitive-behavioral JJ i
therapy NN i
( ( i
CBT NNP i
) ) i
and CC i
standard JJ i
medical JJ i
care NN i
( ( i
SMC NNP i
) ) i
as IN N
treatments NNS N
for IN N
psychogenic JJ p
nonepileptic JJ p
seizures NNS p
( ( p
PNES NNP p
) ) p
. . p

METHODS NNP N
Our PRP$ N
randomized NN N
controlled VBN N
trial NN N
( ( N
RCT NNP N
) ) N
compared VBN N
CBT NNP i
with IN N
SMC NNP i
in IN N
an DT N
outpatient JJ N
neuropsychiatric JJ N
setting NN N
. . N

Sixty-six JJ p
PNES NNP p
patients NNS p
were VBD p
randomized VBN p
to TO N
either DT N
CBT NNP i
( ( N
plus CC N
SMC NNP i
) ) i
or CC N
SMC NNP i
alone RB N
, , N
scheduled VBN N
to TO N
occur VB N
over IN N
4 CD N
months NNS N
. . N

PNES NNP N
diagnosis NN N
was VBD N
established VBN N
by IN N
video-EEG JJ p
telemetry NN p
for IN p
most JJS p
patients NNS p
. . p

Exclusion NNP p
criteria NNS p
included VBD p
comorbid JJ p
history NN p
of IN p
epilepsy NN p
, , p
< VBP p
2 CD p
PNES/month NNP p
, , p
and CC p
IQ NNP p
< NNP p
70 CD p
. . p

The DT N
primary JJ N
outcome NN N
was VBD N
seizure JJ o
frequency NN o
at IN N
end NN N
of IN N
treatment NN N
and CC N
at IN N
6-month JJ N
follow-up NN N
. . N

Secondary JJ N
outcomes NNS N
included VBD N
3 CD o
months NNS o
of IN o
seizure NN o
freedom NN o
at IN o
6-month JJ o
follow-up NN o
, , o
measures NNS o
of IN o
psychosocial JJ o
functioning NN o
, , o
health NN o
service NN o
use NN o
, , o
and CC o
employment NN o
. . o

RESULTS NNP N
In IN N
an DT N
intention-to-treat JJ N
analysis NN N
, , N
seizure NN o
reduction NN o
following VBG o
CBT NNP o
was VBD N
superior JJ N
at IN N
treatment NN N
end NN N
( ( N
group NN N
x NNP N
time NN N
interaction NN N
p NN N
< VBZ N
0.0001 CD N
; : N
large JJ N
to TO N
medium VB N
effect NN N
sizes NNS N
) ) N
. . N

At IN N
follow-up JJ N
, , N
the DT N
CBT NNP i
group NN N
tended VBD N
to TO N
be VB N
more RBR N
likely JJ N
to TO N
have VB N
experienced VBN N
3 CD N
months NNS N
of IN N
seizure NN o
freedom NN o
( ( N
odds NNS N
ratio VBP N
3.125 CD N
, , N
p NN N
= NNP N
0.086 CD N
) ) N
. . N

Both DT N
groups NNS N
improved VBN N
in IN N
some DT N
health NN o
service NN o
use NN o
measures NNS o
and CC o
on IN o
the DT o
Work NN o
and CC o
Social NNP o
Adjustment NNP o
Scale NNP o
. . o

Mood NNP o
and CC o
employment NN o
status NN o
showed VBD N
no DT N
change NN N
. . N

CONCLUSIONS VB N
Our PRP$ N
findings NNS N
suggest VBP N
that IN N
cognitive-behavioral JJ i
therapy NN i
is VBZ N
more RBR N
effective JJ N
than IN N
standard RB N
medical JJ N
care NN N
alone RB N
in IN N
reducing VBG N
seizure NN N
frequency NN N
in IN N
PNES NNP p
patients NNS p
. . p

CLASSIFICATION NNP N
OF IN N
EVIDENCE NNP N
This DT N
study NN N
provides VBZ N
Class NNP N
III NNP N
evidence NN N
that WDT N
CBT NNP i
in IN N
addition NN N
to TO N
SMC NNP i
, , N
as IN N
compared VBN N
to TO N
SMC NNP i
alone RB N
, , N
significantly RB N
reduces VBZ N
seizure NN N
frequency NN N
in IN N
patients NNS p
with IN p
PNES NNP p
( ( N
change NN N
in IN N
median JJ N
monthly JJ N
seizure NN N
frequency NN N
: : N
baseline NN N
to TO N
6 CD N
months NNS N
follow-up RB N
, , N
CBT NNP N
group NN N
, , N
12 CD N
to TO N
1.5 CD N
; : N
SMC NNP N
alone RB N
group NN N
, , N
8 CD N
to TO N
5 CD N
) ) N
. . N

-DOCSTART- -772759- O O

Quantifications NNS p
of IN p
the DT p
major JJ p
urinary JJ o
metabolite NN o
of IN o
the DT o
E NNP o
prostaglandins NNS o
by IN p
mass NN i
spectrometry NN i
: : i
evaluation NN p
of IN p
the DT p
method NN p
's POS p
application NN p
to TO p
clinical JJ p
studies NNS p
. . p

Measurement NN N
of IN N
7alpha-hydroxy-5,11-diketotetranoprostane-1,16-dioic JJ N
acid NN N
, , N
( ( N
PGE-M NNP N
) ) N
, , N
the DT N
major JJ N
urinary JJ N
metabolite NN N
of IN N
prostaglandin NN N
E1 NNP N
and CC N
E2 NNP N
in IN N
man NN p
provides VBZ N
a DT N
useful JJ N
indicator NN N
to TO N
monitor VB N
prostaglandin JJ N
biosynthesis NN N
. . N

For IN N
quantitative JJ N
analysis NN N
of IN N
this DT N
prostaglandin NN N
metabolite NN N
and CC N
the DT N
stable-isotope JJ N
dilution NN N
techniqe NN N
of IN N
selected VBN i
ion NN i
monitoring NN i
( ( N
SIM NNP N
) ) N
is VBZ N
employed VBN N
using VBG N
gas-liquid JJ N
chromatography-mass JJ N
spectrometry NN N
. . N

The DT N
preparation NN N
of IN N
the DT N
bis NN i
( ( i
D3-methyloxime NNP i
) ) i
, , i
bis-methyl JJ i
ester NN i
of IN i
PGE-M NNP i
containing VBG N
a DT N
tritium NN N
tracer NN N
in IN N
position NN N
2 CD N
which WDT N
was VBD N
used VBN N
as IN N
internal JJ N
standard NN N
for IN N
the DT N
SIM NNP N
method NN N
is VBZ N
described VBN N
. . N

The DT N
synthesis NN N
of IN N
this DT N
internal JJ N
standard NN N
includes VBZ N
the DT N
biosynthetic JJ N
conversion NN N
of IN N
11-hydroxy-9,15-diketoprostanoic JJ N
acid NN N
to TO N
PGE-M NNP N
by IN N
the DT N
rabbit NN N
. . N

The DT N
intra-assay JJ N
coefficient NN N
of IN N
variation NN N
of IN N
this DT N
SIM NNP N
method NN N
ranged VBD N
between IN N
4.0 CD N
to TO N
6.7 CD N
percent NN N
. . N

The DT N
recovery NN N
of IN N
authentic JJ N
, , N
underivatized JJ N
PGE-M NNP N
added VBD N
to TO N
urine VB N
was VBD N
93 CD N
+/- JJ N
3 CD N
% NN N
( ( N
mean JJ N
+/- JJ N
SEM NNP N
, , N
n=17 NN N
) ) N
. . N

The DT N
levels NNS o
of IN o
PGE-M NNP o
excreted VBD o
in IN N
urine NN p
were VBD N
higher JJR N
( ( N
p IN N
less JJR N
than IN N
0.001 CD N
) ) N
in IN N
males NNS p
than IN p
in IN p
females NNS p
( ( p
15.2 CD p
+/- JJ p
1.9 CD p
mug/24 NN p
hours NNS p
( ( p
n=24 NN p
) ) p
and CC p
3.3 CD p
+/- JJ p
0.3 CD p
mug/24 NN p
hours NNS p
( ( p
n=17 NN p
) ) p
, , p
respectively RB p
. . p

These DT N
levels NNS N
were VBD N
in IN N
close JJ N
agreement NN N
with IN N
values NNS N
published VBN N
previously RB N
. . N

No DT N
significant JJ N
difference NN N
in IN N
excretion NN N
of IN N
PGE-M NNP N
between IN N
the DT N
sexes NNS p
was VBD p
observed VBN p
in IN p
the DT p
pre-pubertal JJ p
age-grou NN p
( ( p
male NN p
: : p
2.9 CD p
+/- JJ p
0.8 CD p
mug/24 NN p
hours NNS p
, , p
n=5 RB p
; : p
female NN p
: : p
3.1 CD p
+/- JJ p
0.9 CD p
mug/24 NN p
hours NNS p
, , p
n=5 NN p
) ) p
or CC p
in IN p
the DT p
age-group NN p
of IN p
45-80 CD p
years NNS p
( ( p
male NN p
: : p
9.3 CD p
+/- JJ p
1.1 CD p
mug/24 NN p
hours NNS p
, , p
n=21 RB p
; : p
female NN p
: : p
7.3 CD p
+/- JJ p
0.9 CD p
mug/24 NN p
hours NNS p
, , p
n=12 RB p
) ) p
. . p

The DT N
amount NN N
of IN N
PGE-M NNP N
excreted VBD N
decreased VBN N
significantly RB N
after IN N
administration NN N
of IN N
indomethacin NN i
or CC N
acetyl VB i
salicylic JJ i
acid NN i
in IN N
therapeutic JJ N
doses NNS N
. . N

The DT N
concomitant JJ N
reduction NN N
of IN N
the DT N
urinary JJ N
excretion NN N
of IN N
PGE-M NNP N
( ( N
68 CD N
to TO N
85 CD N
% NN N
decrease NN N
) ) N
and CC N
prostaglandin JJ N
E NNP N
( ( N
73 CD N
to TO N
100 CD N
% NN N
decrease NN N
) ) N
after IN N
indomethacin NN i
treatment NN N
in IN N
each DT N
case NN N
( ( N
n=8 NN N
) ) N
is VBZ N
evidence NN N
that IN N
a DT N
diminished JJ N
urinary JJ N
PGE-M NNP N
output NN N
reflects VBZ N
a DT N
decrease NN N
in IN N
prostaglandin NN N
E NNP N
biosynthesis NN N
. . N

-DOCSTART- -25022248- O O

Evidence NN N
for IN N
diminished JJ N
multisensory NN o
integration NN o
in IN N
autism NN p
spectrum NN p
disorders NNS p
. . p

Individuals NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
) ) p
exhibit NN N
alterations NNS N
in IN N
sensory JJ N
processing NN N
, , N
including VBG N
changes NNS N
in IN N
the DT N
integration NN N
of IN N
information NN N
across IN N
the DT N
different JJ N
sensory JJ N
modalities NNS N
. . N

In IN N
the DT N
current JJ N
study NN N
, , N
we PRP N
used VBD N
the DT N
sound-induced JJ i
flash NN i
illusion NN i
to TO N
assess VB N
multisensory JJ o
integration NN o
in IN N
children NNS p
with IN p
ASD NNP p
and CC p
typically-developing NN p
( ( p
TD NNP p
) ) p
controls VBZ p
. . p

Thirty-one CD p
children NNS p
with IN p
ASD NNP p
and CC p
31 CD p
age NN p
and CC p
IQ NNP p
matched VBD p
TD NNP p
children NNS p
( ( p
average JJ p
age NN p
= JJ p
12 CD p
years NNS p
) ) p
were VBD p
presented VBN N
with IN i
simple JJ i
visual JJ i
( ( i
i.e. FW i
, , i
flash NN i
) ) i
and CC i
auditory NN i
( ( i
i.e. FW i
, , i
beep NN i
) ) i
stimuli NN i
of IN i
varying VBG i
number NN i
. . i

In IN i
illusory JJ N
conditions NNS N
, , N
a DT N
single JJ N
flash NN N
was VBD N
presented VBN N
with IN N
2-4 JJ N
beeps NNS N
. . N

In IN N
TD NNP N
children NNS N
, , N
these DT N
conditions NNS N
generally RB N
result VBP N
in IN N
the DT N
perception NN o
of IN o
multiple JJ o
flashes NNS o
, , o
implying VBG o
a DT o
perceptual JJ o
fusion NN o
across IN o
vision NN o
and CC o
audition NN o
. . o

In IN o
the DT N
present JJ N
study NN N
, , N
children NNS N
with IN N
ASD NNP N
were VBD N
significantly RB N
less RBR N
likely JJ N
to TO N
perceive VB o
the DT o
illusion NN o
relative NN o
to TO N
TD NNP N
controls NNS N
, , N
suggesting VBG N
that IN o
multisensory JJ o
integration NN o
and CC o
cross-modal JJ o
binding NN o
may MD o
be VB N
weaker JJR N
in IN N
some DT N
children NNS N
with IN N
ASD NNP N
. . p

These DT p
results NNS N
are VBP N
discussed VBN N
in IN N
the DT N
context NN N
of IN N
previous JJ N
findings NNS N
for IN N
multisensory JJ o
integration NN o
in IN o
ASD NNP N
and CC N
future JJ N
directions NNS N
for IN N
research NN N
. . N

-DOCSTART- -20673485- O O

[ VB N
A NNP N
prospective JJ N
randomized VBN N
study NN N
of IN N
the DT N
radiotherapy NN i
volume NN i
for IN N
limited-stage JJ N
small JJ N
cell NN N
lung NN N
cancer NN N
: : N
a DT N
preliminary JJ N
report NN N
] NNP N
. . N

BACKGROUND NNP N
AND NNP N
OBJECTIVE NNP N
Controversies NNP N
exists VBZ N
with IN N
regard NN N
to TO N
target VB N
volumes NNS N
as RB N
far RB N
as IN N
thoracic JJ i
radiotherapy NN i
( ( i
TRT NNP i
) ) i
is VBZ N
concerned VBN N
in IN N
the DT N
multimodality NN N
treatment NN N
for IN N
limited-stage NN p
small JJ p
cell NN p
lung NN p
cancer NN p
( ( p
LSCLC NNP p
) ) p
. . p

The DT N
aim NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
prospectively RB N
compare VB N
the DT N
local JJ N
control NN N
rate NN N
, , N
toxicity NN N
profiles NNS N
, , N
and CC N
overall JJ N
survival NN N
( ( N
OS NNP N
) ) N
between IN N
patients NNS N
received VBN N
different JJ i
target NN i
volumes NNS i
irradiation VBP i
after IN i
induction NN i
chemotherapy NN i
. . i

METHODS NNP N
LSCLC NNP p
patients NNS p
received VBD N
2 CD N
cycles NNS N
of IN N
etoposide NN i
and CC i
cisplatin NN i
( ( i
EP NNP i
) ) i
induction NN i
chemotherapy NN i
and CC N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
TRT NNP i
to TO N
either VB N
the DT N
post- NN N
or CC N
pre-chemotherapy JJ N
tumor NN N
extent NN N
( ( N
GTV-T NNP N
) ) N
as IN N
study NN N
arm NN N
and CC N
control NN N
arm NN N
, , N
CTV-N NNP N
included VBD N
the DT N
positive JJ N
nodal JJ N
drainage NN N
area NN N
for IN N
both DT N
arms NNS N
. . N

One CD N
to TO N
2 CD N
weeks NNS N
after IN N
induction NN i
chemotherapy NN i
, , i
45 CD i
Gy/30 NNP i
Fx/19 NNP i
d NN i
TRT NNP i
was VBD N
administered VBN N
concurrently RB N
with IN N
the DT N
third JJ N
cycle NN N
of IN N
EP NNP i
regimen NNS i
. . i

After IN N
that DT N
, , N
additional JJ N
3 CD N
cycles NNS N
of IN N
EP NNP i
consolidation NN N
were VBD N
administered VBN N
. . N

Prophylactic JJ i
cranial JJ i
irradiation NN i
( ( i
PCI NNP i
) ) i
was VBD N
administered VBN N
to TO N
patients NNS N
with IN N
a DT N
complete JJ N
response NN N
. . N

RESULTS NNP N
Thirty-seven JJ p
and CC p
40 CD p
patients NNS p
were VBD p
randomly RB p
assigned VBN p
to TO p
study VB p
arm NN p
and CC p
control NN p
arm NN p
. . p

The DT N
local JJ o
recurrence NN o
rates NNS o
were VBD N
32.4 CD N
% NN N
and CC N
28.2 CD N
% NN N
respectively RB N
( ( N
P NNP N
= NNP N
0.80 CD N
) ) N
; : N
the DT N
isolated JJ N
nodal JJ o
failure NN o
( ( o
INF NNP o
) ) o
rates NNS N
were VBD N
3.0 CD N
% NN N
and CC N
2.6 CD N
% NN N
respectively RB N
( ( N
P NNP N
= NNP N
0.91 CD N
) ) N
; : N
all DT N
INF NNP N
sites NNS N
were VBD N
in IN N
the DT N
ipsilateral JJ N
supraclavicular JJ N
fossa NN N
. . N

Medastinal NNP o
N3 NNP o
disease NN o
was VBD N
the DT N
risk NN N
factor NN N
for IN N
INF NNP N
( ( N
P NNP N
= NNP N
0.02 CD N
, , N
OR NNP N
= VBZ N
14.13 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.47-136.13 JJ N
) ) N
. . N

During IN N
radiotherapy NN N
, , N
grade NN o
I PRP o
, , o
II NNP o
weight VBD o
loss NN o
was VBD N
observed VBN N
in IN N
29.4 CD N
% NN N
, , N
5.9 CD N
% NN N
and CC N
56.4 CD N
% NN N
, , N
7.7 CD N
% NN N
patients NNS N
respectively RB N
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

Grade VBN o
0-I JJ o
and CC o
II-III JJ o
late JJ o
pulmonary JJ o
injury NN o
was VBD N
developed VBN N
in IN N
97.1 CD N
% NN N
, , N
2.9 CD N
% NN N
and CC N
86.4 CD N
% NN N
, , N
15.4 CD N
% NN N
patients NNS N
respectively RB N
( ( N
P NNP N
= NNP N
0.07 CD N
) ) N
. . N

Median JJ o
survival JJ o
time NN o
was VBD N
22.1 CD N
months NNS N
and CC N
26.9 CD N
months NNS N
respectively RB N
. . N

The DT N
1 CD o
to TO o
3-year JJ o
OS NNP o
were VBD N
77.9 CD N
% NN N
, , N
44.4 CD N
% NN N
, , N
37.3 CD N
% NN N
and CC N
75.8 CD N
% NN N
, , N
56.3 CD N
% NN N
, , N
41.7 CD N
% NN N
respectively RB N
( ( N
P NNP N
= NNP N
0.79 CD N
) ) N
. . N

CONCLUSIONS VB N
The DT N
preliminary JJ N
results NNS N
of IN N
this DT N
study NN N
indicate VBP N
that WDT N
irradiant VBP N
the DT N
post-chemotherapy JJ N
tumor NN N
extent NN N
( ( N
GTV-T NNP N
) ) N
and CC N
positive JJ N
nodal JJ N
drainage NN N
area NN N
did VBD N
not RB N
decrease VB N
local JJ N
control NN N
and CC N
overall JJ N
survival NN N
while IN N
radiation NN N
toxicity NN N
was VBD N
reduced VBN N
. . N

But CC N
the DT N
current JJ N
sample NN N
size NN N
has VBZ N
not RB N
met VBN N
designed VBN N
requirements NNS N
, , N
and CC N
further JJ N
investigation NN N
is VBZ N
warranted VBN N
before IN N
final JJ N
conclusions NNS N
could MD N
be VB N
drawn VBN N
. . N

-DOCSTART- -20220293- O O

Efficacy NN N
and CC N
safety NN N
of IN N
two CD i
different JJ i
testosterone NN i
undecanoate JJ i
formulations NNS i
in IN N
hypogonadal JJ p
men NNS p
with IN p
metabolic JJ p
syndrome NN p
. . p

AIM NNP N
To TO N
investigate VB N
efficacy NN N
and CC N
safety NN N
of IN N
two CD i
different JJ i
preparations NNS i
of IN i
testosterone NN i
undecanoate NN i
( ( i
TU NNP i
) ) i
in IN N
52 CD p
hypogonadal JJ p
men NNS p
[ VBP p
mean JJ p
age NN p
57 CD p
yr NN p
and CC p
mean VB p
testosterone NN p
( ( p
T NNP p
) ) p
< VBD p
320 CD p
ng/dl JJ p
] NN p
with IN p
metabolic JJ p
syndrome NN p
( ( p
MS NNP p
) ) p
. . p

SUBJECTS NNP N
AND NNP N
METHODS NNP N
Randomized NNP N
, , N
double-blind NN N
, , N
double-dummy JJ N
study NN N
with IN N
three CD N
parallel JJ N
treatment NN N
arms NNS N
[ VBP N
oral JJ N
TU NNP N
; : N
transdermal JJ i
placebo NN i
gel NN i
( ( N
P NNP N
) ) N
; : N
im JJ N
TU NNP i
] NNP i
administration NN N
for IN N
12 CD N
months NNS N
( ( N
mo NN N
) ) N
. . N

Each DT N
subject NN N
was VBD N
randomized VBN N
( ( N
1:1:3 CD N
) ) N
to TO N
receive VB N
either DT N
oral JJ i
TU NNP i
( ( N
2 CD N
capsules NNS N
of IN N
40 CD N
mg/twice NNS N
per IN N
day NN N
at IN N
breakfast NN N
and CC N
dinner NN N
, , N
equalling VBG N
a DT N
total JJ N
dose NN N
of IN N
160 CD N
mg/day NN N
; : N
no.=10 CC N
) ) N
for IN N
6 CD N
mo NN N
and CC N
continued VBN N
with IN N
im JJ N
TU NNP N
for IN N
further JJ N
6 CD N
mo NN N
, , N
or CC N
P NNP i
( ( N
3-4 JJ N
g/day NN N
; : N
no.=10 CC N
) ) N
and CC N
im JJ i
TU NNP i
( ( N
1000 CD N
mg/12 NN N
weeks NNS N
from IN N
week NN N
6 CD N
; : N
no.=32 NNS N
) ) N
for IN N
12 CD N
mo NNS N
. . N

RESULTS NNP N
After IN N
6 CD N
mo NN N
, , N
im JJ N
TU NNP i
increased VBD N
T NNP o
and CC o
free- JJ o
T NNP o
levels NNS o
( ( N
p VB N
< RB N
0.0001 CD N
) ) N
, , N
and CC N
improved VBN N
metabolic JJ o
parameters NNS o
[ VBP N
reduction NN N
in IN N
Homeostasis NNP o
Model NNP o
Assessment NNP o
( ( o
HOMA NNP o
) ) o
index NN o
, , N
p NN N
< VBD N
0.0001 CD N
; : N
waist JJ o
circumference NN o
and CC o
fat JJ o
mass NN o
, , N
p NN N
< VBD N
0.001 CD N
, , N
respectively RB N
] JJ N
, , N
in IN N
International NNP o
Index NNP o
of IN o
Erectile NNP o
Function-5 NNP o
and CC o
Aging NNP o
Males NNP o
' POS o
Symptoms NNP o
scores NNS o
( ( N
p VB N
< RB N
0.01 CD N
, , N
respectively RB N
) ) N
. . N

After IN N
12 CD N
months NNS N
, , N
im JJ i
TU NNP i
produced VBD N
further JJ N
increases NNS N
in IN N
T NNP o
and CC o
free- JJ o
T NNP o
levels NNS o
( ( N
p VB N
< RB N
0.0001 CD N
) ) N
and CC N
metabolic JJ o
parameters NNS o
( ( N
reduction NN N
in IN N
HOMA-index NNP o
, , N
p NN N
< VBD N
0.0001 CD N
; : N
waist JJ o
circumference NN o
p NN N
< VBZ N
0.0001 CD N
; : N
fat JJ o
mass NN o
, , N
p NN N
< NNP N
0.001 CD N
) ) N
. . N

No DT N
major JJ N
adverse JJ N
event NN N
due JJ N
to TO N
T NNP N
treatment NN N
occurred VBD N
. . N

CONCLUSIONS NNP N
Clinical NNP N
efficacy NN N
of IN N
T NNP N
replacement NN N
therapy NN N
in IN N
hypogonadal JJ p
men NNS p
with IN p
MS NNP p
is VBZ N
reached VBN N
when WRB N
its PRP$ N
plasmatic JJ N
levels NNS N
approach VBP N
into IN N
the DT N
medium-high JJ N
range NN N
of IN N
normality NN N
( ( N
> JJ N
5 CD N
ng/ml NN N
) ) N
, , N
although IN N
subjective JJ N
threshold JJ N
values NNS N
may MD N
be VB N
different JJ N
. . N

Administration NN N
of IN N
im JJ N
TU NNP i
was VBD N
more RBR N
effective JJ N
than IN N
oral JJ N
TU NNP N
to TO N
reach VB N
the DT N
target NN N
for IN N
T NNP o
levels NNS o
and CC N
to TO N
improve VB N
MS NNP N
parameters NNS N
. . N

TU NNP N
was VBD N
safe JJ N
over IN N
12 CD N
months NNS N
and CC N
discontinuation NN N
rates NNS N
were VBD N
similar JJ N
to TO N
placebo VB i
. . i

-DOCSTART- -7963648- O O

The DT N
degrees NNS N
of IN N
UVB-induced NNP o
erythema NN o
and CC o
pigmentation NN o
correlate VBP N
linearly RB N
and CC N
are VBP N
reduced VBN N
in IN N
a DT N
parallel JJ N
manner NN N
by IN N
topical JJ i
anti-inflammatory JJ i
agents NNS i
. . i

To TO N
examine VB N
whether IN N
it PRP N
is VBZ N
possible JJ N
to TO N
evaluate VB N
the DT N
degree NN o
of IN o
ultraviolet NN o
B NNP o
( ( o
UVB NNP o
) ) o
-induced VBD o
inflammation NN o
by IN N
measuring VBG N
the DT N
degree NN o
of IN o
hyperpigmentation NN o
, , N
we PRP N
investigated VBD N
the DT N
relationship NN N
between IN N
UVB-induced NNP N
erythema NN N
and CC N
the DT N
subsequent JJ o
pigmentation NN o
quantitatively RB N
. . N

At IN N
24 CD N
h NN N
and CC N
7 CD N
d NN N
after IN N
irradiation NN N
with IN N
erythemogenic JJ N
doses NNS N
of IN N
UVB NNP N
to TO N
the DT N
backs NNS N
of IN N
16 CD p
Japanese JJ p
subjects NNS p
, , N
the DT N
degree NN o
of IN o
induced JJ o
erythema NN o
( ( o
delta JJ o
erythema VBP o
index NN o
) ) o
and CC N
that IN N
of IN N
pigmentation NN o
( ( o
delta JJ o
melanin NN o
index NN o
) ) o
were VBD N
examined VBN N
by IN N
an DT N
image NN i
analytic JJ i
method NN i
using VBG i
a DT i
videomicroscope NN i
interfaced VBN i
with IN i
a DT i
computer NN i
. . i

The DT N
relationship NN N
between IN N
two CD N
indices NNS N
was VBD N
linear JJ N
in IN N
each DT N
subject NN N
, , N
and CC N
the DT N
correlation NN N
coefficient NN N
was VBD N
0.83 CD N
when WRB N
evaluated VBN N
using VBG N
whole JJ N
data NNS N
. . N

The DT N
slope NN N
of IN N
the DT N
regression NN N
line NN N
for IN N
the DT N
delta NN o
melanin NN o
index NN o
against IN o
delta NN o
erythema NN o
index NN o
tended VBD N
to TO N
become VB N
steeper JJ N
as IN N
non-irradiated JJ N
skin NN N
color NN N
became VBD N
darker NN N
( ( N
r JJ N
= NNP N
0.63 CD N
) ) N
, , N
suggesting VBG N
that IN N
more RBR N
efficient JJ N
melanogenesis NN N
takes VBZ N
place NN N
after IN N
the DT N
same JJ N
level NN N
of IN N
inflammation NN N
in IN N
the DT N
subject NN N
with IN N
darker NN N
skin NN N
. . N

Both DT N
erythema NN o
and CC o
hyperpigmentation NN o
were VBD N
suppressed VBN N
significantly RB N
and CC N
in IN N
a DT N
parallel JJ N
manner NN N
by IN N
corticosteroids NNS i
and CC N
indomethacin NN i
applied VBN N
topically RB N
immediately RB N
after IN N
UVB NNP N
irradiation NN N
. . N

These DT N
results NNS N
imply VBP N
that IN N
the DT N
post-inflammatory JJ o
hyperpigmentation NN o
correlates NNS N
closely RB N
with IN N
the DT N
severity NN N
of IN N
the DT N
prior JJ N
inflammation NN N
and CC N
that DT N
chemical NN N
mediators NNS N
released VBN N
in IN N
the DT N
inflammatory NN N
process NN N
have VBP N
considerable JJ N
influence NN N
on IN N
the DT N
melanogenesis NN N
. . N

We PRP N
conclude VBP N
that IN N
the DT N
measurement NN N
of IN N
UVB-induced JJ o
hyperpigmentation NN o
can MD N
be VB N
utilized VBN N
for IN N
the DT N
assessment NN N
of IN N
topical JJ i
anti-inflammatory JJ i
agents NNS i
, , N
unless IN N
these DT N
have VBP N
direct JJ N
actions NNS N
on IN N
the DT N
tyrosinase NN N
activity NN N
of IN N
melanocytes NNS N
. . N

-DOCSTART- -9095512- O O

Studies NNS N
on IN N
section NN o
2D1 CD o
monoclonal JJ o
antibodies NNS o
. . o

Monoclonal JJ N
antibodies NNS N
in IN N
Other JJ N
Blood NNP N
Groups NNP N
were VBD N
tested VBN N
with IN N
random JJ i
blood NN i
samples NNS i
collected VBN N
from IN N
the DT N
various JJ p
ethnic JJ p
groups NNS p
in IN p
KwaZulu-Natal NNP p
, , p
South NNP p
Africa NNP p
, , p
and CC p
with IN p
samples NNS p
of IN p
selected VBN p
red JJ p
cell NN p
phenotypes NNS p
. . p

Standard NNP i
red VBD i
cell NN i
serological JJ i
techniques NNS i
were VBD N
used VBN N
. . N

-DOCSTART- -8891846- O O

Levosulpiride NNP i
in IN N
functional JJ p
dyspepsia NN p
: : p
a DT N
multicentric JJ N
, , N
double-blind JJ N
, , N
controlled JJ N
trial NN N
. . N

Abnormalities NNS N
in IN N
gastrointestinal JJ N
motility NN N
have VBP N
been VBN N
reported VBN N
in IN N
a DT N
substantial JJ N
proportion NN N
of IN N
patients NNS p
with IN p
functional JJ p
dyspepsia NN p
, , p
supporting VBG p
the DT p
use NN p
of IN p
prokinetic JJ i
drugs NNS i
for IN p
treatment NN p
of IN p
dyspeptic JJ p
symptoms NNS p
. . p

To TO N
evaluate VB N
efficacy NN o
and CC o
safety NN o
of IN N
levosulpiride NN i
in IN N
short-term JJ N
treatment NN N
, , N
1298 CD p
patients NNS p
were VBD p
enrolled VBN p
in IN p
a DT p
double-blind JJ p
multicentric NN p
study NN p
carried VBD p
out IN p
in IN p
45 CD p
Italian JJ p
Gastroenterology NNP p
Departments NNP p
. . p

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
levosulpiride NN i
( ( N
25 CD N
mg RB N
tid NN N
) ) N
, , N
domperidone NN i
( ( N
10 CD N
mg RB N
tid NN N
) ) N
, , N
metoclopramide RB i
( ( N
10 CD N
mg RB N
tid NN N
) ) N
or CC N
placebo NN i
( ( N
1 CD N
tablet NN N
tid NN N
) ) N
for IN N
4 CD N
weeks NNS N
. . N

Patients NNS p
were VBD p
selected VBN p
on IN p
the DT p
basis NN p
of IN p
: : p
a DT p
) ) p
occurrence NN p
in IN p
the DT p
last JJ p
4 CD p
weeks NNS p
of IN p
at IN p
least JJS p
5/10 CD p
selected VBN p
symptoms NNS p
( ( o
anorexia NN o
, , o
nausea NN o
, , o
vomiting VBG o
, , o
upper JJ o
abdominal JJ o
pain NN o
, , o
postprandial JJ o
bloating NN o
, , o
abdominal JJ o
fullness NN o
, , o
early JJ o
satiety NN o
, , o
belching NN o
, , o
heartburn NN o
, , o
regurgitation NN o
) ) o
, , p
severity NN p
of IN p
which WDT p
should MD p
reach/exceed VB p
a DT p
total JJ p
score NN p
of IN p
8 CD p
, , p
as IN p
assessed VBN p
by IN p
a DT p
specific JJ p
scale NN p
ranging VBG p
from IN p
0 CD p
( ( p
absent NN p
) ) p
to TO p
3 CD p
( ( p
severe JJ p
) ) p
; : p
b VBN p
) ) p
normal JJ p
results NNS p
of IN p
routine JJ p
biochemical NN p
, , p
ultrasound NN p
and CC p
endoscopic JJ p
examinations NNS p
. . p

In IN N
addition NN N
, , N
each DT N
patient NN N
subjectively RB N
evaluated VBD N
efficacy NN o
of IN N
treatment NN N
by IN N
a DT N
visual JJ N
analogue NN N
scale NN N
. . N

Significant JJ N
improvement NN N
was VBD N
recorded VBN N
for IN N
all DT N
symptoms NNS N
at IN N
days NNS N
10 CD N
and CC N
28 CD N
in IN N
all DT N
groups NNS N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
but CC N
levosulpiride NN i
was VBD N
significantly RB N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
superior NN N
to TO N
domperidone VB i
, , i
metoclopramide NN i
and CC N
placebo VB i
both DT N
in IN N
the DT N
overall JJ N
clinical JJ N
improvement NN N
scale NN N
as RB N
well RB N
as IN N
in IN N
a DT N
subgroup NN N
of IN N
symptoms NNS N
( ( o
postprandial JJ o
bloating NN o
, , o
epigastric JJ o
pain NN o
, , o
heartburn NN o
) ) o
. . N

Active JJ i
treatments NNS i
and CC N
placebo NNS i
were VBD N
comparable JJ N
as RB N
far RB N
as IN N
concerns NNS N
occurrence IN N
of IN N
side-effects NNS N
( ( N
12-20 CD N
% NN N
) ) N
including VBG N
galactorrhoea NN o
, , o
breast NN o
tenderness NN o
and CC o
menstrual JJ o
changes NNS o
. . o

-DOCSTART- -23362251- O O

Design NN N
and CC N
development NN N
of IN N
a DT N
Virtual NNP i
Dolphinarium NNP i
for IN N
children NNS p
with IN p
autism NN p
. . p

The DT N
recent JJ N
proliferation NN N
of IN N
virtual JJ i
reality NN i
( ( i
VR NNP i
) ) i
technology NN i
applications NNS i
in IN N
the DT N
autism NN N
therapy NN N
to TO N
promote VB N
learning NN N
and CC N
positive JJ N
behavior NN N
among IN N
such JJ N
children NNS N
has VBZ N
produced VBN N
optimistic JJ N
results NNS N
in IN N
developing VBG N
a DT N
variety NN N
of IN N
skills NNS N
and CC N
abilities NNS N
in IN N
them PRP N
. . N

Dolphin-assisted JJ i
therapy NN i
has VBZ N
also RB N
become VBN N
a DT N
topic NN N
of IN N
public JJ N
and CC N
research NN N
interest NN N
for IN N
autism NN N
intervention NN N
and CC N
treatment NN N
. . N

This DT N
paper NN N
will MD N
present VB N
an DT N
innovative JJ N
design NN N
and CC N
development NN N
of IN N
a DT N
Virtual NNP i
Dolphinarium NNP i
for IN N
potential JJ N
autism NN N
intervention NN N
. . N

Instead RB N
of IN N
emulating VBG N
the DT N
swimming NN N
with IN N
dolphins NNS N
, , N
our PRP$ N
virtual JJ N
dolphin JJ N
interaction NN N
program NN N
will MD N
allow VB N
children NNS p
with IN p
autism NN p
to TO p
act VB p
as IN p
dolphin JJ p
trainers NNS p
at IN p
the DT p
poolside NN p
and CC p
to TO p
learn VB p
( ( p
nonverbal JJ p
) ) p
communication NN p
through IN p
hand NN p
gestures NNS p
with IN p
the DT p
virtual JJ p
dolphins NNS p
. . p

Immersive JJ i
visualization NN i
and CC N
gesture-based JJ i
interaction NN i
are VBP N
implemented VBN N
to TO N
engage VB N
children NNS p
with IN p
autism NN p
within IN N
an DT N
immersive JJ N
room NN N
equipped VBD N
with IN N
a DT N
curved JJ N
screen NN N
spanning VBG N
a DT N
320 CD N
( ( N
? . N
) ) N
and CC N
a DT N
high-end JJ N
five-panel JJ N
projection NN N
system NN N
. . N

This DT N
paper NN N
will MD N
also RB N
report VB N
a DT N
pilot NN N
study NN N
to TO N
establish VB N
trial NN N
protocol NN N
of IN N
autism NN N
screening VBG N
to TO N
explore VB N
the DT N
participants NNS N
' POS N
readiness NN N
for IN N
the DT i
virtual JJ i
dolphin NN i
interaction NN i
. . i

This DT N
research NN N
will MD N
have VB N
two CD N
potential JJ N
benefits NNS N
in IN N
the DT N
sense NN N
of IN N
helping VBG p
children NNS p
with IN p
autism NN p
and CC N
protecting VBG N
the DT N
endangered VBN N
species NNS N
. . N

-DOCSTART- -15821644- O O

Combined JJ N
administration NN N
of IN N
nitric JJ i
oxide NN i
gas NN i
and CC i
iloprost NN i
during IN N
cardiopulmonary JJ p
bypass NN p
reduces NNS N
platelet VBP N
dysfunction NN N
: : N
a DT N
pilot NN N
clinical JJ N
study NN N
. . N

BACKGROUND NNP N
Thrombocytopenia NNP N
and CC N
platelet VB N
dysfunction NN N
are VBP N
major JJ N
mechanisms NNS N
of IN N
cardiopulmonary JJ N
bypass-induced JJ N
postoperative JJ N
hemorrhage NN N
. . N

This DT N
study NN N
evaluated VBD N
the DT N
effects NNS N
of IN N
low JJ N
amounts NNS N
of IN N
nitric JJ i
oxide NN i
, , i
iloprost NN i
( ( i
prostacyclin JJ i
analog NN i
) ) i
, , N
and CC N
their PRP$ N
combination NN N
administered VBN N
directly RB N
into IN N
the DT N
oxygenator NN N
on IN N
platelet NN N
function NN N
, , N
platelet-leukocyte JJ N
interactions NNS N
, , N
and CC N
postoperative JJ N
blood NN N
loss NN N
in IN N
patients NNS p
undergoing VBG p
coronary JJ p
artery NN p
bypass NN p
grafting NN p
. . p

METHODS NNP N
Blood NNP p
samples NNS p
from IN p
41 CD p
patients NNS p
randomized VBN N
to TO N
the DT N
control NN N
, , N
nitric JJ i
oxide NN i
( ( N
20 CD N
ppm NN N
) ) N
, , N
iloprost FW i
( ( N
2 CD N
ng RB N
x JJ N
kg NN N
-1 NNP N
x NNP N
min NNP N
-1 NNP N
) ) N
, , N
or CC N
nitric JJ i
oxide JJ i
plus CC i
iloprost JJ i
groups NNS N
were VBD N
collected VBN N
during IN N
cardiopulmonary JJ p
bypass NN p
. . p

Platelets NNS N
and CC N
leukocytes NNS N
were VBD N
enumerated VBN N
. . N

Platelet NNP o
membrane NN o
glycoprotein NN o
Ib NNP o
and CC N
glycoprotein NN o
IIb/IIIa NNP o
, , o
P-selectin NNP o
, , o
platelet-derived JJ o
microparticles NNS o
, , o
leukocyte JJ o
CD11b/CD18 NNP o
( ( o
Mac-1 NNP o
) ) o
, , N
and CC N
platelet-leukocyte JJ o
aggregate NN o
were VBD N
quantified VBN N
by IN N
means NNS N
of IN N
flow JJ N
cytometry NN N
. . N

Collagen NNP N
and CC N
thrombin JJ N
receptor-activating JJ N
peptide-induced JJ N
platelet NN N
aggregation NN N
in IN N
whole JJ N
blood NN N
was VBD N
analyzed VBN N
by IN N
means NNS N
of IN N
aggregometry NN N
. . N

RESULTS NNP N
Both NNP N
nitric JJ N
oxide NN N
or CC N
iloprost NN N
attenuated JJ N
cardiopulmonary JJ N
bypass-induced JJ N
thrombocytopenia NN o
, , N
reduction NN N
of IN N
glycoprotein NN o
Ib NNP o
and CC o
glycoprotein VB o
IIb NNP o
levels NNS o
, , N
translocation NN N
of IN N
P-selectin NNP o
, , N
microparticle NN N
formation NN N
, , N
Mac-1 NNP o
upregulation NN o
, , N
and CC N
suppression NN N
of IN N
collagen-induced JJ o
aggregation NN o
. . o

Nitric NNP N
oxide IN N
plus CC N
iloprost NN N
was VBD N
significantly RB N
more RBR N
effective JJ N
in IN N
preventing VBG N
thrombocytopenia NN o
, , o
microparticle NN o
formation NN o
, , o
and CC o
P-selectin NNP o
translocation NN o
. . o

Moreover RB N
, , N
this DT N
treatment NN N
preserved VBD N
thrombin JJ N
receptor-activating JJ N
peptide-induced JJ N
aggregation NN N
, , N
which WDT N
was VBD N
not RB N
rescued VBN N
by IN N
single JJ N
treatments NNS N
. . N

Both DT N
nitric JJ N
oxide NN N
and CC N
nitric JJ N
oxide NN N
plus CC N
iloprost NN N
attenuated JJ N
postoperative JJ N
blood NN o
loss NN o
. . o

CONCLUSIONS NNP N
Nitric NNP N
oxide IN N
plus CC N
iloprost VB N
reduced VBN N
the DT N
deleterious JJ N
effects NNS N
of IN N
cardiopulmonary JJ N
bypass NN N
, , N
such JJ N
as IN N
thrombocytopenia NN o
, , o
platelet NN o
activation NN o
, , o
platelet-leukocyte JJ o
aggregate NN o
formation NN o
, , N
and CC N
suppression NN N
of IN N
platelet NN o
aggregative JJ o
responses NNS o
. . o

The DT N
reduced JJ N
postoperative JJ N
bleeding NN N
observed VBN N
with IN N
this DT N
treatment NN N
suggests VBZ N
that IN N
this DT N
is VBZ N
a DT N
new JJ N
and CC N
clinically RB N
feasible JJ N
therapeutic JJ N
option NN N
for IN N
patients NNS p
subjected VBN p
to TO p
cardiopulmonary JJ p
bypass NN p
. . p

-DOCSTART- -19080323- O O

Changes NNS N
of IN N
activated JJ N
circulating VBG N
endothelial JJ N
cells NNS N
and CC N
survivin NN N
in IN N
patients NNS p
with IN p
non-small JJ p
cell NN p
lung NN p
cancer NN p
after IN p
antiangiogenesis NN i
therapy NN i
. . i

BACKGROUND NNP N
Although IN N
antiangiogenesis NN i
therapy NN i
plays VBZ N
an DT N
important JJ N
role NN N
in IN N
anti-neoplastic JJ i
treatment NN i
with IN N
its PRP$ N
recognized VBN N
efficacy NN N
and CC N
slight JJ N
adverse JJ N
effect NN N
, , N
there EX N
is VBZ N
no DT N
prospective JJ N
clinical JJ N
trial NN N
to TO N
define VB N
ideal JJ N
markers NNS N
for IN N
predicting VBG N
efficacy NN N
of IN N
antiangiogenic JJ i
therapy NN i
. . i

This DT N
study NN N
was VBD N
undertaken VBN N
to TO N
investigate VB N
the DT N
changes NNS N
of IN N
activated JJ N
circulating VBG N
endothelial JJ N
cells NNS N
( ( N
aCECs NN N
) ) N
and CC N
survivin JJ N
after IN N
anti-angiogenesis JJ N
therapy NN N
and CC N
their PRP$ N
significance NN N
in IN N
predicting VBG N
the DT N
efficacy NN N
of IN N
the DT N
therapy NN N
. . N

METHODS NNP N
Patients NNPS p
of IN p
non-small JJ p
cell NN p
lung NN p
cancer NN p
( ( p
NSCLC NNP p
) ) p
treated VBD p
with IN p
chemotherapy NN i
with IN i
or CC i
without IN i
Endostar NNP i
were VBD N
observed VBN N
. . N

The DT N
amount NN N
of IN N
activated JJ N
CECs NNP N
was VBD N
detected VBN N
by IN N
flow JJ N
cytometry NN N
, , N
and CC N
the DT N
expression NN N
of IN N
survivin NN N
mRNA NN N
was VBD N
determined VBN N
by IN N
real-time JJ N
polymerase NN N
chain NN N
reaction NN N
( ( N
PCR NNP N
) ) N
. . N

RESULTS NNP N
After IN N
treatment NN N
, , N
the DT N
amount NN N
of IN N
activated JJ o
CECs NNP o
decreased VBD N
significantly RB N
in IN N
clinical JJ N
benefit NN N
cases NNS N
( ( N
P NNP N
= VBZ N
0.021 CD N
in IN N
chemotherapy NN i
alone RB N
, , N
P NNP N
= VBZ N
0.001 CD N
in IN N
chemotherapy NN i
plus CC i
Endostar NNP i
) ) i
, , N
increased VBN N
in IN N
disease NN o
progressive JJ o
cases NNS o
( ( N
P NNP N
= VBZ N
0.015 CD N
in IN N
chemotherapy NN i
alone RB N
, , N
but CC N
P NNP N
= NNP N
0.293 CD N
in IN N
chemotherapy NN i
with IN i
Endotatar NNP i
) ) i
. . N

After IN N
therapy NN N
, , N
the DT N
expression NN o
of IN o
survivin JJ o
mRNA NN o
decreased VBN N
in IN N
clinical JJ N
benefit NN N
cases NNS N
( ( N
P NNP N
= NNP N
0.001 CD N
) ) N
and CC N
increased VBN N
in IN N
disease NN o
progressive JJ o
cases NNS o
( ( N
P NNP N
= NNP N
0.018 CD N
) ) N
. . N

A DT N
positive JJ N
correlation NN N
was VBD N
found VBN N
between IN N
activated VBN o
CECs NNP o
and CC N
survivin NN N
in IN N
the DT N
chemotherapy NN i
group NN N
pre- JJ N
and CC N
post-therapy JJ N
( ( N
P NNP N
= NNP N
0.001 CD N
and CC N
0.021 CD N
, , N
respectively RB N
) ) N
, , N
but CC N
only RB N
in IN N
the DT N
chemotherapy NN i
with IN i
Endostar NNP i
group NN N
pre-therapy NN N
( ( N
P NNP N
= NNP N
0.030 CD N
) ) N
rather RB N
than IN N
post-therapy NN N
. . N

A DT N
positive JJ N
correlation NN N
was VBD N
found VBN N
between IN N
the DT N
decreased VBN N
activated VBN o
CECs NNP o
after IN N
therapy NN N
and CC N
time NN o
to TO o
progression NN o
( ( o
TTP NNP o
) ) o
( ( N
r JJ N
= NN N
0.322 CD N
, , N
P NNP N
= NNP N
0.012 CD N
) ) N
; : N
a DT N
negative JJ N
correlation NN N
was VBD N
found VBN N
between IN N
the DT N
amount NN o
of IN o
survivin NN o
mRNA NN o
in IN o
serum JJ o
post-therapy NN o
and CC o
TTP NNP o
( ( N
r NN N
= NNP N
-0.291 NNP N
, , N
P NNP N
= NNP N
0.048 CD N
) ) N
. . N

CONCLUSIONS NNP N
Activated NNP N
CECs NNP N
and CC N
survivin NN N
may MD N
be VB N
ideal JJ N
markers NNS N
forecasting VBG N
efficacy NN N
and CC N
prognosis NN N
of IN N
NSCLC NNP N
. . N

The DT N
former JJ N
can MD N
reflect VB N
more RBR N
sensitively RB N
antiangiogenic JJ N
efficacy NN N
and CC N
the DT N
latter NN N
is VBZ N
more RBR N
sensitive JJ N
to TO N
shrinkage VB N
or CC N
swelling VBG N
of IN N
tumors NNS N
. . N

Their PRP$ N
combination NN N
can MD N
evaluate VB N
more RBR N
accurately RB N
the DT N
efficacy NN N
of IN N
antiangiogenic JJ i
therapy NN i
of IN N
NSCLC NNP N
. . N

-DOCSTART- -24261547- O O

Family-centred JJ i
music NN i
therapy NN i
to TO N
promote VB N
social JJ o
engagement NN o
in IN N
young JJ p
children NNS p
with IN p
severe JJ p
autism NN p
spectrum JJ p
disorder NN p
: : p
a DT N
randomized NN N
controlled VBN N
study NN N
. . N

BACKGROUND NNP N
Limited NNP N
capacity NN N
for IN N
social JJ N
engagement NN N
is VBZ N
a DT N
core NN N
feature NN N
of IN N
autism NN N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
, , N
often RB N
evident JJ N
early JJ N
in IN N
the DT N
child NN N
's POS N
development NN N
. . N

While IN N
these DT N
skills NNS N
are VBP N
difficult JJ N
to TO N
train VB N
, , N
there EX N
is VBZ N
some DT N
evidence NN N
that IN N
active JJ N
involvement NN N
in IN N
music-making JJ N
provides VBZ N
unique JJ N
opportunities NNS N
for IN N
social JJ N
interaction NN N
between IN N
participants NNS N
. . N

Family-centred JJ i
music NN i
therapy NN i
( ( i
FCMT NNP i
) ) i
endeavours VBZ N
to TO N
support VB N
social JJ N
engagement NN N
between IN N
child NN N
and CC N
parent NN N
within IN N
active JJ N
music-making NN N
, , N
yet CC N
the DT N
extent NN N
of IN N
benefits NNS N
provided VBN N
is VBZ N
unknown JJ N
. . N

AIM VB N
This DT N
study NN N
investigated VBD N
the DT N
impacts NNS N
of IN N
FCMT NNP i
on IN N
social JJ N
engagement NN N
abilities NNS N
. . N

METHODS NNP N
Twenty-three JJ p
children NNS p
( ( p
36-60 JJ p
months NNS p
) ) p
with IN p
severe JJ p
ASD NNP p
received VBD p
either RB p
16 CD i
weeks NNS i
of IN i
FCMT NNP i
in IN i
addition NN i
to TO i
their PRP$ i
early JJ i
intervention NN i
programmes NNS i
( ( i
n JJ i
= NNP i
12 CD i
) ) i
, , i
or CC i
their PRP$ i
early JJ i
intervention NN i
programme IN i
only RB i
( ( i
n JJ i
= NNP i
11 CD i
) ) i
. . i

Change NN N
in IN N
social JJ N
engagement NN N
was VBD N
measured VBN N
with IN N
standardized JJ o
parent-report JJ o
assessments NNS o
, , o
parent NN o
interviews NNS o
and CC o
clinician JJ o
observation NN o
. . o

RESULTS NNP N
Intention-to-treat JJ N
analysis NN N
for IN N
the DT N
Vineland NNP o
Social NNP o
Emotional NNP o
Early NNP o
Childhood NNP o
Scale NNP o
indicated VBD N
a DT N
significant JJ N
effect NN N
in IN N
favour NN N
of IN N
FCMT NNP i
. . i

Thematic NNP N
qualitative JJ N
analysis NN N
of IN N
the DT N
parent NN N
interviews NNS N
showed VBD N
that IN N
the DT N
parent-child JJ N
relationship NN N
grew VBD N
stronger JJR N
. . N

CONCLUSION NNP N
FCMT NNP i
improves VBZ N
social JJ N
interactions NNS N
in IN N
the DT N
home NN N
and CC N
community NN N
and CC N
the DT N
parent-child JJ N
relationship NN N
, , N
but CC N
not RB N
language NN N
skills NNS N
or CC N
general JJ N
social JJ N
responsiveness NN N
. . N

This DT N
study NN N
provides VBZ N
preliminary JJ N
support NN N
for IN N
the DT N
use NN N
of IN N
FCMT NNP i
to TO N
promote VB N
social JJ N
engagement NN N
in IN N
children NNS p
with IN p
severe JJ p
ASD NNP p
. . p

-DOCSTART- -14506591- O O

Biodistribution NN N
of IN N
three CD N
photosensitizers NNS i
in IN N
dogs NNS p
with IN p
spontaneous JJ p
tumors NNS p
. . p

Photodynamic NNP i
therapy NN i
( ( i
PDT NNP i
) ) i
has VBZ N
been VBN N
considered VBN N
a DT N
potential JJ N
method NN N
for IN N
tumor NN N
eradication NN N
. . N

The DT N
present JJ N
study NN N
was VBD N
designed VBN N
to TO N
assess VB N
the DT N
efficacy NN N
of IN N
PDT NNP i
as IN N
an DT N
alternative JJ N
treatment NN N
approach NN N
. . N

Photosensitizers NNS i
, , i
such JJ i
as IN i
porfimer NN i
sodium NN i
, , i
tin NN i
ethyl NN i
etiopurpurin NN i
, , i
and CC i
aluminum NN i
chlorophthalocyanine NN i
, , N
were VBD N
administered VBN N
i.v NN N
. . N

to TO N
dogs NNS p
, , N
and CC N
tissue NN N
samples NNS N
were VBD N
harvested VBN N
24 CD N
to TO N
300 CD N
hours NNS N
later RB N
. . N

The DT N
uptake NN N
of IN N
the DT N
photosensitizers NNS i
in IN N
tumor NN N
( ( N
fibrosarcoma NN N
) ) N
and CC N
adjacent JJ N
normal JJ N
tissue NN N
biopsies NNS N
was VBD N
quantified VBN N
by IN N
tissue NN N
solubilization NN N
technique NN N
and CC N
fluorimetry NN N
. . N

In IN N
addition NN N
, , N
the DT N
pharmacokinetics NNS N
and CC N
selectivity NN N
of IN N
the DT N
photosensitizers NNS i
were VBD N
addressed VBN N
by IN N
two-phase JJ N
exponential JJ N
function NN N
and CC N
specific JJ N
uptake NN N
ratio NN N
, , N
respectively RB N
. . N

Porfimer NNP i
sodium NN i
exhibited VBD N
a DT N
longer JJR o
elimination NN o
half-life NN o
( ( o
175.3 CD o
hr NN o
) ) o
, , o
slower JJR o
clearance NN o
( ( o
0.0028 CD o
L/kg/hr NNP o
) ) o
, , o
and CC o
a DT o
larger JJR o
area NN o
under IN o
the DT o
curve NN o
( ( N
1075 CD N
microg/g/hr NN N
) ) N
in IN N
tumors NNS N
than IN N
did VBD N
tin VB i
ethyl NN i
etiopurpurin NN i
or CC N
aluminum NN i
chlorophthalocyanine NN i
. . i

As IN N
a DT N
result NN N
, , N
porfimer NN i
sodium NN i
showed VBD N
a DT N
good JJ o
selectivity NN o
in IN o
tumors NNS o
located VBN o
in IN o
muscle NN o
and CC o
skin NN o
. . o

The DT N
study NN N
provided VBD N
clinical JJ N
information NN N
for IN N
determination NN N
of IN N
the DT N
efficacy NN o
of IN N
different JJ N
PDT NNP i
alternatives NNS N
. . N

-DOCSTART- -17521473- O O

Pilot NNP N
comparison NN N
between IN N
potassium NN i
titanyl NN i
phosphate NN i
laser NN i
and CC i
bipolar JJ i
radiofrequency NN i
in IN N
paediatric JJ p
tonsillectomy NN p
. . p

OBJECTIVES NNP N
To TO N
compare VB N
the DT N
advantages NNS N
and CC N
disadvantages NNS N
of IN N
potassium NN i
titanyl NN i
phosphate NN i
laser NN i
with IN i
those DT i
of IN i
bipolar JJ i
radiofrequency NN i
techniques NNS i
, , N
in IN N
paediatric JJ o
tonsillectomy NN o
. . o

STUDY NNP N
DESIGN NNP N
Prospective NNP N
, , N
randomised VBD N
, , N
clinical JJ N
study NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
From NNP p
July NNP p
2004 CD p
to TO p
April NNP p
2006 CD p
, , p
80 CD p
patients NNS p
aged VBN p
between IN p
10 CD p
and CC p
15 CD p
years NNS p
, , p
with IN p
tonsillectomy NN i
planned VBN p
for IN p
chronic JJ p
tonsillitis NN p
, , p
were VBD p
included VBN p
in IN p
the DT p
study NN p
. . p

Children NNP N
were VBD N
prospectively RB N
randomised VBN N
into IN N
two CD N
equal JJ N
groups NNS N
: : N
potassium NN i
titanyl NN i
phosphate NN i
laser NN i
tonsillectomy NN i
and CC i
bipolar JJ i
radiofrequency NN i
tonsillectomy NN i
. . i

Operative JJ N
time NN N
and CC N
intra-operative JJ N
blood NN N
loss NN N
were VBD N
recorded VBN N
. . N

Patients NNS N
were VBD N
scheduled VBN N
for IN N
follow VB N
up RP N
during IN N
the DT N
first JJ N
, , N
second JJ N
and CC N
fourth JJ N
post-operative JJ N
weeks NNS N
. . N

They PRP N
were VBD N
asked VBN N
to TO N
record VB N
their PRP$ N
pain NN N
and CC N
discomfort NN N
on IN N
a DT N
standardised JJ N
visual JJ N
analogue NN N
scale NN N
, , N
from IN N
zero CD N
( ( N
no DT N
pain NN N
) ) N
to TO N
10 CD N
( ( N
severe JJ N
pain NN N
) ) N
. . N

Post-operative JJ N
complications NNS N
were VBD N
also RB N
recorded VBN N
and CC N
managed VBN N
. . N

RESULTS VB N
The DT N
potassium NN i
titanyl NN i
phosphate VBP i
laser NN i
group NN i
showed VBD N
a DT N
slightly RB N
longer RBR o
operative JJ o
time NN o
( ( N
mean JJ N
12 CD N
minutes NNS N
) ) N
than IN N
the DT N
bipolar JJ N
radiofrequency NN N
group NN N
( ( N
mean JJ N
10 CD N
minutes NNS N
) ) N
. . N

Intra-operative JJ o
blood NN o
loss NN o
was VBD N
significantly RB N
less RBR N
in IN N
the DT N
potassium NN i
titanyl NN i
phosphate VBP i
laser NN i
group NN N
( ( N
mean JJ N
21 CD N
cm3 NN N
) ) N
than IN N
in IN N
the DT N
bipolar JJ i
radiofrequency NN i
group NN i
( ( N
mean JJ N
30 CD N
cm3 NN N
) ) N
. . N

In IN N
the DT N
first JJ N
week NN N
, , N
post-operative JJ o
pain NN o
scores NNS o
were VBD N
less RBR N
in IN N
the DT N
potassium NN i
titanyl NN i
phosphate VBP i
laser NN i
group NN N
than IN N
in IN N
the DT N
bipolar JJ N
radiofrequency NN N
group NN N
( ( N
means VBZ N
7.5 CD N
and CC N
8.5 CD N
, , N
respectively RB N
) ) N
. . N

However RB N
, , N
in IN N
the DT N
second JJ N
week NN N
pain NN o
scores NNS o
increased VBD N
more RBR N
in IN N
the DT N
potassium NN N
titanyl NN N
phosphate VBP N
laser NN N
group NN N
than IN N
in IN N
the DT N
bipolar JJ N
radiofrequency NN N
group NN N
( ( N
means VBZ N
8.5 CD N
and CC N
6 CD N
, , N
respectively RB N
) ) N
. . N

In IN N
the DT N
fourth JJ N
week NN N
, , N
both DT N
groups NNS N
showed VBD N
equal JJ N
and CC N
nearly RB N
normal JJ N
pain NN o
scores NNS o
. . o

No DT N
case NN N
of IN N
reactionary JJ o
post-tonsillectomy JJ o
haemorrhage NN o
was VBD N
recorded VBN N
in IN N
either DT N
group NN N
. . N

Only RB N
one CD N
case NN N
of IN N
secondary JJ o
post-tonsillectomy JJ o
haemorrhage NN o
was VBD N
recorded VBN N
, , N
in IN N
the DT N
potassium NN N
titanyl NN N
phosphate VBP N
laser NN N
group NN N
( ( N
2.5 CD N
per IN N
cent NN N
) ) N
, , N
managed VBD N
conservatively RB N
. . N

CONCLUSION NNP N
Both NNP N
the DT N
potassium NN i
titanyl NN i
phosphate NN i
and CC i
the DT i
bipolar JJ i
radiofrequency NN i
techniques NNS i
were VBD N
safe JJ o
and CC o
easy JJ o
to TO o
use VB o
for IN N
tonsillectomy NN o
, , N
with IN N
reduced VBN N
operative JJ o
time NN o
, , o
blood NN o
loss NN o
and CC o
complication NN o
rates NNS o
and CC N
better JJR N
post-operative JJ N
general JJ N
patient NN N
condition NN N
. . N

Potassium NNP i
titanyl JJ i
phosphate NN i
laser NN i
resulted VBD N
in IN N
reduced JJ N
operative JJ o
bleeding NN o
and CC o
immediate JJ o
post-operative JJ o
pain NN o
, , N
compared VBN N
with IN N
the DT N
bipolar JJ N
radiofrequency NN N
technique NN N
. . N

However RB N
, , N
potassium NN i
titanyl NN i
phosphate VBP i
laser NN i
required VBN N
slightly RB N
more RBR N
operative JJ o
time NN o
and CC N
caused VBD N
more JJR N
late JJ o
post-operative JJ o
pain NN o
than IN N
the DT N
bipolar JJ N
radiofrequency NN N
technique NN N
. . N

The DT N
low JJ N
rate NN N
of IN N
recorded VBN N
complications NNS N
showed VBD N
that IN N
both DT N
techniques NNS N
cause VBP N
little JJ N
damage NN N
to TO N
the DT N
tonsillar JJ N
bed NN N
during IN N
dissection NN N
, , N
thus RB N
minimising VBG N
complications NNS N
. . N

-DOCSTART- -15937908- O O

Fulvestrant NNP i
versus NN N
anastrozole NN i
for IN N
the DT N
treatment NN N
of IN N
advanced JJ N
breast NN N
carcinoma NN N
: : N
a DT N
prospectively RB N
planned VBN N
combined VBN N
survival JJ N
analysis NN N
of IN N
two CD N
multicenter NN N
trials NNS N
. . N

BACKGROUND NNP N
Fulvestrant NNP i
is VBZ N
an DT N
estrogen NN N
receptor NN N
antagonist NN N
with IN N
no DT N
agonist JJ N
effects NNS N
. . N

In IN N
the DT N
second-line JJ N
treatment NN N
of IN N
advanced JJ N
breast NN N
carcinoma NN N
, , N
fulvestrant NN N
was VBD N
shown VBN N
previously RB N
to TO N
be VB N
as RB N
effective JJ N
as IN N
the DT N
third-generation NN N
aromatase NN N
inhibitor NN N
, , N
anastrozole NN N
, , N
in IN N
terms NNS N
of IN N
time NN N
to TO N
disease VB N
progression NN N
and CC N
objective JJ N
response NN N
rates NNS N
. . N

The DT N
authors NNS N
reported VBD N
the DT N
overall JJ o
survival JJ o
results NNS N
from IN N
these DT N
studies NNS N
. . N

METHODS VB N
A DT N
prospectively RB N
planned VBN N
, , N
combined VBN N
, , N
overall JJ o
survival NN o
analysis NN N
was VBD N
performed VBN N
, , N
including VBG N
data NNS N
from IN N
two CD N
Phase NNP N
III NNP N
trials NNS N
that WDT N
compared VBN N
the DT N
efficacy NN o
and CC o
tolerability NN o
of IN N
fulvestrant NN i
( ( i
250 CD i
mg NN i
monthly RB i
; : i
n CC i
= VB i
428 CD i
) ) i
with IN i
anastrozole NN i
( ( i
1 CD i
mg NNS i
daily RB i
; : i
n CC N
= VB N
423 CD N
) ) N
in IN N
the DT N
treatment NN N
of IN N
postmenopausal JJ p
women NNS p
with IN p
advanced JJ p
breast NN p
carcinoma NN p
who WP p
had VBD p
disease NN p
progression NN p
after IN p
receipt NN p
of IN p
previous JJ p
endocrine NN i
treatment NN i
. . i

RESULTS NNP N
At IN N
an DT N
extended JJ N
median JJ N
follow-up NN N
of IN N
27.0 CD N
months NNS N
( ( N
range NN N
, , N
0-66.9 JJ N
months NNS N
) ) N
, , N
319 CD p
( ( p
74.5 CD p
% NN p
) ) p
patients NNS p
in IN p
the DT p
fulvestrant JJ p
group NN p
and CC p
322 CD p
( ( p
76.1 CD p
% NN p
) ) p
patients NNS p
in IN p
the DT p
anastrozole JJ p
group NN p
had VBD N
died VBN o
. . o

Prolonged NNP o
survival NN o
was VBD N
observed VBN N
with IN N
both DT N
drugs NNS N
, , N
with IN N
10-20 JJ N
% NN N
of IN N
patients NNS N
still RB N
alive JJ o
> JJ N
5 CD N
years NNS N
after IN N
randomization NN N
. . N

The DT N
median JJ o
overall JJ o
survival NN o
was VBD N
similar JJ N
between IN N
treatments NNS N
, , N
being VBG N
27.4 CD N
months NNS N
and CC N
27.7 CD N
months NNS N
in IN N
fulvestrant JJ i
and CC N
anastrozole-treated JJ i
patients NNS N
, , N
respectively RB N
( ( N
hazards NNS N
ratio NN N
, , N
0.98 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.84-1.15 JJ N
; : N
P NNP N
= NNP N
0.809 CD N
) ) N
. . N

Fulvestrant NNP N
continued VBD N
to TO N
be VB N
well RB N
tolerated VBN N
, , N
and CC N
was VBD N
associated VBN N
with IN N
a DT N
significantly RB N
lower JJR N
incidence NN o
of IN o
joint JJ o
disorders NNS o
compared VBN N
with IN N
anastrozole NN N
( ( N
P NNP N
= NNP N
0.0234 CD N
) ) N
. . N

CONCLUSIONS VB N
The DT N
current JJ N
analysis NN N
showed VBD N
that IN N
fulvestrant NN i
was VBD N
similar JJ N
to TO N
anastrozole VB N
with IN N
respect NN N
to TO N
overall JJ N
survival NN N
in IN N
the DT N
second-line JJ N
treatment NN N
of IN N
postmenopausal JJ p
women NNS p
with IN p
advanced JJ p
breast NN p
carcinoma NN p
. . p

-DOCSTART- -8785132- O O

Metabolic NNP N
and CC N
hormonal JJ N
responses NNS N
to TO N
induced VB i
hypotension NN i
for IN N
middle JJ p
ear NN p
surgery NN p
. . p

We PRP N
have VBP N
investigated VBN N
in IN N
30 CD p
patients NNS p
the DT N
metabolic JJ N
and CC N
hormonal JJ N
responses NNS N
to TO N
middle VB p
ear JJ p
surgery NN p
using VBG p
induced JJ i
hypotension NN i
to TO p
a DT p
mean JJ p
arterial JJ p
pressure NN p
of IN p
55 CD p
mm NN p
Hg NNP p
. . p

A NNP N
standardized JJ N
anaesthetic JJ N
technique NN N
of IN N
propranolol NN i
, , i
thiopentone-vecuronium-isoflurane NN i
was VBD N
used VBN N
in IN N
all DT N
patients NNS N
and CC N
hypotension NN i
induced VBN i
with IN i
sodium NN i
nitroprusside NN i
, , i
trimetaphan JJ i
camsylate NN i
or CC i
additional JJ i
isoflurane NN i
. . i

All DT N
patients NNS N
showed VBD N
a DT N
classic JJ o
stress NN o
response NN o
with IN o
an DT o
increase NN o
in IN o
circulating VBG o
blood NN o
glucose NN o
, , o
cortisol NN o
and CC o
growth NN o
hormone NN o
concentrations NNS o
. . o

Blood NNP o
lactate NN o
and CC o
plasma NN o
uric JJ o
acid NN o
concentrations NNS o
changed VBD N
little JJ N
during IN N
operation NN N
, , N
suggesting VBG N
that IN N
tissue NN N
oxygenation NN N
was VBD N
adequate JJ N
. . N

However RB N
, , N
the DT N
former JJ N
declined VBD N
after IN N
operation NN N
, , N
possibly RB N
as IN N
a DT N
result NN N
of IN N
the DT N
concomitant NN N
use NN N
of IN N
propranolol NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
three CD N
hypotensive NN N
techniques NNS N
in IN N
their PRP$ N
effects NNS N
on IN N
the DT N
hormonal JJ N
and CC N
metabolic JJ N
response NN N
, , N
although IN N
the DT N
increase NN N
in IN N
blood NN o
glucose JJ o
concentration NN o
in IN N
the DT N
trimetaphan NN N
group NN N
was VBD N
obtunded VBN N
. . N

We PRP N
conclude VBP N
that DT N
induced VBD N
hypotension NN N
for IN N
middle JJ p
ear NN p
surgery NN p
induced VBD N
an DT N
endocrine NN N
and CC N
metabolic JJ N
response NN N
of IN N
small JJ N
magnitude NN N
and CC N
short JJ N
duration NN N
. . N

-DOCSTART- -20054544- O O

Paracetamol NNP i
reduces NNS N
postoperative VBP N
pain NN o
and CC o
rescue NN o
analgesic JJ o
demand NN o
after IN N
robot-assisted JJ i
endoscopic NN i
thyroidectomy NN i
by IN i
the DT i
transaxillary JJ i
approach NN i
. . i

BACKGROUND NNP N
Postoperative NNP p
pain NN p
following VBG p
endoscopic NN i
thyroidectomy NN i
, , N
although IN N
less JJR N
severe JJ N
than IN N
after IN N
open JJ N
methods NNS N
, , N
is VBZ N
still RB N
a DT N
source NN N
of IN N
marked JJ N
discomfort NN N
and CC N
surgical JJ N
stress NN N
. . N

This DT N
clinical JJ N
trial NN N
was VBD N
conducted VBN N
to TO N
determine VB N
if IN N
repeated VBN N
intravenous JJ i
paracetamol NN i
could MD N
decrease VB N
postoperative JJ N
pain NN N
and CC N
rescue NN N
analgesic NN N
requirements NNS N
after IN N
robot-assisted JJ i
endoscopic JJ i
thyroidectomy NN i
via IN N
the DT N
transaxillary JJ i
approach NN i
. . i

MATERIALS NNP N
AND CC N
METHODS NNP N
This DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blinded JJ N
, , N
and CC N
placebo-controlled JJ i
study NN N
enrolled VBD N
124 CD p
women NNS p
21-60 CD p
years NNS p
of IN p
age NN p
who WP p
were VBD p
scheduled VBN p
for IN p
elective JJ i
gasless NN i
robot-assisted JJ i
endoscopic NN i
thyroidectomy NN i
via IN p
the DT p
transaxillary JJ i
approach NN i
. . i

The DT N
patients NNS N
were VBD N
given VBN N
placebo NNS i
or CC N
1 CD N
g NN N
of IN N
paracetamol NN i
as IN N
a DT N
100 CD N
ml JJ N
solution NN N
infused VBD N
over IN N
15 CD N
min NNS N
1 CD N
h NN N
before IN N
the DT N
induction NN N
of IN N
anesthesia NN i
, , N
and CC N
then RB N
at IN N
6-h JJ N
intervals NNS N
for IN N
the DT N
following JJ N
24 CD N
h. JJ N
RESULTS NNP N
Postoperative NNP o
pain NN o
scores NNS o
were VBD N
significantly RB N
lower JJR N
at IN N
1 CD N
, , N
3 CD N
, , N
6 CD N
, , N
and CC N
24 CD N
h NN N
after IN N
surgery NN N
in IN N
the DT N
paracetamol NN i
group NN N
than IN N
in IN N
the DT N
placebo NN i
group NN N
. . N

Significantly RB N
fewer JJR N
patients NNS N
in IN N
the DT N
paracetamol NN i
group NN N
received VBD N
rescue NN o
analgesics NNS o
compared VBN N
to TO N
the DT N
placebo NN i
group NN N
( ( N
9.5 CD N
% NN N
vs. FW N
65.6 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

First NNP N
analgesic JJ o
time NN o
was VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
. . N

Postoperative JJ o
nausea NN o
( ( N
44.3 CD N
% NN N
vs. FW N
22.2 CD N
% NN N
) ) N
and CC N
vomiting VBG o
( ( N
21.3 CD N
% NN N
vs. FW N
6.3 CD N
% NN N
) ) N
were VBD N
more RBR N
frequent JJ N
in IN N
the DT N
placebo NN i
group NN N
than IN N
in IN N
the DT N
paracetamol NN i
group NN N
. . N

Other JJ N
postoperative JJ N
side NN N
effects NNS N
, , N
including VBG N
sedation NN o
, , o
confusion NN o
, , o
and CC o
pruritus NN o
, , N
were VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
. . N

CONCLUSIONS NNP N
We PRP N
concluded VBD N
that IN N
repeated JJ N
administration NN N
of IN N
1 CD N
g NN N
of IN N
intravenous JJ i
paracetamol NN i
over IN N
24 CD N
h NN N
is VBZ N
easy JJ N
, , N
effective JJ N
, , N
safe JJ N
, , N
and CC N
well RB N
tolerated VBN N
for IN N
pain NN p
management NN p
in IN p
patients NNS p
with IN p
moderate JJ p
to TO p
severe VB p
postoperative JJ p
pain NN p
after IN p
gasless JJ i
robot-assisted JJ i
endoscopic NN i
thyroidectomy NN i
performed VBD p
via IN p
the DT p
transaxillary JJ i
approach NN i
. . i

-DOCSTART- -8352625- O O

A DT N
multicenter NN N
study NN N
on IN N
the DT N
use NN N
of IN N
pulsed JJ i
low-intensity NN i
direct JJ i
current JJ i
for IN N
healing VBG N
chronic JJ o
stage NN o
II NNP o
and CC o
stage NN o
III NNP o
decubitus NN o
ulcers NNS o
. . o

BACKGROUND NNP N
AND CC N
DESIGN NNP N
Pulsed VBD i
low-intensity NN i
direct JJ i
current JJ i
( ( i
300 CD i
to TO i
600 CD i
microA NN i
) ) i
has VBZ N
been VBN N
used VBN N
in IN N
a DT N
double-blind JJ N
placebo NN N
multicenter NN N
study NN N
in IN N
the DT N
treatment NN N
of IN N
stage NN o
II NNP o
and CC o
stage NN o
III NNP o
chronic JJ o
decubitus NN o
ulcers NNS o
. . o

RESULTS NNP N
Seventy-four JJ p
ulcers NNS p
were VBD p
treated VBN p
in IN p
four CD p
centers NNS p
. . p

Forty-three JJ p
patients NNS p
were VBD p
selected VBN p
for IN p
the DT p
experimental JJ p
group NN p
, , p
and CC p
31 CD p
control NN p
subjects NNS p
used VBD p
the DT p
sham JJ i
instrument NN i
( ( i
placebo JJ i
group NN i
) ) i
. . i

In IN N
the DT N
treated JJ N
group NN N
, , N
25 CD N
ulcers NNS N
( ( N
58 CD N
% NN N
) ) N
healed VBD N
in IN N
8 CD N
weeks NNS N
, , N
whereas NNS N
in IN N
the DT N
placebo NN N
group NN N
, , N
only RB N
one CD N
ulcer NN N
( ( N
3 CD N
% NN N
) ) N
healed VBN N
and CC N
most JJS N
ulcers NNS o
increased VBD N
in IN N
size NN N
. . N

Statistical JJ N
analysis NN N
, , N
based VBN N
on IN N
surface NN N
area NN N
and CC N
ulcer JJ o
depth NN N
before IN N
and CC N
after IN N
treatment NN N
, , N
showed VBD N
that IN N
low-intensity NN i
direct JJ i
current JJ i
had VBD N
a DT N
significant JJ N
influence NN N
on IN N
the DT N
healing NN o
rates NNS o
for IN N
these DT N
ulcers NNS N
( ( N
P NNP N
< NNP N
.0001 NNP N
) ) N
. . N

Experiments NNS N
with IN N
guinea NN N
pigs NNS N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
showed VBD N
that IN N
pulsed VBD i
low-intensity NN i
direct JJ i
current JJ i
caused VBD N
a DT N
rapid JJ o
calcium NN o
flux NN o
in IN N
the DT N
epidermis NN N
. . N

CONCLUSIONS NNP N
Pulsed VBD i
low-intensity NN i
direct JJ i
current JJ i
represents VBZ N
a DT N
useful JJ N
approach NN N
for IN N
the DT N
treatment NN N
of IN N
stage NN o
II NNP o
and CC o
stage NN o
III NNP o
chronic JJ o
decubitus NN o
ulcers NNS o
by IN N
increasing VBG N
the DT N
healing NN N
rate NN N
. . N

The DT N
growth NN N
of IN N
fibroblasts NNS N
and CC N
keratinocytes NNS N
may MD N
be VB N
enhanced VBN N
by IN N
pulsed JJ i
low-intensity NN i
direct JJ i
current JJ i
due JJ N
to TO N
changes NNS N
in IN N
calcium NN o
homeostasis NN o
. . o

-DOCSTART- -15473502- O O

The DT N
relationship NN N
of IN N
changes NNS N
in IN N
EORTC NNP N
QLQ-C30 NNP N
scores NNS N
to TO N
ratings NNS N
on IN N
the DT N
Subjective JJ o
Significance NNP o
Questionnaire NNP o
in IN N
men NNS p
with IN p
localized JJ p
prostate NN p
cancer NN p
. . p

PURPOSE NNP N
To TO N
examine VB N
the DT N
relationship NN N
between IN N
changes NNS o
in IN N
health-related JJ o
quality-of-life NN o
( ( o
HRQOL NNP o
) ) o
on IN i
the DT i
EORTC NNP o
Quality NNP o
of IN o
Life NNP o
Questionnaire NNP o
( ( o
QLQ-C30 NNP o
) ) o
, , N
and CC N
patients NNS N
' POS N
perceptions NNS N
of IN N
HRQOL NNP N
changes NNS N
as IN N
measured VBN N
by IN N
the DT N
Subjective NNP o
Significance NNP o
Questionnaire NNP o
( ( o
SSQ NNP o
) ) o
. . o

PATIENTS NNP N
AND CC N
METHODS NNP N
A NNP p
total NN p
of IN p
101 CD p
patients NNS p
completed VBD N
the DT N
QLQ-C30 NNP i
on IN N
weeks NNS N
1 CD N
, , N
4 CD N
and CC N
7 CD N
of IN N
radical JJ p
external-beam NN i
radiation NN i
therapy NN i
( ( i
RT NNP i
) ) i
for IN p
localized JJ p
cancer NN p
of IN p
the DT p
prostate NN p
. . p

Patients NNS N
rated VBD N
their PRP$ N
change NN N
in IN N
physical JJ o
functioning NN o
, , o
emotional JJ o
functioning NN o
, , o
social JJ o
functioning NN o
, , o
and CC o
overall/global JJ o
quality NN o
of IN o
life NN o
( ( o
QOL NNP o
) ) o
by IN o
completing VBG o
a DT o
seven-category JJ o
SSQ NNP o
at IN N
weeks NNS N
4 CD N
and CC N
7 CD N
. . N

The DT N
association NN N
between IN N
changes NNS N
in IN N
the DT N
QLQ-C30 JJ N
change NN N
and CC N
the DT N
corresponding JJ N
SSQ NNP i
ratings NNS N
were VBD N
determined VBN N
by IN N
calculation NN N
of IN N
mean JJ N
change NN N
scores NNS N
for IN N
each DT N
SSQ NNP i
category NN N
and CC N
by IN N
Spearman NNP N
rank NN N
correlation NN N
coefficient NN N
analysis NN N
. . N

RESULTS JJ N
Patients NNPS N
' POS N
completion NN N
of IN N
the DT N
QLQ-C30 NNP N
and CC N
SSQ NNP i
exceeded VBD N
95 CD N
% NN N
. . N

Statistically NNP N
significant JJ N
changes NNS N
in IN N
fatigue NN o
, , o
pain NN o
, , o
appetite NN o
, , o
diarrhea NN o
, , o
and CC o
global JJ o
QOL NNP o
scores NNS o
were VBD N
detected VBN N
during IN N
RT NNP N
. . N

For IN N
patients NNS N
reporting VBG N
'a JJ N
little JJ N
' POS N
change NN N
in IN N
global JJ o
QOL NNP o
on IN N
the DT N
SSQ NNP i
, , N
absolute JJ N
mean JJ N
QLQ-C30 JJ N
change NN N
scores NNS N
ranged VBD N
between IN N
0 CD N
to TO N
15 CD N
points NNS N
with IN N
12/16 CD N
mean JJ N
change NN N
scores NNS N
between IN N
2.5 CD N
and CC N
8.5 CD N
points NNS N
. . N

In IN N
the DT N
entire JJ N
study NN N
sample NN N
, , N
correlations NNS N
between IN N
SSQ NNP o
patient JJ N
ratings NNS N
and CC N
QLQ-C30 JJ o
change NN o
scores NNS o
were VBD N
lower JJR N
than IN N
previously RB N
reported VBN N
, , N
ranging VBG N
between IN N
0.15 CD N
and CC N
0.24 CD N
for IN N
the DT N
four CD N
different JJ N
domains NNS N
, , N
but CC N
were VBD N
higher JJR N
when WRB N
QOL NNP o
scores VBZ o
producing VBG N
ceiling NN N
effects NNS N
were VBD N
omitted VBN N
. . N

CONCLUSION VB N
The DT N
SSQ NNP i
and CC N
QLQ-C30 NNP i
may MD N
measure VB N
related JJ N
concepts NNS N
that WDT N
could MD N
assist VB N
in IN N
the DT N
interpretation NN N
of IN N
changes NNS N
in IN N
scores NNS N
and CC N
in IN N
the DT N
calibration NN N
of IN N
the DT N
QLQ-C30 NNP i
. . i

However RB N
, , N
the DT N
nature NN N
of IN N
this DT N
relationship NN N
could MD N
not RB N
be VB N
elucidated VBN N
in IN N
this DT N
data NN N
set NN N
because IN N
of IN N
a DT N
lack NN N
of IN N
variance NN N
in IN N
HRQOL NNP N
scores NNS N
in IN N
the DT N
study NN N
sample NN N
. . N

Further JJ N
investigation NN N
should MD N
be VB N
carried VBN N
out RP N
in IN N
study NN N
samples NNS N
with IN N
sufficient JJ N
variance NN N
to TO N
allow VB N
more JJR N
robust JJ N
conclusions NNS N
. . N

-DOCSTART- -2860373- O O

Primary JJ o
hypothyroidism NN o
associated VBN N
with IN N
interferon JJ i
therapy NN p
of IN p
breast NN p
cancer NN p
. . p

-DOCSTART- -17404792- O O

Successful JJ N
new JJ N
method NN N
of IN N
extracorporeal JJ i
percutaneous JJ i
endoscopic NN i
gastrostomy NN i
( ( i
E-PEG NNP i
) ) i
. . i

BACKGROUND NNP N
Although IN N
percutaneous JJ i
endoscopic NNS i
gastrostomy NN i
( ( i
PEG NNP i
) ) i
has VBZ N
become VBN N
popular JJ N
for IN N
patients NNS p
with IN p
swallowing VBG p
disorders NNS p
as IN p
a DT p
nutrition NN p
support NN p
or CC p
a DT p
decompressant NN p
of IN p
gastrointestine NN p
, , p
perioperative JJ p
complications NNS p
associated VBN p
with IN p
PEG NNP i
have VBP p
not RB p
decreased VBN p
, , p
especially RB p
peristomal JJ p
infections NNS p
. . p

To TO N
reduce VB N
peristomal JJ N
infections NNS N
, , N
we PRP N
designed VBD N
a DT N
new JJ N
method NN N
of IN N
gastrostomy NN N
by IN N
extracorporeal JJ N
approach NN N
under IN N
endoscopic JJ N
observation NN N
, , N
named VBN N
as IN N
extra-corporeal JJ i
PEG NNP i
( ( i
E-PEG NNP i
) ) i
. . i

METHODS NNP N
Experimental NNP N
studies NNS N
for IN N
E-PEG NNP i
were VBD N
performed VBN N
repeatedly RB N
using VBG N
pigs NNS p
under IN p
general JJ p
anesthesia NN i
to TO N
confirm VB N
the DT N
safety NN N
of IN N
its PRP$ N
procedure NN N
for IN N
human JJ N
use NN N
. . N

After IN N
approval NN N
of IN N
institutional JJ N
ethics NNS N
review VBP N
board NN N
in IN N
our PRP$ N
university NN N
, , N
thirty JJ p
patients NNS p
with IN p
prior JJ p
consent NN p
participated VBN N
in IN N
this DT N
study NN N
. . N

The DT N
operation NN o
time NN o
, , N
the DT N
incidence NN o
rate NN o
of IN o
complications NNS o
and CC o
the DT o
hospital NN o
stay NN o
were VBD N
compared VBN N
between IN N
E-PEG NNP i
and CC i
ordinary JJ i
pull-method JJ i
PEG NNP i
groups NNS i
. . N

RESULTS NNP N
Two CD N
patients NNS N
( ( N
6.7 CD N
% NN N
) ) N
in IN N
E-PEG NNP i
group NN N
had VBD N
postoperative JJ o
complications NNS o
, , N
i.e. FW N
, , N
aspiration NN o
pneumonia NN o
and CC o
surgical JJ o
site NN o
infection NN o
. . o

The DT N
operation NN o
time NN o
of IN N
E-PEG NNP i
group NN N
was VBD N
5-16 JJ N
( ( N
mean JJ N
+/- JJ N
SD NN N
: : N
10.3 CD N
+/- JJ N
2.96 CD N
) ) N
min NN N
as IN N
compared VBN N
to TO N
14-37 JJ N
( ( N
mean JJ N
+/- JJ N
SD NN N
: : N
26.9 CD N
+/- JJ N
8.39 CD N
) ) N
min NN N
with IN N
pull-method JJ N
PEG NNP i
. . i

The DT N
postoperative JJ o
hospital NN o
day NN o
of IN N
E-PEG NNP i
was VBD N
within IN N
two CD N
days NNS N
except IN N
for IN N
the DT N
two CD N
complicated VBD N
cases NNS N
. . N

Significance NNP N
differences NNS N
of IN N
operation NN o
time NN o
, , o
complication NN o
rate NN o
and CC o
postoperative JJ o
hospital NN o
stay NN o
between IN N
those DT N
groups NNS N
observed VBD N
statistically RB N
. . N

CONCLUSIONS NNP N
These DT N
results NNS N
indicate VBP N
that IN N
E-PEG NNP i
was VBD N
safe JJ o
, , o
tolerable JJ o
and CC N
speedy NN N
when WRB N
compared VBN N
ordinary JJ N
pull-method JJ N
PEG NNP i
. . i

-DOCSTART- -22968615- O O

[ JJ N
Clinical NNP N
efficiency NN N
of IN N
cytokines NNS i
in IN N
prophylactics NNS N
and CC N
treatment NN N
of IN N
infectious JJ p
and CC p
inflammatory JJ p
complications NNS p
after IN p
oral JJ p
surgery NN p
procedures NNS p
] VBP p
. . N

The DT N
study NN N
presents VBZ N
the DT N
results NNS N
of IN N
prevention NN p
and CC p
treatment NN p
of IN p
infectious JJ p
and CC p
inflammatory JJ p
complications NNS p
after IN p
oral JJ p
surgery NN p
procedures NNS p
. . p

Combined VBN i
therapy NN i
with IN i
antibiotics NNS i
and CC i
superlimf NN i
promotes VBZ N
a DT N
more RBR N
rapid JJ N
reduction NN o
in IN N
the DT N
duration NN o
of IN o
clinical JJ o
symptoms NNS o
and CC o
duration NN o
of IN o
treatment NN o
than IN N
monotherapy NN i
with IN i
antibiotics NNS i
. . i

Results NNS N
of IN N
the DT N
study NN N
substantiate VBP N
the DT N
feasibility NN N
of IN N
using VBG N
superlimf NN i
in IN N
outpatient JJ p
oral JJ N
surgical JJ N
procedures NNS N
for IN N
infectious JJ N
and CC N
inflammatory JJ N
complications NNS N
treatment NN N
. . N

-DOCSTART- -17123125- O O

Parent NN N
satisfaction NN N
in IN N
a DT N
multi-site JJ N
acute JJ N
trial NN N
of IN N
risperidone NN i
in IN N
children NNS N
with IN N
autism NN N
: : N
a DT N
social JJ N
validity NN N
study NN N
. . N

RATIONALE NNP N
Subjects NNPS N
who WP N
view VBP N
experimental JJ N
procedures NNS N
as IN N
worthwhile NN N
are VBP N
more RBR N
likely JJ N
to TO N
participate VB N
in IN N
clinical JJ N
trials NNS N
and CC N
comply NN N
with IN N
study NN N
procedures NNS N
. . N

Designing VBG N
studies NNS N
that WDT N
consider VBP N
the DT N
consumer NN N
's POS N
perspective NN N
will MD N
help VB N
to TO N
forge VB N
a DT N
better JJR N
alliance NN N
between IN N
participants NNS N
and CC N
researchers NNS N
. . N

OBJECTIVE NNP N
Participant NNP N
satisfaction NN N
is VBZ N
seldom RB N
assessed VBN N
in IN N
pharmacological JJ N
research NN N
. . N

In IN N
this DT N
paper NN N
, , N
we PRP N
report VBP N
on IN N
parent NN N
satisfaction NN N
in IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
in IN N
children NNS p
with IN p
autistic JJ p
disorder NN p
and CC p
severely RB p
disruptive JJ p
behavior NN p
. . p

METHOD NNP N
Parents NNP p
of IN p
101 CD p
children NNS p
with IN p
autism NN p
who WP p
had VBD p
participated VBN p
in IN p
a DT p
multi-site JJ p
8-week JJ p
double-blind JJ p
clinical JJ p
trial NN p
of IN p
risperidone NN i
were VBD p
given VBN p
a DT p
questionnaire NN i
at IN p
the DT p
end NN p
to TO p
elicit VB p
their PRP$ p
perceptions NNS p
of IN p
the DT p
appropriateness NN p
and CC p
acceptability NN p
of IN p
clinical JJ p
trial NN p
procedures NNS p
. . p

RESULTS VB N
Ninety-six NNP p
( ( p
95.0 CD p
% NN p
) ) p
parents NNS p
returned VBD p
the DT p
questionnaire NN p
. . p

Of IN N
these DT N
, , N
80.0 CD N
to TO N
96.8 CD N
% NN N
, , N
depending VBG N
on IN N
the DT N
question NN N
, , N
expressed VBN N
satisfaction NN N
with IN N
their PRP$ N
child NN N
's POS N
research NN N
participation NN N
regardless NN N
of IN N
treatment NN N
outcome NN N
or CC N
assignment NN N
to TO N
active JJ N
drug NN N
or CC N
placebo NN i
. . i

In IN N
all DT N
, , N
90.5 CD N
% NN N
of IN N
parents NNS N
indicated VBN N
that IN N
they PRP N
would MD N
definitely RB N
recommend VB N
the DT N
clinical JJ N
trial NN N
to TO N
other JJ N
families NNS N
with IN N
similar JJ N
children NNS N
. . N

A DT N
total NN N
of IN N
92.7 CD N
% NN N
indicated VBD N
that IN N
they PRP N
would MD N
rejoin VB N
the DT N
clinical JJ N
trial NN N
if IN N
they PRP N
had VBD N
to TO N
do VB N
it PRP N
all DT N
over RB N
again RB N
. . N

Ethnic JJ N
minority NN N
subjects NNS N
were VBD N
more RBR N
satisfied JJ N
than IN N
white JJ N
participants NNS N
with IN N
the DT N
use NN N
of IN N
learning VBG N
tests NNS N
. . N

CONCLUSIONS NNP N
Parents NNPS N
of IN N
children NNS N
participating VBG N
in IN N
this DT N
trial NN N
were VBD N
highly RB o
satisfied JJ o
and CC o
supportive JJ o
of IN o
the DT o
clinical JJ o
trial NN o
procedures NNS o
. . o

Random NNP N
assignment NN N
to TO N
drug NN N
or CC N
placebo NN i
and CC N
the DT N
clinical JJ N
response NN N
of IN N
their PRP$ N
children NNS N
did VBD N
not RB N
appear VB N
to TO N
influence VB N
their PRP$ N
views NNS N
. . N

Further JJ N
satisfaction NN N
studies NNS N
of IN N
this DT N
sort NN N
are VBP N
encouraged VBN N
. . N

-DOCSTART- -18561117- O O

Onset NNP o
of IN o
action NN o
of IN N
ciclesonide NN i
once RB N
daily RB N
in IN N
the DT N
treatment NN N
of IN N
seasonal JJ N
allergic JJ N
rhinitis NN N
. . N

Ciclesonide NNP i
is VBZ N
an DT N
intranasal JJ N
corticosteroid NN N
approved VBD N
for IN N
the DT N
treatment NN N
of IN N
allergic JJ N
rhinitis NN N
. . N

We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
double-blind JJ N
, , N
parallel-group JJ N
, , N
placebo-controlled JJ N
study NN N
to TO N
evaluate VB o
the DT o
time NN o
to TO o
onset VB o
of IN o
action NN o
of IN o
ciclesonide NN o
200 CD N
microg NN N
once RB N
daily RB N
in IN N
502 CD p
adults NNS p
with IN p
seasonal JJ p
allergic JJ p
rhinitis NN p
of IN p
at IN p
least JJS p
2 CD p
years NNS p
' POS p
duration NN p
. . p

To TO N
trigger VB N
immunologic JJ o
priming NN o
, , N
patients NNS p
underwent VBP i
between IN i
one CD i
and CC i
five CD i
priming NN i
sessions NNS i
with IN i
exposure NN i
to TO i
3,500 CD i
grains/m NN i
( ( i
3 CD i
) ) i
( ( i
+/-500 JJ i
) ) i
of IN i
ragweed NN i
pollen NN i
in IN i
an DT i
environmental JJ i
exposure NN i
chamber NN i
. . i

The DT N
criteria NN N
for IN N
a DT N
successful JJ N
priming NN N
session NN N
were VBD N
a DT N
patient-assessed JJ N
instantaneous JJ N
total NN o
nasal NN o
symptom VBD o
score NN o
of IN N
at IN N
least JJS N
6 CD N
( ( N
of IN N
a DT N
possible JJ N
12 CD N
) ) N
and CC N
a DT N
nasal JJ o
congestion NN o
or CC o
rhinorrhea VB o
score NN o
of IN N
at IN N
least JJS N
2 CD N
( ( N
of IN N
a DT N
possible JJ N
3 CD N
) ) N
90 CD N
minutes NNS N
after IN N
allergen NN N
exposure NN N
during IN N
at IN N
least JJS N
two CD N
consecutive JJ N
priming NN N
sessions NNS N
. . N

Patients NNS p
were VBD N
then RB N
randomly RB N
assigned VBN N
to TO N
receive VB N
either CC N
a DT N
single JJ N
dose NN N
of IN N
ciclesonide JJ i
200 CD N
microg NN N
( ( N
n JJ N
= NNP N
251 CD N
) ) N
or CC N
placebo NN i
( ( N
n JJ N
= NNP N
251 CD N
) ) N
administered VBN N
intranasally RB N
. . N

The DT N
difference NN N
in IN N
the DT N
change NN N
from IN N
baseline NN o
total JJ o
nasal JJ o
symptom NN o
scores NNS o
in IN N
the DT N
two CD N
groups NNS N
was VBD N
assessed VBN N
hourly RB N
for IN N
12 CD N
hours NNS N
after IN N
administration NN N
. . N

Onset NNP o
of IN o
action NN o
was VBD N
determined VBN N
to TO N
have VB N
taken VBN N
place NN N
the DT N
first JJ N
time NN N
that IN N
the DT N
effects NNS N
of IN N
ciclesonide NN i
, , N
as IN N
reflected VBN N
in IN N
the DT N
total JJ o
nasal JJ o
symptom NN o
score NN o
, , N
were VBD N
significantly RB N
greater JJR N
than IN N
those DT N
of IN N
placebo NN i
at IN N
a DT N
particular JJ N
hourly JJ N
assessment NN N
, , N
provided VBD N
that IN N
the DT N
subsequent JJ N
hourly NN N
assessment NN N
also RB N
showed VBD N
a DT N
statistically RB o
significant JJ o
difference NN o
. . o

The DT N
onset NN o
of IN o
action NN o
of IN o
ciclesonide NN o
occurred VBD N
within IN N
1 CD N
hour NN N
of IN N
administration NN N
( ( N
p JJ N
= $ N
0.01 CD N
vs. FW N
placebo NN N
) ) N
, , N
and CC N
the DT N
significant JJ N
difference NN N
in IN N
total JJ o
nasal JJ o
symptom NN o
scores NNS o
between IN N
ciclesonide NN i
and CC N
placebo NN i
was VBD N
maintained VBN N
through IN N
post-treatment JJ N
hour NN N
12 CD N
( ( N
p NN N
= RB N
0.018 CD N
) ) N
. . N

-DOCSTART- -22743137- O O

Early RB N
versus NN N
late JJ N
hCG NN i
administration NN i
to TO N
trigger VB N
ovulation NN N
in IN N
mild NN N
stimulated VBN N
IUI NNP N
cycles NNS N
: : N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

OBJECTIVES UH N
To TO N
verify VB N
non-inferiority NN N
of IN N
the DT N
clinical JJ N
pregnancy NN N
rate NN N
of IN N
Early NNP i
hCG NN i
administration NN i
( ( N
leading VBG N
follicle NN N
sizes NNS N
within IN N
16.0-16.9 JJ N
mm NN N
in IN N
diameter NN N
) ) N
compared VBN N
to TO N
Late NNP i
hCG NN i
administration NN i
( ( N
leading VBG N
follicle NN N
sizes NNS N
within IN N
18.0-18.9 JJ N
mm NN N
in IN N
diameter NN N
) ) N
. . N

STUDY NNP N
DESIGN NNP N
Prospective NNP N
randomized VBD N
trial NN N
. . N

Six CD p
hundred CD p
and CC p
twelve VB p
infertile JJ p
women NNS p
candidates NNS p
for IN p
intrauterine JJ p
insemination NN p
( ( p
IUI NNP p
) ) p
received VBD N
HP-hMG JJ i
75 CD N
IU/day NNP N
SC NNP N
from IN N
cycle NN N
days NNS N
4 CD N
to TO N
8 CD N
and CC N
then RB N
as IN N
per IN N
ovarian JJ N
response NN N
. . N

Ovulation NN N
was VBD N
randomly RB N
triggered VBN N
( ( N
hCG JJ N
5000 CD N
IU NNP N
, , N
IM NNP N
) ) N
when WRB N
the DT N
leading VBG N
follicle NN N
diameter NN N
ranged VBD N
between IN N
either CC N
16.0 CD N
and CC N
16.9 CD N
mm NN N
( ( N
Early JJ N
hCG NN i
group NN N
, , N
n=227 RB N
) ) N
or CC N
18.0 CD N
and CC N
18.9 CD N
mm NNS N
( ( N
Late JJ N
hCG NN N
group NN N
, , N
n=207 NN N
) ) N
and CC N
IUI NNP N
was VBD N
performed VBN N
approximately RB N
36 CD N
h NN N
later RB N
. . N

RESULTS NNP N
Whereas NNP N
population NN o
and CC o
sperm JJ o
characteristics NNS o
were VBD N
comparable JJ N
in IN N
both DT N
groups NNS N
, , N
the DT N
number NN o
of IN o
follicles NNS o
? . N
14 CD N
mm NN N
in IN N
diameter NN N
( ( N
P NNP N
< NNP N
0.007 CD N
) ) N
and CC o
serum JJ o
estradiol NN o
levels NNS o
( ( o
P NNP N
< NNP N
0.001 CD N
) ) N
on IN N
the DT N
day NN N
of IN N
hCG NN i
were VBD i
lower JJR N
in IN N
the DT N
Early JJ N
versus NN N
the DT N
Late NNP i
hCG NN i
groups NNS i
. . N

Clinical NNP N
( ( N
11.9 CD N
% NN N
versus IN N
12.1 CD N
% NN N
) ) N
and CC N
ongoing VBG N
( ( N
11.0 CD N
% NN N
versus IN N
8.6 CD o
% NN o
) ) o
pregnancy NN o
rates NNS o
per IN o
randomized VBN p
women NNS p
were VBD p
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
and CC N
statistical JJ N
non-inferiority NN N
of IN N
clinical JJ o
and CC o
ongoing JJ o
pregnancy NN o
rates NNS o
was VBD N
demonstrated VBN N
. . N

CONCLUSION NNP N
These DT N
results NNS N
suggest VBP N
that IN i
hCG NN i
administered VBD i
when WRB N
the DT N
largest JJS N
follicle NN N
size NN N
reaches VBZ N
16.0-16.9 JJ N
mm NN N
leads VBZ N
to TO N
similar JJ N
clinical JJ N
and CC N
ongoing JJ N
pregnancy NN N
rates NNS N
as IN N
when WRB N
it PRP N
reaches VBZ N
18.0-18.9 JJ N
mm NN N
in IN N
IUI NNP N
cycles NNS N
. . N

-DOCSTART- -20378181- O O

Effects NNS N
of IN N
10 CD N
Hz NNP N
repetitive JJ i
transcranial JJ i
magnetic JJ i
stimulation NN i
( ( i
rTMS NN i
) ) i
on IN N
clinical JJ N
global JJ N
impression NN N
in IN N
chronic JJ p
schizophrenia NN p
. . p

UNLABELLED IN N
We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
sham-controlled JJ N
repetitive JJ i
transcranial JJ i
magnetic JJ i
stimulation NN i
( ( i
rTMS NN i
) ) i
study NN N
in IN N
chronic JJ p
schizophrenia NN p
in-patients NNS p
( ( p
n=35 NN p
) ) p
to TO N
evaluate VB N
the DT N
therapeutic JJ N
efficacy NN N
of IN N
10 CD i
Hz NNP i
stimulation NN N
. . N

Patients NNS p
, , N
who WP N
were VBD N
on IN N
stable JJ p
antipsychotic JJ p
treatment NN p
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
active JJ N
or CC N
sham JJ N
condition NN N
. . N

In IN N
the DT N
active JJ N
rTMS NN i
group NN N
, , N
ten JJ N
sessions NNS N
with IN N
a DT N
total NN N
of IN N
10,000 CD N
stimuli NNS N
were VBD N
applied VBN N
over IN N
the DT N
left JJ N
dorsolateral JJ N
prefrontal JJ N
cortex NN N
at IN N
110 CD N
% NN N
of IN N
motor NN N
threshold NN N
. . N

The DT N
sham NN i
group NN N
received VBD N
corresponding VBG N
sham JJ i
stimulation NN i
. . i

Clinical JJ N
improvement NN N
was VBD N
measured VBN N
by IN N
the DT N
Clinical NNP N
Global NNP N
Impression NNP N
scale NN N
( ( N
primary JJ N
outcome NN N
measure NN N
) ) N
, , N
the DT N
Global NNP N
Assessment NNP N
of IN N
Functioning NNP N
Scale NNP N
( ( N
GAF NNP N
) ) N
and CC N
the DT N
Positive NNP N
and CC N
Negative NNP N
Symptom NNP N
Scale NNP N
( ( N
PANSS NNP N
; : N
secondary JJ N
outcome NN N
measures NNS N
) ) N
. . N

Between-group JJ o
comparisons NNS o
revealed VBD o
no DT o
significant JJ o
differences NNS o
in IN o
clinical JJ o
outcome NN o
variables NNS o
. . o

Only RB o
a DT o
subgroup NN o
of IN o
patients NNS o
with IN o
pronounced JJ o
negative JJ o
symptoms NNS o
developed VBD o
some DT o
clinical JJ o
improvement NN o
as IN o
indicated VBN o
by IN o
significant JJ o
changes NNS o
in IN o
the DT o
GAF-scale NNP o
. . o

Besides IN N
there EX o
is VBZ o
some DT o
evidence NN o
for IN o
a DT o
more RBR o
favourable JJ o
clinical JJ o
outcome NN o
within IN o
this DT o
subgroup NN o
after IN o
rTMS NN o
in IN o
the DT o
CGI-S NNP o
and CC o
PANSS NNP o
negative JJ o
scale NN o
, , o
too RB o
. . o

In IN N
line NN N
with IN N
earlier JJR N
investigations NNS N
, , N
our PRP$ N
results NNS o
suggest VBP o
a DT o
moderate JJ o
- : o
potentially RB o
clinically RB o
relevant JJ o
- : o
treatment NN o
effect NN o
of IN o
prefrontal JJ o
10 CD o
Hz NNP o
rTMS NN o
stimulation NN o
in IN o
chronic JJ o
patients NNS o
. . o

However RB N
, , N
in IN N
our PRP$ N
study NN N
this DT N
beneficial JJ N
effect NN N
was VBD N
restricted VBN N
to TO N
subjects NNS N
with IN N
pronounced JJ N
negative JJ N
symptoms NNS N
. . N

CLINICAL NNP N
TRIAL NNP N
REGISTRATION NNP N
INFORMATION NNP N
ClinicalTrial.gov NNP N
Identifier NNP N
: : N
NCT00169689 NNP N
, , N
http NN N
: : N
//www.clinicaltrials.gov NN N
. . N

-DOCSTART- -11034038- O O

Randomized VBN N
, , N
placebo-controlled JJ N
trial NN N
of IN N
oral JJ N
phytonadione NN i
for IN N
excessive JJ o
anticoagulation NN o
. . o

STUDY NNP N
OBJECTIVE NNP N
To TO N
compare VB N
the DT N
efficacy NN N
of IN N
managing VBG N
excessive JJ N
anticoagulation NN N
in IN N
the DT N
absence NN N
of IN N
bleeding NN N
by IN N
either DT N
omitting VBG N
warfarin JJ N
therapy NN N
alone RB N
or CC N
administering VBG N
oral JJ N
phytonadione NN i
in IN N
addition NN N
to TO N
omitting VBG N
warfarin JJ N
therapy NN N
. . N

DESIGN NNP N
Randomized NNP N
, , N
double-blind NN N
, , N
placebo-controlled JJ N
study NN N
. . N

SETTING NNP N
Clinical JJ N
pharmacy NN N
anticoagulation NN N
service NN N
in IN N
a DT N
group NN N
model NN N
health NN N
maintenance NN N
organization NN N
. . N

SUBJECTS NNP N
Thirty NNP p
nonbleeding VBG p
patients NNS p
with IN p
international JJ p
normalized JJ p
ratios NNS p
( ( p
INRs NNP p
) ) p
ranging VBG p
from IN p
6.0-10.0 JJ p
. . p

INTERVENTIONS JJ N
Patients NNPS p
were VBD p
randomized VBN p
to TO p
receive VB p
either CC p
a DT p
single JJ i
oral JJ i
dose NN i
of IN i
phytonadione NN i
2.5 CD i
mg NN i
or CC i
placebo NN i
. . i

Both DT N
groups NNS N
omitted VBD i
warfarin JJ i
doses NNS i
until IN i
the DT i
INR NNP i
became VBD i
less RBR i
than IN i
or CC i
equal JJ i
to TO i
4.0 CD i
. . i

MEASUREMENTS NNS N
AND CC N
RESULTS NNP N
The DT N
mean NN o
calculated VBD o
time NN o
to TO o
reach VB o
an DT o
INR NNP o
of IN o
4.0 CD o
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
placebo NN N
than IN N
the DT N
phytonadione NN N
group NN N
( ( N
2.6 CD N
vs RB N
1.4 CD N
days NNS N
, , N
p=0.006 NN N
) ) N
. . N

Overcorrection NN o
of IN o
anticoagulation NN o
was VBD N
significantly RB N
more JJR N
common JJ N
in IN N
patients NNS N
receiving VBG N
phytonadione NN N
. . N

Overt NNP o
warfarin VBD o
resistance NN o
was VBD N
not RB N
observed VBN N
in IN N
either DT N
group NN N
after IN N
reinitiating VBG N
warfarin JJ N
therapy NN N
. . N

No DT N
major JJ o
bleeding NN o
or CC o
thromboembolic JJ o
complications NNS o
occurred VBD N
, , N
and CC N
minor JJ N
bleeding NN o
episodes NNS N
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

CONCLUSION NNP N
The DT N
addition NN N
of IN N
oral JJ N
phytonadione NN N
2.5 CD N
mg NN N
reduced VBD N
the DT N
time NN N
to TO N
achieve VB N
an DT N
INR NNP N
of IN N
4.0 CD N
by IN N
approximately RB N
1 CD N
day NN N
compared VBN N
with IN N
omitting VBG N
warfarin JJ N
therapy NN N
alone RB N
. . N

Adverse JJ N
events NNS N
did VBD N
not RB N
differ VB N
between IN N
the DT N
two CD N
groups NNS N
. . N

Both DT N
strategies NNS N
were VBD N
effective JJ N
in IN N
managing VBG N
asymptomatic JJ p
patients NNS p
with IN p
INRs NNP p
of IN p
6.0-10.0 NNP p
. . p

Oral NNP N
phytonadione NN N
may MD N
be VB N
most RBS N
appropriate JJ N
for IN N
patients NNS p
at IN p
high JJ p
risk NN p
for IN p
bleeding VBG p
in IN p
whom WP p
the DT p
benefit NN p
of IN p
prompt JJ p
INR NNP o
reduction NN o
would MD p
outweigh VB p
the DT p
thromboembolic JJ p
risk NN p
associated VBN p
with IN p
INR NNP o
overcorrection NN o
. . o

-DOCSTART- -21346207- O O

Human NNP p
primary JJ p
visual JJ p
cortex NN p
( ( p
V1 NNP p
) ) p
is VBZ p
selective JJ p
for IN p
second-order JJ p
spatial JJ p
frequency NN p
. . p

A DT N
variety NN N
of IN N
cues NNS N
can MD N
differentiate VB N
objects NNS N
from IN N
their PRP$ N
surrounds NNS N
. . N

These DT N
include VBP N
first-order NN N
cues NNS N
such JJ N
as IN N
luminance NN N
modulations NNS N
and CC N
second-order NN N
cues NNS N
involving VBG N
modulations NNS N
of IN N
orientation NN N
and CC N
contrast NN N
. . N

Human NNP p
sensitivity NN N
to TO N
first-order JJ N
modulations NNS N
is VBZ N
well RB N
described VBN N
by IN N
a DT N
computational JJ N
model NN N
involving VBG N
spatially RB N
localized VBN N
filters NNS N
that WDT N
are VBP N
selective JJ N
for IN N
orientation NN N
and CC N
spatial JJ N
frequency NN N
( ( N
SF NNP N
) ) N
. . N

It PRP N
is VBZ N
widely RB N
held VBN N
that IN N
first-order JJ N
modulations NNS N
are VBP N
represented VBN N
by IN N
the DT N
firing VBG N
rates NNS N
of IN N
simple JJ N
and CC N
complex JJ N
cells NNS N
( ( N
first-order JJ N
neurons NNS N
) ) N
in IN N
primary JJ p
visual JJ p
cortex NN p
( ( p
V1 NNP p
) ) p
that IN N
, , N
likewise RB N
, , N
have VBP N
spatially RB N
localized VBN N
receptive JJ N
fields NNS N
that WDT N
are VBP N
selective JJ N
for IN N
orientation- JJ N
and CC N
SF NNP N
. . N

Human NNP N
sensitivity NN N
to TO N
second-order JJ N
modulations NNS N
is VBZ N
well RB N
described VBN N
by IN N
a DT N
filter-rectify-filter NN N
( ( N
FRF NNP N
) ) N
model NN N
, , N
with IN N
first- JJ N
and CC N
second-order JJ N
filters NNS N
selective VBP N
for IN N
orientation NN N
and CC N
SF NNP N
. . N

However RB N
, , N
little JJ N
is VBZ N
known VBN N
about IN N
how WRB N
neuronal JJ N
activity NN N
in IN N
visual JJ N
cortex NN N
represents VBZ N
second-order JJ o
modulations NNS o
. . o

We PRP N
tested VBD N
the DT N
FRF NNP i
model NN i
by IN N
using VBG N
an DT N
functional JJ i
( ( i
f JJ i
) ) i
MRI-adaptation NN i
protocol NN i
to TO N
characterize VB N
the DT N
selectivity NN N
of IN N
activity NN N
in IN N
visual JJ N
cortex NN N
to TO N
second-order NN N
, , N
orientation-defined JJ N
gratings NNS N
of IN N
two CD N
different JJ N
SFs NNP N
. . N

fMRI NN N
responses NNS N
throughout IN N
early JJ p
visual JJ p
cortex NN p
exhibited VBD N
selective JJ N
adaptation NN N
to TO N
these DT N
stimuli NNS N
. . N

The DT N
low-SF JJ N
grating NN N
was VBD N
a DT N
more RBR N
effective JJ N
adapter NN N
than IN N
the DT N
high-SF JJ N
grating NN N
, , N
incompatible JJ N
with IN N
the DT N
FRF NNP N
model NN N
. . N

To TO N
explain VB N
the DT N
results NNS N
, , N
we PRP N
extended VBD N
the DT N
FRF NNP N
model NN N
by IN N
incorporating VBG N
normalization NN N
, , N
yielding VBG N
a DT N
filter-rectify-normalize-filter JJ N
model NN N
, , N
in IN N
which WDT N
normalization NN N
enhances VBZ N
selectivity NN N
for IN N
second-order JJ N
SF NNP N
but CC N
only RB N
for IN N
low JJ N
spatial JJ N
frequencies NNS N
. . N

We PRP N
conclude VBP N
that DT N
neurons NNS N
in IN N
human JJ p
visual JJ p
cortex NN p
are VBP N
selective JJ N
for IN N
second-order NN N
SF NNP N
, , N
that IN N
normalization NN N
( ( N
surround JJ N
suppression NN N
) ) N
contributes VBZ N
to TO N
this DT N
selectivity NN N
, , N
and CC N
that IN N
the DT N
selectivity NN N
in IN N
higher JJR N
visual JJ N
areas NNS N
is VBZ N
simply RB N
fed JJ N
forward RB N
from IN N
V1 NNP N
. . N

-DOCSTART- -17010794- O O

Thrombus NNP N
aspiration NN N
reduces NNS N
microvascular JJ o
obstruction NN o
after IN N
primary JJ p
coronary JJ p
intervention NN p
: : p
a DT N
myocardial JJ N
contrast NN N
echocardiography NN N
substudy NN N
of IN N
the DT N
REMEDIA NNP N
Trial NNP N
. . N

OBJECTIVES CC N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
clarify VB N
the DT N
role NN N
of IN N
microembolization NN N
in IN N
the DT N
genesis NN N
of IN N
microvascular JJ o
obstruction NN o
( ( o
MO NNP o
) ) o
after IN N
percutaneous JJ N
coronary JJ N
intervention NN N
( ( N
PCI NNP N
) ) N
. . N

BACKGROUND NNP N
Fifty NNP p
consecutive JJ p
patients NNS p
entered VBD p
the DT p
myocardial JJ p
contrast NN p
echocardiography NN p
( ( p
MCE NNP p
) ) p
substudy NN p
of IN p
the DT p
REMEDIA NNP p
( ( p
Randomized NNP p
Evaluation NNP p
of IN p
the DT p
Effect NNP p
of IN p
Mechanical NNP p
Reduction NNP p
of IN p
Distal NNP p
Embolization NNP p
by IN p
Thrombus NNP p
Aspiration NNP p
in IN p
Primary NNP p
and CC p
Rescue NNP p
Angioplasty NNP p
) ) p
trial NN p
, , N
which WDT N
defined VBD N
the DT N
role NN N
of IN N
a DT N
new JJ N
thrombus-aspirating JJ N
device NN N
in IN N
preventing VBG N
distal JJ N
microembolization NN o
after IN N
PCI NNP N
. . N

METHODS NNP N
A NNP N
total NN p
of IN p
25 CD p
patients NNS p
were VBD p
randomized VBN p
to TO p
be VB p
pretreated VBN p
with IN p
thrombus JJ i
aspiration NN i
before IN i
PCI NNP i
of IN i
the DT i
culprit NN i
lesion NN i
and CC i
25 CD p
received JJ p
standard JJ i
PCI NNP i
. . i

At IN N
24 CD N
h NN N
, , N
1 CD N
week NN N
, , N
and CC N
6 CD N
months NNS N
after IN N
PCI NNP N
, , N
MCE NNP N
was VBD N
performed VBN N
by IN N
Sonovue NNP N
, , N
and CC N
real-time JJ N
imaging NN N
was VBD N
performed VBN N
by IN N
contrast NN N
pulse JJ N
sequencing VBG N
technology NN N
. . N

Regional NNP o
wall NN o
motion NN o
score NN o
index NN o
( ( o
WMSI NNP o
) ) o
, , o
contrast RB o
score NN o
index NN o
( ( o
CSI NNP o
) ) o
, , o
endocardial JJ o
length NN o
of IN o
wall NN o
motion NN o
abnormality NN o
( ( o
WML NNP o
) ) o
and CC o
contrast NN o
defect NN o
( ( o
CDL NNP o
) ) o
, , o
end-diastolic JJ o
and CC o
end-systolic JJ o
left NN o
ventricular NN o
( ( o
LV NNP o
) ) o
volumes NNS o
, , o
and CC o
ejection NN o
fraction NN o
were VBD N
calculated VBN N
. . N

RESULTS NNP N
At IN N
each DT N
time NN N
point NN N
, , N
in IN N
patients NNS N
treated VBN N
with IN N
a DT N
thrombus-aspiration NN N
filter NN N
device NN N
, , N
WMSI NNP o
, , o
CSI NNP o
, , o
WML NNP o
, , o
and CC o
CDL NNP o
were VBD N
significantly RB N
lower JJR N
and CC N
ejection NN o
fraction NN o
higher JJR N
( ( N
p JJ N
< $ N
0.05 CD N
vs. FW N
control NN N
patients NNS N
) ) N
, , N
whereas JJ N
LV NNP o
volumes NNS o
were VBD N
slightly RB N
but CC N
not RB N
significantly RB N
smaller JJR N
compared VBN N
with IN N
control NN N
patients NNS N
. . N

In IN N
the DT N
overall JJ N
study NN N
population NN N
, , N
the DT N
extent NN o
of IN o
MO NNP o
significantly RB N
correlated VBD N
with IN N
temporal JJ N
changes NNS N
in IN N
LV NNP o
volumes NNS o
. . o

CONCLUSIONS NNP N
Thrombus NNP N
aspiration NN N
used VBN N
at IN N
the DT N
time NN N
of IN N
PCI NNP N
significantly RB N
reduces VBZ N
the DT N
extent NN o
of IN o
MO NNP o
and CC N
myocardial JJ o
dysfunction NN o
, , N
although IN N
it PRP N
does VBZ N
not RB N
have VB N
a DT N
significant JJ N
favorable JJ N
effect NN N
in IN N
preventing VBG N
LV NNP o
remodeling VBG o
. . o

Thus RB N
, , N
the DT N
beneficial JJ N
effect NN N
of IN N
thrombus NN N
aspiration NN N
occurs VBZ N
at IN N
the DT N
microvascular JJ N
level NN N
, , N
but CC N
additional JJ N
mechanisms NN N
may MD N
play VB N
a DT N
role NN N
in IN N
influencing VBG N
the DT N
final JJ N
extent NN N
of IN N
MO NNP o
, , N
which WDT N
strictly RB N
correlates VBZ N
with IN N
post-infarct JJ N
LV NNP o
remodeling NN o
. . o

-DOCSTART- -22446996- O O

Elevated JJ N
concentration NN N
of IN N
placental JJ N
growth NN N
factor NN N
( ( N
PlGF NNP N
) ) N
and CC N
long JJ N
term NN N
risk NN N
in IN N
patients NNS p
with IN p
acute JJ p
coronary JJ p
syndrome NN p
in IN p
the DT p
PROVE NNP p
IT-TIMI NNP p
22 CD p
trial NN p
. . p

Placental JJ o
growth NN o
factor NN o
( ( o
PlGF NNP o
) ) o
, , N
a DT N
member NN N
of IN N
the DT N
vascular JJ N
endothelial JJ N
growth NN N
factor NN N
( ( N
VEGF NNP N
) ) N
family NN N
, , N
acts VBZ N
via IN N
the DT N
flt-1 JJ N
receptor NN N
and CC N
promotes VBZ N
endothelial JJ N
activation NN N
and CC N
macrophage NN N
recruitment NN N
into IN N
atherosclerotic JJ N
lesions NNS N
. . N

We PRP N
investigated VBD N
the DT N
relationship NN N
of IN N
PlGF NNP N
with IN N
cardiovascular JJ N
outcomes NNS N
in IN N
a DT N
large JJ p
cohort NN p
of IN p
patients NNS p
presenting VBG p
across IN p
the DT p
spectrum NN p
of IN p
ACS NNP p
. . p

PlGF NNP o
was VBD N
measured VBN N
at IN N
baseline NN N
( ( p
n JJ p
= NNP p
3,761 CD p
) ) p
and CC N
at IN N
four-months JJ N
( ( N
n JJ N
= NNP N
3,369 CD N
) ) N
in IN N
patients NNS p
randomized VBN p
to TO p
atorvastatin VB i
80 CD i
mg NN i
or CC i
pravastatin NN i
40 CD i
mg NN i
after IN i
ACS NNP i
in IN p
the DT N
PROVE NNP N
IT-TIMI NNP N
22 CD N
trial NN N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
death NN o
, , o
myocardial JJ o
infarction NN o
( ( o
MI NNP o
) ) o
, , o
unstable JJ o
angina NN o
, , o
revascularization NN o
or CC o
stroke NN o
( ( N
mean JJ N
follow-up JJ N
24 CD N
months NNS N
) ) N
. . N

Elevated VBN N
baseline NN N
PlGF NNP N
was VBD N
associated VBN N
with IN N
a DT N
higher JJR N
incidence NN N
of IN N
the DT N
primary JJ N
endpoint NN N
through IN N
2 CD N
years NNS N
( ( N
Q1 NNP N
vs. FW N
Q5 NNP N
: : N
18.7 CD N
vs. IN N
29.3 CD N
% NN N
, , N
p NN N
< NNP N
0.0001 CD N
) ) N
. . N

The DT N
risk NN o
of IN o
death NN o
or CC o
MI NNP o
was VBD N
also RB N
higher JJR N
in IN N
patients NNS p
with IN p
elevated JJ p
baseline NN p
PlGF NNP p
( ( N
Q1 NNP N
vs. FW N
Q5 NNP N
: : N
7.0 CD N
vs. IN N
11.6 CD N
% NN N
, , N
p NN N
= NNP N
0.029 CD N
) ) N
. . N

Adjusting VBG N
for IN N
baseline NN N
characteristics NNS N
and CC N
risk NN N
factors NNS N
, , N
elevated VBD N
baseline NN N
PlGF NNP N
was VBD N
independently RB N
associated VBN N
with IN N
the DT N
risk NN N
of IN N
the DT N
primary JJ N
endpoint NN N
( ( N
adjusted-HR JJ N
for IN N
Q5 NNP N
vs. FW N
Q1 NNP N
1.45 CD N
; : N
95 CD N
% NN N
CI NNP N
1.16-1.83 CD N
; : N
p CC N
= VB N
0.001 CD N
) ) N
. . N

Elevated VBN N
PlGF NNP N
at IN N
four CD N
months NNS N
was VBD N
associated VBN N
with IN N
higher JJR N
risk NN o
of IN o
death NN o
or CC o
MI NNP o
( ( N
Adjusted NNP N
HR NNP N
Q5 NNP N
vs. IN N
Q1 NNP N
2.79 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.37-5.68 JJ N
; : N
p VB N
= $ N
0.005 CD N
) ) N
, , N
and CC N
higher JJR N
risk NN N
of IN N
the DT N
primary JJ N
endpoint NN N
( ( N
Adjusted NNP N
HR NNP N
Q5 NNP N
vs. IN N
Q1 NNP N
1.78 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.26-2.51 JJ N
; : N
p VB N
= $ N
0.001 CD N
) ) N
. . N

Higher JJR N
concentration NN N
of IN N
PlGF NNP o
after IN N
ACS NNP N
is VBZ N
associated VBN N
with IN N
long-term JJ N
risk NN N
of IN N
recurrent JJ N
cardiovascular JJ N
events NNS N
independent JJ N
of IN N
traditional JJ N
risk NN N
factors NNS N
. . N

This DT N
association NN N
is VBZ N
present JJ N
early JJ N
after IN N
ACS NNP N
and CC N
appears VBZ N
to TO N
be VB N
stronger JJR N
at IN N
four CD N
months NNS N
. . N

-DOCSTART- -23716291- O O

Learning VBG N
curve NN N
in IN N
multidetector NN i
CT NNP i
coronary JJ i
angiography NN i
( ( N
MDCT-CA NNP N
) ) N
. . N

PURPOSE NNP N
Coronary NNP i
angiography NN i
using VBG i
multidetector NN i
computed VBD i
tomography NN i
( ( i
MDCT-CA NNP i
) ) i
is VBZ N
a DT N
recent JJ N
technique NN N
for IN N
the DT N
nonivasive JJ N
study NN N
of IN N
coronary JJ N
arteries NNS N
. . N

This DT N
study NN N
assessed VBD N
the DT N
diagnostic JJ o
accuracy NN o
of IN o
coronary JJ o
artery NN o
stenosis NN o
evaluation NN o
obtained VBN N
by IN N
three CD p
readers NNS p
at IN p
different JJ p
levels NNS p
of IN p
training NN p
or CC p
at IN p
different JJ p
points NNS p
of IN p
the DT p
learning VBG p
curve NN p
proposed VBN p
by IN p
the DT p
international JJ p
guidelines NNS p
. . p

MATERIALS NNP N
AND CC N
METHODS NNP N
Three NNP p
radiologists VBZ p
in IN p
training VBG p
with IN p
different JJ p
levels NNS p
of IN p
experience NN p
in IN p
MDCT-CA NNP p
scored VBD N
50 CD N
cases NNS N
at IN N
various JJ N
time NN N
points NNS N
of IN N
the DT N
learning VBG N
curve NN N
: : N
baseline NN N
, , N
4 CD N
weeks NNS N
, , N
8 CD N
weeks NNS N
and CC N
6 CD N
months NNS N
. . N

The DT p
trainee NN p
radiologists VBZ p
evaluated VBD N
the DT N
degree NN o
of IN o
stenosis NN o
on IN o
each DT o
coronary JJ o
segment NN o
, , N
and CC N
overall JJ o
accuracy NN o
was VBD N
calculated VBN N
on IN N
a DT N
per-segment JJ N
, , N
pervessel JJ N
and CC N
per-patient JJ N
basis NN N
. . N

RESULTS NNP N
All NNP N
readers NNS N
improved VBD o
analysis NN o
accuracy NN o
per IN o
segment NN o
( ( N
range NN N
, , N
73-90 CD N
% NN N
) ) N
; : N
sensitivity NN o
reached VBD N
45 CD N
% NN N
per IN N
segment NN N
, , N
84 CD N
% NN N
per IN N
vessel NN N
and CC N
93 CD N
% NN N
per IN N
patient NN N
; : N
specificity NN o
was VBD N
99 CD N
% NN N
per IN N
segment NN N
and CC N
vessel NN N
and CC N
98 CD N
% NN N
per IN N
patient NN N
. . N

Positive JJ o
and CC o
negative JJ o
predictive JJ o
values NNS o
increased VBD o
to TO N
94 CD N
% NN N
and CC N
92 CD N
% NN N
, , N
respectively RB N
. . N

CONCLUSIONS NNP N
Although IN N
all DT N
readers NNS N
improved VBN N
in IN N
diagnostic JJ o
performance NN o
with IN N
growing VBG N
experience NN N
with IN N
MDCT-CA NNP N
, , N
a DT N
longer RBR i
training JJ i
period NN i
may MD N
be VB N
necessary JJ N
to TO N
achieve VB N
adequate JJ N
levels NNS N
of IN N
expertise NN N
in IN N
MDCT-CA NNP N
to TO N
be VB N
able JJ N
to TO N
perform VB N
as IN N
independent JJ N
readers NNS N
. . N

-DOCSTART- -21586714- O O

Effects NNS N
of IN N
vitamin NN i
A NNP i
or CC i
beta NN i
carotene JJ i
supplementation NN i
on IN N
pregnancy-related JJ o
mortality NN o
and CC o
infant JJ o
mortality NN o
in IN p
rural JJ p
Bangladesh NNP p
: : p
a DT N
cluster NN N
randomized VBN N
trial NN N
. . N

CONTEXT NNP N
Maternal NNP N
vitamin FW N
A NNP N
deficiency NN N
is VBZ N
a DT N
public JJ N
health NN N
concern NN N
in IN N
the DT N
developing JJ N
world NN N
. . N

Its PRP$ N
prevention NN N
may MD N
improve VB N
maternal NN N
and CC N
infant JJ N
survival NN N
. . N

OBJECTIVE UH N
To TO N
assess VB N
efficacy NN N
of IN N
maternal JJ N
vitamin NN i
A DT i
or CC N
beta NN i
carotene NN i
supplementation NN N
in IN N
reducing VBG N
pregnancy-related JJ p
and CC p
infant JJ p
mortality NN p
. . p

DESIGN NNP N
, , N
SETTING NNP N
, , N
AND NNP N
PARTICIPANTS NNP N
Cluster NNP N
randomized VBD N
, , N
double-masked JJ N
, , N
placebo-controlled JJ i
trial NN N
among IN N
pregnant JJ p
women NNS p
13 CD p
to TO p
45 CD p
years NNS p
of IN p
age NN p
and CC p
their PRP$ p
live-born JJ p
infants NNS p
to TO p
12 CD p
weeks NNS p
( ( p
84 CD p
days NNS p
) ) p
postpartum VBP p
in IN p
rural JJ p
northern JJ p
Bangladesh NNP p
between IN p
2001 CD p
and CC p
2007 CD p
. . p

Interventions NNS N
Five CD p
hundred VBD p
ninety-six JJ p
community NN p
clusters NNS p
( ( p
study NN p
sectors NNS p
) ) p
were VBD p
randomized VBN p
for IN p
pregnant JJ p
women NNS p
to TO N
receive VB N
weekly JJ N
, , N
from IN N
the DT N
first JJ N
trimester NN N
through IN N
12 CD N
weeks NNS N
postpartum NN N
, , N
7000 CD i
?g NN i
of IN i
retinol NN i
equivalents NNS i
as IN i
retinyl NN i
palmitate NN i
, , i
42 CD i
mg NN i
of IN i
all-trans NNS i
beta JJ i
carotene NN i
, , i
or CC i
placebo NN i
. . i

Married JJ p
women NNS p
( ( p
n JJ p
= NNP p
125,257 CD p
) ) p
underwent JJ N
5-week JJ N
surveillance NN N
for IN N
pregnancy NN N
, , N
ascertained VBN N
by IN N
a DT N
history NN N
of IN N
amenorrhea NN N
and CC N
confirmed VBN N
by IN N
urine JJ N
test NN N
. . N

Blood NN N
samples NNS N
were VBD N
obtained VBN N
from IN N
participants NNS N
in IN N
32 CD N
sectors NNS N
( ( N
5 CD N
% NN N
) ) N
for IN N
biochemical JJ N
studies NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP o
All-cause NNP o
mortality NN o
of IN o
women NNS o
related VBN o
to TO o
pregnancy NN o
, , o
stillbirth NN o
, , o
and CC o
infant JJ o
mortality NN o
to TO N
12 CD N
weeks NNS N
( ( N
84 CD N
days NNS N
) ) N
following VBG N
pregnancy NN N
outcome NN N
. . N

RESULTS JJ N
Groups NNP N
were VBD N
comparable JJ N
across IN N
risk NN N
factors NNS N
. . N

For IN N
the DT o
mortality NN o
outcomes RB o
, , o
neither DT N
of IN N
the DT N
supplement NN N
group NN N
outcomes VBZ N
was VBD N
significantly RB N
different JJ N
from IN N
the DT N
placebo NN N
group NN N
outcomes VBZ N
. . N

The DT N
numbers NNS N
of IN o
deaths NNS o
and CC o
all-cause NN o
, , o
pregnancy-related JJ o
mortality NN o
rates NNS o
( ( N
per IN N
100,000 CD N
pregnancies NNS N
) ) N
were VBD N
41 CD N
and CC N
206 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
140-273 JJ N
) ) N
in IN N
the DT i
placebo NN i
group NN N
, , N
47 CD N
and CC N
237 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
166-309 JJ N
) ) N
in IN N
the DT N
vitamin NN N
A NNP N
group NN N
, , N
and CC N
50 CD N
and CC N
250 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
177-323 JJ N
) ) N
in IN N
the DT N
beta NN N
carotene NN N
group NN N
. . N

Relative JJ N
risks NNS N
for IN o
mortality NN o
in IN N
the DT i
vitamin NN i
A NNP i
and CC i
beta NN i
carotene NN i
groups NNS N
were VBD N
1.15 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.75-1.76 NNP N
) ) N
and CC N
1.21 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.81-1.81 NNP N
) ) N
, , N
respectively RB N
. . N

In IN N
the DT i
placebo NN i
, , i
vitamin FW i
A NNP i
, , i
and CC i
beta NN i
carotene NN i
groups NNS N
the DT N
rates NNS N
of IN o
stillbirth NN o
and CC o
infant JJ o
mortality NN o
were VBD N
47.9 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
44.3-51.5 JJ N
) ) N
, , N
45.6 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
42.1-49.2 JJ N
) ) N
, , N
and CC N
51.8 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
48.0-55.6 JJ N
) ) N
per IN N
1000 CD N
births NNS N
and CC N
68.1 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
63.7-72.5 NNP N
) ) N
, , N
65.0 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
60.7-69.4 NNP N
) ) N
, , N
and CC N
69.8 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
65.4-72.3 JJ N
) ) N
per IN N
1000 CD N
live JJ N
births NNS N
, , N
respectively RB N
. . N

Vitamin VB N
A DT N
compared VBN N
with IN N
either DT N
placebo NN N
or CC N
beta NN N
carotene JJ N
supplementation NN N
increased VBD o
plasma JJ o
retinol NN o
concentrations NNS o
by IN N
end NN N
of IN N
study NN N
( ( N
1.46 CD N
[ RB N
95 CD N
% NN N
CI NNP N
, , N
1.42-1.50 JJ N
] NNP N
?mol/L NNP N
vs VBD N
1.13 CD N
[ JJ N
95 CD N
% NN N
CI NNP N
, , N
1.09-1.17 JJ N
] NNP N
?mol/L NNP N
and CC N
1.18 CD N
[ JJ N
95 CD N
% NN N
CI NNP N
, , N
1.14-1.22 JJ N
] NNP N
?mol/L NNP N
, , N
respectively RB N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
and CC N
reduced VBN N
, , N
but CC N
did VBD N
not RB N
eliminate VB o
, , o
gestational JJ o
night NN o
blindness NN o
( ( o
7.1 CD o
% NN N
for IN N
vitamin NN N
A NNP N
vs RB N
9.2 CD N
% NN N
for IN N
placebo NN N
and CC N
8.9 CD N
% NN N
for IN N
beta NN N
carotene NN N
[ NNP N
P NNP N
< NNP N
.001 NNP N
for IN N
both DT N
] NNP N
) ) N
. . N

CONCLUSION NNP N
Use NNP N
of IN N
weekly JJ i
vitamin NN i
A DT i
or CC i
beta NN i
carotene NN i
in IN i
pregnant JJ p
women NNS p
in IN p
Bangladesh NNP p
, , p
compared VBN p
with IN N
placebo NN N
, , N
did VBD N
not RB N
reduce VB o
all-cause JJ o
maternal NN o
, , o
fetal JJ o
, , o
or CC o
infant JJ o
mortality NN o
. . o

TRIAL NNP o
REGISTRATION NNP N
clinicaltrials.gov NN N
Identifier NNP N
: : N
NCT00198822 NN N
. . N

-DOCSTART- -15897822- O O

Cost-effectiveness NN N
of IN N
combined JJ i
manipulation NN i
, , i
stabilizing VBG i
exercises NNS i
, , i
and CC i
physician JJ i
consultation NN i
compared VBN N
to TO N
physician JJ i
consultation NN i
alone RB i
for IN N
chronic JJ p
low JJ p
back RB p
pain NN p
: : p
a DT N
prospective JJ N
randomized VBN N
trial NN N
with IN N
2-year JJ N
follow-up NN N
. . N

STUDY NNP N
DESIGN NNP N
A NNP N
prospective JJ N
, , N
randomized VBD N
controlled VBN N
trial NN N
. . N

OBJECTIVE UH N
To TO N
examine VB N
long-term JJ N
effects NNS N
and CC N
costs NNS N
of IN N
combined JJ i
manipulative JJ i
treatment NN i
, , i
stabilizing VBG i
exercises NNS i
, , i
and CC i
physician JJ i
consultation NN i
compared VBN i
with IN i
physician JJ i
consultation NN i
alone RB i
for IN N
chronic JJ p
low JJ p
back RB p
pain NN p
( ( p
cLBP NN p
) ) p
. . p

SUMMARY NNP N
OF IN N
BACKGROUND NNP N
DATA NNP N
An DT N
obvious JJ N
gap NN N
exists NNS N
in IN N
knowledge NN N
concerning VBG N
long-term JJ N
efficacy NN N
and CC N
cost-effectiveness NN N
of IN N
manipulative JJ N
treatment NN N
methods NNS N
. . N

METHODS NNP N
Of IN N
204 CD p
patients NNS p
with IN p
cLBP NNS p
whose WP$ p
Oswestry NNP p
Disability NNP p
Index NNP p
( ( p
ODI NNP p
) ) p
was VBD p
at IN p
least JJS p
16 CD p
% NN p
, , p
102 CD p
were VBD p
randomized VBN p
into IN p
a DT p
combined JJ i
manipulative JJ i
treatment NN i
, , i
exercise NN i
, , i
and CC i
physician JJ i
consultation NN i
group NN i
( ( p
i.e. FW p
, , N
a DT p
combination NN p
group NN p
) ) p
, , p
and CC p
102 CD p
to TO p
a DT p
consultation NN i
alone RB i
group NN p
. . p

All DT N
patients NNS N
were VBD N
clinically RB N
examined VBN N
, , N
informed VBN N
about IN N
their PRP$ N
back NN N
pain NN N
, , N
and CC N
encouraged VBD N
to TO N
stay VB N
active JJ N
and CC N
exercise NN N
according VBG N
to TO N
specific JJ N
instructions NNS N
based VBN N
on IN N
clinical JJ N
evaluation NN N
. . N

Treatment NNP N
included VBD N
4 CD N
sessions NNS N
of IN N
manual JJ i
therapy NN i
and CC i
stabilizing NN i
exercises NNS i
aimed VBN N
at IN N
correcting VBG N
the DT N
lumbopelvic JJ N
rhythm NN N
. . N

Questionnaires VBZ N
inquired VBN N
about IN N
pain NN o
( ( o
visual JJ o
analog NN o
scale NN o
( ( o
VAS NNP o
) ) o
) ) o
, , o
disability NN o
( ( o
ODI NNP o
) ) o
, , o
health-related JJ o
quality NN o
of IN o
life NN o
( ( o
15D CD o
Quality NN o
of IN o
Life NNP o
Instrument NNP o
) ) o
, , o
satisfaction NN o
with IN o
care NN o
, , o
and CC o
costs NNS o
. . o

RESULTS NNP N
Significant NNP N
improvement NN N
occurred VBD N
in IN N
both DT N
groups NNS N
on IN N
every DT N
self-rated JJ o
outcome NN o
measurement NN N
. . N

Within IN N
2 CD N
years NNS N
, , N
the DT N
combination NN N
group NN N
showed VBD N
only RB N
a DT N
slightly RB N
more RBR N
significant JJ N
reduction NN N
in IN N
VAS NNP o
( ( N
P NNP N
= NNP N
0.01 CD N
, , N
analysis NN N
of IN N
variance NN N
) ) N
but CC N
clearly RB N
higher JJR N
patient JJ o
satisfaction NN o
( ( N
P NNP N
= NNP N
0.001 CD N
, , N
Pearson NNP N
chi2 NN N
) ) N
as IN N
compared VBN N
to TO N
the DT N
consultation NN N
group NN N
. . N

Incremental JJ N
analysis NN N
showed VBD N
that IN N
for IN N
combined JJ N
group NN N
compared VBN N
to TO N
consultation NN N
group NN N
, , N
a DT N
one-point JJ N
change NN N
in IN N
VAS NNP o
scale NN o
cost NN o
$ $ N
512 CD N
. . N

CONCLUSIONS NNP N
Physician JJ i
consultation NN i
alone RB i
was VBD N
more RBR N
cost-effective JJ o
for IN N
both DT N
health NN N
care NN N
use NN N
and CC N
work NN N
absenteeism NN N
, , N
and CC N
led VBD N
to TO N
equal JJ N
improvement NN N
in IN N
disability NN N
and CC N
health-related JJ N
quality NN N
of IN N
life NN N
. . N

It PRP N
seems VBZ N
obvious JJ N
that IN N
encouraging VBG N
information NN N
and CC N
advice NN N
are VBP N
major JJ N
elements NNS N
for IN N
the DT N
treatment NN N
of IN N
patients NNS p
with IN p
cLBP NN p
. . p

-DOCSTART- -22050796- O O

Rapid JJ N
injection NN N
of IN N
propofol NN i
reduces NNS N
vascular JJ N
pain NN N
and CC N
facilitates NNS N
Laryngeal NNP p
Mask NNP p
Airway NNP p
insertion NN p
. . p

STUDY NNP N
OBJECTIVE NNP N
To TO N
compare VB N
the DT N
clinical JJ N
efficacy NN N
of IN N
a DT N
rapid JJ N
injection NN N
of IN N
propofol NN i
in IN N
regard NN N
to TO N
pain VB N
and CC N
ability NN N
to TO N
facilitate VB N
Laryngeal NNP p
Mask NNP p
Airway NNP p
( ( p
LMA NNP p
) ) p
insertion NN p
. . p

DESIGN NNP N
Randomized NNP N
, , N
single-blinded JJ N
, , N
placebo-controlled JJ i
study NN N
. . N

SETTING NNP N
University NNP N
hospital NN N
. . N

PATIENTS CC N
120 CD p
ASA NNP p
physical JJ p
status NN p
1 CD p
and CC p
2 CD p
patients NNS p
undergoing JJ p
elective JJ p
orthopedic JJ p
surgeries NNS p
. . p

INTERVENTIONS JJ N
Patients NNPS N
were VBD N
randomly RB N
allocated VBN N
to TO N
one CD N
of IN N
4 CD N
groups NNS N
. . N

Group NNP p
A NNP p
patients NNS p
were VBD N
pretreated VBN N
with IN N
normal JJ i
saline NN i
followed VBN i
by IN i
propofol NN i
2.0 CD i
mg/kg NN i
at IN i
3.3 CD i
mg/sec NN i
. . i

Group NNP p
B NNP p
patients NNS p
were VBD N
pretreated VBN N
with IN N
lidocaine JJ i
0.5 CD i
mg/kg NN i
followed VBN i
by IN i
propofol NN i
2.0 CD i
mg/kg NN i
at IN i
3.3 CD i
mg/sec NN i
. . i

In IN N
Group NNP p
C NNP p
, , p
patients NNS p
were VBD N
pretreated VBN N
with IN N
lidocaine JJ i
1.0 CD i
mg/kg NN i
followed VBN i
by IN i
propofol NN i
2.0 CD i
mg/kg NN i
at IN i
3.3 CD i
mg/sec NN i
. . i

In IN N
Group NNP p
D NNP p
, , p
patients NNS p
were VBD N
pretreated VBN N
with IN N
normal JJ i
saline NN i
followed VBN i
by IN i
propofol NN i
2.0 CD i
mg/kg NN i
at IN i
50 CD i
mg/sec NN i
. . i

MEASUREMENTS NNP N
Pain NNP N
on IN N
injection NN N
was VBD N
measured VBN N
using VBG N
a DT N
4-point JJ N
scale NN N
. . N

Scale NNP N
and CC N
success NN N
rate NN N
of IN N
smooth JJ N
LMA NNP N
insertion NN N
also RB N
were VBD N
recorded VBN N
. . N

MAIN NNP N
RESULTS NNP N
Rapid NNP i
injection NN i
was VBD N
less RBR N
painful JJ o
than IN N
after IN N
pretreatment NN N
with IN N
lidocaine JJ i
0.5 CD N
mg/kg NN N
, , N
but CC N
was VBD N
similar JJ N
to TO N
slow VB i
injection NN i
after IN N
pretreatment NN i
with IN i
lidocaine JJ i
1.0 CD N
mg/kg NN N
. . N

Rapid JJ i
injection NN i
facilitated VBD N
LMA NNP o
insertion NN o
, , N
unlike IN N
slow JJ i
injection NN i
with IN i
lidocaine JJ i
0.5 CD N
mg/kg NN N
pretreatment NN N
, , N
and CC N
was VBD N
similarly RB N
successful JJ N
to TO N
slow VB i
injection NN i
after IN i
pretreatment NN i
with IN i
lidocaine JJ i
1.0 CD N
mg/kg NN N
. . N

CONCLUSIONS VB N
The DT N
rapid JJ i
administration NN i
of IN i
propofol JJ i
reduces NNS N
pain NN N
and CC N
facilitates VBZ N
LMA NNP p
insertion NN p
versus NN N
slow JJ i
administration NN i
of IN i
propofol NN i
. . i

-DOCSTART- -23886027- O O

A DT N
randomized JJ N
double JJ N
blind NN N
placebo NN i
controlled VBD N
clinical JJ N
trial NN N
of IN N
N-Acetylcysteine NNP i
added VBD i
to TO i
risperidone VB i
for IN N
treating VBG N
autistic JJ p
disorders NNS p
. . p

BACKGROUND NNP N
This DT N
study NN N
examined VBD N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
N-acetylcysteine NNP i
( ( i
NAC NNP i
) ) i
augmentation NN N
for IN N
treating VBG N
irritability NN N
in IN N
children NNS p
and CC p
adolescents NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
) ) p
. . p

METHOD NNP N
Forty NNP p
children NNS p
and CC p
adolescents NNS p
met VBD p
diagnostic JJ p
criteria NNS p
for IN p
ASD NNP p
according VBG p
to TO p
DSM-IV NNP p
. . p

They PRP N
were VBD N
randomly RB N
allocated VBN N
into IN N
one CD N
of IN N
the DT N
two CD N
groups NNS N
of IN N
NAC NNP i
( ( i
1200 CD i
mg/day NN i
) ) i
+risperidone NN i
or CC i
placebo+risperidone NN i
. . i

NAC NNP i
and CC i
placebo NN i
were VBD i
administered VBN N
in IN N
the DT N
form NN N
of IN N
effervescent NN N
and CC N
in IN N
two CD N
divided JJ N
doses NNS N
for IN N
8 CD N
weeks NNS o
. . o

Irritability NNP o
subscale JJ o
score NN o
of IN o
Aberrant NNP o
Behavior NNP o
Checklist NNP o
( ( o
ABC NNP N
) ) N
was VBD N
considered VBN N
as IN N
the DT N
main JJ N
outcome NN N
measure NN o
. . o

Adverse JJ o
effects NNS o
were VBD o
also RB N
checked VBN N
. . N

RESULTS VB N
The DT o
mean JJ o
score NN o
of IN o
irritability NN o
in IN o
the DT i
NAC+risperidone NNP i
and CC i
placebo+risperidone NN i
groups NNS i
at IN N
baseline NN N
was VBD N
13.2 CD N
( ( N
5.3 CD N
) ) N
and CC N
16.7 CD N
( ( N
7.8 CD N
) ) N
, , N
respectively RB N
. . N

The DT N
scores NNS N
after IN N
8 CD N
weeks NNS N
were VBD N
9.7 CD N
( ( N
4.1 CD N
) ) N
and CC N
15.1 CD N
( ( N
7.8 CD N
) ) N
, , N
respectively RB N
. . N

Repeated VBN N
measures NNS N
of IN N
ANOVA NNP N
showed VBD N
that IN N
there EX N
was VBD N
a DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
after IN N
8 CD N
weeks NNS N
. . N

The DT N
most RBS o
common JJ o
adverse JJ o
effects NNS o
in IN o
the DT i
NAC+risperidone NNP i
group NN i
were VBD o
constipation NN o
( ( o
16.1 CD o
% NN o
) ) o
, , o
increased VBN o
appetite NN o
( ( o
16.1 CD o
% NN o
) ) o
, , o
fatigue NN o
( ( o
12.9 CD o
% NN o
) ) o
, , o
nervousness RB o
( ( o
12.9 CD N
% NN N
) ) N
, , N
and CC o
daytime JJ o
drowsiness NN o
( ( o
12.9 CD N
% NN N
) ) N
. . N

There EX N
was VBD N
no DT N
fatal JJ o
adverse JJ o
effect NN o
. . o

CONCLUSIONS NNP i
Risperidone NNP i
plus CC i
NAC NNP i
more JJR i
than IN N
risperidone NN N
plus CC N
placebo NN N
decreased JJ o
irritability NN o
in IN o
children NNS p
and CC p
adolescents NNS p
with IN p
ASD NNP p
. . p

Meanwhile RB N
, , N
it PRP N
did VBD N
not RB N
change VB N
the DT o
core NN o
symptoms NNS o
of IN o
autism NN o
. . o

Adverse JJ o
effects NNS o
were VBD o
not RB N
common JJ N
and CC i
NAC NNP i
was VBD i
generally RB o
tolerated VBN o
well RB o
. . N

TRIAL NNP N
REGISTRATION NNP N
This DT N
trial NN N
was VBD N
registered VBN N
at IN N
http NN N
: : N
//www.irct.ir NN N
. . N

The DT N
registration NN N
number NN N
of IN N
this DT N
trial NN N
was VBD N
IRCT201106103930N6 NNP N
. . N

-DOCSTART- -7714229- O O

Effects NNS N
of IN N
the DT N
cholinomimetic JJ i
SDZ NNP i
ENS-163 NNP i
on IN N
scopolamine-induced JJ N
cognitive JJ o
impairment NN o
in IN N
humans NNS p
. . p

Scopolamine-induced JJ p
cognitive JJ p
impairment NN p
was VBD p
used VBN p
in IN p
healthy JJ p
men NNS p
to TO N
evaluate VB N
the DT N
central JJ N
nervous JJ N
system NN N
activity NN N
of IN N
the DT N
new JJ i
cholinomimetic JJ i
SDZ NNP i
ENS-163 NNP i
. . i

Eighteen JJ p
subjects NNS p
were VBD N
treated VBN N
in IN N
a DT N
crossover NN N
design NN N
with IN N
oral JJ i
placebo/intravenous JJ i
saline NN i
, , i
50 CD i
mg NN i
of IN i
oral JJ i
SDZ NNP i
ENS-163/intravenous JJ i
saline NN i
, , i
oral JJ i
placebo/0.4 NN i
mg NN i
of IN i
intravenous JJ i
scopolamine NN i
, , i
and CC i
50 CD i
mg NN i
of IN i
oral JJ i
SDZ NNP i
ENS-163/0.4 NNP i
mg NN i
of IN i
intravenous JJ i
scopolamine NN i
. . i

The DT N
administration NN N
of IN N
placebo NN N
with IN N
scopolamine NN N
caused VBN N
significant JJ o
cognitive JJ o
impairment NN o
, , N
as IN N
assessed VBN N
by IN N
the DT N
Computerized NNP o
Neuropsychological NNP o
Test NNP o
Battery NNP o
( ( o
CNTB NNP o
) ) o
, , N
and CC N
also RB N
decreased VBN o
salivation NN o
and CC o
heart NN o
rate NN o
. . o

In IN N
contrast NN N
, , N
SDZ NNP N
ENS-163 NNP N
with IN N
saline NN N
had VBD N
no DT N
effect NN o
on IN o
CNTB NNP o
scores NNS o
, , o
increased VBN o
salivation NN o
, , o
and CC o
increased VBD o
heart NN o
rate NN o
. . o

Despite IN N
the DT N
observed JJ N
cholinomimetic JJ o
effects NNS o
of IN N
SDZ NNP N
ENS-163 NNP N
when WRB N
administered VBN N
with IN N
saline NN N
, , N
the DT N
changes NNS o
in IN o
CNTB NNP o
scores NNS o
, , o
heart NN o
rate NN o
, , o
and CC o
salivation NN o
were VBD N
indistinguishable JJ N
between IN N
placebo/scopolamine NN N
and CC N
SDZ NNP N
ENS-163/scopolamine NNP N
. . N

Thus NNP N
, , N
50 CD N
mg NN N
of IN N
oral JJ N
SDZ NNP N
ENS-163 NNP N
has VBZ N
cholinomimetic JJ o
activity NN o
in IN N
normal JJ N
men NNS N
, , N
but CC N
this DT N
dose NN N
is VBZ N
insufficient JJ N
to TO N
reverse VB N
the DT N
muscarinic JJ o
effects NNS o
of IN N
0.4 CD N
mg NN N
of IN N
intravenous JJ N
scopolamine NN N
. . N

-DOCSTART- -26078323- O O

A DT N
Randomized NNP N
, , N
Placebo-Controlled JJ i
Trial NNP N
Evaluating NNP N
Safety NNP N
and CC N
Immunogenicity NNP N
of IN N
the DT N
Killed NNP N
, , N
Bivalent NNP N
, , N
Whole-Cell NNP i
Oral NNP i
Cholera NNP i
Vaccine NNP i
in IN p
Ethiopia NNP p
. . p

Killed VBN i
whole-cell JJ i
oral JJ i
cholera NN i
vaccine NN i
( ( i
OCV NNP i
) ) i
has VBZ N
been VBN N
a DT N
key JJ N
component NN N
of IN N
a DT N
comprehensive JJ N
package NN N
including VBG N
water NN N
and CC N
sanitation NN N
measures NNS N
for IN N
recent JJ N
cholera NN N
epidemics NNS N
. . N

The DT N
vaccine NN i
, , N
given VBN N
in IN N
a DT N
two-dose JJ N
regimen NN N
, , N
has VBZ N
been VBN N
evaluated VBN N
in IN N
a DT p
large JJ p
number NN p
of IN p
human JJ p
volunteers NNS p
in IN p
India NNP p
, , p
Vietnam NNP p
, , p
and CC p
Bangladesh NNP p
, , N
where WRB N
it PRP N
has VBZ N
demonstrated VBN N
safety NN N
, , N
immunogenicity NN N
, , N
and CC N
clinical JJ N
efficacy NN N
. . N

We PRP N
conducted VBD N
a DT N
double-blind JJ N
randomized JJ N
placebo-controlled JJ i
trial NN N
in IN p
Ethiopia NNP p
, , N
where WRB N
we PRP N
evaluated VBD p
the DT p
safety NN o
and CC o
immunogenicity NN o
of IN p
the DT p
vaccine NN i
in IN p
216 CD p
healthy JJ p
adults NNS p
and CC p
children NNS p
. . p

OCV NNP i
was VBD N
found VBN N
to TO N
be VB N
safe JJ o
and CC o
elicited VBD o
a DT o
robust JJ o
immunological JJ o
response NN o
against IN o
Vibrio NNP o
cholerae NN o
O1 NNP o
, , N
with IN N
81 CD N
% NN N
adults NNS N
and CC N
77 CD N
% NN N
children NNS N
demonstrating VBG N
seroconversion NN o
14 CD N
days NNS N
after IN N
the DT N
second JJ N
dose NN N
of IN N
vaccine NN N
. . N

This DT N
is VBZ N
the DT N
first JJ N
study NN N
to TO N
evaluate VB N
safety NN N
and CC N
immunogenicity NN N
of IN N
the DT N
vaccine NN i
in IN N
a DT N
population NN p
outside IN p
Asia NNP p
using VBG N
a DT N
placebo-controlled JJ i
, , N
double-blind JJ N
, , N
randomized JJ N
study NN N
design NN N
. . N

-DOCSTART- -12139152- O O

Oral JJ N
desensitization NN N
in IN N
papular JJ p
urticaria NN p
in IN p
children NNS p
. . p

Papular JJ p
urticaria NN p
( ( p
PU NNP p
) ) p
is VBZ N
among IN N
the DT N
commonest JJS N
skin NN N
ailments NNS N
in IN N
children NNS N
. . N

Induced NNP N
specific JJ N
desensitization NN N
to TO N
insect VB N
bites NNS N
is VBZ N
theoretically RB N
an DT N
effective JJ N
means NNS N
of IN N
prevention NN N
of IN N
PU NNP N
. . N

In IN N
this DT N
double JJ N
blind NN N
placebo NN i
controlled VBD N
study NN N
, , N
an DT N
oral JJ i
vaccine NN i
prepared VBN i
from IN i
insect JJ i
saliva NN i
was VBD N
compared VBN N
with IN N
placebo NN i
( ( i
stable JJ i
vaccine NN i
solvent NN i
) ) i
. . i

Vaccine NNP i
and CC i
placebo NN i
effectiveness NN N
were VBD N
tested VBN N
by IN N
counting VBG o
active JJ o
PU NNP o
lesions NNS o
, , o
serum NN o
eosinophils NNS o
, , o
and CC o
IgE NNP o
, , N
before IN N
and CC N
after IN N
4 CD N
months NNS N
of IN N
treatment NN N
. . N

Statistically NNP N
significant JJ N
differences NNS N
between IN N
oral JJ N
vaccine NN N
and CC N
placebo NN N
were VBD N
not RB N
found VBN N
in IN N
the DT N
clinical JJ N
or CC N
the DT N
immunological JJ N
variables NNS N
tested VBN N
. . N

We PRP N
conclude VBP N
that IN N
, , N
although IN N
a DT N
lack NN N
of IN N
oral JJ N
vaccine NN N
efficacy NN N
was VBD N
suspected VBN N
, , N
larger JJR N
study NN N
samples NNS N
are VBP N
needed VBN N
to TO N
strengthen VB N
our PRP$ N
conclusion NN N
. . N

-DOCSTART- -23514246- O O

Early-stage JJ p
squamous JJ p
cell NN p
carcinoma NN p
of IN p
the DT p
oropharynx NN p
: : p
radiotherapy NN i
vs. IN i
trans-oral JJ i
robotic JJ i
surgery NN i
( ( i
ORATOR NNP i
) ) i
-- : i
study NN i
protocol NN N
for IN N
a DT N
randomized JJ N
phase NN N
II NNP N
trial NN N
. . N

BACKGROUND VB N
The DT N
incidence NN N
of IN N
oropharyngeal JJ p
squamous JJ p
cell NN p
carcinoma NN p
( ( p
OPSCC NNP p
) ) p
has VBZ N
markedly RB N
increased VBN N
over IN N
the DT N
last JJ N
three CD N
decades NNS N
due JJ N
to TO N
newly RB N
found VBN N
associations NNS N
with IN N
human JJ N
papillomavirus NN N
( ( N
HPV NNP N
) ) N
infection NN N
. . N

Primary JJ i
radiotherapy NN i
( ( i
RT NNP i
) ) i
is VBZ N
the DT N
treatment NN N
of IN N
choice NN N
for IN N
OPSCC NNP N
at IN N
most JJS N
centers NNS N
, , N
and CC N
over IN N
the DT N
last JJ N
decade NN N
, , N
the DT N
addition NN N
of IN N
concurrent NN i
chemotherapy NN i
has VBZ N
led VBN N
to TO N
a DT N
significant JJ N
improvement NN N
in IN N
survival NN N
, , N
but CC N
at IN N
the DT N
cost NN N
of IN N
increased VBN N
acute NN N
and CC N
late JJ N
toxicity NN N
. . N

Transoral NNP i
robotic JJ i
surgery NN i
( ( i
TORS NNP i
) ) i
has VBZ N
emerged VBN N
as IN N
a DT N
promising JJ N
alternative JJ N
treatment NN N
, , N
with IN N
preliminary JJ N
case NN N
series NN N
demonstrating VBG N
encouraging JJ N
oncologic NN N
, , N
functional JJ N
, , N
and CC N
quality NN N
of IN N
life NN N
( ( N
QOL NNP N
) ) N
outcomes VBZ N
. . N

However RB N
, , N
comparisons NNS N
of IN N
TORS NNP i
and CC N
RT NNP i
in IN N
a DT N
non-randomized JJ N
fashion NN N
are VBP N
susceptible JJ N
to TO N
bias VB N
. . N

The DT N
goal NN N
of IN N
this DT N
randomized JJ N
phase NN N
II NNP N
study NN N
is VBZ N
to TO N
compare VB N
QOL NNP o
, , o
functional JJ o
outcomes NNS o
, , o
toxicity NN o
profiles NNS o
, , o
and CC o
survival NN o
following VBG N
primary JJ i
RT NNP i
( ( i
? . i
chemotherapy NN i
) ) i
vs. FW N
TORS NNP i
( ( i
? . i
adjuvant NN i
[ NN i
chemo NN i
] NNP i
RT NNP i
) ) i
in IN i
patients NNS N
with IN N
OPSCC NNP N
. . N

METHODS/DESIGN NNP N
The DT N
target NN N
patient JJ N
population NN N
comprises NNS p
OPSCC NNP p
patients NNS p
who WP p
would MD p
be VB p
unlikely JJ p
to TO p
require VB p
chemotherapy JJ p
post-resection NN p
: : p
Tumor NN p
stage NN p
T1-T2 NN p
with IN p
likely JJ p
negative JJ p
margins NNS p
at IN p
surgery NN p
; : p
Nodal NNP p
stage NN p
N0-2 NNP p
, , p
?3 NNP p
cm NN p
in IN p
size NN p
, , p
with IN p
no DT p
evidence NN p
of IN p
extranodal JJ p
extension NN p
on IN p
imaging VBG p
. . p

Participants NNS p
will MD N
be VB N
randomized VBN N
in IN N
a DT N
1:1 CD N
ratio NN N
between IN N
Arm NNP N
1 CD i
( ( i
RT NNP i
? . i
chemotherapy NN i
) ) i
and CC i
Arm $ N
2 CD N
( ( i
TORS NNP i
? . i
adjuvant JJ i
[ NN i
chemo NN i
] NNP i
RT NNP i
) ) i
. . i

In IN i
Arm NNP i
1 CD N
, , N
patients NNS N
with IN N
N0 NNP N
disease NN N
will MD N
receive VB i
RT NNP i
alone RB i
, , i
whereas JJ N
N1-2 JJ N
patients NNS N
will MD N
receive VB i
concurrent JJ i
chemoradiation NN i
. . i

In IN i
Arm NNP i
2 CD i
, , N
patients NNS N
will MD N
undergo VB i
TORS NNP i
along IN i
with IN i
selective JJ i
neck NN i
dissections NNS i
, , i
which WDT i
may MD i
be VB N
staged VBN N
. . N

Pathologic NNP N
high-risk JJ N
features NNS N
will MD N
be VB N
used VBN N
to TO N
determine VB N
the DT N
requirement NN i
for IN i
adjuvant JJ i
radiotherapy NN i
+/- JJ i
chemotherapy NN i
. . i

The DT i
primary JJ i
endpoint NN N
is VBZ o
QOL NNP o
score NN o
using VBG N
the DT N
M.D NNP o
. . o

Anderson NNP o
Dysphagia NNP o
Inventory NNP o
( ( o
MDADI NNP o
) ) o
, , o
with IN o
secondary JJ o
endpoints NNS o
including VBG o
survival NN o
, , o
toxicity NN o
, , o
other JJ o
QOL NNP o
outcomes NNS o
, , o
and CC o
swallowing VBG o
function NN o
. . o

A DT p
sample NN p
of IN p
68 CD p
patients NNS p
is VBZ N
required VBN N
. . N

DISCUSSION VB N
This DT N
study NN N
, , N
if IN N
successful JJ N
, , N
will MD N
provide VB N
a DT N
much-needed JJ N
randomized JJ N
comparison NN N
of IN N
the DT N
conventional JJ N
strategy NN N
of IN N
primary JJ N
RT NNP N
vs. IN N
the DT N
novel JJ N
strategy NN N
of IN N
primary JJ N
TORS NNP N
. . N

The DT N
trial NN N
is VBZ N
designed VBN N
to TO N
provide VB N
a DT N
definitive JJ N
QOL NNP o
comparison NN o
between IN N
the DT N
two CD N
arms NNS N
, , N
and CC N
to TO N
inform VB N
the DT N
design NN N
of IN N
an DT N
eventual JJ N
phase NN N
III NNP N
trial NN N
for IN N
survival JJ o
outcomes NNS o
. . o

TRIAL NNP N
REGISTRATION NNP N
NCT01590355 NNP N
. . N

-DOCSTART- -12531809- O O

Dexamethasone NNP i
versus NN i
prednisone NN i
and CC N
daily JJ N
oral JJ N
versus NN N
weekly RB N
intravenous JJ i
mercaptopurine NN i
for IN N
patients NNS p
with IN p
standard-risk JJ p
acute JJ p
lymphoblastic JJ p
leukemia NN p
: : p
a DT N
report NN N
from IN N
the DT N
Children NNP N
's POS N
Cancer NNP N
Group NNP N
. . N

Conventional NNP i
therapy NN i
for IN N
childhood NN p
acute NN p
lymphoblastic JJ p
leukemia NN p
( ( p
ALL DT p
) ) p
includes VBZ N
prednisone NN i
and CC i
oral JJ i
6-mercaptopurine JJ i
. . i

Prior JJ N
observations NNS N
suggested VBD N
potential JJ N
advantages NNS N
for IN N
dexamethasone NN i
over IN i
prednisone NN i
and CC i
for IN i
intravenous JJ i
( ( i
IV NNP i
) ) i
over IN i
oral JJ i
6-mercaptopurine CD i
, , N
which WDT N
remain VBP N
to TO N
be VB N
validated VBN N
. . N

We PRP N
report VBP N
the DT N
results NNS N
of IN N
a DT N
randomized JJ N
trial NN N
of IN N
more JJR p
than IN p
1000 CD p
subjects NNS p
that WDT N
examined VBD N
the DT N
efficacy NN o
of IN N
dexamethasone NN i
and CC i
IV NNP i
6-mercaptopurine JJ i
. . i

Children NNP p
with IN p
National NNP p
Cancer NNP p
Institute NNP p
standard-risk NN p
ALL NNP p
were VBD N
randomly RB N
assigned VBN N
in IN N
a DT N
2 CD N
x NN N
2 CD N
factorial JJ N
design NN N
to TO N
receive VB N
dexamethasone NN i
( ( N
6 CD N
mg/m NN N
( ( N
2 CD N
) ) N
/d NN N
) ) N
for IN N
28 CD N
days NNS N
in IN N
induction NN N
, , N
plus CC i
taper NN i
, , N
compared VBN N
with IN N
prednisone NN i
( ( N
40 CD N
mg/m NN N
( ( N
2 CD N
) ) N
/d NN N
) ) N
. . N

The DT N
second JJ N
randomized JJ N
assignment NN N
was VBD N
for IN N
daily JJ N
oral JJ N
or CC N
weekly JJ N
IV NNP i
6-mercaptopurine NN i
during IN N
consolidation NN N
. . N

During IN N
maintenance NN N
, , N
5 CD N
days NNS N
of IN N
the DT N
randomized JJ N
steroid NN N
was VBD N
given VBN N
monthly RB N
, , N
at IN N
the DT N
same JJ N
dose NN N
, , N
and CC N
all DT N
patients NNS N
received VBD N
daily JJ N
oral JJ i
6-mercaptopurine JJ i
. . i

During IN N
delayed JJ N
intensification NN N
, , N
all DT N
patients NNS N
received VBD N
a DT N
dexamethasone JJ i
dosage NN N
of IN N
10 CD N
mg/m NN N
( ( N
2 CD N
) ) N
/d NN N
for IN N
21 CD N
days NNS N
, , N
with IN i
taper NN i
. . i

Intrathecal NNP i
( ( i
IT NNP i
) ) i
methotrexate NN i
was VBD N
the DT N
sole JJ N
central JJ N
nervous JJ N
system-directed JJ N
therapy NN N
. . N

Patients NNS N
randomly RB N
assigned VBN N
to TO N
receive VB N
dexamethasone NN i
had VBD N
a DT N
6-year JJ o
isolated JJ o
central JJ o
nervous JJ o
system-relapse JJ o
rate NN o
of IN N
3.7 CD N
% NN N
+/- JJ N
0.8 CD N
% NN N
, , N
compared VBN N
with IN N
7.1 CD N
% NN N
+/- JJ N
1.1 CD N
% NN N
for IN N
prednisone NN i
( ( N
P NNP N
=.01 NNP N
) ) N
. . N

There EX N
was VBD N
also RB N
a DT N
trend NN N
toward IN N
fewer JJR N
isolated JJ o
bone NN o
marrow NN o
relapses VBZ o
with IN N
dexamethasone NN i
. . i

The DT N
6-year JJ o
event-free JJ o
survival NN o
( ( o
EFS NNP o
) ) o
was VBD N
85 CD N
% NN N
+/- JJ N
2 CD N
% NN N
for IN N
dexamethasone NN i
and CC N
77 CD N
% NN N
+/- JJ N
2 CD N
% NN N
for IN N
prednisone NN i
( ( N
P NNP N
=.002 NNP N
) ) N
. . N

EFS NNP N
was VBD N
similar JJ N
with IN N
oral JJ i
or CC i
IV JJ i
6-mercaptopurine JJ i
; : i
however RB N
, , N
patients NNS N
assigned VBD N
to TO N
IV NNP i
6-mercaptopurine JJ i
had VBD N
decreased VBN N
survival NN o
after IN o
relapse NN o
. . o

-DOCSTART- -19833610- O O

Long-term JJ N
results NNS N
after IN N
intracoronary JJ i
injection NN i
of IN i
autologous JJ i
mononuclear JJ i
bone NN i
marrow NN i
cells NNS i
in IN N
acute JJ p
myocardial JJ p
infarction NN p
: : p
the DT N
ASTAMI NNP p
randomised VBD N
, , N
controlled VBD N
study NN N
. . N

OBJECTIVE NNP N
To TO N
investigate VB N
long-term JJ N
safety NN N
and CC N
efficacy NN N
after IN N
intracoronary JJ i
injection NN i
of IN i
autologous JJ i
mononuclear JJ i
bone NN i
marrow NN i
cells NNS i
( ( i
mBMCs NN i
) ) i
in IN i
acute JJ p
myocardial JJ p
infarction NN p
( ( p
AMI NNP p
) ) p
. . p

DESIGN NNP N
Randomised VBD N
, , N
controlled VBD N
trial NN N
. . N

SETTING NN N
Two CD p
university NN p
hospitals NNS p
in IN p
Oslo NNP p
, , p
Norway NNP p
. . p

PATIENTS NNP N
Patients NNPS p
from IN p
the DT p
Autologous NNP p
Stem NNP p
cell NN p
Transplantation NNP p
in IN p
Acute NNP p
Myocardial NNP p
Infarction NNP p
( ( p
ASTAMI NNP p
) ) p
study NN p
were VBD p
re-assessed JJ p
3 CD p
years NNS p
after IN p
inclusion NN p
. . p

INTERVENTIONS NNP N
100 CD p
patients NNS p
with IN p
anterior JJ p
wall NN p
ST-elevation NNP p
myocardial JJ p
infarction NN p
treated VBN p
with IN p
acute JJ i
percutaneous JJ i
coronary JJ i
intervention NN i
( ( i
PCI NNP i
) ) i
were VBD N
randomised VBN N
to TO N
receive VB N
intracoronary JJ i
injection NN i
of IN i
mBMCs NN i
( ( i
n JJ i
= NNP i
50 CD i
) ) i
or CC i
not RB i
( ( N
n JJ N
= NNP N
50 CD N
) ) N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Change NNP o
in IN o
left JJ o
ventricular NN o
( ( o
LV NNP o
) ) o
ejection NN o
fraction NN o
( ( N
primary JJ N
) ) N
. . N

Change NN o
in IN o
exercise NN o
capacity NN o
( ( o
peak JJ o
VO NNP o
( ( o
2 CD o
) ) o
) ) o
and CC o
quality NN o
of IN o
life NN o
( ( N
secondary JJ N
) ) N
. . N

Infarct NNP o
size NN o
( ( o
additional JJ o
aim NN o
) ) o
, , o
and CC o
safety NN o
. . o

RESULTS VB N
The DT N
rates NNS o
of IN o
adverse JJ o
clinical JJ o
events NNS o
in IN N
the DT N
groups NNS N
were VBD N
low JJ N
and CC N
equal JJ N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
groups NNS N
in IN N
change NN o
of IN o
global JJ o
LV NNP o
systolic JJ o
function NN o
by IN N
echocardiography NN N
or CC N
magnetic JJ N
resonance NN N
imaging NN N
( ( N
MRI NNP N
) ) N
during IN N
the DT N
follow-up JJ N
. . N

On IN N
exercise NN N
testing NN N
, , N
the DT N
mBMC-treated JJ i
patients NNS N
had VBD N
larger JJR N
improvement NN N
in IN N
exercise NN o
time NN o
from IN N
2-3 JJ N
weeks NNS N
to TO N
3 CD N
years NNS N
( ( N
1.5 CD N
minutes NNS N
vs VBP N
0.6 CD N
minutes NNS N
, , N
p VBP N
= RB N
0.05 CD N
) ) N
, , N
but CC N
the DT N
change NN N
in IN N
peak NN o
oxygen NN o
consumption NN o
did VBD N
not RB N
differ VB N
( ( N
3.0 CD N
ml/kg/min NN N
vs NN N
3.1 CD N
ml/kg/min NN N
, , N
p NN N
= NNP N
0.75 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
results NNS N
indicate VBP N
that IN N
intracoronary JJ N
mBMC NN N
treatment NN N
in IN N
AMI NNP N
is VBZ N
safe JJ N
in IN N
the DT N
long JJ N
term NN N
. . N

A DT N
small JJ N
improvement NN N
in IN N
exercise NN N
time NN N
in IN N
the DT N
mBMC NN i
group NN N
was VBD N
found VBN N
, , N
but CC N
no DT N
other JJ N
effects NNS N
of IN N
treatment NN N
could MD N
be VB N
identified VBN N
3 CD N
years NNS N
after IN N
cell NN i
therapy NN i
. . i

-DOCSTART- -7831456- O O

Naltrexone NNP i
plasma NN N
levels NNS N
, , N
clinical JJ N
response NN N
and CC N
effect NN N
on IN N
weight NN N
in IN N
autistic JJ p
children NNS p
. . p

This DT N
research NN N
measured VBD N
naltrexone NN i
levels NNS N
in IN N
plasma NN N
, , N
to TO N
assess VB N
the DT N
relationship NN N
between IN N
behavioral JJ N
response NN N
to TO N
naltrexone CD i
and CC N
plasma NN N
levels NNS N
, , N
and CC N
the DT N
effects NNS N
of IN N
naltrexone NN i
on IN N
weight NN N
in IN N
hospitalized VBN p
autistic JJ p
children NNS p
( ( p
n JJ p
= NNP p
41 CD p
) ) p
. . p

A DT N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
parallel JJ N
groups NNS N
design NN N
with IN i
fixed JJ i
dose NN i
was VBD i
used VBN i
, , i
with IN i
random JJ i
assignment NN i
to TO i
naltrexone CD i
or CC i
placebo VB i
. . i

Drug NNP o
plasma NN o
levels NNS o
were VBD N
analyzed VBN N
by IN N
gas NN i
chromatography/mass NN i
spectrometry NN i
, , i
and CC i
weights NNS i
were VBD i
obtained VBN i
weekly RB i
. . i

Naltrexone NN i
levels NNS N
measured VBN N
in IN N
17 CD p
children NNS p
ranged VBD N
from IN N
0.12 CD N
to TO N
5.60 CD N
ng/mL NNS N
( ( N
mean JJ N
= NN N
0.71 CD N
, , N
standard JJ N
error NN N
of IN N
the DT N
mean JJ N
= NNP N
0.32 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
relationship NN N
between IN N
plasma NN N
levels NNS N
and CC N
age NN N
, , N
level NN N
of IN N
intellectual JJ N
functioning NN N
, , N
scores NNS N
on IN N
the DT N
14 CD p
selected VBD p
Children NNP o
's POS o
Psychiatric NNP o
Rating NNP o
Scale NNP o
( ( o
CPRS NNP o
) ) o
items NNS o
, , o
Clinical NNP o
Global NNP o
Impressions NNP o
, , o
Global NNP o
Clinical NNP o
Consensus NNP o
, , o
and CC o
the DT o
CPRS NNP o
hyperactivity NN o
factor NN o
. . o

There EX N
was VBD N
a DT N
trend NN N
( ( N
p JJ N
= NNP N
.06 NNP N
) ) N
for IN N
children NNS N
receiving VBG N
naltrexone NN N
in IN N
the DT N
highest JJS N
weight NN N
percentile NN N
( ( N
> CD N
or CC N
= VB N
90th CD N
) ) N
to TO N
lose VB N
weight NN N
( ( N
mean JJ N
= NNP N
-0.42 NNP N
kg NN N
) ) N
but CC N
this DT N
was VBD N
not RB N
the DT N
case NN N
for IN N
those DT N
in IN N
the DT N
lower JJR N
weight NN N
percentiles NNS N
( ( N
mean JJ N
= NNP N
+0.03 NNP N
kg NN N
) ) N
. . N

-DOCSTART- -3319640- O O

Comparison NNP N
of IN N
nicardipine NN i
and CC N
propranolol NN i
in IN N
the DT N
treatment NN N
of IN N
mild NN p
and CC p
moderate JJ p
hypertension NN p
. . p

In IN N
a DT N
double-blind NN N
controlled VBN N
trial NN N
22 CD p
patients NNS p
with IN p
mild JJ p
or CC p
moderate JJ p
essential JJ p
hypertension NN p
were VBD N
treated VBN N
with IN N
nicardipine JJ i
30 CD N
mg NN N
t.d.s NN N
. . N

and CC N
19 CD N
patients NNS N
with IN N
propranolol JJ i
80 CD N
mg NN N
t.d.s NN N
. . N

as IN N
monotherapy NN N
for IN N
24 CD N
weeks NNS N
. . N

Blood NNP o
pressure NN o
in IN N
both DT N
groups NNS N
at IN N
the DT N
end NN N
of IN N
trial NN N
was VBD N
equally RB N
and CC N
significantly RB N
reduced VBN N
; : N
systolic JJ N
pressure NN N
22.2 CD N
mmHg NN N
and CC N
diastolic JJ N
pressure NN N
15.5 CD N
mmHg NN N
in IN N
the DT N
supine JJ N
position NN N
, , N
and CC N
24.4 CD N
mmHg NN N
and CC N
18.4 CD N
mmHg NN N
, , N
respectively RB N
, , N
in IN N
the DT N
standing VBG N
position NN N
in IN N
those DT N
on IN N
nicardipine NN i
, , N
and CC N
by IN N
23.7 CD N
and CC N
16.2 CD N
mmHg NN N
and CC N
28.0 CD N
and CC N
19.2 CD N
mmHg NN N
, , N
respectively RB N
, , N
in IN N
the DT N
propranolol NN i
group NN N
. . N

There EX N
was VBD N
an DT N
initial JJ N
increase NN N
in IN N
heart NN o
rate NN o
in IN N
the DT N
nicardipine NN i
group NN N
, , N
but CC N
the DT N
rise NN N
was VBD N
only RB N
moderate JJ N
( ( N
3 CD N
beats/min NN N
supine NN N
p NN N
= VBD N
0.3219 CD N
, , N
and CC N
7 CD N
beats/min NN N
standing NN N
, , N
p VBP N
= RB N
0.0203 CD N
) ) N
at IN N
the DT N
end NN N
of IN N
the DT N
24 CD N
weeks NNS N
. . N

In IN N
the DT N
propranolol NN i
group NN N
heart NN o
rate NN o
was VBD N
reduced VBN N
markedly RB N
. . N

Adverse JJ o
effects NNS o
occurred VBD N
in IN N
77 CD N
% NN N
of IN N
patients NNS N
on IN N
nicardipine NN i
and CC N
in IN N
63 CD N
% NN N
of IN N
those DT N
on IN N
propranolol NN i
, , N
and CC N
there EX N
were VBD N
no DT N
unexpected JJ N
findings NNS N
. . N

The DT N
effects NNS N
were VBD N
mild VBN N
in IN N
both DT N
groups NNS N
and CC N
did VBD N
not RB N
lead VB N
any DT N
patient NN N
to TO N
stop VB N
medication NN N
. . N

One CD N
patient NN N
on IN N
propranolol NN i
was VBD N
withdrawn VBN N
from IN N
the DT N
trial NN N
because IN N
of IN N
poor JJ N
blood NN o
pressure NN o
control NN o
and CC o
suspected VBD o
angina NNS o
pectoris VBP o
after IN N
5 CD N
weeks NNS N
on IN N
active JJ N
medication NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
changes NNS N
in IN N
blood NN o
chemistry NN o
, , o
including VBG o
lipoprotein NN o
classes NNS o
. . o

Overall JJ N
, , N
in IN N
comparison NN N
with IN N
propranolol NN i
, , N
nicardipine NN N
was VBD N
effective JJ N
, , N
well-tolerated JJ N
and CC N
safe JJ N
to TO N
use VB N
in IN N
the DT N
monotherapy NN N
of IN N
mild NN N
or CC N
moderate JJ N
essential JJ N
hypertension NN N
. . N

-DOCSTART- -18462303- O O

Randomized NNP N
clinical JJ N
study NN N
comparing VBG N
Compeed NNP i
cold VBD i
sore RB i
patch NN i
to TO N
acyclovir VB i
cream RB i
5 CD i
% NN i
in IN N
the DT N
treatment NN N
of IN N
herpes NNS p
simplex JJ p
labialis NN p
. . p

BACKGROUND NNP N
Hydrocolloid NNP N
technology NN N
has VBZ N
been VBN N
proven RB N
effective JJ N
in IN N
treating VBG N
dermal JJ N
wounds NNS N
. . N

A DT N
previous JJ N
study NN N
showed VBD N
that IN N
a DT N
newly RB N
developed VBN N
thin JJ i
hydrocolloid NN i
patch NN i
[ NNP i
Compeed NNP i
cold VBD i
sore RB i
patch NN i
( ( i
CSP NNP i
) ) i
] NN i
provided VBD N
multiple JJ N
wound-healing JJ N
benefits NNS N
across IN N
all DT N
stages NNS N
of IN N
a DT N
herpes NNS p
simplex JJ p
labialis NN p
( ( p
HSL NNP p
) ) p
outbreak NN N
. . N

METHODS NNP N
An DT N
assessment NN N
of IN N
CSP NNP N
efficacy NN N
and CC N
safety NN N
was VBD N
conducted VBN N
in IN N
an DT N
international JJ p
, , p
multicentre JJ p
, , N
assessor-blinded JJ N
study NN N
, , N
which WDT N
enrolled VBD p
728 CD p
subjects NNS p
with IN p
a DT p
history NN p
of IN p
recurrent NN p
HSL NNP p
. . p

Of IN N
these DT N
, , N
351 CD p
experienced VBD N
an DT N
HSL NNP N
outbreak NN N
and CC N
were VBD N
randomized VBN N
to TO N
use VB N
CSP NNP N
( ( N
n JJ N
= NNP N
179 CD N
) ) N
or CC N
acyclovir JJ i
cream NN i
5 CD i
% NN i
( ( N
n JJ N
= NNP N
172 CD N
) ) N
at IN N
the DT N
onset NN N
of IN N
symptoms NNS N
until IN N
the DT N
lesion NN N
healed VBD N
, , N
for IN N
a DT N
maximum NN N
of IN N
10 CD N
days NNS N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
the DT N
subject NN o
's POS o
global JJ o
assessment NN o
of IN o
therapy NN o
( ( o
SGAT NNP o
; : o
0-10 JJ o
scale NN o
; : o
0 CD o
= IN o
no DT o
response NN o
, , o
10 CD o
= JJ o
excellent JJ o
response NN o
) ) o
. . o

Multiple NNP N
secondary JJ N
end NN N
points NNS N
included VBD N
clinician-assessed JJ o
healing NN o
time NN o
and CC o
subject JJ o
assessment NN o
of IN o
lesion NN o
protection NN o
, , o
noticeability NN o
and CC o
social JJ o
embarrassment NN o
. . o

RESULTS NNP N
CSP NNP i
and CC i
acyclovir NNS i
were VBD N
highly RB N
effective JJ N
( ( N
mean JJ N
SGAT NNP N
= NNP N
7.89 CD N
and CC N
8.00 CD N
, , N
respectively RB N
) ) N
, , N
with IN N
no DT N
significant JJ N
difference NN N
observed VBD N
( ( N
P NNP N
= NNP N
0.65 CD N
) ) N
. . N

The DT N
difference NN N
in IN N
healing VBG o
times NNS o
between IN o
products NNS o
was VBD N
not RB N
significant JJ N
( ( N
median JJ N
, , N
7.57 CD N
days NNS N
with IN N
CSP NNP N
vs. FW N
7.03 CD N
days NNS N
with IN N
acyclovir NN N
, , N
P NNP N
= NNP N
0.37 CD N
) ) N
. . N

Both DT N
treatments NNS N
were VBD N
well RB N
tolerated VBN o
. . o

CONCLUSION NNP N
CSP NNP i
using VBG i
hydrocolloid JJ i
technology NN i
provides VBZ N
an DT N
efficacious JJ o
and CC o
safe JJ o
alternative NN N
to TO N
topical JJ N
antivirals NNS N
in IN N
treating VBG N
HSL NNP N
as IN N
a DT N
wound NN N
while IN N
affording VBG N
additional JJ N
immediate JJ N
benefits NNS N
of IN N
wound NN N
protection NN N
, , N
discretion NN N
and CC N
relief NN N
of IN N
social JJ N
embarrassment NN N
. . N

-DOCSTART- -7650233- O O

Does NNP N
tetanus CC i
immune VB i
globulin NN i
interfere RB N
with IN N
the DT N
immune JJ o
response NN o
to TO N
simultaneous JJ N
administration NN N
of IN N
tetanus-diphtheria JJ i
vaccine NN i
? . N
A DT N
comparative JJ N
clinical JJ N
trial NN p
in IN p
adults NNS p
. . p

In IN N
the DT N
management NN N
of IN N
wounds NNS N
, , N
sometimes RB N
it PRP N
is VBZ N
recommended VBN N
to TO N
give VB N
an DT N
adult-type JJ N
tetanus-diphtheria NN i
( ( i
Td NNP i
) ) i
vaccine NN i
dose JJ N
plus CC N
tetanus JJ i
immune JJ i
globulin NN i
( ( i
TIG NNP i
) ) i
. . i

Sixty NNP p
and CC p
59 CD p
healthy JJ p
young JJ p
adults NNS p
previously RB p
immunized VBN p
against IN p
tetanus NN p
( ( p
T NNP p
) ) p
and CC p
diphtheria NN p
( ( p
D NNP p
) ) p
were VBD p
randomized VBN p
to TO p
receive VB i
intramuscularly RB i
either DT i
Td NNP i
vaccine NN i
alone RB i
( ( i
group NN i
1 CD i
) ) i
or CC i
Td NNP i
vaccine NN i
plus CC i
500 CD i
IU NNP i
of IN i
TIG NNP i
( ( i
group NN i
2 CD i
) ) i
simultaneously RB i
. . i

Antitoxin NNP o
response NN o
was VBD i
assessed VBN i
after IN i
4 CD i
weeks NNS i
and CC i
4 CD i
months NNS i
. . i

Circulating VBG o
antibodies NNS o
were VBD o
measured VBN o
by IN o
enzyme-linked JJ o
immunosorbent NN o
assay NN o
( ( o
ELISA NNP o
) ) o
. . o

The DT N
cutoff NN N
of IN N
these DT N
tests NNS N
was VBD N
0.1 CD N
IU/mL NNP N
. . N

Titers NNS N
of IN N
0.1 CD N
IU/mL NNP N
or CC N
greater JJR N
were VBD N
considered VBN N
protective JJ N
. . N

For IN N
geometric JJ N
mean NN N
titers NNS N
( ( N
GMT NNP N
) ) N
, , N
antibody NN o
titers NNS o
below IN N
the DT N
cutoff NN N
of IN N
the DT N
assay NN N
were VBD N
given VBN N
, , N
arbitrarily RB N
, , N
0.05 CD N
IU/mL NNP N
. . N

At IN N
4 CD N
weeks NNS N
, , N
98 CD N
% NN N
or CC N
more JJR N
of IN N
the DT N
subjects NNS N
in IN N
group NN N
1 CD N
had VBD N
circulating NN o
T NNP o
and CC o
D NNP o
antitoxin NN o
levels NNS o
of IN N
0.1 CD N
IU/mL NNP N
or CC N
higher JJR N
; : N
in IN N
group NN N
2 CD N
, , N
95 CD N
% NN N
and CC N
90 CD N
% NN N
of IN N
the DT N
subjects NNS N
had VBD N
titers NNS N
above IN N
this DT N
limit NN N
for IN N
T NNP N
and CC N
D NNP N
, , N
respectively RB N
. . N

At IN N
4 CD N
months NNS N
, , N
these DT N
percentages NNS N
were VBD N
98 CD N
% NN N
and CC N
95 CD N
% NN N
for IN N
T NNP o
antitoxin NN o
levels NNS o
in IN N
groups NNS N
1 CD N
and CC N
2 CD N
, , N
respectively RB N
; : N
whereas CC N
96 CD N
% NN N
and CC N
88 CD N
% NN N
of IN N
the DT N
subjects NNS N
in IN N
groups NNS N
1 CD N
and CC N
2 CD N
had VBD N
D NNP o
antitoxin NN o
levels NNS o
of IN N
0.1 CD N
IU/mL NNP N
or CC N
higher JJR N
, , N
respectively RB N
. . N

Significantly NNP N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
higher JJR N
GMTs NNP N
were VBD N
seen VBN N
at IN N
the DT N
4-week JJ N
assessment NN N
( ( N
but CC N
not RB N
at IN N
4 CD N
months NNS N
) ) N
in IN N
group NN N
1 CD N
, , N
as IN N
compared VBN N
with IN N
group NN N
2 CD N
, , N
in IN N
both DT N
T NNP N
and CC N
D NNP N
antitoxin NN N
levels NNS N
( ( N
9.91 CD N
IU/mL NNP N
versus NN N
5.60 CD N
IU/mL NNP N
for IN N
T NNP N
antitoxin NN N
, , N
and CC N
2.86 CD N
IU/mL NNP N
versus NN N
1.45 CD N
IU/mL NNP N
for IN N
D NNP N
antitoxin NN N
) ) N
. . N

This DT N
finding NN N
resulted VBD N
from IN N
those DT N
participants NNS N
with IN N
low JJ N
( ( N
< JJ N
0.1 CD N
IU/mL NNP N
) ) N
prevaccination NN N
antibody NN N
titers NNS N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -20522464- O O

Effect NN N
of IN N
addition NN N
of IN N
single JJ N
dose NN N
of IN N
oral JJ N
montelukast NN i
to TO N
standard VB N
treatment NN N
in IN N
acute JJ p
moderate NN p
to TO p
severe VB p
asthma NN p
in IN p
children NNS p
between IN p
5 CD p
and CC p
15 CD p
years NNS p
of IN p
age NN p
: : p
a DT N
randomised JJ N
, , N
double-blind JJ N
, , N
placebo NN N
controlled VBD N
trial NN N
. . N

OBJECTIVE UH N
To TO N
study VB N
the DT N
effect NN N
of IN N
the DT N
addition NN N
of IN N
a DT N
single JJ N
dose NN N
of IN N
oral JJ i
montelukast NN i
to TO N
standard VB i
therapy NN i
in IN N
acute JJ p
moderate NN p
to TO p
severe VB p
asthma NN p
. . p

DESIGN NNP N
Double-blind NNP N
randomised VBD N
controlled VBN N
trial NN N
. . N

Setting VBG N
Emergency NNP p
room/outpatient NN p
paediatric NN p
services NNS p
of IN p
a DT p
tertiary JJ p
care NN p
hospital NN p
. . p

PATIENTS NNP N
Children NNP p
aged VBD p
5-15 CD p
years NNS p
( ( p
without IN p
prior RB p
use NN p
of IN p
montelukast NN i
) ) i
with IN p
acute JJ p
moderate NN p
to TO p
severe VB p
asthma JJ p
exacerbation NN p
, , p
as IN p
defined VBN p
using VBG p
Modified NNP o
Pulmonary NNP o
Index NNP o
Score NNP o
( ( o
MPIS NNP o
) ) o
> VBD p
or CC p
=9 NNS p
, , p
were VBD p
enrolled VBN p
. . p

INTERVENTION NNP N
Children NNP N
received VBD N
montelukast NN i
( ( N
5-12 JJ N
years NNS N
: : N
5 CD N
mg NN N
and CC N
> $ N
12 CD N
years NNS N
: : N
10 CD N
mg NN N
) ) N
or CC N
placebo VBN i
orally RB N
in IN N
addition NN N
to TO N
the DT N
standard JJ N
therapy NN N
. . N

MPIS NNP o
and CC o
forced VBD o
expiratory JJ o
volume NN o
in IN o
1 CD o
second JJ o
( ( o
FEV NNP o
( ( o
1 CD o
) ) o
) ) o
were VBD N
recorded VBN N
before IN N
administering VBG N
study NN N
medication NN N
and CC N
thereafter RB N
, , N
hourly RB N
for IN N
4 CD N
hours NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
primary JJ N
outcome NN N
was VBD N
decrease NN o
in IN o
MPIS NNP o
to TO N
less JJR N
than IN N
9 CD N
at IN N
the DT N
end NN N
of IN N
4 CD N
hours NNS N
. . N

RESULTS VB N
117 CD p
children NNS p
( ( p
60 CD p
in IN p
montelukast NN i
group NN p
and CC p
57 CD p
in IN p
placebo NN i
group NN p
) ) p
were VBD p
enrolled VBN p
in IN p
the DT p
study NN p
. . p

The DT N
number NN N
of IN N
children NNS N
with IN N
decrease NN o
in IN o
MPIS NNP o
to TO N
less JJR N
than IN N
9 CD N
at IN N
4 CD N
hours NNS N
was VBD N
33 CD N
( ( N
55 CD N
% NN N
) ) N
in IN N
the DT N
montelukast NN i
group NN N
and CC N
36 CD N
( ( N
63.2 CD N
% NN N
) ) N
in IN N
the DT N
placebo NN i
group NN N
( ( N
p=0.37 NN N
) ) N
. . N

There EX N
was VBD N
significant JJ N
improvement NN o
in IN o
MPIS NNP o
and CC o
FEV NNP o
( ( o
1 CD o
) ) o
within IN N
both CC N
the DT N
groups NNS N
from IN N
baseline NN N
to TO N
the DT N
end NN N
of IN N
4 CD N
hours NNS N
. . N

No DT N
differences NNS N
in IN N
side NN o
effects NNS o
and CC o
hospitalisation NN o
rates NNS o
were VBD N
noticed VBN N
between IN N
the DT N
two CD N
groups NNS N
. . N

CONCLUSION NNP N
Single NNP N
dose JJ N
oral JJ i
montelukast NN i
added VBD N
to TO N
standard JJ i
therapy NN i
of IN i
inhaled JJ i
bronchodilators NNS i
and CC i
systemic JJ i
glucocorticoids NNS i
did VBD N
not RB N
provide VB N
additional JJ N
clinical JJ N
benefit NN N
in IN N
children NNS p
with IN p
acute JJ p
moderate NN p
to TO p
severe VB p
asthma NN p
. . p

Trial JJ N
registration NN N
number NN N
The DT N
trial NN N
was VBD N
registered VBN N
at IN N
the DT N
http NN N
: : N
//clinicaltrials.gov JJ N
site NN N
( ( N
trial NN N
ID NNP N
: : N
NCT00565955 NN N
) ) N
. . N

-DOCSTART- -24689172- O O

Safety NNP o
evaluation NN N
of IN N
lasalocid NN i
use NN N
in IN N
Chinese JJ p
ring-necked JJ p
pheasants NNS p
( ( p
Phasianus NNP p
colchicus NN p
) ) p
. . p

Coccidiosis NN N
remains VBZ N
a DT N
significant JJ N
threat NN N
to TO N
the DT N
welfare NN N
of IN N
game NN p
farm-reared JJ p
pheasants NNS p
in IN p
the DT p
United NNP p
States NNPS p
. . p

Although IN N
lasalocid NN i
has VBZ N
been VBN N
demonstrated VBN N
to TO N
be VB N
effective JJ N
against IN N
pheasant JJ N
specific JJ N
coccidia NN N
, , N
information NN N
regarding VBG N
its PRP$ N
safety NN N
in IN N
this DT N
species NNS N
is VBZ N
lacking VBG N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
gather VB N
data NNS N
on IN N
the DT N
safety NN N
of IN N
lasalocid NN i
when WRB N
fed NN N
to TO N
Chinese JJ p
ring-necked JJ p
pheasants NNS p
at IN N
one CD N
, , N
two CD N
, , N
and CC N
three CD N
times NNS N
the DT N
recommended JJ N
high JJ N
dose NN N
of IN N
lasalocid NN i
used VBN N
for IN N
prevention NN N
of IN N
coccidiosis NN N
in IN N
other JJ N
poultry NN N
at IN N
three CD N
times NNS N
the DT N
normal JJ N
treatment NN N
period NN N
. . N

Pheasant JJ p
chicks NNS p
( ( p
approximately RB p
1 CD p
day-old JJ p
; : p
n CC p
= VB p
160 CD p
) ) p
were VBD N
randomly RB N
blocked VBN N
by IN N
sex NN N
into IN N
four CD N
treatment NN N
groups NNS N
and CC N
given VBN N
their PRP$ N
respective JJ N
diets NNS N
continuously RB N
for IN N
6 CD N
wk NN N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
observed VBN N
in IN N
overall JJ o
feed NN o
consumption NN o
, , o
weight NN o
gain NN o
, , o
feed VBN o
conversion NN o
rates NNS o
, , o
clinical JJ o
pathology NN o
measurements NNS o
, , o
or CC o
tissue NN o
gross JJ o
and CC o
histopathologic JJ o
evaluations NNS o
between IN N
controls NNS N
and CC N
treatment NN N
groups NNS N
associated VBN N
with IN N
lasalocid JJ i
administration NN N
. . N

Based VBN N
on IN N
the DT N
results NNS N
of IN N
this DT N
study NN N
it PRP N
appears VBZ N
that IN N
lasalocid NN i
fed VBN N
at IN N
the DT N
recommended JJ N
rate NN N
of IN N
125 CD N
ppm NN N
is VBZ N
safe JJ o
in IN N
Chinese JJ p
ring-necked JJ p
pheasants NNS p
. . p

-DOCSTART- -16472981- O O

Effects NNS N
of IN N
cooking NN i
plant NN i
oils NNS i
on IN N
recurrent NN N
aphthous JJ N
stomatitis NN N
: : N
a DT N
randomized JJ N
, , N
placebo-controlled JJ N
, , N
double-blind JJ N
trial NN N
. . N

OBJECTIVE NNP N
One-third NNP N
of IN N
the DT N
total JJ N
population NN N
seems VBZ N
to TO N
develop VB N
minor JJ N
recurrent NN p
aphthous JJ p
stomatitis NN p
( ( p
RAS NNP p
) ) p
during IN N
their PRP$ N
lifetime NN N
. . N

However RB N
, , N
well-controlled JJ N
dietary JJ N
intervention NN N
studies NNS N
to TO N
prevent VB N
minor JJ N
RAS NNP N
are VBP N
very RB N
rare JJ N
. . N

The DT N
objective NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
investigate VB N
whether IN N
the DT N
prevalence NN N
of IN N
RAS NNP N
decreased VBD N
with IN N
perilla NN i
oil NN i
( ( N
rich JJ N
in IN N
alpha-linolenic JJ N
acid NN N
) ) N
. . N

METHODS NNP N
Thirty NNP p
subjects NNS p
( ( p
8 CD p
men NNS p
and CC p
22 CD p
women NNS p
) ) p
who WP p
had VBD p
minor JJ p
RAS NNP p
at IN p
least JJS p
once RB p
a DT p
month NN p
were VBD N
randomly RB N
allocated VBN N
to TO N
a DT N
soybean JJ i
oil NN i
group NN i
or CC i
a DT i
perilla JJ i
oil NN i
group NN i
in IN i
a DT i
double-blind JJ i
manner NN i
( ( i
experimental JJ i
phase NN i
) ) i
after IN i
a DT i
run-in JJ i
phase NN i
of IN i
4 CD i
mo NN i
during IN i
which WDT i
subjects NNS i
used VBD i
a DT i
reference NN i
oil NN i
, , i
the DT i
most RBS i
popular JJ i
cooking NN i
oil NN i
in IN i
Japan NNP i
, , i
or CC i
a DT i
50/50 CD i
mixture NN i
of IN i
soybean JJ i
oil NN i
and CC i
rapeseed NN i
oil NN i
. . i

During IN N
the DT N
experimental JJ N
phase NN N
, , N
subjects NNS N
were VBD N
asked VBN N
to TO N
use VB N
soybean JJ N
oil NN N
or CC N
perilla NN N
oil NN N
as IN N
the DT N
sole JJ N
cooking NN N
oil NN N
for IN N
8 CD N
mo NN N
. . N

Blood NN o
samples NNS o
were VBD N
collected VBN N
at IN N
the DT N
start NN N
and CC N
end NN N
of IN N
the DT N
experimental JJ N
phase NN N
for IN N
fatty JJ N
acid JJ N
analysis NN N
of IN N
total JJ N
plasma NN N
phospholipid JJ N
fraction NN N
. . N

Occurrence NN o
and CC o
needed VBN o
days NNS o
for IN o
healing NN o
of IN o
minor JJ o
RAS NNP o
were VBD N
recorded VBN N
during IN N
the DT N
two CD N
phases NNS N
and CC N
compared VBN N
. . N

RESULTS NNP N
alpha-Linolenic JJ o
acid JJ o
concentrations NNS o
in IN o
the DT o
plasma NN o
phospholipid JJ o
fraction NN o
increased VBD o
significantly RB N
in IN N
both DT N
groups NNS N
during IN N
the DT N
experimental JJ N
phase NN N
to TO N
a DT N
similar JJ N
extent NN N
. . N

The DT N
prevalence NN N
of IN N
minor JJ o
RAS NNP o
in IN o
the DT o
experimental JJ o
phase NN o
decreased VBD o
significantly RB o
in IN N
both DT N
groups NNS N
compared VBN N
with IN N
the DT N
run-in JJ N
phase NN N
to TO N
a DT N
similar JJ N
extent NN N
, , N
without IN N
intergroup JJ N
differences NNS N
. . N

CONCLUSION NNP N
Perilla NNP N
oil NN N
, , N
which WDT N
is VBZ N
rich JJ N
in IN N
alpha-linolenic JJ N
acid NN N
, , N
was VBD N
not RB N
superior JJ N
to TO N
soybean VB N
oil NN N
in IN N
preventing VBG N
minor JJ N
RAS NNP N
. . N

There EX N
was VBD N
a DT N
possibility NN N
that IN N
avoiding VBG N
rapeseed VB N
oil NN N
might MD N
be VB N
beneficial JJ N
for IN N
prevention NN N
of IN N
minor JJ N
RAS NNP N
. . N

-DOCSTART- -11446476- O O

Comparison NNP N
of IN N
enoxaparin NN i
and CC i
standard JJ i
heparin NN i
in IN N
gynaecologic JJ p
oncologic JJ p
surgery NN p
: : p
a DT N
randomised JJ N
prospective JJ N
double-blind NN N
clinical JJ N
study NN N
. . N

OBJECTIVE NNP N
This DT N
study NN N
aimed VBD N
to TO N
compare VB N
the DT N
haemorrhagic JJ N
complications NNS N
and CC N
efficacy NN N
of IN N
enoxaparin NN i
, , N
a DT N
low JJ N
molecular JJ N
weight NN N
heparin NN N
( ( N
LMWH NNP N
) ) N
, , N
and CC N
conventional JJ N
standard NN i
heparin NN i
( ( i
SH NNP i
) ) i
in IN N
gynaecological JJ p
oncologic NN p
surgery NN p
. . p

MATERIALS NNP N
METHODS NNP N
A NNP N
double JJ N
blind NN N
, , N
randomised VBD N
trial NN N
was VBD N
performed VBN N
on IN N
102 CD p
consecutive JJ p
women NNS p
undergoing VBG p
gynaecologic JJ p
cancer NN p
surgery NN p
with IN p
pelvic NN p
and CC p
paraaortic JJ p
lymphadenectomy NN p
. . p

The DT N
women NNS N
were VBD N
separated VBN N
into IN N
those DT N
who WP N
were VBD N
given VBN N
2,500 CD i
IU NNP i
enoxaparin NN i
once RB i
daily JJ i
and CC i
SH NNP i
in IN i
a DT i
dose NN i
of IN i
5,000 CD i
IU NNP i
three CD i
times NNS i
daily RB i
. . i

The DT N
groups NNS N
were VBD N
analysed VBN N
for IN N
intraoperative JJ N
blood NN N
loss NN N
, , N
drainage NN N
, , N
transfusion NN N
requirements NNS N
, , N
perioperative JJ N
haemoglobin NN N
decrease NN N
, , N
wound NN N
haematoma NN N
, , N
and CC N
clinical JJ N
deep NN N
venous JJ N
thrombosis NN N
. . N

RESULTS VB N
The DT p
two CD p
groups NNS p
were VBD p
well RB p
matched VBN p
for IN p
age NN p
, , p
weight NN p
, , p
and CC p
other JJ p
factors NNS p
, , N
which WDT N
could MD N
predispose VB N
to TO N
the DT N
development NN o
of IN o
deep JJ o
venous JJ o
thrombosis NN o
( ( o
DVT NNP o
) ) o
and CC o
haemorrhage NN o
. . o

No DT N
patient NN N
developed VBD N
clinical JJ o
significant JJ o
DVT NNP o
, , o
wound NN o
haematoma NN o
or CC o
intra-abdominal JJ o
bleeding NN o
. . o

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
bleeding VBG o
complications NNS o
between IN N
the DT N
two CD N
regimens NNS N
. . N

The DT N
antiFXa JJ o
level NN o
in IN N
the DT N
plasma NN N
was VBD N
correlated VBN N
strongly RB N
with IN N
patient JJ N
weight NN N
. . N

CONCLUSIONS VB N
A NNP N
dose NN N
of IN N
2,500 CD N
IU NNP N
enoxaparin/day NN i
does VBZ N
not RB N
cause VB N
more RBR N
bleeding JJ N
complications NNS N
than IN N
SH NNP N
5,000 CD N
IU NNP N
three CD N
times NNS N
daily RB N
when WRB N
used VBN N
to TO N
prevent VB N
thrombosis NN N
. . N

However RB N
, , N
the DT N
dose NN N
of IN N
enoxaparin NN N
must MD N
be VB N
adjusted VBN N
to TO N
the DT N
patient NN N
's POS N
weight NN N
. . N

-DOCSTART- -22795327- O O

Selected VBN N
polymorphisms NNS N
of IN N
GSTP1 NNP N
and CC N
TERT NNP N
were VBD N
associated VBN N
with IN N
glioma NN p
risk NN p
in IN p
Han NNP p
Chinese NNP p
. . p

BACKGROUND NNP N
Current NNP N
evidence NN N
suggests VBZ N
that IN N
a DT N
majority NN N
of IN N
the DT N
inherited JJ N
risks NNS N
play VBP N
a DT N
major JJ N
role NN N
in IN N
glioma JJ p
susceptibility NN p
, , N
and CC N
glioma NN N
is VBZ N
due JJ N
to TO N
the DT N
co-inheritance NN N
of IN N
multiple JJ N
low-risk JJ N
variants NNS N
. . N

These DT N
variants NNS N
can MD N
be VB N
identified VBN N
through IN N
association NN N
studies NNS N
including VBG N
such JJ N
as IN N
genome-wide JJ N
association NN N
studies NNS N
( ( N
GWAS NNP N
) ) N
, , N
which WDT N
has VBZ N
led VBN N
the DT N
glioma NN N
epidemiology NN N
researchers NNS N
to TO N
focus VB N
on IN N
identifying VBG N
potential JJ N
disease-causing JJ N
factors NNS N
. . N

METHODS NNP N
We PRP N
evaluated VBD N
and CC N
validated VBD N
10 CD p
tag NN p
single JJ p
nucleotide JJ p
polymorphisms NN p
( ( p
tSNPs NN p
) ) p
in IN p
seven CD p
genes NNS p
associated VBN p
with IN p
glioma NN p
susceptibility NN p
in IN p
a DT p
Han NNP p
Chinese NNP p
population NN p
, , p
including VBG p
301 CD p
glioma NN p
cases NNS p
and CC p
302 CD p
controls NNS p
, , p
using VBG p
a DT p
multiplexed JJ i
single JJ i
nucleotide NN i
polymorphism NN i
( ( i
SNP NNP i
) ) i
MassEXTEND NNP i
assay NN i
. . i

We PRP N
ascertained VBD N
the DT N
genotypic NN N
frequencies NNS N
for IN N
each DT N
tSNP NN N
in IN N
control NN N
subjects NNS N
were VBD N
within IN N
Hardy-Weinberg NNP N
equilibrium NN N
( ( N
HWE NNP N
) ) N
using VBG N
an DT N
exact JJ N
test NN N
, , N
and CC N
then RB N
compared VBN N
the DT N
genotype NN N
and CC N
allele JJ N
frequencies NNS N
of IN N
glioma NN N
patients NNS N
and CC N
control NN N
subjects NNS N
using VBG N
the DT N
?2 JJ N
test NN N
. . N

We PRP N
then RB N
applied VBD N
three CD N
genetic JJ N
models NNS N
( ( N
dominant JJ N
, , N
recessive JJ N
, , N
and CC N
additive JJ N
) ) N
using VBG N
PLINK NNP N
software NN N
to TO N
assess VB N
the DT N
association NN N
of IN N
each DT N
tSNP NN N
with IN N
glioma NN N
risk NN N
. . N

RESULTS NNP N
We PRP N
identified VBD N
two CD N
tSNPs NN N
to TO N
be VB N
associated VBN N
with IN o
glioma NN o
susceptibility NN o
( ( N
rs1695 NN N
, , N
GSTP1 NNP N
, , N
P NNP N
= NNP N
0.019 CD N
; : N
rs2853676 NN N
, , N
TERT NNP N
, , N
P NNP N
= NNP N
0.039 CD N
) ) N
, , N
which WDT N
we PRP N
confirmed VBD N
using VBG N
dominant NN N
and CC N
additive JJ N
model NN N
analyses NNS N
. . N

The DT N
genotype NN N
& CC N
ldquo NN N
; : N
GA NNP N
& CC N
rdquo NN N
; : N
for IN N
rs1695 NN N
was VBD N
recognized VBN N
to TO N
be VB N
a DT N
protective JJ N
genotype NN N
for IN o
glioma NN o
( ( N
OR NNP N
, , N
0.67 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.47-0.96 NNP N
; : N
P NNP N
= NNP N
0.027 CD N
) ) N
, , N
while IN N
the DT N
genotype NN N
& CC N
ldquo NN N
; : N
AG NNP N
& CC N
rdquo NN N
; : N
for IN N
rs2853676 NN N
was VBD N
shown VBN N
to TO N
be VB N
a DT N
risk NN N
genotype NN N
for IN o
glioma NN o
( ( N
OR NNP N
, , N
1.50 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.05-2.15 JJ N
; : N
P NNP N
= NNP N
0.025 CD N
) ) N
. . N

CONCLUSION NNP N
Our PRP$ N
results NNS N
, , N
and CC N
those DT N
from IN N
previous JJ N
studies NNS N
, , N
suggest VBP N
potential JJ N
genetic JJ N
contributes NNS N
for IN N
GSTP1 NNP N
and CC N
TERT NNP N
in IN N
glioma NN N
development NN N
. . N

-DOCSTART- -1593244- O O

Clinical JJ N
evaluation NN N
of IN N
the DT N
contact NN N
sensitization NN N
potential NN N
of IN N
a DT N
transdermal JJ i
nicotine NN i
system NN i
( ( i
Nicoderm NNP i
) ) i
BACKGROUND NNP N
Transdermal NNP i
nicotine NN i
therapy NN i
has VBZ N
shown VBN N
promise NN N
as IN N
a DT N
smoking NN N
cessation NN N
aid NN N
, , N
but CC N
questions NNS N
about IN N
its PRP$ N
contact NN N
sensitization NN N
potential NN N
and CC N
long-term JJ N
topical JJ N
safety NN N
have VBP N
been VBN N
raised VBN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
contact NN N
sensitization NN N
potential NN N
of IN N
one CD i
nicotine NN i
transdermal NN i
system NN i
( ( p
Nicoderm NNP p
, , p
Marion NNP p
Merrell NNP p
Dow NNP p
Inc NNP p
, , p
Kansas NNP p
City NNP p
, , p
Mo NNP p
, , p
and CC p
ALZA NNP p
Corporation NNP p
, , p
Palo NNP p
Alto NNP p
, , p
Calif NNP p
) ) p
in IN p
a DT p
population NN p
who WP p
were VBD p
allowed VBN p
to TO p
continue VB p
smoking VBG p
. . p

METHODS NNP N
This DT N
study NN N
comprised VBD N
two CD N
phases NNS N
separated VBN N
by IN N
a DT N
2-week JJ N
rest NN N
interval NN N
. . N

During IN N
phase NN N
1 CD N
, , N
a DT N
42-day JJ N
open-label JJ N
induction NN N
period NN N
, , N
subjects VBZ N
wore IN N
only RB N
active JJ i
transdermal JJ i
nicotine JJ i
systems NNS i
. . i

During IN N
phase NN N
2 CD N
, , N
a DT N
4-day JJ N
double-blind JJ N
challenge NN N
period NN N
, , N
subjects NNS N
wore VBD N
active JJ i
and CC i
placebo JJ i
systems NNS i
concurrently RB i
. . i

Upon IN N
removal NN N
of IN N
each DT N
patch NN N
, , N
skin NN N
sites NNS N
were VBD N
evaluated VBN N
for IN N
signs NNS o
of IN o
irritation NN o
, , N
and CC N
subjective JJ o
complaints NNS o
such JJ o
as IN o
itching NN o
or CC o
burning NN o
were VBD N
recorded VBN N
. . N

RESULTS NNP N
Of IN N
the DT N
186 CD p
subjects NNS p
completing VBG p
the DT p
study NN p
, , N
3 CD N
( ( N
1.6 CD N
% NN N
) ) N
exhibited VBD N
evidence NN N
of IN N
delayed JJ N
contact NN N
sensitization NN N
manifested VBD N
as IN N
erythema NN o
with IN o
or CC o
without IN o
infiltration NN o
and CC N
confined VBD N
solely RB N
to TO N
sites NNS N
of IN N
active JJ N
transdermal JJ i
nicotine NN i
system NN i
application NN N
. . N

Nonallergic NNP o
skin JJ o
irritation NN o
was VBD N
observed VBN N
in IN N
less JJR N
than IN N
3 CD N
% NN N
of IN N
all DT N
applications NNS N
. . N

All DT N
reactions NNS N
resolved VBN N
without IN N
incident NN N
. . N

No DT N
subjects NNS N
developed VBD N
systemic JJ o
reactions NNS o
. . o

CONCLUSIONS VB N
The DT N
transdermal JJ i
nicotine NN i
system NN i
used VBN N
in IN N
this DT N
trial NN N
had VBD N
a DT N
low JJ N
contact NN N
sensitization NN N
incidence NN N
and CC N
was VBD N
well RB N
tolerated VBN o
topically RB N
with IN N
minimal JJ N
irritation NN N
. . N

-DOCSTART- -23836550- O O

Reputation NNP N
management NN N
: : N
evidence NN N
for IN N
ability NN N
but CC N
reduced JJ N
propensity NN o
in IN N
autism NN p
. . p

Previous JJ N
research NN N
has VBZ N
reported VBN N
that IN N
autistic JJ p
adults NNS p
do VBP N
not RB N
manage VB N
their PRP$ N
reputation NN N
, , N
purportedly RB N
due JJ N
to TO N
problems NNS N
with IN N
theory NN N
of IN N
mind NN N
[ NNP N
Izuma NNP N
, , N
Matsumoto NNP o
, , N
Camerer NNP N
, , N
& CC N
Adolphs NNP o
] NNP o
. . N

The DT N
current JJ N
study NN N
aimed VBD N
to TO N
test VB i
alternative JJ i
explanations NNS i
for IN N
this DT N
apparent JJ N
lack NN N
of IN N
reputation NN N
management NN N
. . N

Twenty NNP p
typical JJ p
and CC p
19 CD p
autistic JJ p
adults NNS p
donated VBD i
to TO i
charity NN i
and CC i
to TO i
a DT i
person NN i
, , p
both DT p
when WRB p
alone RB p
and CC N
when WRB N
observed VBN N
. . N

In IN N
an DT N
additional JJ N
manipulation NN N
, , N
for IN N
half NN N
of IN N
the DT N
participants NNS N
, , N
the DT N
observer NN N
was VBD N
also RB N
the DT N
recipient NN N
of IN N
their PRP$ N
donations NNS N
, , N
and CC N
participants NNS N
were VBD N
told VBN N
that IN N
this DT N
observer NN N
would MD N
subsequently RB N
have VB N
the DT N
opportunity NN N
to TO N
donate VB i
to TO N
them PRP N
( ( N
motivation NN N
condition NN N
) ) N
. . N

This DT N
manipulation NN N
was VBD N
designed VBN N
to TO N
encourage VB N
an DT N
expectation NN N
of IN N
a DT N
reciprocal JJ N
tit-for-tat NN o
strategy NN N
in IN N
the DT N
participant NN N
, , N
which WDT N
may MD N
motivate VB N
participants NNS N
to TO N
change VB N
their PRP$ N
behavior NN N
to TO N
receive VB N
more JJR N
donations NNS N
. . N

The DT N
remaining VBG N
participants NNS N
were VBD N
told VBN N
that IN N
the DT N
person NN N
watching NN N
was VBD N
just RB N
observing VBG N
the DT N
procedure NN N
( ( N
no DT N
motivation NN N
condition NN N
) ) N
. . N

Our PRP$ N
results NNS N
replicated VBD N
Izuma NNP o
et CC N
al NN N
. . N

's POS N
finding VBG N
that IN p
autistic JJ p
adults NNS p
did VBD p
not RB o
donate VB o
more JJR o
to TO o
charity NN o
when WRB o
observed VBN N
. . N

Yet CC N
, , N
in IN N
the DT N
motivation NN N
condition NN N
, , N
both DT N
typical JJ N
and CC N
autistic JJ N
adults NNS i
donated VBD i
significantly RB i
more RBR N
to TO N
the DT N
observer NN N
when WRB N
watched VBN N
, , N
although IN N
this DT N
effect NN N
was VBD N
significantly RB N
attenuated VBN N
in IN N
autistic JJ p
individuals NNS p
. . p

Results NNS N
indicate VBP N
that IN N
, , N
while IN p
individuals NNS p
with IN p
autism NN p
may MD p
have VB N
the DT N
ability NN N
to TO N
think VB N
about IN N
reputation NN N
, , N
a DT N
reduced JJ N
expectation NN N
of IN N
reciprocal JJ N
behavior NN N
from IN N
others NNS N
may MD N
reduce VB N
the DT N
degree NN N
to TO N
which WDT N
they PRP o
engage VBP o
in IN o
reputation NN N
management NN N
. . N

-DOCSTART- -15200998- O O

Chemotherapy NNP i
for IN N
patients NNS p
with IN p
non-small JJ p
cell NN p
lung NN p
cancer NN p
: : p
the DT N
surgical JJ N
setting NN N
of IN N
the DT N
Big NNP N
Lung NNP N
Trial NNP N
. . N

OBJECTIVES VB N
The DT N
non-small JJ p
cell NN p
lung NN p
cancer NN p
( ( p
NSCLC NNP p
) ) p
meta-analysis NN N
suggested VBD N
a DT N
survival JJ N
benefit NN N
for IN N
cisplatin-based JJ i
chemotherapy NN i
when WRB N
given VBN N
in IN N
addition NN N
to TO N
surgery NN i
, , N
radical JJ N
radiotherapy NN N
or CC N
'best JJS N
supportive JJ N
care NN N
' POS N
. . N

However RB N
, , N
it PRP N
included VBD N
many JJ N
small JJ N
trials NNS N
and CC N
trials NNS N
with IN N
differing VBG N
eligibility NN N
criteria NNS N
and CC N
chemotherapy NN N
regimens NNS N
. . N

The DT N
aim NN N
of IN N
the DT N
Big NNP N
Lung NNP N
Trial NNP N
was VBD N
therefore RB N
to TO N
run VB N
a DT N
large JJ N
pragmatic JJ N
trial NN N
to TO N
confirm VB N
the DT N
survival NN o
benefits NNS o
seen VBN N
in IN N
the DT N
meta-analysis NN N
. . N

METHODS NNP N
In IN N
the DT N
surgery NN i
setting NN N
, , N
a DT N
total NN N
of IN N
381 CD p
patients NNS p
were VBD p
randomised VBN p
to TO p
chemotherapy VB i
( ( p
C NNP p
, , p
192 CD p
patients NNS p
) ) p
or CC p
no DT i
chemotherapy NN i
( ( p
NoC NNP p
, , p
189 CD p
patients NNS p
) ) p
. . p

C NNP N
was VBD N
three CD N
3-weekly JJ N
cycles NNS N
of IN N
cisplatin/vindesine NN i
, , i
mitomycin/ifosfamide/cisplatin NN i
, , i
mitomycin/vinblastine/cisplatin NN i
or CC i
vinorelbine/cisplatin NN i
. . i

RESULTS NNP N
Chemotherapy NNP i
was VBD N
given VBN N
before RB N
surgery NN i
in IN N
3 CD N
% NN N
of IN N
patients NNS N
whilst VBP N
97 CD N
% NN N
received VBD N
adjuvant JJ i
chemotherapy NN i
. . i

Baseline NNP N
characteristics NNS N
were VBD N
: : N
median JJ N
age NN N
61 CD N
years NNS N
, , N
69 CD N
% NN N
male NN N
, , N
48 CD N
% NN N
squamous JJ N
cell NN N
, , N
93 CD N
% NN N
WHO NNP N
PS NNP N
0-1 NNP N
, , N
27 CD N
% NN N
stage NN N
I PRP N
, , N
38 CD N
% NN N
stage NN N
II NNP N
, , N
and CC N
34 CD N
% NN N
stage NN N
III NNP N
. . N

Complete NNP o
resection NN o
was VBD N
achieved VBN N
in IN N
approximately RB N
95 CD N
% NN N
of IN N
patients NNS N
. . N

In IN N
the DT N
C NNP N
group NN N
, , N
13 CD N
% NN N
received VBD N
no DT i
chemotherapy NN i
, , N
21 CD N
% NN N
one CD N
or CC N
two CD N
cycles NNS N
, , N
and CC N
64 CD N
% NN N
all DT N
three CD N
cycles NNS N
of IN N
their PRP$ N
prescribed JJ N
chemotherapy NN i
( ( N
60 CD N
% NN N
of IN N
the DT N
latter NN N
with IN N
no DT N
delays NNS N
or CC N
modification NN N
) ) N
. . N

30 CD N
% NN N
had VBD N
grade VBN N
3/4 CD N
toxicity NN o
, , o
mainly RB o
haematological JJ o
, , o
nausea/vomiting JJ o
and CC o
neutropenic JJ o
fever NN o
, , N
and CC N
six CD N
patients NNS N
were VBD N
reported VBN N
as IN N
having VBG N
a DT N
treatment-related JJ N
death NN o
. . o

198 CD N
( ( N
52 CD N
% NN N
) ) N
of IN N
patients NNS N
have VBP N
died VBN N
, , N
but CC N
there EX N
is VBZ N
currently RB N
no DT N
evidence NN N
of IN N
a DT N
benefit NN o
in IN o
overall JJ o
survival NN o
to TO N
the DT N
C NNP N
group NN N
: : N
HR $ N
1.02 CD N
( ( N
95 CD N
% NN N
CI NNP N
0.77-1.35 NN N
) ) N
, , N
P NNP N
= NNP N
0.90 CD N
) ) N
. . N

CONCLUSIONS VB N
This DT N
trial NN N
has VBZ N
failed VBN N
to TO N
observe VB N
a DT N
survival JJ o
benefit NN o
with IN N
adjuvant JJ i
chemotherapy NN i
following VBG N
complete JJ N
resection NN N
of IN N
stage NN N
I-III JJ N
NSCLC NNP N
. . N

However RB N
, , N
the DT N
hazard NN N
ratio NN N
and CC N
95 CD N
% NN N
confidence NN N
intervals NNS N
are VBP N
consistent JJ N
with IN N
the DT N
previously RB N
reported VBN N
meta-analysis NN N
and CC N
two CD N
large JJ N
recently RB N
reported VBD N
trials NNS N
, , N
which WDT N
suggest VBP N
a DT N
small JJ N
survival NN N
benefit NN N
with IN N
cisplatin-based JJ i
chemotherapy NN i
. . i

-DOCSTART- -6374683- O O

A DT N
comparison NN N
of IN N
an DT N
aqueous JJ i
and CC N
a DT N
pressurized JJ i
nasal NN i
spray NN i
of IN N
beclomethasone NN i
dipropionate NN i
in IN N
the DT N
management NN o
of IN o
seasonal JJ o
rhinitis NN o
. . o

A DT N
multi-centre JJ N
, , N
double-blind JJ N
, , N
parallel JJ N
group NN N
study NN N
was VBD N
carried VBN N
out RP N
in IN N
38 CD p
patients NNS p
with IN p
seasonal JJ p
rhinitis NN p
to TO N
compare VB N
a DT N
new JJ N
aqueous JJ i
nasal NN i
spray NN i
of IN i
beclomethasone NN i
dipropionate NN i
with IN i
the DT i
conventional JJ i
pressurized JJ i
nasal NN i
spray NN i
. . i

Beclomethasone NNP i
dipropionate NN i
( ( N
200 CD N
micrograms NNS N
) ) N
was VBD N
administered VBN N
twice RB N
daily RB N
for IN N
a DT N
treatment NN N
period NN N
of IN N
2 CD N
weeks NNS N
. . N

Both DT N
treatments NNS N
were VBD N
found VBN N
to TO N
be VB N
equally RB N
effective JJ o
and CC o
well RB o
tolerated VBN o
. . o

It PRP N
is VBZ N
suggested VBN N
, , N
therefore RB N
, , N
that IN N
the DT N
new JJ N
aqueous JJ i
nasal NN i
spray NN i
provides VBZ N
an DT N
alternative JJ N
method NN N
of IN N
intranasal JJ N
administration NN N
of IN N
the DT N
steroid NN N
for IN N
patients NNS N
who WP N
may MD N
prefer VB N
an DT N
aqueous JJ N
product NN N
. . N

-DOCSTART- -2663585- O O

Influence NN o
of IN N
ibopamine NN i
on IN N
heart NN o
rate NN o
and CC o
arrhythmic JJ o
pattern NN o
in IN N
patients NNS p
with IN p
congestive JJ p
heart NN p
failure NN p
. . p

A DT N
double-blind JJ N
multicentre NN N
study NN N
. . N

Ibopamine NNP i
is VBZ N
a DT N
dopaminergic NN N
and CC N
adrenergic JJ N
receptor NN N
agonist NN N
, , N
which WDT N
is VBZ N
active JJ N
in IN N
the DT N
treatment NN N
of IN N
congestive JJ N
heart NN N
failure NN N
. . N

Since IN N
the DT N
long-term JJ N
prognosis NN N
for IN N
patients NNS p
with IN p
congestive JJ p
heart NN p
failure NN p
remains VBZ N
very RB N
poor JJ N
and CC N
the DT N
incidence NN N
of IN N
arrhythmic JJ N
death NN N
is VBZ N
high JJ N
, , N
every DT N
new JJ N
drug NN N
to TO N
be VB N
employed VBN N
against IN N
this DT N
disease NN N
should MD N
be VB N
thoroughly RB N
tested VBN N
in IN N
order NN N
to TO N
rule VB N
out RP N
any DT N
possible JJ N
arrhythmogenic JJ o
action NN o
. . o

This DT N
multicentre NN N
study NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
the DT N
effect NN o
of IN N
ibopamine NN i
versus NN N
placebo NN i
in IN N
double-blind JJ N
conditions NNS N
on IN N
heart NN o
rate NN o
, , o
rhythm NN o
and CC o
electrical JJ o
safety NN o
. . o

Ibopamine NNP i
was VBD i
employed VBN i
at IN i
a DT i
dose NN i
of IN i
100 CD i
mg NN i
t.i.d NN i
. . i

in IN i
97 CD i
patients NNS i
( ( i
aged VBN i
31-83 CD i
years NNS i
) ) i
belonging VBG i
to TO i
NYHA NNP i
class NN i
II NNP i
and CC i
III NNP i
with IN i
congestive JJ i
heart NN i
failure NN i
of IN i
different JJ i
aetiology NN i
, , i
but CC i
without IN i
any DT i
complex JJ i
ventricular NN i
arrhythmias NN i
in IN i
basal NN i
conditions NNS i
( ( i
couplets NNS i
with IN i
R'-R NNP i
less JJR i
than IN i
or CC i
equal JJ i
to TO i
400 CD i
msec NNS i
, , i
ventricular JJ i
tachycardia NN i
, , i
R NNP i
on IN i
T NNP i
phenomena NN i
) ) i
. . p

Using VBG N
a DT N
random JJ N
cross-over NN N
design NN N
the DT N
patients NNS N
were VBD N
submitted VBN N
to TO N
48 CD N
hr NN N
. . N

Holter NNP o
recordings NNS o
in IN i
basal NN i
conditions NNS i
and CC i
following VBG i
7 CD i
days NNS i
of IN i
ibopamine NN i
and CC i
placebo NN i
treatment NN i
. . i

No DT N
influence NN N
on IN N
heart NN o
rhythm NN o
was VBD N
noted VBN N
. . N

No DT N
significant JJ N
variations NNS N
in IN N
maximum JJ o
heart NN o
rate NN o
( ( N
ibopamine JJ N
117.7 CD N
+/- JJ N
20.9 CD N
; : N
placebo NN N
118.1 CD N
+/- JJ N
20.7 CD N
) ) N
, , N
medium JJ o
heart NN o
rate NN o
( ( N
ibopamine JJ N
71.8 CD N
+/- JJ N
10.2 CD N
; : N
placebo NN N
72.6 CD N
+/- JJ N
10.1 CD N
) ) N
or CC N
minimum JJ o
heart NN o
rate NN o
( ( N
ibopamine JJ N
55.3 CD N
+/- JJ N
11.7 CD N
; : N
placebo NN N
54.6 CD N
+/- JJ N
10.6 CD N
) ) N
were VBD N
observed VBN N
. . N

The DT N
mean JJ N
number/hr NN N
. . N

of IN N
ectopic JJ o
supraventricular JJ o
beats NNS o
was VBD N
26.1 CD N
+/- JJ N
61.9 CD N
after IN N
ibopamine NN N
and CC N
21.7 CD N
+/- JJ N
35.8 CD N
after IN N
placebo NN N
( ( N
p JJ N
= NNP N
ns NN N
) ) N
. . N

The DT N
complexity NN N
of IN N
ectopic NN o
supraventricular JJ o
beats NNS o
did VBD N
not RB N
change NN N
. . N

The DT N
mean JJ N
number/hr NN N
. . N

of IN N
ectopic JJ o
ventricular JJ o
beats NNS o
was VBD N
31.1 CD N
+/- JJ N
52.5 CD N
after IN N
ibopamine NN N
and CC N
30.4 CD N
+/- JJ N
57.8 CD N
after IN N
placebo NN N
( ( N
p JJ N
= NNP N
ns NN N
) ) N
. . N

Neither CC N
the DT N
distribution NN N
of IN N
the DT N
patients NNS N
among IN N
Lown JJ o
classification NN o
nor CC o
the DT o
Final NNP o
Score NN o
of IN o
the DT o
Italian JJ o
Lown NNP o
Classification NNP o
( ( N
26.1 CD N
+/- JJ N
18.0 CD N
and CC N
26.6 CD N
+/- JJ N
17.9 CD N
in IN N
the DT N
1st CD N
and CC N
2nd CD N
day NN N
of IN N
monitoring NN N
after IN N
ibopamine NN N
and CC N
25.7 CD N
+/- JJ N
18.6 CD N
and CC N
25.7 CD N
+/- JJ N
18.8 CD N
after IN N
placebo NN N
; : N
p CC N
= NNP N
ns NN N
) ) N
showed VBD N
any DT N
difference NN N
between IN N
active JJ N
treatment NN N
and CC N
placebo NN N
. . N

Similar JJ N
results NNS N
were VBD N
achieved VBN N
when WRB N
the DT N
patients NNS N
were VBD N
sub-divided JJ N
into IN N
subgroups NNS N
according VBG N
to TO N
sequences NNS N
of IN N
treatment NN N
( ( N
basal NN N
-- : N
-- : N
ibopamine NN N
-- : N
-- : N
placebo NN N
and CC N
basal NN N
-- : N
-- : N
placebo NN N
-- : N
-- : N
ibopamine NN N
) ) N
, , N
NYHA NNP N
class NN N
II NNP N
or CC N
III NNP N
, , N
aetiology NN N
of IN N
congestive JJ N
heart NN N
failure NN N
( ( N
dilatative JJ N
cardiomyopathy NN N
, , N
ischemic JJ N
cardiomyopathy NN N
and CC N
other JJ N
aetiologies NNS N
) ) N
, , N
associated VBN N
treatment NN N
with IN N
digitalis NN N
or CC N
diuretics NNS N
and CC N
the DT N
number NN N
and CC N
complexity NN N
of IN N
base NN N
ectopic NN N
ventricular JJ N
beats NNS N
. . N

None NN N
of IN N
the DT N
patients NNS N
experienced VBD N
sustained JJ N
ventricular JJ N
tachycardia NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
400 CD N
WORDS NNP N
) ) N
-DOCSTART- -20590478- O O

A DT N
randomized JJ N
clinical JJ N
trial NN N
of IN N
St. NNP N
John NNP N
's POS N
wort NN N
for IN N
smoking VBG o
cessation NN o
. . o

INTRODUCTION NNP N
St. NNP N
John NNP i
's POS i
wort NN i
( ( i
SJW NNP i
) ) i
is VBZ N
a DT N
widely RB N
used VBN N
herbal JJ N
supplement NN N
. . N

The DT N
predominant JJ N
mechanism NN N
( ( N
s PRP N
) ) N
accounting NN N
for IN N
the DT N
activity NN N
of IN N
SJW NNP i
in IN N
vivo NN N
are VBP N
, , N
however RB N
, , N
unclear JJ N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
efficacy NN N
of IN N
SJW NNP i
for IN N
smoking VBG o
cessation NN o
. . o

METHODS NNP N
We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
blinded VBN N
, , N
placebo-controlled JJ N
, , N
three-arm JJ N
, , N
dose-ranging JJ N
clinical JJ N
trial NN N
. . N

A DT N
total NN N
of IN N
118 CD p
subjects NNS p
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
SJW NNP i
300 CD i
mg NN i
, , i
600 CD i
mg NN i
, , i
or CC i
a DT i
matching JJ i
placebo NN i
tablet NN i
3 CD i
times NNS i
a DT i
day NN i
combined VBN i
with IN i
a DT i
behavioral JJ i
intervention NN i
for IN i
12 CD i
weeks NNS i
. . i

Self-reported JJ N
smoking NN o
abstinence NN o
was VBD N
biochemically RB N
confirmed VBN N
with IN N
expired JJ o
air NN o
carbon NN o
monoxide NN o
. . o

RESULTS NNP N
Mean NNP p
age NN p
of IN p
the DT p
study NN p
participants NNS p
was VBD p
37.6 CD p
+/- JJ p
12.4 CD p
years NNS p
; : p
they PRP p
smoked VBD p
an DT p
average NN p
of IN p
20.0 CD p
+/- JJ p
6.6 CD p
cigarettes NNS p
per IN p
day NN p
for IN p
20 CD p
+/- JJ p
12.1 CD p
years NNS p
. . p

The DT p
study NN p
dropout NN p
rate NN p
was VBD p
high JJ p
( ( p
43 CD p
% NN p
) ) p
. . p

By IN N
intention-to-treat JJ N
analysis NN N
, , N
no DT N
significant JJ N
differences NNS N
were VBD N
observed VBN N
in IN N
abstinence NN o
rates NNS N
at IN N
12 CD N
and CC N
24 CD N
weeks NNS N
between IN N
SJW NNP N
dose VBP N
groups NNS N
and CC N
placebo NN N
. . N

SJW NNP i
did VBD N
not RB N
attenuate VB N
withdrawal NN o
symptoms NNS o
among IN N
abstinent JJ N
subjects NNS N
. . N

Abstinence NN o
rates NNS o
did VBD N
not RB N
differ VB N
by IN N
study NN N
group NN N
among IN N
subjects NNS N
who WP N
took VBD N
at IN N
least JJS N
75 CD N
% NN N
of IN N
their PRP$ N
study NN N
medication NN N
. . N

No DT N
significant JJ N
side-effects NNS N
were VBD N
noted VBN N
with IN N
SJW NNP i
. . i

CONCLUSIONS NNP N
In IN N
this DT N
randomized JJ N
trial NN N
, , N
SJW NNP i
did VBD N
not RB N
increase VB N
smoking VBG N
abstinence JJ o
rates NNS N
. . N

Our PRP$ N
data NNS N
, , N
in IN N
combination NN N
with IN N
data NNS N
from IN N
other JJ N
studies NNS N
, , N
suggest VBP N
that IN N
SJW NNP N
has VBZ N
little JJ N
role NN N
in IN N
the DT N
treatment NN N
of IN N
tobacco NN p
dependence NN p
. . p

-DOCSTART- -20837163- O O

A DT N
web-based JJ i
patient NN i
activation NN i
intervention NN i
to TO N
improve VB N
hypertension NN N
care NN N
: : N
study NN N
design NN N
and CC N
baseline NN N
characteristics NNS N
in IN N
the DT N
web NN N
hypertension NN N
study NN N
. . N

BACKGROUND NNP N
Despite IN N
the DT N
known JJ N
health NN N
risks NNS N
of IN N
hypertension NN N
, , N
many JJ N
hypertensive JJ p
patients NNS p
still RB N
have VBP N
uncontrolled VBN N
blood NN N
pressure NN N
. . N

Clinical JJ N
inertia NN N
, , N
the DT N
tendency NN N
of IN N
physicians NNS N
not RB N
to TO N
intensify VB N
treatment NN N
, , N
is VBZ N
a DT N
common JJ N
barrier NN N
in IN N
controlling VBG N
chronic JJ N
diseases NNS N
. . N

This DT N
trial NN N
is VBZ N
aimed VBN N
at IN N
determining VBG N
the DT N
impact NN N
of IN N
activating VBG N
patients NNS N
to TO N
ask VB N
providers NNS N
to TO N
make VB N
changes NNS N
to TO N
their PRP$ N
care NN N
through IN N
tailored VBN N
feedback NN N
. . N

METHODS NNP N
Diagnosed VBD p
hypertensive JJ p
patients NNS p
were VBD N
enrolled VBN N
in IN N
this DT N
RCT NNP N
and CC N
randomized VBN N
to TO N
one CD N
of IN N
two CD N
study NN N
groups NNS N
: : N
( ( N
1 CD N
) ) N
the DT i
intervention NN i
condition NN i
-- : i
Web-based JJ i
hypertension NN i
feedback NN i
, , i
based VBN i
on IN i
the DT i
individual JJ i
patient NN i
's POS i
self-report NN i
of IN i
health NN i
variables NNS i
and CC i
previous JJ i
BP NNP i
measurements NNS i
, , i
to TO i
prompt VB i
them PRP i
to TO i
ask VB i
questions NNS i
during IN i
their PRP$ i
next JJ i
physician NN i
's POS i
visit NN i
about IN i
hypertension NN i
care NN i
( ( N
2 CD N
) ) N
the DT i
control NN i
condition NN i
-- : i
Web-based JJ i
preventive JJ i
health NN i
feedback NN i
, , i
based VBN i
on IN i
the DT i
individual NN i
's POS i
self-report NN i
of IN i
receiving VBG i
preventive JJ i
care NN i
( ( i
e.g. UH i
, , N
pap JJ i
testing VBG i
) ) i
, , i
to TO i
prompt VB i
them PRP i
to TO i
ask VB i
questions NNS i
during IN i
their PRP$ i
next JJ i
physician NN i
's POS i
visit NN i
about IN i
preventive JJ i
care NN i
. . i

The DT N
primary JJ N
outcome NN N
of IN N
the DT N
study NN N
is VBZ N
change VBN o
in IN o
blood NN o
pressure NN o
and CC o
change NN o
in IN o
the DT o
percentage NN o
of IN o
patients NNS o
in IN o
each DT o
group NN o
with IN o
controlled VBN o
blood NN o
pressure NN o
. . o

CONCLUSION NNP N
Five CD p
hundred VBD p
participants NNS p
were VBD p
enrolled VBN p
and CC p
baseline JJ p
characteristics NNS p
include VBP p
a DT p
mean JJ p
age NN p
of IN p
60.0 CD p
years NNS p
; : p
57.6 CD p
% NN p
female NN p
; : p
and CC p
77.6 CD p
% NN p
white JJ p
. . p

Overall JJ N
37.7 CD p
% NN p
participants NNS p
had VBD p
uncontrolled VBN p
blood NN p
pressure NN p
; : p
the DT p
mean NN p
body NN p
mass NN p
index NN p
( ( p
BMI NNP p
) ) p
was VBD p
in IN p
the DT p
obese JJ p
range NN p
( ( p
32.4 CD p
) ) p
and CC p
21.8 CD p
% NN p
had VBD p
diabetes NNS p
. . p

By IN N
activating VBG N
patients NNS N
to TO N
become VB N
involved VBN N
in IN N
their PRP$ N
own JJ N
care NN N
, , N
we PRP N
believe VBP N
the DT N
addition NN N
of IN N
the DT N
web-based JJ N
intervention NN N
will MD N
improve VB N
blood NN o
pressure NN o
control NN o
compared VBN N
to TO N
a DT N
control NN N
group NN N
who WP N
receive VBP N
web-based JJ N
preventive JJ N
messages NNS N
unrelated VBN N
to TO N
hypertension NN N
. . N

-DOCSTART- -12823129- O O

The DT N
prevalence NN N
of IN N
IgE NNP N
sensitization NN N
to TO N
formaldehyde VB N
in IN N
asthmatic JJ p
children NNS p
. . p

BACKGROUND NNP N
Formaldehyde NNP i
( ( N
FA NNP N
) ) N
is VBZ N
well RB N
documented VBN N
as IN N
a DT N
cause NN N
of IN N
occupational JJ o
asthma NN o
. . o

Recently RB N
, , N
attention NN N
has VBZ N
been VBN N
paid VBN N
to TO N
FA NNP N
as IN N
an DT N
allergen NN N
and CC N
a DT N
pollutant NN N
that WDT N
enhances VBZ o
allergic JJ o
sensitization NN o
. . o

We PRP N
have VBP N
investigated VBN N
the DT N
prevalence NN N
of IN N
FA-specific NNP N
IgE NNP N
in IN N
asthmatic JJ p
children NNS p
and CC N
the DT N
correlation NN N
between IN N
IgE NNP N
sensitization NN N
to TO N
FA NNP N
and CC N
the DT N
severity NN o
of IN o
asthma NN o
. . o

METHODS NNP N
One CD p
hundred CD p
and CC p
fifty-five JJ p
children NNS p
were VBD p
investigated VBN p
, , p
122 CD p
of IN p
them PRP p
asthmatic JJ p
and CC p
33 CD p
nonallergic NN p
. . p

Specific JJ o
IgE NNP o
against IN o
FA NNP o
was VBD N
measured VBN N
by IN N
CAP NNP i
RAST NNP i
. . i

In IN N
addition NN N
, , N
the DT N
patients NNS N
answered VBD N
a DT N
questionnaire NN o
, , N
containing VBG N
questions NNS N
on IN N
clinical JJ o
features NNS o
of IN o
their PRP$ o
asthma NN o
, , o
their PRP$ o
living NN o
conditions NNS o
, , o
and CC o
symptoms NNS o
of IN o
mucosal JJ o
irritation NN o
. . o

RESULTS NNP N
Of IN N
all PDT N
the DT N
subjects NNS N
assessed VBN N
, , N
FA-specific NNP o
IgE NNP o
was VBD N
detected VBN N
in IN N
only RB N
two CD N
asthmatics NNS N
, , N
and CC N
their PRP$ N
IgE NNP N
levels NNS N
of IN N
FA NNP N
were VBD N
low JJ N
( ( N
0.42 CD N
and CC N
0.46 CD N
UA/ml NNP N
) ) N
. . N

One CD N
of IN N
the DT N
two CD N
patients NNS N
with IN N
FA-specific NNP N
IgE NNP N
had VBD N
severe JJ o
asthma NN o
and CC o
frequent JJ o
symptoms NNS o
of IN o
mucosal JJ o
irritation NN o
, , N
but CC N
the DT N
other JJ N
had VBD N
mild VBN o
asthma NNS o
and CC o
only RB o
rare JJ o
symptoms NNS o
of IN o
mucosal JJ o
irritation NN o
. . o

CONCLUSIONS VB N
The DT N
prevalence NN N
of IN N
IgE NNP o
sensitization NN o
to TO N
FA NNP N
appears VBZ N
very RB N
low JJ N
in IN N
Japanese JJ p
children NNS p
, , N
whether IN N
or CC N
not RB N
they PRP N
have VBP N
asthma VBN N
. . N

Therefore RB N
, , N
it PRP N
appears VBZ N
likely JJ N
that IN N
FA NNP N
is VBZ N
not RB N
one CD N
of IN N
the DT N
major JJ N
allergens NNS N
causing VBG N
childhood NN p
asthma NN p
. . N

-DOCSTART- -24147543- O O

Comparative NNP N
study NN N
for IN N
the DT N
effect NN N
of IN N
photodynamic JJ i
therapy NN i
, , i
imiquimod JJ i
immunotherapy NN i
and CC i
combination NN i
of IN i
both DT i
therapies NNS i
on IN N
40 CD p
lesions NNS p
of IN p
actinic JJ p
keratosis NN p
in IN p
Japanese JJ p
patients NNS p
. . p

We PRP N
treated VBD N
12 CD p
, , p
15 CD p
and CC p
13 CD p
Japanese JJ p
actinic JJ p
keratosis NN p
( ( p
AK NNP p
) ) p
lesions NNS p
with IN N
5-aminolevulinic JJ i
acid JJ i
photodynamic JJ i
therapy NN i
( ( i
PDT NNP i
) ) i
, , i
5 CD i
% NN i
imiquimod JJ i
cream NN i
and CC i
combination NN i
of IN i
both DT i
therapies NNS i
, , N
respectively RB N
, , N
and CC N
compared VBN N
the DT N
effects NNS N
. . N

Patients NNS N
underwent VBD N
the DT N
second JJ N
course NN N
, , N
when WRB N
AK NNP N
lesions NNS N
remained VBD N
after IN N
the DT N
first JJ N
course NN N
. . N

Efficacy NNP o
was VBD N
evaluated VBN N
1 CD N
month NN N
after IN N
each DT N
treatment NN N
. . N

Combination NNP i
therapy NN i
cleared VBD N
all DT N
AK NNP N
lesions NNS N
only RB N
after IN N
the DT N
first JJ N
course NN N
, , N
while IN i
PDT NNP i
and CC i
imiquimod JJ i
therapy NN i
cleared VBD N
41.7 CD N
% NN N
and CC N
66.7 CD N
% NN N
of IN N
AK NNP N
lesions NNS N
after IN N
the DT N
first JJ N
course NN N
, , N
respectively RB N
. . N

All DT N
residual JJ N
AK NNP N
lesions NNS N
after IN N
the DT N
first JJ N
course NN N
were VBD o
cleared VBN o
by IN N
the DT N
second JJ N
courses NNS N
of IN i
PDT NNP i
or CC i
imiquimod JJ i
therapy NN i
. . i

During IN N
the DT N
course NN N
, , N
erosion NN o
and CC o
crust NN o
developed VBD N
significantly RB N
more RBR N
frequently RB N
in IN N
combination NN N
therapy NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Most JJS p
Japanese JJ p
AK NNP p
lesions NNS p
can MD p
be VB N
satisfactorily RB N
treated VBN N
with IN N
either DT i
PDT NNP i
or CC i
imiquimod JJ i
monotherapy NN i
. . i

However RB i
, , N
only RB N
severe JJ N
cases NNS N
may MD N
better RB N
be VB N
treated VBN N
with IN i
combination NN i
therapy NN i
, , i
which WDT i
show VBP N
higher JJR N
efficacy NN N
even RB N
though IN N
adverse JJ N
events NNS N
occur VBP N
frequently RB N
. . N

-DOCSTART- -2068469- O O

Aztreonam NNP i
versus NN i
gentamicin NN i
for IN N
short-term JJ N
prophylaxis NN N
in IN N
biliary JJ p
and CC p
gastric JJ p
surgery NN p
. . p

Short-term NNP N
antibiotic JJ N
prophylaxis NN N
was VBD N
studied VBN N
in IN N
80 CD p
patients NNS p
undergoing JJ p
biliary JJ p
or CC p
gastric JJ p
surgery NN p
. . p

The DT N
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
1 CD N
g NN N
of IN N
aztreonam NN i
or CC N
80 CD N
mg NN N
of IN N
gentamicin NN i
intravenously RB N
30 CD N
minutes NNS N
before IN N
surgery NN N
and CC N
8 CD N
and CC N
16 CD N
hours NNS N
after IN N
surgery NN N
. . N

Of IN N
samples NNS N
taken VBN N
from IN N
the DT N
abdominal JJ N
cavity NN N
for IN N
bacteriologic NN N
study NN N
, , N
53 CD N
% NN N
were VBD N
culture NN N
positive JJ N
. . N

Wound IN o
infections NNS o
developed VBN N
in IN N
two CD N
( ( N
4.5 CD N
% NN N
) ) N
of IN N
44 CD N
patients NNS N
receiving VBG N
aztreonam NN i
and CC N
in IN N
seven CD N
( ( N
19.4 CD N
% NN N
) ) N
of IN N
36 CD N
patients NNS N
treated VBN N
with IN N
gentamicin NN i
. . i

Staphylococcus NNP o
epidermidis NN o
and CC o
Enterobacter NNP o
species NNS o
were VBD N
isolated VBN N
from IN N
sites NNS N
of IN N
wound JJ o
infection NN o
in IN N
the DT N
aztreonam JJ i
group NN N
; : N
Escherichia NNP N
coli NNS N
( ( N
two CD N
isolates NNS N
) ) N
, , N
Pseudomonas NNP N
aeruginosa NN N
( ( N
two CD N
isolates NNS N
) ) N
, , N
Enterobacter NNP o
species NNS o
, , o
Klebsiella NNP o
species NNS o
, , o
Enterococcus NNP o
faecalis NN o
, , o
and CC o
Aeromonas NNP o
hydrophila NN o
were VBD N
isolated VBN N
from IN N
the DT N
gentamicin NN N
group NN N
. . N

Our PRP$ N
data NNS N
indicate VBP N
that IN N
aztreonam NN i
is VBZ N
safe JJ o
and CC o
effective JJ o
for IN N
the DT N
prevention NN N
of IN N
infections NNS N
following VBG N
biliary JJ p
and CC p
gastric JJ p
surgery NN p
. . p

-DOCSTART- -3675403- O O

A DT N
randomised JJ N
comparison NN N
of IN N
three CD N
drainage NN N
systems NNS N
following VBG p
cholecystectomy NN p
. . p

The DT N
efficacy NN o
of IN N
low JJ i
pressure NN i
, , i
high JJ i
pressure NN i
and CC i
passive JJ i
drainage NN i
systems NNS i
have VBP N
been VBN N
compared VBN N
after IN p
cholecystectomy NN p
. . p

Symptoms NNS o
of IN o
pain NN o
, , o
discomfort NN o
and CC o
nausea NN o
were VBD N
compared VBN N
using VBG N
linear JJ N
analogue NN N
scales NNS N
and CC N
spirometry NN N
was VBD N
used VBN N
to TO N
examine VB N
pre-operative JJ N
and CC N
postoperative JJ N
respiratory NN o
function NN o
. . o

The DT N
low JJ i
pressure NN i
suction NN i
drain NN i
removed VBD N
an DT N
intraperitoneal NN o
marker NN o
, , o
gentamicin NN o
, , N
more RBR N
effectively RB N
than IN N
the DT N
high JJ i
pressure NN i
suction NN i
drain NN i
, , N
but CC N
not RB N
more RBR N
effectively RB N
than IN N
the DT N
passive JJ i
drain NN i
. . i

There EX N
were VBD N
no DT N
differences NNS N
in IN N
postoperative JJ o
respiratory NN o
function NN o
nor CC N
in IN N
the DT N
amount NN o
of IN o
pain NN o
or CC o
discomfort NN o
between IN N
the DT N
groups NNS N
. . N

The DT N
passive JJ N
drain NN N
group NN N
reported VBD N
less JJR N
nausea NN o
than IN N
the DT N
suction NN N
drain NN N
groups NNS N
. . N

If IN N
a DT N
negative JJ N
pressure NN N
drainage NN N
system NN N
is VBZ N
to TO N
be VB N
used VBN N
, , N
a DT N
low JJ N
pressure NN N
suction NN N
drain NN N
should MD N
be VB N
used VBN N
in IN N
preference NN N
to TO N
a DT N
high JJ N
pressure NN N
system NN N
. . N

-DOCSTART- -24318457- O O

Intraluminal NNP N
exfoliated VBD N
cancer NN N
cells NNS N
and CC N
effectiveness NN N
of IN N
bowel NN N
ligatures NNS N
during IN p
sigmoidectomy NN i
for IN p
sigmoid JJ p
colon NN p
cancer NN p
. . p

PURPOSES NNP N
To TO N
establish VB N
the DT N
efficiency NN N
of IN N
bowel NN N
ligatures NNS N
in IN N
colon NN i
cancer NN i
surgery NN i
, , N
focusing VBG N
on IN N
the DT N
extent NN N
to TO N
which WDT N
exfoliated VBD N
cancer NN N
cells NNS N
are VBP N
shed VBN N
in IN N
the DT N
colonic JJ N
lumen NNS N
during IN N
sigmoidectomy NN i
. . i

METHODS NNP N
Twenty NNP p
consecutive JJ p
patients NNS p
who WP p
underwent VBP p
sigmoidectomy NN i
for IN p
sigmoid JJ p
colon NN p
cancer NN p
were VBD N
prospectively RB N
randomized VBN N
into IN N
two CD N
groups NNS N
: : N
the DT i
ligatures NNS i
group NN i
, , i
in IN i
which WDT i
bowel NN i
ligatures NNS i
were VBD i
placed VBN i
, , i
3 CD i
, , i
5 CD i
, , i
10 CD i
cm NN i
from IN i
the DT i
tumor NN i
proximally RB i
and CC i
distally RB i
before IN i
dissection NN i
; : i
and CC i
the DT i
no DT i
ligatures NNS i
group NN i
, , i
in IN i
which WDT i
the DT i
corresponding NN i
sites NNS i
were VBD i
ligated VBN i
only RB i
immediately RB i
before IN i
taking VBG i
the DT i
specimen NNS i
out RP i
. . i

Each DT N
colonic JJ N
segment NN N
ligated VBD N
was VBD N
irrigated VBN i
with IN i
saline NN i
and CC N
samples NNS N
were VBD N
sent VBN N
for IN N
blind JJ N
cytological JJ N
examination NN N
. . N

RESULTS NNP N
Cancer NNP N
cells NNS N
were VBD N
found VBN N
in IN N
the DT N
colonic NN N
segment NN N
where WRB N
the DT N
tumor NN N
was VBD N
located VBN N
, , N
in IN N
18 CD N
of IN N
20 CD N
samples NNS N
. . N

The DT N
frequency NN o
of IN o
free JJ o
cancer NN o
cells NNS o
decreased VBN N
from IN N
50 CD N
to TO N
0 CD N
% NN N
( ( N
p JJ N
< NNP N
0.04 CD N
) ) N
in IN N
the DT N
distal JJ N
3-5 JJ N
cm NN N
colonic JJ N
segment NN N
and CC N
from IN N
80 CD N
to TO N
20 CD N
% NN N
( ( N
p JJ N
< NNP N
0.03 CD N
) ) N
in IN N
the DT N
proximal JJ N
colonic NN N
segment NN N
after IN N
performing VBG N
bowel NN N
ligatures NNS N
. . N

Free JJ o
cancer NN o
cells NNS o
were VBD N
confirmed VBN N
in IN N
1 CD N
of IN N
10 CD N
samples NNS N
at IN N
both DT N
colonic JJ N
segments NNS N
5-10 JJ N
cm NN N
from IN N
the DT N
tumor NN N
, , N
even RB N
after IN N
bowel NN N
ligatures NNS N
. . N

CONCLUSIONS NNP N
Intraluminal NNP N
exfoliated VBD N
cancer NN N
cells NNS N
could MD N
be VB N
eliminated VBN N
by IN N
placing VBG N
bowel NN N
ligatures NNS N
during IN N
sigmoidectomy NN N
. . N

Measures NNS N
should MD N
be VB N
considered VBN N
to TO N
eliminate VB N
exfoliated JJ N
cancer NN N
cells NNS N
during IN p
colectomy NN p
, , N
even RB N
after IN N
placing VBG N
bowel NN N
ligatures NNS N
. . N

-DOCSTART- -23828383- O O

Serum NNP N
selenium NN i
concentration NN N
and CC N
antioxidant JJ N
activity NN N
in IN N
cervical JJ p
cancer NN p
patients NNS p
before IN p
and CC p
after IN p
treatment NN p
. . p

AIM NNP N
In IN N
the DT N
present JJ N
study NN N
, , N
the DT N
effect NN N
of IN N
chemo NN N
and CC N
radio NN N
therapies NNS N
on IN N
serum NN N
trace NN N
elements NNS N
content NN N
and CC N
antioxidant JJ o
activity NN o
in IN N
blood NN N
serum NN N
of IN N
cervical JJ p
cancer NN p
patients NNS p
was VBD N
evaluated VBN N
. . N

METHODS NNP N
Among IN N
104 CD p
cervical JJ p
cancer NN p
patients NNS p
selected VBN p
for IN p
the DT p
present JJ p
study NN p
, , p
54 CD p
and CC p
50 CD p
patients NNS p
were VBD p
treated VBN p
with IN p
chemo- JJ i
and CC i
radiotherapy NN i
respectively RB p
. . p

Plasma NNP N
Se NNP N
, , N
Zn NNP N
, , N
Cu NNP N
and CC N
some DT N
enzymatic JJ N
antioxidants NNS N
activities NNS N
were VBD N
estimated VBN N
in IN N
serum NN N
before IN N
and CC N
after IN N
the DT N
treatment NN N
. . N

RESULTS VB N
The DT N
decreased JJ N
levels NNS N
of IN N
serum NN o
trace NN o
elements NNS o
, , o
glutathione NN o
peroxidase NN o
activity NN o
and CC o
total JJ o
antioxidant JJ o
capacity NN o
, , o
and CC o
increased VBD o
malondialdehyde NN o
, , o
glutathion NN o
reductase NN o
was VBD N
observed VBN N
in IN N
cervical JJ p
cancer NN p
patients NNS p
when WRB N
compared VBN N
to TO N
healthy JJ N
controls NNS N
. . N

The DT N
increased JJ N
concentration NN o
of IN o
serum NN o
Se NNP o
, , o
Zn NNP o
was VBD N
observed VBN N
in IN N
patients NNS p
treated VBN p
with IN p
chemotherapy NN i
. . i

Simultaneously RB N
there EX N
was VBD N
a DT N
significant JJ N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
increase NN N
in IN N
glutathione JJ o
peroxidase NN o
and CC o
total JJ o
antioxidant JJ o
capacity NN o
, , N
and CC N
significant JJ N
decrease NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
in IN N
malondialdehyde NN o
and CC o
glutathion NN o
reductase NN o
levels NNS o
in IN N
the DT N
serum NN N
of IN N
patients NNS N
treated VBN N
with IN N
chemotherapy NN i
compared VBN N
to TO N
the DT N
patients NNS N
treated VBN N
with IN N
radiotherapy NN i
. . i

CONCLUSION VB N
The DT N
results NNS N
demonstrated VBD N
that IN N
chemotherapy NN i
but CC N
not RB N
radiotherapy JJ i
results NNS N
in IN N
significant JJ N
increase NN N
in IN N
the DT N
trace NN o
elements NNS o
levels NNS o
and CC o
antioxidant JJ o
activities NNS o
in IN N
blood NN N
serum NN N
of IN N
cervical JJ p
cancer NN p
patients NNS p
. . p

-DOCSTART- -9449870- O O

Randomised VBN N
community-based JJ N
trial NN N
of IN N
annual JJ N
single-dose JJ N
diethylcarbamazine NN i
with IN N
or CC N
without IN N
ivermectin NN i
against IN N
Wuchereria NNP p
bancrofti JJ p
infection NN p
in IN p
human JJ p
beings NNS p
and CC p
mosquitoes NNS p
. . p

BACKGROUND NNP N
WHO NNP N
has VBZ N
targeted VBN N
lymphatic JJ N
filariasis NN N
for IN N
elimination NN N
. . N

Studies NNS N
of IN N
vector-parasite JJ N
relations NNS N
of IN N
Wuchereria NNP N
bancrofti NN N
suggest VBP N
that IN N
a DT N
reduction NN N
in IN N
the DT N
microfilarial JJ N
reservoir NN N
by IN N
mass NN N
chemotherapy NN i
may MD N
interrupt VB N
transmission NN N
and CC N
thereby RB N
eliminate VB N
infection NN N
. . N

However RB N
, , N
no DT N
field NN N
data NNS N
exist VBP N
on IN N
the DT N
impact NN N
of IN N
chemotherapy NN N
alone RB N
on IN N
vector NN N
efficiency NN N
and CC N
transmission NN N
intensity NN N
of IN N
W NNP N
bancrofti NN N
. . N

We PRP N
compared VBN N
the DT N
impact NN N
of IN N
an DT N
annual JJ i
community-wide JJ i
single-dose JJ i
treatment NN i
with IN i
diethylcarbamazine JJ i
alone NN i
or CC i
with IN i
ivermectin JJ i
on IN N
rate NN N
and CC N
intensity NN N
of IN N
microfilaraemia NN N
, , N
and CC N
transmission NN N
intensity NN N
in IN N
an DT N
area NN N
of IN N
Papua NNP N
New NNP N
Guinea NNP N
endemic VBZ N
for IN N
intense JJ N
W NNP N
bancrofti NN N
transmission NN N
. . N

METHODS NNP N
We PRP N
carried VBD N
out RP N
clinical JJ N
and CC N
parasitological JJ N
surveys NNS N
in IN N
14 CD p
communities NNS p
in IN p
matched JJ p
pairs NNS p
. . p

People NNS p
aged VBD p
5 CD p
years NNS p
or CC p
older JJR p
in IN p
seven CD p
communities NNS p
received VBD p
randomly RB p
assigned VBN p
diethylcarbamazine NN i
6 CD p
mg/kg NN p
and CC p
people NNS p
in IN p
the DT p
other JJ p
seven CD p
communities NNS p
received VBD N
diethylcarbamazine JJ i
6 CD N
mg/kg NN N
plus CC N
ivermectin JJ i
400 CD N
micrograms/kg NN N
. . N

We PRP N
made VBD N
physical JJ N
examinations NNS N
for IN N
hydroceles NNS N
and CC N
leg NN N
oedema NN N
and CC N
investigated JJ N
microfilarial JJ N
densities NNS N
by IN N
membrane NN N
filtration NN N
before IN N
and CC N
after IN N
treatment NN N
. . N

We PRP N
selected VBD N
five CD p
communities NNS p
for IN N
monthly JJ N
entomological JJ N
surveys NNS N
between IN N
September NNP N
, , N
1993 CD N
, , N
and CC N
September NNP N
, , N
1995 CD N
. . N

Mosquitoes NNS N
were VBD N
collected VBN N
in IN N
these DT N
communities NNS N
by IN N
the DT N
all-night JJ N
landing NN N
catch NN N
method NN N
and CC N
were VBD N
individually RB N
dissected VBN N
to TO N
identify VB N
rates NNS N
of IN N
infection NN N
and CC N
infectiveness NN N
. . N

FINDINGS JJ N
2219 CD p
( ( p
87.6 CD p
% NN p
) ) p
of IN p
2534 CD p
eligible JJ p
people NNS p
received VBD p
treatment NN p
. . p

Microfilarial JJ o
rate NN o
and CC o
density NN o
had VBD N
decreased VBN N
1 CD N
year NN N
after IN N
treatment NN N
in IN N
all DT N
14 CD N
communities NNS N
; : N
this DT N
decrease NN N
was VBD N
significantly RB N
higher JJR N
in IN N
communities NNS N
given VBN N
combined VBD N
therapy NN N
than IN N
in IN N
those DT N
given VBN N
diethylcarbamazine VBP i
alone RB N
( ( N
mean JJ N
decreases VBZ N
57.5 CD N
% NN N
and CC N
30.6 CD N
% NN N
, , N
respectively RB N
; : N
p VB N
= $ N
0.0013 CD N
) ) N
. . N

Greater NNP N
decreases NNS N
were VBD N
also RB N
seen VBN N
in IN N
community-specific JJ o
microfilarial JJ o
intensity NN o
with IN N
combined JJ N
therapy NN N
( ( N
mean JJ N
reductions NNS N
91.1 CD N
% NN N
and CC N
69.8 CD N
% NN N
, , N
respectively RB N
; : N
p VB N
= $ N
0.0047 CD N
) ) N
. . N

The DT N
rate NN o
of IN o
leg NN o
oedema NN o
was VBD N
not RB N
altered VBN N
, , N
but CC N
the DT N
frequency NN o
of IN o
advanced JJ o
hydroceles NNS o
decreased VBN N
by IN N
47 CD N
% NN N
with IN N
combined JJ N
therapy NN N
and CC N
56 CD N
% NN N
with IN N
diethylcarbamazine JJ i
alone RB N
. . N

26,641 CD N
Anopheles NNPS N
punctulatus NN N
mosquitoes NNS N
were VBD N
caught VBN N
during IN N
499 CD N
person-nights NNS N
of IN N
landing VBG N
catches NNS N
. . N

Exposure NN o
to TO o
infective VB o
third-stage NN o
larvae NN o
decreased VBN N
in IN N
all DT N
monitored JJ N
five CD N
communities NNS N
. . N

Annual JJ o
transmission NN o
potential NN o
decreased VBN N
by IN N
between IN N
75.7 CD N
% NN N
and CC N
98.8 CD N
% NN N
in IN N
combined-therapy JJ N
communities NNS N
and CC N
between IN N
75.6 CD N
% NN N
and CC N
79.4 CD N
% NN N
in IN N
communities NNS N
given VBN N
diethylcarbamazine JJ N
alone RB N
. . N

Transmission NN N
was VBD N
almost RB N
interrupted VBN N
in IN N
two CD N
communities NNS N
treated VBN N
with IN N
combined JJ N
therapy NN N
. . N

INTERPRETATION NNP N
Annual JJ i
single-dose JJ i
community-wide JJ i
treatment NN i
with IN i
diethylcarbamazine JJ i
alone NN i
or CC i
with IN i
ivermectin NN i
is VBZ N
effective JJ o
for IN N
the DT N
control NN N
of IN N
lymphatic JJ N
filariasis NN N
in IN N
highly RB N
endemic JJ N
areas NNS N
, , N
but CC N
combination NN N
therapy NN N
brings VBZ N
about IN N
greater JJR N
decreases NNS N
in IN N
rates NNS o
and CC o
intensity NN o
of IN o
microfilaraemia NN o
. . o

-DOCSTART- -15477492- O O

Recurrent JJ o
tuberculosis NN o
in IN p
the DT p
United NNP p
States NNPS p
and CC p
Canada NNP p
: : p
relapse NN N
or CC N
reinfection NN N
? . N
Recurrence NN o
of IN o
active JJ o
tuberculosis NN o
after IN p
treatment NN p
can MD N
be VB N
due JJ N
to TO N
relapse VB N
of IN N
infection NN N
with IN N
the DT N
same JJ N
strain NN N
or CC N
reinfection NN N
with IN N
a DT N
new JJ N
strain NN N
of IN N
Mycobacterium NNP N
tuberculosis NN N
. . N

The DT N
proportion NN N
of IN N
recurrent JJ o
tuberculosis NN o
cases NNS o
caused VBN N
by IN N
reinfection NN o
has VBZ N
varied VBN N
widely RB N
in IN N
previous JJ N
studies NNS N
. . N

We PRP N
evaluated VBD N
cases NNS N
of IN N
recurrent JJ o
tuberculosis NN o
in IN N
two CD N
prospective JJ N
clinical JJ N
trials NNS N
: : N
a DT N
randomized JJ N
study NN N
of IN N
two CD N
regimens NNS N
for IN N
the DT N
last JJ N
4 CD N
months NNS N
of IN N
treatment NN N
( ( p
n JJ p
= NNP p
1,075 CD p
) ) p
and CC N
a DT N
study NN N
of IN N
a DT N
twice-weekly JJ N
rifabutin-containing JJ i
regimen NNS i
for IN N
human JJ p
immunodeficiency NN p
virus-infected JJ p
tuberculosis NN p
( ( p
n JJ p
= NNP p
169 CD p
) ) p
. . p

Isolates VBZ N
at IN N
diagnosis NN N
and CC N
from IN N
positive JJ N
cultures NNS N
after IN N
treatment NN N
completion NN N
underwent NN N
genotyping VBG N
using VBG N
IS6110 NNP N
( ( N
with IN N
secondary JJ N
genotyping NN N
for IN N
isolates NNS N
with IN N
less JJR N
than IN N
six CD N
copies NNS N
of IN N
IS6110 NNP N
) ) N
. . N

Of IN N
85 CD p
patients NNS p
having VBG p
a DT p
positive JJ p
culture NN p
after IN p
completing VBG p
treatment NN p
, , N
6 CD N
( ( N
7.1 CD N
% NN N
) ) N
were VBD N
classified VBN N
as IN N
false-positive JJ N
cultures NNS N
by IN N
a DT N
review NN N
committee NN N
blinded VBD N
to TO N
treatment NN N
assignment NN N
. . N

Of IN N
the DT N
remaining VBG N
75 CD N
cases NNS N
with IN N
recurrent JJ N
tuberculosis NN N
and CC N
genotyping VBG N
data NNS N
available JJ N
, , N
72 CD N
( ( N
96 CD N
% NN N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
88.8-99.2 CD N
% NN N
) ) N
paired VBD N
isolates NNS N
had VBD N
the DT N
same JJ N
genotype NN N
; : N
only RB N
3 CD N
( ( N
4 CD N
% NN N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.8-11.2 CD N
% NN N
) ) N
had VBD N
a DT N
different JJ N
genotype NN N
and CC N
were VBD N
categorized VBN N
as IN N
reinfection NN N
. . N

We PRP N
conclude VBP N
that DT N
recurrent NN p
tuberculosis NN p
in IN p
the DT p
United NNP p
States NNPS p
and CC p
Canada NNP p
, , N
countries NNS N
with IN N
low JJ N
rates NNS N
of IN N
tuberculosis NN N
, , N
is VBZ N
rarely RB N
due JJ N
to TO N
reinfection VB N
with IN N
a DT N
new JJ N
strain NN N
of IN N
M. NNP N
tuberculosis NN N
. . N

-DOCSTART- -20726258- O O

[ JJ o
Effect NNP o
analysis NN o
on IN N
non-and-low JJ N
response NN N
infants NNS p
after IN p
revaccinated VBN p
hepatitis NN i
B NNP i
vaccine NN i
] NN i
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
booster NN o
immunization NN o
effect NN o
to TO N
non-and-low JJ N
response NN N
children NNS N
after IN N
3 CD N
doses NNS N
HepB NNP N
immunization NN N
. . N

METHODS NNP N
Non-and-low JJ p
response NN p
infants NNS p
born VBN p
in IN p
2004 CD p
2005 CD p
administered VBD p
3 CD i
doses NNS i
of IN i
HepB NNP i
at IN i
0 CD i
, , i
1 CD i
, , i
6 CD i
months NNS i
in IN i
Guangzhou NNP i
, , i
Beijing NNP i
and CC i
Zhejiang NNP i
were VBD i
divided VBN i
into IN i
4 CD i
groups NNS i
randomly RB i
, , i
and CC i
boosted VBD i
3 CD i
dose NN i
of IN i
4 CD i
different JJ i
types NNS i
of IN i
HepB NNP i
at IN i
0 CD i
, , i
1 CD i
, , i
6 CD i
months NNS i
. . i

RESULTS VB N
The DT N
GMC NNP N
of IN N
non-and-low JJ p
response NN p
children NNS p
in IN N
group NN N
A NNP N
( ( N
before IN N
booster NN N
) ) N
, , N
group NN N
B NNP N
( ( N
after IN N
1 CD N
dose JJ N
booster NN N
) ) N
and CC N
group NN N
C NNP N
( ( N
after IN N
3 CD N
dose JJ N
booster NN N
) ) N
were VBD N
18.66 CD N
mIUml NN N
, , N
88.82 CD N
mIU/ml NN N
, , N
178.24 CD N
mIU/ml NN N
respectively RB N
; : N
the DT N
proportion NN N
of IN N
non-responders NNS N
in IN N
three CD N
groups NNS N
were VBD N
20.4 CD N
% NN N
, , N
9.1 CD N
% NN N
, , N
1.9 CD N
% NN N
respectively RB N
. . N

In IN N
103 CD p
non-and-low JJ p
response NN p
children NNS p
, , N
proportion NN o
of IN o
titers NNS o
of IN N
more JJR N
than IN N
100 CD N
mIU/ml NN N
of IN N
group NN N
B NNP N
and CC N
group NN N
C NNP N
were VBD N
61.2 CD N
% NN N
and CC N
84.5 CD N
% NN N
, , N
and CC N
there RB N
was VBD N
statistical JJ N
significant JJ N
difference NN N
( ( N
chi2 JJ N
= NN N
14.13 CD N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
GMC NNP N
after IN N
3 CD N
doses NNS N
revaccination NN i
with IN N
four CD N
kinds NNS N
of IN N
HepB NNP N
, , N
included VBD N
5 CD N
microg NN N
HepB-Y NNP i
, , N
10 CD N
microg NN N
HepB-Y NNP i
, , N
l0 JJ N
microg NN N
HepB-CHO NNP i
, , N
10 CD N
microg JJ N
HepB-HY NNP i
were VBD N
168.8 CD N
mJU/ml NN N
, , N
174.7 CD N
mIU/ml NN N
, , N
184.9 CD N
mIU/ml NN N
, , N
182.9 CD N
mIU/ml NN N
respectively RB N
. . N

Proportion NN o
of IN o
titers NNS o
of IN N
more JJR N
than IN N
100 CD N
mIU/ml NNS N
for IN N
four CD N
kinds NNS N
HepB NNP N
were VBD N
79.0 CD N
% NN N
, , N
85.7 CD N
% NN N
, , N
88.2 CD N
% NN N
and CC N
84.6 CD N
% NN N
respectively RB N
, , N
and CC N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
( ( N
chi2 JJ N
= NN N
0.75 CD N
, , N
0.05 CD N
) ) N
. . N

CONCLUSION NN N
There EX N
were VBD N
no DT N
different JJ N
of IN N
seroconversion NN o
rate NN o
between IN N
study NN N
population NN N
received VBD N
1 CD N
dose NN N
and CC N
3 CD N
dose JJ N
booster NN N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
, , N
but CC N
high JJ N
titer NN N
was VBD N
observed VBN N
after IN N
3 CD N
dose JJ N
booster NN N
. . N

The DT N
four CD N
kinds NNS N
of IN N
HepB NNP N
, , N
including VBG N
5 CD N
microg JJ N
HepB-Y,10 NNP N
microg NN N
HepB-Y NNP N
, , N
10 CD N
microg NN N
HepB-CHO NNP N
, , N
10 CD N
microg NN N
HepB-HY NNP N
had VBD N
the DT N
same JJ N
immunization NN N
effect NN N
after IN N
3 CD N
doses NNS N
revaccination NN N
at IN N
0 CD N
, , N
1 CD N
, , N
6 CD N
months NNS N
to TO N
non-and-low JJ N
response NN N
children NNS N
. . N

-DOCSTART- -12271298- O O

Efficacy NN o
of IN N
erbium NN i
: : i
yttrium-aluminum-garnet JJ i
laser-assisted JJ i
delivery NN i
of IN N
topical JJ N
anesthetic JJ N
. . N

BACKGROUND NNP N
Penetration NNP N
through IN N
the DT N
stratum NN N
corneum NN N
limits NNS N
effectiveness NN N
of IN N
topical JJ N
anesthetics NNS N
. . N

OBJECTIVE NNP N
Our PRP$ N
aim NN N
was VBD N
to TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
5 CD i
% NN i
lidocaine NN i
( ( i
ELA-Max NNP i
) ) i
cream NN i
applied VBN N
after IN N
erbium NN i
: : i
yttrium-aluminum-garnet NN i
( ( i
Er NNP i
: : i
YAG NN i
) ) i
laser JJR i
ablation NN i
of IN N
the DT N
stratum NN N
corneum NN N
. . N

METHODS NNP N
Randomized NNP N
, , N
controlled VBD N
, , N
split-face JJ N
comparison NN N
of IN N
anesthesia NN N
was VBD N
performed VBN N
on IN N
12 CD p
volunteers NNS p
. . p

The DT N
stratum NN N
corneum NN N
was VBD N
painlessly RB N
ablated VBN N
with IN N
a DT N
low-fluence JJ N
Er NN i
: : i
YAG NNP i
laser NN N
on IN N
half NN N
of IN N
the DT N
face NN N
, , N
then RB N
the DT N
whole JJ N
face NN N
was VBD N
covered VBN N
with IN N
ELA-Max NNP i
cream NN i
for IN N
60 CD N
minutes NNS N
. . N

Full-face NNP N
laser NN N
resurfacing NN N
was VBD N
performed VBN N
, , N
and CC N
visual JJ o
analog NN o
pain NN o
scores NNS o
( ( o
0 CD o
to TO o
10 CD o
) ) o
were VBD N
recorded VBN N
during IN N
each DT N
of IN N
2 CD N
passes NNS N
. . N

RESULTS NNP N
Laser-assisted JJ N
topical JJ N
anesthesia NN N
demonstrated VBD N
significantly RB N
lower JJR N
mean NN o
pain NN o
scores NNS o
than IN N
topical JJ N
anesthesia NN N
alone RB N
. . N

This DT N
was VBD N
more RBR N
pronounced JJ N
during IN N
the DT N
more RBR N
painful JJ N
second JJ N
pass NN N
. . N

Resurfacing VBG N
after IN N
laser-assisted JJ N
topical JJ N
anesthesia NN N
was VBD N
well RB N
tolerated VBN o
by IN N
72 CD N
% NN N
of IN N
subjects NNS N
in IN N
pass NN N
1 CD N
and CC N
58 CD N
% NN N
in IN N
pass NN N
2 CD N
. . N

CONCLUSION NNP N
Laser-assisted JJ i
topical JJ i
anesthesia NN i
is VBZ N
fast RB N
, , N
painless NN N
, , N
and CC N
substantially RB N
more RBR N
effective JJ N
than IN N
conventional JJ N
topical JJ N
anesthesia NN N
but CC N
does VBZ N
not RB N
provide VB N
adequate JJ N
anesthesia NN N
for IN N
full-face NN N
resurfacing NN N
in IN N
all DT N
subjects NNS N
. . N

-DOCSTART- -17548021- O O

Lowering VBG N
of IN N
glucose NN N
in IN N
critical JJ N
care NN N
: : N
a DT N
randomized JJ N
pilot NN N
trial NN N
. . N

BACKGROUND NNP N
Similar NNP N
to TO N
cardiac VB N
surgery NN N
patients NNS N
, , N
medical-surgical JJ p
critically RB p
ill JJ p
patients NNS p
may MD N
benefit VB N
from IN N
intensive JJ i
insulin NN i
therapy NN i
. . i

The DT N
objectives NNS N
of IN N
this DT N
pilot NN N
trial NN N
were VBD N
to TO N
evaluate VB N
the DT N
feasibility NN N
of IN N
a DT N
randomized JJ N
trial NN N
of IN N
intensive JJ i
insulin NN i
therapy NN i
with IN N
respect NN N
to TO N
( ( N
a DT N
) ) N
achieving VBG N
target NN N
glucose JJ N
values NNS N
in IN N
the DT N
2 CD N
ranges NNS N
of IN N
5 CD N
to TO N
7 CD N
and CC N
8 CD N
to TO N
10 CD N
mmol/L NNS N
and CC N
( ( N
b NN N
) ) N
uncovering VBG N
problems NNS N
with IN N
the DT N
protocol NN N
in IN N
anticipation NN N
of IN N
a DT N
larger JJR N
trial NN N
. . N

SETTING VB N
The DT N
trial NN N
was VBD N
conducted VBN N
in IN N
a DT N
15-bed JJ p
medical-surgical JJ p
university-affiliated JJ p
intensive JJ p
care NN p
unit NN p
( ( p
ICU NNP p
) ) p
. . p

METHODS NNP N
We PRP N
included VBD N
patients NNS p
older JJR p
than IN p
18 CD p
years NNS p
, , p
expected VBN p
to TO p
be VB p
in IN p
ICU NNP p
for IN p
more JJR p
than IN p
72 CD p
hours NNS p
, , p
with IN p
a DT p
glucose JJ p
value NN p
of IN p
more JJR p
than IN p
10 CD p
mmol/L NNS p
within IN p
48 CD p
hours NNS p
of IN p
ICU NNP p
admission NN p
. . p

Exclusion NN p
criteria NNS p
were VBD p
diabetic JJ p
ketoacidosis NN p
, , p
severe JJ p
hepatic JJ p
failure NN p
or CC p
hepatic JJ p
resection NN p
, , p
pancreatitis NN p
, , p
glucose NN p
of IN p
less JJR p
than IN p
2.2 CD p
mmol/L NN p
on IN p
admission NN p
to TO p
hospital NN p
, , p
insulin JJ p
infusion NN p
on IN p
admission NN p
to TO p
ICU NNP p
, , p
planned VBD p
withdrawal NN p
of IN p
life NN p
support NN p
, , p
and CC p
inability NN p
to TO p
obtain VB p
informed JJ p
consent NN p
. . p

Patients NNS N
underwent JJ N
concealed JJ i
random NN i
allocation NN i
to TO i
a DT i
target NN i
glucose JJ i
range NN i
of IN i
5 CD i
to TO i
7 CD i
or CC i
8 CD i
to TO i
10 CD i
mmol/L NNS i
using VBG i
pretested JJ i
algorithms NN i
of IN i
insulin NN i
infusions NNS i
. . i

Dedicated VBN N
glucometer JJ N
measurement NN N
of IN N
arterial JJ N
glucose NN N
values NNS N
was VBD N
calibrated VBN N
daily RB N
to TO N
values NNS N
measured VBN N
in IN N
the DT N
laboratory NN N
. . N

RESULTS NNP N
We PRP p
enrolled VBD p
20 CD p
patients NNS p
with IN p
a DT p
mean NN p
( ( p
SD NNP p
) ) p
Acute NNP o
Physiology NNP o
and CC o
Chronic NNP o
Health NNP o
Evaluation NNP o
( ( o
APACHE NNP o
) ) o
II NNP o
score NN o
of IN p
32 CD p
( ( p
10.2 CD p
) ) p
; : p
14 CD p
were VBD p
insulin-dependent JJ p
pre-ICU JJ p
, , p
and CC p
all DT p
were VBD p
medical JJ p
admissions NNS p
. . p

Mean NNP o
glucose JJ o
values NNS o
were VBD N
different JJ N
in IN N
the DT N
2 CD N
groups NNS N
( ( N
7.1 CD N
+/- JJ N
2.6 CD N
vs JJ N
9.4 CD N
+/- JJ N
2.1 CD N
mmol/L NN N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Although IN N
the DT N
intensive JJ i
insulin NN i
therapy NN i
group NN N
had VBD N
more RBR N
glucose JJ o
measurements NNS o
performed VBN N
than IN N
the DT N
control NN N
group NN N
, , N
a DT N
similar JJ N
proportion NN N
of IN N
values NNS N
were VBD N
within IN N
the DT N
target NN N
range NN N
( ( N
682 CD N
[ RB N
42.4 CD N
% NN N
] NN N
of IN N
1607 CD N
values NNS N
in IN N
the DT N
5- JJ N
to TO N
7-mmol/L JJ N
range NN N
; : N
250 CD N
[ $ N
38.7 CD N
% NN N
] NN N
of IN N
660 CD N
values NNS N
in IN N
the DT N
8- JJ N
to TO N
10-mmol/L JJ N
range NN N
, , N
P NNP N
= NNP N
.35 NNP N
) ) N
. . N

Glucose NNP o
values NNS o
of IN N
less JJR N
than IN N
2.5 CD N
mmol/L NN N
developed VBD N
7 CD N
times NNS N
in IN N
5 CD N
patients NNS N
, , N
4 CD N
of IN N
whom WP N
were VBD N
in IN N
the DT N
intensive JJ N
insulin NN i
therapy NN N
group NN N
; : N
however RB N
, , N
no DT N
adverse JJ N
consequences NNS N
were VBD N
documented VBN N
. . N

As IN N
expected VBN N
, , N
there EX N
were VBD N
no DT N
differences NNS N
in IN N
clinically RB N
important JJ N
outcomes NNS N
. . N

CONCLUSIONS NNP N
In IN N
this DT N
pilot JJ N
trial NN N
of IN N
ICU NNP p
patients NNS p
with IN p
high JJ p
illness NN p
severity NN p
, , N
glucose JJ o
values NNS o
were VBD N
in IN N
the DT N
2 CD N
target NN N
ranges VBZ N
only RB N
40 CD N
% NN N
of IN N
the DT N
time NN N
, , N
using VBG N
well-accepted JJ N
initiation NN N
and CC N
maintenance NN N
insulin NN N
infusion NN N
algorithms NN N
. . N

A DT N
large JJ N
randomized JJ N
trial NN N
of IN N
glycemic JJ N
control NN N
is VBZ N
feasible JJ N
in IN N
this DT N
population NN N
to TO N
examine VB N
clinically RB N
important JJ N
outcomes NNS N
, , N
but CC N
will MD N
require VB N
refined JJ N
insulin NN i
algorithms NN N
and CC N
more RBR N
comprehensive JJ N
behavior NN N
change NN N
strategies NNS N
to TO N
achieve VB N
target NN N
values NNS N
. . N

-DOCSTART- -20034362- O O

Effect NN N
of IN N
pravastatin NN i
on IN N
kidney NN o
function NN o
and CC o
urinary JJ o
protein NN o
excretion NN o
in IN N
autosomal JJ p
dominant JJ p
polycystic JJ p
kidney NN p
disease NN p
. . p

OBJECTIVE NNP N
Autosomal NNP p
dominant JJ p
polycystic JJ p
kidney NN p
disease NN p
( ( p
ADPKD NNP p
) ) p
is VBZ N
progressive JJ N
, , N
resulting VBG N
in IN N
end-stage NN p
kidney NN p
failure NN p
in IN p
most JJS p
patients NNS p
. . p

Experimental NNP N
and CC N
clinical JJ N
studies NNS N
have VBP N
suggested VBN N
that IN N
statins NNS i
may MD N
slow VB N
the DT N
progression NN o
of IN o
chronic JJ o
kidney NN o
disease NN o
in IN N
general JJ N
and CC N
ADPKD NNP N
specifically RB N
. . N

MATERIAL NNP N
AND CC N
METHODS NNP N
This DT N
randomized VBD N
open-label JJ N
clinical JJ N
trial NN N
was VBD N
conducted VBN N
to TO N
assess VB N
the DT N
effect NN N
of IN N
pravastatin NN i
20 CD N
mg NN N
on IN N
kidney NN N
function NN N
and CC N
urinary JJ N
protein NN N
excretion NN N
in IN N
patients NNS p
with IN p
ADPKD NNP p
. . p

Sixty CD p
patients NNS p
were VBD p
initially RB p
recruited VBN p
but CC p
49 CD p
of IN p
these DT p
received VBN p
either RB p
pravastatin JJ i
20 CD p
mg NN p
or CC p
no DT i
treatment NN i
for IN p
2 CD p
years NNS p
. . p

Trial JJ N
visits NNS N
were VBD N
conducted VBN N
every DT N
3 CD N
months NNS N
, , N
assessing VBG N
kidney NN o
function NN o
by IN N
estimated VBN N
glomerular JJ o
filtration NN o
rate NN o
and CC o
24 CD o
h NN o
urine JJ o
creatinine NN o
clearance NN o
and CC o
urinary JJ o
protein NN o
excretion NN o
. . o

RESULTS CC N
There EX N
were VBD N
no DT N
significant JJ N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
changes NNS o
in IN N
markers NNS o
of IN o
kidney NN o
function NN o
or CC o
urinary JJ o
protein NN o
excretion NN o
between IN N
groups NNS N
over IN N
the DT N
2 CD N
years NNS N
despite IN N
a DT N
significant JJ N
fall NN N
in IN N
total JJ o
serum NN o
cholesterol NN o
in IN N
pravastatin-treated JJ i
patients NNS N
( ( N
p JJ N
= NNP N
0.029 CD N
) ) N
. . N

CONCLUSION VB N
This DT N
trial NN N
found VBD N
that IN N
taking VBG N
20 CD N
mg NN N
pravastatin NN i
for IN N
2 CD N
years NNS N
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
kidney NN o
function NN o
or CC o
urinary JJ o
protein NN o
excretion NN o
in IN N
patients NNS N
with IN N
ADPKD NNP N
. . N

The DT N
lack NN N
of IN N
statistical JJ N
power NN N
limits VBZ N
the DT N
external JJ N
validity NN N
of IN N
these DT N
findings NNS N
. . N

A NNP N
larger JJR N
, , N
longer JJR N
duration NN N
study NN N
using VBG N
a DT N
higher JJR N
dose NN N
of IN N
a DT N
more RBR N
potent JJ N
statin NN N
is VBZ N
required VBN N
. . N

-DOCSTART- -11832869- O O

Changes NNS N
in IN N
selected VBN N
fitness NN o
parameters NNS o
following VBG N
six CD N
weeks NNS N
of IN N
snowshoe JJ i
training NN i
. . i

BACKGROUND NNP N
Recently RB N
, , N
there EX N
has VBZ N
been VBN N
an DT N
increase NN N
in IN N
popularity NN N
and CC N
participation NN N
in IN N
the DT N
sport NN N
of IN N
snowshoeing VBG i
. . i

While IN N
the DT N
sport NN N
has VBZ N
gained VBN N
considerable JJ N
recognition NN N
, , N
to TO N
date NN N
there EX N
is VBZ N
little JJ N
or CC N
no DT N
scientific JJ N
research NN N
regarding VBG N
training NN o
responses NNS o
to TO N
snowshoeing VBG N
as IN N
a DT N
form NN N
of IN N
exercise NN N
. . N

Therefore RB N
, , N
the DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
snowshoe JJ N
training NN N
could MD N
improve VB N
fitness NN o
measures NNS o
. . o

A DT N
further JJ N
purpose NN N
was VBD N
to TO N
compare VB N
responses NNS N
from IN N
a DT N
snowshoe JJ i
training NN i
program NN i
to TO N
a DT N
similarly RB N
designed VBN N
run RP i
training VBG i
program NN i
. . i

METHODS NNP N
This DT N
prospective JJ N
, , N
comparative JJ N
study NN N
was VBD N
conducted VBN N
with IN N
healthy JJ p
males NNS p
and CC p
females NNS p
between IN p
the DT p
ages NNS p
of IN p
19 CD p
and CC p
24 CD p
. . p

These DT p
subjects NNS p
were VBD p
recruited VBN p
from IN p
the DT p
University NNP p
of IN p
Vermont NNP p
population NN p
and CC p
surrounding VBG p
community NN p
. . p

Following VBG N
baseline NN N
measurements NNS N
in IN N
VO2max NNP o
, , o
running VBG o
time NN o
to TO o
exhaustion NN o
( ( o
RTE NNP o
) ) o
, , o
and CC o
anthropometry NN o
, , N
17 CD p
subjects NNS p
( ( p
10 CD p
snowshoers NNS p
and CC p
7 CD p
runners NNS p
) ) p
participated VBD p
in IN N
a DT N
six CD N
week NN N
conditioning VBG N
program NN N
. . N

Both DT N
groups NNS N
exercised VBD N
for IN N
30 CD N
min NNS N
at IN N
75-85 CD N
% NN N
age NN N
predicted VBD N
maximum JJ N
heart NN N
rate NN N
, , N
3-4 JJ N
times NNS N
per IN N
week NN N
, , N
for IN N
a DT N
total NN N
of IN N
18 CD N
sessions NNS N
. . N

RESULTS NNP N
VO2max NNP o
improved VBD N
significantly RB N
in IN N
both DT N
running NN N
and CC N
snowshoeing VBG N
groups NNS N
, , N
6.3 CD N
and CC N
8.5 CD N
% NN N
, , N
respectively RB N
. . N

Run VB o
time NN o
to TO o
exhaustion NN o
also RB N
improved VBN N
significantly RB N
in IN N
both DT N
groups NNS N
, , N
23.3 CD N
and CC N
33.5 CD N
% NN N
, , N
respectively RB N
. . N

There EX N
were VBD N
no DT N
changes NNS N
in IN N
anthropometry NN o
for IN N
either DT N
group NN N
. . N

With IN N
the DT N
exception NN N
of IN N
RTE NNP o
, , N
there EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
groups NNS N
in IN N
any DT N
other JJ N
measurements NNS N
at IN N
baseline NN N
. . N

CONCLUSIONS NNP N
These DT N
results NNS N
support VBD N
the DT N
acceptability NN N
of IN N
snowshoeing VBG N
as IN N
a DT N
valid JJ N
means NN N
to TO N
improve VB N
or CC N
maintain VB N
cardiovascular JJ o
endurance NN o
. . o

-DOCSTART- -21237718- O O

Triple JJ i
antiretroviral JJ i
compared VBN N
with IN N
zidovudine NN i
and CC N
single-dose JJ N
nevirapine JJ i
prophylaxis NN i
during IN N
pregnancy NN N
and CC N
breastfeeding NN N
for IN N
prevention NN N
of IN N
mother-to-child JJ N
transmission NN N
of IN N
HIV-1 NNP N
( ( N
Kesho NNP N
Bora NNP N
study NN N
) ) N
: : N
a DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Breastfeeding NNP N
is VBZ N
essential JJ N
for IN N
child JJ N
health NN N
and CC N
development NN N
in IN N
low-resource JJ N
settings NNS N
but CC N
carries VBZ N
a DT N
significant JJ N
risk NN N
of IN N
transmission NN N
of IN N
HIV-1 NNP N
, , N
especially RB N
in IN N
late JJ N
stages NNS N
of IN N
maternal JJ N
disease NN N
. . N

We PRP N
aimed VBD N
to TO N
assess VB N
the DT N
efficacy NN o
and CC N
safety NN o
of IN N
triple JJ N
antiretroviral JJ N
compared VBN N
with IN N
zidovudine NN N
and CC N
single-dose JJ N
nevirapine NN N
prophylaxis NN N
in IN N
pregnant JJ p
women NNS p
infected VBN p
with IN p
HIV NNP p
. . p

METHODS NNP N
Pregnant NNP p
women NNS p
with IN p
WHO NNP p
stage VBP p
1 CD p
, , p
2 CD p
, , p
or CC p
3 CD p
HIV-1 JJ p
infection NN p
who WP p
had VBD p
CD4 NNP p
cell NN p
counts NNS p
of IN p
200-500 JJ p
cells NNS p
per IN p
?L NN p
were VBD N
enrolled VBN N
at IN N
five CD N
study NN N
sites NNS N
in IN p
Burkina NNP p
Faso NNP p
, , p
Kenya NNP p
, , p
and CC p
South NNP p
Africa NNP p
to TO p
start VB p
study VB p
treatment NN p
at IN p
28-36 JJ p
weeks NNS p
' POS p
gestation NN p
. . p

Women NNS N
were VBD N
randomly RB N
assigned VBN N
( ( N
1:1 CD N
) ) N
by IN N
a DT N
computer NN N
generated VBD N
random JJ N
sequence NN N
to TO N
either DT N
triple JJ N
antiretroviral JJ N
prophylaxis NN N
( ( N
a DT N
combination NN N
of IN N
300 CD N
mg NNS i
zidovudine NN i
, , i
150 CD N
mg NN i
lamivudine NN i
, , i
and CC N
400 CD N
mg NN i
lopinavir NN i
plus CC i
100 CD N
mg NN i
ritonavir NN i
twice RB N
daily RB N
until IN N
cessation NN N
of IN N
breastfeeding VBG N
to TO N
a DT N
maximum NN N
of IN N
6?5 CD N
months NNS N
post RB N
partum VBP N
) ) N
or CC N
zidovudine NN i
and CC i
single-dose JJ i
nevirapine NN i
( ( i
300 CD N
mg NN N
zidovudine NN i
twice RB i
daily RB N
until IN N
delivery NN N
and CC N
a DT N
dose NN N
of IN N
600 CD N
mg NNS N
zidovudine JJ i
plus CC i
200 CD N
mg JJ N
nevirapine NN i
at IN i
the DT N
onset NN N
of IN N
labour NN N
and CC N
, , N
after IN N
a DT N
protocol NN N
amendment NN N
in IN N
December NNP N
, , N
2006 CD N
, , N
1 CD N
week NN N
post-partum JJ i
zidovudine NN i
300 CD i
mg NN N
twice RB N
daily RB N
and CC N
lamivudine VB N
150 CD N
mg JJ N
twice RB N
daily RB N
) ) N
. . N

All DT p
infants NNS p
received VBD p
a DT N
0?6 CD N
mL NN N
dose NN N
of IN N
nevirapine NN i
at IN i
birth NN N
and CC N
, , N
from IN N
December NNP N
, , N
2006 CD N
, , N
4 CD N
mg/kg NN N
twice RB N
daily RB N
of IN N
zidovudine NN N
for IN N
1 CD N
week NN N
after IN N
birth NN N
. . N

Patients NNS N
and CC N
investigators NNS N
were VBD N
not RB N
masked VBN N
to TO N
treatment NN N
. . N

The DT N
primary JJ N
endpoints NNS N
were VBD o
HIV-free JJ o
infant JJ o
survival NN o
at IN o
6 CD N
weeks NNS N
and CC N
12 CD N
months NNS o
; : o
HIV-free NNP o
survival NN o
at IN o
12 CD N
months NNS N
in IN N
infants NNS N
who WP N
were VBD N
ever RB N
breastfed VBN o
; : o
AIDS-free JJ o
survival NN o
in IN o
mothers NNS N
at IN N
18 CD N
months NNS N
; : N
and CC N
serious JJ o
adverse JJ o
events NNS o
in IN o
mothers NNS N
and CC N
babies NNS o
. . o

Analysis NN o
was VBD N
by IN N
intention NN N
to TO N
treat VB N
. . N

This DT N
trial NN N
is VBZ N
registered VBN N
with IN N
Current NNP N
Controlled NNP N
Trials NNP N
, , N
ISRCTN71468401 NNP N
. . N

FINDINGS NNP p
From IN p
June NNP p
, , p
2005 CD p
, , p
to TO p
August NNP p
, , p
2008 CD p
, , p
882 CD p
women NNS p
were VBD p
enrolled VBN p
, , p
824 CD p
of IN N
whom WP N
were VBD N
randomised VBN N
and CC N
gave VBD N
birth NN N
to TO N
805 CD p
singleton NN p
or CC p
first JJ p
, , p
liveborn JJ p
infants NNS p
. . p

The DT p
cumulative JJ o
rate NN o
of IN o
HIV NNP o
transmission NN o
at IN o
6 CD N
weeks NNS N
was VBD N
3?3 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
1?9-5?6 CD N
% NN N
) ) N
in IN N
the DT N
triple JJ N
antiretroviral JJ N
group NN N
compared VBN N
with IN N
5?0 CD N
% NN N
( ( N
3?3-7?7 CD i
% NN i
) ) i
in IN i
the DT i
zidovudine NN i
and CC i
single-dose JJ i
nevirapine NN i
group NN i
, , i
and CC i
at IN N
12 CD N
months NNS N
was VBD N
5?4 CD N
% NN N
( ( N
3?6-8?1 CD N
% NN N
) ) N
in IN N
the DT N
triple JJ N
antiretroviral JJ N
group NN N
compared VBN N
with IN N
9?5 CD N
% NN N
( ( N
7?0-12?9 CD N
% NN N
) ) N
in IN i
the DT i
zidovudine NN i
and CC N
single-dose JJ N
nevirapine NN i
group NN i
( ( N
p=0?029 NN N
) ) N
. . N

The DT N
cumulative JJ o
rate NN o
of IN o
HIV NNP o
transmission NN o
or CC o
death NN o
at IN o
12 CD o
months NNS N
was VBD N
10?2 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
7?6-13?6 CD N
% NN N
) ) N
in IN N
the DT N
triple JJ N
antiretroviral JJ N
group NN N
compared VBN N
with IN N
16?0 CD N
% NN N
( ( N
12?7-20?0 CD N
% NN N
) ) N
in IN N
the DT N
zidovudine NN i
and CC i
single-dose JJ i
nevirapine NN i
group NN i
( ( i
p=0?017 NN i
) ) N
. . N

In IN N
infants NNS N
whose WP$ N
mothers NNS N
declared VBD N
they PRP N
intended VBD N
to TO N
breastfeed VB N
, , N
the DT o
cumulative JJ o
rate NN o
of IN o
HIV NNP o
transmission NN o
at IN o
12 CD N
months NNS N
was VBD N
5?6 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
3?4-8?9 CD N
% NN N
) ) N
in IN N
the DT N
triple JJ N
antiretroviral JJ N
group NN N
compared VBN N
with IN N
10?7 CD N
% NN N
( ( N
7?6-14?8 CD N
% NN N
) ) N
in IN N
the DT i
zidovudine NN i
and CC i
single-dose JJ i
nevirapine NN i
group NN i
( ( o
p=0?02 NN o
) ) o
. . o

AIDS-free JJ o
survival NN o
in IN N
mothers NNS N
at IN N
18 CD N
months NNS N
will MD N
be VB N
reported VBN N
in IN N
a DT N
different JJ N
publication NN N
. . N

The DT o
incidence NN o
of IN o
laboratory NN o
and CC o
clinical JJ o
serious JJ o
adverse JJ o
events NNS o
in IN o
both DT o
mothers NNS N
and CC N
their PRP$ N
babies NNS N
was VBD N
similar JJ N
between IN N
groups NNS N
. . N

INTERPRETATION NNP N
Triple NNP N
antiretroviral JJ N
prophylaxis NN N
during IN N
pregnancy NN N
and CC N
breastfeeding NN N
is VBZ N
safe JJ o
and CC o
reduces VBZ o
the DT o
risk NN o
of IN o
HIV NNP o
transmission NN o
to TO o
infants NNS o
. . o

Revised VBN N
WHO WP N
guidelines NNS N
now RB N
recommend VBP N
antiretroviral JJ N
prophylaxis NN N
( ( N
either DT N
to TO N
the DT N
mother NN N
or CC N
to TO N
the DT N
baby NN N
) ) N
during IN N
breastfeeding VBG N
if IN N
the DT N
mother NN N
is VBZ N
not RB N
already RB N
receiving VBG N
antiretroviral JJ N
treatment NN N
for IN N
her PRP$ N
own JJ N
health NN N
. . N

FUNDING NN N
Agence NNP N
nationale NN N
de IN N
recherches NNS N
sur VBP N
le JJ N
sida NN N
et NN N
les VBZ N
h?patites NNS N
virales NNS N
, , N
Department NNP N
for IN N
International NNP N
Development NNP N
, , N
European NNP N
and CC N
Developing NNP N
Countries NNP N
Clinical NNP N
Trials NNP N
Partnership NNP N
, , N
Thrasher NNP N
Research NNP N
Fund NNP N
, , N
Belgian JJ N
Directorate NNP N
General NNP N
for IN N
International NNP N
Cooperation NNP N
, , N
Centers NNPS N
for IN N
Disease NNP N
Control NNP N
and CC N
Prevention NNP N
, , N
Eunice NNP N
Kennedy NNP N
Shriver NNP N
National NNP N
Institute NNP N
of IN N
Child NNP N
Health NNP N
and CC N
Human NNP N
Development NNP N
, , N
and CC N
UNDP/UNFPA/World NNP N
Bank/WHO NNP N
Special NNP N
Programme NNP N
of IN N
Research NNP N
, , N
Development NNP N
and CC N
Research NNP N
Training NNP N
in IN N
Human NNP N
Reproduction NNP N
. . N

-DOCSTART- -12642847- O O

Acute NNP N
and CC N
subchronic JJ N
effects NNS N
of IN N
levocetirizine NN i
and CC i
diphenhydramine NN i
on IN N
memory NN o
functioning NN o
, , o
psychomotor NN o
performance NN o
, , N
and CC N
mood NN o
. . o

BACKGROUND NNP N
Central NNP N
nervous JJ N
system NN N
adverse JJ N
effects NNS N
, , N
such JJ N
as IN N
sedation NN o
, , N
often RB N
accompany VBZ N
the DT N
use NN N
of IN N
first-generation NN N
antihistamines NNS N
. . N

These DT N
effects NNS N
might MD N
interfere VB N
with IN N
memory NN N
functioning NN N
and CC N
psychomotor NN N
performance NN N
. . N

Levocetirizine NNP i
was VBD N
recently RB N
introduced VBN N
as IN N
a DT N
new JJ N
antihistamine NN N
said VBD N
to TO N
be VB N
free JJ N
from IN N
sedative JJ N
effects NNS N
. . N

OBJECTIVE IN N
We PRP N
sought VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
levocetirizine NN i
( ( N
5 CD N
mg NN N
) ) N
, , N
diphenhydramine NN i
( ( N
50 CD N
mg NN N
) ) N
, , N
and CC i
placebo NN i
on IN N
memory NN o
and CC o
psychomotor NN o
performance NN o
after IN N
acute JJ N
( ( N
day NN N
1 CD N
) ) N
and CC N
subchronic JJ N
( ( N
day NN N
4 CD N
) ) N
daily JJ N
administration NN N
in IN N
48 CD p
healthy JJ p
volunteers NNS p
( ( p
24 CD p
men NNS p
and CC p
24 CD p
women NNS p
) ) p
. . p

METHODS NNP N
This DT N
study NN N
was VBD N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
randomized JJ N
clinical JJ N
trial NN N
. . N

Treatments NNS N
were VBD N
administrated VBN N
on IN N
days NNS N
1 CD N
, , N
2 CD N
, , N
3 CD N
, , N
and CC N
4 CD N
, , N
3 CD N
hours NNS N
before IN N
the DT N
start NN N
of IN N
the DT N
laboratory JJ N
test NN N
battery NN N
( ( N
performed VBN N
on IN N
days NNS N
1 CD N
and CC N
4 CD N
) ) N
, , N
comprising VBG N
a DT N
word-learning JJ N
test NN N
, , N
the DT N
Sternberg NNP N
Memory NNP N
Scanning NNP N
Test NNP N
, , N
a DT N
tracking VBG N
test NN N
( ( N
easy JJ N
and CC N
hard JJ N
version NN N
) ) N
, , N
and CC N
a DT N
divided JJ N
attention NN N
test NN N
( ( N
tracking VBG N
and CC N
memory NN N
scanning VBG N
simultaneously RB N
) ) N
. . N

Statistical JJ N
analyses NNS N
were VBD N
performed VBN N
separately RB N
for IN N
days NNS N
1 CD N
and CC N
4 CD N
by IN N
using VBG N
analysis NN N
of IN N
variance NN N
. . N

RESULTS VB N
On IN N
day NN N
1 CD N
, , N
diphenhydramine NN i
significantly RB N
impaired VBD N
tracking VBG o
performance NN o
( ( N
easy JJ N
: : N
F NNP N
( ( N
1,90 CD N
) ) N
= NN N
25.9 CD N
, , N
P NNP N
< NNP N
.0001 NNP N
; : N
hard JJ N
: : N
F NNP N
( ( N
1,90 CD N
) ) N
= NN N
20.5 CD N
, , N
P NNP N
< NNP N
.0001 NNP N
) ) N
and CC N
divided VBN o
attention NN o
( ( N
tracking VBG N
: : N
F NNP N
( ( N
1,90 CD N
) ) N
= NN N
23.8 CD N
, , N
P NNP N
< NNP N
.0001 NNP N
; : N
memory NN o
scanning NN o
: : o
F NNP N
( ( N
1,90 CD N
) ) N
= NN N
22.0 CD N
, , N
P NNP N
< NNP N
.0001 NNP N
) ) N
. . N

Results NNS N
on IN N
word-learning JJ o
tests NNS o
and CC o
Sternberg NNP o
Memory NNP o
Scanning VBG o
Tests NNS o
were VBD N
not RB N
significantly RB N
impaired VBN N
. . N

On IN N
day NN N
4 CD N
, , N
the DT N
effects NNS N
of IN N
diphenhydramine NN i
did VBD N
not RB N
reach VB N
significance NN N
. . N

In IN N
contrast NN N
, , N
on IN N
both DT N
days NNS N
1 CD N
and CC N
4 CD N
, , N
levocetirizine NN i
did VBD N
not RB N
significantly RB N
impair JJ N
laboratory JJ o
test NN o
performance NN o
. . o

CONCLUSION NNP N
The DT N
results NNS N
show VBP N
that IN N
memory NN o
, , o
attention NN o
, , o
and CC o
tracking VBG o
performance NN o
are VBP N
unaffected VBN N
after IN N
acute NN N
and CC N
subchronic JJ N
administration NN N
of IN N
levocetirizine NN i
( ( N
5 CD N
mg NN N
) ) N
, , N
whereas JJ N
diphenhydramine NN i
( ( N
50 CD N
mg NN N
) ) N
significantly RB N
affected VBD N
divided JJ o
attention NN o
and CC N
tracking NN o
after IN N
acute JJ N
administration NN N
. . N

-DOCSTART- -10442506- O O

Effects NNS N
of IN N
amlodipine NN i
and CC i
enalapril NN i
on IN N
platelet NN o
function NN o
in IN p
patients NNS p
with IN p
mild JJ p
to TO p
moderate VB p
hypertension NN p
. . p

OBJECTIVE CC N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
effect NN N
of IN N
amlodipine NN i
and CC i
enalapril NN i
on IN N
platelet NN o
aggregation NN o
, , o
and CC o
platelet NN o
production NN o
of IN o
malondialdehyde NN o
in IN N
patients NNS p
with IN p
mild JJ p
to TO p
moderate VB p
arterial JJ p
hypertension NN p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
A NNP N
parallel NN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
study NN N
was VBD N
carried VBN N
out RP N
in IN N
24 CD p
patients NNS p
( ( p
2 CD p
groups NNS p
of IN p
12 CD p
patients NNS p
each DT p
) ) p
. . p

Initially RB N
all DT N
patients NNS N
received VBD N
placebo NNS i
for IN N
four CD N
weeks NNS N
; : N
then RB N
amlodipine VB i
, , N
5 CD N
mg JJ N
daily JJ N
or CC i
enalapril JJ i
20 CD N
mg JJ N
daily RB N
taken VBN N
once RB N
a DT N
day NN N
at IN N
7 CD N
am VBP N
. . N

Dosage NN N
was VBD N
doubled VBN N
after IN N
4 CD N
weeks NNS N
when WRB N
diastolic JJ o
blood NN o
pressure NN o
was VBD N
> JJ N
90 CD N
mmHg NN N
in IN N
sitting VBG N
position NN N
, , N
the DT N
treatment NN N
was VBD N
continued VBN N
for IN N
12 CD N
weeks NNS N
. . N

At IN N
the DT N
end NN N
of IN N
placebo NN i
and CC N
active JJ N
phases NNS N
a DT N
platelet NN N
aggregation NN N
test NN N
, , N
using VBG N
adenosine JJ N
diphosphate NN N
, , N
collagen NN N
and CC N
adrenaline NN N
, , N
and CC N
a DT N
platelet NN N
malondialdehyde NN N
production NN N
test NN N
, , N
either RB N
in IN N
basal NN N
conditions NNS N
( ( N
MDA-basal NNP N
) ) N
and CC N
after IN N
the DT N
stimulation NN N
of IN N
arachidonic JJ N
acid NNS N
pathway RB N
by IN N
adding VBG N
ethylmaleimide NN N
( ( N
MDA-activated JJ N
) ) N
were VBD N
carried VBN N
out RP N
. . N

RESULTS VB N
Blood NNP o
pressure NN o
was VBD N
reduced VBN N
by IN N
both DT N
agents NNS N
, , N
enalapril NN i
and CC i
amlodipine NN i
. . i

Enalapril NNP i
controlled VBD N
58.3 CD N
% NN N
of IN N
hypertensive JJ p
patients NNS p
with IN N
an DT N
average JJ N
dosage NN N
of IN N
31.7 CD N
mg/daily RB N
. . N

Amlodipine NNP i
controlled VBD N
75 CD N
% NN N
of IN N
patients NNS N
with IN N
a DT N
dosage NN N
of IN N
7.1 CD N
mg/daily RB N
. . N

Platelet NNP o
aggregation NN o
was VBD N
reduced VBN N
by IN N
amlodipine NN i
in IN N
15.9 CD N
% NN N
for IN N
ADP NNP N
( ( N
10 CD N
microM NN N
) ) N
; : N
17.4 CD N
% NN N
for IN N
collagen NN N
( ( N
2 CD N
microg/ml NN N
) ) N
and CC N
19.9 CD N
% NN N
for IN N
adrenaline NN N
( ( N
2 CD N
microM NN N
) ) N
( ( N
p JJ N
< NNP N
0.025 CD N
) ) N
. . N

Meanwhile RB N
enalapril JJ i
slightly RB N
increased VBN N
platelet NN o
aggregation NN o
by IN N
6.7 CD N
% NN N
, , N
1.3 CD N
% NN N
and CC N
5.6 CD N
% NN N
for IN N
the DT N
three CD N
agents NNS N
, , N
respectively RB N
( ( N
p JJ N
> NN N
0.05 CD N
, , N
ns NN N
) ) N
. . N

Malondialdehyde NNP o
was VBD N
reduced VBN N
by IN N
amlodipine NN i
in IN N
45.33 CD N
% NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
for IN N
MDA-basal NNP o
; : o
3.76 CD N
% NN N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
for IN N
MDA-activated NNP o
; : o
and CC N
the DT N
ratio JJ N
MDA-basal JJ N
: : N
MDA-activated JJ N
in IN N
36.79 CD N
% NN N
( ( N
p JJ N
< NNP N
0.005 CD N
) ) N
. . N

Meanwhile RB N
enalapril JJ i
increased VBD N
MDA-basal NNP o
in IN N
2.89 CD N
% NN N
; : N
MDA-activated NNP o
in IN N
3.58 CD N
% NN N
and CC N
reduced VBD N
the DT N
ratio NN o
MDA-basal JJ o
: : o
MDA-activated JJ o
, , N
in IN N
10.34 CD N
% NN N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
Both DT N
agents NNS N
, , N
enalapril NN i
and CC N
amlodipine NN i
, , N
reduced VBD N
blood NN o
pressure NN o
, , N
but CC N
only RB N
amlodipine VB i
reduced VBN N
platelet JJ o
aggregation NN o
and CC N
platelet NN o
production NN o
of IN o
malondialdehyde NN o
, , N
indicating VBG N
its PRP$ N
action NN N
on IN N
the DT N
arachidonic JJ N
acid NN N
metabolic JJ N
pathway NN N
. . N

-DOCSTART- -15973098- O O

Stapled VBN o
hemorrhoidopexy JJ o
versus NN i
milligan-morgan JJ o
hemorrhoidectomy NN o
: : o
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
multicenter RBR N
trial NN N
with IN N
2-year JJ N
postoperative NN N
follow VB N
up RP N
. . N

PURPOSE VB N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB o
the DT o
outcome NN o
of IN o
stapled JJ o
hemorrhoidopexy NN o
( ( i
SH NNP i
group NN i
) ) i
performed VBD N
using VBG N
a DT N
circular JJ N
stapler NN N
with IN N
that DT N
of IN N
the DT N
Milligan-Morgan NNP i
technique NN i
( ( i
MM NNP i
group NN i
) ) i
. . i

The DT N
goals NNS N
of IN N
the DT N
study NN N
were VBD N
to TO N
evaluate VB N
the DT N
efficacy NN o
and CC o
reproducibility NN o
of IN N
stapled JJ i
hemorrhoidopexy NN i
and CC N
define VB N
its PRP$ N
place NN N
among IN N
conventional JJ N
techniques NNS N
. . N

METHODS VB N
A NNP N
series NN N
of IN N
134 CD p
patients NNS p
were VBD p
included VBN p
at IN p
7 CD p
hospital NN p
centers NNS p
. . p

They PRP N
were VBD N
randomized VBN N
according VBG N
to TO N
a DT N
single-masked JJ N
design NN N
and CC N
stratified VBN N
by IN N
center NN N
( ( N
with IN N
balancing VBG N
every DT N
4 CD N
patients NNS N
) ) N
. . N

Patients NNS N
were VBD N
clinically RB N
evaluated VBN N
preoperatively RB N
and CC N
at IN N
6 CD N
weeks NNS N
, , N
1 CD N
year NN N
, , N
and CC N
a DT N
minimum NN N
of IN N
2 CD N
years NNS N
after IN N
treatment NN N
. . N

Patients NNS N
completed VBD N
a DT N
questionnaire NN i
before IN N
and CC N
1 CD N
year NN N
after IN N
surgery NN N
to TO N
evaluate VB N
symptoms NNS N
, , N
function NN N
, , N
and CC N
overall JJ N
satisfaction NN N
. . N

RESULTS VB N
The DT N
mean JJ N
follow-up JJ N
period NN N
was VBD N
2.21 CD N
years NNS N
+/- JJ N
0.26 CD N
( ( N
1.89-3.07 JJ N
) ) N
. . N

Nine JJ N
patients NNS N
( ( N
7 CD N
% NN N
) ) N
could MD N
not RB N
be VB N
monitored VBN N
at IN N
1 CD N
or CC N
2 CD N
years NNS N
, , N
but CC N
4 CD N
of IN N
these DT N
9 CD N
nevertheless RB N
filled VBN N
in IN N
the DT N
1-year JJ N
questionnaire NN N
. . N

The DT N
patients NNS N
in IN N
the DT N
SH NNP i
group NN N
experienced VBD N
less RBR N
postoperative JJ o
pain/discomfort NN o
as IN N
scored VBN N
by IN N
pain NN o
during IN o
bowel NN o
movement NN o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
total JJ o
analgesic JJ o
requirement NN o
over IN o
the DT o
first JJ o
3 CD o
days NNS o
( ( N
according VBG N
to TO N
the DT N
World NNP N
Health NNP N
Organization NNP N
[ NNP N
WHO NNP N
] NNP N
class NN N
II NNP N
analgesics NNS N
[ VBP N
P NNP N
= NNP N
0.002 CD N
] NNP N
; : N
class NN N
III NNP N
[ NNP N
P NNP N
= VBD N
0.066 CD N
] NN N
) ) N
, , N
and CC N
per-patient JJ N
consumption NN N
frequency NN N
of IN N
class NN N
III NNP N
analgesics NNS N
( ( N
P NNP N
= NNP N
0.089 CD N
) ) N
. . N

A DT N
clear JJ N
difference NN N
in IN N
morphine JJ o
requirement NN o
became VBD N
evident JJ N
after IN N
24 CD N
hours NNS N
( ( N
P NNP N
= NNP N
0.010 CD N
) ) N
. . N

Hospital NNP o
stay NN o
was VBD N
significantly RB N
shorter JJR N
in IN N
the DT N
SH NNP i
group NN N
( ( N
SH NNP N
2.2 CD N
+/- JJ N
1.2 CD N
[ JJ N
0 CD N
; : N
5.0 CD N
] NNP N
versus NN N
MM NNP i
3.1 CD N
+/- JJ N
1.7 CD N
[ JJ N
1 CD N
; : N
8.0 CD N
] NN N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

At IN N
1 CD N
year NN N
, , N
no DT N
differences NNS o
in IN N
the DT N
resolution NN o
of IN o
symptoms NNS o
were VBD N
observed VBN N
between IN N
the DT N
2 CD N
groups NNS N
, , N
and CC N
over IN N
2 CD N
years NNS N
, , N
the DT N
overall JJ o
incidence NN o
of IN o
complications NNS o
was VBD N
the DT N
same JJ N
, , N
specifically RB N
fecaloma JJ o
( ( N
P NNP N
= NNP N
0.003 CD N
) ) N
in IN N
the DT N
MM NNP i
group NN N
and CC N
external JJ o
hemorrhoidal NN o
thrombosis NN o
( ( N
P NNP N
= NNP N
0.006 CD N
) ) N
in IN N
the DT N
SH NNP i
group NN N
. . N

Impaired NNP o
sphincter NN o
function NN o
was VBD N
observed VBN N
at IN N
1 CD N
year NN N
with IN N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
groups NNS N
for IN N
urgency NN N
( ( N
12 CD N
% NN N
) ) N
, , N
continence NN N
problems NNS N
( ( N
10 CD N
% NN N
) ) N
, , N
or CC N
tenesmus NN N
( ( N
3 CD N
% NN N
) ) N
. . N

No DT N
patient NN N
needed VBD N
a DT N
second JJ o
procedure NN o
for IN N
recurrence NN N
within IN N
2 CD N
years NNS N
, , N
although IN N
partial JJ o
residual JJ o
prolapse NN o
was VBD N
detected VBN N
in IN N
4 CD N
SH JJ i
patients NNS N
( ( N
7.5 CD N
% NN N
) ) N
versus NN N
1 CD N
MM NNP i
patient NN N
( ( N
1.8 CD N
% NN N
) ) N
( ( N
P NNP N
= NNP N
0.194 CD N
) ) N
. . N

CONCLUSION NNP N
Stapled VBD i
hemorrhoidopexy JJ i
causes NNS N
significantly RB N
less RBR N
postoperative JJ o
pain NN o
. . o

The DT N
technique NN N
is VBZ N
reproducible JJ N
and CC N
can MD N
achieve VB N
comparable JJ N
outcomes NNS o
as IN N
those DT N
of IN N
the DT N
MM NNP i
technique NN N
as RB N
long RB N
as IN N
the DT N
well-described JJ N
steps NNS N
of IN N
the DT N
technique NN N
are VBP N
followed VBN N
. . N

Like IN N
with IN N
conventional JJ N
surgery NN i
, , N
anorectal JJ o
dysfunction NN o
can MD N
occur VB N
after IN N
stapled JJ i
hemorrhoidopexy NN i
in IN N
some DT N
patients NNS N
. . N

Its PRP$ N
effectiveness NN o
in IN N
relieving VBG N
symptoms NNS N
is VBZ N
equivalent JJ N
to TO N
conventional JJ N
surgery NN N
, , N
and CC N
the DT N
number NN o
of IN o
hemorrhoidal JJ o
prolapse NN o
recurrences NNS o
at IN o
2 CD o
years NNS o
is VBZ N
not RB N
significantly RB N
different JJ N
. . N

Hemorroidopexy NNP i
is VBZ N
applicable JJ N
for IN N
treating VBG N
reducible JJ N
hemorrhoidal JJ N
prolapse NN N
. . N

-DOCSTART- -20167900- O O

A DT N
randomized JJ N
trial NN N
of IN N
tailored JJ N
skin NN N
cancer NN N
prevention NN N
messages NNS N
for IN N
adults NNS p
: : p
Project NN N
SCAPE NNP N
. . N

OBJECTIVES NNP N
We PRP N
evaluated VBD N
the DT N
impact NN N
of IN N
a DT N
mailed VBN i
, , i
tailored VBN i
intervention NN i
on IN N
skin JJ o
cancer NN o
prevention NN N
and CC N
skin JJ o
self-examination NN o
behaviors NNS o
of IN N
adults NNS p
at IN p
moderate JJ p
and CC p
high JJ p
risk NN p
for IN p
skin JJ p
cancer NN p
. . p

METHODS NNP N
Adults NNP p
at IN p
moderate NNP p
and CC p
high JJ p
risk NN p
for IN p
skin JJ p
cancer NN p
were VBD p
recruited VBN p
in IN p
primary JJ p
health NN p
care NN p
settings NNS p
in IN p
Honolulu NNP p
, , p
HI NNP p
, , p
and CC p
Long NNP p
Island NNP p
, , p
NY NNP p
. . p

After IN N
completing VBG N
a DT N
baseline NN N
survey NN N
, , N
participants NNS N
were VBD N
randomized VBN N
to TO N
2 CD N
groups NNS N
. . N

The DT N
treatment NN N
group NN N
received VBD N
tailored JJ i
materials NNS i
, , i
including VBG i
personalized VBN i
risk NN i
feedback NN i
, , N
and CC N
the DT N
control NN i
group NN N
received VBD N
general JJ i
educational JJ i
materials NNS i
. . i

Multivariate NNP N
analyses NNS N
compared VBN N
sun JJ o
protection NN o
and CC N
skin VB o
self-examination NN o
between IN N
groups NNS N
, , N
controlling VBG N
for IN N
location NN N
, , N
risk NN N
level NN N
, , N
gender NN N
, , N
and CC N
age NN N
. . N

RESULTS VB N
A DT p
total NN p
of IN p
596 CD p
adults NNS p
completed VBD p
the DT p
trial NN p
. . p

The DT N
tailored JJ N
materials NNS N
had VBD N
a DT N
significant JJ N
effect NN N
on IN N
overall JJ o
sun-protection NN o
habits NNS o
, , o
the DT o
use NN o
of IN o
hats NNS o
, , o
the DT o
use NN o
of IN o
sunglasses NNS o
, , o
and CC o
the DT o
recency NN o
of IN o
skin JJ o
self-examination NN o
. . o

Some DT N
effects NNS N
were VBD N
moderated VBN N
by IN N
location NN N
and CC N
risk NN N
level NN N
. . N

CONCLUSIONS NNP N
Tailored NNP i
communications NNS i
including VBG N
personalized VBN N
risk NN N
feedback NN N
can MD N
improve VB N
sun-protection NN o
behaviors NNS o
and CC o
skin JJ o
self-examination NN o
among IN N
adults NNS p
at IN p
increased VBN p
risk NN p
for IN p
skin JJ p
cancer NN p
. . p

These DT N
convenient NN N
, , N
low-cost JJ N
interventions NNS N
can MD N
be VB N
implemented VBN N
in IN N
a DT N
variety NN N
of IN N
settings NNS N
and CC N
should MD N
be VB N
tested VBN N
further JJ N
to TO N
assess VB N
their PRP$ N
long-term JJ N
effectiveness NN N
. . N

-DOCSTART- -16379507- O O

Acute NNP o
and CC o
long-term JJ o
safety NN o
and CC o
tolerability NN o
of IN N
risperidone NN i
in IN N
children NNS p
with IN p
autism NN p
. . p

Treatment-emergent JJ N
adverse JJ o
events NNS o
( ( N
AEs NNP N
) ) N
were VBD N
monitored VBN N
during IN N
an DT N
8-week JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
of IN N
risperidone NN i
( ( N
0.5-3.5 JJ N
mg/day NN N
) ) N
in IN N
101 CD p
children NNS p
and CC p
adolescents NNS p
with IN p
a DT p
lifetime JJ p
diagnosis NN p
of IN p
autistic JJ p
disorder NN p
. . p

In IN N
addition NN N
, , N
37 CD N
placebo NN i
nonresponders NNS N
received VBD N
open-label JJ N
risperidone NN i
for IN N
another DT N
8 CD N
weeks NNS N
. . N

Of IN N
all PDT N
the DT N
risperidone NN i
responders NNS N
( ( N
n=65 NN N
) ) N
, , N
63 CD N
entered VBD N
an DT N
open JJ N
extension NN N
of IN N
another DT N
16 CD N
weeks NNS N
( ( N
6 CD N
months NNS N
total JJ N
risperidone NN i
exposure NN N
) ) N
, , N
and CC N
32 CD N
of IN N
them PRP N
were VBD N
rerandomized VBN N
to TO N
either DT N
continued VBN N
risperidone NN i
therapy NN N
( ( N
n=16 JJ N
) ) N
or CC N
gradual JJ N
replacement NN N
with IN N
placebo NN i
( ( N
n=16 JJ N
) ) N
over IN N
8 CD N
weeks NNS N
. . N

We PRP N
collected VBD N
the DT N
following JJ N
measures NNS N
of IN N
safety NN o
and CC o
tolerability NN o
: : o
( ( N
1 CD N
) ) N
laboratory NN o
blood NN o
assessments NNS o
( ( o
CBC NNP o
with IN o
differential JJ o
, , o
electrolytes NNS o
, , o
and CC o
liver JJ o
function NN o
tests NNS o
) ) o
and CC o
urinalyses NNS o
, , N
( ( N
2 CD N
) ) N
vital NN o
signs NNS o
, , N
( ( N
3 CD N
) ) N
Side NNP o
Effects NNP o
Review NNP o
of IN o
AEs NNP o
thought VBD N
to TO N
be VB N
associated VBN N
with IN N
risperidone NN N
, , N
( ( N
4 CD N
) ) N
sleep NN o
records NNS o
, , N
( ( N
5 CD N
) ) N
Simpson NNP o
Angus NNP o
Neurological NNP o
Rating NNP o
Scale NNP o
( ( o
SARS NNP o
) ) o
, , N
( ( N
6 CD N
) ) N
Abnormal NNP o
Involuntary NNP o
Movement NNP o
Scale NNP o
( ( o
AIMS NNP o
) ) o
, , N
and CC N
( ( N
7 CD N
) ) N
height NN o
and CC o
weight NN o
. . o

No DT N
clinically RB N
significant JJ N
changes NNS N
were VBD N
found VBN N
on IN N
the DT N
lab NN N
tests NNS N
. . N

During IN N
the DT N
8-week JJ N
acute JJ N
trial NN N
, , N
the DT N
most RBS N
common JJ N
AEs NNP N
on IN N
the DT N
Side NNP N
Effects NNP N
Review NNP N
, , N
scored VBD N
as IN N
moderate JJ N
or CC N
higher JJR N
, , N
were VBD N
as IN N
follows VBZ N
( ( i
placebo NN i
and CC N
risperidone NN N
, , N
respectively RB N
) ) N
: : N
Somnolence NN o
( ( N
12 CD N
% NN N
and CC N
37 CD N
% NN N
) ) N
, , N
enuresis NN o
( ( N
29 CD N
% NN N
and CC N
33 CD N
% NN N
) ) N
, , N
excessive JJ o
appetite NN o
( ( N
10 CD N
% NN N
and CC N
33 CD N
% NN N
) ) N
, , N
rhinitis NN o
( ( N
8 CD N
% NN N
and CC N
16 CD N
% NN N
) ) N
, , N
difficulty NN o
waking NN o
( ( N
8 CD N
% NN N
and CC N
12 CD N
% NN N
) ) N
, , N
and CC N
constipation NN o
( ( N
12 CD N
% NN N
and CC N
10 CD N
% NN N
) ) N
. . N

Difficulty NN o
falling VBG o
asleep JJ o
and CC o
anxiety NN o
actually RB N
favored VBD N
the DT N
risperidone NN N
condition NN N
at IN N
statistically RB N
significant JJ N
levels NNS N
. . N

The DT N
same JJ N
AEs NNP o
tended VBD N
to TO N
recur VB N
through IN N
6 CD N
months NNS N
of IN N
treatment NN N
, , N
although IN N
often RB N
at IN N
reduced VBN N
levels NNS N
. . N

Using VBG N
Centers NNPS N
for IN N
Disease NNP N
Control NNP N
( ( N
CDC NNP N
) ) N
standardized VBD N
scores NNS N
, , N
both DT N
weight NN o
and CC o
body NN o
mass NN o
index NN o
( ( o
BMI NNP o
) ) o
increased VBD N
with IN N
risperidone NN i
during IN N
the DT N
acute JJ N
trial NN N
( ( N
0.5 CD N
and CC N
0.6 CD N
SDs NNP N
, , N
respectively RB N
, , N
for IN N
risperidone NN i
; : i
0.0 CD N
and CC N
0.1 CD N
SDs NNP N
, , N
respectively RB N
, , N
for IN N
placebo NN i
) ) i
and CC N
into IN N
open-label JJ N
extension NN N
( ( N
0.19 CD N
and CC N
0.16 CD N
SDs NNP N
, , N
respectively RB N
) ) N
, , N
although IN N
the DT N
amount NN N
of IN N
gain NN N
decelerated VBN N
with IN N
time NN N
. . N

Extrapyramidal NNP o
symptoms NNS o
, , N
as IN N
assessed VBN N
by IN N
the DT N
SARS NNP N
, , N
were VBD N
no DT N
more RBR N
common JJ N
for IN N
drug NN N
than IN N
placebo NN i
, , N
although IN N
drooling NN N
was VBD N
reported VBN N
more RBR N
often RB N
in IN N
the DT N
risperidone NN i
group NN N
. . N

There EX N
were VBD N
no DT N
differences NNS N
between IN N
groups NNS N
on IN N
the DT N
AIMS NNP N
. . N

Two CD N
subjects NNS N
had VBD N
seizures NNS o
( ( N
one CD N
taking VBG N
placebo NN i
) ) i
, , N
but CC N
these DT N
were VBD N
considered VBN N
unrelated JJ N
to TO N
active JJ N
drug NN N
. . N

Most JJS N
AEs NNPS N
were VBD N
mild JJ N
to TO N
moderate VB N
and CC N
failed VBD N
to TO N
interfere VB N
with IN N
therapeutic JJ N
changes NNS N
; : N
there EX N
were VBD N
no DT N
unanticipated JJ N
AEs NNP N
. . N

The DT N
side NN N
effects NNS N
of IN N
most JJS N
concern NN N
were VBD N
somnolence NN o
and CC o
weight JJ o
gain NN o
. . o

-DOCSTART- -19396947- O O

The DT N
effect NN N
of IN N
nebivolol JJ i
treatment NN i
on IN N
oxidative JJ o
stress NN o
and CC o
antioxidant JJ o
status NN o
in IN N
patients NNS p
with IN p
cardiac JJ p
syndrome-X NN p
. . p

BACKGROUND NNP N
Free JJ N
radical-mediated JJ N
oxidative JJ N
stress NN N
has VBZ N
been VBN N
implicated VBN N
in IN N
the DT N
etiopathogenesis NN N
of IN N
several JJ N
disorders NNS N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
elucidate VB N
the DT N
effect NN N
of IN N
treatment NN N
with IN N
nebivolol NN i
on IN N
the DT N
metabolic JJ o
state NN o
of IN o
oxidative JJ o
stress NN o
, , N
and CC N
antioxidant JJ N
status NN N
markers NNS N
in IN N
patients NNS p
with IN p
cardiac JJ p
syndrome-X NN p
( ( p
CSX NNP p
) ) p
, , N
additionally RB N
, , N
to TO N
compare VB N
with IN N
the DT N
effect NN N
of IN N
metoprolol NN i
treatment NN i
. . i

METHODS NNP N
Thirty NNP p
patients NNS p
, , p
17 CD p
female NN p
and CC p
13 CD p
male NN p
, , p
with IN p
CSX NNP p
were VBD p
enrolled VBN p
in IN p
the DT p
study NN p
. . p

Nebivolol NNP i
( ( N
5 CD N
mg/day NN N
) ) N
or CC N
metoprolol NN i
( ( N
50 CD N
mg/day NN N
) ) N
was VBD N
administrated VBN N
for IN N
12 CD N
weeks NNS N
. . N

Twelve VB N
hour NN N
fasting VBG N
blood NN o
samples NNS o
, , N
taken VBN N
at IN N
the DT N
initiation NN N
and CC N
on IN N
the DT N
third JJ N
month NN N
of IN N
therapy NN N
, , N
were VBD N
analyzed VBN N
for IN N
the DT N
levels NNS o
of IN o
malondialdehyde NN o
( ( o
MDA NNP o
) ) o
, , o
nitrite+nitrate JJ o
( ( o
NOx NNP o
) ) o
, , o
and CC o
the DT o
activity NN o
of IN o
myeloperoxidase NN o
( ( o
MPO NNP o
) ) o
, , o
superoxide JJ o
dismutase NN o
( ( o
SOD NNP o
) ) o
. . o

No DT N
patient NN N
presented VBD N
additional JJ N
risk NN N
factors NNS N
for IN N
increased JJ N
reactive JJ N
oxygen NN N
species NNS N
levels NNS N
. . N

RESULTS NNP N
Compared VBD N
with IN N
sixteen JJ N
control NN N
participants NNS N
, , N
patients NNS N
with IN N
CSX NNP N
had VBD N
significantly RB N
higher JJR N
activity NN o
of IN o
MPO NNP o
and CC o
levels NNS o
of IN o
MDA NNP o
, , N
but CC N
significantly RB N
lower JJR o
SOD NNP o
activity NN o
and CC o
levels NNS o
of IN o
NOx NNP o
before IN N
treatment NN N
. . N

After IN N
treatment NN N
, , N
MPO NNP o
activity NN o
and CC o
MDA NNP o
levels NNS o
were VBD N
significantly RB N
reduced VBN N
; : N
SOD NNP o
activity NN o
and CC o
NOx NNP o
levels NNS o
were VBD N
significantly RB N
increased VBN N
with IN N
nebivolol NN i
but CC N
remained VBD N
unchanged JJ N
with IN N
metoprolol NN i
. . i

CONCLUSION NN N
We PRP N
have VBP N
shown VBN N
that IN N
patients NNS p
with IN p
CSX NNP p
who WP N
taken VBN N
nebivolol RB i
have VBP N
lower JJR N
serum NN o
MPO NNP o
activity NN o
, , o
levels NNS o
of IN o
MDA NNP o
and CC N
higher JJR N
serum NN o
SOD NNP o
activity NN o
, , o
NOx NNP o
levels NNS o
when WRB N
compared VBN N
with IN N
metoprolol JJ i
treatment NN N
. . N

Exercise NNP N
stress JJ N
test NN N
parameters NNS N
were VBD N
also RB N
ameliorated VBN N
in IN N
patients NNS N
who WP N
had VBD N
taken VBN N
nebivolol RB i
in IN N
contrast NN N
to TO N
metoprolol VB i
. . i

Nebivolol NNP i
treatment NN N
may MD N
be VB N
a DT N
novel JJ N
treatment NN N
strategy NN N
in IN N
cases NNS N
with IN N
CSX NNP N
in IN N
the DT N
future NN N
. . N

-DOCSTART- -8338088- O O

A DT N
comparison NN N
of IN N
the DT N
effectiveness NN N
and CC N
patient JJ N
tolerance NN N
of IN N
oral JJ N
sodium NN N
phosphate NN N
, , N
castor NN N
oil NN N
, , N
and CC N
standard JJ N
electrolyte NN N
lavage NN N
for IN N
colonoscopy NN p
or CC p
sigmoidoscopy JJ p
preparation NN p
. . p

One CD p
hundred VBD p
thirteen JJ p
patients NNS p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
oral JJ i
sodium NN i
phosphate NN i
( ( i
Fleet NNP i
Phospho-Soda NNP i
) ) i
, , i
lemon-flavored JJ i
castor NN i
oil NN i
( ( i
Purge NNP i
) ) i
, , i
or CC i
standard JJ i
polyethylene NN i
glycol-based JJ i
lavage NN i
solution NN i
( ( i
GoLYTELY NNP i
) ) i
before IN N
elective JJ N
colonoscopy NN N
. . N

The DT N
study NN N
purpose NN N
was VBD N
to TO N
confirm VB N
the DT N
efficacy NN N
of IN N
oral JJ N
sodium NN i
phosphate NN i
and CC N
extend VB N
observations NNS N
to TO N
include VB N
castor JJ i
oil NN i
. . i

Overall NNP N
, , N
patients NNS N
reported VBD N
that IN N
sodium NN i
phosphate NN i
and CC N
castor NN i
oil NN i
were VBD N
easier JJR N
to TO N
complete VB N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Scores NNS o
for IN o
cleansing VBG o
the DT o
entire JJ o
colon NN o
as IN N
determined VBN N
by IN N
endoscopists NNS N
who WP N
were VBD N
blinded VBN N
to TO N
the DT N
cathartic JJ N
agent NN N
were VBD N
highest JJS N
in IN N
patients NNS N
receiving VBG N
sodium NN i
phosphate NN i
( ( N
p JJ N
< NNP N
0.02 CD N
) ) N
. . N

Scores NNS o
of IN o
left-colon NN o
cleansing NN o
for IN o
flexible JJ o
sigmoidoscopy NN o
were VBD N
equally RB N
high JJ N
for IN N
the DT N
three CD N
methods NNS N
. . N

Scores NNS o
for IN o
taste NN o
and CC o
symptom JJ o
side NN o
effects NNS o
were VBD N
similar JJ N
for IN N
each DT N
preparation NN N
. . N

There EX N
were VBD N
no DT N
recognized VBN N
signs NNS o
or CC o
symptoms NNS o
of IN o
hypocalcemia NN o
in IN N
the DT N
sodium NN N
phosphate NN N
group NN N
. . N

Because IN N
of IN N
the DT N
low JJ N
cost NN N
of IN N
oral JJ N
sodium NN i
phosphate NN i
combined VBN N
with IN N
the DT N
lowest JJS N
repeat NN N
endoscopy NN N
rate NN N
for IN N
inadequate JJ N
cleansing NN N
, , N
patient JJ o
savings NNS o
were VBD N
projected VBN N
to TO N
be VB N
$ $ N
5000 CD N
per IN N
100 CD N
patients NNS N
at IN N
this DT N
center NN N
. . N

Oral JJ N
sodium NN i
phosphate NN i
is VBZ N
a DT N
cost-effective JJ N
colonoscopy NN N
preparation NN N
that WDT N
is VBZ N
better RBR N
tolerated VBN N
and CC N
more RBR N
effective JJ N
than IN N
the DT N
polyethylene JJ i
glycol-electrolyte JJ i
lavage NN i
solution NN i
or CC i
castor NN i
oil NN i
. . i

-DOCSTART- -9885327- O O

Comparative JJ N
efficacy NN N
and CC N
safety NN N
of IN N
calcium NN i
carbasalate NN i
plus CC i
metoclopramide JJ i
versus NN i
ergotamine NN i
tartrate NN i
plus CC i
caffeine NN i
in IN N
the DT N
treatment NN N
of IN N
acute JJ p
migraine NN p
attacks NNS p
. . p

This DT N
randomized JJ N
, , N
double-blind JJ N
, , N
double-dummy JJ N
, , N
multicenter NN p
, , N
parallel-group JJ N
study NN N
aimed VBN N
at IN N
comparing VBG N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
calcium NN i
carbasalate NN i
( ( i
equivalent JJ i
to TO i
900 CD i
mg NNS i
aspirin RB i
) ) i
plus CC i
metoclopramide $ i
10 CD i
mg NN i
( ( i
CM NNP i
) ) i
with IN i
ergotamine JJ i
tartrate NN i
1 CD i
mg NN i
plus CC i
caffeine JJ i
100 CD i
mg NN i
( ( i
EC NNP i
) ) i
administered VBN N
in IN N
the DT N
treatment NN N
of IN N
2 CD N
acute JJ N
migraine NN N
attacks NNS N
. . N

A DT N
total NN N
of IN N
296 CD p
patients NNS p
fulfilling VBG p
the DT p
International NNP p
Headache NNP p
Society NNP p
diagnostic JJ p
criteria NNS p
for IN p
migraine NN p
were VBD p
enrolled VBN p
. . p

In IN N
total JJ N
, , N
one CD N
or CC N
two CD N
migraine NN N
attacks NNS N
were VBD N
treated VBN N
in IN N
268 CD N
and CC N
235 CD N
patients NNS N
, , N
respectively RB N
. . N

The DT N
primary JJ N
endpoint NN N
for IN N
the DT N
first JJ N
treated VBD N
attack NN N
was VBD N
headache NN N
relief NN N
, , N
with IN N
intensity NN N
decreasing VBG N
from IN N
moderate JJ N
or CC N
severe JJ N
to TO N
mild VB N
or CC N
absent VB N
2 CD N
h NN N
after IN N
drug NN N
intake NN N
. . N

Usual JJ N
secondary JJ N
efficacy NN N
endpoints NNS N
were VBD N
assessed VBN N
. . N

A DT N
superiority NN N
of IN N
CM NNP i
over IN N
EC NNP i
was VBD N
observed VBN N
for IN N
both DT N
treated JJ N
attacks NNS N
for IN N
the DT N
main JJ N
endpoint NN N
: : N
success NN N
in IN N
54 CD N
versus NN N
36 CD N
% NN N
, , N
p NN N
= VBD N
0.003 CD N
for IN N
the DT N
first JJ N
attack NN N
and CC N
60 CD N
versus NN N
44 CD N
% NN N
, , N
p NN N
= VBD N
0.02 CD N
for IN N
the DT N
second JJ N
attack NN N
. . N

CM NNP o
was VBD o
also RB o
significantly RB o
superior JJ o
to TO o
EC NNP o
during IN o
the DT o
first JJ o
attack NN o
for IN o
complete JJ o
headache NN o
relief NN o
( ( o
20 CD o
vs. FW o
8 CD o
% NN o
, , o
p NN o
= NNP o
0.006 CD o
) ) o
, , o
nausea NN o
( ( o
42 CD o
vs. FW o
63 CD o
% NN o
, , o
p NN o
= VBD o
0 CD o
. . o

007 CD o
) ) o
and CC o
willingness NN o
to TO o
take VB o
the DT o
drug NN o
again RB o
( ( o
90 CD o
vs. FW o
80 CD o
% NN o
, , o
p NN o
= NNP o
0.043 CD o
) ) o
. . o

The DT o
global JJ o
efficacy NN o
evaluation NN o
, , o
rated VBN o
by IN o
the DT o
investigators NNS o
, , o
was VBD o
significantly RB o
more RBR o
favorable JJ o
to TO o
CM NNP o
for IN o
both DT o
attacks NNS o
( ( o
p VB o
= $ o
0.001 CD o
for IN o
the DT o
first JJ o
attack NN o
and CC o
p NN o
= VBP o
0.02 CD o
for IN o
the DT o
second JJ o
) ) o
. . o

The DT o
patients NNS o
' POS o
evaluation NN o
was VBD o
significant JJ o
for IN o
the DT o
first JJ o
attack NN o
( ( o
p JJ o
= NNP o
0.002 CD o
) ) o
. . o

The DT o
global JJ o
incidence NN o
of IN o
adverse JJ o
events NNS o
was VBD o
45 CD o
% NN o
higher JJR o
with IN o
EC NNP o
, , o
though IN o
not RB o
significant JJ o
( ( o
32 CD o
vs. FW o
22 CD o
% NN o
, , o
p NN o
= NNP o
0.075 CD o
) ) o
. . o

They PRP o
were VBD o
most RBS o
often RB o
unspecific JJ o
and CC o
mild JJ o
to TO o
moderate VB o
in IN o
intensity NN o
. . o

Gastrointestinal JJ o
side NN o
effects NNS o
were VBD o
significantly RB o
less RBR o
frequent JJ o
with IN o
CM NNP o
than IN o
EC NNP o
( ( o
7 CD o
vs. FW o
21 CD o
% NN o
, , o
p NN o
= NNP o
0.001 CD o
) ) o
. . o

Thus RB o
, , o
CM NNP o
is VBZ o
more RBR o
effective JJ o
and CC o
has VBZ o
a DT o
better JJR o
gastrointestinal JJ o
safety NN o
than IN o
EC NNP o
in IN o
the DT o
acute JJ o
treatment NN o
of IN o
migraine NN o
attacks NNS o
. . o

-DOCSTART- -9546119- O O

Amoxicillin/metronidazole/omeprazole/clarithromycin NN N
: : N
a DT N
new JJ N
, , N
short JJ N
quadruple NN N
therapy NN p
for IN p
Helicobacter NNP o
pylori JJ o
eradication NN o
. . o

BACKGROUND NNP N
Triple NNP N
therapy NN N
regimens VBZ N
including VBG N
two CD N
antibiotics NNS N
plus CC N
acid JJ N
suppression NN N
have VBP N
become VBN N
the DT N
new JJ N
standard NN N
therapy NN N
in IN N
Helicobacter NNP N
pylori FW N
eradication NN N
because IN N
of IN N
success NN N
rates NNS N
of IN N
about RB N
90 CD N
% NN N
. . N

However RB N
, , N
these DT N
regimens NNS N
are VBP N
still RB N
costly JJ N
, , N
duration NN N
is VBZ N
about IN N
one CD N
week NN N
or CC N
less JJR N
, , N
and CC N
side-effects NNS N
are VBP N
not RB N
negligible JJ N
. . N

We PRP N
therefore RB N
evaluated VBD N
a DT N
new JJ N
quadruple NN N
therapy NN N
, , N
because IN N
theoretically RB N
a DT N
shorter JJR N
duration NN N
of IN N
treatment NN N
may MD N
result VB N
in IN N
reduced JJ N
costs NNS N
, , N
fewer JJR N
side-effects NNS N
, , N
and CC N
possibly RB N
in IN N
a DT N
lower JJR N
potential NN N
for IN N
antibiotic JJ N
resistances NNS N
. . N

METHODS NNP N
Controlled NNP N
, , N
prospective JJ N
pilot NN N
study NN N
including VBG N
H. NNP p
pylori-positive JJ p
patients NNS p
with IN p
gastric JJ p
or CC p
duodenal JJ p
ulcers NNS p
or CC p
erosive JJ p
gastritis NN p
, , p
treated VBN p
after IN p
failure NN p
of IN p
dual JJ p
therapy NN p
( ( p
proton-pump-inhibitors NNS p
or CC p
ranitidine VB p
plus CC p
amoxicillin VB p
) ) p
or CC p
for IN p
the DT p
first JJ p
time NN p
. . p

They PRP N
were VBD N
assigned VBN N
to TO N
a DT N
one CD i
week NN i
triple JJ i
standard NN i
therapy NN i
, , i
consisting VBG i
of IN i
metronidazole JJ i
400 CD i
mg JJ i
bid NN i
+ NNP i
omeprazole VBZ i
20 CD i
mg NN i
bid NN i
+ NNP i
clarithromycin VBZ i
250 CD i
mg NN i
bid NN i
, , i
or CC i
a DT i
newly RB i
created VBN i
quadruple-regimen NNS i
, , i
which WDT i
adds VBZ i
amoxicillin NN i
( ( i
1 CD i
g RB i
bid NN i
) ) i
to TO i
the DT i
above JJ i
triple NN i
regimen NNS i
. . i

Each DT N
of IN N
the DT N
four CD N
drugs NNS N
was VBD N
given VBN N
for IN N
5 CD N
days NNS N
. . N

H. NNP N
pylori NN N
status NN N
was VBD N
checked VBN N
by IN N
13C CD o
urea JJ o
breath NN o
test NN o
before IN N
and CC N
after IN N
four CD N
weeks NNS N
of IN N
therapy NN N
. . N

RESULTS VB N
A DT N
total NN p
of IN p
71 CD p
patients NNS p
were VBD p
treated VBN p
by IN p
quadruple JJ p
therapy NN p
, , p
and CC p
42 CD p
patients NNS p
were VBD p
treated VBN p
by IN p
triple JJ p
therapy NN p
. . p

The DT N
eradication NN o
rate NN o
of IN N
H. NNP N
pylori NN N
for IN N
patients NNS N
under IN N
quadruple JJ N
treatment NN N
, , N
without IN N
vs. FW N
with IN N
previous JJ N
dual JJ N
therapy NN N
, , N
were VBD N
96 CD N
% NN N
vs. FW N
92 CD N
% NN N
( ( N
42/44 CD N
vs. FW N
22/24 CD N
) ) N
by IN N
per IN N
protocol NN N
and CC N
91 CD N
% NN N
vs. FW N
88 CD N
% NN N
( ( N
42/46 CD N
vs. FW N
22/25 CD N
) ) N
by IN N
intention NN N
to TO N
treat VB N
analysis NN N
( ( N
comparisons NNS N
not RB N
significant JJ N
) ) N
. . N

No DT N
major JJ N
side-effects NNS N
were VBD N
reported VBN N
. . N

CONCLUSIONS NNP N
Five-day JJ N
quadruple NN N
therapy NN N
( ( N
with IN N
omeprazole NN N
, , N
metronidazole NN N
, , N
clarithromycin NN N
and CC N
amoxicillin NN N
) ) N
represents VBZ N
an DT N
effective JJ N
and CC N
safe JJ N
new JJ N
regimen NNS N
for IN N
H. NNP N
pylori JJ N
eradication NN N
. . N

-DOCSTART- -20031809- O O

Stress NNP i
reduction NN i
prolongs NNS N
life NN N
in IN N
women NNS p
with IN p
coronary JJ p
disease NN p
: : p
the DT N
Stockholm NNP N
Women NNP N
's POS N
Intervention NNP N
Trial NNP N
for IN N
Coronary NNP N
Heart NNP N
Disease NNP N
( ( N
SWITCHD NNP N
) ) N
. . N

BACKGROUND NNP N
Psychosocial NNP N
stress NN N
may MD N
increase VB N
risk NN N
and CC N
worsen JJ N
prognosis NN N
of IN N
coronary JJ p
heart NN p
disease NN p
in IN p
women NNS p
. . p

Interventions NNS N
that IN N
counteract JJ N
women NNS N
's POS N
psychosocial JJ N
stress NN N
have VBP N
not RB N
previously RB N
been VBN N
presented VBN N
. . N

This DT N
study NN N
implemented VBD N
a DT N
stress JJ i
reduction NN i
program NN i
for IN N
women NNS p
and CC N
investigated VBD N
its PRP$ N
ability NN N
to TO N
improve VB N
survival NN o
in IN o
women NNS o
coronary JJ o
patients NNS o
. . o

METHODS NNP N
AND CC N
RESULTS NNP N
Two CD p
hundred VBD p
thirty-seven JJ p
consecutive JJ p
women NNS p
patients NNS p
, , p
aged VBD p
75 CD p
years NNS p
or CC p
younger JJR p
, , p
hospitalized VBN p
for IN p
acute JJ p
myocardial JJ p
infarction NN p
, , p
coronary JJ p
artery NN p
bypass NN p
grafting NN p
, , p
or CC p
percutaneous JJ p
coronary JJ p
intervention NN p
were VBD N
randomized VBN N
to TO N
a DT N
group-based JJ i
psychosocial JJ i
intervention NN i
program NN i
or CC i
usual JJ i
care NN i
. . i

Initiated VBN N
4 CD N
months NNS N
after IN N
hospitalization NN N
, , N
intervention NN N
groups NNS N
of IN N
4 CD N
to TO N
8 CD N
women NNS N
met VBD N
for IN N
a DT N
total NN N
of IN N
20 CD N
sessions NNS N
that WDT N
were VBD N
spread VBN N
over IN N
a DT N
year NN N
. . N

We PRP N
provided VBD N
education NN i
about IN i
risk NN i
factors NNS i
, , i
relaxation NN i
training NN i
techniques NNS i
, , i
methods NNS i
for IN i
self-monitoring NN i
and CC i
cognitive JJ i
restructuring NN i
, , i
with IN i
an DT i
emphasis NN i
on IN i
coping VBG i
with IN i
stress JJ i
exposure NN i
from IN i
family NN i
and CC i
work NN i
, , i
and CC i
self-care NN i
and CC i
compliance NN i
with IN i
clinical JJ i
advice NN i
. . i

From IN N
randomization NN N
until IN N
end NN N
of IN N
follow-up NN N
( ( N
mean JJ N
duration NN N
, , N
7.1 CD N
years NNS N
) ) N
, , N
25 CD N
women NNS N
( ( N
20 CD N
% NN N
) ) N
in IN N
the DT N
usual JJ N
care NN N
and CC N
8 CD N
women NNS N
( ( N
7 CD N
% NN N
) ) N
in IN N
the DT N
stress NN o
reduction NN o
died VBD N
, , N
yielding VBG N
an DT N
almost RB N
3-fold JJ N
protective JJ N
effect NN N
of IN N
the DT N
intervention NN N
( ( N
odds NNS N
ratio NN N
, , N
0.33 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.15 CD N
to TO N
0.74 CD N
; : N
P=0.007 NNP N
) ) N
. . N

Introducing VBG N
baseline JJ N
measures NNS N
of IN N
clinical JJ N
prognostic JJ N
factors NNS N
, , N
including VBG N
use NN o
of IN o
aspirin NN o
, , o
beta-blockers NNS o
, , o
angiotensin-converting JJ o
enzyme NN o
inhibitors NNS o
, , o
calcium-channel JJ o
blockers NNS o
, , o
and CC o
statins VBZ o
into IN i
multivariate NN i
models NNS i
confirmed VBD N
the DT N
unadjusted JJ N
results NNS N
( ( N
P=0.009 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Although IN N
mechanisms NN N
remain VBP N
unclear JJ N
, , N
a DT N
group-based JJ i
psychosocial JJ i
intervention NN i
program NN i
for IN N
women NNS p
with IN p
coronary JJ p
heart NN p
disease NN p
may MD N
prolong VB N
lives NNS N
independent JJ N
of IN N
other JJ N
prognostic JJ N
factors NNS N
. . N

-DOCSTART- -12814457- O O

A DT N
proof NN N
of IN N
concept NN N
study NN N
to TO N
evaluate VB N
putative JJ o
benefits NNS o
of IN N
montelukast NN i
in IN N
moderate JJ p
persistent NN p
asthmatics NNS p
. . p

AIMS NNP N
Whether NNP N
chronic JJ N
dosing VBG N
with IN N
montelukast JJ i
confers NNS N
benefit VBP N
in IN N
patients NNS p
with IN p
moderate JJ p
to TO p
severe VB p
asthma NN p
remains VBZ N
to TO N
be VB N
fully RB N
established VBN N
. . N

A DT N
proof NN N
of IN N
concept NN N
study NN N
was VBD N
performed VBN N
evaluating VBG N
putative JJ N
benefits NNS N
with IN N
montelukast NN i
in IN N
moderate JJ p
persistent JJ p
asthmatics NNS p
who WP N
were VBD N
taken VBN N
off RP N
inhaled JJ i
corticosteroids NNS i
( ( i
ICS NNP i
) ) i
and CC N
switched VBN N
to TO N
salmeterol VB i
. . i

The DT N
latter NN N
was VBD N
done VBN N
to TO N
dissociate VB N
the DT N
effects NNS N
of IN N
montelukast NN i
from IN N
ICS NNP N
. . N

METHODS NNP N
Twenty NNP p
moderate NN p
to TO p
severe VB p
persistent JJ p
asthmatics NNS p
completed VBD N
a DT N
randomized JJ N
double-blind NN N
crossover NN N
study NN N
. . N

Subjects NNS N
received VBD N
montelukast RB i
10 CD i
mg JJ i
daily JJ i
or CC i
placebo NN i
for IN N
2 CD N
weeks NNS N
each DT N
. . N

This DT N
was VBD N
preceded VBN N
by IN N
a DT N
2-week JJ N
run-in NN N
when WRB N
ICS NNP i
were VBD N
discontinued VBN N
and CC N
salmeterol NN i
started VBD N
, , N
and CC N
used VBD N
on IN N
a DT N
regular JJ N
basis NN N
throughout IN N
the DT N
study NN N
. . N

Measurements NNS N
were VBD N
made VBN N
after IN N
run-in NN N
and CC N
after IN N
both DT N
randomized JJ N
treatments NNS N
. . N

RESULTS VB N
There EX N
were VBD N
no DT N
significant JJ N
sequence NN o
effects NNS o
for IN N
responses NNS N
as IN N
to TO N
whether IN N
placebo NN i
or CC N
montelukast NN i
were VBD N
given VBN N
first RB N
or CC N
second JJ N
. . N

Methacholine NNP o
PD20 NNP o
values NNS o
after IN N
run-in NN N
, , N
first JJ N
and CC N
second JJ N
placebo NN i
were VBD N
63 CD N
micro NN N
g NN N
, , N
60 CD N
micro NN N
g NN N
and CC N
64 CD N
micro NN N
g NN N
, , N
respectively RB N
( ( N
corresponding VBG N
to TO N
2 CD N
, , N
4 CD N
and CC N
6 CD N
weeks NNS N
of IN N
ICS NNP N
washout NN N
, , N
respectively RB N
) ) N
. . N

Lung NNP o
function NN o
deteriorated VBD o
pre JJ N
vs NN N
post NN N
run-in NN N
, , N
which WDT N
was VBD N
significant JJ N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
for IN N
FEF25-75 NNP N
% NN N
predicted VBD N
. . N

Montelukast NNP N
conferred VBD N
significant JJ N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
improvements NNS N
as IN N
change NN N
from IN N
post NN N
run-in NN N
compared VBN N
with IN N
placebo NN i
in IN N
methacholine NN N
PD20 NNP N
, , N
FEV1 NNP o
% NN N
predicted VBD N
, , N
FEF25-75 NNP o
% NN N
predicted VBD N
, , N
diurnal JJ o
peak NN o
expiratory NN o
flow NN o
, , o
symptoms NNS o
and CC N
salbutamol NN o
use NN o
. . o

For IN N
the DT N
primary JJ N
outcome NN N
of IN N
methacholine NN N
PD20 NNP N
, , N
this DT N
amounted VBD N
to TO N
a DT N
1.6-fold JJ N
difference NN N
( ( N
95 CD N
% NN N
CI NNP N
1.1 CD N
, , N
2.5 CD N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
moderate JJ N
persistent NN N
asthmatics NNS N
switched VBD N
from IN N
taking VBG N
ICS NNP N
to TO N
salmeterol VB i
alone RB N
, , N
adding VBG N
montelukast NN i
conferred VBD N
significant JJ N
benefits NNS N
on IN N
all DT N
parameters NNS N
of IN N
asthma NN N
control NN N
. . N

Further JJ N
studies NNS N
are VBP N
indicated VBN N
to TO N
evaluate VB N
whether IN N
montelukast NN i
exhibits NNS N
additive JJ N
effects NNS N
to TO N
ICS/long-acting JJ i
beta2-adrenoceptor JJ i
agonist NN i
combination NN N
inhalers NNS N
upon IN N
clinically RB N
important JJ o
outcomes NNS o
. . o

-DOCSTART- -18791939- O O

Effects NNS N
of IN N
aspirin NN i
and CC N
clopidogrel NN i
in IN N
healthy JJ p
men NNS p
measured VBN N
by IN N
platelet NN N
aggregation NN N
and CC N
PFA-100 NNP N
. . N

There EX N
are VBP N
no DT N
generally RB N
accepted VBN N
definitions NNS N
for IN N
low-response NN N
( ( N
frequently RB N
called VBN N
resistance NN N
) ) N
to TO N
the DT N
platelet NN N
inhibitors NNS N
, , N
aspirin NN i
and CC N
clopidogrel NN i
. . i

Low-response NN N
may MD N
increase VB N
the DT N
risk NN N
of IN N
cardiovascular JJ N
events NNS N
in IN N
atherosclerotic JJ p
patients NNS p
. . p

We PRP N
aimed VBD N
to TO N
define VB N
the DT N
normal JJ N
drug NN N
responses NNS N
in IN N
healthy JJ p
men NNS p
. . p

Platelet NNP N
function NN N
was VBD N
measured VBN N
in IN N
20 CD p
healthy JJ p
men NNS p
during IN N
11 CD N
days NNS N
of IN N
aspirin NN i
or CC i
clopidogrel NN i
intake NN N
, , N
using VBG N
light JJ N
transmission NN N
aggregometry NN N
( ( N
LTA NNP N
) ) N
and CC N
the DT N
Platelet NNP N
Function NNP N
Analyzer NNP N
100 CD N
( ( N
PFA-100 NNP N
) ) N
. . N

The DT N
lower JJR N
limits NNS N
for IN N
LTA NNP N
at IN N
baseline NN N
were VBD N
64 CD N
% NN N
and CC N
61 CD N
% NN N
, , N
using VBG N
arachidonic JJ N
acid NN N
and CC N
ADP NNP N
as IN N
agonists NNS N
, , N
respectively RB N
. . N

During IN N
aspirin JJ i
intake VBP N
the DT N
LTA NNP o
results NNS o
were VBD N
stable JJ N
from IN N
day NN N
to TO N
day NN N
, , N
and CC N
an DT N
upper JJ N
limit NN N
of IN N
9 CD N
% NN N
arachidonic JJ o
acid NN o
stimulated VBD o
aggregation NN o
was VBD N
found VBN N
. . N

Clopidogrel NNP o
intake NN o
was VBD N
best RBS N
shown VBN N
by IN N
ADP NNP N
induced JJ N
aggregation NN N
. . N

However RB N
, , N
two CD N
out IN N
of IN N
20 CD N
individuals NNS N
exhibited VBD N
low-response NN o
to TO o
clopidogrel VB o
. . o

In IN N
the DT N
remaining VBG N
18 CD N
volunteers NNS N
an DT N
upper JJ N
limit NN N
of IN N
48 CD N
% NN N
aggregation NN N
was VBD N
found VBN N
. . N

We PRP N
found VBD N
an DT N
upper JJ N
limit NN N
for IN N
collagen-epinephrine JJ o
stimulated JJ o
PFA-100 JJ o
results NNS o
of IN N
166 CD N
s NNS N
at IN N
baseline NN N
. . N

During IN N
aspirin JJ i
intake NN N
, , N
these DT N
results NNS N
varied VBD N
considerably RB N
from IN N
day NN N
to TO N
day NN N
in IN N
nine CD N
out IN N
of IN N
20 CD p
men NNS p
, , N
resulting VBG N
in IN N
an DT N
overlap NN N
between IN N
the DT N
reference NN N
ranges VBZ N
at IN N
baseline NN N
and CC N
during IN N
therapy NN N
. . N

In IN N
conclusion NN N
, , N
platelet NN o
inhibition NN o
by IN o
aspirin NN o
and CC o
clopidogrel NN o
assessed VBN o
by IN o
aggregometry NN o
was VBD N
stable JJ N
during IN N
11 CD N
days NNS N
of IN N
treatment NN N
and CC N
reference NN N
ranges NNS N
were VBD N
established VBN N
. . N

The DT N
PFA-100 JJ N
results NNS N
varied VBD N
greatly RB N
and CC N
low-response NN N
was VBD N
not RB N
precisely RB N
defined VBN N
by IN N
this DT N
method NN N
. . N

-DOCSTART- -7907677- O O

Warfarin NNP i
versus NN N
aspirin NN i
for IN N
prevention NN N
of IN N
thromboembolism NN o
in IN N
atrial JJ N
fibrillation NN N
: : N
Stroke NNP N
Prevention NNP N
in IN N
Atrial NNP N
Fibrillation NNP N
II NNP N
Study NNP N
. . N

Warfarin NNP i
is VBZ N
an DT N
established JJ N
treatment NN N
for IN N
prevention NN N
of IN N
ischaemic JJ N
stroke NN N
in IN N
patients NNS p
with IN p
atrial JJ p
fibrillation NN p
, , N
but CC N
the DT N
value NN N
of IN N
this DT N
agent JJ N
relative NN N
to TO N
aspirin VB N
in IN N
unclear JJ N
. . N

In IN N
the DT N
first JJ N
Stroke NNP N
Prevention NNP N
in IN N
Atrial NNP N
Fibrillation NNP N
( ( N
SPAF-I NNP N
) ) N
study NN N
, , N
direct JJ N
comparison NN N
of IN N
warfarin NN i
with IN N
aspirin NN i
was VBD N
limited VBN N
by IN N
the DT N
small JJ N
number NN N
of IN N
thromboembolic JJ N
events NNS N
. . N

SPAF-II JJ N
aims NNS N
to TO N
address VB N
this DT N
issue NN N
and CC N
also RB N
to TO N
assess VB N
the DT N
differential JJ N
effects NNS N
of IN N
the DT N
two CD N
treatments NNS N
according VBG N
to TO N
age NN N
. . N

We PRP N
compared VBN N
warfarin NN i
( ( N
prothrombin JJ N
time NN N
ratio JJ N
1.3-1.8 JJ N
, , N
international JJ N
normalised JJ N
ratio NN N
2.0-4.5 JJ N
) ) N
with IN N
aspirin $ i
325 CD i
mg JJ i
daily RB i
for IN N
prevention NN N
of IN N
ischaemic JJ o
stroke NN o
and CC N
systemic JJ o
embolism NN o
( ( N
primary JJ N
events NNS N
) ) N
in IN N
two CD N
parallel NNS N
randomised VBD N
trials NNS N
involving VBG N
715 CD p
patients NNS p
aged VBN p
75 CD p
years NNS p
or CC p
less JJR p
and CC p
385 CD p
patients NNS p
older JJR p
than IN p
75 CD p
; : p
we PRP N
sought VBD N
reductions NNS N
in IN N
the DT N
absolute JJ N
rate NN N
of IN N
primary JJ N
events NNS N
by IN N
warfarin NNS i
compared VBN N
with IN N
aspirin NN i
of IN N
2 CD N
% NN N
per IN N
year NN N
and CC N
4 CD N
% NN N
per IN N
year NN N
, , N
respectively RB N
. . N

In IN N
the DT N
younger JJR N
patients NNS N
, , N
warfarin NNS i
decreased VBD N
the DT N
absolute JJ o
rate NN o
of IN o
primary JJ o
events NNS o
by IN N
0.7 CD N
% NN N
per IN N
year NN N
( ( N
95 CD N
% NN N
CI-0.4 NNP N
to TO N
1.7 CD N
) ) N
. . N

The DT N
primary JJ o
event NN o
rate NN o
per IN o
year NN o
was VBD N
1.3 CD N
% NN N
with IN N
warfarin NN i
and CC N
1.9 CD N
% NN N
with IN N
aspirin NN i
( ( N
relative JJ N
risk NN N
[ NNP N
RR NNP N
] NNP N
0.67 CD N
, , N
p NN N
= NNP N
0.24 CD N
) ) N
. . N

The DT N
absolute JJ o
rate NN o
of IN o
primary JJ o
events NNS o
in IN N
low-risk JJ N
younger NN N
patients NNS N
( ( N
without IN N
hypertension NN N
, , N
recent JJ N
heart NN N
failure NN N
, , N
or CC N
previous JJ N
thromboembolism NN N
) ) N
on IN N
aspirin NN i
was VBD N
0.5 CD N
% NN N
per IN N
year NN N
( ( N
95 CD N
% NN N
CI NNP N
0.1 CD N
to TO N
1.9 CD N
) ) N
. . N

Among IN N
older JJR N
patients NNS N
, , N
warfarin NNS i
decreased VBD N
the DT N
absolute JJ o
rate NN o
of IN o
primary JJ o
events NNS o
by IN N
1.2 CD N
% NN N
per IN N
year NN N
( ( N
95 CD N
% NN N
CI-1.7 NNP N
to TO N
4.1 CD N
) ) N
. . N

The DT N
primary JJ o
event NN o
rate NN o
per IN o
year NN o
was VBD N
3.6 CD N
% NN N
with IN N
warfarin NN i
and CC N
4.8 CD N
% NN N
with IN N
aspirin NN i
( ( N
RR NNP N
0.73 CD N
, , N
p NN N
= NNP N
0.39 CD N
) ) N
. . N

In IN N
this DT N
older JJR N
group NN N
, , N
the DT N
rate NN o
of IN o
all DT o
stroke NN o
with IN o
residual JJ o
deficit NN o
( ( N
ischaemic JJ N
or CC N
haemorrhagic NN N
) ) N
was VBD N
4.3 CD N
% NN N
per IN N
year NN N
with IN N
aspirin NN i
and CC N
4.6 CD N
% NN N
per IN N
year NN N
with IN N
warfarin NN i
( ( N
RR NNP N
1.1 CD N
) ) N
. . N

Warfarin NNP i
may MD N
be VB N
more RBR N
effective JJ N
than IN N
aspirin NN i
for IN N
prevention NN N
of IN N
ischaemic JJ o
stroke NN o
in IN N
patients NNS N
with IN N
atrial JJ N
fibrillation NN N
, , N
but CC N
the DT N
absolute JJ o
reduction NN o
in IN N
stroke NN o
rate NN o
by IN N
warfarin NN i
is VBZ N
small JJ N
. . N

Younger JJR N
patients NNS N
without IN N
risk NN N
factors NNS N
had VBD N
a DT N
low JJ N
rate NN o
of IN o
stroke NN o
when WRB N
treated VBN N
with IN N
aspirin NN i
. . i

In IN N
older JJR N
patients NNS N
the DT N
rate NN o
of IN o
stroke NN o
( ( N
ischaemic JJ N
and CC N
haemorrhagic NN N
) ) N
was VBD N
substantial JJ N
, , N
irrespective NN N
of IN N
which WDT N
agent NN N
was VBD N
given VBN N
. . N

Patient JJ N
age NN N
and CC N
the DT N
inherent JJ N
risk NN N
of IN N
thromboembolism NN N
should MD N
be VB N
considered VBN N
in IN N
the DT N
choice NN N
of IN N
antithrombotic JJ N
prophylaxis NN N
for IN N
patients NNS N
with IN N
atrial JJ N
fibrillation NN N
. . N

-DOCSTART- -3877292- O O

Intraocular JJ N
pressure NN N
changes NNS N
with IN N
propofol NN i
( ( N
'Diprivan NNP N
' POS N
) ) N
: : N
comparison NN N
with IN N
thiopentone NN i
. . i

The DT N
effects NNS N
of IN N
propofol NN i
, , N
a DT N
new JJ N
non-barbiturate JJ N
intravenous JJ N
anaesthetic JJ N
agent NN N
, , N
on IN N
intraocular JJ o
pressure NN o
( ( N
IOP NNP N
) ) N
were VBD N
assessed VBN N
and CC N
compared VBN N
with IN N
those DT N
of IN N
thiopentone NN i
. . i

IOP NNP o
was VBD i
measured VBN i
using VBG i
an DT i
applanation NN i
tonometer NN i
for IN i
5 CD i
min NN i
following VBG i
administration NN i
of IN i
induction NN i
doses NNS i
of IN i
propofol NN i
or CC i
thiopentone NN i
and CC i
inhalation NN i
of IN i
66 CD i
% NN i
nitrous JJ i
oxide NN i
in IN i
oxygen NN i
. . i

Both DT N
agents NNS N
produced VBD N
a DT N
significant JJ N
fall NN N
in IN N
IOP NNP o
for IN N
the DT N
period NN N
of IN N
study NN N
, , N
by IN N
a DT N
maximum NN N
of IN N
53 CD N
% NN N
with IN N
propofol NN N
and CC N
40 CD N
% NN N
with IN N
thiopentone NN N
. . N

Apnoea NNP o
occurred VBD N
with IN N
similar JJ N
frequency NN N
in IN N
the DT N
two CD N
groups NNS N
. . N

Use NNP N
of IN N
propofol NN N
was VBD N
associated VBN N
with IN N
a DT N
significant JJ N
fall NN N
in IN N
arterial JJ o
pressure NN o
and CC o
pain NN o
on IN o
injection NN o
in IN N
5 CD N
out IN N
of IN N
20 CD p
patients NNS p
. . p

-DOCSTART- -8222739- O O

A DT N
double-blind JJ N
comparison NN N
of IN N
oral JJ i
ketoprofen NN i
'controlled VBD i
release NN i
' '' i
and CC N
indomethacin JJ i
suppository NN i
in IN N
the DT N
treatment NN N
of IN N
rheumatoid JJ p
arthritis NN p
with IN p
special JJ p
regard NN p
to TO p
morning NN p
stiffness NN p
and CC p
pain NN p
on IN p
awakening VBG p
. . p

A DT N
double-blind JJ N
, , N
double-dummy JJ N
, , N
crossover NN N
study NN N
was VBD N
carried VBN N
out RP N
in IN N
8 CD p
centres NNS p
to TO N
compare VB N
the DT N
efficacy NN N
and CC N
tolerability NN N
of IN N
'controlled-release NNP i
' POS i
ketoprofen NN i
tablets NNS i
( ( N
200 CD N
mg NN N
) ) N
with IN N
that DT N
of IN N
indomethacin NN i
suppositories NNS i
( ( N
100 CD N
mg NN N
) ) N
in IN N
out-patients NNS p
with IN p
definite NN p
or CC p
classical JJ p
rheumatoid NN p
arthritis NN p
. . p

Patients NNS N
were VBD N
allocated VBN N
at IN N
random NN N
to TO N
receive VB N
a DT N
daily JJ N
bedtime NN N
dose NN N
of IN N
either CC N
1 CD N
ketoprofen JJ i
tablet NN N
or CC N
1 CD N
indomethacin JJ i
suppository NN i
plus CC N
the DT N
dummy NN N
of IN N
the DT N
other JJ N
formulation NN N
for IN N
a DT N
period NN N
of IN N
3 CD N
weeks NNS N
. . N

They PRP N
were VBD N
then RB N
crossed VBN N
over IN N
to TO N
the DT N
alternative JJ N
treatment NN N
for IN N
a DT N
further JJ N
3 CD N
weeks NNS N
. . N

Daily JJ N
diary JJ N
records NNS N
were VBD N
kept VBN N
by IN N
patients NNS N
of IN N
the DT N
number NN N
of IN N
night-time JJ N
awakenings NNS N
due JJ N
to TO N
pain VB N
, , N
pain VB N
severity NN N
at IN N
awakening VBG N
in IN N
the DT N
morning NN N
and CC N
the DT N
duration NN N
of IN N
early JJ N
morning NN N
stiffness NN N
. . N

Treatment NNP N
efficacy NN N
was VBD N
also RB N
assessed VBN N
at IN N
the DT N
end NN N
of IN N
each DT N
trial NN N
period NN N
by IN N
means NNS N
of IN N
an DT N
articular JJ N
index NN N
and CC N
by IN N
physician NN N
's POS N
and CC N
patient NN N
's POS N
overall JJ N
evaluation NN N
of IN N
response NN N
. . N

Adverse JJ N
effects NNS N
spontaneously RB N
mentioned VBN N
by IN N
the DT N
patients NNS N
or CC N
elicited VBN N
by IN N
direct JJ N
questioning VBG N
using VBG N
a DT N
symptom JJ N
check-list NN N
were VBD N
recorded VBN N
. . N

Statistical JJ N
analysis NN N
of IN N
the DT N
results NNS N
from IN N
83 CD p
evaluable JJ p
patients NNS p
showed VBD N
that IN N
the DT N
'controlled-release NNP o
' POS o
tablet NN o
formulation NN o
of IN o
200 CD o
mg NNS o
ketoprofen NN i
was VBD N
equally RB N
as RB N
effective JJ N
as IN N
the DT N
100 CD o
mg NN o
indomethacin NN o
suppository NN o
in IN N
the DT N
treatment NN N
of IN N
rheumatoid NN N
arthritis NN N
, , N
especially RB N
with IN N
regard NN N
to TO N
pain VB o
at IN o
awakening NN o
and CC o
morning NN o
stiffness NN o
. . o

Side-effects NNS N
in IN N
both DT N
groups NNS N
were VBD N
those DT N
commonly JJ N
seen VBN N
with IN N
non-steroidal JJ N
anti-inflammatory JJ N
drugs NNS N
and CC N
, , N
as IN N
expected VBN N
, , N
gastro-intestinal JJ o
and CC o
CNS NNP o
disturbances NNS o
predominated VBD N
. . N

Overall JJ N
, , N
side-effects NNS o
were VBD N
fewer JJR N
with IN N
ketoprofen NN o
than IN o
with IN o
indomethacin NN o
. . o

-DOCSTART- -15374792- O O

Association NNP N
of IN N
race NN i
with IN N
complications NNS N
and CC N
prognosis NN N
following VBG p
acute JJ p
coronary JJ p
syndromes NNS p
. . p

The DT N
baseline NN N
characteristics NNS o
, , o
complications NNS o
, , o
and CC o
survival NN o
of IN N
489 CD p
black JJ p
and CC p
6,890 CD p
non-black JJ p
patients NNS p
with IN p
acute JJ p
coronary JJ p
syndromes NNS p
were VBD N
studied VBN N
. . N

Important NNP N
racial JJ o
differences NNS o
were VBD N
observed VBN N
in IN N
demographic JJ o
features NNS o
, , o
atherosclerosis NN o
risk NN o
factors NNS o
, , o
and CC o
treatment NN o
strategies NNS o
; : o
however RB N
, , N
despite IN N
these DT N
differences NNS N
, , N
no DT N
independent JJ N
difference NN N
was VBD N
observed VBN N
in IN N
clinical JJ N
outcomes NNS N
according VBG N
to TO N
race NN N
. . N

The DT N
1-year JJ N
mortality NN o
rate NN o
was VBD N
2.9 CD N
% NN N
for IN N
black JJ p
patients NNS p
and CC N
2.5 CD N
% NN N
for IN N
non-black JJ p
patients NNS p
( ( N
p JJ N
= NNP N
0.93 CD N
) ) N
. . N

-DOCSTART- -24112670- O O

Use NNP N
of IN N
ketorolac NN i
is VBZ N
associated VBN N
with IN N
decreased VBN N
pneumonia NN N
following VBG N
rib NN p
fractures NNS p
. . p

BACKGROUND IN N
The DT N
effectiveness NN N
of IN N
the DT N
nonsteroidal JJ N
anti-inflammatory JJ N
drug NN N
ketorolac NN i
in IN N
reducing VBG N
pulmonary JJ p
morbidity NN p
after IN p
rib NN p
fractures NNS p
remains VBZ N
largely RB N
unknown JJ N
. . N

METHODS VB N
A DT N
retrospective JJ N
cohort NN N
study NN N
was VBD N
conducted VBN N
spanning VBG N
January NNP N
2003 CD N
to TO N
June NNP N
2011 CD N
assessing VBG N
pneumonia NN N
within IN N
30 CD N
days NNS N
and CC N
potential JJ N
adverse JJ N
effects NNS N
of IN N
ketorolac NN i
among IN N
all DT p
patients NNS p
with IN p
rib JJ p
fractures NNS p
who WP p
received VBD p
ketorolac NN p
< $ p
4 CD p
days NNS p
after IN p
injury NN p
compared VBN p
with IN p
a DT p
random JJ p
sample NN p
of IN p
those DT p
who WP p
did VBD p
not RB p
. . p

RESULTS NNP N
Among IN N
202 CD p
patients NNS p
who WP p
received VBD p
ketorolac NN i
and CC p
417 CD p
who WP p
did VBD p
not RB p
, , N
ketorolac NN N
use NN N
was VBD N
associated VBN N
with IN N
decreased VBN N
pneumonia NN o
( ( N
odds NNS N
ratio NN N
, , N
.14 NNP N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
.04 '' N
to TO N
.46 VB N
) ) N
and CC N
increased VBD N
ventilator-free JJ o
days NNS o
( ( N
difference NN N
, , N
1.8 CD N
days NNS N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
1.1 CD N
to TO N
2.5 CD N
) ) N
and CC N
intensive JJ o
care NN o
unit-free JJ o
days NNS o
( ( N
difference NN N
, , N
2.1 CD N
days NNS N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
1.3 CD N
to TO N
3.0 CD N
) ) N
within IN N
30 CD N
days NNS N
. . N

The DT N
rates NNS o
of IN o
acute JJ o
kidney NN o
injury NN o
, , o
gastrointestinal JJ o
hemorrhage NN o
, , o
and CC o
fracture NN o
nonunion NN o
were VBD N
not RB N
different JJ N
. . N

CONCLUSIONS NNP N
Early JJ N
administration NN N
of IN N
ketorolac NNS i
to TO N
patients NNS p
with IN p
rib JJ p
fractures NNS p
is VBZ N
associated VBN N
with IN N
a DT N
decreased JJ N
likelihood NN N
of IN N
pneumonia NN o
, , N
without IN N
apparent JJ N
risks NNS N
. . N

-DOCSTART- -10337847- O O

Problem-solving JJ i
counseling NN i
for IN N
caregivers NNS N
of IN N
the DT N
cognitively JJ N
impaired JJ N
: : N
effective JJ N
for IN N
whom WP N
? . N
BACKGROUND NNP N
Individualized VBD N
problem-solving JJ i
counseling NN i
for IN N
caregivers NNS N
of IN N
cognitively RB N
impaired JJ N
relatives NNS N
is VBZ N
thought VBN N
to TO N
help VB N
caregivers NNS N
cope VB N
with IN N
the DT N
stress NN N
and CC N
burden NN N
of IN N
caregiving VBG N
. . N

Few JJ N
studies NNS N
have VBP N
shown VBN N
the DT N
effectiveness NN N
of IN N
counseling VBG N
for IN N
these DT N
caregivers NNS N
. . N

OBJECTIVES NNP N
To TO N
determine VB N
the DT N
effectiveness NN N
of IN N
individualized JJ i
problem-solving JJ i
counseling NN i
by IN i
nurses NNS i
for IN N
caregivers NNS N
and CC N
the DT N
expenditures NNS N
of IN N
health NN N
care NN N
utilization NN N
. . N

METHOD NNP N
Caregivers NNP p
( ( p
n JJ p
= NNP p
77 CD p
) ) p
of IN p
the DT p
cognitively RB p
impaired JJ p
living NN p
at IN p
home NN p
were VBD N
randomized VBN N
to TO N
receive VB N
nurse JJ i
counseling NN i
or CC i
not RB i
. . i

Psychosocial JJ N
adjustment NN N
to TO N
their PRP$ N
relative NN o
's POS o
illness NN o
, , o
psychological JJ o
distress NN o
, , o
burden NN o
, , o
coping VBG o
skills NNS o
, , o
and CC o
expenditures NNS o
were VBD N
measured VBN N
after IN N
6 CD N
months NNS N
and CC N
1 CD N
year NN N
. . N

RESULTS NNP N
Although IN N
on IN N
average NN N
, , N
all DT N
caregivers NNS N
receiving VBG N
nurse JJ i
counseling NN i
indicated VBD N
no DT N
improvement NN o
in IN N
psychosocial JJ N
adjustment NN N
to TO N
their PRP$ N
relative NN o
's POS o
illness NN o
, , o
psychological JJ o
distress NN o
, , o
or CC o
caregiver RB o
burden NN o
, , N
they PRP N
found VBD N
counseling VBG N
very RB N
helpful JJ N
and CC N
it PRP N
was VBD N
effective JJ N
for IN N
a DT N
subgroup NN N
of IN N
caregivers NNS N
. . N

Those DT N
with IN N
poor JJ N
logical JJ N
analysis NN N
coping VBG N
skills NNS N
at IN N
baseline NN N
had VBD N
decreased VBN o
psychological JJ o
distress NN o
( ( N
F NNP N
( ( N
1,53 CD N
) ) N
= NN N
9.7 CD N
, , N
p NN N
= NNP N
.003 NNP N
) ) N
and CC N
improved VBN o
psychosocial JJ o
adjustment NN o
( ( N
F NNP N
( ( N
1,53 CD N
) ) N
= NN N
4.7 CD N
, , N
p NN N
= NNP N
.035 NNP N
) ) N
after IN N
1 CD N
year NN N
. . N

Caregivers NNS N
in IN N
control NN i
and CC N
counseling VBG i
groups NNS N
whose WP$ N
relatives NNS N
entered VBD N
a DT N
nursing NN N
home NN N
improved VBD N
their PRP$ N
psychosocial JJ o
adjustment NN o
23 CD N
% NN N
on IN N
average JJ N
whereas NNS N
those DT N
continuing VBG N
to TO N
live VB N
in IN N
the DT N
community NN N
decreased VBN N
by IN N
8 CD N
% NN N
. . N

Almost NNP N
half NN N
as IN N
many JJ N
relatives NNS N
entered VBD N
nursing VBG N
homes NNS N
in IN N
the DT N
counseling NN i
group NN N
( ( N
n JJ N
= $ N
9 CD N
vs. FW N
n JJ N
= NNP N
5 CD N
) ) N
but CC N
these DT N
compared VBN N
to TO N
control VB i
group NN N
relatives NNS N
had VBD N
greater JJR N
annualized VBN N
per IN N
person NN N
expenditures NNS N
for IN N
health NN o
and CC o
social JJ o
services NNS o
( ( N
Cdn NNP N
$ $ N
23,437 CD N
vs. FW N
Cdn NNP N
$ $ N
15,151 CD N
) ) N
. . N

CONCLUSIONS NNP N
Caregivers NNPS N
found VBD N
nurse RB i
counseling VBG i
most JJS N
helpful JJ N
. . N

Those DT N
indicating VBG N
infrequent JJ N
use NN N
of IN N
logical JJ N
analysis NN N
coping VBG N
skills NNS N
showed VBD N
benefits NNS N
. . N

-DOCSTART- -10517189- O O

Ciprofloxacin NNP i
and CC i
rifampicin VB i
versus NN i
doxycycline NN i
and CC i
rifampicin NN i
in IN N
the DT N
treatment NN N
of IN N
brucellosis NN o
. . o

The DT N
present JJ N
study NN N
was VBD N
undertaken VBN N
to TO N
evaluate VB N
the DT N
efficacy NN o
, , o
safety NN o
, , o
and CC o
patient JJ o
tolerability NN o
of IN N
two CD N
antibiotic JJ N
regimens NNS N
for IN N
the DT N
treatment NN N
of IN N
brucellosis NN o
: : o
rifampicin NN i
600 CD i
mg/day NN i
and CC i
doxycycline VB i
200 CD i
mg/day NN i
for IN N
45 CD N
days NNS N
( ( N
group NN N
1 CD N
) ) N
, , N
versus FW N
rifampicin VBZ i
600 CD i
mg/day NN i
and CC i
ciprofloxacin NN i
1 CD i
g/day NN i
for IN i
30 CD i
days NNS i
( ( N
group NN N
2 CD N
) ) N
. . N

Forty JJ p
patients NNS p
were VBD p
diagnosed VBN p
with IN p
brucellosis NN p
based VBN p
on IN p
clinical JJ p
and CC p
microbiological JJ p
findings NNS p
. . p

The DT N
two CD N
groups NNS N
were VBD N
comparable JJ N
regarding VBG N
age NN N
and CC N
sex NN N
distribution NN N
. . N

The DT N
average JJ o
number NN o
of IN o
days NNS o
without IN o
fever NN o
and CC o
symptoms NNS o
was VBD N
lower JJR N
in IN N
group NN N
2 CD N
patients NNS N
than IN N
in IN N
group NN N
1 CD N
patients NNS N
( ( N
mean+/-SD JJ N
: : N
3.85+/-1.98 JJ N
for IN N
group NN N
1 CD N
vs. IN N
2.78+/-1.03 JJ N
for IN N
group NN N
2 CD N
, , N
P=0.044 NNP N
) ) N
. . N

During IN N
the DT N
1-year JJ N
follow-up JJ N
period NN N
, , N
three CD N
( ( N
15 CD N
% NN N
) ) N
patients NNS N
in IN N
group NN N
2 CD N
and CC N
two CD N
( ( N
10 CD N
% NN N
) ) N
patients NNS N
in IN N
group NN N
1 CD N
had VBD N
clinical JJ N
relapses NNS o
; : o
these DT N
rates NNS N
were VBD N
not RB N
significantly RB N
different JJ N
. . N

Ciprofloxacin NNP i
and CC i
rifampicin VB i
treatment NN N
for IN N
brucellosis NN o
is VBZ N
as RB N
effective JJ N
as IN N
the DT N
standard JJ N
regimen NNS N
of IN N
doxycycline NN i
and CC i
rifampicin NN i
and CC N
offers VBZ N
the DT N
advantage NN N
of IN N
a DT N
shorter JJR N
duration NN N
of IN N
treatment NN N
. . N

-DOCSTART- -24067301- O O

Oxytocin NNP i
promotes VBZ N
facial JJ o
emotion NN o
recognition NN o
and CC o
amygdala JJ o
reactivity NN o
in IN N
adults NNS p
with IN p
asperger JJ p
syndrome NN p
. . p

The DT N
neuropeptide JJ i
oxytocin NN i
has VBZ N
recently RB N
been VBN N
shown VBN N
to TO N
enhance VB N
eye NN o
gaze NN o
and CC o
emotion NN o
recognition NN o
in IN N
healthy JJ p
men NNS p
. . p

Here RB N
, , N
we PRP N
report VBP N
a DT N
randomized JJ N
double-blind NN N
, , N
placebo-controlled JJ i
trial NN N
that WDT N
examined VBD N
the DT N
neural JJ N
and CC N
behavioral JJ N
effects NNS N
of IN N
a DT N
single JJ N
dose NN N
of IN N
intranasal JJ i
oxytocin NN i
on IN N
emotion NN N
recognition NN N
in IN N
individuals NNS p
with IN p
Asperger NNP p
syndrome NN p
( ( p
AS IN p
) ) p
, , N
a DT N
clinical JJ N
condition NN N
characterized VBN N
by IN N
impaired JJ N
eye NN N
gaze NN N
and CC N
facial JJ N
emotion NN N
recognition NN N
. . N

Using VBG N
functional JJ i
magnetic JJ i
resonance NN i
imaging NN i
, , N
we PRP N
examined VBD N
whether IN N
oxytocin NN i
would MD N
enhance VB N
emotion NN o
recognition NN o
from IN N
facial JJ N
sections NNS N
of IN N
the DT N
eye NN N
vs VBZ N
the DT N
mouth JJ N
region NN N
and CC N
modulate JJ o
regional JJ o
activity NN o
in IN o
brain NN o
areas NNS o
associated VBN o
with IN o
face NN o
perception NN o
in IN N
both DT N
adults NNS p
with IN p
AS NNP p
, , N
and CC N
a DT N
neurotypical JJ i
control NN i
group NN N
. . N

Intranasal NNP N
administration NN N
of IN N
the DT N
neuropeptide JJ i
oxytocin NN i
improved VBD N
performance NN o
in IN o
a DT o
facial JJ o
emotion NN o
recognition NN o
task NN o
in IN N
individuals NNS p
with IN p
AS NNP p
. . p

This DT N
was VBD N
linked VBN N
to TO N
increased VBN o
left JJ o
amygdala NN o
reactivity NN o
in IN N
response NN N
to TO N
facial JJ N
stimuli NNS N
and CC N
increased JJ o
activity NN o
in IN N
the DT N
neural JJ o
network NN o
involved VBN N
in IN N
social JJ N
cognition NN N
. . N

Our PRP$ N
data NNS N
suggest VBP N
that IN N
the DT N
amygdala NN N
, , N
together RB N
with IN N
functionally RB N
associated VBN N
cortical JJ N
areas NNS N
mediate VBP N
the DT N
positive JJ N
effect NN N
of IN N
oxytocin NN i
on IN N
social JJ o
cognitive JJ o
functioning NN o
in IN N
AS NNP N
. . N

-DOCSTART- -11863211- O O

Effect NN N
of IN N
oxolamine NN i
on IN N
cough JJ o
sensitivity NN o
in IN N
COPD NNP p
patients NNS p
. . p

-DOCSTART- -15830983- O O

Disc NNP i
coablation NN i
and CC i
epidural JJ i
injection NN i
of IN i
steroids NNS i
: : i
a DT N
comparison NN N
of IN N
strategies NNS N
in IN N
the DT N
treatment NN N
of IN N
mechanical JJ p
spinal JJ p
discogenic NN p
pain NN p
. . p

In IN N
this DT N
study NN N
two CD N
strategies NNS N
in IN N
the DT N
treatment NN N
of IN N
Mechanical NNP N
Spinal NNP N
Discogenic NNP N
Pain NNP N
have VBP N
been VBN N
compared VBN N
: : N
Disc NNP i
Coablation NNP i
and CC i
Epidural NNP i
Injection NNP i
of IN i
Steroids NNP i
. . i

In IN p
2003 CD p
50 CD p
patients NNS p
treated VBN p
with IN p
one CD i
or CC i
two CD i
epidural JJ i
injections NNS i
have VBP p
been VBN p
selected VBN p
ad NN p
random NN p
and CC p
50 CD p
patients NNS p
treated VBN p
with IN p
disc JJ i
coablation NN i
. . i

Comparison NNP N
of IN N
the DT N
data NNS N
indicated VBD N
an DT N
improvement NN N
of IN N
average JJ o
VAS NNP o
when WRB N
relaxed NN N
for IN N
both DT N
groups NNS N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
, , N
while IN N
after IN N
slight-moderate JJ N
strain NN N
, , N
this DT N
value NN N
was VBD N
significant JJ N
only RB N
after IN N
coablation NN i
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

Finally RB N
, , N
average JJ o
VAS NNP o
was VBD N
clearly RB N
lower JJR N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
after IN N
coablation NN N
as IN N
compared VBN N
to TO N
epidural JJ i
injections NNS i
. . N

-DOCSTART- -8472567- O O

A DT N
clinical JJ N
evaluation NN N
of IN N
a DT N
blood NN i
conservation NN i
device NN i
in IN N
medical JJ p
intensive JJ p
care NN p
unit NN p
patients NNS p
. . p

OBJECTIVES NNP N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
a DT N
) ) N
document NN N
the DT N
efficacy NN N
of IN N
a DT N
device NN N
intended VBN N
to TO N
conserve VB N
blood NN N
in IN N
critically RB p
ill JJ p
patients NNS p
; : p
b NN N
) ) N
determine VBZ N
the DT N
effect NN N
of IN N
this DT N
blood NN N
conservation NN N
on IN N
hemoglobin JJ o
concentration NN o
and CC N
the DT N
need NN o
for IN o
blood NN o
transfusions NNS o
; : o
c NNS N
) ) N
determine VBP N
if IN N
the DT N
blood NN N
conservation NN N
device NN N
resulted VBD N
in IN N
interference NN N
with IN N
arterial JJ N
pressure NN N
waveforms NNS N
; : N
d NN N
) ) N
determine NN N
if IN N
use NN N
of IN N
the DT N
blood NN N
conservation NN N
device NN N
resulted VBD N
in IN N
a DT N
difference NN N
in IN N
the DT N
number NN N
of IN N
accidental JJ N
needle JJ N
punctures NNS N
suffered VBN N
by IN N
healthcare JJ N
workers NNS N
. . N

DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
, , N
controlled VBD N
trial NN N
. . N

A DT N
clinical JJ N
trial NN N
using VBG N
prospective JJ N
, , N
random JJ N
allocation NN N
of IN N
consecutive JJ N
eligible JJ N
patients NNS N
. . N

SETTING VBG N
The DT p
medical JJ p
intensive JJ p
care NN p
unit NN p
( ( p
ICU NNP p
) ) p
of IN p
a DT p
university NN p
hospital NN p
located VBN p
in IN p
a DT p
large JJ p
metropolitan JJ p
area NN p
. . p

PATIENTS VB N
A DT p
total NN p
of IN p
100 CD p
patients NNS p
who WP p
were VBD p
admitted VBN p
to TO p
the DT p
medical JJ p
ICU NNP p
, , p
required VBD p
arterial JJ p
line NN p
monitoring NN p
for IN p
clinical JJ p
purposes NNS p
, , p
and CC p
were VBD p
managed VBN p
by IN p
the DT p
ICU NNP p
medical JJ p
service NN p
. . p

Exclusion NNP p
criteria NNS p
included VBD p
active JJ p
bleeding NN p
or CC p
chronic JJ p
renal JJ p
failure NN p
at IN p
the DT p
time NN p
of IN p
ICU NNP p
admission NN p
. . p

INTERVENTIONS JJ N
Patients NNPS N
in IN N
the DT N
experimental JJ N
group NN N
had VBD N
a DT N
blood NN i
conservation NN i
device NN i
incorporated VBN i
into IN i
the DT i
arterial JJ i
pressure NN i
monitoring NN i
system NN i
, , N
while IN N
patients NNS N
in IN N
the DT N
control NN i
group NN i
received VBD i
a DT i
conventional JJ i
arterial JJ i
pressure NN i
monitoring NN i
system NN i
. . i

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Data NNP N
gathered VBD N
included VBN N
: : N
age NN N
; : N
gender NN N
; : N
ICU NNP N
discharge NN N
status NN N
; : N
the DT N
duration NN o
of IN o
ICU NNP o
stay NN o
; : o
time NN o
in IN o
the DT o
study NN o
; : o
volume NN o
of IN o
all DT o
blood NN o
drawn NN o
, , o
discarded VBD o
, , o
or CC o
lost VBN o
due JJ o
to TO o
leakage VB o
; : o
hemoglobin JJ o
concentrations NNS o
; : o
blood NN o
transfusions NNS o
; : o
and CC o
accidental JJ o
needle JJ o
injuries NNS o
. . o

Arterial JJ o
pressure NN o
waveforms NNS o
were VBD N
recorded VBN N
and CC N
inspected VBN N
for IN N
dampening VBG N
or CC N
other JJ N
deformation NN N
. . N

Mean NNP o
hemoglobin JJ o
concentrations NNS o
were VBD N
compared VBN N
on IN N
ICU NNP N
admission NN N
and CC N
at IN N
12-hr JJ N
intervals NNS N
. . N

Demographic NNP N
and CC N
clinical JJ N
characteristics NNS N
of IN N
the DT N
two CD N
groups NNS N
were VBD N
not RB N
significantly RB N
different JJ N
. . N

The DT N
volume NN o
of IN o
blood NN o
drawn NN o
and CC o
discarded VBD o
from IN o
arterial JJ o
catheters NNS o
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
blood NN N
conservation NN N
group NN N
( ( N
blood NN N
conservation NN N
device NN N
: : N
5.7 CD N
+/- JJ N
7.5 CD N
mL NN N
; : N
control NN N
: : N
96.4 CD N
+/- JJ N
88.5 CD N
mL NN N
; : N
p CC N
< NNP N
.0001 NNP N
) ) N
, , N
as IN N
was VBD N
the DT N
total JJ o
volume NN o
of IN o
blood NN o
discarded VBN o
( ( N
blood NN N
conservation NN N
device NN N
: : N
19.4 CD N
+/- JJ N
47.4 CD N
mL NN N
; : N
control NN N
: : N
103.5 CD N
+/- JJ N
99.9 CD N
mL NN N
; : N
p CC N
< NNP N
.0001 NNP N
) ) N
. . N

Mean NNP o
hemoglobin JJ o
concentration NN o
on IN N
admission NN N
was VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
( ( N
blood NN N
conservation NN N
device NN N
group NN N
: : N
11.8 CD N
+/- JJ N
2.5 CD N
g/dL NN N
; : N
control NN N
group NN N
: : N
12.6 CD N
+/- JJ N
2.3 CD N
g/dL NN N
) ) N
. . N

In IN N
both DT N
groups NNS N
, , N
the DT N
mean JJ o
hemoglobin NN o
concentration NN o
declined VBD N
most JJS N
rapidly RB N
in IN N
the DT N
first JJ N
24 CD N
hrs NN N
of IN N
ICU NNP N
care NN N
and CC N
, , N
thereafter RB N
, , N
declined VBD N
more RBR N
slowly RB N
. . N

Although IN N
the DT N
mean JJ o
hemoglobin NN o
concentration NN o
was VBD N
higher RBR N
in IN N
the DT N
blood NN N
conservation NN N
group NN N
after IN N
6 CD N
days NNS N
, , N
statistical JJ N
significance NN N
was VBD N
not RB N
reached VBN N
until IN N
9.5 CD N
days NNS N
of IN N
ICU NNP N
care NN N
. . N

The DT N
mean JJ o
change NN o
in IN o
hemoglobin JJ o
concentration NN o
( ( N
overall JJ N
: : N
1.2 CD N
+/- JJ N
2.2 CD N
g/dL NN N
) ) N
during IN N
the DT N
study NN N
represents VBZ N
a DT N
statistically RB N
significant JJ N
( ( N
p JJ N
< NNP N
.0001 NNP N
) ) N
decrease NN N
of IN N
9.7 CD N
% NN N
. . N

Hemoglobin NNP o
concentration NN o
during IN N
the DT N
study NN N
decreased VBN N
by IN N
1.4 CD N
+/- JJ N
2.2 CD N
g/dL NN N
in IN N
the DT N
control NN N
group NN N
and CC N
1.0 CD N
+/- JJ N
2.3 CD N
g/dL NN N
in IN N
the DT N
blood NN N
conservation NN N
group NN N
( ( N
p JJ N
= NNP N
nonsignificant NN N
) ) N
. . N

Univariate NNP o
and CC o
multiple JJ o
regression NN o
analysis NN o
demonstrated VBD N
discarded JJ N
blood NN o
volume NN o
to TO N
be VB N
a DT N
significant JJ N
and CC N
independent JJ N
predictor NN N
of IN N
the DT N
decline NN N
in IN N
hemoglobin JJ N
concentration NN N
. . N

Transfusion NN o
requirements NNS o
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

The DT N
blood NN i
conservation NN i
system NN i
did VBD N
not RB N
alter VB N
or CC N
interfere VB N
with IN N
pressure NN o
waveforms NNS o
. . o

There EX N
were VBD N
no DT N
accidental JJ o
needle JJ o
injuries NNS o
noted VBD N
. . N

CONCLUSIONS VB N
The DT N
conservation NN N
of IN N
blood NN N
in IN N
critically RB p
ill JJ p
patients NNS p
must MD N
be VB N
a DT N
high-priority JJ N
concern NN N
of IN N
all DT N
healthcare JJ N
workers NNS N
. . N

Our PRP$ N
data NNS N
indicate VBP N
that IN N
the DT N
blood NN N
conservation NN N
system NN N
eliminates VBZ N
a DT N
significant JJ N
factor NN N
in IN N
the DT N
decline NN N
in IN N
hemoglobin JJ o
concentration NN o
. . o

With IN N
devices NNS N
as IN N
described NN N
here RB N
, , N
there EX N
is VBZ N
no DT N
reason NN N
to TO N
continue VB N
the DT N
practice NN N
of IN N
wasting VBG N
the DT N
blood NN N
of IN N
critically RB p
ill JJ p
patients NNS p
in IN N
order NN N
to TO N
prevent VB N
preanalytic JJ N
error NN N
. . N

-DOCSTART- -22610128- O O

Study NN N
of IN N
the DT N
therapeutic JJ N
effects NNS N
of IN N
a DT N
hippotherapy NN i
simulator NN i
in IN N
children NNS p
with IN p
cerebral JJ p
palsy NN p
: : p
a DT N
stratified JJ N
single-blind NN N
randomized VBD N
controlled JJ N
trial NN N
. . N

OBJECTIVE UH N
To TO N
investigate VB N
whether IN N
hippotherapy NN i
( ( i
when WRB i
applied VBN i
by IN i
a DT i
simulator NN i
) ) i
improves VBZ N
postural JJ N
control NN N
and CC N
balance NN N
in IN N
children NNS p
with IN p
cerebral JJ p
palsy NN p
. . p

DESIGN NNP N
Stratified VBD N
single-blind JJ N
randomized NN N
controlled VBD N
trial NN N
with IN N
an DT N
independent JJ N
assessor NN N
. . N

Stratification NN N
was VBD N
made VBN N
by IN N
gross JJ N
motor NN N
function NN N
classification NN N
system NN N
levels NNS N
, , N
and CC N
allocation NN N
was VBD N
concealed VBN N
. . N

SUBJECTS NNP N
Children NNP p
between IN p
4 CD p
and CC p
18 CD p
years NNS p
old JJ p
with IN p
cerebral JJ p
palsy NN p
. . p

INTERVENTIONS JJ N
Participants NNS N
were VBD N
randomized VBN N
to TO N
an DT N
intervention NN i
( ( i
simulator NN i
ON NNP i
) ) i
or CC i
control NN i
( ( i
simulator VB i
OFF NNP i
) ) i
group NN N
after IN N
getting VBG N
informed JJ N
consent NN N
. . N

Treatment NNP N
was VBD N
provided VBN N
once RB N
a DT N
week NN N
( ( N
15 CD N
minutes NNS N
) ) N
for IN N
10 CD N
weeks NNS N
. . N

MAIN NNP N
MEASURES NNP N
Gross NNP o
Motor NNP o
Function NNP o
Measure NNP o
( ( o
dimension NN o
B NNP o
for IN o
balance NN o
and CC o
the DT o
Total NNP o
Score NNP o
) ) o
and CC o
Sitting VBG o
Assessment NNP o
Scale NNP o
were VBD N
carried VBN N
out RP N
at IN N
baseline NN N
( ( N
prior JJ N
to TO N
randomization NN N
) ) N
, , N
end NN N
of IN N
intervention NN N
and CC N
12 CD N
weeks NNS N
after IN N
completing VBG N
the DT N
intervention NN N
. . N

RESULTS NNP N
Thirty-eight JJ p
children NNS p
participated VBN p
. . p

The DT N
groups NNS N
were VBD N
balanced VBN N
at IN N
baseline NN N
. . N

Sitting VBG o
balance NN o
( ( N
measured VBN N
by IN N
dimension NN N
B NNP N
of IN N
the DT N
Gross NNP N
Motor NNP N
Function NNP N
Measure NNP N
) ) N
improved VBD N
significantly RB N
in IN N
the DT N
treatment NN N
group NN N
( ( N
effect NN N
size NN N
= $ N
0.36 CD N
; : N
95 CD N
% NN N
CI NNP N
0.01-0.71 NN N
) ) N
and CC N
the DT N
effect NN o
size NN o
was VBD N
greater JJR N
in IN N
the DT N
severely RB N
disabled JJ N
group NN N
( ( N
effect NN N
size NN N
= $ N
0.80 CD N
; : N
95 CD N
% NN N
CI NNP N
0.13-1.47 NN N
) ) N
. . N

The DT N
improvements NNS o
in IN o
sitting VBG o
balance NN o
were VBD N
not RB N
maintained VBN N
over IN N
the DT N
follow-up JJ N
period NN N
. . N

Changes NNS N
in IN N
the DT N
total JJ o
score NN o
of IN o
the DT o
Gross NNP o
Motor NNP o
Function NNP o
Measure NNP o
and CC o
the DT o
Sitting NNP o
Assessment NNP o
Scale NNP o
were VBD N
not RB N
significant JJ N
. . N

CONCLUSION NNP N
Hippotherapy NNP i
with IN N
a DT N
simulator NN N
can MD N
improve VB N
sitting VBG o
balance NN o
in IN N
cerebral JJ p
palsy NN p
children NNS p
who WP N
have VBP N
higher JJR N
levels NNS N
of IN N
disability NN N
. . N

However RB N
, , N
this DT N
did VBD N
not RB N
lead VB N
to TO N
a DT N
change NN N
in IN N
the DT N
overall JJ N
function NN N
of IN N
these DT N
children NNS N
( ( N
Gross NNP N
Motor NNP N
Function NNP N
Classification NNP N
System NNP N
level JJ N
V NNP N
) ) N
. . N

-DOCSTART- -19437058- O O

Effects NNS N
of IN N
dietary JJ N
coconut NN N
oil NN N
on IN N
the DT N
biochemical JJ o
and CC o
anthropometric JJ o
profiles NNS o
of IN N
women NNS p
presenting VBG p
abdominal JJ p
obesity NN p
. . p

The DT N
effects NNS N
of IN N
dietary JJ N
supplementation NN N
with IN N
coconut JJ N
oil NN N
on IN N
the DT N
biochemical JJ o
and CC o
anthropometric JJ o
profiles NNS o
of IN N
women NNS p
presenting VBG p
waist JJ p
circumferences NNS p
( ( p
WC NNP p
) ) p
> VBD p
88 CD p
cm NN p
( ( p
abdominal JJ p
obesity NN p
) ) p
were VBD N
investigated VBN N
. . N

The DT N
randomised JJ N
, , N
double-blind JJ N
, , N
clinical JJ N
trial NN N
involved VBD N
40 CD p
women NNS p
aged VBN p
20-40 JJ p
years NNS p
. . p

Groups NNP N
received VBD i
daily JJ i
dietary JJ i
supplements NNS i
comprising VBG i
30 CD i
mL NN i
of IN i
either DT i
soy JJ i
bean JJ i
oil NN i
( ( i
group NN i
S NNP i
; : i
n CC i
= VB i
20 CD i
) ) i
or CC i
coconut JJ i
oil NN i
( ( i
group NN i
C NNP i
; : i
n CC i
= VB i
20 CD i
) ) i
over IN i
a DT i
12-week JJ i
period NN i
, , i
during IN i
which WDT i
all DT i
subjects NNS i
were VBD i
instructed VBN i
to TO i
follow VB i
a DT i
balanced JJ i
hypocaloric JJ i
diet NN i
and CC i
to TO i
walk VB i
for IN i
50 CD i
min NNS i
per IN i
day NN i
. . i

Data NNS i
were VBD i
collected VBN i
1 CD i
week NN i
before IN i
( ( i
T1 NNP i
) ) i
and CC i
1 CD i
week NN i
after IN i
( ( i
T2 NNP i
) ) i
dietary JJ i
intervention NN i
. . i

Energy NNP o
intake NN o
and CC o
amount NN o
of IN o
carbohydrate NN o
ingested VBN o
by IN N
both DT N
groups NNS N
diminished VBD N
over IN N
the DT N
trial NN N
, , N
whereas IN N
the DT N
consumption NN o
of IN o
protein NN o
and CC o
fibre NN o
increased VBD N
and CC N
lipid JJ N
ingestion NN N
remained VBD N
unchanged JJ N
. . N

At IN N
T1 NNP N
there EX N
were VBD N
no DT N
differences NNS N
in IN N
biochemical JJ o
or CC o
anthropometric JJ o
characteristics NNS o
between IN N
the DT N
groups NNS N
, , N
whereas NNS N
at IN N
T2 NNP N
group NN N
C NNP N
presented VBD N
a DT N
higher JJR N
level NN N
of IN N
HDL NNP N
( ( N
48.7 CD N
+/- JJ N
2.4 CD N
vs. FW N
45.00 CD N
+/- JJ N
5.6 CD N
; : N
P NNP N
= NNP N
0.01 CD N
) ) N
and CC N
a DT N
lower JJR N
LDL NN N
: : N
HDL NNP N
ratio NN N
( ( N
2.41 CD N
+/- JJ N
0.8 CD N
vs. FW N
3.1 CD N
+/- JJ N
0.8 CD N
; : N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

Reductions NNPS o
in IN o
BMI NNP o
were VBD N
observed VBN N
in IN N
both DT N
groups NNS N
at IN N
T2 NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
but CC N
only RB N
group NN N
C NNP N
exhibited VBD N
a DT N
reduction NN N
in IN N
WC NNP o
( ( N
P NNP N
= NNP N
0.005 CD N
) ) N
. . N

Group NNP N
S NNP N
presented VBD N
an DT N
increase NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
in IN N
total JJ o
cholesterol NN o
, , o
LDL NNP o
and CC o
LDL NNP o
: : o
HDL NNP o
ratio NN o
, , N
whilst WP N
HDL NNP o
diminished VBD N
( ( N
P NNP N
= NNP N
0.03 CD N
) ) N
. . N

Such JJ N
alterations NNS N
were VBD N
not RB N
observed VBN N
in IN N
group NN N
C. NNP N
It PRP N
appears VBZ N
that IN N
dietetic JJ N
supplementation NN N
with IN N
coconut JJ N
oil NN N
does VBZ N
not RB N
cause VB N
dyslipidemia NN N
and CC N
seems VBZ N
to TO N
promote VB N
a DT N
reduction NN N
in IN N
abdominal JJ o
obesity NN o
. . o

-DOCSTART- -21055113- O O

[ JJ N
Management NNP N
of IN N
the DT N
perineal NN N
wounds NNS N
after IN N
abdominoperineal JJ N
resection NN N
: : N
simple JJ i
drainage NN i
only RB N
or CC N
with IN N
continuous JJ i
irrigation NN i
? . N
] NN N
. . N

OBJECTIVE UH N
To TO N
compare VB N
the DT N
effects NNS N
of IN N
presacral JJ i
irrigation NN i
and CC N
simple JJ i
drainage NN i
on IN N
the DT N
perineal NN N
wound NN N
healing NN N
in IN N
patients NNS p
after IN p
abdominoperineal JJ i
resection NN i
( ( i
APR NNP i
) ) i
. . i

METHODS NNP N
From IN N
October NNP N
2004 CD N
to TO N
August NNP N
2009 CD N
, , N
patients NNS p
with IN p
rectal JJ p
cancer NN p
, , p
ulcerative JJ p
colitis NN p
or CC p
rectal JJ p
gastrointestinal JJ p
stromal JJ p
tumor NN p
, , p
who WP p
underwent JJ p
APR NNP i
or CC i
proctocolectomy NN i
, , N
were VBD N
randomized VBN N
into IN N
two CD N
arms NNS N
: : N
simple JJ i
drainage NN i
group NN N
( ( N
n JJ N
= NNP N
37 CD N
) ) N
and CC N
continuous JJ i
irrigation NN i
( ( N
n JJ N
= NNP N
37 CD N
) ) N
. . N

Patients NNS N
randomized VBD N
to TO N
arm VB N
B NNP N
received VBD N
simple JJ i
drainage NN i
only RB N
to TO N
presacral JJ N
space NN N
; : N
while IN N
those DT N
patients NNS N
in IN N
arm NN N
A NNP N
received VBD N
continuous JJ i
irrigation NN i
in IN N
addition NN N
to TO N
simple JJ N
drainage NN N
. . N

Perineal NNP N
wound IN N
healing NN N
was VBD N
taken VBN N
as IN N
endpoint NN N
of IN N
this DT N
study NN N
. . N

Major JJ N
complication NN N
was VBD N
defined VBN N
as IN N
wound JJ o
dehiscence NN o
or CC o
wound NN o
infection NN o
that IN o
the DT o
perineal NN o
wound NN o
should MD o
be VB o
reopened VBN o
for IN o
drainage NN o
. . o

Minor JJ N
complication NN N
was VBD N
defined VBN N
as IN N
delayed JJ o
healing VBG o
wound NN o
with IN o
seroma NN o
or CC o
hematoma NN o
. . o

RESULTS VB N
A DT N
total NN N
of IN N
74 CD p
patients NNS p
were VBD p
enrolled VBN p
in IN p
present JJ p
study NN p
, , N
with IN N
37 CD N
patients NNS N
in IN N
each DT N
arm NN N
, , N
and CC N
there EX N
were VBD N
12 CD N
cases NNS N
and CC N
10 CD N
cases NNS N
who WP N
received VBD N
preoperative JJ N
radiation NN N
therapy NN N
, , N
respectively RB N
. . N

In IN N
the DT N
arm NN N
A NNP N
, , N
2 CD N
patients NNS N
developed VBD N
major JJ N
complications NNS N
, , N
3 CD N
patients NNS N
incurred VBN N
with IN N
minor JJ N
complications NNS N
and CC N
32 CD N
patients NNS N
got VBD N
primary JJ N
healing NN o
of IN N
the DT N
perineal NN N
wounds NNS N
. . N

In IN N
arm NN N
B NNP N
, , N
8 CD N
patients NNS N
suffered VBD N
major JJ N
complications NNS N
, , N
3 CD N
patients NNS N
incurred VBN N
with IN N
minor JJ N
complications NNS N
and CC N
26 CD N
patients NNS N
got VBD N
primary JJ N
healing NN N
of IN N
the DT N
perineal NN N
wounds VBZ N
. . N

The DT N
incidence NN o
of IN o
major JJ o
complication NN o
was VBD N
significantly RB N
lower JJR N
in IN N
arm NN N
A NNP N
( ( N
5.4 CD N
% NN N
vs.21.6 NN N
% NN N
, , N
P NNP N
= NNP N
0.042 CD N
) ) N
. . N

Patients NNS N
received VBD N
preoperative JJ N
radiation NN N
therapy NN N
had VBD N
significantly RB N
higher JJR N
rate NN o
of IN o
minor JJ o
complications NNS o
than IN N
patients NNS N
underwent JJ N
surgery NN N
only RB N
( ( N
18.2 CD N
% NN N
vs. FW N
3.9 CD N
% NN N
, , N
P NNP N
= NNP N
0.039 CD N
) ) N
. . N

CONCLUSIONS NNP N
Simple NNP i
drainage NN i
with IN i
continuous JJ i
irrigation NN i
of IN i
the DT i
presacral JJ i
space NN i
, , N
in IN N
patients NNS N
with IN N
abdominoperineal JJ N
resection NN N
or CC N
proctocolectomy NN N
, , N
could MD N
significantly RB N
lower VB N
the DT N
incidence NN N
of IN N
major JJ N
complication NN N
and CC N
improve VB N
wound NN N
healing VBG N
for IN N
perineal NN N
wound NN N
when WRB N
compared VBN N
with IN N
simple JJ N
drainage NN N
only RB N
. . N

Preoperative JJ N
radiation NN N
therapy NN N
tends VBZ N
to TO N
increase VB N
the DT N
incidence NN N
of IN N
minor JJ N
complications NNS N
. . N

-DOCSTART- -8467027- O O

[ JJ N
Prevention NNP N
of IN N
pneumonia NN o
by IN N
endotracheal JJ N
micronebulization NN N
of IN N
tobramycin NN i
] NN i
. . N

In IN N
69 CD p
artificially RB p
ventilated JJ p
patients NNS p
the DT p
clinical JJ o
, , o
bacteriological JJ o
and CC p
pharmacological JJ o
effects NNS o
of IN p
endotracheally RB p
administered VBN p
tobramycin NN i
were VBD N
studied VBN N
in IN N
comparison NN N
to TO N
a DT N
control NN N
group NN N
. . N

In IN N
the DT N
therapy NN N
group NN N
, , N
52 CD N
% NN N
of IN N
all DT N
specimens NNS N
were VBD N
sterile JJ N
, , N
in IN N
the DT N
control NN N
group NN N
only RB N
25 CD N
% NN N
. . N

During IN N
the DT N
first JJ N
4 CD N
days NNS N
these DT N
changes NNS N
were VBD N
significant JJ N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

In IN N
the DT N
therapy NN N
group NN N
the DT N
endotracheal JJ o
colonisation NN o
with IN o
ps NN o
. . o

aeruginosa NN o
was VBD N
significantly RB N
lower JJR N
between IN N
the DT N
4th CD N
and CC N
14th CD N
day NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
incidence NN o
of IN o
secondary JJ o
pneumonia NN o
was VBD N
reduced VBN N
from IN N
42 CD N
% NN N
to TO N
17.5 CD N
% NN N
( ( N
not RB N
significant JJ N
) ) N
. . N

Systemic JJ o
administration NN o
of IN o
antibiotics NNS o
, , N
e.g NN N
. . N

of IN N
aminoglycosides NNS N
, , N
was VBD N
significantly RB N
more RBR N
often RB N
necessary JJ N
in IN N
the DT N
control NN N
group NN N
. . N

No DT N
increasing VBG N
of IN N
growth NN o
of IN o
fungi NN o
in IN o
the DT o
upper JJ o
respiratory NN o
tract NN o
was VBD N
observed VBN N
, , N
but CC N
these DT N
was VBD N
a DT N
non-significantly RB N
higher JJR N
incidence NN o
mainly RB o
of IN o
staph NN o
. . o

epidermidis NN o
. . o

The DT N
application NN N
of IN N
80 CD N
mg NNS N
tobramycin RB N
four CD N
times NNS N
a DT N
day NN N
as IN N
an DT N
aerosol NN N
was VBD N
well RB N
tolerated VBN o
by IN N
the DT N
patients NNS N
. . N

Under IN N
there EX N
conditions NNS N
, , N
tobramycin NN N
could MD N
not RB N
be VB N
measured VBN N
in IN N
the DT N
serum NN N
. . N

No DT N
allergic JJ o
reactions NNS o
, , N
increased VBD N
respiratory NN o
pressures NNS o
or CC N
bronchoconstrictions NNS o
were VBD N
observed VBN N
. . N

-DOCSTART- -17164971- O O

Assisted VBN i
exercise NN i
and CC N
bone NN N
strength NN N
in IN N
preterm JJ p
infants NNS p
. . p

Studies NNS N
have VBP N
previously RB N
demonstrated VBN N
that IN N
brief NN N
( ( N
4 CD N
weeks NNS N
) ) N
passive VBP N
range-of-motion NN N
exercise NN i
is VBZ N
beneficial JJ N
for IN N
bone NN N
development NN N
in IN N
very RB N
low JJ N
birth NN N
weight NN N
( ( N
VLBW NNP N
) ) N
preterm NN N
infants NNS N
. . N

However RB N
, , N
the DT N
optimal JJ N
duration NN N
of IN N
exercise NN N
for IN N
bone NN N
development NN N
in IN N
preterm JJ N
infants NNS N
is VBZ N
yet RB N
unknown JJ N
. . N

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
examine VB N
the DT N
effect NN N
of IN N
8 CD N
weeks NNS N
of IN N
assisted JJ i
exercise NN i
on IN N
bone NN N
strength NN N
and CC N
metabolism NN N
in IN N
VLBW NNP p
premature NN p
infants NNS p
. . p

Sixteen JJ p
infants NNS p
( ( p
mean JJ p
+/- JJ p
standard NN p
error NN p
of IN p
the DT p
mean JJ p
birth NN p
weight VBD p
1,009 CD p
+/- JJ p
55 CD p
g NN p
and CC p
gestational JJ p
age NN p
27.3 CD p
+/- JJ p
0.3 CD p
weeks NNS p
) ) p
were VBD N
randomly RB N
assigned VBN N
into IN N
exercise NN N
( ( N
n JJ N
= NNP N
8 CD N
) ) N
and CC N
control NN i
( ( N
n JJ N
= NNP N
8 CD N
) ) N
groups NNS N
. . N

The DT N
intervention NN N
started VBD N
at IN N
the DT N
first JJ N
week NN N
of IN N
life NN N
and CC N
involved VBD N
8 CD N
weeks NNS N
of IN N
daily JJ i
passive JJ i
extension NN i
and CC i
flexion NN i
range-of-motion NN i
exercise NN i
of IN N
the DT N
upper JJ N
and CC N
lower JJR N
extremities NNS N
. . N

Biochemical JJ o
markers NNS o
of IN o
bone NN o
turnover NN o
were VBD N
measured VBN N
at IN N
enrollment NN N
and CC N
after IN N
8 CD N
weeks NNS N
. . N

Bone NNP o
strength NN o
was VBD N
measured VBN N
weekly JJ N
by IN N
quantitative JJ N
ultrasound JJ N
measurement NN N
of IN N
tibial JJ o
bone NN o
speed NN o
of IN o
sound NN o
( ( N
SOS NNP N
) ) N
. . N

Bone NNP o
SOS NNP o
decreased VBD N
significantly RB N
in IN N
the DT N
control NN N
group NN N
( ( N
-108.1 JJ N
+/- JJ N
33.7 CD N
m/second NN N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
during IN N
the DT N
study NN N
period NN N
, , N
while IN N
remaining VBG N
stable JJ N
in IN N
the DT N
exercise NN N
group NN N
( ( N
11.3 CD N
+/- JJ N
22.8 CD N
m/second NN N
) ) N
. . N

The DT N
main JJ o
beneficial JJ o
effect NN o
of IN o
exercise NN o
occurred VBN N
in IN N
the DT N
first JJ N
4 CD N
weeks NNS N
of IN N
the DT N
intervention NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
bone NN o
turnover NN o
marker NN o
changes NNS o
between IN N
the DT N
groups NNS N
. . N

There EX N
is VBZ N
a DT N
significant JJ N
postnatal JJ o
decrease NN o
in IN o
bone NN o
SOS NNP o
in IN N
VLBW NNP N
preterm NN N
infants NNS N
. . N

Eight NNP N
weeks NNS N
of IN N
assisted JJ N
range-of-motion NN N
exercise NN i
attenuates VBZ N
the DT N
decrease NN o
in IN N
bone NN o
strength NN o
and CC N
may MD N
decrease VB N
the DT N
risk NN o
of IN o
osteopenia NN o
in IN N
premature JJ N
infants NNS N
. . N

-DOCSTART- -24807158- O O

Poor NNP p
prognosis NN p
patients NNS p
with IN p
inoperable JJ p
locally RB p
advanced JJ p
NSCLC NNP p
and CC p
large JJ p
tumors NNS p
benefit VBP N
from IN N
palliative JJ i
chemoradiotherapy NN i
: : i
a DT N
subset NN N
analysis NN N
from IN N
a DT N
randomized JJ N
clinical JJ N
phase NN N
III NNP N
trial NN N
. . N

INTRODUCTION NNP N
Poor NNP p
prognosis NN p
patients NNS p
with IN p
bulky JJ p
stage NN p
III NNP p
locally RB p
advanced VBD p
non-small-cell JJ p
lung NN p
cancer NN p
may MD N
not RB N
be VB N
offered VBN N
concurrent JJ N
chemoradiotherapy NN N
( ( N
CRT NNP N
) ) N
. . N

Following VBG N
a DT N
phase NN N
III NNP N
trial NN N
concerning VBG N
the DT N
effect NN o
of IN N
palliative JJ N
CRT NNP i
in IN N
inoperable JJ N
poor JJ p
prognosis NN p
patients NNS p
, , N
this DT N
analysis NN N
was VBD N
performed VBN N
to TO N
explore VB N
how WRB N
tumor JJ N
size NN N
influenced VBD N
survival JJ o
and CC o
health-related JJ o
quality NN o
of IN o
life NN o
( ( o
HRQOL NNP o
) ) o
. . o

METHODS CC N
A DT p
total NN p
of IN p
188 CD p
poor JJ p
prognosis NN p
patients NNS p
recruited VBN p
in IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
received VBD N
four CD N
courses NNS N
intravenous JJ i
carboplatin NNS i
day NN i
1 CD i
and CC i
oral JJ i
vinorelbine NN i
day NN i
1 CD i
and CC i
8 CD i
, , i
at IN i
3-week JJ i
intervals NNS i
. . i

The DT N
experimental JJ N
arm NN N
( ( N
N NNP N
= NNP N
94 CD N
) ) N
received VBD N
radiotherapy NN i
with IN i
fractionation NN i
42 CD i
Gy/15 NNP i
, , N
starting VBG N
at IN N
the DT N
second JJ N
chemotherapy NN N
course NN N
. . N

This DT N
subset NN N
study NN N
compares VBZ o
outcomes NNS o
in IN o
patients NNS o
with IN o
tumors NNS o
larger JJR o
than IN o
7 CD o
cm NN o
( ( o
N NNP o
= NNP o
108 CD o
) ) o
versus NN o
tumors NNS o
7 CD o
cm NN o
or CC o
smaller JJR o
( ( o
N NNP o
= NNP o
76 CD o
) ) o
. . o

RESULTS NNP N
Among IN N
those DT N
with IN N
tumors NNS N
larger JJR N
than IN N
7 CD N
cm NN N
, , N
the DT N
median JJ o
overall JJ o
survival NN o
in IN N
the DT N
chemotherapy NN i
versus NN N
CRT NNP i
arm NN N
was VBD N
9.7 CD N
and CC N
13.4 CD N
months NNS N
, , N
respectively RB N
( ( N
p JJ N
= NNP N
0.001 CD N
) ) N
. . N

The DT N
1-year JJ o
survival NN o
was VBD N
33 CD N
% NN N
and CC N
56 CD N
% NN N
, , N
respectively RB N
( ( N
p JJ N
= NNP N
0.01 CD N
) ) N
. . N

Except IN N
for IN N
a DT N
temporary JJ N
decline NN N
during IN N
treatment NN N
, , N
HRQOL NNP o
was VBD N
maintained VBN N
in IN N
the DT N
CRT NNP i
arm NN N
, , N
regardless RB N
of IN N
tumor NN N
size NN N
. . N

Among IN N
those DT N
who WP N
did VBD N
not RB N
receive VB N
CRT NNP i
, , N
patients NNS N
with IN N
tumors NNS N
larger JJR N
than IN N
7 CD N
cm NN N
experienced VBD N
a DT N
gradual JJ N
decline NN N
in IN N
the DT N
HRQOL NNP o
. . o

The DT N
CRT NNP i
group NN N
had VBD N
significantly RB o
more RBR o
esophagitis JJ o
and CC o
hospitalizations NNS o
because IN N
of IN N
side NN o
effects NNS o
regardless RB N
of IN N
tumor NN N
size NN N
. . N

CONCLUSION NNP N
In IN N
patients NNS p
with IN p
poor JJ p
prognosis NN p
and CC p
inoperable JJ p
locally RB p
advanced JJ p
non-small-cell JJ p
lung NN p
cancer NN p
, , N
large JJ N
tumor NN N
size NN N
should MD N
not RB N
be VB N
considered VBN N
a DT N
negative JJ N
predictive JJ N
factor NN N
. . N

Except IN N
for IN N
performance NN N
status NN N
2 CD N
, , N
patients NNS N
with IN N
tumors NNS N
larger JJR N
than IN N
7 CD N
cm NNS N
apparently RB N
benefit VBP N
from IN N
CRT NNP i
. . i

-DOCSTART- -15545310- O O

A DT N
randomized VBN N
crossover NN N
study NN N
investigating VBG N
the DT N
influence NN N
of IN N
ranitidine NN i
or CC i
omeprazole NN i
on IN N
the DT N
pharmacokinetics NNS o
of IN o
cephalexin NN o
monohydrate NN o
. . o

Limited VBN N
data NNS N
characterize RBR N
pharmacokinetic JJ N
interactions NNS N
between IN N
cephalexin NN N
and CC N
ranitidine NN N
, , N
and CC N
no DT N
data NNS N
exist VBP N
for IN N
an DT N
interaction NN N
with IN N
proton NN N
pump NN N
inhibitors NNS N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
ranitidine NN i
or CC N
omeprazole JJ i
administration NN N
on IN N
the DT N
pharmacokinetics NNS o
and CC o
pharmacodynamics NNS o
of IN o
cephalexin NN o
. . o

A DT N
randomized JJ N
single- NN N
and CC N
multiple-dose JJ N
crossover NN N
study NN N
was VBD N
conducted VBN N
in IN N
healthy JJ p
subjects NNS p
ingesting VBG p
cephalexin NN i
before IN p
and CC p
after IN p
steady-state JJ p
administration NN p
of IN p
ranitidine NN i
or CC i
omeprazole NN i
. . i

Time-concentration NN o
profiles NNS N
were VBD N
determined VBN N
and CC N
pharmacokinetic JJ o
parameters NNS o
were VBD N
characterized VBN N
using VBG N
noncompartmental JJ N
methods NNS N
. . N

Pharmacokinetic JJ N
data NNS N
were VBD N
analyzed VBN N
in IN N
accordance NN N
with IN N
the DT N
two CD N
1-sided JJ N
test NN N
for IN N
bioequivalence NN N
. . N

The DT N
percentage NN o
of IN o
time NN o
that IN o
serum JJ o
concentrations NNS o
remain VBP o
above IN o
the DT o
MIC NNP o
( ( o
90 CD o
) ) o
during IN o
the DT o
dosing VBG o
interval NN o
( ( o
T NNP o
> NNP o
MIC NNP o
( ( o
90 CD o
) ) o
) ) o
for IN o
Streptococcus NNP o
pyogenes NNS o
and CC o
Staphylococcus NNP o
aureus RB o
associated VBD o
with IN o
the DT o
pharmacokinetic JJ o
profiles NNS o
was VBD o
calculated VBN o
. . o

The DT N
coadministration NN N
of IN N
cephalexin NN N
with IN N
ranitidine NN N
or CC N
omeprazole NN N
resulted VBD N
in IN N
relatively RB N
minor JJ N
changes NNS N
in IN N
C NNP o
( ( o
max NN o
) ) o
, , o
AUC NNP o
( ( o
infinity NN o
) ) o
, , o
t EX o
( ( o
1/2 CD o
) ) o
, , o
or CC o
CL/F NNP o
. . o

t NN o
( ( o
max NN o
) ) o
was VBD N
significantly RB N
prolonged VBN N
when WRB N
cephalexin NN N
was VBD N
administered VBN N
with IN N
ranitidine NN N
or CC N
omeprazole NN N
. . N

Suboptimal NNP o
T NNP o
> NNP o
MIC NNP o
( ( o
90 CD o
) ) o
was VBD N
observed VBN N
for IN N
cephalexin NN N
irrespective NN N
of IN N
acid JJ N
suppression NN N
. . N

Delay NNP N
in IN N
absorption NN N
of IN N
cephalexin NN N
resulted VBN N
in IN N
a DT N
decrease NN N
in IN N
the DT N
percentage NN N
of IN N
T NNP o
> NNP o
MIC NNP o
( ( o
90 CD o
) ) o
for IN N
certain JJ N
acid-suppressive JJ N
regimens NNS N
and CC N
pathogen NN N
combinations NNS N
. . N

With IN N
the DT N
exception NN N
of IN N
an DT N
increase NN N
in IN N
t NN o
( ( o
max NN o
) ) o
, , N
there EX N
were VBD N
no DT N
significant JJ N
pharmacokinetic JJ N
interactions NNS N
between IN N
cephalexin NN N
and CC N
ranitidine NN N
or CC N
omeprazole NN N
. . N

Delayed VBN N
t NN o
( ( o
max NN o
) ) o
associated VBN N
with IN N
acid JJ N
suppression NN N
may MD N
result VB N
in IN N
a DT N
diminished JJ N
T NNP N
> NNP N
MIC NNP N
( ( N
90 CD N
) ) N
. . N

-DOCSTART- -25225698- O O

Methylprednisolone NN i
in IN N
patients NNS p
with IN p
cancer NN p
using VBG p
opioids NNS p
. . p

-DOCSTART- -20638818- O O

Prospective JJ N
randomized VBN N
trial NN N
of IN N
short-term JJ i
neoadjuvant JJ i
chemotherapy NN i
for IN N
advanced JJ p
gastric JJ p
cancer NN p
. . p

BACKGROUND IN N
We PRP N
performed VBD N
short-term JJ i
neoadjuvant JJ i
chemotherapy NN i
( ( i
s-NAC JJ i
) ) i
to TO N
examine VB N
whether IN N
anticancer NN N
drugs NNS N
can MD N
change VB N
the DT N
proliferative JJ N
ability NN N
of IN N
cancer NN N
cells NNS N
in IN N
gastric JJ p
cancer NN p
patients NNS p
. . p

METHODS NNP N
Chemotherapy NNP N
was VBD N
performed VBN N
for IN N
72 CD N
h NN N
before IN N
gastrectomy NN N
in IN N
63 CD p
gastric JJ p
cancer NN p
patients NNS p
. . p

Patients NNS N
were VBD N
classed VBN N
into IN N
four CD N
groups NNS N
: : N
Group NNP p
F NNP p
, , p
16 CD p
cases NNS p
who WP p
received VBD p
a DT p
single JJ p
administration NN p
of IN p
5-fluorouracil JJ i
( ( i
5-FU JJ i
) ) i
; : i
Group NNP p
C NNP p
, , p
15 CD p
cases NNS p
who WP p
received VBD p
a DT p
single JJ p
administration NN p
of IN p
cis-diamminedichloroplatinum NN i
( ( i
CDDP NNP i
; : i
cisplatin NN i
) ) i
; : i
Group NNP p
FC NNP p
, , p
16 CD p
cases NNS p
who WP p
received VBD p
both DT p
5-FU+CDDP JJ i
; : i
and CC N
a DT p
Control NNP p
group NN p
, , p
16 CD p
cases NNS p
who WP p
did VBD p
not RB i
receive VB i
chemotherapy NN i
. . i

We PRP N
reviewed VBD N
neoadjuvant JJ N
biopsy NN N
tissue NN N
and CC N
gastric JJ N
cancer NN N
tissue NN N
delivered VBN N
by IN N
operation NN N
in IN N
these DT N
cases NNS N
. . N

The DT N
TUNEL NNP N
method NN N
and CC N
immunohistochemistry NN N
with IN N
an DT N
anti-MIB-1 JJ N
antibody NN N
were VBD N
used VBN N
to TO N
evaluate VB N
cellular JJ o
apoptosis NN o
and CC o
proliferative JJ o
ability NN o
, , N
respectively RB N
. . N

The DT N
apoptotic JJ o
index NN o
( ( o
AI NNP o
) ) o
and CC o
an DT o
MIB-1 JJ o
index NN o
( ( o
MI NNP o
) ) o
were VBD N
also RB N
calculated VBN N
. . N

RESULTS VB N
There EX N
were VBD N
no DT N
differences NNS N
in IN N
AI NNP o
or CC o
MI NNP o
in IN N
biopsy NN N
tissue NN N
between IN N
the DT N
groups NNS N
. . N

The DT N
AI NNP o
of IN N
gastric JJ o
cancer NN o
tissue NN o
in IN N
Group NNP N
FC NNP N
was VBD N
significantly RB N
higher JJR N
than IN N
in IN N
the DT N
other JJ N
groups NNS N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
MI NNP o
of IN o
Group NNP o
FC NNP o
was VBD N
significantly RB N
lower JJR N
than IN N
in IN N
the DT N
other JJ N
groups NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

In IN N
addition NN N
, , N
after IN N
s-NAC JJ i
operation NN N
there EX N
was VBD N
a DT N
significant JJ N
inhibition NN N
of IN N
proliferative JJ o
potency NN o
and CC N
an DT N
induction NN N
of IN N
apoptosis NN o
in IN N
Group NNP N
FC NNP N
. . N

CONCLUSION NNP N
Combination NNP i
of IN i
CDDP NNP i
and CC i
5-FU JJ i
reduced JJ N
proliferative JJ o
potency NN o
and CC N
increased VBD N
cellular JJ o
apoptosis NN o
in IN N
gastric JJ p
cancer NN p
cells NNS N
. . N

-DOCSTART- -21327867- O O

Effects NNS N
of IN N
weight JJ i
loss NN i
and CC N
exercise NN i
on IN N
insulin NN p
resistance NN p
, , N
and CC N
intramyocellular JJ N
triacylglycerol NN N
, , N
diacylglycerol NN N
and CC N
ceramide NN N
. . N

AIMS/HYPOTHESIS NNP N
Intramyocellular NNP N
lipids NNS N
, , N
including VBG N
diacylglycerol NN N
( ( N
DAG NNP N
) ) N
and CC N
ceramides NNS N
, , N
have VBP N
been VBN N
linked VBN N
to TO N
insulin VB N
resistance NN N
. . N

This DT N
randomised VBD N
repeated-measures NNS N
study NN N
examined VBD N
the DT N
effects NNS N
of IN N
diet-induced JJ i
weight JJ i
loss NN i
( ( i
DIWL NNP i
) ) i
and CC i
aerobic JJ i
exercise NN i
( ( i
EX NNP i
) ) i
on IN N
insulin NN N
sensitivity NN N
and CC N
intramyocellular JJ N
triacylglycerol NN N
( ( N
IMTG NNP N
) ) N
, , N
DAG NNP N
and CC N
ceramide NN N
. . N

METHODS NNP N
Sixteen NNP p
overweight MD p
to TO p
obese VB p
adults NNS p
( ( p
BMI NNP p
30.6 CD p
? . p
0.8 CD p
; : p
67.2 CD p
? . p
4.0 CD p
years NNS p
of IN p
age NN p
) ) p
with IN p
either DT p
impaired JJ p
fasting NN p
glucose NN p
, , p
or CC p
impaired VBD p
glucose JJ p
tolerance NN p
completed VBD p
one CD p
of IN p
two CD p
lifestyle JJ p
interventions NNS p
: : p
DIWL NNP p
( ( p
n JJ p
= NNP p
8 CD p
) ) p
or CC p
EX NNP p
( ( p
n JJ p
= NNP p
8 CD p
) ) p
. . N

Insulin NNP N
sensitivity NN N
was VBD N
determined VBN N
using VBG N
hyperinsulinaemic-euglycaemic JJ N
clamps NNS N
. . N

Intramyocellular JJ N
lipids NNS N
were VBD N
measured VBN N
in IN N
muscle NN N
biopsies NNS N
using VBG N
histochemistry NN N
and CC N
tandem JJ N
mass NN N
spectrometry NN N
. . N

RESULTS NNP o
Insulin NNP o
sensitivity NN o
was VBD o
improved VBN o
with IN N
DIWL NNP N
( ( N
20.6 CD N
? . N
4.7 CD N
% NN N
) ) N
and CC N
EX NNP N
( ( N
19.2 CD N
? . N
12.9 CD N
% NN N
) ) N
. . N

Body NNP o
weight VBD o
and CC o
body NN o
fat NNS o
were VBD o
decreased VBN N
by IN N
both DT N
interventions NNS N
, , N
with IN N
greater JJR N
decreases NNS N
in IN N
DIWL NNP N
compared VBN N
with IN o
EX NNP o
. . o

Muscle NNP o
glycogen NN o
, , o
IMTG NNP o
content NN o
and CC o
oxidative JJ o
capacity NN o
were VBD o
all DT N
significantly RB N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
decreased VBN N
with IN N
DIWL NNP N
and CC N
increased VBD N
with IN N
EX NNP N
. . N

There EX N
were VBD N
decreases NNS N
in IN N
DAG NNP o
with IN N
DIWL NNP N
( ( N
-12.4 NNP N
? . N
14.6 CD N
% NN N
) ) N
and CC N
EX NNP N
( ( N
-40.9 NNP N
? . N
12.0 CD o
% NN o
) ) o
. . o

Ceramide NNP o
decreased VBD o
with IN N
EX NNP N
( ( N
-33.7 NNP N
? . N
11.2 CD N
% NN N
) ) N
, , N
but CC N
not RB N
with IN N
DIWL NNP N
. . o

Dihydroceramide NNP o
was VBD o
decreased VBN o
with IN N
both DT N
interventions NNS o
. . o

Sphingosine NNP o
was VBD N
decreased VBN N
only RB N
with IN o
EX NNP o
. . o

Changes NNS o
in IN o
total JJ o
DAG NNP o
, , o
total JJ o
ceramides NNS o
and CC o
other JJ o
sphingolipids NNS o
did VBD o
not RB N
correlate VB N
with IN N
changes NNS N
in IN N
glucose NN N
disposal NN N
. . N

Stearoyl-coenzyme VB o
A DT o
desaturase NN o
1 CD o
( ( o
SCD1 NNP o
) ) o
content NN o
was VBD o
decreased VBN o
with IN o
DIWL NNP N
( ( N
-19.5 NNP N
? . N
8.5 CD N
% NN N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
, , N
but CC N
increased VBD N
with IN N
EX NNP N
( ( N
19.6 CD N
? . N
7.4 CD N
% NN N
, , N
p NN N
< NNP N
0.05 CD o
) ) o
. . o

Diacylglycerol NNP o
acyltransferase VBD o
1 CD o
( ( o
DGAT1 NNP o
) ) o
was VBD o
unchanged JJ o
with IN N
the DT N
interventions NNS N
. . N

CONCLUSIONS/INTERPRETATION NNP N
Diet-induced NNP N
weight NN N
loss NN N
and CC N
exercise NN N
training NN N
both DT N
improved JJ N
insulin NN N
resistance NN N
and CC N
decreased VBD N
DAG NNP N
, , N
while IN N
only RB N
exercise NN N
decreased VBD N
ceramides NNS N
, , N
despite IN N
the DT N
interventions NNS N
having VBG N
different JJ N
effects NNS N
on IN N
IMTG NNP N
. . N

These DT N
alterations NNS N
may MD N
be VB N
mediated VBN N
through IN N
differential JJ N
changes NNS N
in IN N
skeletal JJ N
muscle NN N
capacity NN N
for IN N
oxidation NN N
and CC N
triacylglycerol NN N
synthesis NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
NCT00766298 NNP N
. . N

-DOCSTART- -19023654- O O

Stepping VBG i
Stones NNP i
Triple NNP i
P NNP i
: : i
an DT N
RCT NNP N
of IN N
a DT N
parenting VBG i
program NN i
with IN N
parents NNS p
of IN p
a DT p
child NN p
diagnosed VBN p
with IN p
an DT p
autism NN p
spectrum NN p
disorder NN p
. . p

Whilst IN N
the DT N
Triple NNP i
P NNP i
Positive NNP i
Parenting NNP i
Program NNP i
has VBZ N
a DT N
large JJ N
evidence NN N
base NN N
( ( N
Sanders NNP N
, , N
Clinical NNP N
Child NNP N
and CC N
Family NNP N
Psychology NNP N
Review NNP N
2:71-90 CD N
, , N
1999 CD N
; : N
Sanders NNP N
, , N
Journal NNP N
of IN N
Consulting NNP N
and CC N
Clinical NNP N
Psychology NNP N
68:624-640 CD N
, , N
2000 CD N
) ) N
and CC N
preliminary JJ N
evidence NN N
indicates VBZ N
that IN N
Stepping VBG i
Stones NNP i
Triple NNP i
P NNP i
is VBZ N
also RB N
efficacious JJ N
( ( N
Roberts NNP N
, , N
Journal NNP N
of IN N
Clinical NNP N
Child NNP N
and CC N
Adolescent NNP N
Psychology NNP N
, , N
35 CD N
( ( N
2 CD N
) ) N
:180-193 NN N
, , N
2006 CD N
) ) N
, , N
to TO N
date NN N
Stepping NNP i
Stones NNP i
has VBZ N
not RB N
been VBN N
evaluated VBN N
with IN N
the DT N
ASD NNP N
population NN N
. . N

Fifty-nine JJ p
families NNS p
with IN p
a DT p
child NN p
with IN p
ASD NNP p
aged VBD p
between IN p
2 CD p
and CC p
9 CD p
participated VBN p
in IN N
this DT N
randomized VBN N
controlled VBD N
trial NN N
. . N

The DT N
results NNS N
demonstrate VBP N
significant JJ N
improvements NNS N
in IN N
parental JJ o
reports NNS o
of IN o
child JJ o
behaviour NN o
and CC o
parenting NN o
styles NNS o
with IN o
the DT o
treatment NN o
effects NNS o
for IN o
child NN o
behaviour NN o
, , o
parental NN o
over IN o
reactivity NN o
and CC o
parental JJ o
verbosity NN o
being VBG N
maintained VBN N
at IN N
follow-up JJ N
6 CD N
months NNS N
later RB N
. . N

Further RBR N
, , N
the DT N
results NNS N
suggest VBP N
significant JJ N
improvements NNS N
in IN N
parental JJ o
satisfaction NN o
and CC o
conflict NN o
about RB o
parenting VBG o
as RB N
well RB N
as IN N
a DT N
sleeper JJ o
effect NN o
for IN o
parental JJ o
efficacy NN o
. . o

The DT N
results NNS N
indicate VBP N
that IN N
Stepping VBG i
Stones NNP i
Triple NNP i
P NNP i
is VBZ N
a DT N
promising JJ N
intervention NN N
for IN N
parents NNS p
of IN p
children NNS p
with IN p
ASD NNP p
. . p

Limitations NNS N
and CC N
future JJ N
research NN N
are VBP N
also RB N
addressed VBN N
. . N

-DOCSTART- -7259216- O O

Topical JJ i
treatment NN i
of IN N
alopecia NN N
areata NN N
. . N

It PRP N
has VBZ N
been VBN N
shown VBN N
previously RB N
that IN N
alopecia JJ N
areata NNS N
can MD N
be VB N
treated VBN N
with IN N
dinitrochlorobenzene NN i
( ( i
DNCB NNP i
) ) i
and CC N
other JJ N
contact NN i
allergens NNS i
. . i

Whether IN N
these DT N
agents NNS N
work NN N
by IN N
inducing VBG N
immunologic JJ N
stimulation NN N
or CC N
simply RB N
a DT N
nonspecific JJ N
inflammatory NN N
reaction NN N
has VBZ N
not RB N
been VBN N
definitively RB N
demonstrated VBN N
. . N

To TO N
test VB N
the DT N
relative JJ N
importance NN N
of IN N
these DT N
two CD N
mechanisms NNS N
, , N
we PRP N
have VBP N
randomly RB N
studied VBN N
22 CD p
patients NNS p
with IN p
alopecia JJ p
areata NNS p
to TO p
whom WP p
either DT p
DNCB NNP i
or CC i
croton VB i
oil NN i
was VBD p
applied VBN p
topically RB p
. . p

Sixty-three JJ N
percent NN N
of IN N
patients NNS N
without IN N
spontaneous JJ N
regrowth NN o
of IN o
hair NN o
regrew NNS o
hair NN o
after IN N
DNCB NNP N
application NN N
. . N

None NN o
of IN N
those DT N
treated VBN N
with IN N
croton NN i
oil NN i
regrew VBD o
hair NN o
when WRB N
treated VBN N
later RB N
with IN N
DNCB NNP i
. . i

Therefore NNP N
, , N
a DT N
proved JJ N
contact NN N
allergen NN N
was VBD N
shown VBN N
to TO N
be VB N
required VBN N
for IN N
therapeutic JJ N
success NN N
. . N

Patient JJ o
acceptance NN o
of IN N
the DT N
induced JJ N
contact NN N
dermatitis NN N
was VBD N
excellent JJ N
. . N

In IN N
light NN N
of IN N
recent JJ N
data NNS N
on IN N
the DT N
mutagenicity NN N
of IN N
DNCB NNP i
to TO N
bacteria NNS N
, , N
other JJ N
contact NN N
allergens NNS N
for IN N
topical JJ N
immunotherapy NN N
are VBP N
being VBG N
sought VBN N
. . N

-DOCSTART- -18957505- O O

Treatment NN N
with IN N
the DT N
dipeptidyl JJ i
peptidase-4 JJ i
inhibitor NN i
vildagliptin NN i
improves VBZ N
fasting VBG N
islet-cell JJ N
function NN N
in IN N
subjects NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
. . p

CONTEXT NNP N
Dipeptidyl NNP i
peptidase NN i
4 CD i
( ( i
DPP-4 NNP i
) ) i
inhibitors NNS i
are VBP N
proposed VBN N
to TO N
lower VB N
blood NN N
glucose NN N
in IN N
type NN p
2 CD p
diabetes NNS p
mellitus FW p
( ( p
T2DM NNP p
) ) p
by IN N
prolonging VBG N
the DT N
activity NN N
of IN N
the DT N
circulating NN N
incretins NNS N
, , N
glucose-dependent JJ N
insulinotropic NN N
polypeptide NN N
( ( N
GIP NNP N
) ) N
and CC N
glucagon-like JJ N
peptide NN N
1 CD N
( ( N
GLP-1 NNP N
) ) N
. . N

Consistent JJ N
with IN N
this DT N
mechanism NN N
of IN N
action NN N
, , N
DPP-4 NNP i
inhibitors NNS i
improve VBP N
glucose JJ N
tolerance NN N
after IN N
meals NNS N
by IN N
increasing VBG N
insulin NN N
and CC N
reducing VBG N
glucagon NN N
levels NNS N
in IN N
the DT N
plasma NN N
. . N

However RB N
, , N
DPP-4 NNP i
inhibitors NNS i
also RB N
reduce VB N
fasting VBG N
blood NN N
glucose NN N
, , N
an DT N
unexpected JJ N
effect NN N
because IN N
circulating VBG N
levels NNS N
of IN N
active JJ N
GIP NNP N
and CC N
GLP-1 NNP N
are VBP N
low JJ N
in IN N
the DT N
postabsorptive JJ N
state NN N
. . N

OBJECTIVE CC N
The DT N
objective NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
examine VB N
the DT N
effects NNS o
of IN o
DPP-4 NNP o
inhibition NN o
on IN o
fasting VBG o
islet NN o
function NN o
. . o

DESIGN NNP N
We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
. . N

SETTING VB N
The DT N
study NN N
was VBD N
performed VBN N
in IN N
General NNP p
Clinical NNP p
Research NNP p
Centers NNPS p
at IN p
two CD p
University NNP p
Hospitals NNP p
. . p

SUBJECTS NNP N
Forty-one JJ p
subjects NNS p
with IN p
T2DM NNP p
were VBD N
treated VBN N
with IN N
metformin NN i
or CC N
diet NN i
, , N
having VBG N
good JJ N
glycemic NNS N
control NN N
with IN N
glycosylated JJ N
hemoglobin NN N
values NNS N
of IN N
6.2-7.5 JJ N
% NN N
. . N

INTERVENTION JJ N
Subjects NNPS N
were VBD N
treated VBN N
with IN N
vildagliptin NN i
( ( N
50 CD N
mg NN N
twice RB N
daily RB N
) ) N
or CC N
placebo NN i
for IN N
3 CD N
months NNS N
, , N
followed VBN N
by IN N
a DT N
2-wk JJ N
washout NN N
. . N

Major JJ N
Outcome JJ N
Measure NN N
: : N
We PRP N
measured VBD N
insulin JJ o
secretion NN o
in IN o
response NN o
to TO o
iv VB o
glucose JJ o
and CC o
arginine JJ o
before NN N
and CC N
after IN N
treatment NN N
and CC N
after IN N
drug NN N
washout NN N
. . N

RESULTS CC N
There EX N
were VBD N
small JJ N
and CC N
comparable JJ N
reductions NNS N
in IN N
glycosylated JJ o
hemoglobin NN o
in IN N
both DT N
groups NNS N
over IN N
3 CD N
months NNS N
. . N

Vildagliptin NNP N
increased VBD N
fasting VBG N
GLP-1 NNP o
levels NNS N
in IN N
subjects NNS N
taking VBG N
metformin NN i
, , N
but CC N
not RB N
those DT N
managed VBN N
with IN N
diet JJ i
, , N
and CC N
raised VBD N
active JJ N
GIP NNP N
levels NNS N
slightly RB N
. . N

DPP-4 JJ i
inhibitor NN i
treatment NN N
improved VBD N
the DT N
acute JJ o
insulin NN o
and CC o
C-peptide JJ o
responses NNS o
to TO N
glucose VB N
( ( N
50 CD N
and CC N
100 CD N
% NN N
respectively RB N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
increased VBD N
the DT N
slope NN N
of IN N
the DT N
C-peptide NNP o
response NN o
to TO N
glucose VB N
( ( N
33 CD N
% NN N
; : N
P NNP N
= NNP N
0.023 CD N
) ) N
. . N

CONCLUSION NNP N
Vildagliptin NNP i
improves VBZ N
islet JJ N
function NN N
in IN N
T2DM NNP N
under IN N
fasting VBG N
conditions NNS N
. . N

This DT N
suggests VBZ N
that IN N
DPP-4 NNP N
inhibition NN N
has VBZ N
metabolic JJ N
benefits NNS N
in IN N
addition NN N
to TO N
enhancing VBG N
meal-induced JJ N
GLP-1 NNP N
and CC N
GIP NNP N
activity NN N
. . N

-DOCSTART- -20415897- O O

A DT N
phase NN N
III NNP N
study NN N
of IN N
belatacept-based JJ i
immunosuppression NN i
regimens NNS i
versus VBP i
cyclosporine NN i
in IN N
renal JJ p
transplant NN p
recipients NNS p
( ( N
BENEFIT NNP N
study NN N
) ) N
. . N

Belatacept NNP i
, , N
a DT N
costimulation NN N
blocker NN N
, , N
may MD N
preserve VB N
renal JJ o
function NN o
and CC N
improve VB N
long-term JJ o
outcomes NNS o
versus IN N
calcineurin JJ i
inhibitors NNS i
in IN N
kidney NN N
transplantation NN N
. . N

This DT N
Phase NNP N
III NNP N
study NN N
( ( N
Belatacept NNP N
Evaluation NNP N
of IN N
Nephroprotection NNP N
and CC N
Efficacy NNP N
as IN N
First-line NNP N
Immunosuppression NNP N
Trial NNP N
) ) N
assessed VBD N
a DT N
more RBR N
intensive JJ N
( ( N
MI NNP N
) ) N
or CC N
less RBR N
intensive JJ N
( ( N
LI NNP N
) ) N
regimen NNS N
of IN N
belatacept JJ i
versus NN i
cyclosporine NN i
in IN N
adults NNS p
receiving VBG p
a DT p
kidney NN p
transplant NN p
from IN p
living NN p
or CC p
standard JJ p
criteria NNS p
deceased VBN p
donors NNS p
. . p

The DT N
co-primary JJ N
endpoints NNS N
at IN N
12 CD N
months NNS N
were VBD N
patient/graft JJ o
survival NN o
, , N
a DT N
composite JJ o
renal JJ o
impairment NN o
endpoint NN o
( ( N
percent NN N
with IN N
a DT N
measured JJ N
glomerular JJ N
filtration NN N
rate NN N
( ( N
mGFR NN N
) ) N
< VBZ N
60 CD N
mL/min/1.73 NN N
m NN N
( ( N
2 CD N
) ) N
at IN N
Month NNP N
12 CD N
or CC N
a DT N
decrease NN N
in IN N
mGFR JJ N
> NN N
or CC N
=10 VB N
mL/min/1.73 JJ N
m NN N
( ( N
2 CD N
) ) N
Month NNP N
3-Month JJ N
12 CD N
) ) N
and CC N
the DT N
incidence NN o
of IN o
acute JJ o
rejection NN o
. . o

At IN N
Month NNP N
12 CD N
, , N
both DT N
belatacept IN i
regimens NNS N
had VBD N
similar JJ N
patient/graft NN o
survival NN o
versus NN N
cyclosporine NN N
( ( N
MI NNP N
: : N
95 CD N
% NN N
, , N
LI NNP N
: : N
97 CD N
% NN N
and CC N
cyclosporine NN i
: : i
93 CD N
% NN N
) ) N
, , N
and CC N
were VBD N
associated VBN N
with IN N
superior JJ o
renal JJ o
function NN o
as IN N
measured VBN N
by IN N
the DT N
composite JJ o
renal JJ o
impairment NN o
endpoint NN o
( ( N
MI NNP N
: : N
55 CD N
% NN N
; : N
LI NNP N
: : N
54 CD N
% NN N
and CC N
cyclosporine NN i
: : i
78 CD N
% NN N
; : N
p CC N
< CD N
or CC N
= VB N
0.001 CD N
MI NNP N
or CC N
LI NNP N
versus IN N
cyclosporine NN i
) ) i
and CC N
by IN N
the DT N
mGFR NN o
( ( N
65 CD N
, , N
63 CD N
and CC N
50 CD N
mL/min NN N
for IN N
MI NNP N
, , N
LI NNP N
and CC N
cyclosporine NN i
; : i
p CC N
< CD N
or CC N
= VB N
0.001 CD N
MI NNP N
or CC N
LI NNP N
versus IN N
cyclosporine NN i
) ) i
. . N

Belatacept IN N
patients NNS N
experienced VBD N
a DT N
higher JJR N
incidence NN o
( ( N
MI NNP N
: : N
22 CD N
% NN N
, , N
LI NNP N
: : N
17 CD N
% NN N
and CC N
cyclosporine NN i
: : i
7 CD N
% NN N
) ) N
and CC N
grade NN o
of IN o
acute JJ o
rejection NN o
episodes NNS o
. . o

Safety NN o
was VBD N
generally RB N
similar JJ N
between IN N
groups NNS N
, , N
but CC N
posttransplant JJ o
lymphoproliferative JJ o
disorder NN o
was VBD N
more RBR N
common JJ N
in IN N
the DT N
belatacept NN i
groups NNS N
. . N

Belatacept NNP i
was VBD N
associated VBN N
with IN N
superior JJ N
renal JJ o
function NN o
and CC N
similar JJ N
patient/graft NN o
survival NN o
versus NN N
cyclosporine NN i
at IN N
1 CD N
year NN N
posttransplant NN N
, , N
despite IN N
a DT N
higher JJR N
rate NN o
of IN o
early JJ o
acute JJ o
rejection NN o
. . o

-DOCSTART- -16700802- O O

Eberconazole JJ i
1 CD N
% NN N
cream NN N
is VBZ N
an DT N
effective JJ o
and CC o
safe JJ o
alternative NN N
for IN N
dermatophytosis NN N
treatment NN N
: : N
multicenter NN N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
comparative JJ N
trial NN N
with IN N
miconazole JJ i
2 CD N
% NN N
cream NN N
. . N

BACKGROUND NNP N
Eberconazole NNP i
is VBZ N
a DT N
topical JJ N
, , N
broad-spectrum JJ N
imidazole NN N
derivative NN N
, , N
effective JJ N
in IN N
dermatophytoses NNS N
, , N
candidiasis NN N
, , N
and CC N
pityriasis NN N
treatment NN N
. . N

In IN N
previous JJ N
trials NNS N
, , N
it PRP N
showed VBD N
a DT N
higher JJR N
efficacy NN N
than IN N
clotrimazole NN N
in IN N
the DT N
treatment NN N
of IN N
dermatophytoses NNS N
. . N

The DT N
purpose NN N
of IN N
this DT N
trial NN N
was VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
eberconazole JJ i
1 CD N
% NN N
cream NN N
compared VBN N
with IN N
miconazole JJ i
2 CD N
% NN N
cream NN N
in IN N
the DT N
treatment NN N
of IN N
dermatophytoses NNS N
. . N

METHODS NNP N
A NNP N
multicenter NN N
, , N
double-blind NN N
, , N
randomized VBN N
trial NN N
was VBD N
performed VBN N
in IN N
653 CD p
patients NNS p
with IN p
dermatophytoses NNS p
, , N
randomized VBN N
to TO N
eberconazole VB i
1 CD N
% NN N
cream NN N
every DT N
12 CD N
h NN N
or CC N
miconazole VB i
2 CD N
% NN N
cream NN N
every DT N
12 CD N
h NN N
for IN N
4 CD N
weeks NNS N
. . N

Treatment NNP o
efficacy NN o
was VBD N
assessed VBN N
on IN N
the DT N
basis NN N
of IN N
the DT N
percentage NN N
of IN N
effective JJ N
response NN N
after IN N
4 CD N
weeks NNS N
through IN N
mycologic NN N
and CC N
clinical JJ N
assessment NN N
. . N

RESULTS NNP N
Of IN N
the DT N
653 CD p
patients NNS p
included VBN p
in IN p
the DT p
trial NN p
, , N
360 CD N
produced VBD N
positive JJ N
baseline NN N
mycologic NN N
cultures NNS N
and CC N
were VBD N
included VBN N
in IN N
the DT N
efficacy NN N
assessment NN N
. . N

Clinical JJ N
efficacy NN N
was VBD N
shown VBN N
in IN N
76.1 CD N
% NN N
of IN N
patients NNS N
receiving VBG N
eberconazole JJ N
and CC N
in IN N
75.0 CD N
% NN N
of IN N
patients NNS N
receiving VBG N
miconazole NN N
. . N

The DT N
incidence NN N
of IN N
adverse JJ o
events NNS o
related VBN N
to TO N
treatment NN N
was VBD N
0.91 CD N
% NN N
for IN N
eberconazole NN N
and CC N
0.92 CD N
% NN N
for IN N
miconazole NN N
, , N
none NN N
being VBG N
serious JJ N
, , N
and CC N
all DT N
being VBG N
local JJ N
and CC N
transient NN N
. . N

CONCLUSIONS NNP N
Eberconazole NNP N
1 CD N
% NN N
cream NN N
is VBZ N
an DT N
effective JJ N
treatment NN N
for IN N
fungal JJ N
infections NNS N
produced VBN N
by IN N
dermatophytes NNS N
, , N
with IN N
a DT N
good JJ N
safety NN o
and CC o
tolerability NN o
profile NN N
, , N
and CC N
can MD N
be VB N
considered VBN N
a DT N
good JJ N
alternative NN N
for IN N
the DT N
treatment NN N
of IN N
dermatophytoses NNS N
. . N

-DOCSTART- -7739439- O O

[ IN N
The DT N
value NN N
of IN N
local JJ i
administration NN i
of IN i
antibiotics NNS i
in IN N
treatment NN p
of IN p
bone NN p
infections NNS p
] NNP p
. . N

An DT N
open JJ N
, , N
controlled VBN N
, , N
randomized VBN N
clinical JJ N
investigation NN N
was VBD N
carried VBN N
out RP N
in IN N
33 CD p
patients NNS p
suffering VBG p
from IN p
osteomyelitis NN p
. . p

In IN N
the DT N
first JJ N
group NN N
, , N
17 CD p
patients NNS p
, , p
a DT p
through IN p
drainage NN p
with IN p
sterile JJ i
physiologic JJ i
solution NN i
was VBD p
applied VBN p
, , p
while IN p
in IN p
the DT p
second JJ p
group NN p
, , p
16 CD p
patients NNS p
, , p
antibiotic JJ i
was VBD i
added VBN i
to TO i
the DT i
sterile JJ i
physiologic JJ i
solution NN i
. . i

In IN N
all DT N
patients NNS N
values NNS N
of IN N
C NNP N
reactive JJ N
protein NN N
( ( N
CRP NNP N
) ) N
in IN N
the DT N
blood NN N
were VBD N
examined VBN N
, , N
and CC N
later RB N
on IN N
every DT N
third JJ N
day NN N
after IN N
the DT N
operation NN N
. . N

A DT o
significant JJ o
difference NN o
of IN o
average JJ o
values NNS o
of IN o
CRP NNP o
between IN o
the DT o
3rd CD o
and CC o
21st CD o
day NN o
in IN o
both DT o
groups NNS o
of IN o
patients NNS o
was VBD o
established VBN o
, , N
as RB N
well RB N
as IN N
the DT N
similarity NN o
in IN o
average JJ o
values NNS o
of IN o
CRP NNP o
, , N
which WDT N
points VBZ N
to TO N
the DT N
fact NN N
that IN N
the DT N
mechanical JJ N
effect NN N
of IN N
through IN N
drainage NN N
is VBZ N
dominant JJ N
, , N
speaking VBG N
about IN N
rinsing VBG N
focus NN N
of IN N
infection NN o
and CC N
eliminating VBG N
necrotic JJ N
tissues NNS N
and CC N
small JJ N
sequesters NNS N
. . N

-DOCSTART- -12185154- O O

Home NN i
based VBN i
management NN i
in IN N
multiple JJ p
sclerosis NN p
: : p
results NNS N
of IN N
a DT N
randomised VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Home NNP i
based VBN i
medical JJ i
care NN i
is VBZ N
a DT N
popular JJ N
alternative NN N
to TO N
standard VB N
hospital NN N
care NN N
but CC N
there EX N
is VBZ N
uncertainty NN N
about IN N
its PRP$ N
cost-effectiveness NN o
. . o

OBJECTIVES NNP N
To TO N
compare VB N
the DT N
effectiveness NN o
and CC o
the DT o
costs NNS o
of IN N
multidisciplinary JJ i
home NN i
based VBN i
care NN i
in IN N
multiple JJ p
sclerosis NN p
with IN N
hospital NN N
care NN N
in IN N
a DT N
prospective JJ N
randomised VBN N
controlled VBN N
trial NN N
with IN N
a DT N
one CD N
year NN N
follow VB N
up RP N
. . N

METHODS NNP N
201 CD p
patients NNS p
with IN p
clinically RB p
definite JJ p
multiple JJ p
sclerosis NN p
were VBD N
studied VBN N
. . N

They PRP N
were VBD N
randomised VBN N
in IN N
a DT N
ratio NN N
2:1 CD N
to TO N
an DT N
intervention NN N
group NN N
( ( N
133 CD N
) ) N
or CC N
a DT N
control NN N
group NN N
( ( N
68 CD N
) ) N
. . N

They PRP N
were VBD N
assessed VBN N
at IN N
baseline NN N
and CC N
one CD N
year NN N
after IN N
randomisation NN N
with IN N
validated JJ o
measures NNS o
of IN o
physical JJ o
and CC o
psychological JJ o
impairment NN o
and CC o
quality NN o
of IN o
life NN o
( ( o
SF-36 NNP o
health NN o
survey NN o
) ) o
. . o

The DT N
costs NNS o
to TO o
the DT o
National NNP o
Health NNP o
Service NNP o
over IN o
the DT o
one CD o
year NN o
follow VBP o
up RP o
were VBD N
calculated VBN N
by IN N
a DT N
cost NN N
minimisation NN N
analysis NN N
. . N

RESULTS CC N
There EX N
were VBD N
no DT N
differences NNS N
in IN N
functional JJ o
status NN o
between IN N
the DT N
home NN N
based VBN N
care NN N
group NN N
and CC N
the DT N
hospital NN N
group NN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
favouring VBG N
home NN N
based VBN N
management NN N
in IN N
four CD o
SF-36 JJ o
health NN o
dimensions-general JJ o
health NN o
, , o
bodily RB o
pain NN o
, , o
role-emotional JJ o
, , o
and CC o
social JJ o
functioning NN o
( ( N
all DT N
p VBP N
< CD N
or CC N
= VB N
0.001 CD N
) ) N
. . N

The DT N
cost NN o
of IN N
home NN N
based VBN N
care NN N
was VBD N
slightly RB N
less JJR N
( ( N
822 CD N
euros/patient/year NN N
) ) N
than IN N
hospital NN N
care NN N
, , N
mainly RB N
as IN N
a DT N
result NN N
of IN N
a DT N
reduction NN N
in IN N
hospital JJ N
admissions NNS N
. . N

CONCLUSIONS NNP N
Comprehensive NNP i
planning NN i
of IN i
home NN i
based VBN i
intervention NN i
implemented VBN N
by IN N
an DT N
interdisciplinary JJ N
team NN N
and CC N
designed VBN N
specifically RB N
for IN N
people NNS N
with IN N
multiple JJ N
sclerosis NN N
may MD N
provide VB N
a DT N
cost-effective JJ o
approach NN N
to TO N
management NN N
and CC N
improve VB N
the DT N
quality NN o
of IN o
life NN o
. . o

-DOCSTART- -7814161- O O

Physiological JJ i
pacing VBG i
improves NNS N
symptoms NNS N
and CC N
increases NNS N
exercise VBP N
capacity NN N
in IN N
the DT N
elderly JJ p
patient NN p
. . p

We PRP N
evaluated VBD N
the DT N
benefits NNS N
of IN N
physiological JJ i
pacing NN i
in IN N
the DT N
elderly JJ p
by IN p
recruiting VBG p
13 CD p
subjects NNS p
> JJ p
75 CD p
years NNS p
of IN p
age NN p
, , p
already RB p
fitted VBN p
with IN p
a DT p
physiological JJ i
pacing NN i
system NN i
. . i

All DT p
had VBD p
been VBN p
paced VBN p
for IN p
complete JJ p
or CC p
Mobitz NNP p
II NNP p
heart NN p
block NN p
. . p

Double NNP N
blind IN N
cross NN N
over IN N
study NN N
was VBD N
performed VBN N
comparing VBG N
exercise NN o
capacity NN o
, , o
measuring VBG o
distance NN o
walked VBD o
on IN o
a DT o
6-min JJ o
walking NN o
test NN o
and CC N
time NN o
taken VBN o
to TO o
climb VB o
two CD o
flights NNS o
of IN o
stairs NNS o
; : o
and CC N
symptoms NNS o
, , N
evaluated VBN N
by IN N
an DT N
activity NN o
of IN o
daily JJ o
living NN o
questionnaire NN o
, , N
in IN N
atrioventricular JJ i
synchronous JJ i
and CC i
ventricular JJ i
pacing NN i
. . i

Mean JJ o
distance NN o
walked VBD o
was VBD N
significantly RB N
higher JJR N
in IN N
atrioventricular JJ i
synchronous JJ i
than IN N
in IN N
ventricular JJ i
pacing NN i
( ( N
360 CD N
+/- JJ N
65 CD N
m NN N
vs. FW N
327 CD N
+/- JJ N
69 CD N
m NN N
; : N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

No DT o
significant JJ o
difference NN o
was VBD N
found VBN N
in IN N
the DT N
ability NN o
to TO o
climb VB o
stairs NNS o
but CC N
there EX N
was VBD N
a DT N
marked JJ o
improvement NN o
in IN N
the DT N
symptomatic JJ o
questionnaire NN o
score NN o
, , N
19 CD N
+/- JJ N
5 CD N
in IN N
physiological JJ o
pacing VBG o
increasing VBG N
to TO N
28 CD N
+/- JJ N
10 CD N
with IN N
ventricular NN N
. . N

Physiological JJ o
pacing NN o
in IN N
the DT N
elderly JJ N
produces VBZ N
an DT N
increase NN o
in IN N
exercise NN o
tolerance NN o
and CC N
improves VBZ o
symptoms NNS o
; : o
therefore RB N
, , N
age NN N
alone RB N
should MD N
not RB N
be VB N
a DT N
contraindication NN N
to TO N
a DT N
physiological JJ N
system NN N
. . N

-DOCSTART- -15922817- O O

Results NNS N
of IN N
a DT N
multicenter NN N
, , N
8-week JJ N
, , N
parallel-group JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
double-dummy JJ N
, , N
Phase NNP N
III NNP N
clinical JJ N
trial NN N
to TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
tolerability NN N
of IN N
amlodipine JJ i
maleate NN i
versus NN i
amlodipine NN i
besylate NN i
in IN N
Korean JJ p
patients NNS p
with IN p
mild JJ p
to TO p
moderate VB p
hypertension NN p
. . p

BACKGROUND NNP N
Recently RB N
, , N
amlodipine JJ i
maleate NN i
was VBD N
developed VBN N
and CC N
tested VBN N
in IN N
preclinical JJ N
and CC N
Phase NNP N
I PRP N
clinical JJ N
trials NNS N
in IN N
Korea NNP p
. . p

The DT N
studies NNS N
found VBD N
pharmacokinetics NNS N
and CC N
pharmacodynamics NNS N
similar JJ N
to TO N
those DT N
of IN N
amlodipine JJ i
besylate NN i
. . i

OBJECTIVE CC N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN N
and CC N
tolerability NN N
of IN N
amlodipine JJ i
maleate NN i
with IN N
those DT N
of IN N
amlodipine JJ i
besylate NN i
in IN N
Korean JJ p
patients NNS p
with IN p
mild JJ p
to TO p
moderate VB p
hypertension NN p
. . p

METHODS NNP N
This DT N
was VBD N
a DT N
multicenter NN N
, , N
8-week JJ N
, , N
parallel-group JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
double-dummy JJ N
, , N
Phase NNP N
III NNP N
clinical JJ N
trial NN N
. . N

Eligible JJ p
patients NNS p
were VBD p
Korean NNP p
, , p
aged VBD p
18 CD p
to TO p
75 CD p
years NNS p
, , p
had VBD p
hypertension NN p
, , p
and CC p
were VBD p
either RB p
taking VBG p
antihypertensive JJ p
medications NNS p
or CC p
had VBD p
a DT p
documented VBN p
sitting VBG p
diastolic JJ p
blood NN p
pressure NN p
of IN p
90 CD p
to TO p
109 CD p
mm NN p
Hg NNP p
. . p

After IN N
a DT N
washout JJ N
period NN N
of IN N
2 CD N
weeks NNS N
, , N
patients NNS N
were VBD N
randomized VBN N
to TO N
amlodipine VB i
maleate NN i
or CC i
amlodipine NN i
besylate NN i
for IN N
8 CD N
weeks NNS N
. . N

In IN N
both DT N
groups NNS N
, , N
the DT N
medications NNS N
were VBD N
initiated VBN N
at IN N
5 CD N
mg NN N
QD NNP N
. . N

At IN N
day NN N
29 CD N
, , N
the DT N
medication NN N
dose NN N
was VBD N
increased VBN N
to TO N
10 CD N
mg NNS N
QD NNP N
if IN N
sitting VBG N
diastolic JJ N
blood NN N
pressure NN N
( ( N
SiDBP NNP N
) ) N
was VBD N
> JJ N
or CC N
= JJ N
90 CD N
mm NN N
Hg NNP N
. . N

RESULTS NNP N
One CD p
hundred VBD p
eighteen JJ p
patients NNS p
were VBD p
enrolled VBN p
. . p

Fifty-seven JJ N
patients NNS N
received VBD N
amlodipine JJ i
maleate NN i
( ( N
29 CD N
men NNS N
, , N
28 CD N
women NNS N
; : N
mean VB N
[ NNP N
SD NNP N
] NNP N
age NN N
, , N
49.0 CD N
[ NN N
11.4 CD N
] CD N
years NNS N
) ) N
and CC N
61 CD N
received VBD N
amlodipine JJ i
besylate NN i
( ( N
35 CD N
men NNS N
, , N
26 CD N
women NNS N
; : N
mean VB N
[ NNP N
SD NNP N
] NNP N
age NN N
, , N
51.6 CD N
[ NN N
9.4 CD N
] CD N
years NNS N
) ) N
. . N

Baseline JJ o
mean NN o
( ( o
SD NNP o
) ) o
values NNS o
for IN N
sitting VBG o
systolic JJ o
blood NN o
pressure NN o
and CC o
SiDBP NNP o
were VBD N
152.0 CD N
( ( N
12.2 CD N
) ) N
mm NN N
Hg NNP N
and CC N
98.1 CD N
( ( N
5.6 CD N
) ) N
mm NN N
Hg NNP N
, , N
respectively RB N
, , N
for IN N
the DT N
amlodipine JJ i
maleate NN i
group NN N
and CC N
153.4 CD N
( ( N
14.0 CD N
) ) N
mm NN N
Hg NNP N
and CC N
98.1 CD N
( ( N
5.5 CD N
) ) N
mm NN N
Hg NNP N
, , N
respectively RB N
, , N
for IN N
the DT N
amlodipine JJ i
besylate NN i
group NN N
. . N

In IN N
this DT N
population NN N
, , N
amlodipine JJ i
maleate NN i
was VBD N
not RB N
inferior JJ N
to TO N
amlodipine VB i
besylate NN i
: : i
the DT N
lower JJR N
limit NN N
of IN N
the DT N
2-sided JJ N
95 CD N
% NN N
CI NNP N
for IN N
the DT N
treatment NN N
difference NN N
in IN N
SiDBP NNP o
was VBD N
greater JJR N
than IN N
-4 JJR N
mm NN N
Hg NNP N
. . N

The DT N
between-group JJ N
difference NN N
in IN N
SiDBP NNP o
response NN o
rate NN o
( ( N
the DT N
proportion NN N
of IN N
patients NNS N
who WP N
experienced VBD N
adequate JJ N
SiDBP NNP N
reductions NNS N
) ) N
did VBD N
not RB N
reach VB N
statistical JJ N
significance NN N
: : N
85.7 CD N
% NN N
( ( N
42/49 CD N
) ) N
for IN N
the DT N
amlodipine JJ i
maleate NN i
group NN N
and CC N
91.8 CD N
% NN N
( ( N
45/49 CD N
) ) N
for IN N
the DT N
amlodipine JJ N
besylate NN N
group NN N
. . N

Compliance NN N
rates NNS N
were VBD N
similar JJ N
between IN N
groups NNS N
, , N
with IN N
mean NN o
( ( o
SD NNP o
) ) o
compliance NN o
rates NNS o
of IN N
97.4 CD N
% NN N
( ( N
2.8 CD N
% NN N
) ) N
and CC N
97.1 CD N
% NN N
( ( N
3.6 CD N
% NN N
) ) N
in IN N
the DT N
amlodipine NN i
maleate NN i
and CC N
amlodipine JJ i
besylate NN i
groups NNS N
, , N
respectively RB N
. . N

Also RB N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
incidences NNS N
of IN N
drug-related JJ N
clinical JJ N
and CC N
laboratory JJ N
adverse JJ N
events NNS N
; : N
the DT N
most RBS N
common JJ N
were VBD N
headache NN o
, , o
flushing NN o
, , o
facial JJ o
edema NN o
, , o
and CC o
paresthesia NN o
. . o

CONCLUSION NN N
In IN N
this DT N
population NN N
, , N
the DT N
efficacy NN N
and CC N
tolerability NN N
observed VBN N
with IN N
amlodipine JJ N
maleate NN N
were VBD N
similar JJ N
to TO N
those DT N
seen VBN N
with IN N
amlodipine JJ N
besylate NN N
. . N

-DOCSTART- -8942899- O O

Is VBZ N
there EX N
a DT N
difference NN N
? . N
A DT N
prospective JJ N
study NN N
comparing VBG N
lateral JJ i
and CC i
standard JJ i
SMAS NNP i
face NN i
lifts NNS i
with IN N
extended JJ i
SMAS NNP i
and CC N
composite JJ i
rhytidectomies NNS i
. . i

Presented VBN N
is VBZ N
a DT N
prospective JJ N
study NN N
comparing VBG N
limited JJ i
SMAS NNP i
( ( i
lateral JJ i
SMASectomy NNP i
) ) i
, , i
conventional JJ i
SMAS NNP i
, , i
extended VBD i
SMAS NNP i
, , N
and CC N
composite JJ i
rhytidectomies NNS i
. . i

Randomized VBN p
patients NNS p
received VBD N
either CC N
a DT N
limited JJ i
SMAS NNP i
or CC i
conventional JJ i
SMAS NNP i
face NN i
lift NN i
on IN i
one CD i
side NN i
and CC i
an DT i
extended JJ i
SMAS NN i
or CC i
composite JJ i
rhytidectomy NN i
on IN N
the DT N
other JJ N
. . N

All DT N
procedures NNS N
were VBD N
performed VBN N
at IN N
Manhattan NNP p
Eye NNP p
, , p
Ear NNP p
and CC p
Throat NNP p
Hospital NNP p
in IN N
accordance NN N
with IN N
their PRP$ N
well-defined JJ N
surgical JJ N
descriptions NNS N
. . N

Postoperative JJ N
courses NNS N
were VBD N
followed VBN N
clinically RB N
for IN N
at IN N
least JJS N
1 CD N
year NN N
. . N

Photographs NNP N
were VBD N
taken VBN N
preoperatively RB N
and CC N
at IN N
6 CD N
and CC N
12 CD N
months NNS N
postoperatively RB N
. . N

Photographs NNP N
were VBD N
reviewed VBN N
by IN N
three CD N
independent JJ N
experienced VBD N
face NN N
lift NN N
surgeons NNS N
. . N

The DT N
study NN N
comprises VBZ N
21 CD p
patients NNS p
, , p
20 CD p
women NNS p
and CC p
1 CD p
man NN p
, , p
with IN p
a DT p
mean JJ p
age NN p
of IN p
59 CD p
years NNS p
( ( p
range VB p
47 CD p
to TO p
70 CD p
years NNS p
) ) p
. . p

Nineteen JJ N
patients NNS N
underwent JJ N
primary JJ i
rhytidectomies NNS i
; : i
two CD N
underwent JJ N
secondary JJ i
face NN i
lifts NNS i
. . i

For IN N
the DT N
first JJ N
12 CD N
patients NNS N
, , N
each DT N
had VBD N
an DT N
extended JJ N
SMAS NNP N
procedure NN N
performed VBD N
on IN N
one CD N
side NN N
; : N
on IN N
the DT N
other JJ N
, , N
7 CD N
had VBD N
a DT N
conventional JJ i
SMAS NNP i
and CC N
5 CD N
had VBD N
a DT N
limited JJ i
SMAS NNP i
( ( N
lateral JJ N
SMASectomy NNP N
) ) N
face NN N
lift NN N
. . N

In IN N
the DT N
last JJ N
9 CD N
patients NNS N
, , N
a DT N
conventional JJ i
SMAS NNP i
was VBD N
carried VBN N
out RP N
on IN N
one CD N
side NN N
in IN N
8 CD N
, , N
a DT N
limited JJ i
SMAS NNP i
in IN N
1 CD N
, , N
and CC N
on IN N
the DT N
opposite JJ N
side NN N
, , N
a DT N
composite JJ i
rhytidectomy NN i
was VBD N
performed VBN N
. . N

Complications NNS o
were VBD N
few JJ N
. . N

Temporary NNP o
weakness NN o
of IN o
the DT o
buccal JJ o
branch NN o
of IN o
the DT o
facial JJ o
nerve NN o
occurred VBD N
in IN N
2 CD N
patients NNS N
on IN N
the DT N
side NN N
of IN N
the DT N
more RBR N
extensive JJ N
surgery NN N
. . N

On IN N
the DT N
operating NN N
table NN N
at IN N
completion NN N
of IN N
the DT N
surgery NN N
, , N
there EX N
was VBD N
more RBR N
improvement NN N
in IN N
reversal NN o
of IN o
midfacial JJ o
ptosis NN o
and CC o
flattening NN o
of IN o
the DT o
nasolabial JJ o
folds NNS o
with IN N
both DT N
extended JJ i
SMAS NNP i
and CC N
composite JJ i
rhytidectomies NNS i
. . i

The DT N
composite JJ N
flap NN N
had VBD N
the DT N
most RBS N
dramatic JJ N
effect NN N
on IN N
the DT N
nasolabial JJ o
folds NNS o
and CC o
oral JJ o
commissure NN o
. . o

After IN N
24 CD N
hours NNS N
, , N
once RB N
swelling VBG o
developed VBN N
and CC N
facial JJ o
motion NN o
became VBD N
reactivated VBN N
, , N
the DT N
noticeable JJ N
differences NNS N
in IN N
the DT N
midface NN N
and CC N
nasolabial JJ N
folds NNS N
were VBD N
lost VBN N
. . N

No DT N
discernible JJ N
differences NNS N
in IN N
facial JJ N
halves NNS N
were VBD N
noted VBN N
again RB N
. . N

Differences NNS o
between IN o
facial JJ o
sides NNS o
on IN N
the DT N
6- JJ N
and CC N
12-month JJ N
postoperative JJ N
photographs NNS N
were VBD N
not RB N
detectable JJ N
. . N

We PRP N
conclude VBP N
that IN N
for IN N
routine JJ N
facial JJ N
plasty NN N
, , N
comparable JJ N
clinical JJ N
outcomes NNS N
are VBP N
obtained VBN N
at IN N
6 CD N
months NNS N
and CC N
1 CD N
year NN N
with IN N
limited JJ i
( ( i
lateral JJ i
SMASectomy NNP i
) ) i
and CC N
conventional JJ i
SMAS NNP i
face NN N
lifts NNS N
compared VBN N
with IN N
extended JJ i
SMAS NNP i
and CC N
composite JJ i
rhytidectomies NNS i
. . i

All DT N
procedures NNS N
are VBP N
lacking VBG N
in IN N
their PRP$ N
improvement NN o
of IN o
midface NN o
ptosis NN o
and CC o
the DT o
nasolabial JJ o
folds NNS o
. . o

The DT N
increased JJ N
surgical JJ N
risks NNS N
, , N
morbidity NN N
, , N
and CC N
convalescence NN N
associated VBN N
with IN N
those DT N
more RBR N
extensive JJ N
procedures NNS N
do VBP N
not RB N
seem VB N
to TO N
be VB N
warranted VBN N
in IN N
the DT N
average JJ N
patient NN N
. . N

-DOCSTART- -1307461- O O

[ JJ N
Myocardial NNP N
ischemia NN N
with IN N
stable JJ N
angina JJ N
pectoris NN N
: : N
clinico-ergometric JJ N
evaluation NN N
after IN N
the DT N
use NN N
of IN N
diltiazem NN i
] NN i
. . N

PURPOSE NNP N
To TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
diltiazem JJ i
versus NN N
placebo NN i
in IN N
patients NNS p
with IN p
stable JJ p
angina NN p
. . p

METHODS NNP N
Eight-seven JJ p
angina NNS p
pectoris JJ p
patients NNS p
, , p
mean JJ p
age NN p
of IN p
57 CD p
+/- JJ p
9 CD p
, , p
82 CD p
white JJ p
and CC p
79 CD p
male NN p
were VBD N
evaluated VBN N
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
trial NN N
of IN N
two CD N
groups NNS N
of IN N
patients NNS N
diltiazem JJ i
and CC i
placebo NN i
, , N
3 CD N
to TO N
4 CD N
tablets NNS N
a DT N
day NN N
( ( i
diltiazem JJ i
180 CD N
to TO N
240 CD N
mg NNS N
daily RB N
) ) N
. . N

The DT N
patients NNS N
were VBD N
evaluated VBN N
after IN N
laboratory NN N
tests NNS N
and CC N
clinical-ergometric JJ N
examinations NNS N
. . N

A DT N
coronary JJ N
arteriography NN N
was VBD N
performed VBN N
on IN N
study NN N
entry NN N
. . N

RESULTS VB N
The DT N
average NN o
of IN o
anginal JJ o
attacks NNS o
, , o
number NN o
of IN o
weekly JJ o
sublingual JJ o
nitrate NN o
, , o
heart NN o
rate NN o
, , o
systolic JJ o
and CC o
diastolic JJ o
pressure NN o
at IN o
rest NN o
and CC o
at IN o
the DT o
end NN o
of IN o
diltiazem JJ o
period NN o
were VBD N
significantly RB N
lower JJR N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
regarding VBG N
same JJ N
periods NNS N
on IN N
placebo NN i
. . i

The DT N
percentage NN N
of IN N
depression NN o
for IN o
ST-segment NNP o
was VBD N
lower JJR N
for IN N
diltiazem NN i
when WRB N
compared VBN N
with IN N
placebo NN i
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
and CC N
the DT N
percentage NN N
of IN N
patients NNS N
that WDT N
reach VBP N
higher JJR N
stages NNS N
in IN N
the DT N
ergometric JJ N
test NN N
was VBD N
significantly RB N
better JJR N
for IN N
diltiazem NN i
. . i

Heart NNP o
rate NN o
and CC o
systolic JJ o
plus CC o
diastolic JJ o
pressures NNS o
after IN N
exercise NN N
did VBD N
not RB N
differ VB N
in IN N
both DT N
groups NNS N
. . N

CONCLUSION NNP N
Diltiazem NNP i
reduced VBD N
the DT N
clinical JJ N
and CC N
electrocardiographical JJ N
aspects NNS N
and CC N
raises VBZ N
the DT N
effort NN N
tolerance NN N
during IN N
the DT N
ergometric JJ N
test NN N
in IN N
patients NNS p
with IN p
stable JJ p
angina NN p
. . p

-DOCSTART- -7035637- O O

Age-related JJ o
response NN o
to TO N
two CD N
Haemophilus NNP i
influenzae NN i
type NN i
b NN i
vaccines NNS i
. . i

Two CD N
types NNS N
of IN N
Hib NNP i
vaccines NNS i
were VBD N
compared VBN N
for IN N
efficacy NN o
and CC o
safety NN o
in IN N
71 CD p
normal JJ p
children NNS p
in IN p
three CD p
age NN p
groups NNS p
: : p
36 CD p
to TO p
72 CD p
months NNS p
, , p
15 CD p
to TO p
18 CD p
months NNS p
, , p
and CC p
6 CD p
to TO p
8 CD p
months NNS p
. . p

One CD N
vaccine NN N
contained VBD N
the DT N
Hib-specific NNP i
capsular JJ i
polysaccharide NN i
, , i
PRP NNP i
; : i
the DT N
second JJ N
vaccine NN N
contained VBN i
PRP NNP i
combined VBN N
with IN N
pertussis NN i
vaccine NN i
, , i
PRP-P. NNP i
A NNP N
third JJ N
vaccine NN N
, , N
DTP NNP i
, , N
was VBD N
administered VBN N
to TO N
a DT N
control NN i
group NN N
for IN N
each DT N
age NN N
. . N

Anti-PRP NNP o
antibody NN o
levels NNS o
were VBD N
greater JJR N
after IN N
vaccination NN N
with IN N
PRP-P NNP N
than IN N
after IN N
PRP NNP N
in IN N
all DT N
three CD p
age NN p
groups NNS p
. . p

Immunoresponsiveness NN o
to TO N
both DT N
vaccines NNS N
increased VBD o
with IN N
age NN N
. . N

A DT N
lower JJR o
incidence NN o
of IN o
side NN o
effects NNS o
was VBD N
seen VBN N
with IN N
both DT N
PRP NNP i
( ( N
15 CD N
% NN N
) ) N
and CC N
PRP-P NNP i
( ( N
20 CD N
% NN N
) ) N
than IN N
with IN N
DTP NNP N
( ( N
56 CD N
% NN N
) ) N
. . N

The DT N
results NNS N
suggest VBP N
that IN N
PRP-P NNP i
is VBZ N
both DT N
well RB o
tolerated VBN o
clinically RB o
and CC o
has VBZ o
greater JJR o
immunogenicity NN o
than IN N
PRP NNP N
. . N

-DOCSTART- -23127292- O O

Prognostic JJ N
interaction NN N
between IN N
expression NN o
of IN o
p53 NN o
and CC N
estrogen NN N
receptor NN N
in IN N
patients NNS p
with IN p
node-negative JJ p
breast NN p
cancer NN p
: : p
results NNS N
from IN N
IBCSG NNP N
Trials NNP N
VIII NNP N
and CC N
IX NNP N
. . N

INTRODUCTION NNP N
The DT N
prognostic JJ N
significance NN N
of IN N
p53 NN N
protein NN N
expression NN N
in IN N
early JJ N
breast NN N
cancer NN N
remains VBZ N
uncertain JJ N
, , N
with IN N
some DT N
but CC N
not RB N
all DT N
studies NNS N
finding VBG N
an DT N
association NN N
with IN N
poorer JJR o
outcomes NNS o
. . o

Estrogen NNP o
receptor NN o
( ( o
ER NNP o
) ) o
expression NN o
is VBZ N
both DT N
a DT N
positive JJ N
prognostic JJ N
marker NN N
and CC N
predictive NN N
of IN N
response NN o
to TO o
endocrine VB o
therapies NNS o
. . o

The DT N
relationship NN N
between IN N
these DT N
biomarkers NNS N
is VBZ N
unknown JJ N
. . N

METHODS NNP N
We PRP N
constructed VBD N
tissue NN N
microarrays NNS N
( ( N
TMAs NNP N
) ) N
from IN N
available JJ N
pathological JJ N
material NN N
from IN N
1113 CD p
patients NNS p
participating VBG p
in IN N
two CD N
randomized JJ N
clinical JJ N
trials NNS N
comparing VBG N
endocrine JJ i
therapy NN i
alone RB i
versus JJ i
chemo-endocrine JJ i
therapy NN i
in IN i
node-negative JJ p
breast NN p
cancer NN p
. . p

Expression NN o
of IN o
p53 NN o
defined VBN N
as IN N
> JJ N
10 CD N
% NN N
positive JJ N
nuclei NN N
was VBD N
analyzed VBN N
together RB N
with IN N
prior JJ N
immunohistochemical JJ N
assays NNS N
of IN N
ER NNP N
performed VBD N
at IN N
central JJ N
pathological JJ N
review NN N
of IN N
whole JJ N
tumor NN N
sections NNS N
. . N

RESULTS NNP N
ER NNP o
was VBD N
present JJ N
( ( N
i.e JJ N
. . N

> VB N
1 CD N
% NN N
positive JJ N
tumor NN N
cell NN N
nuclei NN N
) ) N
in IN N
80.1 CD N
% NN N
( ( N
880/1092 CD N
) ) N
. . N

p53 NN o
expression NN o
was VBD N
significantly RB N
more RBR N
frequent JJ N
when WRB N
ER NNP N
was VBD N
absent JJ N
, , N
125/212 CD N
( ( N
59 CD N
% NN N
) ) N
than IN N
when WRB N
ER NNP N
was VBD N
present JJ N
, , N
171/880 CD N
( ( N
19 CD N
% NN N
) ) N
, , N
p JJ N
< NN N
0.0001 CD N
. . N

A DT N
significant JJ N
qualitative JJ N
interaction NN N
was VBD N
observed VBN N
such JJ N
that IN N
p53 NN o
expression NN o
was VBD N
associated VBN N
with IN N
better JJR N
disease-free NN o
survival NN o
( ( o
DFS NNP o
) ) o
and CC o
overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
among IN N
patients NNS N
whose WP$ N
tumors NNS N
did VBD N
not RB N
express VB N
ER NNP N
, , N
but CC N
worse JJR N
DFS NNP o
and CC N
OS NNP o
among IN N
patients NNS N
whose WP$ N
tumors NNS N
expressed VBD N
ER NNP N
. . N

The DT N
interaction NN N
remained VBD N
significant JJ N
after IN N
allowance NN N
for IN N
pathologic JJ N
variables NNS N
, , N
and CC N
treatment NN N
. . N

Similar JJ N
effects NNS N
were VBD N
seen VBN N
when WRB N
luminal JJ N
and CC N
non-luminal JJ N
intrinsic JJ N
subtypes NNS N
were VBD N
compared VBN N
. . N

CONCLUSIONS NNP N
Interpretation NNP N
of IN N
the DT N
prognostic JJ N
significance NN N
of IN N
p53 NN o
expression NN o
requires VBZ N
knowledge NN N
of IN N
concurrent JJ N
expression NN o
of IN o
ER NNP o
. . o

The DT N
reason NN N
for IN N
the DT N
interaction NN N
between IN N
p53 NN N
and CC N
ER NNP N
is VBZ N
unknown JJ N
but CC N
may MD N
reflect VB N
qualitatively RB N
different JJ N
p53 NN o
mutations NNS o
underlying VBG N
the DT N
p53 NN o
expression NN o
in IN N
tumors NNS N
with IN N
or CC N
without IN N
ER NNP N
expression NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
Current NNP N
Controlled NNP N
Trials NNP N
ACTRN12607000037404 NNP N
( ( N
Trial NNP N
VIII NNP N
) ) N
and CC N
ACTRN12607000029493 NNP N
( ( N
Trial NNP N
IX NNP N
) ) N
. . N

-DOCSTART- -23466353- O O

Topical JJ N
treatment NN N
of IN N
tinea NN p
pedis NNS p
using VBG N
6 CD N
% NN N
coriander NN i
oil NN i
in IN i
unguentum NN N
leniens NNS N
: : N
a DT N
randomized NN N
, , N
controlled VBN N
, , N
comparative JJ N
pilot NN N
study NN N
. . N

BACKGROUND NNP N
The DT N
antifungal JJ N
activity NN N
of IN N
coriander NN i
oil NN i
has VBZ N
already RB N
been VBN N
demonstrated VBN N
in IN N
vitro NN N
. . N

OBJECTIVE NNP N
Evaluation NN N
of IN N
the DT N
efficacy NN o
and CC o
tolerability NN o
of IN N
6 CD i
% NN i
coriander NN i
oil NN i
in IN N
unguentum NN N
leniens NNS N
in IN N
the DT N
treatment NN N
of IN N
interdigital JJ p
tinea NN p
pedis NN p
. . p

METHODS NNP N
Half-side NNP p
comparative NN p
pilot NN N
study NN p
on IN p
subjects NNS p
with IN p
symmetric JJ p
, , p
bilateral JJ p
interdigital JJ p
tinea NN p
pedis NN p
. . p

Active JJ N
drug NN N
and CC N
placebo NN i
control NN N
were VBD N
applied VBN N
twice RB N
daily RB N
on IN N
the DT N
affected JJ N
areas NNS N
, , N
and CC N
follow-up JJ N
visits NNS N
were VBD N
performed VBN N
on IN N
days NNS N
14 CD N
and CC N
28 CD N
. . N

RESULTS VB N
40 CD p
participants NNS p
( ( p
mean JJ p
age NN p
52.5 CD p
years NNS p
, , p
60 CD p
% NN p
male NN p
) ) p
were VBD p
included VBN p
in IN p
the DT p
study NN p
. . p

For IN N
6 CD N
% NN N
coriander NN i
oil NN i
in IN N
unguentum NN N
leniens NNS N
, , N
a DT N
highly RB N
significant JJ N
improvement NN N
of IN N
the DT N
clinical JJ o
signs NNS o
( ( N
p VB N
< RB N
0.0001 CD N
) ) N
was VBD N
observed VBN N
during IN N
the DT N
entire JJ N
observation NN N
period NN N
; : N
the DT N
number NN o
of IN o
positive JJ o
fungal NN o
cultures NNS o
also RB N
tended VBD N
to TO N
decrease VB N
( ( N
p JJ N
= NNP N
0.0654 CD N
) ) N
. . N

The DT N
tolerability NN o
of IN N
the DT N
tested JJ N
substances NNS N
was VBD N
good JJ N
. . N

CONCLUSION NNP N
Coriander NNP i
oil NN i
is VBZ N
effective JJ N
and CC N
well RB N
tolerated VBN N
in IN N
the DT N
treatment NN N
of IN N
interdigital JJ N
tinea NN N
pedis NN N
. . N

-DOCSTART- -2939214- O O

Comparison NNP N
of IN N
ketanserin NN i
and CC N
pindolol NN i
in IN N
hypertension NN p
. . p

The DT N
antihypertensive JJ N
effects NNS N
of IN N
ketanserin NN i
( ( N
40 CD N
mg NN N
twice RB N
daily RB N
) ) N
and CC N
pindolol NN i
( ( N
5 CD N
mg NN N
twice RB N
daily RB N
) ) N
as IN N
monotherapy NN N
were VBD N
compared VBN N
in IN N
a DT N
crossover NN N
, , N
double-blind JJ N
trial NN N
in IN N
17 CD p
patients NNS p
with IN p
essential JJ p
hypertension NN p
. . p

Both DT N
ketanserin NN i
and CC N
pindolol NN i
decreased VBN N
supine JJ o
systolic NN o
and CC o
diastolic JJ o
blood NN o
pressure NN o
significantly RB N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
for IN N
systolic JJ o
and CC o
P NNP o
less JJR N
than IN N
0.001 CD N
for IN N
diastolic NN N
) ) N
when WRB N
evaluated VBN N
at IN N
the DT N
end NN N
of IN N
the DT N
2-month JJ N
treatment NN N
periods NNS N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
drugs NNS N
. . N

No DT N
significant JJ N
changes NNS N
in IN N
heart NN o
rate NN o
were VBD N
observed VBN N
on IN N
either DT N
drug NN N
. . N

Both DT N
drugs NNS N
were VBD N
well RB N
tolerated VBN N
. . N

-DOCSTART- -24628747- O O

Randomized NNP N
clinical JJ N
trial NN N
of IN N
hydrocodone/acetaminophen NN N
versus NN N
codeine/acetaminophen NN N
in IN N
the DT N
treatment NN N
of IN N
acute JJ p
extremity NN p
pain NN p
after IN p
emergency NN p
department NN p
discharge NN p
. . p

OBJECTIVES CC N
The DT N
objective NN N
was VBD N
to TO N
test VB N
the DT N
hypothesis NN N
that WDT N
hydrocodone/acetaminophen NN i
( ( N
Vicodin NNP N
[ VBZ N
5/500 CD N
] NN N
) ) N
provides VBZ N
more RBR N
efficacious JJ N
analgesia NN N
than IN N
codeine/acetaminophen NN i
( ( N
Tylenol NNP N
# # N
3 CD N
[ $ N
30/300 CD N
] NN N
) ) N
in IN N
patients NNS p
discharged VBN p
from IN p
the DT p
emergency NN p
department NN p
( ( p
ED NNP p
) ) p
. . p

Both DT N
are VBP N
currently RB N
Drug NNP N
Enforcement NNP N
Administration NNP N
( ( N
DEA NNP N
) ) N
Schedule NNP N
III NNP N
narcotics NNS N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
clinical JJ N
trial NN N
of IN N
patients NNS p
with IN p
acute JJ p
extremity NN p
pain NN p
who WP p
were VBD p
discharged VBN p
home NN p
from IN p
the DT p
ED NNP p
, , N
comparing VBG N
a DT N
3-day JJ N
supply NN N
of IN N
oral JJ i
hydrocodone/acetaminophen NN i
( ( i
5 CD i
mg/500 RB i
mg NN i
) ) i
to TO i
oral JJ i
codeine/acetaminophen NN i
( ( i
30 CD i
mg/300 RB i
mg NN i
) ) i
. . i

Pain NN o
was VBD N
measured VBN N
on IN N
a DT N
valid JJ N
and CC N
reproducible JJ N
verbal JJ N
numeric NN N
rating NN N
scale NN N
( ( N
NRS NNP N
) ) N
ranging VBG N
from IN N
0 CD N
to TO N
10 CD N
, , N
and CC N
patients NNS N
were VBD N
contacted VBN N
by IN N
telephone NN N
approximately RB N
24 CD N
hours NNS N
after IN N
being VBG N
discharged VBN N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
the DT N
between-group JJ N
difference NN N
in IN N
improvement NN N
in IN N
pain NN o
at IN N
2 CD N
hours NNS N
following VBG N
the DT N
most RBS N
recent JJ N
ingestion NN N
of IN N
the DT N
study NN N
drug NN N
, , N
relative JJ N
to TO N
the DT N
time NN N
of IN N
phone NN N
contact NN N
after IN N
ED NNP N
discharge NN N
. . N

Secondary JJ N
outcomes NNS N
compared VBN N
side-effect JJ o
profiles NNS o
and CC o
patient JJ o
satisfaction NN o
. . o

RESULTS VB N
The DT N
median JJ o
time NN o
from IN o
ED NNP o
discharge NN N
to TO N
follow-up NN N
was VBD N
26 CD N
hours NNS N
( ( N
interquartile JJ N
range NN N
[ NNP N
IQR NNP N
] NNP N
= VBD N
24 CD N
to TO N
39 CD N
hours NNS N
) ) N
. . N

The DT N
mean JJ o
NRS NNP o
pain NN o
score NN o
before IN N
the DT N
most RBS N
recent JJ N
dose NN N
of IN N
pain NN N
medication NN N
after IN N
ED NNP N
discharge NN N
was VBD N
7.6 CD N
NRS NNP N
units NNS N
for IN N
both DT N
groups NNS N
. . N

The DT N
mean JJ o
decrease NN o
in IN o
pain NN o
scores NNS o
2 CD N
hours NNS N
after IN N
pain NN o
medications NNS N
were VBD N
taken VBN N
were VBD N
3.9 CD N
NRS NNP N
units NNS N
in IN N
the DT N
hydrocodone/acetaminophen NN i
group NN N
versus VBD N
3.5 CD N
NRS NNP N
units NNS N
in IN N
the DT N
codeine/acetaminophen NN i
group NN N
, , N
for IN N
a DT N
difference NN N
of IN N
0.4 CD N
NRS NNP N
units NNS N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
= NNP N
-0.3 NNP N
to TO N
1.2 CD N
NRS NNP N
units NNS N
) ) N
. . N

No UH o
differences NNS o
were VBD N
found VBN N
in IN N
side JJ o
effects NNS o
or CC o
patient JJ o
satisfaction NN o
. . o

CONCLUSIONS NNP N
Both NNP N
medications NNS N
decreased VBD o
NRS NNP o
pain NN o
scores NNS o
by IN N
approximately RB N
50 CD N
% NN N
. . N

However RB N
, , N
the DT N
oral JJ N
hydrocodone/acetaminophen NN N
failed VBD N
to TO N
provide VB N
clinically RB N
or CC N
statistically RB N
superior JJ o
pain NN o
relief NN o
compared VBN N
to TO N
oral VB N
codeine/acetaminophen NN i
when WRB N
prescribed VBN N
to TO N
patients NNS N
discharged VBN N
from IN N
the DT N
ED NNP N
with IN N
acute JJ N
extremity NN N
pain NN N
. . N

Similarly RB N
, , N
there EX N
were VBD N
no DT N
clinically RB N
or CC N
statistically RB N
important JJ N
differences NNS N
in IN N
side-effect JJ N
profiles NNS N
or CC N
patient JJ N
satisfaction NN N
. . N

If IN N
the DT N
DEA NNP N
reclassifies VBZ N
hydrocodone NN N
as IN N
a DT N
Schedule NNP N
II NNP N
narcotic JJ N
, , N
as IN N
recently RB N
recommended VBN N
by IN N
its PRP$ N
advisory JJ N
board NN N
, , N
our PRP$ N
data NNS N
suggest VBP N
that IN N
the DT N
codeine/acetaminophen NN i
may MD N
be VB N
a DT N
clinically RB N
reasonable JJ N
Schedule NNP N
III NNP N
substitute NN N
for IN N
hydrocodone/acetaminophen NN N
at IN N
ED NNP N
discharge NN N
. . N

These DT N
findings NNS N
should MD N
be VB N
regarded VBN N
as IN N
tentative JJ N
and CC N
require JJ N
independent JJ N
validation NN N
in IN N
similar JJ N
and CC N
other JJ N
acute NN N
pain NN N
models NNS N
. . N

-DOCSTART- -17479312- O O

Use NNP N
of IN N
the DT N
electrothermal JJ i
bipolar JJ i
vessel NN i
system NN i
( ( i
EBVS NNP i
) ) i
in IN N
laparoscopic JJ N
adrenalectomy NN N
: : N
a DT N
prospective JJ N
study NN N
. . N

BACKGROUND NNP N
Since IN N
laparoscopic NN p
adrenalectomy NN p
( ( p
LA NNP p
) ) p
has VBZ N
been VBN N
adopted VBN N
as IN N
the DT N
gold JJ N
standard NN N
for IN N
the DT N
treatment NN N
of IN N
adrenal JJ N
diseases NNS N
, , N
the DT N
development NN N
of IN N
technology NN N
for IN N
vascular JJ N
control NN N
and CC N
dissection NN N
manoeuvres NNS N
, , N
amongst VBZ N
other JJ N
things NNS N
, , N
may MD N
play VB N
a DT N
pivotal JJ N
role NN N
in IN N
its PRP$ N
further JJ N
improvement NN N
. . N

We PRP N
report VBP N
our PRP$ N
experience NN N
with IN N
the DT N
electrothermal JJ i
bipolar JJ i
vessel NN i
sealing NN i
( ( i
EBVS NNP i
) ) i
device NN N
for IN N
LA NNP N
. . N

METHODS NNP N
From IN p
January NNP p
2004 CD p
to TO p
January NNP p
2006 CD p
, , p
50 CD p
patients NNS p
( ( p
pts NNS p
) ) p
undergoing VBG p
LA NNP p
were VBD N
selected VBN N
and CC N
randomized VBN N
for IN N
use NN N
of IN N
the DT N
EBVS NNP i
( ( i
25 CD i
pts NNS i
, , i
group NN i
A NNP i
) ) i
versus IN i
the DT i
UltraSonic NNP i
Shears NNP i
( ( i
USS NNP i
) ) i
device NN i
( ( N
25 CD N
pts NNS N
, , N
group NN N
B NNP N
) ) N
. . N

Age NNP N
, , N
sex NN N
, , N
body NN N
mass NN N
index NN N
( ( N
BMI NNP N
) ) N
, , N
previous JJ N
surgery NN N
and CC N
associated VBN N
diseases NNS N
were VBD N
similar JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

The DT N
main JJ N
surgical JJ N
parameters NNS N
collected VBN N
for IN N
each DT N
patient NN N
( ( N
pt NN N
) ) N
concerned VBD N
operative JJ N
time NN N
, , N
major JJ N
and CC N
minor JJ N
complications NNS N
, , N
conversion NN N
rate NN N
, , N
blood NN N
loss NN N
, , N
hospital JJ N
stay NN N
and CC N
histology NN N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT o
mortality NN o
in IN N
either DT N
group NN N
. . N

The DT N
right JJ N
adrenalectomy NN N
mean VB o
operative JJ o
time NN o
( ( o
OpT NNP o
) ) o
was VBD N
51.8 CD N
mins NNS N
( ( N
range VB N
40-90 JJ N
mins NNS N
) ) N
and CC N
68.6 CD N
mins NNS N
( ( N
range VB N
50-130 NNP N
mins NNS N
) ) N
in IN N
group NN N
A NNP N
and CC N
B NNP N
, , N
respectively RB N
( ( N
P NNP N
not RB N
significant JJ N
) ) N
. . N

The DT N
left JJ o
adrenalectomy JJ o
mean JJ o
OpT NNP o
was VBD N
72.2 CD N
mins NNS N
( ( N
range VB N
55-100 NNP N
mins NNS N
) ) N
and CC N
94 CD N
mins NNS N
( ( N
range VB N
65-140 NNP N
mins NNS N
) ) N
for IN N
group NN N
A NNP N
and CC N
B NNP N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
mean JJ o
blood NN o
loss NN o
was VBD N
83 CD N
ml NN N
( ( N
group NN N
A NNP N
) ) N
and CC N
210 CD N
ml NN N
( ( N
group NN N
B NNP N
) ) N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Complications NNS N
were VBD N
not RB N
different JJ N
for IN N
the DT N
two CD N
groups NNS N
. . N

The DT N
mean JJ o
hospital NN o
stay NN o
was VBD N
2.9 CD N
and CC N
3.1 CD N
days NNS N
in IN N
group NN N
A NNP N
and CC N
B NNP N
, , N
respectively RB N
( ( N
P NNP N
not RB N
significant JJ N
) ) N
. . N

CONCLUSIONS NNP N
EBVS NNP N
in IN N
LA NNP N
may MD N
provide VB N
a DT N
significantly RB N
short JJ o
operating NN o
time NN o
and CC o
blood NN o
loss NN o
. . o

-DOCSTART- -15169706- O O

Weight NNP o
and CC o
leptin JJ o
changes NNS o
among IN N
risperidone-treated JJ i
youths NNS p
with IN p
autism NN p
: : p
6-month JJ N
prospective JJ N
data NNS N
. . N

OBJECTIVE IN N
The DT N
authors NNS N
examined VBD N
the DT N
developmental JJ N
impact NN N
and CC N
temporal JJ N
characteristics NNS N
of IN N
risperidone-associated JJ i
weight NN o
change NN o
. . o

METHOD NNP N
Weight NNP o
change NN o
was VBD N
measured VBN N
for IN N
63 CD p
children NNS p
and CC p
adolescents NNS p
with IN p
autism NN p
treated VBN p
with IN p
risperidone NN i
for IN p
6 CD p
months NNS p
. . p

Change NNP o
in IN o
serum NN o
leptin NN o
levels NNS o
after IN N
2 CD N
months NNS N
was VBD N
examined VBN N
as IN N
a DT N
predictor NN N
of IN N
final JJ o
weight NN o
gain NN o
in IN N
mixed JJ N
regression NN N
models NNS N
that WDT N
controlled VBD N
for IN N
site NN N
, , N
gender NN N
, , N
age NN N
, , N
and CC N
risperidone NN i
dose NN N
. . N

RESULTS NNP N
Age- JJ N
and CC N
gender-standardized JJ N
weight NN o
increased VBD o
after IN N
6 CD N
months NNS N
of IN N
treatment NN N
( ( N
gross JJ N
: : N
mean=5.6 NN N
kg NN N
[ NNP N
SD=3.9 NNP N
] NNP N
; : N
standardized VBN N
: : N
mean=0.6 NN N
z NN N
[ NNP N
SD=0.5 NNP N
] NNP N
) ) N
and CC N
was VBD N
positively RB N
correlated VBN N
with IN N
weight NN o
gained VBN o
after IN N
1 CD N
month NN N
. . N

Change NN o
in IN o
leptin NN o
levels NNS o
after IN N
2 CD N
months NNS N
of IN N
treatment NN N
( ( N
mean=-0.3 JJ N
ng/ml NN N
, , N
SD=6.2 NNP N
) ) N
( ( N
N=48 NNP N
) ) N
did VBD N
not RB N
predict JJ N
final JJ o
weight NN o
gain NN o
. . o

CONCLUSIONS NNP N
Chronic NNP N
risperidone NN i
exposure NN N
in IN N
children NNS N
with IN N
autism NN N
causes NNS N
weight VBD o
gain NN o
in IN N
excess NN N
of IN N
developmentally RB N
expected VBN N
norms NNS N
that WDT N
follows VBZ N
a DT N
curvilinear JJ N
trajectory NN N
and CC N
decelerates VBZ N
over IN N
time NN N
. . N

Serum NNP o
leptin JJ o
change NN o
does VBZ N
not RB N
reliably VB N
predict JJ N
risperidone-associated JJ N
weight NN o
gain NN o
. . o

-DOCSTART- -11836674- O O

Multicenter NNP N
randomized VBD N
controlled VBN N
trial NN N
of IN N
the DT N
management NN p
of IN p
unresectable JJ p
malignant JJ p
mesothelioma NN p
proposed VBN N
by IN N
the DT N
British JJ N
Thoracic NNP N
Society NNP N
and CC N
the DT N
British JJ N
Medical NNP N
Research NNP N
Council NNP N
. . N

Malignant NNP p
mesothelioma NN p
is VBZ N
almost RB N
invariably RB N
fatal JJ N
. . N

The DT N
incidence NN N
of IN N
the DT N
disease NN N
is VBZ N
rising VBG N
rapidly RB N
in IN N
many JJ N
countries NNS N
, , N
and CC N
there EX N
is VBZ N
no DT N
generally RB N
accepted VBN N
standard JJ N
treatment NN N
for IN N
patients NNS p
with IN p
unresectable JJ p
disease NN p
. . p

According VBG N
to TO N
current JJ N
British JJ N
Thoracic NNP N
Society NNP N
( ( N
BTS NNP N
) ) N
guidelines NNS N
, , N
patients NNS N
should MD N
be VB N
treated VBN N
with IN N
active JJ i
symptom NNS i
control NN i
( ( N
ASC NNP N
) ) N
, , N
involving VBG N
( ( N
1 CD N
) ) N
regular JJ i
follow-up NN i
in IN i
a DT i
specialist NN i
clinic NN i
; : i
( ( i
2 CD i
) ) i
structured VBD i
assessments NNS i
of IN i
physical JJ i
, , i
psychological JJ i
and CC i
social JJ i
problems NNS i
with IN i
appropriate JJ i
action NN i
; : i
( ( i
3 CD i
) ) i
rapid JJ i
involvement NN i
of IN i
additional JJ i
specialists NNS i
; : i
and CC i
( ( i
4 CD i
) ) i
parallel NN i
nursing VBG i
support NN i
. . i

Although IN N
many JJ N
nonrandomized JJ N
studies NNS N
have VBP N
reported VBN N
tumor NN N
responses NNS N
to TO N
anticancer VB N
chemotherapy NN N
, , N
few JJ N
have VBP N
studied VBN N
palliation NN N
and CC N
it PRP N
is VBZ N
not RB N
known VBN N
whether IN N
chemotherapy NN N
prolongs NNS N
survival NN N
or CC N
provides VBZ N
clinically RB N
worthwhile JJ N
palliation NN N
with IN N
acceptable JJ N
toxicity NN N
when WRB N
given VBN N
in IN N
addition NN N
to TO N
ASC NNP N
. . N

We PRP N
therefore VBD N
plan NN N
to TO N
conduct VB N
a DT N
multicenter NN N
randomized VBN N
controlled VBN N
trial NN N
comparing NN N
( ( N
1 CD N
) ) N
ASC NNP i
alone RB i
, , i
( ( i
2 CD i
) ) i
ASC NNP i
plus CC i
mitomycin JJ i
vinblastine NN i
and CC i
cisplatin NN i
( ( i
MVP NNP i
) ) i
, , i
and CC i
( ( i
3 CD i
) ) i
ASC NNP i
plus CC i
vinorelbine NN i
( ( N
N NNP N
; : N
Navelbine NNP N
, , N
Pierre NNP N
Fabre NNP N
Oncology NNP N
, , N
Winchester NNP N
, , N
UK NNP N
) ) N
. . N

We PRP N
chose VBD N
these DT N
chemotherapy NN N
regimens NNS N
because IN N
they PRP N
have VBP N
been VBN N
shown VBN N
in IN N
nonrandomized JJ N
studies NNS N
to TO N
provide VB N
good JJ N
symptom NN N
control NN N
as IN N
recorded VBN N
by IN N
patients NNS N
. . N

The DT N
outcome NN N
measures NNS N
are VBP N
overall JJ o
survival NN o
, , o
palliation NN o
of IN o
symptoms NNS o
, , o
performance NN o
status NN o
, , o
analgesic JJ o
usage NN o
, , o
toxicity NN o
, , o
quality NN o
of IN o
life NN o
, , o
tumor NN o
response NN o
, , o
and CC o
recurrence/progression-free JJ o
survival NN o
. . o

In IN N
a DT N
preliminary JJ N
feasibility NN N
study NN N
, , N
we PRP N
are VBP N
assessing VBG N
the DT N
acceptability NN N
of IN N
the DT N
trial NN N
design NN N
to TO N
patients NNS N
and CC N
the DT N
suitability NN N
of IN N
two CD N
standard JJ N
quality-of-life JJ o
instruments NNS N
in IN N
mesothelioma NN p
. . p

Data NNP N
will MD N
help VB N
us PRP N
to TO N
decide VB N
the DT N
final JJ N
details NNS N
of IN N
the DT N
large JJ N
multicenter NN N
trial NN N
. . N

-DOCSTART- -10355394- O O

A DT N
prospective JJ N
randomized VBN N
trial NN N
of IN N
Duraflo NNP i
II NNP i
heparin-coated JJ i
circuits NNS i
in IN N
cardiac JJ p
reoperations NNS p
. . p

BACKGROUND NNP N
Heparin-coated JJ i
circuits NNS i
in IN N
cardiopulmonary JJ N
bypass NN N
have VBP N
been VBN N
shown VBN N
to TO N
decrease VB N
the DT N
systemic JJ N
inflammatory NN N
responses NNS N
associated VBN N
with IN N
cardiopulmonary JJ N
bypass NN N
. . N

Previous JJ N
clinical JJ N
studies NNS N
on IN N
low-risk JJ p
patients NNS p
who WP p
had VBD p
coronary JJ i
artery NN i
bypass NN i
grafting NN i
( ( p
CABG NNP p
) ) p
and CC N
received VBN N
full-dose JJ N
systemic JJ N
heparin NN i
did VBD N
not RB N
have VB N
clearly RB N
improved VBN N
clinical JJ N
outcomes NNS N
. . N

We PRP N
hypothesized VBD N
that IN N
the DT N
beneficial JJ N
effects NNS N
of IN N
heparin-coated JJ i
circuits NNS i
might MD N
be VB N
seen VBN N
in IN N
patients NNS p
who WP p
had VBD p
cardiac JJ p
reoperations NNS p
. . p

METHODS NNP N
Three CD p
hundred VBD p
fifty JJ p
patients NNS p
who WP p
had VBD p
reoperation NN p
with IN p
CABG NNP p
only RB p
( ( p
58 CD p
% NN p
) ) p
, , p
or CC p
with IN p
valve JJ p
operations NNS p
( ( p
42 CD p
% NN p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either RB N
a DT N
heparin-coated JJ i
( ( i
Duraflo NNP i
II NNP i
; : i
study VB i
group NN i
) ) i
or CC i
uncoated JJ i
( ( i
control VB i
group NN i
) ) i
circuit NN i
. . i

Clinical JJ N
outcomes NNS N
were VBD N
compared VBN N
and CC N
the DT N
variables NNS N
were VBD N
analyzed VBN N
using VBG N
the DT N
following JJ N
three CD N
groups NNS N
: : N
entire JJ N
populations NNS N
of IN N
study NN N
group NN N
and CC N
control NN N
group NN N
, , N
subgroup NN N
of IN N
patients NNS N
who WP N
had VBD N
CABG NNP N
reoperation NN N
only RB N
, , N
and CC N
a DT N
subgroup NN p
who WP p
had VBD p
valve VBN p
reoperation NN p
or CC p
combined VBN p
valve NNS p
and CC p
CABG NNP p
reoperation NN p
. . p

RESULTS NNP N
Preoperative JJ N
variables NNS N
were VBD N
the DT N
same JJ N
in IN N
both DT N
groups NNS N
. . N

No DT N
difference NN N
in IN N
clinical JJ N
outcomes NNS N
could MD N
be VB N
demonstrated VBN N
except IN N
that IN N
the DT N
percentage NN o
of IN o
patients NNS o
with IN o
major JJ o
bleeding VBG o
episodes NNS o
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
study NN p
group NN p
( ( p
1.2 CD p
% NN p
versus IN p
5.4 CD p
% NN p
, , p
p NN p
= NNP p
0.035 CD p
) ) p
. . p

In IN N
the DT N
subgroup NN N
analysis NN N
of IN N
patients NNS N
who WP N
had VBD N
valve NN o
reoperations NNS o
, , N
lower JJR N
blood NN o
transfusion NN o
requirements NNS o
in IN N
the DT N
intensive JJ N
care NN N
unit NN N
( ( N
p JJ N
= NNP N
0.013 CD N
) ) N
were VBD N
found VBN N
in IN N
the DT N
study NN N
group NN N
. . N

When WRB N
the DT N
subgroup NN N
of IN N
patients NNS N
who WP N
had VBD N
CABG NNP N
reoperations NNS N
was VBD N
analyzed VBN N
separately RB N
, , N
there EX N
was VBD N
a DT N
trend NN N
toward IN N
less JJR N
reoperation NN o
for IN o
bleeding VBG o
in IN N
the DT N
study NN N
group NN N
( ( N
0 CD N
% NN N
versus IN N
4.0 CD N
% NN N
, , N
p NN N
= NNP N
0.058 CD N
) ) N
. . N

CONCLUSIONS NNP N
We PRP N
conclude VBP N
that IN N
the DT N
use NN N
of IN N
heparin-coated JJ N
circuits NNS N
was VBD N
safe JJ N
and CC N
imparted JJ N
protection NN N
from IN N
reoperations NNS N
for IN N
bleeding NN N
and CC N
major JJ N
bleeding VBG N
episodes NNS N
. . N

Material-independent JJ N
blood NN N
activation NN N
( ( N
eg JJ N
, , N
blood-air JJ N
interface NN N
and CC N
cardiotomy JJ N
suction NN N
) ) N
blunted VBD N
the DT N
total JJ N
effect NN N
of IN N
the DT N
heparin-coated JJ N
surface NN N
. . N

-DOCSTART- -24436115- O O

No DT N
gains NNS N
in IN N
efficacy NN o
observed VBN N
by IN N
adding VBG N
gemcitabine NN i
to TO i
adjuvant VB i
therapy NN i
for IN N
lymph JJ p
node-positive JJ p
breast NN p
cancer NN p
. . p

-DOCSTART- -6148163- O O

Thyroid NNP i
stimulating VBG i
antibodies NNS i
: : i
an DT N
aid NN N
to TO N
the DT N
strategy NN N
of IN N
treatment NN N
of IN N
Graves NNP p
' POS p
disease NN p
? . N
In IN N
1976 CD N
we PRP N
initiated VBD N
a DT N
prospective JJ N
study NN N
to TO N
specify VB N
the DT N
usefulness NN N
of IN N
thyroid JJ i
stimulating VBG i
antibody NN i
( ( i
TSAb NNP i
) ) i
determinations NNS N
in IN N
predicting VBG N
the DT N
outcome NN N
of IN N
post-antithyroid JJ i
drug NN i
treatment NN i
for IN N
Graves NNP N
' POS N
disease NN N
. . N

This DT p
study NN p
was VBD p
carried VBN p
out RP p
on IN p
55 CD p
patients NNS p
, , p
who WP p
were VBD p
either RB p
treated VBN p
for IN p
six CD p
( ( p
n JJ p
= NNP p
16 CD p
) ) p
or CC p
18 CD p
months NNS p
( ( p
n JJ p
= NNP p
39 CD p
) ) p
and CC p
followed VBD p
up RP p
for IN p
an DT p
additional JJ p
two-year JJ p
period NN p
. . p

TSAb NNP o
was VBD p
determined VBN p
on IN p
whole JJ p
serum NN p
in IN p
29 CD p
patients NNS p
before IN p
and CC p
at IN p
the DT p
end NN p
of IN p
treatment NN p
, , p
and CC p
in IN p
26 CD p
patients NNS p
at IN p
the DT p
end NN p
of IN p
treatment NN p
only RB p
. . p

These DT N
determinations NNS N
were VBD N
carried VBN N
out RP N
using VBG N
a DT N
sensitive JJ N
and CC N
reproducible JJ N
microassay NNS N
based VBN N
on IN N
cAMP JJ N
accumulation NN N
in IN N
human JJ N
thyroid NN N
cell NN N
cultures NNS N
. . N

Before IN N
treatment NN N
, , N
TSAb NNP o
ranging VBG N
from IN N
170 CD N
to TO N
1529 CD N
% NN N
was VBD N
present JJ N
in IN N
28/29 CD N
patients NNS N
and CC N
reached VBN N
significantly RB N
low JJ N
levels NNS N
at IN N
the DT N
end NN N
of IN N
treatment NN N
whatever WDT N
its PRP$ N
duration NN N
. . N

TSAb NNP o
was VBD N
undetectable JJ N
in IN N
24/55 CD N
patients NNS N
at IN N
the DT N
end NN N
of IN N
treatment NN N
. . N

8/16 CD N
'short-treated JJ N
' POS N
and CC N
18/39 CD N
'long-treated JJ N
' POS N
patients NNS N
remained VBD N
in IN N
remission NN o
. . o

As IN N
expected VBN N
, , N
initial JJ o
TSAb NNP o
levels NNS o
had VBD N
no DT N
predictive JJ N
value NN N
. . N

End-treatment JJ o
TSAb NNP o
values NNS o
, , N
when WRB N
low JJ N
( ( N
less JJR N
than IN N
350 CD N
% NN N
) ) N
or CC N
negative JJ N
did VBD N
not RB N
correlate VB N
with IN N
later JJ N
evolution NN N
: : N
in IN N
these DT N
39 CD N
patients NNS N
, , N
relapse NN o
rate NN o
was VBD N
41 CD N
% NN N
. . N

In IN N
contrast NN N
, , N
13/16 CD N
patients NNS N
with IN N
end-treatment JJ o
TSAb NNP o
greater JJR N
than IN N
350 CD N
% NN N
relapsed VBN N
. . N

Relapses NNS o
tended VBD N
to TO N
occur VB N
earlier RBR N
in IN N
patients NNS N
with IN N
the DT N
highest JJS N
TSAb NN o
levels NNS o
. . o

TSAb NNP o
determined VBD p
again RB p
during IN p
follow-up NN p
was VBD p
negative JJ p
in IN p
each DT p
of IN p
the DT p
18 CD p
patients NNS p
in IN p
remission NN p
, , p
and CC p
positive JJ p
in IN p
8/10 CD p
patients NNS p
at IN p
the DT p
time NN p
of IN p
relapse NN p
, , p
whatever WDT p
its PRP$ p
level NN p
at IN p
the DT p
end NN p
of IN p
the DT p
drug NN p
course NN p
. . p

This DT N
study NN N
confirms VBZ N
that IN N
only RB N
end-treatment JJ N
TSAb NNP N
levels NNS N
are VBP N
predictive JJ N
of IN N
relapse NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -24345834- O O

Dietary NNP i
docosahexaenoic NN i
acid NN i
supplementation NN i
in IN N
children NNS p
with IN p
autism NN p
. . p

OBJECTIVE CC N
The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
docosahexaenoic JJ i
acid NN i
( ( i
DHA NNP i
) ) i
supplementation NN i
improves VBZ N
the DT N
behavior NN o
of IN N
children NNS p
with IN p
autism NN p
. . p

METHODS NNP N
A NNP p
group NN p
of IN p
3- JJ p
to TO p
10-year-old JJ p
children NNS p
with IN p
autism NN p
were VBD N
randomized VBN N
in IN N
a DT N
double-blind JJ N
fashion NN N
to TO N
receive VB N
a DT N
supplement NN i
containing VBG N
200 CD N
mg NN N
of IN N
DHA NNP i
or CC N
a DT N
placebo NN i
for IN N
6 CD N
months NNS N
. . N

The DT N
parents NNS N
and CC N
the DT N
investigator NN N
completed VBD N
the DT N
Clinical JJ N
Global NNP N
Impressions-Improvement NNP N
scale NN N
to TO N
rate NN N
changes NNS N
in IN N
core NN N
symptoms NNS N
of IN N
autism NN N
after IN N
3 CD N
and CC N
6 CD N
months NNS N
. . N

The DT N
parents NNS N
completed VBD N
the DT N
Child NNP N
Development NNP N
Inventory NNP N
and CC N
the DT N
Aberrant NNP N
Behavior NNP N
Checklist NNP N
, , N
and CC N
both DT N
parents NNS N
and CC N
teachers NNS N
completed VBD N
the DT N
Behavior NNP o
Assessment NNP o
Scale NNP o
for IN o
Children NNP o
( ( o
BASC NNP o
) ) o
at IN N
enrollment NN N
and CC N
after IN N
6 CD N
months NNS N
. . N

RESULTS VB N
A DT p
total NN p
of IN p
48 CD p
children NNS p
( ( p
40 CD p
[ RB p
83 CD p
% NN p
] JJ p
boys NNS p
, , p
mean JJ p
age NN p
[ NNP p
standard NN p
deviation NN p
] VBD p
6.1 CD p
[ JJ p
2.0 CD p
] CD p
years NNS p
) ) p
were VBD p
enrolled VBN p
; : p
24 CD N
received VBD N
DHA NNP i
and CC N
24 CD N
placebo NN i
. . i

Despite IN N
a DT N
median JJ N
431 CD N
% NN N
increase NN N
in IN N
total JJ o
plasma NN o
DHA NNP o
levels NNS o
after IN N
6 CD N
months NNS N
, , N
the DT N
DHA NNP i
group NN N
was VBD N
not RB N
rated VBN N
as IN N
improved VBN N
in IN N
core NN N
symptoms NNS N
of IN N
autism NN N
compared VBN N
to TO N
the DT N
placebo NN i
group NN N
on IN N
the DT N
CGI-I NNP N
. . N

Based VBN N
on IN N
the DT N
analysis NN N
of IN N
covariance NN N
models NNS N
adjusted VBN N
for IN N
the DT N
baseline NN N
rating NN N
scores NNS N
, , N
parents NNS N
( ( N
but CC N
not RB N
teachers NNS N
) ) N
provided VBD N
a DT N
higher JJR N
average JJ N
rating NN o
of IN o
social JJ o
skills NNS o
on IN o
the DT o
BASC NNP o
for IN N
the DT N
children NNS N
in IN N
the DT N
placebo NN N
group NN N
compared VBN N
to TO N
the DT N
DHA NNP i
group NN N
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
, , N
and CC N
teachers NNS N
( ( N
but CC N
not RB N
parents NNS N
) ) N
provided VBD N
a DT N
higher JJR N
average JJ o
rating NN o
of IN o
functional JJ o
communication NN o
on IN o
the DT N
BASC NNP N
for IN N
the DT N
children NNS N
in IN N
the DT N
DHA NNP i
group NN N
compared VBN N
to TO N
the DT N
placebo NN N
group NN N
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

CONCLUSIONS NNP i
Dietary NNP i
DHA NNP i
supplementation NN i
of IN i
200 CD i
mg/day NN N
for IN N
6 CD N
months NNS N
does VBZ N
not RB N
improve VB N
the DT N
core NN N
symptoms NNS N
of IN N
autism NN N
. . N

Our PRP$ N
results NNS N
may MD N
have VB N
been VBN N
limited VBN N
by IN N
inadequate JJ N
sample NN N
size NN N
. . N

-DOCSTART- -16394797- O O

Similar JJ N
compliance NN N
and CC N
effect NN N
of IN N
treatment NN N
in IN N
chronic JJ p
hepatitis NN p
C NNP p
resulting VBG p
from IN p
intravenous JJ i
drug NN i
use NN i
in IN N
comparison NN N
with IN N
other JJ N
infection NN N
causes NNS N
. . N

OBJECTIVES NNP N
There EX N
is VBZ N
some DT N
reluctance NN N
to TO N
treat VB N
intravenous JJ p
drug NN p
users NNS p
( ( p
IVDUs NNP p
) ) p
with IN p
chronic JJ p
hepatitis NN p
C NNP p
( ( p
CHC NNP p
) ) p
because IN N
of IN N
presumed JJ N
lower JJR N
compliance NN N
and CC N
response NN N
to TO N
antiviral JJ i
therapy NN i
. . i

We PRP N
intended VBD N
to TO N
evaluate VB N
the DT N
compliance NN N
and CC N
response NN N
to TO N
antiviral JJ i
treatment NN i
for IN i
CHC NNP i
in IN N
IVDUs NNP N
compared VBN N
with IN N
non-IVDUs JJ N
. . N

METHODS VB N
A DT N
retrospective JJ N
cohort NN N
study NN N
-- : N
secondary JJ N
analysis NN N
of IN N
the DT N
results NNS N
of IN N
a DT N
treatment NN p
trial NN p
-- : p
was VBD p
performed VBN p
in IN p
Belgium NNP p
and CC p
The DT p
Netherlands NNP p
. . p

A NNP p
total NN p
of IN p
406 CD p
previously RB p
untreated JJ p
CHC NNP p
patients NNS p
, , p
including VBG p
98 CD p
( ( p
24 CD p
% NN p
) ) p
IVDUs NNP p
, , N
were VBD N
studied VBN N
for IN N
compliance NN N
( ( N
presentation NN N
at IN N
the DT N
end NN N
of IN N
treatment NN N
) ) N
, , N
complete JJ N
response NN N
( ( N
alanine JJ N
aminotransferase NN N
within IN N
normal JJ N
limits NNS N
and CC N
serum NN N
hepatitis NN N
C NNP N
virus NN N
polymerase NN N
chain NN N
reaction NN N
negative JJ N
) ) N
at IN N
the DT N
end NN N
of IN N
therapy NN N
and CC N
sustained VBD N
virological JJ N
response NN N
( ( N
SVR NNP N
) ) N
. . N

RESULTS JJ N
Non-compliance NNP o
( ( N
8.2 CD N
% NN N
) ) N
in IN N
IVDUs NNP N
was VBD N
not RB N
different JJ N
from IN N
non-IVDUs JJ N
( ( N
6.8 CD N
% NN N
) ) N
( ( N
relative JJ N
risk=1.20 NN N
; : N
95 CD N
% NN N
confidence NN N
interval=0.55-2.62 NN N
) ) N
. . N

Complete JJ o
response NN o
after IN N
controlling VBG N
for IN N
hepatitis NN N
C NNP N
virus NN N
was VBD N
similar JJ N
( ( N
relative JJ N
risk=1.19 NN N
; : N
95 CD N
% NN N
confidence NN N
interval=0.89-1.60 NN N
) ) N
. . N

Controlling VBG N
for IN N
treatment NN N
arm NN N
, , N
age NN N
, , N
sex NN N
, , N
presence NN N
of IN N
cirrhosis NN N
or CC N
hepatitis NN N
C NNP N
virus NN N
viral JJ N
load NN N
before IN N
treatment NN N
did VBD N
not RB N
change VB N
these DT N
results NNS N
. . N

There EX N
was VBD N
a DT N
marginally RB N
significant JJ N
difference NN N
in IN N
the DT N
sustained JJ o
virological JJ o
response NN o
between IN N
IVDUs NNP N
( ( N
46.6 CD N
% NN N
) ) N
and CC N
non-IVDUs JJ N
( ( N
34.6 CD N
% NN N
) ) N
( ( N
relative JJ N
risk=1.35 NN N
; : N
95 CD N
% NN N
confidence NN N
interval=1.00-1.81 NN N
) ) N
, , N
also RB N
disappearing VBG N
after IN N
adjusting VBG N
for IN N
genotype NN N
. . N

No DT N
difference NN N
in IN N
compliance NN o
or CC o
sustained VBN o
virological JJ o
response NN o
was VBD N
found VBN N
between IN N
active JJ N
and CC N
non-active JJ N
IVDUs NNP N
or CC N
between IN N
IVDU NNP N
patients NNS N
in IN N
or CC N
without IN N
a DT N
methadone NN N
maintenance NN N
program NN N
. . N

CONCLUSIONS NNP N
In IN N
this DT N
group NN N
of IN N
Benelux NNP p
patients NNS p
, , N
IVDUs NNP N
showed VBD N
similar JJ o
compliance NN o
and CC o
response NN o
to TO N
treatment NN N
with IN N
interferon NN N
and CC N
ribavirin NN N
compared VBN N
with IN N
other JJ N
patients NNS N
with IN N
CHC NNP N
infection NN N
. . N

Therefore RB N
, , N
it PRP N
is VBZ N
no RB N
longer RBR N
justifiable JJ N
to TO N
withhold VB N
treatment NN N
to TO N
chronic VB o
hepatitis NN o
C NNP o
patients NNS p
who WP p
use VBP p
intravenous JJ p
drugs NNS p
. . p

-DOCSTART- -3098341- O O

Dose NNP N
dependent JJ N
response NN N
of IN N
symptoms NNS N
, , N
pituitary JJ N
, , N
and CC N
bone NN N
to TO N
transdermal VB N
oestrogen NN N
in IN N
postmenopausal JJ p
women NNS p
. . p

The DT N
effect NN N
of IN N
the DT N
plasma NN N
oestradiol JJ N
concentration NN N
on IN N
climacteric NN o
symptoms NNS o
, , o
gonadotrophin JJ o
release NN o
, , N
and CC N
bone NN o
resorption NN o
was VBD N
studied VBN N
in IN N
three CD p
groups NNS p
of IN p
postmenopausal JJ p
women NNS p
given VBN p
0.025 CD p
mg NNS p
, , p
0.05 CD p
mg NN p
, , p
or CC p
0.1 CD p
mg NNS p
transdermal JJ i
oestradiol JJ i
daily RB p
. . p

There EX N
was VBD N
a DT N
dose JJ N
related JJ N
reduction NN o
in IN o
symptoms NNS o
, , o
plasma JJ o
follicle NN o
stimulating VBG o
hormone NN o
concentration NN o
, , o
and CC o
urinary JJ o
calcium NN o
and CC o
hydroxyproline JJ o
excretion NN o
. . o

The DT N
relation NN o
of IN o
the DT o
response NN o
to TO o
plasma VB o
oestradiol JJ o
values NNS o
was VBD N
similar JJ N
for IN N
each DT N
variable NN N
with IN N
an DT N
initial JJ N
large JJ N
reduction NN N
and CC N
little JJ N
change NN N
in IN N
response NN N
to TO N
increases NNS N
in IN N
the DT N
plasma NN N
oestradiol JJ i
concentration NN N
above IN N
150 CD N
pmol/l NN N
( ( N
41 CD N
pg/ml NN N
) ) N
. . N

Hormone CD N
replacement NN N
therapy NN N
producing VBG N
an DT N
effect NN N
equivalent NN N
to TO N
higher JJR N
oestradiol JJ N
concentrations NNS N
is VBZ N
likely JJ N
to TO N
increase VB N
the DT N
risk NN N
of IN N
side NN o
effects NNS o
without IN N
conferring VBG N
any DT N
additional JJ o
benefit NN o
. . o

-DOCSTART- -14578078- O O

More RBR N
is VBZ N
not RB N
necessarily RB N
better RBR N
: : N
Examining VBG N
the DT N
nature NN N
of IN N
the DT N
temporal JJ N
reference NN N
memory NN N
component NN N
in IN N
timing NN N
. . N

Three CD N
experiments NNS i
compared VBN N
the DT N
timing NN N
performance NN N
of IN N
humans NNS p
on IN p
a DT p
modified JJ p
temporal JJ p
generalization NN p
task NN p
with IN p
1 CD p
, , p
3 CD p
, , p
or CC p
5 CD p
presentations NNS i
of IN i
the DT i
standard JJ i
duration NN i
. . i

In IN N
all DT N
three CD N
experiments NNS N
subjects VBZ N
received JJ N
presentations NNS N
of IN N
a DT N
standard JJ i
duration NN i
at IN N
the DT N
beginning NN N
of IN N
a DT N
trial NN N
block NN N
and CC N
then RB N
had VBD N
to TO N
judge VB N
whether IN N
each DT N
of IN N
a DT N
number NN N
of IN N
comparison NN N
stimuli NN N
was VBD N
or CC N
was VBD N
not RB N
the DT N
standard NN N
. . N

The DT N
duration NN o
of IN N
the DT N
standard NN N
changed VBD N
between IN N
blocks NNS N
. . N

The DT N
three CD N
experiments NNS N
varied VBD N
the DT N
experimental JJ N
design NN N
( ( i
between IN i
or CC i
within IN i
subjects NNS i
) ) i
, , i
task NN o
difficulty NN o
( ( N
how WRB N
closely RB N
the DT N
comparison NN N
stimuli NNS N
were VBD N
spaced VBN N
around IN N
the DT N
standards NNS N
) ) N
, , N
and CC N
presence NN o
or CC o
absence NN o
of IN o
feedback NN o
on IN o
performance NN o
accuracy NN o
. . o

Number NNP N
of IN N
presentations NNS i
of IN i
the DT i
standard NN i
never RB N
affected VBD N
the DT N
proportion NN o
of IN o
identifications NNS o
of IN o
the DT o
standard NN o
when WRB N
it PRP N
was VBD N
presented VBN N
, , N
nor CC N
other JJ N
features NNS N
of IN N
the DT N
temporal JJ N
generalization NN N
gradients NNS N
observed VBD N
. . N

The DT N
implications NNS N
for IN N
the DT N
operation NN N
of IN N
reference NN N
memories NNS N
within IN N
the DT N
scalar JJ N
timing NN N
system NN N
were VBD N
explored VBN N
via IN N
models NNS N
that IN N
made VBD N
different JJ N
assumptions NNS N
about IN N
how WRB N
the DT N
individual JJ o
presentations NNS o
of IN o
the DT o
standard NN o
were VBD o
stored VBN o
and CC o
used VBN o
. . o

-DOCSTART- -10550137- O O

Granulocyte-macrophage JJ i
colony-stimulating JJ i
factor NN i
treatment NN i
before IN N
doxorubicin NN N
and CC N
cyclophosphamide NN N
chemotherapy NN N
priming VBG N
in IN N
women NNS p
with IN p
early-stage JJ p
breast NN p
cancer NN p
. . p

PURPOSE NNP N
To TO N
determine VB N
if IN N
inhibition NN N
of IN N
stem-cell JJ N
activity NN N
induced VBN N
by IN N
granulocyte-macrophage JJ i
colony-stimulating JJ i
factor NN i
( ( N
[ JJ N
GM-CSF NNP N
] NNP N
; : N
Sargramostim NNP N
; : N
Immunex NNP N
Corporation NNP N
, , N
Seattle NNP N
, , N
WA NNP N
) ) N
withdrawal NN N
or CC N
priming VBG N
protects NNS N
hematopoietic JJ N
stem NN N
cells NNS N
from IN N
the DT N
cytotoxic JJ N
effects NNS N
of IN N
adjuvant JJ N
chemotherapy NN N
for IN N
early-stage JJ p
breast NN p
cancer NN p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
Serial NNP N
blood NN N
counts NNS N
were VBD N
performed VBN N
in IN N
20 CD p
women NNS p
with IN p
early-stage JJ p
breast NN p
cancer NN p
receiving VBG p
four CD i
courses NNS i
of IN i
cyclophosphamide NN i
and CC i
doxorubicin NN i
chemotherapy NN i
. . i

By IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
balanced JJ N
randomization NN N
, , N
subjects VBZ i
received VBN i
GM-CSF NNP i
priming VBG i
on IN i
days NNS i
5 CD i
to TO i
1 CD i
for IN i
courses NNS i
1 CD i
and CC i
3 CD i
or CC i
courses NNS i
2 CD i
and CC i
4 CD i
. . i

RESULTS VB N
Compared NNP N
with IN N
before RB N
priming VBG N
, , N
after IN N
priming VBG N
the DT N
times NNS o
to TO o
neutrophil VB o
nadir NN o
( ( N
12.8 CD N
+/- JJ N
2.5 CD N
days NNS N
v RB N
14.8 CD N
+/- JJ N
1.5 CD N
days NNS N
, , N
respectively RB N
; : N
P NNP N
=.0001 NNP N
) ) N
and CC N
platelet NN o
nadir NN o
( ( N
mean JJ N
+/- JJ N
SD NNP N
, , N
10.1 CD N
+/- JJ N
1.9 CD N
days NNS N
v RB N
11.1 CD N
+/- JJ N
2.2 CD N
days NNS N
, , N
P NNP N
< NNP N
.05 NNP N
) ) N
were VBD N
shorter JJR N
, , N
indicating VBG N
a DT N
shift NN N
of IN N
cytotoxicity NN N
to TO N
later RB N
progenitors NNS N
. . N

The DT N
neutrophil JJ o
nadir NN o
was VBD N
similar JJ N
with IN N
and CC N
without IN N
priming VBG N
( ( N
mean JJ N
+/- JJ N
SD NNP N
, , N
490 CD N
+/- JJ N
310/microL CD N
v JJ N
550 CD N
+/- JJ N
350/microL CD N
, , N
respectively RB N
; : N
P NNP N
=.2 NNP N
) ) N
; : N
however RB N
, , N
on IN N
day NN N
16 CD N
the DT N
mean NN N
neutrophil NN o
count NN o
was VBD N
higher JJR N
( ( N
mean JJ N
+/- JJ N
SD NNP N
, , N
1030 CD N
+/- JJ N
580/microL CD N
v JJ N
690 CD N
+/- JJ N
370/microL CD N
, , N
P NNP N
=.004 NNP N
) ) N
, , N
and CC N
the DT N
proportion NN N
of IN N
patients NNS N
with IN N
a DT N
neutrophil JJ o
count NN o
less JJR N
than IN N
500/microL CD N
was VBD N
lower JJR N
after IN N
priming VBG N
than IN N
before IN N
( ( N
six CD N
of IN N
35 CD N
or CC N
17 CD N
. . N

1 CD N
% NN N
v JJ N
12 CD N
of IN N
34 CD N
or CC N
35.3 CD N
% NN N
, , N
respectively RB N
; : N
P NNP N
=.04 NNP N
) ) N
. . N

The DT N
platelet NN o
nadir NN o
was VBD N
higher JJR N
( ( N
mean JJ N
+/- JJ N
SD NNP N
, , N
166,000 CD N
+/- JJ N
51,000/microL CD N
after IN N
priming VBG N
v JJ N
151,000 CD N
+/- JJ N
45,000/microL CD N
before IN N
priming NN N
, , N
P NNP N
=.007 NNP N
) ) N
, , N
and CC N
the DT N
duration NN o
of IN o
thrombocytopenia NN o
, , N
ie NN N
, , N
a DT N
platelet NN N
count NN N
less JJR N
than IN N
150,000/microL CD N
, , N
was VBD N
shorter JJR N
( ( N
1.5 CD N
+/- JJ N
2.1 CD N
days NNS N
v RB N
2.8 CD N
+/- JJ N
2.9 CD N
days NNS N
, , N
P NNP N
=.0025 NNP N
) ) N
after IN N
priming VBG N
. . N

Episodes NNS N
of IN N
fever NN o
and CC o
neutropenia NN o
were VBD N
not RB N
observed VBN N
. . N

CONCLUSIONS NNP N
GM-CSF NNP N
priming VBG N
from IN N
days NNS N
5 CD N
to TO N
1 CD N
before IN N
doxorubicin NN N
and CC N
cyclophosphamide NN N
chemotherapy NN N
was VBD N
associated VBN N
with IN N
an DT N
earlier JJR N
neutrophil NN o
and CC o
platelet NN o
nadir NN o
. . o

On IN N
day NN N
16 CD N
, , N
a DT N
higher JJR N
mean JJ N
neutrophil NN o
count NN o
and CC N
a DT N
lower JJR N
proportion NN N
of IN N
patients NNS N
with IN N
severe JJ N
( ( N
< JJ N
500/microL CD N
) ) N
neutropenia NN o
were VBD N
observed VBN N
. . N

Beneficial JJ N
effects NNS N
on IN N
the DT N
severity NN N
and CC N
duration NN N
of IN N
thrombocytopenia NN o
were VBD N
also RB N
noted VBN N
. . N

These DT N
observations NNS N
support VBP N
the DT N
hypothesis NN N
that IN N
GM-CSF NNP N
priming VBG N
protects NNS N
hematopoietic JJ N
progenitors NNS N
from IN N
the DT N
cytotoxic JJ N
effects NNS N
of IN N
chemotherapy NN i
. . i

-DOCSTART- -10651597- O O

Effectiveness NN N
of IN N
manual JJ i
physical JJ i
therapy NN i
and CC i
exercise NN i
in IN N
osteoarthritis NN p
of IN p
the DT p
knee NN p
. . p

A DT N
randomized JJ N
, , N
controlled JJ N
trial NN N
. . N

BACKGROUND NNP N
Few JJ N
investigations NNS N
include VBP N
both DT N
subjective JJ N
and CC N
objective JJ N
measurements NNS N
of IN N
the DT N
effectiveness NN N
of IN N
treatments NNS N
for IN N
osteoarthritis NN p
of IN p
the DT p
knee NN p
. . p

Beneficial JJ N
interventions NNS N
may MD N
decrease VB N
the DT N
disability NN o
associated VBN N
with IN N
osteoarthritis NN N
and CC N
the DT N
need NN N
for IN N
more RBR N
invasive JJ N
treatments NNS N
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
physical JJ i
therapy NN i
for IN N
osteoarthritis NN N
of IN N
the DT N
knee NN N
, , N
applied VBN N
by IN N
experienced JJ N
physical JJ N
therapists NNS N
with IN N
formal JJ N
training NN N
in IN N
manual JJ N
therapy NN N
. . N

DESIGN NNP N
Randomized NNP N
, , N
controlled VBD N
clinical JJ N
trial NN N
. . N

SETTING NN N
Outpatient NNP p
physical JJ p
therapy NN p
department NN p
of IN p
a DT p
large JJ p
military JJ p
medical JJ p
center NN p
. . p

PATIENTS CC N
83 CD p
patients NNS p
with IN p
osteoarthritis NN p
of IN p
the DT p
knee NN p
who WP p
were VBD p
randomly RB p
assigned VBN p
to TO p
receive VB p
treatment NN i
( ( p
n JJ p
= VBZ p
42 CD p
; : p
15 CD p
men NNS p
and CC p
27 CD p
women NNS p
[ JJ p
mean JJ p
age NN p
, , p
60 CD p
+/- JJ p
11 CD p
years NNS p
] RB p
) ) p
or CC p
placebo NN i
( ( p
n JJ p
= VBZ p
41 CD p
; : p
19 CD p
men NNS p
and CC p
22 CD p
women NNS p
[ JJ p
mean JJ p
age NN p
, , p
62 CD p
+/- JJ p
10 CD p
years NNS p
] RB p
) ) p
. . p

INTERVENTION NNP N
The DT N
treatment NN p
group NN p
received VBD N
manual JJ i
therapy NN i
, , N
applied VBN N
to TO N
the DT N
knee NN N
as RB N
well RB N
as IN N
to TO N
the DT N
lumbar NN N
spine NN N
, , N
hip NN N
, , N
and CC N
ankle RB N
as IN N
required VBN N
, , N
and CC N
performed VBD N
a DT N
standardized JJ i
knee NN i
exercise NN i
program NN i
in IN N
the DT N
clinic NN N
and CC N
at IN N
home NN N
. . N

The DT N
placebo NN i
group NN p
had VBD N
subtherapeutic JJ i
ultrasound NN i
to TO N
the DT N
knee NN N
at IN N
an DT N
intensity NN N
of IN N
0.1 CD N
W/cm2 NNP N
with IN N
a DT N
10 CD N
% NN N
pulsed JJ N
mode NN N
. . N

Both DT N
groups NNS N
were VBD N
treated VBN N
at IN N
the DT N
clinic JJ N
twice JJ N
weekly NN N
for IN N
4 CD N
weeks NNS N
. . N

MEASUREMENTS NNP N
Distance NNP o
walked VBD o
in IN o
6 CD o
minutes NNS o
and CC o
sum NN o
of IN o
the DT o
function NN o
, , o
pain NN o
, , o
and CC o
stiffness JJ o
subscores NNS o
of IN o
the DT o
Western NNP o
Ontario NNP o
and CC o
McMaster NNP o
Universities NNP o
Osteoarthritis NNP o
Index NNP o
( ( o
WOMAC NNP o
) ) o
. . o

A DT N
tester NN N
who WP N
was VBD N
blinded VBN N
to TO N
group NN N
assignment NN N
made VBD N
group NN N
comparisons NNS N
at IN N
the DT N
initial JJ N
visit NN N
( ( N
before IN N
initiation NN N
of IN N
treatment NN N
) ) N
, , N
4 CD N
weeks NNS N
, , N
8 CD N
weeks NNS N
, , N
and CC N
1 CD N
year NN N
. . N

RESULTS NNP N
Clinically NNP N
and CC N
statistically RB N
significant JJ N
improvements NNS N
in IN N
6-minute JJ o
walk NN o
distance NN o
and CC o
WOMAC NNP o
score NN o
at IN N
4 CD N
weeks NNS N
and CC N
8 CD N
weeks NNS N
were VBD N
seen VBN N
in IN N
the DT N
treatment NN i
group NN N
but CC N
not RB N
the DT N
placebo NN i
group NN N
. . N

By IN N
8 CD N
weeks NNS N
, , N
average JJ N
6-minute JJ o
walk NN o
distances NNS o
had VBD N
improved VBN N
by IN N
13.1 CD N
% NN N
and CC N
WOMAC NNP o
scores NNS o
had VBD N
improved VBN N
by IN N
55.8 CD N
% NN N
over IN N
baseline NN N
values NNS N
in IN N
the DT N
treatment NN i
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

After IN N
controlling VBG N
for IN N
potential JJ N
confounding NN N
variables NNS N
, , N
the DT N
average JJ N
distance NN o
walked VBD o
in IN o
6 CD o
minutes NNS o
at IN N
8 CD N
weeks NNS N
among IN N
patients NNS N
in IN N
the DT N
treatment NN i
group NN N
was VBD N
170 CD N
m NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
71 CD N
to TO N
270 CD N
m NN N
) ) N
more JJR N
than IN N
that DT N
in IN N
the DT N
placebo NN i
group NN N
and CC N
the DT N
average JJ N
WOMAC JJ o
scores NNS o
were VBD N
599 CD N
mm NN N
higher JJR N
( ( N
95 CD N
% NN N
CI NNP N
, , N
197 CD N
to TO N
1002 CD N
mm NN N
) ) N
. . N

At IN N
1 CD N
year NN N
, , N
patients NNS N
in IN N
the DT N
treatment NN i
group NN N
had VBD N
clinically RB N
and CC N
statistically RB N
significant JJ N
gains NNS N
over IN N
baseline JJ o
WOMAC NNP o
scores NNS o
and CC o
walking VBG o
distance NN o
; : o
20 CD N
% NN N
of IN N
patients NNS N
in IN N
the DT N
placebo NN i
group NN N
and CC N
5 CD N
% NN N
of IN N
patients NNS N
in IN N
the DT N
treatment NN i
group NN N
had VBD N
undergone JJ N
knee NN o
arthroplasty NN o
. . o

CONCLUSIONS VB N
A DT N
combination NN N
of IN N
manual JJ i
physical JJ i
therapy NN i
and CC i
supervised VBD i
exercise NN i
yields NNS N
functional JJ o
benefits NNS o
for IN N
patients NNS p
with IN p
osteoarthritis NN p
of IN p
the DT p
knee NN p
and CC N
may MD N
delay VB N
or CC N
prevent VB N
the DT N
need NN N
for IN N
surgical JJ o
intervention NN o
. . o

-DOCSTART- -17899340- O O

How WRB N
can MD N
we PRP N
help VB N
witnesses NNS p
to TO N
remember VB o
more JJR o
? . N
It PRP N
's VBZ N
an DT N
( ( N
eyes NNS N
) ) N
open JJ N
and CC N
shut JJ N
case NN N
. . N

Five CD N
experiments NNS N
tested VBD N
the DT N
idea NN N
that IN N
instructing VBG N
a DT N
witness NN p
to TO N
close VB N
their PRP$ N
eyes NNS N
during IN N
retrieval NN N
might MD N
increase VB N
retrieval JJ o
success NN o
. . o

In IN N
Experiment JJ N
1 CD N
participants NNS p
watched VBD i
a DT i
video NN i
, , N
before IN N
a DT N
cued-recall JJ N
test NN N
for IN N
which WDT N
they PRP N
were VBD N
either RB N
instructed VBN N
to TO N
close VB N
their PRP$ N
eyes NNS N
, , N
or CC N
received VBN N
no-instructions NNS i
. . i

Eye-closure NN N
led VBD N
to TO N
an DT N
increase NN N
in IN N
correct JJ o
cued-recall NN o
, , N
with IN N
no DT N
increase NN N
in IN N
incorrect JJ o
responses NNS o
. . o

Experiments NNS N
2-5 JJ N
sought VBD N
to TO N
test VB N
the DT N
generality NN N
of IN N
this DT N
effect NN N
over IN N
variations NNS N
in IN N
study NN N
material NN N
( ( i
video NN i
or CC i
live JJ i
interaction NN i
) ) i
, , N
test JJ N
format NN N
( ( i
cued- JJ i
or CC i
free-recall JJ i
) ) i
and CC N
information NN N
modality NN N
( ( i
visual JJ i
or CC i
auditory JJ i
details NNS i
recalled VBN i
) ) i
. . N

Overall JJ N
, , N
eye-closure NN N
increased VBD N
recall NN o
of IN o
both DT o
visual JJ o
detail NN o
and CC o
auditory NN o
details NNS o
, , N
with IN N
no DT N
accompanying VBG N
increase NN N
in IN N
recall NN o
of IN o
false JJ o
details NNS o
. . o

Collectively RB N
, , N
these DT N
data NNS N
convincingly RB N
demonstrate VBP N
the DT N
benefits NNS N
of IN N
eye-closure NN N
as IN N
an DT N
aid NN N
to TO N
retrieval VB o
, , N
and CC N
offer VB N
insight NN N
into IN N
why WRB N
hypnosis NN N
, , N
which WDT N
usually RB N
involves VBZ N
eye-closure NN N
, , N
may MD N
facilitate VB N
eyewitness NN o
recall NN o
. . o

-DOCSTART- -2139523- O O

Sequential JJ N
alternate JJ N
administration NN N
of IN N
tamoxifen NN i
and CC N
medroxyprogesterone NN i
acetate NN i
in IN N
advanced JJ p
breast NN p
cancer NN p
: : p
clinical-biological JJ N
randomized NN N
study NN N
. . N

From IN p
January NNP p
1985 CD p
to TO p
September NNP p
1988 CD p
, , p
60 CD p
women NNS p
with IN p
advanced JJ p
breast NN p
cancer NN p
were VBD p
randomized VBN p
in IN p
two CD i
arms NNS i
to TO i
receive VB i
: : i
A DT i
) ) i
tamoxifen NN i
( ( i
TAM NNP i
) ) i
( ( i
20 CD i
mg/die NN i
) ) i
until IN i
progression NN i
or CC i
B NNP i
) ) i
TAM NNP i
( ( i
20 CD i
mg/die NN i
for IN i
14 CD i
days NNS i
) ) i
then RB i
medroxyprogesterone NN i
acetate NN i
( ( i
MPA NNP i
) ) i
( ( i
1500 CD i
mg/die NN i
p.o NN i
. . i

for IN i
14 CD i
days NNS i
) ) i
followed VBN i
by IN i
7 CD i
days NNS i
of IN i
wash-out NN i
before IN i
repeating VBG i
the DT i
TAM/MPA NNP i
treatment NN i
. . i

All DT p
patients NNS p
were VBD p
post-menopausal JJ p
, , p
previously RB p
untreated VBN p
with IN p
hormone NN p
therapy NN p
, , p
and CC p
with IN p
tumor NN p
receptor NN p
status NN p
determined VBD p
immediately RB p
before IN p
randomization NN p
; : p
all DT p
had VBD p
objectively RB p
evaluable JJ p
lesions NNS p
. . p

In IN N
order NN N
to TO N
verify VB N
hormone NN o
receptor NN o
variations NNS o
due JJ N
to TO N
the DT N
antiestrogen NN N
, , N
when WRB i
possible JJ i
a DT i
second JJ i
biopsy NN o
was VBD i
performed VBN i
after IN i
the DT i
initial JJ i
14 CD i
day NN i
cycle NN i
of IN i
TAM NNP i
. . i

Thirty-one NN p
and CC p
29 CD p
patients NNS p
were VBD p
included VBN p
respectively RB p
in IN p
arms NNS p
A NNP p
and CC p
B NNP p
. . p

Objective JJ o
regression NN o
( ( N
CR NNP N
+ NNP N
PR NNP N
) ) N
was VBD N
observed VBN N
in IN N
58 CD N
% NN N
of IN N
group NN N
A NNP N
and CC N
75 CD N
% NN N
of IN N
group NN N
B NNP N
, , N
with IN N
CR NNP N
in IN N
11 CD N
% NN N
and CC N
23 CD N
% NN N
, , N
respectively RB N
. . N

Differences NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
. . N

Median JJ o
time NN o
to TO o
progression NN o
was VBD N
12 CD N
months NNS N
for IN N
group NN N
A NNP N
and CC N
9 CD N
for IN N
group NN N
B NNP N
. . N

Overall NNP o
survival NN o
has VBZ N
not RB N
yet RB N
been VBN N
reached VBN N
in IN N
group NN N
A NNP N
while IN N
it PRP N
was VBD N
34 CD N
months NNS N
for IN N
patients NNS N
of IN N
group NN N
B. NNP N
Metrorrhagia NNP o
was VBD N
observed VBN N
in IN N
two CD N
cases NNS N
of IN N
group NN N
A NNP N
and CC N
in IN N
6 CD N
of IN N
group NN N
B NNP N
, , N
and CC N
thrombophlebitis NN N
in IN N
1 CD N
and CC N
3 CD N
cases NNS N
, , N
respectively RB N
. . N

The DT N
second JJ N
biopsy NN N
confirmed VBD N
a DT N
clear JJ N
increase NN N
of IN N
PgR NNP o
content NN o
in IN N
8/11 CD N
cases NNS N
( ( N
75 CD N
% NN N
) ) N
. . N

Plasma NNP o
level JJ o
variations NNS o
of IN o
TAM NNP o
, , o
N-desmethyl NNP o
TAM NNP o
and CC o
MPA NNP o
were VBD N
checked VBN N
at IN N
various JJ N
intervals NNS N
on IN N
3 CD N
patients NNS N
of IN N
group NN N
B NNP N
, , N
and CC N
confirmed VBD N
that IN N
our PRP$ N
schedule NN N
is VBZ N
able JJ N
to TO N
produce VB N
a DT N
drug NN N
wash-out NN N
period NN N
for IN N
tumor NN N
cells NNS N
. . N

In IN N
conclusion NN N
, , N
our PRP$ N
study NN N
demonstrated VBD N
that IN N
while IN N
the DT N
manipulation NN N
of IN N
hormone NN N
receptors NNS N
seems VBZ N
possible JJ N
, , N
results NNS N
indicating VBG N
better JJR N
overall JJ N
survival NN N
and CC N
time NN N
to TO N
progression NN N
were VBD N
not RB N
obtained VBN N
with IN N
alternate JJ N
sequential JJ N
TAM-MPA NNP N
therapy NN N
. . N

-DOCSTART- -19155827- O O

Do VBP N
catheter JJR i
washouts VB i
extend JJ N
patency NN o
time NN o
in IN N
long-term JJ o
indwelling JJ o
urethral JJ N
catheters NNS N
? . N
A DT N
randomized NN N
controlled VBN N
trial NN N
of IN N
acidic JJ i
washout NN i
solution NN i
, , i
normal JJ i
saline NN i
washout NN i
, , N
or CC N
standard JJ i
care NN i
. . i

PURPOSE NNP N
Blockage NNP N
of IN N
long-term JJ N
indwelling VBG N
catheters NNS N
with IN N
mineral JJ N
deposit NN N
is VBZ N
an DT N
ongoing JJ N
management NN N
issue NN N
, , N
but CC N
evidence NN N
on IN N
optimal JJ N
management NN N
is VBZ N
lacking VBG N
. . N

Our PRP$ N
purpose NN N
was VBD N
to TO N
examine VB N
whether IN N
catheter NN i
washouts NNS i
prevent VBP N
or CC N
reduce VB N
catheter JJR o
blockage NN o
. . o

DESIGN VB N
A DT N
multisite NN N
randomized VBN N
controlled VBN N
trial NN N
. . N

SUBJECTS NNP N
AND CC N
SETTING NNP N
Adults NNP p
with IN p
long-term JJ p
indwelling VBG p
catheters NNS p
that WDT p
required VBD p
changing VBG p
every DT p
3 CD p
weeks NNS p
or CC p
less JJR p
, , p
living NN p
in IN p
the DT p
community NN p
, , p
and CC p
requiring VBG p
supportive JJ p
or CC p
continuing VBG p
care NN p
were VBD p
recruited VBN p
. . p

Participants NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
3 CD N
groups NNS N
: : N
control NN i
( ( i
usual JJ i
care NN i
, , i
no DT i
washout NN i
) ) i
, , i
saline JJ i
washout NN i
, , i
or CC i
commercially RB i
available JJ i
acidic JJ i
washout NN i
solution NN i
( ( i
Contisol NNP i
Maelor NNP N
Pharmaceuticals NNP N
Ltd NNP N
, , N
Wrexham NNP N
, , N
UK NNP N
) ) N
. . N

METHODS NNP N
At IN N
baseline JJ N
visit NN N
, , N
the DT N
catheter NN N
was VBD N
changed VBN N
and CC N
participants NNS N
were VBD N
followed VBN N
weekly JJ N
for IN N
8 CD N
weeks NNS N
, , N
with IN N
checks NNS o
for IN o
catheter NN o
patency NN o
and CC o
urine JJ o
pH NN o
. . o

Participants NNS N
randomized VBD N
to TO N
saline VB i
or CC i
commercial JJ i
solution NN i
had VBD N
a DT N
weekly JJ N
washout NN i
with IN N
the DT N
appropriate JJ N
solution NN N
. . N

Endpoints NNS N
were VBD N
8 CD N
weeks NNS N
( ( N
completion NN N
data NNS N
) ) N
, , N
3 CD N
or CC N
more JJR N
catheter NN N
changes NNS N
in IN N
the DT N
8-week JJ N
period NN N
, , N
or CC N
symptomatic JJ o
urinary JJ o
tract NN o
infection NN o
( ( o
UTI NNP o
) ) o
requiring VBG N
antibiotics NNS N
. . N

The DT N
study NN N
hypothesis NN N
was VBD N
that IN N
catheter JJ N
life NN N
would MD N
be VB N
extended VBN N
by IN N
25 CD N
% NN N
in IN N
the DT N
commercial JJ i
solution NN i
group NN N
. . N

It PRP N
was VBD N
not RB N
possible JJ N
to TO N
blind VB N
participants NNS N
or CC N
research NN N
nurses NNS N
to TO N
washout VB i
versus NN i
no DT i
intervention NN i
, , N
but CC N
participants NNS N
in IN N
the DT N
saline NN i
and CC i
washout NN i
solution NN i
groups NNS N
were VBD N
blinded VBN N
to TO N
solution VB N
type NN N
. . N

RESULTS NNP N
One CD p
hundred VBD p
twelve VB p
potential JJ p
participants NNS p
were VBD p
screened VBN p
; : p
73 CD p
were VBD p
enrolled VBN p
, , p
randomized VBN p
, , p
and CC p
included VBD p
in IN N
the DT N
final JJ N
analysis NN N
. . N

Of IN N
these DT N
, , N
53 CD p
completed VBD p
the DT N
full JJ N
8 CD N
weeks NNS N
of IN N
data NNS N
collection NN N
; : N
16 CD p
terminated VBD p
early JJ p
because IN N
of IN N
3 CD N
catheter NN N
changes NNS N
or CC N
self-reported JJ N
'UTI NN N
' POS N
. . N

Other JJ N
reasons NNS N
for IN N
termination NN o
were VBD N
hematuria NNS o
, , o
latex JJ o
sensitivity NN o
, , o
deceased/severe RB o
illness JJ o
, , o
or CC o
personal JJ o
choice NN o
. . o

Analysis NN N
of IN N
variance NN N
was VBD N
used VBN N
to TO N
analyze VB N
mean JJ N
differences NNS N
on IN N
demographic JJ N
variables NNS N
and CC N
mean JJ N
number NN N
of IN N
weeks NNS N
in IN N
study NN N
. . N

Kaplan-Meier NNP N
survival JJ N
curve NN N
analysis NN N
showed VBD N
no DT N
statistical JJ N
difference NN N
between IN N
the DT N
groups NNS N
in IN N
time NN o
to TO o
first JJ o
catheter NN o
change NN o
. . o

CONCLUSION NN N
At IN N
this DT N
time NN N
, , N
the DT N
evidence NN N
is VBZ N
insufficient JJ N
to TO N
state NN N
whether IN N
catheter NN i
washout NN i
with IN i
saline NN i
or CC i
Contisol NNP i
is VBZ N
more RBR N
effective JJ N
than IN N
usual JJ i
care NN i
with IN i
no DT i
washout NN i
in IN N
preventing VBG N
blocking VBG N
. . N

No DT N
increased JJ N
risk NN o
of IN o
UTI NNP o
was VBD N
associated VBN N
with IN N
washout NN i
regimes NNS i
. . i

-DOCSTART- -21067912- O O

The DT N
effect NN N
of IN N
prophylactic JJ i
calcium NN i
and CC i
magnesium NN i
infusions NNS i
on IN N
the DT N
incidence NN N
of IN N
neurotoxicity NN N
and CC N
clinical JJ N
outcome NN N
of IN N
oxaliplatin-based JJ N
systemic JJ N
treatment NN N
in IN N
advanced JJ p
colorectal JJ p
cancer NN p
patients NNS p
. . p

BACKGROUND NNP N
Peripheral NNP N
sensory JJ N
neurotoxicity NN N
is VBZ N
a DT N
frequent JJ N
and CC N
potentially RB N
debilitating JJ N
side NN N
effect NN N
of IN N
oxaliplatin NN N
treatment NN N
. . N

Calcium NN N
and CC N
magnesium NN N
( ( N
Ca/Mg NNP N
) ) N
infusions NNS N
are VBP N
frequently RB N
used VBN N
to TO N
prevent VB N
this DT N
toxicity NN N
. . N

However RB N
, , N
concerns NNS N
about IN N
a DT N
negative JJ N
impact NN N
of IN N
Ca/Mg NNP N
infusions NNS N
on IN N
outcome NN N
have VBP N
been VBN N
raised VBN N
. . N

We PRP N
retrospectively RB N
assessed VBD N
the DT N
effect NN N
of IN N
Ca/Mg NNP N
infusions NNS N
on IN N
the DT N
incidence NN o
of IN o
neurotoxicity NN o
and CC N
on IN N
clinical JJ o
outcome NN o
in IN N
advanced JJ p
colorectal JJ p
cancer NN p
( ( p
ACC NNP p
) ) p
patients NNS p
treated VBN p
in IN p
the DT p
phase NN p
III NNP p
CAIRO2 NNP p
study NN p
. . p

MATERIALS NNP N
AND CC N
METHODS NNP N
Seven NNP p
hundred VBD p
and CC p
fifty JJ p
five CD p
previously RB p
untreated JJ p
ACC NNP p
patients NNS p
were VBD N
randomised VBN N
between IN N
treatment NN i
with IN i
capecitabine NN i
, , i
oxaliplatin NN i
and CC i
bevacizumab NN i
or CC i
the DT i
same JJ i
combination NN i
with IN i
the DT i
addition NN i
of IN i
cetuximab NN i
. . i

Patients NNS N
were VBD N
retrospectively RB N
divided VBN N
into IN N
two CD i
groups NNS i
: : i
patients NNS i
in IN i
the DT i
Ca/Mg NNP i
( ( i
+ NNP i
) ) i
group NN i
received VBD i
Ca/Mg NNP i
at IN i
least JJS i
during IN i
their PRP$ i
first JJ i
treatment NN i
cycle NN i
, , i
and CC i
patients NNS i
in IN i
the DT i
Ca/Mg NNP i
( ( i
- : i
) ) i
group NN i
did VBD i
not RB i
. . i

RESULTS VB N
Seven NNP p
hundred CD p
and CC p
thirty VB p
two CD p
patients NNS p
were VBD p
evaluable JJ p
for IN N
this DT N
analysis NN N
. . N

The DT N
Ca/Mg NNP N
( ( N
+ NNP N
) ) N
group NN N
consisted VBD N
of IN N
551 CD N
patients NNS N
, , N
the DT N
Ca/Mg NNP N
( ( N
- : N
) ) N
group NN N
consisted VBD N
of IN N
181 CD N
patients NNS N
. . N

The DT N
incidence NN N
of IN N
all DT o
grade JJ o
neurotoxicity NN o
in IN N
the DT N
Ca/Mg NNP N
( ( N
+ NNP N
) ) N
group NN N
and CC N
the DT N
Ca/Mg NNP N
( ( N
- : N
) ) N
group NN N
was VBD N
85 CD N
% NN N
and CC N
92 CD N
% NN N
, , N
respectively RB N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
, , N
and CC N
the DT N
incidence NN N
of IN N
grade NN N
? . N
2 CD N
neurotoxicity NN o
was VBD o
40 CD N
% NN N
and CC N
45 CD N
% NN N
, , N
respectively RB N
( ( N
p JJ N
= NNP N
0.22 CD N
) ) N
. . N

The DT o
median JJ o
PFS NNP o
in IN o
the DT N
Ca/Mg NNP N
( ( N
+ NNP N
) ) N
versus NN N
Ca/Mg NNP N
( ( N
- : N
) ) N
group NN N
was VBD N
10.1 CD N
versus NN N
10.7 CD N
months NNS N
( ( N
p JJ N
= NNP N
0.92 CD N
) ) N
, , N
the DT N
median JJ N
OS NNP N
was VBD N
19.8 CD N
versus NN N
20.7 CD N
months NNS N
( ( N
p JJ N
= NNP N
0.10 CD N
) ) N
, , N
and CC N
the DT N
response NN N
rate NN N
was VBD N
43.1 CD N
% NN N
versus IN N
50 CD N
% NN N
( ( N
p JJ N
= NNP N
0.11 CD N
) ) N
, , N
respectively RB N
. . N

CONCLUSIONS NNP N
In IN N
this DT N
largest JJS N
retrospective JJ N
analysis NN N
to TO N
date NN N
we PRP N
observed VBD N
that IN N
Ca/Mg NNP N
infusions NNS N
significantly RB N
reduced VBD N
all DT N
grade JJ N
oxaliplatin-related JJ N
neurotoxicity NN i
. . i

Ca/Mg NNP i
infusions NNS i
did VBD i
not RB N
affect VB N
the DT N
clinical JJ N
efficacy NN N
of IN N
treatment NN N
. . N

-DOCSTART- -347921- O O

Nebulized VBN N
racemic JJ i
epinephrine NN i
by IN N
IPPB NNP p
for IN p
the DT p
treatment NN p
of IN p
croup NN p
: : p
a DT N
double-blind NN N
study NN N
. . N

Racemic NNP i
epinephrine NN i
has VBZ N
been VBN N
advocated VBN N
for IN N
the DT N
treatment NN N
of IN N
croup NN N
, , N
but CC N
controlled VBD N
studies NNS N
have VBP N
not RB N
proved VBN N
it PRP N
more RBR N
effective JJ N
than IN N
saline NN N
. . N

Twenty CD p
patients NNS p
( ( p
aged VBN p
4 CD p
months NNS p
to TO p
5 CD p
years NNS p
) ) p
hospitalized VBD p
with IN p
acute JJ p
croup NN p
and CC p
persistent JJ p
inspiratory NN p
stridor NN p
at IN p
rest NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
treatment NN N
groups NNS N
: : N
saline NN i
or CC i
racemic JJ i
epinephrine NN i
, , N
both DT N
nebulized JJ N
and CC N
delivered VBN N
by IN N
intermittent NN N
positive JJ N
pressure NN N
breathing NN N
. . N

Clinical JJ o
scores NNS o
were VBD N
significantly RB N
improved VBN N
( ( N
P NNP N
less JJR N
than IN N
.01 NN N
) ) N
at IN N
ten NN N
and CC N
30 CD N
minutes NNS N
following VBG N
the DT N
treatment NN N
with IN N
racemic JJ i
epinephrine NN i
but CC N
not RB N
at IN N
120 CD N
minutes NNS N
. . N

Racemic NNP i
epinephrine NN i
was VBD N
significantly RB N
more RBR N
effective JJ o
than IN N
saline NN N
at IN N
10 CD N
( ( N
P NNP N
less JJR N
than IN N
.01 NN N
) ) N
and CC N
30 CD N
minutes NNS N
( ( N
P NNP N
less JJR N
than IN N
.05 NN N
) ) N
but CC N
not RB N
at IN N
120 CD N
minutes NNS N
after IN N
the DT N
treatment NN N
. . N

We PRP N
conclude VBP N
that IN N
nebulized JJ N
racemic JJ i
epinephrine NN i
is VBZ N
effective JJ N
treatment NN N
for IN N
the DT N
acute JJ p
signs NNS p
of IN p
croup NN p
. . p

-DOCSTART- -24472253- O O

Preschool-based JJ i
social JJ i
communication NN i
treatment NN i
for IN N
children NNS p
with IN p
autism NN p
: : p
12-month JJ N
follow-up NN N
of IN N
a DT N
randomized JJ N
trial NN N
. . N

OBJECTIVE VB N
This DT N
study NN N
reports VBZ N
12-month JJ N
follow-up JJ N
data NNS N
from IN N
a DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
preschool-based JJ i
social JJ i
communication NN i
treatment NN i
for IN N
young JJ p
children NNS p
with IN p
autism NN p
. . p

METHOD NNP N
A NNP p
total NN p
of IN p
61 CD p
children NNS p
( ( p
48 CD p
males NNS p
) ) p
with IN p
autism NN p
, , p
29 CD p
to TO p
60 CD p
months NNS p
of IN p
age NN p
, , p
had VBD p
earlier RBR p
been VBN p
randomized VBN p
either RB p
to TO p
8 CD p
weeks NNS p
of IN p
preschool-based JJ i
social JJ i
communication NN i
treatment NN i
in IN i
addition NN i
to TO i
standard JJ i
preschool NN i
program NN i
( ( p
n JJ p
= NNP p
34 CD p
) ) p
or CC p
to TO p
standard JJ i
preschool NN i
program NN i
only RB i
( ( p
n JJ p
= NNP p
27 CD p
) ) p
. . p

Significant JJ N
short-term JJ N
effects NNS N
on IN N
targeted VBN N
social JJ N
communication NN N
skills NNS N
have VBP N
previously RB N
been VBN N
published VBN N
. . N

Long-term JJ N
gains NNS N
in IN N
social JJ o
communication NN o
, , o
language NN o
and CC o
global JJ o
social JJ o
functioning NN o
and CC N
communication NN N
were VBD N
assessed VBN N
from IN N
video-taped JJ N
preschool NN N
teacher-child JJ N
and CC N
mother-child JJ N
interactions NNS N
, , N
Early JJ N
Social NNP N
Communication NNP N
Scales NNP N
, , N
Reynell NNP N
Developmental NNP N
Language NNP N
Scale NNP N
, , N
and CC N
Social NNP N
Communication NNP N
Questionnaire NNP N
. . N

RESULTS NNP N
Compared VBD N
with IN N
those DT N
in IN N
the DT N
control NN N
group NN N
, , N
the DT N
treated JJ N
children NNS N
achieved VBN N
significantly RB N
larger JJR N
improvements NNS N
in IN N
joint JJ o
attention NN o
and CC o
joint JJ o
engagement NN o
from IN N
baseline NN N
to TO N
12-month JJ N
follow-up NN N
. . N

However RB N
, , N
no DT N
effects NNS N
were VBD N
detected VBN N
on IN N
language NN o
and CC o
global JJ o
ratings NNS o
of IN o
social JJ o
functioning NN o
and CC o
communication NN o
. . o

The DT N
treatment NN N
effect NN N
on IN N
child JJ o
initiation NN o
of IN o
joint JJ o
attention NN o
increased VBD N
with IN N
increasing VBG N
level NN o
of IN o
sociability NN o
at IN N
baseline NN N
, , N
whereas WP N
nonverbal JJ o
IQ NNP o
and CC o
expressive JJ o
language NN o
had VBD N
no DT N
moderating VBG N
effect NN N
. . N

CONCLUSIONS VB N
This DT N
study NN N
is VBZ N
the DT N
first JJ N
to TO N
show VB N
that IN N
, , N
similar JJ N
to TO N
specialist-delivered JJ N
treatment NN N
, , N
preschool-based JJ i
treatment NN i
may MD N
produce VB N
small JJ N
but CC N
possibly RB N
clinically RB N
important JJ N
long-term JJ N
changes NNS N
in IN N
social JJ o
communication NN o
in IN o
young JJ N
children NNS N
with IN N
autism NN N
. . N

The DT N
treatment NN N
did VBD N
not RB N
affect JJ N
language NN o
and CC o
global JJ o
ratings NNS o
of IN o
social JJ o
functioning NN o
and CC o
communication NN o
. . o

More JJR N
studies NNS N
are VBP N
needed VBN N
to TO N
better RBR N
understand VB N
whether IN N
treatment NN N
effects NNS N
may MD N
be VB N
improved VBN N
by IN N
increasing VBG N
the DT N
intensity NN N
and CC N
duration NN N
of IN N
the DT N
treatment NN N
. . N

Clinical JJ N
trial NN N
registration NN N
information NN N
-- : N
Joint JJ N
Attention NNP N
Intervention NNP N
and CC N
Young NNP N
Children NNP N
With IN N
Autism NNP N
; : N
http NN N
: : N
//clinicaltrials.gov/ NN N
; : N
NCT00378157 NNP N
. . N

-DOCSTART- -18321372- O O

Influence NN N
of IN N
two CD N
different JJ N
resection NN N
techniques NNS N
( ( i
conventional JJ i
liver NN i
resection NN i
versus IN i
anterior JJ i
approach NN i
) ) i
of IN N
liver NN N
metastases NNS N
from IN N
colorectal JJ N
cancer NN N
on IN N
hematogenous JJ N
tumor NN N
cell NN N
dissemination NN N
- : N
prospective JJ N
randomized VBN N
multicenter NN N
trial NN N
. . N

BACKGROUND NNP N
Surgical NNP i
hepatic JJ i
resection NN i
remains VBZ N
the DT N
treatment NN N
of IN N
choice NN N
for IN N
patients NNS p
with IN p
liver JJ p
metastases NNS p
from IN p
colorectal JJ p
cancer NN p
despite IN N
the DT N
use NN N
of IN N
alternative JJ N
therapeutic JJ N
strategies NNS N
. . N

Although IN N
this DT N
procedure NN N
provides VBZ N
long-term JJ N
survival NN N
in IN N
a DT N
significant JJ N
number NN N
of IN N
patients NNS N
, , N
50-75 JJ N
% NN N
of IN N
the DT N
patients NNS N
develop VB N
intra- JJ N
and/or NN N
extrahepatic JJ N
recurrence NN N
. . N

One CD N
possible JJ N
reason NN N
for IN N
tumor NN N
recurrence NN N
may MD N
be VB N
intraoperative JJ N
hematogenous JJ N
tumor NN N
cell NN N
dissemination NN N
due JJ N
to TO N
mechanical JJ N
manipulation NN N
of IN N
the DT N
tumor NN N
during IN N
hepatic JJ N
resection NN N
. . N

Surgical JJ N
technique NN N
may MD N
have VB N
an DT N
influence NN N
on IN N
hematogenous JJ N
tumor NN N
cell NN N
spread NN N
. . N

We PRP N
hypothesize VBP N
that IN N
hematogenous JJ N
tumor NN N
cell NN N
dissemination NN N
may MD N
be VB N
reduced VBN N
by IN N
using VBG N
the DT N
anterior JJ N
approach NN N
technique NN N
compared VBN N
to TO N
conventional JJ N
liver JJ N
resection NN N
. . N

METHODS/DESIGN NNP N
This DT N
is VBZ N
a DT N
multi-centre JJ N
prospective JJ N
randomized VBN N
controlled VBN N
, , N
superiority NN N
trial NN N
to TO N
compare VB N
two CD N
liver JJ i
resection NN i
techniques NNS i
of IN i
liver NN i
metastases NNS i
from IN N
colorectal JJ N
cancer NN N
. . N

150 CD p
patients NNS p
will MD p
be VB p
included VBN p
and CC p
randomized VBN p
intraoperatively RB p
after IN p
surgical JJ p
exploration NN p
just RB p
prior RB p
to TO p
resection NN p
. . p

The DT N
primary JJ N
objective NN N
is VBZ N
to TO N
compare VB N
the DT N
anterior JJ o
approach NN o
with IN o
the DT o
conventional JJ o
liver JJ o
resection NN o
technique NN o
with IN o
regard NN o
to TO o
intraoperative VB o
haematogenous JJ o
tumor NN o
cell NN o
dissemination NN o
. . o

As IN N
secondary JJ N
objectives NNS N
we PRP N
examine VBP N
five CD o
year NN o
survival NN o
rates NNS o
( ( o
OS NNP o
and CC o
DFS NNP o
) ) o
, , o
blood NN o
loss NN o
, , o
duration NN o
of IN o
operation NN o
, , o
requirement NN o
of IN o
blood NN o
transfusions NNS o
, , o
morbidity NN o
rate NN o
, , o
prognostic JJ o
relevance NN o
of IN o
tumor NN o
cell NN o
detection NN o
in IN o
blood NN o
and CC o
bone NN o
marrow NN o
and CC o
the DT o
comparison NN o
of IN o
tumor NN o
cell NN o
detection NN o
by IN o
different JJ o
detection NN o
methods NNS o
. . o

CONCLUSION VB N
This DT N
trial NN N
will MD N
answer VB N
the DT N
question NN N
whether IN N
there EX N
is VBZ N
an DT N
advantage NN N
for IN N
the DT N
anterior JJ i
approach NN i
technique NN i
compared VBN N
to TO N
the DT N
conventional JJ i
resection NN i
group NN N
with IN N
regard NN N
to TO N
tumor VB N
cell NN N
dissemination NN N
. . N

It PRP N
will MD N
also RB N
add VB N
further JJ N
information NN N
about IN N
prognostic JJ N
differences NNS N
, , N
safety NN N
, , N
advantages NNS N
and CC N
disadvantages NNS N
of IN N
each DT N
technique NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
Current NNP N
controlled VBD N
trials NNS N
- : N
ISRCTN45066244 NNP N
. . N

-DOCSTART- -1526697- O O

Dihydroergocryptine NN i
in IN N
the DT N
management NN N
of IN N
senile JJ p
psycho-organic JJ p
syndrome NN p
. . p

A DT N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
randomized JJ N
study NN N
is VBZ N
described VBN N
of IN N
an DT N
assessment NN N
of IN N
the DT N
efficacy NN o
and CC o
relative JJ o
safety NN o
of IN N
the DT N
ergot NN N
alkaloid NN N
, , N
dihydroergocryptine NN i
, , N
on IN N
52 CD p
patients NNS p
with IN p
mild JJ p
organic JJ p
brain NN p
syndrome NN p
over IN p
a DT p
period NN p
of IN p
three CD p
months NNS p
using VBG p
a DT p
series NN p
of IN p
neurophysiological JJ o
tests NNS o
. . o

The DT N
results NNS N
indicated VBD N
that IN N
short-term JJ N
treatment NN N
with IN N
the DT N
alkaloid NN N
improved VBD N
memory NN o
impairment NN o
. . o

The DT N
side-effects NNS o
were VBD N
mild JJ N
and CC N
transient NN N
in IN N
both CC N
the DT N
dihydroergocryptine NN i
and CC N
placebo NN N
groups NNS N
and CC N
there EX N
were VBD N
no DT N
alterations NNS o
in IN o
blood NN o
chemistry NN o
. . o

-DOCSTART- -11459079- O O

Famotidine NNP i
treatment NN N
of IN N
children NNS p
with IN p
autistic JJ p
spectrum NN p
disorders NNS p
: : p
pilot NN N
research NN N
using VBG N
single JJ N
subject JJ N
research NN N
design NN N
. . N

Using VBG N
single JJ N
subject JJ N
research NN N
design NN N
, , N
we PRP N
performed VBD N
pilot JJ N
research NN N
to TO N
evaluate VB N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
famotidine NN i
for IN N
the DT N
treatment NN N
of IN N
children NNS p
with IN p
autistic JJ p
spectrum NN p
disorders NNS p
. . p

We PRP N
studied VBD N
9 CD p
Caucasian JJ p
boys NNS p
, , p
3.8-8.1 CD p
years NNS p
old JJ p
, , p
with IN p
a DT p
DSM-IV JJ p
diagnosis NN p
of IN p
a DT p
pervasive JJ p
developmental NN p
disorder NN p
, , p
living VBG p
with IN p
their PRP$ p
families NNS p
, , p
receiving VBG p
no DT p
chronic JJ p
medications NNS p
, , p
and CC p
without IN p
significant JJ p
gastrointestinal JJ p
symptoms NNS p
. . p

The DT N
dose NN N
of IN N
oral JJ i
famotidine NN i
was VBD i
2 CD i
mg/kg/day NN i
( ( i
given VBN i
in IN i
two CD i
divided JJ i
doses NNS i
) ) i
; : i
the DT i
maximum JJ i
total JJ i
daily JJ i
dose NN i
was VBD i
100 CD i
mg NN i
. . i

Using VBG N
single-subject JJ N
research NN N
analysis NN N
and CC N
medication NN N
given VBN N
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
cross-over JJ N
design NN N
, , N
4 CD N
of IN N
9 CD N
children NNS N
randomized VBN N
( ( N
44 CD N
% NN N
) ) N
had VBD N
evidence NN N
of IN N
behavioral JJ o
improvement NN o
. . o

Primary JJ N
efficacy NN N
was VBD N
based VBN N
on IN N
data NNS N
kept VBN N
by IN N
primary JJ N
caregivers NNS N
, , N
including VBG N
a DT N
daily JJ o
diary NN o
; : o
daily JJ o
visual JJ o
analogue NN o
scales NNS o
of IN o
affection NN o
, , o
reciting VBG o
, , o
or CC o
aspects NNS o
of IN o
social JJ o
interaction NN o
; : o
Aberrant NNP o
Behavior NNP o
Checklists NNP o
( ( o
ABC NNP o
, , o
Aman NNP o
) ) o
; : o
and CC o
Clinical NNP o
Global NNP o
Improvement NNP o
scales NNS o
. . o

Children NNP p
with IN p
marked VBN p
stereotypy NN p
( ( p
meaningless NN p
, , p
repetitive JJ p
behaviors NNS p
) ) p
did VBD N
not RB N
respond VB N
. . N

Our PRP$ p
subjects NNS p
did VBD p
not RB p
have VB p
prominent JJ p
gastrointestinal JJ o
symptoms NNS o
and CC N
endoscopy NN N
was VBD N
not RB N
part NN N
of IN N
our PRP$ N
protocol NN N
; : N
thus RB N
, , N
we PRP N
can MD N
not RB N
exclude VB N
the DT N
possibility NN N
that IN N
our PRP$ N
subjects NNS N
improved VBN N
due JJ N
to TO N
the DT N
effective JJ N
treatment NN N
of IN N
asymptomatic JJ N
esophagitis NN N
. . N

The DT N
use NN N
of IN N
famotidine NN i
for IN N
the DT N
treatment NN N
of IN N
children NNS p
with IN p
autistic JJ p
spectrum NN p
disorders NNS p
warrants NNS N
further JJ N
investigation NN N
. . N

-DOCSTART- -7528271- O O

Multicyclic NNP i
, , i
dose-intensive JJ i
chemotherapy NN i
supported VBN N
by IN N
sequential JJ N
reinfusion NN N
of IN N
hematopoietic JJ i
progenitors NNS i
in IN N
whole JJ N
blood NN N
. . N

PURPOSE NN N
To TO N
support VB N
multicyclic JJ N
, , N
dose-intensive JJ i
chemotherapy NN i
, , N
we PRP N
assessed VBD N
the DT N
effects NNS N
of IN N
reinfusing VBG i
hematopoietic JJ i
progenitors NNS i
collected VBN N
at IN N
each DT N
cycle NN N
in IN N
leukapheresis JJ N
product NN N
or CC N
whole JJ N
blood NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Twenty-five JJ p
patients NNS p
with IN p
small-cell JJ p
lung NN p
cancer NN p
( ( p
SCLC NNP p
) ) p
were VBD N
treated VBN N
with IN N
six CD N
cycles NNS N
of IN N
ifosfamide NN i
, , i
carboplatin NN i
, , i
and CC i
etoposide RB i
( ( i
ICE NNP i
) ) i
with IN i
granulocyte JJ i
colony-stimulating JJ i
factor NN i
( ( i
G-CSF NNP i
) ) i
300 CD N
micrograms/d NN N
subcutaneously RB N
( ( N
SC NNP N
) ) N
on IN N
days NNS N
4 CD N
to TO N
15 CD N
. . N

Hematopoietic JJ N
progenitors NNS N
collected VBD N
during IN N
each DT N
cycle NN N
were VBD N
reinfused VBN N
on IN N
day NN N
3 CD N
of IN N
the DT N
next JJ N
cycle NN N
. . N

Cohort NNP N
1 CD N
( ( N
n JJ N
= NNP N
6 CD N
) ) N
was VBD N
treated VBN N
every DT N
3 CD N
weeks NNS N
, , N
with IN N
leukapheresis NN i
after IN N
2 CD N
weeks NNS N
and CC N
cryopreservation NN i
of IN i
the DT i
leukapheresis NN i
product NN i
. . i

Chemotherapy NNP i
was VBD N
given VBN N
if IN N
the DT N
WBC NNP N
count NN N
was VBD N
> JJ N
or CC N
= JJ N
3 CD N
x JJ N
10 CD N
( ( N
9 CD N
) ) N
/L NN N
and CC N
platelet NN N
count NN N
> NNP N
or CC N
= $ N
100 CD N
x $ N
10 CD N
( ( N
9 CD N
) ) N
/L NN N
. . N

Cohort NNP N
2 CD N
( ( N
n JJ N
= NNP N
7 CD N
) ) N
was VBD N
treated VBN N
every DT N
2 CD N
weeks NNS N
, , N
with IN N
leukapheresis NN i
on IN N
day NN N
1 CD N
of IN N
the DT N
next JJ N
cycle NN N
and CC N
storage NN N
of IN N
the DT N
leukapheresis NN i
product NN i
at IN N
4 CD N
degrees NNS N
C. NNP N
Cohort NNP N
3 CD N
( ( N
n JJ N
= NNP N
12 CD N
) ) N
was VBD N
treated VBN N
every DT N
2 CD N
weeks NNS N
, , N
with IN N
500 CD N
to TO N
750 CD N
mL NNS N
of IN N
blood NN N
drawn VBN N
by IN N
venesection NN N
on IN N
day NN N
1 CD N
of IN N
the DT N
next JJ N
cycle NN N
and CC N
stored VBD N
at IN N
4 CD N
degrees NNS N
C. NNP N
In IN N
cohorts NNS N
2 CD N
and CC N
3 CD N
, , N
chemotherapy NN i
was VBD N
given VBN N
if IN N
the DT N
WBC NNP N
count NN N
was VBD N
> JJ N
or CC N
= JJ N
3 CD N
x JJ N
10 CD N
( ( N
9 CD N
) ) N
/L NN N
and CC N
platelet NN N
count NN N
> NNP N
or CC N
= $ N
30 CD N
x $ N
10 CD N
( ( N
9 CD N
) ) N
/L NN N
. . N

Blood NNP o
and CC o
leukapheresis NN o
products NNS o
were VBD N
assayed VBN N
for IN N
hematopoietic JJ N
progenitors NNS N
. . N

RESULTS NNP N
ICE NNP i
chemotherapy NN i
with IN N
G-CSF NNP N
was VBD N
effective JJ N
in IN N
mobilizing VBG o
blood NN o
progenitors NNS o
( ( N
median JJ N
, , N
120-fold JJ N
) ) N
. . N

Long-term JJ N
cultures NNS N
showed VBD N
no DT N
evidence NN N
of IN N
stem-cell JJ o
depletion NN o
. . o

The DT N
cytotoxic JJ o
dose-intensity NN o
of IN N
standard JJ N
every-4-weeks JJ N
ICE NNP N
is VBZ N
100 CD N
% NN N
. . N

In IN N
the DT N
first JJ N
three CD N
cycles NNS N
, , N
it PRP N
was VBD N
134 CD N
% NN N
( ( N
median JJ N
) ) N
in IN N
cohort NN N
1 CD N
and CC N
200 CD N
% NN N
in IN N
cohorts NNS N
2 CD N
and CC N
3 CD N
( ( N
P NNP N
< NNP N
.0001 NNP N
) ) N
. . N

Toxicity NN o
and CC o
supportive JJ o
care NN o
requirements NNS o
were VBD N
not RB N
increased VBN N
. . N

CONCLUSION VB N
The DT N
dose-intensity NN N
of IN N
ICE NNP i
chemotherapy NN i
can MD N
be VB N
doubled VBN N
by IN N
reinfusing VBG N
hematopoietic JJ N
progenitors NNS N
collected VBN N
by IN N
leukapheresis NN N
or CC N
venesection NN N
and CC N
stored VBD N
at IN N
4 CD N
degrees NNS N
C NNP N
. . N

-DOCSTART- -9589305- O O

Anti-tumor JJ i
necrosis NN i
factor NN i
alpha NN i
: : i
Crohn NNP p
's POS p
disease NN p
guided VBD N
missile NN N
. . N

-DOCSTART- -20307262- O O

Improvement NN N
of IN N
pain NN N
related VBN N
self JJ N
management NN N
for IN N
oncologic JJ p
patients NNS p
through IN N
a DT N
trans JJ N
institutional JJ N
modular JJ N
nursing NN N
intervention NN N
: : N
protocol NN N
of IN N
a DT N
cluster NN N
randomized VBN N
multicenter RB N
trial NN N
. . N

BACKGROUND NNP N
Pain NNP N
is VBZ N
one CD N
of IN N
the DT N
most RBS N
frequent JJ N
and CC N
distressing VBG N
symptoms NNS N
in IN N
cancer NN p
patients NNS p
. . p

For IN N
the DT N
majority NN N
of IN N
the DT N
patients NNS N
, , N
sufficient JJ N
pain NN N
relief NN N
can MD N
be VB N
obtained VBN N
if IN N
adequate JJ N
treatment NN N
is VBZ N
provided VBN N
. . N

However RB N
, , N
pain NN N
remains NNS N
often RB N
undertreated VBD N
due JJ N
to TO N
institutional JJ N
, , N
health NN N
care NN N
professional JJ N
and CC N
patient JJ N
related JJ N
barriers NNS N
. . N

Patients NNS N
self JJ N
management NN N
skills NNS N
are VBP N
affected VBN N
by IN N
the DT N
patients NNS N
' POS N
knowledge NN N
, , N
activities NNS N
and CC N
attitude NN N
to TO N
pain VB N
management NN N
. . N

This DT N
trial NN N
protocol NN N
is VBZ N
aimed VBN N
to TO N
test VB N
the DT N
SCION-PAIN JJ N
program NN N
, , N
a DT N
multi NN N
modular NN N
structured VBD N
intervention NN N
to TO N
improve VB N
self NN N
management NN N
in IN N
cancer NN p
patients NNS p
with IN p
pain NN p
. . p

METHODS NNP N
240 CD p
patients NNS p
with IN p
diagnosed JJ p
malignancy NN p
and CC p
pain NN p
> VBP p
3 CD p
days NNS p
and CC p
average JJ p
pain NN p
> JJ p
or= NN p
3/10 CD p
will MD p
participate VB p
in IN p
a DT p
cluster NN p
randomized VBN p
trial NN p
on IN p
18 CD p
wards NNS p
in IN p
2 CD p
German JJ p
university NN p
hospitals NNS p
. . p

Patients NNS N
from IN N
the DT N
intervention NN N
wards NNS N
will MD N
receive VB N
, , N
additionally RB N
to TO N
standard VB i
pain NN i
treatment NN i
, , i
the DT i
SCION-PAIN JJ i
program NN i
consisting NN i
of IN i
3 CD i
modules NNS i
: : i
pharmacologic NN i
pain NN i
management NN i
, , i
nonpharmacologic RB i
pain JJ i
management NN i
and CC i
discharge NN i
management NN i
. . i

The DT N
intervention NN N
will MD N
be VB N
conducted VBN N
by IN N
specially RB N
trained JJ N
oncology NN N
nurses NNS N
and CC N
includes VBZ N
components NNS N
of IN N
patient JJ i
education NN i
, , i
skills NNS i
training NN i
and CC i
counseling NN i
to TO i
improve VB i
self PRP i
care VB i
regarding VBG i
pain JJ i
management NN i
beginning VBG i
with IN i
admission NN i
followed VBN i
by IN i
booster NN i
session NN i
every DT i
3rd CD i
day NN i
and CC i
one CD i
follow VBP i
up RP i
telephone NN i
counseling NN i
within IN i
2 CD i
to TO i
3 CD i
days NNS i
after IN i
discharge NN i
. . i

Patients NNS N
in IN N
the DT N
control NN N
group NN N
will MD N
receive VB N
standard NN N
care NN N
. . N

Primary JJ N
endpoint NN N
is VBZ N
the DT N
group NN o
difference NN o
in IN o
patient NN o
related JJ o
barriers NNS o
to TO o
management NN o
of IN o
cancer NN o
pain NN o
( ( N
BQII NNP N
) ) N
, , N
7 CD N
days NNS N
after IN N
discharge NN N
. . N

Secondary JJ N
endpoints NNS N
are VBP N
: : N
pain NN o
intensity NN o
& CC o
interference NN o
, , o
adherence NN o
, , o
coping VBG o
and CC o
HRQoL NNP o
. . o

DISCUSSION NNP N
The DT N
study NN N
will MD N
determine VB N
if IN N
the DT N
acquired VBN N
self NN N
management NN N
skills NNS N
of IN N
the DT N
patients NNS N
continue VBP N
to TO N
be VB N
used VBN N
after IN N
discharge NN N
from IN N
hospital NN N
. . N

It PRP N
is VBZ N
hypothesized VBN N
that IN N
patients NNS N
who WP N
receive VBP N
the DT N
multi NN N
modular NN N
structured VBN N
intervention NN N
will MD N
have VB N
less RBR N
patient JJ N
related JJ N
barriers NNS N
and CC N
a DT N
better JJR N
self JJ N
management NN N
of IN N
cancer NN o
pain NN o
. . o

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials NNP N
NCT00779597 NNP N
. . N

-DOCSTART- -25084009- O O

Physical JJ i
and CC i
perceptual JJ i
cooling NN i
with IN i
beverages NNS i
to TO N
increase VB N
cycle NN N
performance NN N
in IN N
a DT N
tropical JJ N
climate NN N
. . N

PURPOSE VB N
This DT N
study NN N
compares VBZ N
the DT N
effects NNS N
of IN N
neutral JJ i
temperature NN i
, , i
cold JJ i
and CC i
ice-slush JJ i
beverages NNS i
, , i
with IN i
and CC i
without IN i
0.5 CD i
% NN i
menthol NN i
on IN N
cycling NN o
performance NN o
, , o
core NN o
temperature NN o
( ( o
Tco NNP o
) ) o
and CC o
stress JJ o
responses NNS o
in IN N
a DT N
tropical JJ N
climate NN N
( ( N
hot JJ N
and CC N
humid JJ N
conditions NNS N
) ) N
. . N

METHODS NNP N
Twelve NNP p
trained VBD p
male JJ p
cyclists/triathletes NNS p
completed VBN N
six CD i
20-km JJ i
exercise NN i
trials NNS i
against IN i
the DT i
clock NN i
in IN i
30.7?C?0.8?C CD i
and CC i
78 CD i
% NN i
?0.03 CD i
% NN i
relative JJ i
humidity NN i
. . i

Before IN i
and CC N
after IN N
warm-up JJ N
, , N
and CC N
before IN N
exercise NN N
and CC N
every DT N
5 CD N
km NN N
during IN N
exercise NN N
, , N
athletes VBZ N
drank JJ N
190 CD N
mL NN N
of IN N
either DT i
aromatized VBN i
( ( i
i.e. FW i
, , N
with IN N
0.5 CD N
mL NNS N
of IN i
menthol NN i
( ( i
5 CD i
gr/L NN N
) ) N
) ) N
or CC N
a DT N
non-aromatized JJ i
beverage NN i
( ( i
neutral JJ i
temperature NN i
: : i
23?C?0.1?C CD i
, , i
cold NN i
: : i
3?C?0.1?C CD i
, , i
or CC i
ice-slush NN i
: : i
-1?C?0.7?C NN i
) ) i
. . i

During IN i
the DT i
trials NNS o
, , o
heart NN o
rate NN o
( ( o
HR NNP o
) ) o
was VBD o
continuously RB N
monitored VBN N
, , N
whereas NNS o
core VBP o
temperature NN o
( ( o
Tco NNP o
) ) o
, , o
thermal JJ o
comfort NN o
( ( o
TC NNP o
) ) o
, , o
thermal JJ o
sensation NN o
( ( o
TS NNP o
) ) o
and CC o
rate NN o
of IN o
perceived VBN o
exertion NN o
( ( o
RPE NNP o
) ) o
were VBD o
measured VBN o
before IN N
and CC N
after IN N
warm-up JJ N
, , N
every DT N
5 CD N
km NN N
of IN N
exercise NN N
, , N
and CC N
at IN N
the DT N
end NN N
of IN N
exercise NN N
and CC N
after IN N
recovery NN N
. . N

RESULTS NNP N
Both NNP N
the DT o
beverage NN o
aroma NN o
( ( o
P NNP o
< NNP o
0.02 CD o
) ) N
and CC N
beverage JJ o
temperature NN o
( ( N
P NNP N
< NNP N
0.02 CD N
) ) N
had VBD N
significant JJ o
and CC o
positive JJ o
effects NNS o
on IN o
performance NN o
, , N
which WDT N
was VBD N
considerably RB N
better RBR i
with IN i
ice-slush JJ i
than IN i
with IN i
a DT i
neutral JJ i
temperature NN i
beverage NN N
, , N
whatever WDT N
the DT N
aroma NN i
( ( i
P NNP i
< NNP N
0.002 CD N
) ) N
, , N
and CC i
with IN i
menthol JJ i
vs JJ i
non-menthol NN i
( ( N
P NNP N
< NNP N
0.02 CD N
) ) N
. . N

The DT N
best JJS N
performances NNS N
were VBD N
obtained VBN N
with IN N
ice-slush/menthol JJ i
and CC i
cold/menthol NN i
, , N
as IN N
opposed VBN N
to TO N
neutral/menthol VB i
. . i

No DT i
differences NNS i
were VBD N
noted VBN N
in IN N
HR NNP o
and CC o
Tco NNP o
between IN o
trials NNS N
. . N

CONCLUSION NNP i
Cold NNP i
water NN i
or CC i
ice-slush NN i
with IN i
menthol NN i
aroma NN i
seems VBZ i
to TO N
be VB N
the DT N
most RBS N
effective JJ N
beverage NN N
for IN N
endurance NN N
exercise NN N
in IN N
a DT N
tropical JJ N
climate NN N
. . N

Further JJ N
studies NNS N
are VBP N
needed VBN N
to TO N
explore VB N
its PRP$ N
effects NNS N
in IN N
field NN N
competition NN N
. . N

-DOCSTART- -6343259- O O

A DT N
comparison NN N
of IN N
once RB N
and CC N
twice RB N
daily JJ N
atenolol NN i
for IN N
angina JJ p
pectoris NN p
. . p

We PRP N
have VBP N
studied VBN N
the DT N
effects NNS N
of IN N
four CD N
doses NNS N
of IN N
atenolol NN i
in IN N
11 CD p
patients NNS p
with IN p
stable JJ p
angina NNS p
pectoris VBP p
using VBG N
a DT N
symptom-limited JJ N
exercise NN N
test NN N
and CC N
angina NN N
diaries NNS N
. . N

The DT N
doses NNS N
100 CD N
mg JJ N
twice RB N
daily RB N
and CC N
50 CD N
mg NN N
, , N
100 CD N
mg NN N
and CC N
200 CD N
mg NN N
once RB N
daily JJ N
were VBD N
given VBN N
double-blind NNS N
and CC N
randomised VBD N
within IN N
patients NNS N
following VBG N
run-in NN N
on IN N
placebo NN i
. . i

Measurements NNS N
were VBD N
made VBN N
12 CD N
hours NNS N
after IN N
the DT N
last JJ N
twice JJ N
daily RB N
dose JJ N
and CC N
24 CD N
hours NNS N
after IN N
the DT N
last JJ N
once JJ N
daily JJ N
dose NN N
. . N

Exercise NN o
tolerance NN o
was VBD N
improved VBN N
by IN N
40-74 JJ N
% NN N
and CC N
exercise NN o
duration NN o
before IN o
the DT o
onset NN o
of IN o
angina NN o
by IN N
61-94 JJ N
% NN N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

Maximal JJ o
heart NN o
rate NN o
was VBD N
reduced VBN N
further RB N
by IN N
a DT N
total JJ N
daily JJ N
dose NN N
of IN N
200 CD N
mg NNS N
than IN N
by IN N
lower JJR N
doses NNS N
, , N
but CC N
no DT N
extra JJ N
benefit NN N
was VBD N
derived VBN N
by IN N
giving VBG N
the DT N
drug NN N
twice RB N
daily RB N
. . N

The DT N
largest JJS N
increase NN N
in IN N
exercise NN o
tolerance NN o
was VBD N
obtained VBN N
during IN N
treatment NN N
with IN N
50 CD N
mg NNS N
once RB N
daily RB N
. . N

Atenolol NNP i
was VBD N
shown VBN N
to TO N
be VB N
an DT N
effective JJ N
anti-anginal JJ N
agent NN N
when WRB N
given VBN N
once RB N
daily JJ N
, , N
and CC N
there EX N
were VBD N
no DT N
major JJ N
differences NNS N
between IN N
the DT N
doses NNS N
studied VBN N
. . N

-DOCSTART- -9778067- O O

Acute JJ N
effects NNS N
of IN N
caffeine JJ i
ingestion NN i
on IN N
signal-averaged JJ o
electrocardiograms NNS o
. . o

BACKGROUND NNP N
Although IN N
moderate JJ N
caffeine NN N
ingestion NN N
has VBZ N
not RB N
been VBN N
shown VBN N
to TO N
be VB N
arrhythmogenic JJ N
, , N
caffeine JJ N
toxicity NN N
can MD N
cause VB N
severe JJ N
cardiac JJ N
arrhythmias NN N
, , N
including VBG N
atrial JJ N
fibrillation NN N
and CC N
ventricular JJ N
tachycardia NN N
. . N

Atrial JJ N
fibrillation NN N
and CC N
ventricular JJ N
tachycardia NN N
have VBP N
been VBN N
associated VBN N
with IN N
prolongation NN o
of IN o
P-wave NNP o
and CC o
QRS NNP o
complex JJ o
durations NNS o
on IN o
signal-averaged JJ o
electrocardiograms NNS o
. . o

This DT N
study NN N
investigated VBD N
acute JJ N
effects NNS N
of IN N
caffeine JJ N
ingestion NN N
on IN N
signal-averaged JJ o
P-wave NNP o
and CC o
QRS NNP o
complexes NNS o
. . o

METHODS NNP N
AND CC N
RESULTS NNP N
Signal-averaged JJ o
electrocardiograms NNS o
were VBD N
obtained VBN N
from IN N
12 CD p
normal JJ p
subjects NNS p
( ( p
6 CD p
men NNS p
, , p
6 CD p
women NNS p
; : p
ages VBZ p
21 CD p
to TO p
26 CD p
years NNS p
) ) p
before IN p
and CC p
after IN p
ingestion NN p
of IN p
caffeine NN i
( ( N
5 CD N
mg/kg NN N
body NN N
weight NN N
) ) N
or CC N
placebo NN i
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
crossover JJ N
fashion NN N
. . N

Electrocardiograms NNP N
for IN N
signal JJ N
averaging NN N
were VBD N
recorded VBN N
from IN N
electrodes NNS N
left VBN N
in IN N
a DT N
constant JJ N
location NN N
. . N

After IN N
bandpass NN N
filtering NN N
( ( N
30 CD N
to TO N
300 CD N
Hz NNP N
) ) N
and CC N
amplification NN N
, , N
signals NNS N
were VBD N
sampled VBN N
over IN N
7.2 CD N
minutes NNS N
at IN N
2000 CD N
Hz NNP N
. . N

Signal-averaged JJ o
P-wave NNP o
and CC o
QRS NNP o
complex JJ o
durations NNS o
did VBD N
not RB N
significantly RB N
change VBP N
after IN N
placebo NN N
ingestion NN N
. . N

After IN N
caffeine JJ N
ingestion NN N
QRS NNP o
duration NN o
prolonged VBD N
in IN N
9 CD N
of IN N
11 CD N
subjects NNS N
at IN N
90 CD N
minutes NNS N
( ( N
mean JJ N
+/- JJ N
SEM NNP N
= NNP N
0.8+/-0.3 JJ N
ms NN N
, , N
P NNP N
< NNP N
.02 NNP N
) ) N
and CC N
in IN N
8 CD N
of IN N
9 CD N
after IN N
3 CD N
hours NNS N
( ( N
1.1+/-0.2 JJ N
ms NN N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

No DT N
significant JJ N
change NN N
in IN N
P-wave NNP o
duration NN o
or CC o
heart NN o
rate NN o
was VBD N
found VBN N
after IN N
caffeine JJ N
ingestion NN N
at IN N
any DT N
test NN N
interval NN N
. . N

Average JJ o
caffeine JJ o
level NN o
in IN o
saliva JJ o
90 CD N
minutes NNS N
after IN N
ingestion NN N
was VBD N
6.6+/-1.6 JJ N
( ( N
SD NNP N
) ) N
microg/dL NN N
. . N

CONCLUSIONS NNP N
Although IN N
probably RB N
not RB N
arrhythmogenic JJ N
in IN N
normal JJ p
subjects NNS p
, , N
moderate JJ N
caffeine NN N
ingestion NN N
does VBZ N
produce VB N
a DT N
small JJ N
but CC N
statistically RB N
significant JJ N
prolongation NN N
of IN N
signal-averaged JJ o
QRS NNP o
complexes NNS o
. . o

Further JJ N
prolongation NN N
caused VBN N
by IN N
excessive JJ N
caffeine NNS N
intake VBP N
may MD N
be VB N
a DT N
factor NN N
in IN N
the DT N
genesis NN N
of IN N
arrhythmias NNS N
associated VBN N
with IN N
caffeine JJ N
toxicity NN N
. . N

-DOCSTART- -16791814- O O

International NNP p
Czech NNP i
and CC i
Slovak NNP i
cooperation NN i
in IN N
the DT N
treatment NN N
of IN N
patients NNS p
with IN p
differentiated JJ p
thyroid NN p
cancer NN p
. . p

BACKGROUND IN N
The DT N
aim NN N
of IN N
this DT N
paper NN N
is VBZ N
to TO N
present VB N
our PRP$ N
experience NN N
concerning VBG N
cooperation NN N
in IN N
the DT N
treatment NN N
of IN N
Slovak NNP p
patients NNS p
with IN p
differentiated JJ p
thyroid NN p
cancer NN p
in IN p
Slovak NNP p
and CC p
Czech NNP p
hospitals NNS p
. . p

The DT N
objectives NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
demonstrate VB N
the DT N
means NNS o
of IN o
this DT o
cooperation NN o
and CC N
the DT N
results NNS o
of IN N
therapy NN N
. . N

MATERIAL NNP N
AND CC N
METHODS NNP N
From NNP p
September NNP p
1991 CD p
to TO p
October NNP p
2005 CD p
in IN p
the DT p
Department NNP p
of IN p
Nuclear NNP p
Medicine NNP p
in IN p
Ostrava NNP p
357 CD p
patients NNS p
from IN p
the DT p
Slovak NNP p
Republic NNP p
with IN p
differentiated VBN p
thyroid NN p
cancers NNS p
( ( p
follicular JJ p
and CC p
papillary JJ p
) ) p
underwent NN p
complex JJ i
therapy NN i
. . i

They PRP p
were VBD p
diagnosed VBN p
and CC p
operated VBN p
due JJ p
to TO p
the DT p
cancer NN p
( ( p
near-total JJ p
thyroidectomy NN p
and CC p
removal NN p
of IN p
lymph JJ p
node JJ p
metastases NNS p
) ) p
in IN p
Slovak NNP p
hospitals NNS p
. . p

Then RB p
they PRP p
were VBD p
sent VBN p
to TO p
the DT p
Department NNP p
of IN p
Nuclear NNP p
Medicine NNP p
in IN p
Ostrava NNP p
in IN p
the DT p
Czech NNP p
Republic NNP p
. . p

In IN N
this DT N
department NN N
a DT N
radioiodine JJ i
ablation NN N
of IN N
thyroid JJ N
remnants NNS N
, , N
by IN N
means NNS N
of IN N
the DT N
treatment NN i
amount NN N
of IN N
radioiodine NN i
of IN N
a DT N
standard JJ N
activity NN N
of IN N
3.7 CD N
GBq NNP N
, , N
was VBD N
performed VBN N
, , N
and CC N
then RB N
a DT N
suppression NN N
and CC N
substitution NN i
therapy NN i
of IN N
thyroid JJ N
hormones NNS N
was VBD N
started VBN N
. . N

After IN N
3-6 JJ N
months NNS N
some DT N
patients NNS N
were VBD N
examined VBN N
by IN N
means NNS N
of IN N
diagnostic JJ o
whole JJ o
body NN o
scintigraphy NN o
after IN N
application NN N
of IN N
300 CD N
MBq NNP N
131I CD N
. . N

Some DT N
patients NNS N
were VBD N
treated VBN N
by IN N
means NNS N
of IN N
a DT N
standard JJ N
activity NN N
of IN N
7.4 CD N
GBq NNP N
131I CD N
and CC N
after IN N
5 CD N
days NNS N
whole JJ N
body NN N
scintigraphy NN N
( ( N
WBS NNP N
) ) N
was VBD N
performed VBN N
. . N

In IN N
both DT N
of IN N
these DT N
groups NNS N
of IN N
patients NNS N
the DT N
diagnostic JJ N
or CC N
therapeutic JJ N
radioiodine NN i
application NN N
was VBD N
done VBN N
after IN N
withdrawal NN N
of IN N
thyroid JJ N
hormone NN N
treatment NN N
. . N

If IN N
thyroglobulin JJ o
levels NNS o
were VBD N
low JJ N
and CC N
WBSs NNP o
were VBD N
negative JJ N
, , N
patients NNS N
were VBD N
followed VBN N
up RP N
in IN N
the DT N
Department NNP N
of IN N
Nuclear NNP N
Medicine NNP N
in IN N
Martin NNP N
. . N

Patients NNS N
with IN N
radioiodine NN N
accumulated VBN N
metastases NNS N
were VBD N
again RB N
treated VBN N
with IN N
radioiodine NN i
in IN N
Ostrava NNP N
. . N

If IN N
indicated VBN N
, , N
external JJ N
radiation NN i
therapy NN i
targeted VBN N
on IN N
the DT N
neck NN N
and CC N
upper JJ N
mediastinum NN N
was VBD N
performed VBN N
in IN N
the DT N
Slovak NNP p
Republic NNP p
, , p
in IN p
the DT p
University NNP p
Hospital NNP p
in IN p
Martin NNP p
. . p

Newly RB N
formed VBN N
lymph JJ N
node NN N
metastases NNS N
were VBD N
surgically RB N
treated VBN N
in IN N
Slovakia NNP N
, , N
too RB N
. . N

Generally RB N
we PRP N
have VBP N
very RB N
good JJ o
treatment NN o
results NNS o
. . o

Also RB N
, , N
economically RB N
our PRP$ N
partnership NN N
is VBZ N
cost VBN o
effective JJ o
. . o

Our PRP$ N
collaboration NN N
also RB N
successfully RB N
continues VBZ N
after IN N
entrance NN N
of IN N
the DT N
Slovak NNP N
Republic NNP N
and CC N
the DT N
Czech NNP N
Republic NNP N
to TO N
the DT N
European NNP N
Union NNP N
in IN N
2004 CD N
. . N

CONCLUSIONS VB N
The DT N
results NNS N
of IN N
this DT N
multi-centre JJ N
study NN N
show NN N
that IN N
international JJ N
Czech NNP N
and CC N
Slovak NNP N
cooperation NN i
in IN N
the DT N
complex JJ N
therapy NN N
of IN N
patients NNS N
with IN N
differentiated JJ N
thyroid NN N
cancers NNS N
is VBZ N
successful JJ N
, , N
with IN N
high JJ N
efficacy NN N
. . N

The DT N
treatment NN N
results NNS N
were VBD N
very RB N
similar JJ N
to TO N
therapeutic JJ N
results NNS N
in IN N
our PRP$ N
patients NNS N
from IN N
the DT N
Czech NNP N
Republic NNP N
. . N

-DOCSTART- -19176440- O O

BNP-guided JJ N
vs NN N
symptom-guided JJ N
heart NN N
failure NN N
therapy NN N
: : N
the DT N
Trial NNP N
of IN N
Intensified NNP i
vs FW i
Standard NNP i
Medical NNP i
Therapy NNP i
in IN p
Elderly JJ p
Patients NNS p
With IN p
Congestive NNP p
Heart NNP p
Failure NNP p
( ( p
TIME-CHF NNP p
) ) p
randomized VBD N
trial NN N
. . N

CONTEXT VB N
It PRP N
is VBZ N
uncertain JJ N
whether IN N
intensified JJ N
heart NN N
failure NN N
therapy NN N
guided VBN N
by IN N
N-terminal JJ N
brain NN N
natriuretic JJ N
peptide NN N
( ( N
BNP NNP N
) ) N
is VBZ N
superior JJ N
to TO N
symptom-guided JJ N
therapy NN N
. . N

OBJECTIVE UH N
To TO N
compare VB N
18-month JJ N
outcomes NNS N
of IN N
N-terminal JJ N
BNP-guided JJ N
vs NN N
symptom-guided JJ N
heart NN N
failure NN N
therapy NN N
. . N

DESIGN NNP N
, , N
SETTING NNP N
, , N
AND NNP N
PATIENTS NNP N
Randomized NNP N
controlled VBD N
multicenter RBR N
Trial NNP N
of IN N
Intensified NNP N
vs FW N
Standard NNP N
Medical NNP N
Therapy NNP N
in IN N
Elderly JJ p
Patients NNS p
With IN p
Congestive NNP p
Heart NNP p
Failure NNP p
( ( p
TIME-CHF NNP p
) ) p
of IN p
499 CD p
patients NNS p
aged VBN p
60 CD p
years NNS p
or CC p
older JJR p
with IN p
systolic JJ p
heart NN p
failure NN p
( ( p
ejection NN p
fraction NN p
< NN p
or CC p
= VB p
45 CD p
% NN p
) ) p
, , p
New NNP p
York NNP p
Heart NNP p
Association NNP p
( ( p
NYHA NNP p
) ) p
class NN p
of IN p
II NNP p
or CC p
greater JJR p
, , p
prior JJ p
hospitalization NN p
for IN p
heart NN p
failure NN p
within IN p
1 CD p
year NN p
, , p
and CC p
N-terminal JJ p
BNP NNP p
level NN p
of IN p
2 CD p
or CC p
more JJR p
times NNS p
the DT p
upper JJ p
limit NN p
of IN p
normal JJ p
. . p

The DT N
study NN N
had VBD N
an DT N
18-month JJ N
follow-up NN N
and CC N
it PRP N
was VBD N
conducted VBN N
at IN N
15 CD p
outpatient NN p
centers NNS p
in IN p
Switzerland NNP p
and CC p
Germany NNP p
between IN p
January NNP p
2003 CD p
and CC p
June NNP p
2008 CD p
. . p

INTERVENTION NNP N
Uptitration NNP i
of IN i
guideline-based JJ i
treatments NNS i
to TO i
reduce VB i
symptoms NNS i
to TO i
NYHA NNP i
class NN i
of IN i
II NNP i
or CC i
less JJR i
( ( i
symptom-guided JJ i
therapy NN i
) ) i
and CC i
BNP NNP i
level NN i
of IN i
2 CD i
times NNS i
or CC i
less JJR i
the DT i
upper JJ i
limit NN i
of IN i
normal JJ i
and CC i
symptoms NNS i
to TO i
NYHA NNP i
class NN i
of IN i
II NNP i
or CC i
less JJR i
( ( i
BNP-guided JJ i
therapy NN i
) ) i
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Primary NNP N
outcomes NNS N
were VBD N
18-month JJ o
survival JJ o
free JJ o
of IN o
all-cause JJ o
hospitalizations NNS o
and CC o
quality NN o
of IN o
life NN o
as IN o
assessed VBN o
by IN o
structured JJ o
validated JJ o
questionnaires NNS o
. . o

RESULTS NNP N
Heart NNP N
failure NN N
therapy NN N
guided VBN N
by IN N
N-terminal JJ N
BNP NNP N
and CC N
symptom-guided JJ N
therapy NN N
resulted VBD N
in IN N
similar JJ N
rates NNS N
of IN N
survival JJ o
free JJ o
of IN o
all-cause JJ o
hospitalizations NNS o
( ( N
41 CD N
% NN N
vs JJ N
40 CD N
% NN N
, , N
respectively RB N
; : N
hazard PRP N
ratio VBP N
[ JJ N
HR NNP N
] NNP N
, , N
0.91 CD N
[ JJ N
95 CD N
% NN N
CI NNP N
, , N
0.72-1.14 JJ N
] NN N
; : N
P NNP N
= NNP N
.39 NNP N
) ) N
. . N

Patients NNS o
' POS o
quality-of-life JJ o
metrics NNS o
improved VBN N
over IN N
18 CD N
months NNS N
of IN N
follow-up JJ N
but CC N
these DT N
improvements NNS N
were VBD N
similar JJ N
in IN N
both DT N
the DT N
N-terminal JJ N
BNP-guided JJ N
and CC N
symptom-guided JJ N
strategies NNS N
. . N

Compared VBN N
with IN N
the DT N
symptom-guided JJ N
group NN N
, , N
survival JJ o
free JJ o
of IN o
hospitalization NN o
for IN o
heart NN o
failure NN o
, , N
a DT N
secondary JJ N
end NN N
point NN N
, , N
was VBD N
higher JJR N
among IN N
those DT N
in IN N
the DT N
N-terminal JJ N
BNP-guided NNP N
group NN N
( ( N
72 CD N
% NN N
vs JJ N
62 CD N
% NN N
, , N
respectively RB N
; : N
HR NNP N
, , N
0.68 CD N
[ JJ N
95 CD N
% NN N
CI NNP N
, , N
0.50-0.92 JJ N
] NN N
; : N
P NNP N
= NNP N
.01 NNP N
) ) N
. . N

Heart NNP N
failure NN N
therapy NN N
guided VBN N
by IN N
N-terminal NNP N
BNP NNP N
improved VBD N
outcomes NNS N
in IN N
patients NNS p
aged VBD p
60 CD p
to TO p
75 CD p
years NNS p
but CC N
not RB N
in IN N
those DT p
aged VBN p
75 CD p
years NNS p
or CC p
older JJR p
( ( N
P NNP N
< NNP N
.02 NNP N
for IN N
interaction NN N
) ) N
CONCLUSION NNP N
Heart NNP N
failure NN N
therapy NN N
guided VBN N
by IN N
N-terminal JJ N
BNP NNP N
did VBD N
not RB N
improve VB N
overall JJ N
clinical JJ N
outcomes NNS o
or CC N
quality NN o
of IN o
life NN o
compared VBN N
with IN N
symptom-guided JJ N
treatment NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
isrctn.org NN N
Identifier NNP N
: : N
ISRCTN43596477 NNP N
. . N

-DOCSTART- -12813449- O O

Recombinant JJ i
human JJ i
thrombopoietin NN i
augments NNS N
mobilization NN N
of IN N
peripheral JJ o
blood NN o
progenitor NN o
cells NNS o
for IN N
autologous JJ p
transplantation NN p
. . p

This DT N
study NN N
assessed VBD N
the DT N
ability NN N
of IN N
various JJ N
schedules NNS N
of IN N
recombinant JJ i
human JJ i
thrombopoietin NN i
( ( i
rhTPO NN i
) ) i
to TO N
enhance VB N
mobilization NN N
of IN N
peripheral JJ N
blood NN N
progenitor NN N
cells NNS N
( ( N
PBPCs NNP N
) ) N
in IN N
134 CD p
patients NNS p
with IN p
cancer NN p
undergoing VBG p
high-dose JJ p
chemotherapy NN p
and CC p
autologous JJ p
PBPC NNP p
transplantation NN p
. . p

Patients NNS N
received VBD N
the DT N
study NN N
drug NN N
on IN N
days NNS N
1 CD N
, , N
3 CD N
, , N
and CC N
5 CD N
before IN N
initiation NN N
of IN N
granulocyte JJ N
colony-stimulating JJ N
factor NN N
( ( N
G-CSF NNP N
) ) N
10 CD N
microg/kg/day NN N
on IN N
day NN N
5 CD N
and CC N
pheresis NN N
starting VBG N
on IN N
day NN N
9 CD N
. . N

Randomly RB N
assigned JJ N
treatments NNS N
on IN N
days NNS N
1 CD N
, , N
3 CD N
, , N
and CC N
5 CD N
were VBD N
: : N
group NN N
1 CD N
( ( N
n=27 NN N
) ) N
placebo NN i
, , i
placebo NN i
, , i
rhTPO VBZ i
1.5 CD N
microg/kg NN N
; : N
group NN N
2 CD N
( ( N
n=27 NN N
) ) N
rhTPO VBZ N
1.5 CD N
microg/kg NN N
, , N
placebo NN N
, , N
placebo NN N
; : N
groups NNS N
3 CD N
( ( N
n=28 NN N
) ) N
and CC N
4 CD N
( ( N
n=22 NN N
) ) N
rhTPO VBZ N
0.5 CD N
microg/kg NN N
on IN N
all DT N
3 CD N
treatment NN N
days NNS N
; : N
and CC N
group NN N
5 CD N
( ( N
n=30 NN N
) ) N
placebo NN N
on IN N
all DT N
3 CD N
treatment NN N
days NNS N
. . N

After IN N
high-dose JJ i
chemotherapy NN i
and CC i
PBPC NNP i
transplantation NN i
, , N
groups NNS N
1 CD N
through IN N
4 CD N
received VBD N
rhTPO NN N
1.5 CD N
microg/kg NN N
days NNS N
0 CD N
, , N
+2 NNP N
, , N
+4 NNP N
, , N
and CC N
+6 VBZ N
with IN N
either DT N
G-CSF NNP N
5 CD N
microg/kg/day NN N
( ( N
groups NNS N
1-3 CD N
) ) N
or CC N
granulocyte-macrophage JJ N
colony-stimulating JJ N
factor NN N
250 CD N
microg/m NN N
( ( N
2 CD N
) ) N
/day NN N
( ( N
group NN N
4 CD N
) ) N
. . N

Group NNP N
5 CD N
received VBD N
placebo JJ i
plus CC N
G-CSF JJ N
5 CD N
microg/kg/day NN N
. . N

The DT N
addition NN N
of IN N
rhTPO NN i
to TO N
G-CSF NNP N
increased JJ N
median JJ o
CD34+ NNP o
cell NN o
yield/pheresis NN o
in IN N
cohorts NNS N
in IN N
which WDT N
rhTPO NN i
was VBD N
started VBN N
before IN N
day NN N
5 CD N
, , N
with IN N
higher JJR N
yields NNS N
in IN N
groups NNS N
2 CD N
( ( N
2.67 CD N
x RB N
10 CD N
( ( N
6 CD N
) ) N
/kg NN N
) ) N
and CC N
groups NNS N
3 CD N
and CC N
4 CD N
( ( N
3.10 CD N
x RB N
10 CD N
( ( N
6 CD N
) ) N
/kg NN N
) ) N
than IN N
in IN N
group NN N
1 CD N
( ( N
1.86 CD N
x RB N
10 CD N
( ( N
6 CD N
) ) N
/kg NN N
) ) N
or CC N
group NN N
5 CD N
( ( N
1.65 CD N
x RB N
10 CD N
( ( N
6 CD N
) ) N
/kg NN N
) ) N
( ( N
P=.006 NNP N
across IN N
groups NNS N
) ) N
. . N

Comparing VBG N
rhTPO NN i
to TO N
placebo VB i
, , N
higher JJR N
percentages NNS N
of IN N
patients NNS N
achieved VBN N
the DT N
minimum JJ o
yield NN o
of IN o
CD34+ NNP o
> NNP N
or CC N
=2 NNP N
x VBP N
10 CD N
( ( N
6 CD N
) ) N
/kg NN N
( ( N
92 CD N
% NN N
v JJ N
75 CD N
% NN N
; : N
P=.050 NNP N
) ) N
as RB N
well RB N
as IN N
the DT N
target NN N
yield NN N
of IN N
CD34+ NNP N
> NNP N
or CC N
=5 NNP N
x VBP N
10 CD N
( ( N
6 CD N
) ) N
/kg NN N
( ( N
73 CD N
% NN N
v JJ N
46 CD N
% NN N
; : N
P= NNP N
.041 NNP N
) ) N
. . N

rhTPO-treated JJ i
patients NNS N
required VBN N
fewer JJR N
phereses NNS N
to TO N
achieve VB N
minimum NN N
( ( N
P= NNP N
.011 NNP N
) ) N
and CC N
target NN N
( ( N
P= NNP N
.015 NNP N
) ) N
CD34+ NNP o
cell NN o
values NNS o
. . o

rhTPO VB i
given VBN N
after IN N
transplantation NN N
did VBD N
not RB N
speed VB N
platelet NN o
recovery NN o
. . o

No UH N
neutralizing JJ N
antibodies NNS N
were VBD N
observed VBN N
. . N

We PRP N
conclude VBP N
that IN N
rhTPO NN i
can MD N
safely RB N
enhance VB N
mobilization NN N
of IN N
PBPC NNP o
, , N
reduce VB N
the DT N
number NN N
of IN N
leukapheresis NN o
, , N
and CC N
allow VB N
more JJR N
patients NNS N
to TO N
meet VB N
minimal JJ N
cell NN N
yield NN N
requirements NNS N
to TO N
receive VB N
high-dose JJ N
chemotherapy NN i
with IN N
PBPC NNP i
transplantation NN i
. . i

-DOCSTART- -19436938- O O

Osteoporosis NN i
and CC N
gait NN N
and CC N
balance NN N
disturbances NNS N
in IN N
older JJR p
sarcopenic JJ p
obese JJ p
New NNP p
Zealanders NNP p
. . p

UNLABELLED NNP N
Bone NNP N
, , N
muscle NN N
, , N
and CC N
fat NN N
may MD N
affect VB N
gait NN N
and CC N
balance NN N
in IN N
older JJR p
adults NNS p
. . p

Osteoporosis NN p
was VBD p
prevalent JJ p
in IN p
low JJ p
muscle NN p
mass NN p
participants NNS p
and CC p
related VBN p
to TO p
gait VB p
and CC p
balance VB p
deficits NNS p
. . p

Low JJ N
muscle NN N
combined VBN N
with IN N
high JJ N
fat JJ N
mass NN N
had VBD N
more RBR N
functional JJ N
deficits NNS N
and CC N
poorer JJR N
bone NN N
health NN N
, , N
which WDT N
has VBZ N
implications NNS N
for IN N
falls NNS N
risk NN N
and CC N
fractures NNS N
. . N

INTRODUCTION NNP N
Decreasing VBG N
bone NN N
density NN N
and CC N
muscle NN N
mass NN N
and CC N
increasing VBG N
fat JJ N
mass NN N
may MD N
act VB N
synergistically RB N
to TO N
affect VB N
gait NN N
and CC N
balance NN N
in IN N
older JJR N
adults NNS N
. . N

METHODS NNP N
One CD p
hundred VBD p
eighty-three JJ p
older NN p
adults NNS p
( ( p
age NN p
72.7 CD p
+/- JJ p
6 CD p
years NNS p
, , p
range VBP p
56-93 JJ p
; : p
body NN p
mass NN p
index NN p
28.2 CD p
+/- JJ p
4.9 CD p
, , p
range VBP p
16.6-46.0 JJ p
) ) p
were VBD p
recruited VBN p
from IN p
a DT p
New NNP p
Zealand NNP p
falls VBZ p
prevention NN p
intervention NN p
trial NN p
. . p

Total JJ o
and CC o
appendicular JJ o
skeletal JJ o
muscle NN o
mass NN o
( ( o
ASM NNP o
) ) o
, , o
percent JJ o
fat NN o
, , o
and CC o
bone NN o
mineralization NN o
were VBD p
assessed VBN p
by IN p
dual JJ i
energy NN i
X-ray JJ i
absorptiometry NN i
and CC p
used VBD p
to TO p
characterize VB p
normal JJ p
lean JJ p
( ( p
NL NNP p
, , p
n JJ p
= NNP p
51 CD p
) ) p
, , p
sarcopenic JJ p
( ( p
SS NNP p
, , p
n JJ p
= NNP p
18 CD p
) ) p
, , p
sarcopenic JJ p
obese NN p
( ( p
SO NNP p
, , p
n JJ p
= NNP p
29 CD p
) ) p
, , p
and CC p
obese JJ p
( ( p
OO NNP p
, , p
n JJ p
= NNP p
85 CD p
) ) p
phenotypes NNS p
. . p

Functional JJ N
performance NN N
was VBD N
assessed VBN N
using VBG N
timed VBN i
up RP i
and CC i
go VB i
, , i
chair NN i
stand NN i
, , i
single JJ i
leg NN i
stand NN i
, , N
and CC N
step VB i
test NN i
. . i

Regression NN N
models NNS N
were VBD N
adjusted VBN N
for IN N
age NN N
, , N
sex NN N
, , N
medications NNS N
, , N
and CC N
physical JJ N
activity NN N
. . N

RESULTS NNP N
Femoral NNP o
neck NN o
osteoporosis NN o
was VBD N
present JJ N
in IN N
22 CD N
% NN N
SS NNP N
, , N
17 CD N
% NN N
SO NNP N
, , N
12 CD N
% NN N
NL NNP N
, , N
and CC N
7 CD N
% NN N
OO NNP N
. . N

Femoral NNP N
neck NN N
osteoporosis NN N
with IN N
low JJ N
ASM NNP o
predicted VBD N
poor JJ N
chair NN o
stand VBP o
performance NN o
( ( N
beta JJ N
-3.3 NNP N
, , N
standard JJ N
error NN N
1.6 CD N
, , N
p NN N
= NNP N
0.04 CD N
) ) N
. . N

SO RB N
scored JJ N
lowest NN N
on IN N
the DT N
chair NN N
stand NN N
( ( N
p JJ N
= NNP N
0.03 CD N
) ) N
and CC N
step JJ N
test NN N
( ( N
p JJ N
= NNP N
0.03 CD N
) ) N
. . N

Higher JJR o
ASM NNP o
predicted VBD N
faster RBR N
timed VBN N
up RP N
and CC N
go VB N
performance NN N
( ( N
p JJ N
= NNP N
0.001 CD N
) ) N
. . N

CONCLUSIONS NNP N
Osteoporosis NNP N
was VBD N
prevalent VBN N
in IN N
low JJ p
ASM NNP p
groups NNS p
( ( N
SS NNP N
and CC N
SO NNP N
) ) N
and CC N
related VBN N
to TO N
gait VB N
and CC N
balance VB N
deficits NNS N
, , N
particularly RB N
in IN N
the DT N
SO NNP N
. . N

This DT N
has VBZ N
implications NNS N
for IN N
falls NNS N
risk NN N
, , N
fractures NNS N
, , N
and CC N
interventions NNS N
. . N

-DOCSTART- -12505565- O O

Treatment JJ N
effects NNS N
of IN N
eptifibatide NN i
in IN N
planned JJ N
coronary JJ N
stent NN N
implantation NN N
in IN N
patients NNS p
with IN p
chronic JJ p
kidney NN p
disease NN p
( ( N
ESPRIT NNP N
Trial NNP N
) ) N
. . N

The DT N
role NN N
of IN N
platelet NN i
glycoprotein NN i
IIb/IIIa NNP i
inhibitor NN i
therapy NN i
in IN N
patients NNS p
with IN p
mild JJ p
renal JJ p
impairment NN p
is VBZ N
not RB N
well RB N
characterized VBN N
. . N

Our PRP$ N
objective NN N
was VBD N
to TO N
explore VB N
the DT N
associations NNS o
of IN o
creatinine JJ o
clearance NN o
( ( o
CrCl NNP o
) ) o
with IN N
outcomes NNS o
in IN N
a DT N
trial NN N
of IN N
eptifibatide JJ i
therapy NN i
in IN N
patients NNS p
who WP p
underwent VBP p
percutaneous JJ p
coronary JJ p
intervention NN p
( ( p
PCI NNP p
) ) p
. . p

We PRP N
analyzed VBD N
48-hour CD N
and CC N
30-day JJ N
outcomes NNS N
of IN N
patients NNS p
enrolled VBN p
in IN p
the DT p
Enhanced NNP p
Suppression NNP p
of IN p
the DT p
Platelet NNP p
IIb/IIIa NNP p
Receptor NNP p
with IN p
Integrilin NNP i
Therapy NNP i
( ( i
ESPRIT NNP i
) ) i
trial NN i
. . i

Patients NNS p
were VBD p
randomly RB p
assigned VBN p
to TO p
placebo VB i
or CC i
eptifibatide VB i
as IN i
an DT i
adjunct NN i
to TO i
stent VB i
implantation NN i
( ( i
1,755 CD i
with IN i
CrCl NNP i
> NNP i
or CC i
=60 NNP i
ml/min NN i
and CC i
289 CD i
with IN i
CrCl NNP i
< NNP i
60 CD i
ml/min NN i
) ) i
. . N

CrCl NNP o
was VBD N
calculated VBN N
using VBG N
the DT o
Cockcroft NNP o
and CC o
Gault NNP o
formula NN o
, , N
and CC N
the DT N
associations NNS N
of IN N
CrCl NNP o
with IN N
outcomes NNS N
were VBD N
evaluated VBN N
using VBG N
logistic JJ o
regression NN o
models NNS o
. . o

Patients NNS p
with IN p
CrCl NNP p
< NNP p
60 CD p
ml/min NN p
were VBD p
more RBR p
likely JJ p
to TO p
be VB p
older JJR p
, , p
women NNS p
, , N
hypertensive JJ N
, , N
and CC N
have VBP N
a DT N
history NN N
of IN N
coronary JJ N
artery NN N
bypass NN N
surgery NN N
, , N
stroke NN N
, , N
or CC N
peripheral JJ N
vascular JJ N
disease NN N
. . N

The DT N
interaction NN N
of IN N
eptifibatide NN i
with IN N
CrCl NNP N
had VBD N
borderline JJ N
significance NN N
for IN N
the DT N
30-day JJ N
outcome NN N
( ( N
p JJ N
= NNP N
0.109 CD N
) ) N
. . N

Treatment JJ N
effect NN N
trended VBD N
toward IN N
a DT N
greater JJR N
magnitude NN N
in IN N
patients NNS N
with IN N
lower JJR N
CrCl NNP N
( ( N
60 CD N
ml/min NN N
) ) N
( ( N
odds NNS N
ratio VBP N
0.53 CD N
, , N
confidence NN N
interval NN N
0.34 CD N
to TO N
0.83 CD N
) ) N
compared VBN N
with IN N
those DT N
with IN N
higher JJR N
CrCl NNP N
( ( N
90 CD N
ml/min NN N
) ) N
( ( N
odds NNS N
ratio VBP N
0.68 CD N
, , N
confidence NN N
interval NN N
0.49 CD N
to TO N
0.94 CD N
) ) N
. . N

An DT N
accompanying VBG N
increase NN N
in IN N
bleeding VBG o
risk NN o
also RB N
was VBD N
not RB N
apparent JJ N
with IN N
lower JJR N
CrCl NNP N
. . N

The DT N
treatment NN N
effect NN N
of IN N
eptifibatide NN i
is VBZ N
realized VBN N
regardless RB N
of IN N
renal JJ N
function NN N
and CC N
trends VBZ N
toward IN N
being VBG N
greater JJR N
in IN N
patients NNS p
with IN p
mild JJ p
renal JJ o
impairment NN o
. . o

-DOCSTART- -15839875- O O

Topical NNP N
quinolone NN i
vs. FW N
antiseptic JJ i
for IN N
treating VBG N
chronic JJ p
suppurative JJ p
otitis NN p
media NNS p
: : p
a DT p
randomized NN p
controlled VBN p
trial NN p
. . p

-DOCSTART- -15641975- O O

Evaluation NN N
of IN N
apical JJ N
sealing VBG N
ability NN N
and CC N
adaptation NN N
to TO N
dentine VB N
of IN N
two CD i
resin-based JJ i
sealers NNS i
. . i

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
apical JJ N
sealing NN N
ability NN N
and CC N
adaptation NN N
to TO N
dentine VB N
of IN N
two CD i
resin-based JJ i
root NN i
canal JJ i
sealers NNS i
. . i

The DT p
root NN p
canals NNS p
of IN p
55 CD p
human JJ p
maxillary JJ p
anterior NN p
teeth NNS p
were VBD N
prepared VBN N
using VBG N
a DT N
step-back NN N
technique NN N
and CC N
the DT N
smear JJ N
layer NN N
removed VBD N
with IN N
17 CD N
% NN N
ethylenediaminetetraacetic JJ N
acid NN N
. . N

The DT N
teeth NNS N
were VBD N
divided VBN N
into IN N
two CD N
groups NNS N
of IN N
25 CD N
teeth NNS N
and CC N
the DT N
remaining VBG N
five CD N
teeth NNS N
served VBD N
as IN N
control NN N
. . N

Then RB N
the DT N
teeth NNS N
were VBD N
prepared JJ i
and CC i
obturated VBN i
with IN i
gutta-percha JJ i
by IN i
a DT i
lateral JJ i
condensation NN i
and CC i
either DT i
AH NNP i
plus CC i
and CC i
EndoRez NNP i
used VBD i
as IN i
a DT i
sealer NN i
. . i

Twenty NNP N
teeth IN N
from IN N
each DT N
group NN N
were VBD N
used VBN N
for IN N
the DT N
apical JJ N
leakage NN N
test NN N
and CC N
the DT N
remaining VBG N
five CD N
teeth NNS N
from IN N
each DT N
group NN N
were VBD N
used VBN N
for IN N
examination NN N
under IN N
the DT N
scanning NN N
electron NN N
microscope NN N
( ( N
SEM NNP N
) ) N
. . N

For IN N
apical JJ N
leakage NN N
test NN N
, , N
teeth EX i
were VBD i
covered VBN i
with IN i
nail JJ i
varnish NN i
and CC i
sticky JJ i
wax NN i
to TO i
within IN i
1 CD i
mm NN i
of IN i
the DT i
apical JJ i
foramen NNS i
and CC i
placed VBN i
in IN i
2 CD i
% NN i
methylene NN i
blue NN i
for IN i
7 CD i
days NNS i
. . i

After IN N
this DT N
period NN N
, , N
the DT i
teeth NNS i
were VBD i
sectioned VBN i
longitudinally RB i
and CC N
apical JJ N
leakage NN N
measurements NNS N
made VBN N
. . N

The DT N
mean JJ o
value NN o
of IN o
dye JJ o
penetration NN o
for IN o
AH NNP o
plus CC o
was VBD N
2.87 CD N
+/- JJ N
0.43 CD N
mm NN N
, , N
while IN N
that DT N
of IN N
EndoRez NNP i
was VBD N
4.54 CD N
+/- JJ N
0.36 CD N
mm NN N
. . N

The DT N
difference NN N
between IN N
mean NN N
of IN N
dye JJ o
penetration NN o
was VBD N
statistically RB N
significant JJ N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
SEM NNP N
examination NN N
showed VBD N
both DT N
sealers NNS N
had VBD N
better JJR o
adaptation NN o
and CC o
penetration NN o
in IN o
coronal JJ o
and CC o
middle JJ o
thirds NNS o
than IN N
apical JJ N
third NN N
of IN N
root JJ N
canal NN N
. . N

In IN N
apical JJ N
third JJ N
, , N
AH NNP i
plus CC i
was VBD N
adapted VBN o
better RB o
adpated VBN N
to TO N
dentine VB N
than IN N
EndoRez NNP i
. . i

In IN N
conclusion NN N
, , N
AH NNP i
plus CC i
sealer NN i
has VBZ N
better RB o
apical JJ o
sealing VBG o
ability NN o
and CC N
adaptation NN N
to TO N
dentine VB N
than IN N
EndoRez NNP i
sealer NN i
. . i

-DOCSTART- -2868645- O O

Comparison NNP N
of IN N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
esmolol NN i
, , N
a DT N
short-acting JJ N
beta NN N
blocker NN N
, , N
with IN N
placebo NN i
in IN N
the DT N
treatment NN N
of IN N
supraventricular JJ p
tachyarrhythmias NN p
. . p

The DT N
Esmolol NNP i
vs NN i
Placebo NNP i
Multicenter NNP N
Study NNP N
Group NNP N
. . N

The DT N
efficacy NN o
and CC o
safety NN o
of IN N
esmolol NN i
, , N
a DT N
short-acting JJ N
intravenous JJ N
beta-adrenergic-blocking JJ N
agent NN N
, , N
and CC N
placebo NN i
were VBD N
compared VBN N
in IN N
patients NNS p
with IN p
supraventricular JJ p
tachyarrhythmias NN p
( ( p
heart NN p
rate NN p
greater JJR p
than IN p
120 CD p
bpm NN p
) ) p
in IN N
a DT N
multicenter NN N
, , N
double-blind JJ N
, , N
partial-crossover JJ N
study NN N
. . N

Seventy-one CD p
patients NNS p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
esmolol NN i
( ( N
n JJ N
= NNP N
36 CD N
) ) N
or CC N
placebo NN i
( ( N
n JJ N
= NNP N
35 CD N
) ) N
as IN N
initial JJ N
treatment NN N
. . N

Therapeutic JJ N
failures NNS N
were VBD N
crossed VBN N
over IN N
to TO N
the DT N
other JJ N
study NN N
medication NN N
. . N

Therapeutic JJ o
response NN o
was VBD N
defined VBN N
as IN N
greater JJR N
than IN N
or CC N
equal JJ N
to TO N
20 CD N
% NN N
reduction NN N
in IN N
heart NN o
rate NN o
, , o
heart NN o
rate NN o
less JJR o
than IN o
100 CD o
bpm NN o
, , o
or CC o
conversion NN o
to TO o
normal JJ o
sinus NN o
rhythm NN o
. . o

The DT o
therapeutic JJ o
response NN o
to TO N
esmolol VB i
during IN N
the DT N
initial JJ N
treatment NN N
period NN N
( ( N
72 CD N
% NN N
) ) N
was VBD N
similar JJ N
to TO N
that DT N
obtained VBN N
when WRB N
esmolol NN N
was VBD N
given VBN N
as IN N
a DT N
second JJ N
agent NN N
. . N

The DT N
average JJ N
esmolol JJ N
dosage NN N
producing VBG N
a DT N
therapeutic JJ N
response NN N
was VBD N
97.5 CD N
micrograms/kg/min NN N
. . N

Four CD N
patients NNS N
( ( N
6 CD N
% NN N
) ) N
converted VBD N
to TO N
normal JJ o
sinus JJ o
rhythm NN o
during IN N
esmolol JJ N
infusion NN N
. . N

In IN N
the DT N
majority NN N
of IN N
patients NNS N
( ( N
80 CD N
% NN N
) ) N
, , N
therapeutic JJ o
response NN o
was VBD N
lost VBN N
within IN N
30 CD N
minutes NNS N
following VBG N
discontinuation NN N
of IN N
esmolol JJ i
infusion NN N
, , N
a DT N
finding JJ N
indicative NN N
of IN N
rapid JJ N
reversal NN N
of IN N
beta-adrenoceptor NN N
blockade NN N
. . N

The DT N
most RBS N
prevalent JJ N
adverse JJ o
effect NN o
during IN N
esmolol JJ i
infusion NN N
was VBD N
hypotension NN o
which WDT N
occurred VBD N
in IN N
eight CD N
patients NNS N
( ( N
12 CD N
% NN N
) ) N
. . N

Hypotension NN o
and CC o
associated VBN o
symptoms NNS o
resolved VBD N
within IN N
30 CD N
minutes NNS N
after IN N
discontinuation NN N
of IN N
esmolol JJ i
infusion NN N
, , N
which WDT N
is VBZ N
consistent JJ N
with IN N
the DT N
short JJ N
duration NN N
of IN N
action NN N
of IN N
esmolol NN i
( ( N
elimination JJ N
half-life NN N
of IN N
9.2 CD N
minutes NNS N
) ) N
. . N

-DOCSTART- -3745846- O O

Domperidone NN i
, , i
metoclopramide NN i
, , i
and CC i
placebo NN i
. . i

All DT N
give JJ N
symptomatic JJ o
improvement NN o
in IN o
gastroesophageal JJ o
reflux NN o
. . o

A DT N
double-blind JJ N
crossover NN N
study NN N
was VBD N
conducted VBN N
of IN N
two CD N
gastric JJ i
prokinetic JJ i
drugs NNS i
in IN N
23 CD p
patients NNS p
with IN p
gastroesophageal JJ p
reflux NN p
. . p

Patients NNS N
were VBD N
divided VBN N
into IN N
two CD N
groups NNS N
on IN N
the DT N
basis NN N
of IN N
a DT N
dual-isotope JJ N
mixed-meal JJ N
study NN N
of IN N
their PRP$ N
gastric JJ N
emptying NN N
( ( N
GE NNP N
) ) N
. . N

Group NNP p
I PRP p
had VBD N
normal JJ N
GE NNP N
and CC N
group NN N
II NNP N
delayed VBD N
GE NNP N
. . N

Nine NNP N
gastrointestinal JJ N
symptoms NNS N
were VBD N
assessed VBN N
for IN N
frequency NN N
and CC N
severity NN N
before IN N
treatment NN N
. . N

The DT N
trial NN N
had VBD N
three CD N
1-month JJ N
treatment NN N
periods NNS N
using VBG N
metoclopramide RB i
10 CD N
mg NN N
q.i.d. NN N
, , N
domperidone NN i
20 CD N
mg NN N
q.i.d. NN N
, , N
or CC i
placebo NN i
on IN N
a DT N
random JJ N
basis NN N
. . N

Symptoms NNS N
were VBD N
reassessed VBN N
at IN N
the DT N
end NN N
of IN N
each DT N
month NN N
. . N

Taken NNP N
as IN N
a DT N
whole NN N
, , N
the DT N
group NN N
showed VBD N
a DT N
significant JJ N
symptomatic JJ o
response NN o
in IN N
all DT N
three CD N
treatment NN N
periods NNS N
( ( N
p NN N
less JJR N
than IN N
0.0001 CD N
) ) N
, , N
but CC N
patients NNS p
with IN p
delayed JJ p
or CC p
normal JJ p
GE NNP p
did VBD N
not RB N
differ VB N
significantly RB N
in IN N
their PRP$ N
symptomatic JJ N
response NN N
. . N

Eleven JJ N
patients NNS N
complained VBD N
of IN N
side NN o
effects NNS o
with IN N
metoclopramide NN i
and CC N
three CD N
stopped VBD N
therapy NN N
before IN N
the DT N
1-month JJ N
course NN N
was VBD N
completed VBN N
. . N

Two CD N
patients NNS N
described JJ N
side JJ N
effects NNS N
with IN N
domperidone NN i
, , N
including VBG N
one CD N
woman NN N
with IN N
galactorrhea NN o
after IN N
36 CD N
h NN N
of IN N
treatment NN N
. . N

Three CD N
patients NNS N
on IN N
placebo NN i
also RB N
complained VBD N
of IN N
important JJ o
side NN o
effects NNS o
. . o

We PRP N
conclude VBP N
that IN N
a DT N
significant JJ N
placebo NN N
effect NN N
is VBZ N
present JJ N
in IN N
the DT N
treatment NN N
of IN N
gastroesophageal JJ N
reflux NN N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
demonstrated VBN N
in IN N
symptomatic JJ o
improvement NN o
between IN N
placebo NN i
, , i
domperidone NN i
, , N
and CC N
metoclopramide RB i
in IN N
this DT N
study NN N
. . N

-DOCSTART- -9407259- O O

Effects NNS N
of IN N
creatine JJ i
supplementation NN i
on IN N
repetitive JJ N
sprint NN N
performance NN N
and CC N
body NN N
composition NN N
in IN N
competitive JJ p
swimmers NNS p
. . p

In IN N
a DT N
double-blind NN N
and CC N
randomized JJ N
manner NN N
, , N
18 CD p
male NN p
and CC p
female JJ p
junior JJ p
competitive JJ p
swimmers NNS p
supplemented VBD N
their PRP$ N
diets NNS N
with IN N
21 CD N
g.day-1 NN N
of IN N
creatine NN i
monohydrate NN i
( ( i
Cr NNP i
) ) i
or CC N
a DT N
maltodextrin JJ i
placebo NN i
( ( i
P NNP i
) ) i
for IN N
9 CD p
days NNS p
during IN p
training NN p
. . p

Prior NNP N
to TO N
and CC N
following VBG N
supplementation NN N
, , N
subjects NNS N
performed VBD N
three CD N
100-m JJ N
freestyle JJ N
sprint NN N
swims NNS N
( ( N
long JJ N
course NN N
) ) N
with IN N
60 CD N
s JJ N
rest/recovery NN N
between IN N
heats NNS N
. . N

In IN N
addition NN N
, , N
subjects NNS N
performed VBD N
three CD N
20-s JJ N
arm NN N
ergometer NN N
maximal-effort JJ N
sprint NN N
tests NNS N
in IN N
the DT N
prone NN N
position NN N
with IN N
60 CD N
s JJ N
rest/recovery NN N
between IN N
sprint NN N
tests NNS N
. . N

Significant JJ N
differences NNS N
were VBD N
observed VBN N
among IN N
swim JJ o
times NNS o
, , N
with IN N
Cr NNP N
subjects NNS N
swimming VBG N
significantly RB N
faster RBR N
than IN N
P NNP N
subjects NNS N
following VBG N
supplementation NN N
in IN N
Heat NNP N
1 CD N
and CC N
significantly RB N
decreasing VBG N
swim JJ o
time NN o
in IN N
the DT N
second JJ N
100-m JJ N
sprint NN N
. . N

There EX N
was VBD N
also RB N
some DT N
evidence NN N
that IN N
cumulative JJ o
time NN o
to TO o
perform VB o
the DT o
three CD o
100-m JJ o
swims NNS o
was VBD N
decreased VBN N
in IN N
the DT N
Cr NNP N
group NN N
. . N

Results NNP N
indicate VBP N
that IN N
9 CD N
days NNS N
of IN N
Cr NNP i
supplementation NN N
during IN N
swim JJ N
training NN N
may MD N
provide VB N
some DT N
ergogenic JJ N
value NN N
to TO N
competitive JJ N
junior JJ N
swimmers NNS N
during IN N
repetitive JJ N
sprint NN N
performance NN N
. . N

-DOCSTART- -1682643- O O

Specific JJ i
immunoglobulin NN i
for IN N
treatment NN N
of IN N
whooping JJ p
cough NN p
. . p

Immunoglobulin NNP i
treatment NN N
for IN N
whooping JJ N
cough NN N
( ( N
pertussis NN N
) ) N
is VBZ N
widely RB N
believed VBN N
to TO N
be VB N
ineffective JJ o
although IN N
there EX N
are VBP N
sound JJ N
reasons NNS N
for IN N
regarding VBG N
the DT N
condition NN N
as IN N
a DT N
toxin-induced JJ N
disease NN N
. . N

We PRP N
wondered VBD N
whether IN N
the DT N
lack NN o
of IN o
success NN o
with IN N
pertussis NN N
immunoglobulins NNS i
might MD N
be VB N
attributable JJ N
to TO N
inadequate VB N
dose NN N
, , N
so IN N
we PRP N
designed VBD N
a DT N
randomised VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
of IN N
two CD N
immunoglobulin JJ N
preparations NNS N
. . N

The DT N
study NN N
was VBD N
conducted VBN N
at IN N
three CD p
Swedish JJ p
hospitals NNS p
. . p

We PRP N
enrolled VBD N
73 CD p
children NNS p
aged VBD p
less JJR p
than IN p
36 CD p
months NNS p
who WP p
were VBD p
admitted VBN p
with IN p
a DT p
clinical JJ p
diagnosis NN p
of IN p
whooping JJ p
cough NN p
. . p

On IN N
admission NN N
they PRP N
were VBD N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
groups NNS N
: : N
( ( N
a DT N
) ) N
monocomponent NN i
pertussis NN i
toxoid JJ i
vaccine NN i
; : i
( ( i
b NN i
) ) i
two-component NN i
acellular JJ i
vaccine NN i
also RB i
containing VBG i
filamentous JJ i
haemagglutinin NN i
; : i
or CC i
( ( i
c NN i
) ) i
20 CD i
% NN i
albumin JJ i
solution NN i
( ( i
placebo NN i
) ) i
. . i

The DT N
immunoglobulins NNS i
had VBD N
a DT N
high JJ N
antitoxin NN N
content NN N
and CC N
had VBD N
been VBN N
raised VBN N
with IN N
acellular JJ N
pertussis NN N
vaccines NNS N
. . N

Diagnosis NN N
of IN N
pertussis NN N
was VBD N
confirmed VBN N
by IN N
laboratory NN N
tests NNS N
and CC N
the DT N
follow-up NN N
was VBD N
completed VBN N
in IN N
67 CD N
children NNS N
. . N

The DT N
main JJ N
study NN N
group NN N
consisted VBD N
of IN N
47 CD p
children NNS p
with IN p
less JJR p
than IN p
or CC p
equal JJ p
to TO p
14 CD p
days NNS p
of IN p
disease NN p
before IN p
therapy NN p
. . p

Duration NN o
of IN o
whoops JJ o
post-treatment NN o
was VBD N
8.7 CD N
days NNS N
( ( N
95 CD N
% NN N
Cl NNP N
4.8 CD N
, , N
12.6 CD N
) ) N
in IN N
the DT N
33 CD N
children NNS N
receiving VBG N
immunoglobulin NN i
vs NN N
20.6 CD N
( ( N
95 CD N
% NN N
Cl NNP N
11.9 CD N
, , N
29.3 CD N
) ) N
in IN N
the DT N
14 CD N
receiving NN N
placebo NN i
( ( N
p JJ N
= NNP N
0.0041 CD N
) ) N
. . N

Mean JJ o
number NN o
of IN o
whoops NNS o
during IN N
the DT N
first JJ N
week NN N
of IN N
follow-up NN N
was VBD N
also RB N
significantly RB N
reduced VBN N
( ( N
p JJ N
= NNP N
0.0196 CD N
) ) N
. . N

We PRP N
found VBD N
that IN N
early JJ N
treatment NN N
was VBD N
important JJ N
, , N
since IN N
the DT N
effect NN N
on IN N
duration NN o
of IN o
whoops NNS o
was VBD N
most RBS N
pronounced JJ N
when WRB N
disease NN N
duration NN N
before IN N
treatment NN N
was VBD N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
7 CD N
days NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS o
between IN N
the DT N
two CD N
immunoglobulin NN N
preparations NNS N
. . N

High-dose JJ N
specific JJ N
pertussis NN N
immunoglobulin NN i
with IN N
a DT N
high JJ N
antitoxin NN N
concentration NN N
has VBZ N
a DT N
beneficial JJ o
effect NN o
in IN N
the DT N
treatment NN N
of IN N
whooping JJ N
cough NN N
. . N

-DOCSTART- -15623221- O O

Rapeseed NNP i
and CC i
soybean NN i
products NNS i
as IN N
protein NN N
sources NNS N
for IN N
growing VBG p
turkeys NNS p
of IN p
different JJ p
ages NNS p
. . p

( ( N
1 CD N
) ) N
Apparent NNP N
ileal NN N
and CC N
total JJ N
tract NN N
protein NN N
digestibilities NNS N
of IN N
rapeseed NN i
meal NN i
and CC i
cake NN i
and CC i
soybean NN i
meal NN i
and CC i
cake NN i
were VBD N
assayed VBN N
in IN N
growing VBG p
turkeys NNS p
at IN p
4 CD p
, , p
8 CD p
and CC p
12 CD p
weeks NNS p
of IN p
age NN p
. . p

( ( N
2 CD N
) ) N
In IN N
addition NN N
, , N
the DT N
effect NN N
of IN N
killing VBG N
technique NN N
on IN N
apparent JJ N
ileal NN N
protein NN N
digestibility NN N
values NNS N
obtained VBN N
by IN N
a DT N
slaughter NN N
method NN N
and CC N
effect NN N
of IN N
rapeseed NN i
feeding VBG i
on IN N
size NN N
of IN N
specific JJ N
organs NNS N
were VBD N
studied VBN N
. . N

( ( N
3 CD N
) ) N
Protein NNP o
digestibility NN o
coefficients NNS o
of IN o
rapeseed NN o
products NNS o
were VBD N
mostly RB N
0.10 CD N
to TO N
0.15 CD N
units NNS N
lower JJR N
than IN N
those DT N
of IN N
soybean JJ i
products NNS i
. . i

Ileal NNP o
digestibility NN o
of IN o
protein NN o
increased VBD N
slightly RB N
or CC N
remained VBD N
unchanged JJ N
from IN N
4 CD N
to TO N
8 CD N
weeks NNS N
and CC N
decreased JJ N
thereafter NN N
. . N

No DT N
effect NN N
of IN N
feed NN N
processing NN N
method NN N
( ( N
meal JJ N
vs NNS N
cake VBP N
) ) N
on IN N
ileal NN o
digestibility NN o
was VBD N
observed VBN N
. . N

( ( N
4 CD N
) ) N
Killing VBG N
the DT N
birds NNS N
by IN N
carbon NN N
dioxide NN N
inhalation NN N
and CC N
bleeding NN N
led VBD N
to TO N
slightly RB N
lower JJR N
ileal JJ o
digestibility NN o
values NNS o
than IN N
mechanical JJ N
stunning NN N
and CC N
neck NN N
dislocation NN N
. . N

( ( N
5 CD N
) ) N
Total NNP o
tract JJ o
digestibility NN o
of IN o
protein NN o
decreased VBN N
from IN N
4 CD N
to TO N
8 CD N
weeks NNS N
of IN N
age NN N
for IN N
soybean JJ i
meal NN i
and CC N
rapeseed VB i
meal NN i
but CC N
increased VBD N
for IN N
soybean JJ i
cake NN i
and CC N
rapeseed VB i
cake NN i
. . i

From IN N
8 CD N
to TO N
12 CD N
weeks NNS N
of IN N
age NN N
total JJ o
tract JJ o
digestibility NN o
of IN o
protein NN o
decreased VBN N
for IN N
all PDT N
the DT N
products NNS N
tested VBN N
. . N

( ( N
6 CD N
) ) N
Feed NN N
containing VBG N
rapeseed NN i
led VBD N
to TO N
enlargement VB N
of IN N
thyroid JJ N
glands NNS N
and CC N
hearts NNS N
, , N
but CC N
did VBD N
not RB N
affect VB N
liver NN o
size NN o
or CC o
mortality NN o
. . o

-DOCSTART- -9428861- O O

Postoperative JJ N
analgesia NN N
by IN N
D-myo-inositol-1,2,6-trisphosphate NNP i
in IN N
patients NNS p
undergoing VBG p
cholecystectomy NN p
. . p

UNLABELLED JJ N
D-myo-inositol-1,2,6-trisphosphate NNP i
( ( i
1,2,6-IP3 CD i
) ) i
possesses VBZ N
antiinflammatory JJ N
properties NNS N
, , N
such JJ N
as IN N
reduced JJ N
eicosanoid JJ N
synthesis NN N
and CC N
inhibition NN N
of IN N
inflammation-induced JJ N
edema NN N
. . N

These DT N
properties NNS N
suggest VBP N
possible JJ N
analgesic JJ o
effects NNS o
. . o

The DT N
analgesic JJ o
effect NN o
of IN N
1,2,6-IP3 NN N
was VBD N
evaluated VBN N
in IN N
a DT N
double-blind NN N
, , N
randomized VBN N
study NN N
in IN N
24 CD p
patients NNS p
undergoing JJ p
cholecystectomy NN i
. . i

Ten CD p
patients NNS p
received VBD N
1,2,6-IP3 JJ i
as IN N
an DT N
intravenous JJ N
( ( N
i.v JJ N
. . N

) ) N
bolus IN N
dose NN N
of IN N
240 CD N
mg NN N
, , N
followed VBN N
by IN N
a DT N
continuous JJ N
i.v NN N
. . N

infusion NN N
at IN N
90 CD N
mg/h NN N
for IN N
24 CD N
h. PDT N
The DT p
placebo NN i
group NN p
( ( N
n JJ N
= NNP N
14 CD N
) ) N
received VBD N
corresponding VBG N
volumes NNS N
of IN N
isotonic JJ i
saline NN i
. . i

Postoperative JJ o
pain NN o
( ( o
visual JJ o
analog NN o
pain VBP o
scale NN o
; : o
VAS NNP o
) ) o
and CC o
opiate JJ o
analgesic JJ o
requirements NNS o
( ( o
ketobemidon NN o
) ) o
were VBD N
evaluated VBN N
during IN N
five CD N
postoperative JJ N
days NNS N
. . N

Results NNS N
showed VBD N
significantly RB N
reduced VBN N
pain NN o
during IN N
the DT N
first JJ N
five CD N
postoperative JJ N
days NNS N
in IN N
patients NNS p
treated VBN N
with IN N
1,2,6-IP3 JJ N
, , N
as IN N
measured VBN N
by IN N
using VBG N
a DT N
VAS NNP o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
requirements NNS o
of IN o
opioid JJ o
analgesics NNS o
were VBD N
significantly RB N
reduced VBN N
during IN N
the DT N
first JJ N
three CD N
postoperative JJ N
days NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

No DT N
drug-related JJ o
side NN o
effects NNS o
were VBD N
observed VBN N
. . N

Results NNS N
of IN N
the DT N
present JJ N
study NN N
demonstrate VB N
a DT N
potent NN o
and CC o
long-lasting JJ o
analgesic JJ o
effect NN o
of IN N
1,2,6-IP3 JJ N
, , N
possibly RB N
related VBN N
to TO N
its PRP$ N
antiinflammatory NN N
properties NNS N
. . N

IMPLICATIONS VB N
A DT N
new JJ N
antiinflammatory JJ N
drug NN N
under IN N
investigation NN N
, , N
inositol-1,2,6-trisphosphate JJ i
, , N
was VBD N
evaluated VBN N
as IN N
a DT N
possible JJ N
analgesic NN N
in IN N
a DT N
pilot NN N
study NN N
during IN N
the DT N
postoperative JJ N
period NN N
in IN N
cholecystectomized JJ p
patients NNS p
. . p

Results NNS N
showed VBD N
significantly RB N
lower JJR o
pain NN o
assessment NN o
and CC o
opioid JJ o
consumption NN o
, , N
which WDT N
should MD N
encourage VB N
further JJ N
studies NNS N
. . N

-DOCSTART- -21753062- O O

A DT N
high JJ N
intake NN N
of IN N
trans NNS i
fatty JJ i
acids NNS i
has VBZ N
little JJ N
effect NN N
on IN N
markers NNS o
of IN o
inflammation NN o
and CC o
oxidative JJ o
stress NN o
in IN N
humans NNS p
. . p

Consumption NN i
of IN i
industrial JJ i
trans NNS i
fatty JJ i
acids NNS i
( ( i
iTFA NN i
) ) i
increases VBZ N
LDL NNP N
cholesterol NN N
, , N
decreases VBZ N
HDL NNP N
cholesterol NN N
, , N
and CC N
is VBZ N
strongly RB N
associated VBN N
with IN N
a DT N
higher JJR N
risk NN N
of IN N
cardiovascular JJ N
disease NN N
( ( N
CVD NNP N
) ) N
. . N

However RB N
, , N
changes NNS N
in IN N
circulating VBG N
cholesterol NN N
can MD N
not RB N
explain VB N
the DT N
entire JJ N
effect NN N
. . N

Therefore RB N
, , N
we PRP N
studied VBD N
whether IN N
iTFA NN i
and CC N
conjugated VBD i
linoleic JJ i
acid NN i
( ( i
CLA NNP i
) ) i
affect VBP N
markers NNS o
of IN o
inflammation NN o
and CC o
oxidative JJ o
stress NN o
. . o

Sixty-one CD p
healthy JJ p
adults NNS p
consumed VBD p
each DT p
of IN p
3 CD p
diets NNS i
for IN p
3 CD p
wk NN p
, , N
in IN N
random JJ N
order NN N
. . N

Diets NNS N
were VBD N
identical JJ N
except IN N
for IN N
7 CD N
% NN N
of IN N
energy NN N
provided VBN N
by IN N
oleic JJ i
acid NN i
( ( i
control VB i
diet NN i
) ) i
, , i
iTFA JJ i
, , i
or CC i
CLA NNP i
. . i

At IN N
the DT N
end NN N
of IN N
the DT N
3 CD N
wk NN N
, , N
we PRP N
measured VBD N
plasma JJ o
inflammatory JJ o
markers NNS o
IL-6 NNP o
, , o
C-reactive NNP o
protein NN o
, , o
tumor NN o
necrosis NN o
factor NN o
receptors NNS o
I PRP o
and CC o
II NNP o
( ( o
TNF-RI NNP o
and CC o
-RII NNP o
) ) o
, , o
monocyte JJ o
chemotactic JJ o
protein-1 NN o
and CC o
E-selectin NNP o
, , o
and CC o
urinary JJ o
8-iso-PGF NN o
( ( o
2? CD o
) ) o
, , o
a DT o
marker NN o
of IN o
lipid JJ o
peroxidation NN o
. . o

Consumption NN N
of IN i
iTFA NN i
caused VBD N
4 CD N
% NN N
lower JJR o
TNF-RI NNP o
concentrations NNS o
and CC N
6 CD N
% NN N
higher JJR o
E-selectin JJ o
concentrations NNS o
compared VBN N
with IN N
oleic JJ N
acid NN N
( ( N
control NN N
) ) N
and CC N
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
other JJ o
inflammatory JJ o
markers NNS o
. . o

CLA NNP N
did VBD N
not RB N
significantly RB N
affect JJ o
inflammatory NN o
markers NNS o
. . o

The DT o
urine JJ o
concentration NN o
of IN o
8-iso-PGF JJ o
( ( o
2? CD o
) ) o
[ NN o
geometric JJ N
mean NN N
( ( N
95 CD N
% NN N
CI NNP N
) ) N
] NN N
was VBD N
greater JJR N
after IN N
the DT N
iTFA NN N
[ VBZ N
0.54 CD N
( ( N
0.48 CD N
, , N
0.60 CD N
) ) N
nmol/mmol FW N
creatinine NN N
] NN N
and CC N
the DT N
CLA NNP N
[ NNP N
1.2 CD N
( ( N
1.1 CD N
, , N
1.3 CD N
) ) N
nmol/mmol FW N
creatinine NN N
] NNP N
diet VBZ N
periods NNS N
than IN N
after IN N
the DT N
control NN N
period NN N
[ VBD N
0.45 CD N
( ( N
0.41 CD N
, , N
0.50 CD N
) ) N
nmol/mmol FW N
creatinine NN N
; : N
P NNP N
< VBD N
0.05 CD N
] NN N
. . N

In IN N
conclusion NN N
, , N
high JJ N
intakes NNS N
of IN N
iTFA NN i
and CC i
CLA NNP i
did VBD i
not RB N
substantially RB N
affect JJ o
plasma NN o
concentrations NNS o
of IN o
inflammatory JJ o
markers NNS o
, , o
but CC N
they PRP N
increased VBD N
the DT o
urine JJ o
8-iso-PGF JJ o
( ( o
2? CD o
) ) o
concentration NN o
. . o

However RB o
, , N
it PRP N
is VBZ N
unlikely JJ N
this DT N
plays VBZ N
a DT N
major JJ N
role NN N
in IN N
the DT N
mechanism NN N
by IN N
which WDT i
iTFA JJ i
increase NN i
the DT N
risk NN N
of IN N
CVD NNP N
. . N

However RB N
, , N
more JJR N
research NN N
is VBZ N
needed VBN N
to TO N
fully RB N
understand VB N
the DT N
implications NNS N
of IN N
these DT N
findings NNS N
. . N

-DOCSTART- -11706697- O O

Does NNP N
temporary JJ i
clamping NN i
of IN i
drains NNS i
following VBG N
knee NN N
arthroplasty JJ N
reduce VB N
blood NN N
loss NN N
? . N
A DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

In IN N
a DT N
randomised JJ N
, , N
blinded VBD N
study NN N
76 CD p
patients NNS p
undergoing JJ p
primary JJ p
total JJ p
knee NN p
arthroplasty NN p
were VBD p
assigned VBN p
to TO N
either DT N
immediate JJ i
drain NN i
opening NN i
( ( i
n JJ i
= NNP i
45 CD i
) ) i
or CC i
drains NNS i
opened VBN i
at IN i
2 CD i
h NN i
( ( N
n JJ N
= NNP N
31 CD N
) ) N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
between IN N
the DT N
groups NNS N
for IN N
the DT N
volume NN o
of IN o
drained JJ o
blood NN o
, , o
transfusion NN o
requirements NNS o
, , o
knee JJ o
motion NN o
or CC o
wound NN o
status NN o
. . o

The DT N
authors NNS N
conclude VBP N
that IN N
the DT N
practice NN N
of IN N
clamping VBG i
drains NNS i
has VBZ N
no DT N
benefit NN N
in IN N
routine JJ N
knee NN N
arthroplasty NN N
. . N

However RB N
, , N
when WRB N
faced VBN N
with IN N
immediate JJ N
brisk JJ N
blood NN o
loss NN o
, , N
the DT N
results NNS N
suggest VBP N
that IN N
drains NNS i
can MD N
be VB N
clamped VBN N
without IN N
any DT N
excess JJ N
morbidity NN o
. . o

-DOCSTART- -11888774- O O

Mediastinal JJ N
lymphadenectomy NN i
in IN N
non-small JJ p
cell NN p
lung NN p
cancer NN p
: : p
effectiveness NN N
in IN N
patients NNS p
with IN p
or CC p
without IN p
nodal JJ p
micrometastases NNS p
- : N
results NNS N
of IN N
a DT N
preliminary JJ N
study NN N
. . N

OBJECTIVES NNP N
So RB N
far RB N
it PRP N
has VBZ N
not RB N
clearly RB N
been VBN N
demonstrated VBN N
that IN N
systematic JJ N
mediastinal JJ N
lymphadenectomy NN i
improves VBZ N
survival JJ o
in IN N
patients NNS p
with IN p
non-small JJ p
cell NN p
lung NN p
cancer NN p
. . p

One CD N
explanation NN N
might MD N
be VB N
that IN N
in IN N
some DT N
patients NNS N
an DT N
early JJ N
spread NN N
of IN N
tumor NN N
cells NNS N
has VBZ N
occurred VBN N
which WDT N
might MD N
not RB N
be VB N
curable JJ N
by IN N
surgical JJ N
means NNS N
. . N

To TO N
test VB N
this DT N
hypothesis NN N
lymph VBZ N
nodes NNS N
of IN N
patients NNS N
which WDT N
were VBD N
treated VBN N
either RB N
by IN N
lymph NN i
node NN i
sampling VBG i
or CC N
systematic JJ i
lymphadenectomy NN i
were VBD N
screened VBN N
for IN N
micrometastatic JJ N
spread NN N
of IN N
tumor NN N
cells NNS N
and CC N
the DT N
influence NN N
of IN N
nodal JJ N
micrometastases NNS N
on IN N
the DT N
efficacy NN N
of IN N
lymphadenectomy NN i
was VBD N
analyzed VBN N
. . N

METHODS NNP N
Lymph NNP p
nodes NNS p
from IN p
patients NNS p
( ( p
n=94 NN p
) ) p
which WDT N
were VBD N
included VBN N
in IN N
a DT N
randomized JJ N
trial NN N
of IN N
lymph NN i
node NN i
sampling NN i
( ( i
LS NNP i
, , N
n=41 NN N
) ) N
versus NN N
radical JJ i
systematic JJ i
lymphadenectomy NN i
( ( i
LA NNP i
, , N
n=53 RB N
) ) N
were VBD N
screened VBN N
by IN N
immunohistochemistry NN N
for IN N
disseminated JJ N
tumor NN N
cells NNS N
using VBG N
the DT N
antibody NN N
Ber-Ep4 NNP N
. . N

The DT N
median JJ o
observation NN o
time NN o
was VBD N
longer JJR N
than IN N
5 CD N
years NNS N
and CC N
follow-up JJ N
data NNS N
were VBD N
available JJ N
from IN N
all DT N
94 CD N
patients NNS N
. . N

Kaplan-Meier NNP o
curves NNS o
were VBD N
calculated VBN N
and CC N
tested VBN N
for IN N
statistical JJ N
significance NN N
using VBG N
the DT N
log-rank JJ N
test NN N
. . N

RESULTS NNP N
Standard NNP N
histopathological JJ N
analysis NN N
revealed VBD N
no DT o
lymph NN o
node RB o
involvement NN o
( ( N
pN0 NN N
) ) N
in IN N
61 CD N
patients NNS N
, , N
pN1 JJ N
disease NN N
in IN N
13 CD N
patients NNS N
and CC N
pN2 JJ N
disease NN N
in IN N
20 CD N
patients NNS N
without IN N
significant JJ N
differences NNS N
between IN N
LA NNP N
and CC N
LS NNP N
with IN N
respect NN N
to TO N
T-stage NN N
, , N
N-stage NN N
or CC N
age NN N
and CC N
sex NN N
of IN N
the DT N
patients NNS N
. . N

By IN N
immunohistochemistry NN N
a DT N
minimal JJ N
nodal JJ o
spread NN o
of IN o
tumor NN o
cells NNS o
was VBD N
detected VBN N
in IN N
21 CD N
out IN N
of IN N
94 CD N
patients NNS N
( ( N
LS NNP N
, , N
n=10 NN N
( ( N
24 CD N
% NN N
) ) N
; : N
LA NNP N
, , N
n=11 NN N
( ( N
21 CD N
% NN N
) ) N
) ) N
. . N

Similar JJ N
to TO N
the DT N
entire JJ N
group NN N
of IN N
patients NNS N
also RB N
in IN N
the DT N
subset NN N
of IN N
patients NNS N
with IN N
nodal JJ N
micrometastases VBZ N
the DT N
type NN N
of IN N
lymphadenectomy NN N
did VBD N
not RB N
significantly RB N
influence VB N
the DT N
long-term JJ o
survival NN o
( ( N
P=0.27 NNP N
and CC N
P=0.39 NNP N
, , N
respectively RB N
) ) N
. . N

In IN N
contrast NN N
, , N
in IN N
patients NNS N
with IN N
a DT N
negative JJ N
immunohistochemical JJ N
analysis NN N
systematic JJ N
lymphadenectomy NN i
resulted VBD N
in IN N
an DT N
improved JJ o
overall JJ o
survival NN o
( ( N
P=0.044 NNP N
) ) N
. . N

CONCLUSIONS VB N
Our PRP$ N
data NNS N
provide VB N
some DT N
evidence NN N
that IN N
systematic JJ i
lymphadenectomy NN i
improves VBZ N
survival JJ o
in IN N
patients NNS p
without IN p
an DT p
early JJ p
locoregional JJ o
spread NN o
of IN o
cancer NN o
cells NNS o
. . o

As RB N
long RB N
as IN N
these DT N
patients NNS N
can MD N
not RB N
be VB N
identified VBN N
preoperatively RB N
all DT N
patients NNS N
should MD N
undergo VB N
a DT N
systematic JJ N
mediastinal JJ N
lymphadenectomy NN i
. . i

-DOCSTART- -2183734- O O

Treatment NN p
of IN p
renal JJ o
failure NN o
associated VBN p
with IN p
multiple JJ p
myeloma NN p
. . p

Plasmapheresis NN N
, , N
hemodialysis NN N
, , N
and CC N
chemotherapy NN N
. . N

The DT N
aims NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
examine VB N
in IN N
a DT N
prospective JJ N
, , N
randomized JJ N
trial NN N
the DT N
efficacy NN N
of IN N
plasmapheresis NN N
in IN N
preventing VBG N
irreversible JJ o
renal JJ o
failure NN o
in IN N
patients NNS p
with IN p
multiple JJ p
myeloma NN p
and CC N
to TO N
study VB N
the DT N
renal JJ N
biopsy NN N
tissues NNS N
from IN N
such JJ N
patients NNS N
. . N

Twenty-one CD p
patients NNS p
with IN p
active JJ p
myeloma NN p
and CC p
progressive JJ p
renal JJ p
failure NN p
were VBD N
randomized VBN i
to TO i
one CD i
of IN i
two CD i
groups NNS i
: : i
group NN i
1 CD i
, , i
forced VBN i
diuresis NN i
and CC i
chemotherapy NN i
( ( i
10 CD i
patients NNS i
) ) i
, , i
and CC i
group NN i
2 CD i
, , i
forced VBN i
diuresis NN i
, , i
chemotherapy NN i
, , i
and CC i
plasmapheresis NN i
( ( i
11 CD i
patients NNS i
) ) i
. . i

Plasmapheresis NN N
and CC N
chemotherapy NN N
lowered VBD N
the DT N
serum NN o
myeloma NN o
protein IN o
value NN o
much RB N
more RBR N
rapidly RB N
than IN N
chemotherapy VB N
alone JJ N
. . N

Of IN p
5 CD p
patients NNS p
who WP p
were VBD p
oliguric JJ p
and CC p
undergoing JJ p
dialysis NN p
at IN p
presentation NN p
, , N
only RB N
3 CD N
who WP N
were VBD N
treated VBN N
by IN N
plasmapheresis NN N
recovered VBN N
. . N

Of IN p
16 CD p
polyuric JJ p
patients NNS p
, , N
5 CD N
in IN N
group NN N
1 CD N
and CC N
7 CD N
in IN N
group NN N
2 CD N
showed VBD N
improvement NN N
in IN N
renal JJ o
function NN o
. . o

The DT N
main JJ N
factor NN N
that WDT N
determined VBD N
irreversibility NN N
of IN N
renal JJ N
failure NN N
was VBD N
the DT N
severity NN N
of IN N
myeloma NN N
cast NN N
formation NN N
. . N

-DOCSTART- -9512674- O O

Efficacy NN N
of IN N
intravenous JJ N
granisetron NN i
to TO N
control VB N
nausea NN N
and CC N
vomiting VBG N
during IN N
multiple JJ N
cycles NNS N
of IN N
cisplatin-based JJ i
chemotherapy NN i
. . i

The DT N
safety NN N
and CC N
efficacy NN N
of IN N
granisetron NN i
( ( N
10 CD N
micrograms/kg NN N
and CC N
40 CD N
micrograms/kg NN N
) ) N
were VBD N
evaluated VBN N
during IN N
a DT N
second JJ N
( ( N
n JJ N
= NNP N
393 CD N
) ) N
and CC N
third JJ N
( ( N
n JJ N
= NNP N
200 CD N
) ) N
cycle NN N
of IN N
chemotherapy NN N
in IN N
this DT N
multicenter NN p
, , p
double-blind NN p
, , p
randomized VBN p
, , p
parallel-group JJ p
study NN p
. . p

Granisetron NNP i
was VBD N
administered VBN N
as IN N
a DT N
single JJ N
intravenous JJ N
dose NN N
before IN N
the DT N
start NN N
of IN N
cisplatin NN i
chemotherapy NN i
( ( p
> CD p
or CC p
= VB p
60 CD p
mg/m2 NN p
) ) p
. . p

Total JJ o
control NN o
( ( o
no DT o
vomiting NN o
, , o
no DT o
retching NN o
, , o
no DT o
nausea NN o
, , o
and CC o
no DT o
use NN o
of IN o
antiemetic JJ o
rescue NN o
medication NN o
) ) o
after IN o
the DT o
first JJ o
24 CD o
hr NN o
following VBG N
chemotherapy NN i
was VBD N
achieved VBN N
in IN N
40 CD p
% NN p
and CC p
49 CD p
% NN p
of IN p
patients NNS p
in IN p
Cycles NNP p
2 CD p
and CC p
3 CD p
, , p
respectively RB p
, , p
for IN p
the DT p
10 CD p
micrograms/kg NN p
group NN p
, , p
and CC p
in IN p
42 CD p
% NN p
and CC p
38 CD p
% NN p
of IN p
patients NNS p
in IN p
Cycles NNP p
2 CD p
and CC p
3 CD p
, , p
respectively RB p
, , p
for IN p
the DT p
40 CD p
micrograms/kg NN p
group NN p
. . p

Both DT N
dose JJ o
levels NNS o
of IN o
granisetron NN o
were VBD N
well RB N
tolerated VBN o
. . o

The DT N
results NNS N
demonstrate VBP N
comparable JJ N
efficacy NN N
between IN N
the DT N
10 CD N
micrograms/kg NN N
and CC N
40 CD N
micrograms/kg NN N
doses NNS N
of IN N
granisetron NN i
in IN N
preventing VBG N
nausea NN o
and CC o
vomiting VBG o
during IN N
repeat NN N
cycles NNS N
of IN N
high-dose JJ p
cisplatin-based JJ i
chemotherapy NN i
. . i

The DT N
results NNS N
of IN N
this DT N
study NN N
show NN N
that IN N
granisetron VBZ i
10 CD N
micrograms/kg NN N
is VBZ N
safe JJ N
and CC N
well RB N
tolerated VBN N
, , N
and CC N
remains VBZ N
effective JJ N
with IN N
repeat NN N
cycle NN N
use NN N
. . N

-DOCSTART- -19019444- O O

Visual JJ N
field NN N
progression NN N
in IN N
the DT N
Collaborative NNP p
Initial NNP p
Glaucoma NNP p
Treatment NNP p
Study NNP p
the DT N
impact NN N
of IN N
treatment NN N
and CC N
other JJ N
baseline NN N
factors NNS N
. . N

PURPOSE NNP N
To TO N
evaluate VB N
factors NNS N
associated VBN N
with IN N
visual JJ o
field NN o
( ( o
VF NNP o
) ) o
progression NN o
, , N
using VBG N
all DT N
available JJ N
follow-up NNS N
through IN N
9 CD N
years NNS N
after IN N
treatment NN N
initiation NN N
, , N
in IN N
the DT N
Collaborative NNP N
Initial NNP N
Glaucoma NNP N
Treatment NNP N
Study NNP N
( ( N
CIGTS NNP N
) ) N
. . N

DESIGN NNP N
Longitudinal NNP N
follow-up NN N
of IN N
participants NNS N
enrolled VBN N
in IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

PARTICIPANTS NNP N
Six NNP p
hundred VBD p
seven CD p
newly RB p
diagnosed VBN p
glaucoma NN p
patients NNS p
. . p

METHODS NNP N
In IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
, , N
607 CD p
subjects NNS p
with IN p
newly RB p
diagnosed VBN p
open-angle JJ p
glaucoma NN p
initially RB N
were VBD N
treated VBN i
with IN i
either DT i
medication NN i
or CC i
trabeculectomy NN i
. . i

After IN N
treatment NN N
initiation NN N
and CC N
early JJ N
follow-up NN N
, , N
subjects NNS N
were VBD N
evaluated VBN N
clinically RB N
at IN N
6-month JJ N
intervals NNS N
. . N

Study NNP N
participants NNS N
in IN N
both DT N
arms NNS N
of IN N
the DT N
CIGTS NNP N
were VBD N
treated VBN i
aggressively RB i
in IN i
an DT i
effort NN i
to TO i
reduce VB o
intraocular JJ o
pressure NN o
( ( o
IOP NNP o
) ) o
to TO i
a DT i
level NN i
at IN i
or CC i
below IN i
a DT i
predetermined JJ i
, , i
eye-specific JJ i
target NN i
pressure NN i
. . i

Visual JJ i
field NN i
progression NN i
was VBD i
analyzed VBN i
using VBG i
repeated JJ i
measures NNS i
models NNS i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Visual NNP o
field NN o
progression NN o
, , o
measured VBN o
by IN o
Humphrey NNP o
24-2 JJ o
full-threshold JJ o
testing NN o
and CC o
assessed VBN o
by IN o
the DT o
change NN o
in IN o
the DT o
mean JJ o
deviation NN o
( ( o
MD NNP o
) ) o
, , N
and CC N
an DT o
indicator NN o
of IN o
substantial JJ o
worsening NN o
of IN o
the DT o
VF NNP o
( ( N
MD NNP N
decrease NN N
of IN N
> NN N
or CC N
=3 JJ N
dB NN N
from IN N
baseline NN N
) ) N
, , N
assessed VBN N
at IN N
each DT N
follow-up JJ N
visit NN N
. . N

RESULTS NNP N
Follow-up NNP N
indicated VBD N
minimal JJ N
change NN N
from IN N
baseline NN N
in IN N
each DT N
initial JJ N
treatment NN N
group NN N
's POS N
average JJ N
MD NNP o
. . o

However RB N
, , N
at IN N
the DT N
8-year JJ N
follow-up JJ N
examination NN N
, , N
substantial JJ N
worsening NN o
( ( o
> CD o
or CC o
=3 VB o
dB NN o
) ) o
of IN o
MD NNP o
from IN o
baseline NN o
was VBD N
found VBN N
in IN N
21.3 CD N
% NN N
and CC N
25.5 CD N
% NN N
of IN N
the DT N
initial JJ N
surgery NN N
and CC N
initial JJ N
medicine NN N
groups NNS N
, , N
respectively RB N
. . N

The DT N
effect NN N
of IN N
initial JJ N
treatment NN N
on IN N
subsequent JJ N
VF NNP o
loss NN o
was VBD N
modified VBN N
by IN N
time NN N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
baseline JJ N
MD NNP N
( ( N
P NNP N
= NNP N
0.03 CD N
) ) N
, , N
and CC N
diabetes NNS N
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
. . N

Initial JJ i
surgery NN i
led VBD N
to TO N
less RBR N
VF NNP o
progression NN o
than IN N
initial JJ i
medicine NN i
in IN N
subjects NNS p
with IN p
advanced JJ p
VF NNP p
loss NN p
at IN p
baseline NN p
, , N
whereas JJ N
subjects NNS p
with IN p
diabetes NNS p
had VBD N
more RBR N
VF JJ o
loss NN o
over IN N
time NN N
if IN N
treated VBN N
initially RB N
with IN N
surgery NN N
. . N

CONCLUSIONS VB N
The DT N
CIGTS NNP N
intervention NN N
protocol NN N
led VBD N
to TO N
a DT N
lowering NN o
of IN o
IOP NNP o
that WDT N
persisted VBD N
over IN N
time NN N
in IN N
both DT N
treatment NN N
groups NNS N
. . N

Progression NN N
in IN N
VF NNP N
loss NN N
was VBD N
seen VBN N
in IN N
a DT N
subset NN N
, , N
increasing VBG N
to TO N
more JJR N
than IN N
20 CD N
% NN N
of IN N
the DT N
subjects NNS N
. . N

The DT N
findings NNS N
regarding VBG N
initial JJ N
surgery NN N
being VBG N
beneficial JJ N
for IN N
subjects NNS p
with IN p
more RBR p
advanced JJ p
VF NNP o
loss NN o
at IN p
presentation NN p
, , N
but CC N
detrimental JJ N
for IN N
patients NNS p
with IN p
diabetes NNS p
, , N
are VBP N
noteworthy JJ N
and CC N
warrant JJ N
independent JJ N
confirmation NN N
. . N

FINANCIAL NNP N
DISCLOSURE NNP N
( ( N
S NNP N
) ) N
The DT N
author NN N
( ( N
s PRP N
) ) N
have VBP N
no DT N
proprietary JJ N
or CC N
commercial JJ N
interest NN N
in IN N
any DT N
materials NNS N
discussed VBN N
in IN N
this DT N
article NN N
. . N

-DOCSTART- -10619912- O O

Gastric JJ p
carcinoma NN p
: : p
expression NN o
of IN o
c-erbB-2/neu JJ o
oncoprotein NN o
, , o
epidermal JJ o
growth NN o
factor NN o
receptor NN o
, , o
cathepsin NN o
D NNP o
, , o
progesterone NN o
receptor NN o
and CC o
tumor NN o
associated VBN o
glycoprotein-72 JJ o
in IN N
different JJ N
histological JJ N
types NNS N
. . N

OBJECTIVE NNP N
Gastric NNP p
carcinoma NN p
can MD N
be VB N
divided VBN N
into IN N
two CD N
main JJ N
histological JJ N
and CC N
clinical JJ N
types NNS N
: : N
diffuse NN p
and CC p
intestinal JJ p
. . p

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
expression NN o
of IN o
neu/c-erbB-2 JJ o
oncoprotein NN o
, , o
epidermal JJ o
growth NN o
factor NN o
receptor NN o
( ( o
EGFR NNP o
) ) o
, , o
cathepsin JJ o
D NNP o
( ( o
catD NN o
) ) o
, , o
progesterone JJ o
receptor NN o
( ( o
PR NNP o
) ) o
and CC o
tumor-associated JJ o
glycoprotein-72 NN o
( ( o
TAG-72 NNP o
) ) o
in IN N
gastric JJ N
carcinoma NN N
of IN N
these DT N
histological JJ N
types NNS N
. . N

METHOD NN N
In IN N
this DT N
randomized VBN N
, , N
prospective JJ N
study NN N
we PRP N
analyzed VBD N
85 CD p
biopsy NN i
samples NNS i
from IN p
patients NNS p
with IN p
gastric JJ p
adenocarcinoma NN p
. . p

The DT N
control NN p
group NN p
consisted VBD p
of IN p
40 CD p
specimens NNS p
from IN p
normal JJ i
gastric JJ i
mucosa NN i
. . i

Neu NNP o
oncoprotein NN o
and CC o
PR NNP o
were VBD N
determined VBN N
by IN N
ELISA NNP o
. . o

CatD NNP o
and CC o
TAG-72 NNP o
were VBD N
quantified VBN N
with IN N
immunoradiometric JJ o
( ( o
IRMA NNP o
) ) o
methods NNS o
, , N
and CC N
EGFR NNP o
were VBD o
studied VBN o
by IN o
radioimmunoassay NN o
( ( o
RIA NNP o
) ) o
. . o

RESULTS NNP N
Neu NNP o
, , o
EGFR NNP o
, , o
catD NN o
and CC o
TAG-72 JJ o
concentrations NNS o
were VBD N
higher JJR N
in IN N
the DT N
tumoral JJ N
group NN N
( ( N
p JJ N
= NN N
0.02 CD N
, , N
p NN N
= VBD N
0.00001 CD N
, , N
p NN N
= VBD N
0.002 CD N
and CC N
p VB N
= JJ N
0.007 CD N
, , N
respectively RB N
) ) N
. . N

In IN N
diffuse NN N
adenocarcinomas NN N
, , N
catD NN o
and CC o
PR NNP o
expression NN o
was VBD N
increased VBN N
( ( N
p JJ N
= NN N
0.01 CD N
and CC N
p VB N
= JJ N
0.04 CD N
respectively RB N
) ) N
, , N
whereas JJ N
TAG-72 NNP o
concentration NN o
, , N
which WDT N
correlated VBD N
with IN N
neu NN o
( ( N
r JJ N
= NNP N
0.57 CD N
) ) N
, , N
was VBD N
higher RBR N
in IN N
the DT N
intestinal JJ N
type NN N
( ( N
p JJ N
= NNP N
0.04 CD N
) ) N
. . N

No DT N
significant JJ N
differences NNS N
in IN N
EGFR NNP o
and CC o
neu JJ o
concentrations NNS o
were VBD N
seen VBN N
between IN N
the DT N
two CD N
histological JJ N
types NNS N
. . N

CONCLUSIONS VB N
The DT N
higher JJR N
PR NNP o
and CC o
catD JJ o
concentrations NNS o
in IN N
diffuse NN N
adenocarcinomas NN N
, , N
and CC N
the DT N
overexpression NN N
of IN N
TAG-72 NNP o
in IN N
the DT N
intestinal JJ N
type NN N
, , N
support VB N
the DT N
existence NN N
of IN N
two CD N
modes NNS N
of IN N
gastric JJ N
carcinogenesis NN N
. . N

-DOCSTART- -3550340- O O

The DT N
effects NNS N
of IN N
delay NN N
in IN N
standard JJ N
treatment NN N
due JJ N
to TO N
induction VB N
chemotherapy NN N
in IN N
two CD N
randomized JJ N
prospective JJ N
studies NNS N
. . N

It PRP N
is VBZ N
often RB N
suggested VBN N
that IN N
tumors NNS N
will MD N
respond VB N
to TO N
induction VB i
chemotherapy NN i
and CC N
result NN N
in IN N
improved JJ N
survival NN o
for IN N
patients NNS p
with IN p
squamous JJ p
cell NN p
carcinoma NN p
of IN p
the DT p
head NN p
and CC p
neck NN p
. . p

Two CD N
regimens NNS N
of IN N
induction NN N
chemotherapy NN N
were VBD N
studied VBN N
in IN N
separate JJ N
randomized VBN N
, , N
prospective JJ N
trials NNS N
over IN N
the DT N
last JJ N
6 CD N
years NNS N
. . N

Eighty-three JJ p
patients NNS p
with IN p
advanced JJ p
disease NN p
were VBD p
entered VBN p
into IN p
the DT p
first JJ p
study NN p
( ( p
43/chemotherapy CD p
; : p
40/control CD p
) ) p
, , p
and CC p
60 CD p
into IN p
the DT p
second JJ p
( ( N
27/chemotherapy CD N
; : N
33/control CD N
) ) N
. . N

Patient JJ p
randomization NN p
was VBD p
stratified VBN p
by IN p
stage NN p
( ( p
III/IV NNP p
) ) p
and CC p
site NN p
( ( N
oral JJ N
cavity NN N
, , N
oropharynx NN N
, , N
nasopharynx RB N
, , N
hypopharynx NN N
, , N
larynx NN N
, , N
paranasal NN N
sinuses NNS N
) ) N
. . N

The DT N
first JJ N
study NN N
utilized JJ i
bleomycin NN i
, , i
Cytoxan NNP i
, , i
methotrexate NN i
and CC i
5-fluorouracil JJ i
in IN i
two CD i
cycles NNS i
( ( i
one CD i
cycle NN i
if IN i
no DT i
tumor NN i
response NN i
) ) i
, , i
followed VBN i
by IN i
standard NN i
treatment NN i
which WDT i
consisted VBD i
of IN i
combined JJ i
irradiation NN i
and CC i
surgery NN i
or CC i
, , i
in IN i
some DT i
instances NNS i
, , i
primary JJ i
irradiation NN i
alone RB i
. . i

The DT i
second JJ i
study NN i
utilized VBD i
cisplatin NN i
and CC i
5-fluorouracil NN i
in IN i
three CD i
cycles NNS i
prior RB i
to TO i
standard VB i
treatment NN i
. . i

An DT N
objective JJ o
tumor NN o
response NN o
to TO N
chemotherapy NN N
was VBD N
observed VBN N
in IN N
68 CD N
% NN N
in IN N
the DT N
first JJ N
study NN N
and CC N
85 CD N
% NN N
in IN N
the DT N
second JJ N
. . N

The DT N
patient NN o
survival NN o
in IN N
both DT N
studies NNS N
( ( N
at IN N
24 CD N
months NNS N
in IN N
the DT N
first JJ N
; : N
at IN N
19 CD N
in IN N
the DT N
second JJ N
) ) N
was VBD N
better RBR N
in IN N
the DT N
control NN N
than IN N
that DT N
in IN N
the DT N
experimental JJ N
groups NNS N
( ( N
43 CD N
% NN N
to TO N
31 CD N
% NN N
; : N
69 CD N
% NN N
to TO N
46 CD N
% NN N
) ) N
. . N

In IN N
the DT N
second JJ N
study NN N
, , N
the DT N
average JJ o
length NN o
of IN o
delay NN o
of IN o
standard JJ o
treatment NN o
was VBD N
longer JJR N
than IN N
in IN N
the DT N
first JJ N
study NN N
( ( N
95 CD N
days NNS N
vs. FW N
66 CD N
days NNS N
; : N
P NNP N
less JJR N
than IN N
.02 NN N
) ) N
. . N

Results CC N
combining VBG N
the DT N
P-values NNS N
of IN N
both DT N
studies NNS N
indicate VBP N
that IN N
the DT N
relative JJ N
risk NN N
of IN N
having VBG N
persistent JJ N
disease NN N
was VBD N
2.9 CD N
times NNS N
greater JJR N
for IN N
patients NNS N
who WP N
received VBD N
chemotherapy NN N
. . N

While IN N
toxicity NN o
to TO o
chemotherapy VB o
was VBD N
not RB N
a DT N
factor NN N
in IN N
survival NN N
, , N
the DT N
number NN N
of IN N
patients NNS N
who WP N
withdrew VBP N
from IN N
the DT N
studies NNS N
and CC N
those DT N
who WP N
did VBD N
not RB N
comply VB N
with IN N
treatment NN N
were VBD N
greater JJR N
in IN N
the DT N
chemotherapy NN N
groups NNS N
. . N

Except IN N
for IN N
new JJ N
drug NN N
regimens NNS N
of IN N
exceptional JJ N
promise NN N
, , N
it PRP N
is VBZ N
recommended VBN N
that IN N
future JJ N
studies NNS N
be VB N
designed VBN N
so RB N
that IN N
chemotherapy NN N
is VBZ N
given VBN N
concurrent NN N
with IN N
, , N
or CC N
following VBG N
the DT N
completion NN N
of IN N
standard JJ N
treatment NN N
. . N

-DOCSTART- -18701020- O O

Beneficial JJ o
effects NNS o
of IN N
a DT N
diabetes NN i
specific JJ i
formula NN i
on IN N
insulin NN o
sensitivity NN o
and CC o
free JJ o
fatty NN o
acid NN o
in IN N
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
mellitus RB p
. . p

BACKGROUND VB N
This DT N
prospective JJ N
, , N
randomized VBN N
, , N
controlled VBD N
study NN N
was VBD N
designed VBN N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
a DT N
diabetes NN i
specific JJ i
formula NN i
( ( i
Diason NNP i
low JJ i
energy NN i
: : i
313.8 CD i
kJ/100 NNS i
ml NN i
) ) i
, , i
compared VBN i
with IN i
a DT i
standard JJ i
formula NN i
, , N
on IN N
insulin NN o
sensitivity NN o
, , o
serum JJ o
C NNP o
peptide NN o
, , o
serum JJ o
lipids NNS o
and CC o
free JJ o
fatty NN o
acid NN o
( ( o
FFA NNP o
) ) o
in IN N
type NN p
2 CD p
diabetics NNS p
. . p

METHODS NNP N
In IN N
total NN N
of IN N
71 CD p
type NN p
2 CD p
diabetics NNS p
completed VBD p
the DT p
study NN p
. . p

Enteral NNP i
formulas NNS i
were VBD i
given VBN i
orally RB i
as IN i
the DT i
sole JJ i
source NN i
of IN i
nutrition NN i
to TO i
the DT i
subjects NNS i
for IN i
6 CD i
days NNS i
. . i

Venous JJ N
blood NN N
samples NNS N
( ( N
0.5 CD N
, , N
1 CD N
, , N
2 CD N
, , N
3 CD N
hours NNS N
) ) N
were VBD N
collected VBN N
at IN N
day-7 NN N
after IN N
a DT N
75 CD N
g JJ N
oral JJ N
glucose JJ N
tolerance NN N
test NN N
( ( N
OGTT NNP N
) ) N
, , N
day NN N
1 CD N
after IN N
a DT N
standard JJ N
test NN N
meal NN N
( ( N
1673.6 CD N
kJ NN N
) ) N
and CC N
after IN N
6 CD N
days NNS N
of IN N
either CC N
the DT N
test NN N
diabetes VBZ i
specific JJ i
formula NN i
or CC N
a DT N
standard JJ i
formula NN i
. . i

Plasma NNP o
glucose NN o
, , o
serum JJ o
insulin NN o
, , o
C NNP o
peptide NN o
and CC o
lipids NNS o
were VBD N
measured VBN N
. . N

RESULTS NNP N
After IN N
the DT N
intervention NN N
period NN N
, , N
the DT N
diabetes NNS i
specific JJ i
formula NN i
resulted VBD N
in IN N
a DT N
significantly RB N
lower JJR N
postprandial JJ o
rise NN o
in IN o
blood NN o
glucose JJ o
concentrations NNS o
at IN N
0.5 CD N
hour NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
1 CD N
hour NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
; : N
significantly RB N
lower JJR N
peak JJ o
height NN o
of IN o
plasma NN o
glucose NN o
( ( N
P NNP N
= NNP N
0.05 CD N
) ) N
; : N
significantly RB N
lower JJR N
plasma NN o
insulin NN o
concentrations NNS o
at IN N
0.5 CD N
hour NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
1 CD N
hour NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
2 CD N
hours NNS N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
; : N
and CC N
a DT N
significantly RB N
lower JJR N
plasma NN o
insulin NN o
peak NN o
compared VBN N
to TO N
controls NNS N
; : N
both DT N
OGTT NNP N
and CC N
a DT N
standard JJ N
test NN N
meal NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
glucose NN o
and CC o
insulin JJ o
area NN N
under IN N
the DT N
curve NN N
after IN N
the DT N
diabetes NNS i
specific JJ i
formula NN i
compared VBN N
to TO N
the DT N
standard JJ i
formula NN i
were VBD N
significantly RB N
lower JJR N
. . N

The DT N
C NNP o
peptide NN o
level NN o
was VBD N
lower JJR N
after IN N
6 CD N
days NNS N
of IN N
both DT N
nutrition NN i
formulas NNS i
compare VBP N
to TO N
75 CD N
g NN N
OGTT NNP N
, , N
but CC N
not RB N
different JJ N
from IN N
the DT N
standard NN i
mixed JJ i
meal NN i
. . i

Both DT N
formulas NNS N
were VBD N
well RB N
tolerated VBN N
. . N

CONCLUSIONS NNP N
In IN N
summary JJ N
the DT N
diabetes NNS i
specific JJ i
formula NN i
with IN N
a DT N
relatively RB N
high JJ N
monounsaturated VBN N
fatty JJ N
acid NN N
and CC N
high JJ N
multi NN N
fiber NN N
proportion NN N
significantly RB N
improved VBN N
glycemic JJ o
control NN o
. . o

On IN N
top NN N
of IN N
this DT N
, , N
the DT N
insulin NN o
sensitivity NN o
( ( o
HOMA-IS NNP o
) ) o
was VBD N
significantly RB N
improved VBN N
and CC N
may MD N
therefore VB N
directly RB N
improve VB N
the DT N
impact NN N
on IN N
long JJ N
term NN N
complications NNS N
. . N

The DT N
disease NN i
specific JJ i
formula NN i
should MD N
therefore RB N
be VB N
the DT N
preferred JJ N
option NN N
to TO N
be VB N
used VBN N
by IN N
diabetic JJ p
and CC p
hyperglycemic JJ p
patients NNS p
in IN p
need NN p
of IN p
nutritional JJ p
support NN p
. . p

-DOCSTART- -25101527- O O

The DT N
effect NN N
of IN N
implementing VBG N
the DT N
Outcome NNP i
Questionnaire-45.2 NNP i
feedback NN N
system NN N
in IN N
Norway NNP p
: : p
A DT N
multisite JJ p
randomized JJ N
clinical JJ N
trial NN N
in IN N
a DT N
naturalistic JJ N
setting NN N
. . N

It PRP N
has VBZ N
been VBN N
claimed VBN N
that IN N
the DT N
monitoring NN N
of IN N
ongoing VBG N
psychotherapy NN N
is VBZ N
of IN N
crucial JJ N
importance NN N
for IN N
improving VBG N
the DT N
quality NN N
of IN N
mental JJ N
health NN N
care NN N
. . N

This DT N
study NN N
investigated VBD N
the DT N
effect NN N
of IN N
using VBG N
the DT N
Norwegian JJ N
version NN N
of IN N
the DT N
patient NN N
feedback NN N
system NN N
OQ-Analyst NNP N
using VBG N
the DT N
Outcome NNP i
Questionnaire-45.2 NNP i
. . i

Patients NNS p
from IN p
six CD p
psychiatric JJ p
clinics NNS p
in IN p
Southern NNP p
Norway NNP p
( ( p
N NNP p
= NNP p
259 CD p
) ) p
were VBD N
randomized VBN N
to TO N
feedback VB i
( ( i
FB NNP i
) ) i
or CC N
no DT i
feedback NN i
( ( i
NFB NNP i
) ) i
. . i

The DT N
main JJ o
effect NN o
of IN o
feedback NN o
was VBD N
statistical JJ o
significant JJ o
( ( N
p JJ N
= NNP N
.027 NNP N
) ) N
, , N
corroborating VBG N
the DT N
hypothesis NN N
that WDT N
feedback NN i
would MD N
improve VB o
the DT o
quality NN o
of IN o
services NNS o
, , N
although IN N
the DT N
size NN o
of IN o
the DT o
effect NN o
was VBD N
small JJ o
to TO o
moderate VB o
( ( N
d VB N
= RB N
0.32 CD N
) ) N
. . N

The DT N
benefits NNS N
of IN N
feedback NN i
have VBP N
to TO N
be VB N
considered VBN N
against IN N
the DT N
costs NNS o
of IN o
implementation NN o
. . o

-DOCSTART- -19109835- O O

Two CD N
different JJ N
methods NNS N
for IN N
donor JJ p
hepatic JJ p
transection NN p
: : p
cavitron NN i
ultrasonic JJ i
surgical JJ i
aspirator NN i
with IN i
bipolar JJ i
cautery NN i
versus NN N
cavitron NN i
ultrasonic JJ i
surgical JJ i
aspirator NN i
with IN i
radiofrequency NN i
coagulator-A JJ i
randomized VBN N
controlled JJ N
trial NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
Cavitron NNP i
ultrasonic JJ i
surgical JJ i
aspirator NN i
( ( i
CUSA NNP i
) ) i
with IN i
bipolar JJ i
cautery NN i
( ( i
BP NNP i
) ) i
to TO i
CUSA NNP i
with IN i
a DT i
radiofrequency NN i
coagulator NN i
[ NN N
TissueLink NNP N
( ( N
TL NNP N
) ) N
] VBP N
in IN N
terms NNS N
of IN N
efficacy NN N
and CC N
safety NN N
for IN N
hepatic JJ N
transection NN N
in IN N
living VBG N
donor NN N
liver JJ N
transplantation NN N
. . N

Twenty-four CD p
living NN p
liver NN p
donors NNS p
( ( p
n JJ p
= VBP p
12 CD p
for IN p
each DT p
group NN p
) ) p
were VBD N
randomized VBN N
to TO N
undergo VB N
hepatic JJ N
transection NN N
using VBG N
CUSA NNP i
with IN i
BP NNP i
or CC N
CUSA NNP i
with IN i
TL NNP i
. . i

Blood NNP o
loss NN o
during IN o
parenchymal JJ o
transection NN o
and CC o
speed NN o
of IN o
transection NN o
were VBD N
the DT N
primary JJ N
endpoints NNS N
, , N
whereas IN N
the DT N
degree NN o
of IN o
postoperative JJ o
liver JJ o
injury NN o
and CC o
morbidity NN o
were VBD N
secondary JJ N
endpoints NNS N
. . N

Median JJ o
blood NN o
loss NN o
during IN o
liver JJ o
transection NN o
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
TL NNP N
group NN N
than IN N
in IN N
the DT N
BP NNP N
group NN N
( ( N
195.2 CD N
+/- JJ N
84.5 CD N
versus NN N
343.3 CD N
+/- JJ N
198.4 CD N
mL NN N
; : N
P NNP N
= NNP N
0.023 CD N
) ) N
, , N
and CC N
liver JJS o
transection NN o
was VBD N
significantly RB N
faster RBR N
in IN N
the DT N
TL NNP N
group NN N
than IN N
in IN N
the DT N
BP NNP N
group NN N
( ( N
0.7 CD N
+/- JJ N
0.2 CD N
versus NN N
0.5 CD N
+/- JJ N
0.2 CD N
cm NN N
( ( N
2 CD N
) ) N
/minute NN N
; : N
P NNP N
= NNP N
0.048 CD N
) ) N
. . N

Significantly RB N
fewer JJR o
ties NNS o
were VBD N
required VBN N
during IN N
liver JJ N
transection NN N
in IN N
the DT N
TL NNP N
group NN N
than IN N
in IN N
the DT N
BP NNP N
group NN N
( ( N
15.8 CD N
+/- JJ N
4.8 CD N
versus NN N
22.8 CD N
+/- JJ N
7.9 CD N
ties NNS N
; : N
P NNP N
= NNP N
0.023 CD N
) ) N
. . N

The DT N
morbidity NN o
rates NNS o
were VBD N
similar JJ N
for IN N
the DT N
2 CD N
groups NNS N
. . N

In IN N
conclusion NN N
, , N
CUSA NNP N
with IN N
TL NNP N
is VBZ N
superior JJ N
to TO N
CUSA NNP N
with IN N
BP NNP N
for IN N
donor JJ N
hepatectomy NN N
in IN N
terms NNS N
of IN N
blood NN o
loss NN o
and CC o
speed NN o
of IN o
transection NN o
with IN o
no DT o
increase NN o
in IN o
morbidity NN o
. . o

-DOCSTART- -15890448- O O

Comparative NNP N
study NN N
of IN N
the DT N
efficacy NN o
of IN N
eprinomectin JJ i
versus NN i
ivermectin NN i
, , N
and CC N
field NN o
efficacy NN o
of IN N
eprinomectin NN i
only RB N
, , N
for IN N
the DT N
treatment NN N
of IN N
chorioptic JJ p
mange NN p
in IN p
alpacas NN p
. . p

The DT N
efficacy NN o
of IN N
eprinomectin JJ i
versus NN N
ivermectin NN i
( ( N
Study NNP N
1 CD N
: : N
a DT N
single-centre JJ N
, , N
randomised JJ N
, , N
treatment-controlled JJ N
, , N
blinded VBD N
field NN N
trial NN N
) ) N
, , N
and CC N
the DT N
field NN o
efficacy NN o
of IN N
eprinomectin NN i
( ( N
Study NNP N
2 CD N
: : N
a DT N
single-centre JJ N
, , N
open JJ N
, , N
un-controlled JJ N
field NN N
trial NN N
) ) N
for IN N
the DT N
treatment NN N
of IN N
chorioptic JJ N
infestation NN N
in IN N
naturally RB p
infested VBN p
alpacas NN p
were VBD N
assessed VBN N
in IN N
two CD N
studies NNS N
. . N

Thirty NNP p
alpacas NN p
, , p
all DT p
positive JJ p
for IN p
Chorioptes NNP p
sp NN p
. . p

mite NN p
, , p
were VBD p
randomly RB p
allocated VBN p
to TO p
two CD p
treatment NN p
groups NNS p
in IN p
Study NNP p
1 CD p
. . p

Group NNP N
A NNP N
received VBD N
a DT N
single JJ N
topical JJ N
administration NN N
of IN N
a DT N
0.5 CD N
% NN N
formulation NN N
of IN N
eprinomectin NN i
at IN N
the DT N
dose JJ N
rate NN N
of IN N
500mug/kg CD N
. . N

Group NNP N
B NNP N
received VBD N
three CD N
subcutaneous JJ N
administrations NNS N
at IN N
14 CD N
days NNS N
interval NN N
of IN N
a DT N
1 CD N
% NN N
formulation NN N
of IN N
ivermectin NN i
at IN N
the DT N
dose JJ N
rate NN N
of IN N
400mug/kg CD N
. . N

Response NN o
to TO o
treatment NN o
was VBD o
assessed VBN o
by IN o
periodic JJ o
mite NN o
count NN o
, , o
and CC o
skin JJ o
lesions NNS o
scored VBN o
. . o

In IN p
Study NNP p
2 CD p
, , p
one CD p
group NN p
of IN p
19 CD p
alpacas NNS p
received VBD p
four CD p
administrations NNS p
at IN p
weekly JJ p
interval NN p
of IN p
topical JJ p
eprinomectin NN i
at IN p
the DT p
dose JJ p
rate NN p
of IN p
500mug/kg CD p
, , p
and CC p
response NN p
to TO p
treatment NN p
was VBD p
monitored VBN p
by IN p
mite JJ o
counts NNS o
. . o

No DT N
localised VBD o
or CC o
systemic JJ o
side NN o
effects NNS o
were VBD N
observed VBN N
in IN N
either DT N
trial NN N
. . N

There EX N
was VBD N
a DT N
statistically RB N
significant JJ N
decrease NN N
in IN N
mite JJ o
counts NNS o
on IN N
day NN N
7 CD N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
within IN N
treatment NN N
Groups NNP N
A NNP N
and CC N
B NNP N
of IN N
Study NNP N
1 CD N
, , N
but CC N
mite JJ o
counts NNS o
increased VBD N
again RB N
on IN N
day NN N
14 CD N
and CC N
remained VBD N
high JJ N
for IN N
the DT N
duration NN N
of IN N
the DT N
trial NN N
in IN N
both DT N
treatment NN N
groups NNS N
. . N

On IN N
day NN N
14 CD N
of IN N
Study NNP N
2 CD N
, , N
there EX N
was VBD N
a DT N
statistically RB N
significant JJ N
reduction NN N
in IN N
mite JJ o
counts NNS o
( ( N
P NNP N
< NNP N
0.008 CD N
) ) N
and CC N
the DT N
mite JJ o
counts NNS o
remained VBD N
very RB N
low JJ N
throughout IN N
the DT N
remainder NN N
of IN N
the DT N
study NN N
. . N

The DT N
eprinomectin NN i
protocol NN N
employed VBN N
in IN N
Study NNP N
2 CD N
, , N
consisting VBG N
of IN N
four CD N
weekly JJ N
topical JJ N
administrations NNS N
at IN N
the DT N
dose JJ N
rate NN N
of IN N
500mug/kg CD N
of IN N
body NN N
weight NN N
, , N
proved VBD N
highly RB N
effective JJ N
at IN N
reducing VBG N
the DT N
Chorioptes NNPS o
mite JJ o
burden NN o
in IN p
alpacas NN p
. . p

-DOCSTART- -11840031- O O

Immune NNP o
status NN o
of IN p
infants NNS p
fed VBN p
soy-based JJ i
formulas NNS i
with IN p
or CC p
without IN p
added JJ i
nucleotides NNS i
for IN p
1 CD p
year NN p
: : p
part NN N
2 CD N
: : N
immune NN N
cell NN N
populations NNS N
. . N

BACKGROUND NNP N
Infants NNPS p
fed VBD p
a DT p
soy JJ i
protein NN i
isolate-based JJ i
formula NN i
have VBP N
immunization NN o
responses NNS o
similar JJ N
to TO N
breast-fed JJ N
infants NNS N
. . N

However RB N
, , N
cellular JJ o
aspects NNS o
of IN o
the DT o
immunologic JJ o
development NN o
of IN N
soy-fed JJ p
infants NNS p
have VBP N
not RB N
been VBN N
studied VBN N
extensively RB N
. . N

Nucleotides NNP i
added VBD N
to TO N
milk-based JJ N
formula NN N
benefit NN N
infant NN N
immune NN N
status NN N
, , N
but CC N
reports NNS N
of IN N
the DT N
immunologic JJ o
effects NNS o
of IN N
adding VBG N
nucleotides NNS i
to TO N
soy-based JJ i
formula NN i
are VBP N
not RB N
available JJ N
. . N

This DT N
study NN N
examines VBZ N
immune RB o
cell JJ o
populations NNS o
of IN N
infants NNS p
fed VBN p
soy JJ i
protein NN i
isolate NN i
formulas NNS i
with IN p
and CC p
without IN p
added VBN p
nucleotides NNS i
for IN p
1 CD p
year NN p
. . p

METHODS NNP N
Newborn NNP p
, , p
term NN p
infants NNS p
studied VBN p
in IN p
a DT p
masked JJ p
12-month JJ p
feeding VBG p
trial NN p
were VBD N
assigned VBN i
randomly RB i
to TO i
soy VB i
formula NN i
groups NNS i
with IN i
and CC i
without IN i
added VBN i
nucleotides NNS i
( ( i
n JJ i
= NN i
94 CD i
, , i
n RB i
= VBZ i
92 CD i
) ) i
. . i

A DT N
nonrandomized JJ p
human JJ i
milk/formula-fed JJ i
cohort NN i
( ( i
n JJ i
= NNP i
81 CD i
) ) i
, , i
was VBD i
concurrently RB N
enrolled VBN N
. . N

Blood NN i
samples NNS i
were VBD i
collected VBN i
at IN i
6 CD i
, , i
7 CD i
, , i
and CC i
12 CD i
months NNS i
. . i

Thirty-two NNP o
immune NN o
cell NN o
populations NNS o
were VBD N
characterized VBN N
using VBG N
three-color JJ N
flow JJ N
cytometry NN N
. . N

Cellular JJ N
markers NNS N
were VBD N
chosen VBN N
to TO N
assess VB N
general JJ o
pediatric JJ o
immune NN o
status NN o
, , o
emphasizing VBG o
maturation NN o
and CC o
activation NN o
of IN o
B NNP o
, , o
T NNP o
, , o
and CC o
NK NNP o
lymphocytes NNS o
. . o

RESULTS NNP N
All NNP N
cell VBP N
populations NNS N
, , N
number NN N
and CC N
percentages NNS N
, , N
were VBD N
within IN N
age-related JJ N
normal JJ N
ranges NNS N
. . N

The DT N
only JJ N
significant JJ N
difference NN N
found VBD N
between IN N
soy JJ i
formula NN i
and CC p
human JJ i
milk/formula-fed JJ i
infants NNS p
was VBD N
the DT N
percentage NN o
of IN o
CD57 NNP o
+ NNP o
NK NNP o
T NNP o
cells NNS o
at IN N
12 CD N
months NNS N
( ( N
human JJ N
milk/formula NN N
> NNP N
soy NN N
formula NN N
, , N
P NNP N
= NNP N
0.034 CD N
) ) N
. . N

There EX N
were VBD N
significant JJ N
differences NNS N
at IN N
some DT N
time NN N
points NNS N
between IN N
human JJ N
milk/formula-fed JJ N
and CC N
nucleotide-supplemented JJ i
soy NN N
formula-fed JJ N
infants NNS N
in IN N
populations NNS o
of IN o
lymphocytes NNS o
, , o
eosinophils NNS o
, , o
total JJ o
T NNP o
, , o
helper NN o
T NNP o
, , o
naive JJ o
helper NN o
, , o
memory/effector NN o
helper NN o
, , o
CD57 NNP o
- : o
T NN o
, , o
and CC o
CD11b NNP o
+ NNP o
CD8 NNP o
+ NNP o
NK NNP o
cells NNS o
. . o

None NN N
of IN N
the DT N
cell NN o
populations NNS o
differed VBD N
between IN N
infants NNS p
fed VBN p
soy JJ p
formula NN p
versus NN N
soy NN N
plus CC N
nucleotides NNS i
. . i

CONCLUSIONS NNP N
Infants NNPS p
fed VBD p
this DT p
commercial JJ p
soy NN p
formula NN p
demonstrated VBD N
immune JJ o
cell NN o
status NN o
similar JJ N
to TO N
human JJ p
milk/formula-fed JJ p
infants NNS p
, , N
consistent JJ N
with IN N
normal JJ N
immune JJ o
system NN o
development NN o
. . o

The DT N
addition NN N
of IN N
nucleotides NNS i
to TO N
soy VB N
formula NN N
did VBD N
not RB N
significantly RB N
change VBP N
specific JJ N
individual JJ N
immune NN o
cell NN o
populations NNS o
but CC N
tended VBD N
to TO N
increase VB N
numbers NNS o
and CC o
percentages NNS o
of IN o
T NNP o
cells NNS o
and CC N
decreased JJ N
numbers NNS o
and CC o
percentages NNS o
of IN o
NK NNP o
cells NNS o
. . o

-DOCSTART- -12459663- O O

Comparison NNP N
of IN N
acustimulation NN N
and CC N
ondansetron NN N
for IN N
the DT N
treatment NN N
of IN N
established VBN p
postoperative JJ p
nausea NN p
and CC p
vomiting NN p
. . p

BACKGROUND NNP N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
transcutaneous JJ N
electrical JJ N
acupoint NN N
stimulation NN N
( ( N
acustimulation NN N
) ) N
using VBG N
the DT N
ReliefBand NNP N
compared VBN N
with IN N
ondansetron NN N
for IN N
the DT N
treatment NN p
of IN p
established VBN p
postoperative JJ p
nausea NN p
and CC p
vomiting NN p
( ( p
PONV NNP p
) ) p
after IN p
outpatient NN p
laparoscopic NN p
surgery NN p
. . p

METHODS NNP N
After IN N
the DT N
authors NNS N
obtained VBD N
institutional JJ N
review NN N
board NN N
approval NN N
and CC N
written VBN N
informed JJ N
consent NN N
, , N
268 CD p
outpatients NNS p
were VBD N
enrolled VBN N
in IN N
this DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo- JJ N
and CC N
sham-controlled JJ N
study NN N
. . N

All DT N
patients NNS N
received VBN N
antiemetic JJ N
prophylaxis NN N
with IN N
metoclopramide NN N
, , N
10 CD N
mg NN N
intravenously RB N
, , N
or CC N
droperidol NN N
, , N
0.625 CD N
mg NN N
intravenously RB N
, , N
after IN N
induction NN N
of IN N
anesthesia NN N
. . N

A DT N
total NN N
of IN N
90 CD p
patients NNS p
developed VBD p
PONV NNP p
in IN N
the DT N
recovery NN N
units NNS N
and CC N
were VBD N
randomized VBN N
to TO N
one CD i
of IN i
three CD i
treatment NN i
groups NNS i
: : i
( ( i
1 CD i
) ) i
the DT i
ondansetron NN i
group NN i
received VBD i
4 CD i
mg NNS i
intravenous JJ i
ondansetron NN i
and CC i
a DT i
sham JJ i
ReliefBand NNP i
; : i
( ( i
2 CD i
) ) i
the DT i
acustimulation NN i
group NN i
received VBD i
2 CD i
ml NNS i
intravenous JJ i
saline NN i
and CC i
a DT i
ReliefBand NNP i
; : i
and CC i
( ( i
3 CD i
) ) i
the DT i
combination NN i
group NN i
received VBD i
4 CD i
mg NNS i
intravenous JJ i
ondansetron NN i
and CC i
a DT i
ReliefBand NNP i
. . i

A NNP i
rescue NN i
antiemetic NN i
( ( i
10 CD i
mg RB i
intravenous JJ i
metoclopramide NN i
) ) i
was VBD i
administered VBN i
only RB i
if IN i
the DT i
PONV NNP i
symptoms NNS i
persisted VBD i
for IN i
15 CD i
min NN i
or CC i
longer JJR i
after IN i
initiating VBG i
the DT i
treatment NN i
. . i

A DT N
blinded JJ N
observer NN N
recorded VBD N
the DT N
recovery NN o
times NNS o
, , o
emetic JJ o
symptoms NNS o
, , o
rescue NN o
antiemetics NNS o
, , o
maximum JJ o
nausea NN o
scores NNS o
, , o
complete JJ o
response NN o
to TO o
study VB o
treatment NN o
, , o
and CC o
time NN o
to TO o
achieve VB o
discharge NN o
criteria NNS o
. . o

Postdischarge NNP N
side JJ N
effects NNS N
, , N
as RB N
well RB N
as IN N
patient JJ N
satisfaction NN N
and CC N
quality NN N
of IN N
recovery NN N
scores NNS N
, , N
were VBD N
assessed VBN N
at IN N
24 CD N
and CC N
72 CD N
h NN N
after IN N
surgery NN N
. . N

RESULTS VB N
The DT N
combination NN N
group NN N
had VBD N
a DT N
significantly RB N
higher JJR N
complete JJ o
response NN o
rate NN N
than IN N
the DT N
acustimulation NN N
group NN N
( ( N
73 CD N
% NN N
vs.40 NN N
% NN N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

In IN N
addition NN N
, , N
fewer JJR N
patients NNS N
( ( N
8 CD N
vs. FW N
18 CD N
) ) N
in IN N
the DT N
combination NN N
( ( N
vs. IN N
acustimulation NN N
) ) N
group NN N
experienced VBD N
subsequent JJ o
emetic JJ o
events NNS o
( ( N
P NNP N
< NNP N
0.03 CD N
) ) N
. . N

However RB N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
three CD N
groups NNS N
with IN N
respect NN N
to TO N
patient JJ o
satisfaction NN o
and CC o
quality NN o
of IN o
recovery NN o
scores NNS o
. . o

CONCLUSIONS NNP N
Acustimulation NNP N
with IN N
the DT N
ReliefBand NNP N
can MD N
be VB N
used VBN N
as IN N
an DT N
alternative NN N
to TO N
ondansetron VB N
for IN N
the DT N
treatment NN N
of IN N
established VBN p
PONV NNP p
. . p

However RB N
, , N
the DT N
use NN N
of IN N
ondansetron NN N
( ( N
4 CD N
mg RB N
intravenously RB N
) ) N
in IN N
combination NN N
with IN N
the DT N
ReliefBand NNP N
device NN N
improved VBD N
the DT N
complete JJ N
response NN N
rate NN N
to TO N
the DT N
acustimulation NN N
therapy NN N
. . N

-DOCSTART- -11837240- O O

Pacifier NNP i
as IN p
a DT p
risk NN p
factor NN p
for IN p
acute NN p
otitis NN p
media NNS p
. . p

-DOCSTART- -8129324- O O

Topical JJ i
anesthesia NN i
during IN N
infant JJ N
eye NN N
examinations NNS N
: : N
does VBZ N
it PRP N
reduce VB N
stress NN N
? . N
We PRP N
studied VBD N
the DT N
effect NN N
of IN N
topical JJ i
anesthesia NN i
on IN N
infant JJ N
stress NN N
and CC N
corneal NN N
haze NN N
during IN N
the DT N
routine JJ N
eye NN N
examination NN N
for IN N
retinopathy NN N
of IN N
prematurity NN N
. . N

Using VBG N
a DT N
double-blind JJ N
protocol NN N
, , N
55 CD p
premature NN p
infants NNS p
weighing VBG p
less JJR p
than IN p
1501 CD p
g NN p
at IN p
birth NN p
were VBD p
selected VBN p
randomly RB p
to TO N
receive VB N
normal JJ i
saline NN i
or CC i
proparacaine NN i
HCl NNP i
0.5 CD i
% NN i
eye NN i
drops VBZ i
as IN N
a DT N
corneal NN N
wetting VBG N
agent NN N
at IN p
their PRP$ p
initial JJ p
eye NN p
examination NN p
. . p

Before IN N
, , N
during IN N
, , N
and CC N
after IN N
the DT N
procedure NN N
, , N
infant JJ N
stress NN N
was VBD N
evaluated VBN N
by IN N
heart NN o
rate NN o
, , o
respiration NN o
rate NN o
, , o
blood NN o
pressure NN o
, , o
and CC o
transcutaneous JJ o
oxygen NN o
saturation NN o
. . o

Subjective JJ o
assessment NN o
of IN o
the DT o
infant NN o
's POS o
cry NN o
intensity NN o
and CC o
corneal NN o
haze NN o
also RB N
were VBD N
recorded VBN N
. . N

Adequate NNP N
data NNS N
were VBD N
collected VBN N
on IN N
42 CD p
patients NNS p
. . p

Using VBG N
analysis NN N
of IN N
variance NN N
and CC N
chi-square NN N
tests NNS N
, , N
we PRP N
found VBD N
no DT N
difference NN N
in IN N
any DT N
of IN N
these DT N
parameters NNS N
between IN N
the DT N
two CD N
patients NNS N
groups NNS N
. . N

These DT N
data NNS N
suggest VBP N
that IN N
topical JJ N
anesthetic JJ i
agents NNS N
offer VBP N
no DT N
advantage NN N
over IN N
normal JJ N
saline JJ N
eye NN N
drops NNS N
during IN N
the DT N
examination NN N
of IN N
premature JJ p
infants NNS p
. . p

-DOCSTART- -23229426- O O

Does NNP N
single JJ N
use NN N
of IN N
an DT N
autologous JJ N
transfusion NN N
system NN N
in IN N
TKA NNP p
reduce VB N
the DT N
need NN N
for IN N
allogenic JJ N
blood NN N
? . N
: : N
a DT N
prospective JJ N
randomized VBN N
trial NN N
. . N

BACKGROUND NNP N
Mechanical NNP i
autotransfusion NN i
systems NNS i
for IN N
washed JJ N
shed VBN N
blood NN N
( ( N
WSB NNP N
) ) N
were VBD N
introduced VBN N
to TO N
reduce VB N
the DT N
need NN N
for IN N
postoperative JJ N
allogenic JJ N
blood NN N
transfusions NNS N
( ( N
ABTs NNP N
) ) N
. . N

Although IN N
some DT N
authors NNS N
have VBP N
postulated VBN N
decreased JJ N
requirements NNS N
for IN N
ABT NNP N
by IN N
using VBG N
autologous JJ N
retransfusion NN N
devices NNS N
, , N
other JJ N
trials NNS N
, , N
mostly RB N
evaluating VBG N
retransfusion NN N
devices NNS N
for IN N
unwashed JJ N
shed VBN N
blood NN N
( ( N
USB NNP N
) ) N
, , N
verified VBD N
a DT N
small JJ N
or CC N
no DT N
benefit NN N
in IN N
reducing VBG N
the DT N
need NN N
for IN N
postoperative JJ N
ABT NNP N
. . N

Because IN N
of IN N
these DT N
contradictory JJ N
findings NNS N
it PRP N
is VBZ N
still RB N
unclear JJ N
whether IN N
autologous JJ N
retransfusion NN N
systems NNS N
for IN N
WSB NNP N
can MD N
reduce VB N
transfusion NN N
requirements NNS N
. . N

QUESTIONS/PURPOSES NNP N
We PRP N
therefore VBP N
asked VBD N
whether IN N
one CD N
such JJ N
autologous JJ N
transfusion NN N
system NN N
for IN N
WSB NNP N
can MD N
reduce VB N
the DT N
requirements NNS N
for IN N
postoperative JJ N
ABT NNP N
. . N

METHODS NNP N
In IN N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
controlled VBN i
study NN N
, , N
we PRP p
enrolled VBD p
151 CD p
patients NNS p
undergoing JJ p
TKA NNP p
. . p

In IN N
Group NNP p
A NNP p
( ( p
n=76 JJ p
patients NNS p
) ) p
, , N
the DT N
autotransfusion NN i
system NN i
was VBD N
used VBN N
for IN N
a DT N
total NN N
of IN N
6 CD N
hours NNS N
( ( N
intraoperatively RB N
and CC N
postoperatively RB N
) ) N
and CC N
the DT N
WSB NNP i
was VBD i
retransfused VBN i
after IN i
processing VBG i
. . i

In IN N
Control NNP p
Group NNP p
B NNP p
( ( p
n=75 JJ p
patients NNS p
) ) p
, , N
a DT N
regular JJ i
drain NN i
without IN i
suction NN i
was VBD i
used VBN i
. . i

We PRP N
used VBD N
signs NNS N
of IN N
anemia NN N
and/or VBP N
a DT N
hemoglobin NN N
value NN N
less JJR N
than IN N
8 CD N
g/dL NN N
as IN N
indications NNS N
for IN N
transfusion NN N
. . N

If IN N
necessary JJ N
, , N
we PRP N
administered VBD N
one CD N
or CC N
two CD N
units NNS N
of IN N
allogenic JJ N
blood NN N
. . N

RESULTS NNP N
Twenty-three JJ N
patients NNS N
( ( N
33 CD N
% NN N
) ) N
in IN N
Group NNP N
A NNP N
, , N
who WP N
received VBD N
an DT N
average NN N
of IN N
283 CD N
mL NN N
( ( N
range NN N
, , N
160-406 JJ N
mL NN N
) ) N
of IN N
salvaged VBN N
blood NN N
, , N
needed VBD N
a DT N
mean NN N
of IN N
2.1 CD N
units NNS N
of IN N
allogenic JJ N
blood NN N
, , N
compared VBN N
with IN N
23 CD N
patients NNS N
( ( N
33 CD N
% NN N
) ) N
in IN N
Control NNP N
Group NNP N
B NNP N
who WP N
needed VBD N
a DT N
mean NN N
of IN N
2.1 CD N
units NNS N
of IN N
allogenic JJ N
blood NN N
. . N

CONCLUSIONS NNP N
We PRP N
found VBD N
the DT N
use NN N
of IN N
an DT N
autotransfusion NN N
system NN N
did VBD N
not RB N
reduce VB N
the DT N
rate NN N
of IN N
postoperative JJ N
ABTs NNP N
. . N

LEVEL NNP N
OF IN N
EVIDENCE NNP N
Level NNP N
II NNP N
, , N
therapeutic JJ N
study NN N
. . N

See VB N
the DT N
Guidelines NNP N
for IN N
Authors NNP N
for IN N
a DT N
complete JJ N
description NN N
of IN N
levels NNS N
of IN N
evidence NN N
. . N

-DOCSTART- -16254100- O O

Pathology NN N
parameters NNS N
and CC N
adjuvant JJ o
tamoxifen NN o
response NN o
in IN N
a DT N
randomised JJ N
premenopausal NN p
breast NN p
cancer NN p
trial NN N
. . N

BACKGROUND NNP N
Subgroups NNP N
of IN N
breast NN N
cancer NN N
that WDT N
have VBP N
an DT N
impaired JJ N
response NN N
to TO N
endocrine VB N
treatment NN N
, , N
despite IN N
hormone NN N
receptor NN N
positivity NN N
, , N
are VBP N
still RB N
poorly RB N
defined VBN N
. . N

Breast NNP N
cancer NN N
can MD N
be VB N
subdivided VBN N
according VBG N
to TO N
standard JJ N
pathological JJ N
parameters NNS N
including VBG N
histological JJ N
type NN N
, , N
grade NN N
, , N
and CC N
assessment NN N
of IN N
proliferation NN N
. . N

These DT N
parameters NNS N
are VBP N
the DT N
net JJ N
result NN N
of IN N
combinations NNS N
of IN N
genetic JJ N
alterations NNS N
effecting VBG N
tumour JJ N
behaviour NN N
and CC N
could MD N
potentially RB N
reflect VB N
subtypes NNS N
that IN N
respond NN N
differently RB N
to TO N
endocrine VB N
treatment NN N
. . N

AIMS NNP N
To TO N
investigate VB N
the DT N
usefulness NN N
of IN N
these DT N
parameters NNS N
as IN N
predictors NNS N
of IN N
the DT N
response NN N
to TO N
tamoxifen VB i
in IN N
premenopausal JJ p
women NNS p
with IN p
breast NN p
cancer NN p
. . p

MATERIALS/METHODS NNP N
Clinically NNP N
established VBD N
pathological JJ N
parameters NNS N
were VBD N
assessed VBN N
and CC N
related VBN N
to TO N
the DT N
tamoxifen NN i
response NN N
in IN N
500 CD p
available JJ p
tumour NN p
specimens NNS p
from IN p
564 CD p
premenopausal NN p
patients NNS p
with IN p
breast JJ p
cancer NN p
randomised VBD N
to TO N
either DT N
two CD N
years NNS N
of IN N
tamoxifen NN i
or CC N
no DT i
treatment NN i
with IN N
14 CD N
years NNS N
of IN N
follow NN N
up RB N
. . N

Proliferation NN N
was VBD N
further RB N
evaluated VBN N
by IN N
immunohistochemical JJ N
Ki-67 NNP N
expression NN N
. . N

RESULTS NNP N
Oestrogen NNP o
receptor NN o
positive JJ o
ductal JJ o
carcinomas NN o
responded VBD N
as IN N
expected VBN N
to TO N
tamoxifen VB i
, , N
whereas IN N
the DT N
difference NN N
in IN N
recurrence NN o
free JJ o
survival NN o
between IN N
control NN i
and CC N
tamoxifen NN i
treated VBD N
patients NNS N
was VBD N
less RBR N
apparent JJ N
in IN N
the DT N
relatively RB N
few JJ N
lobular JJ N
carcinomas NN N
. . N

For IN N
histological JJ N
grade NN N
, , N
there EX N
was VBD N
no DT N
obvious JJ N
difference NN N
in IN N
treatment NN N
response NN N
between IN N
the DT N
groups NNS N
. . N

The DT N
relation NN N
between IN N
proliferation NN N
and CC N
tamoxifen NN i
response NN N
seemed VBD N
to TO N
be VB N
more RBR o
complex JJ o
, , o
with IN o
a DT o
clear JJ o
response NN o
in IN o
tumours NN o
with IN o
high JJ o
and CC o
low JJ o
proliferation NN o
, , N
whereas JJ N
tumours NN N
with IN N
intermediate JJ N
proliferation NN N
defined VBN N
by IN N
Ki-67 NNP N
responded VBD N
more RBR N
poorly RB o
. . o

CONCLUSIONS NNP N
Clinically NNP N
established VBD N
pathology NN N
parameters NNS N
seem VBP N
to TO N
mirror VB N
the DT N
endocrine NN N
treatment NN N
response NN N
and CC N
could MD N
potentially RB N
be VB N
valuable JJ N
in IN N
future JJ N
treatment NN N
decisions NNS N
for IN N
patients NNS p
with IN p
breast JJ p
cancer NN p
. . p

-DOCSTART- -7551999- O O

Abdominoperineal NNP i
resection NN i
and CC N
anterior JJ i
resection NN i
in IN N
the DT N
treatment NN N
of IN N
rectal JJ p
cancer NN p
: : p
results NNS N
in IN N
relation NN N
to TO N
adjuvant VB i
preoperative JJ i
radiotherapy NN i
. . i

The DT N
outcome NN N
of IN N
patients NNS p
with IN p
rectal JJ p
cancer NN p
treated VBN p
by IN p
abdominoperineal NN i
or CC i
anterior JJ i
resection NN i
, , i
with IN i
or CC i
without IN i
preoperative JJ i
radiotherapy NN i
, , N
was VBD N
assessed VBN N
to TO N
detect VB N
any DT N
differences NNS N
attributable JJ N
to TO N
the DT N
operative JJ N
method NN N
and CC N
interactions NNS N
between IN N
radiotherapy NN N
and CC N
type NN N
of IN N
surgery NN N
. . N

The DT N
study NN N
was VBD N
based VBN N
on IN N
1292 CD p
patients NNS p
included VBN p
in IN p
two CD p
consecutive JJ p
controlled VBN p
randomized JJ p
trials NNS p
of IN p
preoperative JJ i
radiotherapy NN i
in IN p
operable JJ p
rectal JJ p
carcinoma NN p
. . p

The DT N
outcome NN N
was VBD N
not RB N
related VBN N
to TO N
surgical JJ N
method NN N
. . N

Radiotherapy NNP N
increased VBD N
postoperative JJ o
mortality NN o
and CC o
complications NNS o
and CC N
reduced JJ N
local JJ o
and CC o
distant JJ o
recurrence NN o
, , N
but CC N
had VBD N
no DT N
effect NN N
on IN N
overall JJ o
survival NN o
. . o

Effects NNS N
of IN N
radiotherapy NN i
were VBD N
similar JJ N
irrespective NN N
of IN N
the DT N
type NN N
of IN N
surgery NN N
, , N
except IN N
that IN N
the DT N
increase NN N
in IN N
postoperative JJ o
mortality NN o
in IN N
irradiated JJ N
patients NNS N
was VBD N
greater JJR N
in IN N
those DT N
treated VBN N
with IN N
abdominoperineal JJ N
resection NN N
. . N

Sphincter-saving JJ i
procedures NNS i
appear VBP N
to TO N
have VB N
no DT N
adverse JJ N
effects NNS N
on IN N
outcome NN N
of IN N
rectal JJ p
cancer NN p
, , N
but CC N
the DT N
optimum JJ N
use NN N
of IN N
radiotherapy NN N
is VBZ N
still RB N
to TO N
be VB N
defined VBN N
. . N

-DOCSTART- -21463068- O O

Concurrent NNP N
alcohol NN i
dependence NN i
among IN N
methadone-maintained JJ p
cocaine NN p
abusers NNS p
is VBZ N
associated VBN N
with IN N
greater JJR N
abstinence NN o
. . o

Concurrent NNP i
alcohol NN i
dependence NN i
( ( i
AD NNP i
) ) i
among IN N
polysubstance NN N
abusers NNS N
has VBZ N
been VBN N
associated VBN N
with IN N
negative JJ N
consequences NNS N
, , N
although IN N
it PRP N
may MD N
not RB N
necessarily RB N
lead VB N
to TO N
poor JJ N
treatment NN N
outcomes NNS N
. . N

One CD N
of IN N
the DT N
most RBS N
efficacious JJ N
treatments NNS N
for IN N
cocaine NN N
abuse NN N
is VBZ N
contingency JJ i
management NN i
( ( i
CM NNP i
) ) i
, , N
but CC N
little JJ N
research NN N
has VBZ N
explored VBN N
the DT N
impact NN N
of IN N
AD NNP i
on IN N
abstinence NN o
outcomes NNS o
, , N
particularly RB N
among IN N
patients NNS p
in IN p
methadone JJ p
maintenance NN p
. . p

Using VBG N
data NNS N
from IN N
three CD N
trials NNS N
of IN N
CM NNP N
for IN N
cocaine NN N
use NN N
, , N
we PRP N
compared VBN N
baseline JJ o
characteristics NNS o
and CC o
posttreatment NN o
and CC o
follow-up JJ o
cocaine NN o
outcomes NNS o
between IN N
methadone-maintained JJ i
, , i
cocaine-dependent JJ i
patients NNS p
( ( p
N NNP p
= NNP p
193 CD p
) ) p
with IN i
and CC i
without IN i
concurrent JJ i
AD NNP i
, , i
randomized VBN i
to TO i
standard VB i
care NN i
( ( i
SC NNP i
) ) i
with IN i
or CC i
without IN i
CM NNP i
. . i

Patients NNS p
with IN i
and CC i
without IN i
concurrent JJ i
AD NNP i
had VBD N
similar JJ N
baseline NN N
characteristics NNS N
, , N
with IN N
the DT N
exception NN N
that WDT N
AD NNP i
patients NNS N
reported VBD N
more RBR N
alcohol NN N
use NN N
. . N

AD NN i
patients NNS N
achieved VBN N
longer JJR N
durations NNS o
of IN o
cocaine NN o
abstinence NN o
and CC N
were VBD N
more RBR N
likely JJ N
to TO N
submit VB N
a DT N
cocaine-negative JJ o
sample NN o
at IN N
follow-up JJ N
than IN N
non-AD JJ i
patients NNS N
. . N

Patients NNS N
randomized VBD N
to TO N
CM NNP i
achieved VBD N
better RBR N
outcomes NNS o
than IN N
those DT N
randomized VBN N
to TO N
SC NNP i
, , N
but CC N
there EX N
was VBD N
no DT N
interaction NN N
between IN N
treatment NN N
condition NN N
and CC N
AD NNP i
status NN N
. . N

These DT N
findings NNS N
suggest VBP N
that IN N
cocaine-using JJ p
methadone NN p
patients NNS p
with IN N
AD NNP i
achieve VBP N
greater JJR N
cocaine NN o
abstinence NN o
than IN N
their PRP$ N
non-AD JJ i
counterparts NNS N
and CC N
should MD N
not RB N
necessarily RB N
be VB N
viewed VBN N
as IN N
more RBR N
difficult JJ N
to TO N
treat VB N
. . N

-DOCSTART- -11015817- O O

Cost-effectiveness NN N
of IN N
clozapine NN i
compared VBN N
with IN N
conventional JJ i
antipsychotic JJ i
medication NN i
for IN N
patients NNS p
in IN p
state NN p
hospitals NNS p
. . p

BACKGROUND NNP N
An DT N
open-label JJ N
, , N
randomized VBN N
controlled VBD N
trial NN N
compared VBN N
clozapine NN i
with IN N
physicians'-choice JJ N
medications NNS N
among IN N
long-term JJ p
state NN p
hospital NN p
inpatients NNS p
in IN p
Connecticut NNP p
. . p

The DT N
goal NN N
was VBD N
to TO N
examine VB N
clozapine NN N
's POS N
cost-effectiveness NN o
in IN N
routine JJ N
practice NN N
for IN N
people NNS p
experiencing VBG p
lengthy JJ p
hospitalizations NNS p
. . p

METHODS NNP N
Long-stay JJ p
patients NNS p
with IN p
schizophrenia NN p
in IN p
a DT p
state NN p
hospital NN p
were VBD p
randomly RB p
assigned VBN p
to TO p
begin VB p
open-label JJ p
clozapine NN i
( ( p
n JJ p
= NNP p
138 CD p
) ) p
or CC p
to TO p
continue VB i
receiving VBG i
conventional JJ i
antipsychotic JJ i
medications NNS i
( ( p
n JJ p
= NNP p
89 CD p
) ) p
. . p

We PRP N
interviewed VBD N
study NN N
participants NNS N
every DT N
4 CD N
months NNS N
for IN N
2 CD N
years NNS N
to TO N
assess VB o
psychiatric JJ o
symptoms NNS o
and CC o
functional JJ o
status NN o
, , N
and CC N
we PRP N
collected VBD N
continuous JJ N
measures NNS N
of IN N
prescribed JJ N
medications NNS N
, , N
service NN N
utilization NN N
, , N
and CC N
other JJ N
costs NNS N
. . N

We PRP N
used VBD N
both DT N
parametric JJ N
and CC N
nonparametric JJ N
techniques NNS N
to TO N
examine VB N
changes NNS o
in IN o
cost NN o
and CC o
parametric JJ o
analyses NNS o
to TO N
examine VB N
changes NNS o
in IN o
effectiveness NN o
. . o

We PRP N
used VBD N
bootstrap NN o
techniques NNS o
to TO N
estimate VB o
incremental JJ o
cost-effectiveness JJ o
ratios NNS o
and CC N
create VB N
cost-effectiveness JJ o
acceptability NN o
curves NNS o
. . o

RESULTS NNP N
Both NNP N
groups NNS N
incurred VBD N
similar JJ N
costs NNS N
during IN N
the DT N
2-year JJ N
study NN N
period NN N
, , N
with IN N
a DT N
trend NN N
for IN N
clozapine NN N
to TO N
be VB N
less RBR o
costly JJ o
than IN N
usual JJ N
care NN N
in IN N
the DT N
second JJ N
study NN N
year NN N
. . N

Clozapine NNP i
was VBD N
more RBR N
effective JJ o
than IN N
usual JJ N
care NN N
on IN N
many JJ N
but CC N
not RB N
all DT N
measures NNS N
. . N

With IN N
the DT N
use NN N
of IN N
effectiveness NN o
measures NNS o
that WDT N
favored VBD N
clozapine NN N
( ( N
extrapyramidal JJ N
side NN N
effects NNS N
, , N
disruptiveness NN N
) ) N
, , N
bootstrap NN N
techniques NNS N
indicated VBD N
that IN N
, , N
even RB N
when WRB N
a DT N
payer NN N
is VBZ N
unwilling JJ N
to TO N
incur VB N
any DT N
additional JJ N
cost NN N
for IN N
gains NNS N
in IN N
effectiveness NN N
, , N
the DT N
probability NN N
that IN N
clozapine NN i
is VBZ N
more RBR o
cost-effective JJ o
than IN N
usual JJ N
care NN N
is VBZ N
at IN N
least JJS N
0.80 CD N
. . N

These DT N
findings NNS N
were VBD N
not RB N
as IN N
evident JJ N
when WRB N
outcomes NNS N
where WRB N
clozapine NN N
was VBD N
not RB N
clearly RB N
superior JJ N
( ( o
psychotic JJ o
symptoms NNS o
, , o
weight VBD o
gain NN o
) ) o
were VBD N
examined VBN N
. . N

CONCLUSION NNP N
Clozapine NNP i
demonstrated VBD N
cost-effectiveness NN o
on IN N
some DT N
but CC N
not RB N
all DT N
measures NNS N
of IN N
effectiveness NN N
when WRB N
the DT N
alternative NN N
was VBD N
a DT N
range NN N
of IN N
conventional JJ N
antipsychotic JJ N
medications NNS N
. . N

-DOCSTART- -20305865- O O

Short-term JJ N
effects NNS N
of IN N
systemic JJ N
antibiotics NNS i
during IN N
periodontal JJ p
healing NN p
. . p

OBJECTIVES NNP N
To TO N
investigate VB N
the DT N
short-term JJ N
effects NNS o
of IN N
nonsurgical JJ p
therapy NN p
( ( p
scaling VBG p
and CC p
root NN p
planing NN p
, , p
SRP NNP p
) ) p
on IN p
the DT p
subgingival NN p
microbiota NN p
in IN p
chronic NN p
( ( p
CP NNP p
) ) p
and CC p
aggressive JJ p
( ( p
AP NNP p
) ) p
periodontal JJ p
disease NN p
. . p

METHOD NNP N
AND CC N
MATERIALS NNP N
Ninety-seven NNP p
CP NNP p
and CC p
AP NNP p
subjects NNS p
underwent JJ p
full-mouth JJ p
SRP NNP p
on IN p
2 CD p
consecutive JJ p
days NNS p
. . p

AP JJ N
patients NNS N
were VBD N
randomly RB i
assigned VBN i
to TO i
either DT i
receive JJ i
systemic JJ i
metronidazole NN i
plus CC i
amoxicillin NN i
( ( i
AP+AB NNP i
) ) i
or CC i
were VBD i
treated VBN i
mechanically RB i
alone RB i
( ( i
AP NNP i
) ) i
. . i

Pathogens NNS N
were VBD N
identified VBN i
with IN i
16S CD o
rRNA NNS o
oligodeoxynucleotide JJ o
probes NNS o
and CC o
dot-blot JJ o
hybridization NN o
before IN i
and CC i
at IN i
days NNS i
2 CD i
, , i
3 CD i
, , i
4 CD i
, , i
7 CD i
, , i
10 CD i
, , i
and CC i
21 CD i
of IN i
healing VBG i
. . i

CP JJ N
subjects NNS N
were VBD N
treated VBN N
by IN N
scaling VBG N
and CC N
root JJ N
planing NN N
along IN N
with IN N
placebo JJ i
tablets NNS i
. . i

RESULTS NNP N
Initially NNP N
, , N
AP NNP o
cell NN o
counts NNS o
were VBD N
69.9- JJ N
( ( N
Porphyromonas NNP N
gingivalis NN N
) ) N
, , N
10.2- JJ N
( ( N
Aggregatibacter NNP N
actinomycetemcomitans NNS N
) ) N
, , N
5.7- JJ N
( ( N
Tannerella NNP N
forsythia NN N
) ) N
, , N
and CC N
3.3-fold JJ N
( ( N
Prevotella NNP N
intermedia NN N
) ) N
enhanced VBD N
compared VBN N
to TO N
CP NNP o
cell NN o
counts NNS o
. . o

Following VBG N
SRP NNP N
, , N
immediate JJ N
elimination NN N
occurred VBD N
in IN N
single JJ N
individuals NNS N
of IN N
all DT N
three CD N
treatment NN N
groups NNS N
at IN N
day NN N
2 CD N
. . N

After IN N
SRP NNP o
plus CC o
antibiotic JJ o
therapy NN o
( ( N
AP+AB NNP N
) ) N
, , N
the DT N
prevalence NN N
scores NNS N
dropped VBD N
beyond IN N
the DT N
levels NNS N
of IN N
AP NNP o
and CC o
CP NNP o
, , N
beginning VBG N
at IN N
day NN N
7 CD N
, , N
and CC N
remained VBD N
low JJ N
until IN N
day NN N
21 CD N
( ( N
P NNP N
=or NNP N
< NNP N
.05 NNP N
) ) N
. . N

Clinical JJ o
healing VBG o
statistically RB N
benefited VBN N
from IN N
SRP NNP N
with IN N
no DT N
differences NNS N
among IN N
the DT N
three CD N
treatment NN N
groups NNS N
. . N

CONCLUSION NNP N
Nonsurgical NNP N
therapy NN N
resulted VBD N
in IN N
both DT N
a DT N
suppression NN N
and CC N
early JJ N
elimination NN N
of IN N
single JJ o
taxa NN o
immediately RB N
after IN N
completion NN N
of IN N
active JJ N
treatment NN N
. . N

Systemic NNP N
antibiotics NNS N
significantly RB N
accelerate VBP N
the DT N
suppression NN N
of IN N
the DT N
periodontal JJ o
microflora NN o
, , N
but CC N
have VBP N
limited VBN N
effect NN N
on IN N
the DT N
elimination NN o
of IN o
target NN o
isolates NNS o
during IN N
healing NN N
. . N

-DOCSTART- -24840596- O O

A DT N
randomized JJ N
clinical JJ N
trial NN N
comparison NN N
between IN N
pivotal JJ i
response NN i
treatment NN i
( ( i
PRT NNP i
) ) i
and CC i
structured VBN i
applied JJ i
behavior NN i
analysis NN i
( ( i
ABA NNP i
) ) i
intervention NN N
for IN N
children NNS p
with IN p
autism NN p
. . p

Accumulating VBG N
studies NNS N
are VBP N
documenting VBG N
specific JJ N
motivational JJ N
variables NNS N
that IN N
, , N
when WRB N
combined VBN N
into IN N
a DT N
naturalistic JJ i
teaching NN i
paradigm NN i
, , N
can MD N
positively RB N
influence VB N
the DT N
effectiveness NN N
of IN N
interventions NNS N
for IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
. . p

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
two CD N
applied JJ i
behavior NN i
analysis NN i
( ( i
ABA NNP i
) ) i
intervention NN i
procedures NNS i
, , i
a DT i
naturalistic JJ i
approach NN i
, , i
pivotal JJ i
response NN i
treatment NN i
( ( i
PRT NNP i
) ) i
with IN i
a DT i
structured JJ i
ABA NNP i
approach NN i
in IN N
a DT N
school NN N
setting NN N
. . N

A DT N
randomized JJ N
clinical JJ N
trial NN N
design NN N
using VBG N
two CD p
groups NNS p
of IN p
children NNS p
, , p
matched VBD p
according VBG p
to TO p
age NN p
, , p
sex NN p
and CC p
mean JJ p
length NN p
of IN p
utterance NN p
was VBD N
used VBN N
to TO N
compare VB N
the DT N
interventions NNS N
. . N

The DT N
data NN N
showed VBD N
that IN N
the DT N
PRT NNP i
approach NN N
was VBD N
significantly RB N
more RBR N
effective JJ N
in IN N
improving VBG o
targeted VBN o
and CC o
untargeted JJ o
areas NNS o
after IN N
3 CD N
months NNS N
of IN N
intervention NN N
. . N

The DT N
results NNS N
are VBP N
discussed VBN N
in IN N
terms NNS N
of IN N
variables NNS N
that WDT N
produce VBP N
more JJR N
rapid JJ N
improvements NNS N
in IN N
communication NN N
for IN N
children NNS N
with IN N
ASD NNP N
. . N

-DOCSTART- -12113323- O O

Multiple JJ N
doses NNS N
of IN N
secretin NN i
in IN N
the DT N
treatment NN N
of IN N
autism NN p
: : p
a DT N
controlled VBN N
study NN N
. . N

UNLABELLED NNP N
Dramatic JJ N
effects NNS N
on IN N
autistic JJ o
behaviour NN o
after IN N
repeated VBN N
injections NNS N
of IN N
the DT N
gastrointestinal JJ N
hormone NN N
secretin NN i
have VBP N
been VBN N
referred VBN N
in IN N
a DT N
number NN N
of IN N
case NN N
reports NNS N
. . N

In IN N
the DT N
absence NN N
of IN N
curative JJ N
and CC N
effective JJ N
treatments NNS N
for IN N
this DT N
disabling JJ N
condition NN N
, , N
this DT N
information NN N
has VBZ N
created VBN N
new JJ N
hope NN N
among IN N
parents NNS N
. . N

Although IN N
controlled JJ N
studies NNS N
on IN N
the DT N
effect NN N
of IN N
mainly RB N
one CD N
single JJ N
dose NN N
have VBP N
not RB N
documented VBN N
any DT N
effect NN N
, , N
many JJ N
children NNS p
still RB N
continue VBP N
to TO N
receive VB N
secretin NN i
. . i

Six NNP p
children NNS p
enrolled VBD p
in IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ N
crossover NN N
study NN N
in IN N
which WDT N
each DT N
child NN N
was VBD N
its PRP$ N
own JJ N
control NN N
. . N

Human NNP i
synthetic JJ i
secretin NN i
, , i
mean VBP i
dose JJ i
3.4 CD i
clinical JJ i
units NNS i
, , i
and CC i
placebo NN i
were VBD i
administered VBN i
intravenously RB i
in IN i
randomized JJ i
order NN i
every DT i
4th CD i
wk NN i
, , i
on IN i
three CD i
occasions NNS i
each DT i
. . i

The DT N
measurement JJ N
instruments NNS N
were VBD N
the DT N
visual JJ o
analogue NN o
scale NN o
( ( o
VAS NNP o
) ) o
and CC o
the DT o
aberrant JJ o
behaviour NN o
checklist NN o
( ( o
ABC NNP o
) ) o
. . o

Statistically NNP N
significant JJ N
differences NNS N
were VBD N
found VBN N
for IN N
placebo NN N
in IN N
3 CD N
out IN N
of IN N
6 CD N
children NNS p
and CC N
for IN N
secretin NN i
in IN N
one CD N
child NN N
, , N
using VBG N
parental JJ o
ratings NNS o
only RB o
( ( o
VAS NNP o
scores VBZ o
) ) o
. . N

Differences NNS N
were VBD N
small JJ N
and CC N
lacked JJ N
clinical JJ N
significance NN N
, , N
which WDT N
was VBD N
in IN N
accordance NN N
with IN N
the DT N
overall JJ N
impression NN N
of IN N
the DT N
parents NNS N
and CC N
teachers NNS N
and CC N
visual JJ N
inspection NN N
of IN N
graphs NN N
. . N

CONCLUSION NN N
In IN N
this DT N
placebo-controlled JJ N
study NN N
, , N
multiple JJ N
doses NNS N
of IN N
secretin NN N
did VBD N
not RB N
produce VB N
any DT N
symptomatic JJ N
improvement NN N
. . N

-DOCSTART- -18415946- O O

Comparison NNP o
of IN N
the DT N
time NN o
required VBN o
to TO N
administer VB o
three CD N
different JJ N
fluke NNS i
and CC i
worm VB i
combination NN i
products NNS i
to TO N
commercial JJ p
beef NN p
cattle NNS p
at IN p
housing NN p
. . p

Larger NNP N
livestock VBD N
units NNS N
, , N
a DT N
decline NN N
in IN N
the DT N
farm NN N
labor NN N
force NN N
, , N
animal JJ N
welfare NN N
concerns NNS N
, , N
and CC N
a DT N
trend NN N
toward IN N
more RBR N
selective JJ N
use NN N
of IN N
drugs NNS N
have VBP N
increased VBN N
the DT N
focus NN N
on IN N
animal NN N
handling NN N
, , N
time NN N
management NN N
, , N
convenience NN N
, , N
and CC N
compliance NN N
in IN N
administering VBG N
veterinary JJ N
therapeutics NNS N
. . N

This DT N
study NN N
was VBD N
undertaken VBN N
to TO N
quantify VB o
and CC o
compare VB o
the DT o
time NN o
needed VBN o
to TO o
treat VB o
commercial JJ o
beef NN o
cattle NNS o
with IN p
three CD i
fluke NNS i
and CC i
worm VB i
combination NN i
products NNS i
with IN p
different JJ p
administration NN p
profiles NNS p
. . p

Young NNP p
beef NN p
cattle NNS p
( ( p
n JJ p
= NNP p
270 CD p
) ) p
weighing VBG p
approximately RB p
400 CD p
kg NNS p
were VBD p
allocated VBN p
to TO p
batches NNS p
of IN p
five CD p
, , N
which WDT N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
ivermectin NN i
+ NNP i
clorsulon NN i
injection NN i
, , i
ivermectin JJ i
+ JJ i
closantel NN i
injection NN i
, , i
or CC i
levamisole JJ i
+ JJ i
triclabendazole JJ i
oral JJ i
drench NN i
. . i

The DT N
mean JJ o
time NN o
needed VBN o
to TO N
administer VB N
ivermectin JJ i
+ NN i
clorsulon NN i
( ( i
single JJ i
injection NN i
) ) i
to TO N
five CD N
cattle NNS N
was VBD N
31 CD N
seconds NNS N
, , N
which WDT N
was VBD N
significantly RB N
less JJR N
than IN N
the DT N
100 CD N
seconds NNS N
needed VBN N
for IN N
ivermectin JJ i
+ JJ i
closantel NN i
( ( N
two CD N
injections NNS N
) ) N
and CC N
the DT N
126 CD N
seconds NNS N
needed VBN N
for IN N
levamisole JJ i
+ JJ i
triclabendazole NN i
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Such JJ N
quantitative JJ N
data NNS N
can MD N
allow VB N
for IN N
better JJR N
planning NN o
and CC N
selection NN o
of IN N
parasiticide JJ N
treatment NN N
approaches NNS N
at IN N
the DT N
farm NN N
level NN N
. . N

-DOCSTART- -22048089- O O

Arthroscopic NNP i
rotator NN i
cuff NN i
repair NN i
with IN i
and CC i
without IN i
acromioplasty NN i
in IN N
the DT N
treatment NN N
of IN N
full-thickness JJ p
rotator NN p
cuff NN p
tears NNS p
: : p
a DT N
multicenter NN N
, , N
randomized VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND VB N
The DT N
primary JJ N
objective NN N
of IN N
this DT N
prospective JJ N
randomized NN N
controlled VBD N
trial NN N
was VBD N
to TO N
compare VB N
functional JJ o
and CC o
quality-of-life JJ o
indices NNS o
and CC N
rates NNS o
of IN o
revision NN o
surgery NN o
in IN N
arthroscopic NN i
rotator NN i
cuff NN i
repair NN i
with IN i
and CC i
without IN i
acromioplasty JJ i
. . i

METHODS NNP N
Eighty-six JJ p
patients NNS p
consented VBN N
and CC N
were VBD N
randomly RB N
assigned VBN N
intraoperatively RB N
to TO N
one CD N
of IN N
two CD N
study NN N
groups NNS N
, , N
and CC N
sixty-eight NN p
of IN p
them PRP p
completed VBD p
the DT p
study NN p
. . p

The DT N
primary JJ N
outcome NN N
was VBD N
the DT N
Western JJ o
Ontario NNP o
Rotator NNP o
Cuff NNP o
( ( o
WORC NNP o
) ) o
index NN o
. . o

Secondary JJ N
outcome NN N
measures NNS N
included VBD N
the DT N
American JJ o
Shoulder NNP o
and CC o
Elbow NNP o
Surgeons NNP o
( ( o
ASES NNP o
) ) o
shoulder NN o
assessment JJ o
form NN o
and CC o
a DT o
count NN o
of IN o
revisions NNS o
required VBN N
in IN N
each DT N
group NN N
. . N

Outcome NNP N
measures NNS N
were VBD N
completed VBN N
preoperatively RB N
and CC N
at IN N
three CD N
, , N
six CD N
, , N
twelve NN N
, , N
eighteen NN N
, , N
and CC N
twenty-four JJ N
months NNS N
after IN N
surgery NN N
. . N

RESULTS NNP N
WORC NNP o
and CC o
ASES NNP o
scores VBZ o
improved VBN N
significantly RB N
in IN N
each DT N
group NN N
over IN N
time NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
WORC NNP o
or CC o
ASES NNP o
scores NNS o
between IN N
the DT N
groups NNS N
that WDT N
had VBD N
arthroscopic VBN i
cuff JJ i
repair NN i
with IN i
or CC i
without IN i
acromioplasty JJ i
at IN N
any DT N
time NN N
point NN N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
scores NNS N
on IN N
the DT N
basis NN N
of IN N
acromion NN N
type NN N
, , N
nor CC N
were VBD N
any DT N
interaction NN N
effects NNS N
identified VBN N
between IN N
group NN N
and CC N
acromion NN N
type NN N
. . N

Four CD p
participants NNS p
( ( p
9 CD p
% NN p
) ) p
in IN p
the DT p
group NN p
that WDT p
had VBD p
arthroscopic VBN i
cuff JJ i
repair NN o
alone RB p
, , p
one CD p
with IN p
a DT p
Type-2 JJ p
and CC p
three CD p
with IN p
a DT p
Type-3 JJ p
acromion NN p
, , p
required VBN p
additional JJ o
surgery NN o
by IN N
the DT N
twenty-four-month JJ N
time NN N
point NN N
. . N

The DT N
number NN o
of IN o
patients NNS o
who WP o
required VBD o
additional JJ o
surgery NN o
was VBD N
greater JJR N
( ( N
p JJ N
= NNP N
0.05 CD N
) ) N
in IN N
the DT N
group NN N
that WDT N
had VBD N
arthroscopic VBN N
cuff JJ N
repair NN N
alone RB N
than IN N
in IN N
the DT N
group NN N
that WDT N
had VBD N
arthroscopic VBN N
cuff JJ N
repair NN N
and CC N
acromioplasty NN N
. . N

CONCLUSIONS NNP N
Our PRP$ N
findings NNS N
are VBP N
consistent JJ N
with IN N
previous JJ N
research NN N
reports NNS N
in IN N
which WDT N
there EX N
was VBD N
no DT N
difference NN N
in IN N
functional JJ o
and CC o
quality-of-life JJ o
indices NNS o
for IN N
patients NNS p
who WP p
had VBD p
rotator NN p
cuff NN p
repair NN p
with IN p
or CC p
without IN p
acromioplasty JJ p
. . p

The DT N
higher JJR o
reoperation NN o
rate NN o
was VBD N
found VBN N
in IN N
the DT N
group NN p
without IN N
acromioplasty NN N
. . N

Further CC N
study NN N
that WDT N
includes VBZ N
follow-up JJ N
imaging NN N
and CC N
patient-reported JJ N
outcomes NNS N
over IN N
a DT N
greater JJR N
follow-up JJ N
period NN N
is VBZ N
needed VBN N
. . N

-DOCSTART- -8363113- O O

Use NNP N
of IN N
activated JJ N
charcoal NN N
in IN N
a DT N
simulated JJ N
poisoning NN p
with IN p
acetaminophen NN p
: : p
a DT N
new JJ N
loading NN N
dose NN N
for IN N
N-acetylcysteine NNP i
? . N
STUDY NNP N
OBJECTIVES NNP N
To TO N
investigate VB N
the DT N
ability NN N
of IN N
a DT N
supranormal JJ N
dose NN N
of IN N
N-acetylcysteine NNP i
to TO N
overcome VB N
the DT N
effects NNS N
of IN N
activated JJ N
charcoal NN N
on IN N
N-acetylcysteine NNP N
bioavailability NN N
and CC N
to TO N
determine VB N
the DT N
effects NNS N
of IN N
activated JJ N
charcoal NN N
on IN N
serum NN N
acetaminophen NN N
levels NNS N
. . N

DESIGN NNP N
, , N
SETTING NNP N
, , N
AND NNP N
PARTICIPANTS NNP N
Ten NNP p
healthy JJ p
adult NN p
volunteers NNS p
participated VBD N
in IN N
a DT N
controlled JJ N
cross-over JJ N
experiment NN N
. . N

During IN N
phase NN N
I PRP N
( ( N
control NN N
) ) N
, , N
subjects VBZ N
ingested JJ N
3 CD i
g NN i
acetaminophen NN i
, , N
followed VBD N
one CD i
hour NN i
later RB i
by IN i
the DT i
normal JJ i
loading VBG i
dose NN i
of IN i
N-acetylcysteine NNP i
( ( N
140 CD N
mg/kg NN N
) ) N
. . N

During IN N
phase NN N
II NNP N
( ( N
charcoal NN N
) ) N
, , N
subjects VBZ N
ingested JJ N
3 CD i
g NN i
acetaminophen NN i
, , N
followed VBD N
one CD N
hour NN N
later RB N
by IN N
60 CD i
g NNS i
activated VBN i
charcoal NN i
and CC i
a DT i
supranormal JJ i
loading NN i
dose NN i
of IN i
N-acetylcysteine NNP i
( ( N
235 CD N
mg/kg NN N
) ) N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Serum NNP o
levels NNS o
of IN o
N-acetylcysteine NNP o
were VBD N
measured VBN N
every DT N
30 CD N
minutes NNS N
for IN N
six CD N
hours NNS N
. . N

A DT N
serum NN o
acetaminophen NN o
level NN o
was VBD N
measured VBN N
at IN N
four CD N
hours NNS N
. . N

RESULTS VB N
The DT N
area NN o
under IN o
the DT o
curve NN o
for IN o
N-acetylcysteine NNP o
was VBD N
significantly RB N
higher JJR N
for IN N
phase NN N
II NNP N
than IN N
phase NN N
I PRP N
( ( N
P NNP N
< NNP N
.05 NNP N
, , N
two-tailed JJ N
paired VBD N
t-test NN N
) ) N
. . N

Peak VB o
N-acetylcysteine JJ o
and CC o
time NN o
to TO o
peak VB o
were VBD N
not RB N
significantly RB N
different JJ N
. . N

The DT N
four-hour JJ o
serum NN o
acetaminophen NN o
level NN o
was VBD N
significantly RB N
lower JJR N
for IN N
phase NN N
II NNP N
than IN N
phase NN N
I PRP N
( ( N
P NNP N
< NNP N
.05 NNP N
, , N
two-tailed JJ N
paired VBD N
t-test NN N
) ) N
. . N

Diarrhea NNP o
occurred VBD N
during IN N
both DT N
phases NNS N
, , N
but CC N
N-acetylcysteine NNP i
was VBD N
otherwise RB N
well RB N
tolerated VBN o
. . o

CONCLUSION NNP N
These DT N
results NNS N
suggest VBP N
that IN N
activated JJ N
charcoal NN N
can MD N
be VB N
used VBN N
safely RB N
for IN N
victims NNS p
of IN p
acetaminophen NN p
overdose NN p
. . p

A DT N
beneficial JJ N
effect NN N
in IN N
preventing VBG N
acetaminophen JJ N
absorption NN N
can MD N
be VB N
expected VBN N
if IN N
it PRP N
is VBZ N
given VBN N
within IN N
one CD N
hour NN N
after IN N
ingestion NN N
. . N

If IN N
N-acetylcysteine NNP i
is VBZ N
needed VBN N
because IN N
of IN N
a DT N
toxic JJ N
serum NN N
acetaminophen NN N
level NN N
, , N
bioavailability NN N
can MD N
be VB N
ensured VBN N
by IN N
increasing VBG N
the DT N
N-acetylcysteine JJ i
loading NN N
dose NN N
from IN N
140 CD N
mg/kg NNS N
to TO N
235 CD N
mg/kg NNS N
. . N

-DOCSTART- -17019627- O O

DTkid NN N
: : N
interactive JJ N
simulation NN N
software NN N
for IN N
training VBG N
tutors NNS p
of IN p
children NNS p
with IN p
autism NN p
. . p

Discrete-trial JJ i
training NN i
( ( N
DTT NNP N
) ) N
relies VBZ N
critically RB N
on IN N
implementation NN N
by IN N
trained JJ p
tutors NNS p
. . p

We PRP N
report VBP N
three CD N
experiments NNS N
carried VBD N
out RP N
in IN N
the DT N
development NN N
of IN N
DTkid NNP N
-- : N
interactive JJ N
computer NN N
simulation NN N
software NN N
that WDT N
presents VBZ N
SIMon NNP N
, , N
a DT N
realistic JJ N
virtual JJ N
child NN N
with IN N
whom WP N
novice JJ N
tutors NNS N
can MD N
learn VB N
and CC N
practise VB N
DTT NNP N
techniques NNS N
. . N

Experiments NNS N
1 CD N
and CC N
2 CD N
exposed JJ N
groups NNS N
of IN N
participants NNS N
either DT N
to TO N
DTkid NNP i
training NN i
or CC i
to TO i
a DT i
control NN i
task NN i
. . i

Participants NNS N
in IN N
the DT N
former JJ N
groups NNS N
demonstrated VBD N
significantly RB N
greater JJR N
procedural JJ o
and CC o
declarative JJ o
knowledge NN o
of IN o
DTT NNP o
. . o

Experiment NNP N
3 CD N
confirmed VBD N
this DT N
finding NN N
, , N
further JJ N
demonstrating NN N
that IN N
observation NN N
of IN N
DTkid NNP i
training NN i
trials NNS i
alone RB N
was VBD N
sufficient JJ N
to TO N
enhance VB N
participants NNS N
' POS N
declarative NN o
and CC o
procedural JJ o
knowledge NN o
of IN N
DTT NNP N
. . N

Results NNP N
indicate VBP N
that IN N
DTkid NNP N
offers VBZ N
the DT N
potential NN N
for IN N
an DT N
effective JJ N
means NNS N
of IN N
teaching VBG N
DTT NNP N
skills NNS N
to TO N
novice JJ p
tutors NNS p
of IN p
children NNS p
with IN p
autism NN p
. . p

-DOCSTART- -25978402- O O

Multicomponent NNP N
interdisciplinary JJ N
group NN N
intervention NN N
for IN N
self-management NN N
of IN N
fibromyalgia NN p
: : p
a DT N
mixed-methods NNS N
randomized VBN N
controlled JJ N
trial NN N
. . N

BACKGROUND VB N
This DT N
study NN N
evaluated VBD N
the DT N
efficacy NN N
of IN N
the DT N
PASSAGE NNP i
Program NNP i
, , N
a DT N
structured JJ N
multicomponent NN i
interdisciplinary JJ i
group NN i
intervention NN i
for IN N
the DT N
self-management NN N
of IN N
FMS NNP p
. . p

METHODS NNP N
A DT N
mixed-methods NNS N
randomized VBN N
controlled VBN N
trial NN N
( ( i
intervention NN i
( ( i
INT NNP i
) ) i
vs. FW i
waitlist NN i
( ( i
WL NNP i
) ) i
) ) i
was VBD N
conducted VBN N
with IN N
patients NNS p
suffering VBG p
from IN p
FMS NNP p
. . p

Data NNP N
were VBD N
collected VBN N
at IN N
baseline NN N
( ( N
T0 NNP N
) ) N
, , N
at IN N
the DT N
end NN N
of IN N
the DT N
intervention NN N
( ( N
T1 NNP N
) ) N
, , N
and CC N
3 CD N
months NNS N
later RB N
( ( N
T2 NNP N
) ) N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
change NN N
in IN N
pain NN o
intensity NN o
( ( N
0-10 JJ N
) ) N
. . N

Secondary JJ N
outcomes NNS N
were VBD N
fibromyalgia JJ o
severity NN o
, , o
pain NN o
interference NN o
, , o
sleep JJ o
quality NN o
, , o
pain VBP o
coping VBG o
strategies NNS o
, , o
depression NN o
, , o
health-related JJ o
quality NN o
of IN o
life NN o
, , o
patient JJ o
global JJ o
impression NN o
of IN o
change NN o
( ( o
PGIC NNP o
) ) o
, , o
and CC o
perceived VBD o
pain NN o
relief NN o
. . o

Qualitative JJ N
group NN N
interviews NNS N
with IN N
a DT N
subset NN N
of IN N
patients NNS N
were VBD N
also RB N
conducted VBN N
. . N

Complete NNP N
data NN N
from IN N
T0 NNP N
to TO N
T2 NNP N
were VBD N
available JJ N
for IN N
43 CD p
patients NNS p
. . p

RESULTS VB N
The DT N
intervention NN N
had VBD N
a DT N
statistically RB N
significant JJ N
impact NN N
on IN N
the DT N
three CD N
PGIC NNP N
measures NNS N
. . N

At IN N
the DT N
end NN N
of IN N
the DT N
PASSAGE NNP N
Program NNP N
, , N
the DT N
percentages NNS N
of IN N
patients NNS N
who WP N
perceived VBD N
overall JJ N
improvement NN N
in IN N
their PRP$ N
pain NN o
levels NNS o
, , o
functioning NN o
and CC o
quality NN o
of IN o
life NN o
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
INT NNP N
Group NNP N
( ( N
73 CD N
% NN N
, , N
55 CD N
% NN N
, , N
77 CD N
% NN N
respectively RB N
) ) N
than IN N
in IN N
the DT N
WL NNP N
Group NNP N
( ( N
8 CD N
% NN N
, , N
12 CD N
% NN N
, , N
20 CD N
% NN N
) ) N
. . N

The DT N
same JJ N
differences NNS N
were VBD N
observed JJ N
3 CD N
months NNS N
post-intervention NN N
( ( N
Intervention NNP N
group NN N
: : N
62 CD N
% NN N
, , N
43 CD N
% NN N
, , N
38 CD N
% NN N
vs JJ N
Waitlist NNP N
Group NNP N
: : N
13 CD N
% NN N
, , N
13 CD N
% NN N
, , N
9 CD N
% NN N
) ) N
. . N

The DT N
proportion NN N
of IN N
patients NNS N
who WP N
reported VBD N
? . o
50 CD o
% NN o
pain NN o
relief NN o
was VBD o
also RB N
significantly RB N
higher RBR N
in IN N
the DT N
INT NNP N
Group NNP N
at IN N
the DT N
end NN N
of IN N
the DT N
intervention NN N
( ( N
36 CD N
% NN N
vs JJ N
12 CD N
% NN N
) ) N
and CC N
3 CD N
months NNS N
post-intervention NN N
( ( N
33 CD N
% NN N
vs JJ N
4 CD N
% NN N
) ) N
. . N

Results NNS N
of IN N
the DT N
qualitative JJ N
analysis NN N
were VBD N
in IN N
line NN N
with IN N
the DT N
quantitative JJ N
findings NNS N
regarding VBG N
the DT N
efficacy NN N
of IN N
the DT N
intervention NN N
. . N

The DT N
improvement NN N
, , N
however RB N
, , N
was VBD N
not RB N
reflected VBN N
in IN N
the DT N
primary JJ N
outcome NN N
and CC N
other JJ N
secondary JJ N
outcome NN N
measures NNS N
. . N

CONCLUSION NNP N
The DT N
PASSAGE NNP N
Program NNP N
was VBD N
effective JJ N
in IN N
helping VBG p
FMS NNP p
patients NNS p
gain VBP p
a DT N
sense NN N
of IN N
control NN N
over IN N
their PRP$ N
symptoms NNS N
. . N

We PRP N
suggest VBP N
including VBG N
PGIC NNP N
in IN N
future JJ N
clinical JJ N
trials NNS N
on IN N
FMS NNP p
as IN p
they PRP N
appear VBP N
to TO N
capture VB N
important JJ N
aspects NNS N
of IN N
the DT N
patients NNS N
' POS N
experience NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
International NNP N
Standard NNP N
Randomized NNP N
Controlled NNP N
Trial NNP N
Number NNP N
Register NNP N
ISRCTN14526380 NNP N
. . N

-DOCSTART- -17297323- O O

Combination NN N
of IN N
arteriovenous JJ i
extracorporeal NN i
lung NN i
assist NN i
and CC i
high-frequency NN i
oscillatory NN i
ventilation NN i
in IN N
a DT N
porcine JJ p
model NN p
of IN p
lavage-induced JJ p
acute NN p
lung NN p
injury NN p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
To TO N
compare VB N
the DT N
combined JJ N
effects NNS N
of IN N
arteriovenous JJ i
extracorporeal NN i
lung NN i
assist NN i
( ( i
AV-ECLA NNP i
) ) i
and CC i
high-frequency JJ i
oscillatory NN i
ventilation NN i
( ( i
HFOV NNP i
) ) i
on IN N
pulmonary NN o
gas NN o
exchange NN o
, , o
hemodynamics NNS o
, , o
and CC o
respiratory NN o
parameters NNS o
in IN N
a DT N
lavage-induced JJ p
porcine NN p
lung NN p
injury NN p
model NN N
. . N

METHODS CC N
A DT N
prospective JJ N
, , N
randomized VBN N
animal NN N
study NN N
. . N

Saline NNP i
lung NN i
lavage NN i
was VBD N
performed VBN N
in IN N
33 CD p
healthy JJ p
female NN p
pigs NNS p
, , p
weighing VBG p
52 CD p
+/- JJ p
4.1 CD p
kg NN p
( ( p
mean JJ p
+/- NNP p
SD NNP p
) ) p
, , N
until IN N
the DT N
Pao2 NNP N
decreased VBD N
to TO N
53 CD N
+/- JJ N
8 CD N
mm NN N
Hg NNP N
. . N

After IN N
a DT N
stabilization NN N
period NN N
of IN N
60 CD N
minutes NNS N
, , N
the DT N
animals NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
four CD p
groups NNS p
: : p
group NN p
1 CD p
, , N
pressure-controlled JJ i
ventilation NN i
( ( i
PCV NNP i
) ) i
with IN N
a DT N
tidal JJ N
volume NN N
of IN N
6 CD N
mL/kg NNS N
; : N
group NN p
2 CD p
, , N
PCV NNP i
with IN N
a DT N
tidal JJ N
volume NN N
of IN N
6 CD N
mL/kg NNS N
and CC N
AV-ECLA NNP i
; : i
group NN p
3 CD p
, , N
HFOV NNP i
; : i
group NN p
4 CD p
, , N
HFOV NNP i
and CC i
AV-ECLA NNP i
. . i

In IN N
groups NNS N
2 CD N
and CC N
4 CD N
, , N
the DT N
femoral JJ N
artery NN N
and CC N
vein NN N
were VBD N
cannulated VBN N
and CC N
a DT N
low-resistance NN N
membrane NN N
lung NN N
was VBD N
interposed VBN N
. . N

After IN N
isolated JJ N
evaluation NN N
of IN N
AV-ECLA NNP i
, , N
the DT N
mean JJ o
airway NN o
pressure NN o
was VBD N
increased VBN N
by IN N
3 CD N
cm NNS N
H2O NNP N
from IN N
16 CD N
to TO N
34 CD N
cm NNS N
H2O NNP N
every DT N
20 CD N
minutes NNS N
, , N
accompanied VBN N
by IN N
blood NN o
gas NN o
analyses NNS o
and CC o
measurements NNS o
of IN o
respiratory NN o
and CC o
hemodynamic JJ o
variables NNS o
. . o

RESULTS NNP N
Only RB N
in IN N
AV-ECLA-treated JJ i
animals NNS N
was VBD N
normocapnia RB o
achieved VBN N
. . N

No DT N
significant JJ N
increase NN N
of IN N
Pao2 NNP o
attributable JJ o
to TO N
AV-ECLA NNP i
alone RB N
was VBD N
detected VBN N
. . N

Mean NNP o
airway JJ o
pressure NN o
augmentation NN o
resulted VBD N
in IN N
a DT N
significant JJ N
increase NN N
in IN N
Pao2 NNP o
in IN N
all DT N
groups NNS N
. . N

Peak NNP o
inspiratory JJ o
pressure NN o
was VBD N
significantly RB N
lower JJR N
in IN N
HFOV-treated JJ N
animals NNS N
. . N

CONCLUSIONS VB N
The DT N
combination NN N
of IN N
AV-ECLA NNP i
and CC i
HFOV NNP i
resulted VBD N
in IN N
normocapnia NN o
and CC N
comparable JJ N
Pao2 NNP o
, , N
although IN N
a DT N
smaller JJR N
ventilator NN N
pressure NN N
amplitude NN N
was VBD N
applied VBN N
. . N

Long-term JJ N
animal JJ N
studies NNS N
are VBP N
needed VBN N
to TO N
assess VB N
whether IN N
this DT N
approach NN N
results NNS N
in IN N
further JJ N
lung NN N
protection NN N
. . N

-DOCSTART- -11485124- O O

Sulfasalazine NNP i
decreases VBZ N
acute JJ N
gastrointestinal JJ N
complications NNS N
due JJ N
to TO N
pelvic JJ N
radiotherapy NN N
. . N

BACKGROUND NNP N
Radiation-induced NNP N
gastrointestinal JJ N
toxicity NN N
is VBZ N
a DT N
significant JJ N
concern NN N
for IN N
patients NNS p
who WP p
are VBP p
treated VBN p
with IN p
this DT p
modality NN p
for IN p
pelvic JJ p
malignancies NNS p
. . p

Eicosanoids NNS N
and CC N
free JJ N
radicals NNS N
are VBP N
thought VBN N
to TO N
be VB N
among IN N
the DT N
reasons NNS N
for IN N
this DT N
effect NN N
. . N

Sulfasalazine NNP i
is VBZ N
an DT N
inhibitor NN N
of IN N
their PRP$ N
synthesis NN N
in IN N
the DT N
mucosa NN N
. . N

OBJECTlVE NN N
: : N
To TO N
determine VB N
whether IN N
sulfasalazine NN i
can MD N
reduce VB N
the DT N
radiation-induced JJ N
acute JJ N
gastrointestinal JJ N
complications NNS N
. . N

METHODS NNP N
In IN N
this DT N
prospective JJ N
, , N
double-blind JJ N
study NN N
, , N
31 CD p
patients NNS p
receiving VBG p
pelvic JJ p
radiotherapy NN p
were VBD N
randomized VBN N
to TO N
receive VB N
two CD N
sulfasalazine JJ i
500-mg JJ i
tablets NNS i
twice JJ i
daily RB i
or CC i
placebo VB i
, , N
administered VBN N
orally RB N
from IN N
the DT N
first JJ N
day NN N
of IN N
irradiation NN N
. . N

Patients NNS N
were VBD N
evaluated JJ N
weekly JJ N
, , N
and CC N
gastrointestinal JJ o
toxicities NNS o
were VBD N
graded VBN N
according VBG N
to TO N
the DT N
Late JJ o
Effect NNP o
of IN o
Normal NNP o
Tissue-Subjective NNP o
Objective NNP o
Management NNP o
Analytic NNP o
( ( o
LENT-SOMA NNP o
) ) o
toxicity NN o
table NN o
during IN N
pelvic JJ N
radiotherapy NN N
. . N

On IN N
the DT N
last JJ N
day NN N
of IN N
week NN N
5 CD N
, , N
the DT N
subjects NNS N
were VBD N
graded VBN N
endoscopically RB N
, , N
and CC N
biopsies NNS N
taken VBN N
from IN N
the DT N
rectum NN N
were VBD N
classified VBN N
histopathologically RB N
. . N

RESULTS NNP N
Groups NNP p
did VBD p
not RB p
differ VB p
in IN p
age NN p
, , p
gender NN p
, , p
tumor NN p
site NN p
, , p
or CC p
irradiation NN p
procedure NN p
. . p

During IN N
radiotherapy NN N
, , N
grade VBD o
2 CD o
or CC o
higher JJR o
gastrointestinal JJ o
toxicity NN o
occurred VBD N
in IN N
20 CD N
% NN N
( ( N
3/15 CD N
) ) N
and CC N
63 CD N
% NN N
( ( N
10/16 CD N
) ) N
of IN N
the DT N
sulfasalazine NN N
and CC N
placebo NN N
groups NNS N
, , N
respectively RB N
. . N

This DT N
difference NN o
was VBD N
significant JJ N
( ( N
p JJ N
= NNP N
0.017 CD N
) ) N
. . N

No DT N
statistically RB N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
endoscopic NN N
and CC N
histopathologic JJ N
evaluations NNS N
. . N

CONCLUSIONS NNP N
Sulfasalazine NNP N
is VBZ N
effective JJ N
in IN N
decreasing VBG N
clinically RB N
acute JJ N
gastrointestinal JJ N
toxicities NNS N
. . N

Long-term JJ N
follow-up JJ N
with IN N
the DT p
subjects NNS p
will MD N
help VB N
to TO N
determine VB N
the DT N
net JJ N
effect NN N
of IN N
sulfasalazine NN N
on IN N
the DT N
radiation-induced JJ p
gastrointestinal JJ p
injuries NNS p
. . p

-DOCSTART- -3839157- O O

The DT N
Eastern NNP p
Cooperative NNP p
Oncology NNP p
Group NNP p
experience NN N
with IN N
cyclophosphamide NN i
, , i
adriamycin NN i
, , i
and CC i
5-fluorouracil JJ i
( ( i
CAF NNP i
) ) i
in IN N
patients NNS p
with IN p
metastatic JJ p
breast NN p
cancer NN p
. . p

Data NNP N
on IN N
162 CD p
women NNS p
( ( p
90 CD p
premenopausal NN p
and CC p
72 CD p
postmenopausal NN p
) ) p
with IN p
metastatic JJ p
breast NN p
cancer NN p
randomized VBN N
to TO N
receive VB N
cyclophosphamide NN i
, , i
Adriamycin NNP i
( ( i
doxorubicin NN i
) ) i
and CC i
5-fluorouracil JJ i
( ( i
CAF NNP i
) ) i
on IN N
two CD N
Eastern JJ p
Cooperative NNP p
Oncology NNP p
Group NNP p
( ( p
ECOG NNP p
) ) p
protocols NNS N
were VBD N
analyzed VBN N
. . N

Twenty-three JJ N
percent NN N
had VBD N
complete JJ N
remission NN N
; : N
39 CD N
% NN N
had VBD N
partial JJ N
remission NN N
; : N
28 CD N
% NN N
had VBD N
no DT N
change NN N
; : N
and CC N
3 CD N
% NN N
had VBD N
disease VBN N
progression NN N
. . N

Of IN N
those DT N
patients NNS N
in IN N
whom WP N
receptors NNS N
were VBD N
known VBN N
, , N
response NN N
rates NNS N
were VBD N
65 CD N
% NN N
for IN N
estrogen NN N
( ( N
ER NNP N
) ) N
-receptor NN N
positive JJ N
and CC N
70 CD N
% NN N
for IN N
ER-negative JJ N
patients NNS N
. . N

The DT N
median JJ o
duration NN o
of IN N
response NN N
was VBD N
11.4 CD N
months NNS N
. . N

The DT N
median JJ o
survival NN o
time NN o
from IN N
the DT N
start NN N
of IN N
CAF NNP N
was VBD N
20.2 CD N
months NNS N
. . N

The DT N
response NN o
rate NN o
, , o
time NN o
to TO o
treatment NN o
failure NN o
( ( o
TTF NNP o
) ) o
, , o
and CC o
median JJ o
survival NN o
time NN o
were VBD N
superior JJ N
in IN N
the DT N
premenopausal JJ N
women NNS N
. . N

These DT N
differences NNS N
ceased VBD N
, , N
however RB N
, , N
to TO N
be VB N
statistically RB N
significant JJ N
in IN N
logistic JJ N
models NNS N
. . N

Factors NNS N
significantly RB N
associated VBN N
with IN N
longer JJR N
TTF NNP o
and CC N
longer JJR N
survival NN o
were VBD N
as IN N
follows VBZ N
: : N
one CD N
or CC N
two CD N
organs NNS N
with IN N
metastases NNS N
( ( N
TTF NNP N
, , N
P NNP N
less JJR N
than IN N
0.0001 CD N
; : N
survival NN N
, , N
P NNP N
less JJR N
than IN N
0.0001 CD N
) ) N
; : N
dominant JJ N
site NN N
other JJ N
than IN N
soft JJ N
tissue NN N
( ( N
TTF NNP N
, , N
P NNP N
less JJR N
than IN N
0.0001 CD N
; : N
survival NN N
, , N
P NNP N
= NNP N
0.05 CD N
) ) N
; : N
and CC N
an DT N
initial JJ N
good JJ N
performance NN N
status NN N
( ( N
TTF NNP N
, , N
P NNP N
= NNP N
0.007 CD N
; : N
survival NN N
, , N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

Patients NNS N
with IN N
ER-positive JJ N
disease NN N
had VBD N
a DT N
significantly RB N
longer RBR o
median JJ o
survival NN o
time NN o
( ( N
P NNP N
= NNP N
0.003 CD N
) ) N
. . N

-DOCSTART- -26315857- O O

Recruitment NN o
and CC o
Reasons NNP o
for IN o
Non-Participation NNP o
in IN N
a DT N
Family-Coping-Orientated JJ i
Palliative NNP i
Home NNP i
Care NNP i
Trial NNP N
( ( N
FamCope NNP N
) ) N
. . N

Cancer NN p
patients NNS p
and CC p
their PRP$ p
family NN p
caregivers NNS p
need VBP N
support NN N
to TO N
cope VB N
with IN N
physical JJ N
, , N
psychosocial JJ N
, , N
and CC N
existential JJ N
problems NNS N
early RB N
in IN N
the DT N
palliative JJ N
care NN N
trajectory NN N
. . N

Many JJ N
interventions NNS N
target VBP N
patient JJ N
symptomatology NN N
, , N
with IN N
health NN N
care NN N
professionals NNS N
acting VBG N
as IN N
problem-solvers NNS N
. . N

Family RB N
coping VBG N
, , N
however RB N
, , N
is VBZ N
a DT N
new JJ N
research NN N
area NN N
within IN N
palliative JJ N
care NN N
. . N

The DT N
FamCope NNP i
intervention NN i
was VBD N
developed VBN N
to TO N
test VB N
if IN N
a DT N
nurse-led JJ i
family-coping-orientated JJ i
palliative NN i
home NN i
care NN i
intervention NN i
would MD N
help VB N
families NNS N
cope VB N
with IN N
physical JJ N
and CC N
psychosocial JJ N
problems NNS N
at IN N
home NN N
-- : N
together RB N
as IN N
a DT N
family NN N
and CC N
in IN N
interaction NN N
with IN N
health NN N
care NN N
professionals NNS N
. . N

However RB N
, , N
an DT N
unexpectedly RB N
high JJ N
number NN N
of IN N
families NNS N
declined VBD N
participation NN o
in IN N
the DT N
trial NN N
. . N

We PRP N
describe VBP N
and CC N
discuss VBP N
the DT N
recruitment NN o
strategy NN o
and CC N
patient NN o
reported VBD o
reasons NNS o
for IN N
non-participation NN o
to TO N
add VB N
to TO N
the DT N
knowledge NN N
about IN N
what WP N
impedes JJ N
recruitment NN N
and CC N
to TO N
identify VB N
the DT N
factors NNS N
that WDT N
influence NN N
willingness NN N
to TO N
participate VB N
in IN N
research NN N
aimed VBN N
at IN N
family NN N
coping VBG N
early RB N
in IN N
the DT N
palliative JJ N
care NN N
trajectory NN N
. . N

Patients NNS p
with IN p
advanced JJ p
cancer NN p
and CC p
their PRP$ p
closest JJS p
relative NN p
were VBD p
recruited VBN p
from IN p
medical JJ p
, , p
surgical JJ p
, , p
and CC p
oncological JJ p
departments NNS p
. . p

Reasons NNS N
for IN N
non-participation NN o
were VBD N
registered VBN N
and CC N
characteristics NNS N
of IN N
participants NNS N
and CC N
non-participants NNS N
were VBD N
compared VBN N
to TO N
evaluate VB N
differences NNS N
between IN N
subgroups NNS N
of IN N
non-participants NNS N
based VBN N
on IN N
reasons NNS N
not RB N
to TO N
participate VB N
and CC N
reasons NNS N
to TO N
participate VB N
in IN N
the DT N
trial NN N
. . N

A DT N
total NN N
of IN N
65.9 CD N
% NN N
of IN N
the DT N
families NNS N
declined VBD N
participation NN o
. . o

Two CD N
main JJ N
categories NNS N
for IN N
declining VBG N
participation NN o
emerged VBD N
: : N
first RB N
, , N
that IN N
the DT N
burden NN N
of IN N
illness NN N
is VBZ N
too RB N
great JJ N
and CC N
, , N
second JJ N
, , N
that IN N
it PRP N
was VBD N
too RB N
soon RB N
to TO N
receive VB N
this DT N
kind NN N
of IN N
support NN N
. . N

Men NN p
were VBD N
more RBR N
likely JJ N
to TO N
participate VB o
than IN N
women NNS p
. . p

Patients NNS N
in IN N
the DT N
too RB N
soon RB N
group NN N
had VBD N
similar JJ N
characteristics NNS N
to TO N
participants NNS N
in IN N
the DT N
trial NN N
. . N

Timing NN N
of IN N
interventions NNS N
and CC N
readiness NN N
of IN N
patients NNS N
and CC N
their PRP$ N
relatives NNS N
seems VBZ N
to TO N
affect VB N
willingness NN o
to TO o
receive VB o
a DT o
family-coping-orientated JJ o
care NN o
approach NN o
and CC N
impeded JJ N
recruitment NN N
to TO N
this DT N
trial NN N
. . N

Our PRP$ N
findings NNS N
can MD N
be VB N
used VBN N
in IN N
further JJ N
research NN N
and CC N
in IN N
clinical JJ N
practice NN N
in IN N
order NN N
to TO N
construct VB N
interventions NNS N
and CC N
target NN N
relevant JJ N
populations NNS N
for IN N
early JJ N
family-coping-orientated JJ N
palliative NN i
care NN i
. . i

-DOCSTART- -2808984- O O

Rate-modulated JJ N
cardiac NN N
pacing NN N
based VBN N
on IN N
transthoracic JJ N
impedance NN N
measurements NNS N
of IN N
minute JJ N
ventilation NN N
: : N
correlation NN N
with IN N
exercise NN N
gas NN N
exchange NN N
. . N

The DT N
relation NN N
of IN N
pacing VBG N
rate NN N
to TO N
physiologic VB N
variables NNS N
of IN N
metabolic JJ N
demand NN N
was VBD N
examined VBN N
in IN N
10 CD p
consecutive JJ p
patients NNS p
with IN p
a DT p
minute NN p
ventilation-sensing NN p
, , p
rate-modulating JJ p
ventricular JJ p
pacemaker NN p
implanted VBN p
for IN p
complete JJ p
heart NN p
block NN p
. . p

All DT p
patients NNS p
had VBD p
paroxysmal JJ p
( ( p
seven CD p
patients NNS p
) ) p
or CC p
chronic JJ p
( ( p
three CD p
patients NNS p
) ) p
atrial JJ p
fibrillation NN p
and CC p
were VBD p
referred VBN p
for IN p
catheter JJR i
ablation NN i
of IN i
the DT i
atrioventricular JJ i
junction NN i
. . i

Treadmill NNP i
exercise NN i
testing VBG i
with IN N
measurement NN N
of IN N
expired NNP o
gas NN o
exchange NN o
and CC o
respiratory NN o
flow NN o
was VBD N
performed VBN N
before IN N
ablation NN N
and CC N
4 CD N
weeks NNS N
after IN N
pacemaker NN N
implantation NN N
, , N
with IN N
the DT N
pacemaker NN N
programmed VBD N
to TO N
both DT N
the DT N
fixed-rate JJ N
VVI NNP N
and CC N
rate-modulating JJ N
minute NN N
ventilation NN N
VVIR NNP N
pacing VBG N
modes NNS N
in IN N
random JJ N
sequence NN N
. . N

The DT N
relation NN o
of IN o
pacing VBG o
rate NN o
to TO o
oxygen VB o
consumption NN o
( ( o
VO2 NNP o
) ) o
, , o
expired VBD o
carbon NN o
dioxide NN o
concentration NN o
( ( o
VCO2 NNP o
) ) o
, , o
respiratory JJ o
quotient NN o
, , o
tidal JJ o
volume NN o
, , o
respiratory NN o
rate NN o
and CC o
minute NN o
ventilation NN o
was VBD N
determined VBN N
during IN N
exercise NN N
in IN N
the DT N
rate-modulating JJ N
minute NN N
ventilation NN N
pacing VBG N
mode NN N
. . N

Pacing VBG o
rate NN o
was VBD N
highly RB N
correlated VBN N
with IN N
minute JJ o
ventilation NN o
( ( N
r JJ N
= NNP N
0.89 CD N
) ) N
, , N
respiratory JJ o
quotient NN o
( ( N
r JJ N
= NNP N
0.89 CD N
) ) N
, , N
VCO2 NNP o
( ( N
r VB N
= RB N
0.87 CD N
) ) N
, , N
tidal JJ o
volume NN o
( ( N
r JJ N
= NNP N
0.87 CD N
) ) N
, , N
VO2 NNP o
( ( N
r VB N
= RB N
0.84 CD N
) ) N
and CC N
respiratory JJ o
rate NN o
( ( N
r NN N
= RB N
0.84 CD N
) ) N
. . N

The DT N
mean JJ o
exercise NN o
duration NN o
increased VBD N
from IN N
8.3 CD N
+/- JJ N
2.8 CD N
min NN N
in IN N
the DT N
fixed JJ N
rate NN N
pacing VBG N
mode NN N
to TO N
10.2 CD N
+/- JJ N
3.4 CD N
min NN N
in IN N
the DT N
rate-modulating NN N
, , N
minute NN N
ventilation NN N
mode NN N
( ( N
p JJ N
= NNP N
0.0001 CD N
) ) N
. . N

The DT N
maximal JJ o
VO2 NNP o
increased VBD N
from IN N
13.4 CD N
+/- JJ N
3.4 CD N
to TO N
16.3 CD N
+/- JJ N
4.1 CD N
cc/kg NN N
per IN N
min NN N
( ( N
p JJ N
= NNP N
0.0004 CD N
) ) N
. . N

The DT N
maximal JJ N
heart NN N
rate NN N
achieved VBN N
in IN N
the DT N
minute NN N
ventilation NN N
pacing VBG N
mode NN N
was VBD N
136 CD N
+/- JJ N
9.7 CD N
beats/min NN N
, , N
similar JJ N
to TO N
that DT N
observed VBN N
in IN N
the DT N
patient NN N
's POS N
intrinsic JJ N
cardiac JJ N
rhythm NN N
before IN N
ablation NN N
( ( N
134.9 CD N
+/- JJ N
30.1 CD N
beats/min NN N
, , N
p NN N
= NNP N
NS NNP N
) ) N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -11157143- O O

The DT N
effects NNS N
of IN N
treatment NN N
with IN N
interleukin-1 JJ i
receptor NN i
antagonist NN i
on IN N
the DT N
inflamed JJ N
synovial JJ N
membrane NN N
in IN N
rheumatoid JJ p
arthritis NN p
. . p

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
effects NNS N
of IN N
treatment NN N
with IN N
interleukin-1 JJ i
receptor NN i
antagonist NN i
( ( i
IL-1Ra NNP i
) ) i
on IN N
synovial JJ N
tissue NN N
in IN N
rheumatoid NN N
arthritis NN N
( ( N
RA NNP N
) ) N
. . N

METHODS NNP N
Twelve NNP p
patients NNS p
with IN p
RA NNP p
entering VBG p
a DT p
randomized JJ p
clinical JJ p
trial NN p
of IN p
human JJ i
recombinant JJ i
IL-1Ra NNP i
underwent NN N
synovial JJ i
biopsies NNS i
before IN N
and CC N
after IN N
treatment NN N
. . N

Cellular JJ o
infiltration NN o
and CC o
adhesion NN o
molecule NN o
expression NN o
were VBD N
evaluated VBN N
after IN N
immunohistochemical JJ N
staining NN N
. . N

RESULTS NNP N
There EX N
was VBD N
a DT N
notable JJ N
reduction NN o
in IN o
intimal JJ o
layer NN o
macrophages NNS o
and CC o
subintimal JJ o
macrophages NNS o
and CC o
lymphocytes NNS o
after IN N
treatment NN N
with IN N
IL-1Ra NNP i
at IN N
150 CD N
mg/day NN N
( ( N
n=3 JJ N
) ) N
. . N

Increased VBN N
cellular JJ o
infiltration NN o
was VBD N
observed VBN N
in IN N
all DT N
patients NNS N
receiving VBG N
placebo NN i
( ( N
n=3 JJ N
) ) N
; : N
variable JJ N
changes NNS N
were VBD N
observed VBN N
after IN N
IL-1Ra NNP i
30 CD N
mg/day NN N
( ( N
n=6 JJ N
) ) N
. . N

In IN N
a DT N
limited JJ N
study NN N
of IN N
adhesion NN N
molecule NN N
expression NN N
, , N
down-regulation NN o
of IN o
E-selectin NNP o
and CC o
vascular JJ o
cell NN o
adhesion NN o
molecule-1 NN o
was VBD N
observed VBN N
after IN N
treatment NN N
with IN N
IL-1Ra NNP i
150 CD N
mg/day NN N
, , N
but CC N
not RB N
after IN N
IL-1Ra NNP i
30 CD N
mg/day NN N
or CC N
placebo NN i
. . i

The DT N
apparent JJ N
arrest NN o
of IN o
progressive JJ o
joint JJ o
damage NN o
seen VBN N
in IN N
four CD N
patients NNS N
after IN N
treatment NN N
with IN N
IL-1Ra NNP i
was VBD N
associated VBN N
with IN N
reduced JJ N
intimal JJ N
layer NN N
macrophage NN N
accumulation NN N
in IN N
all DT N
patients NNS N
. . N

CONCLUSION NNP N
Treatment NNP N
of IN N
RA NNP N
with IN N
IL-1Ra NNP i
resulted VBD N
in IN N
reduced JJ N
mononuclear NN N
cell NN N
infiltration NN N
of IN N
synovial JJ N
membrane NN N
, , N
which WDT N
may MD N
represent VB N
the DT N
in IN N
vivo JJ N
inhibition NN N
of IN N
biologically RB N
relevant JJ N
IL-1ss-mediated JJ N
pathogenic JJ N
effects NNS N
. . N

-DOCSTART- -16006861- O O

Prospective JJ N
, , N
randomized JJ N
comparison NN N
of IN N
transperitoneal JJ i
versus NN i
retroperitoneal NN i
laparoscopic JJ i
adrenalectomy NN i
. . i

PURPOSE NNP N
We PRP N
report VBP N
a DT N
prospective JJ N
, , N
randomized JJ N
comparison NN N
of IN N
transperitoneal JJ i
laparoscopic JJ i
adrenalectomy NN i
( ( i
TLA NNP i
) ) i
vs FW i
retroperitoneal JJ i
laparoscopic NN i
adrenalectomy NN i
( ( i
RLA NNP i
) ) i
for IN N
adrenal JJ N
lesions NNS N
with IN N
long-term JJ N
followup NN N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Between NNP p
December NNP p
1997 CD p
and CC p
November NNP p
1999 CD p
, , p
57 CD p
consecutive JJ p
eligible JJ p
patients NNS p
with IN p
surgical JJ p
adrenal JJ p
disease NN p
were VBD N
prospectively RB i
randomized VBN i
to TO i
undergo VB i
TLA NNP i
( ( i
25 CD i
) ) i
or CC i
RLA NNP i
( ( i
32 CD i
) ) i
. . i

Study NNP p
exclusion NN p
criteria NNS p
were VBD p
patient JJ p
age NN p
greater JJR p
than IN p
80 CD p
years NNS p
, , p
body NN p
mass NN p
index NN p
greater JJR p
than IN p
40 CD p
, , p
bilateral JJ p
adrenalectomy NN p
and CC p
significant JJ p
prior JJ p
abdominal JJ p
surgery NN p
in IN p
the DT p
quadrant NN p
of IN p
interest NN p
. . p

Mean NNP N
followup NN N
was VBD N
5.96 CD N
years NNS N
in IN N
the DT N
2 CD N
groups NNS N
. . N

RESULTS VB N
The DT N
groups NNS N
were VBD N
matched VBN N
in IN N
regard NN N
to TO N
patient JJ N
age NN N
( ( N
p JJ N
= NNP N
0.84 CD N
) ) N
, , N
body JJ N
mass NN N
index NN N
( ( N
p JJ N
= NNP N
0.43 CD N
) ) N
, , N
American NNP N
Society NNP N
of IN N
Anesthesiologists NNP N
class NN N
( ( N
p JJ N
= NNP N
0.81 CD N
) ) N
and CC N
laterality NN N
( ( N
p JJ N
= NNP N
0.12 CD N
) ) N
. . N

Median JJ N
adrenal JJ o
mass NN o
size NN o
was VBD N
2.7 CD N
cm NN N
( ( N
range VB N
1 CD N
to TO N
9 CD N
) ) N
in IN N
the DT N
TLA NNP N
group NN N
and CC N
2.6 CD N
cm NN N
( ( N
range VB N
0.5 CD N
to TO N
6 CD N
) ) N
in IN N
the DT N
RLA NNP N
group NN N
( ( N
p JJ N
= NNP N
0.83 CD N
) ) N
. . N

TLA NNP N
was VBD N
comparable JJ N
to TO N
RLA NNP N
in IN N
terms NNS N
of IN N
operative JJ o
time NN o
( ( N
130 CD N
vs NN N
126.5 CD N
minutes NNS N
, , N
p VBP N
= RB N
0.64 CD N
) ) N
, , N
estimated VBN o
blood NN o
loss NN o
( ( N
p JJ N
= NNP N
0.92 CD N
) ) N
, , N
specimen NNS o
weight VBD o
( ( N
p JJ N
= NNP N
0.81 CD N
) ) N
, , N
analgesic JJ o
requirements NNS o
( ( N
p JJ N
= NNP N
0.25 CD N
) ) N
, , N
hospital JJ o
stay NN o
( ( N
p JJ N
= NNP N
0.56 CD N
) ) N
and CC N
the DT N
complication NN o
rate NN o
( ( N
p JJ N
= NNP N
0.58 CD N
) ) N
. . N

One CD N
case NN N
per IN N
group NN N
was VBD N
electively RB N
converted VBN N
to TO N
open VB o
surgery NN o
. . o

Pathology NNP N
data NNS N
on IN N
the DT N
intact JJ N
extracted JJ N
specimens NNS N
were VBD N
similar JJ N
between IN N
the DT N
groups NNS N
. . N

Averaged VBD N
convalescence NN o
was VBD N
4.7 CD N
weeks NNS N
in IN N
the DT N
TLA NNP N
group NN N
and CC N
2.3 CD N
weeks NNS N
in IN N
the DT N
RLA NNP N
group NN N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
. . N

During IN N
a DT N
mean JJ N
followup NN N
of IN N
6 CD N
years NNS N
2 CD N
patients NNS N
in IN N
the DT N
TLA NNP N
group NN N
had VBD N
a DT N
late JJ o
complication NN o
( ( o
port JJ o
site NN o
hernia NN o
) ) o
. . o

Mortality NN o
occurred VBD N
in IN N
5 CD N
patients NNS N
, , N
including VBG N
1 CD N
with IN N
TLA NNP N
and CC N
4 CD N
with IN N
RLA NNP N
, , N
during IN N
the DT N
6-year JJ N
followup NN N
. . N

CONCLUSIONS NNP N
For IN N
most JJS N
benign JJ N
adrenal JJ N
lesions NNS N
requiring VBG N
surgery NN N
laparoscopic NN i
adrenalectomy NN i
can MD N
be VB N
performed VBN N
safely RB o
and CC N
effectively RB o
by IN N
the DT N
transperitoneal NN N
or CC N
the DT N
retroperitoneal JJ N
approach NN N
. . N

-DOCSTART- -15310639- O O

Caudal NNP i
neostigmine NN i
with IN i
bupivacaine NN i
produces VBZ N
a DT N
dose-independent JJ N
analgesic JJ N
effect NN N
in IN N
children NNS p
. . p

PURPOSE NNP N
To TO N
evaluate VB o
the DT N
analgesic JJ o
efficacy NN o
and CC o
duration NN o
of IN N
varying VBG N
doses NNS N
of IN N
caudal JJ i
neostigmine NN i
with IN i
plain JJ i
bupivacaine NN i
and CC N
its PRP$ N
side NN N
effects NNS N
in IN N
children NNS p
undergoing VBG p
genito-urinary JJ p
surgery NN p
. . p

METHODS NNP N
In IN N
a DT N
randomized JJ N
double-blind NN N
prospective JJ N
study NN N
80 CD p
boys NNS p
aged VBN p
two CD p
to TO p
eight CD p
years NNS p
scheduled VBN p
for IN p
surgical JJ p
repair NN p
of IN p
hypospadias NNS p
were VBD p
allocated VBN p
randomly RB p
to TO N
one CD N
of IN N
four CD N
groups NNS N
( ( N
n JJ N
= RB N
20 CD N
each DT N
) ) N
and CC N
received VBD N
either CC N
only RB i
caudal JJ i
0.25 CD p
% NN p
plain NN i
bupivacaine NN i
0.5 CD p
mL.kg NN p
( ( p
-1 NN p
) ) p
( ( p
Group NNP p
I PRP p
) ) p
or CC N
0.25 CD i
% NN i
plain NN i
bupivacaine NN i
0.5 CD i
mL.kg NN i
( ( i
-1 NNP i
) ) i
with IN i
neostigmine NN i
( ( p
Groups NNP p
II-IV NNP p
) ) p
in IN N
doses NNS N
of IN N
2 CD N
, , N
3 CD N
and CC N
4 CD N
microg.kg NN N
( ( N
-1 NNP N
) ) N
respectively RB N
. . N

Postoperative JJ o
pain NN o
was VBD N
assessed VBN N
for IN N
24 CD N
hr NN N
using VBG N
an DT N
objective JJ o
pain NN o
score NN o
. . o

Blood NNP o
pressure NN o
, , o
heart NN o
rate NN o
, , o
oxygen NN o
saturation NN o
, , o
total JJ o
amount NN o
of IN o
analgesic JJ o
consumed VBN o
and CC o
adverse JJ o
effects NNS o
were VBD N
also RB N
recorded VBN N
. . N

RESULTS VB N
The DT N
duration NN o
of IN o
postoperative JJ o
analgesia NN o
in IN N
Group NNP N
I PRP N
( ( N
5.1 CD N
+/- JJ N
2.3 CD N
hr NN N
) ) N
was VBD N
significantly RB N
shorter JJR N
than IN N
in IN N
the DT N
other JJ N
three CD N
groups NNS N
( ( N
II NNP N
-16.6 NNP N
+/- JJ N
4.9 CD N
hr NN N
; : N
III NNP N
- : N
17.2 CD N
+/- JJ N
5.5 CD N
hr NN N
; : N
IV NNP N
- : N
17.0 CD N
+/- JJ N
5.8 CD N
hr NN N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Total JJ o
analgesic JJ o
( ( o
paracetamol NN o
) ) o
consumption NN o
was VBD N
significantly RB N
more RBR N
in IN N
Group NNP N
I PRP N
( ( N
697.6 CD N
+/- JJ N
240.7 CD N
mg NN N
) ) N
than IN N
in IN N
the DT N
groups NNS N
receiving VBG N
caudal JJ N
neostigmine NN i
( ( N
II NNP N
- : N
248.0 CD N
+/- JJ N
178.4 CD N
; : N
III NNP N
- : N
270.2 CD N
+/- JJ N
180.8 CD N
and CC N
IV NNP N
-230.6 NNP N
+/- JJ N
166.9 CD N
mg NN N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Groups NNP N
II NNP N
, , N
III NNP N
and CC N
IV NNP N
were VBD N
comparable JJ N
with IN N
regards NNS N
to TO N
duration NN o
of IN o
postoperative JJ o
analgesia NN o
and CC o
total JJ o
analgesic JJ o
consumption NN o
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

Incidence NN N
of IN N
nausea NN o
and CC o
vomiting NN o
were VBD N
comparable JJ N
in IN N
all DT N
four CD N
groups NNS N
. . N

No DT N
significant JJ N
alteration NN N
in IN N
vital JJ o
signs NNS o
or CC N
any DT N
other JJ N
adverse JJ N
effects NNS N
were VBD N
observed VBN N
. . N

CONCLUSIONS NNP N
Caudal NNP i
neostigmine NN i
( ( N
2 CD N
, , N
3 CD N
and CC N
4 CD N
microg.kg NN N
( ( N
-1 NNP N
) ) N
) ) N
with IN N
bupivacaine NN i
produces VBZ N
a DT N
dose-independent JJ N
analgesic JJ o
effect NN o
( ( N
approximately RB N
16-17 JJ N
hr NN N
) ) N
in IN N
children NNS N
as IN N
compared VBN N
to TO N
those DT N
receiving VBG N
caudal JJ N
bupivacaine NN i
alone RB N
( ( N
approximately RB N
five CD N
hours NNS N
) ) N
and CC N
a DT N
reduction NN N
in IN N
postoperative JJ o
rescue NN o
analgesic JJ o
consumption NN o
without IN N
increasing VBG N
the DT N
incidence NN N
of IN N
adverse JJ o
effects NNS o
. . o

-DOCSTART- -6841763- O O

Modifying VBG o
the DT o
Type NN o
A DT o
coronary-prone JJ o
behavior NN o
pattern NN o
. . o

-DOCSTART- -15937606- O O

A DT N
comparison NN N
of IN N
urinary JJ o
and CC o
sexual JJ o
outcomes NNS o
in IN N
women NNS p
experiencing VBG p
vaginal JJ p
and CC p
Caesarean JJ p
births NNS p
. . p

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
urinary JJ o
and CC o
sexual JJ o
consequences NNS o
of IN N
vaginal JJ i
delivery NN i
compared VBN i
with IN i
Caesarean JJ i
section NN i
. . i

METHODS NNP N
We PRP N
performed VBD N
a DT N
cohort NN N
analysis NN N
of IN N
data NNS N
from IN N
a DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
episiotomy NN N
conducted VBN N
in IN N
3 CD p
Montreal NNP p
hospitals NNS p
in IN p
1990-1991 JJ p
. . p

Of IN N
the DT N
999 CD p
trial NN p
participants NNS p
for IN p
whom WP p
follow-up JJ p
data NNS p
were VBD p
available JJ p
, , p
135 CD p
delivered VBN p
by IN p
Caesarean NNP i
section NN i
( ( i
CS NNP i
) ) i
, , p
and CC p
864 CD p
had VBD p
a DT p
vaginal JJ i
birth NN i
( ( i
VB NNP i
) ) i
. . i

After IN N
stratifying VBG N
for IN N
parity NN N
, , N
we PRP N
compared VBN N
rates NNS N
of IN N
urinary JJ o
incontinence NN o
( ( o
UI NNP o
) ) o
and CC o
sexual JJ o
functioning NN o
at IN N
3 CD N
months NNS N
postpartum VBN N
in IN N
women NNS N
who WP N
had VBD N
a DT N
VB NNP N
with IN N
the DT N
rates NNS N
in IN N
women NNS N
who WP N
had VBD N
a DT N
CS NNP N
. . N

RESULTS NNP N
Primiparous JJ p
women NNS p
reported VBD N
unspecified JJ N
UI NNP o
at IN N
3 CD N
months NNS N
postpartum IN N
more RBR N
often RB N
( ( N
17.9 CD N
% NN N
) ) N
in IN N
the DT N
VB NNP N
group NN N
than IN N
in IN N
the DT N
CS NNP N
group NN N
( ( N
6.4 CD N
% NN N
) ) N
. . N

This DT N
difference NN N
remained VBD N
significant JJ N
whether IN N
or CC N
not RB N
there EX N
was VBD N
a DT N
prior JJ N
history NN N
of IN N
UI NNP N
. . N

Multiparous JJ p
women NNS p
showed VBD N
no DT N
difference NN N
in IN N
rates NNS o
of IN o
UI NNP o
( ( N
VB NNP N
17.1 CD N
% NN N
vs. FW N
CS NNP N
16.0 CD N
% NN N
) ) N
, , N
whether IN N
there EX N
was VBD N
a DT N
prior JJ N
history NN N
of IN N
UI NNP N
or CC N
not RB N
. . N

Stress NNP o
incontinence NN o
was VBD N
greater JJR N
among IN N
primiparous JJ N
women NNS N
in IN N
the DT N
VB NNP N
group NN N
( ( N
VB NNP N
34.5 CD N
% NN N
vs. FW N
CS NNP N
12.8 CD N
% NN N
) ) N
regardless NN N
of IN N
prior JJ N
UI NNP N
history NN N
, , N
but CC N
the DT N
proportion NN N
of IN N
women NNS N
whose WP$ N
UI NNP o
was VBD N
severe JJ N
enough RB N
to TO N
wear VB N
a DT N
pad NN N
was VBD N
similar JJ N
in IN N
primiparous JJ N
women NNS N
( ( N
VB NNP N
16.0 CD N
% NN N
, , N
CS NNP N
15.4 CD N
% NN N
) ) N
and CC N
multiparous JJ N
women NNS N
( ( N
VB NNP N
23.8 CD N
% NN N
, , N
CS NNP N
25.0 CD N
% NN N
) ) N
. . N

Women NNP o
's POS o
sexual JJ o
dissatisfaction NN o
was VBD N
greater JJR N
among IN N
primiparous JJ N
women NNS N
who WP N
had VBD N
a DT N
vaginal JJ N
birth NN N
( ( N
VB NNP N
70.1 CD N
% NN N
, , N
CS NNP N
54.5 CD N
% NN N
) ) N
, , N
but CC N
in IN N
multiparous JJ N
women NNS N
, , N
the DT N
rates NNS N
of IN N
sexual JJ o
dissatisfaction NN o
were VBD N
similar JJ N
( ( N
VB NNP N
64.2 CD N
% NN N
, , N
CS NNP N
71.4 CD N
% NN N
) ) N
. . N

The DT N
frequency NN o
of IN o
dyspareunia NN o
for IN N
each DT N
mode NN N
of IN N
delivery NN N
was VBD N
similar JJ N
in IN N
primiparous JJ N
women NNS N
( ( N
VB NNP N
30.7 CD N
% NN N
, , N
CS NNP N
31.6 CD N
% NN N
) ) N
. . N

Overall JJ N
, , N
both DT N
primiparous JJ N
and CC N
multiparous JJ N
women NNS N
who WP N
had VBD N
intact JJ N
perineums NNS N
after IN N
VB NNP N
had VBD N
less RBR N
dyspareunia JJ o
than IN N
those DT N
undergoing JJ N
CS NNP N
( ( N
VB NNP N
26.2 CD N
, , N
CS NNP N
40.7 CD N
% NN N
) ) N
. . N

However RB N
, , N
the DT N
proportion NN N
of IN N
women NNS N
experiencing VBG N
dyspareunia NN o
was VBD N
greatest JJS N
among IN N
those DT p
who WP p
had VBD p
an DT p
episiotomy NN p
with IN p
or CC p
without IN p
forceps NNS p
. . p

-DOCSTART- -25195982- O O

The DT N
dispatcher NN N
assisted VBD N
resuscitation NN N
trial NN N
: : N
indirect JJ o
benefits NNS o
of IN N
emergency NN N
research NN N
. . N

OBJECTIVE NNP N
Conduct NNP N
of IN N
emergency NN N
research NN N
under IN N
waiver NN N
of IN N
consent NN N
produces VBZ N
special JJ N
challenges NNS N
. . N

Moreover RB N
, , N
the DT N
act NN N
of IN N
performing VBG N
research NN N
may MD N
have VB N
unintended JJ N
effects NNS N
, , N
potentially RB N
beneficial JJ N
or CC N
detrimental JJ N
. . N

The DT N
Dispatcher-Assisted JJ N
Randomized NNP N
Trial NNP N
( ( N
DART NNP N
) ) N
was VBD N
designed VBN N
to TO N
compare VB N
2 CD N
types NNS N
of IN N
dispatcher NN o
cardiopulmonary NN o
( ( o
CPR NNP o
) ) o
instruction NN o
, , N
but CC N
not RB N
intended VBN N
to TO N
affect VB N
the DT N
proportion NN N
of IN N
arrest NN N
victims NNS N
that WDT N
received VBD N
bystander JJR N
CPR NNP N
. . N

We PRP N
sought VBD N
to TO N
determine VB N
whether IN N
odds NNS N
of IN N
receiving VBG N
bystander NN o
CPR NNP o
were VBD N
higher JJR N
during IN N
DART NNP N
than IN N
during IN N
the DT N
periods NNS N
before IN N
and CC N
after IN N
. . N

METHODS NNP N
We PRP N
conducted VBD N
an DT N
observational JJ N
cohort NN N
study NN N
of IN N
8626 CD p
adults NNS p
who WP p
suffered VBD p
non-traumatic JJ p
out-of-hospital JJ p
cardiac NN p
arrest NN p
prior RB p
to TO p
emergency NN p
medical JJ p
services NNS p
( ( p
EMS NNP p
) ) p
arrival NN p
in IN p
greater JJR p
King NNP p
County NNP p
, , p
Washington NNP p
, , p
between IN p
January NNP p
1 CD p
, , p
1999 CD p
, , p
and CC p
December NNP p
31 CD p
, , p
2011 CD p
. . p

Bystander NNP o
CPR NNP o
status NN o
was VBD N
assessed VBN N
through IN N
review NN N
of IN N
dispatch NN N
recordings NNS N
and CC N
EMS NNP N
reports NNS N
to TO N
classify VB N
any DT N
bystander NN o
CPR NNP o
( ( o
any DT o
B-CPR NNP o
) ) o
, , N
and CC N
further RB N
categorized VBN N
as IN N
bystander NN o
CPR NNP o
with IN o
or CC o
without IN o
dispatcher JJR o
assistance NN o
( ( o
DA-CPR NNP o
and CC o
B-CPR NNP o
, , o
no DT o
DA NNP o
) ) o
. . o

We PRP N
used VBD N
multivariable JJ N
logistic JJ N
regression NN N
to TO N
evaluate VB N
odds NNS N
of IN N
B-CPR NNP o
before IN N
, , N
during IN N
, , N
and CC N
after IN N
DART NNP N
. . N

RESULTS VB N
The DT p
proportions NNS p
receiving VBG p
any DT p
B-CPR NNP o
were VBD p
52 CD p
% NN p
before IN p
DART NNP p
( ( p
1817/3468 CD p
) ) p
, , p
59 CD p
% NN p
during IN p
DART NNP p
( ( p
2093/3527 CD p
) ) p
, , p
and CC p
54 CD p
% NN p
after IN p
DART NNP p
( ( p
885/1631 CD p
) ) p
. . p

Compared VBN N
to TO N
the DT N
period NN N
before IN N
DART NNP N
, , N
odds NNS N
of IN N
receiving VBG o
any DT o
B-CPR NNP o
were VBD N
higher JJR N
during IN N
DART NNP N
( ( N
OR=1.35 NNP N
, , N
95 CD N
% NN N
CI=1.23-1.49 NNP N
) ) N
, , N
but CC N
no DT N
different JJ N
after IN N
( ( N
OR=1.10 NNP N
, , N
0.98-1.24 NN N
) ) N
. . N

Compared VBN N
to TO N
the DT N
before NN N
period NN N
, , N
odds NNS N
of IN N
DA-CPR NNP o
were VBD N
higher JJR N
during IN N
DART NNP N
( ( N
OR=1.79 NNP N
, , N
1.59-2.02 JJ N
) ) N
but CC N
no DT N
different JJ N
after IN N
( ( N
OR=0.94 NNP N
, , N
0.80-1.10 NN N
) ) N
. . N

CONCLUSIONS NNP N
Odds NNP o
of IN o
bystander NN o
CPR NNP o
were VBD N
higher JJR N
during IN N
the DT N
trial NN N
, , N
an DT N
increase NN N
related VBN N
to TO N
higher JJR N
likelihood NN N
of IN N
DA-CPR NNP o
. . o

The DT N
finding NN N
suggests VBZ N
a DT N
possible JJ N
indirect JJ N
community-wide JJ N
benefit NN N
due JJ N
to TO N
the DT N
interventional JJ N
trial NN N
. . N

-DOCSTART- -17174704- O O

A DT N
comparison NN N
of IN N
three CD N
highly RB N
active JJ N
antiretroviral JJ N
treatment NN N
strategies NNS N
consisting VBG N
of IN N
non-nucleoside JJ i
reverse NN i
transcriptase NN i
inhibitors NNS i
, , i
protease NN i
inhibitors NNS i
, , i
or CC i
both DT i
in IN i
the DT i
presence NN i
of IN i
nucleoside JJ i
reverse NN i
transcriptase NN i
inhibitors NNS i
as IN N
initial JJ N
therapy NN N
( ( N
CPCRA NNP N
058 CD N
FIRST NNP N
Study NNP N
) ) N
: : N
a DT N
long-term JJ N
randomised JJ N
trial NN N
. . N

BACKGROUND NNP N
Long-term NNP N
data NNS N
from IN N
randomised VBN N
trials NNS N
on IN N
the DT N
consequences NNS N
of IN N
treatment NN N
with IN N
a DT N
protease NN i
inhibitor NN i
( ( i
PI NNP i
) ) i
, , i
non-nucleoside JJ i
reverse NN i
transcriptase NN i
inhibitor NN i
( ( i
NNRTI NNP i
) ) i
, , i
or CC i
both DT i
are VBP i
lacking VBG i
. . i

Here RB N
, , N
we PRP N
report VBP N
results NNS N
from IN N
the DT N
FIRST NNP N
trial NN N
, , N
which WDT N
compared VBN N
initial JJ N
treatment NN N
strategies NNS N
for IN N
clinical JJ N
, , N
immunological JJ N
, , N
and CC N
virological JJ N
outcomes NNS N
. . N

METHODS NNP N
Between NNP p
1999 CD p
and CC p
2002 CD p
, , p
1397 CD p
antiretroviral-treatment-naive JJ p
patients NNS p
, , p
presenting VBG p
at IN p
18 CD p
clinical JJ p
trial NN p
units NNS p
with IN p
80 CD p
research NN p
sites NNS p
in IN p
the DT p
USA NNP p
, , N
were VBD N
randomly RB N
assigned VBN N
in IN N
a DT N
ratio NN N
of IN N
1:1:1 CD N
to TO N
a DT N
protease NN i
inhibitor NN i
( ( i
PI NNP i
) ) i
strategy NN i
( ( i
PI NNP i
plus CC i
nucleoside JJ i
reverse NN i
transcriptase NN i
inhibitor NN i
[ NNP i
NRTI NNP i
] NNP i
; : i
n=470 NN N
) ) N
, , N
a DT i
non-nucleoside JJ i
reverse NN i
transcriptase NN i
inhibitor NN i
( ( i
NNRTI NNP i
) ) i
strategy NN i
( ( i
NNRTI NNP i
plus CC i
NRTI NNP i
; : i
n=463 NN N
) ) N
, , N
or CC i
a DT i
three-class JJ i
strategy NN i
( ( i
PI NNP i
plus CC i
NNRTI NNP i
plus CC i
NRTI NNP i
; : i
n=464 NN N
) ) N
. . N

Primary JJ N
endpoints NNS N
were VBD N
a DT N
composite NN N
of IN N
an DT N
AIDS-defining JJ o
event NN o
, , o
death NN o
, , o
or CC o
CD4 NNP o
cell VBP o
count NN o
decline NN o
to TO N
less JJR N
than IN N
200 CD N
cells NNS N
per IN N
mm3 NN N
for IN N
the DT N
PI NNP N
versus NN N
NNRTI NNP N
comparison NN N
, , N
and CC N
average JJ N
change NN o
in IN o
CD4 NNP o
cell NN o
count NN o
at IN N
or CC N
after IN N
32 CD N
months NNS N
for IN N
the DT N
three-class JJ N
versus NN N
combined VBD N
two-class JJ N
comparison NN N
. . N

Analyses NNS N
were VBD N
by IN N
intention-to-treat NN N
. . N

This DT N
study NN N
is VBZ N
registered VBN N
ClinicalTrials.gov NNP N
, , N
number NN N
NCT00000922 NNP N
. . N

FINDINGS NNP N
1397 CD p
patients NNS p
were VBD p
assessed VBN p
for IN p
the DT p
composite JJ p
endpoint NN p
. . p

A DT N
total NN N
of IN N
388 CD p
participants NNS p
developed VBD p
the DT p
composite JJ o
endpoint NN o
, , p
302 CD p
developed VBD p
AIDS NNP p
or CC p
died VBN p
, , p
and CC p
188 CD p
died VBD p
. . p

NNRTI NNP N
versus NN N
PI NNP N
hazard NN o
ratios NNS o
( ( o
HRs NNP o
) ) o
for IN N
the DT N
composite JJ N
endpoint NN N
, , N
for IN N
AIDS NNP o
or CC o
death NN o
, , o
for IN o
death NN o
, , o
and CC o
for IN o
virological JJ o
failure NN o
were VBD N
1.02 CD N
( ( N
95 CD N
% NN N
CI NNP N
0.79-1.31 NN N
) ) N
, , N
1.07 CD N
( ( N
0.80-1.41 NN N
) ) N
, , N
0.95 CD N
( ( N
0.66-1.37 NN N
) ) N
, , N
and CC N
0.66 CD N
( ( N
0.56-0.78 NN N
) ) N
, , N
respectively RB N
. . N

1196 CD N
patients NNS N
were VBD N
assessed VBN N
for IN N
the DT N
three-class JJ N
versus NN N
combined VBN N
two-class JJ N
primary JJ N
endpoint NN N
. . N

Mean JJ o
change NN o
in IN o
CD4 NNP o
cell NN o
count NN o
at IN N
or CC N
after IN N
32 CD N
months NNS N
was VBD N
+234 JJ N
cells NNS N
per IN N
mm3 NN N
and CC N
+227 NNP N
cells NNS N
per IN N
mm3 NN N
for IN N
the DT N
three-class NN N
and CC N
the DT N
combined JJ N
two-class NN N
strategies NNS N
( ( N
p=0.62 NN N
) ) N
, , N
respectively RB N
. . N

HRs NNP o
( ( N
three-class JJ N
vs NN N
combined VBN N
two-class NN N
) ) N
for IN N
AIDS NNP o
or CC o
death NN o
and CC o
virological JJ o
failure NN o
were VBD N
1.15 CD N
( ( N
0.91-1.45 NN N
) ) N
and CC N
0.87 CD N
( ( N
0.75-1.00 NN N
) ) N
, , N
respectively RB N
. . N

HRs NNP o
( ( N
three-class JJ N
vs NN N
combined VBN N
two-class NN N
) ) N
for IN N
AIDS NNP o
or CC o
death NN o
were VBD N
similar JJ N
for IN N
participants NNS N
with IN N
baseline NN N
CD4 NNP N
cell NN N
counts NNS N
of IN N
200 CD N
cells NNS N
per IN N
mm3 NN N
or CC N
less JJR N
and CC N
of IN N
more JJR N
than IN N
200 CD N
cells NNS N
per IN N
mm3 NN N
( ( N
p=0.38 NN N
for IN N
interaction NN N
) ) N
, , N
and CC N
for IN N
participants NNS N
with IN N
baseline NN N
HIV NNP N
RNA NNP N
concentrations NNS N
less JJR N
than IN N
100 CD N
000 CD N
copies NNS N
per IN N
mL NN N
and CC N
100,000 CD N
copies NNS N
per IN N
mL NN N
or CC N
more JJR N
( ( N
p=0.26 NN N
for IN N
interaction NN N
) ) N
. . N

Participants NNS N
assigned VBD N
the DT N
three-class NN N
strategy NN N
were VBD N
significantly RB N
more RBR N
likely JJ N
to TO N
discontinue VB o
treatment NN o
because IN N
of IN N
toxic NN o
effects NNS o
than IN N
were VBD N
those DT N
assigned VBN N
to TO N
the DT N
two-class NN N
strategies NNS N
( ( N
HR NNP N
1.58 CD N
; : N
p NN N
< VBZ N
0.0001 CD N
) ) N
. . N

INTERPRETATION NNP N
Initial NNP N
treatment NN N
with IN N
either DT N
an DT N
NNRTI-based JJ i
regimen NNS i
or CC N
a DT N
PI-based JJ i
regimen NN i
, , N
but CC N
not RB N
both DT N
together RB N
, , N
is VBZ N
a DT N
good JJ N
strategy NN N
for IN N
long-term JJ N
antiretroviral JJ N
management NN N
in IN N
treatment-naive JJ p
patients NNS p
with IN p
HIV NNP p
. . p

-DOCSTART- -10957888- O O

A DT N
comparative JJ N
efficacy NN o
and CC o
safety NN o
study NN N
of IN N
clarithromycin NN i
, , i
roxithromycin NN i
and CC i
erythromycin JJ i
stearate NN i
in IN N
mild JJ p
pneumonia NN p
. . p

The DT N
efficacy NN o
and CC o
safety NN o
of IN N
clarithromycin NN i
, , i
roxithromycin NN i
and CC i
erythromycin JJ i
stearate NN i
in IN N
mild JJ N
pneumonia NN N
were VBD N
compared VBN N
in IN N
an DT N
open JJ N
randomized VBN N
trial NN N
. . N

Eighty-six JJ p
male JJ p
patients NNS p
, , p
doing VBG p
their PRP$ p
obligatory JJ p
military JJ p
service NN p
, , p
ranging VBG p
between IN p
19 CD p
and CC p
24 CD p
years NNS p
of IN p
age NN p
( ( p
mean JJ p
20 CD p
) ) p
, , N
were VBD N
randomly RB N
treated VBN N
: : N
29 CD N
with IN N
clarithromycin NN i
500 CD i
mg NN i
12-hourly RB i
, , i
30 CD i
with IN i
roxithromycin NN i
150 CD i
mg NN i
12-hourly JJ i
, , i
and CC i
27 CD i
with IN i
erythromycin JJ i
stearate NN i
500 CD N
mg NN N
6-hourly RB N
, , N
each DT N
course NN N
being VBG N
administered VBN N
for IN N
10 CD N
days NNS N
. . N

Seventy-eight JJ p
patients NNS p
were VBD p
able JJ p
to TO p
be VB p
evaluated VBN p
for IN p
efficacy NN o
, , N
28 CD N
receiving VBG N
clarithromycin NN i
, , N
28 CD N
roxithromycin NN i
, , N
and CC N
22 CD N
erythromycin JJ i
stearate NN i
. . i

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
among IN N
the DT N
groups NNS N
in IN N
terms NNS o
of IN o
clinical JJ o
success NN o
rates NNS o
( ( N
clinical JJ N
cure NN N
or CC N
improvement NN N
: : N
89 CD N
% NN N
for IN N
clarithromycin NN i
, , N
82 CD N
% NN N
for IN N
roxithromycin NN i
, , N
and CC N
73 CD N
% NN N
for IN N
erythromycin JJ i
stearate NN i
, , N
p NN N
= NNP N
0.32 CD N
) ) N
. . N

However RB N
, , N
we PRP N
found VBD N
that IN N
there EX N
were VBD N
significant JJ N
differences NNS N
among IN N
the DT N
groups NNS N
in IN N
terms NNS N
of IN N
clinical JJ o
cure NN o
rates NNS o
( ( N
75 CD N
% NN N
for IN N
clarithromycin NN i
, , N
64 CD N
% NN N
for IN N
roxithromycin NN i
, , N
and CC N
41 CD N
% NN N
for IN N
erythromycin JJ i
stearate NN i
, , N
p NN N
= NNP N
0.04 CD N
) ) N
. . N

Adverse JJ o
events NNS o
, , o
mostly RB o
gastrointestinal JJ o
, , N
caused JJ N
discontinuation NN N
of IN N
treatment NN N
in IN N
3.4 CD N
% NN N
of IN N
the DT N
patients NNS N
in IN N
the DT N
clarithromycin NN i
group NN N
, , N
in IN N
6.6 CD N
% NN N
of IN N
the DT N
patients NNS N
in IN N
the DT N
roxithromycin NN i
group NN N
, , N
and CC N
in IN N
18.5 CD N
% NN N
of IN N
the DT N
patients NNS N
in IN N
the DT N
erythromycin JJ i
stearate NN i
group NN N
. . N

The DT N
results NNS N
indicate VBP N
that IN N
there EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
among IN N
the DT N
three CD N
treatment NN N
groups NNS N
in IN N
terms NNS N
of IN N
clinical JJ N
success NN N
rates NNS N
, , N
but CC N
that IN N
clarithromycin NN i
and CC N
roxithromycin NN i
were VBD N
better RB N
tolerated VBN o
. . o

-DOCSTART- -9221965- O O

Clozapine NNP i
versus NN i
placebo NN i
in IN N
Huntington NNP p
's POS p
disease NN p
: : p
a DT N
double JJ N
blind NN N
randomised VBD N
comparative JJ N
study NN N
. . N

OBJECTIVES NNP N
To TO N
establish VB N
the DT N
effect NN N
of IN N
the DT N
atypical JJ N
neuroleptic JJ N
clozapine NN i
on IN N
chorea NN N
, , N
voluntary JJ N
motor NN N
performance NN N
, , N
and CC N
functional JJ N
disability NN N
in IN N
patients NNS p
with IN p
Huntington NNP p
's POS p
disease NN p
. . p

METHODS NNP N
Thirty NNP p
three CD p
patients NNS p
with IN p
Huntington NNP p
's POS p
disease NN p
participated VBD p
in IN N
a DT N
double JJ N
blind NN N
randomised VBD N
trial NN N
. . N

A DT N
maximum NN N
of IN N
150 CD N
mg/day JJ N
clozapine NN i
or CC i
placebo NN i
equivalent NN N
was VBD N
given VBN N
for IN N
a DT N
period NN N
of IN N
31 CD N
days NNS N
. . N

Assessments NNS N
were VBD N
performed VBN N
in IN N
the DT N
week NN N
before IN N
and CC N
at IN N
the DT N
last JJ N
day NN N
of IN N
the DT N
trial NN N
. . N

Chorea NNP N
was VBD N
scored VBN N
using VBG N
the DT N
abnormal JJ N
involuntary JJ N
movement NN N
scale NN N
( ( N
AIMS NNP N
) ) N
, , N
the DT N
chorea NN N
score NN N
of IN N
the DT N
unified JJ N
Huntington NNP N
's POS N
disease NN N
rating NN N
scale NN N
( ( N
UHDRS NNP N
) ) N
, , N
and CC N
judgement NN N
of IN N
video JJ N
recordings NNS N
. . N

Voluntary JJ N
motor NN N
performance NN N
was VBD N
assessed VBN N
using VBG N
the DT N
UHDRS NNP N
motor NN N
scale NN N
. . N

Patients NNS p
and CC p
their PRP$ p
partners NNS p
completed VBD N
a DT N
questionnaire NN N
regarding VBG N
functional JJ N
disability NN N
. . N

Twelve CD N
patients NNS N
already RB N
used VBD N
other JJ N
neuroleptic JJ N
medication NN N
, , N
which WDT N
was VBD N
kept FW N
unchanged JJ N
during IN N
the DT N
trial NN N
period NN N
. . N

Results NNS N
of IN N
neuroleptic JJ N
naive JJ N
and CC N
neuroleptic JJ N
treated JJ N
patients NNS N
were VBD N
analysed VBN N
separately RB N
. . N

RESULTS NNP N
Clozapine NNP i
tended VBD N
to TO N
reduce VB N
chorea NN o
in IN N
neuroleptic JJ N
naive JJ N
patients NNS N
only RB N
( ( N
AIMS NNP N
) ) N
; : N
improvement NN N
seemed VBD N
more RBR N
pronounced JJ N
in IN N
patients NNS N
receiving VBG N
higher JJR N
doses NNS N
of IN N
clozapine NN N
. . N

Other JJ N
measures NNS o
of IN o
chorea NN o
( ( o
UHDRS NNP o
chorea NN o
score NN o
, , o
video JJ o
ratings NNS o
) ) o
showed VBD N
no DT N
improvement NN N
. . N

Clozapine NNP i
had VBD N
no DT N
beneficial JJ N
effect NN N
on IN N
chorea NN o
in IN N
patients NNS N
already RB N
receiving VBG N
neuroleptic JJ N
medication NN N
. . N

Voluntary JJ o
motor NN o
performance NN o
did VBD N
not RB N
improve VB N
with IN N
clozapine NN N
. . N

Neuroleptic JJ N
naive JJ N
patients NNS N
reported VBN N
aggravation NN N
of IN N
functional JJ o
disability NN o
, , N
possibly RB N
reflecting VBG N
the DT N
frequent JJ N
occurrence NN N
of IN N
side NN N
effects NNS N
. . N

Adverse JJ N
reactions NNS N
forced VBD N
trial NN N
termination NN N
in IN N
six CD N
patients NNS N
and CC N
dose JJ N
reduction NN N
in IN N
another DT N
eight CD N
, , N
and CC N
consisted VBD N
mainly RB N
of IN N
drowsiness NN o
, , o
fatigue NN o
, , o
anticholinergic NN o
symptoms NNS o
, , o
and CC o
walking VBG o
difficulties NNS o
. . o

CONCLUSIONS NNP N
Clozapine NNP i
has VBZ N
little JJ N
beneficial JJ N
effect NN N
in IN N
patients NNS p
with IN p
Huntington NNP p
's POS p
disease NN p
, , N
although IN N
individual JJ N
patients NNS N
may MD N
tolerate VB N
doses NNS N
high JJ N
enough RB N
to TO N
reduce VB N
chorea NN N
. . N

Because IN N
adverse JJ N
reactions NNS N
are VBP N
often RB N
encountered VBN N
, , N
clozapine NN i
should MD N
be VB N
used VBN N
with IN N
restraint NN N
in IN N
this DT N
patient NN N
group NN N
. . N

-DOCSTART- -26449882- O O

The DT N
neuropeptide JJ i
oxytocin NN i
modulates NNS N
consumer NN N
brand NN N
relationships NNS N
. . N

Each DT N
year NN N
, , N
companies NNS N
invest VBP N
billions NNS N
of IN N
dollars NNS N
into IN N
marketing NN N
activities NNS N
to TO N
embellish VB N
brands NNS N
as IN N
valuable JJ N
relationship NN N
partners NNS N
assuming VBG N
that IN N
consumer NN N
brand NN N
relationships NNS N
( ( N
CBRs NNP N
) ) N
and CC N
interpersonal JJ N
relationships NNS N
rest VBP N
upon IN N
the DT N
same JJ N
neurobiological JJ N
underpinnings NNS N
. . N

Given VBN N
the DT N
crucial JJ N
role NN N
of IN N
the DT N
neuropeptide JJ i
oxytocin NN i
( ( i
OXT NNP i
) ) i
in IN N
social JJ N
bonding NN N
, , N
this DT N
study NN N
tests VBZ N
whether IN N
OXT-based JJ N
mechanisms NNS N
also RB N
determine VBP N
the DT N
bond NN N
between IN N
consumers NNS p
and CC N
brands NNS N
. . N

We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
placebo-controlled JJ N
study NN N
involving VBG N
101 CD p
subjects NNS p
and CC N
analyzed VBD N
the DT N
effect NN N
of IN N
intranasal NN i
OXT NNP i
on IN N
consumers NNS o
' POS o
attribution NN o
of IN o
relationship NN o
qualities NNS o
to TO o
brands NNS o
, , N
brands NNS N
paired VBD N
with IN N
human JJ N
celebrity NN N
endorsers NNS N
, , N
and CC N
familiar JJ N
persons NNS N
. . N

OXT NNP o
indeed RB N
promoted VBD N
the DT N
attribution NN o
of IN o
relationship NN o
qualities NNS o
not RB N
only RB N
in IN N
the DT N
case NN N
of IN N
social JJ N
and CC N
semi-social JJ N
stimuli NNS N
, , N
but CC N
also RB N
brands NNS N
. . N

Intriguingly RB N
, , N
for IN N
subjects NNS p
scoring VBG p
high JJ p
on IN p
autistic-like JJ p
traits NNS p
, , N
the DT N
effect NN N
of IN N
OXT NNP i
was VBD N
completely RB N
reversed VBN N
, , N
evident JJ N
in IN N
even RB N
lower JJR N
relationship NN o
qualities NNS o
across IN N
all DT N
stimulus JJ N
categories NNS N
. . N

The DT N
importance NN N
of IN N
OXT NNP i
in IN N
a DT N
CBR NNP N
context NN N
is VBZ N
further RB N
corroborated VBN N
by IN N
a DT N
three-fold JJ N
increase NN N
in IN N
endogenous JJ o
release NN o
of IN o
OXT NNP o
following VBG N
exposure NN N
to TO N
one CD N
's POS N
favorite JJ N
brand NN N
and CC N
positive JJ N
associations NNS N
between IN N
baseline JJ N
peripheral JJ N
OXT NNP i
concentrations NNS N
and CC N
brand NN N
relationship NN N
qualities NNS N
. . N

Collectively RB N
, , N
our PRP$ N
findings NNS N
indicate VBP N
that IN N
OXT NNP i
not RB N
only RB N
plays VBZ N
a DT N
fundamental JJ N
role NN N
in IN N
developing VBG N
interpersonal JJ o
relationships NNS o
, , N
but CC N
also RB N
enables VBZ N
relationship NN N
formation NN N
with IN N
objects NNS N
such JJ N
as IN N
brands NNS N
. . N

-DOCSTART- -20226548- O O

Argatroban NNP i
for IN N
elective JJ N
percutaneous JJ N
coronary JJ N
intervention NN N
: : N
the DT N
ARG-E04 NNP N
multi-center NN N
study NN N
. . N

UNLABELLED IN N
The DT N
synthetic JJ N
arginine-derived JJ N
direct JJ N
thrombin NN N
inhibitor NN N
argatroban NN i
is VBZ N
an DT N
attractive JJ N
anticoagulant NN N
for IN N
percutaneous JJ i
coronary JJ i
intervention NN i
( ( i
PCI NNP i
) ) i
, , N
because IN N
of IN N
its PRP$ N
rapid JJ N
onset NN N
and CC N
offset NN N
, , N
and CC N
its PRP$ N
hepatic JJ N
elimination NN N
. . N

Argatroban NNP i
was VBD N
approved VBN N
for IN N
PCI NNP N
in IN N
patients NNS p
with IN p
heparin-induced JJ p
thrombocytopenia NN p
( ( p
HIT NNP p
) ) p
. . p

However RB N
, , N
there EX N
are VBP N
limited VBN N
data NNS N
about IN N
argatroban NN i
in IN N
non-HIT JJ N
patients NNS N
. . N

The DT N
objective NN N
of IN N
this DT N
open-label JJ N
, , N
multiple-dose JJ N
, , N
controlled VBD N
study NN N
was VBD N
to TO N
examine VB N
the DT N
safety NN o
and CC o
efficacy NN o
of IN N
argatroban NN i
in IN N
patients NNS p
undergoing VBG p
elective JJ p
PCI NNP p
. . p

METHODS NNP N
AND CC N
RESULTS NNP N
Of IN N
140 CD p
patients NNS p
randomized VBN N
to TO N
three CD N
argatroban NNS i
dose JJ N
groups NNS N
( ( i
ARG250 NNP i
, , i
ARG300 NNP i
, , N
and CC N
ARG350 NNP i
with IN N
250 CD N
, , N
300 CD N
, , N
or CC N
350 CD N
?g/kg JJ N
bolus NN N
, , N
followed VBN N
by IN N
15 CD N
, , N
20 CD N
, , N
or CC N
25 CD N
?g/kg/min JJ N
infusion NN N
) ) N
and CC N
one CD i
unfractionated JJ i
heparin NN i
( ( i
UFH NNP i
) ) i
group NN i
( ( N
70-100 JJ N
IU/kg NNP N
bolus NN p
) ) p
, , p
138 CD p
patients NNS p
were VBD p
analyzed VBN i
. . i

Argatroban NNP i
dose-dependently RB i
prolonged VBD o
activated VBN o
clotting NN o
time NN o
( ( o
ACT NNP o
) ) o
with IN o
more JJR N
patients NNS N
reaching VBG N
the DT N
minimum NN N
target NN o
ACT NNP o
after IN o
the DT N
initial JJ N
bolus NN N
injection NN i
( ( i
ARG250 NNP i
: : i
86.1 CD i
% NN i
, , i
ARG300 NNP i
: : i
89.5 CD i
% NN N
, , N
and CC i
ARG350 NNP i
: : i
96.8 CD i
% NN N
) ) N
compared VBN N
to TO N
45.5 CD N
% NN N
in IN N
UFH NNP N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

The DT o
patient JJ o
proportion NN o
who WP o
did VBD o
not RB o
require VB o
additional JJ o
bolus NN o
injections NNS o
to TO o
start VB N
PCI NNP N
was VBD N
significantly RB N
higher JJR N
in IN N
argatroban NN i
than IN i
in IN N
UFH NNP i
( ( i
p VB N
? . N
0.002 CD N
) ) N
. . N

Consequently RB o
, , o
the DT o
time NN o
to TO o
start VB o
of IN o
PCI NNP o
was VBD N
shortened VBN i
in IN i
argatroban JJ i
groups NNS i
. . N

Composite NNP o
incidences NNS o
of IN o
death NN o
, , o
myocardial JJ o
infarction NN o
, , o
and CC o
urgent JJ o
revascularization NN o
until IN o
day NN N
30 CD N
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
groups NNS i
( ( i
ARG250 NNP i
: : i
2.8 CD i
% NN i
, , i
ARG300 NNP i
: : i
0.0 CD i
% NN i
, , i
ARG350 NNP i
: : i
3.2 CD i
% NN N
vs. FW N
UFH NNP i
: : N
3.0 CD N
% NN N
) ) o
. . o

Major JJ o
bleeding NN o
was VBD o
observed VBN N
only RB N
in IN i
UFH NNP i
( ( N
3.0 CD N
% NN N
) ) N
, , N
while IN o
minor JJ o
bleeding NN o
occurred VBD o
in IN i
ARG350 NNP i
( ( i
3.2 CD i
% NN N
) ) N
and CC N
UFH NNP i
( ( N
6.1 CD N
% NN N
, , N
n.s. NN N
) ) N
. . N

CONCLUSION NNP i
Argatroban NNP i
dose-dependently JJ i
increases NNS o
coagulation NN o
parameters NNS o
and CC o
, , N
compared VBN i
to TO i
UFH NNP i
, , N
demonstrates VBZ N
a DT N
superior JJ N
predictable JJ o
anticoagulant JJ o
effect NN o
in IN o
patients NNS p
undergoing VBG i
elective JJ i
PCI NNP i
. . p

-DOCSTART- -17156222- O O

Midazolam NNP i
vs NN i
ondansetron NN i
for IN N
preventing VBG N
postoperative JJ o
nausea NN o
and CC o
vomiting NN o
: : o
a DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

We PRP N
compared VBN N
the DT N
prophylactic JJ N
anti-emetic JJ N
efficacy NN N
of IN N
midazolam NN i
and CC N
ondansetron NN i
in IN N
90 CD p
patients NNS p
scheduled VBN p
for IN p
minor JJ p
gynaecological JJ p
( ( p
hysteroscopy NN p
) ) p
or CC p
urological JJ p
( ( p
ureteroscopy JJ p
) ) p
procedures NNS p
planned VBN p
to TO p
last JJ p
1-2 JJ p
h NN p
under IN p
sevoflurane NN p
anaesthesia NN p
with IN p
spontaneous JJ p
ventilation NN p
of IN p
the DT p
lungs NNS p
via IN p
a DT p
laryngeal JJ p
mask NN p
airway NN p
. . p

Midazolam NNP i
2 CD i
mg NN i
or CC i
ondansetron $ i
4 CD i
mg NN i
were VBD N
administered VBN N
intravenously RB N
30 CD N
min NN N
before IN N
the DT N
end NN N
of IN N
surgery NN N
. . N

The DT N
proportions NNS N
of IN N
patients NNS p
who WP p
experienced VBD p
postoperative JJ o
nausea NN o
and CC o
vomiting NN o
in IN p
the DT p
first JJ p
24 CD p
h NN p
( ( p
30 CD p
% NN p
and CC p
27 CD p
% NN p
for IN p
the DT p
midazolam NN i
and CC p
ondansetron NN i
groups NNS p
, , p
respectively RB p
) ) p
were VBD p
similar JJ o
in IN p
the DT p
two CD p
groups NNS p
. . p

The DT N
incidence NN N
of IN N
postoperative JJ o
nausea NN o
and CC o
vomiting NN o
was VBD N
significantly RB N
smaller JJR o
in IN N
both DT N
groups NNS N
than IN N
predicted VBN N
according VBG N
to TO N
the DT N
patients NNS p
' POS p
underlying JJ p
risks NNS p
( ( i
midazolam JJ i
group NN p
: : p
p NN p
= VBZ p
0.018 CD p
; : p
ondansetron VBN i
group NN p
: : p
p NN p
= VBZ p
0.017 CD p
) ) p
. . p

There EX N
were VBD N
no DT o
significant JJ o
differences NNS o
in IN N
average JJ o
sedation NN o
scores NNS o
or CC o
pain NN o
scores NNS o
. . o

Treatment NNP N
using VBG N
ondansetron NN i
for IN N
anti-emetic JJ N
prophylaxis NN N
did VBD N
not RB N
provide VB N
a DT N
superior JJ N
benefit NN N
compared VBN N
to TO N
midazolam VB i
in IN N
the DT N
present JJ N
study NN N
. . N

-DOCSTART- -7489845- O O

Cholesterol-lowering JJ i
therapy NN i
may MD N
retard VB N
the DT N
progression NN N
of IN N
diabetic JJ p
nephropathy NN p
. . p

There EX N
is VBZ N
experimental JJ N
evidence NN N
to TO N
suggest VB N
that IN N
hypercholesterolaemia NN N
may MD N
play VB N
a DT N
pathogenetic JJ N
role NN N
in IN N
progressive JJ p
glomerular JJ p
injury NN p
. . p

We PRP N
investigated VBD N
the DT N
effect NN N
of IN N
cholesterol-lowering JJ i
therapy NN i
on IN N
the DT N
progression NN N
of IN N
diabetic JJ N
nephropathy NN N
in IN N
34 CD p
patients NNS p
with IN p
non-insulin-dependent JJ p
diabetes NNS p
mellitus NNS p
. . p

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
in IN N
a DT N
single-blind JJ N
fashion NN N
to TO N
treatment NN N
with IN N
either DT N
lovastatin NN i
, , i
an DT i
HMG NNP i
CoA NNP i
reductase NN i
inhibitor NN i
( ( N
n JJ N
= VBZ N
16 CD N
; : N
mean VB N
dose JJ N
30.0 CD N
+/- JJ N
12.6 CD N
mg/day NN N
) ) N
or CC N
placebo NN i
( ( N
n JJ N
= NNP N
18 CD N
) ) N
for IN N
2 CD N
years NNS N
. . N

Renal JJ N
function NN N
was VBD N
assessed VBN N
by IN N
serially RB N
measuring VBG N
the DT N
serum NN N
creatinine NN N
, , N
glomerular JJ N
filtration NN N
rate NN N
( ( N
using VBG N
Cr51-EDTA NNP N
) ) N
, , N
and CC N
24-h JJ N
urinary JJ N
protein NN N
excretion NN N
. . N

Lovastatin NNP i
treatment NN N
was VBD N
associated VBN N
with IN N
significant JJ N
reductions NNS N
in IN N
total JJ o
cholesterol NN o
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
LDL-cholesterol NNP o
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
and CC N
apo JJ o
B NNP o
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
, , N
the DT N
reductions NNS N
at IN N
24 CD N
months NNS N
being VBG N
26 CD N
, , N
30 CD N
and CC N
18 CD N
% NN N
, , N
respectively RB N
. . N

Beneficial JJ N
effects NNS N
on IN N
serum NN o
triglyceride NN o
, , o
HDL-cholesterol NNP o
and CC o
apo VB o
A1 NNP o
levels NNS o
were VBD N
also RB N
observed VBN N
. . N

Lp NNP o
( ( o
a DT o
) ) o
showed VBD N
no DT o
significant JJ o
change NN N
in IN N
both DT N
groups NNS N
. . N

Glomerular JJ o
filtration NN o
rate NN o
deteriorated VBN o
significantly RB o
in IN N
the DT N
placebo NN i
group NN N
after IN N
24 CD N
months NNS N
( ( N
p JJ N
< NNP N
0.025 CD N
) ) N
but CC N
showed VBD N
no DT o
significant JJ o
change NN o
in IN N
the DT N
lovastatin-treated JJ i
patients NNS N
. . N

The DT N
increase NN o
in IN o
serum JJ o
creatinine NN o
was VBD N
statistically RB o
significant JJ o
( ( N
p JJ N
< NNP N
0.02 CD N
) ) N
in IN N
placebo-treated JJ i
patients NNS N
at IN N
12 CD N
and CC N
24 CD N
months NNS N
, , N
and CC N
in IN N
the DT N
lovastatin NN i
group NN N
after IN N
24 CD N
months NNS N
. . N

Twenty-four CD N
hour NN N
urinary JJ o
protein NN o
excretion NN o
increased VBN o
in IN N
both DT N
groups NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Lovastatin NNP i
treatment NN N
was VBD N
not RB o
associated VBN o
with IN N
significant JJ o
elevations NNS o
in IN N
liver NN o
or CC o
muscle NN o
enzymes NNS o
. . o

We PRP N
conclude VBP N
that IN N
effective JJ N
normalisation NN N
of IN N
hypercholesterolaemia NN o
may MD N
retard VB N
the DT N
progression NN N
of IN N
diabetic JJ o
nephropathy NN o
. . o

-DOCSTART- -20390261- O O

Echocardiographic JJ N
evaluation NN N
of IN N
children NNS p
with IN p
systemic JJ p
ventricular JJ p
dysfunction NN p
treated VBN p
with IN p
carvedilol NN i
. . i

Echocardiography NN i
is VBZ N
used VBN N
to TO N
measure VB N
the DT N
therapeutic JJ N
effectiveness NN N
of IN N
heart NN N
failure NN N
therapy NN N
in IN N
adults NNS p
and CC p
children NNS p
. . p

The DT N
purposes NNS N
of IN N
this DT N
study NN N
were VBD N
( ( N
1 CD N
) ) N
to TO N
assess VB N
baseline JJ N
echocardiographic JJ N
predictors NNS N
of IN N
clinical JJ N
outcome NN N
, , N
( ( N
2 CD N
) ) N
to TO N
investigate VB N
changes NNS N
in IN N
echocardiographic JJ N
parameters NNS N
, , N
and CC N
( ( N
3 CD N
) ) N
to TO N
compare VB N
these DT N
echocardiographic JJ N
changes NNS N
with IN N
changes NNS N
in IN N
plasma NN N
levels NNS N
of IN N
b-type JJ N
natriuretic JJ i
peptide NN i
( ( N
BNP NNP N
) ) N
in IN p
a DT p
population NN p
of IN p
children NNS p
with IN p
systemic JJ p
ventricular JJ p
dysfunction NN p
and CC p
symptomatic JJ p
heart NN p
failure NN p
treated VBN p
with IN p
carvedilol NN i
or CC i
placebo NN i
. . i

All DT N
available JJ N
baseline NN N
and CC N
6-month JJ N
echocardiograms NNS N
from IN N
Pediatric NNP p
Carvedilol NNP p
Trial NNP p
( ( p
PCT NNP p
) ) p
participants NNS p
( ( i
carvedilol JJ i
n RB p
= JJ p
161 CD p
; : p
placebo NN i
n IN p
= $ p
55 CD p
) ) p
were VBD N
reviewed VBN N
. . N

Systolic NNP o
and CC N
diastolic JJ o
sphericity NN o
index NN o
( ( N
SI NNP N
; : N
n CC N
= VB N
110 CD N
) ) N
, , N
TEI NNP N
index NN N
( ( N
n JJ N
= NNP N
145 CD N
) ) N
, , N
and CC N
systemic JJ N
ventricular NN N
dP/dt NN N
( ( N
n JJ N
= NNP N
70 CD N
) ) N
were VBD N
measured VBN N
. . N

The DT N
PCT NNP N
composite JJ N
definition NN N
of IN N
clinical JJ N
outcome NN N
( ( N
i.e. FW N
, , N
worsened VBD N
, , N
improved VBN N
, , N
or CC N
unchanged JJ N
) ) N
was VBD N
used VBN N
. . N

For IN N
all DT N
patients NNS N
, , N
baseline VBP N
TEI NNP N
index NN N
was VBD N
a DT N
predictor NN N
of IN N
worsened JJ o
outcome NN o
. . o

Only RB N
children NNS p
treated VBD p
with IN p
carvedilol NN i
showed VBD N
a DT N
significant JJ N
decrease NN N
in IN N
systolic JJ o
SI NNP o
( ( N
P NNP N
B NNP N
0.0001 CD N
) ) N
, , N
diastolic JJ o
SI NNP o
( ( N
P NNP N
B NNP N
0.0001 CD N
) ) N
, , N
and CC N
TEI NNP o
index NN o
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

An DT N
inverse JJ N
correlation NN N
between IN N
changes NNS o
in IN o
BNP NNP o
and CC N
changes NNS o
in IN o
dP/dt NN o
( ( N
r JJ N
= NNP N
-0.45 NNP N
, , N
P NNP N
= NNP N
0.04 CD N
) ) N
was VBD N
found VBN N
only RB N
in IN N
the DT N
carvedilol NN i
group NN p
. . p

In IN N
conclusion NN N
, , N
TEI NNP N
index NN N
predicted VBD N
outcome NN N
in IN N
children NNS p
with IN N
systemic JJ o
ventricular JJ o
dysfunction NN o
and CC o
heart NN o
failure NN o
. . o

Carvedilol NN i
may MD N
have VB N
a DT N
beneficial JJ N
effect NN N
on IN N
reversal NN N
of IN N
left JJ N
ventricular JJ N
remodeling NN N
and CC N
global JJ N
ventricular NN N
function NN N
in IN N
pediatric JJ N
heart NN N
failure NN N
. . N

-DOCSTART- -2205798- O O

Reduced VBN N
mortality NN N
among IN N
children NNS p
in IN p
southern JJ p
India NNP p
receiving VBG p
a DT p
small JJ p
weekly JJ p
dose NN p
of IN p
vitamin NN i
A NNP i
. . i

BACKGROUND NNP N
Clinical NNP N
vitamin VBD N
A DT N
deficiency NN N
affects VBZ N
millions NNS N
of IN N
children NNS N
worldwide IN N
, , N
and CC N
subclinical JJ N
deficiency NN N
is VBZ N
even RB N
more RBR N
common JJ N
. . N

Supplemental JJ N
vitamin NN N
A NNP N
has VBZ N
been VBN N
reported VBN N
to TO N
reduce VB N
mortality NN N
among IN N
these DT N
children NNS N
, , N
but CC N
the DT N
results NNS N
have VBP N
been VBN N
questioned VBN N
. . N

METHODS NNP N
We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
controlled VBN N
, , N
masked VBD N
clinical JJ N
trial NN N
for IN N
one CD N
year NN N
in IN p
southern JJ p
India NNP p
involving VBG p
15,419 CD p
preschool-age JJ p
children NNS p
who WP p
received VBD p
either CC p
8.7 CD i
mumol NN i
( ( i
8333 CD i
IU NNP i
) ) i
of IN i
vitamin NN i
A NNP i
and CC i
46 CD i
mumol NN i
( ( i
20 CD i
mg NN i
) ) i
of IN i
vitamin NN i
E NNP i
( ( i
the DT i
treated VBN i
group NN i
) ) i
or CC i
vitamin JJ i
E NNP i
alone RB i
( ( i
the DT i
control NN i
group NN i
) ) i
. . N

Vitamin JJ i
supplements NNS i
were VBD N
delivered VBN N
weekly JJ N
by IN N
community NN N
health NN N
volunteers NNS N
who WP N
also RB N
recorded VBD N
mortality NN o
and CC o
morbidity NN o
. . o

Weekly JJ N
contact NN N
was VBD N
made VBN N
with IN N
at IN N
least JJS N
88 CD N
percent NN N
of IN N
the DT N
children NNS N
in IN N
both DT N
study NN N
groups NNS N
. . N

The DT N
base-line JJ N
characteristics NNS N
of IN N
the DT N
children NNS N
were VBD N
similar JJ N
and CC N
documented VBD N
a DT N
high JJ N
prevalence NN N
of IN N
vitamin NN N
A NNP N
deficiency NN N
and CC N
undernutrition NN N
. . N

RESULTS NNP N
One CD N
hundred VBD N
twenty-five JJ N
deaths NNS N
occurred VBD N
, , N
of IN N
which WDT N
117 CD N
were VBD N
not RB N
accidental JJ N
. . N

The DT N
risk NN o
of IN o
death NN o
in IN N
the DT N
group NN N
treated VBD N
with IN N
vitamin NN N
A NNP N
was VBD N
less JJR N
than IN N
half NN N
that IN N
in IN N
the DT N
control NN N
group NN N
( ( N
relative JJ N
risk NN N
, , N
0.46 CD N
; : N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
0.30 CD N
to TO N
0.71 CD N
) ) N
. . N

The DT N
risk NN N
was VBD N
most RBS N
reduced JJ N
among IN N
children NNS N
under IN N
3 CD N
years NNS N
of IN N
age NN N
( ( N
6 CD N
to TO N
11 CD N
months NNS N
-- : N
relative JJ N
risk NN N
, , N
0.28 CD N
; : N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
0.09 CD N
to TO N
0.85 CD N
; : N
12 CD N
to TO N
35 CD N
months NNS N
-- : N
relative JJ N
risk NN N
, , N
0.46 CD N
; : N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
0.26 CD N
to TO N
0.81 CD N
) ) N
and CC N
among IN N
those DT N
who WP N
were VBD N
chronically RB N
undernourished JJ N
, , N
as IN N
manifested VBN N
by IN N
stunting VBG N
( ( N
relative JJ N
risk NN N
, , N
0.11 CD N
; : N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
0.03 CD N
to TO N
0.36 CD N
) ) N
. . N

The DT N
symptom-specific JJ o
risk NN o
of IN o
mortality NN o
was VBD N
significantly RB N
associated VBN N
with IN N
diarrhea NN o
, , o
convulsions NNS o
, , o
and CC o
other JJ o
infection-related JJ o
symptoms NNS o
. . o

CONCLUSIONS VB N
The DT N
regular JJ N
provision NN N
of IN N
a DT N
supplement NN N
of IN N
vitamin NN i
A NNP i
to TO N
children NNS N
, , N
at IN N
a DT N
level NN N
potentially RB N
obtainable JJ N
from IN N
foods NNS N
, , N
in IN N
an DT N
area NN N
where WRB N
vitamin NN N
A DT N
deficiency NN N
and CC N
under-nutrition NN N
are VBP N
documented VBN N
public JJ N
health NN N
problems NNS N
contributed VBD N
substantially RB N
to TO N
children NNS N
's POS N
survival NN N
; : N
mortality NN N
was VBD N
reduced VBN N
on IN N
average NN N
by IN N
54 CD N
percent NN N
. . N

-DOCSTART- -24406481- O O

Changes NNS N
in IN N
body NN o
weight NN o
and CC o
blood NN o
pressure NN o
: : o
paradoxical JJ N
outcome NN N
events NNS N
in IN N
overweight NN p
and CC p
obese JJ p
subjects NNS p
with IN p
cardiovascular JJ p
disease NN p
. . p

BACKGROUND/OBJECTIVES IN N
The DT N
Sibutramine NNP N
Cardiovascular NNP N
OUTcomes NNP N
( ( N
SCOUT NNP N
) ) N
trial NN N
showed VBD N
a DT N
significantly RB N
increased VBN N
relative JJ N
risk NN N
of IN N
nonfatal JJ o
cardiovascular JJ o
events NNS o
, , N
but CC N
not RB N
mortality NN o
, , N
in IN N
overweight JJ p
and CC p
obese JJ p
subjects NNS p
receiving VBG p
long-term JJ i
sibutramine NN i
treatment NN i
with IN i
diet JJ i
and CC i
exercise NN i
. . i

We PRP N
examined VBD N
the DT N
relationship NN N
between IN N
early JJ N
changes NNS N
( ( N
both DT N
increases NNS N
and CC N
decreases NNS N
) ) N
in IN N
body NN o
weight NN o
and CC N
blood NN o
pressure NN o
, , N
and CC N
the DT N
impact NN N
of IN N
these DT N
changes NNS N
on IN N
subsequent JJ N
cardiovascular JJ o
outcome NN o
events NNS o
. . o

SUBJECTS/METHODS VB N
A DT p
total NN p
of IN p
9804 CD p
male NN p
and CC p
female JJ p
subjects NNS p
, , p
aged VBD p
55 CD p
years NNS p
or CC p
older JJR p
, , p
with IN p
a DT p
body NN p
mass NN p
index NN p
of IN p
27-45 JJ p
kg NNS p
m NN p
( ( p
-2 NN p
) ) p
were VBD p
included VBN p
in IN p
this DT p
current JJ p
subanalysis NN p
of IN p
the DT N
SCOUT NNP N
trial NN N
. . N

Subjects NNS N
were VBD N
required VBN p
to TO p
have VB p
a DT p
history NN p
of IN p
cardiovascular JJ p
disease NN p
and/or VBD p
type JJ p
2 CD p
diabetes NNS p
mellitus VBP p
with IN p
at IN p
least JJS p
one CD p
cardiovascular NN p
risk NN p
factor NN p
( ( p
hypertension NN p
, , p
dyslipidemia NN p
, , p
current JJ p
smoking NN p
or CC p
diabetic JJ p
nephropathy NN p
) ) p
to TO p
assess VB N
cardiovascular JJ N
outcomes NNS N
. . N

Post NNP N
hoc NN N
subgroup NN N
analyses NNS o
of IN o
weight NN o
change NN o
( ( o
categories NNS o
) ) N
and CC N
blood NN o
pressure NN o
were VBD o
performed VBN N
overall JJ N
and CC N
by IN N
treatment NN N
group NN N
( ( N
6-week JJ i
sibutramine NN i
followed VBN i
by IN N
randomized JJ i
placebo NN i
or CC i
continued JJ i
sibutramine NN i
) ) i
. . i

The DT i
primary JJ o
outcome NN o
event NN o
( ( o
POE NNP o
) ) o
was VBD o
a DT o
composite NN o
of IN o
nonfatal JJ o
myocardial JJ o
infarction NN o
, , o
nonfatal JJ o
stroke NN o
, , o
resuscitated VBD o
cardiac JJ o
arrest NN o
or CC o
cardiovascular JJ o
death NN o
. . o

Time-to-event JJ o
analyses NNS N
of IN N
the DT N
POE NNP N
were VBD N
performed VBN N
using VBG N
Cox NNP N
regression NN N
models NNS N
with IN N
factors NNS N
for IN N
treatment NN N
, , N
subgroups NNS N
and CC N
interactions NNS N
. . N

RESULTS NNP N
During IN N
the DT N
initial JJ N
6-week JJ i
sibutramine NN i
treatment NN i
period NN o
, , o
systolic JJ o
blood NN o
pressure NN o
decreased VBD o
progressively RB N
with IN N
increasing VBG o
weight JJ o
loss NN o
in IN o
hypertensive JJ N
subjects NNS N
( ( N
-8.1?10.5 JJ N
mm NN N
Hg NNP N
with IN N
< NNP N
5 CD N
kg NN N
weight NN N
loss NN N
to TO N
-10.8?11.0 VB N
mm JJ N
Hg NNP N
with IN N
?5 NNP N
kg FW N
weight JJ N
loss NN N
) ) N
. . N

The DT N
highest JJS o
POE JJ o
incidence NN o
occurred VBD o
mainly RB N
in IN N
groups NNS N
with IN N
increases NNS N
in IN N
both DT o
weight NN o
and CC o
blood NN o
pressure NN o
. . o

However RB N
, , N
with IN N
long-term JJ i
sibutramine NN i
treatment NN i
, , N
a DT N
markedly RB o
lower JJR o
blood NN o
pressure NN o
tended VBD o
to TO N
increase VB o
POEs NNP o
. . o

CONCLUSION NNP o
Modest NNP o
weight VBD o
loss NN o
and CC N
modest JJ N
lower JJR o
blood NN o
pressure NN o
each DT o
reduced VBD N
the DT N
incidence NN N
of IN N
cardiovascular JJ N
events NNS N
, , N
as IN N
expected VBN N
. . N

However RB N
, , N
the DT N
combination NN N
of IN N
early JJ N
marked JJ o
weight NN o
loss NN o
and CC N
rapid JJ o
blood NN o
pressure NN o
reduction NN o
seems VBZ N
to TO N
be VB N
harmful JJ N
in IN N
this DT p
obese JJ p
elderly JJ p
cardiovascular NN p
diseased VBD p
population NN p
. . N

-DOCSTART- -15091267- O O

Should MD N
insertion NN N
of IN N
intramedullary JJ N
nails NNS N
for IN N
tibial JJ p
fractures NNS p
be VB N
with IN N
or CC N
without IN N
reaming VBG N
? . N
A DT N
prospective JJ N
, , N
randomized VBN N
study NN N
with IN N
3.8 CD N
years NNS N
' POS N
follow-up NN N
. . N

OBJECTIVE UH N
To TO N
determine VB N
if IN N
any DT N
differences NNS N
exist VBP N
in IN N
healing NN o
and CC o
complications NNS o
between IN N
reamed VBN i
and CC i
unreamed JJ i
nailing NN i
in IN N
patients NNS p
with IN p
tibial JJ p
shaft NN p
fractures NNS p
. . p

DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
. . N

SETTING NNP N
Level NNP p
1 CD p
trauma NN p
center NN p
. . p

PATIENTS VB N
Forty-five JJ p
patients NNS p
with IN p
displaced NNS p
closed VBD p
and CC p
open JJ p
Gustilo NNP p
type NN p
I-IIIA NNP p
fractures NNS p
of IN p
the DT p
central JJ p
two CD p
thirds NNS p
of IN p
the DT p
tibia NN p
. . p

INTERVENTION NNP N
Stabilization NNP i
of IN i
tibial JJ i
fractures NNS i
either CC i
with IN i
a DT i
slotted VBN i
, , i
stainless JJ i
steel NN i
reamed VBD i
nail JJ i
or CC i
a DT i
solid JJ i
, , i
titanium NN i
unreamed JJ i
nail NN i
. . i

MAIN NNP N
OUTCOME NNP N
MEASUREMENTS NNP N
Nonunions NNP o
, , o
time NN o
to TO o
fracture VB o
healing NN o
, , o
and CC o
rate NN o
of IN o
malunions NNS o
. . o

RESULTS VB N
The DT N
average JJ o
time NN o
to TO o
fracture VB o
healing NN o
was VBD N
16.7 CD N
weeks NNS N
in IN N
the DT N
reamed VBN i
group NN N
and CC N
25.7 CD N
weeks NNS N
in IN N
the DT N
unreamed JJ i
group NN N
. . N

The DT N
difference NN N
was VBD N
statistically RB N
significant JJ N
( ( N
P NNP N
= NNP N
0.004 CD N
) ) N
. . N

There EX N
were VBD N
three CD N
nonunions NNS o
, , N
all DT N
in IN N
the DT N
unreamed JJ i
nail NN i
group NN N
. . N

Two CD N
of IN N
these DT N
fractures NNS N
healed VBD o
after IN o
dynamization NN o
by IN o
removing VBG o
static JJ o
interlocking NN o
screws NNS o
. . o

The DT N
third JJ N
nonunion NN N
did VBD N
not RB N
heal VB o
despite IN N
exchange NN N
reamed VBD i
nailing JJ N
2 CD N
years NNS N
after IN N
the DT N
primary JJ N
surgery NN N
and CC N
dynamization NN N
with IN N
a DT N
fibular JJ N
osteotomy NN N
after IN N
an DT N
additional JJ N
1 CD N
year NN N
. . N

There EX N
were VBD N
two CD N
malunions NNS o
in IN N
the DT N
reamed VBN i
group NN N
and CC N
four CD N
malunions NNS o
in IN N
the DT N
unreamed JJ i
group NN N
. . N

There EX N
were VBD N
no DT N
differences NNS N
for IN N
all DT N
other JJ N
outcome NN N
measurements NNS N
. . N

CONCLUSION NNP N
Unreamed VBD i
nailing VBG i
in IN i
patients NNS p
with IN p
tibial JJ p
shaft NN p
fractures NNS p
may MD N
be VB N
associated VBN N
with IN N
higher JJR N
rates NNS o
of IN o
secondary JJ o
operations NNS o
and CC o
malunions NNS o
compared VBN N
with IN N
reamed JJ i
nailing NN i
. . i

The DT N
time NN o
to TO o
fracture VB o
healing NN o
was VBD N
significantly RB N
longer RBR N
with IN N
unreamed JJ i
nails NNS i
. . i

-DOCSTART- -23586852- O O

Promoting VBG N
question-asking NN i
in IN N
school-aged JJ p
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
: : p
effectiveness NN N
of IN N
a DT N
robot NN i
intervention NN i
compared VBN N
to TO N
a DT N
human-trainer JJ i
intervention NN i
. . i

OBJECTIVE CC N
The DT N
purpose NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effectiveness NN N
of IN N
an DT N
applied JJ i
behaviour NN i
analysis NN i
( ( i
ABA NNP i
) ) i
-based VBD i
intervention NN i
conducted VBN i
by IN i
a DT i
robot NN i
compared VBN i
to TO i
an DT i
ABA-based JJ i
intervention NN i
conducted VBN i
by IN i
a DT i
human JJ i
trainer NN i
in IN i
promoting VBG N
self-initiated JJ N
questions NNS N
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
. . p

METHODS NNP N
Data NNP N
were VBD N
collected VBN N
in IN N
a DT N
combined JJ N
crossover NN N
multiple JJ N
baseline NN N
design NN N
across IN N
participants NNS p
. . p

Six CD p
children NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
two CD N
experimental JJ N
groups NNS N
. . N

RESULTS NNP N
Results NNP N
revealed VBD N
that IN N
the DT N
number NN N
of IN N
self-initiated JJ o
questions NNS o
for IN N
both DT N
experimental JJ N
groups NNS N
increased VBD N
between IN N
baseline NN N
and CC N
the DT N
first JJ N
intervention NN N
and CC N
was VBD N
maintained VBN N
during IN N
follow-up NN N
. . N

The DT N
high JJ N
number NN N
of IN N
self-initiated JJ o
questions NNS o
during IN N
follow-up JJ N
indicates NNS N
that IN N
both DT N
groups NNS N
maintained VBD N
this DT N
skill NN N
. . N

CONCLUSIONS VB N
The DT N
interventions NNS i
conducted VBN i
by IN i
a DT i
robot NN i
and CC i
a DT i
human JJ i
trainer NN i
were VBD N
both DT N
effective JJ N
in IN N
promoting VBG N
self-initiated JJ N
questions NNS N
in IN N
children NNS p
with IN p
ASD NNP p
. . p

No DT N
conclusion NN N
with IN N
regard NN N
to TO N
the DT N
differential JJ N
effectiveness NN N
of IN N
both DT N
interventions NNS N
could MD N
be VB N
drawn VBN N
. . N

Implications NNS N
of IN N
the DT N
results NNS N
and CC N
directions NNS N
for IN N
future JJ N
research NN N
are VBP N
discussed VBN N
. . N

-DOCSTART- -16930934- O O

Heart NNP o
rate NN o
variability NN o
and CC N
QT NNP o
dispersion NN o
in IN N
patients NNS p
with IN p
subclinical JJ p
hypothyroidism NN p
. . p

UNLABELLED IN N
The DT N
effect NN N
of IN N
subclinical JJ p
hypothyroidism NN p
( ( p
SH NNP p
) ) p
on IN N
cardiovascular JJ N
autonomic JJ N
function NN N
and CC N
ventricular JJ N
repolarization NN N
has VBZ N
not RB N
been VBN N
yet RB N
elucidated VBN N
. . N

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
dispersion NN N
of IN N
QT NNP N
interval NN N
, , N
i.e NN N
. . N

an DT N
index NN N
of IN N
inhomogeneity NN N
of IN N
repolarization NN N
, , N
and CC N
heart NN N
rate NN N
variability NN N
( ( N
HRV NNP N
) ) N
, , N
i.e RB N
. . N

a DT N
measure NN N
of IN N
cardiac JJ N
autonomic JJ N
modulation NN N
, , N
in IN N
SH NNP p
patients NNS p
. . p

METHODS NNP N
The DT N
study NN N
included VBD N
42 CD p
patients NNS p
( ( p
29 CD p
women NNS p
and CC p
13 CD p
men NNS p
; : p
mean JJ p
age NN p
53.2+/-14.2 JJ p
years NNS p
; : p
body NN p
surface JJ p
area NN p
1.76+/-0.14 JJ p
m2 NN p
) ) p
with IN p
SH NNP p
, , p
as IN p
judged VBN p
by IN p
elevated JJ p
serum NN p
TSH NNP p
levels NNS p
( ( p
> $ p
3.6 CD p
mIU/l NN p
; : p
range NN p
, , p
3.8-12.0 JJ p
) ) p
and CC p
normal JJ p
free JJ p
thyroid NN p
hormones NNS p
( ( p
FT4 NNP p
and CC p
FT3 NNP p
) ) p
and CC p
30 CD p
euthyroid JJ p
volunteer NN p
. . p

Subjects NNS p
with IN p
cardiac JJ p
, , p
metabolic JJ p
, , p
neurological JJ p
disease NN p
or CC p
any DT p
other JJ p
systemic JJ p
disease NN p
that WDT p
could MD p
affect VB p
autonomic JJ p
activity NN p
were VBD p
excluded VBN p
from IN p
the DT p
study NN p
. . p

Patients NNS p
with IN p
SH NNP p
and CC N
control VB N
subjects NNS N
underwent VB N
a DT N
full JJ N
history NN N
, , N
physical JJ N
examination NN N
, , N
standard JJ N
12-lead JJ i
ECG NNP i
, , i
and CC i
24-h JJ i
ambulatory NN i
ECG NNP i
monitoring NN i
. . i

To TO N
evaluate VB N
the DT N
effect NN N
of IN N
treatment NN N
with IN N
L-thyroxine NNP i
on IN N
QT NNP N
dispersion NN N
and CC N
HRV NNP N
, , N
15 CD N
patients NNS N
with IN N
SH NNP N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
therapy NN N
with IN N
L-thyroxine NNP i
. . i

All PDT N
the DT N
subjects NNS N
were VBD N
evaluated VBN N
at IN N
enrolment NN N
and CC N
after IN N
6 CD N
months NNS N
. . N

RESULTS NNP N
Patients NNPS p
with IN p
SH NNP p
showed VBD N
higher JJR N
QT NNP o
dispersion NN o
and CC N
lower JJR o
HRV NNP o
measures NNS o
than IN N
healthy JJ N
controls NNS N
( ( N
P NNP N
< VBZ N
0.01 CD N
for IN N
all DT N
) ) N
. . N

In IN N
SH NNP N
patients NNS N
, , N
the DT N
standard JJ o
deviation NN o
of IN o
N-Ns NNP o
( ( o
SDNN NNP o
) ) o
was VBD N
negatively RB N
related VBN N
to TO N
TSH NNP N
( ( N
r=-0.42 JJ N
, , N
P=0.006 NNP N
) ) N
, , N
while IN N
low JJ o
frequency NN o
( ( o
LF NNP o
) ) o
/high VBP o
frequency NN o
( ( o
HF NNP o
) ) o
ratio NN o
was VBD N
positively RB N
related VBN N
to TO N
TSH NNP N
( ( N
r=0.42 NN N
, , N
P=0.006 NNP N
) ) N
. . N

Moreover RB N
, , N
in IN N
SH NNP p
patients NNS p
both DT N
QT NNP o
dispersion NN o
and CC o
QTc NNP o
dispersion NN o
were VBD N
positively RB N
related VBN N
to TO N
TSH NNP N
( ( N
r=0.64 NN N
and CC N
r=0.63 NN N
, , N
P NNP N
< VBZ N
0.001 CD N
for IN N
both DT N
) ) N
. . N

After IN N
6 CD N
months NNS N
, , N
the DT N
patients NNS N
treated VBN N
with IN N
L-tiroxine NNP i
exhibited VBD N
a DT N
reduction NN N
of IN N
QT NNP o
dispersion NN o
and CC N
an DT N
increase NN N
of IN N
HRV NNP o
parameters NNS o
. . o

CONCLUSION VB N
The DT N
results NNS N
of IN N
the DT N
present JJ N
study NN N
demonstrated VBD N
that IN N
SH NNP N
can MD N
alter VB N
autonomic JJ N
modulation NN N
of IN N
heart NN o
rate NN o
and CC N
cause NN N
increased VBD N
inhomogeneity NN N
of IN N
ventricular JJ N
recovery NN N
times NNS N
. . N

Accordingly RB N
, , N
early JJ N
L-thyroxine JJ i
treatment NN N
may MD N
be VB N
advised VBN N
not RB N
only RB N
to TO N
prevent VB N
progression NN N
to TO N
overt VB N
hypothyroidism NN N
but CC N
also RB N
to TO N
improve VB N
abnormal JJ N
cardiac JJ N
autonomic JJ N
function NN N
and CC N
ventricular JJ N
repolarization NN N
inhomogeneity NN N
. . N

-DOCSTART- -6111083- O O

A DT N
comparative JJ N
trial NN N
of IN N
fixed JJ N
ratio NN N
beta-adrenoceptor NN i
blocker NN i
and CC i
diuretic JJ i
combination NN i
products NNS i
in IN N
moderate JJ p
hypertension NN p
. . p

Two CD N
fixed JJ N
ratio NN N
combination NN N
tablets NNS N
, , N
10 CD N
mg NN N
pindolol NN i
combined VBN i
with IN i
5 CD i
mg NNS i
clopamide NN i
and CC N
100 CD N
mg NN N
metoprolol NN i
combined VBN i
with IN i
12.5 CD i
mg NNS i
hydrochlorothiazide RB i
, , N
were VBD N
compared VBN N
at IN N
two CD N
dose JJ N
levels NNS N
in IN N
a DT N
double-blind JJ N
crossover NN N
trial NN N
in IN N
10 CD p
previously RB p
untreated JJ i
hypertensive JJ p
patients NNS p
. . p

No DT N
significant JJ N
difference NN N
was VBD N
observed VBN N
between IN N
resting VBG o
blood NN o
pressure NN o
on IN N
the DT N
two CD N
combinations NNS N
at IN N
either DT N
dose JJ N
level NN N
. . N

Exercise NNP o
systolic JJ o
pressure NN o
was VBD N
lower JJR N
after IN N
the DT N
pindolol/clopamide JJ i
combination NN N
at IN N
low JJ N
dose NN N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

The DT N
incidence NN o
of IN o
side-effects NNS o
in IN N
this DT N
trial NN N
was VBD N
high JJ N
but CC N
proper JJ N
comparison NN N
of IN N
the DT N
two CD N
products NNS N
could MD N
not RB N
be VB N
made VBN N
because IN N
of IN N
the DT N
small JJ N
number NN N
of IN N
patients NNS N
. . N

It PRP N
is VBZ N
suggested VBN N
that IN N
combination NN i
products NNS i
should MD N
be VB N
used VBN N
only RB N
after IN N
patients NNS N
have VBP N
failed VBN N
to TO N
respond VB N
adequately RB N
to TO N
a DT N
single JJ N
agent NN N
. . N

-DOCSTART- -9818688- O O

Recombinant JJ i
human JJ i
granulocyte NN i
and CC i
granulocyte-macrophage JJ i
colony-stimulating JJ i
factor NN i
( ( i
G-CSF NNP i
and CC i
GM-CSF NNP i
) ) i
administered VBD N
following VBG N
cytotoxic NN i
chemotherapy NNS i
have VBP N
a DT N
similar JJ N
ability NN N
to TO N
mobilize VB N
peripheral JJ N
blood NN N
stem NN N
cells NNS N
. . N

The DT N
availability NN N
of IN N
hematopoietic JJ N
growth NN N
factors NNS N
has VBZ N
greatly RB N
facilitated VBN N
the DT N
mobilization NN o
and CC o
collection NN o
of IN o
peripheral JJ o
blood NN o
stem NN o
cells NNS o
( ( o
PBSC NNP o
) ) o
. . o

It PRP N
was VBD N
the DT N
aim NN N
of IN N
this DT N
double-blind NN N
study NN N
to TO N
compare VB N
the DT N
PBSC-mobilizing NNP N
efficacy NN N
of IN N
recombinant JJ i
human JJ i
G-CSF NNP i
and CC N
GM-CSF NNP i
when WRB N
administered VBN N
post-chemotherapy NN i
. . i

Twenty-six JJ p
patients NNS p
with IN p
relapsed JJ p
Hodgkin NNP p
's POS p
disease NN p
were VBD N
included VBN N
in IN N
the DT N
study NN N
. . N

Their PRP$ p
median JJ p
age NN p
was VBD p
31 CD p
years NNS p
( ( p
range NN p
, , p
22-59 JJ p
) ) p
and CC p
14 CD p
patients NNS p
were VBD p
males NNS p
and CC p
12 CD p
were VBD p
females NNS p
. . p

Patients NNS p
were VBD p
pretreated VBN p
with IN p
a DT p
median NN p
of IN p
eight CD p
cycles NNS p
of IN p
cytotoxic NN i
chemotherapy NN i
, , p
while IN p
18 CD p
patients NNS p
had VBD p
undergone JJ p
extended JJ p
field NN p
irradiation NN p
. . p

The DT N
patients NNS N
received VBD N
dexamethasone RB i
24 CD i
mg JJ i
days NNS i
1-7 CD i
, , i
melphalan FW i
30 CD i
mg/m2 NNS i
day NN i
3 CD i
, , i
BCNU NNP i
60 CD i
mg/m2 NN i
day NN i
3 CD i
, , i
etoposide RB i
75 CD i
mg/m2 JJ i
days NNS i
4-7 CD i
, , i
Ara-C NNP i
100 CD i
mg/m2 NN i
twice RB i
daily JJ i
days NNS i
4-7 JJ i
( ( i
Dexa-BEAM NNP i
) ) i
. . N

Twelve CD N
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB i
5/microg/kg/day CD i
G-CSF NNP i
and CC N
14 CD N
patients NNS N
to TO N
receive VB N
5 CD i
microg/kg/day JJ i
GM-CSF NNP i
, , N
both DT N
administered VBN N
subcutaneously RB N
starting VBG N
on IN N
day NN N
1 CD N
after IN N
the DT N
end NN N
of IN N
Dexa-BEAM NNP i
. . i

Primary JJ N
endpoints NNS N
of IN N
the DT N
study NN N
were VBD N
the DT N
number NN o
of IN o
CD34+ NNP o
cells NNS o
harvested VBD o
per IN o
kg NN o
body NN o
weight VBD o
on IN o
the DT o
occasion NN o
of IN o
six CD o
consecutive JJ o
leukaphereses NNS o
and CC N
the DT N
time NN o
needed VBN o
for IN o
hematological JJ o
reconstitution NN o
following VBG o
autografting VBG o
. . o

Twenty-one CD N
patients NNS N
completed VBN N
PBSC NNP N
collection NN N
, , N
and CC N
six CD N
patients NNS N
of IN N
the DT N
G-CSF NNP N
group NN N
and CC N
nine CD N
of IN N
the DT N
GM-CSF NNP N
group NN N
were VBD N
autografted VBN N
. . N

No DT N
difference NN N
was VBD N
observed VBN N
with IN N
respect NN N
to TO N
the DT N
median JJ o
yield NN o
of IN o
CFU-GM NNP o
and CC o
CD34+ NNP o
cells NNS o
: : o
32.5 CD N
x $ N
10 CD N
( ( N
4 CD N
) ) N
/kg NN N
vs $ N
31.3 CD N
x $ N
10 CD N
( ( N
4 CD N
) ) N
/kg CD N
CFU-GM NNP N
, , N
and CC N
7.6 CD N
x NNS N
10 CD N
( ( N
6 CD N
) ) N
/kg NN N
vs $ N
5.6 CD N
x $ N
10 CD N
( ( N
6 CD N
) ) N
/kg NN N
CD34+ NNP N
cells NNS N
, , N
for IN N
G-CSF NNP o
and CC o
GM-CSF NNP o
, , N
respectively RB N
( ( N
U NNP N
test NN N
, , N
P= NNP N
0.837 CD N
and CC N
0.696 CD N
) ) N
. . N

High-dose JJ N
chemotherapy NN N
consisted VBN N
of IN N
cyclophosphamide NN i
1.7 CD N
g/m2 JJ N
days NNS N
1-4 CD N
, , N
BCNU NNP i
150 CD N
mg/m2 NN N
days NNS N
1-4 CD N
, , N
etoposide RB i
400 CD N
mg/m2 JJ N
days NNS N
1-4 JJ N
. . N

All DT N
patients NNS N
transplanted VBN N
with IN N
more JJR N
than IN N
5 CD N
x JJ N
10 CD N
( ( N
6 CD N
) ) N
CD34+ NNP N
cells/kg NN N
had VBD N
a DT N
rapid JJ N
platelet NN o
recovery NN o
( ( N
20 CD N
x RB N
10 CD N
( ( N
9 CD N
) ) N
/l NN N
) ) N
between IN N
6 CD N
and CC N
11 CD N
days NNS N
and CC N
neutrophil JJ o
recovery NN o
( ( N
0.5 CD N
x RB N
10 CD N
( ( N
9 CD N
) ) N
/1 NN N
) ) N
between IN N
9 CD N
and CC N
16 CD N
days NNS N
, , N
while IN N
patients NNS N
transplanted VBN N
with IN N
less JJR N
than IN N
5 CD N
x JJ N
10 CD N
( ( N
6 CD N
) ) N
/kg NN N
had VBD N
a DT N
delayed VBN o
reconstitution NN o
, , N
regardless RB N
of IN N
the DT N
kind NN N
of IN N
growth NN N
factor NN N
used VBN N
for IN N
PBSC NNP N
mobilization NN N
. . N

In IN N
conclusion NN N
, , N
our PRP$ N
data NNS N
indicate VBP N
that IN N
in IN N
patients NNS p
with IN p
Hodgkin NNP p
's POS p
disease NN p
G-CSF NNP N
and CC N
GM-CSF NNP N
given VBN N
after IN N
salvage NN N
chemotherapy NN N
appear VBP N
to TO N
be VB N
not RB N
different JJ N
in IN N
their PRP$ N
ability NN o
to TO o
mobilize VB o
PBSC NNP o
resulting VBG N
in IN N
a DT N
similar JJ N
time NN o
needed VBN o
for IN o
hematological JJ o
reconstitution NN o
when WRB N
autografted VBD N
following VBG N
high-dose JJ N
therapy NN N
. . N

-DOCSTART- -15193471- O O

An DT N
open JJ N
and CC N
randomized JJ N
study NN N
comparing VBG N
the DT N
efficacy NN o
of IN N
standard JJ i
danazol NN i
and CC i
modified VBD i
triptorelin NN i
regimens NNS i
for IN N
postoperative JJ p
disease NN p
management NN p
of IN p
moderate JJ p
to TO p
severe JJ p
endometriosis NN p
. . p

OBJECTIVE UH N
To TO N
compare VB N
the DT N
efficacy NN o
of IN N
danazol NN i
and CC i
triptorelin NN i
( ( N
Decapeptyl NNP N
CR NNP N
, , N
Ferring NNP N
, , N
Kiel NNP N
, , N
Germany NNP N
) ) N
in IN N
the DT N
management NN N
of IN N
moderate JJ N
and CC N
severe JJ N
endometriosis NN N
in IN N
terms NNS N
of IN N
symptom NN o
control NN o
and CC N
revised VBN N
American JJ o
Fertility NNP o
Society NNP o
( ( o
AFS NNP o
) ) o
score NN o
reduction NN o
, , N
and CC N
to TO N
evaluate VB N
the DT N
hormonal JJ o
profile NN o
of IN N
patients NNS p
treated VBN p
with IN p
triptorelin NN i
every DT p
6 CD p
weeks NNS p
. . p

DESIGN NNP N
Open NNP N
and CC N
randomized VBN N
trial NN N
. . N

SETTING NN N
Kwong NNP p
Wah NNP p
Hospital NNP p
, , p
a DT p
large JJ p
public JJ p
hospital NN p
in IN p
an DT p
urban JJ p
location NN p
( ( p
Hong NNP p
Kong NNP p
) ) p
. . p

PATIENT NNP N
( ( N
S NNP N
) ) N
Forty NNP p
patients NNS p
after IN p
their PRP$ p
first JJ p
conservative JJ p
operation NN p
for IN p
endometriosis NN p
, , p
with IN p
surgical JJ p
confirmation NN p
of IN p
revised VBN p
AFS NNP p
stage NN p
III NNP p
or CC p
IV NNP p
endometriosis NN p
. . p

INTERVENTION NNP N
( ( N
S NNP N
) ) N
Postoperative VBP N
6 CD N
months NNS N
' POS N
therapy NN N
of IN N
danazol NN i
or CC i
triptorelin NN i
every DT N
6 CD N
weeks NNS N
, , N
postmedical JJ N
therapy NN N
second-look NN N
laparoscopy NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
( ( N
S NNP N
) ) N
Symptom NNP o
control NN o
and CC o
patients NNS o
' POS o
tolerance NN o
during IN N
medical JJ N
therapy NN N
, , N
posttherapy NN o
revised VBD o
AFS NNP o
score NN o
, , o
hormonal JJ o
profile NN o
during IN o
triptorelin JJ o
therapy NN o
. . o

RESULT NNP N
( ( N
S NNP N
) ) N
Pain NNP o
control NN o
was VBD N
similar JJ N
between IN N
danazol NN i
and CC N
triptorelin NN i
therapy NN N
. . N

There EX N
was VBD N
less JJR N
breakthrough IN o
bleeding NN o
with IN N
triptorelin NN i
. . i

More JJR N
patients NNS N
failed VBD N
to TO N
complete VB N
the DT N
whole JJ N
course NN N
of IN N
danazol NN i
because IN N
of IN N
its PRP$ N
side NN o
effects NNS o
. . o

The DT N
revised JJ o
AFS NNP o
score NN o
at IN N
second-look JJ N
laparoscopy NN N
did VBD N
not RB N
show VB N
a DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
medications NNS N
. . N

Adequate NNP o
pituitary JJ o
suppression NN o
was VBD N
observed VBN N
with IN N
injection NN N
of IN N
triptorelin NN i
every DT N
6 CD N
weeks NNS N
. . N

CONCLUSION NNP N
( ( N
S NNP N
) ) N
Lengthening NNP N
of IN N
triptorelin JJ i
administration NN N
intervals NNS N
from IN N
4 CD N
weeks NNS N
to TO N
6 CD N
weeks NNS N
is VBZ N
effective JJ N
in IN N
maintaining VBG N
a DT N
hypoestrogenic JJ o
state NN o
. . o

Patients NNS N
were VBD N
more RBR N
compliant JJ o
with IN N
triptorelin NN i
than IN N
danazol NN i
. . i

Thus RB N
, , N
triptorelin JJ i
injection NN N
every DT N
6 CD N
weeks NNS N
is VBZ N
more JJR N
cost-effective JJ N
than IN N
conventional JJ N
regimens NNS N
. . N

-DOCSTART- -16585311- O O

Evaluation NN N
of IN N
nonpharmacologic JJ i
methods NNS i
of IN i
pain NN i
and CC i
anxiety NN i
management NN i
for IN N
laceration NN N
repair NN N
in IN N
the DT N
pediatric JJ N
emergency NN N
department NN N
. . N

BACKGROUND NNP N
Nonpharmacologic NNP i
interventions NNS i
, , i
such JJ i
as IN i
distraction NN i
, , N
have VBP N
been VBN N
shown VBN N
to TO N
be VB N
powerful JJ N
adjuncts NNS N
in IN N
reducing VBG N
pain NN N
and CC N
anxiety NN N
in IN N
children NNS p
with IN p
both DT p
acute NN p
and CC p
chronic JJ p
painful JJ p
conditions NNS p
. . p

There EX N
are VBP N
no DT N
controlled JJ N
studies NNS N
evaluating VBG N
these DT N
interventions NNS N
as IN N
adjuncts NNS N
to TO N
facilitate VB N
completion NN N
of IN N
painful JJ N
procedures NNS N
in IN N
the DT N
pediatric JJ N
emergency NN N
department NN N
( ( N
ED NNP N
) ) N
. . N

OBJECTIVE IN N
We PRP N
assessed VBD N
the DT N
effectiveness NN N
of IN N
distraction NN i
techniques NNS i
in IN N
reducing VBG N
the DT N
sensory NN N
and CC N
affective JJ N
components NNS N
of IN N
pain NN N
among IN N
pediatric JJ p
patients NNS p
undergoing JJ p
laceration NN p
repair NN p
in IN p
the DT p
ED NNP p
. . p

METHODS NNP N
Eligible JJ p
children NNS p
between IN p
6 CD p
and CC p
18 CD p
years NNS p
of IN p
age NN p
( ( p
N NNP p
= NNP p
240 CD p
) ) p
presenting NN p
to TO p
the DT p
ED NNP p
for IN p
laceration NN p
repair NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
an DT N
intervention NN N
or CC N
control NN N
arm NN N
. . N

Those DT N
assigned VBN N
to TO N
the DT N
intervention NN N
arm NN N
were VBD N
given VBN N
a DT N
choice NN N
of IN N
age-appropriate JJ i
distracters NNS i
during IN N
laceration NN N
repair NN N
. . N

Quantitative JJ N
measures NNS N
of IN N
pain NN o
intensity NN o
, , o
situational JJ o
anxiety NN o
, , o
and CC o
pain NN o
distress NN o
( ( o
as IN o
perceived VBN o
by IN o
the DT o
parent NN o
) ) o
were VBD N
assessed VBN N
by IN N
using VBG N
the DT N
7-point JJ o
Facial NNP o
Pain NNP o
Scale NNP o
, , o
State NNP o
Trait NNP o
Anxiety NNP o
Inventory NNP o
for IN N
Children NNP N
, , N
and CC N
a DT N
visual JJ o
analog NN o
scale NN o
, , N
respectively RB N
, , N
before IN N
and CC N
after IN N
laceration NN N
repair NN N
. . N

The DT N
State NNP o
Trait NNP o
Anxiety NNP o
Inventory NNP o
for IN N
Children NNP N
was VBD N
performed VBN N
in IN N
children NNS N
> VBP N
or CC N
= VBP N
10 CD N
years NNS N
of IN N
age NN N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
difference NN N
in IN N
mean JJ o
change NN o
in IN o
Facial NNP o
Pain NNP o
Scale NNP o
scores VBZ N
between IN N
the DT N
control NN N
and CC N
the DT N
intervention NN N
groups NNS N
in IN N
children NNS N
< VBP N
10 CD N
years NNS N
of IN N
age NN N
. . N

Multivariate NNP N
analysis NN N
in IN N
this DT N
same JJ N
age NN N
group NN N
showed VBD N
that IN N
the DT N
intervention NN N
was VBD N
independently RB N
associated VBN N
with IN N
a DT N
reduction NN o
in IN o
pain NN o
distress NN o
as IN N
perceived VBN N
by IN N
parents NNS N
based VBN N
on IN N
the DT N
mean JJ N
change NN N
in IN N
visual JJ N
analog NN N
scale NN N
scores NNS N
. . N

In IN N
older JJR N
children NNS N
, , N
the DT N
intervention NN N
was VBD N
independently RB N
associated VBN N
with IN N
reduction NN N
in IN N
situational JJ o
anxiety NN o
but CC N
not RB N
in IN N
pain NN o
intensity NN o
or CC o
in IN o
parental JJ o
perception NN o
of IN N
pain NN N
distress NN N
. . N

CONCLUSIONS VB N
The DT N
use NN N
of IN N
distraction NN i
techniques NNS i
is VBZ N
effective JJ N
in IN N
reducing VBG N
situational JJ N
anxiety NN N
in IN N
older JJR p
children NNS p
and CC N
lowering VBG N
parental JJ N
perception NN N
of IN N
pain NN N
distress NN N
in IN N
younger JJR N
children NNS N
. . N

This DT N
technique NN N
may MD N
have VB N
a DT N
role NN N
in IN N
improving VBG N
the DT N
quality NN N
of IN N
management NN N
of IN N
procedural JJ N
pain NN N
in IN N
a DT N
pediatric JJ N
ED NNP N
setting NN N
. . N

-DOCSTART- -12769155- O O

Preservative-free JJ i
ocular JJ i
hydrating VBG i
agents NNS i
in IN N
symptomatic JJ p
contact NN p
lens VBZ p
wearers NNS p
: : p
saline NN i
versus IN i
PVP NNP i
solution NN i
. . i

PURPOSE NNP N
To TO N
compare VB N
two CD N
preservative-free JJ i
hydrating VBG i
agents NNS i
, , N
in IN N
multidose NN N
( ( N
ABAK NNP N
) ) N
bottles NNS N
, , N
in IN N
contact NN p
lens NN p
wearers NNS p
experiencing VBG p
symptoms NNS p
of IN p
ocular JJ o
dryness NN o
. . o

METHODS NNP N
The DT N
endpoint NN N
of IN N
this DT N
4-week JJ N
multicenter NN N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
parallel-group JJ N
study NN N
comparing VBG N
a DT N
2 CD i
% NN i
polyvinylpyrrolidone NN i
( ( i
PVP NNP i
) ) i
solution NN i
with IN i
a DT i
0.9 CD i
% NN i
NaCl NNP i
solution NN i
was VBD N
to TO N
assess VB N
ocular JJ N
discomfort NN N
using VBG N
a DT N
visual JJ N
analog NN N
scale NN N
. . N

A DT N
biomicroscopic NN N
examination NN N
and CC N
a DT N
test NN N
of IN N
tolerability NN N
on IN N
instillation NN N
were VBD N
also RB N
performed VBN N
, , N
and CC N
adverse JJ N
events NNS N
were VBD N
recorded VBN N
. . N

RESULTS NNP N
Thirty-nine JJ p
subjects NNS p
were VBD p
enrolled VBN p
( ( p
23 CD p
PVP NNP p
; : p
16 CD p
NaCl NNP p
) ) p
. . p

The DT N
average JJ p
age NN p
was VBD p
30 CD p
; : p
subjects NNS p
were VBD p
predominantly RB p
female JJ p
, , p
and CC p
mostly RB p
wore VBD p
frequent-replacement JJ p
contact NN p
lenses NNS p
. . p

They PRP p
were VBD p
all DT p
exposed VBN p
to TO p
environmental JJ p
factors NNS p
such JJ p
as IN p
routine JJ p
use NN p
of IN p
video NN p
monitors NNS p
or CC p
air NN p
conditioning NN p
. . p

The DT N
two CD N
groups NNS N
were VBD N
similar JJ N
at IN N
baseline NN N
( ( N
D0 NNP N
) ) N
. . N

Both DT N
PVP NNP i
and CC N
NaCl NNP i
improved VBD N
the DT N
comfort NN o
of IN o
contact NN o
lens NNS o
wear VBP o
( ( N
P NNP N
= NNP N
0.0003 CD N
) ) N
, , N
with IN N
no DT N
difference NN N
between IN N
them PRP N
( ( N
P NNP N
= NNP N
0.25 CD N
) ) N
. . N

The DT N
mean JJ o
daily JJ o
duration NN o
of IN o
lens NNS o
wear JJ o
and CC o
the DT o
daily JJ o
number NN o
of IN o
instillations NNS o
to TO o
relieve VB o
discomfort NN o
( ( N
4.2 CD N
+/- JJ N
2.0 CD N
for IN N
PVP NNP i
ABAK NNP N
; : N
4.6 CD N
+/- JJ N
1.9 CD N
for IN N
NaCl NNP i
ABAK NNP N
) ) N
were VBD N
comparable JJ N
. . N

However RB N
, , N
PVP NNP i
use NN N
led VBD N
to TO N
more RBR N
favorable JJ N
evolution NN N
of IN N
fluorescein-staining JJ o
corneal NN o
punctuations NNS o
( ( N
P NNP N
= NNP N
0.028 CD N
) ) N
. . N

Safety NN o
was VBD N
good JJ N
, , N
with IN N
minimal JJ N
adverse JJ o
events NNS o
considered VBN N
unrelated JJ N
to TO N
the DT N
products NNS N
. . N

Lens NNP o
wettability NN o
was VBD N
excellent JJ N
, , N
and CC N
there EX N
were VBD N
no DT N
clinically RB N
relevant JJ N
deposits NNS N
. . N

Most JJS N
subjects NNS N
also RB N
found VBD N
the DT N
ABAK NNP N
bottles NNS N
convenient NN N
. . N

CONCLUSIONS NNP N
Ocular NNP N
hydration NN N
improves VBZ N
comfort NN o
in IN N
contact NN N
lens NN N
wearers NNS N
. . N

NaCl NNP i
is VBZ N
an DT N
appropriate JJ N
first-line JJ N
treatment NN N
, , N
but CC N
for IN N
subjects NNS N
with IN N
fluorescein-staining JJ N
punctuations NNS N
, , N
lubrication NN N
with IN N
PVP NNP i
is VBZ N
preferable JJ N
. . N

-DOCSTART- -7755996- O O

A DT N
prospective JJ N
comparison NN N
of IN N
the DT N
multiplane NN i
probe NN i
with IN N
the DT N
biplane NN i
probe NN i
in IN N
structure NN o
visualization NN o
and CC o
Doppler NNP o
examination NN o
during IN p
transesophageal JJ p
echocardiography NN p
. . p

To TO N
compare VB N
the DT N
imaging JJ o
capability NN o
of IN N
the DT N
multiplane NN i
probe NN i
with IN N
that DT N
of IN N
the DT N
biplane NN i
probe NN i
, , N
317 CD p
consecutive JJ p
patients NNS p
were VBD N
randomized VBN N
to TO N
undergo VB N
transesophageal JJ i
echocardiography NN i
with IN i
either DT i
probe NN i
. . i

Images NNS N
of IN N
24 CD N
cardiac JJ N
structures NNS N
and CC N
nine CD o
Doppler NNP o
signals NNS o
were VBD N
graded VBN N
prospectively RB N
on IN N
a DT N
three-grade JJ N
system NN N
. . N

Both DT N
multiplane NN i
and CC i
biplane NN i
probes NNS i
provided VBD N
excellent JJ o
visualization NN o
of IN o
cardiac JJ o
structures NNS o
and CC N
Doppler NNP o
signals NNS o
, , N
but CC N
the DT N
multiplane NN i
probe NN i
was VBD N
significantly RB N
superior JJ N
to TO N
the DT N
biplane NN N
probe NN N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
the DT N
number NN o
of IN o
attempts NNS o
at IN o
esophageal JJ o
intubation NN o
, , o
the DT o
amount NN o
of IN o
sedation NN o
used VBN o
, , o
and CC o
the DT o
examination NN o
time NN o
. . o

The DT N
number NN o
of IN o
complications NNS o
was VBD o
similar JJ o
, , N
although IN N
all DT N
failed VBD o
intubations NNS o
occurred VBD N
with IN N
the DT N
multiplane NN i
probe NN i
. . i

-DOCSTART- -17997772- O O

A DT N
prospective JJ N
randomized VBN N
treatment NN N
study NN N
comparing VBG N
three CD N
treatment NN N
options NNS N
for IN N
chalazia NN N
: : N
triamcinolone NN i
acetonide NN i
injections NNS i
, , i
incision NN i
and CC N
curettage NN i
and CC N
treatment NN N
with IN N
hot JJ i
compresses NNS i
. . i

BACKGROUND NNP N
Three NNP N
methods NNS N
of IN N
treating VBG N
chalazia NN N
were VBD N
compared VBN N
: : N
intralesional JJ i
triamcinolone NN i
acetonide NN i
injections NNS i
( ( i
0.2 CD i
mL NN i
of IN i
10 CD i
mg/mL NN i
) ) i
, , i
incision NN i
and CC i
curettage NN i
and CC i
advice NN i
regarding VBG i
the DT i
application NN i
of IN i
hot JJ i
compresses NNS i
to TO i
the DT i
affected JJ i
eyelid NN i
. . i

METHODS NNP N
This DT N
was VBD N
a DT N
single JJ N
centre NN N
randomized VBN N
treatment NN N
study NN N
. . N

Patients NNS p
with IN p
a DT p
chalazion NN p
underwent NN N
either DT N
of IN N
the DT N
three CD N
treatment NN N
options NNS N
. . N

Chalazion NNP o
resolution NN o
, , o
pain NN o
, , o
satisfaction NN o
and CC o
inconvenience NN o
experienced VBD o
because IN o
of IN o
treatments NNS o
were VBD N
the DT N
outcomes NNS N
assessed VBD i
via IN i
a DT i
telephone NN i
interview NN i
at IN i
3 CD i
weeks NNS i
. . i

RESULTS $ N
136 CD p
consecutive JJ p
patients NNS p
were VBD p
enrolled VBN p
into IN p
the DT p
study NN p
. . p

At IN N
the DT N
3-week JJ N
follow NN N
up RB N
, , N
the DT N
resolution NN o
rates NNS o
in IN N
the DT N
triamcinolone NN i
acetonide NN i
injection NN N
and CC N
surgical JJ N
treatment NN N
groups NNS N
were VBD N
not RB N
significantly RB N
different JJ N
from IN N
each DT N
other JJ N
at IN N
84 CD N
% NN N
( ( N
47/56 CD N
) ) N
and CC N
87 CD N
% NN N
( ( N
39/45 CD N
) ) N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
but CC N
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
conservative JJ N
treatment NN N
group NN N
at IN N
46 CD N
% NN N
( ( N
16/35 CD N
) ) N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Pain NN o
scores NNS o
were VBD N
higher JJR N
in IN N
the DT N
surgical JJ N
treatment NN N
group NN N
compared VBN N
with IN N
the DT N
triamcinolone NN N
injection NN N
group NN N
( ( N
P NNP N
< NNP N
0.003 CD N
) ) N
. . N

Inconvenience NN o
experienced VBN o
by IN o
patients NNS o
was VBD N
reported VBN N
as IN N
significantly RB N
less RBR N
in IN N
the DT N
triamcinolone NN N
group NN N
compared VBN N
with IN N
the DT N
conservative JJ N
and CC N
surgical JJ N
treatment NN N
groups NNS N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Patient JJ o
satisfaction NN o
scores NNS o
were VBD N
lower JJR N
in IN N
the DT N
conservative JJ N
treatment NN N
group NN N
compared VBN N
with IN N
each DT N
of IN N
the DT N
other JJ N
two CD N
groups NNS N
which WDT N
in IN N
turn NN N
, , N
were VBD N
no DT N
different JJ N
from IN N
each DT N
other JJ N
regarding VBG N
this DT N
outcome NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSIONS NN N
To TO N
our PRP$ N
knowledge NN N
, , N
this DT N
is VBZ N
the DT N
first JJ N
prospective JJ N
randomized VBN N
study NN N
comparing VBG N
the DT N
three CD N
methods NNS N
of IN N
chalazia NN N
treatment NN N
. . N

Results VB N
suggest VBP N
that IN N
a DT N
single JJ N
triamcinolone NN i
acetonide NN i
injection NN N
followed VBN N
by IN N
lid JJ N
massage NN N
is VBZ N
almost RB N
as RB N
effective JJ N
as IN N
incision NN i
and CC N
curettage NN i
in IN N
the DT N
treatment NN N
of IN N
chalazia NN N
and CC N
with IN N
similar JJ N
patient NN o
satisfaction NN o
and CC N
less JJR N
pain NN o
and CC N
patient JJ o
inconvenience NN o
. . o

-DOCSTART- -23061531- O O

The DT N
effect NN N
of IN N
prethrombolytic JJ i
cyclosporine-A JJ i
injection NN i
on IN N
clinical JJ N
outcome NN N
of IN N
acute JJ p
anterior JJ p
ST-elevation NNP p
myocardial JJ p
infarction NN p
. . p

INTRODUCTION NNP N
Reperfusion NNP N
injury NN N
reduces VBZ N
the DT N
benefits NNS N
of IN N
early JJ N
reperfusion NN N
therapies NNS N
after IN N
acute JJ N
ST-elevation NNP N
myocardial JJ N
infarction NN N
( ( N
STEMI NNP N
) ) N
. . N

Cyclosporine-A NNP i
( ( i
CsA NNP i
) ) i
is VBZ N
a DT N
potent JJ N
inhibitor NN N
of IN N
opening NN N
of IN N
the DT N
mitochondrial JJ N
permeability NN N
transition NN N
pore NN N
, , N
which WDT N
has VBZ N
been VBN N
shown VBN N
to TO N
play VB N
a DT N
key JJ N
role NN N
in IN N
myocardial JJ N
reperfusion NN N
injury NN N
. . N

The DT N
impact NN N
of IN N
this DT N
treatment NN N
on IN N
clinical JJ N
outcomes NNS N
of IN N
acute JJ N
STEMI NNP N
remains VBZ N
unknown JJ N
. . N

Our PRP$ N
aim NN N
was VBD N
to TO N
investigate VB N
the DT N
clinical JJ N
outcomes NNS N
of IN N
using VBG N
this DT N
drug NN N
in IN N
patients NNS p
with IN p
acute JJ p
anterior JJ p
STEMI NNP p
receiving VBG p
thrombolytic JJ p
treatment NN p
( ( p
TLT NNP p
) ) p
. . p

METHODS NNP N
In IN N
this DT N
double-blinded JJ N
randomized JJ N
clinical JJ N
trial NN N
, , N
101 CD p
patients NNS p
with IN p
acute JJ p
anterior JJ p
STEMI NNP p
who WP p
were VBD p
candidate NN p
for IN p
TLT NNP p
, , N
were VBD N
enrolled VBN N
and CC N
randomly RB N
assigned VBN N
into IN N
treatment NN N
or CC N
control NN N
groups NNS N
. . N

Patients NNS i
in IN i
the DT i
treatment NN i
group NN i
received VBD i
an DT i
intravenous JJ i
bolus NN i
injection NN i
of IN i
2.5 CD i
mg/kg NN i
of IN i
CsA NNP i
immediately RB i
before IN i
TLT NNP i
. . i

The DT i
patients NNS i
in IN i
the DT i
control NN i
group NN i
received VBD i
an DT i
equivalent JJ i
volume NN i
of IN i
normal JJ i
saline NN i
. . i

Infarct NNP o
size NN o
, , o
occurrence NN o
of IN o
major JJ o
arrhythmias NNS o
, , o
heart NN o
failure NN o
, , o
left VBD o
ventricular JJ o
ejection NN o
fraction NN o
( ( o
LVEF NNP o
) ) o
, , o
TLT-related JJ o
complications NNS o
, , o
in-hospital JJ o
and CC o
6-month JJ o
mortality NN o
rates NNS o
were VBD N
investigated VBN N
. . N

RESULTS VB N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
among IN N
the DT N
demographics NNS o
, , o
myocardial JJ o
enzyme NN o
release NN o
, , o
occurrence NN o
of IN o
major JJ o
arrhythmias NNS o
[ VBP N
9 CD N
( ( N
18 CD N
% NN N
) ) N
vs. FW N
12 CD N
( ( N
23.5 CD N
% NN N
) ) N
, , N
P NNP N
= VBZ N
0.80 CD N
] NN N
, , N
heart NN o
failure NN o
[ VBZ N
18 CD N
( ( N
36 CD N
% NN N
) ) N
vs. FW N
19 CD N
( ( N
38.3 CD N
% NN N
) ) N
, , N
P NNP N
= VBZ N
0.83 CD N
] NN N
, , N
LVEF NNP o
at IN o
first JJ o
day NN o
[ VB N
34.7 CD N
? . N
9.9 CD N
% NN N
vs. FW N
33.5 CD N
? . N
8.1 CD N
% NN N
, , N
P NNP N
= VBZ N
0.50 CD N
] NN N
or CC N
at IN N
discharge NN o
[ $ o
37.7 CD N
? . N
10 CD N
% NN N
vs. FW N
36.1 CD N
? . N
8.2 CD N
% NN N
, , N
P NNP N
= VBZ N
0.43 CD N
] NN N
, , N
and CC N
in-hospital JJ o
[ NN o
4 CD o
( ( N
8 CD N
% NN N
) ) N
vs. FW N
6 CD N
( ( N
11.8 CD N
% NN N
) ) N
, , N
P NNP N
= VBZ N
0.74 CD N
] NN o
or CC o
6-month JJ o
mortality NN o
rates NNS o
[ VBP o
9 CD o
( ( N
18 CD N
% NN N
) ) N
vs. FW N
10 CD N
( ( N
19.6 CD N
% NN N
) ) N
, , N
P NNP N
= VBZ N
0.99 CD N
] NN N
between IN N
the DT N
CsA NNP N
vs. IN N
the DT N
control NN N
group NN N
. . N

CONCLUSION NNP N
In IN N
this DT N
study NN N
, , N
the DT N
prethrombolytic JJ N
administration NN N
of IN N
CsA NNP N
was VBD N
not RB N
associated VBN N
with IN N
a DT N
reduction NN N
in IN N
the DT N
infarct JJ o
size NN o
or CC o
any DT N
improvement NN N
in IN N
clinical JJ N
outcomes NNS N
. . N

-DOCSTART- -1359809- O O

Dexmedetomidine NNP i
infusion NN N
for IN N
maintenance NN N
of IN N
anesthesia NN N
in IN N
patients NNS p
undergoing JJ p
abdominal JJ p
hysterectomy NN p
. . p

The DT N
usefulness NN N
of IN N
intravenous JJ N
dexmedetomidine NN i
infusion NN N
for IN N
maintenance NN N
of IN N
anesthesia NN N
was VBD N
studied VBN N
in IN N
patients NNS p
anesthetized VBN p
with IN p
thiopental JJ p
, , p
fentanyl JJ p
, , p
nitrous JJ p
oxide NN p
, , p
and CC p
oxygen NN p
. . p

Isoflurane NNP N
was VBD N
added VBN N
as IN N
needed VBN N
. . N

The DT N
study NN N
was VBD N
conducted VBN N
in IN N
two CD N
parts NNS N
, , N
the DT N
first JJ N
of IN N
which WDT N
was VBD N
an DT N
open JJ N
dose-response NN N
study NN N
that WDT N
comprised VBD N
14 CD p
women NNS p
undergoing VBG p
abdominal JJ p
hysterectomy NN p
. . p

After IN N
a DT N
suitable JJ N
infusion NN N
regimen NNS N
of IN N
dexmedetomidine NN i
was VBD N
determined VBN N
according VBG N
to TO N
hemodynamic JJ N
criteria NNS N
, , N
20 CD p
patients NNS p
were VBD p
included VBN p
in IN N
a DT N
double-blind NN N
, , N
randomized VBN N
placebo-controlled JJ i
trial NN N
( ( N
10 CD N
receiving VBG N
dexmedetomidine NN i
, , N
10 CD N
saline JJ i
solution NN i
) ) i
. . N

Dexmedetomidine NNP i
was VBD N
administered VBN N
as IN N
a DT N
two-step JJ N
infusion NN N
to TO N
rapidly RB N
achieve VB N
a DT N
steady-state JJ N
plasma NN N
concentration NN N
. . N

The DT N
infusion NN N
was VBD N
started VBN N
with IN N
an DT N
initial JJ N
dose NN N
given VBN N
over IN N
10 CD N
min NNS N
before IN N
the DT N
induction NN N
of IN N
anesthesia NN N
; : N
at IN N
induction NN N
the DT N
maintenance NN N
rate NN N
was VBD N
begun VBN N
and CC N
continued VBN N
until IN N
closure NN N
of IN N
the DT N
abdominal JJ N
fascia NN N
. . N

The DT N
infusion NN N
regimens NNS N
of IN N
dexmedetomidine NN i
tested VBN N
in IN N
the DT N
dose-response JJ N
study NN N
ranged VBD N
from IN N
120 CD N
ng.kg-1 JJ N
x JJ N
min-1 NN N
, , N
followed VBN N
by IN N
6 CD N
ng.kg-1 JJ N
x JJ N
min-1 NN N
, , N
to TO N
270 CD N
+ NNS N
13.5 CD N
ng.kg-1 JJ N
x JJ N
min-1 NN N
. . N

In IN N
the DT N
second JJ N
part NN N
of IN N
the DT N
study NN N
, , N
an DT N
initial JJ N
infusion NN N
of IN N
170 CD N
ng.kg-1 JJ N
x JJ N
min-1 NN N
was VBD N
chosen VBN N
, , N
followed VBN N
by IN N
10 CD N
ng.kg-1 JJ N
x JJ N
min-1 NN N
for IN N
maintenance NN N
. . N

Anesthesia NNP N
was VBD N
induced VBN N
with IN N
thiopental JJ N
( ( N
4.0 CD N
mg/kg NN N
) ) N
and CC N
maintained VBN N
with IN N
isoflurane NN N
in IN N
70 CD N
% NN N
nitrous JJ N
oxide NN N
and CC N
oxygen NN N
. . N

Isoflurane NNP N
was VBD N
administered VBN N
according VBG N
to TO N
predetermined VBN N
hemodynamic JJ N
criteria NNS N
. . N

Dexmedetomidine NNP o
infusion NN o
did VBD o
not RB o
completely RB o
abolish VB o
the DT o
need NN o
for IN o
isoflurane NN o
but CC o
diminished VBD o
its PRP$ o
requirement NN o
by IN o
> $ o
90 CD o
% NN o
( ( o
P NNP o
= NNP o
0.02 CD o
) ) o
. . o

The DT N
heart NN o
rate NN o
response NN o
to TO o
endotracheal VB o
intubation NN o
was VBD o
significantly RB o
blunted VBN o
. . o

-DOCSTART- -24710131- O O

Low-dose JJ i
prednisolone NN i
treatment NN i
of IN N
early JJ p
rheumatoid NN p
arthritis NN p
and CC N
late JJ o
cardiovascular JJ o
outcome NN o
and CC o
survival NN o
: : o
10-year JJ N
follow-up NN N
of IN N
a DT N
2-year JJ N
randomised JJ N
trial NN N
. . N

OBJECTIVE UH N
To TO N
examine VB N
the DT N
long-term JJ o
effects NNS o
of IN N
early JJ N
low-dose JJ N
prednisolone NN i
use NN N
in IN N
patients NNS p
with IN p
rheumatoid JJ p
arthritis NN p
( ( p
RA NNP p
) ) p
on IN p
cardiovascular NN o
( ( o
CV NNP o
) ) o
morbidity NN o
and CC o
mortality NN o
. . o

DESIGN NNP N
Retrieval NNP N
of IN N
data NNS N
from IN N
a DT N
2-year JJ N
open JJ N
randomised VBN N
trial NN N
comparing VBG N
prednisolone NN i
7.5 CD N
mg/day NN N
in IN N
addition NN N
to TO N
disease-modifying JJ i
antirheumatic JJ i
drugs NNS i
( ( i
DMARDs NNP i
) ) i
with IN i
DMARD NNP i
therapy NN i
alone RB N
. . N

Participants NNS N
were VBD N
followed VBN N
for IN N
10 CD N
years NNS N
since IN N
inclusion NN N
into IN N
the DT N
original JJ N
prednisolone NN i
trial NN N
or CC N
until IN N
occurrence NN N
of IN N
the DT N
studied JJ N
outcomes NNS N
. . N

SETTING NN N
Secondary JJ N
level NN N
of IN N
care NN N
; : N
six CD p
participating VBG p
centres NNS p
from IN p
southern JJ p
Sweden NNP p
; : p
both DT p
urban JJ p
and CC p
rural JJ p
populations NNS p
. . p

PARTICIPANTS NNP N
Overall NNP N
, , N
223 CD p
patients NNS p
with IN p
early JJ p
RA NNP p
were VBD N
included VBN N
. . N

The DT N
participants NNS p
had VBD p
no DT p
history NN p
of IN p
CV NNP o
events NNS o
at IN p
baseline NN p
and CC N
incident JJ N
cases NNS N
were VBD N
identified VBN N
via IN N
the DT N
Swedish JJ N
Hospital NNP N
Discharge NNP N
and CC N
Cause NNP N
of IN N
Death NNP N
Registries NNP N
. . N

OUTCOMES NNP N
Composite NNP o
CV NNP o
events NNS o
, , o
that DT o
is VBZ o
, , o
ischaemic JJ o
coronary NN o
and CC o
cerebrovascular JJ o
events NNS o
, , o
components NNS o
of IN o
the DT o
composite JJ o
CV NNP o
outcome NN o
, , o
and CC o
death NN o
. . o

Relative JJ o
HRs NNP o
from IN o
Cox NNP o
proportional-hazards NNS o
regression NN o
models NNS o
were VBD N
calculated VBN N
. . N

RESULTS NNP N
Within IN N
2041 CD N
person-years NNS N
, , N
17 CD N
incident NN N
composite JJ o
CV NNP o
events NNS o
occurred VBD N
in IN N
112 CD N
patients NNS N
( ( N
15 CD N
% NN N
) ) N
randomised VBD N
to TO N
prednisolone VB i
, , N
and CC N
15 CD N
events NNS N
of IN N
111 CD N
patients NNS N
( ( N
14 CD N
% NN N
) ) N
who WP N
were VBD N
assigned VBN N
not RB N
to TO N
receive VB N
prednisolone NN i
. . i

There EX N
were VBD N
nine CD N
deaths NNS o
( ( N
8 CD N
% NN N
) ) N
in IN N
each DT N
group NN N
. . N

The DT N
age-adjusted JJ o
relative JJ o
hazards NNS o
( ( N
HRs NNP N
; : N
95 CD N
% NN N
CI NNP N
) ) N
for IN N
the DT N
first JJ N
composite JJ o
CV NNP o
event NN o
, , o
first RB o
coronary JJ o
event NN o
and CC o
death NN o
in IN N
the DT N
prednisolone NN i
group NN N
versus IN N
the DT N
group NN N
not RB N
treated VBN N
with IN N
prednisolone NN i
were VBD N
1.8 CD N
( ( N
0.9 CD N
to TO N
3.6 CD N
) ) N
, , N
0.98 CD N
( ( N
0.4 CD N
to TO N
2.6 CD N
) ) N
and CC N
1.6 CD N
( ( N
0.6 CD N
to TO N
4.1 CD N
) ) N
, , N
respectively RB N
. . N

The DT N
risk NN o
for IN o
the DT o
first JJ o
cerebrovascular JJ o
event NN o
showed VBD N
a DT N
3.7-fold JJ N
increased JJ N
relative JJ N
hazard NN N
( ( N
95 CD N
% NN N
CI NNP N
1.2 CD N
to TO N
11.4 CD N
) ) N
among IN N
prednisolone NN i
treated VBD N
patients NNS N
. . N

CONCLUSIONS NNP N
In IN N
this DT N
inception NN N
cohort NN N
study NN N
of IN N
low-dose JJ N
prednisolone NN i
use NN N
during IN N
the DT N
first JJ N
2 CD N
years NNS N
of IN N
RA NNP N
disease NN N
, , N
the DT N
incidence NN o
of IN o
ischaemic JJ o
coronary JJ o
artery NN o
events NNS o
was VBD N
similar JJ N
in IN N
the DT N
two CD N
treatment NN N
groups NNS N
, , N
whereas IN N
the DT N
long-term JJ o
risk NN o
of IN o
ischaemic JJ o
cerebrovascular JJ o
events NNS o
was VBD N
higher RBR N
in IN N
the DT N
prednisolone NN i
group NN N
. . N

There EX N
was VBD N
a DT N
trend NN N
towards NN N
reduced VBD o
survival NN o
in IN N
the DT N
prednisolone NN i
group NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
NUMBER NNP N
ISRCTN20612367 NNP N
. . N

-DOCSTART- -26266420- O O

Homocysteine NNP N
Metabolism NNP N
Gene NNP N
Polymorphisms NNP N
( ( N
MTHFR NNP N
C677T NNP N
, , N
MTHFR NNP N
A1298C NNP N
, , N
MTR NNP N
A2756G NNP N
and CC N
MTRR NNP N
A66G NNP N
) ) N
Jointly RB N
Elevate VBP N
the DT N
Risk NN N
of IN N
Folate NNP N
Deficiency NNP N
. . N

Folate NNP N
deficiency NN N
is VBZ N
strongly RB N
associated VBN N
with IN N
cardiovascular JJ N
disease NN N
. . N

We PRP N
aimed VBD N
to TO N
explore VB N
the DT N
joint JJ N
effect NN N
of IN N
the DT N
methylenetetrahydrofolate NN i
reductase NN i
( ( i
MTHFR NNP i
) ) i
C677T NNP i
and CC i
A1298C NNP i
, , i
methionine NN i
synthase NN i
( ( i
MTR NNP i
) ) i
A2756G NNP i
, , i
and CC i
methionine JJ i
synthase NN i
reductase NN i
( ( i
MTRR NNP i
) ) i
A66G NNP i
polymorphisms NN N
on IN N
folate JJ o
deficiency NN o
in IN N
a DT p
Chinese JJ p
hypertensive JJ p
population NN p
. . p

A DT p
total NN p
of IN p
480 CD p
subjects NNS p
aged VBN p
28-75 CD p
were VBD p
enrolled VBN p
in IN p
this DT p
study NN p
from IN p
September NNP p
2005-December JJ p
2005 CD p
from IN p
six CD p
hospitals NNS p
in IN p
different JJ p
Chinese JJ p
regions NNS p
. . p

Known VBN N
genotypes NNS N
were VBD N
detected VBN N
by IN N
PCR-RFLP NNP N
methods NNS N
and CC N
serum NN o
folate NN o
was VBD N
measured VBN N
by IN N
chemiluminescence NN N
immunoassay NN N
. . N

Our PRP$ N
results NNS N
showed VBD N
that IN N
MTHFR NNP o
677TT CD o
and CC o
MTR NNP o
2756AG CD o
+ NNP o
GG NNP o
were VBD N
independently RB N
associated VBN N
with IN N
a DT N
higher JJR N
risk NN N
of IN N
folate JJ o
deficiency NN o
( ( N
TT NNP N
vs. FW N
CC NNP N
+ NNP N
CT NNP N
, , N
p NN N
< VBD N
0.001 CD N
and CC N
AG NNP N
+ NNP N
GG NNP N
vs. FW N
AA NNP N
p NN N
= NN N
0.030 CD N
, , N
respectively RB N
) ) N
. . N

However RB N
, , N
the DT N
MTHFR NNP i
A1298C NNP i
mutation NN N
may MD N
confer VB N
protection NN N
by IN N
elevating VBG N
the DT N
serum NN o
folate NN o
level NN o
( ( N
p JJ N
= NNP N
0.025 CD N
) ) N
. . N

Furthermore NNP N
, , N
patients NNS N
carrying VBG N
two CD N
or CC N
more JJR N
risk NN N
genotypes NNS N
showed VBD N
higher JJR N
odds NNS N
of IN N
folate NN o
deficiency NN o
than IN N
null JJ N
risk NN N
genotype NN N
carriers NNS N
, , N
especially RB N
those DT N
carrying VBG N
four CD N
risk NN N
genotypes NNS N
. . N

These DT N
findings NNS N
were VBD N
verified VBN N
by IN N
generalized JJ N
multifactor NN N
dimensionality NN N
reduction NN N
( ( N
p JJ N
= NNP N
0.0107 CD N
) ) N
and CC N
a DT N
cumulative JJ N
effects NNS N
model NN N
( ( N
p JJ N
= NNP N
0.001 CD N
) ) N
. . N

The DT N
results NNS N
of IN N
this DT N
study NN N
have VBP N
shown VBN N
that IN N
interactions NNS N
among IN N
homocysteine JJ N
metabolism NN N
gene NN N
polymorphisms JJ N
lead NN N
to TO N
dramatic JJ N
elevations NNS N
in IN N
the DT N
folate NN N
deficiency NN N
risk NN N
. . N

-DOCSTART- -8957368- O O

Thoracoscopic NNP i
talc NN i
insufflation NN i
versus IN N
talc NN i
slurry NN i
for IN N
symptomatic JJ p
malignant JJ p
pleural JJ p
effusion NN p
. . p

BACKGROUND NNP N
Talc NNP N
has VBZ N
been VBN N
generally RB N
accepted VBN N
to TO N
be VB N
the DT N
most RBS N
effective JJ N
sclerosant NN N
for IN N
chemical NN N
pleurodesis NN N
, , N
although IN N
the DT N
optimal JJ N
route NN N
of IN N
administration NN N
remains VBZ N
unclear JJ N
. . N

METHODS NNP N
We PRP N
designed VBD N
a DT N
prospective JJ N
, , N
randomized VBN N
study NN N
to TO N
compare VB N
video-assisted JJ i
thoracoscopic NN i
talc NN i
insufflation NN i
with IN i
bedside JJ i
talc NN i
slurry NN i
in IN i
the DT N
treatment NN N
of IN N
malignant JJ p
pleural JJ p
effusion NN p
. . p

From IN p
September NNP p
1993 CD p
to TO p
November NNP p
1995 CD p
, , p
57 CD p
patients NNS p
were VBD N
recruited VBN N
and CC N
randomized VBN N
to TO N
either DT N
video-assisted JJ i
thoracoscopic NN i
talc NN i
insufflation NN i
under IN N
general JJ i
anesthesia NN i
( ( N
n JJ N
= NNP N
28 CD N
) ) N
or CC N
talc JJ N
slurry NN N
by IN N
the DT N
bedside NN N
( ( N
n JJ N
= NNP N
29 CD N
) ) N
. . N

Patients NNS p
with IN p
poor JJ p
general JJ p
condition NN p
( ( p
Karnofsky NNP p
score RB p
less JJR p
than IN p
30 CD p
% NN p
) ) p
, , p
poor JJ p
pulmonary JJ p
function NN p
( ( p
forced JJ p
expiratory NN p
volume NN p
in IN p
1 CD p
second NN p
less JJR p
than IN p
0.5 CD p
L NNP p
) ) p
, , p
or CC p
trapped VBN p
lungs NNS p
were VBD p
excluded VBN p
from IN p
this DT p
study NN p
. . p

Five CD N
grams NNS N
of IN N
purified JJ N
talc NN N
was VBD N
used VBN N
for IN N
either DT N
video-assisted JJ N
thoracoscopic NN N
talc NN N
insufflation NN N
or CC N
talc NN N
slurry NN N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
statistically RB N
significant JJ o
difference NN o
between IN o
the DT o
two CD o
groups NNS o
of IN o
patients NNS o
with IN o
respect NN o
to TO o
age NN o
, , o
sex NN o
ratio NN o
, , o
chest JJS o
drainage NN o
duration NN o
, , o
postprocedural JJ o
hospital NN o
stay NN o
, , o
parenteral JJ o
narcotics NNS o
requirement NN o
, , o
complications NNS o
, , o
or CC o
procedure NN o
failure NN o
( ( o
ie NN o
, , o
recurrence NN o
) ) o
. . o

CONCLUSIONS NNP N
Video-assisted JJ N
thoracoscopic NN N
talc NN N
insufflation NN N
has VBZ N
not RB N
been VBN N
shown VBN N
to TO N
be VB N
a DT N
superior JJ N
approach NN N
compared VBN N
with IN N
talc NN N
slurry NN N
in IN N
our PRP$ N
study NN N
. . N

Because IN N
the DT N
former JJ N
demands NNS N
more RBR N
resources NNS N
, , N
we PRP N
advocate VBP N
that IN N
talc NN N
slurry NN N
should MD N
be VB N
considered VBN N
as IN N
the DT N
procedure NN N
of IN N
choice NN N
in IN N
the DT N
treatment NN N
of IN N
symptomatic JJ N
malignant JJ N
pleural JJ N
effusion NN N
in IN N
patients NNS p
who WP p
do VBP p
not RB p
have VB p
trapped VBN p
lungs NNS p
. . p

-DOCSTART- -25528326- O O

Diet-Related JJ N
Colorectal NNP N
Cancer NNP N
Prevention NNP N
Beliefs NNP N
and CC N
Dietary NNP i
Intakes NNP i
in IN N
an DT N
Urban JJ p
Minority NNP p
Population NNP p
. . p

In IN N
the DT N
United NNP p
States NNPS p
, , N
colorectal JJ N
cancer NN N
( ( N
CRC NNP N
) ) N
is VBZ N
the DT N
third JJ N
leading JJ N
cause NN N
of IN N
cancer-related JJ N
death NN N
and CC N
third JJ N
most RBS N
commonly RB N
diagnosed JJ N
cancer NN N
among IN N
adults NNS N
. . N

This DT N
study NN N
is VBZ N
the DT N
first JJ N
to TO N
examine VB N
the DT N
relationship NN N
between IN N
diet-related JJ o
beliefs NNS o
for IN o
colorectal JJ o
cancer NN o
prevention NN o
and CC o
dietary JJ o
intake NN o
among IN N
an DT N
urban JJ p
, , p
predominantly RB p
Black NNP p
population NN p
( ( p
n JJ p
= NNP p
169 CD p
) ) p
. . p

More JJR N
than IN N
two-thirds NNS N
reported VBN N
diet-related JJ N
CRC NNP N
prevention NN N
beliefs NN N
. . N

Those DT N
with IN N
diet-related JJ i
CRC NNP N
prevention NN N
beliefs NNS N
had VBD N
healthier JJR N
intakes NNS o
for IN o
dietary JJ o
fiber NN o
( ( N
p JJ N
= NNP N
.005 NNP N
) ) N
, , N
fruit NN o
, , o
vegetable NN o
, , o
bean NN o
( ( N
p JJ N
= NNP N
.027 NNP N
) ) N
, , N
red JJ o
meat NN o
( ( N
p JJ N
= NNP N
.032 NNP N
) ) N
, , N
vitamin FW o
C NNP o
( ( N
p JJ N
= NNP N
.039 NNP N
) ) N
, , N
and CC N
cholesterol NN o
( ( N
p JJ N
= NNP N
.045 NNP N
) ) N
. . N

Most JJS N
people NNS N
may MD N
already RB N
have VB N
diet-related JJ i
CRC NNP i
prevention NN i
beliefs NN i
and CC N
having VBG N
them PRP N
is VBZ N
associated VBN N
with IN N
a DT N
more RBR N
healthful JJ o
dietary JJ o
intake NN o
. . o

-DOCSTART- -16108749- O O

Analgesic JJ o
efficacy NN o
of IN N
caudal JJ i
block NN i
versus NN N
diclofenac NN i
suppository NN i
and CC N
local JJ N
anesthetic JJ N
infiltration NN N
following VBG N
pediatric JJ N
laparoscopy NN N
. . N

AIM NNP N
To TO N
compare VB N
the DT N
analgesic JJ o
efficacy NN N
of IN N
caudal JJ i
block NN i
with IN N
diclofenac JJ i
suppository NN i
and CC i
local JJ i
anesthetic JJ i
infiltration NN i
in IN N
children NNS p
undergoing VBG p
laparoscopy NN p
. . p

METHODS NNP N
We PRP N
studied VBD N
50 CD p
children NNS p
undergoing JJ p
laparoscopy NN p
for IN p
diagnostic JJ p
and CC p
therapeutic JJ p
purposes NNS p
. . p

Their PRP$ p
ages NNS p
ranged VBN p
from IN p
3 CD p
to TO p
13 CD p
years NNS p
, , p
and CC p
all DT p
belonged VBD p
to TO p
American NNP p
Society NNP p
of IN p
Anesthesiologists NNP p
( ( p
ASA NNP p
) ) p
class NN p
I PRP p
or CC p
II NNP p
. . p

Anesthesia NNP i
was VBD i
carried VBN i
out RP i
using VBG i
the DT i
standard JJ i
procedure NN i
. . i

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
groups NNS N
. . N

Group NNP N
1 CD N
received VBD N
caudal JJ i
block NN i
with IN i
bupivacaine NN i
1 CD i
mL/kg NN i
after IN i
anesthetic JJ i
induction NN i
. . i

Group NNP N
2 CD N
received VBD N
diclofenac JJ i
suppository JJ i
3 CD i
mg/kg JJ i
postinduction NN i
and CC i
local JJ i
anesthetic JJ i
infiltration NN i
at IN i
the DT i
port NN i
sites VBZ i
at IN N
the DT N
end NN N
of IN N
the DT N
procedure NN N
. . N

Pain NN o
was VBD o
assessed VBN o
using VBG N
the DT N
Hannallah NNP o
objective JJ o
pain NN o
scale NN o
at IN N
15 CD N
, , N
30 CD N
, , N
60 CD N
, , N
120 CD N
, , N
and CC N
360 CD N
minutes NNS N
postextubation NN N
. . N

RESULTS VB N
The DT N
pain NN o
scores NNS o
were VBD N
comparable JJ N
in IN N
both DT N
groups NNS N
at IN N
all DT N
times NNS N
. . N

Twelve NNP N
percent NN N
of IN N
caudal JJ N
block NN N
patients NNS N
and CC N
20 CD N
% NN N
of IN N
diclofenac NN N
patients NNS N
needed VBN N
rescue NN o
analgesic NN o
, , N
a DT N
statistically RB N
insignificant JJ N
difference NN N
. . N

In IN N
2 CD N
patients NNS N
, , N
caudal JJ N
block NN N
was VBD N
technically RB N
difficult JJ N
and CC N
they PRP N
were VBD N
excluded VBN N
from IN N
the DT N
study NN N
. . N

The DT N
incidence NN N
of IN N
side NN N
effects NNS N
was VBD N
low JJ N
in IN N
our PRP$ N
study NN N
. . N

CONCLUSION NNP N
We PRP N
find VBP N
the DT N
analgesic JJ o
efficacy NN N
of IN N
diclofenac JJ i
suppository NN i
combined VBN N
with IN N
local JJ N
anesthetic JJ i
infiltration NN i
at IN N
port NN N
sites NNS N
comparable JJ N
to TO N
caudal VB N
block NN N
. . N

Given VBN N
the DT N
necessarily RB N
invasive JJ N
nature NN N
of IN N
caudal NN N
block NN N
, , N
we PRP N
suggest VBP N
the DT N
combined JJ N
use NN N
of IN N
diclofenac JJ i
suppository NN i
with IN N
local JJ N
anesthetic JJ i
infiltration NN i
at IN N
port NN N
sites NNS N
as IN N
a DT N
useful JJ N
and CC N
more RBR N
economical JJ N
alternative NN N
for IN N
analgesia NN N
following VBG N
pediatric JJ N
laparoscopy NN N
. . N

-DOCSTART- -19047882- O O

Acceptability NNP N
of IN N
an DT N
Electronic JJ i
Self-Report JJ i
Assessment NNP i
Program NNP i
for IN N
patients NNS p
with IN p
cancer NN p
. . p

Eliciting VBG N
symptom NN N
and CC N
quality NN N
of IN N
life NN N
information NN N
from IN N
patients NNS N
is VBZ N
an DT N
important JJ N
component NN N
of IN N
medical JJ N
and CC N
nursing NN N
care NN N
processes VBZ N
. . N

Traditionally RB N
, , N
this DT N
information NN N
has VBZ N
been VBN N
collected VBN N
with IN N
paper NN N
and CC N
pencil NN N
. . N

However RB N
, , N
this DT N
approach NN N
presents VBZ N
several JJ N
barriers NNS N
, , N
including VBG N
delays NNS N
in IN N
receiving VBG N
information NN N
, , N
difficulty NN N
in IN N
integrating VBG N
responses NNS N
with IN N
electronic JJ N
records NNS N
, , N
and CC N
the DT N
time NN N
required VBN N
to TO N
manually RB N
score VB N
questionnaires NNS N
for IN N
measurement NN N
purposes NNS N
. . N

One CD N
solution NN N
that WDT N
addresses VBZ N
many JJ N
of IN N
these DT N
barriers NNS N
is VBZ N
the DT N
adoption NN i
of IN i
computerized JJ i
screening NN i
for IN i
symptom NN i
and CC i
quality-of-life JJ i
information NN i
. . i

This DT N
research NN N
explored VBD N
the DT N
acceptability NN o
of IN N
asking VBG N
symptom NN N
and CC N
quality-of-life JJ N
questions NNS N
using VBG i
the DT i
Electronic NNP i
Self NNP i
Report NNP i
Assessment-Cancer NNP i
program NN i
on IN i
wireless NN i
laptops NNS i
equipped VBN i
with IN i
touch-screen JJ i
format NN i
. . i

Acceptability NNP o
data NNS o
were VBD N
explored VBN N
with IN N
respect NN N
to TO N
whether IN N
any DT N
differences NNS N
may MD N
be VB N
attributed VBN N
to TO N
demographics NNS N
and CC N
symptom NN N
and CC N
quality-of-life NN o
levels NNS o
, , N
such JJ N
as IN N
depression NN o
and CC o
cognitive JJ o
and CC o
emotional JJ o
functioning NN o
. . o

This DT N
evaluation NN N
used VBN N
descriptive JJ N
and CC N
univariate JJ N
statistics NNS N
to TO N
examine VB N
data NNS N
from IN N
342 CD p
participants NNS p
from IN p
the DT p
ongoing JJ p
ESRA-C NNP i
randomized VBD p
clinical JJ p
trial NN p
. . p

Research NN p
participants NNS p
for IN p
the DT p
ESRA-C NNP i
study NN p
were VBD p
recruited VBN p
from IN p
the DT p
Seattle NNP p
Cancer NNP p
Care NNP p
Alliance NNP p
, , p
a DT p
consortium NN p
among IN p
the DT p
University NNP p
of IN p
Washington NNP p
Medical NNP p
Center NNP p
, , p
Fred NNP p
Hutchinson NNP p
Cancer NNP p
Research NNP p
Center NNP p
, , p
and CC p
Children NNP p
's POS p
Hospital NNP p
and CC p
Regional NNP p
Medical NNP p
Center NNP p
in IN p
Seattle NNP p
, , p
WA NNP p
. . p

The DT N
sample NN N
consisted VBD N
of IN N
342 CD p
adult NN p
participants NNS p
who WP p
completed VBD p
both DT p
baseline NN p
and CC p
follow-up JJ p
survey NN p
sessions NNS p
. . p

Medical NNP N
oncology NN N
represented VBD N
the DT N
largest JJS N
recruitment NN p
group NN p
( ( N
45.3 CD N
% NN N
) ) N
, , N
followed VBN N
by IN N
stem NN N
cell NN N
transplant NN N
( ( N
34.5 CD N
% NN N
) ) N
and CC N
radiation NN N
oncology NN N
( ( N
20.2 CD N
% NN N
) ) N
. . N

The DT N
primary JJ N
finding NN N
was VBD N
that IN N
patients NNS N
were VBD N
generally RB N
able JJ o
to TO o
use VB o
ESRA-C JJ o
quickly RB o
and CC N
without IN N
difficulty NN N
in IN N
a DT N
real-world JJ N
clinical JJ N
setting NN N
and CC N
that IN N
they PRP N
were VBD N
overall JJ N
quite RB N
satisfied VBN o
with IN o
the DT o
ESRA-C JJ o
program NN o
. . o

Significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
several JJ N
acceptability NN o
areas NNS o
with IN N
respect NN N
to TO N
demographics NNS N
and CC N
quality NN N
of IN N
life NN N
measures NNS N
such JJ N
as IN N
age NN N
, , N
sex NN N
, , N
and CC N
severe JJ N
distress NN N
. . N

This DT N
analysis NN N
confirms VBZ N
that IN N
the DT N
ESRA-C NNP i
application NN i
for IN i
collecting VBG i
symptom NN i
and CC i
quality NN i
of IN i
life NN i
information NN i
is VBZ N
easy JJ N
for IN N
patients NNS N
to TO N
use VB N
and CC N
acceptable JJ N
across IN N
a DT N
range NN N
of IN N
user JJ N
characteristics NNS N
. . N

We PRP N
intend VBP N
to TO N
build VB N
on IN N
our PRP$ N
work NN N
by IN N
using VBG N
the DT N
survey NN N
platform NN N
in IN N
other JJ N
modalities NNS N
while IN N
ensuring VBG N
that IN N
the DT N
patient NN N
's POS N
preferences NNS N
are VBP N
considered VBN N
at IN N
all DT N
times NNS N
. . N

-DOCSTART- -10660161- O O

Regression NN N
of IN N
left JJ N
ventricular JJ N
hypertrophy NN N
after IN N
stentless JJ i
versus JJ N
conventional JJ i
aortic JJ i
valve NN i
replacement NN i
. . i

The DT N
goal NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
analyze VB N
regression NN N
of IN N
left JJ N
ventricular JJ N
hypertrophy NN N
after IN N
randomization NN N
to TO N
conventional JJ i
biological JJ i
versus NN i
stentless NN i
aortic JJ i
valve NN i
replacement NN i
. . i

Stentless NNP i
( ( p
Freestyle NNP p
, , p
Toronto NNP p
, , p
n RB p
= VBZ p
106 CD p
) ) p
or CC p
conventional JJ i
biological JJ i
aortic JJ i
valves NNS i
( ( p
Carpentier-Edwards NNP p
, , p
n JJ p
= NNP p
74 CD p
) ) p
were VBD p
evaluated VBN p
prospectively RB N
. . N

Preoperatively RB N
there EX N
were VBD N
no DT N
differences NNS N
with IN N
regard NN N
to TO N
aortic JJ o
valve NN o
pathology NN o
, , o
left VBD o
ventricular JJ o
function NN o
, , o
and CC o
pressure NN o
gradients NNS o
between IN N
the DT N
two CD N
patient NN N
groups NNS N
. . N

The DT N
patient NN o
annulus NN o
index NN o
( ( N
13.55 CD N
vs. FW N
13.46 CD N
mm NN N
; : N
NS NNP N
) ) N
measured VBD N
intraoperatively RB N
was VBD N
used VBN N
as IN N
baseline NN N
for IN N
further JJ N
comparison NN N
. . N

Postoperatively RB N
, , N
left VBD o
ventricular JJ o
mass NN o
index NN o
was VBD N
213+/-77 JJ N
g/m2 NN N
( ( N
stentless NN N
) ) N
compared VBN N
with IN N
202+/-72 JJ N
( ( N
conventional JJ N
group NN N
) ) N
g/m2 NN N
( ( N
NS NNP N
) ) N
, , N
whereas RB N
after IN N
6 CD N
months NNS N
it PRP N
was VBD N
141+/-41 JJ N
g/m2 NN N
in IN N
the DT N
stentless NN N
and CC N
170+/-43 JJ N
g/m2 NN N
in IN N
the DT N
conventional JJ N
group NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

Regression NN o
of IN o
left JJ o
ventricular JJ o
hypertrophy NN o
occurs VBZ N
in IN N
all DT N
patients NNS p
after IN p
aortic JJ p
valve NN p
replacement NN p
. . p

Nevertheless NNP N
, , N
the DT N
use NN N
of IN N
stentless NN i
bioprostheses NNS i
leads VBZ N
to TO N
a DT N
significant JJ N
enhancement NN N
, , N
which WDT N
may MD N
result VB N
in IN N
a DT N
reduction NN N
of IN N
the DT N
cardiac NN N
risk NN N
profile NN N
for IN N
the DT N
patient NN N
. . N

-DOCSTART- -25450124- O O

Differences NNS N
in IN N
quality NN o
of IN o
life NN o
outcomes NNS N
among IN N
depressed JJ p
spinal JJ p
cord NN p
injury NN p
trial NN p
participants NNS p
. . p

OBJECTIVE NN N
To TO N
assess VB N
the DT N
role NN N
that WDT N
treatment NN N
response NN N
plays VBZ N
in IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
of IN N
an DT N
antidepressant JJ i
among IN N
people NNS p
with IN p
spinal JJ p
cord NN p
injury NN p
( ( p
SCI NNP p
) ) p
diagnosed VBD p
with IN p
major JJ p
depressive JJ p
disorder NN p
( ( p
MDD NNP p
) ) p
in IN N
explaining VBG N
quality NN N
of IN N
life NN N
( ( N
QOL NNP N
) ) N
, , N
assessed VBD N
both DT N
globally RB N
as IN N
life NN N
satisfaction NN N
and CC N
in IN N
terms NNS N
of IN N
physical JJ N
and CC N
mental JJ N
health-related JJ N
QOL NNP N
. . N

DESIGN NNP N
Multivariable JJ N
analyses NNS N
were VBD N
conducted VBN N
, , N
controlling VBG N
for IN N
demographic JJ N
, , N
neurologic JJ N
, , N
and CC N
participatory JJ N
factors NNS N
and CC N
perceived VBD N
functional JJ N
limitations NNS N
. . N

SETTING NN N
Rehabilitation NN N
centers NNS N
. . N

PARTICIPANTS NNS N
Of IN p
the DT p
133 CD p
persons NNS p
who WP p
were VBD p
randomized VBN p
into IN p
the DT p
Project NN i
to TO i
Improve VB i
Symptoms NNP i
and CC i
Mood NNP i
after IN p
Spinal NNP p
Cord NNP p
Injury NNP p
randomized VBD p
controlled VBN p
trial NN p
, , p
124 CD p
participated VBN p
in IN p
this DT p
study NN p
. . p

All DT p
participants NNS p
were VBD p
between IN p
the DT p
ages NNS p
of IN p
18 CD p
and CC p
64 CD p
years NNS p
, , p
at IN p
least JJS p
1 CD p
month NN p
post-SCI NN p
, , p
met VBD p
the DT p
Diagnostic NNP p
and CC p
Statistical NNP p
Manual NNP p
of IN p
Mental NNP p
Disorders NNP p
, , p
4th CD p
edition NN p
, , p
criteria NNS p
for IN p
MDD NNP p
, , p
and CC p
completed VBD p
the DT p
core NN p
measures NNS p
used VBN p
in IN p
this DT p
study NN p
. . p

INTERVENTIONS NNP N
Not RB N
applicable JJ N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT o
Satisfaction NNP o
with IN o
Life NNP o
Scale NNP o
and CC o
the DT o
physical JJ o
and CC o
mental JJ o
component NN o
summary JJ o
scores NNS o
of IN o
the DT o
Medical NNP o
Outcomes NNP o
Study NNP o
12-Item JJ o
Short-Form NNP o
Health NNP o
Survey NNP o
. . o

RESULTS NNP N
Reduction NNP o
in IN o
depressive JJ o
symptoms NNS o
over IN N
the DT N
course NN N
of IN N
a DT N
12-week JJ N
trial NN N
was VBD N
predictive JJ N
of IN N
increased JJ N
QOL NNP o
, , o
which WDT o
was VBD o
measured VBN o
as IN o
life NN o
satisfaction NN o
and CC o
mental JJ o
well-being NN o
, , N
within IN N
the DT N
context NN N
of IN N
other JJ N
explanatory JJ N
factors NNS N
. . N

However RB N
, , N
reduction NN o
in IN o
symptoms NNS o
did VBD N
not RB N
explain VB N
differences NNS N
in IN N
physical JJ N
well-being NN N
among IN N
those DT N
with IN N
MDD NNP N
. . N

Perceived NNP o
functional JJ o
disability NN o
explained VBD N
all DT N
3 CD N
indices NNS N
of IN N
QOL NNP N
. . N

CONCLUSIONS NNP N
Greater NNP N
recognition NN N
has VBZ N
been VBN N
given VBN N
to TO N
QOL NNP N
outcomes RB N
as IN N
endpoints NNS N
of IN N
clinical JJ N
trials NNS N
because IN N
these DT N
often RB N
reflect VBP N
participants NNS p
' POS p
reported VBN N
outcomes NNS N
. . N

Our PRP$ N
findings NNS N
support VB N
the DT N
association NN N
of IN N
QOL NNP N
to TO N
the DT N
reduction NN N
of IN N
depression NN N
symptoms NNS N
among IN N
trial NN p
participants NNS p
. . p

This DT N
association NN N
differs VBZ N
depending VBG N
on IN N
how WRB N
QOL NNP N
is VBZ N
defined VBN N
and CC N
measured VBN N
, , N
with IN N
stronger JJR N
relations NNS N
observed VBN N
with IN N
life NN N
satisfaction NN N
and CC N
mental JJ N
well-being NN N
among IN N
those DT N
diagnosed VBN N
with IN N
MDD NNP N
. . N

The DT N
lack NN N
of IN N
association NN N
between IN N
depression NN N
and CC N
physical JJ N
well-being NN N
may MD N
be VB N
explained VBN N
by IN N
participants NNS p
' POS p
subjective JJ N
interpretation NN N
of IN N
physical JJ N
well-being NN N
after IN N
SCI NNP N
and CC N
their PRP$ N
expectations NNS N
and CC N
perceptions NNS N
of IN N
improved JJ N
physical JJ N
health-related JJ N
QOL NNP N
based VBN N
on IN N
the DT N
use NN N
of IN N
assistive JJ N
technology NN N
. . N

Consistent JJ N
with IN N
our PRP$ N
findings NNS N
, , N
pain NN N
is VBZ N
likely JJ N
to TO N
play VB N
a DT N
role NN N
in IN N
decreasing VBG N
physical JJ N
QOL NNP N
among IN N
those DT p
with IN p
incomplete JJ p
injuries NNS p
. . p

Practicing VBG N
caution NN N
is VBZ N
suggested VBN N
in IN N
using VBG N
physical JJ N
well-being NN N
as IN N
an DT N
endpoint NN N
in IN N
trials NNS N
among IN N
people NNS p
with IN p
SCI NNP p
. . p

-DOCSTART- -17083268- O O

The DT N
protective JJ N
effects NNS N
of IN N
angiotensin NN N
II NNP N
blockade NN N
with IN N
olmesartan JJ i
medoxomil NN i
on IN N
resistance NN N
vessel NN N
remodeling VBG N
( ( N
The DT N
VIOS NNP N
study NN N
) ) N
: : N
rationale NN N
and CC N
baseline NN N
characteristics NNS N
. . N

BACKGROUND IN N
The DT N
VIOS NNP N
( ( N
Vascular JJ N
Improvement NN N
with IN N
Olmesartan NNP i
medoxomil NNP i
Study NNP N
) ) N
study NN N
is VBZ N
a DT N
randomized JJ N
, , N
parallel JJ N
study NN N
to TO N
determine VB N
the DT N
relative JJ N
effects NNS N
of IN N
suppressing VBG N
the DT N
renin-angiotensin NN N
system NN N
( ( N
RAS NNP N
) ) N
with IN N
the DT N
angiotensin NN N
receptor NN N
antagonist NN N
olmesartan IN i
medoxomil NN i
versus NN N
suppressing VBG N
sympathetic JJ N
drive NN N
with IN N
the DT N
beta-adrenoceptor JJ N
antagonist NN N
atenolol NN i
on IN N
remodeling NN N
of IN N
the DT N
subcutaneous JJ N
small JJ N
resistance NN N
vessel NN N
. . N

Remodeling VBG N
of IN N
small JJ N
resistance NN N
vessels NNS N
may MD N
be VB N
the DT N
earliest JJS N
pathologic NN N
finding VBG N
associated VBN N
with IN N
hypertension NN N
. . N

It PRP N
may MD N
predate VB N
the DT N
onset NN N
of IN N
clinically RB N
apparent JJ N
hypertension NN N
. . N

METHODS NNP N
In IN N
this DT N
study NN N
, , N
100 CD p
patients NNS p
with IN p
stage NN p
I PRP p
hypertension VBP p
are VBP p
characterized VBN p
at IN p
baseline NN p
before IN p
being VBG p
treated VBN p
for IN p
1 CD p
year NN p
to TO p
obtain VB p
a DT p
goal NN p
BP NNP p
of IN p
less JJR p
than IN p
140/90 CD p
mm JJ p
Hg NNP p
as IN N
defined VBN N
by IN N
Joint NNP N
National NNP N
Committee NNP N
( ( N
JNC NNP N
) ) N
-7 NN N
. . N

Resistance NNP N
vessel NN N
remodeling NN N
is VBZ N
determined VBN N
using VBG N
the DT N
gluteal NN i
fat JJ i
biopsy NN i
technique NN i
in IN N
the DT N
hypertensive JJ N
patients NNS N
and CC N
a DT N
group NN N
of IN N
normotensive JJ N
healthy JJ N
volunteers NNS N
. . N

Additionally RB N
, , N
efforts NNS N
will MD N
be VB N
made VBN N
to TO N
define VB N
whether IN N
noninvasive JJ o
hemodynamic JJ o
parameters NNS o
, , o
retinal JJ o
vessel FW o
measurement NN o
changes NNS N
, , N
or CC N
biologic JJ o
markers NNS o
may MD N
predict VB N
and CC N
track VB N
the DT N
underlying VBG N
vascular JJ o
morphologic NN o
and CC o
physiologic JJ o
changes NNS o
induced VBN N
by IN N
either DT N
regimen NNS N
during IN N
the DT N
12-month JJ N
treatment NN N
period NN N
. . N

RESULTS VB N
The DT N
primary JJ N
endpoint NN N
will MD N
be VB N
the DT N
degree NN o
of IN o
vascular JJ o
remodeling VBG o
as RB o
obtained VBN o
from IN o
percutaneous JJ o
biopsy NN o
of IN o
gluteal NN o
subcutaneous JJ o
resistance NN o
vessels NNS o
in IN N
each DT N
of IN N
two CD N
treatment NN N
arms NNS N
compared VBN N
with IN N
the DT N
normal JJ N
volunteers NNS N
. . N

The DT N
design NN N
of IN N
the DT N
study NN N
and CC N
the DT N
pertinent JJ N
baseline NN N
characteristics NNS N
of IN N
these DT N
patients NNS N
with IN N
uncomplicated JJ N
essential JJ N
hypertension NN N
are VBP N
presented VBN N
. . N

CONCLUSION VB N
The DT N
suppression NN N
of IN N
the DT N
RAS NNP N
by IN N
the DT N
blockade NN N
of IN N
angiotensin NN N
II NNP N
type NN N
1 CD N
( ( N
AT NNP N
( ( N
1 CD N
) ) N
) ) N
receptors NNS N
may MD N
demonstrate VB N
remodeling VBG N
effects NNS N
on IN N
the DT N
ubiquitous JJ N
small JJ N
resistance NN N
vessels NNS N
similar JJ N
to TO N
that DT N
seen VBN N
in IN N
the DT N
myocardium NN N
and CC N
renal JJ N
glomeruli NN N
, , N
thus RB N
affording VBG N
more JJR N
complete JJ N
end-organ JJ N
protection NN N
. . N

-DOCSTART- -21574725- O O

On IN N
the DT N
benign JJ N
qualities NNS N
of IN N
behavioral JJ i
disinhibition NN i
: : i
because IN N
of IN N
the DT N
prosocial JJ p
nature NN p
of IN p
people NNS p
, , N
behavioral JJ N
disinhibition NN N
can MD N
weaken VB N
pleasure NN N
with IN N
getting VBG N
more JJR N
than IN N
you PRP N
deserve VBP N
. . N

This DT N
article NN N
focuses VBZ N
on IN N
social JJ N
situations NNS N
in IN N
which WDT N
people NNS N
are VBP N
surprised VBN N
about IN N
what WP N
is VBZ N
happening VBG N
and CC N
inhibited VBN N
about IN N
how WRB N
to TO N
respond VB N
to TO N
the DT N
situation NN N
at IN N
hand NN N
. . N

We PRP N
study VBP N
these DT N
situations NNS N
by IN N
examining VBG N
a DT N
classic JJ N
topic NN N
in IN N
social JJ N
psychology NN N
: : N
how WRB N
people NNS p
respond VBP p
to TO p
receiving VBG p
better JJR p
outcomes NNS p
than IN p
are VBP p
deserved VBN p
. . p

In IN N
these DT N
situations NNS N
, , N
the DT N
actions NNS N
of IN N
an DT N
authority NN N
or CC N
a DT N
coworker NN N
push NN N
in IN N
the DT N
direction NN N
of IN N
accepting VBG N
and CC N
enjoying VBG N
the DT N
unfair JJ N
outcome NN N
, , N
whereas JJ N
personal JJ N
values NNS N
for IN N
most JJS N
people NNS N
push VBP N
in IN N
the DT N
direction NN N
of IN N
rejecting VBG N
or CC N
being VBG N
displeased VBN N
with IN N
the DT N
outcome NN N
. . N

This DT N
conflict NN N
may MD N
inhibit VB N
people NNS p
's POS p
response NN N
to TO N
the DT N
advantageous JJ N
but CC N
unfair JJ N
outcomes NNS N
. . N

If IN N
people NNS p
are VBP N
indeed RB N
inhibited VBN N
about IN N
how WRB N
to TO N
respond VB N
to TO N
these DT N
kinds NNS N
of IN N
outcomes NNS N
, , N
then RB N
lowering VBG N
behavioral JJ N
inhibition NN N
by IN N
reminding VBG N
people NNS N
of IN N
having VBG N
acted VBN N
in IN N
the DT N
past NN N
without IN N
inhibitions NNS N
( ( N
in IN N
a DT N
manner NN N
that WDT N
is VBZ N
unrelated JJ N
to TO N
the DT N
outcomes NNS N
participants NNS N
subsequently RB N
receive VBP N
) ) N
should MD N
affect VB N
reactions NNS N
to TO N
the DT N
outcomes NNS N
. . N

Specifically RB N
, , N
we PRP N
hypothesize VBP N
that IN N
because IN N
many JJ N
people NNS p
are VBP N
prosocial JJ N
and CC N
want VBP N
to TO N
adhere VB N
to TO N
principles NNS N
of IN N
fairness NN N
, , N
reminders NNS N
of IN N
behavioral JJ i
disinhibition NN i
will MD N
lead VB N
to TO N
less JJR N
pleasure NN N
with IN N
the DT N
unfairly RB N
obtained VBN N
outcomes RB N
. . N

The DT N
results NNS N
of IN N
8 CD N
experiments NNS i
( ( N
conducted VBN N
both DT N
inside IN i
and CC i
outside IN i
the DT i
psychology NN i
laboratory NN i
) ) i
revealed VBD N
evidence NN N
for IN N
this DT N
benign JJ N
disinhibition NN N
effect NN N
on IN N
various JJ N
reactions NNS N
to TO N
outcomes NNS N
that WDT N
are VBP N
better JJR N
than IN N
deserved VBN N
. . N

In IN N
further JJ N
accordance NN N
with IN N
our PRP$ N
line NN N
of IN N
reasoning NN N
, , N
the DT N
effect NN N
is VBZ N
particularly RB N
pronounced VBN N
among IN N
those DT N
who WP N
adhere VBP N
to TO N
a DT N
prosocial JJ N
orientation NN N
or CC N
who WP N
have VBP N
adopted VBN N
a DT N
prosocial JJ N
mindset NN N
and CC N
is VBZ N
not RB N
observed VBN N
among IN N
those DT N
with IN N
proself JJ N
orientations NNS N
or CC N
mindsets NNS N
. . N

-DOCSTART- -21396848- O O

Noninfiltrative JJ i
anesthesia NN i
for IN N
transrectal JJ i
prostate NN i
biopsy NN i
: : i
a DT N
randomized JJ N
prospective JJ N
study NN N
comparing VBG N
lidocaine-prilocaine JJ i
cream NN i
and CC N
lidocaine-ketorolac JJ i
gel NN i
. . i

OBJECTIVES NNP N
Periprostatic NNP N
nerve NN N
block NN N
( ( N
PPNB NNP N
) ) N
is VBZ N
the DT N
standard JJ N
anesthesia NN i
for IN N
ultrasound NN N
( ( N
US NNP N
) ) N
guided VBD N
transrectal JJ p
prostate NN p
biopsy NN p
( ( p
TPB NNP p
) ) p
, , N
but CC N
periprostatic JJ N
infiltration NN N
itself PRP N
constitutes VBZ N
a DT N
major JJ N
, , N
though RB N
often RB N
neglected VBN N
, , N
source NN N
of IN N
discomfort NN N
even RB N
in IN N
patients NNS p
receiving VBG p
perianal-intrarectal JJ i
lidocaine-prilocaine NN i
( ( i
PILP NNP i
) ) i
cream NN i
before IN p
PPNB NNP p
. . p

Noninfiltrative NNP i
anesthesia NN i
therefore NN N
represents VBZ N
an DT N
attractive JJ N
alternative NN N
to TO N
periprostatic JJ N
infiltration NN N
. . N

With IN N
this DT N
in IN N
mind NN N
, , N
we PRP N
aimed VBD N
to TO N
determine VB N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
perianal-intrarectal JJ i
( ( i
PI NNP i
) ) i
lidocaine NN i
gel NN i
, , i
lidocaine-ketorolac JJ i
gel NN i
, , N
and CC N
lidocaine-prilocaine JJ i
cream NN i
in IN N
relieving VBG o
pain NN o
during IN N
TPB NNP N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Three NNP p
hundred VBD p
consecutive JJ p
patients NNS p
scheduled VBN p
for IN p
US-guided JJ p
TPB NNP p
were VBD N
randomized VBN N
1:1:1 CD N
to TO N
receive VB N
PI NNP i
administration NN N
of IN N
5 CD N
g JJ N
2.5 CD N
% NN N
lidocaine JJ i
gel NN i
10 CD N
minutes NNS N
before IN N
TPB NNP N
( ( N
Group NNP N
1 CD N
) ) N
, , N
or CC N
a DT N
mixture NN N
of IN N
5 CD i
g JJ i
2.5 CD i
% NN i
lidocaine JJ i
gel NN i
and CC i
0.3 CD i
% NN i
ketorolac NN i
tromethamine JJ i
solution NN i
1 CD i
hour NN i
before IN i
TPB NNP i
( ( N
Group NNP N
2 CD N
) ) N
, , N
or CC N
5 CD i
g JJ i
2.5 CD i
% NN i
lidocaine NN i
and CC i
2.5 CD i
% NN i
prilocaine NN i
cream NN i
20 CD i
minutes NNS i
before IN i
TPB NNP i
( ( N
Group NNP N
3 CD N
) ) N
. . N

The DT N
0-to-10 JJ o
points NNS o
visual JJ o
analogue JJ o
scale NN o
( ( o
VAS NNP o
) ) o
was VBD N
used VBN N
for IN N
assessing VBG N
pain NN N
at IN N
probe NN N
insertion NN N
and CC N
movements NNS N
( ( N
VAS-1 NNP N
) ) N
, , N
at IN N
prostate NN N
sampling NN N
( ( N
VAS-2 NNP N
) ) N
, , N
and CC N
maximal JJ N
procedural JJ N
pain NN N
( ( N
MPP NNP N
) ) N
. . N

Complications NNS N
occurring VBG N
up RB N
to TO N
20 CD N
days NNS N
after IN N
the DT N
procedure NN N
were VBD N
also RB N
recorded VBN N
. . N

RESULTS VB N
Four NNP N
( ( N
1.3 CD N
% NN N
) ) N
patients NNS N
were VBD N
excluded VBN N
because IN N
of IN N
unbearable JJ o
pain NN o
during IN N
the DT N
procedure NN N
, , N
leaving VBG N
Group NNP N
1 CD N
with IN N
98 CD N
patients NNS N
, , N
Group NNP N
2 CD N
with IN N
99 CD N
, , N
and CC N
Group NNP N
3 CD N
with IN N
99 CD N
; : N
the DT N
3 CD N
groups NNS N
were VBD N
comparable JJ N
for IN N
patients NNS N
' POS N
age NN N
, , N
serum NN o
PSA NNP o
, , o
prostate NN o
volume NN o
, , o
and CC o
cancer NN o
detection NN o
rate NN o
. . o

The DT N
addition NN N
of IN N
either DT N
ketorolac NN i
or CC N
prilocaine NN i
to TO i
lidocaine VB i
significantly RB N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
reduced VBD N
probe-related JJ N
, , N
sampling-related JJ N
, , N
and CC N
maximal JJ N
procedural JJ o
pain NN o
. . o

Compared VBN N
with IN N
lidocaine-prilocaine JJ i
, , i
lidocaine-ketorolac JJ i
was VBD N
less RBR N
effective JJ N
in IN N
relieving VBG N
probe-related JJ o
pain NN o
( ( N
mean JJ N
VAS-1 NNP N
: : N
1.47 CD N
? . N
1.30 CD N
vs. IN N
0.39 CD N
? . N
0.65 CD N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
but CC N
more RBR N
effective JJ N
in IN N
relieving VBG o
sampling-related JJ o
pain NN o
( ( o
mean JJ N
VAS-2 NNP N
: : N
0.76 CD N
? . N
0.94 CD N
vs. IN N
1.54 CD N
? . N
1.02 CD N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
; : N
there EX N
was VBD N
no DT N
difference NN N
in IN N
MPP NNP N
( ( N
mean VB N
1.82 CD N
? . N
1.21 CD N
vs. IN N
1.67 CD N
? . N
0.95 CD N
) ) N
, , N
probably RB N
due JJ N
to TO N
such JJ N
different JJ N
efficacy NN N
on IN N
the DT N
two CD o
pain NN o
sources NNS o
. . o

Complications NNS o
were VBD N
similar JJ N
in IN N
the DT N
3 CD N
groups NNS N
. . N

CONCLUSIONS NNP i
Lidocaine-prilocaine JJ i
cream NN i
was VBD N
most RBS N
effective JJ N
on IN N
probe-related JJ o
pain NN o
, , o
whereas IN i
lidocaine-ketorolac JJ i
gel NN i
was VBD i
most RBS N
effective JJ N
on IN N
sampling-related JJ N
pain NN N
. . N

These DT N
noninfiltrative JJ N
anesthetics NNS N
were VBD N
safe JJ N
, , N
easy JJ N
to TO N
administer VB N
, , N
and CC N
well RB N
accepted VBN N
by IN N
patients NNS N
; : N
the DT N
possibility NN N
to TO N
combine VB N
them PRP N
to TO N
further JJ N
improve VB o
pain NN o
control NN o
during IN o
TPB NNP N
deserves VBZ N
further JJ N
well-designed JJ N
studies NNS N
. . N

-DOCSTART- -10382134- O O

Sleep NNP o
patterns NNS o
in IN N
autistic JJ p
children NNS p
. . p

Sleep JJ o
disturbances NNS o
are VBP N
regarded VBN N
as IN N
a DT N
common JJ N
clinical JJ N
feature NN N
in IN N
autistic JJ p
children NNS p
. . p

This DT N
concept NN N
is VBZ N
based VBN N
primarily RB N
on IN N
informal JJ N
observations NNS N
or CC N
studies NNS N
conducted VBN N
with IN N
questionnaires NNS i
. . i

In IN N
this DT N
study NN N
we PRP N
compared VBN N
data NNS N
obtained VBN N
by IN N
questionnaires NNS i
to TO N
that DT N
obtained VBN N
with IN N
actigraphy NN i
. . i

Among IN N
22 CD p
autistic JJ p
children NNS p
, , p
12 CD p
were VBD p
reported VBN p
as IN p
having VBG p
sleep JJ p
problems NNS p
and CC N
8 CD p
patients NNS p
completed VBD p
72 CD i
hours NNS i
actigraphy RB i
. . i

While IN N
the DT N
employment NN N
of IN N
questionnaires NNS i
disclosed VBN N
that IN N
autistic JJ N
children NNS N
had VBD N
an DT N
earlier JJR o
morning NN o
awakening NN o
time NN o
and CC o
multiple NN o
and CC o
early JJ o
night NN o
arousals NNS o
, , N
actigraphic JJ i
monitoring NN N
showed VBD N
that IN N
with IN N
the DT N
exception NN N
of IN N
an DT N
earlier JJR o
morning NN o
arousal NN o
time NN o
( ( N
p JJ N
= NNP N
.045 NNP N
) ) N
, , N
sleep JJ o
patterns NNS o
of IN N
autistic JJ p
children NNS p
were VBD N
similar JJ N
to TO N
that DT N
of IN N
normal JJ N
children NNS N
. . N

Parental JJ N
oversensitivity NN N
to TO N
sleep VB o
disturbances NNS o
of IN N
the DT N
autistic JJ p
children NNS p
may MD N
explain VB N
this DT N
phenomenon NN N
. . N

-DOCSTART- -19066101- O O

Preliminary JJ N
findings NNS N
of IN N
the DT N
minimally-invasive JJ i
surgery NN i
plus CC i
rtPA NN i
for IN N
intracerebral JJ o
hemorrhage NN o
evacuation NN o
( ( p
MISTIE NNP p
) ) p
clinical JJ N
trial NN N
. . N

INTRODUCTION NNP N
Compared VBD N
to TO N
ischemic VB N
stroke NN N
, , N
intracerebral JJ N
hemorrhage NN N
( ( N
ICH NNP N
) ) N
is VBZ N
easily RB N
and CC N
rapidly RB N
identified VBN N
, , N
occurs VBZ N
in IN N
younger JJR p
patients NNS p
, , p
and CC p
produces VBZ p
relatively RB p
small JJ p
initial JJ p
injury NN p
to TO p
cerebral JJ p
tissues NNS p
-- : p
all DT p
factors NNS p
suggesting VBG p
that IN p
interventional JJ p
amelioration NN p
is VBZ p
possible JJ p
. . p

Investigations NNS N
from IN N
the DT N
last JJ N
decade NN N
established VBD N
that IN N
extent NN N
of IN N
ICH-mediated NNP N
brain NN N
injury NN N
relates VBZ N
directly RB N
to TO N
blood VB N
clot NN N
volume NN N
and CC N
duration NN N
of IN N
blood NN N
exposure NN N
to TO N
brain NN N
tissue NN N
. . N

Using VBG N
minimally-invasive JJ i
surgery NN i
plus CC i
recombinant JJ i
tissue NN i
plasminogen NN i
activator NN i
( ( i
rtPA NN i
) ) i
, , N
MISTIE NNP N
investigators NNS N
explored VBD N
aggressive JJ N
avenues NNS N
to TO N
treat VB N
ICH NNP N
. . N

METHODS NNP N
We PRP N
investigated VBD N
the DT N
difference NN N
between IN N
surgical JJ i
intervention NN i
plus CC i
rtPA NN i
and CC i
standard JJ i
medical JJ i
management NN i
for IN i
ICH NNP N
. . N

Subjects NNS p
in IN p
both DT p
groups NNS p
were VBD N
medically RB p
managed VBN p
according VBG p
to TO p
standard JJ p
ICU NNP p
protocols NNS p
. . p

Subjects NNS N
randomized VBD N
to TO N
surgery VB N
underwent JJ N
stereotactic JJ i
catheter NN i
placement NN i
and CC i
clot NN i
aspiration NN i
. . i

Injections NNS i
of IN i
rtPA NN i
were VBD N
then RB N
given VBN N
through IN N
hematoma NN N
catheter NN N
every DT N
8 CD N
h NN N
, , N
up RB N
to TO N
9 CD N
doses NNS N
, , N
or CC N
until IN N
a DT N
clot-reduction JJ N
endpoint NN N
. . N

After IN N
each DT N
injection NN N
the DT N
system NN N
was VBD N
flushed VBN N
with IN N
sterile JJ i
saline NN i
and CC N
closed VBD N
for IN N
60 CD N
min NN N
before IN N
opening VBG N
to TO N
spontaneous JJ N
drainage NN N
. . N

RESULTS JJ N
Average JJ o
aspiration NN o
of IN o
clots NNS o
for IN N
all DT N
patients NNS N
randomized VBN N
to TO N
surgery VB N
plus CC N
rtPA VB N
was VBD N
20 CD N
% NN N
of IN N
mean JJ N
initial JJ N
clot NN N
size NN N
. . N

After IN N
acute JJ N
treatment NN N
phase NN N
( ( N
aspiration NN N
plus CC N
rtPA NN N
) ) N
, , N
clot NN o
was VBD o
reduced VBN o
an DT N
average NN N
of IN N
46 CD N
% NN N
. . N

Recorded VBN N
adverse JJ N
events NNS N
were VBD N
within IN N
safety NN N
limits NNS N
, , N
including VBG N
30-day JJ o
mortality NN o
, , N
8 CD N
% NN N
; : N
symptomatic JJ o
re-bleeding NN o
, , N
8 CD N
% NN N
; : N
and CC N
bacterial JJ o
ventriculitis NN o
, , N
0 CD N
% NN N
. . N

Patients NNS N
randomized VBD N
to TO N
medical JJ N
management NN N
showed VBD N
4 CD N
% NN N
clot NN o
resolution NN o
in IN N
a DT N
similar JJ N
time NN N
window NN N
. . N

Preliminary JJ N
analysis NN N
indicates VBZ N
that IN N
clot NN o
resolution NN o
rates NNS o
are VBP N
greatly RB N
dependent JJ N
on IN N
catheter NN N
placement NN N
. . N

Location NN N
of IN N
ICH NNP N
also RB N
affects VBZ N
efficacy NN N
of IN N
aggressive JJ N
treatment NN N
of IN N
ICH NNP N
. . N

CONCLUSION NNP N
There EX N
is VBZ N
tentative JJ N
indication NN N
that IN N
minimally-invasive JJ N
surgery NN N
plus CC N
rtPA NN N
shows NNS N
greater JJR o
clot NN o
resolution NN o
than IN N
traditional JJ N
medical JJ N
management NN N
. . N

-DOCSTART- -26382998- O O

Oxygen NNP N
saturation NN N
targets NNS N
in IN N
infants NNS p
with IN p
bronchiolitis NN p
( ( p
BIDS NNP p
) ) p
: : p
a DT N
double-blind NN N
, , N
randomised VBN N
, , N
equivalence JJ N
trial NN N
. . N

BACKGROUND VB N
The DT N
American JJ N
Academy NNP N
of IN N
Pediatrics NNP N
recommends VBZ N
a DT N
permissive JJ N
hypoxaemic JJ N
target NN N
for IN N
an DT N
oxygen NN o
saturation NN o
of IN N
90 CD N
% NN N
for IN N
children NNS N
with IN N
bronchiolitis NN N
, , N
which WDT N
is VBZ N
consistent JJ N
with IN N
the DT N
WHO NNP N
recommendations NNS N
for IN N
targets NNS N
in IN N
children NNS p
with IN p
lower JJR p
respiratory NN p
tract JJ p
infections NNS p
. . p

No DT N
evidence NN N
exists VBZ N
to TO N
support VB N
this DT N
threshold NN N
. . N

We PRP N
aimed VBD N
to TO N
assess VB N
whether IN N
the DT N
90 CD N
% NN N
or CC N
higher JJR N
target NN N
for IN N
management NN N
of IN N
oxygen NN i
supplementation NN i
was VBD N
equivalent JJ N
to TO N
a DT N
normoxic JJ N
94 CD N
% NN N
or CC N
higher JJR N
target NN N
for IN N
infants NNS N
admitted VBN N
to TO N
hospital VB N
with IN N
viral JJ N
bronchiolitis NN N
. . N

METHODS NNP N
We PRP N
did VBD N
a DT N
parallel-group NN N
, , N
randomised VBN N
, , N
controlled VBN N
, , N
equivalence NN N
trial NN N
of IN N
infants NNS p
aged VBN p
6 CD p
weeks NNS p
to TO p
12 CD p
months NNS p
of IN p
age NN p
with IN p
physician-diagnosed JJ p
bronchiolitis NN p
newly RB p
admitted VBN p
into IN p
eight CD p
paediatric JJ p
hospital NN p
units NNS p
in IN p
the DT p
UK NNP p
( ( p
the DT p
Bronchiolitis NNP p
of IN p
Infancy NNP p
Discharge NNP p
Study NNP p
[ NNP p
BIDS NNP p
] NNP p
) ) p
. . p

A DT N
central JJ N
computer NN N
randomly RB N
allocated VBD N
( ( N
1:1 CD N
) ) N
infants NNS N
, , N
in IN N
varying VBG N
length NN N
blocks NNS N
of IN N
four CD N
and CC N
six CD N
and CC N
without IN N
stratification NN N
, , N
to TO N
be VB N
clipped VBN N
to TO N
standard VB i
oximeters NNS i
( ( N
patients NNS N
treated VBN N
with IN N
oxygen NN N
if IN N
pulse JJ N
oxygen NN N
saturation NN N
[ NNP N
SpO2 NNP N
] NNP N
< VBD N
94 CD N
% NN N
) ) N
or CC N
modified VBN i
oximeters NNS i
( ( N
displayed VB N
a DT N
measured JJ N
value NN N
of IN N
90 CD N
% NN N
as IN N
94 CD N
% NN N
, , N
therefore RB N
oxygen IN N
not RB N
given VBN N
until IN N
SpO2 NNP N
< VBD N
90 CD N
% NN N
) ) N
. . N

All DT N
parents NNS N
, , N
clinical JJ N
staff NN N
, , N
and CC N
outcome JJ N
assessors NNS N
were VBD N
masked VBN N
to TO N
allocation NN N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
time NN o
to TO o
resolution NN o
of IN o
cough NN o
( ( N
prespecified JJ N
equivalence NN N
limits NNS N
of IN N
plus CC N
or CC N
minus CC N
2 CD N
days NNS N
) ) N
in IN N
the DT N
intention-to-treat JJ N
population NN N
. . N

This DT N
trial NN N
is VBZ N
registered VBN N
with IN N
ISRCTN NNP N
, , N
number NN N
ISRCTN28405428 NNP N
. . N

FINDINGS NNP N
Between NNP N
Oct NNP N
3 CD N
, , N
and CC N
March NNP N
30 CD N
, , N
2012 CD N
, , N
and CC N
Oct NNP N
1 CD N
, , N
and CC N
March NNP N
29 CD N
, , N
2013 CD N
, , N
we PRP N
randomly VBP N
assigned VBD N
308 CD p
infants NNS p
to TO N
standard VB N
oximeters NNS N
and CC N
307 CD N
infants NNS N
to TO N
modified JJ N
oximeters NNS N
. . N

Cough NNP o
resolved VBN N
by IN N
15?0 CD N
days NNS N
( ( N
median JJ N
) ) N
in IN N
both DT N
groups NNS N
( ( N
95 CD N
% NN N
CI NNP N
for IN N
difference NN N
-1 NN N
to TO N
2 CD N
) ) N
and CC N
so RB N
oxygen JJ N
thresholds NNS N
were VBD N
equivalent JJ N
. . N

We PRP N
recorded VBD N
35 CD o
serious JJ o
adverse JJ o
events NNS o
in IN N
32 CD N
infants NNS N
in IN N
the DT N
standard NN N
care NN N
group NN N
and CC N
25 CD o
serious JJ o
adverse JJ o
events NNS o
in IN N
24 CD N
infants NNS N
in IN N
the DT N
modified NNP N
care NN N
group NN N
. . N

In IN N
the DT N
standard NN N
care NN N
group NN N
, , N
eight CD N
infants NNS o
transferred VBN o
to TO o
a DT o
high-dependency NN o
unit NN o
, , o
23 CD N
were VBD o
readmitted VBN o
, , o
and CC N
one CD N
had VBD N
a DT N
prolonged JJ o
hospital NN o
stay NN o
. . o

In IN N
the DT N
modified NNP N
care NN N
group NN N
, , N
12 CD N
infants NNS N
were VBD N
transferred VBN N
to TO N
a DT N
high-dependency NN o
unit NN o
and CC N
12 CD N
were VBD o
readmitted VBN o
to TO o
hospital NN o
. . o

Recorded VBN N
adverse JJ N
events NNS N
did VBD N
not RB N
differ VB N
significantly RB N
. . N

INTERPRETATION NNP N
Management NNP N
of IN p
infants NNS p
with IN p
bronchiolitis NN p
to TO N
an DT N
oxygen NN N
saturation NN N
target NN N
of IN N
90 CD N
% NN N
or CC N
higher JJR N
is VBZ N
as IN N
safe JJ N
and CC N
clinically RB N
effective JJ N
as IN N
one CD N
of IN N
94 CD N
% NN N
or CC N
higher JJR N
. . N

Future JJ N
research NN N
should MD N
assess VB N
the DT N
benefits NNS N
and CC N
risks NNS N
of IN N
different JJ N
oxygen NN N
saturation NN N
targets NNS N
in IN N
acute JJ N
respiratory NN N
infection NN N
in IN N
older JJR N
children NNS N
, , N
particularly RB N
in IN N
developing VBG N
nations NNS N
where WRB N
resources NNS N
are VBP N
scarce JJ N
. . N

FUNDING NNP N
National NNP N
Institute NNP N
for IN N
Health NNP N
Research NNP N
, , N
Health NNP N
Technology NNP N
Assessment NNP N
programme NN N
. . N

-DOCSTART- -17331650- O O

The DT N
study NN N
of IN N
inhibiting VBG N
systematic JJ N
inflammatory JJ N
response NN N
syndrome NN N
by IN N
applying VBG N
xenogenic JJ i
( ( i
porcine NN i
) ) i
acellular NN i
dermal JJ i
matrix NN i
on IN N
second-degree JJ p
burns NNS p
. . p

OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
influence NN N
of IN N
xenogenic NNP i
( ( i
porcine NN i
) ) i
acellular NN i
dermal JJ i
matrix NN i
on IN N
the DT N
systematic JJ N
inflammatory JJ N
reaction NN N
syndrome NN N
( ( N
SIRS NNP N
) ) N
, , N
and CC N
the DT N
reaction NN N
of IN N
burn NN p
patients NNS p
to TO N
tissue VB N
damage NN N
upon IN N
application NN N
to TO N
second-degree JJ p
burn NN p
wounds NNS p
. . p

METHOD NNP N
Seventy-two JJ p
cases NNS p
of IN p
patients NNS p
with IN p
acute JJ p
second-degree JJ p
burns NNS p
were VBD p
enrolled VBN p
in IN p
the DT p
study NN p
. . p

According VBG N
to TO N
the DT N
total JJ N
burn NN N
surface NN N
area NN N
( ( N
TBSA NNP N
) ) N
and CC N
the DT N
treatment NN N
methods NNS N
, , N
we PRP N
randomly RB N
divided VBD N
the DT N
patients NNS N
into IN N
four CD N
groups NNS N
. . N

Group NNP N
A NNP N
( ( N
treatment NN N
group NN N
) ) N
: : N
patients NNS p
with IN p
less JJR p
than IN p
30 CD p
% NN p
TBSA NNP p
covered VBD p
with IN p
xenogenic JJ i
acellular JJ i
dermal NN i
matrix NN i
. . i

Group NNP N
B NNP N
( ( N
control VB N
group NN N
) ) N
: : N
patients NNS p
with IN p
less JJR p
than IN p
30 CD p
% NN p
TBSA NNP p
covered VBD p
with IN p
betadine JJ i
ointment NN i
gauzes NNS i
. . i

Group NNP N
C NNP N
( ( N
treatment NN N
group NN N
) ) N
: : N
patients NNS p
with IN p
more JJR p
than IN p
30 CD p
% NN p
TBSA NNP p
covered VBD p
with IN p
porcine JJ i
acellular JJ i
dermal NN i
matrix NN i
. . i

Group NNP N
D NNP N
( ( N
control VB N
group NN N
) ) N
: : N
patients NNS p
with IN p
more JJR p
than IN p
30 CD p
% NN p
TBSA NNP p
covered VBD p
with IN p
betadine JJ i
ointment NN i
gauzes NNS i
. . i

Serum NNP N
level NN N
of IN N
C-reactive JJ N
protein NN N
( ( N
CRP NNP N
) ) N
was VBD N
measured VBN N
by IN N
single JJ N
radial JJ N
immunodiffusion NN N
method NN N
on IN N
1 CD N
, , N
4 CD N
, , N
7 CD N
and CC N
14 CD N
days NNS N
postburn VBP N
. . N

RESULTS VB N
The DT N
serum JJ o
level NN o
of IN o
CRP NNP o
in IN N
group NN N
A NNP N
was VBD N
significantly RB N
less JJR N
than IN N
that DT N
of IN N
in IN N
group NN N
B NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
on IN N
days NNS N
4 CD N
, , N
7 CD N
and CC N
14 CD N
. . N

The DT N
serum JJ o
level NN o
of IN o
CRP NNP o
in IN N
group NN N
C NNP N
increased VBD N
slowly RB N
, , N
descended VBD N
quickly RB N
and CC N
was VBD N
significantly RB N
less JJR N
than IN N
that DT N
of IN N
in IN N
group NN N
D NNP N
on IN N
days NNS N
4 CD N
, , N
7 CD N
and CC N
14 CD N
. . N

CONCLUSION VB N
The DT N
application NN N
of IN N
xenogenic NNP i
( ( i
porcine NN i
) ) i
acellular NN i
dermal JJ i
matrix NN i
on IN N
second-degree JJ p
burn NN p
wound NN p
can MD N
decrease VB N
serum JJ o
level NN o
of IN o
CRP NNP o
of IN N
the DT N
patients NNS N
, , N
which WDT N
may MD N
play VB N
an DT N
important JJ N
role NN N
in IN N
reducing VBG N
SIRS NNP N
and CC N
sepsis NN N
incidence NN N
. . N

-DOCSTART- -19040172- O O

Impacts NNS N
of IN N
a DT N
disease JJ i
management NN i
program NN i
for IN N
dually RB p
eligible JJ p
beneficiaries NNS p
. . p

The DT N
LifeMasters NNPS i
Supported NNP i
SelfCare NNP i
demonstration NN i
program NN i
provides VBZ N
disease JJ i
management NN i
( ( i
DM NNP i
) ) i
services NNS i
to TO N
Florida NNP p
Medicare NNP p
beneficiaries NNS p
who WP p
are VBP p
also RB p
enrolled VBN p
in IN p
Medicaid NNP p
and CC p
have VBP p
congestive JJ p
heart NN p
failure NN p
( ( p
CHF NNP p
) ) p
, , p
diabetes VBZ p
, , p
or CC p
coronary JJ p
artery NN p
disease NN p
( ( p
CAD NNP p
) ) p
. . p

The DT N
population-based JJ N
program NN N
provides VBZ N
primarily RB i
telephonic JJ i
patient JJ i
education NN i
and CC i
monitoring NN i
services NNS i
. . i

Findings NNS N
from IN N
the DT N
randomized VBN N
, , N
intent-to-treat JJ N
design NN N
over IN N
the DT N
first JJ N
18 CD N
months NNS N
of IN N
operations NNS N
show VBP N
virtually RB N
no DT N
overall JJ N
impacts NNS o
on IN o
hospital NN o
or CC o
emergency NN o
room NN o
( ( o
ER NNP o
) ) o
use NN o
, , o
Medicare NNP o
expenditures VBZ o
, , o
quality NN o
of IN o
care NN o
, , o
or CC o
prescription NN o
drug NN o
use NN o
for IN N
the DT N
33,000 CD p
enrollees NNS p
. . p

However RB N
, , N
for IN N
beneficiaries NNS p
with IN p
CHF NNP p
who WP p
resided VBD p
in IN p
high-cost NN p
South NNP p
Florida NNP p
counties NNS p
, , N
the DT N
program NN N
reduced VBN N
Medicare NNP o
expenditures NNS o
by IN N
9.6 CD N
percent NN N
. . N

-DOCSTART- -6423162- O O

Endotracheal NNP p
cuff NN p
pressure NN p
and CC p
tracheal NN p
mucosal NN p
blood NN p
flow NN p
: : p
endoscopic NN N
study NN N
of IN N
effects NNS N
of IN N
four CD p
large JJ p
volume NN p
cuffs NNS p
. . p

Large JJ i
volume NN i
, , i
low JJ i
pressure NN i
endotracheal NN i
tube NN i
cuffs NNS i
are VBP N
claimed VBN N
to TO N
have VB N
less RBR N
deleterious JJ N
effect NN N
on IN N
tracheal NN o
mucosa NN o
than IN N
high JJ N
pressure NN N
, , N
low JJ N
volume NN N
cuffs NNS N
. . N

Low JJ i
pressure NN i
cuffs NNS i
, , N
however RB N
, , N
may MD N
easily RB N
be VB N
overinflated VBN N
to TO N
yield VB N
pressures NNS N
that WDT N
will MD N
exceed VB N
capillary JJ N
perfusion NN N
pressure NN N
. . N

Various JJ N
large JJ i
volume NN i
cuffed VBD i
endotracheal JJ i
tubes NNS i
were VBD N
studied VBN N
, , N
including VBG N
Portex NNP i
Profile NNP i
, , i
Searle NNP i
Sensiv NNP i
, , i
Mallinkrodt NNP i
Hi-Lo NNP i
, , N
and CC N
Lanz NNP i
. . i

Tracheal NNP N
mucosal NN N
blood NN N
flow NN N
in IN N
40 CD p
patients NNS p
undergoing JJ p
surgery NN p
was VBD N
assessed VBN N
using VBG N
an DT N
endoscopic JJ i
photographic JJ i
technique NN i
while IN i
varying VBG i
the DT i
cuff NN i
inflation NN i
pressure NN i
. . i

It PRP N
was VBD N
found VBN N
that IN N
these DT N
cuffs NNS N
when WRB N
overpressurised VBN N
impaired JJ o
mucosal NN o
blood NN o
flow NN o
. . o

This DT N
impairment NN N
of IN N
tracheal NN o
mucosal NN o
blood NN o
flow NN o
is VBZ N
an DT N
important JJ N
factor NN N
in IN N
tracheal JJ o
morbidity NN o
associated VBN N
with IN N
intubation NN N
. . N

Hence NN N
it PRP N
is VBZ N
recommended VBN N
that IN N
a DT N
cuff NN o
inflation NN o
pressure NN o
of IN N
30 CD N
cm NNS N
H2O NNP N
( ( N
22 CD N
mm RB N
Hg NNP N
) ) N
should MD N
not RB N
be VB N
exceeded VBN N
. . N

-DOCSTART- -19407805- O O

Ambulatory NNP N
blood NN o
pressure NN o
control NN N
with IN N
bedtime JJ i
aspirin JJ i
administration NN i
in IN N
subjects NNS p
with IN p
prehypertension NN p
. . p

BACKGROUND NNP N
Aspirin NNP i
has VBZ N
been VBN N
found VBN N
to TO N
prevent VB N
angiotensin JJ N
II-induced NNP N
hypertension NN N
and CC N
to TO N
induce VB N
nitric JJ N
oxide NN N
( ( N
NO NNP N
) ) N
release NN N
from IN N
vascular JJ N
endothelium NN N
. . N

Low-dose JJ N
aspirin NN i
has VBZ N
also RB N
been VBN N
shown VBN N
to TO N
reduce VB N
blood NN o
pressure NN o
( ( o
BP NNP o
) ) o
when WRB N
administered VBN N
at IN N
bedtime NN N
, , N
as IN N
opposed VBN N
to TO N
upon IN N
awakening VBG N
, , N
in IN N
untreated JJ p
hypertensive JJ p
patients NNS p
and CC p
high-risk JJ p
pregnant JJ p
women NNS p
. . p

Accordingly RB N
, , N
we PRP N
investigated VBD N
the DT N
effects NNS N
on IN N
ambulatory JJ o
BP NNP o
of IN N
aspirin NN i
administered VBN N
at IN N
different JJ N
times NNS N
of IN N
the DT N
day NN N
in IN N
prehypertension NN p
. . p

METHODS NNP N
We PRP N
studied VBD N
244 CD p
subjects NNS p
with IN p
prehypertension NN p
, , p
43.0 CD p
+/- JJ p
13.0 CD p
years NNS p
of IN p
age NN p
, , N
randomly RB N
divided VBN N
in IN N
three CD N
groups NNS N
: : N
nonpharmacological JJ i
hygienic-dietary JJ i
recommendations NNS i
; : i
the DT i
same JJ i
recommendations NNS i
and CC i
aspirin NN i
( ( i
100 CD i
mg/day NN i
) ) i
on IN i
awakening VBG i
; : i
or CC N
the DT i
same JJ i
recommendations NNS i
and CC i
aspirin NN i
at IN i
bedtime NN i
. . i

BP NNP o
was VBD N
measured VBN N
for IN N
48 CD N
consecutive JJ N
hours NNS N
before IN N
and CC N
after IN N
3 CD N
months NNS N
of IN N
intervention NN N
. . N

RESULTS NNP N
Ambulatory NNP o
BP NNP o
was VBD N
unchanged JJ N
in IN N
subjects NNS N
randomized VBN N
to TO N
either DT N
nonpharmacological JJ i
intervention NN i
or CC N
aspirin NN i
on IN N
awakening VBG N
. . N

A DT N
significant JJ N
ambulatory NN o
BP NNP o
reduction NN N
was VBD N
, , N
however RB N
, , N
observed VBN N
in IN N
the DT N
subjects NNS N
who WP N
received VBD N
aspirin NN i
at IN N
bedtime NN N
( ( N
decrease NN N
of IN N
6/3 CD N
mm NNS N
Hg NNP N
in IN N
the DT N
24-h JJ N
mean NN N
of IN N
systolic NN o
( ( o
SBP NNP o
) ) o
/diastolic VBP o
BP NNP o
( ( o
DBP NNP o
) ) o
, , N
respectively RB N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
without IN N
changes NNS N
in IN N
heart NN o
rate NN o
( ( o
HR NNP o
) ) o
from IN N
baseline NN N
. . N

BP NNP o
was VBD N
homogeneously RB N
controlled VBN N
along IN N
the DT N
24 CD N
h NN N
after IN N
bedtime NN N
aspirin JJ i
administration NN N
( ( N
6/4 CD N
mm NN N
Hg NNP N
reduction NN N
in IN N
activity NN N
mean NN N
of IN N
SBP/DBP NNP N
; : N
6/3 CD N
mm NN N
Hg NNP N
reduction NN N
in IN N
sleep-time JJ N
mean NN N
, , N
respectively RB N
) ) N
. . N

CONCLUSIONS VB N
This DT N
prospective JJ N
trial NN N
documents NNS N
a DT N
significant JJ N
effect NN N
on IN N
BP NNP o
of IN N
low JJ N
dose NN N
aspirin NN i
only RB N
when WRB N
ingested VBN N
at IN N
bedtime NN N
by IN N
prehypertensive JJ p
subjects NNS p
. . p

The DT N
timed JJ N
administration NN N
of IN N
low-dose JJ N
aspirin NN i
could MD N
thus RB N
provide VB N
a DT N
valuable JJ N
and CC N
cost-effective JJ N
approach NN N
for IN N
BP NNP o
control NN o
in IN N
subjects NNS p
at IN p
elevated JJ p
risk NN p
of IN p
developing VBG p
hypertension NN p
. . p

-DOCSTART- -23361105- O O

Contribution NN N
of IN N
endogenous JJ N
bradykinin NN N
to TO N
fibrinolysis NN o
, , o
inflammation NN o
, , o
and CC o
blood NN o
product NN o
transfusion NN o
following VBG p
cardiac JJ p
surgery NN p
: : p
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

Bradykinin NNP N
increases VBZ N
during IN N
cardiopulmonary JJ p
bypass NN p
( ( p
CPB NNP p
) ) p
and CC N
stimulates VBZ N
the DT N
release NN o
of IN o
nitric JJ o
oxide NN o
, , o
inflammatory JJ o
cytokines NNS o
, , o
and CC o
tissue-type JJ o
plasminogen NN o
activator NN o
( ( o
t-PA JJ o
) ) o
, , N
acting VBG N
through IN N
its PRP$ N
B2 NNP N
receptor NN N
. . N

This DT N
study NN N
tested VBD N
the DT N
hypothesis NN N
that WDT N
endogenous JJ N
bradykinin NN N
contributes NNS N
to TO N
the DT N
fibrinolytic JJ o
and CC o
inflammatory JJ o
response NN o
to TO o
CPB NNP o
and CC o
that IN o
bradykinin NN o
B2 NNP o
receptor NN o
antagonism NN o
reduces VBZ o
fibrinolysis NN o
, , o
inflammation NN o
, , o
and CC o
subsequent JJ o
transfusion NN o
requirements NNS o
. . o

Patients NNS p
( ( p
N NNP p
= NNP p
115 CD p
) ) p
were VBD N
prospectively RB N
randomized VBN N
to TO N
placebo VB i
, , i
?-aminocaproic JJ i
acid NN i
( ( i
EACA NNP i
) ) i
, , i
or CC i
HOE NNP i
140 CD i
, , i
a DT N
bradykinin NN N
B2 NNP N
receptor NN N
antagonist NN N
. . N

Bradykinin NNP N
B2 NNP N
receptor NN N
antagonism NN N
decreased VBD o
intraoperative JJ o
fibrinolytic JJ o
capacity NN o
as RB N
much RB N
as IN i
EACA NNP i
, , i
but CC N
only RB i
EACA NNP i
decreased VBD o
D-dimer NNP o
formation NN o
and CC N
tended VBD N
to TO N
decrease VB o
postoperative JJ o
bleeding NN o
. . o

Although IN i
EACA NNP i
and CC i
HOE NNP i
140 CD i
decreased VBD o
fibrinolysis NN o
and CC o
EACA NNP o
attenuated VBD o
blood NN o
loss NN o
, , o
these DT N
treatments NNS N
did VBD N
not RB N
reduce VB N
the DT N
proportion NN N
of IN N
patients NNS N
transfused VBN N
. . N

These DT N
data NNS N
suggest VBP N
that IN N
endogenous JJ N
bradykinin NN N
contributes NNS N
to TO o
t-PA JJ o
generation NN o
in IN p
patients NNS p
undergoing VBG p
CPB NNP p
, , p
but CC N
that IN N
additional JJ N
effects NNS N
on IN o
plasmin NN o
generation NN o
contribute NN N
to TO o
decreased VBN o
D-dimer NNP o
concentrations NNS o
during IN i
EACA NNP i
treatment NN N
. . N

-DOCSTART- -19022794- O O

Parecoxib NNP i
for IN N
analgesia NN p
after IN p
craniotomy NN p
. . p

BACKGROUND NNP N
Pain NNP o
after IN N
craniotomy NN N
is VBZ N
often RB N
under-treated JJ N
. . N

Opiates VBZ N
carry VBP N
distinct JJ N
disadvantages NNS N
. . N

Non-steroidal JJ N
anti-inflammatory JJ N
drugs NNS N
have VBP N
an DT N
anti-platelet JJ N
action NN N
and CC N
carry VBP N
a DT N
bleeding NN N
risk NN N
. . N

Cyclo-oxygenase JJ N
2 CD N
inhibitors NNS N
such JJ N
as IN N
parecoxib NNS N
are VBP N
not RB N
associated VBN N
with IN N
a DT N
bleeding NN N
risk NN N
and CC N
would MD N
be VB N
welcome JJ N
analgesics NNS N
if IN N
shown VBN N
to TO N
be VB N
effective JJ N
. . N

METHODS NNP N
In IN N
a DT N
prospective JJ N
double-blind NN N
, , N
randomized VBN N
, , N
placebo-controlled JJ i
study NN N
, , N
we PRP N
investigated VBD N
the DT N
analgesic JJ N
effect NN N
of IN N
a DT N
single JJ N
dose NN N
of IN N
parecoxib NN i
40 CD i
mg NN i
given VBN N
at IN N
dural JJ N
closure NN N
in IN N
82 CD p
patients NNS p
undergoing JJ p
elective JJ p
craniotomies NNS p
. . p

Remifentanil NNP i
was VBD N
used VBN N
intraoperatively RB N
, , N
and CC N
i.v NN i
. . i

morphine NN i
was VBD N
titrated VBN N
to TO N
the DT N
requirement NN N
in IN N
the DT N
post-anaesthetic JJ N
unit NN N
. . N

On IN N
the DT N
ward NN N
, , N
i.m NN i
. . i

morphine VB i
5 CD i
mg NNS i
as IN N
required VBN N
and CC N
regular JJ N
acetaminophen NN i
was VBD N
prescribed VBN N
. . N

Morphine NNP i
use NN N
and CC N
visual JJ o
analogue NN o
pain NN o
scores NNS o
were VBD N
recorded VBN N
at IN N
1 CD N
, , N
6 CD N
, , N
12 CD N
, , N
and CC N
24 CD N
h NN N
after IN N
surgery NN N
. . N

RESULTS NNP N
Parecoxib NNP N
reduced VBD o
pain NN o
scores NNS o
at IN N
6 CD N
h NN N
and CC N
morphine NN N
use NN N
at IN N
6 CD N
and CC N
12 CD N
h NN N
after IN N
operation NN N
. . N

However RB N
, , N
overall JJ N
, , N
it PRP N
had VBD N
only RB N
minimal JJ N
impact NN N
on IN N
postoperative JJ o
analgesia NN o
. . o

We PRP N
found VBD N
a DT N
wide JJ N
variability NN N
in IN N
analgesic JJ N
requirements NNS N
where WRB N
11 CD N
% NN N
of IN N
patients NNS N
required VBN N
no DT N
opioids NNS N
and CC N
16 CD N
% NN N
required VBN N
more JJR N
than IN N
15 CD N
mg JJ N
i.v NN N
. . N

morphine VB N
1 CD N
h NN N
after IN N
the DT N
surgery NN N
. . N

CONCLUSIONS NNP N
We PRP N
found VBD N
only RB N
limited JJ N
evidence NN N
to TO N
support VB N
parecoxib NN N
as IN N
an DT N
analgesic JJ N
after IN N
craniotomy NN N
. . N

-DOCSTART- -19122080- O O

Detection NN N
of IN N
traumatic JJ N
arthrotomy NN N
of IN N
the DT N
knee NN N
using VBG N
the DT N
saline JJ i
solution NN i
load NN i
test NN i
. . i

BACKGROUND IN N
The DT N
saline JJ i
solution NN i
load NN i
test NN i
helps VBZ N
to TO N
determine VB N
if IN N
a DT N
wound NN N
extends VBZ N
into IN N
the DT N
knee NN N
joint NN N
. . N

Little JJ N
is VBZ N
known VBN N
about IN N
the DT N
volume NN N
of IN N
injected JJ N
intra-articular JJ N
saline NN i
solution NN i
that WDT N
is VBZ N
needed VBN N
to TO N
effectively RB N
rule VB N
in IN N
or CC N
rule VB N
out IN N
a DT N
traumatic JJ N
arthrotomy NN N
of IN N
the DT N
knee NN N
. . N

The DT N
purpose NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
determine VB N
the DT N
appropriate JJ o
volume NN o
and CC N
needle JJ o
location NN o
for IN N
the DT N
diagnosis NN N
of IN N
a DT N
traumatic JJ N
knee NN N
arthrotomy NN N
and CC N
to TO N
assess VB N
the DT N
effect NN o
of IN N
associated JJ o
variables NNS o
, , N
including VBG N
knee NN o
circumference NN o
, , o
body NN o
mass NN o
index NN o
, , o
and CC o
sex NN o
. . o

METHODS NNP N
Fifty-six NNP p
consecutive JJ p
patients NNS p
scheduled VBN p
for IN p
knee NN p
arthroscopy NN p
were VBD N
enrolled VBN N
. . N

A DT i
standard JJ i
inferolateral JJ i
arthroscopic NN i
portal NN i
was VBD i
made VBN i
with IN i
a DT i
single JJ i
stab NN i
incision NN i
with IN i
use NN i
of IN i
a DT i
number-11 JJ i
blade NN i
. . i

Injection NN N
sites NNS N
were VBD N
randomized VBN N
to TO N
either VB N
a DT N
superomedial NN N
or CC N
inferomedial JJ N
location NN N
. . N

The DT N
injection NN i
of IN i
normal JJ i
saline JJ i
solution NN i
at IN i
a DT i
rate NN i
of IN i
5 CD i
mL/sec NNS i
through IN i
an DT i
18-gauge JJ i
needle NN i
was VBD N
continued VBN N
while IN N
the DT N
knee NN N
was VBD N
moved VBN N
through IN N
a DT N
range NN N
of IN N
motion NN N
until IN N
fluid NNS N
extravasated VBN N
from IN N
the DT N
iatrogenic JJ N
laceration NN N
. . N

The DT N
volume NN N
of IN N
injected JJ N
fluid NN N
was VBD N
recorded VBN N
. . N

RESULTS VB N
The DT N
study NN N
group NN N
included VBD N
thirty-one JJ p
female NN p
patients NNS p
and CC p
twenty-five JJ p
male NN p
patients NNS p
with IN p
a DT p
combined JJ p
average JJ p
age NN p
of IN p
fifty JJ p
years NNS p
and CC p
an DT p
average JJ o
body NN o
mass NN o
index NN o
of IN p
30.9 CD p
. . p

In IN N
order NN N
to TO N
effectively RB N
diagnose VB o
50 CD o
% NN o
of IN o
the DT o
arthrotomies NNS o
, , N
75 CD N
mL NN N
of IN N
injected JJ N
fluid NN N
was VBD N
needed VBN N
; : N
the DT N
volumes NNS o
that WDT o
were VBD o
needed VBN o
in IN o
order NN o
to TO o
effectively RB o
diagnose VB o
75 CD o
% NN o
, , N
90 CD N
% NN N
, , N
95 CD N
% NN N
, , N
and CC N
99 CD N
% NN N
of IN N
the DT N
arthrotomies NNS o
were VBD N
110 CD N
, , N
145 CD N
, , N
155 CD N
, , N
and CC N
175 CD N
mL NN N
, , N
respectively RB N
. . N

The DT N
mean JJ o
volumes NNS o
of IN o
injected JJ o
fluid NN o
needed VBN o
for IN o
a DT o
positive JJ o
result NN o
at IN o
the DT o
inferomedial JJ o
and CC o
superomedial JJ o
needle JJ o
locations NNS o
were VBD N
64.0 CD N
and CC N
95.2 CD N
mL NN N
, , N
respectively RB N
; : N
this DT N
difference NN N
was VBD N
significant JJ N
( ( N
p JJ N
= NNP N
0.01 CD N
) ) N
. . N

There EX N
was VBD N
no DT o
correlation NN o
between IN o
necessary JJ o
injection NN o
volume NN o
and CC o
sex NN o
, , o
body NN o
mass NN o
index NN o
, , o
or CC o
knee VB o
circumference NN o
. . o

CONCLUSIONS NNP N
In IN N
order NN N
to TO N
detect VB N
95 CD N
% NN N
of IN N
1-cm JJ N
inferolateral JJ N
arthrotomies NNS N
of IN N
the DT N
knee NN N
with IN N
use NN N
of IN N
the DT N
saline JJ N
solution NN N
load NN N
test NN N
, , N
155 CD N
mL NN N
must MD N
be VB N
injected VBN N
. . N

An DT N
inferomedial JJ o
injection NN o
location NN o
requires VBZ N
significantly RB o
less JJR o
fluid NN o
than IN N
a DT N
superomedial JJ o
injection NN o
location NN o
does VBZ N
for IN N
the DT N
diagnosis NN N
of IN N
inferolateral JJ N
arthrotomies NNS N
of IN N
the DT N
knee NN N
. . N

-DOCSTART- -25223963- O O

Recommending VBG N
self-paced JJ i
exercise NN i
among IN N
overweight JJ p
and CC p
obese JJ p
adults NNS p
: : p
a DT N
randomized JJ N
pilot NN N
study NN N
. . N

BACKGROUND NNP N
National NNP N
guidelines NNS N
call NN N
for IN N
exercise NN N
of IN N
at IN N
least JJS N
moderate JJ N
intensity NN N
; : N
however RB N
, , N
recommending VBG N
self-paced JJ i
exercise NN i
may MD N
lead VB N
to TO N
better JJR N
adherence NN o
, , N
particularly RB N
among IN N
overweight JJ p
and CC p
obese JJ p
adults NNS p
. . p

PURPOSE VB N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
test VB N
proof-of-concept NN N
for IN N
recommending VBG N
self-paced JJ N
exercise NN N
among IN N
overweight JJ N
adults NNS N
. . N

METHODS NNP N
Fifty-nine NNP p
healthy JJ p
, , p
low-active JJ p
( ( p
exercise NN p
< VBZ p
60 CD p
min/week NN p
) ) p
, , p
overweight JJ p
( ( p
body JJ p
mass NN p
index NN p
25.0-39.9 JJ p
) ) p
adults NNS p
( ( p
18-65 JJ p
) ) p
received VBD N
a DT N
6-month JJ i
print-based JJ i
exercise NN i
promotion NN i
program NN i
with IN i
the DT i
goal NN i
of IN i
walking VBG i
30-60 JJ i
min/day NN i
. . i

Participants NNS N
were VBD N
surreptitiously RB N
randomly RB N
assigned VBN N
to TO N
receive VB N
a DT N
recommendation NN i
for IN i
either DT i
self-paced JJ i
( ( i
n JJ i
= NNP i
30 CD i
) ) i
or CC i
moderate JJ i
( ( i
64-76 JJ i
% NN N
maximum JJ N
heart NN N
rate NN N
; : N
n CC N
= VB N
29 CD N
) ) N
intensity NN i
exercise NN i
. . i

All DT p
participants NNS p
used VBN p
electronic JJ p
diaries NNS p
and CC p
heart NN p
rate NN p
monitors NNS p
to TO p
track VB o
exercise NN o
frequency NN o
, , o
duration NN o
, , o
and CC o
intensity NN o
. . o

RESULTS VB N
The DT N
self-paced JJ N
condition NN N
reported VBD N
more RBR o
minutes/week NNS o
of IN o
walking NN o
( ( N
f JJ N
( ( N
2 CD N
) ) N
= NN N
0.17 CD N
, , N
p NN N
= NNP N
0.045 CD N
) ) N
and CC N
a DT N
trend NN N
toward IN N
greater JJR o
exercise-related JJ o
energy NN o
expenditure/week NN o
( ( o
f JJ N
( ( N
2 CD N
) ) N
= NN N
0.12 CD N
, , N
p NN N
= NNP N
0.243 CD N
) ) N
, , N
corresponding VBG N
to TO N
approximately RB N
26 CD N
additional JJ N
minutes/week NN N
and CC N
83 CD N
additional JJ N
kilocalories/week NN N
over IN N
6 CD N
months NNS N
. . N

CONCLUSIONS NNP N
Explicit NNP N
recommendation NN N
for IN N
self-paced JJ i
exercise NN i
may MD i
improve VB o
adherence NN o
to TO o
exercise VB o
programs NNS o
among IN o
overweight JJ p
and CC p
obese JJ p
adults NNS p
. . N

-DOCSTART- -17069543- O O

A DT N
double-blind JJ N
placebo-controlled JJ i
pilot NN N
study NN N
of IN N
olanzapine NN i
in IN N
childhood/adolescent JJ p
pervasive JJ p
developmental NN p
disorder NN p
. . p

Atypical JJ N
antipsychotics NNS N
have VBP N
been VBN N
shown VBN N
to TO N
improve VB N
disruptive NN o
and CC o
repetitive JJ o
behaviors NNS o
in IN N
pervasive JJ N
developmental NN N
disorders NNS N
( ( N
PDDs NNP N
) ) N
, , N
but CC N
they PRP N
require VBP N
assessment NN N
of IN N
potential JJ N
side NN o
effects NNS o
. . o

This DT N
is VBZ N
the DT N
first JJ N
placebo-controlled JJ i
trial NN N
of IN N
olanzapine NN i
in IN N
the DT N
treatment NN N
of IN N
children NNS N
and CC N
adolescents NNS N
with IN N
PDD NNP N
. . N

Eleven NNP p
patients NNS p
with IN p
a DT p
diagnosis NN p
of IN p
either DT p
autism NN p
, , p
Asperger NNP p
's POS p
syndrome NN p
, , p
or CC p
PDD NNP p
not RB p
otherwise RB p
specified VBN p
( ( p
PDD-NOS NNP p
) ) p
and CC p
aged VBN p
6-14 CD p
years NNS p
were VBD N
randomized VBN N
into IN N
an DT N
8-week JJ N
double-blind NN N
, , N
placebo-controlled JJ i
, , N
parallel JJ N
treatment NN N
study NN N
with IN N
olanzapine NN i
. . i

There EX N
was VBD N
a DT N
significant JJ N
linear JJ N
trend NN N
x NNP N
group NN N
interaction NN N
on IN N
the DT N
Clinical JJ o
Global NNP o
Impressions- NNP o
Improvement NNP o
( ( o
CGI-I NNP o
) ) o
and CC N
50 CD N
% NN N
on IN N
olanzapine JJ N
versus NN N
20 CD N
% NN N
on IN N
placebo NN N
were VBD N
responders NNS N
. . N

Olanzapine NNP N
was VBD N
associated VBN N
with IN N
significant JJ o
weight JJ o
gain NN o
( ( N
7.5 CD N
+/- JJ N
4.8 CD N
lbs NN N
vs. FW N
1.5 CD N
+/- JJ N
1.5 CD N
lbs NN N
on IN N
placebo NN N
) ) N
. . N

Olanzapine NN N
may MD N
be VB N
a DT N
promising JJ N
treatment NN N
for IN N
improving VBG N
global JJ o
functioning NN o
of IN o
PDDs NNP o
, , N
but CC N
the DT N
risk NN N
of IN N
significant JJ N
weight JJ o
gain NN o
remains VBZ N
a DT N
concern NN N
. . N

Additional JJ N
studies NNS N
are VBP N
needed VBN N
to TO N
determine VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
olanzapine NN N
in IN N
the DT N
treatment NN N
of IN N
children NNS N
with IN N
PDD NNP N
. . N

-DOCSTART- -18721764- O O

Long-term JJ N
follow-up NN N
of IN N
a DT N
phase NN N
I/II NNP N
randomized VBD N
, , N
placebo-controlled JJ i
trial NN N
of IN N
palifermin NN i
to TO N
prevent VB N
graft-versus-host JJ p
disease NN p
( ( p
GVHD NNP p
) ) p
after IN p
related VBN p
donor NN p
allogeneic NN p
hematopoietic JJ p
cell NN p
transplantation NN p
( ( p
HCT NNP p
) ) p
. . p

We PRP N
previously RB N
conducted VBD N
a DT N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
study NN p
conducted VBN p
from IN p
2000 CD p
to TO p
2003 CD p
of IN p
palifermin NN i
, , p
a DT p
recombinant JJ p
human JJ p
keratinocyte NN p
growth NN p
factor NN p
, , p
dosed VBN p
from IN p
240 CD p
microg/kg NNS p
to TO p
720 CD p
microg/kg NN p
, , p
in IN p
100 CD p
allogeneic JJ p
hematopoietic JJ p
stem NN p
cell NN p
transplantation NN p
( ( p
HCT NNP p
) ) p
recipients NNS p
. . p

Treatment NN N
with IN N
palifermin NN i
showed VBD N
beneficial JJ N
effects NNS o
on IN N
mucositis NN o
, , o
but CC o
no DT o
significant JJ o
effect NN o
on IN o
engraftment NN o
, , o
acute JJ o
graft-versus-host JJ o
disease NN o
( ( o
GVHD NNP o
) ) o
, , o
or CC o
early JJ o
survival NN o
. . o

In IN N
addition NN N
to TO N
the DT N
effect NN N
of IN N
palifermin NN i
on IN N
mucosa NN o
, , o
other JJ o
pleotrophic JJ o
effects NNS o
, , o
including VBG o
more RBR o
rapid JJ o
immune JJ o
reconstitution NN o
, , N
have VBP N
been VBN N
seen VBN N
in IN N
experimental JJ N
transplant NN N
models NNS N
. . N

Therefore RB N
, , N
we PRP N
investigated VBD N
whether IN N
with IN N
longer JJR N
follow-up NN N
we PRP N
could MD N
detect VB N
additional JJ o
differences NNS o
between IN N
the DT N
palifermin-treated JJ i
and CC N
placebo JJ i
cohorts NNS N
. . N

We PRP N
found VBD N
no DT N
differences NNS N
in IN N
CMV NNP o
or CC o
invasive JJ o
fungal JJ o
infections NNS o
, , o
chronic JJ o
GVHD NNP o
, , o
or CC o
long-term JJ o
survival NN o
between IN N
cohorts NNS N
. . N

We PRP N
conclude VBP N
that IN N
the DT N
benefits NNS N
of IN N
palifermin NN i
appear VBP N
primarily RB N
to TO N
be VB N
limited VBN N
to TO N
ameliorating VBG N
mucotoxicity NN o
when WRB N
given VBN N
to TO N
allogeneic VB p
HCT NNP p
recipients NNS p
. . p

-DOCSTART- -15217131- O O

[ JJ N
Comparison NNP N
of IN N
two CD N
methods NNS N
of IN N
local JJ i
anaesthesia NN i
prior RB N
to TO N
transrectal VB N
ultrasound-guided JJ N
prostate NN N
biopsies NNS N
] VBP N
. . N

OBJECTIVE NNP N
To TO N
compare VB N
the DT N
analgesic JJ N
efficacy NN N
of IN N
rectal JJ N
administration NN N
of IN N
Lidoca?ne NNP i
gel NN i
with IN i
Lidoca?ne NNP i
periprostatic JJ i
infiltration NN i
prior RB i
to TO N
transrectal VB N
ultrasound-guided JJ N
prostate NN N
biopsies NNS N
. . N

MATERIAL NNP N
AND CC N
METHODS NNP p
Between NNP p
July NNP p
2002 CD p
and CC p
July NNP p
2003 CD p
, , p
candidates NNS p
to TO p
prostate VB p
biopsies NNS p
were VBD p
randomised VBN N
into IN N
two CD N
groups NNS N
. . N

In IN N
group NN N
1 CD N
, , N
15 CD i
ml VBD i
2 CD i
% NN i
Lidoca?ne NNP i
gel NN i
was VBD i
administered VBN i
intra-rectally RB N
10 CD N
minutes NNS N
prior RB N
to TO N
biopsies NNS N
and CC N
patients NNS N
included VBD N
in IN N
group NN N
2 CD N
received VBD N
10 CD N
ml NN N
of IN N
1 CD i
% NN i
Lidoca?ne NNP i
in IN i
two CD i
p?riprostatique JJ i
equivalent JJ i
injections NNS i
, , i
4 CD i
minutes NNS i
prior RB N
to TO N
prostate VB N
biopsies NNS N
. . N

Pain NN N
was VBD N
assessed VBN N
with IN N
a DT o
Visual JJ o
Analog NNP o
Scale NNP o
, , o
during IN o
anaesthesia NN N
( ( N
VAS NNP N
1 CD N
) ) N
, , N
during IN N
the DT N
biopsies NNS N
procedure NN N
( ( N
VAS NNP N
2 CD N
) ) N
and CC N
30 CD N
minutes NNS N
after IN N
them PRP N
( ( N
VAS NNP N
3 CD N
) ) N
. . N

RESULTS $ p
308 CD p
patients NNS p
were VBD p
included VBN p
in IN p
this DT p
trial NN p
with IN p
156 CD p
patients NNS p
in IN p
group NN p
1 CD p
and CC p
152 CD p
in IN p
group NN p
2 CD p
. . p

Group NNP p
1 CD N
experienced VBD N
statistically RB N
less JJR N
pain NN N
for IN o
VAS NNP o
1 CD o
( ( o
0.1 CD o
versus NN N
1.4 CD N
, , N
p NN N
< NNP N
0.0001 CD o
) ) o
and CC o
VAS $ o
3 CD o
( ( o
0.8 CD o
versus NN N
1.4 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
but CC N
no DT N
significative JJ N
difference NN N
could MD N
be VB N
demonstrated VBN o
for IN o
VAS NNP o
2 CD o
( ( o
1.8 CD o
versus IN N
2.0 CD N
) ) N
. . N

No DT o
major JJ o
complication NN o
was VBD o
noted VBN N
. . N

CONCLUSION NNP N
Rectal NNP N
administration NN i
of IN i
Lidoca?ne NNP i
gel NN i
and CC i
infiltration NN i
of IN i
Lidoca?ne NNP i
lead NN i
to TO i
a DT N
comparable JJ N
level NN N
of IN N
anaesthesia NN N
during IN N
prostatic JJ N
biopsies NNS N
procedure NN N
. . N

However RB N
, , i
the DT i
Lidoca?ne NNP i
gel NN i
, , i
being VBG i
both DT N
safe JJ N
and CC N
simple JJ N
, , N
tends VBZ N
to TO N
maintain VB N
a DT N
better JJR N
comfort NN N
of IN N
the DT N
patient NN N
30 CD N
minutes NNS N
after IN N
the DT N
end NN N
of IN N
the DT N
biopsies NNS N
. . N

-DOCSTART- -10097996- O O

The DT N
TOM NNP i
test NN i
: : i
a DT N
new JJ N
instrument NN N
for IN N
assessing VBG p
theory NN p
of IN p
mind NN p
in IN p
normal JJ p
children NNS p
and CC p
children NNS p
with IN p
pervasive JJ p
developmental NN p
disorders NNS p
. . p

This DT N
article NN N
describes VBZ N
a DT N
first JJ N
attempt NN N
to TO N
investigate VB N
the DT N
reliability NN N
and CC N
validity NN N
of IN N
the DT N
TOM NNP o
test NN o
, , N
a DT N
new JJ N
instrument NN N
for IN N
assessing VBG N
theory NN N
of IN N
mind NN N
ability NN N
in IN N
normal JJ p
children NNS p
and CC p
children NNS p
with IN p
pervasive JJ p
developmental NN p
disorders NNS p
( ( p
PDDs NNP p
) ) p
. . p

In IN N
Study NNP N
1 CD N
, , N
TOM NNP i
test NN i
scores NNS N
of IN N
normal JJ p
children NNS p
( ( p
n JJ p
= NNP p
70 CD p
) ) p
correlated VBD N
positively RB N
with IN N
their PRP$ N
performance NN N
on IN N
other JJ N
theory NN N
of IN N
mind NN N
tasks NNS N
. . N

Furthermore NNP N
, , N
young JJ p
children NNS p
only RB N
succeeded VBD N
on IN N
TOM NNP N
items NNS N
that WDT N
tap VBP N
the DT N
basic JJ N
domains NNS N
of IN N
theory NN N
of IN N
mind NN N
( ( N
e.g. JJ N
, , N
emotion JJ N
recognition NN N
) ) N
, , N
whereas JJ N
older JJR p
children NNS p
also RB N
passed VBD N
items NNS N
that WDT N
measure VBP N
the DT N
more JJR N
mature JJ N
areas NNS N
of IN N
theory NN N
of IN N
mind NN N
( ( N
e.g. JJ N
, , N
understanding NN N
of IN N
humor NN N
, , N
understanding VBG N
of IN N
second-order JJ N
beliefs NNS N
) ) N
. . N

Taken VBN N
together RB N
, , N
the DT N
findings NNS N
of IN N
Study NNP N
1 CD N
suggest NN N
that IN N
the DT N
TOM NNP o
test NN o
is VBZ N
a DT N
valid JJ N
measure NN N
. . N

Study NNP N
2 CD N
showed VBD N
for IN N
a DT N
separate JJ N
sample NN N
of IN N
normal JJ p
children NNS p
( ( p
n JJ p
= NNP p
12 CD p
) ) p
that IN N
the DT N
TOM NNP o
test NN o
possesses VBZ N
sufficient JJ N
test-retest JJ N
stability NN N
. . N

Study NNP N
3 CD N
demonstrated VBD N
for IN N
a DT N
sample NN p
of IN p
children NNS p
with IN p
PDDs NNP p
( ( p
n JJ p
= NNP p
10 CD p
) ) p
that IN N
the DT N
interrater NN o
reliability NN o
of IN N
the DT N
TOM NNP o
test NN o
is VBZ N
good JJ N
. . N

Study VB N
4 CD N
found NN N
that IN N
children NNS p
with IN p
PDDs NNP p
( ( p
n JJ p
= NNP p
20 CD p
) ) p
had VBD N
significantly RB N
lower JJR N
TOM NNP o
test NN o
scores NNS o
than IN N
children NNS p
with IN p
other JJ p
psychiatric JJ p
disorders NNS p
( ( p
e.g. NN p
, , N
children NNS p
with IN p
Attention-deficit NNP p
Hyperactivity NNP p
Disorder NNP p
; : p
n CC p
= VB p
32 CD p
) ) p
, , N
a DT N
finding NN N
that WDT N
underlines VBZ N
the DT N
discriminant JJ N
validity NN N
of IN N
the DT N
TOM NNP i
test NN i
. . i

Furthermore RB N
, , N
Study NNP N
4 CD N
showed VBD N
that DT N
intelligence NN o
as IN N
indexed VBN N
by IN N
the DT N
Wechsler NNP o
Intelligence NNP o
Scale NNP o
for IN o
Children NNP o
was VBD N
positively RB N
associated VBN N
with IN N
TOM NNP o
test NN o
scores NNS o
. . o

Finally RB N
, , N
in IN N
all DT N
studies NNS N
, , N
the DT N
TOM NNP o
test NN o
was VBD N
found VBN N
to TO N
be VB N
reliable JJ N
in IN N
terms NNS N
of IN N
internal JJ N
consistency NN N
. . N

Altogether RB N
, , N
results NNS N
indicate VBP N
that IN N
the DT N
TOM NNP i
test NN i
is VBZ N
a DT N
reliable JJ N
and CC N
valid JJ N
instrument NN N
that WDT N
can MD N
be VB N
employed VBN N
to TO N
measure VB N
various JJ N
aspects NNS N
of IN N
theory NN N
of IN N
mind NN N
. . N

-DOCSTART- -1937073- O O

Evaluation NN N
of IN N
electrofunctional JJ N
data NNS N
following VBG N
argon-laser NN i
trabeculoplasty NN i
in IN N
primary JJ N
open-angle JJ N
glaucoma NN N
. . N

To TO N
establish VB N
whether IN N
or CC N
not RB N
glaucomatous JJ o
damage NN o
is VBZ N
reversible JJ N
, , N
we PRP N
obtained VBD N
pattern-reversal JJ o
electroretinograms NNS o
( ( o
PERGs NNP o
) ) o
and CC o
visual JJ o
evoked VBN o
potentials NNS o
( ( o
VEPs NNP o
) ) o
in IN N
25 CD p
eyes NNS p
of IN p
25 CD p
patients NNS p
suffering VBG p
from IN p
bilateral JJ p
primary JJ p
open-angle JJ p
glaucoma NN p
( ( p
POAG NNP p
) ) p
before IN p
and CC p
after IN p
argon-laser JJ i
trabeculoplasty NN i
. . i

The DT N
laser NN N
treatment NN N
was VBD N
carried VBN N
out RP N
in IN N
only RB N
one CD N
eye NN N
chosen VBN N
at IN N
random NN N
, , N
and CC N
the DT N
fellow JJ N
eye NN N
was VBD N
used VBN N
as IN N
a DT N
control NN N
. . N

In IN N
the DT N
present JJ N
study NN N
we PRP N
intended VBD N
to TO N
verify VB N
the DT N
possibility NN N
of IN N
using VBG N
electrofunctional JJ N
techniques NNS N
to TO N
determine VB N
the DT N
two CD N
distinct NN N
and CC N
, , N
probably RB N
, , N
consecutive JJ N
glaucomatous JJ o
alterations NNS o
occurring VBG o
in IN o
ganglion NN o
cells NNS o
: : o
functional JJ o
( ( o
reversible JJ o
) ) o
and CC o
anatomical JJ o
( ( o
irreversible JJ o
) ) o
. . o

The DT N
results NNS N
obtained VBD N
indicate VBP N
that IN N
glaucomatous JJ o
damage NN o
is VBZ N
irreversible JJ N
. . N

We PRP N
propose VBP N
that IN N
such JJ N
alterations NNS N
differ VBP N
very RB N
slightly RB N
and CC N
that IN N
the DT N
current JJ N
electrofunctional JJ N
techniques NNS N
may MD N
not RB N
be VB N
sufficiently RB N
sophisticated JJ N
to TO N
distinguish VB N
between IN N
them PRP N
. . N

-DOCSTART- -22438600- O O

Comparison NNP N
of IN N
active-learning JJ i
strategies NNS i
for IN N
motivational JJ o
interviewing NN o
skills NNS o
, , o
knowledge NN o
, , o
and CC o
confidence NN o
in IN N
first-year JJ p
pharmacy NN p
students NNS p
. . p

OBJECTIVE NNP N
To TO N
compare VB N
3 CD N
strategies NNS N
for IN N
pharmacy NN p
student NN p
learning NN N
of IN N
motivational JJ N
interviewing NN N
skills NNS o
, , o
knowledge NN o
of IN N
motivational JJ N
interviewing NN N
principles NNS N
, , N
and CC N
confidence NN o
in IN N
and CC N
attitudes NNS o
toward IN N
their PRP$ N
application NN N
. . N

DESIGN NNP N
Following VBG N
a DT N
motivational JJ i
interviewing NN i
lecture NN i
, , N
first-year JJ p
students NNS p
were VBD N
randomized VBN N
to TO N
perform VB N
practice NN i
activities NNS i
( ( i
written VBN i
dialogue NN i
, , i
peer VB i
role-play NN i
, , i
or CC i
mock-patient JJ i
counseling NN i
activities NNS i
) ) i
. . N

Motivational JJ o
interviewing NN o
skills NNS o
, , o
knowledge NN o
, , o
confidence NN o
, , o
and CC o
attitudes NNS o
were VBD N
measured VBN N
. . N

ASSESSMENT NNP N
All NNP N
students NNS N
demonstrated VBD N
improvement NN N
in IN N
skills NNS o
, , o
knowledge NN o
, , o
and CC o
confidence NN o
. . o

Students NNS p
in IN N
the DT N
mock-patient JJ i
counseling NN i
group NN N
demonstrated VBD N
significantly RB N
better RBR N
motivational JJ N
interviewing NN N
skills NNS o
during IN N
practice NN N
and CC N
trended VBD N
toward IN N
higher JJR N
scores NNS N
on IN N
the DT N
summative JJ N
evaluation NN N
. . N

They PRP N
also RB N
demonstrated VBD N
a DT N
significant JJ N
improvement NN N
in IN N
knowledge NN o
compared VBN N
with IN N
that DT N
of IN N
the DT N
written VBN N
dialogue NN N
group NN N
during IN N
practice NN N
. . N

Feedback NN N
at IN N
the DT N
end NN N
was VBD N
generally RB N
positive JJ N
, , N
with IN N
students NNS p
expressing VBG N
recognition NN o
for IN o
the DT o
value NN o
of IN o
motivational JJ o
interviewing NN o
. . o

CONCLUSIONS JJ N
Students NNS N
demonstrated VBD N
their PRP$ N
best JJS N
performance NN N
of IN N
motivational JJ o
interviewing NN o
during IN N
assessments NNS N
using VBG N
interactions NNS N
with IN N
mock NN N
or CC N
standardized JJ N
patients NNS N
. . N

-DOCSTART- -19595104- O O

[ JJ N
Clinical NNP N
effect NN N
of IN N
transcatheter NN i
arterial JJ i
chemoembolization NN i
combined VBN N
with IN N
high JJ i
intensity NN i
focused VBD i
ultrasound JJ i
ablation NN i
in IN N
treatment NN N
of IN N
large JJ p
hepatocellular JJ p
carcinoma NN p
] NNP p
. . N

OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
clinical JJ N
effect NN N
of IN N
transcatheter NN i
arterial JJ i
chemoembolization NN i
( ( i
TACE NNP i
) ) i
combined VBN N
with IN N
high JJ i
intensity NN i
focused VBN i
ultrasound NN i
( ( i
HIFU NNP i
) ) i
ablation NN N
in IN N
treatment NN N
of IN N
large JJ N
hepatocellular JJ p
carcinoma NN p
( ( p
HCC NNP p
) ) p
. . p

METHODS NNP N
Sixty-eight JJ p
patients NNS p
with IN p
unresectable JJ p
HCC NNP p
were VBD N
randomized VBN N
into IN N
2 CD i
age NN i
, , i
tumor NN i
size NN i
, , i
TNM NNP i
stages VBZ i
, , i
and CC i
liver JJ i
function NN i
grade-matched JJ i
groups NNS i
: : i
TACE NNP i
group NN i
( ( i
n=30 RB i
) ) i
undergoing VBG i
TACE NNP i
and CC i
TACE+HIFU NNP i
group NN i
( ( i
n=38 RB i
) ) i
undergoing VBG i
2-3 JJ i
weeks NNS i
after IN i
TACE NNP i
. . i

A NNP N
total NN N
of IN N
88 CD N
tumors NNS N
( ( N
9.3+/-3.2 CD N
) ) N
( ( N
5.0-14.5 JJ N
) ) N
cm NN N
in IN N
diameter NN N
were VBD N
detected VBN N
, , N
and CC N
the DT N
largest JJS N
tumor NN N
in IN N
a DT N
specific JJ N
patients NNS p
with IN p
multiple JJ p
lesions NNS p
was VBD N
selected VBN N
for IN N
observation NN N
. . N

Follow-up NNP N
was VBD N
conducted VBN N
for IN N
( ( N
13+/-7 JJ N
) ) N
( ( N
3-24 JJ N
) ) N
months NNS N
to TO N
observe VB N
the DT N
necrosis NN o
of IN o
tumor NN o
, , o
size NN o
of IN o
tumor NN o
, , o
local JJ o
recurrence NN o
, , N
and CC N
survival NN o
of IN o
patient NN o
. . o

RESULTS VB N
The DT N
clinical JJ o
symptom JJ o
remission NN o
rate NN o
was VBD N
90.6 CD N
% NN N
( ( N
29/32 CD N
) ) N
in IN N
the DT N
TACE+HIFU NNP i
group NN N
and CC N
70.8 CD N
% NN N
( ( N
28/38 CD N
) ) N
in IN N
the DT N
TACE NNP N
group NN N
. . N

The DT N
tumor NN o
necrosis NN o
and CC o
minification NN o
rates NNS o
of IN N
the DT N
TACE+HIFU NNP i
and CC N
TACE NNP i
groups NNS N
were VBD N
73.7 CD N
% NN N
and CC N
68.4 CD N
% NN N
respectively RB N
, , N
both DT N
significantly RB N
higher JJR N
than IN N
those DT N
of IN N
TACE NNP i
group NN N
( ( N
26.7 CD N
% NN N
and CC N
33.3 CD N
% NN N
respectively RB N
, , N
both DT N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
tumor NN o
local JJ o
recurrence NN o
rate NN o
of IN N
the DT N
TACE+HIFU NNP i
group NN N
was VBD N
21.1 CD N
% NN N
, , N
not RB N
significantly RB N
different JJ N
from IN N
that DT N
of IN N
the DT N
TACE NNP i
group NN N
( ( N
33.3 CD N
% NN N
, , N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

The DT N
median JJ o
survival NN o
duration NN o
of IN N
the DT N
TACE+HIFU NNP i
group NN N
was VBD N
18 CD N
months NNS N
, , N
significantly RB N
longer JJR N
than IN N
that DT N
of IN N
the DT N
TACE NNP i
group NN N
( ( N
10 CD N
months NNS N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
Compared NNP N
with IN N
the DT N
TACE NNP i
therapy NN N
alone RB N
, , N
the DT N
combination NN N
therapy NN N
improves VBZ N
the DT N
tumor NN o
necrosis NN o
rate NN o
and CC N
prolongs VBZ N
the DT N
patients NNS o
' POS o
survival JJ o
duration NN o
. . o

-DOCSTART- -20605942- O O

Types NNS N
of IN N
parent NN i
verbal JJ i
responsiveness NN i
that WDT N
predict VBP N
language NN N
in IN N
young JJ p
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

PURPOSE VB N
This DT N
study NN N
examined VBD N
short-term JJ N
predictive JJ N
associations NNS N
between IN N
5 CD N
different JJ N
types NNS N
of IN N
parent NN i
verbal JJ i
responsiveness NN i
and CC N
later RB N
spoken JJ N
vocabulary NN N
for IN N
32 CD p
young JJ p
children NNS p
with IN p
a DT p
confirmed JJ p
diagnosis NN p
of IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
. . p

METHOD NNP N
Parent NNP i
verbal JJ i
utterances NNS i
were VBD N
coded VBN N
from IN N
videotapes NNS i
of IN i
naturalistic JJ i
parent-child JJ i
play NN i
sessions NNS i
using VBG N
interval JJ i
and CC N
event-based JJ i
coding NN i
. . i

A DT N
vocabulary JJ o
difference NN o
score NN o
, , N
calculated VBD N
using VBG N
the DT N
MacArthur NNP N
Communicative NNP N
Development NNP N
Inventories NNP N
( ( N
L. NNP N
Fenson NNP N
et FW N
al. NN N
, , N
1993 CD N
) ) N
, , N
was VBD N
used VBN N
as IN N
the DT N
outcome NN N
measure NN N
of IN N
spoken JJ N
vocabulary JJ N
6 CD N
months NNS N
later RB N
. . N

RESULTS VB N
Parent JJ N
follow-in JJ N
comments NNS N
and CC N
follow-in JJ N
directives NNS N
predicted VBD N
spoken JJ N
vocabulary JJ N
after IN N
controlling VBG N
for IN N
child JJ N
engagement NN N
. . N

Parent NNP o
expansions NNS o
of IN o
child NN o
verbal JJ o
utterances NNS o
predicted VBD N
spoken JJ o
vocabulary JJ o
after IN N
controlling VBG N
for IN N
child NN N
talkativeness NN N
. . N

When WRB N
entered VBN N
together RB N
into IN N
a DT N
regression NN N
analysis NN N
, , N
metrics NNS N
that IN N
represented VBD N
( ( N
a DT N
) ) N
the DT o
number NN o
of IN o
parent NN o
utterances NNS o
following VBG o
into IN o
the DT o
child NN o
's POS o
focus NN o
of IN o
attention NN o
and CC N
( ( N
b NN N
) ) N
the DT o
number NN o
of IN o
parent NN o
utterances NNS o
responding VBG o
to TO o
child VB o
verbal JJ o
communication NN o
acts NNS N
both DT N
accounted VBD N
for IN N
unique JJ N
variance NN N
in IN N
predicting VBG N
change NN N
in IN N
spoken JJ o
vocabulary NN o
from IN N
Time NNP N
1 CD N
to TO N
Time NNP N
2 CD N
. . N

CONCLUSION NNP N
Parent NNP i
verbal JJ i
utterances NNS i
that WDT N
follow VBP N
into IN N
the DT N
child NN N
's POS N
current JJ N
focus NN N
of IN N
attention NN N
or CC N
respond NN N
to TO N
child VB N
verbal JJ N
communication NN N
acts NNS N
may MD N
facilitate VB N
the DT N
process NN N
of IN N
early JJ N
vocabulary JJ N
acquisition NN N
by IN N
mitigating VBG N
the DT N
need NN N
for IN N
children NNS p
with IN p
ASD NNP p
to TO N
use VB N
attention-following JJ N
as IN N
a DT N
word-learning JJ N
strategy NN N
. . N

-DOCSTART- -23972722- O O

Use NNP N
of IN N
EORTC NNP N
target NN N
definition NN N
guidelines NNS N
for IN N
dose-intensified JJ N
salvage NN N
radiation NN N
therapy NN N
for IN N
recurrent JJ N
prostate NN N
cancer NN N
: : N
results NNS N
of IN N
the DT N
quality NN N
assurance NN N
program NN N
of IN N
the DT N
randomized JJ N
trial NN N
SAKK NNP N
09/10 CD N
. . N

PURPOSE NNP N
Different NNP N
international JJ N
target NN N
volume NN N
delineation NN N
guidelines NNS N
exist VBP N
and CC N
different JJ N
treatment NN N
techniques NNS N
are VBP N
available JJ N
for IN N
salvage NN N
radiation NN N
therapy NN N
( ( N
RT NNP N
) ) N
for IN N
recurrent NN N
prostate NN N
cancer NN N
, , N
but CC N
less JJR N
is VBZ N
known VBN N
regarding VBG N
their PRP$ N
respective JJ N
applicability NN N
in IN N
clinical JJ N
practice NN N
. . N

METHODS NNP N
AND NNP N
MATERIALS NNP N
A NNP N
randomized JJ N
phase NN N
III NNP N
trial NN N
testing VBG N
64 CD i
Gy NNP i
vs NN i
70 CD i
Gy NNP i
salvage NN i
RT NNP i
was VBD N
accompanied VBN N
by IN N
an DT N
intense JJ i
quality NN i
assurance NN i
program NN i
including VBG N
a DT N
site-specific JJ N
and CC N
study-specific JJ N
questionnaire NN N
and CC N
a DT N
dummy JJ i
run NN i
( ( i
DR NNP i
) ) i
. . i

Target NN N
volume NN N
delineation NN N
was VBD N
performed VBN N
according VBG N
to TO N
the DT N
European JJ N
Organisation NN N
for IN N
the DT N
Research NNP N
and CC N
Treatment NNP N
of IN N
Cancer NNP N
guidelines NNS N
, , N
and CC N
a DT N
DR-based JJ N
treatment NN N
plan NN N
was VBD N
established VBN N
for IN N
70 CD N
Gy NNP N
. . N

Major NNP N
and CC N
minor JJ N
protocol NN N
deviations NNS N
were VBD N
noted VBN N
, , N
interobserver JJ N
agreement NN N
of IN N
delineated JJ N
target NN N
contours NN N
was VBD N
assessed VBN N
, , N
and CC N
dose-volume JJ N
histogram NN N
( ( N
DVH NNP N
) ) N
parameters NNS N
of IN N
different JJ N
treatment NN N
techniques NNS N
were VBD N
compared VBN N
. . N

RESULTS NNP N
Thirty NNP p
European JJ p
centers NNS p
participated VBD p
, , p
43 CD p
% NN p
of IN p
which WDT p
were VBD p
using VBG p
3-dimensional JJ i
conformal JJ i
RT NNP i
( ( i
3D-CRT JJ i
) ) i
, , p
with IN p
the DT p
remaining VBG p
centers NNS p
using VBG p
intensity NN i
modulated VBN i
RT NNP i
( ( i
IMRT NNP i
) ) i
or CC p
volumetric JJ i
modulated VBN i
arc NN i
technique NN i
( ( i
VMAT NNP i
) ) i
. . i

The DT N
first JJ N
submitted VBN N
version NN N
of IN N
the DT N
DR NNP N
contained VBD N
major JJ N
deviations NNS N
in IN N
21 CD N
of IN N
30 CD N
( ( N
70 CD N
% NN N
) ) N
centers NNS N
, , N
mostly RB N
caused VBN N
by IN N
inappropriately RB N
defined VBN N
or CC N
lack NN N
of IN N
prostate NN N
bed NN N
( ( N
PB NNP N
) ) N
. . N

All DT N
but CC N
5 CD p
centers NNS p
completed VBD p
the DT p
DR NNP p
successfully RB p
with IN N
their PRP$ N
second JJ N
submitted VBN N
version NN N
. . N

The DT N
interobserver JJ N
agreement NN N
of IN N
the DT N
PB NNP N
was VBD N
moderate JJ N
and CC N
was VBD N
improved VBN N
by IN N
the DT N
DR NNP N
review NN N
, , N
as IN N
indicated VBN N
by IN N
an DT N
increased VBN N
? . o
value NN o
( ( N
0.59 CD N
vs RB N
0.55 CD N
) ) N
, , N
mean JJ o
sensitivity NN o
( ( N
0.64 CD N
vs RB N
0.58 CD N
) ) N
, , N
volume NN o
of IN o
total JJ o
agreement NN o
( ( N
3.9 CD N
vs RB N
3.3 CD N
cm NN N
( ( N
3 CD N
) ) N
) ) N
, , N
and CC N
decrease NN N
in IN N
the DT o
union NN o
volume NN o
( ( N
79.3 CD N
vs RB N
84.2 CD N
cm NN N
( ( N
3 CD N
) ) N
) ) N
. . N

Rectal JJ o
and CC o
bladder VB o
wall NN o
DVH NNP o
parameters NNS o
of IN o
IMRT NNP o
and CC o
VMAT NNP o
vs VBP o
3D-CRT JJ o
plans NNS o
were VBD N
not RB N
significantly RB N
different JJ N
. . N

CONCLUSIONS VB N
The DT N
interobserver JJ N
agreement NN N
of IN N
PB NNP N
delineation NN N
was VBD N
moderate JJ N
but CC N
was VBD N
improved VBN N
by IN N
the DT N
DR. NNP N
Major NNP N
deviations NNS N
could MD N
be VB N
identified VBN N
for IN N
the DT N
majority NN N
of IN N
centers NNS N
. . N

The DT N
DR NNP N
has VBZ N
improved VBN N
the DT N
acquaintance NN N
of IN N
the DT N
participating VBG N
centers NNS N
with IN N
the DT N
trial NN N
protocol NN N
. . N

-DOCSTART- -25820842- O O

Serotonergic NNP i
psychedelics NNS i
temporarily RB N
modify VB N
information NN N
transfer NN N
in IN N
humans NNS p
. . p

BACKGROUND NNP N
Psychedelics NNPS i
induce VBP N
intense JJ N
modifications NNS N
in IN N
the DT N
sensorium NN N
, , N
the DT N
sense NN N
of IN N
self NN N
, , N
and CC N
the DT N
experience NN N
of IN N
reality NN N
. . N

Despite IN N
advances NNS N
in IN N
our PRP$ N
understanding NN N
of IN N
the DT N
molecular JJ N
and CC N
cellular JJ N
level NN N
mechanisms NNS N
of IN N
these DT N
drugs NNS N
, , N
knowledge NN N
of IN N
their PRP$ N
actions NNS N
on IN N
global JJ o
brain NN o
dynamics NNS o
is VBZ N
still RB N
incomplete JJ N
. . N

Recent JJ N
imaging VBG N
studies NNS N
have VBP N
found VBN N
changes NNS N
in IN N
functional JJ N
coupling NN N
between IN N
frontal JJ N
and CC N
parietal JJ N
brain NN N
structures NNS N
, , N
suggesting VBG N
a DT N
modification NN N
in IN N
information NN N
flow NN N
between IN N
brain NN N
regions NNS N
during IN N
acute JJ N
effects NNS N
. . N

METHODS NNP N
Here RB N
we PRP N
assessed VBD N
the DT N
psychedelic-induced JJ N
changes NNS o
in IN o
directionality NN o
of IN o
information NN o
flow NN o
during IN N
the DT N
acute JJ N
effects NNS N
of IN N
a DT N
psychedelic NN N
in IN N
humans NNS p
. . p

We PRP N
measured VBD N
modifications NNS N
in IN N
connectivity NN N
of IN N
brain NN o
oscillations NNS o
using VBG N
transfer NN N
entropy NN N
, , N
a DT N
nonlinear JJ N
measure NN N
of IN N
directed JJ N
functional JJ N
connectivity NN N
based VBN N
on IN N
information NN N
theory NN N
. . N

Ten CD p
healthy JJ p
male NN p
volunteers NNS p
with IN p
prior JJ p
experience NN p
with IN p
psychedelics NNS i
participated VBN N
in IN N
2 CD N
experimental JJ N
sessions NNS N
. . N

They PRP N
received VBD N
a DT N
placebo NN i
or CC i
a DT i
dose NN i
of IN i
ayahuasca NN i
, , i
a DT i
psychedelic JJ i
preparation NN i
containing VBG i
the DT i
serotonergic JJ i
5-HT2A JJ i
agonist NN i
N NNP i
, , i
N-dimethyltryptamine NNP i
. . i

RESULTS VB N
The DT N
analysis NN N
showed VBD N
significant JJ N
changes NNS o
in IN o
the DT o
coupling NN o
of IN o
brain NN o
oscillations NNS o
between IN N
anterior JJ N
and CC N
posterior JJ N
recording NN N
sites NNS N
. . N

Transfer VB N
entropy JJ N
analysis NN N
showed VBD N
that IN N
frontal JJ N
sources NNS N
decreased VBD N
their PRP$ N
influence NN N
over IN N
central JJ N
, , N
parietal JJ N
, , N
and CC N
occipital JJ N
sites NNS N
. . N

Conversely RB N
, , N
sources NNS N
in IN N
posterior JJ N
locations NNS N
increased VBD N
their PRP$ N
influence NN N
over IN N
signals NNS N
measured VBN N
at IN N
anterior JJ N
locations NNS N
. . N

Exploratory JJ N
correlations NNS N
found VBD N
that IN N
anterior-to-posterior JJ o
transfer NN o
entropy NN o
decreases NNS N
were VBD N
correlated VBN N
with IN N
the DT N
intensity NN N
of IN N
subjective JJ N
effects NNS N
, , N
while IN N
the DT N
imbalance NN N
between IN N
anterior-to-posterior JJ o
and CC N
posterior-to-anterior JJ o
transfer NN o
entropy NN o
correlated VBN N
with IN N
the DT N
degree NN N
of IN N
incapacitation NN N
experienced VBN N
. . N

CONCLUSIONS NNP N
These DT N
results NNS N
suggest VBP N
that IN N
psychedelics NNS i
induce VBP N
a DT N
temporary JJ o
disruption NN o
of IN N
neural JJ o
hierarchies NNS o
by IN N
reducing VBG N
top-down JJ N
control NN N
and CC N
increasing VBG N
bottom-up JJ N
information NN N
transfer NN N
in IN N
the DT N
human JJ p
brain NN N
. . N

-DOCSTART- -18779477- O O

Treatment NN N
of IN N
posterior JJ p
uveitis NN p
with IN N
a DT N
fluocinolone NN i
acetonide NN i
implant NN i
: : i
three-year JJ N
clinical JJ N
trial NN N
results NNS N
. . N

OBJECTIVES NNP N
To TO N
evaluate VB N
the DT N
safety NN o
and CC o
efficacy NN o
of IN N
0.59-mg JJ N
and CC N
2.1-mg JJ N
fluocinolone NN i
acetonide NN i
( ( N
FA NNP N
) ) N
intravitreous JJ N
implants NNS N
in IN N
noninfectious JJ p
posterior JJ p
uveitis NN p
. . p

DESIGN VB N
A DT N
3-year JJ N
, , N
multicenter NN N
, , N
randomized VBN N
, , N
historically RB N
controlled VBN N
trial NN N
of IN N
the DT N
0.59-mg JJ i
FA NNP i
intravitreous JJ i
implant NN i
in IN p
110 CD p
patients NNS p
and CC p
the DT p
2.1-mg JJ p
FA NNP p
intravitreous JJ p
implant NN p
in IN p
168 CD p
patients NNS p
. . p

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Recurrence NNP o
rate NN o
, , o
vision NN o
, , o
and CC o
complications NNS o
. . o

RESULTS NNP N
Uveitis NNP o
recurrence NN o
was VBD o
reduced VBN o
in IN N
implanted JJ N
eyes NNS N
from IN N
62 CD N
% NN N
( ( N
during IN N
the DT N
1-year JJ N
preimplantation NN N
period NN N
) ) N
to TO N
4 CD N
% NN N
, , N
10 CD N
% NN N
, , N
and CC N
20 CD N
% NN N
during IN N
the DT N
1- JJ N
, , N
2- JJ N
, , N
and CC N
3-year JJ N
postimplantation NN N
periods NNS N
, , N
respectively RB N
, , N
for IN N
the DT N
0.59-mg JJ N
dose NN N
group NN N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
and CC N
from IN N
58 CD N
% NN N
to TO N
7 CD N
% NN N
, , N
17 CD N
% NN N
, , N
and CC N
41 CD N
% NN N
, , N
respectively RB N
, , N
for IN N
the DT N
2.1-mg JJ N
dose NN N
group NN N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
. . N

More RBR N
implanted JJ N
eyes NNS N
than IN N
nonimplanted JJ N
eyes NNS N
had VBD N
improved VBN o
visual JJ o
acuity NN o
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
. . N

Implanted VBN o
eyes NNS o
had VBD o
higher JJR o
incidences NNS o
of IN o
intraocular JJ o
pressure NN o
elevation NN o
( ( N
> CD N
or CC N
= VB N
10 CD N
mm NNS N
Hg NNP N
) ) N
than IN N
nonimplanted VBN N
eyes NNS N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
, , N
and CC N
glaucoma NN o
surgery NN o
was VBD N
required VBN N
in IN N
40 CD N
% NN N
of IN N
implanted JJ N
eyes NNS N
vs VBP N
2 CD N
% NN N
of IN N
nonimplanted JJ N
eyes NNS N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
. . N

Cataracts NNPS o
were VBD N
extracted VBN N
in IN N
93 CD N
% NN N
of IN N
phakic NN N
implanted VBN N
eyes NNS N
vs VBP N
20 CD N
% NN N
of IN N
phakic NN N
nonimplanted VBN N
eyes NNS N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
. . N

CONCLUSIONS VB N
The DT N
FA NNP N
implant NN N
significantly RB N
reduced VBN o
uveitis JJ o
recurrence NN o
and CC o
improved VBD o
or CC o
stabilized VBN o
visual JJ o
acuity NN o
in IN N
subjects NNS p
with IN p
noninfectious JJ p
posterior JJ p
uveitis NN p
. . p

Most JJS N
subjects NNS N
required VBN N
cataract JJ o
extraction NN o
, , N
and CC N
a DT N
significant JJ N
proportion NN N
required VBN N
intraocular JJ o
pressure-lowering JJ o
surgery NN o
. . o

APPLICATION NNP N
TO NNP N
CLINICAL NNP N
PRACTICE NNP N
The DT N
FA NNP N
implant NN N
provides VBZ N
an DT N
alternative JJ N
therapy NN N
for IN N
prolonged JJ N
control NN N
of IN N
inflammation NN N
in IN N
noninfectious JJ N
posterior JJ N
uveitis NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
clinicaltrials.gov NN N
Identifier NNP N
: : N
NCT00407082 NN N
. . N

-DOCSTART- -2564725- O O

Esmolol NNP i
versus NN N
verapamil NN i
in IN N
the DT N
acute JJ N
treatment NN N
of IN N
atrial JJ p
fibrillation NN p
or CC p
atrial JJ p
flutter NN p
. . p

The DT N
effects NNS N
of IN N
esmolol NN i
, , N
an DT N
ultrashort-acting JJ N
beta NN N
blocker NN N
, , N
and CC N
verapamil NN i
were VBD N
compared VBN N
in IN N
controlling VBG N
ventricular JJ o
response NN o
in IN N
45 CD p
patients NNS p
with IN p
atrial JJ p
fibrillation NN p
or CC p
atrial JJ p
flutter NN p
, , p
in IN p
a DT p
randomized JJ p
, , p
parallel JJ p
, , p
open-label JJ p
study NN p
. . p

Patients NNS p
with IN p
either DT p
new JJ p
onset NN p
( ( p
less JJR p
than IN p
48 CD p
hours NNS p
, , p
n JJ p
= NNP p
31 CD p
) ) p
or CC p
old JJ p
onset NN p
( ( p
greater JJR p
than IN p
48 CD p
hours NNS p
, , p
n JJ p
= NNP p
14 CD p
) ) p
of IN p
atrial JJ p
fibrillation NN p
or CC p
flutter NN p
with IN p
rapid JJ p
ventricular JJ p
rate NN p
were VBD p
stratified VBN p
to TO N
receive VB N
esmolol NN i
( ( N
n JJ N
= NNP N
21 CD N
) ) N
or CC N
verapamil NN i
( ( N
n JJ N
= NNP N
24 CD N
) ) N
. . N

Drug NNP o
efficacy NN o
was VBD N
measured VBN N
by IN N
ventricular JJ o
rate NN o
reduction NN o
and CC N
conversion NN o
to TO o
sinus VB o
rhythm NN o
. . o

The DT N
heart NN o
rate NN o
declined VBD N
with IN N
esmolol NN i
from IN N
139 CD N
to TO N
100 CD N
beats/min NN N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
and CC N
with IN N
verapamil NN i
from IN N
142 CD N
to TO N
97 CD N
beats/min NN N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

Fifty NNP N
percent NN N
of IN N
esmolol-treated JJ i
patients NNS N
with IN N
new JJ N
onset NN N
of IN N
arrhythmias NNS N
converted VBN o
to TO o
sinus VB o
rhythm NN o
, , N
whereas IN N
only RB N
12 CD N
% NN N
of IN N
those DT N
who WP N
received VBD N
verapamil RB i
converted VBN N
( ( N
p NN N
less JJR N
than IN N
0.03 CD N
) ) N
. . N

Mild NNP o
hypotension NN o
was VBD N
observed VBN N
in IN N
both DT N
treatment NN N
groups NNS N
. . N

Esmolol NNP i
compares VBZ N
favorably RB N
with IN N
verapamil NN i
with IN N
respect NN N
to TO N
both DT N
efficacy NN o
and CC o
safety NN o
in IN N
acutely RB o
decreasing VBG o
ventricular JJ o
response NN o
during IN N
atrial JJ N
fibrillation NN N
or CC N
flutter NN N
. . N

Moreover RB N
, , N
conversion NN o
to TO o
sinus VB o
rhythm NN o
is VBZ N
significantly RB N
more RBR N
likely JJ N
with IN N
esmolol NN i
. . i

-DOCSTART- -21996342- O O

Epicutaneous JJ N
allergen-specific JJ i
immunotherapy NN i
ameliorates VBZ N
grass JJ N
pollen-induced JJ N
rhinoconjunctivitis NN N
: : N
A DT N
double-blind NN N
, , N
placebo-controlled JJ N
dose NN N
escalation NN N
study NN N
. . N

BACKGROUND NNP N
Epicutaneous NNP i
allergen NN i
administration NN N
using VBG N
a DT N
patch NN N
may MD N
be VB N
an DT N
alternative JJ N
to TO N
subcutaneous JJ N
or CC N
sublingual JJ N
immunotherapy NN N
. . N

OBJECTIVE UH N
To TO N
optimize VB N
treatment NN N
dose NN N
and CC N
to TO N
demonstrate VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
epicutaneous JJ N
immunotherapy NN N
. . N

METHODS NNP N
This DT N
monocentric JJ N
, , N
placebo-controlled JJ N
, , N
double-blind JJ N
trial NN N
included VBD p
132 CD p
patients NNS p
with IN p
grass JJ p
pollen-induced JJ p
rhinoconjunctivitis NN p
. . p

In IN N
February NNP N
2008 CD N
, , N
patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB i
placebo NN i
or CC i
3 CD i
different JJ i
doses NNS i
of IN i
allergen NN i
. . i

Before IN N
and CC N
during IN N
the DT N
pollen NN N
season NN N
2008 CD N
, , N
patients NNS p
received VBD p
6 CD p
weekly JJ p
patches NNS p
. . p

Efficacy NN N
was VBD N
assessed VBN N
4 CD N
to TO N
5 CD N
months NNS N
later RB N
( ( N
n JJ N
= NNP N
110 CD N
) ) N
and CC N
during IN N
the DT N
pollen NN N
season NN N
of IN N
the DT N
treatment-free JJ N
follow-up JJ N
year NN N
in IN N
2009 CD N
( ( N
n JJ N
= NNP N
93 CD N
) ) N
. . N

The DT N
primary JJ N
outcome NN N
was VBD o
patient-reported JJ o
changes NNS o
in IN o
hay NN o
fever NN o
symptoms NNS o
assessed VBN o
by IN o
a DT o
visual JJ o
analog NN o
scale NN o
. . o

Secondary JJ N
outcome NN N
measures NNS N
were VBD o
weekly JJ o
visual JJ o
analog NN o
scale JJ o
symptom NN o
scores NNS o
during IN o
pollen NN o
season NN o
, , o
use NN o
of IN o
rescue NN o
medication NN o
, , o
changes NNS o
in IN o
conjunctival NN o
and CC o
skin NN o
reactivity NN o
, , o
as RB o
well RB o
as IN o
safety NN o
. . o

RESULTS NNP o
Hay NNP o
fever NN o
symptoms NNS o
during IN o
the DT o
pollen NN o
season NN o
were VBD N
reduced VBN N
by IN N
more JJR N
than IN N
30 CD N
% NN N
in IN N
2008 CD N
and CC N
by IN N
24 CD N
% NN N
in IN N
2009 CD N
in IN N
the DT N
high-dose JJ N
group NN N
as IN N
compared VBN N
with IN N
that DT N
in IN N
the DT N
placebo NN N
group NN N
, , N
and CC N
the DT N
alleviation NN N
of IN N
symptoms NNS N
in IN N
the DT N
follow-up JJ N
year NN N
was VBD N
dependent JJ N
on IN N
the DT N
treatment NN N
dose NN N
. . N

Higher JJR N
allergen NN N
doses NNS N
were VBD N
associated VBN N
with IN o
drug-related JJ o
adverse JJ o
events NNS o
( ( o
AEs NNP o
) ) o
, , o
predominantly RB N
manifested VBN N
by IN o
pruritus NN o
, , o
erythema NN o
, , o
wheal NN o
, , o
or CC o
eczema NN o
. . o

Eleven NNP N
systemic JJ o
AEs NNP o
of IN N
grades NNS N
1 CD N
to TO N
2 CD N
required VBN N
treatment NN N
and CC N
led VBD N
to TO N
study VB N
exclusion NN N
. . N

The DT o
dropout NN o
rate NN o
due JJ N
to TO o
AEs NNP o
was VBD N
8.3 CD N
% NN N
. . N

No DT N
drug-related JJ N
serious JJ o
AE NNP o
was VBD N
recorded VBN N
. . N

CONCLUSION NNP N
Epicutaneous NNP i
immunotherapy NN i
is VBZ N
safe JJ N
and CC N
efficacious JJ N
in IN N
a DT N
dose-dependent JJ N
manner NN N
after IN N
6 CD N
patches NNS N
only RB N
. . N

-DOCSTART- -23890774- O O

Effects NNS N
of IN N
Positive NNP i
Action NNP i
on IN N
the DT N
emotional JJ N
health NN N
of IN N
urban JJ p
youth NN p
: : p
a DT N
cluster-randomized JJ N
trial NN N
. . N

PURPOSE NNP N
We PRP N
examined VBD N
the DT N
effects NNS N
of IN N
Positive JJ i
Action NNP i
( ( i
PA NNP i
) ) i
, , N
a DT N
school-based JJ i
social-emotional JJ i
learning NN i
and CC i
health NN i
promotion NN i
program NN i
, , N
on IN N
the DT N
emotional JJ N
health NN N
of IN N
predominately RB p
low-income JJ p
and CC p
ethnic JJ p
minority NN p
urban JJ p
youth NN p
. . p

METHODS NNP N
The DT N
study NN N
was VBD N
a DT N
matched-pair JJ N
, , N
cluster-randomized JJ N
controlled VBN N
trial NN N
involving VBG N
14 CD p
Chicago NNP p
public JJ p
schools NNS p
. . p

Outcomes NNS N
were VBD N
assessed VBN N
over IN N
a DT N
6-year JJ p
period NN p
of IN p
program NN p
implementation NN p
for IN p
a DT p
cohort NN p
of IN p
youth NN p
in IN p
each DT p
school NN p
, , p
followed VBD p
from IN p
grades NNS p
3 CD p
to TO p
8 CD p
. . p

Youth NN N
reported VBD N
on IN N
their PRP$ N
emotional JJ N
health NN N
( ( N
positive JJ N
affect NN N
, , N
life NN N
satisfaction NN N
, , N
depression NN N
, , N
anxiety NN N
) ) N
and CC N
social-emotional JJ N
and CC N
character NN N
development NN N
. . N

Growth-curve NNP N
and CC N
structural-equation NN N
modeling NN N
analyses NNS N
assessed VBD N
overall JJ N
program NN N
effects NNS N
on IN N
the DT N
emotional JJ N
health NN N
outcomes NNS N
as RB N
well RB N
as IN N
mediation NN N
of IN N
these DT N
effects NNS N
via IN N
the DT N
program NN N
's POS N
impact NN N
on IN N
youths NNS N
' POS N
social-emotional JJ N
and CC N
character NN N
development NN N
. . N

RESULTS JJ N
Students NNS N
in IN N
PA NNP i
schools NNS N
, , N
compared VBN N
with IN N
those DT N
in IN N
control NN i
schools NNS N
, , N
had VBD N
more RBR N
favorable JJ N
change NN N
over IN N
the DT N
course NN N
of IN N
the DT N
study NN N
in IN N
positive JJ N
affect NN N
( ( N
standardized JJ N
mean NN N
difference NN N
effect NN N
size NN N
[ NNP N
ES NNP N
] NNP N
= NNP N
.17 NNP N
) ) N
and CC o
life NN o
satisfaction NN o
( ( N
ES NNP N
= NNP N
.13 NNP N
) ) N
as RB N
well RB N
as IN N
significantly RB N
lower JJR o
depression NN o
( ( o
ES NNP N
= NNP N
-.14 NNP N
) ) N
and CC N
anxiety NN o
( ( o
ES NNP o
= NNP N
-.26 NNP N
) ) N
at IN N
study JJ N
end NN N
point NN N
. . N

Program NNP N
effects NNS o
for IN o
positive JJ o
affect NN o
, , o
depression NN o
, , o
and CC o
anxiety NN o
were VBD o
mediated VBN N
by IN N
more RBR N
favorable JJ N
change NN N
over IN N
time NN N
in IN N
social-emotional JJ N
and CC N
character NN N
development NN N
for IN N
students NNS N
in IN N
PA NNP N
schools NNS N
. . N

CONCLUSIONS NNP N
Results NNP N
suggest VBP N
that IN N
universal JJ i
, , i
school-based JJ i
programs NNS i
can MD i
benefit VB i
the DT N
emotional JJ N
health NN N
of IN p
youth NN p
in IN p
low-income JJ p
, , p
urban JJ p
settings NNS p
. . p

The DT p
modest JJ N
magnitude NN N
of IN N
effects NNS N
over IN N
an DT N
extended JJ N
period NN N
of IN N
program NN N
implementation NN N
, , N
however RB N
, , N
reflects VBZ N
the DT N
challenges NNS N
of IN N
both DT N
mounting VBG N
interventions NNS N
and CC N
offsetting VBG N
formidable JJ N
risks NNS N
for IN N
mental JJ N
health NN N
problems NNS N
in IN N
such JJ N
environments NNS N
. . N

-DOCSTART- -26244758- O O

A DT N
Comparison NNP N
of IN N
Outcomes NNP N
Following NNP N
Laparoscopic NNP i
and CC i
Open NNP i
Hysterectomy NNP i
With IN N
or CC N
Without IN N
Lymphadenectomy NNP N
for IN N
Presumed NNP p
Early-Stage NNP p
Endometrial NNP p
Cancer NNP p
: : p
Results NNS N
From IN N
the DT N
Medical NNP N
Research NNP N
Council NNP N
ASTEC NNP N
Trial NNP N
. . N

OBJECTIVES NNP N
Laparoscopic NNP i
hysterectomy NN i
( ( i
LH NNP i
) ) i
is VBZ N
increasingly RB N
used VBN N
for IN N
the DT N
management NN N
of IN N
endometrial JJ N
malignancy NN N
. . N

Its PRP$ N
benefits NNS N
may MD N
be VB N
particularly RB N
pronounced VBN N
as IN N
these DT N
women NNS p
are VBP p
more RBR p
likely JJ p
to TO p
be VB p
older JJR p
or CC p
obese JJ p
. . p

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
outcomes NNS N
for IN N
LH NNP N
are VBP N
comparable JJ N
to TO N
the DT N
open JJ N
hysterectomy NN N
( ( N
OH NNP N
) ) N
. . N

DESIGN NN N
This DT N
was VBD N
a DT N
prospective JJ N
cohort NN N
study NN N
nested VBD N
within IN N
the DT N
multicenter NN N
ASTEC NNP N
( ( N
A NNP N
Study NNP N
in IN N
the DT N
Treatment NNP N
of IN N
Endometrial NNP N
Cancer NNP N
) ) N
randomized VBD N
controlled VBN N
trial NN N
( ( N
1998-2005 JJ N
) ) N
. . N

POPULATION NNP N
Women NNP p
with IN p
presumed JJ p
early JJ p
endometrial JJ p
cancer NN p
were VBD p
included VBN p
. . p

METHODS NNP N
Laparoscopic NNP i
hysterectomy NN i
was VBD N
compared VBN N
with IN N
OH NNP i
with IN i
or CC i
without IN i
systematic JJ i
lymphadenectomy NN i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Overall NNP o
survival NN o
, , o
time NN o
to TO o
first JJ o
recurrence NN o
, , o
complication NN o
rates NNS o
, , o
and CC o
surgical JJ o
outcomes NNS o
were VBD N
the DT N
main JJ N
outcome NN N
measures NNS N
. . N

RESULTS NNP N
Of IN N
1408 CD p
women NNS p
, , p
1309 CD p
( ( p
93 CD p
% NN p
) ) p
received VBD p
OH NNP p
, , N
and CC N
99 CD p
( ( p
7 CD p
% NN p
) ) p
had VBD p
LH NNP p
. . p

LH NNP N
was VBD N
associated VBN N
with IN N
longer RBR N
operating VBG o
time NN o
( ( N
median JJ N
, , N
LH NNP i
105 CD N
minutes NNS N
[ VBP N
interquartile JJ N
range NN N
( ( N
IQR NNP N
) ) N
, , N
60-150 JJ N
] NNP N
vs NN N
OH NNP i
80 CD N
minutes NNS N
[ JJ N
IQR NNP N
, , N
60-95 JJ N
] NN N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
but CC N
50 CD N
% NN N
shorter JJR N
hospital NN o
stay NN o
( ( N
median JJ N
, , N
LH NNP N
4 CD N
days NNS N
[ NNP N
IQR NNP N
, , N
3-5 JJ N
] NNP N
vs NN N
OH NNP i
6 CD N
days NNS N
[ NNP N
IQR NNP N
, , N
5-7 JJ N
] NN N
) ) N
. . N

The DT N
number NN o
of IN o
harvested JJ o
lymph NN o
nodes NNS o
was VBD N
similar JJ N
( ( N
median JJ N
, , N
LH NNP i
13 CD N
[ NNP N
IQR NNP N
, , N
10-16 JJ N
] NNP N
vs NN N
OH NNP i
12 CD N
[ NNP N
IQR NNP N
, , N
11-13 JJ N
] NN N
; : N
P NNP N
= NNP N
0.67 CD N
) ) N
. . N

LH NNP i
had VBD N
fewer JJR N
intraoperative JJ o
and CC o
postoperative JJ o
adverse JJ o
events NNS o
( ( N
9 CD N
% NN N
difference NN N
, , N
LH NNP N
21 CD N
% NN N
vs NN N
OH NNP N
30 CD N
% NN N
; : N
borderline JJ N
significance NN N
; : N
P NNP N
= NNP N
0.07 CD N
) ) N
. . N

The DT N
rate NN o
of IN o
conversion NN o
to TO o
laparotomy VB o
for IN N
the DT N
LH NNP i
group NN N
was VBD N
high JJ N
( ( N
27 CD N
% NN N
) ) N
. . N

The DT N
median JJ N
follow-up NN N
was VBD N
37 CD N
months NNS N
. . N

After IN N
adjusting VBG N
for IN N
significant JJ N
prognostic JJ N
factors NNS N
, , N
the DT N
hazard NN o
ratio NN o
for IN o
overall JJ o
survival NN o
in IN N
those DT N
who WP N
underwent VBP N
LH NNP i
compared VBN N
with IN N
those DT N
who WP N
underwent VBP N
OH NNP i
was VBD N
0.67 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.31-1.43 NN N
) ) N
( ( N
P NNP N
= NNP N
0.30 CD N
) ) N
. . N

CONCLUSIONS NNP N
Laparoscopic NNP i
hysterectomy NN i
for IN N
early JJ N
endometrial JJ N
cancer NN N
is VBZ N
safe JJ N
. . N

Although IN N
it PRP N
requires VBZ N
longer JJR N
operating VBG o
time NN o
it PRP N
is VBZ N
associated VBN N
with IN N
shorter JJR N
hospital NN o
stay NN o
and CC N
favorable JJ N
morbidity NN o
profile NN o
. . o

Further JJ N
studies NNS N
are VBP N
required VBN N
to TO N
assess VB N
the DT N
long-term JJ o
safety NN o
. . o

-DOCSTART- -7946254- O O

Enhanced NNP i
small JJ i
group NN i
instruction NN i
using VBG i
choral JJ i
responding NN i
and CC i
student NN i
interaction NN i
for IN p
children NNS p
with IN p
autism NN p
and CC p
developmental JJ p
disabilities NNS p
. . p

The DT N
use NN N
of IN N
effective JJ i
instructional JJ i
strategies NNS i
in IN N
small JJ N
groups NNS N
was VBD N
investigated VBN N
to TO N
determine VB N
learning JJ N
effects NNS N
for IN N
24 CD p
elementary JJ p
age NN p
students NNS p
with IN p
autism NN p
and CC p
developmental JJ p
disabilities NNS p
. . p

Effective JJ N
strategies NNS N
included VBD N
( ( N
a DT N
) ) N
the DT i
use NN i
of IN i
choral JJ i
responding NN i
; : i
( ( N
b NN N
) ) N
the DT i
use NN i
of IN i
student-to-student JJ i
responding NN i
; : i
( ( N
c NN N
) ) N
the DT i
rotation NN i
of IN i
materials NNS i
every DT i
5 CD i
minutes NNS i
during IN i
the DT i
30-minute JJ i
group NN i
while IN i
teaching VBG i
2 CD i
to TO i
3 CD i
concepts NNS i
; : i
and CC i
( ( N
d NN N
) ) N
the DT i
use NN i
of IN i
random NN i
, , i
unpredictable JJ i
trials NNS i
for IN i
student NN i
responding VBG i
. . i

Thirty-minute JJ N
language NN N
groups NNS N
were VBD N
targeted VBN N
to TO N
teach VB N
receptive JJ N
and CC N
expressive JJ N
skills NNS N
using VBG N
pictures NNS N
and CC N
common JJ N
objects NNS N
across IN N
five CD N
categories NNS N
( ( N
e.g. NN N
, , N
household NN N
items NNS N
, , N
foods NNS N
) ) N
. . N

Results JJ N
showed VBD N
increased JJ o
opportunities NNS o
to TO o
respond VB o
, , o
increased JJ o
levels NNS o
of IN o
responding VBG o
and CC o
academic JJ o
engagement NN o
, , o
higher JJR o
gains NNS o
on IN o
weekly JJ o
criterion-referenced JJ o
pre- NN o
and CC o
posttests NNS o
, , o
and CC o
decreased VBD o
passive JJ o
and CC o
inappropriate JJ o
student NN o
behavior NN o
during IN N
interventions NNS N
. . N

-DOCSTART- -7840362- O O

Dexamethasone NN i
for IN N
the DT N
treatment NN N
of IN N
depression NN N
: : N
a DT N
randomized JJ N
, , N
placebo-controlled JJ N
, , N
double-blind JJ N
trial NN N
. . N

OBJECTIVE CC N
The DT N
authors NNS N
' POS N
goal NN N
was VBD N
to TO N
assess VB N
dexamethasone NN i
for IN N
the DT N
treatment NN N
of IN N
depression NN N
. . N

METHOD NNP N
Thirty-seven JJ p
outpatients NNS p
( ( p
11 CD p
men NNS p
and CC p
26 CD p
women NNS p
) ) p
meeting VBG p
DSM-III-R JJ p
criteria NNS p
for IN p
major JJ p
depressive JJ p
disorder NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
placebo NN i
or CC i
4 CD i
mg/day NN i
of IN i
oral JJ i
dexamethasone NN i
for IN i
4 CD i
days NNS i
. . i

Baseline NNP N
Hamilton NNP o
depression NN o
scale NN o
scores NNS o
were VBD N
compared VBN N
with IN N
scores NNS N
obtained VBN N
14 CD N
days NNS N
after IN N
the DT N
first JJ N
dose NN N
of IN N
study NN N
medication NN N
. . N

Data NNS N
were VBD N
analyzed VBN N
by IN N
using VBG N
two-sample JJ N
t NN N
tests NNS N
, , N
chi-square JJ N
methods NNS N
, , N
and CC N
Fisher NNP N
's POS N
exact JJ N
test NN N
. . N

RESULTS VB N
Seven NNP N
( ( N
37 CD N
% NN N
) ) N
of IN N
the DT N
19 CD N
patients NNS N
given VBN N
dexamethasone NN N
but CC N
only RB N
one CD N
( ( N
6 CD N
% NN N
) ) N
of IN N
the DT N
18 CD N
patients NNS N
given VBN N
placebo NNS N
responded VBD N
positively RB N
. . N

No UH N
adverse JJ o
events NNS o
or CC o
side NN o
effects NNS o
were VBD N
reported VBN N
, , N
and CC N
all DT N
patients NNS N
who WP N
entered VBD N
the DT N
study NN N
completed VBD N
it PRP N
. . N

CONCLUSIONS VB N
A DT N
brief JJ N
course NN N
of IN N
oral JJ N
dexamethasone NN i
( ( N
4 CD N
days NNS N
) ) N
was VBD N
significantly RB N
more RBR N
effective JJ N
than IN N
placebo NN i
within IN N
14 CD N
days NNS N
for IN N
the DT N
treatment NN N
of IN N
depression NN N
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
study NN N
of IN N
depressed JJ N
outpatients NNS N
. . N

-DOCSTART- -22698563- O O

Comparing VBG N
microvascular JJ o
alterations NNS o
during IN N
minimal JJ N
extracorporeal JJ i
circulation NN i
and CC N
conventional JJ N
cardiopulmonary JJ i
bypass NN i
in IN N
coronary JJ i
artery NN i
bypass NN i
graft NN i
surgery NN i
: : i
a DT N
prospective JJ N
, , N
randomized VBN N
study NN N
. . N

OBJECTIVES NNP N
Minimal NNP i
extracorporeal NN i
circulation NN i
( ( i
MECC NNP i
) ) i
has VBZ N
been VBN N
introduced VBN N
in IN N
coronary JJ i
artery NN i
bypass NN i
graft NN i
( ( i
CABG NNP i
) ) i
surgery NN i
, , N
offering VBG N
clinical JJ N
benefits NNS N
owing VBG N
to TO N
reduced VBN N
hemodilution NN N
and CC N
no DT N
blood-air JJ N
interface NN N
. . N

Yet CC N
, , N
the DT N
effects NNS N
of IN N
MECC NNP i
on IN N
the DT N
intraoperative JJ N
microvascular JJ N
perfusion NN N
in IN N
comparison NN N
with IN N
conventional JJ i
extracorporeal JJ i
circulation NN i
( ( i
CECC NNP i
) ) i
have VBP N
not RB N
been VBN N
studied VBN N
so RB N
far RB N
. . N

METHODS VB N
The DT N
current JJ N
study NN N
aimed VBD N
to TO N
analyze VB N
alterations NNS o
in IN o
microvascular JJ o
perfusion NN o
at IN N
4 CD N
predefined JJ N
time NN N
points NNS N
( ( N
T1-T4 NNP N
) ) N
during IN N
on-pump JJ N
CABG NNP N
using VBG N
orthogonal JJ N
polarization NN N
spectral JJ N
imaging NN N
. . N

Forty CD p
patients NNS p
were VBD p
randomized VBN p
for IN N
being VBG N
operated VBN N
on IN N
with IN N
either DT N
MECC NNP i
or CC i
CECC NNP i
. . i

Changes NNS N
in IN N
functional JJ o
capillary JJ o
density NN o
( ( o
FCD NNP o
) ) o
, , o
blood NN o
flow NN o
velocity NN o
, , o
and CC o
vessel RB o
diameter NN o
were VBD N
analyzed VBN N
by IN N
a DT N
blinded JJ N
investigator NN N
. . N

RESULTS NNP N
After IN N
start NN N
of IN N
extracorporeal JJ N
circulation NN N
( ( N
ECC NNP N
) ) N
and CC N
aortic JJ N
crossclamping NN N
( ( N
T2 NNP N
) ) N
, , N
both DT N
groups NNS N
showed VBD N
a DT N
significant JJ N
drop NN N
of IN N
FCD NNP o
, , N
with IN N
a DT N
significantly RB N
higher JJR N
FCD NNP o
in IN N
the DT N
MECC NNP N
group NN N
( ( N
206.8 CD N
? . N
33.6 CD N
cm/cm? NN N
in IN N
CECC NNP N
group NN N
versus VBD N
217.8 CD N
? . N
35.3 CD N
cm/cm? NN N
in IN N
MECC NNP N
group NN N
; : N
P NNP N
= NNP N
.034 NNP N
) ) N
. . N

In IN N
the DT N
late JJ N
phase NN N
of IN N
the DT N
ECC NNP N
( ( N
T3 NNP N
) ) N
, , o
FCD NNP o
in IN N
the DT N
MECC NNP N
group NN N
was VBD N
already RB N
recovered VBN N
, , N
whereas JJ o
FCD NNP o
in IN N
the DT N
CECC NNP N
group NN N
was VBD N
still RB N
significantly RB N
depressed VBN N
( ( N
223.1 CD N
? . N
35.6 CD N
cm/cm? NN N
in IN N
MECC NNP N
group NN N
; : N
P NNP N
= NNP N
.100 NNP N
vs NN N
T1 NNP N
; : N
211.1 CD N
? . N
36.9 CD N
cm/cm? NN N
in IN N
CECC NNP N
group NN N
; : N
P NNP N
= NNP N
.017 NNP N
vs NNP N
T1 NNP N
) ) N
. . N

After IN N
termination NN N
of IN N
ECC NNP N
( ( N
T4 NNP N
) ) N
, , o
FCD NNP o
recovered VBD o
in IN N
both DT N
groups NNS N
to TO N
baseline VB N
. . o

Blood NNP o
flow JJ o
velocity NN o
tended VBD o
to TO N
be VB N
higher JJR N
in IN N
the DT N
MECC NNP N
group NN N
, , N
with IN N
a DT N
significant JJ N
intergroup NN N
difference NN N
after IN N
aortic JJ N
crossclamping NN N
( ( N
T2 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Orthogonal NNP N
polarization NN N
spectral JJ N
imaging VBG N
data NNS N
reveal VBP N
an DT N
impairment NN o
of IN o
microvascular JJ o
perfusion NN o
during IN o
on-pump JJ N
CABG NNP N
. . N

Changes NNS N
in IN o
FCD NNP o
indicate VBP N
a DT N
faster JJ N
recovery NN N
of IN N
the DT N
microvascular JJ N
perfusion NN N
in IN N
MECC NNP N
during IN N
the DT N
reperfusion NN N
period NN N
. . N

Beneficial JJ N
recovery NN N
of IN N
microvascular JJ N
organ JJ N
perfusion NN N
could MD N
partly RB N
explain VB N
the DT N
perioperative JJ N
advantages NNS N
reported VBN N
for IN N
MECC NNP N
. . N

-DOCSTART- -23128568- O O

The DT N
effect NN N
of IN N
values NNS N
affirmation VBP N
on IN N
race-discordant JJ p
patient-provider JJ p
communication NN N
. . N

BACKGROUND NNP N
Communication NNP N
between IN N
African JJ p
American JJ p
patients NNS p
and CC p
white JJ p
health NN p
care NN p
providers NNS p
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
of IN N
poorer JJR N
quality NN N
when WRB N
compared VBN N
with IN N
race-concordant JJ N
patient-provider JJ N
communication NN N
. . N

Fear NN N
on IN N
the DT N
part NN N
of IN N
patients NNS N
that WDT N
providers NNS N
stereotype VBP N
them PRP N
negatively RB N
might MD N
be VB N
one CD N
cause NN N
of IN N
this DT N
poorer JJR N
communication NN N
. . N

This DT N
stereotype JJ N
threat NN N
may MD N
be VB N
lessened VBN N
by IN N
a DT N
values-affirmation NN N
intervention NN N
. . N

METHODS NNP N
In IN N
a DT N
blinded JJ N
experiment NN N
, , N
we PRP N
randomized VBD N
99 CD p
African JJ p
American JJ p
patients NNS p
with IN p
hypertension NN p
to TO N
perform VB N
a DT N
values-affirmation NN i
exercise NN i
or CC i
a DT i
control NN i
exercise NN i
before IN N
a DT N
visit NN N
with IN N
their PRP$ N
primary JJ N
care NN N
provider NN N
. . N

We PRP N
compared VBN N
patient-provider JJ N
communication NN N
for IN N
the DT N
2 CD N
groups NNS N
using VBG N
audio JJ N
recordings NNS N
of IN N
the DT N
visit NN N
analyzed VBN N
with IN N
the DT N
Roter NNP N
Interaction NNP N
Analysis NNP N
System NNP N
. . N

We PRP N
also RB N
evaluated VBD N
visit JJ N
satisfaction NN N
, , N
trust NN N
, , N
stress NN N
, , N
and CC N
mood NN N
after IN N
the DT N
visit NN N
by IN N
means NNS N
of IN N
a DT N
questionnaire NN N
. . N

RESULTS JJ N
Patients NNPS N
in IN N
the DT N
intervention NN N
group NN N
requested VBD N
and CC N
provided VBD N
more JJR N
information NN o
about IN N
their PRP$ N
medical JJ o
condition NN o
( ( N
mean JJ N
[ NNP N
SE NNP N
] NNP N
number NN N
of IN N
utterances NNS N
, , N
66.3 CD N
[ NN N
6.8 CD N
] NN N
in IN N
the DT N
values-affirmation NN N
group NN N
vs VBD N
48.1 CD N
[ JJ N
5.9 CD N
] NN N
in IN N
the DT N
control NN N
group NN N
[ NNP N
P NNP N
= NNP N
.03 NNP N
] NNP N
) ) N
. . N

Patient-provider JJ N
communication NN N
in IN N
the DT N
intervention NN N
group NN N
was VBD N
characterized VBN N
as IN N
being VBG N
more RBR N
interested JJ o
, , o
friendly JJ o
, , o
responsive JJ o
, , o
interactive JJ o
, , o
and CC o
respectful JJ o
( ( N
P NNP N
= NNP N
.02 NNP N
) ) N
and CC N
less JJR N
depressed JJ o
and CC o
distressed JJ o
( ( N
P NNP N
= NNP N
.03 NNP N
) ) N
. . N

Patient JJ N
questionnaires NNS N
did VBD N
not RB N
detect VB N
differences NNS N
in IN N
visit NN o
satisfaction NN o
, , o
trust NN o
, , o
stress NN o
, , o
or CC o
mood NN o
. . o

Mean NNP o
visit NN o
duration NN o
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
groups NNS N
( ( N
19.2 CD N
minutes NNS N
in IN N
the DT N
control NN N
group NN N
vs VBD N
20.5 CD N
minutes NNS N
in IN N
the DT N
intervention NN N
group NN N
[ NNP N
P NNP N
= NNP N
.29 NNP N
] NNP N
) ) N
. . N

CONCLUSIONS VB N
A DT N
values-affirmation NN i
exercise NN i
improves VBZ N
aspects NNS N
of IN N
patient-provider JJ N
communication NN N
in IN N
race-discordant JJ N
primary JJ N
care NN N
visits NNS N
. . N

The DT N
clinical JJ N
impact NN N
of IN N
the DT N
intervention NN N
must MD N
be VB N
defined VBN N
before IN N
widespread JJ N
implementation NN N
can MD N
be VB N
recommended VBN N
. . N

-DOCSTART- -21646599- O O

?-Blockers NNS N
in IN p
patients NNS p
with IN p
intermittent JJ p
claudication NN p
and CC p
arterial JJ p
hypertension NN p
: : p
results NNS N
from IN N
the DT N
nebivolol NN N
or CC N
metoprolol NN N
in IN N
arterial JJ N
occlusive JJ N
disease NN N
trial NN N
. . N

The DT N
use NN N
of IN N
?-receptor NN N
blockers NNS N
in IN N
peripheral JJ N
arterial JJ N
disease NN N
is VBZ N
controversial JJ N
for IN N
their PRP$ N
impact NN N
on IN N
vasomotor NN N
tone NN N
. . N

The DT N
?-blocker NN N
nebivolol NN N
possesses VBZ N
vasodilating VBG N
, , N
endothelium-dependent JJ N
, , N
NO-releasing JJ N
properties NNS N
that WDT N
might MD N
be VB N
beneficial JJ N
in IN N
peripheral JJ N
arterial JJ N
disease NN N
. . N

The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effects NNS o
and CC o
tolerability NN o
of IN o
nebivolol NN i
in IN i
comparison NN N
with IN i
metoprolol NN i
in IN i
these DT N
patients NNS p
. . p

A DT p
total NN p
of IN p
128 CD p
patients NNS p
with IN p
intermittent JJ p
claudication NN p
and CC p
essential JJ p
hypertension NN p
were VBD p
included VBN N
and CC N
double-blind JJ N
randomized VBN N
to TO N
receive VB i
5 CD i
mg NN i
of IN i
nebivolol NN i
( ( i
N=65 NNP i
) ) N
or CC N
95 CD i
mg NN i
of IN i
metoprolol NN i
( ( i
N=63 NNP i
) ) N
once RB N
daily JJ N
. . N

End NN N
points NNS N
were VBD N
changes NNS N
in IN N
ankle-brachial JJ o
index NN o
, , o
initial JJ o
and CC o
absolute JJ o
claudication NN o
distance NN o
, , o
endothelial JJ o
function NN o
assessed VBN o
by IN o
flow-mediated JJ o
dilatation NN o
of IN o
the DT o
brachial JJ o
artery NN o
, , o
blood NN o
pressure NN o
, , o
and CC o
quality NN o
of IN o
life NN o
using VBG o
the DT o
claudication NN o
scale NN o
questionnaire NN o
. . o

End NN o
point NN N
analysis NN N
was VBD N
possible JJ N
in IN N
109 CD N
patients NNS N
( ( N
85.2 CD N
% NN N
) ) N
. . N

After IN N
the DT N
48-week JJ N
treatment NN N
period NN o
, , o
ankle-brachial JJ o
index NN o
and CC o
absolute JJ o
claudication NN o
distance NN o
improved VBD o
significantly RB N
in IN N
both DT N
patient JJ N
groups NNS N
( ( N
P NNP N
< VBZ N
0.05 CD N
for IN N
both DT N
) ) N
, , N
with IN N
no DT N
difference NN N
across IN N
treatments NNS N
. . N

A DT N
significant JJ N
increase NN N
of IN N
initial JJ o
claudication NN o
distance NN o
was VBD o
found VBN N
in IN N
the DT N
nebivolol JJ N
group NN N
. . N

Adjusted VBN N
mean JJ N
change NN N
of IN N
initial JJ o
claudication NN o
distance NN o
was VBD o
33.9 CD N
% NN N
after IN N
nebivolol NN N
( ( N
P=0.003 NNP N
) ) N
and CC N
16.6 CD N
% NN N
after IN N
metoprolol NN N
( ( N
P=0.12 NNP N
) ) N
treatment NN o
. . o

Quality NN o
of IN o
life NN o
was VBD o
not RB N
influenced VBN N
by IN N
either DT N
treatment NN N
, , N
and CC N
there EX N
was VBD N
no DT N
relevant JJ N
change NN N
in IN N
flow-mediated JJ o
dilatation NN o
in IN o
patients NNS N
treated VBN N
with IN N
nebivolol NN N
or CC N
metoprolol NN N
( ( N
P=0.16 NNP N
) ) N
. . N

Both DT N
drugs NNS N
were VBD N
equally RB N
effective JJ N
in IN N
lowering VBG o
blood NN o
pressure NN o
. . o

In IN o
conclusion NN N
, , N
?-blocker JJ N
therapy NN N
was VBD N
well RB N
tolerated VBN p
in IN p
patients NNS p
with IN p
intermittent JJ p
claudication NN p
and CC p
arterial JJ p
hypertension NN p
during IN p
a DT N
treatment NN N
period NN N
of IN N
?1 JJ N
year NN N
. . N

In IN N
the DT N
direct JJ N
comparison NN N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
nebivolol NNS N
and CC N
metoprolol NN N
. . N

-DOCSTART- -19117033- O O

Prevention NN N
of IN N
postoperative JJ N
hypocalcemia NN N
with IN N
routine JJ N
oral JJ N
calcium NN i
and CC N
vitamin NN i
D NNP i
supplements NNS i
in IN N
patients NNS p
with IN p
differentiated JJ p
papillary JJ p
thyroid NN p
carcinoma NN p
undergoing JJ p
total JJ p
thyroidectomy NN p
plus CC p
central JJ p
neck NN p
dissection NN p
. . p

BACKGROUND NNP N
Routine NNP N
oral JJ i
calcium NN i
and CC i
vitamin NN i
D NNP i
supplementation NN i
may MD N
prevent VB N
hypocalcemic JJ N
crisis NN N
, , N
but CC N
its PRP$ N
efficacy NN N
has VBZ N
not RB N
been VBN N
studied VBN N
in IN N
patients NNS p
undergoing VBG p
thyroidectomy JJ p
plus JJ p
central JJ p
neck NN p
dissection NN p
( ( p
CND NNP p
) ) p
. . p

The DT N
authors NNS N
therefore VBP N
prospectively RB N
evaluated VBN N
the DT N
clinical JJ N
usefulness NN N
of IN N
routine JJ N
oral JJ N
calcium NN N
and CC N
vitamin NN N
D NNP N
supplementation NN N
for IN N
prevention NN N
of IN N
hypocalcemia NN N
after IN N
total JJ N
thyroidectomy NN N
and CC N
CND NNP N
. . N

METHODS NNP N
Of IN N
197 CD p
patients NNS p
with IN p
differentiated JJ p
papillary JJ p
thyroid NN p
carcinoma NN p
, , N
49 CD N
underwent JJ N
total JJ N
thyroidectomy NN N
alone RB N
, , N
and CC N
148 CD N
underwent JJ N
total JJ i
thyroidectomy NN i
plus CC i
CND NNP i
. . i

The DT N
latter JJ N
were VBD N
randomized VBN N
to TO N
oral JJ i
calcium NN i
( ( N
3 CD N
g/day NN N
) ) N
plus CC N
vitamin JJ i
D NNP i
( ( N
1 CD N
mg/day NN N
) ) N
( ( N
Group NNP N
A NNP N
, , N
n=49 NN N
) ) N
, , N
calcium NN i
alone RB i
( ( N
Group NNP N
B NNP N
, , N
n=49 NN N
) ) N
, , N
or CC N
no DT i
supplements NNS i
( ( N
Group NNP N
C NNP N
, , N
n=50 RB N
) ) N
. . N

Hypocalcemic NNP o
symptoms NNS o
, , o
serum JJ o
calcium NN o
, , o
and CC o
parathyroid VB o
hormone NN o
( ( o
PTH NNP o
) ) o
levels NNS o
were VBD N
compared VBN N
among IN N
the DT N
groups NNS N
. . N

RESULTS NNP N
Group NNP N
C NNP N
had VBD N
significantly RB N
higher JJR N
incidences NNS N
of IN N
symptomatic JJ N
( ( N
26.0 CD N
% NN N
vs JJ N
6.1 CD N
% NN N
; : N
P NNP N
< NNP N
.015 NNP N
) ) N
and CC N
laboratory NN N
( ( N
44.0 CD N
% NN N
vs JJ N
14.3 CD N
% NN N
; : N
P NNP N
< NNP N
.015 NNP N
) ) N
hypocalcemia NN o
than IN N
the DT N
group NN N
without IN N
CND NNP N
. . N

The DT N
incidences NNS N
of IN N
symptomatic JJ o
and CC o
laboratory JJ o
hypocalcemia NN o
were VBD N
significantly RB N
decreased VBN N
in IN N
Groups NNP N
A NNP N
( ( N
2.0 CD N
% NN N
and CC N
8.2 CD N
% NN N
, , N
respectively RB N
) ) N
and CC N
B NNP N
( ( N
12.2 CD N
% NN N
and CC N
24.5 CD N
% NN N
, , N
respectively RB N
) ) N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

Serum NNP o
calcium NN o
levels NNS o
decreased VBN N
in IN N
most JJS N
patients NNS N
after IN N
surgery NN N
, , N
but CC N
recovered VBD N
earliest JJS N
in IN N
Group NNP N
A. NNP N
Hypercalcemia NNP N
and CC N
PTH NNP N
inhibition NN N
did VBD N
not RB N
occur VB N
in IN N
gs NN N
A NNP N
and CC N
B NNP N
. . N

CONCLUSIONS NNP N
Compared NNP N
with IN N
total JJ N
thyroidectomy NN N
alone RB N
, , N
CND NNP N
significantly RB N
increases VBZ N
the DT N
rate NN N
of IN N
postoperative JJ o
hypocalcemia NN o
, , N
which WDT N
can MD N
be VB N
prevented VBN N
by IN N
routine JJ N
postoperative JJ N
supplementation NN N
with IN N
oral JJ N
calcium NN N
and CC N
vitamin NN N
D NNP N
. . N

-DOCSTART- -8549289- O O

Direct JJ N
analysis NN N
of IN N
resistance NN o
in IN o
the DT o
cutaneous JJ o
microflora NN o
during IN N
treatment NN N
of IN N
acne JJ p
vulgaris NN p
with IN N
topical JJ i
1 CD i
% NN i
nadifloxacin NN i
and CC i
2 CD i
% NN i
erythromycin NN i
. . i

-DOCSTART- -15793648- O O

Stapled VBN i
hemorrhoidopexy NN i
vs. FW i
Harmonic NNP i
Scalpel NNP i
hemorrhoidectomy NN i
: : i
a DT N
randomized JJ N
trial NN N
. . N

PURPOSE VB N
A NNP N
randomized JJ N
trial NN N
was VBD N
undertaken VBN N
to TO N
evaluate VB N
and CC N
compare VB N
stapled VBN i
hemorrhoidopexy NN i
with IN i
excisional JJ i
hemorrhoidectomy NN i
in IN N
which WDT N
the DT N
Harmonic NNP N
Scalpel NNP N
was VBD N
used VBN N
. . N

METHODS JJ N
Patients NNS p
with IN p
Grade NNP p
III NNP p
hemorrhoids NNS p
who WP p
were VBD p
employed VBN p
during IN p
the DT p
trial NN p
period NN p
were VBD N
recruited VBN N
and CC N
randomized VBN N
into IN N
two CD N
groups NNS N
: : N
( ( N
1 CD N
) ) N
Harmonic NNP i
Scalpel NNP i
hemorrhoidectomy NN i
, , i
and CC i
( ( i
2 CD i
) ) i
stapled VBD i
hemorrhoidopexy NN i
. . i

All DT N
operations NNS N
were VBD N
performed VBN N
by IN N
a DT N
single JJ N
surgeon NN N
. . N

In IN N
the DT N
stapled JJ N
group NN N
, , N
the DT N
doughnut NN N
obtained VBN N
was VBD N
sent VBN N
for IN N
histopathologic JJ N
examination NN N
to TO N
determine VB N
whether IN N
smooth JJ N
muscles NNS N
were VBD N
included VBN N
in IN N
the DT N
specimen NNS N
. . N

Operative NNP N
data NN N
and CC N
complications NNS N
were VBD N
recorded VBN N
, , N
and CC N
patients NNS N
were VBD N
followed VBN N
up RP N
through IN N
a DT N
structured JJ N
pro JJ N
forma NN N
protocol NN N
. . N

An DT N
independent JJ N
assessor NN N
was VBD N
assigned VBN N
to TO N
obtain VB N
postoperative JJ N
pain NN o
scores NNS o
and CC o
satisfaction NN o
scores NNS o
at IN N
six-month JJ N
follow-up JJ N
. . N

Patients NNS N
were VBD N
also RB N
administered VBN N
a DT N
simple JJ o
questionnaire NN o
at IN N
follow-up JJ N
to TO N
assess VB N
continence NN N
functions NNS N
. . N

RESULTS NNP N
Over IN p
a DT p
20-month JJ p
period NN p
, , p
88 CD p
patients NNS p
were VBD p
recruited VBN p
. . p

The DT N
two CD N
groups NNS N
were VBD N
matched VBN N
for IN N
age NN N
and CC N
gender NN N
distribution NN N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
identified VBN N
between IN N
the DT N
two CD N
groups NNS N
in IN N
terms NNS N
of IN N
operation NN o
time NN o
, , o
blood NN o
loss NN o
, , o
day NN o
of IN o
first JJ o
bowel NN o
movement NN o
after IN o
surgery NN o
, , o
and CC o
complication NN o
rates NNS o
. . o

Despite IN N
a DT N
similar JJ N
parenteral NN N
and CC N
oral JJ N
analgesic JJ N
requirement NN N
, , N
the DT N
stapled VBN N
group NN N
had VBD N
a DT N
significantly RB N
better RBR N
pain NN o
score NN o
( ( N
P NNP N
= NNP N
0.002 CD N
) ) N
; : N
these DT N
patients NNS N
also RB N
had VBD N
a DT N
significantly RB N
shorter JJR N
length NN o
of IN o
stay NN o
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
, , N
and CC N
on IN N
average NN N
resumed VBN N
work NN N
nine CD N
days NNS N
earlier RBR N
than IN N
the DT N
group NN N
treated VBD N
with IN N
the DT N
Harmonic NNP N
Scalpel NNP N
( ( N
6.7 CD N
vs. FW N
15.6 CD N
, , N
P NNP N
= NNP N
0.002 CD N
) ) N
. . N

Although IN N
88 CD N
percent NN N
of IN N
doughnuts NNS N
obtained VBN N
in IN N
the DT N
stapled JJ N
group NN N
contained VBD N
some DT N
smooth JJ o
muscle NN o
fibers NNS o
, , N
no DT N
association NN N
was VBD N
found VBN N
between IN N
smooth JJ o
muscle NN o
incorporation NN o
and CC N
postoperative JJ o
continence NN o
function NN o
, , N
and CC N
as IN N
a DT N
whole JJ N
the DT N
continence NN N
outcomes NNS N
of IN N
the DT N
stapled VBN N
group NN N
were VBD N
similar JJ N
to TO N
those DT N
after IN N
Harmonic NNP N
Scalpel NNP N
hemorrhoidectomy NN N
. . N

Finally RB N
, , N
at IN N
six-month JJ N
follow-up JJ N
, , N
patients NNS N
who WP N
underwent VBP N
the DT N
stapled JJ i
procedure NN N
had VBD N
significantly RB N
better JJR N
satisfaction NN o
scores NNS o
( ( N
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

CONCLUSION NNP N
Stapled NNP i
hemorrhoidopexy NN i
is VBZ N
a DT N
safe JJ o
and CC o
effective JJ o
procedure NN N
for IN N
Grade NNP N
III NNP N
hemorrhoidal JJ N
disease NN N
. . N

Patients NNS N
derive JJ N
greater JJR N
short-term JJ N
benefits NNS o
of IN N
reduced JJ o
pain NN o
, , o
shorter JJR o
length NN o
of IN o
stay NN o
, , o
and CC o
earlier JJR o
resumption NN o
to TO o
work VB o
. . o

Long-term JJ N
follow-up NN N
is VBZ N
necessary JJ N
to TO N
determine VB N
whether IN N
these DT N
initial JJ N
results NNS N
are VBP N
lasting VBG N
. . N

-DOCSTART- -12844393- O O

The DT N
effects NNS N
of IN N
enterostatin JJ i
intake NN i
on IN N
food NN o
intake NN o
and CC o
energy NN o
expenditure NN o
. . o

Enterostatin NNP i
( ( i
ENT NNP i
) ) i
has VBZ N
been VBN N
found VBN N
to TO N
inhibit VB N
food NN N
intake NN N
and CC N
selectively RB N
inhibit VB N
fat JJ p
intake NN p
in IN p
rats NNS p
. . p

Both DT N
peripheral JJ N
and CC N
central JJ N
mechanisms NNS N
have VBP N
been VBN N
proposed VBN N
. . N

It PRP N
also RB N
has VBZ N
been VBN N
suggested VBN N
that IN N
ENT NNP i
may MD N
increase VB N
thermogenesis NN N
. . N

The DT N
present JJ N
study NN N
investigated VBD N
the DT N
effects NNS N
of IN N
oral JJ N
ENT NNP i
administration NN N
on IN N
food NN o
intake NN o
, , o
energy NN o
expenditure NN o
and CC o
body NN o
weight NN o
in IN N
subjects NNS p
with IN p
a DT p
preference NN p
for IN p
a DT p
high-fat JJ p
diet NN p
. . p

In IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
randomized JJ N
and CC N
crossover JJ N
design NN N
, , N
nine CD p
female NN p
and CC p
three CD p
male NN p
healthy JJ p
subjects NNS p
( ( p
age NN p
34 CD p
( ( p
sd VB p
11 CD p
) ) p
years NNS p
, , p
BMI NNP p
24.5 CD p
( ( p
sd VB p
2.5 CD p
) ) p
kg/m NN p
( ( p
2 CD p
) ) p
) ) p
with IN p
a DT p
preference NN p
for IN p
a DT p
high-fat JJ i
diet NN i
ingested VBN i
ENT NNP i
( ( p
3 CD p
x RB p
15 CD p
mg/d NN p
) ) p
or CC p
placebo NN i
( ( i
PLA NNP i
) ) i
while IN i
consuming VBG i
a DT i
high-fat JJ i
diet JJ i
ad NN i
libitum NN i
for IN p
4 CD p
d. NNS p
Eight JJ p
subjects NNS p
ended VBD N
each DT N
intervention NN N
with IN N
a DT N
36 CD N
h NN N
stay NN N
in IN N
the DT N
respiration NN N
chamber NN N
, , N
continuing VBG N
the DT N
diet JJ N
and CC N
treatment NN N
. . N

Body-weight JJ o
loss NN o
was VBD N
significant JJ N
( ( i
ENT NNP i
0.8 CD N
( ( N
se VB N
0.3 CD N
) ) N
kg NN N
, , N
P NNP N
< NNP N
0.05 CD N
; : N
PLA NNP i
1.3 CD N
( ( N
se VB N
0.3 CD N
) ) N
kg NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
but CC N
not RB N
different JJ N
between IN N
treatments NNS N
. . N

There EX N
was VBD N
no DT N
difference NN N
between IN N
treatments NNS N
in IN N
total JJ o
energy NN o
intake NN o
( ( i
ENT NNP i
37.1 CD N
( ( N
se VB N
2.6 CD N
) ) N
, , N
PLA NNP i
35.9 CD N
( ( N
se VB N
3.2 CD N
) ) N
MJ NNP N
) ) N
, , N
macronutrient JJ o
composition NN o
, , o
hunger NN o
, , o
satiety NN o
and CC o
hedonic JJ o
scores NNS o
during IN N
the DT N
4 CD N
d JJ N
high-fat JJ N
diet NN N
. . N

Energy NNP o
expenditure NN o
( ( N
24 CD N
h NN N
) ) N
( ( i
ENT $ i
9.6 CD N
( ( N
se VB N
0.4 CD N
) ) N
, , N
PLA NNP i
9.5 CD N
( ( N
se VB N
0.4 CD N
) ) N
MJ NNP N
) ) N
, , N
sleeping VBG o
and CC o
resting VBG o
metabolic JJ o
rate NN o
, , o
diet-induced JJ o
thermogenesis NN o
, , o
activity-induced JJ o
energy NN o
expenditure NN o
and CC o
24 CD o
h NN o
RQ NNP o
( ( i
ENT NNP i
0.77 CD N
( ( N
se VB N
0.01 CD N
) ) N
, , N
PLA NNP i
0.77 CD N
( ( N
se VB N
0.01 CD N
) ) N
) ) N
were VBD N
similar JJ N
for IN N
both DT N
treatments NNS N
. . N

We PRP N
conclude VBP N
that IN N
oral JJ N
ENT NNP i
administration NN N
did VBD N
not RB N
affect VB N
food NN o
intake NN o
, , o
energy NN o
expenditure NN o
or CC o
body NN o
weight NN o
in IN N
subjects NNS p
with IN p
a DT p
preference NN p
for IN p
a DT p
high-fat JJ p
diet JJ p
experiencing VBG N
a DT N
negative JJ N
energy NN N
and CC N
fat JJ N
balance NN N
. . N

-DOCSTART- -11297722- O O

Double-blind NNP N
placebo-controlled JJ i
administration NN N
of IN N
fluoxetine NN i
in IN N
restricting- JJ p
and CC p
restricting-purging-type JJ p
anorexia NN p
nervosa NN p
. . p

BACKGROUND NNP N
Anorexia NNP N
nervosa NN N
is VBZ N
an DT N
often RB N
chronic JJ N
disorder NN N
with IN N
high JJ N
morbidity NN N
and CC N
mortality NN N
. . N

Many JJ N
people NNS N
relapse VBP N
after IN N
weight JJ N
restoration NN N
. . N

This DT N
study NN N
was VBD N
designed VBN N
to TO N
determine VB N
whether IN N
a DT N
selective JJ i
serotonin NN i
reuptake NN i
inhibitor NN i
would MD N
improve VB N
outcome NN N
and CC N
reduce VB N
relapse NN N
after IN N
weight JJ o
restoration NN o
by IN o
contributing VBG o
to TO o
maintenance NN o
of IN o
a DT o
healthy JJ o
normal JJ o
weight NN o
and CC o
a DT o
reduction NN o
of IN o
symptoms NNS o
. . o

METHODS NNP N
We PRP N
administered VBD N
a DT N
double-blind JJ N
placebo-controlled JJ i
trial NN N
of IN N
fluoxetine NN i
to TO N
35 CD p
patients NNS p
with IN p
restricting-type JJ p
anorexia NN p
nervosa NN p
. . p

Anorexics NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
fluoxetine VB i
( ( i
n JJ i
= NNP i
16 CD i
) ) i
or CC i
a DT i
placebo NN i
( ( i
n JJ i
= NNP i
19 CD i
) ) i
after IN N
inpatient NN N
weight NN N
gain NN N
and CC N
then RB N
were VBD N
observed VBN N
as IN N
outpatients NNS N
for IN N
1 CD N
year NN N
. . N

RESULTS NNP N
Ten CD N
of IN N
16 CD N
( ( N
63 CD N
% NN N
) ) N
subjects NNS N
remained VBN N
on IN N
fluoxetine NN i
for IN N
a DT N
year NN N
, , N
whereas IN N
only RB N
three CD N
of IN N
19 CD N
( ( N
16 CD N
% NN N
) ) N
remained VBD N
on IN N
the DT N
placebo NN i
for IN N
a DT N
year NN N
( ( N
p IN N
=.006 NN N
) ) N
. . N

Those DT N
subjects NNS N
remaining VBG N
on IN N
fluoxetine NN i
for IN N
a DT N
year NN N
had VBD N
reduced VBN o
relapse NN o
as IN N
determined VBN N
by IN N
a DT N
significant JJ o
increase NN o
in IN o
weight NN o
and CC o
reduction NN o
in IN o
symptoms NNS o
. . o

CONCLUSIONS VB N
This DT N
study NN N
offers VBZ N
preliminary JJ N
evidence NN N
that IN N
fluoxetine NN i
may MD N
be VB N
useful JJ N
in IN N
improving VBG N
outcome NN N
and CC N
preventing VBG N
relapse NN o
of IN N
patients NNS p
with IN p
anorexia JJ p
nervosa NN p
after IN N
weight JJ N
restoration NN N
. . N

-DOCSTART- -8614420- O O

The DT N
sequencing NN N
of IN N
chemotherapy NN i
and CC N
radiation NN i
therapy NN i
after IN N
conservative JJ p
surgery NN p
for IN p
early-stage JJ p
breast NN p
cancer NN p
. . p

BACKGROUND NNP N
Patients NNPS p
with IN p
early-stage JJ p
breast NN p
cancer NN p
who WP p
are VBP p
at IN p
substantial JJ p
risk NN p
for IN p
systemic JJ p
metastases NNS p
are VBP N
increasingly RB N
treated VBN N
with IN N
breast-conserving JJ i
therapy NN i
and CC i
adjuvant JJ i
chemotherapy NN i
. . i

However RB N
, , N
the DT N
optimal JJ N
sequencing NN N
of IN N
chemotherapy NN i
and CC i
radiation NN i
therapy NN i
is VBZ N
not RB N
clear JJ N
. . N

METHODS NNP N
Two CD p
hundred VBD p
forty-four JJ p
patients NNS p
with IN p
stage NN p
I PRP p
or CC p
II NNP p
breast NN p
cancer NN p
who WP p
were VBD p
at IN p
substantial JJ p
risk NN p
for IN p
distant JJ p
metastases NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
a DT N
12-week JJ i
course NN i
of IN i
chemotherapy NN i
either CC i
before IN i
or CC i
after IN i
radiation NN i
therapy NN i
. . i

All DT p
had VBD p
had VBN p
breast-conserving JJ p
surgery NN p
. . p

The DT N
median JJ N
length NN N
of IN N
follow-up NN N
in IN N
surviving VBG N
patients NNS N
was VBD N
58 CD N
months NNS N
( ( N
range NN N
, , N
10 CD N
to TO N
124 CD N
) ) N
. . N

RESULTS VB N
The DT N
five-year JJ o
actuarial JJ o
rates NNS o
of IN o
cancer NN o
recurrence NN o
at IN N
any DT N
site NN N
and CC N
of IN N
distant JJ N
metastases NNS N
in IN N
the DT N
radiotherapy-first JJ i
group NN N
and CC N
the DT N
chemotherapy-first JJ i
group NN N
were VBD N
38 CD N
percent NN N
and CC N
31 CD N
percent NN N
( ( N
P NNP N
= NNP N
0.17 CD N
) ) N
and CC N
36 CD N
percent NN N
and CC N
25 CD N
percent NN N
( ( N
P NNP N
= NNP N
0.05 CD N
) ) N
, , N
respectively RB N
. . N

Overall JJ o
survival NN o
was VBD N
73 CD N
percent NN N
and CC N
81 CD N
percent NN N
( ( N
P NNP N
= NNP N
0.11 CD N
) ) N
, , N
respectively RB N
. . N

The DT N
five-year JJ o
crude NN o
rates NNS o
of IN o
first JJ o
recurrence NN o
according VBG N
to TO N
site NN N
in IN N
the DT N
radiotherapy-first JJ i
and CC i
chemotherapy-first JJ i
groups NNS N
, , N
respectively RB N
, , N
were VBD N
5 CD N
percent NN N
and CC N
14 CD N
percent NN N
for IN N
local JJ N
recurrence NN N
and CC N
32 CD N
percent NN N
and CC N
20 CD N
percent NN N
for IN N
distant NN N
or CC N
regional JJ N
recurrence NN N
or CC N
both DT N
. . N

This DT N
difference NN N
in IN N
the DT N
pattern NN o
of IN o
recurrence NN o
was VBD N
of IN N
borderline JJ N
statistical JJ N
significance NN N
( ( N
P NNP N
= NNP N
0.07 CD N
) ) N
. . N

CONCLUSIONS VB N
This DT N
study NN N
suggests VBZ N
that IN N
for IN N
patients NNS p
ar VBP p
substantial JJ p
risk NN p
for IN p
systemic JJ p
metastases NNS p
, , N
it PRP N
is VBZ N
preferable JJ N
to TO N
give VB N
a DT N
12-week JJ N
course NN N
of IN N
chemotherapy NN i
followed VBN N
by IN N
radiation NN i
therapy NN i
, , N
rather RB N
than IN N
radiation NN i
therapy NN i
followed VBN i
by IN i
chemotherapy NN i
. . i

-DOCSTART- -6108264- O O

A DT N
double JJ N
blind JJ N
trial NN N
of IN N
terfenadine NN i
and CC N
placebo NN i
in IN N
hay NN N
fever NN N
using VBG N
a DT N
substitution NN N
technique NN N
for IN N
non-responders NNS N
. . N

A DT N
double-blind JJ N
study NN N
of IN N
terfenadine NN i
and CC N
placebo NN i
in IN N
110 CD p
patients NNS p
suffering VBG p
from IN p
hay NN p
fever NN p
( ( p
confirmed VBN p
by IN p
skin NN p
tests NNS p
) ) p
was VBD N
conducted VBN N
. . N

A DT N
novel JJ N
technique NN N
was VBD N
applied VBN N
using VBG N
an DT N
escape NN N
envelope NN N
containing VBG N
a DT N
reference NN i
drug NN i
which WDT N
could MD N
be VB N
taken VBN N
under IN N
controlled JJ N
conditions NNS N
if IN N
, , N
after IN N
48 CD N
hours NNS N
, , N
the DT N
patient NN N
experienced VBD N
no DT N
relief NN o
. . o

Significantly RB N
more JJR N
patients NNS N
on IN N
placebo NN i
opened VBD o
the DT o
envelope NN o
than IN N
patients NNS N
taking VBG N
the DT N
active JJ N
drug NN N
. . N

Terfenadine NNP i
was VBD N
demonstrated VBN N
to TO N
be VB N
an DT N
effective JJ o
drug NN o
in IN N
hay NN N
fever NN N
and CC N
produced VBD N
no DT N
more RBR N
drowsiness NN o
than IN N
placebo NN N
. . N

-DOCSTART- -1797999- O O

Home NNP i
blood NN o
pressure NN o
monitoring NN i
: : i
advantages NNS N
and CC N
limitations NNS N
. . N

Home NNP i
blood NN i
pressure NN i
monitoring NN i
is VBZ N
a DT N
useful JJ N
tool NN N
for IN N
clinical JJ o
management NN o
of IN N
patients NNS p
with IN p
hypertension NN p
. . p

Its PRP$ N
major JJ N
advantages NNS N
are VBP N
the DT N
ease NN N
with IN N
which WDT N
the DT N
techniques NNS N
can MD N
be VB N
learned VBN N
, , N
reproducibility NN N
of IN N
values NNS N
, , N
sensitivity NN N
of IN N
measurement NN N
and CC N
availability NN N
of IN N
normotensive JJ N
data NNS N
. . N

In IN N
spite NN N
of IN N
the DT N
ability NN N
to TO N
tell VB N
whether IN N
a DT N
subject NN N
has VBZ N
normal JJ N
or CC N
abnormal JJ N
values NNS N
, , N
because IN N
of IN N
the DT N
lack NN N
of IN N
prospective JJ N
mortality/morbidity NN N
data NNS N
, , N
home NN i
blood NN i
pressure NN i
monitoring NN i
can MD N
not RB N
be VB N
used VBN N
to TO N
decide VB N
whether IN N
treatment NN N
is VBZ N
indicated VBN N
. . N

The DT N
treatment NN N
decision NN N
must MD N
be VB N
based VBN N
on IN N
repeated VBN N
clinic JJ o
blood NN o
pressure NN o
readings NNS o
. . o

After IN N
that IN N
the DT N
home NN i
blood NN o
pressure NN o
monitoring NN i
can MD N
be VB N
used VBN N
to TO N
exclude VB N
individuals NNS N
who WP N
are VBP N
at IN N
risk NN N
for IN N
side NN N
effects NNS N
due JJ N
to TO N
low JJ N
out-of-office JJ N
blood NN o
pressure NN o
readings NNS N
and CC N
to TO N
precisely RB N
monitor VB N
the DT N
blood NN o
pressure NN o
response NN o
to TO N
therapy NN N
. . N

Home NNP i
blood NN i
pressure NN i
monitoring NN i
is VBZ N
frequently RB N
used VBN N
to TO N
find VB N
subjects NNS N
with IN N
'white-coat NNP o
' POS o
hypertension NN o
. . o

In IN N
our PRP$ N
study NN N
of IN N
borderline JJ p
hypertension NN p
in IN p
Tecumseh NNP p
, , N
white-coat JJ N
hypertension NN N
is VBZ N
present JJ N
in IN N
7.1 CD N
% NN N
of IN N
the DT N
whole JJ N
population NN N
and CC N
in IN N
58 CD N
% NN N
of IN N
all DT N
subjects NNS N
with IN N
elevated JJ N
blood NN o
pressures NNS o
in IN N
the DT N
clinic NN N
. . N

Subjects NNS N
with IN N
white-coat JJ N
hypertension NN N
in IN N
Tecumseh NNP N
appear VBP N
to TO N
be VB N
at IN N
an DT N
increased VBN N
risk NN N
for IN N
coronary JJ o
heart NN o
disease NN o
: : o
they PRP N
show VBP N
repeated VBN N
elevated JJ N
clinic NN o
readings NNS o
throughout IN N
their PRP$ N
life NN N
time NN N
, , N
their PRP$ N
parents NNS N
have VBP N
higher JJR N
blood NN o
pressure NN o
, , N
their PRP$ N
high-density NN o
lipoprotein NN o
is VBZ N
decreased VBN N
and CC N
insulin NN o
, , o
cholesterol NN o
and CC o
triglycerides NNS o
are VBP N
elevated VBN N
. . N

Whereas JJ N
subjects NNS N
with IN N
white-coat JJ N
hypertension NN N
should MD N
not RB N
be VB N
treated VBN N
with IN N
antihypertensive JJ N
agents NNS N
, , N
they PRP N
must MD N
be VB N
followed VBN N
and CC N
managed VBN N
through IN N
non-pharmacologic JJ i
means NNS i
. . i

-DOCSTART- -16864164- O O

Long-term JJ N
follow-up NN N
of IN N
the DT N
Stockholm NNP N
randomized VBD N
trials NNS N
of IN N
postoperative JJ i
radiation NN i
therapy NN i
versus NN i
adjuvant JJ i
chemotherapy NN i
among IN N
'high JJ p
risk NN p
' POS p
pre- NN p
and CC p
postmenopausal NN p
breast NN p
cancer NN p
patients NNS p
. . p

For IN N
many JJ N
years NNS N
, , N
loco-regional JJ N
radiotherapy NN N
was VBD N
the DT N
standard JJ N
postoperative JJ N
treatment NN N
for IN N
node JJ p
positive JJ p
breast NN p
cancer NN p
patients NNS p
in IN p
Sweden NNP p
. . p

Because IN N
of IN N
encouraging VBG N
results NNS N
from IN N
trials NNS N
of IN N
adjuvant JJ i
chemotherapy NN i
in IN N
the DT N
mid NN N
1970s CD N
, , N
the DT p
Stockholm NNP p
Breast NNP p
Cancer NNP p
Study NNP p
Group NNP p
decided VBD N
to TO N
directly RB N
compare VB N
postoperative JJ i
radiation NN i
( ( i
RT NNP i
) ) i
with IN i
adjuvant JJ i
CMF-type JJ i
chemotherapy NN i
( ( i
CT NNP i
) ) i
. . i

Long-term JJ N
results NNS N
are VBP N
presented VBN N
from IN N
two CD N
randomized JJ N
trials NNS N
of IN N
RT NNP i
versus NN N
CT NNP i
in IN N
pre- NN p
( ( p
n JJ p
= NNP p
547 CD p
) ) p
and CC p
postmenopausal NN p
( ( p
n JJ p
= NNP p
679 CD p
) ) p
patients NNS p
, , p
respectively RB p
, , p
with IN p
node JJ p
positive JJ p
disease NN p
or CC p
a DT p
tumour JJ p
diameter NN p
> VBD p
30 CD p
mm NN p
. . p

RT NNP N
substantially RB N
reduced VBD N
loco-regional JJ o
recurrences NNS o
among IN N
both DT N
pre- JJ N
and CC N
postmenopausal JJ N
patients NNS N
( ( N
relative JJ N
hazard NN N
RT NNP N
versus NN N
CT NNP N
: : N
0.67 CD N
and CC N
0.43 CD N
, , N
respectively RB N
) ) N
. . N

Among IN N
premenopausal JJ N
patients NNS N
distant JJ o
metastases NNS o
occurred VBD N
less RBR N
frequently RB N
in IN N
the DT N
CT NNP N
group NN N
( ( N
relative JJ N
hazard NN N
: : N
1.68 CD N
, , N
p NN N
> NNP N
0.001 CD N
) ) N
resulting VBG N
in IN N
an DT N
improved JJ N
recurrence-free JJ o
survival NN o
( ( N
p JJ N
= NNP N
0.04 CD N
) ) N
. . N

Overall JJ o
survival NN o
was VBD N
also RB N
better RB N
with IN N
CT NNP N
( ( N
cumulative JJ N
survival NN N
at IN N
15 CD N
years NNS N
: : N
50 CD N
% NN N
and CC N
44 CD N
% NN N
in IN N
the DT N
CT NNP N
and CC N
RT NNP N
groups NNS N
, , N
respectively RB N
) ) N
but CC N
the DT N
difference NN N
was VBD N
not RB N
statistically RB N
significant JJ N
. . N

Among IN N
the DT N
postmenopausal NN N
patients NNS N
there EX N
were VBD N
no DT N
substantial JJ N
differences NNS N
in IN N
terms NNS N
of IN N
recurrence-free NN o
or CC o
overall JJ o
survival NN o
between IN N
the DT N
treatment NN N
groups NNS N
. . N

The DT N
risk NN o
of IN o
a DT o
second JJ o
primary JJ o
malignancy NN o
, , N
however RB N
, , N
was VBD N
doubled VBN N
in IN N
the DT N
RT NNP N
group NN N
( ( N
p JJ N
> NNP N
0.01 CD N
) ) N
. . N

The DT N
most RBS N
pronounced JJ N
excess NN N
concerned JJ N
second JJ o
lung NN o
cancers NNS o
occurring VBG N
after IN N
10 CD N
years NNS N
. . N

The DT N
cumulative JJ o
incidence NN o
at IN o
20 CD o
years NNS o
was VBD N
estimated VBN N
at IN N
0.3 CD N
% NN N
and CC N
3.7 CD N
% NN N
in IN N
the DT N
CT NNP N
and CC N
RT NNP N
groups NNS N
, , N
respectively RB N
. . N

The DT N
trials NNS N
illustrate VBP N
the DT N
role NN N
of IN N
radiotherapy NN N
in IN N
preventing VBG N
loco-regional JJ o
recurrences NNS o
among IN N
high-risk JJ N
patients NNS N
, , N
as RB N
well RB N
as IN N
the DT N
need NN N
for IN N
systemic JJ N
treatment NN N
to TO N
control VB N
the DT N
disease NN N
systemically RB N
. . N

-DOCSTART- -9229263- O O

Brief JJ N
report NN N
: : N
autistic JJ p
children NNS p
's POS p
attentiveness NN o
and CC o
responsivity NN o
improve VBP N
after IN N
touch JJ i
therapy NN i
. . i

-DOCSTART- -25179065- O O

GPs NNP N
' POS N
experiences NNS N
with IN N
brief JJ i
intervention NN i
for IN N
medication-overuse JJ N
headache NN N
: : N
a DT N
qualitative JJ N
study NN N
in IN N
general JJ N
practice NN N
. . N

BACKGROUND NNP N
Medication-overuse NNP N
headache NN N
( ( N
MOH NNP N
) ) N
is VBZ N
common JJ N
in IN N
the DT N
general JJ N
population NN N
, , N
and CC N
most JJS N
patients NNS N
are VBP N
managed VBN N
in IN N
primary JJ N
health NN N
care NN N
. . N

Brief JJ i
Intervention NNP i
( ( i
BI NNP i
) ) i
has VBZ N
been VBN N
used VBN N
as IN N
a DT N
motivational JJ N
technique NN N
for IN N
patients NNS p
with IN p
drug NN p
and CC p
alcohol NN p
overuse NN p
, , N
and CC N
may MD N
a DT N
have VB N
role NN N
in IN N
the DT N
treatment NN N
of IN N
MOH NNP N
. . N

AIM NNP N
To TO N
explore VB N
GPs NNP i
' POS i
experiences NNS i
using VBG i
BI NNP i
in IN i
the DT N
management NN p
of IN p
patients NNS p
with IN p
MOH NNP p
. . p

DESIGN NNP N
AND CC N
SETTING NNP N
Qualitative NNP N
study NN N
in IN N
Norwegian JJ p
general JJ p
practice NN p
. . p

METHOD NNP N
Data NNP N
were VBD N
collected VBN N
through IN N
four CD p
focus NN p
group NN p
interviews VBZ p
with IN p
22 CD p
GPs NNP p
who WP p
participated VBD p
in IN p
an DT p
intervention NN p
study NN p
on IN p
BI NNP i
for IN p
MOH NNP p
. . p

Systematic NNP N
text JJ N
condensation NN N
was VBD N
used VBN N
to TO N
analyse VB N
transcripts NNS N
from IN N
the DT N
focus NN p
group NN p
interviews NNS p
. . p

RESULTS VB N
The DT N
GPs NNP i
experienced VBD i
challenges NNS N
when WRB N
trying VBG N
to TO N
convince VB N
patients NNS N
that IN N
the DT N
medication NN N
they PRP N
used VBD N
to TO N
treat VB N
and CC N
prevent VB N
headache NN N
could MD N
cause VB N
headache NN N
, , N
but CC N
labelling VBG N
MOH NNP N
as IN N
a DT N
diagnosis NN N
opened VBD N
up RP N
a DT N
space NN N
for IN N
change NN N
. . N

GPs NNP N
were VBD N
able JJ N
to TO N
use VB N
BI NNP i
within IN N
the DT N
scope NN N
of IN N
a DT N
regular JJ N
consultation NN N
, , N
and CC N
they PRP N
thought VBD N
that IN N
the DT N
structured JJ N
approach NN N
had VBD N
a DT N
potential JJ N
to TO N
change VB N
patients NNS N
' POS N
views NNS N
about IN N
their PRP$ N
condition NN N
and CC N
medication NN N
use NN N
. . N

Being VBG N
diagnosed VBN N
with IN N
medication NN N
overuse NN N
could MD N
bring VB N
about RP N
feelings NNS N
of IN N
guilt NN o
in IN N
patients NNS N
, , N
and CC N
GPs NNP N
emphasised VBD N
that IN N
a DT N
good JJ N
alliance NN N
with IN N
the DT N
patient NN N
was VBD N
necessary JJ N
for IN N
successful JJ N
change NN N
using VBG N
BI NNP N
to TO N
manage VB N
MOH NNP N
. . N

CONCLUSION NNP N
GPs NNP i
experience NN i
BI NNP i
as IN N
a DT N
feasible JJ N
strategy NN N
to TO N
treat VB N
MOH NNP N
, , N
and CC N
the DT N
technique NN N
relies VBZ N
on IN N
a DT N
good JJ N
alliance NN N
between IN N
the DT N
doctor NN N
and CC N
patient NN N
. . N

When WRB N
using VBG N
BI NNP i
, , N
GPs NNP N
must MD N
be VB N
prepared VBN N
to TO N
counter VB N
patients NNS N
' POS N
misconceptions NNS N
about IN N
medication NN N
used VBN N
for IN N
headache NN N
. . N

-DOCSTART- -19808281- O O

Long-term JJ N
prospective JJ N
, , N
randomized VBN N
, , N
controlled VBN N
study NN N
using VBG N
repetitive JJ N
education NN N
at IN N
six-month JJ N
intervals NNS N
and CC N
monitoring NN N
for IN N
adherence NN N
in IN N
heart NN p
failure NN p
outpatients NNS p
: : p
the DT N
REMADHE NNP N
trial NN N
. . N

BACKGROUND VB N
The DT N
effectiveness NN N
of IN N
heart NN N
failure NN N
disease NN N
management NN N
programs NNS N
in IN N
patients NNS p
under IN p
cardiologists NNS p
' POS p
care NN p
over IN p
long-term JJ p
follow-up NN p
is VBZ N
not RB N
established VBN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
We PRP N
investigated VBD N
the DT N
effects NNS N
of IN N
a DT N
disease JJ i
management NN i
program NN i
with IN i
repetitive JJ i
education NN i
and CC i
telephone NN i
monitoring NN i
on IN N
primary JJ o
( ( o
combined VBN o
death NN o
or CC o
unplanned JJ o
first JJ o
hospitalization NN o
and CC o
quality-of-life JJ o
changes NNS o
) ) o
and CC o
secondary JJ o
end NN o
points NNS o
( ( o
hospitalization NN o
, , o
death NN o
, , o
and CC o
adherence NN o
) ) o
. . o

The DT N
REMADHE NNP N
[ NNP N
Repetitive NNP N
Education NNP i
and CC i
Monitoring NNP i
for IN N
ADherence NNP N
for IN N
Heart NNP N
Failure NNP N
] NNP N
trial NN N
is VBZ N
a DT N
long-term JJ N
randomized NN N
, , N
prospective JJ N
, , N
parallel JJ N
trial NN N
designed VBN N
to TO N
compare VB N
intervention NN N
with IN N
control NN i
. . i

One CD p
hundred VBD p
seventeen JJ p
patients NNS p
were VBD p
randomized VBN p
to TO p
usual JJ p
care NN p
, , p
and CC p
233 CD p
to TO p
additional JJ p
intervention NN p
. . p

The DT N
mean JJ N
follow-up NN N
was VBD N
2.47+/-1.75 CD N
years NNS N
, , N
with IN N
54 CD N
% NN N
adherence NN N
to TO N
the DT N
program NN N
. . N

In IN N
the DT N
intervention NN N
group NN N
, , N
the DT N
primary JJ N
end NN N
point NN N
composite NN o
of IN o
death NN o
or CC o
unplanned JJ o
hospitalization NN o
was VBD N
reduced VBN N
( ( N
hazard JJ N
ratio NN N
, , N
0.64 CD N
; : N
confidence NN N
interval NN N
, , N
0.43 CD N
to TO N
0.88 CD N
; : N
P=0.008 NNP N
) ) N
, , N
driven VBN N
by IN N
reduction NN N
in IN N
hospitalization NN o
. . o

The DT N
quality-of-life JJ o
questionnaire NN o
score NN o
improved VBD N
only RB N
in IN N
the DT N
intervention NN N
group NN N
( ( N
P NNP N
< NNP N
0.003 CD N
) ) N
. . N

Mortality NNP o
was VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

Number NNP o
of IN o
hospitalizations NNS o
( ( N
1.3+/-1.7 JJ N
versus NN N
0.8+/-1.3 NN N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
total JJ o
hospital NN o
days NNS o
during IN o
the DT o
follow-up JJ o
( ( N
19.9+/-51 JJ N
versus NN N
11.1+/-24 JJ N
days NNS N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
and CC N
the DT N
need NN o
for IN o
emergency NN o
visits NNS o
( ( N
4.5+/-10.6 JJ N
versus NN N
1.6+/-2.4 CD N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
were VBD N
lower JJR N
in IN N
the DT N
intervention NN N
group NN N
. . N

Beneficial JJ o
effects NNS o
were VBD N
homogeneous JJ N
for IN N
sex NN N
, , N
race NN N
, , N
diabetes NNS N
and CC N
no DT N
diabetes NN N
, , N
age NN N
, , N
functional JJ N
class NN N
, , N
and CC N
etiology NN N
. . N

CONCLUSIONS NNP N
For IN N
a DT N
longer RBR N
follow-up JJ N
period NN N
than IN N
in IN N
previous JJ N
studies NNS N
, , N
this DT N
heart NN N
failure NN N
disease JJ N
management NN N
program NN N
model NN N
of IN N
patients NNS p
under IN p
the DT p
supervision NN p
of IN p
a DT p
cardiologist NN p
is VBZ N
associated VBN N
with IN N
a DT N
reduction NN N
in IN N
unplanned JJ o
hospitalization NN o
, , N
a DT N
reduction NN N
of IN N
total JJ o
hospital NN o
days NNS o
, , N
and CC N
a DT N
reduced JJ N
need NN o
for IN o
emergency NN o
care NN o
, , N
as RB N
well RB N
as IN N
improved VBN o
quality NN o
of IN o
life NN o
, , N
despite IN N
modest JJ N
program NN o
adherence NN o
over IN N
time NN N
. . N

-DOCSTART- -16904652- O O

Oxytocin NNP i
increases VBZ N
retention NN o
of IN o
social JJ o
cognition NN o
in IN N
autism NN N
. . N

BACKGROUND NNP N
Oxytocin NNP i
dysfunction NN N
might MD N
contribute VB N
to TO N
the DT N
development NN N
of IN N
social JJ N
deficits NNS N
in IN N
autism NN N
, , N
a DT N
core NN N
symptom NN N
domain NN N
and CC N
potential JJ N
target NN N
for IN N
intervention NN N
. . N

This DT N
study NN N
explored VBD N
the DT N
effect NN N
of IN N
intravenous JJ N
oxytocin JJ i
administration NN N
on IN N
the DT N
retention NN N
of IN N
social JJ N
information NN N
in IN N
autism NN N
. . N

METHODS NNP N
Oxytocin NNP i
and CC i
placebo NN i
challenges NNS N
were VBD N
administered VBN N
to TO N
15 CD p
adult NN p
subjects NNS p
diagnosed VBN p
with IN p
autism NN p
or CC p
Asperger NNP p
's POS p
disorder NN p
, , p
and CC p
comprehension NN p
of IN p
affective JJ p
speech NN p
( ( p
happy JJ p
, , p
indifferent JJ p
, , p
angry JJ p
, , p
and CC p
sad NN p
) ) p
in IN N
neutral JJ N
content NN N
sentences NNS N
was VBD N
tested VBN N
. . N

RESULTS NNP N
All NNP N
subjects VBZ N
showed VBD N
improvements NNS N
in IN N
affective JJ o
speech NN o
comprehension NN o
from IN N
pre- JJ N
to TO N
post-infusion NN N
; : N
however RB N
, , N
whereas NNS N
those DT N
who WP N
received VBD N
placebo NN i
first RB N
tended VBD N
to TO N
revert VB N
to TO N
baseline VB N
after IN N
a DT N
delay NN N
, , N
those DT N
who WP N
received VBD N
oxytocin PRP N
first RB N
retained VBD N
the DT N
ability NN N
to TO N
accurately RB N
assign VB o
emotional JJ o
significance NN o
to TO o
speech VB o
intonation NN o
on IN N
the DT N
speech NN N
comprehension NN N
task NN N
. . N

CONCLUSIONS NNP N
These DT N
results NNS N
are VBP N
consistent JJ N
with IN N
studies NNS N
linking VBG N
oxytocin NN i
to TO N
social JJ o
recognition NN o
in IN N
rodents NNS N
as RB N
well RB N
as IN N
studies NNS N
linking VBG N
oxytocin NN N
to TO N
prosocial JJ o
behavior NN o
in IN N
humans NNS N
and CC N
suggest VBP N
that IN N
oxytocin NN N
might MD N
facilitate VB N
social JJ N
information NN N
processing NN N
in IN N
those DT N
with IN N
autism NN N
. . N

These DT N
findings NNS N
also RB N
provide VBP N
preliminary JJ N
support NN N
for IN N
the DT N
use NN N
of IN N
oxytocin NN i
in IN N
the DT N
treatment NN N
of IN N
autism NN N
. . N

-DOCSTART- -22924950- O O

Efficacy NN o
and CC o
safety NN o
of IN N
bexarotene NN i
combined VBN i
with IN i
psoralen-ultraviolet NN i
A NNP i
( ( i
PUVA NNP i
) ) i
compared VBN i
with IN i
PUVA NNP i
treatment NN i
alone RB i
in IN N
stage JJ N
IB-IIA JJ N
mycosis NN N
fungoides NNS N
: : N
final JJ N
results NNS N
from IN N
the DT N
EORTC NNP N
Cutaneous NNP p
Lymphoma NNP p
Task NNP p
Force NNP p
phase NN p
III NNP p
randomized VBD p
clinical JJ p
trial NN p
( ( N
NCT00056056 NNP N
) ) N
. . N

BACKGROUND NNP N
Psoralen NNP i
plus CC i
ultraviolet VB i
A NNP i
( ( i
PUVA NNP i
) ) i
is VBZ N
the DT N
standard JJ N
treatment NN N
for IN N
early JJ p
stages NNS p
of IN p
mycosis NN p
fungoides NNS p
. . p

There EX N
have VBP N
been VBN N
no DT N
adequate JJ N
randomized VBN N
controlled JJ N
trials NNS N
with IN N
sufficient JJ N
power NN N
comparing VBG N
this DT N
modality NN N
with IN N
other JJ N
therapies NNS N
. . N

OBJECTIVE NNP N
To TO N
assess VB N
disease NN o
response NN o
and CC N
to TO N
compare VB N
the DT N
response NN o
rates NNS o
of IN N
patients NNS p
treated VBN p
with IN p
PUVA NNP i
alone RB i
or CC p
PUVA NNP i
and CC i
bexarotene NN i
. . i

METHODS NNP N
EORTC NNP N
21011 CD N
( ( N
NCT NNP N
00056056 CD N
) ) N
was VBD N
a DT N
randomized JJ N
phase NN N
III NNP N
study NN N
comparing VBG N
combined VBN i
bexarotene NN i
( ( i
Targretin NNP i
( ( i
? . i
) ) i
) ) i
and CC i
PUVA NNP i
vs. FW i
PUVA NNP i
alone RB i
in IN p
patients NNS p
with IN p
stage NN p
IB NNP p
and CC p
IIA NNP p
mycosis NN p
fungoides NNS p
( ( p
MF NNP p
) ) p
. . p

The DT N
primary JJ N
endpoint NN N
was VBD N
the DT o
overall JJ o
response NN o
rate NN o
[ NNP o
complete JJ o
clinical JJ o
response NN o
( ( o
CCR NNP o
) ) o
plus CC o
partial JJ o
response NN o
( ( o
PR NNP o
) ) o
] NN o
. . o

RESULTS VB N
The DT N
study NN N
was VBD N
prematurely RB N
closed VBN N
due JJ N
to TO N
low JJ N
accrual JJ N
after IN p
93 CD p
of IN p
145 CD p
required JJ p
patients NNS p
( ( N
65 CD N
% NN N
) ) N
were VBD N
randomized VBN N
. . N

Of IN N
the DT p
93 CD p
randomized JJ p
patients NNS p
, , p
87 CD p
started VBD p
treatment NN p
, , p
41 CD p
received VBD i
PUVA NNP i
and CC p
46 CD p
received VBD i
PUVA NNP i
+ NNP i
bexarotene NN i
. . i

Total JJ o
UVA NNP o
doses NNS o
received VBD N
were VBD N
107 CD N
J NNP N
cm NN N
( ( N
-2 NN N
) ) N
( ( N
range VB N
1?4-489?9 CD N
) ) N
in IN N
the DT N
PUVA NNP i
arm NN i
vs. FW N
101?7 CD N
J NNP N
cm NN N
( ( N
-2 NN N
) ) N
( ( N
0?2-529?9 JJ N
) ) N
in IN N
the DT N
combination NN N
arm NN N
. . N

The DT o
safety NN o
profile NN o
was VBD o
acceptable JJ o
with IN N
few JJ o
grade JJ o
3-4 JJ o
toxicities NNS o
observed VBN o
in IN N
either DT N
arm NN N
. . N

More JJR N
drop-outs NNS o
due JJ o
to TO o
toxicity NN o
were VBD o
observed VBN N
in IN N
the DT N
combination NN N
arm NN N
compared VBN N
with IN N
the DT i
PUVA-alone JJ i
arm NN i
. . i

The DT N
best JJS o
overall JJ o
response NN o
( ( o
CCR NNP o
+ NNP o
PR NNP o
) ) o
rate NN o
was VBD N
71 CD N
% NN N
for IN i
PUVA NNP i
alone RB i
and CC N
77 CD N
% NN N
for IN N
the DT N
combination NN N
arm NN N
( ( N
P NNP N
= NNP N
0?57 CD N
) ) N
. . N

The DT o
median JJ o
duration NN o
of IN o
response NN o
was VBD o
9?7 CD o
months NNS N
for IN i
PUVA NNP i
vs. FW i
5?8 CD N
months NNS N
for IN N
the DT N
combination NN N
arm NN N
( ( N
P NNP N
= NNP N
0?33 CD N
) ) N
. . N

CCR NNP o
was VBD o
seen VBN N
in IN N
25 CD N
patients NNS N
of IN N
whom WP N
10 CD N
received VBD i
PUVA NNP i
alone RB i
( ( o
CCR NNP o
22 CD o
% NN o
) ) o
and CC N
15 CD N
received VBN i
combination NN o
therapy NN o
( ( o
CCR NNP o
31 CD o
% NN o
) ) o
( ( N
P NNP N
= NNP N
0?45 CD N
) ) N
. . o

CCR NNP o
was VBD o
sustained VBN o
in IN N
25 CD N
% NN N
of IN N
patients NNS N
regardless RB N
of IN N
therapy NN N
. . N

There EX N
was VBD N
a DT N
trend NN N
towards VBZ N
fewer JJR i
PUVA NNP i
sessions NNS o
needed VBD o
to TO o
achieve VB o
CCR NNP o
in IN o
the DT o
combination NN N
arm NN N
( ( N
median JJ N
22 CD N
) ) N
compared VBN N
with IN i
the DT i
PUVA NNP i
arm NN i
( ( N
median JJ N
27?5 CD N
) ) N
( ( N
P NNP N
= NNP N
0?11 CD N
) ) N
. . N

Similarly RB N
, , N
a DT N
trend NN N
towards NNS N
lower JJR N
UVA NNP i
dose NN o
required VBN o
to TO o
achieve VB o
CCR NNP o
in IN N
the DT N
combination NN N
arm NN N
( ( N
median JJ N
55?8 CD N
J NNP N
cm NN N
( ( N
-2 NNP N
) ) N
) ) N
compared VBN N
with IN N
the DT i
PUVA NNP i
arm NN N
alone RB N
( ( N
median JJ N
117?5 CD N
J NNP N
cm NN N
( ( N
-2 NNP N
) ) N
) ) N
( ( N
P NNP N
= NNP N
0?5 CD N
) ) N
was VBD N
observed VBN N
. . N

CONCLUSIONS NNP N
No NNP N
significant JJ N
difference NN o
in IN o
response NN o
rate NN o
or CC o
response NN o
duration NN o
was VBD o
observed VBN o
in IN N
this DT N
study NN N
. . N

However RB N
, , N
there EX N
was VBD N
a DT N
trend NN N
towards VBZ N
fewer JJR o
PUVA NNP o
sessions NNS o
and CC o
lower JJR o
UVA NNP o
dose NN o
required VBN o
to TO o
achieve VB o
CCR NNP o
in IN N
the DT N
combination NN N
arm NN N
( ( i
PUVA NNP i
+ NNP i
bexarotene NN i
) ) i
but CC i
this DT N
did VBD N
not RB N
achieve VB N
statistical JJ N
significance NN N
due JJ N
to TO N
insufficient JJ N
power NN N
. . N

-DOCSTART- -8161002- O O

Anticholinergic NNP i
drugs NNS i
: : i
effects NNS N
on IN N
oxygen NN o
consumption NN o
and CC o
energy NN o
expenditure NN o
. . o

Premedication NN N
has VBZ N
been VBN N
shown VBN N
to TO N
affect VB N
both DT N
oxygen NN o
consumption NN o
( ( N
VO2 NNP N
) ) N
and CC N
energy NN o
expenditure NN o
( ( N
EE NNP N
) ) N
. . N

The DT N
metabolic JJ N
responses NNS N
to TO N
anticholinergic VB N
drugs NNS N
have VBP N
not RB N
been VBN N
studied VBN N
. . N

In IN N
this DT N
study NN N
the DT N
effects NNS N
of IN N
anticholinergic JJ i
drugs NNS i
on IN N
VO2 NNP N
and CC N
EE NNP N
( ( N
calculated VBN N
from IN N
the DT N
measured VBN N
rates NNS N
of IN N
VO2 NNP N
and CC N
carbon NN N
dioxide NN N
production NN N
[ NNP N
VCO2 NNP N
] NN N
: : N
EE NNP N
[ NNP N
kcal/d NNP N
] NNP N
= VBD N
3.581 CD N
x NNP N
VO2 NNP N
[ NNP N
L/d NNP N
] NNP N
+ VBD N
1.448 CD N
x NNP N
VCO2 NNP N
[ NNP N
L/d NNP N
] NNP N
- : N
32.4 CD N
) ) N
were VBD N
measured VBN N
in IN N
six CD p
healthy JJ p
female NN p
volunteers NNS p
. . p

They PRP N
were VBD N
given VBN N
intramuscular JJ N
atropine NN i
( ( N
15 CD N
micrograms/kg NN N
) ) N
, , N
glycopyrrolate NN i
( ( N
8 CD N
micrograms/kg NN N
) ) N
, , N
scopolamine NN i
( ( N
8 CD N
micrograms/kg NN N
) ) N
, , N
and CC i
placebo NN i
in IN N
a DT N
random JJ N
double-blind JJ N
cross-over NN N
design NN N
. . N

The DT N
consecutive JJ N
sessions NNS N
were VBD N
at IN N
least JJS N
1 CD N
wk JJ N
apart RB N
for IN N
each DT N
subject NN N
. . N

VO2 NNP o
and CC o
EE NNP o
were VBD N
measured VBN N
using VBG N
an DT N
indirect JJ N
calorimetry NN N
( ( N
Deltatrac NNP N
) ) N
. . N

Cardiovascular JJ o
responses NNS o
were VBD N
assessed VBN N
using VBG N
standard JJ N
noninvasive JJ N
monitoring NN N
. . N

Plasma NNP o
drug NN o
concentrations NNS o
were VBD N
analyzed VBN N
using VBG N
a DT N
sensitive JJ N
modification NN N
of IN N
radioreceptor NN N
assay NN N
. . N

Subjective JJ N
responses NNS N
were VBD N
measured VBN N
with IN N
visual JJ o
analog NN o
scale NN o
( ( o
VAS NNP o
) ) o
. . N

Atropine NNP i
and CC N
glycopyrrolate NN i
induced VBD N
a DT N
significant JJ N
increase NN N
in IN N
heart NN o
rate NN o
with IN N
a DT N
simultaneous JJ N
decrease NN N
in IN N
pressure NN o
rate NN o
quotient NN o
( ( o
PRQ NNP o
) ) o
, , N
while IN N
scopolamine NN N
caused VBD N
a DT N
significant JJ N
decrease NN N
in IN N
heart NN o
rate NN o
with IN N
a DT N
simultaneous JJ N
increase NN o
in IN o
PRQ NNP o
. . o

Scopolamine NNP i
significantly RB N
decreased VBD N
both DT N
VO2 NNP o
and CC o
EE NNP o
, , N
whereas JJ N
glycopyrrolate NN i
increased VBD N
VO2 NNP o
. . o

Atropine NNP i
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
metabolic JJ o
variables NNS o
. . o

Only RB N
scopolamine NN N
induced JJ N
sedation NN o
in IN N
this DT N
study NN N
. . N

In IN N
conclusion NN N
, , N
atropine NN i
, , i
glycopyrrolate NN i
, , N
and CC N
scopolamine NN i
differ NN N
not RB N
only RB N
in IN N
their PRP$ N
cardiovascular NN N
and CC N
central JJ N
nervous JJ N
system NN N
effects NNS N
, , N
but CC N
also RB N
in IN N
their PRP$ N
effects NNS N
on IN N
metabolism NN N
. . N

-DOCSTART- -24530652- O O

Alleviating VBG N
social JJ N
avoidance NN N
: : N
effects NNS N
of IN N
single JJ i
dose NN i
testosterone NN i
administration NN i
on IN N
approach-avoidance JJ o
action NN o
. . o

Testosterone NN i
is VBZ N
an DT N
important JJ N
regulator NN N
of IN N
social-motivational JJ o
behavior NN o
and CC N
is VBZ N
known VBN N
for IN N
its PRP$ N
dominance-enhancing JJ o
and CC o
social-anxiolytic JJ o
properties NNS N
. . N

However RB N
, , N
to TO N
date NN N
no DT N
studies NNS N
have VBP N
systematically RB N
investigated VBN N
the DT N
causal NN N
effect NN N
of IN N
testosterone NN N
on IN N
actual JJ o
social JJ o
approach-avoidance NN o
behavior NN o
in IN N
humans NNS N
. . N

The DT N
present JJ N
study NN N
sets VBZ N
out RP N
to TO N
test VB N
the DT N
effects NNS N
of IN N
testosterone NN i
administration NN i
in IN N
healthy JJ p
female NN p
volunteers NNS p
using VBG p
an DT p
objective JJ p
implicit JJ p
measure NN p
of IN p
social JJ o
motivational JJ o
behavior NN o
: : o
the DT N
social JJ o
Approach-Avoidance NNP o
Task NNP o
, , N
a DT N
reaction NN N
time NN N
task NN N
requiring VBG N
participants NNS N
to TO N
approach VB o
or CC o
avoid VB o
visually RB o
presented VBN o
emotional JJ o
( ( o
happy JJ o
, , o
angry JJ o
, , o
and CC o
neutral JJ o
) ) o
faces VBZ o
. . o

Participants NNS N
showed VBD N
significantly RB N
diminished VBN N
avoidance NN o
tendencies NNS o
to TO N
angry JJ o
faces VBZ o
after IN N
testosterone NN i
administration NN N
. . N

Testosterone CD i
did VBD N
not RB N
affect VB N
approach-avoidance NN o
tendencies NNS o
to TO o
social JJ o
affiliation NN o
( ( o
happy JJ o
) ) o
faces VBZ o
. . o

Thus NNP N
, , N
a DT N
single JJ N
dose NN N
testosterone NN i
administration NN N
reduces VBZ N
automatic JJ o
avoidance NN o
of IN o
social JJ o
threat NN o
and CC o
promotes NNS o
relative JJ o
increase NN o
of IN o
threat NN o
approach NN o
tendencies NNS o
in IN N
healthy JJ p
females NNS p
. . p

These DT N
findings NNS N
further VBP N
the DT N
understanding NN N
of IN N
the DT N
neuroendocrine JJ N
regulation NN N
of IN N
social JJ o
motivational JJ o
behavior NN o
and CC N
may MD N
have VB N
direct JJ N
treatment NN N
implications NNS N
for IN N
social JJ o
anxiety NN o
, , N
characterized VBN N
by IN N
persistent JJ N
social JJ o
avoidance NN o
. . o

-DOCSTART- -6496450- O O

Immunogenicity NN o
and CC N
safety NN o
of IN N
a DT N
plasma-derived JJ i
heat-inactivated JJ i
hepatitis NN i
B NNP i
vaccine NN i
( ( i
CLB NNP i
) ) i
. . N

Studies NNPS N
in IN N
volunteers NNS p
at IN p
a DT p
low JJ p
risk NN p
of IN p
infection NN p
with IN p
hepatitis NN p
B NNP p
virus NN p
. . p

The DT N
safety NN o
and CC N
immunogenicity NN o
of IN N
a DT N
plasma-derived JJ i
heat-inactivated JJ i
hepatitis NN i
B NNP i
vaccine NN i
( ( i
CLB NNP i
) ) i
were VBD N
evaluated VBN N
in IN N
471 CD p
healthy JJ p
human JJ p
volunteers NNS p
, , p
who WP p
, , p
both DT p
in IN p
their PRP$ p
occupations NNS p
and CC p
in IN p
their PRP$ p
private JJ p
lives NNS p
, , p
had VBD p
been VBN p
at IN p
minimal JJ p
risk NN p
of IN p
being VBG p
infected VBN p
with IN p
hepatitis NN p
B NNP p
virus NN p
. . p

The DT N
first JJ N
202 JJ N
individuals NNS N
received VBD N
three CD i
3-micrograms JJ i
doses NNS i
of IN i
heat-inactivated JJ i
hepatitis NN i
B NNP i
surface NN i
antigen NN i
( ( i
HBsAg NNP i
) ) i
at IN i
one-month JJ i
intervals NNS i
( ( N
trial NN N
A DT N
) ) N
. . N

A DT N
total NN N
of IN N
42 CD N
% NN N
one CD N
month NN N
after IN N
the DT N
first JJ N
injection NN N
, , N
84 CD N
% NN N
after IN N
two CD N
months NNS N
, , N
and CC N
93 CD N
% NN N
after IN N
five CD N
months NNS N
had VBD N
become VBN N
anti-HBs JJ N
( ( N
antibody NN N
to TO N
hepatitis VB N
B NNP N
surface NN N
antigen NN N
) ) N
positive JJ N
. . N

In IN N
a DT N
second JJ N
randomized VBN N
study NN N
( ( N
trial NN N
B NNP N
) ) N
, , N
the DT N
immunogenicity NN o
of IN i
five CD i
different JJ i
dosages NNS i
of IN i
the DT i
vaccine NN i
was VBD N
compared VBN N
in IN N
269 CD N
volunteers NNS N
. . N

When WRB N
the DT N
dose NN N
of IN N
HBsAg NNP N
was VBD N
diminished VBN N
from IN N
3 CD N
micrograms NNS N
to TO N
1.5 CD N
, , N
0.6 CD N
, , N
and CC N
0.25 CD N
microgram NN N
, , N
no DT N
decrease NN N
of IN N
the DT N
anti-HBs JJ o
response NN o
was VBD N
observed VBN N
. . N

However RB N
, , N
when WRB N
the DT N
dose NN N
was VBD N
diminished VBN N
to TO N
0.1 CD N
microgram NN N
of IN N
HBsAg NNP N
, , N
the DT N
anti-HBs JJ o
response NN o
dropped VBD N
significantly RB N
to TO N
63 CD N
% NN N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

In IN N
the DT N
recipients NNS N
of IN N
all DT N
five CD N
vaccine NN N
dosages NNS N
, , N
no DT N
influence NN N
of IN N
sex NN N
and CC N
age NN N
was VBD N
found VBN N
on IN N
the DT N
anti-HBs JJ o
conversion NN o
rates NNS o
. . o

During IN N
the DT N
eight-month JJ N
observation NN N
period NN N
, , N
none NN N
of IN N
the DT N
vaccinees NNS N
became VBD N
HBsAg NNP o
and/or IN o
anti-HBc JJ o
( ( o
antibody NN o
to TO o
hepatitis VB o
B NNP o
core NN o
antigen NN o
) ) o
positive JJ o
, , N
and CC N
none NN N
developed VBD N
antibodies NNS o
associated VBN N
with IN N
autoimmune JJ N
liver NN N
disease NN N
. . N

No DT N
serious JJ o
side NN o
effects NNS o
were VBD N
observed VBN N
. . N

-DOCSTART- -17519714- O O

Ropivacaine NNP i
versus NN N
lidocaine NN i
in IN N
digital JJ p
nerve NN p
blocks NNS p
: : p
a DT N
prospective JJ N
study NN N
. . N

BACKGROUND NNP N
Ropivacaine NNP i
is VBZ N
a DT N
relatively RB N
new JJ N
long-acting JJ N
amide JJ N
local JJ N
anesthetic NN N
. . N

Since IN N
its PRP$ N
introduction NN N
in IN N
1996 CD N
, , N
it PRP N
has VBZ N
been VBN N
used VBN N
for IN N
subcutaneous JJ N
infiltration NN N
; : N
epidural JJ N
, , N
intrathecal JJ N
, , N
and CC N
peripheral JJ N
nerve NN N
block NN N
surgery NN N
; : N
and CC N
postoperative JJ N
analgesia NN N
. . N

However RB N
, , N
it PRP N
has VBZ N
never RB N
been VBN N
used VBN N
for IN N
digital JJ N
blocks NNS N
. . N

This DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
study NN N
compares VBZ N
the DT N
digital JJ N
block NN N
results NNS N
following VBG N
the DT N
administration NN N
of IN N
2.5 CD i
ml NN i
of IN i
0.75 CD i
% NN i
ropivacaine JJ i
solution NN i
and CC i
2.5 CD i
ml NN i
of IN i
2 CD i
% NN i
lidocaine JJ i
solution NN i
. . i

METHODS NN N
From IN p
March NNP p
of IN p
1999 CD p
to TO p
March NNP p
of IN p
2001 CD p
, , p
70 CD p
adult NN p
patients NNS p
who WP p
underwent VBP p
immediate JJ p
reconstruction NN i
for IN i
traumatic JJ i
injuries NNS i
of IN i
the DT i
digits NNS i
were VBD N
prospectively RB N
randomized VBN N
into IN N
two CD N
groups NNS N
. . N

Group NNP N
A NNP N
( ( N
n JJ N
= NNP N
35 CD N
) ) N
received VBD N
2.5 CD N
ml NNS N
0.75 CD N
% NN N
ropivacaine NN i
and CC N
group NN N
B NNP N
( ( N
n JJ N
= NNP N
35 CD N
) ) N
received VBD N
2.5 CD N
ml NN N
of IN N
2 CD N
% NN N
lidocaine NN i
for IN N
digital JJ N
anesthesia NN N
. . N

Onset NNP o
time NN o
of IN o
anesthetic JJ o
action NN o
, , o
duration NN o
of IN o
anesthesia NN o
, , o
time NN o
until IN o
first JJ o
postoperative JJ o
requirement NN o
for IN o
pain NN o
medication NN o
, , o
and CC o
digital-brachial JJ o
artery NN o
systolic JJ o
blood NN o
pressure NN o
index NN o
were VBD N
recorded VBN N
and CC N
evaluated VBN N
. . N

Local JJ o
vascular JJ o
effects NNS o
were VBD N
observed VBN N
visually RB N
. . N

RESULTS NNP N
No NNP N
side JJ o
effects NNS o
were VBD N
observed VBN N
. . N

Lidocaine NNP i
had VBD N
the DT N
quickest JJS N
onset NN o
of IN o
anesthesia NN o
, , N
with IN N
a DT N
mean JJ N
time NN N
of IN N
1.3 CD N
minutes NNS N
( ( N
range NN N
, , N
1 CD N
to TO N
2.7 CD N
minutes NNS N
) ) N
. . N

Ropivacaine NNP i
had VBD N
a DT N
mean JJ o
onset NN o
time NN o
of IN N
4.5 CD N
minutes NNS N
( ( N
range NN N
, , N
3.5 CD N
to TO N
5.5 CD N
minutes NNS N
) ) N
. . N

The DT N
mean JJ o
duration NN o
of IN o
postoperative JJ o
anesthesia NN o
for IN N
lidocaine NN i
was VBD N
2.4 CD N
hours NNS N
( ( N
range NN N
, , N
1.4 CD N
to TO N
4 CD N
hours NNS N
) ) N
, , N
compared VBN N
with IN N
21.5 CD N
hours NNS N
for IN N
ropivacaine NN i
and CC N
less RBR N
requirement NN N
for IN N
analgesics NNS N
during IN N
the DT N
first JJ N
24 CD N
postoperative JJ N
hours NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
( ( N
range NN N
, , N
19 CD N
to TO N
23 CD N
hours NNS N
) ) N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
found VBN N
between IN N
the DT N
digital-brachial JJ o
artery NN o
systolic JJ o
blood NN o
pressure NN o
index NN o
of IN N
group NN N
A NNP N
compared VBN N
with IN N
group NN N
B NNP N
. . N

CONCLUSIONS NNP N
Ropivacaine NNP i
can MD N
be VB N
used VBN N
effectively RB o
as IN N
a DT N
local JJ N
anesthetic NN N
for IN N
digital JJ p
nerve NN p
blocks NNS p
. . p

It PRP N
can MD N
be VB N
used VBN N
for IN N
prolonged JJ N
operations NNS N
( ( N
> $ N
1.5 CD N
hours NNS N
) ) N
without IN N
additional JJ N
injections NNS N
and CC N
can MD N
provide VB N
long-lasting JJ N
postoperative JJ N
analgesia NN N
. . N

-DOCSTART- -17037712- O O

Comparison NNP N
of IN N
the DT N
effectiveness NN o
of IN o
fennel NN o
and CC o
mefenamic JJ o
acid NN o
on IN N
pain NN N
intensity NN N
in IN N
dysmenorrhoea NN p
. . p

A DT N
study NN N
in IN N
Kerman NNP p
, , p
Islamic NNP p
Republic NNP p
of IN p
Iran NNP p
in IN p
2002 CD p
compared VBN N
the DT N
effectiveness NN o
of IN o
fennel NN o
and CC o
mefenamic JJ o
acid NN o
on IN N
pain NN N
relief NN N
in IN N
primary JJ p
dysmenorrhoea NN p
. . p

Two CD p
groups NNS p
of IN p
high-school JJ p
girls NNS p
( ( p
mean JJ p
age NN p
13 CD p
years NNS p
) ) p
suffering VBG p
dysmenorrhoea NN p
were VBD p
randomized VBN p
to TO N
receive VB N
fennel NN i
extract NN i
( ( N
n JJ N
= NNP N
55 CD N
) ) N
or CC N
mefenamic JJ i
acid NN i
( ( N
n JJ N
= NNP N
55 CD N
) ) N
for IN N
2 CD N
months NNS N
. . N

In IN N
the DT N
fennel NN i
group NN N
, , N
80 CD N
% NN N
of IN N
girls NNS N
and CC N
in IN N
the DT N
mefenamic JJ i
acid NN i
group NN N
, , N
73 CD N
% NN N
of IN N
girls NNS N
showed VBD N
complete JJ N
pain NN o
relief NN o
or CC o
pain NN o
decrease NN o
, , N
while IN N
80 CD N
% NN N
in IN N
the DT N
fennel NN i
group NN N
and CC N
62 CD N
% NN N
in IN N
the DT N
mefenamic JJ i
acid NN i
group NN N
no RB N
longer RB N
needed VBN N
to TO N
rest VB N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
2 CD N
groups NNS N
in IN N
the DT N
level NN o
of IN o
pain NN o
relief NN o
. . o

-DOCSTART- -12511152- O O

Trials NNS N
and CC N
tribulations NNS N
: : N
current JJ N
challenges NNS N
in IN N
conducting VBG N
clinical JJ i
trials NNS i
. . i

Randomized VBN i
controlled JJ i
trials NNS i
are VBP N
the DT N
gold JJ N
standard NN N
for IN N
the DT N
evaluation NN N
of IN N
new JJ N
therapies NNS N
and CC N
surgical JJ N
procedures NNS N
and CC N
as IN N
such JJ N
require VBP N
strict JJ N
attention NN N
to TO N
study VB N
design NN N
and CC N
statistical JJ N
analysis NN N
. . N

There EX N
are VBP N
, , N
however RB N
, , N
multiple JJ N
challenges NNS N
in IN N
conducting VBG N
a DT N
well-designed JJ N
clinical JJ N
trial NN N
. . N

This DT N
article NN N
describes VBZ N
the DT N
difficulties NNS N
encountered VBD N
at IN N
a DT p
single JJ p
institution NN p
participating VBG p
in IN p
a DT p
multicenter JJ p
drug NN p
study NN p
and CC N
reviews VBZ N
the DT N
challenges NNS N
involved VBN N
in IN N
developing VBG N
a DT N
high-quality NN N
randomized VBN N
controlled VBN N
study NN N
. . N

-DOCSTART- -10492627- O O

Chemotherapy NNP i
for IN N
operable JJ p
gastric JJ p
cancer NN p
: : p
results NNS N
of IN N
the DT N
Dutch NNP N
randomised VBD N
FAMTX NNP N
trial NN N
. . N

The DT N
Dutch JJ p
Gastric NNP N
Cancer NNP N
Group NNP N
( ( N
DGCG NNP N
) ) N
. . N

The DT N
aim NN N
of IN N
this DT N
trial NN N
was VBD N
to TO N
investigate VB N
whether IN N
pre-operative JJ N
chemotherapy NN i
leads VBZ N
to TO N
a DT N
15 CD N
% NN N
higher JJR N
curative JJ o
resectability NN o
rate NN o
in IN N
patients NNS p
with IN p
operable JJ p
gastric JJ p
cancer NN p
. . p

In IN N
this DT N
randomised JJ N
trial NN N
, , N
patients NNS N
were VBD N
allocated VBN N
to TO N
receive VB N
either RB N
four CD N
courses NNS N
of IN N
chemotherapy NN i
using VBG i
5-fluorouracil JJ i
, , i
doxorubicin JJ i
and CC i
methotrexate NN i
( ( i
FAMTX NNP i
) ) i
prior RB i
to TO i
surgery NN i
or CC i
to TO i
undergo VB i
surgery NN i
only RB i
. . i

Patients NNS p
younger JJR p
than IN p
75 CD p
years NNS p
of IN p
age NN p
with IN p
a DT p
good JJ p
physical NN p
and CC p
mental JJ p
condition NN p
and CC p
a DT p
histologically RB p
proven JJ p
adenocarcinoma NN p
of IN p
the DT p
stomach NN p
without IN p
clinical JJ p
or CC p
radiographic JJ p
( ( p
computed JJ p
tomography NN p
scan NN p
) ) p
evidence NN p
of IN p
distant JJ p
metastases NNS p
were VBD N
eligible JJ N
for IN N
this DT N
trial NN N
. . N

Early JJ p
gastric JJ p
cancer NN p
or CC p
cardia VB p
carcinoma NN p
were VBD p
excluded VBN p
. . p

The DT i
response NN i
to TO i
chemotherapy NN i
was VBD i
evaluated VBN i
after IN i
two CD i
and CC i
four CD i
courses NNS i
. . i

In IN N
case NN N
of IN N
progressive JJ N
disease NN N
( ( N
PD NNP N
) ) N
after IN N
two CD N
courses NNS N
, , N
patients NNS N
were VBD N
operated VBN N
upon IN N
as RB N
soon RB N
as IN N
possible JJ N
. . N

Otherwise NNP N
complete JJ N
response NN N
( ( N
CR NNP N
) ) N
partial JJ N
response NN N
( ( N
PR NNP N
) ) N
or CC N
stable JJ N
disease NN N
( ( N
SD NNP N
) ) N
, , N
two CD N
more JJR N
courses NNS N
were VBD N
scheduled VBN N
. . N

The DT N
standard JJ N
surgical JJ N
procedure NN N
was VBD N
a DT N
limited JJ N
lymphadenectomy NN N
( ( N
D1 NNP N
) ) N
with IN N
staging VBG N
biopsy NN N
of IN N
the DT N
para-aortic JJ N
lymph NN N
nodes NNS N
. . N

Between NNP N
September NNP N
1993 CD N
and CC N
February NNP N
1996 CD N
, , N
56 CD p
eligible JJ p
and CC p
evaluable JJ p
patients NNS p
were VBD p
entered VBN p
: : p
27 CD N
were VBD N
randomised VBN N
to TO N
receive VB N
FAMTX NNP N
before IN N
surgery NN N
and CC N
29 CD N
to TO N
undergo VB N
surgery NN N
only RB N
. . N

In IN N
the DT N
FAMTX NNP N
+ NNP N
surgery NN N
treatment NN N
group NN N
, , N
15/27 CD N
( ( N
56 CD N
% NN N
) ) N
had VBD N
curative JJ o
resections NNS o
versus VBP N
18/29 CD N
( ( N
62 CD N
% NN N
) ) N
in IN N
the DT N
surgery NN N
only RB N
arm NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
frequency NN o
of IN o
TNM NNP o
stages NNS o
I PRP o
+ VBP o
II NNP o
in IN N
both DT N
treatment NN N
arms NNS N
: : N
15/27 CD N
versus NN N
15/29 CD N
. . N

Due JJ N
to TO N
PD NNP N
and/or NN N
toxicity NN o
, , N
12 CD N
patients NNS N
( ( N
44 CD N
% NN N
) ) N
could MD N
not RB N
complete VB N
the DT N
planned VBN N
four CD N
courses NNS N
of IN N
FAMTX NNP N
. . N

Response NNP N
evaluation NN N
after IN N
chemotherapy NN N
was VBD N
possible JJ N
in IN N
25 CD N
patients NNS N
: : N
2 CD N
CR NNP N
, , N
6 CD N
PR NNP N
, , N
8 CD N
SD NNP N
and CC N
9 CD N
PD NNP N
. . N

The DT N
difference NN N
in IN N
curative JJ o
resectability NN o
rate NN N
was VBD N
6.5 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
-32 NN N
to TO N
+19 VB N
% NN N
) ) N
in IN N
favour NN N
of IN N
surgery NN N
only RB N
. . N

Downstaging VBG N
for IN N
stages NNS N
I PRP N
+ VBP N
II NNP N
did VBD N
not RB N
occur VB N
. . N

PD NNP N
was VBD N
more RBR N
often RB N
the DT N
reason NN N
for IN N
not RB N
completing VBG N
the DT N
planned VBN N
four CD N
courses NNS N
than IN N
toxicity NN N
. . N

More RBR N
active JJ N
regimens NNS N
than IN N
FAMTX NNP i
are VBP N
required VBN N
for IN N
future JJ N
randomised VBN N
trials NNS N
. . N

-DOCSTART- -24506142- O O

Management NN N
of IN N
large JJ N
bowel NN N
obstruction NN N
with IN N
self-expanding JJ i
metal NN i
stents NNS i
. . i

A DT N
multicentre JJ N
retrospective NN N
study NN N
of IN N
factors NNS N
determining VBG N
outcome NN N
. . N

AIM NNP N
UK NNP N
cancer NN N
guidelines NNS N
recommend VBP N
patients NNS p
with IN p
colonic JJ p
obstruction NN p
due JJ p
to TO p
suspected JJ p
malignancy NN p
be VB N
considered VBN N
for IN N
stenting VBG i
with IN i
a DT i
self-expanding JJ i
metal NN i
stent NN i
( ( i
SEMS NNP i
) ) i
. . i

Considerable JJ N
variation NN N
in IN N
practice NN N
exists NNS N
due JJ N
to TO N
a DT N
lack NN N
of IN N
expertise NN N
, , N
technical JJ N
difficulties NNS N
and CC N
other JJ N
, , N
as IN N
yet RB N
ill-defined JJ N
features NNS N
. . N

This DT N
retrospective JJ N
multi-centre NN N
study NN N
aims VBZ N
to TO N
determine VB N
the DT N
outcome NN N
following VBG N
colonic JJ N
stenting VBG N
for IN N
large JJ N
bowel NN N
obstruction NN N
and CC N
identify VB N
factors NNS N
associated VBN N
with IN N
successful JJ N
intervention NN N
. . N

METHOD NNP N
A NNP N
regional JJ N
programme NN N
of IN N
colonic JJ N
stenting VBG N
for IN N
large JJ N
bowel NN N
obstruction NN N
, , N
in IN p
five CD p
UK NNP p
centres NNS p
from IN p
2005 CD p
to TO p
2010 CD p
was VBD N
evaluated VBN N
for IN N
outcome NN N
including VBG N
technical JJ o
and CC o
clinical JJ o
success NN o
, , o
survival NN o
, , o
complications NNS o
and CC o
reoperation NN o
. . o

RESULTS VB N
A DT p
SEMS NNP i
was VBD p
inserted VBN p
in IN p
334 CD p
patients NNS p
, , p
including VBG p
264 CD p
( ( p
79.0 CD p
% NN p
) ) p
for IN p
palliation NN p
and CC p
52 CD p
( ( p
15.6 CD p
% NN p
) ) p
as IN p
a DT p
bridge NN p
to TO p
surgery NN p
. . p

Technical NNP o
success NN o
was VBD N
achieved VBN N
in IN N
292 CD N
( ( N
87.4 CD N
% NN N
) ) N
patients NNS N
, , N
with IN N
46 CD N
( ( N
13.8 CD N
% NN N
) ) N
experiencing VBG N
a DT N
complication NN N
or CC N
technical JJ N
failure NN N
. . N

Reoperation NN o
was VBD N
required VBN N
in IN N
39 CD N
( ( N
14.8 CD N
% NN N
) ) N
patients NNS N
stented VBN N
for IN N
palliation NN N
of IN N
colorectal JJ p
cancer NN p
of IN N
whom WP N
16 CD N
( ( N
6.1 CD N
% NN N
) ) N
subsequently RB N
required VBN N
a DT N
colostomy NN p
. . p

A DT N
one-stage JJ o
primary JJ o
anastomosis NN o
was VBD N
achieved VBN N
in IN N
35 CD N
( ( N
67.3 CD N
% NN N
) ) N
of IN N
the DT N
52 CD p
patients NNS p
undergoing VBG p
stenting VBG p
as IN p
a DT p
bridge NN p
to TO p
resection NN p
. . p

Technical JJ o
success NN o
did VBD N
not RB N
vary JJ N
by IN N
indication NN o
or CC o
site NN o
of IN o
obstruction NN o
( ( N
P NNP N
= NNP N
0.60 CD N
) ) N
but CC N
was VBD N
higher JJR N
for IN N
operators NNS N
who WP N
had VBD N
performed VBN N
more JJR N
than IN N
10 CD N
procedures NNS N
( ( N
OR NNP N
3.34 CD N
, , N
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

ASA NNP N
grade VBD N
?3 NNP N
predicted VBD N
a DT N
worse JJ o
clinical JJ o
outcome NN o
( ( o
OR CC N
0.43 CD N
, , N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

The DT o
through-the-scope NN o
( ( o
TTS NNP o
) ) o
endoscopy NN o
technique NN o
was VBD o
more RBR o
successful JJ o
than IN o
radiological JJ N
placement NN N
alone RB N
( ( N
90.3 CD N
% NN N
vs JJ N
74.8 CD N
% NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSION NNP N
Experienced VBD N
operators NNS N
using VBG N
a DT N
TTS NNP p
technique NN p
achieved VBD p
a DT N
better JJR N
outcome NN N
for IN N
the DT N
emergency NN N
management NN N
of IN N
large JJ N
bowel NN N
obstruction NN p
. . p

Older JJR p
, , p
sicker NN p
patients NNS p
and CC p
those DT p
with IN p
extracolonic JJ p
and CC p
benign JJ p
strictures NNS p
fared VBD p
less JJR N
well RB N
. . N

-DOCSTART- -22847319- O O

Assessing VBG N
the DT N
bioequivalence NN N
of IN N
topical JJ N
retinoid NN N
products NNS N
by IN N
pharmacodynamic JJ N
assay NN N
. . N

PURPOSE NNP N
To TO N
develop VB N
a DT N
simple JJ N
pharmacodynamic NN p
( ( p
PD NNP p
) ) p
assay VBP p
for IN N
the DT N
evaluation NN N
of IN N
the DT N
bioequivalence NN N
of IN N
topically RB N
applied VBN N
retinoid NN i
products NNS i
. . i

METHODS NNP N
Daily NNP i
applications NNS i
of IN i
products NNS i
containing VBG i
tretinoin NN i
or CC i
adapalene NN i
were VBD N
made VBN N
to TO N
the DT N
forearms NNS p
of IN p
human JJ p
subjects NNS p
for IN N
up IN N
to TO N
21 CD N
days NNS N
. . N

Percutaneous JJ N
absorption NN N
was VBD N
enhanced VBN N
through IN N
the DT N
use NN N
of IN N
polyethylene NN i
film NN i
occlusion NN i
( ( N
5 CD N
h NN N
) ) N
. . N

Pharmacologic NNP N
activity NN N
was VBD N
assessed VBN N
through IN N
the DT N
daily JJ N
measurement NN N
of IN N
three CD N
cutaneous JJ N
responses NNS N
intimately RB N
linked VBN N
to TO N
retinoid-induced JJ N
changes NNS N
in IN N
epidermal JJ N
differentiation NN N
: : N
( ( N
1 CD N
) ) N
erythema NN o
; : o
( ( N
2 CD N
) ) N
exfoliation NN o
( ( o
scaling/peeling VBG o
) ) o
, , N
and CC N
( ( N
3 CD N
) ) N
increased VBD N
transepidermal JJ o
water NN o
loss NN o
. . o

RESULTS VB N
The DT N
PD NNP N
model NN N
exhibited VBD N
the DT N
sensitivity NN o
and CC o
specificity NN o
required VBN N
to TO N
function VB N
as IN N
a DT N
bioequivalence NN N
surrogate NN N
. . N

It PRP N
was VBD N
possible JJ N
to TO N
differentiate VB N
between IN N
: : N
( ( N
1 CD N
) ) N
three CD N
concentrations NNS N
of IN N
tretinoin NN N
in IN N
a DT N
commercial JJ N
cream NN N
product NN N
line NN N
; : N
( ( N
2 CD N
) ) N
two CD N
concentrations NNS N
of IN N
tretinoin NN N
in IN N
a DT N
commercial JJ N
gel NN N
product NN N
line NN N
; : N
( ( N
3 CD N
) ) N
different JJ N
vehicles NNS N
( ( N
gel NN N
vs. FW N
cream NN N
) ) N
containing VBG N
the DT N
same JJ N
concentration NN N
of IN N
tretinoin NN N
, , N
and CC N
( ( N
4 CD N
) ) N
tretinoin NN N
and CC N
adapalene NN N
at IN N
the DT N
same JJ N
concentration NN N
. . N

The DT N
applicability NN o
of IN N
this DT N
model NN N
for IN N
bioequivalence NN N
testing NN N
was VBD N
established VBN N
by IN N
showing VBG N
that IN N
it PRP N
had VBD N
sufficient JJ N
power NN N
to TO N
determine VB N
that DT N
three CD N
test NN N
tretinoin NN N
cream NN N
products NNS N
and CC N
two CD N
approved VBD N
generic JJ N
tretinoin NN N
gel NN N
products NNS N
were VBD N
equivalent JJ N
to TO N
their PRP$ N
corresponding JJ N
reference NN N
products NNS N
. . N

CONCLUSIONS VB N
A DT N
surrogate NN N
PD NNP N
model NN N
to TO N
assess VB N
retinoid JJ o
bioequivalence NN o
has VBZ N
been VBN N
developed VBN N
. . N

-DOCSTART- -19657698- O O

Prognostic JJ N
value NN N
of IN N
postoperative JJ i
CEA NNP i
clearance NN i
in IN N
rectal JJ o
cancer NN o
patients NNS p
with IN p
high JJ p
preoperative JJ p
CEA NNP p
levels NNS p
. . p

PURPOSE NNP N
We PRP N
determined VBD N
the DT N
prognostic JJ N
value NN N
of IN N
carcinoembryonic JJ N
antigen NN N
( ( N
CEA NNP N
) ) N
clearance NN N
after IN N
tumor NN i
resection NN i
with IN N
serial JJ N
evaluation NN N
of IN N
postoperative JJ N
CEA NNP N
levels NNS N
in IN N
rectal JJ p
cancer NN p
. . p

METHODS NNP N
Between NNP p
1994 CD p
and CC p
2004 CD p
, , p
we PRP p
retrospectively RB p
reviewed VBD p
122 CD p
patients NNS p
with IN p
rectal JJ p
cancer NN p
whose WP$ p
serum JJ o
CEA NNP o
levels NNS o
were VBD p
measured VBN p
on IN p
the DT p
preoperative JJ p
day NN p
and CC p
postoperative JJ p
days NNS p
7 CD p
and CC p
30 CD p
. . p

Patients NNS p
with IN p
preoperative JJ p
CEA NNP p
levels NNS p
< VBP p
5.0 CD p
ng/ml NNS p
were VBD p
excluded VBN p
. . p

An DT N
exponential JJ N
trend NN N
line NN N
was VBD N
drawn VBN N
using VBG N
the DT N
three CD N
CEA NNP N
values NNS N
. . N

Patients NNS p
were VBD p
categorized VBN p
into IN p
three CD p
groups NNS p
based VBN p
on IN p
R NNP p
( ( p
2 CD p
) ) p
values NNS p
calculated VBN N
through IN N
trend NN N
line NN N
, , N
which WDT N
indicates VBZ N
the DT N
correlation NN N
coefficient NN N
between IN N
exponential JJ N
graph NN N
and CC N
measured VBD N
CEA NNP o
values NNS o
: : o
exponential JJ p
decrease NN p
group NN p
( ( N
group NN N
1 CD N
: : N
0.9 CD N
< NN N
R NNP N
( ( N
2 CD N
) ) N
< NN N
or CC N
= VB N
1.0 CD N
) ) N
, , N
nearly RB p
exponential JJ p
decrease NN p
group NN p
( ( N
group NN N
2 CD N
: : N
0.5 CD N
< NN N
R NNP N
( ( N
2 CD N
) ) N
< NN N
or CC N
= VB N
0.9 CD N
) ) N
, , N
and CC N
randomized JJ p
clearance NN p
group NN p
( ( N
group NN N
3 CD N
: : N
0.5 CD N
< NN N
or CC N
= VB N
R NNP N
( ( N
2 CD N
) ) N
) ) N
. . N

We PRP N
then RB N
analyzed VBD N
the DT N
CEA NNP N
clearance NN N
pattern NN N
as IN N
a DT N
prognostic JJ N
indicator NN N
. . N

RESULTS NNP N
With IN N
a DT N
median JJ N
follow-up NN N
of IN N
57 CD N
months NNS N
, , N
the DT N
5-year JJ o
overall JJ o
survival NN o
was VBD N
62.3 CD N
% NN N
vs. FW N
48.1 CD N
% NN N
vs. FW N
25 CD N
% NN N
and CC N
the DT N
5-year JJ o
disease-free JJ o
survival NN o
was VBD N
58.6 CD N
% NN N
vs. FW N
52.7 CD N
% NN N
vs. FW N
25 CD N
% NN N
among IN N
groups NNS N
1 CD N
, , N
2 CD N
, , N
and CC N
3 CD N
( ( N
P NNP N
= NNP N
0.014 CD N
, , N
P NNP N
= NNP N
0.027 CD N
, , N
respectively RB N
) ) N
in IN N
patients NNS p
with IN p
stage NN p
III NNP p
rectal JJ p
cancer NN p
. . p

For IN N
those DT N
with IN N
stage NN N
II NNP N
rectal NN N
cancer NN N
, , N
the DT N
5-year JJ o
overall JJ o
survival NN o
rate NN o
of IN N
group NN N
1 CD N
was VBD N
significantly RB N
better JJR N
than IN N
groups NNS N
2 CD N
and CC N
3 CD N
( ( N
88.8 CD N
% NN N
vs. FW N
74.1 CD N
% NN N
, , N
respectively RB N
, , N
P NNP N
= NNP N
0.021 CD N
) ) N
. . N

CONCLUSIONS VB N
The DT N
postoperative JJ i
pattern NN i
of IN i
CEA NNP i
clearance NN i
is VBZ N
a DT N
useful JJ N
prognostic JJ N
determinant NN N
in IN N
patients NNS p
with IN p
rectal JJ p
cancer NN p
. . p

Patients NNS p
with IN p
a DT p
randomized JJ p
pattern NN p
of IN o
CEA NNP o
clearance NN o
after IN N
tumor NN N
resection NN N
should MD N
be VB N
regarded VBN N
as IN N
having VBG N
the DT N
possibility NN N
of IN N
a DT N
persistent JJ N
CEA NNP N
source NN N
and CC N
may MD N
require VB N
consideration NN N
of IN N
intensive JJ N
follow-up NN N
or CC N
adjuvant JJ N
therapy NN N
. . N

-DOCSTART- -10588965- O O

Lack NN N
of IN N
benefit NN N
of IN N
a DT N
single JJ N
dose NN N
of IN N
synthetic JJ i
human JJ i
secretin NN i
in IN N
the DT N
treatment NN N
of IN N
autism NN p
and CC p
pervasive JJ p
developmental JJ p
disorder NN p
. . p

BACKGROUND NNP N
Secretin NNP i
is VBZ N
a DT N
peptide JJ N
hormone NN N
that WDT N
stimulates VBZ N
pancreatic JJ N
secretion NN N
. . N

After IN N
recent JJ N
publicity NN N
about IN N
a DT N
child NN N
with IN N
autism NN N
whose WP$ N
condition NN N
markedly RB N
improved VBN N
after IN N
a DT N
single JJ N
dose NN N
of IN N
secretin NN i
, , N
thousands NNS p
of IN p
children NNS p
with IN p
autistic JJ p
disorders NNS p
may MD N
have VB N
received VBN N
secretin JJ i
injections NNS i
. . i

METHODS NNP N
We PRP N
conducted VBD N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
of IN N
a DT N
single JJ N
intravenous JJ N
dose NN N
of IN N
synthetic JJ i
human JJ i
secretin NN i
in IN N
60 CD p
children NNS p
( ( p
age NN p
, , p
3 CD p
to TO p
14 CD p
years NNS p
) ) p
with IN p
autism NN p
or CC p
pervasive JJ p
developmental JJ p
disorder NN p
. . p

The DT N
children NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
treatment NN N
with IN N
an DT N
intravenous JJ N
infusion NN N
of IN N
synthetic JJ i
human JJ i
secretin NN i
( ( N
0.4 CD N
microg NN N
per IN N
kilogram NN N
of IN N
body NN N
weight NN N
) ) N
or CC N
saline JJ i
placebo NN i
. . i

We PRP N
used VBD N
standardized JJ N
behavioral JJ N
measures NNS N
of IN N
the DT N
primary JJ N
and CC N
secondary JJ N
features NNS N
of IN N
autism NN N
, , N
including VBG N
the DT N
Autism NNP N
Behavior NNP N
Checklist NNP N
, , N
to TO N
assess VB N
the DT N
degree NN N
of IN N
impairment NN N
at IN N
base NN N
line NN N
and CC N
over IN N
the DT N
course NN N
of IN N
a DT N
four-week JJ N
period NN N
after IN N
treatment NN N
. . N

RESULTS NNP N
Of IN N
the DT N
60 CD p
children NNS p
, , p
4 CD p
could MD p
not RB p
be VB p
evaluated VBN p
- : N
2 CD N
received VBD N
secretin NN i
outside IN N
the DT N
study NN N
, , N
and CC N
2 CD N
did VBD N
not RB N
return VB N
for IN N
follow-up JJ N
. . N

Thus NNP N
, , N
56 CD p
children NNS p
( ( p
28 CD p
in IN p
each DT p
group NN p
) ) p
completed VBD p
the DT p
study NN p
. . p

As IN N
compared VBN N
with IN N
placebo NN i
, , i
secretin FW i
treatment NN N
was VBD N
not RB N
associated VBN N
with IN N
significant JJ o
improvements NNS o
in IN o
any DT o
of IN o
the DT o
outcome NN o
measures NNS o
. . o

Among IN N
the DT N
children NNS N
in IN N
the DT N
secretin NN i
group NN N
, , N
the DT N
mean JJ o
total NN o
score NN o
on IN o
the DT o
Autism NNP o
Behavior NNP o
Checklist NNP o
at IN N
base NN N
line NN N
was VBD N
59.0 CD N
( ( N
range NN N
of IN N
possible JJ N
values NNS N
, , N
0 CD N
to TO N
158 CD N
, , N
with IN N
a DT N
larger JJR N
value NN N
corresponding VBG N
to TO N
greater JJR N
impairment NN N
) ) N
, , N
and CC N
among IN N
those DT N
in IN N
the DT N
placebo NN i
group NN N
it PRP N
was VBD N
63.2 CD N
. . N

The DT N
mean JJ o
decreases NNS o
in IN o
scores NNS o
over IN N
the DT N
four-week JJ N
period NN N
were VBD N
8.9 CD N
in IN N
the DT N
secretin NN i
group NN N
and CC N
17.8 CD N
in IN N
the DT N
placebo NN i
group NN N
( ( N
mean JJ N
difference NN N
, , N
-8.9 NNP N
; : N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
-19.4 VBP N
to TO N
1.6 CD N
; : N
P=0.11 NNP N
) ) N
. . N

None NN N
of IN N
the DT N
children NNS p
had VBD N
treatment-limiting JJ o
adverse JJ o
effects NNS o
. . o

After IN N
they PRP N
were VBD N
told VBN N
the DT N
results NNS N
, , N
69 CD N
percent NN N
of IN N
the DT N
parents NNS N
of IN N
the DT N
children NNS N
in IN N
this DT N
study NN N
said VBD N
they PRP N
remained VBD N
interested JJ N
in IN N
secretin NN i
as IN N
a DT N
treatment NN N
for IN N
their PRP$ N
children NNS N
. . N

CONCLUSIONS VB N
A DT N
single JJ N
dose NN N
of IN N
synthetic JJ N
human JJ i
secretin NN i
is VBZ N
not RB o
an DT o
effective JJ o
treatment NN o
for IN N
autism NN N
or CC N
pervasive JJ N
developmental JJ N
disorder NN N
. . N

-DOCSTART- -8707361- O O

Comparison NNP N
of IN N
regimens NNS N
of IN N
amphotericin NN i
B NNP i
deoxycholate NN i
in IN N
kala-azar NN p
. . p

A DT N
total NN N
of IN N
288 CD p
parasitologically RB p
proved JJ p
patients NNS p
of IN p
kala-azar NNS p
were VBD N
randomly RB N
allocated VBN N
to TO N
three CD N
treatment NN N
groups NNS N
. . N

Patients NNS N
in IN N
groups NNS N
A NNP N
, , N
B NNP N
and CC N
C NNP N
received VBD N
amphotericin JJ i
B NNP i
( ( i
AMB NNP i
) ) i
in IN N
a DT N
dose NN N
of IN N
1 CD N
mg/kg NNS N
body NN N
weight NN N
( ( N
bw NN N
) ) N
/day NN N
, , N
0.75 CD N
mg/kg NN N
bw/day NN N
and CC N
0.5 CD N
mg/kg NNS N
bw/day NN N
for IN N
20 CD N
days NNS N
respectively RB N
. . N

Apparent JJ o
cure NN o
( ( N
afebrile NN N
at IN N
the DT N
end NN N
of IN N
therapy NN N
) ) N
occurred VBD N
in IN N
all DT N
patients NNS N
and CC N
parasitological JJ o
cure NN o
in IN N
96 CD N
( ( N
100 CD N
% NN N
) ) N
, , N
92 CD N
( ( N
96 CD N
% NN N
) ) N
and CC N
84 CD N
( ( N
88 CD N
% NN N
) ) N
patients NNS N
respectively RB N
in IN N
groups NNS N
A NNP N
, , N
B NNP N
and CC N
C. NNP N
Ultimate NNP o
cure NN o
( ( N
no DT N
relapse NN N
in IN N
six CD N
months NNS N
of IN N
follow VBP N
up RP N
) ) N
occurred VBD N
in IN N
95 CD N
( ( N
99 CD N
% NN N
) ) N
, , N
87 CD N
( ( N
91 CD N
% NN N
) ) N
and CC N
79 CD N
( ( N
82 CD N
% NN N
) ) N
patients NNS N
in IN N
groups NNS N
A NNP N
, , N
B NNP N
and CC N
C NNP N
respectively RB N
. . N

The DT N
difference NN N
between IN N
the DT N
ultimate JJ o
cure NN o
in IN N
the DT N
three CD N
groups NNS N
was VBD N
significant JJ N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
incidence NN N
of IN N
adverse JJ o
events NNS o
( ( o
rise NN o
in IN o
serum JJ o
creatinine NN o
and CC o
fall NN o
in IN o
serum JJ o
potassium NN o
, , o
loss NN o
of IN o
appetite NN o
and CC o
shivering NN o
, , o
rigor NN o
and CC o
fever NN o
during IN o
infusion NN o
indicative NN o
of IN o
renal JJ o
, , o
GIT NNP o
and CC o
infusion NN o
related JJ o
toxicities NNS o
respectively RB o
) ) o
was VBD N
similar JJ N
in IN N
the DT N
three CD N
groups NNS N
. . N

This DT N
study NN N
showed VBD N
that IN N
amphotericin NN i
B NNP i
should MD N
be VB N
given VBN N
at IN N
a DT N
dosage NN N
of IN N
1 CD N
mg/kg NNS N
bw/day NN N
for IN N
20 CD N
days NNS N
for IN N
Indian JJ p
kala-azar JJ p
patients NNS p
to TO N
minimise VB N
relapses NNS o
and CC N
prevent NN N
development NN o
of IN N
drug NN o
unresponsiveness NN o
. . o

-DOCSTART- -19301691- O O

Ongoing VBG i
Telmisartan NNP i
Alone NNP i
and CC i
in IN i
Combination NNP i
With IN i
Ramipril NNP i
Global NNP i
Endpoint NNP i
Trial NNP i
( ( i
ONTARGET NNP i
) ) i
: : i
implications NNS N
for IN N
reduced JJ N
cardiovascular JJ o
risk NN o
. . o

The DT N
recently RB N
published VBN N
Ongoing NNP i
Telmisartan NNP i
Alone NNP i
and CC i
in IN i
Combination NNP i
With IN i
Ramipril NNP i
Global NNP i
Endpoint NNP i
Trial NNP i
( ( i
ONTARGET NNP i
) ) i
in IN N
patients NNS p
with IN p
vascular JJ p
disease NN p
or CC p
high-risk JJ p
diabetes NNS p
, , N
as IN N
the DT N
largest JJS N
published VBN N
comparative JJ N
trial NN N
of IN N
these DT N
agent NN N
classes NNS N
, , N
provides VBZ N
further JJ N
evidence NN N
concerning VBG N
the DT N
comparison NN N
between IN N
the DT N
angiotensin-receptor NN i
blockers NNS i
( ( i
ARBs NNP i
) ) i
and CC N
the DT N
angiotensin-converting JJ i
enzyme NN i
inhibitors NNS i
( ( i
ACEIs NNP i
) ) i
. . i

In IN N
this DT N
trial NN N
, , N
telmisartan NN i
( ( i
an DT i
ARB NNP i
) ) i
was VBD N
non-inferior JJ N
to TO N
ramipril VB i
( ( i
an DT i
ACEI NNP i
) ) i
in IN N
reducing VBG N
fatal JJ o
and CC o
nonfatal JJ o
cardiovascular JJ o
events NNS o
. . o

Moreover RB N
, , N
ONTARGET NNP i
is VBZ N
an DT N
example NN N
of IN N
a DT N
high-quality JJ N
noninferiority NN N
trial NN N
. . N

However RB N
, , N
the DT N
combination NN N
of IN N
the DT N
2 CD N
agents NNS N
was VBD N
associated VBN N
with IN N
more JJR N
adverse JJ o
effects NNS o
without IN N
an DT N
increase NN N
in IN N
benefit NN N
. . N

The DT N
study NN N
differed VBD N
from IN N
several JJ N
other JJ N
comparative JJ N
studies NNS N
in IN N
which WDT N
the DT N
dose NN N
and CC N
choice NN N
of IN N
ACEI NNP i
was VBD N
left VBN N
to TO N
individual JJ N
physicians NNS N
. . N

Further NNP N
, , N
in IN N
ONTARGET NNP i
, , N
the DT N
ACEI NNP i
was VBD N
not RB N
titrated VBN N
to TO N
the DT N
maximum JJ N
dose NN N
and CC N
patients NNS N
with IN N
heart NN N
failure NN N
were VBD N
excluded VBN N
. . N

-DOCSTART- -20137718- O O

[ JJ N
Value NNP N
of IN N
combining VBG N
64 CD i
multi-slice JJ i
spiral JJ i
computer NN i
tomography NN i
and CC i
serum NN i
amyloid VBP i
A DT i
protein NN i
in IN N
surgical JJ N
decision-making NN N
in IN N
rectal JJ p
cancer NN p
] NNP p
. . N

OBJECTIVE NNP N
To TO N
determine VB N
the DT N
accuracy NN N
and CC N
clinical JJ N
value NN N
of IN N
combining VBG N
64 CD i
multi-slice JJ i
spiral JJ i
computer NN i
tomography NN i
( ( i
MSCT NNP i
) ) i
and CC i
serum $ i
amyloid VB i
A NNP i
protein NN i
( ( i
SAA NNP i
) ) i
in IN N
the DT N
preoperative JJ p
staging NN p
of IN p
rectal JJ p
cancer NN p
. . p

METHODS NNP N
Prospectively RB N
enrolled VBD N
patients NNS p
with IN p
rectal JJ p
cancer NN p
from IN p
October NNP p
2007 CD p
to TO p
October NNP p
2008 CD p
. . p

The DT N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
into IN N
two CD N
groups NNS N
: : N
MSCT NNP i
and CC i
SAA NNP i
combined VBD N
group NN N
: : N
both DT N
MSCT NNP i
and CC i
SAA NNP i
combinative JJ N
assessment NN N
were VBD N
performed VBN N
for IN N
preoperative JJ N
evaluation NN N
; : N
MSCT NNP i
group NN i
: : i
only RB i
MSCT NNP i
was VBD N
performed VBN N
preoperatively RB N
for IN N
tumor NN N
staging NN N
. . N

The DT N
accuracy NN N
of IN N
the DT N
preoperative JJ N
T NNP N
, , N
N NNP N
, , N
M NNP N
, , N
and CC N
TNM NNP N
staging NN N
and CC N
the DT N
concordance NN N
rate NN N
of IN N
predictive JJ N
operative JJ N
strategy NN N
were VBD N
compared VBN N
between IN N
the DT N
two CD N
groups NNS N
. . N

RESULTS NNP N
Total NNP p
of IN p
225 CD p
cases NNS p
with IN p
rectal JJ p
cancer NN p
were VBD p
enrolled VBN p
in IN p
this DT p
study NN p
. . p

There EX N
were VBD N
110 CD p
cases NNS p
in IN p
MSCT NNP i
and CC i
SAA NNP i
combined VBD i
group NN p
and CC p
115 CD p
cases NNS p
in IN p
MSCT NNP i
group NN p
. . p

The DT N
baseline NN N
characteristics NNS N
was VBD N
comparable JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

For IN N
MSCT NNP i
and CC i
SAA NNP i
combined VBD i
group NN N
, , N
the DT N
accuracies NNS o
of IN o
preoperative JJ o
staging NN o
of IN o
T NNP o
, , o
N NNP o
, , o
M NNP o
and CC o
TNM NNP o
was VBD N
87.3 CD N
% NN N
, , N
85.2 CD N
% NN N
, , N
100 CD N
% NN N
and CC N
86.4 CD N
% NN N
, , N
respectively RB N
; : N
and CC N
for IN N
MSCT NNP N
group NN N
, , N
the DT N
corresponding JJ N
rates NNS N
was VBD N
85.2 CD N
% NN N
, , N
67.0 CD N
% NN N
, , N
100 CD N
% NN N
and CC N
66.1 CD N
% NN N
, , N
respectively RB N
. . N

Statistical JJ N
differences NNS N
was VBD N
found VBN N
in IN N
the DT N
accuracy NN o
of IN o
preoperative JJ o
N NNP o
and CC o
TNM NNP o
staging VBG o
between IN N
the DT N
two CD N
groups NNS N
( ( N
P NNP N
= NNP N
0.009 CD N
and CC N
0.001 CD N
, , N
respectively RB N
) ) N
. . N

In IN N
addition NN N
, , N
there EX N
was VBD N
statistical JJ N
difference NN N
in IN N
the DT N
accuracy NN o
of IN o
prediction NN o
to TO o
operative VB o
procedures NNS o
between IN N
the DT N
two CD N
groups NNS N
( ( N
94.7 CD N
% NN N
vs. FW N
81.7 CD N
% NN N
, , N
P NNP N
= NNP N
0.003 CD N
) ) N
. . N

CONCLUSION NNP N
Combinative NNP N
assessment NN N
of IN N
MSCT NNP i
and CC i
SAA NNP i
could MD N
improve VB N
the DT N
accuracy NN N
of IN N
preoperative JJ N
staging NN N
, , N
and CC N
thus RB N
provide VB N
higher JJR N
predictive JJ N
coincidence NN N
rate NN N
of IN N
operative JJ N
procedures NNS N
. . N

-DOCSTART- -22583635- O O

Long-term JJ N
decrease NN N
in IN N
bladder NN o
cancer NN o
recurrence NN o
with IN N
hexaminolevulinate NN i
enabled VBN i
fluorescence NN i
cystoscopy NN i
. . i

PURPOSE NNP N
We PRP N
assessed VBD N
the DT N
impact NN N
of IN N
hexaminolevulinate NN i
fluorescence NN i
cystoscopic NN i
detection NN i
of IN N
papillary JJ N
, , N
nonmuscle JJ N
invasive JJ N
bladder NN N
cancer NN N
on IN N
the DT N
long-term JJ o
recurrence NN o
rate NN o
. . o

MATERIALS NNP N
AND CC N
METHODS NNP N
Long-term NNP p
followup NN p
was VBD p
assessed VBN p
in IN p
551 CD p
participants NNS p
enrolled VBN p
in IN p
a DT p
prospective JJ p
, , p
randomized JJ p
study NN p
of IN p
fluorescence NN i
cystoscopy NN i
for IN i
Ta NNP i
or CC i
T1 NNP i
urothelial JJ i
bladder NN i
cancer NN i
. . i

In IN N
the DT N
original JJ N
study NN N
280 CD p
patients NNS p
in IN p
the DT p
white JJ i
light JJ i
cystoscopy NN i
group NN p
and CC N
271 CD p
in IN p
the DT p
fluorescence NN i
cystoscopy NN i
group NN p
were VBD p
followed VBN p
with IN p
cystoscopy NN i
for IN N
3 CD N
, , N
6 CD N
and CC N
9 CD N
months NNS N
after IN N
initial JJ N
resection NN N
or CC N
until IN N
recurrence NN N
. . N

A DT N
study NN N
extension NN N
protocol NN N
was VBD N
done VBN N
for IN N
long-term JJ N
followup NN N
of IN N
these DT N
patients NNS N
. . N

RESULTS NNP N
Followup NNP N
information NN p
was VBD p
obtained VBN p
for IN p
261 CD p
of IN p
the DT p
280 CD p
patients NNS p
( ( p
93 CD p
% NN p
) ) p
in IN p
the DT p
white JJ i
light NN i
group NN p
and CC N
255 CD p
of IN p
the DT p
271 CD p
( ( p
94 CD p
% NN p
) ) p
in IN p
the DT p
fluorescence NN i
group NN p
. . p

Median JJ N
followup NN N
in IN N
the DT N
white JJ i
light NN i
and CC N
fluorescence NN i
groups NNS N
was VBD N
53.0 CD N
and CC N
55.1 CD N
months NNS N
, , N
and CC N
83 CD N
( ( N
31.8 CD N
% NN N
) ) N
and CC N
97 CD N
patients NNS N
( ( N
38 CD N
% NN N
) ) N
remained VBD N
tumor JJ N
free JJ N
, , N
respectively RB N
. . N

Median JJ o
time NN o
to TO o
recurrence VB o
was VBD N
9.4 CD N
months NNS N
in IN N
the DT N
white JJ i
light NN i
group NN N
and CC N
16.4 CD N
months NNS N
in IN N
the DT N
fluorescence NN i
group NN N
( ( N
p JJ N
= NNP N
0.04 CD N
) ) N
. . N

The DT N
intravesical JJ o
therapy NN o
rate NN o
was VBD N
similar JJ N
in IN N
the DT N
2 CD N
groups NNS N
( ( N
46 CD N
% NN N
and CC N
45 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

Cystectomy NNP i
was VBD N
done VBN N
in IN N
22 CD N
of IN N
280 CD N
cases NNS N
( ( N
7.9 CD N
% NN N
) ) N
in IN N
the DT N
white JJ i
light NN i
group NN N
and CC N
in IN N
13 CD N
of IN N
the DT N
271 CD N
( ( N
4.8 CD N
% NN N
) ) N
in IN N
the DT N
fluorescence NN i
group NN N
( ( N
p JJ N
= NNP N
0.16 CD N
) ) N
. . N

CONCLUSIONS NNP N
Hexaminolevulinate NNP i
fluorescence NN i
cystoscopy NN i
significantly RB N
improves VBZ N
long-term JJ o
bladder NN o
cancer NN o
time NN o
to TO o
recurrence VB o
with IN N
a DT N
trend NN N
toward IN N
improved JJ N
bladder NN N
preservation NN N
. . N

-DOCSTART- -24324004- O O

Conduit NNP N
artery NN N
structure NN N
and CC N
function NN N
in IN N
lowlanders NNS p
and CC p
native JJ p
highlanders NNS p
: : p
relationships NNS N
with IN N
oxidative JJ N
stress NN N
and CC N
role NN N
of IN N
sympathoexcitation NN N
. . N

Research NNP N
detailing VBG N
the DT N
normal JJ N
vascular JJ N
adaptions NNS N
to TO N
high JJ N
altitude NN N
is VBZ N
minimal JJ N
and CC N
often RB N
confounded VBN N
by IN N
pathology NN N
( ( N
e.g. JJ N
, , N
chronic JJ N
mountain NN N
sickness NN N
) ) N
and CC N
methodological JJ N
issues NNS N
. . N

We PRP N
examined VBD N
vascular JJ N
function NN N
and CC N
structure NN N
in IN N
: : N
( ( p
1 CD p
) ) p
healthy JJ p
lowlanders NNS p
during IN p
acute JJ p
hypoxia NN p
and CC p
prolonged JJ p
( ( p
?2 JJ p
weeks NNS i
) ) i
exposure NN i
to TO i
high JJ i
altitude NN i
, , i
and CC p
( ( p
2 CD p
) ) p
high-altitude NN p
natives NNS p
at IN p
5050 CD p
m NN p
( ( p
highlanders NNS p
) ) p
. . p

In IN N
12 CD p
healthy JJ p
lowlanders NNS p
( ( p
aged VBN p
32 CD p
? . p
7 CD p
years NNS p
) ) p
and CC p
12 CD p
highlanders NNS p
( ( p
Sherpa NNP p
; : p
33 CD p
? . p
14 CD p
years NNS p
) ) p
we PRP p
assessed VBD o
brachial JJ o
endothelium-dependent JJ o
flow-mediated JJ o
dilatation NN o
( ( o
FMD NNP o
) ) o
, , o
endothelium-independent JJ o
dilatation NN o
( ( o
via IN o
glyceryl NN i
trinitrate NN i
; : i
GTN NNP i
) ) i
, , o
common JJ o
carotid NN o
intima-media JJ o
thickness NN o
( ( o
CIMT NNP o
) ) p
and CC p
diameter NN p
( ( p
ultrasound JJ p
) ) p
, , p
and CC p
arterial JJ o
stiffness NN o
via IN o
pulse JJ o
wave VBP o
velocity NN o
( ( o
PWV NNP o
; : i
applanation NN i
tonometry NN i
) ) i
. . i

Cephalic NNP i
venous JJ N
biomarkers NNS N
of IN N
free JJ N
radical-mediated JJ N
lipid JJ N
peroxidation NN N
( ( N
lipid JJ N
hydroperoxides NNS N
, , N
LOOH NNP N
) ) N
, , N
nitrite JJ N
( ( N
NO2- NNP N
) ) N
and CC N
lipid JJ N
soluble JJ N
antioxidants NNS N
were VBD N
also RB N
obtained VBN N
at IN N
rest NN N
. . N

In IN N
lowlanders NNS N
, , N
measurements NNS N
were VBD N
performed VBN N
at IN N
sea NN N
level NN N
( ( N
334 CD N
m NN N
) ) N
and CC N
between IN N
days NNS N
3-4 NNP N
( ( N
acute JJ N
high JJ N
altitude NN N
) ) N
and CC N
12-14 JJ N
( ( N
chronic JJ N
high JJ N
altitude NN N
) ) N
following VBG N
arrival NN N
to TO N
5050 CD N
m. NN N
Highlanders NNP N
were VBD N
assessed VBN N
once RB N
at IN N
5050 CD N
m. NN N
Compared NNP N
with IN N
sea NN N
level NN N
, , N
acute JJ N
high JJ N
altitude NN N
reduced VBD o
lowlanders NNS o
' POS o
FMD NNP o
( ( N
7.9 CD N
? . N
0.4 CD N
vs. IN N
6.8 CD N
? . N
0.4 CD N
% NN N
; : N
P NNP N
= NNP N
0.004 CD N
) ) N
and CC o
GTN-induced JJ o
dilatation NN o
( ( o
16.6 CD o
? . N
0.9 CD N
vs. IN N
14.5 CD N
? . N
0.8 CD N
% NN N
; : N
P NNP N
= NNP N
0.006 CD N
) ) N
, , N
and CC N
raised VBD o
central JJ o
PWV NNP o
( ( o
6.0 CD o
? . N
0.2 CD N
vs. IN N
6.6 CD N
? . N
0.3 CD N
m NN N
s NN N
( ( N
-1 NNP N
) ) N
; : N
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

These DT N
changes NNS N
persisted VBD N
at IN N
days NNS N
12-14 CD N
, , N
and CC N
after IN N
allometrically RB N
scaling VBG N
FMD NNP N
to TO N
adjust VB N
for IN N
altered JJ N
baseline NN N
diameter NN N
. . N

Compared VBN N
to TO N
lowlanders NNS N
at IN N
sea NN N
level NN N
and CC N
high JJ N
altitude NN N
, , N
highlanders NNS N
had VBD N
a DT N
lower JJR o
carotid NN o
wall NN o
: : o
lumen NNS o
ratio VBP o
( ( o
?19 CD o
% NN N
, , N
P NNP N
? . N
0.04 CD N
) ) N
, , N
attributable JJ N
to TO N
a DT N
narrower JJR N
CIMT NNP N
and CC N
wider JJR N
lumen NNS N
. . N

Although IN N
both DT N
LOOH NNP o
and CC o
NO2- NNP o
increased VBD N
with IN N
high JJ N
altitude NN N
in IN N
lowlanders NNS N
, , N
only RB o
LOOH NNP o
correlated VBD o
with IN N
the DT N
reduction NN N
in IN o
GTN-induced NNP o
dilatation NN o
evident NN o
during IN N
acute NN N
( ( N
n JJ N
= NN N
11 CD N
, , N
r NN N
= NNP N
-0.53 NNP N
) ) N
and CC N
chronic JJ N
( ( N
n JJ N
= NN N
7 CD N
, , N
r NN N
= NNP N
-0.69 NNP N
; : N
P NNP N
? . N
0.01 CD N
) ) N
exposure NN N
to TO N
5050 CD N
m. NN N
In IN N
a DT N
follow-up JJ N
, , N
placebo-controlled JJ i
experiment NN N
( ( N
n JJ N
= $ N
11 CD N
healthy JJ N
lowlanders NNS N
) ) N
conducted VBN i
in IN i
a DT i
normobaric JJ i
hypoxic NN i
chamber NN i
( ( N
inspired JJ N
O2 NNP N
fraction NN N
( ( N
F NNP N
IO NNP N
2 CD N
) ) N
= NN N
0.11 CD N
; : N
6 CD N
h NN N
) ) N
, , N
a DT N
sustained JJ N
reduction NN o
in IN o
FMD NNP o
was VBD o
evident JJ o
within IN N
1 CD N
h NN N
of IN N
hypoxic NN N
exposure NN N
when WRB N
compared VBN N
to TO N
normoxic VB N
baseline NN N
( ( N
5.7 CD N
? . N
1.6 CD N
vs. IN N
8.0 CD N
?1.3 CD N
% NN N
; : N
P NNP N
< NNP N
0.01 CD N
) ) N
; : N
this DT N
decline NN o
in IN o
FMD NNP o
was VBD o
largely RB N
reversed JJ N
following VBG N
?1-adrenoreceptor NN N
blockade NN N
. . N

In IN N
conclusion NN N
, , N
high-altitude JJ N
exposure NN N
in IN N
lowlanders NNS N
caused VBD o
persistent JJ o
impairment NN o
in IN o
vascular JJ o
function NN o
, , o
which WDT N
was VBD N
mediated VBN N
partially RB N
via IN N
oxidative JJ N
stress NN N
and CC N
sympathoexcitation NN N
. . N

Although IN N
a DT N
lifetime NN N
of IN N
high-altitude JJ N
exposure NN N
neither CC N
intensifies NNS N
nor CC N
attenuates VBZ N
the DT N
impairments NNS N
seen VBN N
with IN N
short-term JJ N
exposure NN N
, , i
chronic JJ i
high-altitude NN i
exposure NN i
appears VBZ N
to TO N
be VB N
associated VBN N
with IN N
arterial JJ N
remodelling NN N
. . N

-DOCSTART- -2015149- O O

Optimal NNP N
dose NN N
of IN N
lignocaine NN i
for IN N
preventing VBG N
pain NN o
on IN N
injection NN N
of IN N
propofol NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
define VB N
the DT N
optimum JJ N
dose NN N
of IN N
lignocaine NN i
required VBN N
to TO N
reduce VB N
pain NN o
on IN N
injection NN N
of IN N
propofol NN N
. . N

We PRP N
conducted VBD N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
trial NN N
on IN N
310 CD p
patients NNS p
undergoing JJ p
anaesthesia JJ p
. . p

Patients NNS N
were VBD N
allocated VBN N
to TO N
four CD N
groups NNS N
according VBG N
to TO N
the DT N
lignocaine JJ i
dosage NN i
: : i
group NN i
A NNP i
( ( i
control NN i
) ) i
, , i
no DT i
lignocaine NN i
; : i
group NN i
B NNP i
, , i
lignocaine NN i
0.1 CD i
mg JJ i
kg-1 NN i
; : i
group NN i
C NNP i
, , i
lignocaine VBZ i
0.2 CD i
mg JJ i
kg-1 NN i
; : i
group NN i
D NNP i
, , i
lignocaine VBZ i
0.4 CD i
mg JJ i
kg-1 NN i
. . i

Our PRP$ N
results NNS N
showed VBD N
that IN N
a DT N
dose NN N
of IN N
lignocaine JJ N
0.1 CD N
mg JJ N
kg-1 NN N
significantly RB N
reduced VBD N
the DT N
incidence NN o
of IN o
pain NN o
and CC N
that IN N
there EX N
was VBD N
no DT N
improvement NN N
when WRB N
the DT N
dose NN N
was VBD N
increased VBN N
. . N

-DOCSTART- -14996144- O O

Short-term JJ N
fluoxetine NN i
monotherapy NN i
for IN N
bipolar JJ p
type NN p
II NNP p
or CC p
bipolar JJ p
NOS NNP p
major JJ p
depression NN p
- : p
low JJ p
manic JJ p
switch NN p
rate NN p
. . p

OBJECTIVES CC N
Current NNP N
guidelines NNS N
for IN N
the DT N
initial JJ N
treatment NN N
of IN N
bipolar JJ p
type NN p
II NNP p
( ( p
BP NNP p
II NNP p
) ) p
major JJ p
depressive JJ p
episode NN p
( ( p
MDE NNP p
) ) p
recommend VBP N
using VBG N
either CC N
a DT N
mood NN N
stabilizer NN N
alone RB N
or CC N
a DT N
combination NN N
of IN N
a DT N
mood NN N
stabilizer NN N
plus CC N
a DT N
selective JJ N
serotonin NN N
re-uptake NN N
inhibitor NN N
( ( N
SSRI NNP N
) ) N
. . N

This DT N
recommendation NN N
is VBZ N
the DT N
result NN N
of IN N
concern NN N
over IN N
antidepressant-induced JJ N
manic JJ N
switch NN N
episodes NNS N
. . N

However RB N
, , N
recent JJ N
evidence NN N
suggests VBZ N
that IN N
the DT N
manic JJ N
switch NN N
rate NN N
may MD N
be VB N
low JJ N
in IN N
BP NNP N
II NNP N
MDE NNP N
during IN N
SSRI NNP N
therapy NN N
. . N

METHODS NNP N
As IN p
part NN p
of IN p
a DT p
randomized JJ p
, , p
double-blind JJ p
, , p
placebo-controlled JJ i
relapse-prevention NN p
study NN p
of IN p
fluoxetine JJ i
monotherapy NN i
in IN p
BP NNP p
II NNP p
MDE NNP p
, , p
37 CD p
patients NNS p
received VBD N
open-label JJ i
fluoxetine NN i
20 CD i
mg NN i
every DT i
day NN i
for IN i
up IN i
to TO i
8 CD i
weeks NNS i
. . i

Outcome NNP N
measures NNS N
included VBD N
the DT N
Hamilton NNP N
Depression NNP N
Rating NNP N
( ( N
HAM-D NNP N
17 CD N
) ) N
rating NN N
and CC N
the DT N
Young NNP N
Mania NNP N
Rating NNP N
( ( N
YMR NNP N
) ) N
scale NN N
. . N

RESULTS NNP N
Eleven NNP N
of IN N
23 CD N
patients NNS N
( ( N
48 CD N
% NN N
) ) N
who WP N
completed VBD N
8 CD N
weeks NNS N
of IN N
fluoxetine NN i
treatment NN N
showed VBD N
a DT N
HAM-D JJ o
17 CD o
reduction NN o
of IN N
> NN N
or CC N
=50 CD N
% NN N
, , N
while IN N
14 CD N
( ( N
38 CD N
% NN N
) ) N
of IN N
all DT N
treated JJ N
patients NNS N
had VBD N
> VBN N
or CC N
=50 CD N
% NN N
reduction NN N
in IN N
baseline JJ N
HAM-D JJ N
17 CD N
score NN N
. . N

Using VBG N
a DT N
conservative JJ N
YMR NNP o
score NN o
of IN o
> NN o
or CC o
=8 VB o
to TO N
identify VB N
hypomanic JJ N
symptoms NNS N
, , N
the DT N
frequency NN N
of IN N
patients NNS N
with IN N
YMR NNP N
score NN N
> NN N
or CC N
=8 NN N
during IN N
fluoxetine NN N
did VBD N
not RB N
differ VB N
from IN N
that DT N
seen VBN N
during IN N
the DT N
screen NN N
and CC N
baseline JJ N
period NN N
. . N

Only RB N
three CD N
patients NNS N
( ( N
7.3 CD N
% NN N
) ) N
had VBD N
symptoms NNS N
suggestive JJ N
of IN N
hypomania NN o
, , N
and CC N
only RB N
one CD N
patient NN N
stopped VBD N
treatment NN N
because IN N
of IN N
a DT N
rapid JJ o
mood NN o
swing VBG o
into IN o
depression NN o
. . o

LIMITATIONS NNP N
Fluoxetine NNP i
was VBD N
given VBN N
at IN N
a DT N
fixed JJ N
dose NN N
of IN N
20 CD N
mg NNS N
everyday JJ N
. . N

Fluoxetine NNP i
was VBD N
prescribed VBN N
in IN N
an DT N
open-label JJ N
manner NN N
, , N
and CC N
the DT N
sample NN N
size NN N
was VBD N
limited VBN N
. . N

CONCLUSIONS NNP N
These DT N
observations NNS N
support VBP N
the DT N
findings NNS N
of IN N
a DT N
low JJ N
manic JJ N
switch NN N
rate NN N
during IN N
SSRI NNP N
monotherapy NN N
of IN N
BP NNP N
II NNP N
MDE NNP N
, , N
and CC N
suggest VBP N
that IN N
fluoxetine JJ i
monotherapy NN i
may MD N
be VB N
a DT N
safe JJ N
and CC N
effective JJ N
initial JJ N
treatment NN N
of IN N
BP NNP p
II NNP p
MDE NNP p
. . p

-DOCSTART- -11916791- O O

The DT N
interaction NN N
between IN N
propofol NN i
and CC i
clonidine NN i
for IN N
loss NN N
of IN N
consciousness NN N
. . N

UNLABELLED NNP N
Clonidine NNP i
premedication NN N
reduces VBZ N
the DT N
intraoperative JJ N
requirement NN N
for IN N
opioids NNS N
and CC N
volatile JJ N
anesthetics NNS N
. . N

Clonidine NNP i
also RB N
reduces VBZ N
the DT N
induction NN N
dose NN N
of IN N
IV NNP N
anesthetics NNS N
. . N

There EX N
is VBZ N
no DT N
information NN N
, , N
however RB N
, , N
regarding VBG N
the DT N
effect NN N
of IN N
oral JJ N
clonidine NN i
premedication NN N
on IN N
the DT N
propofol NN i
blood NN N
concentrations NNS N
required VBD N
for IN N
loss NN N
of IN N
consciousness NN N
, , N
and CC N
the DT N
interaction NN N
between IN N
propofol NN i
and CC i
clonidine NN i
. . i

We PRP N
randomly RB N
administered VBD N
target NN N
effect-site JJ N
concentrations NNS N
of IN N
propofol NN i
ranging VBG N
from IN N
0.5 CD N
to TO N
5 CD N
. . N

0 CD N
microg/mL NN N
by IN N
using VBG N
computer-assisted JJ N
target-controlled JJ N
infusion NN N
to TO N
3 CD p
groups NNS p
of IN p
healthy JJ p
male JJ p
patients NNS p
: : p
Control NNP i
( ( i
n JJ i
= NNP i
35 CD i
) ) i
, , i
2.5 CD i
microg/kg NN i
Clonidine NNP i
( ( i
n JJ i
= NNP i
36 CD i
) ) i
, , i
and CC i
5.0 CD i
microg/kg NNS i
Clonidine NNP i
( ( i
n JJ i
= NNP i
36 CD i
) ) i
groups NNS i
. . i

Nothing NN i
was VBD i
administered VBN i
to TO i
the DT i
Control NNP i
group NN i
. . i

Clonidine NNP i
( ( N
2.5 CD N
or CC N
5.0 CD N
microg/kg NN N
) ) N
was VBD N
administered VBN N
orally RB N
90 CD N
min NN N
before IN N
the DT N
induction NN N
of IN N
anesthesia NN N
in IN N
the DT N
Clonidine NNP i
groups NNS N
. . N

After IN N
equilibration NN N
between IN N
the DT N
blood NN N
and CC N
effect-site NN N
for IN N
15 CD N
min NN N
, , N
a DT N
verbal JJ N
command NN N
to TO N
open VB N
their PRP$ N
eyes NNS N
was VBD N
given VBN N
two CD N
times NNS N
to TO N
the DT N
patients NNS N
. . N

Arterial JJ o
blood NN o
samples NNS o
for IN N
analysis NN N
of IN N
the DT N
serum NN N
propofol NN i
and CC i
clonidine NN i
concentrations NNS N
were VBD N
taken VBN N
immediately RB N
before IN N
verbal JJ N
commands NNS N
were VBD N
given VBN N
. . N

Measured NNP N
serum VBD o
propofol JJ o
concentrations NNS o
in IN o
equilibrium NN o
with IN N
the DT N
effect-site NN N
at IN N
which WDT N
50 CD N
% NN N
of IN N
the DT N
patients NNS N
did VBD N
not RB N
respond VB N
to TO N
verbal VB N
commands NNS N
( ( N
EC50 NNP N
for IN N
loss NN N
of IN N
consciousness NN N
) ) N
were VBD N
determined VBN N
by IN N
logistic JJ N
regression NN N
. . N

The DT N
EC50 NNP o
+/- JJ o
SE NNP o
values NNS o
in IN N
the DT N
Control NNP N
, , N
2.5 CD N
microg/kg NN N
Clonidine NNP i
, , N
and CC N
5.0 CD N
microg/kg NNS N
Clonidine NNP i
groups NNS N
were VBD N
2.67 CD N
+/- JJ N
0.18 CD N
, , N
1.31 CD N
+/- JJ N
0.12 CD N
, , N
and CC N
0.91 CD N
+/- JJ N
0.13 CD N
microg/mL NN N
, , N
respectively RB N
. . N

The DT N
EC50 NNP o
in IN N
the DT N
2.5 CD N
and CC N
5.0 CD N
microg/kg NNS N
clonidine JJ N
groups NNS N
was VBD N
significantly RB N
smaller JJR N
than IN N
that DT N
in IN N
the DT N
Control NNP N
group NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
use NN N
of IN N
a DT N
response NN N
surface NN N
modeling VBG N
analysis NN N
indicated VBD N
that IN N
there EX N
was VBD N
an DT N
additive JJ o
interaction NN o
between IN N
measured VBN N
arterial JJ N
propofol NN i
and CC i
clonidine NN i
concentrations NNS N
in IN N
relation NN N
to TO N
loss NN o
of IN o
consciousness NN o
. . o

These DT N
results NNS N
indicate VBP N
that IN N
propofol NN N
and CC N
clonidine NN N
act NN N
additively RB N
for IN N
loss NN o
of IN o
consciousness NN o
. . o

IMPLICATIONS NNP N
Oral NNP N
clonidine NN i
2.5 CD N
and CC N
5.0 CD N
microg/kg NN N
premedication NN N
decreases VBZ N
the DT N
propofol JJ i
concentration NN N
required VBN N
for IN N
loss NN N
of IN N
consciousness NN N
. . N

-DOCSTART- -15681940- O O

A DT N
phase NN N
III NNP N
, , N
double-blind NN N
, , N
placebo-controlled JJ i
, , N
multicenter NN N
study NN N
on IN N
the DT N
efficacy NN N
of IN N
recombinant JJ i
human JJ i
antithrombin NN i
in IN N
heparin-resistant JJ p
patients NNS p
scheduled VBN p
to TO p
undergo VB p
cardiac JJ p
surgery NN p
necessitating VBG p
cardiopulmonary JJ p
bypass NN p
. . p

BACKGROUND IN N
The DT N
study NN N
evaluated VBD N
the DT N
efficacy NN N
of IN N
recombinant JJ i
human JJ i
antithrombin NN i
( ( i
rhAT NN i
) ) i
for IN N
restoring VBG N
heparin NN o
responsiveness NN o
in IN N
heparin NN p
resistant JJ p
patients NNS p
undergoing VBG p
cardiac JJ p
surgery NN p
. . p

METHODS NNP N
This DT N
was VBD N
a DT N
multicenter NN N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
in IN N
heparin-resistant JJ p
patients NNS p
undergoing VBG p
cardiac JJ p
surgery NN p
with IN p
cardiopulmonary JJ p
bypass NN p
. . p

Heparin NNP i
resistance NN p
was VBD p
diagnosed VBN p
when WRB p
the DT p
activated VBN p
clotting NN p
time NN p
was VBD p
less JJR p
than IN p
480 CD p
s NNS p
after IN p
400 CD p
U/kg NNP p
heparin NN i
. . i

Fifty-four JJ p
heparin-resistant JJ p
patients NNS p
were VBD p
randomized VBN p
. . p

One CD N
cohort NN N
received VBD i
75 CD i
U/kg NNP i
rhAT NN i
, , i
and CC i
the DT i
other JJ i
received VBD i
normal JJ i
saline NN i
. . i

If IN N
the DT N
activated JJ N
clotting NN N
time NN N
remained VBD N
less JJR N
than IN N
480 CD N
s NN N
, , N
this DT N
was VBD N
considered VBN N
treatment NN N
failure NN N
, , N
and CC N
2 CD N
units NNS N
fresh JJ N
frozen JJ N
plasma NN N
was VBD N
transfused VBN N
. . N

Patients NNS N
were VBD N
monitored VBN N
for IN N
adverse JJ N
events NNS N
. . N

RESULTS NNP N
Only RB N
19 CD N
% NN N
of IN N
patients NNS N
in IN N
the DT N
rhAT NN i
group NN N
received VBD N
fresh JJ o
frozen JJ o
plasma NN o
, , N
compared VBN N
with IN N
81 CD N
% NN N
of IN N
patients NNS N
in IN N
the DT N
placebo NN i
group NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

During IN N
their PRP$ N
hospitalization NN N
, , N
48 CD N
% NN N
of IN N
patients NNS N
in IN N
the DT N
rhAT NN i
group NN N
received VBD N
fresh JJ o
frozen JJ o
plasma NN o
, , N
compared VBN N
with IN N
85 CD N
% NN N
of IN N
patients NNS N
in IN N
the DT N
placebo NN i
group NN N
( ( N
P NNP N
= NNP N
0.009 CD N
) ) N
. . N

Patients NNS N
in IN N
the DT N
placebo NN N
group NN N
required VBD N
higher JJR N
heparin NN i
doses NNS N
( ( N
P NNP N
< NNP N
0.005 CD N
) ) N
for IN N
anticoagulation NN N
. . N

There EX N
was VBD N
no DT o
increase NN o
in IN o
serious JJ o
adverse JJ o
events NNS o
associated VBN N
with IN N
rhAT NN i
. . i

There EX N
was VBD N
increased VBN o
blood NN o
loss NN o
12 CD N
h NN N
postoperatively RB N
( ( N
P NNP N
= NNP N
0.05 CD N
) ) N
with IN N
a DT N
trend NN N
toward IN N
increased VBN N
24-h JJ o
bleeding NN o
in IN N
the DT N
rhAT NN i
group NN N
( ( N
P NNP N
= NNP N
0.06 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
difference NN N
between IN N
the DT N
groups NNS N
in IN N
blood NN N
and CC N
platelet NN N
transfusions NNS N
. . N

CONCLUSION NNP N
Treatment NNP N
with IN N
75 CD N
U/kg NNP N
rhAT NN i
is VBZ N
effective JJ o
in IN o
restoring VBG o
heparin NN o
responsiveness NN o
and CC N
promoting VBG N
therapeutic JJ o
anticoagulation NN o
in IN N
the DT N
majority NN N
of IN N
heparin-resistant JJ p
patients NNS p
. . p

Treating VBG N
heparin-resistant JJ p
patients NNS p
with IN N
rhAT NN i
may MD N
decrease VB o
the DT o
requirement NN o
for IN o
heparin NN o
and CC N
fresh JJ N
frozen JJ N
plasma NN N
. . N

-DOCSTART- -19462303- O O

Gamma-hydroxybutyric JJ i
acid NN i
versus NN N
clomethiazole NN i
for IN N
the DT N
treatment NN N
of IN N
alcohol NN o
withdrawal NN o
syndrome NN o
in IN p
a DT p
medical JJ p
intensive JJ p
care NN p
unit NN p
: : p
an DT N
open JJ N
, , N
single-center JJ N
randomized VBN N
study NN N
. . N

BACKGROUND NNP N
Clomethiazole NNP i
( ( i
CLO NNP i
) ) i
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
effective JJ N
in IN N
treating VBG o
alcohol NN o
withdrawal NN o
syndrome NN o
( ( o
AWS NNP o
) ) o
. . o

Gamma-Hydroxybutyric JJ i
acid NN i
( ( i
GHB NNP i
) ) i
has VBZ N
also RB N
been VBN N
introduced VBN N
in IN N
the DT N
treatment NN N
of IN N
alcoholic JJ N
patients NNS N
and CC N
is VBZ N
effective JJ N
in IN N
surgical JJ N
intensive JJ N
care NN N
unit NN N
( ( N
ICU NNP N
) ) N
patients NNS N
in IN N
preventing VBG N
and CC N
treating VBG N
AWS NNP o
. . o

There EX N
are VBP N
no DT N
comparative JJ N
studies NNS N
between IN N
CLO NNP i
and CC N
GHB NNP i
in IN N
a DT N
medical JJ N
ICU NNP N
setting NN N
. . N

METHODS NNP N
Twenty-six NNP p
alcoholic JJ p
patients NNS p
with IN p
severe JJ p
AWS NNP o
and CC p
concomitant JJ p
medical JJ o
diseases NNS o
were VBD p
randomally RB p
enrolled VBN p
in IN p
the DT p
study NN p
. . p

CLO NNP i
was VBD N
given VBN N
orally RB N
to TO N
12 CD N
patients NNS N
in IN N
a DT N
dosage NN N
of IN N
250 CD N
mg NN N
every DT N
4 CD N
hours NNS N
as IN N
a DT N
liquid NN N
; : N
GHB NNP i
( ( N
initially RB N
30 CD N
mg/kg NNS N
body NN N
weight NN N
( ( N
BW NNP N
) ) N
followed VBN N
by IN N
15 CD N
mg/kg NNS N
BW NNP N
) ) N
was VBD N
administered VBN N
intravenously RB N
to TO N
14 CD N
patients NNS N
. . N

Four CD N
major JJ N
AWS NNP o
symptoms NNS o
( ( o
tremor NN o
, , o
sweating VBG o
, , o
nausea NN o
, , o
restlessness NN o
) ) o
were VBD N
scored VBN N
, , N
and CC N
the DT N
administration NN N
of IN N
additional JJ o
medication NN o
was VBD N
registered VBN N
. . N

RESULTS NNP N
GHB NNP i
was VBD N
more RBR N
effective JJ N
in IN N
treating VBG N
AWS NNP N
symptoms NNS N
. . N

In IN N
the DT N
GHB NNP i
group NN N
, , N
AWS NNP o
score NN o
dropped VBD N
from IN N
6.6 CD N
+/- JJ N
2.6 CD N
to TO N
1.8 CD N
+/- JJ N
2.1 CD N
( ( N
p JJ N
< NNP N
.01 NNP N
) ) N
, , N
while IN N
in IN N
the DT N
CLO NNP i
group NN N
, , N
the DT N
score NN N
dropped VBD N
from IN N
6 CD N
+/- JJ N
2.5 CD N
to TO N
4.1 CD N
+/- JJ N
2.4 CD N
( ( N
n. JJ N
s. NN N
) ) N
. . N

Differences NNS N
between IN N
groups NNS N
were VBD N
significant JJ N
( ( N
p JJ N
=.021 NN N
, , N
two-way JJ N
ANOVA NNP N
) ) N
. . N

The DT N
treatment NN N
did VBD N
not RB N
alter VB N
outcome NN o
or CC N
the DT N
duration NN o
of IN o
ICU NNP o
stay NN o
. . o

No DT o
serious JJ o
side NN o
effects NNS o
were VBD N
detected VBN N
. . N

CONCLUSION NNP N
GHB NNP i
effectively RB N
controls VBZ o
AWS NNP o
symptoms NNS o
in IN N
medical JJ N
ICU NNP N
patients NNS N
. . N

The DT N
rapid JJ N
initial JJ N
treatment NN N
response NN N
of IN N
GHB NNP N
in IN N
contrast NN N
to TO N
CLO NNP i
has VBZ N
no DT N
influence NN N
on IN N
duration NN o
of IN o
patient NN o
withdrawal NN o
. . o

-DOCSTART- -22476876- O O

Impact NN N
of IN N
the DT N
quantity NN o
and CC o
flavonoid JJ o
content NN o
of IN N
fruits NNS i
and CC i
vegetables NNS i
on IN N
markers NNS N
of IN N
intake NN N
in IN N
adults NNS p
with IN p
an DT p
increased VBN p
risk NN p
of IN p
cardiovascular JJ p
disease NN p
: : p
the DT N
FLAVURS NNP N
trial NN N
. . N

PURPOSE NNP N
Limited NNP N
robust NN N
randomised VBD N
controlled VBN N
trials NNS N
investigating VBG N
fruit NN o
and CC o
vegetable JJ o
( ( o
F NNP o
& CC o
V NNP o
) ) o
intake VBP o
in IN N
people NNS p
at IN p
risk NN p
of IN p
cardiovascular JJ p
disease NN p
( ( p
CVD NNP p
) ) p
exist VBP N
. . N

We PRP N
aimed VBD N
to TO N
design VB N
and CC N
validate VB N
a DT N
dietary JJ i
strategy NN i
of IN i
increasing VBG i
flavonoid-rich JJ i
versus NN i
flavonoid-poor JJ i
F NNP o
& CC o
V NNP o
consumption NN o
on IN N
nutrient JJ N
biomarker NN N
profile NN N
. . N

METHODS NNP N
A NNP N
parallel NN N
, , N
randomised VBN N
, , N
controlled VBN N
, , N
dose-response JJ N
dietary JJ N
intervention NN N
study NN N
. . N

Participants NNS p
with IN p
a DT p
CVD NNP p
relative JJ p
risk NN p
of IN p
1.5 CD p
assessed VBN p
by IN p
risk NN p
scores NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
the DT N
3 CD N
groups NNS N
: : N
habitual JJ i
( ( i
control NN i
, , i
CT NNP i
) ) i
, , i
high-flavonoid JJ i
( ( i
HF NNP i
) ) i
or CC i
low-flavonoid JJ i
( ( i
LF NNP i
) ) i
diets NNS i
. . i

While IN N
the DT N
CT NNP N
group NN N
( ( N
n JJ N
= NNP N
57 CD N
) ) N
consumed VBD N
their PRP$ N
habitual JJ N
diet NN N
throughout IN N
, , N
the DT N
HF NNP N
( ( N
n JJ N
= NNP N
58 CD N
) ) N
and CC N
LF NNP N
( ( N
n JJ N
= NNP N
59 CD N
) ) N
groups NNS N
sequentially RB N
increased VBD N
their PRP$ N
daily JJ N
F NNP N
& CC N
V NNP N
intake NN N
by IN N
an DT N
additional JJ N
2 CD N
, , N
4 CD N
and CC N
6 CD N
portions NNS N
for IN N
6-week JJ N
periods NNS N
during IN N
the DT N
18-week JJ N
study NN N
. . N

RESULTS NNP N
Compliance NNP N
to TO N
target VB N
numbers NNS N
and CC N
types NNS N
of IN N
F NNP N
& CC N
V NNP N
was VBD N
broadly RB N
met VBN N
and CC N
verified VBN N
by IN N
dietary JJ N
records NNS N
, , N
and CC N
plasma NN o
and CC o
urinary JJ o
biomarkers NNS o
. . o

Mean NNP N
( ( N
? . N
SEM NNP N
) ) N
number NN N
of IN o
F NNP o
& CC o
V NNP o
portions/day NN o
consumed VBN N
by IN N
the DT N
HF NNP N
and CC N
LF NNP N
groups NNS N
at IN N
baseline NN N
( ( N
3.8 CD N
? . N
0.3 CD N
and CC N
3.4 CD N
? . N
0.3 CD N
) ) N
, , N
6 CD N
weeks NNS N
( ( N
6.3 CD N
? . N
0.4 CD N
and CC N
5.8 CD N
? . N
0.3 CD N
) ) N
, , N
12 CD N
weeks NNS N
( ( N
7.0 CD N
? . N
0.3 CD N
and CC N
6.8 CD N
? . N
0.3 CD N
) ) N
and CC N
18 CD N
weeks NNS N
( ( N
7.6 CD N
? . N
0.4 CD N
and CC N
8.1 CD N
? . N
0.4 CD N
) ) N
, , N
respectively RB N
, , N
was VBD N
similar JJ N
at IN N
baseline NN N
yet RB N
higher JJR N
than IN N
the DT N
CT NNP N
group NN N
( ( N
3.9 CD N
? . N
0.3 CD N
, , N
4.3 CD N
? . N
0.3 CD N
, , N
4.6 CD N
? . N
0.4 CD N
, , N
4.5 CD N
? . N
0.3 CD N
) ) N
( ( N
P NNP N
= NNP N
0.015 CD N
) ) N
. . N

There EX N
was VBD N
a DT N
dose-dependent JJ o
increase NN o
in IN o
dietary JJ o
and CC o
urinary JJ o
flavonoids NNS o
in IN o
the DT N
HF NNP N
group NN N
, , N
with IN N
no DT N
change NN N
in IN N
other JJ N
groups NNS N
( ( N
P NNP N
= NNP N
0.0001 CD N
) ) N
. . N

Significantly RB N
higher JJR o
dietary JJ o
intakes NNS o
of IN o
folate NN o
( ( o
P NNP o
= NNP N
0.035 CD N
) ) N
, , N
non-starch JJ o
polysaccharides NNS o
( ( o
P NNP o
= NNP o
0.001 CD o
) ) o
, , o
vitamin FW N
C NNP N
( ( N
P NNP N
= NNP N
0.0001 CD N
) ) N
and CC N
carotenoids NNS o
( ( N
P NNP N
= NNP N
0.0001 CD N
) ) N
were VBD N
observed VBN N
in IN N
both DT N
intervention NN N
groups NNS N
compared VBN N
with IN N
CT NNP N
, , N
which WDT N
were VBD N
broadly RB N
supported VBN N
by IN N
nutrient JJ N
biomarker NN N
analysis NN N
. . N

CONCLUSIONS VB N
The DT N
success NN N
of IN N
improving VBG N
nutrient JJ o
profile NN o
by IN o
active JJ o
encouragement NN N
of IN o
F NNP o
& CC o
V NNP o
intake NN o
in IN o
an DT N
intervention NN N
study NN N
implies VBZ N
the DT N
need NN N
for IN N
a DT N
more RBR N
hands-on JJ N
public JJ N
health NN N
approach NN N
. . N

-DOCSTART- -9917050- O O

Effects NNS N
of IN N
atropine NN i
and CC i
scopolamine NN i
on IN N
bradycardia NN o
and CC o
emetic JJ o
symptoms NNS o
in IN p
otoplasty NN p
. . p

OBJECTIVE UH N
To TO N
assess VB N
the DT N
effects NNS N
of IN N
unilateral JJ i
or CC i
bilateral JJ i
otoplasty NN i
on IN N
bradycardia NN o
and CC o
postoperative JJ o
nausea NN o
and CC o
vomiting NN o
( ( o
PONV NNP o
) ) o
and CC N
the DT N
efficiency NN N
of IN N
transdermal JJ N
scopolamine NN i
in IN N
the DT N
prophylaxis NN o
of IN o
PONV NNP o
. . o

STUDY NNP N
DESIGN NNP N
Post NNP N
hoc JJ N
assessment NN N
of IN N
the DT N
data NNS N
from IN N
a DT N
double-blind NN N
, , N
randomized VBN N
study NN N
. . N

METHODS NNP N
Fifty NNP p
otoplasty JJ p
patients NNS p
were VBD p
studied VBN p
; : p
half NN N
of IN N
them PRP N
received VBD N
randomly RB N
and CC N
in IN N
double-blind JJ N
fashion NN N
a DT N
transdermal JJ N
therapeutic JJ N
system NN N
( ( N
patch NN N
) ) N
of IN N
scopolamine NN i
( ( i
TTS-scopolamine NNP i
) ) i
as IN N
prophylaxis NN N
against IN N
PONV NNP N
before IN N
general JJ N
anesthesia NN N
. . N

The DT N
placebo NN i
group NN N
received VBD N
atropine JJ i
10 CD i
microg NN i
x NN i
kg NN i
( ( i
-1 NNP i
) ) i
intravenously RB i
during IN N
induction NN N
. . N

RESULTS VB N
The DT N
scopolamine-treated JJ i
patients NNS N
suffered VBD N
more RBR N
from IN N
moderate JJ o
peroperative JJ o
bradycardia NN o
( ( N
8/25 CD N
; : N
P NNP N
< NNP N
.05 NNP N
) ) N
than IN N
the DT N
atropine-treated JJ i
patients NNS N
( ( N
1/25 CD N
) ) N
. . N

Two CD N
patients NNS N
wearing VBG N
a DT N
half NN N
of IN N
the DT N
TTS-scopolamine NNP i
patch NN N
needed VBD N
intravenous JJ o
atropine NN o
. . o

After IN N
unilateral JJ N
otoplasty NN N
, , N
none NN N
of IN N
the DT N
TTS-scopolamine-treated JJ i
patients NNS N
and CC N
50 CD N
% NN N
of IN N
the DT N
atropine-treated JJ i
patients NNS N
suffered VBD N
from IN N
PONV NNP o
. . o

After IN N
bilateral JJ N
operation NN N
, , N
the DT N
respective JJ N
incidences NNS N
were VBD N
39 CD N
% NN N
and CC N
81 CD N
% NN N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
. . N

After IN N
unilateral JJ N
otoplasty JJ N
no DT N
patient NN N
needed VBD N
droperidol NN o
, , N
but CC N
after IN N
bilateral JJ N
otoplasty NN N
, , N
12 CD N
of IN N
19 CD N
of IN N
the DT N
atropine-treated JJ i
and CC N
4 CD N
of IN N
18 CD N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
of IN N
the DT N
scopolamine-treated JJ i
patients NNS N
needed VBN N
droperidol NN o
. . o

The DT N
mean JJ o
numbers NNS o
of IN o
doses NNS o
of IN o
droperidol NN o
were VBD N
0.8+/-0.9 JJ N
and CC N
0.3+/-0.6 JJ N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
, , N
respectively RB N
. . N

Two CD N
additional JJ N
patients NNS N
, , N
wearing VBG N
half NN N
of IN N
the DT N
TTS-scopolamine NNP i
patch NN N
, , N
suffered VBD N
from IN N
mild JJ o
central JJ o
anticholinergic JJ o
syndrome NN o
. . o

CONCLUSION NNP N
TTS-scopolamine JJ i
offers NNS N
effective JJ N
prophylaxis NN o
against IN o
PONV NNP o
( ( o
auriculoemetic JJ o
reflex NN o
) ) o
, , N
but CC N
does VBZ N
not RB N
protect VB N
from IN N
bradycardia NN o
( ( o
auriculocardiac JJ o
reflex NN o
) ) o
in IN N
otoplasty NN N
. . N

Cutting NNP N
of IN N
the DT N
TTS-scopolamine NNP i
patch NN N
may MD N
lead VB N
to TO N
undesirable JJ N
side NN o
effects NNS o
. . o

-DOCSTART- -6721970- O O

General NNP i
anaesthesia NN i
for IN N
caesarean JJ p
section NN p
in IN p
severe JJ p
pre-eclampsia NN p
. . p

Comparison NNP N
of IN N
the DT N
renal JJ N
and CC N
hepatic JJ N
effects NNS N
of IN N
enflurane NN i
and CC N
halothane NN i
. . i

In IN N
a DT N
randomized JJ N
study NN N
of IN N
patients NNS p
undergoing VBG p
Caesarean JJ p
section NN p
, , p
either CC p
enflurane NN i
( ( p
mean JJ p
0.24 CD p
MAC-h NN p
) ) p
or CC p
halothane NN i
( ( p
mean JJ p
0.23 CD p
MAC-h NN p
) ) p
and CC p
50 CD i
% NN i
nitrous JJ i
oxide NN i
in IN i
oxygen NN i
were VBD N
administered VBN N
to TO N
women NNS p
( ( p
n JJ p
= NNP p
12 CD p
) ) p
with IN p
severe JJ p
pre-eclampsia-eclampsia NN p
and CC p
to TO p
16 CD p
healthy JJ p
pregnant JJ p
patients NNS p
with IN p
normal JJ p
renal JJ p
and CC p
hepatic JJ p
function NN p
. . p

No DT N
evidence NN N
of IN N
nephrotoxicity NN o
was VBD N
found VBN N
in IN N
any DT N
pre-eclamptic JJ N
or CC N
normal JJ N
patient NN N
. . N

Metabolism NN N
of IN N
enflurane NN i
resulted VBD N
in IN N
plasma NN o
inorganic JJ o
fluoride NN o
concentrations NNS o
( ( N
max $ N
15 CD N
mumol NN N
litre NN N
-1 NNP N
) ) N
which WDT N
were VBD N
well RB N
below IN N
the DT N
toxic NN N
value NN N
. . N

Postoperative JJ N
liver NN o
function NN o
tests NNS N
showed VBD N
no DT N
important JJ N
changes NNS N
from IN N
preoperative JJ N
values NNS N
, , N
although IN N
reductive JJ N
metabolites NNS N
of IN N
halothane NN i
were VBD N
not RB N
measured VBN N
. . N

In IN p
patients NNS p
with IN p
severe JJ p
pre-eclampsia NN p
there EX N
appears VBZ N
no DT N
contraindication NN o
to TO o
enflurane VB o
or CC N
, , N
probably RB N
, , N
halothane NN i
as IN N
volatile JJ N
supplements NNS N
during IN N
general JJ i
anaesthesia NN i
. . i

-DOCSTART- -21189767- O O

In IN N
vitro JJ N
determination NN N
of IN N
the DT N
chromatic JJ o
effect NN o
of IN N
a DT N
silver NN i
nanoparticles VBZ i
solution NN i
linked VBN N
to TO N
the DT N
gantrez JJ i
S-97 NNP i
copolymer NN i
on IN N
tooth DT p
enamel NN p
. . p

Silver NNP i
nanoparticles NNS i
( ( i
NNPs NNP i
) ) i
, , N
alone RB N
or CC N
in IN N
combination NN N
with IN N
the DT N
bioadhesive JJ N
Gantrez NNP i
S-97 NNP i
, , N
have VBP N
demonstrated VBN N
their PRP$ N
efficacy NN N
against IN N
Streptococcus NNP N
mutans NNS N
; : N
however RB N
, , N
it PRP N
is VBZ N
not RB N
known VBN N
if IN N
this DT N
combination NN N
changes VBZ N
the DT N
color NN o
of IN o
teeth NN o
. . o

The DT N
aim NN N
of IN N
this DT N
work NN N
was VBD N
to TO N
measure VB N
the DT N
color NN o
changes NNS o
occurring VBG N
after IN N
the DT N
use NN N
of IN N
a DT N
Gantrez-NNP JJ i
combination NN i
on IN N
enamel JJ N
tooth NN N
blocks NNS N
. . N

Two CD p
study NN p
groups NNS p
were VBD p
randomly RB p
formed VBN p
: : p
enamel NN p
blocks NNS p
brushed VBN p
with IN p
( ( p
a DT p
) ) p
the DT i
Gantrez-NNP JJ i
combination NN i
and CC i
( ( i
b NN i
) ) i
conventional JJ i
toothpaste NN i
, , p
for IN p
1 CD p
minute NN p
once RB p
daily JJ p
for IN p
4 CD p
weeks NNS p
, , p
then RB p
rinsed VBD i
with IN i
distilled JJ i
water NN i
and CC i
placed VBN i
in IN i
thymol JJ i
solution NN i
. . i

Color NN o
changes NNS o
in IN o
the DT o
enamel NN o
blocks NNS o
were VBD N
measured VBN N
using VBG N
a DT N
Minolta NNP o
colorimeter NN o
CR300 NNP o
. . o

Analysis NN N
of IN N
mixed JJ N
models NNS N
was VBD N
performed VBN N
with IN N
R NNP N
2.10.1 CD N
at IN N
a DT N
95 CD N
% NN N
confidence NN N
level NN N
, , N
using VBG N
the DT N
nonlinear JJ N
mixed JJ N
effects NNS N
( ( N
NLME NNP N
) ) N
package NN N
. . N

The DT N
results NNS N
showed VBD N
that IN N
there EX N
were VBD N
no DT o
color NN o
changes VBZ o
over IN o
time NN o
, , N
only RB N
a DT N
high JJ o
luminosity NN o
equal JJ o
in IN N
both DT N
groups NNS N
. . N

Our PRP$ N
study NN N
showed VBD N
that IN N
the DT N
use NN N
of IN N
the DT N
Gantrez-NNP NNP i
combination NN i
is VBZ N
safe JJ o
with IN N
respect NN N
to TO N
dental JJ o
esthetics NNS o
in IN N
the DT N
control NN o
of IN o
S. NNP o
mutans NNS o
. . o

-DOCSTART- -3137065- O O

Control NN N
of IN N
perioperative JJ N
hypertension NN o
during IN N
coronary JJ i
artery NN i
surgery NN i
. . i

A DT N
randomised JJ N
double-blind NN N
study NN N
comparing VBG N
isosorbide JJ i
dinitrate NN i
and CC i
nitroglycerin NN i
. . i

A DT N
reduction NN N
in IN N
the DT N
causes NNS N
of IN N
myocardial JJ o
ischaemia NN o
remains VBZ N
of IN N
prime JJ N
importance NN N
during IN N
coronary JJ N
artery NN N
surgery NN N
. . N

Hypertension NN o
with IN N
the DT N
ensuing VBG N
increase NN N
in IN N
myocardial JJ o
oxygen NN o
demand NN o
is VBZ N
a DT N
major JJ N
factor NN N
in IN N
the DT N
aetiology NN N
of IN N
perioperative JJ N
myocardial JJ o
ischaemia NN o
. . o

Nitroglycerin NNP i
( ( i
NTG NNP i
) ) i
has VBZ N
long RB N
been VBN N
used VBN N
beneficially RB N
to TO N
reduce VB N
myocardial JJ o
oxygen NN o
demand NN o
by IN N
its PRP$ N
effects NNS N
on IN N
the DT N
systemic JJ N
and CC N
peripheral JJ N
vascular JJ N
resistances NNS N
. . N

An DT N
alternative JJ N
nitrate NN i
, , i
isosorbide JJ i
dinitrate NN i
( ( i
ISDN NNP i
) ) i
is VBZ N
now RB N
available JJ N
as IN N
an DT N
intravenous JJ N
preparation NN N
, , N
and CC N
may MD N
offer VB N
technical JJ N
advantages NNS N
, , N
both DT N
due JJ N
to TO N
its PRP$ N
stability NN N
in IN N
solution NN N
and CC N
also RB N
its PRP$ N
longer NN N
in IN N
vivo JJ N
half-life NN N
. . N

We PRP N
designed VBD N
and CC N
carried VBD N
out RP N
a DT N
multi-centre JJ N
study NN N
to TO N
compare VB N
and CC N
evaluate VB N
the DT N
efficacy NN o
of IN o
ISDN NNP o
and CC o
NTG NNP o
in IN N
the DT N
management NN N
of IN N
perioperative JJ N
hypertension NN N
in IN N
85 CD p
patients NNS p
undergoing JJ p
elective JJ i
coronary JJ i
artery NN i
surgery NN i
. . i

A DT p
total NN p
of IN p
288 CD p
events NNS p
in IN p
which WDT p
the DT p
systolic NN o
blood NN o
pressure NN o
( ( o
SBP NNP o
) ) o
exceeded VBD p
a DT p
predetermined JJ p
trigger NN p
value NN p
were VBD p
observed VBN p
. . p

ISDN NNP i
was VBD N
successful JJ o
in IN N
treating VBG N
hypertension NN o
in IN N
63 CD N
% NN N
of IN N
the DT N
events NNS N
, , N
whereas NNS N
NTG NNP i
had VBD N
an DT N
83 CD N
% NN N
success NN N
. . N

The DT N
SBP NNP o
was VBD N
significantly RB N
lowered VBN N
after IN N
treatment NN N
with IN N
either DT N
ISDN NNP i
, , N
155 CD N
mmHg NN N
to TO N
138 CD N
mmHg NN N
, , N
or CC N
NTG NNP N
, , N
160 CD N
mmHg NN N
to TO N
130 CD N
mmHg NN N
. . N

The DT N
mean JJ o
successful JJ o
dose NN o
rate NN o
for IN N
ISDN NNP i
was VBD N
6.5 CD N
micrograms JJ N
kg-1 JJ N
min-1 NN N
, , N
whereas NNS N
for IN N
NTG NNP i
this DT N
was VBD N
3.8 CD N
micrograms JJ N
kg-1 JJ N
min-1 NN N
. . N

In IN N
the DT N
ISDN NNP i
group NN N
less JJR N
events NNS o
took VBD N
place NN N
possibly RB N
due JJ N
to TO N
the DT N
longer JJR N
duration NN N
of IN N
this DT N
drug NN N
. . N

In IN N
many JJ N
previous JJ N
studies NNS N
NTG NNP i
has VBZ N
been VBN N
found VBN N
to TO N
be VB N
effective JJ N
in IN N
controlling VBG N
hypertension NN o
; : o
ISDN NNP i
offers NNS N
and CC N
alternative JJ N
approach NN N
in IN N
reducing VBG o
hypertension NN o
. . o

-DOCSTART- -2865615- O O

Use NNP N
of IN N
transdermal JJ i
glyceryl NN i
trinitrate NN i
to TO N
reduce VB N
failure NN o
of IN o
intravenous JJ o
infusion NN o
due JJ p
to TO p
phlebitis VB p
and CC p
extravasation NN p
. . p

Self-adhesive JJ N
patches NNS N
which WDT N
release VBP N
glyceryl JJ i
trinitrate NN i
at IN N
a DT N
slow JJ N
continuous JJ N
rate NN N
or CC N
placebo NN i
patches NNS i
were VBD N
applied VBN N
to TO N
the DT N
skin NN p
of IN p
patients NNS p
distal JJ N
to TO N
intravenous JJ N
infusion NN N
sites NNS N
in IN N
a DT N
double-blind JJ N
manner NN N
. . N

The DT N
frequency NN o
of IN o
infusion NN o
failure NN o
was VBD N
three CD N
times NNS N
lower RBR N
with IN N
the DT N
glyceryl NN i
trinitrate NN i
than IN N
with IN N
placebo JJ i
patches NNS i
. . i

The DT N
decrease NN N
was VBD N
of IN N
similar JJ N
magnitude NN N
whether IN N
failure NN N
was VBD N
due JJ N
to TO N
extravasation NN N
or CC N
phlebitis NN N
. . N

Headaches NNS o
were VBD N
more JJR N
common JJ N
in IN N
patients NNS p
with IN p
active JJ p
patches NNS p
but CC N
were VBD N
relieved VBN N
by IN N
simple JJ N
analgesics NNS i
. . i

-DOCSTART- -24767004- O O

Cognitive JJ i
control NN i
therapy NN i
and CC i
transcranial JJ i
direct JJ i
current JJ i
stimulation NN o
for IN o
depression NN o
: : o
a DT N
randomized JJ N
, , N
double-blinded JJ N
, , N
controlled JJ N
trial NN N
. . N

BACKGROUND NNP N
Based VBD N
on IN N
findings NNS N
that IN N
major JJ N
depressive JJ N
disorder NN N
( ( N
MDD NNP N
) ) N
is VBZ N
associated VBN N
to TO N
decreased VBN N
dorsolateral JJ N
prefrontal JJ N
cortical NN N
( ( N
DLPFC NNP N
) ) N
activity NN N
; : N
interventions NNS N
that IN N
increase NN N
DLPFC NNP N
activity NN N
might MD N
theoretically RB N
present JJ N
antidepressant JJ N
effects NNS N
. . N

Two CD N
of IN N
them PRP N
are VBP N
cognitive JJ i
control NN i
therapy NN i
( ( i
CCT NNP i
) ) i
, , N
a DT N
neurocognitive JJ N
intervention NN N
that WDT N
uses VBZ N
computer-based JJ N
working VBG N
memory NN N
exercises NNS N
, , N
and CC N
transcranial JJ i
direct JJ i
current JJ i
stimulation NN i
( ( N
tDCS NN N
) ) N
, , N
which WDT N
delivers VBZ N
weak JJ N
, , N
electric JJ N
direct JJ N
currents NNS N
over IN N
the DT N
scalp NN N
. . N

METHODS NNP N
We PRP N
investigated VBD N
whether IN N
tDCS NN N
enhanced VBD N
the DT N
effects NNS o
of IN o
CCT NNP o
in IN N
a DT N
double-blind JJ N
trial NN N
, , N
in IN N
which WDT N
participants NNS p
were VBD p
randomized VBN p
to TO p
sham VB i
tDCS NN i
and CC i
CCT NNP i
( ( p
n=17 NN p
) ) p
vs. FW i
active JJ i
tDCS NN i
and CC i
CCT NNP i
( ( p
n=20 NN p
) ) p
. . p

CCT NNP i
and CC N
tDCS NNS i
were VBD N
applied VBN N
for IN N
10 CD N
consecutive JJ N
workdays NNS N
. . N

Clinicaltrials.gov NNP N
identifier NN N
: : N
NCT01434836 NNP N
. . N

RESULTS NNP N
Both NNP N
CCT NNP N
alone RB N
and CC N
combined VBN N
with IN N
tDCS NN N
ameliorated VBN o
depressive JJ o
symptoms NNS o
after IN N
the DT N
acute JJ N
treatment NN N
period NN N
and CC N
at IN N
follow-up JJ N
, , N
with IN N
a DT N
response NN o
rate NN o
of IN N
approximately RB N
25 CD N
% NN N
. . N

Older JJR p
patients NNS p
and CC p
those DT p
who WP p
presented VBD p
better JJR p
performance NN p
in IN p
the DT p
task NN p
throughout IN p
the DT p
trial NN p
( ( N
possibly RB N
indicating VBG N
greater JJR N
engagement NN N
and CC N
activation NN N
of IN N
the DT N
DLPFC NNP N
) ) N
had VBD N
greater JJR N
depression NN o
improvement NN o
in IN N
the DT N
combined JJ N
treatment NN N
group NN N
. . N

LIMITATIONS NNP N
Our PRP$ N
exploratory JJ N
findings NNS N
should MD N
be VB N
further RB N
confirmed VBN N
in IN N
prospective JJ N
controlled VBN N
trials NNS N
. . N

DISCUSSION NNP N
CCT NNP N
and CC N
tDCS NNS N
combined VBN N
might MD N
be VB N
beneficial JJ N
for IN N
older JJR p
depressed JJ p
patients NNS p
, , N
particularly RB N
for IN N
those DT N
who WP N
have VBP N
cognitive JJ N
resources NNS N
to TO N
adequately RB N
learn VB N
and CC N
improve VB N
task NN o
performance NN o
over IN N
time NN N
. . N

This DT N
combined JJ N
therapy NN N
might MD N
be VB N
specifically RB N
relevant JJ N
in IN N
this DT N
subgroup NN N
that WDT N
is VBZ N
more JJR N
prone NN N
to TO N
present VB N
cognitive JJ N
decline NN N
and CC N
prefrontal JJ N
cortical JJ N
atrophy NN N
. . N

-DOCSTART- -10380161- O O

Inflammatory JJ N
response NN N
in IN N
humans NNS p
exposed VBN p
to TO p
2.0 CD p
ppm NNS p
nitrogen JJ i
dioxide NN i
. . i

Nitrogen NNP i
dioxide NN i
( ( i
NO2 NNP i
) ) i
is VBZ N
a DT N
common JJ N
indoor NN N
air NN N
pollutant NN N
, , N
especially RB N
in IN N
homes NNS N
with IN N
unvented JJ N
combustion NN N
appliances NNS N
. . N

Epidemiological JJ N
studies NNS N
suggest VBP N
that IN N
children NNS N
living VBG N
in IN N
homes NNS N
with IN N
unvented JJ N
heating NN N
sources NNS N
are VBP N
more JJR N
prone NN N
to TO N
respiratory NN N
infections NNS N
than IN N
children NNS N
living VBG N
in IN N
homes NNS N
with IN N
lower JJR N
levels NNS N
of IN N
NO2 NNP i
. . i

However RB N
, , N
experimental JJ N
studies NNS N
in IN N
which WDT N
human JJ N
volunteers NNS N
were VBD N
exposed VBN N
acutely RB N
to TO N
moderate JJ N
levels NNS N
of IN N
NO2 NNP i
( ( N
0.5-2.0 JJ N
ppm NN N
) ) N
have VBP N
shown VBN N
little JJ N
evidence NN N
of IN N
lung NN N
inflammation NN N
or CC N
decreased VBN N
host NN N
resistance NN N
capacity NN N
. . N

In IN N
the DT N
study NN N
reported VBD N
here RB N
, , N
8 CD p
healthy JJ p
volunteers NNS p
were VBD p
exposed VBN p
to TO p
2.0 CD p
ppm NN p
NO2 NNP i
and CC p
to TO p
filtered VB i
air NN i
for IN p
4 CD p
h NNS p
while IN p
undergoing VBG i
intermittent JJ i
moderate JJ i
exercise NN i
. . i

Bronchoalveolar JJ i
lavage NN i
was VBD N
performed VBN N
the DT N
following JJ N
morning NN N
. . N

The DT N
lavage NN N
was VBD N
divided VBN N
into IN N
a DT N
predominantly RB N
bronchial JJ N
washing NN N
( ( N
first JJ N
20 CD N
ml NN N
of IN N
lavage NN N
; : N
BL NNP N
) ) N
and CC N
a DT N
predominantly RB N
alveolar JJ N
washing NN N
( ( N
BAL NNP N
) ) N
. . N

In IN N
the DT N
BL NNP N
, , N
NO2 NNP o
exposure NN o
caused VBD N
increases NNS N
in IN N
polymorphonuclear JJ o
neutrophils NNS o
( ( o
PMNs NNP o
) ) o
, , o
interleukin JJ o
6 CD o
( ( o
IL-6 NNP o
) ) o
, , o
IL-8 NNP o
, , o
alpha1-antitrypsin NN o
, , o
and CC o
tissue NN o
plasminogen NN o
activator NN o
, , N
and CC N
decreases NNS N
in IN N
epithelial JJ o
cells NNS o
. . o

In IN N
the DT N
BAL NNP N
, , N
there EX N
were VBD N
no DT N
NO2-induced JJ N
changes NNS N
in IN N
either DT N
cell NN o
numbers NNS o
or CC o
soluble JJ o
mediators NNS o
. . o

On IN N
the DT N
other JJ N
hand NN N
, , N
alveolar JJ N
macrophages NNS N
from IN N
BAL NNP N
showed VBD N
a DT N
decrease NN N
in IN N
the DT N
ability NN N
to TO N
phagocytose VB o
unopsonized JJ o
Candida NNP o
albicans NNS o
and CC N
a DT N
decrease NN N
in IN N
superoxide JJ o
production NN o
. . o

No DT N
difference NN N
in IN N
susceptibility NN o
to TO o
virus VB o
infection NN o
was VBD N
found VBN N
between IN N
the DT N
NO2- NNP i
and CC N
air-exposed JJ N
macrophages NNS N
. . N

No DT N
changes NNS N
in IN N
lung NN N
function NN N
were VBD N
observed VBN N
, , N
but CC N
the DT N
aerosol JJ N
bolus JJ N
recovery NN N
technique NN N
revealed VBD N
a DT N
statistically RB N
significant JJ N
( ( N
p JJ N
< NNP N
.05 NNP N
) ) N
decrease NN N
in IN N
the DT N
fraction NN N
of IN N
aerosol NN N
recovered VBD N
following VBG N
nitrogen NN i
dioxide NN i
exposure NN N
, , N
which WDT N
is VBZ N
suggestive JJ N
of IN N
small JJ N
obstructive JJ N
changes NNS N
induced VBN N
by IN N
NO2 NNP i
. . i

-DOCSTART- -15468367- O O

Equivalence NNP N
study NN N
of IN N
a DT N
topical JJ i
diclofenac NN i
solution NN i
( ( i
pennsaid NN i
) ) i
compared VBN N
with IN N
oral JJ i
diclofenac NN i
in IN N
symptomatic JJ N
treatment NN N
of IN N
osteoarthritis NN p
of IN p
the DT p
knee NN p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

OBJECTIVE NNP N
. . N

To TO N
compare VB N
the DT N
safety NN o
and CC o
efficacy NN o
of IN N
a DT N
topical JJ i
diclofenac NN i
solution NN i
versus IN N
oral JJ i
diclofenac NN i
in IN N
relieving VBG N
the DT N
symptoms NNS N
of IN N
primary JJ p
osteoarthritis NN p
( ( p
OA NNP p
) ) p
of IN p
the DT p
knee NN p
, , N
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
double-dummy JJ N
equivalence NN N
trial NN N
. . N

METHODS VB N
A DT N
total NN p
of IN p
622 CD p
men NNS p
and CC p
women NNS p
with IN p
radiological JJ p
evidence NN p
of IN p
primary JJ p
knee NN p
OA NNP p
and CC p
mild VB p
to TO p
severe VB p
symptoms NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
treatment NN N
with IN N
a DT N
topical JJ i
diclofenac NN i
solution NN i
plus CC i
placebo JJ i
oral JJ i
capsules NNS i
, , N
or CC N
placebo VB i
topical JJ i
solution NN i
plus CC i
oral JJ i
diclofenac NN i
( ( N
50 CD N
mg NN N
) ) N
capsules NNS N
. . N

Patients NNS N
applied VBD N
50 CD N
drops NNS N
of IN N
study NN N
solution NN N
and CC N
took VBD N
1 CD N
study NN N
capsule NN N
3 CD N
times NNS N
daily RB N
for IN N
12 CD N
weeks NNS N
. . N

Efficacy NN N
variables NNS N
were VBD N
pain NN N
and CC N
physical JJ N
function NN N
, , N
measured VBN N
by IN N
the DT N
Western NNP N
Ontario NNP N
and CC N
McMaster NNP N
Universities NNP N
( ( N
WOMAC NNP N
) ) N
VA NNP N
3.1 CD N
OA NNP N
Index NNP N
, , N
and CC N
patient JJ N
global JJ N
assessment NN N
( ( N
PGA NNP N
) ) N
. . N

Equivalence NN N
in IN N
the DT N
per-protocol JJ N
group NN N
was VBD N
based VBN N
on IN N
previously RB N
defined VBN N
ranges NNS N
of IN N
clinically RB N
significant JJ N
difference NN N
. . N

Safety NN N
was VBD N
assessed VBN N
by IN N
evaluation NN N
of IN N
adverse JJ N
events NNS N
, , N
vital JJ N
signs NNS N
, , N
and CC N
laboratory NN N
data NNS N
. . N

RESULTS VB N
The DT N
difference NN N
in IN N
mean NN N
( ( N
95 CD N
% NN N
CI NNP N
) ) N
change NN N
scores NNS N
( ( N
final JJ N
minus NN N
baseline NN N
) ) N
between IN N
treatments NNS N
was VBD N
13.3 CD N
mm NN N
( ( N
-8.6 UH N
to TO N
35.2 CD N
) ) N
for IN N
pain NN N
( ( N
total JJ N
scale NN N
500 CD N
mm NN N
) ) N
, , N
71.0 CD N
mm NN N
( ( N
-2.4 UH N
to TO N
144.5 CD N
) ) N
for IN N
physical JJ N
function NN N
( ( N
total JJ N
scale NN N
1700 CD N
mm NN N
) ) N
, , N
and CC N
4.3 CD N
mm NN N
( ( N
-1.2 UH N
to TO N
9.8 CD N
) ) N
for IN N
PGA NNP N
( ( N
total JJ N
scale NN N
100 CD N
mm NN N
) ) N
. . N

The DT N
CI NNP N
for IN N
each DT N
efficacy NN N
variable NN N
fell VBD N
within IN N
the DT N
predefined JJ N
equivalence NN N
ranges NNS N
( ( N
pain NN N
, , N
+/- JJ N
75 CD N
mm NN N
; : N
physical JJ N
function NN N
, , N
+/- JJ N
255 CD N
mm NN N
; : N
PGA NNP N
, , N
+/- JJ N
20 CD N
mm NN N
) ) N
, , N
indicating VBG N
that IN N
no DT N
clinically RB N
relevant JJ N
difference NN N
was VBD N
found VBN N
between IN N
the DT N
2 CD N
treatment NN N
arms NNS N
. . N

Safety NN o
analyses NNS o
of IN N
patients NNS N
applying VBG N
topical JJ N
diclofenac NN i
solution NN i
revealed VBD N
some DT N
minor JJ o
skin NN o
irritation NN o
at IN o
the DT o
application NN o
site NN o
-- : o
mostly RB o
skin JJ N
dryness NN N
in IN N
83/311 CD N
( ( N
27 CD N
% NN N
) ) N
patients NNS N
-- : N
but CC N
a DT N
significantly RB N
reduced VBN N
incidence NN N
, , N
relative JJ N
to TO N
oral JJ N
diclofenac NN N
, , N
of IN N
total JJ o
and CC o
severe JJ o
gastrointestinal NN o
( ( o
GI NNP o
) ) o
adverse JJ o
events NNS o
, , o
including VBG o
dyspepsia NN o
, , o
abdominal JJ o
pain NN o
, , o
diarrhea NN o
, , o
and CC o
nausea NN o
. . o

The DT N
number NN N
of IN N
patients NNS N
developing VBG N
abnormal JJ N
liver NN N
function NN N
tests NNS N
( ( N
including VBG N
clinically RB N
significant JJ N
elevation NN N
) ) N
, , N
hemoglobin UH N
, , N
and CC N
creatinine JJ N
clearance NN N
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
oral JJ i
diclofenac NN i
group NN N
. . N

CONCLUSION NNP N
Application NNP N
of IN N
this DT N
topical JJ i
diclofenac NN i
solution NN i
to TO N
the DT N
knee NN N
of IN N
patients NNS p
with IN p
OA NNP p
produced VBD N
relief NN o
of IN o
symptoms NNS o
equivalent JJ N
to TO N
oral JJ i
diclofenac NN i
, , N
with IN N
minor JJ N
local JJ N
skin NN N
irritation NN N
, , N
but CC N
significantly RB N
reduced VBD N
incidence NN o
of IN o
diclofenac-related JJ o
GI NNP o
complaints NNS o
and CC o
abnormal JJ o
laboratory NN o
values NNS o
. . o

-DOCSTART- -11888754- O O

Amiodarone NNP i
versus NN i
digoxin NN i
and CC i
metoprolol NN i
combination NN i
for IN N
the DT N
prevention NN N
of IN N
postcoronary JJ o
bypass NN o
atrial JJ o
fibrillation NN o
. . o

OBJECTIVE CC N
This DT N
prospective JJ N
randomized NN N
study NN N
aims VBZ N
at IN N
evaluation NN N
and CC N
comparison NN N
of IN N
the DT N
prophylactic JJ N
effects NNS N
of IN N
amiodarone NN i
versus NN i
digoxin NN i
and CC i
metoprolol JJ i
combination NN i
in IN N
postcoronary JJ o
bypass NN o
atrial JJ o
fibrillation NN o
. . o

METHODS NNP N
A NNP N
total NN N
of IN N
241 CD p
consecutive JJ p
patients NNS p
undergoing VBG p
elective JJ p
coronary JJ p
artery NN p
bypass NN p
grafting VBG p
were VBD p
randomly RB p
allocated VBN p
into IN p
three CD p
groups NNS p
. . p

Patients NNS N
in IN N
Group1 NNP p
( ( p
n=77 NN p
) ) p
received VBD N
metoprolol $ i
100 CD i
mg/24 NN i
h NN i
per IN i
oral JJ i
( ( N
P.O NNP N
. . N

) ) N
, , N
preoperatively RB N
, , N
2x0.5 CD N
mg NN N
digoxin NN i
intravenously RB i
on IN i
the DT i
operating NN i
day NN i
and CC i
digoxin NN i
0.25 CD i
mg NN i
P.O.+metoprolol NNP i
100 CD i
mg NN i
P.O NNP i
. . i

on IN N
the DT N
first JJ N
postoperative JJ N
day NN N
until IN N
discharge NN N
. . N

Patients NNS N
in IN N
Group NNP p
2 CD p
( ( p
n=72 NN p
) ) p
received VBD N
totally RB N
1200 CD N
mg NN N
intravenous/24 NN N
h NN N
amiodarone NN i
which WDT N
the DT N
300 CD N
mg SYM N
- : N
bolus NN N
dose/1 NN N
h NN N
was VBD N
given VBN N
as RB N
soon RB N
as IN N
the DT N
operation NN N
had VBD N
been VBN N
finished VBN N
. . N

On IN N
the DT N
next JJ N
day NN N
patients NNS N
were VBD N
administered VBN N
450 CD N
mg/24 NN N
h NN N
amiodarone NN i
i.v NN N
. . N

and CC N
600 CD N
mg/day NN N
in IN N
three CD N
doses NNS N
P.O NNP N
. . N

were VBD N
given VBN N
until IN N
discharge NN N
. . N

Group NNP p
3 CD p
( ( p
n=92 NN p
) ) p
was VBD N
the DT N
control NN i
group NN i
with IN N
no DT N
antiarrhythmic JJ N
prophylaxis NN N
. . N

RESULTS NNP N
Preoperative NNP N
patient NN N
characteristics NNS N
and CC N
operative JJ N
parameters NNS N
were VBD N
similar JJ N
in IN N
three CD N
groups NNS N
. . N

Atrial JJ o
fibrillation NN o
occurred VBD N
in IN N
13 CD N
patients NNS N
( ( N
16.8 CD N
% NN N
) ) N
in IN N
Group NNP N
1 CD N
, , N
six CD N
patients NNS N
( ( N
8.3 CD N
% NN N
) ) N
in IN N
Group NNP N
2 CD N
and CC N
31 CD N
patients NNS N
( ( N
33.6 CD N
% NN N
) ) N
in IN N
Group NNP N
3 CD N
. . N

CONCLUSION NNP N
Both NNP N
study NN N
groups NNS N
were VBD N
effective JJ N
in IN N
the DT N
prevention NN N
of IN N
postcoronary JJ o
bypass NN o
atrial JJ o
fibrillation NN o
with IN N
respect NN N
to TO N
control VB N
( ( N
P NNP N
< VBZ N
0.01 CD N
in IN N
Group NNP N
1 CD N
and CC N
P NNP N
< NNP N
0.001 CD N
in IN N
Group NNP N
2 CD N
) ) N
. . N

-DOCSTART- -15656360- O O

[ IN N
The DT N
application NN N
of IN N
naphcon JJ i
eye NN i
drops NNS i
during IN N
Lasik NNP i
surgery NN i
] NN i
. . N

PURPOSE NNP N
To TO N
evaluate VB N
the DT N
effects NNS N
of IN N
Naphcon NNP i
eye NN i
drops NNS i
for IN N
preventing VBG N
conjunctival JJ p
bleeding NN p
during IN p
Lasik NNP p
surgery NN p
. . p

METHODS NNP N
One CD p
hundred VBN p
cases NNS p
( ( p
200 CD p
eyes NNS p
) ) p
were VBD N
divided VBN N
into IN N
treating VBG N
group NN N
and CC N
control NN N
group NN N
randomly RB N
according VBG N
to TO N
using VBG N
and CC N
not RB N
using VBG N
Naphcon NNP i
eye NN i
drops NNS i
before IN N
Lasik NNP N
surgery NN N
. . N

Treating VBG N
group NN N
patients NNS N
received VBD N
three CD N
times NNS N
Naphcon NNP i
eye NN i
drops NNS i
during IN N
15 CD N
minutes NNS N
before IN N
surgery NN N
. . N

RESULTS VB N
The DT N
incidence NN o
of IN o
conjunctival JJ o
bleeding VBG o
from IN N
treating VBG N
and CC N
control VB N
group NN N
were VBD N
8 CD N
% NN N
and CC N
15 CD N
% NN N
respectively RB N
. . N

There EX N
was VBD N
significant JJ N
statistical JJ N
difference NN N
between IN N
them PRP N
. . N

CONCLUSION NNP N
Naphcon NNP i
eye NN i
drop NN i
is VBZ N
an DT N
effective JJ N
agent NN N
to TO N
prevent VB N
conjunctival JJ p
bleeding NN p
. . p

-DOCSTART- -18371465- O O

A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
multicenter NN N
study NN N
to TO N
evaluate VB N
the DT N
cardioprotective JJ N
effects NNS N
of IN N
MC-1 NNP i
in IN N
patients NNS p
undergoing VBG p
high-risk JJ p
coronary JJ p
artery NN p
bypass NN p
graft NN p
surgery NN p
: : p
MC-1 NN i
to TO N
Eliminate VB N
Necrosis NNP N
and CC N
Damage NNP N
in IN N
Coronary NNP o
Artery NNP o
Bypass NNP N
Graft NNP N
Surgery NNP N
Trial NNP N
( ( N
MEND-CABG NNP N
) ) N
II NNP N
-- : N
study NN N
design NN N
and CC N
rationale NN N
. . N

BACKGROUND NNP N
Coronary NNP N
artery NN N
bypass NN N
graft NN N
( ( N
CABG NNP N
) ) N
surgery NN N
is VBZ N
effective JJ N
in IN N
relieving VBG N
angina NN N
and CC N
improving VBG N
survival NN N
and CC N
quality NN N
of IN N
life NN N
in IN N
patients NNS p
with IN p
obstructive JJ p
coronary JJ p
artery NN p
disease NN p
; : p
however RB N
, , N
recurrent JJ N
angina NN N
, , N
myocardial JJ N
infarction NN N
, , N
neurological JJ N
injury NN N
, , N
and CC N
death NN N
can MD N
occur VB N
in IN N
the DT N
perioperative NN N
and CC N
postoperative JJ N
period NN N
. . N

MC-1 NNP i
( ( N
pyridoxal IN N
5'-phosphate NN N
) ) N
is VBZ N
a DT N
novel JJ N
agent NN N
that WDT N
has VBZ N
shown VBN N
promise NN N
in IN N
reducing VBG N
myocardial JJ N
necrosis NN N
by IN N
reducing VBG N
cellular JJ N
calcium NN N
overload NN N
after IN N
percutaneous JJ N
coronary JJ N
intervention NN N
and CC N
CABG NNP N
surgery NN N
in IN N
high-risk JJ p
patients NNS p
undergoing VBG N
these DT N
procedures NNS N
. . N

METHODS NNP N
MEND-CABG NNP N
II NNP N
is VBZ N
a DT N
phase NN N
III NNP N
study NN N
evaluating VBG N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
MC-1 NNP i
in IN N
reducing VBG N
cardiovascular JJ N
morbidity NN N
and CC N
mortality NN N
after IN N
CABG NNP N
. . N

High-risk JJ p
patients NNS p
undergoing VBG p
CABG NNP p
surgery NN p
will MD N
be VB N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
MC-1 NNP i
( ( N
250 CD N
mg/d NN N
) ) N
or CC N
matching VBG N
placebo NNS i
immediately RB N
before IN N
and CC N
continuing VBG N
for IN N
30 CD N
days NNS N
after IN N
the DT N
procedure NN N
. . N

The DT N
primary JJ N
end NN N
point NN N
is VBZ N
the DT N
occurrence NN o
of IN o
cardiovascular JJ o
death NN o
or CC o
nonfatal JJ o
myocardial JJ o
infarction NN o
through IN o
postoperative JJ o
day NN o
30 CD o
. . o

A DT N
total NN N
of IN N
3023 CD p
patients NNS p
were VBD p
enrolled VBN p
at IN p
130 CD p
sites NNS p
in IN p
Canada NNP p
, , p
the DT p
United NNP p
States NNPS p
, , p
and CC p
Germany NNP p
between IN p
October NNP p
2006 CD p
and CC p
September NNP p
2007 CD p
, , p
with IN p
results NNS p
anticipated VBN p
shortly RB p
after IN p
completion NN p
of IN p
90-day JJ p
follow-up NN p
in IN p
March NNP p
2008 CD p
. . p

CONCLUSIONS VB N
The DT N
data NN N
from IN N
the DT N
MEND-CABG NNP N
II NNP N
trial NN N
will MD N
establish VB N
whether IN N
peri- JJ N
and CC N
postoperative JJ N
treatment NN N
with IN N
MC-1 NNP i
can MD N
decrease VB N
the DT N
short- JJ o
and CC o
intermediate-term JJ o
morbidity NN o
and CC o
mortality NN o
of IN N
high-risk JJ N
patients NNS N
undergoing VBG N
CABG NNP N
surgery NN N
. . N

-DOCSTART- -12660676- O O

Sustained VBN N
ventricular JJ N
arrhythmias NNS N
and CC N
mortality NN N
among IN N
patients NNS p
with IN p
acute JJ p
myocardial JJ p
infarction NN p
: : p
results NNS N
from IN N
the DT N
GUSTO-III NNP N
trial NN N
. . N

BACKGROUND NNP N
In IN N
many JJ N
patients NNS N
, , N
ventricular JJ N
arrhythmias NN N
will MD N
develop VB N
early JJ N
after IN N
acute JJ p
myocardial JJ p
infarction NN p
. . p

We PRP N
studied VBD N
the DT N
incidence NN N
, , N
timing NN N
, , N
and CC N
outcomes NNS N
of IN N
such JJ N
arrhythmias NNS N
in IN N
the DT N
international JJ N
Global NNP N
Utilization NNP N
of IN N
Streptokinase NNP N
and CC N
TPA NNP N
( ( N
alteplase NN N
) ) N
for IN N
Occluded NNP N
Coronary NNP N
Arteries NNP N
( ( N
GUSTO NNP N
) ) N
-III VBP N
trial NN N
. . N

METHODS NNP N
We PRP i
identified VBD i
independent JJ i
predictors NNS i
of IN i
inhospital JJ i
ventricular JJ i
fibrillation NN i
( ( i
VF NNP i
) ) i
and CC i
ventricular JJ i
tachycardia NN i
( ( i
VT NNP i
) ) i
and CC i
compared VBN i
30-day JJ i
and CC i
1-year JJ i
mortality NN i
rates NNS i
of IN i
patients NNS i
who WP i
did VBD i
( ( i
n VB i
= NNP i
1121 CD i
) ) i
and CC i
did VBD i
not RB i
( ( i
n JJ i
= NNP i
13,921 CD i
) ) i
have VBP i
these DT i
arrhythmias NNS i
during IN i
the DT i
index NN i
hospitalization NN i
. . i

RESULTS NNP N
Significant NNP N
independent JJ N
predictors NNS N
of IN N
inhospital JJ N
VF NNP N
were VBD N
higher JJR N
Killip NNP o
class NN o
, , o
lower JJR o
baseline NN o
systolic JJ o
pressure NN o
, , o
intravenous JJ o
preenrollment NN o
lidocaine NN o
use NN o
, , N
shorter JJR N
time NN N
to TO N
thrombolysis VB o
, , N
and CC N
beta-blocker NN i
use NN i
< VBZ N
2 CD N
weeks NNS N
before IN N
enrollment NN N
; : N
independent JJ N
predictors NNS N
of IN N
inhospital JJ N
VT NNP N
were VBD N
lower JJR N
baseline NN o
systolic JJ o
pressure NN o
, , o
intravenous JJ o
lidocaine NN o
use NN N
before IN N
enrollment NN N
, , N
higher JJR N
Killip NNP N
class NN N
, , N
faster JJR N
baseline JJ o
heart NN o
rate NN o
, , N
and CC N
advanced JJ N
age NN N
. . N

The DT N
30-day JJ o
mortality NN o
rate NN o
was VBD N
31 CD N
% NN N
in IN N
patients NNS N
with IN N
VF NNP N
, , N
24 CD N
% NN N
in IN N
those DT N
with IN N
VT NNP N
, , N
44 CD N
% NN N
in IN N
those DT N
with IN N
both DT N
, , N
and CC N
6 CD N
% NN N
in IN N
those DT N
with IN N
neither DT N
( ( N
P NNP N
=.001 NNP N
) ) N
. . N

The DT N
corresponding JJ N
1-year JJ o
mortality NN o
rates NNS o
were VBD N
34 CD N
% NN N
, , N
29 CD N
% NN N
, , N
49 CD N
% NN N
, , N
and CC N
9 CD N
% NN N
( ( N
P NNP N
=.001 NNP N
) ) N
. . N

The DT N
30-day JJ o
and CC o
1-year JJ o
mortality NN o
rates NNS o
were VBD N
higher JJR N
for IN N
patients NNS N
with IN N
late JJ N
( ( N
> JJ N
48 CD N
hours NNS N
after IN N
enrollment NN N
) ) N
versus FW N
early JJ N
arrhythmias NN N
( ( N
< CD N
or CC N
=48 VB N
hours NNS N
after IN N
enrollment NN N
) ) N
. . N

CONCLUSIONS NNP N
Despite IN N
thrombolysis NN N
, , N
inhospital JJ N
ventricular NN N
arrhythmias NNS N
are VBP N
associated VBN N
with IN N
higher JJR N
30-day JJ N
and CC N
1-year JJ N
mortality NN o
rates NNS o
after IN N
acute JJ p
myocardial JJ p
infarction NN p
, , N
particularly RB N
when WRB N
occurring VBG N
later RB N
during IN N
the DT N
initial JJ N
hospitalization NN N
. . N

Better JJR N
therapies NNS N
are VBP N
needed VBN N
to TO N
improve VB N
outcomes NNS N
of IN N
these DT N
arrhythmias NNS N
. . N

-DOCSTART- -8090084- O O

Intestinal JJ N
absorption NN N
of IN N
dietary JJ N
fat NN N
in IN N
patients NNS p
with IN p
multiple JJ p
sclerosis NN p
. . p

Fat NNP o
absorption NN o
was VBD N
studied VBN N
in IN N
24 CD p
patients NNS p
with IN p
clinically RB p
definite JJ p
multiple JJ p
sclerosis NN p
and CC p
in IN p
36 CD p
healthy JJ p
control NN i
subjects NNS p
. . p

Beta-carotene NNP o
and CC o
vitamin VB o
A NNP o
in IN o
their PRP$ o
plasma NN o
were VBD i
also RB i
measured VBN i
. . i

This DT N
double-blind JJ N
and CC N
randomized VBN N
study NN N
showed VBD N
no DT N
differences NNS N
between IN N
these DT N
two CD N
populations NNS N
with IN N
regard NN N
to TO N
the DT N
three CD N
parameters NNS N
. . N

We PRP N
did VBD N
not RB N
find VB N
evidence NN N
for IN N
fat JJ N
malabsorption NN N
in IN N
multiple JJ N
sclerosis NN N
. . N

-DOCSTART- -23404659- O O

Sex NN o
risk NN o
behavior NN o
among IN N
adolescent JJ p
and CC p
young JJ p
adult NN p
children NNS p
of IN p
opiate JJ p
addicts NNS p
: : p
outcomes NNS N
from IN N
the DT N
focus NN N
on IN N
families NNS N
prevention VBP N
trial NN N
and CC N
an DT N
examination NN N
of IN N
childhood NN N
and CC N
concurrent JJ N
predictors NNS N
of IN N
sex NN N
risk NN N
behavior NN N
. . N

This DT N
study NN N
reports VBZ N
on IN N
rates NNS o
and CC o
predictors NNS o
of IN o
sex NN o
risk NN o
behavior NN o
among IN N
a DT N
sample NN N
of IN N
adolescent NN p
and CC p
young JJ p
adult NN p
children NNS p
of IN p
parents NNS p
enrolled VBN p
in IN p
methadone NN i
treatment NN p
for IN p
opiate JJ p
addiction NN p
. . p

Data NNS p
are VBP p
from IN p
151 CD p
participants NNS p
( ( p
80 CD p
males NNS p
, , p
71 CD p
females NNS p
) ) p
in IN p
the DT p
Focus NNP p
on IN p
Families NNP p
( ( p
FOF NNP p
) ) p
project NN p
, , p
a DT p
randomized JJ p
trial NN p
of IN p
a DT p
family NN i
intervention NN i
and CC p
a DT p
study NN p
of IN p
the DT p
development NN p
of IN p
at-risk JJ p
children NNS p
. . p

The DT p
study NN p
participants NNS p
are VBP p
children NNS p
of IN p
parents NNS p
enrolled VBN p
in IN p
methadone NN i
treatment NN i
between IN p
1990 CD p
and CC p
1993 CD p
. . p

Participants NNS p
were VBD p
interviewed VBN p
in IN p
2005 CD p
when WRB p
they PRP p
ranged VBD p
in IN p
age NN p
from IN p
15 CD p
to TO p
29 CD p
years NNS p
. . p

In IN N
the DT N
year NN N
prior RB N
to TO N
the DT N
follow-up NN N
, , N
79 CD N
% NN N
of IN N
the DT N
males NNS N
and CC N
83 CD N
% NN N
of IN N
females NNS N
were VBD N
sexually RB N
active JJ N
, , N
26 CD N
% NN N
of IN N
males NNS N
and CC N
10 CD N
% NN N
of IN N
females NNS N
had VBD N
more JJR N
than IN N
one CD N
partner NN N
in IN N
the DT N
prior JJ N
year NN N
, , N
and CC N
34 CD N
% NN N
of IN N
males NNS N
and CC N
24 CD N
% NN N
of IN N
females NNS N
reported VBN N
having VBG N
sex NN N
outside IN N
of IN N
a DT N
committed JJ N
relationship NN N
. . N

Twenty-four CD N
percent NN N
of IN N
males NNS N
and CC N
17 CD N
% NN N
of IN N
females NNS N
met VBD N
criteria NNS N
for IN N
high-risk JJ o
sexual JJ o
behavior NN o
, , N
reporting VBG N
casual JJ N
or CC N
multiple JJ N
partners NNS N
in IN N
the DT N
prior JJ N
year NN N
and CC N
inconsistent NN N
condom NN N
use NN N
. . N

Participants NNS N
in IN N
the DT N
intervention NN i
and CC N
control NN i
conditions NNS N
did VBD N
not RB N
differ VB N
significantly RB N
in IN N
terms NNS N
of IN N
any DT N
measure NN N
of IN N
sex NN o
risk NN o
behavior NN o
examined VBN N
. . N

None NN N
of IN N
the DT N
measures NNS N
of IN N
parent NN N
behavior NN N
and CC N
family NN N
processes NNS N
derived VBN N
from IN N
data NNS N
at IN N
baseline NN N
of IN N
the DT N
FOF NNP N
study NN N
predicted VBD N
whether IN N
participants NNS N
engaged VBN N
in IN N
high-risk JJ o
sex NN o
. . o

Among IN N
measures NNS N
derived VBN N
from IN N
data NNS N
collected VBN N
at IN N
long-term JJ N
follow-up NN N
, , N
however RB N
, , N
having VBG N
ever RB N
met VBN N
criteria NNS N
for IN N
substance NN N
abuse NN N
or CC N
dependence NN N
predicted VBN N
greater JJR N
likelihood NN N
of IN N
high-risk JJ o
sexual JJ o
behavior NN o
, , N
and CC N
being VBG N
married VBD N
or CC N
being VBG N
in IN N
a DT N
romantic JJ N
relationship NN N
was VBD N
associated VBN N
with IN N
lower JJR N
likelihood NN N
of IN N
high-risk JJ o
sexual JJ o
behavior NN o
. . o

The DT N
findings NNS N
point NN N
to TO N
the DT N
important JJ N
role NN N
of IN N
committed JJ N
relationships NNS N
in IN N
regulating VBG N
sex NN o
risk NN o
behavior NN o
among IN N
this DT N
population NN N
, , N
as RB N
well RB N
as IN N
heightened VBN N
levels NNS N
of IN N
sex NN o
risk NN o
behavior NN o
associated VBN N
with IN N
substance NN N
abuse NN N
or CC N
dependence NN N
. . N

-DOCSTART- -25260191- O O

Randomized VBN N
controlled JJ N
trial NN N
of IN N
parental JJ i
responsiveness NN i
intervention NN i
for IN N
toddlers NNS p
at IN p
high JJ p
risk NN p
for IN p
autism NN p
. . p

This DT N
study NN N
tested VBD N
the DT N
effects NNS N
of IN N
a DT N
parent-mediated JJ i
intervention NN i
on IN i
parental JJ i
responsiveness NN i
with IN N
their PRP$ N
toddlers NNS p
at IN p
high JJ p
risk NN p
for IN p
an DT p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
. . p

Participants NNS p
included VBD p
caregivers NNS p
and CC p
their PRP$ p
66 CD p
toddlers NNS p
at IN p
high JJ p
risk NN p
for IN p
ASD NNP p
. . p

Caregivers NNS p
were VBD N
randomized VBN N
to TO N
12 CD N
sessions NNS N
of IN N
an DT N
individualized JJ i
parent NN i
education NN i
intervention NN i
aimed VBN N
at IN N
improving VBG N
parental JJ N
responsiveness NN N
or CC N
to TO N
a DT N
monitoring NN N
control NN N
group NN N
involving VBG N
4 CD N
sessions NNS N
of IN N
behavioral JJ N
support NN N
. . N

Parental NNP o
responsiveness NN o
and CC o
child NN o
outcomes NNS o
were VBD N
measured VBN N
at IN N
three CD N
time NN N
points NNS N
: : N
at IN N
beginning VBG N
and CC N
end NN N
of IN N
the DT N
3-month JJ N
treatment NN N
and CC N
at IN N
12-months JJ N
post-study JJ N
entry NN N
. . N

Parental NNP o
responsiveness NN o
improved VBD N
significantly RB N
in IN N
the DT N
treatment NN N
group NN N
but CC N
not RB N
the DT N
control NN N
group NN N
. . N

However RB N
, , N
parental JJ o
responsiveness NN o
was VBD N
not RB N
fully RB N
maintained VBN N
at IN N
follow VB N
up RP N
. . N

There EX N
were VBD N
no DT N
treatment NN N
effects NNS N
on IN N
child NN o
outcomes NNS o
of IN N
joint JJ o
attention NN o
or CC o
language NN o
. . o

Children NNP N
in IN N
both DT N
groups NNS N
made VBD N
significant JJ N
developmental JJ N
gains NNS N
in IN N
cognition NN o
and CC o
language NN o
skills NNS o
over IN N
one CD N
year NN N
. . N

These DT N
results NNS N
support VBP N
parental JJ i
responsiveness NN i
as IN N
an DT N
important JJ N
intervention NN N
target NN N
given VBN N
its PRP$ N
general JJ N
association NN N
with IN N
child NN N
outcomes NNS N
in IN N
the DT N
extant JJ N
literature NN N
; : N
however RB N
, , N
additional JJ N
supports NNS N
are VBP N
likely JJ N
needed VBN N
to TO N
fully RB N
maintain VB N
the DT N
treatment NN N
effect NN N
and CC N
to TO N
affect VB N
child NN N
outcomes NNS N
. . N

-DOCSTART- -16190799- O O

A DT N
double-blind JJ N
, , N
placebo-controlled JJ i
study NN N
of IN N
valproate NN i
for IN N
aggression NN N
in IN N
youth NN p
with IN p
pervasive JJ p
developmental NN p
disorders NNS p
. . p

OBJECTIVE IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
study VB N
valproate JJ i
efficacy NN N
and CC N
safety NN N
for IN N
aggression NN N
in IN N
children NNS p
and CC p
adolescents NNS p
with IN p
pervasive JJ p
developmental NN p
disorders NNS p
( ( p
PDD NNP p
) ) p
. . p

METHODS NNP N
In IN N
this DT N
prospective JJ N
double-blind NN N
, , N
placebo-controlled JJ i
study NN N
, , N
30 CD p
subjects NNS p
( ( p
20 CD p
boys NNS p
, , p
10 CD p
girls NNS p
) ) p
6-20 CD p
years NNS p
of IN p
age NN p
with IN p
PDD NNP p
and CC p
significant JJ p
aggression NN p
were VBD p
randomized VBN p
and CC N
received VBN N
treatment NN N
with IN N
valproate NN i
( ( i
VPA NNP i
) ) i
or CC N
placebo NN i
( ( i
PBO NNP i
) ) i
for IN N
8 CD N
weeks NNS N
as IN N
outpatients NNS p
. . p

Mean NNP o
VPA NNP o
trough IN o
blood NN o
levels NNS o
were VBD N
75.5 CD N
mcg/mL NNS N
at IN N
week NN N
4 CD N
and CC N
77.8 CD N
mcg/mL NN N
at IN N
week NN N
8 CD N
. . N

RESULTS VB N
No DT N
treatment NN N
difference NN N
was VBD N
observed VBN N
statistically RB N
between IN N
VPA NNP i
and CC N
PBO NNP i
groups NNS N
. . N

The DT N
Aberrant NNP o
Behavior NNP o
Checklist NNP o
-- : o
Community NNP o
Scale NNP o
( ( o
ABC-C NNP o
) ) o
Irritability NNP o
subscale NN o
was VBD N
the DT N
primary JJ N
outcome NN N
measure NN N
( ( N
p JJ N
= NNP N
0.65 CD N
) ) N
, , N
and CC N
CGI NNP o
-- : o
Improvement NNP o
( ( N
p JJ N
= NNP N
0.16 CD N
) ) N
and CC N
OAS NNP o
( ( N
p JJ N
= NNP N
0.96 CD N
) ) N
were VBD N
secondary JJ N
outcome NN N
measures NNS N
. . N

Increased VBN o
appetite NN o
and CC o
skin NN o
rash NN o
were VBD N
significant JJ N
side NN N
effects NNS N
. . N

Only RB N
1 CD N
subject NN N
was VBD N
dropped VBN N
from IN N
the DT N
study NN N
owing VBG N
to TO N
side VB N
effects NNS N
, , N
notably RB N
a DT N
spreading NN o
skin NN o
rash NN o
, , N
which WDT N
then RB N
resolved VBD N
spontaneously RB N
. . N

Two CD N
subjects NNS N
receiving VBG N
VPA NNP i
developed VBD N
increased VBN N
serum NN o
ammonia NN o
levels NNS o
, , N
one CD N
with IN N
an DT N
associated JJ N
parent NN N
report NN N
of IN N
slurred JJ o
speech NN o
and CC o
mild JJ o
cognitive JJ o
slowing NN o
. . o

Poststudy NNP N
, , N
of IN N
16 CD N
VPA NNP i
and CC N
PBO NNP i
subjects NNS N
receiving VBG N
VPA NNP i
, , N
10 CD N
subjects NNS N
demonstrated VBD N
sustained JJ o
response NN o
, , N
4 CD N
of IN N
whom WP N
later RB N
attempted VBN N
taper NN N
, , N
with IN N
significant JJ N
relapse NN o
of IN o
aggression NN o
. . o

CONCLUSION VB N
The DT N
present JJ N
negative JJ N
findings NNS N
can MD N
not RB N
be VB N
viewed VBN N
as IN N
conclusive JJ N
, , N
partly RB N
owing VBG N
to TO N
the DT N
large JJ N
placebo NN i
response NN N
, , N
subject JJ N
heterogeneity NN N
, , N
and CC N
size NN N
of IN N
the DT N
groups NNS N
. . N

Larger JJR N
studies NNS N
are VBP N
needed VBN N
to TO N
expand VB N
upon IN N
these DT N
findings NNS N
. . N

-DOCSTART- -3885865- O O

[ JJ N
Randomized NNP N
control NN N
study NN N
of IN N
high-dose JJ N
metoclopramide NN i
in IN N
the DT N
prevention NN N
of IN N
CDDP-induced NNP o
emesis NN o
] NN o
. . N

The DT N
effect NN N
of IN N
high-dose JJ i
metoclopramide NN i
( ( i
2 CD i
mg/kg NN i
, , i
4 CD i
times NNS i
every DT i
2 CD i
hours NNS i
) ) i
on IN N
the DT N
emesis NN o
of IN N
patients NNS p
treated VBN p
with IN p
CDDP NNP p
( ( p
80 CD p
mg/m2 NN p
) ) p
was VBD N
examined VBN N
by IN N
randomized VBN N
control NN N
trial NN N
. . N

The DT N
above JJ N
metoclopramide NN i
regimen NNS N
significantly RB N
suppressed VBD o
the DT o
frequency NN o
of IN o
vomiting VBG o
on IN N
the DT N
day NN N
of IN N
CDDP NNP N
administration NN N
. . N

The DT N
duration NN N
of IN N
nausea NN o
and CC o
anorexia NN o
after IN N
CDDP NNP N
treatment NN N
was VBD N
also RB N
shortened VBN N
by IN N
high-dose JJ N
metoclopramide JJ i
administration NN N
. . N

-DOCSTART- -7910792- O O

[ JJ N
Postlaparoscopic NNP N
pain NN N
syndrome NN N
. . N

Results NNS N
of IN N
a DT N
prospective JJ N
, , N
randomized VBN N
study NN N
] NN N
. . N

The DT N
so-called JJ N
post-laparoscopic JJ N
algesia NN N
is VBZ N
a DT N
specific JJ N
impairment NN N
of IN N
about RB N
63 CD N
% NN N
of IN N
the DT N
patients NNS p
who WP p
undergo VBP p
laparoscopic JJ i
surgical JJ i
operations NNS i
. . i

This DT N
impairment JJ N
takes VBZ N
the DT N
form NN N
of IN N
mild NN N
to TO N
moderate VB N
shoulder NN N
pain NN N
. . N

Eliminating VBG N
the DT N
causes NNS N
of IN N
pain NN N
has VBZ N
a DT N
clear JJ N
advantage NN N
over IN N
symptomatic JJ N
treatment NN N
using VBG N
analgetics NNS N
, , N
a DT N
fact NN N
worth IN N
a DT N
good JJ N
consideration NN N
especially RB N
with IN N
the DT N
post-operative JJ N
sojourn NN N
at IN N
the DT N
hospital NN N
becoming VBG N
shorter JJR N
and CC N
shorter JJR N
. . N

In IN N
a DT N
prospective JJ N
controlled VBN N
study NN N
, , N
involving VBG N
42 CD p
patients NNS p
subdivided VBD p
into IN p
four CD p
groups NNS p
namely RB p
, , p
higher JJR i
or CC i
lower JJR i
insufflation NN i
pressures NNS i
, , i
chemically RB i
inert JJ i
insufflation NN i
gas NN i
and CC p
control NN i
groups NNS p
; : p
the DT N
use NN N
of IN N
analgetics NNS o
, , o
lung NN o
function NN o
, , o
operation NN o
duration NN o
, , o
amount NN o
of IN o
insufflated JJ o
gas NN o
, , o
intraperitoneal JJ o
pH-values NNS o
and CC o
post-operative JJ o
complications NNS o
in IN N
the DT N
various JJ N
subgroups NNS N
were VBD N
compared VBN N
to TO N
each DT N
other JJ N
with IN N
regard NN N
to TO N
post-operative JJ N
pain NN N
perception NN N
. . N

The DT N
results NNS N
did VBD N
not RB N
show VB N
any DT N
significant JJ N
differences NNS N
among IN N
the DT N
groups NNS N
regarding VBG N
the DT N
main JJ N
parameters NNS N
like IN N
pH-value JJ o
or CC o
different JJ o
insufflation NN o
pressures NNS o
etc VBP N
. . N

These DT N
results NNS N
led VBD N
to TO N
the DT N
termination NN N
of IN N
the DT N
study NN N
based VBN N
on IN N
the DT N
raised VBN N
criteria NNS N
since IN N
we PRP N
anticipated VBD N
the DT N
actual JJ N
cause NN N
of IN N
the DT N
shoulder NN N
pain NN N
to TO N
be VB N
due JJ N
to TO N
an DT N
unknown JJ N
factor NN N
. . N

By IN N
the DT N
evaluation NN N
of IN N
the DT N
individual JJ N
data NN N
, , N
it PRP N
became VBD N
apparent JJ N
that IN N
, , N
the DT N
pains NNS o
increase NN o
with IN N
increasing VBG N
gas NN N
consumption NN N
, , N
a DT N
fact NN N
which WDT N
led VBD N
to TO N
assumption NN N
that IN N
the DT N
pains NNS o
are VBP N
caused VBN N
by IN N
a DT N
physical JJ N
effect NN N
such JJ N
as IN N
the DT N
cooling NN N
of IN N
the DT N
peritoneum NN N
. . N

-DOCSTART- -11718681- O O

Relationship NN N
between IN N
endogenous JJ i
estrogen NN i
concentrations NNS i
and CC N
serum NN i
cholesteryl NN i
ester NN i
transfer NN N
protein NN N
concentrations NNS N
in IN p
Chinese JJ p
women NNS p
. . p

BACKGROUND NNP N
CETP NNP N
plays VBZ N
an DT N
important JJ N
role NN N
in IN N
HDL NNP N
metabolism NN N
and CC N
in IN N
the DT N
reverse NN N
cholesterol NN N
transport NN N
pathway NN N
. . N

METHODS NNP N
The DT N
relationship NN N
between IN N
the DT N
changes NNS N
of IN N
endogenous JJ N
estrogen NN N
and CC N
the DT N
concentration NN N
of IN N
cholesteryl NN N
ester NN N
transfer NN N
protein NN N
( ( N
CETP NNP N
) ) N
in IN N
the DT N
serum NN N
of IN N
Chinese JJ p
women NNS p
was VBD N
investigated VBN N
. . N

Serum NNP o
concentrations NNS o
of IN o
estradiol NN o
( ( o
E NNP o
( ( o
2 CD o
) ) o
) ) o
, , o
follicle-stimulating JJ o
hormone NN o
( ( o
FSH NNP o
) ) o
, , o
CETP NNP o
and CC o
lipid JJ o
profile NN o
were VBD i
determined VBN i
in IN i
196 CD i
Chinese JJ i
women NNS i
( ( i
52 CD i
premenopausal NN i
with IN i
ages NNS i
ranging VBG i
from IN i
18 CD i
to TO i
40 CD i
years NNS i
, , i
57 CD i
perimenopausal NN i
from IN i
41 CD i
to TO i
60 CD i
years NNS i
, , i
and CC i
87 CD i
postmenopausal NN i
from IN i
61 CD i
to TO i
81 CD i
years NNS i
) ) i
. . i

RESULTS NNP N
Serum NNP o
CETP NNP o
concentration NN o
was VBD N
significantly RB N
lower JJR N
in IN N
postmenopausal JJ N
women NNS N
compared VBN N
with IN N
those DT N
in IN N
perimenopausal NN N
and CC N
premenopausal JJ N
women NNS N
( ( N
1.39+/-1.06 JJ N
, , N
2.36+/-1.50 JJ N
and CC N
2.31+/-1.25 JJ N
mg/l NN N
, , N
respectively RB N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

Even RB N
in IN N
the DT N
women NNS p
around IN p
the DT p
menopausal NN p
, , N
CETP NNP o
concentration NN o
in IN N
postmenopause NN N
was VBD N
significantly RB N
lower JJR N
than IN N
that DT N
in IN N
premenopause NN N
( ( N
1.93+/-1.33 JJ N
vs. IN N
3.42+/-1.35 JJ N
mg/l NN N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

In IN N
addition NN N
, , N
CETP NNP N
concentration NN N
had VBD N
a DT N
highly RB N
positive JJ N
correlation NN N
with IN N
serum JJ o
concentration NN o
of IN N
E NNP N
( ( N
2 CD N
) ) N
( ( N
r=0.243 NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
while IN N
negative JJ N
correlation NN N
of IN N
CETP NNP o
concentration NN o
with IN N
serum JJ o
concentration NN o
of IN o
FSH NNP o
was VBD N
found VBN N
( ( N
r=-0.273 JJ N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSIONS NNP N
Estrogen NNP N
may MD N
affect VB N
the DT N
concentration NN o
of IN o
CETP NNP o
. . o

-DOCSTART- -24898665- O O

Patients NNS p
with IN p
relapsed JJ p
follicular JJ p
lymphoma NN p
treated VBN N
with IN N
rituximab JJ i
versus NN i
tositumomab NN i
and CC i
iodine JJ i
I-131 NNP i
tositumomab NN i
. . i

-DOCSTART- -8885803- O O

Efficacy NN N
and CC N
safety NN N
of IN N
triamcinolone NN i
acetonide RB i
aqueous JJ i
nasal NN i
spray NN i
in IN N
patients NNS p
with IN p
seasonal JJ p
allergic JJ p
rhinitis NN p
. . p

BACKGROUND NNP N
In IN N
order NN N
to TO N
accommodate VB N
increasing VBG N
patient JJ N
preferences NNS N
a DT N
new JJ N
aqueous JJ N
formulation NN N
of IN i
triamcinolone NN i
acetonide NN i
nasal NN N
spray NN N
was VBD N
developed VBN N
for IN N
the DT N
relief NN N
of IN N
symptoms NNS N
associated VBN N
with IN N
seasonal JJ N
and CC N
perennial JJ N
allergic NN N
rhinitis NN N
. . N

OBJECTIVE CC N
This DT N
multicenter NN N
, , N
randomized VBN N
, , N
double-blind JJ N
study NN N
was VBD N
designed VBN N
to TO N
compare VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
once-daily JJ N
triamcinolone NN i
acetonide RB i
aqueous JJ i
nasal NN i
spray NN i
( ( N
220 CD N
micrograms/day NN N
) ) N
with IN N
placebo NN i
in IN N
relieving VBG N
the DT N
symptoms NNS N
of IN N
seasonal JJ o
allergic JJ o
rhinitis NN o
due JJ p
to TO p
ragweed VB p
. . p

METHODS NNP N
One CD p
hundred VBD p
forty NN p
patients NNS p
received VBD N
either CC N
a DT N
once RB N
daily JJ N
220-microgram JJ N
dose NN N
of IN N
triamcinolone NN i
acetonide RB i
aqueous JJ i
nasal NN i
spray NN i
or CC i
placebo NN i
for IN N
2 CD N
weeks NNS N
. . N

Patients NNS N
evaluated VBD N
the DT N
severity NN N
of IN N
seasonal JJ o
allergic JJ o
rhinitis NN o
symptoms NNS o
daily RB N
for IN N
2 CD N
weeks NNS N
according VBG N
to TO N
a DT N
4-point JJ N
scale NN N
( ( N
0 CD N
= NNP N
absent NN N
, , N
1 CD N
= NN N
mild NN N
, , N
2 CD N
= NN N
moderate NN N
, , N
3 CD N
= NNP N
severe RB N
) ) N
. . N

Physician JJ N
and CC N
patient JJ N
global JJ N
evaluations NNS N
of IN N
overall JJ N
treatment NN N
effectiveness NN N
were VBD N
assessed VBN N
at IN N
the DT N
end NN N
of IN N
the DT N
treatment NN N
period NN N
. . N

RESULTS JJ N
Patients NNPS N
receiving VBG N
triamcinolone NN N
acetonide RB N
aqueous JJ N
nasal NN N
spray NN N
, , N
220 CD N
micrograms/day NN N
, , N
had VBD N
significantly RB N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
greater JJR N
improvements NNS o
in IN N
all DT N
rhinitis NN o
symptoms NNS o
at IN N
weeks NNS N
1 CD N
and CC N
2 CD N
and CC N
overall JJ N
for IN N
the DT N
2-week JJ N
treatment NN N
period NN N
compared VBN N
with IN N
the DT N
placebo NN N
group NN N
. . N

A DT N
significant JJ N
( ( N
P NNP N
= NNP N
.006 NNP N
) ) N
improvement NN o
in IN o
the DT o
nasal JJ o
index NN o
occurred VBD o
as RB N
early RB N
as IN N
12 CD N
hours NNS N
after IN N
the DT N
first JJ N
dose NN N
of IN N
triamcinolone NN N
acetonide RB N
aqueous JJ N
nasal NN N
spray NN N
. . N

Both DT N
patients NNS N
and CC N
physicians NNS N
reported VBD N
a DT N
greater JJR o
overall JJ o
improvement NN o
in IN o
symptoms NNS o
for IN N
the DT N
triamcinolone NN N
acetonide RB N
aqueous JJ N
nasal NN N
spray NN N
group NN N
. . N

There EX N
were VBD N
no DT N
differences NNS N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
in IN N
the DT N
incidence NN N
of IN N
adverse JJ o
events NNS o
. . o

CONCLUSIONS NNP N
This DT N
study NN N
confirmed VBD N
that IN N
a DT N
220-microgram JJ N
dose NN N
of IN N
triamcinolone NN N
acetonide RB N
aqueous JJ N
nasal NN N
spray NN N
, , N
administered VBN N
once RB N
daily JJ N
for IN N
2 CD N
weeks NNS N
, , N
is VBZ N
well RB N
tolerated VBN N
and CC N
reduces NNS o
effectively RB o
the DT o
severity NN o
of IN o
symptoms NNS o
of IN o
seasonal JJ o
allergic JJ o
rhinitis NN o
due JJ o
to TO o
ragweed VB o
. . o

-DOCSTART- -1390473- O O

Cone NN N
biopsy NN N
: : N
has VBZ N
endocervical JJ i
sampling VBG i
a DT N
role NN N
? . N
OBJECTIVE UH N
To TO N
investigate VB N
the DT N
sensitivity NN N
, , N
specificity NN N
and CC N
predictive JJ N
value NN N
of IN N
endocervical JJ i
sampling NN i
in IN N
women NNS p
with IN p
abnormal JJ p
cervical JJ p
smears NNS p
. . p

DESIGN VB N
A DT N
randomized JJ N
study NN N
of IN N
two CD N
methods NNS N
of IN N
endocervical JJ i
sampling NN i
. . i

SETTING NN N
Colposcopy NNP p
clinic NN p
at IN p
Aberdeen NNP p
Royal NNP p
Infirmary NNP p
. . p

SUBJECTS NNP N
100 CD p
women NNS p
with IN p
abnormal JJ p
cervical JJ p
smears NNS p
selected VBN p
for IN p
cone NN p
biopsy NN p
according VBG p
to TO p
current JJ p
colposcopy NN p
criteria NNS p
. . p

INTERVENTIONS NNP N
53 CD N
women NNS N
were VBD N
randomized VBN N
to TO N
have VB N
endocervical JJ i
sampling VBG i
with IN i
the DT i
Kevorkian NNP i
curette NN i
and CC N
47 CD N
to TO N
have VB N
sampling VBG i
with IN i
the DT i
Medscand NNP i
endocervical JJ i
brush NN i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Cytology NNP o
and CC o
histology NN o
results NNS o
from IN o
endocervical JJ o
sampling NN o
compared VBN o
with IN o
cone NN o
biopsy NN o
histology NN o
. . o

RESULTS VB N
The DT N
overall JJ N
sensitivity NN o
of IN o
endocervical JJ o
sampling NN o
was VBD N
56 CD N
% NN N
, , N
with IN N
a DT N
false JJ o
negative JJ o
rate NN o
of IN N
44 CD N
% NN N
and CC N
a DT N
negative JJ o
predictive JJ o
value NN o
of IN N
26 CD N
% NN N
. . N

CONCLUSIONS NNP N
Endocervical NNP i
sampling VBG i
should MD N
not RB N
influence VB N
management NN N
when WRB N
colposcopy NN N
is VBZ N
unsatisfactory JJ N
. . N

-DOCSTART- -25668435- O O

Oxytocin NNP i
increases VBZ N
eye NN o
contact NN o
during IN N
a DT N
real-time JJ N
, , N
naturalistic JJ N
social JJ N
interaction NN N
in IN N
males NNS p
with IN p
and CC p
without IN p
autism NN p
. . p

Autism NNP p
spectrum JJ p
conditions NNS p
( ( p
autism NN p
) ) p
affect VBP N
~1 CD N
% NN N
of IN N
the DT N
population NN N
and CC N
are VBP N
characterized VBN N
by IN N
deficits NNS N
in IN N
social JJ N
communication NN N
. . N

Oxytocin NNP i
has VBZ N
been VBN N
widely RB N
reported VBN N
to TO N
affect VB N
social-communicative JJ N
function NN N
and CC N
its PRP$ N
neural JJ N
underpinnings NNS N
. . N

Here RB N
we PRP N
report VBP N
the DT N
first JJ N
evidence NN N
that IN N
intranasal NN i
oxytocin JJ i
administration NN N
improves VBZ N
a DT N
core NN N
problem NN N
that IN N
individuals NNS p
with IN p
autism NN p
have VBP N
in IN N
using VBG o
eye NN o
contact NN o
appropriately RB N
in IN N
real-world JJ N
social JJ N
settings NNS N
. . N

A DT N
randomized JJ N
double-blind NN N
, , N
placebo-controlled JJ i
, , N
within-subjects JJ N
design NN N
is VBZ N
used VBN N
to TO N
examine VB N
how WRB N
intranasal JJ N
administration NN N
of IN N
24 CD i
IU NNP i
of IN i
oxytocin JJ i
affects NNS o
gaze VBP o
behavior NN o
for IN o
32 CD p
adult NN p
males NNS p
with IN p
autism NN p
and CC p
34 CD p
controls NNS p
in IN p
a DT p
real-time JJ p
interaction NN p
with IN p
a DT N
researcher NN N
. . N

This DT N
interactive JJ N
paradigm NN N
bypasses VBZ N
many JJ N
of IN N
the DT N
limitations NNS N
encountered VBD N
with IN N
conventional JJ N
static JJ N
or CC N
computer-based JJ N
stimuli NNS o
. . o

Eye NN o
movements NNS o
are VBP o
recorded VBN N
using VBG N
eye NN N
tracking NN N
, , N
providing VBG N
an DT N
objective JJ N
measurement NN N
of IN N
looking VBG N
patterns NNS N
. . N

The DT N
measure NN N
is VBZ N
shown VBN N
to TO N
be VB N
sensitive JJ N
to TO N
the DT N
reduced VBN o
eye NN o
contact NN o
commonly RB o
reported VBD N
in IN N
autism NN N
, , N
with IN N
the DT N
autism NN N
group NN N
spending VBG N
less JJR N
time NN N
looking VBG N
to TO N
the DT N
eye NN N
region NN N
of IN N
the DT N
face NN N
than IN N
controls NNS i
. . i

Oxytocin NNP i
administration NN i
selectively RB N
enhanced VBD o
gaze NN o
to TO o
the DT o
eyes NNS o
in IN o
both DT N
the DT N
autism NN N
and CC N
control NN N
groups NNS N
( ( N
transformed VBN N
mean VBP o
eye-fixation NN o
difference NN o
per IN o
second=0.082 NN o
; : o
95 CD o
% NN N
CI:0.025-0.14 NNP N
, , N
P=0.006 NNP N
) ) N
. . N

Within IN N
the DT N
autism NN N
group NN N
, , N
oxytocin PRP N
has VBZ N
the DT N
most RBS N
effect NN N
on IN N
fixation NN o
duration NN o
in IN o
individuals NNS N
with IN N
impaired JJ N
levels NNS N
of IN N
eye NN o
contact NN o
at IN o
baseline NN N
( ( N
Cohen NNP N
's POS N
d=0.86 NN N
) ) N
. . N

These DT N
findings NNS N
demonstrate VBP N
that IN N
the DT N
potential JJ N
benefits NNS N
of IN N
oxytocin NN N
in IN N
autism NN N
extend VBP N
to TO N
a DT N
real-time JJ N
interaction NN N
, , N
providing VBG N
evidence NN N
of IN N
a DT N
therapeutic JJ N
effect NN N
in IN N
a DT N
key JJ N
aspect NN N
of IN N
social JJ N
communication NN N
. . N

-DOCSTART- -23735703- O O

A DT N
randomised JJ N
trial NN N
comparing VBG N
preoperative JJ i
to TO i
perioperative JJ i
chemotherapy NN i
in IN N
early-stage JJ p
non-small-cell JJ p
lung NN p
cancer NN p
( ( p
IFCT NNP p
0002 CD p
trial NN p
) ) p
. . p

HYPOTHESIS NNP N
There EX N
will MD N
be VB N
a DT N
detectable JJ N
increase NN N
in IN N
overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
using VBG N
preoperative JJ i
( ( i
PRE NNP i
) ) i
as IN i
opposed VBN i
to TO i
perioperative VB i
( ( i
PERI NNP i
) ) i
chemotherapy NN i
in IN N
resectable JJ p
StageI-II JJ p
non-small-cell JJ p
lung NN p
cancer NN p
( ( p
NSCLC NNP p
) ) p
. . p

METHODS NNP N
This DT N
multicenter NN N
, , N
open-label JJ N
, , N
randomised JJ N
trial NN N
with IN N
a DT N
2?2 CD N
factorial JJ N
design NN N
first RB N
compared VBN N
two CD N
chemotherapy NN N
strategies NNS N
( ( N
PRE NNP N
versus NNP N
PERI NNP N
) ) N
, , N
then RB N
two CD i
chemotherapy NN i
regimens NNS i
( ( i
gemcitabine-cisplatin JJ i
[ NNP i
GP NNP i
] NNP i
versus IN i
paclitaxel-carboplatin JJ i
[ NNP i
TC NNP i
] NNP i
) ) i
. . i

The DT i
PRE NNP i
group NN N
received VBD N
two CD N
preoperative JJ N
cycles NNS N
followed VBN N
by IN N
two CD N
additional JJ N
preoperative NN N
cycles NNS N
, , N
while IN N
the DT i
PERI NNP i
group NN N
underwent VBD N
two CD N
preoperative JJ N
cycles NNS N
followed VBN N
by IN N
two CD N
postoperative JJ N
cycles NNS N
, , N
the DT N
3rd CD N
and CC N
4th CD N
cycles NNS N
being VBG N
given VBN N
only RB N
to TO N
responders NNS N
in IN N
both DT N
cases NNS N
. . N

RESULTS VB p
A DT p
total NN p
of IN p
528 CD p
patients NNS p
were VBD N
randomised VBN N
, , N
267 CD N
of IN N
which WDT N
were VBD N
assigned VBN N
to TO N
the DT N
PRE NNP N
group NN N
and CC N
261 CD N
to TO N
the DT N
PERI NNP N
group NN N
. . N

Three-year JJ o
OS NNP o
did VBD N
not RB N
differ VB N
between IN N
the DT N
two CD N
groups NNS N
( ( N
67.4 CD N
% NN N
and CC N
67.7 CD N
% NN N
, , N
respectively RB N
; : N
hazard NN N
ratio NN N
( ( N
HR NNP N
) ) N
=1.01 VBP N
[ JJ N
0.79-1.30 JJ N
] NN N
, , N
p=0.92 NN N
) ) N
, , N
nor CC N
did VBD o
3-year JJ o
disease-free JJ o
survival NN o
, , o
response NN o
rates NNS o
, , o
toxicity NN o
, , o
or CC o
postoperative JJ o
mortality NN o
. . o

Pathological NNP o
complete JJ o
response NN o
was VBD N
observed VBN N
in IN N
22 CD N
( ( N
8.2 CD N
% NN N
) ) N
and CC N
16 CD N
patients NNS N
( ( N
6.1 CD N
% NN N
) ) N
, , N
respectively RB N
. . N

Although IN o
quality NN o
of IN o
life NN o
did VBD N
not RB N
differ VB N
significantly RB N
, , N
chemotherapy NN o
compliance NN o
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
PRE NNP N
group NN N
. . N

The DT N
proportion NN N
of IN N
responders NNS N
who WP N
received VBD N
Cycles NNP N
3 CD N
and CC N
4 CD N
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
PRE NNP N
group NN N
( ( N
90.4 CD N
% NN N
versus IN N
75.2 CD N
% NN N
, , N
p=0.001 NN N
) ) N
. . N

In IN N
responders NNS N
, , N
the DT N
dose JJ N
intensity NN N
of IN N
Cycles NNP N
3 CD N
and CC N
4 CD N
was VBD N
higher RBR N
in IN N
the DT N
PRE NNP N
group NN N
than IN N
in IN N
the DT N
PERI NNP N
group NN N
( ( N
mean JJ N
relative VBP N
dose JJ N
intensity NN N
of IN N
90.4 CD N
% NN N
versus IN N
82.6 CD N
% NN N
, , N
respectively RB N
; : N
p=0.0007 NN N
) ) N
. . N

There EX N
was VBD N
no DT N
difference NN N
between IN o
GP NNP o
and CC o
TC NNP o
in IN N
3-year JJ o
OS NNP o
( ( N
HR=0.97 NNP N
[ RB N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
: : N
0.76-1.25 JJ N
] NN N
, , N
p=0.80 NN N
) ) N
or CC o
response NN o
rates NNS o
. . o

However RB N
, , N
the DT N
regimens NNS o
' POS o
toxicity NN o
profiles NNS N
differed VBN N
. . N

CONCLUSIONS VB N
This DT N
study NN N
failed VBD N
to TO N
demonstrate VB N
any DT N
difference NN N
in IN o
survival NN o
between IN N
patients NNS N
receiving VBG i
preoperative JJ i
and CC i
perioperative JJ i
chemotherapy NN i
in IN p
early-stage JJ p
NSCLC NNP p
. . p

The DT N
increase NN N
from IN N
two CD N
to TO N
four CD N
preoperative JJ N
chemotherapy NN N
cycles NNS N
did VBD N
not RB N
increase VB N
the DT o
pathological JJ o
response NN o
rate NN N
. . N

-DOCSTART- -18040663- O O

Intensive JJ i
insulin NN i
therapy NN i
improves VBZ N
endothelial JJ o
function NN o
and CC N
microvascular JJ N
reactivity NN N
in IN N
young JJ p
people NNS p
with IN p
type JJ p
1 CD p
diabetes NNS p
. . p

AIMS/HYPOTHESIS NNP N
Macrovascular NNP N
disease NN N
is VBZ N
an DT N
important JJ N
cause NN N
of IN N
the DT N
increased VBN N
morbidity NN N
and CC N
mortality NN N
rates NNS N
associated VBN N
with IN N
type NN N
1 CD N
diabetes NNS N
, , N
and CC N
this DT N
vascular JJ N
impairment NN N
begins VBZ N
in IN N
childhood NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
introducing VBG N
intensive JJ i
diabetes NNS i
management NN i
[ RB i
intensive JJ i
insulin NN N
therapy NN N
( ( N
IIT NNP N
) ) N
and CC N
'Sweet $ i
Talk NNP i
' POS i
text-messaging JJ i
support NN i
] NN i
produces VBZ N
measurable JJ N
improvements NNS N
in IN N
endothelial JJ o
function NN o
. . o

METHODS NNP N
One CD p
hundred CD p
and CC p
twenty-six JJ p
patients NNS p
fulfilled VBD p
the DT p
eligibility NN p
criteria NNS p
( ( p
type NN p
1 CD p
diabetes NNS p
for IN p
> NN p
1 CD p
year NN p
; : p
on IN p
conventional JJ i
insulin NN i
therapy NN i
( ( i
CIT NNP i
) ) i
; : i
aged VBN p
between IN p
8 CD p
and CC p
18 CD p
years NNS p
) ) p
, , p
of IN p
whom WP p
92 CD p
enrolled VBD p
. . p

Patients NNS N
were VBD N
randomised VBN N
to TO N
group NN N
1 CD N
, , N
CIT NNP i
only RB i
( ( i
n=28 JJ i
) ) i
; : i
group NN i
2 CD i
, , i
CIT NNP i
and CC i
Sweet NNP i
Talk NNP i
( ( i
n=33 NN i
) ) i
; : i
or CC i
group NN i
3 CD i
, , i
IIT NNP i
and CC i
Sweet NNP i
Talk NNP i
( ( i
n=31 NN i
) ) i
. . i

Vascular JJ o
assessments NNS o
( ( o
including VBG o
measures NNS o
of IN o
endothelial JJ o
damage NN o
, , o
activation NN o
, , o
dysfunction NN o
and CC o
oxidative JJ o
stress NN o
) ) o
and CC o
HbA1c NNP o
were VBD i
performed VBN i
at IN i
baseline NN i
and CC i
repeated VBD i
after IN i
12 CD i
months NNS i
of IN i
the DT i
study NN i
. . i

RESULTS NNP N
Glycaemic NNP o
control NN o
deteriorated VBD N
in IN N
patients NNS N
on IN N
CIT NNP N
, , N
but CC N
improved VBD N
significantly RB N
in IN N
patients NNS N
allocated VBN N
to TO N
IIT NNP N
( ( N
p=0.007 NN N
) ) N
. . N

IIT NNP N
was VBD N
associated VBN N
with IN N
significantly RB N
greater JJR N
improvements NNS N
in IN N
E-selectin NNP o
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
than IN N
CIT NNP N
( ( N
group NN N
1 CD N
, , N
p=0.026 NN N
and CC N
group NN N
2 CD N
, , N
p=0.053 NN N
) ) N
. . N

Vascular JJ o
responses NNS o
to TO N
acetylcholine VB N
improved VBN N
in IN N
patients NNS N
on IN N
IIT NNP N
( ( N
p=0.017 NN N
) ) N
, , N
but CC N
not RB N
in IN N
patients NNS N
receiving VBG N
CIT NNP N
. . N

These DT N
changes NNS N
were VBD N
all DT N
independent JJ N
of IN N
HbA1c NNP N
level NN N
. . N

CONCLUSIONS/INTERPRETATION NNP N
IIT NNP N
appears VBZ N
to TO N
be VB N
associated VBN N
with IN N
improvements NNS N
in IN N
vascular JJ o
markers NNS o
, , N
independently RB N
of IN N
changes NNS N
in IN N
HbA1c NNP N
, , N
suggesting VBG N
that IN N
IIT NNP N
may MD N
confer VB N
vascular JJ N
protection NN N
in IN N
addition NN N
to TO N
improving VBG N
glycaemic JJ o
control NN o
. . o

-DOCSTART- -18056791- O O

Leucine-enriched JJ N
essential JJ N
amino NN N
acid NN N
and CC N
carbohydrate JJ N
ingestion NN N
following VBG N
resistance NN N
exercise NN N
enhances NNS N
mTOR VBP N
signaling VBG N
and CC N
protein JJ N
synthesis NN N
in IN N
human JJ N
muscle NN N
. . N

We PRP N
recently RB N
showed VBD N
that IN N
resistance NN N
exercise NN N
and CC N
ingestion NN N
of IN N
essential JJ i
amino NN i
acids NNS i
with IN i
carbohydrate NN i
( ( i
EAA+CHO NNP i
) ) i
can MD N
independently RB N
stimulate VB N
mammalian JJ N
target NN N
of IN N
rapamycin NN N
( ( N
mTOR NN N
) ) N
signaling NN N
and CC N
muscle NN N
protein NN N
synthesis NN N
in IN N
humans NNS N
. . N

Providing VBG N
an DT N
EAA+CHO NNP N
solution NN N
postexercise NN N
can MD N
further VB N
increase VB N
muscle NN N
protein JJ N
synthesis NN N
. . N

Therefore RB N
, , N
we PRP N
hypothesized VBD N
that IN N
enhanced VBD N
mTOR NNS N
signaling VBG N
might MD N
be VB N
responsible JJ N
for IN N
the DT N
greater JJR N
muscle NN N
protein NN N
synthesis NN N
when WRB N
leucine-enriched JJ N
EAA+CHOs NNP N
are VBP N
ingested VBN N
during IN N
postexercise JJ N
recovery NN N
. . N

Sixteen NNP p
male JJ p
subjects NNS p
were VBD N
randomized VBN N
to TO N
one CD N
of IN N
two CD N
groups NNS N
( ( i
control NN i
or CC i
EAA+CHO NNP i
) ) i
. . N

The DT i
EAA+CHO NNP i
group NN i
ingested VBD i
the DT i
nutrient JJ i
solution NN i
1 CD i
h NN i
after IN i
resistance NN i
exercise NN i
. . i

mTOR NN o
signaling VBG o
was VBD N
assessed VBN N
by IN N
immunoblotting VBG i
from IN i
repeated VBN i
muscle NN i
biopsy NN i
samples NNS i
. . i

Mixed JJ o
muscle NN o
fractional JJ o
synthetic JJ o
rate NN o
( ( o
FSR NNP o
) ) o
was VBD N
measured VBN N
using VBG N
stable JJ N
isotope NN N
techniques NNS N
. . N

Muscle NNP o
protein JJ o
synthesis NN o
and CC o
4E-BP1 JJ o
phosphorylation NN o
during IN N
exercise NN N
were VBD N
significantly RB N
reduced VBN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Postexercise NNP o
FSR NNP o
was VBD N
elevated VBN N
above IN N
baseline NN N
in IN N
both DT N
groups NNS N
at IN N
1 CD N
h NN N
but CC N
was VBD N
even RB N
further RBR N
elevated VBN N
in IN N
the DT N
EAA+CHO NNP N
group NN N
at IN N
2 CD N
h NNS N
postexercise NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Increased VBN o
FSR NNP o
was VBD N
associated VBN N
with IN N
enhanced JJ N
phosphorylation NN N
of IN N
mTOR NN N
and CC N
S6K1 NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Akt NNP o
phosphorylation NN o
was VBD N
elevated VBN N
at IN N
1 CD N
h NN N
and CC N
returned VBN N
to TO N
baseline VB N
by IN N
2 CD N
h NN N
in IN N
the DT N
control NN N
group NN N
, , N
but CC N
it PRP N
remained VBD N
elevated VBN N
in IN N
the DT N
EAA+CHO NNP N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

4E-BP1 JJ o
phosphorylation NN o
returned VBD N
to TO N
baseline VB N
during IN N
recovery NN N
in IN N
control NN N
but CC N
became VBD N
elevated VBN N
when WRB N
EAA+CHO NNP N
was VBD N
ingested VBN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

eEF2 JJ o
phosphorylation NN o
decreased VBD N
at IN N
1 CD N
and CC N
2 CD N
h NN N
postexercise NN N
to TO N
a DT N
similar JJ N
extent NN N
in IN N
both DT N
groups NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Our PRP$ N
data NNS N
suggest VBP N
that IN N
enhanced JJ N
activation NN N
of IN N
the DT N
mTOR NN N
signaling VBG N
pathway NN N
is VBZ N
playing VBG N
a DT N
role NN N
in IN N
the DT N
greater JJR N
synthesis NN N
of IN N
muscle NN N
proteins NNS N
when WRB N
resistance NN N
exercise NN N
is VBZ N
followed VBN N
by IN N
EAA+CHO NNP N
ingestion NN N
. . N

-DOCSTART- -9437974- O O

The DT N
accuracy NN o
of IN N
clinical JJ o
neurosensory NN o
testing VBG o
for IN N
nerve JJ N
injury NN N
diagnosis NN N
. . N

PURPOSE VB N
The DT N
accuracy NN N
of IN N
the DT N
clinical JJ i
neurosensory JJ i
test NN i
to TO N
diagnose VB N
trigeminal JJ N
nerve NN N
injuries NNS N
has VBZ N
never RB N
been VBN N
statistically RB N
evaluated VBN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
statistical JJ o
efficacy NN o
of IN o
the DT o
clinical JJ o
neurosensory JJ o
test NN o
using VBG N
surgical JJ N
findings NNS N
as IN N
the DT N
gold JJ N
standard NN N
, , N
and CC N
to TO N
determine VB N
whether IN N
a DT N
correlation NN N
existed VBN N
between IN N
the DT N
sensory JJ N
impairment NN N
score NN N
obtained VBN N
by IN N
preoperative JJ N
testing NN N
and CC N
the DT N
degree NN N
of IN N
nerve NN N
injury NN N
found VBD N
at IN N
surgery NN N
. . N

MATERIALS NNP N
AND NNP N
METHODS NNP N
A NNP N
multisite NN N
, , N
randomized VBN N
, , N
prospective JJ N
, , N
blinded VBD N
, , N
clinical JJ N
trial NN N
was VBD N
conducted VBN N
on IN N
130 CD p
patients NNS p
with IN p
inferior JJ p
alveolar JJ p
nerve NN p
( ( p
IAN NNP p
) ) p
and CC p
lingual JJ p
nerve NN p
( ( p
LN NNP p
) ) p
injuries NNS p
. . p

Preoperatively RB N
, , N
patients NNS i
were VBD i
provided VBN i
a DT i
sensory JJ i
impairment NN i
score NN i
using VBG i
a DT i
three-level JJ i
drop-out JJ i
clinical JJ i
neurosensory NN i
test NN i
( ( i
NST NNP i
) ) i
, , i
and CC i
blind IN i
comparisons NNS i
were VBD i
made VBN i
with IN i
the DT i
surgical JJ i
findings NNS i
postoperatively RB i
. . i

RESULTS VB N
The DT N
positive JJ o
predictive NN o
and CC o
negative JJ o
predictive NN o
values NNS o
for IN N
LN-injured JJ N
patients NNS N
were VBD N
95 CD N
% NN N
and CC N
100 CD N
% NN N
, , N
respectively RB N
. . N

The DT N
positive JJ N
predictive NN N
and CC N
negative JJ N
predictive NN N
values NNS N
for IN N
IAN NNP p
patients NNS p
were VBD N
77 CD N
% NN N
and CC N
60 CD N
% NN N
, , N
respectively RB N
. . N

There EX N
were VBD N
statistically RB N
significant JJ N
differences NNS N
in IN N
the DT N
distribution NN N
of IN N
age NN N
, , N
duration NN N
of IN N
injury NN N
, , N
cause NN N
of IN N
injury NN N
, , N
presence NN N
of IN N
neuropathic JJ N
pain NN N
, , N
presence NN N
of IN N
trigger NN N
pain NN N
, , N
and CC N
degree NN N
of IN N
injury NN N
between IN N
the DT p
IAN NNP p
and CC p
LN NNP p
patient JJ p
populations NNS p
. . p

There EX N
was VBD N
a DT N
statistically RB o
significant JJ o
positive JJ o
relationship NN o
found VBD o
between IN o
the DT o
sensory JJ o
impairment NN o
score NN o
and CC o
the DT o
degree NN o
of IN o
nerve NN o
injury NN o
. . o

CONCLUSIONS VB N
The DT N
NST NNP i
is VBZ N
a DT N
clinically RB N
useful JJ N
method NN N
to TO N
diagnose VB N
IAN NNP N
and CC N
LN NNP N
injuries NNS N
. . N

However RB N
, , N
the DT N
NST NNP i
results NNS N
are VBP N
less RBR o
efficient JJ o
for IN N
IAN NNP N
injuries NNS N
than IN N
LN NNP N
injuries NNS N
, , N
and CC N
have VBP N
a DT N
high JJ o
incidence NN o
of IN o
false-positive JJ o
( ( N
23 CD N
% NN N
) ) N
and CC N
false-negative JJ o
( ( N
40 CD N
% NN N
) ) N
results NNS N
when WRB N
testing VBG N
patients NNS p
with IN p
IAN NNP p
injuries NNS p
. . p

The DT N
different JJ N
rates NNS N
of IN N
statistical JJ o
efficiency NN o
between IN N
the DT N
two CD N
groups NNS N
of IN N
patients NNS N
may MD N
be VB N
attributable JJ N
to TO N
differences NNS N
in IN N
prevalence NN N
and CC N
biologic NN N
covariates NNS N
. . N

-DOCSTART- -5980490- O O

Alcoholism NN p
, , p
avoidance NN o
learning NN o
and CC p
emotional JJ o
responsiveness NN o
. . o

-DOCSTART- -19480863- O O

Effects NNS N
of IN N
weight-bearing JJ i
versus NN i
nonweight-bearing JJ i
exercise NN i
on IN N
function NN o
, , o
walking VBG o
speed NN o
, , o
and CC o
position NN o
sense NN o
in IN N
participants NNS p
with IN p
knee NN p
osteoarthritis NN p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

OBJECTIVE UH N
To TO N
investigate VB N
whether IN N
weight-bearing NN i
( ( i
WB NNP i
) ) i
exercise NN i
enhances VBZ N
functional JJ o
capacity NN o
to TO N
a DT N
greater JJR N
extent NN N
than IN N
nonweight-bearing JJ i
( ( i
NWB NNP i
) ) i
exercise NN i
in IN N
participants NNS p
with IN p
knee NN p
osteoarthritis NN p
. . p

DESIGN NNP N
Randomized NNP N
controlled VBD N
trial NN N
. . N

SETTING NNP N
Kinesiology NNP N
laboratory NN N
. . N

PARTICIPANTS JJ N
Participants NNS p
( ( p
N=106 NNP p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
WB NNP i
exercise NN i
, , i
NWB NNP i
exercise NN i
, , N
or CC N
a DT N
control NN i
group NN i
( ( i
no DT i
exercise NN i
) ) i
. . i

INTERVENTION NNP N
WB NNP i
exercise NN i
and CC i
NWB NNP i
exercise NN i
groups NNS i
underwent VBD i
an DT N
8-week JJ i
knee NN i
extension-flexion NN i
exercise NN i
program NN i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Western NNP o
Ontario NNP o
and CC o
McMaster NNP o
Universities NNP o
Osteoarthritis NNP o
Index NNP o
( ( o
WOMAC NNP o
) ) o
function NN o
scale NN o
, , o
walking VBG o
speed NN o
, , o
muscle NN o
torque NN o
, , o
and CC o
knee VB o
reposition NN o
error NN o
were VBD N
assessed VBN N
before IN N
and CC N
after IN N
intervention NN N
. . N

RESULTS NNP N
Equally NNP N
significant JJ N
improvements NNS N
were VBD N
apparent JJ N
for IN N
all DT N
outcomes NNS N
after IN N
WB NNP N
exercise NN N
and CC N
NWB NNP N
exercise NN N
, , N
except IN N
for IN N
reposition NN o
error NN o
, , N
for IN N
which WDT N
improvement NN N
was VBD N
greater JJR N
in IN N
the DT N
WB NNP i
exercise NN i
group NN N
. . N

In IN N
contrast NN N
, , N
there EX N
were VBD N
no DT N
improvements NNS N
in IN N
the DT N
control NN N
group NN N
. . N

CONCLUSIONS NNP N
Simple NNP N
knee NNP N
flexion NN N
and CC N
extension NN N
exercises NNS N
( ( i
WB NNP i
and CC N
NWB NNP i
) ) i
performed VBD N
over IN N
8 CD N
weeks NNS N
resulted VBD N
in IN N
significant JJ N
improvement NN N
in IN N
the DT N
WOMAC NNP o
function NN o
scale NN o
and CC o
knee NN o
strength NN o
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

NWB NNP i
exercise NN i
alone RB N
may MD N
be VB N
sufficient JJ N
enough RB N
to TO N
improve VB N
function NN o
and CC o
muscle NN o
strength NN o
. . o

The DT N
additional JJ N
benefit NN N
of IN N
WB NNP i
exercise NN i
was VBD N
improved VBN N
position NN o
sense NN o
, , N
which WDT N
may MD N
enhance VB N
complex JJ o
walking NN o
tasks NNS o
( ( N
walking VBG N
on IN N
figure NN N
of IN N
8 CD N
route NN N
and CC N
spongy JJ N
surface NN N
) ) N
. . N

-DOCSTART- -8570776- O O

Placebo-controlled JJ i
acute JJ N
dosage NN N
naltrexone NN i
study NN N
in IN N
young JJ p
autistic JJ p
children NNS p
. . p

In IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ i
crossover NN N
trial NN N
23 CD p
autistic JJ p
children NNS p
were VBD N
treated VBN N
with IN N
a DT N
single JJ N
40-mg JJ N
dose NN N
of IN N
the DT N
opiate JJ N
antagonist NN N
naltrexone NN i
. . i

Drug JJ N
effects NNS o
were VBD N
monitored VBN N
by IN N
detailed JJ N
playroom NN N
observations NNS N
, , N
actometers NNS N
, , N
and CC N
parents NNS N
' POS N
checklist NN N
ratings NNS N
( ( o
Aberrant NNP o
Behavior NNP o
Checklist NNP o
, , o
social JJ o
items NNS o
and CC o
target NN o
behaviors NNS o
) ) o
. . o

Naltrexone CD i
treatment NN N
failed VBD N
to TO N
produce VB N
significant JJ o
changes NNS o
in IN N
social JJ o
behavior NN o
, , N
but CC N
it PRP N
did VBD N
reduce VB o
irritability NN o
and CC o
target NN o
scores NNS o
on IN o
behavior JJ o
checklists NNS o
. . o

The DT N
playroom NN N
data NNS N
indicated VBD N
that IN N
naltrexone NN i
significantly RB o
affected VBD o
indices NNS N
of IN N
activity NN o
and CC o
attention NN o
. . o

-DOCSTART- -2085344- O O

Acamprosate NNP i
appears VBZ N
to TO N
decrease VB o
alcohol JJ o
intake NN o
in IN N
weaned JJ p
alcoholics NNS p
. . p

Five CD p
hundred JJ p
and CC p
sixty-nine JJ p
alcoholics NNS p
were VBD N
included VBN N
in IN N
a DT N
double-blind JJ N
placebo-controlled JJ i
randomized VBN N
multicenter NN N
study NN N
of IN N
the DT N
effects NNS N
of IN N
Acamprosate NNP i
( ( i
calcium NN i
acetylhomotaurinate NN i
( ( i
CA NNP i
) ) i
, , i
1.3 CD i
g/day NN i
) ) i
on IN N
indicators NNS N
of IN N
alcoholic JJ N
relapse NN N
after IN N
withdrawal NN N
. . N

One CD p
hundred CD p
and CC p
eighty-one JJ p
patients NNS p
in IN p
the DT p
CA NNP i
group NN p
versus VBD p
175 CD p
in IN p
the DT p
placebo NN i
group NN p
completed VBD p
the DT p
three-month JJ p
study NN p
. . p

The DT N
major JJ N
efficacy NN N
criterion NN N
was VBD N
plasma JJ N
gamma-glutamyl JJ N
transpeptidase NN N
( ( N
GGT NNP N
) ) N
, , N
as IN N
an DT N
indicator NN N
of IN N
recent JJ N
alcohol NN N
ingestion NN N
. . N

This DT N
analysis NN N
was VBD N
completed VBN N
by IN N
criteria NNS N
concordance NN N
analysis NN N
on IN N
a DT N
number NN N
of IN N
indicators NNS N
of IN N
alcohol NN N
intake NN N
. . N

Patients NNS N
in IN N
both DT N
groups NNS N
were VBD N
similar JJ N
initially RB N
. . N

After IN N
3 CD N
months NNS N
of IN N
treatment NN N
, , N
the DT N
patients NNS N
in IN N
the DT N
CA NNP i
group NN N
had VBD N
significantly RB N
lower JJR o
GGT NNP o
( ( N
1.4 CD N
+/- JJ N
1.56 CD N
versus NN N
2.0 CD N
+/- JJ N
3.19 CD N
times NNS N
normal JJ N
, , N
P NNP N
= NNP N
0.016 CD N
) ) N
. . N

All DT N
significant JJ N
differences NNS N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
or CC N
trends NNS N
( ( N
0.10 CD N
greater JJR N
than IN N
P NNP N
greater JJR N
than IN N
0.05 CD N
) ) N
were VBD N
in IN N
favor NN N
of IN N
a DT N
superior JJ N
effect NN N
of IN N
CA NNP i
over IN N
placebo NN i
. . i

The DT N
major JJ N
side-effect NN N
of IN N
CA NNP i
was VBD N
diarrhea VBN o
( ( N
present JJ N
in IN N
13 CD N
% NN N
of IN N
CA NNP N
patients NNS N
versus VBP N
7 CD N
% NN N
of IN N
placebo NN i
, , N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

CA NNP i
proved VBD N
superior JJ N
to TO N
placebo VB i
on IN N
the DT N
evolution NN N
of IN N
markers NNS N
of IN N
alcohol NN N
ingestion NN N
at IN N
three CD N
months NNS N
, , N
in IN N
this DT N
large-scale JJ N
multicenter NN N
study NN N
. . N

It PRP N
could MD N
be VB N
a DT N
new JJ N
modality NN N
in IN N
the DT N
drug NN N
therapy NN N
of IN N
alcoholism NN N
, , N
not RB N
involving VBG N
an DT N
antabuse NN N
effect NN N
, , N
an DT N
antidepressant JJ N
action NN N
, , N
or CC N
conditioning NN N
. . N

-DOCSTART- -21864416- O O

Effects NNS N
of IN N
a DT N
Chinese JJ N
medical JJ N
herbs NN N
complex NN N
on IN N
cellular JJ N
immunity NN N
and CC N
toxicity-related JJ N
conditions NNS N
of IN N
breast NN p
cancer NN p
patients NNS p
. . p

Rose NNP i
geranium NN i
( ( N
Pelargonium NNP N
graveolens VBZ N
, , N
Geraniaceae NNP N
) ) N
has VBZ N
anti-cancer JJ N
and CC N
anti-inflammatory JJ N
properties NNS N
, , N
and CC N
promotes VBZ N
wound IN N
healing VBG N
. . N

Similarly RB N
, , N
Ganoderma NNP i
tsugae NN i
( ( N
Ganodermataceae NNP N
) ) N
, , N
Codonopsis NNP i
pilosula NN i
( ( N
Campanulaceae NNP N
) ) N
and CC N
Angelica NNP i
sinensis NN i
( ( N
Apiaceae NNP N
) ) N
are VBP N
traditional JJ N
Chinese JJ N
herbs NNS N
associated VBN N
with IN N
immunomodulatory JJ N
functions NNS N
. . N

In IN N
the DT N
present JJ N
study NN N
, , N
a DT N
randomised JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
was VBD N
conducted VBN N
to TO N
examine VB N
whether IN N
the DT N
Chinese NNP i
medicinal JJ i
herb NN i
complex NN i
, , i
RG-CMH NNP i
, , N
which WDT N
represents VBZ N
a DT N
mixture NN i
of IN i
rose VBD i
geranium NN i
and CC i
extracts NNS i
of IN i
G. NNP i
tsugae NN i
, , i
C. NNP i
pilosula NN i
and CC i
A. NNP i
sinensis NN i
, , N
can MD N
improve VB N
the DT N
immune NN N
cell NN N
count NN N
of IN N
cancer NN p
patients NNS p
receiving VBG p
chemotherapy NN p
and/or NN p
radiotherapy NN p
to TO N
prevent VB N
leucopenia NN N
and CC N
immune JJ N
impairment NN N
that WDT N
usually RB N
occurs VBZ N
during IN N
cancer NN N
therapy NN N
. . N

A DT N
total NN N
of IN N
fifty-eight JJ p
breast NN p
cancer NN p
patients NNS p
who WP p
received VBD p
chemotherapy NN i
or CC p
radiotherapy NN i
were VBD p
enrolled VBN p
. . p

Immune NNP o
cell NN o
levels NNS o
in IN o
patient NN o
serum NN o
were VBD N
determined VBN N
before IN N
, , N
and CC N
following VBG N
, , N
6 CD N
weeks NNS N
of IN N
cancer NN N
treatment NN N
for IN N
patients NNS N
receiving VBG N
either DT N
an DT N
RG-CMH JJ i
or CC i
a DT i
placebo NN i
. . i

Administration NN N
of IN N
RG-CMH NNP N
was VBD N
associated VBN N
with IN N
a DT N
significant JJ N
reduction NN N
in IN N
levels NNS o
of IN o
leucocytes NNS o
from IN N
31?5 CD N
% NN N
for IN N
the DT i
placebo NN i
group NN i
to TO N
13?4 CD N
% NN N
for IN N
the DT N
RG-CMH NNP N
group NN N
. . N

Similarly RB o
, , o
levels NNS o
of IN o
neutrophils NNS o
significantly RB o
decreased VBN N
from IN N
35?6 CD N
% NN N
for IN N
the DT N
placebo NN N
group NN N
to TO N
11?0 CD N
% NN N
for IN N
the DT N
RG-CMH NNP N
group NN N
. . N

RG-CMH JJ N
intervention NN N
was VBD N
also RB N
associated VBN N
with IN N
a DT N
decrease NN N
in IN o
levels NNS o
of IN o
T NNP o
cells NNS o
, , o
helper JJR o
T NNP o
cells NNS o
, , o
cytotoxic NN o
T NNP o
cells NNS o
and CC o
natural JJ o
killer NN o
cells NNS o
compared VBN o
with IN N
the DT N
placebo NN N
group NN N
. . N

However RB N
, , N
these DT N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
. . N

In IN N
conclusion NN N
, , N
administration NN N
of IN N
RG-CMH NNP N
to TO N
patients NNS N
receiving VBG N
chemotherapy/radiotherapy NN N
may MD N
have VB N
the DT N
capacity NN N
to TO N
delay VB N
, , N
or CC N
ease NN N
, , N
the DT N
reduction NN N
in IN N
levels NNS N
of IN N
leucocytes NNS N
and CC N
neutrophils NNS N
that WDT N
are VBP N
experienced VBN N
by IN N
patients NNS N
during IN N
cancer NN N
treatment NN N
. . N

-DOCSTART- -10768434- O O

Photodynamic NNP i
therapy NN i
with IN i
5-aminolaevulinic JJ i
acid NN i
or CC i
placebo NN i
for IN N
recalcitrant JJ p
foot NN o
and CC o
hand NN o
warts NNS o
: : o
randomised VBN N
double-blind JJ N
trial NN N
. . N

BACKGROUND NNP N
Photodynamic NNP i
therapy NN i
( ( i
PDT NNP i
) ) i
with IN i
topical JJ i
5-aminolaevulinic JJ i
acid NN i
( ( i
ALA NNP i
) ) i
followed VBN i
by IN i
irradiation NN i
with IN i
incoherent JJ i
light NN i
( ( i
ALA-PDT NNP i
) ) i
for IN N
recalcitrant NN N
warts NNS N
have VBP N
had VBN N
beneficial JJ N
results NNS N
. . N

Therefore RB N
, , N
we PRP N
undertook VBP N
a DT N
randomised JJ N
, , N
parallel JJ N
, , N
double-blind JJ N
clinical JJ N
trial NN N
of IN N
ALA-PDT NNP N
versus NN N
placeboPDT NN N
for IN N
recalcitrant JJ N
foot NN N
and CC N
hand NN N
warts NNS N
. . N

METHODS NNP N
Recalcitrant NNP p
foot NN p
and CC p
hand NN p
warts NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
six CD N
repetitive JJ N
ALA-PDT NNP i
or CC i
placebo-PDT JJ i
interventions NNS i
combined VBN i
with IN i
standard JJ i
treatment NN i
encompassing VBG i
paring VBG i
followed VBN i
by IN i
a DT i
keratolytic JJ i
( ( i
Verucid NNP i
) ) i
. . i

Standardised VBN N
photographs NN N
of IN N
each DT N
wart NN N
were VBD N
taken VBN N
before RB N
, , N
during IN N
( ( N
week NN N
7 CD N
) ) N
and CC N
after IN N
treatment NN N
( ( N
weeks NNS N
14 CD N
and CC N
18 CD N
) ) N
. . N

The DT N
area NN o
of IN o
each DT o
wart NN o
compared VBN o
with IN o
entry NN o
area NN o
was VBD N
the DT N
primary JJ N
outcome NN N
variable NN N
, , N
measured VBN N
from IN N
photographs NN N
by IN N
an DT N
evaluator NN N
unaware NN N
of IN N
treatment NN N
allocation NN N
for IN N
intervention NN N
. . N

Pain NNP o
intensity NN o
immediately RB N
and CC N
24 CD N
h NN N
after IN N
each DT N
intervention NN N
was VBD N
assessed VBN N
by IN N
a DT N
five-point JJ N
scale NN N
. . N

FINDINGS CC N
A NNP p
total NN p
of IN p
232 CD p
foot NN p
and CC p
hand NN p
warts NNS p
in IN p
45 CD p
patients NNS p
were VBD p
entered VBN p
into IN p
the DT p
trial NN p
: : p
117 CD N
warts NNS N
were VBD N
allocated VBN N
to TO N
ALA-PDT NNP i
and CC N
115 CD N
warts NNS N
to TO N
placebo-PDT NN i
. . i

In IN N
week NN N
14 CD N
, , N
the DT N
median JJ o
relative JJ o
reduction NN o
in IN o
wart JJ o
area NN o
was VBD N
98 CD N
% NN N
in IN N
the DT N
ALA-PDT NNP i
group NN N
( ( N
interquartile JJ N
range VBP N
100 CD N
% NN N
, , N
55 CD N
% NN N
) ) N
versus VBZ N
52 CD N
% NN N
( ( N
100 CD N
% NN N
, , N
0 CD N
) ) N
in IN N
the DT N
placebo NN N
group NN N
( ( N
p=0.0006 NN N
) ) N
. . N

In IN N
week NN N
18 CD N
, , N
the DT N
median JJ o
relative JJ o
reduction NN o
in IN o
wart JJ o
area NN o
was VBD N
100 CD N
% NN N
in IN N
the DT N
ALA-PDT NNP i
group NN N
( ( N
100 CD N
% NN N
, , N
57 CD N
% NN N
) ) N
versus VBZ N
71 CD N
% NN N
( ( N
100 CD N
% NN N
, , N
0 CD N
) ) N
in IN N
the DT N
placebo-PDT JJ i
arm NN N
( ( N
p=0.008 NN N
) ) N
. . N

Both CC N
the DT N
number NN o
of IN o
vanishing VBG o
warts NNS o
and CC o
the DT o
difference NN o
in IN o
relative JJ o
wart JJ o
area NN o
of IN o
persisting VBG o
warts NNS o
at IN N
week NN N
14 CD N
and CC N
18 CD N
were VBD N
significant JJ N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
in IN N
favour NN N
of IN N
ALA-PDT NNP N
. . N

Significantly RB N
more RBR N
ALA-PDT JJ i
warts NNS N
were VBD N
graded VBN N
at IN N
a DT N
higher JJR o
pain NN o
intensity NN o
after IN N
treatment NN N
than IN N
placebo-PDT JJ i
warts NNS N
. . N

INTERPRETATION NNP N
ALA-PDT NNP N
is VBZ N
superior JJ N
to TO N
placebo-PDT NN i
when WRB N
both DT N
wart VBP N
area NN o
and CC o
number NN o
of IN o
vanishing VBG o
warts NNS o
are VBP N
considered VBN N
. . N

-DOCSTART- -16329017- O O

Virtual JJ i
reality NN i
colonoscopy NN i
simulation NN i
: : i
a DT N
compulsory NN N
practice NN N
for IN N
the DT N
future JJ N
colonoscopist NN N
? . N
BACKGROUND NNP N
AND NNP N
STUDY NNP N
AIM NNP N
As IN N
for IN N
any DT N
manual JJ N
procedure NN N
, , N
the DT N
learning NN N
curves NNS N
for IN N
medical JJ N
interventions NNS N
can MD N
have VB N
undesirable JJ N
phases NNS N
, , N
occurring VBG N
mostly RB N
in IN N
the DT N
early JJ N
experience NN N
of IN N
applying VBG N
a DT N
technique NN N
. . N

There EX N
have VBP N
been VBN N
impressive JJ N
advances NNS N
in IN N
endoscopic JJ N
procedures NNS N
during IN N
recent JJ N
years NNS N
, , N
and CC N
there EX N
is VBZ N
an DT N
emerging VBG N
trend NN N
that IN N
the DT N
number NN N
of IN N
procedures NNS N
is VBZ N
increasing VBG N
in IN N
parallel NN N
with IN N
these DT N
. . N

In IN N
addition NN N
, , N
the DT N
introduction NN N
of IN N
screening VBG N
programs NNS N
for IN N
colorectal JJ N
cancer NN N
will MD N
also RB N
increase VB N
the DT N
numbers NNS N
of IN N
procedures NNS N
needed VBN N
. . N

Recent JJ N
developments NNS N
in IN N
medical JJ N
simulation NN N
seem VBP N
promising VBG N
with IN N
regard NN N
to TO N
the DT N
possibility NN N
of IN N
training VBG N
out RP N
undesirable JJ N
parts NNS N
of IN N
the DT N
learning VBG N
curve NN N
outside IN N
the DT N
operating NN N
room NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
whether IN N
the DT N
use NN N
of IN N
the DT N
AccuTouch NNP i
flexible JJ i
endoscopy NN i
simulator NN i
improves VBZ N
the DT N
early JJ o
part NN o
of IN o
the DT o
learning VBG o
curve NN o
in IN N
colonoscopy NN N
training NN N
. . N

METHOD NNP N
12 CD p
endoscopy NN p
trainees NNS p
, , p
10 CD p
surgeons NNS p
and CC p
two CD p
medical JJ p
gastroenterologists NNS p
, , p
all DT p
with IN p
experience NN p
in IN p
gastroscopy NN p
but CC p
with IN p
no DT p
specific JJ p
colonoscopy NN p
experience NN p
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
simulator NN i
training NN i
or CC i
to TO i
a DT i
control NN i
group NN i
. . i

They PRP N
all DT N
received VBD N
the DT N
same JJ N
theoretical JJ N
study NN N
package NN N
and CC N
the DT N
training NN N
group NN N
practiced VBD N
with IN N
the DT N
AccuTouch NNP i
colonoscopy NN i
simulator NN i
until IN N
a DT N
predefined JJ N
expert JJ N
level NN N
of IN N
performance NN N
was VBD N
reached VBN N
. . N

All DT N
trainees NNS N
performed VBD N
their PRP$ N
first JJ N
ten VBN N
individual JJ N
colonoscopies NNS N
described VBN N
in IN N
detail NN N
in IN N
a DT N
separate JJ N
protocol NN N
. . N

RESULTS NNP N
Trainees NNP N
in IN N
the DT N
simulator-trained JJ N
group NN N
performed VBD o
significantly RB o
better RBR o
( ( N
P=0.0011 NNP N
) ) N
and CC N
managed VBN o
to TO o
reach VB o
the DT o
cecum NN o
in IN N
52 CD N
% NN N
of IN N
their PRP$ N
cases NNS N
( ( N
vs. FW N
19 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
) ) N
, , N
and CC N
were VBD N
4.53 CD N
times NNS N
more RBR N
likely JJ N
to TO N
succeed VB N
compared VBN N
with IN N
the DT N
controls NNS N
. . N

Additionally RB N
, , N
there EX N
was VBD N
a DT N
significantly RB N
shorter JJR o
procedure NN o
time NN o
and CC o
less RBR o
patient JJ o
discomfort NN o
in IN N
the DT N
hands NNS N
of IN N
the DT N
simulator-trained JJ N
group NN N
. . N

CONCLUSION NNP N
Skills NNP N
acquired VBD N
using VBG N
the DT N
AccuTouch NNP N
simulator NN N
transfer NN N
well RB N
into IN N
the DT N
clinical JJ N
colonoscopy NN N
environment NN N
. . N

The DT N
results NNS N
of IN N
this DT N
trial NN N
clearly RB N
support VB N
the DT N
plan NN N
to TO N
integrate VB N
simulator NN i
training NN i
into IN N
endoscopic JJ N
education NN N
curricula NN N
. . N

-DOCSTART- -19682100- O O

Long-term JJ N
( ( N
96-week JJ N
) ) N
follow-up NN N
of IN N
antiretroviral-na?ve JJ p
HIV-infected JJ p
patients NNS p
treated VBN p
with IN p
first-line JJ i
lopinavir/ritonavir NN i
monotherapy NN i
in IN p
the DT p
MONARK NNP p
trial NN p
. . p

BACKGROUND VB N
The DT N
toxicities NNS N
, , N
cost NN N
and CC N
complexity NN N
of IN N
triple JJ N
combinations NNS N
warrant VBP N
the DT N
search NN N
for IN N
other JJ N
treatment NN N
options NNS N
, , N
such JJ N
as IN N
boosted JJ N
protease NN N
inhibitor NN N
( ( N
PI NNP N
) ) N
monotherapy NN N
. . N

MONotherapy NNP p
AntiRetroviral NNP p
Kaletra NNP p
( ( p
MONARK NNP p
) ) p
is VBZ p
the DT p
first JJ p
randomized JJ p
trial NN p
comparing VBG i
lopinavir/ritonavir JJ i
monotherapy NN i
to TO i
triple VB i
combination NN i
therapy NN i
with IN i
zidovudine/lamivudine NN i
and CC i
lopinavir/ritonavir NN i
in IN p
antiretroviral-na?ve JJ p
patients NNS p
. . p

METHODS NNP N
A NNP N
total NN N
of IN N
136 CD p
antiretroviral-na?ve JJ p
patients NNS p
, , p
with IN p
a DT p
CD4 NNP p
cell NN p
count NN p
above IN p
100 CD p
cells/microL NN p
and CC p
a DT p
plasma NN p
HIV NNP p
RNA NNP p
below IN p
100,000 CD p
HIV-1 JJ p
RNA NNP p
copies/mL NN p
, , p
were VBD i
randomized VBN i
and CC i
dosed VBN i
with IN i
either DT i
lopinavir/ritonavir JJ i
monotherapy NN i
( ( i
n JJ i
= NNP i
83 CD i
) ) i
or CC i
lopinavir/ritonavir JJ i
+ JJ i
zidovudine/lamivudine NN i
( ( i
n JJ i
= NNP i
53 CD i
) ) i
. . i

We PRP i
focus VBP p
here RB p
on IN p
patients NNS p
in IN p
the DT p
lopinavir/ritonavir NN i
monotherapy NN i
arm NN i
followed VBD p
to TO p
week NN p
96 CD p
. . p

The DT p
intent-to-treat NN N
( ( N
ITT NNP N
) ) N
analysis NN N
initially RB N
involved VBD N
all DT N
patients NNS N
randomized VBN N
to TO N
lopinavir/ritonavir VB i
monotherapy NN i
( ( i
n JJ i
= NNP N
83 CD N
) ) N
, , N
and CC N
then RB N
focused VBD N
on IN N
patients NNS N
who WP N
had VBD N
an DT N
HIV NNP N
RNA NNP N
< VBD N
50 CD N
copies/mL NN N
at IN N
week NN N
48 CD N
( ( N
n JJ N
= NNP N
56 CD N
) ) N
. . N

RESULTS VBN N
At IN N
week NN N
96 CD N
, , N
39 CD N
of IN N
83 CD N
patients NNS N
( ( N
47 CD N
% NN N
) ) N
had VBD N
HIV NNP o
RNA NNP o
< VBD o
50 CD N
copies/mL NN N
, , N
five CD N
of IN N
83 CD N
had VBD N
HIV NNP o
RNA NNP o
between IN o
50 CD N
and CC N
400 CD N
copies/mL NN N
, , N
and CC N
three CD N
of IN N
83 CD N
had VBD N
HIV NNP N
RNA NNP N
> VBD N
400 CD N
copies/mL NN N
. . N

Focusing VBG N
on IN N
the DT N
56 CD N
patients NNS N
with IN N
an DT N
HIV NNP N
RNA NNP N
< VBD N
50 CD N
copies/mL NN N
at IN N
week NN N
48 CD N
, , N
38 CD N
of IN N
56 CD N
patients NNS N
( ( N
68 CD N
% NN N
) ) N
had VBD N
a DT N
sustained VBN N
HIV NNP N
RNA NNP N
< VBD N
50 CD N
copies/mL NN N
to TO N
week NN N
96 CD N
. . N

To TO N
week NN N
96 CD N
, , N
a DT N
total NN N
of IN N
28 CD N
patients NNS N
( ( N
34 CD N
% NN N
) ) N
had VBD N
discontinued VBN N
the DT N
study NN N
treatment NN N
. . N

In IN N
addition NN N
, , N
the DT N
allocated JJ N
treatment NN N
was VBD N
changed VBN N
for IN N
seven CD N
patients NNS o
. . o

PI-associated JJ o
resistance NN o
mutations NNS o
were VBD o
evident JJ N
in IN N
five CD N
of IN N
83 CD N
patients NNS N
in IN N
the DT N
monotherapy NN N
arm NN N
from IN N
baseline NN N
to TO N
week NN N
96 CD N
. . N

CONCLUSION NN N
By IN N
ITT NNP N
analysis NN N
, , N
39 CD N
of IN N
the DT N
83 CD N
patients NNS N
initially RB N
randomized VBN N
to TO N
lopinavir/ritonavir VB N
monotherapy NN N
had VBD N
HIV NNP N
RNA NNP N
< VBD N
50 CD N
copies/mL NN N
at IN N
week NN N
96 CD N
. . N

The DT N
occurrence NN N
in IN N
some DT N
patients NNS N
of IN N
low-level JJ N
viraemia NN N
( ( N
50-500 JJ N
copies/mL NN N
) ) N
may MD N
increase VB N
the DT N
risk NN N
of IN N
drug NN N
resistance NN N
. . N

First-line JJ i
lopinavir/ritonavir JJ i
monotherapy NN i
can MD i
not RB N
be VB N
systematically RB N
recommended VBN N
. . N

-DOCSTART- -396086- O O

Effect NN N
of IN N
increasing VBG N
doses NNS N
of IN N
labetalol NN i
on IN N
blood NN o
pressure NN o
, , o
plasma JJ o
renin NN o
activity NN o
and CC o
aldosterone NN o
in IN N
hypertensive JJ p
patients NNS p
. . p

1 CD N
. . N

Four CD N
different JJ N
doses NNS N
of IN N
labetalol NN i
( ( N
150 CD N
, , N
300 CD N
, , N
600 CD N
and CC N
900 CD N
mg/day NN N
) ) N
were VBD N
given VBN N
for IN N
1 CD N
week NN N
to TO N
each DT N
of IN N
four CD p
groups NNS p
of IN p
patients NNS p
with IN p
essential JJ p
hypertension NN p
( ( p
six CD p
patients NNS p
for IN p
each DT p
group NN p
) ) p
. . p

2 CD N
. . N

Labetalol NNP i
decreased VBD N
mean JJ N
blood NN o
pressure NN o
and CC o
heart NN o
rate NN o
to TO N
the DT N
same JJ N
extent NN N
on IN N
the DT N
first JJ N
and CC N
the DT N
seventh JJ N
days NNS N
of IN N
treatment NN N
. . N

Only RB N
standing VBG N
blood NN o
pressure NN o
showed VBD N
a DT N
dose-dependent JJ N
inhibition NN N
both DT N
in IN N
the DT N
supine NN N
and CC N
upright JJ N
position NN N
. . N

3 CD N
. . N

Labetalol NNP i
exerted VBD N
a DT N
net JJ N
inhibitory NN N
effect NN N
on IN N
plasma NN o
renin NN o
activity NN o
, , N
which WDT N
was VBD N
related VBN N
to TO N
basal VB N
renin NN N
values NNS N
and CC N
was VBD N
already RB N
maximal JJ N
at IN N
the DT N
lowest JJS N
doses NNS N
. . N

This DT N
effect NN N
was VBD N
well RB N
maintained VBN N
in IN N
the DT N
supine JJ N
position NN N
. . N

This DT N
effect NN N
was VBD N
well RB N
maintained VBN N
in IN N
the DT N
supine JJ N
position NN N
, , N
although IN N
during IN N
standing VBG N
it PRP N
tended VBD N
to TO N
be VB N
less RBR N
evident JJ N
with IN N
increasing VBG N
doses NNS N
. . N

4 CD N
. . N

Urinary JJ o
aldosterone NN o
was VBD N
decreased VBN N
in IN N
a DT N
dose-dependent JJ N
fashion NN N
and CC N
its PRP$ N
changes NNS N
were VBD N
largely RB N
independent JJ N
fashion NN N
and CC N
its PRP$ N
changes NNS N
were VBD N
largely RB N
independent JJ N
of IN N
plasma JJ N
renin NN N
activity NN N
. . N

5 CD N
. . N

Neither CC N
basal NN o
values NNS o
nor CC o
changes NNS o
of IN o
renin NN o
and CC o
aldosterone NN o
were VBD N
related VBN N
to TO N
the DT N
hypotensive JJ N
effect NN N
of IN N
labetalol NN i
. . i

6 CD N
. . N

During IN N
labetalol JJ i
treatment NN N
urinary JJ o
sodium NN o
excretion NN o
fell VBD o
for IN N
2-3 JJ N
days NNS N
and CC N
then RB N
returned VBD N
to TO N
basal VB N
values NNS N
. . N

The DT N
retentive JJ N
effect NN N
of IN N
labetalol NN N
on IN N
sodium NN o
was VBD N
directly RB N
related VBN N
to TO N
the DT N
decrease NN N
of IN N
blood NN o
pressure NN o
, , N
and CC N
the DT N
successive JJ o
sodium NN o
escape NN o
might MD N
be VB N
explained VBN N
either RB N
by IN N
the DT N
observed JJ N
increase NN N
of IN N
plasma JJ N
volume NN N
( ( N
indirectly RB N
measured VBN N
by IN N
packed JJ N
cell NN N
volume NN N
) ) N
or CC N
by IN N
aldosterone JJ N
inhibition NN N
. . N

-DOCSTART- -3139179- O O

Comparison NNP N
of IN N
mastectomy NN i
with IN i
tamoxifen NN i
for IN N
treating VBG N
elderly JJ p
patients NNS p
with IN p
operable JJ p
breast NN p
cancer NN p
. . p

STUDY NNP N
OBJECTIVE NNP N
Comparison NNP N
of IN N
tamoxifen NN i
and CC i
mastectomy NN i
in IN N
treatment NN N
of IN N
breast NN p
cancer NN p
in IN p
elderly JJ p
patients NNS p
. . p

DESIGN NNP N
Randomised VBD N
trial NN N
of IN N
treatment NN N
of IN N
operable JJ N
breast NN N
cancer NN N
by IN N
wedge NN i
mastectomy NN i
or CC i
tamoxifen NN i
, , N
with IN N
median JJ N
follow VBP N
up RP N
24 CD N
and CC N
25 CD N
months NNS N
respectively RB N
( ( N
range VB N
1-63 CD N
) ) N
. . N

SETTING NN N
University NNP p
hospital NN p
; : p
most JJS p
patients NNS p
from IN p
primary JJ p
catchment JJ p
area NN p
. . p

PATIENTS CC N
135 CD p
consecutive JJ p
patients NNS p
with IN p
breast JJ p
cancer NN p
aged VBD p
over IN p
70 CD p
with IN p
operable JJ p
tumours NNS p
( ( p
less JJR p
than IN p
5 CD p
cm JJ p
maximum JJ p
diameter NN p
) ) p
; : p
68 CD N
were VBD N
allocated VBN N
to TO N
tamoxifen VB i
group NN i
and CC N
67 CD N
to TO N
mastectomy VB i
group NN i
. . i

Histological JJ N
diagnosis NN N
by IN N
biopsy NN N
. . N

Two CD N
incorrect JJ N
randomisations NNS N
in IN N
each DT N
group NN N
. . N

Patient NNP p
characteristics NNS p
similar JJ p
in IN p
the DT p
two CD p
groups NNS p
and CC p
all DT p
under IN p
care NN p
of IN p
one CD p
surgical JJ p
team NN p
. . p

INTERVENTIONS NNP N
Mastectomy NNP N
group NN N
received VBD N
wedge JJ i
mastectomy NN i
plus CC i
excision NN i
of IN i
symptomatic JJ i
axillary JJ i
lymph NN i
nodes NNS i
. . i

Tamoxifen NNP i
group NN N
received VBD N
continuous JJ N
treatment NN N
with IN N
tamoxifen JJ i
20 CD i
mg JJ i
twice RB N
daily RB N
. . N

Patients NNS N
in IN N
tamoxifen JJ N
group NN N
received VBD N
wedge WP i
mastectomy NN i
if IN i
there EX i
was VBD i
sign NN i
of IN i
local JJ i
progression NN i
. . i

Those DT N
in IN N
mastectomy JJ N
group NN N
received VBD N
further JJ N
excision NN N
or CC N
radiotherapy NN i
for IN N
locoregional JJ N
recurrence NN N
and CC N
when WRB N
local JJ N
treatments NNS N
had VBD N
been VBN N
exhausted VBN N
or CC N
metastatic JJ N
disease NN N
diagnosed VBD N
they PRP N
received VBD N
tamoxifen NN i
. . i

END JJ N
POINT NNP N
Treatment NNP o
efficacy NN o
was VBD N
assessed VBN N
by IN N
local JJ o
control NN o
of IN o
disease NN o
and CC o
by IN o
survival NN o
. . N

MAIN NNP N
RESULTS NNP N
Mortality NNP o
from IN N
metastatic JJ N
cancer NN N
in IN N
tamoxifen NN i
group NN N
was VBD N
7 CD N
( ( N
10.6 CD N
% NN N
) ) N
and CC N
in IN N
mastectomy JJ i
group NN N
10 CD N
( ( N
15.3 CD N
% NN N
) ) N
( ( N
NS NNP N
) ) N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
survival NN o
between IN N
the DT N
two CD N
groups NNS N
. . N

In IN N
mastectomy JJ N
group NN N
70 CD N
% NN N
remained VBD N
alive JJ N
and CC N
free JJ o
of IN o
local JJ o
recurrence NN o
at IN N
24 CD N
months NNS N
; : N
in IN N
tamoxifen NN N
group NN N
only RB N
47 CD N
% NN N
remained VBD N
alive JJ N
and CC N
free JJ N
of IN N
local JJ N
progression NN N
. . N

In IN N
mastectomy JJ N
group NN N
locoregional JJ o
recurrence NN o
occurred VBD N
in IN N
16 CD N
patients NNS N
and CC N
metastatic JJ N
disease NN N
in IN N
13 CD N
; : N
in IN N
tamoxifen NN N
group NN N
locoregional JJ o
progression NN o
occurred VBD N
in IN N
29 CD N
patients NNS N
and CC N
metastatic JJ N
disease NN N
in IN N
seven CD N
. . N

CONCLUSIONS NNP N
As IN N
a DT N
high JJ N
proportion NN N
of IN N
patients NNS N
treated VBN N
with IN N
tamoxifen NNS N
eventually RB N
required VBN N
surgery NN N
treatment NN N
of IN N
elderly JJ p
patients NNS p
with IN p
breast JJ p
cancer NN p
should MD N
include VB N
mastectomy NN N
. . N

Optimum NNP N
treatment NN N
may MD N
include VB N
both DT N
mastectomy NNS N
and CC N
tamoxifen NN N
. . N

-DOCSTART- -1378689- O O

Iloprost NN i
in IN N
cardiopulmonary JJ N
bypass NN N
procedures NNS N
. . N

The DT N
inhibition NN N
of IN N
platelet NN N
aggregation NN N
during IN N
cardiopulmonary JJ p
bypass NN p
and CC N
effects NNS N
on IN N
post-operative JJ p
placebo-controlled JJ i
study NN p
of IN p
145 CD p
patients NNS p
. . p

Significant JJ N
preservation NN N
of IN N
platelet NN N
numbers NNS N
and CC N
function NN N
were VBD N
shown VBN N
without IN N
significant JJ N
haemodynamic JJ N
problems NNS N
, , N
but CC N
no DT N
effect NN N
on IN N
cerebral JJ N
deficits NNS N
could MD N
be VB N
found VBN N
. . N

The DT N
use NN N
of IN N
iloprost NN i
in IN N
patients NNS p
with IN p
severe JJ p
thrombocytopenia NN p
seems VBZ N
justified JJ N
, , N
but CC N
the DT N
clinical JJ N
benefits NNS N
from IN N
its PRP$ N
use NN N
in IN N
routine JJ N
cardiopulmonary JJ N
bypass NN N
remain NN N
to TO N
be VB N
shown VBN N
. . N

-DOCSTART- -24713222- O O

Hemodialysis NNP p
catheter NN p
design NN p
and CC p
catheter NN p
performance NN p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

BACKGROUND VB N
A DT N
complication NN N
of IN N
long-term JJ N
use NN N
of IN N
tunneled JJ i
cuffed NN i
catheters NNS i
for IN N
hemodialysis NN N
is VBZ N
the DT N
high JJ N
rate NN N
of IN N
infection NN o
and CC N
thrombus-related JJ o
dysfunction NN o
. . o

Specific JJ N
mechanical JJ N
features NNS N
of IN N
tunneled JJ i
cuffed NN i
catheters NNS i
may MD N
improve VB N
hemodynamic JJ N
performance NN N
and CC N
decrease NN N
thrombosis NN N
and CC N
infection NN N
rates NNS N
. . N

However RB N
, , N
there EX N
currently RB N
is VBZ N
no DT N
proven JJ N
advantage NN N
of IN N
one CD N
design NN N
over IN N
another DT N
. . N

STUDY NNP N
DESIGN NNP N
Single-center NNP N
randomized VBD N
clinical JJ N
trial NN N
. . N

SETTING NNP N
& CC N
PARTICIPANTS NNP N
302 CD p
hemodialysis NN p
patients NNS p
who WP p
required VBD p
a DT p
tunneled JJ i
cuffed NN i
catheter NN i
as IN p
temporary JJ p
or CC p
definite JJ p
vascular JJ p
access NN p
. . p

INTERVENTION NNP N
Palindrome NNP i
Symmetric NNP i
Tip NNP i
Dialysis NNP i
Catheter NNP i
or CC i
HemoStar NNP i
Long-Term NNP i
Hemodialysis NNP i
Catheter NNP i
. . i

OUTCOMES NNP N
& CC N
MEASUREMENTS NNP N
The DT N
primary JJ N
end NN N
point NN N
was VBD N
primary JJ o
assisted JJ o
patency NN o
. . o

Secondary JJ N
end NN N
points NNS N
were VBD N
incidence NN o
of IN o
catheter-related JJ o
bloodstream NN o
infections NNS o
( ( o
CRBSIs NNP o
) ) o
, , o
thrombosis NN o
, , o
and CC o
2 CD o
indicators NNS o
of IN o
rheologic JJ o
function NN o
: : o
mean JJ o
effective JJ o
blood NN o
flow NN o
rate NN o
and CC o
urokinase NN o
use NN o
. . o

RESULTS JJ N
Mean NNP o
primary NN o
assisted VBD o
patency NN o
was VBD N
135.9 CD N
days NNS N
for IN N
Palindrome NNP N
and CC N
136.5 CD N
days NNS N
for IN N
HemoStar NNP N
( ( N
P=0.8 NNP N
) ) N
. . N

Definite NNP N
CRBSI NNP o
occurred VBD N
in IN N
0.24 CD N
and CC N
0.10/1,000 CD N
catheter-days NNS N
for IN N
Palindrome NNP N
and CC N
HemoStar NNP N
, , N
respectively RB N
( ( N
P=0.3 NNP N
) ) N
. . N

Removal JJ o
rates NNS o
for IN o
thrombosis NN o
that WDT N
could MD N
not RB N
be VB N
resolved VBN N
with IN N
thrombolysis NN N
were VBD N
0.53 CD N
and CC N
0.43/1,000 CD N
catheter-days NNS N
for IN N
Palindrome NNP N
and CC N
HemoStar NNP N
, , N
respectively RB N
( ( N
P=0.7 NNP N
) ) N
. . N

Urokinase NNP o
use NN o
was VBD N
lower JJR N
for IN N
Palindrome NNP N
than IN N
for IN N
HemoStar NNP N
, , N
as IN N
evidenced VBN N
by IN N
a DT N
lower JJR N
number NN N
of IN N
urokinase JJ o
infusions/1,000 NN o
catheter-days NNS N
( ( N
17 CD N
and CC N
35 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
higher JJR N
number NN N
of IN N
catheters NNS o
that WDT o
never RB o
required VBN o
thrombolysis NN o
( ( N
58 CD N
% NN N
and CC N
45 CD N
% NN N
; : N
P=0.03 NNP N
) ) N
. . N

Mean JJ o
effective JJ o
blood NN o
flow NN o
rate NN o
was VBD N
higher JJR N
for IN N
Palindrome NNP N
than IN N
for IN N
HemoStar NNP N
( ( N
333 CD N
and CC N
304mL/min CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

LIMITATIONS JJ N
Single-center NNP N
nonblinded VBD N
trial NN N
. . N

CONCLUSIONS NNP N
Primary NNP o
assisted VBD o
patency NN o
and CC o
incidence NN o
of IN o
infection NN o
and CC o
thrombosis NN o
were VBD N
similar JJ N
for IN N
both DT N
catheter NN N
types NNS N
. . N

The DT N
Palindrome NNP i
catheter NN N
required VBD N
less JJR N
thrombolysis NN o
and CC N
achieved VBD N
higher JJR N
blood NN o
flow NN o
rates NNS o
than IN N
the DT N
HemoStar NNP i
catheter NN N
. . N

These DT N
findings NNS N
suggest VBP N
that IN N
mechanical JJ N
catheter NN N
design NN N
may MD N
improve VB N
catheter NN N
rheology NN N
, , N
but CC N
does VBZ N
not RB N
affect VB N
risks NNS N
for IN N
thrombosis NN o
and CC o
infection NN o
and CC N
hence NN N
catheter NN N
survival NN N
. . N

-DOCSTART- -9170524- O O

[ VB N
A DT N
randomized JJ N
comparative NN N
study NN N
of IN N
surgical JJ i
adjuvant NN i
chemotherapy NN i
using VBG i
5-fluorouracil JJ i
and CC i
dl-leucovorin JJ i
with IN i
CDDP NNP i
5-FU JJ i
and CC i
dl-leucovorin JJ i
for IN N
colorectal JJ p
cancer NN p
] NNP p
. . N

A NNP N
randomized JJ N
comparative NN N
study NN N
of IN N
surgical JJ i
adjuvant NN i
chemotherapy NN i
using VBG N
dl-leucovorin JJ i
( ( i
dl-LV JJ i
) ) i
and CC i
5-fluorouracil JJ i
( ( i
5-FU JJ i
) ) i
( ( i
FL-therapy NNP i
) ) i
with IN i
CDDP NNP i
, , i
5-FU JJ i
, , i
and CC i
dl-LV JJ i
( ( i
PFL-therapy NNP i
) ) i
was VBD N
conducted VBN N
. . N

The DT N
following VBG N
were VBD N
the DT N
administration NN N
schedules NNS N
: : N
Arm VB N
A DT N
was VBD N
13 CD N
mg/m2 NN N
of IN N
CDDP NNP i
, , N
300 CD N
mg/m2 NN N
of IN N
5-FU JJ i
, , N
and CC N
30 CD N
mg/body NN N
of IN N
dl-LV NN i
for IN N
5 CD N
consecutive JJ N
days NNS N
and CC N
arm NN N
B NNP N
was VBD N
300 CD N
mg/m2 NN N
of IN N
5-FU JJ i
and CC N
30 CD N
mg/body NN N
of IN N
dl-LV NN i
for IN N
5 CD N
consecutive JJ N
days NNS N
. . N

Both DT N
regimens NNS N
were VBD N
followed VBN N
by IN N
biweekly JJ N
administration NN N
of IN N
the DT N
same JJ N
dose NN N
of IN N
dl-LV JJ i
and CC N
5-FU JJ i
in IN N
outpatients NNS N
. . N

Arm VB N
A DT N
was VBD N
started VBN N
at IN N
the DT N
26th CD N
postoperative JJ N
day NN N
and CC N
arm NN N
B NNP N
at IN N
the DT N
21st CD N
day NN N
on IN N
average NN N
. . N

Some DT N
26 CD p
cases NNS p
composed VBN p
of IN p
11 CD p
cases NNS p
of IN p
arm NN p
A NNP p
and CC p
15 CD p
cases NNS p
of IN p
arm NN p
B NNP p
completed VBD N
the DT N
administration NN N
schedules NNS N
. . N

Only RB N
one CD N
case NN N
in IN N
arm NN N
A NN N
was VBD N
complicated VBN N
by IN N
local JJ o
recurrence NN o
around IN N
35 CD N
months NNS N
after IN N
operation NN N
. . N

Major JJ N
toxicities NNS o
were VBD N
anorexia JJ o
and CC o
neutropenia NN o
. . o

Both CC N
toxicities NNS o
were VBD N
seen VBN N
more RBR N
in IN N
arm NN N
A NN N
than IN N
in IN N
arm NN N
B NNP N
, , N
showing VBG N
complete JJ N
recovery NN o
in IN N
all DT N
cases NNS N
. . N

These DT N
data NNS N
suggest VBP N
that IN N
PFL-therapy NNP i
and CC N
FL-therapy NNP i
seem VBP N
to TO N
be VB N
possible JJ N
and CC N
promising JJ N
surgical JJ i
adjuvant NN i
therapies NNS i
for IN N
advanced JJ o
colorectal JJ o
carcinoma NN o
. . o

-DOCSTART- -8708224- O O

The DT N
effect NN N
of IN N
body NN N
positioning VBG N
upon IN N
maximal JJ i
oxygenation NN i
of IN N
patients NNS p
with IN p
unilateral JJ p
lung NN p
pathology NN p
. . p

A DT N
quasi-experimental JJ N
, , N
repeated-measures JJ N
cross-over NN N
design NN N
study NN N
on IN N
the DT N
effect NN N
of IN N
body NN N
position NN N
on IN N
oxygenation NN i
( ( i
SaO2 NNP i
) ) i
blood NN N
pressure NN N
, , N
respiration NN N
and CC N
pulse NN N
in IN N
patients NNS p
with IN p
unilateral JJ p
lung NN p
pathology NN p
was VBD N
conducted VBN N
. . N

Previous JJ N
research NN N
strongly RB N
suggests VBZ N
that IN N
positioning VBG N
with IN N
the DT N
healthy JJ N
( ( N
unaffected JJ N
) ) N
lung NN N
in IN N
the DT N
dependent JJ N
lateral NN N
( ( N
down RP N
) ) N
position NN N
is VBZ N
related VBN N
to TO N
improved VBN N
oxygenation NN N
, , N
but CC N
knowledge VBP N
about IN N
whether IN N
this DT N
effect NN N
is VBZ N
maintained VBN N
over IN N
time NN N
is VBZ N
lacking VBG N
. . N

The DT N
purpose NN N
of IN N
this DT N
investigation NN N
was VBD N
to TO N
determine VB N
: : N
( ( N
1 CD N
) ) N
Is VBZ N
positioning VBG N
with IN N
the DT N
unaffected JJ N
lung NN N
in IN N
the DT N
dependent JJ N
lateral JJ N
position NN N
related VBN N
to TO N
increased VBN N
arterial JJ N
blood NN N
saturation NN N
levels NNS N
and CC N
decreased VBD N
blood NN N
pressure NN N
, , N
pulse NN N
and CC N
respiration NN N
? . N
( ( N
2 CD N
) ) N
What WP N
is VBZ N
the DT N
relationship NN N
between IN N
the DT N
dependent JJ N
variables NNS N
-- : N
oxygenation NN N
saturation NN N
levels NNS N
, , N
blood NN N
pressure NN N
, , N
pulse NN N
and CC N
respiration NN N
-- : N
and CC N
the DT N
independent JJ N
variables NNS N
-- : N
body NN N
position NN N
and CC N
time NN N
in IN N
the DT N
position NN N
? . N
Thirty-nine JJ p
patients NNS p
with IN p
unilateral JJ p
lung NN p
pathology NN p
were VBD N
positioned VBN i
on IN i
their PRP$ i
sides NNS i
with IN i
the DT i
unaffected JJ i
lung NN i
down RP i
, , i
on IN i
their PRP$ i
sides NNS i
with IN i
the DT i
affected JJ i
lung NN i
down RB i
, , i
and CC i
also RB i
in IN i
semi-Fowler NN i
's POS i
position NN i
. . i

Arterial NNP o
( ( o
SaO2 NNP o
) ) o
blood NN o
saturation NN o
and CC o
vital JJ o
signs NNS o
were VBD N
measured VBN N
at IN N
baseline NN N
0 CD N
, , N
15 CD N
and CC N
30 CD N
minutes NNS N
. . N

There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
relationship NN N
between IN N
oxygenation NN o
level NN o
or CC o
systolic JJ o
blood NN o
pressure NN o
. . o

Diastolic NNP o
blood NN o
pressure NN o
, , o
respiration NN o
and CC o
pulse NN o
did VBD N
vary JJ N
significantly RB N
with IN N
position NN N
. . N

-DOCSTART- -8323420- O O

A DT N
program NN N
of IN N
screening VBG N
and CC N
prompting VBG N
improves NNS N
short-term JJ N
physician JJ N
counseling NN N
of IN N
dependent NN p
and CC p
nondependent JJ p
harmful JJ p
drinkers NNS p
. . p

BACKGROUND NNP N
Physicians NNPS N
in IN N
the DT N
general JJ N
medical JJ N
setting VBG N
commonly RB N
encounter RB N
but CC N
rarely RB N
counsel NN N
patients NNS p
with IN p
dependent JJ p
or CC p
harmful JJ p
drinking NN p
behaviors NNS p
. . p

We PRP N
tested VBD N
whether IN N
providing VBG N
physicians NNS N
with IN N
their PRP$ N
patients NNS N
' POS N
results NNS N
on IN N
the DT N
alcohol NN N
module NN N
of IN N
the DT N
Diagnostic NNP N
Interview NNP N
Schedule NNP N
and CC N
counseling VBG N
directives NNS N
would MD N
prompt VB N
them PRP N
to TO N
counsel NN N
these DT N
patients NNS N
. . N

METHODS NNP N
We PRP N
randomly VBP N
assigned VBN N
83 CD p
first- JJ p
, , p
second- JJ p
, , p
and CC p
third-year JJ p
medical JJ p
residents NNS p
to TO p
receive VB i
or CC i
not RB i
to TO i
receive VB i
diagnostic JJ i
information NN i
and CC i
counseling VBG i
directives NNS i
on IN i
214 CD p
patients NNS p
who WP p
reported VBD p
at IN p
least JJS p
one CD p
symptom NN p
of IN p
alcohol NN p
impairment NN p
as IN p
defined VBN p
in IN p
the DT p
Diagnostic NNP p
and CC p
Statistical NNP p
Manual NNP p
of IN p
Mental NNP p
Disorders NNP p
, , p
Third NNP p
Edition NNP p
. . p

Using VBG N
binary JJ i
logistic JJ i
regression NN i
, , N
we PRP N
examined VBD N
the DT N
effect NN N
of IN N
specific JJ N
covariables NNS N
on IN N
rates NNS N
of IN N
physician JJ N
counseling NN N
. . N

These DT N
variables NNS N
included VBD N
physician JJ N
information NN N
status NN N
, , N
patient JJ N
gender NN N
, , N
and CC N
drinking VBG N
disorder NN N
severity NN N
and CC N
recency NN N
. . N

We PRP N
also RB N
examined VBD N
the DT N
effect NN N
of IN N
physician JJ N
prompting VBG N
on IN N
counseling NN N
of IN N
female JJ p
patients NNS p
, , p
patients NNS p
with IN p
inactive JJ p
disorders NNS p
, , p
and CC p
nondependent NN p
but CC p
harmful JJ p
drinkers NNS p
. . p

We PRP N
determined VBD N
counseling VBG N
by IN N
post-visit JJ N
patient JJ N
interviews NNS N
. . N

RESULTS NNP N
Physician JJ o
prompting NN o
, , o
dependent JJ o
drinking NN o
, , o
and CC o
recent JJ o
disorder NN o
activity NN o
were VBD N
significant JJ N
correlates NNS N
of IN N
physician JJ N
counseling NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
, , N
while IN N
male JJ N
gender NN N
was VBD N
a DT N
marginally RB N
significant JJ N
correlate NN N
( ( N
P NNP N
= NNP N
.08 NNP N
) ) N
. . N

Informed VBN N
physicians NNS N
counseled VBD N
female JJ N
patients NNS N
, , N
harmful JJ N
but CC N
nondependent JJ N
drinkers NNS N
, , N
and CC N
patients NNS N
with IN N
inactive JJ N
disorders NNS N
more RBR N
often RB N
than IN N
their PRP$ N
uninformed JJ N
colleagues NNS N
, , N
although IN N
only RB N
the DT N
last JJ N
variable JJ N
achieved VBD N
statistical JJ N
significance NN N
. . N

CONCLUSIONS NNP N
Providing VBG N
physicians NNS N
with IN N
the DT N
results NNS N
of IN N
the DT N
Diagnostic NNP N
Interview NNP N
Schedule NNP N
and CC N
counseling VBG N
directives NNS N
resulted VBD N
in IN N
short-term JJ N
improvement NN N
in IN N
their PRP$ N
rates NNS N
of IN N
counseling VBG N
patients NNS N
with IN N
a DT N
history NN N
of IN N
dependent NN N
or CC N
nondependent NN N
but CC N
harmful JJ N
drinking NN N
. . N

Further NNP N
research NN N
is VBZ N
necessary JJ N
to TO N
determine VB N
long-term JJ N
gains NNS N
in IN N
rates NNS N
of IN N
physician JJ i
counseling NN i
and CC i
improvements NNS i
in IN N
the DT N
course NN N
of IN N
these DT N
patients NNS N
. . N

-DOCSTART- -23782128- O O

Effects NNS N
of IN N
extended JJ N
release NN N
methylphenidate NN i
treatment NN i
on IN N
ratings NNS o
of IN o
attention-deficit/hyperactivity NN o
disorder NN o
( ( o
ADHD NNP o
) ) o
and CC o
associated VBN o
behavior NN o
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
and CC p
ADHD NNP p
symptoms NNS p
. . p

OBJECTIVE IN N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
examine VB N
the DT N
behavioral JJ o
effects NNS o
of IN N
four CD N
doses NNS N
of IN N
psychostimulant JJ i
medication NN i
, , i
combining VBG i
extended-release JJ i
methylphenidate NN i
( ( i
MPH NNP i
) ) i
in IN i
the DT i
morning NN i
with IN i
immediate-release JJ i
MPH NNP i
in IN i
the DT i
afternoon NN i
. . i

METHOD NNP N
The DT N
sample NN N
comprised VBD N
24 CD p
children NNS p
( ( p
19 CD p
boys NNS p
; : p
5 CD p
girls NNS p
) ) p
who WP p
met VBD p
American NNP p
Psychiatric NNP p
Association NNP p
, , p
Diagnostic NNP p
and CC p
Statistical NNP p
Manual NNP p
of IN p
Mental NNP p
Disorders NNP p
, , p
4th CD p
ed NN p
. . p

( ( N
DSM-IV-TR NNP N
) ) N
criteria NN N
for IN N
an DT N
autism NN N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
on IN N
the DT N
Autism NNP N
Diagnostic NNP N
Interview-Revised JJ N
( ( N
ADI-R NNP N
) ) N
and CC N
the DT N
Autism NNP N
Diagnostic NNP N
Observation NNP N
Schedule NNP N
( ( N
ADOS NNP N
) ) N
, , N
and CC N
had VBD N
significant JJ N
symptoms NNS N
of IN N
attention-deficit/hyperactivity NN N
disorder NN N
( ( N
ADHD NNP N
) ) N
. . N

This DT N
sample NN N
consisted VBD N
of IN N
elementary JJ p
school-age NN p
, , p
community-based JJ p
children NNS p
( ( p
mean JJ p
chronological JJ p
age=8.8 NN p
years NNS p
, , p
SD=1.7 NNP p
; : p
mean JJ p
intelligence NN p
quotient NN p
[ NNP p
IQ NNP p
] NNP p
=85 NNP p
; : p
SD=16.8 NNP p
) ) p
. . p

Effects NNS N
of IN N
four CD N
dose NN N
levels NNS N
of IN N
MPH NNP i
on IN N
parent NN o
and CC o
teacher RB o
behavioral JJ o
ratings NNS o
were VBD N
investigated VBN N
using VBG N
a DT N
within-subject JJ N
, , N
crossover NN N
, , N
placebo-controlled JJ N
design NN N
. . N

RESULTS NNP N
MPH NNP i
treatment NN N
was VBD N
associated VBN N
with IN N
significant JJ N
declines NNS N
in IN N
hyperactive JJ o
and CC o
impulsive JJ o
behavior NN o
at IN o
both DT o
home NN o
and CC o
school NN o
. . o

Parents NNS N
noted VBD N
significant JJ N
declines NNS N
in IN N
inattentive JJ o
and CC o
oppositional JJ o
behavior NN o
, , N
and CC N
improvements NNS N
in IN N
social JJ o
skills NNS o
. . o

No DT N
exacerbation NN o
of IN o
stereotypies NNS o
was VBD N
noted VBN N
, , N
and CC N
side JJ o
effects NNS o
were VBD N
similar JJ N
to TO N
those DT N
seen VBN N
in IN N
typically RB N
developing VBG N
children NNS N
with IN N
ADHD NNP N
. . N

Dose NNP N
response NN N
was VBD N
primarily RB N
linear JJ N
in IN N
the DT N
dose JJ N
range NN N
studied VBN N
. . N

CONCLUSIONS VB N
The DT N
results NNS N
of IN N
this DT N
study NN N
suggest VBP N
that IN N
MPH NNP N
formulations NNS N
are VBP N
efficacious JJ o
and CC o
well-tolerated JJ o
for IN N
children NNS p
with IN p
ASD NNP p
and CC p
significant JJ p
ADHD NNP p
symptoms NNS p
. . p

-DOCSTART- -17432640- O O

[ JJ N
Clinical NNP N
observation NN N
on IN N
different JJ N
acupuncture NN i
and CC i
moxibustion NN i
therapies NNS i
for IN N
treatment NN N
of IN N
postsurgical JJ p
gastroparesis NN p
syndrome NN p
] NNP p
. . N

OBJECTIVE NNP N
To TO N
optimize VB N
therapy NN N
of IN N
acupuncture NN i
and CC i
moxibustion NN i
for IN N
postsurgical JJ p
gastroparesis NN p
syndrome NN p
( ( p
PGS NNP p
) ) p
. . p

METHODS NNP N
Forty-one JJ p
cases NNS p
of IN p
PGS NNP p
were VBD p
randomly RB p
divided VBN p
into IN p
3 CD p
groups NNS p
in IN p
order NN p
of IN p
visiting VBG p
. . p

Group NNP N
A NNP N
( ( p
n JJ p
= NNP p
17 CD p
) ) p
were VBD N
treated VBN N
by IN N
warming VBG i
needle JJ i
moxibustion NN i
, , N
group NN N
B NNP N
( ( p
n JJ p
= NNP p
12 CD p
) ) p
by IN N
acupuncture NN i
plus CC i
auricular JJ i
point NN i
sticking NN i
, , N
and CC N
group NN N
C NNP N
( ( p
n JJ p
= NNP p
12 CD p
) ) p
by IN N
routine JJ i
acupuncture NN i
. . i

Changes NNS N
of IN N
gastric JJ o
drainage NN o
volume NN o
, , o
therapeutic JJ o
times NNS o
and CC o
cured JJ o
rate NN o
were VBD N
investigated VBN N
in IN N
the DT N
3 CD N
groups NNS N
. . N

RESULTS NNP N
All PDT N
the DT N
3 CD N
therapeutic JJ N
methods NNS N
could MD N
significantly RB N
decrease VB N
gastric JJ o
drainage NN o
volume NN o
. . o

The DT N
cured JJ o
rate NN o
was VBD N
100.0 CD N
% NN N
and CC N
the DT N
therapeutic JJ o
times NNS o
was VBD N
( ( N
7.24 CD N
+/- JJ N
3.87 CD N
) ) N
in IN N
the DT N
group NN N
A NNP N
, , N
66.7 CD N
% NN N
, , N
( ( N
9.83 CD N
+/- JJ N
4.60 CD N
) ) N
times NNS N
in IN N
the DT N
group NN N
B NNP N
and CC N
75.0 CD N
% NN N
, , N
( ( N
15.25 CD N
+/- JJ N
3.81 CD N
) ) N
times NNS N
in IN N
the DT N
group NN N
C NNP N
, , N
with IN N
significant JJ N
differences NNS N
in IN N
the DT N
cured JJ o
rate NN o
and CC o
the DT o
therapeutic JJ o
times NNS o
among IN N
the DT N
3 CD N
groups NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSION NNP N
The DT N
warming VBG i
needle JJ i
moxibustion NN i
is VBZ N
the DT N
best JJS N
method NN N
for IN N
PGS NNP p
, , N
with IN N
less RBR N
therapeutic JJ o
times NNS o
, , N
high JJ N
cured VBN o
rate NN o
and CC N
rapid JJ N
effect NN o
. . o

-DOCSTART- -25187485- O O

Gene NNP N
variants NNS N
in IN N
CYP2C19 NNP N
are VBP N
associated VBN N
with IN N
altered VBN N
in IN N
vivo JJ N
bupropion NN i
pharmacokinetics NNS N
but CC N
not RB N
bupropion-assisted JJ N
smoking VBG p
cessation NN p
outcomes NNS N
. . N

Bupropion NNP i
is VBZ N
used VBN N
clinically RB N
to TO N
treat VB N
depression NN N
and CC N
to TO N
promote VB N
smoking VBG N
cessation NN N
. . N

It PRP N
is VBZ N
metabolized VBN N
by IN N
CYP2B6 NNP N
to TO N
its PRP$ N
active JJ N
metabolite JJ N
hydroxybupropion NN N
, , N
yet CC N
alterations NNS N
in IN N
CYP2B6 NNP N
activity NN N
have VBP N
little JJ N
impact NN N
on IN N
bupropion NN o
plasma NN o
levels NNS o
. . o

Furthermore RB N
, , N
less JJR N
than IN N
10 CD N
% NN N
of IN N
a DT N
bupropion NN i
dose NN N
is VBZ N
excreted VBN N
as IN N
urinary JJ N
bupropion NN i
and CC N
its PRP$ N
characterized JJ N
metabolites NNS N
hydroxybupropion NN N
, , N
threohydrobupropion NN N
, , N
and CC N
erythrohydrobupropion NN N
, , N
suggesting VBG N
that IN N
alternative JJ N
metabolic JJ N
pathways NNS N
may MD N
exist VB N
. . N

In IN N
vitro JJ N
data NNS N
suggested VBD N
CYP2C19 NNP N
could MD N
metabolize VB N
bupropion NN i
. . i

The DT N
current JJ N
study NN N
investigated VBD N
the DT N
impact NN N
of IN N
functional JJ N
CYP2C19 NNP N
genetic JJ N
variants NNS N
on IN N
bupropion NN N
pharmacokinetics NNS N
and CC N
treatment NN N
outcomes NNS N
. . N

In IN N
42 CD p
healthy JJ p
volunteers NNS p
, , N
CYP2C19*2 NNP N
( ( N
a DT N
reduced VBN N
activity NN N
allele NN N
) ) N
was VBD N
associated VBN N
with IN N
higher JJR N
bupropion NN i
area NN N
under IN N
the DT N
plasma JJ N
concentration-time JJ N
curve NN N
( ( N
AUC NNP N
) ) N
, , N
but CC N
similar JJ N
hydroxybupropion NN N
AUC NNP N
. . N

The DT N
mean JJ o
bupropion NN o
AUC NNP o
was VBD N
771 CD N
versus NN N
670 CD N
hours?ng/ml NN N
in IN N
individuals NNS N
with IN N
and CC N
without IN N
CYP2C19*2 NNP N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
0.017 CD N
) ) N
. . N

CYP2C19*2 NNP N
was VBD N
also RB N
associated VBN N
with IN N
higher JJR o
threohydrobupropion NN o
and CC o
erythrohydrobupropion NN o
AUC NNP o
( ( o
P NNP N
< NNP N
0.005 CD N
) ) N
. . N

Adjusting VBG N
for IN N
CYP2B6 NNP N
genotype NN N
did VBD N
not RB N
alter VB N
these DT N
associations NNS N
, , N
and CC N
CYP2C19 NNP N
variants NNS N
did VBD N
not RB N
alter VB N
the DT N
utility NN N
of IN N
the DT o
hydroxybupropion/bupropion NN o
ratio NN o
as IN o
a DT N
measure NN N
of IN N
CYP2B6 NNP N
activity NN N
. . N

Finally RB N
, , N
in IN N
a DT N
clinical JJ N
trial NN N
of IN N
540 CD p
smokers NNS p
, , p
CYP2C19 NNP N
genotype NN N
was VBD N
not RB N
associated VBN N
with IN N
smoking VBG o
cessation NN o
outcomes NNS o
, , o
supporting VBG N
the DT N
hypothesis NN N
that WDT i
bupropion NN i
response NN i
is VBZ N
mediated VBN N
by IN N
hydroxybupropion NN o
, , o
which WDT N
is VBZ N
not RB N
altered VBN N
by IN N
CYP2C19 NNP N
. . N

In IN N
conclusion NN N
, , N
our PRP$ N
study NN N
reports VBZ N
the DT N
first JJ N
in IN N
vivo JJ N
evidence NN N
that IN N
reduced VBD o
CYP2C19 NNP o
activity NN o
significantly RB o
increases VBZ N
the DT o
steady-state JJ o
exposure NN o
to TO o
bupropion NN o
and CC o
its PRP$ o
reductive JJ o
metabolites NNS o
threohydrobupropion NN o
and CC o
erythrohydrobupropion NN o
. . o

These DT N
pharmacokinetic JJ N
changes NNS N
were VBD N
not RB N
associated VBN N
with IN N
differences NNS N
in IN N
bupropion NN N
's POS N
ability NN N
to TO N
promote VB N
smoking VBG N
cessation NN N
in IN N
smokers NNS p
, , p
but CC N
may MD N
influence VB N
the DT o
side NN o
effects NNS o
and CC o
toxicity NN o
associated VBN o
with IN i
bupropion NN i
. . i

-DOCSTART- -26036646- O O

Managing VBG N
repetitive JJ N
behaviours NNS N
in IN N
young JJ p
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
: : p
pilot NN N
randomised VBD N
controlled JJ N
trial NN N
of IN N
a DT N
new JJ N
parent NN p
group NN N
intervention NN N
. . N

Early JJ N
intervention NN N
for IN N
autism NN N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
tends VBZ N
to TO N
focus VB N
on IN N
enhancing VBG N
social-communication NN N
skills NNS N
. . N

We PRP N
report VBP N
the DT N
acceptability NN N
, , N
feasibility NN N
and CC N
impact NN N
on IN N
child NN N
functioning NN N
of IN N
a DT N
new JJ N
8 CD i
weeks NNS i
parent-group JJ i
intervention NN i
to TO i
manage VB i
restricted VBN i
and CC i
repetitive JJ i
behaviours NNS i
( ( p
RRB NNP p
) ) p
in IN p
young JJ p
children NNS p
with IN p
ASD NNP p
aged VBD p
3-7 CD p
years NNS p
. . p

Forty-five JJ p
families NNS p
took VBD p
part NN p
in IN p
the DT p
pilot NN p
RCT NNP p
. . p

A NNP N
range NN N
of IN N
primary JJ N
and CC N
secondary JJ N
outcome NN N
measures NNS N
were VBD N
collected VBN N
on IN N
four CD N
occasions NNS N
( ( N
baseline NN N
, , N
10 CD N
, , N
18 CD N
and CC N
24 CD N
weeks NNS N
) ) N
to TO N
capture VB N
both DT o
independent JJ o
ratings NNS o
and CC o
parent-reported JJ o
changes NNS o
in IN o
RRB NNP o
. . o

This DT o
pilot NN N
established VBD N
that IN p
parents NNS p
were VBD p
willing JJ N
to TO N
be VB N
recruited VBN N
and CC N
randomised VBN N
, , N
and CC N
the DT N
format NN N
and CC N
content NN N
of IN N
the DT N
intervention NN N
was VBD N
feasible JJ o
. . o

Fidelity NNP o
of IN o
delivery NN o
was VBD o
high JJ o
, , o
and CC o
attendance NN o
was VBD o
90 CD N
% NN N
. . N

A NNP N
fully RB N
powered JJ N
trial NN N
is VBZ N
now RB N
planned VBN N
. . N

-DOCSTART- -26016867- O O

Supplementation NN N
with IN N
a DT i
blend NN i
of IN i
krill NN i
and CC i
salmon JJ i
oil NN i
is VBZ N
associated VBN N
with IN N
increased VBN N
metabolic NN N
risk NN N
in IN N
overweight JJ p
men NNS p
. . p

BACKGROUND NNP N
Krill NNP i
is VBZ N
an DT N
increasingly RB N
popular JJ N
source NN N
of IN N
marine JJ N
n-3 JJ N
( ( N
?-3 JJ N
) ) N
PUFA NNP N
that WDT N
is VBZ N
seen VBN N
as IN N
a DT N
premium JJ N
product NN N
. . N

However RB N
, , N
to TO N
our PRP$ N
knowledge NN N
, , N
the DT N
effect NN N
of IN i
krill-oil JJ i
supplementation NN i
on IN N
insulin NN N
sensitivity NN N
in IN N
humans NNS N
has VBZ N
not RB N
been VBN N
reported VBN N
. . N

OBJECTIVE IN N
We PRP N
assessed VBD N
whether IN i
supplementation NN i
with IN i
a DT i
blend NN i
of IN i
krill NN i
and CC i
salmon NN i
( ( i
KS NNP i
) ) i
oil NN i
[ NN N
which WDT N
is VBZ N
rich JJ N
in IN N
eicosapentaenoic JJ N
acid NN N
( ( N
EPA NNP N
) ) N
and CC N
docosahexaenoic JJ N
acid NN N
( ( N
DHA NNP N
) ) N
] VBZ N
affects NNS N
insulin JJ N
sensitivity NN N
in IN p
overweight JJ p
men NNS p
. . p

DESIGN VB N
The DT N
design NN N
was VBD N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
controlled VBD N
crossover RB N
trial NN N
. . N

A DT N
total NN p
of IN p
47 CD p
men NNS p
with IN p
a DT p
mean NN p
? . p
SD NNP p
age NN p
of IN p
46.5 CD p
? . p
5.1 CD p
y NN p
, , p
who WP p
were VBD p
overweight JJ p
[ NNP p
body NN p
mass NN p
index NN p
( ( p
in IN p
kg/m NN p
( ( p
2 CD p
) ) p
) ) p
from IN p
25 CD p
to TO p
30 CD p
] NNS p
but CC p
otherwise RB p
healthy JJ p
, , p
received VBD p
5 CD N
1-g JJ N
capsules NNS N
of IN N
KS NNP i
oil NN i
or CC i
a DT i
control NN i
( ( i
canola JJ i
oil NN i
) ) i
for IN i
8 CD N
wk NN N
and CC N
crossed VBD N
over IN N
to TO N
another DT N
treatment NN N
after IN N
an DT N
8-wk JJ N
washout NN N
period NN N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
insulin JJ o
sensitivity NN o
assessed VBN o
by IN o
using VBG o
the DT o
Matsuda NNP o
method NN o
from IN o
an DT o
oral-glucose-tolerance JJ o
test NN o
. . o

Secondary JJ o
outcomes NNS N
included VBD o
lipid JJ o
profiles NNS o
, , o
inflammatory JJ o
markers NNS o
, , o
24-h JJ o
ambulatory NN o
blood NN o
pressure NN o
, , o
and CC o
carotid JJ o
artery NN o
intimamedia NN o
thickness NN o
. . o

RESULTS NNP o
Unexpectedly RB o
, , o
insulin JJ o
sensitivity NN o
( ( o
per IN o
the DT N
Matsuda NNP N
index NN N
) ) N
was VBD N
14 CD N
% NN N
lower JJR N
with IN N
the DT N
KS NNP i
oil NN i
than IN i
with IN N
the DT N
control NN N
oil NN N
( ( N
P NNP N
= NNP N
0.049 CD N
) ) N
. . N

A DT N
mediation NN N
analysis NN N
showed VBD N
that IN N
, , N
after IN N
controlling VBG N
for IN N
the DT N
likely JJ N
positive JJ N
effects NNS N
of IN N
blood NN o
EPA NNP o
and CC o
DHA NNP o
( ( o
i.e. FW o
, , N
the DT N
omega-3 JJ N
index NN N
) ) N
, , N
the DT N
reduction NN N
in IN N
insulin NN o
sensitivity NN o
after IN o
KS-oil NNP i
supplementation NN i
was VBD i
more RBR N
marked JJ N
[ JJ N
27 CD N
% NN N
lower JJR N
than IN N
with IN N
the DT N
control NN N
oil NN N
( ( N
P NNP N
= NNP N
0.009 CD N
) ) N
] NN N
. . N

CONCLUSIONS NNP i
Supplementation NNP i
with IN i
a DT i
blend NN i
of IN i
KS NNP i
oil NN i
is VBZ i
associated VBN N
with IN N
decreased JJ o
insulin NN o
sensitivity NN o
. . o

Thus RB o
, , i
krill-oil JJ i
supplementation NN i
in IN i
overweight JJ p
adults NNS p
could MD p
exacerbate VB o
risk NN o
of IN o
diabetes NNS o
and CC o
cardiovascular JJ N
disease NN N
. . N

This DT N
trial NN N
was VBD N
prospectively RB N
registered VBN N
at IN N
the DT N
Australian JJ p
New NNP p
Zealand NNP p
Clinical NNP p
Trials NNP N
Registry NNP N
as IN N
ACTRN12611000602921 NNP N
. . N

-DOCSTART- -20569998- O O

Losartan NNP i
vs. FW i
amlodipine NN i
treatment NN N
in IN N
elderly JJ p
oncologic JJ p
hypertensive JJ p
patients NNS p
: : p
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

Elderly JJ p
neoplastic JJ p
patients NNS p
frequently RB N
may MD N
show VB N
hypertension NN p
and CC p
hyperuricemia NN p
, , N
before IN N
and CC N
after IN N
chemotherapeutic JJ N
treatments NNS N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
losartan NN i
which WDT N
is VBZ N
an DT N
antihypertensive JJ i
drug NN i
with IN N
uricosuric JJ i
properties NNS N
vs. FW N
amlodipine NN i
in IN N
hypertensive JJ p
neoplastic JJ p
elderly JJ p
patients NNS p
. . p

This DT N
was VBD N
an DT N
open-labeled JJ N
, , N
randomized VBN N
, , N
comparative JJ N
trial NN N
. . N

The DT N
study NN N
was VBD N
performed VBN N
as IN N
a DT N
30-day JJ N
study NN N
. . N

Seventy NNP p
patients NNS p
with IN p
cancer NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
losartan NN i
or CC i
amlodipine NN i
. . i

Blood NNP o
pressure NN o
( ( o
BP NNP o
) ) o
, , o
blood VBD o
urea JJ o
nitrogen NN o
( ( o
BUN NNP o
) ) o
levels NNS o
, , o
creatinine NN o
, , o
serum NN o
and CC o
urinary JJ o
uric JJ o
acid NN o
, , o
creatinine NN o
and CC o
uric JJ o
acid JJ o
clearance NN o
were VBD N
determined VBN N
before IN N
and CC N
after IN N
chemotherapy NN i
. . i

One CD N
day NN N
after IN N
chemotherapy NN N
in IN N
losartan JJ i
group NN N
vs. FW N
amlodipine NN i
group NN N
we PRP N
observed VBD N
a DT N
significant JJ N
difference NN N
in IN N
urinary JJ o
uric JJ o
acid NN o
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
of IN N
18 CD N
mg/24 NNS N
h VBD N
vs. FW N
40 CD N
mg/24 NN N
h. NN N
Thirty NNP N
days NNS N
after IN N
chemotherapy NN i
we PRP N
observed VBD N
a DT N
significant JJ N
difference NN N
in IN N
azotemia NN o
of IN N
0.0 CD N
mg/dl NNS N
vs. FW N
3.8 CD N
mg/dl NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
serum JJ o
uric JJ o
acid NN o
of IN N
0.05 CD N
mg/dl NNS N
vs. FW N
0.49 CD N
mg/dl NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
urinary JJ o
uric JJ o
acid NN o
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
of IN N
23 CD N
mg/24 NNS N
h VBD N
vs. FW N
0.0 CD N
mg/24 NN N
h NN N
, , N
GFR NNP N
of IN N
2 CD N
ml/min/1.73 NNS N
m NN N
( ( N
2 CD N
) ) N
vs. FW N
-8 FW N
ml/min/1.73 FW N
m NN N
( ( N
2 CD N
) ) N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
and CC N
systolic JJ o
BP NNP o
( ( N
SBP NNP N
) ) N
of IN N
3.6 CD N
mmHg NNS N
vs. FW N
0.8 CD N
mmHg NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
findings NNS N
of IN N
the DT N
present JJ N
study NN N
support VBD N
the DT N
effective JJ N
role NN N
of IN N
losartan JJ i
compared VBN N
to TO N
amlodipine VB i
in IN N
treating VBG N
hypertension NN p
and CC p
hyperuricemia NN p
in IN p
elderly JJ p
patients NNS p
under IN p
chemotherapeutic JJ p
treatment NN p
. . p

-DOCSTART- -10200837- O O

Behavioral NNP N
and CC N
physiological JJ N
effects NNS N
of IN N
deep JJ i
pressure NN i
on IN N
children NNS p
with IN p
autism NN p
: : p
a DT N
pilot NN N
study NN N
evaluating VBG N
the DT N
efficacy NN N
of IN N
Grandin NNP i
's POS i
Hug NNP i
Machine NNP i
. . i

OBJECTIVE NNP N
One CD N
symptom NN N
common JJ N
to TO N
many JJ N
persons NNS p
with IN p
autism NN p
is VBZ N
a DT N
high JJ N
arousal NN N
or CC N
anxiety NN N
level NN N
. . N

This DT N
study NN N
investigated VBD N
the DT N
effects NNS N
of IN N
deep JJ i
pressure NN i
on IN N
arousal NN N
and CC N
anxiety NN N
reduction NN N
in IN N
autism NN N
with IN N
Grandin NNP i
's POS i
Hug NNP i
Machine NNP i
, , N
a DT N
device NN N
that WDT N
allows VBZ N
self-administration NN N
of IN N
lateral JJ N
body NN N
pressure NN N
. . N

METHOD NNP N
Twelve NNP p
children NNS p
with IN p
autism NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
an DT N
experimental JJ N
group NN N
( ( i
receiving VBG i
deep JJ i
pressure NN i
) ) i
or CC N
a DT N
placebo NN i
group NN N
( ( i
not RB i
receiving VBG i
deep JJ i
pressure NN i
but CC i
in IN i
the DT i
disengaged JJ i
Hug NNP i
Machine NNP i
) ) i
. . N

All DT N
children NNS N
received VBD N
two CD N
20-min JJ N
sessions NNS N
a DT N
week NN N
over IN N
a DT N
6-week JJ N
period NN N
. . N

Arousal NNP o
was VBD N
measured VBN N
behaviorally RB N
with IN N
the DT N
Conners NNPS o
Parent NNP o
Rating NNP o
Scale NNP o
and CC o
physiologically RB o
with IN o
galvanic JJ o
skin NN o
response NN o
( ( o
GSR NNP o
) ) o
readings NNS o
. . o

RESULTS NNP N
Behavioral NNP N
results NNS N
indicated VBD N
a DT N
significant JJ o
reduction NN o
in IN o
tension NN o
and CC o
a DT o
marginally RB o
significant JJ o
reduction NN o
in IN o
anxiety NN o
for IN N
children NNS N
who WP N
received VBD N
the DT N
deep JJ i
pressure NN i
compared VBN N
with IN N
the DT N
children NNS N
who WP N
did VBD N
not RB N
. . N

Additionally RB N
, , N
children NNS N
in IN N
the DT N
experimental JJ N
group NN N
, , N
whose WP$ N
GSR NNP o
measures NNS o
decreased VBD N
, , N
on IN N
average NN N
, , N
after IN N
deep JJ N
pressure NN N
, , N
were VBD N
somewhat RB N
more RBR N
likely JJ N
to TO N
have VB N
higher JJR N
GSR NNP o
arousal VBZ o
a DT N
priori NN N
. . N

CONCLUSION NNP N
These DT N
preliminary JJ N
findings NNS N
support VBP N
the DT N
hypothesis NN N
that WDT N
deep JJ i
pressure NN i
may MD N
have VB N
a DT N
calming JJ N
effect NN N
for IN N
persons NNS N
with IN N
autism NN N
, , N
especially RB N
those DT N
with IN N
high JJ N
levels NNS N
of IN N
arousal NN N
or CC N
anxiety NN N
. . N

-DOCSTART- -25238860- O O

A DT N
neuropsychological JJ i
rehabilitation NN i
program NN i
for IN N
patients NNS p
with IN p
Multiple NNP p
Sclerosis NNP p
based VBN p
on IN p
the DT p
model NN p
of IN p
the DT p
ICF NNP p
. . p

BACKGROUND NNP N
Forty NNP N
to TO N
sixty VB N
percent NN N
of IN N
MS NNP N
patients NNS N
suffer VBP N
from IN N
cognitive JJ o
impairments NNS o
. . o

Cognitive JJ o
deficits NNS o
are VBP N
a DT N
great JJ N
burden NN N
for IN N
patients NNS N
affected JJ N
. . N

In IN N
particular JJ N
they PRP N
may MD N
lead VB N
to TO N
a DT N
reduced JJ N
quality NN o
of IN o
life NN o
, , o
loss NN o
of IN o
work NN o
and CC o
problems NNS o
with IN o
the DT o
social JJ o
environment NN o
. . o

OBJECTIVE IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
a DT N
specific JJ i
neuropsychological JJ i
rehabilitation NN i
program NN i
for IN N
MS NNP p
patients NNS p
according VBG p
to TO p
the DT p
ICF NNP p
to TO N
be VB N
able JJ N
to TO N
meet VB N
more JJR N
properly RB N
individual JJ N
requirements NNS N
on IN N
the DT N
therapy NN N
level NN N
of IN N
function NN o
as RB N
well RB N
as IN N
of IN N
activities NNS o
and CC o
participation NN o
. . o

METHODS NNP N
Forty NNP p
patients NNS p
with IN p
MS NNP p
were VBD p
randomised VBN p
in IN p
an DT p
intervention NN i
( ( i
IG NNP i
) ) i
- : i
and CC i
a DT i
control NN i
group NN i
( ( i
CG NNP i
) ) i
. . p

The DT N
outcome JJ o
measure NN o
of IN N
the DT N
IG NNP N
, , N
who WP N
started VBD N
an DT N
intensive JJ i
computer NN i
based VBN i
home NN i
training NN i
of IN i
attention NN i
and CC N
attended VBD N
psychological JJ i
counselling NN i
was VBD N
compared VBN N
to TO N
the DT N
untrained JJ i
CG NNP i
. . i

RESULTS NNP N
In IN N
specific JJ N
domains NNS N
of IN N
attention NN o
( ( o
simple JJ o
and CC o
cued JJ o
alertness NN o
and CC o
divided JJ o
attention NN o
) ) o
significant JJ N
group NN N
differences NNS N
between IN N
CG NNP N
and CC N
IG NNP N
could MD N
be VB N
found VBN N
. . N

The DT N
IG NNP i
reported VBD N
an DT N
improvement NN N
of IN N
mental JJ o
fatigue NN o
and CC o
retardation NN o
. . o

CONCLUSION NNP N
These DT N
findings NNS N
support VBP N
the DT N
idea NN N
that IN N
a DT N
neuropsychological JJ N
rehabilitation NN N
program NN N
, , N
which WDT N
based VBN N
on IN N
the DT N
model NN N
of IN N
ICF NNP N
, , N
could MD N
improve VB N
cognitive JJ o
impairment NN o
and CC N
could MD N
also RB N
have VB N
a DT N
positive JJ N
influence NN N
of IN N
activities NNS o
and CC o
participation NN o
. . o

-DOCSTART- -20723873- O O

A DT N
randomized VBN N
study NN N
comparing VBG N
the DT N
use NN N
of IN N
the DT N
Ligaclip NNP i
with IN N
bipolar JJ N
energy NN N
to TO N
prevent VB N
lymphocele NN N
during IN N
laparoscopic JJ p
pelvic JJ p
lymphadenectomy NN p
for IN p
gynecologic JJ p
cancer NN p
. . p

OBJECTIVE CC N
This DT N
prospective JJ N
randomized NN N
pilot NN N
study NN N
compared VBN N
the DT N
use NN N
of IN N
the DT N
Ligaclip NNP N
( ( N
Ethicon NNP N
Endo-Surgery NNP N
, , N
Cincinnati NNP N
, , N
OH NNP N
) ) N
with IN N
bipolar JJ N
coagulation NN N
in IN N
preventing VBG N
lymphoceles NNS N
after IN N
laparoscopic NN N
pelvic JJ N
lymphadenectomy NN N
for IN N
gynecologic JJ N
cancer NN N
. . N

STUDY NNP N
DESIGN NNP N
Thirty NNP p
patients NNS p
with IN p
gynecologic JJ p
malignancy NN p
, , p
who WP p
had VBD p
laparoscopic VBN p
pelvic JJ p
lymphadenectomy NN p
were VBD N
randomly RB N
assigned VBN N
for IN N
lymphadenectomy NN i
in IN i
1 CD i
side NN i
of IN i
the DT i
pelvis NN i
using VBG i
the DT i
Ligaclip NNP i
, , N
whereas RB N
, , N
in IN N
the DT N
other JJ N
side NN N
, , N
the DT N
bipolar JJ i
coagulation NN i
to TO i
seal VB i
lymphatic JJ i
vessels NNS i
was VBD N
used VBN N
. . N

RESULTS NNP N
At IN N
ultrasound JJ N
examination NN N
, , N
we PRP N
detected VBD N
lymphocele NNS o
in IN p
10 CD p
patients NNS p
( ( N
33 CD N
% NN N
) ) N
. . N

Lymphocele NNP o
developed VBD N
in IN N
9 CD N
( ( N
30 CD N
% NN N
) ) N
patients NNS N
on IN N
the DT N
side NN N
where WRB N
laparoscopic NN N
pelvic JJ N
lymphadenectomy NN N
was VBD N
perfomed VBN N
using VBG N
bipolar JJ N
coagulation NN N
, , N
and CC N
in IN N
1 CD N
( ( N
3.3 CD N
% NN N
) ) N
patient NN N
on IN N
the DT N
side NN N
where WRB N
laparoscopic NN N
pelvic JJ N
lymphadenectomy NN N
was VBD N
performed VBN N
using VBG N
the DT N
Ligaclip NNP N
. . N

Univariate NNP N
analysis NN N
revealed VBD N
that IN N
the DT N
Ligaclip NNP N
's POS N
use NN N
compared VBN N
with IN N
electrocoagulation NN N
in IN N
the DT N
laparoscopic NN N
pelvic JJ N
lymphadenectomy NN N
is VBZ N
an DT N
independent JJ N
predictive JJ N
factor NN N
for IN N
development NN o
of IN o
lymphocele NN o
( ( N
P NNP N
= NNP N
.006 NNP N
) ) N
. . N

CONCLUSION VB N
This DT N
study NN N
demonstrates VBZ N
that IN N
the DT N
use NN N
of IN N
the DT N
Ligaclip NNP N
to TO N
close VB N
lymphatic JJ N
vessels NNS N
may MD N
reduce VB N
the DT N
incidence NN o
of IN o
lymphoceles NNS o
in IN N
patients NNS p
undergoing VBG p
laparoscopic JJ p
pelvic JJ p
lymphadenectomy NN p
. . p

-DOCSTART- -24781567- O O

Sedation NNP o
depth NN o
during IN N
spinal JJ i
anesthesia NN i
and CC N
survival NN N
in IN N
elderly JJ p
patients NNS p
undergoing VBG p
hip JJ p
fracture NN p
repair NN p
. . p

Low JJ N
intraoperative JJ o
Bispectral NNP o
Index NNP o
( ( o
BIS NNP o
) ) o
values NNS o
may MD N
be VB N
associated VBN N
with IN N
increased JJ N
mortality NN N
. . N

In IN N
a DT N
previously RB N
reported VBN N
trial NN N
to TO N
prevent VB N
delirium NN N
, , N
we PRP N
randomized VBD N
patients NNS p
undergoing VBG p
hip JJ o
fracture NN o
repair NN o
under IN p
spinal JJ i
anesthesia NN i
to TO i
light NN i
( ( i
BIS NNP i
> NNP i
80 CD i
) ) i
or CC i
deep JJ i
( ( i
BIS NNP i
approximately RB i
50 CD i
) ) i
sedation NN i
. . i

We PRP N
analyzed VBD N
survival NN o
of IN N
patients NNS N
in IN N
the DT N
original JJ N
trial NN N
. . N

Among IN N
all DT N
patients NNS N
, , N
mortality NN o
was VBD N
equivalent JJ N
across IN N
sedation NN N
groups NNS N
. . N

However RB N
, , N
among IN N
patients NNS N
with IN N
serious JJ N
comorbidities NNS N
( ( N
Charlson NNP N
score RB N
> VBZ N
4 CD N
) ) N
, , N
1-year JJ o
mortality NN o
was VBD N
reduced VBN N
in IN N
the DT N
light NN i
( ( N
22.2 CD N
% NN N
) ) N
vs NN N
deep JJ i
( ( N
43.6 CD N
% NN N
) ) N
sedation NN i
group NN N
( ( N
hazard JJ N
ratio NN N
[ NNP N
HR NNP N
] NNP N
, , N
0.43 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.19-0.97 JJ N
; : N
P NNP N
= NNP N
0.04 CD N
) ) N
during IN N
spinal JJ N
anesthesia NN N
. . N

Similarly RB N
, , N
among IN N
patients NNS N
with IN N
Charlson NNP N
score VBD N
> JJ N
6 CD N
, , N
1-year JJ o
mortality NN o
was VBD N
reduced VBN N
in IN N
the DT N
light NN i
( ( N
28.6 CD N
% NN N
) ) N
vs NN N
deep JJ i
( ( N
52.6 CD N
% NN N
) ) N
sedation NN i
group NN N
( ( N
HR NNP N
0.33 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.12-0.94 JJ N
; : N
P NNP N
= NNP N
0.04 CD N
) ) N
during IN N
spinal JJ i
anesthesia NN i
. . i

Further NNP N
research NN N
on IN N
reduced JJ o
mortality NN o
after IN o
light JJ o
sedation NN o
during IN o
spinal JJ o
anesthesia NN o
is VBZ N
needed VBN N
. . N

-DOCSTART- -18541792- O O

Multiple JJ o
sclerosis NN o
risk NN o
after IN N
optic JJ p
neuritis NN p
: : p
final JJ N
optic JJ N
neuritis NN N
treatment NN N
trial NN N
follow-up NN N
. . N

OBJECTIVE UH N
To TO N
assess VB N
the DT N
risk NN o
of IN o
developing VBG o
multiple JJ o
sclerosis NN o
( ( o
MS NNP o
) ) o
after IN N
optic JJ p
neuritis NN p
and CC N
the DT N
factors NNS N
predictive VBP N
of IN N
high JJ N
and CC N
low JJ N
risk NN N
. . N

DESIGN NNP N
Subjects NNPS p
in IN p
the DT p
Optic NNP i
Neuritis NNP i
Treatment NNP i
Trial NNP p
, , p
who WP p
were VBD p
enrolled VBN p
between IN p
July NNP p
1 CD p
, , p
1988 CD p
, , p
and CC p
June NNP p
30 CD p
, , p
1991 CD p
, , p
were VBD p
followed VBN p
up RP p
prospectively RB p
for IN p
15 CD p
years NNS p
, , p
with IN p
the DT p
final JJ p
examination NN p
in IN p
2006 CD p
. . p

SETTING CC N
Neurologic NNP p
and CC p
ophthalmologic JJ p
examinations NNS p
at IN p
13 CD p
clinical JJ p
sites NNS p
. . p

PARTICIPANTS NNP N
Three CD p
hundred VBD p
eighty-nine JJ p
subjects NNS p
with IN p
acute JJ p
optic JJ p
neuritis NN p
. . p

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Development NNP o
of IN o
MS NNP o
and CC o
neurologic JJ o
disability NN o
assessment NN o
. . o

RESULTS VB N
The DT N
cumulative JJ o
probability NN o
of IN o
developing VBG o
MS NNP o
by IN o
15 CD o
years NNS o
after IN o
onset NN o
of IN o
optic JJ o
neuritis NN o
was VBD N
50 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
44 CD N
% NN N
-56 NNP N
% NN N
) ) N
and CC N
strongly RB N
related VBN N
to TO N
presence NN N
of IN N
lesions NNS N
on IN N
a DT N
baseline JJ N
non-contrast-enhanced JJ N
magnetic JJ N
resonance NN N
imaging NN N
( ( N
MRI NNP N
) ) N
of IN N
the DT N
brain NN N
. . N

Twenty-five JJ N
percent NN N
of IN N
patients NNS N
with IN N
no DT N
lesions NNS N
on IN N
baseline NN N
brain NN i
MRI NNP i
developed VBD N
MS NNP o
during IN N
follow-up JJ N
compared VBN N
with IN N
72 CD N
% NN N
of IN N
patients NNS N
with IN N
1 CD N
or CC N
more JJR N
lesions NNS N
. . N

After IN N
10 CD N
years NNS N
, , N
the DT N
risk NN o
of IN o
developing VBG o
MS NNP o
was VBD N
very RB N
low JJ N
for IN N
patients NNS N
without IN N
baseline JJ N
lesions NNS N
but CC N
remained VBD N
substantial JJ N
for IN N
those DT N
with IN N
lesions NNS N
. . N

Among IN N
patients NNS N
without IN N
lesions NNS N
on IN N
MRI NNP N
, , N
baseline NN N
factors NNS N
associated VBN N
with IN N
a DT N
substantially RB N
lower JJR N
risk NN o
for IN o
MS NNP o
included VBD N
male JJ N
sex NN N
, , N
optic JJ N
disc NN N
swelling NN N
, , N
and CC N
certain JJ N
atypical JJ N
features NNS N
of IN N
optic JJ N
neuritis NN N
. . N

CONCLUSIONS VB N
The DT N
presence NN N
of IN N
brain NN N
MRI NNP N
abnormalities NNS N
at IN N
the DT N
time NN N
of IN N
an DT N
optic JJ N
neuritis NN N
attack NN N
is VBZ N
a DT N
strong JJ N
predictor NN N
of IN N
the DT o
15-year JJ o
risk NN o
of IN o
MS NNP o
. . o

In IN N
the DT N
absence NN N
of IN N
MRI-detected JJ N
lesions NNS N
, , N
male JJ N
sex NN N
, , N
optic JJ N
disc NN N
swelling NN N
, , N
and CC N
atypical JJ N
clinical JJ N
features NNS N
of IN N
optic JJ N
neuritis NN N
are VBP N
associated VBN N
with IN N
a DT N
low JJ N
likelihood NN N
of IN N
developing VBG o
MS NNP o
. . o

This DT N
natural JJ N
history NN N
information NN N
is VBZ N
important JJ N
when WRB N
considering VBG N
prophylactic JJ N
treatment NN N
for IN N
MS NNP o
at IN N
the DT N
time NN N
of IN N
a DT N
first JJ N
acute JJ N
onset NN N
of IN N
optic JJ N
neuritis NN N
. . N

-DOCSTART- -2142040- O O

Nephrotoxicity NN N
of IN N
cyclosporin NN i
A NNP i
in IN N
patients NNS p
with IN p
newly RB p
diagnosed VBN p
type NN p
1 CD p
diabetes NNS p
mellitus RB p
. . p

Renal JJ N
function NN N
was VBD N
studied VBN N
in IN N
18 CD p
patients NNS p
with IN p
Type NNP p
1 CD p
diabetes NNS p
mellitus RB p
. . p

All DT p
were VBD p
participating VBG p
in IN p
the DT p
Canadian-European JJ p
randomized JJ p
placebo-controlled JJ i
cyclosporin NN i
trial NN p
in IN p
newly RB p
diagnosed VBN p
Type NNP p
1 CD p
diabetic JJ p
patients NNS p
, , N
nine CD N
being VBG N
randomized VBN N
to TO N
placebo VB i
, , N
and CC N
nine CD N
to TO N
cyclosporin VB i
A NNP i
. . i

During IN N
treatment NN N
for IN N
12 CD N
to TO N
18 CD N
months NNS N
, , N
cyclosporin VBP i
A DT i
caused JJ N
significant JJ N
reductions NNS N
in IN N
the DT N
glomerular JJ o
filtration NN o
rate NN o
( ( N
before IN N
drug NN N
withdrawal NN N
, , N
cyclosporin JJ i
97 CD N
+/- JJ N
18 CD N
vs NN N
placebo NN N
125 CD N
+/- JJ N
16 CD N
ml JJ N
min-1 JJ N
1.73-m-2 JJ N
, , N
p RB N
less JJR N
than IN N
0.05 CD N
) ) N
, , N
renal JJ o
plasma NN o
flow NN o
( ( N
454 CD N
+/- JJ N
83 CD N
vs JJ N
536 CD N
+/- JJ N
70 CD N
ml JJ N
min-1 JJ N
1.73-m-2 JJ N
, , N
p RB N
less JJR N
than IN N
0.05 CD N
) ) N
, , N
and CC N
lithium JJ o
clearance NN o
( ( N
17 CD N
+/- JJ N
3 CD N
vs JJ N
28 CD N
+/- JJ N
5 CD N
ml JJ N
min-1 JJ N
1.73-m-2 JJ N
, , N
p RB N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

The DT N
fractional JJ o
proximal JJ o
reabsorption NN o
was VBD N
increased VBN N
( ( N
0.82 CD N
+/- JJ N
0.03 CD N
vs JJ N
0.78 CD N
+/- JJ N
0.03 CD N
, , N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
, , N
and CC N
the DT N
fractional JJ o
distal JJ o
sodium NN o
reabsorption NN o
reduced VBD N
( ( N
0.88 CD N
+/- JJ N
0.03 CD N
vs JJ N
0.94 CD N
+/- JJ N
0.02 CD N
, , N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

These DT N
results NNS N
are VBP N
in IN N
accordance NN N
with IN N
the DT N
hypothesis NN N
that IN N
the DT N
nephrotoxic JJ N
effect NN N
of IN N
cyclosporin NN i
A NNP i
results NNS N
from IN N
a DT N
preferential JJ N
constriction NN N
of IN N
afferent JJ N
glomerular JJ N
vessels NNS N
. . N

One CD N
year NN N
after IN N
withdrawal NN N
of IN N
the DT N
drug NN N
, , N
all DT N
variables NNS N
were VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
, , N
except IN N
for IN N
blood NN o
glucose NN o
control NN o
which WDT N
was VBD N
worse RBR N
in IN N
the DT N
cyclosporin NN i
A NNP i
treated VBD N
group NN N
. . N

When WRB N
corrected VBN N
for IN N
differences NNS N
in IN N
blood NN N
glucose NN N
control NN N
it PRP N
appeared VBD N
that IN N
in IN N
three CD N
out IN N
of IN N
nine CD N
patients NNS N
glomerular JJ o
filtration NN o
rate NN o
had VBD N
not RB N
completely RB N
returned VBN N
to TO N
the DT N
reference NN N
range NN N
of IN N
the DT N
placebo NN i
group NN N
. . N

We PRP N
conclude VBP N
that IN N
the DT N
nephrotoxic JJ N
side-effects NNS N
of IN N
cyclosporin NN i
A NNP i
treatment NN N
for IN N
1 CD N
year NN N
are VBP N
reversible JJ N
. . N

There EX N
are VBP N
, , N
however RB N
, , N
signs NNS N
of IN N
minor JJ N
and CC N
perhaps RB N
chronic JJ N
renal JJ N
injury NN N
. . N

-DOCSTART- -9071556- O O

Effect NN N
of IN N
desonide NN i
ointment NN i
, , i
0.05 CD i
% NN i
, , N
on IN N
the DT N
hypothalamic-pituitary-adrenal JJ N
axis NN N
of IN N
children NNS p
with IN p
atopic NN p
dermatitis NN p
. . p

Desonide NNP i
ointment NN i
has VBZ N
demonstrated VBN N
a DT N
good JJ N
safety NN N
and CC N
efficacy NN N
profile NN N
during IN N
the DT N
many JJ N
years NNS N
it PRP N
has VBZ N
been VBN N
used VBN N
in IN N
treating VBG N
dermatoses NNS N
. . N

However RB N
, , N
there EX N
have VBP N
been VBN N
no DT N
controlled JJ N
clinical JJ N
trials NNS N
to TO N
evaluate VB N
its PRP$ N
systemic JJ N
safety NN N
when WRB N
used VBN N
in IN N
treating VBG N
children NNS p
. . p

Suppression NN N
of IN N
the DT N
hypothalamic-pituitary-adrenal JJ N
( ( N
HPA NNP N
) ) N
axis NN N
can MD N
occur VB N
after IN N
repeated JJ N
application NN N
of IN N
topical JJ N
corticosteroids NNS N
. . N

In IN N
general JJ N
, , N
the DT N
degree NN o
of IN o
suppression NN o
of IN o
the DT o
HPA NNP o
axis NN o
function NN o
is VBZ N
related VBN N
to TO N
the DT N
daily JJ N
dosage NN N
of IN N
steroid JJ N
given VBN N
, , N
the DT N
duration NN N
of IN N
its PRP$ N
administration NN N
, , N
the DT N
extent NN N
of IN N
body NN N
surface NN N
covered VBN N
, , N
and CC N
the DT N
potency NN N
of IN N
the DT N
corticosteroid NN N
. . N

This DT N
study NN N
sought VBD N
to TO N
determine VB N
the DT N
comparative JJ N
effects NNS N
of IN N
0.05 CD i
percent NN i
desonide NN i
and CC i
2.5 CD i
percent NN i
hydrocortisone NN i
ointments NNS i
on IN N
the DT N
HPA NNP N
axis NN N
of IN N
children NNS p
with IN p
atopic NN p
dermatitis NN p
. . p

There EX N
was VBD N
no DT N
suppression NN o
of IN o
early JJ o
morning NN o
cortisol NN o
in IN N
either DT N
treatment NN N
group NN N
. . N

The DT N
ACTH-stimulated JJ o
mean NN o
cortisol NN o
values NNS o
after IN N
four CD N
weeks NNS N
of IN N
treatment NN N
were VBD N
not RB N
significantly RB N
different JJ N
from IN N
the DT N
baseline NN N
values VBZ N
for IN N
either DT N
treatment NN N
group NN N
. . N

We PRP N
conclude VBP N
that IN N
neither CC N
0.05 CD i
percent NN i
desonide NN i
ointment NN i
nor CC N
2.5 CD i
percent NN i
hydrocortisone NN i
ointment NN i
compromised VBD N
the DT N
HPA NNP N
axis NN N
of IN N
children NNS p
with IN p
atopic NN p
dermatitis NN p
treated VBD N
topically RB N
for IN N
four CD N
weeks NNS N
. . N

-DOCSTART- -12243889- O O

Treatment NN N
of IN N
canine JJ p
parvoviral JJ N
enteritis NN N
with IN N
interferon-omega JJ i
in IN N
a DT N
placebo-controlled JJ N
challenge NN N
trial NN N
. . N

Canine NNP p
parvoviral JJ p
enteritis NN p
continues VBZ N
to TO N
cause VB N
significant JJ N
morbidity NN N
and CC N
mortality NN N
in IN N
dogs NNS p
worldwide RB N
, , N
and CC N
efficacious JJ N
antiviral JJ i
therapies NNS i
are VBP N
lacking VBG N
. . N

The DT N
present JJ N
trial NN N
was VBD N
aimed VBN N
at IN N
evaluating VBG N
the DT N
therapeutic JJ N
efficacy NN N
of IN N
a DT N
recombinant JJ i
feline NN i
interferon NN i
( ( i
type JJ i
omega NN i
) ) i
preparation NN N
in IN N
the DT N
treatment NN N
of IN N
parvoviral JJ p
enteritis NN p
in IN p
dogs NNS p
. . p

A DT N
double-blind JJ N
, , N
placebo-controlled JJ N
challenge NN N
trial NN N
was VBD N
performed VBN N
in IN N
beagle NN p
pups NNS p
( ( p
8-9 JJ p
weeks NNS p
) ) p
; : p
clinical JJ N
signs NNS N
, , N
body NN N
weight NN N
, , N
hematologic JJ N
parameters NNS N
, , N
and CC N
mortality NN N
were VBD N
monitored VBN N
for IN N
a DT N
period NN N
of IN N
14 CD N
days NNS N
after IN N
challenge NN N
. . N

Fourteen JJ p
animals NNS p
were VBD p
inoculated VBN i
with IN i
virulent JJ i
canine NN i
parvovirus NN i
; : i
10 CD p
animals NNS p
that WDT p
developed VBD p
clinical JJ p
signs NNS p
thereby RB p
meeting VBG p
the DT p
inclusion NN p
criteria NNS p
were VBD p
admitted VBN p
to TO p
the DT p
treatment NN p
phase NN p
in IN N
two CD N
randomly RB N
selected VBN N
groups NNS N
( ( i
placebo NN i
and CC N
IFN NNP i
) ) i
of IN N
equal JJ N
size NN N
. . N

The DT N
IFN NNP N
group NN N
received VBD N
daily RB N
intravenous JJ N
injections NNS N
of IN N
rFeIFN-omega JJ i
( ( N
2.5 CD N
MU/kg NNP N
) ) N
for IN N
three CD N
consecutive JJ N
days NNS N
. . N

The DT N
placebo NN i
group NN N
received VBD N
daily JJ N
injections NNS N
of IN N
saline NN i
without IN N
IFN NNP N
. . N

Both DT N
groups NNS N
of IN N
animals NNS N
received VBN N
individual JJ N
supportive JJ N
treatment NN N
consisting VBG N
of IN N
adjusted VBN N
diet NN N
and CC N
electrolyte JJ N
solution NN N
. . N

All DT N
five CD N
dogs NNS N
in IN N
the DT N
placebo NN N
group NN N
developed VBD N
fulminating VBG o
enteritis NN o
with IN o
typical JJ o
clinical JJ o
signs NNS o
and CC o
died VBD o
within IN N
10 CD N
days NNS N
post-inoculation NN N
( ( N
or CC N
6 CD N
days NNS N
post-treatment JJ N
) ) N
. . N

In IN N
the DT N
IFN-treated NNP N
group NN N
, , N
one CD N
animal NN N
died VBD o
on IN N
day NN N
2 CD N
after IN N
the DT N
treatment NN N
was VBD N
started VBN N
, , N
whereas IN N
the DT N
other JJ N
four CD N
dogs NNS N
survived VBD o
the DT N
challenge NN N
and CC N
gradually RB N
recovered VBN o
. . o

Our PRP$ N
data NNS N
confirm VBP N
that IN N
the DT N
rFeIFN-omega JJ i
can MD N
exert VB N
a DT N
significant JJ N
therapeutic JJ N
effect NN N
on IN N
dogs NNS p
with IN p
parvoviral JJ p
enteritis NN p
by IN N
improving VBG N
clinical JJ N
signs NNS N
and CC N
reducing VBG N
mortality NN N
. . N

-DOCSTART- -22768793- O O

Reaching VBG N
out RP N
, , N
inviting VBG N
back RB N
: : N
using VBG N
Interactive NNP i
voice NN i
response NN i
( ( i
IVR NNP i
) ) i
technology NN i
to TO N
recycle VB N
relapsed JJ p
smokers NNS p
back RB N
to TO N
Quitline NNP i
treatment NN i
-- : i
a DT i
randomized JJ N
controlled JJ N
trial NN N
. . N

BACKGROUND NNP N
Tobacco NNP N
dependence NN N
is VBZ N
a DT N
chronic JJ N
, , N
relapsing VBG N
condition NN N
that WDT N
typically RB N
requires VBZ N
multiple JJ N
quit NN N
attempts NNS N
and CC N
extended VBD N
treatment NN N
. . N

When WRB N
offered VBD N
the DT N
opportunity NN N
, , N
relapsed VBN N
smokers NNS N
are VBP N
interested JJ N
in IN N
recycling VBG N
back RB N
into IN N
treatment NN N
for IN N
a DT N
new JJ N
, , N
assisted VBN N
quit NN N
attempt NN N
. . N

This DT N
manuscript NN N
presents VBZ N
the DT N
results NNS N
of IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
testing VBG N
the DT N
efficacy NN N
of IN N
interactive JJ i
voice NN i
response NN i
( ( i
IVR NNP i
) ) i
in IN N
recycling VBG N
low JJ p
income NN p
smokers NNS p
who WP p
had VBD p
previously RB p
used VBN p
quitline NN i
( ( i
QL NNP i
) ) i
support NN i
back RB N
to TO N
QL NNP N
support NN N
for IN N
a DT N
new JJ N
quit NN N
attempt NN N
. . N

METHODS NNP N
A NNP p
sample NN p
of IN p
2985 CD p
previous JJ p
QL NNP p
callers NNS p
were VBD N
randomized VBN N
to TO N
either DT N
receive JJ N
IVR NNP i
screening NN i
for IN i
current JJ i
smoking NN i
( ( i
control VB i
group NN i
) ) i
or CC N
IVR NNP i
screening VBG i
plus CC i
an DT i
IVR NNP i
intervention NN i
. . i

The DT N
IVR NNP i
intervention NN i
consists VBZ N
of IN N
automated JJ N
questions NNS N
to TO N
identify VB N
and CC N
address VB N
barriers NNS N
to TO N
re-cycling NN N
in IN N
QL NNP N
support NN N
, , N
followed VBN N
by IN N
an DT N
offer NN N
to TO N
be VB N
transferred VBN N
to TO N
the DT N
QL NNP N
and CC N
reinitiate VB N
treatment NN N
. . N

Re-enrollment JJ N
in IN N
QL NNP N
services NNS N
for IN N
both DT N
groups NNS N
was VBD N
documented VBN N
. . N

RESULTS VB N
The DT N
IVR NNP i
system NN i
successfully RB o
reached VBD o
715 CD N
( ( N
23.9 CD N
% NN N
) ) N
former JJ N
QL NNP N
participants NNS N
. . N

Of IN N
those DT N
, , N
27 CD N
% NN N
( ( N
194/715 CD N
) ) N
reported VBD N
to TO N
the DT N
IVR NNP i
system NN i
that IN N
they PRP N
had VBD N
quit NN o
smoking NN o
and CC N
were VBD N
therefore RB N
excluded VBN N
from IN N
the DT N
study NN N
and CC N
analysis NN N
. . N

The DT N
trial NN N
's POS N
final JJ N
sample NN N
was VBD N
composed VBN N
of IN N
521 CD N
current JJ N
smokers NNS N
. . N

The DT N
re-enrollment JJ o
rate NN o
was VBD N
3.3 CD N
% NN N
for IN N
the DT N
control NN N
group NN N
and CC N
28.2 CD N
% NN N
for IN N
the DT N
intervention NN N
group NN N
( ( N
p JJ N
< NNP N
.001 NNP N
) ) N
. . N

Logistic JJ N
regression NN N
results NNS N
indicated VBD N
an DT N
11.2 CD N
times NNS N
higher JJR N
odds NNS N
for IN N
re-enrollment NN N
of IN N
the DT N
intervention NN N
group NN N
than IN N
the DT N
control NN N
group NN N
( ( N
p JJ N
< NNP N
.001 NNP N
) ) N
. . N

Results NNS o
did VBD o
not RB o
vary JJ o
by IN o
gender NN o
, , o
race NN o
, , o
ethnicity NN o
, , o
or CC o
level NN o
of IN o
education NN o
, , N
however RB N
recycled JJ o
smokers NNS o
were VBD o
older JJR o
( ( N
Mean NNP N
= NNP N
45.2 CD N
; : N
SD NNP N
= NNP N
11.7 CD N
) ) N
than IN N
smokers NNS N
who WP N
declined VBD N
a DT N
new JJ N
treatment NN N
cycle NN N
( ( N
Mean NNP N
= NNP N
41.8 CD N
; : N
SD NNP N
= NNP N
13.2 CD N
) ) N
; : N
( ( N
p VB N
= RB N
0.013 CD N
) ) N
. . N

The DT N
main JJ N
barriers NNS N
reported VBD N
for IN N
not RB N
engaging VBG N
in IN N
a DT N
new JJ N
treatment NN N
cycle NN N
were VBD N
low JJ N
self-efficacy NN o
and CC o
lack NN o
of IN o
interest NN o
in IN N
quitting VBG N
. . N

After IN N
delivering VBG N
IVR NNP i
messages NNS i
targeting VBG N
these DT N
reported VBN N
barriers NNS N
, , N
32 CD N
% NN N
of IN N
the DT N
smokers NNS N
reporting VBG N
low JJ o
self-efficacy NN o
and CC N
4.8 CD N
% NN N
of IN N
those DT N
reporting VBG N
lack NN N
of IN N
interest NN N
in IN N
quitting VBG N
re-engaged JJ N
in IN N
a DT N
new JJ N
QL NNP N
treatment NN N
cycle NN N
. . N

CONCLUSION NNP N
Proactive NNP i
IVR NNP i
outreach NN i
is VBZ N
a DT N
promising JJ N
tool NN N
to TO N
engage VB N
low JJ N
income NN N
, , N
relapsed VBD N
smokers NNS N
back RB N
into IN N
a DT N
new JJ N
cycle NN N
of IN N
treatment NN N
. . N

Integration NN N
of IN N
IVR NNP i
intervention NN N
for IN N
recycling VBG N
smokers NNS p
with IN p
previous JJ p
QL NNP p
treatment NN p
has VBZ N
the DT N
potential JJ N
to TO N
decrease VB N
tobacco-related JJ N
disparities NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
Identifier NNP N
: : N
NCT01260597 NN N
. . N

-DOCSTART- -10356632- O O

Event-related JJ N
potential JJ N
indices NNS N
of IN N
auditory JJ N
selective JJ N
attention NN N
in IN N
dependent JJ p
amphetamine NN p
users NNS p
. . p

BACKGROUND VB N
The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
further JJ N
investigate VB N
a DT N
previously RB N
reported VBN N
attention-related JJ N
impairment NN N
in IN N
dependent JJ p
amphetamine NN p
users NNS p
using VBG N
event-related JJ o
potential NN o
( ( o
ERP NNP o
) ) o
indices NNS o
of IN N
selective JJ N
attention NN N
. . N

METHODS NNP N
ERPs NNP N
were VBD N
recorded VBN N
during IN N
an DT N
auditory JJ i
selective JJ i
attention NN i
task NN i
( ( i
SAT NNP i
) ) i
that WDT N
involved VBD N
detecting VBG N
infrequent JJ N
long-duration NN N
target NN N
tones NNS N
presented VBN N
among IN N
short-duration JJ N
tones NNS N
that WDT N
varied VBD N
in IN N
location NN N
( ( N
left VBN N
vs. RB N
right JJ N
ear NN N
) ) N
and CC N
pitch NN N
( ( N
low JJ N
vs. FW N
high JJ N
) ) N
. . N

Amphetamine JJ p
users NNS p
( ( p
n JJ p
= NNP p
19 CD p
) ) p
were VBD p
divided VBN p
into IN p
two CD p
groups NNS p
, , p
high JJ p
dependence NN p
( ( p
n JJ p
= NNP p
10 CD p
) ) p
and CC p
low JJ p
dependence NN p
( ( p
n JJ p
= NNP p
10 CD p
) ) p
, , p
based VBN p
on IN p
amphetamine JJ p
Severity NNP p
of IN p
Dependence NNP p
Scale NNP p
scores NNS p
, , p
and CC p
compared VBN p
to TO p
an DT p
age-matched JJ p
control NN p
group NN p
( ( p
n JJ p
= NNP p
9 CD p
) ) p
. . p

RESULTS VB N
The DT N
high-dependence NN N
group NN N
showed VBD N
slowed VBN o
reaction NN o
time NN o
and CC N
reduced VBD o
early JJ o
processing NN o
negativity NN o
and CC N
peak NN o
N1 NNP o
amplitude NN o
to TO N
location-relevant JJ N
nontarget NN N
stimuli NN N
. . N

Poor NNP N
performance NN N
on IN N
the DT N
SAT NNP N
was VBD N
highly RB N
correlated VBN N
with IN N
deficits NNS N
in IN N
early JJ N
processing NN N
, , N
which WDT N
were VBD N
also RB N
related VBN N
to TO N
poor JJ N
performance NN N
on IN N
the DT N
Wechsler NNP o
Memory NNP o
Scale NNP o
Attention/Concentration NNP o
index NN o
. . o

CONCLUSIONS VB N
It PRP N
is VBZ N
suggested VBN N
that IN N
severely RB N
dependent JJ p
users NNS p
suffer VBP N
an DT N
inability NN N
to TO N
selectively RB N
enhance VB N
the DT N
sensory JJ N
processing NN N
of IN N
relevant JJ N
auditory JJ N
information NN N
. . N

This DT N
may MD N
produce VB N
poor JJ N
automatic JJ N
preferential NN N
processing NN N
of IN N
relevant JJ N
information NN N
and CC N
increase VB N
load NN N
on IN N
limited JJ N
attentional JJ N
resources NNS N
. . N

-DOCSTART- -22151475- O O

Motion NNP i
style NN i
acupuncture NN i
treatment NN i
( ( i
MSAT NNP i
) ) i
for IN N
acute NN p
low JJ p
back RB p
pain NN p
with IN p
severe JJ p
disability NN p
: : p
a DT N
multicenter NN N
, , N
randomized VBN N
, , N
controlled VBN N
trial NN N
protocol NN N
. . N

BACKGROUND NNP N
Acupuncture NNP N
is VBZ N
widely-used JJ N
to TO N
treat VB N
patients NNS p
with IN p
low JJ p
back RB p
pain NN p
, , N
despite IN N
insufficient JJ N
evidence NN N
of IN N
the DT N
technique NN N
's POS N
efficacy NN N
for IN N
acute NN N
back RB N
pain NN N
. . N

Motion NNP i
style NN i
acupuncture NN i
treatment NN i
( ( i
MSAT NNP i
) ) i
is VBZ N
a DT N
non-traditional JJ N
acupuncture NN N
treatment NN N
requiring VBG N
a DT N
patient NN N
to TO N
exercise VB N
while IN N
receiving VBG N
acupuncture NN N
. . N

In IN p
Korea NNP p
, , N
MSAT NNP N
is VBZ N
used VBN N
to TO N
reduce VB N
musculoskeletal JJ N
pain NN N
and CC N
improve VB N
functional JJ N
status NN N
. . N

The DT N
study NN N
aims VBZ N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
MSAT NNP N
on IN N
acute NN N
low JJ N
back RB N
pain NN N
with IN N
severe JJ N
disability NN N
. . N

METHODS/DESIGN NNP N
This DT N
study NN N
is VBZ N
a DT N
multicenter NN N
, , N
randomized VBN N
, , N
active-controlled JJ N
trial NN N
with IN N
two CD N
parallel JJ N
arms NNS N
. . N

Participants NNS p
with IN p
acute NN p
low JJ p
back RB p
pain NN p
and CC p
severe JJ p
functional JJ p
disability NN p
, , p
defined VBD p
as IN p
an DT p
Oswestry NNP p
Disability NNP p
Index NNP p
( ( p
ODI NNP p
) ) p
value NN p
> $ p
60 CD p
% NN p
, , N
will MD N
be VB N
randomly RB N
allocated VBN N
to TO N
the DT N
acupuncture NN i
group NN i
and CC i
the DT i
nonsteroidal JJ i
anti-inflammatory JJ i
drug NN i
( ( i
NSAID NNP i
) ) i
injection NN i
group NN i
. . i

The DT N
acupuncture NN N
group NN N
will MD N
receive VB N
MSAT NNP i
and CC i
the DT i
NSAID NNP i
injection NN i
group NN i
will MD N
receive VB N
an DT N
intramuscular JJ N
injection NN N
of IN N
diclofenac NN i
. . i

All DT N
procedures NNS N
will MD N
be VB N
limited VBN N
to TO N
one CD N
session NN N
and CC N
the DT N
symptoms NNS N
before IN N
and CC N
after IN N
treatment NN N
will MD N
be VB N
measured VBN N
by IN N
assessors NNS N
blinded VBD N
to TO N
treatment NN N
allocation NN N
. . N

The DT N
primary JJ N
outcome NN N
will MD N
be VB N
measured VBN N
at IN N
30 CD N
minutes NNS N
after IN N
treatment NN N
using VBG N
the DT N
numerical JJ o
rating NN o
scale NN o
( ( o
NRS NNP o
) ) o
of IN o
low JJ o
back RB o
pain NN o
while IN o
the DT o
patient NN o
is VBZ o
moving VBG o
. . o

Secondary JJ N
outcomes NNS N
will MD N
be VB N
measured VBN N
at IN N
30 CD N
minutes NNS N
after IN N
treatment NN N
using VBG N
the DT N
NRS NNP o
of IN o
leg NN o
pain NN o
, , o
ODI NNP o
, , o
patient NN o
global JJ o
impression NN o
of IN o
change NN o
, , o
range NN o
of IN o
motion NN o
( ( o
ROM NNP o
) ) o
of IN o
the DT o
lumbar NN o
spine NN o
, , o
and CC o
degrees NNS o
of IN o
straight JJ o
leg NN o
raising VBG o
( ( o
SLR NNP o
) ) o
. . o

Post-treatment JJ N
follow-up NN N
will MD N
be VB N
performed VBN N
to TO N
measure VB N
primary JJ N
and CC N
secondary JJ N
outcomes NNS N
with IN N
the DT N
exception NN N
of IN N
ROM NNP o
and CC o
SLR NNP o
at IN N
2 CD N
, , N
4 CD N
, , N
and CC N
24 CD N
weeks NNS N
after IN N
treatment NN N
. . N

DISCUSSION NNP N
The DT N
results NNS N
of IN N
this DT N
trial NN N
will MD N
be VB N
discussed VBN N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrial.gov NNP N
NCT01315561 NNP N
. . N

-DOCSTART- -23980121- O O

Aftermath NN N
of IN N
a DT N
clinical JJ N
trial NN N
: : N
evaluating VBG N
the DT N
sustainability NN N
of IN N
a DT N
medical JJ i
device NN i
intervention NN i
in IN p
Ghana NNP p
. . p

A NNP N
randomized VBD N
controlled VBN N
trial NN N
recently RB N
demonstrated VBD N
that IN N
continuous JJ i
positive JJ i
airway NN i
pressure NN i
( ( p
CPAP NNP p
) ) p
effectively RB p
decreases VBZ p
respiratory JJ o
rate NN o
in IN p
children NNS p
presenting VBG p
to TO p
Ghanaian NNP p
district NN p
hospitals NNS p
with IN p
respiratory NN p
distress NN p
. . p

A DT N
follow-up JJ N
study NN N
16 CD N
months NNS N
later RB N
evaluated VBD N
the DT N
extent NN N
to TO N
which WDT N
the DT N
skills NNS N
and CC N
equipment NN N
necessary JJ N
for IN N
CPAP NNP N
use NN N
have VBP N
been VBN N
maintained VBN N
. . N

Seven NNP N
of IN N
eight CD N
CPAP NNP N
machines NNS N
were VBD N
functional JJ N
, , N
but CC N
five CD N
of IN N
eight CD N
oxygen NN N
concentrators NNS N
and CC N
three CD N
of IN N
four CD N
electric JJ N
generators NNS N
were VBD N
non-functional JJ N
. . N

Nurses NNS p
trained VBN p
by IN p
US NNP p
study NN p
personnel NNS p
( ( p
first-generation NN p
) ) p
and CC p
nurses NNS p
trained VBN p
by IN p
Ghanaian JJ p
nurses NNS p
after IN p
the DT p
study NN p
( ( p
second-generation NN p
) ) p
were VBD p
evaluated VBN p
on IN p
CPAP NNP p
knowledge NN p
and CC p
skills NNS p
. . p

Twenty-eight JJ p
nurses NNS p
participated VBN p
in IN p
the DT p
study NN p
, , p
9 CD p
first-generation NN p
and CC p
19 CD p
second-generation NN p
. . p

First-generation NN N
trainees NNS N
scored VBD N
significantly RB N
higher JJR N
than IN N
second-generation NN N
trainees NNS N
on IN N
both DT N
skills NNS o
and CC o
knowledge NN o
assessments NNS o
( ( N
p JJ N
= NNP N
0.003 CD N
) ) N
. . N

Appropriate NNP N
technical JJ N
support NN N
and CC N
training NN N
must MD N
be VB N
ensured VBN N
to TO N
address VB N
equipment NN N
maintenance NN N
. . N

Protocolization NN N
of IN N
the DT N
training NN N
program NN N
, , N
in IN N
conjunction NN N
with IN N
skills NNS o
and CC o
knowledge NN o
assessment NN N
, , N
may MD N
improve VB N
acquisition NN o
and CC o
retention NN o
among IN N
second- JJ N
and CC N
future-generation JJ N
trainees NNS N
. . N

-DOCSTART- -24928832- O O

A DT N
randomized VBN N
, , N
phase VB N
II NNP N
study NN N
of IN N
afatinib JJ N
versus NN N
cetuximab NN N
in IN N
metastatic JJ p
or CC p
recurrent JJ p
squamous JJ p
cell NN p
carcinoma NN p
of IN p
the DT p
head NN p
and CC p
neck NN p
. . p

BACKGROUND NNP N
Afatinib NNP N
is VBZ N
an DT N
oral JJ N
, , N
irreversible JJ N
ErbB NNP N
family NN N
blocker NN N
that WDT N
has VBZ N
shown VBN N
activity NN N
in IN N
epidermal JJ N
growth NN N
factor NN N
receptor NN N
( ( N
EGFR NNP N
) ) N
-mutated VBD N
lung NN N
cancer NN N
. . N

We PRP N
hypothesized VBD N
that IN N
the DT N
agent NN N
would MD N
have VB N
greater JJR N
antitumor NN o
activity NN o
compared VBN N
with IN N
cetuximab NN N
in IN N
recurrent NN p
or CC p
metastatic JJ p
( ( p
R/M NNP p
) ) p
head NN p
and CC p
neck NN p
squamous JJ p
cell NN p
carcinoma NN p
( ( p
HNSCC NNP p
) ) p
patients NNS p
, , p
whose WP$ p
disease NN p
has VBZ p
progressed VBN p
after IN p
platinum-containing JJ p
therapy NN p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
An DT N
open-label JJ N
, , N
randomized VBN N
, , N
phase VB N
II NNP N
trial NN N
was VBD N
conducted VBN N
in IN N
43 CD p
centers NNS p
; : p
124 CD p
patients NNS p
were VBD N
randomized VBN i
( ( i
1 CD i
: : i
1 CD i
) ) i
to TO i
either DT i
afatinib NN i
( ( i
50 CD i
mg/day NN i
) ) i
or CC i
cetuximab NN i
( ( i
250 CD i
mg/m NN i
( ( i
2 CD i
) ) i
/week NN i
) ) i
until IN i
disease JJ i
progression NN i
or CC i
intolerable JJ i
adverse JJ i
events NNS i
( ( i
AEs NNP i
) ) i
( ( i
stage NN i
I PRP i
) ) i
, , i
with IN i
optional JJ i
crossover NN i
( ( i
stage JJ i
II NNP i
) ) i
. . i

The DT N
primary JJ N
end NN N
point NN N
was VBD N
tumor JJ o
shrinkage NN o
before IN o
crossover NN o
assessed VBN o
by IN o
investigator NN o
( ( o
IR NNP o
) ) o
and CC o
independent JJ o
central JJ o
review NN o
( ( o
ICR NNP o
) ) o
. . o

RESULTS VB N
A DT p
total NN p
of IN p
121 CD p
patients NNS p
were VBD p
treated VBN p
( ( p
61 CD p
afatinib NN p
, , p
60 CD p
cetuximab NN p
) ) p
and CC p
68 CD p
crossed VBN p
over IN p
to TO p
stage VB p
II NNP p
( ( p
32 CD p
and CC p
36 CD p
respectively RB p
) ) p
. . p

In IN N
stage NN N
I PRP N
, , N
mean JJ o
tumor NN o
shrinkage NN o
by IN o
IR/ICR NNP o
was VBD N
10.4 CD N
% NN N
/16.6 CD N
% NN N
with IN N
afatinib NN N
and CC N
5.4 CD N
% NN N
/10.1 CD N
% NN N
with IN N
cetuximab NN N
( ( N
P NNP N
= NNP N
0.46/0.30 CD N
) ) N
. . N

Objective JJ o
response NN o
rate NN o
was VBD N
16.1 CD N
% NN N
/8.1 CD N
% NN N
with IN N
afatinib NN N
and CC N
6.5 CD N
% NN N
/9.7 CD N
% NN N
with IN N
cetuximab NN N
( ( N
IR/ICR NNP N
) ) N
. . N

Comparable JJ o
disease NN o
control NN o
rates NNS o
were VBD N
observed VBN N
with IN N
afatinib NN N
( ( N
50 CD N
% NN N
) ) N
and CC N
cetuximab NN N
( ( N
56.5 CD N
% NN N
) ) N
by IN N
IR NNP N
; : N
similar JJ N
results NNS N
were VBD N
seen VBN N
by IN N
ICR NNP N
. . N

Most JJS N
common JJ N
grade NN N
?3 JJ o
drug-related JJ o
AEs NNP o
( ( o
DRAEs NNP N
) ) N
were VBD o
rash/acne VBN o
( ( o
18 CD N
% NN N
versus IN N
8.3 CD o
% NN o
) ) o
, , o
diarrhea NN o
( ( o
14.8 CD N
% NN N
versus IN N
0 CD N
% NN N
) ) N
, , N
and CC o
stomatitis/mucositis NN o
( ( o
11.5 CD N
% NN N
versus IN N
0 CD N
% NN N
) ) N
with IN N
afatinib NN N
and CC N
cetuximab NN N
, , N
respectively RB N
. . N

Patients NNS N
with IN o
DRAEs NNP o
leading VBG o
to TO o
treatment NN o
discontinuation NN o
were VBD o
23 CD N
% NN N
with IN N
afatinib NN N
and CC N
5 CD N
% NN N
with IN N
cetuximab NN N
. . N

In IN N
stage NN N
II NNP N
, , o
disease VB o
control NN o
rate NN o
( ( o
IR/ICR NNP o
) ) o
was VBD o
38.9 CD N
% NN N
/33.3 CD N
% NN N
with IN N
afatinib NN N
and CC N
18.8 CD N
% NN N
/18.8 CD N
% NN N
with IN N
cetuximab NN N
. . N

CONCLUSION NNP N
Afatinib NNP N
showed VBD o
antitumor JJ o
activity NN o
comparable JJ o
to TO N
cetuximab VB N
in IN N
R/M NNP p
HNSCC NNP p
in IN p
this DT N
exploratory JJ N
phase NN N
II NNP N
trial NN N
, , N
although IN N
more JJR N
patients NNS N
on IN N
afatinib JJ N
discontinued VBN N
treatment NN N
due JJ N
to TO N
AEs NNP N
. . N

Sequential NNP N
EGFR/ErbB NNP N
treatment NN N
with IN N
afatinib NN N
and CC N
cetuximab NN N
provided VBD N
sustained JJ o
clinical JJ o
benefit NN o
in IN o
patients NNS N
after IN N
crossover NN N
, , N
suggesting VBG N
a DT N
lack NN N
of IN N
cross-resistance NN N
. . N

-DOCSTART- -16981901- O O

Lack NN N
of IN N
a DT N
pharmacokinetic JJ o
interaction NN o
between IN N
steady-state JJ N
roflumilast NN i
and CC N
single-dose JJ N
midazolam NN i
in IN N
healthy JJ p
subjects NNS p
. . p

AIMS IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
roflumilast NN i
, , N
an DT N
investigational JJ N
PDE4 NNP N
inhibitor NN N
for IN N
the DT N
treatment NN N
of IN N
COPD NNP N
and CC N
asthma RB N
, , N
on IN N
the DT N
pharmacokinetics NNS o
of IN o
the DT o
CYP3A NNP o
probe NN o
drug NN N
midazolam NN i
and CC N
its PRP$ N
major JJ N
metabolites NNS N
. . N

METHODS NNP N
In IN N
an DT N
open JJ N
, , N
randomized VBN N
( ( N
for IN N
midazolam NN i
treatment NN N
sequence NN N
) ) N
study NN N
, , N
18 CD p
healthy JJ p
male NN p
subjects NNS p
received VBD N
single JJ N
doses NNS N
of IN N
midazolam NN i
( ( N
2 CD N
mg RB N
oral JJ N
and CC N
1 CD N
mg NN N
i.v. NN N
, , N
1 CD N
day NN N
apart RB N
) ) N
alone RB N
, , N
repeated VBD N
doses NNS N
of IN N
roflumilast NN i
( ( N
500 CD N
microg NN N
once RB N
daily JJ N
for IN N
14 CD N
days NNS N
) ) N
alone RB N
, , N
and CC N
repeated VBD N
doses NNS N
of IN N
roflumilast NN i
together RB i
with IN i
single JJ i
doses NNS i
of IN i
midazolam NN i
( ( N
2 CD N
mg RB N
oral JJ N
and CC N
1 CD N
mg NN N
i.v. NN N
, , N
1 CD N
day NN N
apart RB N
) ) N
. . N

RESULTS VB N
A DT N
comparison NN N
of IN N
clearance NN o
and CC o
peak NN o
and CC o
systemic JJ o
exposure NN o
to TO N
midazolam VB N
following VBG N
administration NN N
of IN N
roflumilast NN N
indicated JJ N
no DT N
effect NN N
of IN N
roflumilast NN N
dosed VBN N
to TO N
steady JJ N
state NN N
on IN N
the DT N
pharmacokinetics NNS o
of IN o
midazolam NN o
. . o

Point NN N
estimates NNS N
( ( N
90 CD N
% NN N
CI NNP N
) ) N
were VBD N
0.97 CD N
( ( N
0.84 CD N
, , N
1.13 CD N
) ) N
for IN N
the DT N
AUC NNP N
of IN N
i.v NN N
. . N

midazolam NN N
and CC N
0.98 CD N
( ( N
0.82 CD N
, , N
1.17 CD N
) ) N
for IN N
that DT N
of IN N
oral JJ N
midazolam NN N
with IN N
and CC N
without IN N
roflumilast NN N
. . N

CONCLUSIONS NNP N
Therapeutic NNP N
steady JJ N
state NN N
concentrations NNS N
of IN N
roflumilast NN N
and CC N
its PRP$ N
N-oxide NNP N
do NN N
not RB N
alter VB N
the DT N
disposition NN o
of IN o
the DT o
CYP3A NNP o
substrate NN o
midazolam NN o
in IN N
healthy JJ p
subjects NNS p
. . p

This DT N
finding NN N
suggests VBZ N
that IN N
roflumilast NN N
is VBZ N
unlikely JJ N
to TO N
alter VB N
the DT N
clearance NN N
of IN N
drugs NNS N
that WDT N
are VBP N
metabolized VBN N
by IN N
CYP3A4 NNP N
. . N

-DOCSTART- -7831455- O O

Scales NNS N
for IN N
the DT N
assessment NN N
of IN N
neuroleptic JJ o
response NN o
in IN N
schizophrenic JJ p
children NNS p
: : p
specific JJ N
measures NNS N
derived VBN N
from IN N
the DT N
CPRS NNP N
. . N

This DT N
article NN N
reports VBZ N
the DT N
psychometric JJ N
properties NNS N
of IN N
two CD N
scales NNS N
for IN N
rating NN N
positive JJ N
and CC N
negative JJ N
schizophrenic JJ N
signs NNS N
and CC N
symptoms NNS N
. . N

These DT N
Positive NNP o
and CC o
Negative NNP o
Syndrome NNP o
Scales NNP o
consist NN N
of IN N
items NNS N
selected VBN N
from IN N
the DT N
Children NNP N
's POS N
Psychiatric NNP N
Rating NNP N
Scale NNP N
( ( N
CPRS NNP N
) ) N
, , N
which WDT N
contains VBZ N
items NNS N
covering VBG N
a DT N
wide JJ N
range NN N
of IN N
childhood NN N
psychopathology NN N
. . N

CPRS NNP N
rating NN N
data NNS N
were VBD N
analyzed VBN N
for IN N
19 CD p
schizophrenic JJ p
children NNS p
, , p
16 CD p
males NNS p
and CC p
3 CD p
females NNS p
, , p
mean JJ p
age NN p
8.9 CD p
years NNS p
( ( p
range VB p
5.5-11.7 NNP p
) ) p
, , N
evaluated VBN N
in IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ i
crossover NN N
study NN N
of IN N
haloperidol NN i
. . i

We PRP N
describe VBP N
the DT N
item NN N
composition NN N
and CC N
coherence NN N
of IN N
each DT N
scale NN N
, , N
the DT N
interrater NN N
reliabilities NNS N
of IN N
clinicians NNS N
using VBG N
the DT N
scales NNS N
, , N
and CC N
the DT N
sensitivity NN N
of IN N
the DT N
scales NNS N
for IN N
resolving VBG N
treatment NN N
response NN N
. . N

Schizophrenic JJ p
children NNS p
showed VBD N
both DT N
positive JJ o
and CC o
negative JJ o
signs NNS o
and CC o
symptoms NNS o
, , N
and CC N
both DT N
improved VBN N
with IN N
neuroleptic JJ o
treatment NN o
. . o

-DOCSTART- -7205145- O O

An DT N
evaluation NN N
method NN N
providing VBG N
confidence NN N
intervals NNS N
applied VBD N
to TO N
radioimmunoassay VB i
. . i

A DT N
method NN N
for IN N
evaluation NN i
of IN i
radioimmunoassay NN i
results NNS N
is VBZ N
described VBN N
. . N

The DT N
order NN N
of IN N
the DT N
single JJ i
tubes NNS i
in IN N
each DT N
assay NN N
run NN N
is VBZ N
randomized VBN N
. . N

A DT N
polynomial NN N
is VBZ N
fitted VBN N
to TO N
untransformed JJ N
data NNS N
( ( N
y JJ N
= NN N
counts NNS N
per IN N
minute NN N
; : N
x CC N
= JJ N
concentration NN N
of IN N
curve.A JJ N
confidence NN N
interval NN N
is VBZ N
calculated VBN N
for IN N
each DT N
sample NN N
, , N
taking VBG N
into IN N
account NN N
the DT N
variance NN N
of IN N
the DT N
standard JJ N
curve NN N
and CC N
that IN N
of IN N
the DT N
actual JJ N
duplicate NN N
assay NN N
jointly RB N
. . N

-DOCSTART- -21669583- O O

A DT N
simple JJ N
meal NN i
plan NN i
of IN i
'eating VBG i
vegetables NNS i
before IN i
carbohydrate NN i
' '' i
was VBD N
more RBR N
effective JJ N
for IN N
achieving VBG N
glycemic JJ o
control NN o
than IN N
an DT N
exchange-based JJ i
meal NN i
plan NN i
in IN N
Japanese JJ p
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
. . p

This DT N
study NN N
aimed VBD N
to TO N
determine VB N
whether IN N
educating VBG N
diabetic JJ N
patients NNS N
to TO N
'eat VB i
vegetables NNS i
before IN i
carbohydrate NN i
' '' i
was VBD N
as IN N
effective JJ N
on IN N
long-term JJ o
glycemic JJ o
control NN o
as IN N
a DT N
traditional JJ N
exchange-based JJ N
meal NN N
plan NN N
. . N

To TO N
test VB N
this DT N
hypothesis NN N
, , N
we PRP N
carried VBD N
out RP N
a DT N
randomized NN N
, , N
controlled VBN N
trial NN N
in IN N
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
that IN N
compared VBN N
changes NNS o
in IN o
HbA1c NNP o
as IN N
the DT N
primary JJ N
outcome NN N
. . N

A DT p
total NN p
of IN p
101 CD p
patients NNS p
were VBD p
stratified VBN p
according VBG p
to TO p
sex NN p
, , p
age NN p
, , p
BMI NNP p
, , p
duration NN p
of IN p
diabetes NNS p
, , p
and CC p
HbA1c NNP p
, , N
and CC N
then RB N
randomized VBN N
to TO N
receive VB N
instructions NNS N
to TO N
eat VB N
either DT N
vegetables NNS i
before IN i
carbohydrate NN i
( ( N
VBC NNP N
, , N
n=69 NN N
) ) N
or CC N
an DT N
exchange-based JJ i
meal NN i
plan NN i
( ( N
EXB NNP N
, , N
n=32 NN N
) ) N
. . N

The DT N
impact NN o
of IN o
the DT o
two CD o
plans NNS o
on IN o
glycemic JJ o
control NN o
was VBD N
compared VBN N
over IN N
24 CD N
months NNS N
of IN N
follow-up NN N
. . N

Significant JJ N
improvements NNS o
in IN o
HbA1c NNP o
over IN N
24 CD N
months NNS N
were VBD N
observed VBN N
in IN N
both DT N
groups NNS N
( ( N
VBC NNP N
, , N
8.3 CD N
to TO N
6.8 CD N
% NN N
vs NN N
EXB NNP N
, , N
8.2 CD N
to TO N
7.3 CD N
% NN N
) ) N
. . N

HbA1c NNP o
levels NNS o
were VBD o
significantly RB o
lower JJR o
in IN N
the DT N
VBC NNP N
group NN N
than IN N
in IN N
the DT N
EXB NNP N
group NN N
after IN N
6 CD N
, , N
9 CD N
, , N
12 CD N
and CC N
24 CD N
months NNS N
of IN N
the DT N
study NN N
. . N

Both DT N
groups NNS N
exhibited VBD N
similar JJ o
improvements NNS o
in IN o
dietary JJ o
practices NNS o
with IN N
respect NN N
to TO N
intake VB N
of IN N
carbohydrate NN N
, , N
fats NNS N
and CC N
sweets NNS N
, , N
while IN N
the DT N
VBC NNP N
group NN N
had VBD N
a DT N
significant JJ N
increase NN o
in IN N
consumption NN o
of IN o
green JJ o
vegetables NNS o
and CC N
a DT N
significant JJ N
decrease NN o
in IN o
fruit NN o
consumption NN o
. . o

A DT N
simple JJ N
meal NN i
plan NN i
of IN i
'eating VBG i
vegetables NNS i
before IN i
carbohydrate NN i
' '' i
achieved VBN N
better RBR o
glycemic JJ o
control NN o
than IN N
an DT N
exchange-based JJ N
meal NN N
plan NN N
in IN N
Japanese JJ p
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
over IN N
a DT N
24-month JJ N
period NN N
. . N

-DOCSTART- -17572835- O O

Effect NN N
of IN N
low-intensity NN i
back RB i
exercise NN i
on IN N
quality NN o
of IN o
life NN o
and CC o
back RB o
extensor JJ o
strength NN o
in IN N
patients NNS p
with IN p
osteoporosis NN p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

UNLABELLED NNP N
Randomized NNP N
controlled VBD N
study NN N
in IN N
80 CD p
postmenopausal JJ p
women NNS p
with IN p
osteoporosis NN p
was VBD N
conducted VBN N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
a DT N
home-based JJ i
, , i
simple JJ i
, , i
low-intensity JJ i
exercise NN i
. . i

Low-intensity JJ i
back-strengthening JJ i
exercise NN i
was VBD N
effective JJ N
in IN N
improving VBG N
the DT N
quality NN o
of IN o
life NN o
and CC o
back RB o
extensor JJ o
strength NN o
. . o

INTRODUCTION NNP N
AND CC N
HYPOTHESIS NNP N
Back-strengthening NNP N
exercise NN N
is VBZ N
effective JJ N
in IN N
increasing VBG o
back RB o
extensor NN o
strength NN o
and CC N
decreasing VBG o
risk NN o
of IN o
vertebral JJ o
fractures NNS o
. . o

We PRP N
hypothesized VBD N
that IN N
a DT N
home-based JJ N
, , N
simple JJ N
, , N
low-intensity JJ N
exercise NN N
could MD N
enhance VB o
back RB o
extensor JJ o
strength NN o
and CC o
improve VB o
the DT o
quality NN o
of IN o
life NN o
and/or IN N
spinal JJ o
range NN o
of IN o
motion NN o
in IN N
postmenopausal JJ p
women NNS p
in IN N
a DT N
short-term JJ N
follow-up NN N
. . N

METHODS NNP N
Eighty NNP p
postmenopausal JJ p
women NNS p
with IN p
osteoporosis NN p
were VBD p
randomly RB p
assigned VBN p
to TO p
a DT p
control NN i
group NN i
( ( p
n JJ p
= NNP p
38 CD p
) ) p
or CC p
an DT p
exercise NN i
group NN i
( ( p
n JJ p
= NNP p
42 CD p
) ) p
. . p

Subjects NNS N
were VBD N
instructed VBN N
to TO N
lift VB N
their PRP$ N
upper JJ N
trunk NN N
from IN N
a DT N
prone NN N
position NN N
antigravity NN N
and CC N
maintain VB N
the DT N
neutral JJ N
position NN N
. . N

Isometric NNP o
back RB o
extensor NN o
strength NN o
, , o
spinal JJ o
range NN o
of IN o
motion NN o
, , o
and CC o
scores NNS o
for IN o
quality NN o
of IN o
life NN o
were VBD N
evaluated VBN N
at IN N
baseline NN N
and CC N
4 CD N
months NNS N
. . N

RESULTS NNP N
Back NNP o
extensor NN o
strength NN o
significantly RB o
increased VBD o
both DT N
in IN N
the DT N
exercise NN N
group NN N
( ( N
26 CD N
% NN N
) ) N
and CC N
in IN N
the DT N
control NN N
group NN N
( ( N
11 CD N
% NN N
) ) N
. . N

Scores NNS o
for IN o
quality NN o
of IN o
life NN o
increased VBN o
in IN N
the DT N
exercise NN N
group NN N
( ( N
7 CD N
% NN N
) ) N
, , N
whereas IN N
it PRP N
remained VBD N
unchanged JJ N
in IN N
the DT N
control NN N
group NN N
( ( N
0 CD N
% NN N
) ) N
. . N

There EX N
was VBD N
a DT N
significant JJ N
difference NN N
in IN N
quality NN o
of IN o
life NN o
score NN o
between IN N
the DT N
groups NNS N
( ( N
p JJ N
= NNP N
0.012 CD N
) ) N
. . N

CONCLUSIONS JJ N
Low-intensity JJ N
back-strengthening NN N
exercise NN N
was VBD N
effective JJ o
in IN o
improving VBG o
the DT o
quality NN o
of IN o
life NN o
and CC o
back RB o
extensor JJ o
strength NN o
in IN N
patients NNS p
with IN p
osteoporosis NN p
. . p

-DOCSTART- -17316832- O O

Ciprofloxacin/dexamethasone NNP i
drops VBZ N
decrease VB N
the DT N
incidence NN N
of IN N
physician JJ N
and CC N
patient JJ N
outcomes NNS N
of IN N
otorrhea NN o
after IN N
tube JJ N
placement NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
ciprofloxacin JJ i
0.3 CD i
% NN i
/dexamethasone CD i
0.1 CD N
% NN N
( ( N
CIPRODEX NNP N
, , N
Alcon NNP N
, , N
Ft. NNP N
Worth NNP N
, , N
TX NNP N
) ) N
for IN N
the DT N
prevention NN N
of IN N
early JJ N
post-operative JJ N
otorrhea NN N
following VBG N
TT NNP N
placement NN N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
single-center JJ N
, , N
randomized VBN N
, , N
evaluator-blinded JJ N
, , N
parallel-group JJ N
study NN N
. . N

Two CD p
hundred VBD p
children NNS p
undergoing VBG p
bilateral JJ p
TT NNP p
placement NN p
were VBD p
categorized VBN p
as IN p
having VBG p
unilateral JJ p
( ( p
wet/dry JJ p
) ) p
, , p
bilateral JJ p
( ( p
wet/wet NN p
) ) p
, , p
or CC p
no DT p
( ( p
dry/dry NN p
) ) p
effusion NN p
at IN p
the DT p
time NN p
of IN p
surgery NN p
. . p

All DT N
patients NNS N
received VBD N
Ciprodex NNP i
or CC i
no DT i
treatment NN i
for IN i
5 CD i
days NNS i
post-operatively RB i
and CC N
returned VBN N
at IN N
2 CD N
weeks NNS N
. . N

RESULTS NNP N
Physician-observed JJ o
otorrhea NN o
was VBD N
reported VBN N
in IN N
5 CD N
( ( N
4.95 CD N
% NN N
) ) N
patients NNS N
receiving VBG N
Ciprodex NNP N
and CC N
39 CD N
( ( N
39.39 CD N
% NN N
) ) N
patients NNS N
receiving VBG N
no DT N
treatment NN N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

Treatment NN N
decreased VBD N
otorrhea NNS o
in IN N
all DT N
groups NNS N
, , N
while IN N
the DT N
greatest JJS N
benefit NN N
was VBD N
observed VBN N
in IN N
patients NNS N
with IN N
bilateral JJ N
effusion NN N
( ( N
93 CD N
% NN N
reduction NN N
) ) N
. . N

Ciprodex NNP N
treatment NN N
also RB N
decreased VBD N
the DT N
rate NN o
of IN o
clinically RB o
diagnosed VBN o
otitis NN o
media NNS o
( ( o
OM NNP o
) ) o
and CC o
effusion NN o
following VBG N
TT NNP N
placement NN N
( ( N
p JJ N
< NN N
or CC N
=0.0006 NN N
) ) N
. . N

CONCLUSION NNP N
Ciprodex NNP N
reduced VBD N
early JJ o
post-operative JJ o
otorrhea NN o
, , o
clinically RB o
diagnosed VBN o
OM NNP o
and CC N
effusion NN o
following VBG N
TT NNP N
insertion NN N
. . N

The DT N
greatest JJS N
reduction NN N
in IN N
otorrhea NN o
was VBD N
observed VBN N
in IN N
patients NNS p
with IN p
bilateral JJ p
effusion NN p
at IN p
the DT p
time NN p
of IN p
surgery NN p
. . p

-DOCSTART- -23566237- O O

Successful JJ N
treatment NN N
of IN N
depressed JJ p
, , p
distensible JJ p
acne NN p
scars NNS p
using VBG N
autologous JJ i
fibroblasts NNS i
: : i
a DT N
multi-site JJ N
, , N
prospective JJ N
, , N
double JJ N
blind NN N
, , N
placebo-controlled JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND VB N
A DT N
previous JJ N
clinical JJ N
trial NN N
evaluating VBG N
autologous JJ i
fibroblasts NNS i
( ( i
human JJ i
dermal NN i
) ) i
injections NNS i
for IN N
the DT N
treatment NN N
of IN N
facial JJ N
contour NN N
deformities NNS N
found VBN N
significantly RB N
greater JJR N
improvements NNS N
in IN N
wrinkle NN o
and CC o
acne NN o
scar NN o
appearance NN o
than IN N
with IN N
placebo JJ i
treatment NN N
. . N

OBJECTIVE UH N
To TO N
compare VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
autologous JJ i
fibroblast JJ i
treatment NN N
of IN N
moderate JJ p
to TO p
severe VB p
, , p
depressed JJ p
, , p
distensible JJ p
facial JJ p
acne NN p
scars NNS p
with IN N
that DT N
of IN N
vehicle NN N
control NN N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
randomized JJ N
multicenter NN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
in IN N
subjects NNS p
with IN p
bilateral JJ p
moderate NN p
to TO p
severe VB p
acne JJ p
scarring NN p
; : p
subjects VBZ N
served VBN N
as IN N
their PRP$ N
own JJ N
controls NNS N
. . N

Skin NNP N
biopsies NNS N
were VBD N
obtained VBN N
from IN N
randomized JJ N
subjects NNS p
for IN N
fibroblast JJ N
production NN N
. . N

Subjects NNS p
( ( p
n JJ p
= NNP p
99 CD p
) ) p
underwent NN N
three CD N
intradermal JJ N
injection NN N
sessions NNS N
with IN N
2 CD i
mL NNS i
of IN i
autologous JJ i
fibroblast JJ i
suspension NN i
( ( N
10-20 CD N
million CD N
cells/mL NN N
) ) N
on IN N
one CD N
cheek NN N
and CC N
vehicle NN i
control NN i
( ( N
cell JJ N
culture NN N
medium NN N
) ) N
on IN N
the DT N
other JJ N
at IN N
14-day JJ N
intervals NNS N
. . N

Efficacy NNP N
was VBD N
based VBN N
on IN N
the DT N
blinded VBN N
subject NN o
's POS o
, , o
evaluator NN o
's POS o
, , o
and CC o
independent JJ o
photographic JJ o
viewer NN o
's POS o
( ( o
IPR NNP o
) ) o
assessment NN o
of IN o
acne NN o
scarring VBG o
1 CD N
to TO N
4 CD N
months NNS N
after IN N
the DT N
last JJ N
treatment NN N
. . N

RESULTS NNP N
Autologous JJ i
fibroblast JJ i
treatment NN i
was VBD N
associated VBN N
with IN N
significantly RB N
greater JJR N
treatment NN N
success NN N
than IN N
vehicle NN N
control NN N
for IN N
the DT N
subject NN N
( ( N
43 CD N
% NN N
vs.18 NN N
% NN N
) ) N
, , N
evaluator NN N
( ( N
59 CD N
% NN N
vs. FW N
2 CD N
% NN N
) ) N
, , N
and CC N
IPR NNP N
assessments NNS N
. . N

Autologous JJ i
fibroblast JJ i
injections NNS i
were VBD N
well RB N
tolerated VBN N
, , N
without IN N
permanent JJ N
adverse JJ N
effects NNS N
. . N

CONCLUSIONS NNP N
Autologous NNP i
fibroblast VBD i
injections NNS i
safely RB N
and CC N
effectively RB N
improved VBD N
the DT N
appearance NN o
of IN o
depressed JJ o
distensible JJ o
acne NN o
scars NNS o
. . o

-DOCSTART- -17388667- O O

A DT N
prospective JJ N
study NN N
of IN N
plasma NN i
vitamin NN i
D NNP i
metabolites VBZ i
, , i
vitamin FW i
D NNP i
receptor NN i
polymorphisms NN i
, , N
and CC N
prostate NN N
cancer NN N
. . N

BACKGROUND NNP N
Vitamin NNP N
D NNP N
insufficiency NN N
is VBZ N
a DT N
common JJ N
public JJ N
health NN N
problem NN N
nationwide NN N
. . N

Circulating VBG N
25-hydroxyvitamin JJ i
D3 NNP i
( ( i
25 CD i
[ NNP i
OH NNP i
] NNP i
D NNP i
) ) i
, , N
the DT N
most RBS N
commonly RB N
used JJ N
index NN N
of IN N
vitamin NN N
D NNP N
status NN N
, , N
is VBZ N
converted VBN N
to TO N
the DT N
active JJ N
hormone NN N
1,25 CD N
dihydroxyvitamin NN N
D3 NNP N
( ( N
1,25 CD N
[ NNP N
OH NNP N
] NNP N
2D CD N
) ) N
, , N
which WDT N
, , N
operating VBG N
through IN N
the DT N
vitamin NN N
D NNP N
receptor NN N
( ( N
VDR NNP N
) ) N
, , N
inhibits VBZ N
in IN N
vitro NN N
cell NN N
proliferation NN N
, , N
induces NNS N
differentiation NN N
and CC N
apoptosis NN N
, , N
and CC N
may MD N
protect VB N
against IN N
prostate JJ N
cancer NN N
. . N

Despite IN N
intriguing JJ N
results NNS N
from IN N
laboratory JJ N
studies NNS N
, , N
previous JJ N
epidemiological JJ N
studies NNS N
showed VBD N
inconsistent JJ N
associations NNS N
of IN N
circulating VBG N
levels NNS N
of IN N
25 CD N
( ( N
OH NNP N
) ) N
D NNP N
, , N
1,25 CD N
( ( N
OH NNP N
) ) N
2D CD N
, , N
and CC N
several JJ N
VDR NNP N
polymorphisms NNS N
with IN N
prostate NN N
cancer NN N
risk NN N
. . N

Few JJ N
studies NNS N
have VBP N
explored VBN N
the DT N
joint JJ N
association NN N
of IN N
circulating VBG N
vitamin JJ N
D NNP N
levels NNS N
with IN N
VDR NNP N
polymorphisms NNS N
. . N

METHODS NNP N
AND CC N
FINDINGS NNP N
During IN N
18 CD N
y NNS N
of IN N
follow-up NN N
of IN N
14,916 CD p
men NNS p
initially RB p
free JJ p
of IN p
diagnosed JJ p
cancer NN p
, , p
we PRP p
identified VBD p
1,066 CD p
men NNS p
with IN p
incident JJ p
prostate NN p
cancer NN p
( ( p
including VBG p
496 CD p
with IN p
aggressive JJ p
disease NN p
, , p
defined VBD p
as IN p
stage NN p
C NNP p
or CC p
D NNP p
, , p
Gleason NNP p
7-10 CD p
, , p
metastatic JJ p
, , p
and CC p
fatal JJ p
prostate NN p
cancer NN p
) ) p
and CC p
1,618 CD p
cancer-free JJ p
, , p
age- JJ p
and CC p
smoking-matched JJ p
control NN p
participants NNS p
in IN p
the DT p
Physicians NNPS p
' POS p
Health NNP p
Study NNP p
. . p

We PRP N
examined VBD N
the DT N
associations NNS N
of IN N
prediagnostic JJ N
plasma NN N
levels NNS N
of IN N
25 CD i
( ( i
OH NNP i
) ) i
D NNP i
and CC N
1,25 CD i
( ( i
OH NNP i
) ) i
2D CD i
, , N
individually RB N
and CC N
jointly RB N
, , N
with IN N
total JJ N
and CC N
aggressive JJ N
disease NN N
, , N
and CC N
explored VBD N
whether IN N
relations NNS N
between IN N
vitamin NN N
D NNP N
metabolites NNS N
and CC N
prostate NN N
cancer NN N
were VBD N
modified VBN N
by IN N
the DT N
functional JJ N
VDR NNP N
FokI NNP N
polymorphism NN N
, , N
using VBG N
conditional JJ N
logistic JJ N
regression NN N
. . N

Among IN N
these DT N
US NNP N
physicians NNS N
, , N
the DT N
median JJ o
plasma NN o
25 CD o
( ( o
OH NNP o
) ) o
D NNP o
levels NNS o
were VBD N
25 CD N
ng/ml NNS N
in IN N
the DT N
blood NN N
samples NNS N
collected VBD N
during IN N
the DT N
winter NN N
or CC N
spring NN N
and CC N
32 CD N
ng/ml NN N
in IN N
samples NNS N
collected VBN N
during IN N
the DT N
summer NN N
or CC N
fall NN N
. . N

Nearly RB N
13 CD N
% NN N
( ( N
summer/fall NN N
) ) N
to TO N
36 CD N
% NN N
( ( N
winter/spring VBG N
) ) N
of IN N
the DT N
control NN N
participants NNS N
were VBD N
deficient JJ N
in IN N
25 CD o
( ( o
OH NNP o
) ) o
D NNP o
( ( N
< JJ N
20 CD N
ng/ml NN N
) ) N
and CC N
51 CD N
% NN N
( ( N
summer/fall NN N
) ) N
and CC N
77 CD N
% NN N
( ( N
winter/spring VBG N
) ) N
had VBD N
insufficient JJ N
plasma NN o
25 CD o
( ( o
OH NNP o
) ) o
D NNP o
levels NNS o
( ( N
< $ N
32 CD N
ng/ml NN N
) ) N
. . N

Plasma NNP o
levels NNS o
of IN o
1,25 CD o
( ( o
OH NNP o
) ) o
2D CD o
did VBD o
not RB N
vary JJ N
by IN N
season NN N
. . N

Men NNP N
whose WP$ N
levels NNS N
for IN N
both DT N
25 CD N
( ( N
OH NNP N
) ) N
D NNP N
and CC N
1,25 CD N
( ( N
OH NNP N
) ) N
2D CD N
were VBD N
below IN N
( ( N
versus IN N
above IN N
) ) N
the DT N
median NN N
had VBD N
a DT N
significantly RB N
increased VBN N
risk NN o
of IN o
aggressive JJ o
prostate NN o
cancer NN o
( ( N
odds NNS N
ratio VBP N
[ CD N
OR NNP N
] NNP N
= POS N
2.1 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
1.2-3.4 JJ N
) ) N
, , N
although IN N
the DT N
interaction NN N
between IN N
the DT N
two CD N
vitamin NN N
D NNP N
metabolites NNS N
was VBD N
not RB N
statistically RB N
significant JJ N
( ( N
pinteraction NN N
= RB N
0.23 CD N
) ) N
. . N

We PRP N
observed VBD N
a DT N
significant JJ N
interaction NN N
between IN N
circulating VBG N
25 CD o
( ( o
OH NNP o
) ) o
D NNP o
levels NNS o
and CC o
the DT o
VDR NNP o
FokI NNP o
genotype NN o
( ( N
pinteraction NN N
< RB N
0.05 CD N
) ) N
. . N

Compared VBN N
with IN N
those DT N
with IN N
plasma JJ o
25 CD o
( ( o
OH NNP o
) ) o
D NNP o
levels NNS o
above IN N
the DT N
median JJ N
and CC N
with IN N
the DT N
FokI NNP N
FF NNP N
or CC N
Ff NNP N
genotype NN N
, , N
men NNS N
who WP N
had VBD N
low JJ N
25 CD N
( ( N
OH NNP N
) ) N
D NNP N
levels NNS N
and CC N
the DT N
less JJR N
functional JJ N
FokI NNP N
ff NN N
genotype NN N
had VBD N
increased VBN N
risks NNS o
of IN o
total JJ o
( ( N
OR NNP N
= VBZ N
1.9 CD N
, , N
95 CD N
% NN N
CI NNP N
1.1-3.3 CD N
) ) N
and CC N
aggressive JJ o
prostate NN o
cancer NN o
( ( N
OR NNP N
= VBZ N
2.5 CD N
, , N
95 CD N
% NN N
CI NNP N
1.1-5.8 CD N
) ) N
. . N

Among IN N
men NNS p
with IN p
plasma NN o
25 CD o
( ( o
OH NNP o
) ) o
D NNP o
levels NNS o
above IN p
the DT p
median NN p
, , N
the DT N
ff NN N
genotype NN N
was VBD N
no RB N
longer RB N
associated VBN N
with IN N
risk NN N
. . N

Conversely RB N
, , N
among IN N
men NNS N
with IN N
the DT N
ff NN N
genotype NN N
, , N
high JJ o
plasma NN o
25 CD o
( ( o
OH NNP o
) ) o
D NNP o
level NN o
( ( N
above IN N
versus NN N
below IN N
the DT N
median NN N
) ) N
was VBD N
related VBN N
to TO N
significant JJ N
60 CD N
% NN N
approximately RB N
70 CD N
% NN N
lower JJR N
risks NNS o
of IN o
total JJ o
and CC o
aggressive JJ o
prostate NN o
cancer NN o
. . o

CONCLUSIONS VB N
Our PRP$ N
data NNS N
suggest VBP N
that IN N
a DT N
large JJ N
proportion NN N
of IN N
the DT N
US NNP N
men NNS N
had VBD N
suboptimal JJ N
vitamin NN i
D NNP i
status NN i
( ( N
especially RB N
during IN N
the DT N
winter/spring NN N
season NN N
) ) N
, , N
and CC N
both DT N
25 CD N
( ( N
OH NNP N
) ) N
D NNP N
and CC N
1,25 CD N
( ( N
OH NNP N
) ) N
2D CD N
may MD N
play VB N
an DT N
important JJ N
role NN N
in IN N
preventing VBG N
prostate NN N
cancer NN N
progression NN N
. . N

Moreover RB N
, , N
vitamin FW N
D NNP N
status NN N
, , N
measured VBN N
by IN N
25 CD o
( ( o
OH NNP o
) ) o
D NNP o
in IN o
plasma NN o
, , N
interacts VBZ N
with IN N
the DT N
VDR NNP i
FokI NNP i
polymorphism NN i
and CC N
modifies NNS N
prostate VBP N
cancer NN N
risk NN N
. . N

Men NN N
with IN N
the DT N
less RBR N
functional JJ N
FokI NNP N
ff NN N
genotype NN N
( ( N
14 CD N
% NN N
in IN N
the DT N
European-descent JJ N
population NN N
of IN N
this DT N
cohort NN N
) ) N
are VBP N
more RBR N
susceptible JJ N
to TO N
this DT N
cancer NN N
in IN N
the DT N
presence NN N
of IN N
low JJ N
25 CD N
( ( N
OH NNP N
) ) N
D NNP N
status NN N
. . N

-DOCSTART- -2975995- O O

Arginine NNP i
vasopressin NN i
dissociates VBZ N
the DT N
diuresis NN o
and CC o
natriuresis NN o
due JJ N
to TO N
atrial JJ N
natriuretic JJ N
factor NN N
in IN N
man NN p
. . p

The DT N
possible JJ N
interaction NN N
between IN N
arginine JJ i
vasopressin NN i
( ( i
AVP NNP i
) ) i
and CC N
atrial JJ N
natriuretic JJ N
factor NN N
( ( N
ANF NNP N
) ) N
in IN N
the DT N
control NN N
of IN N
urinary JJ N
sodium NN N
and CC N
water NN N
excretion NN N
was VBD N
investigated VBN N
in IN N
man NN p
. . p

Nine NNP p
healthy JJ p
male NN p
volunteers NNS p
undergoing VBG p
stable JJ p
maximal JJ p
water NN p
diuresis NN p
were VBD N
studied VBN N
on IN N
four CD N
separate JJ N
occasions NNS N
. . N

Atrial NNP i
natriuretic JJ i
factor NN i
15 CD i
pmol JJ i
kg-1 JJ i
min-1 NN i
or CC i
placebo NN i
( ( N
P NNP N
) ) N
was VBD N
concomitantly RB N
administered VBN N
against IN N
a DT N
background JJ N
infusion NN N
of IN N
either DT N
AVP NNP i
0.003 CD i
pmol JJ i
kg-1 JJ i
min-1 NN i
or CC i
P NNP i
; : i
thus RB N
the DT N
combinations NNS N
P NNP i
+ NNP i
P NNP i
, , i
AVP NNP i
+ NNP N
P NNP N
, , N
P NNP i
+ NNP i
ANF NNP i
and CC i
AVP NNP i
+ NNP i
ANF NNP i
were VBD N
studied VBN N
. . N

Atrial NNP i
natriuretic JJ i
factor NN i
caused VBD N
a DT N
significant JJ N
increase NN N
in IN N
sodium JJ o
excretion NN o
( ( o
UNaV NNP o
) ) o
[ VBP N
+56 CD N
% NN N
] NN N
, , N
urinary JJ o
flow NN o
rate NN o
( ( o
V NNP o
) ) o
[ VBP N
+17 CD N
% NN N
] NN N
and CC N
free JJ o
water NN o
clearance NN o
( ( o
CH2O NNP o
) ) o
[ VBP N
+23 CD N
% NN N
] NN N
; : N
creatinine JJ o
clearance NN o
( ( o
Ccr NNP o
) ) o
did VBD N
not RB N
change NN N
. . N

Arginine NNP i
vasopressin NN i
reduced VBD N
V NNP o
( ( N
-58 NNP N
% NN N
) ) N
and CC N
CH2O NNP o
( ( N
-68 CD N
% NN N
) ) N
but CC N
did VBD N
not RB N
alter VB N
UNaV NNP o
or CC o
Ccr NNP o
. . o

On IN N
the DT N
AVP NNP i
+ NNP i
ANF NNP i
study NN N
day NN N
, , N
UNaV NNP o
increased VBD N
( ( N
+64 CD N
% NN N
) ) N
as IN N
with IN N
P NNP o
+ NNP o
ANF NNP o
, , N
but CC N
V NNP o
( ( N
-44 NNP N
% NN N
) ) N
and CC N
CH2O NNP o
( ( N
-52 NNP N
% NN N
) ) N
continued VBD N
to TO N
decrease VB N
below IN N
baseline NN N
levels NNS N
; : N
analysis NN N
of IN N
variance NN N
showed VBD N
this DT N
antidiuresis NN N
reflected VBD N
the DT N
prevalent JJ N
effect NN N
of IN N
AVP NNP N
rather RB N
than IN N
any DT N
specific JJ N
interaction NN N
. . N

These DT N
results NNS N
show VBP N
that IN N
AVP NNP i
is VBZ N
able JJ N
to TO N
dissociate VB N
the DT N
natriuretic JJ o
and CC o
diuretic JJ o
effects NNS o
of IN N
ANF NNP i
. . i

-DOCSTART- -15764958- O O

Abacavir NNP i
once RB N
or CC N
twice RB N
daily RB N
combined VBN N
with IN N
once-daily JJ N
lamivudine NN i
and CC i
efavirenz NN i
for IN N
the DT N
treatment NN N
of IN N
antiretroviral-naive JJ o
HIV-infected JJ p
adults NNS p
: : p
results NNS N
of IN N
the DT N
Ziagen NNP i
Once NNP N
Daily NNP N
in IN N
Antiretroviral NNP N
Combination NNP N
Study NNP N
. . N

The DT N
long JJ N
intracellular JJ N
half-life NN N
of IN N
abacavir NN i
( ( i
ABC NNP i
) ) i
supports VBZ N
its PRP$ N
once-daily JJ N
use NN N
, , N
and CC N
this DT N
would MD N
be VB N
expected VBN N
to TO N
simplify VB N
treatment NN N
if IN N
ABC NNP i
could MD N
be VB N
given VBN N
as IN N
part NN N
of IN N
a DT N
complete JJ N
once-daily JJ N
regimen NNS N
. . N

A DT N
randomized JJ N
double-blind JJ N
clinical JJ N
trial NN N
compared VBN N
the DT N
efficacy NN o
and CC N
safety NN o
of IN N
600 CD N
mg NN N
of IN N
ABC NNP i
administered VBD N
once RB N
daily JJ N
( ( N
n JJ N
= NNP N
384 CD N
) ) N
versus NN N
300 CD N
mg NN N
of IN N
ABC NNP i
administered VBD N
twice RB N
daily JJ N
( ( N
n JJ N
= NNP N
386 CD N
) ) N
in IN N
combination NN N
with IN N
300 CD N
mg NNS N
of IN N
lamivudine NN i
( ( i
3TC CD i
) ) i
and CC N
600 CD N
mg NN N
of IN N
efavirenz NN i
( ( i
EFV NNP i
) ) i
administered VBD N
once RB N
daily JJ N
in IN N
antiretroviral-naive JJ p
patients NNS p
over IN p
48 CD p
weeks NNS p
. . p

The DT N
baseline NN o
median JJ o
plasma NN o
HIV-1 NNP o
RNA NNP o
level NN o
was VBD N
4.89 CD N
log10 JJ N
copies/mL NN N
( ( N
44 CD N
% NN N
with IN N
viral JJ N
load NN N
> VBD N
100,000 CD N
copies/mL NN N
) ) N
, , N
and CC N
the DT N
median JJ N
CD4 NNP N
cell NN N
count NN N
was VBD N
262 CD N
cells/mm NN N
. . N

ABC NNP i
administered VBD N
once RB N
daily JJ N
was VBD N
non-inferior JJ N
to TO N
the DT N
twice-daily JJ N
regimen NNS N
, , N
with IN N
66 CD N
% NN N
and CC N
68 CD N
% NN N
of IN N
patients NNS N
in IN N
these DT N
respective JJ N
treatment NN N
arms NNS N
achieving VBG N
a DT N
confirmed JJ N
plasma NN o
HIV-1 NNP o
RNA NNP o
level NN o
< VBD N
50 CD N
copies/mL NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
: : N
-8.4 CD N
% NN N
, , N
4.9 CD N
% NN N
) ) N
. . N

The DT N
ABC NNP i
once-daily JJ N
and CC N
twice-daily JJ N
regimens NNS N
were VBD N
similar JJ N
with IN N
respect NN N
to TO N
infrequency NN o
of IN o
virologic JJ o
failure NN o
( ( N
10 CD N
% NN N
vs. FW N
8 CD N
% NN N
) ) N
, , N
emergence NN o
of IN o
resistance NN o
mutations NNS o
, , o
CD4 NNP o
cell NN o
increases NNS o
from IN o
baseline NN o
( ( N
median JJ N
, , N
188 CD N
vs. FW N
200 CD N
cells/mm NN N
) ) N
, , N
safety NN o
profile NN o
, , o
and CC o
incidence NN o
of IN o
ABC-related NNP o
hypersensitivity NN o
reactions NNS o
( ( N
9 CD N
% NN N
vs. FW N
7 CD N
% NN N
) ) N
. . N

ABC NNP i
administered VBD N
once RB N
daily JJ N
in IN N
combination NN N
with IN N
3TC CD i
and CC N
EFV NNP i
administered VBD N
once RB N
daily JJ N
was VBD N
non-inferior JJ N
to TO N
the DT N
ABC NNP i
twice-daily JJ N
dosing NN N
schedule NN N
when WRB N
combined VBN N
with IN N
3TC CD i
and CC N
EFV NNP i
over IN N
48 CD N
weeks NNS N
. . N

-DOCSTART- -19192127- O O

Evaluation NN N
of IN N
mood NN N
profiles NNS N
during IN N
malaria NNS i
chemoprophylaxis NNS i
: : i
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
four-arm JJ N
study NN N
. . N

BACKGROUND NNP N
To TO N
objectively RB N
compare VB N
the DT N
mood NN N
profiles NNS N
of IN N
users NNS p
of IN p
malaria NNS i
chemoprophylaxis JJ i
regimens NNS p
( ( i
atovaquone-proguanil JJ i
, , i
chloroquine-proguanil JJ i
, , i
doxycycline JJ i
, , i
or CC i
mefloquine NN i
) ) i
in IN p
a DT p
group NN p
of IN p
nonimmune JJ p
tourists NNS p
to TO p
sub-Saharan JJ p
Africa NNP p
. . p

METHODS NNP N
In IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
four-arm JJ N
study NN N
with IN N
placebo JJ N
run-in JJ N
phase NN N
conducted VBN N
at IN N
travel NN p
clinics NNS p
in IN p
Switzerland NNP p
, , p
Germany NNP p
, , p
and CC p
Israel NNP p
, , N
we PRP N
compared VBN N
moods NNS N
and CC N
feelings NNS N
in IN N
chemoprophylaxis NN N
users NNS N
( ( p
n= JJ p
547 CD p
) ) p
by IN N
administering VBG N
the DT N
standardized JJ N
Profile NNP i
of IN i
Mood NNP i
States NNPS i
( ( i
POMS NNP i
) ) i
questionnaire NN i
. . i

This DT N
is VBZ N
designed VBN N
to TO N
provide VB N
data NNS N
on IN N
six CD N
categories NNS N
of IN N
feelings NNS N
: : N
tension NN N
, , N
depression NN N
, , N
anger NN N
, , N
vigor NN N
, , N
fatigue NN N
, , N
and CC N
confusion NN N
. . N

The DT N
questionnaire NN N
was VBD N
administered VBN N
at IN N
four CD N
time NN N
points NNS N
: : N
recruitment NN N
( ( N
T1 NNP N
) ) N
, , N
13 CD N
to TO N
11 CD N
days NNS N
before IN N
departure NN N
( ( N
T2 NNP N
) ) N
, , N
6 CD N
to TO N
4 CD N
days NNS N
before IN N
departure NN N
( ( N
T3 NNP N
) ) N
, , N
and CC N
7 CD N
to TO N
14 CD N
days NNS N
after IN N
return NN N
from IN N
Africa NNP N
( ( N
T4 NNP N
) ) N
. . N

RESULTS CC N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
with IN N
respect NN N
to TO N
overall JJ N
mood NN o
impact NN N
between IN N
the DT N
medication NN N
arms NNS N
. . N

All DT N
scores NNS N
were VBD N
in IN N
the DT N
normal JJ N
range NN N
, , N
and CC N
no DT N
means NNS N
were VBD N
more JJR N
than IN N
1 CD N
SD NN N
from IN N
the DT N
norm NN N
. . N

The DT N
POMS NNP N
data NNS N
were VBD N
reanalyzed VBN N
with IN N
respect NN N
to TO N
sex NN N
, , N
age NN N
, , N
medication NN N
group NN N
, , N
and CC N
control NN N
time NN N
points NNS N
( ( N
T1-T4 NNP N
) ) N
. . N

There EX N
were VBD N
significant JJ N
interaction NN N
effects NNS N
between IN N
sex NN N
and CC N
medication NN N
group NN N
-- : N
women NNS N
in IN N
the DT N
mefloquine NN N
group NN N
showed VBD N
more JJR N
fatigue NN o
( ( N
p= JJ N
.011 NN N
) ) N
and CC N
confusion NN o
( ( N
p= JJ N
.011 NN N
) ) N
than IN N
men NNS N
. . N

Significant JJ N
effects NNS N
of IN N
age NN p
group NN p
( ( p
below IN p
median JJ p
age NN p
34 CD p
y NN p
vs NN p
median JJ p
age NN p
and CC p
above IN p
) ) p
were VBD N
noted VBN N
on IN N
the DT N
tension NN o
and CC o
fatigue NN o
scales NNS N
in IN N
that DT N
less JJR N
tension NN o
( ( N
p= JJ N
.045 NN N
) ) N
and CC N
less JJR N
fatigue NN o
( ( N
p= JJ N
.000 NN N
) ) N
were VBD N
noted VBN N
in IN N
those DT N
aged VBN p
34 CD p
years NNS p
and CC p
older JJR p
. . N

Younger JJR p
participants NNS p
, , p
aged VBD p
< JJ p
34 CD p
years NNS p
, , N
reported VBD N
more JJR N
confusion NN o
( ( N
p= JJ N
.013 NN N
) ) N
at IN N
T2 NNP N
than IN N
at IN N
T1 NNP N
and CC N
T4 NNP N
. . N

CONCLUSIONS NNP N
Although IN N
the DT N
overall JJ N
mood NN N
profiles NNS N
were VBD N
similar JJ N
for IN N
the DT N
users NNS N
of IN N
any DT N
of IN N
the DT N
standard JJ i
malaria NN i
chemoprophylaxis NN i
regimens NNS i
, , N
we PRP N
found VBD N
that IN N
women NNS N
using VBG N
mefloquine NN N
showed VBD N
more JJR N
fatigue NN N
and CC N
confusion NN N
than IN N
men NNS N
and CC N
that IN N
younger JJR p
persons NNS p
aged VBD p
less JJR p
than IN p
34 CD p
years NNS p
, , N
regardless RB N
of IN N
chemoprophylaxis NN N
used VBN N
, , N
reported VBD N
more JJR N
tension NN N
and CC N
fatigue NN N
than IN N
their PRP$ N
older JJR p
counterparts NNS p
. . p

-DOCSTART- -1337070- O O

Erythema JJ p
migrans NNS p
: : p
comparison NN N
of IN N
treatment NN N
with IN N
azithromycin NN i
, , i
doxycycline NN i
and CC i
phenoxymethylpenicillin NN i
. . i

Azithromycin NNP i
, , i
doxycycline NN i
and CC i
phenoxymethylpenicillin NN i
were VBD N
compared VBN N
in IN N
a DT N
prospective JJ N
, , N
randomized JJ N
study NN N
of IN N
64 CD p
patients NNS p
with IN p
typical JJ p
erythema NN p
migrans NNS p
. . p

Twenty CD N
patients NNS N
were VBD N
treated VBN N
with IN N
oral JJ i
azithromycin NN i
, , N
250 CD N
mg NN N
bd NN N
for IN N
two CD N
days NNS N
followed VBN N
by IN N
250 CD N
mg NNS N
od NN N
for IN N
eight CD N
days NNS N
, , N
21 CD N
patients NNS N
were VBD N
given VBN N
phenoxymethylpenicillin $ i
1 CD N
million CD N
IU NNP N
tds NN N
for IN N
14 CD N
days NNS N
and CC N
23 CD N
patients NNS N
received JJ N
doxycycline NN i
, , N
100 CD N
mg NN N
bd NN N
for IN N
14 CD N
days NNS N
. . N

All DT N
patients NNS N
were VBD N
followed VBN N
up RP N
for IN N
24 CD N
months NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
groups NNS N
with IN N
respect NN N
to TO N
the DT N
persistence NN N
of IN N
cutaneous JJ o
lesions NNS o
after IN N
starting VBG N
treatment NN N
; : N
the DT N
mean JJ o
durations NNS o
were VBD N
10.5 CD N
days NNS N
in IN N
the DT N
penicillin NN i
group NN N
, , N
8.8 CD N
days NNS N
in IN N
the DT N
doxycycline NN i
group NN N
and CC N
8.6 CD N
days NNS N
in IN N
the DT N
azithromycin NN i
group NN N
. . N

There EX N
were VBD N
statistically RB N
significant JJ N
differences NNS N
in IN N
terms NNS N
of IN N
the DT N
resolution NN o
of IN o
associated JJ o
local JJ o
and/or NN o
systemic NN o
symptoms NNS o
. . o

The DT N
response NN o
time NN o
was VBD N
shortest VBN N
in IN N
patients NNS N
treated VBN N
with IN N
azithromycin NN i
. . i

Two CD N
patients NNS N
who WP N
received VBD N
phenoxymethylpenicillin NN i
and CC N
two CD N
given VBN N
doxycycline VBP i
subsequently RB N
developed VBN N
major JJ N
manifestations NNS N
of IN N
Lyme NNP o
borreliosis NN o
; : o
these DT N
did VBD N
not RB N
occur VB N
in IN N
patients NNS N
receiving VBG N
azithromycin RB i
. . i

Although IN N
azithromycin NN i
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
effective JJ N
in IN N
the DT N
treatment NN N
of IN N
erythema NN N
migrans NNS N
, , N
further JJ N
studies NNS N
will MD N
be VB N
needed VBN N
to TO N
determine VB N
the DT N
optimal JJ N
dosage NN N
and CC N
duration NN N
of IN N
therapy NN N
. . N

-DOCSTART- -15764256- O O

Low-dose JJ i
angiotensin NN i
II NNP i
receptor NN i
antagonists NNS i
and CC i
angiotensin JJ i
II-converting NNP i
enzyme NN i
inhibitors NNS i
alone RB i
or CC i
in IN i
combination NN i
for IN N
treatment NN N
of IN N
primary JJ N
glomerulonephritis NN N
. . N

OBJECTIVE IN N
The DT N
renin-angiotensin NN N
system NN N
is VBZ N
thought VBN N
to TO N
be VB N
involved VBN N
in IN N
the DT N
progression NN N
of IN N
chronic JJ N
renal JJ N
diseases NNS N
of IN N
both DT N
diabetic JJ N
and CC N
non-diabetic JJ N
origin NN N
. . N

It PRP N
has VBZ N
been VBN N
confirmed VBN N
that IN N
angiotensin-converting JJ N
enzyme NN N
inhibitors NNS N
( ( N
ACEIs NNP N
) ) N
and CC N
angiotensin $ N
II NNP N
receptor NN N
blockers NNS N
( ( N
ARBs NNP N
) ) N
reduce VB N
urinary JJ N
protein NN N
excretion NN N
and CC N
attenuate VB N
the DT N
development NN N
of IN N
renal JJ N
injury NN N
. . N

Clinical NNP N
data NNS N
comparing VBG N
the DT N
renal JJ N
effects NNS N
of IN N
ACEIs NNP N
and CC N
ARBs NNP N
, , N
either RB N
singly RB N
or CC N
in IN N
combination NN N
, , N
are VBP N
scarce JJ N
and CC N
usually RB N
concern NN N
the DT N
use NN N
of IN N
standard NN N
or CC N
high JJ N
doses NNS N
. . N

MATERIAL NNP N
AND CC N
METHODS NNP N
This DT N
was VBD N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
9-month JJ N
study NN N
of IN N
the DT N
effects NNS N
of IN N
low JJ N
doses NNS N
of IN N
losartan NN i
( ( N
25 CD N
mg NN N
; : N
n CC N
= VB N
18 CD N
) ) N
versus NN N
enalapril NN i
( ( N
10 CD N
mg NN N
; : N
n CC N
= VB N
18 CD N
) ) N
versus IN N
the DT N
combination NN i
of IN i
losartan NN i
( ( i
25 CD i
mg NN i
) ) i
and CC i
enalapril $ i
( ( N
10 CD N
mg NN N
) ) N
( ( N
n JJ N
= NNP N
16 CD N
) ) N
on IN N
proteinuria NN o
, , o
kidney NN o
function NN o
and CC o
metabolic JJ o
profile NN o
in IN N
54 CD p
patients NNS p
with IN p
biopsy-proven JJ p
chronic JJ p
glomerulonephritis NN p
, , p
hypertension NN p
and CC p
normal JJ p
or CC p
slightly RB p
impaired JJ p
kidney NN p
function NN p
. . p

The DT N
clinical JJ o
evaluation NN o
and CC o
laboratory NN o
tests NNS o
were VBD N
performed VBN N
before IN N
treatment NN N
( ( N
baseline NN N
) ) N
and CC N
after IN N
3 CD N
and CC N
9 CD N
months NNS N
of IN N
therapy NN N
. . N

RESULTS NNP N
After IN N
3 CD N
months NNS N
, , N
significant JJ N
decreases NNS N
in IN N
proteinuria NNS o
were VBD N
observed VBN N
in IN N
all DT N
groups NNS N
: : N
losartan NN N
, , N
22.6 CD N
% NN N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
; : N
enalapril CC N
, , N
43 CD N
% NN N
( ( N
p JJ N
= NNP N
0.012 CD N
) ) N
; : N
and CC N
combined VBD N
therapy NN N
, , N
63 CD N
% NN N
( ( N
p JJ N
= NNP N
0.001 CD N
) ) N
. . N

This DT N
anti-proteinuric JJ o
effect NN o
was VBD N
even RB N
greater JJR N
after IN N
9 CD N
months NNS N
of IN N
therapy NN N
: : N
losartan NN N
, , N
44.2 CD N
% NN N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
; : N
enalapril CC N
, , N
49.6 CD N
% NN N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
; : N
and CC N
combined VBD N
therapy NN N
, , N
51 CD N
% NN N
( ( N
p JJ N
= NNP N
0.003 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
losartan NN N
and CC N
enalapril NN N
with IN N
respect NN N
to TO N
their PRP$ N
impact NN N
on IN N
proteinuria NNS o
level NN o
. . o

Proteinuria NNP o
reduction NN o
was VBD N
significantly RB N
greater JJR N
in IN N
patients NNS N
receiving VBG N
combined JJ N
therapy NN N
in IN N
comparison NN N
with IN N
losartan JJ N
treatment NN N
after IN N
3 CD N
months NNS N
of IN N
therapy NN N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
. . N

Creatinine JJ o
clearance NN o
and CC o
serum JJ o
creatinine NN o
were VBD N
stable JJ N
during IN N
the DT N
entire JJ N
study NN N
period NN N
in IN N
all DT N
patients NNS N
. . N

No DT N
significant JJ N
changes NNS o
in IN o
lipids NNS o
, , o
serum NN o
uric JJ o
acid NN o
or CC o
protein NN o
levels NNS o
were VBD N
observed VBN N
. . N

CONCLUSIONS NNP N
These DT N
results NNS N
indicate VBP N
that IN N
proteinuria NN N
is VBZ N
reduced VBN N
by IN N
low JJ N
doses NNS N
of IN N
losartan NN N
or CC N
enalapril NN N
. . N

The DT N
combination NN N
of IN N
these DT N
drugs NNS N
seems VBZ N
to TO N
be VB N
beneficial JJ N
and CC N
may MD N
offer VB N
an DT N
additional JJ N
renoprotective NN N
effect NN N
. . N

This DT N
needs VBZ N
to TO N
be VB N
confirmed VBN N
in IN N
a DT N
study NN N
with IN N
a DT N
larger JJR N
sample JJ N
size NN N
. . N

-DOCSTART- -2741888- O O

A DT N
comparison NN N
of IN N
high JJ i
and CC i
low JJ i
fat NN i
meals NNS i
on IN N
postprandial JJ p
esophageal JJ p
acid NN p
exposure NN p
. . p

Fatty NNP N
foods NNS N
have VBP N
been VBN N
identified VBN N
as IN N
precipitating VBG N
factors NNS N
in IN N
symptomatic JJ N
gastroesophageal NN p
reflux NN p
( ( p
GER NNP p
) ) p
. . p

A DT N
fat JJ N
meal NN N
has VBZ N
also RB N
been VBN N
found VBN N
to TO N
decrease VB N
lower JJR N
esophageal NN o
sphincter NN o
pressure NN o
( ( o
LESP NNP o
) ) o
in IN N
normal JJ N
subjects NNS N
. . N

We PRP N
used VBD N
the DT N
ambulatory JJ N
24-h JJ N
pH NN N
monitor NN N
to TO N
assess VB N
esophageal JJ N
acid NN N
exposure NN N
in IN N
10 CD p
normal JJ p
subjects NNS p
and CC p
10 CD p
GER NNP p
patients NNS p
following VBG p
low JJ i
and CC i
high JJ i
fat NN i
meals NNS i
eaten VBP i
in IN i
two CD i
body NN i
positions NNS i
. . i

The DT N
meals NNS N
had VBD N
nearly RB N
identical JJ N
protein NN N
content NN N
, , N
volumes NNS N
, , N
and CC N
calories NNS N
. . N

On IN N
successive JJ N
days NNS N
, , N
patients NNS N
ingested VBD N
one CD N
of IN N
the DT N
meals NNS i
twice RB N
, , N
followed VBN N
by IN N
random JJ N
assignment NN N
to TO N
3 CD N
h NN N
upright JJ i
and CC i
3 CD N
h NN N
recumbent JJ i
position NN i
. . i

Acid NNP o
exposure NN o
for IN o
each DT o
hour NN o
over IN N
a DT N
3-h JJ N
postprandial NN N
( ( N
PP NNP N
) ) N
period NN N
was VBD N
assessed VBN N
as IN N
the DT N
percent NN N
time NN N
pH NN N
less JJR N
than IN N
4.0 CD N
. . N

Increased VBN N
upright JJ o
acid NN o
exposure NN o
occurred VBD N
in IN N
normals NNS N
after IN N
the DT N
high JJ N
fat NN N
( ( N
6.2 CD N
+/- JJ N
2.1 CD N
% NN N
; : N
mean JJ N
+/- JJ N
SE NNP N
) ) N
compared VBN N
with IN N
the DT N
low JJ N
fat JJ N
meal NN N
( ( N
1.5 CD N
+/- JJ N
0.5 CD N
% NN N
; : N
p CC N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

GER NNP N
patients NNS N
had VBD N
greater JJR N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
acid NN o
exposure NN o
than IN N
normals NNS N
in IN N
all DT N
study NN N
periods NNS N
, , N
but CC N
no DT N
differences NNS N
were VBD N
found VBN N
between IN N
low JJ N
and CC N
high JJ N
fat NN N
meals NNS N
in IN N
either DT N
study NN N
position NN N
. . N

High JJ N
fat JJ N
meals NNS N
induce VBP N
upright JJ o
GER NNP o
in IN N
normals NNS N
, , N
but CC N
do VBP N
not RB N
significantly RB N
affect VBP N
the DT N
abnormal JJ N
amount NN N
of IN N
GER NNP N
in IN N
patients NNS N
. . N

In IN N
addition NN N
, , N
progressive JJ N
increases NNS N
in IN N
acid JJ o
exposure NN o
were VBD N
found VBN N
over IN N
the DT N
3 CD N
postprandial JJ N
hours NNS N
in IN N
GER NNP N
patients NNS N
in IN N
a DT N
recumbent JJ N
position NN N
. . N

The DT N
findings NNS N
are VBP N
consistent JJ N
with IN N
prior JJ N
data NNS N
showing VBG N
decreased JJ N
LESP NNP o
with IN N
a DT N
fat JJ N
meal NN N
in IN N
normals NNS N
. . N

-DOCSTART- -19681257- O O

Clinical JJ N
trial NN N
of IN N
tooth NN o
whitening VBG o
with IN N
6 CD N
% NN N
hydrogen NN i
peroxide IN i
whitening VBG i
strips NNS i
and CC N
two CD N
whitening NN i
dentifrices NNS i
. . i

PURPOSE NNP N
To TO N
compare VB N
tooth JJ o
whitening VBG o
with IN N
6 CD N
% NN N
hydrogen NN i
peroxide IN i
whitening VBG i
strips NNS i
and CC N
two CD N
whitening VBG i
dentifrices NNS i
in IN N
a DT N
12-week JJ N
randomized NN N
controlled VBD N
trial NN N
at IN N
a DT N
Belgian JJ p
dental JJ p
school NN p
. . p

METHODS NNP N
After IN N
informed JJ N
consent NN N
, , N
46 CD p
healthy JJ p
adults NNS p
were VBD p
randomly RB p
assigned VBN p
to TO N
one CD N
of IN N
three CD N
strip NN i
+ NNP N
dentifrice NN i
treatment NN N
groups NNS N
. . N

Subjects NNS N
received VBD N
either RB N
6 CD i
% NN i
hydrogen NN i
peroxide IN i
whitening VBG i
strips NNS i
( ( i
Crest NNP i
Whitestrips NNP i
) ) i
and CC i
an DT i
anticavity NN i
toothpaste NN i
( ( N
Crest NNP N
Cavity NNP N
Protection NNP N
) ) N
, , N
placebo JJ i
strips NNS i
and CC i
a DT i
sodium NN i
fluoride NN i
( ( i
NaF NNP i
) ) i
whitening VBG i
dentifrice NN i
( ( N
Mentadent NNP N
Whitening NNP N
Toothpaste NNP N
) ) N
or CC N
placebo VBN i
strips NNS i
and CC i
a DT i
sodium NN i
monofluorophosphate NN i
( ( i
MFP NNP i
) ) i
whitening VBG i
dentifrice NN i
( ( N
Rembrandt NNP N
Low NNP N
Abrasion NNP N
Whitening NNP N
Toothpaste NNP N
) ) N
. . N

Strip NNP i
use NN i
( ( i
peroxide NN i
or CC i
placebo NN i
) ) i
was VBD N
for IN N
30 CD N
minutes NNS N
, , N
twice RB N
daily RB N
for IN N
2 CD N
weeks NNS N
, , N
while IN N
dentifrice NN N
use NN N
was VBD N
at IN N
least JJS N
twice JJ N
daily RB N
for IN N
12 CD N
weeks NNS N
. . N

Efficacy NN o
was VBD N
measured VBN N
from IN N
standardized JJ N
digital JJ N
images NNS N
of IN N
the DT N
maxillary JJ N
facial JJ N
tooth NN N
surfaces NNS N
, , N
while IN N
safety NN N
was VBD N
evaluated VBN N
from IN N
oral JJ N
examination NN N
and CC N
interview NN N
. . N

Treatments NNS N
were VBD N
compared VBN N
after IN N
2 CD N
weeks NNS N
( ( N
strip NN N
use NN N
) ) N
and CC N
12 CD N
weeks NNS N
( ( N
dentifrice NN N
use NN N
) ) N
using VBG N
analysis NN N
of IN N
covariance NN N
. . N

RESULTS NNP N
All NNP N
subjects VBZ N
completed VBN N
the DT N
12-week JJ N
evaluation NN N
. . N

Adjusting VBG N
for IN N
baseline NN N
and CC N
age NN N
, , N
the DT N
peroxide JJ N
strip NN N
group NN N
had VBD N
-2.45 NNP N
Deltab* NNP N
, , N
2.39 CD N
DeltaL* NNP N
, , N
and CC N
-0.96 JJ N
Deltaa* NNP N
at IN N
Week NNP N
2 CD N
. . N

Between-group JJ N
comparisons NNS N
demonstrated VBD N
significant JJ N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
reductions NNS N
in IN N
yellowness NN o
and CC o
redness NN o
, , N
and CC N
increased VBD N
brightness NN o
favoring VBG o
the DT N
peroxide JJ N
strip NN N
group NN N
. . N

The DT N
peroxide JJ i
strip NN i
group NN i
demonstrated VBD N
95 CD N
% NN N
+ NNP N
color NN o
retention NN o
( ( N
Deltab* NNP N
& CC N
DeltaL* NNP N
) ) N
at IN N
Week NNP N
12 CD N
, , N
differing VBG N
significantly RB N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
versus NN N
either DT N
of IN N
the DT N
continuously NN N
used VBN N
whitening NN i
dentifrices NNS i
. . i

There EX N
were VBD N
no DT N
significant JJ N
( ( N
P NNP N
> NNP N
0.18 CD N
) ) N
differences NNS N
between IN N
the DT N
whitening VBG N
dentifrice NN N
groups NNS N
at IN N
any DT N
timepoints NNS N
. . N

All DT N
treatments NNS N
were VBD N
well-tolerated JJ o
, , N
with IN N
minor JJ o
tooth DT o
sensitivity NN o
and CC N
oral JJ o
irritation NN o
representing VBG N
the DT N
most RBS N
common JJ N
findings NNS N
. . N

-DOCSTART- -15695500- O O

Long-term JJ N
follow-up NN N
of IN N
a DT N
randomized JJ N
trial NN N
of IN N
fludarabine-mitoxantrone NN i
, , N
compared VBN N
with IN N
cyclophosphamide NN i
, , i
doxorubicin NN i
, , i
vindesine NN i
, , i
prednisone NN i
( ( i
CHVP NNP i
) ) i
, , N
as IN N
first-line JJ N
treatment NN N
of IN N
elderly JJ p
patients NNS p
with IN p
advanced JJ p
, , p
low-grade JJ p
non-Hodgkin NN p
's POS p
lymphoma NN p
before IN p
the DT p
era NN p
of IN p
monoclonal JJ p
antibodies NNS p
. . p

BACKGROUND NNP N
This DT N
randomized VBN N
study NN N
compared VBN N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
fludarabine-mitoxantrone NN i
( ( i
FM NNP i
) ) i
with IN i
mini-CHVP NN i
( ( i
cyclophosphamide NN i
, , i
doxorubicin NN i
, , i
vindesine NN i
, , i
prednisone NN i
) ) i
in IN N
elderly JJ p
patients NNS p
with IN p
advanced JJ p
, , p
low-grade JJ p
non-Hodgkin NN p
's POS p
lymphoma NN p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
End NNP N
points NNS N
were VBD N
remission JJ o
rates NNS o
[ VBP o
overall JJ o
response NN o
( ( o
OR NNP o
) ) o
and CC o
complete JJ o
response NN o
( ( o
CR NNP o
) ) o
] NN o
, , o
failure-free JJ o
survival NN o
( ( o
FFS NNP o
) ) o
, , o
survival JJ o
and CC o
toxicity NN o
. . o

One CD p
hundred CD p
and CC p
fifty-five JJ p
patients NNS p
were VBD p
randomized VBN p
, , p
144 CD p
were VBD p
evaluable JJ p
for IN p
safety NN p
and CC p
142 CD p
for IN p
response NN p
. . p

Each DT N
treatment NN N
arm NN N
was VBD N
given VBN N
as IN N
six CD N
monthly JJ N
cycles NNS N
, , N
followed VBN N
by IN N
three CD N
bimonthly JJ N
cycles NNS N
. . N

FM NNP N
comprised VBD N
fludarabine NN i
( ( N
20 CD N
mg/m NN N
( ( N
2 CD N
) ) N
i.v NN N
. . N

) ) N
, , N
days NNS N
1-5 CD N
, , N
plus CC N
mitoxantrone NN i
( ( N
10 CD N
mg/m NN N
( ( N
2 CD N
) ) N
i.v NN N
. . N

) ) N
, , N
day NN N
1 CD N
. . N

CHVP NNP N
cycles NNS N
comprised VBD N
cyclophosphamide NN i
( ( N
750 CD N
mg/m NN N
( ( N
2 CD N
) ) N
i.v NN N
. . N

infusion NN N
) ) N
, , N
doxorubicin NN i
( ( N
25 CD N
mg/m NN N
( ( N
2 CD N
) ) N
i.v NN N
. . N

) ) N
and CC N
vindesine NN i
( ( N
3 CD N
mg/m NN N
( ( N
2 CD N
) ) N
i.v NN N
. . N

) ) N
on IN N
day NN N
1 CD N
, , N
and CC N
prednisone NN i
( ( N
50 CD N
mg/m NN N
( ( N
2 CD N
) ) N
) ) N
on IN N
days NNS N
1-5 JJ N
. . N

RESULTS NNP N
FM NNP i
therapy NN N
resulted VBD N
in IN N
superior JJ N
remission NN o
rates NNS o
( ( N
OR CC N
81 CD N
% NN N
versus IN N
64 CD N
% NN N
, , N
CR NNP N
49 CD N
% NN N
versus IN N
17 CD N
% NN N
; : N
P NNP N
= NNP N
0.0004 CD N
) ) N
. . N

Median JJ o
FFS NNP o
for IN N
FM NNP i
patients NNS N
was VBD N
36 CD N
months NNS N
, , N
compared VBN N
with IN N
19 CD N
months NNS N
for IN N
CHVP NNP N
patients NNS N
, , N
and CC N
has VBZ N
not RB N
yet RB N
been VBN N
reached VBN N
for IN N
early JJ N
CR NNP N
patients NNS N
at IN N
53 CD N
months NNS N
. . N

Treatment NNP N
arm NN N
was VBD N
the DT N
major JJ N
risk NN N
factor NN N
influencing VBG N
survival NN o
. . o

Both DT N
treatments NNS N
were VBD N
well RB N
tolerated VBN o
, , N
with IN N
only RB N
few JJ N
infectious JJ o
complications NNS o
. . o

CONCLUSION NNP N
FM NNP i
was VBD N
more RBR N
effective JJ o
than IN N
CHVP NNP N
in IN N
achieving VBG N
OR NNP o
and CC o
CR NNP o
, , N
and CC N
favorably RB N
affected VBD N
the DT N
outcome NN N
. . N

-DOCSTART- -20061334- O O

Preoperative JJ N
lanreotide NN i
treatment NN N
in IN N
acromegalic JJ p
patients NNS p
with IN p
macroadenomas JJ p
increases NNS N
short-term JJ o
postoperative JJ o
cure NN o
rates NNS o
: : o
a DT N
prospective JJ N
, , N
randomised JJ N
trial NN N
. . N

OBJECTIVE UH N
To TO N
investigate VB N
whether IN N
4-month JJ N
preoperative JJ N
lanreotide NN N
treatment NN N
would MD N
improve VB N
the DT N
surgical JJ o
cure NN o
rate NN o
of IN N
newly RB p
diagnosed VBN p
acromegalic JJ p
patients NNS p
with IN p
macroadenomas NN p
. . p

DESIGN VB N
A DT N
prospective JJ N
, , N
randomised VBD N
study NN N
. . N

METHODS NNP N
After IN N
a DT N
baseline NN N
evaluation NN N
, , N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
4-month JJ N
preoperative JJ N
treatment NN N
with IN N
lanreotide NN i
( ( N
starting VBG N
with IN N
30 CD N
mg/2 JJ N
weeks NNS N
i.m NN N
. . N

and CC N
increasing VBG N
to TO N
30 CD N
mg/week NN N
i.m NN N
. . N

at IN N
week NN N
8 CD N
if IN N
mean JJ N
GH NNP N
> NNP N
2.5 CD N
microg/l NN N
on IN N
GH NNP N
day NN N
curves VBZ N
; : N
pretreatment NN N
group NN N
, , N
Group NNP N
1 CD N
) ) N
or CC N
to TO N
transsphenoidal VB i
surgery NN i
( ( N
direct JJ N
surgery NN N
group NN N
, , N
Group NNP N
2 CD N
) ) N
. . N

Cure NN o
was VBD N
evaluated VBN N
4 CD N
months NNS N
postoperatively RB N
primarily RB N
by IN N
fasting VBG o
IGF1 NNP o
less JJR N
than IN N
or CC N
equal JJ N
to TO N
age-adjusted JJ N
upper JJ N
limit NN N
of IN N
normal JJ N
. . N

RESULTS VB N
A DT N
pool NN p
of IN p
108 CD p
patients NNS p
was VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
. . N

Five CD N
patients NNS N
in IN N
each DT N
group NN N
were VBD N
lost VBN N
to TO N
follow-up NN N
during IN N
the DT N
study NN N
period NN N
, , N
so RB N
49 CD p
patients NNS p
in IN p
each DT p
group NN p
were VBD N
analysed VBN N
. . N

At IN N
baseline NN N
, , N
no DT N
difference NN N
was VBD N
observed VBN N
between IN N
the DT N
two CD N
groups NNS N
. . N

Cure NN o
was VBD N
established VBN N
in IN N
24 CD N
of IN N
49 CD N
( ( N
49.0 CD N
% NN N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
, , N
35.0-63.0 JJ N
% NN N
) ) N
pretreated VBD N
patients NNS N
( ( N
Group NNP N
1 CD N
) ) N
versus NN N
9 CD N
of IN N
49 CD N
( ( N
18.4 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
, , N
7.6-29.2 CD N
% NN N
) ) N
direct JJ N
surgery NN N
patients NNS N
( ( N
Group NNP N
2 CD N
; : N
P=0.001 NNP N
) ) N
. . N

Surgical JJ o
morbidity NN o
was VBD N
recorded VBN N
in IN N
12 CD N
patients NNS N
( ( N
12.2 CD N
% NN N
) ) N
and CC N
was VBD N
similar JJ N
in IN N
Group NNP N
1 CD N
and CC N
2 CD N
patients NNS N
( ( N
14.3 CD N
and CC N
10.2 CD N
% NN N
respectively RB N
; : N
P=0.538 NNP N
) ) N
. . N

The DT N
postoperative JJ o
hospital NN o
stay NN o
was VBD N
similar JJ N
between IN N
groups NNS N
: : N
being VBG N
4.5+/-1.6 JJ N
days NNS N
in IN N
Group NNP N
1 CD N
vs IN N
4.8+/-1.9 JJ N
days NNS N
in IN N
Group NNP N
2 CD N
( ( N
P=0.328 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Pretreatment NNP N
with IN N
lanreotide NN i
before IN N
transsphenoidal JJ N
surgery NN N
improves VBZ N
surgical JJ o
cure NN o
rates NNS o
in IN N
patients NNS p
with IN p
GH-secreting NNP p
pituitary JJ p
macroadenomas NN p
. . p

Pretreatment NN N
does VBZ N
not RB N
affect VB N
surgical JJ o
complications NNS o
or CC N
duration NN o
of IN o
hospital NN o
stay NN o
( ( N
ClinicalTrials.gov NNP N
number NN N
, , N
NCT00993356 NNP N
) ) N
. . N

-DOCSTART- -22414202- O O

Ambulatory JJ o
activity NN o
of IN N
children NNS p
with IN p
cerebral JJ p
palsy NN p
: : p
which WDT N
characteristics NNS N
are VBP N
important JJ N
? . N
AIM NNP N
To TO N
assess VB N
ambulatory JJ o
activity NN o
of IN N
children NNS p
with IN p
cerebral JJ p
palsy NN p
( ( p
CP NNP p
) ) p
, , p
aged VBD p
7 CD p
to TO p
13 CD p
years NNS p
, , p
and CC N
identify VB N
associated VBN N
characteristics NNS N
. . N

METHOD NNP p
Sixty-two JJ p
children NNS p
with IN p
spastic JJ p
CP NNP p
( ( p
39 CD p
males NNS p
, , p
23 CD p
females NNS p
; : p
mean JJ p
age NN p
10y CD p
1mo CD p
, , p
SD NNP p
1y CD p
8mo CD p
; : p
age NN p
range NN p
7-13y NNP p
) ) p
, , p
classified VBD p
as IN p
Gross NNP p
Motor NNP p
Function NNP p
Classification NNP p
System NNP p
( ( p
GMFCS NNP p
) ) p
levels NNS p
I PRP p
to TO p
III NNP p
, , p
participated VBD o
. . o

Ambulatory NNP o
activity NN o
was VBD o
measured VBN N
during IN N
1 CD N
week NN N
with IN N
a DT N
StepWatch NNP N
activity NN N
monitor NN N
as IN N
steps NNS N
per IN N
day NN N
, , N
and CC N
time NN N
spent VBN N
at IN N
medium NN N
and CC N
high JJ N
step NN N
rates NNS N
. . N

Multiple JJ N
linear JJ N
regression NN N
analyses NNS N
were VBD N
performed VBN N
following VBG N
a DT N
backward JJ N
selection NN N
procedure NN N
until IN N
only RB N
independent JJ N
variables NNS N
with IN N
p JJ N
< $ N
0.05 CD N
remained VBN N
in IN N
the DT N
model NN i
. . i

Ambulatory JJ i
activity NN i
outcome NN i
parameters NNS N
served VBD N
as IN N
dependent JJ N
variables NNS N
, , N
and CC N
disease NN N
, , N
personal JJ N
, , N
and CC N
environmental JJ N
characteristics NNS N
as IN N
independent JJ N
variables NNS o
. . o

Ambulatory NNP o
activity NN o
was VBD o
corrected VBN N
for IN N
body NN N
height NN N
. . N

RESULTS NNP N
Children NNP N
took VBD N
more RBR N
steps NNS N
during IN N
school NN N
days NNS N
( ( N
5169 CD N
steps NNS N
, , N
SD NNP N
1641 CD N
) ) N
than IN N
during IN N
weekend NN N
days NNS N
( ( N
4158 CD N
steps NNS N
, , N
SD NNP N
2048 CD N
; : N
p CC N
< VB N
0.001 CD N
) ) N
. . N

Higher JJR N
GMFCS NNP N
level NN N
, , N
bilateral JJ N
CP NNP N
, , N
and CC N
higher JJR N
age NN N
were VBD N
associated VBN N
with IN N
lower JJR o
ambulatory NN o
activity NN o
on IN o
school NN o
days NNS o
( ( o
R NNP o
( ( o
2 CD N
) ) N
ranged VBD N
from IN N
43-53 CD N
% NN N
) ) N
, , N
whereas JJ N
bilateral JJ N
CP NNP N
, , N
higher JJR N
age NN N
, , N
and CC N
no DT N
sport NN N
club NN N
participation NN N
were VBD N
associated VBN N
with IN N
lower JJR o
ambulatory NN o
activity NN o
in IN o
the DT o
weekend NN o
( ( o
R NNP o
( ( o
2 CD N
) ) N
ranged VBD N
from IN N
21-42 CD o
% NN o
) ) o
. . o

Correcting VBG o
for IN o
body NN o
height NN o
decreased VBD o
the DT N
association NN N
with IN N
age NN N
. . N

INTERPRETATION NNP N
Interventions NNP N
should MD N
focus VB N
at IN N
increasing VBG o
physical JJ o
activity NN o
at IN o
the DT N
weekend NN N
for IN N
children NNS p
with IN p
bilateral JJ p
spastic JJ p
CP NNP p
. . p

-DOCSTART- -12636954- O O

The DT N
effects NNS N
of IN N
peer NN i
counseling VBG i
on IN N
smoking VBG N
cessation NN o
and CC N
reduction NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
a DT N
peer NN i
counseling VBG i
intervention NN i
for IN N
pregnant JJ p
smokers NNS p
. . p

METHODS NNP N
One CD p
hundred VBD p
forty-two NN p
pregnant NN p
, , p
predominantly RB p
Hispanic JJ p
women NNS p
were VBD N
assigned VBN N
to TO N
a DT N
peer-led JJ i
smoking NN i
cessation NN i
program NN i
or CC i
to TO i
usual JJ i
care NN i
. . i

RESULTS NNP N
Compared VBD N
with IN N
usual JJ i
care NN i
, , i
peer NN i
counseling NN i
reduced VBN N
smoking NN N
( ( N
-9.1 JJ N
versus NN N
-4.5 NNP N
cigarettes VBZ N
daily RB N
, , N
P NNP N
=.03 NNP N
) ) N
, , N
but CC N
did VBD N
not RB N
affect VB N
absolute JJ N
quit NN o
rates NNS o
( ( N
24 CD N
% NN N
versus IN N
21 CD N
% NN N
) ) N
at IN N
36 CD N
weeks NNS N
' POS N
gestation NN N
. . N

Infant NNP o
birth NN o
weight VBD o
negatively RB N
correlated VBN N
with IN N
cigarettes NNS N
smoked VBN N
per IN N
day NN N
( ( N
r VB N
= NNP N
-0.29 NNP N
, , N
P NNP N
< NNP N
.01 NNP N
) ) N
and CC N
expired JJ N
carbon NN N
monoxide NN N
( ( N
r JJ N
= NNP N
-0.39 NN N
, , N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
at IN N
delivery NN N
. . N

Birth NNP o
weight VBD o
for IN o
infants NNS o
born VBN o
to TO o
women NNS o
who WP o
quit VBP o
smoking VBG o
averaged VBD N
7.2 CD N
lb JJ N
versus NN N
6.8 CD N
and CC N
6.3 CD N
lb NN N
for IN N
mothers NNS N
smoking VBG N
one CD N
to TO N
six CD N
and CC N
more JJR N
than IN N
six CD N
cigarettes NNS N
per IN N
day NN N
at IN N
delivery NN N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
. . N

CONCLUSION NNP N
Peer NNP o
counseling NN o
reduced VBD N
the DT N
number NN o
of IN o
cigarettes NNS o
smoked VBN o
daily RB o
but CC N
did VBD N
not RB N
increase VB N
cigarette NN o
abstinence NN o
rates NNS o
. . o

Infant NNP o
birth NN o
weight NN o
increases NNS N
with IN N
both DT N
smoking VBG N
cessation NN N
and CC N
smoking NN N
reduction NN N
, , N
suggesting VBG N
that IN N
peer NN i
counseling VBG i
intervention NN i
programs NNS i
may MD N
improve VB N
newborn JJR o
health NN o
despite IN N
their PRP$ N
failure NN N
to TO N
affect VB N
smoking VBG N
cessation NN N
. . N

-DOCSTART- -20338811- O O

CD4+FOXP3+ NNP N
regulatory JJ N
T NNP N
cell NN N
depletion NN N
by IN N
low-dose JJ N
cyclophosphamide NN i
prevents NNS N
recurrence NN o
in IN N
patients NNS p
with IN p
large JJ p
condylomata NNS p
acuminata NNS p
after IN p
laser NN i
therapy NN i
. . i

Condylomata NNP N
acuminata NN N
( ( N
CA NNP N
) ) N
caused VBN N
by IN N
human JJ N
papillomavirus NN N
( ( N
HPV NNP N
) ) N
is VBZ N
a DT N
common JJ N
sexually RB N
transmitted JJ N
disease NN N
with IN N
half PDT N
a DT N
million CD N
new JJ N
cases NNS N
diagnosed VBN N
in IN N
the DT N
United NNP N
States NNPS N
per IN N
year NN N
and CC N
the DT N
annual JJ N
increase NN N
in IN N
incidence NN N
in IN N
China NNP N
. . N

Recurrence NNP o
is VBZ N
a DT N
major JJ N
challenge NN N
for IN N
CA NNP N
treatment NN N
. . N

Recently RB N
, , N
we PRP N
demonstrated VBD N
that IN N
FOXP3 NNP N
( ( N
+ NNP N
) ) N
regulatory JJ N
T NNP N
( ( N
Treg NNP N
) ) N
cells NNS N
mediate VBP N
the DT N
immunosuppression NN o
in IN o
large JJ o
genital JJ o
warts NNS o
. . o

Here RB N
, , N
we PRP N
further VBP N
report VB N
that IN N
low-dose JJ i
cyclophosphamide NN i
( ( i
CY NNP i
) ) i
, , N
a DT N
conventional JJ i
chemotherapy JJ i
drug NN N
, , N
can MD N
effectively RB N
prevent VB N
the DT N
recurrence NN o
of IN o
large JJ o
CA NNP o
in IN N
clinical JJ p
patients NNS p
after IN p
laser NN i
therapy NN i
. . i

Surprisingly RB N
, , N
although IN N
9 CD N
out IN N
of IN N
52 CD p
patients NNS p
recur JJ N
six CD N
weeks NNS N
after IN N
the DT N
combination NN N
treatment NN N
, , N
the DT N
re-administration NN N
of IN N
low-dose JJ N
CY NNP i
alone RB N
completely RB N
eliminates VBZ N
most JJS N
recurred JJ o
lesions NNS o
. . o

We PRP N
provide VBP N
evidence NN N
that IN N
low-dose JJ N
CY NNP i
not RB N
only RB N
depletes VBZ N
patients NNS o
' POS o
Treg NNP o
cells NNS o
and CC N
enhances NNS N
function NN o
of IN o
HPV-specific NNP o
T NNP o
cells NNS o
and CC o
NK NNP o
cells NNS o
in IN N
the DT N
periphery NN N
, , N
but CC N
also RB N
ameliorates VBZ N
the DT N
immune JJ o
milieu NN o
of IN o
the DT o
lesion NN o
site NN o
, , N
leading VBG N
to TO N
the DT N
elimination NN o
of IN o
remnant JJ o
viruses NNS o
. . o

These DT N
findings NNS N
have VBP N
important JJ N
clinical JJ N
significance NN N
, , N
and CC N
potentially RB N
lead JJ N
to TO N
a DT N
therapeutic JJ N
breakthrough NN N
for IN N
the DT N
treatment NN o
of IN o
CA NNP o
. . o

-DOCSTART- -2218657- O O

Comparison NNP N
of IN N
cefuroxime NN i
axetil NN i
, , i
cefaclor NN i
, , N
and CC N
amoxicillin-clavulanate JJ i
potassium NN i
suspensions NNS N
in IN N
acute JJ p
otitis NN p
media NNS p
in IN p
infants NNS p
and CC p
children NNS p
. . p

In IN N
this DT N
randomized VBN N
, , N
blinded VBD N
, , N
multicenter FW N
comparison NN N
study NN N
, , N
377 CD p
infants NNS p
and CC p
children NNS p
with IN p
acute NN p
otitis NN p
media NNS p
( ( p
AOM NNP p
) ) p
received VBD p
a DT p
10-day JJ p
course NN p
of IN p
an DT p
oral JJ p
suspension NN p
of IN N
one CD N
of IN N
the DT N
following NN N
: : N
cefuroxime NN i
axetil NN i
( ( i
CAE NNP i
) ) i
, , N
30 CD N
mg/kg/day NN N
; : N
cefaclor NN i
( ( i
CEC NNP i
) ) i
, , N
40 CD N
mg/kg/day NN N
; : N
or CC N
amoxicillin-clavulanate JJ i
potassium NN i
( ( i
AMX-CL NNP i
) ) i
, , N
40 CD N
mg/kg/day NN N
. . N

Clinical JJ o
efficacy NN o
was VBD N
determined VBN N
by IN N
pneumatic JJ N
otoscopy NN N
and CC N
tympanometric JJ N
testing VBG N
3 CD N
to TO N
5 CD N
, , N
11 CD N
to TO N
14 CD N
, , N
and CC N
22 CD N
to TO N
26 CD N
days NNS N
after IN N
the DT N
initiation NN N
of IN N
therapy NN N
. . N

There EX N
was VBD N
a DT N
statistically RB N
significant JJ N
difference NN N
among IN N
the DT N
three CD N
treatment NN N
groups NNS N
with IN N
respect NN N
to TO N
clinical JJ N
outcome NN N
; : N
more JJR N
patients NNS N
in IN N
the DT N
CAE NNP i
group NN N
( ( N
62 CD N
% NN N
) ) N
than IN N
in IN N
the DT N
CEC NNP N
group NN N
( ( N
46 CD N
% NN N
) ) N
or CC N
the DT N
AMX-CL JJ i
group NN N
( ( N
52 CD N
% NN N
) ) N
had VBD N
complete JJ N
resolution NN N
of IN N
signs NNS o
and CC o
symptoms NNS o
of IN o
AOM NNP o
( ( o
including VBG o
effusion NN o
) ) o
. . o

Paired VBN N
comparisons NNS N
revealed VBD N
a DT N
significant JJ N
difference NN N
in IN N
efficacy NN o
between IN N
CAE NNP i
and CC N
CEC NNP i
and CC N
a DT N
nearly RB N
significant JJ N
difference NN N
between IN N
AMX-CL NNP i
and CC N
CEC NNP i
. . i

Taste NNP o
acceptability NN o
was VBD N
highest JJS N
for IN N
CEC NNP i
and CC N
lowest JJS N
for IN N
this DT N
formulation NN N
of IN N
CAE NNP i
. . i

Significantly RB N
more JJR N
patients NNS N
in IN N
the DT N
AMX-CL NNP i
group NN N
than IN N
in IN N
the DT N
CAE NNP i
or CC N
CEC NNP i
group NN N
had VBD N
a DT N
side NN o
effect NN o
, , o
primarily RB o
diarrhea NN o
, , o
vomiting VBG o
, , o
or CC o
diaper JJ o
rash NN o
. . o

We PRP N
conclude VBP N
that IN N
CAE NNP N
suspension NN N
has VBZ N
greater JJR N
clinical JJ o
efficacy NN o
than IN N
CEC NNP N
and CC N
fewer JJR N
side NN o
effects NNS o
than IN N
AMX-CL NNP i
. . i

-DOCSTART- -3882217- O O

A DT N
randomized VBN N
, , N
prospective JJ N
trial NN N
of IN N
adjuvant JJ i
chemotherapy NN i
in IN N
adults NNS p
with IN p
soft JJ p
tissue NN p
sarcomas NN p
of IN p
the DT p
head NN p
and CC p
neck NN p
, , p
breast NN p
, , p
and CC p
trunk NN p
. . p

Since IN p
1977 CD p
, , p
31 CD p
patients NNS p
were VBD p
entered VBN p
in IN p
a DT p
randomized JJ p
, , p
prospective JJ p
study NN p
testing VBG p
the DT p
efficacy NN p
of IN p
adjuvant JJ i
chemotherapy NN i
after IN p
aggressive JJ p
local JJ p
treatment NN p
of IN p
high-grade JJ p
sarcomas NN p
of IN p
the DT p
head NN p
, , p
neck NN p
, , p
breast NN p
, , p
and CC p
trunk NN p
( ( p
excluding VBG p
retroperitoneal VB p
sarcomas NN p
) ) p
. . p

All DT p
patients NNS p
had VBD p
complete JJ p
resection NN i
of IN i
gross JJ i
tumor NN i
and CC p
underwent JJ p
postoperative JJ i
radiotherapy NN i
( ( p
6000-6300 JJ p
rads NNS p
over IN p
7-8 JJ p
weeks NNS p
) ) p
. . p

Seventeen JJ p
patients NNS p
received VBD p
adjuvant JJ i
chemotherapy NN i
consisting NN i
of IN i
doxorubicin NN i
( ( i
less JJR i
than IN i
or CC i
equal JJ i
to TO i
550 CD i
mg/m2 NN i
) ) i
, , i
cyclophosphamide RB i
( ( i
less JJR i
than IN i
or CC i
equal JJ i
to TO i
5500 CD i
mg/m2 NN i
) ) i
, , i
and CC i
methotrexate NN i
( ( i
less JJR i
than IN i
or CC i
equal JJ i
to TO i
1000 CD i
mg/kg NN i
) ) i
. . N

Three-year JJ N
actuarial JJ o
disease-free JJ o
survival NN o
in IN N
the DT N
chemotherapy NN i
arm NN N
was VBD N
77 CD N
% NN N
, , N
compared VBN N
to TO N
49 CD N
% NN N
in IN N
the DT N
no-chemotherapy JJ i
arm NN N
( ( N
P NNP N
= NNP N
0.075 CD N
) ) N
. . N

Three-year JJ N
overall JJ o
actuarial JJ o
survivals NNS o
in IN N
the DT N
two CD N
treatment NN N
arms NNS N
, , N
however RB N
, , N
were VBD N
68 CD N
% NN N
and CC N
58 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
0.38 CD N
) ) N
. . N

Considering VBG N
only JJ N
patients NNS N
with IN N
tumors NNS N
of IN N
the DT N
trunk NN N
( ( N
22 CD N
patients NNS N
) ) N
, , N
3-year JJ N
actuarial JJ N
disease-free JJ N
survival NN N
in IN N
the DT N
chemotherapy NN N
arm NN N
was VBD N
92 CD N
% NN N
, , N
compared VBN N
to TO N
47 CD N
% NN N
in IN N
the DT N
no-chemotherapy JJ N
arm NN N
( ( N
P NNP N
= NNP N
0.006 CD N
) ) N
. . N

Actuarial JJ N
3-year JJ N
overall JJ N
survival NN N
in IN N
the DT N
chemotherapy NN N
arm NN N
was VBD N
82 CD N
% NN N
, , N
compared VBN N
to TO N
61 CD N
% NN N
in IN N
the DT N
no-chemotherapy JJ N
arm NN N
( ( N
P NNP N
= NNP N
0.18 CD N
) ) N
. . N

An DT p
additional JJ p
26 CD p
patients NNS p
were VBD N
treated VBN N
in IN N
an DT N
identical JJ N
fashion NN N
, , N
but CC N
were VBD N
not RB N
part NN N
of IN N
the DT N
randomized VBN N
trial NN N
because IN N
of IN N
contraindications NNS N
to TO N
chemotherapy VB N
, , N
refusal NN N
to TO N
enter VB N
the DT N
randomized JJ N
trial NN N
, , N
or CC N
because IN N
they PRP N
were VBD N
treated VBN N
before IN N
1977 CD N
in IN N
a DT N
trial NN N
in IN N
which WDT N
all DT N
patients NNS N
received VBD N
chemotherapy NN N
. . N

Considering VBG N
the DT N
entire JJ p
group NN p
of IN p
57 CD p
patients NNS p
, , N
follow-up JJ N
ranged VBD N
from IN N
10 CD N
to TO N
86 CD N
months NNS N
( ( N
median JJ N
, , N
35 CD N
months NNS N
) ) N
. . N

Local JJ o
control NN o
was VBD N
achieved VBN N
in IN N
46 CD N
patients NNS N
( ( N
81 CD N
% NN N
) ) N
; : N
3-year JJ N
actuarial JJ o
disease-free NN o
and CC o
overall JJ o
survivals NNS o
were VBD N
67 CD N
% NN N
and CC N
77 CD N
% NN N
, , N
respectively RB N
. . N

A DT N
tendency NN N
toward IN N
improved JJ N
disease-free JJ o
survival NN o
was VBD N
apparent JJ N
among IN N
patients NNS N
treated VBN N
with IN N
chemotherapy NN N
( ( N
P NNP N
= NNP N
0.018 CD N
) ) N
, , N
but CC N
there EX N
was VBD N
no DT N
statistically RB N
significant JJ N
improvement NN N
in IN N
overall JJ o
actuarial JJ o
survival NN o
( ( N
P NNP N
= NNP N
0.46 CD N
) ) N
. . N

The DT p
subgroup NN p
of IN p
patients NNS p
with IN p
sarcomas NN p
of IN p
the DT p
trunk NN p
( ( p
39 CD p
patients NNS p
) ) p
demonstrated VBD N
the DT N
greatest JJS N
benefit NN N
from IN N
chemotherapy NN i
, , N
with IN N
regard NN N
to TO N
disease-free JJ o
survival NN o
( ( N
P NNP N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
0.001 CD N
) ) N
. . N

The DT N
most RBS N
significant JJ N
toxicity NN o
associated VBN N
with IN N
chemotherapy NN i
was VBD N
doxorubicin-induced JJ o
cardiomyopathy NN o
, , N
which WDT N
resulted VBD N
in IN N
clinically RB N
apparent JJ N
congestive JJ o
heart NN o
failure NN o
in IN N
five CD N
patients NNS N
. . N

Thus RB N
, , N
the DT N
use NN N
of IN N
chemotherapy NN i
when WRB N
combined VBN N
with IN N
aggressive JJ N
local JJ N
measures NNS N
appears VBZ N
to TO N
improve VB N
disease-free JJ o
survival NN o
, , N
but CC N
additional JJ N
patients NNS N
and CC N
longer JJR N
follow-up NN N
are VBP N
necessary JJ N
to TO N
determine VB N
if IN N
improved VBN N
overall JJ o
survival NN o
will MD N
result VB N
. . N

-DOCSTART- -23084676- O O

Hemostasis NN N
by IN N
bipolar JJ i
coagulation NN i
versus NN N
suture NN i
after IN N
surgical JJ i
stripping NN i
of IN N
bilateral JJ N
ovarian JJ N
endometriomas NN N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

STUDY NNP N
OBJECTIVE NNP N
To TO N
estimate VB N
whether IN N
the DT N
suture NN i
of IN i
the DT i
ovary JJ i
is VBZ N
superior JJ N
to TO N
bipolar JJ i
coagulation NN i
in IN N
preserving VBG N
ovarian JJ N
reserve NN N
in IN N
infertile JJ p
women NNS p
undergoing VBG p
laparoscopic JJ i
stripping NN i
of IN i
bilateral JJ i
endometriomas NN i
. . i

DESIGN NNP N
Randomized NNP N
controlled VBD N
trial NN N
( ( N
Canadian JJ N
Task NNP N
Force NNP N
classification NN N
I PRP N
) ) N
. . N

SETTING NN N
University NNP p
teaching NN p
hospital NN p
. . p

PATIENTS CC N
100 CD p
patients NNS p
with IN p
bilateral JJ p
endometriomas NN p
. . p

INTERVENTIONS NNP N
Patients NNPS N
underwent JJ N
stripping NN i
of IN i
bilateral JJ i
endometriomas NNS i
and CC N
were VBD N
randomized VBN N
to TO N
undergo VB N
hemostasis NN N
by IN N
use NN N
of IN N
either DT N
laparoscopic NN i
suturing NN i
( ( i
LS NNP i
group NN i
) ) i
or CC i
bipolar JJ i
coagulation NN i
( ( i
BC NNP i
group NN N
) ) N
. . N

Changes NNS o
in IN o
ovarian JJ o
reserve NN o
were VBD N
investigated VBN N
by IN N
measuring VBG N
the DT N
levels NNS N
of IN N
anti-Mullerian JJ o
hormone NN o
( ( o
AMH NNP o
) ) o
and CC o
basal JJ o
follicle-stimulating JJ o
hormone NN o
( ( o
FSH NNP o
) ) o
before IN N
surgery NN N
and CC N
at IN N
3 CD N
, , N
6 CD N
and CC N
12 CD N
months NNS N
from IN N
surgery NN N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
At IN N
3-month JJ N
, , N
6-month JJ N
, , N
and CC N
12-month JJ N
follow-up NN N
, , N
in IN N
both DT N
study NN N
groups NNS N
, , N
postsurgical JJ o
AMH NNP o
levels NNS o
were VBD N
significantly RB N
lower JJR N
and CC N
basal VB o
FSH NNP o
levels NNS o
were VBD N
significantly RB N
higher JJR N
than IN N
before RB N
surgery NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
mean JJ N
percentage NN N
decrease NN N
of IN N
AMH NNP o
levels NNS o
in IN N
the DT N
BC NNP i
group NN N
and CC N
LS NNP i
group NN N
at IN N
3- JJ N
, , N
6- JJ N
, , N
and CC N
12-month JJ N
follow-up NN N
. . N

The DT N
mean JJ N
percentage NN N
increase NN N
in IN N
basal JJ o
FSH NNP o
was VBD N
higher RBR N
in IN N
the DT N
BC NNP i
group NN N
than IN N
in IN N
the DT N
LS NNP i
group NN N
at IN N
both DT N
3-month JJ N
( ( N
p JJ N
= NNP N
.023 NNP N
) ) N
and CC N
6-month JJ N
follow-up NN N
( ( N
p JJ N
= NNP N
.029 NNP N
) ) N
, , N
but CC N
not RB N
at IN N
12-month JJ N
follow-up NN N
. . N

Pregnancy NNP o
rate NN o
, , o
time NN o
to TO o
conception NN o
, , o
and CC o
rate NN o
of IN o
endometrioma NN o
recurrence NN o
was VBD N
similar JJ N
in IN N
the DT N
2 CD N
study NN N
groups NNS N
. . N

CONCLUSION NNP N
Laparoscopic NNP i
stripping NN i
of IN i
ovarian JJ i
endometriotic JJ i
cyst NN i
significantly RB N
decreases VBZ N
serum JJ o
AMH NNP o
levels NNS o
and CC N
increases VBZ N
basal JJ o
FSH NNP o
levels NNS o
independent JJ N
from IN N
the DT N
method NN N
used VBN N
to TO N
obtain VB N
hemostasis NN N
on IN N
the DT N
ovarian JJ N
tissue NN N
. . N

-DOCSTART- -543887- O O

Comparison NNP p
of IN p
some DT p
pharmacokinetic JJ o
parameters NNS o
of IN p
( ( o
+ NNP o
) ) o
-cyanidanol-3 NN o
obtained VBN p
with IN p
specific JJ p
and CC p
non-specific JJ p
analytical JJ p
methods NNS p
. . p

-DOCSTART- -24964689- O O

Self-management JJ i
improvement NN i
program NN i
combined VBN i
with IN i
community NN i
involvement NN i
in IN N
Thai NNP p
hypertensive JJ p
population NN p
: : p
an DT N
action NN N
research NN N
. . N

OBJECTIVE UH N
To TO N
investigate VB N
the DT N
effectiveness NN o
of IN N
a DT N
program NN i
that WDT i
utilizes VBZ i
community NN i
involvement NN i
to TO N
improve VB N
the DT N
self-management JJ i
strategies NNS i
among IN N
people NNS p
living VBG p
with IN p
hypertension NN p
. . p

MATERIAL NNP N
AND NNP N
METHOD NNP N
Forty-four NNP p
subjects NNS p
, , p
aged VBD p
35 CD p
to TO p
59-year-old JJ p
, , p
with IN p
hypertension NN p
in IN p
Nakhon NNP p
Pathom NNP p
Province NNP p
, , p
Thailand NNP p
, , N
were VBD N
randomly RB N
allocated VBN N
to TO N
either DT N
an DT N
experimental JJ i
group NN i
( ( N
n JJ N
= NNP N
22 CD N
) ) N
or CC N
a DT N
control NN i
group NN i
( ( N
n JJ N
= NNP N
20 CD N
) ) N
. . N

The DT N
experimental JJ N
group NN N
attended VBD N
a DT N
program NN i
to TO i
improve VB i
self-management JJ i
methods NNS i
based VBN i
on IN i
social JJ i
cognitive JJ i
theory NN i
( ( i
SCT NNP i
) ) i
. . i

The DT N
program NN N
lasted VBD N
12 CD N
weeks NNS N
, , N
consisted VBD N
of IN N
1 CD N
1/2 CD N
hours NNS N
meeting VBG N
once RB N
a DT N
week NN N
, , N
including VBG N
group NN i
meetings NNS i
and CC N
home NN i
visit NN i
monitoring NN i
. . N

Mann-Whitney NNP N
U NNP o
test NN o
and CC o
Friedman NNP o
test NN o
were VBD N
employed VBN N
to TO N
analyze VB N
the DT N
program NN N
's POS N
effectiveness NN o
. . o

RESULTS NNP N
After IN N
the DT N
program NN N
, , N
the DT N
mean JJ o
rank NN o
of IN N
the DT N
perceived JJ o
self-efficacy NN o
for IN N
the DT N
self-management JJ o
strategies NNS o
was VBD N
statistically RB N
different JJ N
between IN N
the DT N
two CD N
groups NNS N
( ( N
p JJ N
= NNP N
0.023 CD N
) ) N
. . N

In IN N
the DT N
experimental JJ N
group NN N
, , N
after IN N
the DT N
twelve NN N
week NN N
, , N
the DT N
mean JJ o
rank NN o
of IN o
perceived VBN o
self-efficacy NN o
and CC o
outcome JJ o
expectancy NN o
increased VBD o
and CC N
diastolic JJ o
blood NN o
pressure NN o
decreased VBN o
after IN N
the DT N
eight CD N
week NN N
. . N

CONCLUSION VB N
The DT N
program NN N
applied VBN N
social JJ i
cognitive JJ i
theory NN i
( ( i
SCT NNP i
) ) i
to TO N
promote VB N
self-management JJ i
techniques NNS i
, , N
increased VBD N
the DT N
health NN o
promoting VBG o
behavior NN o
among IN N
hypertensive JJ N
people NNS N
. . N

-DOCSTART- -21720723- O O

Cross-modal JJ N
attention-switching NN N
is VBZ N
impaired VBN N
in IN N
autism NN N
spectrum NN N
disorders NNS N
. . N

This DT N
investigation NN N
aimed VBN N
to TO N
determine VB N
if IN N
children NNS p
with IN p
ASD NNP p
are VBP N
impaired VBN N
in IN N
their PRP$ N
ability NN N
to TO N
switch VB N
attention NN N
between IN N
different JJ N
tasks NNS N
, , N
and CC N
whether IN N
performance NN N
is VBZ N
further RB N
impaired JJ N
when WRB N
required VBN N
to TO N
switch VB N
across IN N
two CD N
separate JJ N
modalities NNS N
( ( N
visual JJ N
and CC N
auditory NN N
) ) N
. . N

Eighteen JJ p
children NNS p
with IN p
ASD NNP p
( ( p
9-13 CD p
years NNS p
old JJ p
) ) p
were VBD p
compared VBN p
with IN p
18 CD p
typically-developing JJ p
children NNS p
matched VBN p
with IN p
the DT p
ASD NNP p
group NN p
for IN p
mental JJ p
age NN p
, , p
and CC p
also RB p
with IN p
18 CD p
subjects NNS p
with IN p
learning VBG p
difficulties NNS p
matched VBN p
with IN p
the DT p
ASD NNP p
group NN p
for IN p
mental JJ p
and CC p
chronological JJ p
age NN p
. . p

Individuals NNS N
alternated VBD N
between IN N
two CD i
different JJ i
visual JJ i
tasks NNS i
, , i
and CC i
between IN i
a DT i
different JJ i
visual JJ i
task NN i
and CC i
an DT i
auditory JJ i
task NN i
. . i

Children NNP N
with IN N
ASD NNP N
performed VBD o
worse JJR o
than IN N
both DT N
comparison JJ N
groups NNS N
at IN N
both DT N
switching VBG o
tasks NNS o
. . o

Moreover RB N
, , N
children NNS N
with IN N
ASD NNP N
had VBD N
greater JJR o
difficulty NN o
when WRB o
different JJ o
modalities NNS o
were VBD o
required VBN o
than IN o
where WRB o
only RB o
one CD o
modality NN o
was VBD o
required VBN o
in IN o
the DT o
switching NN o
task NN o
in IN N
comparison NN N
with IN N
participants NNS N
matched VBN N
in IN N
terms NNS N
of IN N
mental NN N
and CC N
chronological JJ N
age NN N
. . N

-DOCSTART- -17069542- O O

Effect NN N
of IN N
CX516 NNP i
, , N
an DT N
AMPA-modulating JJ i
compound NN i
, , N
on IN N
cognition NN o
and CC o
behavior NN o
in IN p
fragile JJ p
X JJ p
syndrome NN p
: : p
a DT N
controlled JJ N
trial NN N
. . N

A DT N
Phase NNP N
II NNP N
, , N
4-week JJ N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
clinical JJ N
trial NN N
was VBD N
conducted VBN N
to TO N
evaluate VB N
the DT N
safety NN o
and CC o
efficacy NN o
of IN N
the DT N
Ampakine NNP i
compound NN N
CX516 NNP i
as IN N
a DT N
potential JJ N
treatment NN N
for IN N
the DT N
underlying JJ p
disorder NN p
in IN p
fragile JJ p
X NNP p
syndrome NN p
( ( p
FXS NNP p
) ) p
. . p

After IN N
baseline NN N
screening NN N
, , N
subjects VBZ p
with IN p
FXS NNP p
( ( p
n JJ p
= NNP p
49 CD p
) ) p
underwent NN N
a DT N
1-week JJ i
placebo NN i
lead-in NN i
and CC i
then RB i
were VBD i
randomized VBN i
to TO i
study VB i
drug NN i
or CC i
placebo NN i
for IN i
a DT i
4-week JJ i
period NN i
. . i

Cognitive JJ o
and CC o
behavioral JJ o
outcome NN N
measures NNS N
were VBD N
administered VBN N
prior RB N
to TO N
treatment NN N
, , N
at IN N
the DT N
end NN N
of IN N
treatment NN N
, , N
and CC N
2 CD N
weeks NNS N
posttreatment NN N
. . N

There EX N
were VBD N
minimal JJ o
side NN o
effects NNS o
, , N
no DT N
significant JJ o
changes NNS o
in IN o
safety NN o
parameters NNS o
, , N
and CC N
no DT o
serious JJ o
adverse JJ o
events NNS o
. . o

There EX N
was VBD N
a DT N
12.5 CD o
% NN o
frequency NN o
of IN N
allergic JJ o
rash NN o
in IN N
the DT N
CX516 NNP i
group NN N
and CC N
1 CD N
subject NN N
developed VBD N
a DT N
substantial JJ o
rash NN o
. . o

There EX N
was VBD N
also RB N
no DT N
significant JJ o
improvement NN o
in IN N
memory NN o
, , N
the DT N
primary JJ N
outcome NN N
measure NN N
, , N
or CC N
in IN N
secondary JJ N
measures NNS N
of IN N
language NN o
, , o
attention/executive JJ o
function NN o
, , o
behavior NN o
, , o
and CC o
overall JJ o
functioning NN o
in IN N
CX516-treated JJ i
subjects NNS N
compared VBN N
to TO N
placebo VB i
. . i

This DT N
study NN N
did VBD N
demonstrate VB N
that IN N
many JJ N
outcome JJ N
measures NNS o
were VBD N
reproducible JJ N
in IN N
this DT N
test-retest JJ N
setting NN N
for IN N
the DT N
FXS NNP N
population NN N
, , N
yet CC N
some DT N
were VBD N
too RB N
difficult JJ N
or CC N
variable JJ N
. . N

Adult NNP p
subjects VBZ p
with IN p
FXS NNP p
were VBD N
able JJ N
to TO N
complete VB N
an DT N
intensive JJ N
clinical JJ N
trial NN N
, , N
and CC N
some DT N
valid JJ N
outcome NN N
measures NNS N
were VBD N
identified VBN N
for IN N
future JJ N
FXS NNP N
trial NN N
design NN N
. . N

Problems VBZ N
with IN N
potency NN N
of IN N
CX516 NNP i
in IN N
other JJ N
studies NNS N
have VBP N
suggested VBN N
dosing NN N
may MD N
have VB N
been VBN N
inadequate JJ N
for IN N
therapeutic JJ N
effect NN N
and CC N
thus RB N
it PRP N
remains VBZ N
unclear JJ N
whether IN N
modulation NN N
of IN N
AMPA-mediated JJ N
neurotransmission NN N
is VBZ N
a DT N
viable JJ o
therapeutic JJ o
strategy NN o
for IN N
the DT N
treatment NN N
of IN N
FXS NNP N
. . N

-DOCSTART- -12872081- O O

A DT N
prospective JJ N
randomized VBN N
trial NN N
of IN N
two CD N
different JJ N
endoscopic NNS i
resection NN i
techniques NNS i
for IN N
early JJ p
stage NN p
cancer NN p
of IN p
the DT p
esophagus NN p
. . p

BACKGROUND VB N
A DT N
variety NN N
of IN N
different JJ N
endoscopic JJ i
resection NN i
techniques NNS i
for IN N
early JJ N
stage NN N
cancer NN N
of IN N
the DT N
upper JJ N
GI NNP N
tract NN N
have VBP N
been VBN N
described VBN N
that WDT N
are VBP N
more RBR N
effective JJ N
than IN N
strip NN N
biopsy NN N
. . N

However RB N
, , N
there EX N
is VBZ N
no DT N
report NN N
of IN N
a DT N
prospective JJ N
randomized VBN N
comparison NN N
of IN N
different JJ N
techniques NNS N
. . N

METHODS NNP N
In IN N
a DT N
prospective JJ N
randomized NN N
study NN N
, , N
100 CD p
consecutive JJ p
endoscopic NN i
resections NNS i
were VBD p
performed VBN p
in IN p
72 CD p
patients NNS p
with IN p
early JJ p
stage NN p
esophageal JJ p
cancer NN p
. . p

Fifty NNP i
endoscopic JJ i
resections NNS i
were VBD N
performed VBN N
with IN N
a DT N
suck-and-ligate JJ i
device NN i
without IN i
prior JJ i
submucosa NN i
injection NN i
and CC i
50 CD N
with IN N
the DT i
cap NN i
technique NN i
with IN i
prior JJ i
submucosa JJ i
injection NN i
of IN i
a DT i
dilute JJ i
saline JJ i
solution NN i
of IN i
epinephrine NN i
. . i

The DT N
main JJ N
assessment NN N
criteria NNS N
were VBD N
maximum JJ o
diameter NN o
of IN o
the DT o
resection NN o
specimen NNS o
and CC o
of IN o
the DT o
resection NN o
area NN o
, , o
and CC o
the DT o
complication NN o
rate NN o
. . o

RESULTS NNP N
No NNP N
significant JJ N
differences NNS N
were VBD N
observed VBN N
between IN N
the DT N
two CD N
groups NNS N
with IN N
regard NN N
to TO N
the DT N
maximum JJ o
diameters NNS o
and CC o
calculated JJ o
area NN o
of IN o
the DT o
resected VBN o
specimens NNS o
( ( N
ligation NN N
group NN N
: : N
16.4 CD N
[ $ N
4.0 CD N
] NNP N
x VBD N
11 CD N
[ JJ N
3.1 CD N
] JJ N
mm/185 NN N
[ VBD N
84 CD N
] NN N
mm NN N
( ( N
2 CD N
) ) N
vs. FW N
cap NN N
group NN N
: : N
15.5 CD N
[ $ N
4.1 CD N
] NNP N
x VBD N
10.7 CD N
[ JJ N
2.7 CD N
] JJ N
mm/168 NN N
[ VBD N
83 CD N
] NN N
mm NN N
( ( N
2 CD N
) ) N
) ) N
, , N
or CC N
the DT N
maximum JJ o
diameters NNS o
and CC o
calculated JJ o
area NN o
of IN o
the DT o
endoscopic NN o
resection NN o
ulcers NNS o
after IN N
24 CD N
hours NNS N
( ( N
ligation NN N
group NN N
: : N
20.6 CD N
[ $ N
4.8 CD N
] NNP N
x VBD N
14.3 CD N
[ JJ N
4.5 CD N
] JJ N
mm/314 NN N
[ VBD N
160 CD N
] NN N
mm NN N
( ( N
2 CD N
) ) N
vs. FW N
cap NN N
group NN N
: : N
18.9 CD N
[ $ N
5.1 CD N
] NNP N
x VBD N
12.9 CD N
[ JJ N
3.8 CD N
] JJ N
mm/260 NN N
[ VBD N
145 CD N
] NN N
mm NN N
( ( N
2 CD N
) ) N
) ) N
. . N

There EX N
was VBD N
only RB N
a DT N
slight JJ N
advantage NN N
( ( N
greater JJR N
diameter NN N
of IN N
resection NN N
specimens NNS N
) ) N
for IN N
the DT N
ligation NN N
group NN N
in IN N
patients NNS p
who WP p
had VBD p
prior JJ p
endoscopic NN p
treatment NN p
. . p

There EX N
was VBD N
one CD N
minor JJ N
episode NN N
of IN N
bleeding VBG o
in IN N
each DT N
group NN N
; : N
there EX N
was VBD N
no DT N
severe JJ N
complication NN N
. . N

In IN N
41 CD N
of IN N
72 CD N
patients NNS N
( ( N
57 CD N
% NN N
) ) N
, , N
further JJ N
endoscopic NN i
therapy NN i
after IN N
endoscopic JJ N
resection NN N
was VBD N
necessary JJ N
because IN N
of IN N
residual JJ o
neoplasia NN o
at IN N
the DT N
first JJ N
follow-up JJ N
endoscopy NN N
after IN N
resection NN N
( ( N
61 CD N
of IN N
100 CD N
resection NN N
specimens NNS N
[ VBP N
61 CD N
% NN N
] NN N
had VBD N
lateral JJ N
margins NNS N
that WDT N
could MD N
not RB N
be VB N
evaluated VBN N
because IN N
of IN N
coagulation NN N
artifact NN N
or CC N
contained VBN N
malignancy NN N
but CC N
with IN N
the DT N
base NN N
of IN N
the DT N
lesion NN N
free JJ N
of IN N
tumor NN N
) ) N
. . N

CONCLUSIONS VB N
The DT N
cap NN i
technique NN i
with IN N
submucosa JJ N
injection NN N
and CC N
the DT N
ligation NN i
technique NN i
without IN N
submucosa JJ N
injection NN N
are VBP N
similar JJ N
with IN N
respect NN N
to TO N
efficacy NN N
and CC N
safety NN N
for IN N
endoscopic JJ N
resection NN N
of IN N
early JJ N
stage NN N
esophageal NN N
cancers NNS N
. . N

-DOCSTART- -21385365- O O

A DT N
prospective JJ N
, , N
double-blind JJ N
, , N
randomized VBN N
, , N
controlled VBD N
clinical JJ N
trial NN N
comparing VBG N
standard NN i
wound NN i
care NN i
with IN N
adjunctive JJ i
hyperbaric JJ i
oxygen NN i
therapy NN i
( ( i
HBOT NNP i
) ) i
to TO N
standard VB N
wound NN N
care NN N
only RB N
for IN N
the DT N
treatment NN N
of IN N
chronic JJ o
, , o
non-healing JJ o
ulcers NNS o
of IN p
the DT p
lower JJR p
limb NN p
in IN p
patients NNS p
with IN p
diabetes NNS p
mellitus NNS p
: : p
a DT N
study NN N
protocol NN N
. . N

BACKGROUND NNP N
It PRP N
has VBZ N
been VBN N
suggested VBN N
that IN N
the DT N
use NN N
of IN N
adjunctive JJ i
hyperbaric JJ i
oxygen NN i
therapy NN i
improves VBZ N
the DT N
healing NN N
of IN N
diabetic JJ o
foot NN o
ulcers NNS o
, , N
and CC N
decreases VBZ N
the DT N
risk NN N
of IN N
lower JJR o
extremity NN o
amputations NNS o
. . o

A DT N
limited JJ N
number NN N
of IN N
studies NNS N
have VBP N
used VBN N
a DT N
double JJ N
blind NN N
approach NN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
hyperbaric JJ i
oxygen NN i
therapy NN i
in IN N
the DT N
treatment NN N
of IN N
diabetic JJ p
ulcers NNS p
. . p

The DT N
primary JJ N
aim NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
assess VB N
the DT N
efficacy NN N
of IN N
hyperbaric JJ i
oxygen NN i
therapy NN i
plus CC i
standard NN i
wound NN i
care NN i
compared VBN N
with IN N
standard NN i
wound NN i
care NN i
alone RB N
in IN N
preventing VBG N
the DT N
need NN N
for IN N
major JJ o
amputation NN o
in IN N
patients NNS p
with IN p
diabetes NNS p
mellitus NNS p
and CC p
chronic JJ p
ulcers NNS p
of IN p
the DT p
lower JJR p
limb NN p
. . p

METHODS/DESIGN NNP N
One CD p
hundred CD p
and CC p
eighteen JJ p
( ( p
59 CD p
patients NNS p
per IN p
arm NN p
) ) p
patients NNS p
with IN p
non-healing JJ p
diabetic JJ p
ulcers NNS p
of IN p
the DT p
lower JJR p
limb NN p
, , p
referred VBD p
to TO p
the DT p
Judy NNP p
Dan NNP p
Research NNP p
and CC p
Treatment NNP p
Centre NNP p
are VBP p
being VBG p
recruited VBN p
if IN p
they PRP p
are VBP p
at IN p
least JJS p
18 CD p
years NNS p
of IN p
age NN p
, , p
have VBP p
either DT p
Type NNP p
1 CD p
or CC p
2 CD p
diabetes NNS p
with IN p
a DT p
Wagner NNP p
grading NN p
of IN p
foot NN p
lesions NNS p
2 CD p
, , p
3 CD p
or CC p
4 CD p
on IN p
lower JJR p
limb NN p
not RB p
healing VBG p
for IN p
at IN p
least JJS p
4 CD p
weeks NNS p
. . p

Patients NNS N
receive JJ N
hyperbaric JJ i
oxygen NN i
therapy NN i
every DT N
day NN N
for IN N
6 CD N
weeks NNS N
during IN N
the DT N
treatment NN N
phase NN N
and CC N
are VBP N
provided VBN N
ongoing VBG i
wound NN i
care NN i
and CC N
weekly JJ N
assessments NNS N
. . N

Patients NNS N
are VBP N
required VBN N
to TO N
return VB N
to TO N
the DT N
study NN N
centre NN N
every DT N
week NN N
for IN N
an DT N
additional JJ N
6 CD N
weeks NNS N
of IN N
follow-up NN N
for IN N
wound JJ N
evaluation NN N
and CC N
management NN N
. . N

The DT N
primary JJ N
outcome NN N
is VBZ N
freedom RB o
from IN o
having VBG o
, , o
or CC o
meeting VBG o
the DT o
criteria NN o
for IN o
, , o
a DT o
major JJ o
amputation NN o
( ( o
below IN o
knee NN o
amputation NN o
, , o
or CC o
metatarsal VB o
level NN o
) ) o
up RB N
to TO N
12 CD N
weeks NNS N
after IN N
randomization NN N
. . N

The DT N
decision NN N
to TO N
amputate VB N
is VBZ N
made VBN N
by IN N
a DT N
vascular JJ N
surgeon NN N
. . N

Other JJ N
outcomes NNS N
include VBP N
wound IN o
healing NN o
, , o
effectiveness NN o
, , o
safety NN o
, , o
healthcare JJ o
resource NN o
utilization NN o
, , o
quality NN o
of IN o
life NN o
, , o
and CC o
cost-effectiveness NN o
. . o

The DT N
study NN N
will MD N
run VB N
for IN N
a DT N
total NN N
of IN N
about IN N
3 CD N
years NNS N
. . N

DISCUSSION VB N
The DT N
results NNS N
of IN N
this DT N
study NN N
will MD N
provide VB N
detailed JJ N
information NN N
on IN N
the DT N
efficacy NN N
of IN N
hyperbaric JJ i
oxygen NN i
therapy NN i
for IN N
the DT N
treatment NN N
of IN N
non-healing JJ p
ulcers NNS p
of IN p
the DT p
lower JJR p
limb NN p
. . p

This DT N
will MD N
be VB N
the DT N
first JJ N
double-blind JJ N
randomized VBN N
controlled JJ N
trial NN N
for IN N
this DT N
health NN N
technology NN N
which WDT N
evaluates VBZ N
the DT N
efficacy NN N
of IN N
hyperbaric JJ i
oxygen NN i
therapy NN i
in IN N
prevention NN N
of IN N
amputations NNS o
in IN N
diabetic JJ p
patients NNS p
. . p

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
Identifier NNP N
: : N
NCT00621608 NN N
. . N

-DOCSTART- -21801451- O O

Falls NNS o
and CC o
mobility NN o
in IN N
Parkinson NNP p
's POS p
disease NN p
: : p
protocol NN N
for IN N
a DT N
randomised VBN N
controlled JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
Although IN N
physical JJ i
therapy NN i
and CC i
falls VBZ i
prevention NN i
education NN i
are VBP N
argued VBN N
to TO N
reduce VB N
falls NNS o
and CC o
disability NN o
in IN N
people NNS N
with IN N
idiopathic JJ N
Parkinson NNP p
's POS p
disease NN p
, , N
this DT N
has VBZ N
not RB N
yet RB N
been VBN N
confirmed VBN N
with IN N
a DT N
large JJ N
scale NN N
randomised VBD N
controlled JJ N
clinical JJ N
trial NN N
. . N

The DT N
study NN N
will MD N
investigate VB N
the DT N
effects NNS N
on IN N
falls NNS o
, , o
mobility NN o
and CC o
quality NN o
of IN o
life NN o
of IN N
( ( N
i NN N
) ) N
movement NN i
strategy NN i
training NN i
combined VBN i
with IN i
falls NNS i
prevention JJ i
education NN i
, , i
( ( i
ii NN i
) ) i
progressive NN i
resistance NN i
strength NN i
training NN i
combined VBN i
with IN i
falls NNS i
prevention JJ i
education NN i
, , i
( ( i
iii NN i
) ) i
a DT i
generic JJ i
life-skills JJ i
social JJ i
program NN i
( ( i
control VB i
group NN i
) ) i
. . i

METHODS/DESIGN JJ N
People NNS p
with IN p
idiopathic JJ p
Parkinson NNP p
's POS p
disease NN p
who WP p
live VBP p
at IN p
home NN p
will MD N
be VB N
recruited VBN N
and CC N
randomly RB N
allocated VBD N
to TO N
one CD N
of IN N
three CD N
groups NNS N
. . N

Each DT N
person NN N
shall MD N
receive VB N
therapy NN i
in IN N
an DT N
out-patient JJ N
setting NN N
in IN N
groups NNS N
of IN N
3-4 JJ N
. . N

Each DT N
group NN N
shall MD N
be VB N
scheduled VBN N
to TO N
meet VB N
once RB N
per IN N
week NN N
for IN N
2 CD N
hours NNS N
for IN N
8 CD N
consecutive JJ N
weeks NNS N
. . N

All DT N
participants NNS N
will MD N
also RB N
have VB N
a DT N
structured JJ N
2 CD N
hour NN N
home NN i
practice NN i
program NN i
for IN N
each DT N
week NN N
during IN N
the DT N
8 CD N
week NN N
intervention NN N
phase NN N
. . N

Assessments NNS N
will MD N
occur VB N
before IN N
therapy NN N
, , N
after IN N
the DT N
8 CD N
week NN N
therapy NN N
program NN N
, , N
and CC N
at IN N
3 CD N
and CC N
12 CD N
months NNS N
after IN N
the DT N
intervention NN N
. . N

A DT N
falls JJ N
calendar NN N
will MD N
be VB N
kept VBN N
by IN N
each DT N
participant NN N
for IN N
12 CD N
months NNS N
after IN N
outpatient JJ N
therapy.Consistent NN N
with IN N
the DT N
recommendations NNS N
of IN N
the DT N
Prevention NNP N
of IN N
Falls NNP N
Network NNP N
Europe NNP N
group NN N
, , N
three CD N
falls NNS o
variables NNS N
will MD N
be VB N
used VBN N
as IN N
the DT N
primary JJ N
outcome NN N
measures NNS N
: : N
the DT o
number NN o
of IN o
fallers NNS o
, , o
the DT o
number NN o
of IN o
multiple JJ o
fallers NNS o
and CC o
the DT o
falls JJ o
rate NN o
. . o

In IN N
addition NN N
to TO N
quantifying VBG N
falls NNS o
, , N
we PRP N
shall MD N
measure VB N
mobility NN o
, , o
activity NN o
limitations NNS o
and CC o
quality NN o
of IN o
life NN o
as IN N
secondary JJ N
outcomes NNS N
. . N

DISCUSSION NNP N
This DT N
study NN N
has VBZ N
the DT N
potential NN N
to TO N
determine VB N
whether IN N
outpatient JJ N
movement NN N
strategy NN N
training NN N
combined VBN N
with IN N
falls NNS N
prevention JJ N
education NN N
or CC N
progressive JJ N
resistance NN N
strength NN N
training NN N
combined VBN N
with IN N
falls NNS N
prevention JJ N
education NN N
are VBP N
effective JJ N
for IN N
reducing VBG o
falls NNS o
and CC N
improving VBG o
mobility NN o
and CC o
life NN o
quality NN o
in IN N
people NNS p
with IN p
Parkinson NNP p
's POS p
disease NN p
who WP p
live VBP p
at IN p
home NN p
. . p

TRIAL NNP N
REGISTRATION NNP N
Australia NNP N
and CC N
New NNP N
Zealand NNP N
Clinical NNP N
Trials NNP N
Register NNP N
( ( N
ANZCTR NNP N
) ) N
: : N
ACTRN12606000344594 NN N
. . N

-DOCSTART- -20070284- O O

Changes NNS N
in IN N
quality NN o
of IN o
life NN o
and CC N
sexual JJ o
health NN o
are VBP N
associated VBN N
with IN N
low-dose JJ N
peginterferon NN i
therapy NN i
and CC N
disease NN N
progression NN N
in IN N
patients NNS p
with IN p
chronic JJ p
hepatitis NN p
C. NNP p
BACKGROUND NNP N
Primary NNP N
analysis NN N
of IN N
the DT N
Hepatitis NNP p
C NNP p
Antiviral NNP p
Long-Term NNP p
Treatment NNP p
against IN p
Cirrhosis NNP p
( ( p
HALT-C NNP p
) ) p
Trial NNP p
showed VBD N
long-term JJ N
peginterferon NN i
therapy NN i
did VBD N
not RB N
reduce VB N
complications NNS N
in IN N
patients NNS p
with IN p
chronic JJ p
hepatitis NN p
C NNP p
and CC p
advanced JJ p
fibrosis NN p
or CC p
cirrhosis NN p
. . p

AIM NNP N
To TO N
assess VB N
the DT N
effects NNS N
of IN N
long-term JJ N
peginterferon NN i
therapy NN i
and CC N
disease NN N
progression NN N
on IN N
health-related JJ N
quality NN N
of IN N
life NN N
( ( N
HRQOL NNP N
) ) N
, , N
symptoms NNS N
and CC N
sexual JJ N
health NN N
in IN N
HALT-C NNP N
patients NNS N
. . N

METHODS NNP N
A NNP N
total NN p
of IN p
517 CD p
HALT-C JJ p
patients NNS p
received VBD p
peginterferon JJ i
alfa-2a JJ i
( ( p
90 CD p
microg/week NN p
) ) p
; : p
532 CD p
received VBD p
no DT i
additional JJ i
treatment NN i
for IN p
3.5 CD p
years NNS p
. . p

Patients NNS N
were VBD N
followed VBN N
up RP N
for IN N
outcomes NNS N
of IN N
death NN o
, , o
hepatocellular JJ o
carcinoma NN o
and CC N
hepatic JJ o
decompensation NN o
. . o

Sexual JJ o
health NN o
, , o
SF-36 NNP o
scores NNS o
and CC o
symptoms NNS o
were VBD N
serially RB N
assessed VBN N
by IN N
repeated-measures NNS N
analyses NNS N
of IN N
covariance NN N
. . N

RESULTS JJ N
Patients NNS p
with IN p
cirrhosis NN p
( ( p
n JJ p
= NNP p
427 CD p
) ) p
reported VBD N
lower JJR N
general JJ o
well-being NN o
and CC N
more JJR N
fatigue NN o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
than IN N
patients NNS p
with IN p
fibrosis NN p
( ( p
n JJ p
= NNP p
622 CD p
) ) p
. . p

Physical JJ o
scores NNS o
declined VBD N
significantly RB N
over IN N
time NN N
, , N
independent JJ N
of IN N
treatment NN N
, , N
and CC N
patients NNS N
with IN N
cirrhosis NN N
reported VBD N
lower JJR N
scores NNS N
. . N

Vitality NNP o
scores NNS o
were VBD N
lower JJR N
in IN N
those DT N
with IN N
cirrhosis NN N
, , N
and CC N
treated VBD N
patients NNS N
experienced VBD N
a DT N
greater JJR N
decline NN N
over IN N
time NN N
than IN N
untreated JJ N
patients NNS N
; : N
HRQOL NNP N
rebounded VBD N
after IN N
treatment NN N
ended VBN N
. . N

Patients NNS N
with IN N
a DT N
clinical JJ N
outcome NN N
had VBD N
significantly RB N
greater JJR N
declines NNS N
in IN N
all DT N
SF-36 NNP o
and CC o
symptom JJ o
scores NNS o
. . o

Among IN N
men NNS N
, , N
Sexual NNP o
Health NNP o
scores NNS o
were VBD N
significantly RB N
worse JJR N
in IN N
treated JJ N
patients NNS N
and CC N
in IN N
those DT N
with IN N
a DT N
clinical JJ N
outcome NN N
. . N

CONCLUSION NNP N
Clinical NNP N
progression NN N
of IN N
chronic JJ N
hepatitis NN N
C NNP N
and CC N
maintenance NN N
peginterferon NN i
therapy NN i
led VBD N
to TO N
worsening VBG N
of IN N
symptoms NNS o
, , o
HRQOL NNP o
and CC N
, , N
in IN p
men NNS p
, , p
sexual JJ o
health NN o
in IN p
a DT p
large JJ p
patient NN p
cohort NN p
followed VBD N
up RB N
over IN N
4 CD N
years NNS N
( ( N
NCT00006164 NNP N
) ) N
. . N

-DOCSTART- -26181707- O O

Brief JJ N
Report NNP N
: : N
Cobicistat NNP i
Compared NNP N
With IN N
Ritonavir NNP i
as IN N
a DT N
Pharmacoenhancer NNP N
for IN N
Atazanavir NNP i
in IN N
Combination NNP i
With IN i
Emtricitabine/Tenofovir NNP i
Disoproxil NNP i
Fumarate NNP i
: : i
Week JJ N
144 CD N
Results NNPS N
. . N

BACKGROUND NNP N
Cobicistat NNP i
( ( N
COBI NNP N
) ) N
is VBZ N
a DT N
pharmacoenhancer NN N
with IN N
no DT N
antiretroviral JJ N
activity NN N
. . N

METHODS NNP N
International NNP N
, , N
randomized VBD N
double-blind JJ N
active-controlled JJ N
trial NN N
to TO N
evaluate VB N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
COBI NNP i
vs FW i
ritonavir NN i
( ( i
RTV NNP i
) ) i
as IN N
a DT N
pharmacoenhancer NN N
of IN N
atazanavir NN i
in IN i
combination NN i
with IN i
emtricitabine/tenofovir JJ i
disoproxil NN i
fumarate NN i
in IN N
HIV NNP p
treatment-naive JJ p
patients NNS p
followed VBD N
through IN N
week NN N
144 CD N
. . N

RESULTS NN N
At IN N
Week NNP N
144 CD N
, , N
virologic JJ o
suppression NN o
was VBD N
achieved VBN N
in IN N
72 CD N
% NN N
( ( i
COBI NNP i
) ) i
and CC N
74 CD N
% NN N
( ( i
RTV NNP i
) ) i
of IN N
patients NNS N
. . N

Adverse JJ o
events NNS o
leading VBG N
to TO N
study VB N
drug NN N
discontinuation NN N
occurred VBD N
in IN N
11 CD N
% NN N
of IN N
patients NNS N
in IN N
each DT N
group NN N
. . N

Median JJ N
changes NNS o
in IN o
serum NN o
creatinine NN o
( ( N
mg/dL NN N
) ) N
were VBD N
+0.13 NNP N
( ( N
COBI NNP N
) ) N
and CC N
+0.07 NNP N
( ( N
RTV NNP N
) ) N
and CC N
were VBD N
unchanged JJ N
from IN N
week NN N
48 CD N
. . N

CONCLUSIONS VB N
Once-daily JJ N
COBI NNP i
is VBZ N
a DT N
safe JJ N
and CC N
effective JJ N
pharmacoenhancer NN o
of IN N
the DT N
protease NN N
inhibitor NN N
atazanavir NN N
. . N

-DOCSTART- -18787937- O O

Extinction NN o
of IN o
over-selected JJ o
stimuli JJ o
causes NNS N
emergence NN o
of IN N
under-selected JJ o
cues NNS o
in IN N
higher-functioning JJ p
children NNS p
with IN p
autistic JJ p
spectrum NN p
disorders NNS p
. . p

Two CD N
experiments NNS N
examined VBD N
whether IN N
over-selectivity NN N
is VBZ N
the DT N
product NN N
of IN N
a DT N
post-acquisition JJ o
performance NN o
deficit NN o
, , N
rather RB N
than IN N
an DT N
attention NN N
problem NN N
. . N

In IN N
both DT N
experiments NNS N
, , N
children NNS p
with IN p
Autistic NNP p
Spectrum NNP p
Disorder NNP p
were VBD N
presented VBN N
with IN N
a DT N
trial-and-error JJ i
discrimination NN i
task NN i
using VBG N
two CD i
, , i
two-element JJ i
stimuli NNS i
and CC N
over-selected JJ i
in IN N
both DT N
studies NNS N
. . N

After IN N
behavioral JJ N
control NN N
by IN N
the DT N
previously RB N
over-selected JJ o
stimulus NN o
was VBD N
extinguished VBN N
, , N
behavioral JJ o
control NN o
by IN N
the DT N
previously RB N
under-selected JJ N
cue NN N
emerged VBD N
without IN N
direct JJ N
training NN N
. . N

However RB N
, , N
this DT N
effect NN N
was VBD N
only RB N
found VBN N
in IN N
higher-functioning JJ p
children NNS p
, , N
and CC N
not RB N
with IN N
more RBR p
severely RB p
impaired JJ p
children NNS p
. . p

These DT N
findings NNS N
suggest VBP N
that IN N
over-selectivity NN o
is VBZ N
not RB N
simply RB N
due JJ N
to TO N
a DT N
failure NN N
to TO N
attend VB N
to TO N
all DT N
of IN N
the DT N
stimuli NN N
presented VBN N
. . N

They PRP N
also RB N
suggest VBP N
that IN N
extinction NN o
of IN o
over-selected JJ o
stimuli NNS o
may MD N
be VB N
a DT N
fruitful JJ N
line NN N
of IN N
intervention NN N
for IN N
clinical JJ N
intervention NN N
for IN N
some DT N
individuals NNS N
. . N

-DOCSTART- -11384820- O O

Rehabilitation NNP o
outcomes VBZ o
following VBG N
percutaneous JJ p
coronary JJ p
interventions NNS p
( ( p
PCI NNP p
) ) p
. . p

This DT N
prospective JJ N
study NN N
evaluated VBD N
the DT N
effect NN N
of IN N
an DT N
individualized JJ N
, , N
comprehensive JJ N
, , N
home-based JJ N
cardiac JJ N
rehabilitation NN N
program NN N
combining NN N
exercise NN N
training NN N
with IN N
risk NN N
factor NN N
modification NN N
and CC N
psychosocial JJ N
counseling NN N
on IN N
risk NN o
factors NNS o
, , o
psychological JJ o
well-being NN o
, , o
functional JJ o
capacity NN o
, , o
and CC o
work NN o
resumption NN o
in IN N
99 CD p
post-percutaneous JJ i
coronary JJ i
interventions NNS i
( ( i
PCI NNP i
) ) i
patients NNS p
randomized VBN N
to TO N
control VB i
( ( i
standard JJ i
care NN i
plus CC i
telephone NN i
follow-up NN i
, , N
n=49 NN N
) ) N
or CC i
intervention NN i
( ( N
individualized VBN N
, , N
comprehensive JJ N
, , N
home-based JJ N
cardiac JJ N
rehabilitation NN N
, , N
n=50 NN N
) ) N
groups NNS N
. . N

Data NNS N
were VBD N
collected VBN N
at IN N
time NN N
1 CD N
( ( N
T NNP N
( ( N
1 CD N
) ) N
) ) N
during IN N
hospital JJ N
admission NN N
, , N
time NN N
2 CD N
( ( N
T NNP N
( ( N
2 CD N
) ) N
) ) N
approximately RB N
2 CD N
months NNS N
post-PCI JJ i
, , N
and CC N
time NN N
3 CD N
( ( N
T NNP N
( ( N
3 CD N
) ) N
) ) N
approximately RB N
12 CD N
months NNS N
post-PCI JJ N
. . N

Results VB N
suggest JJS N
that IN N
the DT N
allocation NN N
to TO N
an DT N
individualized VBN N
, , N
comprehensive JJ N
, , N
home-based JJ N
cardiac JJ N
rehabilitation NN N
program NN N
provided VBD N
more RBR N
advantageous JJ N
outcomes NNS N
. . N

At IN N
both DT N
follow-ups NNS N
, , N
the DT N
intervention NN N
group NN N
showed VBD N
within-group JJ N
improvement NN N
in IN N
serum NN o
cholesterol NN o
levels NNS o
( ( N
P NNP N
< NNP N
0.02 CD N
; : N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
exercise JJ o
participation NN o
( ( N
P NNP N
< NNP N
0.001 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
with IN N
differences NNS N
in IN N
exercise NN o
participation NN o
favoring VBG N
the DT N
intervention NN N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
at IN N
T NNP N
( ( N
2 CD N
) ) N
. . N

Repeated VBN N
measures NNS N
ANOVA NNP N
showed VBD N
significant JJ N
improvements NNS N
over IN N
time NN N
in IN N
body NN o
mass NN o
index NN o
( ( o
BMI NNP o
) ) o
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
psychological JJ o
well-being NN o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
functional JJ o
capacity NN o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
for IN N
both DT N
groups NNS N
. . N

More JJR N
patients NNS N
in IN N
the DT N
intervention NN N
group NN N
had VBD N
returned VBN o
to TO o
work VB o
at IN N
T NNP N
( ( N
2 CD N
) ) N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
did VBD N
so RB N
more RBR N
quickly RB N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

These DT N
findings NNS N
suggest VBP N
that IN N
an DT N
individualized JJ N
, , N
comprehensive JJ N
, , N
home-based JJ N
cardiac JJ N
rehabilitation NN N
program NN N
improves VBZ N
risk NN o
factor NN o
profiles NNS o
and CC o
work NN o
resumption NN o
patterns NNS o
for IN N
patients NNS p
following VBG p
PCI NNP p
. . p

-DOCSTART- -8208874- O O

Lithium NN i
sustains VBZ N
the DT N
acute NN p
antidepressant JJ o
effects NNS o
of IN p
sleep JJ p
deprivation NN p
: : p
preliminary JJ N
findings NNS N
from IN N
a DT N
controlled VBN N
study NN N
. . N

Early JJ p
morning NN p
sleep JJ p
deprivation NN p
( ( p
patient JJ p
awake NN p
from IN p
0200 CD p
to TO p
2200 CD p
hours NNS p
) ) p
produces VBZ N
a DT N
same-day JJ N
antidepressant JJ o
effect NN o
in IN N
approximately RB N
one-half JJ N
of IN N
patients NNS p
with IN p
major JJ p
depression NN p
. . p

Unfortunately RB N
, , N
these DT N
antidepressant JJ N
effects NNS o
are VBP N
short-lived JJ N
and CC N
patients NNS N
usually RB N
relapse VBP N
to TO N
baseline VB N
depression NN N
levels NNS N
within IN N
48 CD N
hours NNS N
. . N

Recent JJ N
work NN N
suggests VBZ N
, , N
however RB N
, , N
that IN N
the DT N
use NN N
of IN N
lithium NN i
with IN N
early JJ N
morning NN N
sleep JJ N
deprivation NN N
sustains VBZ N
this DT N
rapid JJ N
antidepressant JJ o
effect NN o
and CC N
makes VBZ N
it PRP N
clinically RB N
useful JJ N
. . N

In IN N
a DT N
30-day JJ N
study NN N
, , N
we PRP N
compared VBN N
the DT N
abilities NNS N
of IN N
four CD N
different JJ N
treatments NNS N
( ( i
lithium JJ i
plus CC i
early JJ i
morning NN i
sleep NN i
deprivation NN i
, , i
lithium NN i
plus CC i
a DT i
control NN i
sleep JJ i
deprivation NN i
procedure NN i
, , i
and CC i
desipramine NN i
with IN i
either DT i
of IN i
the DT i
two CD i
sleep JJ i
manipulations NNS i
) ) i
to TO N
induce VB N
a DT N
rapid JJ N
( ( N
next-day JJ N
) ) N
and CC N
sustained VBN N
antidepressant JJ o
response NN o
in IN N
16 CD p
depressed JJ p
patients NNS p
. . p

Lithium NNP i
plus CC i
early JJ i
morning NN i
sleep JJ i
deprivation NN i
produced VBD N
a DT N
quicker NN N
response NN o
than IN N
lithium NN N
with IN N
the DT N
control NN N
sleep JJ N
deprivation NN N
, , N
and CC N
the DT N
response NN o
was VBD N
sustained VBN N
for IN N
at IN N
least JJS N
30 CD N
days NNS N
. . N

In IN N
this DT N
design NN N
, , N
however RB N
, , N
lithium/early RB N
morning NN N
sleep JJ N
deprivation NN N
was VBD N
no DT N
faster JJR N
than IN N
either DT N
of IN N
the DT N
two CD N
desipramine/sleep JJ i
deprivation NN i
conditions NNS N
in IN N
inducing VBG o
remission NN o
. . o

These DT N
results NNS N
support VBD N
the DT N
results NNS N
of IN N
previous JJ N
studies NNS N
and CC N
suggest VBP N
further JJ N
investigation NN N
of IN N
this DT N
novel JJ N
sleep/pharmacologic JJ i
intervention NN i
is VBZ N
warranted VBN N
. . N

-DOCSTART- -16426958- O O

Effect NN N
of IN N
micronutrient NN i
supplement NN i
on IN N
health NN o
and CC o
nutritional JJ o
status NN o
of IN N
schoolchildren NNS p
: : p
study NN N
design NN N
. . N

OBJECTIVE IN N
We PRP N
tested VBD N
the DT N
hypothesis NN N
that WDT N
supplementation NN i
with IN i
a DT i
micronutrient-fortified JJ i
beverage NN i
improves VBZ N
micronutrient JJ N
status NN N
and CC N
physical JJ N
and CC N
mental JJ N
development NN N
in IN N
apparently RB N
healthy JJ N
schoolchildren NNS N
. . N

METHODS NNP N
The DT N
study NN N
was VBD N
carried VBN N
out RP N
in IN N
middle-income JJ p
students NNS p
in IN N
two CD N
residential JJ N
schools NNS N
that WDT N
catered VBD N
to TO N
children NNS p
from IN p
a DT p
semi-urban JJ p
population NN p
near IN p
Hyderabad NNP p
, , p
India NNP p
. . p

Included NNP p
were VBD p
869 CD p
children NNS p
who WP p
were VBD p
6 CD p
to TO p
16 CD p
y NN p
of IN p
age NN p
in IN p
grades NNS p
1 CD p
to TO p
10 CD p
. . p

Because IN N
children NNS N
at IN N
each DT N
grade NN N
were VBD N
distributed VBN N
across IN N
two CD N
classrooms NNS N
( ( N
clusters NNS N
) ) N
and CC N
were VBD N
homogeneous JJ N
, , N
each DT N
grade NN N
was VBD N
considered VBN N
to TO N
consist VB N
of IN N
a DT N
matched JJ N
pair NN N
. . N

There EX N
were VBD N
thus RB N
10 CD N
pairs NNS N
available JJ N
for IN N
the DT N
study NN N
. . N

Classes NNS N
in IN N
each DT N
grade NN N
were VBD N
randomized VBN N
to TO N
receive VB N
a DT N
micronutrient-enriched JJ i
beverage NN i
or CC i
a DT i
placebo NN i
without IN i
added JJ i
micronutrients NNS i
. . i

The DT N
study NN N
was VBD N
double RB N
blinded VBN N
and CC N
the DT N
duration NN N
was VBD N
14 CD N
mo NN N
, , N
with IN N
supervised JJ N
feeding NN N
of IN N
the DT N
micronutrient-enriched JJ i
beverage NN i
. . i

The DT N
effect NN N
of IN N
the DT N
micronutrients NNS i
on IN N
the DT N
outcome NN o
variables NNS o
growth NN o
, , o
biochemical JJ o
status NN o
, , o
mental JJ o
function NN o
, , o
and CC o
bone NN o
health NN o
were VBD N
assessed VBN N
. . N

RESULTS VB N
The DT N
number NN N
of IN N
matched JJ N
pairs NNS N
varied VBD N
between IN N
seven CD N
and CC N
eight CD N
, , N
and CC N
the DT N
required JJ N
number NN p
of IN p
children NNS p
per IN p
treatment NN p
group NN p
ranged VBD p
from IN p
32 CD p
in IN p
the DT p
case NN p
of IN p
bone NN p
heath NN p
to TO p
177 CD p
for IN p
body NN p
weight NN p
. . p

The DT N
power NN N
of IN N
the DT N
outcome NN N
variables NNS N
ranged VBD N
from IN N
74 CD N
% NN N
to TO N
100 CD N
% NN N
and CC N
was VBD N
adequate NN N
for IN N
successful JJ N
pairing NN N
. . N

The DT N
effect NN N
assessed VBD N
at IN N
the DT N
end NN N
of IN N
supplementation NN i
showed VBD N
that IN N
the DT N
intervention NN N
was VBD N
beneficial JJ o
. . o

CONCLUSIONS NNP N
Designing VBG N
an DT N
intervention NN N
, , N
choosing VBG N
outcome NN N
variables NNS N
, , N
and CC N
implementing VBG N
the DT N
protocol NN N
in IN N
a DT N
typical JJ N
Indian JJ N
school NN N
setting VBG N
were VBD N
achieved VBN N
. . N

-DOCSTART- -10741842- O O

Asthma NNP N
and CC N
the DT N
home NN N
environment NN N
of IN N
low-income JJ p
urban JJ p
children NNS p
: : p
preliminary JJ N
findings NNS N
from IN N
the DT N
Seattle-King NNP N
County NNP N
healthy JJ N
homes NNS N
project NN N
. . N

OBJECTIVES NNP N
Childhood NNP N
asthma NN N
is VBZ N
a DT N
growing VBG N
public JJ N
health NN N
concern NN N
in IN N
low-income JJ N
urban JJ N
communities NNS N
. . N

Indoor NNP N
exposure NN N
to TO N
asthma VB N
triggers NNS N
has VBZ N
emerged VBN N
as IN N
an DT N
important JJ N
cause NN N
of IN N
asthma JJ N
exacerbations NNS N
. . N

We PRP N
describe VBP N
indoor JJ N
environmental JJ N
conditions NNS N
related VBN N
to TO N
asthma JJ N
triggers NNS N
among IN N
a DT N
low-income JJ p
urban JJ p
population NN p
in IN p
Seattle/King NNP p
County NNP p
, , p
Washington NNP p
, , p
as RB p
well RB p
as IN p
caregiver NN p
knowledge NN p
and CC N
resources NNS N
related VBN N
to TO N
control VB N
of IN N
these DT N
triggers NNS N
. . N

METHODS NNP N
Data NNP N
are VBP N
obtained VBN N
from IN N
in-person JJ N
, , N
structured JJ N
, , N
closed-end JJ N
interviews NNS N
with IN N
the DT N
caretakers NNS p
of IN p
children NNS p
aged VBN p
4-12 CD p
years NNS p
with IN p
persistent JJ p
asthma NN p
living NN p
in IN p
households NNS p
with IN p
incomes NNS p
less JJR p
than IN p
200 CD p
% NN p
of IN p
poverty NN p
. . p

Additional JJ N
information NN N
is VBZ N
collected VBN N
during IN N
a DT N
home NN N
inspection NN N
. . N

The DT N
children NNS p
and CC p
their PRP$ p
caregivers NNS p
are VBP p
participants NNS p
in IN p
the DT p
ongoing JJ p
Seattle-King JJ p
County NNP p
Healthy NNP p
Homes NNP p
Project NNP p
, , p
a DT p
randomized VBN p
controlled JJ p
trial NN p
of IN p
an DT p
intervention NN i
to TO p
empower VB p
low-income JJ p
families NNS p
to TO p
reduce VB p
exposure NN p
to TO p
indoor VB p
asthma JJ p
triggers NNS p
. . p

We PRP N
report VBP N
findings NNS N
on IN N
the DT N
conditions NNS N
of IN N
the DT N
homes NNS N
prior RB N
to TO N
this DT N
intervention NN N
among IN N
the DT p
first JJ p
112 CD p
enrolled JJ p
households NNS p
. . p

RESULTS VB N
A DT N
smoker NN N
was VBD N
present JJ N
in IN N
37.5 CD N
% NN N
of IN N
homes NNS N
. . N

Mold NNP o
was VBD o
visible JJ o
in IN N
26.8 CD N
% NN N
of IN N
homes NNS N
, , N
water NN o
damage NN o
was VBD N
present JJ N
in IN N
18.6 CD N
% NN N
of IN N
homes NNS N
, , N
and CC N
damp JJ o
conditions NNS o
occurred VBD N
in IN N
64.8 CD N
% NN N
of IN N
households NNS N
, , N
while IN N
39.6 CD N
% NN N
of IN N
caregivers NNS N
were VBD N
aware JJ N
that IN N
excessive JJ N
moisture NN N
can MD N
increase VB N
exposures NNS N
to TO N
allergens NNS N
. . N

Dust-trapping JJ o
reservoirs NNS o
were VBD N
common JJ N
; : N
76.8 CD N
% NN N
of IN N
children NNS N
's POS N
bedrooms NNS N
had VBD N
carpeting NN N
. . N

Cockroach NNP o
infestation NN o
in IN o
the DT o
past JJ o
3 CD o
months NNS o
was VBD N
reported VBN N
by IN N
23.4 CD N
% NN N
of IN N
caregivers NNS N
, , N
while IN N
57.1 CD N
% NN N
were VBD N
unaware JJ N
of IN N
the DT N
association NN o
of IN o
roaches NNS o
and CC o
asthma NN o
. . o

Only RB N
19.8 CD N
% NN N
of IN N
the DT N
children NNS N
had VBD N
allergy-control JJ o
mattress NN o
covers NNS o
. . o

CONCLUSIONS NNP N
Many JJ N
low-income JJ p
urban JJ p
children NNS p
with IN p
asthma NN p
in IN N
King NNP N
County NNP N
live VBP N
in IN N
indoor JJ N
environments NNS N
that WDT N
place VBP N
them PRP N
at IN N
substantial JJ N
risk NN N
of IN N
ongoing VBG N
exposure NN N
to TO N
asthma VB N
triggers NNS N
. . N

Substandard NNP N
housing NN N
and CC N
lack NN N
of IN N
resources NNS N
often RB N
underlie VBP N
these DT N
exposures NNS N
. . N

Initiatives VBZ N
involving VBG N
health NN N
educators NNS N
, , N
outreach NN N
workers NNS N
, , N
medical JJ N
providers NNS N
, , N
health NN N
care NN N
insurers NNS N
, , N
housing NN N
agencies NNS N
, , N
and CC N
elected VBN N
officials NNS N
are VBP N
needed VBN N
to TO N
reduce VB N
these DT N
exposures NNS N
. . N

-DOCSTART- -12676060- O O

Enhanced NNP N
pitch NN N
sensitivity NN N
in IN N
individuals NNS p
with IN p
autism NN p
: : p
a DT N
signal JJ N
detection NN N
analysis NN N
. . N

Past NNP N
research NN N
has VBZ N
shown VBN N
a DT N
superiority NN N
of IN N
participants NNS p
with IN p
high-functioning JJ p
autism NN p
over IN N
comparison NN N
groups NNS N
in IN N
memorizing VBG N
picture-pitch JJ N
associations NNS N
and CC N
in IN N
detecting VBG N
pitch NN N
changes NNS N
in IN N
melodies NNS N
. . N

A DT N
subset NN N
of IN N
individuals NNS p
with IN p
autism NN p
, , p
known VBN p
as IN p
musical JJ p
savants NNS p
, , p
is VBZ N
also RB N
known VBN N
to TO N
possess VB N
absolute JJ N
pitch NN N
. . N

This DT N
superiority NN N
might MD N
be VB N
due JJ N
to TO N
an DT N
abnormally RB N
high JJ N
sensitivity NN N
to TO N
fine-grained JJ N
pitch NN N
differences NNS N
in IN N
sounds NNS N
. . N

To TO N
test VB N
this DT N
hypothesis NN N
, , N
psychoacoustic JJ i
tasks NNS i
were VBD N
devised VBN N
so RB N
as IN N
to TO N
use VB N
a DT N
signal JJ N
detection NN N
methodology NN N
. . N

Participants NNS p
were VBD p
all DT p
musically RB p
untrained JJ p
and CC p
were VBD p
divided VBN p
into IN p
a DT p
group NN p
of IN p
12 CD p
high-functioning JJ p
individuals NNS p
with IN p
autism NN p
and CC p
a DT p
group NN p
of IN p
12 CD p
normally RB p
developing VBG p
individuals NNS p
. . p

Their PRP$ N
task NN N
was VBD N
to TO N
judge VB N
the DT N
pitch NN i
of IN i
pure NN i
tones NNS i
in IN N
a DT N
same-different JJ N
discrimination NN N
task NN N
and CC N
in IN N
a DT N
high-low JJ N
categorization NN N
task NN N
. . N

In IN N
both DT N
tasks NNS N
, , N
the DT N
obtained VBN N
psychometric JJ N
functions NNS N
revealed VBD N
higher JJR o
pitch NN o
sensitivity NN o
for IN N
subjects NNS N
with IN N
autism NN N
, , N
with IN N
a DT N
more RBR N
pronounced JJ N
advantage NN N
over IN N
control NN N
participants NNS N
in IN N
the DT N
categorization NN o
task NN o
. . o

These DT N
findings NNS N
confirm VBP N
that IN N
pitch NN o
processing NN o
is VBZ N
enhanced VBN N
in IN N
high-functioning JJ N
autism NN N
. . N

Superior JJ N
performance NN N
in IN N
pitch NN o
discrimination NN o
and CC o
categorization NN o
extends VBZ N
previous JJ N
findings NNS N
of IN N
enhanced JJ N
visual JJ o
performance NN o
to TO N
the DT N
auditory NN N
domain NN N
. . N

Thus NNP N
, , N
and CC N
as IN N
predicted VBN N
by IN N
the DT N
enhanced JJ N
perceptual JJ N
functioning NN N
model NN N
for IN N
peaks NNS N
of IN N
ability NN N
in IN N
autism NN N
( ( N
Mottron NNP N
& CC N
Burack NNP N
, , N
2001 CD N
) ) N
, , N
autistic JJ p
individuals NNS p
outperform VBP N
typically RB N
developing VBG N
population NN N
in IN N
a DT N
variety NN N
of IN N
low-level JJ N
perceptual JJ N
tasks NNS N
. . N

-DOCSTART- -7774537- O O

Diet NNP i
and CC i
vitamin NNP i
D NNP i
status NN N
among IN N
pregnant JJ p
Pakistani NNP p
women NNS p
in IN p
Oslo NNP p
. . p

OBJECTIVES NNP N
In IN N
the DT N
present JJ N
study NN N
the DT N
diet NN N
and CC N
the DT N
nutritional JJ N
status NN N
of IN N
pregnant JJ p
Pakistani NNP p
immigrant NN p
women NNS p
have VBP N
been VBN N
compared VBN N
with IN N
a DT N
group NN p
of IN p
Norwegian JJ p
women NNS p
. . p

DESIGN VB N
A DT N
cross-sectional JJ N
survey NN N
of IN N
women NNS p
in IN p
the DT p
18th CD p
week NN p
of IN p
pregnancy NN p
. . p

SETTING NNP N
Women NNP p
referred VBD p
to TO p
routine VB p
ultrasound JJ p
examination NN p
at IN p
Aker NNP p
and CC p
Ullev?l NNP p
Hospitals NNP p
in IN p
Norway NNP p
. . p

SUBJECTS NNP p
All NNP p
( ( p
58 CD p
) ) p
healthy JJ p
women NNS p
of IN p
Pakistani NNP p
origin NN p
referred VBD p
from IN p
October NNP p
of IN p
1991 CD p
to TO p
January NNP p
of IN p
1992 CD p
were VBD p
included VBN p
, , p
of IN p
whom WP p
38 CD p
( ( p
66 CD p
% NN p
) ) p
participated VBD p
. . p

Forty-five JJ p
Norwegian JJ p
women NNS p
were VBD p
randomly RB p
included VBN p
in IN p
the DT p
same JJ p
period NN p
and CC p
38 CD p
( ( p
84 CD p
% NN p
) ) p
of IN p
these DT p
women NNS p
participated VBD p
. . p

RESULTS VB N
The DT o
serum NN o
levels NNS o
of IN o
25-hydroxyvitamin JJ o
D3 NNP o
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
Pakistanis NNP N
compared VBN N
with IN N
the DT N
Norwegians NNPS N
( ( N
median JJ N
19 CD N
nmol/l JJ N
vs NN N
55 CD N
nmol/l NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
83 CD N
% NN N
of IN N
the DT N
Pakistani NNP N
women NNS N
had VBD o
25-hydroxyvitamin JJ o
D3 NNP o
levels NNS o
below IN N
the DT N
reference NN N
value NN N
( ( N
< JJ N
30 CD N
nmol/l NN N
) ) N
. . N

The DT N
Pakistanis NNP N
had VBD o
higher JJR o
levels NNS o
of IN o
serum NN o
parathyroid NN o
hormone NN o
( ( N
median JJ N
2.6 CD N
vs NN N
1.6 CD N
pmol/l NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
Pakistanis NNP N
also RB N
had VBD N
a DT N
lower JJR o
dietary JJ o
intake NN o
of IN o
vitamin NN o
D NNP o
than IN N
that DT N
of IN N
the DT N
Norwegians NNPS N
( ( N
median JJ N
2.2 CD N
vs NN N
3.3 CD N
micrograms/day NN N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
and CC N
a DT N
lower JJR N
total JJ N
intake NN N
, , N
including VBG N
supplements NNS N
( ( N
median JJ N
2.9 CD N
vs NN N
7.0 CD N
micrograms/day NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Among IN N
the DT N
Pakistanis NNP N
a DT N
correlation NN N
was VBD N
found VBN N
between IN N
the DT i
dietary JJ i
intake NN i
of IN i
margarine NN i
, , i
the DT N
main JJ N
source NN N
of IN i
vitamin NN i
D NNP i
in IN N
the DT N
diet NN N
, , N
and CC N
the DT N
concentration NN N
of IN N
25-hydroxyvitamin JJ N
D3 NNP N
in IN N
serum NN N
, , N
r NN N
= NN N
0.48 CD N
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
. . N

In IN N
general JJ N
, , N
the DT N
Pakistanis NNP N
avoided VBD N
any DT N
direct JJ N
sunshine NN N
exposure NN N
, , N
and CC N
no DT N
relation NN N
between IN o
outdoor JJ o
activity NN o
and CC o
serum JJ o
level NN o
of IN o
25-hydroxyvitamin JJ o
D3 NNP o
was VBD N
found VBN N
. . N

The DT N
Pakistani NNP N
women NNS N
had VBD N
a DT N
lower JJR o
intake NN o
of IN o
calcium NN o
than IN N
the DT N
Norwegians NNPS N
( ( N
median JJ N
793 CD N
vs NN N
1134 CD N
mg/day NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSION VB N
This DT N
study NN N
has VBZ N
shown VBN N
that IN N
Pakistani NNP N
women NNS N
living VBG N
in IN N
Oslo NNP N
are VBP N
at IN N
great JJ N
risk NN N
of IN N
developing VBG N
vitamin JJ N
D NNP N
deficiency NN N
during IN N
pregnancy NN N
. . N

The DT N
main JJ N
reasons NNS N
for IN N
this DT N
are VBP N
avoidance NN N
of IN N
sun NN N
exposure NN N
, , N
a DT N
low JJ N
dietary JJ N
intake NN N
of IN i
vitamin NN i
D NNP i
, , i
and CC N
no DT N
or CC N
little JJ N
use NN N
of IN N
supplementation NN N
. . N

-DOCSTART- -16879274- O O

Nuclear JJ N
fragments NNS N
and CC N
holes NNS N
in IN N
grading NN p
of IN p
breast NN p
cancer NN p
aspirates VBZ p
. . p

-DOCSTART- -6227244- O O

Effects NNS o
of IN N
nutritional JJ i
supplementation NN i
on IN N
IQ NNP o
and CC N
certain JJ N
other JJ N
variables NNS N
associated VBN N
with IN N
Down NNP p
syndrome NN p
. . p

In IN N
a DT N
double-blind NN N
study NN N
, , N
24 CD p
Down NNP p
syndrome NN p
children NNS p
, , p
ages VBZ p
6 CD p
to TO p
17 CD p
years NNS p
living VBG p
at IN p
home NN p
, , p
were VBD p
given VBN p
a DT p
megadose JJ i
multi-vitamin/mineral JJ i
supplement NN i
for IN p
4 CD p
months NNS p
. . p

A DT N
matched JJ N
group NN N
of IN N
23 CD p
children NNS p
received VBD p
a DT p
placebo NN i
in IN p
identical JJ p
form NN p
. . p

The DT o
children NNS o
's POS o
IQ NNP o
, , o
vision NN o
, , o
and CC o
visual-motor JJ o
integration NN o
were VBD N
tested VBN N
before IN N
and CC N
after IN N
supplementation NN N
, , N
and CC N
weekly JJ N
checks NNS N
were VBD N
made VBN N
to TO N
monitor VB N
behavioral JJ N
changes NNS N
. . N

No DT N
differences NNS N
were VBD N
found VBN N
on IN N
any DT N
measures NNS N
as IN N
a DT N
result NN N
of IN N
supplementation NN N
. . N

-DOCSTART- -21402409- O O

Prenatal JJ N
depression NN N
predicts VBZ N
postpartum JJ N
maternal JJ N
attachment NN N
in IN N
low-income JJ p
Latina NNP p
mothers NNS p
with IN p
infants NNS p
. . p

Although IN N
maternal JJ N
attachment NN N
is VBZ N
an DT N
important JJ N
predictor NN N
of IN N
infant JJ N
attachment JJ N
security NN N
and CC N
other JJ N
developmental JJ N
outcomes NNS N
, , N
little JJ N
is VBZ N
known VBN N
about IN N
the DT N
formation NN N
of IN N
maternal JJ N
attachment NN N
in IN N
the DT N
first JJ N
few JJ N
months NNS N
of IN N
the DT N
infant NN N
's POS N
life NN N
, , N
particularly RB N
among IN N
ethnic JJ N
minority NN N
mothers NNS N
. . N

The DT N
current JJ N
study NN N
examined VBD N
the DT N
predictors NNS N
of IN N
postpartum JJ N
maternal JJ N
attachment NN N
in IN N
a DT N
sample NN N
of IN N
217 CD p
Latina NNP p
women NNS p
enrolled VBD p
in IN p
a DT p
perinatal JJ p
depression NN p
prevention NN p
trial NN p
. . p

Mothers NNS N
' POS N
attachment NN i
to TO N
their PRP$ N
infants NNS N
was VBD N
measured VBN N
at IN N
6-8 JJ i
weeks NNS i
postpartum NN i
using VBG i
the DT i
Maternal NNP o
Postnatal NNP o
Attachment NNP o
Scale NNP o
. . o

A NNP N
variety NN N
of IN N
predictors NNS N
of IN N
early JJ N
attachment NN N
were VBD N
explored VBN N
including VBG N
: : N
depressive JJ o
symptoms NNS o
during IN o
pregnancy NN o
, , o
pregnancy NN o
intention NN o
, , o
feelings NNS o
about IN o
the DT o
pregnancy NN o
, , o
and CC o
the DT o
quality NN o
of IN o
the DT o
partner NN o
relationship NN o
. . o

The DT N
strongest JJS N
predictor NN N
of IN N
lower JJR o
maternal JJ o
attachment NN o
was VBD N
depressive JJ o
symptoms NNS o
late RB N
in IN N
pregnancy NN N
; : N
pregnancy NN N
intention NN N
was VBD N
marginally RB N
predictive JJ N
of IN N
attachment NN o
, , N
with IN N
lower JJR N
scores NNS N
being VBG N
associated VBN N
with IN N
unwanted JJ N
pregnancies NNS N
. . N

The DT N
study NN N
fills VBZ N
a DT N
critical JJ N
gap NN N
in IN N
our PRP$ N
understanding NN N
of IN N
the DT N
role NN N
of IN N
depressive JJ N
symptoms NNS N
during IN N
pregnancy NN N
in IN N
shaping VBG N
mothers NNS N
' POS N
early JJ N
attachment NN N
to TO N
their PRP$ N
infants NNS N
. . N

-DOCSTART- -7924475- O O

Treatment NN N
of IN N
acute JJ N
asthma NN N
. . N

Lack NNP N
of IN N
therapeutic JJ o
benefit NN o
and CC o
increase NN o
of IN o
the DT o
toxicity NN o
from IN N
aminophylline JJ i
given VBN N
in IN N
addition NN N
to TO N
high JJ N
doses NNS N
of IN N
salbutamol NN i
delivered VBN N
by IN N
metered-dose JJ N
inhaler NN N
with IN N
a DT N
spacer NN N
. . N

We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
study NN N
to TO N
determine VB N
if IN N
intravenous JJ N
aminophylline NN i
adds VBZ N
any DT N
benefit NN o
to TO N
high JJ N
doses NNS N
of IN N
inhaled JJ N
salbutamol NN i
in IN N
patients NNS p
who WP p
presented VBD p
for IN p
treatment NN p
of IN p
acute JJ p
asthma NN p
. . p

We PRP N
studied VBD N
94 CD p
patients NNS p
( ( p
mean JJ p
age NN p
, , p
35.6 CD p
+/- JJ p
11.2 CD p
years NNS p
) ) p
with IN p
moderate JJ p
to TO p
severe VB p
acute JJ p
asthma NN p
. . p

All DT N
patients NNS N
received VBD N
therapy NN N
with IN N
salbutamol NN i
delivered VBN N
with IN N
metered-dose JJ i
inhaler NN i
( ( i
MDI NNP i
) ) i
into IN i
a DT i
spacer NN i
device NN i
( ( N
Volumatic NNP N
) ) N
in IN N
four CD N
puffs NNS N
( ( N
400 CD N
micrograms NNS N
) ) N
at IN N
10-min JJ N
interval NN N
, , N
and CC N
intravenous JJ i
hydrocortisone NN i
( ( N
500 CD N
mg NN N
) ) N
. . N

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either CC N
a DT N
loading NN N
dose NN N
of IN N
intravenous JJ N
aminophylline NN i
followed VBN N
by IN N
a DT N
routine JJ N
infusion NN N
( ( N
n JJ N
= NNP N
45 CD N
) ) N
or CC N
an DT N
equal JJ N
volume NN N
of IN N
placebo NN i
as IN N
a DT N
loading NN N
dose NN N
and CC N
infusion NN N
( ( N
n JJ N
= NNP N
49 CD N
) ) N
. . N

The DT N
two CD N
groups NNS N
showed VBD N
no DT N
differences NNS N
in IN N
measurements NNS N
of IN N
peak JJ o
expiratory NN o
flow NN o
, , o
FEV1 NNP o
, , o
and CC o
FVC NNP o
at IN N
baseline NN N
and CC N
at IN N
the DT N
end NN N
of IN N
treatment NN N
. . N

However RB N
, , N
the DT N
patients NNS N
treated VBN N
with IN N
aminophylline NN i
had VBD N
significantly RB N
more RBR N
adverse JJ o
effects NNS o
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
the DT N
final JJ N
mean NN N
dose NN N
of IN N
salbutamol NN N
( ( N
6.3 CD N
+/- JJ N
44.5 CD N
mg NN N
for IN N
the DT N
placebo NN i
group NN N
and CC N
5.8 CD N
+/- JJ N
4.2 CD N
mg NN N
for IN N
the DT N
aminophylline NN N
group NN N
) ) N
, , N
hospital JJ N
admission NN N
rate NN N
( ( N
10.2 CD N
percent NN N
for IN N
the DT N
placebo NN N
group NN N
and CC N
9.0 CD N
percent NN N
for IN N
the DT N
aminophylline NN i
group NN N
) ) N
, , N
and CC N
mean JJ N
duration NN N
of IN N
Emergency NNP N
Department NNP N
treatment NN N
( ( N
2.5 CD N
+/- JJ N
1.83 CD N
h NN N
for IN N
the DT N
placebo NN i
group NN N
and CC N
2.37 CD N
+/- JJ N
1.75 CD N
h NN N
for IN N
the DT N
aminophylline NN i
group NN N
) ) N
. . N

The DT N
results NNS N
were VBD N
similar JJ N
when WRB N
the DT N
patients NNS N
were VBD N
divided VBN N
in IN N
accord NN N
with IN N
the DT N
degree NN N
of IN N
respiratory NN o
obstruction NN o
( ( N
baseline JJ N
FEV1 NNP N
< NNP N
30 CD N
percent NN N
of IN N
predicted VBN N
) ) N
and CC N
theophylline JJ o
level NN o
at IN N
30 CD N
min NN N
of IN N
treatment NN N
( ( N
placebo JJ N
group NN N
patients NNS N
with IN N
theophylline JJ i
level NN N
< VBD N
10 CD N
mg/L NN N
vs NN N
aminophylline NN i
group NN N
patients NNS N
with IN N
theophylline JJ N
level NN N
> NN N
or CC N
= $ N
10 CD N
mg/L NN N
) ) N
. . N

We PRP N
conclude VBP N
that DT N
intravenous JJ N
aminophylline NN N
adds VBZ N
to TO N
the DT N
toxicity NN o
but CC N
not RB N
the DT N
efficacy NN o
of IN N
inhaled JJ N
salbutamol NN i
in IN N
the DT N
treatment NN N
of IN N
acute JJ N
exacerbations NNS N
of IN N
asthma NN N
. . N

-DOCSTART- -2869714- O O

[ JJ N
Potentiation NNP N
of IN N
the DT N
effect NN N
of IN N
non-depolarizing JJ N
muscle NN p
relaxants NNS p
by IN N
acylaminopenicillins NNS i
. . i

Studies NNS N
on IN N
the DT N
example NN N
of IN N
vecuronium NN N
] NN N
. . N

In IN N
a DT N
prospective JJ N
controlled VBN N
clinical JJ N
study NN N
interactions NNS N
between IN N
nondepolarizing VBG i
muscle NN i
relaxants NNS i
and CC i
acylaminopenicillins NNS i
were VBD N
investigated VBN N
electromyographically RB N
. . N

Six CD p
patients NNS p
in IN p
each DT p
group NN p
received VBD N
either RB N
apalcillin JJ i
, , i
azlocillin NN i
, , i
mezlocillin NN i
or CC i
piperacillin NN i
during IN N
the DT N
operation NN N
. . N

Muscle NNP o
relaxation NN o
was VBD N
maintained VBN N
using VBG N
the DT N
short JJ N
acting VBG N
nondepolarizing VBG N
relaxant JJ N
vecuronium NN N
, , N
which WDT N
shows VBZ N
no DT N
cumulative JJ N
effect NN N
within IN N
clinical JJ N
dosages NNS N
. . N

The DT N
intra-individual JJ N
comparison NN N
with IN N
the DT N
control NN N
period NN N
( ( N
100 CD N
% NN N
) ) N
showed VBD N
a DT N
significant JJ N
prolongation NN o
of IN o
the DT o
duration NN o
of IN o
action NN o
after IN N
a DT N
fixed JJ N
dose NN N
of IN N
vecuronium NN N
. . N

The DT N
mean JJ o
increase NN o
was VBD N
+26 JJ N
% NN N
following VBG N
apalcillin NN N
, , N
+46 CD N
% NN N
after IN N
piperacillin NN N
, , N
+38 CD N
% NN N
following VBG N
mezlocillin NN N
and CC N
+55 CD N
% NN N
following VBG N
azlocillin NN N
. . N

The DT N
shortest JJ o
time NN o
of IN N
the DT N
control NN N
periods NNS N
was VBD N
8.6 CD N
min NN N
and CC N
the DT N
maximum JJ N
time NN N
was VBD N
32.6 CD N
min NN N
. . N

We PRP N
also RB N
found VBD N
a DT N
significant JJ N
depression NN o
of IN N
the DT N
EMG-response NNP o
. . o

No NNP N
significant JJ N
differences NNS N
could MD N
be VB N
detected VBN N
between IN N
the DT N
four CD N
antibiotics NNS N
. . N

The DT N
method NN N
described VBN N
here RB N
has VBZ N
proven VBN N
to TO N
be VB N
sensitive JJ N
enough RB N
to TO N
detect VB N
clinically RB o
relevant JJ o
interactions NNS o
with IN N
muscle NN o
relaxants NNS o
. . o

As IN N
a DT N
result NN N
of IN N
our PRP$ N
study NN N
, , N
caution NN N
seems VBZ N
to TO N
be VB N
necessary JJ N
if IN N
acylaminopenicillins NNS i
are VBP N
administered VBN N
in IN N
the DT N
early JJ N
postoperative JJ N
period NN N
. . N

-DOCSTART- -23774272- O O

A DT N
randomized JJ N
trial NN N
evaluating VBG N
the DT N
effects NNS N
of IN N
change NN N
in IN N
dairy NN i
food NN i
consumption NN i
on IN p
cardio-metabolic JJ o
risk NN o
factors NNS o
. . o

BACKGROUND IN N
It PRP N
is VBZ N
currently RB N
not RB N
known VBN N
whether IN N
dairy NN N
food NN N
influences VBZ N
the DT N
risk NN N
of IN N
cardiovascular JJ o
disease NN o
or CC o
diabetes VBZ o
. . o

This DT N
study NN N
evaluates VBZ N
effects NNS N
of IN N
changing VBG i
dairy NN i
intake NN i
on IN N
cardio-metabolic JJ o
risk NN o
factors NNS o
. . o

METHODS NNP N
180 CD p
healthy JJ p
volunteers NNS p
were VBD N
randomised VBN N
to TO N
increase VB i
, , i
reduce VB i
or CC i
not RB i
change VB i
their PRP$ i
dairy NN i
intake NN i
for IN i
1 CD i
month NN i
in IN N
response NN N
to TO N
dietary JJ N
advice NN N
. . N

Body NNP o
weight VBD o
, , o
waist JJ o
circumference NN o
, , o
blood NN o
pressure NN o
, , o
fasting VBG o
plasma NN o
lipids NNS o
, , o
insulin NN o
resistance NN o
and CC o
C-reactive JJ o
protein NN o
( ( o
CRP NNP o
) ) o
were VBD N
measured VBN N
at IN N
baseline NN N
and CC N
after IN N
1 CD N
month NN N
and CC N
compared VBN N
by IN N
dietary JJ N
group NN N
. . N

RESULTS CC N
176 CD p
( ( p
98 CD p
% NN p
) ) p
subjects VBZ p
completed VBN N
the DT N
study NN N
. . N

Average JJ N
change NN N
in IN N
self-reported JJ o
dairy NN o
fat JJ o
intake NN o
for IN N
increased VBN N
dairy NN N
food NN N
was VBD N
+0.9 NNP N
SD NNP N
1.1 CD N
g/day NN N
( ( N
+71 CD N
% NN N
) ) N
, , N
no DT N
change NN N
was VBD N
-2.1 JJ N
SD NNP N
0.4 CD N
g/day NN N
( ( N
-15 CD N
% NN N
) ) N
and CC N
decreased VBN o
dairy NN o
food NN o
was VBD o
-10.8 NNP N
SD NNP N
1.2 CD N
g/day NN N
( ( N
-77 CD N
% NN N
) ) N
respectively RB N
. . N

There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
change NN N
in IN o
LDL NNP o
or CC o
HDL NNP o
cholesterol NN o
, , o
triglycerides NNS o
, , o
systolic JJ o
or CC o
diastolic JJ o
blood NN o
pressure NN o
, , o
C-reactive JJ o
protein NN o
, , o
glucose NN o
or CC o
insulin NN o
with IN o
95 CD N
% NN N
CI NNP N
standard JJ N
mean NN N
differences NNS N
< VBP N
0.2 CD N
for IN N
all DT N
and CC N
CRP NNP N
< NNP N
0.3 CD N
. . N

There EX N
was VBD N
a DT N
small JJ o
increase NN o
in IN o
weight NN o
( ( o
+0.4 JJ o
kg NN N
, , N
SD NNP N
3.1 CD N
) ) N
in IN N
those DT N
asked VBN N
to TO N
increase VB N
dairy NN N
food NN N
. . N

CONCLUSIONS NNP p
In IN p
healthy JJ p
volunteers NNS p
, , p
dietary JJ p
advice NN N
to TO N
change VB N
dairy NN N
intake NN N
for IN N
1 CD N
month NN N
did VBD N
not RB N
have VB N
a DT N
clinically RB N
significant JJ N
effect NN N
on IN o
cardio-metabolic JJ o
risk NN o
factors NNS o
. . N

These DT N
observations NNS N
suggest VBP N
that IN N
dairy NN N
food NN N
can MD N
be VB N
included VBN N
as IN N
part NN N
of IN N
a DT N
normal JJ N
healthy JJ N
diet NN N
without IN N
increasing VBG o
cardio-metabolic JJ o
risk NN o
. . o

TRIAL NNP o
REGISTRATION NNP N
NUMBER NNP N
ACTRN12612000574842 NNP N
. . N

-DOCSTART- -19897063- O O

The DT N
effect NN N
of IN N
cessation NN N
of IN N
raloxifene NN i
treatment NN N
on IN N
bone NN p
turnover NN p
in IN p
postmenopausal JJ p
women NNS p
. . p

There EX N
is VBZ N
evidence NN N
to TO N
suggest VB N
accelerated JJ p
bone NN o
loss NN o
following VBG p
estrogen JJ p
cessation NN p
. . p

The DT N
effect NN N
of IN N
cessation NN N
of IN N
raloxifene NN i
therapy NN N
on IN N
bone NN N
turnover NN N
is VBZ N
unknown JJ N
. . N

Our PRP$ N
aim NN N
was VBD N
to TO N
determine VB N
the DT N
effect NN N
of IN N
cessation NN N
of IN N
raloxifene NN i
treatment NN N
on IN N
bone NN o
turnover NN o
and CC N
bone JJ o
mineral NN o
density NN o
( ( o
BMD NNP o
) ) o
in IN N
postmenopausal NN p
, , p
osteopenic JJ p
women NNS p
. . p

Women NNS p
aged VBD p
50 CD p
to TO p
80 CD p
years NNS p
received VBD N
raloxifene NN i
for IN N
96 CD N
weeks NNS N
and CC N
were VBD N
then RB N
randomized VBN N
to TO N
continue VB N
raloxifene NN i
( ( p
group NN p
1 CD p
, , p
n=20 NN p
) ) p
or CC i
placebo NN i
( ( p
group NN p
2 CD p
, , p
n=20 NN p
) ) p
for IN p
a DT p
further JJ p
96 CD p
weeks NNS p
. . p

A DT p
third JJ p
group NN p
( ( p
group NN p
3 CD p
, , p
n=14 NN p
) ) p
received VBD p
no DT i
treatment NN i
. . i

Bone NNP o
turnover NN o
markers NNS o
and CC o
bone NN o
density NN o
( ( o
BMD NNP o
) ) o
were VBD N
measured VBN N
throughout IN N
the DT N
study NN N
. . N

Raloxifene NNP i
treatment NN N
for IN N
96 CD N
weeks NNS N
resulted VBD N
in IN N
a DT N
decrease NN o
in IN o
bone NN o
turnover NN o
( ( N
PINP NNP N
by IN N
31 CD N
% NN N
) ) N
and CC N
an DT N
increase NN o
in IN o
spine JJ o
BMD NNP o
( ( N
by IN N
2 CD N
% NN N
) ) N
but CC N
no DT N
change NN N
in IN N
hip NN o
BMD NNP o
for IN N
groups NNS N
1 CD N
and CC N
2 CD N
. . N

Continuation NN N
of IN N
raloxifene NN i
( ( N
group NN N
1 CD N
) ) N
maintained VBD N
these DT N
changes NNS N
. . N

Following VBG N
cessation NN N
of IN N
raloxifene NN i
( ( N
group NN N
2 CD N
) ) N
, , N
bone NN o
markers NNS o
returned VBD N
to TO N
baseline NN N
levels NNS N
( ( N
by IN N
120 CD N
weeks NNS N
) ) N
. . N

Hip NNP o
BMD NNP o
was VBD N
decreased VBN N
by IN N
2 CD N
% NN N
at IN N
192 CD N
weeks NNS N
compared VBN N
to TO N
baseline VB N
. . N

Bone NNP o
markers NNS o
in IN N
the DT N
controls NNS N
( ( N
group NN N
3 CD N
) ) N
remained VBD N
at IN N
the DT N
upper JJ N
limit NN N
of IN N
the DT N
reference NN N
range NN N
throughout IN N
, , N
with IN N
decreases NNS N
in IN N
BMD NNP o
of IN N
2.3 CD N
% NN N
( ( N
spine NN N
) ) N
and CC N
2.8 CD N
% NN N
( ( N
hip NN N
) ) N
. . N

Bone NNP o
loss NN o
following VBG N
cessation NN N
of IN N
raloxifene NN i
therapy NN N
at IN N
96 CD N
weeks NNS N
was VBD N
greater JJR N
than IN N
in IN N
the DT N
control NN N
group NN N
, , N
suggesting VBG N
accelerated VBD p
bone JJ p
loss NN p
. . p

The DT N
beneficial JJ N
effect NN N
on IN N
bone NN o
turnover NN o
of IN N
96 CD N
weeks NNS N
of IN N
raloxifene NN N
was VBD N
lost VBN N
6 CD N
months NNS N
after IN N
cessation NN N
of IN N
treatment NN N
. . N

-DOCSTART- -23688859- O O

Effects NNS N
of IN N
exposure NN N
to TO N
thin-ideal JJ N
media NNS N
images NNS N
on IN N
body NN o
dissatisfaction NN o
: : o
testing VBG N
the DT N
inclusion NN N
of IN N
a DT N
disclaimer NN i
versus NN i
warning VBG i
label NN i
. . i

The DT N
current JJ N
study NN N
was VBD N
designed VBN N
to TO N
determine VB N
whether IN N
the DT N
inclusion NN N
of IN N
a DT N
disclaimer NN N
( ( N
i.e. FW N
, , N
Retouched NNP N
photograph NN N
aimed VBN N
at IN N
changing VBG N
a DT N
person NN N
's POS N
physical JJ N
appearance NN N
. . N

) ) N
or CC N
warning VBG N
( ( N
i.e. FW N
, , N
Warning VBG N
: : N
Trying NN N
to TO N
look VB N
as RB N
thin JJ N
as IN N
this DT N
model NN N
may MD N
be VB N
dangerous JJ N
to TO N
your PRP$ N
health NN N
. . N

) ) N
added VBD N
to TO N
images NNS N
of IN N
thin/attractive JJ N
models NNS N
would MD N
affect VB N
body NN o
dissatisfaction NN o
and CC N
intent NN N
to TO N
diet VB N
in IN N
female JJ p
undergraduate JJ p
students NNS p
( ( p
n=342 NN p
) ) p
. . p

Participants NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
four CD N
groups NNS i
: : i
( ( i
a DT i
) ) i
disclaimer NN i
, , i
( ( i
b NN i
) ) i
warning NN i
, , i
( ( i
c NN i
) ) i
model NN i
control NN i
, , i
or CC i
( ( i
d NN i
) ) i
car NN i
control NN i
. . i

Results NNP N
revealed VBD N
a DT N
significant JJ N
interaction NN N
between IN N
group NN N
and CC N
time NN N
, , N
whereby WRB N
only RB N
the DT N
car NN N
control NN N
group NN N
reported VBD N
a DT N
significant JJ N
change NN N
( ( N
i.e. FW N
, , N
decrease NN N
) ) N
in IN N
body NN o
dissatisfaction NN o
over IN N
time NN N
. . N

Groups NNP N
did VBD N
not RB N
differ VB N
on IN N
intent NN N
to TO N
diet VB o
measured VBN N
at IN N
post-exposure NN N
. . N

The DT N
results NNS N
largely RB N
replicate VBP N
other JJ N
findings NNS N
in IN N
this DT N
area NN N
and CC N
call VB N
into IN N
question NN N
advocacy NN N
efforts NNS N
to TO N
label VB N
media NNS N
images NNS N
as IN N
a DT N
strategy NN N
to TO N
decrease VB N
women NNS p
's POS p
identification NN N
with IN N
the DT N
stimuli NNS N
. . N

-DOCSTART- -9818888- O O

Long-term JJ o
outcome NN o
of IN N
migraine JJ i
therapy NN i
: : i
predictive JJ N
value NN N
of IN N
the DT N
frontotemporal JJ i
nitroglycerin JJ i
test NN i
. . i

We PRP N
evaluated VBD N
whether IN N
type NN N
of IN N
response NN N
to TO N
the DT N
migraine-induction JJ N
test NN N
with IN N
a DT N
nitroglycerin JJ i
ointment NN i
applied VBN N
to TO N
the DT N
frontotemporal JJ N
head NN N
region NN N
could MD N
predict VB o
the DT o
efficacy NN o
of IN o
antimigraine JJ o
therapy NN o
. . o

Forty-two JJ p
patients NNS p
with IN p
migraine NN p
without IN p
aura JJ p
underwent NN p
the DT p
test NN p
before IN p
and CC p
2 CD p
months NNS p
after IN p
antimigraine JJ i
therapy NN i
. . i

Two CD N
and CC N
4 CD N
months NNS N
after IN N
treatment NN N
withdrawal NN N
, , N
most RBS N
subjects NNS N
with IN N
a DT N
negative JJ N
response NN N
to TO N
the DT N
post-treatment JJ N
test NN N
maintained VBD o
treatment NN o
benefit NN o
, , N
whereas JJ N
benefit NN o
was VBD N
lost VBN N
in IN N
patients NNS N
with IN N
an DT N
early JJ o
onset NN o
migraine NN o
response NN o
. . o

-DOCSTART- -7036084- O O

[ JJ i
Cred? NNP i
's POS i
prevention NN i
method NN i
has VBZ N
lost VBN N
its PRP$ o
justification NN o
today NN N
] NNP N
. . N

-DOCSTART- -9322152- O O

Acute NNP o
rejection NN o
and CC o
heart NN o
infection NN o
rates NNS o
in IN N
FK NNP i
506- JJ i
versus NN p
cyclosporine NN i
A-treated JJ i
heart NN p
transplant NN p
recipients NNS p
: : p
an DT N
endomyocardial JJ N
biopsy NN N
pathologic NN N
study NN N
. . N

-DOCSTART- -9850026- O O

BEACOPP NNP N
, , N
a DT N
new JJ N
dose-escalated JJ i
and CC i
accelerated JJ i
regimen NNS i
, , N
is VBZ N
at IN N
least JJS N
as RB N
effective JJ N
as IN N
COPP/ABVD NNP i
in IN N
patients NNS p
with IN p
advanced-stage JJ p
Hodgkin NNP p
's POS p
lymphoma NN p
: : p
interim JJ N
report NN N
from IN N
a DT N
trial NN N
of IN N
the DT N
German JJ p
Hodgkin NNP N
's POS N
Lymphoma NNP N
Study NNP N
Group NNP N
. . N

PURPOSE NNP N
The DT N
HD9 NNP N
trial NN N
aims NNS N
to TO N
evaluate VB N
whether IN N
moderate JJ N
dose JJ N
escalation NN N
and/or IN N
acceleration NN N
of IN N
standard JJ i
polychemotherapy NN i
is VBZ N
beneficial JJ N
for IN N
advanced-stage JJ p
Hodgkin NNP p
's POS p
disease NN p
( ( p
HD NNP p
) ) p
. . p

Two CD N
variants NNS N
of IN N
a DT N
novel JJ i
bleomycin NN i
, , i
etoposide RB i
, , i
doxorubicin NN i
, , i
cyclophosphamide NN i
, , i
vincristine NN i
, , i
procarbazine NN i
, , i
and CC i
prednisone NN i
( ( i
BEACOPP NNP i
) ) i
scheme NN i
( ( i
standard JJ i
and CC i
escalated VBD i
dose NN i
) ) i
are VBP N
compared VBN N
with IN N
cyclophosphamide NN i
, , i
vincristine NN i
, , i
procarbazine NN i
, , i
and CC i
prednisone NN i
( ( i
COPP NNP i
) ) i
/doxorubicin NN i
, , i
bleomycin NN i
, , i
vinblastine NN i
, , i
and CC i
dacarbazine NN i
( ( i
ABVD NNP i
) ) i
. . i

PATIENTS NNP N
AND CC N
METHODS NNP N
The DT p
randomized VBN p
, , p
three-arm JJ p
trial NN p
recruited VBD p
patients NNS p
in IN p
stages NNS p
IIB NNP p
and CC p
IIIA NNP p
with IN p
risk NN p
factors NNS p
and CC p
stages NNS p
IIIB NNP p
and CC p
IV NNP p
. . p

BEACOPP NNP N
in IN N
baseline NN N
dose NN N
contains VBZ N
all DT N
drug NN N
dosages NNS N
of IN N
COPP/ABVD NNP i
( ( N
except IN N
vincristine NN N
and CC N
procarbazine NN N
) ) N
rearranged VBD N
in IN N
a DT N
shorter NN N
, , N
3-week JJ N
cycle NN N
. . N

Escalated VBN N
BEACOPP NNP N
uses VBZ N
higher JJR N
doses NNS N
of IN N
cyclophosphamide NN i
, , i
doxorubicin NN i
, , i
and CC i
etoposide RB i
with IN i
granulocyte JJ i
colony-stimulating JJ i
factor NN i
( ( i
G-CSF NNP i
) ) i
support NN N
. . N

After IN N
eight CD N
chemotherapy NN i
cycles NNS N
, , N
initial JJ N
bulky NN N
and CC N
residual JJ N
disease NN N
is VBZ N
irradiated VBN N
. . N

The DT N
trial NN N
is VBZ N
monitored VBN N
and CC N
analyzed VBN N
by IN N
means NNS N
of IN N
a DT N
sequential JJ N
strategy NN N
. . N

RESULTS NNP N
An DT N
interim JJ N
analysis NN N
with IN N
505 CD p
assessable JJ p
patients NNS p
and CC N
a DT N
median JJ N
follow-up NN N
of IN N
23 CD N
months NNS N
showed VBD N
a DT N
significant JJ N
inferiority NN N
( ( N
according VBG N
to TO N
sequential JJ N
monitoring NN N
strategy NN N
) ) N
of IN N
the DT N
COPP/ABVD NNP i
regimen NNS N
in IN N
progression NN o
rate NN o
and CC o
freedom NN o
from IN o
treatment NN o
failure NN o
( ( o
FFTF NNP o
) ) o
compared VBN N
with IN N
the DT N
pooled JJ N
results NNS N
of IN N
both DT N
BEACOPP NNP i
variants NNS N
. . N

The DT N
24-month JJ o
FFTF NNP o
rate NN o
was VBD N
75 CD N
% NN N
for IN N
COPP/ABVD NNP N
and CC N
84 CD N
% NN N
for IN N
BEACOPP NNP i
pooled VBD N
( ( N
P NNP N
= NNP N
.034 NNP N
) ) N
. . N

There EX N
was VBD N
12 CD N
% NN N
progressive JJ o
disease NN o
with IN N
COPP/ABVD NNP N
and CC N
6 CD N
% NN N
with IN N
BEACOPP NNP i
pooled VBD N
. . N

Differences NNS o
in IN o
survival NN o
were VBD N
not RB N
significant JJ N
in IN N
sequential JJ N
analysis NN N
. . N

The DT N
acute JJ o
toxicity NN o
of IN o
baseline NN o
BEACOPP NNP o
resembled VBD N
that IN N
of IN N
COPP/ABVD NNP i
; : i
escalated VBD N
BEACOPP NNP i
showed VBD N
increased VBN N
but CC N
manageable JJ N
hematologic JJ N
toxicity NN N
. . N

CONCLUSION NNP N
Combined VBD N
with IN N
local JJ N
irradiation NN N
, , N
BEACOPP NNP i
in IN N
one CD N
or CC N
both DT N
variants NNS N
shows VBZ N
superior JJ N
disease NN N
control NN N
compared VBN N
with IN N
COPP/ABVD NNP i
, , N
with IN N
acceptable JJ N
acute JJ N
toxicity NN N
. . N

Further JJ N
follow-up NN N
is VBZ N
required VBN N
to TO N
assess VB N
the DT N
effect NN N
of IN N
dosage NN N
and CC N
the DT N
effect NN N
on IN N
survival NN N
and CC N
late JJ N
toxicities NNS N
. . N

-DOCSTART- -22810989- O O

Margarines NNS i
fortified VBN i
with IN i
?-linolenic JJ i
acid NN i
, , i
eicosapentaenoic JJ i
acid NN i
, , i
or CC i
docosahexaenoic JJ i
acid NN i
alter IN N
the DT N
fatty JJ N
acid JJ N
composition NN N
of IN N
erythrocytes NNS N
but CC N
do VBP N
not RB N
affect VB N
the DT N
antioxidant JJ N
status NN N
of IN p
healthy JJ p
adults NNS p
. . p

We PRP N
aimed VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
increased JJ N
intake NN N
of IN i
?-linolenic JJ i
acid NN i
( ( i
ALA NNP i
) ) i
, , i
EPA NNP i
, , i
or CC i
DHA NNP i
incorporated VBN i
into IN N
a DT N
food NN N
matrix NN N
on IN N
the DT N
fatty JJ N
acid JJ N
composition NN N
of IN N
erythrocytes NNS N
and CC N
on IN N
biomarkers NNS N
of IN N
oxidant/antioxidant JJ N
status NN N
. . N

To TO N
this DT N
end NN N
, , N
a DT N
controlled VBN N
dietary NN N
study NN N
was VBD N
conducted VBN N
in IN N
74 CD p
healthy JJ p
men NNS p
and CC p
women NNS p
. . p

The DT N
participants NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
3 CD N
interventions NNS N
in IN N
which WDT i
margarines NNS i
fortified VBD i
with IN i
either DT i
10 CD i
weight NN i
percent NN i
ALA NNP i
, , i
EPA NNP i
, , i
or CC i
DHA NNP i
ethyl VBP i
esters NNS i
replaced VBD i
their PRP$ N
normal JJ N
spread NN N
for IN N
6 CD N
wk NN N
. . N

The DT N
total JJ N
intakes NNS N
of IN N
ALA NNP N
, , N
EPA NNP N
, , N
and CC N
DHA NNP N
were VBD N
4.4 CD N
, , N
2.2 CD N
, , N
and CC N
2.3 CD N
g/d NN N
, , N
respectively RB N
. . N

Consuming VBG N
EPA NNP N
increased VBD N
the DT o
erythrocyte JJ o
proportion NN o
of IN o
EPA NNP o
( ( o
394 CD N
% NN N
) ) N
and CC N
the DT o
omega-3 JJ o
index NN o
( ( o
sum NN N
of IN N
EPA NNP N
and CC N
DHA NNP N
, , N
38 CD N
% NN N
) ) N
. . N

Consumption NN N
of IN N
DHA NNP N
increased VBD o
erythrocyte JJ o
DHA NNP o
( ( o
91 CD N
% NN N
) ) N
, , N
the DT N
omega-3 JJ N
index NN N
( ( N
98 CD N
% NN N
) ) N
, , N
and CC o
EPA NNP o
( ( o
137 CD N
% NN N
) ) N
. . N

The DT o
omega-3 JJ o
index NN o
increased VBD o
to TO N
a DT N
significantly RB N
greater JJR N
extent NN N
in IN N
the DT N
DHA NNP N
group NN N
than IN N
in IN N
the DT N
EPA NNP N
group NN N
. . N

ALA NNP N
did VBD N
not RB N
increase VB o
erythrocyte NN o
EPA NNP o
or CC o
the DT o
omega-3 JJ o
index NN o
. . o

We PRP N
found VBD N
no DT N
change NN N
in IN N
plasma NN o
uric JJ o
acid NN o
or CC o
antioxidant JJ o
capacity NN o
in IN o
any DT N
of IN N
the DT N
groups NNS o
. . o

Plasma NNP o
malondialdehyde NN o
( ( o
MDA NNP o
) ) o
increased VBD o
with IN N
the DT N
EPA NNP N
and CC N
DHA NNP N
interventions NNS N
. . N

All DT N
3 CD N
interventions NNS N
decreased VBD o
erythrocyte JJ o
linoleic NN o
acid NN o
hydroperoxides NNS o
but CC o
did VBD N
not RB N
affect VB N
their PRP$ o
MDA NNP o
concentrations NNS o
. . o

In IN N
conclusion NN N
, , N
the DT N
intake NN N
of IN N
both DT N
isolated JJ N
EPA NNP N
and CC N
DHA NNP N
incorporated VBD N
into IN N
margarine NN N
resulted VBN N
in IN N
an DT N
enhanced JJ o
incorporation NN o
of IN o
EPA NNP o
and CC o
DHA NNP o
into IN o
erythrocytes NNS N
. . N

Our PRP$ N
findings NNS N
indicate VBP N
that IN N
DHA NNP N
is VBZ N
quantitatively RB N
superior JJ N
to TO N
EPA NNP N
in IN N
view NN N
of IN N
the DT N
EPA+DHA NNP N
tissue NN N
incorporation NN N
and CC N
also RB N
that IN N
4 CD N
g/d NN N
ALA NNP N
is VBZ N
not RB N
sufficient JJ N
to TO N
increase VB N
the DT N
omega-3 JJ N
index NN N
over IN N
a DT N
6-wk JJ N
period NN N
. . N

-DOCSTART- -16007391- O O

Effect NN N
of IN N
cigarette NN N
smoking NN N
on IN N
gastric JJ N
emptying NN N
of IN N
solids NNS N
in IN N
Japanese JJ p
smokers NNS p
: : p
a DT N
crossover NN N
study NN N
using VBG N
the DT N
13C-octanoic JJ N
acid NN N
breath NN N
test NN N
. . N

BACKGROUND NNP N
Cigarette NNP N
smoking NN N
is VBZ N
associated VBN N
with IN N
an DT N
increased VBN N
risk NN N
of IN N
peptic JJ N
ulcer NN N
and CC N
gastroesophageal NN N
reflux NN N
disease NN N
. . N

Gastric NNP N
emptying VBG N
disorders NNS N
may MD N
play VB N
a DT N
role NN N
in IN N
the DT N
development NN N
of IN N
these DT N
upper JJ N
gastrointestinal NN N
diseases NNS N
. . N

Thus RB N
, , N
studies NNS N
examining VBG N
a DT N
link NN N
between IN N
smoking VBG N
and CC N
gastric JJ N
emptying VBG N
disorders NNS N
have VBP N
clinical JJ N
relevance NN N
. . N

This DT N
study NN N
was VBD N
conducted VBN N
to TO N
investigate VB N
the DT N
effect NN o
of IN o
smoking VBG o
on IN N
gastric JJ N
emptying NN N
of IN N
solids NNS N
in IN N
Japanese JJ p
smokers NNS p
. . p

METHODS PDT N
The DT N
( ( i
13 CD i
) ) i
C-octanoic NNP i
acid JJ o
breath NN o
test NN o
was VBD N
performed VBN N
in IN N
eight CD p
male JJ p
habitual JJ p
smokers NNS p
on IN N
two CD N
randomized JJ N
occasions NNS N
( ( N
either DT N
sham NN N
smoking NN N
or CC N
actively RB N
smoking VBG N
) ) N
. . N

The DT N
time NN N
vs NN N
( ( N
13 CD N
) ) N
CO NNP N
( ( N
2 CD N
) ) N
excretion NN o
rate NN o
curve NN o
was VBD N
mathematically RB N
fitted VBN N
to TO N
a DT N
conventional JJ N
formula NN N
of IN N
y NN N
( ( N
t NN N
) ) N
= NN N
m*k*beta*e NN N
( ( N
-k*t NNP N
) ) N
* NNP N
( ( N
1 CD N
- : N
e NN N
( ( N
-k*t NNP N
) ) N
) ) N
( ( N
beta-1 NN N
) ) N
, , N
and CC N
the DT N
parameters NNS o
of IN o
k NN o
and CC o
beta NN o
were VBD N
determined VBN N
: : N
under IN N
the DT N
crossover NN N
protocol NN N
, , N
a DT N
larger JJR N
( ( N
smaller JJR N
) ) N
beta NN N
indicates VBZ N
slower JJR o
( ( o
faster RBR o
) ) o
emptying VBG o
in IN N
the DT N
early JJ N
phase NN N
, , N
and CC N
a DT N
larger JJR N
( ( N
smaller JJR N
) ) N
k NN N
indicates VBZ N
faster RBR o
( ( o
slower JJR o
) ) o
emptying VBG o
in IN o
the DT N
later JJ N
phase NN N
. . N

The DT N
half NN o
( ( o
13 CD o
) ) o
CO NNP o
( ( o
2 CD o
) ) o
excretion NN o
time NN o
( ( N
t NN N
( ( N
1/2b CD N
) ) N
= SYM N
- : N
[ NN N
ln NN N
( ( N
1 CD N
- : N
2 CD N
( ( N
-1/beta NNP N
) ) N
) ) N
] FW N
/k NN N
) ) N
and CC N
the DT N
time NN o
of IN o
maximal NN o
( ( o
13 CD o
) ) o
CO NNP o
( ( o
2 CD o
) ) o
excretion NN o
rate NN o
( ( o
t NN o
( ( o
max NN o
) ) o
= VBZ N
[ JJ N
lnbeta NN N
] NNP N
/k NNP N
) ) N
were VBD N
also RB N
calculated VBN N
. . N

Between IN N
the DT N
two CD N
occasions NNS N
, , N
k NN N
, , N
beta NN N
, , N
t NN N
( ( N
1/2b CD N
) ) N
, , N
and CC N
t NN N
( ( N
max NN N
) ) N
were VBD N
compared VBN N
by IN N
the DT N
Wilcoxon NNP N
signed-rank JJ N
test NN N
. . N

RESULTS NNP N
After IN N
smoking VBG N
, , N
k NN o
was VBD o
significantly RB o
increased VBN o
. . o

No DT o
significant JJ o
differences NNS o
were VBD N
found VBN N
in IN N
beta NN o
, , o
t NN o
( ( o
1/2 CD o
) ) o
, , o
and CC o
t NN o
( ( o
max NN o
) ) o
between IN N
the DT N
two CD N
occasions NNS N
. . N

CONCLUSIONS VB N
The DT N
increase NN o
in IN o
k JJ o
suggests VBZ N
the DT N
acceleration NN N
of IN N
gastric JJ N
emptying VBG N
in IN N
the DT N
later JJ N
phase NN N
. . N

For IN N
the DT N
first JJ N
time NN N
, , N
this DT N
study NN N
has VBZ N
revealed VBN N
that IN N
acute JJ N
smoking NN N
speeds VBZ N
the DT N
gastric JJ N
emptying NN N
of IN N
solids NNS N
in IN N
Japanese JJ p
habitual JJ p
smokers NNS p
. . p

-DOCSTART- -15358872- O O

Parent NNP i
management NN i
training NN i
and CC p
Asperger NNP p
syndrome NN p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
to TO N
evaluate VB N
a DT N
parent NN o
based VBN o
intervention NN o
. . o

This DT N
controlled JJ N
trial NN N
of IN N
a DT N
parent NN i
management NN i
intervention NN i
aimed VBN N
to TO N
increase VB N
parental JJ N
competence NN N
in IN N
management NN N
of IN N
problem NN N
behaviours NNS N
associated VBN N
with IN N
Asperger NNP p
syndrome NN p
. . p

The DT N
intervention NN N
compared VBN N
two CD N
formats NNS N
, , N
a DT N
1 CD i
day NN i
workshop NN i
and CC i
six CD i
individual JJ i
sessions NNS i
. . i

Measures NNS N
were VBD N
taken VBN N
on IN N
three CD N
occasions NNS N
: : N
pre-intervention NN N
, , N
at IN N
4 CD N
weeks NNS N
, , N
and CC N
at IN N
3 CD N
month NN N
follow-up NN N
. . N

Variables NNS N
of IN N
interest NN N
were VBD N
number NN o
and CC o
intensity NN o
of IN o
problem NN o
behaviours NN o
, , o
and CC o
parent JJ o
evaluation NN o
of IN o
social JJ o
interaction NN o
skills NNS o
. . o

Results NNS N
showed VBD N
parents NNS N
reporting VBG N
fewer JJR N
and CC N
lower JJR N
intensity NN o
of IN o
problem NN o
behaviours NNS o
and CC N
increased VBD o
social JJ o
interactions NNS o
at IN N
4 CD N
weeks NNS N
and CC N
3 CD N
months NNS N
. . N

Results NNS N
held VBD N
across IN N
formats NNS N
and CC N
suggest VBP N
that IN N
parent NN N
management NN N
training NN N
can MD N
provide VB N
an DT N
effective JJ o
intervention NN o
for IN o
parents NNS o
of IN o
a DT o
child NN o
with IN o
Asperger NNP o
syndrome NN o
. . o

Group NNP N
differences VBZ N
on IN N
outcome NN N
measures NNS N
and CC N
in IN N
the DT N
use NN N
of IN N
strategies NNS N
are VBP N
discussed VBN N
along IN N
with IN N
limitations NNS N
of IN N
the DT N
study NN N
. . N

-DOCSTART- -4459905- O O

[ JJ i
Carticaine NNP i
in IN N
the DT N
therapie NN N
of IN N
pain NN o
( ( N
author NN N
's POS N
transl NN N
) ) N
] NN N
. . N

-DOCSTART- -24083350- O O

Possible JJ N
etiology NN N
of IN N
improvements NNS N
in IN N
both DT N
quality NN o
of IN o
life NN o
and CC o
overlapping VBG o
gastroesophageal JJ o
reflux JJ o
disease NN o
by IN N
proton NN i
pump NN i
inhibitor NN i
treatment NN i
in IN N
a DT N
prospective JJ N
randomized NN N
controlled VBD N
trial NN N
. . N

BACKGROUND NNP N
Symptoms NNP N
suggestive NN N
of IN N
functional JJ N
dyspepsia NN N
( ( N
FD NNP N
) ) N
and CC N
irritable JJ N
bowel NN N
syndrome NN N
( ( N
IBS NNP N
) ) N
frequently RB N
overlap VBP N
with IN N
those DT N
of IN N
gastroesophageal JJ N
reflux JJ N
disease NN N
. . N

Despite IN N
the DT N
high JJ N
prevalence NN N
of IN N
symptomatic JJ N
overlap NN N
, , N
the DT N
underlying JJ N
etiology NN N
remains VBZ N
poorly RB N
defined VBN N
. . N

We PRP N
assessed VBD N
the DT N
correlation NN N
of IN N
symptomatic JJ o
relief NN o
and CC o
health-related JJ o
quality NN o
of IN o
life NN o
( ( o
HRQoL NNP o
) ) o
with IN N
healing NN N
of IN N
reflux NN N
esophagitis NN N
to TO N
further RBR N
derive JJ N
insights NNS N
into IN N
the DT N
underlying JJ N
etiology NN N
. . N

METHODS NNP N
626 CD p
patients NNS p
with IN p
reflux JJ p
esophagitis NN p
were VBD N
enrolled VBN N
into IN N
one CD N
of IN N
two CD N
treatment NN N
groups NNS N
( ( i
classical JJ i
healing NN i
concept NN i
or CC i
the DT i
complete JJ i
remission NN i
concept NN i
) ) i
to TO N
investigate VB N
differences NNS N
in IN N
treatment NN N
intensity NN N
. . N

Patients NNS N
were VBD N
treated VBN N
with IN N
pantoprazole NN i
until IN N
esophageal JJ N
mucosal NN N
healing VBG N
. . N

Remission NN N
was VBD N
followed VBN N
for IN N
up RB N
to TO N
6 CD N
months NNS N
without IN N
treatment NN N
. . N

Gastro-intestinal JJ N
symptoms NNS N
and CC N
HRQoL NNP N
were VBD N
analyzed VBN N
using VBG N
disease-specific JJ N
, , N
psychometrically RB N
validated VBN N
patient-reported JJ N
outcome NN N
instruments NNS N
( ( N
ReQuest? NNP N
, , N
GERDyzer? NNP N
) ) N
. . N

RESULTS NNP o
Symptomatic NNP o
burden NN o
reflected VBN o
by IN o
ReQuest? NNP o
substantially RB o
decreased VBD N
from IN N
baseline NN N
to TO N
end VB N
of IN N
treatment NN N
by IN N
83 CD N
% NN N
and CC N
88 CD N
% NN N
in IN N
either CC N
treatment NN N
group NN N
, , N
respectively RB o
. . o

ReQuest? NNP o
scores VBZ o
significantly RB o
decreased VBN N
in IN N
patients NNS N
with IN N
or CC N
without IN N
heartburn NN N
and CC N
in IN N
those DT N
with IN N
symptoms NNS N
suggestive JJ N
of IN N
FD NNP N
and CC N
IBS NNP N
, , N
indicating VBG N
response NN N
of IN N
all DT N
symptom JJ N
categories NNS N
to TO N
treatment NN N
( ( N
p JJ N
< NNP N
0.005 CD N
) ) N
. . N

Therapy-associated JJ o
relief NN o
of IN o
symptoms NNS o
was VBD N
paralleled VBN N
by IN N
substantial JJ N
gains NNS o
in IN o
HRQoL NNP o
, , o
which WDT o
continued VBD N
to TO N
stabilize VB N
post-treatment JJ N
. . N

CONCLUSIONS NNP N
Pantoprazole NNP i
is VBZ N
effective JJ N
in IN N
relieving VBG N
upper JJ N
and CC N
lower JJR N
gastro-intestinal NN N
symptoms NNS N
overlapping VBG N
with IN N
erosive JJ N
esophagitis NN N
, , N
and CC N
provides VBZ N
sustained JJ N
improvement NN N
in IN N
HRQoL NNP N
post-treatment NN N
. . N

Our PRP$ N
results NNS N
propose VB N
a DT N
link NN N
between IN N
both DT N
healing NN N
of IN o
erosive JJ o
esophagitis NN o
and CC o
the DT o
slower JJR o
remission NN o
of IN o
upper JJ o
and CC o
lower JJR o
gastro-intestinal NN o
symptoms NNS o
. . o

Since IN o
the DT N
improvement NN N
observed VBD N
is VBZ N
likely JJ N
to TO N
be VB N
multifactorial JJ N
, , N
the DT N
possibility NN N
for IN N
an DT N
immune-mediated JJ N
etiology NN N
and CC N
identification NN N
of IN N
putative JJ N
susceptibility NN N
factors NNS N
by IN N
genome-wide JJ N
association NN N
study NN N
may MD N
provide VB N
focus NN N
for IN N
future JJ N
research NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
identifier NN N
: : N
NCT00325676 NNP N
. . N

-DOCSTART- -2678349- O O

Covariance NN i
analysis NN i
in IN p
generalized JJ p
linear JJ p
measurement NN p
error NN p
models NNS p
. . p

We PRP N
summarize VBP N
some DT N
of IN N
the DT N
recent JJ N
work NN N
on IN N
the DT N
errors-in-variables NNS N
problem NN N
in IN N
generalized JJ N
linear JJ N
models NNS N
. . N

The DT N
focus NN N
is VBZ N
on IN N
covariance NN N
analysis NN N
, , N
and CC N
in IN N
particular JJ N
testing NN N
for IN N
and CC N
estimation NN N
of IN N
treatment NN N
effects NNS N
. . N

There EX N
is VBZ N
a DT N
considerable JJ N
difference NN N
between IN N
the DT N
randomized JJ N
and CC N
non-randomized JJ N
models NNS N
when WRB N
testing VBG N
for IN N
an DT N
effect NN N
. . N

In IN N
randomized JJ N
studies NNS N
, , N
simple JJ N
techniques NNS N
exist VBP N
for IN N
testing VBG N
for IN N
a DT N
treatment NN N
effect NN N
. . N

In IN N
some DT N
instances NNS N
, , N
such JJ N
as IN N
linear JJ N
and CC N
multiplicative JJ N
regression NN N
, , N
simple JJ N
methods NNS N
exist VBP N
for IN N
estimating VBG N
the DT N
treatment NN N
effect NN N
. . N

In IN N
other JJ N
examples NNS N
such JJ N
as IN N
logistic JJ N
regression NN N
, , N
estimating VBG N
a DT N
treatment NN N
effect NN N
requires VBZ N
careful JJ N
attention NN N
to TO N
measurement VB N
error NN N
. . N

In IN N
non-randomized JJ N
studies NNS N
, , N
there EX N
is VBZ N
no DT N
recourse NN N
to TO N
understanding NN N
and CC N
modelling VBG N
measurement JJ N
error NN N
. . N

In IN N
particular JJ N
ignoring VBG N
measurement JJ N
error NN N
can MD N
lead VB N
to TO N
the DT N
wrong JJ N
conclusions NNS N
, , N
for IN N
example NN N
the DT N
true JJ N
but CC N
unobserved JJ N
data NNS N
may MD N
indicate VB N
a DT N
positive JJ N
effect NN N
for IN N
treatment NN N
, , N
while IN N
the DT N
observed JJ N
data NNS N
indicate VBP N
the DT N
opposite NN N
. . N

Some DT N
of IN N
the DT N
possible JJ N
methods NNS N
are VBP N
outlined VBN N
and CC N
compared VBN N
. . N

-DOCSTART- -9001833- O O

Comparison NNP N
of IN N
electromotive JJ N
drug NN N
administration NN N
with IN N
ketorolac NNS i
or CC N
with IN N
placebo NN i
in IN N
patients NNS p
with IN p
pain NN o
from IN p
rheumatic JJ p
disease NN p
: : p
a DT N
double-masked JJ N
study NN N
. . N

This DT N
study NN N
was VBD N
undertaken VBN N
to TO N
assess VB N
the DT N
efficacy NN o
of IN N
ketorolac NNS i
compared VBN N
with IN N
placebo NN i
when WRB N
delivered VBN N
by IN N
electromotive JJ i
drug NN i
administration NN i
( ( i
EMDA NNP i
) ) i
in IN N
patients NNS p
with IN p
pain NN o
from IN p
rheumatic JJ p
disease NN p
. . p

In IN N
EMDA NNP i
, , N
or CC N
iontophoresis NN N
, , N
a DT N
low-intensity NN N
electric JJ N
current JJ N
is VBZ N
applied VBN N
over IN N
the DT N
skin NN N
to TO N
deliver VB N
medication NN N
into IN N
body NN N
tissues NNS N
. . N

Although IN N
EMDA NNP i
has VBZ N
been VBN N
used VBN N
to TO N
treat VB N
patients NNS N
with IN N
various JJ N
diseases NNS N
, , N
controlled VBN N
studies NNS N
are VBP N
lacking VBG N
in IN N
patients NNS p
with IN p
rheumatic JJ p
disease NN p
. . p

This DT N
double-masked JJ N
study NN N
included VBD N
60 CD p
patients NNS p
( ( p
43 CD p
women NNS p
and CC p
17 CD p
men NNS p
) ) p
aged VBD p
31 CD p
to TO p
80 CD p
years NNS p
with IN p
the DT p
following JJ p
conditions NNS p
: : p
12 CD p
, , p
epicondylitis NN p
; : p
30 CD p
, , p
scapulohumeral JJ p
periarthritis NN p
; : p
10 CD p
, , p
gonalgia NN p
; : p
and CC p
8 CD p
, , p
metatarsalgia NN p
. . p

They PRP N
were VBD N
divided VBN N
randomly RB N
by IN N
a DT N
physician NN N
into IN N
2 CD N
groups NNS N
of IN N
30 CD N
patients NNS N
each DT N
for IN N
5 CD N
sessions NNS N
of IN N
active JJ N
treatment NN N
( ( i
30 CD i
mg NN i
of IN i
ketorolac NN i
) ) i
or CC N
placebo NN i
( ( i
5 CD i
mL NN i
of IN i
normal JJ i
saline NN i
) ) i
. . N

Treatment NNP N
took VBD N
place NN N
every DT N
other JJ N
day NN N
for IN N
20 CD N
minutes NNS N
. . N

Immediately RB N
before IN N
and CC N
after IN N
the DT N
five CD N
treatment NN N
sessions NNS N
and CC N
7 CD N
days NNS N
after IN N
treatment NN N
ended VBN N
, , N
both DT N
patient NN N
and CC N
physician NN N
measured VBD N
the DT N
degree NN o
of IN o
pain NN o
using VBG N
a DT N
categoric JJ N
scale NN N
( ( N
no DT N
pain NN N
, , N
slight JJ N
pain NN N
, , N
intermediate JJ N
pain NN N
, , N
strong JJ N
pain NN N
, , N
and CC N
very RB N
strong JJ N
pain NN N
) ) N
and CC N
evaluated VBN N
pain NN o
intensity NN o
using VBG N
the DT N
Scott NNP N
and CC N
Huskisson NNP N
Visual NNP N
Analogue NNP N
Scale NNP N
( ( N
VAS NNP N
) ) N
. . N

Seven NNP N
days NNS N
after IN N
treatment NN N
ended VBN N
, , N
both DT N
physician JJ N
and CC N
patient JJ N
judged VBD N
the DT N
result NN N
of IN N
treatment NN N
using VBG N
a DT N
second JJ N
categoric JJ N
scale NN N
( ( N
no DT N
improvement NN N
or CC N
intermediate NN N
, , N
good JJ N
, , N
or CC N
very RB N
good JJ N
result NN N
) ) N
. . N

Both DT N
ketorolac NN i
and CC N
placebo NN i
provided VBN N
immediate JJ N
, , N
significant JJ N
pain NN o
relief NN o
when WRB N
delivered VBN N
by IN N
EMDA NNP i
, , N
but CC N
only RB N
those DT N
patients NNS N
receiving VBG N
ketorolac NN i
experienced VBD N
a DT N
further JJ N
reduction NN o
in IN o
pain NN o
7 CD o
days NNS o
after IN o
treatment NN o
; : o
those DT N
receiving VBG N
placebo NN i
experienced VBD N
a DT N
slight JJ N
increase NN o
in IN o
pain NN o
. . o

VAS NNP o
values NNS o
differed VBD N
significantly RB N
between IN N
the DT N
two CD N
groups NNS N
. . N

Poor NNP o
results NNS o
( ( o
no DT o
improvement NN o
) ) o
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
placebo-treated JJ i
group NN N
, , N
while IN N
good JJ o
results NNS o
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
ketorolac-treated JJ i
group NN N
. . N

No DT N
patient NN N
reported VBD N
any DT N
adverse JJ o
effects NNS o
during IN N
treatment NN N
. . N

This DT N
study NN N
demonstrates VBZ N
that IN N
ketorolac NN i
relieves NNS N
pain VBP o
when WRB N
delivered VBN N
by IN N
EMDA NNP i
and CC N
offers VBZ N
longer-lasting JJ N
pain NN o
relief NN o
than IN N
does VBZ N
placebo VB i
. . i

-DOCSTART- -1991872- O O

Effects NNS N
of IN N
fluoride NN i
and CC i
chlorhexidine NN i
on IN N
the DT N
microflora NN o
of IN o
dental JJ o
root NN o
surfaces NNS o
and CC N
progression NN N
of IN N
root-surface NN N
caries NNS N
. . N

The DT N
effects NNS N
of IN N
fluoride NN i
and CC i
chlorhexidine NN i
varnishes NNS N
on IN N
the DT N
microflora NN N
of IN N
dental JJ N
root NN N
surfaces NNS N
and CC N
on IN N
the DT N
progression NN N
of IN N
root-surface NN N
caries NNS N
were VBD N
studied VBN N
. . N

Forty-four CD p
patients NNS p
, , p
surgically RB p
treated VBN p
for IN p
advanced JJ p
periodontal JJ p
disease NN p
, , N
were VBD N
distributed VBN N
at IN N
random NN N
among IN N
three CD N
groups NNS N
. . N

All DT N
patients NNS N
received VBD N
a DT N
standardized JJ N
preventive JJ N
treatment NN N
. . N

Furthermore RB N
, , N
the DT N
dentition NN N
of IN N
the DT N
patients NNS N
in IN N
the DT N
two CD N
experimental JJ N
groups NNS N
was VBD N
treated VBN N
, , N
at IN N
three-month JJ N
intervals NNS N
, , N
with IN N
chlorhexidine NN i
and CC i
fluoride JJ i
varnish NN i
, , N
respectively RB N
. . N

Patients NNS N
in IN N
the DT N
control NN i
group NN i
received VBD N
no DT N
additional JJ N
treatment NN N
. . N

In IN N
the DT N
experimental JJ N
groups NNS N
, , N
plaque NN N
samples NNS N
were VBD N
collected VBN N
from IN N
selected VBN N
sound NN N
and CC N
carious JJ N
root NN N
surfaces NNS N
at IN N
baseline NN N
and CC N
at IN N
three CD N
, , N
six CD N
, , N
and CC N
nine CD N
months NNS N
after IN N
the DT N
onset NN N
of IN N
the DT N
study NN N
. . N

The DT N
presence NN N
of IN N
root-surface NN N
caries NNS N
was VBD N
scored VBN N
at IN N
baseline NN N
and CC N
after IN N
one CD N
year NN N
. . N

In IN N
addition NN N
, , N
the DT N
texture NN N
, , N
depth NN N
, , N
and CC N
color NN N
of IN N
the DT N
root-surface JJ N
lesions NNS N
were VBD N
monitored VBN N
. . N

Mutans NNPS o
streptococci VBP o
on IN o
root NN o
surfaces NNS o
were VBD o
suppressed VBN o
significantly RB N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
during IN N
the DT N
whole JJ N
experimental JJ N
period NN N
in IN N
the DT N
chlorhexidine NN i
varnish JJ N
group NN N
, , N
but CC N
not RB N
in IN N
the DT N
fluoride JJ i
varnish JJ N
group NN N
. . N

A DT N
non-significant JJ N
increase NN o
in IN o
the DT o
number NN o
of IN o
Actinomyces NNP o
viscosus/naeslundii NN o
was VBD N
noted VBN N
after IN N
treatment NN N
with IN N
chlorhexidine NN i
and CC N
fluoride JJ i
varnish NN N
. . N

The DT N
increase NN o
in IN o
the DT o
number NN o
of IN o
decayed JJ o
and CC o
filled JJ o
root NN o
surfaces NNS o
after IN N
one CD N
year NN N
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
experimental NN N
groups NNS N
than IN N
in IN N
the DT N
control NN N
group NN N
. . N

After IN N
treatment NN N
with IN N
chlorhexidine JJ i
varnish NN N
, , N
significantly RB N
more RBR N
initial JJ o
root-surface JJ o
lesions NNS o
had VBD o
hardened VBN o
than IN N
in IN N
the DT N
other JJ N
groups NNS N
. . N

-DOCSTART- -23438314- O O

A DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
COMPASS NNP i
web-based JJ i
and CC N
face-to-face JJ i
teacher NN i
coaching NN i
in IN N
autism NN p
. . p

OBJECTIVE CC N
Most JJS N
children NNS p
with IN p
autism NN p
rely RB N
on IN N
schools NNS N
as IN N
their PRP$ N
primary JJ N
source NN N
of IN N
intervention NN N
, , N
yet RB N
research NN N
has VBZ N
suggested VBN N
that IN N
teachers NNS N
rarely RB N
use VBP N
evidence-based JJ N
practices NNS N
. . N

To TO N
address VB N
the DT N
need NN N
for IN N
improved JJ N
educational JJ N
outcomes NNS N
, , N
a DT N
previously RB N
tested VBN N
consultation NN N
intervention NN N
called VBD N
the DT N
Collaborative NNP i
Model NNP i
for IN i
Promoting VBG i
Competence NNP i
and CC i
Success NNP i
( ( i
COMPASS NNP i
; : i
Ruble NNP N
, , N
Dalrymple NNP N
, , N
& CC N
McGrew NNP N
, , N
2010 CD N
; : N
Ruble NNP N
, , N
Dalrymple NNP N
, , N
& CC N
McGrew NNP N
, , N
2012 CD N
) ) N
was VBD N
evaluated VBN N
in IN N
a DT N
2nd CD N
randomized VBN N
controlled VBN N
trial NN N
, , N
with IN N
the DT N
addition NN p
of IN p
a DT p
web-based JJ p
group NN p
. . p

METHOD NNP N
Forty-nine JJ p
teacher-child JJ p
dyads NNS p
were VBD N
randomized VBN N
into IN N
1 CD i
of IN i
3 CD i
groups NNS i
: : i
( ( i
1 CD i
) ) i
a DT i
placebo NN i
control NN i
( ( i
PBO NNP i
) ) i
group NN i
, , i
( ( i
2 CD i
) ) i
COMPASS NN i
followed VBN i
by IN i
face-to-face NN i
( ( i
FF NNP i
) ) i
coaching NN i
sessions NNS i
, , i
and CC i
( ( i
3 CD i
) ) i
COMPASS NN i
followed VBN i
by IN i
web-based JJ i
( ( i
WEB NNP i
) ) i
coaching NN i
sessions NNS i
. . i

Three CD i
individualized JJ i
goals NNS i
( ( i
social JJ i
, , i
communication NN i
, , i
and CC i
independence NN i
skills NNS i
) ) i
were VBD N
selected VBN N
for IN N
intervention NN N
for IN N
each DT N
child NN p
. . p

The DT N
primary JJ N
outcome NN N
of IN N
independent JJ o
ratings NNS o
of IN o
child NN o
goal NN o
attainment NN o
and CC o
several JJ o
process NN o
measures NNS o
( ( o
e.g. NN o
, , N
consultant NN o
and CC o
teacher NN o
fidelity NN o
) ) o
were VBD N
evaluated VBN N
. . N

RESULTS NNP N
Using VBG N
an DT N
intent-to-treat JJ N
approach NN N
, , N
findings NNS N
replicated VBD N
earlier RBR N
results NNS N
with IN N
a DT N
very RB N
large JJ N
effect NN N
size NN N
( ( N
d JJ N
= NNP N
1.41 CD N
) ) N
for IN N
the DT N
FF NNP N
group NN N
and CC N
a DT N
large JJ N
effect NN N
size NN N
( ( N
d JJ N
= NNP N
1.12 CD N
) ) N
for IN N
the DT N
WEB NNP N
group NN N
relative NN N
to TO N
the DT N
PBO NNP N
group NN N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
overall JJ N
change NN N
across IN N
goal NN N
domains NNS N
between IN N
the DT N
FF NNP N
and CC N
WEB NNP N
groups NNS N
, , N
suggesting VBG N
the DT N
efficacy NN N
of IN N
videoconferencing VBG N
technology NN N
. . N

CONCLUSIONS NNP N
COMPASS NNP i
is VBZ N
effective JJ N
and CC N
results NNS N
in IN N
improved JJ N
educational JJ N
outcomes NNS N
for IN N
young JJ p
children NNS p
with IN p
autism NN p
. . p

Videoconferencing NNP N
technology NN N
, , N
as IN N
a DT N
scalable JJ N
tool NN N
, , N
has VBZ N
promise NN N
for IN N
facilitating VBG N
access NN N
to TO N
autism NN N
specialists NNS N
and CC N
bridging VBG N
the DT N
research-to-practice JJ N
gap NN N
. . N

-DOCSTART- -8669042- O O

[ JJ i
Radiotherapy NNP i
and/or NN i
chemotherapy NN i
in IN N
children NNS p
with IN p
primitive JJ p
neuroectodermal JJ p
tumor NN p
( ( p
PNET NNP p
) ) p
of IN p
the DT p
pineal JJ p
region NN p
] NN p
. . N

-DOCSTART- -7591314- O O

The DT N
European JJ p
Myocardial NNP N
Infarction NNP N
Project NNP N
: : N
an DT N
assessment NN N
of IN N
pre-hospital JJ p
thrombolysis NN p
. . p

The DT N
use NN N
of IN N
thrombolytic JJ i
agents NNS i
in IN N
patients NNS p
with IN p
suspected JJ p
myocardial JJ p
infarction NN p
has VBZ N
been VBN N
shown VBN N
to TO N
reduce VB N
early JJ N
and CC N
long-term JJ N
mortality NN N
by IN N
about IN N
20 CD N
% NN N
, , N
and CC N
it PRP N
has VBZ N
been VBN N
suggested VBN N
that IN N
since IN N
time NN N
is VBZ N
an DT N
important JJ N
factor NN N
, , N
pre-hospital JJ N
treatment NN N
would MD N
give VB N
better JJR N
results NNS N
. . N

However RB N
, , N
health NN N
deciders NNS N
need VBP N
reliable JJ N
data NNS N
on IN N
which WDT N
to TO N
base VB N
future JJ N
policies NNS N
concerning VBG N
this DT N
. . N

The DT N
European JJ N
Myocardial NNP N
Infarction NNP N
Project NNP N
was VBD N
a DT N
European JJ N
Economic NNP N
Community-supported NNP N
double-blind NN N
study NN N
designed VBN N
to TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
pre-hospital JJ i
early JJ i
thrombolytic JJ i
treatment NN i
in IN N
patients NNS p
with IN p
suspected JJ p
myocardial JJ p
infarction NN p
compared VBN N
with IN N
the DT N
same JJ N
treatment NN N
given VBN N
later RB N
in IN N
a DT N
hospital NN N
setting NN N
. . N

A DT N
total NN p
of IN p
5469 CD p
patients NNS p
in IN p
16 CD p
countries NNS p
were VBD p
randomised VBN p
by IN p
198 CD p
mobile JJ p
emergency NN p
units NNS p
to TO p
receive VB p
either DT p
pre-hospital JJ i
treatment NN i
with IN p
anistreplase NN i
, , p
the DT p
thrombolytic JJ p
agent NN p
used VBN p
, , p
followed VBN i
by IN i
placebo NN i
after IN p
hospital JJ p
admission NN p
( ( p
pre-hospital JJ p
group NN p
; : p
2750 CD p
patients NNS p
) ) p
, , p
or CC p
placebo NN i
followed VBN i
by IN i
anistreplase NN i
( ( p
hospital JJ p
group NN p
; : p
2719 CD p
patients NNS p
) ) p
. . p

The DT N
median JJ o
time NN o
delay NN o
between IN N
the DT N
injections NNS N
was VBD N
55 CD N
min NN N
. . N

A DT N
non-significant JJ o
decrease NN o
in IN o
30-day JJ o
mortality NN o
was VBD o
observed VBN o
in IN o
favour NN o
of IN o
the DT o
pre-hospital JJ o
group NN o
( ( N
13 CD N
% NN N
: : N
P NNP N
= NNP N
0.08 CD N
) ) N
, , N
whereas IN N
the DT o
decrease NN o
in IN o
cardiac JJ o
death NN o
observed VBD o
, , N
also RB N
in IN N
favour NN N
of IN N
the DT N
pre-hospital JJ N
group NN N
, , N
was VBD N
on IN N
the DT N
borderline NN N
of IN N
significance NN N
( ( N
16 CD N
% NN N
; : N
P NNP N
= NNP N
0.049 CD N
) ) N
. . N

Although IN N
some DT o
complications NNS o
occurred VBD o
more RBR o
frequently RB o
in IN o
the DT o
pre-hospital JJ o
group NN o
in IN N
the DT N
pre-hospital JJ N
period NN N
, , N
the DT N
overall JJ o
incidence NN o
for IN o
serious JJ o
complications NNS o
was VBD o
similar JJ o
for IN o
both DT o
groups NNS o
. . o

These DT N
results NNS N
show VBP N
that IN N
the DT o
pre-hospital JJ o
thrombolytic JJ o
strategy NN o
in IN o
patients NNS o
with IN o
suspected JJ o
myocardial JJ o
infarction NN o
is VBZ o
both DT o
effective JJ o
and CC o
safe JJ o
when WRB o
performed VBN o
by IN o
well-equipped JJ o
well-staffed JJ o
mobile JJ o
emergency NN o
units NNS o
. . o

-DOCSTART- -23925092- O O

[ NN N
Risk NN N
factors NNS N
for IN N
atherosclerotic JJ N
disease NN N
from IN N
the DT N
Japanese JJ p
Elderly NNP i
Diabetes NNPS i
Intervention NNP i
Trial NNP p
( ( p
J-EDIT NNP p
) ) p
] NN p
. . N

-DOCSTART- -23465566- O O

Association NNP N
between IN N
frequency NN N
of IN N
ready-to-eat JJ N
cereal NN N
consumption NN N
, , N
nutrient JJ N
intakes NNS N
, , N
and CC N
body NN o
mass NN o
index NN o
in IN N
fourth- JJ p
to TO p
sixth-grade JJ p
low-income JJ p
minority NN p
children NNS p
. . p

BACKGROUND IN N
The DT N
consumption NN N
of IN N
non-ready-to-eat JJ N
cereal NN N
and CC N
ready-to-eat NN i
cereal NN i
( ( i
RTEC NNP i
) ) i
breakfasts NNS N
have VBP N
been VBN N
associated VBN N
with IN N
increased JJ N
nutrient NN o
intakes NNS o
and CC o
lower JJR o
body NN o
mass NN o
index NN o
( ( o
BMI NNP o
) ) o
. . o

These DT N
relationships NNS N
have VBP N
not RB N
been VBN N
examined VBN N
in IN N
low-income JJ p
minority NN p
children NNS p
. . p

OBJECTIVES NNP N
To TO N
evaluate VB N
, , N
in IN N
low-income JJ p
minority NN p
children NNS p
, , N
whether IN N
there EX N
is VBZ N
a DT N
relationship NN N
among IN N
the DT N
frequency NN N
of IN N
RTEC NNP i
consumption NN N
and CC N
nutrient JJ N
intakes NNS N
measured VBN N
at IN N
baseline NN N
, , N
and CC N
whether IN N
there EX N
is VBZ N
a DT N
relationship NN N
between IN N
the DT N
frequency NN N
of IN N
RTEC NNP i
and CC N
BMI NNP o
controlling VBG N
for IN N
age NN N
, , N
sex NN N
, , N
ethnicity NN N
, , N
and CC N
energy NN N
intake NN N
. . N

DESIGN VB N
A DT N
longitudinal JJ N
study NN N
design NN N
where WRB N
a DT N
cohort NN N
was VBD N
followed VBN N
for IN N
3 CD N
years NNS N
. . N

SUBJECTS/SETTING NN N
Participants NNS p
were VBD p
625 CD p
fourth- JJ p
through IN p
sixth-grade JJ p
, , p
low-income JJ p
children NNS p
living VBG p
in IN p
San NNP p
Antonio NNP p
, , p
Texas NNP p
, , p
and CC p
enrolled VBD p
in IN p
the DT p
control NN p
arm NN p
of IN p
the DT p
Bienestar NNP p
Diabetes NNP p
Prevention NNP p
Program NNP p
's POS p
cluster NN p
randomized VBD p
trial NN p
. . p

Three CD N
multiple-pass JJ N
24-hour JJ N
dietary JJ N
recalls NNS N
were VBD N
collected VBN N
at IN N
the DT N
beginning NN N
of IN N
their PRP$ N
fourth-grade JJ N
year NN N
and CC N
at IN N
the DT N
end NN N
of IN N
their PRP$ N
fifth- JJ N
and CC N
sixth-grade JJ N
years NNS N
. . N

Children NNP p
's POS p
age NN p
, , p
sex NN p
, , p
ethnicity NN p
, , N
and CC N
height NN N
and CC N
weight NN N
( ( N
used VBN N
to TO N
calculate VB N
BMI NNP N
) ) N
were VBD N
collected VBN N
between IN N
August NNP N
2001 CD N
and CC N
May NNP N
2004 CD N
. . N

STATISTICAL JJ N
ANALYSES NNP N
PERFORMED NNP N
Descriptive NNP N
and CC N
inferential JJ N
statistical JJ N
analyses NNS N
were VBD N
performed VBN N
. . N

The DT N
frequency NN N
of IN N
breakfast NN N
consumption NN N
was VBD N
examined VBN N
using VBG N
a DT N
6?4 CD N
cross-tabulation NN N
table NN N
with IN N
? . N
( ( N
2 CD N
) ) N
test NN N
to TO N
establish VB N
categorical JJ N
differences NNS N
. . N

The DT N
degree NN N
of IN N
association NN N
between IN o
BMI NNP o
percentile NN o
and CC N
frequency NN N
of IN N
RTEC NNP i
consumption NN i
adjusted VBD N
for IN N
age NN N
, , N
sex NN N
, , N
ethnicity NN N
, , N
and CC N
nutrition-related JJ N
parameters NNS N
were VBD N
calculated VBN N
using VBG N
a DT N
partial JJ N
correlation NN N
multivariate NN N
linear JJ N
model NN N
analysis NN N
. . N

RESULTS NNP N
There EX N
was VBD N
a DT N
significant JJ N
positive JJ N
relationship NN N
between IN N
the DT o
frequency NN o
of IN o
RTEC NNP o
consumption NN o
and CC o
nutrient JJ o
intakes NNS o
measured VBN o
at IN N
baseline NN N
. . N

There EX N
was VBD N
also RB N
a DT N
significant JJ N
inverse NN N
relationship NN N
between IN o
frequency NN o
of IN o
RTEC NNP o
consumption NN o
and CC o
BMI NNP o
percentile NN o
over IN o
the DT N
cumulative JJ N
3-year JJ N
period NN N
controlling VBG N
for IN N
age NN N
, , N
sex NN N
, , N
ethnicity NN N
, , N
and CC N
energy NN N
intake NN N
. . N

CONCLUSIONS NNP p
Children NNP p
who WP p
frequently RB N
consumed VBD i
RTEC NNP i
had VBD i
greater JJR N
intakes NNS N
of IN N
essential JJ o
nutrients NNS o
at IN o
baseline NN N
and CC N
significantly RB N
lower JJR o
BMI NNP o
over IN o
a DT N
3-year JJ N
period NN N
. . N

-DOCSTART- -2943781- O O

Prevention NN N
of IN N
subsequent JJ N
exercise-induced JJ o
periinfarct NN o
ischemia NN o
by IN N
emergency NN i
coronary JJ i
angioplasty NN i
in IN N
acute JJ p
myocardial JJ p
infarction NN p
: : p
comparison NN N
with IN N
intracoronary JJ i
streptokinase NN i
. . i

To TO N
compare VB N
the DT N
efficacy NN N
of IN N
emergency NN i
percutaneous JJ i
transluminal JJ i
coronary NN i
angioplasty NN i
and CC i
intracoronary JJ i
streptokinase NN i
in IN N
preventing VBG N
exercise-induced JJ N
periinfarct NN N
ischemia NN N
, , N
28 CD p
patients NNS p
presenting VBG p
within IN p
12 CD p
hours NNS p
of IN p
the DT p
onset NN p
of IN p
symptoms NNS p
of IN p
acute JJ p
myocardial JJ p
infarction NN p
were VBD p
prospectively RB p
randomized VBN p
. . p

Of IN N
these DT N
, , N
14 CD p
patients NNS p
were VBD p
treated VBN p
with IN p
emergency NN i
angioplasty NN i
and CC p
14 CD p
patients NNS p
received VBD N
intracoronary JJ i
streptokinase NN i
. . i

Recatheterization NN i
and CC i
submaximal JJ i
exercise NN i
thallium-201 JJ i
single JJ i
photon NN i
emission NN i
computed VBD i
tomography NN i
were VBD N
performed VBN N
before IN N
hospital JJ N
discharge NN N
. . N

Periinfarct NNP o
ischemia NN o
was VBD N
defined VBN N
as IN N
a DT N
reversible JJ N
thallium NN N
defect NN N
adjacent NN N
to TO N
a DT N
fixed VBN N
defect NN N
assessed VBN N
qualitatively RB N
. . N

Successful JJ o
reperfusion NN o
was VBD N
achieved VBN N
in IN N
86 CD N
% NN N
of IN N
patients NNS N
treated VBN N
with IN N
emergency NN i
angioplasty NN i
and CC N
86 CD N
% NN N
of IN N
patients NNS N
treated VBN N
with IN N
intracoronary JJ N
streptokinase NN i
( ( N
p JJ N
= NNP N
NS NNP N
) ) N
. . N

Residual JJ o
stenosis NN o
of IN o
the DT o
infarct-related JJ o
coronary JJ o
artery NN o
shown VBN o
at IN o
predischarge NN o
angiography NN o
was VBD N
43.8 CD N
+/- JJ N
31.4 CD N
% NN N
for IN N
the DT N
angioplasty JJ N
group NN N
and CC N
75.0 CD N
+/- JJ N
15.6 CD N
% NN N
for IN N
the DT N
streptokinase NN N
group NN N
( ( N
p VBZ N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

Of IN N
the DT N
angioplasty JJ N
group NN N
, , N
9 CD N
% NN N
developed VBD N
exercise-induced JJ o
periinfarct NN o
ischemia NN o
compared VBN N
with IN N
60 CD N
% NN N
of IN N
the DT N
streptokinase NN N
group NN N
( ( N
p VBZ N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

Thus RB N
, , N
patients NNS p
with IN p
acute JJ p
myocardial JJ p
infarction NN p
treated VBN N
with IN N
emergency NN N
angioplasty NN N
had VBD N
significantly RB N
less RBR N
severe JJ o
residual JJ o
coronary JJ o
stenosis NN o
and CC o
exercise-induced JJ o
periinfarct NN o
ischemia NN o
than IN N
did VBD N
those DT N
treated VBN N
with IN N
intracoronary JJ N
streptokinase NN i
. . i

These DT N
results NNS N
suggest VBP N
further JJ N
application NN N
of IN N
coronary JJ i
angioplasty NN i
in IN N
the DT N
management NN N
of IN N
acute JJ p
myocardial JJ p
infarction NN p
. . p

-DOCSTART- -1707797- O O

The DT N
instruction NN N
to TO N
refrain VB i
from IN i
blinking VBG i
affects NNS N
auditory JJ o
P3 NNP o
and CC o
N1 NNP o
amplitudes NNS o
. . o

Often NNP N
subjects VBZ N
have VBP N
been VBN N
instructed VBN N
to TO N
refrain VB i
from IN i
blinking VBG i
lest JJS N
their PRP$ N
evoked JJ N
EEG NNP N
potentials NNS N
should MD N
be VB N
distorted VBN N
. . N

We PRP N
studied VBD N
whether IN N
these DT N
very RB N
instructions NNS N
have VBP N
any DT N
impact NN N
on IN N
P3 NNP o
amplitude NN o
. . o

Two CD N
tones NNS N
were VBD N
presented VBN N
in IN N
random JJ N
order NN N
, , N
and CC N
subjects NNS N
had VBD N
to TO N
count VB N
the DT N
high-pitched JJ N
tones NNS N
. . N

Half PDT p
the DT p
subjects NNS p
were VBD p
instructed VBN i
not RB i
to TO i
blink VB i
, , N
whereas IN N
this DT N
instruction NN N
was VBD N
omitted VBN N
for IN N
the DT N
other JJ N
subjects NNS N
. . N

Target NNP N
tones NNS N
evoked VBD N
larger JJR N
P3s NNP o
than IN N
non-targets NNS N
in IN N
the DT N
latter JJ N
group NN N
but CC N
not RB N
in IN N
the DT N
former JJ N
, , N
in IN N
particular JJ N
not RB N
in IN N
those DT N
subjects NNS N
that WDT N
actually RB N
blinked VBD N
rarely RB N
. . N

The DT N
groups NNS N
also RB N
differed VBN N
in IN N
their PRP$ N
N1 NNP o
amplitudes NNS o
. . o

These DT N
findings NNS N
might MD N
be VB N
relevant JJ N
to TO N
P3 NNP N
studies NNS N
working VBG N
with IN N
patients NNS N
and CC N
controls NNS N
: : N
the DT N
harder NN N
some DT N
frequently RB N
blinking JJ N
subjects NNS N
try VBP N
to TO N
refrain VB N
from IN N
blinking NN N
, , N
the DT N
smaller JJR N
might MD N
become VB N
their PRP$ N
P3 NNP o
amplitudes NNS o
. . o

Omitting VBG N
the DT N
instruction NN N
and CC N
using VBG N
off-line JJ N
blink NN N
subtraction NN N
procedures NNS N
seems VBZ N
a DT N
viable JJ N
alternative NN N
. . N

This DT N
study NN N
was VBD N
actually RB N
motivated VBN N
by IN N
discrepant JJ N
findings NNS N
on IN N
the DT N
effects NNS o
of IN o
the DT o
preceding VBG o
tone NN o
sequence NN o
on IN o
P3 NNP o
. . o

These DT N
discrepancies NNS N
could MD N
be VB N
largely RB N
resolved VBN N
by IN N
the DT N
instructional JJ N
variable NN N
, , N
in IN N
conjunction NN N
with IN N
different JJ N
tone NN o
intensities NNS o
. . o

It PRP N
is VBZ N
suggested VBN N
that IN N
subjects NNS i
who WP i
are VBP i
discouraged VBN i
from IN i
blinking VBG i
try NN N
to TO N
protect VB N
themselves PRP N
against IN N
the DT N
arousing JJ N
effects NNS N
of IN N
stimuli NN N
. . N

-DOCSTART- -6150716- O O

[ IN N
The DT N
somatostatin NN i
infusion NN i
test NN i
for IN N
the DT N
evaluation NN N
of IN N
glucose JJ o
utilization NN o
in IN N
bezafibrate JJ i
medication NN i
] NN i
. . N

The DT N
utilisation NN N
of IN N
blood NN o
glucose NN o
may MD N
be VB N
used VBN N
for IN N
definition NN N
of IN N
insulin NN N
resistance NN N
in IN N
type NN p
II NNP p
diabetes VBZ p
mellitus NN p
. . p

To TO N
evaluate VB N
this DT N
possibility NN N
we PRP N
adapted VBD N
an DT N
infusion NN i
test NN i
of IN i
somatostatin NN i
in IN p
10 CD p
normal JJ p
persons NNS p
( ( p
age NN p
26 CD p
+/- JJ p
3 CD p
years NNS p
, , p
relative JJ p
body NN p
weight VBD p
26 CD p
+/- JJ p
10 CD p
% NN p
according VBG p
to TO p
Broca NNP p
) ) p
in IN N
a DT N
randomized JJ N
cross-over NN N
therapy NN N
with IN N
bezafibrate NN i
( ( N
3 CD N
X RB N
200 CD N
mg/die NN N
) ) N
. . N

As IN N
the DT N
coefficient NN N
of IN N
variation NN N
( ( N
VC NNP N
) ) N
of IN N
measured VBN N
blood NN o
glucose NN o
continuously RB N
increased VBD N
the DT N
best JJS N
time NN N
of IN N
a DT N
steady JJ N
state NN N
was VBD N
between IN N
90 CD N
and CC N
130 CD N
min NN N
after IN N
beginning VBG N
the DT N
infusion NN N
( ( N
mean JJ N
VC NNP N
8.9 CD N
% NN N
) ) N
. . N

While IN N
insulin NN o
remained VBD N
nearly RB N
constant JJ N
( ( N
41 CD N
( ( N
45 CD N
; : N
38 CD N
) ) N
microU/ml NN N
) ) N
blood NN o
glucose NN o
dropped VBN N
by IN N
about IN N
14 CD N
% NN N
and CC N
reached VBD N
a DT N
steady JJ N
state NN N
of IN N
89 CD N
( ( N
134 CD N
; : N
45 CD N
) ) N
mg/dl NN N
. . N

During IN N
the DT N
therapy NN N
of IN N
bezafibrate NN i
blood NN o
glucose NN o
was VBD N
significantly RB N
decreased VBN N
by IN N
36 CD N
% NN N
130 CD N
min NN N
after IN N
beginning VBG N
the DT N
infusion NN N
. . N

Although IN N
the DT N
effect NN N
was VBD N
not RB N
significant JJ N
during IN N
the DT N
whole JJ N
time NN N
of IN N
the DT N
steady JJ N
state NN N
it PRP N
became VBD N
evident JJ N
by IN N
a DT N
negative JJ N
correlation NN N
with IN N
lactate NN N
( ( N
r JJ N
= NNP N
-0.687 NNP N
) ) N
and CC N
pyruvate NN N
( ( N
r JJ N
= NNP N
-0.843 NNP N
) ) N
. . N

A DT N
correlation NN N
with IN N
a DT N
concomitant JJ N
decrease NN N
of IN N
triglyceride NN o
and CC o
cholesterol NN o
also RB N
induced VBN N
by IN N
bezafibrate NN i
could MD N
not RB N
be VB N
proven RB N
. . N

The DT N
results NNS N
show VBP N
that IN N
the DT N
infusion NN i
test NN i
of IN i
somatostatin NN i
is VBZ N
fitted VBN N
to TO N
measure VB N
a DT N
steady JJ N
state NN N
of IN N
blood NN o
glucose NN o
and CC o
insulin NN o
and CC N
that IN N
it PRP N
is VBZ N
possible JJ N
by IN N
this DT N
technique NN N
to TO N
quantify VB N
a DT N
changed JJ N
utilisation NN N
of IN N
blood NN N
glucose NN N
induced VBN N
by IN N
specific JJ N
therapy NN N
. . N

-DOCSTART- -17968030- O O

Long-term JJ N
psychosocial NN N
and CC N
health NN N
economy NN N
consequences NNS N
of IN N
ADHD NNP p
, , p
autism NN p
, , p
and CC p
reading-writing JJ p
disorder NN p
: : p
a DT N
prospective JJ N
service NN N
evaluation NN N
project NN N
. . N

OBJECTIVE CC N
The DT N
study NN N
aims VBZ N
to TO N
evaluate VB N
psychosocial JJ N
, , N
societal JJ N
, , N
and CC N
family NN N
cost NN N
consequences NNS N
of IN N
a DT N
psychoeducational JJ N
intervention NN N
program NN N
. . N

METHODS NNP N
Sixty NNP p
boys VBZ p
with IN p
ADHD NNP p
, , p
Asperger NNP p
syndrome/high-functioning JJ p
autism NN p
( ( p
AS/HFA NNP p
) ) p
, , p
and CC p
reading NN p
and CC p
writing VBG p
disorder NN p
( ( p
RD/WD NNP p
) ) p
were VBD N
allocated VBN N
to TO N
participate VB N
in IN N
a DT N
service NN N
evaluation NN N
project NN N
. . N

Every DT N
other JJ N
boy NN N
in IN N
each DT N
diagnostic JJ N
group NN N
was VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
either RB N
( ( i
a DT i
) ) i
a DT i
special JJ i
education NN i
program NN i
( ( i
clinical JJ i
index NN i
group NN i
) ) i
or CC i
( ( i
b NN i
) ) i
follow-up NN i
without IN i
the DT i
special JJ i
education NN i
program NN i
( ( i
clinical JJ i
comparison NN i
group NN i
) ) i
. . N

Nine CD N
years NNS N
after IN N
initial JJ N
assessments NNS N
the DT N
stability NN N
of IN N
the DT N
psychosocial NN N
and CC N
economic JJ N
resource NN N
consequences NNS N
over IN N
time NN N
was VBD N
studied VBN N
. . N

RESULTS NNP N
ADHD NNP N
, , N
AS/HFA NNP N
, , N
and CC N
RD/WD NNP N
all DT N
had VBD N
severe JJ N
impact NN N
on IN N
family NN o
life NN o
quality NN o
. . o

The DT N
societal JJ N
costs NNS N
were VBD N
high JJ N
, , N
but CC N
no DT N
significant JJ N
differences NNS N
in IN N
resource NN o
use NN o
or CC o
in IN o
total JJ o
costs NNS o
were VBD N
found VBN N
between IN N
the DT N
clinical JJ N
index NN N
and CC N
the DT N
comparison NN N
groups NNS N
. . N

CONCLUSIONS VB N
The DT N
results NNS N
underscore VBP N
the DT N
very RB N
long-term JJ N
need NN N
for IN N
support NN N
including VBG N
individually RB N
tailored VBN N
reevaluations NNS N
and CC N
carefully RB N
monitored VBN N
intervention NN N
programs NNS N
adapted VBD N
to TO N
family NN N
needs NNS N
and CC N
severity NN N
of IN N
child NN N
disorder NN N
. . N

-DOCSTART- -20145986- O O

Randomized VBN N
controlled VBD N
caregiver RB i
mediated VBN i
joint JJ i
engagement NN i
intervention NN i
for IN N
toddlers NNS p
with IN p
autism NN p
. . p

This DT N
study NN N
aimed VBD N
to TO N
determine VB N
if IN N
a DT N
joint JJ i
attention NN i
intervention NN i
would MD N
result VB N
in IN N
greater JJR N
joint JJ N
engagement NN N
between IN N
caregivers NNS p
and CC p
toddlers NNS p
with IN p
autism NN p
. . p

The DT N
intervention NN i
consisted VBD N
of IN N
24 CD i
caregiver-mediated JJ i
sessions NNS i
with IN N
follow-up JJ N
1 CD N
year NN N
later RB N
. . N

Compared VBN N
to TO N
caregivers NNS N
and CC N
toddlers NNS N
randomized VBN N
to TO N
the DT N
waitlist NN i
control NN i
group NN i
the DT N
immediate JJ N
treatment NN N
( ( N
IT NNP N
) ) N
group NN N
made VBD N
significant JJ N
improvements NNS N
in IN N
targeted JJ N
areas NNS N
of IN N
joint JJ o
engagement NN o
. . o

The DT N
IT NNP N
group NN N
demonstrated VBD N
significant JJ N
improvements NNS N
with IN N
medium NN N
to TO N
large JJ N
effect NN N
sizes NNS N
in IN N
their PRP$ N
responsiveness NN o
to TO o
joint VB o
attention NN o
and CC o
their PRP$ o
diversity NN o
of IN o
functional JJ o
play NN o
acts NNS o
after IN N
the DT N
intervention NN N
with IN N
maintenance NN N
of IN N
these DT N
skills NNS N
1 CD N
year NN N
post-intervention NN N
. . N

These DT N
are VBP N
among IN N
the DT N
first JJ N
randomized VBN N
controlled VBN N
data NNS N
to TO N
suggest VB N
that IN N
short-term JJ i
parent-mediated JJ i
interventions NNS i
can MD N
have VB N
important JJ N
effects NNS N
on IN N
core NN N
impairments NNS N
in IN N
toddlers NNS p
with IN p
autism NN p
. . p

Clinical JJ N
Trials NNS N
# # N
: : N
NCT00065910 NN N
. . N

-DOCSTART- -22459310- O O

Relation NN N
of IN N
improvement NN N
in IN N
estimated VBN N
glomerular JJ N
filtration NN N
rate NN N
with IN N
atorvastatin NN i
to TO N
reductions NNS N
in IN N
hospitalizations NNS N
for IN N
heart NN N
failure NN N
( ( N
from IN N
the DT N
Treating NNP p
to TO p
New NNP p
Targets NNP p
[ NNP p
TNT NNP p
] NNP p
study NN p
) ) p
. . N

Impaired NNP N
kidney NN N
function NN N
often RB N
accompanies VBZ N
heart NN N
failure NN N
( ( N
HF NNP N
) ) N
and CC N
is VBZ N
associated VBN N
with IN N
a DT N
worse JJR N
prognosis NN N
. . N

This DT N
post NN N
hoc NN N
analysis NN N
of IN N
the DT N
Treating NNP p
to TO p
New NNP p
Targets NNP p
( ( p
TNT NNP p
) ) p
trial NN p
examined VBD N
whether IN N
the DT N
observed JJ N
decrease NN N
in IN N
HF NNP N
hospitalizations NNS N
with IN N
high- JJ N
compared VBN N
to TO N
low-dose JJ N
atorvastatin NN i
could MD N
be VB N
related VBN N
to TO N
improvements NNS N
in IN N
kidney NN N
function NN N
. . N

Of IN N
10,001 CD p
TNT NNP p
participants NNS p
, , p
9,376 CD p
had VBD p
estimated VBN p
glomerular JJ o
filtration NN o
rate NN o
( ( o
eGFR NN o
) ) o
measurements NNS p
at IN p
baseline NN p
and CC p
1 CD p
year NN p
and CC p
were VBD p
included VBN p
in IN p
this DT p
analysis NN p
. . p

The DT N
association NN N
of IN N
change NN N
in IN N
year-1 JJ N
eGFR NN N
and CC N
subsequent JJ N
HF NNP N
hospitalization NN N
was VBD N
examined VBN N
using VBG N
Cox NNP N
regression NN N
models NNS N
. . N

In IN N
total JJ N
218 CD N
participants NNS N
developed VBD N
subsequent JJ N
HF NNP N
hospitalization NN N
. . N

Little JJ N
change NN N
in IN N
eGFR NN o
occurred VBD N
over IN N
1 CD N
year NN N
in IN N
the DT N
atorvastatin JJ N
10-mg JJ N
group NN N
, , N
whereas IN N
eGFR NN o
improved VBN N
in IN N
the DT N
80-mg JJ N
group NN N
by IN N
1.48 CD N
ml/min/1.73 NNS N
m NN N
( ( N
2 CD N
) ) N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
1.29 CD N
to TO N
1.67 CD N
, , N
p NN N
< NNP N
0.0001 CD N
) ) N
. . N

Subsequent JJ N
HF NNP N
was VBD N
preceded VBN N
by IN N
a DT N
decrease NN N
in IN N
eGFR NN o
over IN N
1 CD N
year NN N
compared VBN N
to TO N
modest JJ N
improvement NN N
in IN N
those DT N
without IN N
subsequent JJ N
HF NNP N
( ( N
-0.09 NNP N
? . N
7.89 CD N
vs NN N
0.81 CD N
? . N
6.90 CD N
ml/min/1.73 NN N
m NN N
( ( N
2 CD N
) ) N
, , N
p JJ N
= NNP N
0.0015 CD N
) ) N
. . N

After IN N
adjusting VBG N
for IN o
baseline NN o
eGFR NN o
, , o
each DT N
5-ml/min/1.73 JJ N
m NN N
( ( N
2 CD N
) ) N
increase NN N
in IN N
eGFR NN o
at IN o
1 CD N
year NN N
was VBD N
associated VBN N
with IN N
a DT N
lower JJR N
risk NN N
of IN N
subsequent JJ N
HF NNP N
hospitalization NN N
( ( N
hazard JJ N
ratio NN N
0.85 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
0.77 CD N
to TO N
0.94 CD N
, , N
p NN N
= NNP N
0.002 CD N
) ) N
. . N

This DT N
relation NN N
was VBD N
independent JJ N
of IN N
treatment NN N
effect NN N
or CC N
change NN N
in IN N
low-density NN o
lipoprotein NN o
cholesterol NN o
level NN o
at IN N
1 CD N
year NN N
. . N

In IN N
conclusion NN N
, , N
treatment NN N
with IN N
high- JJ N
compared VBN N
to TO N
low-dose JJ N
atorvastatin NN N
was VBD N
associated VBN N
with IN N
improvement NN N
in IN N
eGFR NN o
at IN o
1 CD N
year NN N
, , N
which WDT N
was VBD N
related VBN N
to TO N
a DT N
decrease NN N
in IN N
subsequent JJ o
HF NNP o
hospitalization NN o
. . o

This DT N
suggests VBZ N
that WDT N
improvement NN N
in IN N
kidney NN o
function NN o
may MD o
be VB N
related VBN N
to TO N
the DT N
beneficial JJ N
effect NN N
of IN N
high-dose JJ N
atorvastatin NN N
on IN N
HF NNP N
hospitalization NN N
. . N

-DOCSTART- -16750325- O O

Fifteen-year JJ N
results NNS N
of IN N
a DT N
randomized JJ N
prospective JJ N
trial NN N
of IN N
hyperfractionated VBN i
chest JJS i
wall NN i
irradiation NN i
versus IN i
once-daily RB i
chest JJS i
wall NN i
irradiation NN i
after IN i
chemotherapy NN i
and CC N
mastectomy NN N
for IN N
patients NNS p
with IN p
locally RB p
advanced JJ p
noninflammatory JJ p
breast NN p
cancer NN p
. . p

PURPOSE NNP N
To TO N
analyze VB N
the DT N
results NNS N
of IN N
a DT N
Phase NNP N
III NNP N
clinical JJ N
trial NN N
that WDT N
investigated VBD N
whether IN N
a DT N
hyperfractionated JJ i
radiotherapy NN i
( ( i
RT NNP i
) ) i
schedule NN N
could MD N
reduce VB N
the DT N
risk NN N
of IN N
locoregional JJ N
recurrence NN N
in IN N
patients NNS p
with IN p
locally RB p
advanced JJ p
breast NN p
cancer NN p
treated VBN p
with IN p
chemotherapy NN p
and CC p
mastectomy NN p
. . p

METHODS NNP N
AND CC N
MATERIALS NNP N
Between NNP p
1985 CD p
and CC p
1989 CD p
, , p
200 CD p
patients NNS p
with IN p
clinical JJ p
Stage NNP p
III NNP p
noninflammatory JJ p
breast NN p
cancer NN p
were VBD N
enrolled VBN N
in IN N
a DT N
prospective JJ N
study NN N
investigating VBG N
neoadjuvant JJ N
and CC N
adjuvant JJ N
chemotherapy NN N
. . N

Of IN p
the DT p
179 CD p
patients NNS p
treated VBN p
with IN p
mastectomy NN i
after IN i
neoadjuvant JJ i
chemotherapy NN i
, , p
108 CD p
participated VBN p
in IN N
a DT N
randomized JJ N
component NN N
of IN N
the DT N
trial NN N
that WDT N
compared VBN N
a DT N
dose-escalated JJ N
, , N
hyperfractionated VBN i
( ( i
twice-daily JJ i
, , i
b.i.d NN i
. . i

) ) i
chest JJS i
wall NN i
RT NNP i
schedule NN N
( ( N
72 CD N
Gy NNP N
in IN N
1.2-Gy JJ N
b.i.d NN N
. . N

fractions NNS N
) ) N
with IN N
a DT N
once-daily JJ N
( ( N
q.d JJ N
. . N

) ) N
schedule NN N
( ( N
60 CD N
Gy NNP N
in IN N
2-Gy JJ N
q.d NN N
. . N

fractions NNS N
) ) N
. . N

In IN N
both DT N
arms NNS N
of IN N
the DT N
study NN N
, , N
the DT N
supraclavicular JJ N
fossa NN N
and CC N
axillary JJ N
apex NN N
were VBD N
treated VBN N
once RB N
daily JJ N
to TO N
50 CD N
Gy NNP N
. . N

The DT N
median JJ N
follow-up JJ N
period NN N
was VBD N
15 CD N
years NNS N
. . N

RESULTS VB N
The DT N
15-year JJ o
actuarial JJ o
locoregional JJ o
recurrence NN o
rate NN o
was VBD N
7 CD N
% NN N
for IN N
the DT N
q.d NN i
. . i

arm NN i
and CC N
12 CD N
% NN N
for IN N
the DT N
b.i.d NN i
. . i

arm NN i
( ( N
p=0.36 NN N
) ) N
. . N

The DT N
rates NNS o
of IN o
severe JJ o
acute JJ o
toxicity NN o
were VBD N
similar JJ N
( ( N
4 CD N
% NN N
for IN N
q.d NN N
. . N

vs. FW N
5 CD N
% NN N
for IN N
b.i.d NN N
. . N

) ) N
, , N
but CC N
moist JJ N
desquamation NN N
developed VBD N
in IN N
42 CD N
% NN N
of IN N
patients NNS N
in IN N
the DT N
b.i.d NN i
. . i

arm NN i
compared VBN N
with IN N
28 CD N
% NN N
of IN N
the DT N
patients NNS N
in IN N
the DT N
q.d NN i
. . i

arm NN i
( ( N
p=0.16 NN N
) ) N
. . N

The DT N
15-year JJ o
actuarial JJ o
rate NN o
of IN o
severe JJ o
late JJ o
RT NNP o
complications NNS o
did VBD N
not RB N
differ VB N
between IN N
the DT N
two CD N
arms NNS N
( ( N
6 CD N
% NN N
for IN N
q.d NN N
. . N

vs. FW N
11 CD N
% NN N
for IN N
b.i.d. NN N
, , N
p=0.54 NN N
) ) N
. . N

CONCLUSION NNP N
Although IN N
the DT N
sample JJ N
size NN N
of IN N
this DT N
study NN N
was VBD N
small JJ N
, , N
we PRP N
found VBD N
no DT N
evidence NN N
that IN N
this DT N
hyperfractionation NN N
schedule NN N
of IN N
postmastectomy NN i
RT NNP i
offered VBD N
a DT N
clinical JJ N
advantage NN N
. . N

Therefore RB N
, , N
we PRP N
have VBP N
concluded VBN N
that IN N
it PRP N
should MD N
not RB N
be VB N
further RB N
studied VBN N
in IN N
this DT N
cohort NN N
of IN N
patients NNS N
. . N

-DOCSTART- -24033239- O O

A DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
group NN N
Stepping NNP i
Stones NNP i
Triple NNP i
P NNP i
: : i
a DT N
mixed-disability JJ p
trial NN N
. . N

Stepping VBG i
Stones JJ i
Triple NNP i
P NNP i
( ( i
SSTP NNP i
) ) i
is VBZ N
a DT N
parenting JJ N
program NN N
designed VBN N
for IN N
families NNS p
of IN p
a DT p
child NN p
with IN p
a DT p
disability NN p
. . p

The DT N
current JJ N
study NN N
involved VBD N
a DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
Group NNP i
Stepping NNP i
Stones NNP i
Triple NNP i
P NNP i
( ( i
GSSTP NNP i
) ) i
for IN N
a DT N
mixed-disability NN p
group NN p
. . p

Participants NNS p
were VBD p
52 CD p
families NNS p
of IN p
children NNS p
diagnosed VBN p
with IN p
an DT p
Autism NNP p
Spectrum NNP p
Disorder NNP p
, , p
Down NNP p
syndrome NN p
, , p
Cerebral NNP p
Palsy NNP p
, , p
or CC p
an DT p
intellectual JJ p
disability NN p
. . p

The DT N
results NNS N
demonstrated VBD N
significant JJ N
improvements NNS N
in IN N
parent-reported JJ o
child NN o
behavior NN o
, , o
parenting VBG o
styles NNS o
, , o
parental JJ o
satisfaction NN o
, , o
and CC o
conflict NN o
about IN o
parenting VBG o
. . o

Results NNS N
among IN N
participants NNS N
were VBD N
similar JJ N
despite IN N
children NNS N
's POS N
differing VBG N
impairments NNS N
. . N

The DT N
intervention NN N
effect NN N
was VBD N
maintained VBN N
at IN N
6-month JJ N
follow-up NN N
. . N

The DT N
results NNS N
indicate VBP N
that IN N
GSSTP NNP i
is VBZ N
a DT N
promising JJ N
intervention NN N
for IN N
a DT N
mixed-disability NN N
group NN N
. . N

Limitations NNS N
of IN N
the DT N
study NN N
, , N
along IN N
with IN N
areas NNS N
for IN N
future JJ N
research NN N
, , N
are VBP N
also RB N
discussed VBN N
. . N

-DOCSTART- -19701509- O O

Enamel NNP N
and CC N
dentin VB N
bond NN N
strength NN N
following VBG N
gaseous JJ i
ozone NN i
application NN i
. . i

PURPOSE NNP N
To TO N
evaluate VB N
the DT N
effects NNS N
of IN N
gaseous JJ i
ozone NN i
application NN i
on IN N
enamel NN N
and CC N
dentin VB N
bond NN N
strength NN N
produced VBN N
by IN N
two CD N
self-etching JJ N
adhesive JJ N
systems NNS N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
The DT N
shear JJ N
bond NN N
strength NN N
test NN N
was VBD N
conducted VBN N
to TO N
assess VB N
adhesion NN N
on IN N
enamel NN N
( ( N
protocol JJ N
1 CD N
) ) N
, , N
while IN N
the DT N
microtensile JJ N
bond NN N
strength NN N
test NN N
was VBD N
performed VBN N
on IN N
dentin NN N
( ( N
protocol JJ N
2 CD N
) ) N
. . N

Protocol $ N
1 CD N
: : N
96 CD p
bovine NN p
incisors NNS p
were VBD N
randomly RB N
divided VBN N
into IN N
4 CD N
groups NNS N
, , N
and CC N
enamel JJ N
surfaces NNS N
were VBD N
bonded VBN N
in IN N
accordance NN N
with IN N
the DT N
following JJ N
treatments NNS N
: : N
( ( i
1E CD i
) ) i
ozone NN i
+ NN i
Clearfil NNP i
Protect NNP i
Bond NNP i
; : i
( ( i
2E CD i
) ) i
Clearfil NNP i
Protect NNP i
Bond NNP i
( ( i
control NN i
) ) i
; : i
( ( i
3E CD i
) ) i
ozone NN i
+ JJ i
Xeno NNP i
III NNP i
; : i
( ( i
4E CD i
) ) i
Xeno NN i
III NNP i
( ( i
control NN i
) ) i
. . i

Ozone NNP i
gas NN i
was VBD N
applied VBN N
for IN N
80 CD N
s. JJ N
Shear NNP N
bond NN N
strength NN N
was VBD N
measured VBN N
with IN N
a DT N
universal JJ N
testing NN N
machine NN N
. . N

Protocol CC N
2 CD N
: : N
40 CD p
noncarious JJ p
human JJ p
molars NNS p
were VBD N
selected VBN N
. . N

Middle/deep NNP N
dentin NN N
was VBD N
exposed VBN N
and CC N
bonded VBN N
in IN N
accordance NN N
with IN N
the DT N
following JJ N
treatments NNS N
: : N
( ( i
1D CD i
) ) i
ozone+Clearfil NN i
Protect NNP i
Bond NNP i
; : i
( ( i
2D CD i
) ) i
Clearfil NNP i
Protect NNP i
Bond NNP i
( ( i
control NN i
) ) i
; : i
( ( i
3D CD i
) ) i
ozone+Xeno NN i
III NNP i
( ( i
4D CD i
) ) i
Xeno NN i
III NNP i
( ( i
control NN i
) ) i
. . i

Four-mm-thick JJ N
buildups NNS N
were VBD N
built VBN N
on IN N
the DT N
adhesives NNS N
, , N
then RB N
specimens NNS N
were VBD N
sectioned VBN N
in IN N
accordance NN N
with IN N
the DT N
nontrimming NN N
technique NN N
. . N

Specimens NNS N
were VBD N
stressed VBN N
until IN N
failure NN N
occurred VBD N
, , N
and CC N
failure NN N
modes NNS N
were VBD N
analyzed VBN N
. . N

Shear JJ o
bond NN o
and CC o
microtensile NN o
bond NN o
strength NN o
data NNS o
were VBD N
analyzed VBN N
using VBG N
two-way JJ N
ANOVA NNP N
and CC N
Tukey NNP N
's POS N
post-hoc JJ N
test NN N
. . N

RESULTS NNP N
No NNP N
statistical JJ N
differences NNS N
were VBD N
found VBN N
between IN N
ozone NN N
treated VBN N
specimens NNS N
and CC N
controls NNS N
, , N
neither CC N
on IN N
enamel JJ o
nor CC N
on IN N
dentin JJ o
irrespective NN N
of IN N
the DT N
tested JJ N
adhesive NN N
. . N

Clearfil NNP N
Protect NNP N
Bond NNP N
showed VBD N
higher JJR N
bond NN o
strength NN o
to TO N
enamel VB N
than IN N
Xeno NNP i
III NNP i
, , N
irrespective NN N
of IN N
the DT N
ozone NN i
treatment NN i
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
use NN N
of IN N
ozone NN i
gas NN i
to TO N
disinfect VB N
the DT N
cavity NN N
before IN N
placing VBG N
a DT N
restoration NN N
had VBD N
no DT N
influence NN N
on IN N
immediate JJ N
enamel NN N
and CC N
dentin VB N
bond NN N
strength NN N
. . N

-DOCSTART- -17511685- O O

Tacrolimus NNP i
monotherapy NN N
without IN N
steroids NNS N
after IN p
liver JJ p
transplantation NN p
-- : p
a DT p
prospective JJ N
randomized VBN N
double-blinded JJ N
placebo-controlled JJ N
trial NN N
. . N

Early JJ N
steroid NN N
withdrawal NN N
after IN p
liver JJ p
transplantation NN p
( ( p
LT NNP p
) ) p
is VBZ N
desirable JJ N
in IN N
order NN N
to TO N
reduce VB N
steroid JJ N
side NN N
effects NNS N
. . N

Between NNP p
February NNP p
2000 CD p
and CC p
August NNP p
2004 CD p
, , p
110 CD p
patients NNS p
after IN p
LT NNP p
were VBD N
included VBN N
in IN N
this DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
. . N

Randomization NN N
was VBD N
performed VBN N
before IN N
LT NNP N
. . N

In IN N
all DT N
patients NNS N
, , N
tacrolimus NN i
was VBD i
used VBN i
without IN i
induction NN i
therapy NN i
. . i

All DT p
patients NNS p
received VBD p
methylprednisolon NN i
for IN p
14 CD p
days NNS p
, , N
thereafter RB N
a DT N
double-blinded JJ N
medication NN N
containing VBG N
either CC N
placebo NN i
( ( N
n JJ N
= NNP N
56 CD N
) ) N
or CC N
methylprednisolon NN i
( ( N
n JJ N
= NNP N
54 CD N
) ) N
for IN N
6 CD N
months NNS N
, , N
which WDT N
was VBD N
completely RB N
stopped JJ N
thereafter RB N
. . N

End NN N
points NNS N
were VBD N
patient JJ o
and CC o
graft NN o
survival NN o
, , o
acute NN o
and CC o
chronic JJ o
rejection NN o
, , o
and CC o
incidence NN o
of IN o
steroid JJ o
side NN o
effects NNS o
during IN N
the DT N
first JJ N
year NN N
after IN p
LT NNP p
. . p

One-year JJ N
patient NN o
survival NN o
was VBD N
85.7 CD N
% NN N
( ( N
placebo NN N
) ) N
and CC N
88.8 CD N
% NN N
( ( N
steroid NN N
) ) N
( ( N
p JJ N
= NNP N
0.572 CD N
) ) N
. . N

Twenty-seven NNP N
( ( N
48.2 CD N
% NN N
) ) N
and CC N
19 CD N
( ( N
35.2 CD N
% NN N
) ) N
patients NNS N
experienced VBD N
acute JJ o
rejection NN o
( ( N
placebo JJ N
versus NN N
steroid NN N
, , N
respectively RB N
; : N
p VB N
= $ N
0.116 CD N
) ) N
. . N

Two CD N
patients NNS N
in IN N
the DT N
placebo NN N
group NN N
but CC N
none NN N
in IN N
the DT N
steroid NN N
group NN N
experienced VBD N
chronic JJ o
rejection NN o
( ( N
p JJ N
= NNP N
0.257 CD N
) ) N
. . N

The DT N
rates NNS o
of IN o
side JJ o
effects NNS o
were VBD N
( ( i
placebo JJ i
versus NN N
steroid NN i
, , N
respectively RB N
) ) N
: : N
CMV JJ o
infection NN o
25 CD N
% NN N
versus IN N
33 CD N
% NN N
( ( N
p JJ N
= NNP N
0.336 CD N
) ) N
, , N
post-transplant JJ o
diabetes NNS o
30 CD N
% NN N
versus IN N
53 CD N
% NN N
( ( N
p JJ N
= NNP N
0.024 CD N
) ) N
, , N
hypertension VBP o
39 CD N
% NN N
versus IN N
52 CD N
% NN N
( ( N
p JJ N
= NNP N
0.248 CD N
) ) N
, , N
hypercholesterolemia $ o
10 CD N
% NN N
versus IN N
41 CD N
% NN N
( ( N
p JJ N
= NNP N
0.002 CD N
) ) N
and CC N
hypertriglyceridemia $ o
32 CD N
% NN N
versus IN N
54 CD N
% NN N
( ( N
p JJ N
= NNP N
0.046 CD N
) ) N
. . N

In IN N
conclusion NN N
, , N
early JJ N
steroid NN N
withdrawal NN N
after IN p
LT NNP p
is VBZ N
feasible JJ o
under IN N
tacrolimus NN i
monotherapy NN N
without IN N
increased JJ N
rejection NN N
rates NNS N
and CC N
with IN N
a DT N
lower JJR o
rate NN o
of IN o
side NN o
effects NNS o
. . o

-DOCSTART- -8790079- O O

Warfarin NNP i
for IN N
atrial JJ p
fibrillation NN p
. . p

The DT N
patient NN N
's POS N
perspective NN N
. . N

OBJECTIVE UH N
To TO N
determine VB N
the DT N
minimal JJ o
clinically RB o
important JJ o
difference NN o
( ( o
MCID NNP o
) ) o
of IN N
warfarin NN i
therapy NN i
for IN N
the DT N
treatment NN N
of IN N
nonvalvular JJ p
atrial JJ p
fibrillation NN p
from IN N
the DT N
perspective NN N
of IN N
patients NNS p
using VBG p
2 CD p
different JJ p
elicitation NN p
methods NNS p
. . p

DESIGN NNP N
All DT N
patients NNS N
completed VBD N
2 CD N
face-to-face JJ N
interviews NNS N
, , N
which WDT N
were VBD N
2 CD N
weeks NNS N
apart RB N
. . N

For IN N
each DT N
interview NN N
, , N
they PRP N
were VBD N
randomized VBN N
to TO N
receive VB N
1 CD N
of IN N
2 CD N
elicitation NN N
methods NNS N
: : N
ping-ponging NN N
or CC N
starting VBG N
at IN N
the DT N
known JJ N
efficacy NN N
. . N

SETTING CC N
The DT N
practices NNS p
of IN p
2 CD p
university-affiliated JJ p
family NN p
medicine NN p
centers NNS p
( ( p
8 CD p
physicians NNS p
each DT p
) ) p
, , p
14 CD p
community-based JJ p
family NN p
physicians NNS p
, , p
and CC p
2 CD p
cardiologists NNS p
. . p

PATIENTS VB N
Sixty-four JJ p
patients NNS p
with IN p
nonvalvular JJ p
atrial JJ p
fibrillation NN p
who WP p
were VBD p
initiated VBN p
with IN p
warfarin JJ p
therapy NN p
at IN p
least JJS p
3 CD p
months NNS p
before IN p
the DT p
study NN p
. . p

INTERVENTION NNP N
During IN N
each DT N
interview NN N
, , N
the DT N
patients NNS N
' POS N
MCIDs NNP N
were VBD N
determined VBN N
by IN N
using VBG N
( ( N
1 CD N
) ) N
a DT o
pictorial JJ o
flip NN o
chart NN o
to TO o
describe VB o
atrial JJ o
fibrillation NN o
; : o
the DT o
consequences NNS o
of IN o
a DT o
minor JJ o
stroke NN o
, , o
a DT o
major JJ o
stroke NN o
, , o
and CC o
a DT o
major JJ o
bleeding NN o
episode NN o
; : o
the DT N
chance NN o
of IN o
stroke NN o
if IN o
not RB o
taking VBG o
warfarin NN o
; : o
the DT N
chance NN o
of IN o
a DT o
major JJ o
bleeding NN o
episode NN o
if IN o
taking VBG o
warfarin NN o
; : o
examples NNS N
of IN N
the DT N
inconvenience NN o
, , o
minor JJ o
side NN o
effects NNS o
, , o
and CC o
costs NNS o
of IN o
warfarin JJ o
therapy NN o
; : o
and CC N
then RB N
( ( N
2 CD N
) ) N
1 CD N
of IN N
the DT N
2 CD N
elicitation NN o
methods NNS o
to TO o
determine VB o
their PRP$ o
MCIDs NNP o
( ( o
the DT o
smallest JJS o
reduction NN o
in IN o
stroke NN o
risk NN o
at IN o
which WDT o
the DT o
patients NNS o
were VBD o
willing JJ o
to TO o
take VB o
warfarin NN o
) ) o
. . o

Patients NNS o
' POS o
knowledge NN o
of IN o
their PRP$ o
stroke NN o
risk NN o
, , o
acceptability NN o
of IN o
the DT o
interview NN o
process NN o
, , o
and CC o
factors NNS o
determining VBG o
their PRP$ o
preferences NNS o
were VBD N
also RB N
assessed VBN N
. . N

MAIN NNP N
RESULTS NNP N
Given NNP N
a DT N
baseline NN N
risk NN N
of IN N
having VBG N
a DT N
stroke NN N
in IN N
the DT N
next JJ N
2 CD N
years NNS N
, , N
if IN N
not RB N
taking VBG N
warfarin NN i
, , N
of IN N
10 CD N
of IN N
100 CD N
, , N
the DT N
mean JJ o
MCID NNP o
was VBD N
2.01 CD N
of IN N
100 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
1.60-2.42 JJ N
) ) N
. . N

Fifty-two JJ N
percent NN N
of IN N
the DT N
patients NNS N
would MD N
take VB N
warfarin NN i
for IN N
an DT N
absolute JJ N
decrease NN N
in IN N
stroke NN o
risk NN o
of IN N
1 CD N
% NN N
over IN N
2 CD N
years NNS N
. . N

Before IN N
eliciting VBG N
their PRP$ N
MCIDs NNP N
, , N
patients NNS N
showed VBD N
poor JJ N
knowledge NN o
of IN o
their PRP$ o
stroke NN o
risk NN o
, , N
which WDT N
improved VBD N
afterward RB N
. . N

The DT N
interview NN N
process NN N
was VBD N
well RB N
accepted VBN N
by IN N
the DT N
patients NNS N
. . N

The DT N
MCID NNP o
using VBG N
the DT N
ping-ponging JJ N
elicitation NN N
method NN N
was VBD N
1.015 CD N
of IN N
100 CD N
smaller JJR N
compared VBN N
with IN N
use NN N
of IN N
the DT N
starting NN N
at IN N
the DT N
known JJ N
efficacy NN N
method NN N
( ( N
P NNP N
= NNP N
.01 NNP N
) ) N
. . N

CONCLUSIONS NN N
We PRP N
were VBD N
able JJ N
to TO N
determine VB N
the DT N
MCID NNP o
of IN N
warfarin NN i
therapy NN i
for IN N
the DT N
prevention NN N
of IN N
stroke NN N
from IN N
the DT N
perspective NN N
of IN N
patients NNS p
with IN p
nonvalvular JJ p
atrial JJ p
fibrillation NN p
. . p

Their PRP$ N
MCIDs NNPS N
were VBD N
much RB N
smaller JJR N
than IN N
those DT N
that WDT N
have VBP N
been VBN N
implied VBN N
by IN N
some DT N
experts NNS N
and CC N
clinicians NNS N
. . N

The DT N
interview NN N
process NN N
, , N
using VBG N
the DT N
flip JJ N
chart NN N
approach NN N
, , N
appeared VBD N
to TO N
improve VB N
the DT N
patients NNS o
' POS o
knowledge NN o
of IN o
their PRP$ o
disease NN o
and CC o
its PRP$ o
consequences NNS o
and CC o
treatment NN o
. . o

The DT N
method NN N
used VBN N
to TO N
elicit VB N
the DT N
patients NNS N
' POS N
MCIDs NNP o
can MD N
have VB N
a DT N
clinically RB N
important JJ N
effect NN N
on IN N
patient NN N
responses NNS N
. . N

The DT N
method NN N
used VBN N
in IN N
our PRP$ N
study NN N
can MD N
be VB N
generalized VBN N
to TO N
other JJ N
conditions NNS N
and CC N
, , N
thus RB N
, , N
could MD N
be VB N
helpful JJ N
in IN N
3 CD N
ways NNS N
: : N
( ( N
1 CD N
) ) N
from IN N
a DT N
clinical JJ N
decision-making NN N
perspective NN N
, , N
it PRP N
could MD N
facilitate VB N
patient-physician JJ N
communication NN N
; : N
( ( N
2 CD N
) ) N
it PRP N
could MD N
clarify VB N
the DT N
patient NN N
perspective NN N
when WRB N
interpreting VBG N
the DT N
results NNS N
of IN N
previously RB N
completed VBN N
trials NNS N
; : N
and CC N
( ( N
3 CD N
) ) N
it PRP N
could MD N
be VB N
used VBN N
to TO N
derive VB N
more RBR N
clinically RB N
relevant JJ N
sample NN N
sizes NNS N
for IN N
randomized JJ N
treatment NN N
trials NNS N
. . N

-DOCSTART- -25070364- O O

The DT N
effects NNS N
of IN N
low- JJ N
, , N
medium- JJ N
, , N
and CC N
high-oil NN N
distillers NNS i
dried VBD i
grains NNS i
with IN i
solubles NNS i
on IN N
growth NN o
performance NN o
, , o
nutrient JJ o
digestibility NN o
, , o
and CC o
fat JJ o
quality NN o
in IN N
finishing VBG p
pigs NNS p
. . p

A DT p
total NN p
of IN p
1,480 CD p
pigs NNS p
were VBD N
used VBN N
in IN N
3 CD N
experiments NNS N
to TO N
determine VB N
the DT N
effects NNS N
of IN N
corn NN i
distillers NNS i
dried VBD i
grains NNS i
with IN i
solubles NNS i
( ( i
DDGS NNP i
) ) i
varying VBG N
in IN N
oil NN N
content NN N
on IN N
growth NN o
performance NN o
, , o
carcass NN o
traits NNS o
, , o
and CC o
nutrient JJ o
digestibility NN o
in IN N
finishing VBG p
pigs NNS p
. . p

In IN N
Exp NNP N
. . N

1 CD N
, , N
1,198 CD p
pigs NNS p
( ( p
PIC NNP p
Line NNP p
337 CD p
? . p
1050 CD p
; : p
initially RB p
46.1 CD p
kg NNS p
) ) p
were VBD N
allotted VBN N
to TO N
a DT N
corn-soybean JJ i
meal-based JJ i
diet NN i
or CC i
diets NNS i
with IN i
20 CD i
or CC i
40 CD i
% NN i
of IN i
a DT i
5.4 CD i
% NN i
oil NN i
DDGS NNP i
( ( N
29.5 CD N
% NN N
CP NNP N
, , N
8.9 CD N
% NN N
ADF NNP N
, , N
and CC N
21.8 CD N
% NN N
NDF NNP N
; : N
as-fed JJ N
basis NN N
) ) N
or CC N
a DT N
9.6 CD N
% NN N
oil NN N
DDGS NNP N
( ( N
29.6 CD N
% NN N
CP NNP N
, , N
15.3 CD N
% NN N
ADF NNP N
, , N
and CC N
28.6 CD N
% NN N
NDF NNP N
; : N
as-fed JJ N
basis NN N
) ) N
. . N

From IN N
d JJ N
0 CD N
to TO N
82 CD N
, , N
ADG NNP N
was VBD N
unaffected VBN N
by IN N
DDGS NNP N
source NN N
or CC N
level NN N
. . N

However RB N
, , N
increasing VBG N
5.4 CD N
% NN N
oil NN i
DDGS NNP i
decreased VBD N
( ( N
linear JJ N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
G NN N
: : N
F NNP N
, , N
whereas JJ N
G NNP N
: : N
F NN N
did VBD N
not RB N
change VB N
among IN N
pigs NNS N
fed VBP N
9.6 CD N
% NN N
oil NN i
DDGS NNP i
( ( N
DDGS NNP N
source NN N
? . N
level JJ N
interaction NN N
; : N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Regardless NNP N
of IN N
DDGS NNP N
source NN N
, , N
carcass NN N
yield NN N
and CC N
HCW NNP N
decreased VBD N
( ( N
linear JJ N
, , N
P NNP N
< NNP N
0.04 CD N
) ) N
with IN N
increasing VBG N
DDGS NNP N
. . N

Increasing VBG N
DDGS NNP N
increased VBD o
jowl NN o
iodine NN o
value NN o
( ( o
IV NNP o
) ) o
, , o
but CC N
the DT N
magnitude NN N
was VBD N
greater JJR N
in IN N
pigs NNS N
fed VBP N
the DT N
9.6 CD N
% NN N
oil NN N
DDGS NNP N
compared VBN N
with IN N
those DT N
fed JJ N
5.4 CD N
% NN N
oil NN i
DDGS NNP i
( ( i
DDGS NNP N
source NN N
? . N
level JJ N
interaction NN N
; : N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

In IN N
Exp NNP N
. . N

2 CD N
, , N
270 CD p
pigs NNS p
( ( p
PIC NNP p
Line NNP p
327 CD p
? . p
1050 CD p
; : p
initially RB p
46.5 CD p
kg NNS p
) ) p
were VBD N
allotted VBN i
a DT i
corn-soybean JJ i
meal-based JJ i
diet NN i
or CC i
diets NNS N
with IN N
20 CD N
or CC N
40 CD N
% NN N
of IN N
a DT N
9.4 CD N
% NN N
oil NN N
DDGS NNP i
( ( i
29.4 CD i
% NN i
CP NNP i
, , i
19.6 CD N
% NN i
ADF NNP i
, , N
and CC N
34.5 CD N
% NN i
NDF NNP i
; : N
as-fed JJ N
basis NN N
) ) N
or CC N
a DT N
12.1 CD N
% NN i
oil NN i
DDGS NNP i
( ( i
28.5 CD i
% NN N
CP NNP N
, , N
17.6 CD N
% NN N
ADF NNP N
, , N
and CC N
31.4 CD N
% NN N
NDF NNP N
; : N
as-fed JJ N
basis NN N
) ) N
. . N

From IN N
d JJ N
0 CD N
to TO N
75 CD N
, , N
ADG NNP o
increased VBD N
and CC N
then RB N
decreased VBD N
for IN N
pigs NNS N
fed VBN N
9.4 CD N
% NN N
oil NN N
DDGS NNP N
but CC N
was VBD N
unchanged JJ N
for IN N
pigs NNS N
fed VBN N
12.1 CD N
% NN N
oil NN N
DDGS NNP N
( ( N
quadratic JJ N
interaction NN N
, , N
P NNP N
< NNP N
0.02 CD N
) ) N
. . N

Increasing VBG i
DDGS NNP i
increased VBD i
( ( N
linear JJ N
, , N
P NNP N
< NNP N
0.01 CD N
) ) o
jowl NN o
IV NNP o
and CC N
tended VBD N
( ( N
linear JJ N
, , N
P NNP N
< NNP N
0.07 CD N
) ) N
to TO N
increase VB o
G NNP o
: : o
F. NNP o
Regardless NNP N
of IN N
source NN o
, , o
HCW NNP o
and CC o
carcass JJ o
yield NN o
decreased VBD o
( ( N
linear JJ N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
as IN N
DDGS NNP N
increased VBD N
. . N

In IN N
Exp NNP N
. . N

3 CD N
, , N
nutrient JJ N
digestibility NN N
of IN N
the DT N
4 CD i
DDGS NNP i
sources NNS i
was VBD N
determined VBN N
using VBG N
pigs NNS N
fed VBN N
either RB N
a DT N
corn-based JJ N
basal NN N
diet NN N
( ( N
96.6 CD N
% NN N
corn NN N
and CC N
3.4 CD N
% NN N
vitamins NNS N
and CC N
minerals NNS N
) ) N
or CC N
a DT N
DDGS NNP i
diet NN i
with IN N
50 CD N
% NN N
basal NN N
diet JJ N
and CC N
50 CD N
% NN N
DDGS NNP i
. . i

On IN i
an DT N
as-fed JJ N
basis NN N
, , N
corn NN N
contained VBD N
3,871 CD N
and CC N
3,515 CD N
kcal/kg NN N
GE NNP N
and CC N
DE NNP N
, , N
respectively RB N
. . N

The DT N
5.4 CD N
, , N
9.6 CD N
, , N
9.4 CD N
, , N
and CC N
12.1 CD N
% NN N
oil NN N
DDGS NNP i
contained VBD i
4,347 CD N
, , N
4,648 CD N
, , N
4,723 CD N
, , N
and CC N
4,904 CD N
kcal/kg NN N
( ( N
as-fed JJ N
basis NN N
) ) N
GE NNP N
and CC N
3,417 CD N
, , N
3,690 CD N
, , N
3,838 CD N
, , N
and CC N
3,734 CD N
kcal/kg NN N
DE NNP N
, , N
respectively RB N
( ( N
as-fed JJ N
basis NN N
) ) N
. . N

Stepwise NNP N
regression NN N
indicated VBD N
that IN N
the DT N
oil NN N
( ( N
ether CC N
extract NN N
) ) N
content NN N
was VBD N
the DT N
only JJ N
significant JJ N
variable NN N
to TO N
explain VB N
differences NNS N
in IN N
energy NN N
content NN N
. . N

The DT N
equations NNS N
generated VBD N
to TO N
predict VB N
DE NNP N
and CC N
NE NNP N
as IN N
a DT N
function NN N
of IN N
oil NN N
content NN N
on IN N
an DT N
as-fed JJ N
basis NN N
were VBD N
DE NNP N
( ( N
kcal/kg NN N
) ) N
= VBZ N
62.347 CD N
? . N
ether JJR N
extract NN N
( ( N
% NN N
) ) N
+ VBZ N
3,058.13 CD N
( ( N
n JJ N
= NN N
5 CD N
, , N
adjusted VBN N
R NNP N
( ( N
2 CD N
) ) N
= FW N
0.41 CD N
) ) N
and CC N
NE NNP N
( ( N
kcal/kg NN N
) ) N
= VBZ N
115.011 CD N
? . N
ether JJR N
extract NN N
( ( N
% NN N
) ) N
+ VBZ N
1,501.01 CD N
( ( N
n JJ N
= NN N
5 CD N
, , N
adjusted VBN N
R NNP N
( ( N
2 CD N
) ) N
= FW N
0.86 CD N
) ) N
. . N

-DOCSTART- -8281875- O O

Omeprazole JJ i
ameliorates VBZ N
aspirin-induced JJ N
gastroduodenal JJ p
injury NN p
. . p

Aspirin NNP i
and CC i
nonsteroidal JJ i
antiinflammatory NN i
drugs NNS i
( ( i
NSAIDs NNP i
) ) i
damage VBP N
the DT N
gastroduodenal JJ N
epithelium NN N
by IN N
two CD N
mechanisms NNS N
: : N
direct JJ N
toxic NN N
effects NNS N
and CC N
effects NNS N
related VBN N
to TO N
the DT N
depletion NN N
of IN N
endogenous JJ N
prostaglandins NNS N
. . N

The DT N
prostaglandin-depleted JJ N
mucosa NN N
has VBZ N
increased VBN N
susceptibility NN N
to TO N
luminal JJ N
aggressive JJ N
factors NNS N
, , N
yet RB N
the DT N
role NN N
of IN N
acid NN N
in IN N
the DT N
pathogenesis NN N
of IN N
the DT N
NSAID NNP i
ulcer NN N
is VBZ N
controversial JJ N
. . N

In IN N
humans NNS N
, , N
standard JJ N
doses NNS N
of IN N
H2-receptor NNP N
antagonists NNS N
prevent VBP N
only RB N
duodenal JJ N
injury NN N
and CC N
provide VB N
no DT N
protection NN N
for IN N
the DT N
gastric JJ N
mucosa NN N
. . N

It PRP N
is VBZ N
not RB N
known VBN N
whether IN N
more RBR N
potent JJ N
suppression NN N
of IN N
acid NN N
can MD N
prevent VB N
NSAID NNP N
damage NN N
. . N

Twenty NNP p
healthy JJ p
volunteers NNS p
were VBD p
randomized VBN p
to TO N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
crossover NN N
study NN N
to TO N
determine VB N
if IN N
omeprazole JJ i
, , i
40 CD i
mg/day NN i
prevents NNS N
gastroduodenal JJ N
injury NN N
due JJ N
to TO N
two CD N
weeks NNS N
of IN N
aspirin JJ i
administration NN i
( ( N
650 CD N
mg RB N
four CD N
times NNS N
a DT N
day NN N
) ) N
. . N

The DT N
severity NN o
of IN o
mucosal JJ o
injury NN o
was VBD N
quantitated VBN N
by IN N
endoscopy NN N
and CC N
stratified VBN N
by IN N
a DT N
scale NN N
from IN N
0 CD N
( ( N
normal JJ N
) ) N
to TO N
4 CD N
( ( N
ulcer NN N
) ) N
. . N

Fourteen CD p
of IN p
the DT p
20 CD p
subjects NNS p
had VBD N
less RBR N
gastric JJ o
injury NN o
during IN N
cotherapy NN N
with IN N
omeprazole JJ i
. . i

All DT p
six CD p
with IN p
no DT p
difference NN p
received VBD N
aspirin JJ N
plus CC N
omeprazole JJ i
in IN N
the DT N
first JJ N
treatment NN N
period NN N
. . N

Omeprazole NNP N
significantly RB N
decreased VBD N
aspirin-induced JJ o
gastric JJ o
mucosal NN o
injury NN o
( ( N
P NNP N
< NNP N
0.001 CD N
, , N
Wilcoxon NNP N
signed-rank JJ N
test NN N
) ) N
. . N

Omeprazole NNP i
protected VBD N
85 CD N
% NN N
of IN N
subjects NNS N
from IN N
extensive JJ o
gastric JJ o
erosions NNS o
( ( N
often RB N
associated VBN N
with IN N
evidence NN N
of IN N
intraluminal JJ N
bleeding NN N
) ) N
or CC N
ulceration NN o
, , N
whereas RB N
70 CD N
% NN N
of IN N
the DT N
subjects NNS N
developed VBD N
aspirin-induced JJ o
grades NNS o
3 CD o
and CC o
4 CD o
gastric JJ o
injury NN o
on IN N
placebo NN N
( ( N
P NNP N
< RB N
0.01 CD N
by IN N
chi NNS N
2 CD N
) ) N
. . N

No UH N
subject JJ N
taking VBG N
omeprazole NN i
developed VBD N
duodenal JJ o
injury NN o
of IN o
any DT o
grade NN o
, , N
while IN N
50 CD N
% NN N
taking VBG N
placebo NN i
developed VBD N
erosions NNS o
and CC N
15 CD N
% NN N
had VBD N
ulcer NN o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Medication NNP N
side JJ N
effects NNS N
were VBD N
mild VBN N
in IN N
the DT N
majority NN N
of IN N
subjects NNS N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -21833823- O O

Atypical JJ i
social JJ i
modulation NN i
of IN N
imitation NN N
in IN N
autism NN p
spectrum NN p
conditions NNS p
. . p

Appropriate NNP N
modulation NN i
of IN i
imitation NN i
according VBG N
to TO N
social JJ N
context NN N
is VBZ N
important JJ N
for IN N
successful JJ N
social JJ N
interaction NN N
. . N

In IN N
the DT N
present JJ N
study NN N
we PRP N
subliminally RB N
primed VBD N
high-functioning JJ p
adults NNS p
with IN p
ASC NNP p
and CC p
age- JJ p
and CC p
IQ-matched JJ p
controls NNS p
with IN p
either DT p
a DT p
pro- JJ p
or CC p
non- JJ p
social JJ p
attitude NN p
. . p

Following VBG N
priming NN N
, , N
an DT N
automatic JJ N
imitation NN N
paradigm NN N
was VBD N
used VBN N
to TO N
acquire VB N
an DT N
index NN o
of IN o
imitation NN o
. . o

Whereas NNP N
imitation NN o
levels NNS o
were VBD N
higher JJR N
for IN N
pro-socially RB N
primed JJ N
relative JJ N
to TO N
non-socially RB N
primed VBN N
control NN p
participants NNS p
, , N
there EX N
was VBD N
no DT N
difference NN N
between IN N
pro- JJ N
and CC N
non- JJ N
socially RB N
primed JJ N
individuals NNS p
with IN p
ASC NNP p
. . p

We PRP N
conclude VBP N
that IN N
high-functioning JJ p
adults NNS p
with IN p
ASC NNP p
demonstrate VB N
atypical JJ o
social JJ o
modulation NN o
of IN o
imitation NN o
. . o

Given VBN N
the DT N
importance NN N
of IN N
imitation NN i
in IN i
social JJ i
interaction NN i
we PRP N
speculate VBP N
that IN N
difficulties NNS N
with IN N
the DT N
modulation NN N
of IN N
imitation NN N
may MD N
contribute VB N
to TO N
the DT N
social JJ N
problems NNS N
characteristic JJ N
of IN N
ASC NNP p
. . p

-DOCSTART- -7092002- O O

Antibiotic JJ N
therapy NN N
of IN N
acute JJ N
exacerbations NNS N
of IN N
chronic JJ N
bronchitis NN N
. . N

A DT N
controlled VBN N
study NN N
using VBG N
tetracycline NN i
. . i

We PRP N
conducted VBD N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
placebo-controlled JJ i
trial NN N
in IN N
40 CD p
patients NNS p
to TO p
evaluate VB p
the DT p
need NN p
for IN p
antibiotics NNS p
in IN p
acute JJ p
exacerbations NNS p
of IN p
chronic JJ p
bronchitis NN p
. . p

All DT p
patients NNS p
were VBD p
sufficiently RB p
ill VBN p
to TO p
require VB p
hospitalization NN p
although IN p
none NN p
needed VBD p
ventilatory JJ p
support NN p
; : p
the DT p
presence NN p
of IN p
pneumonia NN p
was VBD p
excluded VBN p
. . p

Treatment NNP N
consisted VBD N
of IN N
bronchodilators NNS i
, , i
corticosteroids NNS i
, , N
and CC N
either DT N
tetracycline NN i
, , N
500 CD N
mg NN N
, , N
or CC i
placebo NN i
by IN N
mouth NN N
every DT N
6 CD N
hours NNS N
for IN N
1 CD N
week NN N
. . N

Arterial JJ o
blood NN o
gases NNS o
, , o
spirometric JJ o
tests NNS o
, , o
bacteriologic JJ o
evaluation NN o
of IN o
sputum NN o
, , o
and CC o
patient NN o
and CC o
physician JJ o
evaluation NN o
of IN o
the DT o
severity NN o
of IN o
illness NN o
were VBD N
assessed VBN N
at IN N
the DT N
beginning NN N
and CC N
end NN N
of IN N
the DT N
study NN N
. . N

All DT N
patients NNS N
improved VBN N
both DT N
symptomatically RB N
and CC N
by IN N
objective JJ N
measures NNS N
of IN N
lung NN N
function NN N
. . N

At IN N
the DT N
end NN N
of IN N
the DT N
study NN N
period NN N
there EX N
were VBD N
no DT N
differences NNS N
between IN N
those DT N
patients NNS N
receiving VBG N
tetracycline NN N
and CC N
those DT N
receiving VBG N
placebo NN i
. . i

We PRP N
conclude VBP N
that IN N
antibiotic JJ N
therapy NN N
is VBZ N
not RB N
needed VBN N
in IN N
moderately RB p
ill JJ p
patients NNS p
with IN p
exacerbations NNS p
of IN p
chronic JJ p
bronchitis NN p
. . p

-DOCSTART- -14977031- O O

Body NNP i
asymmetry NN i
affects VBZ N
conjugate JJ o
lateral JJ o
eye NN o
movement NN o
. . o

A. NNP N
H. NNP N
Baker NNP N
( ( N
1989 CD N
) ) N
and CC N
A. NNP N
H. NNP N
Baker NNP N
and CC N
A. NNP N
I. NNP N
Ledner NNP N
( ( N
1990 CD N
) ) N
reported VBD N
that DT N
asymmetrical JJ N
visual JJ N
stimulation NN N
affects NNS N
conjugate VBP o
lateral JJ o
eye NN o
movement NN o
( ( o
CLEM NNP o
) ) o
. . o

In IN N
the DT N
present JJ N
article NN N
, , N
the DT N
authors NNS N
explored VBD N
whether IN N
asymmetrical JJ N
body NN N
position NN N
similarly RB N
affects VBZ N
CLEM NNP N
. . N

The DT N
authors NNS p
assessed VBD N
CLEMs NNP N
twice RB N
in IN N
a DT N
counterbalanced JJ N
design NN N
. . N

In IN N
the DT N
control NN p
( ( p
symmetric JJ p
) ) p
condition NN p
, , N
each DT N
participant NN p
sat VBD N
in IN N
a DT N
completely RB i
symmetrical JJ i
position NN i
facing VBG N
a DT N
wall NN N
devoid NN N
of IN N
any DT N
asymmetrical JJ N
features NNS N
. . N

In IN N
the DT N
experimental NN N
( ( N
asymmetrical JJ N
) ) N
condition NN N
, , N
half PDT N
the DT N
participants NNS p
rotated VBD i
their PRP$ i
heads NNS i
68 CD i
degrees NNS i
clockwise RB i
relative VBP i
to TO i
their PRP$ i
bodies NNS i
to TO i
face VB i
the DT i
experimenter NN i
, , i
and CC i
the DT i
other JJ i
half NN i
rotated VBD i
their PRP$ i
heads NNS i
68 CD i
degrees NNS i
counterclockwise NN i
, , N
also RB N
to TO N
face VB N
the DT N
experimenter NN N
. . N

CLEM NNP N
was VBD N
predominantly RB N
toward IN N
the DT N
body NN N
's POS N
position NN N
in IN N
the DT N
asymmetrical JJ N
condition NN N
rather RB N
than IN N
toward IN N
the DT N
body NN N
's POS N
position NN N
in IN N
the DT N
symmetrical JJ N
condition NN N
. . N

-DOCSTART- -2240543- O O

Successful JJ N
difficult JJ N
intubation NN i
. . i

Tracheal NNP i
tube JJ i
placement NN i
over IN N
a DT N
gum-elastic JJ i
bougie NN i
. . i

A DT N
randomised JJ N
study NN N
was VBD N
carried VBN N
out IN N
to TO N
assess VB N
the DT N
effect NN N
of IN N
tracheal NN i
tube NN i
rotation NN i
on IN N
the DT N
passage NN N
of IN N
a DT N
tube NN N
over IN N
a DT N
gum-elastic JJ N
bougie NN N
into IN N
the DT N
trachea NN N
in IN N
100 CD p
patients NNS p
. . p

The DT N
effect NN N
of IN N
the DT N
presence NN N
or CC N
absence NN N
of IN N
a DT N
laryngoscope NN N
on IN N
successful JJ N
tube NN N
placement NN N
was VBD N
also RB N
assessed VBN N
. . N

A DT N
grade JJ N
3 CD N
difficult JJ N
intubation NN N
was VBD N
simulated VBN i
in IN N
patients NNS p
with IN p
a DT p
laryngoscope NN i
. . p

There EX N
was VBD N
a DT N
significant JJ N
difference NN N
in IN N
the DT N
rates NNS o
for IN N
successful JJ o
first-time JJ o
intubation NN o
in IN N
those DT N
patients NNS N
with IN N
tube JJ N
orientation NN N
of IN N
-90 NN N
degrees NNS N
( ( N
with IN N
the DT N
bevel NN N
facing VBG N
posteriorly RB N
) ) N
as IN N
compared VBN N
with IN N
a DT N
tube JJ N
orientation NN N
of IN N
0 CD N
degrees NNS N
( ( N
the DT N
normal JJ N
orientation NN N
with IN N
the DT N
bevel NN N
facing NN N
left VBD N
) ) N
. . N

The DT N
unsuccessful JJ o
first-time JJ o
intubations NNS o
with IN N
a DT N
0 CD N
degree JJ N
orientation NN N
were VBD N
frequently RB N
converted VBN N
to TO N
successful JJ o
intubations NNS o
with IN N
the DT N
-90 NN N
degrees VBZ N
position NN N
at IN N
a DT N
second JJ N
attempt NN N
. . N

The DT N
presence NN o
of IN o
a DT o
laryngoscope NN o
in IN N
the DT N
mouth NN N
while IN N
rail-roading VBG N
a DT N
tube NN N
over IN N
the DT N
bougie NN N
also RB N
made VBD N
a DT N
significant JJ N
difference NN N
to TO N
the DT N
rate NN o
of IN o
successful JJ o
first-time JJ o
intubations NNS o
. . o

The DT N
most RBS N
successful JJ o
method NN N
was VBD N
to TO N
leave VB N
the DT N
laryngoscope NN i
in IN N
the DT N
mouth NN N
and CC N
rotate VB N
the DT N
tube NN N
to TO N
-90 VB N
degrees NNS N
. . N

-DOCSTART- -1364154- O O

[ JJ N
Platelet NNP N
serotonin NN N
in IN N
infantile JJ p
autism NN p
. . p

Cross-over JJ N
effects NNS N
of IN N
a DT N
dopamine JJ i
agonist NN i
and CC i
an DT i
antagonist JJ i
] NN i
. . N

In IN N
infantile JJ p
autism NN p
, , N
the DT N
serotoninergic NN N
( ( N
5-HT JJ N
) ) N
hypothesis NN N
is VBZ N
corroborated VBN N
by IN N
biological JJ N
dosages NNS N
and CC N
therapeutic JJ N
effects NNS N
of IN N
fenfluramine NN i
which WDT N
decrease NN N
blood NN N
serotonin NN N
. . N

However RB N
other JJ N
drugs NNS N
, , N
such JJ N
as IN N
dopaminergic JJ i
agonists NNS i
or CC N
antagonists NNS i
, , N
have VBP N
therapeutic JJ N
effects NNS N
. . N

Therefore RB N
, , N
we PRP N
tested VBD N
the DT N
hypothesis NN N
that WDT N
two CD N
dopaminergic NN i
( ( i
DA NNP i
) ) i
drugs NNS i
have VBP N
a DT N
similar JJ N
5-HT JJ N
effect NN N
underlying VBG N
the DT N
therapeutic JJ N
efficiency NN N
. . N

We PRP N
evaluated VBD N
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
and CC N
cross-over JJ N
study NN N
, , N
the DT N
effects NNS N
of IN N
a DT N
DA NNP i
agonist NN i
( ( i
bromocriptine NN i
) ) i
and CC i
a DT i
DA NNP i
antagonist NN i
( ( i
amisulpride RB i
) ) i
on IN N
platelet NN N
5-HT JJ N
in IN N
infantile JJ p
autism NN p
. . p

The DT N
prolactinemia NN N
, , N
reflecting VBG N
the DT N
DA NNP N
action NN N
, , N
has VBZ N
been VBN N
also RB N
measured VBN N
. . N

Nine NNP p
children NNS p
, , p
aged VBN p
from IN p
4 CD p
to TO p
13 CD p
years NNS p
, , p
according VBG p
to TO p
the DT p
DSM NNP p
III NNP p
for IN p
infantile JJ p
autism NN p
, , N
received VBD N
either DT N
drug NN N
in IN N
a DT N
random JJ N
order NN N
during IN N
four CD N
weeks NNS N
with IN N
an DT N
in-between JJ N
placebo NN i
period NN N
of IN N
six CD N
weeks NNS N
. . N

The DT N
dosages NNS N
of IN N
platelet NN i
5-HT JJ i
and CC i
serum JJ i
prolactin NN i
were VBD N
carried VBN N
out RP N
at IN N
the DT N
beginning NN N
and CC N
at IN N
the DT N
end NN N
of IN N
every DT N
phase NN N
of IN N
treatment NN N
( ( N
active JJ N
or CC N
placebo NN i
) ) i
with IN N
radioenzymology NN N
and CC N
radioimmunoassay VB N
methods NNS N
respectively RB N
. . N

The DT N
principal JJ N
results NNS N
on IN N
serum JJ o
prolactin NN o
show NN N
neither DT N
order NN o
x NNP o
treatment NN o
interaction NN o
, , N
nor CC N
order NN N
effect NN N
but CC N
a DT N
significant JJ N
treatment NN o
effect NN o
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
: : N
amisulpride NN i
increases VBZ o
serum JJ o
prolactin NN o
whereas NNS N
bromocriptine VBP o
decreases VBZ o
according VBG N
to TO N
the DT N
usual JJ N
data NN N
. . N

About IN N
platelet NN o
5-HT JJ o
, , N
there EX N
is VBZ N
neither DT N
order NN N
x NNP N
treatment NN N
interaction NN N
, , N
nor CC N
treatment NN N
effect NN N
but CC N
a DT N
significant JJ N
order NN o
effect NN o
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
. . N

Both DT N
drugs NNS N
increase VBP o
platelet NN o
5-HT JJ o
in IN N
the DT N
first JJ N
phase NN N
of IN N
treatment NN N
. . N

This DT N
order NN N
effect NN N
could MD N
be VB N
explained VBN N
by IN N
a DT N
remanent JJ N
effect NN N
of IN N
amisulpride NN N
after IN N
6 CD N
wash-out JJ N
weeks NNS N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -17019624- O O

Risperidone NNP i
improves VBZ N
behavioral JJ o
symptoms NNS o
in IN N
children NNS p
with IN p
autism NN p
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
. . N

Subgroup NNP N
analysis NN N
of IN N
children NNS p
( ( p
5-12 CD p
years NNS p
) ) p
with IN p
autism NN p
enrolled VBN N
in IN N
an DT N
8-week JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
of IN N
risperidone NN i
for IN N
pervasive JJ N
developmental NN N
disorders NNS N
. . N

The DT N
primary JJ N
efficacy NN N
measure NN N
was VBD N
the DT N
Aberrant NNP o
Behavior NNP o
Checklist-Irritability NNP o
( ( o
ABC-I NNP o
) ) o
subscale NN o
. . o

Data NNS N
were VBD N
available JJ N
for IN N
55 CD p
children NNS p
given VBN N
risperidone NN i
( ( N
n=27 JJ N
) ) N
or CC N
placebo NN i
( ( N
n=28 JJ N
) ) N
; : N
mean JJ N
baseline NN N
ABC-I NNP N
( ( N
+/- JJ N
SD NNP N
) ) N
was VBD N
20.6 CD N
( ( N
8.1 CD N
) ) N
and CC N
21.6 CD N
( ( N
10.2 CD N
) ) N
. . N

Risperidone NNP i
[ JJ N
mean NN N
dose NN N
( ( N
+/- JJ N
SD NNP N
) ) N
: : N
1.37 CD N
mg/day NN N
( ( N
0.7 CD N
) ) N
] NN N
resulted VBD N
in IN N
significantly RB N
greater JJR N
reduction NN N
from IN N
baseline NN N
to TO N
endpoint VB N
in IN N
ABC-I NNP o
versus NN N
placebo NN i
[ JJ N
mean JJ N
change NN N
( ( N
+/- JJ N
SD NNP N
) ) N
: : N
-13.4 NN N
( ( N
1.5 CD N
) ) N
vs. FW N
-7.2 NNP N
( ( N
1.4 CD N
) ) N
, , N
P NNP N
< NNP N
0.05 CD N
; : N
ES=-0.7 JJ N
] NN N
. . N

The DT N
most RBS N
common JJ N
adverse JJ N
effect NN N
with IN N
risperidone NN i
was VBD N
somnolence NN o
( ( N
74 CD N
% NN N
vs. FW N
7 CD N
% NN N
with IN N
placebo NN i
) ) i
. . N

Risperidone CD i
treatment NN N
was VBD N
well RB N
tolerated VBN o
and CC N
significantly RB N
improved VBN N
behavioral JJ o
problems NNS o
associated VBN N
with IN N
autism NN N
. . N

-DOCSTART- -9894936- O O

Herpes NNP i
simplex JJ i
virus NN i
vaccine NN i
in IN N
recurrent JJ p
herpetic JJ p
ocular JJ p
infection NN p
. . p

PURPOSE NNP N
To TO N
evaluate VB N
the DT N
efficacy NN o
of IN N
an DT N
antiherpetic JJ i
vaccine NN i
in IN N
recurrent JJ N
herpetic JJ N
ocular JJ N
infections NNS N
. . N

METHODS NNP N
Twenty NNP p
patients NNS p
with IN p
herpes NNS p
simplex JJ p
virus IN p
1-related JJ p
recurrent NN p
keratitis/keratouveitis NN p
were VBD N
prospectively RB N
enrolled VBN N
and CC N
randomly RB N
assigned VBN N
to TO N
receive VB N
either CC N
a DT N
specific JJ i
vaccination NN i
with IN i
heat NN i
shock-inactivated JJ i
herpes NNS i
simplex JJ i
virus NN i
type NN i
1 CD i
( ( N
10 CD N
patients NNS N
) ) N
or CC N
to TO N
be VB N
observed VBN i
as IN i
controls NNS i
( ( N
10 CD N
patients NNS N
) ) N
. . N

The DT N
number NN o
, , o
duration NN o
, , o
and CC o
anatomic JJ o
localization NN o
of IN o
relapses NNS o
were VBD N
recorded VBN N
in IN N
all PDT N
the DT N
patients NNS N
for IN N
12 CD N
months NNS N
before IN N
inclusion NN N
in IN N
the DT N
study NN N
and CC N
for IN N
a DT N
similar JJ N
period NN N
after IN N
the DT N
assignment NN N
of IN N
each DT N
subject NN N
to TO N
vaccine VB N
or CC N
control VB N
group NN N
. . N

RESULTS NNP N
In IN N
the DT N
vaccine NN N
group NN N
, , N
we PRP N
observed VBD N
a DT N
reduction NN N
both DT N
in IN N
the DT N
number NN o
( ( N
p JJ N
= NNP N
0.016 CD N
) ) N
and CC N
average JJ o
duration NN o
( ( N
p JJ N
= NNP N
0.050 CD N
) ) N
of IN N
recurrences NNS o
, , N
whereas NNS N
in IN N
the DT N
control NN N
group NN N
, , N
no DT N
significant JJ N
change NN N
was VBD N
found VBN N
comparing VBG N
a DT N
12-month JJ N
period NN N
before IN N
and CC N
after IN N
inclusion NN N
in IN N
the DT N
study NN N
. . N

The DT N
comparison NN N
between IN N
the DT N
two CD N
groups NNS N
highlighted VBD N
a DT N
significant JJ N
reduction NN N
in IN N
the DT N
number NN o
( ( N
p JJ N
= NNP N
0.013 CD N
) ) N
and CC N
average JJ o
duration NN o
( ( N
p JJ N
= NNP N
0.051 CD N
) ) N
of IN N
relapses NNS o
in IN N
treated JJ N
subjects NNS N
, , N
who WP N
did VBD N
not RB N
show VB N
any DT N
significant JJ o
vaccine-induced JJ o
side NN o
effects NNS o
. . o

CONCLUSION NNP N
The DT N
use NN N
of IN N
a DT N
vaccination NN i
with IN N
heat NN N
shock-inactivated JJ N
herpes NNS N
simplex JJ N
virus NN N
1 CD N
seems VBZ N
to TO N
be VB N
able JJ N
to TO N
reduce VB N
the DT N
number NN o
and CC o
duration NN o
of IN o
relapses NNS o
in IN N
herpes NNS N
simplex JJ N
virus IN N
1-related JJ N
keratitis/keratouveitis NN N
. . N

-DOCSTART- -12512598- O O

The DT N
efficacy NN o
of IN N
intramammary JJ i
tilmicosin NN i
at IN N
drying-off NN N
, , N
and CC N
other JJ N
risk NN N
factors NNS N
for IN N
the DT N
prevention NN N
of IN N
new JJ N
intramammary JJ N
infections NNS N
during IN N
the DT N
dry JJ N
period NN N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
an DT N
intramammary JJ i
infusion NN i
, , i
containing VBG i
tilmicosin NN i
phosphate NN i
, , N
to TO N
an DT N
infusion NN i
of IN i
a DT i
negative JJ i
control NN i
intramammary JJ i
placebo NN i
for IN N
preventing VBG N
new JJ N
intramammary JJ o
infections NNS o
( ( o
IMI NNP o
) ) o
during IN N
the DT N
dry JJ N
period NN N
. . N

Cows NNS p
were VBD p
enrolled VBN p
from IN p
24 CD p
dairy NN p
herds NNS p
from IN p
three CD p
geographical JJ p
regions NNS p
of IN p
Canada NNP p
. . p

Data NNP p
from IN p
248 CD p
cows NNS p
and CC p
938 CD p
bacteriologically RB p
negative JJ p
quarters NNS p
at IN p
drying-off NN p
are VBP p
summarized VBN p
. . p

Overall JJ N
, , N
the DT N
rate NN o
of IN o
new JJ o
IMI NNP o
during IN N
the DT N
dry JJ N
period NN N
was VBD N
16.7 CD N
% NN N
of IN N
quarters NNS N
. . N

The DT N
new JJ o
infection NN o
rates NNS o
for IN N
quarters NNS N
that WDT N
received VBD N
intramammary JJ i
tilmicosin NNS i
compared VBN N
with IN N
the DT N
intramammary JJ i
placebo NN i
were VBD N
14.4 CD N
and CC N
19.4 CD N
% NN N
, , N
respectively RB N
. . N

The DT N
majority NN N
of IN N
new JJ o
IMI NNP o
was VBD N
caused VBN N
by IN N
coagulase-negative JJ N
staphylococci NN N
( ( N
49 CD N
% NN N
) ) N
and CC N
environmental JJ N
streptococcal JJ N
organisms NNS N
( ( N
26.8 CD N
% NN N
) ) N
. . N

The DT N
probability NN N
for IN N
quarters NNS N
to TO N
develop VB N
new JJ o
IMI NNP o
in IN N
the DT N
dry JJ N
period NN N
was VBD N
significantly RB N
increased VBN N
when WRB N
cows NNS N
had VBD N
higher JJR N
milk NN N
production NN N
before IN N
drying-off NN N
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
, , N
when WRB N
cows NNS N
had VBD N
longer RBR N
dry JJ N
periods NNS N
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
, , N
and CC N
when WRB N
dry JJ N
cows NNS N
were VBD N
housed VBN N
in IN N
tie-stall JJ N
barns NNS N
( ( N
P NNP N
= NNP N
0.002 CD N
) ) N
. . N

Higher JJR N
parity NN N
cows NNS N
and CC N
those DT N
that WDT N
had VBD N
a DT N
linear JJ o
score NN o
somatic JJ o
cell NN o
count NN o
( ( o
SCC NNP o
) ) o
above IN N
4 CD N
on IN N
the DT N
last JJ N
DHI NNP N
test NN N
were VBD N
also RB N
at IN N
increased VBN N
risk NN o
for IN o
new JJ o
IMI NNP o
( ( N
P NNP N
< NNP N
0.10 CD N
) ) N
. . N

Administration NN N
of IN N
intramammary JJ i
tilmicosin NN i
appears VBZ N
to TO N
be VB N
an DT N
efficacious JJ N
therapy NN N
for IN N
prevention NN o
of IN o
new JJ o
IMI NNP o
; : o
however RB N
, , N
there EX N
is VBZ N
currently RB N
no DT N
approved VBD N
intramammary JJ N
formulation NN N
of IN N
this DT N
product NN N
available JJ N
. . N

Use NNP N
of IN N
blanket NN N
dry JJ N
cow NN N
antibiotic JJ N
therapy NN N
compared VBN N
to TO N
selective VB N
dry JJ N
cow NN N
therapy NN N
, , N
as RB N
well RB N
as IN N
the DT N
importance NN N
of IN N
identifying VBG N
risk NN N
factors NNS N
and CC N
managing VBG N
the DT N
environment NN N
of IN N
dry JJ N
cows NNS N
are VBP N
discussed VBN N
. . N

-DOCSTART- -21392837- O O

Pharmacist NNP i
directed VBD i
home NN i
medication NN i
reviews NNS N
in IN N
patients NNS p
with IN p
chronic JJ p
heart NN p
failure NN p
: : p
a DT N
randomised JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
Chronic NNP p
heart NN p
failure NN p
( ( p
CHF NNP p
) ) p
accounts NNS N
for IN N
significant JJ N
morbidity NN N
, , N
mortality NN N
and CC N
health NN N
expenditure NN N
. . N

Furthermore NNP N
, , N
patients NNS p
with IN p
CHF NNP p
are VBP N
often RB N
on IN N
numerous JJ N
pharmacological JJ N
agents NNS N
for IN N
their PRP$ N
comorbidities NNS N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
a DT N
pharmacist NN N
directed VBD N
home NN i
medication NN i
review NN N
intervention NN N
had VBD N
positive JJ N
effects NNS N
on IN N
CHF NNP p
patient NN p
outcomes NNS N
. . N

METHODS NNP N
A NNP p
total NN p
of IN p
120 CD p
patients NNS p
hospitalised VBN p
for IN p
CHF NNP p
were VBD N
randomised VBN N
to TO N
receive VB N
a DT N
pharmacist NN i
directed VBD i
post-discharge JJ i
home NN i
medication NN i
review NN i
( ( N
n JJ N
= NN N
64 CD N
, , N
53.3 CD N
% NN N
) ) N
or CC N
standard JJ i
care NN i
( ( N
n JJ N
= NN N
56 CD N
, , N
46.7 CD N
% NN N
) ) N
. . N

Participants NNS N
were VBD N
followed VBN N
for IN N
6 CD N
months NNS N
. . N

Primary JJ N
outcomes NNS N
were VBD N
death NN N
, , N
CHF NNP o
hospitalisation NN o
and CC N
length NN N
of IN N
hospital NN N
stay NN N
. . N

RESULTS CC N
There EX N
were VBD N
no DT N
between IN N
group NN N
differences NNS N
in IN N
mortality NN o
( ( N
hazard JJ N
ratio NN N
= VBD N
1.41 CD N
, , N
0.50 CD N
to TO N
3.97 CD N
; : N
P NNP N
= NNP N
0.514 CD N
) ) N
or CC N
CHF NNP o
hospitalizations NNS o
( ( N
incidence NN N
rate NN N
ratio NN N
[ NNP N
IRR NNP N
] NNP N
= VBD N
1.74 CD N
95 CD N
% NN N
CI NNP N
: : N
0.85-3.60 JJ N
P NNP N
= NNP N
0.131 CD N
) ) N
over IN N
the DT N
6 CD N
month NN N
follow-up JJ N
period NN N
. . N

Days NNS o
of IN o
hospital NN o
stay NN o
for IN o
CHF NNP o
exacerbations NNS o
in IN N
the DT N
6 CD N
month NN N
follow-up NN N
were VBD N
significantly RB N
greater JJR N
in IN N
the DT N
intervention NN N
group NN N
( ( N
IRR NNP N
= NNP N
2.34 CD N
95 CD N
% NN N
CI NNP N
: : N
1.80-3.05 JJ N
P NNP N
= NNP N
0.000 CD N
) ) N
. . N

CONCLUSIONS NNP N
Post-discharge NNP N
pharmacy NN i
directed VBD i
home NN i
medication NN i
review NN i
appeared VBD N
to TO N
have VB N
no DT N
effect NN N
on IN N
mortality NN N
and CC N
health NN N
care NN N
utilisation NN N
above IN N
that DT N
achieved VBD N
with IN N
standard JJ N
care NN N
. . N

The DT N
post-acute JJ N
management NN N
of IN N
CHF NNP N
must MD N
be VB N
a DT N
collaborative JJ N
multi-disciplinary JJ N
effort NN N
by IN N
the DT N
health NN N
care NN N
team NN N
as IN N
it PRP N
is VBZ N
the DT N
additive JJ N
effect NN N
of IN N
interventions NNS N
that WDT N
are VBP N
most RBS N
effective JJ N
. . N

-DOCSTART- -20616786- O O

Physician-pharmacist JJ i
cooperation NN i
program NN i
for IN N
blood NN o
pressure NN o
control NN o
in IN N
patients NNS p
with IN p
hypertension NN p
: : p
a DT N
randomized-controlled JJ N
trial NN N
. . N

BACKGROUND VB N
The DT N
aim NN N
of IN N
the DT N
trial NN N
was VBD N
to TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
a DT N
program NN N
of IN N
cooperation NN i
between IN i
physician NN i
and CC i
pharmacist NN i
to TO N
reduce VB N
cardiovascular JJ p
risk NN p
factors NNS p
in IN p
patients NNS p
with IN p
mild JJ p
to TO p
moderate VB p
hypertension NN p
by IN N
promoting VBG N
better JJR N
blood NN N
pressure NN N
( ( N
BP NNP N
) ) N
control NN N
, , N
appropriate JJ N
changes NNS N
in IN N
antihypertensive JJ N
medications NNS N
, , N
and CC N
beneficial JJ N
changes NNS N
in IN N
lifestyle NN N
. . N

METHODS NNP N
The DT p
132 CD p
subjects NNS p
in IN p
this DT p
randomized VBN p
, , p
controlled VBN p
trial NN p
were VBD p
in IN p
the DT p
age NN p
range NN p
of IN p
40-79 JJ p
years NNS p
. . p

The DT p
inclusion NN p
criteria NNS p
were VBD p
: : p
systolic JJ o
BP NNP o
( ( o
SBP NNP o
) ) o
ranging VBG p
from IN p
140-179 JJ p
mm NN p
Hg NNP p
and/or VBZ p
diastolic JJ o
BP NNP o
( ( o
DBP NNP o
) ) o
ranging VBG p
from IN p
90-99 CD p
mm NNS p
Hg NNP p
and CC p
treatment-naive JJ p
( ( p
untreated JJ p
for IN p
hypertension NN p
) ) p
; : p
or CC p
on IN p
a DT p
regimen NN p
of IN p
medication NN p
for IN p
hypertension NN p
. . p

Of IN p
these DT p
132 CD p
subjects NNS p
, , p
124 CD p
( ( p
94 CD p
% NN p
) ) p
were VBD p
already RB p
receiving VBG p
treatment NN p
with IN p
antihypertensive JJ p
medications NNS p
. . p

Equal JJ N
numbers NNS N
of IN N
subjects NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
groups NNS N
: : N
a DT N
physician-pharmacist JJ i
intervention NN i
group NN i
( ( N
n JJ N
= NNP N
66 CD N
) ) N
and CC N
a DT N
control NN i
group NN i
( ( N
n JJ N
= NNP N
66 CD N
) ) N
. . N

RESULTS VB N
The DT N
6-month JJ N
follow-up JJ N
rate NN N
was VBD N
97 CD N
% NN N
in IN N
both DT N
groups NNS N
. . N

At IN N
6 CD N
months NNS N
, , N
the DT N
mean JJ N
decrease NN N
in IN N
SBP/DBP NNP o
, , N
as IN N
measured VBN N
at IN N
home NN N
in IN N
the DT N
morning NN N
, , N
was VBD N
2.9/3.3 CD N
mm NN N
Hg NNP N
in IN N
the DT N
intervention NN N
group NN N
relative VBP N
to TO N
baseline VB N
( ( N
P NNP N
= NNP N
0.02 CD N
and CC N
P NNP N
< NNP N
0.0001 CD N
for IN N
SBP NNP N
and CC N
DBP NNP N
, , N
respectively RB N
) ) N
. . N

The DT N
mean JJ N
decrease NN N
in IN N
home NN o
morning NN o
SBP NNP o
in IN N
the DT N
intervention NN N
group NN N
was VBD N
not RB N
significantly RB N
greater JJR N
than IN N
in IN N
the DT N
control NN N
group NN N
. . N

However RB N
, , N
the DT N
DBP NNP o
decline NN N
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
intervention NN N
than IN N
control NN N
groups NNS N
, , N
which WDT N
showed VBD N
a DT N
mean JJ N
decrease NN N
of IN N
2.8 CD N
mm NNS N
Hg NNP N
( ( N
confidence NN N
interval NN N
: : N
-5.5 NN N
to TO N
-0.1 VB N
; : N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

The DT N
percentage NN N
of IN N
patients NNS N
in IN N
whom WP N
control NN N
of IN N
home NN o
morning NN o
BP NNP o
was VBD N
achieved VBN N
was VBD N
53 CD N
% NN N
in IN N
the DT N
intervention NN N
group NN N
and CC N
47 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
= NNP N
0.40 CD N
) ) N
. . N

A DT N
higher JJR N
percentage NN N
of IN N
patients NNS N
in IN N
the DT N
intervention NN N
group NN N
, , N
relative VBP N
to TO N
the DT N
control NN N
group NN N
, , N
were VBD N
able JJ N
to TO N
reduce VB N
the DT N
use NN o
of IN o
antihypertensive JJ o
medications NNS o
( ( N
31 CD N
vs. FW N
8 CD N
% NN N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
and CC N
fewer JJR N
patients NNS N
in IN N
this DT N
group NN N
required VBD N
additional JJ o
medications NNS o
or CC N
increases NNS N
in IN N
dosage NN N
relative NN N
to TO N
the DT N
controls NNS N
( ( N
11 CD N
vs. FW N
28 CD N
% NN N
, , N
P NNP N
= NNP N
0.03 CD N
) ) N
. . N

Patients NNS N
of IN N
the DT N
intervention NN N
group NN N
were VBD N
more RBR N
likely JJ N
to TO N
show VB N
reduction NN N
in IN N
body NN o
mass NN o
index NN o
and CC o
sodium NN o
intake NN o
and CC o
to TO o
stop VB o
smoking NN o
, , N
as IN N
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

CONCLUSIONS VB N
A DT N
program NN N
of IN N
cooperation NN N
between IN N
physician NN N
and CC N
pharmacist NN N
was VBD N
successful JJ N
in IN N
reducing VBG N
cardiovascular JJ N
risk NN N
factors NNS N
in IN N
patients NNS p
with IN p
mild JJ p
to TO p
moderate VB p
hypertension NN p
by IN N
promoting VBG N
better JJR N
blood NN N
pressure NN N
( ( N
BP NNP N
) ) N
control NN N
, , N
appropriate JJ N
changes NNS N
in IN N
antihypertensive JJ N
medications NNS N
, , N
and CC N
beneficial JJ N
changes NNS N
in IN N
lifestyle NN N
. . N

-DOCSTART- -12742556- O O

Efficacy NN o
of IN N
second JJ i
versus NN N
third JJ i
generation NN i
oral JJ i
contraceptives NNS i
in IN N
the DT N
treatment NN N
of IN N
hirsutism NN p
. . p

OBJECTIVE UH N
To TO N
compare VB N
second JJ i
versus JJ N
third JJ i
generation NN i
combination NN i
oral JJ i
contraceptives NNS i
( ( i
OCs NNP i
) ) i
in IN N
the DT N
treatment NN N
of IN N
hirsutism NN p
. . p

METHODS NNP N
Women NNP p
with IN p
hirsutism NN p
, , p
as IN p
defined VBN p
by IN p
a DT p
minimum JJ p
Ferriman-Gallwey JJ p
score NN p
of IN p
10 CD p
, , N
were VBD N
randomized VBN N
in IN N
a DT N
double-blind JJ N
fashion NN N
to TO N
receive VB N
an DT N
OC NNP N
containing NN N
either CC N
ethinyl JJ i
estradiol/desogestrel NN i
or CC N
ethinyl NN i
estradiol/levonorgestrel NN i
for IN N
9 CD N
months NNS N
of IN N
treatment NN N
. . N

Ferriman-Gallwey JJ o
scores NNS o
, , o
androgen NN o
levels NNS o
and CC o
sex NN o
hormone-binding JJ o
globulin NN o
were VBD N
measured VBN N
at IN N
baseline NN N
and CC N
every DT N
3 CD N
months NNS N
for IN N
the DT N
duration NN N
of IN N
the DT N
study NN N
. . N

Hormones NNS o
were VBD N
measured VBN N
in IN N
duplicate NN N
by IN N
radioimmunoassay NN N
. . N

RESULTS NNP N
Of IN N
the DT N
47 CD p
women NNS p
enrolled VBD p
, , N
24 CD N
were VBD N
randomized VBN N
to TO N
ethinyl VB i
estradiol/desogestrel NN i
and CC N
23 CD N
were VBD N
randomized VBN N
to TO N
ethinyl VB i
estradiol/levonorgestrel NN i
. . i

Mean JJ o
sex NN o
hormone-binding JJ o
globulin NN o
increased VBD N
significantly RB N
in IN N
subjects NNS N
using VBG N
the DT N
desogestrel-containing JJ i
contraceptive NN i
compared VBN N
with IN N
the DT N
levonorgestrel-containing JJ i
contraceptive NN i
. . i

Ten CD N
subjects NNS N
completed VBD N
the DT N
9 CD N
months NNS N
of IN N
treatment NN N
in IN N
the DT N
levonorgestrel NN i
group NN N
and CC N
11 CD N
completed VBD N
the DT N
study NN N
in IN N
the DT N
desogestrel NN i
group NN N
. . N

Mean NNP o
free JJ o
testosterone NN o
and CC o
3alpha-androstanediol JJ o
glucuronide NN o
decreased VBD N
significantly RB N
in IN N
the DT N
group NN N
receiving VBG N
ethinyl JJ i
estradiol/desogestrel NN i
but CC N
not RB N
in IN N
the DT N
ethinyl NN i
estradiol/levonorgestrel NN i
group NN N
. . N

Mean JJ o
Ferriman-Gallwey JJ o
scores NNS o
decreased VBN N
significantly RB N
in IN N
both DT N
treatment NN N
groups NNS N
. . N

Improvement NNP N
in IN N
mean JJ N
Ferriman-Gallwey NNP o
score NN o
was VBD N
35.7 CD N
+/- JJ N
38.1 CD N
% NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
for IN N
the DT N
ethinyl NN i
estradiol/desogestrel NN i
arm NN N
and CC N
33.4 CD N
+/- JJ N
27.3 CD N
% NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
for IN N
the DT N
ethinyl NN i
estradiol/levonorgestrel NN i
arm NN N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
found VBN N
in IN N
the DT N
improvement NN N
of IN N
Ferriman-Gallwey NNP o
scores NNS o
between IN N
the DT N
two CD N
treatment NN N
arms NNS N
, , N
although IN N
the DT N
power NN N
to TO N
detect VB N
a DT N
difference NN N
was VBD N
limited VBN N
by IN N
the DT N
small JJ N
sample NN N
size NN N
. . N

CONCLUSIONS NNP N
Treatment NNP N
of IN N
hirsute JJ N
women NNS N
with IN N
third JJ i
generation NN i
OCs NNP i
containing VBG N
desogestrel NN i
results NNS N
in IN N
a DT N
significant JJ N
increase NN N
in IN N
sex NN o
hormone-binding JJ o
globulin NN o
and CC N
decrease NN N
in IN N
free JJ o
testosterone NN o
and CC o
3alpha-androstanediol JJ o
glucuronide NN o
. . o

Both DT N
second JJ i
and CC i
third JJ i
generation NN i
OCs NNP i
were VBD N
clinically RB N
effective JJ N
in IN N
treating VBG N
hirsutism NN p
. . p

-DOCSTART- -15241630- O O

Registration NNP N
accuracy NN N
of IN N
153Gd CD N
transmission NN N
images NNS N
of IN N
the DT N
brain NN N
. . N

PURPOSE VB N
The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
accuracy NN N
of IN N
non-rigid JJ N
nine-parameter JJ N
image NN N
registrations NNS N
based VBN N
on IN N
153Gd CD i
transmission NN i
computed VBN i
tomography NN i
( ( N
TCT NNP N
) ) N
images VBZ N
as IN N
compared VBN N
with IN N
those DT N
based VBN N
on IN N
99mTc-ethyl JJ i
cysteinate NN i
dimer NN i
( ( i
ECD NNP i
) ) i
images NNS i
and CC N
to TO N
assess VB N
whether IN N
normalised JJ N
mutual JJ N
information NN N
( ( N
NMI NNP N
) ) N
or CC N
count NN N
difference NN N
( ( N
CD NN N
) ) N
should MD N
be VB N
used VBN N
. . N

METHODS NNP N
TCT NNP N
and CC N
ECD NNP N
data NNS N
were VBD N
acquired VBN N
in IN N
25 CD p
randomly RB p
selected VBN p
patients NNS p
. . p

Emission NN N
images NNS N
were VBD N
registered VBN N
to TO N
an DT N
ECD NNP i
template NN N
with IN N
a DT N
CD NN N
cost NN N
function NN N
. . N

The DT N
same JJ N
registration NN N
parameters NNS N
were VBD N
applied VBN N
to TO N
the DT N
transmission NN N
images VBZ N
to TO N
create VB N
a DT N
TCT NNP N
template NN N
. . N

All DT N
TCT NNP N
images NNS N
were VBD N
registered VBN N
to TO N
the DT N
TCT NNP i
template NN N
and CC N
the DT N
same JJ N
registration NN N
parameters NNS N
were VBD N
applied VBN N
to TO N
the DT N
ECD NNP i
images NNS N
. . N

The DT N
procedure NN N
was VBD N
repeated VBN N
with IN N
NMI NNP N
as IN N
cost NN N
function NN N
. . N

Accuracy NN N
of IN N
both DT N
ECD-based JJ i
and CC N
TCT-based JJ i
registrations NNS N
was VBD N
assessed VBN N
by IN N
comparing VBG N
the DT N
normalisation NN N
parameter NN N
values NNS N
and CC N
regional JJ N
activities NNS N
in IN N
the DT N
spatially RB N
normalised JJ N
ECD NNP N
images NNS N
, , N
using VBG N
a DT N
mixed-model JJ N
analysis NN N
of IN N
variance NN N
( ( N
ANOVA NNP N
) ) N
. . N

Scheffe NNP N
post NN N
hoc NN N
tests NNS N
were VBD N
performed VBN N
. . N

RESULTS NNP N
No NNP o
significant JJ o
differences NNS o
were VBD N
found VBN N
between IN N
ECD/CD NNP i
, , i
ECD/NMI NNP i
and CC N
TCT/CD NNP i
, , N
suggesting VBG N
that IN N
ECD NNP N
registration NN N
can MD N
be VB N
done VBN N
with IN N
either DT N
CD NN N
or CC N
NMI NNP N
, , N
and CC N
that IN N
TCT NNP N
registration NN N
using VBG N
CD NN N
is VBZ N
equally RB N
as RB N
accurate JJ N
as IN N
ECD NNP N
registration NN N
. . N

The DT N
accuracy NN o
of IN o
TCT NNP o
registration NN o
with IN N
NMI NNP N
was VBD N
lower JJR o
, , N
with IN N
discrepancies NNS N
occurring VBG N
in IN N
the DT N
frontal JJ N
inferior JJ N
region NN N
and CC N
the DT N
cerebellum NN N
. . N

The DT N
analysis NN N
of IN N
normalisation NN N
parameters NNS N
indicated VBD N
that IN N
z-scaling NN N
is VBZ N
underestimated JJ N
and CC N
yz-rotation NN N
overestimated VBN N
with IN N
TCT/NMI NNP N
registration NN N
. . N

CONCLUSION NNP N
We PRP N
conclude VBP N
that IN N
ECD NNP i
registrations NNS N
with IN N
CD NN i
or CC N
NMI NNP i
are VBP N
as RB N
accurate JJ N
as IN N
TCT NNP i
registrations NNS N
with IN N
CD NN N
and CC N
that DT N
TCT NNP i
registrations NNS N
with IN N
NMI NNP N
should MD N
be VB N
avoided VBN N
. . N

-DOCSTART- -9105060- O O

Leukotriene NNP i
antagonist NN i
prevents NNS N
exacerbation NN N
of IN N
asthma NN p
during IN N
reduction NN N
of IN N
high-dose JJ N
inhaled JJ N
corticosteroid NN N
. . N

The DT N
Tokyo NNP N
Joshi-Idai NNP N
Asthma NNP N
Research NNP N
Group NNP N
. . N

To TO N
test VB N
whether IN N
the DT N
leukotriene JJ i
antagonist JJ i
ONO-1078 NNP i
( ( i
pranlukast NN i
) ) i
prevents VBZ N
asthma JJ p
exacerbations NNS N
during IN N
reduction NN N
of IN N
high-dose JJ N
inhaled JJ N
corticosteroid NN i
, , N
we PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
in IN N
79 CD p
asthma NN p
patients NNS p
requiring VBG p
high JJ p
doses NNS p
( ( p
1,500 CD p
microg/d NN p
or CC p
more JJR p
) ) p
of IN p
inhaled JJ i
beclomethasone NN i
dipropionate NN i
( ( i
BDI NNP i
) ) i
for IN i
clinical JJ p
control NN p
( ( p
duration NN p
of IN p
asthma NN p
, , p
11.0 CD p
+/- JJ p
3.1 CD p
yr NN p
; : p
duration NN p
of IN p
BDI NNP p
treatment NN p
, , p
0.5 CD p
+/- JJ p
0.3 CD p
yr NN p
; : p
FEV1 NNP p
percentage NN p
of IN p
predicted VBN p
, , p
80.7 CD p
+/- JJ p
2.0 CD p
% NN p
) ) p
. . p

After IN N
a DT N
2-wk JJ N
run-in JJ N
period NN N
, , N
the DT N
doses NNS N
of IN N
BDI NNP N
were VBD N
halved VBN N
, , N
while IN N
the DT N
patients NNS N
were VBD N
assigned VBN N
to TO N
receive VB N
orally RB i
ONO-1078 NNP i
, , i
450 CD i
mg NN i
twice RB i
daily RB i
, , i
or CC i
placebo NN i
. . i

In IN N
the DT N
placebo NN i
group NN N
FEV1 NNP o
decreased VBN N
by IN N
0.33 CD N
+/- JJ N
0.20 CD N
L NNP N
after IN N
6 CD N
wk NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

Likewise NNP N
, , N
morning NN o
and CC o
evening NN o
PEF NNP o
decreased VBN N
by IN N
46 CD N
+/- JJ N
7 CD N
L/min NNP N
and CC N
18 CD N
+/- JJ N
6 CD N
L/min NNP N
, , N
respectively RB N
. . N

By IN N
contrast NN N
these DT N
variables NNS N
were VBD N
sustained VBN N
above IN N
baseline NN N
in IN N
the DT N
ONO-1078 NNP N
group NN N
. . N

The DT N
number NN o
of IN o
daytime NN o
and CC o
nighttime JJ o
asthma NN o
symptoms NNS o
and CC o
the DT o
use NN o
of IN o
beta2-agonist NN o
increased VBN N
in IN N
the DT N
placebo NN N
group NN N
, , N
whereas IN N
they PRP N
remained VBD N
unchanged JJ N
in IN N
the DT N
ONO-1078 NNP N
group NN N
. . N

In IN N
the DT N
placebo NN i
group NN N
concentrations NNS o
of IN o
serum NN o
eosinophil NN o
cationic JJ o
protein NN o
and CC o
exhaled VBD o
nitric JJ o
oxide NN o
increased VBD N
( ( N
p JJ N
= NN N
0.007 CD N
and CC N
p VB N
= JJ N
0.025 CD N
, , N
respectively RB N
) ) N
, , N
compared VBN N
with IN N
no DT N
change NN N
in IN N
the DT N
ONO-1078 NNP N
group NN N
. . N

Therefore RB N
, , N
the DT N
leukotriene JJ i
antagonist JJ i
ONO-1078 JJ i
prevents NNS N
the DT N
asthma JJ p
deterioration NN N
provoked VBN N
by IN N
a DT N
6-wk JJ N
reduction NN N
of IN N
the DT N
dose NN N
of IN N
inhaled JJ N
BDI NNP N
into IN N
half NN N
. . N

-DOCSTART- -19174717- O O

Bevacizumab NNP i
compared VBN N
with IN N
macular JJ i
laser NN i
grid JJ i
photocoagulation NN i
for IN N
cystoid JJ p
macular JJ p
edema NN p
in IN p
branch JJ p
retinal JJ p
vein NN p
occlusion NN p
. . p

INTRODUCTION NNP N
To TO N
evaluate VB N
the DT N
outcome NN N
of IN N
cystoid JJ N
macular JJ N
edema NN N
treated VBN N
with IN N
intravitreal JJ i
injections NNS i
of IN i
bevacizumab NN i
and CC i
macular JJ i
grid NN i
laser NN i
photocoagulation NN i
( ( i
GLP NNP i
) ) i
, , N
in IN N
patients NNS p
with IN p
perfused JJ p
branch NN p
retinal JJ p
vein NN p
occlusion NN p
. . p

METHODS NNP N
Thirty NNP p
eyes NNS p
of IN p
30 CD p
consecutive JJ p
patients NNS p
with IN p
cystoid JJ p
macular JJ p
edema NN p
secondary JJ p
to TO p
nonischemic JJ p
branch NN p
retinal JJ p
vein NN p
occlusion NN p
were VBD p
assigned VBN p
to TO N
either DT N
GLP NNP i
group NN i
or CC N
to TO N
intravitreal VB i
bevacizumab NN i
( ( i
IB NNP i
) ) i
group NN N
. . N

Complete NNP o
ophthalmologic JJ o
examinations NNS o
were VBD N
performed VBN N
just RB N
before IN N
GLP NNP i
and CC N
IB NNP i
injection NN N
at IN N
1 CD N
, , N
3 CD N
, , N
6 CD N
, , N
and CC N
12 CD N
months NNS N
after IN N
treatment NN N
. . N

Changes NNS N
in IN N
logarithm NN o
of IN o
minimum JJ o
angle NN o
of IN o
resolution NN o
( ( o
logMAR JJ o
) ) o
best-corrected JJ o
visual JJ o
acuity NN o
( ( o
BCVA NNP o
) ) o
, , o
central JJ o
macular JJ o
thickness NN o
( ( o
CMT NNP o
) ) o
shown VBN o
by IN o
optical JJ o
coherence NN o
tomography-3 NN o
were VBD N
evaluated VBN N
. . N

RESULTS NNP N
Baseline NNP o
BCVA NNP o
( ( o
logMAR NN o
) ) o
and CC o
CMT NNP o
were VBD N
, , N
respectively RB N
, , N
0.89 CD N
+/- JJ N
0.13 CD N
and CC N
650 CD N
+/- JJ N
140 CD N
microm NN N
for IN N
the DT N
GLP NNP i
group NN N
, , N
0.87 CD N
+/- JJ N
0.16 CD N
and CC N
690 CD N
+/- JJ N
120 CD N
microm NN N
for IN N
the DT N
IB NNP i
group NN N
. . N

After IN N
the DT N
treatment NN N
, , N
at IN N
1 CD N
, , N
3 CD N
, , N
6 CD N
, , N
and CC N
12 CD N
months NNS N
in IN N
the DT N
GLP NNP i
group NN N
, , N
BCVA NNP o
had VBD N
improved VBN N
by IN N
0.19 CD N
, , N
0.22 CD N
, , N
0.21 CD N
, , N
and CC N
0.20 CD N
logMAR NN N
, , N
CMT NNP o
had VBD N
decreased VBN N
by IN N
40 CD N
% NN N
, , N
41.3 CD N
% NN N
, , N
40.5 CD N
% NN N
, , N
and CC N
42 CD N
% NN N
. . N

In IN N
the DT N
IB NNP i
group NN N
, , N
BCVA NNP o
had VBD N
improved VBN N
by IN N
0.31 CD N
, , N
0.32 CD N
, , N
0.30 CD N
, , N
and CC N
0.31 CD N
logMAR NN o
and CC N
CMT NNP o
had VBD N
decreased VBN N
by IN N
59.5 CD N
% NN N
, , N
59 CD N
% NN N
, , N
60 CD N
% NN N
, , N
and CC N
60.3 CD N
% NN N
. . N

The DT N
group NN N
receiving VBG N
bevacizumab NN i
had VBD N
better JJR N
BCVA NNP o
and CC N
lower JJR N
CMT NNP o
values NNS N
at IN N
all DT N
time NN N
points NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
Intravitreal NNP N
bevacizumab NN i
injection NN N
improves VBZ N
BCVA NNP o
and CC N
reduces NNS N
CMT NNP o
more JJR N
than IN N
GLP NNP N
. . N

Intravitreal NNP N
bevacizumab JJ i
injection NN N
was VBD N
well RB N
tolerated VBN N
and CC N
could MD N
be VB N
used VBN N
as IN N
primary JJ N
treatment NN N
in IN N
patients NNS N
with IN N
cystoid JJ N
macular JJ N
edema NN N
secondary JJ N
to TO N
perfused VBN N
branch NN N
retinal JJ N
vein NN N
occlusion NN N
. . N

-DOCSTART- -18328090- O O

Long-term JJ N
retention NN N
on IN N
treatment NN N
with IN N
lumiracoxib JJ i
100 CD N
mg NN N
once RB N
or CC N
twice RB N
daily RB N
compared VBN N
with IN N
celecoxib NN i
200 CD N
mg NN N
once RB N
daily JJ N
: : N
a DT N
randomised JJ N
controlled VBN N
trial NN N
in IN N
patients NNS p
with IN p
osteoarthritis NN p
. . p

BACKGROUND IN N
The DT N
efficacy NN N
, , N
safety NN N
and CC N
tolerability NN N
of IN N
lumiracoxib NN i
, , N
a DT N
novel JJ N
selective JJ N
cyclooxygenase-2 NN N
( ( N
COX-2 NNP N
) ) N
inhibitor NN N
, , N
has VBZ N
been VBN N
demonstrated VBN N
in IN N
previous JJ N
studies NNS N
of IN N
patients NNS p
with IN p
osteoarthritis NN p
( ( p
OA NNP p
) ) p
. . p

As IN N
it PRP N
is VBZ N
important JJ N
to TO N
establish VB N
the DT N
long-term JJ N
safety NN N
and CC N
efficacy NN N
of IN N
treatments NNS N
for IN N
a DT N
chronic JJ N
disease NN N
such JJ N
as IN N
OA NNP N
, , N
the DT N
present JJ N
study NN N
compared VBN N
the DT N
effects NNS N
of IN N
lumiracoxib NN i
at IN i
doses NNS i
of IN i
100 CD i
mg NNS i
once RB i
daily JJ i
( ( i
o.d JJ i
. . i

) ) i
and CC i
100 CD i
mg NN i
twice RB i
daily RB i
( ( N
b.i.d NN N
. . N

) ) N
with IN N
those DT N
of IN N
celecoxib JJ i
200 CD i
mg NN i
o.d NN i
. . i

on IN N
retention NN N
on IN N
treatment NN N
over IN N
1 CD N
year NN N
. . N

METHODS NNP N
In IN N
this DT N
52-week JJ N
, , N
multicentre NN N
, , N
randomised VBN N
, , N
double-blind JJ N
, , N
parallel-group JJ N
study NN N
, , N
male NN p
and CC p
female JJ p
patients NNS p
( ( p
aged VBN p
at IN p
least JJS p
40 CD p
years NNS p
) ) p
with IN p
symptomatic JJ p
primary JJ p
OA NNP p
of IN p
the DT p
hip NN p
, , p
knee NN p
, , p
hand NN p
or CC p
spine NN p
were VBD N
randomised VBN N
( ( N
1:2:1 CD N
) ) N
to TO N
lumiracoxib VB i
100 CD N
mg NN N
o.d NN N
. . N

( ( N
n JJ N
= NNP N
755 CD N
) ) N
, , N
lumiracoxib $ i
100 CD N
mg NN N
b.i.d NN N
. . N

( ( N
n JJ N
= NNP N
1,519 CD N
) ) N
or CC N
celecoxib $ i
200 CD N
mg NN N
o.d NN N
. . N

( ( N
n JJ N
= NNP N
758 CD N
) ) N
. . N

The DT N
primary JJ N
objective NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
demonstrate VB N
non-inferiority NN o
of IN o
lumiracoxib NN o
at IN N
either CC N
dose VB N
compared VBN N
with IN N
celecoxib NN i
200 CD N
mg NN N
o.d NN N
. . N

with IN N
respect NN N
to TO N
the DT N
1-year JJ o
retention NN o
on IN o
treatment NN o
rate NN o
. . o

Secondary JJ N
outcome NN N
variables NNS N
included VBD N
OA NNP o
pain NN o
in IN o
the DT o
target NN o
joint NN o
, , o
patient NN o
's POS o
and CC o
physician NN o
's POS o
global JJ o
assessments NNS o
of IN o
disease NN o
activity NN o
, , o
Short NNP o
Arthritis NNP o
assessment JJ o
Scale NNP o
( ( o
SAS NNP o
) ) o
total NN o
score NN o
, , o
rescue NN o
medication NN o
use NN o
, , o
and CC o
safety NN o
and CC o
tolerability NN o
. . o

RESULTS JJ N
Retention NN o
rates NNS o
at IN N
1 CD N
year NN N
were VBD N
similar JJ N
for IN N
the DT N
lumiracoxib NN i
100 CD N
mg NN N
o.d. NN N
, , N
lumiracoxib VBZ i
100 CD N
mg NN N
b.i.d NN N
. . N

and CC N
celecoxib JJ i
200 CD N
mg NN N
o.d NN N
. . N

groups NNS N
( ( N
46.9 CD N
% NN N
vs JJ N
47.5 CD N
% NN N
vs JJ N
45.3 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

It PRP N
was VBD N
demonstrated VBN N
that IN N
retention NN o
on IN N
treatment NN N
with IN N
lumiracoxib NN N
at IN N
either CC N
dose VB N
was VBD N
non-inferior JJ N
to TO N
celecoxib VB N
200 CD N
mg NN N
o.d NN N
. . N

Similarly RB N
, , N
Kaplan-Meier NNP N
curves VBZ N
for IN N
the DT N
probability NN N
of IN N
premature JJ N
discontinuation NN N
from IN N
the DT N
study NN N
for IN N
any DT N
reason NN N
were VBD N
similar JJ N
across IN N
the DT N
treatment NN N
groups NNS N
. . N

All DT N
three CD N
treatments NNS N
generally RB N
yielded VBN N
comparable JJ N
results NNS N
for IN N
the DT N
secondary JJ N
efficacy NN N
variables NNS N
and CC N
all DT N
treatments NNS N
were VBD N
well RB N
tolerated VBN o
. . o

CONCLUSION NNP N
Long-term JJ N
treatment NN N
with IN N
lumiracoxib JJ i
100 CD N
mg NN N
o.d. NN N
, , N
the DT N
recommended VBN N
dose NN N
for IN N
OA NNP N
, , N
was VBD N
as IN N
effective JJ N
and CC N
well RB N
tolerated VBN o
as IN N
celecoxib NN i
200 CD N
mg NN N
o.d NN N
. . N

in IN N
patients NNS p
with IN p
OA NNP p
. . p

TRIAL NNP N
REGISTRATION NNP N
clinicaltrials.gov NN N
NCT00145301 NNP N
. . N

-DOCSTART- -18077065- O O

Mechanical JJ o
efficiency NN o
and CC o
propulsion NN o
technique NN o
after IN N
7 CD N
weeks NNS N
of IN N
low-intensity JJ N
wheelchair NN N
training NN N
. . N

BACKGROUND NNP N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
a DT N
7-week JJ N
low-intensity NN N
hand NN N
rim VBZ N
wheelchair JJ N
training VBG N
on IN N
the DT N
submaximal JJ N
metabolic NN N
cost NN N
, , N
mechanical JJ o
efficiency NN o
and CC N
propulsion NN N
technique NN N
in IN N
able-bodied JJ p
participants NNS p
. . p

METHODS JJ N
Participants NNS p
were VBD N
randomly RB N
divided VBN N
over RP N
an DT N
experimental JJ N
group NN N
( ( p
n=14 CC p
) ) p
and CC p
a DT p
control NN p
group NN p
( ( p
n=7 RB p
) ) p
. . p

The DT N
experimental JJ N
group NN N
received VBD i
7 CD i
weeks NNS i
wheelchair JJ i
training NN i
( ( i
3 CD i
week NN i
( ( i
-1 NN i
) ) i
, , i
70 CD i
min NN i
) ) i
at IN i
a DT i
low JJ i
intensity NN i
( ( i
30 CD i
% NN i
of IN i
the DT i
heart NN i
rate NN i
reserve NN i
) ) i
, , i
whereas IN i
the DT i
control NN i
group NN i
did VBD i
not RB i
receive VB i
training NN i
. . i

During IN i
pre- JJ i
and CC i
post-tests NNS i
, , i
submaximal JJ i
exercise NN i
was VBD i
performed VBN i
on IN i
a DT i
stationary JJ i
wheelchair NN i
ergometer NN i
at IN i
fixed JJ i
levels NNS i
of IN i
power NN i
output NN i
. . i

Mechanical JJ o
efficiency NN o
, , o
oxygen NN o
uptake NN o
, , o
heart NN o
rate NN o
, , o
timing VBG o
parameters NNS o
and CC o
stroke NN o
angles NNS o
were VBD i
measured VBN i
. . i

Video NNP N
recordings NNS N
were VBD N
made VBN N
to TO N
determine VB N
the DT N
stroke NN o
pattern NN o
. . o

FINDINGS NNP N
Mechanical NNP o
efficiency NN o
increased VBD o
and CC o
metabolic JJ o
cost NN o
decreased VBN o
significantly RB N
in IN N
the DT N
experimental JJ N
group NN N
compared VBN N
to TO N
the DT N
control NN N
group NN N
. . N

Push NNP o
time NN o
increased VBD N
and CC N
cycle NN o
frequency NN o
decreased VBD N
as IN N
a DT N
result NN N
of IN N
training NN N
. . N

The DT N
stroke NN o
angle NN o
increased VBD N
in IN N
the DT N
experimental JJ N
group NN N
during IN N
the DT N
training NN N
period NN N
. . N

The DT N
experimental JJ N
group NN N
preferred VBD N
double-looping NN N
over IN N
propulsion NN N
, , N
while IN N
the DT N
control NN N
group NN N
mainly RB N
used VBD N
single-looping NN o
over IN o
propulsion NN o
patterns NNS N
during IN N
the DT N
post-test JJ N
. . N

INTERPRETATION VB N
A DT N
low-intensity NN N
, , N
7-week JJ N
training NN N
protocol NN N
has VBZ N
a DT N
beneficial JJ N
effect NN N
on IN N
the DT N
mechanical JJ o
efficiency NN o
and CC o
metabolic JJ o
cost NN o
of IN N
wheelchair NN N
propulsion NN N
in IN N
able-bodied JJ p
participants NNS p
. . p

The DT N
improved JJ N
mechanical JJ N
efficiency NN N
seems VBZ N
to TO N
be VB N
the DT N
result NN N
of IN N
changes NNS N
in IN N
propulsion NN N
technique NN N
that WDT N
were VBD N
found VBN N
. . N

-DOCSTART- -26225500- O O

Quadratus NNP N
lumborum NN i
block NN i
for IN N
postoperative NN o
pain NN o
after IN p
caesarean JJ i
section NN i
: : i
A DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Effective NNP N
postoperative JJ N
analgesia NN N
after IN N
caesarean JJ i
section NN N
is VBZ N
important JJ N
because IN N
it PRP N
enables VBZ N
early JJ N
ambulation NN N
and CC N
facilitates VBZ N
breast-feeding NN N
. . N

Several JJ N
case NN N
reports NNS N
have VBP N
shown VBN N
that IN N
local JJ i
anaesthetic JJ i
injection NN i
around IN N
the DT N
quadratus NN N
lumborum NN N
muscle NN N
is VBZ N
effective JJ N
in IN N
providing VBG N
pain NN N
relief NN N
after IN N
various JJ N
abdominal JJ N
operations NNS N
and CC N
in IN N
patients NNS p
with IN p
chronic JJ p
pain NN p
. . p

The DT N
quadratus NN i
lumborum NN i
block NN i
( ( N
QLB NNP N
) ) N
is VBZ N
performed VBN N
in IN N
close JJ N
proximity NN N
to TO N
the DT N
surface NN N
and CC N
uses VBZ N
a DT N
fascial JJ N
compartment NN N
path NN N
to TO N
extend VB N
the DT N
distribution NN N
of IN N
local JJ N
anaesthesia NN N
into IN N
the DT N
posterior JJ N
abdominal JJ N
wall NN N
and CC N
paravertebral JJ N
space NN N
. . N

This DT N
central JJ N
effect NN N
can MD N
be VB N
of IN N
vital JJ N
importance NN N
when WRB N
managing VBG N
the DT N
visceral JJ o
pain NN o
after IN p
caesarean JJ p
section NN p
. . p

OBJECTIVE IN N
We PRP N
hypothesised VBD N
that IN N
the DT N
QLB NNP N
after IN N
caesarean JJ p
section NN p
can MD N
provide VB N
adequate JJ N
pain NN N
relief NN N
as IN N
part NN N
of IN N
a DT N
multimodal JJ N
approach NN N
. . N

DESIGN NNP N
Double-blind NNP N
, , N
randomised VBD N
and CC N
controlled VBD N
clinical JJ N
trial NN N
. . N

SETTING VB N
A DT p
single JJ p
centre NN p
between IN p
June NNP p
2014 CD p
and CC p
December NNP p
2014 CD p
. . p

PATIENTS VB N
Fifty JJ p
patients NNS p
who WP p
were VBD p
American JJ p
Society NNP p
of IN p
Anesthesiologists NNP p
physical JJ p
status NN p
1 CD p
or CC p
2 CD p
, , p
with IN p
normal JJ p
singleton NN p
pregnancies NNS p
with IN p
a DT p
gestation NN p
of IN p
at IN p
least JJS p
37 CD p
weeks NNS p
, , p
and CC p
scheduled VBN p
for IN p
elective JJ p
caesarean JJ p
section NN p
under IN p
spinal JJ p
anaesthesia NN p
, , N
were VBD N
enrolled VBN N
into IN N
the DT N
study NN N
. . N

They PRP N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
a DT N
QLB NNP i
( ( N
n JJ N
= NNP N
25 CD N
) ) N
with IN N
0.125 CD i
% NN i
bupivacaine NN i
0.2 CD i
ml NN N
kg?? NN N
( ( N
Group NNP N
1 CD N
) ) N
or CC i
a DT i
QLB NNP i
( ( i
n JJ N
= NNP N
25 CD N
) ) N
with IN i
0.9 CD i
% NN i
Normal NNP i
saline NN i
0.2 CD N
ml NN N
kg?? NN N
( ( N
Group NNP N
2 CD N
) ) N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
primary JJ N
outcome NN N
measure NN N
for IN N
the DT N
study NN N
was VBD N
the DT N
morphine NN o
demands NNS o
and CC o
doses NNS o
delivered VBN o
by IN o
a DT o
patient-controlled JJ o
analgesia NN o
system NN o
at IN o
predetermined VBN o
intervals NNS N
( ( N
1 CD N
, , N
2 CD N
, , N
4 CD N
, , N
6 CD N
, , N
12 CD N
, , N
24 CD N
and CC N
48 CD N
h NN N
) ) N
after IN N
surgery NN N
. . N

The DT N
secondary JJ N
endpoints NNS N
were VBD N
visual JJ o
analogue NN o
scale NN o
( ( o
VAS NNP o
) ) o
for IN o
pain NN o
at IN o
rest NN o
and CC o
on IN o
movement NN o
( ( o
dynamic JJ o
) ) o
, , o
heart NN o
rate NN o
, , o
blood NN o
pressure NN o
, , o
pruritus NN o
, , o
itching NN o
, , o
nausea NN o
, , o
vomiting VBG o
and CC o
sedation NN o
. . o

RESULTS VB N
The DT N
patients NNS N
who WP N
received VBD N
local JJ N
anaesthetic NN N
used VBN N
significantly RB N
less RBR N
morphine JJ o
than IN o
the DT o
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
at IN N
6 CD N
and CC N
12 CD N
h NN N
, , N
but CC N
not RB N
at IN N
24 CD N
and CC N
48 CD N
hours NNS N
after IN N
caesarean JJ N
section NN N
. . N

The DT N
local JJ N
anaesthetic JJ N
group NN N
had VBD N
significantly RB o
less JJR o
morphine JJ o
demand NN o
than IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
6 CD N
, , N
12 CD N
, , N
24 CD N
and CC N
48 CD N
h NN N
after IN N
caesarean JJ N
section NN N
. . N

The DT N
VAS NNP o
was VBD o
significantly RB N
lower JJR N
in IN N
the DT N
local JJ N
anaesthetic NN N
group NN N
than IN N
the DT N
control NN N
group NN N
, , N
including VBG N
VAS NNP N
for IN N
pain NN N
at IN N
rest NN N
at IN N
all DT N
times NNS N
except IN N
24 CD N
h NN N
after IN N
caesarean JJ N
section NN N
, , N
and CC N
VAS NNP N
for IN N
pain NN N
on IN N
movement NN N
( ( N
dynamic JJ N
) ) N
at IN N
all DT N
times NNS N
. . N

CONCLUSION VB N
The DT N
QLB NNP N
after IN N
caesarean JJ p
section NN p
was VBD p
effective JJ p
and CC N
provided VBD N
satisfactory JJ N
analgesia NN N
in IN N
combination NN N
with IN N
a DT N
typical JJ N
postoperative JJ N
analgesic JJ N
regimen NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
identifier NN N
: : N
NCT02328378 NNP N
. . N

-DOCSTART- -9185746- O O

The DT N
low-dose JJ i
monoethylglycinexylidide JJ i
test NN i
: : i
assessment NN o
of IN N
liver NN p
function NN p
with IN p
fewer JJR p
side NN p
effects NNS p
. . p

The DT N
hepatic JJ N
metabolism NN N
of IN N
lidocaine NN i
( ( N
1 CD N
mg/kg RB N
intravenously RB N
) ) N
to TO N
its PRP$ N
metabolite JJ N
monoethylglycinexylidide NN i
( ( i
MEG-X NNP i
) ) i
is VBZ N
the DT N
basis NN N
of IN N
the DT N
standard JJ N
MEG-X NNP i
test NN N
. . N

To TO N
reduce VB N
the DT N
lidocaine-induced JJ i
side NN N
effects NNS N
, , N
we PRP N
evaluated VBD N
the DT N
MEG-X NNP i
formation NN N
after IN N
0.5 CD N
and CC N
1 CD N
mg/kg NNS N
lidocaine JJ i
intravenously RB N
in IN N
subjects NNS p
with IN p
normal JJ p
( ( p
n JJ p
= NNP p
5 CD p
) ) p
and CC p
severely RB p
impaired JJ p
liver NN p
function NN p
( ( p
n JJ p
= NNP p
7 CD p
) ) p
( ( p
study NN p
I PRP p
) ) p
. . p

From IN N
this DT N
study NN N
, , N
a DT N
low-dose JJ N
test NN N
( ( i
MEG-X NNP i
concentration NN N
30 CD N
minutes NNS N
after IN N
50 CD N
mg JJ N
lidocaine NN i
intravenously RB N
[ JJ i
MEG-X30min NNP i
] NNP i
normalized VBD N
to TO N
standard VB N
MEG-X NNP i
test NN N
results NNS N
) ) N
was VBD N
developed VBN N
. . N

Sensory JJ N
side NN N
effects NNS N
from IN N
this DT N
low JJ N
dose NN N
and CC N
from IN N
the DT N
standard JJ N
MEG-X NNP i
test NN N
were VBD N
compared VBN N
in IN N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
cross-over JJ N
study NN N
( ( N
study VB N
II NNP N
) ) N
comprising VBG N
15 CD p
individuals NNS p
with IN p
normal JJ p
liver NN p
function NN p
and CC p
45 CD p
patients NNS p
with IN p
cirrhosis NN p
( ( p
15 CD p
Child NNP p
A NNP p
, , p
15 CD p
Child NNP p
B NNP p
, , p
and CC p
15 CD p
Child NNP p
C NNP p
) ) p
. . p

In IN N
study NN N
I PRP N
, , N
MEG-X JJ o
formation NN o
rate NN o
was VBD N
dose-independent JJ N
in IN N
patients NNS N
with IN N
severely RB N
impaired JJ N
liver NN N
function NN N
. . N

In IN N
study NN N
II NNP N
, , N
normalized VBD N
MEG-X JJ i
test NN N
results NNS N
( ( N
ranging VBG N
from IN N
< NN N
or CC N
= $ N
4 CD N
to TO N
120 CD N
microg/L NNS N
) ) N
were VBD N
virtually RB N
identical JJ N
to TO N
the DT N
standard JJ N
test NN N
results NNS N
( ( N
mean JJ N
difference NN N
: : N
-1.9 JJ N
microg/L NN N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NN N
: : N
-5.3 NN N
; : N
1.5 CD N
microg/L NN N
) ) N
. . N

Fewer JJR N
individuals NNS N
experienced VBD N
side NN o
effects NNS o
( ( N
30 CD N
% NN N
vs. FW N
53 CD N
% NN N
) ) N
with IN N
the DT N
low-dose JJ N
test NN N
( ( N
P NNP N
= NNP N
.0013 NNP N
) ) N
. . N

In IN N
a DT N
multivariate NN N
analysis NN N
, , N
the DT N
Child-Pugh NNP o
score NN o
was VBD N
inversely RB N
related VBN N
to TO N
the DT N
occurrence NN N
of IN N
side NN o
effects NNS o
. . o

The DT N
low-dose JJ N
MEG-X JJ i
test NN N
gives VBZ N
almost RB N
identical JJ N
results NNS N
to TO N
the DT N
standard JJ N
MEG-X NNP i
test NN N
and CC N
is VBZ N
associated VBN N
with IN N
fewer JJR o
side NN o
effects NNS o
, , N
which WDT N
occur VBP N
less RBR N
often RB N
in IN N
individuals NNS N
with IN N
more RBR N
severely RB N
compromised VBN N
liver NN N
function NN N
. . N

-DOCSTART- -11228756- O O

Effect NN N
of IN N
acarbose NN i
on IN N
additional JJ N
insulin NN i
therapy NN i
in IN N
type NN p
2 CD p
diabetic JJ p
patients NNS p
with IN p
late JJ p
failure NN p
of IN p
sulphonylurea JJ p
therapy NN p
. . p

AIM VB N
The DT N
present JJ N
study NN N
investigated VBD N
the DT N
effect NN N
of IN N
acarbose NN i
on IN N
insulin NN o
requirements NNS o
and CC N
glycaemic JJ o
control NN o
in IN N
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
receiving VBG p
exogenous JJ p
insulin NN i
due JJ p
to TO p
secondary JJ p
failure NN p
of IN p
maximum NN p
dose JJ p
sulphonylurea JJ p
therapy NN p
. . p

METHODS VB N
A DT N
single-centre JJ N
, , N
double-blind JJ N
, , N
randomized VBN N
, , N
placebo-controlled JJ i
study NN N
was VBD N
performed VBN N
in IN N
48 CD p
type NN p
2 CD p
diabetic JJ p
patients NNS p
with IN p
late-term JJ p
failure NN p
following VBG p
at IN p
least JJS p
3 CD p
years NNS p
of IN p
sulphonylurea JJ i
therapy NN p
requiring VBG p
additional JJ p
insulin NN i
therapy NN p
to TO p
determine VB p
the DT p
impact NN p
of IN p
acarbose NN i
on IN p
glycaemic JJ p
control NN p
and CC p
insulin NN p
requirements NNS p
. . p

The DT N
primary JJ N
end NN N
points NNS N
were VBD N
glycaemic JJ o
response NN o
rate NN o
( ( N
responders NNS N
being VBG N
predefined VBN N
as IN N
patients NNS N
who WP N
achieve VBP N
a DT N
decrease NN N
in IN N
HbA1c NNP N
to TO N
less JJR N
than IN N
8 CD N
% NN N
or CC N
a DT N
reduction NN N
by IN N
at IN N
least JJS N
15 CD N
% NN N
as IN N
compared VBN N
to TO N
the DT N
baseline NN N
values NNS N
) ) N
and CC N
the DT N
daily JJ o
insulin NN o
dose NN o
at IN N
6 CD N
months NNS N
. . N

Secondary JJ N
parameters NNS N
assessed VBD N
included VBN N
postprandial JJ o
changes NNS o
in IN o
blood NN o
glucose NN o
, , o
serum JJ o
insulin NN o
and CC o
C-peptide NNP o
during IN N
the DT N
treatment NN N
period NN N
. . N

RESULTS CC N
There EX N
were VBD N
significantly RB N
more JJR N
responders NNS N
in IN N
the DT N
acarbose-treated JJ N
group NN N
compared VBN N
with IN N
the DT N
placebo NN N
group NN N
( ( N
20/24 CD N
patients NNS N
vs. FW N
10/19 CD N
patients NNS N
; : N
p VB N
< $ N
0.05 CD N
) ) N
. . N

The DT N
mean JJ o
daily JJ o
insulin NN o
dose NN o
after IN N
24 CD N
weeks NNS N
of IN N
treatment NN N
was VBD N
16.4 CD N
+/- JJ N
10.1 CD N
IU NNP N
in IN N
the DT N
acarbose JJ i
group NN N
and CC N
22.4 CD N
+/- JJ N
12.2 CD N
IU NNP N
in IN N
the DT N
placebo NN i
group NN N
( ( N
mean JJ N
+/- JJ N
s.d NN N
. . N

; : N
p JJ N
< NNP N
0.07 CD N
) ) N
. . N

Postprandial JJ o
increases NNS o
in IN o
blood NN o
glucose NN o
, , o
insulin NN o
and CC o
C-peptide NNP o
were VBD N
consistently RB N
lower JJR N
in IN N
the DT N
acarbose-treated JJ N
group NN N
than IN N
in IN N
the DT N
placebo NN i
group NN N
. . N

For IN N
example NN N
, , N
the DT N
mean JJ o
increase NN o
in IN o
2-h JJ o
postprandial JJ o
serum NN o
insulin NN o
remained VBD N
almost RB N
unchanged JJ N
in IN N
the DT N
acarbose JJ N
group NN N
at IN N
the DT N
end NN N
of IN N
24 CD N
weeks NNS N
of IN N
treatment NN N
compared VBN N
to TO N
an DT N
increase NN N
to TO N
43 CD N
+/- JJ N
29 CD N
microU/ml NN N
( ( N
mean JJ N
+/- JJ N
s.d NN N
. . N

) ) N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
period NN N
for IN N
the DT N
placebo NN i
group NN N
. . N

CONCLUSIONS VB N
The DT N
findings NNS N
of IN N
this DT N
study NN N
suggest VBP N
that IN N
the DT N
addition NN N
of IN N
acarbose NN i
to TO N
sulphonylurea/insulin VB i
combination NN i
therapy NN i
can MD N
improve VB N
glycaemic JJ o
control NN o
in IN N
type NN p
2 CD p
diabetic JJ p
patients NNS p
. . p

Acarbose NNP i
may MD N
also RB N
reduce VB N
insulin NN o
resistance NN o
and CC o
hyperinsulinaemia NN o
. . o

-DOCSTART- -8644646- O O

Comparative JJ N
efficacy NN N
of IN N
intravenous JJ N
ibutilide JJ i
versus NN N
procainamide NN i
for IN N
enhancing VBG N
termination NN N
of IN N
atrial JJ N
flutter NN N
by IN N
atrial JJ N
overdrive JJ N
pacing NN N
. . N

This DT N
study NN N
compares VBZ N
the DT N
influence NN N
of IN N
intravenous JJ N
ibutilide NN i
, , N
a DT N
class NN N
III NNP N
antiarrhythmic JJ N
agent NN N
, , N
with IN N
procainamide NN i
, , N
a DT N
class NN N
IA NNP N
antiarrhythmic JJ N
agent NN N
, , N
and CC N
with IN N
placebo NN i
on IN N
its PRP$ N
ability NN N
to TO N
terminate VB N
atrial JJ N
flutter NN N
using VBG N
rapid JJ N
atrial JJ N
pacing NN N
. . N

Fifty-nine NNP p
episodes NNS p
of IN p
atrial JJ p
flutter NN p
in IN p
54 CD p
patients NNS p
who WP p
failed VBD p
to TO p
terminate VB p
with IN p
an DT p
intravenous JJ p
infusion NN p
of IN p
ibutilide NN i
, , i
procainamide NN i
, , i
or CC i
placebo VB i
alone JJ p
underwent JJ p
attempts NNS p
at IN p
pacing VBG p
termination NN p
using VBG p
a DT p
standard JJ p
protocol NN p
of IN p
burst JJ p
atrial JJ p
overdrive JJ p
pacing NN p
. . p

Atrial JJ N
flutter NN N
cycle NN N
length NN N
and CC N
atrial JJ N
monophasic JJ N
action NN N
potential JJ N
duration NN N
recorded VBN N
from IN N
the DT N
right JJ N
atrium NN N
during IN N
atrial JJ N
flutter NN N
were VBD N
measured VBN N
at IN N
baseline NN N
and CC N
following VBG N
infusion NN N
of IN N
ibutilide NN i
, , i
procainamide NN i
, , N
or CC N
placebo NN i
. . i

Both DT N
ibutilide JJ i
and CC N
procainamide JJ i
significantly RB N
enhanced VBN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
pacing-induced JJ o
termination NN o
of IN o
atrial JJ o
flutter NN o
compared VBN N
with IN N
placebo NN i
. . i

Pacing VBG N
converted VBD N
2 CD N
of IN N
11 CD N
patients NNS N
( ( N
18 CD N
% NN N
) ) N
who WP N
received VBD N
placebo NN i
, , N
13 CD N
of IN N
15 CD N
patients NNS N
( ( N
87 CD N
% NN N
) ) N
who WP N
received VBD N
ibutilide RB i
, , N
and CC N
29 CD N
of IN N
33 CD N
patients NNS N
( ( N
88 CD N
% NN N
) ) N
who WP N
received VBD N
procainamide RB i
to TO N
sinus VB o
rhythm NN o
. . o

Ibutilide NNP i
and CC N
procainamide RB i
compared VBN N
with IN N
placebo NN i
markedly RB N
reduced VBD N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
the DT N
incidence NN o
of IN o
pacing-induced JJ o
atrial JJ o
fibrillation NN o
. . o

The DT o
atrial JJ o
flutter NN o
cycle NN o
length NN o
was VBD N
prolonged VBN N
significantly RB N
less RBR N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
the DT N
atrial JJ o
monophasic JJ o
action NN o
potential JJ o
duration NN o
was VBD N
increased VBN N
significantly RB N
more RBR N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
by IN N
ibutilide NN i
than IN N
by IN N
procainamide NN i
. . i

Although IN N
the DT N
electrophysiologic JJ N
changes NNS N
induced VBN N
by IN N
these DT N
antiarrhythmic JJ N
agents NNS N
contributed VBD N
to TO N
facilitating VBG N
pacing-induced JJ N
termination NN N
, , N
neither CC N
tachycardia JJ o
cycle NN o
length NN o
nor CC o
action NN o
potential JJ o
duration NN o
were VBD N
useful JJ N
predictors NNS N
of IN N
the DT N
ability NN N
of IN N
pacing VBG N
to TO N
terminate VB N
atrial JJ N
flutter NN N
. . N

In IN N
conclusion NN N
, , N
despite IN N
differing VBG N
electrophysiologic JJ N
effects NNS N
, , N
the DT N
use NN N
of IN N
intravenous JJ N
ibutilide NN i
or CC N
procainamide NN i
enhances VBZ N
the DT N
termination NN o
of IN o
atrial JJ o
flutter NN o
by IN o
atrial JJ o
overdrive JJ o
pacing NN o
. . o

-DOCSTART- -10235220- O O

Long JJ N
term NN N
response NN N
to TO N
therapy NN N
of IN N
chronic JJ p
anti-HBe-positive JJ p
hepatitis NN p
B NNP p
is VBZ N
poor JJ N
independent JJ N
of IN N
type NN N
and CC N
schedule NN N
of IN N
interferon NN N
. . N

OBJECTIVE CC N
The DT N
response NN o
rate NN o
to TO o
alpha VB o
interferon NN o
( ( o
IFN NNP o
) ) o
of IN N
chronic JJ N
anti-HBe-positive JJ N
hepatitis NN N
B NNP N
is VBZ N
variable JJ N
. . N

We PRP N
studied VBD N
whether IN N
type NN N
, , N
dose NN N
, , N
and CC N
schedule NN N
of IN N
IFN NNP i
, , N
and CC N
type NN N
and CC N
frequency NN N
of IN N
posttreatment NN N
monitoring NN N
, , N
influence VB N
the DT N
response NN N
rate NN N
. . N

METHODS NNP N
Seventy-two JJ p
consecutive JJ p
anti-HBe-positive JJ p
chronic NN p
hepatitis NN p
B NNP p
patients NNS p
( ( p
59 CD p
male NN p
and CC p
13 CD p
female NN p
, , p
median JJ p
age NN p
41 CD p
yr NN p
) ) p
stratified VBN p
by IN p
sex NN p
and CC p
histology NN p
were VBD N
randomly RB N
allocated VBN N
to TO N
three CD N
treatment NN N
arms NNS N
. . N

Twenty-seven JJ N
patients NNS N
( ( N
A DT N
) ) N
received VBD N
10 CD N
million CD N
units NNS N
alpha-N1 JJ i
IFN NNP i
i.m NN i
. . i

t.w NN N
. . N

for IN N
24 CD N
wk NN N
( ( N
total JJ N
dose NN N
: : N
720 CD N
million CD N
units NNS N
) ) N
; : N
21 CD N
( ( N
B NNP N
) ) N
received VBD N
9 CD N
million CD N
units NNS N
alpha-2a JJ i
IFN NNP i
i.m NN i
. . i

t.w NN N
. . N

for IN N
4 CD N
wk NN N
, , N
followed VBN N
by IN N
18 CD N
million CD N
units NNS N
for IN N
12 CD N
wk NN N
and CC N
9 CD N
million CD N
units NNS N
for IN N
8 CD N
wk NN N
( ( N
972 CD N
million CD N
units NNS N
) ) N
; : N
24 CD N
( ( N
C NNP N
) ) N
received VBD N
2 CD i
alpha-2a JJ i
IFN NNP i
courses NNS i
( ( N
9 CD N
million CD N
units NNS N
i.m RB N
. . N

t.w NN N
. . N

for IN N
16 CD N
and CC N
12 CD N
wk NN N
separated VBN N
by IN N
a DT N
6-month JJ N
interval NN N
[ $ N
756 CD N
million CD N
units NNS N
] NNP N
) ) N
. . N

Primary JJ N
response NN N
was VBD N
defined VBN N
by IN N
normal JJ o
ALT NNP o
and CC o
serum VB o
HBV-DNA NNP o
levels NNS o
below IN N
10 CD N
pg/ml NN N
at IN N
the DT N
end NN N
of IN N
therapy NN N
and CC N
sustained VBN N
response NN N
by IN N
normal JJ o
ALT NNP o
( ( N
tested VBN N
monthly RB N
) ) N
, , N
undetectable JJ o
HBV-DNA NN o
and CC N
IgM NNP N
anti-HBc NN N
( ( N
< JJ N
7 CD N
I.U NNP N
. . N

Paul NNP N
Ehrlich NNP N
Institute NNP N
) ) N
( ( N
tested VBN N
every DT N
3 CD N
months NNS N
) ) N
during IN N
the DT N
posttreatment JJ N
follow-up NN N
. . N

RESULTS NNP N
At IN N
the DT N
end NN N
of IN N
treatment NN N
, , N
12 CD N
, , N
8 CD N
, , N
and CC N
13 CD N
patients NNS N
from IN N
groups NNS N
A NNP N
, , N
B NNP N
, , N
and CC N
C NNP N
, , N
respectively RB N
, , N
were VBD N
responders NNS N
. . N

At IN N
the DT N
18-month JJ N
follow-up JJ N
, , N
two CD N
patients NNS N
in IN N
group NN N
A NNP N
and CC N
only RB N
one CD N
in IN N
groups NNS N
B NNP N
and CC N
C NNP N
maintained VBD N
the DT N
response NN o
. . o

Overall NNP N
, , N
after IN N
34 CD N
months NNS N
( ( N
median JJ N
posttreatment NN N
follow-up NN N
) ) N
, , N
three CD N
patients NNS N
were VBD N
long JJ N
term NN N
responders NNS N
, , N
whereas NNS N
three CD N
showed VBD N
a DT N
sustained VBN N
remission NN o
after IN N
relapse NN N
. . N

CONCLUSIONS VB N
The DT N
rate NN o
of IN o
long JJ o
term NN o
response NN o
to TO N
interferon VB N
of IN N
anti-HBe-positive JJ N
chronic JJ N
hepatitis NN N
B NNP N
is VBZ N
poor JJ N
, , N
independent JJ N
of IN N
IFN NNP N
type NN N
, , N
dose VB N
, , N
or CC N
schedule NN N
; : N
the DT N
more RBR N
stringent JJ N
the DT N
monitoring NN N
, , N
the DT N
higher JJR N
the DT N
relapse NN N
rate NN N
. . N

-DOCSTART- -1408861- O O

A DT N
randomized JJ N
trial NN N
of IN N
a DT N
health NN i
care NN i
program NN i
for IN i
first-time JJ i
adolescent NN i
mothers NNS i
and CC i
their PRP$ i
infants NNS i
. . i

To TO N
test VB N
the DT N
effectiveness NN N
of IN N
a DT N
special JJ i
health NN i
care NN i
program NN i
for IN N
adolescent JJ p
mothers NNS p
( ( p
17 CD p
years NNS p
old JJ p
or CC p
younger JJR p
) ) p
and CC p
their PRP$ p
infants NNS p
, , p
243 CD p
mother-infant JJ p
pairs NNS p
were VBD p
randomly RB p
assigned VBN p
to TO N
one CD N
of IN N
two CD p
groups NNS p
. . p

All DT p
of IN p
the DT p
mothers NNS p
were VBD p
unwed JJ p
, , p
on IN p
Medicaid NNP p
, , p
and CC p
black JJ p
. . p

The DT N
control NN i
group NN i
received VBD i
routine JJ i
well-baby NN i
care NN i
. . i

The DT N
experimental JJ p
group NN p
received VBD N
routine JJ i
care NN i
and CC i
services NNS i
that WDT i
included VBD i
rigorous JJ i
follow-up NN i
, , i
discussions NNS i
with IN i
the DT i
mother NN i
about IN i
her PRP$ i
plans NNS i
for IN i
return NN i
to TO i
school NN i
and CC i
use NN i
of IN i
family NN i
planning NN i
methods NNS i
, , i
and CC i
extra JJ i
health NN i
teaching NN i
. . i

The DT N
dropout NN N
rate NN N
in IN N
the DT N
experimental JJ N
group NN N
( ( N
60 CD N
% NN N
) ) N
was VBD N
significantly RB N
less JJR N
after IN N
18 CD N
months NNS N
than IN N
the DT N
control NN N
group NN N
( ( N
82 CD N
% NN N
) ) N
. . N

In IN N
spite NN N
of IN N
the DT N
high JJ N
dropout NN N
rate NN N
, , N
91 CD N
% NN N
of IN N
the DT N
mothers NNS N
were VBD N
located VBN N
for IN N
the DT N
18 CD N
month NN N
follow-up JJ N
interview NN N
. . N

The DT N
repeat JJ o
pregnancy NN o
rate NN o
in IN N
the DT N
experimental JJ N
group NN N
was VBD N
12 CD N
% NN N
after IN N
18 CD N
months NNS N
, , N
and CC N
28 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
percentage NN o
returning VBG o
to TO o
school NN o
. . o

After IN N
12 CD N
months NNS N
, , N
the DT N
infants NNS N
in IN N
the DT N
experimental JJ N
group NN N
were VBD N
more RBR N
likely JJ N
to TO N
be VB N
fully RB o
immunized VBN o
( ( N
33 CD N
% NN N
) ) N
than IN N
the DT N
infants NNS N
in IN N
the DT N
control NN N
group NN N
( ( N
18 CD N
% NN N
) ) N
. . N

Mothers NNS N
in IN N
the DT N
special JJ i
care NN i
program NN i
who WP N
continued VBD N
to TO N
attend VB N
clinic NN N
used VBN o
the DT o
emergency NN o
room NN o
less JJR o
than IN N
the DT N
mothers NNS N
who WP N
continued VBD N
to TO N
attend VB N
in IN N
the DT N
control NN N
group NN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
a DT N
comprehensive JJ i
health NN i
care NN i
program NN i
is VBZ N
one CD N
way NN N
to TO N
bring VB N
about RP N
better JJR N
outcomes NNS N
for IN N
both DT N
adolescent JJ N
mothers NNS N
and CC N
their PRP$ N
infants NNS N
. . N

-DOCSTART- -21115906- O O

Inhibin NNP N
A NNP N
is VBZ N
down-regulated JJ N
during IN N
chemotherapy NN i
in IN N
patients NNS p
with IN p
breast JJ p
cancer NN p
. . p

BACKGROUND NNP N
Inhibins NNP N
are VBP N
dimeric JJ N
glycoproteins NNS N
, , N
composed VBN N
of IN N
an DT N
alpha-subunit JJ N
( ( N
INH-? NNP N
) ) N
and CC N
one CD N
of IN N
two CD N
possible JJ N
beta-subunits NNS N
( ( N
?A CD N
or CC N
?B NNP N
) ) N
, , N
with IN N
substantial JJ N
roles NNS N
in IN N
human JJ N
reproduction NN N
and CC N
in IN N
endocrine-responsive JJ N
tumours NNS N
. . N

Aims NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
determine VB N
the DT N
serological JJ N
measurement NN N
of IN N
inhibin NN o
A NNP o
( ( o
?-?A JJ o
) ) o
in IN o
breast NN o
cancer NN p
patients NNS p
during IN p
chemotherapy NN p
. . p

PATIENTS NNP p
AND CC N
METHODS NNP N
A NNP N
series NN p
of IN p
30 CD p
breast NN p
cancer NN p
patients NNS p
who WP p
underwent VBP i
standardised VBN i
chemotherapy NN i
were VBD i
prospectively RB N
evaluated VBN N
before IN i
chemotherapeutic JJ i
treatment NN i
as RB i
well RB i
as IN N
four CD N
weeks NNS N
after IN N
chemotherapy NN i
and CC i
two CD N
years NNS N
after IN N
chemotherapy NN i
for IN i
the DT N
serological JJ N
expression NN N
of IN N
inhibin NN N
A NNP N
. . N

For IN N
statistical JJ N
analysis NN o
the DT o
Wilcoxon NNP o
rank NN o
sum NN o
test NN o
was VBD N
used VBN N
for IN N
paired JJ N
samples NNS N
. . N

Statistical JJ N
significance NN N
was VBD N
assumed VBN N
at IN N
p NN N
< $ N
0.05 CD N
. . N

RESULTS VB o
The DT o
concentration NN o
of IN o
inhibin NN o
A NNP o
showed VBD o
a DT N
significant JJ N
decrease NN N
between IN N
data NNS N
obtained VBN N
before IN i
chemotherapy NN i
and CC i
after IN N
chemotherapy NN i
( ( i
p JJ i
< NNP i
0.005 CD i
) ) N
and CC N
two-year JJ N
follow-up NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

Interestingly RB N
, , N
there EX N
were VBD N
no DT N
differences NNS o
in IN o
inhibin NN o
A NNP o
concentrations NNS o
between IN o
the DT N
four-week JJ N
and CC N
two-year JJ N
follow-up NN N
( ( N
p=0.744 NN N
) ) N
. . N

DISCUSSION NNP i
Chemotherapy NNP i
significantly RB i
decreases VBZ N
inhibin VB N
A DT N
concentration NN N
during IN N
chemotherapy NN N
. . N

This DT N
might MD N
reflect VB N
a DT N
suppression NN N
of IN N
ovarian JJ N
function NN N
, , N
being VBG N
also RB N
a DT N
marker NN N
for IN N
chemotherapy-induced JJ N
amenorrhoea NN N
. . N

Moreover RB N
, , N
it PRP N
has VBZ N
been VBN N
suggested VBN N
that IN N
inhibin VBZ N
A DT N
might MD N
be VB N
a DT N
tumour JJ N
marker NN N
for IN N
breast NN N
cancer NN N
, , N
and CC N
therefore RB N
a DT N
sudden JJ N
increase NN N
in IN N
its PRP$ N
concentration NN N
might MD N
be VB N
indicative JJ N
of IN N
breast NN N
cancer NN N
recurrence NN N
. . N

-DOCSTART- -2188165- O O

[ NNS i
Sublingually RB i
administered VBN i
captopril NN i
versus NN i
nifedipine NN i
in IN N
hypertension NN p
emergencies NNS p
] VBP p
. . N

Aim NNP N
of IN N
the DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
effectiveness NN o
and CC o
tolerability NN o
of IN N
sublingual JJ i
captopril NN i
( ( i
SLC NNP i
) ) i
versus VBP N
sublingual JJ i
nifedipine NN i
( ( i
SLN NNP i
) ) i
in IN N
treating VBG N
hypertensive JJ p
emergencies NNS p
. . p

During IN p
hypertensive JJ p
crises NNS p
( ( p
systolic JJ p
blood NN p
pressure NN p
exceeding VBG p
200 CD p
mmHg NN p
and CC p
diastolic JJ p
blood NN p
pressure NN p
exceeding VBG p
115 CD p
mmHg NN p
) ) p
forty NN p
hypertensive JJ p
patients NNS p
received VBD N
either RB N
25 CD N
mg NN N
of IN N
SLC NNP N
or CC N
10 CD N
mg NN N
of IN N
SLN NNP i
in IN N
a DT N
randomized JJ N
single JJ N
blind NN N
fashion NN N
. . N

Blood NNP o
pressure NN o
and CC o
heart NN o
rate NN o
were VBD N
then RB N
controlled VBN N
after IN N
5 CD N
, , N
10 CD N
, , N
15 CD N
, , N
20 CD N
, , N
30 CD N
, , N
45 CD N
, , N
60 CD N
, , N
120 CD N
min NN N
. . N

and CC N
, , N
in IN N
18 CD N
cases NNS N
, , N
up RB N
to TO N
the DT N
8th CD N
hour NN N
from IN N
the DT N
administration NN N
. . N

Our PRP$ N
results NNS N
showed VBD N
: : N
1 CD N
) ) N
a DT N
satisfactory JJ N
control NN o
of IN o
the DT o
hypertensive JJ o
crises NNS o
in IN N
80 CD N
% NN N
of IN N
patients NNS N
treated VBN N
with IN N
SLC NNP i
with IN N
a DT N
significant JJ N
blood NN o
pressure NN o
reduction NN N
after IN N
10 CD N
min NN N
. . N

( ( N
13/8 CD N
mmHg NN N
, , N
p NN N
less JJR N
than IN N
0.02 CD N
) ) N
, , N
while IN N
the DT N
maximum JJ N
hypotensive JJ o
effect NN o
was VBD N
achieved VBN N
after IN N
30 CD N
min NN N
. . N

( ( N
52/36 CD N
mmHg NN N
, , N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
; : N
SLN NNP i
was VBD N
able JJ N
to TO N
reduce VB N
blood NN o
pressure NN o
in IN N
90 CD N
% NN N
of IN N
all PDT N
the DT N
cases NNS N
, , N
with IN N
a DT N
significant JJ N
reduction NN N
after IN N
5 CD N
min NN N
. . N

( ( N
15/11 CD N
mmHg NN N
, , N
p NN N
less JJR N
than IN N
0.02 CD N
) ) N
and CC N
hypotensive JJ o
peak NN o
after IN N
20 CD N
min NN N
( ( N
57/38 CD N
mmHg NN N
, , N
p NN N
greater JJR N
than IN N
0.001 CD N
) ) N
; : N
2 CD N
) ) N
no DT N
significant JJ N
differences NNS N
for IN N
hypotensive JJ o
effectiveness NN o
between IN N
the DT N
two CD N
groups NNS N
, , N
but CC N
with IN N
SLC NNP i
having VBG N
a DT N
mildly RB N
delayed JJ N
onset NN o
of IN o
action NN o
when WRB N
compared VBN N
to TO N
SLN NNP i
; : i
3 CD N
) ) N
antihypertensive JJ o
effect NN o
lasting VBG N
for IN N
about IN N
6 CD N
hours NNS N
in IN N
patients NNS N
treated VBN N
with IN N
SLC NNP i
and CC N
blood NN o
pressure NN o
progressively RB N
raising VBG N
after IN N
4 CD N
hours NNS N
in IN N
patients NNS N
who WP N
received VBD N
SLN NNP i
; : i
4 CD N
) ) N
a DT N
significant JJ N
correlation NN N
between IN N
blood NN o
pressure NN o
reduction NN N
and CC N
blood NN o
pressure NN o
before IN N
drug NN N
administration NN N
in IN N
both DT N
groups NNS N
; : N
a DT N
significant JJ N
correlation NN N
between IN N
pretreatment NN N
PRA NNP N
and CC N
antihypertensive JJ N
effect NN N
in IN N
the DT N
SLC NNP i
group NN N
. . N

We PRP N
conclude VBP N
that IN N
both DT N
drugs NNS N
are VBP N
effective JJ N
and CC N
useful JJ N
in IN N
treating VBG o
hypertensive JJ o
emergencies NNS o
. . p

Anyway RB N
we PRP N
think VBP N
that IN N
in IN N
severe JJ N
forms NNS N
SLN NNP i
should MD N
be VB N
preferred VBN N
for IN N
the DT N
shorter JJR N
time NN N
preceding VBG N
onset NN o
of IN o
action NN o
. . o

-DOCSTART- -5573167- O O

Response JJ o
latencies NNS o
to TO o
auditory VB o
stimuli NNS o
in IN N
autistic JJ p
children NNS p
engaged VBN p
in IN p
self-stimulatory JJ p
behavior NN p
. . p

-DOCSTART- -2420348- O O

Hypotension NN o
in IN N
response NN N
to TO N
iloprost VB i
, , N
a DT N
prostacyclin NN N
analogue NN N
. . N

-DOCSTART- -24089423- O O

Group NNP i
cognitive JJ i
behavioural JJ i
therapy NN i
and CC i
group NN i
recreational JJ i
activity NN i
for IN N
adults NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
: : p
a DT N
preliminary JJ N
randomized NN N
controlled VBD N
trial NN N
. . N

Although IN N
adults NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
are VBP N
an DT N
increasingly RB N
identified VBN N
patient JJ N
population NN N
, , N
few JJ N
treatment NN N
options NNS N
are VBP N
available JJ N
. . N

This DT N
preliminary JJ N
randomized NN N
controlled VBD N
open JJ N
trial NN N
with IN N
a DT N
parallel JJ N
design NN N
developed VBD N
two CD N
group NN N
interventions NNS N
for IN N
adults NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
and CC p
intelligence NN p
within IN p
the DT p
normal JJ p
range NN p
: : p
cognitive JJ i
behavioural JJ i
therapy NN i
and CC i
recreational JJ i
activity NN i
. . i

Both DT N
interventions NNS N
comprised VBD N
36 CD N
weekly JJ N
3-h JJ N
sessions NNS N
led VBN N
by IN N
two CD N
therapists NNS N
in IN N
groups NNS p
of IN p
6-8 JJ p
patients NNS p
. . p

A DT N
total NN N
of IN N
68 CD p
psychiatric JJ p
patients NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
participated VBD N
in IN N
the DT N
study NN N
. . N

Outcome NNP N
measures NNS N
were VBD N
Quality NNP o
of IN o
Life NNP o
Inventory NNP o
, , o
Sense NNP o
of IN o
Coherence NNP o
Scale NNP o
, , o
Rosenberg NNP o
Self-Esteem NNP o
Scale NNP o
and CC o
an DT o
exploratory JJ o
analysis NN o
on IN o
measures NNS o
of IN o
psychiatric JJ o
health NN o
. . o

Participants NNS N
in IN N
both DT N
treatment NN N
conditions NNS N
reported VBD N
an DT N
increased JJ N
quality NN o
of IN o
life NN o
at IN N
post-treatment JJ N
( ( N
d JJ N
= NN N
0.39 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
with IN N
no DT N
difference NN N
between IN N
interventions NNS N
. . N

No DT N
amelioration NN N
of IN N
psychiatric JJ o
symptoms NNS o
was VBD N
observed VBN N
. . N

The DT N
dropout NN o
rate NN o
was VBD N
lower JJR N
with IN N
cognitive JJ i
behavioural JJ i
therapy NN i
than IN N
with IN N
recreational JJ N
activity NN N
, , N
and CC N
participants NNS N
in IN N
cognitive JJ i
behavioural JJ i
therapy NN i
rated VBN N
themselves PRP N
as IN N
more RBR N
generally RB N
improved VBN N
, , N
as RB N
well RB N
as IN N
more JJR N
improved JJ N
regarding VBG N
expression NN N
of IN N
needs NNS N
and CC N
understanding NN N
of IN N
difficulties NNS N
. . N

Both DT N
interventions NNS N
appear VBP N
to TO N
be VB N
promising JJ N
treatment NN N
options NNS N
for IN N
adults NNS N
with IN N
autism NN N
spectrum NN N
disorder NN N
. . N

The DT N
interventions NNS N
' POS N
similar JJ N
efficacy NN o
may MD N
be VB N
due JJ N
to TO N
the DT N
common JJ N
elements NNS N
, , N
structure NN N
and CC N
group NN N
setting NN N
. . N

Cognitive JJ i
behavioural JJ i
therapy NN i
may MD N
be VB N
additionally RB N
beneficial JJ N
in IN N
terms NNS N
of IN N
increasing VBG N
specific JJ N
skills NNS N
and CC N
minimizing VBG N
dropout NN N
. . N

-DOCSTART- -12270325- O O

Effect NN N
of IN N
mycophenolate NN i
mofetil NN i
on IN N
the DT N
prevention NN o
of IN o
acute JJ o
renal JJ o
allograft NN o
rejection NN o
. . o

-DOCSTART- -15223814- O O

Intravenously RB i
administered VBN i
histamine NN i
increases NNS p
choroidal VBP p
but CC p
not RB p
retinal JJ p
blood NN p
flow NN p
. . p

PURPOSE NNP N
To TO N
determine VB N
the DT N
effect NN N
of IN N
intravenously RB i
administered VBN i
histamine NN i
on IN N
both DT N
retinal JJ N
and CC N
choroidal JJ N
blood NN N
flow NN N
in IN N
humans NNS p
. . p

METHODS NNP N
A NNP N
randomized JJ N
, , N
double-masked JJ N
, , N
two-way JJ N
crossover NN N
study NN N
was VBD N
performed VBN N
in IN N
14 CD p
healthy JJ p
volunteers NNS p
. . p

Placebo NNP i
or CC i
histamine NN i
was VBD N
administered VBN N
intravenously RB N
in IN N
stepwise NN N
increasing VBG N
doses NNS N
( ( N
0.08 CD N
microg/kg/min NN N
, , N
0.16 CD N
microg/kg/min NN N
, , N
and CC N
0.32 CD N
microg/kg/min NN N
) ) N
. . N

Retinal JJ o
vessel NN o
diameters NNS o
were VBD N
measured VBN N
with IN N
a DT N
retinal JJ N
vessel NN N
analyzer NN N
, , N
and CC N
retinal JJ o
venous JJ o
blood NN o
speed NN o
was VBD N
assessed VBN N
by IN N
bi-directional JJ N
laser NN N
Doppler NNP N
velocimetry NN N
. . N

Using VBG N
these DT N
parameters NNS N
retinal VBP o
blood NN o
flow NN o
was VBD N
calculated VBN N
. . N

Subfoveal NNP N
and CC N
pulsatile JJ N
choroidal NN o
blood NN o
flow NN N
were VBD N
measured VBN N
with IN N
laser NN N
Doppler NNP N
flowmetry NN N
and CC N
laser NN N
interferometry NN N
, , N
respectively RB N
. . N

RESULTS NNP N
After IN N
infusion NN N
of IN N
histamine NN i
pulsatile NN o
choroidal NN o
blood NN o
flow NN o
increased VBN N
by IN N
5 CD N
+/- JJ N
3 CD N
% NN N
, , N
9 CD N
+/- JJ N
8 CD N
% NN N
, , N
and CC N
14 CD N
+/- JJ N
7 CD N
% NN N
( ( N
P NNP N
= NNP N
0.001 CD N
, , N
ANOVA NNP N
) ) N
and CC N
subfoveolar JJ o
choroidal NN o
blood NN o
flow NN o
by IN N
8 CD N
+/- JJ N
11 CD N
% NN N
, , N
13 CD N
+/- JJ N
11 CD N
% NN N
, , N
and CC N
13 CD N
+/- JJ N
12 CD N
% NN N
( ( N
P NNP N
= NNP N
0.003 CD N
, , N
ANOVA NNP N
) ) N
. . N

Retinal JJ o
arterial JJ o
and CC o
venous JJ o
vessel NN o
diameter RBR o
significantly RB o
increased VBN o
by IN N
3 CD N
+/- JJ N
4 CD N
% NN N
, , N
2 CD N
+/- JJ N
4 CD N
% NN N
, , N
and CC N
3 CD N
+/- JJ N
5 CD N
% NN N
( ( N
P NNP N
= NNP N
0.047 CD N
, , N
ANOVA NNP N
) ) N
and CC N
1 CD N
+/- JJ N
2 CD N
% NN N
, , N
3 CD N
+/- JJ N
2 CD N
% NN N
, , N
and CC N
3 CD N
+/- JJ N
2 CD N
% NN N
( ( N
P NNP N
= NNP N
0.015 CD N
, , N
ANOVA NNP N
) ) N
, , N
respectively RB N
. . N

Red JJ o
blood NN o
cell NN o
velocity NN o
in IN o
major JJ o
retinal JJ o
veins NNS o
tended VBD N
to TO N
decrease VB N
by IN N
-9 JJ N
+/- JJ N
12 CD N
% NN N
, , N
-9 JJ N
+/- JJ N
20 CD N
% NN N
, , N
and CC N
-13 VBD N
+/- JJ N
12 CD N
% NN N
, , N
but CC N
this DT N
effect NN N
did VBD N
not RB N
reach VB N
levels NNS N
of IN N
significance NN N
. . N

Calculated VBN o
retinal JJ o
blood NN o
flow NN o
was VBD N
not RB N
changed VBN N
by IN N
administration NN i
of IN i
histamine NN i
( ( N
-7 JJ N
+/- JJ N
14 CD N
% NN N
, , N
-4 JJ N
+/- JJ N
20 CD N
% NN N
, , N
and CC N
-8 VBD N
+/- JJ N
12 CD N
% NN N
, , N
P NNP N
= NNP N
0.28 CD N
, , N
ANOVA NNP N
) ) N
. . N

CONCLUSIONS NNP N
Intravenous NNP i
histamine NN i
in IN N
the DT N
selected JJ N
doses NNS N
increased VBD N
choroidal JJ o
blood NN o
flow NN o
. . o

Retinal JJ N
vessels NNS N
showed VBD N
a DT N
small JJ o
diameter NN o
increase NN o
, , N
whereas RB N
red JJ o
blood NN o
cell NN o
speed NN o
decreased VBN N
, , N
resulting VBG N
in IN N
an DT N
unchanged JJ N
total JJ o
retinal JJ o
blood NN o
flow NN o
. . o

This DT N
may MD N
result VB N
from IN N
local JJ N
differences NNS N
in IN N
the DT N
receptor NN N
distribution NN N
in IN N
the DT N
posterior JJ N
part NN N
of IN N
the DT N
eye NN N
. . N

-DOCSTART- -1670445- O O

Thromboprophylaxis VBN N
by IN N
low-molecular-weight JJ i
heparin NN i
in IN N
elective JJ p
hip NN p
surgery NN p
. . p

A DT N
placebo NN i
controlled VBN N
study NN N
. . N

In IN N
a DT N
double-blind NN N
, , N
randomised VBD N
study NN N
of IN N
thromboprophylaxis NN N
in IN N
patients NNS p
undergoing JJ p
total JJ p
hip NN p
replacement NN p
, , N
we PRP N
compared VBN N
a DT N
low-molecular-weight JJ i
heparin NN i
with IN i
a DT i
placebo NN i
. . i

Of IN N
the DT N
120 CD p
patients NNS p
enrolled VBD p
, , p
112 CD p
completed VBD p
the DT N
trial NN N
; : N
58 CD N
in IN N
the DT N
treatment NN N
group NN N
and CC N
54 CD N
in IN N
the DT N
placebo NN N
group NN N
. . N

Nine NNP N
( ( N
16 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
treatment NN N
group NN N
and CC N
19 CD N
( ( N
35 CD N
% NN N
) ) N
in IN N
the DT N
placebo NN i
group NN N
developed VBD N
deep RB o
venous JJ o
thrombosis NN o
, , N
diagnosed VBN N
by IN N
the DT N
125I-fibrinogen JJ N
uptake JJ N
test NN N
( ( N
p JJ N
< NNP N
0.02 CD N
) ) N
. . N

Verification NN N
was VBD N
obtained VBN N
by IN N
phlebography NN N
in IN N
86 CD N
% NN N
of IN N
the DT N
patients NNS N
. . N

Prolonged JJ N
surgery NN N
increased VBD N
the DT N
risk NN o
of IN o
thrombosis NN o
in IN N
the DT N
placebo NN N
group NN N
but CC N
not RB N
in IN N
the DT N
treatment NN N
group NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
were VBD N
significantly RB N
more JJR N
cases NNS o
of IN o
deep JJ o
venous JJ o
thrombosis NN o
in IN N
the DT N
placebo NN N
group NN N
during IN N
the DT N
first JJ N
four CD N
postoperative JJ N
days NNS N
( ( N
p JJ N
< NNP N
0.02 CD N
) ) N
. . N

The DT N
groups NNS N
did VBD N
not RB N
differ VB N
with IN N
respect NN N
to TO N
peroperative VB o
and CC o
postoperative JJ o
bleeding NN o
. . o

Low-molecular-weight JJ i
heparin NN i
offers NNS N
safe JJ N
and CC N
easily RB N
administered VBN N
thromboprophylaxis NN N
in IN N
total JJ N
hip NN N
replacement NN N
. . N

-DOCSTART- -18431444- O O

A DT N
simplified JJ N
4-site JJ N
economical JJ N
intradermal JJ N
post-exposure NN N
rabies NNS i
vaccine VBP i
regimen NNS p
: : p
a DT N
randomised JJ N
controlled VBN N
comparison NN N
with IN N
standard JJ N
methods NNS N
. . N

BACKGROUND IN N
The DT N
need NN N
for IN N
economical JJ N
rabies NNS p
post-exposure JJ p
prophylaxis NN p
( ( p
PEP NNP p
) ) p
is VBZ N
increasing VBG N
in IN N
developing VBG N
countries NNS N
. . N

Implementation NN N
of IN N
the DT N
two CD N
currently RB N
approved VBN N
economical JJ N
intradermal NN N
( ( N
ID NNP N
) ) N
vaccine NN N
regimens VBZ N
is VBZ N
restricted VBN N
due JJ N
to TO N
confusion NN N
over IN N
different JJ N
vaccines NNS N
, , N
regimens NNS N
and CC N
dosages NNS N
, , N
lack NN N
of IN N
confidence NN N
in IN N
intradermal JJ N
technique NN N
, , N
and CC N
pharmaceutical JJ N
regulations NNS N
. . N

We PRP N
therefore RB N
compared VBN N
a DT N
simplified JJ N
4-site JJ N
economical JJ N
PEP NNP N
regimen NNS N
with IN N
standard JJ N
methods NNS N
. . N

METHODS NNP N
Two CD p
hundred VBD p
and CC p
fifty-four JJ p
volunteers NNS p
were VBD p
randomly RB p
allocated VBN p
to TO N
a DT N
single JJ N
blind NN N
controlled VBD N
trial NN N
. . N

Each DT N
received VBD N
purified JJ i
vero NN i
cell NN i
rabies NNS i
vaccine VBP i
by IN N
one CD N
of IN N
four CD N
PEP NNP N
regimens NNS N
: : N
the DT N
currently RB N
accepted VBN N
2-site JJ N
ID NNP N
; : N
the DT N
8-site JJ N
regimen NNS N
using VBG N
0.05 CD N
ml JJ N
per IN N
ID NNP N
site NN N
; : N
a DT N
new JJ N
4-site JJ N
ID NNP N
regimen NNS N
( ( N
on IN N
day NN N
0 CD N
, , N
approximately RB N
0.1 CD N
ml NNS N
at IN N
4 CD N
ID NNP N
sites NNS N
, , N
using VBG N
the DT N
whole JJ N
0.5 CD N
ml JJ N
ampoule NN N
of IN N
vaccine NN N
; : N
on IN N
day NN N
7 CD N
, , N
0.1 CD N
ml NN N
ID NNP N
at IN N
2 CD N
sites NNS N
and CC N
at IN N
one CD N
site NN N
on IN N
days NNS N
28 CD N
and CC N
90 CD N
) ) N
; : N
or CC N
the DT N
standard JJ i
5-dose JJ i
intramuscular JJ N
regimen NNS N
. . N

All DT N
ID NNP N
regimens NNS N
required VBD N
the DT N
same JJ N
total JJ N
amount NN N
of IN N
vaccine NN N
, , N
60 CD N
% NN N
less JJR N
than IN N
the DT N
intramuscular JJ N
method NN N
. . N

Neutralising VBG N
antibody NN N
responses NNS N
were VBD N
measured VBN N
five CD N
times NNS N
over IN N
a DT N
year NN N
in IN N
229 CD N
people NNS N
, , N
for IN N
whom WP N
complete JJ N
data NNS N
were VBD N
available JJ N
. . N

FINDINGS NNP N
All NNP N
ID NNP N
regimens VBZ N
showed VBD N
similar JJ N
immunogenicity NN o
. . o

The DT N
intramuscular JJ N
regimen NNS N
gave VBD N
the DT N
lowest JJS N
geometric JJ o
mean NN o
antibody NN o
titres NNS o
. . o

Using VBG N
the DT N
rapid JJ N
fluorescent JJ N
focus NN N
inhibition NN N
test NN N
, , N
some DT N
sera NN N
had VBD N
unexpectedly RB N
high JJ o
antibody NN o
levels NNS o
that WDT N
were VBD N
not RB N
attributable JJ N
to TO N
previous JJ N
vaccination NN N
. . N

The DT N
results NNS N
were VBD N
confirmed VBN N
using VBG N
the DT N
fluorescent NN N
antibody NN N
virus JJ N
neutralisation NN N
method NN N
. . N

CONCLUSIONS VB N
This DT N
4-site JJ N
PEP NNP N
regimen NNS N
proved VBD N
as RB N
immunogenic JJ o
as IN N
current JJ N
regimens NNS N
, , N
and CC N
has VBZ N
the DT N
advantages NNS N
of IN N
requiring VBG N
fewer JJR N
clinic JJ N
visits NNS N
, , N
being VBG N
more RBR N
practicable JJ N
, , N
and CC N
having VBG N
a DT N
wider JJR N
margin NN N
of IN N
safety NN N
, , N
especially RB N
in IN N
inexperienced JJ N
hands NNS N
, , N
than IN N
the DT N
2-site JJ N
regimen NNS N
. . N

It PRP N
is VBZ N
more RBR N
convenient JJ N
than IN N
the DT N
8-site JJ N
method NN N
, , N
and CC N
can MD N
be VB N
used VBN N
economically RB N
with IN N
vaccines NNS N
formulated VBN N
in IN N
1.0 CD N
or CC N
0.5 CD N
ml NN N
ampoules NNS N
. . N

The DT N
4-site JJ N
regimen NNS N
now RB N
meets VBZ N
all DT N
requirements NNS N
of IN N
immunogenicity NN o
for IN o
PEP NNP o
and CC N
can MD N
be VB N
introduced VBN N
without IN N
further JJ N
studies NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
Controlled-Trials.com NNP N
ISRCTN NNP N
30087513 CD N
. . N

-DOCSTART- -24272416- O O

A DT N
randomized JJ N
trial NN N
comparison NN N
of IN N
the DT N
effects NNS N
of IN N
verbal JJ i
and CC i
pictorial JJ i
naturalistic JJ i
communication NN i
strategies NNS i
on IN N
spoken JJ N
language NN N
for IN N
young JJ p
children NNS p
with IN p
autism NN p
. . p

Presently RB N
there EX N
is VBZ N
no DT N
consensus NN N
on IN N
the DT N
specific JJ N
behavioral JJ N
treatment NN N
of IN N
choice NN N
for IN N
targeting VBG N
language NN N
in IN N
young JJ p
nonverbal JJ p
children NNS p
with IN p
autism NN p
. . p

This DT N
randomized JJ N
clinical JJ N
trial NN N
compared VBN N
the DT N
effectiveness NN N
of IN N
a DT i
verbally-based JJ i
intervention NN i
, , i
Pivotal NNP i
Response NNP i
Training NNP i
( ( i
PRT NNP i
) ) i
to TO i
a DT i
pictorially-based JJ i
behavioral JJ i
intervention NN i
, , i
the DT i
Picture NNP i
Exchange NNP i
Communication NNP i
System NNP i
( ( i
PECS NNP i
) ) i
on IN i
the DT i
acquisition NN i
of IN i
spoken JJ i
language NN i
by IN N
young JJ p
( ( p
2-4 JJ p
years NNS p
) ) p
, , p
nonverbal JJ p
or CC p
minimally RB p
verbal JJ p
( ( p
?9 JJ p
words NNS p
) ) p
children NNS p
with IN p
autism NN p
. . p

Thirty-nine JJ p
children NNS p
were VBD p
randomly RB N
assigned VBN N
to TO N
either CC N
the DT N
PRT NNP i
or CC i
PECS NNP i
condition NN i
. . N

Participants NNS N
received VBD N
on IN N
average JJ N
247 CD N
h NN N
of IN N
intervention NN N
across IN N
23 CD N
weeks NNS N
. . N

Dependent JJ N
measures NNS N
included VBD o
overall JJ o
communication NN o
, , o
expressive JJ o
vocabulary NN o
, , o
pictorial JJ o
communication NN o
and CC o
parent NN o
satisfaction NN o
. . o

Children NNP o
in IN N
both DT N
intervention NN N
groups NNS N
demonstrated VBD N
increases NNS o
in IN o
spoken JJ o
language NN o
skills NNS o
, , o
with IN o
no DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
conditions NNS N
. . N

Seventy-eight JJ N
percent NN N
of IN N
all DT N
children NNS N
exited VBD N
the DT N
program NN N
with IN N
more JJR N
than IN N
10 CD o
functional JJ o
words NNS o
. . o

Parents NNS o
were VBD N
very RB N
satisfied JJ N
with IN N
both DT N
programs NNS N
but CC N
indicated VBD i
PECS NNP i
was VBD N
more RBR N
difficult JJ N
to TO N
implement VB N
. . N

-DOCSTART- -15466792- O O

In-hospital JJ o
costs NNS o
of IN N
self-expanding JJ i
nitinol JJ i
stent NN i
implantation NN i
versus NN N
balloon NN i
angioplasty NN i
in IN N
the DT N
femoropopliteal JJ N
artery NN N
( ( N
the DT N
VascuCoil NNP N
Trial NNP N
) ) N
. . N

PURPOSE NNP N
Although IN N
several JJ N
prospective JJ N
studies NNS N
have VBP N
examined VBN N
the DT N
safety NN o
and CC N
efficacy NN o
of IN N
stent JJ i
placement NN i
for IN N
femoropopliteal JJ p
arterial JJ p
disease NN p
, , N
the DT N
current JJ N
cost NN N
of IN N
these DT N
procedures NNS N
is VBZ N
unknown JJ N
. . N

To TO N
estimate VB N
and CC N
compare VB N
hospital NN o
costs NNS o
associated VBN N
with IN N
conventional JJ i
balloon NN i
angioplasty NN i
( ( i
percutaneous JJ i
transluminal NN i
angioplasty NN i
[ NNP i
PTA NNP i
] NNP i
) ) i
and CC i
stent JJ i
placement NN i
for IN N
patients NNS N
with IN N
symptomatic JJ N
peripheral JJ N
arterial JJ N
disease NN N
, , N
the DT N
authors NNS N
performed VBD N
a DT N
prospective JJ N
economic JJ N
evaluation NN N
in IN N
conjunction NN N
with IN N
the DT N
Intracoil NNP N
Femoropopliteal NNP N
Stent NNP N
Trial NNP N
( ( N
VascuCoil NNP N
) ) N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Between NNP N
May NNP N
1997 CD N
and CC N
December NNP N
1999 CD N
, , N
266 CD p
patients NNS p
with IN p
stenotic JJ p
or CC p
occluded VBN p
superficial JJ p
femoral JJ p
or CC p
popliteal JJ p
arteries NNS p
were VBD N
prospectively RB N
randomized VBN N
to TO N
treatment NN N
with IN N
the DT N
IntraCoil NNP i
stent NN i
or CC N
PTA NNP i
. . i

Detailed NNP N
resource NN o
use NN o
and CC N
cost NN o
data NNS o
for IN N
each DT N
patient NN N
's POS N
initial JJ N
revascularization NN N
procedure NN N
and CC N
ensuing VBG N
hospitalization NN N
were VBD N
collected VBN N
and CC N
analyzed VBN N
on IN N
an DT N
intention-to-treat JJ N
basis NN N
. . N

RESULTS NNP N
Compared VBD N
with IN N
conventional JJ i
balloon NN i
angioplasty NN i
, , i
stent JJ i
placement NN i
did VBD N
not RB N
improve VB N
clinical JJ o
outcomes NNS o
but CC N
increased JJ N
procedure NN o
duration NN o
, , o
equipment NN o
costs NNS o
, , o
and CC o
physician JJ o
services NNS o
. . o

As IN N
a DT N
result NN N
, , N
initial JJ o
hospital NN o
costs NNS o
were VBD N
approximately RB N
3,500 CD N
dollars NNS N
higher JJR N
for IN N
patients NNS N
randomized VBN N
to TO N
the DT N
IntraCoil NNP i
stent NN i
, , N
compared VBN N
with IN N
PTA NNP i
( ( N
8,435 CD N
dollars NNS N
vs RB N
4,980 CD N
dollars NNS N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

CONCLUSIONS NNP N
As IN N
performed VBN N
in IN N
the DT N
VascuCoil NNP N
trial NN N
, , N
primary JJ N
stent NN N
placement NN N
for IN N
femoropopliteal JJ N
disease NN N
did VBD N
not RB N
improve VB N
clinical JJ o
outcomes NNS o
but CC N
increased VBD N
initial JJ o
treatment NN o
costs NNS o
by IN N
more JJR N
than IN N
3,000 CD N
dollars NNS N
. . N

Because IN N
there EX N
were VBD N
no DT N
substantial JJ N
differences NNS N
in IN N
subsequent JJ N
clinical JJ o
outcomes NNS o
between IN N
the DT N
two CD N
treatments NNS N
, , N
it PRP N
is VBZ N
unlikely JJ N
that IN N
these DT N
increased VBN N
initial JJ o
costs NNS o
would MD N
be VB N
offset VBN N
by IN N
savings NNS N
in IN N
follow-up JJ o
costs NNS o
. . o

These DT N
findings NNS N
suggest VBP N
that IN N
a DT N
strategy NN N
of IN N
routine JJ N
stent NN i
implantation NN N
for IN N
patients NNS p
undergoing VBG p
femoropopliteal JJ p
PTA NNP i
is VBZ N
not RB N
optimal JJ N
on IN N
economic JJ N
grounds NNS N
and CC N
that DT N
PTA NNP i
with IN N
provisional JJ i
stent JJ i
implantation NN i
is VBZ N
preferred VBN N
. . N

-DOCSTART- -7936677- O O

Management NN p
of IN p
the DT p
thyroid JJ p
isthmus NN p
in IN p
tracheostomy NN i
: : i
a DT p
prospective JJ p
and CC p
retrospective JJ p
study NN p
. . p

The DT N
thyroid JJ N
isthmus NN N
is VBZ N
often RB N
encountered VBN N
while IN N
a DT N
tracheostomy NN i
is VBZ N
being VBG N
performed VBN N
. . N

This DT N
study NN N
details NNS N
retrospective JJ N
and CC N
prospective JJ N
comparison NN N
of IN N
electrocautery JJ i
division NN i
of IN i
the DT i
isthmus NN i
with IN N
older JJR N
techniques NNS N
. . N

In IN N
this DT N
study NN N
, , N
electrocautery DT i
division NN i
of IN i
the DT i
thyroid JJ o
isthmus NN o
during IN N
tracheostomy NN N
is VBZ N
faster RBR o
and CC o
as RB o
safe JJ o
as IN N
other JJ N
techniques NNS N
with IN N
respect NN N
to TO N
blood NN o
loss NN o
, , o
perioperative JJ o
complications NNS o
, , o
and CC o
airway RB o
outcome NN o
. . o

-DOCSTART- -17089419- O O

Predictors NNS N
of IN N
mental JJ N
health NN N
problems NNS N
and CC N
negative JJ N
caregiving NN N
experiences NNS N
in IN N
carers NNS p
of IN p
adolescents NNS p
with IN p
bulimia NN p
nervosa NN p
. . p

OBJECTIVE CC N
This DT N
exploratory NN N
study NN N
focuses VBZ N
on IN N
the DT N
mental JJ i
health NN i
( ( i
MH NNP i
) ) i
and CC i
caregiving VBG i
experience NN i
of IN i
carers NNS i
of IN i
adolescents NNS i
with IN p
Bulimia NNP p
Nervosa NNP p
( ( p
BN NNP p
) ) p
/Eating VBG p
Disorder NNP p
not RB p
otherwise RB p
specified VBN p
( ( p
EDNOS NNP p
) ) p
, , N
aiming VBG N
to TO N
determine VB N
: : N
levels NNS N
of IN N
MH NNP N
problems NNS N
in IN N
carers NNS N
and CC N
if IN N
a DT N
negative JJ N
experience NN N
of IN N
caregiving VBG N
predicts NNS N
carer VBP N
MH NNP N
status NN N
and CC N
which WDT N
factors NNS N
predict VBP N
a DT N
negative JJ N
experience NN N
of IN N
caregiving VBG N
. . N

METHOD NNP N
Hundred NNP p
and CC p
twelve VB p
carers NNS p
and CC p
68 CD p
adolescents NNS p
with IN p
BN/EDNOS NNP p
completed VBD p
self-report JJ i
measures NNS i
( ( i
General NNP i
Health NNP i
Questionnaire NNP i
, , i
Experience NNP i
of IN i
Caregiving NNP i
Inventory NNP i
, , i
Level NNP i
of IN i
Expressed JJ i
Emotion NNP i
, , i
Self-report NNP i
Family NNP i
Inventory NNP i
, , i
Inventory NNP i
of IN i
Interpersonal NNP i
Problems NNP i
) ) i
. . i

RESULTS NNP N
Over IN N
half NN N
of IN N
the DT N
carers NNS N
reported VBD N
some DT N
MH NNP o
problems NNS o
and CC N
a DT N
minority NN N
( ( N
5.4 CD N
% NN N
) ) N
were VBD N
experiencing VBG N
considerable JJ N
difficulties NNS N
. . N

A DT o
negative JJ o
experience NN o
of IN o
caregiving VBG o
predicted VBN N
carer NN N
MH NNP N
status NN N
. . N

Higher JJR o
weekly JJ o
contact NN o
hours NNS o
and CC o
patient JJ o
ratings NNS o
of IN o
expressed VBN o
emotion NN o
( ( o
EE NNP o
) ) o
predicted VBD N
a DT N
negative JJ N
experience NN N
of IN N
caregiving VBG N
. . N

CONCLUSIONS NNP N
Interventions NNPS i
focusing VBG i
on IN i
reducing VBG i
EE NNP o
and CC i
contact NN o
hours NNS o
could MD N
prove VB N
beneficial JJ N
for IN N
both DT N
patient NN p
and CC N
caregiver NN p
outcomes NNS N
. . N

-DOCSTART- -7873425- O O

Randomized VBN N
, , N
prospective JJ N
comparison NN N
of IN N
halothane NN i
, , i
isoflurane NN i
, , i
and CC i
enflurane NN i
on IN N
baroreflex JJ p
control NN o
of IN o
heart NN o
rate NN o
in IN o
humans NNS o
. . o

-DOCSTART- -16379508- O O

Risperidone-induced JJ N
prolactin NN o
elevation NN o
in IN N
a DT N
prospective JJ N
study NN N
of IN N
children NNS p
, , p
adolescents NNS p
, , p
and CC p
adults NNS p
with IN p
mental JJ p
retardation NN p
and CC p
pervasive JJ p
developmental NN p
disorders NNS p
. . p

OBJECTIVE NNP N
Risperidone NNP N
is VBZ N
widely RB N
prescribed VBN N
for IN N
aggression NN N
and CC N
self-injury NN N
in IN N
children NNS p
, , p
adolescents NNS p
, , p
and CC p
adults NNS p
with IN p
mental JJ p
retardation NN p
( ( p
MR NNP p
) ) p
and CC p
pervasive JJ p
developmental NN p
disorders NNS p
( ( p
PDD NNP p
) ) p
. . p

Risperidone NNP N
elevates VBZ N
prolactin RB o
more JJR N
than IN N
other JJ N
atypical JJ N
antipsychotic JJ N
medications NNS N
. . N

Females NNS N
may MD N
show VB N
greater JJR N
prolactin NN o
elevation NN o
than IN N
males NNS N
. . N

METHOD NNP N
In IN N
this DT N
relatively RB N
long-term JJ N
study NN N
of IN N
risperidone NN i
efficacy NN o
and CC o
safety NN o
for IN N
aggression NN N
and CC N
self-injury NN N
in IN N
children NNS p
, , p
adolescents NNS p
, , p
and CC p
adults NNS p
with IN p
MR NNP p
and CC p
PDDs NNP p
, , N
serum NN o
prolactin NN o
was VBD N
measured VBN N
in IN N
a DT N
21-subject JJ p
subset NN p
during IN p
the DT p
course NN p
of IN p
a DT p
double-blind JJ p
, , p
placebo-controlled JJ i
trial NN p
. . p

Prolactin NNP o
was VBD N
measured VBN N
in IN N
ng/mL NN N
at IN N
baseline NN N
, , N
once RB N
during IN N
acute JJ N
treatment NN N
, , N
and CC N
once RB N
during IN N
maintenance NN N
. . N

RESULTS NNP N
In IN N
children NNS p
and CC p
adolescents NNS p
( ( p
n=10 NN p
) ) p
, , p
mean JJ p
age NN p
of IN p
12.5 CD p
years NNS p
, , N
prolactin NN o
increased VBD N
from IN N
mean JJ N
13.2+/-8.6 CD N
at IN N
baseline NN N
to TO N
31.0+/-11.6 JJ N
acutely RB N
and CC N
remained VBD N
elevated VBN N
at IN N
37.9+/-10.4 JJ N
in IN N
maintenance NN N
. . N

In IN N
adults NNS p
, , p
mean JJ p
age NN p
of IN p
35.3 CD p
years NNS p
, , N
prolactin NN o
increased VBD N
more JJR N
markedly RB N
from IN N
11.6+/-7.4 JJ N
baseline NN N
( ( N
n=11 JJ N
) ) N
to TO N
93.3+/-54.2 CD N
acutely RB N
but CC N
decreased VBD N
to TO N
67.8+/-62.9 JJ N
in IN N
maintenance NN N
( ( N
n=7 JJ N
) ) N
. . N

Prolactin NNP o
remained VBD N
significantly RB N
elevated VBN N
above IN N
normal JJ N
in IN N
all DT N
subjects NNS N
for IN N
at IN N
least JJS N
26 CD N
weeks NNS N
. . N

Mean NNP o
prolactin NN o
of IN N
adult NN N
females NNS N
, , N
while IN N
similar JJ N
to TO N
that DT N
of IN N
adult NN N
males NNS N
at IN N
baseline NN N
, , N
was VBD N
2.2 CD N
times NNS N
male JJ N
levels NNS N
acutely RB N
and CC N
3.7 CD N
times NNS N
greater JJR N
in IN N
maintenance NN N
. . N

CONCLUSION NN N
In IN N
this DT N
small JJ N
subset NN N
, , N
mean JJ o
prolactin NN o
elevation NN o
persisted VBD N
for IN N
at IN N
least JJS N
26 CD N
weeks NNS N
. . N

In IN N
adults NNS N
, , N
females NNS N
showed VBD N
significantly RB N
greater JJR N
elevations NNS N
than IN N
males NNS N
. . N

-DOCSTART- -25690266- O O

The DT N
clinical JJ N
effectiveness NN N
and CC N
cost-effectiveness NN N
of IN N
telephone NN i
triage NN i
for IN N
managing VBG N
same-day JJ N
consultation NN N
requests NNS N
in IN N
general JJ N
practice NN N
: : N
a DT N
cluster NN N
randomised VBN N
controlled VBN N
trial NN N
comparing VBG N
general JJ i
practitioner-led JJ i
and CC i
nurse-led JJ i
management NN i
systems NNS i
with IN N
usual JJ N
care NN N
( ( N
the DT N
ESTEEM NNP N
trial NN N
) ) N
. . N

BACKGROUND NNP N
Telephone NNP i
triage NN i
is VBZ N
proposed VBN N
as IN N
a DT N
method NN N
of IN N
managing VBG N
increasing VBG N
demand NN N
for IN N
primary JJ N
care NN N
. . N

Previous JJ N
studies NNS N
have VBP N
involved VBN N
small JJ N
samples NNS N
in IN N
limited JJ N
settings NNS N
, , N
and CC N
focused VBD N
on IN N
nurse JJ N
roles NNS N
. . N

Evidence NN N
is VBZ N
limited JJ N
regarding VBG N
the DT N
impact NN N
on IN N
primary JJ N
care NN N
workload NN N
, , N
costs NNS N
, , N
and CC N
patient JJ N
safety NN N
and CC N
experience NN N
when WRB N
triage NN i
is VBZ N
used VBN N
to TO N
manage VB N
patients NNS p
requesting VBG p
same-day JJ p
consultations NNS p
in IN p
general JJ p
practice NN p
. . p

OBJECTIVES NNP N
In IN N
comparison NN N
with IN N
usual JJ i
care NN i
( ( i
UC NNP i
) ) i
, , N
to TO N
assess VB N
the DT N
impact NN N
of IN N
GP-led NNP i
telephone NN i
triage NN i
( ( i
GPT NNP i
) ) i
and CC i
nurse-led JJ i
computer-supported JJ i
telephone NN i
triage NN i
( ( i
NT NNP i
) ) i
on IN N
primary JJ N
care NN N
workload NN N
and CC N
cost NN N
, , N
patient JJ N
experience NN N
of IN N
care NN N
, , N
and CC N
patient JJ N
safety NN N
and CC N
health NN N
status NN N
for IN N
patients NNS N
requesting VBG N
same-day JJ N
consultations NNS N
in IN N
general JJ N
practice NN N
. . N

DESIGN NNP N
Pragmatic NNP N
cluster NN N
randomised VBD N
controlled VBN N
trial NN N
, , N
incorporating VBG N
economic JJ N
evaluation NN N
and CC N
qualitative JJ N
process NN N
evaluation NN N
. . N

SETTING NNP N
General NNP p
practices NNS p
( ( p
n JJ p
= NNP p
42 CD p
) ) p
in IN p
four CD p
regions NNS p
of IN p
England NNP p
, , p
UK NNP p
( ( N
Devon NNP N
, , N
Bristol/Somerset NNP N
, , N
Warwickshire/Coventry NNP N
, , N
Norfolk/Suffolk NNP N
) ) N
. . N

PARTICIPANTS JJ p
Patients NNPS p
requesting VBG p
same-day JJ p
consultations NNS p
. . p

INTERVENTIONS NNP p
Practices NNPS N
were VBD N
randomised VBN i
to TO i
GPT NNP i
, , i
NT NNP i
or CC i
UC NNP i
. . i

Data NNP N
collection NN N
was VBD N
not RB N
blinded VBN N
; : N
however RB N
, , N
analysis NN N
was VBD N
conducted VBN N
by IN N
a DT N
statistician NN N
blinded VBD N
to TO N
practice NN N
allocation NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Primary NNP o
- : o
primary JJ o
care NN o
contacts NNS o
[ NNP o
general JJ o
practice NN o
, , o
out-of-hours JJ o
primary NN o
care NN o
, , o
accident NN o
and CC o
emergency NN o
( ( o
A NNP o
& CC o
E NNP N
) ) N
and CC N
walk-in JJ N
centre NN N
attendances NNS N
] VBP N
in IN N
the DT N
28 CD N
days NNS N
following VBG N
the DT N
index NN N
consultation NN N
request NN N
. . N

Secondary JJ o
- : o
resource NN o
use NN o
and CC o
costs NNS o
, , o
patient JJ o
safety NN o
( ( o
deaths NNS o
and CC o
emergency NN o
hospital NN o
admissions NNS o
within IN o
7 CD N
days NNS N
of IN N
index NN N
request NN N
, , N
and CC N
A NNP N
& CC N
E NNP N
attendance NN N
within IN N
28 CD N
days NNS N
) ) N
, , N
health NN N
status NN N
and CC N
experience NN N
of IN N
care NN N
. . N

RESULTS NNP p
Of IN p
20,990 CD p
eligible JJ p
randomised VBN p
patients NNS p
( ( p
UC NNP p
n RB p
= JJ p
7283 CD p
; : p
GPT NNP p
n IN p
= JJ p
6695 CD p
; : p
NT NNP p
n IN p
= NNP p
7012 CD p
) ) p
, , p
primary JJ p
outcome NN p
data NNS p
were VBD p
analysed VBN p
for IN p
16,211 CD p
patients NNS p
( ( N
UC NNP N
n RB N
= JJ N
5572 CD N
; : N
GPT NNP N
n IN N
= JJ N
5171 CD N
; : N
NT NNP N
n IN N
= NNP N
5468 CD N
) ) N
. . N

Compared VBN N
with IN N
UC NNP N
, , N
GPT NNP N
and CC N
NT NNP N
increased VBD o
primary JJ o
outcome NN o
contacts NNS o
( ( o
over IN o
28-day JJ N
follow-up NN N
) ) N
by IN N
33 CD N
% NN N
[ JJ N
rate NN N
ratio NN N
( ( N
RR NNP N
) ) N
1.33 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
1.30 CD N
to TO N
1.36 CD N
] NNS N
and CC N
48 CD N
% NN N
( ( N
RR NNP N
1.48 CD N
, , N
95 CD N
% NN N
CI NNP N
1.44 CD N
to TO N
1.52 CD N
) ) N
, , N
respectively RB N
. . N

Compared VBN N
with IN N
GPT NNP N
, , N
NT NNP N
was VBD N
associated VBN N
with IN N
a DT N
marginal JJ N
increase NN N
in IN N
primary JJ o
outcome NN o
contacts NNS o
by IN N
4 CD N
% NN N
( ( N
RR NNP N
1.04 CD N
, , N
95 CD N
% NN N
CI NNP N
1.01 CD N
to TO N
1.08 CD N
) ) N
. . N

Triage NN N
was VBD N
associated VBN N
with IN N
a DT N
redistribution NN N
of IN N
primary JJ N
care NN N
contacts NNS N
. . N

Although IN N
GPT NNP N
, , N
compared VBN N
with IN N
UC NNP N
, , N
increased VBD N
the DT o
rate NN o
of IN o
overall JJ o
GP NNP o
contacts NNS o
( ( N
face NN N
to TO N
face NN N
and CC N
telephone NN N
) ) N
over IN N
the DT N
28 CD N
days NNS N
by IN N
38 CD N
% NN N
( ( N
RR NNP N
1.38 CD N
, , N
95 CD N
% NN N
CI NNP N
1.28 CD N
to TO N
1.50 CD N
) ) N
, , N
GP NNP N
face-to-face NN N
contacts NNS N
were VBD N
reduced VBN N
by IN N
39 CD N
% NN N
( ( N
RR NNP N
0.61 CD N
, , N
95 CD N
% NN N
CI NNP N
0.54 CD N
to TO N
0.69 CD N
) ) N
. . N

NT NNP N
reduced VBD N
the DT N
rate NN N
of IN o
overall JJ o
GP NNP o
contacts NNS o
by IN N
16 CD N
% NN N
( ( N
RR NNP N
0.84 CD N
, , N
95 CD N
% NN N
CI NNP N
0.78 CD N
to TO N
0.91 CD N
) ) N
and CC N
GP NNP N
face-to-face NN N
contacts NNS N
by IN N
20 CD N
% NN N
( ( N
RR NNP N
0.80 CD N
, , N
95 CD N
% NN N
CI NNP N
0.71 CD N
to TO N
0.90 CD N
) ) N
, , N
whereas JJ N
nurse JJ N
contacts NNS N
increased VBN N
. . N

The DT N
increased JJ o
rate NN o
of IN o
primary JJ o
care NN o
contacts NNS o
in IN o
triage NN N
arms NNS N
is VBZ N
largely RB N
attributable JJ N
to TO N
increased VB N
telephone NN N
contacts NNS N
. . o

Estimated VBN o
overall JJ o
patient-clinician JJ o
contact NN o
time NN o
on IN o
the DT o
index NN o
day NN o
increased VBD o
in IN N
triage NN N
( ( N
GPT NNP N
= VBZ N
10.3 CD N
minutes NNS N
; : N
NT NNP N
= VBD N
14.8 CD N
minutes NNS N
; : N
UC NNP N
= VBD N
9.6 CD N
minutes NNS N
) ) N
, , N
although IN N
patterns NNS N
of IN N
clinician JJ N
use NN N
varied VBD N
between IN N
arms NNS N
. . N

Taking VBG N
account NN N
of IN N
both DT N
the DT N
pattern NN N
and CC N
duration NN N
of IN o
primary JJ o
outcome NN o
contacts NNS o
, , o
overall JJ o
costs NNS o
over IN N
the DT N
28-day JJ N
follow-up NN N
were VBD N
similar JJ N
in IN N
all DT N
three CD N
arms NNS N
( ( N
approximately RB N
?75 VBN N
per IN N
patient NN N
) ) N
. . N

Triage NN N
appeared VBD o
safe JJ o
, , o
and CC N
no DT N
differences NNS N
in IN N
patient JJ N
health NN N
status NN N
were VBD N
observed VBN N
. . N

NT NNP N
was VBD N
somewhat RB N
less RBR N
acceptable JJ N
to TO N
patients NNS N
than IN N
GPT NNP i
or CC i
UC NNP i
. . i

The DT i
process NN N
evaluation NN N
identified VBD N
the DT N
complexity NN N
associated VBN N
with IN N
introducing JJ N
triage NN N
but CC N
found VBD N
no DT N
consistency NN N
across IN N
practices NNS N
about IN N
what WP N
works VBZ N
and CC N
what WP N
does VBZ N
not RB N
work VB N
when WRB N
implementing VBG N
it PRP N
. . N

CONCLUSIONS NNP N
Introducing NNP N
GPT NNP N
or CC N
NT NNP N
was VBD N
associated VBN N
with IN N
a DT N
redistribution NN N
of IN N
primary JJ N
care NN N
workload NN N
for IN N
patients NNS N
requesting VBG N
same-day JJ N
consultations NNS N
, , N
and CC N
at IN N
similar JJ N
cost NN N
to TO N
UC NNP N
. . N

Although IN N
triage NN N
seemed VBD N
to TO N
be VB N
safe JJ N
, , N
investigation NN N
of IN N
the DT N
circumstances NNS N
of IN N
a DT N
larger JJR N
number NN N
of IN N
deaths NNS N
or CC N
admissions NNS N
after IN N
triage NN N
might MD N
be VB N
warranted VBN N
, , N
and CC N
monitoring NN N
of IN N
these DT N
events NNS N
is VBZ N
necessary JJ N
as IN N
triage NN N
is VBZ N
implemented VBN N
. . N

TRIAL NNP N
REGISTRATION NNP N
Current NNP N
Controlled NNP N
Trials NNP N
ISRCTN20687662 NNP N
. . N

FUNDING NN N
This DT N
project NN N
was VBD N
funded VBN N
by IN N
the DT N
NIHR NNP N
Health NNP N
Technology NNP N
Assessment NNP N
programme NN N
and CC N
will MD N
be VB N
published VBN N
in IN N
full JJ N
in IN N
Health NNP N
Technology NNP N
Assessment NNP N
; : N
Vol NNP N
. . N

19 CD N
, , N
No NNP N
. . N

13 CD N
. . N

See VB N
the DT N
NIHR NNP N
Journals NNP N
Library NNP N
website NN N
for IN N
further JJ N
project NN N
information NN N
. . N

-DOCSTART- -20237484- O O

Effect NN N
of IN N
topical JJ i
anesthesia NN i
and CC N
age NN N
on IN N
pain NN o
scores NNS o
during IN N
retinopathy NN N
of IN N
prematurity NN N
screening NN N
. . N

OBJECTIVE CC N
The DT N
efficacy NN o
of IN N
topical JJ i
anesthesia NN i
during IN N
retinopathy NN p
of IN p
prematurity NN p
( ( p
ROP NNP p
) ) p
screening NN N
has VBZ N
been VBN N
a DT N
controversial JJ N
issue NN N
. . N

To TO N
determine VB N
the DT N
efficacy NN o
of IN N
proparacaine NN i
eye NN i
drops NNS i
( ( N
0.5 CD N
% NN N
) ) N
, , N
we PRP N
compared VBN N
the DT N
Premature NNP o
Infant NNP o
Pain NNP o
Profile NNP o
( ( o
PIPP NNP o
) ) o
scores VBZ N
in IN N
40 CD p
preterm JJ p
infants NNS p
undergoing VBG p
ROP NNP p
screening NN p
. . p

STUDY NNP N
DESIGN NNP N
Prospective NNP N
randomized VBD N
double JJ N
masked JJ N
cross-over JJ N
clinical JJ N
trial NN N
. . N

The DT N
study NN N
was VBD N
conducted VBN N
in IN N
the DT N
neonatal JJ p
intensive JJ p
units NNS p
for IN p
infants NNS p
undergoing VBG p
routine JJ p
ROP NNP p
screening VBG p
exams NNS p
. . p

Baseline NNP o
PIPP NNP o
scores NNS o
and CC N
post-examination NN o
PIPP NNP o
scores VBZ o
at IN N
1 CD N
and CC N
5 CD N
min NNS N
were VBD N
compared VBN N
for IN N
: : N
( ( N
1 CD N
) ) N
those DT N
receiving VBG i
saline JJ i
vs NN i
proparacaine NN i
eye NN i
drops NNS i
( ( i
2 CD N
) ) N
first RB N
ROP NNP N
screening VBG N
vs JJ N
second JJ N
ROP NNP N
screening NN N
, , N
regardless RB N
of IN N
the DT N
type NN N
of IN N
eye NN N
drops NNS N
used VBN N
. . N

Wilcoxon NNP N
signed-ranks JJ N
test NN N
was VBD N
used VBN N
to TO N
pair VB o
pain NN o
scores NNS o
. . o

RESULT NNP p
Forty NNP p
preterm NN p
infants NNS p
were VBD p
included VBN p
in IN p
the DT p
study NN o
. . o

Mean NNP o
gestational JJ o
age NN o
( ( o
GA NNP o
) ) o
at IN o
first JJ N
and CC N
second JJ N
examinations NNS N
was VBD N
33.3 CD N
and CC N
35.3 CD N
weeks NNS N
, , N
respectively RB i
. . i

Proparacaine NNP i
use VBP i
significantly RB N
lowered VBN o
mean JJ o
PIPP NNP o
scores NNS o
( ( o
P=0.027 NNP N
) ) N
and CC o
delta JJ o
scores NNS o
( ( o
P=0.013 NNP N
) ) N
at IN N
1 CD N
min NN N
after IN N
examination NN N
, , N
but CC N
there EX N
was VBD N
no DT N
difference NN N
at IN N
5 CD N
min NN N
after IN N
examination NN N
. . N

Second JJ N
examinations NNS N
showed VBD N
significantly RB N
lower JJR N
mean JJ o
PIPP NNP o
scores NNS o
after IN o
examination NN N
( ( N
1 CD N
min NN N
( ( N
P=0.003 NNP N
) ) N
and CC N
5 CD N
min NN N
( ( N
P=0.025 NNP N
) ) N
) ) N
, , N
regardless RB N
of IN N
the DT N
type NN N
of IN N
drop NN N
used VBN N
. . N

CONCLUSION NNP N
Proparacaine NNP i
eye NN i
drops NNS i
offer VBP N
significant JJ o
relief NN o
of IN o
pain NN o
that WDT o
is VBZ N
apparently RB N
short JJ N
lived VBD N
. . N

Significantly NNP o
lower JJR o
PIPP NNP o
scores NNS o
at IN o
second JJ N
ROP NNP N
examinations NNS N
suggested VBD N
that IN N
infants NNS N
of IN N
older JJR N
GA NNP N
may MD N
have VB N
a DT N
greater JJR N
ability NN N
to TO N
tolerate VB N
ROP NNP N
screening VBG N
. . N

We PRP N
recommend VBP N
the DT N
use NN N
of IN N
proparacaine NN i
eye NN i
drops NNS i
for IN N
the DT N
short JJ N
term NN N
, , N
immediate JJ N
relief NN N
of IN N
pain NN o
during IN o
ROP NNP o
screening VBG N
in IN p
preterm JJ p
infants NNS p
of IN p
lesser JJR N
GA NNP N
. . N

-DOCSTART- -3124456- O O

Prospective NNP N
controlled VBD N
study NN N
of IN N
androgen NN i
therapy NN i
in IN N
the DT N
anemia NN o
of IN p
chronic JJ p
renal JJ p
disease NN p
: : p
effects NNS N
on IN N
iron NN N
kinetics NNS N
. . N

Ferrokinetic NNP o
and CC o
RBC NNP o
mass NN o
determinations NNS o
were VBD N
made VBN N
at IN N
3-month JJ N
intervals NNS N
in IN N
iron-replete JJ p
hemodialysis NN p
patients NNS p
randomized VBN N
to TO N
a DT N
control NN i
group NN i
or CC i
to TO i
nandrolone CD i
decanoate NN i
therapy NN i
. . i

After IN N
3 CD N
months NNS N
, , N
RBC NNP o
mass NN o
increased VBD N
in IN N
two CD N
of IN N
4 CD N
androgen-treated JJ N
patients NNS N
. . N

Erythron NNP o
iron NN o
turnover NN o
, , N
an DT N
index NN N
of IN N
RBC NNP N
production NN N
, , N
increased VBN N
in IN N
the DT N
one CD N
responder NN N
studied VBD N
but CC N
not RB N
in IN N
the DT N
two CD N
nonresponders NNS N
. . N

Similarly RB N
, , N
in IN N
a DT N
fifth NN N
subject NN N
, , N
who WP N
was VBD N
not RB N
restudied VBN N
until IN N
6 CD N
months NNS N
of IN N
androgen NN i
therapy NN i
were VBD N
completed VBN N
, , N
an DT N
increase NN N
in IN N
RBC NNP o
mass NN o
was VBD N
associated VBN N
with IN N
an DT N
increase NN N
in IN N
erythron NNP N
iron NN N
turnover NN N
. . N

However RB N
, , N
between IN N
3 CD N
and CC N
6 CD N
months NNS N
, , N
RBC NNP o
mass NN o
increased VBD N
in IN N
all DT N
4 CD p
androgen-treated JJ i
patients NNS p
studied VBD N
even RB N
though IN N
erythron NN N
iron NN N
turnovers NNS N
remained VBD N
unchanged JJ N
and CC N
dialysis-associated JJ o
blood NN o
losses NNS o
did VBD N
not RB N
decrease VB N
. . N

Thus RB N
, , N
at IN N
least JJS N
two CD N
androgen-treated JJ i
patients NNS N
had VBD N
increases NNS N
in IN N
RBC NNP o
mass NN o
without IN N
ever RB N
increasing VBG N
their PRP$ N
erythron NN o
iron NN o
turnover NN o
. . o

Two CD N
of IN N
three CD N
control NN N
subjects NNS N
also RB N
had VBD N
increased VBN N
erythron RB o
iron NN o
turnovers NNS o
, , N
which WDT N
in IN N
one CD N
case NN N
was VBD N
related VBN N
to TO N
increased VBN N
dialysis-associated JJ o
blood NN o
losses NNS o
. . o

Changes NNS N
in IN N
RBC NNP o
mass NN o
were VBD N
not RB N
consistently RB N
paralleled VBN N
by IN N
changes NNS N
in IN N
Hb NNP N
. . N

These DT N
findings NNS N
suggest VBP N
that IN N
increases NNS N
in IN N
RBC NNP o
mass NN o
during IN N
nandrolone JJ N
decanoate NN N
therapy NN N
result NN N
from IN N
two CD N
mechanisms NNS N
: : N
increased VBN N
erythropoiesis NN N
( ( N
shown VBN N
by IN N
simultaneous JJ N
increases NNS N
in IN N
RBC NNP o
mass NN o
and CC N
erythron NN o
iron NN o
turnover NN o
) ) o
and CC N
increased JJ N
RBC NNP o
survival NN o
( ( N
indirectly RB N
shown VBN N
by IN N
increases NNS N
in IN N
RBC NNP o
mass NN o
without IN N
increases NNS N
in IN N
erythron NN o
iron NN o
turnover NN o
) ) o
. . N

The DT N
importance NN N
of IN N
control NN N
groups NNS N
, , N
RBC NNP o
mass NN o
determinations NNS N
and CC N
the DT N
monitoring NN N
of IN N
dialysis-associated JJ o
blood NN o
losses NNS o
in IN N
studying VBG N
the DT N
effects NNS N
of IN N
androgens NNS N
on IN N
erythropoiesis NN N
in IN N
chronic JJ p
hemodialysis NN p
patients NNS p
is VBZ N
also RB N
demonstrated VBN N
. . N

-DOCSTART- -16027809- O O

Simvastatin NNP i
and CC N
preparation NN N
of IN N
polyunsaturated JJ i
phospholipids NNS i
produce VBP N
similar JJ N
changes NNS N
in IN N
the DT N
phospholipid JJ N
composition NN N
of IN N
high-density NN N
lipoproteins NNS N
during IN N
hypercholesterolemia NN p
. . p

We PRP N
studied VBD N
the DT N
phospholipid JJ N
composition NN N
of IN N
high-density NN N
lipoproteins NNS N
in IN N
patients NNS p
with IN p
coronary JJ p
heart NN p
disease NN p
and CC p
hypercholesterolemia NN p
treated VBN p
with IN p
simvastatin NN i
( ( i
Zocor NNP i
, , p
inhibitor NN p
of IN p
the DT p
key JJ p
enzyme NN p
of IN p
cholesterol NN p
synthesis NN p
) ) p
and CC p
preparation NN p
of IN p
polyunsaturated JJ p
phospholipids NNS i
( ( i
lipostabil JJ i
forte NN i
) ) i
. . i

Simvastatin NNP i
produced VBD N
a DT N
hypolipidemic JJ o
effect NN o
and CC o
modulates VBZ o
the DT o
phospholipid JJ o
composition NN o
of IN o
high-density NN o
lipoproteins NNS o
( ( o
similarly RB o
to TO o
lipostabil VB o
forte NN o
) ) o
. . o

These DT N
changes NNS N
contribute VBP N
to TO N
functional JJ o
activity NN o
of IN N
high-density NN o
lipoproteins NNS o
in IN N
the DT N
reverse NN N
cholesterol NN N
transport NN N
. . N

-DOCSTART- -9849475- O O

Ten-year JJ N
results NNS N
of IN N
a DT N
randomised JJ N
trial NN N
comparing VBG N
cisplatin NN i
with IN i
cisplatin NN i
and CC i
cyclophosphamide NN i
in IN N
advanced JJ p
, , p
suboptimally RB p
debulked JJ p
ovarian JJ p
cancer NN p
. . p

176 CD p
eligible JJ p
patients NNS p
with IN p
advanced JJ p
suboptimally RB p
operated JJ p
ovarian JJ p
carcinoma NN p
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
either DT N
cisplatin NN i
75 CD i
mg/m2 NN i
or CC i
cisplatin NN i
50 CD i
mg/m2 NN i
and CC i
cyclophosphamide VB i
500 CD i
mg/m2 NN i
( ( N
CP NNP N
) ) N
every DT N
28 CD N
days NNS N
for IN N
six CD N
courses NNS N
. . N

The DT N
overall JJ o
clinical JJ o
response NN o
rates NNS o
( ( o
complete JJ o
response NN N
plus CC N
partial JJ N
response NN N
) ) N
were VBD N
52 CD N
and CC N
63 CD N
% NN N
for IN N
CP NNP i
and CC i
cisplatin NN i
, , N
respectively RB N
( ( N
non-significant JJ N
) ) N
. . N

Including VBG N
results NNS N
obtained VBN N
by IN N
second-look JJ N
laparotomy NN N
, , N
we PRP N
did VBD N
not RB N
observe VB N
a DT N
statistically RB N
significant JJ N
difference NN N
in IN N
response NN N
rates NNS N
in IN N
the DT N
two CD N
treatment NN N
groups NNS N
. . N

Median JJ o
progression-free JJ o
survival NN o
was VBD N
10 CD N
and CC N
11.9 CD N
months NNS N
for IN N
CP NNP i
and CC i
cisplatin NN i
, , N
respectively RB N
( ( N
non-significant JJ N
) ) N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
observed VBN N
in IN N
overall JJ o
survival NN o
, , N
with IN N
a DT N
median NN N
of IN N
19.4 CD N
and CC N
21.5 CD N
months NNS N
for IN N
CP NNP i
and CC i
cisplatin NN i
, , N
respectively RB N
. . N

Thirty-seven JJ p
platinum-resistant JJ p
and CC p
27 CD p
platinum-sensitive JJ p
tumours NNS p
were VBD N
treated VBN N
with IN N
carboplatin NN i
or CC i
cisplatin NN i
as IN N
second-line JJ N
therapy NN N
. . N

Response JJ o
rates NNS o
to TO N
platinum VB N
second-line JJ N
therapy NN N
were VBD N
6 CD N
and CC N
50 CD N
% NN N
for IN N
resistant NN N
and CC N
sensitive JJ N
tumours NNS N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

This DT N
difference NN N
in IN N
response NN o
rate NN o
was VBD N
also RB N
confirmed VBN N
by IN N
survival NN N
analysis NN N
. . N

Patients NNS p
with IN p
platinum-sensitive JJ p
tumours NNS p
survived VBD N
longer RBR N
when WRB N
they PRP N
were VBD N
treated VBN N
with IN N
platinum-containing JJ i
chemotherapy NN i
( ( N
P NNP N
= NNP N
0.005 CD N
) ) N
. . N

Median JJ o
survival NN o
was VBD N
22.8 CD N
and CC N
8.5 CD N
months NNS N
after IN N
initiation NN N
of IN N
second-line JJ N
treatment NN N
for IN N
the DT N
platinum-containing JJ i
and CC N
platinum-free JJ i
regimens NNS N
, , N
respectively RB N
. . N

In IN N
summary JJ N
, , N
we PRP N
observed VBD N
in IN N
suboptimally RB p
operated JJ p
ovarian JJ p
carcinoma NN p
patients NNS p
similar JJ N
response NN o
rates NNS o
, , o
progression-free JJ o
interval NN o
, , o
and CC o
overall JJ o
survival NN o
for IN N
equitoxic JJ N
cisplatin NN i
and CC i
CP NNP i
. . i

However RB N
, , N
the DT N
doses NNS N
of IN N
cisplatin NN i
and CC i
cyclophosphamide NN i
chosen NNS N
were VBD N
substantially RB N
lower JJR N
than IN N
current JJ N
standard JJ N
doses NNS N
of IN N
CP NNP i
. . i

Our PRP$ N
study NN N
demonstrates VBZ N
, , N
therefore RB N
, , N
that IN N
a DT N
suboptimal JJ N
dose NN N
of IN N
CP NNP i
is VBZ N
as RB N
effective JJ N
as IN N
optimal JJ N
dose JJ N
monotherapy NN N
cisplatin NN i
. . i

Patients NNS p
with IN p
recurrences NNS p
considered VBN p
as IN p
platinum-sensitive JJ p
had VBD N
a DT N
significantly RB N
higher JJR N
response NN o
rate NN o
and CC N
improved VBN N
survival NN o
when WRB N
retreated VBN N
with IN N
platinum-containing JJ i
therapy NN i
. . i

-DOCSTART- -10816058- O O

Heparin-coated JJ i
cardiopulmonary JJ i
bypass NN i
circuits NNS i
reduce VB N
circulating VBG N
complement JJ N
factors NNS N
and CC N
interleukin-6 NN N
in IN N
paediatric JJ p
heart NN p
surgery NN p
. . p

Children NNP p
are VBP N
sensitive JJ N
to TO N
the DT N
inflammatory JJ N
side NN N
effects NNS N
of IN N
cardiopulmonary JJ N
bypass NN N
( ( N
CPB NNP N
) ) N
. . N

Our PRP$ N
intention NN N
was VBD N
to TO N
investigate VB N
if IN N
the DT N
biocompatibility NN N
benefits NNS N
of IN N
heparin-coated JJ i
CPB NNP i
circuits NNS i
apply VBP N
to TO N
children NNS p
. . p

In IN N
20 CD N
operations NNS N
, , N
19 CD p
children NNS p
were VBD p
randomized VBN p
to TO p
heparin-coated JJ i
( ( i
group NN i
HC NNP i
, , i
n JJ i
= NNP i
10 CD i
) ) i
or CC i
standard JJ i
( ( i
group NN i
C NNP i
, , i
n JJ i
= NNP i
10 CD i
) ) i
bypass NN i
circuits NNS i
. . i

Plasma NNP o
levels NNS o
of IN o
acute JJ o
phase NN o
reactants NNS o
, , o
interleukins NNS o
, , o
granulocytic JJ o
proteins NNS o
and CC o
complement JJ o
factors NNS o
were VBD N
measured VBN N
. . N

All DT N
were VBD N
significantly RB N
elevated VBN N
after IN N
CPB NNP N
. . N

Levels NNP o
of IN o
complement NN o
factor NN o
C3a NNP o
( ( N
851 CD N
( ( N
791-959 CD N
) ) N
ng/ml FW N
[ JJ N
median NN N
with IN N
quartiles NNS N
] VBP N
in IN N
group NN N
C NNP N
, , N
497 CD N
( ( N
476-573 JJ N
) ) N
ng/ml NN N
in IN N
group NN N
HC NNP N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
Terminal NNP o
Complement NNP o
Complex NNP o
( ( N
114 CD N
( ( N
71-130 CD N
) ) N
AU/ml NNP N
in IN N
group NN N
C NNP N
, , N
35.5 CD N
( ( N
28.9-51.4 JJ N
) ) N
AU/ml NNP N
in IN N
group NN N
HC NNP N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
interleukin-6 NN o
( ( N
570 CD N
( ( N
203-743 JJ N
) ) N
pg/ml NN N
in IN N
group NN N
C NNP N
, , N
168 CD N
( ( N
111-206 CD N
) ) N
pg/ml NN N
in IN N
group NN N
HC NNP N
, , N
p NN N
= NNP N
0.005 CD N
) ) N
, , N
were VBD N
significantly RB N
reduced VBN N
in IN N
group NN N
HC NNP N
. . N

Heparin-coated JJ i
CPB NNP i
circuits NNS i
improve VBP N
the DT N
biocompatibility NN N
of IN N
CPB NNP N
during IN N
heart NN N
surgery NN N
in IN N
the DT N
paediatric JJ p
patient NN p
population NN N
, , N
as IN N
reflected VBN N
by IN N
significantly RB N
reduced VBN N
levels NNS N
of IN N
circulating VBG N
complement JJ N
factors NNS N
and CC N
interleukin-6 NN N
. . N

-DOCSTART- -9683400- O O

The DT N
effect NN o
of IN N
quality NN N
and CC N
amount NN N
of IN N
dietary JJ N
fat NN N
on IN N
the DT N
susceptibility NN o
of IN o
low JJ o
density NN o
lipoprotein NN o
to TO o
oxidation NN o
in IN p
subjects NNS p
with IN p
impaired JJ p
glucose JJ p
tolerance NN p
. . p

OBJECTIVES IN N
We PRP N
examined VBD N
the DT N
effects NNS N
of IN N
a DT N
high JJ i
fat NN i
diet JJ i
rich JJ i
in IN i
monounsaturated JJ i
fat NN i
( ( i
MUFA-diet NNP i
) ) i
and CC N
a DT N
moderate JJ i
fat NN i
diet JJ i
rich JJ i
in IN i
polyunsaturated JJ i
fat NN i
( ( i
PUFA-diet NNP i
) ) i
on IN N
the DT N
susceptibility NN o
of IN o
LDL NNP o
to TO o
oxidation NN o
. . o

SUBJECTS NNP N
29 CD p
subjects NNS p
with IN p
impaired JJ p
glucose JJ p
tolerance NN p
. . p

METHODS NNP N
After IN N
consuming VBG N
a DT N
run-in JJ N
diet JJ N
[ FW N
37 CD N
% NN N
of IN N
energy NN N
( ( N
E NNP N
% NN N
) ) N
fat NN N
, , N
18 CD N
E NNP N
% NN N
saturated VBD N
fat JJ N
] NN N
for IN N
three CD N
weeks NNS N
, , N
subjects NNS N
were VBD N
randomly RB N
assigned VBN N
either RB N
to TO N
a DT N
MUFA-diet JJ N
( ( N
40 CD N
E NNP N
% NN N
fat NN N
, , N
19 CD N
E NNP N
% NN N
monounsaturated VBD N
fatty JJ N
acids NNS N
) ) N
or CC N
a DT N
PUFA-diet JJ N
( ( N
34 CD N
E NNP N
% NN N
fat NN N
, , N
10 CD N
E NNP N
% NN N
polyunsaturated VBD N
fat NN N
) ) N
for IN N
eight CD N
weeks NNS N
. . N

The DT N
susceptibility NN o
of IN o
LDL NNP o
to TO o
oxidation NN o
was VBD N
measured VBN N
by IN N
challenging VBG N
LDL NNP N
with IN N
hemin NN N
and CC N
H2O2 NNP N
and CC N
measuring VBG N
the DT N
time NN o
for IN o
the DT o
reaction NN o
to TO o
reach VB o
maximum JJ o
velocity NN o
. . o

Results NNS N
are VBP N
expressed VBN N
as IN N
lag NN o
time NN o
to TO o
oxidation NN o
in IN N
minutes NNS N
. . N

RESULTS NNP N
In IN N
the DT N
PUFA-diet JJ N
group NN N
( ( N
n JJ N
= NNP N
15 CD N
) ) N
lag NN o
time NN o
tended VBD N
to TO N
decrease VB N
during IN N
the DT N
experimental JJ N
diet NN N
( ( N
97 CD N
+/- JJ N
28 CD N
vs JJ N
90 CD N
+/- JJ N
25 CD N
min NN N
, , N
mean JJ N
+/- JJ N
s.d. NN N
, , N
P NNP N
= NNP N
0.073 CD N
) ) N
, , N
whereas RB N
in IN N
the DT N
MUFA-diet JJ N
group NN N
( ( N
n JJ N
= NNP N
14 CD N
) ) N
there EX N
was VBD N
no DT N
significant JJ N
change NN N
( ( N
lag JJ N
time NN N
96 CD N
+/- JJ N
24 CD N
vs JJ N
100 CD N
+/- JJ N
16 CD N
min NN N
, , N
P NNP N
= NNP N
0.408 CD N
) ) N
. . N

The DT N
mean JJ o
change NN o
in IN o
lag NN o
time NN o
was VBD N
-7 JJ N
+/- JJ N
14 CD N
min NN N
( ( N
-7.2 CD N
% NN N
) ) N
in IN N
the DT N
PUFA-diet JJ N
group NN N
and CC N
+4 VBZ N
+/- JJ N
16 CD N
min NN N
( ( N
+4.0 CD N
% NN N
) ) N
in IN N
the DT N
MUFA-diet JJ N
group NN N
( ( N
P NNP N
= NNP N
0.029 CD N
, , N
PUFA-diet JJ N
group NN N
vs VBD N
MUFA-diet NNP N
group NN N
) ) N
. . N

The DT N
alpha-tocopherol JJ o
concentration NN o
in IN o
LDL NNP o
increased VBD N
significantly RB N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
in IN N
both DT N
diet JJ N
groups NNS N
relative VBP N
to TO N
the DT N
run-in JJ N
diet JJ N
period NN N
, , N
but CC N
LDL NNP o
particle VBD o
score RB o
did VBD N
not RB N
change VB N
in IN N
either DT N
of IN N
the DT N
diet JJ N
groups NNS N
during IN N
the DT N
dietary JJ N
intervention NN N
. . N

In IN N
subjects NNS p
with IN p
impaired JJ p
glucose JJ p
tolerance NN p
a DT N
PUFA-rich JJ i
diet NN N
with IN N
a DT N
moderate JJ N
amount NN N
of IN N
fat NN N
tended VBN N
to TO N
increase VB N
the DT N
susceptibility NN o
of IN o
LDL NNP o
to TO o
oxidation NN o
as IN N
compared VBN N
to TO N
a DT N
higher JJR N
fat JJ N
diet JJ N
rich NN N
in IN N
MUFA NNP i
. . i

Furthermore NNP N
, , N
the DT N
negative JJ N
mean NN N
change NN N
in IN N
lag NN o
time NN o
to TO o
oxidation NN o
found VBN N
in IN N
the DT N
PUFA-diet JJ N
group NN N
differed VBD N
significantly RB N
from IN N
the DT N
slightly RB N
positive JJ N
mean NN N
change NN N
found VBD N
in IN N
the DT N
MUFA-diet JJ N
group NN N
. . N

-DOCSTART- -17078451- O O

Treatment NN N
of IN N
psoriasis NN p
vulgaris NN p
by IN N
oral JJ N
administration NN N
of IN N
yin JJ i
xie NNP i
ping NN i
granules NNS i
-- : i
a DT i
clinical JJ p
report NN p
of IN p
60 CD p
cases NNS p
. . p

-DOCSTART- -21996146- O O

Residual JJ N
platelet NN N
reactivity NN N
, , N
bleedings NNS N
, , N
and CC N
adherence NN N
to TO N
treatment NN N
in IN N
patients NNS p
having VBG p
coronary JJ p
stent JJ p
implantation NN p
treated VBN p
with IN p
prasugrel NN i
. . i

Recent JJ N
guidelines NNS N
have VBP N
recommended VBN N
the DT N
use NN N
of IN N
aspirin NN N
and CC N
prasugrel NN i
in IN N
patients NNS p
with IN p
acute JJ p
coronary JJ p
syndromes NNS p
undergoing VBG p
percutaneous JJ p
coronary JJ p
intervention NN p
. . p

However RB N
, , N
prasugrel NN i
use NN N
has VBZ N
been VBN N
evaluated VBN N
only RB N
in IN N
randomized JJ N
trials NNS N
. . N

This DT N
study NN N
sought VBD N
to TO N
evaluate VB N
bleeding NN o
rates NNS o
and CC N
adherence NN N
to TO N
treatment NN N
in IN N
real-world JJ N
patients NNS N
treated VBN N
with IN N
prasugrel NN i
. . i

In IN N
total JJ p
298 CD p
consecutive JJ p
patients NNS p
68 CD p
? . p
10 CD p
years NNS p
old JJ p
( ( p
31 CD p
% NN p
> JJ p
75 CD p
years NNS p
old JJ p
) ) p
underwent JJ i
stent JJ i
implantation NN i
and CC i
received VBD i
prasugrel JJ i
therapy NN i
. . i

Indications NNS N
to TO N
prasugrel VB N
therapy NN N
were VBD N
( ( N
1 CD N
) ) N
ST-elevation NNP N
acute JJ N
myocardial JJ N
infarction NN N
( ( N
41 CD N
% NN N
) ) N
, , N
( ( N
2 CD N
) ) N
drug-eluting NN N
stent JJ N
implantation NN N
in IN N
diabetics NNS N
( ( N
24 CD N
% NN N
) ) N
, , N
( ( N
3 CD N
) ) N
stent NN N
thrombosis NN N
( ( N
3 CD N
% NN N
) ) N
, , N
( ( N
4 CD N
) ) N
left VBD N
main JJ N
coronary JJ N
artery NN N
drug-eluting JJ N
stent NN N
implantation NN N
( ( N
6 CD N
% NN N
) ) N
, , N
and CC N
( ( N
5 CD N
) ) N
percutaneous JJ N
coronary JJ N
intervention NN N
in IN N
patients NNS N
with IN N
high JJ N
residual JJ N
platelet NN N
reactivity NN N
on IN N
clopidogrel NN N
therapy NN N
( ( N
26 CD N
% NN N
) ) N
. . N

All DT N
patients NNS N
received VBD N
a DT N
loading NN N
of IN i
prasugrel NN i
60 CD N
mg NN N
. . N

Patients NNS p
?75 CD p
years NNS p
old JJ p
and CC p
with IN p
body NN p
weight JJ p
?60 NNP p
kg NN p
received VBD p
a DT N
maintenance NN N
dose NN N
of IN N
5 CD N
mg/day NN N
( ( N
10 CD N
mg/day NN N
for IN N
all PDT N
the DT N
other JJ N
patients NNS N
) ) N
. . N

Follow-up NNP N
data NNS N
including VBG o
adherence NN o
to TO o
prasugrel VB o
therapy NN o
were VBD o
collected VBN N
by IN N
telephone NN N
interviews NNS N
or CC N
outpatient JJ N
visits NNS N
. . N

Minimal JJ N
follow-up JJ N
length NN N
was VBD N
6 CD N
months NNS N
( ( N
mean VB N
9 CD N
? . N
3 CD N
) ) N
. . N

Major NNP o
, , N
minor NN o
, , o
and CC o
minimal JJ o
bleedings NNS o
( ( o
Thrombolysis NNP o
In IN N
Myocardial NNP N
Infarction NNP N
criteria NNS N
) ) N
occurred VBD N
in IN N
2.7 CD N
% NN N
, , N
4.7 CD N
% NN N
, , N
and CC N
15.1 CD N
% NN N
of IN N
enrolled JJ N
patients NNS o
. . o

Low JJ o
residual JJ o
platelet NN o
reactivity NN o
( ( o
p JJ o
= NNP o
0.001 CD N
) ) N
and CC N
female JJ N
gender NN N
( ( N
p JJ N
= NNP N
0.29 CD N
) ) N
were VBD N
independent JJ N
predictors NNS N
of IN N
bleeding VBG N
events NNS N
. . N

The DT N
most RBS N
frequent JJ N
minimal JJ N
bleeding VBG N
event NN N
was VBD o
epistaxis RB o
. . o

Only RB o
8 CD N
patients NNS N
( ( N
2.7 CD N
% NN N
) ) N
permanently RB N
discontinued VBN N
prasugrel NN N
therapy NN N
because IN o
of IN o
bleeding VBG o
events NNS o
( ( o
n JJ o
= NNP o
4 CD N
) ) N
, , N
possible JJ o
side NN o
effects NNS o
( ( o
n JJ o
= NNP o
2 CD N
) ) N
, , N
or CC N
medical JJ o
decisions NNS o
not RB o
associated VBN o
with IN o
bleeding NN o
or CC o
side NN o
effects NNS o
( ( o
n JJ o
= NNP o
2 CD N
) ) N
. . N

Fourteen JJ N
patients NNS N
( ( N
4.7 CD N
% NN N
) ) N
temporarily RB o
discontinued VBN o
prasugrel NN o
( ( N
average JJ N
6.5 CD N
days NNS N
) ) N
mainly RB N
because IN N
of IN N
surgical JJ N
procedures NNS N
. . N

No DT N
definite NN o
or CC o
probable JJ o
stent JJ o
thrombosis NN o
occurred VBD o
, , N
although IN N
3 CD N
patients NNS N
develop VB o
de FW o
novo FW o
myocardial JJ o
infarction NN o
and CC o
1 CD o
an DT o
ischemic JJ o
stroke NN o
. . o

There EX o
were VBD N
11 CD o
deaths NNS o
because IN o
of IN o
heart NN o
failure NN o
or CC o
refractory NN o
cardiogenic JJ o
shock NN o
in IN N
9 CD N
, , N
pulmonary JJ o
embolism NN o
in IN o
1 CD o
, , o
and CC N
cancer NN o
in IN o
1 CD o
. . o

In IN N
conclusion NN N
, , N
in IN N
clinical JJ N
practice NN o
, , o
major JJ o
and CC o
minor JJ o
bleeding NN o
event NN o
rates NNS o
associated VBN N
with IN N
prasugrel NN N
therapy NN N
are VBP N
comparable JJ N
to TO N
those DT N
reported VBN N
in IN N
controlled JJ N
randomized JJ N
trials NNS N
. . o

The DT o
minimal JJ o
bleeding JJ o
event NN o
rate NN o
is VBZ N
higher JJR N
than IN N
reported VBN N
but CC N
does VBZ N
not RB N
seem VB N
to TO N
affect VB N
adherence NN N
to TO N
treatment NN N
. . N

-DOCSTART- -3732715- O O

[ JJ N
Opposing NNP N
effects NNS N
of IN N
propranolol NN i
and CC i
diltiazem NN i
on IN N
the DT N
angina NN o
threshold NN o
during IN N
an DT N
exercise NN N
test NN N
in IN N
patients NNS p
with IN p
syndrome JJ p
X NNP p
] NNP p
. . N

Patients NNS p
with IN p
angina JJ p
pectoris NN p
, , p
exercise NN p
induced VBN p
myocardial JJ p
ischemia NN p
, , p
normal JJ p
coronary JJ p
arteries NNS p
and CC p
no DT p
evidence NN p
of IN p
epicardial JJ p
spasm NN p
, , p
i.e NN p
. . p

patients NNS p
with IN p
syndrome JJ p
x NN p
, , N
have VBP N
been VBN N
suggested VBN N
to TO N
haven VB N
inadequate JJ N
increase NN N
in IN N
coronary JJ o
blood NN o
flow NN o
during IN o
tachycardia NN o
, , N
possibly RB N
due JJ N
to TO N
a DT N
functional JJ N
disorder NN N
of IN N
small JJ N
coronary JJ N
vessels NNS N
. . N

To TO N
evaluate VB N
the DT N
best JJS N
medical JJ N
management NN N
of IN N
this DT N
syndrome NN N
we PRP N
studied VBD N
13 CD p
patients NNS p
who WP p
showed VBD p
the DT p
above JJ p
set NN p
of IN p
findings NNS p
. . p

Patients NNS N
were VBD N
given VBN N
propranolol NNS i
( ( N
160 CD N
mg NNS N
daily RB N
) ) N
, , N
diltiazem NN i
( ( N
360 CD N
mg NNS N
daily RB N
) ) N
and CC i
placebo NN i
for IN N
2 CD N
weeks NNS N
, , N
using VBG N
a DT N
randomized JJ N
single JJ N
blind NN N
protocol NN N
. . N

Upright NNP i
bicycle NN i
ergometer NN i
testing NN i
was VBD N
performed VBN N
at IN N
the DT N
end NN N
of IN N
each DT N
period NN N
of IN N
treatment NN N
. . N

Compared VBN N
to TO N
placebo VB i
, , i
diltiazem VB i
significantly RB N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
prolonged VBD N
exercise NN o
duration NN o
( ( N
x JJ N
+/- JJ N
SD NNP N
: : N
365 CD N
+/- JJ N
86 CD N
vs JJ N
303 CD N
+/- JJ N
89 CD N
sec NN N
) ) N
and CC N
time NN o
to TO o
onset VB o
of IN o
angina NN o
( ( N
358 CD N
+/- JJ N
88 CD N
vs JJ N
276 CD N
+/- JJ N
90 CD N
sec NN N
) ) N
. . N

Angina NNP o
appeared VBD N
in IN N
7 CD N
patients NNS N
with IN N
diltiazem JJ i
vs NNS N
13 CD N
patients NNS N
with IN N
placebo NN i
and CC N
occurred VBD N
at IN N
a DT N
higher JJR N
rate NN N
pressure NN o
product NN o
( ( N
26.3 CD N
+/- JJ N
3.5 CD N
vs JJ N
24.1 CD N
+/- JJ N
2.8 CD N
X NN N
10 CD N
( ( N
-3 NN N
) ) N
; : N
p VBZ N
less JJR N
than IN N
0.02 CD N
) ) N
. . N

Conversely RB N
, , N
following VBG N
propranolol NN N
exercise NN o
duration NN o
and CC o
time NN o
to TO o
onset VB o
of IN o
angina NNS o
were VBD N
unchanged JJ N
and CC N
angina JJ o
appeared VBN N
in IN N
all DT N
patients NNS N
at IN N
a DT N
lower JJR N
rate NN N
pressure NN o
product NN o
( ( N
18.3 CD N
+/- JJ N
2.9 CD N
vs JJ N
24.4 CD N
+/- JJ N
3.6 CD N
X NN N
10 CD N
( ( N
-3 NN N
) ) N
; : N
p VBZ N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

The DT N
most RBS N
likely JJ N
explanations NNS N
for IN N
these DT N
findings NNS N
are VBP N
: : N
propranolol JJ i
counteracts NNS N
beta VBP N
2-adrenergic JJ N
receptors NNS N
, , N
thus RB N
further RB N
reducing VBG N
coronary JJ o
reserve NN o
. . o

This DT N
may MD N
lower VB N
the DT N
anginal JJ o
threshold NN o
; : o
Diltiazem NNP i
reduces VBZ N
smooth JJ o
muscle NN o
tone NN o
in IN N
small JJ N
coronary JJ N
vessels NNS N
. . N

This DT N
may MD N
result VB N
in IN N
increased JJ N
coronary JJ o
reserve NN o
and CC o
exercise NN o
duration NN o
. . o

-DOCSTART- -18702754- O O

A DT N
controlled VBN N
comparison NN N
between IN N
single JJ N
doses NNS N
of IN N
intravenous JJ i
and CC i
intramuscular JJ i
morphine NN i
with IN N
respect NN N
to TO N
analgesic JJ o
effects NNS o
and CC o
patient JJ o
safety NN o
. . o

UNLABELLED VBN N
BACKGROUND NNP N
AND NNP N
AIM NNP N
OF NNP N
INVESTIGATION NNP N
: : N
Intramuscular NNP N
( ( N
IM NNP N
) ) N
administration NN N
has VBZ N
been VBN N
considered VBN N
to TO N
be VB N
safer JJR N
than IN N
intravenous JJ N
( ( N
IV NNP N
) ) N
for IN N
opioids NNS i
on IN N
wards NNS N
, , N
but CC N
a DT N
comparative JJ N
knowledge NN N
of IN N
patient JJ o
safety NN o
and CC o
analgesic JJ o
potency NN o
following VBG N
a DT N
single JJ N
dose NN N
of IN N
IV NNP N
and CC N
IM NNP N
administration NN N
is VBZ N
lacking VBG N
. . N

This DT N
study NN N
was VBD N
carried VBN N
out IN N
to TO N
compare VB N
patient JJ o
safety NN o
and CC o
analgesic JJ o
efficacy NN o
of IN N
a DT N
single JJ N
and CC N
high JJ N
dose NN N
of IN N
morphine NN i
given VBN i
IM NNP i
or CC i
IV NNP i
for IN N
post-operative JJ p
pain NN p
management NN p
. . p

MATERIALS NNP N
AND CC N
METHODS NNP N
Thirty-eight NNP p
patients NNS p
with IN p
post-operative JJ p
pain NN p
following VBG p
hip NN i
replacement NN i
surgery NN i
were VBD N
given VBN N
IM NNP i
or CC i
IV NNP i
morphine VBP i
10 CD N
mg NN N
at IN N
a DT N
specified JJ N
pain NN N
level NN N
. . N

The DT N
study NN N
was VBD N
randomized VBN N
and CC N
double JJ N
blinded VBN N
. . N

Time NN o
to TO o
onset VB o
of IN o
analgesic JJ o
effect NN o
( ( o
11-point JJ o
numeric NN o
rating NN o
scale NN o
) ) o
, , o
respiratory JJ o
function NN o
( ( o
p NN o
( ( o
a DT o
) ) o
CO2 NNP o
, , o
p NN o
( ( o
a DT o
) ) o
O2 NNP o
, , o
and CC o
respiratory JJ o
rate NN o
) ) o
, , o
level NN o
of IN o
sedation NN o
( ( o
5-point JJ o
verbal NN o
rating NN o
scale NN o
) ) o
, , o
and CC o
hemodynamic JJ o
function NN o
were VBD N
recorded VBN N
. . N

RESULTS NNP N
In IN N
the DT N
IV NNP N
group NN N
there EX N
was VBD N
a DT N
slight JJ N
but CC N
significant JJ N
increase NN N
in IN N
p NN o
( ( o
a DT o
) ) o
CO2 NNP o
after IN N
5 CD N
, , N
10 CD N
, , N
and CC N
15 CD N
min NNS N
compared VBN N
with IN N
the DT N
IM NNP N
group NN N
( ( N
5.2 CD N
vs. FW N
4.8 CD N
, , N
5.4 CD N
, , N
vs. FW N
5.0 CD N
and CC N
5.5 CD N
vs. FW N
5.1 CD N
kPa NN N
, , N
respectively RB N
) ) N
. . N

The DT N
IV NNP N
group NN N
had VBD N
a DT N
significantly RB N
faster RBR N
onset NN o
of IN o
analgesic JJ o
effect NN o
than IN N
the DT N
IM NNP N
group NN N
( ( N
5 CD N
vs. FW N
20 CD N
min NN N
) ) N
. . N

Between $ N
5 CD N
and CC N
25 CD N
min NN N
after IN N
morphine JJ i
administration NN N
, , N
pain NN o
status NN o
in IN N
the DT N
IV NNP N
group NN N
was VBD N
significantly RB N
improved VBN N
compared VBN N
with IN N
the DT N
IM NNP N
group NN N
. . N

Patients NNS N
in IN N
the DT N
IV NNP N
group NN N
were VBD N
slightly RB N
more RBR N
sedated JJ o
than IN N
the DT N
IM NNP N
group NN N
5 CD N
and CC N
10 CD N
min NN N
after IN N
morphine NN N
. . N

CONCLUSION VB N
A DT N
10 CD N
mg NN N
bolus NN N
dose NN N
of IN N
IV NNP N
morphine NN N
given VBN N
to TO N
patients NNS N
with IN N
moderate JJ N
pain NN N
after IN N
surgery NN i
does VBZ N
not RB N
cause VB N
severe JJ o
respiratory NN o
depression NN o
, , N
but CC N
provides VBZ N
more RBR N
rapid JJ N
and CC N
better RBR N
initial JJ o
analgesia NN o
than IN N
10 CD N
mg NNS N
given VBN N
IM NNP N
. . N

IV NNP N
morphine VBD i
even RB N
at IN N
a DT N
dose NN N
as RB N
high JJ N
as IN N
10 CD N
mg NN N
IV NNP N
is VBZ N
well RB N
tolerated VBN o
if IN N
there EX N
is VBZ N
a DT N
certain JJ N
level NN N
of IN N
pain NN N
at IN N
its PRP$ N
administration NN N
. . N

The DT N
safety NN N
of IN N
IV NNP N
morphine NN i
on IN N
the DT N
general JJ N
ward NN N
needs VBZ N
to TO N
be VB N
further RB N
explored VBN N
in IN N
adequately RB N
controlled JJ N
studies NNS N
. . N

-DOCSTART- -23896590- O O

Randomised VBN N
trial NN N
comparing VBG N
the DT N
recording VBG N
ability NN N
of IN N
a DT N
novel NN i
, , i
electronic JJ i
emergency NN i
documentation NN i
system NN i
with IN N
the DT N
AHA NNP i
paper NN i
cardiac NN i
arrest NN i
record NN i
. . i

OBJECTIVE UH N
To TO N
evaluate VB o
the DT o
ability NN o
of IN N
an DT N
electronic JJ i
system NN i
created VBD N
at IN N
the DT N
University NNP N
of IN N
Washington NNP N
to TO N
accurately RB N
document VB N
prerecorded JJ N
VF NNP N
and CC N
pulseless JJ N
electrical JJ N
activity NN N
( ( N
PEA NNP N
) ) N
cardiac VBP N
arrest JJS N
scenarios NNS N
compared VBN N
with IN N
the DT N
American NNP N
Heart NNP N
Association NNP N
paper NN N
cardiac NN N
arrest NN N
record NN N
. . N

METHODS NNP N
16 CD p
anaesthesiology NN p
residents NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
view VB N
one CD N
of IN N
two CD N
prerecorded VBD N
, , N
simulated VBD i
VF NNP i
and CC i
PEA NNP i
scenarios NNS i
and CC N
asked VBD N
to TO N
document VB N
the DT N
event NN N
with IN N
either CC N
the DT N
paper NN i
or CC i
electronic JJ i
system NN i
. . i

Each DT N
subject NN N
then RB N
repeated VBD N
the DT N
process NN N
with IN N
the DT N
other JJ N
video NN N
and CC N
documentation NN N
method NN N
. . N

Five CD N
types NNS N
of IN N
documentation NN N
errors NNS N
were VBD N
defined VBN N
: : N
( ( o
1 CD o
) ) o
omission NN o
, , o
( ( o
2 CD o
) ) o
specification NN o
, , o
( ( o
3 CD o
) ) o
timing NN o
, , o
( ( o
4 CD o
) ) o
commission NN o
and CC o
( ( o
5 CD o
) ) o
noise NN o
. . o

The DT N
mean JJ N
difference NN N
in IN N
errors NNS N
between IN N
the DT N
paper NN o
and CC o
electronic JJ o
methods NNS o
was VBD o
analysed VBN o
using VBG N
a DT N
single JJ N
factor NN N
repeated VBD o
measures NNS o
ANOVA NNP o
model NN o
. . N

RESULTS NNP N
Compared VBD N
with IN N
paper NN N
records NNS N
, , N
the DT N
electronic JJ N
system NN N
omitted VBD N
6.3 CD N
fewer JJR N
events NNS N
( ( N
95 CD N
% NN N
CI NNP N
-10.1 NNP N
to TO N
-2.5 VB N
, , N
p=0.003 NN N
) ) N
, , N
which WDT N
represents VBZ N
a DT N
28 CD N
% NN N
reduction NN N
in IN N
omission NN N
errors NNS N
. . N

Users NNS N
recorded VBD N
2.9 CD N
fewer JJR N
noise NN N
items NNS N
( ( N
95 CD N
% NN N
CI NNP N
-5.3 NNP N
to TO N
-0.6 VB N
, , N
p=0.003 NN N
) ) N
when WRB N
compared VBN N
with IN N
paper NN i
, , N
representing VBG N
a DT N
36 CD N
% NN N
decrease NN N
in IN N
redundant NN N
or CC N
irrelevant JJ N
information NN N
. . N

The DT N
rate NN o
of IN o
timing NN o
( ( N
?=-3.2 JJ N
, , N
95 CD N
% NN N
CI NNP N
-9.3 NNP N
to TO N
3.0 CD N
, , N
p=0.286 NN N
) ) N
and CC o
commission NN o
( ( N
?=-4.4 JJ N
, , N
95 CD N
% NN N
CI NNP N
-9.4 NNP N
to TO N
0.5 CD N
, , N
p=0.075 NN N
) ) N
errors NNS N
were VBD N
similar JJ N
between IN N
the DT i
electronic JJ i
system NN i
and CC i
paper NN i
, , i
while IN N
the DT N
rate NN N
of IN N
specification NN N
errors NNS N
were VBD N
about IN N
a DT N
third JJ N
lower JJR N
for IN N
the DT N
electronic JJ N
system NN N
when WRB N
compared VBN N
with IN N
the DT N
paper NN N
record NN N
( ( N
?=-3.2 JJ N
, , N
95 CD N
% NN N
CI NNP N
-6.3 NNP N
to TO N
-0.2 VB N
, , N
p=0.037 NN N
) ) N
. . N

CONCLUSIONS NNP N
Compared NNP N
with IN i
paper NN i
documentation NN i
, , i
documentation NN i
with IN i
the DT i
electronic JJ i
system NN i
captured VBD i
24 CD N
% NN N
more JJR N
critical JJ N
information NN N
during IN N
a DT N
simulated JJ N
medical JJ N
emergency NN N
without IN N
loss NN N
in IN N
data NNS N
quality NN N
. . N

-DOCSTART- -8644688- O O

Effect NN N
of IN N
n-3 JJ i
polyunsaturated JJ i
fatty JJ i
acid NNS i
intake VBP i
on IN N
phospholipid JJ N
fatty JJ N
acid JJ N
composition NN N
in IN N
plasma NN N
and CC N
erythrocytes NNS N
. . N

To TO N
characterize VB N
the DT N
time NN N
course NN N
of IN N
plasma NN N
and CC N
red JJ N
blood NN N
cell NN N
( ( N
RBC NNP N
) ) N
changes NNS N
after IN N
n-3 JJ i
polyunsaturated JJ i
fatty JJ i
acid NN i
( ( i
PUFA NNP i
) ) i
supplementation NN i
, , N
20 CD p
healthy JJ p
male NN p
volunteers NNS p
were VBD p
randomly RB p
assigned VBN p
to TO N
receive VB N
either DT N
four CD i
1-g JJ i
capsules NNS i
of IN i
n-3 JJ i
PUFA NNP i
ethyl NN i
esters NNS i
or CC i
four CD i
1-g JJ i
capsules NNS i
of IN i
olive JJ i
oil NN i
( ( i
as IN i
placebo NN i
) ) i
for IN N
a DT N
period NN N
of IN N
4 CD N
mo NN N
, , N
followed VBN N
by IN N
a DT N
3-mo JJ N
washout NN N
period NN N
. . N

Fatty NNP o
acids NNS o
of IN o
plasma NN o
and CC o
RBC NNP o
phospholipid JJ o
fractions NNS o
were VBD N
analyzed VBN N
at IN N
0 CD N
, , N
2 CD N
, , N
and CC N
4 CD N
mo NN N
of IN N
treatment NN N
and CC N
at IN N
1 CD N
, , N
2 CD N
, , N
and CC N
3 CD N
mo NN N
of IN N
washout NN N
. . N

During IN N
n-3 JJ i
PUFA NNP i
supplementation NN i
, , N
accumulations NNS N
of IN N
eicosapentaenoic NN o
( ( o
EPA NNP o
) ) o
, , o
docosapentaenoic FW o
( ( o
DPA NNP o
) ) o
, , o
and CC o
docosahexaenoic NN o
( ( o
DHA NNP o
) ) o
acids NNS o
were VBD N
marked VBN N
after IN N
2 CD N
mo NN N
with IN N
differences NNS N
among IN N
different JJ N
fractions NNS N
of IN N
plasma NN N
and CC N
RBCs NNP N
in IN N
further JJ N
accumulation NN N
up RB N
to TO N
4 CD N
mo NN N
. . N

During IN N
the DT N
first JJ N
and CC N
second JJ N
months NNS N
of IN N
the DT N
washout NN N
, , N
slight JJ N
differences NNS N
were VBD N
observed VBN N
in IN N
changes NNS o
of IN o
various JJ o
fatty JJ o
acids NNS o
among IN o
different JJ o
phospholipid JJ o
fractions NNS o
, , N
but CC N
after IN N
3 CD N
mo NN N
of IN N
washout NN N
, , N
only RB N
minor JJ N
alterations NNS N
were VBD N
still RB N
detectable JJ N
with IN N
respect NN N
to TO N
pretreatment VB N
values NNS N
. . N

These DT N
data NNS N
confirm VBP N
the DT N
complex JJ N
relations NNS N
among IN N
different JJ o
fatty JJ o
acid NN o
pools NNS o
after IN N
n-3 JJ i
PUFA NNP i
supplementation NN i
. . i

-DOCSTART- -15176685- O O

Clarithromycin NNP i
reduces VBZ N
the DT N
severity NN o
of IN o
bronchial JJ o
hyperresponsiveness NN o
in IN N
patients NNS p
with IN p
asthma NN p
. . p

A DT N
randomised JJ N
double-blind JJ N
placebo-controlled JJ i
study NN N
was VBD N
designed VBN N
to TO N
evaluate VB o
the DT o
effects NNS o
of IN N
a DT N
semisynthetic JJ i
macrolide NN i
antibiotic JJ i
, , i
clarithromycin NN i
, , N
on IN N
bronchial JJ o
hyperresponsiveness NN o
to TO N
methacholine VB i
in IN N
patients NNS p
with IN p
a DT p
diagnosis NN p
of IN p
asthma NN p
. . p

Adult NNP p
asthma JJ p
patients NNS p
undergoing VBG p
treatment NN p
with IN p
budesonide JJ i
400 CD p
microg NN p
b.i.d NN p
. . p

and CC p
salbutamol JJ i
200 CD p
microg NN p
p.r.n NN p
. . p

less JJR p
than IN p
twice RB p
weekly JJ p
were VBD p
studied VBN p
. . p

Arm VB p
A NNP p
( ( p
16 CD p
males/six NN p
females NNS p
, , p
aged VBD p
48 CD p
+/- JJ p
16 CD p
yrs NN p
) ) p
received VBD p
clarithromycin JJ i
250 CD p
mg NN p
b.i.d NN p
. . p

for IN p
8 CD p
weeks NNS p
, , p
arm NN p
B NNP p
( ( p
eight CD p
males/12 NN p
females NNS p
, , p
aged VBD p
42 CD p
+/- JJ p
12 CD p
yrs NN p
) ) p
clarithromycin VBZ i
250 CD N
mg NN N
t.id NN N
. . N

and CC N
arm JJ N
C NNP N
( ( N
six CD N
males/15 NN N
females NNS N
, , N
aged VBD N
41 CD N
+/- JJ N
16 CD N
yrs NN N
) ) N
placebo NN i
dextrose JJ i
tablets NNS N
. . N

Bronchial NNP o
hyperresponsiveness NN o
was VBD o
quantified VBN o
by IN N
measurement NN N
of IN N
the DT N
provocative JJ o
dose NN o
of IN o
methacholine NN o
causing VBG N
a DT N
20 CD o
% NN o
fall NN o
in IN o
forced JJ o
expiratory NN o
volume NN o
in IN o
one CD o
second NN o
( ( o
PD20 NNP o
) ) o
. . o

Median JJ o
( ( o
interquartile JJ o
range NN o
) ) o
PD20 NNP o
in IN N
the DT N
three CD N
groups NNS N
before IN N
and CC N
after IN N
treatment NN N
with IN N
clarithromycin NNS i
were VBD N
: : N
arm NN N
A NN N
: : N
0.3 CD N
( ( N
0.1-1 NN N
) ) N
and CC N
1.3 CD N
( ( N
0.6-2 NN N
) ) N
mg NN N
; : N
arm NN N
B NN N
: : N
0.4 CD N
( ( N
0.1-0.9 NN N
) ) N
and CC N
2 CD N
( ( N
2-2 JJ N
) ) N
mg NN N
; : N
and CC N
arm JJ N
C NNP N
: : N
0.4 CD N
( ( N
0.1-0.9 NN N
) ) N
and CC N
0.3 CD N
( ( N
0.1-0.6 NN N
) ) N
mg NN N
, , N
respectively RB N
. . N

Serum NNP o
free JJ o
cortisol NN o
levels NNS o
were VBD N
determined VBN N
and CC N
remained VBN N
unchanged JJ N
from IN N
baseline NN N
in IN N
the DT N
clarithromycin-treated JJ i
patients NNS p
. . p

It PRP N
is VBZ N
concluded VBN N
that IN N
clarithromycin NN i
reduces VBZ N
the DT N
degree NN o
of IN o
bronchial JJ o
hyperresponsiveness NN o
in IN N
patients NNS p
with IN p
asthma NN p
. . p

-DOCSTART- -25101966- O O

That DT N
looks VBZ N
familiar JJ N
: : N
attention NN N
allocation NN N
to TO N
familiar JJ N
and CC N
unfamiliar JJ N
faces VBZ N
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

INTRODUCTION NNP N
Existing VBG N
eye-tracking JJ i
literature NN N
has VBZ N
shown VBN N
that IN N
both DT N
adults NNS p
and CC p
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
) ) p
show VBP N
fewer JJR N
and CC N
slower JJR N
fixations NNS N
on IN N
faces VBZ N
. . N

Despite IN N
this DT N
reduced JJ N
saliency NN N
and CC N
processing NN N
of IN N
other JJ N
faces VBZ N
, , N
recognition NN N
of IN N
their PRP$ N
own JJ N
face NN N
is VBZ N
reported VBN N
to TO N
be VB N
more JJR N
typical JJ N
in IN N
nature NN N
. . N

This DT N
study NN N
uses VBZ N
eye-tracking VBG i
to TO N
explore VB N
the DT N
typicality NN N
of IN N
gaze NN N
patterns NNS N
when WRB N
children NNS p
with IN p
ASD NNP p
attend VBP N
their PRP$ N
own JJ N
faces VBZ N
compared VBN N
to TO N
other JJ N
familiar JJ N
and CC N
unfamiliar JJ N
faces VBZ N
. . N

METHODS NNP N
Eye-tracking JJ i
methodology NN i
was VBD N
used VBN N
to TO N
explore VB N
fixation NN o
duration NN o
and CC N
time NN o
taken VBN o
to TO o
fixate VB o
on IN o
the DT o
Eye NNP o
and CC o
Mouth NNP o
regions NNS o
of IN o
familiar JJ o
, , o
unfamiliar JJ o
and CC o
Self NNP o
Faces NNP o
. . o

Twenty-one CD p
children NNS p
with IN p
ASD NNP p
( ( p
9-16 CD p
years NNS p
) ) p
were VBD p
compared VBN p
to TO p
typically RB p
developing VBG p
matched VBN p
groups NNS p
. . p

RESULTS VB N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
children NNS p
with IN p
ASD NNP p
and CC N
typically RB p
matched VBD p
groups NNS p
for IN N
fixation NN o
patterns NNS o
to TO o
the DT o
Eye NNP o
and CC o
Mouth NNP o
areas NNS o
of IN N
all DT N
face NN N
types NNS N
( ( N
familiar JJ N
, , N
unfamiliar JJ N
and CC N
self NN N
) ) N
. . N

Correlational JJ N
analyses NNS N
showed VBD N
that IN N
attention NN N
to TO N
the DT N
Eye NNP N
area NN N
of IN N
unfamiliar JJ N
and CC N
Self NNP N
Faces NNP N
was VBD N
related VBN N
to TO N
socio-communicative JJ N
ability NN N
in IN N
children NNS p
with IN p
ASD NNP p
. . p

CONCLUSIONS NNP N
Levels NNP N
of IN N
socio-communicative JJ N
ability NN N
in IN N
children NNS p
with IN p
ASD NNP p
were VBD N
related VBN N
to TO N
gaze VB o
patterns NNS o
on IN o
unfamiliar JJ o
and CC o
Self NNP o
Faces NNP o
, , N
but CC N
not RB N
familiar JJ N
faces VBZ N
. . N

This DT N
lack NN N
of IN N
relationship NN N
between IN N
ability NN o
and CC o
attention NN o
to TO N
familiar JJ N
faces VBZ N
may MD N
indicate VB N
that IN N
children NNS N
across IN N
the DT N
autism NN N
spectrum NN N
are VBP N
able JJ N
to TO N
fixate VB N
these DT N
faces VBZ N
in IN N
a DT N
similar JJ N
way NN N
. . N

The DT N
implications NNS N
for IN N
these DT N
findings NNS N
are VBP N
discussed VBN N
. . N

-DOCSTART- -11508634- O O

The DT N
effect NN N
of IN N
neighborhood-based JJ i
community NN i
organizing VBG i
: : i
results NNS N
from IN N
the DT N
Seattle NNP p
Minority NNP p
Youth NNP p
Health NNP p
Project NNP p
. . p

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
a DT N
community NN i
mobilization NN i
and CC i
youth NN i
development NN i
strategy NN i
to TO N
prevent VB N
drug NN o
abuse NN o
, , o
violence NN o
, , o
and CC o
risky JJ o
sexual JJ o
activity NN o
. . o

DATA NNP N
SOURCES/STUDY NNP N
SETTING NNP N
Primary NNP N
surveys NNS N
of IN N
youth NN p
, , p
parents NNS p
, , p
and CC p
key JJ p
neighborhood NN p
leaders NNS p
were VBD N
carried VBN N
out RP N
at IN N
baseline NN N
( ( N
1994 CD N
) ) N
and CC N
at IN N
the DT N
end NN N
of IN N
the DT N
intervention NN N
period NN N
( ( N
1997 CD N
) ) N
. . N

The DT N
study NN N
took VBD N
place NN N
in IN N
four CD p
intervention NN p
and CC p
six CD p
control NN p
neighborhoods NNS p
in IN p
Seattle NNP p
. . p

STUDY NNP N
DESIGN NNP N
The DT N
study NN N
was VBD N
designed VBN N
as IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
with IN N
neighborhood NN p
as IN N
the DT N
unit NN N
of IN N
randomization NN N
. . N

The DT N
intervention NN N
consisted VBD N
of IN N
a DT N
paid VBN i
community NN i
organizer NN i
in IN i
each DT i
neighborhood NN i
who WP i
recruited VBD i
a DT i
group NN i
of IN i
residents NNS i
to TO i
serve VB i
as IN i
a DT i
community NN i
action NN i
board NN i
. . i

Key NNP N
variables NNS N
included VBD N
perceptions NNS o
of IN o
neighborhood NN o
mobilization NN o
by IN N
youth NN N
, , N
parents NNS N
, , N
and CC N
key JJ N
neighborhood NN N
leaders NNS N
. . N

DATA NNP N
COLLECTION/EXTRACTION NNP N
METHODS NNP N
Youth NNP N
surveys NNS N
were VBD N
self-administered JJ N
during IN N
school NN N
hours NNS N
. . N

Parent NN N
and CC N
neighborhood NN N
leader NN N
surveys NNS N
were VBD N
conducted VBN N
over IN N
the DT N
phone NN N
by IN N
trained JJ N
interviewers NNS N
. . N

PRINCIPAL NNP N
FINDINGS NNP N
Survey NNP N
results NNS N
showed VBD N
that IN N
mobilization NN o
increased VBD N
to TO N
the DT N
same JJ N
degree NN N
in IN N
both DT N
intervention NN N
and CC N
control NN N
neighborhoods NNS N
with IN N
no DT N
evidence NN N
of IN N
an DT N
overall JJ N
intervention NN N
effect NN N
. . N

There EX N
did VBD N
appear VB N
to TO N
be VB N
a DT N
relative JJ N
increase NN N
in IN N
mobilization NN o
in IN N
the DT N
neighborhood NN N
with IN N
the DT N
highest JJS N
level NN o
of IN o
intervention NN o
activity NN o
. . o

CONCLUSION NN N
This DT N
randomized VBN N
study NN N
failed VBD N
to TO N
demonstrate VB N
a DT N
measurable JJ N
effect NN N
for IN N
a DT N
community NN i
mobilization NN o
intervention NN o
. . o

It PRP N
is VBZ N
uncertain JJ N
whether IN N
the DT N
negative JJ N
finding NN N
was VBD N
because IN N
of IN N
a DT N
lack NN N
of IN N
strength NN N
of IN N
the DT N
interventions NNS N
or CC N
problems NNS N
detecting VBG N
intervention NN N
effects NNS N
using VBG N
individual-level JJ N
closed-end JJ N
surveys NNS N
. . N

-DOCSTART- -12120773- O O

A DT N
scanning NN N
electron NN N
microscopic NN N
study NN N
of IN N
different JJ N
caries NNS p
removal VBP o
techniques NNS o
on IN p
human JJ p
dentin NN p
. . p

Scanning VBG N
electron NN N
microscopy NN N
( ( N
SEM NNP N
) ) N
evaluated VBD N
the DT N
effect NN o
of IN o
different JJ o
caries NNS o
removal VBP o
techniques NNS o
on IN p
human JJ p
dentin NN p
topography NN p
. . p

Thirty-six NNP p
extracted VBD p
human JJ p
carious JJ p
mandibular NN p
molars NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
six CD p
groups NNS p
according VBG p
to TO p
caries NNS p
removal NN p
technique NN p
. . p

Carious JJ N
tissue NN N
was VBD N
removed VBN N
by IN N
hand NN o
excavation NN o
, , o
bur JJ o
excavation NN o
, , o
air-abrasion NN o
, , o
laser JJR o
ablation NN o
, , o
chemomechanical JJ o
methods NNS o
and CC o
sono-abrasion NN o
. . o

The DT N
remaining VBG N
dentin NN N
surfaces NNS N
were VBD N
replicated VBN i
and CC i
gold-coated JJ i
. . i

The DT N
surfaces NNS N
were VBD N
examined VBN N
using VBG N
SEM NNP N
and CC N
distinct JJ N
differences NNS N
in IN N
appearance NN N
were VBD N
observed VBN N
among IN N
specimens NNS N
treated VBN N
with IN N
different JJ N
caries NNS N
removal NN N
techniques NNS N
. . N

While IN N
hand-excavated JJ N
, , N
bur-excavated JJ N
and CC N
air-abraded JJ N
carious JJ N
dentin NN N
surfaces NNS N
were VBD N
covered VBN N
with IN N
a DT N
residual JJ o
smear NN o
layer NN o
, , N
sono-abrasion NN N
with IN N
patent JJ N
dentinal JJ N
tubules NNS N
completely RB N
removed VBD N
the DT N
smear JJ N
layer NN N
. . N

A DT N
few JJ N
patent NN o
orifices NNS o
of IN o
dentinal JJ o
tubules NNS o
were VBD N
observed VBN N
in IN N
dentin NN N
subjected VBN N
to TO N
laser VB N
ablation NN N
and CC N
chemo-mechanical JJ N
caries NNS N
removal NN N
. . N

-DOCSTART- -3331506- O O

Physicians NNS p
' POS p
management NN i
of IN i
hypertension NN i
: : i
a DT N
randomized VBN N
controlled VBN N
CME NNP N
trial NN N
. . N

-DOCSTART- -8255984- O O

A DT N
preliminary JJ N
trial NN N
of IN N
ascorbic JJ i
acid NN i
as IN N
supplemental JJ N
therapy NN N
for IN N
autism NN p
. . p

1 CD N
. . N

This DT N
study NN N
presents VBZ N
the DT N
results NNS N
of IN N
a DT N
30-week JJ N
double-blind NN N
, , N
placebo-controlled JJ i
trial NN N
exploring VBG N
the DT N
effectiveness NN N
of IN N
ascorbic JJ i
acid NN i
( ( N
8g/70kg/day CD N
) ) N
as IN N
a DT N
supplemental JJ N
pharmacological JJ N
treatment NN N
for IN N
autistic JJ p
children NNS p
in IN p
residential JJ p
treatment NN p
. . p

2 CD N
. . N

Residential JJ p
school NN p
children NNS p
( ( p
N NNP p
= NNP p
18 CD p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
ascorbate-ascorbate-placebo JJ i
treatment NN i
order NN i
group NN i
or CC i
ascorbate-placebo-ascorbate JJ i
treatment NN i
order NN i
group NN N
. . N

Each DT N
treatment NN N
phase NN N
lasted VBD N
10 CD N
weeks NNS N
and CC N
behaviors NNS N
were VBD N
rated VBN N
weekly JJ N
using VBG N
the DT N
Ritvo-Freeman NNP N
scale NN N
. . N

3 CD N
. . N

Significant JJ N
group NN N
by IN N
phase NN N
interactions NNS N
were VBD N
found VBN N
for IN N
total JJ o
scores NNS o
and CC N
also RB N
sensory JJ o
motor NN o
scores NNS o
indicating VBG N
a DT N
reduction NN N
in IN N
symptom JJ o
severity NN o
associated VBN N
with IN N
the DT N
ascorbic JJ i
acid NN i
treatment NN i
. . i

4 CD N
. . N

These DT N
results NNS N
were VBD N
consistent JJ N
with IN N
a DT N
hypothesized VBN N
dopaminergic NN N
mechanism NN N
of IN N
action NN N
of IN N
ascorbic JJ i
acid NN i
. . i

-DOCSTART- -18592368- O O

The DT N
effects NNS o
of IN N
improvisational JJ i
music NN i
therapy NN i
on IN N
joint JJ N
attention NN N
behaviors NNS N
in IN N
autistic JJ p
children NNS p
: : p
a DT N
randomized NN N
controlled VBN N
study NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effects NNS o
of IN N
improvisational JJ i
music NN i
therapy NN i
on IN N
joint JJ N
attention NN N
behaviors NNS N
in IN N
pre-school JJ p
children NNS p
with IN p
autism NN p
. . p

It PRP N
was VBD N
a DT N
randomized VBN N
controlled VBN N
study NN N
employing VBG N
a DT N
single JJ N
subject NN N
comparison NN N
design NN N
in IN N
two CD N
different JJ N
conditions NNS N
, , N
improvisational JJ i
music NN i
therapy NN i
and CC i
play NN i
sessions NNS i
with IN i
toys NNS i
, , N
and CC N
using VBG N
standardized JJ N
tools NNS N
and CC N
DVD NNP N
analysis NN N
of IN N
sessions NNS N
to TO N
evaluate VB N
behavioral JJ N
changes NNS N
in IN N
children NNS p
with IN p
autism NN p
. . p

The DT N
overall JJ o
results NNS o
indicated VBD N
that IN N
improvisational JJ N
music NN N
therapy NN N
was VBD N
more RBR o
effective JJ o
at IN N
facilitating VBG o
joint JJ o
attention NN o
behaviors NNS o
and CC o
non-verbal JJ o
social JJ o
communication NN o
skills NNS o
in IN N
children NNS N
than IN N
play NN N
. . N

Session NN N
analysis NN N
showed VBD N
significantly RB o
more RBR o
and CC o
lengthier JJR o
events NNS o
of IN o
eye NN o
contact NN o
and CC o
turn-taking NN o
in IN N
improvisational JJ i
music NN i
therapy NN i
than IN N
play NN N
sessions NNS N
. . N

The DT N
implications NNS N
of IN N
these DT N
findings NNS N
are VBP N
discussed VBN N
further RBR N
. . N

-DOCSTART- -6367857- O O

Adjuvant JJ i
therapy NN i
of IN N
breast NN N
cancer NN N
: : N
the DT N
Southwest NNP N
Oncology NNP N
Group NNP N
experience NN N
. . N

The DT N
Southwest NNP N
Oncology NNP N
Group NNP N
in IN N
a DT N
prospective JJ N
randomized NN N
study NN N
compared VBN N
one CD N
year NN N
of IN N
adjuvant JJ i
combination NN i
chemotherapy NN i
with IN i
continuous JJ i
CMFVP NNP i
( ( i
cyclophosphamide NN i
, , i
methotrexate NN i
, , i
5-fluorouracil JJ i
, , i
vincristine NN i
, , i
and CC i
prednisone NN i
) ) i
to TO i
two CD i
years NNS i
of IN i
intermittent JJ i
L-phenylalanine JJ i
mustard NN i
( ( i
L-PAM NNP i
) ) i
in IN N
women NNS p
with IN p
operable JJ p
breast NN p
cancer NN p
with IN p
histologically RB p
positive JJ p
axillary JJ p
lymph NN p
nodes NNS p
. . p

In IN N
fully RB N
and CC N
partially RB N
evaluable JJ N
patients NNS p
with IN p
a DT p
68-month JJ p
median JJ p
follow-up NN p
, , N
treatment NN o
failures NNS o
have VBP N
occurred VBN N
in IN N
27 CD N
% NN N
of IN N
172 CD p
receiving VBG p
CMFVP NNP i
and CC N
47 CD N
% NN N
of IN N
186 CD p
women NNS p
given VBN p
L-PAM NNP i
( ( N
p JJ N
= NNP N
0.002 CD N
) ) N
. . N

The DT N
advantage NN N
for IN N
women NNS N
receiving VBG N
CMFVP NNP i
was VBD N
seen VBN N
for IN N
all DT N
subsets NNS N
regardless RB N
of IN N
menopausal NN N
status NN N
except IN N
among IN N
women NNS p
who WP p
were VBD p
premenopausal NN p
and CC N
had VBD N
1-3 JJ N
positive JJ N
nodes NNS N
. . N

Based VBN N
on IN N
this DT N
study NN N
, , N
a DT N
second JJ N
study NN N
was VBD N
implemented VBN N
using VBG N
both DT N
the DT N
estrogen-receptor NN N
( ( N
ER NNP N
) ) N
content NN N
of IN N
the DT N
primary JJ N
tumor NN N
and CC N
axillary JJ N
nodal NN N
status NN N
to TO N
select VB N
therapy NN N
. . N

-DOCSTART- -23806094- O O

Randomized VBN N
trial NN N
of IN N
tailored JJ N
skin NN p
cancer NN p
prevention NN p
for IN p
children NNS p
: : p
the DT N
Project NNP N
SCAPE NNP N
family NN p
study NN p
. . p

This DT N
study NN N
evaluated VBD N
a DT N
tailored VBN i
intervention NN i
to TO N
promote VB i
sun NN i
protection NN i
in IN N
parents NNS p
and CC p
their PRP$ p
children NNS p
, , N
hypothesizing VBG N
that IN N
the DT N
tailored VBN N
intervention NN N
would MD N
lead VB N
to TO N
improved JJ o
skin NN o
cancer NN o
prevention NN o
behaviors NNS o
compared VBN N
to TO N
generic JJ N
materials NNS N
. . N

Families NNS p
were VBD p
recruited VBN p
through IN p
schools NNS p
and CC p
community NN p
centers NNS p
and CC p
were VBD p
included VBN p
if IN p
there EX p
was VBD p
1 CD p
child NN p
in IN p
Grades NNP p
1-3 JJ p
at IN p
moderate JJ p
to TO p
high JJ p
risk NN p
for IN p
skin JJ p
cancer NN p
. . p

Participants NNS N
were VBD N
randomized VBN N
into IN N
one CD N
of IN N
two CD N
intervention NN N
groups NNS N
: : N
a DT N
tailored JJ i
intervention NN i
, , i
in IN i
which WDT i
they PRP i
received VBD i
personalized JJ i
skin NN i
cancer NN i
education NN i
through IN i
the DT i
mail NN i
; : i
or CC i
a DT i
control NN i
group NN i
who WP i
received VBD i
generic JJ i
skin NN i
cancer NN i
information NN i
materials NNS i
. . i

Before IN N
and CC N
after IN N
intervention NN N
, , N
parents NNS N
completed VBD N
questionnaires NNS N
about IN N
their PRP$ N
and CC N
their PRP$ N
children NNS N
's POS N
skin NN N
cancer NN N
risk NN N
and CC N
prevention NN N
knowledge NN N
and CC N
behaviors NNS N
. . N

Parents NNS p
also RB N
completed VBD N
4-day JJ N
sun NN N
exposure NN N
and CC N
protection NN N
diaries NNS N
for IN N
their PRP$ N
child NN N
and CC N
themselves PRP N
. . N

Tailored VBN p
group NN p
participants NNS p
demonstrated VBD N
significantly RB o
greater JJR o
positive JJ o
changes NNS o
in IN o
prevention NN o
behavior NN o
after IN N
the DT N
intervention NN N
, , N
including VBG N
children NNS o
's POS o
use NN o
of IN o
sunscreen NN o
, , o
shirts NNS o
, , o
and CC o
hats NNS o
, , o
and CC o
parents NNS o
' POS o
use NN o
of IN o
shade NN o
, , o
and CC o
skin JJ o
examinations NNS o
. . o

Effect JJ o
sizes NNS o
were VBD N
small JJ o
and CC o
perceived JJ o
benefits NNS o
and CC o
social JJ o
norms NNS o
mediated VBN o
intervention NN o
effects NNS o
. . o

Findings NNS N
from IN N
this DT N
study NN N
support VBD N
the DT N
efficacy NN N
of IN N
focusing VBG N
tailored VBN N
communications NNS N
to TO N
families NNS p
in IN N
order NN N
to TO N
change VB N
skin JJ p
cancer NN p
prevention NN p
practices NNS p
in IN p
young JJ p
children NNS p
. . p

-DOCSTART- -22750958- O O

Modified VBN i
constraint-induced JJ i
movement NN i
therapy NN i
improved VBD N
upper JJ N
limb NN N
function NN N
in IN N
subacute JJ p
poststroke NN p
patients NNS p
: : p
a DT N
small-scale JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
Constraint-induced JJ i
movement NN i
therapy NN i
( ( i
CIMT NNP i
) ) i
has VBZ N
been VBN N
advocated VBN N
as IN N
a DT N
means NN N
of IN N
facilitating VBG N
motor NN N
function NN N
in IN N
poststroke NN p
patients NNS p
; : p
however RB N
, , N
the DT N
evidence NN N
for IN N
its PRP$ N
efficacy NN N
is VBZ N
controversial JJ N
. . N

OBJECTIVE NN N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
modified VBN N
CIMT NNP i
on IN N
improving VBG N
paretic JJ N
arm NN N
function NN N
in IN N
poststroke NN p
patients NNS p
during IN N
a DT N
subacute JJ N
rehabilitation NN N
period NN N
. . N

METHODS VB N
A DT N
single-blinded JJ N
randomized NN N
controlled VBD N
trial NN N
was VBD N
conducted VBN N
at IN N
the DT N
Loewenstein NNP p
Rehabilitation NNP p
Hospital NNP p
, , p
Israel NNP p
. . p

Twenty-eight NNP p
subacute JJ p
stroke VBD p
patients NNS p
with IN p
arm JJ p
paresis NN p
after IN p
a DT p
first JJ p
ischemic JJ p
stroke NN p
in IN p
the DT p
middle JJ p
cerebral JJ p
artery NN p
area NN p
were VBD N
randomized VBN N
into IN N
a DT N
modified JJ i
CIMT NNP i
or CC i
control VB i
group NN i
by IN N
a DT N
1:2 CD N
ratio NN N
. . N

The DT N
modified JJ N
CIMT NNP i
group NN N
received VBD N
1-hour JJ N
daily JJ N
physical JJ i
rehabilitation NN i
sessions NNS N
for IN N
2 CD N
weeks NNS N
. . N

The DT N
unaffected JJ N
arm NN N
was VBD N
restrained VBN N
during IN N
the DT N
sessions NNS N
. . N

Subjects NNS N
were VBD N
encouraged VBN N
to TO N
wear VB N
a DT N
restrictive NN i
mitten VBZ i
up RP N
to TO N
4 CD N
hours NNS N
a DT N
day NN N
. . N

The DT N
control NN N
group NN N
received VBD N
similar JJ N
intensive JJ N
regular JJ N
rehabilitation NN N
. . N

Three CD N
upper JJ N
limb NN N
function NN N
tests NNS N
, , N
developed VBD N
for IN N
this DT N
study NN N
, , N
were VBD N
used VBN N
as IN N
outcome JJ N
measures NNS N
. . N

The DT N
subjects NNS N
were VBD N
asked VBN N
to TO N
perform VB N
the DT N
following JJ N
tasks NNS N
, , N
with IN N
the DT N
affected JJ N
hand NN N
for IN N
30 CD N
seconds NNS N
: : N
( ( N
1 CD N
) ) N
transfer NN N
pegs NN N
from IN N
a DT N
saucer NN N
to TO N
a DT N
pegboard NN N
; : N
( ( N
2 CD N
) ) N
grasp NN N
, , N
carry NN N
, , N
and CC N
release VB N
a DT N
hard JJ N
rubber NN N
ball NN N
; : N
and CC N
( ( N
3 CD N
) ) N
eating NN N
, , N
using VBG N
a DT N
spoon NN N
to TO N
remove VB N
the DT N
jelly NN N
from IN N
the DT N
plate NN N
, , N
bring VBG N
it PRP N
towards IN N
the DT N
mouth NN N
, , N
and CC N
then RB N
place VB N
it PRP N
on IN N
another DT N
plate NN N
. . N

The DT o
number NN o
of IN o
repetitions NNS o
in IN o
each DT o
test NN o
was VBD o
recorded VBN o
as IN o
an DT o
outcome NN o
. . o

RESULTS VB N
The DT N
modified JJ N
CIMT NNP i
group NN p
showed VBD N
significantly RB N
higher JJR N
changes NNS N
in IN N
all DT N
3 CD N
tests NNS N
compared VBN N
to TO N
the DT N
standard JJ N
rehabilitation NN N
group NN N
. . N

CONCLUSION NNP N
Our PRP$ N
study NN N
provides VBZ N
additional JJ N
support NN N
for IN N
the DT N
use NN N
of IN N
modified JJ i
CIMT NNP i
during IN N
a DT N
subacute JJ N
rehabilitation NN N
period NN N
of IN N
poststroke NN N
patients NNS N
. . N

CIMT NNP i
may MD N
facilitate VB N
functional JJ N
improvement NN N
of IN N
a DT N
plegic JJ N
hand NN N
. . N

-DOCSTART- -15943172- O O

A DT N
short-term JJ i
cognitive JJ i
group NN i
treatment NN i
program NN i
gives VBZ N
substantial JJ N
weight NN o
reduction NN o
up RB N
to TO N
18 CD N
months NNS N
from IN N
the DT N
end NN N
of IN N
treatment NN N
. . N

A DT N
randomized JJ N
controlled JJ N
trial NN N
. . N

OBJECTIVE UH N
To TO N
describe VB N
and CC N
evaluate VB N
long-term JJ N
efficacy NN N
( ( N
18 CD N
months NNS N
from IN N
the DT N
end NN N
of IN N
treatment NN N
) ) N
of IN N
a DT N
new JJ N
cognitive JJ i
short-term JJ i
weight NN i
reducing VBG i
treatment NN i
program NN i
for IN N
obese JJ p
patients NNS p
. . p

SUBJECTS NNP N
One CD p
hundred CD p
and CC p
five CD p
obese JJ p
[ NN p
Body NNP p
Mass NNP p
Index NNP p
( ( p
BMI NNP p
) ) p
> VBD p
or CC p
= $ p
30 CD p
] JJ p
patients NNS p
participated VBN p
in IN p
the DT p
study NN p
. . p

Of IN N
these DT N
, , N
62 CD p
took VBD p
part NN p
in IN p
the DT p
treatment NN p
program NN p
and CC p
43 CD p
served VBD p
as IN p
controls NNS p
. . p

METHOD NNP N
From IN N
an DT N
obesity NN p
unit NN p
's POS p
waiting VBG p
list NN p
, , N
the DT N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
either VB N
a DT N
treatment NN N
group NN N
or CC N
remained VBN N
in IN N
the DT N
waiting VBG N
list NN N
to TO N
serve VB N
as IN N
a DT N
control NN i
group NN N
. . N

The DT N
treatment NN N
group NN N
participated VBD N
in IN N
a DT N
10-week JJ i
( ( i
30 CD i
hours NNS i
) ) i
cognitive VBP i
group NN i
treatment NN i
program NN i
. . i

All DT N
participants NNS N
were VBD N
weighed VBN N
at IN N
the DT N
outset NN N
of IN N
the DT N
study NN N
, , N
directly RB N
after IN N
treatment NN N
and CC N
at IN N
a DT N
6- JJ N
, , N
12- JJ N
and CC N
18-month JJ N
post-treatment JJ i
follow-up NN N
without IN N
any DT N
booster NN N
treatment NN i
after IN N
the DT N
10-week JJ N
program NN N
. . N

RESULTS NNP N
Fifty-seven NNP p
( ( p
92 CD p
% NN p
) ) p
patients NNS p
completed VBN p
treatment NN i
. . i

For IN N
the DT N
34 CD N
( ( N
60 CD N
% NN N
) ) N
patients NNS N
who WP N
participated VBD N
in IN N
the DT N
study NN N
18 CD N
months NNS N
after IN N
treatment NN N
was VBD N
terminated VBN N
, , N
the DT N
mean JJ o
weight NN o
loss NN o
at IN N
treatment NN N
's POS N
end NN N
was VBD N
8.5 CD N
kg NN N
( ( N
SD=16.1 NNP N
) ) N
. . N

Eighteen JJ N
months NNS N
later RB N
their PRP$ N
mean JJ o
weight NN o
loss NN o
was VBD N
10.4 CD N
kg NN N
( ( N
SD=10.8 NNP N
) ) N
. . N

The DT N
control NN N
patients NNS N
( ( N
n=31.72 JJ N
% NN N
) ) N
that WDT N
participated VBD N
in IN N
the DT N
study NN N
during IN N
the DT N
same JJ N
period NN N
increased VBD N
in IN N
weight NN o
by IN N
2.3 CD N
kg NNS N
( ( N
SD=7.0 NNP N
) ) N
. . N

The DT N
weight NN o
difference NN o
between IN N
the DT N
treatment NN N
and CC N
control NN N
group NN N
at IN N
the DT N
18-month JJ N
follow-up NN N
was VBD N
highly RB N
significant JJ N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
cognitive JJ i
group NN i
treatment NN i
program NN i
was VBD N
highly RB N
acceptable JJ N
among IN N
the DT N
participants NNS N
and CC N
was VBD N
completed VBN N
by IN N
nearly RB N
all PDT N
the DT N
patients NNS N
. . N

The DT N
10-week JJ N
treatment NN N
program NN N
resulted VBD N
in IN N
satisfactory JJ N
weight JJ o
loss NN o
. . o

The DT N
weight NN N
difference NN N
between IN N
the DT N
treatment NN i
group NN N
and CC N
controls NNS i
was VBD N
nearly RB N
the DT N
same JJ N
at IN N
18 CD N
months NNS N
after IN N
end NN N
of IN N
treatment NN N
as IN N
at IN N
six CD N
months NNS N
. . N

The DT N
study NN N
, , N
therefore RB N
, , N
does VBZ N
not RB N
provide VB N
support NN N
for IN N
the DT N
contention NN N
that IN N
a DT N
lengthy JJ N
therapy NN N
for IN N
obesity NN N
is VBZ N
necessary JJ N
if IN N
treatment NN N
results NNS N
are VBP N
lasting VBG N
. . N

-DOCSTART- -21087288- O O

A DT N
placebo-controlled JJ i
, , N
randomized JJ N
clinical JJ N
trial NN N
using VBG N
testosterone NN i
undecanoate NN i
with IN i
injectable JJ i
norethisterone JJ i
enanthate NN i
: : i
effect NN N
on IN N
anthropometric NN p
, , p
metabolic JJ p
and CC p
biochemical JJ p
parameters NNS p
. . p

Testosterone CD N
administered VBD N
alone RB N
or CC N
in IN N
combination NN N
with IN N
progestogens NNS N
in IN N
male JJ N
contraception NN N
induces NNS N
reversible JJ N
oligo-azoospermia JJ N
, , N
but CC N
its PRP$ N
effects NNS N
on IN N
body NN N
composition NN N
and CC N
metabolism NN N
are VBP N
less RBR N
known JJ N
. . N

We PRP N
analysed VBD p
anthropometric JJ p
and CC p
metabolic JJ p
parameters NNS p
in IN p
five CD p
groups NNS p
of IN p
10 CD p
males NNS p
: : p
four CD p
receiving VBG p
testosterone NN i
undecanoate NN i
( ( N
TU NNP N
: : N
1000 CD N
mg NN N
) ) N
plus CC i
norethisterone JJ i
enanthate NN i
( ( N
NETE NNP N
: : N
200 CD N
mg NN N
) ) N
at IN N
different JJ N
intervals NNS N
( ( N
every DT N
8 CD N
weeks NNS N
: : N
NETE-8 JJ N
; : N
every DT N
12 CD N
weeks NNS N
: : N
NETE-12 NN N
; : N
every DT N
6 CD N
weeks NNS N
for IN N
12 CD N
weeks NNS N
and CC N
then RB N
every DT N
12 CD N
weeks NNS N
: : N
NETE-6/12 JJ N
; : N
every DT N
6 CD N
weeks NNS N
for IN N
12 CD N
weeks NNS N
and CC N
then RB N
TU NNP i
plus CC i
placebo JJ i
every DT N
12 CD N
weeks NNS N
: : N
NETE-6/12/0 NNP N
) ) N
and CC N
one CD N
placebo NN i
( ( N
NETE-0/0 NNP N
) ) N
for IN N
a DT N
total NN N
of IN N
48 CD N
weeks NNS N
. . N

Body NNP o
mass NN o
index NN o
( ( o
BMI NNP o
) ) o
and CC o
waist JJ o
circumference NN o
did VBD o
not RB o
change VB o
in IN N
any DT N
groups NNS N
except IN N
for IN N
the DT N
NETE-8 NNP N
in IN N
which WDT N
BMI NNP o
increased VBD o
significantly RB o
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
at IN N
the DT N
end NN N
of IN N
the DT N
treatment NN N
period NN N
. . N

Lean JJ o
body NN o
mass NN o
( ( o
MAMC NNP o
or CC o
AMA NNP o
) ) o
increased VBD o
significantly RB o
in IN N
the DT N
highest JJS N
hormonal JJ N
dose NN N
groups NNS N
( ( N
p JJ N
= NN N
0.04 CD N
, , N
NETE-6/12 NNP N
; : N
p VBZ N
= $ N
0.004 CD N
, , N
NETE-8 NNP N
) ) N
. . N

No UH N
differences NNS N
were VBD N
observed VBN N
in IN N
glucose JJ o
levels NNS o
, , o
insulin NN o
sensitivity NN o
index NN o
and CC o
lipid JJ o
profile NN o
as RB N
well RB N
as IN N
in IN N
biochemical JJ o
and CC o
cell NN o
count NN o
parameters NNS o
in IN N
any DT N
groups NNS N
. . N

In IN N
conclusion NN N
, , N
NETE NNP N
and CC N
TU NNP N
for IN N
48 CD N
weeks NNS N
were VBD N
not RB N
accompanied VBN N
by IN N
any DT N
metabolic JJ o
changes NNS o
and CC o
any DT o
adverse JJ o
effects NNS o
. . o

The DT N
weight JJ o
gain NN o
of IN N
the DT N
highest JJS N
NETE JJ N
plus CC N
TU JJ N
dosage NN N
was VBD N
mainly RB N
because IN N
of IN N
gain NN N
in IN N
muscle NN N
mass NN N
. . N

-DOCSTART- -8828933- O O

Regular JJ N
replacement NN N
of IN N
extended VBN i
wear NN i
rigid JJ i
gas NN i
permeable JJ i
contact NN i
lenses NNS i
. . i

PURPOSE NNP N
While IN N
the DT N
benefits NNS N
of IN N
planned JJ N
replacement NN N
of IN N
soft JJ i
contact NN i
lenses NNS i
have VBP N
been VBN N
investigated VBN N
, , N
the DT N
question NN N
of IN N
whether IN N
there EX N
are VBP N
any DT N
clinical JJ N
benefits NNS N
to TO N
planned VBN N
replacement NN N
of IN N
rigid JJ i
gas NN i
permeable NN i
( ( i
RGP NNP i
) ) i
lenses VBZ i
does VBZ N
not RB N
appear VB N
to TO N
have VB N
been VBN N
addressed VBN N
experimentally RB N
. . N

We PRP N
aimed VBD N
to TO N
determine VB N
the DT N
benefits NNS N
of IN N
regular JJ i
replacement NN i
of IN N
extended VBN i
wear NN i
RGP NNP i
contact NN i
lenses VBZ i
. . i

METHODS NNP N
We PRP N
conducted VBD N
a DT N
prospective JJ N
, , N
single-center JJ p
, , p
controlled VBN p
, , p
double-masked JJ p
study NN p
of IN p
39 CD p
RGP NNP p
lens VBZ p
wearers NNS p
. . p

The DT N
subjects NNS N
were VBD N
divided VBN N
into IN N
two CD N
groups NNS N
and CC N
wore NN i
extended VBD i
wear JJ i
Quantum NNP i
2 CD i
lenses NNS i
( ( N
Dk NNP N
= NNP N
120 CD N
) ) N
for IN N
12 CD N
months NNS N
. . N

Subjects NNS N
in IN N
Group NNP N
I PRP N
replaced VBD i
lenses NNS i
every DT i
3 CD i
months NNS i
, , N
whereas VBP N
those DT N
in IN N
Group NNP N
II NNP N
were VBD N
not RB i
scheduled VBN i
to TO i
replace VB i
their PRP$ i
lenses NNS i
. . i

The DT N
integrity NN o
of IN o
the DT o
lenses NNS o
and CC o
the DT o
ocular JJ o
responses NNS o
to TO N
lens NNS N
wear WDT N
were VBD N
monitored VBN N
in IN N
both DT N
groups NNS N
every DT N
three CD N
months NNS N
. . N

RESULTS NNP N
Compared VBD N
to TO N
lenses NNS N
worn VBN N
by IN N
subjects NNS N
in IN N
Group NNP N
I PRP N
, , N
lenses VBZ N
worn VBN N
by IN N
Group NNP N
II NNP N
subjects VBZ N
showed VBD N
significantly RB N
more RBR N
mucous JJ o
coating NN o
, , o
lens VBZ o
binding NN o
, , o
and CC o
corneal NN o
staining NN o
over IN N
time NN N
( ( N
P NNP N
< NNP N
0.05 CD N
; : N
ANCOVA NNP N
) ) N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
microcystic JJ o
or CC o
tarsal JJ o
conjunctiva JJ o
response NN o
, , o
lens VBZ o
comfort NN o
, , o
refractive JJ o
change NN o
, , o
or CC o
visual JJ o
acuity NN o
between IN N
the DT N
two CD N
groups NNS N
. . N

CONCLUSIONS NNP N
We PRP N
advocate VBP N
that DT N
to TO N
maintain VB N
optimal JJ o
lens NNS o
integrity NN o
and CC o
ocular JJ o
health NN o
, , N
RGP NNP p
lenses VBZ p
used VBN N
for IN N
extended JJ N
wear NN N
should MD N
be VB N
replaced VBN N
every DT N
3 CD N
to TO N
6 CD N
months NNS N
. . N

-DOCSTART- -15948916- O O

Lessons NNS N
learnt VBP N
in IN N
conducting VBG N
a DT N
clinical JJ i
drug NN i
trial NN i
in IN N
children NNS p
with IN p
Asperger NNP p
Syndrome NNP p
. . p

OBJECTIVE NNP N
To TO N
describe VB N
the DT N
authors NNS N
' POS N
experience NN N
of IN N
conducting VBG N
a DT N
clinical JJ N
drug NN N
trial NN N
in IN N
children NNS p
with IN p
Asperger NNP p
Syndrome NNP p
, , N
including VBG N
the DT N
pitfalls NNS N
encountered VBD N
and CC N
lessons NNS N
learnt VBP N
. . N

CONCLUSIONS VB N
The DT o
main JJ o
barrier NN o
encountered VBD o
was VBD o
in IN o
the DT o
recruitment NN o
of IN o
children NNS o
: : o
it PRP p
was VBD p
not RB p
possible JJ p
to TO p
recruit VB p
the DT p
target NN p
of IN p
60 CD p
patients NNS p
. . p

The DT N
recruitment NN o
of IN o
children NNS o
is VBZ N
often RB N
the DT N
major JJ N
barrier NN N
to TO N
the DT N
progress NN N
of IN N
a DT N
successful JJ N
clinical JJ N
trial NN N
. . N

Conducting VBG N
the DT N
clinical JJ N
drug NN N
trial NN N
was VBD N
greatly RB N
facilitated VBN N
by IN N
the DT N
appropriate JJ N
setting NN N
and CC N
experienced VBD N
clinical JJ N
pharmacology NN N
staff NN N
. . N

-DOCSTART- -6391269- O O

Fentanyl NNP i
supplementation NN N
to TO N
inhalation NN p
anaesthesia NN p
. . p

In IN N
eight CD p
out IN p
of IN p
15 CD p
healthy JJ p
patients NNS p
undergoing VBG p
body NN p
surface NN p
surgery NN p
, , N
the DT N
effect NN N
of IN N
a DT N
fentanyl JJ i
infusion NN i
on IN N
a DT N
conventional JJ N
thiopentone NN i
, , i
nitrous JJ i
oxide NN i
, , i
oxygen NN i
and CC N
halothane NN i
anaesthetic NN i
was VBD N
studied VBN N
. . N

The DT N
fentanyl JJ i
infusion NN i
( ( N
2 CD N
micrograms/kg/hour NN N
) ) N
reduced VBD N
the DT N
induction NN o
dose NN o
of IN o
thiopentone NN o
and CC N
caused VBD N
marked JJ o
respiratory JJ o
depression NN o
with IN N
a DT N
reduction NN N
in IN N
the DT N
patients NNS N
' POS N
response NN N
to TO N
surgery NN N
. . N

The DT N
mean JJ o
arterial JJ o
pressures NNS o
and CC o
pulse JJ o
rates NNS o
were VBD N
not RB N
significantly RB N
different JJ N
in IN N
each DT N
group NN N
throughout IN N
the DT N
course NN N
of IN N
the DT N
operation NN N
. . N

The DT N
fentanyl NN i
made VBD N
no DT N
difference NN N
to TO N
the DT N
patients NNS N
' POS N
postoperative JJ N
analgesic JJ N
requirements NNS N
or CC N
to TO N
their PRP$ N
recovery NN N
in IN N
the DT N
first JJ N
24 CD N
hours NNS N
. . N

-DOCSTART- -7706098- O O

The DT N
effect NN N
of IN N
patient JJ i
position NN i
on IN N
the DT N
reproducibility NN N
of IN N
cardiac JJ N
output NN N
measurements NNS N
. . N

OBJECTIVE NN N
To TO N
determine VB N
the DT N
effect NN N
of IN N
patient JJ i
position NN i
on IN N
the DT N
reproducibility NN N
of IN N
cardiac JJ N
output NN N
measurements NNS N
. . N

DESIGN NNP N
Prospective NNP N
, , N
two-group JJ N
quasi-experimental JJ N
design NN N
. . N

Convenience NN N
sample NN N
. . N

SETTING CC N
The DT N
study NN N
involved VBD N
two CD p
intensive JJ p
care NN p
units NNS p
in IN p
two CD p
adult NN p
acute NN p
care NN p
hospitals NNS p
. . p

PATIENTS NNP N
Thirty NNP p
patients NNS p
admitted VBD p
to TO p
the DT p
intensive JJ p
care NN p
unit NN p
who WP p
had VBD p
a DT p
thermodilution NN p
pulmonary JJ p
artery NN p
catheter NN p
in IN p
place NN p
. . p

Ages NNS p
ranged VBD p
from IN p
39 CD p
to TO p
80 CD p
years NNS p
( ( p
mean NN p
of IN p
66.4 CD p
+/- JJ p
11.3 CD p
years NNS p
) ) p
. . p

OUTCOME NNP N
MEASURES NNP N
Thermodilution NNP o
cardiac NN o
output NN o
measurements NNS o
. . o

INTERVENTION NNP N
The DT N
subjects NNS N
were VBD N
placed VBN N
in IN N
one CD N
of IN N
two CD N
groups NNS N
, , N
initially RB N
by IN N
flipping VBG N
a DT N
coin NN N
then RB N
into IN N
alternate NN N
groups NNS N
. . N

Group NNP N
A NNP N
subjects NNS N
were VBD N
placed VBN N
supine NN i
, , N
and CC N
after IN N
5 CD N
minutes NNS N
had VBD N
cardiac JJ N
output NN N
measurements NNS N
performed VBN N
. . N

They PRP N
were VBD N
then RB N
placed VBN N
in IN N
the DT N
45-degree JJ i
upright JJ i
position NN i
, , N
and CC N
after IN N
an DT N
additional JJ N
5 CD N
minutes NNS N
had VBD N
cardiac JJ N
output NN N
measurements NNS N
performed VBN N
. . N

Group NNP N
B NNP N
subjects NNS N
were VBD N
first RB N
placed VBN N
in IN N
the DT N
45-degree JJ i
upright JJ i
position NN i
, , N
and CC N
after IN N
5 CD N
minutes NNS N
had VBD N
cardiac JJ N
output NN N
measurements NNS N
performed VBN N
. . N

They PRP N
were VBD N
then RB N
placed VBN N
in IN N
the DT N
supine NN i
flat JJ i
position NN i
, , N
and CC N
after IN N
an DT N
additional JJ N
5 CD N
minutes NNS N
had VBD N
cardiac JJ N
output NN N
measurements NNS N
performed VBN N
. . N

RESULTS NNP N
Seventy NNP N
percent NN N
( ( N
n JJ N
= NNP N
30 CD N
) ) N
of IN N
the DT N
sample JJ N
population NN N
displayed VBD N
a DT N
lower JJR o
cardiac NN o
output NN o
in IN N
the DT N
45-degree JJ N
upright JJ N
position NN N
than IN N
that DT N
obtained VBN N
in IN N
the DT N
supine JJ N
position NN N
, , N
with IN N
the DT N
decrease NN N
ranging VBG N
from IN N
1 CD N
% NN N
to TO N
32 CD N
% NN N
( ( N
mean JJ N
decrease NN N
11 CD N
% NN N
) ) N
. . N

Forty CD N
percent NN N
( ( N
n JJ N
= NNP N
30 CD N
) ) N
of IN N
cardiac JJ o
output NN o
measurements NNS o
obtained VBN N
in IN N
the DT N
45-degree JJ N
upright NN N
were VBD N
greater JJR N
than IN N
or CC N
equal JJ N
to TO N
10 CD N
% NN N
less JJR N
than IN N
those DT N
obtained VBN N
in IN N
the DT N
supine NN N
flat JJ N
position NN N
. . N

The DT N
differences NNS o
in IN o
cardiac JJ o
output NN o
were VBD N
analyzed VBN N
with IN N
the DT N
paired JJ N
t JJ N
test NN N
. . N

which WDT N
produced VBD N
a DT N
95 CD N
% NN N
confidence NN N
interval NN N
from IN N
-0.539 NN N
to TO N
-0.083 VB N
. . N

The DT N
two-group JJ N
Wilcoxon NNP N
test NN N
was VBD N
used VBN N
to TO N
analyze VB N
the DT N
mean JJ o
cardiac JJ o
output NN o
with IN N
the DT N
patient NN N
in IN N
the DT N
supine NN N
, , N
flat JJ N
position NN N
and CC N
in IN N
the DT N
45-degree JJ N
upright JJ N
position NN N
. . N

The DT N
mean JJ o
cardiac JJ o
output NN o
at IN N
0 CD N
degrees NNS N
was VBD N
found VBN N
to TO N
be VB N
statistically RB N
significant JJ N
higher JJR N
( ( N
p JJ N
= NNP N
0.0083 CD N
) ) N
than IN N
the DT N
mean JJ N
cardiac JJ N
output NN N
at IN N
45 CD N
degrees NNS N
. . N

The DT N
effect NN N
of IN N
coexisting VBG N
variables NNS N
was VBD N
analyzed VBN N
with IN N
the DT N
Kruskal-Wallis NNP N
. . N

The DT N
use NN N
of IN N
vasoconstrictors NNS N
was VBD N
the DT N
only JJ N
variable NN N
that WDT N
had VBD N
a DT N
statistically RB N
significant JJ N
change NN N
in IN N
cardiac JJ o
output NN o
associated VBN N
with IN N
a DT N
change NN N
in IN N
position NN N
. . N

CONCLUSIONS NNP N
These DT N
results NNS N
indicate VBP N
that IN N
cardiac JJ N
output NN N
measurements NNS N
are VBP N
affected VBN N
by IN N
alterations NNS N
in IN N
patient JJ N
position NN N
. . N

To TO N
ensure VB N
accurate JJ N
comparisons NNS N
between IN N
consecutive JJ N
cardiac JJ N
output NN N
measurements NNS N
, , N
the DT N
researchers NNS N
recommend VBP N
that IN N
the DT N
position NN N
in IN N
which WDT N
the DT N
cardiac NN N
output NN N
measurements NNS N
are VBP N
performed VBN N
be VB N
documented VBN N
and CC N
the DT N
cardiac JJ N
output NN N
measurements NNS N
be VB N
conducted VBN N
in IN N
a DT N
uniform JJ N
position NN N
. . N

-DOCSTART- -500415- O O

New NNP i
methods NNS i
applied VBN N
to TO N
the DT N
analysis NN N
and CC N
treatment NN N
of IN N
ovarian JJ p
cancer NN p
. . p

-DOCSTART- -17356153- O O

Compliance NN N
with IN N
continuous JJ i
passive JJ i
movement NN i
is VBZ N
low JJ N
after IN N
surgical JJ N
treatment NN N
of IN N
idiopathic JJ p
club JJ p
foot NN p
in IN p
infants NNS p
: : p
a DT N
prospective JJ N
, , N
double-blinded JJ N
clinical JJ N
study NN N
. . N

Treatment NN N
by IN N
continuous JJ i
passive JJ i
movement NN i
at IN i
home NN i
is VBZ N
an DT N
alternative JJ N
to TO N
immobilisation NN N
in IN N
a DT N
cast NN N
after IN p
surgery NN p
for IN p
club JJ p
foot NN p
. . p

Compliance NN N
with IN N
the DT N
recommended JJ N
treatment NN N
, , N
of IN N
at IN N
least JJS N
four CD N
hours NNS N
daily RB N
, , N
is VBZ N
unknown JJ N
. . N

The DT N
duration NN N
of IN N
treatment NN N
was VBD N
measured VBN N
in IN N
24 CD p
of IN p
27 CD p
consecutive JJ p
children NNS p
with IN p
a DT p
mean JJ p
age NN p
of IN p
24 CD p
months NNS p
( ( p
5 CD p
to TO p
75 CD p
) ) p
following VBG p
posteromedial JJ p
release NN p
for IN p
idiopathic JJ p
club JJ p
foot NN p
. . p

Only RB N
21 CD N
% NN N
( ( N
5 CD N
) ) N
of IN N
the DT N
children NNS N
used VBD N
the DT N
continuous JJ i
passive JJ i
movement NN i
machine NN N
as IN N
recommended JJ N
. . N

The DT N
mean JJ N
duration NN N
of IN N
treatment NN N
at IN N
home NN N
each DT N
day NN N
was VBD N
126 CD N
minutes NNS N
( ( N
11 CD N
to TO N
496 CD N
) ) N
. . N

The DT N
mean JJ o
range NN o
of IN o
movement NN o
for IN o
plantar NN o
flexion NN o
improved VBD o
from IN o
15.2 CD o
degrees NNS o
( ( o
10.0 CD o
degrees NNS o
to TO o
20.6 CD o
degrees NNS o
) ) o
to TO o
18.7 CD o
degrees NNS o
( ( o
10.0 CD o
degrees NNS o
to TO o
33.0 CD o
degrees NNS o
) ) o
and CC o
for IN o
dorsiflexion NN o
from IN o
12.3 CD o
degrees NNS o
( ( o
7.4 CD o
degrees NNS o
to TO o
19.4 CD o
degrees NNS o
) ) o
to TO o
18.9 CD o
degrees NNS o
( ( o
10.0 CD o
degrees NNS o
to TO o
24.1 CD o
degrees NNS o
) ) o
( ( o
both DT o
, , o
p NN o
= NNP o
0.0001 CD o
) ) o
when WRB o
the DT o
first JJ o
third NN o
of IN o
therapy NN o
was VBD o
compared VBN o
with IN o
the DT o
last JJ o
third JJ o
. . o

A DT N
low JJ N
level NN N
of IN N
patient JJ N
compliance NN N
must MD N
be VB N
considered VBN N
when WRB N
the DT N
outcome NN N
after IN N
treatment NN N
at IN N
home NN N
is VBZ N
interpreted VBN N
. . N

-DOCSTART- -2586565- O O

Peritoneovenous JJ i
shunting VBG i
as IN N
compared VBN N
with IN N
medical JJ i
treatment NN i
in IN N
patients NNS p
with IN p
alcoholic JJ p
cirrhosis NN p
and CC p
massive JJ p
ascites NNS p
. . p

Veterans NNPS N
Administration NNP N
Cooperative NNP N
Study NNP N
on IN N
Treatment NNP N
of IN N
Alcoholic NNP N
Cirrhosis NNP N
with IN N
Ascites NNP N
. . N

The DT N
optimal JJ N
management NN N
of IN N
severe JJ N
ascites NNS N
in IN N
patients NNS p
with IN p
alcoholic JJ p
cirrhosis NN p
has VBZ N
not RB N
been VBN N
defined VBN N
. . N

in IN N
a DT N
5 CD N
1/2-year JJ N
study NN N
, , N
we PRP N
randomly VBP N
assigned VBN N
299 CD p
men NNS p
with IN p
alcoholic JJ p
cirrhosis NN p
, , p
who WP p
had VBD p
persistent NN p
or CC p
recurrent NN p
severe JJ p
ascites VBZ p
despite IN p
a DT p
standard JJ p
medical JJ p
regimen NNS p
, , p
to TO p
receive VB p
either RB p
intensive JJ i
medical JJ i
treatment NN i
or CC i
peritoneovenous JJ i
( ( i
LeVeen NNP i
) ) i
shunting VBG i
. . i

We PRP N
identified VBD N
three CD N
risk NN N
groups NNS N
: : N
Group NNP p
1 CD p
had VBD p
normal JJ p
or CC p
mildly RB p
abnormal JJ p
results NNS p
on IN p
liver-function NN p
tests NNS p
, , p
Group NNP p
2 CD p
had VBD p
more RBR p
severe JJ p
liver NN p
dysfunction NN p
or CC p
previous JJ p
complications NNS p
, , p
and CC p
Group NNP p
3 CD p
had VBD p
severe JJ p
prerenal JJ p
azotemia NN p
without IN p
kidney NN p
disease NN p
. . p

For IN N
the DT N
patients NNS N
who WP N
received VBD N
the DT N
medical JJ N
treatment NN N
and CC N
those DT N
who WP N
received VBD N
the DT N
surgical JJ N
treatment NN N
combined VBN N
, , N
the DT N
median JJ N
survival NN N
times NNS N
were VBD N
1093 CD N
days NNS N
in IN N
Group NNP N
1 CD N
, , N
222 CD N
days NNS N
in IN N
Group NNP N
2 CD N
, , N
and CC N
37 CD N
days NNS N
in IN N
Group NNP N
3 CD N
( ( N
P NNP N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
0.01 CD N
) ) N
for IN N
all DT N
comparisons NNS N
) ) N
. . N

For IN N
all PDT N
the DT N
groups NNS N
combined VBN N
, , N
the DT N
median JJ N
time NN N
to TO N
the DT N
resolution NN N
of IN N
ascites NNS N
was VBD N
5.4 CD N
weeks NNS N
for IN N
medical JJ N
patients NNS N
and CC N
3.0 CD N
weeks NNS N
for IN N
surgical JJ N
patients NNS N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

Within IN N
each DT N
risk NN N
group NN N
, , N
mortality NN o
during IN N
the DT N
initial JJ N
hospitalization NN N
and CC N
median JJ o
long-term JJ o
survival NN o
were VBD N
similar JJ N
among IN N
patients NNS N
receiving VBG N
either DT N
treatment NN N
. . N

However RB N
, , N
the DT N
median JJ N
time NN N
to TO N
the DT N
recurrence NN o
of IN o
ascites NNS o
in IN N
Group NNP N
1 CD N
was VBD N
4 CD N
months NNS N
in IN N
medical JJ N
patients NNS N
, , N
as IN N
compared VBN N
with IN N
18 CD N
months NNS N
in IN N
surgical JJ N
patients NNS N
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
; : N
in IN N
Group NNP N
2 CD N
it PRP N
was VBD N
3 CD N
months NNS N
in IN N
medical JJ N
patients NNS N
as IN N
compared VBN N
with IN N
12 CD N
months NNS N
in IN N
surgical JJ N
patients NNS N
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

The DT N
median JJ o
duration NN o
of IN o
hospitalization NN o
was VBD N
longer RBR N
in IN N
medical JJ p
patients NNS p
than IN N
in IN N
surgical JJ p
patients NNS p
( ( N
6.1 CD N
vs. RB N
2.4 CD N
weeks NNS N
in IN N
Group NNP N
1 CD N
[ NNP N
P NNP N
less JJR N
than IN N
0.001 CD N
] NNS N
and CC N
5.0 CD N
vs. FW N
3.1 CD N
weeks NNS N
in IN N
Group NNP N
2 CD N
[ NNP N
P NNP N
less JJR N
than IN N
0.01 CD N
] NN N
) ) N
. . N

Group NNP N
3 CD N
was VBD N
too RB N
small JJ N
to TO N
permit VB N
a DT N
meaningful JJ N
comparison NN N
. . N

During IN N
the DT N
initial JJ N
hospitalization NN N
, , N
the DT N
incidence NN o
of IN o
infections NNS o
, , o
gastrointestinal JJ o
bleeding NN o
, , o
and CC o
encephalopathy NN o
was VBD N
similar JJ N
among IN N
the DT N
medical JJ p
and CC p
surgical JJ p
patients NNS p
. . p

We PRP N
conclude VBP N
that DT N
peritoneovenous JJ N
shunting NN N
alleviated VBD N
disabling VBG o
ascites NNS o
more RBR N
rapidly RB N
than IN N
medical JJ N
management NN N
. . N

However RB N
, , N
survival NN o
was VBD N
closely RB N
related VBN N
to TO N
the DT N
severity NN N
of IN N
the DT N
illness NN N
at IN N
the DT N
time NN N
of IN N
randomization NN N
and CC N
was VBD N
not RB N
altered VBN N
by IN N
shunting VBG N
. . N

-DOCSTART- -24557758- O O

Evaluation NN N
of IN N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
the DT N
ophthalmic JJ i
insert NN i
Mydriasert NNP i
in IN N
patients NNS p
undergoing JJ p
retinal JJ p
angiography NN p
. . p

PURPOSE NNP N
To TO N
verify VB N
the DT N
efficacy NN N
to TO N
obtain VB N
mydriasis NN N
and CC N
cardiovascular JJ N
safety NN N
of IN N
Mydriasert NNP i
( ( i
ophthalmic JJ i
insert NN i
containing VBG i
tropicamide NN i
and CC i
phenylephrine NN i
) ) i
in IN N
diabetic JJ p
and CC p
nondiabetic JJ p
patients NNS p
undergoing VBG p
retinal JJ p
angiography NN p
by IN p
comparing VBG p
it PRP p
with IN p
usually RB p
administered VBN p
eyedrops NNS p
( ( i
tropicamide VB i
1 CD i
% NN i
and CC i
phenylephrine VB i
10 CD i
% NN i
) ) i
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
prospective JJ N
randomized NN N
study NN N
. . N

A DT N
total NN p
of IN p
154 CD p
eyes NNS p
of IN p
77 CD p
patients NNS p
were VBD p
randomly RB p
divided VBN p
into IN p
2 CD p
groups NNS p
: : p
group NN N
1 CD N
consisted VBD N
of IN N
78 CD N
eyes NNS N
, , N
group NN N
2 CD N
consisted VBD N
of IN N
76 CD N
eyes NNS N
, , N
and CC N
the DT N
patients NNS N
were VBD N
monitored VBN N
for IN N
pupillary JJ N
dilation NN N
, , N
blood NN N
pressure NN N
, , N
heart NN N
rate NN N
, , N
and CC N
possible JJ N
adverse JJ N
effects NNS N
at IN N
0 CD N
, , N
20 CD N
, , N
40 CD N
, , N
60 CD N
, , N
and CC N
90 CD N
minutes NNS N
. . N

RESULTS NNP N
No NNP N
severe JJ o
adverse JJ o
effects NNS o
were VBD N
observed VBN N
in IN N
either DT N
group NN N
. . N

In IN N
the DT N
entire JJ N
sample NN N
studied VBD N
, , N
the DT N
mean JJ o
pupillary JJ o
diameter NN o
was VBD N
greater JJR N
in IN N
the DT N
eyedrops NNS N
group NN N
after IN N
20 CD N
and CC N
40 CD N
minutes NNS N
, , N
while IN N
mydriasis NN o
was VBD N
similar JJ N
in IN N
the DT N
2 CD N
groups NNS N
after IN N
60 CD N
minutes NNS N
. . N

The DT N
diabetic JJ p
patients NNS p
treated VBN N
with IN N
Mydriasert NNP i
had VBD N
less JJR N
mydriasis NN o
than IN N
those DT N
treated VBN N
with IN N
eyedrops NNS N
after IN N
20 CD N
and CC N
40 CD N
minutes NNS N
, , N
and CC N
diabetic JJ N
patients NNS N
showed VBD N
less JJR N
mydriasis NN N
than IN N
the DT N
nondiabetic JJ N
patients NNS N
after IN N
60 CD N
and CC N
90 CD N
minutes NNS N
. . N

There EX N
was VBD N
no DT N
significant JJ N
between-group JJ N
difference NN N
in IN N
mean JJ o
heart NN o
rate NN o
or CC o
systolic NN o
and CC o
diastolic JJ o
blood NN o
pressure NN o
at IN N
any DT N
of IN N
the DT N
time NN N
points NNS N
. . N

CONCLUSIONS NNP N
Mydriasert NNP i
assures VBZ N
an DT N
adequate JJ N
degree NN N
of IN N
mydriasis NN N
for IN N
retinal JJ N
angiography NN N
in IN N
both DT N
diabetic JJ p
and CC p
nondiabetic JJ p
patients NNS p
. . p

There EX N
are VBP N
no DT N
differences NNS N
in IN N
efficacy NN N
or CC N
safety NN N
between IN N
the DT N
insert NN N
and CC N
the DT N
usually RB N
administered VBN N
eyedrops NNS N
, , N
but CC N
the DT N
low JJ N
total JJ N
drug NN N
dose NN N
administered VBN N
with IN N
the DT N
insert NN N
reduces VBZ N
the DT N
risk NN N
of IN N
cardiovascular JJ N
side NN N
effects NNS N
. . N

-DOCSTART- -24327720- O O

Impact NN N
of IN N
vitamin NN i
D NNP i
supplementation NN i
on IN N
inflammatory JJ o
markers NNS o
in IN N
African JJ p
Americans NNPS p
: : p
results NNS N
of IN N
a DT N
four-arm JJ N
, , N
randomized VBN N
, , N
placebo-controlled JJ N
trial NN N
. . N

African JJ p
Americans NNPS p
have VBP p
a DT p
disproportionate JJ p
burden NN p
of IN p
inflammation-associated JJ p
chronic JJ p
diseases NNS p
such JJ N
as IN N
cancer NN N
and CC N
lower JJR N
circulating NN N
levels NNS N
of IN N
25-hydroxyvitamin JJ N
D NNP N
[ NN N
25 CD N
( ( N
OH NNP N
) ) N
D NNP N
] NNP N
. . N

The DT N
effect NN N
of IN N
vitamin NN i
D3 NNP i
( ( i
cholecalciferol NN i
) ) i
supplementation NN i
on IN N
inflammatory JJ o
markers NNS o
is VBZ N
uncertain JJ N
. . N

We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
of IN N
supplemental JJ i
oral JJ i
vitamin NN i
D NNP i
( ( i
placebo NN i
, , N
1,000 CD N
, , N
2,000 CD N
, , N
or CC N
4,000 CD N
IU/day NN N
of IN N
vitamin NN N
D3 NNP N
orally RB N
for IN N
3 CD N
months NNS N
) ) N
in IN N
328 CD p
African JJ p
Americans NNPS p
( ( p
median JJ p
age NN p
, , p
51 CD p
years NNS p
) ) p
of IN p
public JJ p
housing NN p
communities NNS p
in IN p
Boston NNP p
, , p
MA NNP p
, , p
who WP p
were VBD p
enrolled VBN p
over RP p
three CD p
consecutive JJ p
winter NN p
periods NNS p
( ( p
2007-2010 JJ p
) ) p
. . p

Change NN N
from IN N
0 CD N
to TO N
3 CD N
months NNS N
of IN N
plasma NN o
levels NNS o
of IN o
25 CD o
( ( o
OH NNP o
) ) o
D NNP o
, , o
high-sensitivity JJ o
C-reactive JJ o
protein NN o
( ( o
CRP NNP o
) ) o
, , o
interleukin FW o
( ( o
IL NNP o
) ) o
-6 NN o
, , o
IL-10 NNP o
, , o
and CC o
soluble JJ o
TNF-? NNP o
receptor NN o
type NN o
2 CD o
( ( o
sTNF-R2 NN o
) ) o
in IN N
292 CD N
( ( N
89 CD N
% NN N
) ) N
participants NNS N
were VBD N
measured VBN N
. . N

Overall NNP N
, , N
no DT N
statistically RB N
significant JJ N
changes NNS N
in IN o
CRP NNP o
, , o
IL-6 NNP o
, , o
IL-10 NNP o
, , o
and CC o
sTNF-R2 NNS o
were VBD N
observed VBN N
after IN N
the DT N
vitamin NN N
D NNP N
supplementation NN N
period NN N
. . N

Baseline NNP o
CRP NNP o
was VBD N
significantly RB N
inversely RB N
associated VBN N
with IN N
the DT o
baseline NN o
25 CD o
( ( o
OH NNP o
) ) o
D NNP o
level NN o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
in IN N
unadjusted JJ N
and CC N
adjusted JJ N
models NNS N
. . N

An DT N
interaction NN N
between IN N
baseline NN o
25 CD o
( ( o
OH NNP o
) ) o
D NNP o
and CC o
vitamin NNP o
D NNP o
supplementation NN o
was VBD N
observed VBN N
for IN N
outcome JJ N
change NN N
in IN o
log NN o
CRP NNP o
( ( N
month NN N
3-month RB N
0 CD N
; : N
P NNP N
for IN N
interaction NN N
= NNP N
0.04 CD N
) ) N
. . N

Within IN N
an DT N
unselected JJ N
population NN N
of IN N
African JJ N
Americans NNPS N
, , N
short-term JJ i
exposure NN i
to TO i
vitamin VB i
D NNP i
supplementation NN i
produced VBD N
no DT N
change NN N
in IN o
circulating VBG o
inflammatory JJ o
markers NNS o
. . o

This DT N
study NN N
confirms VBZ N
the DT N
strong JJ N
independent JJ N
association NN N
of IN o
CRP NNP o
with IN o
25 CD o
( ( o
OH NNP o
) ) o
D NNP o
status NN N
even RB N
after IN N
adjusting VBG N
for IN N
body NN N
mass NN N
index NN N
. . N

Future JJ N
studies NNS N
of IN N
longer JJR N
supplemental JJ N
vitamin NN N
D3 NNP N
duration NN N
are VBP N
necessary JJ N
to TO N
examine VB N
the DT N
complex JJ N
influence NN N
of IN N
vitamin NN N
D3 NNP N
on IN N
CRP NNP N
and CC N
other JJ N
chronic JJ N
inflammatory NN N
cytokines NNS N
for IN N
possible JJ N
reduction NN N
of IN p
cancer NN p
health NN p
disparities NNS p
in IN p
African JJ p
Americans NNPS p
. . p

-DOCSTART- -2196621- O O

Naltrexone NN i
in IN N
autistic JJ p
children NNS p
: : p
a DT N
double-blind JJ N
and CC N
placebo-controlled JJ N
study NN N
. . N

A DT N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
was VBD N
designed VBN N
to TO N
assess VB N
critically RB N
the DT N
effects NNS N
of IN N
naltrexone NN i
on IN N
behavioral JJ o
symptoms NNS o
and CC N
learning VBG o
in IN N
autistic JJ p
children NNS p
, , N
and CC N
its PRP$ N
safety NN N
. . N

This DT N
is VBZ N
a DT N
preliminary JJ N
report NN N
on IN N
18 CD p
children NNS p
, , p
ages VBZ p
3.08 CD p
to TO p
7.99 CD p
years NNS p
, , p
who WP p
completed VBD p
this DT p
ongoing JJ p
study NN p
. . p

Subjects NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
naltrexone CD i
or CC i
placebo NN i
and CC i
received VBD i
daily JJ i
doses NNS i
over IN i
a DT i
period NN i
of IN i
21 CD i
days NNS i
. . i

Naltrexone NN i
was VBD N
superior JJ N
to TO N
placebo VB i
according VBG N
to TO N
blind VB N
Clinical JJ o
Global NNP o
Consensus NNP o
Ratings NNP o
( ( N
unpublished JJ N
scale NN N
) ) N
. . N

However RB N
, , N
other JJ N
behavioral JJ N
rating NN N
measures NNS N
did VBD N
not RB N
confirm VB N
this DT N
result NN N
. . N

There EX N
was VBD N
only RB N
a DT N
suggestion NN N
that IN N
naltrexone NN i
reduced VBD N
fidgety NN o
and CC o
hyperactive JJ o
behavior NN o
and CC N
tended VBD N
to TO N
alleviate VB N
overall JJ o
symptomatology NN o
in IN N
older JJR p
children NNS p
. . p

Naltrexone NN i
did VBD N
not RB N
appear VB N
to TO N
affect VB N
discrimination NN o
learning VBG o
. . o

Results NNS N
are VBP N
preliminary JJ N
and CC N
, , N
owing VBG N
to TO N
the DT N
small JJ N
sample NN N
size NN N
, , N
can MD N
be VB N
considered VBN N
only RB N
suggestive JJ N
until IN N
this DT N
study NN N
is VBZ N
completed VBN N
or CC N
replication NN N
is VBZ N
obtained VBN N
from IN N
independent JJ N
research NN N
. . N

-DOCSTART- -9647873- O O

Prevention NN N
of IN N
a DT N
first JJ N
stroke NN N
by IN N
transfusions NNS N
in IN N
children NNS p
with IN p
sickle NN p
cell NN p
anemia NN p
and CC p
abnormal JJ p
results NNS p
on IN p
transcranial JJ p
Doppler NNP p
ultrasonography NN p
. . p

BACKGROUND NNP N
Blood NNP i
transfusions NNS i
prevent VBP N
recurrent JJ N
stroke NN N
in IN N
children NNS p
with IN p
sickle NN p
cell NN p
anemia NN p
, , N
but CC N
the DT N
value NN N
of IN N
transfusions NNS N
in IN N
preventing VBG N
a DT N
first JJ N
stroke NN N
is VBZ N
unknown JJ N
. . N

We PRP N
used VBD N
transcranial JJ N
Doppler NNP N
ultrasonography NN N
to TO N
identify VB N
children NNS p
with IN p
sickle NN p
cell NN p
anemia NN p
who WP p
were VBD p
at IN p
high JJ p
risk NN p
for IN p
stroke NN p
and CC N
then RB N
randomly RB N
assigned VBN N
them PRP N
to TO N
receive VB N
standard JJ N
care NN N
or CC N
transfusions NNS N
to TO N
prevent VB N
a DT N
first JJ N
stroke NN N
. . N

METHODS NNP N
To TO N
enter VB N
the DT N
study NN N
, , N
children NNS p
with IN p
sickle NN p
cell NN p
anemia NN p
and CC p
no DT p
history NN p
of IN p
stroke NN p
had VBD p
to TO p
have VB p
undergone JJ p
two CD p
transcranial JJ p
Doppler NNP p
studies NNS p
that WDT p
showed VBD p
that IN p
the DT p
time-averaged JJ p
mean JJ p
blood-flow JJ p
velocity NN p
in IN p
the DT p
internal JJ p
carotid NN p
or CC p
middle JJ p
cerebral JJ p
artery NN p
was VBD p
200 CD p
cm JJ p
per IN p
second NN p
or CC p
higher JJR p
. . p

The DT N
patients NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
standard JJ i
care NN i
or CC i
transfusions NNS i
to TO N
reduce VB N
the DT N
hemoglobin NN N
S NNP N
concentration NN N
to TO N
less JJR N
than IN N
30 CD N
percent NN N
of IN N
the DT N
total JJ N
hemoglobin NN N
concentration NN N
. . N

The DT N
incidence NN N
of IN N
stroke NN N
( ( N
cerebral JJ N
infarction NN N
or CC N
intracranial JJ N
hemorrhage NN N
) ) N
was VBD N
compared VBN N
between IN N
the DT N
two CD N
groups NNS N
. . N

RESULTS VB N
A DT N
total NN N
of IN N
130 CD p
children NNS p
( ( p
mean JJ p
[ NNP p
+/-SD NN p
] NNP p
age NN p
, , p
8.3+/-3.3 CD p
years NNS p
) ) p
were VBD p
enrolled VBN p
; : p
63 CD p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
transfusions NNS N
and CC N
67 CD N
to TO N
receive VB N
standard NN N
care NN N
. . N

At IN N
base NN N
line NN N
, , N
the DT N
transfusion NN N
group NN N
had VBD N
a DT N
slightly RB N
lower JJR N
mean NN o
hemoglobin NN o
concentration NN o
( ( N
7.2 CD N
vs. FW N
7.6 CD N
g NN N
per IN N
deciliter NN N
, , N
P=0.001 NNP N
) ) N
and CC N
hematocrit NN o
( ( N
20.4 CD N
vs. FW N
21.7 CD N
percent NN N
, , N
P=0.002 NNP N
) ) N
. . N

Ten CD N
patients NNS N
dropped VBD N
out IN N
of IN N
the DT N
transfusion NN N
group NN N
, , N
and CC N
two CD N
patients NNS N
crossed VBD N
over IN N
from IN N
the DT N
standard-care JJ N
group NN N
to TO N
the DT N
transfusion NN N
group NN N
. . N

There EX N
were VBD N
10 CD N
cerebral JJ o
infarctions NNS o
and CC N
1 CD N
intracerebral JJ o
hematoma NN o
in IN N
the DT N
standard-care JJ N
group NN N
, , N
as IN N
compared VBN N
with IN N
1 CD N
infarction NN o
in IN N
the DT N
transfusion NN N
group NN N
-- : N
a DT N
92 CD N
percent NN N
difference NN N
in IN N
the DT N
risk NN N
of IN N
stroke NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

This DT N
result NN N
led VBD N
to TO N
the DT N
early JJ N
termination NN N
of IN N
the DT N
trial NN N
. . N

CONCLUSIONS NNP N
Transfusion NNP i
greatly RB N
reduces VBZ N
the DT N
risk NN o
of IN o
a DT o
first JJ o
stroke NN o
in IN N
children NNS p
with IN p
sickle NN p
cell NN p
anemia NN p
who WP p
have VBP p
abnormal JJ p
results NNS p
on IN p
transcranial JJ p
Doppler NNP p
ultrasonography NN p
. . p

-DOCSTART- -7069027- O O

Perception NN N
of IN N
social JJ o
interactions NNS o
in IN N
depressed JJ p
psychiatric JJ p
patients NNS p
. . p

-DOCSTART- -20569725- O O

A DT N
multicenter NN N
, , N
open-label JJ N
study NN N
of IN N
vernakalant NN N
for IN N
the DT N
conversion NN N
of IN N
atrial JJ p
fibrillation NN p
to TO N
sinus VB N
rhythm NN N
. . N

BACKGROUND IN N
The DT N
efficacy NN o
and CC o
safety NN o
of IN N
vernakalant NN N
, , N
a DT N
relatively RB N
atrial-selective JJ N
antiarrhythmic JJ N
agent NN N
, , N
in IN N
converting VBG N
atrial JJ o
fibrillation NN o
( ( o
AF NNP o
) ) o
to TO N
sinus VB o
rhythm NN o
( ( o
SR NNP o
) ) o
were VBD N
evaluated VBN N
in IN N
this DT N
multicenter NN p
, , p
open-label JJ p
study NN p
of IN p
patients NNS p
with IN p
AF NNP p
lasting VBG p
> RB p
3 CD p
hours NNS p
and CC p
< NNP p
or CC p
=45 JJ p
days NNS p
( ( N
RCT NNP N
no DT N
. . N

NCT00281554 NNP N
) ) N
. . N

METHODS NNP N
Adult NNP p
patients NNS p
with IN p
AF NNP p
and CC p
an DT p
indication NN p
for IN p
conversion NN p
to TO p
SR NNP o
received VBD i
a DT i
10-minute JJ i
intravenous JJ i
infusion NN i
of IN i
vernakalant NN i
( ( i
3 CD i
mg/kg NN i
) ) i
. . i

If IN i
after IN i
a DT i
15-minute JJ i
observation NN i
period NN i
AF NNP i
was VBD i
present JJ i
, , i
a DT i
second JJ i
10-minute JJ i
infusion NN i
of IN i
intravenous JJ i
vernakalant NN i
( ( i
2 CD i
mg/kg NN i
) ) i
was VBD i
given VBN i
. . i

The DT N
primary JJ N
efficacy JJ N
end NN N
point NN N
was VBD N
the DT N
proportion NN N
of IN N
patients NNS i
with IN i
recent-onset JJ i
AF NNP o
( ( i
AF NNP i
lasting VBG i
> RB i
3 CD i
hours NNS i
to TO i
< VB i
or CC i
=7 VB i
days NNS i
) ) i
who WP i
converted VBD i
to TO i
SR NNP i
within IN i
90 CD i
minutes NNS i
of IN i
the DT i
start NN i
of IN i
the DT i
first JJ i
infusion NN i
. . i

Safety NNP i
evaluations NNS i
included VBD i
vital JJ o
signs NNS o
, , o
telemetry NN o
and CC o
Holter NNP o
monitoring NN o
, , o
12-lead JJ o
electrocardiography NN o
, , o
clinical JJ o
laboratory NN o
tests NNS o
, , o
physical JJ o
examinations NNS o
, , o
and CC o
adverse JJ o
events NNS o
( ( o
AEs NNP o
) ) o
. . o

RESULTS VB N
A DT N
total NN N
of IN N
236 CD p
hemodynamically RB p
stable JJ p
patients NNS p
with IN p
AF NNP p
received VBD N
intravenous JJ N
vernakalant NN N
. . N

Among IN N
them PRP N
, , N
167 CD p
( ( p
71 CD p
% NN p
) ) p
had VBD p
recent-onset VBN o
AF NNP o
and CC N
were VBD N
eligible JJ N
for IN N
the DT N
primary JJ N
efficacy JJ N
end NN N
point NN N
. . N

Vernakalant NNP N
rapidly RB N
converted VBD N
recent-onset JJ o
AF NNP o
to TO o
SR NNP o
in IN N
50.9 CD N
% NN N
of IN N
patients NNS N
, , N
with IN N
a DT N
median JJ N
time NN N
to TO N
conversion NN N
of IN N
14 CD N
minutes NNS N
among IN N
responders NNS N
. . N

The DT N
most RBS N
common JJ N
AEs NNP N
were VBD N
dysgeusia NNS o
, , o
sneezing VBG o
, , o
and CC o
paresthesia NN o
. . o

These DT N
occurred VBD N
at IN N
the DT N
time NN N
of IN N
vernakalant JJ N
infusion NN N
, , N
were VBD N
transient JJ N
, , N
and CC N
resolved VBD N
spontaneously RB N
. . N

Ten CD N
patients NNS N
( ( N
4.2 CD N
% NN N
) ) N
discontinued VBN N
vernakalant JJ N
treatment NN N
because IN N
of IN N
AEs NNP N
, , N
most JJS N
commonly RB N
( ( N
in IN N
4 CD N
of IN N
10 CD N
) ) N
hypotension NN o
. . o

There EX N
were VBD N
no DT N
episodes NNS N
of IN N
torsades NNS o
de FW o
pointes NNS o
, , o
ventricular JJ o
fibrillation NN o
, , o
or CC o
sustained VBD o
ventricular JJ o
tachycardia NN o
. . o

CONCLUSIONS NNP N
Vernakalant NNP N
rapidly RB N
converted VBD N
recent-onset JJ N
AF NNP N
to TO N
SR NNP N
, , N
was VBD N
well RB N
tolerated VBN N
, , N
and CC N
may MD N
be VB N
a DT N
valuable JJ N
therapeutic JJ N
alternative NN N
for IN N
reestablishing VBG N
SR NNP N
in IN N
patients NNS p
with IN p
recent-onset JJ p
AF NNP p
. . p

-DOCSTART- -6134039- O O

Ceftriaxone NNP i
versus NN i
ampicillin NN i
and CC i
chloramphenicol NN i
for IN N
treatment NN N
of IN N
bacterial JJ o
meningitis NN o
in IN p
children NNS p
. . p

78 CD p
patients NNS p
with IN p
bacterial JJ p
meningitis NN p
were VBD p
evaluated VBN p
in IN N
a DT N
prospective JJ N
, , N
randomised VBD N
study NN N
comparing VBG N
twice-daily RB N
ceftriaxone NN i
as IN N
single-drug JJ N
therapy NN N
with IN N
ampicillin NN i
and CC i
chloramphenicol NN i
given VBN N
every DT N
6 CD N
h. PDT N
The DT N
groups NNS N
were VBD N
comparable JJ N
in IN N
age NN N
, , N
sex NN N
, , N
days NNS N
of IN N
illness NN N
before IN N
admission NN N
, , N
and CC N
bacterial JJ N
colony NN N
counts NNS N
in IN N
cerebrospinal JJ N
fluid NN N
( ( N
CSF NNP N
) ) N
. . N

The DT N
pathogens NNS N
were VBD N
Haemophilus NNP N
influenzae JJ N
type NN N
b NN N
( ( N
54 CD N
cases NNS N
) ) N
, , N
streptococci NN N
( ( N
9 CD N
cases NNS N
) ) N
, , N
meningococci FW N
( ( N
9 CD N
cases NNS N
) ) N
, , N
and CC N
unknown JJ N
( ( N
6 CD N
cases NNS N
) ) N
. . N

In IN N
40 CD N
CSF NNP N
specimens NNS N
obtained VBD N
4-12 CD N
h NN N
after IN N
initiation NN N
of IN N
therapy NN N
, , N
cultures NNS o
were VBD o
negative JJ o
in IN N
57 CD N
% NN N
of IN N
the DT N
ceftriaxone NN N
patients NNS N
and CC N
in IN N
42 CD N
% NN N
of IN N
the DT N
others NNS N
. . N

The DT N
mean NN o
falls VBZ o
in IN o
the DT o
CSF NNP o
bacterial JJ o
colony NN o
counts NNS o
were VBD N
4.7 CD N
and CC N
5.0 CD N
log10 JJ N
colony-forming JJ N
units/ml NN N
, , N
respectively RB N
. . N

Mean NNP o
bactericidal JJ o
activity NN o
in IN o
CSF NNP o
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
ceftriaxone NN i
than IN N
in IN N
the DT N
conventional JJ N
treatment NN N
group NN N
at IN N
the DT N
beginning NN N
and CC N
end NN N
of IN N
therapy NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
clinical JJ o
responses NNS o
or CC N
in IN N
frequency NN o
of IN o
complications NNS o
, , o
except IN o
for IN o
mild JJ o
diarrhoea NN o
, , N
which WDT N
occurred VBD N
in IN N
16 CD N
ceftriaxone NN i
patients NNS N
and CC N
in IN N
8 CD N
in IN N
the DT N
other JJ N
group NN N
( ( N
p VBZ N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

-DOCSTART- -18303031- O O

Prognosis NN N
of IN N
advanced JJ p
hepatocellular JJ p
carcinoma NN p
: : p
comparison NN N
of IN N
three CD N
staging VBG N
systems NNS N
in IN N
two CD N
French JJ p
clinical JJ p
trials NNS p
. . p

OBJECTIVE CC N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
performance NN N
of IN N
three CD i
staging VBG i
systems NNS i
[ NNP i
Okuda NNP i
, , i
Cancer NNP i
of IN i
the DT i
Liver NNP i
Italian JJ i
Program NNP i
( ( i
CLIP NNP i
) ) i
and CC i
Barcelona NNP i
Clinic NNP i
Liver NNP i
Cancer NNP i
group NN i
( ( i
BCLC NNP i
) ) i
] NN i
, , N
for IN N
predicting VBG N
survival NN o
in IN N
patients NNS p
with IN p
hepatocellular JJ p
carcinoma NN p
( ( p
HCC NNP p
) ) p
and CC N
to TO N
explore VB N
how WRB N
to TO N
improve VB N
prognostic JJ N
classification NN N
among IN N
French JJ p
patients NNS p
with IN p
HCC NNP p
whose WP$ p
main JJ p
etiology NN p
is VBZ p
alcoholic JJ p
cirrhosis NN p
. . p

METHODS NNP N
We PRP p
have VBP p
pooled VBN p
two CD p
randomized JJ p
clinical JJ p
trials NNS p
in IN p
palliative JJ p
condition NN p
from IN p
the DT p
F?d?ration NNP p
Francophone NNP p
de FW p
Cancerologie NNP p
Digestive NNP p
. . p

They PRP p
had VBD p
included VBN p
416 CD p
and CC p
122 CD p
patients NNS p
. . p

Performances NNS N
of IN N
Okuda NNP N
, , N
CLIP NNP N
and CC N
BCLC NNP N
scores NNS N
have VBP N
been VBN N
compared VBN N
using VBG N
Akaike NNP N
information NN N
criterion NN N
, , N
discriminatory JJ N
ability NN N
( ( N
Harrell NNP N
's POS N
C NNP N
and CC N
the DT N
Royston NNP N
's POS N
D NNP N
statistics NNS N
) ) N
, , N
monotonicity NN N
of IN N
gradients NNS N
and CC N
predictive JJ N
accuracy NN N
( ( N
Schemper NNP N
statistics NNS N
Vs NNP N
) ) N
. . N

To TO N
explore VB N
how WRB N
to TO N
improve VB N
classifications NNS N
, , N
univariate JJ N
and CC N
multivariate JJ N
Cox NNP N
model NN N
analyses NNS N
were VBD N
carried VBN N
out RP N
. . N

RESULTS VB N
The DT N
pooled JJ N
database NN N
included VBD p
538 CD p
patients NNS o
. . o

The DT o
median JJ o
survival NN o
was VBD o
5.3 CD N
months NNS N
( ( N
95 CD N
% NN N
confidence NN N
interval JJ N
4.6-6.2 JJ N
) ) N
. . N

For IN N
all DT o
statistics NNS o
CLIP NNP o
staging VBG o
system NN o
had VBD o
a DT N
better RBR o
prognostic JJ o
ability NN o
. . o

Performances NNS o
of IN o
all DT N
staging VBG N
systems NNS N
were VBD N
rather RB o
disappointing JJ o
. . o

World NNP o
Health NNP o
Organization NNP o
performance NN o
status NN o
( ( o
WHO NNP o
PS NNP o
) ) o
for IN o
CLIP NNP i
or CC i
alpha-fetoprotein NN i
for IN i
BCLC NNP N
allowed VBD N
a DT N
significant JJ o
improvement NN o
of IN o
prognostic JJ o
information NN o
. . o

CONCLUSION NNP N
Our PRP$ N
results NNS N
indicate VBP N
that IN i
CLIP NNP i
staging VBG i
seems VBZ i
to TO N
be VB N
most RBS N
adapted VBN N
to TO N
palliative VB N
setting NN N
and CC N
that IN N
it PRP N
could MD N
be VB N
better JJR N
by IN N
associating VBG o
WHO NNP o
PS NNP o
. . o

-DOCSTART- -1592650- O O

[ JJ N
Final NNP N
evaluation NN N
of IN N
the DT N
randomized JJ p
multicenter NN p
study NN p
SAKK NNP p
40/81 CD p
: : p
adjuvant JJ i
portal JJ i
chemotherapy NN i
of IN N
curatively RB p
resected VBN p
colorectal JJ p
cancer NN p
] NN p
. . N

Between JJ p
1981 CD p
and CC p
1987 CD p
, , p
533 CD p
patients NNS p
from IN p
9 CD p
institutions NNS p
have VBP p
been VBN p
entered VBN p
in IN p
a DT p
randomized JJ p
trial NN p
to TO N
assess VB N
the DT N
value NN N
of IN N
adjuvant JJ i
portal JJ i
infusion NN i
( ( i
5-Fluorouracil JJ i
, , i
Mitomycin NNP i
C NNP i
) ) i
compared VBN i
to TO i
radical JJ i
surgery NN i
alone RB i
. . i

Analysis NN N
of IN N
469 CD p
evaluable JJ p
patients NNS p
at IN p
a DT p
median JJ p
follow-up NN p
of IN p
5.8 CD p
years NNS p
revealed VBD p
110 CD p
recurrences NNS p
in IN p
the DT p
control NN p
and CC p
94 CD p
recurrences NNS p
in IN p
the DT p
infusion NN p
group NN p
. . p

Estimated VBN N
5-year JJ o
disease-free JJ o
survival NN o
was VBD N
52 CD N
% NN N
and CC N
61 CD N
% NN N
respectively RB N
( ( N
hazard JJ N
ratio NN N
1:0.75 CD N
; : N
95 CD N
% NN N
confidence NN N
interval JJ N
0.57-0.99 NN N
; : N
p CC N
= VB N
0.046 CD N
) ) N
. . N

Overall JJ o
survival NN o
was VBD N
59 CD N
% NN N
in IN N
the DT N
control NN N
and CC N
69 CD N
in IN N
the DT N
infusion NN N
group NN N
( ( N
p JJ N
= NNP N
0.048 CD N
) ) N
. . N

Adjuvant JJ N
portal JJ N
infusion NN N
did VBD N
not RB N
influence VB N
the DT N
occurrence NN o
of IN o
liver NN o
metastases NNS o
but CC N
reduced VBD N
the DT N
overall JJ o
recurrence NN o
rate NN o
. . o

-DOCSTART- -10441604- O O

Phenobarbital JJ i
compared VBN N
with IN N
phenytoin NN i
for IN N
the DT N
treatment NN N
of IN N
neonatal JJ p
seizures NNS p
. . p

BACKGROUND NNP N
Seizures NNP N
occur VBP N
in IN N
1 CD N
to TO N
2 CD N
percent NN N
of IN N
neonates NNS p
admitted VBN p
to TO p
an DT p
intensive JJ p
care NN p
unit NN p
. . p

The DT N
treatment NN N
is VBZ N
usually RB N
with IN N
either DT N
phenobarbital NN i
or CC N
phenytoin NN i
, , N
but CC N
the DT N
efficacy NN o
of IN N
the DT N
two CD N
drugs NNS N
has VBZ N
not RB N
been VBN N
compared VBN N
directly RB N
. . N

METHODS NNP N
From IN N
1990 CD N
to TO N
1995 CD N
, , N
we PRP N
studied VBD N
59 CD p
neonates NNS p
with IN p
seizures NNS p
that WDT p
were VBD p
confirmed VBN p
by IN p
electroencephalography NN p
. . p

The DT N
neonates NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
phenobarbital NN i
or CC N
phenytoin NN i
intravenously RB N
, , N
at IN N
doses NNS N
sufficient JJ N
to TO N
achieve VB N
free JJ N
plasma NN N
concentrations NNS N
of IN N
25 CD N
microg NNS N
per IN N
milliliter NN N
for IN N
phenobarbital NN N
and CC N
3 CD N
microg NNS N
per IN N
milliliter NN N
for IN N
phenytoin NN N
. . N

Neonates NNS N
whose WP$ N
seizures NNS N
were VBD N
not RB N
controlled VBN N
by IN N
the DT N
assigned JJ N
drug NN N
were VBD N
then RB N
treated VBN N
with IN N
both DT N
drugs NNS N
. . N

Seizure NN o
control NN o
was VBD N
assessed VBN N
by IN N
electroencephalographic JJ N
criteria NNS N
. . N

RESULTS NNP N
Seizures NNPS o
were VBD N
controlled VBN N
in IN N
13 CD N
of IN N
the DT N
30 CD p
neonates NNS p
assigned VBN p
to TO p
receive VB p
phenobarbital NN p
( ( N
43 CD N
percent NN N
) ) N
and CC N
13 CD N
of IN N
the DT N
29 CD p
neonates NNS p
assigned VBN p
to TO p
receive VB p
phenytoin NN p
( ( N
45 CD N
percent NN N
; : N
P=1.00 NNP N
) ) N
. . N

When WRB N
combined JJ N
treatment NN N
is VBZ N
considered VBN N
, , N
seizure NN o
control NN o
was VBD N
achieved VBN N
in IN N
17 CD N
( ( N
57 CD N
percent NN N
) ) N
of IN N
the DT N
neonates NNS N
assigned VBD N
to TO N
receive VB N
phenobarbital NN N
first RB N
and CC N
18 CD N
( ( N
62 CD N
percent NN N
) ) N
of IN N
those DT N
assigned VBN N
to TO N
receive VB N
phenytoin NN N
first RB N
( ( N
P=0.67 NNP N
) ) N
. . N

The DT N
severity NN o
of IN o
the DT o
seizures NNS o
was VBD N
a DT N
stronger JJR N
predictor NN N
of IN N
the DT N
success NN N
of IN N
treatment NN N
than IN N
was VBD N
the DT N
assigned JJ N
agent NN N
. . N

Neonates VBZ N
with IN N
mild JJ o
seizures NNS o
or CC N
with IN N
seizures NNS o
that WDT N
were VBD N
decreasing VBG N
in IN N
severity NN o
before IN N
treatment NN N
were VBD N
more RBR N
likely JJ N
to TO N
have VB N
their PRP$ N
seizures NNS o
end VBP o
, , N
regardless RB N
of IN N
the DT N
treatment NN N
assignment NN N
. . N

CONCLUSIONS NNP N
Phenobarbital NNP i
and CC N
phenytoin NN i
are VBP N
equally RB N
but CC N
incompletely RB N
effective JJ N
as IN N
anticonvulsants NNS o
in IN N
neonates NNS p
. . p

With IN N
either DT N
drug NN N
given VBN N
alone RB N
, , N
the DT N
seizures NNS o
were VBD N
controlled VBN o
in IN N
fewer JJR N
than IN N
half NN N
of IN N
the DT N
neonates NNS N
. . N

-DOCSTART- -10554112- O O

Comparison NNP p
of IN p
nasal JJ o
deposition NN o
and CC o
clearance NN o
of IN o
aerosol NN o
generated VBN N
by IN N
nebulizer NN i
and CC i
an DT i
aqueous JJ i
spray NN i
pump NN i
. . i

-DOCSTART- -24737062- O O

Classification NN N
of IN N
motor NN o
imagery NN o
performance NN o
in IN N
acute JJ p
stroke NN p
. . p

OBJECTIVE NNP N
Effective NNP o
motor NN o
imagery NN o
performance NN o
, , N
seen VBN N
as IN N
strong JJ N
suppression NN N
of IN N
the DT N
sensorimotor NN N
rhythm NN N
, , N
is VBZ N
the DT N
key JJ N
element NN N
in IN N
motor NN i
imagery NN i
therapy NN i
. . i

Therefore RB N
, , N
optimization NN N
of IN N
methods NNS N
to TO N
classify VB N
whether IN N
the DT N
subject NN N
is VBZ N
performing VBG N
the DT N
imagery NN N
task NN N
is VBZ N
a DT N
prerequisite NN N
. . N

An DT N
optimal JJ N
classification NN N
method NN N
should MD N
have VB N
high JJ N
performance NN N
accuracy NN N
and CC N
use VB N
a DT N
small JJ N
number NN N
of IN N
channels NNS N
. . N

We PRP N
investigated VBD N
the DT N
additional JJ N
benefit NN N
of IN N
the DT N
common JJ N
spatial JJ N
pattern NN N
filtering NN N
( ( N
CSP NNP N
) ) N
to TO N
a DT N
linear JJ N
discriminant JJ N
analysis NN N
( ( N
LDA NNP N
) ) N
classifier NN N
, , N
for IN N
different JJ N
channel NN N
configurations NNS N
. . N

METHODS NNP N
Ten NNP p
hemispheric JJ p
acute NN p
stroke NN p
patients NNS p
and CC p
11 CD p
healthy JJ p
subjects NNS p
were VBD p
included VBN p
. . p

EEGs NNP i
were VBD N
recorded VBN N
using VBG N
60 CD N
channels NNS N
. . N

The DT N
classifier NN N
was VBD N
trained VBN N
with IN N
a DT N
motor NN N
execution NN N
task NN N
. . N

For IN N
both DT N
healthy JJ N
controls NNS N
and CC N
patients NNS N
, , N
analysis NN N
of IN N
recordings NNS N
was VBD N
initially RB N
limited VBN N
to TO N
3 CD N
and CC N
11 CD N
electrodes NNS N
recording VBG N
from IN N
the DT N
motor NN N
cortex JJ N
area NN N
, , N
and CC N
later RB N
repeated VBD N
using VBG N
45 CD N
electrodes NNS N
. . N

RESULTS NNP N
No NNP N
significant JJ N
improvement NN N
on IN N
the DT N
addition NN N
of IN N
CSP NNP N
to TO N
LDA NNP o
was VBD N
found VBN N
( ( N
in IN N
both DT N
cases NNS N
, , N
the DT N
area NN o
under IN o
the DT o
receiving NN o
operating VBG o
characteristic JJ o
( ( o
AU-ROC NNP o
) ) o
? . N
0.70 CD N
( ( N
acceptable JJ N
) ) N
) ) N
. . N

We PRP N
then RB N
repeated VBD N
the DT N
LDA+CSP NNP N
method NN N
on IN N
recordings NNS N
of IN N
45 CD N
electrodes NNS N
, , N
since IN N
the DT N
use NN N
of IN N
imagery JJ N
neuronal JJ N
circuits NNS N
may MD N
well RB N
extend VB N
beyond IN N
the DT N
motor NN N
area NN o
. . o

AU-ROC NNP o
rose VBD o
to TO N
0.90 CD N
, , N
but CC N
no DT N
virtual JJ o
'most POS o
responsible JJ o
' '' o
electrode NN o
was VBD o
observed VBN N
. . N

Finally RB N
, , N
in IN N
mild-to-moderate JJ p
stroke NN p
patients NNS p
we PRP p
could MD N
successfully RB N
use VB N
the DT o
EEG NNP o
data NNS o
recorded VBD o
from IN N
the DT N
healthy JJ N
hemisphere NN N
to TO N
train VB N
the DT N
classifier NN N
( ( N
AU-ROC NNP N
? . N
0.70 CD N
) ) N
. . N

SIGNIFICANCE NNP N
Including VBG N
only RB N
the DT N
channels NNS N
on IN N
the DT N
unaffected JJ N
motor NN N
cortex NN N
is VBZ N
sufficient JJ N
to TO N
train VB N
a DT N
classifier NN N
. . N

-DOCSTART- -15482080- O O

Transitions NNS N
during IN N
effective JJ N
treatment NN N
for IN N
cocaine-abusing JJ p
homeless JJ p
persons NNS p
: : p
establishing VBG N
abstinence NN N
, , N
lapse NN N
, , N
and CC N
relapse NN N
, , N
and CC N
reestablishing VBG N
abstinence NN N
. . N

Data NNS N
are VBP N
reported VBN N
on IN N
drug NN N
use NN N
among IN N
cocaine-dependent JJ p
homeless NN p
persons NNS p
who WP p
participated VBD p
in IN p
a DT p
clinical JJ p
trial NN p
that WDT p
compared VBN p
day NN i
treatment NN i
only RB i
( ( p
DT NNP p
, , p
n JJ p
= NNP p
69 CD p
) ) p
with IN p
day NN i
treatment NN i
plus CC i
abstinent-contingent JJ i
housing NN i
and CC i
work NN i
( ( p
DT+ NNP p
, , p
n JJ p
= NNP p
72 CD p
) ) p
. . p

Drug NNP o
use NN o
was VBD o
measured VBN o
with IN o
multiple JJ o
weekly JJ o
urine NN o
toxicologies NNS o
. . o

Compared VBN N
with IN N
DT NNP N
participants NNS N
, , N
more JJR N
DT+ JJ N
participants NNS N
established VBN N
abstinence NN o
, , o
maintained VBD o
abstinence NN o
for IN o
longer JJR o
durations NNS o
, , N
were VBD N
marginally RB N
significantly RB N
more RBR N
likely JJ N
to TO N
lapse VB o
, , N
and CC N
significantly RB N
less RBR N
likely JJ N
to TO N
relapse VB o
. . o

Of IN N
all DT N
participants NNS N
who WP N
established VBD N
abstinence NN N
and CC N
then RB N
relapsed VBD N
, , N
DT+ NNP N
participants NNS N
relapsed VBD N
later RB N
and CC N
were VBD N
more RBR N
likely JJ N
to TO N
reestablish VB o
abstinence NN o
. . o

These DT N
analyses NNS N
yield VBP N
information NN N
on IN N
the DT N
processes NNS N
involved VBN N
in IN N
the DT N
manner NN N
in IN N
which WDT N
drug NN N
use NN N
changes NNS N
as IN N
a DT N
result NN N
of IN N
abstinent-contingent JJ i
housing NN i
and CC i
work NN i
. . i

-DOCSTART- -23052635- O O

Computer-navigated JJ i
versus NN i
conventional JJ i
total JJ i
knee NN i
arthroplasty IN i
a DT N
prospective JJ N
randomized VBN N
trial NN N
. . N

BACKGROUND VB N
The DT N
literature NN N
lacks VBZ N
studies NNS N
that IN N
confirm VBP N
whether IN N
the DT N
improved JJ N
radiographic JJ N
alignment NN N
that WDT N
can MD N
be VB N
achieved VBN N
with IN N
computer-navigated JJ i
total JJ i
knee NN i
arthroplasty NN i
improves VBZ N
patients? JJ N
activities NNS N
of IN N
daily JJ N
living NN N
or CC N
the DT N
durability NN N
of IN N
total JJ N
knee NN N
prostheses NNS N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN i
computer-navigated JJ i
total JJ i
knee NN i
arthroplasty NN i
improves VBZ i
the DT N
clinical JJ N
function NN N
, , N
alignment NN N
, , N
and CC N
survivorship NN N
of IN N
the DT N
components NNS N
. . N

METHODS NNP N
We PRP N
prospectively RB N
compared VBN N
the DT N
results NNS N
of IN N
520 CD p
patients NNS p
with IN p
osteoarthritis NN p
who WP p
underwent VBD i
computer-navigated JJ i
total JJ i
knee NN i
arthroplasty NN i
for IN i
one CD i
knee NN i
and CC i
conventional JJ i
total JJ i
knee NN i
arthroplasty NN i
for IN i
the DT i
other JJ i
. . i

The DT N
assignment NN N
of IN N
the DT N
knee NN N
to TO N
navigation NN N
or CC N
not RB N
was VBD N
done VBN N
randomly RB N
. . N

There EX N
were VBD p
452 CD p
women NNS p
( ( p
904 CD p
knees NNS p
) ) p
and CC p
sixty-eight JJ p
men NNS p
( ( p
136 CD p
knees NNS p
) ) p
with IN p
a DT p
mean JJ p
age NN p
of IN p
sixty-eight JJ p
years NNS p
( ( p
range NN p
, , p
forty-nine JJ p
to TO p
eighty-eight JJ p
years NNS p
) ) p
at IN p
the DT p
time NN p
of IN p
the DT p
index NN p
arthroplasty NN p
. . p

The DT N
mean JJ N
follow-up JJ N
period NN N
was VBD N
10.8 CD N
years NNS N
( ( N
range NN N
, , N
ten VB N
to TO N
twelve VB N
years NNS N
) ) N
. . N

The DT N
patients NNS N
were VBD N
assessed VBN N
clinically RB N
and CC N
radiographically RB N
with IN N
the DT o
rating NN o
system NN o
of IN o
the DT o
Knee NNP o
Society NNP o
and CC o
with IN N
the DT o
Western NNP o
Ontario NNP o
and CC o
McMaster NNP o
Universities NNP o
Osteoarthritis NNP o
Index NNP o
( ( o
WOMAC NNP o
) ) o
score NN o
at IN o
three CD N
months NNS N
, , N
one CD N
year NN N
, , N
and CC N
annually RB N
thereafter RB N
. . N

RESULTS NNP o
Total JJ o
knee NN o
scores NNS o
, , o
knee NN o
function NN o
scores NNS o
, , o
pain NN o
scores NNS o
, , o
WOMAC NNP o
scores VBZ o
, , o
knee VB o
motion NN o
, , o
and CC o
activity NN o
scores NNS o
did VBD o
not RB N
show VB N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
preoperatively RB N
or CC N
at IN N
the DT N
time NN N
of IN N
the DT N
final JJ N
follow-up NN N
. . N

Alignment NNP N
and CC N
the DT N
survivorship NN N
of IN N
the DT N
components NNS N
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

The DT o
Kaplan-Meier NNP o
survivorship NN o
with IN o
revision NN o
as IN o
the DT N
end NN N
point NN N
at IN N
10.8 CD N
years NNS N
was VBD N
98.8 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.96 CD N
to TO N
1.00 CD N
) ) N
in IN N
the DT i
computernavigated JJ i
total JJ i
knee NN i
arthroplasty NN i
group NN i
and CC N
99.2 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.96 CD N
to TO N
1.00 CD N
) ) N
in IN N
the DT i
conventional JJ i
total JJ i
knee NN i
arthroplasty NN i
group NN i
. . N

CONCLUSIONS NNP N
Our PRP$ N
data NNS N
demonstrated VBD N
no DT N
difference NN N
in IN N
clinical JJ N
function NN N
or CC N
alignment NN N
and CC N
survivorship NN N
of IN N
the DT N
components NNS N
between IN N
the DT p
knees NNS p
that WDT p
underwent VBD i
computer-navigated JJ i
total JJ i
knee NN i
arthroplasty NN i
and CC i
those DT p
that WDT p
underwent JJ i
conventional JJ i
total JJ i
knee NN i
arthroplasty NN i
. . i

-DOCSTART- -3434628- O O

Effect NN N
of IN N
negative JJ i
air NN i
ionization NN i
on IN N
hyperactive JJ p
and CC p
autistic JJ p
children NNS p
. . p

Twenty-one CD p
attention NN p
deficit NN p
disorder NN p
with IN p
hyperactivity NN p
and CC p
seven CD p
autistic JJ p
children NNS p
were VBD N
randomly RB i
exposed VBN i
to TO i
negatively RB i
ionized JJ i
and CC i
ambient JJ i
atmospheres NNS i
under IN i
rigorously RB i
controlled VBN i
experimental JJ i
conditions NNS i
. . i

The DT N
negatively RB i
ionized JJ i
condition NN i
did VBD N
not RB N
significantly RB N
affect JJ N
measurements NNS N
of IN N
activity NN o
level NN o
, , o
impulsivity NN o
, , o
reality NN o
orientation NN o
, , o
destructive/constructiveness NN o
, , o
attention NN o
, , o
or CC o
task NN o
performance NN o
. . o

Significant JJ N
results NNS N
might MD N
be VB N
obtained VBN N
if IN N
subgroups NNS N
of IN N
known JJ p
hyperserotoninemic JJ p
autistic NN p
and CC p
attention NN p
deficit NN p
disorder NN p
children NNS p
were VBD N
exposed VBN N
to TO N
negatively RB i
ionized JJ i
conditions NNS i
. . i

-DOCSTART- -8033763- O O

Relationship NN N
between IN N
subjective JJ N
effects NNS N
and CC N
drug NN p
preferences NNS p
: : p
ethanol NN i
and CC N
diazepam NN i
. . i

The DT N
relationship NN N
between IN N
subjective JJ N
effects NNS N
and CC N
drug NN N
preferences NNS N
in IN N
normal JJ p
volunteers NNS p
was VBD N
explored VBN N
in IN N
a DT N
meta-analysis NN N
of IN N
several JJ N
previously RB N
published VBN N
studies NNS N
. . N

Subjective JJ N
effects NNS N
of IN N
, , N
and CC N
preference NN N
for IN N
, , N
ethanol NN i
and CC i
diazepam NN i
vs. FW i
placebo NN i
were VBD N
measured VBN N
using VBG N
a DT N
choice NN N
procedure NN N
. . N

Subjects NNS N
were VBD N
grouped VBN N
according VBG N
to TO N
their PRP$ N
drug NN N
choices NNS N
: : N
'non-choosers NNS p
' POS p
never RB p
chose JJ p
drug NN p
, , p
whereas IN p
'choosers NNS p
' POS p
always RB p
chose JJ p
drug NN p
. . p

The DT N
two CD N
groups NNS N
were VBD N
compared VBN N
on IN N
their PRP$ N
subjective JJ N
responses NNS N
to TO N
drug NN N
and CC N
on IN N
demographic JJ N
variables NNS N
. . N

Ethanol NNP i
decreased VBD o
Arousal NNP o
, , o
Elation NNP o
, , o
Positive NNP o
Mood NNP o
and CC o
Vigor NNP o
, , N
and CC N
increased VBD o
Anxiety NNP o
, , o
Depression NNP o
and CC o
Fatigue NNP o
in IN N
the DT N
non-choosers NNS N
, , N
whereas IN N
it PRP N
increased VBD o
Arousal NNP o
and CC o
Vigor NNP o
in IN N
the DT N
choosers NNS N
. . N

Ethanol JJ i
choosers NNS N
were VBD N
also RB N
more RBR N
likely JJ o
to TO o
be VB o
males NNS o
and/or IN o
full-time JJ o
students NNS o
than IN N
non-choosers NNS N
. . N

Diazepam NNP i
produced VBD N
sedative-like JJ o
effects NNS o
in IN N
both DT N
choosers NNS N
and CC N
non-choosers NNS N
, , N
but CC N
markedly RB N
decreased VBD o
Anxiety NNP o
and CC o
increased VBD o
Friendliness NNP o
in IN N
choosers NNS N
only RB N
. . N

Diazepam NNP i
choice NN N
was VBD N
also RB N
associated VBN N
with IN N
more RBR o
frequent JJ o
recreational JJ o
use NN o
of IN o
marijuana NN o
and CC o
stimulants NNS o
. . o

Thus RB N
, , N
both DT N
demographic JJ o
variables NNS o
and CC o
subjective JJ o
drug NN o
effects NNS o
were VBD N
related VBN N
to TO N
drug NN N
preference NN N
. . N

-DOCSTART- -15449150- O O

Enhanced NNP N
induction NN o
of IN N
apoptosis NN N
in IN N
lung NN p
adenocarcinoma NN p
after IN N
preoperative JJ N
chemotherapy NN N
with IN N
tegafur NN i
and CC N
uracil NN i
( ( N
UFT NNP N
) ) N
. . N

PURPOSE NN N
To TO N
determine VB N
if IN N
the DT N
preoperative JJ N
administration NN N
of IN N
tegafur NN i
and CC i
uracil NN i
( ( i
UFT NNP i
) ) i
to TO N
patients NNS p
with IN p
lung NN p
adenocarcinoma NN p
could MD N
induce VB N
apoptosis NN N
. . N

METHODS NNP N
We PRP N
conducted VBD N
a DT N
randomized JJ N
prospective JJ p
study NN p
on IN p
30 CD p
patients NNS p
with IN p
lung NN p
adenocarcinoma NN p
, , p
divided VBN p
into IN p
two CD p
groups NNS p
of IN p
15 CD p
patients NNS p
each DT p
. . p

One CD N
group NN N
received VBD N
UFT NNP N
600 CD N
mg/day NN N
preoperatively RB N
for IN N
7 CD N
consecutive JJ N
days NNS N
and CC N
a DT N
control NN N
group NN N
received VBD N
no DT i
chemotherapy NN i
or CC i
radiotherapy NN i
. . i

The DT N
apoptotic JJ o
index NN o
( ( o
AI NNP o
) ) o
was VBD N
determined VBN N
by IN N
the DT N
terminal JJ N
deoxynucleotidyl NN N
transferase-mediated JJ o
deoxyuridine NN o
triphosphate NN o
biotin NN o
nick JJ o
end-labeling NN o
( ( o
TUNEL NNP o
) ) o
method NN N
. . N

Expression NN o
of IN o
Ki-67 NNP o
was VBD N
examined VBN N
by IN N
immunohistochemical JJ o
staining NN o
. . o

The DT N
concentration NN o
of IN o
5-fluorouracil JJ o
( ( o
5-FU JJ o
) ) o
in IN o
tumor NN o
tissue NN o
was VBD o
measured VBN o
by IN o
chemical NN o
assay NN o
. . o

RESULTS VB N
The DT N
AI NNP o
of IN o
lung NN o
adenocarcinoma NN o
cells NNS o
increased VBD N
significantly RB N
in IN N
the DT N
UFT-treated JJ N
group NN N
but CC N
not RB N
in IN N
the DT N
control NN N
group NN N
. . N

A DT N
significant JJ N
positive JJ N
correlation NN N
was VBD N
seen VBN N
between IN N
the DT N
AI NNP o
and CC o
the DT o
5-FU JJ o
concentrations NNS o
in IN N
the DT N
tumor NN N
tissue NN N
. . N

CONCLUSIONS VB N
The DT N
continuous JJ N
oral JJ N
administration NN N
of IN N
UFT NNP N
for IN N
7 CD N
days NNS N
preoperatively RB N
resulted VBD N
in IN N
enhanced JJ N
apoptosis NN o
and CC N
a DT N
significant JJ N
positive JJ N
correlation NN N
between IN N
the DT N
AI NNP o
and CC o
5-FU JJ o
concentrations NNS N
in IN N
lung NN N
adenocarcinoma NN N
. . N

Therefore RB N
, , N
it PRP N
may MD N
be VB N
possible JJ N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
adjuvant JJ N
chemotherapy NN N
based VBN N
on IN N
the DT N
AI NNP N
. . N

-DOCSTART- -7485923- O O

[ NN i
Erythropoietin NNP i
therapy NN N
during IN N
frequent JJ N
autologous JJ p
blood NN p
donations NNS p
. . p

Dose-finding NN N
study NN N
] NNP N
. . N

Avoidance NN N
of IN N
homologous JJ N
blood NN N
products NNS N
and CC N
patients NNS N
' POS N
demand NN N
for IN N
preoperative JJ N
autologous JJ N
blood NN N
donation NN N
programs NNS N
are VBP N
increasing VBG N
. . N

As IN N
many JJ N
of IN N
these DT N
patients NNS p
are VBP p
older JJR p
, , p
with IN p
a DT p
compromised VBN p
cardiovascular NN p
system NN p
and CC N
a DT N
slow JJ N
response NN N
of IN N
the DT N
erythropoietic JJ N
system NN N
when WRB N
anemia NN N
occurs VBZ N
, , N
the DT N
feasibility NN N
and CC N
benefit NN N
of IN N
autologous JJ N
blood NN N
donation NN N
is VBZ N
often RB N
limited JJ N
. . N

Augmentation NN N
of IN N
preoperative JJ N
blood NN N
donation NN N
by IN N
therapy NN N
with IN N
recombinant JJ i
human JJ i
erythropoietin NN i
( ( N
rHuEPO NN N
) ) N
has VBZ N
been VBN N
described VBN N
in IN N
animal JJ N
models NNS N
and CC N
in IN N
patients NNS N
. . N

METHODS NNP N
. . N

In IN N
a DT N
multicenter NN N
, , N
controlled VBN N
, , N
randomized VBN N
trial NN N
, , N
49 CD p
patients NNS p
scheduled VBN p
for IN p
orthopaedic JJ p
or CC p
vascular JJ p
surgery NN p
received VBD N
0 CD N
( ( N
control NN N
group NN N
, , N
n RB N
= VBZ N
9 CD N
) ) N
, , N
200 CD N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
, , N
300 CD N
( ( N
n JJ N
= NNP N
11 CD N
) ) N
, , N
400 CD N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
or CC N
500 CD N
( ( N
n JJ N
= NNP N
9 CD N
) ) N
U/kg NNP N
rHuEPO NN i
( ( i
Erypo NNP i
, , i
Cilag NNP i
, , i
Sulzbach NNP i
, , i
distributor NN i
Fresenius NNP i
, , i
Oberursel NNP i
, , N
Germany NNP N
) ) N
subcutaneously RB N
twice RB N
a DT N
week NN N
for IN N
3 CD N
weeks NNS N
while IN N
every DT N
week NN N
450 CD N
ml NN N
blood NN N
was VBD N
collected VBN N
. . N

Iron NNP i
sulphate NN i
100 CD i
mg NN i
was VBD N
prescribed VBN N
orally RB N
twice RB N
a DT N
day NN N
. . N

Patients NNS p
were VBD p
ineligible JJ p
if IN p
they PRP p
had VBD p
uncontrolled VBN p
hypertension NN p
, , p
recent JJ p
myocardial JJ p
infarction NN p
, , p
haematological JJ p
disorders NNS p
or CC p
a DT p
history NN p
of IN p
seizures NNS p
. . p

Blood NNP N
donation NN N
had VBD N
to TO N
be VB N
cancelled VBN N
if IN N
the DT N
haematocrit NN p
was VBD p
below IN p
30 CD p
% NN p
. . p

RESULTS NNP N
. . N

There EX N
was VBD N
a DT N
significant JJ N
( ( N
ANOVA NNP N
) ) N
drop NN N
of IN N
the DT N
haematocrit NN o
value NN o
only RB N
in IN N
the DT N
control NN N
group NN N
, , N
and CC N
end-point NN o
values NNS o
for IN o
haematocrit NN o
and CC o
haemoglobin NN o
were VBD N
significantly RB N
elevated VBN N
in IN N
the DT N
400 CD N
and CC N
500 CD N
U/kg NNP N
groups NNS N
compared VBN N
with IN N
the DT N
control NN N
group NN N
( ( N
Table NNP N
9 CD N
) ) N
. . N

DISCUSSION NNP N
. . N

The DT N
erythropoietic JJ N
stimulus NN N
of IN N
phlebotomy NN N
for IN N
autologous JJ N
blood NN N
donations NNS N
is VBZ N
often RB N
not RB N
efficient JJ N
enough RB N
to TO N
guarantee VB N
a DT N
constant JJ N
haematocrit NN o
. . o

Lowering VBG N
of IN N
the DT N
preoperative JJ N
haematocrit NN o
jeopardizes VBZ N
the DT N
aim NN N
of IN N
avoidance NN N
of IN N
homologous JJ N
blood NN N
transfusions NNS N
. . N

rHuEPO NN N
increased VBD N
the DT N
efficiency NN o
of IN N
autologous JJ N
blood NN N
collections NNS N
, , N
as IN N
predonation NN N
haematocrit NN N
values NNS N
could MD N
be VB N
preserved VBN N
in IN N
the DT N
high-dosage NN N
groups NNS N
. . N

As IN N
a DT N
consequence NN N
, , N
homologous JJ N
transfusions NNS N
could MD N
be VB N
avoided VBN N
. . N

However RB N
, , N
there EX N
were VBD N
broad JJ N
interindividual JJ N
differences NNS N
in IN N
the DT N
erythropoietic JJ o
response NN o
, , N
possibly RB N
due JJ N
to TO N
limitations NNS N
in IN N
iron NN N
availability NN N
. . N

Adverse JJ N
effects NNS N
of IN N
rHuEPO NN i
therapy NN N
, , N
such JJ N
as IN N
hypertension NN o
, , o
thrombosis NN o
or CC o
neurologic JJ o
disorders NNS o
, , N
are VBP N
mostly RB N
reported VBN N
in IN N
patients NNS p
with IN p
terminal JJ o
kidney NN o
failure NN o
. . o

No DT N
such JJ N
disturbances NNS N
were VBD N
observed VBN N
in IN N
the DT N
present JJ N
study NN N
. . N

CONCLUSION NNP N
. . N

rHuEPO NN N
ameliorates VBZ o
the DT N
preoperative JJ N
decrease NN N
of IN N
haemoglobin NN o
and CC o
haematocrit NN o
values NNS o
due JJ N
to TO N
autologous JJ p
blood NN p
donations NNS p
in IN N
a DT N
dose-related JJ N
fashion NN N
. . N

The DT N
individually RB N
adjusted VBN N
dosage NN N
of IN N
rHuEPO NN N
and CC N
iron NN N
supplementation NN N
merits NNS N
further JJ N
investigation NN N
. . N

-DOCSTART- -18078449- O O

A DT N
randomized JJ N
, , N
placebo-controlled JJ i
trial NN N
of IN N
controlled JJ N
release NN N
melatonin NN i
treatment NN i
of IN N
delayed JJ p
sleep JJ p
phase NN p
syndrome NN p
and CC N
impaired JJ p
sleep JJ p
maintenance NN p
in IN N
children NNS p
with IN p
neurodevelopmental JJ p
disabilities NNS p
. . p

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
efficacy NN o
of IN N
controlled-release NN N
( ( N
CR NNP N
) ) N
melatonin NN i
in IN N
the DT N
treatment NN N
of IN N
delayed JJ p
sleep JJ p
phase NN p
syndrome NN p
and CC N
impaired JJ p
sleep JJ p
maintenance NN p
of IN N
children NNS p
with IN p
neurodevelopmental JJ p
disabilities NNS p
including VBG p
autistic JJ p
spectrum NN p
disorders NNS p
. . p

A DT N
randomized JJ N
double-blind NN N
, , N
placebo-controlled JJ i
crossover NN N
trial NN N
of IN N
CR NNP i
melatonin NN i
( ( N
5 CD N
mg NN N
) ) N
followed VBN N
by IN N
a DT N
3-month JJ N
open-label NN N
study NN N
was VBD N
conducted VBN N
during IN N
which WDT N
the DT N
dose NN N
was VBD N
gradually RB N
increased VBN N
until IN N
the DT N
therapy NN N
showed VBD N
optimal JJ N
beneficial JJ N
effects NNS N
. . N

Sleep JJ o
characteristics NNS o
were VBD N
measured VBN N
by IN N
caregiver NN N
who WP N
completed VBD N
somnologs NNS N
and CC N
wrist JJ N
actigraphs NN N
. . N

Clinician JJ o
rating NN o
of IN N
severity NN N
of IN N
the DT N
sleep JJ N
disorder NN N
and CC N
improvement NN N
from IN N
baseline NN N
, , N
along IN N
with IN N
caregiver JJ o
ratings NNS o
of IN N
global JJ N
functioning NN N
and CC N
family NN N
stress NN N
were VBD N
also RB N
obtained VBN N
. . N

Fifty-one CD p
children NNS p
( ( p
age NN p
range NN p
2-18 CD p
years NNS p
) ) p
who WP p
did VBD p
not RB p
respond VB p
to TO p
sleep VB p
hygiene NN p
intervention NN p
were VBD N
enrolled VBN N
. . N

Fifty JJ N
patients NNS N
completed VBD N
the DT N
crossover NN N
trial NN N
and CC N
47 CD N
completed VBD N
the DT N
open-label JJ N
phase NN N
. . N

Recordings NNS N
of IN N
total JJ o
night-time JJ o
sleep NN o
and CC N
sleep JJ o
latency NN o
showed VBD N
significant JJ N
improvement NN N
of IN N
approximately RB N
30 CD N
min NNS N
. . N

Similarly RB N
, , N
significant JJ o
improvement NN o
was VBD N
observed VBN N
in IN N
clinician JJ o
and CC o
parent JJ o
ratings NNS o
. . o

There EX N
was VBD N
additional JJ N
improvement NN o
in IN N
the DT N
open-label JJ o
somnolog NN o
measures NNS o
of IN N
sleep JJ o
efficiency NN o
and CC N
the DT o
longest JJS o
sleep JJ o
episode NN o
in IN N
the DT N
open-label JJ N
phase NN N
. . N

Overall UH N
, , N
the DT N
therapy NN N
improved VBD o
the DT o
sleep NN o
of IN N
47 CD N
children NNS N
and CC N
was VBD N
effective JJ o
in IN o
reducing VBG o
family NN o
stress NN o
. . o

Children NNP p
with IN p
neurodevelopmental JJ p
disabilities NNS p
, , N
who WP N
had VBD p
treatment NN o
resistant JJ o
chronic JJ o
delayed VBN o
sleep JJ o
phase NN o
syndrome NN o
and CC p
impaired JJ o
sleep JJ o
maintenance NN o
, , N
showed VBD N
improvement NN N
in IN N
melatonin NN i
therapy NN i
. . i

-DOCSTART- -26551184- O O

Elective JJ i
Induction NNP i
of IN i
Labor NNP i
Compared NNP N
With IN N
Expectant NNP i
Management NNP i
of IN i
Nulliparous NNP i
Women NNP i
at IN p
39 CD p
Weeks NNP p
of IN p
Gestation NNP p
: : p
A DT N
Randomized NNP N
Controlled NNP N
Trial NNP N
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
whether IN N
the DT N
elective JJ i
induction NN i
of IN i
labor NN i
in IN N
nulliparous JJ p
women NNS p
with IN p
an DT p
unfavorable JJ p
cervix NN p
affects VBZ N
the DT N
cesarean JJ N
delivery NN N
rate NN N
. . N

METHODS NNP N
We PRP N
conducted VBD N
a DT N
randomized VBN N
controlled VBN N
trial NN N
at IN N
a DT N
tertiary JJ N
care NN N
medical JJ N
center NN N
. . N

Nulliparous JJ p
woman NN p
between IN p
38 CD p
0/7 CD p
and CC p
38 CD p
6/7 CD p
weeks NNS p
of IN p
gestation NN p
who WP p
were VBD p
least JJS p
18 CD p
years NNS p
of IN p
age NN p
with IN p
a DT p
singleton NN p
gestation NN p
and CC p
a DT p
Bishop NNP p
score NN p
of IN p
5 CD p
or CC p
less JJR p
were VBD p
randomized VBN p
to TO p
elective JJ i
induction NN i
of IN i
labor NN i
or CC i
expectant JJ i
management NN i
. . i

The DT N
induction NN i
of IN i
labor NN i
group NN N
was VBD N
induced VBN N
within IN N
1 CD N
week NN N
of IN N
enrollment NN N
but CC N
not RB N
before IN N
39 CD N
0/7 CD N
weeks NNS N
of IN N
gestation NN N
. . N

The DT N
control NN N
group NN N
continued VBD N
routine JJ N
prenatal NN i
care NN i
with IN i
admission NN i
for IN i
labor NN i
or CC N
obstetric JJ i
indication NN i
. . i

The DT N
primary JJ N
outcome NN N
was VBD N
cesarean JJ N
delivery NN N
. . N

Assuming VBG N
a DT N
20 CD N
% NN N
rate NN N
in IN N
women NNS N
in IN N
a DT N
control NN N
group NN N
, , N
80 CD N
% NN N
power NN N
, , N
and CC N
a DT N
goal NN N
to TO N
detect VB N
a DT N
twofold JJ N
increase NN N
to TO N
40 CD N
% NN N
in IN N
the DT N
induction NN N
of IN N
labor NN N
group NN N
, , N
162 CD N
patients NNS N
were VBD N
needed VBN N
. . N

RESULTS NN N
From IN p
March NNP p
2010 CD p
to TO p
February NNP p
2014 CD p
, , p
82 CD p
patients NNS p
were VBD p
randomly RB p
allocated VBN p
to TO p
induction NN p
of IN p
labor NN p
and CC p
80 CD p
to TO p
expectant VB p
management NN p
. . p

Baseline VB N
characteristics NNS N
were VBD N
similar JJ N
between IN N
groups NNS N
. . N

The DT N
cesarean JJ o
delivery NN o
rate NN o
in IN N
the DT N
induction NN N
of IN N
labor NN N
group NN N
was VBD N
30.5 CD N
% NN N
( ( N
25/82 CD N
) ) N
compared VBN N
with IN N
17.7 CD N
% NN N
( ( N
14/79 CD N
) ) N
in IN N
the DT N
expectant JJ N
management NN N
group NN N
( ( N
relative JJ N
risk NN N
1.72 CD N
, , N
95 CD N
% NN N
confidence NN N
interval JJ N
0.96-3.06 NN N
) ) N
. . N

CONCLUSION NNP N
In IN N
nulliparous JJ p
women NNS p
with IN p
a DT p
Bishop NNP p
score NN p
of IN p
5 CD p
or CC p
less JJR p
, , N
elective JJ i
induction NN i
after IN N
39 CD N
0/7 CD N
weeks NNS N
of IN N
gestation NN N
compared VBN N
with IN N
expectant JJ i
management NN i
of IN i
pregnancy NN i
did VBD N
not RB N
double VB N
the DT N
rate NN N
of IN N
cesarean JJ N
delivery NN N
. . N

CLINICAL NNP N
TRIAL NNP N
REGISTRACTION NNP N
ClinicalTrials.gov NNP N
, , N
www.clinicaltrials.gov NN N
, , N
NCT01076062 NNP N
. . N

LEVEL NNP N
OF IN N
EVIDENCE NNP N
I PRP N
. . N

-DOCSTART- -18157013- O O

Minimally RB N
invasive JJ N
treatment NN N
combined VBN N
with IN N
cytokine-induced JJ i
killer NN i
cells NNS i
therapy VBP i
lower JJR N
the DT N
short-term JJ N
recurrence NN N
rates NNS N
of IN N
hepatocellular JJ p
carcinomas NN p
. . p

The DT N
recurrence NN N
of IN N
hepatocellular JJ N
carcinoma NN N
( ( N
HCC NNP N
) ) N
after IN N
minimally RB N
invasive JJ N
therapy NN N
is VBZ N
frequent JJ N
. . N

Adoptive JJ i
immunotherapy NN i
is VBZ N
thought VBN N
to TO N
be VB N
an DT N
effective JJ N
method NN N
to TO N
lower JJR N
recurrence NN N
and CC N
metastasis NN N
rates NNS N
of IN N
malignant JJ N
tumors NNS N
. . N

Therefore RB N
, , N
85 CD p
HCC NNP p
patients NNS p
after IN p
transcatheter JJ i
arterial JJ i
chemoembolization NN i
and CC p
radiofrequency NN i
ablation NN i
therapy NN i
were VBD p
randomized VBN p
to TO p
immunotherapy VB i
group NN p
and CC p
no DT i
adjuvant JJ i
therapy NN i
group NN p
. . p

Autologous JJ i
cytokine-induced JJ i
killer NN i
( ( i
CIK NNP i
) ) i
cells NNS i
were VBD i
transfused VBN i
via IN N
hepatic JJ N
artery NN N
to TO N
the DT N
patients NNS N
. . N

The DT N
alteration NN N
of IN N
levels NNS N
of IN N
lymphocyte JJ N
subsets NNS N
in IN N
peripheral JJ N
blood NN N
of IN N
patients NNS N
was VBD N
examined VBN N
by IN N
flow JJ N
cytometry NN N
. . N

All DT p
patients NNS p
were VBD p
screened VBN p
by IN p
computed JJ p
tomography NN p
every DT p
2 CD p
months NNS p
to TO p
observe VB p
the DT p
tumor NN p
recurrent NN p
conditions NNS p
. . p

After IN N
CIK NNP i
cell NN i
infusions NNS N
, , N
the DT N
percentages NNS o
of IN o
CD3+ NNP o
, , o
CD4+ NNP o
, , o
CD56+ NNP o
, , o
CD3+CD56+ NNP o
cells NNS o
, , o
and CC o
CD4+/CD8+ NNP o
ratio VBP o
increased VBN N
from IN N
68.6+/-11.0 CD N
% NN N
, , N
31.1+/-9.0 CD N
% NN N
, , N
15.6+/-7.9 CD N
% NN N
, , N
5.2+/-3.1 CD N
% NN N
, , N
and CC N
1.1+/-0.5 JJ N
to TO N
70.7+/-10.1 CD N
% NN N
, , N
33.5+/-8.0 CD N
% NN N
, , N
18.4+/-9.4 CD N
% NN N
, , N
5.9+/-2.8 CD N
% NN N
, , N
and CC N
1.3+/-0.7 JJ N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
; : N
whereas IN N
the DT N
percentage NN o
of IN o
CD8 NNP o
cells NNS o
decreased VBN N
from IN N
31.1+/-7.8 CD N
% NN N
to TO N
28.6+/-8.3 CD N
% NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
1-year JJ o
and CC o
18-month JJ o
recurrence NN o
rates NNS o
of IN o
the DT o
study NN o
group NN o
were VBD N
8.9 CD N
% NN N
and CC N
15.6 CD N
% NN N
, , N
compared VBN N
with IN N
30.0 CD N
% NN N
and CC N
40.0 CD N
% NN N
of IN N
the DT N
control NN N
group NN N
( ( N
both DT N
P NNP N
value NN N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
data NN N
suggest NN N
that IN N
CIK NNP i
cell NN i
transfusion NN i
is VBZ N
an DT N
effective JJ N
treatment NN N
. . N

It PRP N
can MD N
boost VB N
the DT N
immunologic JJ N
function NN N
in IN N
HCC NNP p
patients NNS p
and CC N
plays VBZ N
an DT N
important JJ N
role NN N
in IN N
reducing VBG N
the DT N
recurrence NN N
rate NN N
of IN N
HCC NNP N
. . N

-DOCSTART- -3410812- O O

Speech NN i
following VBG i
sign JJ i
language NN i
training NN i
in IN N
autistic JJ p
children NNS p
with IN p
minimal JJ p
verbal JJ p
language NN p
. . p

This DT N
study NN N
was VBD N
carried VBN N
out IN N
to TO N
test VB N
the DT N
main JJ o
and CC o
interaction JJ o
effects NNS o
of IN N
training VBG N
condition NN N
and CC N
pretreatment-elicited JJ N
verbal JJ N
imitation NN N
ability NN N
when WRB N
predicting VBG N
spoken JJ N
language NN N
use NN N
during IN N
language NN i
training NN i
of IN N
60 CD p
minimally RB p
verbal JJ p
autistic JJ p
children NNS p
. . p

Subjects NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
Speech NNP o
Alone NNP o
, , o
Sign NNP o
Alone NNP o
, , o
Simultaneous NNP o
Presentation NNP o
of IN o
Sign NNP o
and CC o
Speech NNP o
, , o
and CC o
Alternating NNP o
Presentation NNP o
of IN o
Sign NNP o
and CC o
Speech NNP o
training NN o
conditions NNS o
. . o

Speech NNP o
Alone RB o
, , o
Simultaneous JJ o
Presentation NNP o
, , o
and CC o
Alternating NNP o
Presentation NNP o
condition NN o
facilitated VBD N
more RBR N
child-initiated JJ N
speech NN N
during IN N
treatment NN N
than IN N
did VBD N
the DT N
Sign NNP i
Alone NNP i
condition NN N
. . N

Regardless NNP N
of IN N
training VBG N
condition NN N
, , N
pretreatment NN N
verbal JJ N
imitation NN N
ability NN N
positively RB N
predicted VBD N
the DT N
size NN o
of IN o
child-initiated JJ o
spoken JJ o
vocabulary JJ o
observed VBD N
during IN N
training NN N
. . N

Exploratory JJ N
analyses NNS N
indicated VBD N
that IN N
, , N
in IN N
addition NN N
to TO N
verbal JJ N
imitation NN N
, , N
pretreatment JJ N
age NN N
and CC N
IQ NNP N
may MD N
also RB N
predict VB N
spoken JJ N
language NN N
developed VBD N
during IN N
training NN N
. . N

-DOCSTART- -22669453- O O

Tumor NN o
budding NN o
is VBZ N
an DT N
independent JJ N
predictor NN N
of IN N
outcome NN N
in IN N
AJCC/UICC NNP p
stage NN p
II NNP p
colorectal NN p
cancer NN p
. . p

BACKGROUND NNP N
In IN N
colorectal JJ N
cancer NN N
, , N
the DT N
morphology NN N
of IN N
the DT N
invasive JJ N
tumor NN N
margin NN N
may MD N
reflect VB N
aggressiveness NN N
of IN N
tumor NN N
growth NN N
, , N
thus RB N
providing VBG N
important JJ N
prognostic JJ N
information NN N
. . N

The DT N
tumor NN N
growth NN N
pattern VBP N
according VBG N
to TO N
Jass NNP N
and CC N
the DT N
extent NN N
of IN N
tumor NN i
budding NN i
were VBD N
analyzed VBN N
in IN N
patients NNS p
with IN p
American JJ p
Joint NNP p
Committee NNP p
on IN p
Cancer/Union NNP p
for IN p
International NNP p
Cancer NNP p
Control NNP p
( ( p
AJCC/UICC NNP p
) ) p
stage NN p
II NNP p
disease NN p
. . p

METHODS NNP N
Tumors NNPS p
of IN p
120 CD p
randomly RB p
selected VBN p
patients NNS p
with IN p
AJCC/UICC NNP p
stage NN p
II NNP p
disease NN p
were VBD p
retrospectively RB p
reviewed VBN p
for IN N
tumor NN p
growth NN p
pattern NN p
( ( p
expanding VBG p
vs. IN p
infiltrating VBG p
) ) p
and CC N
the DT N
extent NN N
of IN N
tumor NN i
budding NN i
, , N
with IN N
high-grade JJ N
budding VBG N
reflecting VBG N
presence NN N
of IN N
10 CD N
or CC N
more JJR N
budding JJ N
foci NN N
scattered VBN N
at IN N
the DT N
invasive JJ N
tumor NN N
margin NN N
. . N

Progression-free JJ o
and CC o
cancer-specific JJ o
survivals NNS o
were VBD N
determined VBN N
by IN N
the DT N
Kaplan-Meier NNP N
method NN N
. . N

For IN N
multivariable JJ i
analysis NN i
, , N
Cox NNP N
's POS N
proportional JJ N
hazards NNS N
regression NN N
models NNS N
were VBD N
performed VBN N
. . N

RESULTS VB N
The DT N
infiltrating JJ N
growth NN N
pattern NN N
was VBD N
significantly RB N
associated VBN N
with IN N
histological JJ N
subtype NN N
and CC N
lymphovascular JJ N
invasion NN N
, , N
while IN N
high-grade JJ N
budding NN N
was VBD N
significantly RB N
associated VBN N
with IN N
tumor NN o
grade NN o
and CC o
lymphovascular JJ o
invasion NN o
. . o

High-grade JJ i
budding NN i
, , N
but CC N
not RB N
the DT N
infiltrating NN N
growth NN N
pattern NN N
, , N
was VBD N
significantly RB N
associated VBN N
with IN N
outcome NN N
in IN N
univariable JJ N
analysis NN N
. . N

Cox NNP N
's POS N
proportional JJ N
hazards NNS N
regression NN N
models NNS N
proved VBD N
tumor JJ i
budding NN i
to TO N
be VB N
an DT N
independent JJ N
predictor NN N
of IN N
disease NN o
progression NN o
( ( N
hazard JJ N
ratio NN N
3.91 CD N
, , N
95 CD N
% NN N
confidence NN N
interval JJ N
1.3-11.77 JJ N
; : N
P NNP N
= NNP N
0.02 CD N
) ) N
and CC N
cancer-related JJ o
death NN o
( ( o
hazard JJ o
ratio NN N
5.90 CD N
, , N
95 CD N
% NN N
confidence NN N
interval JJ N
1.62-21.51 JJ N
; : N
P NNP N
= NNP N
0.007 CD N
) ) N
. . N

The DT N
combination NN N
of IN N
infiltrating VBG N
growth NN N
pattern NN N
and CC N
high-grade JJ N
budding NN N
did VBD N
not RB N
have VB N
a DT N
stronger JJR N
prognostic JJ N
significance NN i
than IN i
tumor NN i
budding VBG i
alone RB i
. . N

CONCLUSIONS NNP N
Tumor NNP N
budding VBG N
independently RB N
predicted VBN N
patient JJ N
outcome NN p
in IN p
patients NNS p
with IN p
AJCC/UICC NNP p
stage NN p
II NNP p
colorectal NN p
cancer NN p
and CC p
may MD p
therefore RB N
be VB N
used VBN N
for IN N
accurate JJ N
prognostication NN N
, , N
patient JJ N
counseling NN N
, , N
and CC N
design NN N
of IN N
clinical JJ N
trials NNS N
by IN N
using VBG N
integrated JJ i
multimodal JJ i
therapy NN i
. . i

-DOCSTART- -12602669- O O

Randomized VBN N
controlled JJ N
trial NN N
evaluating VBG N
the DT N
clinical JJ N
benefit NN N
of IN N
montelukast NN i
for IN N
treating VBG N
spring NN o
seasonal JJ o
allergic JJ o
rhinitis NN o
. . o

BACKGROUND NNP N
Symptoms NNP N
of IN N
allergic JJ N
rhinitis NN N
are VBP N
mediated VBN N
in IN N
part NN N
by IN N
cysteinyl NN N
leukotrienes NNS N
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
clinical JJ N
benefit NN N
of IN N
montelukast NN i
, , i
a DT i
cysteinyl JJ i
leukotriene NN i
receptor NN i
antagonist NN i
, , N
administered VBN N
once RB N
daily JJ N
for IN N
treating VBG N
seasonal JJ o
allergic JJ o
rhinitis NN o
. . o

METHODS NNP N
This DT p
multicenter NN p
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo- JJ i
and CC N
active-controlled JJ N
study NN N
enrolled VBD p
1,214 CD p
healthy JJ p
, , p
nonsmoking JJ p
outpatients NNS p
aged VBD p
15 CD p
to TO p
85 CD p
years NNS p
with IN p
spring NN p
allergic NN p
rhinitis NN p
, , p
positive JJ p
skin NN p
test NN p
to TO p
a DT p
spring NN p
allergen NN p
, , p
and CC p
predefined VBD p
daytime JJ p
nasal NN p
symptoms NNS p
. . p

After IN N
a DT N
3- JJ N
to TO N
5-day JJ N
placebo JJ i
run-in JJ N
period NN N
, , N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
treatment NN N
with IN N
montelukast JJ i
10 CD N
mg NN N
( ( N
n JJ N
= NNP N
522 CD N
) ) N
, , N
loratadine JJ i
10 CD N
mg NN N
( ( N
n JJ N
= NNP N
171 CD N
) ) N
, , N
or CC i
placebo NN i
( ( N
n JJ N
= NNP N
521 CD N
) ) N
once RB N
daily JJ N
at IN N
bedtime NN N
for IN N
2 CD N
weeks NNS N
. . N

During IN N
the DT N
run-in JJ N
and CC N
treatment NN N
periods NNS N
, , N
symptoms NNS o
were VBD N
evaluated VBN N
in IN N
a DT N
daily JJ N
diary NN N
using VBG N
a DT N
0 CD N
( ( N
best RBS N
) ) N
to TO N
3 CD N
( ( N
worst JJS N
) ) N
scale NN N
. . N

RESULTS NNP N
Baseline NNP N
characteristics NNS N
of IN N
randomized JJ N
patients NNS N
were VBD N
clinically RB N
similar JJ N
in IN N
the DT N
three CD N
treatment NN N
groups NNS N
. . N

Montelukast NNP i
was VBD N
significantly RB N
more RBR N
effective JJ N
than IN N
placebo NN i
( ( N
P NNP N
= NNP N
0.003 CD N
) ) N
in IN N
improving VBG N
the DT N
daytime NN o
nasal NN o
symptoms NNS o
score NN o
( ( N
difference NN N
in IN N
least JJS N
square JJ N
means NNS N
, , N
-0.09 NNP N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
-0.16 NNP N
, , N
-0.03 NNP N
) ) N
averaged VBD N
over RB N
2 CD N
weeks NNS N
of IN N
therapy NN N
. . N

The DT N
treatment NN N
effect NN N
of IN N
montelukast NN i
was VBD N
significantly RB N
greater JJR N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
relative JJ N
to TO N
placebo VB N
, , N
for IN N
all DT N
secondary JJ N
endpoints NNS N
, , N
including VBG N
nighttime NN o
symptoms NNS o
and CC o
daytime JJ o
eye NN o
symptoms NNS o
, , o
patient NN o
and CC o
physician JJ o
global JJ o
evaluations NNS o
of IN o
allergic JJ o
rhinitis NN o
, , o
and CC o
rhinoconjunctivitis VBP o
quality NN o
of IN o
life NN o
. . o

Loratadine NNP i
, , N
which WDT N
served VBD N
as IN N
a DT N
positive JJ N
control NN N
, , N
was VBD N
significantly RB N
more RBR N
effective JJ N
than IN N
placebo NN N
for IN N
most JJS N
endpoints NNS N
, , N
validating VBG N
the DT N
study NN N
results NNS N
. . N

Both DT N
montelukast NN i
and CC N
loratadine NN i
were VBD N
well RB o
tolerated VBN o
. . o

CONCLUSION NNP N
Therapy NNP N
with IN N
montelukast NN i
significantly RB N
improves VBZ N
assessments NNS N
of IN N
symptom JJ o
severity NN o
as RB N
well RB N
as IN N
quality-of-life JJ o
parameters NNS o
for IN N
patients NNS p
with IN p
seasonal JJ p
allergic JJ p
rhinitis NN p
. . p

-DOCSTART- -24214189- O O

QT/QTc NNP N
study NN N
conducted VBD N
in IN N
Japanese JJ p
adult NN p
healthy JJ p
subjects NNS p
: : p
a DT N
novel JJ N
xanthine NN N
oxidase NN N
inhibitor NN N
topiroxostat NN i
was VBD N
not RB N
associated VBN N
with IN N
QT NNP N
prolongation NN N
. . N

A DT N
QT/QTc NNP N
study NN N
was VBD N
conducted VBN N
in IN N
compliance NN N
with IN N
ICH NNP N
E14 NNP N
guideline NN N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
a DT N
new JJ i
xanthine JJ i
oxidase NN i
inhibitor NN i
topiroxostat NN i
in IN N
Japanese JJ p
healthy JJ p
subjects NNS p
. . p

Forty-eight JJ p
Japanese JJ p
healthy JJ p
subjects NNS p
( ( p
males NNS p
24 CD p
; : p
females NNS p
24 CD p
) ) p
received VBD N
a DT N
single JJ N
oral JJ i
dose NN i
of IN i
topiroxostat NN i
( ( N
60 CD N
or CC N
180 CD i
mg NN i
) ) i
, , i
moxifloxacin FW i
( ( i
400 CD i
mg NN i
) ) i
or CC i
placebo NN i
in IN i
a DT N
single-center JJ p
, , p
double-blind JJ p
, , N
four-period JJ N
crossover NN N
design NN o
. . o

Fridericia NNP o
's POS o
formula NN o
( ( o
QTcF NNP o
= NNP o
QT/RR NNP o
( ( o
0.33 CD o
) ) o
) ) o
was VBD o
used VBN o
as IN N
a DT N
primary JJ N
method NN N
for IN o
QT-interval JJ o
correction NN o
. . o

The DT o
mean JJ o
QTcF NNP o
was VBD o
prolonged VBN i
by IN i
moxifloxacin NN i
, , i
of IN i
which WDT i
largest JJS N
time-matched JJ N
difference NN N
from IN N
placebo JJ N
administration NN N
was VBD N
13.6 CD N
milliseconds NNS N
with IN N
90 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
of IN N
11.2 CD N
and CC N
15.9 CD N
milliseconds NNS N
at IN N
4 CD N
hours NNS N
post-dose JJ N
. . N

The DT N
mean JJ o
QTcF NNP o
was VBD N
hardly RB N
affected VBN N
by IN N
either DT N
dose NN N
of IN N
topiroxostat NN N
, , N
of IN N
which WDT N
largest JJS N
time-matched JJ N
difference NN N
from IN N
placebo JJ N
administration NN N
was VBD N
2.9 CD N
milliseconds NNS N
with IN N
90 CD N
% NN N
CI NNP N
of IN N
0.6 CD N
and CC N
5.3 CD N
milliseconds NNS N
at IN N
4 CD N
hours NNS N
post-dose JJ N
for IN N
60 CD N
mg NN N
, , N
and CC N
2.3 CD N
milliseconds NNS N
with IN N
90 CD N
% NN N
CI NNP N
of IN N
0 CD N
and CC N
4.7 CD N
milliseconds NNS N
at IN N
1 CD N
hour NN N
post-dose NN N
for IN N
180 CD N
mg NN N
. . N

The DT N
results NNS N
were VBD N
essentially RB N
the DT N
same JJ N
in IN N
the DT N
sex NN N
subgroup NN N
analysis NN N
. . N

Moxifloxacin NNP i
can MD i
be VB i
used VBN N
as IN N
a DT N
positive JJ N
control NN N
for IN N
QT/QTc NNP N
studies NNS N
in IN N
Japanese JJ p
subjects NNS p
; : p
and CC N
topiroxostat VB N
may MD N
not RB N
cause VB N
QT-interval JJ N
prolongation NN N
in IN N
males NNS N
as RB N
well RB N
as IN N
females NNS N
. . N

-DOCSTART- -18606932- O O

Complementary JJ N
feeding NN N
with IN N
fortified JJ N
spread NN N
and CC N
incidence NN N
of IN N
severe JJ o
stunting VBG o
in IN N
6- JJ p
to TO p
18-month-old JJ p
rural JJ p
Malawians NNPS p
. . p

OBJECTIVE NNP N
To TO N
compare VB N
growth NN o
and CC N
incidence NN N
of IN N
malnutrition NN o
in IN N
infants NNS p
receiving VBG p
long-term JJ p
dietary JJ p
supplementation NN p
with IN p
ready-to-use NN p
fortified VBN i
spread NN i
( ( i
FS NNP i
) ) i
or CC p
micronutrient-fortified JJ i
maize-soy JJ i
flour NN i
( ( i
likuni JJ i
phala NN i
[ NNP p
LP NNP p
] NNP p
) ) p
. . p

DESIGN NNP N
Randomized NNP N
, , N
controlled VBD N
, , N
single-blind JJ N
trial NN N
. . N

SETTING NNP N
Rural JJ N
Malawi NNP N
. . N

PARTICIPANTS VB N
A DT p
total NN p
of IN p
182 CD p
six-month-old JJ p
infants NNS p
. . p

INTERVENTION NN N
Participants NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
1 CD N
year NN N
of IN N
daily JJ N
supplementation NN N
with IN N
71 CD N
g NN N
of IN N
LP NNP i
( ( N
282 CD N
kcal NN N
) ) N
, , N
50 CD N
g NN N
of IN N
FS NNP i
( ( N
FS50 NNP N
) ) N
( ( N
256 CD N
kcal NN N
) ) N
, , N
or CC N
25 CD N
g NN N
of IN N
FS NNP i
( ( i
FS25 NNP i
) ) i
( ( N
130 CD N
[ RB N
corrected VBN N
] NNP N
kcal JJ N
) ) N
. . N

OUTCOME NNP N
MEASURES NNP N
Weight NNP o
and CC o
length NN o
gains NNS o
and CC o
the DT o
incidences NNS o
of IN o
severe JJ o
stunting NN o
, , o
underweight JJ o
, , o
and CC o
wasting VBG o
. . o

RESULTS NNP N
Mean NNP o
weight NN o
and CC o
length NN o
gains NNS o
in IN N
the DT N
LP NNP i
, , N
FS50 NNP N
, , N
and CC N
FS25 NNP N
groups NNS N
were VBD N
2.37 CD N
, , N
2.47 CD N
, , N
and CC N
2.37 CD N
kg NN N
( ( N
P NNP N
= NNP N
.66 NNP N
) ) N
and CC N
12.7 CD N
, , N
13.5 CD N
, , N
and CC N
13.2 CD N
cm NN N
( ( N
P NNP N
= NNP N
.23 NNP N
) ) N
, , N
respectively RB N
. . N

In IN N
the DT N
same JJ N
groups NNS N
, , N
the DT N
cumulative JJ N
12-month JJ N
incidence NN N
of IN N
severe JJ o
stunting NN o
was VBD N
13.3 CD N
% NN N
, , N
0.0 CD N
% NN N
, , N
and CC N
3.5 CD N
% NN N
( ( N
P NNP N
= NNP N
.01 NNP N
) ) N
, , N
of IN N
severe JJ N
underweight NN o
was VBD N
15.0 CD N
% NN N
, , N
22.5 CD N
% NN N
, , N
and CC N
16.9 CD N
% NN N
( ( N
P NNP N
= NNP N
.71 NNP N
) ) N
, , N
and CC N
of IN N
severe JJ o
wasting NN o
was VBD N
1.8 CD N
% NN N
, , N
1.9 CD N
% NN N
, , N
and CC N
1.8 CD N
% NN N
( ( N
P NNP N
> NNP N
.99 NNP N
) ) N
. . N

Compared VBN N
with IN N
LP-supplemented JJ i
infants NNS N
, , N
those DT N
given VBN N
FS50 NNP N
gained VBD N
a DT N
mean NN N
of IN N
100 CD N
g NNS N
more JJR N
weight NN o
and CC N
0.8 CD N
cm NN N
more JJR N
length NN o
. . o

There EX N
was VBD N
a DT N
significant JJ N
interaction NN N
between IN N
baseline NN N
length NN N
and CC N
intervention NN N
( ( N
P NNP N
= NNP N
.04 NNP N
) ) N
; : N
in IN N
children NNS N
with IN N
below-median JJ N
length NN N
at IN N
enrollment NN N
, , N
those DT N
given VBN N
FS50 NNP N
gained VBD N
a DT N
mean NN N
of IN N
1.9 CD N
cm NNS N
more JJR N
than IN N
individuals NNS N
receiving VBG N
LP NNP i
. . i

CONCLUSION NNP N
One-year-long JJ N
complementary JJ N
feeding NN N
with IN N
FS NNP i
does VBZ N
not RB N
have VB N
a DT N
significantly RB N
larger JJR N
effect NN N
than IN N
LP NNP i
on IN N
mean JJ o
weight NN o
gain NN o
in IN N
all DT N
infants NNS N
, , N
but CC N
it PRP N
is VBZ N
likely JJ N
to TO N
boost VB N
linear JJ o
growth NN o
in IN N
the DT N
most RBS N
disadvantaged JJ N
individuals NNS N
and CC N
, , N
hence RB N
, , N
decrease VB N
the DT N
incidence NN o
of IN o
severe JJ o
stunting NN o
. . o

-DOCSTART- -21038654- O O

[ JJ N
Effect NNP N
of IN N
treatment NN N
of IN N
non-nephrotic JJ p
syndrome JJ p
IgA NNP p
nephropathy NN p
with IN N
Shenyanning NNP i
] NNP i
. . N

OBJECTIVE NNP N
To TO N
observe VB N
the DT N
curative JJ o
effect NN o
of IN N
Shenyanning NNP i
( ( i
SYN NNP i
) ) i
on IN N
non-nephrotic JJ p
syndrome NN p
IgA NNP p
nephropathy NN p
( ( p
IgAN NNP p
) ) p
. . p

METHODS NNP N
Seventy NNP p
primary JJ p
IgAN NNP p
patients NNS p
were VBD N
equally RB N
randomized VBN N
into IN N
two CD N
groups NNS N
, , N
the DT N
treatment NN N
group NN N
and CC N
the DT N
control NN N
group NN N
, , N
they PRP N
were VBD N
orally RB N
treated VBN N
with IN N
SYN NNP i
Decoction NNP i
( ( N
one CD N
dose NN N
per IN N
day NN N
) ) N
and CC N
Losartan NNP i
( ( N
50 CD N
mg NNS N
per IN N
day NN N
) ) N
respectively RB N
for IN N
1 CD N
year NN N
. . N

Efficacy NNP o
of IN o
treatment NN o
, , o
Chinese JJ o
medicine JJ o
syndrome NN o
scores NNS o
, , o
end-point JJ o
events NNS o
occurrence NN o
as RB N
well RB N
as IN N
changes NNS N
of IN N
related JJ N
laboratory NN o
indices NNS o
were VBD N
observed VBN N
. . N

RESULTS VB N
The DT N
total JJ o
effective JJ o
rate NN o
in IN N
the DT N
treatment NN N
group NN N
was VBD N
obviously RB N
higher JJR N
than IN N
that DT N
in IN N
the DT N
control NN N
group NN N
( ( N
77.1 CD N
% NN N
vs. FW N
54.3 CD N
% NN N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

After IN N
treatment NN N
, , N
the DT N
Chinese JJ o
medicine JJ o
syndrome NN o
scores NNS o
, , o
urinary JJ o
protein NN o
and CC o
urinary JJ o
red-cell NN o
count NN o
reduced VBD N
significantly RB N
in IN N
the DT N
treatment NN N
group NN N
( ( N
P NNP N
< VBZ N
0.05 CD N
or CC N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
showed VBD N
significant JJ N
difference NN N
as IN N
compared VBN N
with IN N
those DT N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< VBZ N
0.05 CD N
or CC N
P NNP N
< NNP N
0.01 CD N
) ) N
; : N
while IN N
the DT N
endogenous JJ o
creatinine NN o
clearance NN o
was VBD N
changed VBN N
insignificantly RB N
in IN N
both DT N
groups NNS N
. . N

Beside NNP N
, , N
the DT N
occurrence NN N
of IN N
end-point JJ o
events NNS o
in IN N
the DT N
treatment NN N
group NN N
was VBD N
slightly RB N
lower JJR N
than IN N
that DT N
in IN N
the DT N
control NN N
group NN N
, , N
though IN N
showed VBN N
no DT N
statistical JJ N
difference NN N
between IN N
them PRP N
. . N

CONCLUSION VB N
The DT N
curative JJ N
effect NN N
of IN N
SYN NNP i
in IN N
treating VBG N
IgAN NNP N
was VBD N
obviously RB N
better JJR N
than IN N
that DT N
of IN N
simple JJ N
Western JJ N
medicine NN N
. . N

-DOCSTART- -11134799- O O

A DT p
randomized JJ p
trial NN p
in IN p
simultaneous JJ p
pancreas-kidney JJ i
transplantation NN i
: : i
portal JJ i
versus NN i
systemic JJ o
venous JJ o
drainage NN o
of IN i
the DT i
pancreas NN i
allograft NN i
. . i

-DOCSTART- -15623613- O O

Genetic JJ N
polymorphisms NNS N
of IN N
human JJ N
flavin JJ N
monooxygenase NN N
3 CD N
in IN N
sulindac-mediated JJ i
primary JJ N
chemoprevention NN N
of IN N
familial JJ p
adenomatous JJ p
polyposis NN p
. . p

PURPOSE NNP N
Sulindac NNP i
is VBZ N
a DT N
nonsteroidal JJ N
anti-inflammatory JJ N
drug NN N
( ( N
NSAID NNP N
) ) N
effective JJ N
in IN N
regressing VBG N
adenomas NN N
in IN N
patients NNS p
with IN p
familial JJ p
adenomatous JJ p
polyposis NN p
( ( p
FAP NNP p
) ) p
. . p

However RB N
, , N
a DT N
recent JJ N
randomized JJ N
trial NN N
showed VBD N
that IN N
sulindac NN i
, , N
when WRB N
compared VBN N
with IN N
placebo NN i
, , N
failed VBD N
to TO N
prevent VB N
the DT N
development NN N
of IN N
adenomatous JJ N
polyps NNS N
in IN N
genotypically RB N
positive JJ N
but CC N
phenotypically RB N
negative JJ N
FAP NNP N
patients NNS N
. . N

The DT N
present JJ N
study NN N
determined VBD N
whether IN N
polymorphisms NNS N
in IN N
the DT N
gene NN N
encoding VBG N
flavin JJ N
monooxygenase NN N
3 CD N
( ( N
FMO3 NNP N
) ) N
, , N
a DT N
hepatic JJ N
microsomal NN N
enzyme NN N
that WDT N
inactivates VBZ N
sulindac RB i
, , N
played VBD N
a DT N
role NN N
in IN N
determining VBG N
the DT N
efficacy NN N
of IN N
sulindac NN i
in IN N
preventing VBG N
polyposis NN N
in IN N
this DT N
cohort NN N
of IN N
FAP NNP p
patients NNS p
. . p

EXPERIMENTAL NNP N
DESIGN NNP N
Genotyping NNP N
was VBD N
performed VBN N
on IN N
seven CD N
established VBD N
FMO3 NNP N
polymorphisms NNS N
previously RB N
shown VBN N
to TO N
have VB N
functional JJ N
relevance-M66I NN p
, , p
P153L NNP p
, , p
E158K NNP p
, , p
V257M NNP p
, , p
E305X NNP p
, , p
E308G NNP p
, , p
and CC p
R492W-in NNP p
21 CD p
and CC p
20 CD p
FAP NNP p
patients NNS p
, , p
who WP p
received VBD p
sulindac NN i
and CC i
placebo NN i
, , p
respectively RB p
. . p

RESULTS NNP N
None NN N
of IN N
the DT N
41 CD p
patients NNS p
exhibited VBN N
heterozygous JJ o
or CC o
homozygous JJ o
M66I NNP o
and CC o
R492W NNP o
variant NN o
alleles NNS o
, , o
or CC o
homozygous JJ o
P153L NNP o
, , o
V257M NNP o
, , o
and CC o
E305X NNP o
variant JJ o
alleles NNS o
. . o

Among IN N
sulindac-treated JJ i
patients NNS p
who WP N
did VBD N
not RB N
develop VB N
adenomas NN N
( ( N
responders NNS N
) ) N
, , N
4 CD N
( ( N
33 CD N
% NN N
) ) N
were VBD N
homozygous JJ o
for IN o
E158K NNP o
and CC N
2 CD N
( ( N
17 CD N
% NN N
) ) N
were VBD N
homozygous JJ o
for IN o
E308G NNP o
variant JJ o
alleles NNS o
. . o

In IN N
contrast NN N
, , N
none NN N
of IN N
the DT N
patients NNS p
on IN p
sulindac NN p
who WP N
developed VBD N
adenomas NN N
( ( N
nonresponders NNS N
) ) N
exhibited VBD N
homozygosity NN o
for IN N
either DT N
of IN N
the DT N
two CD N
variant JJ N
alleles NNS N
. . N

In IN N
addition NN N
, , N
polymorphisms NN N
in IN N
the DT N
E158K NNP N
or CC N
E308G NNP N
allele NNS N
were VBD N
associated VBN N
with IN N
a DT N
significant JJ N
reduction NN N
in IN N
mucosal NN o
prostanoid NN o
levels NNS o
in IN N
patients NNS N
treated VBN N
with IN N
sulindac NN i
. . i

CONCLUSIONS NNP N
Polymorphisms NNP N
in IN N
FMO3 NNP N
, , N
particularly RB N
at IN N
the DT N
E158K NNP N
and CC N
E308G NNP N
loci NN N
, , N
may MD N
reduce VB N
activity NN N
in IN N
catabolizing VBG N
sulindac NN i
and CC N
result NN N
in IN N
an DT N
increased JJ N
efficacy NN N
to TO N
prevent VB N
polyposis NN N
in IN N
FAP NNP N
. . N

-DOCSTART- -16214598- O O

Secondary JJ N
prevention NN N
of IN N
macrovascular JJ o
events NNS o
in IN N
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
in IN p
the DT p
PROactive NNP p
Study NNP p
( ( N
PROspective NNP N
pioglitAzone RB N
Clinical JJ N
Trial NNP N
In IN N
macroVascular JJ N
Events NNS N
) ) N
: : N
a DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Patients NNPS p
with IN p
type JJ p
2 CD p
diabetes NNS p
are VBP N
at IN N
high JJ N
risk NN N
of IN N
fatal JJ N
and CC N
non-fatal JJ N
myocardial JJ o
infarction NN o
and CC N
stroke NN o
. . o

There EX N
is VBZ N
indirect JJ N
evidence NN N
that IN N
agonists NNS N
of IN N
peroxisome JJ N
proliferator-activated JJ N
receptor NN N
gamma NN N
( ( N
PPAR NNP N
gamma NN N
) ) N
could MD N
reduce VB N
macrovascular JJ o
complications NNS o
. . o

Our PRP$ N
aim NN N
, , N
therefore RB N
, , N
was VBD N
to TO N
ascertain VB N
whether IN N
pioglitazone NN i
reduces NNS N
macrovascular JJ o
morbidity NN o
and CC N
mortality NN o
in IN N
high-risk JJ p
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
. . p

METHODS NNP N
We PRP N
did VBD N
a DT N
prospective NN N
, , N
randomised VBD N
controlled VBN N
trial NN N
in IN N
5238 CD p
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
who WP p
had VBD p
evidence NN p
of IN p
macrovascular JJ o
disease NN o
. . o

We PRP N
recruited VBD N
patients NNS p
from IN p
primary-care JJ p
practices NNS p
and CC p
hospitals NNS p
. . p

We PRP N
assigned VBD N
patients NNS N
to TO N
oral JJ i
pioglitazone NN i
titrated VBD i
from IN i
15 CD i
mg NNS i
to TO i
45 CD i
mg NN i
( ( N
n=2605 JJ N
) ) N
or CC i
matching VBG i
placebo NN i
( ( N
n=2633 JJ N
) ) N
, , N
to TO N
be VB N
taken VBN N
in IN i
addition NN i
to TO i
their PRP$ i
glucose-lowering JJ i
drugs NNS i
and CC i
other JJ i
medications NNS i
. . i

Our PRP$ N
primary JJ N
endpoint NN N
was VBD N
the DT N
composite NN o
of IN o
all-cause JJ o
mortality NN o
, , o
non JJ o
fatal JJ o
myocardial JJ o
infarction NN o
( ( o
including VBG o
silent JJ o
myocardial JJ o
infarction NN o
) ) o
, , o
stroke VBD o
, , o
acute JJ o
coronary JJ o
syndrome NN o
, , o
endovascular JJ o
or CC o
surgical JJ o
intervention NN o
in IN o
the DT o
coronary NN o
or CC o
leg NN o
arteries NNS o
, , o
and CC o
amputation NN o
above IN o
the DT o
ankle NN o
. . o

Analysis NN N
was VBD N
by IN N
intention NN N
to TO N
treat VB N
. . N

This DT N
study NN N
is VBZ N
registered VBN N
as IN N
an DT N
International NNP N
Standard NNP N
Randomised VBD N
Controlled NNP N
Trial NNP N
, , N
number NN N
ISRCTN NNP N
NCT00174993 NNP N
. . N

FINDINGS NNP N
Two CD N
patients NNS N
were VBD N
lost VBN N
to TO N
follow-up JJ N
, , N
but CC N
were VBD N
included VBN N
in IN N
analyses NNS N
. . N

The DT N
average JJ N
time NN N
of IN N
observation NN N
was VBD N
34.5 CD N
months NNS N
. . N

514 CD p
of IN p
2605 CD p
patients NNS p
in IN N
the DT N
pioglitazone NN N
group NN N
and CC N
572 CD N
of IN N
2633 CD N
patients NNS N
in IN N
the DT N
placebo NN N
group NN N
had VBD N
at IN N
least JJS N
one CD N
event NN N
in IN N
the DT N
primary JJ o
composite JJ o
endpoint NN o
( ( N
HR NNP N
0.90 CD N
, , N
95 CD N
% NN N
CI NNP N
0.80-1.02 CD N
, , N
p=0.095 NN N
) ) N
. . N

The DT N
main JJ N
secondary JJ N
endpoint NN N
was VBD N
the DT N
composite NN o
of IN o
all-cause JJ o
mortality NN o
, , o
non-fatal JJ o
myocardial JJ o
infarction NN o
, , o
and CC o
stroke VBD o
. . o

301 CD N
patients NNS N
in IN N
the DT N
pioglitazone NN N
group NN N
and CC N
358 CD N
in IN N
the DT N
placebo NN N
group NN N
reached VBD N
this DT N
endpoint NN o
( ( N
0.84 CD N
, , N
0.72-0.98 CD N
, , N
p=0.027 NN N
) ) N
. . N

Overall JJ o
safety NN o
and CC o
tolerability NN o
was VBD N
good JJ N
with IN N
no DT N
change NN N
in IN N
the DT N
safety NN o
profile NN o
of IN N
pioglitazone NN N
identified VBN N
. . N

6 CD N
% NN N
( ( N
149 CD N
of IN N
2065 CD N
) ) N
and CC N
4 CD N
% NN N
( ( N
108 CD N
of IN N
2633 CD N
) ) N
of IN N
those DT N
in IN N
the DT N
pioglitazone NN N
and CC N
placebo NN N
groups NNS N
, , N
respectively RB N
, , N
were VBD N
admitted VBN N
to TO N
hospital VB N
with IN N
heart NN o
failure NN o
; : o
mortality NN o
rates NNS o
from IN o
heart NN o
failure NN o
did VBD N
not RB N
differ VB N
between IN N
groups NNS N
. . N

INTERPRETATION NNP N
Pioglitazone NNP N
reduces VBZ N
the DT N
composite NN N
of IN N
all-cause JJ N
mortality NN o
, , o
non-fatal JJ o
myocardial JJ o
infarction NN o
, , N
and CC N
stroke VBD o
in IN N
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
who WP p
have VBP p
a DT p
high JJ p
risk NN p
of IN p
macrovascular JJ p
events NNS p
. . p

-DOCSTART- -14616279- O O

Vaginal JJ i
electrical JJ i
stimulation NN i
of IN i
the DT i
pelvic JJ i
floor NN i
: : i
a DT N
randomized JJ N
feasibility NN N
study NN N
in IN N
urinary JJ p
incontinent NN p
elderly JJ p
women NNS p
. . p

BACKGROUND NNP N
To TO N
evaluate VB N
the DT N
effectiveness NN o
of IN N
intravaginal JJ i
electrical JJ i
stimulation NN i
( ( i
ES NNP i
) ) i
of IN N
the DT N
pelvic JJ N
floor NN N
for IN N
urinary JJ N
incontinence NN N
in IN N
elderly JJ p
women NNS p
, , N
and CC N
to TO N
determine VB N
whether IN N
ES NNP i
of IN i
the DT i
pelvic JJ i
floor NN i
is VBZ N
a DT N
preferable JJ N
treatment NN N
for IN N
urinary JJ p
incontinence NN p
in IN p
elderly JJ p
women NNS p
. . p

METHODS NNP N
Postmenopausal NNP p
women NNS p
( ( p
age NN p
65 CD p
years NNS p
or CC p
older JJR p
) ) p
were VBD N
enrolled VBN N
in IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
and CC N
underwent JJ N
every-other-day JJ N
ES NNP i
of IN i
the DT i
pelvic JJ i
floor NN i
, , i
or CC i
a DT i
daily JJ i
Kegel NNP i
exercise NN i
( ( i
KE NNP i
) ) i
program NN i
. . i

Objective NNP N
outcome NN N
variables NNS N
were VBD N
: : N
( ( o
1 CD o
) ) o
Urinary JJ o
leakage NN o
( ( o
during IN o
a DT o
standardized JJ o
PAD NNP o
test NN o
) ) o
, , o
( ( o
2 CD o
) ) o
pelvic NN o
muscle NN o
strength NN o
( ( o
measured VBN o
by IN o
a DT o
perineometer NN o
) ) o
, , o
and CC o
( ( o
3 CD o
) ) o
detrusor NN o
instability NN o
( ( o
on IN o
ambulant NN o
urodynamic JJ o
registration NN o
) ) o
. . o

Subjective JJ N
outcome NN N
variables NNS N
were VBD N
women NNS o
's POS o
subjective JJ o
assessment NN o
of IN o
change NN o
in IN o
urinary JJ o
symptoms NNS o
based VBN o
on IN o
the DT o
PRAFAB NNP o
score NN o
. . o

Twenty-four JJ p
women NNS p
treated VBN p
with IN p
ES NNP i
and CC p
11 CD p
women NNS p
treated VBN p
with IN p
Kegel NNP i
exercises NNS i
completed VBD N
the DT N
8-week JJ N
study NN N
program NN N
. . N

The DT N
Chi-square JJ N
test NN N
was VBD N
used VBN N
for IN N
statistical JJ N
analysis NN N
. . N

RESULTS NNP N
No NNP N
significant JJ N
improvement NN N
in IN N
objective JJ N
outcome NN N
variables NNS N
was VBD N
observed VBN N
in IN N
the DT N
population NN N
treated VBD N
with IN N
ES NNP i
compared VBN N
with IN N
the DT N
population NN N
treated VBD N
with IN N
KE NNP i
( ( N
with IN N
29.2 CD N
% NN N
vs. FW N
36.4 CD N
% NN N
of IN N
the DT N
women NNS N
showing VBG N
objective JJ N
improvement NN N
in IN N
measured JJ o
urinary JJ o
leakage NN o
) ) o
. . N

Neither CC N
was VBD N
subjective JJ N
improvement NN N
significant JJ N
, , N
with IN N
29.2 CD N
% NN N
vs. FW N
27.3 CD N
% NN N
of IN N
the DT N
women NNS N
reporting VBG N
improvement NN N
in IN N
the DT N
amount NN o
of IN o
urinary JJ o
leakage NN o
. . o

CONCLUSIONS NNP N
Although IN N
the DT N
number NN N
of IN N
enrolled JJ N
women NNS N
was VBD N
very RB N
small JJ N
this DT N
study NN N
shows VBZ N
that IN N
: : N
1 CD N
. . N

Treating VBG N
elderly JJ p
women NNS p
with IN N
vaginal JJ N
ES NNP N
of IN N
the DT N
pelvic JJ N
floor NN N
has VBZ N
a DT N
high JJ N
physical JJ N
and CC N
emotional JJ N
cost NN N
for IN N
the DT N
individual NN N
. . N

2 CD N
. . N

The DT N
effectiveness NN o
of IN N
ES NNP i
of IN N
the DT N
pelvic JJ N
floor NN N
in IN N
urinary JJ N
incontinent NN N
elderly JJ N
women NNS N
is VBZ N
low JJ N
. . N

3 CD N
. . N

There EX N
is VBZ N
no DT N
great JJ N
discrepancy NN N
between IN N
objective JJ N
amelioration NN N
( ( N
PAD NNP N
test NN N
) ) N
and CC N
subjective JJ N
amelioration NN N
( ( N
PRAFAB NNP N
score/quantity NN N
of IN N
urinary JJ N
leakage NN N
) ) N
, , N
if IN N
the DT N
objective JJ N
improvement NN N
is VBZ N
adequately RB N
defined VBN N
. . N

4 CD N
. . N

It PRP N
is VBZ N
not RB N
reasonable JJ N
to TO N
advise VB N
elderly JJ N
women NNS N
with IN N
urinary JJ N
incontinence NN N
to TO N
undertake VB N
this DT N
treatment NN N
procedure NN N
. . N

The DT N
effectiveness NN N
of IN N
treatment NN N
does VBZ N
not RB N
compensate VB N
for IN N
the DT N
long-lasting JJ N
and CC N
intense JJ N
treatment NN N
protocol NN N
. . N

5 CD N
. . N

We PRP N
terminated VBD N
this DT N
study NN N
because IN N
of IN N
the DT N
negative JJ N
outcome NN N
with IN N
ES NNP i
. . i

-DOCSTART- -3704665- O O

Therapeutic JJ N
recommendations NNS o
in IN N
polycythemia NN N
vera NN N
based VBN N
on IN N
Polycythemia NNP N
Vera NNP N
Study NNP N
Group NNP N
protocols VBZ N
. . N

The DT N
PVSG NNP N
was VBD N
organized VBN N
in IN N
1967 CD N
to TO N
establish VB N
effective JJ N
diagnostic JJ N
criteria NNS N
for IN N
polycythemia NN N
vera NN N
, , N
to TO N
study VB N
the DT N
natural JJ N
history NN N
of IN N
the DT N
disease NN N
and CC N
to TO N
define VB N
the DT N
optimal JJ N
treatment NN N
. . N

Although IN N
polycythemia NN p
vera NN p
and CC p
the DT p
other JJ p
myeloproliferative JJ p
diseases NNS p
are VBP N
relatively RB N
uncommon JJ N
, , N
the DT N
PVSG NNP N
was VBD N
able JJ N
to TO p
accumulate VB p
well RB p
over IN p
1,000 CD p
patients NNS p
with IN p
these DT p
various JJ p
disorders NNS p
and CC N
to TO N
study VB N
them PRP N
according VBG N
to TO N
a DT N
total NN N
of IN N
15 CD N
different JJ N
protocols NNS N
. . N

PVSG-01 NNP N
, , N
a DT N
long-term JJ N
randomized NN N
controlled VBD N
study NN N
of IN N
phlebotomy NN i
alone RB i
compared VBN N
with IN N
the DT N
myelosuppressive JJ i
agents NNS i
, , i
32P CD i
or CC i
chlorambucil NN i
supplemented VBN i
by IN i
phlebotomy NN i
, , N
continues VBZ N
to TO N
receive VB N
follow-up JJ N
data NNS N
on IN N
93 CD N
% NN N
of IN N
surviving VBG N
patients NNS N
18 CD N
years NNS N
after IN N
initiation NN N
of IN N
the DT N
study NN N
. . N

During IN N
its PRP$ N
lifetime NN N
, , N
PVSG NNP N
has VBZ N
developed VBN N
a DT N
widely RB N
accepted VBN N
and CC N
highly RB N
effective JJ N
set NN N
of IN N
criteria NNS N
for IN N
the DT N
specific JJ N
diagnosis NN N
of IN N
polycythemia NN N
vera NN N
as RB N
well RB N
as IN N
useful JJ N
criteria NNS N
for IN N
the DT N
diagnosis NN N
of IN N
essential JJ N
thrombocythemia NN N
. . N

It PRP N
has VBZ N
gathered VBN N
an DT N
enormous JJ N
volume NN N
of IN N
data NNS N
on IN N
the DT N
natural JJ N
history NN N
of IN N
the DT N
myeloproliferative JJ N
diseases NNS N
and CC N
in IN N
particular JJ N
on IN N
the DT N
nature NN N
of IN N
the DT N
prevalent JJ N
complications NNS N
, , N
such JJ N
as IN N
thrombotic JJ N
events NNS N
and CC N
hematologic NN N
and CC N
nonhematologic JJ N
malignancies NNS N
. . N

With IN N
respect NN N
to TO N
the DT N
final JJ N
question NN N
, , N
the DT N
optimal JJ N
treatment NN N
for IN N
polycythemia NN N
vera NN N
, , N
it PRP N
is VBZ N
apparent JJ N
that IN N
the DT N
expectation NN N
of IN N
a DT N
single JJ i
optimal JJ i
therapy NN i
that WDT N
would MD N
apply VB N
to TO N
all DT N
patients NNS N
at IN N
all DT N
ages NNS N
and CC N
stages NNS N
of IN N
the DT N
disease NN N
was VBD N
naive JJ N
. . N

Nevertheless NNP N
considerable JJ N
progress NN N
has VBZ N
been VBN N
made VBN N
. . N

Moreover RB N
, , N
the DT N
group NN N
has VBZ N
defined VBN N
more RBR N
precisely RB N
than IN N
ever RB N
before IN N
the DT N
nature NN o
of IN o
the DT o
complications NNS o
of IN N
the DT N
disease NN N
and CC N
the DT N
association NN N
of IN N
the DT N
risks NNS o
of IN o
specific JJ o
complications NNS o
with IN N
specific JJ N
forms NNS N
of IN N
therapy NN N
. . N

It PRP N
thus RB N
has VBZ N
made VBN N
it PRP N
possible JJ N
to TO N
pose VB N
the DT N
next JJ N
series NN N
of IN N
therapeutic JJ N
questions NNS N
that WDT N
must MD N
be VB N
addressed VBN N
in IN N
this DT N
disorder NN N
with IN N
a DT N
greater JJR N
degree NN N
of IN N
sophistication NN N
than IN N
was VBD N
previously RB N
possible JJ N
. . N

-DOCSTART- -17501728- O O

The DT N
effectiveness NN N
of IN N
Picture NNP i
Exchange NNP i
Communication NNP i
System NNP i
( ( i
PECS NNP i
) ) i
training NN i
for IN N
teachers NNS p
of IN p
children NNS p
with IN p
autism NN p
: : p
a DT N
pragmatic JJ N
, , N
group NN N
randomised VBD N
controlled VBN N
trial NN N
. . N

OBJECTIVE UH N
To TO N
assess VB N
the DT N
effectiveness NN N
of IN N
expert JJ N
training NN N
and CC N
consultancy NN N
for IN N
teachers NNS p
of IN p
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
in IN N
the DT N
use NN N
of IN N
the DT N
Picture NNP i
Exchange NNP i
Communication NNP i
System NNP i
( ( i
PECS NNP i
) ) i
. . i

METHOD NNP N
DESIGN NNP N
Group NNP N
randomised VBD N
, , N
controlled VBN N
trial NN N
( ( N
3 CD N
groups NNS N
: : N
immediate JJ N
treatment NN N
, , N
delayed VBN N
treatment NN N
, , N
no DT N
treatment NN N
) ) N
. . N

PARTICIPANTS $ N
84 CD p
elementary JJ p
school NN p
children NNS p
, , p
mean JJ p
age NN p
6.8 CD p
years NNS p
. . p

TREATMENT VB N
A DT i
2-day JJ i
PECS NNP i
workshop NN i
for IN i
teachers NNS i
plus CC i
6 CD i
half-day JJ i
, , i
school-based JJ i
training NN i
sessions NNS i
with IN i
expert JJ i
consultants NNS i
over IN i
5 CD i
months NNS i
. . i

OUTCOME NNP N
MEASURES NNP N
Rates NNPS N
of IN N
: : N
communicative JJ o
initiations NNS o
, , o
use NN o
of IN o
PECS NNP o
, , o
and CC o
speech NN o
in IN o
the DT o
classroom NN o
; : o
Autism NNP o
Diagnostic NNP o
Observation NNP o
Schedule-Generic NNP o
( ( o
ADOS-G NNP o
) ) o
domain NN o
scores NNS o
for IN o
Communication NNP o
and CC o
Reciprocal NNP o
Social NNP o
Interaction NNP o
; : o
scores NNS o
on IN o
formal JJ o
language NN o
tests NNS o
. . o

RESULTS NNP N
Controlling VBG N
for IN N
baseline NN N
age NN N
, , N
developmental JJ o
quotient NN o
( ( o
DQ NNP o
) ) o
and CC o
language NN o
; : o
rates NNS o
of IN o
initiations NNS o
and CC o
PECS NNP o
usage NN o
increased VBD N
significantly RB N
immediately RB N
post-treatment JJ N
( ( N
Odds NNP N
Ratio NNP N
( ( N
OR NNP N
) ) N
of IN N
being VBG N
in IN N
a DT N
higher JJR N
ordinal JJ N
rate NN N
category NN N
2.72 CD N
, , N
95 CD N
% NN N
confidence NN N
interval JJ N
1.22-6.09 JJ N
, , N
p JJ N
< NNP N
.05 NNP N
and CC N
OR NNP N
3.90 CD N
( ( N
95 CD N
% NN N
CI NNP N
1.75-8.68 CD N
) ) N
, , N
p JJ N
< NNP N
.001 NNP N
, , N
respectively RB N
) ) N
. . N

There EX N
were VBD N
no DT N
increases NNS N
in IN N
frequency NN o
of IN o
speech NN o
, , o
or CC o
improvements NNS o
in IN o
ADOS-G NNP o
ratings NNS o
or CC o
language NN o
test NN o
scores NNS o
. . o

CONCLUSIONS VB N
The DT N
results NNS N
indicate VBP N
modest JJ N
effectiveness NN N
of IN N
PECS NNP i
teacher NN i
training/consultancy NN i
. . i

Rates NNS N
of IN N
pupils NNS N
' POS N
initiations NNS N
and CC N
use NN N
of IN N
symbols NNS N
in IN N
the DT N
classroom NN N
increased VBD N
, , N
although IN N
there EX N
was VBD N
no DT N
evidence NN N
of IN N
improvement NN N
in IN N
other JJ N
areas NNS N
of IN N
communication NN N
. . N

TREATMENT NNP N
effects NNS N
were VBD N
not RB N
maintained VBN N
once RB N
active JJ N
intervention NN N
ceased VBD N
. . N

-DOCSTART- -8115195- O O

Pain NN N
relief NN N
can MD N
reduce VB N
hypoxemia NN o
in IN N
distressed JJ p
neonates NNS p
during IN N
routine JJ N
treatment NN N
procedures NNS N
. . N

OBJECTIVE NN N
To TO N
determine VB N
whether IN N
the DT N
use NN N
of IN N
opioids NNS i
could MD N
reduce VB N
the DT N
hypoxemia NN o
and CC o
hemodynamic JJ o
instability NN o
associated VBN N
with IN N
routine JJ N
intensive JJ N
care NN N
procedures NNS N
in IN N
neonates NNS p
with IN p
respiratory JJ p
distress NN p
. . p

DESIGN NNP N
Randomized NNP N
and CC N
placebo-controlled JJ i
study NN N
. . N

METHODS NNP N
Physiological NNP N
, , N
plasma JJ N
beta-endorphin NN N
, , N
cortisol NN N
, , N
and CC N
glucose JJ N
responses NNS N
to TO N
routine VB N
treatment NN N
procedures NNS N
were VBD N
studied VBN N
in IN N
84 CD p
mechanically RB p
ventilated VBN p
distressed JJ p
neonates NNS p
randomized VBN N
into IN N
groups NNS N
receiving VBG N
1 CD i
mg/kg JJ i
meperidine NN i
or CC i
0.9 CD i
% NN i
saline NN i
15 CD N
minutes NNS N
before IN N
tracheal JJ i
suction NN i
or CC i
routine JJ i
nursing NN i
care NN i
. . i

RESULTS VB N
The DT N
duration NN o
of IN o
hypoxemia NN o
( ( o
transcutaneous JJ o
partial JJ o
pressure NN o
of IN o
O2 NNP o
< NNP N
6.6 CD N
kPa NN N
( ( N
< JJ N
50 CD N
mm NN N
Hg NNP N
) ) N
and/or VBP N
arterial JJ o
blood NN o
oxygen NN o
saturation NN o
< VBD N
80 CD N
% NN N
) ) N
during IN N
treatment NN N
procedures NNS N
was VBD N
significantly RB N
longer RBR N
in IN N
the DT N
saline NN N
group NN N
( ( N
mean JJ N
82 CD N
vs NN N
36 CD N
seconds NNS N
, , N
P NNP N
= NNP N
.001 NNP N
) ) N
and CC N
distress JJ N
quantified VBN N
by IN N
a DT N
novel JJ N
behavioral JJ N
scoring VBG N
method NN N
was VBD N
much RB N
higher JJR N
. . N

Changes NNS N
in IN N
arterial JJ o
blood NN o
pressure NN o
, , o
heart NN o
rate NN o
, , o
or CC o
plasma VB o
beta-endorphin JJ o
, , o
cortisol NN o
, , o
and CC o
glucose JJ o
concentration NN o
did VBD N
not RB N
show VB N
any DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
groups NNS N
. . N

CONCLUSION NNP N
Newborns NNP p
with IN p
respiratory JJ p
difficulties NNS p
often RB N
suffer VBP N
from IN N
hypoxemia NN N
during IN N
essential JJ N
treatment NN N
procedures NNS N
. . N

The DT N
use NN N
of IN N
opioid JJ i
analgesia NN i
may MD N
reduce VB N
the DT N
duration NN o
of IN o
hypoxemia NN o
and CC N
the DT N
associated JJ N
distress NN o
and CC N
, , N
therefore RB N
, , N
may MD N
improve VB N
the DT N
long-term JJ N
results NNS N
of IN N
neonatal JJ N
intensive JJ N
care NN N
. . N

-DOCSTART- -12370849- O O

Effect NN N
of IN N
macronutrient JJ i
composition NN N
of IN N
the DT N
diet NN N
on IN N
the DT N
regulation NN o
of IN o
lipolysis NN o
in IN o
adipose JJ o
tissue NN o
at IN N
rest NN N
and CC N
during IN N
exercise NN N
: : N
microdialysis NN N
study NN N
. . N

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
elucidate VB N
, , N
using VBG N
a DT N
microdialysis NN N
technique NN N
, , N
whether IN N
modifications NNS N
in IN N
the DT N
proportion NN N
of IN N
fat NN i
in IN i
the DT i
diet JJ i
influence NN N
lipid JJ o
mobilization NN o
from IN N
adipose JJ N
tissue NN N
in IN N
situ NN N
. . N

Nine NNP p
healthy JJ p
volunteers NNS p
( ( p
age NN p
, , p
23.4 CD p
+/- JJ p
0.2 CD p
years NNS p
; : p
body NN p
mas VBZ p
index NN p
[ NNP p
BMI NNP p
] NNP p
, , p
23.5 CD p
+/- JJ p
1.6 CD p
kg/m NN p
( ( p
2 CD p
) ) p
) ) p
were VBD N
fed VBN N
, , N
in IN N
random JJ N
order NN N
, , N
with IN N
a DT N
high-fat JJ i
diet NN i
( ( i
HFD NNP i
) ) i
( ( i
65 CD i
% NN i
of IN i
energy NN i
content NN i
fat NN i
, , i
15 CD i
% NN i
protein NN i
, , i
20 CD i
% NN i
carbohydrate NN i
) ) i
or CC i
a DT i
high-carbohydrate JJ i
diet NN i
( ( i
HCD NNP i
) ) i
( ( i
70 CD i
% NN i
carbohydrate NN i
, , i
15 CD i
% NN i
protein NN i
, , i
15 CD i
% NN i
fat NN i
) ) i
for IN i
5 CD i
days NNS i
, , i
with IN i
a DT i
washout JJ i
period NN i
of IN i
10 CD i
days NNS i
between IN i
the DT i
diets NNS i
. . i

Subjects NNS N
were VBD N
studied VBN N
in IN N
the DT N
fasting NN N
state NN N
on IN N
the DT N
morning NN N
following VBG N
days NNS N
4 CD N
and CC N
5 CD N
of IN N
each DT N
diet NN N
. . N

We PRP N
measured VBD N
the DT N
concentration NN o
of IN o
extracellular JJ o
glycerol NN o
( ( o
EGC NNP o
) ) o
in IN o
adipose JJ o
tissue NN o
in IN N
response NN N
to TO N
( ( N
1 CD N
) ) N
pharmacologic NN N
stimulation NN N
with IN N
isoprenaline NN i
( ( N
1 CD N
and CC N
10 CD N
micromol/L NN N
) ) N
in IN N
situ NN N
, , N
( ( N
2 CD N
) ) N
stimulation NN N
with IN N
intravenous JJ N
infusion NN N
of IN N
epinephrine NN i
( ( N
0.0375 CD N
microg/min/kg NN N
body NN N
weight NN N
) ) N
, , N
and CC N
( ( N
3 CD N
) ) N
submaximal NN N
aerobic JJ i
exercise NN i
( ( N
50 CD N
% NN N
V*O2max NNP N
, , N
60-minute JJ N
duration NN N
) ) N
. . N

No DT N
effect NN N
of IN N
the DT N
diet JJ o
composition NN o
was VBD N
found VBN N
in IN N
the DT N
increases NNS o
of IN o
EGC NNP o
in IN N
response NN N
to TO N
isoprenaline VB N
( ( N
area NN N
under IN N
the DT N
curve NN N
[ NNP N
AUC NNP N
] NN N
: : N
HFD NNP N
, , N
1,534 CD N
+/- JJ N
370 CD N
micromol/90 NN N
min NN N
; : N
HCD NNP N
, , N
1,108 CD N
+/- JJ N
465 CD N
micromol/90 NN N
min NN N
; : N
not RB N
significant JJ N
[ NNP N
NS NNP N
] NNP N
) ) N
or CC N
epinephrine JJ o
stimulations NNS o
( ( N
AUC NNP N
: : N
HFD NNP N
, , N
190 CD N
+/- JJ N
92 CD N
micromol/30 NN N
min NN N
; : N
HCD NNP N
, , N
251 CD N
+/- JJ N
298 CD N
micromol/30 NN N
min NN N
; : N
NS NNP N
) ) N
. . N

The DT N
exercise-induced JJ o
increase NN o
in IN o
EGC NNP o
was VBD o
higher RBR o
during IN N
the DT N
HFD NNP N
( ( N
AUC NNP N
: : N
HFD NNP N
, , N
1,641 CD N
+/- JJ N
181 CD N
micromol/60 NN N
min NN N
; : N
HCD NNP N
, , N
963 CD N
+/- JJ N
156 CD N
micromol/60 NN N
min NN N
; : N
P NNP N
< NNP N
.05 NNP N
) ) N
and CC N
was VBD N
associated VBN N
with IN N
a DT N
higher JJR o
exercise-induced JJ o
response NN o
of IN N
norepinephrine NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
and CC N
epinephrine NN N
( ( N
P NNP N
=.056 NNP N
) ) N
and CC N
lower JJR N
insulinemia NN o
during IN N
exercise NN N
. . N

The DT N
results NNS N
suggest VBP N
that IN N
macronutrient JJ N
composition NN N
of IN N
diet NN N
does VBZ N
not RB N
affect VB N
the DT N
beta-adrenergic JJ o
responsiveness NN o
of IN o
adipose JJ o
tissue NN o
to TO N
catecholamine VB N
action NN N
at IN N
rest NN N
. . N

During IN N
exercise NN N
, , N
the DT N
HFD NNP i
promotes VBZ N
higher JJR o
lipolysis NN o
in IN o
adipose JJ o
tissue NN o
and CC N
this DT N
is VBZ N
associated VBN N
with IN N
a DT N
higher JJR N
catecholamine NN N
response NN N
and CC N
lower JJR N
insulinemia NN N
. . N

-DOCSTART- -20027352- O O

Efficiency NN N
of IN N
anaferon NN i
in IN N
complex JJ i
therapy NN i
of IN N
genital JJ p
herpes NNS p
. . p

We PRP N
studied VBD N
clinical JJ N
efficiency NN N
and CC N
IFN-inducing JJ N
activity NN N
of IN N
anaferon NN i
in IN N
chronic JJ p
recurrent NN p
genital JJ p
herpes NNS p
with IN p
high JJ p
incidence NN p
of IN p
relapses NNS p
. . p

The DT N
use NN N
of IN N
anaferon NN i
in IN N
complex JJ i
therapy NN i
reduced VBD N
the DT N
duration NN o
of IN o
intoxication NN o
symptoms NNS o
and CC o
local JJ o
symptoms NNS o
, , N
shortened VBD N
the DT N
duration NN o
of IN o
the DT o
relapse NN o
, , o
activated JJ o
expression NN o
of IN o
IFN-gamma NNP o
mRNA NN o
, , o
and CC o
improved VBD o
IFN-gamma-producing NNP o
capacity NN o
of IN o
blood NN o
leukocytes NNS o
. . o

-DOCSTART- -11237545- O O

Comparison NNP N
of IN N
provocative JJ N
tests NNS N
for IN N
unexplained JJ p
syncope NN p
: : p
isoprenaline NN i
and CC i
glyceryl NN i
trinitrate NN i
for IN N
diagnosing VBG N
vasovagal JJ o
syncope NN o
. . o

AIMS NNP N
To TO N
compare VB N
the DT N
sensitivity NN N
, , N
specificity NN N
and CC N
adverse JJ N
event NN N
profile NN N
of IN N
glyceryl JJ i
trinitrate JJ i
head-up NN N
tilt NN N
with IN N
isoprenaline JJ i
head-up JJ N
tilt NN N
in IN N
the DT N
diagnosis NN N
of IN N
vasovagal JJ N
syncope NN N
in IN N
patients NNS p
with IN p
unexplained JJ p
syncope NN p
and CC p
healthy JJ p
controls NNS p
. . p

METHODS NNP N
AND CC N
RESULTS NNP N
Forty-eight NNP p
patients NNS p
with IN p
unexplained JJ p
syncope NN p
and CC p
negative JJ p
passive JJ p
head-up NN p
tilt NN p
at IN p
70 CD p
degrees NNS p
for IN p
40 CD p
min NN p
, , p
and CC p
14 CD p
healthy JJ p
controls NNS p
underwent JJ N
glyceryl JJ i
trinitrate NN i
head-up NN i
tilt NN i
and CC i
isoprenaline JJ i
head-up NN i
tilt NN i
( ( N
maximum JJ N
dose RB N
5 CD N
microg NNS N
x JJ N
min NN N
( ( N
-1 NNP N
) ) N
) ) N
one CD N
week NN N
apart RB N
in IN N
random JJ N
order NN N
. . N

Outcome CC N
measures NNS N
were VBD N
production NN o
of IN o
symptoms NNS o
( ( o
syncope NN o
, , o
pre-syncope NN o
) ) o
with IN o
development NN o
of IN o
hypotension NN o
. . o

In IN N
those DT N
with IN N
negative JJ p
passive JJ p
head-up NN p
tilt NN p
, , N
the DT N
sensitivity NN o
of IN o
glyceryl NN o
trinitrate NN o
for IN N
diagnosing VBG N
vasovagal JJ o
syncope NN o
was VBD N
48 CD N
% NN N
and CC N
the DT N
specificity NN N
was VBD N
71 CD N
% NN N
. . N

Glyceryl NNP N
trinitrate NN N
was VBD N
well RB N
tolerated VBN o
. . o

Isoprenaline NNP o
sensitivity NN o
was VBD N
21 CD N
% NN N
with IN N
specificity NN o
64 CD N
% NN N
. . N

Side-effects NNS o
prevented JJ N
completion NN N
of IN N
the DT N
test NN N
in IN N
68 CD N
% NN N
. . N

Commonest NNP N
adverse JJ N
events NNS N
were VBD N
the DT N
development NN o
of IN o
hypertension NN o
or CC o
tachycardia NN o
and CC o
intolerable JJ o
flushing NN o
or CC o
nausea NN o
. . o

CONCLUSIONS NNP N
Glyceryl NNP i
trinitrate VB i
head-up JJ i
tilt NN i
is VBZ N
as RB N
effective JJ o
as IN N
isoprenaline JJ i
head-up JJ i
tilt NN i
as IN N
a DT N
provocative JJ N
agent NN N
for IN N
vasovagal JJ o
syncope NN o
and CC o
has VBZ o
a DT o
lower JJR o
incidence NN o
of IN o
adverse JJ o
events NNS o
. . o

-DOCSTART- -1904908- O O

Treatment NN N
of IN N
bulimia NN o
nervosa NN o
with IN N
lithium JJ i
carbonate NN i
. . i

A DT N
controlled JJ N
study NN N
. . N

Ninety-one CD p
female JJ p
bulimic JJ p
outpatients NNS p
received VBD N
lithium JJ i
carbonate NN i
or CC i
placebo NN i
on IN N
a DT N
random JJ N
basis NN N
, , N
after IN N
being VBG N
separated VBN N
into IN N
depressed JJ p
and CC p
nondepressed JJ p
subgroups NNS N
, , N
in IN N
an DT N
8-week JJ N
double-blind JJ N
trial NN N
. . N

Sixty-eight JJ p
patients NNS p
who WP p
completed VBD p
the DT p
study NN p
experienced VBD N
a DT N
significant JJ N
decrease NN N
in IN N
bulimic JJ o
episodes NNS o
after IN N
the DT N
8 CD N
weeks NNS N
. . N

Lithium NNP i
, , N
in IN N
a DT N
dosage NN N
yielding VBG N
relatively RB o
low JJ o
plasma NN o
levels NNS o
, , N
was VBD N
not RB N
more RBR N
effective JJ N
than IN N
placebo NN i
. . i

However RB N
, , N
depression NN o
and CC o
other JJ o
psychopathologies NNS o
decreased VBN N
with IN N
improvement NN N
in IN N
bulimic JJ o
behavior NN o
. . o

-DOCSTART- -23475835- O O

Parenting VBG o
stress NN o
in IN p
the DT p
infant JJ p
aphakia NN p
treatment NN p
study NN N
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
parenting VBG p
stress NN p
following VBG p
infants NNS p
' POS p
cataract NN i
extraction NN i
surgery NN i
, , N
and CC N
to TO N
determine VB N
if IN N
levels NNS N
of IN N
stress NN N
differ NN N
between IN N
2 CD N
treatments NNS N
for IN N
unilateral JJ o
congenital JJ o
cataract NN N
in IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

METHODS NNP N
At IN N
surgery NN N
, , N
an DT N
intraocular JJ i
lens NNS i
( ( i
IOL NNP i
) ) i
was VBD i
implanted VBN i
or CC N
children NNS N
were VBD N
left VBN i
aphakic NN i
, , i
treated VBD i
with IN i
contact NN i
lens NNS i
( ( i
CL NNP i
) ) i
. . i

Stress JJ N
measures NNS N
were VBD N
administered VBN N
3 CD N
months NNS N
after IN N
surgery NN N
and CC N
at IN N
the DT N
first JJ N
visit NN N
after IN N
the DT N
visual JJ N
acuity NN N
( ( N
VA NNP N
) ) N
assessment NN N
done VBN N
at IN N
12 CD N
months NNS N
of IN N
age NN N
. . N

RESULTS NNP N
Caregivers NNPS p
in IN N
the DT N
IOL NNP i
group NN N
reported VBD N
higher JJR N
levels NNS N
of IN N
stress NN o
than IN N
those DT N
in IN N
the DT N
CL NNP i
group NN N
3 CD N
months NNS N
after IN N
surgery NN N
, , N
but CC N
there EX N
were VBD N
no DT N
group NN N
differences VBZ N
in IN N
stress NN o
scores NNS o
at IN N
the DT N
post-VA JJ o
assessment NN o
. . o

Stress NNP o
scores NNS o
did VBD N
not RB N
change VB N
differentially RB N
for IN N
participants NNS N
assigned VBN N
to TO N
IOL NNP i
versus NN N
CL NNP i
treatments NNS N
. . N

CONCLUSIONS NNP N
Treatment NNP N
assignment NN N
did VBD N
not RB N
have VB N
a DT N
significant JJ N
impact NN N
on IN N
caregiver NN o
stress NN o
during IN p
infancy NN p
or CC N
on IN N
the DT N
change NN N
in IN N
stress NN N
during IN N
the DT N
child NN N
's POS N
first JJ N
2 CD N
years NNS N
of IN N
life NN N
. . N

-DOCSTART- -9493479- O O

The DT N
cognitive NN o
, , o
subjective JJ o
, , o
and CC o
physical JJ o
effects NNS o
of IN N
a DT N
ginkgo NN i
biloba/panax NN i
ginseng NN i
combination NN i
in IN N
healthy JJ p
volunteers NNS p
with IN p
neurasthenic JJ p
complaints NNS p
. . p

We PRP N
evaluated VBD N
the DT N
effects NNS o
of IN N
a DT N
Ginkgo NNP i
biloba/ginseng NN i
combination NN i
on IN N
cognitive JJ o
function NN o
in IN N
this DT N
90-day JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
parallel-group JJ N
study NN N
. . N

Sixty-four CD p
healthy JJ p
volunteers NNS p
( ( p
aged VBN p
40 CD p
to TO p
65 CD p
years NNS p
) ) p
, , p
selected VBN p
on IN p
the DT p
basis NN p
of IN p
fulfilling VBG p
the DT p
ICD-10 NNP p
F48.0 NNP p
criteria NNS p
for IN p
neurasthenia NN p
, , N
were VBD N
assigned VBN N
randomly RB N
to TO N
four CD N
equal JJ N
dosing NN N
groups NNS N
, , N
receiving VBG N
80 CD N
, , N
160 CD N
, , N
or CC N
320 CD N
mg NN N
of IN N
the DT N
combination NN N
b.i.d NN N
. . N

or CC N
placebo NN i
. . i

Assessments NNS N
were VBD N
performed VBN N
on IN N
the DT N
day NN N
before IN N
dosing NN N
, , N
and CC N
again RB N
at IN N
Days NNP N
1 CD N
, , N
30 CD N
, , N
and CC N
90 CD N
at IN N
1 CD N
hour NN N
after IN N
the DT N
morning NN N
dose NN N
and CC N
1 CD N
hour NN N
after IN N
the DT N
afternoon NN N
dose NN N
. . N

The DT N
assessments NNS N
included VBD N
the DT N
Cognitive NNP o
Drug NNP o
Research NNP o
( ( o
CDR NNP o
) ) o
computerized VBD o
assessment NN o
system NN o
, , o
the DT o
Vienna NNP o
Determination NNP o
Unit NNP o
, , o
cycle NN o
ergometry NN o
, , o
and CC o
various JJ o
questionnaires NNS o
. . o

The DT N
treatments NNS N
were VBD N
well RB o
tolerated VBN o
by IN N
all DT N
volunteers NNS N
. . N

On IN N
Day NNP N
90 CD N
at IN N
1 CD N
hour NN N
post NN N
morning NN N
dosing NN N
, , N
dose-related JJ o
improvements NNS o
were VBD N
seen VBN N
on IN N
the DT N
CDR NNP N
tests NNS N
, , N
the DT N
320 CD N
mg NN N
dose NN N
being VBG N
significantly RB N
superior JJ N
to TO N
placebo VB i
. . i

These DT N
effects NNS N
, , N
however RB N
, , N
were VBD N
reversed VBN N
1 CD N
hour NN N
after IN N
the DT N
afternoon NN N
dose NN N
, , N
possibly RB N
suggesting VBG N
that IN N
a DT N
longer JJR N
inter-dosing JJ N
interval NN N
would MD N
be VB N
preferable JJ N
. . N

The DT N
80-mg JJ N
dose NN N
produced VBD N
a DT N
significant JJ N
benefit NN N
on IN N
the DT N
ergometry NN o
assessment NN o
of IN o
heart NN o
rate NN o
at IN N
maximum JJ N
load NN N
. . N

There EX N
were VBD N
also RB N
several JJ N
supporting VBG N
changes NNS N
from IN N
other JJ N
assessments NNS N
, , N
including VBG N
an DT N
advantage NN N
of IN N
320 CD N
mg NN N
over IN N
placebo NN i
on IN N
the DT N
global JJ N
score NN N
from IN N
the DT N
Symptom NNP N
Checklist-90-revised JJ N
( ( N
SCL-90-R NNP N
) ) N
at IN N
Day NNP N
90 CD N
. . N

-DOCSTART- -23104617- O O

Brief JJ N
Report NNP N
: : N
social JJ o
disability NN o
in IN p
autism NN p
spectrum NN p
disorder NN p
: : p
results NNS N
from IN N
Research NNP p
Units NNP p
on IN p
Pediatric NNP p
Psychopharmacology NNP p
( ( p
RUPP NNP p
) ) p
Autism NNP p
Network NNP p
trials NNS p
. . p

There EX N
is VBZ N
growing VBG N
interest NN N
in IN N
measuring VBG N
social JJ o
disability NN o
as IN N
a DT N
core NN N
element NN N
of IN N
autism NN p
spectrum NN p
disorders NNS p
in IN N
medication NN N
trials NNS N
. . N

We PRP N
conducted VBD N
a DT N
secondary JJ N
analysis NN N
on IN N
the DT N
Aberrant NNP o
Behavior NNP o
Checklist NNP o
Social NNP o
Withdrawal NNP o
subscale JJ o
using VBG N
data NNS p
from IN p
two CD p
federally-funded JJ p
, , p
multi-site JJ p
, , p
randomized JJ p
trials NNS p
with IN p
risperidone NN i
. . i

Study NNP p
1 CD p
included VBD p
52 CD p
subjects NNS p
assigned VBN p
to TO p
placebo VB i
and CC p
49 CD p
subjects NNS p
to TO p
risperidone VB i
under IN p
double-blind JJ p
conditions NNS p
. . p

Study NNP p
2 CD p
included VBD p
49 CD p
subjects NNS p
assigned VBN p
to TO p
risperidone VB i
only RB i
and CC p
75 CD p
subjects NNS p
assigned VBN p
to TO p
risperidone VB i
plus JJ i
parent NN i
training NN i
. . i

After IN N
8 CD N
weeks NNS N
of IN N
treatment NN N
, , N
all DT N
active JJ N
treatments NNS N
were VBD N
superior JJ N
to TO N
placebo VB N
( ( N
effect NN N
sizes VBZ N
ranging VBG N
from IN N
0.42 CD N
to TO N
0.65 CD N
) ) N
. . N

The DT N
findings NNS N
suggest VBP N
that IN N
the DT N
Social NNP N
Withdrawal NNP N
subscale NN N
may MD N
be VB N
a DT N
useful JJ N
measure NN N
of IN N
social JJ o
disability NN o
in IN N
acute JJ N
treatment NN N
trials NNS N
. . N

-DOCSTART- -9507846- O O

Incidence NN N
and CC N
clinical JJ N
significance NN N
of IN N
false-negative JJ p
sextant JJ p
prostate NN p
biopsies NNS p
. . p

PURPOSE NNP N
Since IN N
most JJS N
patients NNS N
do VBP N
not RB N
undergo VB N
repeat NN N
sextant JJ N
prostate NN N
biopsies NNS N
after IN N
a DT N
biopsy NN N
is VBZ N
positive JJ N
for IN N
prostate NN N
cancer NN N
, , N
the DT N
true JJ N
incidence NN N
of IN N
false-negative JJ N
biopsies NNS N
is VBZ N
not RB N
well RB N
defined VBN N
. . N

We PRP N
assess VBP N
the DT N
incidence NN N
and CC N
clinical JJ N
significance NN N
of IN N
false-negative JJ p
sextant JJ p
prostate NN p
biopsies NNS p
in IN p
patients NNS p
undergoing VBG p
radical JJ i
prostatectomy NN i
. . i

MATERIALS NNP N
AND NNP N
METHODS NNP N
A NNP p
total NN p
of IN p
118 CD p
patients NNS p
with IN p
biopsy NN p
proved VBN p
prostate JJ p
cancer NN p
underwent JJ N
repeat NN i
sextant JJ i
prostate NN i
biopsy NN i
before IN N
enrollment NN N
in IN N
a DT N
prospective JJ N
randomized VBN N
trial NN N
of IN N
radical JJ i
prostatectomy NN i
with IN i
or CC i
without IN i
neoadjuvant JJ i
hormonal JJ i
therapy NN i
. . i

Clinical JJ N
parameters NNS N
were VBD N
assessed VBN N
to TO N
determine VB N
potential JJ N
sources NNS N
of IN N
bias NN N
. . N

Pathological JJ N
parameters NNS N
and CC N
prostate NN o
specific JJ o
antigen NN o
relapse-free JJ o
survival NN o
rates NNS o
were VBD N
compared VBN N
to TO N
determine VB N
the DT N
clinical JJ N
significance NN N
of IN N
false-negative JJ N
biopsies NNS N
. . N

RESULTS NNP N
Of IN N
the DT N
118 CD p
patients NNS p
27 CD N
( ( N
23 CD N
% NN N
) ) N
had VBD N
a DT N
negative JJ N
repeat NN N
sextant JJ N
biopsy NN N
. . N

Except IN N
for IN N
initial JJ N
clinical JJ N
stage NN N
, , N
no DT N
differences NNS N
were VBD N
noted VBN N
in IN N
the DT N
clinical JJ o
or CC o
pathological JJ o
parameters NNS o
, , N
or CC N
prostate VB o
specific JJ o
antigen NN o
relapse NN o
rates NNS o
in IN N
patients NNS N
with IN N
negative JJ N
versus NN N
positive JJ N
repeat NN N
biopsies NNS N
. . N

CONCLUSIONS NNP N
Our PRP$ N
findings NNS N
suggest VBP N
that IN N
this DT N
23 CD N
% NN N
incidence NN N
of IN N
false-negative JJ N
biopsies NNS N
represents VBZ N
significant JJ N
cancer NN N
. . N

This DT N
relatively RB N
high JJ N
incidence NN N
is VBZ N
important JJ N
to TO N
consider VB N
in IN N
treatment NN N
modalities NNS N
in IN N
which WDT N
prostate VBP N
biopsy NN N
may MD N
be VB N
performed VBN N
to TO N
determine VB N
response NN N
to TO N
therapy NN N
. . N

-DOCSTART- -9558860- O O

[ RB N
Clinical JJ N
benefits NNS N
of IN N
normothermic JJ i
cardiopulmonary JJ i
bypass NN i
on IN N
postoperative JJ N
systemic JJ N
metabolism NN N
] NNP N
. . N

To TO N
evaluate VB N
the DT N
influence NN N
of IN N
body NN N
temperature NN N
during IN N
cardiopulmonary JJ i
bypass NN i
( ( i
CPB NNP i
) ) i
on IN N
postoperative JJ o
systemic JJ o
metabolism NN o
, , N
32 CD p
patients NNS p
undergoing JJ p
elective JJ p
cardiac NN p
surgery NN p
were VBD p
randomly RB p
assigned VBN p
to TO p
either DT p
hypothermia NN i
( ( p
n JJ p
= NNP p
16 CD p
) ) p
or CC p
normothermia NN i
( ( p
n JJ p
= NNP p
16 CD p
) ) p
. . p

Serial JJ N
hemodynamic JJ N
parameters NNS N
and CC N
blood NN N
samples NNS N
were VBD N
obtained VBN N
after IN N
surgery NN N
. . N

CPB NNP o
and CC o
operation NN o
times NNS o
were VBD N
significantly RB N
shorter JJR N
and CC N
the DT N
platelet NN o
reduction NN o
ratio NN o
during IN N
CPB NNP i
[ NNP N
= NNP N
( ( N
platelets NNS N
before IN N
CPB-platelets NNS N
after IN N
CPB NNP N
) ) N
/platelets VBZ N
before IN N
CPB NNP N
] NNP N
was VBD N
significantly RB N
lower JJR N
in IN N
normothermic JJ N
patients NNS N
than IN N
in IN N
hypothermic JJ N
patients NNS N
. . N

The DT N
platelet NN o
reduction NN o
ratio NN o
was VBD N
dependent JJ N
on IN N
the DT N
minimum JJ N
rectal JJ N
temperature NN N
during IN N
CPB NNP o
, , o
the DT o
operation NN o
time NN o
, , o
and CC o
the DT o
CPB NNP o
time NN o
. . o

In IN N
the DT N
early JJ N
postoperative JJ N
period NN N
, , N
hypothermic JJ N
patients NNS N
had VBD N
abnormally RB N
high JJ o
systemic JJ o
vascular NN o
resistance NN o
and CC o
a DT o
reduced JJ o
cardiac JJ o
index NN o
compared VBN o
with IN o
the DT o
normothermic JJ o
patients NNS o
. . o

There EX N
were VBD N
no DT N
differences NNS N
between IN N
2 CD N
groups NNS N
in IN N
postoperative JJ o
hepatic JJ o
and CC o
renal JJ o
functions NNS o
, , o
changes NNS o
in IN o
oxygen NN o
consumption NN o
, , o
arterial-venous JJ o
PCO2 NNP o
or CC o
arterial-venous JJ o
pH JJ o
gradient NN o
. . o

This DT N
study NN N
suggested VBD N
a DT N
beneficial JJ N
influence NN N
of IN N
normothermic JJ i
CPB NNP i
on IN N
postoperative JJ o
hemodynamics NNS o
. . o

Normothermic NNP i
CPB NNP i
was VBD N
not RB N
associated VBN N
with IN N
adverse JJ o
effects NNS o
on IN N
postoperative JJ o
metabolic JJ o
recovery NN o
. . o

-DOCSTART- -8047747- O O

Surrogate NNP i
and CC i
auxiliary JJ i
endpoints NNS i
in IN i
clinical JJ i
trials NNS i
, , p
with IN p
potential JJ p
applications NNS p
in IN p
cancer NN p
and CC p
AIDS NNP p
research NN p
. . p

Surrogate NNP i
endpoints NNS i
have VBP N
been VBN N
defined VBN N
by IN N
Prentice NNP N
as IN N
response NN N
variables NNS N
that WDT N
can MD N
substitute VB N
for IN N
a DT N
'true NN N
' POS N
endpoint NN N
for IN N
the DT N
purpose NN N
of IN N
comparing VBG N
specific JJ N
interventions NNS N
or CC N
treatments NNS N
in IN N
a DT N
clinical JJ N
trial NN N
. . N

The DT N
applicability NN N
of IN N
this DT N
definition NN N
, , N
and CC N
of IN N
related JJ N
surrogate NN N
endpoint NN N
criteria NNS N
, , N
is VBZ N
discussed VBN N
, , N
with IN N
emphasis NN p
on IN p
cancer NN p
and CC p
AIDS NNP p
research NN p
settings NNS p
. . p

Auxiliary JJ i
endpoints NNS i
are VBP N
defined VBN N
as IN N
response NN N
variables NNS N
, , N
or CC N
covariates NNS N
, , N
that WDT N
can MD N
strengthen VB N
true JJ N
endpoint NN N
analyses NNS N
. . N

Specifically RB N
, , N
such JJ N
response NN N
variables NNS N
provide VBP N
some DT N
additional JJ N
information NN N
on IN N
true JJ N
endpoint NN N
occurrence NN N
times NNS N
for IN N
study NN N
subjects NNS N
having VBG N
censored VBN N
values NNS N
for IN N
such JJ N
times NNS N
. . N

Auxiliary JJ i
variables NNS i
will MD N
very RB N
frequently RB N
be VB N
available JJ N
, , N
and CC N
they PRP N
may MD N
be VB N
able JJ N
to TO N
be VB N
used VBN N
without IN N
making VBG N
additional JJ N
strong JJ N
assumptions NNS N
. . N

Approaches NNS N
to TO N
the DT N
use NN N
of IN N
auxiliary JJ i
variables NNS i
using VBG N
ideas NNS N
based VBN N
on IN N
augmented VBN N
score NN N
and CC N
augmented VBD N
likelihood NN N
methods NNS N
are VBP N
described VBN N
. . N

-DOCSTART- -16281190- O O

Single-session JJ N
behavioral JJ i
treatment NN i
of IN N
earthquake-related JJ p
posttraumatic JJ p
stress NN p
disorder NN p
: : p
a DT N
randomized JJ N
waiting NN N
list NN N
controlled VBD N
trial NN N
. . N

In IN N
an DT N
attempt NN N
to TO N
develop VB N
a DT N
brief JJ N
treatment NN N
for IN N
disaster NN p
survivors NNS p
, , N
the DT N
present JJ N
study NN N
examined VBD N
the DT N
effectiveness NN N
of IN N
a DT N
single JJ N
session NN N
of IN N
modified JJ i
behavioral JJ i
treatment NN i
in IN N
earthquake-related JJ N
posttraumatic JJ N
stress NN N
disorder NN N
. . N

Fifty-nine JJ p
earthquake NN p
survivors NNS p
in IN p
Turkey NNP p
were VBD N
randomized VBN N
into IN N
either DT N
single-session NN i
modified VBD i
behavioral JJ i
treatment NN i
( ( i
SSBT NNP i
) ) i
designed VBN i
to TO i
enhance VB i
sense NN i
of IN i
control NN i
over IN i
earthquake-related JJ o
fears NNS o
or CC i
waiting VBG i
list NN i
control NN i
condition NN i
( ( i
WL NNP i
) ) i
. . i

The DT N
WL NNP N
group NN N
received VBD N
SSBT NNP i
after IN N
a DT N
second JJ N
baseline NN N
assessment NN N
. . N

Follow-ups NNS N
were VBD N
at IN N
weeks NNS N
6 CD N
, , N
12 CD N
, , N
24 CD N
, , N
and CC N
at IN N
1-2 JJ N
years NNS N
posttreatment NN N
. . N

Significant JJ o
treatment NN o
effects NNS o
were VBD N
found VBN N
on IN N
all DT N
measures NNS N
at IN N
posttreatment NN N
. . N

The DT N
improvement NN o
rate NN o
was VBD N
49 CD N
% NN N
at IN N
week NN N
6 CD N
; : N
it PRP N
rose VBD N
to TO N
80 CD N
% NN N
by IN N
week NN N
12 CD N
, , N
85 CD N
% NN N
by IN N
week NN N
24 CD N
, , N
and CC N
83 CD N
% NN N
by IN N
the DT N
1-2-year JJ N
follow-up NN N
. . N

Brief JJ N
behavioral JJ i
treatment NN i
has VBZ N
promise VBN N
as IN N
a DT N
cost-effective JJ o
intervention NN N
for IN N
disaster NN p
survivors NNS p
. . p

-DOCSTART- -9531360- O O

Impact NN N
of IN N
surgical JJ i
staging NN i
in IN N
evaluating VBG N
the DT N
radiotherapeutic JJ N
outcome NN N
in IN N
RTOG NNP N
# # N
77-06 NNP N
, , N
a DT N
phase NN N
III NNP N
study NN N
for IN N
T1BN0M0 NNP N
( ( N
A2 NNP N
) ) N
and CC N
T2N0M0 NNP N
( ( N
B NNP N
) ) N
prostate NN N
carcinoma NN N
. . N

PURPOSE NNP N
To TO N
evaluate VB N
survival NN N
and CC N
time NN N
to TO N
metastatic JJ N
disease NN N
in IN N
patients NNS p
treated VBN p
for IN p
localized JJ p
prostatic JJ p
carcinoma NN p
in IN p
a DT p
Phase NNP i
III NNP i
radiotherapy NN i
( ( p
RT NNP p
) ) p
protocol NN p
, , p
Radiation NNP i
Therapy NNP i
Oncology NNP i
Group NNP i
( ( p
RTOG NNP p
) ) p
77-06 NN p
. . p

Patients NNS p
with IN p
T18N0M0 NNP p
( ( p
A2 NNP p
) ) p
or CC p
T2N0M0 NNP p
( ( p
B NNP p
) ) p
disease NN p
after IN p
lymphangiogram NN p
( ( p
LAG NNP p
) ) p
or CC p
staging VBG p
laparotomy NN p
( ( p
SL NNP p
) ) p
were VBD p
randomized VBN p
between IN p
prophylactic JJ p
radiation NN p
to TO p
the DT p
pelvic JJ p
lymph NN p
nodes NNS p
and CC p
prostatic JJ p
bed NN p
vs. FW p
prostatic JJ p
bed NN p
alone RB p
. . p

The DT N
outcome NN N
of IN N
both DT N
treatment NN N
arms NNS N
, , N
as RB N
well RB N
as IN N
a DT N
comparison NN N
of IN N
the DT N
LAG NNP N
group NN N
, , N
to TO N
that DT N
of IN N
the DT N
SL NNP N
group NN N
, , N
are VBP N
updated VBN N
. . N

METHODS NNP N
AND NNP N
MATERIALS NNP N
A NNP p
total NN p
of IN p
449 CD p
eligible JJ p
males NNS p
were VBD p
entered VBN p
into IN p
RTOG NNP p
protocol NN p
7706 CD p
between IN p
1978 CD p
and CC p
1983 CD p
. . p

Lymph NNP N
node IN N
staging VBG N
was VBD N
mandatory JJ N
but CC N
at IN N
the DT N
physician NN N
's POS N
discretion NN N
; : N
117 CD p
( ( p
26 CD p
% NN p
) ) p
patients NNS p
had VBD p
SL NNP p
, , p
while IN p
332 CD p
( ( p
74 CD p
% NN p
) ) p
had VBD p
LAG NNP p
. . p

Follow-up NNP N
was VBD N
a DT N
median NN N
of IN N
12 CD N
years NNS N
and CC N
a DT N
maximum NN N
of IN N
16 CD N
years NNS N
. . N

For IN N
those DT N
randomized VBN N
to TO N
receive VB N
prophylactic JJ N
pelvic NNS N
lymph VBP N
nodal JJ N
irradiation NN N
, , N
45 CD N
Gy NNP N
of IN N
megavoltage NN N
RT NNP N
was VBD N
delivered VBN N
via IN N
multiple JJ N
portals NNS N
in IN N
4.5-5 JJ N
weeks NNS N
, , N
while IN N
all DT N
patients NNS N
received VBD N
65 CD N
Gy NNP N
in IN N
6.5-8 JJ N
weeks NNS N
to TO N
the DT N
prostatic JJ N
bed NN N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
survival JJ o
whether IN N
treatment NN N
was VBD N
administered VBN N
to TO N
the DT N
prostate NN N
or CC N
prostate NN N
and CC N
pelvic JJ N
lymph NN N
nodes NNS N
. . N

The DT N
SL NNP N
group NN N
had VBD N
greater JJR N
12-year JJ o
survival NN o
than IN N
the DT N
LAG NNP N
group NN N
( ( N
48 CD N
% NN N
vs. FW N
38 CD N
% NN N
, , N
p NN N
= NNP N
0.02 CD N
) ) N
. . N

Disease-free JJ o
survival NN o
was VBD N
statistically RB N
significant JJ N
, , N
with IN N
38 CD N
% NN N
for IN N
the DT N
SL NNP N
group NN N
vs. FW N
26 CD N
% NN N
for IN N
the DT N
LAG NNP N
group NN N
( ( N
p JJ N
= NNP N
0.003 CD N
) ) N
. . N

Bone NNP o
metastasis NN o
was VBD N
less JJR N
common JJ N
in IN N
the DT N
SL NNP N
group NN N
( ( N
14 CD N
% NN N
) ) N
than IN N
the DT N
LAG NNP N
group NN N
( ( N
27 CD N
% NN N
) ) N
( ( N
p JJ N
= NNP N
0.003 CD N
) ) N
. . N

CONCLUSION NN N
At IN N
12-year JJ N
median JJ N
follow-up NN N
, , N
there EX N
still RB N
was VBD N
no DT N
survival JJ N
difference NN N
in IN N
those DT N
patients NNS N
treated VBD N
prophylactically RB N
to TO N
the DT N
pelvic JJ N
nodes NNS N
and CC N
prostatic JJ N
bed NN N
vs. IN N
the DT N
prostatic JJ N
bed NN N
alone RB N
. . N

Those DT N
patients NNS N
not RB N
surgically RB N
staged VBN N
with IN N
only RB N
LAG NNP N
for IN N
lymph JJ N
node JJ N
evaluation NN N
were VBD N
less RBR N
accurately RB N
staged VBN N
, , N
as IN N
reflected VBN N
by IN N
a DT N
statistically RB N
significant JJ N
reduced VBN N
survival NN N
and CC N
earlier JJR N
metastases NNS N
. . N

-DOCSTART- -23865673- O O

Unexpected JJ N
random NN N
urinary JJ N
protein NN N
: : N
creatinine NN N
ratio VBZ N
results-limitations NNS N
of IN N
the DT N
pyrocatechol NN i
violet-dye JJ i
method NN i
. . i

BACKGROUND NNP N
For IN N
clinicians NNS N
, , N
it PRP N
is VBZ N
important JJ N
to TO N
rely VB N
on IN N
accurate JJ N
laboratory NN N
results NNS N
for IN N
patient JJ N
care NN N
and CC N
optimal JJ N
use NN N
of IN N
health NN N
care NN N
resources NNS N
. . N

We PRP N
sought VBD N
to TO N
explore VB N
our PRP$ N
observations NNS N
that IN N
urine JJ N
protein NN N
: : N
creatinine JJ N
ratios NNS N
( ( N
PrCr NNP N
) ) N
?30 NN N
mg/mmol NN N
are VBP N
seen VBN N
not RB N
infrequently RB N
associated VBN N
with IN N
normal JJ N
pregnancy NN N
outcome NN N
. . N

METHODS NNP N
Urine NNP N
samples NNS N
were VBD N
collected VBN N
prospectively RB N
from IN p
160 CD p
pregnant JJ p
women NNS p
attending VBG p
high-risk JJ p
maternity NN p
clinics NNS p
at IN p
a DT p
tertiary JJ p
care NN p
facility NN p
. . p

Urinary NNP p
protein NN N
was VBD N
measured VBN N
using VBG i
a DT i
pyrocatechol NN i
violet NN i
assay NN i
and CC i
urinary JJ N
creatinine NN N
by IN N
an DT N
enzymatic JJ i
method NN i
on IN i
Vitros NNP i
analysers NNS i
. . i

Maternal/perinatal JJ i
outcomes NNS N
were VBD N
abstracted VBN N
from IN N
hospital NN N
records NNS N
. . N

RESULTS VB N
91/233 CD N
( ( N
39.1 CD N
% NN N
) ) N
samples NNS N
had VBD N
a DT N
PrCr NNP N
?30 NNP N
mg/mmol NN N
, , N
especially RB N
when WRB N
urinary JJ N
creatinine NN N
concentration NN N
was VBD N
< JJ N
3 CD N
mM NN N
( ( N
94.1 CD N
% NN N
) ) N
vs. FW N
?3 FW N
mM NN N
( ( N
16.4 CD N
% NN N
) ) N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

When WRB N
using VBG N
the DT N
last JJ N
sample NN N
before IN N
delivery NN N
, , N
47/160 CD N
( ( N
29.4 CD N
% NN N
) ) N
had VBD N
a DT N
PrCr NNP N
?30 NNP N
mg/mmol NN N
in IN N
diluted JJ N
urine NN N
vs. IN N
only RB N
17/160 CD N
( ( N
15.4 CD N
% NN N
) ) N
in IN N
more RBR N
concentrated JJ N
urine NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
; : N
PrCr NNP N
positive JJ N
results NNS N
were VBD N
also RB N
more RBR N
frequent JJ N
among IN N
the DT N
32 CD N
( ( N
20.0 CD N
% NN N
) ) N
women NNS N
with IN N
known VBN N
normal JJ N
pregnancy NN N
outcome NN N
( ( N
90.9 CD N
% NN N
vs. FW N
0 CD N
) ) N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

Using VBG N
the DT N
same JJ N
analyser NN N
, , N
0.12 CD N
g/L NN N
urinary JJ N
protein NN N
was VBD N
'detected VBN N
' '' N
in IN N
deionised JJ N
water NN N
. . N

Re-analysis NN N
of IN N
data NNS N
from IN N
two CD N
cohorts NNS N
revealed VBD N
substantially RB N
less JJR N
inflation NN N
of IN N
PrCr NNP N
in IN N
dilute NN N
urine NN N
using VBG N
a DT N
pyrogallol NN N
red JJ N
assay NN N
. . N

CONCLUSIONS NNP N
Random NNP N
urinary JJ N
PrCr NNP N
was VBD N
overestimated VBN N
in IN N
dilute NN N
urine NN N
when WRB N
tested VBN N
using VBG N
a DT N
common JJ N
pyrocatechol NN i
violet NN i
dye-based JJ i
method NN i
. . i

This DT N
effect NN N
was VBD N
reduced VBN N
in IN N
cohorts NNS N
when WRB N
pyrogallol NN N
red VBD N
assays NNS N
were VBD N
used VBN N
. . N

False JJ N
positive JJ N
results NNS N
can MD N
impact VB N
on IN N
diagnosis NN N
and CC N
patient JJ N
care NN N
. . N

This DT N
highlights VBZ N
the DT N
need NN N
for IN N
both DT N
clinical JJ N
and CC N
laboratory JJ N
quality NN N
improvement NN N
projects NNS N
and CC N
standardization NN N
of IN N
laboratory NN N
protein NN N
measurement NN N
. . N

-DOCSTART- -11331721- O O

Repeated VBN N
doses NNS N
of IN N
porcine NN i
secretin NN i
in IN N
the DT N
treatment NN N
of IN N
autism NN p
: : p
a DT N
randomized JJ N
, , N
placebo-controlled JJ N
trial NN N
. . N

BACKGROUND NNP N
AND CC N
OBJECTIVES NNP N
Anecdotal NNP N
reports NNS N
on IN N
the DT N
efficacy NN N
of IN N
secretin NN i
in IN N
autism NN N
raised VBN N
great JJ N
hopes NNS N
for IN N
the DT N
treatment NN N
of IN N
children NNS p
with IN N
this DT N
disorder NN N
. . N

Initial JJ N
single-dose JJ N
, , N
randomized VBN N
, , N
controlled VBN N
trials NNS N
failed VBD N
to TO N
demonstrate VB N
any DT N
therapeutic JJ N
effects NNS N
of IN N
secretin NN i
. . i

The DT N
present JJ N
study NN N
is VBZ N
the DT N
first JJ N
to TO N
test VB N
the DT N
outcome NN N
of IN N
repeated VBN N
doses NNS N
and CC N
to TO N
examine VB N
whether IN N
there EX N
is VBZ N
a DT N
subgroup NN N
of IN N
children NNS N
who WP N
are VBP N
more RBR N
likely JJ N
to TO N
achieve VB N
positive JJ N
effects NNS N
. . N

METHOD NNP N
Sixty-four JJ p
children NNS p
with IN p
autism NN p
( ( p
ages VBZ p
2-7 CD p
years NNS p
; : p
55 CD p
boys NNS p
and CC p
9 CD p
girls NNS p
) ) p
with IN p
a DT p
range NN p
of IN p
intelligence NN p
quotient NN p
and CC p
verbal JJ p
ability NN p
were VBD N
randomly RB N
assigned VBN N
, , N
in IN N
a DT N
double-blind JJ N
manner NN N
, , N
to TO N
secretin VB i
or CC i
placebo VB i
groups NNS N
. . N

Children NNP N
received VBD N
2 CD N
doses NNS N
of IN N
placebo NN i
or CC i
porcine NN i
secretin NN i
, , N
6 CD N
weeks NNS N
apart RB N
. . N

Assessments NNS N
were VBD N
performed VBN N
at IN N
baseline NN N
and CC N
3 CD N
weeks NNS N
after IN N
each DT N
injection NN N
using VBG N
several JJ N
outcome JJ N
measures NNS N
. . N

RESULTS NNP N
There EX N
were VBD N
no DT N
group NN N
differences VBZ N
on IN N
formal JJ o
measures NNS o
of IN o
language NN o
, , o
cognition NN o
, , o
or CC o
autistic JJ o
symptomatology NN o
. . o

Subgroupings NNS N
based VBN N
on IN N
cognitive JJ o
level NN o
, , o
the DT o
presence NN o
or CC o
absence NN o
of IN o
diarrhea NN o
, , N
or CC N
a DT N
history NN N
of IN N
regression NN o
failed VBD N
to TO N
show VB N
any DT N
significant JJ N
therapeutic JJ N
effects NNS N
of IN N
secretin NN i
. . i

CONCLUSION NNP N
No DT N
evidence NN N
is VBZ N
provided VBN N
for IN N
the DT N
efficacy NN o
of IN N
repeated JJ N
doses NNS N
of IN N
porcine NN i
secretin NN i
in IN N
the DT N
treatment NN N
of IN N
children NNS p
with IN p
autism NN p
. . p

The DT N
possible JJ N
relationship NN N
between IN N
relief NN N
of IN N
biological JJ o
symptoms NNS o
and CC N
enhanced VBD N
skill JJ o
performance NN o
is VBZ N
discussed VBN N
. . N

-DOCSTART- -8276557- O O

Enoxaparin NNP i
in IN N
the DT N
prevention NN N
of IN N
deep JJ N
venous JJ o
thrombosis NN o
after IN N
major JJ p
surgery NN p
: : p
multicentric NN N
study NN N
. . N

The DT N
Italian JJ p
Study NNP p
Group NNP p
. . p

DVT NNP o
is VBZ N
a DT N
very RB N
frequent JJ N
complication NN N
of IN N
general JJ N
surgery NN N
. . N

Heparin NNP N
and CC N
, , N
more RBR N
recently RB N
, , N
LMWHs NNP i
can MD N
successfully RB N
prevent VB N
post NN o
surgical JJ o
thromboembolism NN o
. . o

One CD p
thousand CD p
one CD p
hundred CD p
and CC p
twenty-two JJ p
patients NNS p
( ( p
533 CD p
males NNS p
and CC p
589 CD p
females NNS p
; : p
mean JJ p
age NN p
62.2 CD p
+/- JJ p
11.4 CD p
yrs NN p
) ) p
were VBD p
enrolled VBN p
in IN p
a DT p
multicentre NN p
controlled VBN p
study NN p
, , N
to TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
enoxaparin NN i
in IN N
comparison NN N
to TO N
calcium VB i
heparin NN i
in IN N
the DT N
prevention NN N
of IN N
deep JJ o
venous JJ o
thrombosis NN o
( ( o
DVT NNP o
) ) o
following VBG N
general JJ N
surgery NN N
. . N

Patients NNS N
assigned VBD N
to TO N
the DT N
enoxaparin NN i
and CC N
the DT N
calcium NN i
heparin NN i
groups NNS N
received VBD N
1 CD N
daily JJ N
dose NN N
of IN N
20 CD N
mg NN N
( ( N
2000 CD N
I.U NNP N
. . N

) ) N
and CC N
2 CD N
daily JJ N
doses NNS N
of IN N
0.2 CD N
ml NN N
( ( N
5000 CD N
I.U NNP N
. . N

) ) N
, , N
respectively RB N
starting VBG N
2 CD N
hours NNS N
before IN N
the DT N
operation NN N
. . N

Both DT N
drugs NNS N
were VBD N
given VBN N
by IN N
subcutaneous JJ N
route NN N
. . N

A DT N
Doppler NNP N
or CC N
Duplex NNP N
Scan NNP N
diagnosis NN N
of IN N
DVT NNP o
was VBD N
made VBN N
in IN N
3 CD N
( ( N
0.5 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
enoxaparin NN i
group NN N
( ( N
2 CD N
cases NNS N
during IN N
treatment NN N
and CC N
1 CD N
patient NN N
at IN N
the DT N
end NN N
of IN N
treatment NN N
) ) N
and CC N
in IN N
6 CD N
( ( N
1.1 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
calcium NN i
heparin NN i
group NN N
( ( N
5 CD N
cases NNS N
during IN N
treatment NN N
and CC N
1 CD N
, , N
bilateral NN N
, , N
after IN N
the DT N
end NN N
of IN N
treatment NN N
) ) N
. . N

Pulmonary JJ o
embolism NN o
( ( o
PE NNP o
) ) o
was VBD N
ascertained VBN N
by IN N
angiography NN N
in IN N
1 CD N
patient NN N
( ( N
0.18 CD N
% NN N
) ) N
in IN N
the DT N
enoxaparin NN i
group NN N
and CC N
in IN N
2 CD N
patients NNS N
( ( N
0.36 CD N
% NN N
) ) N
in IN N
the DT N
calcium NN i
heparin NN i
one CD N
. . N

Hemorrhagic NNP o
complications NNS o
occurred VBD N
in IN N
29 CD N
patients NNS N
( ( N
5.2 CD N
% NN N
) ) N
in IN N
the DT N
enoxaparin NN i
group NN N
and CC N
in IN N
34 CD N
( ( N
6.1 CD N
% NN N
) ) N
in IN N
the DT N
calcium NN i
heparin NN i
group NN N
. . N

Haematomas NNP o
located VBN N
in IN N
the DT N
injection NN N
site NN N
were VBD N
reported VBN N
in IN N
16.1 CD N
% NN N
and CC N
25.3 CD N
% NN N
in IN N
the DT N
enoxaparin NN i
and CC N
calcium NN i
heparin NN i
groups NNS N
respectively RB N
( ( N
p JJ N
= NNP N
0.0001 CD N
) ) N
. . N

Local JJ N
pain NN N
in IN N
the DT N
injection NN N
site NN N
at IN N
the DT N
5th JJ N
day NN N
of IN N
treatment NN N
was VBD N
reported VBN N
in IN N
8.4 CD N
% NN N
and CC N
16.6 CD N
% NN N
in IN N
the DT N
enoxaparin NN N
and CC N
calcium NN N
heparin NN N
groups NNS N
respectively RB N
( ( N
p JJ N
= NNP N
0.0001 CD N
) ) N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -23776270- O O

Long-term JJ N
effects NNS N
of IN N
choline NN i
on IN N
productive JJ o
performance NN o
and CC o
egg NN o
quality NN o
of IN N
brown-egg NN p
laying NN p
hens NNS p
. . p

A DT N
total NN p
of IN p
five CD p
hundred JJ p
forty NN p
19-wk-old JJ p
HyLine NNP p
Brown NNP p
hens NNS p
were VBD p
used VBN p
to TO p
study VB p
the DT N
long-term JJ N
effects NNS N
of IN N
increasing VBG N
choline NN i
with IN i
0 CD i
( ( i
control NN i
) ) i
, , i
425 CD i
, , i
850 CD i
, , i
1,700 CD i
, , i
3,400 CD i
, , N
and CC N
6,800 CD i
mg/kg NN i
of IN i
corn-soybean JJ i
meal-based JJ i
diets NNS i
on IN N
productive JJ o
performance NN o
and CC o
egg NN o
quality NN o
. . o

Phase VB N
1 CD N
was VBD N
from IN N
19 CD N
to TO N
58 CD N
wk NN N
, , N
and CC N
phase NN N
2 CD N
was VBD N
from IN N
59 CD N
to TO N
68 CD N
wk NN N
. . N

During IN N
the DT N
whole JJ N
experimental JJ N
period NN N
, , N
dietary JJ N
choline NN N
had VBD N
no DT N
significant JJ N
effects NNS N
on IN N
feed NN o
intake NN o
, , o
egg NN o
weight NN o
, , o
and CC o
egg NN o
mass NN o
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

During IN N
phase NN N
1 CD N
, , N
egg NN o
production NN o
decreased VBD N
linearly RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
feed JJ o
conversion NN o
ratio NN o
( ( o
FCR NNP o
) ) o
tended VBD N
to TO N
increase VB N
linearly RB N
( ( N
P NNP N
= NNP N
0.057 CD N
) ) N
with IN N
increasing VBG N
choline JJ N
level NN N
in IN N
the DT N
diet NN N
. . N

Moreover RB N
, , N
BW NNP o
decreased VBD N
both DT N
linearly RB N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
quadratically RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
as IN N
choline NN N
increased VBN N
from IN N
0 CD N
to TO N
6,800 CD N
mg/kg NNS N
. . N

No DT N
significant JJ N
treatment NN N
effects NNS N
were VBD N
found VBN N
for IN N
shell NN o
thickness NN o
and CC o
shell NN o
strength NN o
of IN N
eggs NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

However RB N
, , N
albumen NNS o
height VBD o
and CC o
Haugh NNP o
units NNS o
increased VBD N
linearly RB N
( ( N
P NNP N
< NNP N
0.01 CD N
and CC N
P NNP N
< NNP N
0.05 CD N
, , N
respectively RB N
) ) N
as IN N
choline NN N
increased VBD N
during IN N
phase NN N
2 CD N
. . N

Compared VBN N
with IN N
the DT N
control NN N
group NN N
, , N
diets NNS N
supplemented VBD N
with IN N
425 CD N
or CC N
850 CD N
mg NN N
of IN N
choline/kg NN N
significantly RB N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
improved VBN N
yolk JJ o
color NN o
during IN N
phase NN N
1 CD N
. . N

This DT N
study NN N
indicates VBZ N
that IN N
a DT N
dietary JJ N
choline NN N
level NN N
of IN N
no DT N
more JJR N
than IN N
700 CD N
mg/kg NN N
is VBZ N
sufficient JJ N
to TO N
maintain VB N
egg NN N
production NN N
. . N

The DT N
effect NN N
of IN N
choline NN N
on IN N
egg NN o
quality NN o
was VBD N
minimal JJ N
when WRB N
hens NNS N
were VBD N
fed VBN N
a DT N
corn-soybean JJ i
meal-based JJ i
diet NN i
from IN N
19 CD N
to TO N
68 CD N
wk NN N
of IN N
age NN N
. . N

-DOCSTART- -3065176- O O

[ JJ p
Vulvovaginal NNP p
Candida NNP p
mycoses VBZ p
-- : p
treatment NN p
with IN N
clotrimazole NN i
. . i

Comparison NNP N
of IN N
single-dose JJ N
treatment NN N
with IN N
6-day JJ N
therapy NN N
] NN N
. . N

-DOCSTART- -20369616- O O

[ JJ o
Hepatoprotective NNP o
activity NN o
of IN N
remaxol NN i
in IN N
patients NNS p
with IN p
chronic JJ p
hepatic JJ p
disorders NNS p
] VBP p
. . N

This DT N
milticentre NN N
randomized VBD N
clinical JJ N
study NN N
of IN N
the DT N
efficiency NN o
of IN N
remaxol JJ i
infusion NN i
solution NN i
( ( N
hepatoprotective JJ N
medicine NN N
for IN N
chronic JJ N
liver NN N
dysfunction NN N
) ) N
included VBD N
494 CD p
patients NNS p
with IN p
chronic JJ p
hepatitis NN p
B NNP p
and CC p
C. NNP p
294 CD N
of IN N
them PRP N
staying VBG p
in IN p
7 CD p
clinics NNS p
were VBD N
given VBN N
remaxol NNS i
and CC N
200 CD N
ones NNS N
received VBD N
placebo NN i
. . i

Randomization NN N
was VBD N
achieved VBN N
by IN N
the DT N
envelope NN N
method NN N
. . N

A DT N
detailed JJ N
description NN N
of IN N
clinical JJ N
and CC N
laboratory JJ N
characteristics NNS N
of IN N
the DT N
diseases NNS N
is VBZ N
presented VBN N
. . N

Effects NNS N
of IN N
remaxol NN i
vs NN i
placebo NN i
on IN N
the DT N
functional JJ o
activity NN o
of IN N
affected VBN N
liver NN N
are VBP N
discussed VBN N
. . N

Results NNS N
of IN N
laboratory NN N
and CC N
clinical JJ N
analysis NN N
indicate VBP N
that IN N
mechanism NN N
of IN N
remaxol JJ i
action NN N
is VBZ N
based VBN N
on IN N
hepatoprotective JJ o
, , o
antioxidative JJ o
, , o
and CC o
anticholestatic JJ o
activities NNS o
of IN N
the DT N
drug NN N
. . N

-DOCSTART- -20636866- O O

Evaluation NN N
of IN N
the DT N
effect NN N
of IN N
topical JJ i
agents NNS i
on IN N
radiation-induced JJ o
skin NN o
disease NN o
by IN N
reflectance NN N
spectrophotometry NN N
. . N

OBJECTIVES NNP N
Radiotherapy NNP N
may MD N
cause VB N
severe JJ N
skin NN N
changes NNS N
that WDT N
significantly RB N
interfere VBZ N
with IN N
the DT N
patient NN N
's POS N
quality NN N
of IN N
life NN N
and CC N
reduce VB N
radiotherapy NN N
effectiveness NN N
. . N

Many JJ N
skin NN N
care NN N
instructions NNS N
and CC N
various JJ N
topical JJ N
agents NNS N
are VBP N
recommended VBN N
to TO N
help VB N
patients NNS N
in IN N
the DT N
management NN N
of IN N
radiation NN N
skin NN N
reactions NNS N
, , N
but CC N
evidence NN N
to TO N
support VB N
the DT N
value NN N
of IN N
the DT N
topical JJ N
treatments NNS N
of IN N
the DT N
irradiated JJ N
skin NN N
is VBZ N
lacking VBG N
. . N

In IN N
the DT N
present JJ N
study NN N
we PRP N
investigated VBD N
the DT N
effects NNS N
of IN N
topical JJ i
agents NNS i
used VBN N
as IN N
supportive JJ N
care NN N
to TO N
minimise VB N
radiation-induced JJ o
skin NN o
disease NN o
using VBG N
an DT N
instrumental JJ N
method NN N
. . N

METHODS NNP N
Subjects NNPS p
who WP p
were VBD p
undergoing VBG p
a DT p
planned JJ p
course NN p
of IN p
radiation NN p
therapy NN p
after IN p
breast-conserving JJ p
surgery NN p
were VBD N
randomised VBN N
to TO N
treatment NN N
( ( N
using VBG N
one CD N
of IN N
two CD N
topical JJ i
agents NNS i
) ) i
or CC i
non-treatment JJ i
( ( i
control NN i
) ) i
groups NNS N
and CC N
monitored VBD N
over IN N
8 CD N
weeks NNS N
. . N

The DT N
intensity NN o
of IN o
skin NN o
erythema NN o
was VBD N
evaluated VBN N
once RB N
per IN N
week NN N
by IN N
non-invasive JJ N
instrumental JJ N
reflectance NN N
spectrophotometry NN N
in IN N
comparison NN N
with IN N
a DT N
visual JJ N
scoring NN N
system NN N
. . N

KEY NNP N
FINDINGS NNP N
Examination NNP N
of IN N
the DT N
erythema JJ o
time NN o
course NN o
by IN N
a DT N
sensitive JJ N
spectrophotometric JJ N
reflectance NN N
method NN N
showed VBD N
a DT N
significant JJ N
increase NN N
of IN N
skin JJ o
reactions NNS o
in IN N
the DT N
non-treated JJ N
group NN N
after IN N
the DT N
second JJ N
week NN N
of IN N
treatment NN N
and CC N
maximal JJ N
alterations NNS N
between IN N
the DT N
fourth JJ N
and CC N
sixth JJ N
week NN N
. . N

CONCLUSIONS NN N
From IN N
the DT N
results NNS N
obtained VBD N
, , N
we PRP N
observed VBD N
that DT N
application NN N
of IN N
topical JJ i
agents NNS i
used VBN N
in IN N
radio-induced JJ N
skin JJ N
disease NN N
were VBD N
able JJ N
to TO N
significantly RB N
reduce VB N
the DT N
erythema NN o
extent NN N
compared VBN N
to TO N
the DT N
non-treated JJ N
group NN N
. . N

-DOCSTART- -21851906- O O

Impact NN N
of IN N
pentoxifylline NN i
on IN N
platelet NN o
function NN o
profiles NNS o
in IN N
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
mellitus NN p
and CC p
coronary JJ p
artery NN p
disease NN p
on IN p
dual JJ p
antiplatelet NN p
therapy NN p
with IN p
aspirin NN p
and CC p
clopidogrel NN p
. . p

OBJECTIVES CC N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
impact NN N
of IN N
the DT N
phosphodiesterase NN i
( ( i
PDE NNP i
) ) i
inhibitor NN i
pentoxifylline NN i
on IN N
platelet NN o
function NN o
profiles NNS o
in IN N
patients NNS p
receiving VBG p
dual JJ p
antiplatelet NN p
therapy NN p
( ( p
DAPT NNP p
) ) p
. . p

BACKGROUND NNP N
Previous NNP N
studies NNS N
have VBP N
shown VBN N
that IN N
, , N
in IN N
patients NNS N
receiving VBG N
DAPT NNP N
, , N
the DT N
adjunctive JJ N
use NN N
of IN N
a DT N
PDE NNP i
inhibitor NN i
enhances NNS N
platelet NN o
inhibition NN o
, , N
particularly RB N
in IN N
those DT N
presenting VBG N
with IN N
diabetes NNS N
mellitus NNS N
( ( N
DM NNP N
) ) N
. . N

However RB N
, , N
the DT N
pharmacodynamic NN N
( ( N
PD NNP N
) ) N
effects NNS N
of IN N
the DT N
PDE NNP i
inhibitor NN i
pentoxifylline NN i
on IN N
platelet NN o
function NN o
profiles NNS o
in IN N
DM NNP N
patients NNS N
receiving VBG N
DAPT NNP N
are VBP N
unknown JJ N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
parallel JJ N
design NN N
study NN N
conducted VBN N
in IN N
DM NNP p
patients NNS p
with IN p
stable JJ p
coronary JJ p
artery NN p
disease NN p
receiving VBG p
DAPT NNP p
. . p

Patients NNS N
were VBD N
randomly RB i
assigned VBN i
to TO i
either DT i
pentoxifylline NN i
400 CD i
mg NN i
or CC i
placebo NN i
3 CD i
times NNS i
daily RB i
for IN i
14 CD i
days NNS i
. . i

The DT N
PD NNP N
effects NNS N
were VBD N
assessed VBN N
by IN N
vasodilator-stimulated JJ o
phosphoprotein NN o
phosphorylation NN o
assay NN o
, , o
light JJ o
transmittance NN o
aggregometry NN o
, , o
VerifyNow NNP o
P2Y12 NNP o
assay NN o
( ( o
Accumetric NNP o
, , o
Inc. NNP o
, , N
San NNP o
Diego NNP o
, , o
California NNP o
) ) o
, , o
and CC o
multiple JJ o
electrode NN o
aggregometry NN o
at IN N
baseline NN N
and CC N
14 CD N
days NNS N
. . N

The DT N
PD NNP N
effects NNS N
were VBD N
also RB N
assessed VBN N
according VBG N
the DT N
presence NN N
or CC N
absence NN N
of IN N
high JJ o
on-treatment JJ o
platelet NN o
reactivity NN o
status NN o
. . o

RESULTS VB N
A DT N
total NN N
of IN N
40 CD p
patients NNS p
were VBD N
available JJ N
for IN N
analysis NN N
. . N

At IN N
14 CD N
days NNS N
, , N
there EX N
were VBD N
no DT N
differences NNS N
in IN N
the DT N
P2Y NNP o
( ( o
12 CD o
) ) o
reactivity NN o
index NN o
as IN N
assessed VBN N
by IN N
vasodilator-stimulated JJ o
phosphoprotein NN o
phosphorylation NN o
between IN N
treatment NN N
groups NNS N
( ( N
primary JJ N
endpoint NN N
; : N
p CC N
= VB N
0.93 CD N
) ) N
. . N

Intra-group JJ N
comparisons NNS N
also RB N
failed VBD N
to TO N
show VB N
any DT N
differences NNS N
between IN N
baseline NN N
and CC N
14-day JJ o
P2Y NNP o
( ( o
12 CD o
) ) o
reactivity NN o
index NN o
assessment NN o
in IN N
the DT N
placebo NN i
and CC N
pentoxifylline NN i
arms NNS N
( ( N
p JJ N
= NNP N
0.61 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
inter- JJ N
and CC N
intra-group JJ N
differences NNS N
in IN N
all DT N
other JJ N
PD NNP o
measures NNS o
. . o

The DT N
PD NNP N
effects NNS N
did VBD N
not RB N
vary JJ N
according VBG N
the DT N
presence NN N
or CC N
absence NN N
of IN N
high JJ N
on-treatment JJ N
platelet NN N
reactivity NN N
. . N

CONCLUSIONS NNP N
Adjunctive NNP N
treatment NN N
with IN N
pentoxifylline NN i
is VBZ N
not RB N
associated VBN N
with IN N
increased JJ N
platelet NN o
inhibitory NN o
effects NNS o
in IN N
DM NNP p
patients NNS p
with IN p
coronary JJ p
artery NN p
disease NN p
receiving VBG p
DAPT NNP p
. . p

-DOCSTART- -24399100- O O

Utilization NN N
patterns NNS N
of IN N
conventional JJ i
and CC i
complementary/alternative JJ i
treatments NNS i
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
and CC p
developmental JJ p
disabilities NNS p
in IN p
a DT p
population-based JJ p
study NN p
. . p

OBJECTIVE NNP N
To TO N
compare VB N
the DT N
utilization NN N
of IN N
conventional JJ i
treatments NNS i
and CC i
utilization NN i
of IN i
complementary JJ i
and CC i
alternative JJ i
medicine NN i
in IN N
preschoolers NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
) ) p
and CC p
other JJ p
developmental JJ p
disabilities NNS p
( ( p
DD NNP p
) ) p
. . p

METHODS JJ N
Participants NNS p
were VBD p
578 CD p
children NNS p
who WP p
were VBD p
part NN p
of IN p
an DT p
ongoing JJ p
population-based JJ p
, , p
case-control JJ p
study NN p
of IN p
2- JJ p
to TO p
5-year JJ p
olds NNS p
with IN p
ASD NNP p
, , p
DD NNP p
, , p
and CC p
the DT p
general JJ p
population NN p
. . p

Parents NNS N
completed VBD N
an DT N
interview NN N
on IN N
past JJ N
and CC N
current JJ N
services NNS N
. . N

RESULTS NNP N
Four CD p
hundred VBD p
fifty-three JJ p
children NNS p
with IN p
ASD NNP p
and CC p
125 CD p
DD NNP p
children NNS p
were VBD p
included VBN p
. . p

ASD NNP N
families NNS N
received VBD N
more RBR N
hours NNS N
of IN N
conventional JJ o
services NNS o
compared VBN N
with IN N
DD NNP N
families NNS N
( ( N
17.8 CD N
vs RB N
11 CD N
; : N
p NN N
< NNP N
.001 NNP N
) ) N
. . N

The DT N
use NN N
of IN N
psychotropic NN N
medications NNS N
was VBD N
low JJ N
in IN N
both DT N
groups NNS N
( ( N
approximately RB N
3 CD N
% NN N
) ) N
. . N

Overall JJ N
, , N
complementary JJ o
and CC o
alternative JJ o
medicine NN o
( ( o
CAM NNP o
) ) o
use NN N
was VBD N
not RB N
significantly RB N
different JJ N
in IN N
ASD NNP N
( ( N
39 CD N
% NN N
) ) N
versus NN N
DD NNP N
( ( N
30 CD N
% NN N
) ) N
. . N

Hispanic JJ p
families NNS p
in IN N
both DT N
groups NNS N
used VBD N
CAM NNP o
less RBR N
often RB N
than IN N
non-Hispanic JJ p
families NNS p
. . p

Variables NNS N
such JJ N
as IN N
level NN o
of IN o
function NN o
, , o
immunization NN o
status NN o
, , o
and CC o
the DT o
presence NN o
of IN o
an DT o
identified VBN o
neurogenetic JJ o
disorder NN o
were VBD N
not RB N
predictive JJ N
of IN N
CAM NNP i
use NN N
. . N

A DT N
higher JJR N
level NN o
of IN o
parental JJ o
education NN o
was VBD N
associated VBN N
with IN N
an DT N
increased VBN N
CAM NNP o
use NN N
in IN N
ASD NNP N
and CC N
DD NNP N
. . N

Families NNS p
who WP N
used VBD N
> $ N
20 CD N
hours NNS N
per IN N
week NN N
of IN N
conventional JJ i
services NNS i
were VBD N
more RBR N
likely JJ N
to TO N
use VB N
CAM NNP i
, , N
including VBG N
potentially RB N
unsafe JJ N
or CC N
disproven JJ N
CAM NNP i
. . i

Underimmunized VBN p
children NNS p
were VBD N
marginally RB N
more RBR N
likely JJ N
to TO N
use VB N
CAM NNP i
but CC N
not RB N
more RBR N
likely JJ N
to TO N
have VB N
received VBN N
potentially RB N
unsafe JJ N
or CC N
disproven JJ N
CAM NNP i
. . i

CONCLUSION NNP N
Use NNP N
of IN N
CAM NNP i
is VBZ N
common JJ N
in IN N
families NNS p
of IN p
young JJ p
children NNS p
with IN p
neurodevelopmental JJ p
disorders NNS p
, , N
and CC N
it PRP N
is VBZ N
predicted VBN N
by IN N
higher JJR N
parental JJ N
education NN N
and CC N
non-Hispanic JJ N
ethnicity NN N
but CC N
not RB N
developmental JJ N
characteristics NNS N
. . N

Further NNP N
research NN N
should MD N
address VB N
how WRB N
health NN N
care NN N
providers NNS N
can MD N
support VB N
families NNS N
in IN N
making VBG N
decisions NNS N
about IN N
CAM NNP i
use NN N
. . N

-DOCSTART- -22156577- O O

Genetic JJ N
associations NNS N
with IN N
lipoprotein JJ i
subfractions NNS i
provide VBP N
information NN N
on IN N
their PRP$ N
biological JJ N
nature NN N
. . N

Adverse JJ N
levels NNS N
of IN N
lipoproteins NNS i
are VBP N
highly RB N
heritable JJ N
and CC N
constitute JJ N
risk NN N
factors NNS N
for IN N
cardiovascular JJ N
outcomes NNS N
. . N

Hitherto NNP N
, , N
genome-wide JJ N
association NN N
studies NNS N
revealed VBD N
95 CD N
lipid-associated JJ N
loci NN N
. . N

However RB N
, , N
due JJ N
to TO N
the DT N
small JJ N
effect NN N
sizes NNS N
of IN N
these DT N
associations NNS N
large JJ N
sample JJ N
numbers NNS N
( ( N
> $ N
100 CD N
000 CD N
samples NNS N
) ) N
were VBD N
needed VBN N
. . N

Here RB N
we PRP N
show VBP N
that IN N
analyzing VBG N
more JJR N
refined JJ N
lipid JJ N
phenotypes NNS N
, , N
namely RB N
lipoprotein JJ i
subfractions NNS i
, , N
can MD N
increase VB N
the DT N
number NN N
of IN N
significantly RB N
associated VBN N
loci NN N
compared VBN N
with IN N
bulk JJ N
high-density NN i
lipoprotein NN i
and CC N
low-density NN i
lipoprotein NN i
analysis NN N
in IN N
a DT N
study NN N
with IN N
identical JJ N
sample NN N
numbers NNS N
. . N

Moreover RB N
, , N
lipoprotein JJ i
subfractions NNS i
provide VBP N
novel JJ N
insight NN N
into IN N
the DT N
human JJ N
lipid JJ N
metabolism NN N
. . N

We PRP N
measured VBD N
15 CD i
lipoprotein JJ i
subfractions NNS i
( ( i
L1-L15 NNP i
) ) i
in IN p
1791 CD p
samples NNS p
using VBG p
( ( i
1 CD i
) ) i
H-NMR NNP i
( ( i
nuclear JJ i
magnetic JJ i
resonance NN i
) ) i
spectroscopy NN i
. . i

Using VBG N
cluster NN N
analyses NNS N
, , N
we PRP N
quantified VBD N
inter-relationships NNS N
among IN N
lipoprotein JJ i
subfractions NNS i
. . i

Additionally RB N
, , N
we PRP N
analyzed VBD N
associations NNS N
with IN N
subfractions NNS i
at IN N
known VBN N
lipid JJ N
loci NN N
. . N

We PRP N
identified VBD N
five CD N
distinct JJ N
groups NNS N
of IN N
subfractions NNS N
: : N
one CD N
( ( i
L1 NNP i
) ) i
was VBD N
only RB N
marginally RB N
captured VBN N
by IN N
serum NN N
lipids NNS N
and CC N
therefore RB N
extends VBZ N
our PRP$ N
knowledge NN N
of IN N
lipoprotein JJ N
biochemistry NN N
. . N

During IN N
a DT N
lipid-tolerance JJ N
test NN N
, , N
L1 NNP i
lost VBD N
its PRP$ N
special JJ N
position NN N
. . N

In IN N
the DT N
association NN N
analysis NN N
, , N
we PRP N
found VBD N
that IN N
eight CD N
loci NNS N
( ( N
LIPC NNP N
, , N
CETP NNP N
, , N
PLTP NNP N
, , N
FADS1-2-3 NNP N
, , N
SORT1 NNP N
, , N
GCKR NNP N
, , N
APOB NNP N
, , N
APOA1 NNP N
) ) N
were VBD N
associated VBN N
with IN N
the DT N
subfractions NNS N
, , N
whereas IN N
only RB N
four CD N
loci NN N
( ( N
CETP NNP N
, , N
SORT1 NNP N
, , N
GCKR NNP N
, , N
APOA1 NNP N
) ) N
were VBD N
associated VBN N
with IN N
serum JJ N
lipids NNS N
. . N

For IN N
LIPC NNP N
, , N
we PRP N
observed VBD N
a DT N
10-fold JJ N
increase NN N
in IN N
the DT N
variance NN N
explained VBN N
by IN N
our PRP$ N
regression NN N
models NNS N
. . N

In IN N
conclusion NN N
, , N
NMR-based JJ N
fine JJ N
mapping NN N
of IN N
lipoprotein JJ i
subfractions NNS i
provides VBZ N
novel JJ N
information NN N
on IN N
their PRP$ N
biological JJ N
nature NN N
and CC N
strengthens VBZ N
the DT N
associations NNS N
with IN N
genetic JJ N
loci NN N
. . N

Future NNP N
clinical JJ N
studies NNS N
are VBP N
now RB N
needed VBN N
to TO N
investigate VB N
their PRP$ N
biomedical JJ N
relevance NN N
. . N

-DOCSTART- -3881176- O O

Randomized VBN N
trial NN N
of IN N
combination NN N
chemotherapy NN i
in IN N
hormone-resistant JJ p
metastatic JJ p
prostate NN p
carcinoma NN p
. . p

A DT N
prospective JJ N
randomized NN N
study NN N
was VBD N
conducted VBN N
in IN N
51 CD p
patients NNS p
with IN p
stage JJ p
D NNP p
hormone-resistant JJ p
prostatic JJ p
carcinoma NN p
, , N
comparing VBG N
a DT N
combination NN N
of IN N
doxorubicin NN i
and CC i
lomustine NN i
( ( N
DC NNP N
) ) N
with IN N
cyclophosphamide NN i
and CC i
5-FU JJ i
( ( i
CF NNP i
) ) i
. . i

Patients NNS N
were VBD N
assessed VBN N
objectively RB N
( ( N
employing VBG N
National NNP N
Prostate NNP N
Cancer NNP N
Project NNP N
criteria NNS N
) ) N
and CC N
subjectively RB N
( ( N
using VBG N
a DT N
numerical JJ N
scoring NN N
scheme NN N
) ) N
. . N

Each DT N
regimen NN N
was VBD N
well RB N
tolerated VBN o
with IN N
acceptable JJ N
levels NNS o
of IN o
myelosuppression NN o
. . o

The DT N
objective JJ o
partial JJ o
response NN o
rate NN o
was VBD N
57 CD N
% NN N
for IN N
DC NNP N
and CC N
8 CD N
% NN N
for IN N
CF NNP N
. . N

Objective NNP o
stabilization NN o
occurred VBD N
, , N
respectively RB N
, , N
in IN N
14 CD N
% NN N
and CC N
44 CD N
% NN N
of IN N
the DT N
patients NNS N
. . N

Similarly RB N
, , N
DC NNP N
demonstrated VBD N
a DT N
significantly RB N
superior JJ N
subjective JJ o
response NN o
rate NN o
( ( o
partial JJ o
plus CC o
complete JJ o
) ) o
of IN N
82 CD N
% NN N
, , N
compared VBN N
to TO N
48 CD N
% NN N
for IN N
CF NNP i
. . i

Patients NNS N
with IN N
poor JJ p
initial JJ p
performance NN p
status NN p
or CC p
liver VB p
involvement NN p
had VBD N
significantly RB N
lower JJR N
response NN o
rates NNS o
and CC N
reduced JJ N
survival NN o
. . o

Overall JJ N
, , N
there EX o
was VBD o
no DT o
significant JJ o
difference NN o
in IN o
survival NN o
between IN o
the DT o
two CD o
arms NNS o
, , o
reflecting VBG o
the DT o
similarity NN o
between IN o
DC NNP o
and CC o
CF NNP o
in IN o
total JJ o
objective JJ o
response NN o
rate NN o
( ( o
partial JJ o
response NN o
plus CC o
stable JJ o
disease NN o
) ) o
. . o

DC NNP i
provided VBD N
superior JJ N
palliation NN o
and CC N
was VBD N
well RB N
tolerated VBN o
by IN N
an DT N
essentially RB p
geriatric JJ p
population NN p
. . p

-DOCSTART- -9751681- O O

Atrioventricular JJ o
conduction NN N
during IN N
long-term JJ N
follow-up NN N
of IN N
patients NNS p
with IN p
sick JJ p
sinus NN p
syndrome NN p
. . p

BACKGROUND NNP N
It PRP N
has VBZ N
been VBN N
claimed VBN N
that IN N
patients NNS p
with IN p
sick JJ p
sinus NN p
syndrome NN p
have VBP N
an DT N
increased VBN N
risk NN o
of IN o
developing VBG o
AV NNP o
block NN o
, , N
but CC N
this DT N
has VBZ N
never RB N
been VBN N
assessed VBN N
prospectively RB N
. . N

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
evaluate VB N
in IN N
a DT N
prospective JJ N
trial NN N
AV NNP N
conduction NN N
during IN N
the DT N
long-term JJ N
follow-up NN N
of IN N
patients NNS p
with IN p
sick JJ p
sinus NN p
syndrome NN p
. . p

METHODS NNP N
Two CD p
hundred VBD p
twenty-five JJ p
consecutive JJ p
patients NNS p
with IN p
sick JJ p
sinus NN p
syndrome NN p
and CC p
intact JJ p
AV NNP p
conduction NN p
were VBD N
randomized VBN N
to TO N
undergo VB N
single-chamber JJ i
atrial JJ i
pacing NN i
( ( N
110 CD N
patients NNS N
) ) N
or CC N
single-chamber JJ i
ventricular JJ i
pacing NN i
( ( N
115 CD N
patients NNS N
) ) N
. . N

Follow-up NN N
after IN N
3 CD N
months NNS N
and CC N
then RB N
yearly RB N
included VBN N
measurement NN N
of IN N
the DT N
PQ NNP o
interval NN o
and CC N
, , N
in IN N
patients NNS p
with IN N
atrial JJ N
pacemakers NNS N
, , N
determination NN N
of IN N
the DT N
atrial JJ o
stimulus-Q JJ o
intervals NNS o
at IN o
pacing VBG o
rates NNS o
of IN o
100 CD o
and CC o
120 CD o
bpm NN o
. . o

The DT N
occurrence NN o
of IN o
AV NNP o
block NN o
in IN N
the DT N
atrial JJ N
group NN N
was VBD N
recorded VBN N
. . N

During IN N
follow-up JJ N
( ( N
mean JJ N
, , N
5.5+/-2.4 JJ N
years NNS N
) ) N
, , N
there EX N
was VBD N
no DT N
change NN N
in IN N
PQ NNP o
interval NN o
in IN N
either DT N
group NN N
and CC N
no DT N
change NN N
in IN N
atrial JJ o
stimulus-Q JJ o
intervals NNS o
or CC o
Wenckebach NNP o
block NN o
point NN o
in IN N
the DT N
atrial JJ N
group NN N
. . N

Four CD N
of IN N
110 CD N
patients NNS N
in IN N
the DT N
atrial JJ N
group NN N
developed VBD N
grade $ o
2 CD o
to TO o
3 CD o
AV NNP o
block NN o
that WDT N
required VBD N
upgrading NN N
of IN N
the DT N
pacemaker NN N
( ( N
0.6 CD N
% NN N
per IN N
year NN N
) ) N
. . N

Two CD N
of IN N
these DT N
4 CD N
patients NNS N
had VBD N
right JJ o
bundle-branch JJ o
block NN o
at IN N
pacemaker NN N
implantation NN N
. . N

CONCLUSIONS NNP N
AV NNP N
conduction NN N
, , N
estimated VBN N
as IN N
PQ NNP o
interval NN o
and CC o
atrial JJ o
stimulus-Q JJ o
interval NN o
at IN N
atrial JJ N
pacing VBG N
rates NNS N
of IN N
100 CD N
and CC N
120 CD N
bpm NN N
and CC N
the DT N
Wenckebach NNP N
block NN N
point NN N
, , N
remains VBZ N
stable JJ N
during IN N
long-term JJ N
follow-up JJ N
. . N

Thus RB N
, , N
treatment NN N
with IN N
single-chamber JJ i
atrial JJ i
pacing NN i
is VBZ N
safe JJ o
and CC N
can MD N
be VB N
recommended VBN N
to TO N
patients NNS p
with IN p
sick JJ p
sinus NN p
syndrome NN p
without IN N
bundle-branch JJ N
block NN N
. . N

-DOCSTART- -8964218- O O

[ JJ i
Therapy NNP i
of IN N
metastatic JJ p
endocrine NN p
tumors NNS p
of IN p
the DT p
gastrointestinal JJ p
tract NN p
] NN p
. . p

-DOCSTART- -22548691- O O

Effectiveness NN N
of IN N
Dader NNP i
Method NNP i
for IN N
pharmaceutical JJ N
care NN N
on IN N
control NN o
of IN o
blood NN o
pressure NN o
and CC o
total JJ o
cholesterol NN o
in IN N
outpatients NNS p
with IN p
cardiovascular JJ p
disease NN p
or CC p
cardiovascular JJ p
risk NN p
: : p
EMDADER-CV JJ N
randomized NNS N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Although IN N
some DT N
studies NNS N
have VBP N
demonstrated VBN N
that IN N
pharmacist JJ i
intervention NN i
can MD N
improve VB N
drug NN N
therapy NN N
among IN N
patients NNS p
with IN p
cardiovascular JJ p
disease NN p
( ( p
CVD NNP p
) ) p
, , N
more JJR N
evidence NN N
derived VBN N
from IN N
randomized VBN N
controlled VBN N
trials NNS N
( ( N
RCTs NNP N
) ) N
is VBZ N
needed VBN N
, , N
including VBG N
assessment NN N
of IN N
the DT N
effect NN N
of IN N
community NN i
pharmacist NN i
interventions NNS i
in IN N
patients NNS p
with IN p
CVD NNP p
. . p

OBJECTIVE NNP N
To TO N
assess VB N
the DT N
effectiveness NN N
of IN N
the DT N
Dader NNP i
Method NNP i
for IN i
pharmaceutical JJ i
care NN i
on IN N
achieving VBG N
therapeutic JJ N
goals NNS N
for IN N
blood NN o
pressure NN o
( ( o
BP NNP o
) ) o
, , o
total JJ o
cholesterol NN o
( ( o
TC NNP o
) ) o
, , N
and CC N
both DT o
BP NNP o
and CC o
TC NNP o
( ( o
BP/TC NNP o
) ) o
in IN N
patients NNS p
with IN p
CVD NNP p
and/or VBP p
high JJ p
or CC p
intermediate JJ p
cardiovascular NN p
( ( p
CV NNP p
) ) p
risk NN p
attending VBG p
community NN p
pharmacies NNS p
in IN p
Spain NNP p
. . p

METHODS NNP N
Patients NNPS p
aged VBD p
25 CD p
to TO p
74 CD p
years NNS p
attending VBG p
community NN p
pharmacies NNS p
with IN p
a DT p
prescription NN p
for IN p
at IN p
least JJS p
1 CD p
drug NN p
indicated VBN p
for IN p
CVD NNP p
or CC p
CV NNP p
risk NN p
factors NNS p
were VBD N
randomized VBN N
to TO N
2 CD N
groups NNS N
: : N
an DT N
intervention NN i
group NN i
that WDT i
received VBD i
pharmaceutical JJ i
care NN i
, , i
which WDT i
was VBD i
provided VBN i
by IN i
specially RB i
trained JJ i
pharmacists NNS i
working VBG i
in IN i
collaboration NN i
with IN i
physicians NNS i
, , N
and CC N
a DT N
control NN i
group NN i
that WDT i
received VBD i
usual JJ i
care NN i
( ( i
routine JJ i
dispensing VBG i
counseling NN i
) ) i
and CC i
verbal JJ i
and CC i
written VBN i
counseling VBG i
regarding VBG i
CVD NNP i
prevention NN i
. . i

Patients NNS p
were VBD p
recruited VBN p
from IN p
December NNP p
2005 CD p
to TO p
September NNP p
2006 CD p
, , N
and CC N
both DT N
groups NNS N
were VBD N
followed VBN N
for IN N
8 CD N
months NNS N
. . N

Study NNP N
outcomes NNS N
were VBD N
assessed VBN N
at IN N
baseline NN N
and CC N
at IN N
16 CD N
and CC N
32 CD N
weeks NNS N
after IN N
randomization NN N
. . N

The DT N
primary JJ N
outcome NN N
measures NNS N
were VBD N
the DT N
proportions NNS o
of IN o
patients NNS o
achieving VBG o
BP NNP o
, , o
TC NNP o
, , o
and CC o
BP/TC NNP o
therapeutic JJ o
goals NNS o
( ( N
BP NNP N
lower JJR N
than IN N
140/90 CD N
mm NNS N
Hg NNP N
for IN N
patients NNS N
with IN N
uncomplicated JJ N
hypertension NN N
and CC N
lower JJR N
than IN N
130/80 CD N
mm NNS N
Hg NNP N
for IN N
patients NNS N
with IN N
diabetes NNS N
, , N
chronic JJ N
kidney NN N
disease NN N
, , N
or CC N
history NN N
of IN N
myocardial JJ N
infarction NN N
or CC N
stroke NN N
; : N
TC NNP N
lower JJR N
than IN N
200 CD N
mg NNS N
per IN N
dL NN N
for IN N
patients NNS N
without IN N
CVD NNP N
and CC N
lower JJR N
than IN N
175 CD N
mg NNS N
per IN N
dL NN N
for IN N
patients NNS N
with IN N
CVD NNP N
) ) N
. . N

Secondary JJ N
outcomes NNS N
were VBD N
mean JJ o
BP NNP o
and CC o
TC NNP o
values NNS o
. . o

BP NNP o
was VBD o
assessed VBN o
manually RB o
by IN N
the DT N
pharmacist NN N
after IN N
a DT N
10-minute JJ N
rest NN N
in IN N
the DT N
supine JJ N
position NN N
. . N

This DT N
measurement NN N
was VBD N
performed VBN N
twice RB N
for IN N
every DT N
participant NN N
, , N
and CC N
the DT N
average NN N
of IN N
the DT N
2 CD N
measurements NNS N
was VBD N
calculated VBN N
. . N

TC NNP o
was VBD N
measured VBN N
by IN N
the DT N
pharmacist NN N
during IN N
the DT N
study NN N
visit NN N
using VBG N
the DT N
enzymatic JJ o
dry JJ o
method NN o
. . o

Statistical JJ N
analyses NNS N
were VBD N
performed VBN N
using VBG N
2-tailed JJ N
McNemar NNP N
tests NNS N
, , N
Pearson NNP N
chi-square NN N
tests NNS N
, , N
and CC N
Student NNP N
's POS N
t-tests NNS N
; : N
P NNP N
< VBD N
0.05 CD N
was VBD N
considered VBN N
statistically RB N
significant JJ N
. . N

RESULTS VB N
714 CD p
patients NNS p
were VBD N
included VBN N
in IN N
the DT N
study NN N
( ( N
356 CD N
intervention NN i
, , N
358 CD N
control NN i
) ) i
, , N
and CC N
the DT N
mean JJ p
[ NNP p
SD NNP p
] NNP p
age NN p
was VBD p
62.8 CD p
[ JJ p
8.1 CD p
] JJ p
years NNS p
. . p

The DT N
2 CD N
groups NNS N
were VBD N
similar JJ N
at IN N
baseline NN N
in IN N
clinical JJ N
and CC N
demographic JJ N
characteristics NNS N
, , N
including VBG N
the DT N
proportion NN N
of IN N
patients NNS N
at IN N
therapeutic JJ N
goals NNS o
for IN o
BP NNP o
, , o
TC NNP o
, , o
and CC o
BP/TC NNP o
. . o

After IN N
8 CD N
months NNS N
of IN N
follow-up NN N
, , N
there EX N
were VBD N
statistically RB N
significant JJ N
differences NNS N
in IN N
favor NN N
of IN N
pharmaceutical JJ N
care NN N
in IN N
the DT N
proportions NNS N
of IN N
patients NNS N
who WP N
achieved VBD N
therapeutic JJ N
goals NNS o
for IN o
BP NNP o
( ( N
52.5 CD N
% NN N
vs. FW N
43.0 CD N
% NN N
, , N
P=0.017 NNP N
) ) N
, , N
TC NNP o
( ( N
56.5 CD N
% NN N
vs. FW N
44.1 CD N
% NN N
, , N
P=0.001 NNP N
) ) N
, , N
and CC N
BP/TC NNP o
( ( N
37.1 CD N
% NN N
vs. FW N
21.8 CD N
% NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSION NNP N
Compared NNP N
with IN N
usual JJ i
care NN i
plus CC i
written VBN i
education NN i
, , i
pharmaceutical JJ i
care NN i
focused VBN i
on IN i
patient JJ i
evaluation NN i
and CC i
follow-up NN i
in IN i
collaboration NN i
with IN i
physicians NNS i
improved VBN N
the DT N
achievement NN N
of IN N
BP NNP o
, , o
TC NNP o
, , o
and CC o
BP/TC NNP o
treatment NN N
goals NNS N
in IN N
patients NNS p
with IN p
CVD NNP p
and/or VBP p
high JJ p
or CC p
intermediate JJ p
CV NNP p
risk NN p
attending VBG p
community NN p
pharmacies NNS p
in IN p
Spain NNP p
. . p

-DOCSTART- -17872451- O O

Nateglinide NNP i
reduces VBZ N
carotid JJ o
intima-media JJ o
thickening NN o
in IN N
type NN p
2 CD p
diabetic JJ p
patients NNS p
under IN p
good JJ p
glycemic JJ p
control NN p
. . p

OBJECTIVE NNP N
Postprandial NNP N
hyperglycemia NN N
observed VBD N
in IN N
type NN p
2 CD p
diabetes NNS p
mellitus NN N
is VBZ N
a DT N
risk NN N
factor NN N
for IN N
atherosclerosis NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
strict JJ i
glycemic NNS i
control NN i
by IN N
nateglinide NN N
on IN N
common JJ N
carotid NN o
far RB o
wall JJ o
intima-media JJ o
thickness NN o
in IN N
type NN p
2 CD p
diabetic JJ p
patients NNS p
who WP p
were VBD p
already RB p
under IN p
good JJ p
glycemic JJ p
control NN p
. . p

METHODS NNP N
AND CC N
RESULTS NNP N
We PRP N
performed VBD N
an DT N
open JJ N
labeled VBN N
randomized JJ N
prospective JJ N
trial NN N
on IN N
78 CD i
drug-naive JJ i
type NN i
2 CD i
diabetic JJ i
patients NNS i
whose WP$ i
HbA1c NNP i
was VBD i
less JJR i
than IN i
6.5 CD i
% NN i
. . i

Thirty-eight JJ p
patients NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
nateglinide NN i
( ( i
270 CD i
mg/dL NN i
) ) i
and CC i
40 CD i
to TO i
control VB i
group NN i
( ( i
no DT i
treatment NN i
) ) i
. . i

After IN N
12 CD N
months NNS N
, , N
a DT N
significant JJ N
reduction NN N
in IN N
HbA1c NNP o
was VBD N
observed VBN N
in IN N
the DT N
nateglinide JJ N
group NN N
, , N
whereas IN N
a DT N
significant JJ N
increase NN N
of IN N
HbA1c NNP o
was VBD N
observed VBN N
in IN N
the DT N
untreated JJ N
group NN N
. . N

The DT N
carotid JJ o
intima-media JJ o
thickness NN o
at IN N
the DT N
end NN N
of IN N
1-year JJ N
follow-up NN N
was VBD N
significantly RB N
reduced VBN N
in IN N
the DT N
nateglinide JJ N
group NN N
compared VBN N
with IN N
the DT N
untreated JJ i
group NN i
( ( N
-0.017+/-0.054 JJ N
mm/year VBP N
versus IN N
0.024+/-0.066 JJ N
mm/year NN N
, , N
P=0.0064 NNP N
) ) N
. . N

Whereas NNP N
nateglinide JJ N
treatment NN N
also RB N
reduced VBD N
triglyceride JJ o
, , o
highly-sensitive JJ o
C-reactive JJ o
protein NN o
, , o
and CC o
E-selectin NNP o
, , N
multiple JJ N
regression NN N
analysis NN N
identified VBN N
HbA1c NNP o
as IN N
the DT N
only JJ N
significant JJ N
independent JJ N
determinant NN N
of IN N
the DT N
change NN N
in IN N
carotid JJ o
intima-media JJ o
thickness NN o
. . o

CONCLUSION NNP N
In IN N
type NN p
2 CD p
diabetic JJ p
patients NNS p
with IN p
good JJ p
glycemic NNS p
control NN p
, , N
further JJ N
strict JJ i
glycemic NNS i
control NN i
by IN i
nateglinide JJ i
results NNS N
in IN N
regression NN N
of IN N
carotid JJ o
intima-media JJ o
thickness NN o
. . o

-DOCSTART- -17717132- O O

Clinical JJ N
application NN i
of IN i
C-reactive JJ i
protein NN i
across IN N
the DT p
spectrum NN p
of IN p
acute JJ p
coronary JJ p
syndromes NNS p
. . p

BACKGROUND NNP N
High-sensitivity NNP i
C-reactive JJ i
protein NN i
( ( i
hsCRP NN i
) ) i
is VBZ N
associated VBN N
with IN N
adverse JJ N
cardiovascular JJ N
outcomes NNS N
in IN N
acute JJ p
coronary JJ p
syndromes NNS p
( ( p
ACS NNP p
) ) p
. . p

The DT N
ability NN N
to TO N
formulate VB N
recommendations NNS N
regarding VBG N
clinical JJ N
use NN N
of IN N
hsCRP NN i
is VBZ N
limited VBN N
by IN N
a DT N
paucity NN N
of IN N
data NNS N
regarding VBG N
several JJ N
key JJ N
issues NNS N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
hsCRP NN i
across IN N
the DT N
spectrum NN N
of IN N
ACS NNP N
. . N

METHODS NNP N
hsCRP NN o
was VBD N
measured VBN N
on IN N
admission NN N
in IN N
3225 CD p
patients NNS p
with IN p
ACS NNP p
. . p

hsCRP NN o
concentrations NNS o
were VBD N
compared VBN N
in IN N
patients NNS N
who WP N
suffered VBD N
an DT N
adverse JJ N
cardiac NN N
outcome NN N
within IN N
10 CD N
months NNS N
of IN N
study NN N
entry NN N
and CC N
in IN N
patients NNS N
who WP N
had VBD N
no DT N
adverse JJ N
event NN N
. . N

Because IN N
of IN N
heterogeneity NN N
in IN N
the DT N
relationship NN N
between IN N
hsCRP NN i
and CC N
clinical JJ N
outcomes NNS N
, , N
evaluation NN N
was VBD N
limited VBN N
to TO N
patients NNS N
from IN N
whom WP N
samples NNS N
were VBD N
collected VBN N
within IN N
48 CD N
h NN N
of IN N
symptom JJ N
onset NN N
. . N

RESULTS JJ N
Patients NNPS N
in IN N
the DT N
highest JJS N
quartile NN N
of IN N
hsCRP NN i
compared VBN N
to TO N
those DT N
in IN N
the DT N
lowest JJS N
quartile NN N
were VBD N
at IN N
increased VBN N
risk NN o
of IN o
death NN o
at IN N
30 CD N
days NNS N
[ RB N
adjusted VBN N
hazard NN N
ratio NN N
( ( N
adjHR NN N
) ) N
4.6 CD N
, , N
P NNP N
< VBZ N
0.001 CD N
] NN N
and CC N
10 CD N
months NNS N
( ( N
adjHR JJ N
3.9 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

In IN N
patients NNS N
with IN N
unstable JJ N
angina/non-ST-elevation JJ N
myocardial JJ N
infarction NN N
( ( N
STEMI NNP N
) ) N
, , N
hsCRP JJ i
> FW N
3 CD N
mg/L NN N
was VBD N
associated VBN N
with IN N
increased JJ o
10-month JJ o
mortality NN o
( ( N
adjHR JJ N
2.3 CD N
, , N
P NNP N
= NNP N
0.002 CD N
) ) N
, , N
whereas RB N
in IN N
STEMI NNP N
a DT N
relationship NN N
with IN N
mortality NN N
was VBD N
seen VBN N
at IN N
hsCRP JJ N
> $ N
10 CD N
mg/L NN N
( ( N
adjHR JJ N
3.0 CD N
, , N
P NNP N
= NNP N
0.008 CD N
) ) N
. . N

Increased VBN N
concentrations NNS N
of IN N
hsCRP NN o
were VBD N
strongly RB N
associated VBN N
with IN N
the DT N
development NN N
of IN N
heart NN o
failure NN o
at IN N
30 CD N
days NNS N
( ( N
adjHR JJ N
8.2 CD N
, , N
P NNP N
= NNP N
0.001 CD N
) ) N
and CC N
10 CD N
months NNS N
( ( N
adjHR JJ N
2.6 CD N
, , N
P NNP N
= NNP N
0.014 CD N
) ) N
. . N

CONCLUSION NNP N
Increased VBD N
baseline JJ o
concentrations NNS o
of IN o
hsCRP NN o
are VBP N
strongly RB N
associated VBN N
with IN N
mortality NN o
and CC o
heart NN o
failure NN o
across IN N
the DT N
ACS NNP N
spectrum NN N
. . N

hsCRP JJ i
measurement NN N
should MD N
be VB N
performed VBN N
early RB N
after IN N
presentation NN N
and CC N
index NN N
diagnosis-specific JJ N
cutpoints NNS N
should MD N
be VB N
used VBN N
. . N

-DOCSTART- -9481466- O O

Randomized VBN N
controlled VBD N
study NN N
of IN N
customized JJ N
preventive JJ N
medicine NN N
reminder NN N
letters NNS N
in IN N
a DT N
community NN N
practice NN N
. . N

OBJECTIVE UH N
To TO N
test VB N
the DT N
effectiveness NN o
of IN N
customized JJ N
, , N
family-oriented JJ N
reminder NN N
letters NNS N
in IN N
activating VBG N
patients NNS p
to TO N
seek VB N
appropriate JJ N
preventive JJ N
services NNS N
. . N

DESIGN NNP N
Randomized NNP N
clinical JJ N
trial NN N
. . N

One CD i
group NN i
received VBD i
computer-generated JJ i
, , i
customized JJ i
letters NNS i
explaining VBG i
recommended VBD i
preventive JJ i
procedures NNS i
for IN i
each DT i
family NN i
member NN i
. . i

A DT i
second JJ i
group NN i
received VBD i
a DT i
form JJ i
letter NN i
listing NN i
recommendations NNS i
for IN i
all DT i
preventive JJ i
procedures NNS i
for IN i
all DT i
age NN i
and CC i
sex NN i
groups NNS i
. . i

A DT i
third JJ i
group NN i
( ( i
control VB i
group NN i
) ) i
received VBD i
no DT i
letters NNS i
. . i

SETTING VBG N
A DT p
private JJ p
medical JJ p
centre NN p
, , p
without IN p
university NN p
affiliation NN p
, , p
in IN p
rural JJ p
Quebec NNP p
. . p

PARTICIPANTS NN N
From IN p
8770 CD p
patients NNS p
who WP p
met VBD p
study NN p
criteria NNS p
, , p
719 CD p
families NNS p
were VBD p
randomly RB p
selected VBN p
. . p

Data NNS p
were VBD p
available JJ p
for IN p
1971 CD p
of IN p
1998 CD p
patients NNS p
in IN p
these DT p
families NNS p
. . p

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT o
Family NNP o
Received NNP o
Index NNP o
is VBZ N
the DT N
proportion NN N
of IN N
all DT N
procedures NNS N
for IN N
which WDT N
a DT N
family NN N
was VBD N
overdue JJ N
that IN N
they PRP N
received VBD N
. . N

The DT N
Family JJ o
End-of-study NNP o
Up-to-date NNP o
Index NNP o
is VBZ N
the DT N
proportion NN N
of IN N
procedures NNS N
for IN N
which WDT N
the DT N
family NN N
was VBD N
eligible JJ N
and CC N
for IN N
which WDT N
they PRP N
were VBD N
up-to-date JJ N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
. . N

RESULTS VB N
The DT N
Family NNP o
Received NNP o
Index NNP o
for IN N
families NNS N
mailed VBN N
customized JJ i
letters NNS i
was VBD N
more RBR N
than IN N
double RB N
the DT N
index NN N
for IN N
patients NNS N
not RB N
mailed VBN N
letters NNS N
( ( N
Kruskal-Wallis NNP N
P NNP N
= NNP N
.0139 NNP N
) ) N
. . N

Comparison NNP N
of IN N
the DT N
Family NNP o
End-of-study NNP o
Up-to-date NNP o
indices NNS o
also RB N
demonstrated VBD N
that IN N
families NNS N
of IN N
patients NNS N
sent JJ N
customized JJ i
letters NNS i
were VBD N
more RBR N
likely JJ N
to TO N
be VB N
up-to-date JJ N
than IN N
families NNS N
not RB N
sent VBD N
letters NNS N
( ( N
Kruskal-Wallis NNP N
P NNP N
= NNP N
.0054 NNP N
) ) N
. . N

No DT N
statistically RB N
significant JJ N
difference NN N
appeared VBD N
between IN N
the DT N
number NN N
of IN N
preventive JJ N
measures NNS N
received VBN N
by IN N
the DT N
control NN i
group NN N
and CC N
the DT N
form-letter JJ i
group NN N
. . N

CONCLUSIONS NNP N
This DT N
study NN N
demonstrates VBZ N
a DT N
clinically RB N
small JJ N
but CC N
statistically RB N
significant JJ N
value NN N
to TO N
customizing VBG i
reminder NN i
letters NNS i
. . i

-DOCSTART- -6871470- O O

Delayed VBN o
alloimmunization NN o
using VBG N
random JJ i
single JJ i
donor NN i
platelet NN i
transfusions NNS i
: : i
a DT N
prospective JJ N
study NN N
in IN N
thrombocytopenic JJ p
patients NNS p
with IN p
acute JJ p
leukemia NN p
. . p

A DT N
randomized JJ N
study NN N
was VBD N
performed VBN N
in IN N
54 CD p
thrombocytopenic JJ p
patients NNS p
with IN p
acute JJ p
leukemia NN p
. . p

Alloimmunization NN N
of IN N
recipients NNS N
of IN N
random JJ N
multiple-donor JJ i
platelet NN i
concentrates NNS i
( ( N
MD NNP N
group NN N
) ) N
was VBD N
compared VBN N
to TO N
that DT N
of IN N
patients NNS N
receiving VBG N
random JJ i
single-donor JJ i
platelets NNS i
( ( N
SD NNP N
group NN N
) ) N
. . N

In IN N
the DT N
SD NNP N
patients NNS N
, , N
formation NN o
of IN o
alloantibodies NNS o
( ( o
mostly RB o
anti-HLA RB o
) ) o
occurred VBD N
less RBR N
frequently RB N
( ( N
p NN N
less JJR N
than IN N
0.002 CD N
) ) N
, , N
after IN N
a DT N
longer JJR N
time NN N
period NN N
( ( N
p NN N
less JJR N
than IN N
0.002 CD N
) ) N
, , N
and CC N
after IN N
a DT N
higher JJR N
number NN N
of IN N
transfusions NNS N
( ( N
p NN N
less JJR N
than IN N
0.005 CD N
) ) N
as IN N
compared VBN N
to TO N
MD NNP N
patients NNS N
. . N

SD NNP N
patients NNS N
also RB N
became VBD N
refractory JJ N
to TO N
random VB N
platelets NNS N
less RBR N
frequently RB N
( ( N
p NN N
less JJR N
than IN N
0.005 CD N
) ) N
, , N
after IN N
a DT N
longer JJR N
time NN N
period NN N
, , N
and CC N
after IN N
a DT N
higher JJR o
number NN o
of IN o
transfusions NNS o
( ( N
p NN N
less JJR N
than IN N
0.02 CD N
) ) N
. . N

In IN N
SD NNP N
patients NNS N
, , N
the DT N
increments NNS o
after IN N
the DT N
first JJ o
and CC o
the DT o
last JJ o
transfusion NN o
were VBD N
in IN N
the DT N
same JJ N
range NN N
, , N
whereas NNS N
in IN N
MD NNP N
patients NNS N
, , N
the DT N
1-hr JJ N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
and CC N
the DT N
24-hr JJ N
( ( N
p NN N
less JJR N
than IN N
0.025 CD N
) ) N
increments NNS o
decreased VBN N
from IN N
the DT N
first JJ N
to TO N
the DT N
last JJ N
transfusion NN N
. . N

Thus RB N
, , N
the DT N
use NN N
of IN N
random NN i
SD NNP i
platelet NN i
transfusions NNS i
postponed VBD N
alloimmunization NN N
. . N

-DOCSTART- -20598044- O O

Comparison NNP N
of IN N
gonadotropin-releasing JJ i
hormone NN i
agonists NNS i
and CC N
antagonists NNS i
in IN N
assisted JJ N
reproduction NN N
cycles NNS N
of IN N
polycystic JJ p
ovarian JJ p
syndrome NN p
patients NNS p
. . p

AIM NNP N
Gonadotropin-releasing NNP N
hormone NN N
( ( N
GnRH NNP N
) ) N
antagonists NNS N
have VBP N
reduced VBN N
the DT N
incidence NN N
of IN N
severe JJ N
ovarian JJ N
hyper NN N
stimulation NN N
syndrome NN N
( ( N
OHSS NNP N
) ) N
and CC N
rate NN N
of IN N
hospitalization NN N
due JJ N
to TO N
severe JJ N
OHSS NNP N
, , N
especially RB N
in IN N
polycystic JJ p
ovarian JJ p
syndrome NN p
( ( p
PCOS NNP p
) ) p
patients NNS p
. . p

The DT N
present JJ N
study NN N
aimed VBN N
to TO N
compare VB N
the DT N
outcomes NNS N
of IN N
patients NNS p
with IN p
PCOS NNP p
undergoing VBG p
controlled VBN p
ovarian JJ p
hyperstimulation NN p
( ( p
COH NNP p
) ) p
with IN p
GnRH NNP i
agonist VBP i
versus NN i
GnRH NNP i
antagonist NN i
protocols NNS i
for IN N
assisted JJ N
reproduction NN N
cycles NNS N
. . N

METHODS NNP N
The DT N
present JJ N
clinical JJ N
trial NN N
compared VBN N
GnRH NNP i
antagonist NN i
( ( i
cetrorelix NN i
) ) i
and CC N
GnRH NNP i
agonist NN i
( ( i
buserelin NN i
) ) i
protocols VBZ N
during IN N
COH NNP N
of IN N
112 CD p
infertile JJ p
PCOS NNP p
patients NNS p
entering VBG p
assisted JJ p
reproduction NN p
cycles NNS p
. . p

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
pregnancy NN o
occurrence NN o
. . o

Basal NNP N
characteristics NNS N
of IN N
the DT N
participants NNS N
, , N
stimulation NN o
cycle NN o
responses NNS o
, , o
pregnancy NN o
outcomes NNS o
, , o
incidence NN o
of IN o
OHSS NNP o
and CC o
types NNS o
of IN o
OHSS NNP o
were VBD N
considered VBN N
in IN N
both DT N
groups NNS N
. . N

RESULTS NNP N
Regarding VBG N
chemical NN o
and CC o
clinical JJ o
pregnancy NN o
rates NNS o
, , N
the DT N
number NN o
of IN o
retrieved JJ o
oocytes NNS o
was VBD N
significantly RB N
higher JJR N
and CC N
OHSS NNP N
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
antagonist NN N
group NN N
. . N

Follicle NNP o
stimulating VBG o
hormone NN o
( ( o
FSH NNP o
) ) o
, , o
luteinizing VBG o
hormone NN o
( ( o
LH NNP o
) ) o
levels NNS o
, , o
number NN o
of IN o
follicles NNS o
, , o
number NN o
of IN o
follicles NNS o
> VBP o
18 CD o
mm NN o
, , o
relative JJ o
frequency NN o
of IN o
mature NN o
oocytes NNS o
, , o
number NN o
and CC o
days NNS o
of IN o
gonadotropin JJ o
injections NNS o
, , o
day NN o
of IN o
human JJ o
chorionic JJ o
gonadotropin NN o
( ( o
HCG NNP o
) ) o
administration NN o
, , o
estradiol JJ o
level NN o
and CC o
abortion NN o
were VBD N
similar JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

CONCLUSION NNP N
GnRH NNP N
antagonists NNS N
are VBP N
more RBR N
effective JJ N
, , N
safe JJ N
and CC N
a DT N
well RB N
tolerated JJ N
alternative NN N
to TO N
agonists NNS N
for IN N
assisted JJ N
reproduction NN N
cycles NNS N
in IN N
PCOS NNP N
patients NNS N
. . N

GnRH NNP N
antagonists NNS N
are VBP N
associated VBN N
with IN N
a DT N
reduction NN N
in IN N
the DT N
incidence NN N
of IN N
OHSS NNP N
in IN N
these DT N
patients NNS N
. . N

-DOCSTART- -24097277- O O

The DT N
efficacy NN o
and CC o
safety NN o
of IN N
simultaneous JJ N
transurethral JJ i
GreenLight NNP i
photoselective JJ i
vaporization NN i
of IN N
bladder NN N
tumor NN N
and CC N
prostate NN N
in IN N
patients NNS p
with IN p
bladder JJ p
tumor NN p
and CC p
lower JJR p
urinary JJ p
tract NN p
symptoms NNS p
. . p

PURPOSE NNP N
We PRP N
compared VBN N
the DT N
safety NN o
and CC o
efficacy NN o
of IN N
simultaneous JJ o
transurethral JJ o
GreenLight NNP o
photoselective JJ o
vaporization NN o
of IN i
bladder NN o
tumor NN o
and CC o
prostate NN o
( ( i
PVBT/PVP NNP i
) ) i
in IN N
patients NNS p
with IN p
bladder JJ p
tumor NN p
and CC p
bladder NN p
outlet NN p
obstruction NN p
caused VBN p
by IN p
benign JJ p
prostate NN p
hyperplasia NN p
( ( p
BPH NNP p
) ) p
. . p

METHODS NNP N
Sixty-two JJ p
patients NNS p
with IN p
bladder JJ p
tumor NN p
were VBD N
enrolled VBN N
in IN N
our PRP$ N
prospective JJ N
and CC N
randomized JJ N
trial NN N
. . N

A DT N
total NN N
of IN N
37 CD p
men NNS p
underwent JJ N
simultaneous JJ N
transurethral JJ i
PVBT/PVP NNP i
, , N
and CC N
25 CD p
patients NNS p
underwent JJ N
PVBT NNP i
alone RB N
. . N

The DT N
clinicopathological JJ o
parameters NNS o
and CC o
the DT o
recurrence NN o
of IN o
bladder NN o
tumor NN o
on IN o
the DT o
bladder NN o
neck/prostatic JJ o
fossa NN o
were VBD N
evaluated VBN N
in IN N
all DT N
patients NNS N
. . N

RESULTS NNP N
Clinicopathological JJ N
parameters NNS N
of IN N
both DT N
groups NNS N
were VBD N
similar JJ N
. . N

The DT N
rates NNS o
of IN o
recurrence NN o
, , o
progression NN o
and CC o
tumor NN o
recurrence NN o
of IN o
bladder NN o
neck/prostatic JJ o
fossa NN o
were VBD N
16.0 CD N
, , N
4.0 CD N
and CC N
4.0 CD N
% NN N
in IN N
the DT N
simultaneous JJ N
resection NN N
group NN N
, , N
and CC N
18.9 CD N
, , N
5.4 CD N
and CC N
8.1 CD N
% NN N
in IN N
the DT N
group NN N
PVBT NNP N
, , N
respectively RB N
. . N

No DT N
statistically RB N
significant JJ N
differences NNS N
were VBD N
found VBN N
between IN N
the DT N
two CD N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
Simultaneous NNP N
PVBT/PVP NNP i
may MD N
help VB N
decrease VB N
the DT N
overall JJ o
recurrence NN o
rate NN o
and CC o
tumor NN o
recurrence NN o
in IN o
bladder NN o
neck/prostatic JJ o
fossa NN o
. . o

PVBT/PVP CC i
can MD N
be VB N
performed VBN N
effectively RB N
and CC N
safely RB N
in IN N
patients NNS p
with IN p
bladder JJ p
tumor NN p
and CC p
BPH NNP p
. . p

-DOCSTART- -12080735- O O

[ JJ N
Effect NNP N
of IN N
valociclovir NN i
hydrochloride NN i
on IN N
patients NNS p
with IN p
herpes NNS o
zoster NN o
] NN o
. . p

-DOCSTART- -21214129- O O

Impact NN o
of IN N
a DT N
fixed JJ N
combination NN N
of IN N
clindamycin JJ i
phosphate JJ i
1.2 CD i
% NN i
-benzoyl NNP i
peroxide RB i
2.5 CD i
% NN i
aqueous JJ i
gel NN i
on IN N
health-related JJ N
quality NN N
of IN N
life NN N
in IN N
moderate JJ N
to TO N
severe VB N
acne JJ N
vulgaris NN N
. . N

The DT N
acne-specific JJ N
quality NN N
of IN N
life NN N
( ( N
Acne-QoL NNP N
) ) N
questionnaire NN N
was VBD N
developed VBN N
to TO N
measure VB o
the DT o
impact NN o
of IN o
facial JJ o
acne NN o
across IN N
4 CD N
domains NNS N
( ( N
acne NN N
symptoms NNS N
, , N
role-emotional JJ N
, , N
self-perception JJ N
, , N
role-social JJ N
) ) N
of IN N
health-related JJ o
quality NN o
of IN o
life NN o
( ( o
HRQL NNP o
) ) o
. . o

This DT N
analysis NN N
assessed VBD N
the DT N
impact NN N
of IN N
clindamycin NN i
phosphate VBP i
1.2 CD i
% NN i
-benzoyl NNP i
peroxide RB i
2.5 CD i
% NN i
( ( i
clindamycin-BPO JJ i
2.5 CD i
% NN i
) ) i
gel NN i
on IN N
HRQL NNP N
in IN N
a DT N
combined JJ p
study NN p
population NN p
( ( p
N NNP p
= NNP p
2813 CD p
) ) p
of IN p
participants NNS p
with IN p
moderate JJ p
to TO p
severe VB p
acne JJ p
vulgaris NN p
. . p

Although IN N
the DT N
results NNS N
presented VBD N
within IN N
do VBP N
not RB N
include VB N
factors NNS N
of IN N
study NN N
and CC N
study-by-treatment JJ N
interaction NN N
, , N
analyses NNS N
were VBD N
performed VBN N
to TO N
confirm VB N
that IN N
the DT N
results NNS N
were VBD N
consistent JJ N
across IN N
the DT N
2 CD N
identical JJ N
, , N
double-blind JJ N
, , N
randomized JJ N
studies NNS N
and CC N
within IN N
each DT N
treatment NN N
group NN N
across IN N
studies NNS N
to TO N
justify VB N
pooling VBG N
the DT N
data NN N
from IN N
both DT N
studies NNS N
. . N

The DT N
Acne-QoL NNP o
questionnaire NN o
was VBD N
administered VBN N
at IN N
baseline NN N
and CC N
at IN N
the DT N
end NN N
of IN N
treatment NN N
( ( N
week NN N
12 CD N
) ) N
. . N

Treatment NN N
with IN N
clindamycin-BPO JJ i
2.5 CD N
% NN N
gel NN N
significantly RB p
improved VBN p
participant-reported JJ p
HRQL NNP o
across IN N
all DT N
4 CD N
domains NNS N
compared VBN N
with IN N
individual JJ N
active JJ N
ingredients NNS N
and CC N
vehicle NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

The DT N
percentage NN N
improvement NN N
in IN N
mean JJ o
Acne-QoL NNP o
domain NN o
scores NNS o
with IN N
clindamycin-BPO JJ i
2.5 CD N
% NN N
gel NN N
ranged VBD N
from IN N
37 CD N
% NN N
to TO N
59 CD N
% NN N
. . N

Because IN N
the DT N
negative JJ N
impact NN N
of IN N
facial JJ N
acne NN N
on IN N
HRQL NNP o
is VBZ N
one CD N
of IN N
the DT N
primary JJ N
motivators NNS N
for IN N
patients NNS N
to TO N
seek VB N
treatment NN N
, , N
this DT N
analysis NN N
underscores VBZ N
the DT N
importance NN N
of IN N
physicians NNS N
incorporating VBG N
assessments NNS N
of IN N
HRQL NNP N
into IN N
their PRP$ N
clinical JJ N
decision NN N
making NN N
. . N

-DOCSTART- -1336890- O O

Changes NNS N
in IN N
calcanean JJ N
bone NN N
mineral NN N
occurring VBG N
spontaneously RB N
and CC N
during IN N
hormone JJ i
replacement NN i
therapy NN i
in IN N
early JJ p
post-menopausal JJ p
women NNS p
. . p

The DT N
spontaneous JJ p
calcanean JJ p
bone NN p
loss NN p
occurring VBG p
in IN p
healthy JJ p
early JJ p
post-menopausal JJ p
women NNS p
and CC N
the DT N
effect NN N
of IN N
two CD i
hormone NN i
replacement NN i
therapies NNS i
( ( i
HRT NNP i
's POS i
) ) i
were VBD N
investigated VBN N
in IN N
a DT N
longitudinal JJ N
study NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
between IN N
the DT N
right NN N
and CC N
left VBD N
calcanean JJ N
BMC NNP N
or CC N
BMD NNP N
( ( N
p JJ N
> NNP N
0.15 CD N
) ) N
. . N

The DT N
spontaneous JJ N
bone NN N
loss NN N
was VBD N
similar JJ N
at IN N
all PDT N
the DT N
skeletal JJ N
sites NNS N
measured VBD N
, , N
with IN N
a DT N
mean JJ N
spontaneous JJ N
loss NN N
in IN N
calcanean JJ N
BMD NNP N
of IN N
1.6 CD N
% NN N
over IN N
one CD N
year NN N
. . N

Both DT N
HRT NNP N
's POS N
significantly RB N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
prevented VBD N
the DT N
bone NN o
loss NN o
from IN N
all DT N
skeletal JJ N
sites NNS N
irrespective VBP N
of IN N
the DT N
weight-bearing NN N
or CC N
content NN N
of IN N
trabecular JJ N
bone NN N
, , N
and CC N
( ( N
for IN N
the DT N
weight-bearing JJ N
bones NNS N
) ) N
there EX N
was VBD N
even RB N
a DT N
gain NN N
in IN N
calcanean JJ o
BMC NNP o
and CC o
BMD NNP o
and CC o
spinal JJ o
BMD NNP o
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
. . N

Bone NNP N
mineral NN N
of IN N
the DT N
calcaneus NN N
and CC N
the DT N
spine NN N
correlated VBN N
equally RB N
to TO N
body NN N
weight NN N
( ( N
r VB N
approximately RB N
0.4 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
whereas WP N
bone RB N
mineral NN N
in IN N
the DT N
forearm NN N
was VBD N
not RB N
correlated VBN N
to TO N
body VB N
weight NN N
. . N

The DT N
correlations NNS N
between IN N
the DT N
changes NNS N
in IN N
bone NN N
mineral NN N
at IN N
the DT N
sites NNS N
measured VBN N
were VBD N
all DT N
significant JJ N
( ( N
r VB N
approximately RB N
0.2-0.4 JJ N
) ) N
. . N

-DOCSTART- -22983407- O O

Randomized VBN N
trial NN N
of IN N
partial JJ i
vs. FW N
stepwise NN i
caries NNS p
removal NN N
: : N
3-year JJ N
follow-up NN N
. . N

This DT N
randomized JJ N
, , N
multicenter RB N
clinical JJ N
trial NN N
evaluated VBD N
the DT N
effectiveness NN N
of IN N
2 CD N
treatments NNS N
for IN N
deep JJ p
caries NNS p
lesions NNS p
- : N
partial JJ i
caries NNS i
removal NN i
( ( i
PCR NNP i
) ) i
and CC i
stepwise JJ i
excavation NN i
( ( i
SW NNP i
) ) i
- : N
with IN N
respect NN N
to TO N
the DT N
primary JJ N
outcome NN N
of IN N
pulp NN N
vitality NN N
for IN N
a DT N
3-year JJ N
follow-up JJ N
period NN N
. . N

Inclusion NN p
criteria NNS p
were VBD p
as IN p
follows VBZ p
: : p
patients NNS p
with IN p
permanent JJ p
molars NNS p
presenting VBG p
deep JJ p
caries NNS p
lesions NNS p
( ( p
lesion NN p
affecting VBG p
? . p
1/2 CD p
of IN p
the DT p
dentin NN p
on IN p
radiographic JJ p
examination NN p
) ) p
, , p
positive JJ p
response NN p
to TO p
a DT p
cold JJ p
test NN p
, , p
absence NN p
of IN p
spontaneous JJ p
pain NN p
, , p
negative JJ p
sensitivity NN p
to TO p
percussion NN p
, , p
and CC p
absence NN p
of IN p
periapical JJ p
lesions NNS p
( ( p
radiographic JJ p
examination NN p
) ) p
. . p

Teeth NNP N
randomly RB N
assigned VBD N
to TO N
PCR NNP N
( ( N
test NN N
) ) N
received VBD N
incomplete JJ N
caries NNS N
removal NN N
and CC N
filling NN N
in IN N
a DT N
single JJ N
session NN N
. . N

Outcome NNP N
success NN N
was VBD N
evaluated VBN N
by IN N
assessment NN N
of IN N
pulp NN o
vitality NN o
, , o
determined VBN N
by IN N
pulp NN N
sensitivity NN N
to TO N
a DT N
cold JJ N
test NN N
and CC N
the DT N
absence NN N
of IN N
periapical JJ N
lesions NNS N
. . N

Data NNS N
were VBD N
analyzed VBN N
by IN N
a DT N
Weibull NNP N
regression NN N
model NN N
with IN N
shared VBN N
frailty NN N
term NN N
( ( N
survival JJ N
analysis NN N
) ) N
. . N

At IN N
baseline NN p
, , p
299 CD p
treatments NNS p
were VBD p
executed VBN p
: : p
PCR NNP p
, , N
152 CD N
and CC N
SW NNP N
, , N
147 CD p
. . p

By IN N
the DT N
end NN N
of IN N
the DT N
3-year JJ N
follow-up JJ N
period NN p
, , p
213 CD p
teeth NNS p
had VBD p
been VBN p
evaluated VBN o
. . o

Adjusted VBN o
survival JJ o
rates NNS o
were VBD o
91 CD N
% NN N
for IN N
PCR NNP N
and CC N
69 CD N
% NN N
for IN N
SW NNP N
( ( N
p JJ N
= NNP N
0.004 CD N
) ) N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
there EX N
is VBZ N
no DT N
need NN N
to TO N
re-open VB N
a DT N
cavity NN N
and CC N
perform VB N
a DT N
second JJ N
excavation NN N
for IN o
pulp NN o
vitality NN o
to TO o
be VB N
preserved VBN N
( ( N
Clinical JJ N
trials NNS N
registration VBP N
NCT00887952 NNP N
) ) N
. . N

-DOCSTART- -21593282- O O

Effects NNS N
of IN N
alcohol NN i
on IN N
the DT N
pharmacokinetics NNS o
of IN N
morphine NN i
sulfate NN i
and CC N
naltrexone NN i
hydrochloride NN i
extended VBD N
release NN N
capsules NNS N
. . N

Although IN N
contraindicated VBN N
, , N
coingestion NN N
of IN N
alcohol NN N
and CC N
opioids NNS i
by IN N
patients NNS N
or CC N
drug NN N
abusers NNS N
is VBZ N
a DT N
major JJ N
health NN N
concern NN N
because IN N
of IN N
dangerous JJ N
additive JJ N
and CC N
potentially RB N
life-threatening JJ N
sedative JJ N
and CC N
respiratory JJ N
effects NNS N
. . N

In IN N
addition NN N
, , N
alcohol NN N
has VBZ N
been VBN N
shown VBN N
to TO N
disrupt VB N
the DT N
extended-release JJ N
characteristics NNS N
of IN N
certain JJ N
extended-release JJ N
opioid NN N
formulations NNS N
, , N
releasing VBG N
a DT N
hazardous JJ N
amount NN N
of IN N
opioid NN N
over IN N
a DT N
short JJ N
time NN N
period NN N
. . N

Morphine NNP i
sulfate NN i
and CC i
naltrexone NN i
hydrochloride NN i
extended VBD i
release NN i
capsules NNS i
( ( i
MS-sNT NNP i
) ) i
, , N
which WDT N
contain VBP N
naltrexone RB N
sequestered VBN N
in IN N
each DT N
pellet NN N
core NN N
, , N
are VBP N
indicated VBN N
for IN N
management NN N
of IN N
chronic NN N
, , N
moderate VB N
to TO N
severe VB N
pain NN N
. . N

Sequestered NNP N
naltrexone NN N
is VBZ N
designed VBN N
for IN N
release NN N
upon IN N
product NN N
tampering NN N
( ( N
crushing VBG N
) ) N
to TO N
potentially RB N
mitigate VB N
morphine-induced JJ N
subjective JJ N
effects NNS N
. . N

This DT N
open-label JJ N
, , N
single-dose JJ N
, , N
4-way JJ N
crossover NN N
, , N
pharmacokinetic JJ N
drug NN N
interaction NN N
study NN N
compared VBN N
the DT N
relative JJ o
bioavailability NN o
of IN o
morphine NN o
and CC o
naltrexone NN o
when WRB o
MS-sNT NNP o
is VBZ o
administered VBN o
( ( o
under IN o
fasting VBG o
conditions NNS o
) ) o
with IN o
increasing VBG o
doses NNS o
of IN o
alcohol NN o
. . o

Thirty-two NNP p
healthy JJ p
, , p
opioid-naive JJ p
adults NNS p
were VBD N
randomized VBN N
to TO N
MS-sNT NNP i
administered VBN N
with IN N
240 CD N
mL NNS N
of IN N
4 CD N
% NN N
, , N
20 CD N
% NN N
, , N
or CC N
40 CD N
% NN N
alcohol NN i
or CC N
water NN N
. . N

No DT N
drug NN o
interaction NN o
was VBD N
found VBN N
between IN N
morphine NN N
in IN N
MS-sNT NNP N
and CC N
4 CD N
% NN N
or CC N
20 CD N
% NN N
alcohol NN N
. . N

Administration NN N
with IN N
40 CD N
% NN N
alcohol NN N
did VBD N
not RB N
affect VB N
overall JJ o
morphine NN o
exposure NN o
but CC N
was VBD N
associated VBN N
with IN N
a DT N
2-fold JJ N
increase NN N
in IN N
C NNP o
( ( o
max NN o
) ) o
and CC N
reduction NN N
of IN N
t NN o
( ( o
max NN o
) ) o
from IN N
9 CD N
to TO N
4 CD N
hours NNS N
versus IN N
MS-sNT NNP N
taken VBN N
with IN N
water NN N
. . N

Naltrexone CD o
sequestering NN o
was VBD o
successful JJ o
in IN N
all DT N
treatment NN N
arms NNS N
and CC N
not RB N
affected VBN N
by IN N
coadministration NN N
with IN N
alcohol NN N
over IN N
the DT N
dose JJ N
range NN N
tested VBD N
. . N

-DOCSTART- -16448427- O O

Plasmakinetic JJ i
prostate NN i
resection NN i
in IN N
the DT N
treatment NN N
of IN N
benign JJ N
prostate JJ N
hyperplasia NN N
: : N
results NNS N
of IN N
1-year JJ N
follow VBP N
up RP N
. . N

AIM NNP N
In IN N
our PRP$ N
randomized JJ N
prospective JJ N
study NN N
, , N
we PRP N
aimed VBD N
to TO N
evaluate VB N
the DT N
efficiency NN N
of IN N
plasmakinetic JJ i
resection NN i
of IN i
prostate NN i
( ( i
PKRP NNP i
) ) i
by IN N
comparing VBG N
the DT N
preoperative NN N
and CC N
postoperative JJ N
results NNS N
of IN N
the DT N
transurethral JJ i
resection NN i
of IN i
prostate NN i
( ( N
TURP NNP N
) ) N
and CC N
PKRP NNP N
techniques NNS N
which WDT N
we PRP N
administered VBD N
in IN N
patients NNS p
with IN p
benign JJ p
prostate NN p
hyperplasia NN p
( ( p
BPH NNP p
) ) p
in IN p
our PRP$ p
clinic NN p
. . p

METHODS NNP N
Of IN N
57 CD p
patients NNS p
for IN p
whom WP p
we PRP p
thought VBD p
an DT p
operative JJ p
intervention NN p
was VBD p
necessary JJ p
, , N
30 CD N
cases NNS N
in IN N
the DT N
first JJ N
group NN N
had VBD N
a DT N
TURP NNP i
and CC N
24 CD N
cases NNS N
in IN N
the DT N
second JJ N
group NN N
had VBD N
a DT N
PKRP NNP i
. . i

International NNP o
prostate JJ o
symptom NN o
scores NNS o
( ( o
I-PSS NNP o
) ) o
, , o
uroflowmetry UH o
, , o
measurement NN o
of IN o
residual JJ o
urine JJ o
amount NN o
and CC o
ultrasonography NN o
were VBD N
performed VBN N
for IN N
each DT N
patient NN N
both DT N
preoperatively RB N
and CC N
postoperatively RB N
( ( N
first JJ N
month NN N
and CC N
first JJ N
year NN N
) ) N
. . N

Operation NNP o
times NNS o
, , o
urethral JJ o
catheterization NN o
times NNS o
, , o
preoperative JJ o
and CC o
postoperative JJ o
Hb NNP o
, , o
Htc NNP o
and CC o
serum VB o
Na NNP o
values NNS o
of IN N
the DT N
patients NNS N
were VBD N
compared VBN N
and CC N
the DT N
complications NNS N
of IN N
the DT N
groups NNS N
were VBD N
also RB N
compared VBN N
. . N

RESULTS VB N
On IN N
first JJ N
month NN N
and CC N
first JJ N
year NN N
follow VBP N
up RP N
between IN N
the DT N
groups NNS N
, , N
there EX N
was VBD N
no DT N
significant JJ N
statistical JJ o
difference NN o
in IN N
I-PSS NNP o
, , o
maximum JJ o
flow NN o
rate NN o
, , o
average NN o
flow NN o
, , o
residual JJ o
urine NN o
and CC o
size NN o
of IN o
the DT o
prostate NN o
. . o

The DT N
decrease NN N
in IN N
serum NN o
Na NNP o
level NN o
was VBD N
found VBN N
to TO N
be VB N
significantly RB N
higher JJR N
in IN N
the DT N
TURP NNP N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
operation NN o
times NNS o
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
groups NNS N
. . N

While IN N
the DT N
postoperative JJ o
catheterization NN o
time NN o
was VBD N
75.7 CD N
h NN N
in IN N
TURP NNP N
group NN N
, , N
it PRP N
was VBD N
found VBN N
to TO N
be VB N
42 CD N
h NN N
in IN N
PKRP NNP N
group NN N
and CC N
it PRP N
was VBD N
clear JJ N
that IN N
catheterization NN o
time NN o
was VBD N
significantly RB N
shorter JJR N
( ( N
P NNP N
< NNP N
0001 CD N
) ) N
. . N

CONCLUSION VB N
It PRP N
is VBZ N
obvious JJ N
that IN N
PKRP NNP i
is VBZ N
as RB N
efficient JJ N
as IN N
TURP NNP N
and CC N
it PRP N
has VBZ N
a DT N
similar JJ N
morbidity NN N
. . N

In IN N
our PRP$ N
opinion NN N
, , N
PKRP NNP i
makes VBZ N
a DT N
promising JJ N
treatment NN N
for IN N
BPH NNP N
with IN N
its PRP$ N
advantages NNS N
, , N
such JJ N
as IN N
early JJ N
removal NN N
of IN N
postoperative JJ N
urethral JJ N
catheter NN N
, , N
a DT N
shorter JJR N
hospital NN N
stay NN N
and CC N
the DT N
absence NN N
of IN N
TUR NNP N
syndrome NN N
risk NN N
. . N

-DOCSTART- -26036434- O O

Melatonin NNP i
improves VBZ N
bone RB N
mineral JJ N
density NN N
at IN N
the DT N
femoral JJ N
neck NN N
in IN N
postmenopausal JJ p
women NNS p
with IN p
osteopenia NN p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

Melatonin NNP i
is VBZ N
known VBN N
for IN N
its PRP$ N
regulation NN N
of IN N
circadian JJ N
rhythm NN N
. . N

Recently RB N
, , N
studies NNS N
have VBP N
shown VBN N
that IN N
melatonin NN i
may MD N
have VB N
a DT N
positive JJ N
effect NN N
on IN N
the DT N
skeleton NN N
. . N

By IN N
increasing VBG N
age NN N
, , N
the DT N
melatonin NN N
levels NNS N
decrease NN N
, , N
which WDT N
may MD N
lead VB N
to TO N
a DT N
further RB N
imbalanced JJ N
bone NN N
remodeling VBG N
. . N

We PRP N
aimed VBD N
to TO N
investigate VB N
whether IN N
treatment NN N
with IN N
melatonin NN i
could MD N
improve VB N
bone NN N
mass NN N
and CC N
integrity NN N
in IN N
humans NNS N
. . N

In IN N
a DT N
double-blind JJ N
RCT NNP N
, , N
we PRP N
randomized VBD N
81 CD p
postmenopausal NN p
osteopenic JJ p
women NNS p
to TO p
1-yr JJ p
nightly RB p
treatment NN p
with IN p
melatonin NN i
1 CD p
mg NN p
( ( p
N NNP p
= NNP p
20 CD p
) ) p
, , p
3 CD p
mg NN p
( ( p
N NNP p
= NNP p
20 CD p
) ) p
, , p
or CC p
placebo NN i
( ( p
N NNP p
= NNP p
41 CD p
) ) p
. . p

At IN N
baseline NN N
and CC N
after IN N
1-yr JJ N
treatment NN N
, , N
we PRP N
measured VBD N
bone JJ N
mineral JJ N
density NN N
( ( N
BMD NNP N
) ) N
by IN N
dual JJ i
X-ray JJ i
absorptiometry NN i
, , i
quantitative JJ i
computed VBN i
tomography NN i
( ( N
QCT NNP N
) ) N
, , N
and CC N
high-resolution JJ i
peripheral JJ i
QCT NNP i
( ( N
HR-pQCT NNP N
) ) N
and CC N
determined VBN N
calciotropic NN N
hormones NNS N
and CC N
bone NN N
markers NNS N
. . N

Mean NNP p
age NN p
of IN p
the DT p
study NN p
subjects NNS p
was VBD p
63 CD p
( ( p
range VB p
56-73 NNP p
) ) p
yr NN p
. . p

Compared VBN N
to TO N
placebo VB i
, , N
femoral JJ o
neck NN o
BMD NNP o
increased VBN N
by IN N
1.4 CD N
% NN N
in IN N
response NN N
to TO N
melatonin VB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
in IN N
a DT N
dose-dependent JJ N
manner NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
as IN N
BMD NNP o
increased VBD N
by IN N
0.5 CD N
% NN N
in IN N
the DT N
1 CD N
mg/day NN N
group NN N
( ( N
P NNP N
= NNP N
0.55 CD N
) ) N
and CC N
by IN N
2.3 CD N
% NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
in IN N
the DT N
3 CD N
mg/day NN N
group NN N
. . N

In IN N
the DT N
melatonin NN N
group NN N
, , N
trabecular JJ o
thickness NN o
in IN o
tibia NN o
increased VBN N
by IN N
2.2 CD N
% NN N
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
, , N
and CC N
volumetric JJ o
bone NN o
mineral JJ o
density NN o
( ( o
vBMD NN o
) ) o
in IN N
the DT N
spine NN o
, , N
by IN N
3.6 CD N
% NN N
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
in IN N
the DT N
3 CD N
mg/day NN N
. . N

Treatment NN N
did VBD N
not RB N
significantly RB N
affect JJ N
BMD NNP o
at IN N
other JJ N
sites NNS N
or CC N
levels NNS o
of IN o
bone NN o
turnover NN o
markers NNS o
; : o
however RB N
, , N
24-hr JJ o
urinary JJ o
calcium NN o
was VBD N
decreased VBN N
in IN N
response NN N
to TO N
melatonin VB i
by IN N
12.2 CD N
% NN N
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

In IN N
conclusion NN N
, , N
1-yr JJ N
treatment NN N
with IN N
melatonin NN i
increased VBN N
BMD NNP o
at IN o
femoral JJ o
neck NN o
in IN N
a DT N
dose-dependent JJ N
manner NN N
, , N
while IN N
high-dose JJ N
melatonin NN N
increased VBD N
vBMD NN o
in IN N
the DT N
spine NN o
. . o

Further JJ N
studies NNS N
are VBP N
needed VBN N
to TO N
assess VB N
the DT N
mechanisms NN N
of IN N
action NN N
and CC N
whether IN N
the DT N
positive JJ N
effect NN N
of IN N
nighttime JJ N
melatonin NN i
will MD N
protect VB N
against IN N
fractures NNS N
. . N

-DOCSTART- -17999404- O O

Obesity NN N
and CC N
mortality NN N
in IN N
men NNS p
with IN p
locally RB p
advanced JJ p
prostate NN p
cancer NN p
: : p
analysis NN N
of IN N
RTOG NNP N
85-31 JJ N
. . N

BACKGROUND NNP N
Greater NNP N
body NN o
mass NN o
index NN o
( ( o
BMI NNP o
) ) o
is VBZ N
associated VBN N
with IN N
shorter JJR N
time NN N
to TO N
prostate-specific JJ N
antigen NN N
( ( N
PSA NNP N
) ) N
failure NN N
following VBG N
radical JJ i
prostatectomy NN i
and CC N
radiation NN i
therapy NN i
( ( N
RT NNP N
) ) N
. . N

Whether NNP N
BMI NNP N
is VBZ N
associated VBN N
with IN N
prostate JJ N
cancer-specific JJ N
mortality NN N
( ( N
PCSM NNP N
) ) N
was VBD N
investigated VBN N
in IN N
a DT N
large JJ N
randomized JJ N
trial NN N
of IN N
men NNS p
treated VBN p
with IN p
RT NNP i
and CC i
androgen JJ i
deprivation NN i
therapy NN i
( ( i
ADT NNP i
) ) i
for IN i
locally RB p
advanced JJ p
prostate NN p
cancer NN p
. . p

METHODS NNP N
Between NNP p
1987 CD p
and CC p
1992 CD p
, , p
945 CD p
eligible JJ p
men NNS p
with IN p
locally RB p
advanced JJ p
prostate NN p
cancer NN p
were VBD p
enrolled VBN p
in IN p
a DT p
phase NN p
3 CD p
trial NN p
( ( p
RTOG NNP p
85-31 CD p
) ) p
and CC N
randomized VBN N
to TO N
RT NNP i
and CC i
immediate JJ i
goserelin NN i
or CC i
RT NNP i
alone RB i
followed VBD i
by IN i
goserelin NN i
at IN i
recurrence NN i
. . i

Height NNP N
and CC N
weight VBN N
data NNS N
were VBD N
available JJ N
at IN N
baseline NN N
for IN p
788 CD p
( ( p
83 CD p
% NN p
) ) p
subjects VBZ p
. . p

Cox NNP i
regression NN i
analyses NNS i
were VBD N
performed VBN N
to TO N
evaluate VB N
the DT N
relations NNS N
between IN N
BMI NNP o
and CC o
all-cause JJ o
mortality NN o
, , o
PCSM NNP o
, , o
and CC o
nonprostate JJ o
cancer NN o
mortality NN o
. . o

Covariates NNS N
included VBD N
age NN N
, , N
race NN N
, , N
treatment NN N
arm NN N
, , N
history NN N
of IN N
prostatectomy NN N
, , N
nodal JJ N
involvement NN N
, , N
Gleason NNP N
score NN N
, , N
clinical JJ N
stage NN N
, , N
and CC N
BMI NNP N
. . N

RESULTS VB N
The DT N
5-year JJ o
PCSM NNP o
rate NN o
for IN N
men NNS N
with IN N
BMI NNP o
< NNP N
25 CD N
kg/m NN N
( ( N
2 CD N
) ) N
was VBD N
6.5 CD N
% NN N
, , N
compared VBN N
with IN N
13.1 CD N
% NN N
and CC N
12.2 CD N
% NN N
in IN N
men NNS N
with IN N
BMI NNP N
> NNP N
or CC N
=25 VB N
to TO N
< VB N
30 CD N
and CC N
BMI NNP N
> NNP N
or CC N
=30 NNP N
, , N
respectively RB N
( ( N
Gray NNP N
's POS N
P NNP N
= NNP N
.005 NNP N
) ) N
. . N

In IN N
multivariate NN N
analyses NNS N
, , N
greater JJR N
BMI NNP N
was VBD N
significantly RB N
associated VBN N
with IN N
higher JJR o
PCSM NNP o
( ( N
for IN N
BMI NNP N
> NNP N
or CC N
=25 VB N
to TO N
< VB N
30 CD N
, , N
hazard RB N
ratio NN N
[ NNP N
HR NNP N
] NNP N
1.52 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
1.02-2.27 JJ N
, , N
P NNP N
= NNP N
.04 NNP N
; : N
for IN N
BMI NNP N
> NNP N
or CC N
=30 NNP N
, , N
HR NNP N
1.64 CD N
, , N
95 CD N
% NN N
CI NNP N
, , N
1.01-2.66 JJ N
, , N
P NNP N
= NNP N
.04 NNP N
) ) N
. . N

BMI NNP o
was VBD N
not RB N
associated VBN N
with IN N
nonprostate JJ o
cancer NN o
or CC N
all-cause JJ o
mortality NN o
. . o

CONCLUSIONS NNP N
Greater NNP N
baseline NN o
BMI NNP o
is VBZ N
independently RB N
associated VBN N
with IN N
higher JJR N
PCSM NN o
in IN N
men NNS p
with IN p
locally RB p
advanced JJ p
prostate NN p
cancer NN p
. . p

Further JJ N
studies NNS N
are VBP N
warranted VBN N
to TO N
evaluate VB N
the DT N
mechanism NN N
( ( N
s NN N
) ) N
for IN N
increased VBN N
cancer-specific JJ o
mortality NN o
and CC N
to TO N
assess VB N
whether IN N
weight JJ o
loss NN o
after IN N
prostate JJ N
cancer NN N
diagnosis NN N
alters NNS N
disease VBP N
course NN N
. . N

-DOCSTART- -22332211- O O

Evaluation NN N
of IN N
masking VBG N
study NN N
participants NNS p
to TO N
intravitreal VB N
injections NNS N
in IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
success NN o
of IN N
masking VBG N
study NN N
participants NNS p
to TO N
treatment NN N
allocation NN N
using VBG N
sham JJ i
intravitreal JJ i
injections NNS i
. . i

METHODS NNP N
Eyes NNP p
were VBD N
randomized VBN N
to TO N
receive VB N
sham NN i
injections NNS i
plus CC i
prompt JJ i
laser NN i
, , i
intravitreal JJ i
ranibizumab NN i
injections NNS i
plus CC i
prompt JJ i
laser NN i
, , i
intravitreal JJ i
ranibizumab NN i
injections NNS i
plus CC i
deferred JJ i
laser NN i
, , i
or CC i
intravitreal VB i
triamcinolone JJ i
acetonide JJ i
injections NNS i
plus CC i
prompt NN i
laser NN i
up RB N
to TO N
every DT N
16 CD N
weeks NNS N
with IN N
sham JJ N
injections NNS N
intermittently RB N
. . N

All DT p
eyes NNS p
could MD N
receive VB N
treatment NN N
or CC N
sham NN N
as RB N
often RB N
as IN N
every DT N
4 CD N
weeks NNS N
. . N

Participants NNS p
with IN p
2 CD p
study NN p
eyes NNS p
had VBD N
1 CD N
eye NN N
randomized VBN N
to TO N
sham VB i
plus JJ i
prompt JJ i
laser NN i
and CC N
1 CD N
eye NN N
randomized VBN N
to TO N
a DT N
real JJ i
injection NN i
group NN N
. . N

Sham NNP N
injections NNS N
were VBD N
performed VBN N
by IN N
pressing VBG N
the DT N
syringe NN N
hub NN N
against IN N
the DT N
conjunctiva NN N
to TO N
mimic VB N
a DT N
real JJ N
injection NN N
. . N

Laser NNP i
treatment NN i
was VBD N
not RB N
masked VBN N
. . N

At IN N
the DT N
1-year JJ N
visit NN N
, , N
participants NNS N
were VBD N
asked VBN N
if IN N
they PRP N
believed VBD N
that IN N
the DT N
injections NNS N
received VBD N
during IN N
the DT N
study NN N
were VBD N
real JJ N
, , N
sham NN i
, , N
or CC N
sometimes RB i
real JJ i
and CC i
sometimes RB i
sham JJ i
. . i

RESULTS NNP N
Among IN N
423 CD p
participants NNS p
with IN p
1 CD p
study NN p
eye NN p
, , N
the DT N
correct JJ o
assignment NN o
was VBD N
stated VBN N
by IN N
9.9 CD N
% NN N
of IN N
the DT N
sham NN i
plus CC i
prompt JJ i
laser NN i
group NN N
, , N
88.0 CD N
% NN N
of IN N
the DT N
ranibizumab NN i
plus CC i
prompt JJ i
laser NN i
group NN N
, , N
89.6 CD N
% NN N
of IN N
the DT N
unmasked JJ N
ranibizumab NN i
plus CC i
deferred JJ i
laser NN i
group NN N
, , N
and CC N
44.0 CD N
% NN N
of IN N
the DT N
triamcinolone NN i
plus CC i
prompt JJ i
laser NN i
group NN N
. . N

Among IN N
112 CD p
participants NNS p
with IN p
2 CD p
study NN p
eyes NNS p
, , N
the DT N
correct JJ o
assignment NN o
was VBD N
stated VBN N
for IN N
24.1 CD N
% NN N
of IN N
the DT N
sham NN N
plus CC N
prompt JJ N
laser NN N
eyes NNS N
. . N

CONCLUSIONS NNP N
Successful NNP o
masking NN o
of IN N
an DT N
intravitreal JJ N
injection NN N
can MD N
be VB N
accomplished VBN N
when WRB N
a DT N
sham NN i
injection NN i
procedure NN N
carefully RB N
mimics VBZ N
a DT N
real JJ i
injection NN i
procedure NN N
. . N

Masking VBG o
seems VBZ N
less RBR N
successful JJ o
when WRB N
one CD N
eye NN N
is VBZ N
receiving VBG N
a DT N
real JJ N
injection NN N
and CC N
the DT N
other JJ N
eye NN N
is VBZ N
receiving VBG N
a DT N
sham JJ N
injection NN N
or CC N
when WRB N
an DT N
individual JJ N
eye NN N
receives VBZ N
both DT N
real JJ N
and CC N
sham JJ N
injections NNS N
. . N

-DOCSTART- -6125181- O O

The DT N
influence NN N
of IN N
beta-adrenoceptor NN i
blockade NN N
on IN N
left JJ p
ventricular JJ p
function NN p
. . p

1 CD N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
compare VB N
in IN N
a DT N
randomized JJ N
cross-over JJ N
trial NN N
pindolol NN i
, , N
a DT N
beta-adrenoceptor NN i
blocking VBG i
agent NN i
with IN N
intrinsic JJ N
sympathomimetic JJ N
activity NN N
and CC N
metoprolol NN i
, , N
a DT N
cardioselective JJ N
beta-adrenoceptor NN N
blocker NN N
lacking VBG N
sympathomimetic JJ N
activity NN N
in IN N
hypertensives NNS p
with IN p
incipient JJ p
heart NN p
failure NN p
. . p

Cardiac NNP o
function NN o
was VBD N
investigated VBN N
by IN N
M-Mode NNP o
and CC o
2D-echo-cardiography JJ o
. . o

2 CD N
Both DT N
pindolol NN i
and CC i
metoprolol NN i
in IN N
equipotent JJ N
doses NNS N
lowered VBD N
blood NN o
pressure NN o
to TO N
the DT N
same JJ N
extent NN N
. . N

3 CD N
There EX N
was VBD N
no DT N
difference NN N
in IN N
overall JJ o
left VBD o
ventricular JJ o
function NN o
in IN o
ventricular JJ o
geometry NN o
or CC o
in IN o
wall NN o
dynamics NNS o
after IN N
either DT N
drug NN N
. . N

4 CD N
In IN N
comparison NN N
to TO N
metoprolol VB i
, , i
pindolol VB i
produced VBN N
less JJR N
reduction NN N
in IN N
resting VBG o
heart NN o
rate NN o
, , o
cardiac JJ o
index NN o
and CC o
ejection NN o
velocity NN o
reflecting VBG N
the DT N
intrinsic JJ N
sympathomimetic JJ N
activity NN N
of IN N
the DT N
drug NN N
. . N

-DOCSTART- -12237625- O O

Hysteroscopic NNP i
transcervical JJ i
endometrial JJ i
resection NN i
versus IN N
thermal JJ i
destruction NN i
for IN N
menorrhagia NN N
: : N
a DT N
prospective JJ N
randomized VBN N
trial NN N
on IN N
satisfaction NN N
rate NN N
. . N

OBJECTIVE IN N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
satisfaction NN o
rate NN o
and CC o
the DT o
effectiveness NN o
of IN N
transcervical JJ i
hysteroscopic NN i
endometrial JJ i
resection NN i
and CC N
thermal JJ i
destruction NN i
of IN N
the DT N
endometrium NN N
in IN N
the DT N
treatment NN N
of IN N
menorrhagia NN p
. . p

STUDY NNP N
DESIGN NNP N
A NNP N
prospective JJ N
randomized VBN N
trial NN N
with IN N
2 CD N
years NNS N
of IN N
follow-up NN N
was VBD N
carried VBN N
out RP N
in IN N
the DT N
Department NNP p
of IN p
Gynecology NNP p
of IN p
the DT p
University NNP p
of IN p
Naples NNP p
. . p

Eighty-two JJ p
patients NNS p
who WP p
were VBD p
affected VBN p
by IN p
menorrhagia NN p
that WDT p
was VBD p
unresponsive JJ p
to TO p
medical JJ p
treatment NN p
were VBD N
respectively RB N
randomized VBN N
to TO N
transcervical JJ i
hysteroscopic NN i
endometrial JJ i
resection NN i
or CC i
to TO i
thermal JJ i
destruction NN i
of IN i
the DT i
endometrium NN i
. . i

Satisfaction NN o
rate NN o
, , o
operative JJ o
time NN o
, , o
discharge NN o
time NN o
, , o
complication NN o
rate NN o
, , o
reintervention NN o
rate NN o
, , o
and CC o
resumption NN o
of IN o
normal JJ o
activity NN o
were VBD N
evaluated VBN N
in IN N
each DT N
group NN N
. . N

RESULTS VB N
The DT N
satisfaction NN o
rate NN o
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
thermal JJ i
destruction NN i
group NN N
. . N

Operative JJ o
time NN o
was VBD N
significantly RB N
shorter JJR N
in IN N
the DT N
thermal JJ N
destruction NN N
group NN N
( ( N
24 CD N
+/- JJ N
4 CD N
minutes NNS N
vs JJ N
37 CD N
+/- JJ N
6 CD N
minutes NNS N
) ) N
. . N

Intraoperative JJ o
blood NN o
loss NN o
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
thermal JJ N
destruction NN N
group NN N
( ( N
7.2 CD N
+/- JJ N
2.8 CD N
mL NN N
vs NN N
89 CD N
+/- JJ N
38 CD N
mL NN N
) ) N
. . N

Reintervention NN o
rates NNS o
were VBD N
higher JJR N
in IN N
the DT N
transcervical JJ i
hysteroscopic NN i
endometrial JJ i
resection NN i
group NN N
, , N
although IN N
postoperative JJ N
pain NN N
was VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

Discharge NNP o
time NN o
, , o
complication NN o
rate NN o
, , o
and CC o
resumption NN o
of IN o
normal JJ o
activity NN o
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

CONCLUSION NNP N
Thermal NNP i
destruction NN i
of IN i
the DT i
endometrium NN i
for IN N
the DT N
treatment NN N
of IN N
menorrhagia NN p
should MD N
be VB N
considered VBN N
an DT N
effective JJ N
therapeutic JJ N
option NN N
because IN N
of IN N
its PRP$ N
acceptability NN o
among IN N
patients NNS N
, , N
shorter RB o
operative JJ o
time NN o
, , o
and CC o
lower JJR o
blood NN o
loss NN o
. . o

-DOCSTART- -8712092- O O

[ JJ N
Clinical NNP N
early JJ N
phase NN N
II NNP N
study NN N
of IN N
bicalutamide NN i
( ( i
Casodex NNP i
) ) i
in IN N
patients NNS p
with IN p
prostatic JJ p
cancer NN p
] NN p
. . N

To TO N
investigate VB N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
bicalutamide NN i
( ( N
Casodex NNP N
) ) N
with IN N
its PRP$ N
clinically NN N
recommended VBD N
dose NN N
, , N
the DT N
randomized VBN N
early JJ N
phase NN N
II NNP N
study NN N
was VBD N
performed VBN N
in IN N
124 CD p
patients NNS p
with IN p
prostatic JJ p
cancer NN p
( ( p
stage NN p
C NNP p
, , p
D NNP p
) ) p
. . p

The DT N
patients NNS N
were VBD N
given VBN N
50 CD i
, , i
80 CD i
or CC i
100 CD i
mg NN i
of IN i
bicalutamide NN i
orally RB N
once RB N
a DT N
day NN N
in IN N
fixed JJ N
doses NNS N
for IN N
12 CD N
weeks NNS N
; : N
122 CD N
patients NNS N
were VBD N
eligible JJ N
for IN N
evaluation NN N
. . N

The DT N
overall JJ o
response NN o
rate NN o
was VBD N
50.0 CD N
% NN N
( ( N
20/40 CD N
) ) N
, , N
61.0 CD N
% NN N
( ( N
25/41 CD N
) ) N
and CC N
53.7 CD N
% NN N
( ( N
22/41 CD N
) ) N
in IN N
the DT N
50 CD N
mg NN N
, , N
80 CD N
mg NN N
and CC N
100 CD N
mg NN N
groups NNS N
, , N
respectively RB N
. . N

The DT N
response NN o
rate NN o
in IN o
prostate NN o
lesion NN o
, , o
bone NN o
and CC o
lymph NN o
node NN o
metastases NNS o
was VBD N
slightly RB N
higher JJR N
in IN N
the DT N
80 CD N
mg NN N
group NN N
than IN N
in IN N
the DT N
50 CD N
mg NN N
and CC N
100 CD N
mg NN N
groups NNS N
. . N

The DT N
proportion NN o
of IN o
patients NNS o
showing VBG o
a DT o
response NN o
with IN o
regard NN o
to TO o
serum VB o
PSA NNP o
( ( o
CR NNP o
and CC o
PR NNP o
) ) o
was VBD N
84.2 CD N
, , N
92.7 CD N
and CC N
97.6 CD N
% NN N
in IN N
the DT N
50 CD N
, , N
80 CD N
and CC N
100 CD N
mg NN N
groups NNS N
, , N
respectively RB N
. . N

The DT N
incidence NN o
of IN o
adverse JJ o
reactions NNS o
was VBD N
65.0 CD N
, , N
61.0 CD N
and CC N
61.0 CD N
% NN N
in IN N
the DT N
50 CD N
, , N
80 CD N
and CC N
100 CD N
mg NN N
groups NNS N
, , N
respectively RB N
, , N
and CC N
there EX N
was VBD N
no DT o
significant JJ o
difference NN o
in IN N
overall JJ o
safety NN o
rating NN o
in IN N
the DT N
three CD N
groups NNS N
. . N

Frequent JJ o
adverse JJ o
reactions NNS o
were VBD N
gynecomastia JJ o
and CC o
breast NN o
pain NN o
. . o

Only RB N
one CD N
patient NN N
in IN N
the DT N
80 CD N
mg NN N
group NN N
was VBD N
withdrawn VBN o
due JJ o
to TO o
shortness VB o
of IN o
breath NN o
. . o

Serum NNP o
concentrations NNS o
of IN o
LH NNP o
, , o
testosterone NN o
and CC o
estradiol NN o
increased VBD o
significantly RB o
after IN N
treatment NN N
. . N

Bicalutamide NNP i
was VBD N
concluded VBN N
to TO N
be VB N
effective JJ N
and CC N
well RB N
tolerated VBN N
in IN N
patients NNS p
with IN p
prostatic JJ p
cancer NN p
, , N
and CC N
its PRP$ N
recommended VBD N
dose NN N
was VBD N
80 CD N
mg NN N
once RB N
daily RB N
. . N

-DOCSTART- -11824175- O O

A DT N
double-blind JJ N
, , N
placebo-controlled JJ i
crossover NN N
study NN N
investigating VBG N
the DT N
effect NN N
of IN N
porcine NN i
secretin NN i
in IN N
children NNS p
with IN p
autism NN p
. . p

OBJECTIVES CC N
A DT N
recent JJ N
patient NN N
series NN N
reported VBD N
the DT N
incidental JJ N
findings NNS N
of IN N
improved VBN N
social JJ N
and CC N
language NN N
skills NNS N
in IN N
3 CD p
children NNS p
with IN p
autistic JJ p
spectrum NN p
disorders NNS p
after IN p
the DT p
administration NN p
of IN p
secretin NN i
, , p
a DT p
peptide NN p
hormone NN p
. . p

However RB N
, , N
a DT N
subsequent JJ N
study NN N
did VBD N
not RB N
find VB N
evidence NN N
for IN N
a DT N
drug NN N
effect NN N
. . N

Parents NNS N
are VBP N
seeking VBG N
treatment NN N
with IN N
secretin JJ i
despite IN N
the DT N
absence NN N
of IN N
empirical JJ N
investigations NNS N
demonstrating VBG N
amelioration NN N
in IN N
autism NN N
symptomology NN N
. . N

In IN N
order NN N
to TO N
more RBR N
precisely RB N
measure VB N
the DT N
effects NNS N
of IN N
secretin NN i
, , N
this DT N
study NN N
investigated VBD N
the DT N
effect NN N
of IN N
a DT N
single JJ N
intravenous JJ i
dose NN i
of IN i
porcine NN i
secretin NN i
on IN N
12 CD p
autistic JJ p
children NNS p
through IN N
a DT N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
crossover NN N
study NN N
. . N

Children NNP N
were VBD N
assessed VBN N
on IN N
objective JJ o
language NN o
and CC o
on IN o
social JJ o
, , o
neuropsychological JJ o
, , o
and CC o
gastrointestinal JJ o
measures NNS o
to TO N
evaluate VB N
drug NN N
effects NNS N
. . N

The DT N
study NN N
was VBD N
conducted VBN N
over IN N
a DT N
16-week JJ N
trial NN N
. . N

The DT N
results NNS N
indicated VBD N
that IN N
significant JJ N
differences NNS N
were VBD N
not RB N
observed VBN N
on IN N
the DT N
majority NN N
of IN N
the DT N
dependent JJ N
variables NNS N
. . N

Statistically NNP N
significant JJ N
differences NNS N
were VBD N
observed VBN N
on IN N
measures NNS o
of IN o
positive JJ o
affect NN o
and CC o
activity NN o
level NN o
following VBG N
secretin JJ i
infusion NN N
. . N

In IN N
general JJ N
, , N
the DT N
autistic JJ p
children NNS p
did VBD N
not RB N
demonstrate VB N
the DT N
improvements NNS N
described VBN N
in IN N
the DT N
initial JJ N
retrospective JJ N
report NN N
. . N

-DOCSTART- -10424316- O O

Effects NNS N
of IN N
captopril NN i
and CC N
enalapril NN i
on IN N
electroencephalogram NN o
and CC o
cognitive JJ o
performance NN o
in IN N
healthy JJ p
volunteers NNS p
. . p

OBJECTIVE NNP N
Captopril NNP i
and CC N
enalapril NNS i
have VBP N
been VBN N
reported VBN N
to TO N
influence VB N
cognitive JJ o
functions NNS o
and CC o
quality NN o
of IN o
life NN o
in IN N
hypertensive JJ p
patients NNS p
. . p

METHODS NNP N
The DT N
effects NNS N
of IN N
captopril NN i
( ( N
12.5 CD N
mg NN N
and CC N
25 CD N
mg NN N
) ) N
and CC N
enalapril $ i
( ( N
5 CD N
mg NN N
and CC N
10 CD N
mg NN N
) ) N
administered VBD N
during IN N
7-day JJ N
periods NNS N
on IN N
electroencephalogram NN o
( ( o
EEG NNP o
) ) o
, , o
cognitive JJ o
functions NNS o
, , o
and CC o
subjective JJ o
assessments NNS o
were VBD N
investigated VBN N
in IN N
healthy JJ p
males NNS p
. . p

RESULTS NNP N
Neither NNP N
captopril NN N
nor CC N
enalapril NN N
influenced VBN N
EEG NNP o
and CC o
cognitive JJ o
functions NNS o
compared VBN N
with IN N
placebo NN N
. . N

Captopril NNP i
12.5 CD N
mg NN N
decreased VBD N
subjective JJ o
activity NN o
compared VBN N
with IN N
placebo NN i
. . i

Enalapril NNP i
did VBD N
not RB N
alter VB N
subjective JJ o
ratings NNS o
. . o

Both DT N
systolic JJ o
and CC o
diastolic JJ o
blood NN o
pressure NN o
were VBD N
significantly RB N
lower JJR N
after IN N
administration NN N
of IN N
captopril JJ i
25 CD N
mg NN N
, , N
whereas WP N
blood NN o
pressure NN o
was VBD N
unaffected VBN N
by IN N
enalapril NNS i
compared VBN N
with IN N
placebo NN N
. . N

CONCLUSION NNP N
Our PRP$ N
results NNS N
suggest VBP N
that IN N
central JJ N
effects NNS N
of IN N
captopril NN i
and CC N
enalapril NN i
were VBD N
minor JJ N
and CC N
not RB N
constant JJ N
in IN N
young JJ p
healthy JJ p
men NNS p
. . p

-DOCSTART- -23246790- O O

Differences NNS N
in IN N
reach NN o
and CC o
attrition NN o
between IN o
Web-based JJ o
and CC o
print-delivered JJ o
tailored JJ o
interventions NNS o
among IN N
adults NNS p
over IN p
50 CD p
years NNS p
of IN p
age NN p
: : p
clustered VBN N
randomized JJ N
trial NN N
. . N

BACKGROUND VB N
The DT N
Internet NNP N
has VBZ N
the DT N
potential JJ N
to TO N
provide VB N
large JJ N
populations NNS N
with IN N
individual JJ N
health NN N
promotion NN N
advice NN N
at IN N
a DT N
relatively RB N
low JJ N
cost NN N
. . N

Despite IN N
the DT N
high JJ N
rates NNS N
of IN N
Internet NNP N
access NN N
, , N
actual JJ N
reach NN N
by IN N
Web-based JJ N
interventions NNS N
is VBZ N
often RB N
disappointingly RB N
low JJ N
, , N
and CC N
differences NNS N
in IN N
use NN N
between IN N
demographic JJ N
subgroups NNS N
are VBP N
present JJ N
. . N

Furthermore RB N
, , N
Web-based JJ N
interventions NNS N
often RB N
have VBP N
to TO N
deal VB N
with IN N
high JJ N
rates NNS N
of IN N
attrition NN N
. . N

OBJECTIVE CC N
This DT N
study NN N
aims VBZ N
to TO N
assess VB N
user JJ o
characteristics NNS o
related VBN o
to TO o
participation NN o
and CC o
attrition NN o
when WRB N
comparing VBG N
Web-based JJ i
and CC i
print-delivered JJ i
tailored JJ i
interventions NNS i
containing VBG N
similar JJ N
content NN N
and CC N
thereby RB N
to TO N
provide VB N
recommendations NNS N
in IN N
choosing VBG N
the DT N
appropriate JJ N
delivery NN N
mode NN N
for IN N
a DT N
particular JJ N
target NN N
audience NN N
. . N

METHODS NNP N
We PRP N
studied VBD N
the DT N
distribution NN N
of IN N
a DT N
Web-based JJ i
and CC i
a DT i
print-delivered JJ i
version NN i
of IN i
the DT i
Active NNP i
Plus NNP i
intervention NN i
in IN N
a DT N
clustered JJ N
randomized NN N
controlled VBN N
trial NN N
( ( N
RCT NNP N
) ) N
. . N

Participants NNS p
were VBD p
recruited VBN p
via IN p
direct JJ p
mailing NN p
within IN p
the DT p
participating VBG p
Municipal NNP p
Health NNP p
Council NNP p
regions NNS p
and CC p
randomized VBN p
to TO p
the DT p
printed VBN i
or CC i
Web-based VBN i
intervention NN i
by IN p
their PRP$ p
region NN p
. . p

Based VBN N
on IN N
the DT N
answers NNS N
given VBN N
in IN N
a DT N
prior JJ N
assessment NN N
, , N
participants NNS N
received VBD N
tailored JJ N
advice NN N
on IN N
3 CD N
occasions NNS N
: : N
( ( N
1 CD N
) ) N
within IN N
2 CD N
weeks NNS N
after IN N
the DT N
baseline NN N
, , N
( ( N
2 CD N
) ) N
2 CD N
months NNS N
after IN N
the DT N
baseline NN N
, , N
and CC N
( ( N
3 CD N
) ) N
within IN N
4 CD N
months NNS N
after IN N
the DT N
baseline NN N
( ( N
based VBN N
on IN N
a DT N
second JJ N
assessment NN N
at IN N
3 CD N
months NNS N
) ) N
. . N

The DT N
baseline NN N
( ( N
printed VBN N
or CC N
Web-based VBN N
) ) N
results NNS N
were VBD N
analyzed JJ N
using VBG N
ANOVA NNP N
and CC N
chi-square JJ N
tests NNS N
to TO N
establish VB N
the DT N
differences NNS N
in IN N
user JJ N
characteristics NNS N
between IN N
both DT N
intervention NN N
groups NNS N
. . N

We PRP N
used VBD N
logistic JJ N
regression NN N
analyses NNS N
to TO N
study VB N
the DT N
interaction NN N
between IN N
the DT N
user NN o
characteristics NNS o
and CC N
the DT N
delivery NN N
mode NN N
in IN N
the DT N
prediction NN N
of IN N
dropout NN o
rate NN o
within IN N
the DT N
intervention NN N
period NN N
. . N

RESULTS VB N
The DT N
printed JJ N
intervention NN N
resulted VBD N
in IN N
a DT N
higher JJR o
participation NN o
rate NN o
( ( N
19 CD N
% NN N
) ) N
than IN N
the DT N
Web-based JJ N
intervention NN N
( ( N
12 CD N
% NN N
) ) N
. . N

Participants NNS N
of IN N
the DT N
Web-based JJ N
intervention NN N
were VBD N
significantly RB N
younger JJR N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
more RBR N
often RB N
men NNS N
( ( N
P=.01 NNP N
) ) N
, , N
had VBD N
a DT N
higher JJR N
body NN N
mass NN N
index NN N
( ( N
BMI NNP N
) ) N
( ( N
P=.001 NNP N
) ) N
and CC N
a DT N
lower JJR N
intention NN N
to TO N
be VB N
physically RB N
active JJ N
( ( N
P=.03 NNP N
) ) N
than IN N
participants NNS N
of IN N
the DT N
printed VBN N
intervention NN N
. . N

The DT N
dropout NN o
rate NN o
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
Web-based JJ N
intervention NN N
group NN N
( ( N
53 CD N
% NN N
) ) N
compared VBN N
to TO N
the DT N
print-delivered JJ N
intervention NN N
( ( N
39 CD N
% NN N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

A DT N
low JJ N
intention NN o
to TO o
be VB o
physically RB o
active JJ o
was VBD N
a DT N
strong JJ N
predictor NN N
for IN N
dropout NN o
within IN N
both DT N
delivery NN N
modes FW N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

The DT N
difference NN N
in IN N
dropout NN o
rate NN o
between IN N
the DT N
Web-based JJ N
and CC N
the DT N
printed JJ N
intervention NN N
was VBD N
not RB N
explained VBN N
by IN N
user JJ N
characteristics NNS N
. . N

CONCLUSIONS VB N
The DT N
reach NN N
of IN N
the DT N
same JJ N
tailored JJ o
physical JJ o
activity NN o
( ( o
PA NNP o
) ) o
intervention NN N
in IN N
a DT N
printed JJ N
or CC N
Web-based JJ N
delivery NN N
mode NN N
differed VBD N
between IN N
sociodemographic JJ N
subgroups NNS N
of IN N
participants NNS N
over IN N
50 CD N
years NNS N
of IN N
age NN N
. . N

Although IN N
the DT N
reach NN N
of IN N
the DT N
Web-based JJ N
intervention NN N
is VBZ N
lower JJR N
, , N
Web-based JJ N
interventions NNS N
can MD N
be VB N
a DT N
good JJ N
channel NN N
to TO N
reach VB N
high-risk JJ N
populations NNS N
( ( N
lower JJR N
PA NNP N
intention NN N
and CC N
higher JJR N
BMI NNP N
) ) N
. . N

While IN N
the DT N
dropout NN o
rate NN o
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
Web-based JJ N
intervention NN N
group NN N
, , N
no DT N
specific JJ N
user NN N
characteristics NNS N
explained VBD N
the DT N
difference NN N
in IN N
dropout NN o
rates NNS o
between IN N
the DT N
delivery NN N
modes NN N
. . N

More JJR N
research NN N
is VBZ N
needed VBN N
to TO N
determine VB N
what WP N
caused VBD N
the DT N
high JJ N
rate NN o
of IN o
dropout NN o
in IN N
the DT N
Web-based JJ N
intervention NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
Dutch NNP N
Trial NNP N
Register NNP N
( ( N
NTR NNP N
) ) N
: : N
2297 CD N
: : N
http NN N
: : N
//www.trialregister.nl/trialreg/admin/rctview.asp NN N
? . N
TC=2297 NNP N
( ( N
Archived VBN N
by IN N
WebCite NNP N
at IN N
http NN N
: : N
//www.webcitation.org/65TkwoESp NN N
) ) N
. . N

-DOCSTART- -20201949- O O

Final JJ N
analysis NN N
of IN N
the DT N
UKLG NNP N
LY02 NNP N
trial NN N
comparing VBG N
6-8 JJ N
cycles NNS N
of IN N
CHOP NNP i
with IN N
3 CD N
cycles NNS N
of IN i
CHOP NNP i
followed VBN i
by IN i
a DT i
BEAM NNP i
autograft NN i
in IN N
patients NNS p
< JJ p
65 CD p
years NNS p
with IN p
poor JJ p
prognosis NN p
histologically RB p
aggressive JJ p
NHL NNP p
. . p

This DT N
trial NN N
involved VBD N
457 CD p
patients NNS p
and CC N
sought VBD N
to TO N
assess VB N
the DT N
value NN N
of IN N
early JJ N
intensification NN N
with IN N
autologous JJ N
transplantation NN N
in IN N
patients NNS p
with IN p
poor JJ p
prognosis NN p
histologically RB p
aggressive JJ p
non-Hodgkin JJ p
lymphoma NN p
( ( p
NHL NNP p
) ) p
showing VBG p
a DT p
response NN p
to TO p
initial JJ p
CHOP NNP i
( ( i
cyclophosphamide NN i
, , i
doxorubicin NN i
, , i
vincristine NN i
, , i
prednisolone NN i
) ) i
chemotherapy NN i
. . i

Randomization NN N
was VBD N
made VBN N
at IN N
the DT N
time NN N
of IN N
diagnosis NN N
with IN N
223 CD N
assigned VBD N
to TO N
continuing VBG N
CHOP NNP i
and CC N
234 CD N
to TO N
3 CD N
cycles NNS N
of IN N
CHOP NNP i
followed VBN i
by IN i
a DT i
BEAM NNP i
( ( i
carmustine NN i
, , i
etoposide RB i
, , i
cytarabine NN i
, , i
melphalan NN i
) ) i
autograft NN i
. . i

Analysis NN N
was VBD N
on IN N
an DT N
intention NN N
to TO N
treat VB N
basis NN N
. . N

After IN N
the DT N
initial JJ N
three CD N
cycles NNS N
of IN N
CHOP NNP i
19 CD N
% NN N
of IN N
the DT N
whole JJ N
group NN N
were VBD N
in IN N
complete JJ o
response NN o
( ( o
CR NNP o
) ) o
and CC N
53 CD N
% NN N
in IN N
partial JJ o
remission NN o
( ( o
PR NNP o
) ) o
. . o

At IN N
the DT N
end NN N
of IN N
treatment NN N
86 CD N
% NN N
of IN N
patients NNS N
in IN N
the DT N
CHOP NNP i
arm NN N
had VBD N
responded VBN N
with IN N
58 CD N
% NN N
in IN N
CR NNP N
. . N

In IN N
the DT N
high-dose JJ N
therapy NN N
arm NN N
the DT o
overall JJ o
response NN o
rate NN o
was VBD N
83 CD N
% NN N
with IN N
64 CD N
% NN N
in IN N
CR NNP N
( ( N
difference NN N
between IN N
arms NNS N
not RB N
significant JJ N
) ) N
. . N

The DT o
progression-free JJ o
survival NN o
( ( o
PFS NNP o
) ) o
and CC o
overall JJ o
survival NN o
at IN o
5 CD o
years NNS o
for IN N
the DT N
continuing VBG N
CHOP NNP N
arm NN N
were VBD N
38 CD N
% NN N
and CC N
50 CD N
% NN N
respectively RB N
, , N
and CC N
for IN N
the DT N
autograft NN N
arm NN N
were VBD N
44 CD N
% NN N
and CC N
50 CD N
% NN N
( ( N
differences NNS N
not RB N
significant JJ N
) ) N
. . N

Of IN N
the DT N
patients NNS N
who WP N
attained VBD N
CR NNP N
and CC N
subsequently RB N
relapsed VBN o
, , N
there EX N
were VBD N
no DT N
long-term JJ o
survivors NNS o
in IN N
the DT N
autograft NN N
recipients NNS N
compared VBN N
to TO N
46 CD N
% NN N
of IN N
the DT N
continuing VBG N
CHOP NNP i
recipients NNS N
( ( N
P NNP N
= NNP N
0.0008 CD N
) ) N
. . N

In IN N
conclusion NN N
, , N
no DT N
survival JJ N
benefit NN N
was VBD N
demonstrated VBN N
for IN N
an DT N
early JJ N
autograft NN N
in IN N
first JJ N
response NN N
. . N

-DOCSTART- -24282036- O O

Prediction NN N
of IN N
gestational JJ N
diabetes NNS N
mellitus VBP N
in IN N
the DT N
first JJ p
trimester NN p
, , N
comparison NN N
of IN N
fasting VBG N
plasma NN N
glucose NN N
, , N
two-step JJ N
and CC N
one-step JJ N
methods NNS N
: : N
a DT N
prospective JJ N
randomized NN N
controlled VBD N
trial NN N
. . N

Our PRP$ N
aim NN N
was VBD N
to TO N
evaluate VB N
and CC N
compare VB N
the DT N
diagnostic JJ o
performance NN o
of IN N
three CD N
methods NNS N
commonly RB N
used VBD N
for IN N
GDM NNP N
screening NN N
: : N
fasting NN i
plasma NN i
glucose NN i
( ( i
FPG NNP i
) ) i
, , N
two-step JJ N
50 CD N
g NN N
glucose JJ i
challenge NN i
test NN i
( ( i
GCT NNP i
) ) i
, , N
and CC N
75 CD i
g NN i
glucose JJ i
tolerance NN i
test NN i
( ( i
GTT NNP i
) ) i
in IN N
a DT N
randomized JJ N
study NN N
design NN N
to TO N
predict VB N
GDM NNP N
in IN N
the DT N
first JJ p
trimester NN p
and CC N
determine VB N
the DT N
best JJS N
approach NN N
in IN N
predicting VBG N
GDM NNP N
. . N

In IN N
a DT N
non-blind JJ N
, , N
parallel-group JJ N
prospective JJ N
randomized VBN N
controlled VBN N
study NN N
; : N
736 CD p
singleton NN p
pregnant JJ p
women NNS p
underwent JJ N
FPG NNP N
testing NN N
in IN N
the DT N
first JJ N
trimester NN N
and CC N
randomly RB N
assigned VBN N
to TO N
two CD N
groups NNS N
; : N
two-step JJ i
50 CD i
g NN i
GCT NNP i
and CC i
75 CD i
g NN i
GTT NNP i
. . i

GDM NNP N
diagnosis NN N
was VBD N
made VBN N
according VBG N
to TO N
Carpenter-Coustan NNP N
or CC N
ADA NNP N
( ( N
American NNP N
Diabetes NNP N
Association NNP N
) ) N
criteria NNS N
in IN N
two-step JJ N
50 CD N
g NN N
GCT NNP N
and CC N
75 CD N
g NN N
GTT NNP N
groups NNS N
, , N
respectively RB N
. . N

Subsequent JJ N
testing NN N
was VBD N
performed VBN N
by IN N
two-step JJ N
50 CD N
g NN N
GCT NNP N
at IN N
24-28 JJ N
weeks NNS N
for IN N
screen JJ N
negatives NNS N
. . N

After IN p
excluding VBG p
the DT p
women NNS p
who WP p
were VBD p
lost VBN p
to TO p
follow-up NN p
or CC p
withdrawn NN p
as IN p
a DT p
result NN p
of IN p
pregnancy NN p
loss NN p
, , p
486 CD p
pregnant JJ p
women NNS p
were VBD p
recruited VBN p
in IN p
the DT p
study NN p
. . p

The DT N
FPG NNP N
, , N
two-step JJ N
GCT NNP N
, , N
and CC N
one-step JJ N
GTT NNP N
methods NNS N
identified VBD N
GDM NNP o
in IN N
25/486 CD N
( ( N
5.1 CD N
% NN N
) ) N
, , N
15/248 CD N
( ( N
6.0 CD N
% NN N
) ) N
, , N
and CC N
27/238 CD N
( ( N
11.3 CD N
% NN N
) ) N
women NNS p
, , N
respectively RB N
. . N

Area NNP o
under IN o
ROC NNP o
curves NNS o
were VBD N
0.623 CD N
, , N
0.708 CD N
, , N
and CC N
0.792 CD N
, , N
respectively RB N
. . N

Sensitivities NNS o
were VBD N
47.17 CD N
, , N
68.18 CD N
, , N
and CC N
87.1 CD N
% NN N
, , N
respectively RB N
. . N

Specificities NNS o
were VBD N
77.37 CD N
, , N
100 CD N
, , N
and CC N
100 CD N
% NN N
, , N
respectively RB N
. . N

Positive JJ o
predictive JJ o
values NNS o
were VBD N
20.33 CD N
, , N
100 CD N
, , N
and CC N
100 CD N
% NN N
, , N
respectively RB N
. . N

Negative JJ o
predictive JJ o
values NNS o
were VBD N
92.29 CD N
, , N
97 CD N
, , N
and CC N
98.1 CD N
% NN N
, , N
respectively RB N
. . N

Until IN N
superior JJ N
screening VBG N
alternatives NNS N
become VBP N
available JJ N
, , N
the DT N
75 CD N
g NNS N
GTT NNP N
may MD N
be VB N
preferred VBN N
for IN N
GDM NNP N
screening NN N
in IN N
the DT N
first JJ p
trimester NN p
. . p

-DOCSTART- -19864187- O O

Enhancing VBG N
antiepileptic JJ i
drug NN i
adherence NN N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

Suboptimal JJ N
adherence NN N
to TO N
antiepileptic JJ i
drug NN i
( ( i
AED NNP i
) ) i
treatment NN i
is VBZ N
commonplace NN N
, , N
and CC N
increases VBZ N
the DT N
risk NN N
of IN N
status NN N
epilepticus NN N
and CC N
sudden JJ N
unexplained JJ N
death NN N
in IN N
epilepsy NN N
. . N

This DT N
randomized VBD N
controlled JJ N
trial NN N
was VBD N
designed VBN N
to TO N
demonstrate VB N
whether IN N
an DT N
implementation NN i
intention NN i
intervention NN i
involving VBG N
the DT N
completion NN N
of IN N
a DT N
simple JJ N
self-administered JJ i
questionnaire NN i
linking VBG N
the DT N
intention NN i
of IN i
taking VBG i
medication NN i
with IN i
a DT i
particular JJ i
time NN i
, , i
place NN i
, , i
and CC i
other JJ i
activity NN i
can MD N
improve VB N
AED NNP i
treatment NN N
schedule NN N
adherence NN N
. . N

Of IN N
the DT N
81 CD p
patients NNS p
with IN p
epilepsy NN p
who WP N
were VBD N
randomized VBN N
, , N
69 CD p
completed VBD p
a DT p
1-month JJ p
monitoring NN p
period NN p
with IN N
an DT N
objective JJ N
measure NN N
of IN N
tablet NN N
taking NN N
( ( N
electronic JJ N
registration NN N
of IN N
pill NN N
bottle JJ N
openings NNS N
, , N
Medication NNP N
Event NNP N
Monitoring NNP N
System NNP N
[ NNP N
MEMS NNP N
] NNP N
) ) N
. . N

Intervention NN i
participants NNS N
showed VBD N
improved JJ o
adherence RB o
relative JJ o
to TO o
controls VB o
on IN N
all DT N
three CD N
outcomes NNS N
: : N
doses NNS o
taken VBN o
in IN o
total JJ o
( ( N
93.4 CD N
% NN N
vs. FW N
79.1 CD N
% NN N
) ) N
, , N
days NNS N
on IN N
which WDT N
correct VBP o
dose NN o
was VBD o
taken VBN o
( ( N
88.7 CD N
% NN N
vs. FW N
65.3 CD N
% NN N
) ) N
, , N
and CC N
doses VBZ o
taken VBN o
on IN o
schedule NN o
( ( N
78.8 CD N
% NN N
vs. FW N
55.3 CD N
% NN N
) ) N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
implementation NN N
intention NN i
intervention NN i
may MD N
be VB N
an DT N
easy-to-administer JJ N
and CC N
effective JJ N
means NNS N
of IN N
promoting VBG N
AED NNP i
adherence NN N
. . N

-DOCSTART- -792738- O O

[ JJ N
Report NNP N
of IN N
a DT N
controlled JJ N
clinical JJ N
trial NN N
of IN N
a DT N
new JJ N
synthetic JJ N
drug NN N
, , N
parsalmide NN i
, , N
in IN N
rheumatic JJ p
arthropathies NNS p
( ( p
inflammatory NN p
and CC p
degenerative NN p
) ) p
] NN p
. . N

The DT N
anti-inflammatory JJ N
, , N
analgesic JJ N
and CC N
tranquillizing JJ N
activity NN N
of IN N
a DT N
synthetic JJ N
compound NN N
called VBD N
parsalmide NN i
was VBD N
investigated VBN N
in IN N
patients NNS p
suffering VBG p
from IN p
inflammatory NN p
and CC p
degenerative JJ p
rheumatic JJ p
arthropathies NNS p
. . p

The DT N
study NN N
was VBD N
carried VBN N
out RP N
in IN N
30 CD p
subjects NNS p
using VBG p
the DT p
controlled JJ p
experiment NN p
technique NN p
according VBG p
to TO p
the DT p
between IN p
patient NN p
pattern NN p
, , p
attributing VBG p
parsalmide NN i
and CC i
indomethacin NN i
at IN p
random NN p
to TO p
two CD p
groups NNS p
. . p

Both DT N
preparations NNS N
were VBD N
found VBN N
to TO N
possess VB N
good JJ N
anti-inflammatory JJ o
and CC o
analgesic JJ o
action NN o
, , N
comparable JJ N
clinically RB N
and CC N
statistically RB N
. . N

Tolerance NN o
was VBD N
very RB N
good JJ N
, , N
particularly RB N
at IN N
gastroenteric JJ N
level NN N
( ( N
no DT N
side NN N
and/or RB N
undesired JJ N
effects NNS N
were VBD N
observed VBN N
) ) N
and CC N
at IN N
the DT N
level NN N
of IN N
haemopoietic JJ N
, , N
renal JJ N
and CC N
hepatic JJ N
function NN N
. . N

-DOCSTART- -937075- O O

Maximal NNP o
bioavailability NN o
of IN p
digoxin NN i
from IN p
tablets NNS p
and CC p
oral JJ p
solution NN p
in IN p
steady JJ p
state NN p
. . p

Comparison NNP N
has VBZ N
been VBN N
made VBN N
between IN N
the DT N
absorption NN o
of IN o
digoxin NN o
from IN N
Lanoxin NNP i
tablets NNS N
and CC N
the DT N
absorption NN N
of IN N
international JJ N
chemical NN N
reference NN N
substance NN N
digoxin NN o
from IN i
an DT i
oral JJ i
solution NN i
. . i

Plasma NNP o
levels NNS o
, , o
areas NNS o
under IN o
24-hour JJ o
plasma NN o
concentration NN o
curves NNS o
and CC o
urinary JJ o
excretion NN o
were VBD N
similar JJ N
by IN N
both DT N
formulations NNS N
in IN N
steady JJ N
state NN N
. . N

78 CD N
% NN N
of IN N
the DT N
digoxin NN o
administered VBD N
was VBD N
absorbed VBN N
from IN N
the DT N
tablets NNS N
and CC N
76 CD N
% NN N
from IN N
the DT N
solution NN N
. . N

Rapid JJ N
dissolution NN N
in IN N
the DT N
intestinal JJ N
fluids NNS N
accounts NNS N
for IN N
the DT N
high JJ N
digoxin NN o
bioavailability NN o
of IN N
the DT N
tablets NNS N
. . N

-DOCSTART- -21534846- O O

Predictors NNS N
of IN N
smoking VBG p
cessation NN p
among IN p
cancer NN p
patients NNS p
enrolled VBN p
in IN p
a DT p
smoking NN i
cessation NN i
program NN p
. . p

UNLABELLED NNP N
Many JJ N
cancer NN p
patients NNS p
continue VBP N
to TO N
smoke VB N
postdiagnosis NN N
, , N
which WDT N
is VBZ N
associated VBN N
with IN N
poorer JJR N
clinical JJ N
outcomes NNS N
. . N

Identifying VBG N
prospective JJ N
predictors NNS N
of IN N
smoking VBG N
cessation NN N
among IN N
patients NNS N
currently RB N
receiving VBG N
smoking VBG i
cessation NN i
treatment NN N
can MD N
help VB N
guide VB N
the DT N
development NN N
and CC N
implementation NN N
of IN N
smoking VBG i
cessation NN i
programs NNS i
with IN N
this DT N
population NN N
. . N

MATERIAL NNP N
AND CC N
METHODS NNP N
Data NNP p
from IN p
246 CD p
cancer NN p
patients NNS p
participating VBG p
in IN p
a DT p
randomized JJ p
placebo-controlled JJ i
smoking NN p
cessation NN p
clinical JJ p
trial NN p
were VBD N
used VBN N
to TO N
examine VB N
baseline JJ N
predictors NNS N
of IN N
end-of-treatment JJ N
and CC N
six-month JJ N
postbaseline NN N
smoking NN i
cessation NN i
outcomes RB N
. . N

Baseline NNP N
demographic JJ N
, , N
smoking-related JJ N
, , N
disease-related JJ N
, , N
and CC N
psychological JJ N
variables NNS N
were VBD N
examined VBN N
as IN N
predictors NNS N
of IN N
biochemically-confirmed JJ N
point-prevalence NN N
abstinence NN N
. . N

RESULTS NNP N
Multivariate NNP o
analysis NN N
indicated VBD N
that IN N
, , N
for IN N
end-of-treatment JJ o
abstinence NN o
, , N
patients NNS N
were VBD N
significantly RB N
more RBR N
likely JJ N
to TO N
have VB N
quit NN o
smoking VBG o
if IN N
they PRP N
were VBD N
older JJR N
( ( N
OR NNP N
= VBZ N
1.06 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.03-1.10 JJ N
, , N
p JJ N
< NNP N
0.05 CD N
) ) N
and CC N
were VBD N
diagnosed VBN N
with IN N
a DT N
non-tobacco JJ N
related JJ N
cancer NN N
( ( N
OR NNP N
= VBZ N
2.54 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.24-5.20 JJ N
, , N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Likewise NNP N
, , N
for IN N
six-month JJ o
abstinence NN o
, , N
patients NNS N
were VBD N
significantly RB N
more RBR N
likely JJ N
to TO N
have VB N
quit NN o
smoking VBG o
if IN N
they PRP N
were VBD N
older JJR N
( ( N
OR NNP N
= VBZ N
1.04 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.01-1.08 JJ N
, , N
p JJ N
< NNP N
0.05 CD N
) ) N
and CC N
were VBD N
significantly RB N
less RBR N
likely JJ N
to TO N
have VB N
quit NN N
smoking VBG N
if IN N
they PRP N
were VBD N
female JJ N
( ( N
OR NNP N
= VBZ N
0.47 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
0.22-0.97 JJ N
, , N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Patients NNS p
with IN p
tobacco-related JJ p
cancers NNS p
and CC p
female JJ p
patients NNS p
reported VBD N
significantly RB N
higher JJR N
levels NNS o
of IN o
depression NN o
symptoms NNS o
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
, , N
which WDT N
proved VBD N
predictive NN o
of IN o
smoking VBG o
relapse NN o
. . o

CONCLUSIONS NNP N
Patient NNP N
age NN N
, , N
gender NN N
, , N
and CC N
cancer-type NN N
may MD N
be VB N
important JJ N
factors NNS N
to TO N
consider VB N
when WRB N
developing VBG N
and CC N
implementing VBG N
smoking VBG i
cessation NN i
interventions NNS i
for IN N
cancer NN p
patients NNS p
. . p

-DOCSTART- -21629200- O O

A DT N
prospective JJ N
double-blind NN N
, , N
randomized VBD N
clinical JJ N
trial NN N
of IN N
levocarnitine NN i
to TO N
treat VB N
autism NN p
spectrum NN p
disorders NNS p
. . p

BACKGROUND NNP N
L-carnitine NNP i
was VBD N
proposed VBN N
as IN N
a DT N
potential JJ N
treatment NN N
for IN N
patients NNS p
diagnosed VBN p
with IN p
an DT p
autism NN p
spectrum NN p
disorder NN p
to TO N
improve VB N
mitochondrial JJ N
dysfunction NN N
, , N
but CC N
no DT N
prior JJ N
randomized VBN N
controlled VBN N
trials NNS N
have VBP N
been VBN N
conducted VBN N
. . N

MATERIAL/METHODS NNP N
Thirty NNP p
subjects NNS p
diagnosed VBD p
with IN p
an DT p
ASD NNP p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
a DT N
standardized JJ i
regimen NN i
( ( i
50 CD i
mg RB i
L-carnitine/kg NNP i
bodyweight/day NN i
) ) i
of IN i
liquid JJ i
L-carnitine NNP i
( ( i
n=19 NN i
) ) i
or CC i
placebo NN i
( ( i
n=11 JJ i
) ) i
for IN i
3-months JJ i
. . i

Measures NNS N
included VBD N
changes NNS N
in IN N
professionally RB N
completed VBN N
Childhood NNP o
Autism NNP o
Rating NNP o
Scale NNP o
( ( o
CARS NNP o
) ) o
, , o
hand NN o
muscle NN o
testing NN o
, , o
and CC o
modified VBD o
clinical JJ o
global JJ o
impression NN o
( ( o
CGI NNP o
) ) o
forms VBZ o
; : o
parent NN o
completed VBD o
Autism NNP o
Treatment NNP o
Evaluation NNP o
Checklist NNP o
( ( o
ATEC NNP o
) ) o
, , o
treatment NN o
adherence NN o
measurement NN o
( ( o
TAM NNP o
) ) o
, , o
frequency NN o
and CC o
intensity NN o
of IN o
side JJ o
effect NN o
rating NN o
( ( o
FISER NNP o
) ) o
/global VBD o
rating NN o
of IN o
side JJ o
effect NN o
burden NN o
( ( o
GRSEB NNP o
) ) o
/patient VBD o
report NN o
of IN o
incidence NN o
of IN o
side NN o
effects NNS o
( ( o
PRISE NNP o
) ) o
forms NNS o
; : o
and CC o
lab VB o
testing VBG o
. . o

RESULTS NNP N
Significant JJ N
improvements NNS N
were VBD N
observed VBN N
in IN N
CARS NNP o
( ( N
-2.03 NNP N
, , N
95 CD N
% NN N
CI=-3.7 NNP N
to TO N
-0.31 VB N
) ) N
, , N
CGI NNP o
( ( N
-0.69 NNP N
, , N
95 CD N
% NN N
CI=-1.1 NNP N
to TO N
-0.06 VB N
) ) N
, , N
and CC N
ATEC NNP o
scores NNS o
. . o

Significant JJ N
correlations NNS N
between IN N
changes NNS N
in IN N
serum JJ N
free-carnitine JJ N
levels NNS N
and CC N
positive JJ N
clinical JJ N
changes NNS N
were VBD N
observed VBN N
for IN N
hand NN o
muscle NN o
strength NN o
( ( N
R2=0.23 NNP N
, , N
P=0.046 NNP N
) ) N
, , N
cognitive JJ o
scores NNS o
( ( N
R2=0.27 NNP N
, , N
P=0.019 NNP N
) ) N
, , N
and CC N
CARS NNP o
scores NNS o
( ( N
R2=0.20 NNP N
, , N
P=0.047 NNP N
) ) N
. . N

Study NNP N
subjects NNS N
were VBD N
protocol-compliant JJ N
( ( N
average JJ N
adherence NN N
was VBD N
> JJ N
85 CD N
% NN N
) ) N
and CC N
generally RB N
well-tolerated VBD N
the DT N
L-carnitine JJ i
therapy NN i
given VBN N
. . N

CONCLUSIONS NNP N
L-carnitine JJ i
therapy NN i
( ( N
50 CD N
mg/kilogram-bodyweight/day NN N
) ) N
administered VBD N
for IN N
3-months JJ N
significantly RB N
improved VBN N
several JJ N
clinical JJ N
measurements NNS N
of IN N
ASD NNP N
severity NN N
, , N
but CC N
subsequent JJ N
studies NNS N
are VBP N
recommended VBN N
. . N

-DOCSTART- -16855426- O O

Rotigotine NNP i
transdermal JJ i
patch NN i
enables NNS N
rapid JJ N
titration NN N
to TO N
effective JJ N
doses NNS N
in IN N
advanced-stage JJ p
idiopathic JJ p
Parkinson NNP p
disease NN p
: : p
subanalysis NN N
of IN N
a DT N
parallel JJ N
group NN N
, , N
open-label JJ N
, , N
dose-escalation NN N
study NN N
. . N

OBJECTIVE NNP N
Rotigotine NNP i
( ( i
Neupro NNP i
) ) i
is VBZ N
formulated VBN N
as IN N
a DT N
transdermal JJ N
delivery NN N
system NN N
designed VBN N
to TO N
provide VB N
a DT N
selective JJ N
, , N
non-ergot JJ N
D3/D2/D1 NNP N
agonist NN N
to TO N
the DT N
systemic JJ N
blood NN N
flow NN N
over IN N
a DT N
24-hour JJ N
period NN N
. . N

In IN N
clinical JJ N
trials NNS N
, , N
patches NNS i
were VBD i
applied VBN i
once RB i
daily JJ i
and CC i
uptitrated JJ i
to TO i
the DT i
individual JJ i
effective JJ i
dose NN i
in IN i
increments NNS i
of IN i
2 CD i
mg/24 NNS i
h RB i
every DT i
week NN i
. . i

The DT N
aim NN N
of IN N
this DT N
analysis NN N
was VBD N
to TO N
determine VB N
the DT N
safety NN o
of IN N
a DT N
more RBR N
rapid JJ N
titration NN N
of IN N
rotigotine NN i
by IN N
assessing VBG N
the DT N
tolerability NN o
of IN N
escalating VBG N
transdermal JJ N
doses NNS N
of IN N
rotigotine NN i
given VBN N
in IN N
2 CD N
different JJ N
titration NN N
schemes NNS N
. . N

METHODS NNP N
We PRP N
analyzed VBD N
the DT N
safety NN o
of IN N
rotigotine NN i
in IN N
2 CD p
groups NNS p
of IN p
patients NNS p
with IN p
advanced JJ p
stage NN p
Parkinson NNP p
Disease NNP p
. . p

The DT N
starting VBG N
dose NN N
of IN N
4 CD N
mg/24 NN N
h NN N
was VBD N
increased VBN N
every DT N
week NN N
by IN N
2 CD N
mg/24 NNS N
h NN N
in IN N
the DT N
slow-titration NN N
group NN N
and CC N
4 CD N
mg/24 NN N
h NN N
in IN N
the DT N
fast-titration NN N
group NN N
. . N

The DT N
primary JJ N
focus NN N
of IN N
this DT N
subanalysis NN N
was VBD N
the DT N
separate JJ N
tolerability NN o
of IN o
rotigotine NN o
in IN N
each DT N
randomized JJ N
treatment NN N
arm NN N
, , N
during IN N
the DT N
dose-escalation JJ N
period NN N
. . N

However RB N
, , N
the DT N
2 CD N
titration NN N
schemes NNS N
were VBD N
also RB N
compared VBN N
with IN N
each DT N
other JJ N
. . N

RESULTS VB N
The DT N
dose NN N
of IN N
first JJ N
reported VBD N
nausea JJ o
and/or NN o
vomiting NN o
was VBD N
8 CD N
mg/24 NN N
h NN N
for IN N
the DT N
fast-titration NN N
group NN N
and CC N
4 CD N
mg/ NN N
24 CD N
h NN N
for IN N
the DT N
slow-titration NN N
group NN N
. . N

There EX N
were VBD N
no DT N
remarkable JJ N
differences NNS N
concerning VBG N
the DT N
side-effect JJ o
profile NN o
between IN N
the DT N
2 CD N
different JJ N
titration NN N
schemes NNS N
. . N

CONCLUSIONS VB N
The DT N
fast-titration JJ N
regimen NNS N
had VBD N
a DT N
similar JJ N
adverse JJ o
event NN o
profile NN o
to TO N
slower JJR N
titration NN N
, , N
and CC N
allowed VBD N
rotigotine NN i
to TO N
be VB N
introduced VBN N
quickly RB N
. . N

This DT N
subanalysis NN N
suggests VBZ N
that IN N
rotigotine NN i
may MD N
be VB N
uptitrated VBN N
more RBR N
rapidly RB N
. . N

-DOCSTART- -6365881- O O

Netilmicin NNP i
versus NN i
tobramycin NN i
in IN N
multi-centre JJ p
studies NNS p
. . p

In IN N
two CD N
prospective JJ N
, , N
randomized JJ N
studies NNS N
conducted VBN N
in IN N
West NNP p
Germany NNP p
and CC p
involving VBG p
80 CD p
patients NNS p
, , N
netilmicin-ticarcillin NN i
was VBD N
compared VBN N
to TO N
tobramycin-ticarcillin NN i
in IN N
the DT N
treatment NN N
of IN N
serious JJ p
systemic JJ p
infections NNS p
. . p

Both DT N
regimens NNS N
were VBD N
essentially RB N
identical JJ N
with IN N
respect NN N
to TO N
the DT N
clinical JJ N
and CC N
bacteriological JJ N
results NNS N
they PRP N
produced VBD N
. . N

The DT N
netilmicin JJ N
group NN N
developed VBD N
significantly RB N
less JJR N
nephrotoxicity NN o
than IN N
the DT N
tobramycin NN N
group NN N
( ( N
0 CD N
% NN N
versus IN N
15 CD N
% NN N
, , N
P NNP N
= NNP N
0.03 CD N
) ) N
. . N

Ototoxicity NNP o
also RB N
occurred VBD N
less RBR N
frequently RB N
in IN N
the DT N
netilmicin-treated JJ N
patients NNS N
( ( N
3 CD N
% NN N
versus IN N
10 CD N
% NN N
, , N
P NNP N
= NNP N
0.4 CD N
) ) N
. . N

In IN N
a DT N
large JJ p
collaborative NN p
study NN p
involving VBG p
15 CD p
centres NNS p
, , p
254 CD p
patients NNS p
were VBD p
enrolled VBN p
. . p

Clinical JJ o
and CC o
bacteriological JJ o
responses NNS o
were VBD N
excellent JJ N
, , N
with IN N
netilmicin JJ N
and CC N
tobramycin JJ N
equally RB N
effective JJ o
, , N
but CC N
the DT N
incidences NNS N
of IN N
nephrotoxicity NN o
and CC o
ototoxicity NN o
were VBD N
lower JJR N
in IN N
patients NNS N
treated VBN N
with IN N
netilmicin NN N
than IN N
those DT N
receiving VBG N
tobramycin NN N
. . N

-DOCSTART- -9931796- O O

[ JJ i
Plasma NNP i
separation NN i
combined VBN N
with IN N
CVVHF NNP i
in IN N
septic JJ p
and CC p
SIRS JJ p
patients NNS p
] VBP p
. . N

In IN N
a DT N
prospective JJ N
non-randomized JJ N
trial NN N
, , N
59 CD p
patients NNS p
with IN p
sepsis NN p
( ( p
n JJ p
= NNP p
43 CD p
) ) p
and CC p
SIRS NNP p
( ( p
n JJ p
= NNP p
16 CD p
) ) p
were VBD N
treated VBN N
on IN N
a DT N
surgical JJ N
intensive JJ N
care NN N
unit NN N
. . N

In IN N
22 CD p
patients NNS p
plasmapheresis NN i
in IN i
combination NN i
with IN i
continuous JJ i
venovenous JJ i
hemofiltration NN i
( ( i
CVVHF NNP i
) ) i
was VBD N
administered VBN N
. . N

Lethality NNP o
was VBD o
56 CD o
% NN o
in IN o
the DT o
sepsis NN o
group NN o
; : o
in IN o
the DT o
therapy NN o
group NN o
lethality NN o
was VBD o
significantly RB o
lower JJR o
in IN o
patients NNS o
with IN o
plasmapheresis NN o
, , o
even RB o
though IN o
in IN o
this DT o
population NN o
the DT o
organic JJ o
failure NN o
rate NN o
was VBD o
higher JJR o
. . o

Finally RB N
the DT o
dependency NN o
of IN o
lethality NN o
and CC o
age NN o
was VBD o
similar JJ o
in IN o
both DT o
groups NNS o
. . o

Lethality NNP o
at IN o
22 CD o
% NN o
in IN o
the DT o
plasmapheresis NN o
group NN o
with IN o
double JJ o
organ JJ o
failure NN o
was VBD o
significantly RB o
lower JJR o
( ( o
P NNP o
> NNP o
0.01 CD o
) ) o
than IN o
in IN o
controls NNS o
. . o

Reduction NN o
of IN o
lethality NN o
seemed VBD o
to TO o
be VB o
as RB o
high JJ o
as IN o
18 CD o
% NN o
in IN o
patients NNS o
with IN o
sepsis NN o
, , o
while IN o
patients NNS o
with IN o
SIRS NNP o
did VBD o
not RB o
profit NN o
from IN o
the DT o
additional JJ o
therapy NN o
. . o

A DT N
prospective JJ N
randomized VBN N
trial NN N
in IN N
sepsis NN N
and CC N
double JJ N
organic JJ N
failure NN N
should MD N
be VB N
projected VBN N
. . N

-DOCSTART- -10735838- O O

A DT N
comparison NN N
of IN N
local JJ i
anaesthetics NNS i
for IN N
venepuncture NN i
. . i

AIM NNP N
To TO N
compare VB N
the DT N
effectiveness NN N
of IN N
EMLA NNP i
cream NN i
and CC N
Ametop NNP i
gel NN i
in IN N
providing VBG N
analgesia NN N
for IN N
venous JJ p
cannulation NN p
. . p

METHODS NNP N
Single NNP N
blind NN N
study NN N
in IN N
120 CD p
children NNS p
. . p

RESULTS NNP N
Both NNP N
anaesthetic JJ N
agents NNS N
produced VBN N
adequate JJ o
analgesia NN o
. . o

However RB N
, , N
Ametop NNP i
gel NN i
was VBD N
more RBR N
effective JJ N
, , N
with IN N
a DT N
statistically RB N
significant JJ N
difference NN N
in IN N
the DT N
pain NN o
scores NNS o
of IN N
the DT N
two CD N
groups NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

-DOCSTART- -15963401- O O

Inhibition NN N
of IN N
awake JJ N
sympathetic JJ N
nerve NN N
activity NN N
of IN N
heart NN p
failure NN p
patients NNS p
with IN p
obstructive JJ p
sleep NN p
apnea NN p
by IN N
nocturnal JJ i
continuous JJ i
positive JJ i
airway NN i
pressure NN i
. . i

OBJECTIVES CC N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
determine VB N
whether IN N
reductions NNS N
in IN N
morning NN o
systolic JJ o
blood NN o
pressure NN o
( ( o
BP NNP o
) ) o
elicited VBN N
by IN N
treatment NN N
of IN N
moderate JJ N
to TO N
severe VB N
obstructive JJ o
sleep JJ o
apnea NN o
( ( N
OSA NNP N
) ) N
in IN N
heart NN p
failure NN p
( ( p
HF NNP p
) ) p
patients NNS p
are VBP N
associated VBN N
with IN N
a DT N
reduction NN N
in IN N
sympathetic JJ o
vasoconstrictor NN o
tone NN o
. . o

BACKGROUND NNP N
Daytime NNP o
muscle NN o
sympathetic JJ o
nerve NN o
activity NN o
( ( o
MSNA NNP o
) ) o
is VBZ N
elevated VBN N
in IN N
HF NNP p
patients NNS p
with IN p
coexisting VBG p
OSA NNP p
. . p

In IN N
our PRP$ N
recent JJ N
randomized VBN N
trial NN N
in IN N
HF NNP N
, , N
abolition NN N
of IN N
OSA NNP N
by IN N
continuous JJ i
positive JJ i
airway NN i
pressure NN i
( ( i
CPAP NNP i
) ) i
increased VBD N
left JJ o
ventricular JJ o
ejection NN o
fraction NN o
( ( o
LVEF NNP o
) ) o
and CC o
lowered VBD N
morning NN o
systolic JJ o
BP NNP o
. . o

METHODS NNP N
Muscle NNP o
sympathetic JJ o
nerve NN o
activity NN o
, , o
BP NNP o
, , o
and CC o
heart NN o
rate NN o
( ( o
HR NNP o
) ) o
of IN i
medically RB i
treated VBN i
HF NNP i
patients NNS i
( ( i
EF NNP i
< RB i
45 CD i
% NN i
) ) i
and CC i
OSA NNP i
( ( o
apnea-hypopnea JJ o
index NN o
> VBD i
or CC i
=20/h CD i
of IN i
sleep NN i
) ) i
were VBD i
recorded VBN i
on IN i
the DT i
morning NN i
after IN i
overnight JJ i
polysomnography NN i
, , i
and CC i
again RB i
one CD i
month NN i
after IN i
patients NNS i
were VBD i
randomly RB i
allocated VBN i
nocturnal JJ i
CPAP NNP i
treatment NN i
or CC i
no DT i
CPAP NNP i
( ( i
control NN i
) ) i
. . N

RESULTS NNP N
In IN p
nine CD p
control NN p
patients NNS p
, , N
there EX N
were VBD N
no DT N
significant JJ N
changes NNS N
in IN N
the DT N
severity NN N
of IN N
OSA NNP o
, , o
MSNA NNP o
, , o
systolic JJ o
BP NNP o
, , o
or CC o
HR NNP o
. . o

In IN N
contrast NN N
, , N
in IN N
the DT N
8 CD p
CPAP-treated JJ i
patients NNS p
, , N
OSA NNP o
was VBD N
attenuated VBN N
, , N
and CC N
there EX N
were VBD N
significant JJ N
reductions NNS N
in IN N
daytime JJ o
MSNA NNP o
( ( N
from IN N
58 CD N
+/- JJ N
4 CD N
bursts/min NN N
to TO N
48 CD N
+/- JJ N
5 CD N
bursts/min NN N
; : N
84 CD N
+/- JJ N
4 CD N
bursts/100 JJ N
heart NN N
beats VBZ N
to TO N
72 CD N
+/- JJ N
5 CD N
bursts/100 JJ N
heart NN N
beats VBZ N
; : N
p NN N
< VBZ N
0.001 CD N
and CC N
p VB N
= JJ N
0.003 CD N
, , N
respectively RB N
) ) N
, , N
systolic JJ o
BP NNP o
( ( N
from IN N
135 CD N
+/- JJ N
5 CD N
mm NN N
Hg NNP N
to TO N
120 CD N
+/- JJ N
6 CD N
mm NN N
Hg NNP N
, , N
p NN N
= NNP N
0.03 CD N
) ) N
, , N
and CC N
HR NNP o
( ( N
from IN N
69 CD N
+/- JJ N
2 CD N
min NN N
( ( N
-1 NN N
) ) N
to TO N
66 CD N
+/- JJ N
2 CD N
min NN N
( ( N
-1 NNP N
) ) N
; : N
p CC N
= VB N
0.013 CD N
) ) N
. . N

CONCLUSIONS NNP N
Treatment NNP p
of IN p
coexisting VBG p
OSA NNP p
by IN p
CPAP NNP i
in IN p
HF NNP p
patients NNS p
lowers NNS N
daytime JJ o
MSNA NNP o
, , o
systolic JJ o
BP NNP o
, , o
and CC o
HR NNP o
. . o

Inhibition NNP N
of IN N
increased JJ N
central JJ N
sympathetic JJ N
vasoconstrictor NN N
outflow NN N
is VBZ N
one CD N
mechanism NN N
by IN N
which WDT N
nocturnal JJ i
CPAP NNP i
reduces NNS N
awake VBP N
BP NNP o
in IN N
HF NNP p
patients NNS p
with IN p
moderate JJ p
to TO p
severe VB p
OSA NNP p
. . p

-DOCSTART- -19814586- O O

Efficacy NN N
and CC N
long-term JJ N
tolerability NN N
of IN N
sublingual JJ i
fentanyl NN i
orally RB i
disintegrating VBG i
tablet NN i
in IN N
the DT N
treatment NN N
of IN N
breakthrough NN N
cancer NN N
pain NN N
. . N

BACKGROUND NNP N
AND NNP N
OBJECTIVES NNP N
Breakthrough NNP N
cancer NN N
pain NN N
( ( N
BTcP NNP N
) ) N
represents VBZ N
an DT N
important JJ N
clinical JJ N
challenge NN N
in IN N
the DT N
care NN N
of IN N
patients NNS p
with IN p
cancer NN p
. . p

This DT N
trial NN N
evaluated VBD N
the DT N
efficacy NN N
and CC N
long-term JJ N
tolerability NN N
of IN N
a DT N
sublingual JJ N
formulation NN N
of IN N
the DT N
fast-acting JJ i
opioid NN i
fentanyl NN i
, , N
for IN N
the DT N
treatment NN N
of IN N
BTcP NNP N
in IN N
opioid-tolerant JJ p
patients NNS p
with IN p
cancer NN p
. . p

RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
This DT N
was VBD N
a DT N
randomized JJ N
, , N
placebo-controlled JJ N
, , N
multi-center JJ N
, , N
phase JJ N
III NNP N
trial NN N
, , N
conducted VBN p
in IN p
opioid-tolerant JJ p
male NN p
and CC p
female JJ p
patients NNS p
( ( p
aged VBN p
> NN p
or CC p
=17 CD p
years NNS p
) ) p
with IN p
BTcP NNP p
. . p

The DT N
study NN N
was VBD N
conducted VBN N
at IN N
36 CD N
centers NNS N
across IN N
the DT N
USA NNP N
. . N

The DT N
study NN N
comprised VBD N
a DT N
2-week JJ N
open-label JJ N
titration NN N
phase NN N
, , N
followed VBN N
by IN N
a DT N
double-blind JJ N
efficacy NN N
phase NN N
, , N
during IN N
which WDT N
patients NNS N
received VBD N
sublingual JJ i
fentanyl NN i
citrate NN i
orally RB i
disintegrating VBG i
tablet NN i
( ( i
sublingual JJ i
fentanyl NN i
ODT NNP i
) ) i
or CC i
placebo NN i
, , N
in IN N
a DT N
random JJ N
order NN N
. . N

The DT N
primary JJ N
efficacy NN N
endpoint NN N
was VBD N
the DT N
sum NN o
of IN o
pain NN o
intensity NN o
difference NN o
( ( o
SPID NNP o
) ) o
over IN o
30 CD o
min JJ o
post-administration NN o
. . o

Secondary JJ N
efficacy NN N
endpoints NNS N
included VBD N
pain NN o
intensity NN o
difference NN o
( ( o
PID NNP o
) ) o
and CC o
pain NN o
relief NN o
( ( o
PR NNP o
) ) o
throughout IN N
the DT N
60-min JJ N
post-dose JJ N
assessment NN N
period NN N
. . N

Following VBG N
efficacy NN N
evaluation NN N
, , N
patients NNS N
entered VBD N
a DT N
long-term JJ o
safety NN o
phase NN o
of IN o
up IN o
to TO o
12 CD o
months NNS o
. . o

Adverse JJ o
events NNS o
were VBD N
recorded VBN N
throughout IN N
the DT N
study NN N
. . N

[ VB N
CLINICAL NNP N
TRIAL NNP N
REGISTRATION NNP N
NCT00262678 NNP N
] NNP N
RESULTS NNP N
A NNP N
total NN N
of IN N
131 CD p
patients NNS p
entered VBD p
the DT p
titration NN p
phase NN p
, , p
of IN p
whom WP p
61 CD p
were VBD p
included VBN p
in IN p
the DT p
primary JJ p
efficacy NN p
analysis NN p
. . p

Sublingual JJ N
fentanyl NN N
ODT NNP N
provided VBD N
significant JJ N
improvements NNS N
in IN N
SPID NNP o
relative VBP N
to TO N
placebo VB N
at IN N
30 CD N
min NN N
( ( N
49.5 CD N
vs. FW N
36.6 CD N
, , N
p NN N
= NNP N
0.0004 CD N
) ) N
and CC N
60 CD N
min NNS N
post-administration NN N
( ( N
143.0 CD N
vs. FW N
104.5 CD N
, , N
p NN N
= NNP N
0.0002 CD N
) ) N
. . N

Furthermore UH N
, , N
sublingual JJ N
fentanyl NN N
ODT NNP N
provided VBD N
significant JJ N
improvements NNS N
in IN N
PID NNP o
and CC o
PR NNP o
compared VBN N
to TO N
placebo VB N
, , N
from IN N
10 CD N
min NNS N
post-dose JJ N
( ( N
p JJ N
= NN N
0.0055 CD N
and CC N
p VB N
= $ N
0.049 CD N
for IN N
PID NNP N
and CC N
PR NNP N
, , N
respectively RB N
) ) N
. . N

Patient JJ N
recruitment NN N
was VBD N
stopped VBN N
early RB N
, , N
due JJ N
to TO N
positive JJ N
interim JJ N
analysis NN N
results NNS N
( ( N
significant JJ N
at IN N
prespecified JJ N
level NN N
, , N
p JJ N
< NN N
or CC N
= VB N
0.0414 CD N
) ) N
. . N

Overall JJ N
, , N
sublingual JJ N
fentanyl NN N
ODT NNP N
was VBD N
well-tolerated JJ o
both DT o
systemically RB o
and CC o
sublingually RB o
, , N
with IN N
41 CD N
patients NNS N
experiencing VBG N
> NN N
or CC N
=1 NN N
study NN N
drug-related JJ o
adverse JJ o
event NN o
( ( N
AE NNP N
) ) N
. . N

The DT N
most RBS N
common JJ N
AEs NNP N
included VBD N
nausea NN o
( ( N
12.2 CD N
% NN N
) ) N
, , N
vomiting VBG o
( ( N
5.3 CD N
% NN N
) ) N
and CC N
somnolence NN o
( ( N
4.6 CD N
% NN N
) ) N
. . N

One CD N
serious JJ o
AE NNP o
( ( o
mild JJ o
affect VBP o
lability NN o
) ) o
was VBD N
considered VBN N
possibly RB N
related VBN N
to TO N
study VB N
medication NN N
. . N

The DT N
observed JJ N
pattern NN N
of IN N
AEs NNP N
was VBD N
consistent JJ N
with IN N
that DT N
previously RB N
observed VBN N
with IN N
fentanyl NN N
. . N

CONCLUSIONS NNP N
Sublingual NNP N
fentanyl NN i
ODT NNP i
was VBD N
efficacious JJ N
and CC N
well-tolerated JJ N
for IN N
the DT N
treatment NN N
of IN N
BTcP NNP N
in IN N
opioid-tolerant JJ p
patients NNS p
with IN p
cancer NN p
. . p

Sublingual JJ N
fentanyl NN N
ODT NNP N
provided VBD N
significant JJ N
improvements NNS N
in IN N
pain NN N
intensity NN N
compared VBN N
to TO N
placebo VB N
, , N
from IN N
10 CD N
min JJ N
post-administration NN N
and CC N
throughout IN N
the DT N
60-min JJ N
post-dose JJ N
assessment NN N
period NN N
. . N

Sublingual JJ N
fentanyl NN N
ODT NNP N
was VBD N
well RB N
tolerated VBN N
over IN N
12 CD N
months NNS N
of IN N
treatment NN N
. . N

-DOCSTART- -17631392- O O

A DT N
randomized JJ N
placebo-controlled JJ i
trial NN N
comparing VBG N
the DT N
efficacy NN N
of IN N
etoricoxib $ i
30 CD N
mg NN N
and CC N
ibuprofen NN i
2400 CD N
mg NN N
for IN N
the DT N
treatment NN N
of IN N
patients NNS p
with IN p
osteoarthritis NN p
. . p

OBJECTIVE IN N
We PRP N
compared VBN N
the DT N
efficacy NN N
of IN N
etoricoxib $ i
30 CD N
mg NN N
to TO N
placebo VB i
and CC N
ibuprofen VB i
2400 CD N
mg NN N
for IN N
the DT N
treatment NN N
of IN N
osteoarthritis NN p
( ( p
OA NNP p
) ) p
of IN p
the DT p
hip NN p
and CC p
knee NN p
. . p

DESIGN NN N
In IN N
this DT N
12-week JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo- JJ i
and CC N
active-comparator-controlled JJ N
trial NN N
, , N
548 CD p
patients NNS p
( ( p
median JJ p
age NN p
63 CD p
years NNS p
) ) p
with IN p
OA NNP p
of IN p
the DT p
hip NN p
or CC p
knee NN p
were VBD p
randomized VBN p
to TO N
receive VB N
placebo NN i
, , i
etoricoxib VBZ i
30 CD N
mg NN N
q.d. NN N
, , N
or CC N
ibuprofen VB i
800 CD N
mg NN N
t.i.d NN N
. . N

Demonstration NN N
of IN N
etoricoxib NN i
's POS i
efficacy NN N
vs NN N
placebo NN i
and CC N
comparison NN N
of IN N
its PRP$ N
efficacy NN N
to TO N
ibuprofen VB i
were VBD N
assessed VBN N
using VBG N
three CD N
co-primary JJ N
endpoints NNS N
: : N
Western JJ o
Ontario NNP o
and CC o
McMaster NNP o
's POS o
University NNP o
Osteoarthritis NNP o
Index NNP o
( ( o
WOMAC NNP o
) ) o
Pain NNP o
Subscale NNP o
( ( o
WOMAC-PS NNP o
) ) o
; : o
WOMAC NNP o
Physical NNP o
Function NNP o
Subscale NNP o
( ( o
WOMAC-PFS NNP o
) ) o
; : o
and CC o
Patient NNP o
Global NNP o
Assessment NNP o
of IN o
Disease NNP o
Status NNP o
( ( o
PGADS NNP o
) ) o
. . o

Each DT N
primary JJ N
endpoint NN N
utilizes VBZ N
a DT N
0-100 JJ N
mm NN N
visual JJ N
analog NN N
scale NN N
. . N

To TO N
demonstrate VB N
comparable JJ N
efficacy NN N
of IN N
etoricoxib JJ i
vs NN N
ibuprofen NN i
, , N
the DT N
95 CD N
% NN N
confidence NN N
intervals NNS N
( ( N
CIs NNP N
) ) N
for IN N
the DT N
difference NN N
in IN N
the DT N
least JJS o
squares NNS o
( ( o
LS NNP o
) ) o
mean VBP o
change NN o
over IN N
12 CD N
weeks NNS N
for IN N
all DT N
three CD N
co-primary JJ N
endpoints NNS N
had VBD N
to TO N
fall VB N
within IN N
+/-10 JJ N
mm NN N
. . N

Safety NNP o
and CC o
tolerability NN o
data NNS o
were VBD N
collected VBN N
throughout IN N
the DT N
study NN N
. . N

RESULTS NNP N
Mean NNP o
baseline NN o
values NNS o
for IN N
the DT N
three CD N
co-primary JJ N
endpoints NNS N
ranged VBD N
from IN N
62.52 CD N
to TO N
70.14 CD N
mm NN N
. . N

Both DT N
etoricoxib JJ i
and CC N
ibuprofen JJ i
demonstrated VBN N
superior JJ N
( ( N
P NNP N
< NNP N
or CC N
=0.002 NNP N
) ) N
efficacy NN o
for IN N
all DT N
primary JJ N
endpoints NNS N
. . N

The DT N
LS NNP N
mean NN N
( ( N
mm NN N
) ) N
changes NNS N
( ( N
95 CD N
% NN N
CI NNP N
) ) N
over IN N
12 CD N
weeks NNS N
for IN N
etoricoxib NN i
and CC N
ibuprofen NN i
, , N
respectively RB N
, , N
compared VBN N
to TO N
placebo VB i
were VBD N
given VBN N
as IN N
follows VBZ N
: : N
WOMAC-PS JJ o
: : o
-11.66 NN N
( ( N
-16.31 UH N
, , N
-7.01 NNP N
) ) N
and CC N
-7.62 NNP N
( ( N
-12.30 NNP N
, , N
-2.94 NNP N
) ) N
; : N
WOMAC-PFS JJ o
: : o
-10.15 NN N
( ( N
-14.74 UH N
, , N
-5.57 NNP N
) ) N
and CC N
-7.23 NNP N
( ( N
-11.85 NNP N
, , N
-2.61 NNP N
) ) N
; : N
PGADS NNP o
: : o
-11.65 NN N
( ( N
-16.81 UH N
, , N
-6.50 NNP N
) ) N
and CC N
-8.11 NNP N
( ( N
-13.30 NNP N
, , N
-2.92 NNP N
) ) N
. . N

The DT N
efficacy NN o
of IN N
etoricoxib $ i
30 CD N
mg NN N
was VBD N
comparable JJ N
to TO N
ibuprofen VB i
2400 CD N
mg. NN N
All DT N
treatments NNS N
were VBD N
similarly RB N
well RB N
tolerated VBN o
. . o

CONCLUSION NNP N
Treatment NNP N
with IN N
etoricoxib JJ i
30 CD N
mg NN N
q.d NN N
. . N

provides VBZ N
superior JJ N
efficacy NN o
vs NN N
placebo NN i
and CC N
comparable JJ N
clinical JJ N
efficacy NN N
vs NN N
ibuprofen NN i
2400 CD N
mg NN N
( ( N
800 CD N
mg NN N
t.i.d NN N
. . N

) ) N
for IN N
the DT N
treatment NN N
of IN N
OA NNP p
of IN p
the DT p
hip NN p
and CC p
knee NN p
. . p

-DOCSTART- -22740508- O O

Pentraxin-3 NN i
in IN N
chronic JJ p
heart NN p
failure NN p
: : p
the DT N
CORONA NNP N
and CC N
GISSI-HF NNP N
trials NNS N
. . N

AIMS NNP N
Pentraxin-3 NNP i
( ( i
PTX3 NNP i
) ) i
is VBZ N
a DT N
component NN N
of IN N
the DT N
humoral JJ N
arm NN N
of IN N
innate NN N
immunity NN N
which WDT N
can MD N
regulate VB N
inflammatory JJ N
processes NNS N
. . N

Since IN N
the DT N
role NN N
of IN N
inflammation NN N
in IN N
the DT N
progression NN N
of IN N
chronic JJ N
heart NN N
failure NN N
( ( N
HF NNP N
) ) N
is VBZ N
debated VBN N
, , N
we PRP N
investigated VBD N
the DT N
prognostic JJ N
value NN N
of IN N
PTX3 NNP i
and CC N
the DT N
effect NN N
of IN N
a DT N
statin NN i
in IN N
two CD p
large JJ p
populations NNS p
of IN p
patients NNS p
with IN p
HF NNP p
. . p

METHODS NNP N
AND CC N
RESULTS NNP N
Plasma NNP N
levels NNS N
of IN N
PTX3 NNP i
were VBD N
measured VBN N
at IN N
randomization NN N
and CC N
after IN N
3 CD N
months NNS N
in IN N
1457 CD p
patients NNS p
enrolled VBN p
in IN p
the DT p
Controlled NNP p
Rosuvastatin NNP p
Multinational NNP p
Trial NNP p
in IN p
HF NNP p
( ( p
CORONA NNP p
) ) p
and CC p
1233 CD p
patients NNS p
enrolled VBN p
in IN p
the DT p
GISSI-Heart NNP p
Failure NNP p
trial NN p
( ( p
GISSI-HF NNP p
) ) p
. . p

The DT N
relationships NNS N
between IN N
baseline NN i
PTX3 NNP i
levels NNS i
or CC N
their PRP$ N
changes NNS N
over IN N
time NN N
and CC N
mortality NN N
were VBD N
evaluated VBN N
with IN N
multivariable JJ N
Cox NNP N
proportional JJ N
hazard NN N
models NNS N
including VBG N
clinical JJ N
factors NNS N
, , N
high JJ N
sensitivity NN N
C-reactive JJ N
protein NN N
( ( N
hsCRP NN N
) ) N
, , N
and CC N
N-terminal JJ N
pro JJ N
brain NN N
natriuretic JJ N
peptide NN N
( ( N
NT-proBNP NNP N
) ) N
. . N

PTX3 NNP o
concentration NN o
[ NN N
median JJ N
( ( N
Q1-Q3 NNP N
) ) N
= VBZ N
5.34 CD N
( ( N
3.55-7.64 CD N
) ) N
ng/mL NN N
, , N
n RB N
= JJ N
2690 CD N
] NN N
was VBD N
higher RBR N
in IN N
females NNS N
, , N
in IN N
older JJR N
patients NNS N
, , N
and CC N
those DT N
with IN N
lower JJR N
body NN N
mass NN N
index NN N
. . N

Baseline NNP i
elevated VBD i
PTX3 NNP i
was VBD N
associated VBN N
with IN N
a DT N
higher JJR N
risk NN o
of IN o
all-cause JJ o
mortality NN o
[ $ N
759 CD N
events NNS N
, , N
hazard NN N
ratio NN N
( ( N
HR NNP N
) ) N
for IN N
1 CD N
SD NNP N
increase NN N
1.20 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
1.12-1.30 CD N
, , N
P NNP N
< VBZ N
0.0001 CD N
] NN N
, , N
cardiovascular JJ o
mortality NN o
( ( N
587 CD N
events NNS N
, , N
HR NNP N
1.27 CD N
, , N
95 CD N
% NN N
CI NNP N
1.17-1.38 CD N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
or CC N
hospitalization NN o
for IN o
worsening VBG o
HF NNP o
( ( N
720 CD N
events NNS N
, , N
HR NNP N
1.21 CD N
, , N
95 CD N
% NN N
CI NNP N
1.12-1.30 CD N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
and CC N
marginally RB N
improved VBN N
discrimination NN N
. . N

Three-month JJ N
changes NNS N
in IN N
PTX3 NNP N
were VBD N
associated VBN N
with IN N
fatal JJ o
events NNS o
after IN N
adjustment NN N
for IN N
hsCRP NN N
or CC N
NT-proBNP NNP N
. . N

Rosuvastatin NNP N
lowered VBD N
hsCRP JJ o
levels NNS o
but CC N
significantly RB N
raised VBD N
PTX3 NNP o
. . o

CONCLUSION NNP N
In IN N
two CD N
independent JJ N
clinical JJ N
trials NNS N
that WDT N
enrolled VBD N
patients NNS p
with IN p
chronic JJ p
HF NNP p
, , N
PTX3 NNP i
was VBD N
consistently RB N
associated VBN N
with IN N
outcomes NNS N
. . N

The DT N
opposite JJ N
effects NNS N
of IN N
a DT N
statin NN i
on IN N
hsCRP NN N
and CC N
PTX3 NNP i
call VB N
for IN N
further JJ N
investigation NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
NCT00336336 NNP N
( ( N
GISSI-HF NNP N
) ) N
, , N
NCT00206310 NNP N
( ( N
CORONA NNP N
) ) N
. . N

-DOCSTART- -2228570- O O

Enhancing VBG N
the DT N
self-esteem NN o
of IN N
inpatient JJ p
alcoholics NNS p
. . p

This DT N
study NN N
examined VBD N
the DT N
effect NN N
of IN N
pairing VBG N
inpatient JJ p
alcoholics NNS p
with IN p
nursing NN i
home NN i
residents NNS i
( ( i
NHRs NNP i
) ) i
on IN N
the DT N
alcoholics NNS o
' POS o
self-esteem NN o
. . o

In IN N
this DT N
PALS NNP N
program NN N
, , N
the DT N
alcoholic JJ N
inpatients NNS N
assumed VBD N
a DT N
helping-companion NN N
relationship NN N
with IN N
the DT N
NHRs NNP N
for IN N
2 CD N
hr NNS N
per IN N
day NN N
during IN N
their PRP$ N
last JJ N
2 CD N
weeks NNS N
of IN N
treatment NN N
. . N

Fifty NNP p
alcoholic JJ p
inpatients NNS p
were VBD p
randomly RB p
assigned VBN p
to TO p
the DT p
PALS NNP i
program NN i
( ( p
n JJ p
= NNP p
25 CD p
) ) p
or CC p
to TO p
the DT p
library NN i
for IN i
free JJ i
reading NN i
time NN i
( ( p
n JJ p
= NNP p
25 CD p
) ) p
. . p

The DT N
Tennessee NNP o
Self-Concept NNP o
Scale NNP o
( ( o
TSCS NNP o
) ) o
was VBD N
administered VBN N
to TO N
all DT N
subjects NNS N
in IN N
both DT N
groups NNS N
before IN N
and CC N
after IN N
the DT N
interventions NNS N
. . N

Of IN N
the DT N
nine CD N
TSCS NNP o
scales NNS o
, , N
the DT N
improvement NN N
on IN N
the DT N
Moral-Ethical JJ o
scale NN o
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
PALS NNP N
group NN N
. . N

Because IN N
the DT N
alcoholic JJ N
inpatients NNS N
in IN N
the DT N
PALS NNP N
group NN N
engaged VBD N
in IN N
altruistic JJ o
( ( o
moral JJ o
) ) o
behavior NN o
, , N
this DT N
study NN N
provides VBZ N
a DT N
logical JJ N
link NN N
between IN N
the DT N
intervention NN N
and CC N
the DT N
outcome NN N
, , N
which WDT N
has VBZ N
been VBN N
a DT N
prevalent JJ N
weakness NN N
in IN N
previous JJ N
studies NNS N
of IN N
self-esteem NN N
in IN N
alcoholics NNS N
. . N

-DOCSTART- -22133872- O O

Object JJ o
interest NN o
in IN N
autism NN p
spectrum NN p
disorder NN p
: : p
a DT N
treatment NN N
comparison NN N
. . N

A DT N
randomized JJ N
control NN N
trial NN N
comparing VBG N
two CD N
social JJ i
communication NN i
treatments NNS i
for IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
examined VBD N
the DT N
effect NN N
of IN N
treatment NN N
on IN N
object JJ N
interest NN N
. . N

Thirty-two JJ p
children NNS p
, , p
18-60 JJ p
months NNS p
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
Picture NNP i
Exchange NNP i
Communication NNP i
System NNP i
( ( i
PECS NNP i
) ) i
or CC i
Responsive JJ i
Education NN i
and CC i
Prelinguistic NNP i
Milieu NNP i
Teaching NNP i
( ( i
RPMT NNP i
) ) i
condition NN i
. . i

Assessment NN N
of IN N
object JJ o
interest NN o
was VBD N
conducted VBN N
in IN N
an DT N
unstructured JJ N
play NN N
session NN N
with IN N
different JJ N
toys NNS N
, , N
activities NNS N
, , N
adult NN N
, , N
and CC N
location NN N
than IN N
experienced VBN N
in IN N
treatment NN N
. . N

Results NNS N
indicated VBD N
children NNS N
in IN N
the DT N
RPMT NNP i
condition NN N
showed VBD N
greater JJR N
increases NNS N
in IN N
object JJ o
interest NN o
as IN N
compared VBN N
to TO N
children NNS N
in IN N
the DT N
PECS NNP i
condition NN N
. . N

Because IN N
child JJ N
characteristics NNS N
such JJ N
as IN N
interest NN N
in IN N
objects NNS N
may MD N
influence VB N
response NN N
to TO N
interventions NNS N
using VBG N
object JJ N
play NN N
as IN N
contexts NN N
for IN N
treatment NN N
, , N
it PRP N
is VBZ N
important JJ N
to TO N
improve VB N
our PRP$ N
understanding NN N
of IN N
whether IN N
intervention NN N
can MD N
affect VB N
object JJ N
interest NN N
. . N

-DOCSTART- -23632800- O O

The DT N
use NN N
of IN N
transvaginal JJ i
synthetic JJ i
mesh NN i
for IN N
anterior JJ p
vaginal JJ p
wall NN p
prolapse NN p
repair NN N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

INTRODUCTION NNP N
AND CC N
HYPOTHESIS NNP N
The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
transvaginal JJ i
trocar-guided JJ i
polypropylene NN i
mesh JJ i
insertion NN i
with IN i
traditional JJ i
colporrhaphy NN i
for IN N
treatment NN N
of IN N
anterior JJ p
vaginal JJ p
wall NN p
prolapse NN p
. . p

METHODS NNP N
This DT N
is VBZ N
a DT N
randomized JJ N
controlled JJ N
trial NN N
in IN N
which WDT N
women NNS p
with IN p
advanced JJ p
anterior JJ p
vaginal NN p
wall NN p
prolapse NN p
, , p
at IN p
least JJS p
stage NN p
II NNP p
with IN p
Ba NNP p
? . p
+1 NN p
cm NN p
according VBG p
to TO p
the DT p
Pelvic NNP p
Organ NNP p
Prolapse NNP p
Quantification NNP p
( ( p
POP-Q NNP p
) ) p
classification NN p
, , p
were VBD N
randomly RB N
assigned VBN N
to TO N
have VB N
either DT i
anterior JJ i
colporrhaphy NN i
( ( i
n JJ N
= NNP N
39 CD N
) ) N
or CC N
repair NN i
using VBG i
trocar-guided JJ i
transvaginal JJ i
mesh NN i
( ( i
n JJ N
= NNP N
40 CD N
) ) N
. . N

The DT N
primary JJ N
outcome NN N
was VBD o
objective JJ o
cure NN o
rate NN o
of IN o
the DT o
anterior JJ o
compartment NN o
( ( o
point NN o
Ba NNP o
) ) o
assessed VBD o
at IN N
the DT N
12-month JJ N
follow-up JJ N
visit NN N
, , N
with IN N
stages NNS N
0 CD N
and CC N
I PRP N
defined VBD N
as IN N
anatomical JJ N
success NN N
. . N

Secondary JJ N
outcomes NNS N
included VBD o
quantification NN o
of IN o
other JJ o
vaginal JJ o
compartments NNS o
( ( o
POP-Q NNP o
points NNS o
) ) o
, , o
comparison NN o
of IN o
quality NN o
of IN o
life NN o
by IN o
the DT o
prolapse NN o
quality NN o
of IN o
life NN o
( ( o
P-QOL NNP o
) ) o
questionnaire NN o
, , o
and CC o
complication NN o
rate NN o
between IN o
the DT N
groups NNS N
after IN N
1 CD N
year NN N
. . N

Study NNP N
power NN N
was VBD N
fixed VBN N
as IN N
80 CD N
% NN N
with IN N
5 CD N
% NN N
cutoff NN N
point NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
for IN N
statistical JJ N
significance NN N
. . N

RESULTS VB N
The DT N
groups NNS N
were VBD N
similar JJ N
regarding VBG N
demographic JJ N
and CC N
clinical JJ N
preoperative NN N
parameters NNS o
. . o

Anatomical JJ o
success NN o
rates NNS o
for IN o
colporrhaphy NN o
and CC o
repair NN o
with IN o
mesh JJ i
placement NN i
groups NNS i
were VBD N
56.4 CD N
vs JJ N
82.5 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval JJ N
0.068-0.54 NN N
) ) N
, , N
respectively RB N
, , N
and CC N
the DT N
difference NN N
between IN N
the DT N
groups NNS N
was VBD N
statistically RB N
significant JJ N
( ( N
p JJ N
= NNP N
0.018 CD N
) ) N
. . N

Similar JJ o
total JJ o
complication NN o
rates NNS o
were VBD o
observed VBN N
in IN N
both DT N
groups NNS N
, , N
with IN N
tape NN N
exposure NN N
observed VBN N
in IN N
5 CD N
% NN N
of IN N
the DT N
patients NNS N
. . N

There EX N
was VBD N
a DT N
significant JJ N
improvement NN N
in IN N
all DT o
P-QOL NNP o
domains NNS o
as IN o
a DT N
result NN N
of IN N
both DT N
procedures NNS N
( ( N
p VB N
< RB N
0.001 CD N
) ) N
, , N
but CC N
they PRP N
were VBD N
not RB N
distinct JJ N
between IN N
groups NNS N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP i
Trocar-guided JJ i
transvaginal JJ i
synthetic JJ i
mesh NN i
for IN i
advanced JJ N
anterior JJ N
POP NNP N
repair NN N
is VBZ N
associated VBN N
with IN N
a DT N
higher JJR o
anatomical JJ o
success NN o
rate NN o
for IN o
the DT N
anterior JJ N
compartment NN N
compared VBN N
with IN N
traditional JJ i
colporrhaphy NN o
. . o

Quality NN o
of IN o
life NN o
equally RB o
improved VBN o
after IN N
both DT N
techniques NNS N
. . N

However RB N
, , N
the DT N
trial NN N
failed VBD N
to TO N
detect VB N
differences NNS N
in IN N
P-QOL NNP o
scores NNS o
and CC o
complication NN o
rates NNS o
between IN o
the DT N
groups NNS N
. . N

-DOCSTART- -22499291- O O

Visit-to-visit NNP N
blood NN o
pressure NN o
variability NN o
in IN N
the DT N
European NNP N
Lacidipine NNP N
Study NNP N
on IN N
Atherosclerosis NNP N
: : N
methodological JJ N
aspects NNS N
and CC N
effects NNS N
of IN N
antihypertensive JJ i
treatment NN i
. . i

BACKGROUND NNP N
Recent NNP N
studies NNS N
have VBP N
reported VBN N
that IN N
in IN N
patients NNS p
under IN p
antihypertensive JJ p
treatment NN p
visit-to-visit NN p
( ( p
or CC p
long-term JJ p
) ) p
variability NN o
of IN o
clinic JJ o
BP NNP o
within IN N
a DT N
given VBN N
patient NN N
has VBZ N
an DT N
independent JJ N
prognostic JJ N
significance NN N
. . N

Partly RB N
based VBN N
on IN N
between-patient JJ N
dispersion NN N
of IN N
BP NNP N
values NNS N
during IN N
treatment NN N
( ( N
interindividual JJ N
variability NN N
) ) N
it PRP N
has VBZ N
also RB N
been VBN N
reported VBN N
that IN N
long-term JJ o
clinic JJ o
BP NNP o
variability NN o
is VBZ N
greater JJR N
for IN N
?-blocker JJR i
than IN N
for IN i
calcium NN i
antagonist NN i
and CC N
other JJ N
types NNS N
of IN N
treatment NN N
. . N

GOALS NNP N
To TO N
measure VB o
visit-to-visit JJ o
intraindividual JJ o
variations NNS o
of IN N
both DT N
clinic JJ N
and CC N
24-h JJ N
mean NN N
BP NNP N
in IN N
the DT p
hypertensive JJ p
patients NNS p
of IN p
the DT p
European NNP p
Lacidipine NNP p
Study NNP p
on IN p
Atherosclerosis NNP p
( ( p
ELSA NNP p
) ) p
trial NN p
treated VBD p
for IN p
4 CD p
years NNS p
with IN p
either DT i
atenolol NN i
or CC i
lacidipine NN i
, , i
and CC N
to TO N
check VB N
whether IN N
interindividual JJ N
clinic NN N
and CC N
24-h JJ o
BP NNP o
variabilities NNS o
during IN N
treatment NN N
can MD N
really RB N
be VB N
considered VBN N
a DT N
surrogate NN N
of IN N
intraindividual JJ N
variabilities NNS N
in IN N
exploring VBG N
differences NNS N
between IN i
?-blocker NN i
and CC i
calcium NN i
antagonist NN i
treatments NNS i
. . i

METHODS NNP o
Long-term JJ o
intraindividual JJ o
BP NNP o
variability NN o
was VBD o
defined VBN N
as IN N
the DT o
coefficient NN o
of IN o
variation NN o
of IN o
the DT o
average JJ o
systolic JJ o
or CC o
diastolic JJ o
values NNS o
of IN o
clinic JJ o
and CC o
24-h JJ o
BP NNP o
measured VBD o
at IN N
each DT N
visit NN N
throughout IN N
the DT N
treatment NN N
period NN p
. . p

Patients NNS p
in IN p
whom WP p
at IN p
least JJS p
seven CD p
clinic JJ p
( ( p
6-month JJ p
intervals NNS p
) ) p
or CC p
at IN p
least JJS p
three CD p
( ( p
yearly JJ p
intervals NNS p
) ) p
24-h JJ p
values NNS p
were VBD p
available JJ p
from IN p
the DT p
end NN p
of IN p
the DT p
drug NN p
titration NN p
phase NN p
to TO p
the DT p
end NN p
of IN p
the DT p
study NN p
were VBD p
considered VBN p
. . p

RESULTS JJ o
Visit-to-visit JJ o
24-h JJ o
SBP/DBP NNP o
variabilities NNS o
were VBD o
20-25 CD N
% NN N
smaller JJR N
than IN N
, , N
and CC N
loosely RB N
correlated VBN N
with IN o
clinic JJ o
BP NNP o
variability NN o
( ( o
r NN N
( ( N
2 CD N
) ) N
< FW N
0.022 CD N
) ) N
. . N

There EX N
was VBD N
also RB N
a DT N
very RB N
limited JJ N
relationship NN N
( ( N
r NN N
( ( N
2 CD N
) ) N
< FW o
0.026 CD o
) ) o
between IN o
visit-to-visit NN o
and CC o
within IN o
24-h JJ o
ambulatory NN o
BP NNP o
variabilities NNS o
, , o
the DT o
latter JJ o
being VBG N
two CD N
to TO N
three CD N
times NNS N
greater JJR N
than IN N
the DT N
former JJ N
. . o

Visit-to-visit JJ o
intraindividual JJ o
clinic NN o
SBP NNP o
variability NN o
was VBD o
only RB o
slightly RB N
lower JJR N
on IN N
calcium NN N
antagonist NN N
than IN N
on IN N
?-blocker JJ N
treatment NN N
but CC N
little JJ N
or CC N
no DT N
between-treatment JJ N
difference NN N
was VBD N
found VBN N
for IN o
visit-to-visit NN o
clinic NN o
DBP NNP o
and CC o
ambulatory JJ o
SBP/DBP NNP o
particularly RB o
in IN N
patients NNS N
under IN N
monotherapy NN N
throughout IN N
the DT N
study NN N
. . N

Interindividual NNP o
BP NNP o
variability NN o
was VBD o
markedly RB o
greater JJR N
than IN N
the DT N
intra-individiual JJ N
one CD N
of IN N
which WDT N
it PRP N
did VBD N
not RB N
precisely RB N
reflect VB N
the DT N
treatment-induced JJ N
changes NNS N
. . N

CONCLUSION NN N
In IN p
mild-to-moderate JJ p
hypertensive JJ o
patients NNS o
, , o
visit-to-visit JJ o
BP NNP o
variability NN o
does VBZ o
not RB o
differ VB o
substantially RB i
between IN i
?-blocker NN i
and CC i
calcium NN i
antagonist NN i
treatment NN i
. . i

Major JJ N
discrepancies NNS N
exist VBP N
between IN N
visit-to-visit NN N
BP NNP N
variability NN N
as IN N
quantified VBN N
by IN N
24-h JJ N
vs. FW N
clinic JJ N
BP NNP N
, , N
making VBG N
investigation NN N
of IN N
which WDT N
of IN N
these DT N
indices NNS N
is VBZ N
clinically RB N
more RBR N
relevant JJ N
important JJ N
. . N

Interindividual JJ o
BP NNP o
variability NN o
during IN N
treatment NN N
shows NNS N
marked VBD N
quantitative JJ N
differences NNS N
with IN N
intraindividual JJ N
BP NNP N
variability NN N
questioning VBG N
whether IN N
its PRP$ N
use NN N
can MD N
accurately RB N
reflect VB N
individual JJ N
BP NNP N
variations NNS N
from IN N
one CD N
visit NN N
to TO N
another DT N
. . N

-DOCSTART- -25348544- O O

A DT N
5-year JJ N
randomized JJ N
trial NN N
to TO N
compare VB N
1 CD N
or CC N
2 CD N
implants NNS i
for IN N
implant JJ p
overdentures NNS p
. . p

The DT N
hypothesis NN N
of IN N
this DT N
5-y JJ N
randomized JJ N
clinical JJ N
trial NN N
was VBD N
that IN N
there EX N
would MD N
be VB N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
satisfaction NN o
of IN N
edentulous JJ p
participants NNS p
with IN p
removable JJ p
complete JJ p
overdentures NNS p
attached VBN p
to TO p
1 CD p
or CC p
2 CD p
mandibular JJ i
implants NNS i
. . i

Secondary JJ N
aims NNS N
were VBD N
to TO N
test VB N
changes NNS N
in IN N
satisfaction NN o
between IN N
and CC N
within IN N
the DT N
groups NNS N
from IN N
baseline NN N
to TO N
5 CD N
y NNS N
and CC N
differences NNS N
between IN N
the DT N
groups NNS N
in IN N
implant JJ o
survival NN o
and CC N
prosthodontic JJ N
maintenance NN N
over IN N
5 CD N
y NNS N
. . N

Each DT N
of IN N
the DT N
86 CD p
participants NNS p
( ( p
mean JJ p
age NN p
, , p
67 CD p
y NN p
) ) p
was VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
either RB N
1 CD i
implant NN i
in IN i
the DT i
midline NN i
( ( N
group NN N
1 CD N
) ) N
or CC N
2 CD i
implants NNS i
in IN i
the DT i
canine NN i
areas NNS i
( ( N
group NN N
2 CD N
) ) N
attached VBN N
to TO N
a DT N
mandibular JJ N
overdenture NN N
opposing VBG N
a DT N
maxillary JJ N
complete JJ N
denture NN N
. . N

Satisfaction NN o
was VBD o
self-assessed VBN o
by IN N
participants NNS N
on IN N
a DT N
visual JJ o
analog NN o
scale NN o
at IN N
baseline NN N
prior RB N
to TO N
implants NNS N
, , N
as RB N
well RB N
as IN N
at IN N
2 CD N
mo NN N
and CC N
1 CD N
, , N
3 CD N
, , N
and CC N
5 CD N
y NN N
with IN N
implant JJ N
overdentures NNS N
, , N
whereas JJ N
implant NN o
survival NN o
and CC o
prosthodontic JJ o
maintenance NN o
were VBD N
assessed VBN o
by IN o
clinical JJ o
examination NN o
. . o

After IN N
5 CD N
y NN N
, , N
29 CD N
participants NNS N
in IN N
group NN N
1 CD N
and CC N
33 CD N
in IN N
group NN N
2 CD N
were VBD N
available JJ N
, , N
with IN N
most JJS N
dropouts NNS N
due JJ N
to TO N
death NN o
. . o

Satisfaction NN o
with IN N
the DT N
implant JJ N
denture NN N
after IN N
5 CD N
y NN N
was VBD N
significantly RB N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
higher JJR N
than IN N
at IN N
baseline NN N
in IN N
both DT N
groups NNS N
and CC N
remained VBD N
with IN N
no DT N
significant JJ N
difference NN N
( ( N
P NNP N
= NNP N
0.32 CD N
) ) N
between IN N
the DT N
groups NNS N
. . N

No DT N
implants NNS N
failed VBD o
in IN N
group NN N
1 CD N
but CC N
5 CD N
failed VBD N
before IN N
loading VBG N
in IN N
4 CD N
participants NNS N
in IN N
group NN N
2 CD N
. . N

Most JJS N
participants NNS N
required VBN N
maintenance NN o
or CC N
occasionally RB N
denture JJ o
replacement NN o
, , N
and CC N
although IN N
differences NNS N
between IN N
the DT N
groups NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
, , N
group NN N
1 CD N
experienced VBD N
almost RB N
twice RB N
as IN N
many JJ N
fractured JJ o
dentures NNS o
usually RB N
adjacent VBP N
to TO N
the DT N
implant JJ N
attachment NN N
. . N

We PRP N
conclude VBP N
that IN N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
after IN N
5 CD N
y NN N
in IN N
satisfaction NN o
or CC o
survival NN o
of IN o
implants NNS o
with IN N
mandibular JJ N
overdentures NNS N
retained VBN N
by IN N
1 CD N
implant NN N
or CC N
2 CD N
implants NNS N
. . N

Additional NNP N
research NN N
is VBZ N
required VBN N
to TO N
confirm VB N
long-term JJ N
treatment NN N
effectiveness NN o
of IN N
single-implant JJ N
dentures NNS N
and CC N
the DT N
implications NNS N
of IN N
prosthetic JJ N
maintenance NN N
with IN N
implant JJ N
overdentures NNS N
( ( N
ClinicalTrials.gov NNP N
: : N
NCT02117856 NN N
) ) N
. . N

-DOCSTART- -19035420- O O

Efficacy NN p
of IN p
wrist NN i
working VBG i
splints NNS i
in IN p
patients NNS p
with IN p
rheumatoid JJ p
arthritis NN p
: : p
a DT N
randomized NN N
controlled VBN N
study NN N
. . N

OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
efficacy NN N
of IN N
wrist NN i
working VBG i
splints NNS i
after IN N
a DT N
period NN N
of IN N
splinting VBG N
in IN N
patients NNS N
with IN N
rheumatoid JJ N
arthritis NN N
( ( N
RA NNP N
) ) N
. . N

METHODS NNP N
We PRP N
performed VBD N
a DT N
4-week JJ N
randomized NN N
controlled VBN p
trial NN p
among IN p
33 CD p
RA NNP p
patients NNS p
with IN p
wrist JJ p
arthritis NN p
. . p

Patients NNS p
were VBD p
randomly RB p
allocated VBN p
to TO p
the DT p
splinting VBG i
group NN p
( ( p
n JJ p
= NNP p
17 CD p
) ) p
or CC p
the DT p
control NN i
group NN i
( ( p
n JJ p
= NNP p
16 CD p
) ) p
. . p

Patients NNS p
in IN p
the DT p
splinting NN p
group NN p
received VBD N
a DT N
prefabricated JJ i
wrist NN i
working VBG i
splint NN i
and CC i
were VBD i
instructed VBN i
to TO i
use VB i
this DT i
splint NN i
as RB i
much RB i
as IN i
possible JJ i
during IN i
the DT i
day NN i
. . i

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
average JJ o
wrist JJ o
pain NN o
during IN o
the DT o
past JJ o
week NN o
, , N
measured VBN N
using VBG N
a DT N
visual JJ N
analog NN N
scale NN N
( ( N
VAS NNP N
) ) N
. . N

Secondary JJ N
outcome NN N
measures NNS N
were VBD N
grip JJ o
strength NN o
and CC o
functional JJ o
ability NN o
. . o

The DT N
latter NN N
was VBD N
measured VBN N
using VBG N
the DT N
Disabilities NNPS N
of IN N
the DT N
Arm NNP N
, , N
Shoulder NNP N
, , N
and CC N
Hand NNP N
questionnaire NN N
and CC N
the DT N
short JJ N
version NN N
of IN N
the DT N
Sequential NNP N
Occupational NNP N
Dexterity NNP N
Assessment NNP N
. . N

Measurements NNS N
were VBD N
performed VBN N
at IN N
baseline NN N
and CC N
after IN N
4 CD N
weeks NNS N
. . N

Performance NN N
tests NNS N
were VBD N
performed VBN N
without IN N
splint NN N
. . N

Differences NNS N
in IN N
change NN N
scores NNS N
between IN N
the DT N
splinting NN N
and CC N
the DT N
control NN N
group NN N
were VBD N
analyzed VBN N
using VBG N
analysis NN N
of IN N
covariance NN N
. . N

To TO N
indicate VB N
the DT N
magnitude NN N
of IN N
the DT N
treatment NN N
effects NNS N
, , N
effect NN N
sizes NNS N
were VBD N
calculated VBN N
. . N

RESULTS VB N
A DT N
large JJ N
and CC N
highly RB N
significant JJ N
treatment NN N
effect NN N
on IN N
wrist NN o
pain NN o
was VBD N
found VBN N
. . N

VAS NNP o
pain NN o
scores NNS o
decreased VBN N
by IN N
32 CD N
% NN N
in IN N
the DT N
splinting NN N
group NN N
and CC N
increased VBN N
by IN N
17 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
. . N

Small NNP N
and CC N
nonsignificant JJ N
treatment NN N
effects NNS N
were VBD N
found VBN N
with IN N
regard NN N
to TO N
nonsplinted VBN o
grip NN o
strength NN o
and CC o
functional JJ o
ability NN o
. . o

CONCLUSION NNP N
Prefabricated NNP N
wrist NN i
working VBG i
splints NNS i
are VBP N
highly RB N
effective JJ N
in IN N
reducing VBG N
wrist NN N
pain NN N
after IN N
4 CD N
weeks NNS N
of IN N
splint NN N
wearing NN N
in IN N
RA NNP p
patients NNS p
with IN p
wrist JJ p
arthritis NN p
. . p

-DOCSTART- -4353587- O O

A DT N
study NN N
of IN N
postoperative JJ i
cytostatic JJ i
medication NN i
in IN p
patients NNS p
with IN p
operable JJ p
carcinoma NN p
of IN p
the DT p
lung NN p
. . p

-DOCSTART- -17849093- O O

[ JJ i
Stent NNP i
and CC i
surgery NN i
for IN N
symptomatic JJ p
carotid NN p
stenosis NN p
. . p

SPACE NNP N
study NN N
results NNS N
] NNP N
. . N

The DT N
SPACE NNP N
trial NN N
compared VBN N
risk NN N
and CC N
effectiveness NN N
of IN N
stent-supported JJ i
angioplasty NN i
( ( i
CAS NNP i
) ) i
vs NN i
carotid NN i
endarterectomy NN i
( ( i
CEA NNP i
) ) i
using VBG N
a DT N
noninferiority NN N
design NN N
in IN N
patients NNS p
with IN p
symptomatic JJ p
stenoses NNS p
. . p

Intention-to-treat JJ N
analysis NN N
of IN N
the DT N
entire JJ N
study NN N
population NN N
of IN N
1,214 CD p
patients NNS p
showed VBD N
that IN N
primary JJ N
endpoint NN N
events NNS N
( ( N
ipsilateral JJ N
stroke NN N
or CC N
death NN N
between IN N
randomisation NN N
and CC N
day NN N
30 CD N
) ) N
occurred VBD N
in IN N
6.92 CD N
% NN N
of IN N
the DT N
CAS NNP i
group NN N
and CC N
6.45 CD N
% NN N
of IN N
the DT N
CEA NNP i
group NN N
. . N

The DT N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
of IN N
the DT N
absolute NN o
risk NN o
difference NN o
ranged VBD N
from IN N
-1.94 CD N
% NN N
to TO N
+2.87 CD N
% NN N
, , N
therefore RB N
the DT N
noninferiority NN N
was VBD N
not RB N
proven RB N
. . N

The DT N
same JJ N
was VBD N
true JJ N
for IN N
the DT N
analysis NN N
of IN N
protocols NNS N
. . N

No DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
treatment NN N
methods NNS N
were VBD N
found VBN N
in IN N
primary JJ N
or CC N
any DT N
of IN N
the DT N
secondary JJ N
endpoints NNS N
. . N

There EX N
were VBD N
also RB N
no DT N
differences NNS N
in IN N
short-term JJ o
prevention NN o
. . o

The DT N
endpoint JJ N
'ipsilateral JJ o
ischemic JJ o
stroke NN o
or CC o
vascular JJ o
death NN o
between IN o
randomisation NN o
and CC o
6 CD o
months NNS o
' POS o
occurred VBD N
in IN N
7.4 CD N
% NN N
of IN N
the DT N
CAS NNP i
and CC N
6.5 CD N
% NN N
of IN N
the DT N
CEA NNP i
patients NNS N
( ( N
odds NNS N
ratio VBP N
1.16 CD N
, , N
95 CD N
% NN N
confidence NN N
interval JJ N
0.74-1.82 NN N
) ) N
. . N

Instent JJ o
restenoses NNS o
were VBD N
significantly RB N
more JJR N
common JJ N
in IN N
the DT N
CAS NNP i
group NN N
( ( N
4.6 CD N
% NN N
vs JJ N
2.2 CD N
% NN N
, , N
odds NNS N
ratio VBP N
2.14 CD N
, , N
95 CD N
% NN N
CI NNP N
1.10-4.18 CD N
) ) N
. . N

Surgery NN N
remains VBZ N
the DT N
gold JJ N
standard NN N
in IN N
treatment NN N
of IN N
patients NNS p
with IN p
symptomatic JJ p
carotid NN p
artery NN p
stenosis NN p
. . p

Stent-supported JJ i
angioplasty NN i
can MD N
be VB N
an DT N
alternative JJ N
only RB N
in IN N
the DT N
hands NNS N
of IN N
an DT N
experienced JJ N
interventionalist NN N
with IN N
proven JJ N
low JJ N
periprocedural JJ o
complication NN o
rate NN o
. . o

-DOCSTART- -16900709- O O

The DT N
efficacy NN N
of IN N
conventional JJ i
PCNL NNP i
and CC i
two CD i
modifications NNS i
to TO i
standard JJ i
procedure NN i
. . i

OBJECTIVE UH N
To TO N
compare VB N
the DT N
efficacy NN N
of IN N
conventional JJ i
Percutaneous JJ i
Nephrolithotomy NNP i
( ( i
PCNL NNP i
) ) i
with IN N
two CD N
of IN N
its PRP$ N
modified JJ N
procedures NNS N
. . N

METHODS NNP N
A NNP N
randomized VBD N
controlled VBN N
trial NN N
, , N
was VBD N
performed VBN N
on IN N
60 CD p
patients NNS p
undergoing JJ p
PCNL NNP i
. . i

Cases NNS p
of IN p
renal JJ p
stone NN p
regardless NN p
of IN p
stone NN p
size NN p
and CC p
configuration NN p
, , p
having VBG p
pre-operative JJ p
negative JJ p
urine JJ p
culture NN p
, , p
no DT p
coagulopathy NN p
, , p
and CC p
no DT p
visible JJ p
residual JJ p
stone NN p
in IN p
intra-operative JJ p
fluoroscopy NN p
, , p
were VBD p
included VBN p
. . p

They PRP N
were VBD N
randomly RB N
divided VBN N
into IN N
3 CD N
groups NNS N
of IN N
20 CD N
cases NNS N
each DT N
with IN N
nephrostomy JJ i
tube NN i
( ( i
NT NNP i
) ) i
and CC i
temporary JJ i
ureteral JJ i
catheter NN i
( ( i
TU NNP i
) ) i
in IN N
group NN N
A NNP N
, , N
only RB i
TU NNP i
in IN N
group NN N
B NNP N
and CC N
only RB i
indwelling VBG i
ureteral JJ i
catheter NN i
( ( i
IU NNP i
) ) i
in IN N
group NN N
C. NNP N
Mean NNP p
age NN p
of IN p
cases NNS p
were VBD p
43.2 CD p
( ( p
25-70 JJ p
) ) p
, , p
40.1 CD p
( ( p
25-73 JJ p
) ) p
, , p
and CC p
44 CD p
( ( p
25-70 JJ p
) ) p
years NNS p
in IN p
groups NNS p
A NNP p
, , p
B NNP p
and CC p
C NNP p
, , p
respectively RB p
( ( N
P NNP N
= NNP N
0.6 CD N
) ) N
. . N

Procedures NNS N
were VBD N
performed VBN N
under IN N
general JJ N
anaesthesia NN N
, , N
using VBG N
standard JJ N
techniques NNS N
for IN N
access NN N
and CC N
lithotomy NN N
. . N

Forty-eight JJ N
hours NNS N
, , N
2 CD N
weeks NNS N
and CC N
3 CD N
months NNS N
after IN N
PCNL NNP i
, , N
plain VBP N
X-ray JJ N
abdomen NNS N
, , N
ultrasonography NN N
and CC N
IVP NNP N
were VBD N
performed VBN N
for IN N
each DT N
case NN N
. . N

RESULTS NNP N
Only RB N
one CD N
case NN N
in IN N
group NN N
A NNP N
had VBD N
urinary JJ o
leakage NN o
after IN N
removal NN N
of IN N
nephrostomy JJ N
tube NN N
. . N

No DT N
cases NNS N
in IN N
the DT N
other JJ N
two CD N
groups NNS N
encountered VBD N
this DT N
problem NN N
. . N

There EX N
was VBD N
no DT N
haemorrhagic JJ o
episode NN o
. . o

Ultrasonic JJ N
evaluation NN N
showed VBD N
mild JJ o
residue NNS o
in IN N
3 CD N
, , N
1 CD N
and CC N
1 CD N
cases NNS N
of IN N
groups NNS N
A NNP N
, , N
B NNP N
and CC N
C NNP N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
0.2 CD N
) ) N
. . N

No UH N
collective JJ o
fluid NN o
was VBD N
found VBN N
in IN N
these DT N
groups NNS N
. . N

IVP NNP N
showed VBD N
dilatation NN o
without IN o
obstruction NN o
in IN N
3 CD N
subjects NNS N
of IN N
group NN N
A NNP N
and CC N
none NN N
in IN N
group NN N
B NNP N
or CC N
C NNP N
( ( N
P NNP N
= NNP N
0.03 CD N
) ) N
. . N

CONCLUSION NNP N
Tubeless NNP i
PCNL NNP i
seems VBZ N
to TO N
be VB N
accompanied VBN N
by IN N
better JJR N
outcome NN N
. . N

So RB N
, , N
further JJ N
evaluation NN N
on IN N
more JJR N
patients NNS N
seems VBZ N
necessary JJ N
. . N

-DOCSTART- -3976757- O O

Prevention NN N
of IN N
premature JJ N
labor NN N
by IN N
17 CD i
alpha-hydroxyprogesterone JJ i
caproate NN i
. . i

Eighty NNP p
pregnant JJ p
women NNS p
at IN p
high JJ p
risk NN p
of IN p
giving VBG p
birth NN p
prematurely RB p
were VBD N
divided VBN N
randomly RB N
into IN N
two CD N
groups NNS N
. . N

Treatment NN N
with IN N
either DT N
17 CD i
alpha-hydroxyprogesterone NN i
caproate NN i
, , i
250 CD i
mg NN i
by IN i
intramuscular JJ i
injection NN i
once RB i
a DT i
week NN i
, , i
or CC i
a DT i
placebo NN i
was VBD N
given VBN N
in IN N
a DT N
double-blind JJ N
fashion NN N
. . N

Imminent JJ N
premature NN N
labor NN N
occurred VBD N
in IN N
29.0 CD N
% NN N
of IN N
the DT N
treated VBN N
group NN N
and CC N
in IN N
59.4 CD N
% NN N
of IN N
the DT N
control NN i
group NN N
( ( N
p VBZ N
less JJR N
than IN N
0.025 CD N
) ) N
. . N

The DT N
rate NN o
of IN o
premature NN o
deliveries NNS o
was VBD N
also RB N
significantly RB N
lower JJR N
in IN N
the DT N
treated JJ N
group NN N
( ( N
16.1 CD N
% NN N
) ) N
than IN N
in IN N
the DT N
control NN N
group NN N
( ( N
37.82 CD N
% NN N
) ) N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
cases NNS N
of IN N
perinatal JJ o
death NN o
or CC o
fetal JJ o
malformations NNS o
in IN N
either DT N
group NN N
. . N

The DT N
mean JJ o
birth NN o
weight NN o
of IN N
all DT N
infants NNS N
of IN N
the DT N
treated JJ N
group NN N
was VBD N
significantly RB N
higher JJR N
than IN N
in IN N
those DT N
of IN N
the DT N
control NN N
group NN N
( ( N
3111.9 CD N
+/- JJ N
905 CD N
gm NN N
versus NN N
2680 CD N
+/- JJ N
813.4 CD N
gm NN N
, , N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

The DT N
results NNS N
support VB N
treatment NN N
with IN N
progesterone NN i
caproate NN i
for IN N
the DT N
prevention NN N
of IN N
premature JJ N
labor NN N
. . N

-DOCSTART- -12057986- O O

Impact NN N
of IN N
different JJ N
platelet NN N
glycoprotein NN N
IIb/IIIa NNP N
receptor NN N
inhibitors NNS N
among IN N
diabetic JJ p
patients NNS p
undergoing VBG p
percutaneous JJ p
coronary JJ p
intervention NN p
: : p
: : N
Do VB N
Tirofiban NNP N
and CC N
ReoPro NNP N
Give NNP N
Similar NNP N
Efficacy NNP N
Outcomes NNP N
Trial NNP N
( ( N
TARGET NNP N
) ) N
1-year JJ N
follow-up NN N
. . N

BACKGROUND IN N
The DT N
platelet NN N
glycoprotein NN N
IIb/IIIa NNP N
receptor NN N
inhibitor NN N
abciximab NN N
, , N
a DT N
monoclonal JJ N
antibody NN N
, , N
has VBZ N
been VBN N
shown VBN N
to TO N
improve VB N
early JJ N
and CC N
late JJ N
outcomes NNS N
among IN N
diabetic JJ p
patients NNS p
undergoing VBG p
percutaneous JJ p
coronary JJ p
intervention NN p
( ( p
PCI NNP p
) ) p
. . p

It PRP N
is VBZ N
unknown JJ N
whether IN N
small-molecule JJ N
agents NNS N
confer VBP N
similar JJ N
benefits NNS N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
In IN p
18 CD p
countries NNS p
, , p
4809 CD p
patients NNS p
undergoing VBG p
PCI NNP p
with IN p
stent JJ p
implantation NN p
were VBD N
randomized VBN N
to TO N
tirofiban VB i
or CC i
abciximab VB i
. . i

At IN N
the DT N
time NN N
of IN N
enrollment NN N
, , N
patients NNS N
were VBD N
stratified VBN N
according VBG N
to TO N
diabetes NNS N
status NN N
. . N

As IN N
compared VBN N
with IN N
non-diabetic JJ N
patients NNS N
, , N
patients NNS N
with IN N
diabetes NNS N
( ( N
n=1117 NN N
) ) N
showed VBD N
similar JJ N
30-day JJ N
ischemic JJ N
outcomes NNS N
, , N
an DT N
increased JJ N
incidence NN o
of IN o
any DT o
target NN o
vessel NN o
revascularization NN o
( ( o
TVR NNP o
) ) o
at IN N
6 CD N
months NNS N
( ( N
10.3 CD N
% NN N
versus IN N
7.8 CD N
% NN N
; : N
P= NNP N
0.008 CD N
) ) N
, , N
and CC N
a DT N
trend NN N
toward IN N
higher JJR o
1-year JJ o
mortality NN o
( ( N
2.5 CD N
% NN N
versus IN N
1.6 CD N
% NN N
; : N
P=0.056 NNP N
) ) N
. . N

Among IN N
diabetic JJ N
patients NNS N
randomized VBN N
to TO N
tirofiban VB N
( ( N
n=560 NN N
) ) N
, , N
the DT N
incidence NN o
of IN o
death NN o
, , o
myocardial JJ o
infarction NN o
( ( o
MI NNP o
) ) o
, , o
or CC o
urgent JJ o
TVR NNP o
at IN N
30 CD N
days NNS N
was VBD N
6.2 CD N
% NN N
, , N
and CC N
among IN N
those DT N
randomized VBN N
to TO N
abciximab VB N
( ( N
n=557 NN N
) ) N
it PRP N
was VBD N
5.4 CD N
% NN N
( ( N
hazard JJ N
ratio NN N
[ NNP N
HR NNP N
] NNP N
1.16 CD N
; : N
P=0.540 NNP N
) ) N
. . N

At IN N
6 CD N
months NNS N
, , N
the DT N
composite NN N
of IN N
death NN o
, , o
MI NNP o
, , o
or CC o
any DT o
TVR NNP o
occurred VBD N
in IN N
15.7 CD N
% NN N
and CC N
in IN N
16.9 CD N
% NN N
of IN N
tirofiban NN N
and CC N
abciximab NN N
patients NNS N
, , N
respectively RB N
( ( N
HR NNP N
0.93 CD N
; : N
P=0.610 NNP N
) ) N
. . N

Any DT N
TVR NNP o
occurred VBD N
in IN N
9.5 CD N
% NN N
and CC N
11.1 CD N
% NN N
, , N
respectively RB N
( ( N
HR NNP N
0.84 CD N
; : N
P= NNP N
0.366 CD N
) ) N
. . N

The DT N
1-year JJ o
mortality NN o
was VBD N
2.1 CD N
% NN N
in IN N
the DT N
tirofiban NN N
group NN N
and CC N
2.9 CD N
% NN N
in IN N
the DT N
abciximab NN N
group NN N
( ( N
HR NNP N
0.74 CD N
; : N
P= NNP N
0.436 CD N
) ) N
. . N

CONCLUSIONS NNP N
Among IN N
diabetic JJ p
patients NNS p
undergoing VBG p
PCI NNP p
, , N
tirofiban NN N
and CC N
abciximab NN N
were VBD N
associated VBN N
with IN N
comparable JJ N
event NN N
rates NNS N
, , N
including VBG N
similar JJ N
rates NNS N
of IN N
6-month JJ N
TVR NNP N
and CC N
1-year JJ N
mortality NN N
. . N

These DT N
findings NNS N
suggest VBP N
that IN N
the DT N
non-glycoprotein JJ N
IIb/IIIa NNP N
properties NNS N
of IN N
abciximab NNS N
do VBP N
not RB N
translate VB N
into IN N
a DT N
discernible JJ N
long-term JJ N
clinical JJ N
benefit NN N
among IN N
diabetic JJ p
patients NNS p
. . p

-DOCSTART- -8640699- O O

Fadrozole NNP i
HCL NNP i
( ( i
CGS-16949A NNP i
) ) i
versus NN N
megestrol NN i
acetate VBP i
treatment NN N
of IN N
postmenopausal NN p
patients NNS p
with IN p
metastatic JJ p
breast NN p
carcinoma NN p
: : p
results NNS N
of IN N
two CD N
randomized JJ N
double JJ N
blind NN N
controlled VBD N
multiinstitutional JJ N
trials NNS N
. . N

BACKGROUND NNP N
Breast NNP p
cancer NN p
patients NNS p
with IN p
prior JJ p
response NN p
to TO p
endocrine VB p
therapy NN p
achieve VB N
subsequent JJ N
benefit NN N
from IN N
additional JJ N
endocrine NN N
therapies NNS N
. . N

The DT N
efficacy NN N
and CC N
safety NN N
of IN N
an DT N
aromatase NN N
inhibitor NN N
, , N
fadrozole JJ i
HCL NNP i
, , N
were VBD N
compared VBN N
with IN N
megestrol NN N
acetate NN N
in IN N
post NN p
menopausal NN p
patients NNS p
who WP p
had VBD p
disease NN p
progression NN p
after IN p
receiving VBG p
antiestrogen NN p
therapy NN p
either DT p
for IN p
metastatic JJ p
disease NN p
or CC p
as IN p
adjuvant JJ p
therapy NN p
. . p

METHODS NNP N
In IN p
2 CD p
multiinstitutional JJ p
prospective JJ p
trials NNS p
, , p
683 CD p
postmenopausal NN p
patients NNS p
were VBD N
randomized VBN i
to TO i
receive VB i
either DT i
fadrozole JJ i
HCL NNP i
, , i
1 CD i
mg NN i
twice RB i
daily RB i
, , i
or CC i
megestrol NN i
acetate NN i
, , i
40 CD i
mg NN i
4 CD i
times NNS i
daily RB i
, , i
in IN i
a DT i
double JJ i
blind NN i
fashion NN i
after IN i
progression NN i
on IN i
first-line JJ i
hormonal JJ i
therapy NN i
. . i

Objective JJ o
response NN o
rates NNS o
, , o
time NN o
to TO o
progression NN o
, , o
survival NN o
and CC o
safety NN o
of IN N
the DT N
two CD N
regimens NNS N
were VBD N
compared VBN N
. . N

RESULTS NNP N
Results NNP N
of IN N
intent-to-treat JJ N
analyses NNS N
are VBP N
presented VBN N
in IN N
this DT N
study NN N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
detected VBN N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
in IN N
time NN o
to TO o
progression NN o
, , o
objective JJ o
response NN o
rates NNS o
, , o
duration NN o
of IN o
response NN o
, , o
and CC o
survival NN o
in IN N
either DT N
trial NN N
. . N

There EX N
were VBD N
no DT N
clinically RB N
meaningful JJ N
differences NNS N
between IN N
the DT N
treatment NN N
groups NNS N
in IN N
the DT N
incidence NN N
and CC N
severity NN N
of IN N
adverse JJ o
experiences NNS o
, , N
except IN N
that DT N
weight NN o
gain NN o
, , o
fluid JJ o
retention NN o
, , o
and CC o
dyspnea NN o
were VBD N
observed VBN N
in IN N
more JJR N
patients NNS N
in IN N
the DT N
megestrol NN N
acetate NN N
group NN N
compared VBN N
with IN N
those DT N
receiving VBG N
fadrozole JJ N
HCL NNP N
, , N
whereas JJ N
nausea NN o
and CC o
vomiting NN o
were VBD N
observed VBN N
in IN N
more JJR N
patients NNS N
in IN N
the DT N
fadrozole JJ N
HCL NNP N
group NN N
compared VBN N
with IN N
those DT N
receiving VBG N
megestrol NN N
acetate NN N
. . N

CONCLUSIONS NNP N
Fadrozole NNP i
HCL NNP i
was VBD N
as RB N
efficacious JJ o
as IN N
megestrol NN N
acetate NN N
in IN N
postmenopausal NN p
patients NNS p
with IN p
metastatic JJ p
breast NN p
carcinoma NN p
after IN N
one CD N
hormonal JJ N
therapy NN N
. . N

Adverse JJ N
experiences NNS N
were VBD N
mild JJ N
with IN N
both DT N
therapies NNS N
, , N
but CC N
megestrol NN N
acetate NN N
was VBD N
associated VBN N
wiht PDT N
a DT N
higher JJR N
frequency NN N
of IN N
weight NN o
gain NN o
, , o
fluid JJ o
retention NN o
and CC o
dyspnea NN o
, , N
whereas JJ N
fadrozole NN i
HCL NNP i
was VBD N
associated VBN N
with IN N
a DT N
higher JJR N
frequency NN N
of IN N
nausea NN o
and CC o
vomiting NN o
. . o

-DOCSTART- -10992834- O O

Comparison NNP N
of IN N
succinylcholine NN i
with IN N
two CD N
doses NNS N
of IN N
rocuronium NN i
using VBG N
a DT N
new JJ N
method NN N
of IN N
monitoring VBG N
neuromuscular JJ o
block NN o
at IN p
the DT p
laryngeal NN p
muscles NNS p
by IN N
surface NN p
laryngeal NN p
electromyography NN p
. . N

We PRP N
compared VBN N
the DT N
onset NN o
of IN o
neuromuscular JJ o
block NN o
with IN N
succinylcholine NN i
( ( i
1 CD i
mg RB i
kg-1 NN i
) ) i
and CC i
two CD i
doses NNS i
of IN i
rocuronium NN i
( ( i
0.6 CD i
and CC i
0.9 CD i
mg JJ i
kg-1 NN i
) ) i
at IN N
the DT N
adductor NN N
pollicis NN N
muscle NN N
using VBG N
electromyography NN i
( ( i
EMG NNP i
) ) i
and CC i
acceleromyography NN i
( ( N
AMG NNP N
) ) N
, , N
and CC N
at IN N
the DT N
adductor NN N
laryngeal NN N
muscles NNS N
with IN N
a DT N
new JJ N
electromyographic JJ i
method NN i
using VBG N
a DT N
disposable JJ N
surface NN N
electrode NN N
attached VBN N
to TO N
the DT N
cuff NN N
of IN N
a DT N
tracheal JJ N
tube NN N
. . N

At IN N
the DT N
larynx NN N
, , N
the DT N
mean NN o
( ( o
+/- JJ o
SD NNP o
) ) o
time NN o
to TO o
90 CD o
% NN o
block NN o
and CC o
the DT o
onset JJ o
time NN o
of IN N
succinylcholine NN o
( ( N
38 CD N
+/- JJ N
15 CD N
and CC N
47 CD N
+/- JJ N
19 CD N
s NN N
, , N
respectively RB N
) ) N
were VBD N
significantly RB N
shorter JJR N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
than IN N
for IN N
rocuronium NN i
0.6 CD N
mg NN N
kg-1 NN N
( ( N
92 CD N
+/- JJ N
42 CD N
and CC N
106 CD N
+/- JJ N
38 CD N
s NN N
) ) N
and CC N
rocuronium $ i
0.9 CD N
mg JJ N
kg-1 NN N
( ( N
52 CD N
+/- JJ N
31 CD N
and CC N
64 CD N
+/- JJ N
30 CD N
s NN N
) ) N
. . N

We PRP N
found VBD N
that IN N
, , N
with IN N
comparable JJ N
degrees NNS N
of IN N
neuromuscular JJ o
block NN o
, , N
the DT N
onset JJ o
time NN o
of IN o
succinylcholine NN o
at IN o
the DT o
adductor NN o
pollicis NN o
was VBD N
significantly RB N
shorter JJR N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
than IN N
for IN N
rocuronium NN i
0.6 CD N
mg NN N
kg-1 NN N
and CC N
0.9 CD N
mg NNS N
kg-1 JJ N
( ( N
EMG NNP N
, , N
80 CD N
+/- JJ N
39 CD N
vs JJ N
145 CD N
+/- JJ N
48 CD N
s NN N
and CC N
99 CD N
+/- JJ N
31 CD N
s NN N
; : N
AMG NNP N
, , N
90 CD N
+/- JJ N
39 CD N
vs JJ N
124 CD N
+/- JJ N
53 CD N
s NN N
and CC N
106 CD N
+/- JJ N
38 CD N
s NN N
) ) N
. . N

Clinical JJ o
duration NN o
at IN o
the DT o
adductor NN o
pollicis NN o
( ( o
AMG NNP o
) ) o
was VBD N
significantly RB N
longer JJR N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
for IN N
both DT N
rocuronium NN i
groups NNS N
than IN N
for IN N
succinylcholine NN i
( ( N
T4 NNP N
: : N
T1 NNP N
= VBZ N
0.7 CD N
, , N
54 CD N
+/- JJ N
18 CD N
and CC N
77 CD N
+/- JJ N
21 CD N
vs JJ N
8 CD N
+/- JJ N
6 CD N
min NN N
) ) N
. . N

The DT N
surface NN N
laryngeal JJ N
electrode NN N
proved VBD N
non-invasive JJ N
, , N
easy JJ N
to TO N
use VB N
and CC N
reliable VB N
in IN N
measuring VBG N
onset NN o
of IN o
the DT o
neuromuscular JJ o
block NN o
at IN p
the DT p
larynx NN p
. . p

-DOCSTART- -6836750- O O

Pilot NN N
study NN N
with IN N
adjuvant JJ i
hormone NN i
therapy NN i
in IN N
FIGO NNP p
stage NN p
I PRP p
endometrial JJ p
carcinoma NN p
with IN p
myometrial JJ p
invasion NN p
. . p

A DT N
pilot NN N
study NN N
with IN N
adjuvant JJ i
hormone NN i
therapy NN i
in IN N
FIGO NNP p
stage NN p
I PRP p
endometrial JJ p
carcinoma NN p
with IN p
myometrial JJ p
invasion NN p
was VBD N
carried VBN N
out RP N
. . N

All DT N
patients NNS p
received VBD N
total JJ i
abdominal JJ i
hysterectomy NN i
and CC i
bilateral JJ i
salpingo-oophorectomy JJ i
plus CC i
complementary JJ i
radium NN i
therapy NN i
on IN i
the DT i
vaginal JJ i
stump NN i
. . i

After IN N
the DT N
conventional JJ N
treatment NN N
, , N
patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
adjuvant VB i
hormone NN i
therapy NN i
or CC i
no DT i
further JJ i
treatment NN i
. . i

Hormone NNP N
therapy NN N
consisted VBD N
of IN N
gestonorone NN i
caproate NN i
( ( i
17 CD i
alpha-hydroxy-19-norpregn-4-en JJ i
3 CD i
, , i
20 CD i
dione NN i
caproate NN i
) ) i
administered VBD i
i.m NN i
. . i

at IN i
the DT i
dose NN i
of IN i
200 CD i
mg/week NN i
for IN i
1 CD i
year NN i
. . i

Of IN N
the DT N
62 CD p
patients NNS p
who WP p
entered VBD p
the DT p
study NN p
, , N
51 CD N
were VBD N
considered VBN N
evaluable JJ N
( ( N
24 CD N
with IN N
adjuvant JJ i
hormone NN i
therapy NN i
and CC N
27 CD N
with IN N
no DT i
further JJ i
treatment NN i
) ) i
. . N

Five CD p
patients NNS p
had VBD p
a DT p
relapse NN o
: : o
four CD N
of IN N
these DT N
were VBD N
in IN N
the DT N
group NN N
with IN N
no DT o
further JJ o
treatment NN o
. . o

Actuarial JJ o
relapse-free JJ o
survival NN o
analysis NN N
at IN N
5 CD N
years NNS N
was VBD N
95.7 CD N
% NN N
in IN N
the DT N
group NN N
of IN N
adjuvant-treated JJ N
patients NNS N
and CC N
82.8 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
. . N

Although IN N
there EX N
is VBZ N
no DT N
statistical JJ N
significance NN N
, , N
adjuvant JJ i
therapy NN i
appears VBZ N
to TO N
result VB N
in IN N
an DT N
increase NN N
in IN N
relapse-free JJ o
survival NN o
in IN N
the DT N
group NN N
of IN N
patients NNS N
with IN N
deep JJ N
myometrial JJ N
invasion NN N
and CC N
undifferentiated JJ N
carcinoma NN N
. . N

Further JJ N
studies NNS N
are VBP N
necessary JJ N
to TO N
assess VB N
the DT N
effectiveness NN N
of IN N
hormone NN i
adjuvant JJ i
treatment NN i
in IN N
FIGO NNP p
stage NN p
I PRP p
endometrial JJ p
carcinoma NN p
with IN p
myometrial JJ p
invasion NN p
. . p

-DOCSTART- -8063943- O O

Intracapillary JJ o
glomerular NN o
metastases NNS o
in IN N
a DT N
nephrectomy JJ p
specimen NNS p
removed VBD p
for IN p
ipsilateral JJ p
renal JJ p
cell NN p
carcinoma NN p
. . p

A DT N
case NN N
of IN N
intraglomerular JJ i
metastases NNS i
observed VBN N
in IN N
a DT N
nephrectomy JJ p
specimen NNS p
removed VBD p
for IN p
primary JJ p
renal JJ p
cell NN p
carcinoma NN p
is VBZ N
reported VBN N
. . N

The DT N
intraglomerular JJ i
metastases NNS i
arose VBP N
by IN N
dissemination NN N
of IN N
malignant JJ N
cells NNS N
into IN N
the DT N
systemic JJ N
circulation NN N
via IN N
invasion NN N
of IN N
the DT N
renal JJ N
veins NNS N
. . N

Intraglomerular JJ N
metastases NNS N
are VBP N
therefore RB N
an DT N
indicator NN N
of IN N
malignant JJ N
dissemination NN N
which WDT N
in IN N
turn NN N
should MD N
be VB N
associated VBN N
with IN N
a DT N
poor JJ N
prognosis NN N
. . N

It PRP N
is VBZ N
recommended VBN N
that IN N
in IN N
nephrectomies NNS N
undertaken VBP N
for IN N
primary JJ p
renal JJ p
cell NN p
carcinoma NN p
at IN N
least JJS N
one CD N
random NN N
block NN N
of IN N
renal JJ N
cortex NN N
should MD N
be VB N
examined VBN i
to TO N
confirm VB N
or CC N
exclude VB N
intraglomerular JJ N
metastases NNS N
. . N

-DOCSTART- -23535873- O O

Effect NN N
of IN N
beta-alanine NN i
, , N
with IN N
and CC N
without IN N
sodium NN i
bicarbonate NN i
, , N
on IN N
2000-m JJ o
rowing NN o
performance NN o
. . o

PURPOSE NNP N
To TO N
examine VB N
the DT N
effect NN N
of IN N
beta-alanine NN N
only RB N
and CC N
beta-alanine JJ i
with IN i
sodium NN i
bicarbonate NN i
supplementation NN i
on IN N
2,000-m JJ o
rowing NN o
performance NN o
. . o

METHODS NNP N
Twenty NNP p
well-trained JJ p
rowers NNS p
( ( p
age NN p
23 CD p
? . p
4 CD p
y NN p
; : p
height VBD p
1.85 CD p
? . p
0.08 CD p
m NN p
; : p
body NN p
mass NN p
82.5 CD p
? . p
8.9 CD p
kg NN p
) ) p
were VBD p
assigned VBN N
to TO N
either VB i
a DT i
placebo NN i
or CC i
beta-alanine NN i
( ( i
6.4 CD i
g NN N
? . N
d NN N
( ( N
-1 NNP N
) ) N
for IN N
4 CD N
weeks NNS N
) ) N
group NN o
. . o

A DT o
2,000-m JJ o
rowing NN o
time NN o
trial NN o
( ( o
TT NNP o
) ) o
was VBD o
performed VBN N
before IN i
supplementation NN i
( ( i
Baseline NNP i
) ) N
and CC N
after IN N
28 CD N
and CC N
30 CD N
days NNS N
of IN i
supplementation NN i
. . i

The DT i
post NN N
supplementation NN N
trials NNS N
involved VBN N
supplementation NN N
with IN N
either DT N
maltodextrin NN N
or CC N
sodium NN N
bicarbonate NN N
in IN N
a DT N
double-blind NN N
, , N
crossover NN N
design NN N
, , N
creating VBG N
four CD N
study NN N
conditions NNS i
( ( i
placebo NN i
with IN i
maltodextrin NN i
; : i
placebo NN i
with IN i
sodium JJ i
bicarbonate NN i
; : i
beta-alanine JJ i
with IN i
maltodextrin NN i
; : i
beta-alanine JJ i
with IN i
sodium JJ i
bicarbonate NN o
) ) o
. . o

Blood NNP o
lactate NN o
, , o
pH NN o
, , o
bicarbonate NN o
, , o
and CC o
base NN o
excess NN o
were VBD o
measured VBN N
pre-TT JJ N
, , N
immediately RB N
post-TT JJ N
and CC N
at IN N
TT+5 NNP N
min NN N
. . N

Performance NNP o
data NNS o
were VBD o
analyzed VBN N
using VBG o
magnitude NN o
based VBN o
inferences NNS o
. . o

RESULTS NNP o
Beta-alanine JJ i
supplementation NN i
was VBD i
very RB N
likely JJ N
to TO N
be VB N
beneficial JJ o
to TO o
2,000-m JJ o
rowing NN o
performance NN o
( ( o
6.4 CD o
? . N
8.1 CD N
s JJ N
effect NN N
compared VBN N
with IN N
placebo NN N
) ) N
, , N
with IN N
the DT N
effect NN N
of IN N
sodium NN N
bicarbonate NN N
having VBG N
a DT N
likely JJ N
benefit NN N
( ( N
3.2 CD N
? . N
8.8 CD N
s NN N
) ) N
. . N

There EX N
was VBD N
a DT N
small JJ N
( ( N
1.1 CD N
? . N
5.6 CD N
s NN N
) ) N
but CC N
possibly RB N
beneficial JJ o
additional JJ o
effect NN o
when WRB N
combining VBG N
chronic JJ N
beta-alanine JJ N
supplementation NN N
with IN N
acute JJ N
sodium NN N
bicarbonate NN N
supplementation NN N
compared VBN N
with IN N
chronic JJ N
beta-alanine JJ N
supplementation NN N
alone RB N
. . N

Sodium JJ N
bicarbonate NN N
ingestion NN N
led VBD N
to TO N
increases NNS o
in IN o
plasma NN o
pH NN o
, , o
base NN o
excess NN o
, , o
bicarbonate NN o
, , o
and CC o
lactate JJ o
concentrations NNS o
. . o

CONCLUSIONS NNP o
Both NNP i
chronic JJ i
beta-alanine NN i
and CC i
acute JJ i
sodium NN i
bicarbonate NN i
supplementation NN i
alone RB i
had VBD N
positive JJ N
effects NNS N
on IN o
2,000-m JJ o
rowing NN o
performance NN o
. . o

The DT o
addition NN o
of IN i
acute JJ i
sodium NN i
bicarbonate NN i
to TO i
chronic VB i
beta-alanine JJ i
supplementation NN i
may MD i
further VB i
enhance NN N
rowing VBG o
performance NN o
. . o

-DOCSTART- -10963640- O O

Epirubicin-based JJ i
chemotherapy NN i
in IN N
metastatic JJ p
breast NN p
cancer NN p
patients NNS p
: : p
role NN N
of IN N
dose-intensity NN N
and CC N
duration NN N
of IN N
treatment NN N
. . N

PURPOSE NNP N
To TO N
determine VB N
whether IN N
the DT N
duration NN N
and CC N
the DT N
dose NN N
of IN N
epirubicin JJ i
modify VB o
the DT o
long-term JJ o
outcome NN o
of IN N
patients NNS p
with IN p
metastatic JJ p
breast NN p
cancer NN p
( ( p
MBC NNP p
) ) p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
Four NNP p
hundred VBD p
seventeen JJ p
anthracycline-naive JJ p
MBC NNP p
patients NNS p
were VBD N
randomized VBN N
to TO N
receive VB N
one CD N
of IN N
the DT N
following JJ N
regimens NNS N
: : N
arm NN N
A NN N
: : N
11 CD N
cycles NNS N
of IN N
fluorouracil NN i
500 CD N
mg/m NN N
( ( N
2 CD N
) ) N
, , N
epirubicin $ i
75 CD N
mg/m NN N
( ( N
2 CD N
) ) N
, , N
and CC N
cyclophosphamide RB i
500 CD N
mg/m NN N
( ( N
2 CD N
) ) N
( ( i
FEC NNP i
75 CD N
) ) N
every DT N
21 CD N
days NNS N
; : N
arm NN N
B NN N
: : N
four CD N
cycles NNS N
of IN N
FEC NNP i
100 CD i
( ( N
same JJ N
regimen NNS N
but CC N
with IN N
epirubicin JJ i
100 CD N
mg/m NN N
( ( N
2 CD N
) ) N
) ) N
then RB N
eight CD N
cycles NNS N
of IN N
FEC NNP i
50 CD i
( ( i
epirubicin JJ i
50 CD N
mg/m NN N
( ( N
2 CD N
) ) N
) ) N
; : N
and CC N
arm JJ N
C NNP N
: : N
four CD N
cycles NNS N
of IN N
FEC NNP i
100 CD i
then RB N
restart VB N
the DT N
same JJ N
regimen NN N
at IN N
disease NN N
progression NN N
in IN N
case NN N
of IN N
prior JJ N
response NN N
or CC N
stabilization NN N
. . N

RESULTS NNP N
Hematologic NNP o
toxicity NN o
was VBD N
similar JJ N
. . N

Nausea/vomiting NN o
and CC o
stomatitis NN o
were VBD N
significantly RB N
less RBR N
frequent JJ N
in IN N
arm NN N
A NN N
as IN N
was VBD N
left VBN o
ventricular JJ o
ejection NN o
fraction NN o
decrease NN N
in IN N
arm NN N
C NNP N
( ( N
A NNP N
= NNP N
six CD N
patients NNS N
, , N
B NNP N
= NNP N
five CD N
patients NNS N
, , N
and CC N
C NNP N
= NNP N
one CD N
patient NN N
) ) N
. . N

Six CD N
patients NNS N
died VBD o
of IN o
infections NNS o
( ( N
A DT N
= RB N
four CD N
patients NNS N
and CC N
C NNP N
= NNP N
two CD N
patients NNS N
) ) N
. . N

After IN N
four CD N
cycles NNS N
, , N
the DT N
objective JJ o
response NN o
rate NN o
( ( o
ORR NNP o
) ) o
was VBD N
better RBR N
with IN N
FEC NNP i
100 CD N
than IN N
with IN N
FEC NNP i
75 CD N
( ( N
49.2 CD N
% NN N
v JJ N
40 CD N
% NN N
, , N
respectively RB N
; : N
P NNP N
: : N
=.07 NN N
) ) N
. . N

The DT N
ORR NNP o
was VBD N
better RBR N
with IN N
the DT N
longer JJR N
regimens NNS N
( ( N
arm NN N
A NNP N
, , N
56.9 CD N
% NN N
; : N
B NNP N
, , N
64 CD N
% NN N
; : N
and CC N
C NNP N
, , N
47.6 CD N
% NN N
; : N
P NNP N
: : N
=.06 NN N
) ) N
and CC N
was VBD N
41 CD N
% NN N
after IN N
second-line JJ N
FEC NNP i
100 CD N
. . N

After IN N
a DT N
median JJ N
follow-up NN N
of IN N
41 CD N
months NNS N
, , N
the DT N
response NN o
duration NN o
and CC o
time NN o
to TO o
progression NN o
( ( o
TTP NNP o
) ) o
were VBD N
significantly RB N
better RBR N
with IN N
arm NN N
B NNP N
, , N
the DT N
longer JJR N
regimen NNS N
( ( N
P NNP N
: : N
=.012 NN N
and CC N
P NNP N
: : N
< NN N
10 CD N
( ( N
-3 NN N
) ) N
, , N
respectively RB N
) ) N
. . N

The DT N
median JJ o
survival NN o
times NNS o
for IN N
arms NNS N
A NNP N
, , N
B NNP N
, , N
and CC N
C NNP N
were VBD N
similar JJ N
( ( N
17.9 CD N
, , N
18.9 CD N
, , N
and CC N
16 CD N
. . N

3 CD N
months NNS N
, , N
respectively RB N
; : N
P NNP N
: : N
=.49 NN N
) ) N
. . N

CONCLUSION NNP N
In IN N
MBC NNP N
, , N
longer JJR N
epirubicin-based JJ N
regimens NNS N
are VBP N
better RBR N
in IN N
terms NNS N
of IN N
response NN o
duration NN o
and CC o
TTP NNP o
. . o

FEC NNP i
100 CD N
regimens NNS N
improve VBP N
the DT N
ORR NNP o
. . o

However RB N
, , N
four CD N
initial JJ N
cycles NNS N
of IN N
FEC NNP i
100 CD N
and CC N
identical JJ N
retreatment NN N
at IN N
disease NN N
progression NN N
yielded VBN N
equivalent JJ N
overall JJ o
survival NN o
to TO N
longer JJR N
regimens NNS N
. . N

-DOCSTART- -23952897- O O

Community-based JJ i
treatment NN i
for IN N
opioid JJ p
dependent JJ p
offenders NNS p
: : p
a DT N
pilot NN N
study NN N
. . N

BACKGROUND NNP N
Primary NNP i
care NN i
opioid JJ i
substitution NN i
treatment NN i
( ( i
OST NNP i
) ) i
has VBZ N
not RB N
been VBN N
compared VBN N
to TO N
program-based JJ N
OST NNP i
for IN N
community-supervised JJ p
offenders NNS p
. . p

OBJECTIVE IN N
The DT N
purpose NN N
of IN N
this DT N
project NN N
was VBD N
to TO N
compare VB N
primary JJ N
care NN N
to TO N
specialist VB N
supervised JJ N
OST NNP N
for IN N
opioid JJ N
dependent JJ N
offenders NNS N
in IN N
terms NNS N
of IN N
substance NN o
use NN o
and CC N
HIV NNP o
risk NN o
outcomes NNS o
. . o

METHODS NNP N
This DT N
project NN N
randomly RB N
assigned VBD N
15 CD p
jail NN p
diversion NN p
participants NNS p
to TO N
either DT N
: : N
( ( N
i NN N
) ) N
primary NN i
care NN i
buprenorphine NN i
OST NNP i
, , i
( ( i
ii NN i
) ) i
specialist NN i
facility NN i
buprenorphine NN i
OST NNP i
, , i
or CC i
( ( i
iii JJ i
) ) i
specialist NN i
facility NN i
methadone NN i
OST NNP i
. . i

Participation NNP N
lasted VBD N
13.5 CD N
months NNS N
( ( N
12-month JJ N
active JJ N
treatment NN N
plus CC N
a DT N
post-participation JJ N
visit NN N
) ) N
. . N

RESULTS NNP N
All NNP N
subjects VBZ N
endorsed VBN N
0 CD N
days NNS N
of IN N
opioid JJ N
use NN N
in IN N
the DT N
previous JJ N
14 CD N
at IN N
follow-up NN N
. . N

Specialty NNP N
care NN N
reduced VBD N
HIV NNP o
risk NN o
( ( o
Risk NNP o
Assessment NNP o
Battery NNP o
composite JJ o
score NN o
) ) o
over IN N
6 CD N
months NNS N
( ( N
-.24 VB N
? . N
.17 NN N
) ) N
compared VBN N
to TO N
primary VB N
care NN N
( ( N
.02 VB N
? . N
.14 NN N
; : N
p CC N
= NNP N
.032 NNP N
) ) N
. . N

CONCLUSION NNP N
Findings NNP N
support NN N
primary NN N
care NN i
OST NNP i
feasibility NN i
for IN N
a DT N
community-supervised JJ N
offender NN N
sample NN N
. . N

Specialist NNP N
care NN N
may MD N
facilitate VB N
improvements NNS N
in IN N
secondary JJ N
outcomes NNS N
, , N
such JJ N
as IN N
HIV NNP o
risk NN o
behaviors NNS o
. . o

SCIENTIFIC NNP o
SIGNIFICANCE NNP N
Further NNP N
research NN N
is VBZ N
needed VBN N
to TO N
clarify VB N
( ( N
i NN N
) ) N
the DT N
role NN N
of IN N
primary JJ N
care NN N
in IN N
addicted VBN N
offender NN N
management NN N
, , N
and CC N
( ( N
ii NN N
) ) N
the DT N
matching NN N
of IN N
offenders NNS N
, , N
based VBN N
upon IN N
history NN N
and CC N
co-morbidity NN N
, , N
to TO N
care VB N
coordination NN N
conditions NNS N
. . N

-DOCSTART- -18523583- O O

Heart NNP N
rate NN N
variability NN N
characteristics NNS N
in IN p
sedentary JJ p
postmenopausal JJ p
women NNS p
following VBG N
six CD N
months NNS N
of IN N
exercise NN i
training NN i
: : i
the DT N
DREW NNP N
study NN N
. . N

BACKGROUND NNP N
Decreased VBD N
heart NN N
rate NN N
variability NN N
( ( N
HRV NNP N
) ) N
is VBZ N
associated VBN N
with IN N
a DT N
higher JJR N
risk NN N
of IN N
mortality NN N
. . N

Overall JJ N
, , N
postmenopausal JJ p
women NNS p
have VBP N
lower JJR N
levels NNS N
of IN N
HRV NNP N
than IN N
premenopausal JJ N
women NNS N
, , N
which WDT N
may MD N
be VB N
additionally RB N
complicated VBN N
by IN N
lifestyle JJ N
related JJ N
behaviors NNS N
such JJ N
as IN N
physical JJ N
inactivity NN N
and CC N
obesity NN N
. . N

Though IN N
cardiorespiratory JJ i
exercise NN i
training NN i
increases NNS N
HRV NNP N
, , N
little JJ N
is VBZ N
known VBN N
regarding VBG N
the DT N
exercise NN N
dose NN N
necessary JJ N
to TO N
promote VB N
this DT N
improvement NN N
. . N

METHODOLOGY/PRINCIPAL NNP N
FINDINGS NNP N
Our PRP$ N
primary JJ N
aim NN N
was VBD N
to TO N
measure VB N
HRV NNP N
in IN N
post-menopausal JJ p
women NNS p
following VBG N
6-months JJ N
of IN N
exercise NN i
training NN i
. . i

We PRP N
examined VBD N
supine JJ p
resting VBG p
HRV NNP p
in IN p
373 CD p
post-menopausal JJ p
women NNS p
( ( p
45-75 JJ p
y NN p
) ) p
after IN p
6-months CD p
of IN p
randomly NN p
assigned VBN p
and CC N
double-blinded JJ N
administered JJ N
exercise NN i
training NN i
exercise NN i
training NN i
at IN N
50 CD N
% NN N
, , N
100 CD N
% NN N
and CC N
150 CD N
% NN N
of IN N
the DT N
NIH NNP N
Consensus NNP N
Development NNP N
Panel NNP N
's POS N
recommended JJ N
minimal JJ N
physical JJ N
activity NN N
level NN N
. . N

This DT N
corresponded VBD N
to TO N
4 CD N
, , N
8 CD N
, , N
or CC N
12 CD N
kcal/kg NNS N
per IN N
week NN N
( ( N
KKW NNP N
) ) N
of IN N
energy NN N
expenditure NN N
. . N

At IN N
baseline NN N
, , N
we PRP N
observed VBD N
no DT N
significant JJ N
differences NNS N
in IN N
HRV NNP o
or CC N
hormone NN o
replacement NN N
use NN N
between IN N
treatment NN N
groups NNS N
. . N

However RB N
, , N
we PRP N
did VBD N
observe VB N
that DT N
Caucasian JJ N
women NNS N
and CC N
those DT N
taking VBG N
antidepressant JJ N
medications NNS N
had VBD N
lower JJR N
levels NNS N
of IN N
baseline NN o
HRV NNP o
. . o

After IN N
6-months JJ N
of IN N
exercise NN i
intervention NN i
, , N
we PRP N
observed VBD N
a DT N
dose JJ N
dependent JJ N
increase NN N
in IN N
all DT N
parasympathetically RB N
derived VBN N
time NN o
and CC o
frequency NN o
domain NN o
measurements NNS o
across IN N
exercise NN N
groups NNS N
after IN N
adjustment NN N
for IN N
age NN N
, , N
ethnicity NN N
, , N
antidepressants NNS o
, , N
and CC N
baseline NN N
rMSSD NN N
( ( N
all DT N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

For IN N
example NN N
, , N
the DT N
parasympathetic JJ o
index NN o
rMSSD NN o
was VBD N
greater JJR N
than IN N
control NN N
( ( N
23.19+/-1.0 JJ N
) ) N
for IN N
the DT N
4-KKW JJ N
( ( N
25.98+/-0.8 JJ N
; : N
P NNP N
= NNP N
0.14 CD N
) ) N
, , N
8-KKW JJ N
( ( N
27.66+/-1.0 JJ N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
and CC N
12-KKW JJ N
( ( N
27.40+/-0.0 JJ N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
groups NNS N
at IN N
follow-up JJ N
. . N

CONCLUSIONS/SIGNIFICANCE NNP N
Moderate NNP i
intensity NN i
exercise NN i
training NN i
exercise NN i
is VBZ N
sufficient JJ N
to TO N
improve VB N
HRV NNP N
in IN N
previously RB N
sedentary JJ p
postmenopausal NN p
women NNS p
in IN N
a DT N
dose-dependent JJ N
manner NN N
, , N
as IN N
4-KKW JJ N
is VBZ N
insufficient JJ N
to TO N
improve VB N
parasympathetic JJ N
indices NNS N
of IN N
HRV NNP N
, , N
while IN N
12-KKW JJ N
conferred VBD N
no DT N
greater JJR N
improvement NN N
than IN N
8-KKW JJ N
. . N

TRIAL NNP N
REGISTRATION NNP N
Clinicaltrials.gov NNP N
NCT NNP N
00011193 CD N
. . N

-DOCSTART- -7733424- O O

The DT N
costs NNS o
and CC N
effects NNS o
of IN N
a DT N
nutritional JJ i
education NN i
program NN i
following VBG N
work-site JJ N
cholesterol NN N
screening NN N
. . N

OBJECTIVES CC N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
costs NNS o
and CC N
impact NN o
of IN N
a DT N
nutrition JJ i
education NN i
program NN i
following VBG N
a DT N
cholesterol NN N
screening NN N
. . N

METHODS NNP N
Forty NNP p
work-sites NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
educational JJ i
interventions NNS i
: : i
a DT N
usual JJ i
intervention NN i
of IN i
5 CD i
minutes NNS i
of IN i
counseling NN i
, , i
or CC i
a DT i
special JJ i
intervention NN i
of IN i
2 CD i
hours NNS i
of IN i
behaviorally RB i
based VBN i
education NN i
on IN i
dietary JJ i
changes NNS i
to TO i
lower VB i
serum NN i
cholesterol NN i
. . i

Costs NNS o
were VBD N
monitored VBN N
, , N
and CC N
cholesterol NN o
levels NNS o
were VBD N
retested VBN N
6 CD N
and CC N
12 CD N
months NNS N
later RB N
. . N

RESULTS VB N
The DT N
total JJ o
per-person JJ o
cost NN o
for IN N
screening VBG N
and CC N
the DT N
educational JJ N
intervention NN N
was VBD N
about IN N
$ $ N
50 CD N
. . N

Cholesterol NN o
levels NNS o
differed VBD N
little RB N
between IN N
the DT N
two CD N
intervention NN N
groups NNS N
6 CD N
months NNS N
after IN N
screening VBG N
, , N
but CC N
after IN N
12 CD N
months NNS N
those DT N
in IN N
the DT N
special JJ N
intervention NN N
worksites NNS N
showed VBD N
a DT N
6.5 CD N
% NN N
drop NN N
in IN N
cholesterol NN o
, , N
whereas IN N
those DT N
at IN N
the DT N
usual JJ N
intervention NN N
worksites NNS N
showed VBD N
a DT N
drop NN N
of IN N
only RB N
3.0 CD N
% NN N
. . N

Hence NNP N
a DT N
3.5 CD N
% NN N
cholesterol NN o
reduction NN o
was VBD N
attributable JJ N
to TO N
the DT N
special JJ N
intervention NN N
. . N

CONCLUSIONS VB N
A NNP N
behaviorally RB i
based VBN i
nutrition JJ i
education NN i
program NN i
following VBG N
cholesterol NN N
screening VBG N
can MD N
have VB N
a DT N
meaningful JJ N
impact NN N
on IN N
long-term JJ N
cholesterol NN N
levels NNS N
at IN N
a DT N
low JJ N
cost NN N
. . N

Nutrition NNP i
education NN i
in IN N
work-sites NNS N
may MD N
therefore RB N
be VB N
a DT N
useful JJ N
way NN N
to TO N
lower VB N
the DT N
risk NN N
of IN N
heart NN N
disease NN N
in IN N
communities NNS N
. . N

-DOCSTART- -15051597- O O

LDL NNP N
cholesterol-raising JJ N
effect NN N
of IN N
low-dose JJ N
docosahexaenoic NN i
acid NN i
in IN N
middle-aged JJ p
men NNS p
and CC p
women NNS p
. . p

BACKGROUND NNP N
Long-chain JJ N
n-3 JJ N
polyunsaturated VBN N
fatty JJ N
acids NNS N
have VBP N
variable JJ N
effects NNS N
on IN N
LDL NNP N
cholesterol NN N
, , N
and CC N
the DT N
effects NNS N
of IN N
docosahexaenoic NN i
acid NN i
( ( i
DHA NNP i
) ) i
are VBP N
uncertain JJ N
. . N

OBJECTIVE IN N
The DT N
objective NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
effect NN o
on IN o
blood NN o
lipids NNS o
of IN N
a DT N
daily JJ N
intake NN N
of IN N
0.7 CD N
g JJ N
DHA NNP i
as IN N
triacylglycerol NN N
in IN N
middle-aged JJ p
men NNS p
and CC p
women NNS p
. . p

DESIGN NNP N
Men NNP p
and CC p
women NNS p
aged VBN p
40-65 JJ p
y NN p
( ( p
n JJ p
= NNP p
38 CD p
) ) p
underwent NN p
a DT p
double-blind NN p
, , p
randomized VBN p
, , p
placebo-controlled JJ i
, , p
crossover JJ p
trial NN p
of IN p
treatment NN p
with IN p
0.7 CD p
g NNS p
DHA/d NNP i
for IN p
3 CD p
mo NNS p
. . p

RESULTS NNP N
DHA NNP N
supplementation NN N
increased VBD o
the DT N
DHA NNP o
concentration NN o
in IN o
plasma NN o
by IN N
76 CD N
% NN N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
and CC N
the DT N
proportion NN o
in IN o
erythrocyte JJ o
lipids NNS o
by IN N
58 CD N
% NN N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

Values NNS N
for IN N
serum NN o
total JJ o
cholesterol NN o
, , o
LDL NNP o
cholesterol NN o
, , o
and CC o
plasma NN o
apolipoprotein NN o
B NNP o
concentrations NNS o
were VBD N
4.2 CD N
% NN N
( ( N
0.22 CD N
mmol/L NN N
; : N
P NNP N
= NNP N
0.04 CD N
) ) N
, , N
7.1 CD N
% NN N
( ( N
0.23 CD N
mmol/L NN N
; : N
P NNP N
= NNP N
0.004 CD N
) ) N
, , N
and CC N
3.4 CD N
% NN N
( ( N
P NNP N
= NNP N
0.03 CD N
) ) N
higher JJR N
, , N
respectively RB N
, , N
with IN N
DHA NNP i
treatment NN N
than IN N
with IN N
placebo NN i
. . i

In IN N
addition NN N
, , N
the DT N
LDL NNP o
cholesterol NN o
: : o
apolipoprotein NN o
B NNP o
ratio NN o
was VBD N
3.1 CD N
% NN N
higher JJR N
with IN N
DHA NNP N
treatment NN N
than IN N
with IN N
placebo NN i
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
, , N
which WDT N
suggested VBD N
an DT N
increase NN o
in IN o
LDL NNP o
size NN o
. . o

Plasma NNP o
lathosterol NN o
and CC o
plant NN o
sterol NN o
concentrations NNS o
were VBD N
unaffected VBN N
by IN N
treatment NN N
. . N

CONCLUSION VB N
A DT N
daily JJ N
intake NN N
of IN N
approximately RB N
0.7 CD N
g JJ N
DHA NNP i
increases VBZ o
LDL NNP o
cholesterol NN o
by IN N
7 CD N
% NN N
in IN N
middle-aged JJ p
men NNS p
and CC p
women NNS p
. . p

It PRP N
is VBZ N
suggested VBN N
that IN N
DHA NNP i
down-regulates VBZ N
the DT N
expression NN N
of IN N
the DT N
LDL NNP N
receptor NN N
. . N

-DOCSTART- -12402011- O O

Preliminary JJ N
findings NNS N
from IN N
a DT N
prospective JJ N
, , N
randomized JJ N
trial NN N
of IN N
two CD N
palatal JJ i
operations NNS i
for IN N
sleep-disordered JJ N
breathing NN N
. . N

OBJECTIVES IN N
We PRP N
compared VBN N
the DT N
efficacy NN o
of IN N
2 CD i
palatal JJ i
surgical JJ i
procedures NNS i
in IN N
the DT N
treatment NN N
of IN N
patients NNS p
with IN p
mild JJ p
sleep-disordered JJ p
breathing NN p
( ( p
SDB NNP p
) ) p
. . p

STUDY NNP N
DESIGN NNP N
AND NNP N
SETTING NNP N
We PRP N
conducted VBD N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
crossover RB N
surgical JJ N
trial NN N
at IN N
a DT N
university NN N
hospital NN N
. . N

METHODS NNP N
Twenty NNP p
patients NNS p
with IN p
mild JJ p
SDB NNP p
for IN p
whom WP p
conservative JJ p
treatment NN p
failed VBD p
were VBD N
identified VBN N
and CC N
consecutively RB N
enrolled VBD N
into IN N
an DT N
institutional JJ N
review NN N
board-approved JJ N
surgical JJ N
protocol NN N
. . N

They PRP N
were VBD N
randomly RB N
assigned VBN N
to TO N
undergo VB N
either DT N
radiofrequency NN i
ablation NN i
of IN i
the DT i
palate NN i
( ( i
RFAP NNP i
) ) i
for IN i
a DT i
planned JJ i
3-stage JJ i
treatment NN i
or CC i
laser-assisted JJ i
uvulopalatoplasty JJ i
( ( i
LAUP NNP i
) ) i
, , i
also RB i
for IN i
3 CD i
stages NNS i
of IN i
treatment NN i
, , i
using VBG i
a DT i
CO NNP i
( ( i
2 CD i
) ) i
laser NN i
. . i

Parameters NNS N
assessed VBD N
included JJ N
severity NN o
of IN o
SDB NNP o
( ( o
polysomnography NN o
) ) o
, , o
subjective JJ o
and CC o
objective JJ o
loudness NN o
of IN o
snoring VBG o
( ( o
visual JJ o
analog NN o
scale NN o
and CC o
SNAP NNP o
recording NN o
) ) o
, , o
sleepiness NN o
( ( o
Epworth NNP o
Sleepiness NNP o
Scale NNP o
) ) o
, , N
and CC N
anatomic JJ o
changes NNS o
( ( o
upper JJ o
airway RB o
endoscopy NN o
) ) o
, , N
as RB N
well RB N
as IN N
demographic JJ N
factors NNS N
. . N

Patients NNS N
not RB N
achieving VBG N
satisfactory JJ N
improvement NN N
in IN N
their PRP$ N
condition NN N
were VBD N
crossed VBN N
over IN N
to TO N
the DT N
alternative JJ i
surgical JJ i
therapy NN i
for IN i
attempted JJ i
salvage NN i
. . i

RESULTS NNP N
Seventeen NNP N
of IN N
the DT N
enrolled JJ N
patients NNS N
have VBP N
completed VBN N
the DT N
protocol NN N
. . N

Ten CD N
of IN N
these DT N
were VBD N
randomized VBN N
to TO N
the DT N
RFAP NNP i
group NN N
, , N
and CC N
7 CD N
to TO N
the DT N
LAUP NNP i
group NN N
. . N

Six CD N
of IN N
the DT N
RFAP NNP i
patients NNS N
( ( N
60 CD N
% NN N
) ) N
achieved VBD N
a DT N
satisfactory JJ N
resolution NN N
of IN N
their PRP$ N
snoring NN o
, , N
and CC N
4 CD N
failed VBD N
and CC N
were VBD N
salvaged VBN N
with IN N
LAUP NNP i
. . i

Six NNP N
of IN N
the DT N
LAUP NNP i
patients NNS N
( ( N
86 CD N
% NN N
) ) N
achieved VBD N
a DT N
satisfactory JJ N
resolution NN N
of IN N
their PRP$ N
snoring NN o
, , N
and CC N
1 CD N
patient NN N
failed VBD N
and CC N
was VBD N
salvaged VBN N
with IN N
nasal JJ i
surgery NN i
. . i

One CD N
patient NN N
who WP N
was VBD N
initially RB N
cured VBN N
had VBD N
a DT N
relapse NN N
after IN N
9 CD N
months NNS N
and CC N
was VBD N
successfully RB N
salvaged VBN N
with IN N
RFA NNP i
. . i

CONCLUSION NNP N
Prospective NNP N
, , N
randomized VBD N
trials NNS N
of IN N
surgery NN N
for IN N
SDB NNP N
are VBP N
possible JJ N
. . N

Preliminary JJ N
findings NNS N
from IN N
the DT N
current JJ N
protocol NN N
reveal NN N
a DT N
slight JJ N
advantage NN N
of IN N
LAUP NNP i
over IN N
RFAP NNP i
but CC N
with IN N
a DT N
greater JJR N
degree NN N
of IN N
discomfort NN N
postoperatively RB N
. . N

-DOCSTART- -19470807- O O

Randomized NNP N
clinical JJ N
trial NN N
of IN N
balance-based JJ N
torso NN i
weighting VBG i
for IN N
improving VBG N
upright JJ o
mobility NN o
in IN N
people NNS p
with IN p
multiple JJ p
sclerosis NN p
. . p

BACKGROUND NNP N
Torso NNP N
weighting NN N
has VBZ N
sometimes RB N
been VBN N
effective JJ N
for IN N
improving VBG N
upright JJ o
mobility NN o
in IN N
people NNS p
with IN p
multiple JJ p
sclerosis NN p
, , N
but CC N
parameters NNS o
for IN o
weighting VBG o
have VBP N
been VBN N
inconsistent JJ N
. . N

OBJECTIVE NN N
To TO N
determine VB N
whether IN N
balance-based JJ i
torso NN i
weighting NN i
( ( i
BBTW NNP i
) ) i
has VBZ N
immediate JJ N
effects NNS N
on IN N
upright JJ N
mobility NN N
in IN N
people NNS N
with IN N
multiple JJ p
sclerosis NN p
. . p

METHODS NNP N
This DT N
was VBD N
a DT N
2-phase JJ N
randomized JJ N
clinical JJ N
trial NN N
. . N

In IN p
phase NN p
1 CD p
, , p
36 CD p
participants NNS p
were VBD p
randomly RB p
assigned VBN p
to TO p
experimental VB p
and CC p
control VB p
groups NNS p
. . p

In IN N
phase NN p
2 CD p
, , p
the DT p
control NN p
group NN p
was VBD N
subsequently RB N
randomized VBN N
into IN N
2 CD N
groups NNS N
with IN N
alternate JJ N
weight-placement JJ N
. . N

Tests NNS N
of IN N
upright JJ o
mobility NN o
included VBD N
: : N
timed VBN o
up RP o
and CC o
go VB o
( ( o
TUG NNP o
) ) o
, , o
sharpened VBD o
Romberg NNP o
, , o
360-degree JJ o
turns NNS o
, , o
25-foot JJ o
walk NN o
, , o
and CC o
computerized JJ o
platform NN o
posturography NN o
. . o

Participants NNS N
were VBD N
tested VBN N
at IN N
baseline NN N
and CC N
again RB N
with IN N
weights NNS N
placed VBN N
according VBG N
to TO N
group NN N
membership NN N
. . N

In IN N
both DT N
phases NNS N
, , N
a DT N
physical JJ N
therapist NN N
assessed VBD N
balance NN N
for IN N
the DT N
BBTW NNP N
group NN N
and CC N
then RB N
placed VBD N
weights NNS N
to TO N
decrease VB N
balance NN o
loss NN o
. . o

In IN N
phase NN N
1 CD N
, , N
the DT N
control NN N
group NN N
had VBD N
no DT N
weights NNS N
placed VBN N
. . N

In IN N
phase NN N
2 CD N
, , N
the DT N
alternate NN N
treatment NN N
group NN N
received VBD N
standard JJ N
weight JJ N
placement NN N
of IN N
1.5 CD N
% NN N
body NN N
weight NN N
. . N

RESULTS JJ N
People NNS N
with IN N
BBTW NNP i
showed VBD N
a DT N
significant JJ N
improvement NN N
in IN N
the DT N
25-foot JJ o
walk NN o
( ( N
P NNP N
= NNP N
.01 NNP N
) ) N
over IN N
those DT N
with IN N
no DT N
weight NN N
, , N
and CC N
the DT N
TUG NNP o
( ( N
P NNP N
= NNP N
.01 NNP N
) ) N
over IN N
those DT N
with IN N
standard JJ N
weight NN N
placement NN N
. . N

BBTW NNP N
participants NNS N
received VBD N
an DT N
average NN N
of IN N
0.5 CD N
kg NNS o
, , N
less JJR N
than IN N
1.5 CD N
% NN N
of IN N
any DT N
participant NN N
's POS N
body NN N
weight NN N
. . N

CONCLUSION NNP N
BBTW NNP i
can MD N
have VB N
immediate JJ N
advantages NNS N
over IN N
a DT N
nonweighted JJ N
condition NN N
for IN N
gait NN o
velocity NN o
and CC N
over IN N
a DT N
standardized JJ N
weighted JJ N
condition NN N
for IN N
a DT N
functional JJ o
activity NN o
in IN N
people NNS p
with IN p
multiple JJ p
sclerosis NN p
( ( p
MS NNP p
) ) p
who WP N
are VBP N
ambulatory JJ N
but CC N
have VBP N
balance NN N
and CC N
mobility NN N
abnormalities NNS N
. . N

-DOCSTART- -8453557- O O

Adjuvant NNP N
cyclophosphamide NN i
, , i
doxorubicin NN i
, , i
vincristine NN i
, , i
and CC i
prednisone NN i
chemotherapy NN i
after IN N
radiation NN N
therapy NN N
in IN N
stage NN p
I PRP p
low-grade JJ p
and CC p
intermediate-grade JJ p
non-Hodgkin JJ p
lymphoma NN p
. . p

Results NNS N
of IN N
a DT N
prospective JJ N
randomized NN N
study NN N
. . N

BACKGROUND NNP N
In IN N
a DT N
prospective JJ N
randomized NN N
manner NN N
, , N
this DT N
study NN N
evaluated VBD N
the DT N
effect NN N
of IN N
adjuvant JJ i
chemotherapy NN i
( ( i
cyclophosphamide NN i
, , i
doxorubicin NN i
, , i
vincristine NN i
, , i
and CC i
prednisone NN i
; : i
CHOP NNP i
) ) i
in IN N
patients NNS p
with IN p
Stage NNP p
I PRP p
non-Hodgkin JJ p
lymphoma NN p
( ( p
NHL NNP p
) ) p
who WP p
have VBP p
achieved VBN p
a DT p
complete JJ p
response NN p
( ( p
CR NNP p
) ) p
after IN p
radiation NN p
therapy NN p
( ( p
RT NNP p
) ) p
. . p

METHODS NNP N
Forty-four JJ p
patients NNS p
with IN p
clinical JJ p
or CC p
pathologic JJ p
Stage NN p
I PRP p
intermediate-grade VBP p
or CC p
low-grade JJ p
NHL NNP p
were VBD N
randomized VBN N
to TO N
receive VB i
regional JJ i
RT NNP i
alone RB i
( ( i
median JJ i
dose NN i
, , i
40 CD i
Gy NNP i
) ) i
or CC i
regional JJ i
RT NNP i
followed VBN i
by IN i
six CD i
cycles NNS i
of IN i
CHOP NNP i
chemotherapy NN i
. . i

There EX N
were VBD N
no DT N
differences NNS N
in IN N
clinical JJ N
and CC N
pathologic JJ N
characteristics NNS o
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
. . N

RESULTS VB N
The DT N
median JJ o
follow-up NN o
was VBD N
7 CD N
years NNS N
( ( N
range NN N
, , N
2-10 JJ N
years NNS N
) ) N
. . N

The DT N
actuarial JJ o
relapse-free JJ o
survival NN o
( ( o
RFS NNP o
) ) o
rate NN o
for IN N
the DT N
RT NNP N
plus CC N
CHOP NNP N
group NN N
at IN N
7 CD N
years NNS N
was VBD N
83 CD N
% NN N
compared VBN N
with IN N
47 CD N
% NN N
( ( N
P NNP N
< NNP N
0.03 CD N
) ) N
for IN N
the DT N
RT-alone NNP N
group NN N
. . N

The DT N
overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
for IN N
the DT N
two CD N
groups NNS N
was VBD N
88 CD N
% NN N
and CC N
66 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
0.2 CD N
) ) N
. . N

In IN N
patients NNS N
with IN N
intermediate-grade JJ N
NHL NNP N
, , N
the DT N
7-year JJ o
actuarial JJ o
RFS NNP o
for IN N
RT NNP N
and CC N
CHOP NNP N
was VBD N
86 CD N
% NN N
compared VBN N
with IN N
20 CD N
% NN N
for IN N
RT NNP N
alone RB N
( ( N
P NNP N
= NNP N
0.004 CD N
) ) N
. . N

The DT N
corresponding JJ o
actuarial JJ o
survival NN o
rates NNS o
were VBD N
92 CD N
% NN N
and CC N
47 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
0.08 CD N
) ) N
. . N

In IN N
patients NNS N
with IN N
low-grade JJ N
histologic JJ N
findings NNS N
, , N
the DT N
addition NN N
of IN N
adjuvant JJ N
CHOP NNP i
did VBD N
not RB N
improve VB N
RFS NNP o
( ( N
P NNP N
= NNP N
0.6 CD N
) ) N
or CC N
OS NNP N
. . N

All DT N
relapses VBZ N
in IN N
this DT N
study NN N
were VBD N
at IN N
sites NNS N
remote VBP N
from IN N
the DT N
initially RB N
involved JJ N
areas NNS N
, , N
and CC N
in IN N
5 CD N
of IN N
11 CD N
patients NNS N
( ( N
45 CD N
% NN N
) ) N
, , N
there EX N
were VBD N
recurrences NNS N
5 CD N
years NNS N
or CC N
longer JJR N
after IN N
initial JJ N
treatment NN N
. . N

CONCLUSIONS VB N
This DT N
study NN N
showed VBD N
that IN N
adjuvant JJ N
CHOP NNP i
chemotherapy NN i
significantly RB N
improves VBZ N
RFS NNP N
in IN N
patients NNS N
with IN N
Stage NNP N
I PRP N
intermediate-grade VBP N
NHL NNP N
who WP N
achieve VBP N
a DT N
CR NNP N
after IN N
regional-field JJ N
RT NNP N
. . N

The DT N
chemotherapeutic JJ N
regimen NNS N
favorably RB N
affected VBD N
their PRP$ N
probability NN o
of IN N
survival NN o
. . o

-DOCSTART- -10077140- O O

Switching VBG N
patients NNS p
with IN p
asthma NN p
from IN N
chlorofluorocarbon NN N
( ( N
CFC NNP N
) ) N
albuterol NN N
to TO N
hydrofluoroalkane-134a NN i
( ( i
HFA NNP i
) ) i
albuterol NN i
. . i

Chlorofluorocarbon NNP N
( ( N
CFC NNP N
) ) N
propellants VBZ N
deplete JJ N
stratospheric JJ N
ozone NN N
. . N

Production NN N
and CC N
use NN N
of IN N
CFCs NNS N
, , N
except IN N
for IN N
certain JJ N
critical JJ N
exemptions NNS N
, , N
has VBZ N
been VBN N
prohibited VBN N
by IN N
the DT N
Montreal NNP N
Protocol NNP N
. . N

Use NNP N
of IN N
CFCs NNPS N
as IN N
propellants NNS N
in IN N
metered-dose JJ N
inhalers NNS N
( ( N
MDIs NNP N
) ) N
is VBZ N
still RB N
allowed VBN N
, , N
but CC N
the DT N
U.S. NNP N
Food NNP N
and CC N
Drug NNP N
Administration NNP N
is VBZ N
planning VBG N
the DT N
transition NN N
to TO N
alternative JJ N
propellants NNS N
for IN N
use NN N
in IN N
MDIs NNP N
. . N

Hydrofluoroalkane-134a NNP i
( ( i
HFA NNP i
) ) i
, , N
a DT N
non-ozone-depleting JJ N
propellant NN N
, , N
has VBZ N
been VBN N
used VBN N
to TO N
reformulate VB N
albuterol NN N
( ( N
HFA NNP N
albuterol NN N
) ) N
. . N

This DT N
study NN N
evaluates VBZ N
whether IN N
comparable JJ N
safety NN N
and CC N
efficacy NN N
continues VBZ N
for IN N
12 CD N
weeks NNS N
after IN N
patients NNS p
with IN p
asthma NNS p
are VBP N
switched VBN i
from IN i
CFC NNP i
albuterol NN i
to TO i
HFA NNP i
albuterol NN i
. . i

Patients NNS p
with IN p
asthma JJ p
stabilized VBN p
on IN p
CFC NNP p
albuterol NN p
during IN N
a DT N
12-week JJ N
safety NN N
and CC N
efficacy NN N
trial NN N
were VBD N
randomized VBN N
to TO N
either DT i
continue NN i
receiving VBG i
CFC NNP i
albuterol NN i
or CC i
to TO i
be VB i
switched VBN i
to TO i
receive VB i
HFA NNP i
albuterol NN i
in IN i
a DT i
yearlong JJ i
safety NN i
and CC i
efficacy NN i
trial NN i
. . i

Safety NN o
and CC o
efficacy NN o
were VBD N
compared VBN N
over IN N
the DT N
first JJ N
12 CD N
weeks NNS N
of IN N
the DT N
yearlong JJ N
trial NN N
between IN N
patients NNS N
who WP N
had VBD N
remained VBN N
on IN N
CFC NNP N
albuterol NN N
and CC N
those DT N
who WP N
had VBD N
been VBN N
switched VBN N
to TO N
HFA NNP N
albuterol NN N
. . N

Bronchodilator NNP o
efficacy NN o
was VBD N
evaluated VBN N
by IN N
serial JJ o
spirometry NN o
for IN N
6 CD N
hr NN N
after IN N
the DT N
patients NNS N
self-administered VBD N
the DT N
study NN N
drug NN N
in IN N
the DT N
clinic NN N
. . N

Safety NNP o
was VBD N
assessed VBN N
by IN N
measuring VBG N
changes NNS o
in IN o
pulse JJ o
rate NN o
, , o
blood NN o
pressure NN o
, , o
and CC o
electrocardiogram NN o
( ( o
ECG NNP o
) ) o
intervals NNS o
after IN N
dosing VBG N
with IN N
study JJ N
drug NN N
, , N
monitoring VBG o
adverse JJ o
events NNS o
, , N
and CC N
performing VBG N
prestudy NN N
and CC N
poststudy NN N
laboratory NN o
testing NN o
and CC o
physical JJ o
examinations NNS o
. . o

No DT N
significant JJ N
differences NNS N
in IN N
bronchodilator NN o
efficacy NN o
between IN N
the DT N
patients NNS N
continuing VBG N
to TO N
receive VB N
CFC NNP N
albuterol NN N
and CC N
those DT N
switched VBN N
to TO N
HFA NNP i
albuterol NN i
were VBD N
found VBN N
in IN N
the DT N
12 CD N
weeks NNS N
after IN N
the DT N
switch NN N
. . N

No DT N
differences NNS N
between IN N
the DT N
two CD N
products NNS N
were VBD N
found VBN N
for IN N
changes NNS N
in IN N
pulse JJ o
rate NN o
, , o
blood NN o
pressure NN o
, , o
and CC o
ECG NNP o
intervals NNS o
. . o

Adverse JJ o
event NN o
profiles NNS o
were VBD N
similar JJ N
for IN N
the DT N
two CD N
products NNS N
, , N
except IN N
the DT N
patients NNS N
remaining VBG N
on IN N
CFC NNP N
albuterol NN N
reported VBD N
increased JJ N
asthma NN N
symptoms NNS N
and CC N
rhinitis VB N
significantly RB N
more RBR N
often RB N
than IN N
the DT N
patients NNS N
switched VBD N
to TO N
HFA NNP N
albuterol NN N
. . N

No DT N
clinically RB N
meaningful JJ N
changes NNS o
in IN N
laboratory NN N
tests NNS N
or CC N
physical JJ N
examinations NNS N
were VBD N
found VBN N
in IN N
either DT N
treatment NN N
group NN N
. . N

Patients NNS p
with IN p
asthma JJ p
switched VBN N
from IN N
CFC NNP N
albuterol NN N
to TO N
HFA NNP i
albuterol NN i
receive VBP N
comparable JJ N
bronchodilation NN N
with IN N
a DT N
similar JJ N
safety NN N
profile NN N
as IN N
those DT N
continuing VBG N
to TO N
receive VB N
CFC NNP N
albuterol NN N
. . N

-DOCSTART- -12718385- O O

A DT N
randomized JJ N
trial NN N
comparing VBG N
intravesical JJ i
instillations NNS i
of IN N
mitoxantrone NN i
and CC i
doxorubicin NN i
in IN N
patients NNS p
with IN p
superficial JJ p
bladder NN p
cancer NN p
. . p

BACKGROUND NNP N
This DT N
randomized JJ N
trial NN N
was VBD N
conducted VBN N
to TO N
compare VB N
the DT N
efficacy NN o
and CC N
side JJ o
effects NNS o
of IN N
intravesical JJ i
mitoxantrone NN i
instillation NN i
with IN N
those DT N
of IN N
doxorubicin NN i
in IN N
superficial JJ p
bladder NN p
cancer NN p
following VBG p
transurethral JJ p
resection NN p
. . p

METHODS NNP N
Sixty-three JJ p
patients NNS p
were VBD p
randomized VBN p
into IN N
mitoxantrone NN i
and CC i
doxorubicin NN i
groups NNS N
. . N

Most JJS N
of IN N
the DT N
patients NNS p
enrolled VBN p
were VBD p
elderly JJ p
people NNS p
( ( p
mean JJ p
age NN p
, , p
71 CD p
years NNS p
) ) p
. . p

The DT N
instilled JJ N
doses NNS N
of IN N
doxorubicin NN i
and CC i
mitoxantrone NN i
were VBD N
30 CD N
and CC N
14 CD N
mg NN N
, , N
respectively RB N
. . N

Disease NNP o
recurrence NN o
and CC o
side NN o
effects NNS o
were VBD N
compared VBN N
using VBG N
Fisher NNP N
's POS N
exact JJ N
test NN N
. . N

The DT N
interval NN o
to TO o
recurrence NN o
was VBD N
shown VBN N
by IN N
Kaplan-Meier NNP N
survivorship NN N
curves NNS N
, , N
and CC N
the DT N
log-rank JJ N
test NN N
was VBD N
used VBN N
to TO N
compare VB N
the DT N
time NN o
to TO o
recurrence VB o
. . o

RESULTS VB N
The DT N
median JJ N
follow-up JJ N
period NN N
was VBD N
36 CD N
months NNS N
. . N

Thirty-three JJ N
patients NNS N
received VBD N
mitoxantrone NN i
, , N
whereas JJ N
30 CD N
patients NNS N
used VBN N
doxorubicin NN i
. . i

The DT N
recurrence NN o
rate NN o
in IN N
the DT N
doxorubicin NN i
group NN N
was VBD N
30 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
: : N
19.8 CD N
% NN N
-38.8 NNP N
% NN N
) ) N
, , N
while IN N
it PRP N
was VBD N
27.3 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
: : N
17.5 CD N
% NN N
-36.8 NNP N
% NN N
) ) N
in IN N
the DT N
mitoxantrone NN i
group NN N
. . N

The DT N
median JJ o
recurrence-free JJ o
survival NN o
in IN N
the DT N
mitoxantrone NN i
group NN N
and CC N
in IN N
the DT N
doxorubicin NN i
group NN N
was VBD N
22 CD N
and CC N
20 CD N
months NNS N
, , N
respectively RB N
( ( N
p=0.580 NN N
) ) N
. . N

Higher JJR N
recurrence NN o
rates NNS o
were VBD N
found VBN N
for IN N
Grade NNP N
III NNP N
and CC N
multiple JJ N
primary JJ N
tumors NNS N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
response NN o
rates NNS o
( ( N
p=0.784 NN N
) ) N
. . N

The DT N
incidence NN N
of IN N
side NN o
effects NNS o
was VBD N
20 CD N
% NN N
in IN N
the DT N
doxorubicin NN i
group NN N
and CC N
21.2 CD N
% NN N
in IN N
the DT N
mitoxantrone NN i
group NN N
. . N

However RB N
, , N
the DT N
difference NN N
was VBD N
not RB N
significant JJ N
( ( N
p JJ N
> NNP N
0.99 CD N
) ) N
. . N

CONCLUSIONS VB N
The DT N
results NNS N
revealed VBD N
that IN N
the DT N
efficacy NN o
and CC o
side JJ o
effects NNS o
of IN N
mitoxantrone NN i
were VBD N
similar JJ N
to TO N
those DT N
of IN N
doxorubicin NN i
. . i

Especially RB N
for IN N
patients NNS p
with IN p
pulmonary JJ p
tuberculosis NN p
or CC p
aged VBN p
patients NNS p
with IN p
primary JJ p
bladder NN p
tumors NNS p
, , N
mitoxantrone NN i
and CC N
doxorubicin NN i
may MD N
be VB N
the DT N
tolerable JJ N
and CC N
effective JJ N
intravesical JJ N
agents NNS N
. . N

-DOCSTART- -24713181- O O

Effect NN N
of IN N
body NN i
mass NN i
index NN i
on IN N
hemiparetic JJ N
gait NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
relationship NN N
between IN N
body NN i
mass NN i
index NN i
( ( i
BMI NNP i
) ) i
and CC N
spatiotemporal JJ o
, , o
kinematic JJ o
, , o
and CC o
kinetic JJ o
gait NN o
parameters NNS o
in IN N
chronic JJ p
hemiparetic JJ p
stroke NN p
survivors NNS p
. . p

DESIGN NNP N
Secondary JJ N
analysis NN N
of IN N
data NNS N
collected VBN N
in IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
comparing VBG N
two CD N
12-week JJ N
ambulation NN i
training NN i
treatments NNS i
. . i

SETTING NN N
Academic NNP N
medical JJ N
center NN N
. . N

PARTICIPANTS NNP N
Chronic NNP p
hemiparetic JJ p
stroke NN p
survivors NNS p
( ( p
N NNP p
= NNP p
108 CD p
, , p
> RB p
3 CD p
months NNS p
poststroke RB p
) ) p
METHODS NNP N
Linear NNP i
regression NN i
analyses NNS i
were VBD i
performed VBN i
of IN i
BMI NNP i
, , i
and CC i
selected VBN i
pretreatment JJ i
gait NN i
parameters NNS i
were VBD i
recorded VBN i
using VBG i
quantitative JJ i
gait NN i
analysis NN i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Spatiotemporal NNP o
, , o
kinematic JJ o
, , o
and CC o
kinetic JJ o
gait NN o
parameters NNS o
. . o

RESULTS VB N
A NNP N
series NN N
of IN N
linear JJ N
regression NN N
models NNS N
that WDT N
controlled VBD N
for IN N
age NN N
, , N
gender NN N
, , N
stroke VBD N
type NN N
( ( N
ischemic JJ N
versus NN N
hemorrhagic NN N
) ) N
, , N
interval JJ N
poststroke NN N
, , N
level NN N
of IN N
motor NN N
impairment NN N
( ( N
Fugl-Meyer NNP N
score NN N
) ) N
, , N
and CC N
walking VBG N
speed NN N
found VBD N
BMI NNP N
to TO N
be VB N
positively RB N
associated VBN N
with IN N
step NN N
width NN N
( ( N
m NN N
) ) N
( ( N
? . N
= RB N
0.364 CD N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
positively RB N
associated VBN N
with IN o
peak JJ o
hip NN o
abduction NN o
angle NN o
of IN o
the DT o
nonparetic JJ o
limb NN o
during IN N
stance NN N
( ( N
deg NN N
) ) N
( ( N
? . N
= RB N
0.177 CD N
, , N
P NNP N
= NNP N
.040 NNP N
) ) N
, , N
negatively RB N
associated VBN N
with IN o
ankle JJ o
dorsiflexion NN o
angle NN o
at IN o
initial JJ N
contact NN N
of IN N
the DT N
paretic JJ N
limb NN N
( ( N
deg NN N
) ) N
( ( N
? . N
= NN N
-0.222 NN N
, , N
P NNP N
= NNP N
.023 NNP N
) ) N
, , N
and CC N
negatively RB N
associated VBN N
with IN o
peak NN o
ankle JJ o
power NN o
at IN o
push-off NN o
( ( o
W/kg NNP o
) ) N
of IN N
the DT N
paretic JJ N
limb NN N
( ( N
W/kg NNP N
) ) N
( ( N
? . N
= NN N
-0.142 NN N
, , N
P NNP N
= NNP N
.026 NNP N
) ) N
. . N

CONCLUSIONS NNP N
When WRB N
walking VBG N
at IN N
a DT N
similar JJ N
speed NN p
, , p
chronic JJ p
hemiparetic JJ p
stroke NN p
subjects NNS p
with IN p
a DT p
higher JJR o
BMI NNP o
demonstrated VBD N
greater JJR o
step NN o
width NN o
, , o
greater JJR o
hip NN o
hiking NN o
of IN o
the DT o
paretic JJ o
lower JJR o
limb NN o
, , o
less RBR o
paretic JJ o
limb NN o
dorsiflexion NN o
at IN o
initial JJ o
contact NN o
, , o
and CC o
less RBR N
paretic JJ o
ankle NN o
power NN o
at IN o
push-off NN o
as IN o
compared VBN N
to TO N
stroke VB N
subjects NNS N
with IN N
a DT N
lower JJR N
BMI NNP N
and CC N
similar JJ N
level NN N
of IN N
motor NN N
impairment NN N
. . N

Further JJ N
studies NNS N
are VBP N
necessary JJ N
to TO N
determine VB N
the DT N
clinical JJ N
relevance NN N
of IN N
these DT N
findings NNS N
with IN N
respect NN N
to TO N
rehabilitation NN N
strategies NNS N
for IN N
gait JJ N
dysfunction NN p
in IN p
hemiparetic JJ p
patients NNS p
with IN p
higher JJR p
BMIs NNP p
. . p

-DOCSTART- -23827399- O O

Percutaneous JJ i
coronary JJ i
intervention NN i
in IN N
patients NNS p
with IN p
previous JJ p
coronary JJ p
artery NN p
bypass NN p
grafting NN p
( ( p
from IN p
the DT p
j-Cypher JJ p
Registry NNP p
) ) p
. . p

A DT N
paucity NN N
of IN N
data NNS N
is VBZ N
available JJ N
from IN N
large-scale JJ N
studies NNS N
evaluating VBG N
the DT N
long-term JJ N
outcomes NNS N
of IN N
percutaneous JJ i
coronary JJ i
intervention NN i
in IN N
patients NNS p
who WP p
had VBD p
previously RB p
undergone JJ p
coronary JJ i
artery NN i
bypass NN i
grafting NN i
( ( i
CABG NNP i
) ) i
in IN p
the DT p
drug-eluting JJ p
stent NN p
era NN p
. . p

Of IN N
12,812 CD p
patients NNS p
who WP p
had VBD p
undergone JJ p
sirolimus-eluting JJ p
stent NN p
implantation NN p
in IN p
the DT p
j-Cypher JJ p
registry NN p
, , p
919 CD p
( ( p
7.2 CD p
% NN p
) ) p
had VBD p
a DT p
history NN p
of IN p
CABG NNP p
and CC p
had VBD p
significantly RB p
higher JJR p
crude JJ o
5-year JJ o
mortality NN o
( ( p
19.9 CD p
% NN p
vs JJ p
14.0 CD p
% NN p
, , p
p NN p
< NNP p
0.001 CD p
) ) p
. . p

After IN N
adjusting VBG N
for IN N
confounders NNS N
, , N
the DT o
excess JJ o
risk NN o
of IN o
death NN o
was VBD N
no RB N
longer RBR N
significant JJ N
( ( N
hazard JJ N
ratio NN N
0.99 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
0.83 CD N
to TO N
1.18 CD N
, , N
p NN N
= NNP N
0.90 CD N
) ) N
, , N
and CC N
the DT N
adjusted VBN o
risk NN o
of IN o
target NN o
lesion NN o
revascularization NN o
was VBD o
significantly RB N
higher JJR N
in IN N
patients NNS p
with IN p
previous JJ p
CABG NNP p
than IN p
in IN N
those DT N
without IN N
( ( N
hazard NN N
ratio NN N
1.25 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
1.06 CD N
to TO N
1.47 CD N
, , N
p NN N
= NNP N
0.01 CD N
) ) N
. . N

Of IN N
the DT N
patients NNS p
with IN p
previous JJ p
CABG NNP p
, , p
those DT p
who WP N
had VBD N
undergone JJ N
?1 NNP N
saphenous JJ N
vein NN N
graft NN N
intervention NN N
had VBD N
significantly RB N
higher JJR o
adjusted JJ o
risks NNS o
of IN o
cardiac JJ o
death NN o
( ( o
hazard JJ o
ratio NN N
2.21 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
1.26 CD N
to TO N
3.76 CD N
, , N
p NN N
= NNP N
0.01 CD N
) ) N
, , N
myocardial JJ o
infarction NN o
( ( o
hazard JJ o
ratio NN N
2.56 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
1.10 CD N
to TO N
5.60 CD N
, , N
p NN N
= NNP N
0.03 CD N
) ) N
, , N
target NN o
lesion NN o
revascularization NN o
( ( o
hazard JJ o
ratio NN N
2.65 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
1.82 CD N
to TO N
3.81 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , o
and CC o
definite JJ o
stent NN o
thrombosis NN o
( ( o
hazard JJ o
ratio NN N
7.70 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
1.99 CD N
to TO N
29.1 CD N
, , N
p NN N
= NNP N
0.004 CD N
) ) N
compared VBN N
with IN N
those DT N
who WP N
underwent VBP i
percutaneous JJ i
coronary JJ i
intervention NN i
only RB i
for IN i
the DT N
native JJ N
coronary JJ N
artery NN N
. . N

In IN N
conclusion NN o
, , o
the DT o
adjusted JJ o
mortality NN o
was VBD o
similar JJ o
between IN N
patients NNS N
with IN N
and CC N
without IN N
previous JJ N
CABG NNP N
, , N
despite IN N
a DT N
significantly RB N
different JJ o
risk NN o
of IN o
target NN o
lesion NN o
revascularization NN o
. . o

Among IN o
the DT p
patients NNS p
with IN p
previous JJ p
CABG NNP p
, , p
those DT p
with IN N
saphenous JJ N
vein NN N
graft NN N
intervention NN N
using VBG N
a DT N
first-generation JJ N
drug-eluting JJ N
stent NN N
had VBD o
worse JJR o
clinical JJ o
outcomes NNS o
than IN o
those DT o
with IN N
a DT N
native JJ N
coronary JJ N
artery NN N
target NN N
only RB N
. . N

-DOCSTART- -23020253- O O

Effects NNS N
of IN N
saxagliptin NN i
added VBN N
to TO N
sub-maximal JJ N
doses NNS N
of IN N
metformin NNS i
compared VBN N
with IN N
uptitration NN N
of IN N
metformin NN i
in IN N
type NN p
2 CD p
diabetes NNS p
: : p
the DT N
PROMPT NNP N
study NN N
. . N

OBJECTIVE CC N
The DT N
PROMPT NNP N
study NN N
compared VBN N
efficacy NN N
and CC N
tolerability NN N
of IN N
two CD N
treatment NN N
intensification NN N
strategies NNS N
: : N
adding VBG N
saxagliptin NN i
or CC N
uptitrating JJ N
metformin NN i
monotherapy NN i
, , N
in IN N
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
( ( p
T2D NNP p
) ) p
and CC p
inadequate JJ p
glycaemic NNS p
control NN p
on IN p
a DT p
sub-maximal JJ p
metformin NN p
dose NN p
. . p

RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
In IN N
this DT N
double-blind NN N
, , N
24-week JJ N
study NN N
, , N
metformin-tolerant JJ p
patients NNS p
with IN p
T2D NNP p
on IN p
metformin NN i
monotherapy NN p
were VBD N
randomised VBN N
to TO N
receive VB N
fixed-dose JJ i
metformin NN i
1500 CD i
mg/day NN i
, , i
plus CC i
either DT i
add-on JJ i
saxagliptin NN i
5 CD i
mg/day NN i
( ( i
SAXA-MET NNP i
) ) i
or CC i
a DT i
two-step JJ i
metformin NN i
uptitration NN i
( ( i
MET-UP NNP i
) ) i
to TO i
a DT i
maximum JJ i
dose NN i
( ( i
2500 CD i
mg/day NN i
) ) i
. . i

CLINICAL JJ i
TRIAL NNP N
REGISTRATION NNP N
NCT01006590 NNP N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Primary NNP N
: : N
absolute JJ o
change NN o
from IN o
baseline NN o
in IN o
glycated JJ o
haemoglobin NN o
A NNP o
( ( o
1c CD o
) ) o
( ( o
HbA NNP o
( ( o
1c CD o
) ) o
) ) o
( ( o
Week $ o
24 CD N
) ) N
. . N

Secondary JJ N
: : N
proportion NN N
of IN N
patients NNS N
achieving VBG o
a DT o
therapeutic JJ o
glycaemic JJ o
response NN o
( ( o
Week NNP o
24 CD N
) ) N
; : N
change NN N
from IN N
baseline NN o
in IN o
fasting VBG o
plasma NN o
glucose NN o
( ( o
Week NNP o
24 CD o
) ) o
; : o
safety NN o
and CC o
tolerability NN o
. . o

Exploratory JJ o
analyses NNS N
comprised VBD N
three CD N
patient-related JJ N
questionnaires NNS N
, , N
including VBG N
the DT N
validated JJ N
5-dimension JJ N
Digestive NNP N
Health NNP N
Status NNP N
Index NNP N
( ( N
DHSI NNP N
) ) N
. . N

RESULTS VB p
A DT p
total NN p
of IN p
286 CD p
patients NNS p
were VBD p
randomised VBN N
: : N
( ( N
SAXA-MET JJ N
: : N
147 CD N
; : N
MET-UP JJ N
: : N
139 CD N
) ) N
. . N

Baseline JJ o
mean NN o
( ( o
SD NNP o
) ) o
HbA NNP o
( ( o
1c CD o
) ) o
: : o
7.71 CD o
( ( N
0.85 CD N
; : N
SAXA-MET NNP N
) ) N
; : N
7.80 CD N
( ( N
0.82 CD N
; : N
MET-UP NNP N
) ) o
. . o

Adjusted VBN o
mean JJ o
reductions NNS o
from IN o
baseline NN o
in IN o
HbA NNP o
( ( o
1c CD o
) ) o
( ( o
Week $ o
24 CD N
) ) N
: : N
-0.47 CD N
% NN N
( ( N
SAXA-MET NNP N
) ) N
; : N
-0.38 CD N
% NN N
( ( N
MET-UP NNP N
) ) N
; : N
mean NN N
( ( N
95 CD N
% NN N
CI NNP N
) ) N
difference NN N
in IN N
treatment NN N
effect NN N
, , N
-0.10 CD N
% NN N
( ( N
-0.26 NNP N
, , N
0.07 CD N
) ) N
; : N
p CC N
= $ N
0.260 CD N
. . N

The DT N
proportion NN N
of IN N
patients NNS N
( ( N
95 CD N
% NN N
CI NNP N
) ) N
achieving VBG N
a DT o
therapeutic JJ o
glycaemic JJ o
response NN o
( ( o
HbA NNP o
( ( o
1c CD o
) ) o
< VBD N
7 CD N
% NN N
) ) N
: : N
43.8 CD N
% NN N
( ( N
34.8 CD N
, , N
49.6 CD N
) ) N
( ( N
SAXA-MET NNP N
) ) N
vs. FW N
35.0 CD N
% NN N
( ( N
29.0 CD N
, , N
43.8 CD N
) ) N
( ( N
MET-UP NNP N
) ) N
. . N

Of IN N
the DT N
five CD N
DHSI NNP N
domains NNS N
, , N
mean NN N
( ( N
95 CD N
% NN N
CI NNP N
) ) N
differences NNS N
were VBD N
observed VBN N
for IN o
diarrhoea-predominant JJ o
score NN o
( ( o
+0.8 JJ o
[ NNP o
-2.5 NNP N
, , N
4.0 CD N
] NN N
vs. FW N
+7.9 NNP N
[ NNP N
4.6 CD N
, , N
11.2 CD N
] NN N
) ) N
and CC o
dysmotility NN o
score NN o
( ( N
-0.5 JJ N
[ NNP N
-2.0 NNP N
, , N
1.0 CD N
] NN N
vs. FW N
+1.9 NNP N
[ NNP N
0.3 CD N
, , N
3.4 CD N
] NN N
) ) N
, , N
( ( N
SAXA-MET JJ N
and CC N
MET-UP NNP N
, , N
respectively RB N
) ) N
. . N

The DT N
most RBS N
common JJ N
adverse JJ N
event NN N
was VBD o
diarrhoea NN o
: : N
6.1 CD N
% NN N
( ( N
SAXA-MET NNP N
) ) N
vs. FW N
12.2 CD N
% NN N
( ( N
MET-UP NNP N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
metformin-tolerant JJ p
patients NNS p
with IN p
T2D NNP p
( ( p
inadequately RB p
controlled VBN p
on IN p
sub-maximal JJ p
metformin NN p
monotherapy NN p
) ) p
, , p
saxagliptin NN i
was VBD N
well RB N
tolerated VBN N
. . N

Although IN N
HbA NNP N
( ( N
1c CD N
) ) N
reduction NN N
was VBD N
not RB N
significantly RB N
different JJ N
between IN N
treatment NN N
groups NNS N
, , N
the DT N
lower JJR N
occurrence NN N
of IN N
gastrointestinal JJ N
symptoms NNS N
in IN N
the DT N
SAXA-MET NNP N
group NN N
suggests VBZ N
that IN N
saxagliptin JJ N
add-on JJ N
treatment NN N
may MD N
be VB N
a DT N
suitable JJ N
alternative JJ N
treatment NN N
strategy NN N
to TO N
metformin VB N
uptitration NN N
. . N

-DOCSTART- -15025886- O O

Strength NN N
of IN N
vital JJ N
force NN N
in IN N
classical JJ N
homeopathy NN N
: : N
bio-psycho-social-spiritual JJ N
correlates NNS N
within IN N
a DT N
complex JJ N
systems NNS N
context NN N
. . N

OBJECTIVE UH N
To TO N
explore VB N
associations NNS N
between IN N
a DT N
global JJ N
rating NN N
for IN N
the DT N
classical JJ N
homeopathic JJ N
construct NN N
of IN N
vital JJ N
force NN N
and CC N
clinician JJ N
and CC N
patient JJ N
ratings NNS N
on IN N
previously RB N
validated VBN N
bio-psycho-social-spiritual JJ N
questionnaires NNS N
. . N

METHODS NNP N
Sixty-two NNP p
( ( p
62 CD p
) ) p
community-recruited JJ p
patients NNS p
with IN p
fibromyalgia NN p
( ( p
FM NNP p
) ) p
were VBD N
assessed VBN N
at IN N
baseline NN N
prior RB N
to TO N
a DT N
clinical JJ N
trial NN N
of IN N
individualized JJ N
homeopathy NN N
. . N

Two CD p
homeopaths NNS p
jointly RB p
performed VBD p
case-taking JJ i
interviews NNS i
. . i

A DT p
conventional JJ p
medical JJ p
provider NN p
independently RB p
evaluated VBD p
patients NNS p
with IN p
a DT p
standardized JJ p
history NN p
and CC p
physical JJ p
examination NN p
. . p

Homeopaths NNP N
rated VBD N
each DT N
patient NN N
's POS N
vital JJ N
force NN N
( ( N
five-point JJ N
Likert NNP N
scale NN N
, , N
with IN N
1 CD N
= JJ N
very RB N
weak JJ N
to TO N
5 CD N
= NNS N
very RB N
strong JJ N
) ) N
. . N

Homeopaths NNP N
and CC N
the DT N
conventional JJ N
medical JJ N
provider NN N
rated VBN N
their PRP$ N
Clinical JJ o
Global NNP o
Impression NNP o
( ( o
CGI NNP o
) ) o
of IN o
the DT o
severity NN o
of IN o
illness NN o
( ( N
1 CD N
= NNP N
normal JJ N
; : N
7 CD N
= NN N
among IN N
the DT N
most RBS N
extremely RB N
ill JJ N
) ) N
. . N

Patients NNS N
completed VBD N
self-rating JJ o
scales NNS o
on IN o
pain NN o
, , o
global JJ o
health NN o
, , o
mood NN o
, , o
quality NN o
of IN o
life NN o
, , o
coping VBG o
style NN o
, , o
health NN o
locus NN o
of IN o
control NN o
, , o
multidimensional JJ o
well-being NN o
, , o
spirituality NN o
, , o
sense NN o
of IN o
coherence NN o
, , o
positive JJ o
states NNS o
of IN o
mind NN o
, , o
and CC o
social JJ o
desirability NN o
. . o

RESULTS NNP N
Greater NNP N
vital JJ o
force NN o
ratings NNS o
( ( N
mean VB N
2.9 CD N
standard JJ N
deviation NN N
[ NNP N
SD NNP N
] NNP N
0.6 CD N
) ) N
correlated VBN N
moderately RB N
( ( N
p JJ N
< NN N
or CC N
= VB N
0.005 CD N
) ) N
with IN N
less JJR N
severe JJ N
CGI NNP o
illness NN o
ratings NNS N
by IN N
the DT N
homeopaths NNS N
( ( N
r VB N
=-0.59 NN N
) ) N
, , N
decreased VBD N
patient-rated JJ o
mental JJ o
confusion NN o
( ( N
r VB N
=-0.43 NN N
) ) N
, , N
higher JJR N
vigor NN o
( ( N
r JJ N
= NNP N
0.38 CD N
) ) N
, , N
and CC N
greater JJR N
positive JJ o
states NNS o
of IN o
mind NN o
( ( N
r JJ N
= NNP N
0.36 CD N
) ) N
. . N

Vital NNP N
force NN N
also RB N
showed VBD N
correlations NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
with IN N
lower JJR N
CGI NNP o
ratings NNS o
by IN N
the DT N
conventional JJ N
medical JJ N
provider NN N
( ( N
r VB N
=-0.32 NN N
) ) N
, , N
better RB N
selfrated VBN N
quality NN o
of IN o
life NN o
( ( N
r JJ N
= NNP N
0.33 CD N
) ) N
, , N
lesser JJR N
fatigue NN o
( ( N
r VB N
=-0.31 NN N
) ) N
, , N
better JJR o
global JJ o
health NN o
( ( N
r VB N
= RB N
0.29 CD N
) ) N
, , N
greater JJR o
sense NN o
of IN o
coherence NN o
( ( N
r JJ N
= NNP N
0.28 CD N
) ) N
, , N
powerful-others JJ o
health NN o
locus NN o
of IN o
control NN o
( ( N
r JJ N
= NNP N
0.27 CD N
) ) N
, , N
increased VBD o
emotional JJ o
well-being NN o
( ( N
r JJ N
= NNP N
0.27 CD N
) ) N
, , N
and CC N
higher JJR o
social JJ o
desirability NN o
( ( N
r JJ N
= NNP N
0.27 CD N
) ) N
, , N
but CC N
not RB N
with IN N
age NN N
, , N
pain NN N
, , N
or CC N
illness JJ N
duration NN N
. . N

CONCLUSION NNP N
Homeopathic NNP N
vital JJ N
force NN N
ratings NNS N
reflect VBP N
better JJR N
perceived VBN N
mental JJ N
function NN N
, , N
energy NN N
, , N
and CC N
positive JJ N
dimensions NNS N
of IN N
the DT N
individual NN N
, , N
beyond IN N
absence NN N
of IN N
disease NN N
. . N

-DOCSTART- -17334477- O O

Comparison NNP N
of IN N
the DT N
effect NN N
of IN N
gonadotropin-releasing NN i
hormone NN i
analog NN i
( ( i
Diphereline NNP i
) ) i
and CC N
Cabergoline NNP i
( ( i
Dostinex NNP i
) ) i
treatment NN N
on IN N
uterine JJ p
myoma NN p
regression NN p
. . p

OBJECTIVE UH N
To TO N
investigate VB N
the DT N
effect NN N
of IN N
cabergoline NN i
( ( i
Dostinex NNP i
, , i
a DT i
dopamine JJ i
agonist NN i
) ) i
on IN N
the DT N
myoma NN N
growth NN N
compared VBN N
to TO N
Diphereline NNP i
( ( i
a DT i
gonadotropin-releasing NN i
hormone NN i
agonist NN i
) ) i
. . i

METHODS NNP N
This DT p
study NN p
took VBD p
place NN p
in IN p
the DT p
Department NNP p
of IN p
Obstetrics NNP p
and CC p
Gynecology NNP p
of IN p
Tabriz NNP p
University NNP p
of IN p
Medical NNP p
Sciences NNPS p
, , p
Tabriz NNP p
, , p
Iran NNP p
from IN p
July NNP p
2004 CD p
to TO p
December NNP p
2005 CD p
. . p

Fifty NNP p
women NNS p
with IN p
uterine JJ p
myoma NN p
, , p
who WP p
met VBD p
the DT p
criteria NNS p
of IN p
the DT p
study NN p
thoroughly RB p
, , N
were VBD N
randomly RB N
allocated VBN N
into IN N
2 CD N
equal JJ N
groups NNS N
to TO N
take VB N
either DT N
Diphereline NNP i
or CC N
Cabergoline NNP i
. . i

The DT N
first JJ N
Group NNP N
took VBD N
3.75 CD N
mg NN N
of IN N
Diphereline NNP i
4 CD N
times NNS N
every DT N
28 CD N
days NNS N
and CC N
the DT N
second JJ N
group NN N
took VBD N
0.5 CD N
mg NN N
of IN N
Cabergoline NNP i
once RB N
a DT N
week NN N
for IN N
6 CD N
weeks NNS N
. . N

RESULTS VB N
The DT N
Cabergoline NNP i
was VBD N
well RB o
tolerated VBN o
and CC N
fewer JJR o
adverse JJ o
effects NNS o
were VBD N
noted VBN N
. . N

The DT N
tumor NN o
regressed VBD o
significantly RB o
and CC N
volume NN o
reduction NN o
rate NN o
of IN o
individual JJ o
tumor NN o
nodule NN o
varied VBD N
from IN N
46-53 CD N
% NN N
. . N

The DT N
gonadotropin NN i
releasing VBG i
hormone JJ i
agonist NN i
group NN N
all DT N
responded VBD N
to TO N
the DT N
treatment NN N
, , N
and CC N
volume NN o
reduction NN o
rate NN o
of IN N
the DT N
individual JJ N
tumor NN N
nodule NN N
varied VBD N
from IN N
21-97 CD N
% NN N
. . N

The DT N
extent NN N
of IN N
tumor NN o
shrinkage NN o
was VBD N
positively RB N
correlated VBN N
to TO N
the DT N
number NN o
of IN o
nodules NNS o
( ( N
p=0.881 NN N
, , N
p NN N
< VBD N
0.005 CD N
and CC N
0.701 CD N
, , N
p NN N
< NNP N
0.005 CD N
) ) N
. . N

CONCLUSION NNP N
In IN N
light NN N
of IN N
therapeutic JJ N
efficacy NN N
and CC N
few JJ N
adverse JJ N
effects NNS N
, , N
the DT N
dopamine NN i
agonists NNS i
may MD N
hold VB N
promise NN N
as IN N
novel JJ N
treatment NN N
modalities NNS N
for IN N
leiomyoma NN N
. . N

Further JJ N
studies NNS N
are VBP N
warranted VBN N
to TO N
determine VB N
the DT N
optimal JJ N
strategy NN N
for IN N
the DT N
treatment NN N
of IN N
leiomyoma NN N
through IN N
these DT N
agents NNS N
. . N

-DOCSTART- -23524367- O O

Acute JJ N
effects NNS N
of IN N
different JJ N
stretching VBG i
durations NNS i
on IN N
passive JJ o
torque NN o
, , o
mobility NN o
, , o
and CC o
isometric JJ o
muscle NN o
force NN o
. . o

Static JJ i
stretching NN i
is VBZ N
widely RB N
applied VBN N
in IN N
various JJ N
disciplines NNS N
. . N

However RB N
, , N
the DT N
acute JJ N
effects NNS N
of IN N
different JJ N
durations NNS N
of IN N
stretching VBG i
are VBP N
unclear JJ N
. . N

Therefore RB N
, , N
this DT N
study NN N
was VBD N
designed VBN N
to TO N
investigate VB N
the DT N
acute JJ N
effects NNS N
of IN N
different JJ i
stretching VBG i
durations NNS i
on IN N
muscle NN N
function NN N
and CC N
flexibility NN N
, , N
and CC N
provide VB N
an DT N
insight NN N
into IN N
the DT N
optimal JJ N
duration NN N
of IN N
static JJ i
stretching NN i
. . i

This DT N
randomized VBD N
crossover NN N
trial NN N
included VBD N
24 CD p
healthy JJ p
students NNS p
( ( p
17 CD p
men NNS p
and CC p
7 CD p
women NNS p
) ) p
who WP p
stretched VBD i
their PRP$ p
right JJ p
hamstrings NNS p
for IN p
durations NNS p
of IN p
20 CD p
, , p
60 CD p
, , N
180 CD N
, , N
and CC N
300 CD N
seconds NNS N
in IN N
a DT N
random JJ N
order NN N
. . N

The DT N
following JJ N
outcomes NNS N
were VBD N
assessed VBN N
using VBG N
an DT N
isokinetic JJ N
dynamometer NN N
as IN N
markers NNS N
of IN N
lower-limb JJ o
function NN o
and CC o
flexibility NN o
: : o
static JJ o
passive NN o
torque NN o
( ( o
SPT NNP o
) ) o
, , o
dynamic JJ o
passive JJ o
torque NN o
( ( o
DPT NNP o
) ) o
, , o
stiffness NN o
, , o
straight VBD o
leg NN o
raise NN o
( ( o
SLR NNP o
) ) o
, , o
and CC o
isometric JJ o
muscle NN o
force NN o
. . o

Static JJ o
passive JJ o
torque NN o
was VBD N
significantly RB N
decreased VBN N
after IN N
all DT N
stretching JJ i
durations NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Static JJ o
passive JJ o
torque NN o
was VBD N
significantly RB N
lower JJR N
after IN N
60 CD N
, , N
180 CD N
, , N
and CC N
300 CD N
seconds NNS N
of IN N
stretching VBG i
compared VBN N
with IN N
that DT N
after IN N
20-second JJ i
stretching NN i
, , N
and CC N
stiffness NN N
decreased VBN N
significantly RB N
after IN N
180- JJ i
and CC i
300-second JJ i
stretching NN i
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

In IN N
addition NN N
, , N
DPT NNP o
and CC o
stiffness NN o
were VBD N
significantly RB N
lower JJR N
after IN N
300 CD N
seconds NNS N
than IN N
after IN N
20-second JJ i
stretching NN i
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
, , N
and CC N
SLR NNP o
increased VBD N
significantly RB N
after IN N
all DT N
stretching JJ i
durations NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Straight NNP o
leg NN o
raise NN o
was VBD N
higher JJR o
after IN N
180- JJ N
and CC N
300-second JJ i
stretching NN i
than IN N
after IN N
20-second JJ i
stretching NN i
and CC N
higher JJR N
after IN N
300-second CD i
stretching VBG i
than IN N
after IN N
60-second JJ i
stretching NN i
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Isometric JJ o
muscle NN o
force NN o
significantly RB o
decreased VBN o
after IN N
all DT N
stretching JJ i
durations NNS i
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Therefore RB N
, , N
increased VBD N
duration NN N
of IN N
stretching NN i
is VBZ N
associated VBN N
with IN N
a DT N
decrease NN N
in IN N
SPT NNP o
but CC N
an DT N
increase NN N
in IN N
SLR NNP o
. . o

Over IN N
180 CD i
seconds NNS i
of IN i
stretching VBG i
was VBD N
required VBN N
to TO N
decrease VB N
DPT NNP o
and CC o
stiffness NN o
, , N
but CC N
isometric JJ o
muscle NN o
force NN o
decreased VBD N
regardless RB N
of IN N
the DT N
stretching VBG i
duration NN i
. . i

In IN N
conclusion NN N
, , N
these DT N
results NNS N
indicate VBP N
that IN N
longer JJR N
durations NNS N
of IN N
stretching VBG i
are VBP N
needed VBN N
to TO N
provide VB N
better JJR N
flexibility NN N
. . N

-DOCSTART- -3430295- O O

Comparison NNP N
of IN N
ketoconazole NN i
and CC N
griseofulvin NN i
in IN N
the DT N
treatment NN N
of IN N
tinea NN p
pedis NN p
. . p

Twenty-nine JJ p
patients NNS p
with IN p
mycologically RB p
proven VBN p
tinea NN p
pedis NNS p
were VBD N
randomly RB N
allocated VBN N
to TO N
oral JJ N
treatment NN N
with IN N
either DT N
ketoconazole JJ i
200 CD i
mg JJ i
daily JJ i
or CC i
griseofulvin JJ i
1 CD i
g JJ i
daily RB N
for IN N
a DT N
period NN N
of IN N
up IN N
to TO N
8 CD N
weeks NNS N
. . N

Mycological JJ o
cure NN o
rate NN o
at IN N
4 CD N
weeks NNS N
was VBD N
33 CD N
% NN N
for IN N
ketoconazole NN i
and CC N
29 CD N
% NN N
for IN N
griseofulvin NN i
, , N
and CC N
at IN N
8 CD N
weeks NNS N
was VBD N
53 CD N
% NN N
and CC N
57 CD N
% NN N
respectively RB N
. . N

The DT N
efficacy NN o
of IN N
both DT N
drugs NNS N
in IN N
the DT N
treatment NN N
of IN N
interdigital JJ N
tinea NN N
pedis NN N
is VBZ N
similar JJ N
, , N
and CC N
is VBZ N
considerably RB N
lower JJR N
than IN N
that DT N
found VBD N
with IN N
topical JJ N
imidazole NN N
preparations NNS N
where WRB N
cure NN o
rates NNS o
of IN N
over IN N
70 CD N
% NN N
are VBP N
generally RB N
expected VBN N
. . N

-DOCSTART- -18991158- O O

A DT N
controlled VBN N
study NN N
of IN N
the DT N
effect NN N
of IN N
cognitive-behavioural JJ i
group NN i
therapy NN i
for IN N
pathological JJ p
gamblers NNS p
. . p

As IN N
the DT N
number NN N
of IN N
pathological JJ p
gamblers NNS p
has VBZ N
increased VBN N
recently RB N
, , N
the DT N
need NN N
for IN N
effective JJ N
treatment NN N
has VBZ N
become VBN N
more RBR N
evident JJ N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
a DT N
short-term JJ i
cognitive-behavioural JJ i
group NN i
therapy NN i
programme NN i
for IN N
pathological JJ p
gamblers NNS p
. . p

Fourteen JJ p
subjects NNS p
( ( p
three CD p
females NNS p
and CC p
11 CD p
males NNS p
) ) p
, , p
who WP p
met VBD p
the DT p
criteria NNS p
for IN p
pathological JJ p
gambling NN p
in IN p
accordance NN p
with IN p
the DT p
Diagnostic NNP p
and CC p
Statistical NNP p
Manual NNP p
of IN p
Mental NNP p
Disorders NNP p
IV NNP p
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
Treatment NNP i
Group NNP i
( ( i
n=7 RB i
) ) i
or CC N
a DT N
waiting JJ i
list NN i
Control NNP i
Group NNP i
( ( i
n=7 RB i
) ) i
. . i

An DT N
experimental JJ N
design NN N
with IN N
three CD N
repeated VBD N
measures NNS N
was VBD N
used VBN N
( ( N
pre-treatment JJ N
, , N
post-treatment/post-waiting JJ N
list NN N
and CC N
follow-up NN N
) ) N
. . N

The DT N
dependent JJ N
variables NNS N
were VBD N
DSM-IV NNP o
Criteria NNP o
for IN o
Pathological NNP o
Gambling NNP o
, , o
Money NNP o
Spent NNP o
on IN o
Gambling VBG o
During IN o
the DT o
Last JJ o
Week NNP o
and CC o
Gamblers NNP o
Inventory NNP o
of IN o
Negative NNP o
Consequences NNPS o
. . o

The DT N
Treatment NNP N
Group NNP N
improved VBD N
on IN N
the DT N
DSM-IV NNP o
Criteria NNP o
for IN o
Pathological NNP o
Gambling NNP o
, , N
but CC N
did VBD N
not RB N
show VB N
a DT N
significant JJ N
improvement NN N
on IN N
Money NNP o
Spent NNP o
on IN o
Gambling VBG o
During IN o
the DT o
Last JJ o
week NN o
from IN N
pre-treatment JJ N
to TO N
post-treatment JJ N
. . N

Combining VBG N
both DT N
groups NNS N
at IN N
3-months JJ N
follow-up NN N
, , N
there EX N
was VBD N
a DT N
significant JJ N
improvement NN N
on IN N
all DT N
three CD N
variables NNS N
from IN N
pre-treatment JJ N
to TO N
follow-up JJ N
. . N

The DT N
results NNS N
of IN N
this DT N
controlled VBN N
study NN N
indicate NN N
that IN N
a DT N
short-term JJ i
cognitive-behavioural JJ i
group NN i
treatment NN i
for IN N
pathological JJ p
gamblers NNS p
had VBD N
an DT N
effect NN N
. . N

-DOCSTART- -15172423- O O

Comparative JJ N
effects NNS N
of IN N
valsartan JJ i
versus NN N
amlodipine NN i
on IN N
left JJ N
ventricular JJ N
mass NN N
and CC N
reactive JJ N
oxygen NN N
species NNS N
formation NN N
by IN N
monocytes NNS N
in IN N
hypertensive JJ p
patients NNS p
with IN p
left JJ p
ventricular JJ p
hypertrophy NN p
. . p

OBJECTIVES NNP N
To TO N
compare VB N
the DT N
effects NNS N
of IN N
the DT N
angiotensin NN i
receptor NN i
blocker NN i
( ( i
ARB NNP i
) ) i
valsartan VBP i
versus IN N
the DT N
calcium NN i
channel NN i
blocker NN i
amlodipine NN i
, , N
reactive JJ N
oxygen NN N
species NNS N
( ( N
ROS NNP N
) ) N
formation NN N
by IN N
monocytes NNS N
, , N
C-reactive JJ N
protein NN N
( ( N
CRP NNP N
) ) N
, , N
and CC N
left VBD N
ventricular NN N
( ( N
LV NNP N
) ) N
mass NN N
were VBD N
studied VBN N
in IN N
104 CD p
hypertensive JJ p
patients NNS p
with IN p
left JJ p
ventricular JJ p
hypertrophy NN p
( ( p
LVH NNP p
) ) p
. . p

BACKGROUND NNP N
There EX N
is VBZ N
evidence NN N
that IN N
ARBs NNP i
have VBP N
blood VBN N
pressure NN N
( ( N
BP NNP N
) ) N
-independent NN N
effects NNS N
on IN N
LV NNP N
mass NN N
. . N

Whether NNP N
regression NN N
of IN N
LV NNP N
mass NN N
by IN N
ARBs NNP i
is VBZ N
correlated VBN N
to TO N
ROS NNP N
formation NN N
by IN N
monocytes NNS N
and CC N
CRP NNP N
is VBZ N
not RB N
fully RB N
understood JJ N
yet RB N
. . N

METHODS VB N
A DT N
cross-sectional JJ N
and CC N
prospective JJ N
study NN N
was VBD N
performed VBN N
. . N

Participants NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
either VB N
the DT N
80-mg JJ i
valsartan NN i
( ( N
n JJ N
= NNP N
52 CD N
) ) N
or CC N
5-mg JJ i
amlodipine NN i
( ( N
n JJ N
= NNP N
52 CD N
) ) N
group NN N
and CC N
were VBD N
treated VBN N
for IN N
eight CD N
months NNS N
. . N

The DT N
left JJ N
ventricular JJ N
mass NN N
index NN N
( ( N
LVMI NNP N
) ) N
was VBD N
calculated VBN N
from IN N
two-dimensional JJ N
M-mode NNP N
echocardiography NN N
. . N

Formation NN N
of IN N
ROS NNP N
by IN N
monocytes NNS N
was VBD N
measured VBN N
by IN N
gated VBN N
flow JJ N
cytometry NN N
. . N

In IN N
addition NN N
, , N
CRP NNP N
, , N
plasma JJ N
renin NN N
activity NN N
, , N
plasma NN N
aldosterone NN N
, , N
and CC N
traditional JJ N
risk NN N
factors NNS N
were VBD N
assessed VBN N
. . N

RESULTS NNP N
Multiple NNP N
regression NN N
analysis NN N
showed VBD N
a DT N
significant JJ N
correlation NN N
between IN N
LVMI NNP N
and CC N
ROS NNP N
formation NN N
by IN N
monocytes NNS N
and CC N
between IN N
LVMI NNP N
and CC N
CRP NNP N
. . N

Treatment NNP o
reduced VBD o
BP NNP o
to TO N
a DT N
similar JJ o
extent NN o
in IN N
both DT N
groups NNS N
. . N

Valsartan NNP o
significantly RB o
reduced VBD o
LVMI NNP o
after IN N
eight CD N
months NNS N
, , N
but CC N
amlodipine NN i
had VBD N
less RBR o
effect NN o
( ( N
16 CD N
% NN N
vs. FW N
1.2 CD N
% NN N
, , N
n JJ N
= NN N
50 CD N
, , N
p NN N
< NNP N
0.01 CD N
) ) N
. . N

Formation NN o
of IN o
ROS NNP o
by IN o
monocytes NNS o
was VBD N
reduced VBN o
to TO o
a DT o
greater JJR o
extent NN o
with IN N
valsartan NN i
than IN N
with IN N
amlodipine NN i
( ( N
28 CD N
% NN N
vs. FW N
2 CD N
% NN N
, , N
n JJ N
= NN N
50 CD N
, , N
p NN N
< NNP N
0.01 CD N
) ) N
. . N

Valsartan NNP i
but CC N
not RB N
amlodipine VB i
reduced VBN o
CRP NNP o
levels NNS o
. . o

A DT N
significant JJ o
correlation NN o
between IN N
changes NNS o
in IN o
ROS NNP o
formation NN o
by IN o
monocytes NNS o
and CC o
LVMI NNP o
or CC o
between IN o
CRP NNP o
and CC o
LVMI NNP o
was VBD N
observed VBN N
. . N

CONCLUSIONS VB N
The DT N
ARB NNP i
valsartan NN i
has VBZ N
BP-independent JJ N
effects NNS N
on IN N
LVH NNP N
, , N
ROS NNP N
formation NN N
by IN N
monocytes NNS N
, , N
and CC N
CRP NNP N
in IN N
hypertensive JJ p
patients NNS p
with IN p
LVH NNP p
. . p

-DOCSTART- -15481334- O O

Effect NN N
of IN N
ibuprofen NN i
on IN N
cyclooxygenase NN o
and CC o
nitric JJ o
oxide JJ o
synthase NN o
of IN o
gastric JJ o
mucosa NN o
: : o
correlation NN N
with IN N
endoscopic JJ o
lesions NNS o
and CC o
adverse JJ o
reactions NNS o
. . o

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
ibuprofen NN i
on IN N
gastric JJ o
mucosa NN o
and CC o
enzymes NNS o
involved VBN o
in IN o
gastroprotection NN o
in IN N
healthy JJ p
volunteers NNS p
. . p

Twenty-four JJ p
Helicobacter NNP p
pylori-negative JJ p
subjects NNS p
were VBD N
randomized VBN N
to TO N
treatment NN N
with IN N
ibuprofen NN i
or CC i
ibuprofen-arginate NN i
( ( N
each DT N
600 CD N
mg/6 NN N
hr NN N
during IN N
3 CD N
days NNS N
) ) N
. . N

Endoscopies NNS i
were VBD N
performed VBN N
1 CD N
week NN N
before IN N
and CC N
after IN N
treatment NN N
. . N

Biopsies NNS N
were VBD N
taken VBN N
from IN N
the DT N
gastric JJ N
antrum NN N
and CC N
corpus NN N
for IN N
determination NN N
of IN N
prostaglandin NN N
E2 NNP N
( ( N
PGE2 NNP N
) ) N
by IN N
ELISA NNP i
and CC N
cyclooxygenase NN N
( ( N
COX-1 JJ N
and CC N
COX-2 NNP N
) ) N
and CC N
nitric JJ N
oxide NN N
synthase NN N
( ( N
eNOS JJ N
and CC N
iNOS NN N
) ) N
by IN N
western JJ N
blot NN N
. . N

All DT N
subjects NNS N
had VBD N
at IN N
least JJS N
one CD N
gastric JJ N
lesion NN N
except IN N
for IN N
two CD N
individuals NNS N
taking VBG N
ibuprofen-arginate NN N
. . N

Ibuprofen-arginate NNP N
caused VBD N
a DT N
lower JJR N
rate NN N
of IN N
clinical JJ o
adverse JJ o
reactions NNS o
than IN N
ibuprofen NN N
. . N

Subjects NNS N
with IN N
gastric JJ o
lesions NNS o
or CC N
adverse JJ N
reactions NNS N
had VBD N
lower JJR N
PGE2 NNP N
levels NNS N
. . N

COX-1 NNP o
, , o
COX-2 NNP o
, , o
eNOS NN o
, , o
and CC o
iNOS NNS o
were VBD N
detectable JJ N
in IN N
all DT N
subjects NNS N
. . N

The DT N
constitutive JJ N
enzymes NNS N
( ( N
COX-1 NNP N
and CC N
eNOS NN N
) ) N
did VBD N
not RB N
change VB N
after IN N
treatment NN N
. . N

COX-2 NNP N
was VBD N
higher RBR N
in IN N
corpus NN N
than IN N
antrum NN N
and CC N
it PRP N
increased VBD N
after IN N
ibuprofen JJ N
treatment NN N
. . N

iNOS NN N
tended VBD N
to TO N
increase VB N
mildly RB N
in IN N
the DT N
corpus NN N
in IN N
subjects NNS N
with IN N
adverse JJ N
reactions NNS N
or CC N
endoscopic JJ N
lesions NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
ibuprofen NN N
and CC N
ibuprofen-arginate NN N
in IN N
PGE2 NNP N
, , N
or CC N
enzymes NNS N
. . N

-DOCSTART- -3884411- O O

The DT N
treatment NN N
of IN N
senile JJ o
dementia NN o
associated VBN N
with IN N
cerebrovascular JJ N
insufficiency NN N
: : N
a DT N
comparative JJ N
study NN N
of IN N
buflomedil NN i
and CC i
dihydrogenated VBD i
ergot JJ i
alkaloids NNS i
. . i

Seventy-six JJ p
patients NNS p
took VBD p
part NN p
in IN p
a DT p
randomized JJ p
, , p
comparative JJ p
study NN p
of IN p
the DT p
efficacy NN p
of IN p
buflomedil NN i
hydrochloride NN i
and CC i
dihydrogenated VBD i
ergot JJ i
alkaloids NNS i
in IN p
the DT p
treatment NN p
of IN p
senile JJ o
dementia NN o
associated VBN p
with IN p
cerebrovascular JJ p
insufficiency NN p
. . p

Efficacy NN o
was VBD N
assessed VBN N
by IN N
the DT N
patients NNS N
' POS N
performance NN N
in IN N
four CD N
psychometric JJ o
tests NNS o
. . o

The DT N
results NNS N
showed VBD N
that IN N
a DT N
trend NN N
in IN N
favour NN N
of IN N
the DT N
buflomedil NN N
group NN N
in IN N
three CD N
of IN N
the DT N
tests NNS N
became VBD N
statistically RB N
significant JJ N
in IN N
the DT N
fourth JJ N
. . N

Both DT N
drugs NNS N
appeared VBD N
to TO N
be VB N
safe JJ o
, , N
causing VBG N
no DT N
marked JJ N
adverse JJ o
reactions NNS o
. . o

In IN N
conclusion NN N
, , N
buflomedil NN N
is VBZ N
as IN N
effective JJ N
or CC N
more RBR N
effective JJ N
than IN N
dihydrogenated VBN N
ergot JJ N
alkaloids NNS N
in IN N
the DT N
treatment NN N
of IN N
senile JJ o
dementia NN o
associated VBN p
with IN p
cerebrovascular JJ p
insufficiency NN p
and CC N
could MD N
prove VB N
a DT N
valuable JJ N
addition NN N
to TO N
long-term JJ N
therapy NN N
if IN N
further JJ N
studies NNS N
support VBP N
the DT N
trend NN N
shown VBN N
in IN N
this DT N
study NN N
. . N

-DOCSTART- -23952636- O O

A DT N
study NN N
to TO N
evaluate VB N
safety NN o
and CC N
tolerability NN o
of IN N
repeated JJ N
doses NNS N
of IN N
tirasemtiv NN i
in IN N
patients NNS p
with IN p
amyotrophic JJ p
lateral JJ p
sclerosis NN p
. . p

Abstract NNP i
Tirasemtiv NNP i
is VBZ N
a DT N
fast JJ N
skeletal JJ N
muscle NN N
activator NN N
that WDT N
increases VBZ N
the DT N
sensitivity NN N
of IN N
the DT N
sarcomere NN N
to TO N
calcium NN N
, , N
increasing VBG N
the DT N
efficiency NN N
of IN N
muscle NN N
contraction NN N
when WRB N
the DT N
muscle NN N
is VBZ N
stimulated VBN N
at IN N
submaximal JJ N
contraction NN N
frequencies NNS N
. . N

A DT N
previous JJ N
study NN N
showed VBD N
single JJ N
doses NNS N
of IN N
tirasemtiv NN N
to TO N
be VB N
well RB N
tolerated VBN N
and CC N
associated VBN N
with IN N
potentially RB N
important JJ N
improvements NNS N
in IN N
a DT N
variety NN N
of IN N
functional JJ N
outcomes NNS N
. . N

This DT N
study NN N
determined VBD N
safety NN o
of IN N
tirasemtiv NN i
when WRB N
given VBN N
at IN N
doses NNS N
up RB N
to TO N
500 CD N
mg NNS N
daily RB N
for IN N
three CD N
weeks NNS N
. . N

Tirasemtiv NNP i
was VBD N
given VBN N
as IN N
a DT N
single JJ N
daily NN N
dose VB N
up IN N
to TO N
375 CD N
mg NNS N
for IN N
two CD N
weeks NNS N
, , N
with IN N
and CC N
without IN N
concomitant JJ N
riluzole NN N
. . N

In IN N
a DT N
separate JJ N
cohort NN N
, , N
an DT N
ascending VBG N
dose NN N
protocol NN N
evaluated VBD N
a DT N
total JJ N
dose NN N
of IN N
500 CD N
mg JJ N
daily JJ N
given VBN N
in IN N
two CD N
divided JJ N
doses NNS N
. . N

Safety NN o
and CC o
tolerability NN o
were VBD N
assessed VBN N
, , N
as RB N
well RB N
as IN N
measures NNS o
of IN o
function NN o
, , o
muscle NN o
strength NN o
and CC o
endurance NN o
. . o

Results NNS N
showed VBD N
that IN N
tirasemtiv NN N
was VBD N
well RB N
tolerated VBN o
, , N
with IN N
dizziness PDT o
the DT N
most RBS N
common JJ N
adverse JJ N
event NN N
. . N

Tirasemtiv NNP N
approximately RB N
doubled VBD N
the DT N
serum JJ o
concentration NN o
of IN o
riluzole NN o
. . o

Trends NNS N
were VBD N
noted VBN N
for IN N
improvement NN N
in IN N
ALSFRS-R NNP o
, , o
Maximum NNP o
Minute NNP o
Ventilation NNP o
, , o
and CC o
Nasal NNP o
Inspiratory NNP o
Pressure NNP o
. . o

In IN N
conclusion NN N
, , N
tirasemtiv NN N
is VBZ N
well RB N
tolerated VBN N
and CC N
can MD N
be VB N
given VBN N
safely RB o
with IN N
a DT N
reduced VBN N
dose NN N
of IN N
riluzole NN N
. . N

Positive JJ N
trends NNS N
in IN N
multiple JJ o
exploratory JJ o
outcome NN o
measures NNS o
support VB N
the DT N
further JJ N
study NN N
of IN N
this DT N
agent NN N
in IN N
ALS NNP p
. . p

-DOCSTART- -8624213- O O

Antihistaminics NNS i
in IN N
idiopathic JJ o
dystonia NN o
. . o

-DOCSTART- -21429223- O O

A DT N
randomised JJ N
non-inferiority NN N
controlled VBD N
trial NN N
of IN N
a DT N
single JJ N
versus NN N
a DT N
four CD N
intradermal NN N
sterile JJ i
water NN i
injection NN i
technique NN i
for IN N
relief NN N
of IN N
continuous JJ N
lower JJR N
back RB N
pain NN N
during IN N
labour NN N
. . N

BACKGROUND NNP N
Almost NNP N
one CD N
third NN N
of IN N
women NNS p
suffer VBP N
continuous JJ N
lower JJR N
back RB N
pain NN N
during IN N
labour NN N
. . N

Evidence NN N
from IN N
three CD N
systematic JJ N
reviews NNS N
demonstrates VBZ N
that IN N
sterile JJ i
water NN i
injections NNS i
( ( i
SWI NNP i
) ) i
provide VBP N
statistically RB N
and CC N
clinically RB N
significant JJ N
pain NN o
relief NN o
in IN N
women NNS N
experiencing VBG N
continuous JJ N
lower JJR N
back RB N
pain NN N
during IN N
labour NN N
. . N

The DT N
most RBS N
effective JJ N
technique NN N
to TO N
administer VB N
SWI NNP i
is VBZ N
yet RB N
to TO N
be VB N
determined VBN N
. . N

Therefore RB N
, , N
the DT N
aim NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
determine VB N
if IN N
the DT N
single JJ N
injection NN N
SWI NNP N
technique NN N
is VBZ N
no DT N
less RBR N
effective JJ N
than IN N
the DT N
routinely RB N
used VBN N
four CD N
injection NN N
SWI NNP i
method NN N
in IN N
reducing VBG N
continuous JJ N
lower JJR N
back RB N
pain NN N
during IN N
labour NN N
. . N

METHODS/DESIGN NNP N
The DT N
trial NN N
protocol NN N
was VBD N
developed VBN N
in IN N
consultation NN N
with IN N
an DT N
interdisciplinary JJ N
team NN N
of IN N
clinical JJ N
researchers NNS N
. . N

We PRP N
aim VBP N
to TO N
recruit VB N
319 CD p
women NNS p
presenting VBG p
at IN p
term NN p
, , p
seeking VBG p
analgesia NN p
for IN p
continuous JJ p
severe JJ p
lower JJR p
back RB p
pain NN p
during IN p
labour NN p
. . p

Participants NNS p
will MD p
be VB p
recruited VBN p
from IN p
two CD p
major JJ p
maternity NN p
hospitals NNS p
in IN p
Australia NNP p
. . p

Randomised VBN N
participants NNS N
are VBP N
allocated VBN N
to TO N
receive VB N
a DT N
four CD N
or CC N
single JJ N
intradermal JJ i
needle JJ i
SWI NNP i
technique NN i
. . i

The DT N
primary JJ N
outcome NN N
is VBZ N
the DT N
change NN o
in IN o
self-reported JJ o
pain NN o
measured VBN N
by IN N
visual JJ o
analogue NN o
scale NN o
at IN N
baseline NN N
and CC N
thirty NN N
minutes NNS N
post VBP N
intervention NN N
. . N

Secondary JJ N
outcomes NNS N
include VBP N
VAS NNP o
change NN o
scores NNS o
at IN o
10 CD o
, , o
60 CD o
, , o
90 CD o
and CC o
120 CD o
min NN o
, , o
analgesia NN o
use NN o
, , o
mode NN o
of IN o
birth NN o
and CC o
maternal JJ o
satisfaction NN o
. . o

STATISTICAL JJ N
ANALYSIS NNP N
Sample NNP N
size NN N
was VBD N
calculated VBN N
to TO N
achieve VB N
90 CD N
% NN N
power NN N
at IN N
an DT N
alpha NN N
of IN N
0.025 CD N
to TO N
detect VB N
a DT N
non-inferiority JJ N
margin NN N
of IN N
?1 NNP N
cm NN N
on IN N
the DT o
VAS NNP o
, , o
using VBG N
a DT N
one-sided JJ N
, , N
two-sample JJ N
t-test NN N
. . N

Baseline NNP N
demographic JJ N
and CC N
clinical JJ N
characteristics NNS N
will MD N
be VB N
analysed VBN N
for IN N
comparability NN N
between IN N
groups NNS N
. . N

Differences NNS N
in IN N
primary JJ o
( ( o
VAS NNP o
pain RB o
score RB o
) ) o
and CC o
secondary JJ N
outcomes NNS N
between IN N
groups NNS N
will MD N
be VB N
analysed VBN N
by IN N
intention NN N
to TO N
treat VB N
and CC N
per IN N
protocol NN N
analysis NN N
using VBG N
Student NNP N
's POS N
t-test NN N
and CC N
ANOVA NNP N
. . N

CONCLUSION NNP N
This DT N
study NN N
will MD N
determine VB N
if IN N
a DT N
single JJ N
intradermal JJ i
SWI NNP i
technique NN i
is VBZ N
no DT N
less RBR N
effective JJ N
than IN N
the DT N
routinely RB N
used VBN N
four CD N
injection NN N
technique NN N
for IN N
lower JJR N
back NN N
pain NN N
during IN N
labour NN N
. . N

The DT N
findings NNS N
will MD N
allow VB N
midwives NNS N
to TO N
offer VB N
women NNS N
requesting VBG i
SWI NNP i
during IN i
labour PRP$ N
an DT N
evidence-based JJ N
alternative NN N
technique NN N
more RBR N
easily RB N
administered VBN N
by IN N
staff NN N
and CC N
accepted VBN N
by IN N
labouring VBG p
women NNS p
. . p

TRIAL NNP N
REGISTRATION NNP N
ACTRN12609000964213 NNP N
. . N

-DOCSTART- -7540705- O O

Randomised VBN N
, , N
placebo-controlled JJ i
, , N
double-blind JJ N
clinical JJ N
trial NN N
of IN N
beta-sitosterol NN i
in IN N
patients NNS p
with IN p
benign JJ p
prostatic JJ p
hyperplasia NN p
. . p

Beta-sitosterol NNP p
Study NNP p
Group NNP p
. . p

Medical NNP N
treatments NNS N
have VBP N
become VBN N
available JJ N
for IN N
benign JJ N
hypertrophy NN N
of IN N
the DT N
prostate NN N
, , N
including VBG N
alpha-receptor JJ N
blocking NN N
agents NNS N
and CC N
5-alpha-reductase JJ N
inhibitors NNS N
. . N

Drugs NNS N
derived VBN N
from IN N
plants NNS N
, , N
for IN N
which WDT N
no DT N
precise NN N
mechanism NN N
of IN N
action NN N
has VBZ N
been VBN N
described VBN N
, , N
are VBP N
widely RB N
used VBN N
for IN N
this DT N
purpose NN N
in IN N
Europe NNP N
. . N

In IN N
a DT N
randomised JJ p
, , p
double-blind JJ p
, , p
placebo-controlled JJ i
multicentre NN p
study NN p
, , p
200 CD p
patients NNS p
( ( p
recruited VBN p
between IN p
April NNP p
and CC p
October NNP p
1993 CD p
) ) p
with IN p
symptomatic JJ p
benign NN p
prostatic JJ p
hyperplasia NN p
were VBD p
treated VBN p
with IN N
either DT N
20 CD i
mg NN i
beta-sitosterol NN i
( ( N
which WDT N
contains VBZ N
a DT N
mixture NN N
of IN N
phytosterols NNS i
) ) i
three CD N
times NNS N
per IN N
day NN N
or CC N
placebo NN i
. . i

Primary JJ N
end-point NN N
was VBD N
a DT N
difference NN N
of IN N
modified JJ N
Boyarsky NNP o
score NN o
between IN N
treatment NN N
groups NNS N
after IN N
6 CD N
months NNS N
; : N
secondary JJ N
end-points NNS N
were VBD N
changes NNS N
in IN N
International NNP o
Prostate NNP o
Symptom NNP o
Score NNP o
( ( o
IPSS NNP o
) ) o
, , o
urine JJ o
flow NN o
, , o
and CC o
prostate NN o
volume NN o
. . o

Modified NNP o
Boyarsky NNP o
score NN o
decreased VBD N
significantly RB N
with IN N
a DT N
mean NN N
of IN N
-6.7 NNP N
( ( N
SD NNP N
4.0 CD N
) ) N
points NNS N
in IN N
the DT N
beta-sitosterol-treated JJ N
group NN N
versus NN N
-2.1 NNP N
( ( N
3.2 CD N
) ) N
points NNS N
in IN N
the DT N
placebo NN N
group NN N
p VBD N
< RB N
0.01 CD N
. . N

There EX N
was VBD N
a DT N
decrease NN N
in IN N
IPSS NNP o
( ( N
-7.4 NNP N
[ VBZ N
3.8 CD N
] NN N
points NNS N
in IN N
the DT N
beta-sitosterol-treated JJ N
group NN N
vs NN N
-2.1 NNP N
[ VBZ N
3.8 CD N
] NN N
points NNS N
in IN N
the DT N
placebo NN N
group NN N
) ) N
and CC N
changes NNS N
in IN N
urine JJ o
flow NN o
parameters NNS o
: : o
beta-sitosterol NN N
treatment NN N
resulted VBD N
in IN N
increasing VBG N
peak NN o
flow NN o
( ( N
15.2 CD N
[ RB N
5.7 CD N
] JJ N
mL/s NN N
from IN N
9.9 CD N
[ $ N
2.5 CD N
] NNP N
mL/s NN N
) ) N
, , N
and CC N
decrease NN N
of IN N
mean JJ o
residual JJ o
urinary JJ o
volume NN o
( ( N
30.4 CD N
[ RB N
39.9 CD N
] JJ N
mL NN N
from IN N
65.8 CD N
[ $ N
20.8 CD N
] NNP N
mL NN N
) ) N
. . N

These DT N
parameters NNS N
did VBD o
not RB o
change VB o
in IN N
the DT N
placebo NN N
group NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
. . N

No DT N
relevant JJ N
reduction NN N
of IN N
prostatic JJ o
volume NN o
was VBD N
observed VBN N
in IN N
either DT N
group NN N
. . N

Significant JJ N
improvement NN N
in IN N
symptoms NNS o
and CC o
urinary JJ o
flow NN o
parameters NNS o
show VBP N
the DT N
effectiveness NN N
of IN N
beta-sitosterol NN N
in IN N
the DT N
treatment NN N
of IN N
benign JJ N
prostatic JJ N
hyperplasia NN N
. . N

-DOCSTART- -24738609- O O

Effectiveness NN o
and CC o
Safety NNP o
of IN N
Tapentadol NNP i
Prolonged NNP N
Release NNP N
( ( N
PR NNP N
) ) N
Versus NNP N
a DT N
Combination NNP i
of IN i
Tapentadol NNP i
PR NNP i
and CC i
Pregabalin NNP i
for IN N
the DT N
Management NNP N
of IN N
Severe NNP p
, , p
Chronic NNP p
Low NNP p
Back NNP p
Pain NNP p
With IN p
a DT p
Neuropathic JJ p
Component NN p
: : p
A DT N
Randomized NNP N
, , N
Double-blind NNP N
, , N
Phase NNP N
3b CD N
Study NNP N
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
effectiveness NN o
and CC o
tolerability NN o
of IN N
tapentadol NN i
PR NNP i
monotherapy NN N
versus NN N
tapentadol NN i
PR/pregabalin NNP i
combination NN N
therapy NN N
for IN N
severe JJ p
, , p
chronic JJ p
low JJ p
back RB p
pain NN p
with IN p
a DT p
neuropathic JJ p
component NN p
. . p

METHODS NNP N
Eligible JJ p
patients NNS p
had VBD p
painDETECT VBN p
unclear JJ p
or CC p
positive JJ p
ratings NNS p
and CC p
average JJ p
pain NN p
intensity NN p
? . p
6 CD p
( ( p
11-point JJ p
NRS-3 NNP p
[ NNP p
average JJ p
3-day JJ p
pain NN p
intensity NN p
] NN p
) ) p
at IN p
baseline NN i
. . i

Patients NNS i
were VBD i
titrated VBN i
to TO i
tapentadol VB i
PR NNP i
300 CD i
mg/day NN i
over IN i
3 CD i
weeks NNS i
. . i

Patients NNS i
with IN N
? . N
1-point JJ N
decrease NN N
in IN o
pain NN o
intensity NN o
and CC o
average JJ o
pain NN o
intensity NN o
? . o
4 CD o
were VBD o
randomized VBN N
to TO i
tapentadol VB i
PR NNP i
( ( i
500 CD i
mg/day NN i
) ) i
or CC i
tapentadol JJ i
PR NNP i
( ( i
300 CD i
mg/day NN i
) ) i
/pregabalin NN i
( ( i
300 CD i
mg/day NN i
) ) i
during IN N
an DT N
8-week JJ N
comparative JJ N
period NN N
. . N

RESULTS NNP N
In IN N
the DT N
per-protocol JJ N
population NN N
( ( N
n JJ N
= NNP N
288 CD N
) ) N
, , N
the DT N
effectiveness NN o
of IN o
tapentadol NN i
PR NNP i
was VBD i
clinically RB N
and CC N
statistically RB N
comparable JJ i
to TO i
tapentadol VB i
PR/pregabalin NNP i
based VBN i
on IN N
the DT N
change NN N
in IN N
pain NN o
intensity NN o
from IN N
randomization NN N
to TO N
final JJ N
evaluation NN N
( ( N
LOCF NNP N
; : N
LSMD NNP N
[ VBD N
95 CD N
% NN N
CI NNP N
] NNP N
, , N
-0.066 NNP N
[ NNP N
-0.57 NNP N
, , N
0.43 CD N
] NN N
; : N
P NNP N
< VBZ N
0.0001 CD N
for IN N
noninferiority NN N
) ) o
. . o

Neuropathic JJ o
pain NN o
and CC o
quality-of-life JJ o
measures NNS o
improved VBN o
significantly RB N
in IN N
both DT o
groups NNS o
. . o

Tolerability NNP o
was VBD o
good JJ N
in IN N
both DT N
groups NNS N
, , N
in IN N
line NN N
with IN N
prior JJ N
trials NNS N
in IN N
the DT N
high JJ N
dose NN N
range NN N
of IN N
500 CD N
mg/day NN N
for IN N
tapentadol NN i
PR NNP i
monotherapy NN N
, , N
and CC N
favorable JJ N
compared VBN N
with IN N
historical JJ N
combination NN N
trials NNS N
of IN N
strong JJ N
opioids NNS N
and CC N
anticonvulsants NNS N
for IN N
combination NN N
therapy NN N
. . N

The DT N
incidence NN N
of IN N
the DT N
composite NN N
of IN N
dizziness NN o
and/or NN o
somnolence NN o
was VBD N
significantly RB N
lower JJR N
with IN i
tapentadol JJ i
PR NNP i
( ( N
16.9 CD N
% NN i
) ) i
than IN i
tapentadol NN i
PR/pregabalin NNP i
( ( i
27.0 CD i
% NN N
; : N
P NNP N
= NNP N
0.0302 CD N
) ) N
. . N

CONCLUSIONS NNP i
Tapentadol NNP i
PR NNP i
500 CD i
mg NN i
is VBZ N
associated VBN N
with IN N
comparable JJ o
improvements NNS o
in IN o
pain NN o
intensity NN o
and CC o
quality-of-life JJ o
measures NNS o
to TO o
tapentadol VB o
PR NNP i
300 CD i
mg/pregabalin NN N
300 CD N
mg NN o
, , o
with IN o
improved JJ o
central JJ o
nervous JJ o
system NN o
tolerability NN o
, , o
suggesting VBG o
that IN N
tapentadol NN N
PR NNP N
monotherapy NN N
may MD N
offer VB N
a DT N
favorable JJ N
treatment NN N
option NN p
for IN p
severe JJ p
low JJ p
back RB p
pain NN p
with IN p
a DT p
neuropathic JJ p
component NN p
. . N

-DOCSTART- -12197822- O O

Should MD N
we PRP N
debrief VB N
and CC N
counsel NN N
people NNS N
who WP N
have VBP N
had VBN N
psychological JJ N
shock NN N
? . N
-DOCSTART- -7492424- O O

Ebeltoft NNP N
project NN N
: : N
baseline NN N
data NNS N
from IN N
a DT N
five-year JJ N
randomized NN N
, , N
controlled VBN N
, , N
prospective JJ N
health NN N
promotion NN N
study NN N
in IN N
a DT p
Danish JJ p
population NN p
. . p

BACKGROUND NNP N
There EX N
is VBZ N
increasing VBG N
political JJ N
pressure NN N
on IN N
the DT N
medical JJ N
profession NN N
to TO N
approach VB N
welfare NN N
diseases NNS N
, , N
such JJ N
as IN N
coronary JJ N
heart NN N
disease NN N
and CC N
diabetes NNS N
, , N
through IN N
prevention NN N
. . N

General JJ N
practitioners NNS N
are VBP N
required VBN N
to TO N
offer VB N
regular JJ i
health NN i
checks NNS i
to TO i
healthy JJ i
people NNS i
, , N
in IN N
spite NN N
of IN N
the DT N
lack NN N
of IN N
scientific JJ N
evidence NN N
for IN N
the DT N
universal JJ N
need NN N
, , N
usefulness JJ N
and CC N
side JJ N
effects NNS N
of IN N
such JJ N
an DT N
intervention NN N
. . N

Randomized VBN N
controlled JJ N
trials NNS N
are VBP N
needed VBN N
. . N

AIM VB N
A DT N
study NN N
was VBD N
carried VBN N
out IN N
to TO N
investigate VB N
people NNS N
's POS N
interest NN N
in IN N
participating VBG N
in IN N
health NN i
checks NNS i
and CC N
in IN N
discussions NNS N
about IN N
health NN N
with IN N
their PRP$ N
own JJ N
general JJ N
practitioner NN N
, , N
participants NNS N
' POS N
health NN N
status NN N
, , N
the DT N
proportion NN N
who WP N
received VBD N
health NN N
advice NN N
following VBG N
health NN N
checks NNS N
, , N
and CC N
the DT N
lifestyle JJ N
goals NNS N
they PRP N
set VBP N
following VBG N
discussion NN N
with IN N
their PRP$ N
general JJ N
practitioner NN N
. . N

This DT N
study NN N
reports VBZ N
the DT N
baseline NN N
data NNS N
from IN N
a DT N
five-year JJ N
randomized NN N
, , N
controlled VBN N
, , N
prospective JJ N
, , N
population-based JJ p
study NN p
in IN p
general JJ p
practices NNS p
in IN p
Ebeltoft NNP p
, , p
Denmark NNP p
. . p

METHOD NNP N
All NNP p
general JJ p
practitioners NNS p
from IN p
the DT p
four CD p
practices NNS p
in IN p
Ebeltoft NNP p
and CC p
a DT p
random JJ p
sample NN p
of IN p
2000 CD p
people NNS p
aged VBN p
between IN p
30 CD p
and CC p
50 CD p
years NNS p
were VBD p
invited VBN p
to TO p
participate VB p
. . p

Participants NNS N
were VBD N
randomly RB N
divided VBN N
into IN N
three CD N
groups NNS N
-- : N
one CD N
control NN i
group NN N
and CC N
two CD N
intervention NN i
groups NNS N
. . N

One CD N
intervention NN N
group NN N
were VBD N
given VBN N
a DT N
health NN i
check NN i
which WDT i
included VBD i
being VBG i
screened VBN i
for IN i
cardiovascular JJ i
risk NN i
factors NNS i
, , i
lung NN i
and CC i
liver NN i
function NN i
, , i
fitness NN i
, , i
sight NN i
and CC i
hearing NN i
and CC i
an DT i
optional JJ i
test NN i
for IN i
the DT i
human JJ i
immunodeficiency NN i
virus NN i
( ( i
HIV NNP i
) ) i
; : i
this DT i
group NN i
received VBD i
written VBN i
feedback RB i
from IN i
the DT i
general JJ i
practitioner NN i
. . i

The DT N
other JJ N
intervention NN N
group NN N
were VBD N
also RB N
given VBN N
a DT N
health NN i
check NN i
and CC i
written VBN i
feedback NN i
; : i
in IN i
addition NN i
, , i
they PRP i
were VBD i
given VBN i
the DT i
opportunity NN i
to TO i
attend VB i
their PRP$ i
general JJ i
practitioner NN i
to TO i
discuss VB i
preventive JJ i
health NN i
. . i

RESULTS VB N
A DT N
total NN p
of IN p
1370 CD p
people NNS p
participated VBN p
in IN p
the DT p
study NN p
( ( N
69 CD N
% NN N
response NN N
rate NN N
) ) N
. . N

Health NNP o
advice NN o
was VBD N
given VBN N
to TO N
76 CD N
% NN N
of IN N
905 CD N
participants NNS N
following VBG N
health NN N
checks NNS N
. . N

Almost NNP N
all DT N
of IN N
the DT N
456 CD p
participants NNS p
( ( p
96 CD p
% NN p
) ) p
who WP N
were VBD N
offered VBN N
the DT N
opportunity NN N
of IN N
discussing VBG N
their PRP$ N
health NN N
with IN N
their PRP$ N
general JJ N
practitioner NN N
took VBD N
up RP N
the DT N
offer NN N
; : N
64 CD p
% NN p
of IN p
the DT p
456 CD p
participants NNS p
reported VBD N
that IN N
they PRP N
had VBD N
decided VBN N
to TO N
undertake VB o
lifestyle JJ o
changes NNS o
. . o

Eleven NNP p
of IN N
those DT N
who WP N
discussed VBD N
their PRP$ N
health NN N
with IN N
the DT N
doctor NN N
were VBD N
referred VBN o
to TO o
a DT o
specialist NN o
( ( N
2 CD N
% NN N
) ) N
. . N

CONCLUSION NNP N
There EX N
was VBD N
considerable JJ N
interest NN N
in IN N
participating VBG N
in IN N
health NN N
promotion NN N
. . N

Three CD N
out IN N
of IN N
four CD N
of IN N
those DT N
having VBG N
a DT N
health NN N
check NN N
were VBD N
given VBN N
health NN N
advice NN N
. . N

Two CD N
out IN N
of IN N
three CD N
of IN N
those DT N
offered VBN N
a DT N
health NN N
talk NN N
with IN N
the DT N
general JJ N
practitioner NN N
appeared VBD N
willing JJ N
to TO N
make VB N
relevant JJ N
lifestyle JJ N
changes NNS N
. . N

Long-term NN N
follow NN N
up RP N
is VBZ N
needed VBN N
to TO N
determine VB N
effects NNS N
and CC N
side JJ N
effects NNS N
of IN N
health NN i
checks NNS i
and CC N
health NN N
talks NNS N
. . N

-DOCSTART- -2014978- O O

Prospective JJ N
study NN N
of IN N
Clostridium NNP o
difficile JJ o
intestinal JJ N
colonization NN N
and CC N
disease NN N
following VBG N
single-dose JJ i
antibiotic JJ i
prophylaxis NN i
in IN N
surgery NN N
. . N

A DT N
total NN N
of IN N
108 CD p
volunteers NNS p
undergoing VBG p
an DT p
elective JJ p
surgical JJ p
procedure NN p
were VBD N
randomly RB N
given VBN N
a DT N
single JJ N
2-g JJ N
intravenous JJ i
prophylactic JJ i
dose NN i
of IN i
either CC i
a DT i
cephalosporin NN i
or CC i
mezlocillin NN i
. . i

Stool NNP N
samples NNS N
were VBD N
cultured VBN N
for IN N
Clostridium NNP N
difficile VBP N
the DT N
day NN N
before IN N
the DT N
operation NN N
and CC N
later RB N
on IN N
postoperative JJ N
days NNS N
4 CD N
, , N
7 CD N
, , N
and CC N
14 CD N
. . N

C. NNP o
difficile NN o
was VBD N
detected VBN N
in IN N
23.0 CD N
% NN N
of IN N
patients NNS p
who WP N
received VBD N
a DT N
cephalosporin NN i
( ( i
cefoxitin NN i
, , i
8.3 CD i
% NN i
; : i
cefazolin NN i
, , i
14.3 CD i
% NN i
; : i
cefotetan NN i
, , i
20.0 CD i
% NN i
; : i
ceftriaxone NN i
, , i
25.0 CD i
% NN i
; : i
cefoperazone NN i
, , i
43.7 CD i
% NN i
) ) i
, , N
in IN N
3.3 CD N
% NN N
of IN N
patients NNS p
given VBN N
mezlocillin NNS i
, , N
and CC N
in IN N
none NN N
of IN N
15 CD p
control NN p
volunteers NNS p
given VBN N
no DT i
antimicrobial JJ i
agent NN i
. . i

No DT N
patient NN N
experienced VBD N
diarrhea NN o
. . o

-DOCSTART- -15994720- O O

Risperidone NNP i
treatment NN N
of IN N
autistic JJ N
disorder NN N
: : N
longer-term JJ N
benefits NNS N
and CC N
blinded VBD N
discontinuation NN N
after IN N
6 CD N
months NNS N
. . N

OBJECTIVE NNP N
Risperidone NNP i
is VBZ N
effective JJ N
for IN N
short-term JJ N
treatment NN N
of IN N
aggression NN N
, , N
temper JJ N
outbursts NNS N
, , N
and CC N
self-injurious JJ N
behavior NN N
in IN N
children NNS p
with IN p
autism NN p
. . p

Because IN N
these DT N
behaviors NNS N
may MD N
be VB N
chronic JJ N
, , N
there EX N
is VBZ N
a DT N
need NN N
to TO N
establish VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
longer-term JJ N
treatment NN N
with IN N
this DT N
agent NN N
. . N

METHOD NNP N
The DT N
authors NNS N
conducted VBD N
a DT N
multisite NN N
, , N
two-part JJ N
study NN N
of IN N
risperidone NN i
in IN p
children NNS p
ages NNS p
5 CD p
to TO p
17 CD p
years NNS p
with IN p
autism NN p
accompanied VBN p
by IN p
severe JJ p
tantrums NNS p
, , p
aggression NN p
, , p
and/or JJ p
self-injurious JJ p
behavior NN p
who WP p
showed VBD p
a DT p
positive JJ p
response NN p
in IN p
an DT p
earlier JJR p
8-week JJ p
trial NN p
. . p

Part NN N
I PRP N
consisted VBD N
of IN N
4-month JJ N
open-label JJ N
treatment NN N
with IN N
risperidone NN i
, , N
starting VBG N
at IN N
the DT N
established VBN N
optimal JJ N
dose NN N
; : N
part NN N
II NNP N
was VBD N
an DT N
8-week JJ N
randomized NN N
, , N
double-blind JJ N
, , N
placebo-substitution JJ i
study NN N
of IN N
risperidone NN i
withdrawal NN N
. . N

Primary JJ N
outcome JJ N
measures NNS N
were VBD N
the DT N
Aberrant NNP o
Behavior NNP o
Checklist NNP o
irritability NN o
subscale NN o
and CC o
the DT o
Clinical NNP o
Global NNP o
Impression NNP o
improvement NN o
scale NN o
. . o

RESULTS NNP N
Part NNP p
I PRP p
included VBD p
63 CD p
children NNS p
. . p

The DT N
mean JJ N
risperidone NN i
dose NN N
was VBD N
1.96 CD N
mg/day NN N
at IN N
entry NN N
and CC N
remained VBD N
stable JJ N
over IN N
16 CD N
weeks NNS N
of IN N
open JJ N
treatment NN N
. . N

The DT N
change NN N
on IN N
the DT N
Aberrant NNP o
Behavior NNP o
Checklist NNP o
irritability NN o
subscale NN o
was VBD N
small JJ N
and CC N
clinically JJ N
insignificant NN N
. . N

Reasons NNS N
for IN N
discontinuation NN N
of IN N
part NN N
I PRP N
included VBD N
loss NN o
of IN o
efficacy NN o
( ( N
N=5 NNP N
) ) N
and CC N
adverse JJ o
effects NNS o
( ( N
N=1 NNP N
) ) N
. . N

The DT N
subjects NNS N
gained VBD N
an DT N
average NN N
of IN N
5.1 CD N
kg NNS N
. . N

Part NNP p
II NNP p
included VBD p
32 CD p
patients NNS p
. . p

The DT N
relapse NN o
rates NNS o
were VBD N
62.5 CD N
% NN N
for IN N
gradual JJ N
placebo NN N
substitution NN N
and CC N
12.5 CD N
% NN N
for IN N
continued JJ N
risperidone NN i
; : i
this DT N
difference NN N
was VBD N
statistically RB N
significant JJ N
. . N

CONCLUSIONS NNP N
Risperidone NNP i
showed VBD N
persistent JJ N
efficacy NN o
and CC N
good JJ N
tolerability NN o
for IN N
intermediate-length JJ N
treatment NN N
of IN N
children NNS p
with IN p
autism NN p
characterized VBN p
by IN p
tantrums NNS p
, , p
aggression NN p
, , p
and/or JJ p
self-injurious JJ p
behavior NN p
. . p

Discontinuation NN N
after IN N
6 CD N
months NNS N
was VBD N
associated VBN N
with IN N
a DT N
rapid JJ N
return NN N
of IN N
disruptive JJ N
and CC N
aggressive JJ N
behavior NN N
in IN N
most JJS N
subjects NNS N
. . N

-DOCSTART- -11396751- O O

A DT N
comparative JJ N
study NN N
of IN N
caudal JJ i
bupivacaine NN i
and CC i
midazolam-bupivacaine JJ i
mixture NN i
for IN N
post-operative JJ N
analgesia NN N
in IN N
children NNS p
undergoing VBG p
genitourinary JJ p
surgery NN p
. . p

OBJECTIVE CC N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
the DT N
analgesic JJ N
efficacy NN N
of IN N
caudal JJ i
midazolam-bupivacaine JJ i
combination NN i
in IN N
providing VBG N
post-operative JJ N
pain NN N
relief NN N
in IN N
children NNS p
undergoing VBG p
genitourinary JJ p
surgery NN p
and CC N
to TO N
study VB N
the DT N
occurrence NN N
of IN N
adverse JJ N
effects NNS N
. . N

SUBJECTS NNP N
AND NNP N
METHODS NNP N
Thirty NNP p
children NNS p
, , p
aged VBD p
2 CD p
to TO p
8 CD p
years NNS p
, , p
scheduled VBN p
for IN p
genitourinary JJ p
surgery NN p
were VBD N
allocated VBN N
randomly RB N
to TO N
receive VB N
either RB N
0.25 CD N
% NN N
bupivacaine NN i
0.5 CD N
ml/kg NN N
( ( N
group NN N
B NNP N
; : N
n CC N
= VB N
15 CD N
) ) N
or CC N
0.25 CD N
% NN N
bupivacaine NN i
0.5 CD i
ml/kg NN i
with IN i
50 CD i
microg/kg NNS i
midazolam NN i
( ( N
group NN N
BM NNP N
; : N
n CC N
= VB N
15 CD N
) ) N
by IN N
the DT N
caudal JJ N
route NN N
immediately RB N
after IN N
induction NN N
of IN N
general JJ N
anesthesia NN N
. . N

Heart NNP o
rate NN o
, , o
arterial JJ o
blood NN o
pressure NN o
and CC o
oxygen NN o
saturation NN o
were VBD N
monitored VBN N
throughout IN N
the DT N
study NN N
period NN N
. . N

Postoperative JJ o
pain NN o
was VBD N
assessed VBN N
at IN N
regular JJ N
intervals NNS N
for IN N
12 CD N
hours NNS N
using VBG N
an DT N
objective JJ N
pain NN o
score NN o
. . o

Analgesia NNP o
was VBD N
supplemented VBN N
whenever IN N
the DT N
pain NN o
score NN o
was VBD N
> JJ N
or CC N
= JJ N
4 CD N
. . N

Duration NN o
of IN o
analgesia NN o
, , N
as RB N
well RB N
as IN N
the DT N
requirement NN N
of IN N
additional JJ N
analgesics NNS N
, , N
were VBD N
noted VBN N
. . N

RESULTS NNP N
Lowest NNP N
pain NN o
scores NNS o
were VBD N
observed VBN N
with IN N
the DT N
addition NN N
of IN N
midazolam NN i
to TO i
caudal VB i
bupivacaine NN i
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
. . N

Duration NN o
of IN o
analgesia NN o
was VBD N
longer RBR N
in IN N
group NN N
BM NNP N
( ( N
11 CD N
+/- JJ N
0.5 CD N
h NN N
) ) N
as IN N
compared VBN N
to TO N
group NN N
B NNP N
( ( N
7.4 CD N
+/- JJ N
2.1 CD N
hours NNS N
) ) N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Fewer JJR N
children NNS N
( ( N
26.6 CD N
% NN N
) ) N
required VBD N
additional JJ o
analgesia NN o
in IN N
the DT N
combination NN N
group NN N
whereas VBZ N
in IN N
group NN N
B NNP N
, , N
60 CD N
% NN N
of IN N
the DT N
children NNS N
received VBD N
analgesic JJ o
supplements NNS o
within IN N
6 CD N
hours NNS N
after IN N
surgery NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
changes NNS N
in IN N
heart NN o
rate NN o
, , o
blood NN o
pressure NN o
and CC o
oxygen NN o
saturation NN o
in IN N
both DT N
groups NNS N
. . N

We PRP N
observed VBD N
no DT N
untoward JJ o
event NN o
in IN N
either DT N
of IN N
the DT N
groups NNS N
. . N

CONCLUSION NNP N
Caudal NNP i
administration NN i
of IN i
bupivacaine-midazolam JJ i
mixture NN i
prolongs NNS N
post-operative JJ N
analgesia NNS N
compared VBN N
to TO N
bupivacaine VB i
alone RB N
without IN N
causing VBG N
any DT N
adverse JJ N
effects NNS N
. . N

-DOCSTART- -15486373- O O

Skin NNP o
manifestations NNS o
of IN o
inhaled JJ o
corticosteroids NNS o
in IN N
COPD NNP p
patients NNS p
: : p
results NNS N
from IN N
Lung NNP N
Health NNP N
Study NNP N
II NNP N
. . N

OBJECTIVE NNP N
To TO N
define VB N
the DT N
relationship NN N
between IN N
skin NN o
bruising NN o
( ( o
as RB o
well RB o
as IN o
other JJ o
cutaneous JJ o
manifestations NNS o
) ) o
and CC N
inhaled VBN N
corticosteroid NN i
( ( i
ICS NNP i
) ) i
therapy NN N
vs NN N
placebo NN N
in IN N
subjects NNS p
with IN p
COPD NNP p
who WP N
were VBD N
participating VBG N
in IN N
a DT N
clinical JJ N
trial NN N
. . N

To TO N
explore VB N
the DT N
relationship NN N
between IN N
easy JJ o
skin NN o
bruising NN o
and CC o
other JJ o
systemic JJ o
effects NNS o
of IN o
ICS NNP o
therapy NN o
, , N
including VBG N
adrenal JJ o
suppression NN o
and CC o
loss NN o
of IN o
bone JJ o
mineral JJ o
density NN o
( ( o
BMD NNP o
) ) o
. . o

DESIGN NNP N
Double-blind NNP N
, , N
randomized VBN N
, , N
placebo-controlled JJ N
clinical JJ N
trial NN N
of IN N
triamcinolone NN i
acetonide NN i
( ( N
1200 CD N
microg FW N
daily RB N
) ) N
vs NN N
placebo NN i
in IN N
participants NNS p
with IN p
mild-to-moderate JJ p
COPD NNP p
. . p

SETTING NNP N
Lung NNP N
Health NNP N
Study NNP N
II NNP N
, , N
a DT N
clinical JJ N
trial NN N
to TO N
assess VB N
the DT N
effect NN N
of IN N
ICS NNP i
compared VBN N
to TO N
placebo VB i
in IN N
1,116 CD p
participants NNS p
in IN p
10 CD p
centers NNS p
over IN p
> $ p
3.5 CD p
to TO p
4.5 CD p
years NNS p
. . p

PARTICIPANTS VB N
A DT p
total NN p
of IN p
1,116 CD p
smokers NNS p
or CC p
recent JJ p
ex-smokers NNS p
with IN p
mild-to-moderate JJ p
COPD NNP p
( ( p
age NN p
range NN p
, , p
40 CD p
to TO p
69 CD p
years NNS p
; : p
mean JJ p
age NN p
, , p
56.3 CD p
years NNS p
; : p
37.2 CD p
% NN p
female NN p
) ) p
. . p

MEASUREMENTS NNP N
AND CC N
RESULTS NNP N
Every NNP N
6 CD N
months NNS N
, , N
a DT N
structured JJ N
questionnaire NN N
was VBD N
administered VBN N
to TO N
elicit VB N
reports NNS N
of IN N
any DT N
bruising NN o
and/or NN o
skin NN o
rashes NNS o
, , o
slow JJ o
healing NN o
of IN o
cuts NNS o
or CC o
sores NNS o
, , o
or CC o
other JJ o
skin JJ o
changes NNS o
. . o

Compliance NN N
with IN N
inhaler NN N
use NN N
was VBD N
assessed VBN N
by IN N
canister NN N
weighing VBG N
. . N

A DT N
significantly RB N
higher JJR N
proportion NN N
of IN N
ICS NNP i
than IN N
placebo NN i
participants NNS N
who WP N
complied VBD N
with IN N
using VBG N
their PRP$ N
inhaler NN N
reported VBD N
easy JJ o
bruising NN o
( ( N
11.2 CD N
% NN N
vs JJ N
3.5 CD N
% NN N
, , N
respectively RB N
) ) N
and CC N
the DT N
slow JJ o
healing NN o
of IN o
skin NN o
cuts NNS o
or CC o
sores NNS o
( ( N
2.4 CD N
% NN N
vs JJ N
0.5 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

Older JJR p
men NNS p
in IN N
the DT N
ICS NNP i
group NN N
with IN N
good JJ N
inhaler NN N
compliance NN N
appeared VBD N
to TO N
be VB N
at IN N
the DT N
greatest JJS N
risk NN o
of IN o
bruising VBG o
. . o

In IN N
those DT N
participants NNS N
undergoing VBG N
serial JJ N
measurements NNS N
of IN N
adrenal JJ N
function NN N
and CC N
BMD NNP N
, , N
no DT N
association NN N
was VBD N
noted VBN N
between IN N
skin JJ o
bruising NN o
and CC N
either CC N
the DT N
suppression NN o
of IN o
adrenal JJ o
function NN o
or CC o
the DT o
loss NN o
of IN o
BMD NNP o
as IN N
systemic JJ N
complications NNS N
of IN N
ICS NNP N
use NN N
. . N

CONCLUSION NNP N
These DT N
findings NNS N
indicate VBP N
that IN N
moderate-to-high JJ N
doses NNS N
of IN N
ICSs NNP N
result NN N
in IN N
an DT N
increased JJ N
incidence NN N
of IN N
easy JJ o
bruising NN o
and CC o
impairment NN o
in IN o
skin NN o
healing NN o
in IN N
middle-aged JJ p
to TO p
elderly JJ p
persons NNS p
with IN p
COPD NNP p
. . p

No DT N
association NN N
was VBD N
noted VBN N
between IN N
skin JJ o
bruising NN o
and CC N
other JJ N
markers NNS N
of IN N
systemic JJ o
toxicity NN o
from IN N
the DT N
use NN N
of IN N
ICSs NNP i
. . N

-DOCSTART- -1444872- O O

[ NN N
Unstable JJ N
angina NN N
: : N
comparison NN N
of IN N
the DT N
effects NNS N
of IN N
diltiazem NN i
and CC i
propranolol NN i
] NN i
. . N

PURPOSE NNP N
To TO N
evaluate VB N
the DT N
effects NNS N
of IN N
diltiazem NN i
and CC i
propranolol NN i
in IN N
patients NNS p
with IN p
unstable JJ p
angina NN p
. . p

METHODS NNP N
Fifty-six JJ p
patients NNS p
with IN p
unstable JJ p
angina NN p
, , p
mean JJ p
age NN p
of IN p
55.4 CD p
+/- JJ p
8.5 CD p
, , p
41 CD p
men NNS p
and CC p
15 CD p
women NNS p
, , N
were VBD N
evaluated VBN N
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
study NN N
of IN N
two CD N
groups NNS N
of IN N
patients NNS N
treated VBN N
with IN N
diltiazem NN i
or CC i
propranolol NN i
at IN N
total JJ N
daily JJ N
doses NNS N
of IN N
180 CD N
mg NNS N
and CC N
120 CD N
mg NN N
respectively RB N
during IN N
the DT N
first JJ N
48 CD N
hours NNS N
. . N

After IN N
that IN N
the DT N
total JJ N
daily JJ N
doses NNS N
was VBD N
adjusted VBN N
to TO N
240 CD N
mg NNS N
and CC N
160 CD N
mg NN N
, , N
respectively RB N
, , N
until IN N
the DT N
7th JJ N
day NN N
. . N

The DT N
first JJ N
48 CD N
hours NNS N
, , N
four CD N
times NNS N
daily RB N
, , N
clinical JJ o
evaluation NN o
, , o
CKMB NNP o
data NN o
, , o
ECG NNP o
were VBD N
obtained VBN N
and CC N
two CD N
times NNS N
daily RB N
until IN N
7th CD N
day NN N
. . N

A DT N
coronary JJ i
arteriography NN i
was VBD N
done VBN N
on IN N
study NN N
entry NN N
. . N

RESULTS VB N
A NNP N
significative JJ N
reduction NN o
of IN o
angina NN o
crisis NN o
number NN o
, , o
duration NN o
, , o
intensity NN o
and CC o
the DT o
number NN o
of IN o
sublingual JJ o
nitrates NNS o
doses NNS o
were VBD N
observed VBN N
equally RB N
in IN N
both DT N
groups NNS N
. . N

The DT N
SAP NNP o
, , o
DAP NNP o
, , o
HR NNP o
and CC o
RR NNP o
did VBD N
not RB N
show VB N
statistical JJ N
differences NNS N
between IN N
groups NNS N
. . N

Individual NNP N
groups NNS N
analysis NN N
showed VBD N
significative JJ N
reductions NNS o
of IN N
SAP NNP o
, , o
DAP NNP o
and CC o
HR NNP o
in IN N
propranolol NN i
group NN N
. . N

The DT N
CKMB NNP o
data NNS o
, , o
ECG NNP o
alterations NNS o
and CC o
coronary JJ o
arteriography NN o
characteristics NNS N
were VBD N
similar JJ N
. . N

CONCLUSION NNP N
Both NNP N
drugs NNS N
were VBD N
effective JJ N
for IN N
the DT N
unstable JJ N
angina NN N
treatment NN N
. . N

-DOCSTART- -8856425- O O

Counselling NN i
of IN N
postnatal JJ N
depression NN N
: : N
a DT N
controlled VBN N
study NN N
on IN N
a DT N
population NN p
based VBN p
Swedish JJ p
sample NN p
. . p

In IN N
a DT N
two-stage JJ N
screening NN N
procedure NN N
using VBG N
the DT N
Edinburgh NNP o
Postnatal NNP o
Depression NNP o
Scale NNP o
( ( o
EPDS NNP o
) ) o
at IN N
8 CD N
and CC N
12 CD N
weeks NNS N
postpartum NN p
and CC N
the DT N
Montgomery-Asberg NNP o
Depression NNP o
Rating NNP o
Scale NNP o
( ( o
MADRS NNP o
) ) o
and CC N
DSM-III-R NNP o
at IN N
about RB N
13 CD N
weeks NNS N
postpartum NN N
, , N
41 CD p
women NNS p
identified VBN p
as IN p
depressed JJ p
were VBD N
randomly RB N
allocated VBN N
to TO N
a DT N
study NN N
and CC N
a DT N
control NN N
group NN N
. . N

The DT N
women NNS N
in IN N
the DT N
study NN N
group NN N
received VBD N
6 CD i
weekly JJ i
, , i
counselling VBG i
visits NNS i
by IN i
the DT i
Child NNP i
Health NNP i
Clinic NNP i
nurse NN i
and CC i
the DT i
control NN i
group NN i
received VBD i
routine JJ i
primary NN i
care NN i
. . i

Twelve NNP N
( ( N
80 CD N
% NN N
) ) N
of IN N
15 CD N
women NNS N
with IN N
major JJ N
depression NN N
in IN N
the DT N
study NN N
group NN N
were VBD N
fully RB o
recovered VBN o
after IN N
the DT N
intervention NN N
compared VBN N
to TO N
4 CD N
( ( N
25 CD N
% NN N
) ) N
of IN N
16 CD N
in IN N
the DT N
control NN N
group NN N
. . N

Counselling VBG i
by IN N
health NN N
nurses NNS N
is VBZ N
helpful JJ N
in IN N
managing VBG N
postnatal JJ N
depression NN N
and CC N
seems VBZ N
to TO N
work VB N
well RB N
within IN N
the DT N
Swedish JJ N
Primary NNP N
Health NNP N
Care NNP N
system NN N
. . N

-DOCSTART- -7887018- O O

Immune NNP o
response NN o
in IN N
healthy JJ p
volunteers NNS p
vaccinated VBD p
with IN p
BCG NNP i
plus CC i
killed VBN p
leishmanial JJ p
promastigotes NNS p
: : p
antibody NN N
responses VBZ N
to TO N
mycobacterial VB N
and CC N
leishmanial JJ N
antigens NNS N
. . N

Antibody NNP o
( ( o
IgG NNP o
) ) o
responses VBZ o
to TO N
mycobacterial VB N
( ( N
BCG NNP N
; : N
PPD NNP N
; : N
Mycobacterium NNP N
leprae VBZ N
soluble JJ N
antigen NN N
, , N
MLSA NNP N
) ) N
and CC N
leishmanial JJ N
( ( N
Leishmania NNP N
mexicana NNP N
LV4 NNP N
) ) N
antigens NNS N
were VBD N
measured VBN N
in IN N
208 CD p
initially RB p
PPD NNP p
and CC p
leishmanin JJ p
skin-test JJ p
negative JJ p
volunteers NNS p
divided VBD N
into IN N
four CD i
vaccine NN i
groups NNS i
as IN i
follows VBZ i
: : i
68 CD i
received VBD i
BCG NNP i
plus CC i
killed VBN i
promastigotes NNS i
( ( i
group NN i
A NNP i
) ) i
, , i
47 CD i
received VBD i
BCG NNP i
alone RB i
( ( i
group NN i
B NNP i
) ) i
, , i
47 CD i
received VBD i
killed VBN i
promastigotes NNS i
alone RB i
( ( i
group NN i
C NNP i
) ) i
, , i
and CC i
46 CD i
formed VBD i
the DT i
diluent NN i
control NN i
( ( i
placebo NN i
, , i
group NN i
D NNP i
) ) i
. . i

Three CD i
vaccine NN i
doses NNS i
were VBD i
administered VBN i
at IN i
8-12 JJ i
week NN i
intervals NNS i
. . i

Vaccinees NNS i
were VBD i
bled VBN i
immediately RB i
prior JJ i
to TO i
each DT i
vaccination NN i
, , i
and CC i
again RB i
at IN i
3- JJ i
and CC i
12-month JJ i
follow-up NN i
. . i

Skin JJ o
tests NNS o
were VBD i
performed VBN i
prevaccination NN i
, , i
and CC i
again RB i
at IN i
the DT i
3- JJ i
and CC i
12-month JJ i
follow-up NN i
. . i

Anti-BCG JJ N
, , N
anti-PPD JJ N
and CC N
anti-MLSA JJ N
IgG NNP N
levels NNS N
increased VBD N
significantly RB N
in IN N
groups NNS N
A NNP N
and CC N
B NNP N
receiving VBG N
BCG NNP N
. . N

The DT N
presence NN N
of IN N
leishmanial JJ N
antigen NN N
( ( N
with IN N
BCG NNP N
) ) N
in IN N
the DT N
inoculum NN N
suppressed VBD N
the DT N
IgG NNP N
response NN N
to TO N
Mycobacterium NNP N
tuberculosis/Mycobacterium NN N
bovis-related JJ N
( ( N
PPD NNP N
and CC N
BCG NNP N
) ) N
, , N
but CC N
not RB N
M. NNP N
leprae-related JJ N
( ( N
MLSA NNP N
) ) N
-related VBD N
, , N
antigens NNS N
. . N

A DT N
small JJ N
but CC N
significant JJ N
increase NN N
( ( N
relative JJ N
to TO N
prevaccination VB N
level NN N
) ) N
in IN N
response NN N
to TO N
MLSA NNP N
, , N
but CC N
not RB N
to TO N
BCG NNP N
or CC N
PPD NNP N
was VBD N
observed VBN N
in IN N
the DT N
non-BCG-vaccinated JJ N
groups NNS N
. . N

The DT N
background NN N
level NN N
of IN N
response NN N
to TO N
mycobacterial JJ N
and CC N
leishmanial JJ N
antigens NNS N
was VBD N
higher RBR N
in IN N
the DT N
Venezuelan NNP p
vaccinees NNS p
than IN N
in IN N
non-endemic JJ p
( ( p
British JJ p
) ) p
volunteers NNS p
. . p

Responses NNS N
to TO N
leishmanial JJ o
antigen NN o
were VBD N
not RB N
enhanced VBN N
in IN N
the DT N
two CD N
vaccine NN N
groups NNS N
receiving VBG N
killed VBN N
promastigotes NNS N
( ( N
with/without IN N
BCG NNP N
) ) N
compared VBN N
with IN N
the DT N
BCG NNP N
alone RB N
and CC N
placebo JJ N
groups NNS N
. . N

Instead RB N
, , N
all DT N
vaccine NN N
groups NNS N
showed VBD N
a DT N
pattern NN N
of IN N
response NN N
consistent NN N
with IN N
either DT N
( ( N
i NN N
) ) N
a DT N
response NN N
to TO N
the DT N
skin-test JJ N
antigen NN N
or CC N
, , N
more RBR N
likely JJ N
, , N
( ( N
ii NN N
) ) N
seasonal JJ N
endemic JJ N
exposure NN N
to TO N
leishmanial JJ N
antigen NN N
. . N

Interestingly RB N
, , N
this DT N
endemic JJ N
response NN N
to TO N
leishmanial JJ N
antigen NN N
was VBD N
enhanced VBN N
in IN N
the DT N
vaccine NN N
groups NNS N
receiving VBG N
BCG NNP N
, , N
despite IN N
the DT N
fact NN N
that IN N
group NN N
B NNP N
received VBD N
no DT N
leishmanial JJ N
antigen NN N
in IN N
the DT N
vaccine NN N
inoculum NN N
. . N

When WRB N
prevaccination NN N
IgG NNP N
levels NNS N
( ( N
mean VB N
+ RB N
3 CD N
standard JJ N
deviations NNS N
) ) N
were VBD N
used VBN N
to TO N
determine VB N
a DT N
negative JJ N
cut-off NN N
, , N
a DT N
low JJ N
percentage NN N
( ( N
< JJ N
38 CD N
% NN N
) ) N
of IN N
vaccinees NNS N
converted VBN N
to TO N
responder VB N
status NN N
for IN N
either DT N
anti-mycobacterial JJ N
or CC N
anti-leishmanial JJ N
responses NNS N
, , N
and CC N
those DT N
who WP N
did VBD N
would MD N
be VB N
classified VBN N
as IN N
'low-responder NN N
' '' N
status NN N
compared VBN N
with IN N
titres NNS N
observed VBN N
in IN N
severe JJ N
forms NNS N
of IN N
disease NN N
. . N

Hence NNP N
, , N
although IN N
there EX N
was VBD N
evidence NN N
for IN N
a DT N
background NN N
endemic JJ N
response NN N
to TO N
both DT N
leishmanial JJ N
and CC N
mycobacterial JJ N
antigens NNS N
, , N
there EX N
was VBD N
no DT N
evidence NN N
that IN N
vaccination NN N
per IN N
se NN N
led VBD N
to TO N
a DT N
potentially RB N
disease JJ N
exacerbatory JJ N
level NN N
of IN N
TH2-associated NNP N
antibody NN N
response NN N
especially RB N
with IN N
respect NN N
to TO N
the DT N
anti-leishmanial JJ N
response NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
400 CD N
WORDS NNP N
) ) N
-DOCSTART- -3307414- O O

Diclofenac NNP i
, , N
a DT N
nonsteroidal JJ N
anti-inflammatory JJ N
drug NN N
, , N
decreases VBZ N
proteinuria NN N
in IN N
some DT N
glomerular JJ p
diseases NNS p
: : p
a DT N
controlled VBN N
study NN N
. . N

Treatment NN N
with IN N
nonsteroidal JJ i
anti-inflammatory JJ i
drugs NNS i
( ( i
NSAIDs NNP i
) ) i
was VBD N
first RB N
used VBN N
in IN N
glomerulonephritis NN p
( ( N
GN NNP N
) ) N
in IN N
1966 CD N
but CC N
its PRP$ N
efficiency NN N
is VBZ N
still RB N
debated VBN N
. . N

We PRP N
studied VBD N
the DT N
antiproteinuric JJ o
effect NN o
of IN N
such JJ N
a DT N
treatment NN N
in IN N
a DT N
double-blind NN N
study NN N
. . N

29 CD p
GN NNP p
patients NNS p
with IN p
normal JJ p
renal JJ p
function NN p
( ( p
17 CD p
membranoproliferative NN p
GN NNP p
, , p
12 CD p
IgA NNP p
GN NNP p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
100 CD N
mg/day NN N
of IN N
diclofenac NN i
or CC i
placebo NN i
for IN N
at IN N
least JJS N
2 CD N
months NNS N
. . N

There EX N
was VBD N
a DT N
significant JJ N
antiproteinuric JJ o
effect NN o
of IN N
diclofenac NN i
versus NN N
placebo NN i
with IN N
a DT N
fall NN N
of IN N
70 CD N
% NN N
in IN N
the DT N
diclofenac NN N
group NN N
versus VBD N
6 CD N
% NN N
in IN N
the DT N
placebo NN i
group NN N
( ( N
p VBZ N
less JJR N
than IN N
0.001 CD N
with IN N
the DT N
Mann-Whitney NNP N
test NN N
) ) N
. . N

The DT N
median NN N
was VBD N
3 CD N
mg/min NN N
at IN N
onset NN N
and CC N
2.45 CD N
mg/min NN N
after IN N
2 CD N
months NNS N
treatment NN N
with IN N
the DT N
placebo NN N
. . N

In IN N
the DT N
diclofenac NN i
group NN N
, , N
it PRP N
was VBD N
2.2 CD N
and CC N
0.95 CD N
mg/min NN N
, , N
respectively RB N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

Diclofenac NNP i
did VBD N
not RB N
significantly RB N
increase VB N
creatinine NN o
levels NNS o
. . o

Gastric NNP o
irritation NN o
was VBD N
noted VBN N
only RB N
once RB N
. . N

This DT N
study NN N
establishes VBZ N
the DT N
short-term JJ o
antiproteinuric JJ o
action NN o
of IN N
diclofenac NN N
. . N

Whether IN N
this DT N
action NN N
affects VBZ N
the DT N
final JJ N
outcome NN N
is VBZ N
not RB N
yet RB N
determined VBN N
. . N

-DOCSTART- -18492829- O O

Gene NNP N
expression NN N
is VBZ N
altered VBN N
in IN N
piglet NN p
small JJ N
intestine NN N
by IN N
weaning VBG N
and CC N
dietary JJ i
glutamine NN i
supplementation NN i
. . i

Dietary JJ i
supplementation NN i
of IN i
glutamine NN i
prevents NNS N
intestinal JJ N
dysfunction NN N
and CC N
atrophy NN N
in IN N
weanling VBG N
piglets NNS N
, , N
but CC N
the DT N
underlying JJ N
mechanism NN N
( ( N
s NN N
) ) N
are VBP N
largely RB N
unknown JJ N
. . N

This DT N
study NN N
was VBD N
conducted VBN N
to TO N
test VB N
the DT N
hypothesis NN N
that IN N
weaning VBG N
or CC N
glutamine NN N
may MD N
modulate VB N
expression NN N
of IN N
genes NNS N
that WDT N
are VBP N
crucial JJ N
for IN N
intestinal JJ N
metabolism NN N
and CC N
function NN N
. . N

In IN N
Expt NNP N
. . N

1 CD N
, , N
we PRP N
obtained VBD N
small JJ p
intestine NN p
from IN p
28-d-old JJ p
pigs NNS p
weaned VBD p
at IN p
21 CD p
d NN p
of IN p
age NN p
and CC p
from IN p
age-matched JJ p
suckling VBG p
piglets NNS p
. . p

In IN N
Expt NNP N
. . N

2 CD N
, , N
piglets NNS N
were VBD N
weaned VBN N
at IN N
21 CD N
d NN N
of IN N
age NN N
and CC N
then RB N
had VBD N
free JJ i
access NN i
to TO i
diets NNS i
supplemented VBN i
with IN i
1 CD i
% NN i
L-glutamine NNP i
( ( i
wt NN i
: : i
wt NN i
) ) i
or CC i
isonitrogenous JJ i
L-alanine JJ i
( ( i
control NN i
) ) i
. . i

At IN N
d JJ N
28 CD N
, , N
we PRP N
collected VBD N
small JJ N
intestine NN N
for IN N
biochemical JJ N
and CC N
morphological JJ N
measurements NNS N
and CC N
microarray JJ N
analysis NN N
of IN N
gene NN o
expression NN o
using VBG N
the DT N
Operon NNP N
Porcine NNP N
Genome NNP N
Oligo NNP N
set NN N
. . N

Early JJ N
weaning NN N
resulted VBD N
in IN N
increased VBN N
( ( N
52-346 CD N
% NN N
) ) N
expression NN o
of IN o
genes NNS o
related VBN o
to TO o
oxidative JJ o
stress NN o
and CC o
immune JJ o
activation NN o
but CC N
decreased JJ N
( ( N
35-77 CD N
% NN N
) ) N
expression NN o
of IN o
genes NNS o
related VBN o
to TO o
macronutrient VB o
metabolism NN o
and CC N
cell NN o
proliferation NN o
in IN o
the DT o
gut NN o
. . o

Dietary NNP i
glutamine JJ i
supplementation NN i
increased VBD N
intestinal JJ o
expression NN o
( ( o
120-124 CD o
% NN o
) ) o
of IN o
genes NNS o
that WDT N
are VBP N
necessary JJ N
for IN N
cell NN N
growth NN N
and CC N
removal NN o
of IN o
oxidants NNS o
, , N
while IN N
reducing VBG N
( ( N
34-75 CD N
% NN N
) ) N
expression NN o
of IN o
genes NNS o
that WDT N
promote VBP N
oxidative JJ o
stress NN o
and CC o
immune JJ o
activation NN o
. . o

Functionally RB N
, , N
the DT i
glutamine NN i
treatment NN i
enhanced VBD N
intestinal JJ o
oxidative-defense JJ o
capacity NN o
( ( N
indicated VBN N
by IN N
a DT N
29 CD N
% NN N
increase NN N
in IN N
glutathione JJ N
concentration NN N
) ) N
, , N
prevented VBD N
jejunal JJ o
atrophy NN o
, , N
and CC N
promoted VBD N
small JJ o
intestine JJ o
growth NN o
( ( N
+12 CD N
% NN N
) ) N
and CC N
body NN o
weight JJ o
gain NN o
( ( N
+19 CD N
% NN N
) ) N
in IN N
weaned JJ N
piglets NNS N
. . N

These DT N
findings NNS N
reveal VBP N
coordinate JJ N
alterations NNS N
of IN N
gene NN N
expression NN N
in IN N
response NN N
to TO N
weaning VBG N
and CC N
aid NN N
in IN N
providing VBG N
molecular JJ N
mechanisms NNS N
for IN N
the DT N
beneficial JJ N
effect NN N
of IN N
dietary JJ N
glutamine NN i
supplementation NN i
to TO N
improve VB N
nutrition NN N
status NN N
in IN N
young JJ p
mammals NNS p
. . p

-DOCSTART- -23339584- O O

A DT N
pilot NN N
randomised VBN N
controlled JJ N
trial NN N
of IN N
cognitive JJ i
behavioural JJ i
therapy NN i
for IN N
antenatal JJ p
depression NN p
. . p

BACKGROUND NNP N
Few JJ N
trials NNS N
have VBP N
evaluated VBN N
the DT N
effectiveness NN N
of IN N
psychological JJ N
treatment NN N
in IN N
improving VBG N
depression NN N
by IN N
the DT N
end NN N
of IN N
pregnancy NN p
. . p

This DT N
is VBZ N
the DT N
first JJ N
pilot NN N
randomised VBN N
controlled VBN N
trial NN N
( ( N
RCT NNP N
) ) N
of IN N
individual JJ i
cognitive JJ i
behavioural JJ i
therapy NN i
( ( i
CBT NNP i
) ) i
looking VBG N
at IN N
treating VBG N
depression NN N
by IN N
the DT N
end NN N
of IN N
pregnancy NN N
. . N

Our PRP$ N
aim NN N
was VBD N
to TO N
assess VB N
the DT N
feasibility NN N
of IN N
delivering VBG N
a DT N
CBT NNP i
intervention NN i
modified VBD N
for IN N
antenatal JJ N
depression NN N
during IN N
pregnancy NN N
. . N

METHODS NNP N
Women NNP p
in IN p
North NNP p
Bristol NNP p
, , p
UK NNP p
between IN p
8-18 JJ p
weeks NNS p
pregnant JJ p
were VBD p
recruited VBN p
through IN p
routine JJ p
contact NN p
with IN p
midwives NNS p
and CC N
randomised VBN N
to TO N
receive VB N
up RP N
to TO N
12 CD N
sessions NNS N
of IN i
individual JJ i
CBT NNP i
in IN i
addition NN i
to TO i
usual JJ i
care NN i
or CC N
to TO N
continue VB N
with IN i
usual JJ i
care NN i
only RB i
. . i

Women NNS p
were VBD p
eligible JJ p
for IN p
randomisation NN p
if IN N
they PRP N
screened VBD N
positive JJ N
on IN N
a DT N
3-question JJ N
depression NN N
screen NN N
used VBN N
routinely RB N
by IN p
midwives NNS p
and CC p
met VBD p
ICD-10 NNP p
criteria NNS p
for IN p
depression NN p
assessed VBN p
using VBG p
the DT p
clinical JJ p
interview NN p
schedule NN p
- : p
revised VBN p
version NN p
( ( p
CIS-R NNP p
) ) p
. . p

Two CD i
CBT NNP i
therapists NNS N
delivered VBD N
the DT N
intervention NN N
. . N

Follow-up NN N
was VBD N
at IN N
15 CD N
and CC N
33 CD N
weeks NNS N
post-randomisation NN N
when WRB N
assessments NNS N
of IN N
mental JJ o
health NN o
were VBD o
made VBN N
using VBG N
measures NNS N
which WDT N
included VBD N
the DT N
CIS-R NNP N
. . N

RESULTS NNP p
Of IN p
the DT p
50 CD p
women NNS p
assessed VBD p
for IN p
the DT p
trial NN p
, , p
36 CD p
met VBD p
ICD-10 NNP p
depression NN p
criteria NNS p
and CC p
were VBD p
randomised VBN p
: : p
18 CD p
to TO p
the DT p
intervention NN p
and CC p
18 CD p
to TO p
usual JJ p
care NN p
. . p

Thirteen NNP p
of IN p
the DT p
18 CD p
( ( p
72 CD p
% NN p
) ) p
women NNS p
who WP p
were VBD N
allocated VBN N
to TO N
receive VB N
the DT N
intervention NN N
completed VBD N
9 CD N
or CC N
more JJR N
sessions NNS N
of IN N
CBT NNP i
before IN i
the DT N
end NN N
of IN N
pregnancy NN N
. . N

Follow-up JJ N
rates NNS N
at IN N
15 CD N
and CC N
33 CD N
weeks NNS N
post-randomisation NN N
were VBD N
higher JJR N
in IN N
the DT N
group NN N
who WP N
received VBD N
the DT N
intervention NN N
( ( N
89 CD N
% NN N
vs. FW N
72 CD N
% NN N
at IN N
15 CD N
weeks NNS N
and CC N
89 CD N
% NN N
vs. FW N
61 CD N
% NN N
at IN N
33 CD N
weeks NNS N
post-randomisation NN N
) ) N
. . N

At IN N
15 CD N
weeks NNS N
post-randomisation NN N
( ( N
the DT N
end NN N
of IN N
pregnancy NN N
) ) N
, , N
there EX N
were VBD N
more JJR N
women NNS N
in IN N
the DT N
intervention NN N
group NN N
( ( N
11/16 CD N
; : N
68.7 CD N
% NN N
) ) N
who WP N
recovered VBD N
( ( N
i.e NN N
. . N

no RB N
longer RBR N
met VBD N
ICD-10 NNP N
criteria NNS o
for IN o
depression NN o
) ) o
, , o
than IN o
those DT N
receiving VBG N
only RB N
usual JJ N
care NN N
( ( N
5/13 CD N
; : N
38.5 CD N
% NN N
) ) N
. . N

CONCLUSIONS VB N
This DT N
pilot NN N
trial NN N
shows VBZ N
the DT N
feasibility NN N
of IN N
conducting VBG N
a DT N
large JJ N
RCT NNP N
to TO N
assess VB N
the DT N
effectiveness NN i
of IN i
CBT NNP i
for IN i
treating VBG N
antenatal JJ N
depression NN N
before IN N
the DT N
end NN N
of IN N
pregnancy NN N
. . N

The DT N
intervention NN N
could MD N
be VB N
delivered VBN N
during IN N
the DT N
antenatal JJ N
period NN N
and CC N
there EX N
was VBD N
some DT N
evidence NN N
to TO N
suggest VB N
that IN N
it PRP N
could MD N
be VB N
effective JJ N
. . N

TRIAL NNP N
REGISTRATION NNP N
ISRCTN44902048 NNP N
. . N

-DOCSTART- -8245359- O O

Femoral NNP N
vein NN N
delivery NN N
of IN N
contrast NN N
medium NN N
enhances VBZ N
transthoracic JJ o
echocardiographic JJ o
detection NN o
of IN N
patent NN o
foramen NNS o
ovale VBP o
. . o

OBJECTIVES IN N
We PRP N
postulated VBD N
that IN N
femoral JJ N
vein JJ N
delivery NN N
of IN N
contrast NN N
medium NN N
because IN N
of IN N
streaming NN N
, , N
might MD N
enhance VB N
precordial JJ o
echocardiographic JJ o
detection NN o
of IN N
patent NN N
foramen NNS N
ovale VBP N
. . N

BACKGROUND NNP N
Although IN N
precordial JJ N
contrast NN N
echocardiography NN N
is VBZ N
widely RB N
used VBN N
to TO N
diagnose VB N
patent JJ N
foramen NNS N
ovale RB N
, , N
this DT N
method NN N
is VBZ N
limited VBN N
by IN N
poor JJ N
sensitivity NN N
. . N

Previous JJ N
investigators NNS N
have VBP N
demonstrated VBN N
enhanced JJ N
detection NN N
of IN N
atrial JJ o
defects NNS o
by IN N
the DT N
dye-dilution NN N
technique NN N
after IN N
delivery NN N
of IN N
contrast NN N
medium NN N
into IN N
the DT N
inferior NN N
rather RB N
than IN N
the DT N
superior JJ N
vena NN N
cava NN N
. . N

METHODS NNP N
Transthoracic NNP i
contrast NN i
examinations NNS i
were VBD N
performed VBN N
in IN N
a DT N
randomly RB N
selected VBN N
group NN N
of IN N
70 CD p
patients NNS p
( ( p
without IN p
previous JJ p
history NN p
of IN p
cerebral JJ p
or CC p
systemic JJ p
embolus NN p
) ) p
undergoing VBG p
cardiac JJ p
catheterization NN p
. . p

Paired VBN N
contrast NN i
agent NN i
injections NNS i
( ( i
10 CD i
ml NN i
dextrose NN i
in IN i
water/0.25 NN i
ml NNP i
air NN i
) ) i
were VBD N
administered VBN N
from IN N
an DT N
upper JJ N
extremity NN N
vein NN N
and CC N
femoral JJ N
vein NN N
in IN N
each DT N
patient NN N
during IN N
spontaneous JJ N
respiration NN N
, , N
cough NN N
and CC N
Valsalva NNP N
maneuvers NNS N
. . N

Studies NNS N
were VBD N
interpreted VBN N
by IN N
an DT N
experienced JJ N
echocardiographer NN N
unaware NN N
of IN N
the DT N
sequence NN N
and CC N
site NN N
of IN N
injections NNS N
. . N

Positive JJ N
studies NNS N
were VBD N
semiquantitatively RB N
graded VBN N
from IN N
+1 NNP N
( ( N
minimal JJ N
left VBD N
ventricular JJ N
opacification NN N
) ) N
to TO N
+4 VB N
( ( N
intense JJ N
left VBD N
ventricular JJ N
opacification NN N
) ) N
. . N

Catheterization NN o
and CC o
echocardiographic JJ o
assessment NN o
of IN o
patent NN o
foramen NNS o
ovale VBP o
were VBD N
compared VBN N
in IN N
21 CD N
subjects NNS N
. . N

RESULTS NNP N
Patent NNP o
foramen NNS o
ovale NN o
was VBD N
detected VBN N
significantly RB N
more RBR N
often RB N
during IN N
femoral JJ N
vein NNS N
versus VBP N
upper JJ N
extremity NN N
contrast NN N
delivery NN N
( ( N
23 CD N
of IN N
70 CD N
patients NNS N
[ JJ N
prevalence RB N
33 CD N
% NN N
] NNP N
vs. IN N
9 CD N
of IN N
70 CD N
patients NNS N
[ JJ N
prevalence RB N
13 CD N
% NN N
] NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
intensity NN o
of IN o
left JJ o
ventricular JJ o
opacification NN o
was VBD N
also RB N
greater JJR N
during IN N
femoral JJ N
vein NNS N
contrast NN N
injection NN N
. . N

Precordial JJ N
echocardiography NN N
combined VBN N
with IN N
femoral JJ N
contrast NN N
delivery NN N
was VBD N
significantly RB N
more RBR N
sensitive JJ o
than IN N
cardiac JJ N
catheterization NN N
for IN N
assessment NN o
of IN o
patent NN o
foramen NNS o
ovale VBP o
( ( N
8 CD N
of IN N
21 CD N
patients NNS N
vs. FW N
2 CD N
of IN N
21 CD N
patients NNS N
, , N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
Femoral NNP i
vein NNP i
contrast NN i
delivery NN i
significantly RB N
enhances VBZ N
the DT N
ability NN o
of IN o
precordial JJ o
contrast NN o
echocardiography NN o
to TO o
diagnose VB o
patent JJ o
foramen NNS o
ovale VBP o
. . o

Physiologic NNP N
patency NN N
of IN N
the DT N
foramen NNS N
ovale VBP N
is VBZ N
more RBR N
common JJ N
( ( N
prevalence JJ N
33 CD N
% NN N
) ) N
than IN N
previously RB N
documented VBN N
. . N

-DOCSTART- -11943119- O O

A DT N
role NN N
for IN N
error NN i
training NN i
in IN N
surgical JJ i
technical JJ i
skill NN i
instruction NN i
and CC i
evaluation NN i
. . i

BACKGROUND NNP N
During IN N
the DT N
evaluation NN N
of IN N
many JJ N
instances NNS N
of IN N
the DT N
same JJ N
basic JJ N
surgical NN N
skill NN N
, , N
we PRP N
observed VBD N
that IN N
there EX N
were VBD N
several JJ N
errors NNS N
that WDT N
occurred VBD N
frequently RB N
. . N

Two CD N
studies NNS N
were VBD N
undertaken VBN N
to TO N
examine VB N
the DT N
use NN N
of IN N
these DT N
errors NNS N
for IN N
improving VBG N
the DT N
instruction NN N
and CC N
evaluation NN N
of IN N
the DT N
skill NN N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
For IN N
both DT N
studies NNS N
, , N
two CD i
types NNS i
of IN i
rater NN i
training NN i
videotapes NNS i
were VBD N
developed VBN N
. . N

One CD N
involved VBD N
the DT N
use NN N
of IN N
examples NNS i
of IN i
common JJ i
errors NNS i
( ( i
error NN i
) ) i
and CC N
the DT N
other JJ N
demonstrated VBD N
the DT N
skill NN i
being VBG i
performed VBN i
correctly RB i
( ( i
correct NN i
) ) i
. . N

A DT N
testing VBG N
videotape NN N
was VBD N
created VBN N
consisting NN N
of IN N
24 CD N
performances NNS N
of IN N
the DT N
skill NN N
that WDT N
ranged VBD N
in IN N
quality NN N
of IN N
the DT N
performance NN N
. . N

The DT N
first JJ N
study NN N
was VBD N
designed VBN N
to TO N
assess VB N
the DT N
impact NN N
of IN N
error NN i
instruction NN i
on IN N
skill JJ o
acquisition NN o
. . o

In IN N
this DT N
study NN N
, , N
a DT p
group NN p
of IN p
30 CD p
senior JJ p
medical JJ p
students NNS p
were VBD p
randomly RB p
assigned VBN p
to TO N
one CD N
of IN N
four CD N
different JJ N
training VBG N
groups NNS N
: : N
none NN i
, , i
error NN i
only RB i
, , i
correct VBP i
only RB i
, , i
and CC i
error+correct NN i
. . i

Subjects NNS N
were VBD N
videotaped VBN N
performing VBG N
the DT N
skill NN N
before IN N
and CC N
after IN N
the DT N
training NN N
and CC N
three CD N
experts NNS N
evaluated VBD N
these DT N
performances NNS o
independently RB N
using VBG N
a DT N
7-point JJ N
rating NN N
scale NN N
. . N

The DT N
second JJ N
study NN N
was VBD N
designed VBN N
to TO N
assess VB N
the DT N
impact NN N
of IN N
error NN i
training NN i
on IN N
skill JJ N
evaluation NN N
and CC N
was VBD N
done VBN N
using VBG N
both DT N
novice NN N
and CC N
expert JJ N
raters NNS N
. . N

The DT N
same JJ N
group NN N
of IN N
30 CD p
senior JJ p
medical JJ p
students NNS p
used VBN p
in IN p
the DT p
first JJ p
study NN p
was VBD p
used VBN p
as IN p
novice JJ p
raters NNS p
. . p

Following VBG N
training NN N
in IN N
one CD N
of IN N
the DT N
four CD N
training NN N
groups NNS N
, , N
each DT N
subject NN N
rated VBD N
the DT N
24 CD N
performances NNS N
on IN N
the DT N
testing NN i
videotape NN i
and CC i
interrater NN i
reliability NN i
was VBD N
assessed VBN N
for IN N
each DT N
group NN N
. . N

Surgical NNP N
faculty NN N
served VBD N
as IN N
expert JJ N
raters NNS N
in IN N
this DT N
study NN N
and CC N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
error NN i
training NN i
or CC N
no DT i
training NN i
. . i

Each DT N
subject NN N
viewed VBD N
the DT N
testing NN N
videotape NN N
, , N
rating NN N
the DT N
performances NNS N
and CC N
giving VBG N
feedback JJ N
commentary NN N
. . N

Interrater NNP o
reliability NN o
was VBD N
calculated VBN N
for IN N
the DT N
two CD N
groups NNS N
and CC N
the DT N
precision NN N
of IN N
the DT N
feedback NN N
was VBD N
assessed VBN N
. . N

RESULTS NNP N
Significant JJ N
improvement NN N
in IN N
posttest JJ o
performance NN o
scores NNS o
was VBD N
seen VBN N
only RB N
in IN N
the DT N
error+correct JJ i
training NN N
group NN N
. . N

Interrater NNP o
reliability NN o
was VBD N
somewhat RB N
lower JJR N
for IN N
the DT N
correct NN i
only RB i
and CC N
error VBZ i
only RB i
training VBG N
groups NNS N
in IN N
both DT N
the DT N
student NN N
and CC N
faculty NN N
studies NNS N
. . N

Faculty NN N
raters NNS N
receiving VBG N
error NN N
training NN N
had VBD N
a DT N
higher JJR N
proportion NN N
of IN N
specific JJ N
comments NNS N
than IN N
the DT N
group NN N
that WDT N
received VBD N
no DT N
training NN N
although IN N
this DT N
difference NN N
was VBD N
not RB N
statistically RB N
significant JJ N
. . N

CONCLUSIONS NNP N
Instruction NN N
about IN N
common JJ i
errors NNS i
, , N
when WRB N
combined VBN N
with IN N
instruction NN N
about IN N
the DT N
correct JJ N
performance NN N
enhanced VBD N
the DT N
acquisition NN N
of IN N
this DT N
surgical JJ N
skill NN N
. . N

This DT N
suggests VBZ N
a DT N
role NN N
for IN N
the DT N
use NN N
of IN N
errors NNS N
in IN N
surgical JJ i
technical JJ i
skill NN i
instruction NN i
. . i

Our PRP$ N
study NN N
provides VBZ N
no DT N
support NN N
for IN N
a DT N
role NN N
for IN N
error NN i
training NN i
in IN N
improving VBG N
skill JJ N
evaluation NN N
. . N

-DOCSTART- -20087785- O O

Influence NN N
of IN N
sentinel NN N
lymph NN N
node JJ N
tumor NN N
burden NN N
on IN N
survival NN N
in IN N
melanoma NN p
. . p

BACKGROUND NNP N
Completion NNP i
lymph NN i
node NN i
dissection NN i
( ( i
CLND NNP i
) ) i
is VBZ N
the DT N
standard JJ N
procedure NN N
for IN N
patients NNS p
with IN p
positive JJ p
sentinel NNS p
lymph NN p
nodes NNS p
( ( p
SLN NNP p
) ) p
. . p

With IN N
extensive JJ N
pathological JJ N
workup NN N
, , N
increased VBD N
numbers NNS N
of IN N
small JJ N
metastatic JJ N
deposits NNS N
are VBP N
detected VBN N
in IN N
SLN NNP N
. . N

This DT N
study NN N
evaluated VBD N
the DT N
prognostic JJ N
significance NN N
of IN N
SLN NNP N
metastatic JJ N
deposits NNS N
< VBP N
or CC N
= VBP N
0.2 CD N
mm NNS N
in IN N
patients NNS p
treated VBN p
in IN p
a DT p
referral JJ p
cancer NN p
center NN p
in IN p
Brazil NNP p
. . p

METHODS NNP N
Patients NNPS p
with IN p
stage NN p
I/II NNP p
melanoma NN p
, , p
consecutively RB p
submitted VBN p
to TO p
a DT p
SLN NNP i
procedure NN i
by IN p
the DT p
same JJ p
surgeon NN p
from IN p
2000 CD p
to TO p
2006 CD p
, , p
were VBD p
evaluated VBN p
. . p

All DT N
positive JJ N
SLN NNP N
and CC N
randomly RB N
selected VBN N
negative JJ N
cases NNS N
were VBD N
reviewed VBN N
by IN N
two CD N
pathologists NNS N
. . N

Different NNP N
prognostic JJ N
factors NNS N
and CC N
SLN NNP N
tumor NN N
burden NN N
were VBD N
recorded VBN N
. . N

Additional JJ N
positive JJ N
non-SLN NN N
after IN N
CLND NNP N
, , N
and CC N
disease VB N
outcome NN N
were VBD N
evaluated VBN N
. . N

RESULTS NNP N
Of IN N
381 CD p
patients NNS p
who WP p
underwent VBP p
SLN NNP p
biopsy NN p
, , p
103 CD p
( ( p
27 CD p
% NN p
) ) p
were VBD p
positive JJ p
. . p

The DT N
mean/median JJ N
Breslow NNP N
tumor NN o
thickness NN o
in IN N
the DT N
overall JJ N
group NN N
was VBD N
3.4/2.0 CD N
mm NN N
and CC N
in IN N
the DT N
SLN NNP N
positive JJ N
patients NNS N
was VBD N
5.72/4.0 CD N
mm NN N
. . N

Among IN N
these DT N
patients NNS N
, , N
48 CD N
( ( N
47 CD N
% NN N
) ) N
had VBD N
metastatic JJ N
deposits NNS N
> VBP N
2 CD N
mm NN N
( ( N
macrometastasis NN N
) ) N
, , N
49 CD N
( ( N
47 CD N
% NN N
) ) N
had VBD N
metastatic JJ N
deposits NNS N
< VBP N
or CC N
=2 VBP N
mm NNS N
but CC N
> $ N
0.2 CD N
mm NN N
( ( N
micrometastasis NN N
) ) N
, , N
and CC N
6 CD N
( ( N
6 CD N
% NN N
) ) N
had VBD N
metastatic JJ N
deposits NNS N
< VBP N
or CC N
=0.2 VBP N
mm NNS N
( ( N
submicrometastasis NN N
) ) N
. . N

Additional JJ N
positive JJ N
non-SLN NNS N
were VBD N
detected VBN N
in IN N
29 CD N
% NN N
of IN N
patients NNS N
with IN N
macrometastasis NN N
, , N
in IN N
25 CD N
% NN N
of IN N
patients NNS N
with IN N
micrometastasis NN N
, , N
and CC N
in IN N
0 CD N
% NN N
of IN N
patients NNS N
with IN N
submicrometastases NNS N
. . N

At IN N
median JJ N
follow-up NN N
of IN N
35 CD N
months NNS N
, , N
the DT N
estimated VBN N
3-year JJ N
overall JJ N
survival NN N
was VBD N
92 CD N
% NN N
for IN N
negative JJ N
SLN NNP N
, , N
64 CD N
% NN N
for IN N
micrometastases NNS N
, , N
53 CD N
% NN N
for IN N
macrometastases NNS N
, , N
and CC N
100 CD N
% NN N
for IN N
submicrometastases NNS N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSION NN N
In IN N
the DT N
present JJ N
study NN N
, , N
patients NNS N
with IN N
SLN NNP N
metastatic JJ N
deposits NNS N
< VBP N
or CC N
=0.2 VBP N
mm NNS N
had VBD N
no DT N
additional JJ N
positive JJ N
non-SLNs NN N
, , N
and CC N
no DT N
recurrences NNS N
or CC N
deaths NNS N
were VBD N
recorded VBN N
, , N
suggesting VBG N
that IN N
their PRP$ N
prognosis NN N
is VBZ N
equivalent JJ N
to TO N
that DT N
of IN N
patients NNS N
with IN N
negative JJ N
SLN NNP N
. . N

-DOCSTART- -12882611- O O

Phonophoresis NNP i
versus NN N
topical JJ N
application NN N
of IN N
ketoprofen NN i
: : i
comparison NN N
between IN N
tissue NN N
and CC N
plasma NN N
levels NNS N
. . N

BACKGROUND NNP N
AND CC N
PURPOSE NNP N
Over IN N
the DT N
last JJ N
few JJ N
decades NNS N
, , N
application NN N
of IN N
ultrasound NN N
has VBZ N
been VBN N
attempted VBN N
to TO N
enhance VB N
transdermal JJ N
transport NN N
of IN N
several JJ N
drugs NNS N
, , N
a DT N
method NN N
referred VBD N
to TO N
as IN N
phonophoresis NN N
. . N

The DT N
purposes NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
examine VB N
the DT N
influence NN N
of IN N
ultrasound NN N
on IN N
the DT N
transdermal JJ N
delivery NN N
of IN N
ketoprofen NN N
in IN N
humans NNS N
and CC N
to TO N
compare VB N
the DT N
concentrations NNS N
found VBD N
after IN N
continuous JJ N
and CC N
pulsed JJ N
application NN N
. . N

SUBJECTS NNP N
AND NNP N
METHODS NNP N
Twenty-six NNP p
patients NNS p
with IN p
knee NN p
disorders NNS p
requiring VBG p
arthroscopy NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
3 CD N
groups NNS N
. . N

Just NNP N
before IN N
surgery NN N
, , N
phonophoresis NN i
of IN i
a DT i
ketoprofen NN i
gel NN i
( ( N
Fastum NNP N
gel NN N
) ) N
was VBD N
given VBN N
to TO N
group NN N
A NNP N
using VBG N
continuous JJ i
ultrasound NN i
( ( N
1 CD N
MHz NNP N
, , N
1.5 CD N
W/cm2 NNP N
, , N
for IN N
5 CD N
minutes NNS N
) ) N
. . N

Group NNP N
B NNP N
received VBD N
the DT N
same JJ N
treatment NN N
but CC N
with IN N
pulsed JJ i
ultrasound NN i
( ( N
100 CD N
Hz NNP N
, , N
20 CD N
% NN N
duty NN N
cycle NN N
) ) N
. . N

Group NNP N
C NNP N
received VBD N
5 CD N
minutes NNS N
of IN N
sham NN i
ultrasound NN i
with IN i
the DT i
ketoprofen NN i
gel NN i
. . i

The DT N
ultrasound JJ N
head NN N
was VBD N
moved VBN N
over IN N
a DT N
10-cm2 JJ N
area NN N
using VBG N
small JJ N
, , N
continuous JJ N
, , N
circular JJ N
movements NNS N
. . N

Biopsies NNS N
of IN N
adipose JJ N
tissue NN N
and CC N
synovial JJ N
tissue NN N
were VBD N
taken VBN N
during IN N
surgery NN N
to TO N
evaluate VB o
the DT o
local JJ o
penetration NN o
of IN o
the DT o
drug NN o
. . o

Blood NN N
samples NNS N
also RB N
were VBD N
collected VBN N
to TO N
determine VB o
whether IN o
ketoprofen NN o
entered VBD o
the DT o
systemic JJ o
circulation NN o
. . o

RESULTS VB N
The DT N
concentration NN o
of IN o
ketoprofen NN o
in IN N
plasma NN N
was VBD N
negligible JJ N
in IN N
all DT N
3 CD N
groups NNS N
. . N

The DT N
concentration NN o
of IN o
ketoprofen NN o
in IN N
synovial JJ N
tissue NN N
differed VBD N
from IN N
that IN N
in IN N
fat JJ N
tissue NN N
. . N

A DT N
difference NN N
in IN N
concentration NN o
of IN o
ketoprofen NN o
in IN N
synovial JJ N
tissue NN N
was VBD N
found VBN N
between IN N
group NN N
C NNP N
and CC N
groups NNS N
A NNP N
and CC N
B NNP N
. . N

The DT N
concentration NN o
of IN o
ketoprofen NN o
in IN o
fat JJ o
tissue NN o
and CC o
synovial JJ o
tissue NN o
was VBD N
consistently RB N
higher JJR N
in IN N
group NN N
B NNP N
than IN N
in IN N
group NN N
A NNP N
. . N

DISCUSSION NNP N
AND CC N
CONCLUSION NNP N
This DT N
study NN N
confirms VBZ N
that IN N
phonophoresis NN N
of IN N
ketoprofen NN N
allows VBZ N
the DT N
attainment NN N
of IN N
higher JJR N
local JJ N
concentrations NNS N
, , N
whereas JJ N
systemic JJ N
exposure NN N
is VBZ N
lower JJR N
. . N

The DT N
results NNS N
indicate VBP N
that IN N
, , N
in IN N
contrast NN N
to TO N
sham VB N
phonopheresis NN N
, , N
ultrasound NN N
can MD N
increase VB N
the DT N
transdermal JJ N
delivery NN N
of IN N
ketoprofen NN N
. . N

-DOCSTART- -11779598- O O

Metformin NNP i
therapy NN i
improves VBZ N
ovulatory JJ o
rates NNS o
, , o
cervical JJ o
scores NNS o
, , o
and CC o
pregnancy NN o
rates NNS o
in IN N
clomiphene JJ p
citrate-resistant JJ p
women NNS p
with IN p
polycystic JJ p
ovary JJ p
syndrome NN p
. . p

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
metformin NN i
therapy NN i
on IN N
hyperandrogenism NN N
, , N
insulin NN N
resistance NN N
, , N
cervical JJ N
scores NNS N
, , N
ovulation NN N
, , N
and CC N
pregnancy NN N
rates NNS N
in IN N
clomiphene JJ p
citrate-resistant JJ p
women NNS p
with IN p
polycystic JJ p
ovary JJ p
syndrome NN p
( ( p
PCOS NNP p
) ) p
. . p

DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
study NN N
. . N

SETTING NNP N
Infertility NNP p
clinic NN p
of IN p
a DT p
tertiary JJ p
referral NN p
center NN p
. . p

PATIENT NNP N
( ( N
S NNP N
) ) N
Fifty-six NNP p
women NNS p
with IN p
clomiphene JJ p
citrate-resistant JJ p
PCOS NNP p
. . p

INTERVENTION NNP N
( ( N
S NNP N
) ) N
Two CD N
cycles NNS N
of IN N
oral JJ i
metformin NN i
therapy NN i
( ( N
850 CD N
mg NN N
, , N
twice RB N
daily RB N
) ) N
in IN N
group NN N
I PRP N
and CC N
placebo VB i
therapy NN i
( ( N
twice JJ N
daily RB N
) ) N
in IN N
group NN N
II NNP N
. . N

Clomiphene NNP i
citrate NN i
( ( N
100 CD N
mg/day NN N
) ) N
on IN N
cycle NN N
days NNS N
3-7 CD N
of IN N
the DT N
second JJ N
cycle NN N
in IN N
both DT N
groups NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
( ( N
S NNP N
) ) N
Insulin NNP o
, , o
T NNP o
, , o
DHEAS NNP o
, , o
FSH NNP o
, , o
LH NNP o
, , o
body NN o
mass NN o
index NN o
( ( o
BMI NNP o
) ) o
, , o
waist-to-hip JJ o
ratio NN o
, , o
endometrial JJ o
thickness NN o
, , o
cervical JJ o
score NN o
, , o
ovulation NN o
, , o
and CC o
pregnancy NN o
rates NNS o
in IN N
clomiphene-induced JJ N
cycles NNS N
after IN N
metformin JJ i
therapy NN N
. . N

RESULT NNP N
( ( N
S NNP N
) ) N
Metformin NNP i
therapy NN N
resulted VBD N
in IN N
a DT N
significant JJ N
decrease NN N
in IN N
total JJ o
T NNP o
, , o
LH NNP o
level NN o
, , o
LH/FSH NNP o
ratio NN o
, , o
insulin NN o
resistance NN o
, , o
and CC o
mean JJ o
BMI NNP o
. . o

No DT N
difference NN N
in IN N
waist-to-hip JJ o
ratio NN o
, , o
DHEAS NNP o
level NN o
, , o
and CC o
fasting VBG o
insulin JJ o
level NN o
was VBD N
observed VBN N
. . N

Clomiphene NNP N
citrate JJ N
induction NN N
resulted VBD N
in IN N
higher JJR N
ovulation NN o
rates NNS o
and CC o
thicker NN o
endometrium NN o
in IN N
the DT N
metformin NN i
group NN N
than IN N
in IN N
the DT N
placebo NN i
group NN N
. . N

There EX N
was VBD N
higher JJR N
cumulative JJ o
pregnancy NN o
rate NN o
in IN N
the DT N
metformin NN N
group NN N
; : N
however RB N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
pregnancy NN o
rate NN o
between IN N
the DT N
two CD N
groups NNS N
. . N

CONCLUSION NNP N
( ( N
S NNP N
) ) N
Metformin NNP i
therapy NN N
not RB N
only RB N
decreases VBZ N
hyperandrogenism NN o
and CC o
insulin NN o
resistance NN o
but CC N
also RB N
improves VBZ N
ovulation NN o
rates NNS o
, , o
cervical JJ o
scores NNS o
, , o
and CC o
pregnancy NN o
rates NNS o
in IN N
clomiphene JJ p
citrate-resistant JJ p
women NNS p
with IN p
PCOS NNP p
. . p

-DOCSTART- -19786879- O O

The DT N
experience NN N
of IN N
pleasure NN N
before IN N
and CC N
after IN N
hearing VBG i
rehabilitation NN i
. . i

Hearing NNP p
loss NN p
may MD N
lead VB N
to TO N
major JJ N
changes NNS N
in IN N
the DT N
social JJ N
and CC N
emotional JJ N
aspects NNS N
of IN N
daily JJ N
life NN N
. . N

This DT N
follow-up JJ N
study NN N
investigated VBD N
the DT N
effect NN N
of IN N
hearing-aid NN i
use NN N
on IN N
emotional JJ N
experience NN N
in IN N
adults NNS p
with IN p
hearing VBG p
impairment NN p
. . p

Thirteen JJ p
individuals NNS p
with IN p
impaired JJ p
hearing NN p
were VBD p
tested VBN p
before IN p
and CC p
after IN p
6 CD p
months NNS p
of IN p
hearing-aid JJ i
use NN i
, , N
and CC N
were VBD N
compared VBN N
with IN N
19 CD p
individuals NNS p
who WP p
had VBD p
worn VBN p
hearing NN p
aids NNS p
for IN p
many JJ p
years NNS p
. . p

The DT N
participants NNS N
reported VBD N
their PRP$ N
daily JJ o
emotional JJ o
experiences NNS o
, , N
by IN N
completing VBG N
questionnaires NNS o
relating VBG o
to TO o
sensory JJ o
and CC o
social JJ o
pleasure NN o
. . o

After IN N
6 CD N
months NNS N
of IN N
hearing-aid JJ i
use NN N
, , N
individuals NNS N
experienced VBD N
more JJR N
physical JJ o
and CC o
social JJ o
pleasure NN o
, , N
whereas JJ N
individuals NNS N
using VBG N
hearing NN N
aids NNS N
for IN N
long JJ N
periods NNS N
of IN N
time NN N
reported VBD N
similar JJ N
levels NNS N
of IN N
pleasure NN N
at IN N
the DT N
beginning NN N
and CC N
at IN N
the DT N
end NN N
of IN N
a DT N
6-month JJ N
interval NN N
. . N

The DT N
participants NNS N
also RB N
performed VBD N
a DT N
visual JJ N
task NN N
, , N
in IN N
which WDT N
they PRP N
rated VBD N
the DT N
intensity NN o
of IN o
pleasure NN o
they PRP o
experienced VBD o
in IN o
response NN o
to TO o
emotionally RB o
positive JJ o
and CC o
neutral JJ o
pictures NNS o
differing VBG o
in IN o
luminance NN o
contrast NN o
. . o

In IN N
this DT N
task NN N
, , N
pleasure NN N
typically RB N
decreases VBZ N
with IN N
decreasing VBG N
contrast NN N
of IN N
the DT N
positive JJ N
images NNS N
displayed VBN N
. . N

Once IN N
they PRP N
had VBD N
been VBN N
fitted VBN N
with IN N
hearing NN N
aids NNS N
, , N
the DT N
participants NNS N
reported VBD N
lower JJR N
levels NNS o
of IN o
pleasure NN o
, , N
especially RB N
at IN N
low JJ N
contrast NN N
. . N

These DT N
findings NNS N
highlight VBD N
that IN N
the DT N
anhedonia NN o
scales VBZ o
provide VBP N
a DT N
measure NN N
sensitive JJ N
to TO N
emotional JJ N
improvements NNS N
that WDT N
accompany VBP N
the DT N
partial JJ N
restoration NN N
of IN N
hearing VBG N
function NN N
, , N
although IN N
these DT N
scales NNS N
were VBD N
not RB N
specifically RB N
designed VBN N
for IN N
hearing-impaired JJ N
populations NNS N
. . N

In IN N
contrast NN N
, , N
the DT N
surprising JJ N
decrease NN N
in IN N
pleasure NN N
ratings NNS N
for IN N
pictures NNS N
after IN N
the DT N
introduction NN N
of IN N
hearing-aid JJ i
use NN N
may MD N
be VB N
because IN N
of IN N
the DT N
compensation NN N
of IN N
hearing VBG N
loss NN N
by IN N
changes NNS N
in IN N
visual JJ N
attention NN N
functions NNS N
. . N

-DOCSTART- -8383874- O O

Sodium-potassium JJ i
pump NN i
activity NN i
in IN N
white JJ N
blood NN N
cells NNS N
from IN N
children NNS p
with IN p
an DT p
increased VBN p
risk NN p
of IN p
developing VBG p
hypertension NN p
-- : p
The DT p
Odense NNP N
Schoolchild NNP N
Study NNP N
. . N

We PRP N
have VBP N
measured VBN N
the DT N
capacity NN N
of IN N
the DT N
sodium-potassium JJ i
pump NN i
, , N
as IN N
assessed VBN N
by IN N
86rubidium CD N
uptake NN N
and CC N
the DT N
number NN N
of IN N
[ $ N
3H CD N
] NNP N
-ouabain NN N
binding VBG N
sites NNS N
on IN N
white JJ N
blood NN N
cells NNS N
, , N
in IN N
children NNS p
aged VBN p
9-11 CD p
years NNS p
, , p
partly RB p
cross-sectionally RB p
and CC p
partly RB p
longitudinally RB p
after IN p
a DT p
physical JJ i
training NN i
programme NN i
. . i

Children NNP p
from IN p
a DT p
hypertensive JJ p
subgroup NN p
comprising VBG p
the DT p
upper JJ p
5 CD p
% NN p
of IN p
the DT p
blood NN p
pressure NN p
distribution NN p
and CC p
children NNS p
from IN p
a DT p
randomly RB p
selected VBN p
normotensive JJ p
subgroup NN p
were VBD p
eligible JJ p
for IN p
the DT p
study NN p
. . p

In IN p
the DT p
cross-sectional JJ p
study NN p
40 CD p
children NNS p
from IN p
the DT p
hypertensive JJ p
subgroup NN p
and CC p
40 CD p
children NNS p
from IN p
the DT p
normotensive JJ p
subgroup NN p
were VBD p
evaluated VBN p
. . p

A DT N
significant JJ N
increase NN N
in IN N
86rubidium CD o
uptake NN o
was VBD N
present JJ N
in IN N
boys NN N
as IN N
compared VBN N
to TO N
girls NNS N
. . N

After IN N
adjustment NN N
for IN N
differences NNS N
in IN N
sexual JJ N
maturation NN N
the DT N
observed JJ N
significant JJ N
difference NN N
disappeared VBD N
. . N

Important NNP N
correlates NNS N
of IN N
pump NN i
activity NN i
were VBD N
height VBN N
, , N
plasma FW N
glucose NN N
, , N
and CC N
physical JJ N
fitness NN N
. . N

In IN N
the DT N
training NN N
study NN N
10 CD p
boys NNS p
from IN p
the DT p
hypertensive JJ p
subgroup NN p
and CC p
10 CD p
boys NNS p
from IN p
the DT p
normotensive JJ p
subgroup NN p
were VBD N
also RB N
evaluated VBN N
after IN N
eight CD N
months NNS N
of IN N
physical JJ N
training NN N
. . N

A DT N
significant JJ N
fall NN N
in IN N
86rubidium CD o
uptake NN o
was VBD N
observed VBN N
. . N

No DT N
control NN N
group NN N
was VBD N
examined VBN N
and CC N
probably RB N
the DT N
changes NNS N
reflect VBP N
some DT N
effects NNS N
of IN N
sexual JJ o
maturation NN o
on IN o
cation NN o
handling NN o
of IN o
cells NNS o
. . o

These DT N
results NNS N
indicate VBP N
a DT N
significant JJ N
effect NN N
of IN N
sexual JJ o
maturation NN o
in IN o
capacity NN o
of IN o
sodium-potassium JJ o
pump NN o
in IN N
children NNS p
. . p

-DOCSTART- -12239480- O O

Clinical JJ N
evaluation NN N
of IN N
two CD N
adhesive JJ N
composite JJ i
cements NNS i
for IN N
the DT N
suppression NN o
of IN o
dentinal JJ o
cold JJ o
sensitivity NN o
. . o

STATEMENT NNP N
OF IN N
PROBLEMS NNP N
Postoperative NNP p
cold VBD p
sensitivity NN p
after IN p
the DT p
cementation NN p
of IN p
indirect JJ p
restorations NNS p
with IN p
composite JJ p
cements NNS p
has VBZ N
been VBN N
reported VBN N
frequently RB N
but CC N
not RB N
scientifically RB N
documented VBN N
. . N

PURPOSE VB N
This DT N
controlled JJ N
clinical JJ N
study NN N
was VBD N
designed VBN N
to TO N
simulate VB N
the DT N
dentin/composite JJ N
cement NN N
interface NN N
immediately RB N
after IN N
cementation NN N
of IN N
a DT N
cast NN N
restoration NN N
. . N

The DT N
desensitizing VBG N
capabilities NNS N
of IN N
a DT N
composite JJ N
cement NN N
that WDT N
contains VBZ N
a DT N
self-etching JJ N
, , N
dual-polymerizing JJ N
resin NN N
adhesive JJ N
system NN N
were VBD N
compared VBN N
with IN N
those DT N
of IN N
a DT N
composite JJ N
cement NN N
that WDT N
use VBP N
phosphoric JJ i
acid NN i
etching VBG N
followed VBN N
by IN N
a DT N
single-bottle JJ N
, , N
light-activated JJ N
primer/resin-based JJ N
adhesive NN N
. . N

MATERIAL NNP N
AND CC N
METHODS NNP N
The DT p
hypersensitive JJ p
root NN p
surfaces NNS p
of IN p
selected VBN p
teeth NNS p
were VBD N
randomized VBN N
to TO N
receive VB N
1 CD N
of IN N
3 CD N
treatments NNS N
: : N
coating NN i
with IN i
a DT i
self-etching JJ i
adhesive NN i
( ( i
Linkmax NNP i
) ) i
and CC i
its PRP$ i
respective JJ i
cement NN i
, , i
coating VBG i
with IN i
a DT i
conventionally RB i
etched VBN i
adhesive NN i
( ( i
RelyX NNP i
ARC NNP i
) ) i
and CC i
its PRP$ i
cement NN i
, , i
or CC i
no DT i
treatment NN i
( ( N
negative JJ N
control NN N
) ) N
. . N

The DT N
sample JJ p
size NN p
was VBD p
22 CD p
. . p

Dentin NNP o
sensitivity NN o
was VBD N
ascertained VBN N
with IN N
an DT N
accurate NN N
cold NN N
testing VBG N
device NN N
that IN N
slowly RB N
decreased VBN N
in IN N
temperature NN N
. . N

Tooth DT o
sensitivity NN o
was VBD N
measured VBN N
both DT N
immediately RB N
and CC N
at IN N
7 CD N
days NNS N
after IN N
placement NN N
. . N

Two-way JJ N
analysis NN N
of IN N
variance NN N
and CC N
Fisher NNP N
's POS N
least JJS N
significant JJ N
difference NN N
test NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
were VBD N
used VBN N
to TO N
determine VB N
whether IN N
significant JJ N
differences NNS N
existed VBD N
as IN N
a DT N
function NN N
of IN N
treatment NN N
type NN N
or CC N
time NN N
. . N

RESULTS NNP N
Immediately RB N
after IN N
placement NN N
, , N
the DT N
self-etching JJ i
adhesive NN i
and CC i
its PRP$ i
respective JJ i
cement NN i
resulted VBD N
in IN N
more RBR N
suppression NN o
of IN o
cold JJ o
sensitivity NN o
than IN N
no DT N
treatment NN N
( ( N
control NN N
) ) N
; : N
with IN N
Linkmax NNP N
treatment NN N
, , N
the DT N
temperature NN N
at IN N
which WDT N
teeth EX N
responded VBD N
was VBD N
reduced VBN N
by IN N
8.4 CD N
degrees NNS N
C. NNP N
The DT N
conventionally RB N
etched VBN i
adhesive JJ i
and CC i
its PRP$ i
cement NN i
reduced VBD N
the DT N
temperature NN o
at IN o
which WDT o
teeth NN o
responded VBD o
by IN N
9.4 CD N
degrees NNS N
C. NNP N
After IN N
1 CD N
week NN N
, , N
these DT N
temperature NN o
reductions NNS o
were VBD N
7.0 CD N
degrees NNS N
C NNP N
and CC N
4.3 CD N
degrees NNS N
C NNP N
, , N
respectively RB N
. . N

Untreated VBN N
controls NNS N
at IN N
the DT N
2 CD N
intervals NNS N
showed VBD N
a DT N
mean JJ N
decrease NN o
in IN o
sensitivity NN o
to TO o
cold VB o
of IN N
3.6 CD N
degrees NNS N
C NNP N
and CC N
4.1 CD N
degrees NNS N
C. NNP N
Statistical NNP N
analysis NN N
showed VBD N
type NN N
of IN N
composite JJ N
cement NN N
to TO N
be VB N
a DT N
significant JJ N
factor NN N
. . N

CONCLUSION NNP N
Within IN N
the DT N
limitations NNS N
of IN N
this DT N
study NN N
and CC N
in IN N
comparison NN N
to TO N
untreated JJ N
control NN N
teeth NN N
, , N
Linkmax NNP i
treatment NN i
resulted VBD N
in IN N
a DT N
significant JJ N
reduction NN N
in IN N
tooth DT o
root NN o
sensitivity NN o
over IN N
1 CD N
week NN N
( ( N
P=.02 NNP N
) ) N
, , N
whereas JJ N
RelyX NNP N
ARC NNP N
did VBD N
not RB N
( ( N
P=.066 NNP N
) ) N
. . N

-DOCSTART- -23065117- O O

A DT N
pilot NN N
study NN N
on IN N
the DT N
efficacy NN N
of IN N
melodic NNS i
based VBN i
communication NN i
therapy NN i
for IN N
eliciting VBG o
speech NN o
in IN N
nonverbal JJ p
children NNS p
with IN p
autism NN p
. . p

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
melodic NNS i
based VBN i
communication NN i
therapy NN i
( ( i
MBCT NNP i
) ) i
to TO i
traditional JJ i
speech NN i
and CC i
language NN i
therapy NN i
for IN N
eliciting VBG o
speech NN o
in IN N
nonverbal JJ p
children NNS p
with IN p
autism NN p
. . p

Participants NNS p
were VBD p
12 CD p
nonverbal JJ p
children NNS p
with IN p
autism NN p
ages NNS p
5 CD p
through IN p
7 CD p
randomly RB p
assigned VBN p
to TO p
either DT p
treatment NN p
group NN p
. . p

Both DT N
groups NNS N
made VBD N
significant JJ N
progress NN o
after IN N
treatment NN N
. . N

The DT N
MBCT NNP N
group NN N
progressed VBD N
significantly RB N
in IN N
number NN o
of IN o
verbal JJ o
attempts NNS o
after IN N
weeks NNS N
1 CD N
through IN N
4 CD N
and CC N
number NN o
of IN o
correct JJ o
words NNS o
after IN N
weeks NNS N
1 CD N
and CC N
3 CD N
, , N
while IN N
the DT N
traditional JJ N
group NN N
progressed VBD N
significantly RB N
after IN N
weeks NNS N
4 CD N
and CC N
5 CD N
. . N

No DT N
significant JJ N
differences NNS N
in IN N
number NN o
of IN o
verbal JJ o
attempts NNS o
or CC o
number NN o
of IN o
correct JJ o
words NNS o
were VBD N
noted VBN N
between IN N
groups NNS N
following VBG N
treatment NN N
. . N

A DT N
significant JJ N
number NN o
of IN o
new JJ o
words NNS o
were VBD N
heard VBN N
in IN N
the DT N
home NN N
environment NN N
for IN N
the DT N
MBCT NNP i
group NN N
( ( N
p JJ N
= NNP N
.04 NNP N
) ) N
. . N

Participants NNS N
in IN N
the DT N
MBCT NNP i
group NN N
had VBD N
more RBR N
imitative JJ o
attempts NNS o
( ( N
p JJ N
= NNP N
.03 NNP N
) ) N
. . N

MBCT NNP i
appears VBZ N
to TO N
be VB N
a DT N
valid JJ N
form NN N
of IN N
intervention NN N
for IN N
children NNS p
with IN p
autism NN p
. . p

-DOCSTART- -21665462- O O

Single-agent JJ N
irinotecan JJ i
or CC i
FOLFIRI NNP i
as IN N
second-line JJ N
chemotherapy NN i
for IN N
advanced JJ o
colorectal JJ o
cancer NN o
; : o
results NNS N
of IN N
a DT N
randomised JJ N
phase NN N
II NNP N
study NN N
( ( N
DaVINCI NNP N
) ) N
and CC N
meta-analysis JJ N
[ NN N
corrected VBD N
] NNP N
. . N

BACKGROUND NNP N
Second-line JJ N
treatment NN N
with IN N
irinotecan JJ i
for IN N
advanced JJ N
or CC N
metastatic JJ N
colorectal JJ N
cancer NN N
prolongs NNS N
survival NN o
. . o

It PRP N
is VBZ N
uncertain JJ N
whether IN N
irinotecan JJ i
is VBZ N
better RBR N
administered VBN N
with IN N
5-fluorouracil JJ i
or CC N
alone RB N
in IN N
patients NNS p
previously RB p
treated VBN p
with IN p
a DT p
fluoropyrimidine NN i
. . i

We PRP N
compared VBN N
toxicity NN N
( ( N
particularly RB N
diarrhoea NN N
) ) N
, , N
quality NN N
of IN N
life NN N
, , N
and CC N
efficacy NN N
of IN N
combination NN N
chemotherapy NN i
and CC p
irinotecan JJ i
in IN p
these DT p
patients NNS p
. . p

METHODS NNP N
In IN N
DaVINCI NNP N
, , N
a DT N
randomised JJ N
phase NN N
II NNP N
trial NN N
, , N
patients NNS p
with IN p
advanced JJ p
colorectal JJ p
cancer NN p
were VBD N
randomly RB N
allocated VBN N
to TO N
: : N
Combination NN i
therapy NN i
( ( i
FOLFIRI NNP i
) ) i
, , i
irinotecan JJ i
( ( N
180 CD N
mg/m NN N
( ( N
2 CD N
) ) N
IV NNP N
over IN N
90 CD N
min NNS N
, , N
day NN N
1 CD N
) ) N
, , N
5-fluorouracil JJ i
( ( N
400mg/m CD N
( ( N
2 CD N
) ) N
IV NNP N
bolus NN N
and CC N
2400 CD N
mg/m NN N
( ( N
2 CD N
) ) N
by IN N
46-hour JJ N
infusion NN N
from IN N
day NN N
1 CD N
) ) N
and CC N
folinic JJ i
acid NN i
( ( N
20mg/m CD N
( ( N
2 CD N
) ) N
IV NNP N
bolus NN N
, , N
day NN N
1 CD N
) ) N
, , N
2-weekly JJ N
; : N
or CC N
Single-agent JJ N
, , N
irinotecan JJ i
( ( N
350 CD N
mg/m NN N
( ( N
2 CD N
) ) N
IV NNP N
over IN N
90 CD N
min NN N
) ) N
, , N
3-weekly JJ N
. . N

Toxicity NN o
was VBD N
evaluated VBN N
every DT N
treatment NN N
cycle NN N
; : N
QOL NNP N
and CC N
response NN N
6-weekly JJ N
. . N

Analysis NN N
was VBD N
by IN N
intention NN N
to TO N
treat VB N
. . N

The DT N
trial NN N
, , N
amended VBN N
from IN N
a DT N
larger JJR N
factorial JJ N
design NN N
, , N
was VBD N
terminated VBN N
early RB N
due JJ N
to TO N
slow VB N
recruitment NN N
. . N

Results NNS N
were VBD N
also RB N
combined VBN N
with IN N
other JJ N
second-line JJ N
irinotecan JJ i
trials NNS N
. . N

FINDINGS IN N
We PRP N
randomised VBD N
44 CD p
patients NNS p
to TO p
combination NN p
and CC p
45 CD p
to TO p
single JJ p
agent NN p
. . p

Eight CD p
patients NNS p
in IN p
the DT p
irinotecan JJ p
arm NN p
and CC p
4 CD p
in IN p
the DT p
combination NN p
arm NN p
had VBD p
grade VBN o
3/4 CD o
diarrhoea NN o
( ( p
P=0.24 NNP p
) ) p
. . N

Treatment JJ N
groups NNS N
did VBD N
not RB N
differ VB N
significantly RB N
in IN N
overall JJ o
QOL NNP o
changes NNS o
, , o
response NN o
rate NN o
or CC o
progression NN o
free JJ o
or CC o
overall-survival JJ o
. . o

In IN N
a DT N
systematic JJ N
review NN N
of IN N
29 CD N
trials NNS N
of IN N
second-line JJ N
irinotecan-based JJ i
treatment NN N
, , N
single-agent JJ N
irinotecan NN i
was VBD N
associated VBN N
with IN N
more JJR N
diarrhoea NN o
and CC o
alopecia NN o
than IN N
the DT N
combination NN N
but CC N
efficacy NN N
was VBD N
similar JJ N
. . N

INTERPRETATION NNP N
Combination NNP i
treatment NN i
compared VBN N
with IN N
single-agent JJ N
irinotecan JJ i
reduces NNS N
alopecia NN o
and CC o
diarrhoea NN o
without IN o
compromising VBG o
efficacy NN o
on IN o
clinical JJ o
outcomes NNS o
. . o

Both DT N
regimens NNS N
remain VBP N
as IN N
reasonable JJ N
treatment NN N
options NNS N
. . N

FUNDING NNP N
Research NNP N
grant NN N
( ( N
Pfizer NNP N
) ) N
. . N

-DOCSTART- -24761456- O O

Evidence-based JJ i
narratives NNS i
to TO N
improve VB N
recall NN o
of IN N
opioid JJ N
prescribing VBG N
guidelines NNS N
: : N
a DT N
randomized JJ N
experiment NN N
. . N

OBJECTIVES NNP N
Physicians NNPS N
adopt VBP N
evidence-based JJ N
guidelines NNS N
with IN N
variable JJ N
consistency NN N
. . N

Narratives NNS N
, , N
or CC N
stories NNS N
, , N
offer VBP N
a DT N
novel JJ N
dissemination NN N
strategy NN N
for IN N
clinical JJ N
recommendations NNS N
. . N

The DT N
study NN N
objective NN N
was VBD N
to TO N
compare VB N
whether IN N
evidence-based JJ i
narrative JJ i
versus NN N
traditional JJ i
summary JJ i
improved VBN N
recall NN N
of IN N
opioid JJ N
prescribing VBG N
guidelines NNS N
from IN N
the DT N
American NNP N
College NNP N
of IN N
Emergency NNP N
Physicians NNP N
( ( N
ACEP NNP N
) ) N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
prospective JJ N
, , N
randomized VBN N
controlled VBD N
experiment NN N
to TO N
compare VB N
whether IN N
narrative JJ i
versus NN N
summary JJ i
promoted VBD N
short-term JJ N
recall NN N
of IN N
six CD N
themes NNS N
contained VBN N
in IN N
the DT N
ACEP NNP N
opioid JJ N
guideline NN N
. . N

The DT N
experiment NN N
was VBD N
modeled VBN N
after IN N
the DT N
free-recall JJ N
test NN N
, , N
an DT N
established VBN N
technique NN N
in IN N
studies NNS N
of IN N
memory NN N
. . N

At IN N
a DT N
regional JJ N
conference NN N
, , N
emergency NN p
physicians NNS p
( ( p
EPs NNP p
) ) p
were VBD N
randomized VBN N
to TO N
read VB i
either CC i
a DT i
summary NN i
of IN i
the DT i
guideline NN i
( ( i
control NN i
) ) i
or CC i
a DT i
narrative JJ i
( ( i
intervention NN i
) ) i
. . i

The DT N
fictional JJ N
narrative NN N
was VBD N
constructed VBN N
to TO N
match VB N
the DT N
summary NN N
in IN N
content NN N
and CC N
length NN N
. . N

One CD N
hour NN N
after IN N
reading VBG N
the DT N
text NN N
, , N
participants NNS N
listed VBD N
all DT N
content NN N
that IN N
they PRP N
could MD N
recall VB N
. . N

Two CD N
reviewers NNS N
independently RB N
scored VBD N
the DT N
responses NNS N
to TO N
assess VB o
recall NN o
of IN N
the DT N
six CD N
themes NNS N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
the DT N
total JJ o
number NN o
of IN o
themes NNS o
recalled VBN o
per IN o
participant NN o
. . o

Secondary JJ N
outcomes NNS N
included VBD N
the DT N
proportion NN o
of IN o
responses NNS o
in IN N
each DT N
study NN N
arm NN N
that WDT N
recalled VBD o
individual JJ o
themes NNS o
and CC N
the DT N
proportion NN o
of IN o
responses NNS o
in IN N
each DT N
arm NN N
that WDT N
contained VBD N
falsely RB o
recalled VBN o
or CC o
extraneous JJ o
information NN o
. . o

RESULTS NNP N
Ninety-five JJ p
physicians NNS p
were VBD p
randomized VBN p
. . p

Eighty-two JJ p
physicians NNS p
completed VBD p
the DT p
experiment NN p
, , p
for IN p
a DT p
response NN p
rate NN p
of IN p
86 CD p
% NN p
. . p

The DT N
mean NN o
of IN o
the DT o
total JJ o
number NN o
of IN o
themes NNS o
recalled VBN o
per IN N
participant NN N
was VBD N
3.1 CD N
in IN N
the DT N
narrative JJ N
arm NN N
versus NN N
2.0 CD N
in IN N
the DT N
summary JJ N
arm NN N
( ( N
difference NN N
= RB N
1.1 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
= VBD N
0.6 CD N
to TO N
1.7 CD N
) ) N
. . N

For IN N
three CD N
themes NNS N
, , N
the DT N
proportion NN o
of IN o
responses NNS o
that WDT N
recalled VBD N
the DT N
theme NN N
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
narrative JJ N
arm NN N
compared VBN N
to TO N
the DT N
summary JJ N
arm NN N
, , N
with IN N
the DT N
differences NNS N
ranging VBG N
from IN N
20 CD N
% NN N
to TO N
51 CD N
% NN N
. . N

For IN N
one CD N
theme NN N
, , N
recall NN o
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
summary JJ N
arm NN N
. . N

For IN N
two CD N
themes NNS N
, , N
there EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
in IN N
recall NN o
between IN N
the DT N
arms NNS N
. . N

In IN N
the DT N
summary JJ N
arm NN N
, , N
54 CD N
% NN N
of IN N
responses NNS N
were VBD N
found VBN N
to TO N
contain VB N
falsely RB o
recalled VBN o
or CC o
extraneous JJ o
information NN o
versus IN N
21 CD N
% NN N
of IN N
responses NNS N
in IN N
the DT N
narrative JJ N
arm NN N
( ( N
difference NN N
= RB N
33 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
= NNP N
14 CD N
% NN N
to TO N
53 CD N
% NN N
) ) N
. . N

CONCLUSIONS NNP N
Physicians NNPS p
exposed VBD N
to TO N
a DT N
narrative JJ N
about IN N
opioid JJ i
guidelines NNS i
were VBD N
more RBR N
likely JJ N
to TO N
recall VB N
guideline JJ N
content NN N
at IN N
1 CD N
hour NN N
than IN N
those DT N
exposed VBN N
to TO N
a DT N
summary NN N
of IN N
the DT N
guidelines NNS N
. . N

Future JJ N
studies NNS N
should MD N
examine VB N
whether IN N
the DT N
incorporation NN N
of IN N
narratives NNS N
in IN N
dissemination NN N
campaigns NNS N
improves VBZ N
guideline JJ N
adoption NN N
and CC N
changes NNS N
clinical JJ N
practice NN N
-DOCSTART- -555487- O O

Generalizability NNP o
and CC o
durability NN o
of IN o
treatment NN o
effects NNS o
in IN N
an DT N
intervention NN i
program NN i
for IN N
coronary-prone NN p
( ( p
Type NNP p
A NNP p
) ) p
managers NNS p
. . p

To TO N
test VB N
the DT N
reliability NN o
and CC o
durability NN o
of IN o
positive JJ o
treatment NN o
effects NNS o
obtained VBN N
in IN N
a DT N
type NN i
A DT i
intervention NN i
project NN i
for IN p
healthy JJ p
managers NNS p
, , N
the DT N
analysis NN N
was VBD N
extended VBN N
to TO N
data NNS N
available JJ N
from IN N
a DT N
third JJ N
treatment NN N
group NN N
( ( i
a DT i
special JJ i
behavior JJ i
therapy NN i
group NN i
for IN N
participants NNS N
eliminated VBN N
from IN N
the DT N
main JJ N
sample NN N
because IN N
of IN N
manifestations NNS p
of IN p
clinical JJ p
CHD NNP p
) ) p
and CC N
to TO N
measures NNS N
obtained VBN N
6 CD N
months NNS N
following VBG N
the DT N
end NN N
of IN N
treatment NN N
. . N

Immediately RB N
after IN N
treatment NN N
all DT p
three CD p
groups NNS p
showed VBD N
a DT N
similar JJ N
pattern NN N
of IN N
improvement NN N
, , N
although IN N
the DT N
two CD N
behavior JJ i
therapy NN i
groups NNS N
did VBD N
show VB N
a DT N
greater JJR N
decrease NN N
in IN N
serum NN o
cholesterol NN o
levels NNS o
. . o

Six NNP N
months NNS N
after IN N
treatment NN N
the DT N
sample NN N
as IN N
a DT N
whole NN N
showed VBD N
good JJ o
maintenance NN o
of IN o
treatment NN o
effects NNS o
, , N
but CC N
the DT N
differences NNS N
between IN N
groups NNS N
had VBD N
become VBN N
somewhat RB N
sharper JJ N
, , N
with IN N
the DT N
special JJ i
behavior JJ i
therapy NN i
group NN N
faring VBG N
best JJS N
, , N
the DT N
regular JJ i
behavior NN i
therapy NN i
group NN N
intermediate NN N
, , N
and CC N
the DT N
psychotherapy NN i
group NN N
worst WDT N
. . N

The DT N
logical JJ N
consistency NN N
of IN N
these DT N
findings NNS N
increases VBZ N
our PRP$ N
confidence NN N
in IN N
the DT N
initial JJ N
treatment NN N
results NNS N
, , N
as RB N
well RB N
as IN N
permitting VBG N
cautious JJ N
optimism NN N
concerning VBG N
the DT N
possibility NN N
of IN N
developing VBG N
effective JJ N
intervention NN N
programs NNS N
for IN N
coronary-type NN N
( ( N
type VB N
A DT N
) ) N
behavior NN N
. . N

-DOCSTART- -8454478- O O

A DT N
randomized JJ N
trial NN N
of IN N
radiation NN i
therapy NN i
compared VBN N
to TO N
split VB i
course NN i
radiation NN i
therapy NN i
combined VBN i
with IN i
mitomycin JJ i
C NNP i
and CC i
5 CD i
fluorouracil NN i
as IN N
initial JJ N
treatment NN N
for IN N
advanced JJ p
laryngeal NN p
and CC p
hypopharyngeal NN p
squamous JJ p
carcinoma NN p
. . p

Two CD p
hundred VBD p
and CC p
twelve JJ p
patients NNS p
with IN p
previously RB p
untreated VBN p
advanced JJ p
squamous JJ p
carcinoma NN p
of IN p
the DT p
larynx NN p
or CC p
hypopharynx NN p
were VBD N
randomized VBN N
to TO N
receive VB N
initial JJ N
treatment NN N
with IN N
radiotherapy NN i
, , i
50 CD i
Gy NNP i
in IN i
20 CD i
fractions NNS i
in IN i
28 CD i
days NNS i
or CC N
split JJ i
course NN i
radiotherapy NN i
and CC i
concurrent NN i
chemotherapy NN i
, , i
25 CD i
Gy NNP i
in IN i
10 CD i
fractions NNS i
in IN i
14 CD i
days NNS i
followed VBN i
by IN i
a DT i
4 CD i
week NN i
rest NN i
and CC i
a DT i
further JJ i
25 CD i
Gy NNP i
in IN i
10 CD i
fractions NNS i
in IN i
14 CD i
days NNS i
starting VBG i
on IN i
day NN i
43 CD i
; : i
Mitomycin NNP i
C NNP i
was VBD i
given VBN i
on IN i
day NN i
1 CD i
and CC i
day NN i
43 CD i
and CC i
5FU CD i
continuous JJ i
infusions NNS i
on IN i
days NNS i
1 CD i
-- : i
4 CD i
and CC i
days NNS i
43 CD i
-- : i
46 CD i
. . i

Surgery NN N
was VBD N
reserved VBN N
for IN N
persistent NN N
or CC N
recurrent JJ N
disease NN N
. . N

Two CD p
hundred VBD p
and CC p
nine CD p
of IN p
the DT p
212 CD p
patients NNS p
randomized VBN p
were VBD p
included VBN p
in IN p
the DT p
analyses NNS p
. . p

Outcome NN N
analyses NNS N
were VBD N
performed VBN N
at IN N
a DT N
median JJ N
follow-up JJ N
interval NN N
of IN N
4.4 CD N
years NNS N
. . N

No DT N
patients NNS N
were VBD N
lost VBN N
to TO N
follow-up NN N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
found VBN N
between IN N
the DT N
two CD N
arms NNS N
for IN N
the DT N
end NN N
points NNS N
of IN N
local JJ o
relapse-free JJ o
rate NN o
( ( N
p JJ N
= NNP N
0.91 CD N
) ) N
, , N
regional JJ o
relapse-free JJ o
rate NN o
( ( N
p JJ N
= NN N
0.17 CD N
, , N
adjusted VBN N
) ) N
or CC N
overall JJ o
survival NN o
( ( N
p JJ N
= NNP N
0.86 CD N
) ) N
. . N

Eight-eight JJ N
patients NNS N
had VBD N
attempted VBN N
surgical JJ o
resection NN o
following VBG o
radiotherapy JJ o
failure NN o
. . o

The DT N
contribution NN N
of IN N
salvage NN N
surgery NN N
to TO N
overall JJ o
survival NN o
was VBD o
similar JJ N
for IN N
both DT N
arms NNS N
of IN N
the DT N
study NN N
as IN N
was VBD N
the DT N
surgical JJ o
complication NN o
rate NN o
. . o

Serious JJ o
late JJ o
radiation NN o
toxicity NN o
was VBD N
minimal JJ N
( ( N
3 CD N
% NN N
in IN N
the DT N
RT NNP N
group NN N
, , N
0 CD N
% NN N
in IN N
the DT N
radiation NN N
therapy NN N
plus CC N
chemotherapy NN N
group NN N
) ) N
. . N

The DT N
result NN N
of IN N
the DT N
trial NN N
shows VBZ N
no DT N
advantage NN N
in IN N
terms NNS N
of IN N
local JJ N
control NN N
or CC N
survival NN N
for IN N
the DT N
experimental JJ N
treatment NN N
arm NN N
of IN N
split NN N
course NN N
radiotherapy NN i
and CC N
concurrent JJ i
chemotherapy NN i
with IN i
Mitomycin NNP i
C NNP i
and CC i
5 CD i
Fluorouracil NNP i
compared VBN N
to TO N
radiotherapy VB N
alone RB N
. . N

-DOCSTART- -3089263- O O

Comparison NNP N
of IN N
amiodarone NN i
and CC i
disopyramide NN i
in IN N
the DT N
control NN o
of IN o
paroxysmal JJ o
atrial JJ o
fibrillation NN o
and CC o
atrial JJ o
flutter NN o
( ( N
interim JJ N
report NN N
) ) N
. . N

-DOCSTART- -8709689- O O

Removing VBG i
bee JJ i
stings NNS i
. . i

BACKGROUND NNP N
Conventional NNP N
advice NN N
on IN N
immediate JJ N
treatment NN N
of IN N
honey-bee JJ N
stings NNS N
has VBZ N
emphasised VBN N
that IN N
the DT N
sting NN N
should MD N
be VB N
scraped VBN N
off RP N
, , N
never RB N
pinched VBN N
. . N

The DT N
morphology NN N
of IN N
the DT N
sting NN N
suggested VBD N
little JJ N
basis NN N
for IN N
this DT N
advice NN N
, , N
which WDT N
is VBZ N
likely JJ N
to TO N
slow VB N
down RP N
removal NN N
of IN N
the DT N
sting NN N
. . N

METHODS NNP N
The DT N
response NN N
to TO N
honey-bee JJ p
stings NNS p
was VBD N
assayed VBN N
with IN N
a DT N
measurement NN N
of IN N
the DT N
size NN N
of IN N
the DT N
resulting VBG N
weal NN N
. . N

Injection NN N
of IN N
known JJ N
quantities NNS N
of IN N
venom NN i
showed VBD N
that IN N
this DT N
measurement NN N
is VBZ N
a DT N
good JJ N
indicator NN N
of IN N
envenomisation NN N
. . N

FINDINGS NNP N
Weal NNP o
size NN o
, , N
and CC N
thus RB N
envenomisation NN N
, , N
increased VBD N
as IN N
the DT N
time NN o
from IN o
stinging VBG o
to TO o
removal NN o
of IN o
the DT o
sting NN o
increased VBD N
, , N
even RB N
within IN N
a DT N
few JJ N
seconds NNS N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
response NN N
between IN N
stings NNS o
scraped VBD o
or CC o
pinched VBD o
off RP o
after IN N
2 CD N
s. JJ N
INTERPRETATION NNP N
These DT N
data NNS N
suggest VBP N
that IN N
advice NN N
to TO N
patients NNS p
on IN p
the DT p
immediate JJ p
treatment NN p
of IN p
bee JJ o
stings NNS o
should MD N
emphasise VB N
quick JJ i
removal NN i
, , N
without IN N
concern NN N
for IN N
the DT N
method NN N
of IN N
removal NN N
. . N

-DOCSTART- -9801481- O O

A DT N
comparison NN N
of IN N
the DT N
recovery NN o
times NNS o
of IN N
desflurane NN i
and CC N
isoflurane NN i
in IN N
outpatient JJ p
anesthesia NN p
. . p

The DT N
low JJ N
solubility NN N
of IN N
desflurane NN i
has VBZ N
been VBN N
shown VBN N
to TO N
contribute VB N
to TO N
faster VB N
awakening VBG N
from IN N
anesthesia NN N
when WRB N
compared VBN N
with IN N
other JJ N
anesthetics NNS N
in IN N
common JJ N
use NN N
. . N

However RB N
, , N
research NN N
has VBZ N
failed VBN N
to TO N
consistently RB N
demonstrate VB N
faster RBR N
discharge NN N
times NNS N
from IN N
the DT N
postanesthesia NN N
care NN N
unit NN N
following VBG N
the DT N
use NN N
of IN N
desflurane NN i
. . i

This DT N
study NN N
was VBD N
undertaken VBN N
to TO N
compare VB N
the DT N
recovery NN o
and CC o
discharge NN o
times NNS o
of IN N
outpatients NNS p
undergoing VBG p
procedures NNS p
greater JJR p
than IN p
2 CD p
hours NNS p
in IN p
length NN p
. . p

Thirty-three JJ p
patients NNS p
aged VBD p
18 CD p
to TO p
70 CD p
years NNS p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
desflurane NN i
or CC N
isoflurane NN i
following VBG N
a DT N
standard JJ N
intravenous JJ N
induction NN N
with IN N
propofol NN i
. . i

Patients NNS p
received VBD N
premedication NN N
and CC N
opioids NNS N
consistent JJ N
with IN N
institutional JJ N
practice NN N
, , N
and CC N
inhalation NN N
agents NNS N
were VBD N
titrated VBN N
to TO N
effect NN N
during IN N
anesthetic JJ N
maintenance NN N
. . N

Following VBG N
surgery NN N
, , N
patients NNS p
were VBD N
evaluated VBN N
for IN N
time NN o
to TO o
emergence VB o
and CC o
time NN o
to TO o
meeting VBG o
discharge JJ o
criteria NNS o
. . o

The DT N
results NNS N
demonstrated VBD N
no DT N
differences NNS N
between IN N
the DT N
emergence NN N
or CC N
discharge NN N
times NNS N
following VBG N
desflurane NN i
or CC N
isoflurane NN i
. . i

In IN N
addition NN N
, , N
measured VBD N
parameters NNS N
, , N
such JJ N
as IN N
intraoperative JJ o
vital JJ o
signs NNS o
and CC o
postoperative JJ o
emesis NN o
and CC o
opioid NN o
requirements NNS o
, , N
were VBD N
not RB N
different JJ N
between IN N
the DT N
groups NNS N
. . N

The DT N
use NN N
of IN N
desflurane NN i
as IN N
part NN N
of IN N
a DT N
balanced JJ N
anesthetic JJ N
technique NN N
did VBD N
not RB N
speed VB N
the DT N
emergence NN N
or CC N
discharge NN o
time NN o
when WRB N
compared VBN N
with IN N
isoflurane NN i
. . i

-DOCSTART- -2248073- O O

Moclobemide NNP i
, , i
imipramine NN i
and CC i
placebo NN i
in IN N
the DT N
treatment NN N
of IN N
major JJ p
depression NN o
. . o

Moclobemide NNP i
was VBD N
compared VBN N
with IN N
imipramine NN i
and CC N
placebo NN i
in IN N
the DT N
treatment NN N
of IN N
major JJ N
depressive JJ N
episodes NNS N
in IN N
75 CD p
outpatients NNS p
. . p

The DT N
dosage NN N
of IN N
moclobemide NN i
( ( i
25 CD i
patients NNS i
) ) i
was VBD i
300 CD i
mg JJ i
daily RB i
for IN i
the DT i
first JJ i
5 CD i
days NNS i
, , i
after IN i
which WDT i
it PRP i
could MD i
be VB i
increased VBN i
to TO i
600 CD i
mg. NNS i
Imipramine NNP i
( ( i
25 CD i
patients NNS i
) ) i
was VBD i
given VBN i
in IN i
a DT i
dosage NN i
starting VBG i
with IN i
33 CD i
mg NNS i
and CC i
gradually RB i
increased VBD i
to TO i
100 CD i
mg/day NN i
in IN i
the DT i
first JJ i
5 CD i
days NNS i
, , N
after IN N
which WDT N
it PRP N
could MD N
be VB N
further RB N
increased VBN N
; : N
25 CD p
patients NNS p
received VBD N
placebo NN i
. . i

Both DT N
drugs NNS N
were VBD N
equally RB N
effective JJ N
as IN N
measured VBN N
by IN N
the DT N
Hamilton NNP o
Rating NNP o
Scale NNP o
for IN o
Depression NNP o
, , N
the DT N
overall JJ o
assessment NN o
of IN o
efficacy NN o
and CC N
the DT N
Zung NNP o
Self-rating NNP o
Scale NNP o
, , N
and CC N
clearly RB N
superior JJ N
to TO N
placebo VB N
; : N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
2 CD N
active JJ N
drugs NNS N
. . N

Moclobemide NNP i
was VBD N
better RBR o
tolerated VBN o
than IN N
imipramine NN i
, , N
and CC N
was VBD N
almost RB N
comparable JJ N
to TO N
placebo VB N
in IN N
this DT N
respect NN N
. . N

-DOCSTART- -26040302- O O

Impact NN N
of IN N
empagliflozin NN i
added VBN N
on IN N
to TO N
basal VB N
insulin NN N
in IN N
type NN p
2 CD p
diabetes NNS p
inadequately RB p
controlled VBN p
on IN p
basal NN p
insulin NN p
: : p
a DT N
78-week JJ N
randomized NN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
. . N

AIMS NNP N
To TO N
investigate VB N
the DT N
efficacy NN o
and CC o
tolerability NN o
of IN N
empagliflozin NN i
added VBN N
to TO N
basal VB N
insulin-treated JJ N
type NN N
2 CD N
diabetes NNS N
. . N

METHODS NNP N
Patients NNPS p
inadequately RB p
controlled VBN p
[ NN p
glycated VBN p
haemoglobin NN p
( ( p
HbA1c NNP p
) ) p
> VBD p
7 CD p
to TO p
?10 VB p
% NN p
( ( p
> JJ p
53 CD p
to TO p
?86 VB p
mmol/mol NN p
) ) p
] NN p
on IN p
basal NN p
insulin NN p
( ( p
glargine NN p
, , p
detemir NN p
, , p
NPH NNP p
) ) p
were VBD p
randomized VBN i
to TO i
empagliflozin VB i
10 CD i
mg NN i
( ( p
n JJ p
= NNP p
169 CD p
) ) i
, , i
empagliflozin $ i
25 CD i
mg NN i
( ( i
n JJ i
= NNP i
155 CD i
) ) i
or CC i
placebo NN i
( ( i
n JJ i
= NNP i
170 CD i
) ) p
for IN p
78 CD p
weeks NNS p
. . p

The DT p
baseline NN p
characteristics NNS N
were VBD N
balanced VBN N
among IN N
the DT N
groups NNS N
[ VBP N
mean JJ N
HbA1c NNP N
8.2 CD N
% NN N
( ( N
67 CD N
mmol/mol NN N
) ) N
, , N
BMI NNP N
32.2 CD N
kg/m NN N
( ( N
2 CD N
) ) N
] NN N
. . N

The DT N
basal NN N
insulin NN N
dose NN N
was VBD N
to TO N
remain VB N
constant JJ N
for IN N
18 CD N
weeks NNS N
, , N
then RB N
could MD N
be VB N
adjusted VBN N
at IN N
investigator NN N
's POS N
discretion NN N
. . N

The DT N
primary JJ N
endpoint NN o
was VBD o
change NN o
from IN o
baseline NN o
in IN o
HbA1c NNP o
at IN N
week NN N
18 CD N
. . N

Key NNP N
secondary JJ N
endpoints NNS N
were VBD N
changes NNS o
from IN o
baseline NN o
in IN o
HbA1c NNP o
and CC o
insulin NN o
dose NN o
at IN o
week NN N
78 CD N
. . N

RESULTS NN N
At IN N
week NN N
18 CD N
, , N
the DT N
adjusted VBN N
mean NN N
? . N
standard JJ N
error NN N
changes NNS N
from IN N
baseline NN N
in IN N
HbA1c NNP N
were VBD N
0.0 CD N
? . N
0.1 CD N
% NN N
( ( N
-0.1 NNP N
? . N
0.8 CD N
mmol/mol NN N
) ) N
for IN N
placebo NN N
, , N
compared VBN N
with IN N
-0.6 NNP N
? . N
0.1 CD N
% NN N
( ( N
-6.2 NNP N
? . N
0.8 CD N
mmol/mol NN N
) ) N
and CC N
-0.7 $ N
? . N
0.1 CD N
% NN N
( ( N
-7.8 NNP N
? . N
0.8 CD N
mmol/mol NN N
) ) N
for IN N
empagliflozin $ N
10 CD N
and CC N
25 CD N
mg NN N
, , N
respectively RB N
( ( N
both DT N
p VBP N
< $ N
0.001 CD N
) ) N
. . N

At IN N
week NN N
78 CD N
, , N
empagliflozin VBD i
10 CD N
and CC N
25 CD N
mg NN N
significantly RB N
reduced VBN N
HbA1c NNP o
, , o
insulin NN o
dose NN N
and CC N
weight NN i
vs NN i
placebo NN i
( ( N
all DT N
p VBP N
< $ N
0.01 CD N
) ) N
, , N
and CC i
empagliflozin RB i
10 CD i
mg NNS N
significantly RB N
reduced VBN N
systolic JJ o
blood NN o
pressure NN o
vs NN o
placebo NN o
( ( N
p JJ N
= NNP N
0.004 CD N
) ) N
. . N

Similar JJ N
percentages NNS N
of IN N
patients NNS N
had VBD N
confirmed VBN N
hypoglycaemia NN o
in IN N
all DT N
groups NNS N
( ( N
35-36 CD N
% NN N
) ) N
. . N

Events NNS N
consistent JJ o
with IN o
urinary JJ o
tract NN o
infection NN o
were VBD o
reported VBN N
in IN N
9 CD N
, , N
15 CD N
and CC N
12 CD N
% NN N
of IN N
patients NNS N
on IN i
placebo NN i
, , i
empagliflozin CC i
10 CD i
and CC N
25 CD N
mg NN N
, , N
and CC N
events NNS N
consistent JJ N
with IN N
genital JJ o
infection NN o
were VBD o
reported VBN N
in IN N
2 CD N
, , N
8 CD N
and CC N
5 CD N
% NN N
, , N
respectively RB N
. . N

CONCLUSIONS NNP i
Empagliflozin NNP i
for IN i
78 CD N
weeks NNS N
added VBD N
to TO N
basal VB N
insulin NN N
improved JJ o
glycaemic JJ o
control NN o
and CC o
reduced JJ o
weight NN o
with IN o
a DT o
similar JJ o
risk NN o
of IN o
hypoglycaemia NN o
to TO o
placebo VB i
. . i

-DOCSTART- -7505498- O O

Randomized VBN N
trial NN N
of IN N
Sandostatin NNP i
prophylaxis NN i
for IN p
preservation NN o
injury NN o
after IN p
pancreas JJ p
transplantation NN p
. . p

-DOCSTART- -1793881- O O

Midazolam NNP i
as IN N
a DT N
main JJ N
anesthesia NN N
induction NN N
agent NN N
-- : N
a DT N
comparison NN N
with IN N
thiopental JJ i
and CC i
diazepam NN i
. . i

A DT N
clinical JJ N
randomized JJ N
investigation NN N
was VBD N
undertaken VBN N
to TO N
determine VB N
the DT N
value NN o
of IN N
midazolam NN i
as IN N
a DT N
narcotic JJ N
adjuvant NN N
for IN N
anesthetic JJ N
induction NN N
. . N

Thirty NNP p
ASA NNP p
I-II NNP p
adult NN p
patients NNS p
undergoing VBG p
selective JJ p
surgery NN p
were VBD N
allocated VBN N
randomly RB N
into IN N
two CD N
groups NNS N
to TO N
receive VB N
one CD N
of IN N
the DT N
following JJ N
agents NNS N
: : N
midazolam NN i
0.3 CD i
mg/kg NN i
, , i
thiopental JJ i
5 CD i
mg/kg NN i
, , i
or CC i
diazepam VB i
0.4 CD i
mg/kg NN i
. . i

The DT N
induction NN o
time NN o
as IN o
measured VBN o
from IN o
the DT o
onset NN o
of IN o
injection NN o
to TO o
loss NN o
of IN o
the DT o
eyelash NN o
reflex NN o
was VBD N
shortest VBN N
in IN N
the DT N
case NN N
of IN N
thiopental NN N
; : N
while IN N
a DT N
lower JJR o
frequency NN o
of IN o
apnea NN o
, , o
lesser JJR o
suppression NN o
of IN o
circulation NN o
, , N
and CC N
lack NN o
of IN o
venous JJ o
irritation NN o
were VBD N
points NNS N
favoring VBG N
midazolam NN N
. . N

However RB N
, , N
further JJ N
study NN N
is VBZ N
needed VBN N
to TO N
clarify VB N
the DT N
moderate JJ o
cardiovascular JJ o
response NN o
seen VBN N
during IN N
intubation NN N
in IN N
some DT N
cases NNS N
as RB N
well RB N
as IN N
to TO N
elucidate VB N
any DT N
patient JJ N
population NN N
differences NNS N
. . N

-DOCSTART- -12505733- O O

Is VBZ N
the DT N
orientation NN N
of IN N
the DT N
apical JJ p
defibrillation NN p
paddle NN p
of IN p
importance NN p
during IN N
manual JJ i
external JJ i
defibrillation NN i
? . N
OBJECTIVE NNP N
Transthoracic NNP o
impedance NN o
( ( o
TTI NNP o
) ) o
is VBZ N
a DT N
factor NN N
determining VBG N
the DT N
magnitude NN N
of IN N
the DT N
transmyocardial JJ N
current JJ N
during IN N
external JJ i
defibrillation NN i
. . i

Minimising VBG N
TTI NNP N
increases VBZ N
the DT N
chances NNS N
of IN N
successful JJ N
defibrillation NN N
. . N

Most JJS N
external JJ N
defibrillation NN N
paddles NNS N
are VBP N
rectangular JJ N
in IN N
shape NN N
and CC N
can MD N
, , N
therefore RB N
, , N
be VB N
placed VBN N
in IN N
a DT N
transverse NN N
or CC N
longitudinal JJ N
orientation NN N
. . N

The DT N
apical JJ N
paddle NN N
is VBZ N
often RB N
placed VBN N
in IN N
a DT N
transverse JJ N
orientation NN N
. . N

This DT N
may MD N
theoretically RB N
result VB N
in IN N
a DT N
higher JJR N
TTI NNP N
than IN N
a DT N
longitudinal JJ N
orientation NN N
because IN N
of IN N
poorer NN N
contact NN N
at IN N
the DT N
lateral JJ N
paddle NN N
edges NNS N
. . N

We PRP N
compared VBN N
TTI NNP N
with IN N
the DT N
apical JJ N
paddle NN N
in IN N
both DT N
a DT N
transverse NN N
and CC N
longitudinal JJ N
orientation NN N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Twenty NNP p
sequential NN p
anaesthetised VBD p
patients NNS p
were VBD N
studied VBN N
. . N

A DT N
pair NN N
of IN N
defibrillator NN i
paddles NNS i
were VBD N
instrumented VBN N
to TO N
measure VB N
paddle JJ o
force NN o
. . o

TTI NNP o
was VBD N
recorded VBN N
pre-operatively RB N
at IN N
end-expiration NN N
with IN N
the DT N
apical JJ N
paddle NN N
in IN N
both DT N
longitudinal JJ N
and CC N
transverse JJ N
orientations NNS N
. . N

The DT N
sternal JJ N
paddle NN N
was VBD N
placed VBN N
in IN N
a DT N
longitudinal JJ N
orientation NN N
for IN N
all DT N
measurements NNS N
. . N

RESULTS NNP N
TTI NNP o
decreased VBD N
in IN N
both DT N
transverse NN N
and CC N
longitudinal JJ N
orientations NNS N
as IN N
paddle JJ N
force NN N
increased VBD N
. . N

Transverse NNP i
paddle JJ i
orientation NN i
resulted VBD N
in IN N
a DT N
significantly RB N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
higher JJR N
TTI NNP o
than IN N
longitudinal JJ N
orientation NN N
at IN N
all DT N
paddle JJ N
forces NNS N
below IN N
12 CD N
kg NNS N
force NN N
. . N

CONCLUSION VB N
The DT N
longitudinal JJ N
orientation NN N
of IN N
a DT N
rectangular JJ N
defibrillation NN N
paddle NN N
provides VBZ N
a DT N
lower JJR N
TTI NNP o
than IN N
orientation NN N
horizontally RB N
. . N

-DOCSTART- -15356085- O O

Flutamide-metformin JJ N
plus CC N
ethinylestradiol-drospirenone JJ N
for IN N
lipolysis NN o
and CC o
antiatherogenesis NN o
in IN N
young JJ p
women NNS p
with IN p
ovarian JJ p
hyperandrogenism NN p
: : p
the DT N
key JJ N
role NN N
of IN N
early JJ N
, , N
low-dose JJ N
flutamide NN N
. . N

A DT N
low-dose JJ N
combination NN N
of IN N
flutamide-metformin JJ i
and CC i
ethinylestradiol-drospirenone NN i
was VBD N
recently RB N
found VBN N
to TO N
reduce VB N
the DT N
excess NN o
of IN o
total JJ o
and CC o
abdominal JJ o
fat NN o
, , N
to TO N
diminish VB N
the DT N
deficit NN N
in IN N
lean JJ o
mass NN o
, , N
and CC N
to TO N
attenuate VB N
the DT N
dysadipocytokinemia NN o
of IN N
young JJ p
women NNS p
with IN p
ovarian JJ p
hyperandrogenism NN p
, , p
a DT p
variant NN p
of IN p
polycystic JJ p
ovary JJ p
syndrome NN p
. . p

We PRP N
questioned VBD N
the DT N
need NN N
to TO N
give VB N
flutamide NN N
, , N
an DT N
androgen NN N
receptor NN N
blocker NN N
, , N
together RB N
with IN N
an DT N
oral JJ N
contraceptive NN N
that WDT N
contains VBZ N
drospirenone NN i
, , N
a DT N
progestin NN N
claimed VBN N
to TO N
have VB N
antiandrogen NN N
properties NNS N
. . N

The DT N
additive JJ N
effects NNS N
of IN N
low-dose JJ i
flutamide NN i
( ( N
62.5 CD N
mg/d NN N
) ) N
were VBD N
assessed VBN N
over IN N
3 CD N
months NNS N
in IN N
young JJ p
patients NNS p
with IN p
hyperinsulinemic JJ p
ovarian JJ p
hyperandrogenism NN p
( ( p
n JJ p
= VBZ p
40 CD p
; : p
age NN p
, , p
approximately RB p
17 CD p
yr NNS p
; : p
body NN p
mass NN p
index NN p
, , p
approximately RB p
22 CD p
kg/m NNS p
( ( p
2 CD p
) ) p
) ) p
; : p
all DT p
participants NNS p
started VBD p
on IN p
metformin NN i
( ( p
850 CD p
mg/d NN p
) ) p
and CC p
a DT p
fourth-generation JJ p
contraceptive NN p
( ( i
ethinylestradiol JJ i
30 CD i
microg NN i
plus CC i
drospirenone NN i
3 CD i
mg NN i
, , i
21 CD i
d/month NN i
) ) i
, , N
and CC N
they PRP N
were VBD N
randomized VBN N
to TO N
receive VB N
flutamide NN i
in IN N
addition NN N
( ( N
n JJ N
= NNP N
20 CD N
) ) N
or CC N
not RB N
( ( N
n JJ N
= NNP N
20 CD N
) ) N
. . N

Fasting VBG o
blood NN o
glucose NN o
, , o
serum JJ o
insulin NN o
, , o
lipid JJ o
profile NN o
, , o
testosterone NN o
, , o
adiponectin NN o
, , o
and CC o
IL-6 NNP o
were VBD N
determined VBN N
at IN N
baseline NN N
and CC N
after IN N
3 CD N
months NNS N
, , N
together RB N
with IN N
body NN N
composition NN N
( ( N
by IN N
dual JJ N
x-ray JJ N
absorptiometry NN N
) ) N
and CC N
with IN N
Doppler NNP N
assessment NN N
of IN N
ovarian JJ N
arterial JJ N
resistance NN N
. . N

At IN N
start NN N
, , N
the DT N
pulsatility NN o
and CC o
resistance NN o
indices NNS o
of IN N
ovarian JJ N
arteries NNS N
were VBD N
elevated VBN N
. . N

By IN N
comparison NN N
of IN N
3-month JJ N
changes NNS N
between IN N
randomized VBN N
subgroups NNS N
, , N
the DT N
addition NN N
of IN N
low-dose JJ N
flutamide NN i
was VBD N
found VBN N
to TO N
have VB N
consistently RB N
( ( N
more RBR N
) ) N
normalizing VBG N
effects NNS N
on IN N
low-density NN o
lipoprotein NN o
cholesterol NN o
, , o
IL-6 NNP o
, , o
and CC o
adiponectin NN o
, , o
lean JJ o
body NN o
mass NN o
, , o
total JJ o
and CC o
abdominal JJ o
fat JJ o
mass NN o
, , o
and CC o
arterial JJ o
flow NN o
in IN o
the DT o
ovaries NNS o
. . o

In IN N
conclusion NN N
, , N
low-dose JJ N
flutamide NN N
is VBZ N
herewith JJ N
identified VBN N
as IN N
a DT N
pivotal JJ N
component NN N
within IN N
a DT N
first JJ N
contraceptive JJ N
combination NN N
therapy NN N
that WDT N
has VBZ N
been VBN N
shown VBN N
to TO N
attenuate VB N
the DT N
hypoadiponectinemia NN o
, , o
ovarian JJ o
vascular NN o
hyperresistance NN o
, , o
lean JJ o
mass NN o
deficit NN o
, , o
and CC o
central JJ o
adiposity NN o
of IN N
young JJ N
women NNS N
with IN N
polycystic JJ N
ovary JJ N
syndrome NN N
. . N

Finally RB N
, , N
these DT N
data NNS N
challenge VBP N
any DT N
claim NN N
that IN N
drospirenone NN i
, , N
as IN N
currently RB N
used VBN N
in IN N
a DT N
contraceptive NN N
, , N
is VBZ N
a DT N
clinically RB N
significant JJ N
antiandrogen NN N
. . N

-DOCSTART- -21389925- O O

Role NNP N
of IN N
oxidized VBN i
regenerated VBN i
cellulose NN i
in IN N
preventing VBG N
infections NNS N
at IN N
the DT N
surgical JJ N
site NN N
: : N
prospective JJ N
, , N
randomized VBN N
study NN N
in IN N
98 CD p
patients NNS p
affected VBN p
by IN p
a DT p
dirty NN p
wound NN p
. . p

AIM IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
whether IN N
oxidized JJ o
regenerated VBN o
cellulose NN o
( ( o
ORC NNP o
) ) o
, , N
applied VBN N
to TO N
dirty VB N
surgical JJ N
wounds NNS N
, , N
is VBZ N
able JJ N
to TO N
reduce VB N
the DT N
microbial JJ N
load NN N
and CC N
, , N
consequently RB N
, , N
the DT N
infection NN o
rate NN o
as IN N
compared VBN N
to TO N
conventional JJ N
local JJ N
wound NN N
treatment NN N
. . N

METHODS NNP N
The DT p
study NN p
included VBD p
98 CD p
patients NNS p
who WP p
underwent VBP p
intestinal JJ p
recanalization NN p
procedures NNS p
between IN p
December NNP p
2003 CD p
and CC p
December NNP p
2008 CD p
, , p
with IN p
the DT p
stoma NN p
as IN p
the DT p
surgical JJ p
site NN p
. . p

Authors NNS N
considered VBD N
several JJ N
risk NN N
factors NNS N
for IN N
SSI NNP N
. . N

The DT N
patients NNS N
were VBD N
divided VBN N
into IN N
two CD N
groups NNS N
. . N

In IN N
group NN N
A NNP N
( ( N
50 CD N
patients NNS N
) ) N
, , N
the DT N
surgical JJ o
wound NN o
, , N
previous JJ N
site NN N
of IN N
the DT N
stoma NN N
, , N
was VBD N
packed VBN i
with IN i
ORC NNP i
, , N
whereas RB N
in IN N
group NN N
B NNP N
( ( N
48 CD N
patients NNS N
) ) N
gauze VBP i
soaked VBN i
in IN i
iodine NN i
was VBD N
used VBN N
. . N

Microbial JJ o
contamination NN o
was VBD N
evaluated VBN N
with IN N
three CD N
swabs NNS N
( ( N
in IN N
subcutaneous JJ N
tissue NN N
and CC N
the DT N
dermis NN N
) ) N
, , N
in IN N
the DT N
operating NN N
room NN N
before IN N
wound NN N
packing NN N
and CC N
on IN N
the DT N
2nd CD N
and CC N
3rd CD N
postoperative JJ N
day NN N
( ( N
before IN N
suturing VBG N
the DT N
skin NN N
) ) N
. . N

RESULTS CC N
There EX N
were VBD N
no DT o
cases NNS o
of IN o
wound NN o
dehiscence NN o
and CC N
no DT o
clinically RB o
evident JJ o
superficial NN o
or CC o
deep JJ o
surgical JJ o
site NN o
infections NNS o
in IN N
either DT N
group NN N
. . N

Analysis NN N
of IN N
all DT N
data NNS N
revealed VBD N
that IN N
there EX N
was VBD N
no DT o
or CC o
reduced VBN o
bacterial JJ o
contamination NN o
in IN N
the DT N
second JJ N
and CC N
third JJ N
swab NN N
in IN N
33 CD N
patients NNS N
( ( N
66 CD N
% NN N
) ) N
of IN N
Group NNP N
A NNP N
versus NN N
12 CD N
patients NNS N
( ( N
25 CD N
% NN N
) ) N
of IN N
Group NNP N
B NNP N
. . N

CONCLUSION NNP N
Although IN N
it PRP N
is VBZ N
necessary JJ N
to TO N
consider VB N
all DT N
factors NNS N
which WDT N
can MD N
have VB N
an DT N
influence NN N
on IN N
SSI NNP N
and CC N
use VB N
all PDT N
the DT N
means NNS N
shown VBN N
to TO N
be VB N
effective JJ N
to TO N
reduce VB N
the DT N
risk NN N
of IN N
SSI NNP N
, , N
there EX N
is VBZ N
a DT N
rationale NN N
for IN N
using VBG N
ORC NNP i
to TO N
prevent VB N
this DT N
kind NN N
of IN N
infection NN N
, , N
especially RB N
in IN N
patients NNS N
who WP N
undergo VBP N
dirty JJ N
surgery NN N
. . N

-DOCSTART- -25564411- O O

Hepatectomy NNP i
Versus NNP i
Hepatectomy NNP i
With IN i
Lymphadenectomy NNP i
in IN N
Hepatocellular NNP N
Carcinoma NNP N
: : N
A DT N
Prospective NNP N
, , N
Randomized NNP N
Controlled NNP N
Clinical NNP N
Trial NNP N
. . N

GOALS NNP N
AND CC N
BACKGROUND NNP N
The DT N
role NN N
of IN N
preventive JJ N
lymphadenectomy NN N
has VBZ N
not RB N
yet RB N
been VBN N
determined VBN N
for IN N
hepatocellular JJ p
carcinoma NN p
( ( p
HCC NNP p
) ) p
patients NNS p
. . p

We PRP N
designed VBD N
a DT N
study NN N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
hepatectomy NN i
combined VBN i
with IN i
preventive JJ i
lymphadenectomy NN i
on IN N
HCC NNP p
patients NNS p
. . p

STUDY NNP N
Patients NNPS N
were VBD N
randomly RB N
divided VBN N
into IN N
group NN N
A NNP N
( ( i
treated VBN i
with IN i
hepatectomy JJ i
alone RB i
) ) i
and CC N
group NN N
B NNP N
( ( i
underwent JJ i
hepatectomy NN i
combined VBN i
with IN i
lymphadenectomy NN i
) ) i
. . N

The DT N
postoperative JJ N
complications NNS N
and CC N
oncologic JJ o
prognoses NNS o
were VBD N
analyzed VBN N
. . N

RESULTS NNP N
Of IN N
the DT N
85 CD p
patients NNS p
enrolled VBD p
into IN p
this DT p
study NN p
, , p
79 CD p
cases NNS p
( ( p
38 CD p
in IN p
group NN p
A NNP p
and CC p
41 CD p
in IN p
group NN p
B NNP p
) ) p
were VBD N
pathologically RB p
confirmed VBN p
to TO p
have VB p
HCC NNP p
and CC N
received VBD N
curative JJ N
resection NN N
. . N

One CD N
hundred CD N
and CC N
sixteen JJ N
lymph NN N
nodes NNS N
were VBD N
dissected VBN N
and CC N
evaluated VBN N
as IN N
negative JJ N
by IN N
the DT N
pathologist NN N
. . N

The DT N
12- JJ N
, , N
36- JJ N
, , N
and CC N
60-month JJ N
disease-free JJ o
survival NN o
rates NNS o
of IN N
group NN N
A NNP N
were VBD N
81.6 CD N
% NN N
, , N
68.4 CD N
% NN N
, , N
and CC N
63.2 CD N
% NN N
, , N
respectively RB N
, , N
whereas IN N
they PRP N
were VBD N
78.0 CD N
% NN N
, , N
65.9 CD N
% NN N
, , N
and CC N
63.4 CD N
% NN N
, , N
respectively RB N
, , N
for IN N
group NN N
B NNP N
. . N

The DT N
12- JJ N
, , N
36- JJ N
, , N
and CC N
60-month JJ N
overall JJ o
survival NN o
rates NNS o
in IN N
group NN N
A NNP N
were VBD N
94.7 CD N
% NN N
, , N
78.9 CD N
% NN N
, , N
and CC N
65.8 CD N
% NN N
, , N
respectively RB N
, , N
whereas IN N
they PRP N
were VBD N
87.8 CD N
% NN N
, , N
78.0 CD N
% NN N
, , N
and CC N
70.7 CD N
% NN N
, , N
respectively RB N
, , N
in IN N
group NN N
B NNP N
. . N

The DT N
differences NNS N
in IN N
the DT N
disease-free JJ o
survival NN o
and CC o
overall JJ o
survival NN o
between IN N
the DT N
2 CD N
groups NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
according VBG N
to TO N
the DT N
log-rank JJ N
test NN N
( ( N
P=0.811 NNP N
and CC N
P=0.881 NNP N
, , N
respectively RB N
) ) N
. . N

The DT N
difference NN N
in IN N
the DT N
surgical JJ o
complication NN o
rate NN o
between IN N
groups NNS N
A NNP N
and CC N
B NNP N
was VBD N
not RB N
statistically RB N
significant JJ N
( ( N
47.4 CD N
% NN N
vs. FW N
36.6 CD N
% NN N
, , N
P=0.332 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Although IN N
hepatectomy NN i
combined VBN i
with IN i
regional JJ i
lymphadenectomy NN i
is VBZ N
a DT N
safe JJ N
procedure NN N
, , N
preventive JJ N
lymphadenectomy NN N
may MD N
not RB N
decrease VB N
the DT N
rate NN N
of IN N
tumor NN N
recurrence NN o
nor CC N
improve VB N
the DT N
prognosis NN o
in IN N
early-stage JJ p
HCC NNP p
patients NNS p
. . p

-DOCSTART- -8580292- O O

[ NN p
Evaluating VBG p
an DT p
interactive JJ i
, , i
multi-media JJ i
learning NN i
system NN i
for IN p
the DT p
study NN p
of IN p
primary JJ p
open JJ p
angle NN p
glaucoma NN p
] NNP p
. . N

Using VBG N
the DT N
interactive JJ i
multimedia NN i
learning NN i
system NN i
for IN N
studying VBG N
open-angle JJ p
glaucoma NN p
[ $ N
3 CD N
] CC N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
case-controlled JJ N
study NN N
was VBD N
carried VBN N
out IN N
to TO N
determine VB N
the DT N
value NN N
of IN N
this DT N
new JJ N
form NN N
of IN N
learning VBG N
in IN N
terms NNS N
of IN N
acceptance NN o
and CC o
the DT o
imparting NN o
of IN o
knowledge NN o
. . o

This DT N
article NN N
describes VBZ N
details NNS N
of IN N
the DT N
study NN N
and CC N
presents NNS N
their PRP$ N
results NNS N
. . N

Results NNS N
were VBD N
established VBN N
on IN N
the DT N
basis NN N
of IN N
targeted JJ N
questions NNS N
asked VBD N
prior JJ N
to TO N
and CC N
after IN N
the DT N
learning NN N
phase NN N
, , N
followed VBN N
by IN N
an DT N
analysis NN N
of IN N
frequencies NNS N
and CC N
significance NN N
testing NN N
by IN N
the DT N
Chi NNP N
squared VBD N
method NN N
. . N

It PRP N
was VBD N
shown VBN N
that IN N
the DT N
imparting NN o
of IN o
knowledge NN o
is VBZ N
significantly RB N
improved VBN N
when WRB N
this DT N
learning NN i
system NN i
is VBZ N
employed VBN N
. . N

In IN N
addition NN N
, , N
after IN N
its PRP$ N
first JJ N
use NN N
, , N
acceptance NN o
of IN o
this DT o
new JJ o
medium NN o
rose VBD N
dramatically RB N
. . N

-DOCSTART- -19459553- O O

Local NNP N
anaesthetic JJ N
use NN N
for IN N
the DT N
iliac JJ N
crest-donor JJ N
site NN N
: : N
pharmacokinetic JJ N
and CC N
pharmacodynamic JJ N
evaluations NNS N
. . N

During IN p
orthopaedic JJ i
surgery NN i
of IN p
the DT p
limb NN p
, , N
we PRP N
performed VBD N
a DT N
prospective JJ N
, , N
double JJ N
blind NN N
controlled VBD N
study NN N
on IN N
three CD p
parallel JJ p
groups NNS p
in IN p
30 CD p
patients NNS p
to TO N
evaluate VB N
the DT N
pharmacokinetic JJ N
and CC N
pharmacodynamic JJ N
effect NN N
of IN N
infiltration NN N
of IN N
the DT N
iliac JJ N
crest NN N
bone NN N
graft NN N
harvest NN N
site NN N
with IN N
20 CD i
ml NNS i
of IN i
bupivacaine NN i
( ( i
100 CD i
mg NN i
) ) i
, , i
ropivacaine NN i
( ( i
150 CD i
mg NN i
) ) i
or CC i
saline JJ i
as IN i
control NN i
group NN i
( ( i
n JJ i
= NN i
10 CD i
in IN i
each DT i
group NN i
) ) i
. . N

Then RB N
, , N
in IN N
a DT N
sheep JJ N
model NN N
of IN N
iliac JJ N
crest NN N
infiltration NN N
, , N
we PRP N
compared VBN N
the DT N
pharmacokinetics NNS N
of IN N
single JJ i
administration NN i
of IN i
plain JJ i
bupivacaine NN i
( ( i
100 CD i
mg NN i
) ) i
and CC i
bupivacaine NN i
( ( i
500 CD i
mg NN i
) ) i
-loaded VBD i
microspheres NNS i
. . i

In IN N
the DT N
clinical JJ N
control NN N
group NN N
, , N
pain NN N
from IN N
the DT N
iliac JJ N
crest NN N
was VBD N
worse JJR N
than IN N
pain NN N
from IN N
the DT N
primary JJ N
surgical JJ N
site NN N
. . N

Pain NN o
from IN o
the DT o
iliac JJ o
crest NN o
was VBD N
significantly RB o
reduced VBN o
during IN N
the DT N
first JJ N
12 CD N
postoperative JJ N
hours NNS N
in IN N
local JJ N
anaesthetic JJ N
groups NNS N
compared VBN N
to TO N
the DT N
control NN N
group NN N
. . N

However RB N
, , N
during IN N
this DT N
period NN N
, , N
pain NN o
from IN o
the DT o
primary JJ o
surgical JJ o
site NN o
was VBD o
increased VBN o
compared VBN N
to TO N
the DT N
control NN N
group NN N
. . N

Finally RB N
, , N
there EX N
was VBD N
no DT o
difference NN o
between IN N
the DT N
three CD N
groups NNS N
in IN N
the DT N
average JJ N
intake NN N
of IN N
PCA NNP N
morphine NN i
. . i

There EX N
was VBD N
no DT o
significant JJ o
pharmacokinetic JJ o
and CC o
pharmacodynamic JJ o
difference NN o
between IN N
plain JJ N
bupivacaine NN i
and CC N
ropivacaine NN i
. . i

The DT N
maximal JJ o
plasma NN o
concentration NN o
( ( o
Cmax NNP o
) ) o
of IN N
ropivacaine NN i
and CC N
bupivacaine NN i
were VBD N
964 CD N
( ( N
282 CD N
) ) N
ng NN N
ml NN N
( ( N
-1 NNP N
) ) N
and CC N
638 CD N
( ( N
366 CD N
) ) N
ng NN N
ml NN N
( ( N
-1 NNP N
) ) N
, , N
respectively RB N
. . N

In IN N
the DT N
sheep JJ N
model NN N
, , N
it PRP N
was VBD N
clearly RB N
shown VBN N
that IN N
the DT N
release NN N
of IN N
bupivacaine NN i
from IN N
microspheres NNS N
was VBD N
controlled VBN N
and CC N
prolonged VBN N
despite IN N
the DT N
largest JJS N
dose NN N
of IN N
bupivacaine NN i
used VBN N
( ( N
500 CD N
mg NN N
; : N
n CC N
= VB N
4 CD N
) ) N
. . N

Wound NNP N
infiltration NN N
of IN N
iliac JJ N
crest NN N
harvest NN N
site NN N
with IN N
local JJ N
anaesthetic NN N
is VBZ N
an DT N
easy JJ N
technique NN N
for IN N
postoperative JJ N
analgesia NN N
. . N

However RB N
, , N
this DT N
effect NN N
lasts VBZ N
only RB N
12 CD N
hours NNS N
without IN N
reducing VBG N
the DT N
morphine NN o
consumption NN o
due JJ N
to TO N
an DT N
increase NN N
of IN N
pain NN N
from IN N
the DT N
primary JJ N
surgical JJ N
site NN N
. . N

The DT N
local JJ N
anaesthetic JJ N
infiltration NN N
produced VBD N
a DT N
significant JJ o
peak NN o
of IN o
plasma JJ o
level NN o
, , N
which WDT N
could MD N
be VB N
dangerous JJ N
if IN N
another DT N
infiltration NN N
or CC N
regional JJ N
anaesthetic JJ N
technique NN N
was VBD N
associated VBN N
with IN N
it PRP N
. . N

Experimentally RB N
, , N
as IN N
a DT N
drug NN N
delivery NN N
system NN N
, , N
the DT N
use NN N
of IN N
local JJ N
anaesthetic-loaded JJ i
microspheres NNS i
could MD N
be VB N
an DT N
interesting JJ N
alternative NN N
. . N

-DOCSTART- -8035029- O O

Paromomycin NNP i
for IN N
cryptosporidiosis NN N
in IN N
AIDS NNP p
: : p
a DT N
prospective JJ N
, , N
double-blind JJ N
trial NN N
. . N

To TO N
test VB N
the DT N
effects NNS N
of IN N
paromomycin NN i
, , N
10 CD p
patients NNS p
with IN p
AIDS NNP p
and CC p
cryptosporidiosis NN p
were VBD N
randomized VBN N
to TO N
paromomycin VB i
or CC i
placebo VB i
in IN N
a DT N
double-blind JJ N
trial NN N
. . N

After IN N
14 CD N
days NNS N
, , N
patients NNS N
were VBD N
switched VBN N
to TO N
the DT N
other JJ N
treatment NN N
for IN N
14 CD N
additional JJ N
days NNS N
. . N

Measures NNS N
included VBD N
the DT N
number NN o
and CC o
character NN o
of IN o
each DT o
stool NN o
and CC N
weekly JJ N
24-h JJ N
stool NN o
specimens NNS o
for IN o
weight NN o
and CC o
oocyst NN o
excretion NN o
. . o

During IN N
the DT N
paromomycin NN i
treatment NN N
phase NN N
, , N
oocyst JJ o
excretion NN o
decreased VBD N
from IN N
314 CD N
x NNS N
10 CD N
( ( N
6 CD N
) ) N
to TO N
109 CD N
x NNS N
10 CD N
( ( N
6 CD N
) ) N
24 CD N
h NN N
( ( N
P NNP N
< NNP N
.02 NNP N
) ) N
. . N

Oocyst NNP o
excretion NN o
increased VBD N
for IN N
the DT N
4 CD N
patients NNS N
initially RB N
on IN N
placebo NNS i
compared VBN N
to TO N
a DT N
median JJ N
decrease NN N
of IN N
128 CD N
x NNS N
10 CD N
( ( N
6 CD N
) ) N
/24 NN N
h NN N
for IN N
the DT N
6 CD N
initially RB N
treated VBN N
with IN N
drug NN N
( ( N
P NNP N
< NNP N
.02 NNP N
) ) N
. . N

Stool NNP o
frequency NN o
also RB N
decreased VBD N
more RBR N
in IN N
those DT N
treated VBN N
with IN N
drug NN i
( ( N
3.6 CD N
fewer JJR N
vs. NN N
1.25 CD N
fewer/24 NN N
h NN N
, , N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

Trends NNS N
favored JJ N
drug NN N
over IN N
placebo NN i
for IN N
stool NN o
weight NN o
, , o
stool JJ o
character NN o
, , o
and CC o
Karnofsky NNP o
score NN o
. . o

Paromomycin NNP i
treatment NN N
resulted VBD N
in IN N
improvement NN N
in IN N
both DT N
clinical JJ N
and CC N
parasitologic JJ N
parameters NNS N
in IN N
cryptosporidiosis NN N
in IN N
AIDS NNP N
. . N

-DOCSTART- -18717174- O O

A DT N
prospective JJ N
study NN N
on IN N
the DT N
clinical JJ N
performance NN N
of IN N
polysiloxane NN i
soft JJ i
liners NNS i
: : i
one-year JJ N
results NNS N
. . N

OBJECTIVE IN N
The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
clinical JJ N
performance NN N
of IN N
four CD N
denture NN i
soft NN i
liners VBZ i
up IN N
to TO N
12 CD N
months NNS N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Thirty-three NNP p
edentulous JJ p
patients NNS p
who WP p
experienced VBD p
difficulties NNS p
when WRB p
using VBG p
hard JJ p
denture NN p
bases NNS p
because IN p
of IN p
changes NNS p
in IN p
denture-supporting JJ p
tissues NNS p
were VBD N
accepted VBN N
for IN N
the DT N
study NN N
and CC N
randomly RB N
received VBD N
Molloplast NNP i
B NNP i
, , i
GC NNP i
Reline NNP i
Soft NNP i
, , i
Silagum NNP i
Comfort NNP i
, , i
or CC i
Mollosil NNP i
Plus NNP i
relines NNS i
. . i

Performance NN N
of IN N
the DT N
materials NNS N
was VBD N
evaluated VBN N
using VBG N
nine CD N
criteria NNS N
at IN N
3 CD N
, , N
6 CD N
, , N
and CC N
12 CD N
months NNS N
: : N
physical JJ o
integrity NN o
, , o
surface NN o
detail NN o
, , o
adhesion NN o
, , o
color NN o
, , o
odor NN o
, , o
plaque JJ o
accumulation NN o
, , o
resilience NN o
, , o
hygiene NN o
, , o
and CC o
mucosal JJ o
condition NN o
. . o

A DT N
four-point JJ N
categorized VBN N
scale NN N
( ( N
1=poor CD N
, , N
2=fair CD N
, , N
3=good CD N
, , N
4=excellent CD N
) ) N
was VBD N
used VBN N
. . N

Unscheduled JJ o
maintenance NN o
events NNS o
and CC o
the DT o
presence NN o
of IN o
fungal JJ o
colonization NN o
were VBD N
also RB N
recorded VBN N
. . N

RESULTS VB N
The DT p
percentage NN p
of IN p
patients NNS p
available JJ p
at IN p
3 CD p
, , p
6 CD p
, , p
and CC p
12 CD p
months NNS p
were VBD p
91 CD p
% NN p
, , p
91 CD p
% NN p
, , p
and CC p
66 CD p
% NN p
. . p

Main NNP N
reasons NNS N
for IN N
dropouts NNS N
and CC N
discontinuation NN N
were VBD N
fractured VBN o
dentures NNS o
and CC o
patient JJ o
dissatisfaction NN o
. . o

At IN N
6 CD N
months NNS N
, , N
96 CD N
% NN N
of IN N
the DT N
performance NN o
scores NNS o
were VBD N
good JJ N
or CC N
excellent JJ N
and CC N
the DT N
largest JJS N
changes NNS N
were VBD N
observed VBN N
for IN N
physical JJ o
integrity NN o
, , o
surface NN o
detail NN o
, , o
color NN o
, , o
and CC o
fungal JJ o
colonization NN o
. . o

Fungal NNP o
colonization NN o
was VBD N
the DT N
most RBS N
commonly RB N
observed VBN N
problem NN N
and CC N
was VBD N
the DT N
only JJ N
reason NN N
of IN N
failure NN N
at IN N
12 CD N
months NNS N
. . N

CONCLUSIONS VB N
The DT N
clinical JJ N
performance NN N
of IN N
all DT N
soft JJ N
liners NNS N
was VBD N
slightly RB N
impaired VBN N
over IN N
the DT N
12-month JJ N
observation NN N
. . N

Except IN N
for IN N
cases NNS N
showing VBG N
extensive JJ N
fungal JJ o
colonization NN o
, , N
the DT N
observed JJ N
changes NNS N
in IN N
clinical JJ N
performance NN N
did VBD N
not RB N
necessitate JJ N
remaking NN N
of IN N
the DT N
dentures NNS N
. . N

Mollosil NNP i
Plus CC i
showed VBD N
a DT N
performance NN N
comparable JJ N
to TO N
that DT N
of IN N
Molloplast NNP i
B NNP i
, , N
and CC N
the DT N
other JJ N
materials NNS N
had VBD N
slightly RB N
lower JJR N
performance NN N
especially RB N
in IN N
terms NNS N
of IN N
fungal JJ o
colonization NN o
. . o

-DOCSTART- -20500493- O O

Efficacy NN N
and CC N
safety NN N
of IN N
de FW N
novo FW N
or CC N
early JJ N
everolimus NN i
with IN N
low JJ N
cyclosporine NN N
in IN N
deceased-donor JJ p
kidney NN p
transplant NN p
recipients NNS p
at IN p
specified VBN p
risk NN p
of IN p
delayed JJ p
graft NN p
function NN p
: : p
12-month JJ N
results NNS N
of IN N
a DT N
randomized VBN N
, , N
multicenter RBR N
trial NN N
. . N

Immediate NNP N
or CC N
early JJ N
use NN N
of IN N
proliferation NN N
signal NN N
inhibitor NN N
( ( N
PSI NNP N
) ) N
/mammalian JJ N
target NN N
of IN N
rapamycin NN N
( ( N
mTOR NN N
) ) N
inhibitor NN N
therapy NN N
can MD N
avoid VB N
high JJ N
exposure NN N
to TO N
calcineurin VB N
inhibitors NNS N
but CC N
concerns NNS N
exist VBP N
relating VBG N
to TO N
the DT N
risk NN N
of IN N
delayed JJ o
graft NN o
function NN o
( ( o
DGF NNP o
) ) o
and CC o
impaired JJ o
wound NN o
healing VBG o
with IN N
the DT N
mTOR NN N
sirolimus NN N
. . N

CALLISTO NNP N
was VBD N
a DT N
12-month JJ N
, , N
prospective JJ N
, , N
multicenter NN p
, , N
open-label JJ N
study NN N
. . N

Deceased-donor NNP p
kidney NN p
transplant NN p
patients NNS p
at IN p
protocol-specified JJ p
risk NN p
of IN p
DGF NNP p
were VBD N
randomized VBN N
to TO N
start VB N
everolimus VB i
on IN N
day NN N
1 CD N
( ( i
immediate JJ i
everolimus NN i
, , N
IE NNP N
; : N
n CC i
= VB i
65 CD i
) ) i
or CC i
week NN i
5 CD i
( ( i
delayed VBN i
everolimus NN i
, , i
DE NNP i
; : N
n CC N
= VB N
74 CD N
) ) N
. . N

Incidence NN N
of IN N
the DT N
primary JJ N
endpoint NN N
( ( o
biopsy-proven JJ o
acute NN o
rejection NN o
, , o
BPAR NNP o
; : o
graft NN o
loss NN o
, , o
death NN o
, , o
DGF NNP o
, , o
wound VBD o
healing VBG o
complications NNS o
related VBN o
to TO o
transplant VB o
surgery NN o
or CC o
loss NN o
to TO o
follow-up NN o
) ) o
was VBD o
64.6 CD o
% NN N
and CC N
66.2 CD N
% NN N
in IN N
the DT N
IE NNP N
and CC N
DE NNP N
groups NNS N
, , N
respectively RB N
, , N
at IN N
month NN N
12 CD N
( ( N
P NNP N
= NNP N
0.860 CD N
) ) N
. . N

The DT N
overall JJ N
incidence NN N
of IN N
BPAR NNP N
was VBD N
20.1 CD N
% NN N
. . N

Median JJ N
estimated VBD o
glomerular JJ o
filtration NN o
rate NN o
was VBD o
48 CD o
ml/min/1.73 JJ N
m NN N
( ( N
2 CD N
) ) N
and CC N
49 CD N
ml/min/1.73 NNS N
m NN N
( ( N
2 CD N
) ) N
in IN N
the DT N
IE NNP N
and CC N
DE NNP N
groups NNS N
, , N
respectively RB N
, , N
at IN N
month NN o
12 CD o
. . o

DGF NNP o
and CC o
wound VBD o
healing VBG o
complications NNS o
were VBD o
similar JJ N
between IN N
groups NNS o
. . o

Adverse JJ o
events NNS o
led VBD o
to TO N
study VB N
drug NN N
discontinuation NN N
in IN p
17 CD p
IE JJ p
patients NNS p
( ( p
26.2 CD N
% NN N
) ) N
and CC N
28 CD N
DE NNP N
patients NNS N
( ( N
37.8 CD N
% NN N
) ) N
( ( N
NS NNP N
) ) N
. . N

In IN N
conclusion NN N
, , N
introduction NN N
of IN N
everolimus NN N
immediately RB N
or CC N
early JJ N
posttransplant NN N
in IN p
DGF-risk JJ p
patients NNS p
is VBZ N
associated VBN N
with IN N
good JJ o
efficacy NN o
, , o
renal JJ o
function NN o
and CC o
safety NN o
profile NN o
. . o

There EX o
seems VBZ N
no DT N
benefit NN N
in IN N
delaying VBG N
initiation NN N
of IN N
everolimus NN i
. . i

-DOCSTART- -24320862- O O

Learning VBG N
the DT N
'traceback NN i
' POS i
approach NN i
for IN N
interscalene JJ p
block NN p
. . p

-DOCSTART- -8604728- O O

Five-year JJ N
follow-up NN N
of IN N
the DT N
Fluorouracil NNP i
Filtering NNP i
Surgery NNP i
Study NNP N
. . N

The DT N
Fluorouracil NNP i
Filtering NNP i
Surgery NNP i
Study NNP i
Group NNP N
. . N

PURPOSE NNP N
To TO N
determine VB N
the DT N
efficacy NN o
and CC N
safety NN o
of IN N
subconjunctival JJ i
5- JJ i
fluorouracil NN i
injections NNS i
after IN N
trabeculectomy NN N
in IN N
patients NNS p
with IN p
poor JJ p
prognoses NNS p
, , p
to TO p
determine VB p
risk NN p
factors NNS p
for IN p
surgical JJ p
failure NN p
and CC p
to TO p
examine VB p
the DT p
relationship NN p
of IN p
intraocular JJ o
pressure NN o
and CC o
visual JJ o
function NN o
. . o

METHODS NNP N
In IN N
this DT N
multicenter NN N
clinical JJ N
trial NN N
, , N
213 CD p
patients NNS p
with IN p
previous JJ p
cataract NN p
surgery NN p
or CC p
previous JJ p
failed VBD p
filtering VBG p
surgery NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
trabeculectomy NN i
alone RB i
or CC i
trabeculectomy VB i
with IN i
postoperative JJ i
subconjunctival JJ i
5-fluorouracil JJ i
injections NNS i
. . i

Measurements NNS N
of IN N
intraocular JJ o
pressure NN o
, , o
visual JJ o
acuity NN o
, , o
and CC o
visual JJ o
fields NNS o
were VBD N
performed VBN N
throughout IN N
the DT N
five CD N
years NNS N
, , N
with IN N
the DT N
clinician JJ N
masked NN N
to TO N
the DT N
treatment NN N
group NN N
. . N

Failure NN N
was VBD N
defined VBN N
as IN N
a DT N
reoperation NN N
to TO N
control VB N
intraocular JJ o
pressure NN o
or CC N
an DT N
intraocular JJ o
pressure NN o
greater JJR N
than IN N
21 CD N
mm JJ N
Hg NNP N
at IN N
or CC N
after IN N
the DT N
first-year JJ N
examination NN N
. . N

RESULTS JJ N
Fifty-four NNP N
( ( N
51 CD N
% NN N
) ) N
of IN N
the DT N
105 CD N
eyes NNS N
in IN N
the DT N
5-fluorouracil JJ i
group NN N
and CC N
80 CD N
( ( N
74 CD N
% NN N
) ) N
of IN N
the DT N
108 CD N
eyes NNS N
in IN N
the DT N
standard NN N
filtering VBG N
surgery NN N
group NN N
were VBD N
classified VBN N
as IN N
failures NNS N
( ( N
P NNP N
< NNP N
.001 NNP N
, , N
Mantel-Cox NNP N
survival NN N
analysis NN N
) ) N
. . N

Risk NN N
factors NNS N
for IN N
failure NN N
include VBP N
high JJ o
intraocular JJ o
pressure NN o
, , N
a DT N
short JJ N
time NN N
interval NN N
after IN N
the DT N
last JJ N
procedure NN N
involving VBG N
a DT N
conjunctival JJ N
incision NN N
, , N
the DT N
number NN N
of IN N
procedures NNS N
with IN N
conjunctival JJ N
incisions NNS N
, , N
and CC N
Hispanic NNP N
ethnicity NN N
. . N

Patients NNS N
in IN N
both DT N
treatment NN N
groups NNS N
with IN N
controlled JJ N
intraocular JJ N
pressures NNS N
were VBD N
more RBR N
likely JJ N
to TO N
maintain VB N
visual JJ o
acuity NN o
. . o

Patients NNS N
in IN N
the DT N
5-fluorouracil JJ i
group NN N
had VBD N
a DT N
higher JJR N
risk NN N
of IN N
late-onset JJ o
bleb NN o
leaks NNS o
( ( N
9 CD N
% NN N
nine CD N
of IN N
105 CD N
) ) N
than IN N
those DT N
in IN N
the DT N
standard NN N
filtering VBG N
surgery NN N
group NN N
( ( N
2 CD N
% NN N
two CD N
of IN N
108 CD N
) ) N
( ( N
P NNP N
= NNP N
.032 NNP N
, , N
Fisher NNP N
's POS N
exact JJ N
test NN N
) ) N
. . N

CONCLUSIONS NNP N
We PRP N
recommend VBP N
the DT N
use NN N
of IN N
subconjunctival JJ i
5-fluorouracil JJ i
after IN N
trabeculectomy NN N
in IN N
eyes NNS p
after IN p
previous JJ p
cataract NN p
surgery NN p
or CC p
unsuccessful JJ p
filtering NN p
surgery NN p
, , N
but CC N
caution NN N
against IN N
its PRP$ N
routine JJ N
use NN N
in IN N
patients NNS N
with IN N
good JJ N
prognoses NNS N
. . N

-DOCSTART- -26446239- O O

U.S. NNP N
Food NNP N
and CC N
Drug NNP N
Administration NNP N
Approval NNP N
Summary NNP N
: : N
Ramucirumab NN i
for IN N
the DT N
Treatment NNP N
of IN N
Metastatic NNP p
Non-Small NNP p
Cell NNP p
Lung NNP p
Cancer NNP p
Following NNP p
Disease NNP p
Progression NNP p
On IN p
or CC p
After IN p
Platinum-Based JJ p
Chemotherapy NNP p
. . p

UNLABELLED NN N
On IN N
December NNP N
12 CD N
, , N
2014 CD N
, , N
the DT N
U.S. NNP N
Food NNP N
and CC N
Drug NNP N
Administration NNP N
( ( N
FDA NNP N
) ) N
approved VBD N
ramucirumab NN i
for IN N
use NN N
in IN N
combination NN N
with IN N
docetaxel NN i
for IN N
the DT N
treatment NN N
of IN N
patients NNS p
with IN p
metastatic JJ p
non-small NN p
cell NN p
lung NN p
cancer NN p
( ( p
NSCLC NNP p
) ) p
with IN p
disease NN p
progression NN p
on IN p
or CC p
after IN p
platinum-based JJ p
chemotherapy NN p
. . p

Patients NNS p
with IN p
epidermal JJ p
growth NN p
factor NN p
receptor NN p
or CC p
anaplastic JJ p
lymphoma NN p
kinase NN p
genomic JJ p
tumor NN p
aberrations NNS p
should MD N
have VB N
disease NN N
progression NN N
on IN N
FDA-approved NNP N
therapy NN N
for IN N
these DT N
aberrations NNS N
prior VBP N
to TO N
receiving VBG N
ramucirumab NN i
. . i

This DT N
approval NN N
was VBD N
based VBN N
on IN N
an DT N
improvement NN N
in IN N
overall JJ N
survival NN N
( ( N
OS NNP N
) ) N
with IN N
an DT N
acceptable JJ N
toxicity NN N
profile NN N
in IN N
a DT N
randomized JJ N
, , N
multicenter NN N
, , N
double-blinded JJ N
, , N
placebo-controlled JJ N
trial NN N
of IN N
1,253 CD p
patients NNS p
with IN p
metastatic JJ p
NSCLC NNP p
previously RB p
treated VBD p
with IN p
a DT p
platinum-based JJ p
combination NN p
therapy NN p
. . p

Patients NNS N
were VBD N
randomized VBN N
1:1 CD N
to TO N
receive VB N
either DT N
ramucirumab NN i
in IN i
combination NN i
with IN i
docetaxel NN i
or CC i
placebo NN i
in IN i
combination NN i
with IN i
docetaxel NN i
. . i

The DT N
primary JJ N
endpoint NN N
was VBD N
OS NNP o
. . o

Patients NNS N
who WP N
received VBD N
ramucirumab NN N
in IN N
combination NN N
with IN N
docetaxel NN N
had VBD N
improved VBN o
OS NNP o
( ( N
hazard JJ N
ratio NN N
[ NNP N
HR NNP N
] NN N
: : N
0.86 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NN N
: : N
0.75 CD N
, , N
0.98 CD N
) ) N
. . N

Median JJ o
OS NNP o
was VBD N
10.5 CD N
months NNS N
on IN N
the DT N
ramucirumab NN N
plus CC N
docetaxel JJ N
arm NN N
versus NN N
9.1 CD N
months NNS N
on IN N
the DT N
placebo NN N
plus CC N
docetaxel JJ N
arm NN N
. . N

The DT N
most RBS N
frequent JJ N
( ( N
? . N
30 CD N
% NN o
) ) o
adverse JJ o
reactions NNS o
in IN o
ramucirumab-treated JJ N
patients NNS N
were VBD o
fatigue JJ o
, , o
neutropenia JJ o
, , o
and CC o
diarrhea NN o
. . o

The DT N
most RBS N
frequent JJ N
( ( N
? . N
5 CD N
% NN N
) ) N
grade VBD N
3 CD N
and CC N
4 CD o
adverse JJ o
reactions NNS o
in IN o
the DT N
ramucirumab NN N
arm NN N
were VBD N
fatigue JJ o
, , o
neutropenia RB o
, , o
febrile JJ o
neutropenia NN o
, , o
leukopenia NN o
, , o
and CC o
hypertension NN o
. . o

IMPLICATIONS NNP o
FOR NNP N
PRACTICE NNP N
This DT N
report NN N
presents VBZ N
key JJ N
information NN N
on IN N
the DT N
U.S. NNP N
Food NNP N
and CC N
Drug NNP N
Administration NNP N
approval NN N
of IN N
ramucirumab NN N
, , N
a DT N
monoclonal JJ N
antibody NN N
targeting VBG N
vascular JJ N
endothelial JJ N
growth NN N
factor NN N
receptor-2 NN N
, , N
given VBN N
in IN N
combination NN N
with IN N
docetaxel NN N
for IN N
the DT N
treatment NN p
of IN p
patients NNS p
with IN p
metastatic JJ p
non-small NN p
cell NN p
lung NN p
cancer NN p
whose WP$ p
disease NN p
has VBZ p
progressed VBN p
on IN p
or CC p
after IN p
platinum-based JJ p
chemotherapy NN p
. . p

This DT p
report NN N
specifically RB N
addresses VBZ N
the DT N
issues NNS N
of IN N
safety NN p
in IN p
patients NNS p
with IN p
squamous JJ p
cell NN p
tumors NNS p
, , p
effect NN p
of IN N
treatment NN p
in IN p
elderly JJ p
patients NNS p
, , p
and CC p
uncertainties NNS N
regarding VBG N
effects NNS p
in IN p
patients NNS p
with IN p
tumors NNS p
harboring VBG p
epidermal JJ p
growth NN p
factor NN p
receptor NN p
or CC p
anaplastic JJ p
lymphoma NN p
kinase NN p
genomic JJ p
tumor NN p
aberrations NNS p
. . p

-DOCSTART- -18431478- O O

Does VBZ N
3-day JJ N
course NN N
of IN N
oral JJ i
amoxycillin NN i
benefit NN N
children NNS p
of IN p
non-severe JJ p
pneumonia NN p
with IN p
wheeze NN p
: : p
a DT N
multicentric NN N
randomised VBD N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
WHO-defined JJ N
pneumonias NN N
, , N
treated VBN N
with IN N
antibiotics NNS N
, , N
are VBP N
responsible JJ N
for IN N
a DT N
significant JJ N
proportion NN N
of IN N
childhood NN N
morbidity NN N
and CC N
mortality NN N
in IN N
the DT N
developing NN p
countries NNS p
. . p

Since IN N
substantial JJ N
proportion NN N
pneumonias NNS N
have VBP N
a DT N
viral JJ N
etiology NN N
, , N
where WRB N
children NNS N
are VBP N
more RBR N
likely JJ N
to TO N
present VB N
with IN N
wheeze NN N
, , N
there EX N
is VBZ N
a DT N
concern NN N
that WDT N
currently RB N
antibiotics NNS N
are VBP N
being VBG N
over-prescribed JJ N
for IN N
it PRP N
. . N

Hence VB N
the DT N
current JJ N
trial NN N
was VBD N
conducted VBN N
with IN N
the DT N
objective NN N
to TO N
show VB N
the DT N
therapeutic JJ N
equivalence NN N
of IN N
two CD N
treatments NNS N
( ( i
placebo NN i
and CC N
amoxycillin NN i
) ) i
for IN N
children NNS p
presenting VBG p
with IN p
non-severe JJ p
pneumonia NN p
with IN p
wheeze NN p
, , p
who WP p
have VBP p
persistent VBN p
fast RB p
breathing NN p
after IN p
nebulisation NN p
with IN p
salbutamol NN p
, , p
and CC p
have VBP p
normal JJ p
chest NN p
radiograph NN p
. . p

METHODOLOGY NNP N
This DT N
multi-centric JJ N
, , N
randomised VBD N
placebo NN i
controlled VBN N
double JJ N
blind NN N
clinical JJ N
trial NN N
intended VBN N
to TO N
investigate VB N
equivalent JJ N
efficacy NN N
of IN N
placebo NN i
and CC N
amoxicillin NN i
and CC N
was VBD N
conducted VBN N
in IN N
ambulatory NN N
care NN N
settings NNS N
in IN N
eight CD p
government NN p
hospitals NNS p
in IN p
India NNP p
. . p

Participants NNS p
were VBD p
children NNS p
aged VBN p
2-59 JJ p
months NNS p
of IN p
age NN p
, , N
who WP N
received VBD N
either DT N
oral JJ N
amoxycillin NN i
( ( N
31-54 JJ N
mg/Kg/day NN N
, , N
in IN N
three CD N
divided JJ N
doses NNS N
for IN N
three CD N
days NNS N
) ) N
or CC N
placebo NN N
, , N
and CC N
standard JJ i
bronchodilator NN i
therapy NN i
. . i

Primary JJ N
outcome NN N
was VBD N
clinical JJ o
failure NN o
on IN o
or CC o
before IN o
day- JJ o
4 CD o
. . o

PRINCIPAL JJ N
FINDINGS NNP N
We PRP N
randomized VBD N
836 CD p
cases NNS p
in IN p
placebo NN p
and CC p
835 CD p
in IN p
amoxycillin NN p
group NN p
. . p

Clinical JJ o
failures NNS o
occurred VBD N
in IN N
201 CD N
( ( N
24.0 CD N
% NN N
) ) N
on IN N
placebo NN N
and CC N
166 CD N
( ( N
19.9 CD N
% NN N
) ) N
on IN N
amoxycillin NN i
( ( N
risk NN N
difference NN N
4.2 CD N
% NN N
in IN N
favour NN N
of IN N
antibiotic JJ N
, , N
95 CD N
% NN N
CI NNP N
: : N
0.2 CD N
to TO N
8.1 CD N
) ) N
. . N

Adherence NN o
for IN N
both DT N
placebo NN N
and CC N
amoxycillin NN i
was VBD N
> JJ N
96 CD N
% NN N
and CC N
98.9 CD N
% NN N
subjects NNS N
were VBD N
followed VBN N
up RP N
on IN N
day- JJ N
4 CD N
. . N

Clinical JJ o
failure NN o
was VBD N
associated VBN N
with IN N
( ( N
i NN N
) ) N
placebo NN o
treatment NN o
( ( N
adjusted VBN N
OR NNP N
= $ N
1.28 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.01 CD N
to1.62 NN N
) ) N
, , N
( ( N
ii NN N
) ) N
excess JJ o
respiratory JJ o
rate NN o
of IN o
> $ o
10 CD o
breaths NNS o
per IN o
minute NN o
( ( N
adjusted VBN N
OR NNP N
= $ N
1.51 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.19 CD N
, , N
1.92 CD N
) ) N
, , N
( ( N
iii NN N
) ) N
vomiting VBG o
at IN o
enrolment NN o
( ( N
adjusted VBN N
OR NNP N
= $ N
1.49 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.13 CD N
, , N
1.96 CD N
) ) N
, , N
( ( N
iv NN N
) ) N
history NN o
of IN o
use NN o
of IN o
broncho-dilators NNS o
( ( N
adjusted VBN N
OR NNP N
= $ N
1.71 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.30 CD N
, , N
2.24 CD N
) ) N
and CC N
( ( N
v NN N
) ) N
non-adherence NN o
( ( N
adjusted VBN N
OR NNP N
= $ N
8.06 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
4.36 CD N
, , N
14.92 CD N
) ) N
. . N

CONCLUSIONS NNP N
Treating NNP N
children NNS p
with IN p
non-severe JJ p
pneumonia NN p
and CC p
wheeze NN p
with IN N
a DT N
placebo NN N
is VBZ N
not RB N
equivalent JJ N
to TO N
treatment NN N
with IN N
oral JJ N
amoxycillin NN i
. . i

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
NCT00407394 NNP N
. . N

-DOCSTART- -22906338- O O

Irrigation NN p
with IN p
bupivacaine NN i
at IN p
the DT p
surgical JJ p
bed NN p
for IN p
postoperative JJ o
pain NN o
relief NN o
after IN p
laparoscopic JJ p
cholecystectomy NN p
. . p

PURPOSE VB N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effect NN o
of IN N
bupivacaine NN i
irrigated VBN N
at IN N
the DT N
surgical JJ N
bed NN N
on IN N
postoperative JJ o
pain NN o
relief NN o
in IN N
laparoscopic JJ p
cholecystectomy NN p
patients NNS p
. . p

METHODS NNP N
This DT N
study NN N
included VBD N
60 CD p
patients NNS p
undergoing JJ p
elective JJ p
laparoscopic NN p
cholecystectomy NN p
who WP p
were VBD p
prospectively RB p
randomized VBN p
into IN p
2 CD p
groups NNS p
. . p

The DT N
placebo NN i
group NN N
( ( N
n=30 NN N
) ) N
received VBD N
20cc CD i
saline NN i
without IN i
bupivacaine NN i
, , N
installed VBN N
into IN N
the DT N
gallbladder NN N
bed NN N
. . N

The DT N
bupivacaine NN i
group NN N
( ( N
n=30 NN N
) ) N
received VBD N
20cc CD N
of IN N
0.5 CD i
% NN i
bupivacaine NN i
in IN N
at IN N
the DT N
same JJ N
surgical JJ N
site NN N
. . N

Pain NNP o
was VBD N
assessed VBN N
at IN N
0 CD N
, , N
6 CD N
, , N
12 CD N
, , N
and CC N
24 CD N
hours NNS N
by IN N
using VBG N
a DT N
visual JJ N
analog NN N
scale NN N
( ( N
VAS NNP N
) ) N
. . N

RESULTS VB N
A DT N
significant JJ N
difference NN N
( ( N
P=.018 NNP N
) ) N
was VBD N
observed VBN N
in IN N
pain NN o
levels NNS o
between IN N
both DT N
groups NNS N
at IN N
6 CD N
hours NNS N
postoperatively RB N
. . N

The DT N
average JJ o
analgesic JJ o
requirement NN o
was VBD N
lower JJR N
in IN N
the DT N
bupivacaine NN i
group NN N
, , N
but CC N
this DT N
did VBD N
not RB N
reach VB N
statistical JJ N
significance NN N
. . N

CONCLUSIONS NNP N
In IN N
our PRP$ N
study NN N
, , N
the DT N
use NN N
of IN N
bupivacaine NN i
irrigated VBN N
over IN N
the DT N
surgical JJ N
bed NN N
was VBD N
an DT N
effective JJ N
method NN N
for IN N
reducing VBG N
pain NN o
during IN N
the DT N
first JJ N
postoperative JJ N
hours NNS N
after IN N
laparoscopic JJ N
cholecystectomy NN N
. . N

-DOCSTART- -25453593- O O

A DT N
step-by-step JJ N
introduction NN N
to TO N
vegetables NNS i
at IN N
the DT N
beginning NN N
of IN N
complementary JJ N
feeding NN N
. . N

The DT N
effects NNS N
of IN N
early JJ N
and CC N
repeated JJ N
exposure NN N
. . N

Breastfeeding NNP p
( ( p
BF NNP p
) ) p
is VBZ N
associated VBN N
with IN N
willingness NN N
to TO N
accept VB N
vegetables NNS N
. . N

This DT N
may MD N
be VB N
due JJ N
to TO N
the DT N
variety NN N
of IN N
flavours NNS N
delivered VBN N
via IN N
breast NN N
milk NN N
. . N

Some DT N
mothers NNS p
add VBP N
vegetables NNS N
to TO N
milk VB N
during IN N
complementary JJ N
feeding NN N
( ( N
CF NNP N
) ) N
to TO N
enhance VB N
acceptance NN N
. . N

The DT N
present JJ N
study NN N
tested VBD N
a DT N
step-by-step JJ N
exposure NN N
to TO N
vegetables NNS i
in IN i
milk NN i
then RB i
rice NN i
during IN N
CF NNP N
, , N
on IN N
intake NN N
and CC N
liking NN N
of IN N
vegetables NNS N
. . N

Just NNP N
before IN N
CF NNP N
, , N
enrolled VBD p
mothers NNS p
were VBD p
randomised VBN p
to TO p
an DT p
intervention NN p
( ( p
IG NNP p
, , p
n JJ p
= VBP p
18 CD p
; : p
6 CD p
BF NNP p
) ) p
or CC p
control VB p
group NN p
( ( p
CG NNP p
, , p
n JJ p
= VBP p
18 CD p
; : p
6 CD p
BF NNP p
) ) p
. . p

IG JJ p
infants NNS p
received VBD N
12 CD N
daily JJ N
exposures NNS i
to TO i
vegetable JJ i
puree NN i
added VBD i
to TO i
milk VB i
( ( N
days NNS N
1-12 RB N
) ) N
, , N
then RB N
12 CD N
? . N
2 CD N
daily JJ N
exposures NNS N
to TO N
vegetable JJ i
puree NN i
added VBD i
to TO i
rice VB i
at IN i
home NN i
( ( N
days NNS N
13-24 RB N
) ) N
. . N

Plain NNP i
milk NN i
and CC i
rice NN i
were VBD i
given VBN N
to TO N
CG NNP N
. . N

Then RB N
both DT N
received VBD N
11 CD N
daily JJ N
exposures NNS N
to TO N
vegetable JJ i
puree NN i
. . i

Intake NNP i
was VBD N
weighed VBN N
and CC N
liking VBG N
rated VBN N
on IN N
days NNS N
25-26 JJ N
and CC N
33-35 JJ N
after IN N
the DT N
start NN N
of IN N
CF NNP N
in IN N
the DT N
laboratory NN N
, , N
supplemented VBN N
by IN N
the DT N
same JJ N
data NN N
recorded VBD N
at IN N
home NN N
. . N

Vegetables NNS N
were VBD N
rotated VBN N
daily RB N
( ( N
carrots NNS N
, , N
green JJ N
beans NNS N
, , N
spinach NN N
, , N
broccoli NN o
) ) o
. . o

Intake NNP o
, , o
liking VBG o
and CC o
pace NN o
of IN o
eating VBG o
were VBD o
greater JJR N
for IN N
IG NNP N
than IN N
CG NNP N
infants NNS o
. . o

Intake NNP o
and CC o
liking NN o
of IN o
carrots NNS o
were VBD o
greater JJR N
than IN N
green JJ N
beans NNS N
. . N

However RB N
, , N
at IN N
6m CD N
then RB N
18m CD N
follow VBP N
up RB N
, , N
vegetable JJ N
( ( N
carrot JJ N
> NN N
green JJ N
beans NNS N
) ) N
but CC N
not RB N
group NN N
differences NNS N
were VBD N
observed VBN p
. . p

Mothers NNS p
reported VBD p
appreciation NN N
of IN N
the DT N
structure NN N
and CC N
guidance NN N
of IN N
this DT N
systematic JJ N
approach NN N
. . N

Early JJ N
exposure NN N
to TO N
vegetables NNS i
in IN i
a DT N
step-by-step JJ N
method NN N
could MD N
be VB N
included VBN N
in IN N
CF NNP N
guidelines NNS N
and CC N
longer JJR N
term NN N
benefits NNS N
assessed VBN N
by IN N
extending VBG N
the DT N
exposure NN N
period NN N
. . N

-DOCSTART- -3314599- O O

Continuous JJ i
thoracic JJ i
epidural JJ i
analgesia NN i
for IN N
postoperative JJ o
pain NN o
relief NN o
following VBG p
thoracotomy NN i
: : i
a DT N
randomized JJ N
prospective JJ N
study NN N
. . N

-DOCSTART- -23228924- O O

Myocardial JJ N
extracellular JJ N
volume NN N
by IN N
cardiac JJ N
magnetic JJ N
resonance NN N
imaging NN N
in IN N
patients NNS p
treated VBN p
with IN p
anthracycline-based JJ p
chemotherapy NN p
. . p

We PRP N
aimed VBD N
to TO N
determine VB N
whether IN N
the DT N
myocardial JJ o
extracellular JJ o
volume NN o
( ( o
ECV NNP o
) ) o
, , N
measured VBN N
using VBG N
T1 NNP o
measurements NNS o
obtained VBD N
during IN N
cardiac JJ N
magnetic JJ N
resonance NN N
imaging NN N
were VBD N
increased VBN N
in IN N
patients NNS i
treated VBN i
with IN i
anthracyclines NNS i
. . i

We PRP N
performed VBD N
cardiac JJ i
magnetic JJ i
resonance NN i
imaging NN i
and CC i
echocardiography NN i
and CC i
measured VBD i
the DT i
ECV NNP o
in IN N
42 CD p
patients NNS p
treated VBN p
with IN p
anthracyclines NNS i
. . i

The DT N
data NN N
from IN N
the DT N
cardiac JJ N
magnetic JJ N
resonance NN N
study NN N
were VBD N
compared VBN N
to TO N
those DT N
from IN N
healthy JJ p
volunteers NNS p
. . p

The DT N
anthracycline-treated JJ N
cohort NN N
consisted VBD N
of IN N
21 CD p
men NNS p
and CC p
21 CD p
women NNS p
with IN p
a DT p
mean JJ p
age NN p
of IN p
55 CD p
? . p
17 CD p
years NNS p
, , p
who WP p
presented VBD p
a DT p
median NN p
of IN p
84 CD p
months NNS p
after IN p
chemotherapy NN p
with IN p
a DT p
cumulative JJ p
anthracycline NN p
exposure NN p
of IN p
282 CD p
? . p
65 CD p
mg/m NN p
( ( p
2 CD p
) ) p
and CC p
a DT p
mean NN o
left VBD o
ventricular JJ o
ejection NN o
fraction NN o
of IN o
52 CD p
? . p
12 CD p
% NN p
. . p

The DT p
ECV NNP o
was VBD o
elevated VBN N
in IN N
the DT N
anthracycline-treated JJ N
patients NNS N
compared VBN N
to TO N
the DT N
age- JJ N
and CC N
gender-matched JJ N
controls NNS N
( ( N
0.36 CD N
? . N
0.03 CD N
vs NN N
0.28 CD N
? . N
0.02 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
. . N

A NNP N
positive JJ N
association NN N
was VBD N
found VBN N
between IN o
the DT o
ECV NNP o
and CC N
left VBD N
atrial JJ N
volume NN o
( ( o
ECV NNP o
vs RB o
indexed VBD o
left JJ o
atrial JJ o
volume NN o
, , o
r NN o
= VBD o
0.65 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
negative JJ N
association NN N
was VBD N
found VBN N
between IN N
the DT N
ECV NNP N
and CC o
diastolic JJ o
function NN o
( ( o
E NNP o
' POS o
lateral NN N
, , N
r NN N
= NNP N
-0.64 NNP N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
. . N

In IN N
conclusion NN N
, , N
the DT N
myocardial JJ o
ECV NNP o
is VBZ N
elevated VBN p
in IN p
patients NNS p
with IN p
previous JJ p
anthracycline NN p
treatment NN p
and CC p
is VBZ N
associated VBN N
with IN N
the DT N
diastolic JJ N
function NN N
and CC N
increased VBD N
atrial JJ N
volumes NNS N
. . N

-DOCSTART- -26499867- O O

Do NNP N
cognitive JJ N
measures NNS N
and CC N
brain NN N
circuitry NN N
predict VBP N
outcomes NNS N
of IN N
exercise NN N
in IN N
Parkinson NNP p
Disease NNP p
: : p
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
There EX N
is VBZ N
emerging VBG N
research NN N
detailing VBG N
the DT N
relationship NN N
between IN N
balance/gait/falls NNS N
and CC N
cognition NN N
. . N

Imaging VBG N
studies NNS N
also RB N
suggest VBP N
a DT N
link NN N
between IN N
structural JJ N
and CC N
functional JJ N
changes NNS N
in IN N
the DT N
frontal JJ N
lobe NN N
( ( N
a DT N
region NN N
commonly RB N
associated VBN N
with IN N
cognitive JJ N
function NN N
) ) N
and CC N
mobility NN N
. . N

People NNS p
with IN p
Parkinson NNP p
's POS p
disease NN p
have VBP N
important JJ N
changes NNS N
in IN N
cognitive JJ N
function NN N
that WDT N
may MD N
impact VB N
rehabilitation NN N
efficacy NN N
. . N

Our PRP$ N
underlying JJ N
hypothesis NN N
is VBZ N
that IN N
cognitive JJ N
function NN N
and CC N
frontal JJ N
lobe NN N
connections NNS N
with IN N
the DT N
basal NN N
ganglia NN N
and CC N
brainstem NN N
posture/locomotor NN N
centers NNS N
are VBP N
responsible JJ N
for IN N
postural JJ N
deficits NNS N
in IN N
people NNS p
with IN p
Parkinson NNP p
's POS p
disease NN p
and CC N
play VB N
a DT N
role NN N
in IN N
rehabilitation NN N
efficacy NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
1 CD N
) ) N
determine NN N
if IN N
people NNS p
with IN p
Parkinson NNP p
's POS p
disease NN p
can MD N
improve VB N
mobility NN N
and/or IN N
cognition NN N
after IN N
partaking VBG N
in IN N
a DT N
cognitively RB i
challenging JJ i
mobility NN i
exercise NN i
program NN i
and CC N
2 CD N
) ) N
determine NN N
if IN N
cognition NN N
and CC N
brain NN N
circuitry NN N
deficits NNS N
predict VBP N
responsiveness NN N
to TO N
exercise VB i
rehabilitation NN i
. . i

METHODS/DESIGN NNP N
This DT N
study NN N
is VBZ N
a DT N
randomized JJ N
cross-over NN N
controlled VBN N
intervention NN N
to TO N
take VB N
place NN N
at IN N
a DT N
University NNP p
Balance NNP p
Disorders NNP p
Laboratory NNP p
. . p

The DT N
study NN p
participants NNS p
will MD p
be VB p
people NNS p
with IN p
Parkinson NNP p
's POS p
disease NN p
who WP p
meet VBZ p
inclusion NN p
criteria NNS p
for IN p
the DT p
study NN p
. . p

The DT N
intervention NN N
will MD N
be VB N
6 CD i
weeks NNS i
of IN i
group NN i
exercise NN i
( ( i
case NN i
) ) i
and CC i
6 CD i
weeks NNS i
of IN i
group NN i
education NN i
( ( i
control NN i
) ) i
. . i

The DT N
exercise NN N
is VBZ N
a DT N
cognitively JJ i
challenging VBG i
program NN i
based VBN i
on IN i
the DT i
Agility NNP i
Boot NNP i
Camp NNP i
for IN N
people NNS N
with IN N
PD NNP N
. . N

The DT i
education NN i
program NN i
is VBZ N
a DT N
6-week JJ N
program NN N
to TO N
teach VB i
people NNS i
how WRB i
to TO i
better RBR i
live JJ i
with IN i
a DT i
chronic JJ i
disease NN i
. . i

The DT N
primary JJ N
outcome JJ N
measure NN N
is VBZ N
the DT N
MiniBESTest NNP o
and CC N
the DT N
secondary JJ N
outcomes NNS N
are VBP N
measures NNS N
of IN N
mobility NN o
, , o
cognition NN o
and CC o
neural JJ o
imaging NN o
. . o

DISCUSSION NNP N
The DT N
results NNS N
from IN N
this DT N
study NN N
will MD N
further VB N
our PRP$ N
understanding NN N
of IN N
the DT N
relationship NN N
between IN N
cognition NN N
and CC N
mobility NN N
with IN N
a DT N
focus NN N
on IN N
brain NN N
circuitry NN N
as IN N
it PRP N
relates VBZ N
to TO N
rehabilitation VB N
potential JJ N
. . N

TRIAL NNP N
REGISTRATION NNP N
This DT N
trial NN N
is VBZ N
registered VBN N
at IN N
clinical JJ N
trials.gov NN N
( ( N
NCT02231073 NNP N
) ) N
. . N

-DOCSTART- -16767966- O O

Dexamethasone NNP i
effectively RB N
reduces VBZ N
postoperative JJ N
nausea NN N
and CC N
vomiting NN N
in IN N
a DT N
general JJ p
surgical JJ p
adult NN p
patient JJ p
population NN p
. . p

BACKGROUND NNP N
Postoperative NNP N
nausea NN N
and CC N
vomiting NN N
( ( N
PONV NNP N
) ) N
is VBZ N
still RB N
a DT N
common JJ N
and CC N
major JJ N
complication NN N
for IN N
surgical JJ p
patients NNS p
, , N
which WDT N
may MD N
delay VB N
post-anesthetic JJ N
care NN N
unit NN N
discharge NN N
, , N
prolong JJ N
hospital NN N
stay NN N
and CC N
thus RB N
increase VB N
the DT N
cost NN N
of IN N
hospitalization NN N
. . N

It PRP N
is VBZ N
understood JJ N
that IN N
PONV NNP N
is VBZ N
a DT N
multi-factorial JJ N
outcome NN N
and CC N
occurs VBZ N
more RBR N
often RB N
with IN N
general JJ N
anesthesia NN N
than IN N
with IN N
other JJ N
anesthetic JJ N
methods NNS N
. . N

Prophylactic JJ N
administration NN N
of IN N
antihistamines NNS N
, , N
antidopaminergics NNS N
, , N
anticholinergics NNS N
, , N
phenothiazines NNS N
, , N
serotonin JJ N
antagonist NN N
, , N
steroids NNS N
and CC N
even RB N
acupuncture NN N
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
effective JJ N
. . N

However RB N
, , N
expenses NNS N
and CC N
side JJ N
effects NNS N
of IN N
these DT N
agents NNS N
have VBP N
also RB N
been VBN N
a DT N
concern NN N
for IN N
clinical JJ N
doctors NNS N
. . N

The DT N
aim NN N
for IN N
this DT N
prospective JJ N
study NN N
was VBD N
to TO N
find VB N
an DT N
agent NN N
that WDT N
is VBZ N
cost RBS N
effective JJ N
and CC N
side JJ N
effect NN N
free JJ N
( ( N
or CC N
at IN N
least JJS N
with IN N
a DT N
low JJ N
incidence NN N
of IN N
side JJ N
effects NNS N
) ) N
for IN N
the DT N
prevention NN N
of IN N
PONV NNP N
. . N

METHODS NNP N
A NNP p
total NN p
of IN p
700 CD p
adult NN p
surgical JJ p
patients NNS p
who WP p
planned VBD p
to TO p
have VB p
surgery NN p
under IN p
general JJ p
anesthesia NN p
were VBD N
enrolled VBN N
in IN N
this DT N
double-blinded JJ N
, , N
randomized JJ N
and CC N
placebo-controlled JJ i
study NN N
. . N

Group NNP N
P NNP N
received VBD N
the DT N
placebo NN i
( ( N
0.9 CD N
% NN N
normal JJ i
saline JJ i
2 CD N
ml NN N
) ) N
and CC N
Group NNP N
D NNP N
received VBD N
10 CD N
mg NNS N
dexamethasone RB i
intravenously RB N
right JJ N
before IN N
the DT N
induction NN N
of IN N
anesthesia NN N
. . N

RESULTS NNP N
We PRP N
found VBD N
that IN N
during IN N
the DT N
postoperative JJ N
period NN N
of IN N
1-8 JJ N
h NN N
, , N
patients NNS N
in IN N
Group NNP N
D NNP N
reported VBD N
a DT N
lower JJR N
incidence NN N
of IN N
PONV NNP o
( ( N
24 CD N
% NN N
) ) N
than IN N
those DT N
in IN N
Group NNP N
P NNP N
( ( N
39 CD N
% NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
. . N

Patients NNS N
in IN N
Group NNP N
D NNP N
also RB N
requested VBD N
less JJR N
rescue JJ N
anti-emetic JJ N
( ( N
17 CD N
% NN N
) ) N
than IN N
those DT N
in IN N
Group NNP N
P NNP N
( ( N
30 CD N
% NN N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
same JJ N
phenomenon NN N
was VBD N
also RB N
noted VBN N
in IN N
the DT N
8-to-24-hour JJ N
interval NN N
( ( N
PONV NNP N
4 CD N
% NN N
vs. FW N
12 CD N
% NN N
, , N
p NN N
< VBD N
0.05 CD N
and CC N
rescue VB N
anti-emetic JJ N
3 CD N
% NN N
vs. FW N
9 CD N
% NN N
, , N
p NN N
< VBD N
0.05 CD N
in IN N
Group NNP N
D NNP N
vs. FW N
Group NNP N
P NNP N
, , N
respectively RB N
. . N

) ) N
CONCLUSIONS IN N
We PRP N
conclude VBP N
that IN N
the DT N
prophylactic JJ N
intravenous JJ N
administration NN N
of IN N
10 CD N
mg NNS N
dexamethasone VBP N
immediately RB N
before IN N
the DT N
induction NN N
of IN N
anesthesia NN N
is VBZ N
effective JJ N
in IN N
preventing VBG N
PONV NNP N
in IN N
the DT N
general JJ p
surgical JJ p
adult NN p
patient JJ p
population NN p
. . p

-DOCSTART- -25001365- O O

Neck NNP i
circumference NN i
and CC p
early JJ p
stage NN p
atherosclerosis NN p
: : p
the DT N
cardiometabolic NN N
risk NN N
in IN N
Chinese NNP N
( ( N
CRC NNP N
) ) N
study NN N
. . N

BACKGROUND NNP N
Neck NNP N
circumference NN N
( ( N
NC NNP N
) ) N
has VBZ N
been VBN N
previously RB N
related VBN N
to TO N
cardiometabolic JJ N
risk NN N
factors NNS N
. . N

In IN N
this DT N
study NN N
we PRP N
examined VBD N
the DT N
association NN N
between IN N
NC NNP p
and CC p
early JJ p
stage NN p
atherosclerosis NN p
in IN p
Chinese JJ p
adults NNS p
. . p

METHODS NNP N
The DT N
study NN i
samples NNS i
were VBD i
from IN i
a DT i
community-based JJ i
health NN i
examination NN i
survey NN i
in IN N
central JJ p
China NNP p
. . p

In IN p
total JJ p
2,318 CD p
men NNS p
and CC p
women NNS p
( ( p
18-64 JJ p
y NN p
) ) p
were VBD p
included VBN p
in IN p
the DT p
final JJ p
analyses NNS p
. . p

Carotid NNP o
radial JJ o
pulse NN o
wave NN o
velocity NN o
( ( o
crPWV NN o
) ) o
, , o
carotid JJ o
femoral JJ o
PWV NNP o
( ( o
cfPWV NN o
) ) o
, , o
carotid JJ o
artery NN o
dorsalis NN o
pedis NN o
PWV NNP o
( ( o
cdPWV NN o
) ) o
and CC o
NC NNP o
were VBD i
measured VBN i
. . i

RESULTS NNP N
After IN N
adjustment NN N
for IN N
age NN N
, , N
sex NN N
, , N
lipids NNS N
, , N
glucose NN N
, , N
blood NN N
pressure NN N
, , N
heart NN N
rate NN N
, , N
body NN N
mass NN N
index NN N
( ( N
BMI NNP N
) ) N
, , N
high JJ N
NC NNP N
was VBD N
significantly RB N
associated VBN N
with IN N
an DT N
increasing VBG N
trend NN o
of IN N
cfPWV NN o
, , o
cdPWV NN o
and CC o
crPWV NN o
( ( N
P NNP N
= NNP N
0.001 CD N
, , N
0.049 CD N
, , N
and CC N
0.038 CD N
; : N
respectively RB N
) ) N
. . N

In IN N
addition NN N
, , N
we PRP N
found VBD N
significant JJ N
interaction NN N
between IN N
hypertension NN o
status NN o
and CC o
NC NNP o
level NN o
in IN N
relation NN N
to TO N
cfPWV VB N
, , N
adjusted VBN N
for IN N
age NN N
, , N
sex NN N
, , N
BMI NNP N
, , N
fasting VBG N
glucose NN N
, , N
lipids NNS N
and CC N
heart NN N
rate NN N
( ( N
P NNP N
for IN N
interaction NN N
= NNP N
0.034 CD N
) ) N
. . N

The DT N
associations NNS N
between IN N
NC NNP N
and CC N
cfPWV NN N
were VBD N
significant JJ N
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
among IN N
those DT N
with IN N
hypertension NN N
, , N
but CC N
not RB N
significant JJ N
among IN N
those DT N
without IN N
hypertension NN N
. . N

CONCLUSIONS VB N
Our PRP$ N
data NNS N
showed VBD N
that IN N
high JJ N
NC NNP N
was VBD N
associated VBN N
with IN N
an DT N
increased VBN N
risk NN N
of IN N
early JJ p
stage NN p
atherosclerosis NN p
in IN p
Chinese JJ p
adults NNS p
, , p
independent JJ N
of IN N
other JJ N
metabolic JJ N
risk NN N
factors NNS N
. . N

Hypertension NN N
might MD N
modify VB N
the DT N
association NN N
between IN N
NC NNP N
and CC N
cfPWV NN N
. . N

-DOCSTART- -20932687- O O

Late JJ N
patient-reported JJ N
toxicity NN N
after IN N
preoperative JJ N
radiotherapy NN i
or CC N
chemoradiotherapy NN i
in IN N
nonresectable JJ p
rectal JJ p
cancer NN p
: : p
results NNS N
from IN N
a DT N
randomized JJ N
Phase NNP N
III NNP N
study NN N
. . N

PURPOSE NNP N
Preoperative NNP i
chemoradiotherapy NN i
( ( N
CRT NNP N
) ) N
is VBZ N
superior JJ N
to TO N
radiotherapy VB i
( ( N
RT NNP N
) ) N
in IN N
locally RB p
advanced JJ p
rectal JJ p
cancer NN p
, , N
but CC N
the DT N
survival JJ o
gain NN o
is VBZ N
limited JJ N
. . N

Late JJ N
toxicity NN o
is VBZ N
, , N
therefore RB N
, , N
important JJ N
. . N

The DT N
aim NN N
was VBD N
to TO N
compare VB N
late JJ o
bowel NN o
, , o
urinary JJ o
, , N
and CC N
sexual JJ o
functions NNS o
after IN N
CRT NNP N
or CC N
RT NNP N
. . N

METHODS NNP N
AND CC N
MATERIALS NNP N
Patients NNP p
( ( p
N NNP p
= NNP p
207 CD p
) ) p
with IN p
nonresectable JJ p
rectal JJ p
cancer NN p
were VBD p
randomized VBN p
to TO p
preoperative VB i
CRT NNP i
or CC i
RT NNP i
( ( p
2 CD p
Gy NNP p
? . p
25 CD p
? . p
5-fluorouracil/leucovorin JJ i
) ) i
. . i

Extended VBN N
surgery NN N
was VBD N
often RB N
required VBN o
. . o

Self-reported JJ o
late JJ o
toxicity NN o
was VBD o
scored VBN N
according VBG N
to TO N
the DT o
LENT NNP o
SOMA NNP o
criteria NNS o
in IN o
a DT N
structured JJ o
telephone NN o
interview NN o
and CC o
with IN o
questionnaires NNS o
European JJ o
Organisation NNP o
for IN o
Research NNP o
and CC o
Treatment NNP o
of IN o
Cancer NNP o
( ( o
EORTC NNP o
) ) o
Quality NN o
of IN o
Life NNP o
Questionnaire NNP o
( ( o
QLQ-C30 NNP o
) ) o
, , o
International NNP o
Index NNP o
of IN o
Erectile NNP o
Function NNP o
( ( o
IIEF NNP o
) ) o
, , o
and CC o
sexual JJ o
function-vaginal JJ o
changes NNS o
questionnaire VBP o
( ( o
SVQ NNP o
) ) o
. . o

RESULTS NNP N
Of IN N
the DT p
105 CD p
patients NNS p
alive JJ p
in IN p
Norway NNP p
and CC p
Sweden NNP p
after IN p
4 CD p
to TO p
12 CD p
years NNS p
of IN p
follow-up NN p
, , p
78 CD p
( ( p
74 CD p
% NN p
) ) p
responded VBD p
. . N

More JJR N
patients NNS N
in IN N
the DT N
CRT NNP N
group NN N
had VBD N
received VBN N
a DT N
stoma NN o
( ( o
73 CD N
% NN N
vs. FW N
52 CD N
% NN N
, , N
p NN N
= NNP N
0.09 CD N
) ) N
. . N

Most JJS N
patients NNS N
without IN N
a DT N
stoma NN o
( ( o
7 CD N
of IN N
12 CD N
in IN N
CRT NNP N
group NN N
and CC N
9 CD N
of IN N
16 CD N
in IN N
RT NNP N
group NN N
) ) N
had VBD N
incontinence NN N
for IN o
liquid NN o
stools NNS o
or CC o
gas NN o
. . o

No DT o
stoma NN o
and CC o
good JJ o
anal JJ o
function NN o
were VBD o
seen VBN N
in IN N
5 CD N
patients NNS N
( ( N
11 CD N
% NN N
) ) N
in IN N
the DT N
CRT NNP N
group NN N
and CC N
in IN N
11 CD N
( ( N
30 CD N
% NN N
) ) N
in IN N
the DT N
RT NNP N
group NN N
( ( N
p JJ N
= NNP N
0.046 CD N
) ) N
. . N

Of IN N
44 CD p
patients NNS p
in IN p
the DT p
CRT NNP p
group NN p
, , p
12 CD N
( ( N
28 CD N
% NN N
) ) N
had VBD N
had VBN o
bowel VBN o
obstruction NN o
compared VBN o
with IN N
5 CD N
of IN N
33 CD N
( ( N
15 CD N
% NN N
) ) N
in IN N
the DT N
RT NNP N
group NN N
( ( N
p JJ N
= NNP N
0.27 CD N
) ) N
. . N

One-quarter NN N
of IN N
the DT N
patients NNS N
reported VBD o
urinary JJ o
incontinence NN o
. . o

The DT N
majority NN N
of IN N
men NNS N
had VBD o
severe JJ o
erectile JJ o
dysfunction NN o
. . o

Few JJ N
women NNS N
reported VBD o
sexual JJ o
activity NN o
during IN o
the DT N
previous JJ N
month NN N
. . N

However RB N
, , N
the DT N
majority NN N
did VBD N
not RB N
have VB N
concerns NNS N
about IN N
their PRP$ N
sex NN N
life NN N
. . N

CONCLUSIONS NNP o
Fecal NNP o
incontinence NN o
and CC o
erectile JJ o
dysfunction NN o
are VBP o
frequent JJ N
after IN N
combined JJ N
treatment NN N
for IN p
locally RB p
advanced JJ p
rectal JJ p
cancer NN p
. . p

There EX N
was VBD N
a DT N
clear JJ N
tendency NN N
for IN N
the DT N
problems NNS N
to TO N
be VB N
more JJR N
common JJ N
after IN N
CRT NNP N
than IN N
after IN N
RT NNP N
. . N

-DOCSTART- -8162628- O O

Influence NN N
of IN N
glyceryl NN i
trinitrate NN i
on IN N
venous JJ N
and CC N
arterial JJ N
effects NNS N
of IN N
chronic NN N
, , N
asymmetric JJ N
isosorbide NN i
dinitrate NN i
treatment NN i
in IN N
patients NNS p
with IN p
ischemic JJ p
heart NN p
disease NN p
. . p

Asymmetric JJ N
dosage NN N
regimes NNS N
have VBP N
been VBN N
introduced VBN N
to TO N
circumvent VB N
development NN N
of IN N
nitrate JJ N
tolerance NN N
. . N

This DT N
study NN N
assessed VBD N
invasively RB N
the DT N
hemodynamics NNS N
during IN N
supine JJ N
rest NN N
and CC N
exercise NN N
before RB N
and CC N
after IN N
4 CD N
weeks NNS N
treatment NN N
with IN N
30 CD i
mg NNS i
isosorbide JJ i
dinitrate NN i
( ( i
ISDN NNP i
) ) i
or CC i
placebo VB i
asymmetrically RB N
b.i.d JJ N
. . N

in IN N
14 CD p
randomized JJ p
patients NNS p
with IN p
stable JJ p
ischemic JJ p
heart NN p
disease NN p
in IN N
a DT N
double-blinded JJ N
study NN N
. . N

An DT N
intravenous JJ i
infusion NN i
of IN i
glyceryl NN i
trinitrate NN i
( ( i
GTN NNP i
) ) i
was VBD N
used VBN N
to TO N
assess VB N
possible JJ N
nitrate JJ N
tolerance NN N
. . N

During IN N
the DT N
initial JJ N
, , N
medication-free JJ N
exercise NN N
all DT N
patients NNS N
had VBD N
increased VBN N
pulmonary JJ o
arterial JJ o
wedge NN o
pressure NN o
( ( o
PAWP NNP o
) ) o
31.4 CD N
+/- JJ N
5.56 CD N
mmHg NN N
( ( N
mean JJ N
+/- NNP N
SD NNP N
) ) N
, , N
showing VBG N
impaired JJ N
left VBD N
ventricular JJ N
function NN N
, , N
while IN N
mean JJ o
arterial JJ o
pressures NNS o
( ( o
MAP NNP o
) ) o
rose VBD N
from IN N
112 CD N
+/- JJ N
16.3 CD N
mmHg NN N
at IN N
rest NN N
to TO N
141 CD N
+/- JJ N
15.9 CD N
mmHg NN N
during IN N
exercise NN N
. . N

After IN N
4 CD N
weeks NNS N
ISDN NNP i
treatment NN N
, , N
mean JJ o
exercise NN o
PAWP NNP o
and CC o
MAP NNP o
, , N
3 CD N
h NN N
after IN N
morning NN N
dose NN N
, , N
were VBD N
reduced VBN N
to TO N
22.4 CD N
+/- JJ N
7.09 CD N
mmHg NN N
and CC N
127 CD N
+/- JJ N
18.2 CD N
mmHg NN N
, , N
respectively RB N
. . N

Before IN N
the DT N
ISDN NNP i
treatment NN i
, , i
GTN NNP i
reduced VBD N
exercise NN N
PAWP NNP o
to TO N
13.9 CD N
+/- JJ N
5.27 CD N
mmHg NN N
and CC N
MAP NNP N
to TO N
119 CD N
+/- JJ N
11.2 CD N
mmHg NN N
, , N
whereas NNS N
after IN N
4 CD N
weeks NNS N
ISDN NNP i
treatment NN N
, , N
the DT N
addition NN N
of IN N
GTN NNP N
did VBD N
not RB N
reduce VB N
exercise NN N
PAWP NNP o
and CC o
MAP NNP o
to TO N
the DT N
same JJ N
low JJ N
levels NNS N
. . N

Thus RB N
, , N
the DT N
applied JJ N
ISDN NNP i
regimen NNS N
improved VBD N
the DT N
hemodynamics NNS N
, , N
but CC N
induced VBD N
a DT N
definite NN N
, , N
partial JJ N
nitrate NN N
tolerance NN N
. . N

-DOCSTART- -12599844- O O

[ VB N
The DT N
effect NN N
of IN N
losartan JJ i
versus NN i
atenolol NN i
on IN N
cardiovascular JJ o
morbidity NN o
and CC o
mortality NN o
in IN N
patients NNS p
with IN p
diabetes NNS p
mellitus NNS p
in IN p
the DT p
LIFE-study NNP p
] NNP p
. . N

INTRODUCTION NNP N
The DT N
most RBS N
suitable JJ N
antihypertensive JJ N
drug NN N
to TO N
reduce VB N
the DT N
risk NN N
of IN N
cardiovascular JJ N
disease NN N
in IN N
patients NNS p
with IN p
hypertension NN p
and CC p
diabetes VBZ p
is VBZ N
unclear JJ N
. . N

In IN N
a DT N
prespecified JJ N
analysis NN N
of IN N
the DT N
LIFE-study NNP N
we PRP N
compared VBN N
the DT N
effects NNS N
of IN N
losartan NN i
and CC i
atenolol NN i
on IN N
cardiovascular JJ o
morbidity NN o
and CC o
mortality NN o
in IN N
diabetic JJ p
patients NNS p
. . p

MATERIAL NNP N
AND NNP N
METHODS NNP N
A NNP p
total NN p
of IN p
1195 CD p
patients NNS p
in IN p
the DT p
LIFE-study NNP p
had VBD p
diabetes NNS p
at IN N
the DT N
time NN N
of IN N
the DT N
randomisation NN N
. . N

The DT N
patients NNS N
were VBD N
randomised VBN N
for IN N
double-blind JJ N
treatment NN N
with IN N
losartan JJ i
versus NN i
atenolol NN i
. . i

The DT N
patients NNS p
had VBD p
ECG-verified JJ p
left JJ p
ventricular NN p
hypertrophy NN p
, , p
mean JJ p
age NN p
67 CD p
years NNS p
, , p
blood NN p
pressure NN p
177/96 CD p
mmHg NN p
after IN p
two CD p
weeks NNS p
placebo JJ i
run-in JJ p
period NN p
. . p

Patients NNS p
were VBD p
followed VBN p
for IN p
at IN p
least JJS p
four CD p
years NNS p
( ( p
mean JJ p
4.7 CD p
years NNS p
) ) p
. . p

The DT N
primary JJ N
composite JJ N
endpoint NN N
was VBD N
cardiovascular JJ o
death NN o
, , o
stroke VBD o
or CC o
myocardial JJ o
infarction NN o
. . o

RESULTS NNP N
Blood NNP o
pressure NN o
was VBD N
reduced VBN N
to TO N
146/79 CD N
and CC N
148/79 CD N
in IN N
losartan-treated JJ i
patients NNS N
and CC N
atenolol-treated JJ i
patients NNS N
, , N
respectively RB N
. . N

The DT N
primary JJ N
endpoint NN N
occurred VBD N
in IN N
103 CD N
patients NNS N
assigned VBN N
losartan JJ i
( ( N
n JJ N
= NNP N
586 CD N
) ) N
and CC N
139 CD N
assigned VBN N
atenolol NN i
( ( N
n JJ N
= NNP N
609 CD N
) ) N
. . N

Relative JJ o
risk NN o
reduction NN o
24 CD N
% NN N
( ( N
p JJ N
< NNP N
0.031 CD N
) ) N
. . N

Cardiovascular JJ o
mortality NN o
was VBD N
reduced VBN N
by IN N
37 CD N
% NN N
in IN N
favour NN N
of IN N
losartan NN i
( ( N
p JJ N
< NNP N
0.028 CD N
) ) N
, , N
and CC N
all DT N
cause NN N
mortality NN o
by IN N
39 CD N
% NN N
( ( N
p JJ N
< NNP N
0.002 CD N
) ) N
. . N

DISCUSSION NNP N
Losartan NNP i
was VBD N
very RB N
effective JJ N
in IN N
reducing VBG N
cardiovascular JJ o
morbidity NN o
and CC o
mortality NN o
as RB N
compared VBN N
to TO N
atenolol VB i
. . i

These DT N
results NNS N
will MD N
have VB N
a DT N
major JJ N
impact NN N
on IN N
the DT N
choice NN N
of IN N
anti-hypertensive JJ N
treatment NN N
for IN N
patients NNS p
with IN p
hypertension NN p
and CC p
diabetes NNS p
. . p

-DOCSTART- -14714361- O O

[ JJ N
Clinical NNP N
observation NN N
on IN N
effect NN o
of IN N
fuzheng NN i
yiliu NN i
granule NN i
on IN N
cell NN N
cycle NN N
and CC N
nuclear JJ N
transcription NN N
factor-kappa NN N
B NNP N
in IN N
tissue NN N
of IN N
esophageal-gastric JJ N
carcinoma NN N
] NNP N
. . N

OBJECTIVE NNP N
To TO N
observe VB N
the DT N
effect NN o
of IN N
Fuzheng NNP i
Yiliu NNP i
Granule NNP i
( ( i
FZYLG NNP i
) ) i
on IN N
cell NN N
cycle NN N
and CC N
nuclear JJ N
transcription NN N
factor-kappa NN N
B NNP N
( ( N
NF-kappa NNP N
B NNP N
) ) N
in IN N
tissue NN N
of IN N
esophageal-gastric JJ N
carcinoma NN N
. . N

METHODS NNP N
Seventy-six JJ p
patients NNS p
with IN p
esophageal JJ p
gastric JJ p
carcinoma NN p
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
, , N
the DT N
FZYLG NNP i
group NN p
and CC N
the DT N
control NN i
group NN i
. . i

FZYLG NNP i
was VBD N
given VBN N
to TO N
the DT N
former JJ N
for IN N
15 CD N
days NNS N
. . N

The DT N
tumor NN N
tissue NN N
in IN N
both DT N
groups NNS N
was VBD N
resected VBN N
and CC N
cell JJ o
cycle NN o
and CC N
apoptosis NN o
rate NN o
as RB N
well RB N
as IN N
NF-kappa NNP N
B NNP N
were VBD N
determined VBN N
by IN N
flowcytometry NN N
. . N

RESULTS NNP N
Level NNP o
of IN o
NF-kappa NNP o
B NNP o
in IN N
the DT N
treated JJ N
group NN N
was VBD N
significantly RB N
higher JJR N
than IN N
that DT N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

In IN N
the DT N
treated JJ N
group NN N
, , N
the DT N
percentage NN o
of IN o
G0/G1 NNP o
stage NN o
cells NNS o
were VBD N
significantly RB N
increased VBN N
and CC N
that IN N
of IN N
S NNP o
stage NN o
significantly RB N
decreased VBN N
( ( N
both DT N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

At IN N
the DT N
same JJ N
time NN N
, , N
obvious JJ N
cell NN o
apoptosis NN o
was VBD N
found VBN N
in IN N
the DT N
treated JJ N
group NN N
, , N
the DT N
apoptosis NN o
rate NN o
of IN N
which WDT N
was VBD N
significantly RB N
higher JJR N
than IN N
that DT N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSION NNP N
FZYLG NNP i
can MD N
increase VB N
the DT N
NF-kappa NNP N
B NNP N
expression NN N
, , N
block VB N
the DT N
proliferation NN N
to TO N
promote VB N
the DT N
apoptosis NN o
of IN N
tumor NN N
cells NNS N
. . N

-DOCSTART- -22419350- O O

Most RBS N
effective JJ o
regimen NNS o
of IN o
tranexamic JJ o
acid NN o
in IN N
knee NN p
arthroplasty NN p
: : p
a DT N
prospective JJ N
randomized NN N
controlled VBD N
study NN N
in IN N
240 CD p
patients NNS p
. . p

BACKGROUND NNP N
The DT N
antifibrinolytic JJ i
tranexamic JJ i
acid NN i
reduces NNS N
surgical JJ N
blood NN N
loss NN N
, , N
but CC N
studies NNS N
have VBP N
not RB N
identified VBN N
an DT N
optimal JJ N
regimen NNS N
. . N

QUESTIONS/PURPOSES NNP N
We PRP N
studied VBD N
different JJ N
dosages NNS N
, , N
timings NNS N
, , N
and CC N
modes NNS N
of IN N
administration NN N
to TO N
identify VB N
the DT N
most RBS N
effective JJ N
regimen NNS N
of IN N
tranexamic JJ i
acid NN i
in IN N
achieving VBG N
maximum JJ N
reduction NN N
of IN N
blood NN N
loss NN N
in IN N
TKA NNP N
. . N

METHODS NNP N
We PRP N
prospectively RB N
studied VBD N
five CD p
regimens NNS p
( ( p
four CD p
intravenous NN i
, , p
one CD p
local JJ i
; : i
40 CD p
patients NNS p
each DT p
) ) p
with IN p
a DT p
control NN p
group NN p
( ( N
no DT N
tranexamic JJ i
acid NN i
) ) i
. . N

The DT N
four CD N
intravenous JJ i
( ( N
10-mg/kg JJ N
dose NN N
) ) N
regimens VBZ N
included VBN N
( ( N
1 CD N
) ) N
intraoperative NN i
dose NN i
( ( i
IO NNP i
) ) i
given VBN i
before IN i
tourniquet JJ i
deflation NN i
, , i
( ( i
2 CD i
) ) i
additional JJ i
preoperative NN i
dose NN i
( ( i
POIO NNP i
) ) i
, , i
( ( i
3 CD i
) ) i
additional JJ i
postoperative NN i
dose NN i
( ( i
IOPO NNP i
) ) i
, , i
and CC i
( ( i
4 CD i
) ) i
all DT i
three CD i
doses NNS i
( ( i
POIOPO NNP i
) ) i
. . N

The DT N
fifth JJ N
regimen NN N
was VBD N
a DT N
single JJ N
local JJ i
application NN i
( ( N
LA NNP N
) ) N
. . N

Two CD N
independent JJ N
parameters NNS N
of IN N
drain NN o
loss NN o
and CC o
total JJ o
blood NN o
loss NN o
, , o
calculated VBN o
by IN o
the DT o
hemoglobin NN o
balance NN o
method NN o
, , N
were VBD N
evaluated VBN N
statistically RB N
. . N

RESULTS NNP N
Both NNP N
parameters NNS N
were VBD N
reduced VBN N
in IN N
all DT N
five CD N
regimens NNS N
as IN N
against IN N
the DT N
control NN N
. . N

A DT N
significant JJ N
reduction NN N
in IN N
drain NN o
loss NN o
was VBD N
seen VBN N
in IN N
the DT N
POIO NNP N
, , N
IOPO NNP N
, , N
and CC N
POIOPO NNP N
groups NNS N
whereas VBP N
total JJ N
blood NN o
loss NN o
was VBD N
significantly RB N
reduced VBN N
in IN N
the DT N
POIO NNP N
, , N
POIOPO NNP N
, , N
and CC N
LA NNP N
groups NNS N
. . N

The DT N
POIOPO NNP N
group NN N
had VBD N
the DT N
least JJS N
drain JJ o
loss NN o
( ( N
303 CD N
mL NN N
) ) N
and CC N
least JJS N
total JJ N
blood NN o
loss NN o
( ( N
688 CD N
mL NN N
) ) N
. . N

The DT N
IO NNP N
group NN N
had VBD N
the DT N
greatest JJS N
drain NN o
loss NN o
and CC N
the DT N
IOPO NNP N
group NN N
the DT N
greatest JJS N
total JJ o
blood NN o
loss NN o
. . o

CONCLUSIONS NNP N
Single-dose JJ N
tranexamic JJ i
acid NN i
did VBD N
not RB N
give VB N
effective JJ N
results NNS N
. . N

The DT N
two-dose JJ N
regimen NNS N
of IN N
POIO NNP N
was VBD N
the DT N
least JJS N
amount NN N
necessary JJ N
for IN N
effective JJ N
results NNS N
. . N

When WRB N
compared VBN N
against IN N
the DT N
control NN N
, , N
this DT N
regimen NNS N
produced VBD N
reduction NN o
of IN o
drain NN o
loss NN o
and CC o
total JJ o
blood NN o
loss NN o
, , N
whereas IN N
the DT N
IOPO NNP N
regimen NNS N
did VBD N
not RB N
. . N

The DT N
three-dose JJ N
regimen NNS N
of IN N
POIOPO NNP N
produced VBD N
maximum JJ N
effective JJ N
reduction NN N
of IN N
drain NN o
loss NN o
and CC o
total JJ o
blood NN o
loss NN o
. . o

-DOCSTART- -2831788- O O

Combined VBN N
action NN N
of IN N
enalapril NN i
or CC N
timolol NN i
with IN N
hydrochlorothiazide JJ i
plus CC i
amiloride JJ i
in IN N
hypertension NN p
. . p

59 CD p
mild NN p
to TO p
moderate VB p
hypertensives NNS p
were VBD N
treated VBN N
for IN N
four CD N
weeks NNS N
with IN N
50 CD N
mg NNS N
hydrochlorothiazide JJ i
plus CC N
5 CD N
mg NN N
of IN N
amiloride NN i
, , N
then RB N
concomitantly RB N
with IN N
these DT N
diuretics NNS N
with IN N
either DT N
enalapril NN i
( ( N
10-20 JJ N
mg NN N
) ) N
or CC N
timolol JJ i
( ( N
10-20 JJ N
mg NN N
) ) N
in IN N
two CD N
parallel JJ N
treatment NN N
groups NNS N
for IN N
an DT N
additional JJ N
12 CD N
weeks NNS N
in IN N
an DT N
open JJ N
study NN N
. . N

Addition NN N
of IN N
these DT N
drugs NNS N
lowered VBD N
the DT N
blood NN o
pressure NN o
by IN N
25 CD N
+/- JJ N
3/16 CD N
+/- JJ N
2 CD N
mm NN N
Hg NNP N
and CC N
15 CD N
+/- JJ N
3/14 CD N
+/- JJ N
1 CD N
mm NN N
Hg NNP N
, , N
respectively RB N
. . N

The DT N
difference NN N
of IN N
the DT N
reduction NN N
of IN N
the DT N
systolic JJ o
blood NN o
pressure NN o
between IN N
enalapril NN N
and CC N
timolol NN N
group NN N
at IN N
the DT N
end NN N
of IN N
the DT N
combined JJ N
treatment NN N
was VBD N
statistically RB N
significant JJ N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

The DT N
mean JJ o
serum NN o
potassium NN o
was VBD N
elevated VBN N
by IN N
0.3 CD N
mmol/l NNS N
after IN N
addition NN N
of IN N
enalapril NN N
to TO N
the DT N
diuretic JJ N
treatment NN N
, , N
but CC N
none NN N
of IN N
the DT N
patients NNS N
developed VBD N
hyperkalaemia NN o
. . o

No DT N
adverse JJ o
effects NNS o
on IN N
other JJ N
routine JJ N
laboratory NN N
values NNS N
were VBD N
observed VBN N
. . N

Both DT N
drug NN N
combinations NNS N
can MD N
be VB N
considered VBN N
efficient JJ N
, , N
well RB N
tolerated VBN o
and CC o
safe JJ o
in IN N
the DT N
treatment NN N
of IN N
mild NN N
to TO N
moderate VB N
hypertension NN N
. . N

-DOCSTART- -21260940- O O

[ JJ N
Intravesical NNP N
electrostimulation NN N
and CC N
magnetophoresis NN N
in IN N
overactive JJ p
bladder NN p
in IN p
females NNS p
: : p
efficacy NN N
of IN N
Amus-01-Intramag NNP N
device NN N
with IN N
Intrastim NNP N
attachment NN N
] NN N
. . N

High-frequency NNP i
intravesical JJ i
electroneurostimulation NN i
was VBD i
made VBN i
simultaneously RB i
with IN i
magnetophoresis NN i
of IN i
the DT i
mixture NN i
based VBN i
on IN i
oxibutinin NN i
. . i

Compared VBN N
to TO N
effects NNS N
of IN N
oral JJ N
intake NN N
of IN N
oxibutinin NN i
, , N
such JJ N
method NN N
was VBD N
two CD N
times NNS N
more RBR N
effective JJ N
in IN N
relation NN N
to TO N
overactive JJ o
bladder NN o
symptoms NNS o
relief NN o
in IN N
shorter JJR N
duration NN N
of IN N
the DT N
treatment NN N
and CC N
reduced JJ o
side NN o
effects NNS o
. . o

Laser NNP N
Doppler NNP N
flowmetry NN N
discovered VBD N
that IN N
the DT N
above NN N
combined VBD N
treatment NN N
corrects NNS N
microcirculation NN N
in IN N
bladder NN N
mucosa NN N
. . N

-DOCSTART- -15013543- O O

The DT N
influence NN N
of IN N
pre- NN i
and CC i
intraoperative JJ i
positioning NN i
of IN i
the DT i
condyle NN i
in IN N
the DT N
centre NN N
of IN N
the DT N
articular JJ N
fossa NN N
on IN N
the DT N
position NN N
of IN N
the DT N
disc NN N
in IN N
orthognathic JJ i
surgery NN i
. . i

A NNP N
magnetic JJ N
resonance NN N
study NN N
. . N

OBJECTIVE IN N
We PRP N
investigated VBD N
the DT N
changes NNS N
in IN N
the DT N
temporomandibular JJ p
joint NN p
( ( p
TMJ NNP p
) ) p
after IN p
bilateral JJ i
sagittal JJ i
split NN i
osteotomy NN i
of IN i
the DT i
mandible JJ i
for IN p
orthognathic JJ p
surgery NN p
and CC N
the DT N
influence NN N
of IN N
positioning NN i
of IN i
the DT i
condylar JJ i
process NN i
in IN N
the DT N
centre NN N
of IN N
the DT N
articular JJ N
fossa NN N
before IN N
and CC N
during IN N
the DT N
operation NN N
for IN N
preventing VBG N
changes NNS N
in IN N
the DT N
TMJ NNP N
postoperatively RB N
. . N

STUDY NNP N
DESIGN NNP N
A NNP p
total NN p
of IN p
28 CD p
patients NNS p
with IN p
mandibular JJ p
retrognathism NN p
had VBD p
bilateral JJ i
sagittal JJ i
split NN i
osteotomies NNS i
for IN i
mandibular JJ i
advancement NN i
. . i

In IN N
one CD N
group NN N
of IN N
14 CD p
patients NNS p
( ( p
28 CD p
TMJ NNP p
) ) p
, , N
the DT N
condyles NNS i
were VBD i
placed VBN i
in IN i
the DT i
centre NN i
of IN i
the DT i
articular JJ i
fossa NN i
before IN i
and CC i
during IN i
the DT i
operation NN i
, , i
and CC i
in IN i
the DT i
other JJ i
group NN i
they PRP i
were VBD i
not RB i
. . i

Differences NNS o
on IN o
magnetic JJ o
resonance NN o
imaging NN o
( ( o
MRI NNP o
) ) o
were VBD N
calculated VBN N
and CC N
the DT N
results NNS N
were VBD N
evaluated VBN N
. . N

RESULTS VB N
The DT N
main JJ N
differences NNS N
were VBD N
found VBN N
at IN N
maximal JJ o
mouth NN o
opening NN o
. . o

15/28 CD p
TMJs NNP p
( ( p
54 CD p
% NN p
) ) p
that WDT p
had VBD p
not RB p
been VBN p
positioned VBN p
changed VBD p
the DT N
position NN N
of IN N
the DT N
disc NN N
from IN N
physiological JJ N
to TO N
anterior VB N
disc JJ N
derangement NN N
with IN N
and CC N
without IN N
reduction NN N
postoperatively RB N
. . N

In IN N
the DT N
28 CD p
that WDT p
had VBD p
been VBN p
positioned VBN p
, , p
changes NNS p
were VBD p
found VBN p
in IN p
only RB p
3 CD p
TMJs NNP o
( ( p
11 CD p
% NN p
) ) p
postoperatively RB p
. . p

CONCLUSIONS NNP N
Fixing VBG i
the DT i
condylar JJ i
process NN i
in IN i
the DT i
centre NN i
of IN i
the DT i
articular JJ i
fossa NN i
intraoperatively RB i
before IN N
bilateral JJ N
sagittal JJ N
split NN N
osteotomy NN N
is VBZ N
a DT N
factor NN N
in IN N
preventing VBG N
postoperative JJ N
structural JJ N
changes NNS N
in IN N
the DT N
temporomandibular JJ N
joint NN N
. . N

-DOCSTART- -16202291- O O

[ NN N
Study NNP N
on IN N
classification NN N
and CC N
treatment NN N
of IN N
vulvovaginal JJ p
candidiasis NN p
] NN p
. . N

OBJECTIVE UH N
To TO N
determine VB N
the DT N
clinical JJ N
manifestations NNS N
of IN N
vulvovaginal JJ p
candidiasis NN p
( ( p
VVC NNP p
) ) p
and CC N
to TO N
study VB N
the DT N
mycologic JJ o
eradication NN o
rate NN o
of IN N
different JJ N
miconazole JJ i
treatment NN N
courses NNS N
for IN N
VVC NNP N
. . N

METHODS NNP N
Three CD p
hundred VBD p
cases NNS p
of IN p
VVC NNP p
were VBD p
recruited VBN p
. . p

The DT N
Candidas NNPS N
were VBD N
cultured VBN N
. . N

A DT N
prospective JJ N
and CC N
randomized VBD N
study NN N
was VBD N
performed VBN N
to TO N
compare VB N
the DT N
treatment NN N
effect NN N
of IN N
3 CD i
day NN i
miconazole NN i
( ( N
400 CD N
mg/d NN N
) ) N
, , N
6 CD i
day NN i
miconazole NN i
( ( N
400 CD N
mg/d NN N
) ) N
, , N
and CC N
7 CD i
day NN i
miconazole NN i
( ( N
200 CD N
mg/d NN N
) ) N
for IN N
uncomplicated JJ N
and CC N
complicated VBD N
VVC NNP N
. . N

RESULTS NNP N
Among IN N
300 CD p
cases NNS p
of IN p
VVC NNP p
, , N
uncomplicated VBD N
, , N
complicated VBN N
and CC N
recurrent JJ N
VVC NNP N
were VBD N
56.0 CD N
% NN N
, , N
44.0 CD N
% NN N
and CC N
9.7 CD N
% NN N
( ( N
29/300 CD N
) ) N
respectively RB N
. . N

C. NNP N
albicans NNS N
was VBD N
isolated VBN N
most JJS N
frequently RB N
90.3 CD N
% NN N
( ( N
271/300 CD N
) ) N
, , N
followed VBN N
by IN N
C. NNP N
glabrata NN N
( ( N
7.3 CD N
% NN N
) ) N
, , N
C. NNP N
tropicalis NN N
( ( N
1.3 CD N
% NN N
) ) N
, , N
C. NNP N
krusei NNP N
( ( N
0.7 CD N
% NN N
) ) N
, , N
and CC N
C. NNP N
parapsilosis NN N
( ( N
0.3 CD N
% NN N
) ) N
. . N

Mycologic JJ o
eradication NN o
rate NN o
of IN N
3 CD N
day NN N
, , N
6 CD N
day NN N
and CC N
7 CD N
day NN N
miconazole NN i
courses NNS N
for IN N
uncomplicated JJ N
VVC NNP N
at IN N
day NN N
14 CD N
was VBD N
96.0 CD N
% NN N
, , N
93.5 CD N
% NN N
and CC N
98.0 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

Eradication NNP o
rate NN o
of IN N
3 CD N
day NN N
, , N
6 CD N
day NN N
and CC N
7 CD N
day NN N
miconazole NN i
courses NNS N
for IN N
complicated VBN N
VVC NNP N
at IN N
day NN N
14 CD N
was VBD N
86.7 CD N
% NN N
, , N
92.5 CD N
% NN N
, , N
and CC N
86.4 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

Eradication NNP o
rate NN o
of IN N
3 CD N
day NN N
, , N
6 CD N
day NN N
and CC N
7 CD N
day NN N
miconazole NN i
courses NNS N
for IN N
uncomplicated JJ N
VVC NNP N
at IN N
day NN N
35 CD N
was VBD N
93.8 CD N
% NN N
, , N
95.3 CD N
% NN N
, , N
and CC N
89.8 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

Eradication NNP o
rate NN o
of IN N
3 CD N
day NN N
, , N
6 CD N
day NN N
and CC N
7 CD N
day NN N
miconazole NN i
courses NNS N
for IN N
complicated VBN N
VVC NNP N
at IN N
day NN N
35 CD N
was VBD N
89.7 CD N
% NN N
, , N
97.3 CD N
% NN N
and CC N
86.8 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
Treatment NNP N
of IN N
VVC NNP N
should MD N
be VB N
individualized VBN N
, , N
and CC N
women NNS p
with IN p
complicated JJ p
VVC NNP p
achieve VBP N
superior JJ N
mycologic JJ o
eradication NN o
by IN N
a DT N
6 CD N
day NN N
miconazole JJ i
course NN N
. . N

-DOCSTART- -8141223- O O

Maternal NNP o
erythropoietin NN o
in IN p
singleton NN p
pregnancies NNS p
: : p
a DT N
randomized JJ N
trial NN N
on IN N
the DT N
effect NN N
of IN N
oral JJ N
hematinic JJ N
supplementation NN i
. . i

OBJECTIVE CC N
Our PRP$ N
purpose NN N
was VBD N
to TO N
study VB N
the DT N
effect NN N
of IN N
hematinic JJ N
supplementation NN N
on IN N
the DT N
maternal JJ o
erythropoietin NN o
response NN o
during IN N
singleton JJ N
pregnancy NN N
. . N

STUDY NNP N
DESIGN NNP N
In IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
trial NN N
97 CD p
patients NNS p
with IN p
a DT p
first-trimester JJ p
hemoglobin NN p
level NN p
> NN p
or CC p
= $ p
14.0 CD p
gm/dl NN p
received VBD N
either CC N
iron NN i
and CC i
folic JJ i
acid NN i
( ( p
hematinic JJ p
group NN p
, , p
n RB p
= VBZ p
53 CD p
) ) p
or CC p
a DT p
placebo NN i
( ( p
n JJ p
= NNP p
44 CD p
) ) p
. . p

Serial JJ o
hemoglobin NN o
, , o
hematocrit NN o
, , o
and CC o
serum NN o
erythropoietin NN o
were VBD N
recorded VBN N
from IN N
maternal JJ N
blood NN N
and CC N
from IN N
cord NN N
blood NN N
on IN N
delivery NN N
. . N

Serum NNP o
ferritin NN o
was VBD N
measured VBN N
in IN N
the DT N
first JJ N
trimester NN N
, , N
at IN N
36 CD N
weeks NNS N
' POS N
gestation NN N
, , N
and CC N
in IN N
cord NN N
blood NN N
. . N

RESULTS NN N
In IN N
both DT N
groups NNS N
( ( N
1 CD N
) ) N
the DT N
mean JJ o
hemoglobin NN o
was VBD N
lower JJR N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
at IN N
40 CD N
weeks NNS N
' POS N
gestation NN N
than IN N
when WRB N
first JJ N
examined VBN N
and CC N
( ( N
2 CD N
) ) N
the DT N
mean JJ N
serum NN N
erythropoietin NN N
was VBD N
higher JJR N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
mean JJ o
serum NN o
ferritin NN o
was VBD N
lower JJR N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
in IN N
both DT N
groups NNS N
at IN N
36 CD N
weeks NNS N
' POS N
gestation NN N
than IN N
at IN N
presentation NN N
but CC N
higher JJR N
( ( N
p JJ N
= NNP N
0.04 CD N
) ) N
in IN N
the DT N
hematinic NN N
group NN N
than IN N
in IN N
the DT N
placebo NN N
group NN N
. . N

The DT N
mean JJ o
hemoglobin NN o
and CC o
hematocrit NN o
were VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
until IN N
the DT N
third JJ N
trimester NN N
but CC N
thereafter RB N
were VBD N
higher JJR N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
in IN N
the DT N
hematinic JJ N
group NN N
. . N

The DT N
mean JJ o
maternal JJ o
serum NN o
erythropoietin NN o
was VBD N
higher JJR N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
in IN N
the DT N
placebo NN N
group NN N
than IN N
in IN N
the DT N
hematinic JJ N
group NN N
after IN N
24 CD N
weeks NNS N
' POS N
gestation NN N
. . N

The DT N
mean JJ o
cord NN o
blood NN o
hematologic NN o
values NNS o
were VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
. . N

CONCLUSION NNP N
Maternal NNP o
serum NN o
erythropoietin NN o
increased VBD N
during IN N
pregnancy NN N
, , N
but CC N
this DT N
response NN N
was VBD N
reduced VBN N
in IN N
the DT N
third JJ N
trimester NN N
in IN N
the DT N
hematinic-supplemented JJ N
group NN N
. . N

-DOCSTART- -11683967- O O

Equivalent JJ N
efficacy NN o
of IN o
mitomycin NN o
C NNP o
plus CC o
doxorubicin JJ o
instillation NN N
to TO N
bacillus VB N
Calmette-Guerin NNP N
therapy NN N
for IN N
carcinoma NN p
in IN p
situ NN p
of IN p
the DT p
bladder NN p
. . p

BACKGROUND NNP N
To TO N
elucidate VB N
the DT N
most RBS N
efficient JJ N
topical JJ N
therapy NN N
for IN N
carcinoma NN N
in IN N
situ NN N
of IN N
the DT N
bladder NN N
, , N
the DT N
efficacy NN N
of IN N
intravesical JJ N
mitomycin NN N
C NNP N
plus CC N
doxorubicin JJ N
therapy NN N
was VBD N
compared VBN N
with IN N
bacillus JJ N
Calmette-Guerin NNP N
( ( N
BCG NNP N
) ) N
therapy NN N
. . N

The DT N
clinical JJ N
behavior NN N
of IN N
the DT N
tumor NN N
was VBD N
analysed VBN N
according VBG N
to TO N
the DT N
histological JJ N
grade NN N
. . N

METHODS NNP N
Forty-two JJ p
patients NNS p
with IN p
carcinoma NN p
in IN p
situ NN p
of IN p
the DT p
bladder NN p
were VBD N
randomized VBN N
to TO N
intravesical JJ i
BCG NNP i
( ( N
21 CD N
patients NNS N
) ) N
or CC N
mitomycin JJ i
C NNP i
plus CC i
doxorubicin JJ i
sequential JJ i
therapy NN i
( ( N
21 CD N
patients NNS N
) ) N
as IN N
first JJ N
line NN N
treatment NN N
. . N

The DT N
non-responders JJ N
underwent NN N
the DT N
subsequent JJ N
instillation NN N
of IN N
the DT N
other JJ N
intravesical JJ N
therapy NN N
alternately RB N
. . N

Of IN p
the DT p
patients NNS p
, , p
27 CD p
had VBD p
grade VBN p
2 CD p
and CC p
15 CD p
had VBD p
grade VBN p
3 CD p
cancer NN p
. . p

RESULTS NNP N
Both NNP N
topical JJ N
therapies NNS N
were VBD N
equally RB N
effective JJ N
with IN N
initial JJ N
response NN o
rates NNS o
of IN N
86 CD N
% NN N
( ( N
18/21 CD N
) ) N
for IN N
BCG NNP N
and CC N
81 CD N
% NN N
( ( N
17/21 CD N
) ) N
for IN N
mitomycin NN N
C NNP N
plus CC N
doxorubicin NN N
, , N
irrespective NN N
of IN N
the DT N
tumor NN N
grade NN N
. . N

Of IN N
seven CD N
initial JJ N
non-responders NNS N
, , N
five CD N
patients NNS N
achieved VBD N
a DT N
complete JJ N
response NN N
by IN N
subsequent JJ N
instillation NN N
, , N
resulting VBG N
in IN N
a DT N
total JJ o
response NN o
rate NN o
of IN N
95 CD N
% NN N
. . N

After IN N
a DT N
mean JJ N
follow-up NN N
of IN N
47 CD N
months NNS N
, , N
five CD N
patients NNS N
( ( N
12 CD N
% NN N
) ) N
developed VBD N
disease JJ o
progression NN o
. . o

The DT N
progression NN o
rates NNS o
were VBD N
not RB N
different JJ N
between IN N
the DT N
topical JJ N
therapies NNS N
, , N
but CC N
were VBD N
significantly RB N
higher JJR N
in IN N
grade NN N
3 CD N
than IN N
in IN N
grade JJ N
2 CD N
cases NNS N
. . N

CONCLUSION VB N
It PRP N
appears VBZ N
likely JJ N
that IN N
mitomycin VBZ N
C NNP N
plus CC N
doxorubicin JJ N
instillation NN N
has VBZ N
an DT N
equivalent JJ N
efficacy NN o
to TO o
BCG NNP o
as IN N
the DT N
initial JJ N
therapy NN N
of IN N
carcinoma NN N
in IN N
situ NN N
and CC N
the DT N
combination NN N
of IN N
them PRP N
would MD N
be VB N
the DT N
most RBS N
efficient JJ N
treatment NN N
for IN N
the DT N
disease NN N
. . N

Moreover RB N
, , N
histological JJ N
grading NN N
would MD N
be VB N
clinically RB N
useful JJ N
in IN N
defining VBG N
the DT N
tumor NN N
characteristics NNS N
and CC N
behavior NN N
of IN N
carcinoma NN N
in IN N
situ NN N
of IN N
the DT N
bladder NN N
. . N

-DOCSTART- -15264973- O O

The DT N
effect NN N
of IN N
reinforcement NN i
or CC i
stimulus NN i
control NN i
to TO N
reduce VB N
sedentary JJ o
behavior NN o
in IN N
the DT N
treatment NN N
of IN N
pediatric JJ p
obesity NN p
. . p

Obese JJ p
children NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
family-based JJ i
behavioral JJ i
treatment NN i
that WDT i
included VBD i
either DT i
stimulus NN i
control NN i
or CC i
reinforcement NN i
to TO N
reduce VB N
sedentary JJ N
behaviors NNS N
. . N

Significant NNP N
and CC N
equivalent JJ N
decreases NNS N
in IN N
sedentary JJ o
behavior NN o
and CC o
high JJ o
energy NN o
density NN o
foods NNS o
, , N
increases NNS N
in IN N
physical JJ o
activity NN o
and CC o
fruits NNS o
and CC o
vegetables NNS o
, , N
and CC N
decreases NNS N
in IN N
standardized JJ N
body NN o
mass NN o
index NN o
( ( o
z-BMI NN o
) ) o
were VBD N
observed VBN N
. . N

Children NNP N
who WP N
substituted VBD N
active JJ N
for IN N
sedentary JJ o
behaviors NNS o
had VBD N
significantly RB N
greater JJR N
z-BMI JJ o
changes NNS o
at IN N
6 CD N
( ( N
-1.21 NNP N
vs. IN N
-0.76 NNP N
) ) N
and CC N
12 CD N
( ( N
-1.05 NNP N
vs. IN N
-0.51 NNP N
) ) N
months NNS N
, , N
respectively RB N
. . N

Substitution NN N
of IN N
physically RB N
active JJ N
for IN N
sedentary JJ o
behaviors NNS o
and CC N
changes NNS o
in IN o
activity NN o
level NN o
predicted VBD N
6- CD N
and CC N
12-month JJ N
z-BMI NN o
changes NNS o
. . o

Results NNS N
suggest VBP N
stimulus JJ i
control NN i
and CC i
reinforcing VBG i
reduced VBN N
sedentary JJ o
behaviors NNS o
are VBP N
equivalent JJ N
ways NNS N
to TO N
decrease VB N
sedentary JJ o
behaviors NNS o
, , N
and CC N
behavioral JJ o
economic JJ o
relationships NNS o
in IN o
eating NN o
and CC o
activity NN o
may MD N
mediate VB N
the DT N
effects NNS N
of IN N
treatment NN N
. . N

-DOCSTART- -9825384- O O

High-intensity NNP i
physical JJ i
training NN i
in IN N
adults NNS p
with IN p
asthma NN p
. . p

A DT N
comparison NN N
between IN N
training VBG i
on IN i
land NN i
and CC i
in IN i
water NN i
. . i

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
inactive JJ p
asthmatic JJ p
patients NNS p
could MD N
perform VB N
high-intensity JJ i
physical JJ i
training NN i
equally RB N
well RB N
on IN i
land NN i
as IN i
in IN i
water NN i
, , N
and CC N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
these DT N
training NN N
forms NNS N
. . N

Thirty-two JJ p
adults NNS p
with IN p
asthma NN p
, , N
randomized VBN N
into IN N
two CD N
groups NNS N
, , N
underwent VBD N
a DT N
10-week JJ i
supervised JJ i
rehabilitation NN i
program NN i
with IN i
emphasis NN i
on IN i
physical JJ i
training NN i
. . i

All DT N
patients NNS N
, , N
irrespective JJ N
of IN N
training VBG N
form NN N
, , N
were VBD N
able JJ N
to TO N
exercise VB N
to TO N
maximal VB N
intensity NN N
( ( N
80-90 CD N
% NN N
of IN N
estimated VBN N
maximal JJ N
heart NN N
rate NN N
) ) N
. . N

No UH N
asthmatic JJ o
attacks NNS o
occurred VBD N
in IN N
connection NN N
with IN N
the DT N
training NN N
sessions NNS N
. . N

Respiratory NNP o
variables NNS o
remained VBD N
almost RB N
unchanged JJ N
in IN N
both DT N
groups NNS N
. . N

The DT N
asthma NN o
symptoms NNS o
declined VBD o
during IN N
the DT N
rehabilitation NN N
period NN N
, , N
and CC N
the DT N
subjects NNS N
needed VBN N
less JJR N
acute JJ N
asthma NN N
care NN N
after IN N
the DT N
rehabilitation NN N
. . N

The DT N
cardiovascular JJ o
condition NN o
improved VBN N
significantly RB N
and CC N
similarly RB N
in IN N
the DT N
two CD N
groups NNS N
. . N

Ten CD p
patients NNS p
, , p
5 CD p
in IN p
each DT p
group NN p
, , N
had VBD N
exercise-induced JJ o
asthma NN o
at IN N
the DT N
start NN N
of IN N
the DT N
rehabilitation NN N
. . N

Only RB N
3 CD N
patients NNS N
, , N
2 CD N
from IN N
the DT N
water NN N
group NN N
and CC N
1 CD N
from IN N
the DT N
land NN N
group NN N
, , N
had VBD N
exercise-induced VBN o
asthma NNS o
after IN N
10 CD N
weeks NNS N
. . N

We PRP N
conclude VBP N
that IN N
indoor JJ N
training NN N
, , N
either CC N
on IN N
land NN N
or CC N
in IN N
water NN N
, , N
is VBZ N
beneficial JJ N
. . N

The DT N
effects NNS o
of IN N
these DT N
two CD N
training NN N
forms NNS N
are VBP N
almost RB N
equivalent JJ N
. . N

-DOCSTART- -8056005- O O

Evolution NN N
of IN N
coronary JJ N
stenoses NNS N
is VBZ N
related VBN N
to TO N
baseline VB N
severity NN N
-- : N
a DT N
prospective JJ N
quantitative JJ N
angiographic JJ N
analysis NN N
in IN N
patients NNS p
with IN p
moderate JJ p
coronary JJ p
disease NN p
. . p

INTACT JJ N
Investigators NNPS N
. . N

International NNP N
Nifedipine NNP N
Trial NNP N
on IN N
Antiatherosclerotic NNP N
Therapy NNP N
. . N

A DT N
correlation NN N
of IN N
the DT N
angiographic JJ N
evolution NN N
of IN N
coronary JJ N
stenoses NNS N
( ( N
stenosis NN N
diameter NN N
> NN N
or CC N
= VB N
20 CD N
% NN N
) ) N
with IN N
morphological JJ N
stenosis NN N
parameters NNS N
at IN N
baseline NN N
could MD N
help VB N
to TO N
identify VB o
the DT o
risk NN o
of IN o
progressive JJ o
stenoses NNS o
. . o

Therefore RB N
, , N
the DT N
data NN N
of IN N
the DT N
prospective JJ N
INTACT NNP N
study NN N
( ( N
International NNP N
Nifedipine NNP N
Trial NNP N
on IN N
Antiatherosclerotic NNP N
Therapy NNP N
) ) N
were VBD N
reviewed VBN N
. . N

In IN N
348 CD p
patients NNS p
with IN p
moderate JJ p
coronary JJ p
artery NN p
disease NN p
, , p
standardized VBD i
coronary JJ i
angiograms NNS i
were VBD p
taken VBN p
3 CD p
years NNS p
apart RB p
and CC N
were VBD N
quantitatively RB N
analysed VBN N
. . N

Changes NNS N
in IN N
the DT N
minimal JJ o
diameter NN o
of IN N
the DT N
1063 CD N
preexisting VBG N
coronary JJ N
stenoses NNS N
compared VBN N
between IN N
both DT N
angiograms NNS N
were VBD N
set VBN N
in IN N
relation NN N
to TO N
a DT N
number NN o
of IN o
conventional JJ o
stenosis NN o
parameters NNS o
at IN N
baseline NN N
. . N

Regression NNP N
analysis NN N
demonstrated VBD N
a DT N
significant JJ N
correlation NN o
of IN N
the DT N
changes NNS o
in IN o
minimal JJ o
diameter NN o
with IN N
baseline NN o
% NN o
diameter NN o
stenosis NN o
( ( N
r JJ N
= VBZ N
0.30 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
minimal JJ o
diameter NN o
( ( N
r JJ N
= NNP N
-0.28 NNP N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
reference NN o
diameter NN o
of IN o
stenoses NNS o
( ( N
r NN N
= NNP N
-0.14 NNP N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
changes NNS o
were VBD o
not RB o
correlated VBN o
with IN N
stenosis NN o
length NN o
and CC o
plaque JJ o
area NN o
. . o

The DT N
baseline NN N
parameters NNS N
of IN N
22 CD N
preexisting VBG N
stenoses NNS N
progressing VBG o
to TO o
occlusions NNS o
differed VBN N
from IN N
those DT N
remaining VBG o
patent NN o
only RB N
with IN N
regard NN N
to TO N
the DT N
% NN o
diameter NN o
stenosis NN o
( ( N
43 CD N
+/- JJ N
9 CD N
% NN N
vs JJ N
39 CD N
+/- JJ N
11 CD N
% NN N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Additional JJ N
progression NN o
of IN o
coronary JJ o
disease NN o
became VBD N
manifest JJS N
through IN N
development NN N
of IN N
228 CD N
stenoses NNS o
and CC N
19 CD N
occlusions NNS o
at IN N
arterial JJ N
sites NNS N
free VBP N
from IN N
definitive JJ N
stenoses NNS N
in IN N
the DT N
baseline NN N
angiograms NN N
. . N

Thus RB N
, , N
progression NN o
of IN o
atherosclerosis NN o
predominantly RB o
occurred VBD o
in IN N
mild NN N
preexisting VBG N
coronary JJ N
stenoses NNS N
and CC N
developed VBN N
at IN N
previously RB N
angiographically RB N
normal JJ N
sites NNS N
. . N

Since IN N
the DT N
conventional JJ N
angiographic JJ N
parameters NNS N
analysed VBN N
in IN N
this DT N
study NN N
failed VBD N
to TO N
identify VB N
individual JJ N
arterial JJ N
sites NNS N
with IN N
an DT N
increased VBN N
risk NN N
for IN N
progression NN N
, , N
definition NN N
of IN N
new JJ N
angiographic JJ N
parameters NNS N
or CC N
application NN N
of IN N
new JJ N
techniques NNS N
seem VBP N
mandatory JJ N
to TO N
this DT N
end NN N
. . N

-DOCSTART- -21243370- O O

Pars NNS i
plana VBP i
vitrectomy NN i
for IN N
diabetic JJ N
macular JJ N
edema NN N
. . N

Internal NNP i
limiting VBG i
membrane NN i
delamination NN i
vs FW N
posterior JJ i
hyaloid NN i
removal NN i
. . i

A DT N
prospective JJ N
randomized VBN N
trial NN N
. . N

BACKGROUND NNP N
Diabetes VBZ N
mellitus RB N
, , N
as RB N
well RB N
as IN N
subsequent JJ N
ocular JJ N
complications NNS N
such JJ N
as IN N
cystoid JJ N
macular JJ N
edema NN N
( ( N
CME NNP N
) ) N
, , N
are VBP N
of IN N
fundametal JJ N
socio-economic JJ N
relevance NN N
. . N

Therefore RB N
, , N
we PRP N
evaluated VBD N
the DT N
influence NN N
of IN N
internal JJ i
limiting VBG i
membrane NN i
( ( i
ILM NNP i
) ) i
removal NN i
on IN N
longterm JJ N
morphological JJ N
and CC N
functional JJ N
outcome NN N
in IN N
patients NNS p
with IN p
diabetes NNS p
mellitus NNS p
( ( p
DM NNP p
) ) p
type NN p
2 CD p
and CC p
chronic JJ p
CME NNP p
without IN p
evident JJ p
vitreomacular JJ p
traction NN p
. . p

METHOD NNP N
Forty NNP p
eyes NNS p
with IN p
attached JJ p
posterior JJ p
hyaloid NN p
were VBD N
included VBN N
in IN N
this DT N
prospective JJ N
trial NN N
and CC N
randomized VBN N
intraoperatively RB N
. . N

Prior NNP N
focal JJ N
( ( N
n JJ N
= NNP N
31 CD N
) ) N
or CC N
panretinal JJ N
( ( N
n JJ N
= NNP N
25 CD i
) ) i
laser JJR i
coagulation NN i
was VBD i
permitted VBN i
. . N

Group NNP N
I PRP N
( ( N
n JJ N
= $ N
19 CD N
patients NNS N
) ) N
underwent JJ i
surgical JJ i
induction NN i
of IN i
posterior JJ i
vitreous JJ i
detachment NN i
( ( i
PVD NNP i
) ) i
, , i
group NN i
II NNP N
( ( N
n JJ N
= $ N
20 CD N
patients NNS i
) ) i
PVD NNP i
and CC i
removal NN i
of IN i
the DT i
ILM NNP i
. . i

Eleven NNP i
patients NNS N
with IN N
detached JJ N
posterior JJ N
hyaloid NN N
( ( N
group NN N
III NNP N
) ) N
were VBD N
not RB N
randomized VBN N
, , N
and CC N
ILM NNP i
removal NN i
was VBD N
performed VBN N
. . N

One CD N
eye NN N
had VBD N
to TO N
be VB N
excluded VBN N
from IN N
further JJ N
analysis NN N
. . N

Examinations NNS N
included VBD o
ETDRS NNP o
best-corrected JJ o
visual JJ o
acuity NN o
( ( o
BCVA NNP o
) ) o
, , o
fluorescein JJ o
angiography NN o
( ( o
FLA NNP o
) ) o
and CC o
OCT NNP o
at IN o
baseline NN N
, , N
3 CD N
and CC N
6 CD N
months NNS N
postoperatively RB N
. . N

Main NNP N
outcome JJ N
measure NN N
was VBD o
BCVA NNP o
at IN N
6 CD N
months NNS N
, , N
secondary JJ o
was VBD o
foveal JJ o
thickness NN o
. . o

RESULTS NNP N
Mean NNP o
BCVA NNP o
over IN N
6 CD N
months NNS N
remained VBD N
unchanged JJ N
in IN N
85 CD N
% NN N
of IN N
patients NNS N
of IN N
group NN N
II NNP N
, , N
and CC N
decreased VBD N
in IN N
53 CD N
% NN N
of IN N
patients NNS N
of IN N
group NN N
I PRP N
. . N

Results NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
different JJ N
[ NNP N
group NN N
I PRP N
: : N
mean JJ N
decrease NN N
log NN N
MAR NNP N
95 CD N
% NN N
CI NNP N
( ( N
0.06 CD N
; : N
0.32 CD N
) ) N
, , N
group NN N
II NNP N
: : N
( ( N
-0.02 VBP N
; : N
0.11 CD N
) ) N
] NN N
. . N

OCT NNP N
revealed VBD N
a DT N
significantly RB N
greater JJR N
reduction NN N
of IN o
foveal JJ o
thickness NN o
following VBG o
PVD NNP N
with IN N
ILM NNP N
removal NN N
[ NNP N
group NN N
I PRP N
: : N
mean JJ N
change NN N
: : N
95 CD N
% NN N
CI NNP N
( ( N
-208.95 NNP N
?m NNP N
; : N
-78.05 NNP N
?m NNP N
) ) N
, , N
group NN N
II NNP N
: : N
( ( N
-80.90 JJ N
?m NN N
: : N
+59.17 JJ N
?m NN N
) ) N
] NN N
. . i

CONCLUSION NNP i
Vitrectomy NNP i
, , i
PVD NNP i
with IN i
or CC i
without IN i
ILM NNP i
removal NN i
does VBZ i
not RB N
improve VB N
vision NN N
in IN N
patients NNS p
with IN p
DM NNP p
type NN p
2 CD p
and CC p
cystoid JJ p
diabetic JJ p
macular NN p
edema NN p
without IN p
evident JJ p
vitreoretinal JJ p
traction NN p
. . p

ILM NNP p
delamination NN N
shows VBZ N
improved JJ N
morphological JJ N
results NNS N
, , N
and CC N
appears VBZ N
to TO N
be VB N
beneficial JJ N
in IN N
eyes NNS p
with IN p
preexisting VBG p
PVD NNP p
. . p

-DOCSTART- -24550145- O O

Two CD N
to TO N
ten CD N
years NNS N
: : N
developmental JJ N
trajectories NNS N
of IN N
joint JJ N
attention NN N
in IN N
children NNS p
with IN p
ASD NNP p
who WP p
received VBD p
targeted VBN i
social JJ i
communication NN i
interventions NNS i
. . i

This DT N
study NN N
follows VBZ N
40 CD p
children NNS p
who WP p
were VBD p
participants NNS p
in IN p
a DT p
randomized NN p
controlled VBD p
early JJ p
intervention NN p
trial NN p
( ( p
Kasari NNP p
et RB p
al RB p
. . p

) ) p
from IN p
early JJ p
childhood NN p
( ( p
2-5 CD p
years NNS p
of IN p
age NN p
) ) p
to TO p
elementary JJ p
school NN p
age NN p
( ( p
8-10 CD p
years NNS p
) ) p
. . p

To TO N
fully RB N
utilize VB N
the DT N
available JJ N
longitudinal JJ N
data NNS N
, , N
the DT N
general JJ N
linear NN N
mixed JJ N
model NN N
was VBD N
the DT N
primary JJ N
analytical JJ N
approach NN N
. . N

The DT N
growth NN N
trajectories NNS N
of IN N
joint JJ o
attention NN o
skills NNS o
( ( o
pointing VBG o
, , o
coordinated VBD o
joint JJ o
looking VBG o
, , o
and CC o
showing VBG o
) ) o
and CC o
expressive JJ o
language NN o
outcomes NNS o
in IN o
these DT N
children NNS N
were VBD N
estimated VBN N
based VBN N
on IN N
five CD N
time NN N
points NNS N
during IN N
the DT N
measurement JJ N
period NN N
. . N

The DT N
children NNS N
were VBD N
grouped VBN N
by IN N
diagnosis NN N
at IN N
the DT N
last JJ N
follow-up JJ N
( ( N
autism NN N
, , N
autism NN N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
, , N
no DT N
diagnosis NN N
) ) N
and CC N
by IN N
their PRP$ N
original JJ N
treatment NN N
group NN N
assignment NN i
( ( i
joint JJ i
attention NN i
, , i
symbolic JJ i
play NN i
, , i
control NN i
) ) i
, , i
and CC N
differences NNS N
between IN N
these DT N
groups NNS N
were VBD N
evaluated VBN N
. . N

Results NNS N
showed VBD N
that IN o
joint JJ o
attention NN o
skills NNS o
of IN o
coordinated VBN o
joint NN o
looking VBG o
and CC o
showing VBG o
increased VBN o
over IN N
time NN N
, , N
and CC o
pointing VBG o
to TO o
share NN o
interest NN o
increased VBN o
over IN N
the DT N
first JJ N
year NN N
measured VBN N
and CC N
decreased VBN N
thereafter RB N
. . N

These DT o
trajectories NNS o
were VBD o
influenced VBN N
by IN N
both DT N
original JJ N
treatment NN N
assignment NN N
and CC N
diagnostic JJ N
status NN N
at IN N
follow-up NN N
. . N

In IN N
addition NN N
, , N
a DT N
cross-lagged JJ N
panel NN N
analysis NN N
revealed VBD N
a DT N
causal NN N
relationship NN N
between IN o
early JJ o
pointing NN o
and CC o
later RB o
language NN o
development NN o
. . o

This DT N
study NN N
highlights VBZ N
the DT N
longitudinal JJ N
and CC N
developmental JJ N
importance NN N
of IN N
measures NNS N
of IN N
early JJ o
core NN o
deficits NNS o
in IN o
autism NN o
, , o
and CC N
suggests VBZ N
that IN N
both DT N
treatment NN N
and CC N
ASD NNP N
symptomatology NN o
may MD o
influence VB N
growth NN N
in IN N
these DT N
skills NNS N
over IN N
time NN N
. . N

-DOCSTART- -9642484- O O

Proposed VBN N
synergistic JJ N
effect NN N
of IN N
calcium NN i
channel NN i
blockers NNS i
with IN N
lipid-lowering JJ i
therapy NN i
in IN N
retarding VBG p
progression NN o
of IN o
coronary JJ o
atherosclerosis NN o
. . o

Lipid-lowering JJ i
therapy NN i
now RB N
has VBZ N
undoubtedly RB N
proven VBN N
to TO N
be VB N
an DT N
effective JJ N
therapeutic JJ N
modality NN N
to TO N
retard VB N
the DT N
progression NN N
of IN N
coronary JJ N
atherosclerosis NN o
. . o

An DT N
additional JJ N
approach NN N
for IN N
prevention NN N
of IN N
the DT N
progression NN o
of IN o
atherosclerosis NN o
is VBZ N
calcium JJ i
channel NN i
blocker NN i
( ( i
CCB NNP i
) ) i
treatment NN N
. . N

Evidence NN N
indicating VBG N
that IN N
CCBs NNP i
inhibit NN N
atherosclerosis NN N
is VBZ N
less RBR N
unequivocal JJ N
than IN N
the DT N
clear JJ N
evidence NN N
for IN N
lipid-lowering JJ i
therapy NN i
. . i

Many JJ N
investigations NNS N
support VBP N
the DT N
view NN N
that IN N
a DT N
number NN N
of IN N
key JJ N
processes NNS N
in IN N
atherosclerosis NN N
may MD N
be VB N
influenced VBN N
by IN N
CCBs NNP i
. . N

From IN N
the DT N
negative JJ N
and CC N
positive JJ N
studies NNS N
with IN N
CCBs NNP i
performed VBD N
in IN N
animals NNS p
and CC p
humans NNS p
we PRP N
must MD N
conclude VB N
that DT N
apparently RB N
some DT N
, , N
but CC N
not RB N
all DT N
, , N
types NNS N
or CC N
stages NNS N
of IN N
the DT N
atherosclerotic JJ N
process NN N
are VBP N
inhibited VBN N
by IN N
CCBs NNP i
. . N

To TO N
assess VB N
whether IN N
lipid-lowering JJ i
therapy NN i
and CC N
CCB NNP i
treatment NN N
may MD N
have VB N
an DT N
additive JJ N
or CC N
synergistic JJ N
beneficial JJ N
effect NN N
on IN N
human JJ N
atherosclerosis NN o
, , N
which WDT N
is VBZ N
conceivable JJ N
because IN N
their PRP$ N
anti-atherosclerotic JJ N
properties NNS N
differ VBP N
, , N
data NNS p
from IN p
the DT p
angiographic JJ p
lipid-lowering JJ p
trial NN p
REGRESS NNP p
( ( i
pravastatin NN i
vs. FW p
placebo NN i
) ) i
were VBD N
reviewed VBN N
. . N

In IN N
REGRESS NNP N
, , N
patients NNS N
in IN N
the DT N
pravastatin NN i
group NN N
had VBD N
significantly RB N
less JJR N
progression NN o
if IN N
cotreated VBN N
with IN N
CCBs NNP i
as IN N
compared VBN N
with IN N
those DT N
with IN N
no DT N
CCB NNP i
cotreatment NN N
, , N
whereas NNS N
in IN N
the DT N
placebo NN i
( ( i
no DT i
pravastatin NN i
) ) i
group NN N
no DT N
effect NN N
of IN N
CCB NNP i
treatment NN N
was VBD N
observed VBN N
. . N

With IN N
respect NN N
to TO N
angiographic VB o
new JJ o
lesion NN o
formation NN o
, , N
in IN N
the DT N
pravastatin NN i
group NN N
there EX N
were VBD N
50 CD N
% NN N
less JJR N
patients NNS N
with IN N
new JJ N
angiographic JJ o
lesions NNS o
if IN N
cotreated VBN N
with IN N
CCBs NNP i
as IN N
compared VBN N
with IN N
no DT N
CCB NNP i
cotreatment NN N
, , N
whereas NNS N
in IN N
the DT N
placebo NN i
( ( i
no DT i
pravastatin NN i
) ) i
group NN N
, , N
again RB N
, , N
no DT N
significant JJ N
effect NN N
of IN N
CCB NNP i
treatment NN N
was VBD N
observed VBN N
. . N

No DT N
beneficial JJ N
effects NNS N
of IN N
CCB NNP i
treatment NN N
on IN N
clinical JJ o
events NNS o
were VBD N
observed VBN N
during IN N
the DT N
2-year JJ N
study NN N
follow-up NN N
. . N

In IN N
view NN N
of IN N
the DT N
correlation NN N
between IN N
angiographic JJ o
progression NN o
and CC N
subsequent JJ N
clinical JJ o
events NNS o
as IN N
demonstrated VBN N
in IN N
several JJ N
large JJ N
trials NNS N
, , N
it PRP N
is VBZ N
not RB N
unrealistic JJ N
to TO N
also RB N
anticipate VB N
in IN N
this DT N
population NN N
, , N
a DT N
beneficial JJ N
effect NN N
on IN N
clinical JJ N
events NNS N
with IN N
longer JJR N
follow-up NN N
. . N

Although IN N
the DT N
REGRESS NNP N
trial NN N
was VBD N
not RB N
designed VBN N
to TO N
evaluate VB N
combination NN N
therapy NN N
, , N
the DT N
results NNS N
suggest VBP N
that IN N
addition NN N
of IN N
CCBs NNP i
to TO N
HMG-CoA NNP N
reductase NN N
inhibitor NN N
therapy NN N
( ( i
pravastatin NN i
) ) i
acts VBZ N
synergistically RB N
in IN N
retarding VBG N
the DT N
progression NN o
of IN o
established VBN o
coronary JJ o
atherosclerosis NN o
. . o

These DT N
results NNS N
appear VBP N
to TO N
warrant VB N
prospective JJ N
randomized VBN N
trials NNS N
to TO N
determine VB N
in IN N
a DT N
more RBR N
definitive JJ N
manner NN N
the DT N
merits NNS N
of IN N
this DT N
combination NN N
in IN N
the DT N
prevention NN N
of IN N
progression NN o
of IN o
coronary JJ o
atherosclerosis NN o
. . o

Currently RB N
a DT N
number NN N
of IN N
studies NNS N
in IN N
these DT N
fields NNS N
are VBP N
being VBG N
designed VBN N
or CC N
are VBP N
already RB N
underway RB N
. . N

-DOCSTART- -15616772- O O

Efficiency NN o
of IN i
adjuvant JJ i
immunochemotherapy NN i
following VBG N
curative JJ N
resection NN N
in IN N
patients NNS p
with IN p
locally RB p
advanced JJ p
gastric JJ p
cancer NN p
. . p

BACKGROUND NNP N
Despite IN N
curative JJ N
resection NN N
, , N
50 CD N
% NN N
-90 CD N
% NN N
of IN N
gastric JJ p
cancer NN p
patients NNS p
die VBP N
of IN N
disease NN o
relapse NN o
. . o

Although IN N
some DT N
clinical JJ N
trials NNS N
have VBP N
indicated VBN N
that IN N
chemotherapy NN N
and CC N
immunochemotherapy NN N
may MD N
be VB N
effective JJ N
modalities NNS N
, , N
more RBR N
recent JJ N
studies NNS N
have VBP N
not RB N
been VBN N
able JJ N
to TO N
define VB N
the DT N
standard JJ N
treatment NN N
for IN N
advanced JJ p
gastric JJ p
cancer NN p
. . p

The DT N
present JJ N
study NN N
evaluated VBD N
the DT N
effect NN N
of IN N
adjuvant JJ i
immunochemotherapy NN i
with IN i
the DT i
use NN i
of IN i
BCG NNP i
( ( i
bacille IN i
Calmette-Guerin NNP i
) ) i
and CC i
FAM NNP i
( ( i
5-fluorouracil JJ i
, , i
adriamycin JJ i
, , i
mitomycin JJ i
C NNP i
) ) i
chemotherapy NN i
on IN N
the DT N
survival NN o
of IN o
patients NNS o
with IN p
locally RB p
advanced VBN p
resectable JJ p
gastric JJ p
cancer NN p
. . p

METHODS NNP N
A NNP N
total NN N
of IN N
156 CD p
patients NNS p
with IN p
stage NN p
III NNP p
or CC p
IV NNP p
gastric JJ p
cancer NN p
who WP p
had VBD p
undergone JJ p
curative JJ p
resection NN p
were VBD N
randomly RB i
assigned VBN i
to TO i
three CD i
treatment NN i
groups NNS i
: : i
BCG NNP i
+ NNP i
FAM NNP i
( ( i
immunochemotherapy NN i
) ) i
, , i
FAM NNP i
( ( i
chemotherapy NN i
) ) i
, , i
and CC i
control NN i
( ( i
surgery NN i
only RB i
) ) i
. . i

Treatment NN i
was VBD i
continued VBN i
for IN i
2 CD i
years NNS i
or CC i
until IN i
death NN i
. . i

Further NNP i
postsurgical JJ i
follow VBP i
up RP i
was VBD i
carried VBN i
on IN i
for IN i
up IN i
to TO i
10 CD i
years NNS i
. . i

RESULTS VB N
Overall JJ N
10-year JJ o
survival NN o
was VBD N
47.1 CD N
% NN N
for IN N
the DT N
immunochemotherapy NN N
group NN N
( ( N
P NNP N
< VBZ N
0.037 CD N
vs NN N
FAM NNP i
and CC N
P NNP N
< NNP N
0.0006 CD N
vs NNS N
control NN N
) ) N
, , N
30 CD N
% NN N
for IN N
the DT N
chemotherapy NN i
group NN N
( ( N
vs FW N
control NN N
, , N
NS NNP N
) ) N
, , N
and CC N
15.2 CD N
% NN N
for IN N
the DT N
control NN N
group NN N
. . N

In IN N
patients NNS p
with IN p
pT2/T3 JJ p
primary JJ p
tumors NNS p
, , N
10-year JJ o
survival NN o
was VBD N
55.3 CD N
% NN N
for IN N
BCG NNP i
+ NNP i
FAM NNP i
vs VBD N
28.2 CD N
% NN N
for IN N
FAM NNP N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
14.6 CD N
% NN N
for IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.00018 CD N
) ) N
. . N

BCG NNP i
+ NNP i
FAM NNP i
significantly RB N
improved VBD N
the DT N
survival NN o
of IN o
patients NNS o
with IN p
intestinal-type JJ p
but CC p
not RB p
diffuse-type JJ p
cancer NN p
. . p

Immunochemotherapy NNP i
was VBD N
well RB N
tolerated VBN N
. . N

CONCLUSION VB N
This DT N
study NN N
, , N
based VBN N
on IN N
a DT N
limited JJ p
number NN p
of IN p
patients NNS p
, , N
indicates VBZ N
that IN N
adjuvant JJ N
immunochemotherapy NN N
( ( N
BCG NNP N
+ NNP N
FAM NNP N
) ) N
may MD N
prolong VB N
the DT N
survival NN o
of IN N
gastric JJ p
cancer NN p
patients NNS p
after IN p
curative JJ p
gastrectomy NN p
; : p
in IN p
particular JJ p
, , p
in IN p
patients NNS p
with IN p
pT2/T3 JJ p
tumors NNS p
and CC p
intestinal-type JJ p
primary JJ p
tumors NNS p
. . p

There EX N
was VBD N
no DT N
survival JJ o
benefit NN o
from IN N
FAM NNP i
adjuvant JJ i
chemotherapy NN i
. . i

-DOCSTART- -19772883- O O

Double-blind JJ N
placebo-controlled JJ N
trial NN N
of IN N
pentoxifylline NN i
added VBN i
to TO i
risperidone VB i
: : i
effects NNS N
on IN N
aberrant JJ o
behavior NN o
in IN o
children NNS o
with IN o
autism NN o
. . o

BACKGROUND IN N
There EX N
are VBP N
several JJ N
lines NNS N
of IN N
evidence NN N
to TO N
indicate VB N
that IN N
the DT N
immune NN N
system NN N
plays VBZ N
an DT N
important JJ N
role NN N
in IN N
the DT N
pathophysiology NN N
of IN N
autism NN N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
access NN N
the DT N
effects NNS N
of IN N
pentoxifylline NN i
plus CC i
risperidone NN i
in IN N
the DT N
treatment NN o
of IN o
autistic JJ o
disorder NN o
. . o

METHODS NNP N
Forty NNP p
children NNS p
between IN p
the DT p
ages NNS p
4 CD p
and CC p
12 CD p
years NNS p
with IN p
a DT p
DSM NNP p
IV-TR NNP p
clinical JJ p
diagnosis NN p
of IN p
autism NN p
were VBD p
recruited VBN p
. . p

The DT p
children NNS p
presented VBN p
with IN p
a DT p
chief JJ p
complaint NN p
of IN p
severely RB p
disruptive JJ p
symptoms NNS p
related VBN p
to TO p
autistic JJ p
disorder NN p
. . p

Patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
pentoxifylline+risperidone VB i
or CC i
placebo+risperidone VB i
for IN N
a DT N
10-week JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
. . N

The DT N
dose NN N
of IN N
risperidone NN i
was VBD N
titrated VBN N
up RB N
to TO N
3 CD N
mg/day NN N
, , N
pentoxifylline NN i
was VBD N
titrated VBN N
to TO N
600 CD N
mg/day NN N
. . N

Patients NNS N
were VBD N
assessed VBN N
at IN N
baseline NN N
and CC N
after IN N
2 CD N
, , N
4 CD N
, , N
6 CD N
, , N
8 CD N
and CC N
10 CD N
weeks NNS N
of IN N
starting VBG N
medication NN N
. . N

The DT N
measure NN N
of IN N
the DT N
outcome NN N
was VBD N
the DT N
Aberrant NNP o
Behavior NNP o
Checklist-Community NNP o
( ( o
ABC-C NNP o
) ) o
. . o

RESULTS VB N
The DT N
difference NN N
between IN N
the DT N
two CD N
protocols NNS N
was VBD N
significant JJ N
as IN N
the DT N
group NN N
that WDT N
received VBD N
pentoxifylline NN i
had VBD N
greater JJR N
reduction NN N
in IN N
ABC-C NNP o
subscale NN o
scores NNS o
for IN o
Irritability NNP o
, , o
Lethargy/Social NNP o
Withdrawal NNP o
, , o
Stereotypic NNP o
Behavior NNP o
, , o
Hyperactivity/Noncompliance NNP o
and CC o
Inappropriate NNP o
Speech NNP o
. . o

CONCLUSION NNP N
The DT N
results NNS N
suggest VBP N
that IN N
combination NN i
of IN i
atypical JJ i
antipsychotic JJ i
medications NNS i
and CC i
pentoxifylline NN i
might MD N
have VB N
synergistic JJ N
effects NNS N
in IN N
treatment NN N
of IN N
behavioral JJ o
problems NNS o
of IN o
children NNS o
with IN o
autism NN o
. . o

-DOCSTART- -8077143- O O

Milk NN o
production NN o
in IN N
cows NNS p
with IN p
endotoxin-induced JJ i
mastitis NN i
treated VBN N
with IN N
isotonic JJ i
or CC i
hypertonic JJ i
sodium NN i
chloride NN i
solution NN i
. . i

Milk NNP o
production NN o
was VBD N
monitored VBN N
in IN N
16 CD p
cows NNS p
for IN p
6 CD p
milkings NNS p
after IN N
intramammary JJ N
infusion NN N
of IN N
1 CD N
mg NN N
of IN N
endotoxin NN i
in IN N
a DT N
single JJ N
forequarter NN N
. . N

The DT N
cows NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
2 CD N
treatment NN N
groups NNS N
; : N
8 CD p
cows NNS p
were VBD p
treated VBN p
with IN p
isotonic JJ i
saline NN i
solution NN i
and CC N
8 CD p
cows NNS p
were VBD p
treated VBN p
with IN p
hypertonic JJ i
saline JJ i
solution NN i
. . i

Saline JJ i
solutions NNS N
were VBD N
administered VBN N
IV NNP N
( ( N
5 CD N
ml/kg NN N
of IN N
body NN N
weight NN N
) ) N
4 CD N
hours NNS N
after IN N
infusion NN N
of IN N
endotoxin NN i
. . i

Mean NNP o
cumulative JJ o
change NN o
in IN o
milk NN o
yield NN o
and CC o
interval JJ o
change NN o
in IN o
milk NN o
yield NN o
were VBD N
greater JJR N
in IN N
cows NNS p
treated VBN N
with IN N
isotonic JJ N
saline NN N
solution NN i
than IN N
in IN N
cows NNS N
treated VBN N
with IN N
hypertonic JJ i
saline JJ i
solution NN i
. . i

Significant JJ N
differences NNS N
between IN N
treatment NN N
groups NNS N
were VBD N
not RB N
detected VBN N
. . N

-DOCSTART- -19526613- O O

Leucocyte NNP N
depletion NN N
of IN N
perioperative JJ i
blood NN i
transfusion NN i
does VBZ N
not RB N
affect VB N
long-term JJ o
survival NN o
and CC N
recurrence NN N
in IN N
patients NNS p
with IN p
gastrointestinal JJ p
cancer NN p
. . p

BACKGROUND NNP N
Perioperative NNP i
red VBD i
blood NN i
cell NN i
( ( i
RBC NNP i
) ) i
transfusion NN i
may MD N
be VB N
associated VBN N
with IN N
a DT N
poor JJ N
prognosis NN N
in IN N
cancer NN N
surgery NN N
. . N

Allogeneic NNP N
leucocytes NNS N
are VBP N
assumed VBN N
to TO N
play VB N
a DT N
causal JJ N
role NN N
. . N

This DT N
study NN N
evaluated VBD N
the DT N
long-term JJ N
effect NN N
of IN N
transfusion NN i
with IN i
leucocyte-depleted JJ o
( ( N
LD NNP N
) ) N
blood NN N
in IN N
patients NNS p
with IN p
gastrointestinal JJ p
cancer NN p
. . p

METHODS NNP N
The DT N
Transfusion NNP N
Associated NNP N
Complications NNP N
= NNP N
Transfusion NNP N
Induced NNP N
Complications NNP N
? . N
( ( N
TACTIC NNP N
) ) N
study NN N
is VBZ N
a DT N
multicentre JJ N
randomized NN N
controlled VBD N
trial NN N
evaluating VBG N
the DT N
short-term JJ N
benefits NNS N
of IN N
LD NNP i
versus IN i
non-LD JJ i
RBC NNP i
transfusions NNS i
. . i

The DT N
present JJ N
study NN N
evaluated VBD N
5-year JJ N
survival NN N
and CC N
cancer NN N
recurrence NN N
among IN p
512 CD p
patients NNS p
with IN p
gastrointestinal JJ p
cancer NN p
included VBD p
in IN p
the DT p
TACTIC NNP p
study NN p
. . p

RESULTS NNP N
Some DT N
89.2 CD p
per IN p
cent NN p
of IN p
patients NNS p
had VBD p
a DT p
primary JJ p
tumour NN p
and CC p
79.7 CD p
per IN p
cent NN p
underwent NN p
surgery NN i
with IN p
curative JJ p
intent NN p
; : p
243 CD p
patients NNS p
received VBD p
perioperative JJ o
RBC NNP o
transfusion NN o
( ( p
median JJ p
3 CD p
units NNS p
) ) p
. . p

The DT N
5-year JJ o
overall JJ o
survival NN o
rate NN o
of IN o
patients NNS o
with IN o
any DT o
type NN o
of IN o
gastrointestinal JJ o
cancer NN o
was VBD N
50.8 CD N
per IN N
cent NN N
in IN N
the DT N
LD NNP p
group NN p
and CC N
45.8 CD N
per IN N
cent NN N
in IN N
the DT N
non-LD JJ p
group NN p
( ( N
P NNP N
= NNP N
0.191 CD N
) ) N
. . N

Corresponding VBG N
5-year JJ o
disease-free JJ o
survival NN o
rates NNS o
were VBD N
60.0 CD N
and CC N
56.6 CD N
per IN N
cent NN N
( ( N
P NNP N
= NNP N
0.482 CD N
) ) N
, , N
and CC N
recurrence NN o
rates NNS o
32.9 CD N
and CC N
34.3 CD N
per IN N
cent NN N
( ( N
P NNP N
= NNP N
0.864 CD N
) ) N
. . N

CONCLUSION NNP N
Leucocyte NNP N
depletion NN N
is VBZ N
not RB N
associated VBN N
with IN N
better JJR N
long-term JJ o
survival NN o
and CC o
lower JJR o
recurrence NN o
rates NNS o
in IN N
patients NNS p
with IN p
gastrointestinal JJ p
cancer NN p
. . p

-DOCSTART- -12031927- O O

Thiabendazole NN i
for IN N
the DT N
prophylaxis NN N
of IN N
strongyloidiasis NN N
in IN N
immunosuppressed JJ p
patients NNS p
with IN p
hematological JJ p
diseases NNS p
: : p
a DT N
randomized JJ N
double-blind JJ N
placebo-controlled JJ i
study NN N
. . N

-DOCSTART- -9809262- O O

Treatment NN N
of IN N
children NNS p
with IN p
autism NN p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
to TO N
evaluate VB N
a DT N
caregiver-based JJ i
intervention NN i
program NN i
in IN N
community NN p
day-care NN p
centers NNS p
. . p

This DT N
study NN N
reports VBZ N
on IN N
the DT N
results NNS N
of IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
that WDT N
evaluated VBD N
a DT N
caregiver-based JJ i
intervention NN i
program NN i
for IN N
children NNS p
with IN p
autism NN p
in IN p
community NN p
day-care NN p
centers NNS p
. . p

Thirty-five JJ p
preschool NN p
children NNS p
with IN p
a DT p
DSM NNP p
III-R NNP p
diagnosis NN p
of IN p
autism NN p
or CC p
pervasive JJ p
developmental JJ p
disorder NN p
were VBD N
randomized VBN N
to TO N
an DT N
experimental JJ N
or CC N
control NN N
group NN N
. . N

Children NNP N
in IN N
the DT N
experimental JJ N
group NN N
were VBD N
enrolled VBN N
in IN N
day NN N
care NN N
and CC N
their PRP$ N
parents NNS i
and CC i
child NN i
care NN i
workers NNS i
received VBD i
a DT i
12-week JJ i
intervention NN i
consisting NN i
of IN i
lectures NNS i
and CC i
on-site JJ i
consultations NNS i
to TO i
day-care JJ i
centers NNS i
. . i

In IN N
addition NN N
, , N
supportive JJ N
work NN N
was VBD N
undertaken VBN N
with IN N
families NNS N
. . N

Control NNP N
subjects VBZ N
received VBN N
day NN i
care VB i
alone RB i
. . i

In IN N
the DT N
experimental JJ N
group NN N
, , N
there EX N
were VBD N
greater JJR N
gains NNS N
in IN N
language NN o
abilities NNS o
, , N
significant JJ N
increases NNS N
in IN N
caregivers NNS o
' POS o
knowledge NN o
about IN o
autism NN o
, , N
greater JJR N
perception NN o
of IN o
control NN o
on IN o
the DT o
part NN o
of IN o
mothers NNS o
, , N
and CC N
greater JJR N
parent NN o
satisfaction NN o
. . o

We PRP N
conclude VBP N
that IN N
this DT N
research NN N
design NN N
demonstrated VBD N
that IN N
the DT N
intervention NN N
was VBD N
significantly RB N
superior JJ N
to TO N
day NN N
care VB N
alone RB N
. . N

-DOCSTART- -14567804- O O

GnRH NNP i
agonist NN i
treatment NN i
before IN N
total JJ N
laparoscopic NN N
hysterectomy NN N
for IN N
large JJ N
uteri NN N
. . N

STUDY NNP N
OBJECTIVE NNP N
To TO N
evaluate VB N
whether IN N
uterine JJ N
shrinkage NN N
induced VBN N
by IN N
gonadotropin-releasing VBG i
hormone NN i
( ( i
GnRH NNP i
) ) i
agonists VBZ i
in IN N
women NNS p
with IN p
a DT p
large JJ p
uterus NN p
( ( p
> JJ p
14 CD p
wks NNS p
) ) p
may MD N
facilitate VB N
total JJ N
laparoscopic JJ N
hysterectomy NN N
. . N

DESIGN NNP N
Randomized NNP N
, , N
prospective JJ N
study NN N
( ( N
Canadian JJ N
Task NNP N
Force NNP N
classification NN N
I PRP N
) ) N
. . N

SETTING CC N
University-affiliated JJ N
hospital NN N
. . N

PATIENTS VB N
Sixty-two JJ p
women NNS p
with IN p
symptomatic JJ p
uterine JJ p
myomas NN p
( ( p
size NN p
16-20 CD p
wks NN p
) ) p
. . p

INTERVENTIONS NNP N
Total NNP i
laparoscopic NN i
hysterectomy NN i
for IN i
benign JJ i
pathology NN i
. . i

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Before IN N
surgery NN N
, , N
women NNS N
were VBD N
assigned VBN N
, , N
at IN N
a DT N
ratio NN N
of IN N
1:1 CD N
by IN N
random NN N
selection NN N
, , N
to TO N
receive VB N
injections NNS N
of IN N
triptorelin NN i
depot NN i
11.25 CD N
mg NN N
3 CD N
months NNS N
before IN N
surgery NN N
( ( N
group NN N
A NNP N
) ) N
or CC N
no DT N
treatment NN N
( ( N
group NN N
B NNP N
) ) N
. . N

Uterine JJ o
volume NN o
, , o
mean VB o
operating NN o
time NN o
, , o
uterine JJ o
weight NN o
, , o
drop NN o
in IN o
hemoglobin NN o
, , o
intraoperative JJ o
complications NNS o
, , o
conversions NNS o
to TO o
laparotomy VB o
, , o
and CC o
hospital NN o
stay NN o
were VBD N
recorded VBN N
. . N

Triptorelin NNP N
decreased VBD N
uterine JJ o
volume NN o
, , N
calculated VBN N
by IN N
ultrasonography NN N
, , N
by IN N
26.5 CD N
% NN N
in IN N
group NN N
A NNP N
, , N
whereas IN N
the DT N
volume NN N
remained VBD N
unchanged JJ N
in IN N
group NN N
B NNP N
. . N

Statistical JJ N
differences NNS N
were VBD N
found VBN N
between IN N
groups NNS N
concerning VBG N
uterine JJ o
weight NN o
, , o
operating VBG o
time NN o
, , o
and CC o
drop NN o
in IN o
hemoglobin JJ o
level NN o
. . o

Three CD N
patients NNS N
in IN N
group NN N
B NNP N
were VBD N
converted VBN N
to TO N
laparotomy VB N
because IN N
of IN N
uterine JJ N
size NN N
. . N

CONCLUSION NNP N
In IN N
women NNS p
with IN p
a DT p
large JJ p
uterus NN p
, , N
a DT N
3-month JJ N
preoperative JJ N
course NN N
of IN N
GnRH NNP i
may MD N
facilitate VB N
laparoscopic NN N
hysterectomy NN N
, , N
decreasing VBG N
uterine JJ N
size NN N
, , N
operating VBG N
time NN N
, , N
and CC N
blood NN N
loss NN N
. . N

-DOCSTART- -7617857- O O

Effect NN N
of IN N
postmenopausal JJ i
hormonal JJ i
replacement NN i
therapy NN i
on IN N
mammographic JJ o
density NN o
and CC o
parenchymal JJ o
pattern NN o
. . o

PURPOSE NNP N
To TO N
measure VB N
changes NNS N
and CC N
predictors NNS N
of IN N
change NN N
in IN N
mammograms NNS N
obtained VBN N
in IN N
postmenopausal JJ p
women NNS p
undergoing VBG p
continuous JJ p
combined VBN p
hormonal JJ i
replacement NN i
therapy NN i
( ( i
HRT NNP i
) ) i
. . i

MATERIALS NNP N
AND CC N
METHODS NNP N
Mammograms NNP i
of IN N
41 CD p
postmenopausal JJ p
women NNS p
obtained VBN p
before IN p
and CC p
1 CD p
year NN p
after IN p
the DT p
initiation NN p
of IN p
HRT NNP i
were VBD N
evaluated VBN N
blindly RB N
according VBG N
to TO N
the DT N
quantitative JJ N
density NN N
percentage NN N
method NN N
and CC N
the DT N
Wolfe NNP N
classification NN N
system NN N
. . N

RESULTS NNP N
Mammographic NNP o
densities NNS o
increased VBD N
compared VBN N
with IN N
baseline NN N
values NNS N
in IN N
73 CD N
% NN N
of IN N
subjects NNS N
( ( N
mean JJ N
increase NN N
, , N
6.7 CD N
% NN N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
2.5 CD N
% NN N
, , N
11.0 CD N
% NN N
; : N
P NNP N
= NNP N
.003 NNP N
) ) N
. . N

A DT N
shift NN N
in IN N
Wolfe NNP N
classification NN N
from IN N
lower JJR o
to TO o
greater JJR o
parenchymal JJ o
density NN o
was VBD N
noted VBN N
in IN N
24 CD N
% NN N
of IN N
subjects NNS N
( ( N
P NNP N
= NNP N
.016 NNP N
) ) N
. . N

Multivariate NNP N
analysis NN N
results NNS N
indicated VBD N
that IN N
the DT N
lower JJR N
the DT N
tissue NN o
density NN o
percentage NN o
before IN N
treatment NN N
, , N
the DT N
greater JJR N
the DT N
increase NN o
in IN o
density NN o
percentage NN o
after IN N
treatment NN N
. . N

CONCLUSION NNP N
An DT N
increase NN N
in IN N
mammographic JJ o
density NN o
was VBD N
demonstrated VBN N
in IN N
most JJS N
subjects NNS p
undergoing VBG p
continuous JJ p
combined VBN p
HRT NNP p
and CC N
was VBD N
most RBS N
pronounced JJ N
in IN N
subjects NNS N
with IN N
a DT N
lower JJR N
baseline NN N
density NN N
percentage NN N
. . N

-DOCSTART- -20089562- O O

Epirubicin NNP i
and CC i
cyclophosphamide VB i
versus NN N
epirubicin NN i
and CC i
docetaxel NN i
as IN N
first-line JJ N
therapy NN N
for IN N
women NNS p
with IN p
metastatic JJ p
breast NN p
cancer NN p
: : p
final JJ N
results NNS N
of IN N
a DT N
randomised JJ N
phase NN N
III NNP N
trial NN N
. . N

BACKGROUND VB N
This DT N
randomised JJ N
phase NN N
III NNP N
trial NN N
was VBD N
carried VBN N
out IN N
to TO N
compare VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
epirubicin NN i
and CC i
cyclophosphamide NN i
( ( i
EC NNP i
) ) i
with IN i
epirubicin NN i
and CC i
docetaxel NN i
( ( i
Taxotere NNP i
) ) i
( ( i
ED NNP i
) ) i
as IN N
first-line JJ N
chemotherapy NN N
for IN N
metastatic JJ p
breast NN p
cancer NN p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNP p
( ( p
n JJ p
= NNP p
240 CD p
) ) p
were VBD p
randomly RB p
assigned VBN p
to TO N
receive VB N
either DT N
ED NNP i
( ( i
epirubicin JJ i
75 CD N
mg/m NN N
( ( N
2 CD N
) ) N
and CC i
docetaxel $ i
75 CD N
mg/m NN N
( ( N
2 CD N
) ) N
) ) N
or CC N
EC NNP i
( ( i
epirubicin VBP i
90 CD N
mg/m NN N
( ( N
2 CD N
) ) N
and CC N
cyclophosphamide $ i
600 CD N
mg/m NN N
( ( N
2 CD N
) ) N
) ) N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
objective JJ o
response NN o
rate NN o
( ( o
ORR NNP o
) ) o
. . o

Secondary JJ N
end NN N
points NNS N
were VBD N
progression-free JJ o
survival NN o
( ( o
PFS NNP o
) ) o
, , o
overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
, , o
and CC o
safety NN o
. . o

RESULTS NNP N
ORR NNP o
for IN N
patients NNS N
randomly RB N
assigned VBN N
to TO N
receive VB N
EC NNP i
and CC N
ED NNP i
were VBD N
42 CD N
% NN N
and CC N
47 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
0.63 CD N
) ) N
. . N

Median JJ o
PFS NNP o
[ NNP N
10.1 CD N
versus NN N
10.3 CD N
months NNS N
; : N
hazard VBN N
ratio NN N
( ( N
HR NNP N
) ) N
0.98 CD N
; : N
log-rank JJ N
P NNP N
= NNP N
0.38 CD N
] NN N
and CC N
OS NNP o
( ( N
19.9 CD N
versus NN N
30.0 CD N
months NNS N
; : N
HR NNP N
0.663 CD N
; : N
log-rank JJ N
P NNP N
= NNP N
0.21 CD N
) ) N
were VBD N
comparable JJ N
in IN N
both DT N
arms NNS N
. . N

Although IN N
grade JJ o
3/4 CD o
leucopenia NN o
occurred VBD N
more RBR N
frequently RB N
with IN N
ED NNP i
( ( N
81 CD N
% NN N
versus IN N
73 CD N
% NN N
; : N
P NNP N
= NNP N
0.01 CD N
) ) N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
incidence NN N
of IN N
febrile JJ o
neutropenia NN o
and CC o
grade VBD o
3/4 CD o
infections NNS o
. . o

Grade VB o
3/4 CD o
non-haematologic JJ o
toxicity NN o
was VBD N
infrequent JJ N
in IN N
both DT N
arms NNS N
. . N

Congestive JJ o
heart NN o
failure NN o
was VBD N
observed VBN N
in IN N
one CD N
patient NN N
in IN N
each DT N
arm NN N
. . N

CONCLUSION NN N
In IN N
this DT N
randomised JJ N
trial NN N
, , N
no DT N
differences NNS N
in IN N
the DT N
efficacy NN N
study VBD N
end JJ N
points NNS N
were VBD N
observed VBN N
between IN N
the DT N
two CD N
treatment NN N
arms NNS N
. . N

-DOCSTART- -17574073- O O

The DT N
relationship NN N
between IN N
histology NN o
and CC o
outcome NN o
in IN N
advanced JJ p
and CC p
recurrent JJ p
endometrial JJ p
cancer NN p
patients NNS p
participating VBG p
in IN p
first-line JJ p
chemotherapy NN i
trials NNS p
: : p
a DT N
Gynecologic NNP N
Oncology NNP N
Group NNP N
study NN N
. . N

OBJECTIVES NNP N
To TO N
explore VB N
associations NNS N
between IN N
histology NN o
and CC o
outcome NN o
in IN N
advanced JJ p
or CC p
recurrent JJ p
endometrial JJ p
cancer NN p
patients NNS p
participating VBG p
in IN p
Gynecologic NNP p
Oncology NNP p
Group NNP p
chemotherapy NN p
trials NNS p
. . p

METHODS NNP N
Age NNP o
, , o
race NN o
, , o
performance NN o
status NN o
, , o
histologic JJ o
type NN o
( ( o
serous=S JJ o
; : o
clear JJ o
cell=CC NN o
; : o
endometrioid=E CC o
) ) o
, , o
disease JJ o
stage NN o
, , o
and CC o
prior JJ o
radiation NN o
were VBD N
evaluated VBN N
using VBG N
various JJ i
analytic JJ i
methods NNS i
to TO i
evaluate VB i
the DT i
probability NN i
of IN i
response NN i
and CC i
identify VB i
independent JJ i
predictors NNS i
of IN i
progression-free JJ o
survival NN o
( ( o
PFS NNP o
) ) o
and CC o
overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
. . o

RESULTS NNP N
Single NNP i
agent NN i
or CC N
combination NN i
chemotherapy NN i
regimens VBZ i
including VBG N
doxorubicin NN i
( ( i
A DT i
) ) i
( ( N
12 CD N
% NN N
) ) N
, , N
doxorubicin/cisplatin NN i
( ( N
AP NNP N
) ) N
( ( N
63 CD N
% NN N
) ) N
, , N
doxorubicin/paclitaxel FW i
( ( N
AT NNP N
) ) N
( ( N
13 CD N
% NN N
) ) N
, , N
and CC N
paclitaxel/doxorubicin/cisplatin NN i
( ( N
TAP NNP N
) ) N
( ( N
11 CD N
% NN N
) ) N
were VBD N
used VBN N
among IN N
1203 CD p
patients NNS p
treated VBN p
on IN p
4 CD p
randomized JJ p
clinical JJ p
trials NNS p
. . p

Breakdown NNP N
of IN N
disease NN o
stage NN o
was VBD N
7.8 CD N
% NN N
stage NN N
III NNP N
, , N
22.8 CD N
% NN N
stage NN N
IV NNP N
, , N
and CC N
69.4 CD N
% NN N
recurrent JJ N
disease NN N
. . N

Histologic NNP o
distribution NN o
was VBD N
18 CD N
% NN N
S NNP N
, , N
3.7 CD N
% NN N
CC NNP N
, , N
8.5 CD N
% NN N
mixed JJ N
, , N
51.7 CD N
% NN N
E NNP N
and CC N
18.1 CD N
% NN N
other JJ N
. . N

More JJR N
S/CC JJ N
patients NNS N
enrolled VBN N
on IN N
trials NNS N
with IN N
advanced JJ N
stage NN N
( ( N
III-IV NNP N
) ) N
disease NN N
( ( N
as IN N
opposed VBN N
to TO N
recurrent VB N
disease NN N
) ) N
compared VBN N
to TO N
E VB N
patients NNS N
( ( N
45 CD N
% NN N
vs. FW N
24 CD N
% NN N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
. . N

Overall JJ o
response NN o
rate NN o
was VBD N
42 CD N
% NN N
( ( N
E=44 NNP N
% NN N
, , N
S=44 NNP N
% NN N
, , N
CC=32 NNP N
% NN N
) ) N
. . N

Histologic NNP o
type NN o
was VBD N
not RB N
an DT N
independent JJ N
predictor NN N
of IN N
response NN N
. . N

Independent JJ N
predictors NNS N
of IN N
PFS NNP N
included VBD N
race NN o
, , o
performance NN o
status NN o
, , o
disease NN o
stage NN o
, , o
and CC o
CC NNP o
histology NN o
. . o

Histology NNP o
was VBD N
also RB N
an DT N
independent JJ N
predictor NN N
of IN N
OS NNP N
; : N
the DT N
relative JJ o
hazard NN o
ratio NN o
for IN N
S NNP N
histology NN N
was VBD N
1.2 CD N
( ( N
1.02-1.4 CD N
; : N
p=0.03 NN N
) ) N
, , N
and CC N
for IN N
CC NNP N
was VBD N
1.51 CD N
( ( N
1.1-2.07 CD N
; : N
p=0.01 NN N
) ) N
. . N

CONCLUSION NNP N
In IN N
patients NNS p
with IN p
advanced/recurrent JJ p
endometrial JJ p
cancer NN p
treated VBN N
with IN N
A NNP N
, , N
P NNP N
and/or VBZ N
T NNP N
, , N
response NN N
was VBD N
not RB o
associated VBN o
with IN o
histology NN o
. . o

This DT N
exploratory JJ N
analysis NN N
does VBZ N
not RB N
support VB N
exclusion NN N
of IN N
S NNP N
tumors NNS N
in IN N
future JJ N
trials NNS N
. . N

Poorer NNP o
PFS NNP o
and CC o
OS NNP o
were VBD N
observed VBN N
in IN N
CC NNP N
compared VBN N
to TO N
other JJ N
types NNS N
, , N
but CC N
a DT N
lack NN N
of IN N
benefit NN N
from IN N
chemotherapy NN N
was VBD N
not RB N
shown VBN N
, , N
and CC N
as IN N
this DT N
histology NN N
represents VBZ N
such PDT N
a DT N
small JJ N
fraction NN N
, , N
it PRP N
does VBZ N
not RB N
seem VB N
feasible JJ N
to TO N
have VB N
separate JJ N
chemotherapy NN N
trials NNS N
for IN N
CC NNP N
. . N

-DOCSTART- -15591456- O O

Sialyl NNP i
Lewisa NNP i
expression NN i
as IN N
a DT N
predictor NN N
of IN N
the DT N
prognosis NN N
of IN N
colon NN p
carcinoma NN p
patients NNS p
in IN N
a DT N
prospective JJ N
randomized VBN N
clinical JJ N
trial NN N
. . N

BACKGROUND VB N
The DT N
metastatic JJ N
potential NN N
of IN N
tumors NNS N
is VBZ N
dependent JJ N
on IN N
the DT N
cell NN N
to TO N
cell VB N
adhesion NN N
by IN N
cell NN N
surface NN N
carbohydrate NN N
antigens NNS N
. . N

Thus RB N
, , N
expression NN N
of IN N
sialyl NN N
Lewis NNP N
( ( N
a DT N
) ) N
, , N
which WDT N
is VBZ N
one CD N
of IN N
the DT N
important JJ N
molecules NNS N
of IN N
cell NN N
surface NN N
carbohydrates NNS N
, , N
may MD N
serve VB N
as IN N
a DT N
prognostic JJ N
marker NN N
of IN N
aggressive JJ N
and CC N
metastasizing VBG N
tumor NN N
growth NN N
. . N

However RB N
, , N
the DT N
prognostic JJ N
value NN N
of IN N
sialyl JJ N
Lewis NNP N
( ( N
a DT N
) ) N
expression NN N
in IN N
colon NN N
cancer NN N
is VBZ N
still RB N
controversial JJ N
. . N

METHODS NNP N
In IN N
this DT N
study NN N
, , N
we PRP N
investigated VBD N
the DT N
expression NN i
of IN i
sialyl NN i
Lewis NNP i
( ( i
a DT i
) ) i
antigen NN i
in IN N
233 CD p
colon NN i
cancer NN i
specimens NNS i
from IN p
patients NNS p
who WP p
were VBD p
registered VBN p
in IN p
a DT p
prospective JJ p
adjuvant NN i
immunochemotherapy NN i
clinical JJ p
trial NN p
. . p

The DT N
clinical JJ N
course NN N
and CC N
the DT N
prognosis NN N
of IN N
the DT N
patients NNS N
were VBD N
evaluated VBN N
after IN N
all PDT N
the DT N
immunohistochemical JJ N
analyses NNS N
had VBD N
been VBN N
performed VBN N
. . N

RESULTS NNP N
Sialyl NNP N
Lewis NNP N
( ( N
a DT N
) ) N
expression NN N
levels NNS N
were VBD N
correlated VBN N
with IN N
both DT N
overall JJ o
survival NN o
( ( N
P NNP N
= NNP N
0.0006 CD N
) ) N
and CC N
disease-free JJ o
survival NN o
( ( N
P NNP N
= NNP N
0.004 CD N
) ) N
in IN N
all DT N
patients NNS N
with IN N
the DT N
log-rank JJ N
test NN N
. . N

This DT N
result NN N
could MD N
be VB N
assumed VBN N
to TO N
have VB N
been VBN N
influenced VBN N
by IN N
the DT N
difference NN N
in IN N
the DT N
metastatic JJ N
preponderance NN N
in IN N
a DT N
high JJ N
versus NN N
low JJ N
sialyl NN N
Lewis NNP N
( ( N
a DT N
) ) N
expression NN N
in IN N
the DT N
tumor NN N
cells NNS N
. . N

CONCLUSION VB N
This DT N
prospective JJ N
study NN N
in IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
suggests VBZ N
that IN N
sialyl NN N
Lewis NNP N
( ( N
a DT N
) ) N
expression NN N
levels NNS N
may MD N
serve VB N
as IN N
an DT N
indicator NN N
of IN N
the DT N
metastatic JJ N
potential NN N
of IN N
colon NN N
cancer NN N
cells NNS N
, , N
which WDT N
would MD N
strongly RB N
predict VB N
the DT N
prognosis NN N
. . N

-DOCSTART- -11331049- O O

A DT N
randomized VBN N
controlled VBN N
trial NN N
assessing VBG N
the DT N
health NN o
economics NNS o
of IN o
realtime NN o
teledermatology NN o
compared VBN i
with IN i
conventional JJ i
care NN i
: : i
an DT N
urban JJ p
versus NN p
rural JJ p
perspective NN p
. . p

A DT N
randomized JJ N
controlled JJ N
trial NN N
was VBD N
carried VBN N
out IN N
to TO N
measure VB N
the DT N
cost-effectiveness NN o
of IN o
realtime NN o
teledermatology NN o
compared VBN N
with IN N
conventional JJ i
outpatient NN i
dermatology NN i
care NN i
for IN N
patients NNS p
from IN p
urban JJ p
and CC p
rural JJ p
areas NNS p
. . p

One CD N
urban NN N
and CC N
one CD N
rural JJ N
health NN N
centre NNS N
were VBD N
linked VBN N
to TO N
a DT N
regional JJ N
hospital NN N
in IN N
Northern NNP N
Ireland NNP N
by IN N
ISDN NNP N
at IN N
128 CD N
kbit/s NN N
. . N

Over IN p
two CD p
years NNS p
, , p
274 CD p
patients NNS p
required VBD p
a DT p
hospital JJ p
outpatient NN p
dermatology NN p
referral JJ p
-- : p
126 CD p
patients NNS p
( ( p
46 CD p
% NN p
) ) p
were VBD N
randomized VBN N
to TO N
a DT N
telemedicine JJ i
consultation NN i
and CC N
148 CD N
( ( N
54 CD N
% NN N
) ) N
to TO N
a DT N
conventional JJ i
hospital NN i
outpatient JJ i
consultation NN i
. . i

Of IN N
those DT N
seen VBN N
by IN N
telemedicine NN i
, , N
61 CD N
% NN N
were VBD N
registered VBN N
with IN N
an DT N
urban JJ N
practice NN N
, , N
compared VBN N
with IN N
71 CD N
% NN N
of IN N
those DT N
seen VBN N
conventionally RB i
. . i

The DT N
clinical JJ o
outcomes NNS o
of IN N
the DT N
two CD N
types NNS N
of IN N
consultation NN o
were VBD N
similar JJ o
-- : o
almost RB o
half PDT N
the DT N
patients NNS N
were VBD N
managed VBN N
after IN N
a DT N
single JJ N
consultation NN N
with IN N
the DT N
dermatologist NN N
. . N

The DT N
observed JJ o
marginal JJ o
cost NN o
per IN o
patient NN o
of IN N
the DT N
initial JJ N
realtime NN i
teledermatology NN i
consultation NN i
was VBD N
52.85 CD N
Pounds NNS N
for IN N
those DT N
in IN N
urban JJ N
areas NNS N
and CC N
59.93 CD N
Pounds NNS N
per IN N
patient NN N
for IN N
those DT N
from IN N
rural JJ N
areas NNS N
. . N

The DT N
observed JJ o
marginal JJ o
cost NN o
of IN N
the DT N
initial JJ N
conventional JJ i
consultation NN i
was VBD N
47.13 CD N
Pounds NNS N
for IN N
urban JJ p
patients NNS p
and CC N
48.77 CD N
Pounds NNS N
for IN N
rural JJ p
patients NNS p
. . p

The DT N
total JJ o
observed JJ o
costs NNS o
of IN N
teledermatology NN o
were VBD N
higher JJR N
than IN N
the DT N
costs NNS N
of IN N
conventional JJ i
care NN i
in IN N
both DT N
urban JJ N
and CC N
rural JJ N
areas NNS N
, , N
mainly RB N
because IN N
of IN N
the DT N
fixed JJ N
equipment NN N
costs NNS N
. . N

Sensitivity NNP N
analysis NN N
using VBG N
a DT N
real-world NN N
scenario NN N
showed VBD N
that IN N
in IN p
urban JJ p
areas NNS p
the DT N
average JJ o
costs NNS o
of IN N
the DT N
telemedicine NN i
and CC N
conventional JJ i
consultations NNS i
were VBD N
about RB N
equal JJ N
, , N
while IN N
in IN p
rural JJ p
areas NNS p
the DT N
average JJ N
cost NN N
of IN N
the DT N
telemedicine NN i
consultation NN i
was VBD N
less JJR N
than IN N
that DT N
of IN N
the DT N
conventional JJ i
consultation NN i
. . i

-DOCSTART- -11828556- O O

Carpal NNP N
tunnel NN N
release NN N
by IN N
limited JJ i
palmar NN i
incision NN i
vs IN i
traditional JJ i
open JJ i
technique NN i
: : i
randomized VBN N
controlled JJ N
trial NN N
. . N

AIM NNP N
To TO N
compare VB N
a DT N
limited JJ i
palmar NN i
incision NN i
for IN i
carpal JJ i
tunnel NN i
release NN i
( ( i
CTR NNP i
) ) i
with IN i
a DT i
traditional JJ i
open JJ i
technique NN i
, , N
which WDT N
is VBZ N
still RB N
considered VBN N
the DT N
gold JJ N
standard NN N
. . N

METHODS NNP N
Seventy-two JJ p
patients NNS p
with IN p
a DT p
carpal JJ p
tunnel NN p
syndrome NN p
were VBD p
individually RB p
randomized VBN p
into IN p
the DT p
trial NN p
( ( i
limited JJ i
incision NN i
CTR NNP i
) ) i
( ( p
n=36 JJ p
) ) p
and CC p
control NN p
group NN p
( ( i
traditional JJ i
technique NN i
CTR NNP i
) ) i
( ( p
n=36 JJ p
) ) p
. . p

In IN p
the DT p
trial NN p
group NN p
, , p
skin FW p
incision NN p
parallel NN p
to TO p
the DT p
thenar NN p
crease NN p
was VBD p
made VBN p
up RP p
to TO p
2.5 CD p
cm NN p
in IN p
length NN p
, , p
under IN p
an DT p
operating NN p
microscope NN p
and CC p
endoscopic JJ p
transillumination NN p
. . p

Skin NNP i
incision NN i
in IN p
the DT p
control NN p
group NN p
began VBD p
at IN p
the DT p
distal JJ p
border NN p
of IN p
the DT p
carpal JJ p
ligament NN p
, , p
followed VBD p
the DT p
longitudinal JJ p
crease NN p
of IN p
the DT p
palm NN p
, , p
and CC p
crossed VBD p
the DT p
base NN p
of IN p
the DT p
palm NN p
in IN p
a DT p
zigzag JJ p
fashion NN p
. . p

Three CD p
months NNS p
after IN p
surgery NN p
, , N
the DT N
patients NNS N
were VBD N
asked VBN N
about IN N
symptomatic JJ o
relief NN o
and CC o
intervals NNS o
between IN o
the DT o
operation NN o
and CC o
return NN o
to TO o
their PRP$ o
daily JJ o
activities NNS o
and CC o
work NN o
, , o
and CC o
examined VBD o
for IN o
scar NN o
tenderness NN o
and CC o
esthetic JJ o
outcome NN o
. . o

Distal NNP o
motor NN o
latency NN o
, , o
conduction NN o
velocity NN o
, , o
scar NN o
length NN o
, , o
scar NN o
width NN o
, , o
and CC o
operation NN o
time NN o
were VBD N
measured VBN N
. . N

RESULTS VB N
There EX N
were VBD N
no DT N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
in IN N
symptomatic JJ o
relief NN o
and CC o
electrophysiological JJ o
parameters NNS o
. . o

Intervals NNS o
between IN o
the DT o
operation NN o
and CC o
return NN o
to TO o
daily JJ o
activities NNS o
( ( N
median JJ N
5 CD N
days NNS N
, , N
range VBP N
2-15 JJ N
) ) N
were VBD N
shorter JJR N
in IN N
the DT N
trial NN N
group NN N
than IN N
in IN N
the DT N
control NN N
group NN N
( ( N
median JJ N
10 CD N
days NNS N
, , N
range VBP N
2-21 JJ N
; : N
p VB N
< $ N
0.001 CD N
) ) N
, , N
as RB N
well RB N
as IN N
the DT N
intervals NNS o
between IN o
the DT o
operation NN o
and CC o
return NN o
to TO o
work VB o
( ( N
median JJ N
15 CD N
days NNS N
, , N
range VBP N
5-45 JJ N
vs NN N
median JJ N
30 CD N
days NNS N
, , N
range VBP N
10-60 JJ N
; : N
p VB N
< $ N
0.001 CD N
) ) N
. . N

Scar/pillar JJ o
tenderness NN o
, , o
scar NN o
length NN o
and CC o
width NN o
, , o
esthetic JJ o
outcome NN o
, , o
and CC o
operation NN o
time NN o
were VBD N
significantly RB N
better RBR N
in IN N
the DT N
trial NN N
group NN N
. . N

CONCLUSION NNP N
Limited NNP i
palmar NN i
incision NN i
CTR NNP i
is VBZ N
as IN N
effective JJ N
and CC N
safe JJ N
as IN N
traditional JJ i
CTR NNP i
technique NN i
, , N
but CC N
with IN N
better JJR N
postoperative JJ N
recovery NN N
and CC N
cosmetic JJ N
results NNS N
. . N

-DOCSTART- -7680306- O O

[ NN N
Late NNP N
cardiac NN o
toxicity NN o
in IN N
Hodgkin NNP N
's POS N
disease NN N
. . N

A DT N
study NN N
with IN N
pulsed JJ i
Doppler NNP i
echocardiography NN i
] NNP i
. . N

49 CD p
patients NNS p
( ( p
22 CD p
women NNS p
, , p
27 CD p
men NNS p
, , p
mean JJ p
age NN p
43.7 CD p
[ JJ p
21-65 JJ p
] NNP p
years NNS p
) ) p
with IN p
Hodgkin NNP p
's POS p
disease NN p
were VBD N
examined VBN N
by IN N
Doppler NNP i
echocardiography NN i
a DT N
median NN p
of IN p
5.37 CD p
( ( p
2-10 JJ p
) ) p
years NNS p
after IN p
the DT p
end NN p
of IN p
chemotherapy NN p
( ( p
given VBN p
according VBG p
to TO p
the DT p
COPP/ABVD NNP p
scheme NN p
, , p
with IN p
or CC p
without IN p
mediastinal JJ i
irradiation NN i
) ) i
for IN N
possible JJ N
chronic JJ o
changes NNS o
in IN o
myocardium NN o
, , o
pericardium NN o
or CC o
cardiac JJ o
valves NNS o
, , N
as RB N
well RB N
as IN N
for IN N
any DT N
haemodynamic JJ o
sequelae NN o
. . o

Maximal NNP o
and CC o
integrated VBN o
early JJ o
( ( o
E NNP o
, , o
Ei NNP o
) ) o
and CC N
late JJ o
( ( o
A NNP o
, , o
Ai NNP o
) ) o
diastolic NN o
flow NN o
velocities NNS o
and CC o
their PRP$ o
ratio NN o
( ( o
E/A NNP o
, , o
Ei/Ai NNP o
) ) o
were VBD N
measured VBN N
by IN N
pulsed JJ i
Doppler NNP i
over IN N
the DT N
mitral JJ N
and CC N
tricuspid JJ N
valves NNS N
. . N

Although IN N
on IN N
two-dimensional JJ N
echo JJ N
21 CD N
patients NNS N
( ( N
42.9 CD N
% NN N
) ) N
were VBD N
found VBN N
to TO N
have VB N
valvar NN o
thickening NN o
, , N
19 CD N
( ( N
38.8 CD N
% NN N
) ) N
pericardial NN o
thickening NN o
and CC N
9 CD N
( ( N
18.4 CD N
% NN N
) ) N
a DT N
reduced VBN o
fibre NN o
shortening VBG o
fraction NN o
, , o
the DT o
Doppler NNP o
indices NNS o
were VBD N
statistically RB N
not RB N
significantly RB N
different JJ N
from IN N
those DT N
in IN N
25 CD N
controls NNS N
with IN N
normal JJ N
hearts NNS N
. . N

These DT N
echocardiographic JJ N
data NNS N
of IN N
functional JJ o
and CC o
morphological JJ o
parameters NNS o
indicate VBP N
that IN N
there EX N
was VBD N
no DT N
effect NN N
on IN N
various JJ N
measurements NNS o
of IN o
diastolic JJ o
function NN o
after IN N
chemotherapy NN N
with IN N
or CC N
without IN N
mediastinal JJ N
radiation NN N
. . N

In IN N
successfully RB p
treated VBN p
patients NNS p
with IN p
Hodgkin NNP p
's POS p
disease NN p
the DT N
described VBN N
changes NNS N
are VBP N
of IN N
minor JJ N
significance NN N
. . N

-DOCSTART- -17848325- O O

Small-diameter JJ i
hysteroscopy NN i
with IN i
Versapoint NNP i
versus NN N
resectoscopy NN i
with IN i
a DT i
unipolar JJ i
knife NN i
for IN N
the DT N
treatment NN N
of IN N
septate JJ p
uterus NN p
: : p
a DT N
prospective JJ N
randomized NN N
study NN N
. . N

STUDY NNP N
OBJECTIVE NNP N
To TO N
compare VB N
2 CD N
procedures NNS N
for IN N
metroplasty NN N
: : N
resectoscopy NN i
with IN i
monopolar JJ i
knife NNS i
versus IN N
small-diameter JJ i
hysteroscopy NN i
fitted VBN i
with IN i
a DT i
Versapoint NNP i
device NN i
. . i

DESIGN NNP N
Prospective NNP N
randomized VBN N
study NN N
( ( N
Canadian JJ N
Task NNP N
Force NNP N
classification NN N
I PRP N
) ) N
. . N

SETTING NN N
Endoscopic NNP p
gynecology NN p
units NNS p
at IN p
tertiary JJ p
care NN p
university NN p
hospitals NNS p
. . p

PATIENTS VB N
One CD p
hundred-sixty JJ p
patients NNS p
with IN p
septate JJ p
uterus NNS p
and CC p
a DT p
history NN p
of IN p
recurrent JJ p
abortion NN p
or CC p
primary JJ p
infertility NN p
undergoing VBG p
hysteroscopic NN p
metroplasty NN p
from IN p
2001 CD p
to TO p
2005 CD p
. . p

INTERVENTIONS NNP N
Hysteroscopic NNP i
resection NN N
of IN N
the DT N
uterine JJ N
septum NN N
performed VBN N
with IN N
either CC N
a DT N
26F CD i
resectoscope NN i
with IN i
unipolar JJ i
knife NN i
( ( N
80 CD N
women NNS N
, , N
group NN N
A NNP N
) ) N
or CC N
a DT N
5-mm JJ i
diameter NN i
hysteroscope NN i
with IN i
Versapoint NNP i
device NN i
( ( N
80 CD N
women NNS N
, , N
group NN N
B NNP N
) ) N
. . N

All DT N
patients NNS N
were VBD N
managed VBN N
expectantly RB N
, , N
with IN N
follow-up JJ N
lasting VBG N
1 CD N
year NN N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Operative NNP N
parameters NNS N
( ( o
operative JJ o
time NN o
, , o
fluid JJ o
absorption NN o
, , o
complications NNS o
, , o
need VBP o
for IN o
second JJ o
intervention NN o
) ) o
and CC N
reproductive JJ N
outcome NN N
parameters NNS N
( ( o
pregnancy NN o
, , o
abortion NN o
, , o
term NN o
and CC o
preterm JJ o
delivery NN o
, , o
modality NN o
of IN o
delivery NN o
, , o
cervical JJ o
cerclage NN o
) ) o
were VBD N
measured VBN N
. . N

Operative JJ o
time NN o
and CC o
fluid JJ o
absorption NN o
were VBD N
significantly RB N
greater JJR N
in IN N
group NN N
A NNP N
than IN N
in IN N
group NN N
B NNP N
( ( N
23.4 CD N
+/- JJ N
5.7 CD N
vs JJ N
16.9 CD N
+/- JJ N
4.7 CD N
minutes NNS N
and CC N
486.4 CD N
+/- JJ N
170.0 CD N
vs JJ N
222.1 CD N
+/- JJ N
104.9 CD N
mL NN N
, , N
respectively RB N
) ) N
. . N

The DT N
cumulative JJ o
complication NN o
rate NN o
was VBD N
significantly RB N
lower JJR N
in IN N
group NN N
B NNP N
than IN N
in IN N
group NN N
A NNP N
. . N

No DT N
difference NN N
in IN N
any DT N
of IN N
the DT N
reproductive JJ o
parameters NNS o
was VBD N
observed VBN N
between IN N
the DT N
2 CD N
groups NNS N
: : N
pregnancy NN o
and CC o
delivery NN o
rates NNS o
were VBD N
70 CD N
% NN N
and CC N
81.6 CD N
% NN N
in IN N
group NN N
A NNP N
vs RB N
76.9 CD N
% NN N
and CC N
84 CD N
% NN N
in IN N
group NN N
B NNP N
. . N

Nine NNP N
women NNS N
( ( N
18.4 CD N
% NN N
) ) N
from IN N
group NN N
B NNP N
and CC N
8 CD N
women NNS N
( ( N
16 CD N
% NN N
) ) N
from IN N
group NN N
B NNP N
experienced VBD N
spontaneous JJ o
abortions NNS o
. . o

Most JJS N
patients NNS N
( ( N
54/82 CD N
) ) N
delivered VBN N
by IN N
cesarean JJ o
section NN o
without IN o
differences NNS o
according VBG N
to TO N
the DT N
hysteroscopic NN N
technique NN N
used VBN N
for IN N
metroplasty NN N
( ( N
65 CD N
% NN N
in IN N
group NN N
A NNP N
vs RB N
67.7 CD N
% NN N
in IN N
group NN N
B NNP N
) ) N
or CC N
to TO N
the DT N
gestational JJ N
age NN N
( ( N
65.1 CD N
% NN N
of IN N
term NN N
and CC N
68.7 CD N
% NN N
of IN N
preterm JJ N
deliveries NNS N
) ) N
. . N

CONCLUSIONS NNP N
Small-diameter NNP N
hysteroscopy NN i
with IN N
bipolar JJ N
electrode NN N
for IN N
the DT N
incision NN N
of IN N
uterine JJ N
septum NN N
is VBZ N
as RB N
effective JJ N
as IN N
resectoscopy NN i
with IN N
unipolar JJ N
electrode NN N
regarding VBG N
reproductive JJ N
outcome NN N
and CC N
is VBZ N
associated VBN N
with IN N
shorter JJR N
operating NN o
time NN o
and CC N
lower JJR N
complication NN o
rate NN o
. . o

-DOCSTART- -9241341- O O

2-Chloroprocaine JJ i
antagonism NN N
of IN N
epidural JJ N
morphine NN N
analgesia NN N
. . N

BACKGROUND NNP N
2-Chloroprocaine JJ i
( ( i
2-CP JJ i
) ) i
used VBN N
for IN N
lumbar JJ N
epidural JJ N
anesthesia NN N
( ( N
LEA NNP N
) ) N
reportedly RB N
decreases VBZ N
the DT N
efficacy NN N
of IN N
epidural JJ N
morphine NN i
( ( i
EM NNP i
) ) i
administered VBD N
for IN N
post-cesarean JJ p
section NN p
( ( p
CS NNP p
) ) p
analgesia NN N
. . N

The DT N
amount NN N
of IN N
supplemental JJ N
i.v NN N
. . N

morphine VB i
self-administered JJ p
by IN p
the DT p
patient NN p
via IN p
the DT p
patient-controlled JJ p
analgesia NN p
device NN p
( ( p
PCA NNP p
) ) p
is VBZ N
used VBN N
to TO N
study VB N
the DT N
interaction NN N
between IN N
EM NNP i
and CC N
2-CP JJ i
. . i

METHODS NNP N
Forty-two JJ p
patients NNS p
scheduled VBN p
for IN p
elective JJ p
CS NNP p
were VBD N
randomly RB N
divided VBN N
into IN N
3 CD N
equal JJ N
groups NNS N
, , N
and CC N
received VBD N
2-CP JJ i
, , i
2-CP JJ i
+ NN i
epinephrine NN i
( ( N
Epi NNP N
, , N
5 CD N
micrograms.ml-1 NN N
) ) N
or CC N
2 CD i
% NN i
lidocaine NN i
( ( i
Lido NNP i
) ) i
with IN i
Epi NNP i
for IN N
LEA NNP N
. . N

All DT p
patients NNS p
received VBD p
5 CD N
mg NNS N
EM NNP i
and CC N
i.v NN N
. . N

PCA NNP i
morphine NN i
for IN N
postoperative JJ N
pain NN N
. . N

Cumulative JJ o
amount NN o
of IN o
i.v NN o
. . o

morphine NN o
used VBN o
in IN o
the DT o
first JJ o
24 CD o
hours NNS o
as RB N
well RB N
as IN N
the DT N
amount NN o
of IN o
the DT o
drug NN o
used VBN o
during IN o
each DT o
2-h JJ o
period NN o
were VBD N
noted VBN N
. . N

Nonparametric JJ N
analysis NN N
of IN N
variance NN N
and CC N
Chi-squared JJ N
analysis NN N
were VBD N
used VBN N
for IN N
statistical JJ N
comparisons NNS N
. . N

RESULTS VB N
The DT N
mean JJ o
cumulative JJ o
24-h JJ o
i.v NN o
. . o

PCA NNP o
morphine JJ o
requirement NN o
in IN N
the DT N
2-CP JJ i
, , i
2-CP+Epi JJ i
and CC N
Lido+Epi NNP i
groups NNS N
respectively RB N
was VBD N
20.5 CD N
+/- JJ N
24 CD N
, , N
33.1.5 CD N
+/- JJ N
27 CD N
and CC N
4.07 CD N
+/- JJ N
( ( N
mean JJ N
+/- NNP N
SD NNP N
) ) N
. . N

The DT N
Lido NNP N
+ NNP N
Epi NNP N
group NN N
used VBD N
significantly RB N
less JJR o
morphine NN o
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
compared VBN N
to TO N
either DT N
of IN N
the DT N
2-CP JJ i
groups NNS N
with IN N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
2-CP JJ i
groups NNS N
. . N

The DT N
maximum JJ o
i.v NN o
. . o

PCA NNP o
morphine NN o
use NN o
occurred VBD N
in IN N
the DT N
first JJ N
4 CD N
hours NNS N
following VBG N
surgery NN N
in IN N
all DT N
three CD N
groups NNS N
. . N

CONCLUSION NNP N
Analgesic NNP o
efficacy NN o
of IN N
EM NNP i
is VBZ N
decreased VBN N
when WRB N
2-CP JJ i
is VBZ N
used VBN N
for IN N
LEA NNP N
compared VBN N
to TO N
when WRB N
Lido NNP i
+ NNP i
Epi NNP i
is VBZ N
used VBN N
. . N

-DOCSTART- -23647705- O O

Predicting VBG N
the DT N
effect NN N
of IN N
anthelmintic JJ i
treatment NN i
on IN N
milk NN o
production NN o
of IN o
dairy NN o
cattle NNS o
in IN p
Canada NNP p
using VBG N
an DT N
Ostertagia NNP N
ostertagi NN N
ELISA NNP N
from IN N
individual JJ N
milk NN N
samples NNS N
. . N

Gastrointestinal NNP p
nematodes NNS p
, , p
such JJ p
as IN p
Ostertagia NNP p
ostertagi NN p
and CC p
several JJ p
species NNS p
of IN p
Cooperia NNP p
, , p
are VBP p
ubiquitous JJ p
in IN p
temperate NN p
climates NNS p
and CC p
have VBP p
been VBN p
shown VBN p
to TO p
have VB p
detrimental JJ p
effects NNS p
on IN p
production NN p
in IN p
adult NN p
dairy NN p
cattle NNS p
. . p

A DT N
published VBN N
meta-analysis NN N
demonstrated VBD N
that IN N
overall JJ N
, , N
producers NNS N
lose VBP p
approximately RB p
0.35 CD p
kg NNS p
of IN p
milk NN p
per IN p
parasitized VBN p
cow NN p
per IN p
day NN p
. . p

Enzyme-linked JJ i
immunosorbent NN i
assays NNS i
( ( N
ELISAs NNP N
) ) N
have VBP N
the DT N
ability NN N
to TO N
quantify VB N
nematode JJ N
infections NNS N
in IN N
cattle NNS N
, , N
and CC N
thus RB N
, , N
could MD N
be VB N
used VBN N
to TO N
estimate VB N
the DT N
amount NN N
of IN N
milk NN N
production NN N
loss NN N
due JJ N
to TO N
differing VBG N
levels NNS N
of IN N
parasitism NN N
at IN N
the DT N
individual JJ N
cow NN N
level NN N
. . N

ELISA JJ p
results NNS p
from IN p
individual JJ p
cow NN p
milk NN p
samples NNS p
were VBD p
used VBN p
to TO p
predict VB p
milk NN p
production NN p
response NN p
following VBG N
a DT N
randomized JJ N
anthelmintic JJ N
treatment NN N
in IN N
a DT N
large JJ N
field NN N
trial NN N
. . N

To TO N
increase VB N
statistical JJ N
power NN N
, , N
the DT N
data NNS N
collected VBN N
from IN N
this DT N
field NN N
trial NN N
was VBD N
pooled VBN N
with IN N
data NNS N
from IN N
two CD N
other JJ N
published VBN N
field NN N
trials NNS N
to TO N
form VB N
an DT N
individual JJ N
patient NN N
data NNS N
meta-analysis NN N
( ( N
IPDMA NNP N
) ) N
. . N

The DT N
ability NN N
to TO N
predict VB N
the DT N
effect NN N
of IN N
anthelmintic JJ N
treatment NN N
on IN N
milk NN N
production NN N
depends VBZ N
on IN N
the DT N
level NN N
of IN N
parasitism NN N
quantified VBN N
by IN N
an DT N
ELISA NNP N
measuring NN N
milk NN o
antibodies NNS o
against IN N
O. NNP N
ostertagi NN N
, , N
and CC N
reported VBD N
as IN N
optical JJ o
density NN o
ratios NNS o
( ( o
ODRs NNP o
) ) o
. . N

Therefore RB N
, , N
the DT N
estimates NNS N
from IN N
the DT N
interaction NN N
between IN N
ODR NNP N
and CC N
treatment NN N
on IN N
milk NN N
production NN N
were VBD N
used VBN N
to TO N
determine VB N
how WRB N
well RB N
the DT N
ODR NNP N
predicted VBD N
the DT N
response NN N
of IN N
the DT N
treatment NN N
. . N

It PRP N
was VBD N
anticipated VBN N
that IN N
the DT N
relationship NN N
between IN N
milk NN o
production NN o
and CC N
ODR NNP o
was VBD N
unlikely JJ N
to TO N
be VB N
linear JJ N
, , N
so IN N
fractional JJ N
polynomials NNS N
were VBD N
applied VBN N
to TO N
the DT N
continuous JJ N
ODR NNP o
values NNS o
. . o

The DT N
interaction NN N
in IN N
the DT N
field NN N
trial NN N
showed VBD N
a DT N
trend NN N
( ( N
p=0.138 NN N
) ) N
toward IN N
a DT N
beneficial JJ N
treatment NN N
effect NN N
when WRB N
the DT N
individual JJ N
ODR NNP o
values NNS o
, , N
measured VBN N
in IN N
late JJ N
lactation NN N
and CC N
using VBG N
Svanovir NNP N
( ( N
? . N
) ) N
, , N
were VBD N
greater JJR N
than IN N
0.12 CD N
. . N

When WRB N
individual JJ N
data NNS N
from IN N
two CD N
other JJ N
similar JJ N
studies NNS N
were VBD N
included VBN N
in IN N
an DT N
IPDMA NNP N
, , N
the DT N
interaction NN N
terms NNS N
became VBD N
statistically RB N
significant JJ N
( ( N
p=0.009 NN N
) ) N
indicating NN N
that IN N
there EX N
is VBZ N
a DT N
beneficial JJ N
treatment NN N
effect NN N
when WRB o
ODR NNP o
values NNS o
are VBP N
slightly RB N
elevated VBN N
. . N

A DT N
graph NN N
was VBD N
used VBN N
to TO N
demonstrate VB N
the DT N
treatment NN N
effect NN N
( ( N
the DT N
estimated VBN N
difference NN N
of IN N
kg/cow/day NN N
of IN N
milk NN N
yield NN N
between IN N
the DT N
treated VBN N
and CC N
placebo JJ N
cows NNS N
) ) N
, , N
with IN N
95 CD N
% NN N
confidence NN N
intervals NNS N
, , N
as IN N
the DT o
ODR NNP o
values NNS o
increase NN N
. . N

It PRP N
is VBZ N
important JJ N
to TO N
note VB N
that IN N
the DT N
methods NNS N
of IN N
quantifying VBG N
the DT N
ODR NNP N
values NNS N
differed VBD N
between IN N
the DT N
three CD N
studies NNS N
in IN N
the DT N
IPDMA NNP N
, , N
therefore RB N
some DT N
caution NN N
should MD N
be VB N
used VBN N
when WRB N
using VBG N
these DT N
final JJ N
estimated VBN N
values NNS N
. . N

However RB N
, , N
the DT N
shape NN N
and CC N
magnitude NN N
of IN N
the DT N
treatment NN N
effects NNS N
, , N
as RB N
well RB N
as IN N
the DT N
other JJ N
fixed JJ N
model NN N
estimates NNS N
, , N
were VBD N
very RB N
similar JJ N
between IN N
the DT N
field NN N
trial NN N
and CC N
the DT N
IPDMA NNP N
suggesting VBG N
that IN N
any DT N
bias NN N
would MD N
likely RB N
be VB N
minimal JJ N
. . N

-DOCSTART- -7960300- O O

Assessing VBG N
drug NN N
use NN N
prevalence NN N
in IN N
the DT N
workplace NN N
: : N
a DT N
comparison NN N
of IN N
self-report JJ N
methods NNS N
and CC N
urinalysis NN N
. . N

A DT p
random JJ p
sample NN p
of IN p
800 CD p
employees NNS p
of IN p
a DT p
steel NN p
manufacturing VBG p
company NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
four CD N
self-report JJ i
methods NNS i
of IN N
assessing VBG N
illicit JJ i
drug NN i
use NN i
: : i
1 CD i
) ) i
Individual NNP i
interview NN i
in IN i
the DT i
workplace NN i
, , i
2 CD i
) ) i
group-administered JJ i
questionnaire NN i
in IN i
the DT i
workplace NN i
, , i
3 CD i
) ) i
telephone NN i
interview NN i
, , i
and CC i
4 CD i
) ) i
individual JJ i
interview NN i
off IN i
the DT i
worksite NN i
. . i

All DT p
621 CD p
subjects NNS p
participating VBG p
in IN p
the DT p
research NN p
were VBD p
also RB p
tested VBN p
by IN p
urinalysis NN p
. . p

Rates NNS o
of IN o
drug NN o
use IN o
self-report NN o
were VBD N
highest JJS N
in IN N
the DT N
workplace NN N
interview NN N
condition NN N
and CC N
lowest JJS N
in IN N
the DT N
overall JJ N
group NN N
questionnaire NN N
condition NN N
. . N

Although IN N
the DT N
overall JJ o
prevalence NN o
rates NNS o
produced VBN N
by IN N
self-reports NNS N
and CC N
urinalysis NN N
were VBD N
similar JJ N
, , N
there EX N
was VBD N
little JJ N
concordance NN N
between IN N
urinalysis NN o
positives NNS o
and CC N
self-report JJ o
positives NNS o
. . o

The DT N
results NNS N
indicated VBD N
that IN N
self-reports NNS N
and CC N
urinalysis NN N
are VBP N
complementary JJ N
methods NNS N
of IN N
drug NN o
use NN o
assessment NN o
, , N
and CC N
are VBP N
best JJS N
used VBN N
in IN N
combination NN N
. . N

-DOCSTART- -15587240- O O

Scent NN N
and CC N
mood NN N
state NN N
following VBG N
an DT N
anxiety-provoking JJ N
task NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
effects NNS N
of IN N
water NN i
, , i
lavender NN i
, , i
or CC i
rosemary JJ i
scent NN i
on IN N
physiology NN o
and CC o
mood NN o
state NN o
following VBG N
an DT N
anxiety-provoking JJ N
task NN N
. . N

The DT p
nonsmoking JJ p
participants NNS p
, , p
ages VBZ p
18-30 CD p
years NNS p
, , p
included VBD p
42 CD p
women NNS p
and CC p
31 CD p
men NNS p
who WP p
reported VBD p
demographic JJ p
information NN p
and CC p
measures NNS p
of IN p
external JJ p
temperature NN p
and CC p
heart NN p
rate NN p
were VBD p
taken VBN p
prior RB p
to TO p
introduction NN p
of IN p
an DT p
anxiety-eliciting JJ i
task NN i
and CC p
exposure NN p
to TO p
lavender VB i
, , i
rosemary JJ i
, , i
or CC i
water NN i
scents NNS i
. . i

Following VBG N
the DT N
task NN N
, , N
participants NNS N
completed VBD N
the DT N
Profile NNP N
of IN N
Mood NNP N
States NNPS N
to TO N
assess VB N
mood NN o
, , o
and CC o
temperature NN o
and CC o
heart NN o
rate NN o
were VBD N
reassessed VBN N
. . N

Participants NNS N
rated VBD N
the DT N
pleasantness NN N
of IN N
the DT N
scent NN N
received VBD N
. . N

When WRB N
pleasantness JJ N
ratings NNS N
of IN N
scent NN N
were VBD N
covaried VBN N
, , N
physiological JJ o
changes NNS o
in IN o
temperature NN o
and CC o
heart NN o
rate NN o
did VBD N
not RB N
differ VB N
based VBN N
on IN N
scent NN N
exposure NN N
, , N
but CC N
mood VBD o
ratings NNS o
differed VBN N
by IN N
scent JJ N
condition NN N
. . N

Participants NNS N
in IN N
the DT N
rosemary JJ N
condition NN N
scored VBD N
higher JJR N
on IN N
measures NNS N
of IN N
tension-anxiety NN o
and CC o
confusion-bewilderment JJ o
relative NN N
to TO N
the DT N
lavender NN N
and CC N
control NN N
conditions NNS N
. . N

The DT N
lavender NN N
and CC N
control NN N
conditions NNS N
showed VBD N
higher JJR N
mean JJ o
vigor-activity NN o
ratings NNS o
relative VBP N
to TO N
the DT N
rosemary JJ N
group NN N
, , N
while IN N
both DT N
rosemary JJ N
and CC N
lavender JJ N
scents NNS N
were VBD N
associated VBN N
with IN N
lower JJR N
mean NN o
ratings NNS o
on IN o
the DT o
fatigue-inertia JJ o
subscale NN o
, , N
relative JJ N
to TO N
the DT N
control NN N
group NN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
, , N
when WRB N
individual JJ N
perception NN N
of IN N
scent JJ N
pleasantness NN N
is VBZ N
controlled VBN N
, , N
scent NN N
has VBZ N
the DT N
potential JJ N
to TO N
moderate VB N
different JJ N
aspects NNS N
of IN N
mood NN N
following VBG N
an DT N
anxiety-provoking JJ N
task NN N
. . N

-DOCSTART- -12375315- O O

Combination NNP N
therapy NN N
with IN N
methotrexate NN i
and CC i
hydroxychloroquine NN i
for IN N
rheumatoid JJ p
arthritis NN p
increases NNS N
exposure VBP N
to TO N
methotrexate VB N
. . N

OBJECTIVE NNP N
To TO N
examine VB N
the DT N
bioavailability NN N
of IN N
methotrexate NN i
( ( i
MTX NNP i
) ) i
in IN N
the DT N
presence NN N
of IN N
hydroxychloroquine NN i
( ( i
HCQ NNP i
) ) i
, , N
and CC N
vice NN N
versa NN N
, , N
to TO N
determine VB N
a DT N
possible JJ N
pharmacokinetic JJ N
explanation NN N
for IN N
the DT N
observation NN N
that IN N
combination NN N
treatment NN N
of IN N
rheumatoid JJ N
arthritis NN N
with IN N
MTX NNP i
and CC N
HCQ NNP i
has VBZ N
been VBN N
shown VBN N
, , N
clinically RB N
, , N
to TO N
be VB N
more RBR N
potent JJ N
than IN N
MTX NNP i
used VBD N
alone RB N
. . N

METHODS NNP N
In IN N
a DT N
randomized VBN N
crossover NN N
study NN N
, , N
10 CD p
healthy JJ p
subjects NNS p
received VBN p
, , N
on IN N
each DT N
of IN N
5 CD N
dosing VBG N
occasions NNS N
, , N
MTX NNP i
alone RB N
as IN N
tablets NNS N
or CC N
intravenous JJ N
solution NN N
, , N
HCQ NNP i
alone RB N
as IN N
a DT N
tablet NN N
or CC N
oral JJ N
solution NN N
, , N
or CC N
a DT N
coadministered JJ N
dose NN N
of IN N
MTX NNP i
tablets NNS N
with IN N
an DT N
HCQ NNP i
tablet NN N
. . N

The DT N
area NN N
under IN N
the DT N
concentration-time JJ o
curve NN o
( ( o
AUC NNP o
) ) o
was VBD N
determined VBN N
for IN N
each DT N
subject NN N
, , N
on IN N
each DT N
dosing VBG N
occasion NN N
, , N
for IN N
each DT N
compound NN N
. . N

RESULTS VB N
The DT N
mean JJ o
AUC NNP o
for IN o
MTX NNP o
was VBD N
increased VBN N
( ( N
p JJ N
= NNP N
0.005 CD N
) ) N
and CC N
the DT N
maximum JJ o
MTX NNP o
concentration NN o
( ( o
Cmax NNP o
) ) o
decreased VBD N
( ( N
p JJ N
= NNP N
0.025 CD N
) ) N
when WRB N
MTX NNP i
was VBD N
coadministered VBN N
with IN N
HCQ NNP i
, , N
compared VBN N
to TO N
MTX NNP i
administered VBD N
alone RB N
. . N

The DT N
time NN o
to TO o
reach VB o
Cmax NNP o
for IN o
MTX NNP o
administration NN o
, , o
tmax NN o
, , N
was VBD N
also RB N
increased VBN N
during IN N
the DT N
coadministration NN N
with IN N
HCQ NNP i
( ( N
p JJ N
= NNP N
0.072 CD N
) ) N
. . N

The DT N
AUC NNP N
of IN N
HCQ NNP i
showed VBD N
no DT N
significant JJ N
difference NN o
( ( N
p JJ N
= NNP N
0.957 CD N
) ) N
between IN N
any DT N
of IN N
the DT N
dosing NN N
occasions NNS N
. . N

CONCLUSION NNP N
These DT N
results NNS N
may MD N
explain VB N
the DT N
increased JJ N
potency NN N
of IN N
the DT N
MTX-HCQ NNP i
combination NN N
over RB N
MTX NNP i
as IN N
a DT N
single JJ N
agent NN N
and CC N
also RB N
the DT N
sustained JJ N
effects NNS N
of IN N
MTX NNP i
when WRB N
administered VBN N
with IN N
HCQ NNP i
. . i

In IN N
addition NN N
, , N
the DT N
reduced JJ N
Cmax NNP N
of IN N
MTX NNP i
observed VBD N
during IN N
the DT N
coadministration NN N
may MD N
explain VB N
diminution NN N
of IN N
acute JJ N
liver JJ N
adverse JJ N
effects NNS N
. . N

Extra NNP N
vigilance NN N
for IN N
MTX NNP i
adverse JJ N
effects NNS N
during IN N
combination NN N
therapy NN N
with IN N
HCQ NNP i
is VBZ N
recommended VBN N
, , N
especially RB N
if IN N
renal JJ N
function NN N
is VBZ N
known VBN N
to TO N
be VB N
decreased VBN N
. . N

-DOCSTART- -24022375- O O

The DT N
effect NN N
of IN N
person-centred JJ i
dementia NN i
care NN i
to TO N
prevent VB N
agitation NN N
and CC N
other JJ N
neuropsychiatric JJ N
symptoms NNS N
and CC N
enhance JJ N
quality NN N
of IN N
life NN N
in IN N
nursing NN p
home NN p
patients NNS p
: : p
a DT N
10-month JJ N
randomized NN N
controlled VBD N
trial NN N
. . N

AIMS IN N
We PRP N
examined VBD N
whether IN N
Dementia NNP i
Care NNP i
Mapping NNP i
( ( i
DCM NNP i
) ) i
or CC N
the DT N
VIPS NNP i
practice NN i
model NN i
( ( i
VPM NNP i
) ) i
is VBZ N
more RBR N
effective JJ N
than IN N
education NN N
of IN N
the DT N
nursing NN N
home NN N
staff NN N
about IN N
dementia NN i
( ( N
control VB N
group NN N
) ) N
in IN N
reducing VBG N
agitation NN N
and CC N
other JJ N
neuropsychiatric JJ N
symptoms NNS N
as RB N
well RB N
as IN N
in IN N
enhancing VBG N
the DT N
quality NN N
of IN N
life NN N
among IN N
nursing JJ p
home NN p
patients NNS p
. . p

METHODS VB N
A DT N
10-month JJ N
three-armed JJ N
cluster-randomized JJ N
controlled VBN N
trial NN N
compared VBN N
DCM NNP i
and CC N
VPM NNP i
with IN N
control NN N
. . N

Of IN N
624 CD p
nursing NN p
home NN p
patients NNS p
with IN p
dementia NN p
, , p
446 CD p
completed VBD p
follow-up JJ p
assessments NNS p
. . p

The DT N
primary JJ N
outcome NN N
was VBD N
the DT N
change NN N
on IN N
the DT N
Brief JJ o
Agitation NNP o
Rating NNP o
Scale NNP o
( ( o
BARS NNP o
) ) o
. . o

Secondary JJ N
outcomes NNS N
were VBD N
changes NNS N
on IN N
the DT N
10-item JJ o
version NN o
of IN o
the DT o
Neuropsychiatric NNP o
Inventory NNP o
Questionnaire NNP o
( ( o
NPI-Q NNP o
) ) o
, , o
the DT o
Cornell NNP o
Scale NNP o
for IN o
Depression NNP o
in IN o
Dementia NNP o
( ( o
CSDD NNP o
) ) o
and CC o
the DT o
Quality NN o
of IN o
Life NNP o
in IN o
Late-Stage NNP o
Dementia NNP o
( ( o
QUALID NNP o
) ) o
scale NN o
. . o

RESULTS NNP N
Changes NNP N
in IN N
the DT N
BARS NNP o
score NN o
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
DCM NNP N
and CC N
the DT N
control NN N
group NN N
or CC N
between IN N
the DT N
VPM NNP N
and CC N
the DT N
control NN N
group NN N
after IN N
10 CD N
months NNS N
. . N

Positive JJ N
differences NNS N
were VBD N
found VBN N
for IN N
changes NNS N
in IN N
the DT N
secondary JJ N
outcomes NNS N
: : N
the DT N
NPI-Q NNP o
sum NN o
score NN o
as RB N
well RB N
as IN N
the DT N
subscales NNS N
NPI-Q NNP o
agitation NN o
and CC o
NPI-Q JJ o
psychosis NN o
were VBD N
in IN N
favour NN N
of IN N
both DT N
interventions NNS N
versus VBP N
control NN N
, , N
the DT N
QUALID NNP o
score NN o
was VBD N
in IN N
favour NN N
of IN N
DCM NNP N
versus NN N
control NN N
and CC N
the DT N
CSDD NNP o
score NN o
was VBD N
in IN N
favour NN N
of IN N
VPM NNP N
versus NN N
control NN N
. . N

CONCLUSIONS NNP N
This DT N
study NN N
failed VBD N
to TO N
find VB N
a DT N
significant JJ N
effect NN N
of IN N
both DT N
interventions NNS N
on IN N
the DT N
primary JJ N
outcome NN N
. . N

Positive JJ N
effects NNS N
on IN N
the DT N
secondary JJ N
outcomes NNS N
indicate VBP N
that IN N
the DT N
methods NNS N
merit VBP N
further JJ N
investigation NN N
. . N

-DOCSTART- -11570022- O O

A DT N
randomized VBN N
intervention NN N
to TO N
improve VB N
ongoing VBG o
participation NN o
in IN o
mammography NN o
. . o

OBJECTIVE UH N
To TO N
test VB N
the DT N
effectiveness NN N
of IN N
interventions NNS i
intended VBN i
to TO N
increase VB N
rates NNS o
of IN o
regular JJ o
breast NN o
cancer NN o
screening NN o
, , N
according VBG N
to TO N
recommended VBN N
guidelines NNS N
. . N

STUDY NNP N
DESIGN NNP N
A NNP N
randomized VBD N
controlled JJ N
trial NN N
of IN N
2 CD N
outreach NN i
interventions NNS i
( ( i
a DT i
mail NN i
reminder NN i
and CC i
a DT i
telephone NN i
reminder NN i
plus CC i
appointment JJ i
scheduling NN i
) ) i
compared VBN N
with IN N
a DT N
routine JJ i
publicity NN i
campaign NN i
to TO N
encourage VB N
continued JJ o
participation NN o
in IN o
mammography NN o
screening NN o
. . o

PARTICIPANTS NNP N
AND CC N
METHODS NNP N
Participants NNS p
were VBD p
1908 CD p
women NNS p
aged VBD p
50 CD p
to TO p
75 CD p
years NNS p
continuously RB p
enrolled VBD p
in IN p
a DT p
large JJ p
group-model JJ p
HMO NNP p
during IN p
the DT p
study NN p
who WP p
underwent VBD p
a DT p
bilateral JJ p
mammogram NN p
during IN p
the DT p
first JJ p
quarter NN p
of IN p
1994 CD p
and CC p
no DT p
subsequent JJ p
mammogram NN p
during IN p
the DT p
next JJ p
18 CD p
to TO p
21 CD p
months NNS p
. . p

Data NNS N
were VBD N
obtained VBN N
from IN N
health NN N
plan NN N
administrative JJ N
data NNS N
files NNS N
supplemented VBN N
by IN N
medical JJ N
chart NN N
review NN N
. . N

Women NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
( ( N
1 CD N
) ) N
a DT i
mail NN i
reminder NN i
, , i
( ( i
2 CD i
) ) i
a DT i
telephone NN i
reminder NN i
, , i
or CC i
( ( i
3 CD i
) ) i
routine JJ i
publicity NN i
on IN i
mammography NN i
for IN i
all DT i
women NNS i
. . i

The DT N
outcome NN N
measure NN N
was VBD N
a DT N
mammogram NN o
received VBN o
after IN o
the DT o
intervention NN o
period NN o
and CC o
within IN o
2 CD o
years NNS o
of IN o
the DT o
initial JJ o
mammogram NN o
date NN o
. . o

RESULTS NNP N
Bivariate NNP N
and CC N
multivariate VB N
statistical JJ N
analyses NNS N
showed VBD N
that IN N
participation NN N
was VBD N
significantly RB N
higher JJR N
for IN N
women NNS N
contacted VBN N
by IN N
telephone NN N
than IN N
through IN N
routine JJ N
publicity NN N
. . N

Mail NN N
reminders NNS N
were VBD N
no DT N
more RBR N
effective JJ N
than IN N
a DT N
routine JJ i
publicity NN i
campaign NN i
. . i

Primary NNP N
care NN N
physician NN N
and CC N
gynecologist JJ N
visits NNS N
increased VBD N
the DT N
likelihood NN N
of IN N
a DT N
subsequent JJ o
mammogram NN o
for IN N
women NNS N
in IN N
all DT N
intervention NN N
groups NNS N
. . N

CONCLUSIONS NNP N
Telephone NNP i
contact NN i
by IN N
regular JJ N
health NN N
plan NN N
staff NN N
was VBD N
more RBR N
successful JJ N
than IN N
publicity NN N
in IN N
encouraging VBG N
continued JJ N
participation NN o
in IN N
mammography NN o
screening NN o
in IN N
women NNS N
enrolled VBN N
in IN N
a DT N
group-model JJ N
managed NN N
health NN N
care NN N
plan NN N
. . N

Because IN N
mailings NNS N
did VBD N
not RB N
influence VB N
participation NN N
in IN N
mammography NN o
screening NN o
, , N
health NN N
plans NNS N
should MD N
be VB N
cautious JJ N
about IN N
investing VBG N
in IN N
member NN N
mailings NNS N
without IN N
first JJ N
evaluating VBG N
their PRP$ N
effectiveness NN N
in IN N
the DT N
context NN N
of IN N
existing VBG N
outreach NN N
efforts NNS N
. . N

-DOCSTART- -19951297- O O

The DT N
role NN N
of IN N
ethnic JJ N
matching VBG N
between IN N
patient NN N
and CC N
provider NN N
on IN N
the DT N
effectiveness NN o
of IN N
brief NN i
alcohol NN i
interventions NNS i
with IN N
Hispanics NNPS p
. . p

BACKGROUND NNP N
Evaluating VBG N
the DT N
effectiveness NN N
of IN N
treatments NNS N
such JJ N
as IN N
brief JJ N
alcohol JJ N
interventions NNS N
among IN N
Hispanics NNPS p
is VBZ N
essential JJ N
to TO N
effectively RB N
addressing VBG N
their PRP$ N
treatment NN N
needs NNS N
. . N

Clinicians NNPS N
of IN N
the DT N
same JJ N
ethnicity NN N
as IN N
the DT N
client NN N
may MD N
be VB N
more RBR N
likely JJ N
to TO N
understand VB N
the DT N
culture-specific JJ N
values NNS N
, , N
norms NNS N
, , N
and CC N
attitudes NNS N
and CC N
, , N
therefore RB N
, , N
the DT N
intervention NN N
may MD N
be VB N
more RBR N
effective JJ N
. . N

Thus RB N
, , N
in IN N
cases NNS N
in IN N
which WDT N
Hispanic JJ p
patients NNS p
were VBD N
provided VBN N
intervention NN N
by IN N
a DT N
Hispanic JJ N
clinician NN N
improved VBD N
drinking NN N
outcomes NNS N
were VBD N
expected VBN N
. . N

METHODS NNP N
Patients NNPS p
were VBD p
recruited VBN p
from IN p
an DT p
urban JJ p
Level NN p
I PRP p
Trauma VBP p
following VBG p
screening NN p
for IN p
an DT p
alcohol-related JJ p
injury NN p
or CC p
alcohol NN p
problems NNS p
. . p

Five CD p
hundred VBD p
thirty-seven JJ p
Hispanics NNPS p
were VBD N
randomly RB N
assigned VBN N
to TO N
brief VB i
intervention NN i
or CC i
treatment NN i
as IN i
usual JJ i
. . i

Hierarchical JJ N
linear JJ N
modeling NN N
was VBD N
used VBN N
to TO N
determine VB N
the DT N
effects NNS o
of IN o
ethnic JJ o
match NN o
on IN o
drinking NN o
outcomes NNS o
including VBG N
volume NN o
per IN o
week NN o
, , o
maximum JJ o
amount NN o
, , o
and CC o
frequency NN o
of IN o
5 CD o
or CC o
more JJR o
drinks NNS o
per IN o
occasion NN o
. . o

Analyses NNS N
controlled VBD N
for IN N
level NN N
of IN N
acculturation NN N
and CC N
immigration NN N
status NN N
. . N

RESULTS NNP N
For IN N
Hispanics NNPS p
who WP N
received VBD N
brief JJ N
motivational JJ N
intervention NN N
, , N
an DT N
ethnic JJ N
match NN N
between IN N
patient NN N
and CC N
provider NN N
resulted VBD N
in IN N
a DT N
significant JJ o
reduction NN o
in IN o
drinking NN o
outcomes NNS o
at IN N
12-month JJ N
follow-up NN N
. . N

In IN N
addition NN N
, , N
there EX N
was VBD N
a DT N
tendency NN N
for IN N
ethnic JJ N
match NN N
to TO N
be VB N
most RBS o
beneficial JJ o
to TO N
foreign-born JJ N
Hispanics NNPS N
and CC N
less RBR o
acculturated JJ N
Hispanics NNPS N
. . N

CONCLUSION NNP N
As IN N
hypothesized VBN N
, , N
an DT N
ethnic JJ N
match NN N
between IN N
patient NN N
and CC N
provider NN N
significantly RB N
enhanced VBD N
the DT N
effectiveness NN o
of IN o
brief JJ o
intervention NN o
among IN N
Hispanics NNPS p
. . p

Ethnic JJ N
concordance NN N
between IN N
patient NN N
and CC N
provider NN N
may MD N
have VB N
impacted VBN N
the DT N
effectiveness NN o
of IN N
the DT N
intervention NN N
through IN N
several JJ N
mechanisms NNS N
including VBG N
cultural JJ N
scripts NNS N
, , N
ethnic-specific JJ N
perceptions NNS N
pertaining VBG N
to TO N
substance NN N
abuse NN N
, , N
and CC N
ethnic-specific JJ N
preferred JJ N
channels NNS N
of IN N
communication NN N
. . N

-DOCSTART- -7491394- O O

A DT N
comparison NN N
of IN N
live JJ N
and CC N
videotape JJ N
ratings NNS N
: : N
clomipramine NN i
and CC i
haloperidol NN i
in IN p
autism NN p
. . p

This DT N
study NN N
compared VBN N
live JJ N
ratings NNS N
with IN N
ratings NNS N
of IN N
videotapes NNS N
and CC N
compared VBN N
response NN N
to TO N
clomipramine VB i
with IN N
response NN N
to TO N
haloperidol VB i
in IN N
8 CD p
subjects NNS p
, , p
mean JJ p
age NN p
5.62 CD p
years NNS p
, , p
who WP p
met VBD p
criteria NNS p
for IN p
autism NN p
. . p

They PRP N
were VBD N
consecutive JJ N
admissions NNS N
to TO N
a DT N
pilot NN N
study NN N
of IN N
clomipramine NN i
( ( N
n JJ N
= NNP N
4 CD N
) ) N
or CC N
a DT N
double-blind JJ N
, , N
placebo NN i
controlled VBD N
study NN N
of IN N
haloperidol NN i
( ( N
n JJ N
= NNP N
4 CD N
) ) N
. . N

Live JJ N
ratings NNS N
were VBD N
performed VBN N
by IN N
two CD N
raters NNS N
at IN N
the DT N
end NN N
of IN N
the DT N
pre-treatment JJ N
placebo NN i
baseline NN N
period NN N
and CC N
at IN N
the DT N
end NN N
of IN N
the DT N
drug NN N
treatment NN N
period NN N
on IN N
the DT N
CPRS NNP N
and CC N
the DT N
CGI NNP N
and CC N
were VBD N
videotaped VBN N
. . N

Employing VBG N
the DT N
same JJ N
instruments NNS N
, , N
these DT N
videotapes NNS N
were VBD N
rated VBN N
by IN N
two CD N
raters NNS N
who WP N
did VBD N
not RB N
know VB N
the DT N
subjects NNS N
and CC N
were VBD N
blind NNS N
to TO N
study VB N
design NN N
, , N
treatment NN N
, , N
and CC N
study NN N
phase NN N
. . N

Ratings NNS o
of IN o
videotapes NNS o
significantly RB N
differed VBN N
from IN N
live JJ o
ratings NNS o
. . o

A DT N
treatment NN N
effect NN N
for IN N
haloperidol NN N
was VBD N
detected VBN N
only RB N
on IN N
live JJ o
ratings NNS o
and CC N
not RB N
on IN N
ratings NNS o
of IN o
videotapes NNS o
. . o

No DT N
treatment NN N
effect NN N
was VBD N
detected VBN N
for IN N
clomipramine NN i
in IN N
either CC N
live JJ o
or CC o
videotape JJ o
ratings NNS o
. . o

-DOCSTART- -17724294- O O

Statin NNP i
treatment NN i
withdrawal NN i
in IN N
ischemic JJ p
stroke NN p
: : p
a DT N
controlled VBN N
randomized NN N
study NN N
. . N

BACKGROUND NNP N
Pretreatment NNP N
with IN N
statins NNS N
has VBZ N
been VBN N
shown VBN N
to TO N
reduce VB N
brain NN N
injury NN N
in IN N
cerebral JJ N
ischemia NN N
. . N

In IN N
this DT N
controlled VBN N
randomized NN N
study NN N
, , N
we PRP N
investigated VBD N
the DT N
influence NN N
of IN N
statin NN i
pretreatment NN i
and CC i
its PRP$ i
withdrawal NN i
on IN N
the DT N
outcome NN N
of IN N
acute JJ p
ischemic JJ p
stroke NN p
patients NNS p
. . p

METHODS NNP N
From IN p
215 CD p
patients NNS p
admitted VBD p
within IN p
24 CD p
hours NNS p
of IN p
a DT p
hemispheric JJ p
ischemic JJ p
stroke NN p
, , p
89 CD p
patients NNS p
on IN p
chronic JJ p
statin NN i
treatment NN p
were VBD p
randomly RB p
assigned VBN p
either RB N
to TO N
statin VB i
withdrawal NN i
for IN i
the DT i
first JJ i
3 CD i
days NNS i
after IN i
admission NN i
( ( i
n JJ i
= NNP i
46 CD i
) ) i
or CC i
to TO i
immediately RB i
receive VB i
atorvastatin NN i
20 CD i
mg/day NN i
( ( i
n JJ i
= NNP i
43 CD i
) ) i
. . N

The DT N
primary JJ N
outcome JJ N
event NN N
was VBD N
death NN o
or CC o
dependency NN o
( ( o
modified JJ o
Rankin NNP o
Scale NNP o
[ NNP o
mRS NN o
] NNP o
score NN N
> NNP N
2 CD N
) ) N
at IN N
3 CD N
months NNS N
. . N

Early JJ o
neurologic JJ o
deterioration NN o
( ( o
END NNP o
) ) o
and CC N
infarct JJ o
volume NN o
at IN N
days NNS N
4 CD N
to TO N
7 CD N
were VBD N
secondary JJ N
outcome NN N
variables NNS N
. . N

In IN N
a DT N
secondary JJ N
analysis NN N
, , N
outcome JJ N
variables NNS N
were VBD N
compared VBN N
with IN N
the DT N
nonrandomized JJ N
patients NNS N
without IN N
previous JJ N
statin NN N
therapy NN N
( ( N
n JJ N
= NNP N
126 CD N
) ) N
. . N

RESULTS JJ N
Patients NNS p
with IN p
statin NN p
withdrawal NN p
showed VBD N
a DT N
higher JJR N
frequency NN N
of IN N
mRS NN o
score NN o
> VBD N
2 CD N
at IN N
the DT N
end NN N
of IN N
follow-up NN N
( ( N
60.0 CD N
% NN N
vs JJ N
39.0 CD N
% NN N
; : N
p CC N
= VB N
0.043 CD N
) ) N
, , N
END NNP N
( ( N
65.2 CD N
% NN N
vs JJ N
20.9 CD N
% NN N
; : N
p CC N
< VB N
0.0001 CD N
) ) N
, , N
and CC N
greater JJR N
infarct NN o
volume NN o
( ( N
74 CD N
[ RB N
45 CD N
, , N
126 CD N
] NN N
vs NN N
26 CD N
[ NN N
12 CD N
, , N
70 CD N
] JJ N
mL NN N
; : N
p CC N
= VB N
0.002 CD N
) ) N
compared VBN N
with IN N
the DT N
non-statin-withdrawal JJ i
group NN N
. . N

Statin NNP i
withdrawal NN N
was VBD N
associated VBN N
with IN N
a DT N
4.66 CD N
( ( N
1.46 CD N
to TO N
14.91 CD N
) ) N
-fold VBD N
increase NN N
in IN N
the DT N
risk NN o
of IN o
death NN o
or CC o
dependency NN o
, , N
a DT N
8.67 CD N
( ( N
3.05 CD N
to TO N
24.63 CD N
) ) N
-fold VBD N
increase NN N
in IN N
the DT N
risk NN N
of IN N
END NNP o
, , N
and CC N
an DT N
increase NN N
in IN N
mean JJ o
infarct JJ o
volume NN o
of IN N
37.63 CD N
mL NN N
( ( N
SE NNP N
10.01 CD N
; : N
p NN N
< VBZ N
0.001 CD N
) ) N
after IN N
adjusting VBG N
for IN N
age NN N
and CC N
baseline NN N
stroke NN N
severity NN N
. . N

Compared VBN N
with IN N
patients NNS p
without IN p
previous JJ p
treatment NN p
with IN p
statins NNS p
, , N
statin NN N
withdrawal NN N
was VBD N
associated VBN N
with IN N
a DT N
19.01 CD N
( ( N
1.96 CD N
to TO N
184.09 CD N
) ) N
-fold VBD N
increase NN N
in IN N
the DT N
risk NN N
of IN N
END NNP o
and CC N
an DT N
increase NN N
in IN N
mean JJ o
infarct JJ o
volume NN o
of IN N
43.51 CD N
mL NN N
( ( N
SE NNP N
21.91 CD N
; : N
p NN N
= VBZ N
0.048 CD N
) ) N
. . N

CONCLUSION NNP N
Statin NNP N
withdrawal NN N
is VBZ N
associated VBN N
with IN N
increased JJ N
risk NN N
of IN N
death NN N
or CC N
dependency NN N
at IN N
90 CD N
days NNS N
. . N

Hence NNP N
, , N
this DT N
treatment NN N
should MD N
be VB N
continued VBN N
in IN N
the DT N
acute JJ N
phase NN N
of IN N
ischemic JJ N
stroke NN N
. . N

-DOCSTART- -16472720- O O

Brain NNP N
mechanisms NNS N
of IN N
expectation NN N
associated VBN N
with IN N
insula NN p
and CC p
amygdala JJ p
response NN N
to TO N
aversive JJ N
taste NN N
: : N
implications NNS N
for IN N
placebo NN i
. . i

The DT N
experience NN N
of IN N
aversion NN N
is VBZ N
shaped VBN N
by IN N
multiple JJ N
physiological JJ N
and CC N
psychological JJ N
factors NNS N
including VBG N
one CD N
's POS N
expectations NNS N
. . N

Recent JJ N
work NN N
has VBZ N
shown VBN N
that IN N
expectancy NN N
manipulation NN N
can MD N
alter VB N
perceptions NNS N
of IN N
aversive JJ N
events NNS N
and CC N
concomitant JJ N
brain NN N
activation NN N
. . N

Accruing VBG N
evidence NN N
indicates VBZ N
a DT N
primary JJ N
role NN N
of IN N
altered JJ N
expectancies NNS N
in IN N
the DT N
placebo NN i
effect NN N
. . N

Here RB N
, , N
we PRP N
probed VBD N
the DT N
mechanism NN N
by IN N
which WDT N
expectation NN N
attenuates VBZ N
sensory JJ N
taste NN N
transmission NN N
by IN N
examining VBG N
how WRB N
brain NN p
areas NNS p
activated VBN p
by IN p
misleading VBG i
information NN i
during IN p
an DT p
expectancy NN p
period NN p
modulate NN N
insula NN N
and CC N
amygdala JJ N
activation NN N
to TO N
a DT N
highly RB i
aversive JJ i
bitter NN i
taste NN i
. . i

In IN N
a DT N
rapid JJ N
event-related JJ N
fMRI NN i
design NN i
, , N
we PRP N
showed VBD N
that IN N
activations NNS N
in IN N
the DT N
rostral JJ p
anterior JJ p
cingulate NN p
cortex NN p
( ( p
rACC NN p
) ) p
, , p
orbitofrontal JJ p
cortex NN p
( ( p
OFC NNP p
) ) p
, , p
and CC p
dorsolateral JJ p
prefrontal NN p
cortex NN p
to TO N
a DT N
misleading NN N
cue NN N
that IN N
the DT N
taste NN N
would MD N
be VB N
mildly RB N
aversive JJ N
predicted VBN N
decreases NNS N
in IN N
insula NN o
and CC o
amygdala JJ o
activation NN o
to TO N
the DT N
highly RB N
aversive JJ N
taste NN N
. . N

OFC NNP N
and CC N
rACC VB N
activation NN N
to TO N
the DT N
misleading NN i
cue NN i
were VBD N
also RB N
associated VBN N
with IN N
less RBR N
aversive JJ o
ratings NNS o
of IN o
that DT o
taste NN o
. . o

Additional JJ N
analyses NNS N
revealed VBD N
consistent JJ N
results NNS N
demonstrating VBG N
functional JJ N
connectivity NN N
among IN N
the DT N
OFC NNP N
, , N
rACC NN N
, , N
and CC N
insula NN N
. . N

Altering VBG N
expectancies NNS N
of IN N
upcoming VBG N
aversive JJ N
events NNS N
are VBP N
shown VBN N
here RB N
to TO N
depend VB N
on IN N
robust JJ N
functional JJ N
associations NNS N
among IN N
brain NN N
regions NNS N
implicated VBN N
in IN N
prior JJ N
work NN N
on IN N
the DT N
placebo NN N
effect NN N
. . N

-DOCSTART- -8296409- O O

[ JJ N
Hemostatic NNP N
balance NN N
during IN N
treatment NN N
with IN N
the DT N
newest JJS N
contraceptives NNS N
] RB N
. . N

Thirty-four CD p
healthy JJ p
young JJ p
women NNS p
were VBD N
allocated VBN i
to TO i
12 CD i
consecutive JJ i
cycles NNS i
of IN i
treatment NN i
with IN i
monophasic JJ i
combinations NNS i
of IN i
: : i
20 CD i
micrograms NNS i
ethinyl VBP i
estradiol NN i
and CC i
150 CD i
micrograms NNS i
desogestrel NN i
( ( i
n JJ i
= NNP i
15 CD i
) ) i
or CC i
30 CD i
micrograms NNS i
ethinyl VBP i
estradiol NN i
and CC i
75 CD i
micrograms NNS i
gestodene NN i
( ( i
n JJ i
= NNP i
19 CD i
) ) i
. . N

In IN N
both DT N
groups NNS N
plasma VBP o
levels NNS o
of IN o
fibrinogen NN o
and CC o
factor NN o
VII NNP o
increased VBD N
while IN N
the DT N
capacity NN N
of IN N
coagulation NN N
inhibition NN N
was VBD N
affected VBN N
by IN N
increased JJ o
protein NN o
C NNP o
and CC o
decreased VBN o
protein NN o
S NNP o
levels NNS o
. . o

Increased VBN N
fibrinolytic JJ o
capacity NN o
was VBD N
indicated VBN N
by IN N
elevated JJ N
activity NN N
and CC N
reduced JJ N
antigen NN o
levels NNS o
of IN o
tissue NN o
plasminogen NN o
activator NN o
and CC N
reduced JJ N
activity NN N
and CC N
concentration NN o
of IN o
tissue NN o
plasminogen NN o
activator NN o
inhibitor NN o
. . o

The DT N
ratio NN o
between IN o
thrombin-antithrombin-III-complexes NNS o
and CC o
fibrin JJ o
degradation NN o
products NNS o
were VBD o
unchanged JJ o
signifying VBG N
no DT N
effect NN N
of IN N
hormonal JJ N
intake NN N
on IN N
the DT N
balance NN N
between IN N
thrombin JJ N
formation NN N
and CC N
fibrin JJ N
resolution NN N
. . N

In IN N
conclusion NN N
, , N
the DT N
dynamic JJ N
balance NN N
between IN N
generation NN N
and CC N
resolution NN N
of IN N
fibrin NN N
was VBD N
undisturbed JJ N
during IN N
treatment NN N
with IN N
both DT N
hormonal JJ N
compounds NNS N
and CC N
our PRP$ N
findings NNS N
do VBP N
not RB N
provide VB N
evidence NN N
for IN N
increased VBN N
risk NN N
of IN N
thrombosis NN N
in IN N
normal JJ p
women NNS p
. . p

-DOCSTART- -24122191- O O

Characterization NN N
of IN N
early JJ p
thermal JJ p
burns NNS p
and CC N
the DT N
effects NNS N
of IN N
hyperbaric JJ i
oxygen NN i
treatment NN i
: : i
a DT N
pilot NN N
study NN N
. . N

BACKGROUND NNP N
AND CC N
AIMS NNP N
Studies NNP N
investigating VBG N
hyperbaric JJ i
oxygen NN i
treatment NN i
( ( i
HBOT NNP i
) ) i
to TO N
improve VB N
outcome NN N
in IN N
burns NNS N
have VBP N
been VBN N
inconclusive JJ N
. . N

In IN N
this DT N
study NN N
, , N
we PRP N
aimed VBD N
to TO N
characterize VB N
early JJ p
thermal NN p
burns NNS p
injury NN p
in IN p
adult NN p
patients NNS p
with IN p
< JJ p
40 CD p
% NN p
total JJ p
body NN p
surface NN p
area NN p
( ( p
TBSA NNP p
) ) p
and CC N
to TO N
determine VB N
the DT N
effects NNS N
of IN N
HBOT NNP i
administered VBD N
within IN N
24 CD N
h NN N
to TO N
48 CD N
h NN N
of IN N
a DT N
burn JJ N
injury NN N
. . N

METHODS NNP N
Seventeen JJ p
subjects NNS p
were VBD p
randomized VBN p
into IN p
control NN p
( ( p
n JJ p
= NNP p
9 CD p
) ) p
and CC p
HBOT NNP i
treatment NN i
( ( p
n JJ p
= NNP p
8 CD p
) ) p
arms NNS p
. . p

Burn NNP o
depth NN o
, , N
measured VBN N
by IN N
laser NN N
Doppler NNP i
imaging NN i
( ( N
LDI NNP N
) ) N
and CC N
histologically RB N
, , N
white JJ o
blood NN o
cell NN o
( ( o
WBC NNP o
) ) o
count NN o
and CC N
plasma JJ o
cytokine NN o
inflammatory NN o
markers NNS o
were VBD N
assessed VBN N
at IN N
24 CD N
h NN N
( ( N
pre JJ N
HBOT NNP N
) ) N
and CC N
48 CD N
h NN N
( ( N
post VB N
HBOT NNP N
) ) N
post NN N
burn NN N
, , N
as IN N
were VBD N
immunohistochemistry NN N
and CC N
microbiology NN N
of IN N
burns NNS N
tissue NN N
samples NNS N
at IN N
48 CD N
h NN N
post NN N
burn NN N
. . N

RESULTS NNP N
WBC NNP o
count NN o
and CC o
serum NN o
interleukin NN o
( ( o
IL NNP o
) ) o
-1? NN o
, , o
IL-4 NNP o
, , o
IL-6 NNP o
, , o
IL-10 NNP o
and CC o
interferon-? NNS o
were VBD o
significantly RB N
elevated VBN N
24 CD N
h NN N
after IN N
burn NN N
, , N
but CC N
no DT N
significant JJ N
changes NNS N
in IN N
any DT N
of IN N
these DT N
parameters NNS N
were VBD N
found VBN N
with IN N
HBOT NNP N
. . N

HBOT NNP N
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
burn NN o
depth NN o
. . o

Two CD i
HBOT NNP i
patients NNS i
and CC p
four CD p
control NN p
patients NNS p
developed VBD o
positive JJ o
bacterial JJ o
cultures NNS o
. . o

CONCLUSIONS NNP N
Slower JJR N
than IN N
anticipated VBN N
recruitment NN N
resulted VBD N
in IN N
considerably RB N
fewer JJR N
patients NNS N
than IN N
planned VBN N
being VBG N
studied VBN o
. . o

Inflammatory JJ o
markers NNS o
were VBD o
significantly RB N
increased VBN N
at IN N
24 CD N
h NN N
in IN N
patients NNS N
with IN N
< JJ N
40 CD N
% NN N
TBSA NNP N
burn NN N
. . N

Early JJ i
HBOT NNP i
had VBD i
no DT N
apparent JJ N
effects NNS N
on IN N
any DT N
of IN N
the DT N
parameters NNS N
measured VBN N
in IN N
this DT N
small JJ N
pilot NN N
study NN i
. . i

HBOT NNP i
may MD i
possibly RB N
have VB N
a DT N
broad-spectrum JJ N
antimicrobial JJ N
effect NN N
worthy NN N
of IN N
further JJ N
study NN N
. . N

We PRP N
report VBP N
our PRP$ N
methodology NN N
in IN N
detail NN N
as IN N
a DT N
possible JJ N
model NN N
for IN N
future JJ N
burns NNS N
studies NNS N
. . N

-DOCSTART- -8259746- O O

Comparison NNP o
of IN N
outcome NN N
of IN N
labetalol NN i
or CC p
hydralazine JJ i
therapy NN p
during IN p
hypertension NN p
in IN p
pregnancy NN p
in IN p
very RB p
low JJ p
birth NN p
weight NN p
infants NNS p
. . p

Ninety-seven JJ p
women NNS p
with IN p
moderate JJ p
to TO p
severe VB p
preeclampsia NN p
( ( p
PE NNP p
) ) p
were VBD N
allocated VBN N
at IN N
random NN N
to TO N
labetalol VB i
or CC i
hydralazine VB i
treatment NN N
. . N

Of IN N
these DT N
, , N
22 CD p
women NNS p
with IN p
severe JJ p
PE NNP p
gave VBD p
birth NN p
to TO p
neonates NNS p
with IN p
VLBW NNP p
( ( p
very RB p
low JJ p
birth NN p
weight NN p
< NN p
or CC p
= JJ p
1500 CD p
g NN p
) ) p
. . p

Seven VBN p
were VBD p
allocated VBN p
to TO p
labetalol VB i
treatment NN i
( ( i
Group NNP i
A NNP i
) ) i
, , p
eight CD p
to TO p
hydralazine VB i
treatment NN i
( ( i
Group NNP i
B NNP i
) ) i
and CC i
seven CD p
women NNS p
received VBD i
both DT i
drugs NNS i
due JJ i
to TO i
poor JJ i
blood NN i
pressure NN i
control NN i
with IN i
a DT i
single JJ i
drug NN i
therapy NN i
( ( N
Group NNP N
C NNP N
) ) N
. . N

No DT N
difference NN N
in IN N
cesarean JJ o
section NN o
rate NN o
or CC o
in IN o
the DT o
indication NN o
for IN o
operative JJ o
delivery NN o
could MD N
be VB N
seen VBN N
. . N

Gestational JJ o
age NN o
was VBD p
29.9 CD p
weeks NNS p
( ( p
25.4-32.5 JJ p
) ) p
in IN N
Group NNP N
A NNP N
, , N
28.6 CD p
weeks NNS p
( ( p
26.6-33.4 JJ p
) ) p
in IN N
Group NNP N
B NNP N
and CC N
27.3 CD p
weeks NNS p
( ( p
26.7-31.1 JJ p
) ) p
in IN N
Group NNP N
C NNP N
( ( N
median JJ N
and CC N
range NN N
) ) N
. . N

Birth NNP o
weight VBD o
did VBD N
not RB N
differ VB N
between IN N
groups NNS N
and CC N
13 CD p
of IN p
the DT p
22 CD p
infants NNS p
weighed VBN p
below IN p
1000 CD p
g. NN p
There EX N
was VBD N
a DT N
tendency NN N
to TO N
lower VB o
Apgar NNP o
scores NNS o
at IN N
five CD N
minutes NNS N
in IN N
the DT N
hydralazine NN N
group NN N
. . N

Time NNP o
spent NN o
in IN o
the DT o
neonatal JJ o
intensive JJ o
care NN o
unit NN o
did VBD N
not RB N
differ VB N
between IN N
groups NNS N
. . N

Five CD N
of IN N
the DT N
11 CD N
neonates NNS p
with IN N
gestational JJ N
age NN N
( ( N
GA NNP N
) ) N
< VBD N
or CC N
= $ N
28 CD N
weeks NNS N
and CC N
three CD N
of IN N
the DT N
seven CD N
neonates NNS p
in IN N
GA NNP N
29-30 JJ N
weeks NNS N
died VBD o
. . o

Neither CC N
the DT N
number NN o
of IN o
infants NNS o
requiring VBG o
intermittent JJ o
positive JJ o
pressure NN o
ventilation NN o
or CC o
duration NN o
of IN o
O2- NNP o
treatment NN o
, , o
nor CC o
number NN o
of IN o
infants NNS o
with IN o
respiratory JJ o
distress JJ o
syndrome NN o
differed VBD N
between IN N
groups NNS N
. . N

We PRP N
did VBD N
not RB N
find VB N
any DT N
difference NN N
in IN N
the DT N
outcome NN N
of IN N
the DT N
VLBW NNP p
infants NNS p
when WRB p
the DT p
hypertensive NN p
mother NN p
had VBD p
been VBN p
treated VBN p
with IN p
either DT p
hydralazine NN i
or CC p
labetalol NN i
. . i

-DOCSTART- -23500669- O O

MEG NNP o
premotor NN o
abnormalities NNS o
in IN N
children NNS p
with IN p
Asperger NNP p
's POS p
syndrome NN p
: : p
determinants NNS N
of IN N
social JJ o
behavior NN o
? . N
Children NNP N
with IN N
Asperger NNP N
's POS N
syndrome NN N
show NN N
deficits NNS N
in IN N
social JJ o
functioning VBG o
while IN N
their PRP$ N
intellectual JJ N
and CC N
language NN N
development NN N
is VBZ N
intact JJ N
suggesting VBG N
a DT N
specific JJ N
dysfunction NN N
in IN N
mechanisms NNS N
mediating VBG N
social JJ o
cognition NN o
. . o

An DT N
action NN N
observation/execution NN N
matching VBG N
system NN N
might MD N
be VB N
one CD N
such JJ N
mechanism NN N
. . N

Recent JJ N
studies NNS N
indeed RB N
showed VBD N
that IN N
electrophysiological JJ o
modulation NN o
of IN o
the DT o
Mu-rhythm NNP o
in IN N
the DT N
10-12Hz JJ N
range NN N
is VBZ N
weaker JJR N
when WRB N
individuals NNS N
with IN N
Asperger NNP N
's POS N
syndrome JJ N
observe NN N
actions NNS N
performed VBN N
by IN N
others NNS N
compared VBN N
to TO N
controls NNS N
. . N

However RB N
, , N
electrophysiological JJ N
studies NNS N
typically RB N
fall VBP N
short JJ N
in IN N
revealing VBG N
the DT N
neural JJ N
generators NNS N
of IN N
this DT N
activity NN N
. . N

To TO N
fill VB N
this DT N
gap NN N
we PRP N
assessed VBD N
magnetoencephalographic JJ o
Mu-modulations NNS o
in IN N
Asperger NNP p
's POS p
and CC p
typically RB p
developed JJ p
children NNS p
, , N
while IN N
observing VBG i
grasping VBG o
movements NNS o
. . o

Mu-power NN o
increased VBD N
at IN N
frontal JJ N
and CC N
central JJ N
sensors NNS N
during IN N
movement NN N
observation NN N
. . N

This DT N
modulation NN N
was VBD N
stronger JJR N
in IN N
typical JJ N
than IN N
in IN N
Asperger NNP N
children NNS N
. . N

Source NNP o
localization NN o
revealed VBD N
stronger JJR N
sources NNS N
in IN N
premotor NN N
cortex NN N
, , N
the DT N
intraparietal JJ N
lobule NN N
( ( N
IPL NNP N
) ) N
and CC N
the DT N
mid-occipito-temporal JJ N
gyrus NN N
( ( N
MOTG NNP N
) ) N
and CC N
weaker JJR N
sources NNS N
in IN N
prefrontal JJ N
cortex NN N
in IN N
typical JJ N
participants NNS N
compared VBN N
to TO N
Asperger NNP N
. . N

Activity NN o
in IN o
premotor NN o
regions NNS o
, , o
IPL NNP o
and CC o
MOTG NNP o
correlated VBD N
positively RB N
with IN N
social JJ o
competence NN o
, , N
whereas JJ N
prefrontal JJ N
Mu-sources NNS N
correlated VBD N
negatively RB N
with IN N
social JJ o
competence NN o
. . o

No DT N
correlation NN o
with IN o
intellectual JJ o
ability NN o
was VBD N
found VBN N
at IN N
any DT N
of IN N
these DT N
sites NNS N
. . N

These DT N
findings NNS N
localize VBP N
abnormal JJ o
Mu-activity NNP o
in IN N
the DT N
brain NN N
of IN N
Asperger NNP p
children NNS p
providing VBG N
evidence NN N
which WDT N
associates VBZ N
motor-system NN N
abnormalities NNS N
with IN N
social-function NN o
deficits NNS o
. . o

-DOCSTART- -17525360- O O

Effect NN N
of IN N
facial JJ i
sensory JJ i
re-training NN i
on IN N
sensory JJ N
thresholds NNS N
. . N

Nearly RB N
100 CD N
% NN N
of IN N
patients NNS p
experience JJ p
trauma NN p
to TO p
the DT p
trigeminal JJ p
nerve NN p
during IN p
orthognathic JJ i
surgery NN i
, , p
impairing VBG p
sensation NN p
and CC p
sensory JJ p
function NN p
on IN p
the DT p
face NN p
. . p

In IN N
a DT N
recent JJ N
randomized JJ N
clinical JJ N
trial NN N
, , N
people NNS p
who WP p
performed VBD p
sensory JJ i
re-training JJ i
exercises NNS i
reported VBD p
less RBR N
difficulty NN N
related VBN N
to TO N
residual JJ N
numbness NN N
and CC N
decreased VBD N
lip JJR N
sensitivity NN N
than IN N
those DT N
who WP N
performed VBD N
standard JJ i
opening NN i
exercises VBZ i
only RB N
. . N

We PRP N
hypothesized VBD N
that IN N
re-training JJ i
reduces NNS N
the DT N
impaired JJ N
performance NN N
on IN N
neurosensory JJ N
tests NNS N
of IN N
tactile JJ N
function NN N
that WDT N
is VBZ N
commonly RB N
observed JJ N
post-surgically RB N
. . N

We PRP N
analyzed VBD N
thresholds NNS N
for IN N
contact NN N
detection NN N
, , N
two-point JJ N
discrimination NN N
, , N
and CC N
two-point JJ N
perception NN N
, , N
obtained VBN N
during IN N
the DT N
clinical JJ N
trial NN N
before IN N
and CC N
at IN N
1 CD N
, , N
3 CD N
, , N
and CC N
6 CD N
months NNS N
after IN N
surgery NN N
, , N
to TO N
assess VB N
tactile JJ N
detection NN N
and CC N
discriminative JJ N
sensitivities NNS N
, , N
and CC N
subjective JJ N
interpretation NN N
of IN N
tactile JJ N
stimulation NN N
, , N
respectively RB N
. . N

Post-surgery NN N
, , N
the DT p
retrained JJ p
persons NNS p
exhibited VBD p
less RBR p
impairment JJ o
, , N
on IN N
average NN N
, , N
than IN N
non-retrained JJ N
persons NNS N
only RB N
in IN N
two-point JJ N
perception NN N
( ( N
P NNP N
< NNP N
0.025 CD N
) ) N
, , N
suggesting VBG N
that IN N
retrained VBD N
persons NNS N
experienced VBD N
or CC N
interpreted VBD N
the DT N
tactile NN o
stimuli VBZ o
differently RB N
than IN N
did VBD N
non-retrained JJ N
persons NNS N
. . N

-DOCSTART- -7032533- O O

Double-blind NNP N
study NN N
on IN N
the DT N
activity NN N
of IN N
plafibride NN i
in IN N
the DT N
treatment NN N
of IN N
type NN p
IV NNP p
hyperlipoproteinemia NN p
. . p

The DT N
effects NNS N
of IN N
a DT N
new JJ N
drug NN N
, , N
N-2- NNP i
( ( i
p-chlorophenoxy JJ i
) ) i
-isobutyryl-N'-morpholinomethylurea NN i
( ( i
plafibride NN i
, , i
ITA NNP i
104 CD i
) ) i
, , N
were VBD N
studied VBN N
in IN N
a DT N
double JJ N
blind NN N
study NN N
lasting VBG N
four CD N
months NNS N
on IN N
a DT N
group NN p
of IN p
30 CD p
patients NNS p
with IN p
a DT p
type NN p
IV NNP p
hyperlipoproteinemia NN p
. . p

In IN N
the DT N
patients NNS N
treated VBN N
with IN N
the DT N
active JJ N
drug NN N
significant JJ N
reductions NNS N
in IN N
blood NN o
triglycerides NNS o
were VBD N
obtained VBN N
, , N
with IN N
a DT N
trend NN N
to TO N
normal JJ N
. . N

Reduction NN N
in IN N
blood NN o
cholesterol NN o
was VBD N
inconsistent JJ N
and CC N
not RB N
significant JJ N
. . N

As IN N
for IN N
the DT N
lipoproteinogram NN N
, , N
a DT N
tendency NN N
towards IN N
a DT N
decrease NN N
in IN N
the DT N
pre-beta-lipoprotein JJ o
fraction NN o
was VBD N
observed VBN N
and CC N
so RB N
was VBD N
a DT N
non-significant JJ N
tendency NN N
towards IN N
an DT N
increase NN N
in IN N
the DT N
alpha- JJ N
and CC N
beta-lipoprotein JJ N
fractions NNS N
. . N

Studies NNS N
on IN N
the DT N
platelet NN N
functioning NN N
showed VBD N
an DT N
obvious JJ N
decrease NN N
in IN N
platelet NN o
aggregation NN o
in IN N
those DT N
patients NNS N
treated VBN N
with IN N
the DT N
active JJ N
drug NN N
. . N

This DT N
was VBD N
very RB N
evident JJ N
for IN N
the DT N
ADP NNP N
and CC N
adrenaline JJ N
inductors NNS N
and CC N
rather RB N
less RBR N
significant JJ N
for IN N
collagen NN N
. . N

Neither CC N
platelet NN o
adhesiveness NN o
nor CC o
aggregation NN o
rate NN o
changed VBN N
. . N

Tolerance NN o
of IN N
the DT N
drug NN N
was VBD N
generally RB N
excellent JJ N
. . N

In IN N
one CD N
patient NN N
a DT N
decrease NN N
in IN N
some DT N
palpebral JJ o
xanthelasmas NN o
was VBD N
observed VBN N
after IN N
two CD N
months NNS N
of IN N
treatment NN N
with IN N
the DT N
active JJ N
drug NN N
. . N

In IN N
only RB N
one CD N
case NN N
there EX N
was VBD N
heartburn NN o
and CC N
this DT N
was VBD N
corrected VBN N
with IN N
alkalines NNS N
. . N

In IN N
one CD N
other JJ N
case NN N
an DT N
urticarial JJ o
rash NN o
appeared VBD N
, , N
but CC N
disappeared VBD N
spontaneously RB N
when WRB N
the DT N
drug NN N
was VBD N
temporarily RB N
stopped VBN N
and CC N
did VBD N
not RB N
reappear VB N
when WRB N
it PRP N
was VBD N
administered VBN N
again RB N
. . N

During IN N
the DT N
trial NN N
no DT N
evidence NN N
of IN N
renal JJ o
, , o
hepatic JJ o
or CC o
hematological JJ o
malfunctions NNS o
were VBD N
observed VBN N
. . N

However RB N
, , N
a DT N
slight JJ N
tendency NN N
towards IN N
an DT N
increase NN N
in IN N
the DT N
GOT NNP o
, , o
GPT NNP o
and CC o
LDH NNP o
was VBD N
observed VBN N
, , N
which WDT N
was VBD N
not RB N
statistically RB N
significant JJ N
. . N

The DT N
drug NN N
tested VBD N
may MD N
be VB N
very RB N
useful JJ N
in IN N
the DT N
treatment NN N
of IN N
type NN o
IV NNP o
hyperlipoproteinemia NN o
, , N
especially RB N
in IN N
those DT N
forms NNS N
in IN N
which WDT N
an DT N
increase NN N
in IN N
thromboembolic JJ o
risk NN o
is VBZ N
suspected VBN N
, , N
either RB N
associated VBN N
with IN N
, , N
or CC N
secondary JJ N
to TO N
, , N
the DT N
actual JJ N
atherosclerotic JJ N
disease NN N
. . N

-DOCSTART- -21915740- O O

Social NNP i
skills NNS i
training VBG i
for IN N
young JJ p
adults NNS p
with IN p
high-functioning JJ p
autism NN p
spectrum NN p
disorders NNS p
: : p
a DT N
randomized VBN N
controlled VBN N
pilot NN N
study NN N
. . N

Despite IN N
the DT N
psychosocial JJ N
difficulties NNS N
common JJ N
among IN N
young JJ p
adults NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
) ) p
, , N
little JJ N
to TO N
no DT N
evidence-based JJ N
social JJ i
skills NNS i
interventions NNS i
exist VBP N
for IN N
this DT N
population NN N
. . N

Using VBG N
a DT N
randomized VBN N
controlled VBN N
trial NN N
( ( N
RCT NNP N
) ) N
design NN N
, , N
the DT N
current JJ N
study NN N
tested VBD N
the DT N
effectiveness NN N
of IN N
an DT i
evidence-based JJ i
, , i
caregiver-assisted JJ i
social JJ i
skills NNS i
intervention NN i
known VBN i
as IN i
PEERS NNP i
for IN i
Young NNP i
Adults NNP i
with IN N
high-functioning JJ p
young JJ p
adults NNS p
with IN p
ASD NNP p
( ( p
ages VBZ p
18-23 CD p
) ) p
using VBG N
self- JJ o
and CC o
caregiver-report JJ o
measures NNS o
. . o

Results NNS N
revealed VBD N
that IN N
treated JJ N
young JJ p
adults NNS p
reported VBD N
significantly RB N
less JJR N
loneliness JJ o
and CC N
improved VBN o
social JJ o
skills NNS o
knowledge VBP o
, , N
while IN N
caregivers NNS N
reported VBD N
significant JJ N
improvements NNS N
in IN N
young JJ p
adults NNS p
' POS p
overall JJ o
social JJ o
skills NNS o
, , o
social JJ o
responsiveness NN o
, , o
empathy NN o
, , o
and CC o
frequency NN o
of IN o
get-togethers NNS o
. . o

Results NNS N
support VBD N
the DT N
effectiveness NN N
of IN N
using VBG N
this DT N
caregiver-assisted JJ i
, , i
manualized VBN i
intervention NN i
for IN N
young JJ p
adults NNS p
with IN p
ASD NNP p
. . p

-DOCSTART- -21272822- O O

Using VBG N
baby NN N
books NNS N
to TO N
increase VB N
new JJ o
mothers NNS o
' POS o
safety NN o
practices NNS o
. . o

OBJECTIVE NN N
To TO N
determine VB N
whether IN N
educational JJ i
baby NN i
books NNS i
are VBP N
an DT N
effective JJ N
method NN N
for IN N
increasing VBG N
low-income JJ o
, , o
first-time JJ o
mothers NNS o
' POS o
safety NN o
practices NNS o
during IN p
their PRP$ p
child NN p
's POS p
first JJ p
18 CD p
months NNS p
. . p

METHODS NNP N
Primiparous JJ p
women NNS p
( ( p
n JJ p
= NNP p
167 CD p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
3 CD N
groups NNS N
: : N
an DT i
educational JJ i
book NN i
group NN i
, , i
a DT i
noneducational JJ i
book NN i
group NN i
, , i
or CC i
a DT i
no-book JJ i
group NN i
. . i

Home NNP N
visits NNS N
and CC N
interviews NNS N
measured VBN N
safety NN o
practices NNS o
when WRB N
women NNS N
were VBD N
in IN N
their PRP$ N
third JJ N
trimester NN N
of IN N
pregnancy NN N
( ( N
baseline NN N
) ) N
and CC N
when WRB N
their PRP$ N
children NNS N
were VBD N
2 CD N
, , N
4 CD N
, , N
6 CD N
, , N
9 CD N
, , N
12 CD N
, , N
and CC N
18 CD N
months NNS N
of IN N
age NN N
. . N

RESULTS NNP N
Women NNP N
in IN N
the DT N
educational JJ N
book NN N
group NN N
had VBD N
fewer JJR o
risks NNS o
in IN o
their PRP$ o
homes NNS o
and CC N
exercised VBD N
more JJR N
safety NN o
practices NNS o
than IN N
the DT N
no-book JJ N
group NN N
( ( N
- : N
20 CD N
% NN N
risk NN N
reduction NN N
; : N
effect NN N
size NN N
= NNP N
-.30 NNP N
) ) N
. . N

When WRB N
the DT N
safety NN N
practices NNS o
involved VBN N
little JJ o
time NN o
or CC o
expense NN o
( ( N
eg UH N
, , N
putting VBG N
away RB N
sharp JJ N
objects NNS N
) ) N
, , N
the DT N
educational JJ N
book NN N
group NN N
was VBD N
significantly RB N
more RBR N
likely JJ N
to TO N
engage VB N
in IN N
these DT N
behaviors NNS N
than IN N
the DT N
no-book JJ N
group NN N
( ( N
40 CD N
% NN N
higher JJR N
practices NNS N
; : N
effect NN N
size NN N
= NNP N
0.19 CD N
) ) N
or CC N
noneducational JJ N
book NN N
group NN N
( ( N
27 CD N
% NN N
higher JJR N
practices NNS N
; : N
effect NN N
size NN N
= NNP N
0.13 CD N
) ) N
. . N

However RB N
, , N
no DT N
differences NNS N
were VBD N
found VBN N
between IN N
groups NNS N
for IN o
behaviors NNS o
that WDT o
required VBD o
high JJ o
effort NN o
in IN o
time NN o
, , o
money NN o
, , o
or CC o
hassle NN o
( ( N
eg JJ N
, , N
installing VBG N
latches NNS N
on IN N
cabinets NNS N
) ) N
. . N

CONCLUSIONS NNP N
Educational NNP N
baby NN N
books NNS N
appear VBP N
to TO N
be VB N
an DT N
easy JJ N
and CC N
low-cost JJ N
way NN N
to TO N
increase VB N
the DT o
safety NN o
practices NNS o
of IN o
new JJ o
mothers NNS o
, , o
especially RB N
if IN N
the DT N
practices NNS N
involve VBP N
little JJ N
to TO N
no DT N
time NN N
, , N
money NN N
, , N
or CC N
hassle NN N
. . N

-DOCSTART- -17943674- O O

Effects NNS N
of IN N
vacuum-compression NN o
therapy NN o
on IN N
healing NN N
of IN N
diabetic JJ o
foot NN o
ulcers NNS o
: : o
randomized VBN N
controlled JJ N
trial NN N
. . N

A DT N
single-blind JJ N
, , N
randomized VBN N
controlled VBD N
trial NN N
was VBD N
conducted VBN N
to TO N
evaluate VB N
vacuum-compression NN o
therapy NN o
( ( o
VCT NNP o
) ) o
for IN N
the DT N
healing NN N
of IN N
diabetic JJ o
foot NN o
ulcers NNS o
. . o

Eighteen NNP p
diabetic JJ p
patients NNS p
with IN p
foot JJ o
ulcers NNS o
were VBD p
recruited VBN p
through IN p
simple JJ p
nonprobability NN p
sampling VBG p
. . p

Subjects NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
an DT N
experimental JJ N
or CC N
a DT N
control NN i
group NN N
. . N

Before IN N
and CC N
after IN N
intervention NN N
, , N
the DT N
foot NN o
ulcer JJ o
surface NN o
area NN o
was VBD N
estimated VBN N
stereologically RB N
, , N
based VBN N
on IN N
Cavalieri NNP N
's POS N
principle NN N
. . N

The DT N
experimental JJ N
group NN N
was VBD N
treated VBN N
with IN N
VCT NNP o
in IN i
addition NN i
to TO i
conventional JJ o
therapy NN o
for IN N
10 CD N
sessions NNS N
. . N

The DT N
control NN N
group NN N
received VBD N
only RB N
conventional JJ o
therapy NN o
, , i
including VBG i
debridement NN o
, , o
blood NN o
glucose NNS o
control NN o
agents NNS o
, , o
systemic JJ o
antibiotics NNS o
, , o
wound IN o
cleaning VBG o
with IN o
normal JJ o
saline NN o
, , o
offloading VBG o
( ( o
pressure NN o
relief NN o
) ) o
, , i
and CC i
daily RB o
wound JJ o
dressings NNS o
. . o

The DT N
mean JJ N
foot NN o
ulcer JJ o
surface NN o
area NN o
decreased VBD N
from IN N
46.88 CD N
+/- JJ N
9.28 CD N
mm NN N
( ( N
2 CD N
) ) N
to TO N
35.09 CD N
+/- JJ N
4.09 CD N
mm NN N
( ( N
2 CD N
) ) N
in IN N
the DT N
experimental JJ N
group NN N
( ( N
p JJ N
= NNP N
0.006 CD N
) ) N
and CC N
from IN N
46.62 CD N
+/- JJ N
10.03 CD N
mm NN N
( ( N
2 CD N
) ) N
to TO N
42.89 CD N
+/- JJ N
8.1 CD N
mm NN N
( ( N
2 CD N
) ) N
in IN N
the DT N
control NN N
group NN N
( ( N
p JJ N
= NNP N
0.01 CD N
) ) N
. . N

After IN N
treatment NN N
, , N
the DT N
experimental JJ N
group NN N
significantly RB N
improved VBN N
in IN N
measures NNS o
of IN o
foot NN o
ulcer JJ o
surface NN o
area NN o
compared VBN N
with IN N
the DT N
control NN N
group NN N
( ( N
p JJ N
= NNP N
0.024 CD N
) ) N
. . N

VCT NNP o
enhances VBZ N
diabetic JJ o
foot NN o
ulcer NN o
healing VBG o
when WRB N
combined VBN N
with IN N
appropriate JJ N
wound NN N
care NN N
. . N

-DOCSTART- -23639612- O O

Galactomannan NNP i
and CC i
PCR NNP i
versus NN N
culture NN N
and CC N
histology NN N
for IN N
directing VBG N
use NN N
of IN N
antifungal JJ N
treatment NN N
for IN N
invasive JJ p
aspergillosis NN p
in IN p
high-risk JJ p
haematology NN p
patients NNS p
: : p
a DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Empirical NNP N
treatment NN N
with IN N
antifungal JJ N
drugs NNS N
is VBZ N
often RB N
used VBN N
in IN N
haematology NN p
patients NNS p
at IN p
high JJ p
risk NN p
of IN p
invasive JJ p
aspergillosis NN p
. . p

We PRP N
compared VBN N
a DT N
standard JJ N
diagnostic JJ N
strategy NN N
( ( N
culture NN N
and CC N
histology NN N
) ) N
with IN N
a DT N
rapid JJ N
biomarker-based JJ N
diagnostic JJ N
strategy NN N
( ( N
aspergillus JJ N
galactomannan NN N
and CC N
PCR NNP N
) ) N
for IN N
directing VBG N
the DT N
use NN N
of IN N
antifungal JJ N
treatment NN N
in IN N
this DT N
group NN N
of IN N
patients NNS N
. . N

METHODS NNP N
In IN N
this DT N
open-label JJ N
, , N
parallel-group JJ N
, , N
randomised VBD N
controlled VBN N
trial NN N
, , N
eligible JJ p
patients NNS p
were VBD p
adults NNS p
undergoing VBG p
allogeneic JJ p
stem-cell JJ p
transplantation NN p
or CC p
chemotherapy NN i
for IN p
acute JJ p
leukaemia NN p
, , p
with IN p
no DT p
history NN p
of IN p
invasive JJ p
fungal JJ p
disease NN p
. . p

Enrolled JJ N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
( ( N
1:1 CD N
) ) N
by IN N
a DT N
computer-generated JJ N
schedule NN N
to TO N
follow VB N
either RB N
a DT N
standard JJ i
diagnostic JJ i
strategy NN i
( ( N
based VBN N
on IN N
culture NN N
and CC N
histology NN N
) ) N
or CC N
a DT N
biomarker-based JJ i
diagnostic JJ i
strategy NN i
( ( i
aspergillus JJ i
galactomannan NN i
and CC i
PCR NNP i
) ) i
to TO N
direct VB N
treatment NN N
with IN N
antifungal JJ N
drugs NNS N
. . N

Patients NNS N
, , N
were VBD N
followed VBN N
up RP N
for IN N
26 CD N
weeks NNS N
or CC N
until IN N
death NN N
. . N

Masking NNP N
of IN N
the DT N
use NN N
of IN N
different JJ N
diagnostic JJ N
tests NNS N
was VBD N
not RB N
possible JJ N
for IN N
patients NNS N
, , N
treating VBG N
physicians NNS N
, , N
or CC N
investigators NNS N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
empirical JJ o
treatment NN o
with IN o
antifungal JJ o
drugs NNS o
in IN N
the DT N
26 CD N
weeks NNS N
after IN N
enrolment NN N
( ( N
for IN N
the DT N
biomarker-based JJ N
diagnostic JJ N
strategy NN N
, , N
a DT N
single JJ N
postive JJ N
galactomannan NN N
or CC N
PCR NNP N
result NN N
was VBD N
deemed VBN N
insufficient JJ N
to TO N
confirm VB N
invasive JJ N
aspergillosis NN N
, , N
so RB N
treatment NN N
in IN N
this DT N
context NN N
was VBD N
classified VBN N
as IN N
empirical JJ N
) ) N
. . N

This DT N
outcome NN N
was VBD N
assessed VBN N
by IN N
an DT N
independent JJ N
data NN N
review NN N
committee NN N
from IN N
which WDT N
the DT N
study NN N
allocations NNS N
were VBD N
masked VBN N
. . N

Analyses NNS N
were VBD N
by IN N
intention NN N
to TO N
treat VB N
and CC N
included VB N
all DT N
enrolled JJ N
patients NNS N
. . N

This DT N
study NN N
is VBZ N
registered VBN N
with IN N
ClinicalTrial.gov NNP N
, , N
number NN N
NCT00163722 NNP N
. . N

FINDINGS NNP N
240 CD p
eligible JJ p
patients NNS p
were VBD p
recruited VBN p
from IN p
six CD p
Australian JJ p
centres NNS p
between IN p
Sept NNP p
30 CD p
, , p
2005 CD p
, , p
and CC p
Nov NNP p
19 CD p
, , p
2009 CD p
. . p

122 CD N
were VBD N
assigned VBN N
the DT N
standard JJ N
diagnostic JJ N
strategy NN N
and CC N
118 CD N
the DT N
biomarker-based JJ N
diagnostic JJ N
strategy NN N
. . N

39 CD N
patients NNS N
( ( N
32 CD N
% NN N
) ) N
in IN N
the DT N
standard JJ N
diagnosis NN N
group NN N
and CC N
18 CD N
( ( N
15 CD N
% NN N
) ) N
in IN N
the DT N
biomarker NN N
diagnosis NN N
group NN N
received VBD N
empirical JJ N
antifungal JJ N
treatment NN N
( ( N
difference NN N
17 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
4-26 CD N
; : N
p=0?002 NN N
) ) N
. . N

The DT o
numbers NNS o
of IN o
patients NNS o
who WP o
had VBD o
hepatotoxic NN o
and CC o
nephrotoxic JJ o
effects NNS o
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
standard JJ N
diagnosis NN N
and CC N
biomarker NN N
diagnosis NN N
groups NNS N
( ( N
hepatotoxic JJ o
effects NNS o
: : o
21 CD N
[ $ N
17 CD N
% NN N
] NNP N
vs NN N
12 CD N
[ JJ N
10 CD N
% NN N
] NN N
, , N
p=0?11 NN o
; : o
nephrotoxic JJ o
effects NNS o
: : o
52 CD o
[ $ N
43 CD N
% NN N
] NNP N
vs NN N
60 CD N
[ JJ N
51 CD N
% NN N
] NN N
, , N
p=0?20 NN N
) ) N
. . N

INTERPRETATION NNP N
Use NNP N
of IN N
aspergillus JJ N
galactomannan NN N
and CC N
PCR NNP N
to TO N
direct VB N
treatment NN N
reduced VBN o
use NN o
of IN o
empirical JJ o
antifungal JJ o
treatment NN o
. . o

This DT o
approach NN N
is VBZ N
an DT N
effective JJ N
strategy NN N
for IN N
the DT N
management NN N
of IN N
invasive JJ N
aspergillosis NN N
in IN N
high-risk JJ p
haematology NN p
patients NNS p
. . p

FUNDING NNP p
Australian JJ N
National NNP N
Health NNP N
and CC N
Medical NNP N
Research NNP N
Council NNP N
, , N
Cancer NNP N
Council NNP N
New NNP N
South NNP N
Wales NNP N
, , N
Pfizer NNP N
, , N
Merck NNP N
, , N
Gilead NNP N
Sciences NNPS N
. . N

-DOCSTART- -24602973- O O

Prospective JJ N
randomized VBN N
trial NN N
of IN N
bispectral JJ N
index NN N
monitoring NN i
of IN N
sedation NN N
depth NN N
during IN N
flexible JJ N
bronchoscopy NN N
. . N

BACKGROUND IN N
The DT N
clinical JJ N
benefits NNS N
associated VBN N
with IN N
the DT N
use NN N
of IN N
the DT N
bispectral JJ i
index NN i
( ( i
BIS NNP i
) ) i
to TO N
monitor VB N
the DT N
depth NN o
of IN o
sedation NN o
during IN N
flexible JJ N
fiberoptic JJ N
bronchoscopy NN N
( ( N
FFB NNP N
) ) N
are VBP N
questionable JJ N
. . N

OBJECTIVES NNP N
To TO N
evaluate VB N
the DT N
added JJ N
value NN N
in IN N
terms NNS N
of IN N
procedural JJ N
safety NN N
and CC N
patients NNS N
' POS N
awareness NN N
of IN N
monitoring VBG N
sedation NN N
depth NN N
using VBG N
the DT N
BIS NNP N
compared VBN N
to TO N
conventional JJ N
clinical JJ N
judgment NN N
alone RB N
in IN N
patients NNS N
undergoing VBG N
FFB NNP N
under IN N
propofol JJ N
sedation NN N
. . N

METHODS NNP N
The DT N
cohort NN N
included VBD N
81 CD p
patients NNS p
undergoing JJ p
diagnostic JJ p
or CC p
therapeutic JJ p
bronchoscopy NN p
under IN p
propofol NN i
sedation NN i
that WDT N
were VBD N
prospectively RB i
randomized VBN i
to TO i
guide VB i
the DT i
depth NN o
of IN o
sedation NN o
by IN i
BIS NNP i
monitoring NN i
( ( i
BIS NNP i
group NN i
; : i
n CC i
= VB i
40 CD i
) ) i
or CC i
conventional JJ i
monitoring NN i
( ( i
control JJ i
group NN i
; : i
n CC i
= VB i
41 CD i
) ) i
. . i

RESULTS VB N
The DT N
mean JJ N
durations NNS N
of IN N
the DT N
procedure NN N
were VBD N
18 CD N
and CC N
19 CD N
min NN N
in IN N
the DT N
BIS NNP N
and CC N
control NN N
groups NNS N
, , N
respectively RB N
. . N

No UH N
significant JJ N
difference NN N
was VBD N
noted VBN N
in IN N
the DT N
dosage NN o
of IN o
propofol NN o
used VBN N
between IN N
the DT N
BIS NNP N
and CC N
control NN N
groups NNS N
( ( N
168.7 CD N
vs. FW N
167.3 CD N
mg NN N
, , N
respectively RB N
) ) N
. . N

Average JJ o
sedation-related JJ o
oxygen NN o
saturation NN o
drop NN N
and CC N
transcutaneous JJ o
CO2 NNP o
rise NN N
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
groups NNS N
. . N

There EX N
was VBD N
also RB N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
percentage NN N
of IN N
patients NNS N
that WDT N
required VBD N
either DT N
hemodynamic JJ N
support NN N
( ( N
5 CD N
vs. FW N
7.5 CD N
% NN N
, , N
respectively RB N
) ) N
, , N
oxygen JJ N
supplementation NN N
by IN N
100 CD N
% NN N
O2 NNP N
mask NN N
( ( N
67.5 CD N
vs. FW N
82.5 CD N
% NN N
, , N
respectively RB N
) ) N
or CC N
Ambu NNP N
face VBP N
mask JJ N
manual JJ N
ventilation NN N
( ( N
2.5 CD N
vs. FW N
5 CD N
% NN N
, , N
respectively RB N
) ) N
between IN N
the DT N
groups NNS N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
noted VBN N
in IN N
terms NNS N
of IN N
patients NNS o
' POS o
awareness NN o
during IN N
the DT N
procedure NN N
, , N
which WDT N
was VBD N
assessed VBN N
following VBG N
recovery NN N
by IN N
a DT N
structured JJ N
Brice NNP N
interview NN N
. . N

CONCLUSION NNP N
Using VBG N
BIS NNP N
to TO N
guide VB N
the DT N
depth NN N
of IN N
sedation NN N
during IN N
propofol JJ N
sedation NN N
in IN N
patients NNS p
undergoing VBG p
FFB NNP p
of IN p
relatively RB p
short JJ p
duration NN p
offers VBZ N
no DT N
clinically RB N
significant JJ N
advantages NNS N
over IN N
conventional JJ N
monitoring NN N
. . N

-DOCSTART- -16845576- O O

Teaching VBG N
young JJ p
nonverbal JJ p
children NNS p
with IN p
autism NN p
useful JJ N
speech NN N
: : N
a DT N
pilot NN N
study NN N
of IN N
the DT N
Denver NNP i
Model NNP i
and CC i
PROMPT NNP i
interventions NNS i
. . i

This DT N
single JJ N
subject NN N
design NN N
study NN N
examined VBD N
two CD N
models NNS N
of IN N
intervention NN N
: : N
Denver NNP i
Model NNP i
( ( i
which WDT i
merges VBZ i
behavioral JJ i
, , i
developmental JJ i
, , i
and CC i
relationship-oriented JJ i
intervention NN i
) ) i
, , i
and CC i
PROMPT NNP i
( ( i
a DT i
neuro-developmental JJ i
approach NN i
for IN i
speech JJ i
production NN i
disorders NNS i
) ) i
. . i

Ten CD p
young JJ p
, , p
nonverbal JJ p
children NNS p
with IN p
autism NN p
were VBD N
matched VBN N
in IN N
pairs NNS N
and CC N
randomized VBN N
to TO N
treatment NN N
. . N

They PRP N
received VBD N
12 CD N
1-h JJ N
weekly JJ N
sessions NNS N
of IN N
therapy NN N
and CC N
daily JJ N
1-h JJ N
home NN N
intervention NN N
delivered VBN N
by IN N
parents NNS N
. . N

Fidelity NNP N
criteria NNS N
were VBD N
maintained VBN N
throughout IN N
. . N

Eight NNP N
of IN N
the DT N
ten JJ N
children NNS N
used VBN N
five CD N
or CC N
more JJR N
novel JJ N
, , N
functional JJ o
words NNS N
spontaneously RB N
and CC N
spoke VBD N
multiple JJ o
times NNS o
per IN o
hour NN o
by IN N
the DT N
conclusion NN N
of IN N
treatment NN N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
acquired VBN o
language NN o
skills NNS o
by IN N
intervention NN N
group NN N
. . N

Initial JJ N
characteristics NNS N
of IN N
the DT N
best JJS N
responders NNS N
were VBD N
mild JJ p
to TO p
moderate VB p
symptoms NNS p
of IN p
autism NN p
, , p
better JJR p
motor NN o
imitation NN o
skills NNS o
, , o
and CC o
emerging VBG o
joint JJ o
attention NN o
skills NNS o
. . o

-DOCSTART- -19309326- O O

Cognitive JJ i
behavioral JJ i
therapy NN i
for IN N
anxiety NN o
in IN p
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
: : p
a DT N
randomized NN N
, , N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Children NNP p
with IN p
autism NN p
spectrum NN p
disorders NNS p
often RB N
present JJ N
with IN N
comorbid NN p
anxiety NN p
disorders NNS p
that WDT p
cause VBP p
significant JJ p
functional JJ o
impairment NN o
. . o

This DT N
study NN N
tested VBD N
a DT N
modular JJ i
cognitive JJ i
behavioral JJ i
therapy NN i
( ( i
CBT NNP i
) ) i
program NN N
for IN N
children NNS N
with IN N
this DT N
profile NN N
. . N

A DT N
standard JJ N
CBT NNP i
program NN N
was VBD N
augmented VBN N
with IN N
multiple JJ N
treatment NN N
components NNS N
designed VBN N
to TO N
accommodate VB N
or CC N
remediate VB N
the DT N
social JJ N
and CC N
adaptive JJ N
skill NN N
deficits NNS N
of IN N
children NNS p
with IN p
ASD NNP p
that WDT N
could MD N
pose VB N
barriers NNS N
to TO N
anxiety VB o
reduction NN o
. . o

METHOD NNP N
Forty NNP p
children NNS p
( ( p
7-11 CD p
years NNS p
old JJ p
) ) p
were VBD p
randomly RB p
assigned VBN p
to TO N
16 CD N
sessions NNS N
of IN N
CBT NNP i
or CC N
a DT N
3-month JJ i
waitlist NN i
( ( N
36 CD N
completed VBN N
treatment NN N
or CC N
waitlist NN N
) ) N
. . N

Therapists NNS N
worked VBD N
with IN N
individual JJ N
families NNS N
. . N

The DT N
CBT NNP i
model NN N
emphasized VBD N
behavioral JJ N
experimentation NN N
, , N
parent-training NN N
, , N
and CC N
school NN N
consultation NN N
. . N

Independent JJ N
evaluators NNS N
blind VBP N
to TO N
treatment NN N
condition NN N
conducted VBN N
structured JJ N
diagnostic JJ N
interviews NNS N
and CC N
parents NNS N
and CC N
children NNS N
completed VBN N
anxiety NN o
symptom NN o
checklists NNS o
at IN N
baseline NN N
and CC N
posttreatment/postwaitlist NN N
. . N

RESULTS NNP N
In IN N
intent-to-treat JJ N
analyses NNS N
, , N
78.5 CD N
% NN N
of IN N
the DT N
CBT NNP i
group NN N
met VBD N
Clinical JJ o
Global NNP o
Impressions-Improvement NNP o
scale NN o
criteria NNS o
for IN N
positive JJ N
treatment NN N
response NN N
at IN N
posttreatment NN N
, , N
as IN N
compared VBN N
to TO N
only RB N
8.7 CD N
% NN N
of IN N
the DT N
waitlist NN i
group NN N
. . N

CBT NNP i
also RB N
outperformed VBD N
the DT N
waitlist NN i
on IN N
diagnostic JJ N
outcomes NNS N
and CC N
parent NN o
reports NNS o
of IN o
child NN o
anxiety NN o
, , N
but CC N
not RB N
children NNS N
's POS N
self-reports NNS N
. . N

Treatment NN N
gains NNS N
were VBD N
maintained VBN N
at IN N
3-month JJ N
follow-up NN N
. . N

CONCLUSIONS VB N
The DT N
CBT NNP i
manual JJ N
employed VBN N
in IN N
this DT N
study NN N
is VBZ N
one CD N
of IN N
the DT N
first JJ N
adaptations NNS N
of IN N
an DT N
evidence-based JJ N
treatment NN N
for IN N
children NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
. . N

Remission NN N
of IN N
anxiety NN o
disorders NNS o
appears VBZ N
to TO N
be VB N
an DT N
achievable JJ N
goal NN N
among IN N
high-functioning JJ N
children NNS N
with IN N
autism NN N
. . N

-DOCSTART- -10209728- O O

Effects NNS o
of IN N
oral JJ N
brovincamine NN i
on IN N
visual JJ N
field NN N
damage NN N
in IN N
patients NNS p
with IN p
normal-tension JJ p
glaucoma NN p
with IN p
low-normal JJ p
intraocular JJ p
pressure NN p
. . p

PURPOSE NNP N
To TO N
prospectively RB N
study VB N
the DT N
effect NN o
of IN N
oral JJ i
brovincamine NN i
, , N
a DT N
relatively RB N
selective JJ N
cerebral JJ i
vasodilator NN i
, , N
on IN N
further JJ N
deterioration NN N
of IN N
visual JJ N
field NN N
in IN N
patients NNS p
with IN p
normal-tension JJ p
glaucoma NN p
( ( p
NTG NNP p
) ) p
with IN p
low-normal JJ p
intraocular JJ p
pressure NN p
( ( p
IOP NNP p
) ) p
. . p

METHODS NNP N
Fifty-two JJ p
patients NNS p
with IN p
NTG NNP p
( ( p
average JJ p
age NN p
57.7 CD p
years NNS p
) ) p
with IN p
an DT p
IOP NNP p
that WDT p
was VBD p
consistently RB p
less JJR p
than IN p
15 CD p
mmHg NNS p
were VBD p
randomly RB p
assigned VBN p
to TO p
receive VB N
oral JJ i
brovincamine NN i
( ( N
20 CD N
mg NN N
three CD N
times NNS N
daily RB N
) ) N
or CC N
to TO N
an DT N
untreated JJ i
control NN i
group NN i
. . i

The DT N
groups NNS N
were VBD N
prospectively RB N
followed VBN N
for IN N
2 CD N
years NNS N
with IN N
visual JJ i
field NN i
examinations NNS i
every DT N
4 CD N
months NNS N
, , N
using VBG N
the DT N
30-2 JJ N
Humphrey NNP N
perimeter NN N
program NN N
. . N

Changes NNS o
in IN o
mean JJ o
deviation NN o
( ( o
MD NNP o
) ) o
, , o
corrected VBD o
pattern JJ o
standard JJ o
deviation NN o
( ( o
CPSD NNP o
) ) o
, , N
and CC N
total JJ o
deviation NN o
( ( o
TD NNP o
) ) o
at IN N
74 CD N
test NN N
points NNS N
were VBD N
analyzed VBN N
using VBG N
regression NN N
analysis NN N
with IN N
linear JJ N
mixed JJ N
model NN N
. . N

Data NNS N
from IN N
one CD N
eye NN N
without IN N
media NNS N
opacity NN N
of IN N
each DT N
subject NN N
were VBD N
analyzed VBN N
. . N

RESULTS VB N
There EX N
were VBD N
no DT o
differences NNS o
between IN N
groups NNS N
in IN N
age NN o
; : o
sex NN o
distribution NN o
; : o
refraction NN o
; : o
blood NN o
pressure NN o
; : o
baseline JJ o
IOP NNP o
; : o
MD NNP o
, , o
CPSD NNP o
, , o
or CC o
TD NNP o
at IN N
each DT N
point NN N
. . N

Changes NNS o
in IN o
MD NNP o
( ( N
standard JJ N
error NN N
[ NNP N
SE NNP N
] NNP N
) ) N
during IN N
the DT N
study NN N
period NN N
were VBD N
-0.778 NNP N
( ( N
0.178 CD N
) ) N
and CC N
-0.071 NNP N
( ( N
0.195 CD N
) ) N
dB/year NN N
in IN N
the DT N
control NN N
and CC N
brovincamine NN i
groups NNS N
, , N
respectively RB N
; : N
change NN N
in IN N
the DT N
control NN N
group NN N
was VBD N
significantly RB N
more RBR N
negative JJ N
than IN N
in IN N
the DT N
brovincamine NN i
group NN N
. . N

Change NNP o
in IN o
CPSD NNP o
( ( o
SE NNP o
) ) o
was VBD N
0.032 CD N
( ( N
0.015 CD N
) ) N
and CC N
0.004 CD N
( ( N
0.016 CD N
) ) N
dB/year NN N
in IN N
the DT N
control NN N
and CC N
brovincamine NN i
groups NNS N
, , N
respectively RB N
. . N

Change NN o
in IN N
the DT N
control NN N
group NN N
was VBD N
significantly RB N
positive JJ N
, , N
but CC N
the DT N
intergroup NN N
difference NN N
was VBD N
not RB N
significant JJ N
. . N

Change NN o
in IN o
TD NNP o
was VBD N
significantly RB N
negative JJ N
at IN N
six CD N
test NN N
points NNS N
in IN N
the DT N
control NN N
group NN N
, , N
whereas IN N
no DT N
points NNS N
showed VBD N
a DT N
significant JJ o
trend NN N
in IN N
the DT N
brovincamine NN i
group NN N
; : N
the DT N
intergroup NN N
difference NN N
was VBD N
significant JJ N
. . N

The DT N
average JJ o
IOP NNP o
was VBD N
13.2 CD N
mmHg NN N
and CC N
13.1 CD N
mmHg NN N
in IN N
the DT N
control NN N
and CC N
brovincamine NN i
groups NNS N
, , N
respectively RB N
, , N
and CC N
there EX N
was VBD N
no DT o
significant JJ o
intergroup NN N
difference NN N
. . N

CONCLUSION NNP N
Oral NNP i
brovincamine NN i
may MD N
retard VB N
further JJ N
visual JJ N
field NN N
deterioration NN N
in IN N
patients NNS p
with IN p
NTG NNP p
who WP p
have VBP p
low-normal JJ p
IOP NNP p
. . p

-DOCSTART- -8487344- O O

Abdominal NNP p
surgical JJ p
wound NN p
infection NN N
is VBZ N
lowered VBN N
with IN N
improved JJ N
perioperative JJ i
enterococcus NN i
and CC i
bacteroides NNS i
therapy NN i
. . i

Perioperative JJ i
antibiotics NNS i
decrease VBP N
surgical JJ o
wound NN o
infection NN o
( ( o
SWI NNP o
) ) o
in IN N
trauma NN p
patients NNS p
requiring VBG p
abdominal JJ p
exploration NN p
. . p

This DT N
investigation NN N
evaluated VBD N
24 CD N
hours NNS N
of IN N
cefoxitin NN i
or CC i
ampicillin/sulbactam NN i
used VBN N
for IN N
early JJ N
therapy NN N
in IN N
such JJ N
patients NNS N
. . N

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
treatment NN N
groups NNS N
. . N

The DT N
primary JJ N
endpoint NN N
evaluated VBN N
was VBD N
SWI NNP o
, , N
which WDT N
was VBD N
defined VBN N
as IN N
purulent JJ N
drainage NN N
or CC N
active JJ N
wound NN N
treatment NN N
. . N

Five CD p
hundred VBD p
ninety-two JJ p
patients NNS p
were VBD p
evaluated VBN p
: : p
283 CD p
received VBD p
ampicillin/sulbactam NN i
and CC p
309 CD p
received VBD p
cefoxitin NN i
. . i

The DT N
incidence NN o
of IN o
wound JJ o
infection NN o
among IN N
the DT N
ampicillin/sulbactam NN N
patients NNS N
was VBD N
2 CD N
% NN N
and CC N
among IN N
cefoxitin JJ N
patients NNS N
it PRP N
was VBD N
7 CD N
% NN N
( ( N
p JJ N
< NNP N
0.004 CD N
) ) N
. . N

The DT N
cefoxitin NN N
patients NNS N
with IN N
colon NN N
injuries NNS N
were VBD N
analyzed VBN N
( ( N
p JJ N
< NNP N
0.007 CD N
) ) N
. . N

The DT N
major JJ N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
was VBD N
an DT N
increased JJ N
incidence NN o
of IN o
enterococcal JJ o
infections NNS o
in IN N
the DT N
cefoxitin-treated JJ N
patients NNS N
. . N

A DT N
single JJ N
broad-spectrum JJ N
antibiotic JJ N
given VBN N
for IN N
24 CD N
hour NN N
perioperatively RB N
effectively RB N
controls VBZ N
SWI NNP N
. . N

Use NNP N
of IN N
ampicillin/sulbactam JJ N
results NNS N
in IN N
a DT N
significantly RB N
lower JJR N
SWI NNP o
rate NN o
than IN N
use NN N
of IN N
cefoxitin NN N
, , N
which WDT N
may MD N
be VB N
a DT N
result NN N
of IN N
improved JJ N
enterococcal JJ o
and CC o
Bacteroides NNP o
coverage NN o
. . o

-DOCSTART- -17280773- O O

Desmopressin NNP i
in IN N
the DT N
treatment NN N
of IN N
nocturia NNS p
: : p
a DT N
double-blind NN N
, , N
placebo-controlled JJ N
study NN N
. . N

OBJECTIVES NNP N
To TO N
investigate VB N
efficacy NN o
, , o
safety NN o
, , N
and CC N
impact NN N
on IN N
quality NN o
of IN o
sleep NN o
of IN N
desmopressin NN i
in IN N
the DT N
treatment NN N
of IN N
nocturia NNS N
. . N

METHODS NNP N
Adults NNP p
aged VBD p
> NNP p
or CC p
=18 NNP p
yr NN p
with IN p
nocturia NNS p
( ( p
> CD p
or CC p
=2 VB p
voids/night NN p
) ) p
received VBD N
desmopressin JJ i
tablets NNS N
( ( N
0.1 CD N
, , N
0.2 CD N
, , N
or CC N
0.4 CD N
mg NN N
) ) N
during IN N
a DT N
3-wk JJ N
dose-titration NN N
period NN N
. . N

Patients NNS N
should MD N
show VB N
sufficient JJ N
response NN N
during IN N
the DT N
dose-titration JJ N
period NN N
( ( N
> CD N
or CC N
=20 CD N
% NN N
reduction NN N
in IN N
nocturnal JJ N
diuresis NN N
) ) N
and CC N
a DT N
return NN N
of IN N
nocturnal JJ N
diuresis NN N
to TO N
> VB N
or CC N
=80 VB N
% NN N
of IN N
baseline NN N
levels NNS N
during IN N
washout NN N
. . N

Eligible JJ N
patients NNS N
then RB N
entered VBD N
a DT N
3-wk JJ N
double-blind JJ N
treatment NN N
period NN N
and CC N
received VBD N
either CC N
desmopressin NN i
or CC N
placebo NN i
. . i

RESULTS CC N
127 CD p
patients NNS p
were VBD p
randomised VBN p
to TO N
either DT N
desmopressin NN i
( ( N
n=61 JJ N
) ) N
or CC N
placebo NN i
( ( N
n=66 JJ N
) ) N
. . N

Twenty NNP N
( ( N
33 CD N
% NN N
) ) N
desmopressin-treated JJ i
patients NNS N
compared VBN N
with IN N
seven CD N
( ( N
11 CD N
% NN N
) ) N
placebo-treated JJ i
patients NNS N
showed VBD N
a DT N
clinical JJ N
response NN N
, , N
defined VBD N
as IN N
a DT N
> NN N
or CC N
=50 CD N
% NN N
reduction NN N
in IN N
the DT N
number NN o
of IN o
nocturnal JJ o
voids NNS o
compared VBN N
with IN N
baseline NN N
( ( N
p=0.0014 NN N
) ) N
. . N

Compared VBN N
with IN N
placebo NN N
, , N
desmopressin NN i
resulted VBD N
in IN N
a DT N
significant JJ N
reduction NN N
in IN N
the DT N
mean JJ o
number NN o
of IN o
nocturnal JJ o
voids NNS o
( ( N
39 CD N
% NN N
reduction NN N
with IN N
desmopressin NN i
vs. FW N
15 CD N
% NN N
with IN N
placebo NN i
; : i
absolute JJ N
difference NN N
-0.84 NN N
, , N
p NN N
< NNP N
0.0001 CD N
) ) N
and CC N
duration NN o
of IN o
the DT o
first JJ o
sleep JJ o
period NN o
( ( N
prolonged VBN N
by IN N
108 CD N
min NNS N
with IN N
desmopressin NN i
vs. FW N
41 CD N
min NN N
with IN N
placebo NN i
; : i
p CC N
< VB N
0.0001 CD N
) ) N
. . N

Quality NN o
of IN o
sleep NN o
was VBD N
also RB N
improved VBN N
with IN N
desmopressin NN i
versus NN N
placebo NN i
( ( N
statistically RB N
significant JJ N
for IN N
one CD N
of IN N
the DT N
two CD N
parameters NNS N
evaluated VBD N
) ) N
. . N

Adverse JJ o
events NNS o
were VBD N
mainly RB N
mild JJ N
. . N

CONCLUSIONS NNP N
Oral NNP N
desmopressin NN i
tablets NNS N
provide VBP N
an DT N
effective JJ N
and CC N
well-tolerated JJ N
treatment NN o
for IN N
nocturia NN N
. . N

Compared VBN N
with IN N
placebo NN i
, , N
nocturnal JJ o
voiding NN o
frequency NN o
is VBZ N
reduced VBN N
, , N
duration NN N
of IN N
the DT N
first JJ N
sleep JJ N
period NN N
is VBZ N
increased VBN N
, , N
and CC N
sleep JJ o
quality NN o
may MD N
be VB N
improved VBN N
. . N

-DOCSTART- -16275814- O O

Randomized VBN N
, , N
controlled VBN N
, , N
crossover JJ N
trial NN N
of IN N
methylphenidate NN i
in IN N
pervasive JJ N
developmental NN N
disorders NNS N
with IN N
hyperactivity NN N
. . N

CONTEXT NNP N
Hyperactivity NNP N
and CC N
inattention NN N
are VBP N
common JJ N
symptoms NNS N
in IN N
children NNS N
with IN N
autistic JJ N
disorder NN N
and CC N
related JJ N
pervasive JJ N
developmental NN N
disorders NNS N
, , N
but CC N
studies NNS N
of IN N
stimulants NNS N
in IN N
these DT N
conditions NNS N
have VBP N
been VBN N
inconclusive JJ N
. . N

OBJECTIVES NN N
To TO N
determine VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
methylphenidate JJ i
hydrochloride NN i
in IN p
children NNS p
with IN N
pervasive JJ N
developmental NN N
disorders NNS N
and CC N
hyperactivity NN N
. . N

DESIGN NNP N
Double-blind NNP N
, , N
placebo-controlled JJ N
, , N
crossover JJ N
trial NN N
followed VBN N
by IN N
open-label JJ N
continuation NN N
. . N

SETTING NNP N
Five CD N
academic JJ N
outpatient NN N
clinics NNS N
. . N

PARTICIPANTS VB N
Seventy-two JJ p
drug-free JJ p
children NNS p
, , p
aged VBD p
5 CD p
to TO p
14 CD p
years NNS p
, , p
with IN p
pervasive JJ p
developmental NN p
disorders NNS p
accompanied VBN p
by IN p
moderate JJ p
to TO p
severe JJ p
hyperactivity NN p
. . p

INTERVENTIONS NNP N
Prior NNP N
to TO N
randomization NN N
, , N
subjects NNS p
entered VBD N
a DT N
1-week JJ N
test-dose JJ N
phase NN N
in IN N
which WDT N
each DT N
subject NN N
received VBD N
placebo NN i
for IN N
1 CD N
day NN N
followed VBN N
by IN N
increasing VBG N
doses NNS i
of IN i
methylphenidate NN i
( ( N
low JJ N
, , N
medium NN N
, , N
and CC N
high JJ N
doses NNS N
) ) N
that WDT N
were VBD N
each DT N
given VBN N
for IN N
2 CD N
days NNS N
. . N

The DT N
low JJ N
, , N
medium NN N
, , N
and CC N
high JJ N
doses NNS N
of IN N
methylphenidate NN i
hydrochloride NN i
were VBD N
based VBN N
on IN N
weight NN N
, , N
and CC N
they PRP N
ranged VBD N
from IN N
7.5 CD N
mg/d NNS N
to TO N
50.0 CD N
mg/d NNS N
in IN N
divided JJ N
doses NNS N
. . N

Subjects NNS p
who WP p
tolerated VBD p
the DT p
test NN p
dose NN p
( ( N
n JJ N
= NNP N
66 CD N
) ) N
were VBD N
assigned VBN N
to TO N
receive VB N
placebo NN i
for IN N
1 CD N
week NN N
and CC N
then RB N
3 CD N
methylphenidate NN i
doses NNS N
in IN N
random JJ N
order NN N
during IN N
a DT N
double-blind NN N
, , N
crossover NN N
phase NN N
. . N

Children NNP p
responding VBG p
to TO p
methylphenidate VB i
then RB N
entered VBD N
8 CD N
weeks NNS N
of IN N
open-label JJ N
treatment NN N
at IN N
the DT N
individually RB N
determined VBN N
best JJS N
dose NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
the DT N
teacher-rated JJ o
hyperactivity NN o
subscale NN o
of IN o
the DT o
Aberrant NNP o
Behavior NNP o
Checklist NNP o
. . o

Response NNP N
was VBD N
defined VBN N
as IN N
much JJ o
improved VBN o
or CC N
very RB o
much JJ o
improved VBN o
on IN N
the DT N
Clinical NNP o
Global NNP o
Impressions NNP o
Improvement NNP o
item NN o
coupled VBD N
with IN N
considerable JJ N
reductions NNS N
in IN N
the DT N
parent-rated JJ o
and/or JJ o
teacher-rated JJ o
Aberrant NNP o
Behavior NNP o
Checklist NNP o
hyperactivity NN o
subscale NN o
score NN o
. . o

RESULTS NNP N
Methylphenidate NNP i
was VBD N
superior JJ N
to TO N
placebo VB i
on IN N
the DT N
primary JJ N
outcome NN N
measure NN N
, , N
with IN N
effect NN o
sizes NNS o
ranging VBG N
from IN N
0.20 CD N
to TO N
0.54 CD N
depending VBG N
on IN N
dose NN N
and CC N
rater NN N
. . N

Thirty-five JJ p
( ( p
49 CD p
% NN p
) ) p
of IN p
72 CD p
enrolled JJ p
subjects NNS p
were VBD N
classified VBN N
as IN N
methylphenidate NN i
responders NNS N
. . N

Adverse JJ o
effects NNS o
led VBN N
to TO N
the DT N
discontinuation NN N
of IN N
study NN N
medication NN N
in IN N
13 CD p
( ( p
18 CD p
% NN p
) ) p
of IN p
72 CD p
subjects NNS p
. . p

CONCLUSIONS NNP N
Methylphenidate NNP i
was VBD N
often RB N
efficacious JJ N
in IN N
treating VBG N
hyperactivity NN N
associated VBN N
with IN N
pervasive JJ N
developmental NN N
disorders NNS N
, , N
but CC N
the DT N
magnitude NN N
of IN N
response NN N
was VBD N
less JJR N
than IN N
that DT N
seen VBN N
in IN N
typically RB N
developing VBG N
children NNS N
with IN N
attention-deficit/hyperactivity NN N
disorder NN N
. . N

Adverse JJ N
effects NNS N
were VBD N
more RBR N
frequent JJ N
. . N

-DOCSTART- -1673324- O O

Deliberate NNP o
hypotension NN o
in IN N
patients NNS p
with IN p
intracranial JJ p
arteriovenous JJ p
malformations NNS p
: : p
esmolol NN i
compared VBN N
with IN N
isoflurane NN i
and CC i
sodium NN i
nitroprusside RB i
. . i

Thirty JJ p
patients NNS p
undergoing VBG p
resection NN p
of IN p
arteriovenous JJ p
malformations NNS p
with IN p
deliberate JJ p
hypotension NN p
were VBD N
randomized VBN N
to TO N
receive VB N
1 CD N
of IN N
3 CD N
hypotensive JJ N
agents NNS N
. . N

Anesthesia NNP N
was VBD N
maintained VBN N
with IN N
isoflurane NN i
and CC i
nitrous JJ i
oxide NN i
in IN N
all DT N
patients NNS N
. . N

Mean NNP N
arterial JJ N
pressure NN N
was VBD N
reduced VBN N
20 CD N
% NN N
to TO N
60-65 JJ N
mm NN N
Hg NNP N
with IN N
use NN N
of IN N
either DT N
isoflurane NN i
( ( N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
4 CD N
% NN N
) ) N
, , N
sodium JJ i
nitroprusside NN i
( ( N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
8 CD N
micrograms.kg-1.min-1 NN N
) ) N
, , N
or CC N
esmolol NN i
( ( N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
24 CD N
mg/min NN N
) ) N
. . N

Esmolol NNP i
was VBD N
associated VBN N
with IN N
a DT N
decrease NN N
in IN N
cardiac JJ o
output NN o
from IN N
6.2 CD N
+/- JJ N
1.3 CD N
to TO N
3.8 CD N
+/- JJ N
0.8 CD N
L/min NNP N
, , N
which WDT N
, , N
because IN N
of IN N
a DT N
22 CD N
% NN N
increase NN N
in IN N
systemic JJ o
vascular JJ o
resistance NN o
, , N
far RB N
exceeded VBD N
the DT N
reduction NN N
in IN N
mean JJ N
arterial JJ o
pressure NN o
. . o

Systemic NNP o
vascular JJ o
resistance NN o
increased VBD N
despite IN N
a DT N
32 CD N
% NN N
decrease NN N
in IN N
plasma JJ o
renin NN o
activity NN o
. . o

In IN N
contrast NN N
, , N
with IN N
sodium JJ i
nitroprusside NN i
or CC N
isoflurane NN i
, , N
the DT N
decrease NN N
in IN N
mean JJ o
arterial JJ o
pressure NN o
was VBD N
associated VBN N
with IN N
decreases NNS N
in IN N
systemic JJ o
vascular JJ o
resistance NN o
of IN N
similar JJ N
magnitude NN N
, , N
with IN N
no DT N
change NN N
in IN N
cardiac JJ o
output NN o
. . o

Plasma NNP o
renin NN o
activity NN o
levels NNS o
increased VBD N
48 CD N
% NN N
with IN N
sodium NN i
nitroprusside NN i
and CC N
126 CD N
% NN N
with IN N
isoflurane NN i
. . i

Heart NNP o
rate NN o
increased VBD N
13 CD N
% NN N
with IN N
sodium NN i
nitroprusside NN i
, , N
remained VBD N
unchanged JJ N
with IN N
isoflurane NN N
, , N
and CC N
decreased VBD N
23 CD N
% NN N
with IN N
esmolol NN i
. . i

Although IN N
esmolol NN i
may MD N
be VB N
used VBN N
as IN N
a DT N
primary JJ N
hypotensive JJ N
agent NN N
, , N
the DT N
potential NN N
for IN N
marked JJ o
myocardial JJ o
depression NN o
must MD N
be VB N
recognized VBN N
. . N

The DT N
differences NNS N
in IN N
pharmacologic NN N
properties NNS N
for IN N
the DT N
different JJ N
hypotensive JJ N
agents NNS N
suggest VBP N
that IN N
combinations NNS N
of IN N
these DT N
agents NNS N
may MD N
provide VB N
a DT N
pharmacologic NN N
profile NN N
superior JJ N
to TO N
either DT N
agent NN N
alone RB N
. . N

-DOCSTART- -15302787- O O

Randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
of IN N
oral JJ N
sirolimus NN N
for IN N
restenosis NN o
prevention NN N
in IN N
patients NNS p
with IN p
in-stent JJ p
restenosis NN p
: : p
the DT N
Oral NNP N
Sirolimus NNP i
to TO N
Inhibit NNP N
Recurrent NNP N
In-stent JJ N
Stenosis NNP N
( ( N
OSIRIS NNP N
) ) N
trial NN N
. . N

BACKGROUND NNP N
Despite IN N
recent JJ N
advances NNS N
in IN N
interventional JJ N
cardiology NN N
, , N
including VBG N
the DT N
introduction NN N
of IN N
drug-eluting JJ N
stents NNS N
for IN N
de FW N
novo FW N
coronary JJ N
lesions NNS N
, , N
the DT N
treatment NN N
of IN N
in-stent JJ N
restenosis NN N
( ( N
ISR NNP N
) ) N
remains VBZ N
a DT N
challenging JJ N
clinical JJ N
issue NN N
. . N

Given VBN N
the DT N
efficacy NN N
of IN N
systemic JJ N
sirolimus JJ N
administration NN N
to TO N
prevent VB N
neointimal JJ o
hyperplasia NN o
in IN N
animal JJ N
models NNS N
and CC N
to TO N
halt VB N
and CC N
even RB N
reverse VB N
the DT N
progression NN N
of IN N
allograft NN N
vasculopathy NN N
, , N
the DT N
aim NN N
of IN N
the DT N
present JJ N
double-blind NN N
, , N
placebo-controlled JJ N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
a DT N
10-day JJ N
oral JJ N
sirolimus NN N
treatment NN N
with IN N
2 CD N
different JJ N
loading VBG N
regimens NNS N
for IN N
the DT N
prevention NN N
of IN N
recurrent JJ N
restenosis NN N
in IN N
patients NNS p
with IN p
ISR NNP p
. . p

METHODS NNP N
AND CC N
RESULTS NNP N
Three NNP p
hundred VBD p
symptomatic JJ p
patients NNS p
with IN p
ISR NNP p
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
3 CD N
treatment NN N
arms NNS N
: : N
placebo NN i
or CC i
usual-dose JJ i
or CC i
high-dose JJ i
sirolimus NN i
. . i

Patients NNS N
received VBD N
a DT N
cumulative JJ N
loading NN N
dose NN N
of IN N
0 CD N
, , N
8 CD N
, , N
or CC N
24 CD N
mg NN N
of IN N
sirolimus JJ N
2 CD N
days NNS N
before IN N
and CC N
the DT N
day NN N
of IN N
repeat NN N
intervention NN N
followed VBN N
by IN N
maintenance NN N
therapy NN N
of IN N
2 CD N
mg/d NN N
for IN N
7 CD N
days NNS N
. . N

Angiographic JJ o
restenosis NN o
at IN o
6-month JJ o
angiography NN o
was VBD N
the DT N
primary JJ N
end NN N
point NN N
of IN N
the DT N
study NN N
. . N

Restenosis NNP o
was VBD N
significantly RB N
reduced VBN N
from IN N
42.2 CD N
% NN N
to TO N
38.6 CD N
% NN N
and CC N
to TO N
22.1 CD N
% NN N
in IN N
the DT N
placebo NN N
, , N
usual-dose JJ N
, , N
and CC N
high-dose JJ N
sirolimus NN N
groups NNS N
, , N
respectively RB N
( ( N
P=0.005 NNP N
) ) N
. . N

Similarly RB N
, , N
the DT N
need NN o
for IN o
target NN o
vessel JJ o
revascularization NN o
was VBD N
reduced VBN N
from IN N
25.5 CD N
% NN N
to TO N
24.2 CD N
% NN N
and CC N
to TO N
15.2 CD N
% NN N
in IN N
the DT N
placebo NN N
, , N
usual-dose JJ N
, , N
and CC N
high-dose JJ N
groups NNS N
, , N
respectively RB N
( ( N
P=0.08 NNP N
) ) N
. . N

The DT o
sirolimus JJ o
blood NN o
concentration NN o
on IN N
the DT N
day NN N
of IN N
the DT N
procedure NN N
correlated VBD N
significantly RB N
with IN N
the DT N
late JJ N
lumen NNS N
loss NN N
at IN N
follow-up JJ N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
patients NNS N
with IN N
ISR NNP N
, , N
an DT N
oral JJ N
adjunctive JJ N
sirolimus NN N
treatment NN N
with IN N
an DT N
intensified JJ N
loading NN N
regimen NNS N
before IN N
coronary JJ N
intervention NN N
resulted VBD N
in IN N
a DT N
significant JJ N
improvement NN N
in IN N
the DT N
angiographic JJ o
parameters NNS o
of IN o
restenosis NN o
. . o

-DOCSTART- -14710214- O O

Randomized VBN N
Phase NNP N
II NNP N
trial NN N
assessing VBG N
estramustine NN i
and CC i
vinblastine JJ i
combination NN i
chemotherapy NN i
vs JJ i
estramustine NN i
alone RB i
in IN N
patients NNS p
with IN p
progressive JJ p
hormone-escaped JJ p
metastatic JJ p
prostate NN p
cancer NN p
. . p

Based VBN N
on IN N
the DT N
results NNS N
of IN N
combined JJ N
data NNS N
from IN N
three CD N
North JJ N
American JJ N
Phase NNP N
II NNP N
studies NNS N
, , N
a DT N
randomised JJ N
Phase NNP N
II NNP N
study NN N
in IN N
the DT N
same JJ N
patient JJ N
population NN N
was VBD N
performed VBN N
, , N
using VBG N
combination NN N
chemotherapy NN i
with IN i
estramustine JJ i
phosphate NN i
( ( i
EMP NNP i
) ) i
and CC i
vinblastine NN i
( ( i
VBL NNP i
) ) i
in IN N
hormone NN N
refractory NN N
prostate NN N
cancer NN N
patients NNS N
. . N

In IN N
all DT N
, , N
92 CD p
patients NNS p
were VBD p
randomised VBN p
into IN p
a DT p
Phase NNP p
II NNP p
study NN p
of IN N
oral JJ i
EMP NNP i
( ( i
10 CD i
mg NNS i
kg JJ i
day NN i
continuously RB i
) ) i
or CC i
oral JJ i
EMP NNP i
in IN i
combination NN i
with IN i
intravenous JJ i
VBL NNP i
( ( N
4 CD N
mg NN N
m NN N
( ( N
2 CD N
) ) N
week NN N
for IN N
6 CD N
weeks NNS N
, , N
followed VBN N
by IN N
2 CD N
weeks NNS N
rest NN N
) ) N
. . N

The DT N
end NN N
points NNS N
were VBD N
toxicity NN o
and CC o
PSA NNP o
response NN o
in IN N
both DT N
groups NNS N
, , N
with IN N
the DT N
option NN N
to TO N
continue VB N
the DT N
trial NN N
as IN N
a DT N
Phase NNP N
III NNP N
study NN N
with IN N
time NN o
to TO o
progression NN o
and CC N
survival NN o
as IN N
end NN N
points NNS N
, , N
if IN N
sufficient JJ N
responses NNS N
were VBD N
observed VBN N
. . N

Toxicity NNP o
was VBD N
unexpectedly RB N
high JJ N
in IN N
both DT N
treatment NN N
arms NNS N
and CC N
led VBD N
to TO N
treatment NN N
withdrawal NN N
or CC N
refusal NN N
in IN N
49 CD N
% NN N
of IN N
all DT N
patients NNS N
, , N
predominantly RB N
already RB N
during IN N
the DT N
first JJ N
treatment NN N
cycle NN N
. . N

The DT N
mean JJ o
treatment NN o
duration NN o
was VBD N
10 CD N
and CC N
14 CD N
weeks NNS N
, , N
median JJ o
time NN o
to TO o
PSA NNP o
progression NN o
was VBD N
27.2 CD N
and CC N
30.8 CD N
weeks NNS N
, , N
median JJ o
survival NN o
time NN o
was VBD N
44 CD N
and CC N
50.9 CD N
weeks NNS N
, , N
and CC N
PSA NNP o
response NN o
rate NN o
was VBD N
only RB N
24.6 CD N
and CC N
28.9 CD N
% NN N
in IN N
the DT N
EMP/VBL NNP i
and CC N
EMP NNP i
arms NNS N
, , N
respectively RB N
. . N

There EX N
was VBD N
no DT N
correlation NN N
between IN N
PSA NNP o
response NN o
and CC o
survival NN o
. . o

While IN N
the DT N
PSA NNP o
response NN o
in IN N
the DT N
patients NNS N
tested VBD N
was VBD N
less JJR N
than IN N
half NN N
that WDT N
recorded VBD N
in IN N
the DT N
North JJ N
American JJ N
studies NNS N
, , N
the DT N
toxicity NN o
of IN o
EMP NNP o
monotherapy NN o
or CC N
in IN N
combination NN N
with IN N
VBL NNP i
was VBD N
much RB N
higher JJR N
than IN N
expected VBN N
. . N

Further NNP N
research NN N
on IN N
more RBR N
effective JJ o
and CC N
less RBR N
toxic JJ o
treatment NN N
strategies NNS N
for IN N
hormone NN N
refractory NN N
prostate NN N
cancer NN N
is VBZ N
mandatory JJ N
. . N

-DOCSTART- -1984893- O O

Unstable JJ p
angina NN p
. . p

Quality NN o
of IN o
life NN o
. . o

-DOCSTART- -17171539- O O

Treating VBG N
anxiety NN p
disorders NNS p
in IN p
children NNS p
with IN p
high JJ p
functioning VBG p
autism NN p
spectrum NN p
disorders NNS p
: : p
a DT N
controlled JJ N
trial NN N
. . N

A DT N
family-based JJ N
, , N
cognitive JJ N
behavioural JJ N
treatment NN N
for IN N
anxiety NN N
in IN N
47 CD p
children NNS p
with IN p
comorbid NN p
anxiety NN p
disorders NNS p
and CC p
High NNP p
Functioning NNP p
Autism NNP p
Spectrum NNP p
Disorder NNP p
( ( p
HFA NNP p
) ) p
was VBD N
evaluated VBN N
. . N

Treatment NNP i
involved VBD i
12 CD i
weekly JJ i
group NN i
sessions NNS i
and CC i
was VBD i
compared VBN i
with IN i
a DT i
waiting VBG i
list NN i
condition NN i
. . i

Changes NNS i
between IN i
pre- NN i
and CC i
post-treatment NN i
were VBD i
examined VBN i
using VBG i
clinical JJ i
interviews NNS i
as RB i
well RB i
as IN i
child- NN i
, , i
parent- JJ i
and CC i
teacher-report JJ i
measures NNS i
. . i

Following VBG N
treatment NN N
, , N
71.4 CD N
% NN N
of IN N
the DT N
treated JJ N
participants NNS N
no RB N
longer RB N
fulfilled VBN N
diagnostic JJ N
criteria NNS N
for IN N
an DT N
anxiety NN N
disorder NN N
. . N

Comparisons NNS N
between IN N
the DT N
two CD N
conditions NNS N
indicated VBD N
significant JJ N
reductions NNS N
in IN N
anxiety NN o
symptoms NNS o
as IN o
measured VBN o
by IN o
self-report NN o
, , o
parent NN o
report NN o
and CC o
teacher JJ o
report NN o
. . o

Discussion NNP N
focuses VBZ N
on IN N
the DT N
implications NNS N
for IN N
the DT N
use NN N
of IN N
cognitive JJ N
behaviour NN N
therapy NN N
with IN N
HFA NNP p
children NNS p
, , N
for IN N
theory NN N
of IN N
mind NN N
research NN N
and CC N
for IN N
further JJ N
research NN N
on IN N
the DT N
treatment NN N
components NNS N
. . N

-DOCSTART- -8840371- O O

The DT N
comparative JJ N
safety NN o
and CC o
diagnostic JJ o
accuracy NN o
of IN N
adenosine JJ i
myocardial JJ i
perfusion NN i
imaging VBG i
in IN N
women NNS p
versus IN p
men NNS p
. . p

STUDY NNP N
OBJECTIVE NNP N
To TO N
determine VB N
if IN N
the DT N
diagnostic JJ N
accuracy NN N
and CC N
safety NN N
of IN N
intravenous JJ N
adenosine JJ i
myocardial JJ i
perfusion NN i
imaging NN i
is VBZ N
significantly RB N
different JJ N
in IN N
men NNS N
compared VBN N
with IN N
women NNS N
. . N

DESIGN NNP N
Prospective NNP N
, , N
comparative JJ N
, , N
open-label JJ N
clinical JJ N
trial NN N
. . N

SETTING NN N
Nuclear JJ p
medicine NN p
laboratory NN p
in IN p
a DT p
university-affiliated JJ p
hospital NN p
. . p

PATIENTS NNP N
Consecutive JJ p
patients NNS p
who WP p
were VBD p
referred VBN p
for IN p
evaluation NN p
of IN p
known VBN p
or CC p
suspected VBN p
coronary JJ p
artery NN p
disease NN p
. . p

Patients NNS p
were VBD p
judged VBN p
not RB p
to TO p
be VB p
able JJ p
to TO p
exercise VB p
adequately RB p
. . p

INTERVENTIONS NNP N
Coronary NNP i
angiography NN i
was VBD i
conducted VBN i
within IN i
6 CD i
weeks NNS i
of IN i
an DT i
adenosine JJ i
thallium-201 JJ i
myocardial JJ i
perfusion NN i
imaging VBG i
study NN i
. . i

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Diagnostic NNP o
accuracy NN o
is VBZ N
shown VBN N
in IN N
the DT N
table NN N
. . N

[ CC N
table JJ N
: : N
see VB N
text JJ N
] NNP N
Overall NNP N
, , N
side NN o
effects NNS o
from IN N
adenosine NN N
were VBD N
not RB N
different JJ N
between IN N
men NNS N
and CC N
women NNS N
. . N

The DT N
frequencies NNS o
of IN o
ST NNP o
depression NN o
and CC o
chest NN o
pain NN o
were VBD N
significantly RB N
greater JJR N
in IN N
women NNS N
than IN N
men NNS N
, , N
although IN N
their PRP$ N
etiologies NNS N
are VBP N
unknown JJ N
. . N

The DT N
frequency NN o
of IN o
severe JJ o
side NN o
effects NNS o
such JJ o
as IN o
heart NN o
block NN o
and CC o
hypotension NN o
was VBD N
not RB N
different JJ N
between IN N
men NNS p
and CC p
women NNS p
. . p

CONCLUSIONS VB N
The DT N
diagnostic JJ N
accuracy NN N
and CC N
safety NN N
of IN N
adenosine JJ i
thallium-201 JJ i
myocardial JJ i
perfusion NN i
imaging NN i
are VBP N
generally RB N
similar JJ N
in IN N
women NNS p
and CC p
men NNS p
. . p

-DOCSTART- -25801058- O O

Effects NNS N
of IN N
four CD N
traditional JJ i
Chinese NNP i
medicines NNS i
on IN N
the DT N
pharmacokinetics NNS p
of IN p
simvastatin NN i
. . i

1 CD i
. . i

Concomitant JJ i
traditional JJ i
Chinese JJ i
medicines NNS i
( ( i
TCMs NNP i
) ) i
could MD i
be VB N
the DT N
reason NN N
for IN N
relative JJ N
poor JJ N
efficacy NN N
of IN N
statins NNS p
in IN p
dyslipidemia NN p
patients NNS p
in IN p
China NNP p
. . p

2 CD N
. . N

An DT N
open-label JJ N
, , N
randomized VBN N
, , N
5-period JJ N
crossover NN N
study NN p
in IN p
healthy JJ p
Chinese NNP p
was VBD p
designed VBN N
to TO N
evaluate VB N
the DT N
pharmacokinetic JJ o
interaction NN o
and CC o
tolerability NN o
of IN o
multiple JJ N
doses NNS i
of IN i
certain JJ i
TCMs NNP i
on IN i
a DT N
single JJ N
dose NN N
of IN i
simvastatin NN i
. . i

In IN i
each DT N
period NN N
, , N
subjects VBZ N
received VBN N
one CD N
of IN N
five CD N
treatments NNS N
. . N

In IN N
Treatment NNP N
A NNP N
, , N
subjects VBZ N
received VBN N
a DT N
single JJ N
dose NN N
of IN N
20 CD N
mg NN i
simvastatin NN i
. . i

In IN i
Treatment NNP i
B NNP N
, , N
C NNP N
, , N
D NNP N
or CC N
E NNP N
, , N
subjects VBZ N
received VBN i
Tong NNP i
Xin NNP i
Luo NNP i
, , i
Nao NNP i
Xin NNP i
Tong NNP i
, , i
Guan NNP i
Mai NNP i
Ning NNP i
or CC i
Yin NNP i
Xing NNP i
Ye NNP i
for IN i
7 CD N
days NNS N
and CC N
a DT N
single JJ N
dose NN N
of IN N
20 CD N
mg NNS N
simvastatin NN i
on IN i
Day NNP i
7 CD N
. . N

The DT N
washout NN N
period NN N
was VBD N
7 CD N
days NNS N
. . N

3 CD N
. . N

The DT N
97.5 CD N
% NN N
confidence NN N
interval NN N
of IN o
the DT o
AUC0-48 NNP o
h NN o
geometric JJ o
mean JJ o
ratio NN o
of IN i
simvastatin NN i
acid NN i
and CC i
simvastatin NN i
for IN i
simvastatin NN i
given VBN N
after IN N
multiple JJ N
oral JJ N
doses NNS N
of IN N
one CD N
of IN N
the DT i
TCMs NNP i
versus NN i
simvastatin NN i
given VBN i
alone RB i
were VBD N
fully RB N
contained VBN N
within IN N
the DT N
prespecified JJ N
bounds NNS N
of IN N
( ( N
0.50 CD N
, , N
2.00 CD N
) ) N
. . o

4 CD o
. . o

Exposures NNS o
to TO o
simvastatin VB o
acid NN o
and CC o
simvastatin NN o
following VBG o
a DT N
single JJ N
dose NN N
of IN N
simvastatin NN i
alone RB i
were VBD N
similar JJ N
to TO N
those DT N
following JJ N
coadministration NN N
of IN N
a DT N
single JJ N
dose NN N
of IN N
simvastatin NN i
with IN i
multiple JJ N
doses NNS N
of IN N
each DT N
of IN N
the DT N
TCM NNP i
preparations NNS i
tested VBD i
. . i

Simvastatin NNP i
and CC i
these DT i
TCMs NNP i
were VBD o
well RB o
tolerated VBN o
. . o

-DOCSTART- -23101743- O O

Research NNP p
Units NNP p
of IN p
Pediatric NNP p
Psychopharmacology NNP p
( ( p
RUPP NNP p
) ) p
autism NN p
network NN p
randomized VBD N
clinical JJ N
trial NN N
of IN N
parent NN N
training NN N
and CC N
medication NN N
: : N
one-year JJ N
follow-up NN N
. . N

OBJECTIVE UH N
To TO N
follow VB N
up RP N
on IN N
a DT N
three-site JJ p
, , N
24-week JJ N
randomized JJ N
clinical JJ N
trial NN N
( ( p
N NNP p
= NNP p
124 CD p
) ) p
comparing VBG N
antipsychotic JJ i
medication NN i
alone RB i
( ( N
MED NNP N
) ) N
with IN N
antipsychotic JJ i
medication NN i
plus CC i
parent NN i
training NN i
in IN N
the DT N
behavior JJ o
management NN o
( ( N
COMB NNP N
) ) N
of IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
and CC p
severe JJ p
behavior NN p
problems NNS p
. . p

The DT N
COMB NNP N
treatment NN N
had VBD N
shown VBN N
a DT N
significant JJ N
advantage NN N
for IN N
child JJ o
behavioral JJ o
noncompliance NN o
( ( N
p JJ N
= NNP N
.006 NNP N
, , N
d NN N
= NNP N
0.34 CD N
) ) N
, , N
irritability NN N
( ( N
p JJ N
= NNP N
.01 NNP N
, , N
d NN N
= NNP N
0.48 CD N
) ) N
, , N
and CC N
hyperactivity/noncompliance NN o
( ( N
p JJ N
= NNP N
.04 NNP N
, , N
d NN N
= NNP N
0.55 CD N
) ) N
with IN N
a DT N
lower JJR N
medication NN N
dose NN N
. . N

METHOD NNP N
One CD N
year NN N
after IN N
each DT N
participant NN N
's POS N
termination NN N
, , N
the DT N
authors NNS N
mailed VBD i
an DT i
assessment NN i
packet NN i
with IN i
a DT i
return-addressed JJ i
envelope NN i
; : i
a DT i
telephone NN i
call NN i
alerted VBD i
the DT i
family NN i
. . i

Failure NN N
to TO N
return VB N
packets NNS N
within IN N
1 CD N
month NN N
elicited VBD N
another DT N
contact NN N
and CC N
offers VBZ N
to TO N
resend VB N
. . N

RESULTS NNP N
Eighty-seven NNP N
of IN N
124 CD N
families NNS N
( ( N
70.2 CD N
% NN N
) ) N
participated VBD N
in IN N
the DT N
follow-up NN N
. . N

The DT N
improvement NN N
difference NN N
between IN N
treatments NNS N
attenuated VBN N
from IN N
after IN N
treatment NN N
to TO N
follow-up NN N
for IN N
noncompliance NN N
( ( N
d JJ N
= RB N
0.32 CD N
to TO N
0.12 CD N
) ) N
and CC N
irritability NN N
( ( N
d JJ N
= RB N
0.46 CD N
to TO N
0.03 CD N
) ) N
. . N

The DT N
follow-up JJ N
differences NNS N
were VBD N
nonsignificant JJ N
( ( N
the DT N
noncompliance NN N
difference NN N
also RB N
was VBD N
nonsignificant JJ N
after IN N
treatment NN N
for IN N
these DT N
87 CD N
families NNS N
) ) N
. . N

Sixty-seven JJ N
percent NN N
of IN N
the DT N
COMB NNP N
group NN N
and CC N
53 CD N
% NN N
of IN N
the DT N
MED NNP N
group NN N
were VBD N
still RB N
taking VBG N
risperidone NN i
, , N
the DT N
original JJ N
study NN N
medication NN N
. . N

Most JJS N
needed JJ N
dose NN N
adjustments NNS N
or CC N
additional JJ N
medication NN N
, , N
and CC N
the DT N
COMB NNP N
group NN N
no RB N
longer RB N
had VBD N
a DT N
significantly RB N
lower JJR N
dose NN N
. . N

All DT N
COMB NNP N
families NNS N
but CC N
only RB N
39 CD N
% NN N
of IN N
MED NNP N
families NNS N
reported VBD N
seeking VBG o
parent NN o
training NN o
after IN N
treatment NN N
. . N

Improvements NNS o
in IN o
daily JJ o
living NN o
skills NNS o
during IN N
treatment NN N
predicted VBD N
noncompliance NN N
improvement NN N
at IN N
follow-up NN N
for IN N
the DT N
COMB NNP N
children NNS N
, , N
but CC N
noncompliance JJ o
deterioration NN o
and CC o
especially RB o
hyperactivity/noncompliance JJ o
deterioration NN o
for IN N
the DT N
MED NNP N
children NNS N
. . N

CONCLUSIONS VB N
The DT N
study NN N
treatment NN N
experience/familiarity NN N
greatly RB N
influenced VBD N
the DT N
follow-up JJ N
treatment NN N
: : N
those DT N
who WP N
had VBD N
received VBN N
parent NN N
training NN N
reported VBD N
seeking VBG N
it PRP N
, , N
whereas IN N
those DT N
who WP N
had VBD N
not RB N
received VBN N
it PRP N
tended VBD N
not RB N
to TO N
seek VB N
it PRP N
. . N

The DT N
superiority NN N
of IN N
COMB NNP N
over IN N
MED NNP N
after IN N
treatment NN N
attenuated VBN N
by IN N
more JJR N
than IN N
half NN N
at IN N
follow-up NN N
. . N

-DOCSTART- -19523608- O O

Randomized VBN N
placebo NN i
controlled VBN N
human JJ p
volunteer NN p
trial NN p
of IN N
a DT N
live JJ i
oral JJ i
cholera NN i
vaccine NN i
VA1.3 NNP i
for IN N
safety NN o
and CC N
immune JJ N
response NN N
. . N

A DT N
live JJ i
oral JJ i
cholera NN i
vaccine NN i
developed VBN i
from IN i
a DT i
non-toxigenic JJ i
Vibrio NNP i
cholerae NN i
O1 NNP i
El NNP i
Tor NNP i
strain NN i
VA1.3 NNP i
was VBD N
tested VBN N
in IN N
a DT N
double-blind JJ N
randomized JJ N
placebo NN i
controlled VBD N
study NN N
for IN N
safety NN N
and CC N
immunogenicity NN N
in IN N
304 CD p
men NNS p
aged VBN p
between IN p
16 CD p
and CC p
50 CD p
years NNS p
from IN p
Kolkata NNP p
, , p
India NNP p
. . p

A NNP N
dose NN N
of IN N
5 CD N
x NNS N
10 CD N
( ( N
9 CD N
) ) N
CFU NNP N
( ( N
n=186 NN N
) ) N
or CC N
a DT N
placebo NN i
( ( N
n=116 JJ N
) ) N
containing VBG N
the DT N
diluent NN N
buffer NN N
was VBD N
administered VBN N
. . N

The DT N
vaccine NN N
did VBD N
not RB N
elicit JJ N
adverse JJ o
events NNS o
except IN N
in IN N
two CD N
vaccine NN N
recipients NNS N
with IN N
mild JJ o
diarrhoea NN o
and CC o
vomiting NN o
. . o

None NN o
excreted VBD o
the DT N
vaccine NN N
strain NN N
. . N

Vibriocidal NNP o
antibody NN o
response NN o
developed VBD N
in IN N
105/186 CD N
( ( N
57 CD N
% NN N
) ) N
and CC N
5/116 CD N
( ( N
4 CD N
% NN N
) ) N
in IN N
vaccine NN N
and CC N
placebo NN N
recipients NNS N
, , N
respectively RB N
. . N

In IN N
a DT N
subgroup NN N
, , N
anti-CT JJ o
antibody NN o
rose VBD o
( ( N
> JJ N
or CC N
=2-folds NNS N
) ) N
in IN N
23/30 CD N
( ( N
77 CD N
% NN N
) ) N
and CC N
6/19 CD N
( ( N
32 CD N
% NN N
) ) N
in IN N
vaccine NN N
and CC N
placebo NN N
recipients NNS N
, , N
respectively RB N
. . N

These DT N
studies NNS N
demonstrate VBP N
that IN N
VA1.3 NNP i
at IN N
a DT N
dose NN N
of IN N
5 CD N
x NNS N
10 CD N
( ( N
9 CD N
) ) N
is VBZ N
safe JJ o
and CC o
immunogenic JJ o
in IN N
adults NNS p
from IN p
a DT p
cholera NN p
endemic JJ p
region NN p
. . p

-DOCSTART- -6849742- O O

Changes NNS N
in IN N
heart NN o
rate NN o
and CC o
forearm NN o
blood NN o
flow NN o
following VBG N
intravenous JJ N
boluses NNS N
of IN N
isoprenaline NN i
in IN N
the DT N
presence NN N
of IN N
practolol NN N
and CC N
propranolol NN N
. . N

1 CD N
Increases NNS N
in IN N
heart NN o
rate NN o
and CC o
forearm NN o
blood NN o
flow NN o
following VBG N
graded VBD N
intravenous JJ N
bolus JJ N
injections NNS N
of IN N
isoprenaline JJ i
sulphate NN i
, , N
were VBD N
measured VBN N
in IN N
a DT N
double-blind NN N
randomised VBN N
study NN N
of IN N
six CD p
subjects NNS p
who WP p
received VBD p
either DT p
placebo NN i
, , i
practolol VBP i
50 CD i
mg NN i
, , i
practolol VBP i
200 CD i
mg NN i
, , i
propranolol VBP i
10 CD i
mg NN i
or CC i
propranolol VB i
40 CD i
mg. NN i
2 CD N
Dose NNP N
related JJ N
increases NNS N
in IN N
forearm NN o
blood NN o
flow NN o
were VBD N
produced VBN N
by IN N
the DT N
graded JJ N
boluses NNS N
of IN N
isoprenaline JJ i
sulphate NN i
. . i

3 CD N
Practolol NNP i
50 CD N
mg NN N
attenuated VBD N
the DT N
heart NN o
rate NN o
response NN o
to TO N
isoprenaline VB N
but CC N
did VBD N
not RB N
significantly RB N
affect VB N
the DT N
changes NNS N
in IN N
forearm NN o
blood NN o
flow NN o
. . o

Practolol CC i
200 CD N
mg NN N
further RB N
attenuated VBD N
the DT N
heart NN o
rate NN o
responses NNS o
but CC N
also RB N
decreased VBD N
the DT N
forearm NN o
blood NN o
flow NN o
responses NNS o
. . o

4 CD N
Propranolol NNP i
10 CD N
mg NN N
and CC N
propranolol NN N
40 CD N
mg NN N
significantly RB N
attenuated VBD N
both DT N
the DT N
heart NN o
rate NN o
and CC o
forearm NN o
blood NN o
flow NN o
responses NNS o
. . o

The DT N
effect NN N
on IN N
forearm NN o
blood NN o
flow NN o
tended VBD N
to TO N
be VB N
greater JJR N
than IN N
the DT N
effect NN N
on IN N
heart NN o
rate NN o
. . o

5 CD N
Practolol NNP i
200 CD N
mg NN N
had VBD N
the DT N
same JJ N
effect NN N
on IN N
heart NN o
rate NN o
responses NNS o
as IN N
propranolol NN i
10 CD N
mg NN N
but CC N
a DT N
significantly RB N
smaller JJR N
effect NN N
on IN N
the DT N
forearm NN o
blood NN o
flow NN o
responses NNS o
. . o

6 CD N
The DT N
measurement NN N
of IN N
forearm NN o
blood NN o
flow NN o
following VBG N
intravenous JJ N
bolus JJ N
injections NNS N
of IN N
isoprenaline NN N
provides VBZ N
useful JJ N
information NN N
about IN N
the DT N
beta NN N
2-adrenoceptor JJ N
antagonism NN N
of IN N
propranolol NN i
and CC N
practolol NN i
. . N

However RB N
, , N
application NN N
of IN N
the DT N
technique NN N
may MD N
be VB N
limited VBN N
by IN N
the DT N
magnitude NN N
of IN N
the DT N
heart NN o
rate NN o
response NN N
and CC N
by IN N
the DT N
short-lived JJ N
nature NN N
of IN N
the DT N
increase NN N
in IN N
forearm JJ o
blood NN o
flow NN o
. . o

-DOCSTART- -18376682- O O

Post-laparoscopic NNP p
cholecystectomy NN p
pain NN p
: : p
effects NNS o
of IN N
intraperitoneal JJ N
local JJ N
anesthetics NNS i
on IN N
pain NN N
control NN N
-- : N
a DT N
randomized JJ N
prospective JJ N
double-blinded JJ N
placebo-controlled JJ N
trial NN N
. . N

Postoperative NNP p
pain NN p
after IN p
laparoscopic NN p
cholecystectomy NN p
( ( p
LC NNP p
) ) p
is VBZ N
generally RB N
less JJR N
than IN N
open JJ N
cholecystectomy NN N
; : N
however RB N
, , N
the DT N
postoperative JJ N
shoulder NN N
and CC N
abdominal JJ N
pain NN N
experienced VBN N
by IN N
patients NNS N
still RB N
causes VBZ N
preventable JJ N
distress NN N
. . N

Intraperitoneal NNP N
irrigation NN N
of IN N
the DT N
diaphragmatic JJ N
surface NN N
and CC N
gallbladder NN N
fossa NN N
using VBG N
normal JJ N
saline NN i
, , i
bupivacaine NN i
, , N
or CC N
lignocaine NN i
may MD N
effectively RB N
control VB N
visceral JJ o
abdominal JJ o
pain NN o
after IN N
an DT N
LC NNP N
. . N

Two CD p
hundred VBD p
patients NNS p
with IN p
similar JJ p
demographics NNS p
undergoing JJ p
elective JJ p
LC NNP p
were VBD N
randomized VBN N
to TO N
one CD N
of IN N
four CD p
groups NNS p
of IN p
50 CD p
patients NNS p
each DT p
, , N
including VBG N
Group NNP N
A NNP N
placebo NN i
control NN N
, , N
Group NNP N
B NNP N
with IN N
isotonic JJ i
saline NN i
irrigation NN i
, , N
Group NNP N
C NNP N
with IN N
bupivacaine JJ i
irrigation NN i
, , N
and CC N
Group NNP N
D NNP N
with IN N
lignocaine JJ i
irrigation NN i
. . i

All DT N
patients NNS p
received VBD N
preperitoneal JJ N
abdominal JJ N
wall NN N
infiltration NN N
with IN N
0.25 CD N
per IN N
cent NN N
bupivacaine NN i
to TO N
control VB N
parietal JJ p
( ( p
somatic JJ p
) ) p
abdominal JJ p
pain NN p
. . p

The DT N
visual JJ o
analogue NN o
and CC o
verbal JJ o
rating NN o
pain NN o
scores NNS o
at IN N
0 CD N
, , N
4 CD N
, , N
8 CD N
, , N
12 CD N
and CC N
24 CD N
hours NNS N
for IN N
both DT N
shoulder NN N
and CC N
abdominal JJ N
pain NN N
were VBD N
recorded VBN N
in IN N
a DT N
prospective JJ N
double-blind JJ N
fashion NN N
at IN N
four CD N
points NNS N
during IN N
the DT N
first JJ N
24 CD N
postoperative JJ N
hours NNS N
. . N

Analgesia NNP o
requirements NNS o
, , o
vital JJ o
signs NNS o
, , o
blood NN o
glucose NN o
, , o
and CC o
incidence NN o
of IN o
nausea NN o
and CC o
vomiting NN o
were VBD N
also RB N
recorded VBN N
. . N

Patients NNS p
in IN p
each DT p
group NN p
demonstrated VBD N
a DT N
significant JJ N
difference NN N
in IN N
visual JJ o
analogue NN o
and CC o
verbal JJ o
rating NN o
pain NN o
scores NNS o
and CC o
analgesic JJ o
consumption NN o
when WRB N
compared VBN N
with IN N
controls NNS N
. . N

Lignocaine NNP i
controlled VBD o
pain NN o
significantly RB N
better JJR N
than IN N
saline NN i
or CC N
bupivacaine NN i
. . i

Bowel NNP o
function NN o
recovery NN o
was VBD N
similar JJ o
in IN N
all DT p
patients NNS p
, , N
and CC N
there EX N
were VBD N
no DT N
significant JJ N
complications NNS N
. . N

We PRP N
conclude VBP N
that DT N
intraperitoneal JJ N
irrigation NN N
with IN N
either DT N
saline NN i
, , i
bupivacaine NN i
, , N
or CC N
lignocaine NN i
can MD N
significantly RB N
reduce VB N
visceral JJ o
abdominal NN o
pain NN o
after IN N
LC NNP N
. . N

Lignocaine NNP i
was VBD N
the DT N
most RBS N
efficacious JJ N
local JJ N
anesthetic NN N
in IN N
this DT N
trial NN N
and CC N
has VBZ N
a DT N
high JJ N
safety NN N
profile NN N
when WRB N
used VBN N
at IN N
recommended JJ N
doses NNS N
. . N

-DOCSTART- -25234481- O O

Measuring VBG N
and CC N
supporting VBG N
language NN p
function NN p
for IN N
children NNS p
with IN p
autism NN p
: : p
evidence NN N
from IN N
a DT N
randomized VBN N
control NN N
trial NN N
of IN N
a DT N
social-interaction-based JJ i
therapy NN i
. . i

In IN N
a DT N
report NN N
of IN N
the DT N
effectiveness NN o
of IN N
MEHRIT NNP i
, , i
a DT i
social-interaction-based JJ i
intervention NN i
for IN N
autism NN N
, , N
Casenhiser NNP N
et CC N
al NN N
. . N

( ( p
Autism $ p
17 CD p
( ( p
2 CD p
) ) p
:220-241 NN p
, , p
2013 CD p
) ) p
failed VBD N
to TO N
find VB N
a DT N
significant JJ N
advantage NN N
for IN N
language NN N
development NN N
in IN N
the DT N
treatment NN N
group NN N
using VBG N
standardized JJ N
language NN N
assessments NNS N
. . N

We PRP N
present VBD N
the DT N
results NNS N
from IN N
a DT N
re-analysis NN N
of IN N
their PRP$ N
results NNS N
to TO N
illustrate VB N
the DT N
importance NN N
of IN N
measuring VBG N
communicative JJ o
language NN o
acts NNS o
( ( N
formally RB N
called VBN N
speech NN N
acts NNS N
) ) N
. . N

Reanalysis NN N
confirmed VBD N
that IN N
children NNS N
in IN N
the DT N
MEHRIT NNP i
group NN N
outperformed VBD o
the DT N
community NN N
treatment NN N
group NN N
on IN N
measures NNS N
of IN N
MLUm NNP o
, , o
number NN o
of IN o
utterances NNS o
produced VBN o
, , o
and CC o
various JJ o
speech NN o
act NN o
categories NNS o
. . o

The DT N
study NN N
underscores VBZ N
the DT N
importance NN N
of IN N
functional JJ o
language NN o
measures NNS o
in IN N
guiding VBG N
and CC N
evaluating VBG N
treatment NN N
for IN N
children NNS p
with IN p
autism NN p
, , N
and CC N
suggests VBZ N
that DT N
MEHRIT NNP N
is VBZ N
effective JJ N
in IN N
improving VBG N
children NNS o
's POS o
use NN o
of IN o
language NN o
during IN o
parent-child JJ o
interactions NNS o
. . o

-DOCSTART- -8712112- O O

Influence NN N
of IN N
acute JJ p
myocardial JJ p
infarction NN p
location NN N
on IN N
in-hospital JJ N
and CC N
late JJ N
outcome NN N
after IN N
primary JJ i
percutaneous JJ i
transluminal JJ i
coronary NN i
angioplasty NN i
versus NN i
tissue NN i
plasminogen NN i
activator NN i
therapy NN i
. . i

In IN N
the DT N
Primary NNP N
Angioplasty NNP N
in IN N
Myocardial NNP N
Infarction NNP N
trial NN N
, , N
395 CD p
patients NNS p
with IN p
acute JJ p
myocardial JJ p
infarction NN p
( ( p
AMI NNP p
) ) p
were VBD N
prospectively RB N
randomized VBN N
to TO N
tissue VB i
plasminogen NN i
activator NN i
( ( i
tPA NN i
) ) i
or CC i
primary JJ i
percutaneous JJ i
transluminal JJ i
coronary NN i
angioplasty NN i
( ( i
PTCA NNP i
) ) i
. . i

In IN N
138 CD p
patients NNS p
with IN p
anterior JJ p
wall NN p
AMI NNP p
, , N
in-hospital JJ o
mortality NN o
was VBD N
significantly RB N
reduced VBN N
by IN N
treatment NN N
with IN N
PTCA NNP N
compared VBN N
with IN N
tPA NN N
( ( N
1.4 CD N
% NN N
vs JJ N
11.9 CD N
% NN N
, , N
p NN N
= NNP N
0.01 CD N
) ) N
. . N

PTCA NNP N
also RB N
resulted VBD N
in IN N
lower JJR N
rates NNS o
of IN N
death NN o
or CC o
reinfarction NN o
( ( N
1.4 CD N
% NN N
vs JJ N
18.0 CD N
% NN N
, , N
p NN N
= NNP N
0.0009 CD N
) ) N
, , N
recurrent JJ o
myocardial JJ o
ischemia NN o
( ( N
11.3 CD N
% NN N
vs JJ N
28.4 CD N
% NN N
, , N
p NN N
= NNP N
0.01 CD N
) ) N
, , N
and CC N
stroke VBD o
( ( N
0.0 CD N
% NN N
vs JJ N
6.0 CD N
% NN N
, , N
p NN N
= NNP N
0.037 CD N
) ) N
in IN N
anterior JJ N
wall NN N
AMI NNP N
. . N

The DT N
independent JJ N
beneficial JJ N
effect NN N
of IN N
treatment NN N
with IN N
primary JJ N
PTCA NNP N
rather RB N
than IN N
tPA VB N
in IN N
anterior JJ N
wall NN N
AMI NNP N
was VBD N
confirmed VBN N
by IN N
multivariate NN N
analysis NN N
and CC N
interaction NN N
testing NN N
. . N

The DT N
in-hospital JJ o
mortality NN o
of IN N
257 CD p
patients NNS p
with IN p
nonanterior JJ p
wall NN p
AMI NNP p
was VBD N
similar JJ N
after IN N
PTCA NNP N
and CC N
tPA NNP N
( ( N
3.2 CD N
% NN N
vs JJ N
3.8 CD N
% NN N
, , N
p NN N
= NNP N
0.82 CD N
) ) N
. . N

Compared VBN N
with IN N
tPA NN N
, , N
however RB N
, , N
primary JJ N
PTCA NNP N
resulted VBD N
in IN N
a DT N
markedly RB N
lower JJR N
rate NN N
of IN N
recurrent NN o
myocardial JJ o
ischemia NN o
( ( N
9.7 CD N
% NN N
vs JJ N
27.8 CD N
% NN N
, , N
p NN N
= NNP N
0.0002 CD N
) ) N
, , N
fewer JJR N
unscheduled JJ o
catheterization NN o
and CC o
revascularization NN o
procedures NNS o
, , N
and CC N
a DT N
shorter JJR N
hospital NN o
stay NN o
( ( N
7.0 CD N
vs RB N
8.6 CD N
days NNS N
, , N
p VBP N
= RB N
0.01 CD N
) ) N
in IN N
nonanterior JJ N
wall NN N
AMI NNP N
. . N

Thus NNP N
, , N
compared VBN N
with IN N
tPA NN N
, , N
primary JJ N
PTCA NNP N
in IN N
patients NNS p
with IN p
anterior JJ p
wall NN p
AMI NNP p
results NNS N
in IN N
significantly RB N
improved VBN o
survival NN o
, , N
with IN N
lower JJR N
rates NNS o
of IN o
stroke NN o
, , o
reinfarction NN o
, , o
and CC o
recurrent JJ o
myocardial JJ o
ischemia NN o
. . o

In IN N
nonanterior JJ N
wall NN N
AMI NNP N
, , N
treatment NN N
with IN N
PTCA NNP N
and CC N
tPA JJ N
results NNS N
in IN N
similar JJ N
early JJ N
mortality NN o
, , N
although IN N
PTCA-treated JJ N
patients NNS N
have VBP N
a DT N
more RBR N
stable JJ N
hospital NN N
course NN N
characterized VBN N
by IN N
reduced JJ N
recurrent NN o
ischemia NN o
, , N
fewer JJR N
subsequent JJ o
invasive NN o
procedures NNS o
, , N
and CC N
earlier RB N
discharge NN o
. . o

-DOCSTART- -19786383- O O

A DT N
good JJ N
response NN N
to TO N
oil NN i
with IN i
medium- NN i
and CC i
long-chain JJ i
fatty JJ i
acids NNS i
in IN N
body NN o
fat JJ o
and CC p
blood NN o
lipid JJ o
profiles NNS o
of IN p
male JJ p
hypertriglyceridemic JJ p
subjects NNS p
. . p

A DT N
double JJ N
blind NN N
clinical JJ N
trial NN N
was VBD N
carried VBN N
out IN N
to TO N
clarify VB N
the DT N
effects NNS N
of IN N
oil NN i
with IN i
medium- NN i
and CC i
long-chain JJ i
triglyceride NN i
( ( i
MLCT NNP i
) ) i
on IN N
body NN o
fat JJ o
and CC p
blood NN o
lipid JJ o
profiles NNS o
in IN p
hypertriglyceridemic JJ p
subjects NNS p
. . p

One-hundred-and-twelve JJ p
subjects NNS p
were VBD N
enrolled VBN N
and CC N
divided VBN N
into IN N
two CD N
groups NNS N
; : N
those DT i
that IN i
consumed VBD i
MLCT NNP i
oil NN i
and CC i
those DT i
that WDT i
consumed VBD i
long-chain JJ i
triglyceride NN i
( ( i
LCT NNP i
) ) i
oil NN i
for IN N
8 CD N
weeks NNS N
. . N

All DT N
subjects NNS N
were VBD N
requested VBN N
to TO N
consume VB N
25-30 JJ N
g NN N
of IN N
the DT N
oils NNS N
daily RB N
and CC N
maintain VB N
a DT N
fixed JJ N
level NN N
of IN N
energy NN N
intake NN N
and CC N
exercise NN N
. . N

Anthropometric NNP o
and CC o
blood NN o
biochemical JJ o
parameters NNS o
were VBD N
measured VBN N
when WRB N
the DT N
study NN N
was VBD N
initiated VBN N
and CC N
completed VBN N
. . N

The DT N
LCT NNP i
group NN N
consisted VBD N
of IN N
50 CD p
subjects NNS p
( ( p
34 CD p
men NNS p
and CC p
16 CD p
women NNS p
) ) p
, , p
while IN p
the DT p
MLCT NNP i
group NN p
consisted VBD p
of IN p
51 CD p
subjects NNS p
( ( p
33 CD p
men NNS p
and CC p
18 CD p
women NNS p
) ) p
who WP p
completed VBD p
the DT p
study NN p
. . p

Larger NNP N
decreases VBZ N
in IN N
body NN o
weight NN o
, , o
body NN o
mass NN o
index NN o
, , o
waist NN o
circumference NN o
, , o
body NN o
fat NN o
, , o
total JJ o
fat JJ o
area NN o
and CC o
subcutaneous JJ o
fat JJ o
area NN o
in IN o
the DT o
abdomen NNS o
and CC o
serum NN o
triglycerides NNS o
, , o
low-density NN o
lipoprotein NN o
cholesterol NN o
, , o
apolipoprotein NN o
B NNP o
, , o
C2 NNP o
, , o
C3 NNP o
and CC o
E NNP o
were VBD N
observed VBN N
in IN N
male JJ N
subjects NNS N
in IN N
the DT N
MLCT NNP i
group NN N
than IN N
those DT N
in IN N
the DT N
LCT NNP i
group NN N
. . N

However RB N
, , N
no DT N
significant JJ N
differences NNS N
in IN N
these DT o
parameters NNS o
between IN N
the DT N
female JJ N
subjects NNS N
in IN N
the DT N
two CD N
groups NNS N
were VBD N
observed VBN N
. . N

Data NNS N
from IN N
this DT N
study NN N
indicate VBP N
that IN N
consumption NN N
of IN N
medium-and JJ N
long-chain JJ N
triglycerides NNS N
can MD N
reduce VB N
body NN o
weight NN o
and CC N
body NN o
fat NN o
and CC N
improve VB N
blood NN o
lipid JJ o
profiles NNS o
in IN N
male JJ p
hypertriglyceridemic JJ p
subjects NNS p
. . p

-DOCSTART- -5556863- O O

The DT p
effects NNS p
of IN p
premedication NN p
with IN p
pentazocine NN i
and CC i
pethidine NN i
on IN p
respiration NN o
during IN p
general JJ p
anaesthesia NN p
. . p

-DOCSTART- -9690266- O O

The DT N
Treatment NNP N
of IN N
Lead-exposed JJ p
Children NNP p
( ( p
TLC NNP p
) ) p
trial NN N
: : N
design NN N
and CC N
recruitment NN N
for IN N
a DT N
study NN N
of IN N
the DT N
effect NN N
of IN N
oral JJ i
chelation NN i
on IN N
growth NN N
and CC N
development NN N
in IN N
toddlers NNS p
. . p

Exposure NN N
to TO N
lead VB N
impairs NNS N
cognitive JJ N
development NN N
in IN N
young JJ p
children NNS p
, , N
but CC N
the DT N
benefits NNS N
of IN N
lowering VBG N
blood NN N
lead NN N
pharmacologically RB N
are VBP N
not RB N
clear JJ N
. . N

This DT N
report NN N
describes VBZ N
the DT N
design NN N
, , N
recruitment NN N
, , N
enrolment NN N
and CC N
baseline JJ N
results NNS N
of IN N
the DT N
Treatment NNP N
of IN N
Lead-Exposed JJ p
Children NNP p
( ( N
TLC NNP N
) ) N
trial NN N
, , N
a DT N
randomised VBN N
, , N
multicentre FW N
, , N
placebo-controlled JJ N
, , N
double-blind JJ N
clinical JJ N
trial NN N
of IN N
the DT N
effects NNS N
of IN N
treating VBG N
lead-exposed JJ p
children NNS p
with IN N
succimer NN i
, , N
a DT N
drug NN N
that WDT N
enhances VBZ N
urinary JJ N
excretion NN N
of IN N
lead NN N
, , N
on IN N
cognitive JJ N
, , N
behavioural JJ N
and CC N
physical JJ N
development NN N
. . N

TLC NNP N
clinical JJ N
sites NNS N
were VBD N
in IN N
Baltimore NNP p
, , p
Cincinnati NNP p
and CC p
Columbus NNP p
, , p
Newark NNP p
and CC p
Philadelphia NNP p
. . p

Children NNP p
were VBD p
eligible JJ p
for IN p
TLC NNP p
if IN p
they PRP p
were VBD p
between IN p
12 CD p
and CC p
33 CD p
months NNS p
of IN p
age NN p
, , p
had VBD p
a DT p
confirmed VBN p
blood NN p
lead NN p
concentration NN p
between IN p
20 CD p
and CC p
44 CD p
micrograms/dL NN p
and CC p
lived VBD p
in IN p
a DT p
residence NN p
suitable JJ p
for IN p
lead JJ p
dust NN p
reduction NN p
. . p

Randomised JJ N
children NNS p
received VBD N
up RP N
to TO N
three CD N
26-day JJ N
courses NNS N
of IN N
succimer NN i
or CC i
placebo NN i
, , N
and CC N
were VBD N
then RB N
followed VBN N
for IN N
3 CD N
years NNS N
. . N

The DT N
study NN N
can MD N
detect VB N
a DT N
three-point JJ N
difference NN N
in IN N
full-scale JJ o
IQ NNP o
at IN N
3-year JJ N
follow-up NN N
. . N

Statistical JJ N
power NN N
for IN N
the DT N
other JJ N
end NN N
points NNS N
is VBZ N
more RBR N
difficult JJ N
to TO N
estimate VB N
. . N

A DT p
total NN p
of IN p
1854 CD p
children NNS p
were VBD p
evaluated VBN p
and CC p
780 CD p
children NNS p
were VBD p
randomised VBN p
between IN p
August NNP p
1994 CD p
and CC p
January NNP p
1997 CD p
. . p

The DT p
mean JJ p
age NN p
of IN p
randomised JJ p
children NNS p
was VBD p
24 CD p
months NNS p
and CC p
mean VB p
blood NN p
lead JJ p
level NN p
26 CD p
micrograms/dL NN p
. . p

Three-quarters NNS p
were VBD p
African-American JJ p
. . p

Most JJS p
children NNS p
had VBD p
poor JJ p
, , p
single JJ p
mothers NNS p
who WP p
had VBD p
completed VBN p
12 CD p
or CC p
fewer JJR p
years NNS p
of IN p
school NN p
and CC p
who WP p
lived VBD p
in IN p
older JJR p
, , p
poorly RB p
maintained VBD p
residences NNS p
. . p

-DOCSTART- -21183747- O O

Relationship NN N
between IN N
baseline NN N
blood NN N
pressure NN N
parameters NNS N
( ( N
including VBG N
mean JJ N
pressure NN N
, , N
pulse JJ N
pressure NN N
, , N
and CC N
variability NN N
) ) N
and CC N
early JJ N
outcome NN N
after IN N
stroke NN p
: : p
data NN N
from IN N
the DT N
Tinzaparin NNP i
in IN i
Acute NNP i
Ischaemic NNP i
Stroke NNP i
Trial NNP i
( ( p
TAIST NNP p
) ) p
. . p

BACKGROUND NNP N
AND NNP N
PURPOSE NNP N
High NNP p
blood NN p
pressure NN p
( ( p
BP NNP p
) ) p
in IN p
acute JJ p
stroke NN p
is VBZ N
associated VBN N
independently RB N
with IN N
a DT N
poor JJ N
outcome NN N
. . N

Recent JJ N
evidence NN N
suggests VBZ N
that IN N
other JJ N
hemodynamic JJ N
parameters NNS N
may MD N
also RB N
be VB N
associated VBN N
with IN N
outcomes NNS N
following VBG N
stroke NN N
. . N

METHODS NNP N
The DT N
relationship NN N
between IN N
baseline NN N
BP NNP N
, , N
heart NN N
rate NN N
, , N
and CC N
other JJ N
hemodynamic JJ N
parameters NNS N
, , N
and CC N
early RB N
outcomes NNS N
were VBD N
assessed VBN N
using VBG p
data NNS p
from IN p
TAIST NNP p
trial NN p
. . p

RESULTS NNP N
Death NNP o
or CC o
neurological JJ o
deterioration NN o
at IN o
day NN o
10 CD o
was VBD N
associated VBN N
, , N
both DT N
in IN N
unadjusted JJ N
and CC N
adjusted JJ N
analyses NNS N
, , N
with IN N
systolic JJ o
BP NNP o
( ( N
adjusted VBN N
OR NNP N
, , N
1.02 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.01-1.03 JJ N
) ) N
, , N
mean JJ o
arterial JJ o
pressure NN o
( ( N
OR NNP N
, , N
1.02 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.01-1.04 JJ N
) ) N
, , N
pulse JJ o
pressure NN o
( ( N
OR NNP N
, , N
1.02 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.01-1.03 JJ N
) ) N
, , N
and CC N
BP NNP o
variability NN o
( ( N
OR NNP N
, , N
1.03 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.01-1.05 JJ N
) ) N
. . N

Similar JJ N
relationships NNS N
were VBD N
noted VBN N
for IN N
deterioration NN o
alone RB o
, , o
and CC o
recurrent JJ o
stroke NN o
. . o

CONCLUSIONS NNP N
Early JJ N
death NN o
or CC N
neurologic JJ o
deterioration NN o
, , o
deterioration NN o
, , N
and CC N
recurrent JJ o
stroke NN o
are VBP N
associated VBN N
independently RB N
with IN N
high JJ o
systolic JJ o
BP NNP o
, , o
mean JJ o
arterial JJ o
pressure NN o
, , o
pulse JJ o
pressure NN o
, , o
and CC o
BP NNP o
variability NN o
. . o

These DT N
measures NNS N
offer VBP N
potential JJ N
therapeutic JJ i
targets NNS i
for IN N
improving VBG N
early JJ N
outcome NN N
after IN N
acute JJ p
ischemic JJ p
stroke NN p
. . p

-DOCSTART- -17073957- O O

Polydioxanone NNP i
sternal JJ i
sutures NNS i
for IN N
prevention NN N
of IN N
sternal JJ N
dehiscence NN N
. . N

BACKGROUND NNP N
Sternal NNP o
dehiscence NN o
and CC o
wound NN o
instability NN o
are VBP N
troublesome JJ N
complications NNS N
following VBG N
median JJ N
sternotomy NN N
. . N

Classic JJ N
sternal JJ N
approximation NN N
with IN N
stainless JJ N
steel NN N
wires NNS N
may MD N
not RB N
be VB N
the DT N
ideal JJ N
approach NN N
in IN N
patients NNS N
predisposed VBN N
to TO N
these DT N
complications NNS N
. . N

We PRP N
tested VBD N
the DT N
efficacy NN o
of IN N
polydioxanone NN i
( ( i
PDS NNP i
) ) i
suture NN i
in IN N
sternal JJ o
closure NN o
and CC N
in IN N
prevention NN N
of IN N
complications NNS o
in IN N
comparison NN N
to TO N
steel NN N
wires NNS N
in IN N
high-risk JJ p
individuals NNS p
. . p

METHODS NNP N
Three CD p
hundred VBD p
sixty-six JJ p
patients NNS p
undergoing VBG p
elective JJ p
cardiac JJ p
surgery NN p
with IN p
full JJ p
median JJ p
sternotomy NN p
and CC p
having VBG p
body NN p
surface JJ p
area NN p
( ( p
BSA NNP p
) ) p
less JJR p
than IN p
1.5 CD p
m NN p
( ( p
2 CD p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
PDS NNP i
( ( N
n JJ N
= NNP N
181 CD N
) ) N
or CC N
stainless JJ i
steel NN i
( ( N
SS NNP N
, , N
n JJ N
= NNP N
185 CD N
) ) N
sternal JJ N
approximation NN N
. . N

The DT N
study NN N
was VBD N
focused VBN N
on IN N
aseptic JJ N
sternal JJ N
complications NNS N
, , N
namely RB N
bone JJ o
dehiscence NN o
and CC o
superficial JJ o
wound NN o
instability NN o
. . o

RESULTS NNP N
Both NNP N
bone VBD o
dehiscence NN o
and CC o
superficial JJ o
wound NN o
instability NN o
were VBD N
less JJR N
frequent JJ N
in IN N
the DT N
PDS NNP i
Group NNP N
( ( N
4 CD N
and CC N
3 CD N
cases NNS N
in IN N
the DT N
SS NNP N
Group NNP N
, , N
respectively RB N
, , N
vs. IN N
no DT N
cases NNS N
in IN N
the DT N
PDS NNP N
Group NNP N
) ) N
. . N

Cox NNP o
proportional JJ o
hazards NNS o
regression NN o
model NN N
in IN N
the DT N
whole NN N
study NN N
population NN N
identified VBN N
female JJ o
sex NN o
, , o
chronic JJ o
renal JJ o
insufficiency NN o
, , o
diabetes VBZ o
, , o
advanced JJ o
age NN o
, , o
lower JJR o
sternal JJ o
thickness NN o
, , o
osteoporosis NN o
, , o
corticosteroid JJ o
therapy NN o
, , o
and CC o
prolonged VBD o
CPB NNP o
or CC o
ventilation NN o
times NNS o
as IN N
predisposing VBG N
factors NNS N
to TO N
any DT N
of IN N
the DT N
two CD N
studied VBD N
sternal JJ N
complications NNS N
. . N

DISCUSSION NNP N
Data NNP N
suggest NN N
that IN N
PDS NNP i
suture NN N
can MD N
protect VB N
against IN N
development NN N
of IN N
aseptic JJ o
sternal JJ o
complications NNS o
following VBG p
median JJ p
sternotomy NN p
in IN p
high-risk JJ p
patients NNS p
with IN p
little JJ p
body NN p
mass NN p
. . p

The DT N
adoption NN N
of IN N
PDS NNP i
in IN N
other JJ N
subsets NNS N
of IN N
patients NNS N
, , N
i.e. FW N
, , N
obese JJ N
individuals NNS N
, , N
is VBZ N
to TO N
be VB N
questioned VBN N
. . N

-DOCSTART- -24201696- O O

Do VB N
ACE NNP N
inhibitors NNS N
improve VBP N
the DT N
response NN o
to TO N
exercise VB o
training NN o
in IN N
functionally RB p
impaired JJ p
older JJR p
adults NNS p
? . N
A DT N
randomized NN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Loss NNP o
of IN o
muscle NN o
mass NN o
and CC o
strength NN o
with IN N
ageing NN N
is VBZ N
a DT N
major JJ N
cause NN N
for IN N
falls NNS o
, , o
disability NN o
, , o
and CC o
morbidity NN o
in IN N
older JJR p
people NNS p
. . p

Previous JJ N
studies NNS N
have VBP N
found VBN N
that IN N
angiotensin-converting JJ N
enzyme NN N
inhibitors NNS N
( ( N
ACEi NNP N
) ) N
may MD N
improve VB N
physical JJ o
function NN o
in IN N
older JJR N
people NNS N
. . N

It PRP N
is VBZ N
unclear JJ N
whether IN N
ACEi NNP N
provide VBP N
additional JJ N
benefit NN N
when WRB N
added VBD N
to TO N
a DT N
standard JJ N
exercise NN N
training NN N
program NN N
. . N

We PRP N
examined VBD N
the DT N
effects NNS N
of IN N
ACEi NNP N
therapy NN N
on IN N
physical JJ o
function NN o
in IN N
older JJR N
people NNS N
undergoing VBG N
exercise NN N
training NN N
. . N

METHODS NNP N
Community-dwelling JJ p
people NNS p
aged VBN p
? . p
65 CD p
years NNS p
with IN p
functional JJ p
impairment NN p
were VBD p
recruited VBN N
through IN N
general JJ N
( ( N
family NN N
) ) N
practices NNS N
. . N

All DT N
participants NNS N
received VBD i
progressive JJ i
exercise NN i
training NN i
. . i

Participants NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
either RB i
4 CD i
mg NNS i
perindopril NN i
or CC i
matching VBG i
placebo JJ i
daily JJ i
for IN N
20 CD N
weeks NNS N
. . N

The DT N
primary JJ N
outcome NN N
was VBD o
between-group JJ o
change NN o
in IN o
6-minute JJ o
walk NN o
distance NN o
from IN o
baseline NN N
to TO N
20 CD N
weeks NNS N
. . N

Secondary JJ N
outcomes NNS N
included VBD o
changes NNS o
in IN o
Short NNP o
Physical NNP o
Performance NNP o
Battery NNP o
, , o
handgrip NN o
and CC o
quadriceps JJ o
strength NN o
, , o
self-reported JJ o
quality NN o
of IN o
life NN o
using VBG o
the DT o
EQ-5D NNP o
, , o
and CC o
functional JJ o
impairment NN o
measured VBD o
using VBG o
the DT o
Functional NNP o
Limitations NNP o
Profile NNP o
. . o

RESULTS VB p
A DT p
total NN p
of IN p
170 CD p
participants NNS p
( ( p
n JJ p
= $ p
86 CD p
perindopril NN i
, , i
n JJ p
= FW p
84 CD p
placebo NN p
) ) p
were VBD p
randomized VBN p
. . p

Mean JJ p
age NN p
was VBD p
75.7 CD p
( ( p
standard JJ p
deviation NN p
[ NNP p
SD NNP p
] NNP p
6.8 CD p
) ) p
years NNS p
. . p

Baseline NNP o
6-minute JJ o
walk NN o
distance NN o
was VBD o
306 CD N
m NN N
( ( N
SD NNP N
99 CD N
) ) N
. . N

Both DT N
groups NNS N
increased VBD N
their PRP$ o
walk NN o
distance NN o
( ( o
by IN N
29.6 CD N
m NNS N
perindopril NN N
, , N
36.4 CD N
m NN N
placebo NN N
group NN N
) ) N
at IN N
20 CD N
weeks NNS N
, , N
but CC N
there EX N
was VBD N
no DT N
statistically RB N
significant JJ N
treatment NN N
effect NN N
between IN N
groups NNS N
( ( N
-8.6m JJ N
[ RB N
95 CD N
% NN N
confidence NN N
interval NN N
: : N
-30.1 NN N
, , N
12.9 CD N
] NN N
, , N
p NN N
= NNP N
.43 NNP N
) ) N
. . N

No DT N
statistically RB N
significant JJ N
treatment NN N
effects NNS N
were VBD N
observed VBN N
between IN N
groups NNS N
for IN N
the DT N
secondary JJ N
outcomes NNS N
. . N

Adverse JJ N
events NNS N
leading VBG N
to TO N
withdrawal VB N
were VBD N
few JJ N
( ( N
n JJ N
= $ N
0 CD N
perindopril NN N
, , N
n JJ N
= FW N
4 CD N
placebo NN N
) ) N
. . N

INTERPRETATION NNP N
ACE NNP N
inhibitors NNS N
did VBD N
not RB N
enhance VB N
the DT N
effect NN N
of IN N
exercise NN o
training NN o
on IN o
physical JJ o
function NN o
in IN o
functionally RB p
impaired JJ p
older JJR p
people NNS p
. . p

-DOCSTART- -19223284- O O

Cardiovascular JJ o
safety NN o
and CC o
gastrointestinal JJ o
tolerability NN o
of IN N
etoricoxib JJ i
vs NN i
diclofenac NN i
in IN N
a DT N
randomized NN N
controlled VBD N
clinical JJ N
trial NN N
( ( N
The DT N
MEDAL NNP N
study NN N
) ) N
. . N

OBJECTIVE UH N
To TO N
compare VB N
cardiovascular JJ o
( ( o
CV NNP o
) ) o
and CC o
other JJ o
safety NN o
and CC o
efficacy NN o
parameters NNS o
of IN N
etoricoxib JJ i
60 CD N
and CC N
90 CD N
mg NN N
, , N
and CC N
diclofenac VBZ i
150 CD N
mg. NN N
METHODS NNP N
This DT N
double-blind NN N
study NN N
randomized VBD N
OA NNP p
patients NNS p
to TO N
etoricoxib VB i
90 CD N
mg NN N
, , N
then RB N
to TO N
60 CD N
mg NNS N
once RB N
daily JJ N
vs NNS N
diclofenac VBP i
75 CD N
mg JJ N
twice RB N
daily RB N
; : N
RA NNP p
patients NNS p
were VBD N
randomized VBN N
to TO N
etoricoxib VB i
90 CD N
mg NNS N
once RB N
daily JJ N
or CC N
diclofenac JJ i
75 CD N
mg JJ N
twice RB N
daily RB N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
non-inferiority NN N
of IN N
etoricoxib JJ i
vs NN N
diclofenac NN i
for IN N
thrombotic JJ N
CV NNP N
events NNS N
( ( N
95 CD N
% NN N
CI NNP N
upper JJ N
bound NN N
of IN N
hazard NN N
ratio NN N
< NNP N
1.30 CD N
) ) N
. . N

Other JJ o
safety NN o
and CC o
efficacy NN o
parameters NNS o
were VBD N
evaluated VBN N
in IN N
cohorts NNS N
of IN N
patients NNS N
based VBN N
on IN N
etoricoxib NN i
dose NN N
and CC N
disease NN N
. . N

RESULTS VB N
A DT p
total NN p
of IN p
23 CD p
504 CD p
patients NNS p
were VBD N
randomized VBN N
with IN N
mean JJ N
treatment NN N
duration NN N
from IN N
19.4 CD N
to TO N
20.8 CD N
months NNS N
. . N

The DT N
thrombotic JJ o
CV NNP o
risk NN o
hazard NN o
ratio NN o
( ( o
HR NNP o
) ) o
( ( i
etoricoxib UH i
to TO N
diclofenac VB N
) ) N
was VBD N
0.96 CD N
( ( N
95 CD N
% NN N
CI NNP N
0.81 CD N
, , N
1.15 CD N
) ) N
, , N
consistent JJ N
with IN N
non-inferiority NN N
of IN N
etoricoxib NN i
to TO N
diclofenac VB i
. . i

The DT N
cumulative JJ o
gastrointestinal NN o
( ( o
GI NNP o
) ) o
/liver VBP o
adverse JJ o
events NNS o
( ( o
AEs NNP o
) ) o
discontinuation NN o
rate NN o
was VBD N
significantly RB N
lower JJR N
for IN N
etoricoxib JJR i
than IN N
diclofenac NN i
in IN N
each DT N
patient NN N
cohort NN N
; : N
HR NNP N
( ( N
95 CD N
% NN N
CI NNP N
) ) N
of IN N
0.46 CD N
( ( N
0.39 CD N
, , N
0.54 CD N
) ) N
, , N
0.52 CD N
( ( N
0.42 CD N
, , N
0.63 CD N
) ) N
and CC N
0.49 CD N
( ( N
0.39 CD N
, , N
0.62 CD N
) ) N
for IN N
the DT N
60 CD N
mg NN N
OA NNP N
, , N
90 CD N
mg NN N
OA NNP N
and CC N
RA NNP N
cohorts NNS N
. . N

The DT N
maximum JJ o
average JJ o
change NN o
in IN o
systolic JJ o
blood NN o
pressure NN o
( ( o
BP NNP o
) ) o
with IN N
etoricoxib NN i
was VBD N
3.4-3.6 JJ N
mmHg NN N
( ( N
diastolic JJ N
BP NNP N
: : N
1.0-1.5 JJ N
mmHg NN N
) ) N
, , N
while IN N
diclofenac NN N
produced VBD N
a DT N
maximum JJ N
average JJ N
change NN N
of IN N
0.9-1.9 JJ N
mmHg NN N
( ( N
diastolic JJ N
BP NNP N
: : N
0.0-0.5 JJ N
mmHg NN N
) ) N
. . N

Both DT N
agents NNS N
resulted VBD N
in IN N
similar JJ N
efficacy NN o
regardless NN N
of IN N
etoricoxib NN N
dose NN N
. . N

CONCLUSION NNP N
Long-term NNP N
etoricoxib NN i
use NN N
is VBZ N
associated VBN N
with IN N
a DT N
risk NN o
of IN o
thrombotic JJ o
CV NNP o
events NNS o
comparable JJ N
with IN N
that DT N
of IN N
diclofenac NN i
. . i

Compared VBN N
with IN N
diclofenac NN i
, , i
etoricoxib RB i
demonstrated VBD N
a DT N
greater JJR N
risk NN o
of IN o
renovascular JJ o
AEs NNP o
, , N
but CC N
a DT N
more RBR N
favourable JJ N
GI/liver NNP o
tolerability NN o
profile NN o
. . o

-DOCSTART- -11837468- O O

Glibenclamide NNP i
vs NN i
gliclazide NN i
in IN N
reducing VBG N
oxidative JJ o
stress NN o
in IN N
patients NNS p
of IN p
noninsulin JJ p
dependent JJ p
diabetes VBZ p
mellitus NN p
-- : p
a DT p
double JJ N
blind NN N
randomized VBN N
study NN N
. . N

OBJECTIVE NNP N
Parameters NNPS N
of IN N
oxidative JJ o
stress NN o
were VBD N
quantitated VBN N
in IN N
50 CD p
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
mellitus VBP p
in IN p
uncontrolled JJ p
state NN p
and CC N
after IN N
control NN N
using VBG N
oral JJ N
glibenclamide NN i
or CC i
gliclazide NN i
. . i

The DT N
estimates NNS N
were VBD N
further RB N
compared VBN N
between IN N
the DT N
two CD N
groups NNS N
irrespective JJ N
of IN N
drug NN N
used VBN N
to TO N
evaluate VB N
the DT N
difference NN N
, , N
if IN N
any DT N
. . N

METHODS NNP N
The DT N
study NN N
was VBD N
a DT N
double JJ N
blind NN N
, , N
uncontrolled JJ N
, , N
noncrossover RB N
and CC N
randomized JJ N
trial NN N
. . N

Fifty JJ p
patients NNS p
of IN p
uncontrolled JJ p
type NN p
2 CD p
diabetes NNS p
were VBD N
divided VBN N
in IN N
to TO N
two CD N
groups NNS N
. . N

Group NNP N
I PRP N
( ( N
25 CD N
patients NNS N
) ) N
received VBD N
capsule NN i
A NNP i
( ( i
glibenclamide NN i
) ) i
while IN N
Group NNP N
II NNP N
( ( N
25 CD N
patients NNS N
) ) N
received VBD N
capsule NN i
B NNP i
( ( i
gliclazide NN i
) ) i
. . i

The DT N
parameters NNS N
studied VBN N
were VBD N
Superoxide NNP o
dismutase NN o
( ( o
SOD NNP o
) ) o
, , o
malonyl-dialdehyde JJ o
( ( o
MDA NNP o
) ) o
and CC o
reduced VBN o
glutathione NN o
( ( o
GSH NNP o
) ) o
. . o

They PRP N
were VBD N
done VBN N
at IN N
( ( N
a DT N
) ) N
uncontrolled JJ N
stage NN N
( ( N
FBS NNP N
-- : N
165 CD N
+/- JJ N
16.7 CD N
mg/dl NN N
, , N
PP NNP N
-- : N
240 CD N
+/- JJ N
30.1 CD N
mg/dl NN N
and CC N
HbA1 NNP N
-- : N
10.5 CD N
+/- JJ N
0.9 CD N
% NN N
in IN N
group NN N
I PRP N
and CC N
FBS NNP N
-- : N
150 CD N
+/- JJ N
15.8 CD N
mg/dl NN N
, , N
PP NNP N
-- : N
246 CD N
+/- JJ N
29.1 CD N
mg/dl NN N
HbA1 NNP N
10.6 CD N
+/- JJ N
0.8 CD N
% NN N
in IN N
group NN N
II NNP N
) ) N
and CC N
during IN N
controlled VBN N
stage NN N
at IN N
12 CD N
weeks NNS N
( ( N
FBS NNP N
-- : N
120 CD N
+/- JJ N
18.5 CD N
mg/dl NN N
, , N
PP NNP N
-- : N
180 CD N
+/- JJ N
19.1 CD N
mg/dl NN N
and CC N
HbA1 NNP N
-- : N
8.4 CD N
+/- JJ N
0.29 CD N
% NN N
in IN N
group NN N
I PRP N
and CC N
FBS NNP N
-- : N
118 CD N
+/- JJ N
17.6 CD N
mg/dl NN N
, , N
PP NNP N
-- : N
176 CD N
+/- JJ N
20.1 CD N
mg/dl NN N
and CC N
HbA1 NNP N
-- : N
8.5 CD N
+/- JJ N
0.39 CD N
% NN N
in IN N
group NN N
II NNP N
patients NNS N
) ) N
. . N

RESULTS VB N
The DT N
significantly RB N
raised VBN N
levels NNS o
of IN o
MDA NNP o
and CC o
SOD NNP o
, , N
and CC N
decreased JJ N
levels NNS o
of IN o
reduced VBN o
glutathione NN o
( ( o
GSH NNP o
) ) o
during IN N
uncontrolled JJ N
stage NN N
of IN N
diabetes NNS N
indicated VBD N
free JJ N
radical JJ N
stress NN N
induced VBD N
lipid JJ N
peroxidation NN N
. . N

The DT N
significant JJ N
fall NN o
of IN o
MDA NNP o
and CC o
SOD NNP o
and CC o
increased VBD o
levels NNS o
of IN o
GSH NNP o
in IN o
blood NN o
in IN N
both DT N
groups NNS N
after IN N
control NN N
revealed VBD N
beneficial JJ N
effects NNS N
of IN N
glycemic JJ N
control NN N
on IN N
oxidative JJ o
stress NN o
. . o

The DT N
levels NNS N
were VBD N
not RB N
normalized VBN N
and CC N
stayed VBD N
higher JJR N
than IN N
those DT N
in IN N
controls NNS N
. . N

On IN N
intergroup JJ N
comparison NN N
; : N
the DT N
control NN N
of IN N
diabetes NNS N
with IN N
gliclazide NN i
( ( N
group NN N
II NNP N
) ) N
showed VBD N
improvement NN N
in IN N
oxidative JJ o
stress NN o
( ( o
MDA NNP o
, , o
GSH NNP o
) ) o
better JJR N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
than IN N
glibenclamide NN i
( ( N
group NN N
I PRP N
) ) N
. . N

CONCLUSION NNP N
Oxidative NNP o
stress NN o
in IN N
uncontrolled JJ N
diabetes NNS N
is VBZ N
decreased VBN N
with IN N
glycemic JJ N
control NN N
. . N

The DT N
control NN N
of IN N
diabetes NNS N
with IN N
gliclazide NN i
reduced VBN N
oxidative JJ o
stress NN o
more JJR N
than IN N
glibenclamide NN i
, , N
indicating VBG N
higher JJR N
antioxidant JJ N
properties NNS N
of IN N
gliclazide NN N
. . N

Normalization NN N
of IN N
oxidative JJ o
stress NN o
was VBD N
not RB N
achieved VBN N
. . N

Further JJ N
studies NNS N
are VBP N
required VBN N
to TO N
see VB N
long-term JJ N
effect NN N
of IN N
drug NN N
therapy NN N
in IN N
combating VBG N
oxidative JJ o
stress NN o
after IN N
achieving VBG N
acceptable JJ N
control NN N
of IN N
diabetes NNS N
. . N

-DOCSTART- -23046525- O O

Dalteparin NNP i
low JJ N
molecular JJ N
weight NN N
heparin NN i
( ( N
LMWH NNP N
) ) N
in IN N
ovarian JJ p
cancer NN p
: : p
a DT N
phase NN N
II NNP N
randomized VBD N
study NN N
. . N

OBJECTIVE NNP N
Low NNP N
molecular JJ N
weight NN N
heparin NN N
reduces VBZ N
the DT N
risk NN N
of IN N
venous JJ N
thromboembolism NN N
( ( N
VTE NNP N
) ) N
and CC N
may MD N
have VB N
antineoplastic JJ N
effects NNS N
by IN N
interfering VBG N
with IN N
angiogenesis NN N
and CC N
with IN N
tumor NN N
growth NN N
and CC N
metastasis NN N
. . N

A DT N
multicentre JJ N
phase NN N
II NNP N
randomized VBD N
trial NN N
was VBD N
done VBN N
to TO N
evaluate VB N
the DT N
antineoplastic JJ N
potential NN N
of IN N
dalteparin NN i
in IN N
ovarian JJ N
cancer NN N
( ( N
OC NNP N
) ) N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Women NNP p
with IN p
newly-diagnosed JJ p
epithelial JJ p
OC NNP p
were VBD N
randomized VBN N
to TO N
receive VB N
standard JJ i
chemotherapy NN i
( ( i
CT NNP i
) ) i
and CC N
one CD N
of IN N
3 CD N
doses NNS N
of IN N
dalteparin NN i
( ( N
50 CD N
IU/kg NNP N
, , N
100 CD N
IU/kg NNP N
, , N
or CC N
150 CD N
IU/kg NNP N
) ) N
subcutaneously RB N
once RB N
daily JJ N
during IN N
the DT N
first JJ N
3 CD N
of IN N
6 CD N
cycles NNS N
of IN N
3-weekly JJ N
CT NNP N
. . N

Blood NNP N
was VBD N
drawn VBN N
on IN N
day NN N
1 CD N
of IN N
each DT N
cycle NN N
for IN N
CA125 NNP N
and CC N
, , N
in IN N
a DT N
substudy NN N
of IN N
randomized JJ N
patients NNS N
, , N
for IN N
markers NNS N
of IN N
coagulation NN N
activation NN N
and CC N
angiogenesis NN N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
tumor JJ o
response NN o
defined VBN o
by IN o
? . o
50 CD o
% NN o
reduction NN o
in IN o
serum NN o
CA125 NNP o
from IN o
baseline NN o
sustained VBN o
for IN o
at IN o
least JJS o
28 CD o
days NNS o
. . o

Patients NNS N
were VBD N
followed VBN N
until IN N
the DT N
end NN N
of IN N
CT NNP N
. . N

RESULTS VB N
The DT N
study NN N
was VBD N
terminated VBN N
early RB N
due JJ N
to TO N
poor JJ N
recruitment NN p
. . p

Seventy-seven JJ p
women NNS p
were VBD p
evaluable JJ p
for IN p
the DT p
primary JJ p
outcome NN p
. . p

A DT N
50 CD N
% NN N
drop NN N
in IN N
CA125 NNP o
at IN o
the DT N
end NN N
of IN N
cycle NN N
3 CD N
was VBD N
seen VBN N
in IN N
85 CD N
% NN N
of IN N
the DT N
50 CD N
IU/kg NNP N
group NN N
, , N
92 CD N
% NN N
of IN N
the DT N
100 CD N
IU/kg NNP N
group NN N
, , N
and CC N
85 CD N
% NN N
of IN N
the DT N
150 CD N
IU/kg NNP N
group NN N
. . N

There EX N
were VBD N
no DT N
symptomatic JJ o
VTE NNP o
or CC o
major JJ o
bleeding VBG o
events NNS o
while IN o
on IN N
dalteparin NN N
. . N

Two CD N
patients NNS N
experienced VBD o
VTE NNP o
several JJ o
days NNS N
after IN N
discontinuing VBG N
study JJ N
drug NN N
. . N

Women NNS N
on IN N
dalteparin NN N
had VBD N
lower JJR N
levels NNS N
of IN N
D-dimer NNP o
and CC o
thrombin-antithrombin NN o
, , o
and CC o
higher JJR o
levels NNS o
of IN o
tissue NN o
factor NN o
pathway NN o
inhibitor NN o
, , o
relative JJ N
to TO N
baseline VB N
. . N

CONCLUSION NNP i
Dalteparin NNP i
is VBZ i
safe JJ o
and CC o
well RB o
tolerated VBN o
in IN o
women NNS p
receiving VBG p
CT NNP p
for IN p
newly-diagnosed JJ p
epithelial JJ p
OC NNP p
. . p

A DT N
dose-response JJ N
effect NN N
was VBD N
not RB N
identified VBN N
. . N

The DT N
lack NN N
of IN N
control NN N
group NN N
precluded VBD N
any DT N
inference NN N
on IN N
the DT N
antineoplastic JJ N
effect NN N
of IN N
dalteparin NN i
. . i

-DOCSTART- -7906128- O O

Evaluation NN N
of IN N
an DT N
intervention NN N
to TO N
change VB N
benzodiazepine-prescribing JJ i
behavior NN N
in IN N
a DT N
prepaid NN N
group NN N
practice NN N
setting VBG N
. . N

To TO N
determine VB N
the DT N
effect NN N
of IN N
two CD N
levels NNS N
of IN N
educational JJ i
intervention NN i
on IN i
benzodiazepine-prescribing JJ i
behavior NN i
in IN N
an DT N
elderly JJ p
population NN p
in IN N
a DT N
controlled JJ N
prepaid NN N
group NN N
practice NN N
( ( N
PPGP NNP N
) ) N
setting NN N
, , N
we PRP N
designed VBD N
a DT N
prospective JJ N
controlled VBN N
trial NN N
, , N
with IN N
six-month JJ N
follow-up NN N
. . N

Our PRP$ N
setting NN p
was VBD p
a DT p
270,000 CD p
member NN p
group-model JJ p
PPGP NNP p
in IN p
Colorado NNP p
, , p
from IN p
1990 CD p
to TO p
1991 CD p
. . p

Participants NNS p
included VBD p
91 CD p
physicians NNS p
, , p
62 CD p
men NNS p
and CC p
29 CD p
women NNS p
; : p
median JJ p
age NN p
was VBD p
38.7 CD p
years NNS p
. . p

Group NNP N
1 CD N
received VBD N
a DT N
one-on-one JJ i
educational JJ i
presentation NN i
by IN i
a DT i
clinical JJ i
pharmacist NN i
, , i
written VBN i
educational JJ i
materials NNS i
, , i
a DT i
brief JJ i
follow-up JJ i
visit NN i
, , i
and CC i
feedback NN i
with IN i
recommendations NNS i
. . i

Group NNP N
2 CD N
received VBD N
only RB N
a DT N
face-to-face JJ i
presentation NN i
, , i
given VBN i
to TO i
departmental VB i
groups NNS i
, , i
as RB i
well RB i
as IN i
the DT i
same JJ i
written VBN i
educational JJ i
materials NNS i
used VBN i
in IN i
group NN i
1 CD i
. . i

Controls NNP N
received VBD N
no DT i
intervention NN i
. . i

Our PRP$ N
primary JJ N
outcome JJ N
measure NN N
was VBD N
the DT N
benzodiazepine NN o
on/off NN o
status NN o
of IN o
the DT o
elderly JJ o
PPGP NNP o
members NNS o
. . o

The DT N
secondary JJ N
outcome NN N
measure NN N
was VBD N
the DT N
median JJ o
change NN o
( ( o
preintervention NN o
minus IN o
postintervention NN o
) ) o
in IN o
a DT o
standardized JJ o
amount NN o
of IN o
benzodiazepines NNS o
prescribed VBN o
per IN o
physician NN o
. . o

Logistic JJ N
regression NN N
analysis NN N
failed VBD N
to TO N
show VB N
a DT N
significant JJ N
effect NN N
on IN N
postintervention NN N
benzodiazepine NN o
on/off NN o
status NN o
between IN N
study NN N
groups NNS N
, , N
when WRB N
controlling VBG N
for IN N
preintervention NN N
on/off NN N
status NN N
, , N
PPGP-member NNP N
age NN N
, , N
PPGP-member NNP N
gender NN N
, , N
and CC N
all DT N
possible JJ N
interactions NNS N
. . N

Analysis NN N
of IN N
variance NN N
failed VBD N
to TO N
demonstrate VB N
an DT N
effect NN N
of IN N
either DT N
intervention NN N
on IN N
the DT N
median JJ o
change NN o
in IN o
standardized JJ o
amount NN o
of IN o
benzodiazepines NNS o
prescribed VBN N
per IN N
physician NN N
, , N
with IN N
groups NNS N
1 CD N
, , N
2 CD N
, , N
and CC N
controls NNS N
yielding VBG N
values NNS N
of IN N
-278 NN N
( ( N
range NN N
: : N
-4,137 NN N
, , N
2,844 CD N
) ) N
, , N
-330 NNP N
( ( N
-1,531 NNP N
, , N
1,358 CD N
) ) N
, , N
and CC N
-541 NNP N
( ( N
range NN N
: : N
-3,716 NN N
, , N
2,185 CD N
) ) N
, , N
respectively RB N
. . N

We PRP N
conclude VBP N
that IN N
strategies NNS N
effective JJ N
in IN N
changing VBG N
physician JJ N
prescribing VBG N
behavior NN N
in IN N
other JJ N
settings NNS N
may MD N
not RB N
be VB N
effective JJ N
in IN N
a DT N
PPGP NNP N
setting VBG N
with IN N
benzodiazepines NNS i
in IN N
the DT N
elderly JJ N
as IN N
the DT N
target NN N
for IN N
change NN N
. . N

-DOCSTART- -4407133- O O

Letter NN p
: : p
Cephaloridine NN i
and CC i
gentamicin NN i
in IN p
prophylaxis NN o
of IN p
surgical JJ o
wound NN o
infection NN o
. . o

-DOCSTART- -9101850- O O

[ RB N
Restorative NNP N
proctectomy NN N
, , N
reconstruction NN N
of IN N
continuity NN N
with IN N
or CC N
without IN N
colon NN N
J NNP N
pouch JJ N
] NNP N
. . N

Of IN N
63 CD p
patients NNS p
undergoing JJ p
deep JJ p
anterior JJ p
resection NN p
of IN p
the DT p
rectum NN p
, , p
39 CD p
patients NNS p
received VBD p
a DT p
straight JJ i
colo-anal JJ i
anastomosis NN i
( ( i
CAA NNP i
) ) i
, , N
24 CD N
additionally RB N
had VBD N
a DT N
colon-j-pouch JJ i
( ( i
CPA NNP i
) ) i
constructed VBD i
. . i

Local NNP o
septic JJ o
complications NNS o
occurred VBD N
in IN N
12.5 CD N
% NN N
of IN N
patients NNS N
after IN N
pouch-anal JJ N
anastomosis NN N
compared VBN N
to TO N
20.5 CD N
% NN N
after IN N
colo-anal JJ N
anastomosis NN N
: : N
stool NN o
frequency NN o
, , N
after IN N
pouch-anal JJ N
anastomosis NN N
was VBD N
3.3 CD N
per IN N
24 CD N
h NN N
compared VBN N
to TO N
5.2 CD N
per IN N
24 CD N
h NN N
after IN N
straight JJ N
anastomosis NN N
within IN N
the DT N
first JJ N
year NN N
after IN N
ileostomy JJ N
closure NN N
( ( N
p JJ N
= NNP N
0.053 CD N
) ) N
; : N
continence NN o
was VBD N
slightly RB N
better RBR N
in IN N
the DT N
pouch JJ N
group NN N
( ( N
n.s RB N
. . N

) ) N
; : N
and CC N
anal JJ o
manometry NN o
showed VBD N
a DT N
significant JJ N
postoperative JJ N
decrease NN N
only RB N
in IN N
resting VBG N
pressure NN N
after IN N
straight JJ N
colo-anal JJ N
anastomosis NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

Pouch JJ N
construction NN N
should MD N
be VB N
considered VBN N
after IN N
deep JJ N
rectal JJ N
resection NN N
, , N
as IN N
it PRP N
seems VBZ N
to TO N
improve VB N
functional JJ o
outcome NN o
and CC N
has VBZ N
fewer JJR N
local JJ o
septic NN o
complications NNS o
than IN N
straight JJ N
anastomosis NN N
. . N

-DOCSTART- -24012722- O O

Why WRB N
does VBZ N
lag NN i
affect VB N
the DT N
durability NN o
of IN o
memory-based JJ o
automaticity NN o
: : o
loss NN N
of IN N
memory NN N
strength NN N
or CC N
interference NN N
? . N
In IN N
Rickard NNP N
, , N
Lau NNP N
, , N
and CC N
Pashler NNP N
's POS N
( ( N
2008 CD N
) ) N
investigation NN N
of IN N
the DT N
lag NN N
effect NN N
on IN N
memory-based JJ o
automaticity NN o
, , N
response NN N
times NNS N
were VBD N
faster RBR N
and CC N
proportion NN N
of IN N
trials NNS i
retrieved VBN N
was VBD N
higher JJR N
at IN N
the DT N
end NN N
of IN N
practice NN i
for IN N
short JJ N
lag NN N
items NNS N
than IN N
for IN N
long JJ N
lag NN N
items NNS N
. . N

However RB N
, , N
during IN N
testing VBG i
after IN i
a DT i
delay NN i
, , N
response NN o
times NNS o
were VBD N
slower JJR N
and CC N
proportion NN N
of IN N
trials NNS N
retrieved VBN N
was VBD N
lower JJR N
for IN N
short JJ N
lag NN N
items NNS N
than IN N
for IN N
long JJ N
lag NN N
items NNS N
. . N

The DT N
current JJ N
study NN N
investigated VBD N
the DT N
extent NN N
to TO N
which WDT N
the DT N
lag NN N
effect NN N
on IN N
the DT N
durability NN o
of IN o
memory-based JJ o
automaticity NN o
is VBZ N
due JJ N
to TO N
interference VB N
or CC N
to TO N
the DT N
loss NN N
of IN N
memory NN N
strength NN N
with IN N
time NN N
. . N

Participants NNS p
repeatedly RB N
practiced VBD N
alphabet JJ i
subtraction NN i
items NNS i
in IN i
short JJ i
lag NN i
and CC i
long JJ i
lag NN i
conditions NNS i
. . i

After IN N
practice NN N
, , N
half NN N
of IN N
the DT N
participants NNS N
were VBD N
immediately RB i
tested VBN i
and CC N
the DT N
other JJ N
half NN N
were VBD N
tested VBN i
after IN i
a DT i
7-day JJ i
delay NN i
. . i

Results VB N
indicate JJ N
that IN N
the DT N
lag NN o
effect NN o
on IN N
the DT N
durability NN o
of IN o
memory-based JJ o
automaticity NN o
is VBZ N
primarily RB N
due JJ N
to TO N
interference VB N
. . N

We PRP N
discuss VBP N
potential JJ N
modification NN N
of IN N
current JJ N
memory-based JJ N
processing NN N
theories NNS N
to TO N
account VB N
for IN N
these DT N
effects NNS N
. . N

-DOCSTART- -19153828- O O

Adjuvant NNP N
goserelin NN N
and CC N
ovarian JJ N
preservation NN N
in IN N
chemotherapy NN N
treated VBD N
patients NNS p
with IN p
early JJ p
breast NN p
cancer NN p
: : p
results NNS N
from IN N
a DT N
randomized JJ N
trial NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
randomized VBN N
study NN N
was VBD N
to TO N
examine VB N
if IN N
goserelin JJ N
concomitant NN N
to TO N
CMF-chemotherapy NNP N
as IN N
adjuvant JJ N
treatment NN N
for IN N
premenopausal NN N
breast NN N
cancer NN N
, , N
protects VBZ o
the DT o
ovaries NNS o
from IN N
premature JJ N
failure NN N
. . N

A DT N
total NN N
of IN N
285 CD p
premenopausal NN p
breast NN p
cancer NN p
patients NNS p
, , p
in IN p
a DT p
randomized JJ p
adjuvant JJ p
trial NN p
( ( i
Zoladex NNP i
in IN p
premenopausal NN p
patients NNS p
( ( p
ZIPP NNP p
) ) p
) ) p
, , N
were VBD N
assigned VBN N
to TO N
a DT N
study NN N
on IN N
ovarian JJ N
function NN N
. . N

Node NNP p
positive JJ p
patients NNS p
were VBD N
assigned VBN N
to TO N
CMF- NNP i
( ( i
cyclophosphamide NN i
, , i
methotrexate NN i
and CC i
5-fluorouracil NN i
) ) i
chemotherapy NN i
in IN i
addition NN i
to TO i
endocrine VB i
therapy NN i
. . i

All DT N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
2 CD N
years NNS N
of IN N
goserelin NN i
, , i
goserelin NN i
plus CC i
tamoxifen NN i
, , i
tamoxifen VB i
alone RB i
or CC i
no DT i
endocrine JJ i
treatment NN i
. . i

We PRP N
studied VBD N
, , N
if IN N
menses NNS o
were VBD N
affected VBN N
in IN N
the DT N
treatment NN N
groups NNS N
, , N
up RB N
to TO N
36 CD N
months NNS N
after IN N
randomization NN N
. . N

One CD N
year NN N
after IN N
completed VBN N
CMF- NNP N
and CC N
endocrine JJ N
therapy NN N
, , N
36 CD N
% NN N
of IN N
the DT N
women NNS N
in IN N
the DT N
goserelin NN N
group NN N
reported VBD N
menses NNS o
, , N
compared VBN N
to TO N
7 CD N
% NN N
in IN N
the DT N
goserelin NN N
plus CC N
tamoxifen JJ N
group NN N
, , N
13 CD N
% NN N
in IN N
the DT N
tamoxifen NN N
group NN N
and CC N
10 CD N
% NN N
of IN N
the DT N
controls NNS N
. . N

Among IN N
women NNS N
treated VBN N
with IN N
goserelin NN N
, , N
there EX N
was VBD N
a DT N
statistically RB N
significant JJ N
increase NN o
in IN N
the DT N
proportion NN o
of IN o
menstruating VBG o
women NNS o
, , N
1 CD N
year NN N
after IN N
completed VBN N
treatment NN N
compared VBN N
to TO N
at IN N
24 CD N
months NNS N
of IN N
treatment NN N
( ( N
P NNP N
= NNP N
0.006 CD N
) ) N
, , N
in IN N
contrast NN N
to TO N
all DT N
other JJ N
treatment NN N
groups NNS N
, , N
who WP N
were VBD N
unchanged JJ N
or CC N
more RBR N
often RB N
amenorrheic JJ o
. . o

In IN N
our PRP$ N
study NN N
, , N
there EX N
is VBZ N
some DT N
evidence NN N
of IN N
protective JJ o
effect NN o
of IN o
goserelin NN o
on IN o
ovarian JJ o
function NN o
in IN N
CMF NNP N
treated VBD N
women NNS N
. . N

This DT N
effect NN N
was VBD N
not RB N
observed VBN N
in IN N
the DT N
combined JJ N
tamoxifen NN N
and CC N
goserelin NN N
treatment NN N
. . N

-DOCSTART- -22659656- O O

[ JJ N
Effect NNP N
of IN N
probucol NN i
on IN N
serum NN N
malondialdehyde NN N
and CC N
superoxide JJ N
dismutase NN N
in IN N
patients NNS p
with IN p
primary JJ p
hypertension NN p
] NN p
. . N

OBJECTIVE UH N
To TO N
observe VB N
the DT N
therapeutic JJ N
effect NN N
of IN N
probucol NN i
on IN N
serum NN N
malondialdehyde NN N
( ( N
MDA NNP N
) ) N
and CC N
superoxide JJ N
dismutase NN N
( ( N
SOD NNP N
) ) N
in IN N
patients NNS p
with IN p
primary JJ p
hypertension NN p
. . p

METHODS NNP N
A NNP N
randomized VBD N
study NN N
was VBD N
performed VBN N
on IN N
40 CD p
patients NNS p
with IN p
hypertension NN p
. . p

The DT N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
control NN i
( ( i
levamlodipine JJ i
besylate NN i
2.5 CD N
mg/d NN N
plus CC i
benazepril JJ i
10 CD i
mg/d NN N
, , N
n=20 NN N
) ) N
or CC i
probucol VBN i
group NN i
( ( i
levamlodipine JJ i
besylate NN i
2.5 CD N
mg/d NN N
plus CC i
benazepril JJ i
10 CD N
mg/d NN N
plus CC i
probucol JJ i
500 CD N
mg/d NN N
, , N
n=20 NN N
) ) N
. . N

An DT p
additional JJ p
twenty NN p
healthy JJ p
people NNS p
were VBD p
enrolled VBN p
in IN p
the DT p
study NN p
( ( i
normal JJ i
group NN i
) ) i
. . p

All DT N
subjects NNS N
were VBD N
followed VBN N
up RP N
for IN N
a DT N
period NN N
of IN N
four CD N
weeks NNS N
. . N

Lipids NNS N
and CC N
hepatic/renal JJ N
function NN N
were VBD N
measured VBN N
at IN N
baseline NN N
and CC N
after IN N
4 CD N
weeks NNS N
. . N

The DT N
levels NNS N
of IN N
serum NN o
MDA NNP o
and CC o
SOD NNP o
activity NN N
were VBD N
assayed VBN N
by IN N
chemical NN N
colorimetry NN N
, , N
and CC N
other JJ N
indices NNS N
, , N
including VBG N
blood NN o
pressure NN o
, , o
lipids NNS o
and CC o
hepatic/renal JJ o
function NN o
, , N
were VBD N
measured VBN N
at IN N
baseline NN N
and CC N
after IN N
4 CD N
weeks NNS N
. . N

RESULTS NNP N
Compared VBD N
to TO N
the DT N
normal JJ N
group NN N
, , N
the DT N
levels NNS o
of IN o
MDA NNP o
in IN N
all DT N
of IN N
the DT N
hypertension NN o
patient NN o
groups NNS o
were VBD o
higher JJR o
, , o
SOD NNP o
was VBD o
lower JJR o
. . o

The DT N
antihypertensive JJ N
treatment NN N
decreased VBD o
serum JJ o
MDA NNP o
levels NNS o
but CC o
increased VBD o
SOD NNP o
content NN o
, , N
and CC N
probucol NN o
treatment NN o
exaggerated VBD o
these DT o
effects NNS o
, , N
with IN N
greater JJR o
reduction NN o
of IN o
serum NN o
MDA NNP o
levels NNS o
and CC N
greater JJR o
increase NN o
of IN o
SOD NNP o
content NN o
. . o

CONCLUSION VB N
The DT N
treatment NN N
with IN N
probucol NN N
can MD N
improve VB o
oxidative JJ o
stress NN o
in IN o
hypertension NN o
patients NNS o
, , N
resulting VBG N
in IN N
reduced VBN o
serum NN o
MDA NNP o
levels NNS o
and CC N
improved VBN o
SOD NNP o
activity NN o
, , N
thus RB N
contributing VBG N
agreater RBR N
antihypertensive JJ o
effect NN o
. . o

-DOCSTART- -12748567- O O

Systematic JJ i
approach NN i
to TO N
benign VB p
paroxysmal JJ p
positional JJ p
vertigo NN p
in IN p
the DT p
elderly JJ p
. . p

OBJECTIVE IN N
We PRP N
evaluated VBD N
the DT N
effectiveness NN N
of IN N
a DT N
management NN N
approach NN N
that WDT N
combines VBZ N
the DT N
canalith NN i
repositioning VBG i
maneuver NN i
( ( i
CRM NNP i
) ) i
and CC i
vestibular JJ i
rehabilitation NN i
( ( i
VR NNP i
) ) i
in IN N
the DT N
treatment NN N
of IN N
benign JJ p
positional JJ p
paroxysmal NN p
vertigo NN p
( ( p
BPPV NNP p
) ) p
in IN p
elderly JJ p
persons NNS p
. . p

STUDY NNP N
DESIGN NNP N
AND NNP N
SETTING NNP N
Forty-seven JJ p
patients NNS p
( ( p
> JJ p
/=70 CD p
years NNS p
old JJ p
) ) p
with IN p
the DT p
diagnosis NN p
of IN p
unilateral JJ p
posterior JJ p
semicircular JJ p
canal NN p
BPPV NNP p
formed VBD N
the DT N
study NN N
population NN N
. . N

This DT N
study NN N
has VBZ N
2 CD N
parts NNS N
. . N

In IN N
the DT N
first JJ N
part NN N
, , N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
2 CD N
groups NNS N
: : N
the DT i
CRM NNP i
and CC i
avoidance NN i
( ( i
no DT i
treatment NN i
) ) i
. . i

Patients NNS N
were VBD N
evaluated VBN N
1 CD N
month NN N
after IN N
the DT N
first JJ N
visit NN N
. . N

Those DT N
patients NNS N
not RB N
responding VBG N
to TO N
treatment NN N
were VBD N
enrolled VBN N
in IN N
the DT N
second JJ N
part NN N
of IN N
the DT N
study NN N
, , N
treated VBN N
with IN N
an DT i
individualized JJ i
combination NN i
of IN i
CRM NNP i
and CC i
VR NNP i
, , N
and CC N
then RB N
reevaluated VBD N
3 CD N
months NNS N
later RB N
. . N

RESULTS NNP N
Statistically NNP N
significant JJ N
improvement NN o
of IN o
vertigo NN o
and CC o
provoked VBD o
nystagmus NNS o
in IN N
64 CD N
% NN N
of IN N
patients NNS N
in IN N
the DT N
CRM NNP N
group NN N
compared VBN N
with IN N
the DT N
no-treatment JJ N
group NN N
. . N

After IN N
the DT N
addition NN N
of IN N
VR NNP o
, , N
77 CD N
% NN N
of IN N
all DT N
patients NNS N
improved VBN N
. . N

CONCLUSION VB N
A DT N
combination NN N
of IN N
CRM NNP N
and CC N
VR NNP N
improves VBZ N
BPPV NNP o
in IN p
the DT p
elderly JJ p
. . p

SIGNIFICANCE NNP N
These DT N
findings NNS N
suggest VBP N
that IN N
although IN N
CRM NNP N
is VBZ N
more RBR N
effective JJ N
than IN N
no DT N
treatment NN N
, , N
VR NNP N
can MD N
be VB N
added VBN N
to TO N
improve VB N
the DT N
results NNS N
in IN N
the DT N
treatment NN N
of IN N
BPPV NNP N
. . N

-DOCSTART- -24119994- O O

Entomological JJ N
determinants NNS N
of IN N
insecticide-treated JJ N
bed JJ N
net JJ N
effectiveness NN o
in IN N
Western JJ p
Myanmar NNP p
. . p

BACKGROUND NNP N
In IN N
a DT N
large JJ N
cluster NN N
randomized VBD N
control JJ N
trial NN N
of IN N
insecticide-treated JJ i
bed NN i
nets NNS i
( ( i
ITN NNP i
) ) i
in IN N
Western JJ p
Myanmar NNP p
the DT N
malaria NN N
protective JJ o
effect NN o
of IN N
ITN NNP i
was VBD N
found VBN N
to TO N
be VB N
highly RB N
variable JJ N
and CC N
, , N
in IN N
aggregate NN N
, , N
the DT N
effect NN N
was VBD N
not RB N
statistically RB N
significant JJ N
. . N

A DT N
coincident JJ N
entomological JJ N
investigation NN N
measured VBD N
malaria NNS o
vector NN o
abundance NN o
and CC o
biting VBG o
behaviour NN o
and CC N
the DT N
human JJ o
population NN o
sleeping VBG o
habits NNS o
, , N
factors NNS N
relevant VBP N
to TO N
ITN NNP i
effectiveness NN o
. . o

METHODS NNP N
Entomological JJ N
surveys NNS N
were VBD N
carried VBN N
out RP N
using VBG N
different JJ N
catching VBG N
methods NNS N
to TO N
identify VB N
potential JJ o
malaria NNS o
vector NN o
species NNS o
and CC N
characterise VB N
their PRP$ N
biting NN o
habits NNS o
. . o

The DT N
salivary JJ i
glands NNS i
were VBD i
dissected VBN i
from IN N
all DT N
female JJ N
anophelines NNS N
caught VBD N
to TO N
identify VB N
sporozoites NNS N
by IN N
microscopy NN i
. . i

FINDINGS NNP N
Between NNP N
1995 CD N
and CC N
2000 CD N
a DT N
total NN N
of IN N
4,824 CD p
female JJ p
anopheline NN p
mosquitoes NNS p
were VBD N
caught VBN N
with IN N
various JJ N
catching VBG N
methods NNS N
. . N

A DT N
total NN N
of IN N
916 CD p
person NN p
nights NNS p
yielded VBD p
3,009 CD p
female JJ p
anopheline NN p
mosquitoes NNS p
between IN p
6 CD p
pm NNS p
and CC p
6 CD p
am VBP p
. . p

Except IN N
for IN N
Anopheles NNP N
annularis NN N
, , N
which WDT N
showed VBD N
no DT N
apparent JJ N
preference NN o
( ( N
51 CD N
% NN N
outdoor JJ N
biting NN N
) ) N
, , N
all DT N
major JJ N
species NNS N
showed VBD N
a DT N
strong JJ N
preference NN o
for IN N
outdoor JJ o
biting NN o
; : o
Anopheles NNP N
epiroticus FW N
( ( N
79 CD N
% NN N
) ) N
, , N
Anopheles NNP N
subpictus NN N
( ( N
72 CD N
% NN N
) ) N
, , N
Anopheles NNP N
maculatus NNP N
( ( N
92 CD N
% NN N
) ) N
, , N
Anopheles NNP N
aconitus NN N
( ( N
85 CD N
% NN N
) ) N
and CC N
Anopheles NNP N
vagus NNP N
( ( N
72 CD N
% NN N
) ) N
. . N

Most JJS N
human JJ o
biting NN o
occurred VBD N
in IN N
the DT N
early JJ N
evening NN N
with IN N
the DT N
peak NN o
biting VBG o
time NN o
between IN N
6 CD N
pm NNS N
and CC N
7 CD N
pm NN N
( ( N
35 CD N
% NN N
) ) N
. . N

Overall JJ N
51 CD N
% NN N
( ( N
1447/2837 CD N
) ) N
of IN N
all DT N
bites NNS o
recorded VBN o
were VBD N
between IN N
6 CD N
pm NNS N
and CC N
8 CD N
pm NN N
. . N

A DT p
large JJ p
proportion NN o
of IN o
children NNS o
were VBD N
not RB N
sleeping VBG o
under IN N
an DT N
ITN NNP i
during IN N
peak NN o
biting VBG o
times NNS o
. . o

Only RB N
one CD N
An DT N
. . N

annularis NN N
mosquito NN N
( ( N
0.02 CD N
% NN N
) ) N
had VBD N
malaria VBN o
sporozoites NNS o
identified VBN N
in IN N
the DT N
salivary JJ N
glands NNS N
. . N

CONCLUSIONS NNP N
Peak NNP o
vector NN o
biting NN o
occurred VBD N
early RB N
in IN N
the DT N
evening NN N
and CC N
mainly RB N
occurred VBD N
outdoors NNS o
. . o

The DT N
limited JJ N
efficacy NN o
of IN N
ITN NNP i
in IN N
this DT N
area NN N
of IN N
Western JJ p
Myanmar NNP p
may MD N
be VB N
explained VBN N
by IN N
the DT N
biting VBG N
behaviour NN N
of IN N
the DT N
prevalent NN N
Anopheles NNP N
mosquito NN N
vectors NNS N
in IN N
this DT N
area NN N
. . N

-DOCSTART- -17868242- O O

Injury NNP o
and CC o
illness NN o
costs NNS o
in IN N
the DT N
Certified NNP N
Safe NNP N
Farm NNP N
study NN N
. . N

CONTEXT NNP N
The DT i
Certified NNP i
Safe NNP i
Farm NNP i
( ( i
CSF NNP i
) ) i
intervention NN i
program NN i
aims VBZ N
to TO N
reduce VB N
occupational JJ N
injuries NNS N
and CC N
illnesses NNS N
, , N
and CC N
promote VB N
wellness NN N
to TO N
reduce VB N
health NN N
care NN N
and CC N
related JJ N
costs NNS N
to TO N
farmers NNS p
, , p
insurers NNS p
, , p
and CC p
other JJ p
stakeholders NNS p
. . p

PURPOSE NNP N
To TO N
evaluate VB N
the DT N
cost NN o
effectiveness NN o
of IN o
CSF NNP o
. . o

METHODS NNP N
Farms NNP p
( ( p
316 CD p
) ) p
located VBN p
in IN p
a DT p
9-county JJ p
area NN p
of IN p
northwestern JJ p
Iowa NNP p
were VBD p
recruited VBN p
and CC p
randomized VBN p
into IN p
intervention NN i
and CC p
control NN i
cohorts NNS p
. . p

Intervention NN i
farms NNS N
received VBD N
occupational JJ i
health NN i
screenings NNS i
, , i
health NN i
and CC i
wellness NN i
screening NN i
, , i
education NN i
, , i
on-farm JJ i
safety NN i
reviews NNS i
, , i
and CC i
performance NN i
incentives NNS i
. . i

For IN N
both DT N
cohorts NNS N
, , N
quarterly JJ N
calls NNS N
over IN N
3 CD N
years NNS N
were VBD N
used VBN N
to TO N
collect VB N
self-reported JJ N
occupational JJ N
injury NN N
and CC N
illness JJ N
information NN N
, , N
including VBG N
costs NNS N
to TO N
the DT N
farmers NNS N
and CC N
their PRP$ N
insurers NNS N
. . N

FINDINGS NNP N
Annual NNP o
occupational JJ o
injury NN o
and CC o
illness NN o
costs NNS o
per IN N
farmer NN N
paid VBN N
by IN N
insurers NNS N
were VBD N
45 CD N
% NN N
lower JJR N
in IN N
the DT N
intervention NN i
cohort NN N
( ( N
$ $ N
183 CD N
) ) N
than IN N
in IN N
the DT N
control NN i
cohort NN N
( ( N
$ $ N
332 CD N
) ) N
. . N

Although IN N
out-of-pocket NN o
expenses NNS o
were VBD N
similar JJ N
for IN N
both DT N
cohorts NNS N
, , N
combined VBN o
costs NNS o
of IN o
insurance NN o
and CC o
out-of-pocket NN o
expenses NNS o
were VBD N
27 CD N
% NN N
lower JJR N
in IN N
the DT N
intervention NN i
cohort NN N
( ( N
$ $ N
374/year CD N
per IN N
farmer NN N
) ) N
compared VBN N
to TO N
the DT N
control NN i
cohort NN N
( ( N
$ $ N
512/year CD N
per IN N
farmer NN N
) ) N
. . N

Within IN N
the DT N
cohort NN N
of IN N
intervention NN i
farmers NNS N
, , N
annual JJ o
occupational JJ o
injury NN o
and CC o
illness NN o
cost NN o
savings NNS o
were VBD N
directly RB N
associated VBN N
with IN N
on-farm JJ N
safety NN N
review NN N
scores NNS N
. . N

Reported VBD N
health NN o
care NN o
costs NNS o
were VBD N
$ $ N
237 CD N
per IN N
farmer NN N
in IN N
the DT N
safest NN N
farms NNS N
( ( N
those DT N
farms NNS N
scoring VBG N
in IN N
the DT N
highest JJS N
tertile NN N
) ) N
versus VBD N
$ $ N
485 CD N
per IN N
farmer NN N
in IN N
the DT N
least JJS N
safe JJ N
farms NNS N
( ( N
lowest JJS N
tertile NN N
) ) N
. . N

CONCLUSIONS JJ N
Results NNP N
suggest VBP N
that IN N
farmers NNS N
receiving VBG N
the DT N
intervention NN i
had VBD N
lower JJR N
health NN o
care NN o
costs NNS o
for IN N
occupational JJ N
injuries NNS N
and CC N
illnesses NNS N
than IN N
control NN i
farmers NNS N
. . N

These DT N
cost NN o
savings NNS o
more JJR N
than IN N
cover VB N
the DT N
cost NN N
of IN N
providing VBG N
CSF NNP N
services NNS N
( ( N
about IN N
$ $ N
100 CD N
per IN N
farm NN N
per IN N
year NN N
) ) N
. . N

-DOCSTART- -23296213- O O

Contingency NNP i
management NN i
for IN N
the DT N
treatment NN N
of IN N
antipsychotic-induced JJ N
weight JJ o
gain NN o
: : o
a DT N
randomized VBN N
controlled VBN N
pilot NN N
study NN N
. . N

OBJECTIVE NNP N
Weight NNP N
gain NN N
is VBZ N
common JJ N
for IN N
individuals NNS p
with IN p
serious JJ p
mental JJ p
illness NN p
( ( p
SMI NNP p
) ) p
receiving VBG p
antipsychotic JJ p
drug NN p
therapy NN p
. . p

Contingency NNP i
management NN i
( ( i
CM NNP i
) ) i
is VBZ N
a DT N
behavioral JJ N
intervention NN N
that IN N
rewards NNS N
positive JJ N
performance NN N
and CC N
has VBZ N
demonstrated VBN N
effectiveness NN N
in IN N
reducing VBG N
drug NN N
use NN N
in IN N
SMI NNP N
populations NNS N
. . N

This DT N
study NN N
evaluated VBD N
the DT N
feasibility NN N
of IN N
using VBG N
CM NNP i
to TO N
promote VB N
weight JJ N
loss NN N
in IN N
individuals NNS p
with IN p
SMI NNP p
over IN p
8 CD p
weeks NNS p
. . p

METHOD NNP N
30 CD p
individuals NNS p
( ( p
BMI NNP p
? . p
28 CD p
kg/m NN p
( ( p
2 CD p
) ) p
) ) p
were VBD p
randomized VBN N
to TO N
one CD N
of IN N
three CD N
conditions NNS N
: : N
i NN N
) ) N
The DT i
combination NN i
of IN i
a DT i
standardized JJ i
lifestyle NN i
modification NN i
( ( i
LM NNP i
) ) i
program NN i
for IN i
individuals NNS i
with IN i
SMI NNP i
and CC i
payment NN i
for IN i
group NN i
attendance NN i
( ( i
CM NNP i
( ( i
attendance NN i
) ) i
) ) i
, , i
ii NN i
) ) i
The DT i
combination NN i
of IN i
LM NNP i
and CC i
payment NN i
for IN i
weight JJ i
loss NN i
( ( i
CM NNP i
( ( i
weight NN i
) ) i
) ) i
, , i
and CC i
iii NN i
) ) i
waitlist NN i
control NN i
( ( i
CON NNP i
) ) i
. . i

After IN N
the DT N
waitlist JJ N
period NN N
, , N
those DT N
participants NNS N
joined VBD N
a DT N
LM NNP i
group NN i
and CC i
received VBD i
payment NN i
for IN i
behavioral JJ i
change NN i
( ( i
CM NNP i
( ( i
behavior NN i
) ) i
) ) i
. . i

RESULTS JJ N
Subjects NNPS N
in IN N
the DT N
CM NNP N
( ( N
attendance NN N
) ) N
and CC N
in IN N
the DT N
CM NNP N
( ( N
weight NN N
) ) N
group NN N
lost VBD N
a DT N
mean NN o
of IN o
1.16 CD N
kg NNS N
and CC N
1.23 CD N
kg NN N
, , N
respectively RB N
, , N
while IN N
subjects NNS N
in IN N
the DT N
CON NNP o
gained VBD o
a DT o
mean NN N
of IN N
0.68 CD N
kg NNS N
. . N

Subjects NNS N
receiving VBG N
CM NNP N
( ( N
behavior NN N
) ) N
, , N
lost VBD N
a DT N
mean NN N
of IN N
2.54 CD N
kg NNS N
, , N
which WDT N
was VBD N
a DT N
significant JJ o
weight NN o
loss NN o
compared VBN o
to TO N
the DT N
control NN N
period NN N
. . N

CONCLUSION NNP i
LM NNP i
supplemented VBD i
with IN i
CM NNP i
may MD i
facilitate VB o
weight NN o
loss NN o
in IN o
patients NNS p
taking VBG p
antipsychotic JJ p
medications NNS p
; : p
financial JJ p
reimbursement NN N
for IN N
behavioral JJ N
change NN N
may MD N
be VB N
particularly RB N
effective JJ N
in IN N
this DT N
population NN N
. . N

-DOCSTART- -15533466- O O

Botulinum NNP i
toxin NN i
a DT N
has VBZ N
antinociceptive JJ o
effects NNS o
in IN N
treating VBG N
interstitial JJ N
cystitis NN N
. . N

OBJECTIVES NNP N
To TO N
present VB N
clinical JJ N
evidence NN N
with IN N
botulinum NN i
toxin NN i
A NNP i
( ( i
BTX-A NNP i
) ) i
suggesting VBG N
an DT N
antinociceptive JJ o
role NN o
in IN N
patients NNS p
with IN p
interstitial JJ p
cystitis NN p
( ( p
IC NNP p
) ) p
. . p

Intriguing VBG N
evidence NN N
in IN N
a DT N
somatic JJ N
pain NN N
model NN N
has VBZ N
suggested VBN N
that IN N
BTX-A NNP i
injection NN i
may MD N
have VB N
an DT N
antinociceptive JJ o
effect NN o
on IN N
both DT N
acute NN N
and CC N
chronic NN N
( ( N
inflammatory NN N
) ) N
pain NN N
. . N

METHODS NNP N
Thirteen NNP p
female JJ p
patients NNS p
( ( p
6 CD p
in IN p
the DT p
United NNP p
States NNPS p
and CC p
7 CD p
in IN p
Poland NNP p
) ) p
with IN p
IC NNP p
according VBG p
to TO p
the DT p
criteria NNS p
of IN p
the DT p
National NNP p
Institute NNP p
of IN p
Diabetes NNP p
, , p
Digestive NNP p
and CC p
Kidney NNP p
Disease NNP p
were VBD p
included VBN p
. . p

Under IN N
short JJ N
general JJ N
anesthesia NN N
or CC N
sedation NN N
, , N
100 CD p
to TO p
200 CD p
U NNP p
of IN p
Dysport NNP i
( ( p
Polish JJ p
patients NNS p
) ) p
or CC p
Botox NNP i
( ( p
U.S. NNP p
patients NNS p
) ) p
was VBD N
injected VBN N
through IN N
a DT N
cystoscope NN N
into IN N
20 CD N
to TO N
30 CD N
sites NNS N
submucosally RB N
in IN N
the DT N
trigone NN N
and CC N
floor NN N
of IN N
the DT N
bladder NN N
. . N

Patients NNS N
were VBD N
evaluated VBN N
with IN N
the DT N
O'Leary-Sant NNP o
validated VBD o
IC NNP o
questionnaire NN o
or CC o
with IN o
voiding JJ o
charts NNS o
and CC o
a DT o
visual JJ o
analog NN o
pain VBP o
scale JJ o
1 CD N
month NN N
postoperatively RB N
and CC N
at IN N
subsequent JJ N
3-month JJ N
intervals NNS N
. . N

The DT N
Polish JJ p
patients NNS p
also RB N
underwent JJ N
pretreatment NN N
and CC N
post-treatment JJ N
urodynamic JJ o
evaluations NNS o
. . o

RESULTS NNP N
Overall NNP N
, , N
9 CD N
( ( N
69 CD N
% NN N
) ) N
of IN N
13 CD N
patients NNS N
noted JJ N
subjective JJ o
improvement NN o
after IN N
BTX-A NNP i
treatment NN N
. . N

The DT N
Interstitial NNP o
Cystitis NNP o
Symptom NNP o
Index NNP o
and CC o
Interstitial NNP o
Cystitis NNP o
Problem NNP o
Index NNP o
mean NN o
scores NNS o
improved VBN N
by IN N
71 CD N
% NN N
and CC N
69 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Daytime NNP o
frequency NN o
, , o
nocturia NN o
, , o
and CC o
pain NN o
by IN o
visual JJ o
analog NN o
scale NN o
decreased VBN N
by IN N
44 CD N
% NN N
, , N
45 CD N
% NN N
, , N
and CC N
79 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
first JJ o
desire NN o
to TO o
void VB o
and CC o
maximal VB o
cystometric JJ o
capacity NN o
increased VBN N
by IN N
58 CD N
% NN N
and CC N
57 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSIONS NNP N
Our PRP$ N
results NNS N
suggest VBP N
that IN N
BTX-A NNP i
has VBZ N
an DT N
antinociceptive JJ o
effect NN o
on IN N
bladder NN N
afferent NN N
pathways NNS N
in IN N
patients NNS N
with IN N
IC NNP N
, , N
producing VBG N
both DT N
symptomatic JJ N
and CC N
functional JJ N
( ( N
ie JJ N
, , N
urodynamic JJ N
) ) N
improvements NNS N
. . N

-DOCSTART- -15220012- O O

Effects NNS N
of IN N
pioglitazone NN i
and CC i
glimepiride NN i
on IN N
glycemic JJ N
control NN N
and CC N
insulin NN N
sensitivity NN N
in IN N
Mexican JJ p
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
mellitus NN p
: : p
A DT N
multicenter NN N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
parallel-group JJ N
trial NN N
. . N

BACKGROUND NNP N
Pioglitazone NNP i
and CC N
glimepiride VB i
improve VB N
glycemic JJ N
control NN N
in IN N
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
mellitus VBN p
by IN N
different JJ N
mechanisms NNS N
. . N

Pioglitazone NN i
is VBZ N
a DT N
thiazolidinedione NN N
that WDT N
reduces VBZ N
insulin NN N
resistance NN N
, , N
and CC N
glimepiride NN i
is VBZ N
a DT N
sulfonylurea JJ N
insulin NN N
secretagogue NN N
. . N

OBJECTIVE CC N
The DT N
goals NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
compare VB N
changes NNS N
in IN N
measures NNS N
of IN N
glycemic JJ N
control NN N
and CC N
insulin NN N
sensitivity NN N
in IN N
Mexican JJ p
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
who WP p
received VBD p
pioglitazone NN i
or CC p
glimepiride NN i
for IN p
1 CD p
year NN p
. . p

METHODS NNP N
This DT N
was VBD N
a DT N
multicenter NN N
, , N
52-week JJ N
, , N
double-blind JJ N
, , N
parallel-group JJ N
trial NN N
. . N

Patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
monotherapy NN N
with IN N
either DT N
glimepiride NN i
( ( N
2 CD N
mg NN N
QD NNP N
initially RB N
) ) N
or CC i
pioglitazone NN i
( ( N
15 CD N
mg NN N
QD NNP N
initially RB N
) ) N
. . N

Doses NNS N
were VBD N
titrated VBN N
( ( N
maximal JJ N
doses NNS N
: : N
pioglitazone NN i
45 CD N
mg NN N
, , N
glimepiride RB i
8 CD N
mg NN N
) ) N
to TO N
achieve VB N
glycemic JJ N
targets NNS N
( ( N
fasting VBG N
blood NN N
glucose JJ N
< NN N
or CC N
=7 VB N
mmol/L NNS N
and CC N
1-hour JJ N
postprandial JJ N
blood NN N
glucose JJ N
< NN N
or CC N
=10 VB N
mmol/L NN N
) ) N
. . N

Insulin NNP N
sensitivity NN N
( ( N
primary JJ N
end NN N
point NN N
) ) N
was VBD N
evaluated VBN N
in IN N
terms NNS N
of IN N
the DT N
Homeostasis NNP N
Model NNP N
Assessment NNP N
for IN N
Insulin NNP N
Sensitivity NNP N
( ( N
HOMA-S NNP N
) ) N
, , N
the DT N
Quantitative NNP N
Insulin NNP N
Sensitivity NNP N
Check NNP N
Index NNP N
( ( N
QUICKI NNP N
) ) N
, , N
and CC N
fasting VBG N
serum JJ N
insulin NN N
( ( N
FSI NNP N
) ) N
concentrations NNS N
. . N

Glycemic NNP N
control NN N
was VBD N
evaluated VBN N
in IN N
terms NNS N
of IN N
glycosylated VBN N
hemoglobin NN N
( ( N
HbA NNP N
( ( N
1c CD N
) ) N
) ) N
values NNS N
and CC N
fasting VBG N
plasma NN N
glucose NN N
( ( N
FPG NNP N
) ) N
concentrations NNS N
. . N

Patients NNS N
were VBD N
encouraged VBN N
to TO N
maintain VB N
their PRP$ N
individual JJ N
diet NN N
and CC N
exercise NN N
regimens NNS N
throughout IN N
the DT N
study NN N
. . N

RESULTS NNP N
Two CD p
hundred VBD p
forty-four JJ p
patients NNS p
( ( p
125 CD p
women NNS p
, , p
119 CD p
men NNS p
; : p
all DT p
but CC p
1 CD p
Hispanic NNP p
) ) p
were VBD p
randomized VBN p
to TO N
receive VB N
pioglitazone NN i
( ( N
n JJ N
= NNP N
121 CD N
) ) N
or CC N
glimepiride NN i
( ( N
n JJ N
= NNP N
123 CD N
) ) N
. . N

In IN N
the DT N
intent-to-treat JJ N
sample NN N
, , N
pioglitazone NN i
and CC N
glimepirede NN i
produced VBN N
comparable JJ N
reductions NNS o
in IN o
HbA NNP o
( ( o
1c CD o
) ) o
from IN N
baseline NN N
to TO N
the DT N
end NN N
of IN N
the DT N
study NN N
( ( N
-0.78 CD N
% NN N
and CC N
-0.68 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

The DT N
pioglitazone NN i
group NN N
had VBD N
significantly RB N
higher JJR N
HbA NNP o
( ( o
1c CD o
) ) o
values NNS N
compared VBN N
with IN N
the DT N
glimepiride NN i
group NN N
after IN N
12 CD N
weeks NNS N
of IN N
therapy NN N
( ( N
8.66 CD N
% NN N
vs JJ N
7.80 CD N
% NN N
; : N
P NNP N
= NNP N
0.007 CD N
) ) N
but CC N
had VBD N
significantly RB N
lower JJR N
values NNS N
after IN N
52 CD N
weeks NNS N
( ( N
7.46 CD N
% NN N
vs JJ N
7.77 CD N
% NN N
; : N
P NNP N
= NNP N
0.027 CD N
) ) N
. . N

Pioglitazone NN i
significantly RB N
reduced VBD N
FPG NNP o
compared VBN N
with IN N
glimepiride NN i
( ( N
-0.6 JJ N
vs NN N
0.6 CD N
mmol/L NN N
; : N
P NNP N
= NNP N
0.01 CD N
) ) N
. . N

Pioglitazone NNP i
therapy NN N
was VBD N
associated VBN N
with IN N
significant JJ N
increases NNS N
in IN N
insulin NN o
sensitivity NN o
( ( o
reduced JJ o
insulin NN o
resistance NN o
) ) o
, , N
whereas JJ N
glimepiride NN i
had VBD N
no DT N
effect NN N
. . N

HOMA-S JJ o
values NNS o
changed VBD N
18.0 CD N
% NN N
for IN N
pioglitazone NN i
and CC N
-7.9 CD N
% NN N
for IN N
glimepiride NN i
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
QUICKI NNP N
values VBZ N
changed VBD N
a DT N
respective JJ N
0.013 CD N
and CC N
-0.007 NNP N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
FSI NNP N
values NNS N
were VBD N
-21.1 NNP N
and CC N
15.1 CD N
pmol/L NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Both DT N
drugs NNS N
were VBD N
well RB N
tolerated VBN o
, , N
with IN N
pioglitazone NN i
associated VBN N
with IN N
more RBR N
peripheral JJ o
edema NN o
( ( N
number NN N
of IN N
treatment-emergent JJ N
cases NNS N
: : N
35/121 CD N
[ $ N
28.9 CD N
% NN N
] NNP N
vs NN N
17/123 CD N
[ JJ N
13.8 CD N
% NN N
] NN N
; : N
P NNP N
= NNP N
0.005 CD N
) ) N
and CC N
fewer JJR N
hypoglycemic JJ o
episodes NNS o
( ( N
19 CD N
[ RB N
15.7 CD N
% NN N
] NNP N
vs NN N
38 CD N
[ JJ N
30.9 CD N
% NN N
] NN N
; : N
P NNP N
= NNP N
0.024 CD N
) ) N
. . N

The DT N
incidence NN N
of IN N
weight JJ o
gain NN o
was VBD N
not RB N
significantly RB N
different JJ N
between IN N
treatment NN N
groups NNS N
. . N

CONCLUSIONS NNP N
These DT N
data NNS N
suggest VBP N
that IN N
long-term JJ N
treatment NN N
with IN N
pioglitazone NN i
enhances NNS N
insulin VBP N
sensitivity NN N
relative VBP N
to TO N
glimepiride VB i
in IN N
Mexican JJ p
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
and CC N
that IN N
pioglitazone NN i
may MD N
have VB N
a DT N
more RBR N
sustained JJ N
antihyperglycemic JJ N
effect NN N
. . N

-DOCSTART- -21266651- O O

Factors NNS N
predictive VBP N
of IN N
severe JJ o
hypoglycemia NN o
in IN N
type NN p
1 CD p
diabetes NNS p
: : p
analysis NN N
from IN N
the DT N
Juvenile NNP N
Diabetes NNP N
Research NNP N
Foundation NNP N
continuous JJ N
glucose JJ N
monitoring VBG N
randomized VBN N
control NN N
trial NN N
dataset NN N
. . N

OBJECTIVE NNP N
Identify NNP N
factors NNS N
predictive VBP N
of IN N
severe JJ o
hypoglycemia NN o
( ( o
SH NNP o
) ) o
and CC N
assess VB N
the DT N
clinical JJ o
utility NN o
of IN N
continuous JJ o
glucose JJ o
monitoring NN o
( ( o
CGM NNP o
) ) o
to TO N
warn VB N
of IN N
impending VBG N
SH NNP N
. . N

RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
In IN N
a DT N
multicenter NN p
randomized VBN N
clinical JJ N
trial NN N
, , N
436 CD p
children NNS p
and CC p
adults NNS p
with IN p
type JJ p
1 CD p
diabetes NNS p
were VBD N
randomized VBN N
to TO N
a DT N
treatment NN N
group NN N
that WDT N
used VBD N
CGM NNP i
( ( N
N NNP N
= NNP N
224 CD N
) ) N
, , N
or CC N
a DT N
control NN i
group NN N
that WDT N
used VBD N
standard JJ i
home NN i
blood NN i
glucose JJ i
monitoring NN i
( ( N
N NNP N
= NNP N
212 CD N
) ) N
and CC N
completed VBD N
12 CD N
months NNS N
of IN N
follow-up NN N
. . N

After IN N
6 CD N
months NNS N
, , N
the DT N
original JJ N
control NN N
group NN N
initiated VBD N
CGM NNP i
while IN N
the DT N
treatment NN N
group NN N
continued VBD N
use NN N
of IN N
CGM NNP N
for IN N
6 CD N
months NNS N
. . N

Baseline NNP N
risk NN N
factors NNS N
for IN N
SH NNP N
were VBD N
evaluated VBN N
over IN N
12 CD N
months NNS N
of IN N
follow-up JJ N
using VBG N
proportional JJ N
hazards NNS N
regression NN N
. . N

CGM-derived JJ o
indices NNS o
of IN o
hypoglycemia NN o
were VBD N
used VBN N
to TO N
predict VB N
episodes NNS N
of IN N
SH NNP N
over IN N
a DT N
24-h JJ N
time NN N
horizon NN N
. . N

RESULTS VB N
The DT N
SH NNP o
rate NN o
was VBD N
17.9 CD N
per IN N
100 CD N
person-years NNS N
, , N
and CC N
a DT N
higher JJR N
rate NN o
was VBD N
associated VBN N
with IN N
the DT N
occurrence NN N
of IN N
SH NNP o
in IN N
the DT N
prior JJ N
6 CD N
months NNS N
and CC N
female JJ N
sex NN N
. . N

SH NNP o
frequency NN o
increased VBD N
eightfold RB N
when WRB N
30 CD N
% NN N
of IN N
CGM NNP o
values NNS o
were VBD N
? . N
70 CD N
mg/dL NN N
on IN N
the DT N
prior JJ N
day NN N
( ( N
4.5 CD N
vs. FW N
0.5 CD N
% NN N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
but CC N
the DT o
positive JJ o
predictive JJ o
value NN o
( ( o
PPV NNP o
) ) o
was VBD o
low JJ N
( ( N
< JJ N
5 CD N
% NN N
) ) N
. . N

Results NNS N
were VBD N
similar JJ N
for IN o
hypoglycemic JJ o
area NN o
under IN o
the DT o
curve NN o
and CC o
the DT o
low JJ o
blood NN o
glucose NN o
index NN o
calculated VBN o
by IN N
CGM NNP o
. . o

CONCLUSIONS NNP o
SH NNP o
in IN o
the DT N
6 CD N
months NNS N
prior RB N
to TO N
the DT N
study NN N
was VBD N
the DT N
strongest JJS N
predictor NN N
of IN N
SH NNP o
during IN o
the DT N
study NN o
. . o

CGM-measured JJ o
hypoglycemia NN o
over IN o
a DT N
24-h JJ N
span NN N
is VBZ N
highly RB N
associated VBN N
with IN o
SH NNP o
the DT o
following JJ N
day NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
but CC N
the DT o
PPV NNP o
is VBZ o
low JJ N
. . N

-DOCSTART- -5653418- O O

One-trial JJ o
learning VBG o
with IN p
control NN p
of IN p
item-difficulty NN i
. . i

-DOCSTART- -25367544- O O

Parent-implemented JJ i
social JJ i
intervention NN i
for IN N
toddlers NNS p
with IN p
autism NN p
: : p
an DT N
RCT NNP N
. . N

OBJECTIVES NNP N
To TO N
compare VB N
the DT N
effects NNS N
of IN N
two CD N
9-month JJ N
parent-implemented JJ i
interventions NNS i
within IN N
the DT N
Early JJ i
Social NNP i
Interaction NNP i
( ( i
ESI NNP i
) ) i
Project NN i
. . i

Both DT N
individual-ESI JJ i
, , N
offered VBD N
2 CD N
or CC N
3 CD N
times NNS N
per IN N
week NN N
at IN N
home NN N
or CC N
in IN N
the DT N
community NN N
, , N
and CC N
group-ESI NN i
, , N
offered VBN N
once RB N
per IN N
week NN N
in IN N
a DT N
clinic NN N
, , N
taught VBD N
parents NNS N
how WRB N
to TO N
embed VB i
strategies NNS i
to TO i
support VB i
social JJ i
communication NN i
throughout IN N
everyday JJ N
activities NNS N
. . N

METHODS NNP N
Participants NNPS N
in IN N
the DT N
randomized NN N
controlled VBD N
trial NN N
included VBD N
82 CD p
children NNS p
diagnosed VBN p
with IN p
autism NN p
spectrum NN p
disorder NN p
at IN p
16 CD p
to TO p
20 CD p
months NNS p
. . p

Children NNP N
were VBD N
matched VBN N
on IN N
pretreatment NN N
nonverbal JJ N
developmental JJ N
level NN N
and CC N
pairs NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
treatment NN N
condition NN N
. . N

Child NNP N
outcomes VBZ N
included JJ N
measures NNS N
of IN N
social JJ o
communication NN o
, , o
autism NN o
symptoms NNS o
, , o
adaptive JJ o
behavior NN o
, , o
and CC o
developmental JJ o
level NN o
. . o

Child NNP N
outcomes NNS N
are VBP N
reported VBN N
from IN N
baseline NN N
to TO N
the DT N
end NN N
of IN N
the DT N
9-month JJ N
interventions NNS N
. . N

RESULTS NNP N
Children NNP N
in IN N
individual-ESI NN i
showed VBD N
differential JJ N
change NN N
on IN N
a DT N
standardized JJ N
examiner-administered JJ N
observational JJ N
measure NN N
of IN N
social JJ N
communication NN N
, , N
as IN N
they PRP N
improved VBD N
at IN N
a DT N
faster JJR N
rate NN N
than IN N
children NNS N
in IN N
group-ESI NN i
. . i

Individual-ESI NNP i
also RB N
showed VBD N
differential JJ N
efficacy NN N
on IN N
a DT N
parent NN N
report NN N
measure NN N
of IN N
communication NN o
, , o
daily JJ o
living NN o
, , o
and CC o
social JJ o
skills NNS o
, , N
as IN N
they PRP N
showed VBD N
improvement NN N
or CC N
stability NN N
, , N
whereas IN N
group-ESI NN i
led VBD N
to TO N
worsening VBG N
or CC N
no DT N
significant JJ N
change NN N
on IN N
these DT N
skills NNS N
. . N

Finally RB N
, , N
individual-ESI JJ i
showed VBD N
differential JJ N
change NN N
on IN N
examiner-administered JJ N
measures NNS N
of IN N
receptive JJ o
language NN o
skills NNS o
, , N
as IN N
children NNS N
in IN N
individual-ESI NN N
improved VBN N
significantly RB N
, , N
whereas IN N
group-ESI JJ i
showed VBD N
no DT N
change NN N
. . N

CONCLUSIONS NNP N
These DT N
findings NNS N
support VBP N
the DT N
efficacy NN N
of IN N
individual-ESI JJ i
compared VBN N
with IN N
group-ESI NN i
on IN N
child NN N
outcomes NNS N
, , N
suggesting VBG N
the DT N
importance NN N
of IN N
individualized JJ i
parent NN i
coaching NN i
in IN N
natural JJ N
environments NNS N
. . N

The DT N
efficacy NN N
of IN N
a DT N
parent-implemented JJ i
intervention NN i
using VBG N
little JJ N
professional JJ N
time NN N
has VBZ N
potential JJ N
for IN N
community NN N
viability NN N
, , N
which WDT N
is VBZ N
particularly RB N
important JJ N
in IN N
light NN N
of IN N
the DT N
lack NN N
of IN N
main JJ N
effects NNS N
on IN N
child NN N
outcomes NNS N
of IN N
most JJS N
other JJ N
parent-implemented JJ i
interventions NNS i
. . i

-DOCSTART- -24958585- O O

Caregiver-mediated JJ N
intervention NN i
for IN N
low-resourced JJ p
preschoolers NNS p
with IN p
autism NN p
: : p
an DT N
RCT NNP N
. . N

OBJECTIVES NNP N
To TO N
compare VB N
2 CD N
short-term JJ N
, , N
community NN i
caregiver RB i
training NN i
interventions NNS i
for IN N
preschool-aged JJ p
children NNS p
with IN p
Autism NNP p
Spectrum NNP p
Disorder NNP p
who WP p
had VBD p
low JJ p
resources NNS p
. . p

Low NNP N
resource NN N
was VBD N
defined VBN N
by IN N
the DT N
US NNP N
Department NNP N
of IN N
Housing NNP N
and CC N
Urban NNP N
Development NNP N
low-income JJ N
index NN N
or CC N
1 CD N
indicator NN o
, , N
( ( N
e.g. UH N
, , N
Medicaid NNP N
eligibility NN N
) ) N
. . N

Child NNP N
outcomes NNS N
focused VBD N
on IN N
joint JJ N
engagement NN o
, , N
joint JJ N
attention NN N
, , N
and CC N
play NN N
. . N

METHODS NNP N
Participants NNP p
included VBD p
112 CD p
families NNS p
of IN p
a DT p
child NN p
who WP p
had VBD p
Autism NNP p
Spectrum NNP p
Disorder NNP p
who WP p
met VBD p
criteria NNS p
for IN p
being VBG p
low-resourced JJ p
and CC p
who WP p
were VBD p
randomly RB p
assigned VBN p
to TO p
1 CD p
of IN p
2 CD i
3-month JJ i
interventions NNS i
, , i
group NN i
caregiver NN o
education NN i
or CC i
individualized VBN i
caregiver-mediated JJ i
intervention NN i
( ( i
CMM NNP i
) ) i
. . i

Children NNP N
were VBD N
assessed VBN N
for IN N
social JJ N
communication NN N
skills NNS N
pre- JJ o
and CC o
post-treatment JJ o
, , N
and CC N
followed VBD N
up RB N
at IN N
3 CD N
months NNS N
. . N

RESULTS NNP N
All NNP N
children NNS N
improved VBN N
in IN N
joint JJ o
engagement NN o
and CC o
initiating VBG o
joint JJ o
attention NN o
, , N
with IN N
significantly RB N
greater JJR N
improvement NN N
by IN N
the DT N
CMM NNP i
group NN N
. . N

Outcomes CC N
on IN N
play NN o
skills NNS o
were VBD N
mixed JJ N
, , N
with IN N
improvement NN N
of IN N
symbolic JJ o
play NN o
for IN N
the DT N
CMM NNP N
group NN N
and CC N
no DT N
change NN N
in IN N
functional JJ o
play NN o
skills NNS o
. . o

Joint JJ N
engagement NN N
maintained VBD N
over IN N
time NN N
for IN N
the DT N
CMM NNP i
group NN N
, , N
and CC N
initiating VBG N
joint JJ N
attention NN N
maintained VBD N
for IN N
both DT N
groups NNS N
over IN N
time NN N
. . N

CONCLUSIONS VB N
This DT N
study NN N
is VBZ N
among IN N
the DT N
first JJ N
randomized JJ N
trials NNS N
comparing VBG N
2 CD N
active JJ N
interventions NNS N
with IN N
a DT N
large JJ N
sample NN N
of IN N
low-resourced JJ p
families NNS p
. . p

Results NNP N
suggest JJ N
improvements NNS N
in IN N
core NN N
autism NN N
deficits NNS N
of IN N
joint JJ N
engagement NN N
, , N
joint JJ o
attention NN o
, , N
and CC N
symbolic JJ N
play NN N
with IN N
relatively RB N
brief JJ N
, , N
caregiver-mediated JJ o
interventions NNS N
, , N
but CC N
additional JJ N
support NN N
is VBZ N
necessary JJ N
to TO N
maintain VB N
and CC N
generalize VB N
these DT N
gains NNS N
over IN N
time NN N
. . N

-DOCSTART- -17472838- O O

Efficacy NN o
and CC o
safety NN o
of IN N
a DT N
very-low-protein JJ i
diet NN i
when WRB N
postponing VBG p
dialysis NN p
in IN p
the DT p
elderly JJ p
: : p
a DT N
prospective JJ N
randomized VBN N
multicenter NN N
controlled VBN N
study NN N
. . N

BACKGROUND NNP N
A NNP N
supplemented VBD i
very-low-protein JJ i
diet NN i
( ( i
sVLPD NN i
) ) i
seems VBZ N
to TO N
be VB N
safe JJ o
when WRB N
postponing VBG N
dialysis NN N
therapy NN N
. . N

STUDY NNP N
DESIGN NNP N
Prospective NNP N
multicenter NN N
randomized VBD N
controlled VBN N
study NN N
designed VBN N
to TO N
assess VB N
the DT N
noninferiority NN N
of IN N
diet JJ i
versus JJ N
dialysis NN i
in IN N
1-year JJ N
mortality NN N
assessed VBN N
by IN N
using VBG N
intention-to-treat JJ i
and CC N
per-protocol JJ N
analysis NN N
. . N

SETTING NNP N
& CC N
PARTICIPANTS NNP N
Italian JJ p
uremic JJ p
patients NNS p
without IN p
diabetes NNS p
older JJR p
than IN p
70 CD p
years NNS p
with IN p
glomerular JJ p
filtration NN p
rate NN p
of IN p
5 CD p
to TO p
7 CD p
mL/min NN p
( ( p
0.08 CD p
to TO p
0.12 CD p
mL/s NN p
) ) p
. . p

INTERVENTION NNP N
Randomization NNP N
to TO N
an DT N
sVLPD NN i
( ( i
diet JJ i
group NN i
) ) i
or CC N
dialysis NN i
. . i

The DT N
sVLPD NN i
is VBZ N
a DT N
vegan JJ N
diet NN N
( ( N
35 CD N
kcal NN N
; : N
proteins NNS N
, , N
0.3 CD N
g/kg NN N
body NN N
weight VBD N
daily RB N
) ) N
supplemented VBD N
with IN N
keto-analogues NNS N
, , N
amino JJ N
acids NNS N
, , N
and CC N
vitamins NNS N
. . N

Patients NNS N
following VBG N
an DT N
sVLPD NN i
started VBD N
dialysis NN i
therapy NN i
in IN N
the DT N
case NN N
of IN N
malnutrition NN N
, , N
intractable JJ N
fluid NN N
overload NN N
, , N
hyperkalemia NN N
, , N
or CC N
appearance NN N
of IN N
uremic JJ N
symptoms NNS N
. . N

OUTCOMES NNP N
& CC N
MEASUREMENTS NNP N
Mortality NNP o
, , o
hospitalization NN o
, , o
and CC o
metabolic JJ o
markers NNS o
. . o

RESULTS VB N
56 CD p
patients NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
each DT N
group NN N
, , N
median JJ N
follow-up NN N
was VBD N
26.5 CD N
months NNS N
( ( N
interquartile JJ N
range NN N
, , N
40 CD N
) ) N
, , N
and CC N
patients NNS N
in IN N
the DT N
diet JJ i
group NN i
spent VBD N
a DT N
median NN N
of IN N
10.7 CD N
months NNS N
( ( N
interquartile JJ N
range NN N
, , N
11 CD N
) ) N
following VBG N
an DT N
sVLPD NN i
. . i

Forty CD N
patients NNS N
in IN N
the DT N
diet JJ N
group NN N
started VBD N
dialysis NN i
treatment NN i
because IN N
of IN N
either DT N
fluid JJ o
overload NN o
or CC o
hyperkalemia NN o
. . o

There EX N
were VBD N
31 CD N
deaths NNS N
( ( N
55 CD N
% NN N
) ) N
in IN N
the DT N
dialysis NN i
group NN i
and CC N
28 CD N
deaths NNS o
( ( N
50 CD N
% NN N
) ) N
in IN N
the DT N
diet JJ i
group NN i
. . i

One-year JJ o
observed JJ o
survival NN o
rates NNS o
at IN N
intention NN N
to TO N
treat VB N
were VBD N
83.7 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
74.5 CD N
to TO N
94.0 CD N
) ) N
in IN N
the DT N
dialysis NN i
group NN N
versus VBD N
87.3 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
78.9 CD N
to TO N
96.5 CD N
) ) N
in IN N
the DT N
diet JJ i
group NN N
( ( N
log-rank JJ N
test NN N
for IN N
noninferiority NN N
, , N
P NNP N
< NNP N
0.001 CD N
; : N
for IN N
superiority NN N
, , N
P NNP N
= NNP N
0.6 CD N
) ) N
: : N
the DT N
difference NN N
in IN N
survival NN o
was VBD N
-3.6 JJ N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
-17 NNP N
to TO N
+10 VB N
; : N
P NNP N
= NNP N
0.002 CD N
) ) N
. . N

The DT o
hazard NN o
ratio NN o
for IN o
hospitalization NN o
was VBD N
1.50 CD N
for IN N
the DT N
dialysis NN i
group NN i
( ( N
95 CD N
% NN N
CI NNP N
, , N
1.11 CD N
to TO N
2.01 CD N
; : N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

LIMITATIONS VB N
The DT N
unblinded JJ N
nature NN N
of IN N
the DT N
study NN N
, , N
exclusion NN N
of IN N
patients NNS N
with IN N
diabetes NNS N
, , N
and CC N
incomplete JJ N
enrollment NN N
. . N

CONCLUSION NNP N
An DT N
sVLPD NN i
was VBD N
effective JJ o
and CC o
safe JJ o
when WRB N
postponing VBG N
dialysis NN N
treatment NN N
in IN N
elderly JJ p
patients NNS p
without IN p
diabetes NNS p
. . p

-DOCSTART- -22348801- O O

Virtual JJ i
reality NN i
for IN N
acute NN N
pain NN N
reduction NN N
in IN N
adolescents NNS p
undergoing VBG p
burn NN p
wound NN p
care NN p
: : p
a DT N
prospective JJ N
randomized NN N
controlled VBD N
trial NN N
. . N

BACKGROUND NNP N
Effective NNP N
pain NN i
management NN i
remains VBZ N
a DT N
challenge NN N
for IN N
adolescents NNS p
during IN p
conscious JJ p
burn NN p
wound NN p
care NN p
procedures NNS p
. . p

Virtual JJ i
reality NN i
( ( i
VR NNP i
) ) i
shows VBZ N
promise NN N
as IN N
a DT N
non-pharmacological JJ N
adjunct NN N
in IN N
reducing VBG N
pain NN N
. . N

AIMS VB N
This DT N
study NN N
assessed VBD N
off-the-shelf JJ i
VR NNP i
for IN N
( ( N
1 CD N
) ) N
its PRP$ N
effect NN N
on IN N
reducing VBG N
acute JJ N
pain NN N
intensity NN N
during IN N
adolescent JJ N
burn NN N
wound NN N
care NN N
, , N
and CC N
( ( N
2 CD N
) ) N
its PRP$ N
clinical JJ N
utility NN N
in IN N
a DT N
busy JJ N
hospital NN N
setting NN N
. . N

METHODS NNP N
Forty-one CD p
adolescents NNS p
( ( p
11-17 CD p
years NNS p
) ) p
participated VBD N
in IN N
this DT N
prospective JJ N
randomized NN N
controlled VBD N
trial NN N
. . N

Acute NNP N
pain NN N
outcomes NNS N
including VBG N
adolescent JJ N
self-report NN N
, , N
nursing VBG N
staff NN N
behavioral JJ N
observation NN N
, , N
caregiver NN N
observation NN N
and CC N
physiological JJ N
measures NNS N
were VBD N
collected VBN N
. . N

Length NNP N
of IN N
procedure NN N
times NNS N
and CC N
adolescent JJ N
reactions NNS N
were VBD N
also RB N
recorded VBN N
to TO N
inform VB N
clinical JJ N
utility NN N
. . N

RESULTS NNP N
Nursing JJ N
staff NN N
reported VBD N
a DT N
statistically RB N
significant JJ N
reduction NN N
in IN N
pain NN o
scores NNS o
during IN N
dressing VBG N
removal NN N
, , N
and CC N
significantly RB N
less JJR N
rescue JJ o
doses NNS o
of IN o
Entonox NNP o
given VBN N
to TO N
those DT N
receiving VBG N
VR NNP i
, , N
compared VBN N
to TO N
those DT N
receiving VBG N
standard JJ N
distraction NN N
. . N

For IN N
all DT N
other JJ N
pain NN N
outcomes NNS N
and CC N
length NN N
of IN N
treatment NN N
, , N
there EX N
was VBD N
a DT N
trend NN N
for IN N
lower JJR N
pain NN o
scores NNS o
and CC o
treatment NN o
times NNS o
for IN N
those DT N
receiving VBG N
VR NNP i
, , N
but CC N
these DT N
differences NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
. . N

CONCLUSION NNP N
Despite IN N
only RB N
minimal JJ N
pain NN N
reduction NN N
achieved VBD N
using VBG N
off-the-shelf JJ N
VR NNP i
, , N
other JJ N
results NNS N
from IN N
this DT N
trial NN N
and CC N
previous JJ N
research NN N
on IN N
younger JJR N
children NNS N
with IN N
burns NNS N
suggest VBP N
a DT N
customized JJ N
, , N
adolescent JJ N
and CC N
hospital JJ N
friendly JJ N
device NN N
may MD N
be VB N
more RBR N
effective JJ N
in IN N
pain NN N
reduction NN N
. . N

-DOCSTART- -3116609- O O

[ JJ i
Bupivacaine-CO2 NNP i
and CC i
bupivacaine-HCl NN i
at IN N
various JJ N
injection NN N
temperatures NNS N
in IN N
peridural JJ i
anesthesia NN i
for IN N
extracorporeal NN N
shock NN N
wave VBP N
lithotripsy VBN N
] NNP N
. . N

INTRODUCTION NNP N
The DT N
effect NN N
of IN N
different JJ N
injection NN N
temperatures NNS N
on IN N
carbonated JJ i
anesthetics NNS i
has VBZ N
been VBN N
controversial JJ N
since IN N
1965 CD N
. . N

The DT N
current JJ N
study NN N
was VBD N
undertaken VBN N
to TO N
determine VB N
onset JJ o
times NNS o
of IN o
sensory NN o
and CC o
motor NN o
blockade NN o
after IN N
epidural JJ i
anesthesia NN i
with IN N
0.5 CD N
% NN N
bupivacaine-CO2 JJ i
and CC N
0.5 CD N
% NN N
bupivacaine-HCl NN i
at IN N
various JJ N
injection NN N
temperatures NNS N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
The DT N
study NN N
was VBD N
performed VBN N
on IN N
90 CD p
ASA NNP p
class NN p
I-II NNP p
urologic JJ p
patients NNS p
during IN p
extracorporeal JJ i
shock NN i
wave NN i
lithotripsy NN i
. . i

The DT N
patients NNS N
were VBD N
randomized VBN N
in IN N
six CD N
groups NNS N
to TO N
receive VB N
either RB N
0.5 CD N
% NN N
bupivacaine-CO2 NN i
or CC N
0.5 CD N
% NN N
bupivacaine-HCl NN i
at IN N
temperatures NNS N
of IN N
4 CD N
degrees NNS N
, , N
20 CD N
degrees NNS N
, , N
or CC N
36 CD N
degrees NNS N
C. NNP N
The DT N
six CD p
groups NNS p
were VBD N
comparable JJ N
in IN N
age NN N
, , N
height NN N
, , N
and CC N
weight NN N
. . N

Epidural JJ i
anesthesia NN i
was VBD N
performed VBN N
at IN N
the DT N
L2-3 NNP N
interspace NN N
with IN N
an DT N
18-gauge JJ i
Tuohy NNP i
needle MD N
using VBG N
loss NN N
of IN N
resistance NN N
. . N

A DT N
catheter NN N
was VBD N
advanced JJ N
4 CD N
cm NN N
in IN N
the DT N
epidural JJ N
space NN N
and CC N
4 CD N
ml NNS N
0.5 CD N
% NN N
bupivacaine NN i
with IN i
adrenaline JJ i
1:200,000 CD N
was VBD N
given VBN N
as IN N
a DT N
test NN N
dose NN N
. . N

After IN N
4 CD N
min VBD N
the DT N
full JJ N
anesthetic JJ N
dose NN N
, , N
based VBN N
on IN N
body NN N
size NN N
, , N
was VBD N
injected VBN N
with IN N
the DT N
patient JJ N
supine NN N
. . N

Sensory NNP o
blockade NN o
was VBD N
determined VBN N
by IN N
the DT N
pinprick NN N
method NN N
and CC N
motor NN o
blockade NN o
by IN N
the DT N
Bromage NNP N
method NN N
at IN N
2-min JJ N
intervals NNS N
for IN N
the DT N
first JJ N
20 CD N
min NN N
, , N
at IN N
5-min JJ N
intervals NNS N
for IN N
the DT N
next JJ N
10 CD N
min NN N
, , N
and CC N
then RB N
every DT N
15 CD N
min NN N
to TO N
a DT N
total NN N
of IN N
240 CD N
min NN N
. . N

Statistical JJ N
analysis NN N
was VBD N
done VBN N
by IN N
the DT N
Mann-Whitney NNP N
test NN N
, , N
with IN N
P NNP N
less JJR N
than IN N
0.05 CD N
considered VBN N
significant JJ N
. . N

RESULTS NNP N
Spread NNP o
of IN o
sensory NN o
blockade NN o
was VBD N
significantly RB N
faster RBR N
with IN N
bupivacaine-CO2 JJ i
and CC N
-HCl NN i
at IN N
a DT N
temperature NN N
of IN N
36 CD N
degrees NNS N
C NNP N
as IN N
compared VBN N
to TO N
4 CD N
degrees NNS N
or CC N
20 CD N
degrees NNS N
C NNP N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
( ( N
Figs NNP N
. . N

1 CD N
, , N
2 CD N
and CC N
Table NNP N
2 CD N
) ) N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -8198938- O O

Trimetazidine NN i
: : i
a DT N
new JJ N
concept NN N
in IN N
the DT N
treatment NN N
of IN N
angina NN N
. . N

Comparison NNP N
with IN N
propranolol NN i
in IN N
patients NNS N
with IN N
stable JJ p
angina NN p
. . p

Trimetazidine JJ N
European JJ N
Multicenter NNP N
Study NNP N
Group NNP N
. . N

1 CD N
. . N

Trimetazidine NN i
has VBZ N
a DT N
direct JJ N
anti-ischaemic JJ o
effect NN o
on IN N
the DT N
myocardium NN N
without IN N
altering VBG N
the DT N
rate NN o
x JJ o
pressure NN o
product NN o
or CC N
coronary JJ o
blood NN o
flow NN o
. . o

2 CD N
. . N

The DT N
effects NNS N
of IN N
trimetazidine NN i
( ( N
20 CD N
mg NN N
three CD N
times NNS N
daily RB N
) ) N
were VBD N
compared VBN N
with IN N
those DT N
of IN N
propranolol NN i
( ( N
40 CD N
mg NN N
three CD N
times NNS N
daily RB N
) ) N
in IN N
a DT N
double-blind JJ N
parallel NN N
group NN N
multicentre VBD N
study NN N
in IN N
149 CD p
men NNS p
with IN p
stable JJ p
angina NN p
. . p

3 CD N
. . N

Reproducibility NN N
of IN N
exercise NN N
performance NN N
was VBD N
verified VBN N
during IN N
a DT N
3 CD N
week NN N
run-in JJ N
placebo NN N
washout IN N
period NN N
. . N

All DT N
patients NNS N
had VBD N
> JJ N
1 CD N
mm JJ N
ST-depression NN N
on IN N
exercise NN N
test NN N
. . N

4 CD N
. . N

After IN N
3 CD N
months NNS N
, , N
similar JJ N
anti-anginal JJ o
efficacy NN o
was VBD N
observed VBN N
between IN N
the DT N
trimetazidine NN i
( ( N
n JJ N
= NNP N
71 CD N
) ) N
and CC N
propranolol NN i
( ( N
n JJ N
= NNP N
78 CD N
) ) N
groups NNS N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
observed VBN N
between IN N
trimetazidine NN i
and CC N
propranolol NN i
as IN N
regards NNS N
anginal JJ o
attack NN o
rate NN o
per IN o
week NN o
( ( N
mean JJ N
difference NN N
P-TMZ NN N
: : N
2 CD N
; : N
95 CD N
% NN N
CI NNP N
: : N
-4.4 NN N
, , N
0.5 CD N
) ) N
and CC N
exercise NN o
duration NN o
( ( N
mean JJ N
difference NN N
P-TMZ NN N
: : N
0 CD N
s NN N
; : N
95 CD N
% NN N
CI NNP N
: : N
-33 NN N
, , N
34 CD N
) ) N
or CC N
time NN N
to TO N
1 CD N
mm NNS N
ST NNP o
segment NN o
depression NN o
( ( N
mean JJ N
difference NN N
P-TMZ NN N
: : N
13 CD N
s NN N
; : N
95 CD N
% NN N
CI NNP N
: : N
-24 NN N
, , N
51 CD N
) ) N
. . N

Heart NNP o
rate NN o
and CC o
rate NN o
x JJ o
pressure NN o
product NN o
at IN o
rest NN o
and CC N
at IN N
peak JJ N
exercise NN N
remained VBD N
unchanged JJ N
in IN N
the DT N
trimetazidine NN i
group NN N
but CC N
significantly RB N
decreased VBN N
with IN N
propranolol NN i
( ( N
P NNP N
< VBZ N
0.001 CD N
in IN N
all DT N
cases NNS N
) ) N
. . N

With IN N
both DT N
drugs NNS N
there EX N
was VBD N
a DT N
trend NN N
to TO N
decreased VBN N
ischaemic JJ o
episodes NNS o
in IN N
the DT N
46 CD N
% NN N
patients NNS N
who WP N
experienced VBD N
ambulatory JJ N
ischaemia NN N
on IN N
Holter NNP N
monitoring NN N
. . N

Six CD N
patients NNS N
stopped VBD N
trimetazidine NN i
and CC N
12 CD N
propranolol NN i
. . i

Of IN N
these DT N
, , N
five CD N
in IN N
each DT N
group NN N
were VBD N
withdrawn VBN o
because IN N
of IN N
deterioration NN N
in IN N
cardiovascular JJ N
status NN N
. . N

5 CD N
. . N

The DT N
results NNS N
suggest VBP N
that IN N
trimetazidine NN N
and CC N
propranolol NN N
at IN N
the DT N
doses NNS N
studied VBN N
have VBP N
similar JJ N
efficacy NN N
in IN N
patients NNS N
with IN N
stable JJ N
angina JJ N
pectoris NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -8801151- O O

Intraumbilical JJ N
vein NN N
injection NN N
of IN N
prostaglandin NN i
F2 NNP i
alpha NN i
in IN N
retained JJ p
placenta NN p
. . p

A DT N
randomized JJ N
protocol NN N
was VBD N
used VBN N
to TO N
study VB N
the DT N
effect NN N
of IN N
intraumbilical JJ i
prostaglandin NN i
F2 NNP i
alpha NN i
( ( i
Hembate NNP i
, , i
Upjohn NNP i
) ) i
and CC N
oxytocin JJ i
injection NN i
in IN N
women NNS p
with IN p
retained JJ p
placenta NN p
. . p

Prostaglandin NNP i
F2 NNP i
alpha NN i
, , i
20 CD i
mg NN i
, , i
diluted VBD i
to TO i
20 CD i
ml NNS i
in IN i
normal JJ i
saline JJ i
solution NN i
( ( p
10 CD p
women NNS p
, , p
group NN p
1 CD p
) ) p
, , N
30 CD i
IU NNP i
of IN i
oxytocin NN i
, , i
diluted VBD i
to TO i
20 CD i
ml NNS i
in IN i
normal JJ i
saline JJ i
solution NN i
( ( p
11 CD p
women NNS p
, , p
group NN p
2 CD p
) ) p
, , N
or CC N
20 CD i
ml NNS i
of IN i
normal JJ i
saline JJ i
solution NN i
alone RB i
( ( p
7 CD p
women NNS p
, , p
group NN p
3 CD p
) ) p
, , N
were VBD N
injected VBN N
into IN N
the DT N
umbilical JJ N
vein NN N
1 CD N
h NN N
after IN N
delivery NN N
. . N

Nine NNP p
women NNS p
( ( p
group NN p
4 CD p
, , p
controls NNS p
) ) p
underwent VBP p
manual JJ p
removal NN p
of IN p
the DT p
retained JJ p
placenta NN p
. . p

In IN N
group NN N
1 CD N
, , N
placental JJ o
expulsion NN o
occurred VBD N
in IN N
all DT N
patients NNS N
and CC N
the DT N
duration NN o
of IN o
the DT o
placental JJ o
expulsion NN o
after IN o
prostaglandin NN o
F2 NNP o
alpha NN o
injection NN o
was VBD N
6.8 CD N
+/- JJ N
1.36 CD N
( ( N
mean JJ N
+/- NNP N
SE NNP N
) ) N
min NN N
: : N
in IN N
group NN N
2 CD N
, , N
six CD N
placental JJ o
expulsions NNS o
occurred VBD N
after IN N
13.3 CD N
+/- JJ N
1.97 CD N
min NN N
( ( N
mean JJ N
+/- NNP N
SE NNP N
) ) N
; : N
and CC N
in IN N
group NN N
3 CD N
, , N
no DT N
effect NN N
was VBD N
recorded VBN N
after IN N
intraumbilical JJ N
saline NN N
injection NN N
. . N

We PRP N
suggest VBP N
that DT N
intraumbilical JJ N
vein NN N
injection NN N
of IN N
prostaglandin NN i
F2 NNP i
alpha NN i
might MD N
be VB N
a DT N
beneficial JJ N
, , N
non-surgical JJ N
method NN N
for IN N
treating VBG N
retained VBN N
placenta NN N
. . N

Oxytocin CC i
might MD N
reduce VB N
the DT N
incidence NN o
of IN o
manual JJ o
lysis NN o
of IN o
the DT o
placenta NN o
and CC N
achieve VBP N
partial JJ N
success NN N
. . N

-DOCSTART- -21610189- O O

Do VB N
sheltered VBD i
workshops NNS i
enhance VB N
employment NN o
outcomes NNS o
for IN N
adults NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
? . N
This DT N
study NN N
investigated VBD N
whether IN N
sheltered VBN i
workshops NNS i
help VBP N
prepare VB N
individuals NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
for IN N
competitive JJ o
employment NN o
within IN N
the DT N
community NN N
. . N

Two CD N
groups NNS N
of IN N
individuals NNS N
were VBD N
compared VBN N
: : N
( ( p
a DT p
) ) p
215 CD p
supported VBN p
employees NNS p
who WP p
were VBD p
in IN p
sheltered JJ i
workshops NNS i
prior RB p
to TO p
entering VBG p
supported JJ p
employment NN p
and CC p
( ( p
b NN p
) ) p
215 CD p
supported VBN p
employees NNS p
who WP p
were VBD p
not RB i
in IN i
sheltered JJ i
workshops NNS i
. . i

Individuals NNS N
from IN N
both DT N
groups NNS N
were VBD N
matched VBN N
based VBN N
on IN N
their PRP$ N
primary JJ N
diagnosis NN N
, , N
secondary JJ N
diagnosis NN N
( ( N
if IN N
present NN N
) ) N
, , N
and CC N
gender NN N
. . N

Results NNS N
showed VBD N
that IN N
there EX N
were VBD N
no DT N
differences NNS N
in IN N
rates NNS o
of IN o
employment NN o
between IN N
these DT N
two CD N
groups NNS N
. . N

However RB N
, , N
individuals NNS N
who WP N
participated VBD N
in IN N
sheltered JJ i
workshops NNS i
earned VBD o
significantly RB o
less JJR o
( ( N
US NNP N
$ $ N
129.36 CD N
versus NN N
US NNP N
$ $ N
191.42 CD N
per IN N
week NN N
) ) N
, , N
and CC N
cost NN o
significantly RB o
more RBR o
to TO N
serve VB N
( ( N
US NNP N
$ $ N
6,065.08 CD N
versus NN N
US NNP N
$ $ N
2,440.60 CD N
) ) N
, , N
than IN N
their PRP$ N
non-sheltered JJ i
workshop NN i
peers NNS N
. . N

Results NNS N
presented VBD N
here RB N
suggest VBP N
that IN N
individuals NNS p
with IN p
ASD NNP p
achieve VBP N
better RBR o
vocational JJ o
outcomes NNS o
if IN N
they PRP N
do VBP N
not RB N
participate VB N
in IN N
sheltered JJ N
workshops NNS N
prior RB N
to TO N
enrolling VBG N
in IN N
supported JJ N
employment NN N
. . N

-DOCSTART- -2968595- O O

[ JJ N
Effects NNS N
of IN N
simvastatin NN i
on IN N
plasma NN o
lipids NNS o
, , o
lipoproteins NNS o
and CC N
apoproteins NNS o
( ( N
A1 NNP N
and CC N
B NNP N
) ) N
. . N

24 CD N
cases NNS N
of IN N
major JJ N
primary JJ N
hypercholesterolemia NN p
] NN p
. . N

We PRP N
studied VBD N
the DT N
effects NNS N
of IN N
simvastatin NN i
( ( i
MK NNP i
733 CD i
) ) i
, , N
a DT N
new JJ N
competitive JJ N
inhibitor NN N
of IN N
HMG NNP i
CoA NNP i
reductase NN i
, , i
alone RB i
and CC i
in IN i
combination NN i
with IN i
a DT i
bile JJ i
acid NN i
sequestrant NN i
, , i
cholestyramine NN i
, , N
on IN N
serum NN N
levels NNS N
of IN N
lipoproteins NNS N
and CC N
apoproteins NNS N
A1 NNP N
and CC N
B NNP N
, , N
in IN N
24 CD p
patients NNS p
with IN p
familial JJ p
hypercholesterolemia NN p
. . p

After IN N
simvastatin JJ i
treatment NN i
( ( N
40 CD N
mg/day NN N
) ) N
alone RB N
for IN N
12 CD N
weeks NNS N
, , N
serum JJ N
total NN N
and CC N
low JJ o
density NN o
lipoprotein NN o
cholesterol NN o
decreased VBN N
by IN N
31 CD N
and CC N
36 CD N
percent NN N
respectively RB N
. . N

With IN N
the DT N
addition NN N
of IN N
cholestyramine NN i
, , N
there EX N
was VBD N
a DT N
41 CD N
per IN N
cent NN N
total JJ N
decrease NN N
in IN N
serum NN o
cholesterol NN o
from IN N
the DT N
control NN N
value NN N
and CC N
a DT N
50 CD N
percent NN N
decrease NN N
in IN N
low JJ o
density NN o
lipoprotein NN o
cholesterol NN o
. . o

After IN N
cholestyramine JJ i
treatment NN i
alone RB N
for IN N
12 CD N
weeks NNS N
, , N
serum JJ o
total NN o
and CC o
low JJ o
density NN o
lipoprotein NN o
cholesterol NN o
decreased VBN N
by IN N
20 CD N
percent NN N
and CC N
29 CD N
percent NN N
respectively RB N
. . N

With IN N
the DT N
addition NN N
of IN N
simvastatin NN i
( ( N
20 CD N
mg NNS N
per IN N
day NN N
) ) N
, , N
there EX N
was VBD N
a DT N
32 CD N
percent NN N
total JJ N
decrease NN N
in IN N
serum NN o
cholesterol NN o
from IN N
the DT N
control NN N
value NN N
and CC N
a DT N
43 CD N
percent NN N
decrease NN N
in IN N
low JJ N
density NN o
lipoprotein NN o
cholesterol NN o
. . o

High JJ o
density NN o
lipoprotein VBP o
cholesterol NN o
remained VBD N
unchanged JJ N
. . N

No DT N
major JJ o
adverse JJ o
effect NN o
was VBD N
observed VBN N
. . N

If IN N
long JJ N
term NN N
safety NN N
can MD N
be VB N
confirmed VBN N
, , N
the DT N
simvastatin-cholestyramine JJ i
regimen NNS i
may MD N
prove VB N
useful JJ N
in IN N
heterozygous JJ p
familial JJ p
hypercholesterolemia NN p
. . p

-DOCSTART- -9734727- O O

Aspartame NN i
: : i
neuropsychologic JJ N
and CC N
neurophysiologic JJ N
evaluation NN N
of IN N
acute NN N
and CC N
chronic JJ N
effects NNS N
. . N

BACKGROUND NNP N
Neurobehavioral NNP N
symptoms NNS N
have VBP N
been VBN N
reported VBN N
anecdotally RB N
with IN N
aspartame NN i
. . i

OBJECTIVE CC N
This DT N
study NN N
sought VBD N
to TO N
determine VB N
whether IN N
aspartame NN i
can MD N
disrupt VB p
cognitive JJ p
, , p
neurophysiologic JJ p
, , p
or CC p
behavioral JJ p
functioning NN p
in IN p
normal JJ p
individuals NNS p
. . p

DESIGN NNP N
Forty-eight NNP p
healthy JJ p
volunteers NNS p
completed VBD N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
crossover NN N
study NN N
. . N

The DT N
first JJ N
month NN N
was VBD N
aspartame JJ i
free JJ N
. . N

Subjects NNS N
then RB N
consumed VBD N
sodas NNS i
and CC i
capsules NNS i
with IN i
placebo NN i
, , i
aspartame NN i
, , i
or CC i
sucrose VB i
for IN i
20 CD i
d JJ i
each DT i
. . i

Order NN N
was VBD N
randomized VBN N
and CC N
subjects NNS N
were VBD N
assigned VBN N
to TO N
either VB N
a DT N
high- NN N
( ( N
45 CD N
mg NN N
x NNP N
kg VBZ N
body NN N
wt NN N
( ( N
-1 NNP N
) ) N
x VBP N
d NN N
( ( N
-1 NNP N
) ) N
) ) N
or CC N
low- JJ N
( ( N
15 CD N
mg NN N
x NNP N
kg VBZ N
body NN N
wt NN N
( ( N
-1 NNP N
) ) N
x VBP N
d NN N
( ( N
-1 NNP N
) ) N
) ) N
dose VBP N
aspartame JJ i
group NN N
. . N

Neuropsychologic NNP N
and CC N
laboratory JJ N
testing NN N
was VBD N
done VBN N
on IN N
day NN N
10 CD N
of IN N
each DT N
treatment NN N
period NN N
to TO N
determine VB N
possible JJ N
acute JJ N
effects NNS N
and CC N
on IN N
day NN N
20 CD N
for IN N
possible JJ N
chronic JJ N
effects NNS N
. . N

RESULTS NNP N
Plasma NNP N
phenylalanine JJ N
concentrations NNS N
increased VBD N
significantly RB N
during IN N
aspartame JJ N
treatment NN N
. . N

Neuropsychologic NNP N
results NNS N
; : N
adverse JJ N
experiences NNS N
; : N
amino NN N
acid NN N
, , N
insulin NN N
, , N
and CC N
glucose JJ N
values NNS N
; : N
and CC N
electroencephalograms NNS N
were VBD N
compared VBN N
by IN N
sex NN N
and CC N
by IN N
treatment NN N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
for IN N
any DT N
dependent JJ N
measure NN N
. . N

CONCLUSION NNP N
Large NNP N
daily JJ N
doses NNS N
of IN N
aspartame NN i
had VBD N
no DT N
effect NN N
on IN N
neuropsychologic NN N
, , N
neurophysiologic JJ N
, , N
or CC N
behavioral JJ N
functioning NN N
in IN N
healthy JJ p
young JJ p
adults NNS p
. . p

-DOCSTART- -3059450- O O

Comparison NNP N
of IN N
5-aminosalicylic JJ i
acid NN i
( ( N
3 CD N
g NN N
) ) N
and CC N
prednisolone JJ i
phosphate NN i
sodium NN i
enemas NN N
( ( N
30 CD N
mg NN N
) ) N
in IN N
the DT N
treatment NN N
of IN N
distal JJ o
ulcerative JJ o
colitis NN o
. . o

A DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
trial NN N
. . N

Twenty-nine JJ p
patients NNS p
with IN p
attacks NNS p
of IN p
distal JJ p
ulcerative JJ p
colitis NN p
were VBD N
treated VBN N
randomly RB N
with IN N
3 CD N
g JJ N
5-aminosalicylic JJ i
acid NN i
( ( i
5-ASA JJ i
) ) i
or CC N
30 CD N
mg NN N
of IN N
prednisolone NN i
phosphate NN i
sodium NN i
( ( i
PP NNP i
) ) i
enemas NN N
( ( N
40 CD N
ml NN N
) ) N
. . N

Endoscopic NNP o
, , o
clinical JJ o
, , o
and CC o
histologic JJ o
improvement NN o
were VBD N
comparable JJ N
in IN N
the DT N
two CD N
treatment NN N
groups NNS N
. . N

Our PRP$ N
study NN N
showed VBD N
that IN N
topical JJ N
treatment NN N
with IN N
5-ASA JJ i
is VBZ N
as RB N
efficacious JJ N
as IN N
PP NNP i
in IN N
improving VBG N
distal JJ o
ulcerative JJ o
colitis NN o
. . o

-DOCSTART- -24981013- O O

The DT N
impact NN N
of IN N
the DT N
amount NN N
of IN N
social JJ i
evaluation NN i
on IN N
psychobiological JJ N
responses NNS N
to TO N
a DT N
body NN p
image NN p
threat NN p
. . p

The DT N
present JJ N
study NN N
examined VBD N
the DT N
impact NN N
of IN N
amount NN N
of IN N
social-evaluative JJ N
body NN N
image NN N
threat NN N
on IN N
psychobiological JJ N
responses NNS N
. . N

Women NNP p
( ( p
N=123 NNP p
) ) p
were VBD p
randomized VBN p
into IN p
an DT p
individual-threat JJ p
, , p
group-threat JJ p
or CC p
no-threat JJ p
condition NN p
. . p

Participants NNS N
completed VBD N
a DT N
measure NN N
of IN N
state NN i
body NN i
shame NN i
and CC N
provided VBD N
a DT N
sample NN N
of IN N
saliva NN N
( ( N
to TO N
assess VB N
cortisol NN N
) ) N
at IN N
baseline NN N
and CC N
following VBG N
their PRP$ N
condition NN N
. . N

Both DT N
threat NN N
conditions NNS N
had VBD N
higher JJR N
baseline-adjusted JJ N
body NN N
shame NN N
following VBG N
the DT N
threat NN N
compared VBN N
to TO N
the DT N
no-threat JJ N
condition NN N
; : N
however RB N
, , N
no DT N
difference NN N
on IN N
baseline-adjusted JJ N
body NN N
shame NN N
between IN N
the DT N
threat NN N
conditions NNS N
was VBD N
found VBN N
. . N

The DT N
same JJ N
pattern NN N
of IN N
results NNS N
was VBD N
found VBN N
for IN N
cortisol NN N
- : N
both DT N
threat NN N
conditions NNS N
had VBD N
higher JJR N
baseline-adjusted JJ N
response NN N
cortisol NN N
than IN N
the DT N
no-threat JJ N
condition NN N
, , N
with IN N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
threat NN N
groups NNS N
. . N

Findings NNS N
suggest VBP N
that IN N
the DT N
magnitude NN N
of IN N
psychobiological JJ N
responses NNS N
to TO N
a DT N
social-evaluative JJ N
body NN N
image NN N
threat NN N
does VBZ N
not RB N
differ VB N
with IN N
the DT N
amount NN N
of IN N
social-evaluative JJ N
threat NN N
( ( N
individual- JJ N
versus IN N
group-threat NN N
) ) N
. . N

These DT N
findings NNS N
provide VBP N
insight RB N
into IN N
the DT N
context NN N
of IN N
body NN N
image NN N
threats NNS N
of IN N
women NNS p
. . p

-DOCSTART- -18852963- O O

Development NNP N
of IN N
autistic JJ p
children NNS p
based VBN N
on IN N
maternal JJ N
responses NNS N
to TO N
the DT N
Autism NNP N
Behavior NNP N
Checklist NNP N
. . N

BACKGROUND NNP N
language NN i
and CC i
speech-language JJ i
intervention NN i
. . i

AIM NNP N
to TO N
evaluate VB N
the DT N
development NN N
process NN N
of IN N
autistic JJ p
children NNS p
, , N
in IN N
a DT N
direct JJ i
and CC i
indirect JJ i
intervention NN i
context NN N
based VBN N
on IN N
the DT N
responses NNS N
of IN N
mothers NNS N
to TO N
the DT N
Autism NNP N
Behavior NNP N
Checklist NNP N
. . N

METHOD NNP N
the DT N
research NN N
sample NN N
consisted VBD N
of IN N
11 CD p
mothers NNS p
of IN p
children NNS p
diagnosed VBN p
, , p
according VBG p
to TO p
the DT p
criteria NNS p
established VBN p
by IN p
the DT p
DSM NNP p
IVtr NNP p
( ( p
APA NNP p
, , p
2002 CD p
) ) p
, , p
with IN p
autism NN p
( ( p
six CD p
) ) p
and CC p
with IN p
Asperger NNP p
Syndrome NNP p
( ( p
five CD p
) ) p
and CC p
who WP p
were VBD p
seen VBN p
at IN p
the DT p
Investigation NNP p
Laboratory NNP p
of IN p
Global NNP p
Developmental NNP p
Disorders NNP p
of IN p
the DT p
Federal NNP p
University NNP p
of IN p
S?o NNP p
Paulo NNP p
. . p

These DT N
children NNS N
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
: : N
Six CD N
were VBD N
receiving VBG i
both DT i
direct JJ i
and CC i
indirect JJ i
intervention NN i
( ( i
TG NNP i
) ) i
, , i
and CC N
five CD N
were VBD N
receiving VBG i
indirect JJ i
intervention NN i
exclusively RB i
( ( N
OG NNP N
) ) N
. . N

The DT o
Autism NNP o
Behavior NNP o
Checklist NNP o
( ( N
Krug NNP N
et RB N
al. RB N
, , N
1993 CD N
) ) N
was VBD N
used VBN N
, , N
adapted VBD N
to TO N
the DT p
Portuguese JJ p
language NN p
by IN N
Marteleto NNP N
( ( N
2003 CD N
) ) N
. . N

This DT N
behavior JJ N
checklist NN N
( ( N
57 CD N
items NNS N
) ) N
allows VBZ N
the DT N
detailed JJ N
description NN N
of IN o
non-adaptable JJ o
characteristics NNS o
regarding VBG N
the DT N
following JJ N
areas NNS o
: : o
sensory NN o
, , o
use NN o
of IN o
the DT o
body NN o
and CC o
object NN o
, , o
Language NNP o
, , o
Psycho-social NNP o
and CC o
Relational NNP o
. . o

The DT N
questionnaire NN N
was VBD N
filled VBN N
in IN N
during IN N
an DT N
interview NN N
on IN N
three CD N
occasions NNS N
: : N
at IN N
the DT N
beginning NN N
of IN N
intervention NN N
, , N
after IN N
six CD N
months NNS N
and CC N
at IN N
the DT N
end NN N
of IN N
12 CD N
months NNS N
. . N

RESULTS NNP N
after IN N
statistical JJ N
analysis NN N
it PRP N
was VBD N
observed VBN N
that IN N
there EX N
was VBD N
a DT N
greater JJR N
development NN N
in IN N
the DT o
total JJ o
scores NNS o
and CC o
in IN o
the DT o
areas NNS o
of IN o
language NN o
, , o
psycho-social JJ o
and CC o
relational JJ o
for IN o
the DT o
TG NNP o
. . o

This DT N
suggests VBZ N
a DT N
greater JJR N
development NN N
pattern NN N
during IN N
the DT N
studied JJ N
period NN N
for IN N
this DT N
group NN N
. . N

CONCLUSION NNP N
the DT p
mothers NNS p
of IN N
both DT N
groups NNS N
observed VBD o
behavioral JJ o
changes NNS o
. . o

The DT N
better JJR N
scores NNS N
observed VBD N
for IN N
the DT N
TG NNP N
is VBZ N
probably RB N
related VBN N
to TO N
the DT N
effectiveness NN N
of IN N
direct JJ N
intervention NN N
, , N
and CC N
not RB N
to TO N
the DT N
lack NN N
of IN N
attention NN N
of IN p
parents NNS p
in IN N
the DT i
OG NNP i
in IN N
recognizing VBG N
behavioral JJ N
changes NNS N
in IN N
their PRP$ N
children NNS N
. . N

-DOCSTART- -2663834- O O

The DT N
effects NNS N
of IN N
haloperidol NN i
on IN N
discrimination NN o
learning NN o
and CC o
behavioral JJ o
symptoms NNS o
in IN N
autistic JJ p
children NNS p
. . p

This DT N
double-blind JJ N
and CC N
placebo-controlled JJ i
clinical JJ N
trial NN N
in IN N
autistic JJ p
children NNS p
had VBD N
three CD N
objectives NNS N
: : N
( ( N
a DT N
) ) N
to TO N
replicate VB N
earlier JJR N
findings NNS N
that IN N
haloperidol JJ i
administration NN N
is VBZ N
associated VBN N
with IN N
a DT N
significant JJ N
reduction NN N
of IN N
behavioral JJ o
symptoms NNS o
; : o
( ( N
b NN N
) ) N
to TO N
further JJ N
assess NN N
its PRP$ N
safety NN o
when WRB N
given VBN N
on IN N
a DT N
short-term JJ N
basis NN N
; : N
and CC N
( ( N
c NN N
) ) N
to TO N
assess VB N
whether IN N
it PRP N
has VBZ N
an DT N
effect NN o
on IN o
discrimination NN o
learning NN o
. . o

Forty-five JJ p
children NNS p
, , p
2.02 CD p
to TO p
7.58 CD p
years NNS p
old JJ p
( ( p
M NNP p
= NNP p
4.49 CD p
) ) p
, , N
completed VBD N
this DT N
crossover NN N
design NN N
, , N
with IN N
random JJ N
assignment NN N
to TO N
treatment NN N
sequences NNS N
. . N

Haloperidol NNP i
was VBD N
shown VBN N
to TO N
be VB N
a DT N
powerful JJ N
therapeutic JJ N
agent NN N
when WRB N
administered VBN N
for IN N
4 CD N
weeks NNS N
and CC N
free JJ N
of IN N
side JJ o
effects NNS o
; : o
at IN N
doses NNS N
ranging VBG N
from IN N
0.25 CD N
to TO N
4.0 CD N
mg/day NN N
( ( N
M NNP N
= NNP N
0.844 CD N
) ) N
, , N
there EX N
was VBD N
a DT N
clinically RB N
and CC N
statistically RB N
significant JJ N
reduction NN N
of IN N
a DT N
variety NN o
of IN o
symptoms NNS o
. . o

Under IN N
the DT N
given VBN N
conditions NNS N
, , N
the DT N
children NNS N
failed VBD N
to TO N
learn VB N
on IN N
either DT N
haloperidol NN i
or CC N
placebo NN i
. . i

-DOCSTART- -26691535- O O

Cost-effectiveness JJ o
analysis NN o
of IN N
a DT N
communication-focused JJ i
therapy NN i
for IN N
pre-school JJ p
children NNS p
with IN p
autism NN p
: : p
results NNS N
from IN N
a DT N
randomised VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Autism NNP N
is VBZ N
associated VBN N
with IN N
impairments NNS N
that WDT N
have VBP N
life-time JJ N
consequences NNS N
for IN N
diagnosed JJ N
individuals NNS N
and CC N
a DT N
substantial JJ N
impact NN N
on IN N
families NNS N
. . N

There EX N
is VBZ N
growing VBG N
interest NN N
in IN N
early JJ N
interventions NNS N
for IN N
children NNS N
with IN N
autism NN N
, , N
yet RB N
despite IN N
the DT N
substantial JJ N
economic JJ N
burden NN N
, , N
there EX N
is VBZ N
little JJ N
evidence NN N
of IN N
the DT N
cost-effectiveness NN N
of IN N
such JJ N
interventions NNS N
with IN N
which WDT N
to TO N
support VB N
resource NN N
allocation NN N
decisions NNS N
. . N

This DT N
study NN N
reports VBZ N
an DT N
economic JJ N
evaluation NN N
of IN N
a DT N
parent-mediated JJ i
, , i
communication-focused JJ i
therapy NN i
carried VBD N
out IN N
within IN N
the DT N
Pre-School JJ i
Autism NNP i
Communication NNP i
Trial NNP i
( ( i
PACT NNP i
) ) i
. . i

METHODS $ N
152 CD p
pre-school JJ p
children NNS p
with IN p
autism NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
treatment NN i
as IN i
usual JJ i
( ( i
TAU NNP i
) ) i
or CC i
PACT NNP i
+ NNP i
TAU NNP i
. . i

Primary NNP i
outcome NN N
was VBD N
severity NN N
of IN N
autism NN N
symptoms NNS N
at IN N
13-month JJ N
follow-up NN o
. . o

Economic NNP o
data NN o
included VBD o
health NN o
, , o
education NN o
and CC o
social JJ o
services NNS o
, , o
childcare NN o
, , o
parental JJ o
productivity NN o
losses NNS o
and CC o
informal JJ o
care NN o
. . o

RESULTS NNP o
Clinically NNP o
meaningful JJ o
symptom NN o
improvement NN o
was VBD o
evident JJ N
for IN N
53 CD N
% NN N
of IN N
PACT NNP i
+ NNP i
TAU NNP i
versus VBD i
41 CD N
% NN N
of IN N
TAU NNP i
( ( N
odds NNS N
ratio VBP N
1.91 CD N
, , N
p NN N
= NNP N
0.074 CD o
) ) o
. . o

Service NNP o
costs NNS o
were VBD o
significantly RB i
higher JJR i
for IN i
PACT NNP i
+ NNP i
TAU NNP i
( ( N
mean JJ N
difference NN N
?4,489 NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
but CC N
the DT N
difference NN N
in IN N
societal JJ o
costs NNS o
was VBD o
smaller JJR N
and CC N
non-significant JJ N
( ( N
mean JJ N
difference NN N
?1,385 NN N
, , N
p NN N
= NNP N
0.788 CD N
) ) N
due NN N
to TO N
lower VB N
informal JJ N
care NN N
rates NNS N
for IN i
PACT NNP i
+ NNP i
TAU NNP i
. . N

CONCLUSIONS NNP N
Improvements NNPS N
in IN N
outcome NN N
generated VBN i
by IN i
PACT NNP i
come VBP N
at IN N
a DT N
cost NN N
. . N

Although IN N
this DT N
cost NN N
is VBZ N
lower JJR N
when WRB N
burden NN N
on IN N
parents NNS N
is VBZ N
included VBN N
, , N
the DT N
cost NN N
and CC N
effectiveness JJ N
results NNS N
presented VBN N
do VBP N
not RB N
support VB N
the DT N
cost-effectiveness NN N
of IN i
PACT NNP i
+ NNP i
TAU NNP i
compared VBN i
to TO i
TAU NNP i
alone RB i
. . i

TRIAL NNP i
REGISTRATION NNP i
Current NNP N
Controlled NNP N
Trials NNP N
ISRCTN58133827 NNP N
. . N

-DOCSTART- -17934527- O O

Rehabilitation NN i
of IN N
therapy-related JJ N
cognitive JJ N
deficits NNS N
in IN N
patients NNS p
after IN p
hematopoietic JJ p
stem NN p
cell NN p
transplantation NN p
. . p

Neuropsychological JJ N
deficits NNS N
are VBP N
potential JJ N
side NN N
effects NNS N
of IN N
hematopoietic JJ i
stem NN i
cell NN i
therapy NN i
( ( i
HSCT NNP i
) ) i
. . i

Systematic JJ N
data NNS N
on IN N
the DT N
long-term JJ N
course NN N
of IN N
and CC N
therapeutic JJ N
options NNS N
for IN N
these DT N
consequences NNS N
are VBP N
limited VBN N
. . N

One CD p
hundred VBD p
fifty-seven JJ p
patients NNS p
were VBD p
screened VBN p
for IN p
cognitive JJ p
deficits NNS p
following VBG p
HSCT NNP i
for IN p
malignant JJ p
diseases NNS p
at IN p
an DT p
in-patient JJ p
oncologic NN p
rehabilitation NN p
clinic NN p
. . p

Patients NNS p
showing VBG p
evidence NN p
of IN p
impairment NN p
were VBD p
randomly RB p
assigned VBN p
to TO p
one CD p
of IN p
two CD p
training VBG p
groups NNS p
: : p
individualized VBN i
PC-supported JJ i
training NN i
or CC i
neuropsychological JJ i
group NN i
therapy NN i
. . i

The DT p
control NN p
group NN p
consisted VBD p
of IN p
patients NNS p
who WP p
received VBD p
no DT i
specific JJ i
training NN i
. . i

During IN N
in-patient JJ N
rehabilitation NN N
, , N
the DT N
results NNS o
of IN o
a DT o
comprehensive JJ o
neuropsychological JJ o
test NN o
battery NN o
improved VBD N
significantly RB N
in IN N
all DT N
three CD N
groups NNS N
, , N
and CC N
no DT N
specific JJ N
intervention NN N
effects NNS N
were VBD N
identified VBN N
. . N

Neuropsychological JJ o
deficits NNS o
were VBD N
still RB N
evident JJ N
in IN N
a DT N
subgroup NN N
of IN N
patients NNS N
6 CD N
months NNS N
later RB N
. . N

Correlation NN o
between IN o
neuropsychological JJ o
testing NN o
and CC o
patients NNS o
' POS o
self-evaluation NN o
of IN o
cognitive JJ o
functioning NN o
in IN o
daily JJ o
life NN o
was VBD N
generally RB N
low JJ N
. . N

Sustained VBN o
attention NN o
and CC o
verbal-semantic JJ o
memory NN o
played VBD N
the DT N
main JJ N
role NN N
for IN N
self-appraisal JJ N
and CC N
in IN N
the DT N
designation NN N
as IN N
'neuropsychologically RB N
impaired VBN N
' '' N
. . N

In IN N
conclusion NN N
, , N
a DT N
substantial JJ N
number NN N
of IN N
patients NNS N
revealed JJ N
evidence NN N
of IN N
cognitive JJ N
deficits NNS N
a DT N
long JJ N
time NN N
after IN N
HSCT NNP i
. . i

There EX N
is VBZ N
a DT N
need NN N
for IN N
more JJR N
studies NNS N
and CC N
for IN N
the DT N
development NN N
of IN N
differentiated JJ N
rehabilitative JJ N
measures NNS N
for IN N
such JJ N
therapeutic JJ N
consequences NNS N
. . N

-DOCSTART- -16167251- O O

[ JJ N
Usage NN N
of IN N
titanoreine NN i
after IN N
procedure NN p
for IN p
prolapse NN p
and CC p
hemorrhoids NNS p
] NNP p
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
titanoreine NN i
on IN N
early JJ N
postoperative NN N
symptoms NNS N
after IN N
procedure NN N
for IN N
prolapse NN N
and CC N
hemorrhoids NNS N
( ( N
PPH NNP N
) ) N
. . N

METHODS NNP N
From IN p
November NNP p
2002 CD p
to TO p
July NNP p
2003 CD p
, , p
80 CD p
patients NNS p
who WP p
received VBD p
PPH NNP p
were VBD N
randomly RB N
divided VBN N
in IN N
to TO N
titanoreine VB i
group NN N
( ( N
n=42 CC N
) ) N
and CC N
control VB i
group NN i
without IN i
titanoreine NN i
( ( N
n=38 JJ N
) ) N
. . N

Symptom JJ o
relief NN o
was VBD N
recorded VBN N
24 CD N
hours NNS N
, , N
6 CD N
days NNS N
and CC N
12 CD N
days NNS N
after IN N
PPH NNP N
, , N
urine JJ o
retention NN o
24h CD N
after IN N
PPH NNP N
, , N
first RB o
stool JJ o
time NN o
, , o
wound IN o
healing VBG o
time NN o
, , o
mean JJ o
hospital NN o
stay NN o
were VBD N
also RB N
recorded VBN N
. . N

RESULTS VB N
The DT N
score NN o
of IN o
symptom NN o
was VBD N
lower JJR N
in IN N
titanoreine NN i
group NN N
( ( N
4.4 CD N
) ) N
than IN N
that DT N
in IN N
the DT N
control NN N
group NN N
( ( N
6.1 CD N
) ) N
24 CD N
hours NNS N
after IN N
PPH NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
but CC N
no DT N
significant JJ N
difference NN N
in IN N
symptom NN o
grade NN o
was VBD N
found VBN N
between IN N
the DT N
two CD N
groups NNS N
6 CD N
days NNS N
and CC N
12 CD N
days NNS N
after IN N
PPH NNP N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

Decrements NNS o
of IN o
symptom NN o
grade NN o
were VBD N
lower JJR N
in IN N
titanoreine NN i
group NN N
than IN N
those DT N
of IN N
control NN N
group NN N
at IN N
any DT N
point NN N
after IN N
PPH NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
urine JJ o
retention NN o
rate NN o
and CC o
mean JJ o
hospital NN o
stay NN o
between IN N
two CD N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
Titanoreine NNP i
can MD N
effectively RB N
relieve VB o
the DT N
early JJ N
postoperative NN N
symptoms NNS N
after IN N
PPH NNP N
. . N

-DOCSTART- -10080319- O O

Masticatory JJ N
performance NN N
and CC N
chewing VBG N
experience NN N
with IN N
implant-retained JJ p
mandibular JJ p
overdentures NNS p
. . p

The DT N
relationship NN N
between IN N
masticatory NN N
performance NN N
and CC N
chewing VBG N
experience NN N
has VBZ N
not RB N
yet RB N
been VBN N
explored VBN N
for IN N
patients NNS p
with IN p
implant-retained JJ i
overdentures NNS i
. . i

Although IN N
many JJ N
relationships NNS N
have VBP N
been VBN N
found VBN N
between IN N
parameters NNS N
of IN N
objective JJ N
and CC N
subjective JJ N
oral JJ N
function NN N
, , N
the DT N
structure NN N
of IN N
these DT N
relationships NNS N
remain VBP N
unclear JJ N
. . N

Therefore RB N
, , N
we PRP N
studied VBD N
in IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
the DT N
relationship NN N
between IN N
the DT N
comminution NN N
of IN N
an DT N
artificial JJ N
test NN N
food NN N
, , N
i.e NN i
. . i

masticatory JJ o
performance NN o
, , o
and CC o
the DT o
subjective JJ o
chewing NN o
experience NN o
. . o

The DT N
trial NN N
involved VBD N
a DT N
comparison NN N
between IN N
two CD N
groups NNS N
receiving VBG N
implant JJ i
treatment NN i
and CC i
one CD i
group NN i
receiving VBG i
conventional JJ i
complete JJ i
dentures NNS i
( ( i
CD NN i
) ) i
. . i

The DT N
implant JJ N
treatment NN N
involved VBN N
either CC N
a DT N
mainly RB N
implant-supported JJ i
mandibular JJ i
overdenture NN i
on IN N
a DT N
transmandibular JJ i
implant NN i
( ( i
TMI NNP i
) ) i
or CC N
an DT N
implant-tissue-supported JJ i
mandibular JJ i
overdenture NN i
on IN N
two CD N
IMZ JJ i
implants NNS i
( ( i
IMZ NNP i
) ) i
. . i

Masticatory JJ o
performance NN o
as RB o
well RB o
as IN o
chewing VBG o
experience NN o
were VBD N
substantially RB N
better JJR N
for IN N
the DT N
implant-retained JJ N
overdentures NNS N
compared VBN N
with IN N
the DT N
complete JJ N
denture NN N
group NN N
. . N

No DT N
significant JJ N
differences NNS N
emerged VBD N
between IN N
the DT N
TMI NNP i
and CC N
the DT N
IMZ NNP i
group NN N
. . N

A DT N
multiple JJ N
regression NN N
analysis NN N
did VBD N
not RB N
provide VB N
any DT N
comprehensibility NN N
in IN N
the DT N
relationship NN N
between IN N
masticatory NN o
performance NN o
and CC o
the DT o
variables NNS o
of IN o
chewing VBG o
experience NN o
. . o

In IN N
the DT N
linear JJ N
structural JJ N
relation NN N
analysis NN N
( ( N
LISREL NNP N
) ) N
no DT N
direct JJ N
relationship NN N
was VBD N
found VBN N
between IN N
masticatory JJ o
performance NN o
and CC o
functional JJ o
complaints NNS o
mandibular JJ o
denture NN o
. . o

The DT N
results NNS N
show VBP N
that IN N
an DT N
improvement NN N
in IN N
masticatory JJ N
performance NN N
does VBZ N
not RB N
imply VB N
the DT N
same JJ N
improvement NN N
in IN N
chewing VBG N
experience NN N
and CC N
vice NN N
versa NN N
. . N

-DOCSTART- -10754477- O O

The DT N
GH NNP N
response NN N
to TO N
low-dose JJ i
bolus JJ i
growth NN i
hormone-releasing VBG i
hormone NN i
( ( i
GHRH NNP i
( ( i
1-29 JJ i
) ) i
NH2 NNP i
) ) i
is VBZ N
attenuated VBN N
in IN N
patients NNS p
with IN p
longstanding JJ p
post-irradiation NN p
GH NNP p
insufficiency NN p
. . p

OBJECTIVE NNP N
Previous JJ N
studies NNS N
have VBP N
suggested VBN N
that IN N
post-irradiation NN N
GH NNP N
insufficiency NN N
results NNS N
from IN N
a DT N
loss NN N
of IN N
GHRH NNP N
secretion NN N
, , N
since IN N
many JJ N
patients NNS N
were VBD N
able JJ N
to TO N
release VB N
GH NNP N
following VBG N
exogenous JJ N
GHRH NNP N
stimulation NN N
. . N

However RB N
, , N
supramaximal JJ i
doses NNS i
of IN i
GHRH NNP i
were VBD N
used VBN N
and CC N
the DT N
response NN N
may MD N
decline VB N
with IN N
time NN N
after IN N
radiotherapy NN i
. . i

We PRP N
re-evaluated VBD N
the DT N
GHRH NNP i
dose-response JJ N
curve NN N
in IN N
patients NNS p
post VBP p
cranial JJ p
irradiation NN p
and CC p
in IN p
controls NNS p
. . p

DESIGN NNP N
Randomized NNP N
controlled VBD N
study NN N
. . N

METHODS NNP N
Five CD p
adult NN p
male NN p
long-term JJ p
survivors NNS p
of IN p
childhood NN p
brain NN p
tumours NNS p
( ( p
median JJ p
age NN p
21.8 CD p
years NNS p
( ( p
18.4-26.7 JJ p
) ) p
; : p
13.7 CD p
years NNS p
( ( p
11.4-15.7 JJ p
) ) p
post-radiotherapy NN p
, , p
> NNP p
30Gy CD p
) ) p
and CC p
five CD p
matched VBN p
controls NNS p
were VBD p
studied VBN p
. . p

An DT N
intravenous JJ N
bolus NN N
of IN N
GHRH NNP i
( ( i
1-29 JJ i
) ) i
NH NNP i
( ( i
2 CD i
) ) i
was VBD N
administered VBN N
in IN N
doses NNS N
at IN N
the DT N
lower JJR N
( ( N
0.05 CD N
microg/kg NN N
) ) N
and CC N
upper JJ N
( ( N
0.15 CD N
microg/kg NN N
) ) N
range NN N
of IN N
the DT N
dose-response JJ N
curves NNS N
for IN N
young JJ p
males NNS p
, , N
as RB N
well RB N
as IN N
the DT N
standard NN N
supramaximal NN N
dose NN N
( ( N
1 CD N
. . N

0 CD N
microg/kg NN N
) ) N
. . N

GH NNP o
was VBD N
measured VBN N
before IN N
stimulation NN N
, , N
every DT N
2min CD N
for IN N
the DT N
first JJ N
hour NN N
and CC N
every DT N
5min CD N
for IN N
the DT N
second JJ N
hour NN N
. . N

All DT N
studies NNS N
were VBD N
conducted VBN N
in IN N
a DT N
random JJ N
fashion NN N
. . N

RESULTS NNP N
Significantly NNP o
lower JJR o
peak NN o
and CC o
area NN o
under IN o
the DT o
curve NN o
( ( o
AUC NNP o
) ) o
GH NNP o
concentrations NNS o
occurred VBD N
in IN N
the DT N
irradiated JJ N
group NN N
using VBG N
0.15 CD N
microg/kg NN N
( ( N
median JJ N
peak NN N
Irradiated NNP N
, , N
4 CD N
. . N

5mU/l CD N
vs NN N
median NN N
Controls NNP N
, , N
37.4mU/l CD N
; : N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
1.0 CD N
microg/kg NN N
( ( N
median JJ N
peak NN N
Irradiated NNP N
, , N
4.8mU/l CD N
vs NN N
median NN N
Controls NNP N
, , N
15.2mU/l CD N
; : N
P NNP N
< VBD N
0 CD N
. . N

05 CD N
) ) N
GHRH NNP N
( ( N
1-29 JJ N
) ) N
NH NNP N
( ( N
2 CD N
) ) N
. . N

In IN N
irradiated JJ N
subjects NNS N
there EX N
was VBD N
an DT N
incremental JJ N
rise NN o
in IN o
GH NNP o
output NN o
with IN N
increasing VBG N
doses NNS N
of IN N
GHRH NNP i
( ( i
1-29 JJ i
) ) i
NH NNP i
( ( i
2 CD i
) ) i
( ( i
median JJ i
AUC NNP N
: : N
122mU/l.min CD N
vs NN N
179mU/l.min CD N
vs NN N
268mU/l.min CD N
; : N
P=0.007 NNP N
) ) N
reflecting VBG N
altered VBN N
pituitary JJ o
sensitivity NN o
and CC o
reduced JJ o
responsiveness NN o
. . o

CONCLUSION VB N
The DT N
GH NNP N
response NN N
to TO N
bolus VB N
GHRH NNP i
( ( i
1-29 JJ i
) ) i
NH NNP i
( ( i
2 CD i
) ) i
is VBZ N
attenuated VBN N
in IN N
adult JJ p
long-term JJ p
survivors NNS p
of IN p
childhood NN p
brain NN p
tumours NN p
. . p

This DT N
may MD N
reflect VB N
direct JJ N
pituitary JJ N
damage NN N
and/or VBD N
the DT N
loss NN N
of IN N
the DT N
tropic NN N
effects NNS N
of IN N
chronic JJ N
GHRH NNP N
deficiency NN N
. . N

-DOCSTART- -25296247- O O

Nicardipine NNP i
is VBZ N
superior JJ N
to TO N
esmolol VB i
for IN N
the DT N
management NN N
of IN N
postcraniotomy NN p
emergence NN p
hypertension NN o
: : o
a DT N
randomized JJ N
open-label NN N
study NN N
. . N

BACKGROUND NNP N
Emergence NNP N
hypertension NN o
after IN p
craniotomy NN p
is VBZ N
a DT N
well-documented JJ N
phenomenon NN N
for IN N
which WDT N
natural JJ N
history NN N
is VBZ N
poorly RB N
understood JJ N
. . N

Most JJS N
clinicians NNS N
attribute VBP N
this DT N
phenomenon NN N
to TO N
an DT N
acute NN N
and CC N
transient JJ N
increase NN N
in IN N
catecholamine JJ N
release NN N
, , N
but CC N
other JJ N
mechanisms NNS N
such JJ N
as IN N
neurogenic JJ N
hypertension NN N
or CC N
activation NN N
of IN N
the DT N
renin-angiotensin-aldosterone NN N
system NN N
have VBP N
also RB N
been VBN N
proposed VBN N
. . N

In IN N
this DT N
open-label JJ N
study NN N
, , N
we PRP N
compared VBN N
the DT N
monotherapeutic JJ N
antihypertensive JJ N
efficacy NN N
of IN N
the DT N
2 CD N
most RBS N
titratable JJ N
drugs NNS N
used VBN N
to TO N
treat VB N
postcraniotomy JJ N
emergence NN N
hypertension NN N
: : N
nicardipine NN i
and CC i
esmolol NN i
. . i

We PRP N
also RB N
investigated VBD N
the DT N
effect NN N
of IN N
preoperative JJ N
hypertension NN N
on IN N
postcraniotomy JJ N
hypertension NN N
and CC N
the DT N
natural JJ N
history NN N
of IN N
postcraniotomy JJ N
hypertension NN N
in IN N
the DT N
early JJ N
postoperative JJ N
period NN N
. . N

METHODS NNP N
Fifty-two JJ p
subjects NNS p
were VBD N
prospectively RB N
randomized VBN N
to TO N
receive VB N
either DT N
nicardipine NN i
or CC i
esmolol NN i
as IN N
the DT N
sole JJ N
drug NN N
for IN N
treatment NN N
of IN N
emergence NN N
hypertension NN N
at IN N
the DT N
conclusion NN N
of IN N
brain NN p
tumor NN p
resection NN p
( ( p
40 CD p
subjects NNS p
finally RB p
analyzed VBN p
) ) p
. . p

After IN N
a DT N
uniform JJ N
anesthetic JJ N
, , N
standardized JJ N
protocols NNS N
of IN N
these DT N
antihypertensive JJ N
medications NNS N
were VBD N
administered VBN N
for IN N
the DT N
treatment NN N
of IN N
systolic JJ o
blood NN o
pressure NN o
( ( o
SBP NNP o
) ) o
> VBD N
130 CD N
, , N
with IN N
the DT N
goal NN N
of IN N
maintaining VBG N
SBP NNP o
< $ N
140 CD N
throughout IN N
the DT N
first JJ N
postoperative JJ N
day NN N
. . N

In IN N
the DT N
event NN N
of IN N
study NN N
medication NN N
failure NN N
, , N
a DT N
rescue NN N
antihypertensive NN N
( ( i
labetalol JJ i
or CC i
hydralazine NN i
) ) i
was VBD N
used VBN N
. . N

The DT N
O'Brien-Fleming JJ N
Spending NN N
Function NNP N
was VBD N
used VBN N
to TO N
calculate VB N
the DT N
appropriate NN N
? . N
value NN N
for IN N
each DT N
interim JJ N
analysis NN N
of IN N
the DT N
primary JJ N
outcome NN N
; : N
univariate JJ N
analysis NN N
was VBD N
performed VBN N
otherwise RB N
, , N
with IN N
a DT N
2-sided JJ N
P NNP N
< NNP N
0.05 CD N
considered VBN N
statistically RB N
significant JJ N
. . N

RESULTS VB N
The DT o
incidence NN o
of IN o
nicardipine JJ o
failure NN o
( ( N
5 CD N
% NN N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] VBD N
0.1 CD N
% NN N
-24.9 NNP N
% NN N
) ) N
was VBD N
significantly RB N
less JJR N
than IN N
that DT N
of IN N
esmolol NN N
( ( N
55 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
31.5 CD N
% NN N
-76.9 NNP N
% NN N
) ) N
as IN N
a DT N
sole JJ N
drug NN N
in IN N
controlling VBG N
SBP NNP N
after IN N
brain NN N
tumor NN N
resection NN N
( ( N
difference NN N
99 CD N
% NN N
CI NNP N
13.8 CD N
% NN N
-75.7 CD N
% NN N
, , N
P NNP N
= NNP N
0.0012 CD N
) ) N
. . N

The DT N
presence NN N
of IN o
preoperative JJ o
hypertension NN o
or CC N
the DT N
approach NN N
to TO N
surgery NN N
( ( N
open JJ N
craniotomy NN N
versus NN N
endonasal NN N
transsphenoidal NN N
) ) N
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
the DT N
incidence NN N
of IN N
failure NN N
of IN N
the DT N
antihypertensive JJ N
regimen NNS N
used VBN N
. . N

We PRP N
did VBD N
not RB N
observe VB N
a DT N
difference NN N
in IN N
the DT N
need NN N
for IN i
opioid JJ i
therapy NN i
for IN N
postcraniotomy NN N
pain NN N
between IN N
drug NN N
groups NNS N
( ( N
99 CD N
% NN N
CI NNP N
difference NN N
-39.2 CD N
% NN N
-30.2 NNP N
% NN N
) ) N
. . N

Failure NN N
of IN N
the DT N
study NN N
drug NN N
predicted VBD N
the DT o
need NN o
for IN o
rescue JJ o
drug NN o
therapy NN o
in IN N
the DT N
initial JJ N
12 CD N
hours NNS N
after IN N
discharge NN N
from IN N
the DT N
recovery NN N
room NN N
( ( N
difference NN N
success NN N
versus IN N
failure NN N
= NNP N
-41.7 NNP N
% NN N
, , N
99 CD N
% NN N
CI NNP N
difference NN N
-72.3 CD N
% NN N
to TO N
-1.8 CD N
% NN N
, , N
P NNP N
= NNP N
0.0336 CD N
) ) N
but CC N
not RB N
during IN N
the DT N
period NN N
12 CD N
to TO N
24 CD N
hours NNS N
after IN N
discharge NN N
from IN N
the DT N
recovery NN N
room NN N
( ( N
difference NN N
success NN N
versus IN N
failure NN N
= NNP N
-27.4 NNP N
% NN N
, , N
99 CD N
% NN N
CI NNP N
difference NN N
-63.8 CD N
% NN N
-9.2 CD N
% NN N
, , N
P NNP N
= NNP N
0.143 CD N
) ) N
. . N

However RB N
, , N
in IN N
those DT p
patients NNS p
carrying VBG p
a DT p
preoperative JJ p
diagnosis NN p
of IN p
hypertension NN p
, , p
the DT o
need NN o
for IN o
rescue NN o
medication NN o
was VBD N
only RB N
different JJ N
during IN N
the DT N
period NN N
12 CD N
to TO N
24 CD N
hours NNS N
after IN N
discharge NN N
from IN N
the DT N
recovery NN N
room NN N
( ( N
difference NN N
normotensive JJ N
versus NN N
hypertensive JJ N
= NNP N
-35.4 NNP N
% NN N
, , N
99 CD N
% NN N
CI NNP N
difference NN N
-66.9 CD N
% NN N
to TO N
-0.3 CD N
% NN N
, , N
P NNP N
= NNP N
0.0254 CD N
) ) N
. . N

CONCLUSIONS NNP i
Nicardipine NNP i
is VBZ N
superior JJ N
to TO i
esmolol VB i
for IN N
the DT N
treatment NN N
of IN N
postcraniotomy JJ N
emergence NN N
hypertension NN N
. . N

This DT N
type NN N
of IN N
hypertension NN N
is VBZ N
thought VBN N
to TO N
be VB N
a DT N
transient NN N
phenomenon NN N
not RB N
solely RB N
related VBN N
to TO N
sympathetic JJ N
activation NN N
and CC N
catecholamine NN N
surge NN N
but CC N
also RB N
possibly RB N
encompassing VBG N
other JJ N
physiologic JJ N
factors NNS N
. . N

For IN N
treating VBG N
postcraniotomy JJ N
emergence NN N
hypertension NN N
, , N
nicardipine NN N
is VBZ N
a DT N
relatively RB N
effective JJ N
sole JJ N
drug NN N
, , N
whereas IN N
if IN N
esmolol NN N
is VBZ N
used VBN N
, , N
rescue JJ N
antihypertensive JJ N
medications NNS N
should MD N
be VB N
readily RB N
available JJ N
. . N

-DOCSTART- -23678498- O O

Supporting VBG N
families NNS p
in IN p
challenging VBG p
contexts NN p
: : p
the DT N
CAPEDP NNP N
project NN N
. . N

Although IN N
France NNP p
has VBZ N
one CD N
of IN N
the DT N
most RBS N
generous JJ N
health NN N
and CC N
social JJ N
care NN N
systems NNS N
for IN N
infant NN N
and CC N
maternal JJ N
well-being NN N
in IN N
the DT N
Western JJ N
world NN N
, , N
professionals NNS N
have VBP N
been VBN N
increasingly RB N
concerned VBN N
by IN N
the DT N
rising VBG N
number NN N
of IN N
children NNS p
being VBG p
referred VBN p
for IN p
mental JJ p
health NN p
problems NNS p
. . p

The DT N
present JJ N
article NN N
describes VBZ N
the DT N
first JJ N
home-visiting JJ i
program NN i
in IN N
France NNP N
to TO N
specifically RB N
target VB N
mental JJ N
health NN N
questions NNS N
in IN N
families NNS p
living VBG p
in IN p
vulnerable JJ p
contexts NN p
. . p

The DT N
CAPEDP NNP N
project NN N
, , N
involving VBG N
440 CD p
women NNS p
and CC p
their PRP$ p
families NNS p
, , p
took VBD p
place NN p
in IN p
Paris NNP p
and CC p
its PRP$ p
inner JJ p
suburbs NNS p
from IN p
2006 CD p
to TO p
2011 CD p
. . p

To TO p
be VB p
eligible JJ p
for IN p
inclusion NN p
, , p
women NNS p
had VBD p
to TO p
be VB p
( ( p
i NN p
) ) p
under IN p
26 CD p
years NNS p
old JJ p
, , p
( ( p
ii NN p
) ) p
less JJR p
that IN p
27 CD p
weeks NNS p
pregnant JJ p
, , p
( ( p
iii NN p
) ) p
sufficiently RB p
fluent VBN p
in IN p
French JJ p
to TO p
give VB p
truly NN p
informed JJ p
consent NN p
to TO p
participate VB p
in IN p
the DT p
study NN p
and CC p
benefit NN p
from IN p
the DT p
intervention NN p
and CC p
( ( p
iv NN p
) ) p
presenting VBG p
with IN p
one CD p
or CC p
more JJR p
of IN p
the DT p
following JJ p
social JJ p
vulnerability NN p
factors NNS p
: : p
low JJ p
income NN p
, , p
low JJ p
educational JJ p
level NN p
, , p
and/or RB p
intending VBG p
to TO p
bring VB p
up RP p
the DT p
child NN p
without IN p
the DT p
child NN p
's POS p
father NN p
. . p

The DT i
intervention NN i
consisted VBD i
of IN i
44 CD i
home NN i
visits NNS i
from IN i
the DT i
third JJ i
trimester NN i
of IN i
pregnancy NN i
through IN i
to TO i
the DT i
child NN i
's POS i
second JJ i
birthday NN i
. . i

The DT N
aim NN N
of IN N
the DT N
intervention NN N
was VBD N
to TO N
promote VB N
infant JJ o
mental JJ o
health NN o
and CC N
reduce VB N
the DT N
incidence NN o
of IN o
infant JJ o
mental JJ o
health NN o
problems NNS o
at IN N
the DT N
age NN N
of IN N
two CD N
years NNS N
. . N

The DT N
intervention NN N
paid VBD N
particular JJ N
attention NN N
to TO N
postnatal JJ N
maternal JJ N
depression NN N
and CC N
promoting VBG N
parenting VBG N
skills NNS N
and CC N
attachment JJ N
security NN N
, , N
particularly RB N
through IN N
the DT N
use NN i
of IN i
video NN i
during IN i
home-visits NNS i
. . i

A DT N
major JJ N
issue NN N
was VBD N
that IN N
of IN N
adapting VBG N
international JJ N
best JJS N
practice NN N
recommendations NNS N
with IN N
regard NN N
to TO N
home-visiting JJ N
programs NNS N
to TO N
the DT N
particularities NNS N
of IN N
the DT N
existing VBG N
French JJ N
social JJ N
and CC N
health NN N
care NN N
system NN N
. . N

An DT N
original JJ N
aspect NN N
of IN N
the DT N
intervention NN N
was VBD N
to TO N
use VB N
trained JJ N
clinical JJ N
psychologists NNS N
to TO N
conduct VB N
all DT N
home NN N
visits NNS N
. . N

-DOCSTART- -6182816- O O

Anti-IgG JJ N
antibodies NNS N
during IN N
immunotherapy NN N
with IN N
purified JJ N
grass NN N
pollen NN N
extracts NNS N
. . N

In IN N
a DT N
double JJ N
blind NN N
study NN N
40 CD p
patients NNS p
were VBD p
allocated VBN p
specific JJ i
immunotherapy NN i
( ( i
hyposensitization NN i
) ) i
with IN i
partially RB i
purified VBN i
timothy JJ i
extract NN i
or CC i
two CD i
timothy JJ i
major JJ i
allergens NNS i
19 CD i
, , i
25 CD i
. . i

All DT p
patients NNS p
had VBD p
typical JJ p
grass NN p
pollen NN p
hay NN p
fever NN p
, , p
in IN p
27 CD p
% NN p
associated VBN p
with IN p
grass NN p
pollen NN p
asthma NN p
and CC p
in IN p
13 CD p
% NN p
with IN p
birch NN p
pollen NN p
allergy NN p
. . p

Serum NNP o
IgG NNP o
anti-IgG JJ o
antibodies NNS o
were VBD N
determined VBN N
after IN N
dithiothreitol JJ p
treatment NN p
. . p

Before IN N
hyposensitization NN N
, , N
IgG NNP o
anti-IgG JJ o
titres NNS o
greater JJR p
than IN p
or CC p
equal JJ p
to TO p
9 CD p
were VBD p
demonstrated VBN p
in IN p
45 CD p
% NN p
of IN p
the DT p
patients NNS p
. . p

During IN N
hyposensitization NN N
IgG NNP o
anti-IgG NN o
titres NNS o
showed VBD N
a DT N
slight JJ N
initial JJ N
increase NN N
followed VBN N
by IN N
a DT N
decrease NN N
below IN N
pretreatment JJ N
level NN N
. . N

Neither CC N
increase VB N
nor CC N
decrease VB N
was VBD N
statistically RB N
significant JJ N
. . N

Reactions NNS o
to TO o
rabbit VB o
IgG NNP o
F NNP o
( ( o
ab IN o
' POS o
) ) o
2 CD o
fractions NNS N
were VBD N
only RB N
obtained VBN N
during IN N
hyposensitization NN N
. . N

The DT N
occurrence NN N
of IN N
anti-IgG JJ o
antibodies NNS o
did VBD N
no DT N
correlate NN N
with IN N
symptoms NNS o
, , o
side NN o
effects NNS o
, , o
or CC o
the DT o
level NN o
of IN o
allergen-specific JJ o
IgG NNP o
. . o

In IN N
a DT N
previous JJ N
study NN N
it PRP N
was VBD N
demonstrated VBN N
that IN N
patients NNS N
with IN N
multiallergy JJ N
hyposensitized VBN N
with IN N
combined JJ N
allergen NN N
extracts NNS N
showed VBD N
a DT N
statistically RB N
significant JJ N
increase NN N
in IN N
IgG NNP o
anti-IgG JJ o
titres NNS o
during IN N
treatment NN N
. . N

The DT N
increase NN N
failed VBD N
to TO N
appear VB N
in IN N
the DT N
present JJ N
patients NNS N
allergic VBZ N
only RB N
to TO N
pollen VB N
and CC N
treated VBN N
with IN N
purified JJ N
allergen NN N
extracts NNS N
. . N

It PRP N
is VBZ N
therefore RB N
suggested VBN N
that IN N
a DT N
multiallergic JJ N
condition NN N
and CC N
the DT N
combination NN N
and/or JJ N
purification NN N
of IN N
allergen NN N
extracts NNS N
administered VBN N
during IN N
hyposensitization NN N
may MD N
influence VB N
the DT N
production NN N
of IN N
IgG NNP o
anti- JJ o
IgG NNP o
antibodies NNS o
. . o

-DOCSTART- -7969211- O O

Naltrexone NN i
, , N
an DT N
opiate JJ i
antagonist NN i
, , N
fails VBZ N
to TO N
modify VB N
motor NN o
symptoms NNS o
in IN N
patients NNS p
with IN p
Parkinson NNP p
's POS p
disease NN p
. . p

One CD N
month NN N
of IN N
adjunct JJ N
treatment NN N
with IN N
naltrexone NN i
( ( N
100 CD N
mg/day NN N
) ) N
was VBD N
compared VBN N
with IN N
placebo NN i
in IN N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
cross-over JJ N
design NN N
in IN N
two CD p
groups NNS p
of IN p
patients NNS p
with IN p
Parkinson NNP p
's POS p
disease NN p
. . p

The DT N
first JJ N
group NN N
was VBD N
composed VBN N
of IN N
10 CD p
patients NNS p
with IN p
a DT p
moderate JJ p
motor NN o
impairment NN o
insufficiently RB p
controlled VBN p
by IN p
monotherapy NN p
with IN p
bromocriptine NN i
. . i

The DT N
second JJ N
group NN N
was VBD N
composed VBN N
of IN N
eight CD p
patients NNS p
with IN p
L-dopa-induced JJ p
peak-dose JJ p
dyskinesia NN p
. . p

Naltrexone CC i
as IN N
compared VBN N
with IN N
placebo NN i
did VBD N
not RB N
demonstrate VB N
any DT N
significant JJ N
change NN N
in IN N
motor NN o
function NN o
in IN N
either DT N
group NN N
. . N

These DT N
negative JJ N
clinical JJ N
results NNS N
do VBP N
not RB N
support VB N
a DT N
significant JJ N
role NN N
of IN N
endogenous JJ N
opioid JJ N
systems NNS N
in IN N
the DT N
pathophysiology NN N
of IN N
motor NN o
impairment NN o
in IN N
Parkinson NNP N
's POS N
disease NN N
. . N

-DOCSTART- -24691455- O O

A DT N
study NN N
of IN N
noninvasive JJ i
positive-pressure JJ i
mechanical JJ i
ventilation NN i
in IN N
the DT N
treatment NN N
of IN N
acute NN p
lung NN p
injury NN p
with IN p
a DT p
complex JJ p
critical JJ p
care NN p
ventilator NN p
. . p

OBJECTIVE UH N
To TO N
test VB N
the DT N
hypothesis NN N
that IN N
there EX N
would MD N
be VB N
better RB N
clinical JJ N
outcomes NNS N
following VBG N
the DT N
treatment NN N
of IN N
patients NNS p
with IN p
acute JJ p
lung NN p
injury NN p
( ( p
ALI NNP p
) ) p
using VBG N
noninvasive JJ i
positive-pressure JJ i
mechanical JJ i
ventilation NN i
( ( i
NIPPV NNP i
) ) i
delivered VBD i
via IN i
a DT i
complex JJ i
critical JJ i
care NN i
ventilator NN i
compared VBN i
with IN i
a DT i
conventional JJ i
mini-ventilator NN i
. . i

METHODS NNP N
Patients NNPS p
with IN p
ALI NNP p
who WP p
required VBD p
NIPPV NNP p
were VBD p
prospectively RB p
enrolled VBN p
and CC N
randomly RB N
divided VBD N
between IN N
three CD N
intervention NN N
groups NNS N
: : N
group NN N
A DT N
was VBD N
ventilated VBN N
using VBG N
a DT N
mini-ventilator NN i
; : i
groups NNS N
B NNP N
and CC N
C NNP N
were VBD N
ventilated VBN N
using VBG N
a DT N
complex JJ i
critical JJ i
care NN i
ventilator NN i
using VBG i
different JJ i
settings NNS i
. . i

Clinical JJ o
parameters NNS o
were VBD N
recorded VBN N
before IN N
and CC N
after IN N
8 CD N
h NN N
of IN N
mechanical JJ N
ventilation NN N
. . N

RESULTS VB N
A DT N
total NN N
of IN N
51 CD p
patients NNS p
with IN p
ALI NNP p
were VBD N
enrolled VBN N
in IN N
the DT N
study NN N
. . N

Clinical JJ N
parameters NNS N
in IN N
groups NNS N
B NNP N
and CC N
C NNP N
underwent JJ N
greater JJR N
improvements NNS N
than IN N
those DT N
in IN N
group NN N
A NNP N
. . N

Group NNP N
C NNP N
demonstrated VBD N
the DT N
lowest JJS N
treatment NN o
failure NN o
rate NN o
( ( N
23.5 CD N
% NN N
) ) N
. . N

Failure NN o
rates NNS o
were VBD N
highest JJS N
in IN N
group NN N
A NNP N
( ( N
58.8 CD N
% NN N
) ) N
. . N

CONCLUSION VB N
The DT N
findings NNS N
of IN N
this DT N
present JJ N
study NN N
suggest VBP N
that IN N
there EX N
were VBD N
more JJR N
satisfactory JJ N
clinical JJ o
outcomes NNS o
following VBG N
the DT N
treatment NN N
of IN N
patients NNS p
with IN p
ALI NNP p
when WRB N
NIPPV NNP N
was VBD N
delivered VBN N
using VBG N
a DT N
complex JJ N
critical JJ N
care NN N
ventilator NN N
compared VBN N
with IN N
a DT N
conventional JJ N
mini-ventilator NN N
. . N

-DOCSTART- -2014078- O O

Prophylactic JJ p
amnioinfusion NN i
in IN p
pregnancies NNS p
complicated VBN p
by IN p
oligohydramnios NNS p
: : p
a DT N
prospective JJ N
study NN N
. . N

Prophylactic JJ N
amnioinfusion NN i
was VBD N
assessed VBN N
in IN N
term NN p
and CC p
post-dates NNS p
pregnancies NNS p
with IN p
decreased JJ p
amniotic JJ p
fluid NN p
volume NN p
. . p

Subjects NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
groups NNS N
: : N
amnioinfusion NN i
with IN i
warmed JJ i
saline JJ i
solution NN i
, , i
room-temperature JJ i
saline NN i
, , i
or CC i
control NN i
. . i

Patients NNS p
receiving VBG p
prophylactic JJ p
amnioinfusion NN i
had VBD N
a DT N
significant JJ N
decrease NN N
in IN N
both CC N
the DT N
frequency NN o
and CC o
severity NN o
of IN o
variable JJ o
decelerations NNS o
in IN o
the DT o
first JJ o
stage NN o
of IN o
labor NN o
( ( N
P NNP N
= NNP N
.006 NNP N
) ) N
and CC N
in IN N
the DT N
average JJ N
total JJ N
number NN N
of IN N
variable JJ N
decelerations NNS N
in IN N
the DT N
first JJ N
and CC N
second JJ N
stages NNS N
of IN N
labor NN N
( ( N
P NNP N
= NNP N
.01 NNP N
) ) N
compared VBN N
with IN N
controls NNS N
. . N

There EX N
was VBD N
no DT N
observed JJ N
effect NN N
on IN N
newborn JJ o
serum NN o
electrolyte NN o
levels NNS o
with IN N
amnioinfusion NN i
, , N
nor CC N
was VBD N
there EX N
any DT N
apparent JJ N
benefit NN N
of IN N
infusion NN N
of IN N
warmed JJ N
saline NN N
compared VBN N
with IN N
room-temperature JJ N
saline NN N
. . N

In IN N
contrast NN N
to TO N
premature VB N
gestations NNS N
with IN N
oligohydramnios NNS N
, , N
prophylactic JJ N
amnioinfusion NN i
was VBD N
not RB N
associated VBN N
with IN N
a DT N
significant JJ N
improvement NN N
in IN N
mean JJ o
umbilical JJ o
arterial NN o
and CC o
venous JJ o
pH NN o
or CC N
a DT N
significant JJ o
decrease NN o
in IN N
cesarean JJ o
delivery NN o
for IN o
fetal JJ o
distress NN o
( ( N
P NNP N
= NNP N
.09 NNP N
) ) N
. . N

This DT N
is VBZ N
perhaps RB N
because IN N
the DT N
term NN N
fetus NN N
has VBZ N
an DT N
enhanced VBN N
ability NN N
to TO N
tolerate VB N
recurrent JJ N
episodes NNS N
of IN N
heart NN o
rate NN o
decelerations NNS o
without IN N
demonstrating VBG N
the DT N
rapid JJ N
metabolic JJ N
changes NNS N
seen VBN N
in IN N
the DT N
premature NN N
fetus NN N
. . N

-DOCSTART- -10337433- O O

Comparative JJ N
evaluation NN N
of IN N
olopatadine JJ i
ophthalmic JJ i
solution NN i
( ( N
0.1 CD N
% NN N
) ) N
versus NN N
ketorolac NN i
ophthalmic JJ i
solution NN i
( ( N
0.5 CD N
% NN N
) ) N
using VBG N
the DT N
provocative JJ N
antigen NN N
challenge NN N
model NN N
. . N

OBJECTIVE CC N
This DT N
study NN N
was VBD N
conducted VBN N
to TO N
compare VB N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
olopatadine JJ i
ophthalmic JJ i
solution NN i
( ( N
0.1 CD N
% NN N
) ) N
with IN N
ketorolac NN i
ophthalmic JJ i
solution NN i
( ( N
0.5 CD N
% NN N
) ) N
in IN N
a DT N
clinical JJ N
model NN N
of IN N
acute JJ p
allergic JJ p
conjunctivitis NN p
. . p

Olopatadine NNP i
is VBZ N
a DT N
dual JJ N
acting NN N
H1 NNP N
histamine NN N
receptor NN N
antagonist NN N
and CC N
a DT N
mast NN N
cell NN N
stabilizer NN N
, , N
shown VBN N
to TO N
be VB N
effective JJ N
in IN N
treating VBG N
allergic JJ p
conjunctivitis NN p
. . p

Ketorolac NNP i
is VBZ N
a DT N
non-steroidal JJ N
anti-inflammatory JJ N
drug NN N
approved VBN N
in IN N
the DT N
United NNP N
States NNPS N
for IN N
the DT N
relief NN N
of IN N
ocular JJ N
itching NN N
associated VBN N
with IN N
seasonal JJ N
allergic JJ p
conjunctivitis NN p
. . p

METHODS NNP N
The DT N
provocative JJ N
antigen NN N
challenge NN N
model NN N
was VBD N
used VBN N
in IN N
this DT N
randomized JJ N
, , N
double-blind JJ N
, , N
single-center JJ N
, , N
crossover NN N
study NN N
. . N

The DT N
allergen NN N
and CC N
concentration NN N
that WDT N
consistently RB N
elicited VBD N
a DT N
positive JJ N
allergic JJ N
reaction NN N
was VBD N
used VBN N
for IN N
challenge NN N
. . N

After IN N
at IN N
least JJS N
14 CD N
days NNS N
, , N
subjects NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
olopatadine NN i
in IN N
one CD N
eye NN N
and CC N
placebo NN i
in IN N
the DT N
contralateral JJ N
eye NN N
, , N
or CC N
ketorolac NN i
in IN N
one CD N
eye NN N
and CC N
placebo NN i
in IN N
the DT N
contralateral JJ N
eye NN N
. . N

Twenty-seven JJ N
minutes NNS N
after IN N
drug NN N
instillation NN N
subjects NNS N
were VBD N
challenged VBN N
with IN N
allergen NN N
. . N

At IN N
3 CD N
, , N
10 CD N
, , N
and CC N
20 CD N
minutes NNS N
following VBG N
allergen NN N
challenge NN N
, , N
subjects NNS N
graded VBD o
ocular JJ o
itching NN o
and CC N
were VBD N
assessed VBN N
for IN N
hyperemia NN o
in IN o
conjunctival NN o
, , o
ciliary JJ o
, , o
and CC o
episcleral JJ o
vessel NN o
beds NNS o
. . o

Approximately RB N
14 CD N
days NNS N
later RB N
, , N
subjects NNS N
received VBD N
the DT N
alternate NN i
treatment NN i
in IN N
one CD N
eye NN N
and CC N
placebo NN i
in IN N
the DT N
contralateral JJ N
eye NN N
. . N

They PRP N
were VBD N
again RB N
challenged VBN N
with IN N
allergen NN N
and CC N
their PRP$ N
responses NNS N
were VBD N
rated VBN N
in IN N
the DT N
same JJ N
manner NN N
. . N

RESULTS NNP N
Olopatadine NNP i
significantly RB N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
reduced VBD N
both DT N
ocular JJ o
itching NN o
and CC o
hyperemia NN o
in IN N
all DT N
three CD N
vessel NN N
beds NNS N
compared VBN N
to TO N
placebo VB i
at IN N
all DT N
time NN N
points NNS N
tested VBD N
following VBG N
allergen NN N
challenge NN N
. . N

Ketorolac NNP i
did VBD N
not RB N
significantly RB N
reduce VB N
itching NN o
and CC N
showed VBD N
a DT N
trend NN N
of IN N
increased VBN N
hyperemia NN o
compared VBN N
to TO N
placebo VB i
. . i

Olopatadine NNP i
was VBD N
significantly RB N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
more RBR N
effective JJ o
than IN N
ketorolac NN i
in IN N
reducing VBG N
hyperemia NN o
and CC o
ocular JJ o
itching NN o
at IN N
all DT N
time NN N
points NNS N
and CC N
was VBD N
also RB N
significantly RB N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
more RBR N
comfortable JJ o
than IN N
ketorolac NN i
as IN N
reported VBN N
by IN N
subjects NNS N
immediately RB N
following VBG N
drug NN N
instillation NN N
. . N

CONCLUSION VB N
The DT N
study NN N
demonstrated VBD N
that IN N
olopatadine NN i
is VBZ N
effective JJ N
and CC N
safe JJ N
in IN N
preventing VBG N
and CC N
treating VBG N
ocular JJ o
itching NN o
and CC o
hyperemia NN o
associated VBN N
with IN N
acute JJ p
allergic JJ p
conjunctivitis NN p
and CC N
is VBZ N
more RBR N
effective JJ N
and CC N
more RBR N
comfortable JJ N
than IN N
ketorolac NN i
. . i

-DOCSTART- -20058059- O O

A DT N
randomized VBN N
controlled VBN N
study NN N
of IN N
parent-assisted JJ i
Children NNP i
's POS i
Friendship NNP i
Training NNP i
with IN N
children NNS p
having VBG p
autism NN p
spectrum NN p
disorders NNS p
. . p

This DT N
study NN N
evaluated VBD N
Children NNP i
's POS i
Friendship NNP i
Training NNP i
( ( i
CFT NNP i
) ) i
, , i
a DT i
manualized JJ i
parent-assisted JJ i
intervention NN i
to TO N
improve VB N
social JJ N
skills NNS N
among IN N
second JJ p
to TO p
fifth VB p
grade JJ p
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

Comparison NNP N
was VBD N
made VBN N
with IN N
a DT N
delayed JJ i
treatment NN i
control NN i
group NN i
( ( i
DTC NNP i
) ) i
. . N

Targeted VBN N
skills NNS N
included VBD N
conversational JJ o
skills NNS o
, , o
peer VBP o
entry NN o
skills NNS o
, , o
developing VBG o
friendship JJ o
networks NNS o
, , o
good JJ o
sportsmanship NN o
, , o
good JJ o
host NN o
behavior NN o
during IN o
play NN o
dates NNS o
, , o
and CC o
handling VBG o
teasing NN o
. . o

At IN N
post-testing NN N
, , N
the DT N
CFT NNP p
group NN p
was VBD N
superior JJ N
to TO N
the DT N
DTC NNP p
group NN p
on IN N
parent NN N
measures NNS N
of IN N
social JJ o
skill NN o
and CC o
play NN o
date NN o
behavior NN o
, , N
and CC N
child JJ N
measures NNS N
of IN N
popularity NN o
and CC o
loneliness NN o
, , N
At IN N
3-month JJ N
follow-up NN N
, , N
parent NN N
measures NNS N
showed VBD N
significant JJ N
improvement NN N
from IN N
baseline NN N
. . N

Post-hoc JJ N
analysis NN N
indicated VBD N
more JJR N
than IN N
87 CD N
% NN N
of IN N
children NNS N
receiving VBG N
CFT NNP i
showed VBD N
reliable JJ N
change NN N
on IN N
at IN N
least JJS N
one CD N
measure NN N
at IN N
post-test NN N
and CC N
66.7 CD N
% NN N
after IN N
3 CD N
months NNS N
follow-up RB N
. . N

-DOCSTART- -813984- O O

[ VB N
A NNP N
controlled JJ N
study NN N
of IN N
treating VBG N
haemophilia PRP N
A NNP N
on IN N
an DT N
out-patient JJ N
basis NN N
( ( N
author NN N
's POS N
transl NN N
) ) N
] NN N
. . N

For IN N
six CD N
months NNS N
36 CD i
U NNP i
factor NN i
VIII NNP i
concentrates VBZ i
per IN N
kg NN N
bodyweight NN N
and CC N
week NN N
were VBD N
administered VBN N
to TO N
six CD p
out-patients NNS p
with IN p
severe JJ p
haemophilia NN p
A NNP p
. . p

The DT N
injection NN N
regimen NN N
was VBD N
changed VBN N
in IN N
every DT N
patient NN N
every DT N
two CD N
months NNS N
, , N
from IN N
36 CD N
U/kg NNP N
once RB N
to TO N
18 CD N
U/kg NNP N
twice RB N
and CC N
12 CD N
U/kg NNP N
three CD N
times NNS N
, , N
intravenously RB N
. . N

The DT N
six CD N
possible JJ N
combinations NNS N
of IN N
these DT N
three CD N
dosage NN N
schedules NNS N
were VBD N
used VBN N
in IN N
the DT N
patients NNS N
in IN N
a DT N
strictly RB N
randomised JJ N
manner NN N
, , N
and CC N
all DT N
patients NNS N
were VBD N
treated VBN N
during IN N
the DT N
same JJ N
period NN N
. . N

In IN N
the DT N
pre-trial JJ N
period NN N
( ( N
treatment NN N
as IN N
needed VBN N
) ) N
there EX N
were VBD N
an DT N
average NN N
of IN N
35 CD N
bleedings NNS o
per IN N
two CD N
months NNS N
. . N

On IN N
continual JJ N
treatment NN N
there EX N
were VBD N
21 CD N
bleedings NNS o
on IN N
weekly JJ N
injections NNS N
of IN N
36 CD N
U NNP i
factor NN i
VIII NNP i
per IN N
kg NN N
, , N
14 CD N
on IN N
twice JJ N
weekly JJ N
18 CD N
U/kg NNP N
and CC N
none NN N
on IN N
12 CD N
U/kg NNP N
, , N
three CD N
times NNS N
weekly RB N
. . N

The DT N
differences NNS N
are VBP N
statistically RB N
significant JJ N
. . N

The DT N
absence NN o
of IN o
bleeding VBG o
on IN N
the DT N
last JJ N
dosage NN N
schedule NN N
was VBD N
achieved VBN N
during IN N
normal JJ N
working VBG N
. . N

Days NNPS o
lost VBD o
from IN o
work NN o
per IN o
patient JJ o
per IN o
month NN o
was VBD N
zero NN N
on IN N
three CD N
times NNS N
12 CD N
U/kg NNP N
, , N
0.4 CD N
day NN N
on IN N
twice RB N
18 CD N
U/kg NNP N
and CC N
once RB N
36 CD N
U/kg NNP N
, , N
while IN N
it PRP N
had VBD N
been VBN N
five CD N
days NNS N
in IN N
the DT N
pre-trial JJ N
period NN N
. . N

In IN N
addition NN N
to TO N
freedom NN o
from IN o
bleeding VBG o
and CC N
no DT N
lost JJ o
days NNS o
from IN N
work NN N
, , N
there EX N
was VBD N
increased VBN N
mobility NN o
and CC o
physical JJ o
capacity NN o
. . o

-DOCSTART- -9718870- O O

Combined VBN i
modality NN i
therapy NN i
in IN N
advanced JJ N
Hodgkin NNP N
's POS N
disease NN N
: : N
a DT p
report NN p
on IN p
218 CD p
patients NNS p
with IN p
a DT p
median JJ p
follow-up NN p
of IN p
eight CD p
years NNS p
. . p

BACKGROUND NNP N
AND CC N
OBJECTIVE NNP N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
the DT N
efficacy NN o
and CC o
toxicity NN o
of IN N
monthly JJ N
alternating VBG N
ABVD/MOPP NNP i
compared VBN i
to TO i
ABVD/OPP NNP i
regimens NNS N
in IN N
patients NNS p
with IN p
advanced JJ p
stage NN p
Hodgkin NNP p
's POS p
disease NN p
( ( p
HD NNP p
) ) p
, , p
as RB p
well RB p
as IN p
in IN p
early JJ p
stage NN p
patients NNS p
with IN p
systemic JJ p
symptoms NNS p
and/or VBP p
bulky JJ p
disease NN p
. . p

DESIGN NNP N
AND NNP N
METHODS NNP N
218 CD p
patients NNS p
with IN p
previously RB p
untreated VBN p
HD NNP p
entered VBD p
this DT p
study NN p
: : p
106 CD p
patients NNS p
in IN p
arm NN p
A NNP p
( ( i
ABVD/MOPP NNP i
) ) i
and CC p
112 CD p
in IN p
arm NN p
B NNP p
( ( i
ABVD/OPP NNP i
) ) i
. . i

Patients NNPS N
received VBD N
eight CD N
courses NNS N
of IN N
one CD N
of IN N
the DT N
two CD N
regimens NNS N
after IN N
stratification NN N
according VBG N
to TO N
the DT N
stage NN N
. . N

Patients NNS N
in IN N
complete JJ N
remission NN N
( ( N
CR NNP N
) ) N
received VBD N
20 CD N
Gy NNP N
to TO N
the DT N
involved JJ N
field NN N
and CC N
40 CD N
Gy NNP N
to TO N
the DT N
spleen NN N
. . N

The DT N
actuarial JJ o
survival NN o
curves NNS o
were VBD N
performed VBN N
according VBG N
to TO N
Kaplan NNP N
and CC N
Meier NNP N
. . N

RESULTS NNP N
No NNP N
statistically RB N
significant JJ N
differences NNS N
were VBD N
observed VBN N
between IN N
the DT N
two CD N
arms NNS N
in IN N
terms NNS N
of IN N
CR NNP o
rate NN o
and CC o
toxicity NN o
. . o

However RB N
, , N
analysis NN N
of IN N
total JJ o
relapses NNS o
revealed VBD N
that IN N
patients NNS N
treated VBN N
with IN N
ABVD/OPP NNP i
had VBD N
a DT N
significantly RB N
higher JJR N
likelihood NN N
of IN N
achieving VBG N
a DT N
second JJ o
CR NNP o
compared VBN N
to TO N
patients NNS p
who WP p
entered VBD p
the DT p
ABVD/MOPP NNP i
arm NN p
. . p

INTERPRETATION NNP N
AND CC N
CONCLUSIONS NNP N
Both NNP N
schemes NNS N
of IN N
chemotherapy NN N
followed VBN N
by IN N
radiotherapy NN N
produce VBP N
high JJ N
percentages NNS N
of IN N
CR NNP o
, , o
low JJ o
risk NN o
of IN o
relapse NN o
and CC o
an DT o
acceptable JJ o
toxicity NN o
. . o

-DOCSTART- -10089089- O O

Piperacillin/tazobactam NNP i
plus CC i
tobramycin JJ i
versus NN i
ceftazidime NN i
plus CC i
tobramycin NN i
as IN N
empiric JJ N
therapy NN N
for IN N
fever NN o
in IN N
severely RB p
neutropenic JJ p
patients NNS p
. . p

The DT N
objective NN N
of IN N
this DT N
trial NN N
was VBD N
to TO N
evaluate VB N
the DT N
potential JJ N
advantages NNS N
of IN N
the DT N
combination NN N
of IN N
piperacillin NN i
and CC i
tazobactam NN i
in IN N
the DT N
control NN N
of IN N
fever NN o
in IN p
neutropenic JJ p
patients NNS p
. . p

In IN N
this DT N
single-center NN N
study NN N
, , N
patients NNS p
who WP p
experienced VBD p
a DT p
total NN p
of IN p
247 CD p
febrile JJ p
episodes NNS p
were VBD N
prospectively RB N
randomized VBN N
to TO N
receive VB N
either RB N
our PRP$ N
standard JJ N
regimen NNS N
, , N
ceftazidime RB i
3 CD N
g/day NN N
( ( N
1 CD N
g NN N
t.i.d NN N
. . N

) ) N
plus CC N
tobramycin $ i
3 CD N
mg/kg JJ N
per IN N
day NN N
( ( N
1.5 CD N
mg/kg NN N
b.i.d NN N
. . N

) ) N
, , N
or CC N
piperacillin VB i
12 CD N
g/day JJ N
plus CC N
tazobactam JJ i
1.5 CD N
g/day NN N
( ( N
4 CD N
g+0.5 NN N
g NN N
t.i.d NN N
. . N

) ) N
plus CC N
tobramycin $ i
3 CD N
mg/kg JJ N
per IN N
day NN N
( ( N
1.5 CD N
mg/kg RB N
b.i.d. NN N
) ) N
. . N

Vancomycin NNP i
was VBD N
added VBN N
in IN N
all DT N
cases NNS N
of IN N
persistent JJ N
fever NN N
in IN N
the DT N
ceftazidime NN i
arm NN N
, , N
but CC N
only RB N
when WRB N
there EX N
was VBD N
microbiologically RB N
documented VBN N
resistance NN N
in IN N
the DT N
piperacillin/tazobactam NN i
arm NN N
. . N

All DT p
247 CD p
episodes NNS p
were VBD p
evaluable JJ p
by IN N
intent-to-treat JJ N
analysis NN N
. . N

The DT N
two CD N
populations NNS N
were VBD N
well RB N
matched VBN N
in IN N
terms NNS N
of IN N
age NN N
, , N
gender NN N
, , N
underlying VBG N
disease NN N
, , N
chemotherapy NN N
received VBD N
, , N
oral JJ N
decontamination NN N
, , N
clinical JJ N
and CC N
bacterial JJ N
documentation NN N
, , N
and CC N
severity NN N
and CC N
duration NN N
of IN N
neutropenia NN N
. . N

Initial JJ N
antibacterial JJ i
therapy NN i
was VBD N
successful JJ o
( ( o
apyrexia NN o
at IN N
72 CD N
h NN N
, , N
without IN N
antibiotic JJ N
change NN N
) ) N
more RBR N
frequently RB N
( ( N
P NNP N
= NNP N
0.008 CD N
) ) N
with IN N
the DT N
regimen NNS N
containing VBG N
piperacillin/tazobactam NN i
( ( N
54.4 CD N
% NN N
) ) N
than IN N
with IN N
the DT N
one CD N
including VBG N
ceftazidime NN i
( ( N
37.6 CD N
% NN N
) ) N
. . N

Fewer JJR N
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
major JJ N
infectious JJ N
events NNS N
( ( o
infectious JJ o
death NN o
or CC o
delay NN o
in IN o
treatment NN o
of IN o
underlying JJ o
disease NN o
due JJ o
to TO o
infection NN o
) ) o
were VBD N
observed VBN N
during IN N
piperacillin/ JJ i
tazobactam JJ i
treatment NN N
( ( N
2.6 CD N
% NN N
) ) N
than IN N
with IN N
the DT N
ceftazidime NN i
regimen NNS N
( ( N
11.3 CD N
% NN N
) ) N
, , N
despite IN N
a DT N
lower JJR N
frequency NN N
of IN N
glycopeptide JJ o
addition NN o
when WRB N
piperacillin/tazobactam NN i
was VBD N
used VBN N
( ( N
54.4 CD N
% NN N
versus IN N
77.4 CD N
% NN N
) ) N
according VBG N
to TO N
the DT N
rules NNS N
adopted VBN N
. . N

This DT N
trial NN N
confirmed VBD N
the DT N
efficacy NN o
of IN N
the DT N
piperacillin/tazobactam NN i
combination NN N
for IN N
empirical JJ N
treatment NN N
of IN N
febrile JJ p
neutropenic JJ p
patients NNS p
. . p

This DT N
antibiotic JJ N
combination NN N
permitted VBD N
a DT N
dramatic JJ N
decrease NN N
in IN N
empiric JJ o
glycopeptide NN o
antibiotic JJ o
administration NN o
in IN N
such JJ N
patients NNS N
. . N

-DOCSTART- -25265769- O O

Comparison NNP N
of IN N
intrathecal JJ i
bupivacaine NN i
, , i
levobupivacaine NN i
for IN N
cesarean JJ N
section NN N
. . N

BACKGROUND NNP N
Some DT N
investigators NNS N
found VBD N
a DT N
greater JJR N
incidence NN N
of IN N
hypotension NN N
in IN N
patients NNS p
receiving VBG p
intrathecal JJ i
hyperbaric JJ i
solution NN i
than IN p
in IN p
patients NNS p
receiving VBG p
plain JJ p
solution NN p
for IN p
cesarean JJ p
section NN p
. . p

OBJECTIVE CC N
Compare NNP N
the DT N
effects NNS N
of IN N
intrathecal JJ i
hyperbaric JJ i
bupivacaine NN i
10 CD N
mg NN N
with IN N
intrathecal JJ i
bupivacaine NN i
11 CD N
mg NN N
and CC N
intrathecal JJ i
levobupivacaine NN i
11 CD N
mg NN N
, , N
all DT N
with IN N
10 CD N
microg NNS N
of IN N
fentanyl NN i
, , N
for IN N
cesarean JJ N
section NN N
. . N

MATERIAL NNP N
AND CC N
METHOD NNP N
This DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blinded JJ N
study NN N
was VBD N
approved VBN N
by IN N
the DT N
Ethics NNP N
Committee NNP N
. . N

Ninety NNP p
ASA NNP p
I-II NNP p
parturients NNS p
undergoing VBG p
elective JJ p
cesarean JJ p
section NN p
were VBD p
enrolled VBN p
. . p

Group NNP N
H NNP N
received VBD N
10 CD N
mg NN N
of IN N
0.5 CD i
% NN i
hyperbaric JJ i
bupivacaine NN i
plus CC i
fentanyl JJ i
10 CD i
g NN i
, , N
Group NNP N
B NNP N
received VBD N
11 CD N
mg NN N
of IN N
0.5 CD i
% NN i
bupivacaine NN i
plus CC i
fentanyl JJ i
10 CD i
g NN i
, , N
and CC N
Group NNP N
L NNP N
received VBD N
11 CD i
mg NN i
of IN i
0.5 CD i
% NN i
levobupivacaine JJ i
plus CC i
fentanyl JJ i
10 CD i
g. JJ i
Spinal NNP i
anesthesia NN i
( ( i
SA NNP i
) ) i
was VBD N
undertaken VBN N
in IN N
right JJ N
lateral JJ N
position NN N
and CC N
spinal JJ N
solutions NNS N
were VBD N
injected VBN N
approximately RB N
30 CD N
to TO N
40 CD N
seconds NNS N
. . N

Sensory NNP N
and CC N
motor NN N
block NN N
were VBD N
assessed VBN N
at IN N
5-minute JJ N
intervals NNS N
. . N

Side-effects NNS N
such JJ N
as IN N
hypotension NN o
, , o
nausea NN o
, , o
pruritus NN o
, , o
shivering NN o
, , o
and CC o
headache NN o
were VBD N
recorded VBN N
RESULTS NNP N
Demographic NNP N
data NNS N
were VBD N
similar JJ N
in IN N
all DT N
groups NNS N
. . N

The DT N
level NN N
of IN N
an DT N
absence NN o
of IN o
cold JJ o
sensation NN o
, , N
the DT N
level NN o
of IN o
pinprick JJ o
analgesia NN o
, , N
and CC N
time NN o
to TO o
achieve VB o
sensory JJ o
block NN o
to TO o
T4 NNP o
level NN o
of IN N
Group NNP N
H NNP N
was VBD N
significantly RB N
higher JJR N
than IN N
Group NNP N
B NNP N
and CC N
Group NNP N
L. NNP N
The DT N
degree NN N
of IN N
motor NN o
block NN o
was VBD N
comparable JJ N
in IN N
all DT N
groups NNS N
. . N

The DT N
incidence NN N
of IN N
visceral JJ o
pain NN o
was VBD N
minimal JJ N
, , N
rated VBN N
as IN N
mild JJ N
pain NN N
and CC N
only RB N
found VBD N
in IN N
Group NNP N
B NNP N
. . N

The DT N
incidence NN N
of IN N
hypotension NN o
was VBD N
comparable JJ N
with IN N
Group NNP N
H NNP N
= VBZ N
67 CD N
% NN N
, , N
Group NNP N
B NNP N
= VBZ N
56 CD N
% NN N
, , N
and CC N
Group NNP N
L NNP N
= VBZ N
50 CD N
% NN N
. . N

Other JJ N
side JJ N
effects NNS N
such JJ N
as IN N
nausea NN o
, , o
vomiting VBG o
, , o
pruritus NN o
, , o
shivering NN o
, , o
and CC o
headache NN o
were VBD N
not RB N
statistically RB N
significant JJ N
. . N

Patient NNP N
's POS N
satisfaction NN o
rated VBN N
as IN N
very RB N
good JJ N
and CC N
was VBD N
not RB N
different JJ N
between IN N
the DT N
three CD N
groups NNS N
. . N

CONCLUSION NNP N
The DT o
level NN o
of IN o
absence NN o
of IN o
cold JJ o
sensation NN o
, , o
level NN o
of IN o
pinprick JJ o
analgesia NN o
, , o
and CC o
time NN o
to TO o
achieve VB o
sensory JJ o
block NN o
to TO o
T4 NNP o
level NN o
were VBD N
statistically RB N
higher JJR N
in IN N
patients NNS N
receiving VBG N
hyperbaric JJ i
bupivacaine NN i
than IN N
in IN N
patients NNS N
receiving VBG N
plain JJ N
bupivacaine NN i
and CC N
plain NN N
levobupivacaine NN i
, , N
while IN N
the DT N
differences NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
in IN N
all DT N
groups NNS N
regarding VBG N
effective JJ o
surgical JJ o
anesthesia NN o
, , o
postoperative JJ o
analgesia NN o
, , o
and CC o
side JJ o
effects NNS o
. . o

Therefore RB N
, , N
Levobupivacaine NNP i
can MD N
be VB N
an DT N
alternative JJ o
to TO N
bupivacaine VB i
. . i

-DOCSTART- -18957157- O O

Impact NN N
of IN N
isotonic JJ i
and CC i
hypertonic JJ i
saline NN i
solutions NNS i
on IN N
mucociliary JJ N
activity NN N
in IN N
various JJ p
nasal JJ p
pathologies NNS p
: : p
clinical JJ N
study NN N
. . N

OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
impact NN N
of IN N
nasal JJ N
irrigation NN N
with IN N
isotonic JJ i
or CC i
hypertonic JJ i
sodium NN i
chloride JJ i
solution NN i
on IN N
mucociliary JJ N
clearance NN N
time NN N
in IN N
patients NNS p
with IN p
allergic JJ p
rhinitis NN p
, , p
acute JJ p
sinusitis NN p
and CC p
chronic JJ p
sinusitis NN p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
Mucociliary NNP N
clearance NN N
time NN N
was VBD N
measured VBN N
using VBG N
the DT N
saccharine JJ N
clearance NN N
test NN N
on IN N
132 CD p
adults NNS p
before IN N
and CC N
after IN N
10 CD N
days NNS N
' POS N
application NN i
of IN i
intranasal NN i
isotonic NN i
or CC i
hypertonic JJ i
saline NN i
. . i

Patient JJ p
numbers NNS p
were VBD p
as IN p
follows VBZ p
: : p
controls NNS p
, , p
45 CD p
; : p
allergic JJ p
rhinitis NN p
, , p
21 CD p
; : p
acute JJ p
sinusitis NN p
, , p
24 CD p
; : p
and CC p
chronic JJ p
sinusitis NN p
, , p
42 CD p
. . p

The DT N
results NNS N
before IN N
and CC N
after IN N
irrigation NN N
were VBD N
compared VBN N
using VBG N
the DT N
Wilcoxon NNP N
t-test NN N
. . N

RESULTS NNP N
Before IN N
application NN N
of IN N
saline JJ i
solutions NNS i
, , N
mucociliary JJ o
clearance NN o
times NNS o
in IN N
the DT N
three CD N
patient NN N
treatment NN N
groups NNS N
were VBD N
found VBN N
to TO N
be VB N
significantly RB N
delayed VBN N
, , N
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

Irrigation NN N
with IN N
hypertonic JJ i
saline NN i
restored VBN o
impaired JJ o
mucociliary JJ o
clearance NN o
in IN o
chronic JJ o
sinusitis NN o
patients NNS o
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
, , N
while IN N
isotonic JJ i
saline NN i
improved VBD o
mucociliary JJ o
clearance NN o
times NNS o
significantly RB o
in IN N
allergic JJ N
rhinitis NN N
and CC N
acute JJ N
sinusitis NN N
patients NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
Nasal NNP N
irrigation NN N
with IN N
isotonic JJ i
or CC i
hypertonic JJ i
saline NN i
can MD N
improve VB N
mucociliary JJ o
clearance NN o
time NN o
in IN N
various JJ N
nasal JJ N
pathologies NNS N
. . N

However RB N
, , N
these DT N
solutions NNS N
should MD N
be VB N
selectively RB N
prescribed IN N
rather RB N
than IN N
used VBN N
based VBN N
on IN N
anecdotal JJ N
evidence NN N
. . N

Further JJ N
studies NNS N
should MD N
be VB N
conducted VBN N
to TO N
develop VB N
a DT N
protocol NN N
for IN N
standardised VBN N
use NN N
of IN N
saline JJ i
solution NN i
irrigation NN i
in IN N
various JJ N
nasal JJ N
pathologies NNS N
. . N

-DOCSTART- -11352886- O O

L-arginine JJ i
and CC N
S-nitrosoglutathione JJ i
reduce VB N
embolization NN o
in IN N
humans NNS p
. . p

BACKGROUND NNP N
L-Arginine JJ i
reduces NNS N
platelet POS o
aggregation NN o
and CC o
adhesion NN o
in IN N
ex JJ N
vivo NN N
studies NNS N
, , N
but CC N
there EX N
is VBZ N
no DT N
evidence NN N
as IN N
yet RB N
that IN N
it PRP N
has VBZ N
a DT N
therapeutic JJ N
effect NN N
on IN N
clinical JJ N
end NN N
points NNS N
. . N

Doppler NNP N
ultrasound NN N
can MD N
detect VB N
cerebral JJ N
emboli NN N
noninvasively RB N
. . N

Such JJ N
embolic JJ N
signals NNS N
are VBP N
common JJ N
after IN N
carotid JJ N
endarterectomy NN N
, , N
and CC N
their PRP$ N
frequency NN N
predicts VBZ N
risk NN N
of IN N
stroke NN N
recurrence NN N
. . N

We PRP N
used VBD N
this DT N
situation NN N
to TO N
determine VB N
the DT N
antiplatelet NN o
efficacy NN o
of IN N
L-arginine NNP i
and CC N
S-nitrosoglutathione NNP i
( ( i
GSNO NNP i
) ) i
, , N
a DT N
physiological JJ N
nitric JJ N
oxide IN N
donor NN N
with IN N
possible JJ N
platelet NN N
specificity NN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
Patients NNP p
undergoing JJ p
carotid NNS p
endarterectomy VBP p
were VBD N
randomized VBN N
in IN N
a DT N
double-blind JJ N
manner NN N
between IN N
L-arginine NNP i
( ( p
n=14 NN p
) ) p
, , N
GSNO NNP i
( ( p
n=14 NN p
) ) p
, , N
or CC N
placebo NN i
( ( p
n=14 JJ p
) ) p
administered VBD N
intravenously RB N
for IN N
90 CD N
minutes NNS N
, , N
starting VBG N
30 CD N
minutes NNS N
after IN N
skin JJ N
closure NN N
. . N

All DT p
patients NNS p
were VBD p
pretreated VBN p
with IN p
aspirin NN i
and CC p
given VBN p
heparin NNS i
during IN p
surgery NN p
. . p

Transcranial NNP N
Doppler NNP N
recordings NNS N
were VBD N
made VBN N
from IN N
the DT N
ipsilateral JJ N
middle JJ N
cerebral JJ N
artery NN N
for IN N
4 CD N
hours NNS N
after IN N
surgery NN N
, , N
beginning VBG N
30 CD N
minutes NNS N
after IN N
skin JJ N
closure NN N
, , N
and CC N
also RB N
at IN N
6 CD N
and CC N
24 CD N
hours NNS N
. . N

There EX N
were VBD N
highly RB N
significant JJ N
reductions NNS N
in IN N
the DT N
number NN o
of IN o
Doppler NNP o
embolic JJ o
signals NNS o
in IN o
the DT o
L-arginine NNP o
and CC o
GSNO NNP o
groups NNS N
; : N
first RB N
4 CD N
hours NNS N
, , N
median JJ N
( ( N
range NN N
) ) N
number NN o
of IN o
embolic JJ o
signals NNS o
, , N
placebo NN i
44.7 CD N
( ( N
6 CD N
to TO N
778 CD N
) ) N
, , N
L-arginine JJ i
9.5 CD N
( ( N
0 CD N
to TO N
225 CD N
) ) N
, , N
and CC N
GSNO NNP i
0.8 NNP N
( ( N
0 CD N
to TO N
8 CD N
) ) N
, , N
both DT N
P NNP N
< VBD N
0.001 CD N
versus NN N
control NN N
values NNS N
. . N

The DT o
reduction NN o
in IN o
the DT o
signals NNS o
persisted VBN N
at IN N
the DT N
24-hour JJ N
recording NN N
. . N

CONCLUSIONS NNP N
Intravenous NNP N
L-arginine NNP i
and CC N
GSNO NNP i
attenuate VBP o
Doppler NNP o
embolic JJ o
signals NNS o
in IN N
humans NNS N
. . N

Modulation NN N
of IN N
the DT N
NO NNP N
system NN N
with IN N
these DT N
agents NNS N
may MD N
have VB N
applications NNS N
in IN N
the DT N
treatment NN N
of IN N
thromboembolic JJ p
disease NN p
. . p

This DT N
study NN N
demonstrates VBZ N
the DT N
potential JJ N
application NN N
of IN N
ultrasonic JJ N
embolic JJ N
signal JJ N
detection NN N
to TO N
examine VB N
the DT N
efficacy NN N
of IN N
new JJ N
antiplatelet NN N
agents NNS N
in IN N
relatively RB p
small JJ p
numbers NNS p
of IN p
patients NNS p
. . p

-DOCSTART- -23699515- O O

The DT N
aging VBG N
motor NN N
system NN N
as IN N
a DT N
model NN N
for IN N
plastic JJ N
changes NNS N
of IN N
GABA-mediated NNP N
intracortical JJ N
inhibition NN N
and CC N
their PRP$ N
behavioral JJ N
relevance NN N
. . N

Since IN N
GABAA-mediated JJ N
intracortical JJ N
inhibition NN N
has VBZ N
been VBN N
shown VBN N
to TO N
underlie VB N
plastic NN N
changes NNS N
throughout IN N
the DT N
lifespan NN N
from IN N
development NN N
to TO N
aging VBG N
, , N
here RB N
, , N
the DT N
aging VBG N
motor NN N
system NN N
was VBD N
used VBN N
as IN N
a DT N
model NN N
to TO N
analyze VB N
the DT N
interdependence NN N
of IN N
plastic JJ N
alterations NNS N
within IN N
the DT N
inhibitory JJ N
motorcortical JJ N
network NN N
and CC N
level NN N
of IN N
behavioral JJ N
performance NN N
. . N

Double-pulse JJ i
transcranial JJ i
magnetic JJ i
stimulation NN i
( ( i
dpTMS NN i
) ) i
was VBD i
used VBN i
to TO i
examine VB i
inhibition NN i
by IN i
means NNS i
of IN i
short-interval JJ i
intracortical JJ i
inhibition NN i
( ( i
SICI NNP i
) ) i
of IN i
the DT i
contralateral JJ i
primary JJ i
motor NN i
cortex NN i
in IN N
a DT N
sample NN N
of IN N
64 CD p
healthy JJ p
right-handed JJ p
human JJ p
subjects NNS p
covering VBG p
a DT p
wide JJ p
range NN p
of IN p
the DT p
adult NN p
lifespan NN p
( ( p
age NN p
range NN p
20-88 CD p
years NNS p
, , p
mean VB p
47.6 CD p
? . p
20.7 CD p
, , p
34 CD p
female NN p
) ) p
. . p

SICI NNP o
was VBD N
evaluated VBN N
during IN N
resting VBG N
state NN N
and CC N
in IN N
an DT N
event-related JJ N
condition NN N
during IN N
movement NN N
preparation NN N
in IN N
a DT N
visually RB N
triggered VBN N
simple JJ N
reaction NN N
time NN N
task NN N
. . N

In IN N
a DT N
subgroup NN N
( ( N
N NNP N
= NNP N
23 CD N
) ) N
, , N
manual JJ o
motor NN o
performance NN o
was VBD N
tested VBN N
with IN N
tasks NNS N
of IN N
graded VBN N
dexterous JJ N
demand NN N
. . N

Weak JJ o
resting-state JJ o
inhibition NN o
was VBD N
associated VBN N
with IN N
an DT N
overall JJ N
lower JJR N
manual JJ N
motor NN N
performance NN N
. . N

Better RBR o
event-related JJ o
modulation NN o
of IN o
inhibition NN o
correlated VBN N
with IN N
better JJR N
performance NN N
in IN N
more RBR N
demanding JJ N
tasks NNS N
, , N
in IN N
which WDT N
fast RB N
alternating VBG N
activation NN N
of IN N
cortical JJ N
representations NNS N
are VBP N
necessary JJ N
. . N

Declining VBG o
resting-state JJ o
inhibition NN o
was VBD N
associated VBN N
with IN N
weakened JJ N
event-related JJ N
modulation NN N
of IN N
inhibition NN N
. . N

Therefore NN N
, , N
reduced VBD o
resting-state JJ o
inhibition NN N
might MD N
lead VB N
to TO N
a DT N
subsequent JJ N
loss NN N
of IN N
modulatory JJ N
capacity NN N
, , N
possibly RB N
reflecting VBG N
malfunctioning VBG N
precision NN N
in IN N
GABAAergic NNP N
neurotransmission NN N
; : N
the DT N
consequence NN N
is VBZ N
an DT N
inevitable JJ N
decline NN N
in IN N
motor NN N
function NN N
. . N

-DOCSTART- -16651950- O O

Evaluation NN N
of IN N
a DT N
novel NN i
technique NN i
for IN N
wound NN i
closure NN i
using VBG i
a DT i
barbed JJ i
suture NN i
. . i

BACKGROUND NNP N
Suture NNP N
knots FW N
present JJ N
several JJ N
disadvantages NNS N
in IN N
wound NN N
closure NN N
, , N
because IN N
they PRP N
are VBP N
tedious JJ N
to TO N
tie VB N
and CC N
place VB N
ischemic JJ N
demands NNS N
on IN N
tissue NN N
. . N

Bulky NNP N
knots NNS N
may MD N
be VB N
a DT N
nidus NN N
for IN N
infection NN N
, , N
and CC N
they PRP N
may MD N
extrude VB N
through IN N
skin JJ N
weeks NNS N
after IN N
surgery NN N
. . N

Needle NNP N
manipulations NNS N
during IN N
knot-tying JJ N
predispose VBP N
the DT N
surgeon NN N
to TO N
glove VB N
perforation NN N
. . N

A DT N
barbed JJ i
suture NN i
was VBD N
developed VBN N
that DT N
is VBZ N
self-anchoring JJ N
, , N
requiring VBG N
no DT N
knots NNS N
or CC N
slack VB N
management NN N
for IN N
wound NN N
closure NN N
. . N

The DT N
elimination NN N
of IN N
knot NN N
tying NN N
may MD N
have VB N
advantages NNS N
over IN N
conventional JJ N
wound JJ N
closure NN N
methods NNS N
. . N

METHODS NNP N
This DT N
prospective JJ N
, , N
randomized VBN N
, , N
controlled VBD N
trial NN N
was VBD N
designed VBN N
to TO N
show VB N
that IN N
the DT N
use NN N
of IN N
barbed JJ i
suture NN i
in IN N
dermal JJ p
closure NN p
of IN p
the DT p
Pfannenstiel NNP p
incision NN p
during IN p
nonemergent JJ p
cesarean JJ p
delivery NN p
surgery NN p
produces VBZ p
scar JJR N
cosmesis NN N
at IN N
5 CD N
weeks NNS N
that WDT N
is VBZ N
no DT N
worse JJR N
than IN N
that DT N
observed VBD N
with IN N
conventional JJ i
closure NN i
using VBG N
3-0 JJ i
polydioxanone NN i
suture NN i
. . i

Cosmesis NN o
was VBD N
assessed VBN N
by IN N
review NN N
of IN N
postoperative JJ N
photographs NN N
by IN N
a DT N
blinded VBN N
, , N
independent JJ N
plastic NN N
surgeon NN N
using VBG N
the DT N
modified VBN N
Hollander NNP N
cosmesis NN N
score NN N
. . N

Secondary JJ N
endpoints NNS N
included VBD N
infection NN o
, , o
dehiscence NN o
, , o
pain NN o
, , o
closure NN o
time NN o
, , o
and CC o
other JJ o
adverse JJ o
events NNS o
. . o

RESULTS VB N
The DT N
study NN N
enrolled VBD p
195 CD p
patients NNS p
, , p
of IN p
whom WP p
188 CD p
were VBD p
eligible JJ p
for IN p
analysis NN p
. . p

Cosmesis NNP o
scores NNS o
did VBD N
not RB N
significantly RB N
differ VBP N
between IN N
the DT N
barbed JJ N
suture NN N
group NN N
and CC N
the DT N
control NN N
group NN N
. . N

Rates NNS o
of IN o
infection NN o
, , o
dehiscence NN o
, , o
and CC o
other JJ o
adverse JJ o
events NNS o
did VBD N
not RB N
significantly RB N
differ VBP N
between IN N
the DT N
two CD N
groups NNS N
. . N

Closure NN o
time NN o
and CC o
pain NN o
scores NNS o
were VBD N
comparable JJ N
between IN N
the DT N
groups NNS N
. . N

CONCLUSIONS VB N
The DT N
barbed JJ N
suture NN N
represents VBZ N
an DT N
innovative JJ N
option NN N
for IN N
wound NN N
closure NN N
. . N

With IN N
a DT N
cosmesis NN o
and CC o
safety NN o
profile NN o
that WDT N
is VBZ N
similar JJ N
to TO N
that DT N
of IN N
conventional JJ i
suture NN i
technique NN N
, , N
it PRP N
avoids VBZ N
the DT N
drawbacks NNS N
inherent JJ N
to TO N
suture VB N
knots NNS N
. . N

-DOCSTART- -839327- O O

Milk NNP N
protein NN N
quantity NN N
and CC N
quality NN N
in IN N
low-birth-weight JJ p
infants NNS p
. . p

IV NNP N
. . N

Effects NNS N
on IN N
tyrosine NN o
and CC N
phenylalanine NN o
in IN o
plasma NN o
and CC o
urine NN o
. . o

Well UH N
, , N
appropriate-for-gestational JJ p
age NN p
, , p
low-birth-weight JJ p
infants NNS p
were VBD N
divided VBN N
into IN N
three CD N
gestational JJ N
age NN N
groups NNS N
and CC N
assigned VBD N
randomly RB N
within IN N
each DT N
age NN N
group NN N
to TO N
one CD N
of IN N
five CD N
feeding VBG N
regimens NNS N
: : N
pooled VBN i
human JJ i
milk NN i
( ( i
BM NNP i
) ) i
; : i
formula $ i
1 CD i
( ( i
F1 NNP i
) ) i
= VBD i
1.5 CD i
gm/dl NN i
protein NN i
, , i
60 CD i
parts NNS i
bovine NN i
whey NN i
proteins NNS i
: : i
40 CD i
parts NNS i
bovine NN i
caseins NNS i
; : i
F2 NNP i
= VBD i
3.0 CD i
gm/dl NN i
, , i
60:40 CD i
; : i
F3 NNP i
= VBD i
1.5 CD i
gm/dl NN i
, , i
18:82 CD i
; : i
F4 NNP i
= VBD i
3.0 CD i
gm/dl NN i
, , N
18:82 CD N
. . N

Plasma NNP o
and CC o
urine JJ o
concentrations NNS o
of IN o
tyrosine NN o
and CC o
phenylalanine NN o
were VBD N
far RB N
higher JJR o
in IN N
the DT N
infants NNS N
fed VBP N
F1 NNP N
to TO N
F4 NNP N
, , N
especially RB N
F2 NNP N
and CC N
F4 NNP N
, , N
than IN N
in IN N
the DT N
infants NNS N
fed VBN N
BM NNP N
. . N

These DT N
findings NNS N
offer VBP N
further JJ N
evidence NN N
for IN N
the DT N
limited JJ N
capacity NN N
of IN N
the DT N
low-birth-weight JJ N
infant NN N
to TO N
catabolize VB o
tyrosine NN o
. . o

Infants NNS N
fed VBD N
F3 NNP N
had VBD N
significantly RB o
higher JJR o
plasma JJ o
tyrosine NN o
concentrations NNS o
than IN N
infants NNS N
fed VBN N
F1 NNP N
, , N
and CC N
those DT N
fed VBN N
F4 NNP N
had VBD N
higher JJR N
concentrations NNS N
than IN N
those DT N
fed JJ N
F2 NNP N
. . N

Thus NNP N
, , N
increased VBD o
plasma JJ o
tyrosine NN o
concentrations NNS o
in IN N
low-birth-weight JJ N
infants NNS N
are VBP N
related VBN N
directly RB N
both DT N
to TO N
the DT N
quantity NN N
and CC N
to TO N
the DT N
quality NN N
of IN N
the DT N
protein NN N
in IN N
their PRP$ N
diets NNS N
. . N

-DOCSTART- -25640884- O O

Reducing VBG N
cancer NN o
screening VBG o
disparities NNS N
in IN N
medicare NN N
beneficiaries NNS N
through IN N
cancer NN i
patient JJ i
navigation NN i
. . i

Significant NNP N
racial JJ N
disparities NNS N
in IN N
cancer NN o
mortality NN o
are VBP N
seen VBN N
between IN N
Medicare NNP p
beneficiaries NNS p
. . p

A DT N
randomized JJ N
controlled VBN N
trial NN N
tested VBD N
the DT N
use NN N
of IN N
lay NN i
navigators NNS i
( ( i
care NN i
managers NNS i
) ) i
to TO i
increase VB i
cancer NN o
screening NN o
of IN p
Asian JJ p
and CC p
Pacific NNP p
Islander NNP p
Medicare NNP p
beneficiaries NNS p
. . p

The DT p
study NN p
setting NN p
was VBD p
Moloka'i NNP p
General NNP p
Hospital NNP p
on IN p
the DT p
island NN p
of IN p
Moloka'i NNP p
, , p
Hawai'i NNP p
, , p
which WDT p
was VBD p
one CD p
of IN p
six CD p
sites NNS p
participating VBG p
in IN p
the DT p
Cancer NNP p
Prevention NNP p
and CC p
Treatment NNP p
Demonstration NNP p
sponsored VBN p
by IN p
the DT p
Centers NNPS p
for IN p
Medicare NNP p
and CC p
Medicaid NNP p
Services NNPS p
. . p

Between JJ p
2006 CD p
and CC p
2009 CD p
, , p
488 CD p
Medicare NNP p
beneficiaries NNS p
( ( p
45 CD p
% NN p
Hawaiian JJ p
, , p
35 CD p
% NN p
Filipino NNP p
, , p
11 CD p
% NN p
Japanese JJ p
, , p
8 CD p
% NN p
other JJ p
) ) p
were VBD N
randomized VBN N
to TO N
have VB N
a DT N
navigator NN i
help NN i
them PRP i
access NN i
cancer NN i
screening NN i
services NNS i
( ( i
experimental JJ i
condition NN i
, , N
n JJ N
= NNP N
242 CD N
) ) N
or CC i
cancer NN i
education NN i
( ( i
control JJ i
condition NN i
, , N
n JJ N
= NNP N
246 CD N
) ) N
. . N

Self-reported JJ o
data NNS o
on IN o
screening VBG o
participation NN o
were VBD N
collected VBN N
at IN N
baseline NN i
and CC N
exit NN N
from IN N
the DT N
study NN N
, , N
and CC N
differences NNS N
were VBD N
tested VBN N
using VBG N
chi-square NN N
. . N

Groups NNP N
were VBD N
similar JJ N
in IN N
demographic JJ o
characteristics NNS o
and CC o
baseline NN o
screening VBG o
prevalence NN o
of IN o
breast NN o
, , o
cervical JJ o
, , o
prostate NN o
, , o
and CC o
colorectal JJ o
cancers NNS o
. . o

At IN N
study NN N
exit NN N
, , N
57.0 CD N
% NN N
of IN N
women NNS N
in IN N
the DT N
experimental JJ N
arm NN N
and CC N
36.4 CD N
% NN N
of IN N
controls NNS N
had VBD N
had VBN N
a DT N
Papanicolaou NNP o
test NN o
in IN o
the DT o
past JJ o
24 CD o
months NNS o
( ( N
P NNP N
= NNP N
.001 NNP N
) ) N
, , N
61.7 CD N
% NN N
of IN N
women NNS N
in IN N
the DT N
experimental JJ N
arm NN N
and CC N
42.4 CD N
% NN N
of IN N
controls NNS N
had VBD N
had VBN N
a DT N
mammogram NN o
in IN o
the DT o
past JJ o
12 CD o
months NNS o
( ( N
P NNP N
= NNP N
.003 NNP N
) ) N
, , N
54.4 CD N
% NN N
of IN N
men NNS N
in IN N
the DT N
experimental JJ N
arm NN N
and CC N
36.0 CD N
% NN N
of IN N
controls NNS N
had VBD N
had VBN N
a DT N
prostate-specific JJ o
antigen NN o
test NN o
in IN o
the DT o
past JJ o
12 CD o
months NNS o
( ( N
P NNP N
= NNP N
.008 NNP N
) ) N
, , N
and CC N
43.0 CD N
% NN N
of IN N
both DT N
sexes NNS N
in IN N
the DT N
experimental JJ N
arm NN N
and CC N
27.2 CD N
% NN N
of IN N
controls NNS N
had VBD N
had VBN N
a DT N
flexible JJ o
sigmoidoscopy NN o
or CC o
colonoscopy NN o
in IN o
the DT o
past JJ o
5 CD o
years NNS o
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Findings NNS N
suggest VBP N
that IN N
navigation NN i
services NNS i
can MD N
increase VB N
cancer NN o
screening VBG o
in IN N
Medicare NNP N
beneficiaries NNS N
in IN N
groups NNS N
with IN N
significant JJ N
disparities NNS N
. . N

-DOCSTART- -25407464- O O

Anthropometric JJ N
indices NNS N
of IN N
Gambian JJ p
children NNS p
after IN N
one CD N
or CC N
three CD N
annual JJ N
rounds NNS N
of IN N
mass JJ i
drug NN i
administration NN i
with IN N
azithromycin NN i
for IN N
trachoma NN p
control NN N
. . N

BACKGROUND NNP N
Mass NNP N
drug NN N
administration NN N
( ( N
MDA NNP N
) ) N
with IN N
azithromycin NN i
, , N
carried VBD N
out RP N
for IN N
the DT N
control NN N
of IN N
blinding VBG N
trachoma NN N
, , N
has VBZ N
been VBN N
linked VBN N
to TO N
reduced VBN N
mortality NN N
in IN N
children NNS p
. . p

While IN N
the DT N
mechanism NN N
behind IN N
this DT N
reduction NN N
is VBZ N
unclear JJ N
, , N
it PRP N
may MD N
be VB N
due JJ N
, , N
in IN N
part NN N
, , N
to TO N
improved VBN N
nutritional JJ N
status NN N
via IN N
a DT N
potential JJ N
reduction NN N
in IN N
the DT N
community NN N
burden NN N
of IN N
infectious JJ N
disease NN N
. . N

To TO N
determine VB N
whether IN N
MDA NNP i
with IN i
azithromycin JJ i
improves NNS N
anthropometric JJ N
indices NNS N
at IN N
the DT N
community NN N
level NN N
, , N
we PRP N
measured VBD N
the DT N
heights NNS o
and CC o
weights NNS o
of IN N
children NNS p
aged VBN p
1 CD p
to TO p
4 CD p
years NNS p
in IN p
communities NNS p
where WRB p
one CD p
( ( p
single JJ p
MDA NNP p
arm NN p
) ) p
or CC p
three CD p
annual JJ p
rounds NNS p
( ( p
annual JJ p
MDA NNP p
arm NN p
) ) p
of IN p
azithromycin NN i
had VBD N
been VBN N
distributed VBN N
. . N

METHODS NNP N
Data NNP N
collection NN N
took VBD N
place NN N
three CD N
years NNS N
after IN N
treatment NN N
in IN N
the DT N
single JJ N
MDA NNP N
arm NN N
and CC N
one CD N
year NN N
after IN N
the DT N
final JJ N
round NN N
of IN N
treatment NN N
in IN N
the DT N
annual JJ N
MDA NNP N
arm NN N
. . N

Mean JJ o
height-for-age NN o
, , o
weight-for-age NN o
and CC o
weight-for-height JJ o
z NN o
scores NNS o
were VBD N
compared VBN N
between IN N
treatment NN N
arms NNS N
. . N

RESULTS NNP N
No NNP N
significant JJ o
differences NNS o
in IN N
mean JJ o
height-for-age NN o
, , o
weight-for-age NN o
or CC o
weight-for-height JJ o
z NN o
scores NNS o
were VBD N
found VBN N
between IN N
the DT N
annual JJ N
MDA NNP N
and CC N
single JJ N
MDA NNP N
arms NNS N
, , N
nor CC N
was VBD N
there EX N
a DT N
significant JJ o
reduction NN o
in IN N
prevalence NN o
of IN o
stunting NN o
, , o
wasting VBG o
or CC o
underweight JJ o
between IN N
arms NNS N
. . N

CONCLUSIONS VB N
Our PRP$ N
data NNS N
do VBP N
not RB N
provide VB N
evidence NN N
that IN N
community NN N
MDA NNP i
with IN i
azithromycin NN i
improved VBN N
anthropometric JJ o
outcomes NNS o
of IN N
children NNS p
in IN p
The DT p
Gambia NNP p
. . p

This DT N
may MD N
suggest VB N
reductions NNS N
in IN N
mortality NN N
associated VBN N
with IN N
azithromycin JJ i
MDA NNP i
are VBP N
due JJ N
to TO N
a DT N
mechanism NN N
other JJ N
than IN N
improved JJ N
nutritional JJ N
status NN N
. . N

-DOCSTART- -22115710- O O

A DT N
randomized JJ N
, , N
dose-escalation JJ N
study NN N
of IN N
subconjunctival NN N
and CC N
intravitreal JJ N
injections NNS N
of IN N
sirolimus NN i
in IN N
patients NNS p
with IN p
diabetic JJ p
macular JJ p
edema NN p
. . p

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
safety NN o
and CC o
tolerability NN o
of IN N
a DT N
single JJ i
subconjunctival NN i
( ( i
SCJ NNP i
) ) i
or CC N
intravitreal NN i
( ( i
IVT NNP i
) ) i
injection NN i
of IN N
an DT N
ophthalmic JJ N
sirolimus NN i
formulation NN N
in IN N
eyes NNS N
with IN N
diabetic JJ N
macular NN N
edema NN N
( ( N
DME NNP N
) ) N
. . N

DESIGN NNP N
Randomized NNP N
, , N
open-label JJ N
, , N
dose-escalating JJ N
phase NN N
I PRP N
study VBP N
. . N

PARTICIPANTS NNP N
Fifty NNP p
eyes NNS p
among IN p
50 CD p
patients NNS p
with IN p
DME NNP p
, , p
retinal JJ p
thickness NN p
? . p
300 CD p
microns NNS p
and CC p
best-corrected JJ p
visual JJ p
acuity NN p
( ( p
BCVA NNP p
) ) p
20/40 CD p
to TO p
20/200 CD p
. . p

METHODS VB N
A DT N
single JJ N
dose NN N
of IN N
sirolimus NN i
administered VBN i
SCJ NNP N
( ( N
220 CD N
, , N
440 CD N
, , N
880 CD N
, , N
1320 CD N
, , N
or CC N
1760 CD N
?g NN N
) ) N
or CC N
IVT NNP N
( ( N
44 CD N
, , N
110 CD N
, , N
176 CD N
, , N
264 CD N
, , N
or CC N
352 CD N
?g NNS N
) ) N
on IN N
day NN N
0 CD N
; : N
observation NN N
through IN N
day NN N
90 CD N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Primary NNP N
end NN N
points NNS N
were VBD N
the DT N
frequency NN o
and CC o
severity NN o
of IN o
ocular JJ o
and CC o
systemic JJ o
adverse JJ o
events NNS o
. . o

Secondary JJ o
end NN N
points NNS N
were VBD N
changes NNS o
in IN o
BCVA NNP o
and CC o
retinal JJ o
thickness NN o
. . o

RESULTS NNP o
No NNP o
dose-limiting JJ o
toxicities NNS o
were VBD o
observed VBN N
and CC N
ocular JJ o
adverse JJ o
events NNS o
were VBD o
mostly RB N
mild JJ N
and CC N
transient NN o
. . o

Conjunctival NNP o
hyperemia NN o
, , o
hemorrhage NN o
, , o
and CC o
edema NN o
were VBD o
common JJ N
after IN N
the DT N
SCJ NNP N
injection NN N
procedure NN N
and CC N
conjunctival JJ o
hemorrhage NN o
was VBD o
common JJ N
after IN N
the DT N
IVT NNP N
injection NN N
procedure NN N
. . N

Three CD N
patients NNS N
experienced VBD o
ocular JJ o
adverse JJ o
events NNS o
considered VBN o
possibly RB N
related VBN N
to TO N
study VB N
drug NN N
: : o
Conjunctival NNP o
edema NN o
and CC o
reduced JJ o
visual JJ o
acuity NN o
were VBD o
reported VBN N
in IN N
1 CD N
SCJ NNP N
patient JJ N
each DT N
and CC N
iritis NN N
was VBD N
reported VBN N
in IN N
1 CD N
IVT NNP N
patient NN N
. . N

No DT N
serious JJ o
ocular JJ o
adverse JJ o
events NNS o
were VBD o
reported VBN o
. . o

No DT o
nonocular JJ o
adverse JJ o
events NNS o
were VBD o
considered VBN N
related VBN N
to TO N
study VB N
drug NN N
. . o

Systemic JJ o
exposure NN o
to TO o
sirolimus VB o
was VBD o
low JJ N
, , N
with IN N
blood NN o
concentrations NNS o
below IN o
levels NNS N
necessary JJ N
for IN N
systemic JJ N
immunosuppression NN N
. . N

For IN N
the DT N
SCJ NNP N
group NN N
( ( N
n JJ N
= NNP N
25 CD N
) ) N
, , N
a DT o
median JJ o
increase NN o
in IN o
BCVA NNP o
started VBD o
at IN N
day NN N
7 CD N
( ( N
5.0 CD N
letters NNS N
) ) N
and CC N
was VBD N
3.0 CD N
, , N
4.0 CD N
, , N
and CC N
4.0 CD N
letters NNS N
at IN N
days NNS N
14 CD N
, , N
45 CD N
and CC N
90 CD N
, , N
respectively RB N
. . N

At IN N
day NN N
45 CD N
, , N
median JJ o
decrease NN o
in IN o
retinal JJ o
thickness NN o
was VBD o
-23.7 JJ N
?m NNP N
. . N

For IN N
the DT N
IVT NNP N
group NN N
( ( N
n JJ N
= NNP N
25 CD N
) ) N
, , N
the DT N
median JJ o
increase NN o
in IN o
BCVA NNP o
was VBD N
2.0 CD N
letters NNS N
at IN N
day NN N
7 CD N
; : N
at IN N
days NNS N
14 CD N
, , N
45 CD N
, , N
and CC N
90 CD N
, , N
the DT N
median JJ N
increase NN N
was VBD N
maintained VBN N
( ( N
4.0 CD N
letters NNS o
) ) o
; : o
the DT o
median JJ o
decrease NN o
in IN o
retinal JJ o
thickness NN o
was VBD o
-52.0 JJ N
?m NN N
at IN N
day NN N
45 CD N
. . N

CONCLUSIONS NNP N
Locally RB N
administered VBD i
sirolimus NN i
was VBD i
well-tolerated JJ i
with IN N
minimal JJ N
systemic JJ N
exposure NN N
at IN N
all DT N
doses NNS N
tested VBN N
in IN N
this DT N
small JJ N
phase NN N
I PRP N
population VBP N
. . N

These DT N
findings NNS N
support NN N
advancing VBG N
the DT N
present JJ N
sirolimus NN N
formulation NN N
into IN N
phase NN N
II NNP N
studies NNS N
. . N

FINANCIAL NNP N
DISCLOSURE NNP N
( ( N
S NNP N
) ) N
Proprietary NNP N
or CC N
commercial JJ N
disclosure NN N
may MD N
be VB N
found VBN N
after IN N
the DT N
references NNS N
. . N

-DOCSTART- -23680243- O O

Pregnancy NNP N
outcome NN N
and CC N
glycemic JJ o
control NN o
in IN N
women NNS p
with IN p
type JJ p
1 CD p
diabetes NNS p
: : p
a DT N
retrospective JJ N
comparison NN N
between IN N
CSII NNP i
and CC N
MDI NNP i
treatment NN N
. . N

AIM NNP N
Present NNP N
study NN N
was VBD N
aimed VBN N
to TO N
evaluate VB N
glycemic JJ o
control NN o
and CC o
maternal-fetal JJ o
outcome NN o
in IN p
pregnant JJ p
type NN p
1 CD p
diabetic JJ p
patient NN p
treated VBN N
with IN N
continuous JJ i
subcutaneous JJ i
insulin NN i
infusion NN i
( ( i
CSII NNP i
) ) i
or CC i
multiple JJ i
daily JJ i
injections NNS i
of IN i
insulin NN i
( ( i
MDI NNP i
) ) i
. . i

PATIENTS NNP N
AND CC N
METHODS NNP N
A NNP p
retrospective JJ p
observational NN p
study NN p
included VBD p
thirty-four JJ p
pregnant JJ p
type NN p
1 CD p
diabetic JJ p
patients NNS p
. . p

Patients NNS N
were VBD N
divided VBN N
into IN N
two CD N
group NN N
, , N
CSII NNP i
treated VBD i
group NN i
( ( p
n=14 CC p
) ) p
and CC i
MDI NNP i
treated VBD i
group NN i
( ( p
n=20 RB p
) ) p
. . p

The DT N
HbA1c NNP N
level NN N
and CC N
maternal-fetal JJ N
outcome NN N
were VBD N
evaluated VBN N
in IN N
both DT N
the DT N
treatment NN N
group NN N
. . N

Outcome NNP N
parameters NNS N
such JJ N
as IN N
glycemic JJ o
control NN o
( ( o
HbA1c NNP o
) ) o
, , o
hypoglycemic JJ o
events NNS o
, , o
time NN o
and CC o
mode NN o
of IN o
delivery NN o
and CC o
labor NN o
results NNS o
( ( o
abortion NN o
, , o
premature NN o
labor NN o
, , o
perinatal JJ o
mortality NN o
, , o
neonatal JJ o
weight NN o
, , o
Apgar NNP o
score NN o
, , o
neonatal JJ o
hypoglycaemia NN o
, , o
presence NN o
of IN o
congenital JJ o
abnormalities NNS o
) ) o
were VBD N
analyzed VBN N
. . N

RESULTS NNP N
Pregnancy NNP o
outcome NN o
and CC o
glycemic JJ o
control NN o
in IN N
pregnant JJ N
type NN N
1 CD N
diabetic JJ N
patients NNS N
treated VBN N
with IN N
CSII NNP N
and CC N
MDI NNP N
were VBD N
evaluated VBN N
and CC N
compared VBN N
. . N

Two CD N
groups NNS N
were VBD N
compared VBN N
for IN N
their PRP$ N
epidemiological JJ N
parameters NNS N
, , N
although IN N
patients NNS N
on IN N
CSII NNP N
treatment NN N
had VBD N
longer JJR o
duration NN o
of IN o
diabetes NNS o
compared VBN N
to TO N
MDI NNP N
treated VBD N
group NN N
. . N

Reduction NN o
in IN o
HbA1c NNP o
level NN o
was VBD N
higher RBR N
in IN N
CSII NNP N
treated VBD N
patients NNS N
at IN N
first JJ N
( ( N
CSII NNP N
: : N
0.9 CD N
% NN N
vs JJ N
MDI NNP N
: : N
0.46 CD N
% NN N
) ) N
, , N
second JJ N
( ( N
CSII NNP N
: : N
1.58 CD N
% NN N
vs JJ N
MDI NNP N
: : N
0.78 CD N
% NN N
) ) N
and CC N
third JJ N
trimester NN N
( ( N
CSII NNP N
: : N
1.74 CD N
% NN N
vs JJ N
MDI NNP N
: : N
1.09 CD N
% NN N
) ) N
of IN N
pregnancy NN N
compared VBN N
to TO N
MDI NNP N
treated VBD N
patients NNS N
. . N

Duration NNP o
of IN o
pregnancy NN o
and CC o
new JJ o
born VBN o
baby NN o
weight NN o
were VBD N
founded VBN N
similar JJ N
in IN N
both DT N
group NN N
. . N

Moreover RB N
, , N
the DT N
rate NN o
of IN o
abortion NN o
, , o
preterm JJ o
labor NN o
, , o
cesarean JJ o
section NN o
and CC o
hypoglycemia NN o
in IN o
new JJ o
born NNS o
were VBD N
founded VBN N
less RBR N
in IN N
CSII NNP N
treated VBD N
group NN N
compared VBN N
to TO N
MDI NNP N
treated VBN N
group NN N
and CC N
Apgar NNP o
score NN o
was VBD N
significantly RB N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
higher JJR N
in IN N
CSII NNP N
treated VBD N
group NN N
compared VBN N
to TO N
MDI NNP N
treated VBD N
group NN N
. . N

CONCLUSION NNP N
Results NNP N
of IN N
present JJ N
study NN N
revealed VBD N
that IN N
the DT N
CSII NNP N
gives VBZ N
better JJR N
glycemic JJ N
control NN N
and CC N
pregnancy NN N
outcome NN N
in IN N
pregnant JJ p
type NN p
1 CD p
diabetic JJ p
patients NNS p
compared VBN N
to TO N
MDI NNP N
treatment NN N
. . N

CSII NNP N
also RB N
decreases VBZ N
the DT N
daily JJ N
insulin NN N
requirement NN N
compared VBN N
MDI NNP N
. . N

-DOCSTART- -17402204- O O

[ JJ N
Evaluation NN N
on IN N
the DT N
effect NN N
of IN N
intervention NN N
regarding VBG N
breast JJ N
self-examination NN N
for IN N
decreasing VBG N
breast NN N
cancer NN N
mortality NN N
] NNP N
. . N

OBJECTIVE CC N
A DT N
randomized JJ N
trial NN N
of IN N
breast NN i
self-examination NN i
( ( i
BSE NNP i
) ) i
Program NNP i
was VBD N
carried VBN N
out IN N
to TO N
evaluate VB N
whether IN N
the DT N
intensive JJ N
BSE NNP i
could MD N
reduce VB N
the DT N
number NN N
of IN N
deaths NNS N
among IN N
women NNS p
from IN p
breast NN p
cancer NN p
. . p

METHODS NNP N
This DT N
study NN N
was VBD N
a DT N
randomized VBN N
controlled VBN N
trial NN N
( ( N
RCT NNP N
) ) N
. . N

A DT p
total NN p
of IN p
266 CD p
064 CD p
women NNS p
( ( p
age NN p
of IN p
30 CD p
to TO p
64 CD p
years NNS p
) ) p
associated VBD p
with IN p
519 CD p
textile NN p
factories NNS p
in IN p
Shanghai NNP p
had VBD p
been VBN p
randomly RB p
assigned VBN p
to TO p
a DT p
BSE NNP i
group NN p
( ( p
132 CD p
979 CD p
women NNS p
) ) p
or CC p
a DT p
control NN i
group NN i
( ( p
133 CD p
085 CD p
women NNS p
) ) p
since IN p
1989 CD p
. . p

Initial JJ N
instruction NN N
in IN N
BSE NNP N
group NN N
would MD N
include VB N
demonstration NN N
of IN N
proper JJ N
palpation NN N
techniques NNS N
and CC N
was VBD N
followed VBN N
by IN N
2 CD N
reinforcement JJ N
sessions NNS N
during IN N
the DT N
subsequent JJ N
4 CD N
years NNS N
including VBG N
video NN N
shows NNS N
, , N
BSE NNP N
instruction NN N
sessions NNS N
and CC N
BSE NNP i
practice NN N
under IN N
medical JJ N
supervision NN N
. . N

These DT N
activities NNS N
were VBD N
continued VBN N
for IN N
5 CD N
years NNS N
. . N

Attendance NN N
at IN N
all DT N
events NNS N
was VBD N
recorded VBN N
. . N

The DT N
cohort NN N
was VBD N
followed VBN N
through IN N
July NNP N
2000 CD N
for IN N
development NN N
of IN N
breast NN N
diseases NNS N
, , N
and CC N
the DT N
breast NN N
cancer NN N
cases NNS N
were VBD N
followed VBN N
through IN N
2001 CD N
for IN N
vital JJ N
status NN N
. . N

Data NNP N
analysis NN N
methods NNS N
used VBN N
would MD N
include VB N
Kaplan-Meier NNP N
plots NNS N
, , N
log-rank JJ N
test NN N
and CC N
Cox NNP N
modeling NN N
. . N

RESULTS NNP N
Among IN N
women NNS N
under IN N
instruction NN N
, , N
864 CD N
breast NN N
cancers NNS N
detected VBD N
and CC N
133 CD N
breast NN N
cancer NN N
deaths NNS N
occurred VBD N
while IN N
896 CD N
breast NN N
cancers NNS N
were VBD N
detected VBN N
and CC N
130 CD N
deaths NNS N
recorded VBN N
in IN N
the DT N
control NN N
group NN N
. . N

The DT N
tumor NN N
size NN N
( ( N
P NNP N
= NNP N
0.07 CD N
) ) N
, , N
TNM NNP N
stage NN N
( ( N
P NNP N
= NNP N
0.39 CD N
) ) N
and CC N
cumulative JJ N
breast NN o
cancer NN o
mortality NN o
rate NN o
( ( N
P NNP N
= NNP N
0.72 CD N
) ) N
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
2 CD N
groups NNS N
. . N

However RB N
, , N
more JJR N
and CC N
smaller JJR N
fibroadenomas NN N
were VBD N
detected VBN N
in IN N
the DT N
instruction NN N
group NN N
than IN N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSION NNP N
Intensive NNP o
instruction NN o
in IN o
BSE NNP o
did VBD o
not RB o
seem VB o
to TO o
have VB o
reduced VBN o
the DT o
mortality NN o
rate NN o
of IN o
breast NN o
cancer NN o
, , o
but CC o
more JJR o
and CC o
smaller JJR o
benign NN o
breast NN o
lumps NNS o
could MD o
be VB o
detected VBN o
. . o

-DOCSTART- -25287262- O O

Detection NN p
and CC p
quantification NN p
of IN p
the DT p
solid JJ p
component NN p
in IN p
pulmonary JJ p
subsolid JJ p
nodules NNS p
by IN p
semiautomatic JJ i
segmentation NN i
. . i

OBJECTIVE UH N
To TO N
determine VB N
whether IN N
semiautomatic JJ i
volumetric NNS i
software NN i
can MD N
differentiate VB N
part-solid JJ N
from IN N
nonsolid JJ N
pulmonary JJ N
nodules NNS N
and CC N
aid JJ N
quantification NN N
of IN N
the DT N
solid JJ N
component NN N
. . N

METHODS NNP N
As IN N
per IN N
reference NN N
standard NN N
, , N
115 CD p
nodules NNS p
were VBD N
differentiated VBN N
into IN N
nonsolid JJ N
and CC N
part-solid JJ N
by IN N
two CD N
radiologists NNS N
; : N
disagreements NNS N
were VBD N
adjudicated VBN N
by IN N
a DT N
third JJ N
radiologist NN N
. . N

The DT N
diameters NNS N
of IN N
solid JJ N
components NNS N
were VBD N
measured VBN N
manually RB N
. . N

Semiautomatic JJ N
volumetric JJ N
measurements NNS N
were VBD N
used VBN N
to TO N
identify VB N
and CC N
quantify VB N
a DT N
possible JJ N
solid JJ N
component NN N
, , N
using VBG N
different JJ N
Hounsfield NNP N
unit NN N
( ( N
HU NNP N
) ) N
thresholds NNS N
. . N

The DT N
measurements NNS N
were VBD N
compared VBN N
with IN N
the DT N
reference NN N
standard NN N
and CC N
manual JJ N
measurements NNS N
. . N

RESULTS VB N
The DT N
reference NN N
standard NN N
detected VBD N
a DT N
solid JJ N
component NN N
in IN N
86 CD N
nodules NNS N
. . N

Diagnosis NN N
of IN N
a DT N
solid JJ N
component NN N
by IN N
semiautomatic JJ N
software NN N
depended VBN N
on IN N
the DT N
threshold JJ N
chosen NN N
. . N

A DT N
threshold NN N
of IN N
-300 NNP N
HU NNP N
resulted VBD N
in IN N
the DT N
detection NN o
of IN o
a DT o
solid JJ o
component NN o
in IN N
75 CD N
nodules NNS N
with IN N
good JJ N
sensitivity NN N
( ( N
90 CD N
% NN N
) ) N
and CC N
specificity NN N
( ( N
88 CD N
% NN N
) ) N
. . N

At IN N
a DT N
threshold NN N
of IN N
-130 NNP N
HU NNP N
, , N
semiautomatic JJ N
measurements NNS N
of IN N
the DT N
diameter NN N
of IN N
the DT N
solid JJ o
component NN o
( ( N
mean JJ N
2.4 CD N
mm NN N
, , N
SD NNP N
2.7 CD N
mm NN N
) ) N
were VBD N
comparable JJ N
to TO N
manual JJ N
measurements NNS N
at IN N
the DT N
mediastinal JJ N
window NN N
setting NN N
( ( N
mean JJ N
2.3 CD N
mm NN N
, , N
SD NNP N
2.5 CD N
mm NN N
[ NNP N
p NN N
= VBD N
0.63 CD N
] NN N
) ) N
. . N

CONCLUSION NNP N
Semiautomatic NNP N
segmentation NN N
of IN N
subsolid JJ N
nodules NNS N
could MD N
diagnose VB N
part-solid JJ N
nodules NNS N
and CC N
quantify VB N
the DT N
solid JJ N
component NN N
similar JJ N
to TO N
human JJ N
observers NNS N
. . N

Performance NNP N
depends VBZ N
on IN N
the DT N
attenuation NN N
segmentation NN N
thresholds NNS N
. . N

This DT N
method NN N
may MD N
prove VB N
useful JJ N
in IN N
managing VBG N
subsolid JJ N
nodules NNS N
. . N

KEY NNP N
POINTS NNP N
? . N
Semiautomatic JJ N
segmentation NN N
can MD N
accurately RB N
differentiate VB N
nonsolid JJ N
from IN N
part-solid JJ N
pulmonary JJ N
nodules NNS N
? . N
Semiautomatic JJ N
segmentation NN N
can MD N
quantify VB N
the DT N
solid JJ N
component NN N
similar JJ N
to TO N
manual JJ N
measurements NNS N
? . N
Semiautomatic JJ N
segmentation NN N
may MD N
aid VB N
management NN N
of IN N
subsolid JJ N
nodules NNS N
following VBG N
Fleischner NNP N
Society NNP N
recommendations NNS N
? . N
Performance NN N
for IN N
the DT N
segmentation NN N
of IN N
subsolid JJ N
nodules NNS N
depends VBZ N
on IN N
the DT N
chosen VBN N
attenuation NN N
thresholds NNS N
. . N

-DOCSTART- -15769967- O O

Effects NNS N
of IN N
long-term JJ i
vitamin NN i
E NNP i
supplementation NN i
on IN N
cardiovascular JJ o
events NNS o
and CC o
cancer NN o
: : o
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

CONTEXT NNP N
Experimental NNP N
and CC N
epidemiological JJ N
data NNS N
suggest VBP N
that IN N
vitamin NN i
E NNP i
supplementation NN i
may MD N
prevent VB N
cancer NN p
and CC p
cardiovascular JJ p
events NNS p
. . p

Clinical JJ N
trials NNS N
have VBP N
generally RB N
failed VBN N
to TO N
confirm VB N
benefits NNS N
, , N
possibly RB N
due JJ N
to TO N
their PRP$ N
relatively RB N
short JJ N
duration NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
whether IN N
long-term JJ i
supplementation NN i
with IN i
vitamin JJ i
E NN i
decreases VBZ N
the DT N
risk NN o
of IN o
cancer NN o
, , o
cancer NN o
death NN o
, , o
and CC o
major JJ o
cardiovascular JJ o
events NNS o
. . o

DESIGN NNP N
, , N
SETTING NNP N
, , N
AND NNP N
PATIENTS NNP N
A NNP N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
international JJ p
trial NN N
( ( N
the DT N
initial JJ N
Heart NNP N
Outcomes NNP N
Prevention NNP N
Evaluation NNP N
[ NNP N
HOPE NNP N
] NNP N
trial NN N
conducted VBD N
between IN N
December NNP N
21 CD N
, , N
1993 CD N
, , N
and CC N
April NNP N
15 CD N
, , N
1999 CD N
) ) N
of IN N
patients NNS p
at IN p
least JJS p
55 CD p
years NNS p
old JJ p
with IN p
vascular JJ p
disease NN p
or CC p
diabetes VBZ p
mellitus NN p
was VBD p
extended VBN p
( ( p
HOPE-The NNP p
Ongoing NNP p
Outcomes NNP p
[ NNP p
HOPE-TOO NNP p
] NNP p
) ) p
between IN p
April NNP p
16 CD p
, , p
1999 CD p
, , p
and CC p
May NNP p
26 CD p
, , p
2003 CD p
. . p

Of IN N
the DT N
initial JJ N
267 CD p
HOPE NNP p
centers NNS p
that WDT p
had VBD p
enrolled VBN p
9541 CD p
patients NNS p
, , p
174 CD p
centers NNS p
participated VBN p
in IN p
the DT p
HOPE-TOO NNP p
trial NN p
. . p

Of IN N
7030 CD p
patients NNS p
enrolled VBN p
at IN p
these DT p
centers NNS p
, , p
916 CD p
were VBD p
deceased VBN p
at IN p
the DT p
beginning NN p
of IN p
the DT p
extension NN p
, , p
1382 CD p
refused VBD p
participation NN p
, , p
3994 CD p
continued VBD p
to TO p
take VB p
the DT p
study NN p
intervention NN p
, , p
and CC p
738 CD p
agreed VBD p
to TO p
passive VB p
follow-up NN p
. . p

Median JJ N
duration NN N
of IN N
follow-up NN N
was VBD N
7.0 CD N
years NNS N
. . N

INTERVENTION NNP N
Daily NNP i
dose NN i
of IN i
natural JJ i
source NN i
vitamin NN i
E NNP i
( ( i
400 CD i
IU NNP i
) ) i
or CC i
matching VBG i
placebo NN i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Primary NNP N
outcomes NNS N
included VBD N
cancer NN o
incidence NN o
, , o
cancer NN o
deaths NNS o
, , o
and CC o
major JJ o
cardiovascular JJ o
events NNS o
( ( o
myocardial JJ o
infarction NN o
, , o
stroke NN o
, , o
and CC o
cardiovascular JJ o
death NN o
) ) o
. . o

Secondary JJ N
outcomes NNS N
included VBD N
heart NN o
failure NN o
, , o
unstable JJ o
angina NN o
, , o
and CC o
revascularizations NNS o
. . o

RESULTS NNP N
Among IN N
all DT N
HOPE NNP N
patients NNS N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
primary JJ N
analysis NN N
: : N
for IN N
cancer NN o
incidence NN o
, , N
there EX N
were VBD N
552 CD N
patients NNS N
( ( N
11.6 CD N
% NN N
) ) N
in IN N
the DT N
vitamin NN i
E NNP i
group NN N
vs VBD N
586 CD N
( ( N
12.3 CD N
% NN N
) ) N
in IN N
the DT N
placebo NN i
group NN N
( ( N
relative JJ N
risk NN N
[ NNP N
RR NNP N
] NNP N
, , N
0.94 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.84-1.06 NNP N
; : N
P NNP N
= NNP N
.30 NNP N
) ) N
; : N
for IN N
cancer NN o
deaths NNS o
, , N
156 CD N
( ( N
3.3 CD N
% NN N
) ) N
vs NN N
178 CD N
( ( N
3.7 CD N
% NN N
) ) N
, , N
respectively RB N
( ( N
RR NNP N
, , N
0.88 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.71-1.09 NNP N
; : N
P NNP N
= NNP N
.24 NNP N
) ) N
; : N
and CC N
for IN N
major JJ o
cardiovascular JJ o
events NNS o
, , N
1022 CD N
( ( N
21.5 CD N
% NN N
) ) N
vs NN N
985 CD N
( ( N
20.6 CD N
% NN N
) ) N
, , N
respectively RB N
( ( N
RR NNP N
, , N
1.04 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.96-1.14 NNP N
; : N
P NNP N
= NNP N
.34 NNP N
) ) N
. . N

Patients NNS N
in IN N
the DT N
vitamin NN i
E NNP i
group NN N
had VBD N
a DT N
higher JJR N
risk NN o
of IN o
heart NN o
failure NN o
( ( N
RR NNP N
, , N
1.13 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.01-1.26 JJ N
; : N
P NNP N
= NNP N
.03 NNP N
) ) N
and CC N
hospitalization NN o
for IN o
heart NN o
failure NN o
( ( N
RR NNP N
, , N
1.21 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.00-1.47 JJ N
; : N
P NNP N
= NNP N
.045 NNP N
) ) N
. . N

Similarly RB N
, , N
among IN N
patients NNS N
enrolled VBN N
at IN N
the DT N
centers NNS N
participating VBG N
in IN N
the DT N
HOPE-TOO NNP N
trial NN N
, , N
there EX N
were VBD N
no DT N
differences NNS N
in IN N
cancer NN o
incidence NN o
, , o
cancer NN o
deaths NNS o
, , o
and CC o
major JJ o
cardiovascular JJ o
events NNS o
, , N
but CC N
higher JJR N
rates NNS o
of IN o
heart NN o
failure NN o
and CC o
hospitalizations NNS o
for IN o
heart NN o
failure NN o
. . o

CONCLUSION NNP N
In IN N
patients NNS p
with IN p
vascular JJ p
disease NN p
or CC p
diabetes VBZ p
mellitus NNS p
, , N
long-term JJ i
vitamin NN i
E NNP i
supplementation NN i
does VBZ N
not RB N
prevent VB N
cancer NN o
or CC o
major JJ o
cardiovascular JJ o
events NNS o
and CC N
may MD N
increase VB N
the DT N
risk NN o
for IN o
heart NN o
failure NN o
. . o

-DOCSTART- -24635039- O O

Brief JJ N
acceptance-based JJ i
intervention NN i
for IN N
increasing VBG N
intake JJ o
attendance NN o
at IN p
a DT p
community NN p
mental JJ p
health NN p
center NN p
. . p

Intake VB N
no-show JJ N
rates NNS N
for IN N
psychotherapy NN N
vary NN N
from IN N
20 CD N
% NN N
to TO N
57 CD N
% NN N
( ( N
Swenson NNP N
& CC N
Pekarik NNP N
, , N
1988 CD N
) ) N
, , N
and CC N
experiential JJ N
avoidance NN N
may MD N
be VB N
related VBN N
to TO N
failure NN N
to TO N
attend VB N
intake JJ N
sessions NNS N
. . N

This DT N
pilot NN N
study NN N
attempted VBD N
to TO N
increase VB N
intake VB N
attendance NN N
at IN p
a DT p
community NN p
mental JJ p
health NN p
center NN p
by IN N
employing VBG N
a DT N
brief JJ N
experiential JJ N
acceptance-based JJ N
intervention NN N
. . N

Those DT p
who WP p
scheduled VBD p
intakes NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
2 CD N
groups NNS N
: : N
orientation NN i
letter NN i
or CC i
acceptance-enhanced JJ i
orientation NN i
letter NN i
; : i
rates NNS N
from IN N
these DT N
conditions NNS N
were VBD N
compared VBN N
with IN N
a DT N
retrospective JJ N
comparison NN N
control NN N
group NN N
. . N

Participants NNS N
were VBD N
randomized VBN N
by IN N
way NN N
of IN N
an DT N
online JJ N
random NN N
number NN N
generator NN N
. . N

Persons NNS N
assigned VBD N
to TO N
the DT N
orientation NN N
group NN N
did VBD N
not RB N
have VB N
a DT N
higher JJR N
show NN o
rate NN o
than IN N
persons NNS N
within IN N
the DT N
control NN i
group NN N
( ( N
?48 CD N
% NN N
compared VBN N
with IN N
?52 NNP N
% NN N
) ) N
. . N

Persons NNS N
assigned VBD N
to TO N
the DT N
acceptance NN i
group NN i
did VBD N
have VB N
higher JJR o
show NN o
rates NNS o
than IN o
persons NNS N
in IN N
the DT N
other JJ N
two CD N
groups NNS N
( ( N
?67 CD N
% NN N
compared VBN N
with IN N
?48 NNP N
% NN N
and CC N
?52 CD N
% NN N
, , N
respectively RB N
) ) N
, , N
however RB N
this DT N
difference NN N
was VBD N
nonsignificant JJ N
. . N

Results VB N
suggest JJS N
that DT N
brief JJ N
acceptance-based JJ N
interventions NNS N
should MD N
be VB N
further JJ N
studied VBN N
for IN N
their PRP$ N
potential JJ N
value NN N
in IN N
maximizing VBG N
client NN N
attendance NN N
. . N

-DOCSTART- -7449282- O O

Cardiac NNP N
and CC N
haemodynamic JJ N
measurements NNS N
in IN N
hypertensive JJ p
pregnancy NN p
. . p

1 CD N
. . N

Haemodynamic NNP N
and CC N
left VBD N
ventricular JJ N
variables NNS N
were VBD N
determined VBN N
by IN N
M-mode NNP N
echocardiography NN N
in IN N
21 CD p
normotensive JJ p
and CC p
36 CD p
hypertensive JJ p
patients NNS p
during IN p
the DT p
last JJ p
trimester NN p
of IN p
pregnancy NN p
. . p

2 CD N
. . N

Blood NNP o
pressure NN o
of IN N
hypertensive JJ p
patients NNS p
was VBD N
lowered VBN N
by IN N
bed NN N
rest NN N
only RB N
, , N
or CC N
by IN N
oxprenolol JJ i
or CC i
methyldopa NN i
, , N
but CC N
remained VBD N
elevated VBN N
. . N

3 CD N
. . N

Cardiac NNP o
output NN o
was VBD N
raised VBN N
in IN N
the DT N
last JJ N
trimester NN N
of IN N
pregnancy NN N
in IN N
both DT N
normotensive JJ p
and CC p
hypertensive JJ p
patients NNS p
. . p

4 CD N
. . N

Left VBN o
ventricular JJ o
mass NN o
was VBD N
increased VBN N
in IN N
normal JJ N
pregnancy NN N
, , N
but CC N
displayed VBD N
an DT N
exaggerated JJ N
increase NN N
in IN N
hypertensive JJ p
patients NNS p
. . p

5 CD N
. . N

Total JJ o
peripheral JJ o
resistance NN o
was VBD N
inappropriately RB N
elevated VBN N
in IN N
hypertensive JJ N
pregnancy NN N
, , N
except IN N
in IN N
the DT N
oxprenolol-treated JJ N
group NN N
. . N

6 CD N
. . N

There EX N
ws VBZ N
no DT N
reduction NN N
in IN N
heart NN o
rate NN o
or CC o
cardiac JJ o
output NN o
in IN N
the DT N
group NN N
treated VBD N
with IN N
beta-adrenoreceptor NN i
blocking VBG i
agents NNS i
. . i

These DT N
factors NNS N
, , N
in IN N
combination NN N
with IN N
normal JJ N
peripheral JJ N
resistance NN N
, , N
may MD N
contribute VB N
to TO N
the DT N
improvement NN N
in IN N
foetal JJ o
outcome NN o
described VBN N
in IN N
maternal JJ N
hypertension NN N
of IN N
pregnancy NN N
treated VBN N
with IN N
oxprenolol NN i
. . i

-DOCSTART- -16855475- O O

Divalproex NNP i
versus NN i
placebo NN i
for IN N
the DT N
prevention NN N
of IN N
irritability NN o
associated VBN N
with IN N
fluoxetine JJ i
treatment NN N
in IN N
autism NN p
spectrum NN p
disorder NN p
. . p

-DOCSTART- -16963850- O O

Anecortave NNP i
acetate NN i
treatment NN i
for IN N
retinal JJ p
angiomatous JJ p
proliferation NN p
: : p
a DT N
pilot NN N
study NN N
. . N

PURPOSE VB N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
anecortave JJ i
acetate JJ i
treatment NN i
of IN N
retinal JJ p
angiomatous JJ p
proliferation NN p
( ( p
RAP NNP p
) ) p
, , N
a DT N
neovascular JJ N
form NN N
of IN N
age-related JJ N
macular JJ N
degeneration NN N
, , N
with IN N
specific JJ N
regard NN N
to TO N
inhibition NN o
of IN o
neovascularization NN o
and CC o
maintenance NN o
of IN o
vision NN o
. . o

METHODS NNP N
Thirty-four JJ p
patients NNS p
with IN p
RAP NNP p
with IN p
any DT p
stage NN p
of IN p
neovascularization NN p
were VBD N
randomized VBN N
1:1:1 CD N
for IN N
treatment NN N
with IN N
three CD N
different JJ N
quantities NNS N
( ( N
30 CD N
mg NN N
, , N
15 CD N
mg NN N
, , N
3 CD N
mg NN N
) ) N
of IN N
anecortave NN i
acetate NN i
sterile JJ i
suspension NN i
for IN i
juxtascleral JJ i
administration NN i
. . i

Best-corrected JJ o
visual JJ o
acuity NN o
( ( o
Early JJ o
Treatment NNP o
Diabetic NNP o
Retinopathy NNP o
Study NNP o
chart NN o
) ) o
, , o
intraocular JJ o
pressure NN o
measurement NN o
, , o
biomicroscopy NN o
, , o
funduscopy NN o
, , o
digital JJ o
fluorescein NN o
, , o
and CC o
indocyanine NN o
green JJ o
angiography NN o
were VBD N
recorded VBN N
at IN N
baseline NN N
and CC N
at IN N
3 CD N
months NNS N
. . N

A DT N
6-month JJ N
retreatment NN N
interval NN N
was VBD N
established VBN N
for IN N
this DT N
study NN N
with IN N
a DT N
follow-up NN N
of IN N
12 CD N
months NNS N
. . N

In IN N
selected JJ N
patients NNS N
optical JJ N
coherence NN N
tomography NN N
was VBD N
performed VBN N
. . N

The DT N
outcomes NNS N
were VBD N
mean JJ o
changes NNS o
in IN o
visual JJ o
acuity NN o
and CC o
lesion NN o
size NN o
at IN o
1 CD o
year NN o
. . o

RESULTS VB N
The DT N
detachment NN o
of IN o
the DT o
neurosensory JJ o
retina NN o
and CC o
retinal JJ o
pigment NN o
epithelium NN o
improved VBN N
in IN N
all DT N
eyes NNS N
, , N
but CC N
all DT N
neovascular JJ o
lesions NNS o
increased VBD o
in IN o
size NN o
. . o

Vision NNP o
loss NN o
occurred VBD N
in IN N
the DT N
majority NN N
of IN N
study NN N
eyes NNS N
( ( N
22 CD N
out IN N
of IN N
34 CD N
eyes NNS N
, , N
64.7 CD N
% NN N
) ) N
independent JJ N
of IN N
the DT N
concentration NN N
administered VBD N
. . N

CONCLUSION NNP N
The DT N
results NNS N
suggest VBP N
that IN N
a DT N
posterior JJ N
juxtascleral JJ N
injection NN N
of IN N
anecortave JJ i
acetate NN i
reduces NNS N
capillary JJ o
permeability NN o
in IN N
patients NNS p
with IN p
RAP NNP p
. . p

However RB N
, , N
in IN N
spite NN N
of IN N
improvement NN N
of IN N
the DT N
exudation NN N
there EX N
is VBZ N
a DT N
progression NN N
of IN N
neovascularization NN o
and CC N
a DT N
significant JJ o
loss NN o
of IN o
vision NN o
in IN N
all PDT N
these DT N
patients NNS N
. . N

Like IN N
other JJ N
monotherapeutic JJ N
methods NNS N
used VBN N
to TO N
treat VB N
this DT N
variant NN N
of IN N
neovascular JJ N
age-related JJ N
macular JJ N
degeneration NN N
, , N
anecortave VBP i
acetate JJ i
alone RB N
does VBZ N
not RB N
appear VB N
to TO N
benefit VB N
these DT N
patients NNS N
. . N

Future JJ N
studies NNS N
should MD N
investigate VB N
a DT N
combination NN N
form NN N
of IN N
therapy NN N
. . N

